<SEC-DOCUMENT>0001193125-21-278969.txt : 20210922
<SEC-HEADER>0001193125-21-278969.hdr.sgml : 20210922
<ACCEPTANCE-DATETIME>20210922083519
ACCESSION NUMBER:		0001193125-21-278969
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		152
FILED AS OF DATE:		20210922
DATE AS OF CHANGE:		20210922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bioventus Inc.
		CENTRAL INDEX KEY:			0001665988
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				810980861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259392
		FILM NUMBER:		211268229

	BUSINESS ADDRESS:	
		STREET 1:		4721 EMPEROR BOULEVARD, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		(919) 474-6700

	MAIL ADDRESS:	
		STREET 1:		4721 EMPEROR BOULEVARD, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d180330ds4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:bvs="http://bio.com/20210703" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-4/A</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden26389481" contextRef="P01_01_2021To07_03_2021">S-4/A</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2021To07_03_2021">true</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2021To07_03_2021">0001665988</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden26390211" contextRef="P02_01_2021To02_28_2021_MinimumMembersrtRangeAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P2Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden26390212" contextRef="P02_01_2021To02_28_2021_MinimumMembersrtRangeAxis_RestrictedStockUnitsAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P1Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="hidden26390228" contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis">P15D</ix:nonNumeric><ix:nonFraction name="bvs:AdditionalMarginPercentageToReferenceRates" id="hidden26390186" contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4">0.0050</ix:nonFraction><ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" id="hidden26390235" contextRef="PAsOn02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0">31838589</ix:nonFraction><ix:footnote id="FN_89660" xml:lang="en-US">Per share information for the six months ended July 3, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through July 3, 2021, the period following Bioventus Inc.&#8217;s initial public offering and related transactions described in Note 1. Organization and Note 7. Earnings per share within the Notes to the Unaudited Condensed Consolidated Financial Statements.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bvs-20210703.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="bvs-20210703_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bvs-20210703_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bvs-20210703_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bvs-20210703_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P04_04_2021To07_03_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_28_2020To06_27_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-28</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To07_03_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_28_2019To06_27_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-28</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_10_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To07_03_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To04_03_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-04-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_12_2021To02_10_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-12</xbrli:startDate> <xbrli:endDate>2021-02-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_15_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_08_2021To06_08_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-08</xbrli:startDate> <xbrli:endDate>2021-06-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_02_2021To08_02_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-02</xbrli:startDate> <xbrli:endDate>2021-08-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_02_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_28_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_27_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >bvs:LimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_UnvestedClassACommonSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >bvs:UnvestedClassACommonSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_NonUsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >us-gaap:NonUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:PainTreatmentsAndJointPreservationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_RestorativeTherapiesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:RestorativeTherapiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_BoneGraftSubstitutesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_A2021PlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:A2021PlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_28_2020To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-28</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_28_2020To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-28</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BVLLCMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BVLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:HarborMedtechIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:HarborMedtechIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:RevolvingCreditFacilitySubAxis" >bvs:SwingLineCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >bvs:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:HarborMedtechIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >bvs:UsaoAndOigMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AssetUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >bvs:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" >bvs:BmpResearchAndDevelopmentProgrammeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:DistributionRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:IntellectualPropertyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AcquiredInProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis" >bvs:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:HarborMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NonUsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >us-gaap:NonUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FederalAndStateMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >bvs:FederalAndStateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >bvs:YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FederalAndStateMemberusgaapIncomeTaxAuthorityAxis_IndefinitelyMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >bvs:FederalAndStateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >bvs:IndefinitelyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:HarborMedtechIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >bvs:MeasurementInputEquityVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MaximumMembersrtRangeAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >bvs:MeasurementInputEquityVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >bvs:MeasurementInputEquityVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputDiscountForLackOfMarketabilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputDiscountForLackOfMarketabilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MaximumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelvePreferredUnitsMemberusgaapPreferredUnitsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PreferredUnitsByNameAxis" >bvs:TwoThousandAndTwelvePreferredUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PreferredUnitsByNameAxis" >bvs:TwoThousandAndFifteenPreferredUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:HarborMedtechIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >bvs:UsaoAndOigMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AssetUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >bvs:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:DistributionRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:IntellectualPropertyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AcquiredInProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis" >bvs:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:HarborMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To07_03_2021_A2021PlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:A2021PlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_28_2019To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-28</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_28_2019To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-28</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_28_2019To06_27_2020_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-28</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_28_2019To06_27_2020_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-28</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:HarborMedtechIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" >bvs:BmpResearchAndDevelopmentProgrammeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >bvs:PreferredUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ReclassificationOfIprdMemberBVSEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:EventAxis" >bvs:ReclassificationOfIprdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountsPayableMemberusgaapBalanceSheetLocationAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:AccountsPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:DistributionRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:OAJointPainTreatmentAndJointPreservationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:MinimallyInvasiveFractureTreatmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:IntellectualPropertyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:DistributionRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductDMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2015MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:TaxYear2015Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2020MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:TaxYear2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:OtherChargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndEighteenPlanMemberusgaapRestructuringPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis" >bvs:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:OtherPhantomUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodOneMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >bvs:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:DebtInstrumentSchedulePeriodicPaymentAxis" >bvs:DebtInstrumentSchedulePeriodicPaymentPeriodOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >bvs:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:DebtInstrumentSchedulePeriodicPaymentAxis" >bvs:DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:EurodollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:BaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:EurodollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:BaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:EurodollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:BaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:EurodollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:BaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeFiveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:EurodollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeFiveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:BaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis" >bvs:LeverageRatioRangeFiveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >bvs:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >bvs:UsaoAndOigMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" >bvs:BmpResearchAndDevelopmentProgrammeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >bvs:PreferredUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:OAJointPainTreatmentAndJointPreservationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:MinimallyInvasiveFractureTreatmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductDMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:OtherChargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:OtherPhantomUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:OtherPhantomUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:OtherPhantomUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:PriorCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" >bvs:BmpResearchAndDevelopmentProgrammeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >bvs:PreferredUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:OAJointPainTreatmentAndJointPreservationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:MinimallyInvasiveFractureTreatmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:ProductDMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis" >bvs:SupplierCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwentyPlanMemberusgaapRestructuringPlanAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis" >bvs:TwoThousandAndTwentyPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-30</xbrli:startDate> <xbrli:endDate>2021-03-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:IntellectualPropertyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-30</xbrli:startDate> <xbrli:endDate>2021-03-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-30</xbrli:startDate> <xbrli:endDate>2021-03-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-30</xbrli:startDate> <xbrli:endDate>2021-03-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:CartiHealMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_BVLLCMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:BVLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:BVLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:A2021PlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:CartiHealMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:IntellectualPropertyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ObtainingFDAApprovalOfCertainProductsMemberusgaapContingentConsiderationByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis" >bvs:ObtainingFDAApprovalOfCertainProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMemberusgaapContingentConsiderationByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis" >bvs:MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMemberusgaapContingentConsiderationByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis" >bvs:MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ForObtainingCMSCoverageAndReimbursementForCertainProductsMemberusgaapContingentConsiderationByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis" >bvs:ForObtainingCMSCoverageAndReimbursementForCertainProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_EquityParticipationRightUnitMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BVLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_BVLLCMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BVLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BVLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BVLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BVLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2021To02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-16</xbrli:startDate> <xbrli:endDate>2021-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_RestatedLimitedLiabilityCompanyAgreementMemberBVSEventAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:EventAxis" >bvs:RestatedLimitedLiabilityCompanyAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InvestorAxis" >bvs:ContinuingLlcOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InvestorAxis" >bvs:NewLlcOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BVLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:MisonixIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:MisonixIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:BVLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-10</xbrli:startDate> <xbrli:endDate>2021-08-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_10_2021To08_10_2021_BioventusIncMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-10</xbrli:startDate> <xbrli:endDate>2021-08-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BionessIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-30</xbrli:startDate> <xbrli:endDate>2021-03-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingApril102022MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BionessIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PaycheckProtectionProgramCARESActMaturingApril102022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-30</xbrli:startDate> <xbrli:endDate>2021-03-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingFebruary52026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BionessIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PaycheckProtectionProgramCARESActMaturingFebruary52026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-30</xbrli:startDate> <xbrli:endDate>2021-03-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_29_2021To07_29_2021_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanFacilityMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:TermLoanFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-29</xbrli:startDate> <xbrli:endDate>2021-07-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_29_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_31_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_PaycheckProtectionProgramLoanMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_29_2021_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanFacilityMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:TermLoanFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SecuredDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_29_2021_A2019CreditAgreementMemberusgaapDebtInstrumentAxis_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:A2019CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SecuredDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:HarborMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-08-23</xbrli:startDate> <xbrli:endDate>2019-08-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_23_2019To08_23_2019_HarborMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:HarborMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-08-23</xbrli:startDate> <xbrli:endDate>2019-08-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:HarborMedtechIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-08-23</xbrli:startDate> <xbrli:endDate>2019-08-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_09_2016To02_09_2016_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis" >bvs:ThreeInjectionOAProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-02-09</xbrli:startDate> <xbrli:endDate>2016-02-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_09_2016To02_09_2016_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis" >bvs:ThreeInjectionOAProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-02-09</xbrli:startDate> <xbrli:endDate>2016-02-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2020To12_22_2020_HarborMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:HarborMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-22</xbrli:startDate> <xbrli:endDate>2020-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2020To12_22_2020_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis" >bvs:ThreeInjectionOAProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-22</xbrli:startDate> <xbrli:endDate>2020-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >bvs:LimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_UnvestedClassACommonSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >bvs:UnvestedClassACommonSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_NonUsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >us-gaap:NonUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:PainTreatmentsAndJointPreservationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_RestorativeTherapiesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:RestorativeTherapiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_BoneGraftSubstitutesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_BVLLCEmployeesTerminatedPriorToIPOMembersrtTitleOfIndividualAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >bvs:BVLLCEmployeesTerminatedPriorToIPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_BionessIncMemberusgaapLitigationStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis" >bvs:BionessIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_BVLLCEmployeesActiveAtIPOMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >bvs:BVLLCEmployeesActiveAtIPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bvs:PublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bvs:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bvs:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:CartiHealMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-07-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_NonUsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >us-gaap:NonUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:PainTreatmentsAndJointPreservationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_RestorativeTherapiesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:RestorativeTherapiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_BoneGraftSubstitutesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_15_2021_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_10_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >bvs:BVLLCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_10_2021_BioventusIncMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_NonUsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >us-gaap:NonUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:PainTreatmentsAndJointPreservationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_RestorativeTherapiesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:RestorativeTherapiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_BoneGraftSubstitutesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:USSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >bvs:InternationalSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:OperatingSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis" >us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_24_2021_VaporoxMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:VaporoxMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-04-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_12_2021To02_10_2021_ManagementIncentivePlanAwardMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAwardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-12</xbrli:startDate> <xbrli:endDate>2021-02-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_12_2021To02_10_2021_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-12</xbrli:startDate> <xbrli:endDate>2021-02-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_31_2021_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To01_04_2021_BioVentusLlcMemberdeiLegalEntityAxis_ConvertibleDebtInstrumentsMemberusgaapInvestmentTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >bvs:ConvertibleDebtInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-01-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InvestorAxis" >bvs:NewLlcOwnerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-17</xbrli:startDate> <xbrli:endDate>2021-02-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InvestorAxis" >bvs:NewLlcOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-17</xbrli:startDate> <xbrli:endDate>2021-02-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_17_2021To02_17_2021_BioventusIncMembersrtOwnershipAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InvestorAxis" >bvs:ContinuingLlcOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-17</xbrli:startDate> <xbrli:endDate>2021-02-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_17_2021To02_17_2021_BioventusIncMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-17</xbrli:startDate> <xbrli:endDate>2021-02-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InvestorAxis" >bvs:NewLlcOwnerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InvestorAxis" >bvs:ContinuingLlcOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:InvestorAxis" >bvs:NewLlcOwnerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_23_2021To02_23_2021_BioVentusLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsaoAndOigMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >bvs:UsaoAndOigMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-23</xbrli:startDate> <xbrli:endDate>2021-02-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_28_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:A2021PlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_28_2021_MaximumMembersrtRangeAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:AgreementAxis" >bvs:OptionAndEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_28_2021_MaximumMembersrtRangeAxis_RestrictedStockUnitsAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:AgreementAxis" >bvs:RestrictedStockUnitsAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_28_2021_MinimumMembersrtRangeAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:AgreementAxis" >bvs:OptionAndEquityPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_28_2021_MinimumMembersrtRangeAxis_RestrictedStockUnitsAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:AgreementAxis" >bvs:RestrictedStockUnitsAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_22_2021To03_22_2021_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-22</xbrli:startDate> <xbrli:endDate>2021-03-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-27</xbrli:startDate> <xbrli:endDate>2020-03-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >bvs:HarborSeriesCPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-27</xbrli:startDate> <xbrli:endDate>2020-03-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborCommonStockMemberusgaapStatementEquityComponentsAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >bvs:HarborCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-27</xbrli:startDate> <xbrli:endDate>2020-03-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >bvs:HarborSeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_30_2020To11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >bvs:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >bvs:HarborSeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-30</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_05_2020To10_05_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >bvs:HarborSeriesCPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-05</xbrli:startDate> <xbrli:endDate>2020-10-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-01-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_30_2018To01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >bvs:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-30</xbrli:startDate> <xbrli:endDate>2018-01-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_22_2020To01_22_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SimpleAgreementForFutureEquityMemberBVSAgreementForFutureEquityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:AgreementForFutureEquityAxis" >bvs:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-22</xbrli:startDate> <xbrli:endDate>2020-01-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_15_2020To07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesG1PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >bvs:SeriesG1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-15</xbrli:startDate> <xbrli:endDate>2020-07-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_15_2020To07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:AgreementAxis" >bvs:OptionAndEquityPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-15</xbrli:startDate> <xbrli:endDate>2020-07-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:AgreementAxis" >bvs:OptionAndEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bvs:CartiHealLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2012To05_31_2012_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2012-05-01</xbrli:startDate> <xbrli:endDate>2012-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2012To05_31_2012_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelvePreferredUnitsMemberusgaapPreferredUnitsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PreferredUnitsByNameAxis" >bvs:TwoThousandAndTwelvePreferredUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2012-05-01</xbrli:startDate> <xbrli:endDate>2012-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2015To11_30_2015_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PreferredUnitsByNameAxis" >bvs:TwoThousandAndFifteenPreferredUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-11-01</xbrli:startDate> <xbrli:endDate>2015-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2020To06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-06-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >bvs:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_LetterOfCreditMemberBVSRevolvingCreditFacilitySubAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:RevolvingCreditFacilitySubAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_BrInterestRateBasisMemberBVSInterestRateBasisAxis_EurodollarMemberusgaapVariableRateAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:EurodollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InterestRateBasisAxis" >bvs:BrInterestRateBasisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-06</xbrli:startDate> <xbrli:endDate>2019-12-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:EurodollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-06</xbrli:startDate> <xbrli:endDate>2019-12-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_06_2019To12_06_2019_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:BaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-06</xbrli:startDate> <xbrli:endDate>2019-12-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-06</xbrli:startDate> <xbrli:endDate>2019-12-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:RevolvingCreditFacilitySubAxis" >bvs:SwingLineCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-06</xbrli:startDate> <xbrli:endDate>2019-12-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-06</xbrli:startDate> <xbrli:endDate>2019-12-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:RevolvingCreditFacilitySubAxis" >bvs:SwingLineCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-06</xbrli:startDate> <xbrli:endDate>2019-12-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_BrInterestRateBasisMemberBVSInterestRateBasisAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >bvs:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:InterestRateBasisAxis" >bvs:BrInterestRateBasisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-06</xbrli:startDate> <xbrli:endDate>2019-12-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis" >bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_10_2021_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:OtherChargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioventusIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioventusIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:OtherChargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >bvs:OtherChargesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:OtherPhantomUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:OtherPhantomUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:OtherPhantomUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >bvs:OtherPhantomUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >bvs:BioVentusLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_28_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001665988</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_EMPLOYEE" > <xbrli:measure>bvs:EMPLOYEE</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_employee" > <xbrli:measure>bvs:employee</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Plan" > <xbrli:measure>bvs:Plan</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Segment" > <xbrli:measure>bvs:Segment</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Business" > <xbrli:measure>bvs:Business</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Loans" > <xbrli:measure>bvs:Loans</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Vote" > <xbrli:measure>bvs:Vote</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Entities" > <xbrli:measure>bvs:Entities</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_26388121" toRefs="FN_89660"/><ix:relationship fromRefs="Fact_26388122" toRefs="FN_89660"/><ix:relationship fromRefs="Fact_26388127" toRefs="FN_89660"/><ix:relationship fromRefs="Fact_26388128" toRefs="FN_89660"/></ix:resources></ix:header></div><div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">As filed with the U.S. Securities and Exchange Commission on September 22, 2021 </div></div></div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-259392</div> </div></div></div> </div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 14pt;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 14pt; font-size: 14pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 14pt;;display:inline;">UNITED STATES </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 14pt;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 14pt;;font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:AmendmentDescription" contextRef="P01_01_2021To07_03_2021">Amendment No. 1</ix:nonNumeric> </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">to </div></div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 14pt;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 14pt; font-size: 14pt;;font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; line-height: 14pt;;display:inline;"><span style="-sec-ix-hidden:hidden26389481">S-</span>4</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 14pt;"><div style="font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 14pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 5pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2021To07_03_2021">BIOVENTUS INC.</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact Name of Registrant as Specified in Its Charter) </div></div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 5pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Delaware</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3841</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">94-0980861</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State of Incorporation)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Primary Standard Industrial</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Classification Code Number)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(IRS Employer</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 400 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div> </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices) </div></div></div></div> <div style="text-align: center; text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 5pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Kenneth M. Reali </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 400 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(919)&#160;474-6700</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service) </div></div></div></div> <div style="text-align: center; text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 5pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Wesley Holmes</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Mark Bekheit</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Latham&#160;&amp; Watkins LLP</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">140 Scott Drive</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Menlo Park, California 94025</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(650) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">328-4600</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jonn R. Beeson, Esq.</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jones Day</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">3161 Michelson Drive, Suite 800</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Irvine, California 92612</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(949) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">553-7528</div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="text-align: center; text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 5pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale of the securities to the public:</div></div> As soon as practicable after this registration statement is declared effective. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If the securities being registered on this form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, please check the following box.&#160;&#160;&#9744; </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div></div> </div> </div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 67%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2021To07_03_2021" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2021To07_03_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2021To07_03_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2021To07_03_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric> </div></div></div> <div style="font-family: Times New Roman; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </div></div></div> <div style="font-family: Times New Roman; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Exchange&#160;Act&#160;Rule&#160;13e-4(i)&#160;(Cross-Border&#160;Issuer&#160;Tender&#160;Offer)&#160;&#160;&#9744;</div> </div></div> <div style="font-family: Times New Roman; font-size: 7.5pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Exchange&#160;Act&#160;Rule&#160;14d-1(d)&#160;(Cross-Border&#160;Third-Party&#160;Tender&#160;Offer)&#160;&#160;&#9744;</div> </div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 2pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">CALCULATION OF REGISTRATION FEE </div></div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 44%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td> </tr>
<tr style="font-size: 1px;">
<td colspan="9" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class of</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">securities to be registered</div></div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amount</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">to be</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">registered<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Proposed</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">offering price</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">per share<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Proposed</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">aggregate</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">offering price<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of<br/> registration fee<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(3)</div></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-top: 0.75pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Common Stock, $0.001 par value per share</div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="display:inline;">18,322,984</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="display:inline;">$25.95</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="display:inline;">$268,985,195.25</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="display:inline;">$29,346.28<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(4)</div></div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="9" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td colspan="9" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="display:inline;">(1)</div></td>
<td style="vertical-align: top; font-size: 7.5pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of shares of class A common stock, par value $0.001 per share (&#8220;Bioventus class A common stock&#8221;), of the registrant, Bioventus Inc. (&#8220;Bioventus&#8221;), being registered is based upon the estimated maximum number of shares of Bioventus class A common stock issuable upon completion of the merger of Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus (&#8220;Merger Sub I&#8221;), with and into Misonix, Inc. (&#8220;Misonix&#8221;), with Misonix as the surviving corporation, described in the joint proxy statement/prospectus contained herein, and is calculated by assuming that the stock election consideration is oversubscribed by holders of Misonix common stock, which results in proration of the stock election consideration based on the maximum cash amount. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="display:inline;">(2)</div></td>
<td style="vertical-align: top; font-size: 7.5pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated solely for purposes of calculating the registration fee required by Section&#160;6(b) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and calculated in accordance with Rules 457(c), 457(f)(1) and 457(f)(3) promulgated thereunder. The proposed maximum aggregate offering price is solely for the purposes of calculating the registration fee and was calculated based upon the market value of shares of Misonix common stock (the securities to be cancelled in the merger) in accordance with Rule 457(c) under the Securities Act as follows: (a)&#160;the product of (i) $25.95, the average of the high and low prices per share of Misonix common stock on September 7, 2021, as quoted on the Nasdaq Global Market, and (ii) 17,410,045, the estimated number of shares of Misonix common stock estimated to be outstanding immediately prior to the merger based on the number of shares presently outstanding, minus (b) $182,805,472.50, which is the estimated maximum amount of cash consideration to be delivered in the merger based on the number of shares of Misonix common stock presently outstanding. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="display:inline;">(3)</div></td>
<td style="vertical-align: top; font-size: 7.5pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Calculated pursuant to Section&#160;6(b) of the Securities Act at a rate equal to $109.10 per $1,000,000 of the proposed maximum aggregate offering price. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="display:inline;">(4)</div></td>
<td style="vertical-align: top; font-size: 7.5pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Paid in connection with the initial filing of this registration statement. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 3pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act or until the registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said section 8(a), may determine. </div></div></div></div> </div> </div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Arial Narrow; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(255, 67, 56); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The information in this joint proxy statement/prospectus is not complete and may be changed. A registration statement relating to the securities described in this joint proxy statement/prospectus has been filed with the U.S. Securities and Exchange Commission. These securities may not be issued or sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This joint proxy statement/prospectus does not constitute an offer to sell or the solicitation of offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(255, 67, 56); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PRELIMINARY&#8212;SUBJECT TO COMPLETION, DATED SEPTEMBER 22, 2021 </div></div></div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 47%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g03a11.jpg" style="width: 293px; height: 65px;"/></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g03b22.jpg"/></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div id="toc180330_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MERGER PROPOSAL&#8212;YOUR VOTE IS VERY IMPORTANT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dear Bioventus Stockholders and Misonix Stockholders: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;29, 2021, Bioventus Inc., which is referred to as &#8220;Bioventus,&#8221; Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, which is referred to as &#8220;Merger Sub I,&#8221; Oyster Merger Sub II, LLC, a wholly owned subsidiary of Bioventus, which is referred to as &#8220;Merger Sub II,&#8221; and Misonix, Inc., which is referred to as &#8220;Misonix,&#8221; entered into an Agreement and Plan of Merger, as it may be amended from time to time, which is referred to as the &#8220;merger agreement,&#8221; that provides for the acquisition of Misonix by Bioventus. Upon the terms and subject to the conditions of the merger agreement, Bioventus will acquire Misonix through a merger of Merger Sub I with and into Misonix, with Misonix continuing as the surviving corporation, which is referred to as the &#8220;first merger,&#8221; followed by a merger of Misonix with and into Merger Sub II, with Merger Sub II continuing as the surviving entity and a wholly owned subsidiary of Bioventus, which is referred to as the &#8220;second merger&#8221; and, together with the first merger is referred to as the &#8220;mergers.&#8221; The combined company created by the mergers will be named Bioventus Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the successful completion of the mergers, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus or Merger Sub I, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Bioventus class A common stock, based on the election of the holder thereof and subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described below and in the accompanying joint proxy statement/prospectus. Bioventus stockholders will continue to own their existing shares of Bioventus common stock. The exchange ratio is fixed and will not be adjusted for changes in the market price of either Bioventus class A common stock or Misonix common stock between the date of signing of the merger agreement and the completion date of the first merger. As such, the market value of the merger consideration payable to Misonix stockholders will fluctuate with the market price of the Bioventus class A common stock and will not be known at the time that Misonix stockholders vote on the merger agreement. Upon completion of the mergers, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the mergers are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Bioventus class A common stock is traded on the Nasdaq Global Select Market, which is referred to as &#8220;Nasdaq,&#8221; under the symbol &#8220;BVS.&#8221; Misonix common stock is traded on Nasdaq under the symbol &#8220;MSON.&#8221; We encourage you to obtain current quotes for both the Bioventus class A common stock and the Misonix common stock before voting at the special meetings of stockholders described below. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate amount of cash payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock at 5:00 p.m., New York City time, on the election deadline. If the aggregate amount of cash that holders of Misonix common stock elect to receive exceeds the available cash amount, the number of shares of Misonix common stock as to which the holder elected to receive cash consideration will be reduced on a pro rata basis and each such share will be paid $28.00 per share in cash, and the remainder of such shares of Misonix common stock as to which a cash election was made will be paid 1.6839 shares of Bioventus class A common stock. In such case, for each share of Misonix common stock as to which the holder elected to receive the stock consideration or made no election, the holder will receive 1.6839 shares of Bioventus common stock. If the aggregate amount of cash that holders of Misonix common stock elect to receive is less than the available cash amount, each share of Misonix common stock as to which the holder elected to receive cash consideration will receive $28.00 per share in cash. In such case, the remaining excess cash consideration will be first paid at a rate of $28.00 for each share of Misonix common stock as to which the holder made no election (with such cash being distributed on a pro rata basis based on the number of shares for </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">which no election was made if the number of such shares multiplied by $28.00 is less than the remaining cash to be paid), and thereafter (to the extent any excess cash consideration remains) at a rate of $28.00 per share in cash to the shares of Misonix common stock as to which the holder elected to receive the stock consideration on a pro rata basis based on the amount of cash remaining to be paid, if any. The balance of the shares of Misonix common stock will receive 1.6839 shares of Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While the value of merger consideration to be received by a specific holder of Misonix common stock will depend on whether they elect to receive the cash consideration, elect to receive the stock consideration, or make no election, if all Misonix stockholders elect to receive the cash consideration (or if all Misonix stockholders elect to receive the stock consideration), each holder of Misonix common stock would receive, on an aggregate basis, $10.50 in cash and 1.0524 shares of Bioventus class A common stock for each share of Misonix common stock that they own. Based on the Bioventus class A common stock price of $ $16.63 per share, which is the average of the daily volume weighted average price per share for the seven consecutive trading day period up to and including July&#160;27, 2021, two trading days prior to the entry by Bioventus and Misonix into the merger agreement, the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders elect to receive the stock consideration), was $28.00 per share of Misonix common stock. On September&#160;1, 2021, the latest practicable trading day before the date of the filing of this joint proxy statement/prospectus, the closing price of Bioventus class A common stock on Nasdaq was $14.98 per share, resulting in the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders elect to receive the stock consideration), was $26.27 per share of Misonix common stock. The value of the merger consideration to Misonix stockholders will continue to fluctuate with the value of Bioventus class A common stock until the completion of the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix will each hold special meetings of their respective stockholders to vote on the proposals necessary to complete the mergers. Such special meetings are referred to as the &#8220;Bioventus special meeting&#8221; and the &#8220;Misonix special meeting,&#8221; respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the Bioventus special meeting, Bioventus stockholders will be asked to consider and vote on (i)&#160;a proposal to approve the issuance of shares of Bioventus class A common stock to Misonix stockholders in connection with the first merger, which proposal is referred to as the &#8220;Bioventus share issuance proposal,&#8221; and (ii)&#160;a proposal to adjourn the Bioventus special meeting to solicit additional proxies if there are insufficient votes to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Bioventus stockholders. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Bioventus board unanimously recommends that Bioventus stockholders vote &#8220;FOR&#8221; each of the proposals to be considered at the Bioventus special meeting.</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the Misonix special meeting, Misonix stockholders will be asked to consider and vote on (i)&#160;a proposal to adopt the merger agreement, which proposal is referred to as the &#8220;Misonix merger proposal,&#8221; (ii)&#160;a proposal to approve, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory basis, the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement and (iii)&#160;a proposal to adjourn the Misonix special meeting to solicit additional proxies, if necessary or appropriate, if there are insufficient votes to approve the Misonix merger proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Misonix stockholders. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Misonix board unanimously recommends that Misonix stockholders vote &#8220;FOR&#8221; each of the proposals to be considered at the Misonix special meeting.</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot complete the mergers unless the Bioventus share issuance proposal is approved by Bioventus stockholders and the Misonix merger proposal is approved by Misonix stockholders. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Your vote on these matters is very important, regardless of the number of shares you own. Whether or not you plan to attend your company&#8217;s respective special meeting, please vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to authorize the individuals named on your proxy card to vote your shares at the applicable special meeting.</div></div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying joint proxy statement/prospectus provides you with important information about the special meetings, the mergers and each of the proposals. We encourage you to read the entire document carefully, in particular the information under &#8220;<a href="#toc180330_10">Risk Factors</a>&#8221; beginning on page&#160;39 for a discussion of risks relevant to the mergers. </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We look forward to the successful completion of the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sincerely, </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ken Reali</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biovenuts Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stavros Vizirgianakis</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc.</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">* * * * * </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of the mergers, the adoption of the merger agreement, the Bioventus class A common stock to be issued in the first merger or any of the other transactions described in the accompanying joint proxy statement/prospectus or determined if the accompanying joint proxy statement/prospectus is accurate or complete. Any representation to the contrary is a criminal offense. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying joint proxy statement/prospectus is dated as of, and is first being mailed to Bioventus and Misonix stockholders on or about, [&#9679;], 2021. </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g03a11.jpg"/></div> </div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 400 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div> </div></div> <div id="toc180330_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TO BE HELD ON [</div></div>&#9679;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">], 2021 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Stockholders of Bioventus Inc.: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice is hereby given that Bioventus Inc., which is referred to as &#8220;Bioventus,&#8221; will hold a special meeting of its stockholders, which is referred to as the &#8220;Bioventus special meeting,&#8221; virtually via live webcast on [&#9679;], 2021, beginning at [&#9679;], Eastern Time. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In light of ongoing developments related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Bioventus special meeting will be held solely in a virtual meeting format via live webcast. You will be able to virtually attend and vote at the Bioventus special meeting by visiting www.virtualshareholdermeeting.com/BVS2021SM, which is referred to as the &#8220;Bioventus special meeting website.&#8221; </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus special meeting will be held for the purpose of Bioventus stockholders considering and voting on the following proposals: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to approve the issuance of shares of Bioventus class A common stock to the stockholders of Misonix, Inc., which is referred to as &#8220;Misonix,&#8221; in connection with the merger contemplated by the Agreement and Plan of Merger, dated July&#160;29, 2021, as it may be amended from time to time, which is referred to as the &#8220;merger agreement,&#8221; by and among Bioventus, Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, Oyster Merger Sub II, LLC, a wholly owned subsidiary of Bioventus and Misonix, which issuance is referred to as the &#8220;share issuance&#8221; and which proposal is referred to as the &#8220;Bioventus share issuance proposal&#8221;; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to approve the adjournment of the Bioventus special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Bioventus stockholders, which proposal is referred to as the &#8220;Bioventus adjournment proposal.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus will transact no other business at the Bioventus special meeting except such business as may properly be brought before the Bioventus special meeting or any adjournment or postponement thereof. The accompanying joint proxy statement/prospectus, including the merger agreement attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A</div> thereto, contains further information relating to these matters. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only holders of record of Bioventus common stock at the close of business on [&#9679;], 2021, the record date for voting at the Bioventus special meeting, which is referred to as the &#8220;Bioventus record date,&#8221; are entitled to notice of and to vote at the Bioventus special meeting and any adjournments or postponements thereof. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Bioventus board has unanimously determined that the terms of the merger agreement and the merger are fair to and in the best interests of Bioventus and its stockholders, and has approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accordingly, the Bioventus board unanimously recommends that Bioventus stockholders vote: </div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;FOR&#8221; the Bioventus share issuance proposal; and </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;FOR&#8221; the Bioventus adjournment proposal. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Your vote is very important, regardless of the number of shares of Bioventus common stock you own.</div></div> The parties cannot complete the merger unless the Bioventus share issuance proposal is approved by Bioventus stockholders. Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Your vote is important. Whether or not you plan to virtually attend the Bioventus special meeting, please vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to authorize the individuals named on your proxy card to vote your shares of Bioventus common stock at the Bioventus special meeting. If you hold your shares through a broker, bank or other nominee in &#8220;street name&#8221; (instead of as a registered holder) please follow the instructions on the voting instruction form provided by your bank, broker or nominee to vote your shares. The list of Bioventus stockholders entitled to vote at the Bioventus special meeting will be available at Bioventus&#8217; headquarters during regular business hours for examination by any Bioventus stockholder for any purpose germane to the Bioventus special meeting for a period of at least ten days prior to the Bioventus special meeting. If you would like to examine the list of Bioventus stockholders of record, please contact Bioventus&#8217; Corporate Secretary at tony.dadamio@bioventus.com.com to schedule an appointment or request access. If Bioventus&#8217; headquarters are closed for health and safety reasons related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic during such period, the list of stockholders will be made available for examination electronically upon request to Bioventus&#8217; Corporate Secretary, subject to satisfactory verification of stockholder status. The list of Bioventus stockholders entitled to vote at the Bioventus special meeting will also be available for examination by any Bioventus stockholder during the Bioventus special meeting via the Bioventus special meeting website. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If you have any questions about the transactions, please contact Bioventus at (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div> or write to Bioventus Inc., Attn: Corporate Secretary, at tony.dadamio@bioventus.com.com. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By Order of the Board of Directors, </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">William A. Hawkins III </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chairperson </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dated: [&#9679;], 2021 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g03b22.jpg" style="width: 287px; height: 45px;"/></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1938 New Highway </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, New York 11735 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(631) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">694-9555</div> </div></div> <div id="toc180330_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </div></div></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TO BE HELD ON [</div></div>&#9679;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">], 2021 </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Stockholders of Misonix, Inc.: </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice is hereby given that Misonix, Inc., which is referred to as &#8220;Misonix,&#8221; will hold a special meeting of its stockholders, which is referred to as the &#8220;Misonix special meeting,&#8221; at Misonix&#8217;s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on [&#9679;], 2021, beginning at [&#9679;], Eastern Time. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As part of Misonix&#8217;s precautions regarding the novel coronavirus or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> Misonix is planning for the possibility that the meeting may be held solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and details on how to participate, including details on how to inspect a list of stockholders of record, will be posted on our website at www.misonix.com and filed with the SEC as proxy material. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix special meeting will be held for the purpose of Misonix stockholders considering and voting on the following proposals: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">to adopt the Agreement and Plan of Merger, dated July&#160;29, 2021, as it may be amended from time to time, which is referred to as the &#8220;merger agreement,&#8221; by and among Bioventus Inc. (which is referred to as &#8220;Bioventus&#8221;), Oyster Merger Sub I, Inc., a wholly owned subsidiary of Bioventus, Oyster Merger Sub II, LLC, a wholly owned subsidiary of Bioventus, and Misonix, a copy of which is attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex A</div> to the accompanying joint proxy statement/prospectus and which proposal is referred to as the &#8220;Misonix merger proposal&#8221;; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">to approve, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory basis, the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement, which proposal is referred to as the &#8220;Misonix compensation proposal&#8221;; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">3.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to approve the adjournment of the Misonix special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Misonix special meeting to approve the Misonix merger proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Misonix stockholders, which proposal is referred to as the &#8220;Misonix adjournment proposal.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Misonix will transact no other business at the Misonix special meeting except such business as may properly be brought before the Misonix special meeting or any adjournment or postponement thereof. The accompanying joint proxy statement/prospectus, including the merger agreement attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A</div> thereto, contains further information relating to these matters. </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only holders of record of Misonix common stock at the close of business on [&#9679;], 2021, the record date for voting at the Misonix special meeting, which is referred to as the &#8220;Misonix record date,&#8221; are entitled to notice of and to vote at the Misonix special meeting and any adjournments or postponements thereof. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Misonix board has unanimously determined that the terms of the merger agreement and the merger are fair to and in the best interests of Misonix and its stockholders, and has approved and declared advisable the merger agreement and the transactions contemplated thereby, including the mergers. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accordingly, the Misonix board unanimously recommends that Misonix stockholders vote: </div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;FOR&#8221; the Misonix merger proposal; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;FOR&#8221; the Misonix compensation proposal; and </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;FOR&#8221; the Misonix adjournment proposal. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Your vote is very important, regardless of the number of shares of Misonix common stock you own.</div></div> The parties cannot complete the merger unless the Misonix merger proposal is approved by Misonix stockholders. Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Misonix common stock. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Your vote is important. Whether or not you plan to attend the Misonix special meeting, please vote your shares of Misonix common stock either electronically over the Internet, by telephone, or by completing and returning the accompanying proxy card. Voting instructions are provided in the accompanying joint proxy statement/prospectus and in the Notice of Internet Availability of Proxy Materials. By submitting your proxy promptly, you will save us the expense of further proxy solicitation. We encourage you to submit your proxy as soon as possible by Internet, by telephone or by signing, dating and returning the accompanying proxy cards provided. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you have any questions about the transactions, please contact Misonix at misonixproxy@misonix.com or write to Misonix, Inc., Attn: Secretary, at our principal executive offices at 1938 New Highway, Farmingdale, New York 11735. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If you have any questions about how to vote or direct a vote in respect of your shares of Misonix common stock, please contact, MacKenzie Partners, Inc., Misonix&#8217;s proxy solicitor, by telephone toll-free at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-800-322-2885,</div></div></div> Monday through Friday (except bank holidays), between 8:00 a.m. and 8:00 p.m., Eastern time, or by email at proxy@mackenziepartners.com. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By Order of the Board of Directors, </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Joseph P. Dwyer </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Secretary </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, New York </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dated: [&#9679;], 2021 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REFERENCES TO ADDITIONAL INFORMATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This joint proxy statement/prospectus incorporates important business and financial information about Bioventus and Misonix from other documents that Bioventus and Misonix have filed with the SEC and that are not contained in and are instead incorporated by reference in this joint proxy statement/prospectus. For a list of documents incorporated by reference in this joint proxy statement/prospectus, see &#8220;Where You Can Find More Information.&#8221; This information is available for you, without charge, to review through the SEC&#8217;s website at www.sec.gov. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You may request a copy of this joint proxy statement/prospectus, any of the documents incorporated by reference in this joint proxy statement/prospectus or other information filed with the SEC by Bioventus or Misonix, without charge, by written or telephonic request directed to the appropriate company at the following contacts: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 47%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">For Bioventus stockholders:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">For Misonix stockholders:</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Corporate Secretary</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tony.dadamio@bioventus.com</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">(919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Secretary</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">misonixproxy@misonix.com</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">(631) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">694-9555</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">In order for you to receive timely delivery of the documents in advance of the special meeting of Bioventus stockholders to be held on [</div></div>&#9679;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">], 2021, which is referred to as the &#8220;Bioventus special meeting,&#8221; or the special meeting of Misonix stockholders to be held on [</div></div>&#9679;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">], 2021, which is referred to as the &#8220;Misonix special meeting,&#8221; as applicable, you must request the information no later than [</div></div>&#9679;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">], 2021. </div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">If you have any questions about the Misonix special meeting, or need to obtain proxy cards or other information, please contact MacKenzie Partners, Inc., Misonix&#8217;s proxy solicitor, by telephone toll-free at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-800-322-2885,</div></div></div> or for banks and brokers, collect at (212) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">929-5500,</div> Monday through Friday (except bank holidays), between 8:00 a.m. and 8:00 p.m., Eastern time, or by email at proxy@mackenziepartners.com. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g10c33.jpg"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The contents of the websites of the SEC, Bioventus, Misonix or any other entity are not incorporated in this joint proxy statement/prospectus.</div></div> The information about how you can obtain certain documents that are incorporated by reference in this joint proxy statement/prospectus at these websites is being provided only for your convenience. </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ABOUT THIS JOINT PROXY STATEMENT/PROSPECTUS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This joint proxy statement/prospectus, which forms part of a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> filed with the SEC by Bioventus, constitutes a prospectus of Bioventus under Section&#160;5 of the Securities Act with respect to the shares of Bioventus class A common stock to be issued to Misonix stockholders pursuant to the Agreement and Plan of Merger, dated July&#160;29, 2021, as it may be amended from time to time, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix, which is referred to as the &#8220;merger agreement.&#8221; This document also constitutes a proxy statement of each of Bioventus and Misonix under Section&#160;14(a) of the Exchange Act. This joint proxy statement/prospectus also constitutes a notice of meeting with respect to each of the Bioventus and Misonix special meetings. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has supplied all information contained or incorporated by reference in this joint proxy statement/prospectus relating to Bioventus, Merger Sub I and Merger Sub II, and Misonix has supplied all such information relating to Misonix. Bioventus and Misonix have both contributed to such information relating to the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should rely only on the information contained or incorporated by reference in this joint proxy statement/prospectus. Bioventus and Misonix have not authorized anyone to provide you with information that is different from that contained or incorporated by reference in this joint proxy statement/prospectus. This joint proxy statement/prospectus is dated [&#9679;], 2021, and you should not assume that the information contained in this joint proxy statement/prospectus is accurate as of any date other than such date unless otherwise specifically provided herein. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, you should not assume that the information incorporated by reference in this joint proxy statement/prospectus is accurate as of any date other than the date of the incorporated document. Neither the mailing of this joint proxy statement/prospectus to Bioventus or Misonix stockholders nor the issuance by Bioventus of shares of Bioventus class A common stock pursuant to the merger agreement will create any implication to the contrary. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This joint proxy statement/prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction to or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless otherwise indicated or the context otherwise requires, when used in this joint proxy statement/prospectus: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus&#8221; refers to Bioventus Inc., a Delaware corporation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus adjournment proposal&#8221; refers to the proposal to approve the adjournment of the Bioventus special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Bioventus stockholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus board&#8221; refers to the board of directors of Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus class A common stock&#8221; refers to the Class&#160;A common stock, par value $0.001 per share, of Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus class B common stock&#8221; refers to the Class&#160;B common stock, par value $0.001 per share, of Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus common stock&#8221; refers Bioventus class A common stock and the Bioventus Class&#160;B common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus LLC agreement&#8221; refers to the Second Amended and Restated Limited Liability Company Agreement of Bioventus LLC dated as of February&#160;16, 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus record date&#8221; refers to [&#9679;], 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus share issuance proposal&#8221; refers to the proposal to approve the issuance of shares of Bioventus common stock to Misonix stockholders in connection with the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bioventus special meeting&#8221; refers to the special meeting of Bioventus stockholders to consider and vote upon the Bioventus share issuance proposal and the Bioventus adjournment proposal; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;BV LLC&#8221; refers to Bioventus LLC, a subsidiary of Bioventus Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;cash election consideration&#8221; refers to an amount of cash equal to $28.00, without interest, which reflects the amount of cash that Misonix stockholders will be entitled to receive in the first merger for each share of Misonix common stock held immediately prior to the effective time, if such stockholder elects the cash election consideration and subject to proration under the terms of the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Code&#8221; refers to the Internal Revenue Code of 1986, as amended; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;combined company&#8221; refers to Bioventus immediately following the completion of the merger and the other transactions contemplated by the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;DGCL&#8221; refers to the General Corporation Law of the State of Delaware; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;DLLCA&#8221; refers to the Limited Liability Company Act of the State of Delaware; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;effective time&#8221; refers to the date and time when the first merger becomes effective under the DGCL, which will be the date and time at which the certificate of merger with respect to the first merger is filed with the Secretary of State of the State of Delaware, or such later date and time as may be mutually agreed to in writing by Bioventus and Misonix and specified in such certificate of merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;end date&#8221; refers to January&#160;31, 2022, the date on which, subject to certain limitations in the merger agreement, the merger agreement may be terminated and the merger abandoned by either Bioventus or Misonix (which date will be automatically extended in certain circumstances related to the receipt of required regulatory approvals or the absence of restraints under certain competition laws to March&#160;31, 2022, pursuant to the terms of the merger agreement); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Exchange Act&#8221; refers to the Securities Exchange Act of 1934, as amended; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;first merger&#8221; refers to the merger of Merger Sub I with and into Misonix; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;former LLC owners&#8221; refers to certain members of BV LLC; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;GAAP&#8221; refers to U.S. generally accepted accounting principles; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;HSR Act&#8221; refers to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;J.P Morgan&#8221; refers to J.P. Morgan Securities LLC, financial advisor to Misonix in connection with the proposed mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;LLC interests&#8221; refers to single class of common membership interests in BV LLC; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;mergers&#8221; refers to the first merger and the second merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;merger agreement&#8221; refers to the Agreement and Plan of Merger, dated July&#160;29, 2021, as it may be amended from time to time, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;merger consideration&#8221; refers to the aggregate cash election consideration and stock election consideration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Merger Sub I&#8221; refers to Oyster Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Bioventus, formed for the purpose of effecting the first merger as described in this joint proxy statement/prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Merger Sub II&#8221; refers to Oyster Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Bioventus, formed for the purpose of effecting the second merger as described in this joint proxy statement/prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Misonix&#8221; refers to Misonix, Inc., a Delaware corporation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Misonix adjournment proposal&#8221; refers to the proposal to approve the adjournment of the Misonix special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at the time of the Misonix special meeting to approve the Misonix merger proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to Misonix stockholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Misonix board&#8221; refers to the board of directors of Misonix; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Misonix common stock&#8221; refers to the common stock, par value $0.0001 per share, of Misonix; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#8220;Misonix compensation proposal&#8221; refers to the proposal to approve, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory basis, the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Misonix merger proposal&#8221; refers to the proposal to adopt the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Misonix record date&#8221; refers to [&#9679;], 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Misonix special meeting&#8221; refers to the special meeting of Misonix stockholders to consider and vote upon the Misonix merger proposal and related matters; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Nasdaq&#8221; refers to the Nasdaq Global Select Market; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;original LLC owners&#8221; refers to the holders of BV LLC membership interests prior to the execution of the Bioventus LLC agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Perella Weinberg&#8221; refers to Perella Weinberg Partners L.P., financial advisor to Bioventus in connection with the proposed mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SEC&#8221; refers to the U.S. Securities and Exchange Commission; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;second effective time&#8221; refers to the date and time when the second merger becomes effective under the DGCL, which will be the date and time at which the certificate of merger with respect to the second merger is filed with the Secretary of State of the State of Delaware, or such later date and time as may be mutually agreed to in writing by Bioventus and Misonix and specified in such certificate of merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;second merger&#8221; refers to the merger of Misonix with and into Merger Sub II; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Securities Act&#8221; refers to the Securities Act of 1933, as amended; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;share issuance&#8221; refers to the issuance of shares of Bioventus class A common stock to Misonix stockholders in connection with the merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">&#8220;stock election consideration&#8221; refers to 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Bioventus class A common stock, which figure reflects the number of shares of Bioventus class A common stock that Misonix stockholders will be entitled to receive in the first merger for each share of Misonix common stock held immediately prior to the effective time if such stockholder elects the stock election consideration; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;stockholders agreement&#8221; refers to Stockholders Agreement, dated February&#160;16, 2021, by and among Bioventus Inc., Bioventus LLC and the principal stockholders named therein; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;TRA&#8221; refers to the Tax Receivable Agreement, dated as of February&#160;16, 2021, by and among Bioventus Inc., Bioventus LLC and the continuing LLC owner; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;transaction&#8221; refers to the transactions contemplated by the merger agreement including the mergers. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 96%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_6">QUESTIONS AND ANSWERS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_7">SUMMARY</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_8">MARKET PRICE AND DIVIDEND INFORMATION</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_9">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_10">RISK FACTORS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_11">THE PARTIES TO THE MERGER</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_12">THE BIOVENTUS SPECIAL MEETING</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_13">BIOVENTUS PROPOSAL 1: APPROVAL OF THE SHARE ISSUANCE</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_14">BIOVENTUS PROPOSAL 2: ADJOURNMENT OF THE BIOVENTUS SPECIAL MEETING</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_15">THE MISONIX SPECIAL MEETING</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_16">MISONIX PROPOSAL 1: ADOPTION OF THE MERGER AGREEMENT</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><a href="#toc180330_17">MISONIX PROPOSAL 2: ADVISORY <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-BINDING</span> VOTE ON MERGER-RELATED COMPENSATION FOR NAMED EXECUTIVE OFFICERS</a></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_18">MISONIX PROPOSAL 3: ADJOURNMENT OF THE MISONIX SPECIAL MEETING</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_19">THE MERGER</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_20">THE MERGER AGREEMENT</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_21">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_22">DESCRIPTION OF BIOVENTUS&#8217; BUSINESS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_23">BIOVENTUS&#8217; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">294</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_24">BIOVENTUS DIRECTOR AND OFFICER COMPENSATION</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_25">SECURITIES AUTHORIZED FOR ISSUANCE UNDER BIOVENTUS&#8217; EQUITY COMPENSATION PLANS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_26">INTERESTS OF BIOVENTUS DIRECTORS AND EXECUTIVE OFFICERS IN THE MERGER</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_27">INTERESTS OF MISONIX DIRECTORS AND EXECUTIVE OFFICERS IN THE MERGERS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_28">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE FIRST MERGER AND THE SECOND MERGER</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_29">COMPARISON OF STOCKHOLDERS&#8217; RIGHTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_30">APPRAISAL RIGHTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_31">LEGAL MATTERS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_32">EXPERTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">368</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_33">CERTAIN BENEFICIAL OWNERS OF BIOVENTUS COMMON STOCK</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_34">CERTAIN BENEFICIAL OWNERS OF MISONIX COMMON STOCK</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">372</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_35">STOCKHOLDER PROPOSALS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_36">HOUSEHOLDING OF PROXY MATERIALS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">375</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_37">WHERE YOU CAN FIND MORE INFORMATION</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">376</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_38">INDEX TO BIOVENTUS INC. FINANCIAL STATEMENTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_39">PART II: INFORMATION NOT REQUIRED IN PROSPECTUS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">II-1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_40">Annex A&#8212;Merger Agreement</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_41">Annex B&#8212;Opinion of Perella Weinberg Partners L.P.</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_42">Annex C&#8212;Opinion of J.P. Morgan Securities LLC</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc180330_43">Annex D&#8212;Appraisal Rights</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QUESTIONS AND ANSWERS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following are brief answers to certain questions that you, as a Bioventus stockholder or Misonix stockholder, may have regarding the mergers and the other matters being considered at the Bioventus and Misonix special meetings, as applicable. You are urged to carefully read this joint proxy statement/prospectus and the other documents referred to in this joint proxy statement/prospectus in their entirety because this section may not provide all the information that is important to you regarding these matters. See &#8220;Summary&#8221; for a summary of important information regarding the merger agreement, the mergers and the related transactions. Additional important information is contained in the annexes to, and the documents incorporated by reference in, this joint proxy statement/prospectus. You may obtain the information incorporated by reference in this joint proxy statement/prospectus, without charge, by following the instructions under &#8220;Where You Can Find More Information.&#8221; </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Why am I receiving this joint proxy statement/prospectus? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">You are receiving this joint proxy statement/prospectus because Misonix has agreed to be acquired by Bioventus through a merger of Merger Sub I with and into Misonix with Misonix continuing as the surviving corporation, and immediately following, a merger of Misonix with and into Merger Sub II, with Merger Sub II continuing as the surviving entity in the merger and a wholly owned subsidiary of Bioventus. The merger agreement, which governs the terms and conditions of the mergers, is attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex A</div> hereto. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Your vote is required in connection with the mergers. Bioventus and Misonix are sending these materials to their respective stockholders to help them decide how to vote their shares at the Bioventus special meeting and Misonix special meeting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What matters am I being asked to vote on? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to complete the mergers, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus stockholders must approve the Bioventus share issuance proposal; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix stockholders must approve the Misonix merger proposal. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus</div></div>: Bioventus is holding the Bioventus special meeting to obtain approval of the Bioventus share issuance proposal and the Bioventus adjournment proposal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix</div></div>: Misonix is holding the Misonix special meeting to obtain approval of the Misonix merger proposal. At the Misonix special meeting, Misonix stockholders will also be asked to consider and vote on the Misonix compensation proposal and the Misonix adjournment proposal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Your vote is very important, regardless of the number of shares that you own. The approval of the Bioventus share issuance proposal and the Misonix merger proposal are conditions to the obligations of Bioventus and Misonix to complete the mergers. The approval of the Bioventus adjournment proposal, the Misonix compensation proposal and the Misonix adjournment proposal are not conditions to the obligations of Bioventus or Misonix to complete the mergers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When and where will each of the special meetings take place? </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus</div></div>: The Bioventus special meeting will be held solely virtually via live webcast on [&#9679;], 2021, beginning at [&#9679;], Eastern Time. Bioventus stockholders will be able to virtually attend and vote at the Bioventus special meeting by visiting www.virtualshareholdermeeting.com/BVS2021SM, which is referred to as the &#8220;Bioventus special meeting website.&#8221; In order to virtually attend and vote at the Bioventus special meeting, you will need the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16-digit</div> control number located on your proxy card. Bioventus has retained Broadridge Financial Solutions, </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">which is referred to as &#8220;Broadridge,&#8221; to host the live webcast of the Bioventus special meeting. Thirty minutes prior to the Bioventus special meeting, Broadridge may be contacted at (855) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">499-0991</div> (U.S. toll-free) or (720) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">378-5962</div> (international toll), and will be available to answer any questions regarding how to virtually attend the Bioventus special meeting or if you encounter any technical difficulty accessing or during the Bioventus special meeting. Technical support phone numbers will also be available via the virtual meeting url 30 minutes prior to the start of the meeting. See &#8220;The Bioventus Special Meeting&#8212;Virtually Attending the Bioventus Special Meeting.&#8221; </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix</div></div>: The Misonix special meeting will be held at Misonix&#8217;s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on [&#9679;], 2021, beginning at [&#9679;], Eastern Time. As part of Misonix&#8217;s precautions regarding the novel coronavirus or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> Misonix is planning for the possibility that the meeting may be held solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and details on how to participate, including details on how to inspect a list of stockholders of record, will be posted on our website at www.misonix.com and filed with the SEC as proxy material. </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if you plan to attend your respective company&#8217;s special meeting, Bioventus and Misonix recommend that you vote by proxy in advance as described below so that your vote will be counted if you later decide not to or become unable to attend the applicable special meeting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you hold your shares in &#8220;street name,&#8221; you may attend and vote at your respective company&#8217;s special meeting only if you obtain a specific control number from your bank, broker or other nominee giving you the right to vote such shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Does my vote matter? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yes, your vote is very important, regardless of the number of shares that you own. The mergers cannot be completed unless the Bioventus share issuance proposal is approved by Bioventus stockholders and the Misonix merger proposal is approved by Misonix stockholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus Share Issuance Proposal. </div></div>Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of a Bioventus stockholder who holds shares of Bioventus common stock in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention, or other failure of any shares of Bioventus common stock virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal, will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if a Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus Adjournment Proposal. </div></div>Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bioventus adjournment proposal. An abstention or other failure of any shares of Bioventus common stock virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal to vote on the Bioventus adjournment proposal, will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus adjournment proposal. However, if a Bioventus stockholder who holds shares of Bioventus common stock in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix merger proposal</div></div>. Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proxy card. Brokerage firms and nominees will not have the authority to vote their customers&#8217; unvoted shares on the Misonix merger proposal or to vote their customers&#8217; shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares of Misonix common stock in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the Misonix merger proposal, will each have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Misonix merger proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix compensation proposal</div></div>. Assuming a quorum is present at the Misonix special meeting, approval of the Misonix compensation proposal requires the affirmative vote of the holders of a majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting. For the Misonix compensation proposal, a Misonix stockholder may indicate &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation proposal, only those votes cast &#8220;FOR&#8221; or &#8220;AGAINST&#8221; are included. Brokerage firms and nominees will not have the authority to vote their customers&#8217; unvoted shares on the Misonix compensation proposal or to vote their customers&#8217; shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Abstentions and broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes</div> are counted only for purposes of determining whether a quorum is present at the meeting and therefore will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of the mergers, and the vote with respect to this proposal is advisory only and will not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation may be paid to Misonix&#8217;s named executive officers to the extent payable in accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding,</div> advisory vote, the Misonix compensation proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix adjournment proposal.</div></div> Whether or not a quorum is present at the Misonix special meeting, approval of the Misonix adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the shares of Misonix common stock present or represented by proxy at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. An abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Misonix adjournment proposal. However, if a Misonix stockholder who holds shares of Misonix common stock in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix adjournment proposal, voting power will deemed to be withheld with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What will Misonix stockholders receive for their shares of Misonix common stock if the mergers are completed? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If the mergers are completed, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus, Merger Sub I or Merger Sub II, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Bioventus class A common stock, based on the election of the holder thereof and, in each case, subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described under &#8220;The Merger Agreement&#8212;The Mergers; Merger Consideration&#8212;Proration and Reallocation&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What is the value of the merger consideration payable to holders of Misonix common stock? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exchange ratio of 1.6839 shares of Bioventus class A common stock is fixed and will not be adjusted for changes in the market price of either Bioventus class A common stock or Misonix common stock between the date of signing of the merger agreement and the completion date of the first merger. As such, the market value of the merger consideration payable to Misonix stockholders will fluctuate with the market price of the Bioventus class A common stock and will not be known at the time that Misonix stockholders vote on the Misonix merger proposal. Upon completion of the mergers, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the mergers are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Bioventus class A common stock is traded on the Nasdaq Global Select Market, which is referred to as &#8220;Nasdaq,&#8221; under the symbol &#8220;BVS.&#8221; Misonix common stock is traded on Nasdaq under the symbol &#8220;MSON.&#8221; We encourage you to obtain current quotes for both the Bioventus class A common stock and the Misonix common stock before voting at the Misonix special meeting. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While the value of merger consideration to be received by a specific holder of Misonix common stock will depend on whether they elect to receive the cash consideration, elect to receive the stock consideration, or make no election, if all Misonix stockholders elect to receive the cash consideration (or if all Misonix stockholders elect to receive the stock consideration), each holder of Misonix common stock would receive, on an aggregate basis, $10.50 in cash and 1.0524 shares of Bioventus class A common stock for each share of Misonix common stock that they own. Based on the Bioventus class A common stock price of $16.63 per share, which is the average of the daily volume weighted average price per share for the seven consecutive trading day period up to and including July&#160;27, 2021, two trading days prior to the entry by Bioventus and Misonix into the merger agreement, the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders elect to receive the stock consideration), was $28.00 per share of Misonix common stock. On September&#160;1, 2021, the latest practicable trading day before the date of the filing of this joint proxy statement/prospectus, the closing price of Bioventus class A common stock on the Nasdaq was $14.98 per share, resulting in the implied value of the merger consideration to Misonix stockholders (assuming all Misonix stockholders elect to receive the cash consideration or all Misonix stockholders elect to receive the stock consideration), was $26.27 per share of Misonix common stock. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How do I elect the type of merger consideration I prefer to receive? </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Not less than 30 days prior to the anticipated closing date of the first merger, letter of election and transmittal will be mailed to each Misonix stockholder that is a holder of record as of five business days prior to the mailing date. To elect to receive the cash consideration, the stock consideration or a combination of the two, you must indicate on the letter of election and transmittal the number of shares of Misonix common stock with respect to which you elect to receive the cash consideration, the number of shares of Misonix common stock with respect to which you elect to receive the stock consideration and the number of shares of Misonix common stock with respect to which you make no election. Misonix intends to issue a press release at least five business days prior to the expiration of the election period informing Misonix, stockholders of the expiration of the election period, which expiration we refer to as the &#8220;election deadline.&#8221; You must return the letter of election and transmittal in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-addressed,</div> return envelope provided so that it is received no later than 5:00&#160;p.m. (New York City time) on the election deadline for your election to be properly submitted. </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you hold shares of Misonix common stock in &#8220;street name&#8221;, you should receive instructions from the bank, brokerage firm or other nominee that is holding your shares advising you of the procedures for making your election. If these instructions are not received, you should contact the bank, brokerage firm or other nominee holding your shares of Misonix common stock as soon as possible. Election forms must be returned to the broker, bank or nominee in time for it to respond prior to the election deadline, therefore, you are encouraged to pay close attention to, and abide by, any election deadlines provided by the bank, brokerage firm or other nominee holding your shares, as that deadline may be earlier than the election deadline described in this joint proxy statement/prospectus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Can I make one election for some of my shares of Misonix common stock and another election for the rest? </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yes. The letter of election and transmittal permits you to specify, among the shares of Misonix common stock you hold, (i)&#160;the number of shares of Misonix common stock for which you are electing to receive the cash consideration of $28.00 per share, (ii)&#160;the number of shares of Misonix common stock for which you are electing to receive the stock consideration of 1.6839 shares of Bioventus class A common stock, or (iii)&#160;the number of shares of Misonix common stock for which you make no election. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What if I do not make an election or my letter of election and transmittal is not received before the election deadline? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you do not submit a properly completed and signed letter of election and transmittal to the exchange agent by the election deadline (or if you submit a properly completed letter of election and transmittal indicating no election), then you will be deemed to have made no election and will therefore receive the cash consideration or the stock consideration or a combination of both, depending on the elections made by other Misonix stockholders (as described in the section entitled &#8220;The Merger Agreement&#8212;The Mergers; Effects of the Mergers&#8212;Proration and Reallocation&#8221; of this joint proxy statement/prospectus), except with respect to shares as to which you have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Can I change my election after I submit a letter of election and transmittal? </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yes. You may revoke your election of the form of merger consideration you will receive with respect to all or a portion of your shares of Misonix common stock by delivering written notice of your revocation to the exchange </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agent prior to the election deadline. If you instructed a bank, brokerage firm or other nominee to submit an election for your shares, you must follow its directions for changing those instructions, as the deadline to revoke your election may be earlier than the election deadline described in this joint proxy statement/prospectus. In addition, any election of merger consideration you make will automatically be revoked if the merger agreement is terminated. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix stockholders will not be entitled to revoke or change their election following the election deadline. For Misonix stockholders who hold shares in &#8220;street name&#8221;, the election deadline provided by the bank, brokerage firm or other nominee holding your shares may be earlier than the election deadline described in this joint proxy statement/prospectus. As a result, if you make an election, you will be unable to revoke your election or sell your shares of Misonix common stock after the applicable election deadline unless the merger agreement is terminated. </div></div> <div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">May I submit a letter of election and transmittal even if I vote against the Misonix merger proposal? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yes. You should submit a letter of election and transmittal even if you vote against the Misonix merger proposal. </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">May I transfer my shares of Misonix common stock once I have made an election? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yes you may transfer your shares prior to the election deadline, however, for Misonix stockholders who have made an election, any further transfer of shares made on the stock transfer books of Misonix will be deemed to be a revocation of their election. Furthermore, you will not be able to transfer your shares of Misonix common stock after the election deadline unless the merger agreement is terminated. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What happens if I am eligible to receive a fraction of a share of Bioventus class A common stock as part of the merger consideration? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the aggregate number of shares of Bioventus class A common stock, if any, that you are entitled to receive as merger consideration includes a fraction of a share of Bioventus class A common stock, you will receive cash in lieu of that fractional share. See the section entitled &#8220;The Merger Agreement&#8212;Fractional Shares&#8221; of this joint proxy statement/prospectus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What will holders of Misonix equity compensation awards receive in the mergers? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Each outstanding Misonix stock option held by employees and directors of Misonix who meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> definition of &#8220;employee&#8221; shall (i)&#160;become fully vested immediately upon the effective time and (ii)&#160;be assumed by Bioventus and converted automatically into an option to purchase Bioventus Class&#160;A Common Stock based on the option exchange ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). Aside from the foregoing adjustments, the assumed options will generally remain subject to the same vesting and other terms and conditions that applied to such awards immediately prior to the effective time. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each outstanding Misonix stock option held by an individual who does not meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> definition of &#8220;employee&#8221; will become fully vested and be settled in cash immediately prior to the effective time in an amount equal to the product of (x)&#160;the number of shares of Misonix common stock subject to the applicable option and (y)&#160;the excess, if any, of (i)&#160;the average of the volume-weighted average trading price per share of Bioventus Class&#160;A Common Stock on Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii)&#160;the per share exercise price of such option. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See the section entitled &#8220;The Merger Agreement&#8212;Treatment of Misonix Equity Awards&#8221; of this joint proxy statement/prospectus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How will the mergers be financed? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus expects to fund the aggregate cash consideration upon completion of the mergers with cash on hand, together with the proceeds of senior secured term loans in an aggregate principal amount of approximately $262.0 to be incurred initially by Merger Sub I. The receipt of financing by Bioventus is not a condition to completion of the mergers and, accordingly, Bioventus will be required to complete the mergers (assuming that all of the conditions to its obligations under the merger agreement are satisfied) whether or not debt financing is available at all or on acceptable terms. See the section entitled &#8220;Financing of the Mergers&#8221; of this joint proxy statement/prospectus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How does the Bioventus board recommend that I vote at the Bioventus special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Bioventus board unanimously recommends that you vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus share issuance proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus adjournment proposal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than with respect to continued service for, employment by and the right to continued indemnification by the combined company, as of the date of this joint proxy statement/prospectus, Bioventus directors and executive officers do not have interests in the merger that are different from, or in addition to, the interests of other Bioventus stockholders generally. See &#8220;Interests of Bioventus Directors and Executive Officers in the Merger.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How does the Misonix board recommend that I vote at the Misonix special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Misonix board unanimously recommends that you vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix merger proposal, &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix compensation proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix adjournment proposal. For a description of some of the factors considered by the Misonix board in reaching its decision to approve the merger agreement and the transactions contemplated thereby, including the merger, and additional information on the recommendation of the Misonix board, see &#8220;The Merger&#8212;Recommendation of the Misonix Board of Directors; Misonix&#8217;s Reasons for the Merger.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Who is entitled to vote at each special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All holders of record of shares of Bioventus common stock who held shares at the close of business on [&#9679;], 2021 (the Bioventus record date) are entitled to receive notice of, and to vote at, the Bioventus special meeting. Each such holder of Bioventus common stock is entitled to cast one vote on each matter properly brought before the Bioventus special meeting for each share of Bioventus common stock that such holder owned of record as of the Bioventus record date. Virtual attendance at the Bioventus special meeting via the Bioventus special meeting website is not required to vote. See below and &#8220;The Bioventus Special Meeting&#8212;Methods of Voting&#8221; for instructions on how to vote without virtually attending the Bioventus special meeting. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All holders of record of shares of Misonix common stock who held shares at the close of business on [&#9679;], 2021 (the Misonix record date) are entitled to receive notice of, and to vote at, the Misonix special meeting. Each such holder of Misonix common stock is entitled to cast one vote on each matter properly brought before the Misonix special meeting for each share of Misonix common stock that such holder owned of record as of the Misonix record date. Physical attendance at the Misonix special meeting is not required to vote. See below and &#8220;The Misonix Special Meeting&#8212;Methods of Voting&#8221; for instructions on how to vote without attending the Misonix special meeting. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What is a proxy? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A proxy is a stockholder&#8217;s legal designation of another person to vote shares owned by such stockholder on their behalf. The document used to designate a proxy to vote your shares of Bioventus or Misonix common stock, as applicable, is referred to as a &#8220;proxy card.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How many votes do I have at each special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Bioventus stockholder is entitled to one vote for each share of Bioventus common stock held of record as of the close of business on the Bioventus record date. As of the close of business on the Bioventus record date, there were [&#9679;] shares of Bioventus common stock outstanding. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Misonix stockholder is entitled to one vote for each share of Misonix common stock held of record as of the close of business on the Misonix record date. As of the close of business on the Misonix record date, there were [&#9679;] shares of Misonix common stock outstanding. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What constitutes a quorum for each special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A quorum is the minimum number of shares required to be represented, either through virtual attendance or through representation by proxy, to hold a valid meeting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of a majority of in voting power of the stock issued and outstanding and entitled to vote at the meeting, must be present in person, or by remote communication, if applicable, or represented by proxy to constitute a quorum. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of a majority in voting power of the shares of stock issued and outstanding and entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Where will the Bioventus common stock that I receive in the merger be publicly traded? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of Bioventus class A common stock to be issued to Misonix stockholders in the merger will be listed for trading on Nasdaq under the symbol &#8220;BVS.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What happens if the merger is not completed? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Bioventus share issuance proposal is not approved by Bioventus stockholders, if the Misonix merger proposal is not approved by Misonix stockholders or if the mergers are not completed for any other reason, Misonix stockholders will not receive the merger consideration or any other consideration in connection with the mergers, and their shares of Misonix common stock will remain outstanding. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the mergers are not completed, Misonix will remain an independent public company, the Misonix common stock will continue to be listed and traded on Nasdaq under the symbol &#8220;MSON&#8221; and Bioventus will not complete the share issuance contemplated by the merger agreement, regardless of whether the Bioventus share issuance proposal has been approved by Bioventus stockholders. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the merger agreement, Bioventus and Misonix will each be required to pay a termination fee of $20,661,000 to the other party if the merger agreement is terminated in certain circumstances, including if the respective party&#8217;s board changes its recommendation in connection with the mergers and the other party terminates the merger agreement. Additionally, Misonix may terminate the merger agreement if it enters into an alternative acquisition agreement with respect to a superior proposal and pays Bioventus the termination fee. See &#8220;The Merger Agreement&#8212;Termination Fee.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How can I vote my shares at my respective special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Shares held directly in your name as a Bioventus stockholder of record may be virtually voted at the Bioventus special meeting via the Bioventus special meeting website. You will need the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16-digit</div> control number included on your proxy card in order to access and vote via the Bioventus special meeting website as described under &#8220;The Bioventus Special Meeting&#8212;Virtually Attending the Bioventus Special Meeting.&#8221; </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares held in &#8220;street name&#8221; may be virtually voted at the Bioventus special meeting via the Bioventus special meeting website only if you obtain a specific control number and follow the instructions provided by your bank, broker or other nominee. See &#8220;The Bioventus Special Meeting&#8212;Virtually Attending the Bioventus Special Meeting.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You may vote by attending the Misonix special meeting and voting in person or by submitting a proxy. The method of voting by proxy differs (i)&#160;depending on whether you are viewing this proxy statement on the Internet or submitting a paper copy and (ii)&#160;for shares of Misonix common stock held as a record holder and shares held in &#8220;street name.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If you hold your shares of Misonix common stock as a record holder and you are viewing this joint proxy statement/prospectus on the Internet, you may submit a proxy over the Internet by following the instructions on the proxy card that was included with this joint proxy statement/prospectus. If you hold your shares of Misonix common stock as a record holder and you are reviewing a paper copy of this joint proxy statement/prospectus, you may submit a proxy over the Internet or by telephone by following the instructions on the proxy card, or by completing, dating and signing the proxy card that was included with this joint proxy statement/prospectus and promptly returning it in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-addressed,</div> postage-paid envelope provided to you. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Street name&#8221; holders generally cannot submit a proxy or vote their shares directly and must instead instruct the broker, bank, trust or other nominee how to vote their shares using the methods described below. If you hold your shares of Misonix common stock in street name, you will receive a notice from your broker, bank, trust or other nominee that includes instructions on how to vote your shares. Your broker, bank, trust or other nominee may allow you to deliver your voting instructions over the Internet and may also permit you to submit your voting instructions by telephone. In addition, you may request paper copies of this proxy statement and accompanying proxy card from your broker by following the instructions on the notice provided by your broker, bank, trust or other nominee. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For additional information on virtually attending the special meetings, see &#8220;The Bioventus Special Meeting&#8221; and &#8220;The Misonix Special Meeting.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How can I vote my shares without attending my company&#8217;s special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether you hold your shares directly as a stockholder of record of Bioventus or Misonix or beneficially in &#8220;street name,&#8221; you may direct your vote by proxy without attending the Bioventus or Misonix special meeting, as applicable. If you are a stockholder of record, you can vote by proxy over the internet, by telephone or by mail by </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">following the instructions provided in the enclosed proxy card. If you hold shares beneficially in &#8220;street name,&#8221; you should follow the voting instructions provided by your bank, broker or other nominee. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For additional information on voting procedures, see &#8220;The Bioventus Special Meeting&#8221; and &#8220;The Misonix Special Meeting.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">What is a &#8220;broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vote&#8221;?</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under Nasdaq rules, banks, brokers and other nominees may use their discretion to vote &#8220;uninstructed&#8221; shares (i.e., shares of record held by banks, brokers or other nominees, but with respect to which the beneficial owner of such shares has not provided instructions on how to vote on a particular proposal) with respect to matters that are considered to be &#8220;routine,&#8221; but not with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matters. All of the proposals currently expected to be brought before the Bioventus and Misonix special meetings are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matters under Nasdaq rules. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A &#8220;broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vote&#8221;</div> occurs on an item when (i)&#160;a bank, broker or other nominee has discretionary authority to vote on one or more proposals to be voted on at a meeting of stockholders, but is not permitted to vote on other proposals without instructions from the beneficial owner of the shares, and (ii)&#160;the beneficial owner fails to provide the bank, broker or other nominee with such instructions. Because all of the proposals currently expected to be voted on at the Bioventus and Misonix special meetings are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-routine</div> matters under Nasdaq rules for which brokers do not have discretionary authority to vote, Bioventus and Misonix do not expect there to be any broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes</div> at the Bioventus or Misonix special meetings. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Are there any Misonix stockholders already committed to vote in favor of the Misonix merger proposal and Misonix compensation proposal? Are there any Bioventus stockholders already committed to vote in favor of the Bioventus share issuance proposal? </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus:</div></div> Yes. Subsequent to the execution of the merger agreement, Misonix entered into a voting agreement (the &#8220;Bioventus support agreement&#8221;) with EW Healthcare Partners Acquisition Fund, L.P., White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.), Smith&#160;&amp; Nephew, Inc., Smith&#160;&amp; Nephew USD Ltd and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AMP-CF</div> Holdings, LLC (together, the &#8220;Bioventus supporting stockholders&#8221;), pursuant to which such stockholders have agreed, among other things, to vote the shares of Bioventus common stock that they beneficially own at the time such vote is taken in favor of Bioventus share issuance proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Bioventus special meeting, such stockholders beneficially own approximately [&#9679;]% of the outstanding shares of Bioventus common stock. Therefore, the Bioventus supporting stockholders hold a sufficient number of shares of Bioventus common stock in order to approve the Bioventus share issuance proposal. On July&#160;29, 2021, in connection with execution of the merger agreement, each of the Bioventus supporting stockholders have entered into lock up agreements with Bioventus (each a &#8220;lock up agreement&#8221;) restricting the sale and transfer of the capital stock of Bioventus for a period of 90 or 180 days, subject to the terms of the lock up agreement. </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix: </div></div>Yes. Subsequent to the execution of the merger agreement, Bioventus entered into a voting agreement (the &#8220;Misonix support agreement&#8221;) with each of Stavros G. Vizirgianakis, 1315 Capital, LLC, SV Life Sciences Fund VI Strategic Partners, L.P. and SV Life Sciences Fund VI, L.P. (together, the &#8220;Misonix supporting stockholders&#8221;), pursuant to which such stockholders have agreed, among other things, to vote the shares of Misonix common stock that they own at the time such vote is taken in favor of the Misonix merger proposal and Misonix compensation proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Misonix special meeting, the Misonix supporting stockholders beneficially own approximately [&#9679;]% of the outstanding shares of Misonix common stock. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What stockholder vote is required for the approval of each proposal at the Bioventus special meeting? What will happen if I fail to vote or abstain from voting on each proposal at the Bioventus special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus Proposal 1: Bioventus Share Issuance Proposal </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if a Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus Proposal 2: Bioventus Adjournment Proposal </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of a Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal to vote on the Bioventus adjournment proposal will have the same effect as a vote &#8220;AGAINST&#8221; the Bioventus adjournment proposal. However, if a Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What stockholder vote is required for the approval of each proposal at the Misonix special meeting? What will happen if I fail to vote or abstain from voting on each proposal at the Misonix special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Proposal 1: Misonix Merger Proposal </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proxy card. Brokerage firms and nominees will not have the authority to vote their customers&#8217; unvoted shares on the Misonix merger proposal or to vote their customers&#8217; shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares of Misonix common stock in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the Misonix merger proposal, will each have the same effect as a vote <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8220;AGAINST&#8221;</div></div> the Misonix merger proposal. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Proposal 2: Misonix Compensation Proposal </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Assuming a quorum is present at the Misonix special meeting, approval of the Misonix compensation proposal requires the affirmative vote of the holders of a majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting. For the Misonix compensation proposal, a Misonix stockholder may indicate &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation proposal, only those votes cast &#8220;FOR&#8221; or &#8220;AGAINST&#8221; are included. Brokerage firms and nominees will not have the authority to vote their customers&#8217; unvoted shares on the Misonix compensation proposal or to vote their customers&#8217; shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Abstentions and broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes</div> are counted only for purposes of determining whether a quorum is present at the meeting and therefore will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of the mergers, and the vote with respect to this proposal is advisory only and will not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation may be paid to Misonix&#8217;s named executive officers to the extent payable in accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding,</div> advisory vote, the Misonix compensation proposal.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Proposal 3: Misonix Adjournment Proposal </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Whether or not a quorum is present at the Misonix special meeting, approval of the Misonix adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the shares of Misonix common stock present or represented by proxy at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. An abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Misonix adjournment proposal. However, if a Misonix stockholder who holds shares of Misonix common stock in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix adjournment proposal, voting power will deemed to be withheld with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment proposal. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Why am I being asked to consider and vote on a proposal to approve, by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory vote, the merger-related compensation for named executive officers (the Misonix compensation proposal)? </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under SEC rules, Misonix is required to seek a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory vote of its stockholders relating to the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the merger (also known as &#8220;golden parachute&#8221; compensation). </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">What happens if Misonix stockholders do not approve, by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory vote, the merger-related compensation for Misonix named executive officers (the Misonix compensation proposal)? </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because the vote on the proposal to approve the Misonix compensation proposal is advisory in nature, the outcome of the vote will not be binding upon Misonix or the combined company. Accordingly, the merger-related compensation, which is described under &#8220;Interests of Misonix Directors and Executive Officers in the Merger,&#8221; may be paid to Misonix named executive officers even if Misonix stockholders do not approve the Misonix compensation proposal. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What if I hold shares of both Bioventus and Misonix common stock? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If you are both a Bioventus stockholder and a Misonix stockholder, you will receive two separate packages of proxy materials. A vote cast as a Bioventus stockholder will not count as a vote cast as a Misonix stockholder, and a vote cast as a Misonix stockholder will not count as a vote cast as a Bioventus stockholder. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Therefore, please follow the instructions received with each set of materials you receive in order to submit separate proxies for your shares of Bioventus common stock and your shares of Misonix common stock.</div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What is the difference between holding shares as a stockholder of record and as a beneficial owner of shares held in &#8220;street name&#8221;? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If your shares of Bioventus or Misonix common stock are registered directly in your name with the transfer agent of Bioventus and Misonix, respectively, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to vote directly at the applicable special meeting. You may also grant a proxy directly to Bioventus or Misonix, as applicable, or to a third party to vote your shares at the applicable special meeting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If your shares of Bioventus or Misonix common stock are held by a bank, broker or other nominee, you are considered the beneficial owner of shares held in &#8220;street name.&#8221; Your bank, broker or other nominee will send you, as the beneficial owner, a package describing the procedures for voting your shares. You should follow the instructions provided by them to vote your shares. In order to attend and vote at the Bioventus special meeting via the Bioventus special meeting website or the Misonix special meeting in person, you will need to obtain a specific control number and follow the other procedures provided by your bank, broker or other nominee. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If my shares of Bioventus or Misonix common stock are held in &#8220;street name&#8221; by my bank, broker or other nominee, will my bank, broker or other nominee automatically vote those shares for me? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">No. Your bank, broker or other nominee will only be permitted to vote your shares of Bioventus or Misonix common stock, as applicable, if you instruct your bank, broker or other nominee how to vote. You should follow the procedures provided by your bank, broker or other nominee regarding the voting of your shares. Under Nasdaq rules, banks, brokers and other nominees who hold shares of Bioventus or Misonix common stock in &#8220;street name&#8221; for their customers have authority to vote on &#8220;routine&#8221; proposals when they have not received instructions from beneficial owners. However, banks, brokers and other nominees are prohibited from exercising their voting discretion with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-routine</div> matters, which include all the proposals currently scheduled to be considered and voted on at the Bioventus and Misonix special meetings. As a result, absent specific instructions from the beneficial owner of such shares, banks, brokers and other nominees are not empowered to vote such shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Bioventus stockholders, the effect of not instructing your bank, broker or other nominee how you wish to vote your shares of Bioventus common stock will have no effect on the Bioventus share issuance proposal or the Bioventus adjournment proposal (assuming a quorum is present at the Bioventus special meeting). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For Misonix stockholders, the effect of not instructing your bank, broker or other nominee how you wish to vote your shares of Misonix common stock will be the same as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Misonix merger proposal, but will have no effect on the Misonix compensation proposal (assuming a quorum is present at the Misonix special meeting) or the Misonix adjournment proposal. In addition, if a Misonix stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix compensation proposal or the Misonix adjournment proposal, it will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; such proposal. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What should I do if I receive more than one set of voting materials for the same special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you hold shares of Bioventus or Misonix common stock in &#8220;street name&#8221; and also directly in your name as a stockholder of record or otherwise, or if you hold shares of Bioventus or Misonix common stock in more than one brokerage account, you may receive more than one set of voting materials relating to the same special meeting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Record Holders</div></div>. For shares held directly, please vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, in order to ensure that all of your shares of Bioventus or Misonix common stock are voted. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shares in &#8220;street name.&#8221; </div></div>For shares held in &#8220;street name&#8221; through a bank, broker or other nominee, you should follow the procedures provided by your bank, broker or other nominee to submit a proxy or vote your shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a stockholder gives a proxy, how are the shares of Bioventus or Misonix common stock voted? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regardless of the method you choose to vote, the individuals named on the enclosed proxy card will vote your shares of Bioventus or Misonix common stock, as applicable, in the way that you indicate. For each item before the Bioventus or Misonix special meeting, as applicable, you may specify whether your shares of Bioventus or Misonix common stock, as applicable, should be voted for or against, or abstain from voting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How will my shares of Bioventus common stock be voted if I return a blank proxy? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If you sign, date and return your proxy and do not indicate how you want your shares of Bioventus common stock to be voted, then your shares of Bioventus common stock will be voted in accordance with the recommendation of the Bioventus board: &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus share issuance proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus adjournment proposal. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How will my shares of Misonix common stock be voted if I return a blank proxy? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If you sign, date and return your proxy and do not indicate how you want your shares of Misonix common stock to be voted, then your shares of Misonix common stock will be voted in accordance with the recommendation of the Misonix board: &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix merger proposal, &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix compensation proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix adjournment proposal. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Can I change my vote after I have submitted my proxy? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any Bioventus or Misonix&#8217;s stockholder giving a proxy has the right to revoke the proxy and change their vote before the proxy is voted at the applicable special meeting by doing any of the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subsequently submitting a new proxy (including over the internet or telephone) for the applicable special meeting that is received by the deadline specified on the accompanying proxy card; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">giving timely written notice of your revocation to Bioventus&#8217; or Misonix&#8217;s Corporate Secretary, as applicable; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">attending and voting at the applicable special meeting. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Execution or revocation of a proxy will not in any way affect your right to attend and vote at the applicable special meeting, whether in person or, in the case of the Bioventus special meeting, via the special meeting website. Written notices of revocation and other communications relating to the revocation of proxies should be addressed: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 47%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If you are an Bioventus stockholder:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If you are a Misonix stockholder:</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 400</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Corporate Secretary</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tony.dadamio@bioventus.com</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">(919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1938 New Highway</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, NY 11735</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Secretary</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">misonixproxy@misonix.com</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(631) 694-9555</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc.</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;The Bioventus Special Meeting&#8212;Revocability of Proxies&#8221; and &#8220;The Misonix Special Meeting&#8212;Revocability of Proxies.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If I hold my shares in &#8220;street name,&#8221; can I change my voting instructions after I have submitted voting instructions to my bank, broker or other nominee? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If your shares are held in the name of a bank, broker or other nominee and you previously provided voting instructions to your bank, broker or other nominee, you should follow the instructions provided by your bank, broker or other nominee to revoke or change your voting instructions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Where can I find the voting results of the special meetings? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The preliminary voting results for each special meeting are expected to be announced at that special meeting. In addition, within four business days following certification of the final voting results, each of Bioventus and Misonix will file the final voting results of its respective special meeting (or, if the final voting results have not yet been certified, the preliminary results) with the SEC on a Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Do Misonix stockholders have dissenters&#8217; or appraisal rights? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the closing of the mergers, Misonix stockholders who do not vote in favor of the Misonix merger proposal and otherwise comply with the procedures and satisfy the conditions set forth in Section&#160;262 of the DGCL are entitled to appraisal rights under Section&#160;262 of the DGCL. For more information regarding appraisal rights, see the section entitled &#8220;Appraisal Rights,&#8221; In addition, a copy of Section&#160;262 of the DGCL is attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex D</div> to this joint proxy statement/prospectus. Failure to strictly comply with Section&#160;262 of the DGCL may result in your waiver of, or inability to, exercise appraisal rights. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Are there any risks that I should consider in deciding whether to vote for the approval of the Bioventus share issuance proposal or the Misonix merger proposal? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Yes. You should read and carefully consider the risk factors set forth under &#8220;Risk Factors.&#8221; You also should read and carefully consider the risk factors relating to Bioventus and Misonix that are contained in the documents that are incorporated by reference in this joint proxy statement/prospectus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What happens if I sell my shares of Bioventus or Misonix common stock after the respective record date but before the respective special meeting? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus record date is earlier than the date of the Bioventus special meeting, and the Misonix record date is earlier than the date of the Misonix special meeting. If you sell or otherwise transfer your shares of Bioventus </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or Misonix common stock after the applicable record date but before the applicable special meeting, you will, unless special arrangements are made, retain your right to vote at the applicable special meeting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Who will solicit and pay the cost of soliciting proxies? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Misonix has engaged the services of MacKenzie Partners to assist in the distribution of the proxies. Misonix estimates that it will pay a fee of approximately $18,500 plus reasonable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses to MacKenzie Partners for this service. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix also may be required to reimburse banks, brokers and other custodians, nominees and fiduciaries or their respective agents for their expenses in forwarding proxy materials to beneficial owners of Bioventus Misonix common stock, respectively. Bioventus and Misonix directors, officers and employees also may solicit proxies by telephone, by electronic means or in person. They will not be paid any additional amounts for soliciting proxies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When are the mergers expected to be completed? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the satisfaction or waiver of the closing conditions described under &#8220;The Merger Agreement&#8212;Conditions to the Completion of the Merger,&#8221; including approval of the Bioventus share issuance proposal by Bioventus stockholders and approval of the Misonix merger proposal by Misonix stockholders, the mergers are currently expected to be completed by the end of the 2021 calendar year. However, neither Bioventus nor Misonix can predict the actual date on which the mergers will be completed, or if the mergers will be completed at all, because completion of the mergers is subject to conditions and factors beyond the control of both companies, including the receipt of certain required regulatory approvals. Bioventus and Misonix hope to complete the merger as soon as reasonably practicable. Also see &#8220;The Mergers&#8212;Regulatory Approvals.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What respective equity stakes will Bioventus and Misonix stockholders hold in the combined company immediately following the merger? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the number of shares of Bioventus and Misonix common stock outstanding on September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. The relative ownership interests of Bioventus stockholders and former Misonix stockholders in the combined company immediately following the merger will depend on the number of shares of Bioventus and Misonix common stock issued and outstanding immediately prior to the merger. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If I am a Misonix stockholder, how will I receive the merger consideration to which I am entitled? </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Your receipt of the merger consideration will depend on whether your shares of Misonix common stock are represented by stock certificates (&#8220;Misonix stock certificates&#8221;) or if you hold book-entry shares (&#8220;Misonix book-entry shares&#8221;). Not less than 30 days prior to the anticipated closing date of the first merger, the exchange agent will mail to each holder of record of Misonix common stock a letter of election and transmittal. You are encouraged to complete and return your letter of election and transmittal in accordance with the instructions therein as soon as reasonably practicable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Misonix stock certificates, no later than three business days after the consummation of the mergers, the exchange agent will mail to each holder of record of Misonix stock certificates (a)&#160;a notice advising such holder of the effectiveness of the mergers, and (b)&#160;a letter of transmittal and (c)&#160;instructions for surrendering Misonix stock certificates to the exchange agent. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon surrender of a Misonix stock certificate and a duly executed letter of election and transmittal (or letter of transmittal if an election is not submitted) to the exchange agent in compliance with the instructions for surrender, the exchange agent will mail to each holder of record, as promptly as reasonably practicable thereafter: </div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a statement reflecting the number of whole shares of Bioventus class A common stock, if any, that such holder is entitled to receive in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> book-entry form in the name of such record holder; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&#160;any applicable cash election consideration, (b)&#160;any cash in lieu of fractional shares of Bioventus class A common stock plus (c)&#160;any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to the merger agreement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Misonix book-entry shares that are not held through DTC, upon the later of the consummation of the mergers and the holder&#8217;s delivery to the exchange agent of a duly executed letter of election and transmittal (or letter of transmittal, if an election is not submitted), the exchange agent will pay and deliver to each such holder of record of any such Misonix book-entry shares: </div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the applicable stock election consideration, if any, that such holder is entitled to receive in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> book-entry form in the name of such record holder; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&#160;any applicable cash election consideration, (b)&#160;any cash in lieu of fractional shares of Bioventus class A common stock plus (c)&#160;any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly cancel each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-DTC</div> book-entry share. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Misonix book-entry shares that are held through DTC, no later than three business days after the consummation of the mergers, the exchange agent will transmit to DTC or its nominees, upon surrender of shares held of record by DTC or its nominees in accordance with DTC&#8217;s customary surrender procedures: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the applicable stock election consideration, if any, that such holder is entitled to receive in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> book-entry form in the name of such record holder; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&#160;any applicable cash election consideration, (b)&#160;any cash in lieu of fractional shares of Bioventus Class&#160;A Common Stock plus (c)&#160;any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly cancel each such DTC book-entry share. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">What should I do now? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should read this joint proxy statement/prospectus carefully and in its entirety, including the annexes. Then, you may vote by proxy over the internet or telephone using the instructions included with the accompanying proxy card, or promptly complete your proxy card and return it in the enclosed postage-paid envelope, so that your shares will be voted in accordance with your instructions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">How can I find more information about Bioventus and Misonix? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You can find more information about Bioventus and Misonix from various sources described under &#8220;Where You Can Find More Information.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whom do I call if I have questions about the special meetings or the merger? </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you have questions about the special meetings or the merger, or desire additional copies of this joint proxy statement/prospectus or additional proxies, you may contact the applicable company contacts below: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If you are an Bioventus stockholder:</div></div></div> <div style="text-align: left; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc.,</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attn: Corporate Secretary</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 100,</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tony.dadamio@bioventus.com</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">(919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If you are a Misonix stockholder:</div></div></div> <div style="text-align: left; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Secretary</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1938 New Highway</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, NY 11735</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">misonixproxy@misonix.com</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">(631) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">694-9555</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div id="toc180330_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SUMMARY </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">For your convenience, provided below is a brief summary of certain information contained in this joint proxy statement/prospectus. This summary highlights selected information from this joint proxy statement/ prospectus and does not contain all of the information that may be important to you as a Bioventus or Misonix stockholder. To understand the merger fully and for a more complete description of the terms of the merger, you should read carefully this entire joint proxy statement/prospectus, its annexes and the other documents to which you are referred. Items in this summary include a page reference directing you to a more complete description of those items. You may obtain the information incorporated by reference in this joint proxy statement/prospectus, without charge, by following the instructions under &#8220;Where You Can Find More Information.&#8221; </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Parties to the Merger </div></div>(Page&#160;117) </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus Inc. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus is a global leader of innovations for active healing. Through a combination of internal product development, product/business acquisition, and distribution agreements, it will bring to market products which address a growing need for clinically effective, cost efficient, minimally invasive medical treatments, that engage and enhance the body&#8217;s natural healing processes. Bioventus&#8217; principal place of business is 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix, Inc. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Misonix designs, manufactures and markets minimally invasive surgical ultrasonic medical devices. These products are used for precise bone sculpting, removal of soft and hard tumors, and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. Misonix also exclusively markets, sells and distributes skin allografts and wound care products used to support healing of wounds, and which complement Misonix&#8217;s ultrasonic medical devices. Misonix&#8217;s principal place of business is 1938 New Highway, Farmingdale, New York, and its telephone number is (631) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">694-9555.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Oyster Merger Sub I, Inc. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Merger Sub I was formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of any nature other than as set forth in the merger agreement. By operation of the merger, Merger Sub I will be merged with and into Misonix, with Misonix continuing as the surviving corporation. Merger Sub&#8217;s principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Oyster Merger Sub II, LLC </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Merger Sub II was formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of any nature other than as set forth in the merger agreement. By operation of the merger, following the first merger, Misonix will be merged with and into Merger Sub II, with Merger Sub II continuing as the surviving entity (renamed as Misonix LLC) and a wholly owned subsidiary of Bioventus. Merger Sub&#8217;s principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700.</div> </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Mergers and the Merger Agreement </div></div>(Pages&#160;137 and 198) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The terms and conditions of the merger are contained in the merger agreement, a copy of which is attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex A</div> hereto. Bioventus and Misonix encourage you to read the merger agreement carefully and in its entirety, as it is the legal document that governs the merger.<br/> <br/></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement provides that, subject to the terms and conditions of the merger agreement, Merger Sub I will be merged with and into Misonix, with Misonix continuing as the surviving corporation and subsequently, Misonix will be merged with and into Merger Sub II, with Merger Sub II continuing as the surviving entity in the second merger and as a wholly owned subsidiary of Bioventus. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Merger Consideration </div></div>(Page&#160;137) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If the mergers are completed, each issued and outstanding share of Misonix common stock (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus or Merger Sub I, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Bioventus class A common stock, based on the election of the holder thereof and, in each case, subject to automatic proration and adjustment in accordance with the terms of the merger agreement, as described under &#8220;The Merger Agreement&#8212;The Merger Consideration&#8221; </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proration and Reallocation</div></div> (Page&#160;137) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate amount of cash payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock at 5:00 p.m., New York City time, on the election deadline. In order to deliver this aggregate cash amount, the merger agreement provides for pro rata adjustments to, and reallocation of, the cash and stock elections made by Misonix stockholders, as well as the allocation of consideration to be paid with respect to shares of Misonix common stock as to which no election regarding the form of merger consideration to be paid to them, is received prior to the election deadline. Such no election shares will be exchanged for the cash consideration, the stock consideration or a combination of both. Additionally, depending on the elections made by other Misonix stockholders, each Misonix stockholder who elects to receive Bioventus class A common stock for their shares in the mergers, referred to as &#8220;stock election shares&#8221; may receive a portion of their consideration in cash, and each Misonix stockholder who elects to receive cash for their shares in the mergers, referred to as &#8220;cash election shares&#8221; may receive a portion of their consideration in Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration, which is the amount equal to the aggregate number of cash election shares multiplied by $28.00, exceeds the available cash amount, then: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all stock election shares and all no election shares will be exchanged for 1.6839 shares of Bioventus class A common stock; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a portion of the cash election shares of each Misonix stockholder will be exchanged for $28.00 in cash as follows: cash election shares exchanged for $28.00 in cash = </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of such stockholder&#8217;s cash election shares) * (maximum cash amount) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">elected cash consideration </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration is less than the available cash amount, which difference we refer to as the shortfall amount, then: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all cash election shares will be exchanged for the cash consideration; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all stock election shares and no election shares will be treated in the following manner: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the shortfall amount is less than or equal to the product of the aggregate number of no election shares and $28.00, which we refer to as the &#8220;no election value&#8221;, then (1)&#160;all stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock, and (2)&#160;a portion of the<br/> </div><br/></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">no election shares of each Misonix stockholder, calculated as follows, will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#8217;s no election shares, if any, will be exchanged for 1.6839 shares of Bioventus class A common stock): </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">no election shares exchanged for cash consideration = </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of no election shares of such stockholder) * (shortfall amount) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(no election value) </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the shortfall amount is more than the no election value, then (1)&#160;all no election shares will be exchanged for $28.00 in cash and (2)&#160;a portion of the stock election shares of each stockholder will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#8217;s stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock): </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock election shares exchanged for cash consideration = </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of stock election shares of such stockholder) * (shortfall amount &#8211; no election value) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(aggregate number of stock election shares) * $28.00 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration equals the available cash amount, then: (1)&#160;all cash election shares will be converted into the right to receive $28.00 in cash and (2)&#160;all stock election shares and all no election shares will be converted into the right to receive 1.6839 shares of Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;The Merger Agreement&#8212;Proration&#8221;. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Election Procedures </div></div>(Page&#160;138)<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exchange agent will mail to Misonix stockholders of record not less than 30 days prior to the anticipated closing date of the first merger a letter of election and transmittal. The letter of election and transmittal enables Misonix stockholders to choose to make a cash election, a stock election or no election with respect to each share of Misonix common stock eligible to receive the merger consideration. Misonix intends to issue a press release at least five business days prior to the expiration of the election period informing Misonix stockholders of the expiration of the election period, which expiration we refer to as the &#8220;election deadline&#8221;, to make their election and return their completed letters of election and transmittal. If a Misonix stockholder holds shares of Misonix common stock through a bank, brokerage firm or other nominee, such bank, brokerage firm, or other nominee, as applicable, will provide such stockholder with instructions on how to make an election. Election forms must be returned to the broker, bank or nominee in time for it to respond prior to the election deadline, therefore, you are encouraged to pay close attention to, and abide by, any election deadlines provided by the bank, brokerage firm or other nominee holding your shares, as that deadline may be earlier than the election deadline described in this joint proxy statement/prospectus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any election will have been properly made only if the exchange agent has actually received a properly completed letter of election and transmittal by the election deadline. Any election form may be revoked or changed by written notice received by the exchange agent prior to the election deadline. If an election form is revoked, the shares of Misonix common stock as to which such election previously applied will be no election shares unless an election is subsequently submitted by the Misonix stockholder prior to the election deadline. For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. See &#8220;The Merger Agreement&#8212;Election Procedures&#8221;.<br/> </div><br/></div> </div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treatment of Misonix Equity Awards </div></div>(Page&#160;204) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Each outstanding Misonix stock option held by employees and directors of Misonix who meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> definition of &#8220;employee&#8221; shall (i)&#160;become fully vested immediately upon the effective time and (ii)&#160;be assumed by Bioventus and converted automatically into an option to purchase Bioventus class A common stock based on the option exchange ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). Aside from the foregoing adjustments, the assumed options will generally remain subject to the same vesting and other terms and conditions that applied to such awards immediately prior to the effective time. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each outstanding Misonix stock option held by an individual who does not meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> definition of &#8220;employee&#8221; will become fully vested and be settled in cash immediately prior to the effective time in an amount equal to the product of (x)&#160;the number of shares of Misonix common stock subject to the applicable option and (y)&#160;the excess, if any, of (i)&#160;the average of the volume-weighted average trading prices per share of Bioventus Class&#160;A Common Stock on Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii)&#160;the per share exercise price of such option. </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See the section entitled &#8220;The Merger Agreement&#8212;Treatment of Misonix Equity Awards&#8221; of this joint proxy statement/prospectus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recommendation of the Bioventus Board of Directors; Bioventus&#8217; Reasons for the Merger </div></div>(Page&#160;155)<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Bioventus board unanimously recommends that you vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus share issuance proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus adjournment proposal. For a description of some of the factors considered by the Bioventus board in reaching its decision to approve the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, and additional information on the recommendation of the Bioventus board, see &#8220;The Mergers&#8212;Recommendation of the Bioventus Board of Directors; Bioventus&#8217; Reasons for the Merger.&#8221; </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recommendation of the Misonix Board of Directors; Misonix&#8217;s Reasons for the Merger </div></div>(Page&#160;158)<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Misonix board unanimously recommends that you vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix merger proposal, &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix compensation proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix adjournment proposal. For a description of some of the factors considered by the Misonix board in reaching its decision to approve the merger agreement and the transactions contemplated thereby, including the merger, and additional information on the recommendation of the Misonix board, see &#8220;The Mergers&#8212;Recommendation of the Misonix Board of Directors; Misonix&#8217;s Reasons for the Merger.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinions of Bioventus&#8217; Financial Advisor </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion of Perella Weinberg </div></div>(Page&#160;165; <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex B</div>)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus retained Perella Weinberg Partners LP, or Perella Weinberg, to act as its financial advisor in connection with the mergers. Bioventus selected Perella Weinberg based on its qualifications, expertise and reputation and its knowledge of the business and affairs of Bioventus, Misonix and the industries in which Bioventus and Misonix conduct their respective businesses. Perella Weinberg and its affiliates, as part of their investment banking business, are continually engaged in performing financial analyses with respect to businesses and their securities in connection with mergers and acquisitions, leveraged buyouts and other transactions as well as for corporate and other purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;28, 2021, Perella Weinberg rendered its oral opinion, subsequently confirmed in writing, to the Bioventus board that, as of such date and based upon and subject to the various assumptions made, procedures<br/> </div><br/></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">followed, matters considered and qualifications and limitations set forth therein, the merger consideration to be paid by Bioventus pursuant to the merger agreement, consisting of, at the option of the holders of Misonix common stock issued and outstanding immediately prior to the effective time of the first merger, (other than treasury shares of Misonix, shares held by a subsidiary of Misonix, Bioventus or Merger Sub I, and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law), and subject to certain limitations and proration procedures set forth in the merger agreement (as to which Perella Weinberg expressed no opinion), (i) $28.00 in cash per share of Misonix common stock, or the cash election consideration, or (ii) 1.6839 shares of Bioventus common stock per share of Misonix common stock, or the stock election consideration was, as of the date of the opinion, fair, from a financial point of view, to Bioventus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">The full text of Perella Weinberg&#8217;s written opinion, dated July&#160;29, 2021 which sets forth, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by Perella Weinberg, is attached hereto as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;B</div> and is incorporated by reference herein. Perella Weinberg&#8217;s opinion was not intended to be and does not constitute a recommendation to any holder of Bioventus common stock or any other person as to how such person should vote or otherwise act with respect to the mergers or any other matter. Perella Weinberg&#8217;s opinion does not in any manner address the prices at which Misonix common stock or Bioventus common stock will trade at any time. In addition, Perella Weinberg expressed no opinion as to the fairness of the mergers to the holders of any class of securities, creditors or other constituents of Bioventus or Misonix or as to the underlying decision by any person to engage in the mergers or as to the relative merits of the mergers compared to alternative transactions or business strategies. Perella Weinberg provided its opinion for the information and assistance of the Bioventus board in connection with, and for the purposes of its evaluation of, the mergers. This summary is qualified in its entirety by reference to the full text of the opinion. Opinion of Misonix&#8217;s Financial Advisor. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion of JP Morgan Securities </div></div>(Page 176; <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex C</div>)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan rendered an oral opinion to the Misonix board on July 28, 2021 (subsequently confirmed in writing on July 29, 2021) to the effect that, as of such date and based on and subject to the assumptions made, procedures followed, matters considered and other limitations on the review undertaken by J.P.&#160;Morgan in preparing its opinion, the merger consideration to be paid to the holders of Misonix common stock in the merger was fair, from a financial point of view, to such holders, as more fully described in the section entitled &#8220;Opinion of Misonix&#8217;s Financial Advisor&#8221; of this joint proxy statement/prospectus. The full text of the written opinion of J.P. Morgan, dated July&#160;29, 2021, which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P.&#160;Morgan in preparing its opinion, is attached as Annex C to this joint proxy statement/prospectus&#160;and is incorporated herein by reference. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Bioventus Special Meeting </div></div>(Page&#160;119) </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In light of ongoing developments related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Bioventus special meeting will be held solely in a virtual meeting format via live webcast on [&#9679;], 2021, beginning at [&#9679;], Eastern Time. Bioventus stockholders will be able to virtually attend and vote at the Bioventus special meeting by visiting the Bioventus special meeting website at www.virtualshareholdermeeting.com/BVS2021SM. </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purposes of the Bioventus special meeting are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bioventus Proposal 1</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">: Approval of the Share Issuance.</div></div> To consider and vote on the Bioventus share issuance proposal; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bioventus Proposal 2</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">: Adjournment of the Bioventus Special Meeting. </div></div>To consider and vote on the Bioventus adjournment proposal.<br/> <br/></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Completion of the mergers is conditioned on the approval of the Bioventus share issuance proposal (Bioventus Proposal 1) by Bioventus stockholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only holders of record of shares of Bioventus common stock outstanding as of the close of business on [&#9679;], 2021 (the Bioventus record date) are entitled to notice of, and to vote at, the Bioventus special meeting or any adjournment or postponement thereof. Bioventus stockholders may cast one vote for each share of Bioventus common stock that they own of record as of the Bioventus record date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A quorum of Bioventus stockholders is necessary to hold the Bioventus special meeting. A quorum will exist at the Bioventus special meeting if holders of record of shares of Bioventus common stock representing a majority in voting power of the stock issued and outstanding and entitled to vote at the meeting, is present in person, or by remote communication, if applicable, or represented by proxy. All shares of Bioventus common stock represented by a valid proxy and all abstentions will be counted as present for purposes of establishing a quorum. All of the proposals for consideration at the Bioventus special meeting are considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matters under Nasdaq rules, and, therefore, brokers are not permitted to vote on any of the matters to be considered at the Bioventus special meeting unless they have received instructions from the beneficial owners. As a result, no &#8220;broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes&#8221;</div> are expected at the Bioventus special meeting, and shares held in &#8220;street name&#8221; will not be counted as present for the purpose of determining the existence of a quorum unless the Bioventus stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals brought before the Bioventus special meeting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote on the Bioventus adjournment proposal to vote at the Bioventus special meeting on the Bioventus adjournment proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus adjournment proposal. However, if an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal.<br/> <br/></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Misonix Special Meeting </div></div>(Page&#160;128) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of the Misonix special meeting is to consider and vote on each of the following proposals, each of which is further described in this joint proxy statement/prospectus: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 1</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">: Adoption of the Merger Agreement.</div></div> To consider and vote on the Misonix merger proposal; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 2</div></div>: <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Approval, on an Advisory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Binding</div> Basis, of Certain Merger-Related Compensatory Arrangements with Misonix&#8217;s Named Executive Officers.</div></div> To consider and vote on the Misonix compensation proposal; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 3</div></div>: <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjournment of the Misonix Special Meeting.</div></div> To consider and vote on the Misonix adjournment proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Completion of the mergers is conditioned on the approval of the Misonix merger proposal (Misonix Proposal 1) by Misonix stockholders. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only holders of record of shares of Misonix common stock outstanding as of the close of business on [&#9679;], 2021 (the Misonix record date) are entitled to notice of, and to vote at, the Misonix special meeting or any adjournment or postponement thereof. Misonix stockholders may cast one vote for each share of Misonix common stock that they own of record as of the Misonix record date. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A quorum of Misonix stockholders is necessary to conduct the Misonix special meeting. The presence of the holders of a majority of the outstanding shares of Misonix common stock entitled to vote at the Misonix special meeting will constitute a quorum. Shares of Misonix common stock represented at the Misonix special meeting in person or by a properly authorized and submitted proxy (submitted by mail, by telephone or over the Internet), entitled to vote, but not voted, including shares for which a Misonix stockholder directs an &#8220;abstention&#8221; from voting, will be counted for purposes of determining a quorum. However, because all of the proposals for consideration at the Misonix special meeting are considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matters under Nasdaq rules, shares held in &#8220;street name&#8221; will not be counted as present for the purpose of determining the existence of a quorum unless the Misonix stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals at the Misonix special meeting. If a quorum is not present, Misonix expects that the Misonix special meeting will be adjourned or postponed until the holders of the number of shares of Misonix common stock required to constitute a quorum attend. At any subsequent reconvening of the Misonix special meeting, all proxies will be voted in the same manner as the proxies would have been voted at the original convening of the Misonix special meeting, except for any proxies that have been effectively revoked or withdrawn prior to the subsequent meeting. </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Misonix special meeting will be held at Misonix&#8217;s corporate offices, located at 1938 New Highway, Farmingdale, NY 11735 on [&#9679;], 2021, beginning at [&#9679;], Eastern Time. As part of Misonix&#8217;s precautions regarding the novel coronavirus or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> Misonix is planning for the possibility that the meeting may be held solely by means of remote communications. If Misonix takes this step, Misonix will announce the decision to do so in advance, and details on how to participate, including details on how to inspect a list of stockholders of record, will be posted on our website at www.misonix.com and filed with the SEC as proxy material. </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assuming a quorum is present at the Misonix special meeting, approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the outstanding shares of Misonix common stock. For the Misonix compensation proposal, a Misonix stockholder may indicate &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proxy card. Brokerage firms and nominees will not have the authority to vote their customers&#8217; unvoted shares on the Misonix merger proposal or to vote their customers&#8217; shares if the customers have not furnished voting<br/> </div><br/></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">instructions within a specified period of time prior to the Misonix special meeting. Any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares of Misonix common stock in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) and any abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix merger proposal to vote on the Misonix merger proposal, will each have the same effect as a vote <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8220;AGAINST&#8221;</div></div> the Misonix merger proposal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Assuming a quorum is present at the Misonix special meeting, approval of the Misonix compensation proposal requires the affirmative vote of the holders of a majority of the votes cast on the Misonix compensation proposal by holders of Misonix common stock present or represented by proxy at the Misonix special meeting. For the Misonix compensation proposal, a Misonix stockholder may indicate &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proxy card. For purposes of determining the number of votes cast with respect to the Misonix compensation proposal, only those votes cast &#8220;FOR&#8221; or &#8220;AGAINST&#8221; are included. Brokerage firms and nominees will not have the authority to vote their customers&#8217; unvoted shares on the Misonix compensation proposal or to vote their customers&#8217; shares if the customers have not furnished voting instructions within a specified period of time prior to the Misonix special meeting. Abstentions and broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes</div> are counted only for purposes of determining whether a quorum is present at the meeting and therefore will have no effect on the outcome of the vote for the Misonix compensation proposal. Approval of the Misonix compensation proposal is not a condition to completion of the mergers, and the vote with respect to this proposal is advisory only and will not be binding on Misonix, the surviving corporation, the surviving company or Bioventus. If the mergers are completed, the transactions-related executive compensation may be paid to Misonix&#8217;s named executive officers to the extent payable in accordance with the terms of the compensation arrangements even if Misonix stockholders fail to approve, by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding,</div> advisory vote, the Misonix compensation proposal.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Whether or not a quorum is present at the Misonix special meeting, approval of the Misonix adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the shares of Misonix common stock present or represented by proxy at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. An abstention, or other failure of any shares of Misonix common stock present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal, will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Misonix adjournment proposal. However, if a Misonix stockholder who holds shares of Misonix common stock in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Misonix adjournment proposal, voting power will deemed to be withheld with respect to the Misonix adjournment proposal and such failure to provide voting instructions will have no effect on the Misonix adjournment proposal. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Support Agreements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 12pt;">Subsequent to the execution of the merger agreement, Misonix entered into a voting agreement (the &#8220;Bioventus support agreement&#8221;) with EW Healthcare Partners Acquisition Fund, L.P., White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.), Smith&#160;&amp; Nephew, Inc., Smith&#160;&amp; Nephew USD Ltd and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AMP-CF</div> Holdings, LLC (together, the &#8220;Bioventus supporting stockholders&#8221;), pursuant to which such stockholders have agreed, among other things, to vote the shares of Bioventus common stock that they beneficially own at the time such vote is taken in favor of Bioventus share issuance proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Bioventus special meeting, such stockholders beneficially own approximately [&#9679;]% of the outstanding shares of Bioventus common stock. Therefore, the Bioventus supporting </div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stockholders hold a sufficient number of shares of Bioventus common stock in order to approve the Bioventus share issuance proposal. On July&#160;29, 2021, in connection with execution of the merger agreement, each of the Bioventus supporting stockholders have entered into lock up agreements with Bioventus (each a &#8220;lock up agreement&#8221;) restricting the sale and transfer of the capital stock of Bioventus for a period of 90 or 180 days, subject to the terms of the lock up agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to the execution of the merger agreement, Bioventus entered into a voting agreement (the &#8220;Misonix support agreement&#8221;) with each of Stavros G. Vizirgianakis, 1315 Capital, LLC, SV Life Sciences Fund&#160;VI Strategic Partners, L.P. and SV Life Sciences Fund&#160;VI, L.P. (together, the &#8220;Misonix supporting stockholders&#8221;), pursuant to which such stockholders have agreed, among other things, to vote the shares of Misonix common stock that they own at the time such vote is taken in favor of the Misonix merger proposal and Misonix compensation proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Misonix special meeting, the Misonix supporting stockholders beneficially own approximately [&#9679;]% of the outstanding shares of Misonix common stock. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interests of Bioventus Directors and Executive Officers in the Mergers </div></div>(Page&#160;337)<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than with respect to continued service for, employment by and the right to continued indemnification by the combined company, as of the date of this joint proxy statement/prospectus, Bioventus directors and executive officers do not have interests in the mergers that are different from, or in addition to, the interests of other Bioventus stockholders generally. See &#8220;Interests of Bioventus Directors and Executive Officers in the Mergers.&#8221; </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interests of Misonix Directors and Executive Officers in the Merger </div></div>(Page&#160;338) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In considering the recommendations of the Misonix board, Misonix stockholders should be aware that Misonix directors and executive officers have interests in the mergers, including financial interests, which may be different from, or in addition to, the interests of other Misonix stockholders generally. The Misonix board was aware of and considered these interests, among other matters, when it determined that the mergers are fair to and in the best interests of Misonix and its stockholders, approving and declaring advisable the merger agreement and the transactions contemplated thereby, and recommending that Misonix stockholders approve the Misonix mergers. These interests are discussed in more detail under &#8220;Interests of Misonix Directors and Executive Officers in the Mergers.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For an estimate of the value of the benefits and financial interests that the Misonix named executive officers may become eligible to receive as a result of their interests in the mergers, assuming, among other things, that the merger was completed on August&#160;31, 2021 and each such named executive officer experienced a qualifying termination of employment immediately thereafter, see &#8220;Interests of Misonix Directors and Executive Officers in the Mergers&#8212;Quantification of Payments and Benefits to Misonix Named Executive Officers&#8212;Golden Parachute Compensation.&#8221; </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Governance of the Combined Company </div></div>(Page&#160;205)<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has agreed to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board, the opportunity to join the Bioventus board as of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No other governance changes are planned in connection with the mergers. </div></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Organizational Documents and Directors and Officers of the Surviving Corporation </div></div>(Page&#160;205) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the effective time, Misonix&#8217;s certificate of incorporation as in effect immediately prior to the effective time and Misonix&#8217;s bylaws as in effect immediately prior to the effective time will continue to be the certificate of incorporation and the bylaws of the surviving company of the first merger. At the second effective time, the certificate of formation and the limited liability company agreement of Merger Sub II in effect immediately prior to the second effective time, will continue to be the certificate of formation and the limited liability company agreement of Merger Sub II, as the surviving entity of the second merger. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Certain Beneficial Owners of Bioventus Common Stock </div></div>(Page&#160;369) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the close of business on September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Bioventus directors and executive officers and their affiliates, as a group, owned and were entitled to vote less than 1% of the shares of Bioventus common stock outstanding on such date. Although none of them has entered into any agreement obligating them to do so, Bioventus currently expects that all Bioventus directors and executive officers will vote their shares &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus share issuance proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus adjournment proposal. For more information regarding the security ownership of Bioventus directors and executive officers, see &#8220;Certain Beneficial Owners of Bioventus Common Stock&#8212;Security Ownership of Bioventus Directors and Executive Officers.&#8221; </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Certain Beneficial Owners of Misonix Common Stock </div></div>(Page&#160;372) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the close of business on September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/ prospectus, Misonix directors and executive officers and their affiliates, as a group, owned and were entitled to vote approximately 31.62% of the shares of Misonix common stock outstanding on such date. On July&#160;29, 2021, Stavros Vizirgianakis, Misonix&#8217;s Chief Executive Officer and Director, entered into a Voting and Support Agreement with Bioventus and the stockholders named therein, pursuant to which he agreed to, among other things, vote his shares of Misonix common stock in favor of the adoption of the Misonix merger proposal. Although no Misonix director or executive officer other than Mr. Vizirgianakis has entered into any agreement obligating them to vote their shares of Misonix common stock in favor of the proposals at the special meeting, Misonix currently expects that all Misonix directors and executive officers will vote their shares of Misonix common stock &#8220;FOR&#8221; the Misonix merger proposal, &#8220;FOR&#8221; the Misonix compensation proposal and &#8220;FOR&#8221; the Misonix adjournment proposal. See &#8220;Interests of Misonix Directors and Executive Officers in the Merger&#8221; and the arrangements described in Misonix&#8217;s Annual Report on Form 10-K, which is incorporated by reference in this joint proxy statement/prospectus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Regulatory Approvals </div></div>(Page&#160;195) </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus, Merger Sub I, Merger Sub II and Misonix have each agreed to cooperate with each other and to use (and to cause their subsidiaries to use) reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary to cause the conditions to the closing to be satisfied as promptly as reasonably practicable (and in any event no later than the end date) and to consummate and make effective the transactions contemplated by the merger agreement, including to obtain all required regulatory approvals as promptly as practicable, subject to certain limits. See &#8220;The Mergers&#8212;Regulatory Approvals.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The obligations of Bioventus and Misonix to consummate the mergers are subject to, among other conditions, the termination or expiration of any waiting period (or any extension thereof) applicable to the transactions contemplated by the merger agreement under the HSR Act. </div></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ownership of the Combined Company</div></div> (Page&#160;196) </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the number of shares of Bioventus and Misonix common stock outstanding as of September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. The relative ownership interests of Bioventus stockholders and former Misonix stockholders in the combined company immediately following the merger will depend on the number of shares of Bioventus and Misonix common stock issued and outstanding immediately prior to the merger. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Appraisal Rights </div></div>(Page&#160;361) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Section&#160;262 of the DGCL, Misonix stockholders who do not vote in favor of Misonix merger proposal and who comply with the applicable requirements of Section&#160;262 of the DGCL have the right to seek appraisal of such shares by the Delaware Court of Chancery and to receive payment in cash of the fair value of those shares. It is possible that the fair value as determined by the Delaware Court of Chancery may be more or less than, or the same as, the per share value of the merger consideration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix stockholders who wish to preserve their appraisal rights must make a demand for appraisal prior to the time the Misonix stockholder vote is taken on the Misonix merger proposal. In addition to submitting a demand for appraisal, such Misonix stockholders must continuously hold such shares through the effective time, must not vote in favor of the Misonix merger proposal, must not surrender their shares in exchange for the merger consideration, and must otherwise follow the procedures prescribed by Section&#160;262 of the DGCL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">You are encouraged to read Section&#160;262 of the DGCL carefully and in their entirety. Due to the complexity of the procedures for exercising your appraisal rights, Misonix stockholders who are considering exercising such rights are encouraged to seek the advice of legal counsel. Failure to strictly comply with these provisions will result in the loss of appraisal rights. See the section entitled &#8220;Appraisal Rights&#8221; of this joint proxy statement/prospectus for additional information and the text of Section&#160;262 of the DGCL reproduced in its entirety as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex D</div> to this proxy statement/prospectus. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus stockholders are not entitled to appraisal rights in connection with the mergers. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conditions to the Completion of the Mergers </div></div>(Page&#160;222) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The obligations of each of Bioventus and Misonix to complete the mergers are subject to the satisfaction or waiver, as of the closing, of each of the following conditions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> of which this joint proxy statement/prospectus forms a part must have become effective in accordance with the provisions of the Securities Act, no stop order may have been issued by the SEC and remain in effect with respect to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> and no proceedings for that purpose may have been commenced or threatened in writing by the SEC and not withdrawn; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval by Misonix stockholders of the Misonix merger proposal must have been obtained; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval by Bioventus stockholders of the Bioventus share issuance proposal must have been obtained; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any waiting period (or any agreed upon extension of any waiting period or commitment not to consummate the mergers for any period of time) applicable to the consummation of the mergers under the HSR Act must have expired or been terminated by the relevant governmental entity, and there must be no pending agreement between Bioventus and any governmental entity not to close; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the shares of Bioventus class A common stock to be issued pursuant to the first merger, including the shares of Bioventus class A common stock to be issued upon the exercise of converted Misonix stock </div></div> </td> </tr> </table> <br/> <div style="clear:both;max-height:0pt;"></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">options and upon vesting of converted Misonix RSUs, must have been approved for listing (subject to notice of issuance) on Nasdaq; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">no law or order preventing, enjoining or making illegal the consummation of the mergers may have been entered, issued or adopted by any court of competent jurisdiction or other governmental entity of competent jurisdiction and remain in effect. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, each party&#8217;s obligation to complete the mergers is subject to, among other things, the accuracy of certain representations and warranties of the other party and the compliance by such other party with certain of its covenants, in each case, subject to the materiality standards set forth in the merger agreement, and the absence of the occurrence of any material adverse effect. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither Bioventus nor Misonix can be certain when, or if, the conditions to the mergers will be satisfied or waived, or that the mergers will be completed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;The Merger Agreement&#8212;Conditions to the Completion of the Mergers.&#8221; </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">No Solicitation of Acquisition Proposals </div></div>(Page&#160;211)<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As more fully described under &#8220;The Merger Agreement&#8212;No Solicitation of Acquisition Proposals,&#8221; subject to the exceptions summarized below, Bioventus and Misonix have each agreed that they will not (a)&#160;solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries regarding, or the submission or announcement by any person (other than, in the case of Misonix, Bioventus or in the case of Bioventus, Misonix, or its respective affiliates and representatives) of, any proposal or offer that constitutes, or would reasonably be expected to lead to, an acquisition proposal (as defined under &#8220;The Merger Agreement&#8212;No Solicitation of Acquisition Proposals&#8221;) (with certain exceptions related to each board of directors informing itself of an acquisition proposal), (b) furnish any information regarding such party or its subsidiaries (other than to the other party and its subsidiaries) or afford access to such party&#8217;s or its subsidiaries&#8217; representatives, books, records or property, in each case in connection with, or for the purpose of soliciting, initiating, encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to an acquisition proposal, (c)&#160;engage in, enter into, continue or otherwise participate in any discussions or negotiations with any person (other than, in the case of Bioventus, Misonix, or in the case of Misonix, Bioventus, or its respective representatives) with respect to any acquisition proposal or any inquiry, proposal or offer that would reasonably be expected to lead to an acquisition proposal (with certain exceptions related to each board of directors informing itself of an acquisition proposal), (d)&#160;approve, adopt, recommend, agree to or enter into, or publicly propose to approve, adopt, recommend, agree to or enter into, any letter of intent, memorandum of understanding or similar document, agreement, commitment or agreement in principle with respect to any acquisition proposal or (e)&#160;resolve or agree to do any of the foregoing. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 12pt;">Notwithstanding the restrictions described above, if at any time prior to obtaining approval of the Misonix merger proposal, in the case of Misonix, or the Bioventus share issuance proposal, in the case of Bioventus, Bioventus or Misonix, as applicable, receives a bona fide, written acquisition proposal after the date of the merger agreement that did not result from a breach of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> provisions in the merger agreement and that the Bioventus board or the Misonix board, as applicable, determines in good faith (after consultation with its outside legal counsel and financial advisor) that such acquisition proposal constitutes or would reasonably be expected to lead to a superior proposal (as defined under &#8220;The Merger Agreement&#8212;No Solicitation of Acquisition Proposals&#8221;), Bioventus or Misonix, as applicable, may (a)&#160;engage in discussions or negotiations with the party making such acquisition proposal and (b)&#160;following the receipt from such party making the acquisition proposal, (or there is then in effect with such party) an executed confidentiality agreement with nondisclosure provisions at least as restrictive of such third party as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> agreement with Bioventus or Misonix, as applicable, furnish information to such party with respect to Bioventus or Misonix, as applicable, in either case, subject to certain conditions and obligations in the merger agreement. </div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix have also agreed to notify the other (a)&#160;promptly following (and in any event, within 48 hours of the receipt of) any acquisition proposal or any inquiry or request for information with respect to an acquisition proposal or that is reasonably likely to lead to an acquisition proposal and (b)&#160;to keep the other party reasonably informed on a current basis (and in any event, within 48 hours) as to the status of any acquisition proposal, including informing the other party of any material change to such acquisition proposal&#8217;s terms, the status of any negotiations, and any change in its intentions. See &#8220;The Merger Agreement&#8212;No Solicitation of Acquisition Proposals.&#8221; </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">No Change of Recommendation </div></div>(Page&#160;214) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement provides that, among other restrictions and subject to certain exceptions, neither the Bioventus board nor the Misonix board may (a)&#160;withhold, withdraw, modify, amend or qualify (or publicly propose to do so), in a manner adverse the other party, the Bioventus board&#8217;s recommendation to Bioventus stockholders to approve the share issuance or the Misonix board&#8217;s recommendation to Misonix stockholders to adopt the merger agreement, as applicable, or (b)&#160;approve, recommend or declare advisable (or publicly propose to do so) any acquisition proposal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the restrictions described above, at any time prior to obtaining the approval by Bioventus stockholders of the Bioventus share issuance proposal or by Misonix stockholders of the Misonix merger proposal, as the case may be, the Bioventus board or the Misonix board, as applicable, may make a change of recommendation and/or terminate the merger agreement to concurrently enter into a definitive agreement with respect to an acquisition proposal if it determines in good faith (after consultation with its outside legal counsel and financial advisor) that such acquisition proposal is a superior proposal and that failure to take such action with respect to such acquisition proposal would reasonably be expected to be inconsistent with the such board of directors&#8217; fiduciary duties to such party and its stockholders under applicable laws (and subject to compliance with certain obligations set forth in the merger agreement, including providing the other party with prior notice and the opportunity to negotiate for a period to make such acquisition proposal no longer a superior proposal and payment of a the applicable termination fee in connection with any such termination of the merger agreement). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the Bioventus board or the Misonix board, as the case may be, is permitted under certain circumstances, prior to obtaining stockholder approval of the Bioventus share issuance proposal, in the case of Bioventus, or the Misonix merger proposal, in the case of Misonix, and subject to compliance with certain obligations set forth in the merger agreement (including providing the other party with prior notice and the opportunity to negotiate during such notice period to amend the terms of the merger agreement) to make a change of recommendation in response to an intervening event (unrelated to an acquisition proposal) if the Bioventus board or the Misonix board, as applicable, determines in good faith (after consultation with its outside legal counsel and financial advisor) that the failure to do so would be reasonably likely to be inconsistent with its fiduciary duties. See &#8220;The Merger Agreement&#8212;No Change of Recommendation.&#8221; </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Termination of the Merger Agreement </div></div>(Page&#160;225) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement may be terminated: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by mutual written consent of Bioventus and Misonix at any time prior to the effective time; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either Bioventus or Misonix, if the merger has not been consummated at or prior to the end date, provided, that the end date will be automatically extended in the event the only closing condition not satisfied or waived is the condition related to antitrust laws (however, a party may not terminate the merger agreement if such party&#8217;s material breach of any of its obligations under the merger agreement materially contributed to the failure of the closing to have occurred by the end date); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either Bioventus or Misonix at any time prior to the effective time if a relevant legal restraint permanently preventing, enjoining or making illegal the consummation of the mergers shall have<br/> </div><br/></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">become final and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable;</div> provided, that the party seeking to terminate the merger agreement must have used reasonable best efforts to prevent the entry of and to remove such relevant legal restraint in accordance with the merger agreement; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">by Bioventus at any time prior to Misonix obtaining its required stockholder approval, if the Misonix board has made a change in recommendation or Misonix has willfully breached in any material respect the covenants applicable to it regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation,</div> special meetings and changes in recommendation; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">by Misonix at any time prior to Bioventus obtaining its required stockholder approval, if (a)&#160;the Bioventus board has made a change in recommendation, (b)&#160;Bioventus has willfully breached in any material respect the covenants applicable to it regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation,</div> special meetings and changes in recommendation or (c)&#160;if Bioventus has materially breached its representations and warranties regarding financing and solvency under the merger agreement or its covenants regarding financing and financing cooperation under the merger agreement, and (i)&#160;any such breach is not cured by the earlier of the end date or prior to the twentieth business day after Misonix gives written notice of such breach to Bioventus, (ii)&#160;all of the conditions, the satisfaction or waiver of which would be necessary to trigger the obligation of Bioventus to consummate the mergers (not including the condition related to the certificate to be provided by Misonix), have been satisfied and continue to be satisfied (other than those conditions that by their nature cannot be satisfied other than at the closing), (iii) Misonix has committed to Bioventus that Misonix is ready, willing and able to consummate the transactions contemplated by the merger agreement, and (iv)&#160;Bioventus, Merger Sub I or Merger Sub II fails to consummate the transactions contemplated by the merger agreement by the earlier of the end date or within two business days following the written notice delivered by Misonix to Bioventus following the expiration of the cure period specified above; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Misonix, if prior to obtaining its required stockholder approval, (a)&#160;the Misonix board has authorized Misonix to enter into a definitive agreement relating to a superior proposal in material compliance with the merger agreement and (b)&#160;substantially concurrently with the termination of the merger agreement, Misonix enters into the definitive agreement relating to a superior proposal and pays Bioventus the applicable termination fee pursuant to the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either Bioventus or Misonix, if the approval by Misonix stockholders of the Misonix merger proposal has not been obtained after a vote on approval of such proposal has been taken at the Misonix special meeting (including any postponement or adjournment thereof); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either Bioventus or Misonix, if the approval by Bioventus stockholders of the Bioventus share issuance proposal has not been obtained after a vote on approval of such proposal has been taken at the Bioventus special meeting (including any postponement or adjournment thereof); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Bioventus (a)&#160;if any of Misonix&#8217;s representations and warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied or (b)&#160;if Misonix has breached any covenant in the merger agreement and such breach would result in the failure of a condition to closing, provided, that if an inaccuracy in any of Misonix&#8217;s representations and warranties or a breach of a covenant of Misonix is curable by Misonix by the end date and Misonix is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Bioventus may not terminate the merger agreement under this paragraph on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of thirty business days commencing on the date that Misonix receives written notice of such inaccuracy or breach from Bioventus; provided, further, that Bioventus shall not have the right to terminate the merger agreement pursuant to this paragraph if Bioventus is then in breach of any of its representations, warranties or agreements contained in the merger agreement, which breach would give rise to the failure of a condition to closing; or<br/> </div><br/></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Misonix if: (a)&#160;any of Bioventus&#8217;, Merger Sub I&#8217;s or Merger Sub II&#8217;s representations and warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied; or (b)&#160;any of Bioventus&#8217; covenants contained in the merger agreement will have been breached such that the conditions to closing would not be satisfied; provided, however, that for purposes of clauses (a)&#160;and (b) above, if an inaccuracy in any of Bioventus&#8217;, Merger Sub I&#8217;s or Merger Sub II&#8217;s representations and warranties or a breach of a covenant of Bioventus is curable by Bioventus by the end date and Bioventus is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Misonix may not terminate the merger agreement under this paragraph on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of thirty business days commencing on the date that Bioventus receives written notice of such inaccuracy or breach from Misonix; provided, further, that Misonix shall not have the right to terminate the merger agreement pursuant to this paragraph if Misonix is then in breach of any of its representations, warranties or agreements contained in the merger agreement, which breach would give rise to the failure of a condition to closing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;The Merger Agreement&#8212;Termination of the Merger Agreement.&#8221; </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Termination </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fees</div></div> (Page&#160;226) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix have each agreed to pay a termination fee of $20,661,000 in cash (the &#8220;termination fee&#8221;) to the other party, if the merger agreement is terminated in certain circumstances involving a change of recommendation, breach of certain covenants of such party or termination of the merger agreement to enter into a superior proposal, in each case by the party obligated to pay the fee. Bioventus and Misonix are also required to pay the applicable termination fee if the party obligated to pay the termination fee enters into or consummates a superior proposal following certain terminations of the merger agreement, including a termination due to such party&#8217;s failure to obtain the required stockholder approval. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A termination fee will be payable by a party only once and not in duplication even though the termination fee may be payable by such party pursuant to multiple circumstances. Furthermore, except in the case of fraud or intentional and material breach of the merger agreement, if a party receives a termination fee, then the termination fee will be the recipient&#8217;s sole and exclusive remedy against the other party, its affiliates and its and their respective representatives in connection with the merger agreement. See &#8220;The Merger Agreement&#8212;Termination Fees.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounting Treatment </div></div>(Page&#160;197) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus prepares its financial statements in accordance with GAAP. The mergers will be accounted for using the acquisition method of accounting under the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 805, Business Combinations, with Bioventus representing the accounting acquirer under this guidance. Bioventus will record assets acquired, including identifiable intangible assets, and liabilities assumed from Misonix at their respective fair values at the date of completion of the mergers. Any excess of the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial condition and results of operations of Bioventus after completion of the mergers will reflect Misonix after completion of the mergers, but will not be restated retroactively to reflect the historical financial condition or results of operations of Misonix. The earnings of Bioventus following completion of the mergers will reflect acquisition accounting adjustments, including the effect of changes in the carrying value for assets and liabilities on depreciation expense and amortization expense. Indefinite-lived intangible assets, including goodwill, will not be amortized but will be tested for impairment at least annually, and all tangible and intangible assets including goodwill will be tested for impairment when certain indicators are present. If, in the future, Bioventus determines that tangible or intangible assets (including goodwill) are impaired, Bioventus would record an impairment charge at that time.<br/> </div><br/></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S. Federal Income Tax Consequences of the Mergers </div></div>(Page&#160;343)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div> </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For U.S. federal income tax purposes, the first merger and the second merger, taken together, are intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code. Assuming the mergers so qualify, a U.S. holder (as defined under &#8220;Material U.S. Federal Income Tax Consequences of the First Merger and Second Merger&#8221;) of Misonix common stock generally will not recognize any gain or loss for U.S. federal income tax purposes upon the exchange of Misonix common stock for Bioventus class A common stock in the mergers, except with respect to cash received by Misonix stockholders in lieu of fractional shares of Bioventus common stock, but a U.S. holder of Misonix common stock generally will recognize any gain for U.S. federal income tax purposes upon the exchange of Misonix common stock for cash consideration. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Material U.S. Federal Income Tax Consequences of the First Merger and the Second Merger&#8221; for a more complete description of certain U.S. federal income tax consequences of the mergers. You are urged to consult your own tax advisor as to the specific tax consequences to you of the mergers in light of your particular circumstances. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Comparison of Stockholders&#8217; Rights </div></div>(Page&#160;351) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of the merger, Misonix stockholders receiving shares of Bioventus common stock will become Bioventus stockholders. The rights of Bioventus stockholders will be governed by the DGCL and the Bioventus charter and bylaws in effect at the effective time. As Bioventus and Misonix are both Delaware corporations, the rights of Bioventus and Misonix stockholders are not materially different. However, there are certain differences in the rights of Bioventus stockholders under the Bioventus charter and bylaws and of Misonix stockholders under the Misonix charter and bylaws. See &#8220;Comparison of Stockholders&#8217; Rights.&#8221; </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Listing of Bioventus Common Stock; Delisting and Deregistration of Misonix Common Stock </div></div>(Page&#160;197)<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is a condition to the merger that the shares of Bioventus common stock to be issued to Misonix stockholders in the merger be approved for listing on Nasdaq, subject to official notice of issuance. If the transaction is completed, Misonix common stock will be delisted from Nasdaq and deregistered under the Exchange Act, following which Misonix will no longer be required to file periodic reports with the SEC with respect to Misonix common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix has agreed to cooperate with Bioventus prior to the closing to cause the Misonix common stock to be delisted from Nasdaq and be deregistered under the Exchange Act as soon as practicable after the effective time. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Risk Factors </div></div>(Page&#160;39) </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In evaluating the merger agreement, the merger and the share issuance, you should carefully read this joint proxy statement/prospectus and give special consideration to the factors discussed under &#8220;Risk Factors.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Developments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;15, 2020, BV LLC made a $15.0&#160;million equity investment in CartiHeal (2009)&#160;Ltd. (&#8220;CartiHeal&#8221;), a privately-held company headquartered in Israel and developer of the proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. Concurrent with the July&#160;15, 2020 investment, BV LLC entered into an Option and Equity Purchase Agreement with CartiHeal and its shareholders, which provides BV LLC with an exclusive option to acquire 100% of CartiHeal&#8217;s shares, or the Call Option, and provides CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal&#8217;s shares under certain conditions, or the Put Option. The Call Option is exercisable by BV LLC at any time. The Put Option is<br/> <br/></div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> device with a label consistent in all respects with pivotal clinical trial success. If not previously exercised, the Call Option and the Put Option terminate 45 days following FDA approval of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> (subject to final review by BV LLC of updated disclosures by CartiHeal). Should the Put Option or Call Option be exercised and the acquisition of CartiHeal consummated, consideration for the acquisition of all of the shares of CartiHeal pursuant to the Option and Equity Purchase Agreement would be $350.0&#160;million in cash, subject to customary adjustments, all of which would be payable at closing, with an additional $150.0&#160;million payable upon achievement of certain sales milestones related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;27, 2021, the Bioventus board, after its review of the statistical report for CartiHeal&#8217;s pivotal clinical trial and determination that the results of the statistical report indicated a Pivotal Clinical Trial Success (as contemplated by the Option and Equity Purchase Agreement), approved BV LLC&#8217;s continued pursuit of a potential acquisition of CartiHeal. BV LLC thereafter deposited $50.0&#160;million in escrow in accordance with the terms of the Option and Equity Purchase Agreement. Should the Put Option or Call Option be exercised and the acquisition of CartiHeal consummated, the escrowed funds will be applied towards the consideration payable by BV LLC pursuant to the Option and Equity Purchase Agreement. The closing of the transaction is subject to, among other things (including customary closing conditions), the valid exercise of the Call Option or the Put Option. CartiHeal plans to submit the clinical module of their PMA later this year, and the decision from the FDA is expected in the second half of 2022. </div></div> <div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Litigation Relating to the Merger </div></div>(Page 197)<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">O</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">n September 16, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.). The complaint asserts claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on September 8, 2021, regarding Misonix and Bioventus&#8217;s projections and J.P. Morgan&#8217;s financial analysis. The complaint purports to seek, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger, (ii) rescission in the event that the merger is consummated, and (iii) an award of costs, including attorneys&#8217; and experts&#8217; fees. More information can be found under &#8220;The Merger&#8212;Litigation Relating to the Merge</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">r.&#8221;<br/> </div><br/></div> </div> </div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MARKET PRICE AND DIVIDEND INFORMATION </div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Class&#160;A Common Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus class A common stock is currently listed on The Nasdaq Global Select Market under the symbol &#8220;BVS.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The closing price of Bioventus class A common stock on July&#160;28, 2021, the trading day immediately prior to the public announcement of the Merger on July&#160;29, 2021, as reported on The Nasdaq Global Select Market, was $17.15 per share. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because the market price of Bioventus class A common stock is subject to fluctuation, the market value of the shares of Bioventus class A common stock that Misonix stockholders who elect the stock election consideration will be entitled to receive in the first merger may increase or decrease. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of [&#9679;], 2021, the record date for the Bioventus special meeting, there were approximately [&#9679;] holders of record of Bioventus class A common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has never declared or paid any cash dividends on Bioventus class A common stock and does not anticipate paying cash dividends on Bioventus class A common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the mergers will be at the discretion of the combined company&#8217;s then-current board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> of which this joint proxy statement/prospectus forms a part, the documents that Bioventus and Misonix refer you to in the registration statement and oral statements made or to be made by Bioventus and Misonix include certain &#8220;forward-looking statements&#8221; within the meaning of, and subject to the safe harbor created by, Section&#160;27A of the Securities Act, Section&#160;21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995, which are referred to as the &#8220;safe harbor provisions.&#8221; Statements contained or incorporated by reference in the registration statement of which this joint proxy statement/prospectus forms a part that are not historical facts are forward-looking statements, including statements about the beliefs and expectations of Bioventus and Misonix management relating to the merger and future financial condition and performance. Words such as &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intends,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative thereof and similar expressions are intended to identify such forward-looking statements that are intended to be covered by the safe harbor provisions. Investors are cautioned that any forward-looking statements are subject to known and unknown risks and uncertainties, many of which are beyond the control of both companies, and which may cause actual results and future trends to differ materially from those matters expressed in, or implied or projected by, such forward-looking statements, which speak only as of the date of this joint proxy statement/prospectus. Although these forward-looking statements are based on assumptions that Bioventus and Misonix management, as applicable, believe to be reasonable, they can give no assurance that these expectations will prove to be correct. Investors are cautioned not to place undue reliance on these forward-looking statements. Among the risks and uncertainties that could cause actual results to differ from those described in forward-looking statements are the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the occurrence of any change, event, series of events or circumstances that could give rise to the termination of the merger agreement, including a termination of the merger agreement under circumstances that could require Bioventus to pay a termination fee to Misonix or require Misonix to pay a termination fee to Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">uncertainties related to the timing of the receipt of required regulatory approvals for the merger and the possibility that Bioventus and Misonix may be required to accept conditions that could reduce or eliminate the anticipated benefits of the merger as a condition to obtaining regulatory approvals or that the required regulatory approvals might not be obtained at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the price of Bioventus and Misonix common stock could change before the completion of the merger, including as a result of uncertainty as to the long-term value of the common stock of the combined company or as a result of broader stock market movements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that the parties are unable to complete the merger due to the failure of Bioventus stockholders to approve the share issuance or of Misonix stockholders to adopt the merger agreement, or the failure to satisfy any of the other conditions to the completion of the merger, or unexpected delays in satisfying any conditions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in closing, or the failure to close, the merger for any reason, could negatively impact Bioventus, Misonix or the combined company; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks that the pendency or completion of the merger and the other transactions contemplated by the merger agreement disrupt current plans and operations, which may adversely impact Bioventus&#8217;s or Misonix&#8217;s respective businesses; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulties or delays in integrating the businesses of Bioventus and Misonix following completion of the merger or fully realizing the anticipated synergies or other benefits expected from the merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain restrictions during the pendency of the proposed merger that may impact the ability of Bioventus or Misonix to pursue certain business opportunities or strategic transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk of legal proceedings that have been or may be instituted against Bioventus, Misonix, their directors and/or others relating to the merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks related to the diversion of the attention and time of Bioventus or Misonix management from ongoing business concerns; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that the proposed merger or any announcement relating to the proposed merger could have an adverse effect on the ability of Bioventus or Misonix to retain and hire key personnel or maintain relationships with customers, suppliers, distributors, vendors, strategic partners or other third parties, including regulators and other governmental authorities or agencies, or on Bioventus&#8217;s or Misonix&#8217;s respective operating results and businesses generally; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potentially significant amount of any costs, fees, expenses, impairments or charges related to the merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential dilution of Bioventus and Misonix stockholders&#8217; ownership percentage of the combined company as compared to their ownership percentage of Bioventus or Misonix, as applicable, prior to the merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the business, economic, political and other conditions in the countries in which Bioventus or Misonix operate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">events beyond the control of Bioventus and Misonix, such as acts of terrorism or the continuation or worsening of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and changes in applicable law, including changes in Bioventus&#8217;s or Misonix&#8217;s estimates of their expected tax rate based on current tax law; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential dilution of the combined company&#8217;s earnings per share as a result of the merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix directors and executive officers having interests in the merger that are different from, or in addition to, the interests of Bioventus and Misonix stockholders generally; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that the combined company&#8217;s results of operations, cash flows and financial position after the merger may differ materially from the unaudited pro forma condensed combined financial information contained in this proxy statement/prospectus. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For further discussion of these and other risks, contingencies and uncertainties applicable to Bioventus and Misonix, their respective businesses and the proposed merger, see &#8220;Risk Factors&#8221; in this joint proxy statement/prospectus and in similarly titled sections in Bioventus&#8217;s and Misonix&#8217;s other filings with the SEC that are incorporated by reference herein. See &#8220;Where You Can Find More Information.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All subsequent written or oral forward-looking statements attributable to Bioventus, Misonix or any person acting on either of their behalf are expressly qualified in their entirety by these cautionary statements. Neither Bioventus nor Misonix is under any obligation to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise, and each expressly disclaims any obligation to do so, except as may be required by law. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RISK FACTORS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In considering how to vote on the proposals to be considered and voted on at the Bioventus and Misonix special meetings, you are urged to carefully consider all of the information contained or incorporated by reference in this joint proxy statement/prospectus. See &#8220;Where You Can Find More Information.&#8221; You should also read and consider the risks associated with each of the businesses of Bioventus and Misonix because those risks will affect the combined company. The risks associated with the business of Bioventus are presented below and the risks associated with the business of Misonix can be found in Misonix Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended June&#160;30, 2021, as such risks may be updated or supplemented in Misonix&#8217;s subsequently filed Quarterly Reports on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-Q</div> and Current Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> (excluding any information and exhibits furnished under Item&#160;2.02 or 7.01 thereof), each of which is incorporated by reference in this joint proxy statement/prospectus. In addition, you are urged to carefully consider the following material risks relating to the merger and the businesses of Bioventus, Misonix and the combined company. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Factor Summary </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Relating to the Mergers </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because the exchange ratio is fixed and will not be adjusted in the event of any change in the price of either Bioventus or Misonix common stock, the value of the consideration that Misonix stockholders will receive in the first merger is uncertain. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market price of Bioventus common stock will continue to fluctuate after the mergers. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The mergers may not be completed and the merger agreement may be terminated in accordance with its terms. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The termination of the merger agreement could negatively impact Bioventus or Misonix and the trading prices of the Bioventus or Misonix common stock. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Relating to the Combined Company </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Combining the businesses of Bioventus and Misonix may be more difficult, costly or time-consuming than expected and the combined company may fail to realize the anticipated benefits of the merger, which may adversely affect the combined company&#8217;s business results and negatively affect the value of the combined company&#8217;s common stock. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure to successfully integrate the businesses and operations of Bioventus and Misonix in the expected time frame may adversely affect the combined company&#8217;s future results. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The combined company may not be able to retain customers, suppliers or distributors, or customers, suppliers or distributors may seek to modify contractual relationships with the combined company, which could have an adverse effect on the combined company&#8217;s business and operations. Third parties may terminate or alter existing contracts or relationships with Bioventus or Misonix. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The combined company may be exposed to increased litigation, which could have an adverse effect on the combined company&#8217;s business and operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus and Misonix unaudited prospective financial information is inherently subject to uncertainties, the unaudited pro forma condensed combined financial information included in this document is preliminary and the combined company&#8217;s actual financial position and results of operations after the transaction may differ materially from these estimates and the unaudited pro forma condensed combined financial information included in this joint proxy statement/prospectus. The unaudited pro forma condensed combined financial information does not reflect the effect of any divestitures that may be required in connection with the transaction. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Relating to Bioventus </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bioventus&#8217; business may continue to experience adverse impacts as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is highly dependent on a limited number of products. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; long-term growth depends on its ability to develop, acquire and commercialize new products, line extensions or expanded indications. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may be unable to successfully commercialize newly developed or acquired products or therapies in the United States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; products and operations are subject to extensive governmental regulation, and its failure to comply with applicable requirements could cause its business to suffer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may be subject to enforcement action if it engages in improper claims submission practices and resulting audits or denials of Bioventus&#8217; claims by government agencies could reduce Bioventus&#8217; net sales or profits. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent Bioventus from commercializing its products. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Protection of Bioventus&#8217; intellectual property rights may be difficult and costly, and Bioventus&#8217; inability to protect its intellectual property could adversely affect its competitive position. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus depends on certain technologies that are licensed to it. Bioventus does not control the intellectual property rights covering these technologies and any loss of Bioventus&#8217; rights to these technologies or the rights licensed to Bioventus could prevent Bioventus from selling Bioventus&#8217; products, which could adversely impact its business, results of operations and financial condition. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the past, Bioventus identified material weaknesses in its internal control over financial reporting. If Bioventus experiences additional material weaknesses in the future or otherwise fails to maintain an effective system of internal controls, Bioventus may not be able to accurately or timely requirements applicable to public companies, which may adversely affect investor confidence in Bioventus, and, as a result, the market price of Bioventus class A common stock. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is a &#8220;controlled company&#8221; within the meaning of Nasdaq listing standards and, as a result, will qualify for, and intend to rely on, exemptions from certain corporate governance requirements. You will not have the same protections afforded to stockholders of companies that are subject to such requirements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; principal asset is Bioventus&#8217; interest in BV LLC, and, accordingly, Bioventus depends on distributions from BV LLC to pay Bioventus&#8217; taxes and expenses, including payments under the Tax Receivable Agreement. BV LLC&#8217;s ability to make such distributions may be subject to various limitations and restrictions. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The TRA with Smith&#160;&amp; Nephew, Inc. (&#8220;the continuing LLC owner&#8221;) requires Bioventus to make cash payments to it in respect of certain tax benefits to which Bioventus is or may become entitled, and Bioventus expects that the payments it will be required to make could be significant. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taking advantage of the reduced disclosure requirements applicable to &#8220;emerging growth companies&#8221; may make Bioventus class A common stock less attractive to investors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to the Mergers </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because the exchange ratio is fixed and will not be adjusted in the event of any change in the price of either Bioventus or Misonix common stock, the value of the consideration that Misonix stockholders will receive in the first merger is uncertain. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon completion of the first merger, each issued and outstanding share of Misonix common stock (other than treasury shares and shares held by Bioventus, Merger Sub&#160;I or Merger Sub&#160;II and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and prefected and not withdrawn a demand for appraisal rights pursuant to Delaware law) will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Bioventus class A common stock, based on the election of the holder thereof and subject to proration in accordance with the terms of the merger agreement. Bioventus stockholders will continue to own their existing shares of Bioventus common stock. The exchange ratio for the stock election consideration is fixed in the merger agreement and will not be adjusted for changes in the market price of either Bioventus or Misonix common stock prior to the completion of the mergers. The market prices of Bioventus and Misonix common stock have fluctuated prior to and after the date of the announcement of the merger agreement and will continue to fluctuate from the date of this joint proxy statement/prospectus to the dates of the Bioventus and Misonix special meetings, and through the date the mergers are consummated. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because the exchange ratio is fixed, the market value of the stock election consideration to Misonix stockholders will fluctuate with the market price of the Bioventus class A common stock and will not be known at the time that Misonix stockholders vote on the mergers. Similarly, Bioventus stockholders will not know or be able to determine at the time of the Bioventus special meeting the market value of the shares of Bioventus common stock to be issued to those Misonix stockholders receiving the stock election consideration pursuant to the merger agreement compared to the market value of the shares of Misonix common stock that are being exchanged in the first merger. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Stock price changes may result from a variety of factors, including, among others, general market and economic conditions, changes in Bioventus&#8217; or Misonix&#8217;s respective businesses, operations and prospects, the uncertainty as to the extent of the duration, scope and impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, market assessments of the likelihood that the mergers will be completed, interest rates, general market, industry and economic conditions and other factors generally affecting the respective prices of Bioventus and Misonix common stock, federal, state and local legislation, governmental regulation and legal developments in the industry segments in which Bioventus and Misonix operate, and the timing of the mergers and receipt of required regulatory approvals. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of these factors are beyond the control of Bioventus and Misonix, and neither Bioventus nor Misonix is permitted to terminate the merger agreement solely due to a decline in the market price of the common stock of the other party. You are urged to obtain current market quotations for Bioventus and Misonix common stock in determining whether to vote in favor of the Bioventus share issuance proposal, in the case of Bioventus stockholders, or the Misonix merger proposal, in the case of Misonix stockholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The market price of Bioventus common stock will continue to fluctuate after the mergers. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of the first merger, Misonix stockholders who receive the stock election consideration will become holders of Bioventus common stock. The market price of the common stock of the combined company will continue to fluctuate, potentially significantly, following completion of the mergers, including for the reasons described above. As a result, former Misonix stockholders could lose some or all of the value of their investment in Bioventus common stock. In addition, any significant price or volume fluctuations in the stock market generally could have a material adverse effect on the market for, or liquidity of, the Bioventus common stock received in the first merger, regardless of the combined company&#8217;s actual operating performance. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The mergers may not be completed and the merger agreement may be terminated in accordance with its terms. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The mergers are subject to a number of conditions that must be satisfied, including the approval by Bioventus stockholders of the Bioventus share issuance proposal and approval by Misonix stockholders of the Misonix </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">merger proposal, or waived (to the extent permitted), in each case prior to the completion of the mergers. These conditions are described under &#8220;The Merger Agreement&#8212;Conditions to the Completion of the Mergers.&#8221; These conditions to the completion of the mergers, some of which are beyond the control of Bioventus and Misonix, may not be satisfied or waived in a timely manner or at all, and, accordingly, the merger may be delayed or not completed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, either Bioventus or Misonix may terminate the merger agreement under certain circumstances, including, among other reasons, if the mergers are not completed by the end date. Under the merger agreement, Bioventus and Misonix will each be required to pay a termination fee of $20,661,000 to the other party if the merger agreement is terminated in certain circumstances, including if the respective party&#8217;s board changes its recommendation in connection with the mergers. Additionally, Misonix may terminate the merger agreement if it enters into an alternative acquisition agreement with respect to a superior proposal and pays Bioventus the termination fee. See &#8220;The Merger Agreement&#8212;Termination of the Merger Agreement&#8221; and &#8220;The Merger Agreement&#8212;Termination Fee&#8221; for a more complete discussion of the circumstances under which the merger agreement could be terminated and when a termination fee may be payable by Bioventus or Misonix. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The termination of the merger agreement could negatively impact Bioventus or Misonix and the trading prices of the Bioventus or Misonix common stock. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the mergers are not completed for any reason, including because Bioventus stockholders fail to approve the Bioventus share issuance proposal or because Misonix stockholders fail to approve the Misonix merger proposal, the ongoing businesses of Bioventus and Misonix may be adversely affected and, without realizing any of the expected benefits of having completed the mergers, Bioventus and Misonix would be subject to a number of risks, including the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each company may experience negative reactions from the financial markets, including negative impacts on its stock price; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each company may experience negative reactions from its customers, suppliers, distributors and employees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each company will be required to pay its respective costs relating to the mergers, such as financial advisory, legal, financing and accounting costs and associated fees and expenses, whether or not the mergers are completed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the merger agreement places certain restrictions on the conduct of each company&#8217;s business prior to completion of the mergers and such restrictions, the waiver of which is subject to the consent of the other company (not to be unreasonably withheld, conditioned or delayed), which may have prevented Bioventus and Misonix from taking actions during the pendency of the mergers that would have been beneficial (see &#8220;The Merger Agreement&#8212;Conduct of Business Prior to Completion of the Mergers&#8221; for a description of the restrictive covenants applicable to Bioventus and Misonix); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">matters relating to the mergers (including integration planning) will require substantial commitments of time and resources by Bioventus and Misonix management, which could otherwise have been devoted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations or to other opportunities that may have been beneficial to Bioventus or Misonix, as applicable, as an independent company. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The market price for shares of Bioventus common stock may be affected by factors different from, or in addition to, those that historically have affected or currently affect the market prices of shares of Bioventus or Misonix common stock. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon consummation of the first merger, Bioventus stockholders and the Misonix stockholders who receive the stock election consideration will both hold shares of common stock in the combined company. Bioventus&#8217; businesses differ from those of Misonix, and Misonix&#8217;s businesses differ from those of Bioventus, and, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accordingly, the results of operations of the combined company will be affected by some factors that are different from those currently or historically affecting the results of operations of Bioventus and Misonix. The results of operations of the combined company may also be affected by factors different from those that currently affect or have historically affected either Bioventus or Misonix. For a discussion of the businesses of each of Bioventus and Misonix and some important factors to consider in connection with those businesses, see &#8220;The Parties to the Mergers&#8221; and the other information contained or incorporated in this joint proxy statement/prospectus. See &#8220;Where You Can Find More Information.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the number of shares of Misonix common stock outstanding as of September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, it is expected that Bioventus will issue approximately 18,322,984 million shares of Bioventus common stock in the first merger. Former Misonix stockholders may decide not to hold the shares of Bioventus common stock that they will receive in the first merger, and Bioventus stockholders may decide to reduce their investment in Bioventus as a result of the changes to Bioventus&#8217; investment profile as a result of the transaction. Such sales of Bioventus common stock could have the effect of depressing the market price for Bioventus common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The shares of common stock of the combined company to be received by Misonix stockholders as a result of the first merger will have rights different from the shares of Misonix common stock. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of the transaction, Misonix stockholders will no longer be stockholders of Misonix, but will instead become stockholders of Bioventus. As Bioventus and Misonix are both Delaware corporations, the rights of Bioventus and Misonix stockholders are not materially different. However, there are certain differences in the rights of Bioventus stockholders under Bioventus&#8217; amended and restated certificate of incorporation, which is referred to as the &#8220;Bioventus charter,&#8221; and Bioventus&#8217; amended and restated bylaws, which are referred to as the &#8220;Bioventus bylaws,&#8221; and of Misonix stockholders under Misonix&#8217;s amended and restated certificate of incorporation, which is referred to as the &#8220;Misonix charter,&#8221; and Misonix&#8217;s amended and restated bylaws, which are referred to as the &#8220;Misonix bylaws.&#8221; See &#8220;Comparison of Stockholders&#8217; Rights&#8221; for a discussion of these rights. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">After the transaction, Misonix stockholders will have a significantly lower ownership and voting interest in Bioventus than they currently have in Misonix and will exercise less influence over management and policies of the combined company. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the number of shares of Bioventus and Misonix common stock outstanding on September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the first merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the first merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. Consequently, former Misonix stockholders will have less influence over the management and policies of the combined company than they currently have over the management and policies of Misonix. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Until the completion of the transaction or the termination of the merger agreement in accordance with its terms, Bioventus and Misonix are each prohibited from entering into certain transactions and taking certain actions that might otherwise be beneficial to Bioventus, Misonix and/or their respective stockholders. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From and after the date of the merger agreement and prior to completion of the transaction, the merger agreement restricts Bioventus and Misonix from taking specified actions without the consent of the other party and requires that the business of each company and its respective subsidiaries be conducted in the ordinary course in all material respects. These restrictions may prevent Bioventus or Misonix, as applicable, from taking actions during the pendency of the transaction that would have been beneficial. Adverse effects arising from these restrictions during the pendency of the transaction could be exacerbated by any delays in consummation of the transaction or termination of the merger agreement. See &#8220;The Merger Agreement&#8212;Conduct of Business Prior to Completion of the Mergers.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining required approvals and satisfying closing conditions may prevent or delay completion of the transaction. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The transaction is subject to a number of conditions to closing as specified in the merger agreement. These closing conditions include, among others, the effectiveness of the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> of which this joint proxy statement/prospectus forms a part registering the Bioventus common stock issuable pursuant to the merger agreement and the absence of any stop order or proceedings by the SEC with respect thereto, the expiration or earlier termination of any applicable waiting period (or any extension thereof), and the receipt of required approvals, under U.S. antitrust laws, approval for listing on Nasdaq of the shares of Bioventus common stock to be issued pursuant to the merger agreement, and the absence of governmental restraints or prohibitions preventing the consummation of the transaction. To the extent required, foreign investment filings will also be made, though these are not closing conditions. The obligation of each of Bioventus and Misonix to consummate the transaction is also conditioned on, among other things, the truth and accuracy of the representations and warranties made by the other party on the date of the merger agreement and on the closing date (subject to certain materiality and material adverse effect qualifiers), and the performance by the other party in all material respects of its obligations under the merger agreement. No assurance can be given that the required stockholder, governmental and regulatory consents and approvals will be obtained or that the required conditions to closing will be satisfied, and, if all required consents and approvals are obtained and the required conditions are satisfied, no assurance can be given as to the terms, conditions and timing of such consents and approvals. Any delay in completing the transaction could cause the combined company not to realize, or to be delayed in realizing, some or all of the benefits that Bioventus and Misonix expect to achieve if the transaction is successfully completed within its expected time frame. For a more complete summary of the conditions that must be satisfied or waived prior to completion of the transaction, see &#8220;The Merger Agreement&#8212;Conditions to the Completion of the Mergers.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus and Misonix must obtain certain regulatory approvals and clearances to consummate the transaction, which, if delayed, not granted or granted with burdensome or unacceptable conditions, could prevent, substantially delay or impair consummation of the transaction, result in additional expenditures of money and resources or reduce the anticipated benefits of the transaction. </div></div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The completion of the transaction is subject to the termination or expiration of any applicable waiting period (or extension thereof) under the HSR Act, which occurred as of 11:59 p.m., Eastern Time, on September&#160;13, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the HSR Act, the transaction may not be completed until Notification and Report Forms have been filed with the U.S. Federal Trade Commission, which is referred to as the &#8220;FTC,&#8221; and the U.S. Department of Justice, which is referred to as the &#8220;DOJ,&#8221; and the applicable waiting period (or any extension thereof) has expired or been terminated. A transaction requiring notification under the HSR Act may not be completed until the expiration of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> waiting period following the parties&#8217; filing of their respective HSR notifications or the early termination of that waiting period, at the earliest. Each of Bioventus and Misonix filed an HSR notification with the FTC and the DOJ on August&#160;12, 2021. Effective as of 11:59 p.m., Eastern Time, on September 13, 2021, the waiting period under the HSR Act expired with respect to the transactions contemplated by the merger agreement. </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At any time before or after consummation of the transaction, notwithstanding the expiration or termination of the applicable waiting period under the HSR Act, the DOJ or the FTC, or any state, could take such action under competition laws as it deems necessary or desirable in the public interest, including seeking to enjoin the completion of the transaction, seeking divestiture of substantial assets of the parties or requiring the parties to license, or hold separate, assets or to terminate existing relationships and contractual rights. Under certain circumstances, private parties may also seek to take legal action against the transaction under competition laws. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is no assurance that Bioventus and Misonix will obtain all required regulatory clearances or approvals on a timely basis, or at all. Failure to obtain the necessary clearances in any of these jurisdictions could substantially delay or prevent the consummation of the transaction, which could negatively impact both Bioventus and Misonix. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to attract, motivate and retain executives and other key employees could diminish the anticipated benefits of the transaction. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The success of the transaction will depend in part on the combined company&#8217;s ability to retain the talents and dedication of the professionals currently employed by Bioventus and Misonix. It is possible that these employees may decide not to remain with Bioventus or Misonix, as applicable, while the transaction is pending, or with the combined company. If key employees terminate their employment, or if an insufficient number of employees are retained to maintain effective operations, the combined company&#8217;s business activities may be adversely affected and management&#8217;s attention may be diverted from successfully integrating Bioventus and Misonix to hiring suitable replacements, all of which may cause the combined company&#8217;s business to suffer. In addition, Bioventus and Misonix may not be able to locate suitable replacements for any key employees that leave either company or offer employment to potential replacements on reasonable terms. In addition, there could be disruptions to or distractions for the workforce and management, including disruptions associated with integrating employees into the combined company. No assurance can be given that the combined company will be able to attract or retain key employees of Bioventus and Misonix to the same extent that those companies have been able to attract or retain their own employees in the past. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The transaction, and uncertainty regarding the transaction, may cause customers, suppliers, distributors or strategic partners to delay or defer decisions concerning Bioventus or Misonix and adversely affect each company&#8217;s ability to effectively manage its respective business. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction will happen only if the stated conditions are met, including the approval of the Bioventus share issuance proposal, the approval of the Misonix merger proposal and the receipt of required regulatory approvals, among other conditions. Many of the conditions are beyond the control of Bioventus and Misonix, and both parties also have certain rights to terminate the merger agreement. Accordingly, there may be uncertainty regarding the completion of the transaction. This uncertainty may cause customers, suppliers, distributors, vendors, strategic partners or others that deal with Bioventus or Misonix to delay or defer entering into contracts with Bioventus or Misonix or making other decisions concerning Bioventus or Misonix or seek to change or cancel existing business relationships with Bioventus or Misonix, which could negatively affect their respective businesses. Any delay or deferral of those decisions or changes in existing agreements could have an adverse impact on the respective businesses of Bioventus and Misonix, regardless of whether the transaction is ultimately completed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the merger agreement restricts Bioventus, Misonix and their respective subsidiaries from taking certain actions during the pendency of the transaction without the consent of the other parties. These restrictions may prevent Bioventus and Misonix from pursuing attractive business opportunities or strategic transactions that may arise prior to the completion of the transaction. See &#8220;The Merger Agreement&#8212;Conduct of Business Prior to Completion of the Mergers&#8221; for a description of the restrictive covenants to which each of Bioventus and Misonix is subject. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The opinions rendered to Bioventus and Misonix from their respective financial advisors will not reflect changes in circumstances between the dates of such opinions and the completion of the transaction. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg delivered its oral opinion to the Bioventus board on July&#160;28, 2021, which opinion was subsequently confirmed in a written opinion dated as of July&#160;29, 2021, to the effect that as of such date and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken and other matters considered in connection with the preparation of the opinion, the merger consideration to be paid by Bioventus pursuant to the merger agreement was fair, from a financial point of view, to Bioventus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan rendered its oral opinion to the Misonix board on July&#160;28, 2021, which opinion was subsequently confirmed in writing dated as of July&#160;29, 2021, to the effect that, as of such date and based on and subject to the assumptions made, procedures followed, matters considered and other limitations on the review undertaken by J.P. Morgan in preparing its opinion, the merger consideration to be paid to the holders of Misonix common </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock in the merger was fair, from a financial point of view, to such holders, as more fully described in the section entitled &#8220;Opinion of Misonix&#8217;s Financial Advisor&#8221;. The full text of the written opinion of J.P. Morgan, dated July&#160;29, 2021, which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan in preparing its opinion, is attached as Annex C to this joint proxy statement/prospectus and is incorporated herein by reference. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Neither Bioventus nor Misonix has obtained, nor will either of them obtain, an updated opinion from Perella Weinberg or J.P. Morgan, as applicable, regarding the fairness, from a financial point of view, of the merger consideration or exchange ratio, including as of the date of this joint proxy statement/prospectus or of the special meetings, or prior to the completion of the transaction. Each of the respective opinions of Perella Weinberg and J.P. Morgan was necessarily based on general financial, economic, monetary, market and other conditions and circumstances as in effect on, and the information made available to Perella Weinberg and J.P. Morgan as applicable, only as of the dates of the respective opinions of Perella Weinberg and J.P. Morgan, and such opinions do not address the fairness of the merger consideration, from a financial point of view, at the time the transaction is completed. Changes in the operations and prospects of Bioventus or Misonix, general financial, economic, monetary, market and other conditions, circumstances and factors that may be beyond the control of Bioventus and Misonix, and on which each of the respective opinions of Perella Weinberg and J.P. Morgan was based, may alter the value of Bioventus or Misonix or the prices of shares of Bioventus or Misonix common stock by the time the mergers are completed. The opinions of Perella Weinberg and J.P. Morgan do not speak as of any date other than the respective dates of such opinions. The recommendation of the Bioventus board that Bioventus stockholders vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus share issuance proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus adjournment proposal and the recommendation of the Misonix board that Misonix stockholders vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix merger proposal, &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix compensation proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix adjournment proposal are each made as of the date of this joint proxy statement/prospectus. For a description of the opinions that Bioventus and Misonix received from their respective financial advisors, see &#8220;The Merger&#8212;Opinion of Bioventus&#8217; Financial Advisor&#8221; and &#8220;The Merger&#8212;Opinion of Misonix&#8217;s Financial Advisor.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Whether or not the transaction is completed, the announcement and pendency of the mergers could cause disruptions in the businesses of Bioventus and Misonix, which could have an adverse effect on their respective businesses and financial results. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether or not the transaction is completed, the announcement and pendency of the mergers could cause disruptions in the businesses of Bioventus and Misonix, including by diverting the attention of Bioventus and Misonix management toward the completion of the transaction. In addition, Bioventus and Misonix have each diverted significant management resources in an effort to complete the transaction and are each subject to restrictions contained in the merger agreement on the conduct of their respective businesses. If the transaction is not completed, Bioventus and Misonix will have incurred significant costs, including the diversion of management resources, for which they will have received little or no benefit. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix directors and executive officers have interests and arrangements that may be different from, or in addition to, those of Misonix stockholders generally. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When considering the recommendations of the Misonix board on how to vote on the proposals described in this joint proxy statement/prospectus, Misonix stockholders should be aware that Misonix directors and executive officers have interests in the transaction that are different from, or in addition to, those of Misonix stockholders generally. These interests include the continued service of certain Misonix directors as directors of the combined company, the treatment in the mergers of outstanding equity, equity-based and incentive awards, severance arrangements, other compensation and benefit arrangements, and the right to continued indemnification of former Misonix directors and officers by the combined company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix stockholders should be aware of these interests when they consider the recommendations of the Misonix board that they vote to approve the Misonix merger proposal. The Misonix board was aware of and considered these interests when it determined that the transaction was fair to and in the best interests of Misonix and its stockholders, approved and declared advisable the merger agreement, and recommended that Misonix stockholders adopt the merger agreement. The interests of Misonix directors and executive officers are described in more detail under &#8220;Interests of Misonix Directors and Executive Officers in the Mergers.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus or Misonix may waive one or more of the closing conditions without <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-soliciting</div> stockholder approval. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">To the extent permitted by law, Bioventus or Misonix may determine to waive, in whole or part, one or more of the conditions to their respective obligations to consummate the mergers. Bioventus and Misonix currently expect to evaluate the materiality of any waiver and its effect on Bioventus or Misonix stockholders, as applicable, in light of the facts and circumstances at the time to determine whether any amendment of this joint proxy statement/prospectus or any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-solicitation</div> of proxies is required in light of such waiver. Any determination as to whether to waive any condition to the transaction, and as to whether to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-solicit</div> stockholder approval and/or amend this joint proxy statement/prospectus as a result of such waiver, will be made by Bioventus or Misonix, as applicable, at the time of such waiver based on the facts and circumstances as they exist at that time. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The merger agreement contains provisions that could discourage a potential competing acquirer that might be willing to pay more to acquire or merge with either Bioventus or Misonix. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement contains &#8220;no shop&#8221; provisions that restrict the ability of Bioventus and Misonix to, among other things (each as described under &#8220;The Merger Agreement&#8212;No Solicitation of Acquisition Proposals&#8221;): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">solicit, initiate, knowingly encourage, knowingly induce, knowingly assist, or knowingly facilitate any inquiries regarding, or the submission or announcement by any person of, any proposal or offer that constitutes, or would reasonably be expected to lead to, an acquisition proposal; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">furnish any information regarding Bioventus, Misonix or their respective subsidiaries in connection with, for the purpose of soliciting, initiating, encouraging or facilitating, or in response to, an acquisition proposal; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">engage in or otherwise participate in any discussions or negotiations with any person with respect to any acquisition proposal or any inquiry, proposal or offer that would reasonably be expected to lead to an acquisition proposal; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approve, adopt, recommend, agree to, or enter into, or propose to approve, adopt, recommend, agree to, or enter into, any letter of intent or similar document, agreement, commitment, or agreement in principle with respect to any acquisition proposal. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, there are only limited exceptions to the requirement under the merger agreement that neither the Bioventus nor Misonix boards of directors withdraw, modify, amend or qualify the Bioventus recommendation or the Misonix recommendation, as applicable (each as defined under &#8220;The Merger Agreement&#8212;Representations and Warranties&#8221;). Although the Bioventus or Misonix board is permitted to effect a change of recommendation, after complying with certain procedures set forth in the merger agreement, in response to a superior proposal or to an intervening event (if the applicable board of directors determines in good faith after consultation with its outside legal counsel and its financial advisor that a failure to do so would be reasonably likely to be inconsistent with its fiduciary duties under applicable law), such change of recommendation by the Misonix board would entitle Bioventus to terminate the merger agreement and collect a termination fee from Misonix. See &#8220;The Merger Agreement&#8212;Termination of the Merger Agreement&#8221; and &#8220;The Merger Agreement&#8212;Termination Fees.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These provisions could discourage a potential competing acquirer from considering or proposing an acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the exchange ratio in the first merger, or might result in a potential competing acquirer proposing to pay a lower per share price than it might otherwise have proposed to pay because of the added expense of the termination fee. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The transaction will involve substantial costs. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus and Misonix have incurred and expect to incur <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs associated with combining the operations of the two companies, as well as transaction fees and other costs related to the transaction. As of the date of this joint proxy statement/prospectus, Bioventus and Misonix estimate that their aggregate costs associated with the transaction and related transactions will be approximately $18.0&#160;million and $10.4&#160;million, respectively. These costs include filing and registration fees with the SEC, printing and mailing costs associated with this joint proxy/registration statement, and legal, accounting, investment banking, consulting, public relations and proxy solicitation fees. These costs do not include severance and retention payments that may be made to certain Misonix employees and costs that will be incurred in connection with the integration of Bioventus&#8217; and Misonix&#8217;s businesses. Some of these costs are payable by Bioventus or Misonix regardless of whether the transaction is completed. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The combined company will also incur restructuring and integration costs in connection with the mergers. The costs related to restructuring will be expensed as a cost of the ongoing results of operations of either Bioventus or the combined company. There are processes, policies, procedures, operations, technologies and systems that must be integrated in connection with the mergers and the integration of Misonix&#8217;s business. Although Bioventus expects that the elimination of duplicative costs, strategic benefits, and additional income, as well as the realization of other efficiencies related to the integration of the businesses, may offset incremental transaction, merger-related and restructuring costs over time, any net benefit may not be achieved in the near term or at all. Many of these costs will be borne by Bioventus even if the mergers are not completed. While Bioventus has assumed that certain expenses would be incurred in connection with the transaction, there are many factors beyond Bioventus&#8217; control that could affect the total amount or the timing of the integration and implementation expenses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus stockholders will not be entitled to appraisal rights in the transaction, though Misonix stockholders will be entitled to appraisal rights in the transaction. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Appraisal rights are statutory rights that, if applicable under law, enable stockholders of a corporation to dissent from an extraordinary transaction, such as a merger, and to demand that such corporation pay the fair value for their shares as determined by a court in a judicial proceeding instead of receiving the consideration offered to such stockholders in connection with the extraordinary transaction. Under the DGCL, stockholders generally do not have appraisal rights if the shares of stock they hold are either listed on a national securities exchange or held of record by more than 2,000 holders. Notwithstanding the foregoing, appraisal rights are available if stockholders are required by the terms of the merger agreement to accept for their shares anything other than (a)&#160;shares of stock of the surviving corporation, (b)&#160;shares of stock of another corporation that will either be listed on a national securities exchange or held of record by more than 2,000 holders, (c)&#160;cash in lieu of fractional shares or (d)&#160;any combination of the foregoing. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because the mergers are of Merger Sub with and into Misonix and then Misonix with and into Merger Sub II and holders of Bioventus common stock will continue to hold their shares following completion of the mergers, holders of Bioventus common stock are not entitled to appraisal rights in connection with the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Section&#160;262 of the DGCL, Misonix stockholders who do not vote in favor of Misonix merger proposal and who comply with the applicable requirements of Section&#160;262 of the DGCL have the right to seek appraisal of such shares by the Delaware Court of Chancery and to receive payment in cash of the fair value of those shares. It is possible that the fair value as determined by the Delaware Court of Chancery may be more or less than, or the same as, the per share value of the merger consideration. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix stockholders who wish to preserve their appraisal rights must make a demand for appraisal prior to the time the Misonix stockholder vote is taken on the Misonix merger proposal. In addition to submitting a demand for appraisal, such Misonix stockholders must continuously hold such shares through the effective time, must not vote in favor of the Misonix merger proposal, must not surrender their shares in exchange for the merger consideration, and must otherwise follow the procedures prescribed by Section&#160;262 of the DGCL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Misonix stockholders are encouraged to read Section&#160;262 of the DGCL carefully and in their entirety. Due to the complexity of the procedures for exercising your appraisal rights, Misonix stockholders who are considering exercising such rights are encouraged to seek the advice of legal counsel. Failure to strictly comply with these provisions will result in the loss of appraisal rights. See the section entitled &#8220;Appraisal Rights&#8221; of this joint proxy statement/prospectus for additional information and the text of Section&#160;262 of the DGCL reproduced in its entirety as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex D</div> to this proxy statement/prospectus. See &#8220;Appraisal Rights.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lawsuits filed against Bioventus and/or Misonix may delay or prevent the transaction from being completed. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus, Misonix and members of the Bioventus and Misonix boards of directors may in the future be parties, among others, to various claims and litigation related to the merger agreement and the merger, including putative shareholder class actions. See &#8220;The Mergers&#8212;Litigation Relating to the Mergers.&#8221; Among other remedies, the plaintiffs in such matters are seeking to enjoin the transaction. The results of complex legal proceedings are difficult to predict, and could prevent or delay the merger from being completed in a timely manner, and could result in substantial costs to Bioventus and Misonix, including, but not limited to, costs associated with the indemnification of their respective directors and officers. The existence of litigation relating to the merger could also impact the likelihood of obtaining the required approvals from either Bioventus or Misonix stockholders. Moreover, the pending litigation and any future additional litigation could be time consuming and expensive, could divert the attention of Bioventus and Misonix management away from their regular businesses and, if any one of these lawsuits is adversely resolved against either Bioventus or Misonix, could have a material adverse effect on Bioventus&#8217; or Misonix&#8217;s respective financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the conditions to the completion of the mergers is that no relevant legal restraint (as defined in the merger agreement) will be in effect. As such, any relevant legal restraint may delay or prevent the mergers from becoming effective. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to the Combined Company </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Combining the businesses of Bioventus and Misonix may be more difficult, costly or time-consuming than expected and the combined company may fail to realize the anticipated benefits of the merger, which may adversely affect the combined company&#8217;s business results and negatively affect the value of the combined company&#8217;s common stock. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The success of the mergers will depend on, among other things, the ability of Bioventus and Misonix to combine their businesses in a manner that facilitates growth opportunities and realizes expected cost savings. Bioventus and Misonix have entered into the merger agreement because each believes that the transaction is fair to and in the best interests of their respective stockholders and that combining the businesses of Bioventus and Misonix will produce benefits and cost savings. See &#8220;The Mergers&#8212;Recommendation of the Bioventus Board of Directors; Bioventus&#8217; Reasons for the Mergers&#8221; and &#8220;The Mergers&#8212;Recommendation of the Misonix Board of Directors; Misonix&#8217;s Reasons for the Mergers.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, Bioventus and Misonix must successfully combine their respective businesses in a manner that permits these benefits to be realized. In addition, the combined company must achieve the anticipated growth and cost savings without adversely affecting current revenues and investments in future growth. If the combined company is not able to successfully achieve these objectives, the anticipated benefits of the transaction may not be realized fully, or at all, or may take longer to realize than expected. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An inability to realize the full extent of the anticipated benefits of the transaction, as well as any delays encountered in the integration process, could have an adverse effect upon the revenues, level of expenses and operating results of the combined company, which may adversely affect the value of the common stock of the combined company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the actual integration may result in additional and unforeseen expenses, and the anticipated benefits of the integration plan may not be realized. Actual growth and cost savings, if achieved, may be lower than what Bioventus and Misonix expect and may take longer to achieve than anticipated. If Bioventus and Misonix are not able to adequately address integration challenges, they may be unable to successfully integrate their operations or realize the anticipated benefits of the integration of the two companies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The failure to successfully integrate the businesses and operations of Bioventus and Misonix in the expected time frame may adversely affect the combined company&#8217;s future results. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix have operated and, until the completion of the transaction, will continue to operate independently. There can be no assurances that their businesses can be integrated successfully. It is possible that the integration process could result in the loss of key Bioventus or Misonix employees, the loss of customers, the disruption of either company&#8217;s or both companies&#8217; ongoing businesses, inconsistencies in standards, controls, procedures and policies, unexpected integration issues, higher than expected integration costs and an overall post-completion integration process that takes longer than originally anticipated. Specifically, the following issues, among others, must be addressed in integrating the operations of Bioventus and Misonix in order to realize the anticipated benefits of the transaction so the combined company performs as expected: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">combining the companies&#8217; operations and corporate functions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">combining the businesses of Bioventus and Misonix and meeting the capital requirements of the combined company, in a manner that permits the combined company to achieve any cost savings or other synergies anticipated to result from the mergers, the failure of which would result in the anticipated benefits of the transaction not being realized in the time frame currently anticipated or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">integrating personnel from the two companies, especially in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> environment which has required many employees to work remotely; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">integrating the companies&#8217; technologies and technologies licensed from third parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">integrating and unifying the offerings and services available to customers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">identifying and eliminating redundant and underperforming functions and assets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">harmonizing the companies&#8217; operating practices, employee development and compensation programs, internal controls and other policies, procedures and processes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintaining existing agreements with customers, suppliers, distributors and vendors, avoiding delays in entering into new agreements with prospective customers, suppliers, distributors and vendors, and leveraging relationships with such third parties for the benefit of the combined company; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">addressing possible differences in business backgrounds, corporate cultures and management philosophies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consolidating the companies&#8217; administrative and information technology infrastructure; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">coordinating distribution and marketing efforts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">managing the movement of certain positions to different locations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">coordinating geographically dispersed organizations; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effecting actions that may be required in connection with obtaining regulatory or other governmental approvals. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, at times the attention of certain members of either company&#8217;s or both companies&#8217; management and resources may be focused on completion of the transaction and the integration of the businesses of the two companies and diverted from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> business operations or other opportunities that may have been beneficial to such company, which may disrupt each company&#8217;s ongoing business and the business of the combined company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The combined company may not be able to retain customers, suppliers or distributors, or customers, suppliers or distributors may seek to modify contractual relationships with the combined company, which could have an adverse effect on the combined company&#8217;s business and operations. Third parties may terminate or alter existing contracts or relationships with Bioventus or Misonix. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the transaction, the combined company may experience impacts on relationships with customers, suppliers and distributors that may harm the combined company&#8217;s business and results of operations. Certain customers, suppliers or distributors may seek to terminate or modify contractual obligations following the transaction whether or not contractual rights are triggered as a result of the transaction. There can be no guarantee that customers, suppliers and distributors will remain with or continue to have a relationship with the combined company or do so on the same or similar contractual terms following the transaction. If any customers, suppliers or distributors seek to terminate or modify contractual obligations or discontinue the relationship with the combined company, then the combined company&#8217;s business and results of operations may be harmed. Furthermore, the combined company will not have long-term arrangements with many of its significant suppliers. If the combined company&#8217;s suppliers were to seek to terminate or modify an arrangement with the combined company, then the combined company may be unable to procure necessary supplies from other suppliers in a timely and efficient manner and on acceptable terms, or at all. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix also have contracts with vendors, landlords, licensors and other business partners which may require Bioventus or Misonix, as applicable, to obtain consent from these other parties in connection with the transaction, or which may otherwise contain limitations applicable to such contracts following the transaction. If these consents cannot be obtained, the combined company may suffer a loss of potential future revenue, incur costs and lose rights that may be material to the combined company&#8217;s business. In addition, third parties with whom Bioventus or Misonix currently have relationships may terminate or otherwise reduce the scope of their relationship with either party in anticipation of the transaction. Any such disruptions could limit the combined company&#8217;s ability to achieve the anticipated benefits of the transaction. The adverse effect of any such disruptions could also be exacerbated by a delay in the completion of the transaction or by a termination of the merger agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The combined company may be exposed to increased litigation, which could have an adverse effect on the combined company&#8217;s business and operations. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The combined company may be exposed to increased litigation from stockholders, customers, suppliers, distributors, consumers and other third parties due to the combination of Bioventus&#8217; and Misonix&#8217;s businesses following the mergers. Such litigation may have an adverse impact on the combined company&#8217;s business and results of operations or may cause disruptions to the combined company&#8217;s operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Bioventus and Misonix unaudited prospective financial information is inherently subject to uncertainties, the unaudited pro forma condensed combined financial information included in this document is preliminary and the combined company&#8217;s actual financial position and results of operations after the transaction may differ materially from these estimates and the unaudited pro forma condensed combined financial information included in this joint proxy statement/prospectus. The unaudited pro forma condensed combined financial information does not reflect the effect of any divestitures that may be required in connection with the transaction. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial information included in this joint proxy statement/prospectus is presented for illustrative purposes only, contains a variety of adjustments, assumptions and preliminary estimates and is not necessarily indicative of what the combined company&#8217;s actual financial position or results of operations would have been had the transaction been completed on the dates indicated. The combined company&#8217;s actual results and financial position after the transaction may differ materially and adversely from the unaudited pro forma condensed combined financial information included in this joint proxy statement/prospectus. The unaudited pro forma condensed combined financial information does not reflect the effect of any divestitures that may be required in connection with the transaction. See &#8220;Unaudited Pro Forma Condensed Combined Financial Statements.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While presented with numeric specificity, the Bioventus and Misonix unaudited pro forma condensed combined financial information provided in this joint proxy statement/prospectus is based on numerous variables and assumptions (including, but not limited to, those related to industry performance and competition, general business, the semiconductor and related industries, and economic, market and financial conditions and additional matters specific to Bioventus&#8217; or Misonix&#8217;s business, as applicable) that are inherently subjective and uncertain and are beyond the control of the respective management teams of Bioventus and Misonix. As a result, actual results may differ materially from the unaudited pro forma condensed combined financial information. Important factors that may affect actual results and cause these unaudited projected financial forecasts to not be achieved include, but are not limited to, risks and uncertainties relating to Bioventus&#8217; or Misonix&#8217;s business, as applicable (including each company&#8217;s ability to achieve strategic goals, objectives and targets over applicable periods), industry performance, general business and economic conditions. See &#8220;The Merger&#8212;Bioventus Unaudited Financial Projections,&#8221; &#8220;The Merger&#8212;Misonix Unaudited Financial Projections&#8221; and &#8220;The Merger&#8212;Certain Estimated Synergies.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The combined company&#8217;s debt may limit its financial flexibility. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix continue to review the treatment of their existing indebtedness. Bioventus and Misonix may seek to repay, refinance, repurchase, redeem, exchange or otherwise terminate their existing indebtedness prior to, in connection with or following the completion of the mergers. If either Bioventus or Misonix seeks to refinance its existing indebtedness, there can be no guarantee that it will be able to execute the refinancing on favorable terms or at all. Alternatively, Bioventus and Misonix may seek to leave all or a portion of their existing indebtedness outstanding as the primary obligation of the combined company or to incur additional indebtedness or refinancing indebtedness prior to, in connection with or following the completion of the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; or Misonix&#8217;s substantial indebtedness could have adverse effects on such company&#8217;s and/or the combined company&#8217;s financial condition and results of operations, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increasing its vulnerability to changing economic, regulatory and industry conditions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limiting its ability to compete and its flexibility in planning for, or reacting to, changes in its business and the industry; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limiting its ability to pay dividends to its stockholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limiting its ability to borrow additional funds; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increasing its interest expense and requiring it to dedicate a substantial portion of its cash flow from operations to payments on its debt, thereby reducing funds available for working capital, capital expenditures, acquisitions, and share repurchases, dividends and other purposes. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The companies&#8217; ability to arrange any additional financing for the purposes described above or otherwise will depend on, among other factors, the companies&#8217; respective financial positions and performance, as well as prevailing market conditions and other factors beyond their control. The level and quality of the combined company&#8217;s earnings, operations, business and management, among other things, will impact the determination of the combined company&#8217;s credit ratings. A decrease in the ratings assigned to the combined company by the ratings agencies may negatively impact the combined company&#8217;s access to the debt capital markets and increase the combined company&#8217;s cost of borrowing. There can be no assurance that the combined company will be able to obtain financing on acceptable terms or at all. In addition, there can be no assurance that the combined company will be able to maintain the current creditworthiness or prospective credit ratings of Bioventus or Misonix, and any actual or anticipated changes or downgrades in such credit ratings may have a negative impact on the liquidity, capital position or access to capital markets of the combined company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If the existing indebtedness of Bioventus and/or Misonix remains outstanding, or if either company refinances its existing indebtedness, covenants contained in the agreements governing such indebtedness will impose restrictions on the combined company and certain of its subsidiaries that may affect their ability to operate their businesses. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The agreements that govern the indebtedness of Bioventus and Misonix, in addition to any refinanced indebtedness, may contain various affirmative and negative covenants. Such covenants may, subject to certain significant exceptions, restrict the ability of the combined company and certain of its subsidiaries to, among other things, incur liens, incur debt, engage in mergers, consolidations and acquisitions, transfer assets outside the ordinary course of business, make loans or other investments, pay dividends, repurchase equity interests, make other payments with respect to equity interests, repay or repurchase subordinated debt and engage in affiliate transactions. In addition, the agreements governing the existing indebtedness of Bioventus and Misonix contain financial covenants that would require the combined company to maintain certain financial ratios under certain circumstances. The ability of the combined company and its subsidiaries to comply with these provisions may be affected by events beyond their control. Failure to comply with these covenants could result in an event of default, which, if not cured or waived, could accelerate the combined company&#8217;s repayment obligations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Declaration, payment and amounts of dividends, if any, distributed to stockholders of the combined company will be uncertain. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has not historically paid cash dividends on its capital stock. Whether any dividends are declared or paid to stockholders of the combined company, and the amounts of any such dividends that are declared or paid, are uncertain and depend on a number of factors. If dividends are paid to stockholders of the combined company, they may not be of the same amount as paid by Misonix to its stockholders prior to the mergers. The Bioventus board will have the discretion to determine the dividend policy of the combined company, including the amount and timing of dividends, if any, that the combined company may declare from time to time, which may be impacted by any of the following factors: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the combined company may not have enough cash to pay such dividends or to repurchase shares due to its cash requirements, capital spending plans, cash flow or financial position; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decisions on whether, when and in which amounts to make any future distributions will remain at all times entirely at the discretion of the Bioventus board, which could change its dividend practices at any time and for any reason; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the combined company&#8217;s desire to maintain or improve the credit ratings on its debt; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount of dividends that the combined company may distribute to its stockholders is subject to restrictions under Delaware law and is limited by restricted payment and leverage covenants in the </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">combined company&#8217;s credit facilities and indentures and, potentially, the terms of any future indebtedness that the combined company may incur; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain limitations on the amount of dividends subsidiaries of the combined company can distribute to the combined company, as imposed by state law, regulators or agreements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders should be aware that they have no contractual or other legal right to dividends that have not been declared. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The combined company is subject to risks arising from the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The outbreak <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;COVID-19,</div> which the World Health Organization declared a pandemic in March 2020, has spread across the globe and disrupted the global economy. Governmental actions to reduce the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> have negatively impacted the macroeconomic environment in many ways, while the pandemic itself has significantly increased economic uncertainty and abruptly reduced economic activity. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will impact the combined company is highly uncertain and is difficult to predict. The pandemic&#8217;s effects and their extent will depend on various factors, including, but not limited to, the duration, scope and impact of the pandemic, restrictions on business and social distancing guidelines that may be requested or mandated by governmental authorities and how quickly and to what extent normal economic and operating conditions can resume. Relevant adverse consequences of the pandemic could include reduced liquidity, increased volatility of the combined company&#8217;s stock price, operational disruption or failure due to spread of disease within the combined company or due to restrictions on business and social distancing guidelines imposed or requested by governmental authorities, unavailability of raw materials, disruption in the supply chain and increased cybersecurity and fraud risks due to increased online and remote activity, as well as the adverse consequences of a macroeconomic slowdown, recession or depression. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Even after <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19</div> pandemic has subsided, the combined company may continue to experience adverse impacts to its business as a result of the&#160;global economic impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, including reduced availability of credit, adverse impacts on liquidity and the negative financial effects from any recession or depression that may occur. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any impairment of the combined company&#8217;s tangible, definite-lived intangible or indefinite-lived intangible assets, including goodwill, may adversely impact the combined company&#8217;s financial position and results of operations. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The mergers will be accounted for using the acquisition method of accounting under the provisions of ASC 805, Business Combinations, with Bioventus representing the accounting acquirer under this guidance. Bioventus will record assets acquired, including identifiable intangible assets, and liabilities assumed from Misonix at their respective fair values at the date of completion of the mergers. Any excess of the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill. In connection with the mergers, the combined company is expected to record significant goodwill and other intangible assets on its consolidated balance sheet. See &#8220;Unaudited Pro Forma Condensed Combined Financial Statements.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible assets, including goodwill, will be tested for impairment at least annually, and all tangible and intangible assets including goodwill will be tested for impairment when certain indicators are present. If, in the future, the combined company determines that tangible or intangible assets, including goodwill, are impaired, the combined company would record an impairment charge at that time. Impairment testing of goodwill and intangible assets requires significant use of judgment and assumptions, particularly as it relates to the determination of fair value. A decrease in the long-term economic outlook and future cash flows of the combined company&#8217;s business could significantly impact asset values and potentially result in the impairment of intangible assets, including goodwill, which may have a material adverse impact on the combined company&#8217;s financial position and results of operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Bioventus charter designates, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) as the exclusive forums for substantially all disputes between Bioventus and its stockholders, which will restrict the ability of stockholders of the combined company to choose the judicial forum for disputes with the combined company or its directors, officers or employees. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus charter provides that, unless Bioventus consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for the following types of actions, suits or proceedings: (i)&#160;any derivative action, suit or proceeding brought on behalf of Bioventus; (ii)&#160;any action, suit or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former Bioventus director, officer, employee or stockholder to Bioventus or its stockholders; (iii)&#160;any action, suit or proceeding asserting a claim arising pursuant to any provision of the DGCL, the Bioventus charter, the Bioventus bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or (iv)&#160;any action, suit or proceeding asserting a claim governed by the internal affairs doctrine. Nothing in the Bioventus charter or the Bioventus bylaws would preclude stockholders that assert claims under the Exchange Act from bringing such claims in federal court to the extent the Exchange Act confers exclusive federal jurisdiction over such claims, subject to applicable law. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. The Bioventus charter provides that the U.S. federal district courts are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. However, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These forum selection provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the combined company or its directors, officers or other employees, which may discourage such lawsuits. While Delaware courts have determined that such forum selection provisions are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against the combined company and its directors, officers or other employees in a venue other than in the U.S. federal district courts. In such instance, the combined company would expect to vigorously assert the validity and enforceability of these forum selection provisions. This may require further significant additional costs associated with resolving the dispute in other jurisdictions, and there can be no assurance that the forum selection provisions will be enforced by a court in those other jurisdictions, any of which could seriously harm the combined company&#8217;s business. </div></div> <div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Bioventus&#8217; Business </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; business may continue to experience adverse impacts as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2020, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic spread around the world and in the U.S. and, more recently, new variants of the virus have emerged, some of which have shown to be more contagious. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments have implemented measures in an effort to minimize the spread of the virus and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of business, work from home, supply chain logistical changes and other measures, which have caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Bioventus&#8217; business, results of operations and financial condition have been, and may continue to be, materially impacted due to the decrease in patient visits and elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments from customers, supply chain interruptions, extended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;shelter-in-place&#8221;</div></div> orders </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on Bioventus&#8217; business will depend on many factors, including, but not limited to, the duration and severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability and effectiveness of vaccines to combat <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on Bioventus&#8217; partners, patients and communities in which Bioventus operates, all of which continue to be uncertain. For example, there has been a decrease in patient visits to hospitals due to risk and fear of exposure to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> as well as decreases in, or temporary moratoriums on, elective procedures, which may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-imposed</div> in the future. In addition to lower sales, Bioventus has experienced decreased costs as a result of the pandemic including declines in travel and lower compensation related expenses. Bioventus has also implemented other various cost reduction initiatives and measures to safeguard liquidity, refer to &#8220;Bioventus&#8217; Management&#8217;s Discussion and Analysis&#8221; for further details on the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on Bioventus&#8217; business. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To the extent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> disruptions continue to adversely impact Bioventus&#8217; business, results of operations and financial condition, it may also have the effect of heightening many of the other risks described in &#8220;Risk Factors&#8221; including risks relating to Bioventus&#8217; ability to successfully commercialize new developed or acquired products or therapies, consolidation in the healthcare industry, disruptions in the supply or manufacturing of Bioventus&#8217; products or their components, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of Bioventus&#8217; numerous contractual relationships. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus is highly dependent on a limited number of products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus&#8217; pain treatment and joint preservation products accounted for 53%, 54% and 49% of Bioventus&#8217; total revenue for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Bioventus expects that sales of such products will continue to account for a substantial portion of its revenue, and therefore, its ability to execute its growth strategy and maintain profitability will depend upon the continued demand for these products. In addition, Bioventus&#8217; supply and distribution agreements for Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> and SUPARTZ FX are subject to renewal and their terms end in December 2115, February 2026 and December 2028, respectively. If the supply and distribution agreements for any of Bioventus&#8217; HA viscosupplementation therapies were terminated, its revenue would be impaired. If Bioventus&#8217; pain treatment and joint preservation products fail to maintain their market acceptance for any reason, its business, results of operations and financial condition may be adversely affected. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; long-term growth depends on its ability to develop, acquire and commercialize new products, line extensions or expanded indications. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; industry is highly competitive and subject to rapid change and technological advancements. Therefore, it is important to Bioventus&#8217; business that it continues to introduce new products and/or enhance its existing product offerings through line extensions or expanded indications. Developing, acquiring and commercializing products is expensive, time-consuming and could divert management&#8217;s attention away from Bioventus&#8217; existing business. Even if Bioventus is successful in developing additional products, the success of any new product offering or enhancements to existing products will depend on several factors, including its ability to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">properly identify and anticipate the needs of healthcare professionals and patients; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">develop and introduce new products, line extensions and expanded indications in a timely manner; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distinguish Bioventus&#8217; products from those of its competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">avoid infringing upon the intellectual property rights of third-parties and maintain necessary intellectual property licenses from third-parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain clearance or approval, if required, from the FDA and other regulatory agencies, for such new products, line extensions and expanded indications, and maintain full compliance with FDA and other regulatory requirements applicable to new devices or products or modifications of existing devices or products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provide adequate training to potential users of Bioventus&#8217; products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">receive adequate coverage and reimbursement for Bioventus&#8217; products; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintain an effective and dedicated sales and marketing team. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Bioventus is unsuccessful in developing, acquiring and commercializing new products or enhancing its existing product offerings through line extensions and expanded indications, Bioventus&#8217; ability to increase its net sales may be impaired. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, Bioventus&#8217; research and development efforts may require a substantial investment of time and resources before Bioventus is adequately able to determine the commercial viability of a new product, technology, material or other innovation. Such efforts may not result in the development of a viable product. In addition, even if Bioventus is able to successfully develop new active healing products, line extensions and expanded indications, these products may not produce sales in excess of the costs of development and they may be rendered obsolete by changing customer preferences or the introduction by Bioventus&#8217; competitors of products embodying new technologies or features. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may be unable to successfully commercialize newly developed or acquired products or therapies in the United States. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The commercial success of newly acquired or developed products, such as MOTYS, in the United States will depend upon the awareness and acceptance of such products among the medical community, including physicians and patients. Market acceptance will depend on a number of factors, including, among others: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the perceived advantages and disadvantages of such products over existing therapies and other competitive treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">availability of alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to secure and maintain adequate coverage, including obtaining a unique reimbursement code; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the extent to which physicians prescribe the Company&#8217;s products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the willingness of the target patient population to try new therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the strength of marketing and distribution support of the Company&#8217;s new products and competitive products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">publicity concerning the Company&#8217;s new products, Bioventus&#8217; existing products or competing products and treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pricing and cost effectiveness of such new therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the effectiveness of Bioventus&#8217; sales and marketing strategies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the willingness of patients to pay <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> in the absence of third-party reimbursement. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; efforts to educate the medical community about the benefits of newly acquired or developed products may require significant resources and Bioventus may never be successful. If such newly acquired or developed products do not achieve an adequate level of acceptance by patients and physicians in the United States, its business, results of operations and financial condition may be adversely affected. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Demand for Bioventus&#8217; existing portfolio of products and any new products, line extensions or expanded indications depends on the continued and future acceptance of its products by physicians, patients, third-party payers and others in the medical community. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus cannot be certain that its existing portfolio of products and any new products, line extensions or expanded indications that it develops will achieve or maintain market acceptance. With respect to Bioventus&#8217; pain treatment and joint preservation products, third-party payers may be reluctant to continue to cover Bioventus&#8217; HA viscosupplementation therapies at their current prices. Further, new injectable therapies or oral medications may become available that help manage pain in a more convenient and/or cost effective manner than Bioventus&#8217; HA viscosupplementation therapies. With respect to Bioventus&#8217; BGS products, new allograft, DBMs, synthetics, growth factors, or other enhancements to Bioventus&#8217; existing implants may never achieve broad market acceptance, which can be affected by a lack of clinical acceptance of BGSs and technologies, introduction of competitive treatment options which render BGSs and technologies too expensive or obsolete and difficulty training surgeons in the use of BGSs and technologies. Media reports or other negative publicity concerning both methods of tissue recovery from donors and actual or potential disease transmission from donated tissue may limit widespread acceptance by the medical community of Bioventus&#8217; allografts, growth factor and DBMs, whether directed at these products generally or Bioventus&#8217; products specifically. Unfavorable reports of improper or illegal tissue recovery practices by any participant in the industry, both in the United States and internationally, as well as incidents of improperly processed tissue leading to transmission of disease, may broadly affect the rate of future tissue donation and market acceptance of allograft based technologies by the medical community. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, Bioventus believes that even if the medical community generally accepts its existing portfolio of products and any new products, line extensions or expanded indications, acceptance and recommendations by influential members of the medical community will be important to their broad commercial success. If the medical community does not broadly accept its products, Bioventus may not remain competitive in the market, which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; commercial success depends on its ability to differentiate the HA viscosupplementation therapies that it owns or distributes from alternative therapies for the treatment of OA. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; ability to achieve commercial success will, at least in part, depend on its ability to differentiate the HA viscosupplementation therapies that Bioventus owns or distributes in such a way that physicians and patients will select them. The HA viscosupplementation therapies that Bioventus owns or distributes could face competition from steroid injections, other HA viscosupplementation therapies, combination HA viscosupplementation/steroid therapies and alternate therapies for the treatment of OA, including those currently in development. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus expects that the HA viscosupplementation therapies that it owns or distributes will continue to be used primarily after oral analgesics and steroid injections no longer provide adequate pain relief. In addition, the five and three injection HA viscosupplementation therapies that Bioventus distributes face competition from single injection therapies. Bioventus expects the three injection market to decline by a projected 3.1% CAGR and the five injection market to decline by a projected 13.6% CAGR from 2019 to 2024. Due to the convenience associated with the single injection treatments, it is expected that these products will continue to capture increasing market share of the HA viscosupplementation therapies market, which may adversely affect its business, results of operations and financial condition to the extent physicians and patients do not select Durolane, its single injection HA viscosupplementation therapy. There are also a number of combination HA viscosupplementation/steroid therapies currently in development. The American Association of Orthopedic Surgeons (AAOS), since the release of their May 2013 clinical practice guidelines, does not recommend the use of HA for patients with symptomatic knee OA. The evidence for the AAOS recommendation is based on two or more high quality studies with consistent findings for recommending for or against the intervention. The AAOS recommendation states that practitioners should follow a strong recommendation, such as this one, unless a clear </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and compelling rationale for an alternative approach is present. In May 2018, the Journal of the AAOS ranked the nonsteroidal anti-inflammatory drug naproxen the most effective in individual knee OA treatment for improving both pain and function. To the extent that any additional therapies receive approval or alternative therapies receive positive support from the AAOS or other physician associations, they could reduce the market share represented by HA viscosupplementation therapies for OA treatment and adversely affect Bioventus&#8217; commercial success. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Bioventus is unable to differentiate the HA viscosupplementation therapies it owns or distributes from other therapies, physicians and patients may not be willing to use them or be willing to switch from existing therapies with which they are familiar. Once physicians incorporate a particular treatment into their practice, they may not alter their practice absent compelling clinical evidence of safety and/or effectiveness and/or significant pricing reimbursement advantages. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The proposed down-classification of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> bone growth stimulators, including Bioventus&#8217; Exogen system, by the FDA could increase future competition for bone growth stimulators and otherwise adversely affect the Company&#8217;s sales of Exogen. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;17, 2020, FDA published a Federal Register notice announcing its proposal to reclassify <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> bone growth stimulators, such as Exogen, from Class&#160;III medical devices to Class&#160;II with special controls. Class&#160;III devices are subject to the most stringent regulatory pathway for approval for medical devices requiring, among other things, rigorous clinical studies and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> manufacturing review. Class&#160;II devices may be cleared for marketing by the FDA under the 510(k) pathway if they are determined to be substantially equivalent to a legally marketed predicate device. The 510(k) clearance process does not always require clinical testing, and is generally less onerous than the premarket approval process applicable to Class&#160;III devices. On September <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-9,</div> 2020, the Orthopaedic and Rehabilitation Devices Panel of the FDA Medical Devices Advisory Committee met and discussed FDA&#8217;s proposal. The Panel, whose authority is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> but nonetheless considered by FDA, ultimately voted in favor of FDA&#8217;s proposal to down-classify <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> bone growth stimulators. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA has proposed that any final order would become effective 30 days after publication. While FDA has not yet finalized its proposal to down-classify <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> bone growth stimulators, should such down-classification occur now or in the future, Bioventus may face additional competition from new market entrants who would be able to pursue marketing authorization through the 510(k) clearance pathway instead of the more onerous and burdensome PMA approval process. Class&#160;II devices that qualify as durable medical equipment under the Medicare program may also be eligible for inclusion in Medicare&#8217;s competitive bidding program for durable medical equipment, prosthetics, orthotics and supplies. As a result of down-classification, Exogen could face additional competition or Bioventus could receive lower reimbursement amounts for Exogen, all of which could adversely affect its business, results of operations and financial condition. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus is unable to achieve and maintain adequate levels of coverage and/or reimbursement for its products, the procedures using its products, or any future products it may seek to commercialize, the commercial success of these products may be severely hindered. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus&#8217; products are purchased by healthcare providers and customers who typically bill third-party payers, such as government programs, including Medicare and Medicaid, or private insurance plans and healthcare networks, to cover all or a portion of the costs and fees associated with its products. Patients may also be billed for deductibles or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> in accordance with third-party payer policies. These third-party payers and insurers may deny reimbursement if they determine that a device or product provided to a patient or used in a procedure does not meet applicable payment criteria or if the policyholder&#8217;s healthcare insurance benefits are limited. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As required by law, the CMS, which administers the Medicare program, has continued efforts to implement a competitive bidding program for selected durable medical equipment, prosthetic and orthotic supplies items paid </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for by the Medicare program. In this program, Medicare rates are based on bid amounts for certain products in designated geographic areas, rather than the Medicare fee schedule amount. Bone growth stimulation products like Bioventus&#8217; Exogen system are currently exempt from this competitive bidding process, but may be eligible for inclusion if the FDA&#8217;s proposed down-classification order becomes effective. Bioventus cannot predict which products from any of its businesses may ultimately be affected or whether or when the competitive bidding process may be extended to its businesses. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limits put on reimbursement by third-party payers, whether foreign or domestic, governmental or commercial, could make it more difficult to buy Bioventus&#8217; products and substantially reduce, or possibly eliminate, patient access to its products. The healthcare industry in the United States has experienced a trend toward cost containment as government and private insurers seek to control rising healthcare costs by imposing lower payment rates and negotiating reduced contract rates with providers and suppliers. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is no uniform policy of coverage and reimbursement for Bioventus&#8217; products or procedures using Bioventus&#8217; products among third-party payers in the United States, and coverage and reimbursement for Bioventus&#8217; products and procedures using Bioventus&#8217; products can differ significantly from payer to payer. Further, these payers regularly review new and existing technologies for possible coverage and can, without notice, deny or reverse coverage for new or existing products and treatments. Third-party payers may not consider Bioventus&#8217; products to be medically necessary or cost-effective for certain indications or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses or for all uses, and as a result, may not provide coverage for the products. For example, Blue Cross Blue Shield Association&#8217;s Evidence Street platform issued a report in April 2018 questioning the efficacy of Bioventus&#8217; Exogen system, which resulted in several non-coverage policies being issued by member organizations. Additionally, to the extent that third party payers decide that they are no longer willing to provide reimbursement for physician prescribed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses of Exogen, sales may be negatively impacted. See <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div>&#8220;Risk Factors&#8212;Risks Relating to Government Regulation.&#8221; Bioventus may be subject to enforcement action if it engages in improper marketing or promotion of Bioventus&#8217; products, and the misuse or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use of Bioventus&#8217; products may harm its image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if Bioventus is deemed to have engaged in the promotion of these uses, any of which could be costly to Bioventus&#8217; business.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may also be required to conduct expensive clinical studies to justify coverage and reimbursement and/or the level of reimbursement relative to other therapies. In addition, should governmental authorities continue to enact legislation or adopt regulations that affect third-party coverage and reimbursement, access to Bioventus&#8217; products and coverage by private or public insurers may be reduced. If third-party payers or insurers that currently cover or reimburse Bioventus&#8217; products or the procedures in which they are used limit their coverage or reimbursement in the future, or if other third-party payers or insurers issue similar policies, this could impact Bioventus&#8217; ability to sell its products, force Bioventus to lower the price it charges for Bioventus&#8217; products, and adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; ability to market and sell its products could be harmed by future actions by CMS, other government agencies or private payers to diminish payments to healthcare providers and suppliers. For example, the CMS, in its ongoing implementation of the Medicare program, periodically reviews medical study literature to determine how the literature addresses certain procedures and therapies in the Medicare population. The impact that these assessments could have on Medicare or third-party payer coverage determinations for Bioventus&#8217; products is currently unknown, but Bioventus cannot provide assurances that the resulting actions will not restrict Medicare or other insurance coverage for its products. In addition, there can be no assurance that Bioventus or Bioventus&#8217; distributors will not experience significant coverage or reimbursement impediments in the future related to these or other programs and policies of CMS. Specifically, drug pricing reform legislation and executive orders, which could negatively affect the reimbursement rates paid for HA viscosupplements, have been issued by the White House and proposed and enacted by Congress. For example, the Consolidated Appropriations Act, 2021(CAA), was signed into law on December&#160;27, 2020, and will expand price reporting obligations for manufacturers of certain products reimbursed under Medicare Part B beginning, January&#160;1, 2022. CMS could utilize the new </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pricing information to adjust Medicare payment for these products, which may include HA viscosupplements. Bioventus cannot predict how this law will be implemented by CMS, or the extent to which this law, or other proposals that may be enacted in the future, may impact the Medicare payment available for its HA viscosupplements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private payers may adopt coverage decisions and payment amounts determined by CMS as guidelines in setting their coverage and reimbursement policies. In addition, for some governmental programs, such as Medicaid, coverage and reimbursement differs from state to state. Medicaid payments to physicians, facilities and other providers are often lower than payments by other third-party payers and some state Medicaid programs may not pay an adequate amount for the procedures performed with Bioventus&#8217; products, if any payment is made at all. If CMS, other government agencies or private payers lower their reimbursement rates, or if any of the proposed drug pricing executive orders or legislative reforms are enacted, the commercial success of Bioventus&#8217; products may be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions or if a GPO, third-party payers or other similar entities exclude Bioventus from being a supplier. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Healthcare costs have risen significantly over the past decade, which has resulted in or led to numerous cost reform initiatives by legislators, regulators and third-party payers. Cost reform has triggered a consolidation trend in the healthcare industry to aggregate purchasing power, which may increase requests for pricing concessions or risk vendor exclusion. For example, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> staff at hospitals are increasingly involved in the evaluation of products and product purchasing decisions. In order for Bioventus to sell its products, Bioventus must convince such staff as well as physicians and hospitals that its products are attractive alternatives to competing products for use in surgical procedures. Additionally, GPOs, independent delivery networks and large single accounts may continue to use their market power to consolidate purchasing decisions for physicians. Third-party payers may also continue to use their market power to reduce the reimbursement for Bioventus&#8217; products by increasing the rebates Bioventus is required to pay them when its products are covered, which may negatively impact its results. Bioventus expects that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among Bioventus&#8217; customers, which may exert further downward pressure on the prices of its products. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus chooses to acquire or invest in new businesses, products or technologies, it may be unable to complete these acquisitions or to successfully integrate them in a cost-effective and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disruptive</div> manner. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus&#8217; success depends on its ability to enhance and broaden its product offerings in response to changing customer demands, competitive pressures and advances in technologies. Bioventus continues to search for viable acquisition candidates or strategic alliances that would expand its market sector and/or global presence, as well as additional products appropriate for current distribution channels. Accordingly, Bioventus may in the future pursue the acquisition of, or joint ventures relating to, new businesses, products or technologies instead of developing them internally. For example, BV LLC entered into an Option and Equity Purchase Agreement with CartiHeal providing, among other things, (i)&#160;BV LLC with an exclusive option to acquire 100% of CartiHeal&#8217;s shares, or the Call Option, and (ii)&#160;CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal&#8217;s shares, or the Put Option, in each case pursuant to the terms and subject to the conditions set forth in the Option and Equity Purchase Agreement and as described above. See &#8220;Description of Bioventus&#8217; Business&#8212;Development and Clinical Pipeline&#8212;Treatment of Cartilage for Osteochondral defects&#8212;CartiHeal (developer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C)</div> investment and option and equity purchase agreement.&#8221; Other risks involving potential future and completed acquisitions and strategic investments include: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks associated with conducting due diligence; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">problems integrating the purchased technologies, products or business operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to achieve the anticipated synergies and overpaying for acquisitions or unanticipated costs associated with acquisitions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">invalid net sales assumptions for potential acquisitions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issues maintaining uniform standards, procedures, controls and policies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of management&#8217;s attention from Bioventus&#8217; core business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adverse effects on existing business relationships with suppliers, distributors and customers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks associated with entering new markets in which Bioventus has limited or no experience; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential loss of key employees of acquired businesses; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increased legal, accounting and compliance costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus competes with other companies for these opportunities, and it may be unable to consummate such acquisitions or joint ventures on commercially reasonable terms, or at all. In addition, acquired businesses may have ongoing or potential liabilities, legal claims (including tort and/or personal injury claims) or adverse operating issues that Bioventus fails to discover through due diligence prior to the acquisition. Even if Bioventus is aware of such liabilities, claims or issues, it may not be able to accurately estimate the magnitude of the related liabilities and damages. In particular, to the extent that prior owners of any acquired businesses or properties failed to comply with or otherwise violated applicable laws or regulations, failed to fulfill their contractual obligations to their customers, or failed to satisfy legal obligations to employees or third parties, we, as the successor, may be financially responsible for these violations and failures and may suffer reputational harm or otherwise be adversely affected. Acquisitions also frequently result in the recording of goodwill and other intangible assets which are subject to potential impairment in the future that could harm Bioventus&#8217; financial results. If Bioventus were to issue additional equity in connection with such acquisitions, this may dilute its stockholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pricing pressure from Bioventus&#8217; competitors or hospitals may affect its ability to sell its products at prices necessary to support its current business strategies. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medical device companies, healthcare systems and GPOs have intensified competitive pricing pressure as a result of industry trends and new technologies. Purchasing decisions are gradually shifting to hospitals, IDNs and other hospital groups, with surgeons and other physicians increasingly acting only as &#8220;employees.&#8221; Changes in the purchasing behavior of hospitals or the amount third-party payers are willing to reimburse Bioventus&#8217; customers for procedures using its products, including those as a result of healthcare reform initiatives, could create additional pricing pressure on Bioventus. In addition to these competitive forces, Bioventus continues to see pricing pressure as hospitals introduce new pricing structures into their contracts and agreements, including fixed price formulas, capitated pricing and episodic or bundled payments intended to contain healthcare costs. If such trends continue to drive down the prices Bioventus is able to charge for its products, its profit margins will shrink, adversely affecting its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus fails to successfully enter into purchasing contracts for its BGS products or engage in contract bidding processes internationally, Bioventus may not be able to receive access to certain hospital facilities and its sales may decrease. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the hospital facilities where physicians treat patients with Bioventus&#8217; BGS products typically require Bioventus to enter into purchasing contracts. The process of securing a satisfactory contract can be lengthy and time-consuming and require extensive negotiations and management time. In certain international jurisdictions, from time to time, certain institutions require Bioventus to engage in a contract bidding process in the event that such institutions are considering making purchase commitments that exceed specified cost thresholds, which vary by jurisdiction. These processes are only open at certain periods of time, and Bioventus </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">may not be successful in the bidding process. If Bioventus does not receive access to hospital facilities through these contracting processes or otherwise, or if Bioventus is unable to secure contracts or tender successful bids, its sales may stagnate or decrease and its operating results may be harmed. Furthermore, Bioventus may expend significant effort in these time-consuming processes and still may not obtain a purchase contract from such hospitals. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Governments outside the United States may not provide coverage or reimbursement of Bioventus&#8217; products, which may adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acceptance of Bioventus&#8217; products in international markets may depend, in part, upon the availability of coverage and reimbursement within prevailing healthcare payment systems. Reimbursement and healthcare payment systems in international markets vary significantly by country, and include both government-sponsored healthcare and private insurance. Bioventus&#8217; products may not obtain international coverage and reimbursement approvals in a timely manner, if at all, which may require consumers desiring Bioventus&#8217; products to purchase them directly. Third-party coverage and reimbursement for Bioventus&#8217; products or any of its products in development for which it may receive regulatory approval may not be available or adequate in international markets, which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; future growth depends on physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of its products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus focuses its sales, marketing and training efforts on physicians, surgeons and other health care professionals. The acceptance of Bioventus&#8217; products depends in part on its ability to educate physicians as to the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of Bioventus&#8217; products compared to alternative products, procedures and therapies. If physicians, surgeons or other healthcare professionals are not properly trained, they may misuse or ineffectively use Bioventus&#8217; products, which may result in unsatisfactory patient outcomes, patient injury, negative publicity or lawsuits against Bioventus. In addition, a failure to educate physicians, surgeons or other healthcare professionals regarding Bioventus&#8217; products may impair its ability to achieve market acceptance of its products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus competes and may compete in the future against other companies, some of which have longer operating histories, more established products or greater resources than Bioventus does, which may prevent Bioventus from achieving increased market penetration or improved operating results. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The medical device industry is characterized by intense competition, subject to rapid change and significantly affected by market activities of industry participants, new product introductions and other technological advancements. Bioventus believes that its competitors have historically dedicated and will continue to dedicate significant resources to promote their products or to develop new products. Bioventus has competitors in the United States and internationally, including major medical device and pharmaceutical companies, biotechnology companies and universities and other research institutions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These companies and other industry participants may develop alternative treatments, products or procedures that compete directly or indirectly with Bioventus&#8217; products. If alternative treatments are, or are perceived to be, superior to Bioventus&#8217; products, sales of Bioventus&#8217; products could be adversely affected and its results of operations could suffer. Bioventus&#8217; competitors may also develop and patent processes or products earlier than Bioventus can or obtain regulatory clearance or approvals for competing products more rapidly than it can, which could impair Bioventus&#8217; ability to develop and commercialize similar processes or products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of Bioventus&#8217; current and potential competitors are major medical device and pharmaceutical companies that have substantially greater financial, technical and marketing resources than Bioventus does, and they may succeed in developing products that would render Bioventus&#8217; products obsolete or noncompetitive. It is also possible that Bioventus&#8217; competition will be able to leverage their large market share to set prices at a level below that which is profitable for Bioventus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of Bioventus&#8217; competitors enjoy several competitive advantages over Bioventus, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">greater financial, human and other resources for product research and development, sales and marketing and litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significantly greater name recognition; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">control of intellectual property and more expansive portfolios of intellectual property rights, which could impact future products under development; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">greater experience in obtaining and maintaining regulatory clearances or approvals for products and product enhancements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">established relationships with hospitals and other healthcare providers, physicians, suppliers, customers and third-party payers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional lines of products, and the ability to bundle products to offer greater incentives to gain a competitive advantage; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">more established sales, marketing and worldwide distribution networks. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The potential introduction by competitors of products that compete with Bioventus&#8217; existing or planned products may also make it difficult to market or sell its products. In addition, the entry of multiple new products and competitors may lead some of Bioventus&#8217; competitors to employ pricing strategies that could adversely affect the pricing of its products and pricing in the market generally. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, Bioventus&#8217; ability to compete successfully will depend on its ability to develop proprietary products that reach the market in a timely manner, receive adequate coverage and reimbursement from third-party payers, and are safer, less invasive and more effective than alternatives available for similar purposes. If Bioventus is unable to do so, its sales or margins could decrease, which would adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The reclassification of Bioventus&#8217; HA products from medical devices to drugs in the United States by the FDA could negatively impact its ability to market these products and may require that Bioventus conduct costly additional clinical studies to support current or future indications for use of those products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;18, 2018, the FDA published notice in the Federal Register announcing its intention to reconsider the appropriate classification of HA intra-articular products intended for the treatment of pain in OA of the knee. Although HA products intended for this use have previously been regulated as medical devices, in its notice the FDA stated that current published scientific literature supports that HA products achieve their primary intended purpose of treatment of pain in OA of the knee through biological action in the body which would require such products being classified as drugs. The FDA has encouraged organizations intending to submit applications for changes in indications for use, formulation, or route of administration of their HA products to obtain from the FDA an informal or formal classification and jurisdiction determination as a drug or device through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-request</div> for designation or request for designation, respectively, prior to submission of such application. However, the FDA to date has taken no action to reclassify HA products from medical devices to drugs, or indicated what the potential ramifications would be for currently marketed HA products if a reclassification were to occur. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus currently markets three HA products: Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> and SUPARTZ FX. If the reclassification of HA products were to occur, the FDA may not allow Bioventus to continue to market these products without submitting additional clinical trial data, obtaining approval of a NDA for these products, or without otherwise complying with new conditions or limitations on how those products are marketed. Clinical testing can take years to complete, can be expensive and carries uncertain outcomes, and there is no guarantee that would be able to successfully obtain and maintain any required regulatory approvals. These new regulatory obligations could </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">result in increased regulation of Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> and SUPARTZ FX and would subject these products to a new set of regulatory requirements to which they have not been previously subject. These changes could ultimately increase Bioventus&#8217; costs and adversely impact its business, results of operations and financial condition if they were to be implemented. See &#8220;Risk Factors&#8212;Risks Relating to Bioventus&#8217; Business.&#8221; If Bioventus is unable to achieve and maintain adequate levels of coverage and/or reimbursement for Bioventus&#8217; products, the procedures using Bioventus&#8217; products, or any future products Bioventus may seek to commercialize, the commercial success of these products may be severely hindered. </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; ability to maintain its competitive position depends on its ability to attract, retain and motivate its senior management team and highly qualified personnel, and Bioventus&#8217; failure to do so could adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus believes that its continued success depends to a significant extent upon the skill, experience and performance of members of its senior management team, who have been critical to the management of Bioventus&#8217; operations and implementation of its strategy, as well as Bioventus&#8217; ability to continue to attract, retain and motivate additional executive officers, and other key employees and consultants, such as those individuals who are engaged in Bioventus&#8217; research and development efforts. The replacement of any of Bioventus&#8217; key personnel likely would involve significant time and costs and may significantly delay or prevent the achievement of Bioventus&#8217; business objectives and could therefore adversely affect its business, results of operations and financial condition. In addition, Bioventus does not carry any &#8220;key person&#8221; insurance policies that could offset potential loss of service under applicable circumstances. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition for experienced employees in the medical device industry can be intense. To attract, retain and motivate qualified employees, Bioventus may utilize equity-based incentive awards such as employee stock options. If the value of such equity incentive awards does not appreciate as measured by the performance of the price of Bioventus class A common stock and ceases to be viewed as a valuable benefit, Bioventus&#8217; ability to attract, retain and motivate its employees could be adversely impacted, which could adversely affect its business, results of operations and financial condition and/or require Bioventus to increase the amount Bioventus expends on cash and other forms of compensation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Since inception, Bioventus&#8217; history of operations has included periods of net losses, and Bioventus may not be able to sustain profitability. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2020, 2019 and 2018, Bioventus had net income from continuing operations of $14.7&#160;million, $8.1&#160;million and $4.4&#160;million, respectively. Bioventus had an accumulated deficit of $144.5&#160;million and $141.7&#160;million as of December&#160;31, 2020 and 2019, respectively. Bioventus&#8217; ability to generate sufficient net sales from its existing products or from any of its products in development or products that Bioventus acquires, in order to sustain profitability, is uncertain, and, since inception, Bioventus&#8217; history of operations has previously included periods of net loss. Bioventus expects that its operating expenses will continue to increase as Bioventus continues to develop, enhance and commercialize new products and incur additional operational costs associated with being a public company. Furthermore, Bioventus may not be able to sustain or increase profitability on an ongoing basis. If Bioventus does not achieve sustained profitability, it will be more difficult for Bioventus to finance its business and accomplish its strategic objectives. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus fails to properly manage its anticipated growth, its business could suffer. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus has been growing steadily in recent periods, prior to the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Bioventus intends to continue to grow and may experience periods of rapid growth and expansion, which could place a significant additional strain on Bioventus&#8217; limited personnel, information technology systems and other resources. In particular, Bioventus&#8217; sales force and distributor network requires significant management, training, financial and other supporting resources. Any failure by Bioventus to manage its growth effectively could have an adverse effect on Bioventus&#8217; ability to achieve its development and commercialization goals. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To achieve its revenue goals, Bioventus must also successfully increase supply of its products to meet expected customer demand. In the future, Bioventus may experience difficulties with yields, quality control, component supply and shortages of qualified personnel, among other problems. These problems could result in delays in product availability and increases in expenses. Any such delay or increased expense could adversely affect Bioventus&#8217; ability to generate revenue. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future growth will also impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. In addition, rapid and significant growth will place a strain on Bioventus&#8217; administrative and operational infrastructure. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to manage its operations and growth Bioventus will need to continue to improve its operational and management controls, reporting and information technology systems and financial internal control procedures. If Bioventus is unable to manage its growth effectively, it may be difficult for Bioventus to execute its business strategy and its operating results and business could suffer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may not be able to strengthen Bioventus&#8217; brand and the brands associated with Bioventus&#8217; products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus believes that strengthening the Bioventus brand and the brands associated with Bioventus&#8217; products is critical to achieving widespread acceptance of its products, particularly because of the rapidly developing nature of the market for active healing products. Promoting and positioning Bioventus&#8217; brand will depend largely on the success of its marketing efforts and the reliability of its products. Historically, Bioventus&#8217; efforts to build its brand have involved marketing expenses, and it is likely that Bioventus&#8217; future marketing efforts will require it to incur additional expenses. These brand promotion activities may not yield increased sales and, even if they do, any sales increases may not offset the expenses Bioventus incurs to promote its brand and its products. If Bioventus fails to successfully promote and maintain its brand, or if Bioventus incurs substantial expenses in an unsuccessful attempt to promote and maintain its brand and the brands of its products, Bioventus&#8217; products may not be accepted by healthcare providers, which would cause Bioventus&#8217; sales to decrease and would adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus faces the risk of product liability claims that could be expensive, divert management&#8217;s attention and harm its reputation and business. Bioventus may not be able to maintain adequate product liability insurance. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; business exposes Bioventus to the risk of product liability claims that are inherent in the testing, manufacturing and marketing of its products. This risk exists even if a product is cleared or approved for commercial sale by the FDA and manufactured in facilities regulated by the FDA or an applicable foreign regulatory authority. Bioventus&#8217; products are designed to affect, and any future products will be designed to affect, important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with Bioventus&#8217; products or Bioventus&#8217; products in development could result in patient injury or death. The medical device industry has historically been subject to extensive litigation over product liability claims, and Bioventus cannot assure you that it will not face product liability claims. Bioventus may be subject to product liability claims if its products or products in development cause, or merely appear to have caused, patient injury or death, even if such injury or death was as a result of supplies or components that are produced by third-party suppliers. Product liability claims may be brought against Bioventus by consumers, healthcare providers or others selling or otherwise coming into contact with Bioventus&#8217; products, among others. If Bioventus cannot successfully defend Bioventus against product liability claims, Bioventus will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs of litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distraction of management&#8217;s attention from Bioventus&#8217; primary business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to commercialize existing or new products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreased demand for Bioventus&#8217; products or, if cleared or approved, products in development; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">damage to Bioventus&#8217; business reputation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product recalls or withdrawals from the market; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of clinical trial participants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial monetary awards to patients or other claimants; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss of net sales. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While Bioventus has attempted and may continue to attempt to manage Bioventus&#8217; product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of Bioventus&#8217; products may delay the supply of those products to its customers and may impact its reputation. For example, Bioventus has in the past instituted a voluntary recall for certain of its products. Bioventus cannot assure you that it will be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also be used by Bioventus&#8217; competitors to harm its reputation for product safety or be perceived by patients as a safety risk when considering the use of Bioventus&#8217; products, either of which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, although Bioventus has product liability and clinical study liability insurance that Bioventus believes is appropriate, this insurance is subject to deductibles and coverage limitations. Bioventus&#8217; current product liability insurance may not continue to be available to it on acceptable terms, if at all, and, if available, coverage may not be adequate to protect Bioventus against any future product liability claims. If Bioventus is unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, Bioventus could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fluctuations in the demand for Bioventus&#8217; products or its inability to forecast demand accurately may influence the ability of Bioventus&#8217; suppliers to meet its delivery needs or result in excess product inventory. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus is required by some of its contracts with suppliers of its products to forecast future product demand or meet minimum purchase requirements. Bioventus&#8217; supply agreement for Durolane is subject to a minimum order volume for each order and purchase amounts are based in part on forecasts. Bioventus is also subject to certain annual minimum purchase requirements for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> and SUPARTZ FX and purchase amounts are based on rolling annual forecasts. Bioventus&#8217; forecasts are based on multiple assumptions of product and market demand, which may cause Bioventus&#8217; estimates to be inaccurate. If Bioventus underestimates demand, it may not have adequate supplies and could have reduced control over pricing, availability and delivery schedules with Bioventus&#8217; suppliers, which could prevent Bioventus from meeting increased customer or consumer demand and harm Bioventus&#8217; business. However, if Bioventus overestimates its demand, it may have underutilized assets and may experience reduced margins. If Bioventus does not accurately align its supplies with demand and/or fail to meet contractual minimum purchase requirements, its business, results of operations and financial condition may be adversely affected. For example, if Bioventus fails to order the minimum order quantity of SUPARTZ FX from SKK Bioventus is obligated to pay SKK a specified fee equal to the number of units needed to meet the minimum order quantity multiplied by a specified percentage of the purchase price. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may face issues with respect to the supply of Bioventus&#8217; products or their components, including increased costs, disruptions of supply, shortages, contamination or mislabeling. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is dependent on a limited number of suppliers for Bioventus&#8217; products and components used in the manufacturing process of its products. Bioventus&#8217; top three suppliers provide Bioventus with products and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">components that constituted 53%, 54% and 49% of total net sales for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> and SUPARTZ FX are supplied by single-source third-party manufacturers. Bioventus&#8217; Exogen system undergoes final assembly with components procured from various suppliers, including a transducer, which is a key component that is supplied by a single source supplier. Bioventus may not be able to renew or enter into new contracts with its existing suppliers following the expiration of such contracts on commercially reasonable terms, or at all. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In particular, the success of Bioventus&#8217; bone graft substitutions product portfolio, depends on its suppliers continuing to have access to donated human cadaveric tissue, as well as the maintenance of high standards in their processing methodology. The supply of such donors can fluctuate over time. Bioventus cannot be certain that its current suppliers who rely on allograft bone tissue, plus any additional sources that its suppliers identify in the future, will be sufficient to meet its product needs. Bioventus&#8217; dependence on a limited number of third-party suppliers and the challenges that they may face in obtaining adequate supplies of allograft bone tissue involve several risks, including limited control over pricing, availability, quality and delivery schedules. Bioventus may be unable to find an alternative supplier in a reasonable time period or on commercially reasonable terms, if at all, which would adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of Bioventus&#8217; products or the components used in its products are alleged or proven to include quality or product defects, including as a result of improper methods of tissue recovery from donors and disease transmission from donated tissue or illegal harvesting, Bioventus may need to find alternate supplies, delay production of its products, discard or otherwise dispose of its products, or engage in a product recall, all of which may adversely affect its business, results of operations and financial condition. If Bioventus&#8217; products or the components in its products are affected by adverse prices or quality or other concerns, Bioventus may not be able to identify alternate sources of components or other supplies that meet its quality controls and standards to sustain its sales volumes or on commercially reasonable terms, or at all. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus relies on a limited number of third-party manufacturers to manufacture certain of Bioventus&#8217; products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Third-party manufacturers generally manufacture Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3,</div> SUPARTZ FX, Exogen components and Bioventus&#8217; bone graft substitutions product portfolio. Bioventus has developed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> assembly capabilities for its Exogen system. Bioventus and its third-party manufacturers are required to comply with the QSR which is a set of FDA regulations that establishes cGMP requirements for medical devices and covers the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of such devices. Moreover, certain of Bioventus&#8217; products may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-classified</div> as drugs, and Bioventus is planning to seek approval of a product pursuant to the BLA pathway. In each case, such products would be required to comply with the cGMP requirements that apply to drugs and biologics, respectively. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are a limited number of suppliers and third-party manufacturers that operate under FDA&#8217;s QSR requirements and that have the necessary expertise and capacity to manufacture Bioventus&#8217; products or components for its products. As a result, it may be difficult for Bioventus to locate manufacturers for its anticipated future needs, and its anticipated growth could strain the ability of its current suppliers and third-party manufacturers to deliver products, materials and components to Bioventus. Upon expiration of Bioventus&#8217; existing agreements with these third-party manufacturers, Bioventus may not be able to renegotiate the terms of its agreements with these third-party manufacturers on a commercially reasonable basis, or at all. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If Bioventus or its third-party manufacturers fail to maintain facilities in accordance with the FDA&#8217;s QSR, the noncomplying party could lose the ability to manufacture Bioventus&#8217; products on a commercial scale. Loss of this manufacturing capability would limit Bioventus&#8217; ability to sell its products, including Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3,</div> SUPARTZ FX and Bioventus&#8217; bone graft substitutions product portfolio, which are manufactured by single-source third-party manufacturers. See &#8220;Description of Bioventus&#8217; Business&#8212;Manufacturing and supply.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The manufacturing of Bioventus&#8217; products may not be easily transferable to other sites in the event that any of its third-party manufacturers experience breakdown, failure or substandard performance of equipment, disruption of supply or shortages of, or quality issues with, components of Bioventus&#8217; products and other supplies, labor problems, power outages, adverse weather conditions, natural disasters, global pandemics, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> or the need to comply with environmental and other directives of governmental agencies. From time to time, a third-party manufacturer may experience financial difficulties, bankruptcy or other business disruptions, which could disrupt Bioventus&#8217; supply of finished goods or require that Bioventus incur additional expense by providing financial accommodations to the third-party manufacturer or taking other steps to seek to minimize or avoid supply disruption, such as establishing a new third-party manufacturing arrangement with another provider. The loss of any of these third-party manufacturers or the failure for any reason of any of these third-party manufacturers to fulfill their obligations under their agreements with Bioventus, including a failure to meet Bioventus&#8217; quality controls and standards, may result in disruptions to Bioventus&#8217; supply of finished goods. Bioventus may be unable to locate an additional or alternate third-party manufacturing arrangement that meets Bioventus&#8217; quality controls and standards in a timely manner or on commercially reasonable terms, if at all. If this occurs, its business, results of operations and financial condition will be adversely affected. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus&#8217; facilities are damaged or become inoperable, Bioventus will be unable to continue to research, develop and manufacture its products and, as a result, its business, results of operations and financial condition may be adversely affected until Bioventus is able to secure a new facility. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus does not have redundant facilities for the final assembly of its Exogen system. Bioventus&#8217; other facilities and equipment would be costly to replace and could require substantial lead-time to repair or replace. Bioventus&#8217; facilities may be harmed or rendered inoperable by natural or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">man-made</div> disasters, including, but not limited to, tornadoes, flooding, fire and power outages. Such disasters may render it difficult or impossible to manufacture and commercialize Bioventus&#8217; products and conduct its research and development activities for new products, line extensions and expanded indications. The inability to perform those activities, combined with Bioventus&#8217; limited inventory of supplies, components and finished product, may result in the inability to continue manufacturing or supplying Bioventus&#8217; products during such periods and the loss of customers or harm to Bioventus&#8217; reputation. Although Bioventus possesses insurance for damage to its facilities and the disruption of its business, this insurance may not be sufficient to cover all of Bioventus&#8217; potential losses and this insurance may not continue to be available to Bioventus on acceptable terms, or at all. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus fails to maintain its numerous contractual relationships, its business, results of operations and financial condition could be adversely affected. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus is party to numerous contracts in the normal course of its business, including its supply and distribution agreements for Durolane, which has a current term expiring in December 2115, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3,</div> which has a current term expiring in February 2026, and SUPARTZ FX, which has a current term expiring in December 2028. Bioventus has contractual relationships with suppliers, distributors and agents, as well as service providers. In the aggregate, these contractual relationships are necessary for Bioventus to operate its business. From time to time, Bioventus amends, terminates or negotiates its contracts. Bioventus may also periodically be subject to, or make claims of breach of contract, or threaten legal action relating to Bioventus&#8217; contracts. These actions may result in litigation. At any one time, Bioventus has a number of negotiations under way for new or amended commercial agreements. Bioventus devotes substantial time, effort and expense to the administration and negotiation of contracts involved in Bioventus&#8217; business. However, these contracts may not continue in effect past their current term or Bioventus may not be able to negotiate satisfactory contracts in the future with current or new business partners, which may adversely affect its business, results of operations and financial condition. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus is unable to manage, train, maintain and grow its direct sales team and network of independent distributors, Bioventus may not be able to generate anticipated sales or it may be subject to regulatory or enforcement action. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; operating results are directly dependent upon the sales and marketing efforts of not only its direct sales team, but also its independent distributors. If Bioventus&#8217; direct sales team or independent distributors fail to adequately promote, market and sell its products, its sales could significantly decrease. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus faces significant challenges and risks in managing its geographically dispersed distribution network and retaining the individuals who make up that network. If any members of Bioventus&#8217; direct sales team were to leave Bioventus, or if any of its independent distributors were to cease to do business with Bioventus, Bioventus&#8217; sales could be adversely affected. In such a situation, Bioventus may need to seek alternative independent distributors or increase its reliance on its direct sales team, which may not prevent Bioventus&#8217; sales from being adversely affected. If a member of Bioventus&#8217; direct sales team or independent distributor were to depart and be retained by one of its competitors, Bioventus may be unable to prevent them from helping competitors solicit business from its existing customers, which could further adversely affect Bioventus&#8217; sales. Because of the competition for their services, Bioventus may be unable to recruit or retain additional qualified independent distributors or to hire additional direct sales team members to work with Bioventus on favorable or commercially reasonable terms, if at all. Failure to hire or retain qualified members of its direct sales team or independent distributors would prevent Bioventus from maintaining or expanding its business and generating sales. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If Bioventus launches new products or increase its marketing efforts with respect to existing products, it will need to expand the reach of Bioventus&#8217; marketing and sales networks. Bioventus&#8217; future success will depend largely on its ability to continue to hire, train, retain and motivate skilled members of its direct sales team and independent distributors with significant technical knowledge in active healing products. New hires require training and take time to achieve full productivity. If Bioventus fails to train new hires adequately, or if Bioventus experiences high turnover in its sales force in the future, Bioventus cannot be certain that new hires will become as productive as may be necessary to maintain or increase its sales. Further, if Bioventus is unable to adequately train new hires and/or members of Bioventus&#8217; direct sales team, if new hires and/or members of Bioventus&#8217; direct sales team engage in practices such as the promotion of unapproved or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses of its devices or if new hires and/or members of its direct sales team assist with the reimbursement process in a manner that results in false or fraudulent claims for reimbursement being submitted to government or private payers, Bioventus may be subject to investigations or regulatory or enforcement actions by governmental authorities or third party payers for reasons such as the promotion of unapproved or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses of Bioventus&#8217; devices, inappropriate actions and involvement in the reimbursement process, or inappropriate completion of reimbursement forms. See &#8220;Risk Factors&#8212;Risks Relating to Government Regulation.&#8221; Bioventus may be subject to enforcement action if it engages in improper claims submission practices and resulting audits or denials of Bioventus&#8217; claims by government agencies could reduce Bioventus&#8217; net sales or profits.&#8221; </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Bioventus is unable to expand its sales and marketing capabilities domestically and internationally, it may not be able to effectively commercialize Bioventus&#8217; products, which would adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Actual or attempted breaches of security, unauthorized disclosure of information, denial of service attacks or the perception that personal and/or other sensitive or confidential information in Bioventus&#8217; possession or control is not secure, could result in a material loss of business, substantial legal liability or significant harm to Bioventus&#8217; reputation. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus receives, collects, processes, use and stores a large amount of information, including personally identifiable, protected health and other sensitive and confidential information. This data is often accessed by Bioventus through transmissions over public and private networks, including the Internet. The secure transmission of such information over the Internet and other mechanisms is essential to maintain confidence in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; Information Technology (IT) systems. Despite the privacy and security measures Bioventus has in place to ensure compliance with applicable laws, regulations and contractual requirements, Bioventus&#8217; facilities and systems, and those of Bioventus&#8217; third-party vendors and service providers, are vulnerable to privacy and security incidents including, but not limited to, computer hacking, breaches, acts of vandalism or theft, computer viruses and other malware, including ransomware or other forms of cyber-attack, misplaced or lost data, programming and/or human errors or other similar events. A party, whether internal or external, that is able to circumvent Bioventus&#8217; security systems could, among other things, misappropriate or misuse sensitive or confidential information, user information or other proprietary information, or cause significant interruptions in Bioventus&#8217; operations. Internal or external parties have and will continue to attempt to circumvent Bioventus&#8217; security systems, and Bioventus expects that it may in the future experience external attacks on its network, such as, reconnaissance probes, denial of service attempts, malicious software attacks and phishing attacks. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because the techniques used to circumvent security systems can be highly sophisticated and change frequently, often are not recognized until launched against a target and may originate from less regulated and remote areas around the world, Bioventus may be unable to proactively address all possible techniques or implement adequate preventive measures for all situations. Recent, well-publicized attacks on prominent companies have resulted in the theft of significant amounts of sensitive and personal information and demonstrate the sophistication of the perpetrators and magnitude of the threat posed to companies across the nation, including the health care industry. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If someone is able to circumvent or breach Bioventus&#8217; security systems, they could steal any information located therein or cause interruptions to its operations. Security breaches or attempts thereof could also damage Bioventus&#8217; reputation and expose Bioventus to a risk of monetary loss and/or litigation, fines and sanctions. Bioventus also faces risks associated with security breaches affecting third parties that conduct business with Bioventus or its customers and others who interact with its data. While Bioventus maintains insurance that covers certain security and privacy breaches, it may not carry appropriate insurance or maintain sufficient coverage to compensate for all potential liability. Additionally, the costs incurred to remediate any data security or privacy incident could be substantial. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus cannot assure you that its third-party service providers with access to Bioventus&#8217; or its customers&#8217;, suppliers&#8217;, trial patients&#8217;, and employees&#8217; personally identifiable and other sensitive or confidential information in relation to which Bioventus is responsible will not breach contractual obligations imposed by Bioventus, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on Bioventus&#8217; business including putting Bioventus in breach of its obligations under privacy laws and regulations and/or which could in turn adversely affect its business, results of operations and financial condition. While Bioventus attempts to address the associated risks by performing security assessments and detailed due diligence, it cannot assure you that these contractual measures and Bioventus&#8217; own privacy and security-related safeguards will protect it from the risks associated with the third-party processing, storage and transmission of such information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure of a key information technology and communication system, process or site could adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus relies extensively on information technology and communication systems and software and hardware products, including those of external providers, to conduct business. These systems and software and hardware impact, among other things, ordering and managing components of Bioventus&#8217; products from suppliers, shipping products to customers on a timely basis, processing transactions, coordinating its sales activities across all of its products, summarizing and reporting results of operations, complying with regulatory, legal or tax requirements, data security and other processes necessary to manage its business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Despite any precautions Bioventus may take, Bioventus&#8217; systems and software and hardware could be exposed to damage or interruption from circumstances beyond its control, such as fire, natural disasters, systems failures, power outages, cyber-attacks, terrorism, energy loss, telecommunications failure, security breaches and attempts </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">thereof, computer viruses and similar disruptions affecting the global Internet. Although Bioventus has taken steps to prevent system failures and have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> systems and procedures to prevent or reduce disruptions, such steps may not prevent an interruption of services and Bioventus&#8217; disaster recovery planning may not be adequate or account for all contingencies. Additionally, Bioventus&#8217; insurance may not adequately compensate Bioventus for all losses or failures that may occur. If Bioventus&#8217; systems or software and hardware are damaged or cease to function properly and Bioventus&#8217; business continuity plans do not effectively compensate on a timely basis, Bioventus may suffer interruptions in Bioventus&#8217; operations, which could adversely affect its business, results of operations and financial condition. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus will need to improve and upgrade Bioventus&#8217; systems and infrastructure as Bioventus&#8217; operations grow in scale in order to maintain the reliability and integrity of Bioventus&#8217; systems and infrastructure. The expansion of Bioventus&#8217; systems and infrastructure will require Bioventus to commit substantial financial, operational and technical resources before the volume of Bioventus&#8217; business increases, with no assurance that the volume of business will increase. Any service outages or delays due to the installation of any new or upgraded technology (and customer issues therewith), or the impact on the reliability of Bioventus&#8217; data from any new or upgraded technology could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; business subjects Bioventus to economic, political, regulatory and other risks associated with international sales and operations that could adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since Bioventus sells Bioventus&#8217; products in many different jurisdictions outside the United States, Bioventus&#8217; business is subject to risks associated with conducting business internationally. Bioventus anticipates that net sales from international operations will continue to represent a portion of Bioventus&#8217; total net sales. In addition, a number of Bioventus&#8217; third-party manufacturing facilities and suppliers of Bioventus&#8217; products are located outside the United States. Accordingly, Bioventus&#8217; future results could be harmed by a variety of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">customers in some foreign countries potentially having longer payment cycles; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disadvantages of competing against companies from countries that are not subject to U.S. laws and regulations, including the U.S. Foreign Corrupt Practices Act (FCPA), regulations of the U.S. Office of Foreign Assets Controls, and U.S. anti-money laundering regulations, as well as exposure of Bioventus&#8217; foreign operations to liability under these regulatory regimes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">training of third-parties on Bioventus&#8217; products and the procedures in which they are used; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reduced protection for and greater difficulty enforcing Bioventus&#8217; intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unexpected changes in tariffs, trade barriers and regulatory requirements, export licensing requirements or other restrictive actions by foreign governments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulty in staffing and managing widespread operations, including compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">foreign taxes, including withholding of payroll taxes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">workforce uncertainty in countries where labor unrest is more common than in the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">international regulators and third-party payers requiring additional clinical studies prior to approving or allowing reimbursement for Bioventus&#8217; products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">complexities associated with managing multiple payer reimbursement regimes, government payers or patient <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">self-pay</div> systems; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">production shortages resulting from any events affecting material supply or manufacturing capabilities abroad; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business interruptions resulting from geopolitical actions, including war and terrorism, global pandemics or natural disasters including earthquakes, typhoons, floods and fires. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, further expansion into new international markets may require significant resources and the efforts and attention of Bioventus&#8217; management and other personnel, which may divert resources from its existing business operations. As Bioventus expands its business internationally, Bioventus&#8217; success will depend, in large part, on its ability to anticipate and effectively manage these and other risks associated with its operations outside of the United States. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus is exposed to foreign currency risks, which may adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">External events such as the withdrawal by the United Kingdom from the EU, global pandemics, the ongoing uncertainty regarding actual and potential shifts in U.S. and foreign trade, economic and other policies and the passage of U.S. taxation reform legislation each have caused, and may continue to cause, significant volatility in currency exchange rates. Because some of Bioventus&#8217; revenue, expenses, assets and liabilities are denominated in foreign currencies, Bioventus is subject to exchange rate and currency risks. In preparing Bioventus&#8217; financial statements, which are presented in U.S. dollars, Bioventus must convert all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> dollar financial results to U.S. dollars at varying exchange rates. This may ultimately result in currency gain or loss, the outcome of which Bioventus cannot predict. Furthermore, to the extent that Bioventus incurs expenses or earn revenue in currencies other than in U.S. dollars, any change in the values of those foreign currencies relative to the U.S. dollar could cause Bioventus&#8217; profits to decrease or its products to be less competitive against those of its competitors. To the extent that Bioventus&#8217; current assets denominated in foreign currency are greater or less than its current liabilities denominated in foreign currencies, Bioventus faces potential foreign exchange exposure. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To minimize such exposures, Bioventus has entered, and may in the future enter, into derivative instruments related to forecasted foreign currency transactions or currency hedges from time to time. Losses from changes in the value of the Euro or other foreign currencies relative to the U.S. dollar could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus is subject to differing tax rates in several jurisdictions in which Bioventus operates, which may adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus will be subject to taxes in the United States and certain foreign jurisdictions. Due to economic and political conditions, tax rates in various jurisdictions, including the United States, may be subject to change. Bioventus&#8217; future effective tax rates could be affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities and changes in tax laws or their interpretation. In addition, Bioventus may be subject to income tax audits by various tax jurisdictions. Although Bioventus believes its income tax liabilities are reasonably estimated and accounted for in accordance with applicable laws and principles, an adverse resolution by one or more taxing authorities could have a material impact on the results of Bioventus&#8217; operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International tariffs applied to goods traded between the United States and China may adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International tariffs, including tariffs applied to goods traded between the United States and China, may adversely affect its business, results of operations and financial condition. Since the beginning of 2018, there has </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">been increasing rhetoric, in some cases coupled with legislative or executive action, from several U.S. and foreign leaders regarding the possibility of instituting tariffs against foreign imports of certain materials. More specifically, in March and April of 2018, the U.S. and China applied tariffs to certain of each other&#8217;s exports. The institution of trade tariffs both globally and between the U.S. and China specifically carries the risk of adversely affecting overall economic condition, which could have a negative impact on Bioventus as imposition of tariffs could cause an increase in the cost of Bioventus&#8217; products and the components for Bioventus&#8217; products, specifically with respect to Bioventus&#8217; Exogen system, which may adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The 2019 Credit Agreement contains financial and operating restrictions that may limit Bioventus&#8217; access to credit. If Bioventus fails to comply with financial or other covenants in the 2019 Credit Agreement, it may be required to repay indebtedness to its existing lenders, which may harm Bioventus&#8217; liquidity. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;6, 2019, Bioventus entered into a $250.0&#160;million credit and guaranty agreement, or the 2019 Credit Agreement, with Wells Fargo Bank National Association, as administrative agent and collateral agent, and a syndicate of other entities as lenders. As of December&#160;31, 2020, Bioventus had outstanding indebtedness of $190.0&#160;million under its term loan (leaving $49.9&#160;million available under Bioventus&#8217; revolving credit facility after giving effect to $0.1&#160;million in an outstanding letter of credit). Bioventus is subject to certain covenants under the 2019 Credit Agreement, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a minimum interest coverage ratio and a maximum debt leverage ratio requirement as defined in Bioventus&#8217; credit agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the declaration or payment of certain distributions on or in respect of Bioventus&#8217; equity interests; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on acquisitions, investments and certain other payments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limitations on the incurrence of new indebtedness; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limitations on the incurrence of new liens on property or assets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limitations on transfers, sales and other dispositions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limitations on entering into transactions with affiliates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limitations on making any material change in any of Bioventus&#8217; business objectives that could reasonably be expected to have a material adverse effect on the repayment of Bioventus&#8217; credit agreement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Such indebtedness could have significant consequences, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requiring a substantial portion of Bioventus&#8217; cash flows to be dedicated to debt service payments instead of funding growth, working capital, capital expenditures, investments or other cash requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reducing Bioventus&#8217; flexibility to adjust to changing business conditions or obtain additional financing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exposing Bioventus to the risk of increased interest rates as certain of Bioventus&#8217; borrowings, including borrowings under Bioventus&#8217; term loan, are at variable rates, making it more difficult for Bioventus to make payments on Bioventus&#8217; indebtedness; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">restricting Bioventus from making strategic acquisitions or causing Bioventus to make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-strategic</div> divestitures; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subjecting Bioventus to restrictive covenants that may limit Bioventus&#8217; flexibility in operating Bioventus&#8217; business; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limiting Bioventus&#8217; ability to obtain additional financing for working capital, capital expenditures, debt service requirements and general corporate or other purposes. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, Bioventus may not be able to comply with these financial covenants described above in the future. In the absence of a waiver from Bioventus&#8217; lenders, any failure by Bioventus to comply with these covenants in the future may result in the declaration of an event of default, which could adversely affect Bioventus&#8217; business, results of operations and financial position. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;</div></div>Bioventus&#8217; Management&#8217;s Discussion and Analysis&#8212;Indebtedness.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Uncertainty relating to the LIBOR calculation process and potential phasing out of LIBOR in the future may adversely affect Bioventus&#8217; financing costs. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currently, the 2019 Credit Agreement utilizes the London Interbank Offered Rate (LIBOR), or various alternative methods set forth in the 2019 Credit Agreement to calculate interest on any borrowings. National and international regulators and law enforcement agencies have conducted investigations into a number of rates or indices known as &#8220;reference rates.&#8221; Actions by such regulators and law enforcement agencies may result in changes to the manner in which certain reference rates are determined, their discontinuance or the establishment of alternative reference rates. In particular, on July&#160;27, 2017, the Chief Executive of the United Kingdom Financial Conduct Authority (FCA), which regulates LIBOR, announced that the FCA will no longer persuade or compel banks to submit rates for the calculation of LIBOR after 2021 or, in certain cases, 2023, pursuant to an updated announcement in November 2020. Such announcements indicate that the continuation of LIBOR on the current basis cannot and will not be guaranteed after such dates, as applicable, and it appears highly likely that LIBOR will be discontinued or modified by 2021 or, in certain cases 2023. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At this time, it is not possible to predict the effect that these developments, any discontinuance, modification or other reforms to LIBOR or any other reference rate, or the establishment of alternative reference rates may have on LIBOR, other benchmarks or LIBOR-based debt instruments. Uncertainty as to the nature of such potential discontinuance, modification, alternative reference rates or other reforms could cause the interest rates calculated for the 2019 Credit Agreement to be materially different than expected, which could have a material adverse effect on Bioventus&#8217; financing costs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Due to the high degree of uncertainty regarding the implementation and impact of the CARES Act and other legislation related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> there can be no assurance as to the total amount of financial assistance Bioventus will receive or that Bioventus will be able to comply with the applicable terms and conditions for retaining such assistance. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was signed into law, which is aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. The CARES Act and similar legislation intended to provide assistance related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic also authorized $175.0&#160;billion in funding to be distributed by HHS to eligible health care providers. This funding, known as the Provider Relief Fund, is designated to fund eligible healthcare providers&#8217; healthcare-related expenses or lost revenues attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> On December&#160;27, 2020, the Consolidated Appropriations Act, 2021 was signed into law, which adds $3.0&#160;billion to the Provider Relief Fund. Payments from the Provider Relief Fund are subject to certain eligibility criteria, as well as reporting and auditing requirements, but do not need to be repaid to the U.S. government if recipients comply with the applicable terms and conditions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In reliance on the CARES Act, Bioventus deferred its employer social security payroll tax payments from May 2020 until the remainder of the 2020 calendar year of which, 50% is deferred until December&#160;31, 2021, with the remaining 50% deferred until December&#160;31, 2022. The Company has deferred $1.9&#160;million of payroll tax payments as of December&#160;31, 2020, half of which has been recorded in accrued liabilities and the remainder in other long-term liabilities on the condensed consolidated balance sheet. Bioventus is in the process of analyzing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other provision of the CARES Act to determine the financial impact on Bioventus&#8217; condensed consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In April 2020, Bioventus received, without request, a $1.2&#160;million payment from the Provider Relief Fund from HHS. Bioventus determined that it complied with the conditions to be able to keep and use the funds as reimbursement for health care related expenses and lost revenue attributable to the public health emergency resulting from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and submitted to HHS the required attestation to agree to the applicable terms and conditions of the Provider Relief Fund Phase I General Distribution. In July 2020, Bioventus applied for and received a second Provider Relief Fund payment totaling $2.9&#160;million, which is subject to the same conditions as the initial payment. The payments were recorded as other income on the condensed consolidated statement of operations and comprehensive income (loss) for year ended December&#160;31, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Due to the high degree of uncertainty regarding the implementation of the CARES Act, the Consolidated Appropriations Act, 2021 and other stimulus legislation, there can be no assurance that the terms and conditions of the Provider Relief Fund or other relief programs will not change or be interpreted in ways that affect Bioventus&#8217; ability to comply with such terms and conditions in the future, which could affect Bioventus&#8217; ability to retain such assistance. Bioventus will continue to monitor its compliance with the terms and conditions of the Provider Relief Fund, including demonstrating that the distributions received have been used for healthcare-related expenses or lost revenue attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> If Bioventus is unable to comply with current or future terms and conditions, Bioventus&#8217; ability to retain some or all of the distributions received may be impacted, and Bioventus may be subject to actions including payment recoupment, audits and inquiries by governmental authorities, and criminal, civil or administrative penalties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; future capital needs are uncertain and Bioventus may need to raise additional funds in the future, and such funds may not be available on acceptable terms or at all. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus believes that its current cash and cash equivalents, in combination with the borrowing availability under Bioventus&#8217; credit facility and its expected cash from operations, will be sufficient to meet Bioventus&#8217; projected operating requirements for the foreseeable future. However, Bioventus may seek additional funds from public and private stock offerings, borrowings under Bioventus&#8217; existing or new credit facilities or other sources in order to fund future initiatives related to the expansion of Bioventus&#8217; business, which financing may not be available on acceptable or commercially reasonable terms, if at all. For example, pursuant to the Option and Equity Purchase Agreement with CartiHeal and its shareholders, CartiHeal has a put option that, if validly exercised, would require BV LLC to purchase 100% of CartiHeal&#8217;s shares for $350.0&#160;million following pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> device with a label consistent in all respects with pivotal clinical trial success, pursuant to the terms and subject to the conditions of the Option and Equity Purchase Agreement. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;</div></div>Bioventus&#8217; Management&#8217;s Discussion and Analysis&#8212;Strategic transactions&#8212;CartiHeal (developer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C)</div> investment and option and equity purchase agreement.&#8221; </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, if Bioventus issues equity or debt securities to raise additional capital, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of Bioventus&#8217; existing stockholders. In addition, if Bioventus raises additional capital through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to Bioventus&#8217; products, potential products or proprietary technologies, or grant licenses on terms that are not favorable to Bioventus. If Bioventus cannot raise capital on acceptable terms, it may not be able to develop or enhance Bioventus&#8217; products, execute Bioventus&#8217; business plan, take advantage of future opportunities, or respond to competitive pressures, changes in Bioventus&#8217; supplier relationships, or unanticipated customer requirements. Any of these events could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Government Regulation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk factors listed below describe the risks Bioventus faces related to government regulation. The companies who manufacture or produce certain of the products Bioventus distributes face similar risks with respect to government regulation relating to such products. If such suppliers are unable to comply with government regulations, they may not be able to continue to supply Bioventus with products, which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; products and operations are subject to extensive governmental regulation, and its failure to comply with applicable requirements could cause its business to suffer. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The healthcare industry, and in particular the medical device industry, are regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies and authorities. The FDA and other U.S. and foreign governmental agencies and authorities regulate and oversee, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">design, development and manufacturing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">testing, labeling, content and language of instructions for use and storage; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product safety; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketing, sales and distribution; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">premarket clearance and approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conformity assessment procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">record-keeping procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advertising and promotion; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recalls and other field safety corrective actions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">postmarket surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">postmarket studies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product import and export. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The regulations to which Bioventus is subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on Bioventus&#8217; ability to carry on or expand its operations, higher than anticipated costs or lower than anticipated sales. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure to comply with applicable regulations could jeopardize Bioventus&#8217; ability to sell its products and result in enforcement actions such as: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrative or judicially imposed sanctions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unanticipated expenditures to address or defend such actions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injunctions, consent decrees or the imposition of civil penalties or fines; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recall or seizure of Bioventus&#8217; products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">total or partial suspension of production or distribution; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to grant pending or future clearances or approvals for Bioventus&#8217; products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal or suspension of regulatory clearances or approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical holds; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">untitled letters or warning letters; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to permit the import or export of Bioventus&#8217; products; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">criminal prosecution of Bioventus or Bioventus&#8217; employees. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and harm Bioventus&#8217; reputation, business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, governmental authorities outside the United States have become increasingly stringent in their regulation of medical devices, and Bioventus&#8217; products may become subject to more rigorous regulation by non U.S. governmental authorities in the future. U.S. or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> government regulations may be imposed in the future that adversely affect its business, results of operations and financial condition. The European Commission has harmonized national regulations for the control of medical devices through European Medical Device Directives with which manufacturers must comply. Under these new regulations, manufacturing plants must have received a full Quality Assurance Certification from a &#8220;Notified Body&#8221; in order to be able to sell products within the member states of the EU. This certification allows manufacturers to stamp the products of certified plants with a &#8220;CE&#8221; mark. Products covered by European Commission regulations that do not bear the CE mark cannot be sold or distributed within the EU. Bioventus has received certification for all of Bioventus&#8217; manufacturing facilities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may be subject to enforcement action if it engages in improper claims submission practices and resulting audits or denials of Bioventus&#8217; claims by government agencies could reduce Bioventus&#8217; net sales or profits. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with its Exogen system, Bioventus submits claims directly to, and receive payments directly from, the Medicare and Medicaid programs and private payers. Therefore, Bioventus is subject to extensive government regulation, including detailed requirements for submitting claims under appropriate codes and maintaining certain documentation, including evidence that all medical necessity requirements are met to support Bioventus&#8217; claims. Billing for Bioventus&#8217; Exogen system is complex, time-consuming and expensive, particularly for items and services provided to government healthcare program beneficiaries, such as Medicare and Medicaid. Reimbursement claims may be adversely affected by improper completion of the CMN required in connection with Medicare claims for the Exogen system and Bioventus may be subject to investigations by governmental authorities or third party payers and required to prove the validity of the claims or the authenticity of the signatures on the CMNs under investigation. Reimbursement claims may also be adversely affected by the promotion of Bioventus&#8217; devices for unapproved or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses or assistance with the reimbursement process that could result in false or fraudulent claims for reimbursement being submitted to government or private payers. Depending on the billing arrangement and applicable law, Bioventus bills various payers, all of which may have different prior authorization, patient qualification and medical necessity requirements, as well as patients for any applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-insurance</div> amounts. In addition, Bioventus may also face increased risk in Bioventus&#8217; collection efforts, including potential write-offs of doubtful accounts and long collection cycles, any of which could adversely affect its business, results of operations and financial condition. </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus is also required to implement compliance procedures and oversight, train and monitor Bioventus&#8217; employees, appeal coverage and payment denials, and perform internal audits periodically to assess compliance with applicable laws and regulations as well as internal compliance policies and procedures. Bioventus is required to report and return any overpayments received from government payers within 60 days of identification and exercise of reasonable diligence to investigate credible information regarding potential overpayments. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;</div></div>Risk Factors&#8212;Risks Relating to Government Regulation.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8221; </div></div></div></div>Bioventus is subject to federal, state and foreign laws and regulations relating to Bioventus&#8217; healthcare business, and could face substantial </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">penalties if Bioventus is determined not to have fully complied with such laws, which would adversely affect its business, results of operations and financial condition.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div>Moreover, Medicare contractors and Medicaid agencies periodically conduct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> and post-payment reviews and other audits of claims and are under increasing pressure to more closely scrutinize healthcare claims and supporting documentation. Bioventus may be subject to prepayment and post-payment reviews, as well as audits of claims in the future. Private payers may from time to time conduct similar reviews and audits. Any third-party payer reviews and audits of Bioventus&#8217; claims could result in material delays in payment, material recoupments, overpayments, claim denials, fines, revocations of billing privileges, bars on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-enrollment</div> in federal or state healthcare programs, cancellation of Bioventus&#8217; agreements or damage to Bioventus&#8217; reputation, any of which would reduce its net sales and profitability. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For example, in July of 2018 Bioventus became aware of allegations that certain of Bioventus&#8217; sales personnel may have been completing Section B of the CMN required in connection with Medicare claims for the Exogen system, which, under federal law, must be completed by the physician and/or physician staff. Together with Bioventus&#8217; outside counsel, Ropes&#160;&amp; Gray LLP, Bioventus initiated an investigation into these allegations, and Bioventus determined that the CMN forms for a portion of Medicare claims for the Exogen system were in fact improperly completed by Bioventus&#8217; sales representatives, some of which also failed to meet CMS coverage requirements. As a result of its findings, Bioventus made a self-disclosure on November&#160;30, 2018 to the OIG, under the Provider Self-Disclosure Protocol. Bioventus&#8217; self-disclosure disclosed the extent of its findings relating to the inappropriate completion of CMN forms by its sales personnel and offered to make repayment for such claims which failed to meet CMS coverage requirements and which Bioventus submitted to the Medicare program between October&#160;1, 2012 and September&#160;30, 2018, the statutory period applicable to such conduct. The total value of impacted claims was $30.1&#160;million in the aggregate. In October 2019, Bioventus&#8217; outside counsel received a letter from the Office of the United States Attorney in the Middle District of North Carolina (USAO), stating that the USAO would be working with the OIG to resolve Bioventus&#8217; self-disclosure. After settlement discussions with the USAO and OIG, on January&#160;25, 2021 Bioventus reached a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which Bioventus&#8217; sales representatives completed Section B of the CMN forms. On February&#160;22, 2021, Bioventus finalized all terms related to the settlement and entered into a formal settlement agreement with the USAO and OIG consistent with Bioventus&#8217; previous agreement in principle and which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type. Under the agreement, Bioventus resolved the potential liability related to Bioventus&#8217; self-disclosure for $3.6&#160;million, of which $2.4&#160;million had already been paid through Bioventus&#8217; 2019 return of overpayments described previously, leaving a net payment to be made of $1.2&#160;million. Bioventus made payment of the $1.2&#160;million net settlement amount due under the agreement on February&#160;23, 2021. The settlement amount noted above was recorded in the consolidated financial statements for the year ended December&#160;31, 2020. In connection with this settlement, Bioventus was not subjected to any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> penalties, such as monitoring agreements or requirements to conduct audits and submit reports to the HHS. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent Bioventus from commercializing its products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Before Bioventus can market or sell a new medical device or other product or a new use of or a claim for or significant modification to an existing medical device in the United States, Bioventus must obtain either clearance from the FDA under 510(k) pathway or approval of a PMA, unless an exemption applies. In the United States, Bioventus has obtained 510(k) premarket clearance from the FDA to market products such as Signafuse Bioactive Bone Graft Putty, Interface Bioactive Bone Graft and Signafuse Mineralized Collagen Scaffold. Bioventus&#8217; pain treatment and joint preservation products, including Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> and SUPARTZ FX, and its Exogen system, have obtained PMA approval. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May&#160;28, 1976 (preamendments device), a device that was originally on the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. market pursuant to an approved PMA application and later downclassified, or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence. In the PMA process, the FDA must determine that a proposed product is safe and effective for Bioventus&#8217; intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for products that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Modifications to products that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from six to 18 months, or even longer, from the time the application is filed with the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, Bioventus cannot assure you that any particular device will be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory approvals could harm Bioventus&#8217; business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any modification to one of Bioventus&#8217; 510(k) cleared products that would constitute a major change in its intended use, or any change that could significantly affect the safety or effectiveness of the device would require Bioventus to obtain a new 510(k) marketing clearance and may even, in some circumstances, require the submission of a PMA application, if the change raises complex or novel scientific issues or the product has a new intended use. The FDA requires every manufacturer to make the determination regarding the need for a new 510(k) submission in the first instance, but the FDA may review any manufacturer&#8217;s decision. Bioventus may make changes to its 510(k)-cleared products in the future that it may determine do not require a new 510(k) clearance or PMA approval. If the FDA disagrees with Bioventus&#8217; decision not to seek a new 510(k) or PMA approval for changes or modifications to existing devices and requires new clearances or approvals, Bioventus may be required to recall and stop marketing its products as modified, which could require Bioventus to redesign its products, conduct clinical trials to support any modifications, and pay significant regulatory fines or penalties. If there is any delay or failure in obtaining required clearances or approvals or if the FDA requires Bioventus to go through a lengthier, more rigorous examination for future products or modifications to existing products than Bioventus had expected, its ability to introduce new or enhanced products in a timely manner would be adversely affected, which in turn would result in delayed or no realization of revenue from such product enhancements or new products and could also result in substantial additional costs which could decrease Bioventus&#8217; profitability. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may not be able to demonstrate to the FDA&#8217;s satisfaction that the product or modification is substantially equivalent to the proposed predicate device or safe and effective for its intended use; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the data from Bioventus&#8217; preclinical studies and clinical trials may be insufficient to support clearance or approval, where required; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the manufacturing process or facilities Bioventus uses may not meet applicable requirements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of Bioventus&#8217; future products under development or impact its ability to modify its currently cleared or approved products on a timely basis. Even after clearance or approval for Bioventus&#8217; products is obtained, Bioventus and the products are subject to extensive postmarket regulation by the FDA, including with respect to advertising, marketing, labeling, manufacturing, distribution, import, export, and clinical evaluation. For example, as a condition of approving a </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">PMA application, the FDA may require some form of post-approval study or post-market surveillance, whereby the applicant conducts a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device. The product labeling must be updated and submitted in a PMA supplement once results, including any adverse event data from the post-approval study, become available. Failure to conduct post-approval studies in compliance with applicable regulations or to timely complete required post-approval studies or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm Bioventus&#8217; business. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is also required to timely file various reports with regulatory agencies. If these reports are not timely filed, regulators may impose sanctions and sales of Bioventus&#8217; products may suffer, and Bioventus may be subject to product liability or regulatory enforcement actions, all of which could harm Bioventus&#8217; business. In addition, if Bioventus initiates a correction or removal for one of its devices, issue a safety alert, or undertake a field action or recall to reduce a risk to health posed by the device, Bioventus may be required to submit a report to the FDA, and in many cases, to other regulatory agencies. Such reports could lead to increased scrutiny by the FDA, other international regulatory agencies and Bioventus&#8217; customers regarding the quality and safety of its devices and to negative publicity, including FDA alerts, press releases, or administrative or judicial actions. Furthermore, the submission of these reports has been and could be used by competitors against Bioventus in competitive situations and cause customers to delay purchase decisions or cancel orders, which would harm Bioventus&#8217; reputation and business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA and state authorities have broad enforcement powers. Bioventus&#8217; failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adverse publicity, warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizures of Bioventus&#8217; products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operating restrictions, partial suspension or total shutdown of production; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">customer notifications or repair, replacement or refunds; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusing Bioventus&#8217; requests for 510(k) clearance or PMA approvals or foreign regulatory approvals of new products, new intended uses or modifications to existing products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawals of current 510(k) clearances or PMAs or foreign regulatory approvals, resulting in prohibitions on sales of Bioventus&#8217; products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">criminal prosecution. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales and adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Bioventus&#8217; product candidates. If Bioventus is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if it is not able to maintain regulatory compliance as a result of a changing regulatory landscape, Bioventus may lose any marketing approvals or clearances that Bioventus has already obtained or fail to obtain new marketing approvals or clearances, and Bioventus may not be able to achieve or sustain profitability, which would adversely affect Bioventus&#8217; business, prospects, financial condition and results of operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The results of the 2020 Presidential election may impact Bioventus&#8217; business and industry. Moreover, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rule making, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these executive actions, including the Executive Orders, will be implemented, or whether they will be rescinded or replaced under the Biden administration. The policies and priorities of an incoming administration are unknown and could materially impact the regulatory framework governing Bioventus&#8217; products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Once obtained, Bioventus cannot guarantee that FDA or international product approvals will not be withdrawn or rescinded or that relevant regulatory authorities will not require other corrective action, and any withdrawal, rescission or corrective action could materially affect Bioventus&#8217; business and financial results. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once obtained, marketing approval can be withdrawn by the FDA or comparable foreign regulatory authorities for a number of reasons, including the failure to comply with ongoing regulatory requirements or the occurrence of unforeseen problems following initial approval. Regulatory authorities could also limit or prevent the manufacture or distribution of Bioventus&#8217; products. Any regulatory limitations on the use of Bioventus&#8217; products or any withdrawal, suspension or rescission of approval by the FDA or a comparable foreign regulatory authority could have a material adverse effect on its business, financial condition, and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legislative or regulatory reforms, including those currently under consideration by FDA, could make it more difficult or costly for Bioventus to obtain regulatory clearance or approval of any future products and to manufacture, market and distribute its products after clearance or approval is obtained, which could adversely affect its competitive position and materially affect Bioventus&#8217; business and financial results. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, propose new reclassification orders, or take other actions, which may prevent or delay approval or clearance of Bioventus&#8217; future products under development or impact Bioventus&#8217; ability to market or modify its currently cleared products on a timely basis. FDA and foreign regulations depend heavily on administrative interpretation, and Bioventus cannot assure you that future interpretations made by the FDA or other regulatory bodies, with possible retroactive effect, will not adversely affect Bioventus. Additionally, any changes, whether in interpretation or substance, in existing regulations or policies, or any future adoption of new regulations or policies by relevant regulatory bodies, could prevent or delay approval of Bioventus&#8217; products. In the event Bioventus&#8217; future, or current, products, including HA generally, are classified, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-classified,</div> as human drugs, combination products, or biologics by the FDA or an applicable international regulatory body, the applicable review process related to such products is typically substantially longer and substantially more expensive than the review process to which they are currently subject as medical devices. In 2018, FDA publicly indicated its intent to consider HA products for certain indications as drugs and has indicated that sponsors of HA products who submit PMAs or PMA supplements for changes in indications for use, formulation or route of administration should obtain an informal or formal classification and jurisdictional determination through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-request</div> for determination or request for determination prior to submission. There exists uncertainty with respect to the final interpretation, implementation, and consequences of this development, and this or any other potential regulatory changes in approach or interpretation similar in substance to those mentioned in this paragraph and affecting Bioventus&#8217; products could materially impact its competitive position, business, and financial results. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section&#160;510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. The FDA also announced that it intended to finalize guidance to establish a premarket review pathway for &#8220;manufacturers of certain well-understood device types&#8221; as an alternative to the 510(k) clearance pathway and that such premarket review pathway would allow manufacturers to rely on objective safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, the FDA solicited public feedback on its plans to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates, including whether the FDA should publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on Bioventus that could delay its ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict Bioventus&#8217; ability to maintain its current clearances, or otherwise create competition that may negatively affect its business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">More recently, in September 2019, the FDA finalized the aforementioned guidance to describe an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway, by demonstrating that such device meets objective safety and performance criteria established by the FDA, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to maintain a list device types appropriate for the &#8220;safety and performance based pathway&#8221; and develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance, where feasible. The FDA may establish performance criteria for classes of devices for which Bioventus or Bioventus&#8217; competitors seek or currently has received clearance, and it is unclear the extent to which such performance standards, if established, could impact its ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect its business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect Bioventus&#8217; business and its products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute Bioventus&#8217; products. Bioventus cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on Bioventus&#8217; business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of Bioventus&#8217; products; or additional record keeping. Additionally, the implementation of the new EU MDR set to take full effect on May&#160;26, 2021 after a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> postponement due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, is expected to change several aspects of the existing regulatory framework in Europe. Specifically, the EU MDR will require changes in the clinical evidence required for medical devices, post-market clinical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> evidence, annual reporting of safety information for Class&#160;III products, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-annual</div> reporting for Class&#160;II products, Unique Device Identification (UDI) for all products, submission of core data elements to a European UDI database prior to placement of a device on the market, reclassification of medical devices, and multiple other labeling changes. While Bioventus will be able to continue </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">marketing its currently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CE-marked</div> products in the EEA after the EU MDR enters into full effect and until the associated CE mark certificates expire, acquiring approvals for new products or renewing Bioventus&#8217; existing CE mark certificates once these expire could be more challenging and costly. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; HCT/P products are subject to extensive government regulation and Bioventus&#8217; failure to comply with these requirements could cause its business to suffer. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the United States, Bioventus sells human tissue-derived BGSs, such as PureBone and OsteoAMP, which are referred to by the FDA as human cells, tissues and cellular or tissue-based products, or HCT/Ps. In the U.S., Bioventus is marketing its HCT/Ps pursuant to Section&#160;361 of the PHSA and 21 CFR Part 1271 of FDA&#8217;s regulations. Bioventus does not manufacture these HCT/P products, but serve as a distributor for them. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">So-called</div> Section&#160;361 HCT/Ps are not currently subject to the FDA requirements to obtain marketing authorizations as long as they meet certain criteria provided in FDA&#8217;s regulations. HCT/Ps regulated as &#8220;361 HCT/Ps&#8221; are currently subject to requirements relating to registering facilities and listing products with the FDA, screening and testing for tissue donor eligibility, cGTP, when processing, storing, labeling and distributing HCT/Ps, including required labeling information, stringent record keeping and adverse event reporting. If Bioventus or Bioventus&#8217; suppliers fail to comply with these requirements, Bioventus could be subject to FDA enforcement action, including, for example, warning letters, fines, injunctions, product recalls or seizures, and, in the most serious cases, criminal penalties. To be regulated as Section&#160;361 HCT/Ps, these products must meet FDA&#8217;s criteria to be considered &#8220;minimally manipulated&#8221; and intended for &#8220;homologous use,&#8221; among other requirements. HCT/Ps that do not meet the criteria to be considered Section&#160;361 HCT/Ps are subject to the FDA&#8217;s regulatory requirements applicable to medical devices, biologics or drugs. Device, biologic or drug HCT/Ps must comply both with the requirements exclusively applicable to Section&#160;361 HCT/Ps and, in addition, with other requirements, including requirements for marketing authorization. For example, Section&#160;361 HCT/Ps do not require 510(k) clearance, PMA approval, approval of a BLA, or other premarket authorization from FDA before marketing. Except as described below with regard to MOTYS, Bioventus believes its HCT/Ps are regulated solely under Section&#160;361 of the PHSA, and therefore, Bioventus has not sought or obtained 510(k) clearance, PMA approval, or licensure through a BLA for such HCT/Ps. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA could disagree with Bioventus&#8217; determination that these human tissue products are Section&#160;361 HCT/Ps and could determine that these products are biologics requiring a BLA or medical devices requiring 510(k) clearance or PMA approval, and could require that Bioventus cease marketing such products and/or recall them pending appropriate clearance, approval or licensure from the FDA. For example, the FDA&#8217;s CDRH issued Bioventus a letter in March 2016 in which it asserted that OsteoAMP meets the definition of a medical device, and requested that Bioventus provide CDRH with information in support of its position that OsteoAMP does not require 510(k) clearance or PMA approval. Bioventus provided CDRH with the requested information in support of this position in May 2016 and Bioventus has received no further inquiries to date. Bioventus believes that CDRH&#8217;s assertion is unfounded and inconsistent with a 2011 letter from the FDA concluding that OsteoAMP meets the criteria for regulation solely as a Section&#160;361 HCT/P. However, if the FDA were to disagree, and if Bioventus is otherwise unsuccessful in asserting its position, the FDA may then require that Bioventus obtains 510(k) clearance or PMA approval and that it ceases marketing OsteoAMP and/or recall OsteoAMP unless and until Bioventus receives clearance or approval. If Bioventus has to cease marketing and/or has to recall any of Bioventus&#8217; BGSs products, including OsteoAmp, Bioventus&#8217; net sales would decrease, which would adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HCT/Ps that do not meet the criteria of Section&#160;361 are regulated under Section&#160;351 of the PHSA. Unlike Section&#160;361 HCT/Ps, HCT/Ps regulated as &#8220;351&#8221; HCT/Ps are subject to premarket review and approval by the FDA. In November 2017, the FDA released a guidance document entitled &#8220;Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue&#8212;Based Products: Minimal Manipulation and Homologous Use&#8212;Guidance for Industry and Food and Drug Administration Staff.&#8221; The guidance outlined the FDA&#8217;s position that all lyophilized amniotic products are more than minimally manipulated and would therefore require a BLA to be lawfully marketed in the United States. The guidance also indicated that the FDA would exercise enforcement </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">discretion, using a risk-based approach, with respect to the IND application and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> approval requirements for certain HCT/Ps for a period of 36 months from the issuance date of the guidance to allow manufacturers to pursue its IND application. Under this approach, FDA indicated that high-risk products and uses could be subject to immediate enforcement action; at that time FDA has not clearly stated what must happen by the end of its enforcement discretion period in order to avoid enforcement (i.e., whether a BLA must be approved by that time, or merely submitted). In July 2020, the FDA extended its period of enforcement discretion to May&#160;31, 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In light of the expiration of the enforcement discretionary period and FDA&#8217;s decision not to further extend it, Bioventus discontinued it limited marketing of MOTYS on May&#160;31, 2021, which had commenced as Bioventus pursued marketing authorization under a BLA for the product, to avoid being subject to enforcement on the grounds that Bioventus was marketing a product at the same time Bioventus is investigating that product pursuant to an IND, in violation of FDA&#8217;s prohibition on the preapproval promotion of an investigational product. In addition, Bioventus expects the cost to manufacture Bioventus&#8217; products will be higher than its other HCT/Ps because of the costs to comply with the more stringent requirements that apply to products regulated as biologics for which a BLA is required (and not just as Section&#160;361 HCT/Ps). These requirements include satisfying cGMP manufacturing standards and performing ongoing product testing. If Bioventus does receive BLA approval for this product, changes such as adding new indications, manufacturing changes and additional labeling claims, will be subject to further testing requirements and FDA review and approval. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the FDA may in the future modify the scope of its enforcement discretion with respect to Section&#160;361 HCT/Ps or change its position on which current or future products qualify as Section&#160;361 HCT/Ps, or determine that some or all of Bioventus&#8217; HCT/P products should not have been marketed under the FDA&#8217;s policy of enforcement discretion. Any regulatory changes could have adverse consequences for Bioventus and make it more difficult or expensive for Bioventus to conduct its business by requiring <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> clearance or approval and compliance with additional post-market regulatory requirements with respect to those products. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If clinical studies of Bioventus&#8217; future products do not produce results necessary to support regulatory clearance or approval in the United States or elsewhere, Bioventus will be unable to expand the indications for or commercialize these products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus will likely need to conduct additional clinical studies in the future to support new indications for Bioventus&#8217; products or for clearances or approvals of new product lines, or for the approval of the use of Bioventus&#8217; products in some foreign countries. Clinical testing can take many years, can be expensive and carries uncertain outcomes. The initiation and completion of any of these studies may be prevented, delayed, or halted for numerous reasons. Conducting successful clinical studies requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators and support staff, proximity of patients to clinical sites, patient ability to meet the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in Bioventus&#8217; clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> to assess the safety and effectiveness of Bioventus&#8217; products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may also not participate in Bioventus&#8217; clinical trials if they choose to participate in contemporaneous clinical trials of competitive products. In addition, patients participating in clinical trials may die before completion of the trial or suffer adverse medical events unrelated to investigational products. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, in late 2017 Bioventus began enrollment for the B.O.N.E.S. clinical study, a uniquely designed trial to further broaden the label of Bioventus&#8217; Exogen system to include a fuller range of bones that may be treated as fresh fractures in predisposed patients at risk of nonunion. The B.O.N.E.S clinical study design includes </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">prospective inclusion of 3,000 Exogen-treated patients presenting certain risk factors observed over the course of 12 months. In April 2021, Bioventus received a letter from the FDA identifying certain deficiencies in the PMA supplement for Exogen that must be addressed before the FDA can complete its review of the PMA supplement. The deficiencies include concerns about the data and endpoints from the B.O.N.E.S. study, and requests for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-analyses</div> of certain data and provision of other information to support the findings. Bioventus continues to evaluate the FDA&#8217;s comments and are initiating discussions with them to address their concerns. See<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>&#8220;Description of Bioventus&#8217; Business&#8212;Development and Clinical Pipeline&#8212;Exogen clinical data&#8212;Ongoing Bioventus-sponsored clinical studies (B.O.N.E.S.).&#8221; If Bioventus is unable to successfully complete enrollment and conclude the B.O.N.E.S. study, or the data generated from the study does not support these new indications, future demand for Bioventus&#8217; Exogen system may be affected. In October 2020, Bioventus received FDA confirmation indicating its authorization of its IND, which will allow Bioventus to conduct a clinical trial to support a BLA submission for MOTYS, as well as an additional clinical trial based on a registry of patients who received MOTYS during Bioventus&#8217; limited commercial sale of the product, which has since been discontinued, or during the trial. If Bioventus is unable to complete enrollment of these trials or if these trials do not support Bioventus&#8217; desired clinical indications for use or show clinical efficacy of the MOTYS product, Bioventus may not obtain approval of the BLA and may not be able to continue to sell MOTYS or obtain coverage or reimbursement for the product. </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Clinical failure can occur at any stage of testing. Bioventus&#8217; clinical studies may produce negative or inconclusive results, and Bioventus may decide, or regulators may require Bioventus, to conduct additional clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies in addition to those Bioventus has planned. In addition, failure to adequately demonstrate the safety and efficacy of any of Bioventus&#8217; devices would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that device or indication for use. Even if Bioventus&#8217; future products are cleared in the United States, commercialization of Bioventus&#8217; products in foreign countries would require approval by regulatory authorities in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials. Any of these occurrences could adversely affect its business, results of operations and financial condition. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;top-line&#8221;</div> and preliminary data from Bioventus&#8217; clinical trials that Bioventus announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">From time to time, Bioventus may publish interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;top-line&#8221;</div> or preliminary data from its clinical trials. Interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line,</div> or preliminary data from clinical trials that Bioventus may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;top-line,&#8221;</div> or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data Bioventus previously published. As a result, interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;top-line,&#8221;</div> and preliminary data should be viewed with caution until the final data are available. Differences between preliminary, interim, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;top-line&#8221;</div> data and final data could significantly harm Bioventus&#8217; business prospects and may cause the trading price of its common stock to fluctuate significantly. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, others, including regulatory agencies, may not accept or agree with Bioventus&#8217; assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and Bioventus&#8217; business in general. In addition, the information Bioventus chooses to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Bioventus determines is the material or otherwise appropriate information to include in its disclosure, and any information it determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or Bioventus&#8217; business. If the interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;top-line,&#8221;</div> or preliminary data that Bioventus </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, its ability to obtain approval for and commercialize its product candidates, its business, operating results, prospects or financial condition may be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may be subject to enforcement action if it engages in improper marketing or promotion of Bioventus&#8217; products, and the misuse or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use of Bioventus&#8217; products may harm its image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if Bioventus is deemed to have engaged in the promotion of these uses, any of which could be costly to Bioventus&#8217; business. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The medical devices that Bioventus currently markets have been cleared or approved by the FDA and other foreign regulatory bodies for specific treatments. However, Bioventus cannot prevent a physician from using its products outside of such cleared or approved indications for use, known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, when in the physician&#8217;s independent professional medical judgment, he or she deems it appropriate, and Bioventus does not analyze the ordering practices of physicians with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses. In cases where prescriptions of Bioventus&#8217; Exogen system are written for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, Bioventus could be subject to regulatory or enforcement actions if it was determined to have engaged in promotion of Bioventus&#8217; products for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, or otherwise determined to have made false or misleading statements about its products. There may be increased risk of injury to patients if physicians attempt to use Bioventus&#8217; products <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label.</div> Furthermore, the use of Bioventus&#8217; products for indications other than those cleared or approved by the FDA or any foreign regulatory body may not effectively treat such conditions, which could harm Bioventus&#8217; reputation in the marketplace among physicians and patients. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, physicians may misuse Bioventus&#8217; products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If Bioventus&#8217; products are misused or used with improper technique, Bioventus may become subject to costly litigation by its customers or their patients. Product liability claims could divert management&#8217;s attention from Bioventus&#8217; core business, be expensive to defend and result in sizeable damage awards against Bioventus that may not be covered by insurance. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Bioventus&#8217; promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition of the promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use. If the FDA or any foreign regulatory body determines that Bioventus&#8217; promotional materials or training constitute promotion of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use, the FDA could request that Bioventus modify Bioventus&#8217; training, promotional materials or subject Bioventus to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider Bioventus&#8217; business activities to constitute promotion of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use, which could result in significant penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Such enforcement actions may include, but are not limited to, criminal, civil and administrative penalties, treble damages, fines, disgorgement, exclusion from participation in government healthcare programs, additional reporting requirements and oversight if Bioventus becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these laws and the curtailment or restructuring of Bioventus&#8217; operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; products may cause or contribute to adverse medical events that Bioventus is required to report to the FDA, and if Bioventus fails to do so, it would be subject to sanctions that could materially harm its business. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of Bioventus&#8217; marketed products are subject to MDR obligations, which require that Bioventus report to the FDA any incident in which its products may have caused or contributed to a death or serious injury, or in which Bioventus&#8217; products malfunctioned and, if the malfunction were to recur, it could likely cause or contribute to a death or serious injury. The timing of Bioventus&#8217; obligation to report under the MDR regulations is triggered by the date Bioventus becomes aware of the adverse event as well as the nature of the event. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may fail to report adverse events of which it becomes aware within the prescribed timeframe. Bioventus may also fail to recognize that it has become aware of a reportable adverse event, especially if it is not reported to Bioventus as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of Bioventus&#8217; products. If Bioventus fails to comply with Bioventus&#8217; reporting obligations, the FDA could take action including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of Bioventus&#8217; device clearances, seizure of Bioventus&#8217; products, or delay in clearance of future products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus and Bioventus&#8217; third-party manufacturers and suppliers are subject to various governmental regulations related to the manufacturing of Bioventus&#8217; products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus&#8217; products and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such products, will be subject to continued regulatory review, oversight and periodic inspection by the FDA and other domestic and foreign regulatory bodies. In particular, the methods used in, and the facilities used for, the manufacture of the products that Bioventus owns and distributes that are regulated as medical devices must comply with the FDA&#8217;s QSR, which covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces the QSR through periodic announced or unannounced inspections of manufacturing facilities, and both Bioventus and Bioventus&#8217; third-party manufacturers and suppliers are subject to such inspections. Similarly, the devices Bioventus distributes on behalf of third-party manufacturers that are regulated as Section&#160;361 HCT/Ps must be manufactured in compliance with cGTP requirements and other related requirements. Moreover, should any of Bioventus&#8217; HA products be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-classified</div> as drugs, such products would be required to comply with a different set of manufacturing requirements under FDA&#8217;s cGMP requirements for drugs. Similarly, if Bioventus is successful in obtaining BLA approval for MOTYS, that product will need to comply with the cGMP requirements for biologics, instead of the cGTP requirements that will apply to the product upon Bioventus&#8217; planned launch of the product as a Section&#160;361 HCT/P. The need to comply with different manufacturing requirements may require Bioventus to seek new suppliers. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with Bioventus&#8217; products or the manufacturing processes of Bioventus&#8217; third-party manufacturers and suppliers, including any failure to take satisfactory corrective action in response to an adverse regulatory inspection, can result in, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrative or judicially imposed sanctions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injunctions or the imposition of civil penalties or fines; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recall or seizure of Bioventus&#8217; products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">total or partial suspension of production or distribution; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to grant pending or future clearances or approvals for Bioventus&#8217; products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal or suspension of regulatory clearances or approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical holds; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">untitled letters or warning letters; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to permit the import or export of Bioventus&#8217; products; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">criminal prosecution of Bioventus or Bioventus&#8217; employees. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these actions could prevent or delay Bioventus from marketing, distributing or selling Bioventus&#8217; products and would likely harm its business. Furthermore, Bioventus&#8217; suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in Bioventus&#8217; failure to produce its products on a timely basis and in the required quantities, if at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; products may be subject to product recalls. A recall of Bioventus&#8217; products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with its products, could adversely affect Bioventus. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in their design or manufacture. The FDA&#8217;s authority to require a recall for medical devices must be based on a finding that there is reasonable probability that the device would cause serious injury or death. Bioventus may also decide to voluntarily recall Bioventus&#8217; products if certain deficiencies are found. Bioventus has in the past instituted a voluntary recall for certain of Bioventus&#8217; products, and Bioventus is currently undertaking a voluntary Class&#160;II recall of certain vials of ultrasound gel that Bioventus provide with Bioventus&#8217; Exogen system due to particulates, which were microbial in nature, found in the gel. The gel is manufactured by a third-party supplier, and Bioventus has discontinued the use of that suppliers&#8217; gel and has replaced that gel with that of another manufacturer. Bioventus has identified the affected lots and has notified patients to discard gel bottles from those lots. A government-mandated or voluntary recall could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of Bioventus&#8217; products would divert managerial and financial resources and could adversely affect Bioventus&#8217; reputation and business, which could impair Bioventus&#8217; ability to produce Bioventus&#8217; products in a cost-effective and timely manner in order to meet Bioventus&#8217; customers&#8217; demands. Bioventus may also be subject to liability claims, be required to bear other costs, or take other actions that could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. Bioventus may initiate voluntary recalls or corrections for Bioventus&#8217; products in the future that Bioventus determines do not require notification of the FDA. If the FDA disagrees with Bioventus&#8217; determinations, they could require Bioventus to report those actions as recalls and Bioventus may be subject to enforcement action. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">As Bioventus conducts clinical studies designed to generate long-term data on some of Bioventus&#8217; existing products, the data Bioventus generates may not be consistent with its existing data and may demonstrate less favorable safety or efficacy. Data Bioventus generates may ultimately not be favorable, or could even hurt the commercial prospects for its products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is currently collecting and plans to continue collecting long-term clinical data regarding the quality, safety and effectiveness of some of Bioventus&#8217; existing products. The clinical data collected and generated as part of these studies will further strengthen Bioventus&#8217; clinical evaluation concerning safety and performance of these products. Bioventus believes that this additional data will help with the marketing of its products by providing surgeons and physicians with additional confidence in their long-term safety and efficacy. If the results of these clinical studies are negative, these results could reduce demand for Bioventus&#8217; products and significantly reduce its ability to achieve expected net sales. Bioventus does not expect to undertake such studies for all of its products and will only do so in the future where Bioventus anticipates the benefits will outweigh the costs and risks. For these reasons, surgeons and physicians could be less likely to purchase Bioventus&#8217; products than competing products for which longer-term clinical data are available. Also, Bioventus may not choose or be able to generate the comparative data that some of its competitors have or are generating and it may be subject to greater regulatory and product liability risks. If Bioventus is unable to or unwilling to collect sufficient long-term clinical data supporting the quality, safety and effectiveness of Bioventus&#8217; existing products, its business, results of operations and financial condition could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may rely on third parties to conduct Bioventus&#8217; clinical studies and to assist it with preclinical development and if they fail to perform as contractually required or expected, Bioventus may not be able to obtain regulatory clearance or approval to commercialize its products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has relied upon and may continue to rely upon third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to assist in conducting Bioventus&#8217; clinical </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">studies, which must be conducted in accordance with applicable regulations, including GCP and its preclinical development activities. Bioventus relies on these parties for execution of its studies, and control only certain aspects of their activities. Nevertheless, Bioventus is responsible for ensuring that each of its clinical studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and Bioventus&#8217; reliance on these third parties does not relieve Bioventus of its regulatory responsibilities. GCPs are regulations and guidelines enforced by the FDA and other regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, trial sites, and CROs. Bioventus cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Bioventus&#8217; clinical trials comply with GCP regulations. In addition, Bioventus&#8217; clinical trials must be conducted with product produced under applicable manufacturing requirements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If these third parties fail to successfully carry out their contractual duties, comply with applicable regulatory obligations, including GCP requirements, or meet expected deadlines, or if these third parties must be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to clinical protocols or applicable regulatory requirements or for other reasons, Bioventus&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> development activities or clinical studies may be extended, delayed, suspended or terminated. Under these circumstances Bioventus may not be able to obtain regulatory clearance or approval for, or successfully commercialize, Bioventus&#8217; products on a timely basis, if at all, and its business, results of operations and financial condition may be adversely affected. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If any of its relationships with these third parties terminate, Bioventus may not be able to enter into arrangements with alternative third parties or to do so on commercially reasonable terms. In addition, Bioventus&#8217; third parties are not its employees, and except for remedies available to Bioventus under its agreements with them, Bioventus cannot control whether or not they devote sufficient time and resources to its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> clinical, nonclinical and preclinical programs. Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new contract research organization (CRO) or other third party vendor commences work. As a result, delays occur, which can materially impact Bioventus&#8217; ability to meet its desired development timelines. Though Bioventus carefully manages its relationships with Bioventus&#8217; third party vendors including CROs, there can be no assurance that Bioventus will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on Bioventus&#8217; business, financial condition and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare regulatory reform may affect Bioventus&#8217; ability to sell its products profitably and could adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States and in certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the regulatory and healthcare systems in ways that could prevent or delay marketing approval of Bioventus&#8217; products in development, restrict or regulate post-approval activities of its products and impact its ability to sell its products profitably. In the United States in recent years, new legislation has been proposed and adopted at the federal and state level that is effecting major changes in the healthcare system. In addition, new regulations and interpretations of existing healthcare statutes and regulations are frequently adopted. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2010, the Affordable Care Act was signed into law. While the goal of healthcare reform is to expand coverage to more individuals, it also involves increased government price controls, additional regulatory mandates and other measures designed to constrain medical costs. The Affordable Care Act substantially changes the way healthcare is financed by both governmental and private insurers, encourages improvements in the quality of healthcare items and services and significantly impacts the medical device industry. Among other things, the Affordable Care Act: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">extended manufacturers&#8217; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expanded eligibility criteria for Medicaid programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as efforts by the former Trump administration to repeal or replace certain aspects of the ACA, and Bioventus expects such challenges and amendments to continue. For example, the Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&#160;1, 2019, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-based</div> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the U.S. Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. On December&#160;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On March&#160;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and the Court held oral argument on November&#160;10, 2020. The case is expected to be decided in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2021.</div> It is unclear how this decision and other efforts to challenge, repeal or replace the Affordable Care Act will impact the Affordable Care Act or Bioventus&#8217; business. Bioventus expects there will be additional challenges and amendments to the Affordable Care Act in the future. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The results of the 2020 U.S. presidential and congressional elections have created regulatory uncertainty, including with respect to the U.S. government&#8217;s role, in the U.S. healthcare industry. As a result of such elections, there are renewed and reinvigorated calls for health insurance reform, which could cause significant uncertainty in the U.S. healthcare market, could increase Bioventus&#8217; costs, decrease its revenues or inhibit its ability to sell its products. Bioventus cannot predict with certainty what impact any U.S. federal and state health reforms will have on Bioventus, but such changes could impose new and/or more stringent regulatory requirements on Bioventus&#8217; activities or result in reduced reimbursement for its products, any of which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, third-party payers regularly update payments to physicians and hospitals where Bioventus&#8217; products are used. For example, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) ended the use of the Sustainable Growth Rate Formula, and provided for a 0.5% annual increase in payment rates under the Medicare Physician Fee Schedule through 2019, but no annual update from 2020 through 2025. MACRA also introduced a merit based incentive bonus program for Medicare physicians beginning in 2019. At this time, it is unclear how the introduction of the merit based incentive program will impact overall physician reimbursement under the Medicare program. In addition, the Budget Control Act of 2011 imposed reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013. Subsequent legislative amendments related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic suspended this Medicare sequestration payment reduction from May&#160;1, 2020 through March&#160;31, 2021, but extended sequestration through 2030. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These and other payment updates </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">could directly impact the demand for Bioventus&#8217; products or any products Bioventus may develop in the future, if cleared or approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus expects that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that Bioventus receives for any cleared or approved products. Furthermore, Bioventus believes that many individuals who have obtained insurance coverage through the health insurance exchanges which arose as a result of the Affordable Care Act have done so with policies that have significantly higher deductibles than policies they may have obtained prior to its enactment. Because the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs of undergoing certain procedures for patients who have not met their deductible for a given year would be significantly higher than they historically would have been, these patients may be discouraged from undergoing certain procedures due to the cost. Any reluctance on the part of patients to undergo procedures utilizing Bioventus&#8217; products due to cost could impact its ability to expand sales of its products and could adversely impact its business, results of operations and financial condition. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus is subject to federal, state and foreign laws and regulations relating to Bioventus&#8217; healthcare business, and could face substantial penalties if Bioventus is determined not to have fully complied with such laws, which would adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Both in Bioventus&#8217; capacity as a pharmaceutical and medical device manufacturer and/or as a supplier of covered items and services to federal health care program beneficiaries, with respect to which items and services Bioventus submits claims for reimbursement from such programs, Bioventus is subject to healthcare fraud and abuse regulation and enforcement by federal, state and foreign governments, which could adversely impact its business, results of operations and financial condition. Healthcare fraud and abuse and health information privacy and security laws potentially applicable to Bioventus&#8217; operations include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal Anti-Kickback Statute, which applies to Bioventus&#8217; marketing practices, educational programs, pricing and discounting policies and relationships with healthcare providers, by prohibiting, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or providing remuneration intended to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare or Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation. Violations are also subject to civil monetary penalties up to $100,000 for each violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations of the federal Anti-Kickback Statute may also result civil and criminal penalties, including criminal fines of up to $100,000 and imprisonment of up to ten years, or exclusion from Medicare, Medicaid or other governmental programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the &#8220;Stark Law,&#8221; which prohibits a physician from referring Medicare or Medicaid patients to an entity providing &#8220;designated health services,&#8221; which includes durable medical equipment, if the physician or immediate family member of the physician, has an ownership or investment interest in or compensation arrangement with such entity that does not comply with the requirements of a Stark exception; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal civil and criminal false claims laws, including the False Claims Act, which impose civil and criminal penalties through governmental, civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government. Suits filed under the False Claims Act, can be brought by any individual on behalf of the government, known as &#8216;&#8216;qui tam&#8217;&#8217; actions, and such individuals, commonly </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">known as &#8216;&#8216;whistleblowers,&#8217;&#8217; may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of pharmaceutical, medical device and other healthcare companies to have to defend a False Claims Act action. When an entity is determined to have violated the False Claims Act, the government may impose civil fines and penalties ranging from $11,665 to $23,331 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. The government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA and its implementing regulations, which created federal criminal laws that prohibit, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA, as amended by HITECH, and its implementing regulations, which also imposes certain regulatory and contractual requirements regarding the privacy, security and transmission of protected health information, or PHI; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to certain payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and, beginning in 2022, physician assistants, nurse practitioners, and other practitioners, and requires applicable manufacturers to report annually to the government ownership and investment interests held by the providers described above and their immediate family members and payments or other &#8220;transfers of value&#8221; to such provider owners. Failure to submit required information may result in civil monetary penalties of $11,766 per failure up to an aggregate of $176,495 per year (or up to an aggregate of $1.177&#160;million per year for &#8220;knowing failures&#8221;), for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal government price reporting laws, which require Bioventus to calculate and report complex pricing metrics in an accurate and timely manner to government programs, and where the failure to report such prices may expose Bioventus to potential liability; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">state and foreign law equivalents of each of the above federal laws and regulations, such as anti-kickback, self-referral, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fee-splitting</div> and false claims laws that may apply to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise that restrict payments that may be made to healthcare providers; state laws that require drug and device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and state and foreign </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">laws governing the privacy and security of certain health information, such as GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the EU (including health data), many of which differ from each other in significant ways and some of which may be more stringent than HIPAA or HITECH. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk of Bioventus being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Bioventus is unable to predict what additional federal, state or foreign legislation or regulatory initiatives may be enacted in the future regarding Bioventus&#8217; business or the healthcare industry in general, or what effect such legislation or regulations may have on Bioventus. Federal, state or foreign governments may impose additional restrictions or adopt interpretations of existing laws that could adversely affect Bioventus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under such laws, it is possible that some of Bioventus&#8217; business activities, including certain sales and marketing practices and financial arrangements with physicians and other healthcare providers, some of whom recommend, use, prescribe or purchase Bioventus&#8217; products, and other customers, could be subject to challenge under one or more of such laws. Any action against Bioventus for violation of these laws, even if Bioventus successfully defends against it, could cause Bioventus to incur significant legal expenses and divert its management&#8217;s attention from the operation of its business. If Bioventus&#8217; operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to Bioventus, Bioventus may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from governmental healthcare programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of Bioventus&#8217; operations, any of which could adversely impact its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus is subject to governmental regulation and other legal obligations, particularly related to privacy, data protection and information security, and Bioventus is subject to consumer protection laws that regulate its marketing practices and prohibit unfair or deceptive acts or practices. Bioventus&#8217; actual or perceived failure to comply with such obligations could harm its business. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is subject to diverse laws and regulations relating to data privacy and security, including, in the United States, HIPAA and, in the EU, EEA, Regulation 2016/679, known as the GDPR. New privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened. Complying with these numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, whether by Bioventus, one of Bioventus&#8217; business associates or another third-party, could adversely affect its business, results of operations and financial condition, including but not limited to: investigation costs, material fines and penalties; compensatory, special, punitive, and statutory damages; litigation; reputational damage; consent orders regarding Bioventus&#8217; privacy and security practices; requirements that Bioventus provide notices, credit monitoring services and/or credit restoration services or other relevant services to impacted individuals; adverse actions against Bioventus&#8217; licenses to do business; and injunctive relief. Furthermore, these rules are constantly changing. For example, the CCPA took effect on January&#160;1, 2020. The CCPA establishes a new privacy framework for covered businesses and provides new and enhanced data privacy rights to California residents, such as affording consumers the right to access and delete their information and to opt out of certain sharing and sales of personal information. The CCPA imposes severe statutory damages as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action is expected to increase the likelihood of, and risks associated with, data breach litigation. It remains unclear how various provisions of the CCPA will be interpreted and enforced. The CCPA contains an exemption for medical information governed by the CMIA and for PHI collected by a covered entity or business associate governed by the privacy, security and breach notification rules established pursuant to HIPAA, but the precise application and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">scope of this exemption is not yet clear, and the law may still apply to certain aspects of Bioventus&#8217; business. The CCPA may lead other states to pass comparable legislation, with potentially greater penalties, and more rigorous compliance requirements relevant to Bioventus&#8217; business, and that may not include exemptions for businesses subject to HIPAA. The effects of the CCPA, and other similar state or federal laws, are potentially significant and may require Bioventus to modify its data processing practices and policies and to incur substantial costs and potential liability in an effort to comply with such legislation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The privacy laws in the EU have been significantly reformed. On May&#160;25, 2018, the GDPR entered into force and became directly applicable in all EU member states. The GDPR implements more stringent operational requirements than its predecessor legislation. For example, the GDPR requires Bioventus to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which Bioventus can process personal data, makes it harder for Bioventus to obtain valid consent for processing, requires the appointment of data protection officers when sensitive personal data, such as health data, is processed on a large scale, provides more robust rights for data subjects, introduces mandatory data breach notification through the EU, imposes additional obligations on Bioventus when contracting with service providers and requires Bioventus to adopt appropriate privacy governance including policies, procedures, training and data audit. If Bioventus does not comply with its obligations under the GDPR, Bioventus could be exposed to fines of up to the greater of &#8364;20&#160;million or up to 4% of its total global annual revenue in the event of a significant breach. In addition, Bioventus may be the subject of litigation and/or adverse publicity, which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prior to the effectiveness of the GDPR, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-EU</div> Safe Harbor framework provided a method which permitted the transfer of personal data to the United States under European privacy law; in 2015 it was declared invalid and replaced with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">US-EU</div> Privacy Shield framework, or Privacy Shield. On July&#160;16, 2020, the Court of Justice of the European Union, or CJEU, invalidated Privacy Shield. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances; this has created increasing uncertainty. This recent development will require Bioventus to review and amend the legal mechanisms by which Bioventus makes and/or receive personal data transfers to/in the U.S. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, Bioventus could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if Bioventus is otherwise unable to transfer personal data between and among countries and regions in which Bioventus operates, it could affect the manner in which Bioventus provides its services, the geographical location or segregation of Bioventus&#8217; relevant systems and operations, and could adversely affect Bioventus&#8217; financial results. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally starting on January&#160;1, 2021 (following the United Kingdom&#8217;s departure from the EU), Bioventus will have to comply with the GDPR and the UK GDPR (i.e. the GDPR as implemented into UK law) if Bioventus offers services to UK users, monitor their behavior or are established in the United Kingdom. Failure to comply with the UK GDPR can result in fines up to the greater of &#163;17&#160;million (approximately $20 million), or 4% of global revenue. However, the relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear. For example, it is unclear what the role of the Information Commissioner&#8217;s Office will be following the end of the transitional period. In addition, it is likely that documentation will need to be put in place between UK entities and entities in European member states to ensure adequate safeguards are in place for data transfers, which may result in increased costs with respect to transfers of personal data between the European Union and the UK, which would increase Bioventus&#8217; expenses. Bioventus may find it necessary or advantageous to join industry bodies or self-regulatory organizations that impose stricter compliance requirements than those set out in applicable laws, including the GDPR. Bioventus may also be bound by contractual restrictions that prevent Bioventus from participating in data processing activities that would otherwise be permissible under applicable laws, including the GDPR. Such strategic choices may impact Bioventus&#8217; ability to use and exploit data, and may have an adverse impact on Bioventus&#8217; business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to comply with the FCPA and laws associated with Bioventus&#8217; activities outside the United States could adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus is subject to the FCPA and other anti-bribery legislation around the world. The FCPA generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments, offers or promises to foreign officials for the purpose of obtaining or retaining business or other advantages. In addition, the FCPA imposes recordkeeping and internal controls requirements on publicly traded corporations and their foreign affiliates, which are intended to, among other things, prevent the diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of &#8220;off books&#8221; slush funds from which such improper payments can be made. As Bioventus conducts its business in jurisdictions outside of the United States, Bioventus faces significant risks if it fails to comply with the FCPA and other laws that prohibit improper payments, offers or promises of payment to foreign governments and their officials and political parties by Bioventus and other business entities for the purpose of obtaining or retaining business or other advantages. In many foreign countries, particularly in countries with developing economies, it may be a local custom that businesses operating in such countries engage in business practices that are prohibited by the FCPA or other laws and regulations. Although Bioventus has implemented a company policy requiring its employees and consultants to comply with the FCPA and similar laws, such policy may not be effective at preventing all potential FCPA or other violations. Although Bioventus&#8217; agreements with its international distributors clearly state Bioventus&#8217; expectations for its distributors&#8217; compliance with U.S. laws, including the FCPA, and provide Bioventus with various remedies upon any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance,</div> including the ability to terminate the agreement, Bioventus also cannot guarantee its distributors&#8217; compliance with U.S. laws, including the FCPA. Therefore, there can be no assurance that Bioventus&#8217; employees and agents, or those companies to which Bioventus outsources certain of its business operations, have not and will not take actions that violate its policies or applicable laws, for which Bioventus may be ultimately held responsible. Any violation of the FCPA and related policies could result in severe criminal or civil sanctions, which could adversely affect its business, results of operations and financial condition. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, Bioventus is subject to the export controls and economic embargo rules and regulations of the United States, including, but not limited to, the Export Administration Regulations and trade sanctions against embargoed countries, which are administered by the Office of Foreign Assets Control within the Department of the Treasury, as well as the laws and regulations administered by the Department of Commerce. These regulations limit Bioventus&#8217; ability to market, sell, distribute or otherwise transfer its products or technology to prohibited countries or persons. A determination that Bioventus has failed to comply, whether knowingly or inadvertently, may result in substantial penalties, including fines, enforcement actions, civil and/or criminal sanctions, the disgorgement of profits, the imposition of a court-appointed monitor, as well as the denial of export privileges, and may adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus fails to meet Medicare accreditation and surety bond requirements or DMEPOS supplier standards, it could adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus&#8217; Exogen system is classified by CMS and third-party payers as durable medical equipment. Suppliers of Medicare durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) must be accredited by an approved accreditation organization as meeting DMEPOS quality standards adopted by CMS and are required to meet surety bond requirements. In addition, Medicare DMEPOS suppliers must comply with Medicare supplier standards in order to obtain and retain billing privileges, including meeting all applicable federal and state licensure and regulatory requirements. CMS periodically expands or otherwise clarifies the Medicare DMEPOS supplier standards, and states periodically change licensure requirements, including licensure rules imposing more stringent requirements on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-state</div></div> DMEPOS suppliers. Bioventus believes it is currently in compliance with these requirements. If Bioventus fails to maintain Bioventus&#8217; Medicare accreditation status and/or do not comply with Medicare surety bond or supplier standard requirements or state licensure requirements in the future, or if these requirements are changed or expanded, it could adversely affect its business, results of operations and financial condition. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; operations involve the use of hazardous and toxic materials, and Bioventus must comply with environmental, health and safety laws and regulations, which can be expensive, and could adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is subject to a variety of federal, state, local and foreign laws and regulations relating to the protection of the environment or of human health and safety, including laws pertaining to the use, handling, storage, disposal and human exposure to hazardous and toxic materials. Liability under environmental laws can be imposed on a joint and several basis (which could result in an entity paying more than its fair share) and without regard to comparative fault, and environmental laws are likely to become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; employees, independent distributors, independent contractors, suppliers and other third parties may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could expose Bioventus to liability and hurt its reputation. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is exposed to the risk that Bioventus&#8217; employees, independent distributors, independent contractors, suppliers and others may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to Bioventus that violates: (1)&#160;FDA laws and regulations, including those laws that require the reporting of true, complete and accurate information to the FDA, (2)&#160;manufacturing standards, (3)&#160;healthcare fraud and abuse laws, or (4)&#160;laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in Bioventus&#8217; preclinical studies or clinical trials or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to Bioventus&#8217; reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions Bioventus takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting it from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, Bioventus is subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any such actions are instituted against Bioventus, and Bioventus is not successful in defending Bioventus or asserting its rights, those actions could have a significant impact on Bioventus&#8217; business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reputational harm, diminished profits and future earnings, and curtailment of Bioventus&#8217; operations, any of which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Intellectual Property Matters </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk factors listed below describe the risks Bioventus faces related to intellectual property matters. The companies who own certain of the products Bioventus distributes face similar risks with respect to intellectual property relating to such products. If such suppliers are unable to protect their intellectual property rights, they may not be able to continue to supply Bioventus with products, which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Protection of Bioventus&#8217; intellectual property rights may be difficult and costly, and Bioventus&#8217; inability to protect its intellectual property could adversely affect its competitive position. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; success depends on its ability to protect its proprietary rights to the technologies and inventions used in, or embodied by, Bioventus&#8217; products. To protect Bioventus&#8217; proprietary technology, Bioventus relies on patent protection, as well as a combination of copyright, trade secret and trademark laws, as well as nondisclosure, confidentiality and other contractual restrictions in Bioventus&#8217; consulting and employment </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agreements. These legal means afford only limited protection, however, and may not adequately protect Bioventus&#8217; rights or permit Bioventus to gain or keep any competitive advantage. Bioventus&#8217; existing confidentiality and/or invention assignment agreements with employees, contractors, and others who participate in IP development activities could be breached, or Bioventus may not enter into sufficient and adequate agreements with those individuals in the first instance, and it may not have adequate remedies for such breaches. Furthermore, Bioventus may be subject to, and forced to defend against, third-party claims of ownership to its intellectual property. If Bioventus fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or rights to use, valuable intellectual property. Such an outcome could adversely affect its business, results of operations and financial condition. Even if Bioventus is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The process of applying for patent protection is time-consuming and expensive and Bioventus cannot assure you that all of Bioventus&#8217; patent applications will issue as patents or that, if issued, they will issue in a form that will be advantageous to Bioventus. The rights granted to Bioventus under its patents, including prospective rights sought in Bioventus&#8217; pending patent applications, may not be meaningful or provide Bioventus with any commercial advantage, and they could be opposed, contested, narrowed, or circumvented by Bioventus&#8217; competitors or declared invalid or unenforceable in judicial or administrative proceedings. Bioventus may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that Bioventus will fail to identify patentable aspects of its research and development output before it is too late to obtain patent protection. As a result, some of Bioventus&#8217; products are not, and in the future may not be, protected by patents. Bioventus generally applies for patents in those countries where it intends to make, has made, use, offer for sale, or sell products and where it assesses the risk of infringement to justify the cost of seeking patent protection. However, Bioventus does not seek protection in all countries where it sells products and Bioventus may not accurately predict all the countries where patent protection would ultimately be desirable. If Bioventus fails to timely file a patent application in any such country or major market, it may be precluded from doing so at a later date. Competitors may use Bioventus&#8217; technologies in jurisdictions where Bioventus has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which Bioventus has patent protection but where such protection may not be sufficient to terminate infringing activities. Furthermore, Bioventus may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to Bioventus by third-parties. Therefore, these patents and applications may not be prosecuted or enforced in a manner consistent with the best interests of Bioventus&#8217; business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights Bioventus has licensed may be reduced or eliminated, which could also adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus owns numerous issued patents and pending patent applications relating to its technology and products. The rights granted to Bioventus under these patents, including prospective rights sought in Bioventus&#8217; pending patent applications, could be opposed, contested or circumvented by its competitors or declared invalid or unenforceable in judicial or administrative proceedings. If any of Bioventus&#8217; patents are challenged, invalidated or legally circumvented by third-parties, and if Bioventus does not own other enforceable patents protecting its products, competitors could market products and use processes that are substantially similar to, or superior to, those of Bioventus&#8217;, and Bioventus&#8217; business will suffer. In addition, the patents Bioventus owns may not be of sufficient scope or strength to provide it with any meaningful protection or commercial advantage, and competitors may be able to design around Bioventus&#8217; patents or develop products that provide outcomes comparable to those of Bioventus&#8217; without infringing on Bioventus&#8217; intellectual property rights. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if Bioventus&#8217; patents are determined by the U.S. Patent and Trademark Office (USPTO) foreign patent office, or a court to be valid and enforceable, they may not be drafted or interpreted sufficiently broadly to prevent others from marketing products and services similar to Bioventus&#8217; or designing around Bioventus&#8217; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">patents. For example, third parties may be able to develop products that are similar to Bioventus&#8217; but that are not covered by the claims of Bioventus&#8217; patents. Third parties may assert that Bioventus or its licensors were not the first to make the inventions covered by Bioventus&#8217; issued patents or pending patent applications. The claims of Bioventus&#8217; issued patents or patent applications when issued may not cover Bioventus&#8217; commercial technology or the future products and services that it develops. Bioventus may not have freedom to operate unimpeded by the patent rights of others. Third parties may have dominating, blocking or other patents relevant to Bioventus&#8217; technology of which Bioventus is not aware. In addition, because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after the filing of certain priority documents (or, in some cases, are not published until they issue as patents) and because publications in the scientific literature often lag behind actual discoveries, Bioventus cannot be certain that others have not filed patent applications for Bioventus&#8217; technology or its contemplated technology. Any such patent applications may have priority over Bioventus&#8217; patent applications or issued patents, which could require Bioventus to obtain rights from third parties to issued patents or pending patent applications covering such technologies to allow it to commercialize its technology. If another party has filed a U.S. patent application on inventions similar to Bioventus&#8217;, depending on when the timing of the filing date falls under certain patent laws, Bioventus may have to participate in a priority contest (such as an interference proceeding) declared by the USPTO to determine priority of invention in the United States. There may be prior public disclosures of which Bioventus is not aware that could invalidate its patents or a portion of the claims of its patents. Further, Bioventus may not develop additional proprietary technologies and, even if Bioventus does, they may not be patentable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement, and defense of Bioventus&#8217; patents and applications. Bioventus may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or other patent office proceedings or litigation, in the United States or elsewhere, challenging Bioventus&#8217; patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, Bioventus&#8217; patent rights, allow third-parties to commercialize Bioventus&#8217; technology or products and compete directly with Bioventus, without payment to Bioventus, or result in its inability to manufacture or commercialize products without infringing third-party patent rights. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of fees and failure to properly legalize and submit formal documents. If Bioventus fails to maintain the patents and patent applications covering Bioventus&#8217; products or procedures, it may not be able to stop a competitor from marketing products that are the same as or similar to its products, which would adversely affect its business, results of operations and financial condition. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing, prosecuting and defending patents on Bioventus&#8217; products in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries may not protect Bioventus&#8217; intellectual property rights to the same extent as laws in the United States. Consequently, Bioventus may not be able to prevent third parties from practicing its inventions in all countries outside the United States. Competitors may use Bioventus&#8217; technologies in jurisdictions where Bioventus has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which Bioventus has patent protection that may not be sufficient to terminate infringing activities. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to differences between foreign and U.S. patent laws, Bioventus&#8217; patented intellectual property rights may not receive the same degree of protection in every jurisdiction in which Bioventus obtains patents. Furthermore, Bioventus does not have patent rights in certain foreign countries in which a market may exist in the future. Bioventus may need to expend additional resources to protect or defend its intellectual property rights in these countries, and the inability to protect or defend the same could impair Bioventus&#8217; brand or adversely affect the growth of Bioventus&#8217; business internationally. For example, Bioventus may not be able to stop a competitor from marketing and selling in foreign countries products that are the same as or similar to Bioventus&#8217; products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patents have a limited lifespan, and the protection patents affords is limited. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> filing date. Even if patents covering Bioventus&#8217; products are obtained, once the patent life has expired for patents covering a product, Bioventus may be open to competition from competitive products and services. As a result, Bioventus&#8217; patent portfolio may not provide it with sufficient rights to exclude others from commercializing product candidates similar or identical to Bioventus&#8217;. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trademarks </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus relies on its trademarks as one means to distinguish Bioventus&#8217; products from the products of its competitors, and have registered or applied to register many of these trademarks. However, Bioventus may not be able to successfully secure trademark registrations for all such applications. Third-parties may oppose Bioventus&#8217; trademark applications, or otherwise challenge Bioventus&#8217; use of both registered and unregistered trademarks. In the event that Bioventus&#8217; trademarks are successfully challenged, Bioventus could be forced to rebrand its products, which could result in loss of brand recognition and could require Bioventus to devote resources to advertising and marketing new brands. Bioventus&#8217; competitors may infringe Bioventus&#8217; trademarks and Bioventus may not have adequate resources to enforce its trademarks. Over the long term, if Bioventus is unable to establish name recognition based on its trademarks, then Bioventus may not be able to compete effectively and its business, results of operations and financial condition may be adversely affected. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may not be able to prevent the unauthorized disclosure or use of its technical knowledge or other trade secrets by consultants, vendors, former employees or current employees, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures of Bioventus&#8217; intellectual property is difficult, and Bioventus does not know whether the steps it has taken to protect Bioventus&#8217; intellectual property will be effective. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, Bioventus&#8217; competitors may independently develop equivalent knowledge, methods and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how.</div> For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that Bioventus may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Bioventus&#8217; competitors could use any of the information Bioventus may be required to disclose by the FDA to develop independently technology similar to those of Bioventus&#8217;. Competitors could purchase Bioventus&#8217; products and attempt to replicate some or all of the competitive advantages Bioventus derives from Bioventus&#8217; development efforts, willfully infringe Bioventus&#8217; intellectual property rights, design around Bioventus&#8217; protected technology or develop their own competitive technologies that fall outside of Bioventus&#8217; intellectual property rights. If Bioventus&#8217; intellectual property is not adequately protected so as to protect Bioventus&#8217; market against competitors&#8217; products and methods, its competitive position could be adversely affected, as could its business, results of operations and financial condition. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Bioventus was to enforce a claim that a third-party had illegally obtained, misappropriated or was using Bioventus&#8217; trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. If any of the technology or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information that Bioventus protects as trade secrets were to be independently developed by a competitor, Bioventus would have no right to prevent them from using that technology or information to compete with Bioventus. Misappropriation or unauthorized disclosure of Bioventus&#8217; trade secrets could impair Bioventus&#8217; competitive position and may adversely affect its business, results of operations and financial condition. Additionally, if the steps taken to maintain Bioventus&#8217; trade secrets are deemed inadequate, Bioventus may have insufficient recourse against third parties for misappropriating the trade secret. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus depends on certain technologies that are licensed to it. Bioventus does not control the intellectual property rights covering these technologies and any loss of Bioventus&#8217; rights to these technologies or the rights licensed to Bioventus could prevent Bioventus from selling Bioventus&#8217; products, which could adversely impact its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is a party to license agreements under which Bioventus is granted rights to intellectual property that is important to Bioventus&#8217; business, and Bioventus may need to enter into additional license agreements in the future. Bioventus relies on these licenses in order to be able to use and sell various proprietary technologies that are material to Bioventus&#8217; business, as well as technologies which Bioventus intends to use in its future commercial activities. Bioventus&#8217; rights to use these technologies and the inventions claimed in the licensed patents are subject to the continuation of and Bioventus&#8217; compliance with the terms of those licenses. Bioventus&#8217; existing license agreements impose, and Bioventus expects that future license agreements will impose on Bioventus, various diligence obligations, payment of milestones or royalties and other obligations. If Bioventus fails to comply with Bioventus&#8217; obligations under these agreements, or Bioventus is subject to a bankruptcy, the licensor may have the right to terminate the license, in which case Bioventus would not be able to market products covered by the license, which would adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As Bioventus has done previously, Bioventus may need to obtain licenses from third parties to advance Bioventus&#8217; research or allow commercialization of Bioventus&#8217; products and technologies. Bioventus may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if Bioventus is able to obtain a license, it may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> thereby giving Bioventus&#8217; competitors access to the same technologies licensed to Bioventus. In the event that Bioventus is not able to acquire a license, Bioventus may be required to expend significant time and resources to develop or license replacement technology. If Bioventus is unable to do so, Bioventus may be unable to develop or commercialize the affected products and technologies, which could materially harm Bioventus&#8217; business. In addition, the third parties owning such intellectual property rights could seek either an injunction prohibiting Bioventus&#8217; sales, or, with respect to Bioventus&#8217; sales, an obligation on Bioventus&#8217; part to pay royalties or other forms of compensation and damages. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some cases, Bioventus may not have the right to control the prosecution, maintenance, or filing of the patents that are licensed to Bioventus, or the enforcement of these patents against infringement by third parties. Some of Bioventus&#8217; patents and patent applications were not filed by Bioventus, but were either acquired by Bioventus or are licensed from third parties. Thus, these patents and patent applications were not drafted by Bioventus or Bioventus&#8217; attorneys, and Bioventus did not control or have any input into the prosecution of these patents and patent applications prior to Bioventus&#8217; acquisition of, or Bioventus&#8217; entry into a license with respect to, such patents and patent applications. Bioventus cannot be certain that the drafting or prosecution of the patents and patent applications licensed to Bioventus will result or has resulted in valid and enforceable patents. Further, Bioventus does not always retain complete control over Bioventus&#8217; ability to enforce Bioventus&#8217; licensed patent rights against third-party infringement. In those cases, Bioventus cannot be certain that Bioventus&#8217; licensor will elect to enforce these patents to the extent that Bioventus would choose to do so, or in a way that will ensure that Bioventus retains the rights Bioventus currently has under Bioventus&#8217; license. If Bioventus&#8217; licensor fails to properly enforce the patents subject to Bioventus&#8217; license in the event of third-party infringement, Bioventus&#8217; ability to retain Bioventus&#8217; competitive advantage with respect to Bioventus&#8217; products may be materially and adversely affected. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing of intellectual property is an important part of Bioventus&#8217; business and involves complex legal, business and scientific issues. Disputes may arise between Bioventus and Bioventus&#8217; licensors regarding intellectual property that is subject to a license agreement, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of rights granted under the license agreement and other interpretation-related issues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether and the extent to which Bioventus&#8217; technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; right to sublicense patent and other rights to third parties under collaborative development relationships; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; diligence obligations with respect to the use of the licensed technology in relation to Bioventus&#8217; development and commercialization of its products and technologies, and what activities satisfy those diligence obligations; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the ownership of inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> resulting from the joint creation or use of intellectual property by Bioventus&#8217; licensors and Bioventus and Bioventus&#8217; partners. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, Bioventus may become the owner of intellectual property that was obtained through assignments which may be subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assignment</div> back to the original assignor upon Bioventus&#8217; failure to prosecute or maintain such intellectual property, upon Bioventus&#8217; breach of the agreement pursuant to which such intellectual property was assigned, or upon Bioventus&#8217; bankruptcy. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If disputes over intellectual property that Bioventus has licensed prevent or impair Bioventus&#8217; ability to maintain its current licensing arrangements on acceptable terms, or if intellectual property is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assigned</div> back to the original assignor, Bioventus may be unable to successfully develop and commercialize the affected products and technologies. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of Bioventus&#8217; rights to the relevant intellectual property or technology. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain provisions in Bioventus&#8217; intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of Bioventus&#8217; rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, while it is Bioventus&#8217; policy to require its employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to it, Bioventus may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that Bioventus regards as its own. Bioventus&#8217; assignment agreements may not be self-executing or may be breached, and Bioventus may be forced to bring claims against third parties, or defend claims they may bring against Bioventus, to determine the ownership of what Bioventus regards as its intellectual property. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may in the future be a party to patent and other intellectual property litigation and administrative proceedings that could be costly and could interfere with Bioventus&#8217; ability to successfully market Bioventus&#8217; products. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The medical device industry has been characterized by frequent and extensive intellectual property litigation and is highly competitive. Bioventus&#8217; competitors or other patent holders may assert that Bioventus&#8217; products and/or the methods employed in Bioventus&#8217; products are covered by their patents or that Bioventus is infringing, misappropriating, or misusing their trademark, copyright, trade secret, and/or other proprietary rights. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Bioventus&#8217; products or methods are found to infringe, Bioventus could be prevented from manufacturing or marketing Bioventus&#8217; products. In the event that Bioventus becomes involved in such a dispute, Bioventus may incur significant costs and expenses and may need to devote resources to resolving any claims, which would reduce the cash Bioventus has available for operations and may be distracting to management and other employees, including those involved in the development of intellectual property. Bioventus does not know whether Bioventus&#8217; competitors or potential competitors have applied for, will apply for, or will obtain patents that will prevent, limit or interfere with Bioventus&#8217; ability to make, use, sell, import or export Bioventus&#8217; products. Because patent applications can take many years to issue, third parties may have currently pending patent applications which may later result in issued patents that Bioventus&#8217; products and technologies may infringe, or which such third parties claim are infringed by the use of Bioventus&#8217; products or technologies. There is no guarantee that patents will not issue in the future from currently pending applications that may be infringed by Bioventus&#8217; technology or products. In addition, identification of third-party patent rights that may be relevant to Bioventus&#8217; technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and difficulty in assessing the meaning of patent claims. Moreover, as the medical device industry expands and more patents are issued in this area, the risk increases that Bioventus may be subject to claims of infringement of the patent rights of third parties. Bioventus cannot assure you that Bioventus will prevail in such actions, or that other actions alleging misappropriation or misuse by Bioventus of third-party trade secrets or infringement by Bioventus of third-party patents, copyrights, trademarks or other rights or challenging the validity of Bioventus&#8217; patents, copyrights, trademarks or other rights will not be asserted against Bioventus. Competing products may also be sold in other countries in which Bioventus&#8217; patent coverage might not exist or be as strong. If Bioventus loses a foreign patent lawsuit alleging Bioventus&#8217; infringement of a competitor&#8217;s patents, Bioventus could be prevented from marketing Bioventus&#8217; products in one or more foreign countries. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may also initiate litigation against third-parties to enforce Bioventus&#8217; patent and proprietary rights or to determine the scope, enforceability or validity of the proprietary rights of others. Bioventus&#8217; intellectual property has not been tested in litigation. If Bioventus initiates litigation to protect Bioventus&#8217; rights, Bioventus runs the risk of having Bioventus&#8217; patents and other proprietary rights invalidated, canceled or narrowed, which could undermine Bioventus&#8217; competitive position. Further, if the scope of protection provided by Bioventus&#8217; patents or patent applications or other proprietary rights is threatened or reduced as a result of litigation, it could discourage third parties from entering into collaborations with Bioventus that are important to the commercialization of Bioventus&#8217; products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or others who are involved in developing Bioventus&#8217; product. Furthermore, if a license to necessary technology is terminated, the licensor may initiate litigation claiming that Bioventus&#8217; processes or products infringe or misappropriate its patent or other intellectual property rights and/or that Bioventus breached Bioventus&#8217; obligations under the license agreement, and Bioventus and Bioventus&#8217; collaborators would need to defend against such proceedings. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time and attention of managerial and technical personnel, which could materially adversely affect its business, results of operations and financial condition. Any such claim could also force use to do one or more of the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">incur substantial monetary liability for infringement or other violations of intellectual property rights, which Bioventus may have to pay if a court decides that the product, service, or technology at issue infringes or violates the third-party&#8217;s rights, and if the court finds that the infringement was willful, Bioventus could be ordered to pay treble damages and the third-party&#8217;s attorneys&#8217; fees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">pay substantial damages to Bioventus&#8217; customers or end users to discontinue use or replace infringing technology with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> technology; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">103 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stop manufacturing, offering for sale, selling, using, importing, exporting or licensing the product or technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such product, service, or technology; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain from the owner of the infringed intellectual property right a license, which may require Bioventus to pay substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on commercially reasonable terms, or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">redesign Bioventus&#8217; products, services, and technology so they do not infringe or violate the third-party&#8217;s intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">enter into cross-licenses with Bioventus&#8217; competitors, which could weaken Bioventus&#8217; overall intellectual property position; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lose the opportunity to license Bioventus&#8217; technology to others or to collect royalty payments based upon successful protection and assertion of Bioventus&#8217; intellectual property against others; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">find alternative suppliers for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> products and technologies, which could be costly and create significant delay; or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">relinquish rights associated with one or more of Bioventus&#8217; patent claims, if Bioventus&#8217; claims are held invalid or otherwise unenforceable. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of Bioventus&#8217; competitors may be able to sustain the costs of complex intellectual property litigation more effectively than Bioventus can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, divert the time, attention and resources of management, or prohibit Bioventus from manufacturing, marketing or otherwise commercializing Bioventus&#8217; products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely affect Bioventus&#8217; ability to raise additional funds or otherwise adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Bioventus&#8217; confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If these results are perceived to be negative, the price of Bioventus class A common stock could be adversely affected. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, certain of Bioventus&#8217; agreements with suppliers, distributors, customers and other entities with whom Bioventus does business may require Bioventus to defend or indemnify these parties to the extent they become involved in infringement claims relating to Bioventus&#8217; technologies or products, or rights licensed to them by Bioventus. Bioventus could also voluntarily agree to defend or indemnify third parties in instances where Bioventus is not obligated to do so if Bioventus determines it would be important to Bioventus&#8217; business relationships. If Bioventus is required or agree to defend or indemnify any of these third parties in connection with any infringement claims, Bioventus could incur significant costs and expenses that could adversely affect Bioventus&#8217; business, results of operation and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may be subject to damages resulting from claims that Bioventus or Bioventus&#8217; employees have wrongfully used or disclosed alleged trade secrets of Bioventus&#8217; competitors or former employers or are in breach of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> agreements with Bioventus&#8217; competitors or former employers. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus could in the future be subject to claims that Bioventus or Bioventus&#8217; employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of former employers or competitors. In addition, Bioventus may in the future be subject to claims that Bioventus caused an employee to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">breach the terms of his or her <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> agreement. Litigation may be necessary to defend against these claims. Even if Bioventus is successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If Bioventus&#8217; defense to those claims fails, in addition to paying monetary damages, a court could prohibit Bioventus from using technologies or features that are essential to Bioventus&#8217; products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the competitors or former employers. An inability to incorporate technologies or features that are important or essential to Bioventus&#8217; products could adversely affect its business, results of operations and financial condition, and may prevent Bioventus from selling Bioventus&#8217; products. In addition, Bioventus may lose valuable intellectual property rights or personnel. Any litigation or the threat thereof may adversely affect Bioventus&#8217; ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent Bioventus&#8217; ability to commercialize Bioventus&#8217; products, which could adversely affect its business, results of operations and financial condition. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any product candidates that Bioventus develops as biologics subject to the BLA pathway may be subject to competition sooner than anticipated. </div></div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus expects to submit a BLA to allow for the marketing of MOTYS. See &#8220;Risk Factors&#8211;&#8211;Risks Relating to Government Regulation.&#8221; Bioventus&#8217; HCT/P products are subject to extensive government regulation and Bioventus&#8217; failure to comply with these requirements could cause its business to suffer. These products could be subject to significant additional regulatory requirements. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when processes intended to implement BPCIA may be fully adopted by the FDA, any of these processes could have a material adverse effect on the future commercial prospects for Bioventus&#8217; biological products. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus believes that any of the product candidates Bioventus develops that is approved in the United States as a biological product under a BLA should qualify for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-year</div> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biological</div> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the approval of a biologic product biosimilar to one of Bioventus&#8217; products could have a material adverse impact on Bioventus&#8217; business as it may be significantly less costly to bring to market and may be priced significantly lower than Bioventus&#8217; products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property rights do not necessarily address all potential threats to Bioventus&#8217; business. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Once granted, patents may remain open to invalidity challenges including opposition, interference, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-examination,</div> post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the degree of future protection afforded by Bioventus&#8217; intellectual property rights is uncertain because even granted intellectual property rights have limitations, and may not adequately protect Bioventus&#8217; business, provide a barrier to entry against Bioventus&#8217; competitors or potential competitors or permit Bioventus to maintain Bioventus&#8217; competitive advantage. Moreover, if a third-party has intellectual property rights that cover the practice of Bioventus&#8217; technology, Bioventus may not be able to fully exercise or extract value from Bioventus&#8217; intellectual property rights. The following examples are illustrative: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to develop and/or practice technology that is similar to Bioventus&#8217; technology or aspects of Bioventus&#8217; technology, but that are not covered by the claims of the patents that Bioventus owns or controls, assuming such patents have issued or do issue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus or Bioventus&#8217; licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that Bioventus owns or has exclusively licensed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus or Bioventus&#8217; licensors or any future strategic partners might not have been the first to file patent applications covering certain of Bioventus&#8217; inventions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may independently develop similar or alternative technologies or duplicate any of Bioventus&#8217; technologies without infringing Bioventus&#8217; intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; pending patent applications may not lead to issued patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issued patents that Bioventus owns or exclusively licenses may not provide Bioventus with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by Bioventus&#8217; competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; competitors might conduct research and development activities in countries where Bioventus does not have patent rights and then use the information learned from such activities to develop competitive products for sale in Bioventus&#8217; major commercial markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">third parties performing manufacturing or testing for Bioventus using Bioventus&#8217; products or technologies could use the intellectual property of others without obtaining a proper license; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">parties may assert an ownership interest in Bioventus&#8217; intellectual property and, if successful, such disputes may preclude Bioventus from exercising exclusive rights over that intellectual property; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bioventus may not develop or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> additional proprietary technologies that are patentable; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the patents of others may adversely affect Bioventus&#8217; business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should any of these events occur, they could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Bioventus&#8217; Organizational Structure and the Tax Receivable Agreement </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; principal asset is Bioventus&#8217; interest in BV LLC, and, accordingly, Bioventus depends on distributions from BV LLC to pay Bioventus&#8217; taxes and expenses, including payments under the Tax Receivable Agreement. BV LLC&#8217;s ability to make such distributions may be subject to various limitations and restrictions. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is a holding company and has no material assets other than Bioventus&#8217; ownership of LLC interests of BV LLC. As such, Bioventus has no independent means of generating net sales or cash flow, and Bioventus&#8217; ability to pay Bioventus&#8217; taxes and operating expenses or declare and pay dividends in the future, if any, will be dependent upon the financial results and cash flows of BV LLC and its subsidiaries and distributions Bioventus </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">receives from BV LLC. There can be no assurance that BV LLC and its subsidiaries will generate sufficient cash flow to distribute funds to Bioventus or that applicable state law and contractual restrictions, including negative covenants in Bioventus&#8217; debt instruments, will permit such distributions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BV LLC is treated as a partnership for U.S. federal income tax purposes and, as such, generally will not be subject to any entity-level U.S. federal income tax. Instead, taxable income will be allocated to holders of LLC interests, including Bioventus. Accordingly, Bioventus will incur income taxes on Bioventus&#8217; allocable share of any net taxable income of BV LLC. Under the terms of the Bioventus LLC agreement, BV LLC will be obligated to make tax distributions to holders of LLC interests, including Bioventus, subject to any limitations or restrictions in Bioventus&#8217; debt arrangements. In addition to tax expenses, Bioventus will also incur expenses related to Bioventus&#8217; operations, including payments under the Tax Receivable Agreement (TRA), which Bioventus expects could be significant. See &#8220;Description of Bioventus&#8217; Business&#8212;Tax Receivable Agreement.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus intends, as its managing member, to cause BV LLC to make cash distributions to the owners of LLC interests, including Bioventus, in an amount sufficient to (i)&#160;fund their or Bioventus&#8217; tax obligations in respect of allocations of taxable income from BV LLC and (ii)&#160;cover Bioventus&#8217; operating expenses, including payments under the TRA. However, BV LLC&#8217;s ability to make such distributions may be subject to various limitations and restrictions, such as restrictions on distributions that would either violate any contract or agreement to which BV LLC is then a party, including debt agreements, or any applicable law, or that would have the effect of rendering BV LLC insolvent. If Bioventus does not have sufficient funds to pay taxes or other liabilities or to fund Bioventus&#8217; operations, Bioventus may have to borrow funds, which could materially adversely affect Bioventus&#8217; liquidity and financial condition and subject Bioventus to various restrictions imposed by any such lenders. To the extent that Bioventus is unable to make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA. See &#8220;Description of Bioventus&#8217; Business&#8212;Tax Receivable Agreement&#8221;. In addition, if BV LLC does not have sufficient funds to make distributions, Bioventus&#8217; ability to declare and pay cash dividends will also be restricted or impaired. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The TRA with the continuing LLC owner requires Bioventus to make cash payments to it in respect of certain tax benefits to which Bioventus is or may become entitled, and Bioventus expects that the payments it will be required to make could be significant. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus is a party to a TRA with the continuing LLC owner. Under the TRA, Bioventus is required to make cash payments to the continuing LLC owner equal to 85% of the tax benefits, if any, that Bioventus actually realizes, or in certain circumstances are deemed to realize, as a result of (1)&#160;increases in the tax basis of assets of BV LLC resulting from (a)&#160;any future redemptions or exchanges of LLC interests described under<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>&#8220;Description of Bioventus&#8217; Business&#8212;Bioventus LLC Agreement&#8212;LLC Interest Redemption Right,&#8221; and (b)&#160;certain distributions (or deemed distributions) by BV LLC and (2)&#160;certain other tax benefits arising from payments under the TRA. Bioventus expects the amount of the cash payments that it will be required to make under the TRA will be significant. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including the timing of redemptions or exchanges by the continuing LLC owner, the amount of gain recognized by the continuing LLC owner, the amount and timing of the taxable income Bioventus generates in the future, and the federal tax rates then applicable. Any payments made by Bioventus to the continuing LLC owner under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to Bioventus. To the extent that Bioventus is unable to make timely payments under the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until paid by Bioventus. Furthermore, Bioventus&#8217; obligation to make payments under the TRA could make it a less attractive target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax benefits that are the subject of the TRA. Payments under the TRA are not conditioned on the continuing LLC owner&#8217;s continued ownership of LLC interests or Bioventus class A common stock. For more information, see &#8220;Description of Bioventus&#8217; Business&#8212;Tax Receivable Agreement.&#8221; The actual amounts Bioventus will be required to pay under the TRA will depend </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on, among other things, the timing of subsequent redemptions or exchanges of LLC interests by the continuing LLC owner, the price of Bioventus&#8217; shares of Class&#160;A common stock at the time of each such redemption or exchange, and the amounts and timing of Bioventus&#8217; future taxable income, and may be significantly different from the amounts described in the preceding sentence. Additionally, in certain cases such payments may be accelerated or significantly exceed the actual benefits Bioventus realize. In certain cases, payments under the TRA to the continuing LLC owners may be accelerated or significantly exceed the actual benefits Bioventus realizes in respect of tax attributes subject to the TRA. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; organizational structure, including the TRA, confers certain tax benefits upon the continuing LLC owner that may not benefit Class&#160;A common stockholders to the same extent as they will benefit the continuing LLC owner. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; organizational structure, including the TRA, confers certain tax benefits upon the continuing LLC owner that may not benefit the holders of Bioventus class A common stock to the same extent as they will benefit the continuing LLC owner. Bioventus entered into the TRA with BV LLC and the continuing LLC owner that provides for Bioventus&#8217; payment to the continuing LLC owner of 85% of the amount of tax benefits, if any, that Bioventus actually realizes (or in some circumstances are deemed to realize) as a result of (i)&#160;increases in the tax basis of assets of BV LLC resulting from (a)&#160;any future redemptions or exchanges of LLC interests described under &#8220;Description of Bioventus&#8217; Business&#8212;Bioventus LLC agreement&#8212;LLC Interest Redemption Right&#8221;, and (b)&#160;certain distributions (or deemed distributions) by BV LLC and (ii)&#160;certain other tax benefits arising from payments under the TRA. Although Bioventus will retain 15% of such tax benefits, this and other aspects of Bioventus&#8217; organizational structure may adversely impact the future trading market for the Class&#160;A common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In certain cases, payments under the TRA to the continuing LLC owner may be accelerated or significantly exceed the actual benefits Bioventus realizes in respect of the tax attributes subject to the TRA. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The TRA provides that if (i)&#160;Bioventus materially breaches any of Bioventus&#8217; material obligations under the TRA, (ii)&#160;certain mergers, asset sales, other forms of business combinations or other changes of control were to occur on or before December&#160;31, 2021 or (iii)&#160;Bioventus elects an early termination of the TRA, then Bioventus&#8217; obligations or Bioventus&#8217; successor&#8217;s obligations under the TRA to make payments thereunder would be based on certain assumptions, including an assumption that Bioventus would have sufficient taxable income to fully utilize all potential future tax benefits that are subject to the TRA (or, in the case of certain mergers, asset sales, other forms of business combinations or other changes of control occurring after December&#160;31, 2021, that Bioventus would have taxable income at least equal to Bioventus&#8217; times the highest taxable income in any of the Bioventus&#8217; fiscal quarters ending prior to the closing date of such transaction (increased by 10% for each taxable year beginning with the second taxable year following such closing date)). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the foregoing, (i)&#160;Bioventus could be required to make payments under the TRA that are greater than the specified percentage of the actual benefits Bioventus ultimately realizes in respect of the tax benefits that are subject to the TRA and (ii)&#160;if Bioventus materially breaches any of its material obligations under the TRA or if Bioventus elected to terminate the TRA early, it would be required to make an immediate cash payment equal to the present value of the anticipated future tax benefits that are the subject of the TRA, which payment may be made significantly in advance of the actual realization, if any, of such future tax benefits. In these situations, Bioventus&#8217; obligations under the TRA could have a substantial negative impact on its liquidity and could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations or other changes of control. There can be no assurance that Bioventus will be able to fund or finance its obligations under the TRA. Bioventus may elect to completely terminate the TRA early only with the written approval of a majority of its directors other than any directors that have been appointed or designated by the continuing LLC owner or any of such person&#8217;s affiliates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may make payments to the continuing LLC owner under the TRA that exceed the tax benefits actually realized by it in the event that any tax benefits are disallowed by a taxing authority. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments under the TRA are based on the tax reporting positions that Bioventus determines, and the Internal Revenue Service (IRS) or another tax authority may challenge all or part of the tax basis increases, as well as other related tax positions Bioventus takes, and a court could sustain such challenge. Pursuant to the TRA, the continuing LLC owner is required to reimburse Bioventus for any cash payments previously made to it under the TRA in the event that any tax benefits actually realized by Bioventus and for which payment has been made under the TRA are subsequently challenged by a taxing authority and are ultimately disallowed. In addition, but without duplication of any amounts previously reimbursed by the continuing LLC owner, any excess cash payments made by Bioventus to the continuing LLC owner will be netted against any future cash payments that Bioventus might otherwise be required to make to the continuing LLC owner under the terms of the TRA. However, Bioventus might not determine that it has effectively made an excess cash payment to the continuing LLC owner for a number of years following the initial time of such payment. Moreover, there can be no assurance that any excess cash payments for which the continuing LLC owner has a reimbursement obligation under the TRA will be repaid to Bioventus. As a result, payments could be made under the TRA in excess of the tax savings that Bioventus realizes in respect of the tax attributes with respect to the continuing LLC owner that are the subject of the TRA. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of Bioventus&#8217; income or other tax returns could adversely affect its results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is subject to taxes by the U.S. federal, state, local and foreign tax authorities, and Bioventus&#8217; tax liabilities will be affected by the allocation of expenses to differing jurisdictions. Bioventus&#8217; future effective tax rates could be subject to volatility or adversely affected by a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in the valuation of Bioventus&#8217; deferred tax assets and liabilities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expected timing and amount of the release of any tax valuation allowances; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tax effects of equity-based compensation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in tax laws, regulations or interpretations thereof; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">future earnings being lower than anticipated in countries where Bioventus has lower statutory tax rates and higher than anticipated earnings in countries where it has higher statutory tax rates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, Bioventus may be subject to audits of its income, sales and other transaction taxes by U.S. federal, state, local and foreign taxing authorities. Outcomes from these audits could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If Bioventus was deemed to be an investment company under the Investment Company Act of 1940, as amended, or the 1940 Act, as a result of Bioventus&#8217; ownership of BV LLC, applicable restrictions could make it impractical for Bioventus to continue its business as contemplated and could adversely affect its business, results of operations and financial condition. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Sections 3(a)(1)(A) and (C)&#160;of the 1940 Act, a company generally will be deemed to be an &#8220;investment company&#8221; for purposes of the 1940 Act if (i)&#160;it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (ii)&#160;it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. Bioventus does not believe that it is an &#8220;investment company,&#8221; as such term is defined in either of those sections of the 1940 Act. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the sole managing member of BV LLC, Bioventus controls and operates BV LLC. On that basis, Bioventus believes that its interest in BV LLC is not an &#8220;investment security&#8221; as that term is used in the 1940 Act. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, if Bioventus was to cease participation in the management of BV LLC, Bioventus&#8217; interest in BV LLC could be deemed an &#8220;investment security&#8221; for purposes of the 1940 Act. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and BV LLC intend to conduct Bioventus&#8217; operations so that it will not be deemed an investment company. However, if Bioventus was to be deemed an investment company, restrictions imposed by the 1940 Act, including limitations on its capital structure and its ability to transact with affiliates, could make it impractical for Bioventus to continue its business as contemplated and could adversely affect its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus is controlled by the original LLC owners, whose interests may differ from those of Bioventus&#8217; public stockholders. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;22, 2021, the original LLC owners control approximately 83.8% of the combined voting power of Bioventus&#8217; common stock through their ownership of both Bioventus class A common stock and Bioventus class B common stock. The original LLC owners will, for the foreseeable future, have the ability to substantially influence Bioventus through their ownership position over corporate management and affairs, and will be able to control virtually all matters requiring stockholder approval. The original LLC owners are able to, subject to applicable law, and the voting arrangements described in the stockholders agreement, elect a majority of the members of Bioventus&#8217; Board control actions to be taken by Bioventus and Bioventus board, including amendments to Bioventus&#8217; certificate of incorporation and bylaws and approval of significant corporate transactions, including mergers and sales of substantially all of Bioventus&#8217; assets. The directors so elected will have the authority, subject to the terms of Bioventus&#8217; indebtedness and applicable rules and regulations, to issue additional stock, implement stock repurchase programs, declare dividends and make other decisions. It is possible that the interests of the original LLC owners may in some circumstances conflict with Bioventus&#8217; interests and the interests of its other stockholders, including you. For example, the continuing LLC owner may have different tax positions from Bioventus, especially in light of the TRA that could influence Bioventus&#8217; decisions regarding whether and when to dispose of assets, whether and when to incur new or refinance existing indebtedness, and whether and when Bioventus should terminate the TRA and accelerate its obligations thereunder. In addition, the determination of future tax reporting positions and the structuring of future transactions may take into consideration the continuing LLC owner&#8217;s tax or other considerations, which may differ from the considerations of Bioventus or Bioventus&#8217; other stockholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to Ownership of Bioventus&#8217; Class&#160;A Common Stock </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In the past, Bioventus identified material weaknesses in its internal control over financial reporting. If Bioventus experiences additional material weaknesses in the future or otherwise fails to maintain an effective system of internal controls, Bioventus may not be able to accurately or timely requirements applicable to public companies, which may adversely affect investor confidence in Bioventus, and, as a result, the market price of Bioventus class A common stock. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ensuring that Bioventus has adequate internal financial and accounting controls and procedures in place so that it can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Bioventus&#8217; internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A material weakness is a deficiency, or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of Bioventus&#8217; financial statements will not be prevented or detected on a timely basis. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the audit of Bioventus&#8217; consolidated financial statements as of and for the year ended December&#160;31, 2020, Bioventus determined that it no longer has a material weakness associated with the proper </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">processing of Exogen reimbursement claims in accordance with regulations and contractual terms. Bioventus implemented measures designed to improve its internal control over financial reporting to remediate such material weakness. These efforts included: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the augmentation, reorganization and training of Bioventus&#8217; prescription to cash staff, which includes its direct sales team, order management personnel, patient financial services personnel and reimbursement services and accounts receivable personnel, regarding key aspects of regulations and requirements and how to deal with inconsistencies within patient medical records; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">implementation of monthly sales order testing on sampling basis by Bioventus&#8217; Compliance department including a review of medical necessity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishment of a cross functional governance committee, reporting to an executive steering committee to review and approve Bioventus&#8217; Exogen Medicare policy and oversee future Exogen policy and process interpretations and changes; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">implementation of a checklist to be completed for each Medicare order to ensure compliance with Bioventus&#8217; policy for Medicare claims and then further automating this checklist. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus cannot assure you that the measures Bioventus has taken to date, and actions Bioventus may take in the future, will be sufficient to prevent or avoid potential future material weaknesses. If Bioventus identifies any additional material weaknesses, the accuracy and timing of its financial reporting may be adversely affected, Bioventus may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in its financial reporting, and the market price of its Class&#160;A common stock may decline as a result. Bioventus could also become subject to investigations by the SEC or other regulatory authorities, which could require additional financial and management resources. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to establish and maintain effective internal controls in accordance with Section&#160;404 of the Sarbanes-Oxley Act could adversely affect Bioventus&#8217; business and stock price. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is required to comply with the SEC&#8217;s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which require management to certify financial and other information in its quarterly and annual reports and provide an annual management report on the effectiveness of internal controls over financial reporting. Though Bioventus will be required to disclose changes made in its internal controls and procedures on a quarterly basis, Bioventus will not be required to make Bioventus&#8217; first annual assessment of its internal control over financial reporting pursuant to Section&#160;404 until the year following its first annual report required to be filed with the SEC. However, as an emerging growth company, Bioventus&#8217; independent registered public accounting firm will not be required to formally attest to the effectiveness of its internal control over financial reporting pursuant to Section&#160;404 until the later of the year following its first annual report required to be filed with the SEC or the date it is no longer an emerging growth company. At such time, Bioventus&#8217; independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which Bioventus&#8217; controls are documented, designed or operating. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To comply with the requirements of being a public company, Bioventus has undertaken various actions, and may need to take additional actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. Testing and maintaining internal controls can divert Bioventus&#8217; management&#8217;s attention from other matters that are important to the operation of Bioventus&#8217; business. Additionally, when evaluating Bioventus&#8217; internal controls over financial reporting, Bioventus may identify material weaknesses that Bioventus may not be able to remediate in time to meet the applicable deadline imposed upon Bioventus for compliance with the requirements of Section&#160;404. If Bioventus identifies any material weaknesses in Bioventus&#8217; internal controls over financial reporting or are unable to comply with the requirements of Section&#160;404 in a timely manner or assert that Bioventus&#8217; internal controls over financial reporting is effective, or if Bioventus&#8217; independent registered public accounting firm is unable to express an opinion as to the effectiveness of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; internal controls over financial reporting once Bioventus is no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of Bioventus&#8217; financial reports and the market price of Bioventus class A common stock could be adversely affected, and Bioventus could become subject to investigations by the stock exchange on which Bioventus&#8217; securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus is a &#8220;controlled company&#8221; within the meaning of Nasdaq listing standards and, as a result, will qualify for, and intend to rely on, exemptions from certain corporate governance requirements. You will not have the same protections afforded to stockholders of companies that are subject to such requirements. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The former LLC owners and continuing LLC owner (&#8220;Voting Group&#8221;), which holds Bioventus class A common stock and Bioventus class B common stock representing approximately 83.8% of the combined voting power of Bioventus&#8217; common stock, entered into a stockholders agreement filed as exhibit 10.4 hereto. For a period of time, the parties to the stockholders agreement will agree to vote their shares of Bioventus class A common stock and Bioventus class B common stock in favor of the election of the nominees of certain members of the Voting Group to Bioventus&#8217; Board upon their nomination by the nominating and corporate governance committee of Bioventus&#8217; Board. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of the stockholders agreement and the aggregate voting power over Bioventus class A common stock and Bioventus class B common stock held by the parties to the stockholders agreement, Bioventus is considered a &#8220;controlled company&#8221; for the purposes of Nasdaq. As such, Bioventus is exempt from certain corporate governance requirements of Nasdaq, including (1)&#160;the requirement that a majority of the Board consist of independent directors, (2)&#160;the requirement that Bioventus has a nominating and corporate governance committee that is composed entirely of independent directors and (3)&#160;the requirement that Bioventus has a compensation committee that is composed entirely of independent directors. Bioventus intends to rely on some or all of these exemptions. As a result, Bioventus does not have a majority of independent directors and Bioventus&#8217; compensation and nominating and corporate governance committees do not consist entirely of independent directors. Accordingly, you will not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Taking advantage of the reduced disclosure requirements applicable to &#8220;emerging growth companies&#8221; may make Bioventus class A common stock less attractive to investors. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The JOBS Act provides that, so long as a company qualifies as an &#8220;emerging growth company,&#8221; it will, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be exempt from the provisions of Section&#160;404(b) of the Sarbanes-Oxley Act requiring that its independent registered public accounting firm provide an attestation report on the effectiveness of its internal control over financial reporting; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be exempt from the &#8220;say on pay&#8221; and &#8220;say on golden parachute&#8221; advisory vote requirements of the Dodd-Frank Wall Street Reform and Customer Protection Act, or the Dodd-Frank Act; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be exempt from certain disclosure requirements of the Dodd-Frank Act relating to compensation of its executive officers and be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Exchange Act; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be permitted to provide a reduced level of disclosure concerning executive compensation and be exempt from any rules that have been adopted by the Public Company Accounting Oversight Board requiring a supplement to the auditor&#8217;s report on the financial statements or that may be adopted requiring mandatory audit firm rotations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and Bioventus could be an emerging growth company for up to five years following its IPO. For as long as Bioventus continues to be an emerging </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">growth company, Bioventus may choose to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. Bioventus has irrevocably elected not to take advantage of the extension of time to comply with new or revised financial accounting standards available under Section&#160;107(b) of the JOBS Act. Bioventus has also taken advantage of certain reduced reporting burdens in this joint proxy statement/prospectus. Bioventus could be an emerging growth company for up to five years after its IPO and will continue to be an emerging growth company unless Bioventus&#8217; total annual gross revenues are $1.07&#160;billion or more, Bioventus has issued more than $1&#160;billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt in the past three years or Bioventus becomes a &#8220;large accelerated filer&#8221; as defined in the Exchange Act. If Bioventus remains an &#8220;emerging growth company&#8221;, Bioventus may take advantage of other exemptions, including the exemptions from the advisory vote requirements and executive compensation disclosures under the Dodd-Frank Act and the exemption from the provisions of Section&#160;404(b) of the Sarbanes-Oxley Act. Bioventus cannot predict if investors will find its Bioventus class A common stock less attractive if Bioventus elects to rely on these exemptions, or if taking advantage of these exemptions would result in less active trading or more volatility in the price of Bioventus class A common stock. Also, as a result of Bioventus&#8217; intention to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to Bioventus as long as Bioventus qualifies as an &#8220;emerging growth company,&#8221; Bioventus&#8217; financial statements may not be comparable to those of companies that fully comply with regulatory and reporting requirements upon the public company effective dates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus does not currently expect to pay any cash dividends. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus does not anticipate declaring or paying any cash dividends to holders of its Bioventus class A common stock in the foreseeable future. Bioventus currently intends to retain future earnings, if any, to finance its growth. Any determination to pay cash dividends in the future will be at the sole discretion of Bioventus&#8217; Board, subject to limitations under applicable law and may be discontinued at any time. In addition, Bioventus&#8217; ability to pay cash dividends is currently restricted by the terms of Bioventus&#8217; 2019 Credit Agreement. Therefore, you are not likely to receive any dividends on your Bioventus class A common stock for the foreseeable future, and the success of an investment in Bioventus class A common stock will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of Bioventus class A common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee that Bioventus class A common stock will appreciate in value or even maintain the price at which Bioventus&#8217; stockholders have purchased Bioventus class A common stock. Investors seeking cash dividends should not purchase Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, Bioventus&#8217; operations are currently conducted entirely through BV LLC and its subsidiaries and Bioventus&#8217; ability to generate cash to meet its debt service obligations or to make future dividend payments, if any, is highly dependent on the earnings and the receipt of funds from BV LLC and its subsidiaries via dividends or intercompany loans. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; amended and restated certificate of incorporation, to the extent permitted by applicable law, contains provisions renouncing Bioventus&#8217; interest and expectation to participate in certain corporate opportunities identified or presented to certain of its original LLC owners. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of the original LLC owners are in the business of making or advising on investments in companies and these Original LLC owners may hold, and may, from time to time in the future, acquire interests in or provide advice to businesses that directly or indirectly compete with certain portions of Bioventus&#8217; business or the business of Bioventus&#8217; suppliers. Bioventus&#8217; amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, none of the original LLC owners or any director who is not employed by Bioventus or his or her affiliates will have any duty to refrain from engaging in a corporate opportunity in the same or similar lines of business as Bioventus. The original LLC owners may also pursue acquisitions that may be complementary to Bioventus&#8217; business, and, as a result, those acquisition opportunities may not be available to Bioventus. As a result, these arrangements could adversely affect Bioventus&#8217; business, results of operations, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial condition or prospects if attractive business opportunities are allocated to any of the original LLC owners instead of to Bioventus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus may issue shares of preferred stock in the future, which could make it difficult for another company to acquire Bioventus or could otherwise adversely affect holders of Bioventus class A common stock, which could depress the price of Bioventus class A common stock. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; amended and restated certificate of incorporation will authorize Bioventus to issue one or more series of preferred stock. Bioventus&#8217; Board will have the authority to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by Bioventus&#8217; stockholders. Bioventus&#8217; preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of Bioventus class A common stock. The potential issuance of preferred stock may delay or prevent a change in control of Bioventus, discourage bids for Bioventus class A common stock at a premium to the market price, and materially and adversely affect the market price and the voting and other rights of the holders of Bioventus class A common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-takeover provisions in Bioventus&#8217; governing documents and under Delaware law could make an acquisition of its company more difficult, limit attempts by Bioventus&#8217; stockholders to replace or remove Bioventus&#8217; current management, and depress the market price of Bioventus&#8217; common stock. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could have the effect of rendering more difficult, delaying or preventing an acquisition deemed undesirable by Bioventus&#8217; Board and include the following provisions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">authorizing the issuance of &#8220;blank check&#8221; preferred stock that could be issued by Bioventus&#8217; Board to increase the number of outstanding shares and thwart a takeover attempt; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing a classified Board so that not all members of Bioventus&#8217; Board are elected at one time; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the removal of directors only for cause; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prohibiting the use of cumulative voting for the election of directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limiting the ability of stockholders to call special meetings or amend Bioventus&#8217; bylaws; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requiring all stockholder actions to be taken at a meeting of Bioventus&#8217; stockholders; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing advance notice and duration of ownership requirements for nominations for election to the Board or for proposing matters that can be acted upon by stockholders at stockholder meetings. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in Bioventus&#8217; management. As a Delaware corporation, Bioventus is also subject to provisions of Delaware law, including Section&#160;203 of the DGCL, which prevents interested stockholders, such as certain stockholders holding more than 15% of Bioventus&#8217; outstanding common stock from engaging in certain business combinations unless (i)&#160;prior to the time such stockholder became an interested stockholder, the board approved the transaction that resulted in such stockholder becoming an interested stockholder, (ii)&#160;upon consummation of the transaction that resulted in such stockholder becoming an interested stockholder, the interested stockholder owned 85% of the common stock or (iii)&#160;following board approval, the business combination receives the approval of the holders of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of Bioventus&#8217; outstanding common stock not held by such interested stockholder. Because Bioventus has &#8220;opted out&#8221; of Section&#160;203 of the DGCL in its amended and restated certificate of incorporation, the statute will not apply to business combinations involving Bioventus. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any provision of Bioventus&#8217; amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying, preventing or deterring a change in control could limit the opportunity for Bioventus&#8217; stockholders to receive a premium for their shares of Bioventus&#8217; common stock and could also affect the price that some investors are willing to pay for Bioventus&#8217; common stock. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between Bioventus and Bioventus&#8217; stockholders, which could limit Bioventus&#8217; stockholders&#8217; ability to obtain a favorable judicial forum for disputes with Bioventus or Bioventus&#8217; directors, officers or employees. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; amended and restated certificate of incorporation provides that, unless Bioventus consents to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for: (a)&#160;any derivative action, suit or proceeding brought on its behalf; (b)&#160;any action, suit or proceeding asserting a claim of breach of fiduciary duty owed by any of Bioventus&#8217; directors, officers or stockholders to Bioventus or to Bioventus&#8217; stockholders; (c)&#160;any action, suit or proceeding arising pursuant to any provision of the DGCL, Bioventus&#8217; amended and restated certificate of incorporation or amended bylaws (as either may be amended from time to time); or, (d)&#160;any action, suit or proceeding asserting a claim governed by the internal affairs doctrine; provided that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with Bioventus or Bioventus&#8217; directors, officers or other employees, which may discourage such lawsuits against Bioventus and Bioventus&#8217; directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in Bioventus&#8217; amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, Bioventus may incur additional costs associated with resolving such action in other jurisdictions, which could harm its business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Relating to the Proposed Acquisition of Misonix </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus is subject to various risks related to the proposed acquisition of Misonix. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has entered into a merger agreement with Misonix pursuant to which Bioventus has agreed to acquire Misonix. The risks, contingencies and other uncertainties that could result in the failure of the proposed acquisition to be completed or, if completed, that could have a material adverse effect on Bioventus&#8217; business, financial condition or results of operations following the proposed acquisition, and any anticipated benefits of the proposed acquisition, include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the failure to obtain necessary stockholder approvals for the share issuance and the adoption of the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the failure to satisfy required closing conditions or complete the proposed acquisition in a timely manner or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the effect of the announcement of the proposed acquisition on each company&#8217;s ability to retain and hire key personnel, maintain business relationships, and on operating results and the businesses generally; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of Misonix to pursue alternatives to the proposed acquisition with us pursuant to the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the diversion of Bioventus&#8217; management&#8217;s attention from its core business as Bioventus works to take all steps necessary to close the transaction and integrate Misonix&#8217;s business into Bioventus&#8217;; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuance of additional equity in connection with the acquisition may dilute Bioventus&#8217; stockholders and the uncertainties related to the potential impact of the proposed acquisition on Bioventus&#8217; stock price; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to achieve the anticipated synergies and Bioventus&#8217; incurrence of significant transaction related costs in connection with the proposed acquisition that are, and will be, incurred regardless of whether the proposed acquisition is completed; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the occurrence of any event giving rise to the right to terminate the merger agreement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px;;font-style:italic;display:inline;">Bioventus&#8217; future results following the proposed acquisition will suffer if Bioventus does not effectively manage the expanded operations or successfully integrate the businesses of Misonix.</div></div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; future success will depend, in part, upon its ability to manage the expanded business, including challenges related to the management and monitoring of new operations and associated increased costs and complexity associated with the acquisition of Misonix and other acquisitions. If Bioventus is not able to successfully complete integrations in an efficient and effective manner, the anticipated benefits of these acquisitions may not be realized fully, or at all, or may take longer to realize than expected, and the value of Bioventus&#8217; common stock may be affected adversely. An inability to realize the full extent of the anticipated benefits of the proposed acquisitions, as well as any delays encountered in the integration processes, could have an adverse effect upon on Bioventus&#8217; business, financial condition or results of operations. In addition, the actual integrations may result in additional and unforeseen expenses, including increased legal, accounting and compliance costs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to complete the proposed acquisition may negatively impact Bioventus&#8217; share price, the future business and Bioventus&#8217; financial results. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the proposed acquisition is not completed on a timely basis, Bioventus&#8217; and Misonix ongoing businesses may be adversely affected. If the proposed acquisition is not completed at all, Bioventus will be subject to a number of risks, including the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">being required to pay costs and expenses relating to the transactions, such as legal, accounting, financial advisory and printing fees; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">time and resources committed by Bioventus&#8217; management to matters relating to the proposed acquisition could otherwise have been devoted to pursuing other beneficial opportunities. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the proposed acquisition is not completed, the price of Bioventus&#8217; common stock may decline to the extent that the current market price reflects a market assumption that the proposed acquisition will be completed and that the related benefits will be realized, or a market perception that the proposed acquisition was not completed due to an adverse change in Bioventus&#8217; business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Risk Factors of Misonix </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Misonix&#8217;s business is and will be subject to the risks described above. In addition, Misonix is, and will continue to be, subject to the risks described in its Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K</div> for the fiscal year ended June&#160;30, 2021, as such risks may be updated or supplemented in Misonix&#8217;s subsequently filed Quarterly Reports on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-Q</div> and Current Reports on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;8-K,</div> each of which are filed with the SEC and incorporated by reference in this joint proxy statement/prospectus. See &#8220;Where You Can Find More Information.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE PARTIES TO THE MERGER </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">4721 Emperor Boulevard, Suite 400 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Durham, North Carolina 27703 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus is a global leader of innovations for active healing. Through a combination of internal product development, product/business acquisition, and distribution agreements, it will bring to market products which address a growing need for clinically effective, cost efficient, minimally invasive medical treatments, that engage and enhance the body&#8217;s natural healing processes. Bioventus&#8217; principal place of business is 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is a Delaware corporation and Bioventus common stock is listed on Nasdaq under the ticker symbol &#8220;BVS.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information about Bioventus, visit Bioventus&#8217; website at www.bioventus.com. The information contained on or accessible through Bioventus&#8217; website (other than the documents incorporated by reference herein) does not constitute a part of this joint proxy statement/prospectus or any other report or document on file with or furnished to the SEC. Additional information about Bioventus is included in the documents incorporated by reference in this joint proxy statement/prospectus. See &#8220;Where You Can Find More Information.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">1938 New Highway </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Farmingdale, New York </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(631) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">694-9555</div> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Misonix designs, manufactures and markets minimally invasive surgical ultrasonic medical devices. These products are used for precise bone sculpting, removal of soft and hard tumors, and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. Misonix also exclusively markets, sells and distributes skin allografts and wound care products used to support healing of wounds, and which complement Misonix&#8217;s ultrasonic medical devices Misonix&#8217;s principal place of business is 1938 New Highway, Farmingdale, New York, and its telephone number is (631) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">694-9555.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix is a Delaware corporation and Misonix common stock is listed on Nasdaq under the ticker symbol &#8220;MSON.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information about Misonix, visit Misonix&#8217;s website at www.Misonix.com. The information contained on or accessible through Misonix&#8217;s website (other than the documents incorporated by reference herein) does not constitute a part of this joint proxy statement/prospectus or any other report or document on file with or furnished to the SEC. Additional information about Misonix is included in the documents incorporated by reference in this joint proxy statement/prospectus. See &#8220;Where You Can Find More Information.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Oyster Merger Sub I, Inc. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">4721 Emperor Boulevard, Suite 100 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Durham, North Carolina 27703 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Merger Sub I was formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of any nature other than as set forth in the merger agreement. By operation of the merger, Merger Sub I will be merged with and into Misonix, with Misonix continuing as the surviving corporation. Merger Sub I&#8217;s principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-67002485.</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">117 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Oyster Merger Sub II, LLC </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">4721 Emperor Boulevard, Suite 100 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Durham, North Carolina 27703 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700</div> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Merger Sub II was formed by Bioventus solely in contemplation of the merger, has not conducted any business and has no assets, liabilities or obligations of any nature other than as set forth in the merger agreement. By operation of the merger, following the first merger, Misonix will be merged with and into Merger Sub II, with Merger Sub II continuing as the surviving entity (renamed as Misonix LLC) and a wholly owned subsidiary of Bioventus. Merger Sub II&#8217;s principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703, and its telephone number is (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700.</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">118 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE BIOVENTUS SPECIAL MEETING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This joint proxy statement/prospectus is being provided to Bioventus stockholders in connection with the solicitation of proxies by the Bioventus board for use at the Bioventus special meeting and at any adjournments or postponements thereof. Bioventus stockholders are encouraged to read this entire document carefully, including its annexes and the documents incorporated by reference herein, for more detailed information regarding the merger agreement and the transactions contemplated thereby. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date, Time and Place of the Bioventus Special Meeting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus special meeting is scheduled to be held virtually via live webcast on [&#9679;], 2021, beginning at [&#9679;], Eastern Time, unless postponed to a later date. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In light of ongoing developments related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, Bioventus has elected to hold the Bioventus special meeting solely by means of remote communication via live webcast. Bioventus stockholders will be able to virtually attend and vote at the Bioventus special meeting by visiting www.virtualshareholdermeeting.com/BVS2021SM, which is referred to as the &#8220;Bioventus special meeting website.&#8221; Bioventus stockholders will need the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16-digit</div> control number found on their proxy card in order to access the Bioventus special meeting website and to access the list of Bioventus stockholders entitled to vote at the Bioventus special meeting during the time of the meeting. </div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus has retained Broadridge to host the live webcast of the Bioventus special meeting. Thirty minutes prior to the Bioventus special meeting, Broadridge may be contacted at (855) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">499-0991</div> (U.S. toll-free) or (720) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">378-5962</div> (international toll), and will be available to answer any questions regarding how to virtually attend the Bioventus special meeting or if you encounter any technical difficulty accessing or during the Bioventus special meeting. Technical support phone numbers will also be available via the virtual meeting url 30 minutes prior to the start of the meeting. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matters to Be Considered at the Bioventus Special Meeting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of the Bioventus special meeting is to consider and vote on each of the following proposals, each of which is further described in this joint proxy statement/prospectus: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bioventus Proposal 1:</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Approval of the Share Issuance</div></div>. To consider and vote on the Bioventus share issuance proposal; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bioventus Proposal 2:</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjournment of the Bioventus Special Meeting</div></div>. To consider and vote on the Bioventus adjournment proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recommendation of the Bioventus Board of Directors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board unanimously recommends that Bioventus stockholders vote: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bioventus Proposal 1:</div></div> &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus share issuance proposal; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bioventus Proposal 2:</div></div> &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus adjournment proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After careful consideration, the Bioventus board unanimously: (i)&#160;determined that the terms of the merger agreement and the merger are fair to and in the best interests of Bioventus and its stockholders; (ii)&#160;approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, each on the terms and subject to the conditions set forth in the merger agreement; and (iii)&#160;recommended that Bioventus stockholders approve of the Bioventus share issuance proposal. See &#8220;The Mergers&#8212;Recommendation of the Bioventus Board of Directors; Bioventus&#8217;s Reasons for the Merger.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">119 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Record Date for the Bioventus Special Meeting and Voting Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The record date to determine Bioventus stockholders who are entitled to receive notice of and to vote at the Bioventus special meeting or any adjournments or postponements thereof is [&#9679;], 2021. As of the close of business on the Bioventus record date, there were [&#9679;] shares of Bioventus common stock issued and outstanding and entitled to vote at the Bioventus special meeting. Each Bioventus stockholder is entitled to one vote for each share of Bioventus common stock such holder owned of record at the close of business on the Bioventus record date with respect to each matter properly brought before the Bioventus special meeting. Only Bioventus stockholders of record at the close of business on the Bioventus record date are entitled to receive notice of and to vote at the Bioventus special meeting and any and all adjournments or postponements thereof. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Quorum; Abstentions and Broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Votes</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A quorum of Bioventus stockholders is necessary to conduct the Bioventus special meeting. The presence, virtually via the Bioventus special meeting website or by proxy, of the holders of a majority in voting power of the stock issued and outstanding and entitled to vote at the Bioventus special meeting will constitute a quorum. Shares of Bioventus common stock represented at the Bioventus special meeting by virtual attendance via the Bioventus special meeting website or by proxy and entitled to vote, but not voted, including shares for which an Bioventus stockholder directs an &#8220;abstention&#8221; from voting, will be counted for purposes of determining a quorum. However, because all of the proposals for consideration at the Bioventus special meeting are considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matters under Nasdaq rules (as described below), shares held in &#8220;street name&#8221; will not be counted as present for the purpose of determining the existence of a quorum unless the Bioventus stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals at the Bioventus special meeting. If a quorum is not present, the Bioventus special meeting will be adjourned or postponed until the holders of the number of shares of Bioventus common stock required to constitute a quorum attend. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under Nasdaq rules, banks, brokers or other nominees who hold shares in &#8220;street name&#8221; on behalf of the beneficial owner of such shares have the authority to vote such shares in their discretion on certain &#8220;routine&#8221; proposals when they have not received voting instructions from the beneficial owners. However, banks, brokers or other nominees are not allowed to exercise their voting discretion with respect to matters that under Nasdaq rules are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine.&#8221;</div> This can result in a &#8220;broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vote,&#8221;</div> which occurs on an item when (i)&#160;a bank, broker or other nominee has discretionary authority to vote on one or more &#8220;routine&#8221; proposals to be voted on at a meeting of stockholders, but is not permitted to vote on other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> proposals without instructions from the beneficial owner of the shares, and (ii)&#160;the beneficial owner fails to provide the bank, broker or other nominee with voting instructions on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matter. All of the proposals before the Bioventus special meeting are considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matters under Nasdaq rules, and banks, brokers or other nominees will not have discretionary authority to vote on any matter before the Bioventus special meeting. As a result, Bioventus does not expect any broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes</div> at the Bioventus special meeting and if you hold your shares of Bioventus common stock in &#8220;street name,&#8221; your shares will not be represented and will not be voted on any matter unless you affirmatively instruct your bank, broker or other nominee how to vote your shares in accordance with the voting instructions provided by your bank, broker or other nominee. It is therefore critical that you cast your vote by instructing your bank, broker or other nominee on how to vote. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Brokers will not be able to vote on any of the proposals before the Bioventus special meeting unless they have received voting instructions from the beneficial owners.</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">120 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Required Votes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Except for the Bioventus adjournment proposal, the vote required to approve each of the proposals listed below assumes the presence of a quorum at the Bioventus special meeting. As described above, Bioventus does not expect there to be any broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes</div> at the Bioventus special meeting. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 15%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 42%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 41%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Proposal</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Required Vote</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effects of Certain Actions</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Proposal&#160;1:</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus share issuance proposal</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Assuming a quorum is present at the Bioventus special meeting, approval requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus share issuance proposal.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Proposal 2:</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus adjournment proposal</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast on the Bioventus adjournment proposal.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal.</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus adjournment proposal. However, if an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal.</div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to the execution of the merger agreement, Misonix entered into the Bioventus support agreement with the Bioventus supporting stockholders, pursuant to which such stockholders have agreed, among other things, to vote the shares of Bioventus common stock that they beneficially own at the time such vote is taken in favor of Bioventus share issuance proposal and against approval of any proposal made in opposition to, in competition with, or inconsistent with, the merger agreement or the transaction. As of the record date for the Bioventus special meeting, such stockholders beneficially own approximately [&#9679;]% of the outstanding shares of Bioventus common stock. Therefore, the Bioventus supporting stockholders hold a sufficient number of shares of Bioventus common stock in order to approve the Bioventus share issuance proposal. On July&#160;29, 2021, in connection with execution of the merger agreement, each of the Bioventus supporting stockholders have entered into lock up agreements with Bioventus (each a &#8220;lock up agreement&#8221;) restricting the sale and transfer of the capital stock of Bioventus for a period of 90 or 180 days, subject to the terms of the lock up agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vote of Bioventus Directors and Executive Officers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Bioventus directors and executive officers, and their affiliates, as a group, owned and were entitled to vote less than 1% of the total outstanding shares of Bioventus common stock. Although none of them has entered into any agreement obligating them to do so, Bioventus currently expects that all Bioventus directors and executive officers will vote their shares &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus share issuance proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Bioventus adjournment proposal. See &#8220;Interests of Bioventus Directors and Executive Officers in the Merger&#8221; and &#8220;Bioventus Executive Officer and Director Compensation&#8221; in this joint proxy statement/prospectus. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Methods of Voting </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registered Stockholders </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you are an Bioventus stockholder of record, you may vote at the Bioventus special meeting by proxy over the Internet or telephone or by mail, or by virtually attending and voting at the Bioventus special meeting via the Bioventus special meeting website, as described below. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">By Internet</div></div>: By following the instructions provided on your proxy card. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">By Telephone</div></div>: By following the instructions provided on your proxy card. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">By Mail</div></div>: If you have received a paper copy of the proxy materials by mail, you may complete and return by mail the enclosed proxy card in the postage-paid envelope. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Virtually via the Bioventus Special Meeting Website</div></div>: By visiting the Bioventus special meeting website, you can virtually attend and vote at the Bioventus special meeting. Bioventus stockholders who plan to virtually attend the Bioventus special meeting will need the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16-digit</div> control number included on their proxy card in order to access the Bioventus special meeting website. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless revoked, all duly executed proxies representing shares of Bioventus common stock entitled to vote at the Bioventus special meeting will be voted at the Bioventus special meeting and, where a choice has been specified on the proxy card, will be voted in accordance with such specification. If you submit an executed proxy without providing instructions for any proposal, then the Bioventus officers identified on the proxy will vote your shares consistent with the recommendation of the Bioventus board on such proposal. If you are an Bioventus stockholder of record, proxies submitted over the internet or by telephone as described above must be received by [&#9679;], Eastern Time, on [&#9679;], 2021. To reduce administrative costs and help the environment by conserving natural resources, Bioventus asks that you submit a proxy to vote your shares through the internet or by telephone. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By executing and delivering a proxy in connection with the Bioventus special meeting, you designate certain Bioventus officers identified therein as your proxies at the Bioventus special meeting. If you deliver an executed </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">proxy, but do not specify a choice for any proposal properly brought before the Bioventus special meeting, such proxies will vote your shares of Bioventus common stock on such uninstructed proposal in accordance with the recommendation of the Bioventus board. Bioventus does not expect that any matter other than the proposals listed above will be brought before the Bioventus special meeting, and the Bioventus bylaws provide that the only business that may be conducted at the Bioventus special meeting are those proposals brought before the Bioventus special meeting by or at the direction of the Bioventus board. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Beneficial (Street Name) Stockholders </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If you hold your shares of Bioventus common stock through a bank, broker or other nominee in &#8220;street name&#8221; instead of as a registered holder, you must follow the voting instructions provided by your bank, broker or other nominee in order to vote your shares. Your voting instructions must be received by your bank, broker or other nominee prior to the deadline set forth in the information from your bank, broker or other nominee on how to submit voting instructions. If you do not provide voting instructions to your bank, broker or other nominee for a proposal, your shares of Bioventus common stock will not be voted on that proposal because your bank, broker or other nominee does not have discretionary authority to vote on any of the proposals to be voted on at the Bioventus special meeting. See &#8220;&#8212;Quorum; Abstentions and Broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Votes.&#8221;</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you hold your shares of Bioventus common stock through a bank, broker or other nominee in &#8220;street name&#8221; (instead of as a registered holder), you must obtain a specific control number from your bank, broker or other nominee in order to virtually attend and vote at the Bioventus special meeting via the Bioventus special meeting website. See &#8220;&#8212;Virtually Attending the Bioventus Special Meeting.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revocability of Proxies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any Bioventus stockholder giving a proxy has the right to revoke it at any time before the proxy is voted at the Bioventus special meeting. If you are an Bioventus stockholder of record, you may revoke your proxy by any one of the following actions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by sending a signed written notice of revocation to Bioventus&#8217;s Corporate Secretary, provided such notice is received no later than [&#9679;], 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by voting again over the internet or telephone as instructed on your proxy card before the closing of the voting facilities at [&#9679;], Eastern Time, on [&#9679;], 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by submitting a properly signed and dated proxy card with a later date that is received by Bioventus no later than the close of business on [&#9679;], 2021; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by virtually attending the Bioventus special meeting via the Bioventus special meeting website and requesting that your proxy be revoked, or virtually voting via the Bioventus special meeting website as described above. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only your last submitted proxy will be considered. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Execution or revocation of a proxy will not in any way affect an Bioventus stockholder&#8217;s right to virtually attend and vote at the Bioventus special meeting via the Bioventus special meeting website. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Written notices of revocation and other communications relating to the revocation of proxies should be addressed to: </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attn: Corporate Secretary </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tony.dadamio@bioventus.com </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 400 </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">123 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If your shares of Bioventus common stock are held in &#8220;street name&#8221; and you previously provided voting instructions to your broker, bank or other nominee, you should follow the instructions provided by your broker, bank or other nominee to revoke or change your voting instructions. You may also change your vote by obtaining your specific control number and instructions from your bank, broker or other nominee and voting your shares at the Bioventus special meeting via the Bioventus special meeting website. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proxy Solicitation Costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is soliciting proxies to provide an opportunity to all Bioventus stockholders to vote on agenda items, whether or not such Bioventus stockholders are able to virtually attend the Bioventus special meeting or any adjournment or postponement thereof. Bioventus will bear the entire cost of soliciting proxies from Bioventus stockholders. In addition to the solicitation of proxies by mail, Bioventus will request that banks, brokers and other nominee record holders send proxies and proxy material to the beneficial owners of Bioventus common stock and secure their voting instructions, if necessary. Bioventus may be required to reimburse those banks, brokers and other nominees on request for their reasonable expenses in taking those actions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proxies may be solicited on behalf of Bioventus or by Bioventus directors, officers and other employees in person or by mail, telephone, facsimile, messenger, the internet or other means of communication, including electronic communication. Bioventus directors, officers and employees will not be paid any additional amounts for their services or solicitation in this regard. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Virtually Attending the Bioventus Special Meeting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you wish to virtually attend the Bioventus special meeting via the Bioventus special meeting website, you must (i)&#160;be a Bioventus stockholder of record at the close of business on [&#9679;], 2021 (the Bioventus record date), (ii) hold your shares of Bioventus common stock beneficially in the name of a broker, bank or other nominee as of the Bioventus record date or (iii)&#160;hold a valid proxy for the Bioventus special meeting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To enter the Bioventus special meeting website and virtually attend the Bioventus special meeting, you will need the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16-digit</div> control number located on your proxy card. If you hold your shares of Bioventus common stock in street name beneficially through a broker, bank or other nominee and you wish to virtually attend the Bioventus special meeting via the Bioventus special meeting website, you will need to obtain your specific control number and further instructions from your bank, broker or other nominee. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16-digit</div> control number is also needed to access the list of Bioventus stockholders entitled to vote at the Bioventus special meeting during the time of the meeting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you plan to virtually attend and vote at the Bioventus special meeting via the Bioventus special meeting website, Bioventus still encourages you to vote in advance by the internet, telephone or (if you received a paper copy of the proxy materials) by mail so that your vote will be counted even if you later decide not to virtually attend the Bioventus special meeting via the Bioventus special meeting website. Voting your proxy by the internet, telephone or mail will not limit your right to virtually attend and vote at the Bioventus special meeting via the Bioventus special meeting website if you later decide to do so. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Householding </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and notices with respect to two or more stockholders sharing the same address by delivering a single proxy statement or a single notice addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; provides cost savings for companies. Bioventus has previously adopted householding for Bioventus stockholders of record. As a result, Bioventus stockholders with the same address and last name may receive only one copy of this joint proxy statement/prospectus. Registered Bioventus stockholders (those who hold shares of Bioventus common stock directly in their name with Bioventus&#8217;s transfer agent) may opt out of householding and receive a separate joint proxy statement/prospectus or other proxy materials by sending a written request to Bioventus at the address below. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some brokers household proxy materials, delivering a single proxy statement or notice to multiple Bioventus stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement or notice, or if your household is receiving multiple copies of these documents and you wish to request that future deliveries be limited to a single copy, please notify your broker. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus will promptly deliver a copy of this joint proxy statement/prospectus to any Bioventus stockholder who only received one copy of these materials due to householding upon request in writing to: Bioventus Inc., Attn: Corporate Secretary, tony.dadamio@bioventus.com, 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703 or by calling (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tabulation of Votes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board will appoint an independent inspector of election for the Bioventus special meeting. The inspector of election will, among other matters, determine the number of shares of Bioventus common stock virtually present or represented by proxy at the Bioventus special meeting to confirm the existence of a quorum, determine the validity of all proxies and ballots and certify the results of voting on all proposals submitted to Bioventus stockholders at the Bioventus special meeting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjournments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a quorum is present at the Bioventus special meeting but there are insufficient votes at the time of the Bioventus special meeting to approve the Bioventus share issuance proposal, then Bioventus stockholders may be asked to vote on the Bioventus adjournment proposal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At any subsequent reconvening of the Bioventus special meeting at which a quorum is present, any business may be transacted that might have been transacted at the original meeting, and all proxies will be voted in the same manner as they would have been voted at the original convening of the Bioventus special meeting, except for any proxies that have been effectively revoked or withdrawn prior to the time the proxy is voted at the reconvened meeting. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">BIOVENTUS STOCKHOLDERS SHOULD CAREFULLY READ THIS JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY FOR MORE DETAILED INFORMATION CONCERNING THE MERGER AGREEMENT AND THE MERGER. IN PARTICULAR, BIOVENTUS STOCKHOLDERS ARE DIRECTED TO THE MERGER AGREEMENT, WHICH IS ATTACHED AS <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ANNEX</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A</div> HERETO. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS PROPOSAL 1: APPROVAL OF THE SHARE ISSUANCE </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This joint proxy statement/prospectus is being furnished to you as an Bioventus stockholder in connection with the solicitation of proxies by the Bioventus board for use at the Bioventus special meeting. At the Bioventus special meeting, Bioventus is asking Bioventus stockholders to consider and vote upon a proposal to approve the issuance of shares of Bioventus common stock to Misonix stockholders in connection with the merger. Based on the number of shares of Misonix common stock outstanding as of September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Bioventus expects to issue approximately 18,322,984 million shares of Bioventus common stock to Misonix stockholders in connection with the merger. The actual number of shares of Bioventus common stock to be issued in connection with the merger will be determined at the effective time based on the exchange ratio of 1.6839 shares of Bioventus common stock for each share of Misonix common stock and the number of shares of Misonix common stock outstanding at such time. Based on the number of shares of Bioventus common stock and Misonix common stock outstanding as of September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the merger, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the merger are expected to own approximately 75% of the outstanding shares of Bioventus common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board, after careful consideration, unanimously determined that the terms of the merger agreement and the merger are fair to and in the best interests of Bioventus and its stockholders, and approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board unanimously recommends that Bioventus stockholders vote &#8220;FOR&#8221; the Bioventus share issuance proposal. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Assuming a quorum is present at the Bioventus special meeting, approval of the Bioventus share issuance proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus share issuance proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus share issuance proposal to vote on the Bioventus share issuance proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus share issuance proposal. However, assuming a quorum is present at the Bioventus special meeting, if an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus share issuance proposal, voting power will deemed to be withheld with respect to the Bioventus share issuance proposal and such failure to provide voting instructions will have no effect on the Bioventus share issuance proposal. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IF YOU ARE AN BIOVENTUS STOCKHOLDER, THE BIOVENTUS BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; THE BIOVENTUS SHARE ISSUANCE PROPOSAL </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(BIOVENTUS PROPOSAL&#160;1) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS PROPOSAL 2: ADJOURNMENT OF THE BIOVENTUS SPECIAL MEETING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus special meeting may be adjourned to another time and place if necessary or appropriate to permit the solicitation of additional proxies if there are insufficient votes to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Bioventus stockholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is asking Bioventus stockholders to authorize the holder of any proxy solicited by the Bioventus board to vote in favor of any adjournment of the Bioventus special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the Bioventus share issuance proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Bioventus stockholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board unanimously recommends that Bioventus stockholders vote &#8220;FOR&#8221; the Bioventus adjournment proposal. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Whether or not a quorum is present at the Bioventus special meeting, approval of the Bioventus adjournment proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Bioventus common stock that are virtually present via the Bioventus special meeting website or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal. Accordingly, any shares not virtually present or represented by proxy (including due to the failure of an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Bioventus adjournment proposal. An abstention or other failure of any shares virtually present or represented by proxy and entitled to vote at the Bioventus special meeting on the Bioventus adjournment proposal to vote on the Bioventus adjournment proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Bioventus adjournment proposal. However, if an Bioventus stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee provides voting instructions for one or more other proposals, but not for the Bioventus adjournment proposal, voting power will deemed to be withheld with respect to the Bioventus adjournment proposal and such failure to provide voting instructions will have no effect on the Bioventus adjournment proposal. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IF YOU ARE AN BIOVENTUS STOCKHOLDER, THE BIOVENTUS BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; THE BIOVENTUS ADJOURNMENT PROPOSAL </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(BIOVENTUS PROPOSAL&#160;2) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE MISONIX SPECIAL MEETING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This joint proxy statement/prospectus is being provided to Misonix stockholders in connection with the solicitation of proxies by the Misonix board for use at the Misonix special meeting and at any adjournments or postponements thereof. Misonix stockholders are encouraged to read this entire document carefully, including its annexes and the documents incorporated by reference herein, for more detailed information regarding the merger agreement and the transactions contemplated thereby. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date, Time and Place of the Misonix Special Meeting </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix special meeting is scheduled to be held at [&#9679;] on [&#9679;], 2021, at the Misonix corporate offices, located at 1938 New Highway, Farmingdale, NY 11735. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Misonix currently intends to hold the special meeting in person. However, as part of its precautions regarding the novel coronavirus or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> Misonix is planning for the possibility that the special meeting may be held solely by means of remote communications. If Misonix takes this step, it will announce the decision to do so in advance, and details on how to participate will be posted on its website at www.misonix.com and filed with the SEC as proxy material. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matters to Be Considered at the Misonix Special Meeting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of the Misonix special meeting is to consider and vote on each of the following proposals, each of which is further described in this joint proxy statement/prospectus: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 1</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">: Adoption of the Merger Agreement.</div></div> To consider and vote on the Misonix merger proposal; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 2</div></div>: <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Approval, on an Advisory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Binding</div> Basis, of Certain Merger-Related Compensatory Arrangements with Misonix&#8217;s Named Executive Officers.</div></div> To consider and vote on the Misonix compensation proposal; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 3</div></div>: <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjournment of the Misonix Special Meeting.</div></div> To consider and vote on the Misonix adjournment proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recommendation of the Misonix Board </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix board unanimously recommends that Misonix stockholders vote: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 1: &#8220;FOR&#8221;</div></div> the Misonix merger proposal; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 2: &#8220;FOR&#8221;</div></div> the Misonix compensation proposal; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Misonix Proposal 3: &#8220;FOR&#8221;</div></div> the Misonix adjournment proposal. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After careful consideration, the Misonix board unanimously: (i)&#160;determined that the terms of the merger agreement and the transactions contemplated thereby are fair to and in the best interests of Misonix and its stockholders; (ii)&#160;declared advisable, approved and authorized in all respects the merger agreement, the performance of Misonix of its obligations thereunder and the consummation of the transactions contemplated thereby, on the terms and subject to the conditions set forth in the merger agreement; and (iii)&#160;recommended that Misonix stockholders adopt the merger agreement. See &#8220;The Merger&#8212;Recommendation of the Misonix Board of Directors; Misonix&#8217;s Reasons for the Merger.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Record Date for the Misonix Special Meeting and Voting Rights </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The record date to determine Misonix stockholders who are entitled to receive notice of and to vote at the Misonix special meeting or any adjournments or postponements thereof is [&#9679;], 2021. As of the close of business on the Misonix record date, there were [&#9679;] shares of Misonix common stock issued and outstanding and entitled to vote at the Misonix special meeting. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">128 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Misonix stockholder is entitled to one vote for each share of Misonix common stock such holder owned of record at the close of business on the Misonix record date with respect to each matter properly brought before the Misonix special meeting. Only Misonix stockholders of record at the close of business on the Misonix record date are entitled to receive notice of and to vote at the Misonix special meeting and any and all adjournments or postponements thereof. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Quorum; Abstentions and Broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Votes</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A quorum of Misonix stockholders is necessary to conduct the Misonix special meeting. The presence of the holders of a majority of the outstanding shares of Misonix common stock entitled to vote at the Misonix special meeting will constitute a quorum. Shares of Misonix common stock represented at the Misonix special meeting in person or by a properly authorized and submitted proxy (submitted by mail, by telephone or over the Internet), entitled to vote, but not voted, including shares for which a Misonix stockholder directs an &#8220;abstention&#8221; from voting, will be counted for purposes of determining a quorum. However, because all of the proposals for consideration at the Misonix special meeting are considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matters under Nasdaq rules (as described below), shares held in &#8220;street name&#8221; will not be counted as present for the purpose of determining the existence of a quorum unless the Misonix stockholder provides their bank, broker or other nominee with voting instructions for at least one of the proposals at the Misonix special meeting. If a quorum is not present, Misonix expects that the Misonix special meeting will be adjourned or postponed until the holders of the number of shares of Misonix common stock required to constitute a quorum attend. At any subsequent reconvening of the Misonix special meeting, all proxies will be voted in the same manner as the proxies would have been voted at the original convening of the Misonix special meeting, except for any proxies that have been effectively revoked or withdrawn prior to the subsequent meeting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the listing requirements of Nasdaq rules, banks, brokers or other nominees who hold shares in &#8220;street name&#8221; on behalf of the beneficial owner of such shares have the authority to vote such shares in their discretion on certain &#8220;routine&#8221; proposals when they have not received voting instructions from the beneficial owners. However, banks, brokers or other nominees are not allowed to exercise their voting discretion with respect to matters that under Nasdaq rules are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine.&#8221;</div> This can result in a &#8220;broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vote,&#8221;</div> which occurs on an item when (i)&#160;a bank, broker or other nominee has discretionary authority to vote on one or more &#8220;routine&#8221; proposals to be voted on at a meeting of stockholders, but is not permitted to vote on other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> proposals without instructions from the beneficial owner of the shares, and (ii)&#160;the beneficial owner fails to provide the bank, broker or other nominee with voting instructions on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matter. All of the proposals before the Misonix special meeting are considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-routine&#8221;</div> matters under Nasdaq rules, and banks, brokers or other nominees will not have discretionary authority to vote on any matter before the Misonix special meeting. As a result, Misonix does not expect any broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes</div> at the Misonix special meeting and if you hold your shares of Misonix common stock in &#8220;street name,&#8221; your shares will not be represented and will not be voted on any matter unless you affirmatively instruct your bank, broker or other nominee how to vote your shares in accordance with the voting instructions provided by your bank, broker or other nominee. It is therefore critical that you cast your vote by instructing your bank, broker or other nominee on how to vote. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Brokers will not be able to vote on any of the proposals before the Misonix special meeting unless they have received voting instructions from the beneficial owners. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">129 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Required Votes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The vote required to approve each of the proposals is listed below. As described above, Misonix does not expect there to be any broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes</div> at the Misonix special meeting. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 15%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 42%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 41%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Proposal</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Required Vote</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effects of Certain Actions</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix Proposal 1:</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix merger proposal</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Approval requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Misonix common stock.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">An abstention or other failure to vote on the Misonix merger proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Misonix merger proposal.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix Proposal 2:</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix compensation proposal</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Approval requires the affirmative vote of the holders of a majority of the votes cast at the Misonix special meeting.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">An abstention or other failure to vote on the Misonix compensation proposal will not have an effect on the Misonix compensation proposal, assuming a quorum is present.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix Proposal&#160;3:</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix adjournment proposal</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Approval requires the affirmative vote of the holders of a majority of the votes cast at the Misonix special meeting.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">An abstention or other failure to vote on the Misonix adjournment proposal will not have an effect on the Misonix adjournment proposal.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vote of Misonix Directors and Executive Officers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of September 1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, Misonix directors and executive officers, and their affiliates, as a group, owned and were entitled to vote 31.62% of the total outstanding shares of Misonix common stock. On July&#160;29, 2021, Stavros Vizirgianakis, Misonix&#8217;s Chief Executive Officer and Director, entered into a Voting and Support Agreement with Bioventus and the stockholders named therein, pursuant to which he agreed to, among other things, vote his shares of Misonix common stock in favor of the adoption of the Misonix merger proposal. Although no Misonix director or executive officer other than Mr.&#160;Vizirgianakis has entered into any agreement obligating them to vote their shares of Misonix common stock in favor of the proposals at the special meeting, Misonix currently expects that all Misonix directors and executive officers will vote their shares of Misonix common stock &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix merger proposal, &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix compensation proposal and &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the Misonix adjournment proposal. See &#8220;Interests of Misonix Directors and Executive Officers in the Merger&#8221; and the arrangements described in Misonix&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> which is incorporated by reference in this joint proxy statement/prospectus. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Methods of Voting </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registered Stockholders </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you are a Misonix stockholder of record, you may vote at the Misonix special meeting by proxy through the Internet, by telephone or by mail, or by attending and voting at the Misonix special meeting, as described below. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">By Internet</div></div>: By following the instructions provided on your proxy card. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">By Telephone</div></div>: By following the instructions provided on your proxy card. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">By Mail</div></div>: If you have received a paper copy of the proxy materials by mail, you may complete and return by mail the enclosed proxy card in the postage-paid envelope. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">In person at the Misonix Special Meeting</div></div>: By attending the Misonix special meeting and voting in person. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless revoked, all duly executed proxies representing shares of Misonix common stock entitled to vote at the Misonix special meeting will be voted at the Misonix special meeting and, where a choice has been specified on the proxy card, will be voted in accordance with such specification. If you submit an executed proxy without providing instructions for any proposal, then the Misonix officers identified on the proxy will vote your shares consistent with the recommendation of the Misonix board on such proposal. If you are a Misonix stockholder of record, proxies submitted over the Internet or by telephone as described above must be received by [&#9679;], Eastern Time, on [&#9679;], 2021. To reduce administrative costs and help the environment by conserving natural resources, Misonix asks that you submit a proxy to vote your shares through the Internet or by telephone. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By executing and delivering a proxy in connection with the Misonix special meeting, you designate certain Misonix officers identified therein as your proxies at the Misonix special meeting. If you deliver an executed proxy, but do not specify a choice for any proposal properly brought before the Misonix special meeting, such proxies will vote your shares of Misonix common stock on such uninstructed proposal in accordance with the recommendation of the Misonix board. Misonix does not expect that any matter other than the proposals listed above will be brought before the Misonix special meeting, and the Misonix bylaws provide that the only business that may be conducted at the Misonix special meeting are those proposals brought before the Misonix special meeting by or at the direction of the Misonix board. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Beneficial (Street Name) Stockholders </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If you hold your shares of Misonix common stock through a bank, broker or other nominee in &#8220;street name&#8221; instead of as a registered holder, you must follow the voting instructions provided by your bank, broker or other nominee in order to vote your shares. Your voting instructions must be received by your bank, broker or other nominee prior to the deadline set forth in the information from your bank, broker or other nominee on how to submit voting instructions. If you do not provide voting instructions to your bank, broker or other nominee for a proposal, your shares of Misonix common stock will not be voted on that proposal because your bank, broker or other nominee does not have discretionary authority to vote on any of the proposals to be voted on at the Misonix special meeting. See &#8220;&#8212;Quorum; Abstentions and Broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Votes.&#8221;</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If your shares of Misonix common stock are held of record by a broker, bank, trust or other nominee, and you decide to attend and vote at the Misonix special meeting, your vote in person at the Misonix special meeting will not be effective unless you present a legal proxy, issued in your name from the record holder (your broker, bank, trust or other nominee). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revocability of Proxies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any Misonix stockholder giving a proxy has the right to revoke it at any time before the proxy is voted at the Misonix special meeting. If you are a Misonix stockholder of record, you may revoke your proxy by any of the following actions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by sending a signed written notice of revocation to Misonix&#8217;s Secretary, provided such notice is received no later than [&#9679;], 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by voting again over the internet or via telephone as instructed on your proxy card before the closing of the voting facilities at [&#9679;], Eastern Time, on [&#9679;], 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by submitting a properly signed and dated proxy card with a later date that is received by Misonix no later than the close of business on [&#9679;], 2021; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by attending the Misonix special meeting in person and requesting that your proxy be revoked. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only your last submitted proxy will be considered. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Execution or revocation of a proxy will not in any way affect a Misonix stockholder&#8217;s right to attend and vote at the Misonix special meeting. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Written notices of revocation and other communications relating to the revocation of proxies should be addressed to: </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc. </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attn: Secretary </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1938 New Highway </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, NY 11735 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If your shares of Misonix common stock are held in &#8220;street name&#8221; and you previously provided voting instructions to your broker, bank or other nominee, you should follow the instructions provided by your broker, bank or other nominee to revoke or change your voting instructions. If your shares of Misonix common stock are held in street name and you decide to attend and vote at the Misonix special meeting, your vote in person at the Misonix special meeting will not be effective unless you present a legal proxy, issued in your name from the record holder (your broker, bank, trust or other nominee). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proxy Solicitation Costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix is soliciting proxies to provide an opportunity to all Misonix stockholders to vote on agenda items, whether or not such Misonix stockholders are able to attend the Misonix special meeting or any adjournment or </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">postponement thereof. Misonix will bear the entire cost of soliciting proxies from Misonix stockholders, provided that Bioventus has agreed to pay for the printing and mailing costs associated with this joint proxy statement/prospectus. In addition to the solicitation of proxies by mail, Misonix will request that banks, brokers and other nominee record holders send proxies and proxy material to the beneficial owners of Misonix common stock and secure their voting instructions, if necessary. Misonix may be required to reimburse those banks, brokers and other nominees on request for their reasonable expenses in taking those actions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Misonix has also retained MacKenzie Partners to assist in soliciting proxies and in communicating with Misonix stockholders and estimates that it will pay them a fee of approximately $18,500, plus reimbursement for certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> fees and expenses. Misonix also has agreed to indemnify MacKenzie Partners against various liabilities and expenses that relate to or arise out of its solicitation of proxies (subject to certain exceptions). Proxies may be solicited on behalf of Misonix or Misonix directors, officers and other employees in person or by mail, telephone, facsimile, messenger, the Internet or other means of communication, including electronic communication. Misonix directors, officers and employees will not be paid any additional amounts for their services or solicitation in this regard. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Householding </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and notices with respect to two or more stockholders sharing the same address by delivering a single proxy statement or a single notice addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; provides cost savings for companies. Misonix has previously adopted householding for Misonix stockholders of record. As a result, Misonix stockholders with the same address and last name may receive only one copy of this joint proxy statement /prospectus. Registered Misonix stockholders (those who hold shares of Misonix common stock directly in their name with Misonix&#8217;s transfer agent) may opt out of householding and receive a separate joint proxy statement/prospectus or other proxy materials by sending a written request to Misonix at the address below. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some brokers also household proxy materials, delivering a single proxy statement or notice to multiple Misonix stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement or notice, or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if your household is receiving multiple copies of these documents and you wish to request that future deliveries be limited to a single copy, please notify your broker. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix will promptly deliver a copy of this joint proxy statement/prospectus to any Misonix stockholder who received only one copy of these materials due to householding upon request in writing to: Misonix, Inc., Attn: Secretary, 1938 New Highway, Farmingdale, NY 11735. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tabulation of Votes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix board will appoint an independent inspector of election for the Misonix special meeting. The inspector of election will, among other matters, determine the number of shares of Misonix common stock represented at the Misonix special meeting to confirm the existence of a quorum, determine the validity of all proxies and ballots and certify the results of voting on all proposals submitted to Misonix stockholders at the Misonix special meeting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjournments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a quorum is present at the Misonix special meeting but there are insufficient votes at the time of the Misonix special meeting to approve the Misonix merger proposal, then Misonix stockholders may be asked to vote on the Misonix adjournment proposal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At any subsequent reconvening of the Misonix special meeting at which a quorum is present, any business may be transacted that might have been transacted at the original meeting and all proxies will be voted in the same manner as they would have been voted at the original convening of the Misonix special meeting, except for any proxies that have been effectively revoked or withdrawn prior to the time the proxy is voted at the reconvened meeting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assistance </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If you need assistance voting or completing your proxy card, or if you have questions regarding the Misonix special meeting, please contact Mackenzie Partners, Misonix&#8217;s proxy solicitor for the Misonix special meeting, by telephone toll-free at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-800-322-2885,</div></div></div> Monday through Friday (except bank holidays), between 8:00 a.m. and 8:00 p.m., Eastern time, or by email at proxy@mackenziepartners.com. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g10c33.jpg"/></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">MISONIX STOCKHOLDERS SHOULD CAREFULLY READ THIS JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY FOR MORE DETAILED INFORMATION CONCERNING THE MERGER AGREEMENT AND THE MERGER. IN PARTICULAR, MISONIX STOCKHOLDERS ARE DIRECTED TO THE MERGER AGREEMENT, WHICH IS ATTACHED AS <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ANNEX A</div> HERETO. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MISONIX PROPOSAL 1: ADOPTION OF THE MERGER AGREEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This joint proxy statement/prospectus is being furnished to you as a Misonix stockholder in connection with the solicitation of proxies by the Misonix board for use at the Misonix special meeting. At the Misonix special meeting, Misonix is asking Misonix stockholders to consider and vote upon a proposal to adopt the merger agreement to enable Misonix to consummate the mergers and effect the other transactions in accordance with the terms of the merger agreement. You should read carefully and in its entirety this joint proxy statement/prospectus, including the annexes attached hereto and the documents incorporated by reference, for more detailed information concerning the Misonix merger proposal and the transactions contemplated thereby. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The merger and a summary of the terms of the merger agreement are described in more detail under &#8220;The Merger&#8221; and &#8220;The Merger Agreement,&#8221; and Misonix stockholders are encouraged to read the full text of the merger agreement, which is attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A</div> hereto. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix board, after careful consideration, unanimously determined that the mergers are fair to and in the best interests of Misonix and its stockholders, and approved and declared advisable the merger agreement and the transactions contemplated thereby, including the merger. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix board accordingly unanimously recommends that Misonix stockholders vote &#8220;FOR&#8221; the Misonix merger proposal. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Approval of the Misonix merger proposal requires the affirmative vote of the holders of a majority of the issued and outstanding shares of Misonix common stock. Accordingly, an abstention or other failure to vote on the Misonix merger proposal will have the same effect as a vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AGAINST</div></div>&#8221; the Misonix merger proposal. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is a condition to the completion of the merger that Misonix stockholders approve the Misonix merger proposal. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IF YOU ARE A MISONIX STOCKHOLDER, THE MISONIX BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; THE MISONIX MERGER PROPOSAL </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(MISONIX PROPOSAL 1) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">MISONIX PROPOSAL 2: ADVISORY <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-BINDING</div> VOTE ON MERGER-RELATED COMPENSATION FOR NAMED EXECUTIVE OFFICERS </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to Section&#160;14A of the Exchange Act and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14a-21(c)</div> thereunder, Misonix is required to submit to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory stockholder vote certain compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the merger as disclosed under &#8220;Interests of Misonix Directors and Executive Officers in the Merger&#8212;Quantification of Payments and Benefits to Misonix Named Executive Officers&#8212;Golden Parachute Compensation.&#8221; The Misonix compensation proposal gives Misonix stockholders the opportunity to express their views on the merger-related compensation of Misonix named executive officers. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Accordingly, Misonix is asking Misonix stockholders to vote &#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FOR</div></div>&#8221; the adoption of the following resolution, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory basis: </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">&#8220;RESOLVED, that the compensation that may be paid or become payable to Misonix named executive officers that is based on or otherwise relates to the merger, as disclosed pursuant to Item&#160;402(t) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> under the heading &#8220;Interests of Misonix Directors and Executive Officers in the Merger&#8212;Quantification of Payments and Benefits to Misonix Named Executive Officers&#8212;Golden Parachute Compensation,&#8221; including the associated narrative discussion and the agreements, plans, arrangements or understandings pursuant to which such compensation may be paid or become payable, are hereby APPROVED.&#8221; </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The vote on the Misonix compensation proposal is a vote separate and apart from the vote to adopt the merger agreement. Accordingly, if you are a Misonix stockholder, you may vote to approve the Misonix merger proposal and vote not to approve the Misonix compensation proposal, and vice versa. The vote on the Misonix compensation proposal is advisory and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding.</div> As a result, if the mergers are completed, the merger-related compensation may be paid to Misonix named executive officers to the extent payable in accordance with the terms of the compensation agreements and arrangements, even if Misonix stockholders do not approve the Misonix compensation proposal. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix board unanimously recommends that Misonix stockholders vote &#8220;FOR&#8221; the Misonix compensation proposal. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assuming a quorum is present, approval of the Misonix compensation proposal requires the affirmative vote of a majority of the votes cast and entitled to vote at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix compensation proposal, assuming a quorum is present. In addition, an abstention or other failure of any shares present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix compensation proposal to vote on the Misonix compensation proposal will have no effect on the outcome of the Misonix compensation proposal. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IF YOU ARE A MISONIX STOCKHOLDER, THE MISONIX BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; THE MISONIX COMPENSATION PROPOSAL </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(MISONIX PROPOSAL 2) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MISONIX PROPOSAL 3: ADJOURNMENT OF THE MISONIX SPECIAL MEETING </div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix special meeting may be adjourned to another time and place if necessary or appropriate in order to permit the solicitation of additional proxies if there are insufficient votes to approve the Misonix merger proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Misonix stockholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix is asking Misonix stockholders to authorize the holder of any proxy solicited by the Misonix board to vote in favor of any adjournment of the Misonix special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the Misonix merger proposal or to ensure that any supplement or amendment to this joint proxy statement/prospectus is timely provided to Misonix stockholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix board unanimously recommends that Misonix stockholders approve the proposal to adjourn the Misonix special meeting, if necessary or appropriate. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approval of the Misonix adjournment proposal requires the affirmative vote of a majority of the votes cast and entitled to vote at the Misonix special meeting. Accordingly, any shares not present or represented by proxy (including due to the failure of a Misonix stockholder who holds shares in &#8220;street name&#8221; through a bank, broker or other nominee to provide voting instructions to such bank, broker or other nominee) will have no effect on the outcome of the Misonix adjournment proposal. Additionally, an abstention or other failure of any shares present or represented by proxy and entitled to vote at the Misonix special meeting on the Misonix adjournment proposal to vote on the Misonix adjournment proposal will have will have no effect on the outcome of the Misonix adjournment proposal. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IF YOU ARE A MISONIX STOCKHOLDER, THE MISONIX BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; THE MISONIX ADJOURNMENT PROPOSAL </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(MISONIX PROPOSAL 3) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">136 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE MERGER </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following is a description of material aspects of the merger. While Bioventus and Misonix believe that the following description covers the material terms of the merger, the description may not contain all of the information that is important to you. You are encouraged to read carefully this entire joint proxy statement/prospectus, including the text of the merger agreement attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A</div> hereto, for a more complete understanding of the merger. In addition, important business and financial information about each of Bioventus and Misonix is contained or incorporated by reference in this joint proxy statement/prospectus. See &#8220;Where You Can Find More Information.&#8221; </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus, Merger Sub I, Merger Sub II and Misonix have entered into the merger agreement, which provides for the merger of Merger Sub I with and into Misonix with Misonix surviving, and subsequently, the merger of Misonix with and into Merger Sub II. As a result of the mergers, the separate existences of Merger Sub I and Misonix will cease and Merger Sub II will continue its existence under the DGCL as the surviving entity and as a wholly owned subsidiary of Bioventus. The surviving entity will be named &#8220;Misonix, LLC.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger Consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the effective time, each share of Misonix common stock (other than shares held in treasury by Misonix or held directly by Bioventus, Merger Sub I or Merger Sub II (which shares will be cancelled) and shares held by Misonix stockholders who have not voted in favor of the Misonix merger proposal and perfected and not withdrawn a demand for appraisal rights pursuant to Delaware law) that was issued and outstanding immediately prior to the effective time will be converted into, based on each such Misonix stockholders&#8217; election and subject to proration in accordance with the terms of the merger agreement, the right to receive (a) 1.6839 shares of Bioventus class A common stock as well as cash (without interest and less any applicable withholding taxes) in lieu of any fractional shares of Bioventus class A common stock or (b)&#160;an amount of cash equal to $28.00. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exchange ratio is fixed, which means that it will not change between now and the date of the merger, regardless of whether the market price of Bioventus or Misonix common stock changes. Therefore, the value of the merger consideration will depend on the market price of Bioventus common stock at the effective time. The market price of Bioventus common stock has fluctuated since the date of the announcement of the merger agreement and is expected to continue to fluctuate from the date of this joint proxy statement/prospectus to the dates of the respective Bioventus and Misonix special meetings, through the date the merger is completed and thereafter. The market price of Bioventus common stock, when received by Misonix stockholders who have elected the stock election consideration in connection with the first merger, could be greater than, less than or the same as the market price of Bioventus class A common stock on the date of this joint proxy statement/prospectus or at the time of the Misonix special meeting. Accordingly, you should obtain current market quotations for Bioventus and Misonix common stock before deciding how to vote on any of the proposals described in this joint proxy statement/prospectus. Bioventus common stock is traded on Nasdaq under the symbol &#8220;BVS&#8221; and Misonix common stock is traded on Nasdaq under the symbol &#8220;MSON.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proration and Reallocation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate amount of cash payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock as of 5:00 p.m. New York City time on the election deadline. In order to deliver this aggregate cash amount, the merger agreement provides for pro rata adjustments to, and reallocation of, the cash and stock elections made by Misonix stockholders, as well as the allocation of consideration to be paid with respect to shares of Misonix common stock as to which no election regarding the form of merger consideration to be paid to them, is received prior to the election deadline. Such no election shares will be exchanged for the cash consideration, the stock consideration or a combination of both. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">137 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, depending on the elections made by other Misonix stockholders, each Misonix stockholder who elects to receive Bioventus class A common stock for their shares in the mergers, referred to as &#8220;stock election shares&#8221; may receive a portion of their consideration in cash, and each Misonix stockholder who elects to receive cash for their shares in the mergers, referred to as &#8220;cash election shares&#8221; may receive a portion of their consideration in Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration, which is the amount equal to the aggregate number of cash election shares multiplied by $28.00, exceeds the available cash amount, then: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all stock election shares and all no election shares will be exchanged for 1.6839 shares of Bioventus class A common stock; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a portion of the cash election shares of each Misonix stockholder will be exchanged for $28.00 in cash as follows: cash election shares exchanged for $28.00 in cash = </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of such stockholder&#8217;s cash election shares) * (maximum cash amount) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">elected cash consideration </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration is less than the available cash amount, which difference we refer to as the shortfall amount, then: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all cash election shares will be exchanged for the cash consideration; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all stock election shares and no election shares will be treated in the following manner: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the shortfall amount is less than or equal to the product of the aggregate number of no election shares and $28.00, which we refer to as the &#8220;no election value&#8221;, then (1)&#160;all stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock, and (2)&#160;a portion of the no election shares of each Misonix stockholder, calculated as follows, will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#8217;s no election shares, if any, will be exchanged for 1.6839 shares of Bioventus class A common stock): </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">no election shares exchanged for cash consideration = </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of no election shares of such stockholder) * (shortfall amount) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(no election value) </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the shortfall amount is more than the no election value, then (1)&#160;all no election shares will be exchanged for $28.00 in cash and (2)&#160;a portion of the stock election shares of each stockholder will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#8217;s stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock): </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock election shares exchanged for cash consideration = </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of stock election shares of such stockholder) * (shortfall amount &#8211; no election value) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(aggregate number of stock election shares) * $28.00 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration equals the available cash amount, then: (1)&#160;all cash election shares will be converted into the right to receive $28.00 in cash and (2)&#160;all stock election shares and all no election shares will be converted into the right to receive 1.6839 shares of Bioventus class A common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Election Procedures </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exchange agent will mail to Misonix stockholders of record not less than 30 days prior to the anticipated closing date of the first merger a letter of election and transmittal. The letter of election and transmittal enables Misonix stockholders to choose to make a cash election, a stock election or no election with respect to each share </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">138 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of Misonix common stock eligible to receive the merger consideration. Misonix intends to issue a press release at least five business days prior to the expiration of the election period informing Misonix stockholders of the expiration of the election period, which expiration we refer to as the &#8220;election deadline&#8221;, to make their election and return their completed letters of election and transmittal. If a Misonix stockholder holds shares of Misonix common stock through a bank, brokerage firm or other nominee, such bank, brokerage firm, or other nominee, as applicable, will provide such stockholder with instructions on how to make an election. Election forms must be returned to the broker, bank or nominee in time for it to respond prior to the election deadline, therefore, you are encouraged to pay close attention to, and abide by, any election deadlines provided by the bank, brokerage firm or other nominee holding your shares, as that deadline may be earlier than the election deadline described in this joint proxy statement/prospectus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any election will have been properly made only if the exchange agent has actually received a properly completed letters of election and transmittal by the election deadline. Any election form may be revoked or changed by written notice received by the exchange agent prior to the election deadline. If an election form is revoked, the shares of Misonix common stock as to which such election previously applied will be no election shares unless an election is subsequently submitted by the Misonix stockholder prior to the election deadline. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Background of the Merger </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of Bioventus&#8217; and Misonix&#8217;s board of directors and senior management team regularly reviews their respective company&#8217;s performance, future growth prospects and overall strategic direction and considers potential opportunities to strengthen their respective businesses and enhance stockholder value. These reviews have included consideration of whether the continued execution of each company&#8217;s strategy or possible strategic opportunities, joint ventures or combination with third parties offered the best avenue to maximize stockholder value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October of 2020, the Executive Chairman of a publicly traded medical device company (&#8220;Company&#160;A&#8221;) contacted Stavros Vizirgianakis, Chief Executive Officer of Misonix regarding a potential collaboration arrangement involving both Misonix&#8217;s surgical products and existing products of Company&#160;A, which collaboration arrangement would be material to Misonix. Through October and November of 2020, management of Company&#160;A and Misonix conducted visits at the other&#8217;s headquarters for workshops on their respective products and discussions on areas of potential collaboration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;6, 2020, Mr.&#160;Vizirgianakis held an introductory meeting with the Chief Executive Officer of a medical device company (&#8220;Company&#160;B&#8221;) at the invitation of Company&#160;B&#8217;s financial advisor. Mr.&#160;Vizirgianakis and the Chief Executive Officer of Company&#160;B discussed the operations of their respective companies and areas of potential collaboration or synergies between the companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;10, 2020, representatives of Company&#160;A provided Misonix management with an initial draft of a non-binding term sheet reflecting terms that would potentially govern the collaboration arrangement. In late December 2020, representatives of Company&#160;A sent Misonix management Company&#160;A&#8217;s financial analysis of the potential collaboration arrangement based on terms that had been proposed by Company&#160;A. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;23, 2020, the Misonix board held a meeting at which members of management and a representative of Jones Day, Misonix&#8217;s outside legal advisor, were present to discuss the financial analysis prepared by Company&#160;A. At the conclusion of the meeting, the Misonix board authorized Misonix management to continue the collaboration </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">139 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discussions with Company&#160;A and to continue to negotiate for improved financial terms to the collaboration arrangement. Later in the day on December&#160;23, 2020, Mr.&#160;Vizirgianakis spoke with a representative of Company&#160;A to convey proposed revisions to the financial terms of the collaboration arrangement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From December of 2020 through May of 2021, Company&#160;A and Misonix exchanged revised drafts of the non-binding term sheet reflecting terms that would potentially govern the collaboration arrangement and engaged in discussions in an effort to align on mutually-agreeable terms. Throughout the negotiations, Company&#160;A continued to propose profit-sharing, intellectual property licensing and other economic terms that representatives of Misonix did not deem acceptable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January of 2021, the Vice President of Corporate Development of another publicly traded medical device company (&#8220;Company&#160;C&#8221;) contacted Mr.&#160;Vizirgianakis about potential collaboration between Company&#160;C and Misonix. Mr.&#160;Vizirgianakis and the representative of Company&#160;C discussed their respective company&#8217;s products at a high level, but the individuals made no specific plans for next steps in the collaboration discussions at that time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;22, 2021, the Chief Executive Officer of Company&#160;B contacted Mr.&#160;Vizirgianakis regarding Company&#160;B&#8217;s interest in a potential acquisition of Misonix. To facilitate information-sharing in connection with a potential acquisition, Company&#160;B proposed a draft mutual non-disclosure agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;25, 2021, the Misonix board held a meeting, at which members of management and a representative of Jones Day were present, to discuss Company B&#8217;s interest in a potential acquisition of Misonix. A representative of Jones Day discussed the potential issues that the Misonix board would need to consider, including their fiduciary duties, in connection with a potential acquisition. The Misonix board authorized management to provide Company&#160;B with additional information to facilitate a proposal from Company&#160;B, subject to a non-disclosure agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In late January of 2021, Bioventus management contacted Perella Weinberg Partners L.P. (&#8220;Perella Weinberg&#8221;) to assist in the potential acquisition of Misonix as Bioventus&#8217; financial advisor. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;2, 2021, the Misonix board held a meeting at which members of management and a representative of Jones Day were present. During the course of this meeting, Mr.&#160;Vizirgianakis provided the Misonix board with an update on the discussion of a potential collaboration arrangement with Company&#160;A and the potential acquisition of Misonix by Company&#160;B. The Misonix board considered the advisability of engaging an investment bank to serve as Misonix&#8217;s financial advisor in connection with the potential acquisition of Misonix by Company&#160;B. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;4, 2021, Company&#160;B and Misonix signed a mutual non-disclosure agreement, which included a mutual 12-month standstill restriction on each party making proposals to acquire the other party that are not supported by the target company&#8217;s board (but which standstill would fall away upon Misonix entering into a definitive acquisition agreement with a third party). Shortly after entering into the mutual non-disclosure agreement, Misonix provided certain limited financial and operational information and documentation to representatives of Company&#160;B in response to Company&#160;B&#8217;s initial due diligence requests. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;5, 2021, Mr.&#160;Vizirgianakis and Joseph Dwyer, Chief Financial Officer of Misonix, held a meeting with senior management team of Company&#160;B and representatives of Company&#160;B&#8217;s financial advisor, at the request of Company&#160;B to facilitate an acquisition proposal. Messrs.&#160;Vizirgianakis and Dwyer delivered to representatives of Company&#160;B a presentation on Misonix, including an overview of its business, history and strategy. The representatives of Company&#160;B similarly delivered to Messrs.&#160;Vizirgianakis and Dwyer a presentation on Company&#160;B, including its history, strategy and potential synergies and strategic plans for the combined company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">140 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;8, 2021, Mr.&#160;Dwyer held a call with representatives of Company&#160;B&#8217;s financial advisor to discuss the data room being prepared by Misonix to share requested documentation and information, as well as timing and next steps for further discussions between representatives of Misonix and Company&#160;B. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In early February, 2021, Messrs. Vizirgianakis and Dwyer contacted representatives of J.P. Morgan, who had assisted Misonix in connection with its acquisition of Solsys Medical, LLC in September 2019, to obtain support in connection any offer that may be presented by Company&#160;A, in connection with a collaboration arrangement, or by Company&#160;B, in connection with an acquisition. In late February and early March 2021, representatives of J.P. Morgan assisted Misonix management by reviewing financial projections and synergy analyses prepared by Misonix management in connection with a potential acquisition of Misonix by Company&#160;B, and by recommending a process to progress negotiations with Company&#160;A and Company&#160;B. On March&#160;2, 2021, J.P. Morgan provided Misonix management with a market overview of Misonix&#8217;s and Company&#160;B&#8217;s current market valuation. Representatives of Misonix shared with representatives of Company&#160;B preliminary financial projections that were substantially similar to the Misonix preliminary unaudited projections (as defined below). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2021, members of Misonix&#8217;s management again met with members of Company&#160;B&#8217;s management, with representatives of Company&#160;B&#8217;s financial advisor and J.P. Morgan in attendance. Representatives of each company gave an additional presentation on their company, including its history, product lines, organizational charts and product roadmaps. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;2, 2021, Ken Reali, Chief Executive Officer of Bioventus, contacted Mr.&#160;Vizirgianakis by telephone expressing Mr.&#160;Reali&#8217;s interest in holding a meeting with senior executives of Bioventus and Misonix to discuss potential collaboration between the two companies. The specific nature of the transaction, or the possibility that it would be a proposed acquisition of Misonix, was not discussed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;5, 2021 and March&#160;19, 2021, Mr.&#160;Vizirgianakis and Mr.&#160;Reali held follow-up calls during which Messrs.&#160;Vizirgianakis and Reali continued to discuss the potential for collaboration between their respective companies and Bioventus&#8217; strategic plans. Mr.&#160;Reali and Mr.&#160;Vizirgianakis agreed to meet in person with other members of management of their respective companies on April&#160;1, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;12, 2021, the Chief Executive Officer of Company&#160;B contacted Mr.&#160;Vizirgianakis to convey that Company&#160;B was still interested in an acquisition of Misonix and that their representatives were working to prepare a long-term financial model to share with Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;20, 2021, the Chief Executive Officer of Company&#160;B contacted Mr.&#160;Vizirgianakis to indicate that Company&#160;B&#8217;s long-term financial model would be forthcoming to Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;22, 2021, representatives of Company&#160;B&#8217;s financial advisor sent representatives of J.P. Morgan a summarized five-year version of Company&#160;B&#8217;s financial model, which representatives of J.P. Morgan forwarded to Misonix management. On March&#160;23, 2021, representatives of Company&#160;B&#8217;s financial advisor sent representatives of J.P. Morgan supplemental detail on the revenue breakout in Company&#160;B&#8217;s five-year financial model, which representatives of J.P. Morgan also forwarded to Misonix management. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;24, 2021, representatives of J.P. Morgan, at the direction of Misonix management, sent Misonix&#8217;s synergy analysis to representatives of Company B&#8217;s financial advisor. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;26, 2021, the Chief Executive Officer of Company&#160;B contacted Mr.&#160;Vizirgianakis to convey that, after review of the preliminary financial projections Misonix provided, Company&#160;B remained interested in an acquisition of Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;29, 2021, members of Misonix&#8217;s management met with members of Company&#160;B&#8217;s management, with representatives of Company&#160;B&#8217;s financial advisor and J.P. Morgan in attendance. At the meeting, the parties reviewed Misonix&#8217;s synergy analysis and discussed each party&#8217;s financial projections. Company&#160;B also shared a copy of its revenue synergy analysis and allowed Misonix management the opportunity to ask questions about this analysis. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">141 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2021, Mr.&#160;Dwyer contacted the Chief Financial Officer of Company&#160;B to inquire whether members of Company&#160;B&#8217;s management had further questions about Misonix&#8217;s synergy analysis or its preliminary financial projections. The Chief Executive Officer of Company&#160;B indicated that Company&#160;B would likely submit a further list of questions and a possible supplemental due diligence request list in the near future. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;1, 2021, Bioventus entered into a non-disclosure agreement with Misonix to facilitate Misonix&#8217;s sharing of information at the proposed meeting. Later in the day, Mr.&#160;Vizirgianakis and Mr.&#160;Dwyer met with Mr.&#160;Reali and Chris Yamamoto, Senior Vice President of Business Development and Strategy of Bioventus. At the meeting, the companies&#8217; respective representatives discussed potential ways in which the companies could collaborate together or if there were potential benefits to the parties of Bioventus&#8217; acquisition of Misonix. At the conclusion of these meetings, the representatives of Bioventus indicated they would contact Misonix in late May or early June 2021 to continue the discussions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also on April&#160;1, 2021, the Chief Executive Officer of Company&#160;B contacted Mr.&#160;Vizirgianakis to preview that an offer for the acquisition of Misonix would be forthcoming on or around April&#160;4, 2021. On April&#160;3, 2021, representatives of Company&#160;B&#8217;s financial advisor contacted representatives of J.P. Morgan to convey a similar message. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;5, 2021, a representative of Company&#160;B&#8217;s financial advisor contacted Mr.&#160;Vizirgianakis to deliver a verbal to offer acquire Misonix for $21.00 in cash per outstanding share of Misonix common stock. Misonix common stock was priced at $19.73 per share as of the close of trading on April&#160;1, 2021. Mr.&#160;Vizirgianakis engaged in internal deliberation and discussion with members of the Misonix board, where board members and Misonix senior management concluded that Company&#160;B&#8217;s offer did not provide sufficient value to Misonix stockholders, given their understanding of the value of Misonix&#8217;s business and its prospects. Misonix&#8217;s senior management informed representatives of Company&#160;B that Company&#160;B&#8217;s offer was inadequate and terminated discussions with Company&#160;B at that time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2021, the Misonix board held a meeting at which members of management and a representative of Jones Day were present. During the course of this meeting, Mr.&#160;Vizirgianakis provided the Misonix board with a further update on the discussion of a potential collaboration arrangement with Company&#160;A, including that the parties had not been able to reach agreement on terms that would be mutually acceptable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In early May 2021, Mr.&#160;Vizirgianakis was contacted by the Vice President of Corporate Development at Company&#160;C to continue discussions from earlier in the year regarding a potential collaboration arrangement involving Misonix&#8217;s surgical products. At that point, discussions with Company&#160;A had not progressed beyond the term sheet stage and it appeared that Company&#160;A and Misonix may not be able to reach mutually-acceptable terms regarding the potential collaboration arrangement between the parties. In a follow-up discussion in mid-May, 2021, representatives of Company&#160;C indicated that Company&#160;C was still interested in a potential collaboration arrangement with Misonix and proposed a meeting between the companies&#8217; respective representatives. To facilitate the sharing of information between Misonix and Company C, the parties entered into a mutual confidentiality agreement on May&#160;25, 2021 and representatives of the companies met in person later that day. At this meeting, representatives of Misonix provided a demonstration of some of Misonix&#8217;s surgical products in a laboratory environment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the May&#160;25, 2021 meeting, a representative of Company&#160;C contacted Mr.&#160;Vizirgianakis to schedule a follow-up meeting for June&#160;18, 2021 to discuss further a potential collaboration arrangement between Misonix and Company&#160;C. On June&#160;4, 2021, Company&#160;C provided a proposed non-binding term sheet for the potential collaboration, which included, among other things, opportunities for the companies to combine specified products and jointly develop future products. The term sheet also included a proposal that Company&#160;C would be granted exclusive rights to distribute Misonix&#8217;s existing spine and cranial products and future products co-developed by the parties in the United States. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">142 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;2, 2021, as a result of the Misonix and Bioventus discussions focusing on an acquisition of Misonix instead of a collaboration, and to facilitate Misonix sharing more sensitive information regarding its business, Misonix and Bioventus entered into a revised non-disclosure agreement, which added an 18-month standstill restriction on Bioventus making proposals to acquire Misonix that were not supported by the Misonix board (but which standstill would fall away upon Misonix entering into a definitive acquisition agreement), as well as restrictions on Bioventus&#8217; ability to solicit Misonix employees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;3, 2021, Messrs. Reali and Yamamoto and Greg Anglum, Senior Vice President and Chief Financial Officer of Bioventus, held a meeting with Messrs. Vizirgianakis and Dwyer to discuss a potential acquisition of Misonix by Bioventus. At this meeting, the representatives from Misonix and Bioventus discussed their view of public Wall Street analyst projections for each of their respective companies&#8217; future financial performance. The parties also discussed potential revenue and expense synergies between Bioventus and Misonix if the parties were to consummate an acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;7, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Mr.&#160;Vizirgianakis provided an update to the Misonix board on recent discussions with Bioventus, as well as discussions with Company&#160;A and Company&#160;C. The Misonix board provided their views and input on potential ways to coordinate and structure the opportunities and thereafter instructed Messrs.&#160;Vizirgianakis and Dwyer to continue discussions with each of the potential counterparties with respect to the strategic opportunities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;8, 2021, representatives of Company&#160;C provided Misonix management with a non-binding discussion outline with Company&#160;C&#8217;s proposed terms for a collaboration arrangement between Company&#160;C and Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;10, 2021, the Bioventus board held a meeting at which members of Bioventus management and representatives of Perella Weinberg, Bioventus&#8217; financial advisor, attended. Mr.&#160;Yamamoto reviewed the potential acquisition of Misonix and presented the materials provided to the Bioventus board in advance of the meeting, which included a summary of an initial meeting held on June&#160;3, 2021 with Messrs.&#160;Vizirgianakis and Dwyer, an overview of the strategic merits of the potential combination and a financial overview of Misonix. The materials also included preliminary valuations of potential transaction scenarios and potential bid tactic considerations, which Mr.&#160;Yamamoto presented together with representatives of Perella Weinberg. After considering the potential challenges in consummating the transaction and integrating the combined companies, the Bioventus board authorized Bioventus management to proceed with delivering a non-binding indication of interest to Misonix at an initial offer price of $26.00 per share of Misonix common stock in a mix of cash and shares of Bioventus class A common stock. The Bioventus board also agreed to form a special committee of the Bioventus board to oversee the potential transaction with Misonix. The special committee consisted of Messrs.&#160;Phil Cowdy, William Hawkins, Ken Reali and Martin Sutter. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2021, Mr.&#160;Reali contacted Mr.&#160;Vizirgianakis by telephone to indicate that Bioventus intended to submit a formal non-binding indication of interest to Misonix to consummate an acquisition. Misonix received Bioventus&#8217; written indication of interest later that day, which Mr. Vizirgianakis circulated to the Misonix board for initial review. The indication of interest proposed that Bioventus would acquire Misonix for $26.00 per share of Misonix common stock, consisting of $7.80 in cash and 0.988 shares of Bioventus class&#160;A common stock. The indication of interest further stated that Bioventus&#8217; willingness to advance discussions was conditioned on Misonix negotiating with Bioventus on an exclusive basis for a period of six weeks. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;15, 2021, Mr.&#160;Vizirgianakis met with the Executive Chairman of Company&#160;A. Mr.&#160;Vizirgianakis informed the Executive Chairman of Company&#160;A that Misonix&#8217;s circumstances had since changed and that the parties would need to transition discussions from a collaboration arrangement to an acquisition of Misonix. If not, Misonix was not in a position to continue forward with the collaboration discussion. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">143 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;16, 2021, Mr.&#160;Vizirgianakis and representatives of J.P. Morgan, at the direction of Misonix, each contacted representatives of Company&#160;C to inform Company&#160;C that Misonix had received an expression of interest for an acquisition of Misonix and to inquire whether Company&#160;C would consider an acquisition. The Vice President of Corporate Development at Company&#160;C indicated that Company C would be interested in discussing an acquisition of Misonix and requested that J.P. Morgan have Misonix prepare a forecast and presentation for Company&#160;C. As a result of this message, Misonix and Company&#160;C canceled the planned June&#160;18, 2021 follow-up meeting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also on June&#160;16, 2021, Mr.&#160;Vizirgianakis contacted Mr.&#160;Reali and confirmed that Misonix was still considering the Bioventus indication of interest and would be discussing the offer with the Misonix board on June&#160;21, 2021. Later in the day, Mr.&#160;Dwyer contacted Mr.&#160;Yamamoto to discuss the potential revenue and cost synergies that could be achieved by Bioventus&#8217; acquisition of Misonix. Mr.&#160;Yamamoto also provided Mr.&#160;Dwyer with the data underlying Bioventus&#8217; public Wall Street analyst projections. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;16, 2021, the Misonix board acted by written consent to approve the engagement of J.P. Morgan as its financial advisor. The Misonix board selected J.P. Morgan on the basis of its qualifications, expertise and reputation, as well as its knowledge and understanding of Misonix&#8217;s business, industry and affairs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;17, 2021, Misonix executed an engagement letter pursuant to which it formally retained J.P. Morgan its exclusive financial advisor in connection with a potential sale of Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on June&#160;17, 2021, a representative of Company&#160;A contacted Mr.&#160;Vizirgianakis to confirm Company&#160;A&#8217;s interest in shifting from a collaboration arrangement to a potential acquisition of Misonix. The representative of Company&#160;A requested that Mr.&#160;Vizirgianakis prepare a presentation and meet with Company&#160;A&#8217;s executive team the week of June&#160;21, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;18, 2021, representatives of Bioventus provided Misonix management with public Wall Street analyst </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial projections for Bioventus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on June&#160;18, 2021, Mr.&#160;Reali provided Messrs. Vizirgianakis and Dwyer with a presentation regarding Bioventus&#8217; business, how Misonix&#8217;s business could be combined with Bioventus&#8217; business and public Wall Street analyst financial projections for Bioventus. Mr.&#160;Reali asked that he be given an opportunity to make the presentation to the Misonix board. Misonix management forwarded this presentation to the Misonix board in advance of Mr.&#160;Reali&#8217;s and Mr.&#160;Yamamoto&#8217;s in-person presentation to the Misonix board, which ultimately occurred on June&#160;30, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;21, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. At the meeting, representatives of Jones Day discussed with the Misonix board their fiduciary duties in the context of the proposed transaction with Bioventus and other legal matters. Representatives of Misonix management discussed with the Misonix board an assessment of Misonix&#8217;s current market position, including an analysis of its share price and an overview of its current market valuation, and Misonix&#8217;s future prospects as a stand-alone enterprise. During this discussion, representatives of Misonix management presented the public Wall Street analyst financial projections for Misonix&#8217;s business that had been shared with Bioventus at the June&#160;3, 2021 meeting. Representatives of J.P. Morgan provided the Misonix board with a preliminary financial analysis of the Bioventus indication of interest and of potential ranges for a value of Misonix based on Misonix&#8217;s financial projections. Mr.&#160;Vizirgianakis updated the Misonix board on the status of recent discussions with Company&#160;A and Company&#160;C, including that collaboration discussions with Company&#160;C that had been scheduled for June&#160;18, 2021 were postponed in light of the indication of interest received from Bioventus, but Mr.&#160;Vizirgianakis noted that Company&#160;C may be interested in an acquisition of Misonix and was awaiting feedback from Misonix in terms of next steps. Following extensive discussion regarding the proposed form of merger consideration in Bioventus&#8217; offer, the value of Bioventus&#8217; offer, Bioventus&#8217; request for exclusivity, the ongoing discussions with potential other counterparties, and the potential benefits and potential risks of each of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">144 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the foregoing, the Misonix board instructed J.P. Morgan to determine if Company&#160;A and Company&#160;C would be interested in further discussion regarding an acquisition of Misonix, and to advise Bioventus that Misonix was interested in engaging in further discussions regarding a transaction, but would not agree to exclusivity at the current value offered. The Misonix board also confirmed its willingness to receive a presentation from Mr.&#160;Reali regarding Bioventus&#8217; proposal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;22, 2021, Mr.&#160;Vizirgianakis contacted Mr.&#160;Reali to inform him that the Misonix board was not prepared to grant Bioventus with exclusivity and that Bioventus needed to improve the value of its offer in order for exclusivity to be seriously considered. Mr.&#160;Vizirgianakis confirmed that Misonix was otherwise amenable to engaging in further discussions regarding a transaction. Mr.&#160;Vizirgianakis also invited Mr.&#160;Reali to present to the Misonix board at a mutually agreeable time, pursuant to Mr.&#160;Reali&#8217;s request. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;28, 2021, as a result of the parties transitioning to more detailed discussion of an acquisition of Misonix, Misonix and Company&#160;A entered into a revised mutual non-disclosure agreement, which added an 18-month standstill restriction on Company&#160;A making proposals to acquire Misonix that were not supported by the Misonix board (but which standstill would fall away upon Misonix entering into a definitive acquisition agreement with a third party), as well as restrictions on Company&#160;A&#8217;s ability to solicit Misonix employees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;29, 2021, Mr.&#160;Vizirgianakis met with representatives of Company&#160;A where Mr.&#160;Vizirgianakis presented Misonix&#8217;s background and business strategy. At the conclusion of the meeting, the representatives of Company&#160;A indicated that they would consider an acquisition of Misonix, but were skeptical whether Misonix&#8217;s wound care business line would be a logical fit with Company&#160;A&#8217;s product lines. As a result, Misonix&#8217;s management believed it was unlikely that Company&#160;A would present a competitive acquisition offer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on June&#160;29, 2021, Company C presented J.P. Morgan with an indication of interest to acquire Misonix for $27.43 per share of Misonix common stock, to be paid in cash. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;30, 2021, the Misonix board held a meeting, with management, representatives of Jones Day, representatives of J.P. Morgan, and Messrs.&#160;Reali and Yamamoto from Bioventus attending. Messrs.&#160;Reali and Yamamoto gave the Misonix board a presentation on Bioventus, including its history, strategy and the potential synergies and strategic plans for the combined company. Messrs.&#160;Reali and Yamamoto stressed Bioventus&#8217; desire to sign a merger agreement and announce before Bioventus&#8217; scheduled August&#160;10, 2021 earnings release. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later in the day on June&#160;30, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. At the meeting, Mr.&#160;Vizirgianakis reported on his meeting with Company&#160;A on the previous day. Representatives of J.P. Morgan discussed the proposal received on the previous day from Company&#160;C with the Misonix board and relayed that Company&#160;C would require additional due diligence, including a workshop with Company&#160;C&#8217;s own doctors, on Misonix&#8217;s surgical products in the area of neurosurgery, which Company C requested to schedule for the week of July&#160;19, 2021. The Misonix board confirmed that, based on the presentation by Messrs.&#160;Reali and Yamamoto earlier in the day, it was apparent Bioventus had undertaken thoughtful analysis, there was general alignment on the potential synergies that could be realized from a potential acquisition by Bioventus, and Bioventus had proposed a well-articulated plan for integration. The Misonix board also considered the potential risks associated with engaging in a transaction with Bioventus and the different risks presented by Company&#160;C&#8217;s proposed all-cash consideration and Bioventus&#8217; proposed part-cash and part-stock consideration. The Misonix board also discussed the recent decline in Bioventus&#8217; stock price and the current value implied by the proposed exchange ratio. The Misonix board discussed with J.P. Morgan potential options to preserve value for Misonix stockholders in connection with the Bioventus offer, including a &#8220;collar&#8221; on the exchange ratio of Bioventus class&#160;A common stock exchanged for Misonix stock and a contingent value right. The Misonix board discussed at length the options currently available and the potential benefits and risks of each of the options, including the risk that Bioventus would be unwilling to allow for a time delay that would be sufficient for Company&#160;C to complete further due diligence and lab tests. The Misonix board directed management and the representatives of J.P. Morgan to convey their positive disposition to Bioventus&#8217; presentation, indicate that Misonix would need to undertake due diligence on Bioventus </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">145 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">given the stock portion of the consideration, and indicate that exclusivity was not appropriate at the current offer price. The Misonix board also directed representatives of J.P. Morgan to engage with Company&#160;C on value and to ask Company&#160;C to accelerate the timing of its due diligence efforts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;1, 2021, at the direction of Misonix, representatives of J.P. Morgan contacted a representative of Company C to request that Company C improve the value of its offer. The representative of Company&#160;C responded that Company&#160;C&#8217;s offer would remain at $27.43 per share of Misonix common stock until completion of Company&#160;C&#8217;s due diligence, including lab tests of Misonix&#8217;s neurosurgery products. The representative of Company C followed up with a further call to representatives of J.P. Morgan to indicate that the necessary lab tests for neurosurgery products could be scheduled the week of July&#160;19, 2021, but that Company&#160;C would also require an additional week after completion of the lab tests to validate its views on the results. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;2, 2021, the special committee of the Bioventus board held a meeting, which members of Bioventus management and representatives of Perella Weinberg attended. During the meeting the status of the potential transaction with Misonix was reviewed along with the due diligence process and potential timeline to closing. Mr.&#160;Reali updated the special committee based on his conversation with Misonix management regarding Bioventus&#8217; initial offer price. Mr.&#160;Reali reported that Mr.&#160;Vizirgianakis had indicated that the initial offer was inadequate to establish exclusivity between the companies. The special committee discussed alternative merger consideration proposals and agreed to increase its offer to $27.50 per share of Misonix common stock in a mix of cash and shares of Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;2, 2021, Bioventus submitted a revised proposal, increasing its offer to what it characterized as $27.50 per share of Misonix common stock based on the 30-day volume weighted average share price of the Bioventus class&#160;A common stock of $17.80 as of the close of trading on July&#160;1, 2021. The consideration proposed comprised 0.983&#160;shares of Bioventus class A common stock and $10.00 in cash for each share of Misonix common stock. Bioventus indicated its revised proposal was conditioned upon Misonix committing to negotiate exclusively with Bioventus and signing the merger agreement no later than July&#160;30, 2021. However, on July&#160;1, 2021, Goldman Sachs issued a report downgrading the Bioventus class&#160;A common stock. As a result, the closing price and the seven day volume weighted average share price of the Bioventus class&#160;A common stock on July&#160;2, 2021 was $16.51 and $17.84, respectively. Based on these values, the value of the merger consideration proposed by Bioventus was $26.23 and $27.54, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;2, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Representatives of J.P. Morgan provided the Misonix board with an update on the discussions with Company&#160;C, including the fact that successful lab performance of Misonix&#8217;s neurosurgery products would be critical to Company&#160;C&#8217;s value determination. The representatives of J.P. Morgan highlighted the timing difficulties raised by Company&#160;C&#8217;s request for lab trials, but also noted that Company C may be able to provide a significant increase in value if it deemed the lab trials of Misonix&#8217;s neurosurgery products to be successful. Mr.&#160;Vizirgianakis provided the Misonix board with an update on the discussions with Bioventus, including the revised proposal received earlier in the day. The Misonix board discussed the current value Bioventus proposed to pay, the status of discussions with Company&#160;C and Company&#160;A and the risks and benefits of a number of possible next steps with each of the potential counterparties. Members of the Misonix board placed particular emphasis on the recent decline in Bioventus&#8217; stock price, which had caused the value offered by Bioventus to be lower than the per share value offered by Company C, and the need for price protection to the Misonix stockholders as the Misonix board considered its options. The Misonix board also considered the risk that if the results of the lab trials of neurosurgery products with Company&#160;C were not positive, there was a high degree of risk to execution with Company&#160;C as well as risk to potential upside. The Misonix board determined that Bioventus&#8217; revised proposal was not sufficient to warrant exclusivity at the time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July&#160;2, 2021, as directed by the Misonix board, Mr.&#160;Vizirgianakis contacted Mr.&#160;Reali to inform him that the Misonix board considered the value presented in Bioventus&#8217; revised proposal to be insufficient and that the Misonix board needed price protection in the event of a potential further decline in Bioventus&#8217; stock price </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">146 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">between signing a merger agreement and closing the transaction. At the conclusion of the discussion, Mr.&#160;Reali proposed that the parties work towards signing a merger agreement an announcing the transaction by July&#160;29, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;5, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. After receiving a summary of the current terms proposed in Bioventus&#8217; offer and Company&#160;C&#8217;s indication of interest, discussion focused on the fact that the current value implied by the Bioventus&#8217; offer was less than Company&#160;C&#8217;s indication of interest given the decline in Bioventus&#8217; stock price after the proposal was made. The Misonix board also noted that the downgrade by Goldman Sachs of the Bioventus class A common stock on July&#160;1, 2021 further underscored the importance of downside price protection for Misonix stockholders. The representatives of Jones Day discussed with the Misonix board the operation and use of collars on exchange ratios in mergers with stock consideration as a mechanism for increasing price certainty. The Misonix board directed J.P. Morgan to engage with Bioventus to seek price protection, to commit to commencing reverse due diligence, and to decline to provide Bioventus with exclusivity. The Misonix board also directed Jones Day to inform Bioventus&#8217; outside legal counsel, Latham&#160;&amp; Watkins LLP (&#8220;Latham&#8221;) that the Misonix board would require price protection in connection with a transaction involving the use of Bioventus class A common stock as consideration. The Misonix board further instructed Jones Day to explore with Latham the feasibility of a transaction in which Misonix&#8217;s stockholders could make an election between cash and stock consideration. The Misonix board also discussed the binary nature of the decision that Company&#160;C would potentially make following the lab trials of neurosurgery products, and the importance of timing and maintaining optionality. The Misonix board engaged in an extensive discussion of the options available to Misonix, including remaining a standalone business, whether a sale of Misonix was advisable now or in the near future and the potential benefits and risks of the options considered. The Misonix board encouraged Misonix management to continue engagement with Company&#160;C and Company&#160;A. The Misonix board considered whether it would be appropriate to contact any of a number of potential additional third parties (other than Company&#160;C and Company&#160;A) to gauge their interest in an acquisition of Misonix. After discussing the business of each party, their competitive position relative to Misonix, prior contacts between such parties and Misonix, the Misonix board&#8217;s perception of the parties&#8217; resources and recent transactions that some of the parties had engaged in, the Misonix board determined not to proceed with additional contacts at that time. At the conclusion of the meeting, the Misonix board discussed with management and representatives of J.P. Morgan and Jones Day a preliminary timeline for signing a merger agreement with an acquiror and announcing the transaction by July&#160;29, 2021 (as proposed by Bioventus) and the steps necessary to achieve this goal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July&#160;5, 2021, Mr.&#160;Vizirgianakis contacted a representative of Company&#160;C to confirm Company&#160;C&#8217;s interest in pursuing an acquisition of Misonix, advise Company&#160;C that the timing of Misonix&#8217;s discussions with another party had accelerated, and request that Company C accelerate its due diligence efforts. Company&#160;C&#8217;s representative indicated that Company C had a high degree of interest in pursuing a transaction with Misonix, but noted that Company&#160;C would want to understand Misonix&#8217;s soft tissue opportunities as well as conduct lab tests on Misonix&#8217;s neurosurgery products, which lab tests were not scheduled to take place until the week of July&#160;19. Company&#160;C&#8217;s representative confirmed that Company&#160;C would plan to sell Misonix&#8217;s wound business within a year, making that element of Misonix&#8217;s business difficult to accurately value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After receiving Bioventus&#8217; revised offer of July&#160;2, 2021, Misonix and Bioventus began mutual due diligence in earnest, particularly over the weeks of July&#160;5, July&#160;12 and July&#160;19, 2021, with a number of videoconference meetings and telephone calls attended by members of Misonix senior management, representatives of Misonix&#8217;s outside advisors, members of Bioventus senior management and representatives of Bioventus&#8217; outside advisors, as applicable, on various business, financial, tax, accounting and legal matters. Concurrently with mutual due diligence between Misonix and Bioventus, Company C conducted its due diligence on Misonix, involving a number of videoconference meetings and telephone calls attended by members of Misonix senior management, representatives of Misonix&#8217;s outside advisors, members of Company&#160;C&#8217;s senior management and representatives of Company&#160;C&#8217;s outside advisors, as applicable, on various business, financial, tax, accounting and legal matters. As discussed below, Company C also conducted lab tests of Misonix&#8217;s neurosurgery products during the week of July&#160;19, 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;6, 2021, Mr.&#160;Vizirgianakis contacted Mr.&#160;Reali to discuss the Misonix board&#8217;s rationale for not providing exclusivity to Bioventus at that time, including that the current value implied by Bioventus&#8217; offer was insufficient. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July&#160;6, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Representatives of J.P. Morgan confirmed to the Misonix board that they had not received a response from Company C following their prior discussions over the past few days. Mr. Vizirgianakis provided the Misonix board an update on the response he received from the representative of Company C on the prior day&#8217;s telephone call. The Misonix board also confirmed, after discussing the volatility of Bioventus&#8217; stock price and the need to undertake due diligence on Bioventus, that it would still be unable to commit to exclusive negotiations with Bioventus. The Misonix board directed management and representatives of J.P. Morgan and Jones Day to continue engagement with each of the potential counterparties. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 7, 2021, representatives of J.P. Morgan, at the direction of Misonix, contacted representatives of Company A telephonically to confirm Company A&#8217;s continued interest in an acquisition of Misonix. Company A&#8217;s representatives indicated that they were still interested in a transaction, but would need to wait until technical developments in Misonix&#8217;s discectomy and neurological products had reached a more advanced stage before committing to an acquisition, which in Company A&#8217;s estimation would not likely occur for a period of six to nine months. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also on July 7, 2021, representatives of Jones Day, at the direction of Misonix, contacted representatives of Latham to advise them that the Misonix board had not yet agreed to Bioventus&#8217; proposed price, that the Misonix board wanted assurance as to the value of the equity consideration that Bioventus proposed to pay in the transaction (including a collar on any decline in Bioventus&#8217; stock price between signing and closing), and that the Misonix board would be interested in a transaction in which Misonix stockholders could make an election between cash consideration and Bioventus class A common stock consideration, subject to a maximum amount of cash that Bioventus would be required to pay in the transaction. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also on July 7, 2021, representatives of Bioventus provided Misonix, J.P. Morgan and Jones Day with a proposed transaction timeline necessary to meet the proposed July 29, 2021 deadline for signing a merger agreement and announcing the transaction. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 8, 2021, Messrs. Reali and Yamamoto provided Messrs. Vizirgianakis, Dwyer and the senior management of Misonix a corporate presentation on Bioventus, including the company&#8217;s history, its strategy and potential synergies and strategic plans for the combined company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July 8, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Mr. Vizirgianakis and representatives of Jones Day and J.P. Morgan provided the Misonix board with an update on the status of discussions with Bioventus, Latham and Company C and the proposed timeline for entering into a definitive acquisition agreement by the end of July. Representatives of J.P. Morgan informed the Misonix board of Company A&#8217;s decision to delay its engagement in the sale process to await more advanced technical developments in Misonix&#8217;s discectomy and neurological products, such that it was not a currently viable aquiror of Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 9, 2021, the Bioventus and Misonix management teams, along with their respective outside legal counsel and financial advisors held a conference call to review the timeline proposed by Bioventus to reach a signed merger agreement by July 29, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 13, 2021, as a result of the parties transitioning to a more detailed discussion of an acquisition of Misonix and in advance of a Misonix management presentation, Misonix and Company C amended and restated their confidential disclosure agreement, which added a 12-month standstill restriction on Company C (but which standstill would fall away upon Misonix entering into a definitive acquisition agreement with a third party) as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">148 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">well as a limited non-solicitation of Misonix employees. Thereafter, the Misonix management team, including Messrs. Vizirgianakis and Dwyer, provided a presentation to Company C and its representatives and advisors. The presentation provided Company C with a detailed summary of Misonix&#8217;s business, product portfolio and new product pipeline. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July 13, 2021, representatives of Latham delivered an initial draft merger agreement to representatives of Jones Day. The draft included the following key terms: (a) a fixed exchange ratio of 0.983 shares of Bioventus class A common stock and $10.00 in cash for each share of Misonix common stock; (b) a requirement that both parties use reasonable best efforts to obtain antitrust approvals, but with Bioventus excused from having to agree to any divestures or limitations on its post-closing business in order to obtain such approvals; (c) a mutual &#8220;force the vote&#8221; that would require each of Misonix and Bioventus to hold special meetings of their stockholders to consider the company&#8217;s respective transactions, even if the Misonix board or Bioventus board had changed its recommendation to stockholders with respect to the respective transactions as a result of an intervening event or as a result of a superior proposal; (d) a fiduciary termination fee payable by Misonix to Bioventus equal to 4.5% of Misonix&#8217;s equity value in the event of a termination of the merger agreement under various circumstances, including a change in recommendation by the Misonix board or a failure to obtain Misonix stockholder adoption of the merger agreement after the announcement of a superior proposal relating to Misonix; and (e) a fiduciary termination fee payable by Bioventus to Misonix equal to 4.5% of Misonix&#8217;s equity value in the event of a termination of the merger agreement under various circumstances, including a change in recommendation by the Bioventus board or a failure to obtain Bioventus stockholder approval of the stock issuance after the announcement of a superior proposal relating to Bioventus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 18, 2021, representatives of Jones Day delivered a revised draft merger agreement to representatives of Latham. The draft included the following key terms: (a) an indication that the price proposed by Bioventus had not been accepted by Misonix and was subject to further negotiation; (b) (i) the option for Misonix stockholders to elect to receive all cash or all shares of Bioventus class A common stock in exchange for each share of Misonix common stock, subject to proration and with the aggregate cash consideration fixed and (ii) a &#8220;collar&#8221; on the exchange ratio to fix the value of the stock consideration if the 14-day volume weighted average of Bioventus&#8217; share price fell between the signing of the merger agreement and the completion of the transactions; (c) (i) agreement to use reasonable best efforts to obtain antitrust approvals, with Bioventus obligated to agree to divestures or limitations on its post-closing business unless those remedies, individually or in the aggregate, would have a material adverse effect on Misonix or Bioventus and (ii) an obligation for each party to refrain from conducting acquisitions or divestitures prior to completion of the mergers, to the extent they could reasonably be expected to hinder or delay completion of the mergers; (d) no &#8220;force the vote&#8221; provision and a right of Misonix to terminate the merger agreement and pay to Bioventus a termination fee equal to 2.0% of Misonix&#8217;s equity value in the event Misonix accepts a superior proposal; (e) a termination fee payable by Bioventus to Misonix equal to 2.0% of Misonix&#8217;s equity value in the event of a termination of the merger agreement by Misonix upon a Bioventus financing failure, in addition to other damages that Miosnix may recover if such failure resulted from a willful and material breach of Bioventus&#8217; covenants in the merger agreement; and (f) reducing the termination fee payable in all other circumstances to 2.0% of Misonix&#8217;s equity value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 19, 2021, representatives of Latham delivered initial drafts of the form of voting and support agreements for both Bioventus stockholders and Misonix stockholders to representatives of Jones Day. The terms and conditions of the voting and support agreements were largely identical, except that the voting and support agreement to be executed by Bioventus stockholders provided that such stockholders would be required to vote only a portion of their Bioventus common stock in favor of the Bioventus stock issuance. This portion was equal to the number of shares that constituted the same percentage of outstanding Bioventus common stock as the percentage of outstanding Misonix common stock held by Misonix stockholders executing their respective voting and support agreements. Latham&#8217;s draft of the form of voting and support agreement for Misonix stockholders also indicated, by footnote, Bioventus&#8217; request that each of the significant Misonix stockholders would also sign a separate lock-up agreement whereby such Misonix stockholders would agree to restrictions on the post-closing sale of their shares of Bioventus class A common stock. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">149 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also on July 19, 2021, the Bioventus board held a meeting at which members of Bioventus management and representatives of Latham were present. Messrs. Reali and Yamamoto provided the Bioventus board with an update on the potential acquisition of Misonix and then representatives of Latham provided an overview of the Bioventus board&#8217;s fiduciary duties related to the potential acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July 19, 2021, representatives of Jones Day delivered an initial draft merger agreement to representatives of Company C. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 20, 2021, representatives of Company C met with Misonix&#8217;s management. Misonix management delivered presentations detailing Misonix&#8217;s operations, including product development, research and development, manufacturing, supply chain, marketing and business development. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 21, 2021, Bioventus&#8217; executed an engagement letter pursuant to which it formally retained Perella Weinberg its exclusive financial advisor in connection with a potential acquisition of Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also on July 21, 2021, representatives of Jones Day and of Latham held a conference call to discuss the open issues in the revised draft of the merger agreement circulated by representatives of Jones Day. Representatives of Latham conveyed Bioventus&#8217; objection to any collar on the exchange ratio for the Bioventus class A common stock consideration, preferring instead an exchange ratio fixed at the time of signing the merger agreement using a 30-day volume weighted average price for Bioventus class A common stock. The representatives of Latham indicated, however, that Bioventus would agree to modify the exchange ratio such that the implied value of the merger consideration (using a volume weighted average share price of Bioventus class A common stock over a period to be determined) would, as of the signing of the merger agreement, be equal to $27.50 per share of Misonix common stock. Representatives of both Jones Day and Latham agreed that Misonix&#8217;s request for a collar on the exchange ratio would remain an open discussion point for the parties. Representatives of Latham then confirmed that Bioventus was agreeable to (a) allowing Misonix stockholders to elect cash or stock consideration (subject to a fixed amount of aggregate cash), (b) Bioventus&#8217; significant stockholders signing a voting and support agreement binding all of their outstanding Bioventus shares, (c) a reverse termination fee payable by Bioventus in the event of a financing failure and (d) a restriction on Bioventus conducting certain other acquisitions during the pre-closing period. Representatives of Latham then explained Bioventus&#8217; continued objection to providing Misonix with the ability to terminate the merger agreement to accept a superior proposal, instead favoring the requirement for Misonix to proceed with a stockholder vote. Representatives of both Jones Day and Latham agreed that Misonix&#8217;s ability to terminate the merger agreement to accept a superior proposal, as well as the amount of the termination fee, would remain open discussion points for the parties. Representatives of Jones Day informed Latham that the significant stockholders of Misonix signing the voting and support agreement would not be willing to also execute separate lock-up agreements requested by Bioventus. The representatives of Jones Day and Latham concluded by discussing the efforts standard for obtaining HSR clearance as well as the appropriate scope of the representations and warranties to be given by Bioventus in the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July 21, 2021, representatives of J.P. Morgan, at the direction of Misonix, spoke with representatives of Perella Weinberg and Mr. Vizirgianakis spoke with Mr. Reali. During these discussions, Mr. Reali and the representatives of Perella Weinberg each separately confirmed that Bioventus would agree to modify the exchange ratio such that the implied value of the merger consideration as of the signing of the merger agreement would be equal to $27.50 per share of Misonix common stock, based on the 15- or 30-day volume weighted average price of the Bioventus class A common stock ending on the date of the signing of the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 22, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Mr. Vizirgianakis and the representatives of J.P. Morgan informed the Misonix board that Company C&#8217;s lab tests of Misonix&#8217;s neurosurgery products was nearing completion and that Misonix could expect feedback on the test results and a potential revised acquisition proposal from Company C early in the week of July 26, 2021. The Misonix board considered this timing in connection with the accelerated timeline of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">150 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ongoing negotiations with Bioventus. The Misonix board also considered the fact that Company C&#8217;s board of directors may not be in a position to approve any transaction between Misonix and Company C until late August. The representatives of Jones Day and J.P. Morgan and Mr. Vizirgianakis provided the Misonix board with an update of the discussions with Bioventus, particularly Bioventus&#8217; continued resistance to the Misonix board&#8217;s request for a collar on the exchange ratio to provide downside protection to Misonix stockholders, but that Bioventus was prepared to set the exchange ratio so as to ensure that the offer price represented a value of $27.50 as of the signing date based on a volume weighted average of Bioventus&#8217; stock price over a period of 15 or 30 days preceding the signing of the merger agreement. Representatives of Jones Day thereafter provided the Misonix board with an update on negotiations with Latham and Bioventus&#8217; objection to Misonix&#8217;s proposal that the Misonix board be permitted to cause Misonix to terminate the merger agreement to accept a superior proposal. The Misonix board discussed the implications of that objection, in particular, that this restriction would likely have a significant chilling effect on the willingness of any other party to make a superior proposal after the merger agreement had been signed. As a result, the Misonix board instructed representatives of Jones Day to continue to seek an ability for Misonix to terminate the merger agreement to accept a superior proposal. The representatives of Jones Day reviewed additional material issues discussed with Latham, including the cash/stock election mechanics, antitrust provisions, scope of Bioventus&#8217; representations and warranties proposed in Misonix&#8217;s comments to the proposed merger agreement, the scope of proposed stockholder and support agreements for certain stockholders of Bioventus and Misonix, and Bioventus&#8217; request for significant stockholders to execute post-closing lock-up agreements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July 22, 2021, representatives of Latham delivered to Jones Day a revised draft of the merger agreement. The draft included the following key terms that remained under negotiation between the parties: (a) the ability of Misonix stockholders to elect to receive either $27.50 in cash or a fixed number of shares of Bioventus class A common stock having a value equal to $27.50 based on the 30-day volume weighted average share price ending on the date of the signing of the merger agreement, in each case, subject to proration; (b) agreement of the parties to use their reasonable best efforts to obtain antitrust approvals, with Bioventus obligated to agree to divestures or limitations on Misonix&#8217;s or Bioventus&#8217; post-closing business unless those remedies, individually or in the aggregate, would materially reduce the reasonably anticipated benefits of the merger to Bioventus or impact Bioventus or Misonix in a manner or amount that is material relative to the value of Misonix; (c) a mutual &#8220;force the vote&#8221; in the event the boards of directors of Misonix or Bioventus were to change its recommendation to stockholders with respect to the transaction as a result of either an intervening event or as a result of a superior proposal; (d) no termination fee payable upon a Bioventus financing failure; and (e) increasing the termination fee payable in all circumstances to 4.25% of Misonix&#8217;s equity value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 23, 2021, representatives of Jones Day delivered a revised drafts of the forms of voting and support agreements to representatives of Latham. The revised draft of the voting and support agreement to be executed by Bioventus stockholders removed the limitation on the number of shares of Bioventus class A common stock applicable to the voting restrictions and also removed the footnote proposal that Misonix&#8217;s significant stockholders also execute separate lock-up agreements restricting the post-closing sale of their shares of Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 24, 2021, representatives of Jones Day and Latham discussed the open issues in the revised draft of the merger agreement previously circulated by representatives of Latham. Representatives of Jones Day confirmed that Misonix&#8217;s request for a collar on the exchange ratio, Misonix&#8217;s ability to terminate the merger agreement to accept a superior proposal, the amount of the termination fee, and Bioventus&#8217; request for significant Misonix stockholders to execute separate post-closing lock-up agreements were the remaining key outstanding issues for the parties. Over the course of July 24, 2021 through to the parties&#8217; execution of the merger agreement on July 29, 2021, representatives of Jones Day and Latham exchanged revised drafts of the merger agreement, along with the disclosure schedules and other ancillary exhibits thereto, and the voting and support agreements until those documents were agreed by the parties to be in final form. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">151 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 26, 2021, Messrs. Vizirgianakis and Dwyer met with Messrs. Reali, Yamamoto and Anglum from Bioventus and with representatives of Perella Weinberg, with Messrs. Vizirgianakis and Anglum attending via telephone. The parties discussed anticipated timing for reaching agreement on the merger agreement and voting agreements, and the parties&#8217; communications that they would propose to issue if the parties could favorably conclude their discussions on the merger agreement. The parties acknowledged that material issues remained outstanding, including Misonix&#8217;s request for a collar on the exchange ratio and an ability to terminate the merger agreement to accept a superior proposal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July 26, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Representatives of J.P. Morgan reported that Company C had held its internal strategic development committee meeting to consider Company C&#8217;s due diligence conducted on Misonix, including the lab tests of Misonix&#8217;s neurosurgery products. While the lab results were reported as being positive, Company C had developed an internal concern that owning Misonix&#8217;s TheraSkin product (a biologically active human skin allograft) could create unacceptable liability for Company C. The representatives of J.P. Morgan reported that this view was based on Company C&#8217;s anecdotal experience with an allograft previously owned by Company C that had resulted in significant litigation for Company C. As a result, Company C indicated that it would not be prepared to acquire all of Misonix at this time. The representatives of J.P. Morgan noted that Company C had instead inquired whether Misonix would be interested in completing a sale of assets relating to its surgical business, while retaining its wound care business. Mr. Vizirgianakis then reported that he had received a similar call from his primary contact at Company C and, although Mr. Vizirgianakis had distinguished Misonix&#8217;s Theraskin product from the product of concern to Company C, his contact at Company C made clear that significant internal discussion over an extended period of time would be required for Company C to change its view and, in the contact&#8217;s view, there was a high degree of risk that a change in view would not be possible. During the Misonix board meeting, a representative from J.P. Morgan received a call from Company C. Upon returning to the meeting, he reported that Company C had not changed its view and was not making an offer at that time, but had indicated that, if Company C were to change its view and if Company C received further requisite internal approvals, which would not be available in the near term, Company C might be able to offer an asset purchase transaction that valued Misonix&#8217;s surgical business up to as much as $30.00 per share of Misonix common stock. The Misonix board engaged in a lengthy discussion of the feasibility of a potential transaction with Company C under the structure proposed by Company C. During this discussion, the Misonix board discussed with representatives of J.P. Morgan and Jones Day (a) potential structures for a sale of Misonix&#8217;s surgical business to Company C, including a direct sale of assets or a potential spin-off of Misonix&#8217;s wound care business to Misonix&#8217;s stockholders and sale of the remaining portion of Misonix to Company C, (b) the potential benefits and risks associated with such structures, the perceived tax implications of such structures, and the value that could be obtained for Misonix stockholders if such transactions were successfully structured, negotiated and completed based on the preliminary value indicated by Company C, (c) the further internal approvals that Company C would need to obtain to complete a transaction, the potential timing of such approvals and the risk that such approvals would not be obtained, (d) the fact that an asset sale would require the identification of assets to be sold, the negotiation of representations and warranties relating to an asset sale, indemnification arrangements customary for an asset sale and other terms that were very different than those reflected in the proposed definitive merger agreement that Misonix had provided to Company C, and (e) the fact that none of these terms had been discussed with Company C and the resultant risk that such terms may not be acceptable to Misonix when or if ultimately proposed by Company C. The Misonix board and management also concluded that the recent indication regarding Misonix&#8217;s surgical business (provided by Company C during the course of the meeting) was highly speculative, not based on a full analysis of Misonix by Company C, and therefore unlikely to ultimately materialize. The Misonix board then considered this new proposal in connection with the status of negotiations with Bioventus. A representative of Jones Day informed the Misonix board that Bioventus continued to resist any collar on the exchange ratio or any arrangement that would provide Misonix stockholders protection against a potential decline in Bioventus&#8217; stock price between the announcement and closing of a transaction (but that Bioventus would increase its proposed exchange ratio to provide value at signing equal to $27.50 per share of Misonix common stock), that Bioventus continued to require that Misonix not have the ability to terminate a merger agreement to accept a superior proposal and that Bioventus continued to seek a termination fee equal to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">152 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.25% of Misonix&#8217;s equity value. The representative of Jones Day indicated that if these issues could be resolved, it was likely that Misonix&#8217;s and Bioventus&#8217; respective management and advisors could prepare the necessary documentation and communication materials to sign a definitive agreement within the next few days. At the conclusion of this discussion, the Misonix board determined that (i) pursuing a transaction with Company C would require complex structuring, (ii) a transaction with Company C would require the negotiation of terms that had not yet been proposed by Company C and may be unacceptable to Misonix, (iii) Company C may not receive the internal approvals it would need to pursue a transaction with Misonix in a timely manner or at all, and (iv) if Misonix delayed entering into a transaction with Bioventus to pursue a transaction with Company C, there was a significant likelihood that Bioventus would no longer be willing to enter into a transaction with Misonix if the transaction with Company C did not materialize. At the conclusion of this discussion, the Misonix board determined that Misonix should terminate discussions with Company C and continue discussions of a potential transaction with Bioventus. The Misonix board instructed representatives of J.P. Morgan and Jones Day to convey to Bioventus that the Misonix board would support a transaction with Bioventus if (i)&#160;Bioventus increased the value of the merger consideration in its offer, (ii)&#160;Bioventus would allow Misonix to terminate the merger agreement to accept a superior proposal and (iii)&#160;the termination fee payable under the circumstances set forth in the proposed merger agreement was lowered to 3.5% of Misonix&#8217;s equity value. The Misonix board further indicated that, on this basis, it would be willing to forego its request that Bioventus provide a collar to protect against a decline in value of the merger consideration as a result of a decrease in Bioventus&#8217; stock price between the signing of the merger agreement and completion of the transaction. The Misonix board made this determination based on its consideration, among other factors, of its perception of the short- and long-term value of the Bioventus class A common stock (including the view of Misonix&#8217;s management based on the Bioventus public Wall Street analyst financial projections that were previously provided) and that the anticipated mergers could likely be completed prior to the end of 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 27, 2021, as directed by the Misonix board, representatives of J.P. Morgan and Jones Day contacted representatives of Perella Weinberg and Latham, respectively, to present the proposal approved by the Misonix board during its meeting of July 26, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July&#160;27, 2021, Mr.&#160;Reali contacted Mr.&#160;Vizirgianakis by telephone in response to the Misonix board&#8217;s proposal, as delivered by representatives of J.P. Morgan and Jones Day, on behalf of Misonix, earlier in the day. Mr.&#160;Reali informed Mr.&#160;Vizirgianakis that, in exchange for Misonix agreeing to forego a collar on the exchange ratio on the Bioventus class A common stock consideration, (a)&#160;Bioventus would agree to increase cash portion of its offer to $10.50 to provide aggregate value, at signing of the merger agreement, of $28.00 per share of Misonix common stock, (b)&#160;Bioventus and Misonix would need to agree on the appropriate exchange ratio to use to reflect this value, (c)&#160;Bioventus would allow Misonix to terminate the merger agreement to accept a superior proposal, and (d)&#160;Bioventus would not agree to a termination fee payable under the circumstances set forth in the proposed draft merger agreement of less than 4.0% of Misonix&#8217;s equity value. Mr.&#160;Reali emphasized that $28.00 per share of Misonix common stock was the highest price that Bioventus would be willing to pay for Misonix. Mr.&#160;Vizirgianakis agreed to take this revised proposal to the Misonix board at its meeting later in the day. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also on July&#160;27, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. Mr.&#160;Vizirgianakis provided an update on recent discussions with Mr.&#160;Reali and the terms of Bioventus&#8217; revised proposal. After discussing this proposal, the Misonix board determined that it would still be willing to forego its request that Bioventus provide a collar to protect against a decline in value of the merger consideration. The representatives of Jones Day then discussed with the Misonix board their fiduciary duties in the context of the proposed transaction with Bioventus and reviewed the material terms of the transaction and the present draft of the merger agreement with the Misonix board. Thereafter, the Misonix board engaged in extensive discussion of the various terms and conditions, including open negotiation points, the status of discussions regarding the voting and support agreements and Bioventus&#8217; continued request for significant stockholders of Misonix to enter into lock-up agreements pursuant to which they would agree to refrain from selling their shares of Bioventus class A common stock for a period of time following completion of the mergers. The representatives of J.P. Morgan reviewed with the Misonix board the mechanics of the merger consideration and various metrics for analyzing the value implied by the Bioventus class A common stock consideration and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">153 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the implied value of the cash consideration to be paid in the mergers, but also noted for the Misonix board that the period for calculating the value weighted average price of Bioventus class&#160;A common stock had not yet been agreed with Bioventus. As part of the presentation, the representative of J.P. Morgan reviewed the increases in value offered by Bioventus as a result of Misonix&#8217;s negotiations with Bioventus during the process thus far. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July&#160;27 and early July&#160;28, 2021, representatives of J.P. Morgan and Perella Weinberg conducted a series of calls to discuss the period for calculating the value weighted average price of Bioventus class&#160;A common stock. Following the discussions, representatives of Perella Weinberg, at the direction of the Bioventus board, confirmed that Bioventus would agree to calculate the exchange ratio for Bioventus class&#160;A common stock based on the seven-day volume weighted average share price of the Bioventus class A common stock ended on July&#160;27, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;28, 2021, the Misonix board held a meeting, with management and representatives of Jones Day and J.P. Morgan attending. At this meeting, representatives of J.P. Morgan presented their financial analyses of the merger consideration, including both the cash component and the Bioventus class&#160;A common stock component of the merger consideration. The representatives of J.P. Morgan also informed the Misonix board that Bioventus agreed to calculate the exchange ratio for Bioventus class A common stock based on the seven-day volume weighted average share price of the Bioventus class A common stock ended on July&#160;27, 2021. The representatives of Jones Day then discussed with the Misonix board their fiduciary duties in the context of the proposed transaction with Bioventus and presented the final material terms of the transaction and the current draft of the merger agreement. J.P. Morgan then delivered to the Misonix board an oral opinion, which was subsequently confirmed by delivery of a written opinion dated July 29, 2021, to the effect that, as of that date and based on and subject to the considerations set forth in the written opinion, the merger consideration to be paid to holders of Misonix common stock in the proposed transaction was fair, from a financial point of view, to such holders, as more fully described below under &#8220;&#8212;Opinion of Misonix&#8217;s Financial Advisor&#8221;. After discussions, including as to the matters described below under &#8220;&#8212;Recommendation of the Misonix board of Directors; Misonix&#8217;s Reasons for the Merger,&#8221; the Misonix board unanimously: (i)&#160;determined that the merger and the other transactions contemplated by the merger agreement are fair to, and in the best interests of, Misonix and its stockholders; (ii)&#160;declared advisable, approved and authorized in all respects the merger agreement, the performance of Misonix of its obligations thereunder and the consummation of the transactions contemplated thereby, on the terms and subject to the conditions set forth in the merger agreement; and (iii)&#160;recommended that Misonix stockholders adopt the merger agreement. Simultaneously, the Misonix board approved and authorized in all respects the voting and support agreement between Misonix and certain significant stockholders of Bioventus. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;28, 2021, the Bioventus board held a meeting at which Bioventus management and representatives of Latham and Perella Weinberg were present. At this meeting, representatives of Perella Weinberg presented their financial analyses of the merger consideration and the principal terms of the potential transaction. Representatives of Latham then discussed that the definitive agreement had been fully negotiated, presented the final material terms of the transaction and discussed with the Bioventus board their fiduciary duties in connection with the proposed transaction. Perella Weinberg then delivered to the Bioventus board an oral opinion, which was subsequently confirmed by delivery of a written opinion dated July 29, 2021, that as of that date and based upon and subject to the various assumptions made, procedures followed, matters considered and qualifications and limitations set forth in the written opinion, the merger consideration to be paid by Bioventus was fair, from a financial point of view, to Bioventus, as more fully described under &#8220;Opinion of Bioventus&#8217; Financial Advisor.&#8221; After discussions, including as to the matters described below under &#8220;&#8212;Recommendation of the Bioventus Board of Directors; Bioventus&#8217; Reasons for the Merger,&#8221; the Bioventus board unanimously: (i)&#160;determined that the terms of the merger agreement, the mergers and the other transactions contemplated by the merger agreement, are fair to and in the best interests of Bioventus and its stockholders; (ii)&#160;approved and declared advisable the merger agreement and the transactions contemplated thereby, including the mergers and the share issuance, each on the terms and subject to the conditions set forth in the merger agreement; and (iii) recommended that Bioventus stockholders approve the Bioventus share issuance proposal. Simultaneously, the Bioventus board approved and authorized in all respects the voting and support agreement between Bioventus and certain significant stockholders of Misonix. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">154 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the course of the evening of July&#160;28, 2021, representatives of Jones Day and Latham finalized the merger agreement, the voting and support agreements and the other ancillary documents contemplated thereby. During this period, representatives of Latham confirmed that Bioventus would not require the significant stockholders of Misonix to execute lock-up agreements in connection with the transactions. On July&#160;29, 2021, representatives of Latham finalized and executed the debt commitment letter and related fee letter with legal counsel for Wells Fargo Securities, LLC and Wells Fargo Bank, National Association, regarding Bioventus&#8217; transaction financing to facilitate Bioventus&#8217; entry into the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July&#160;29, 2021, following the final completion of the execution version of the merger agreement and the execution of the debt commitment letter and related fee letter, the Misonix board, upon reviewing the execution version of the merger agreement and all ancillary documents contemplated thereby, executed a unanimous written consent that unanimously: (i)&#160;determined that the merger and the other transactions contemplated by the merger agreement are fair to, and in the best interests of, Misonix and its stockholders; (ii)&#160;declared advisable, approved and authorized in all respects the merger agreement, the performance of Misonix of its obligations thereunder and the consummation of the transactions contemplated thereby, on the terms and subject to the conditions set forth in the merger agreement; and (iii)&#160;recommended that Misonix stockholders adopt the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later on July&#160;29, 2021, following the approval of the merger agreement and the merger by the Bioventus board and the Misonix board, Bioventus and Misonix executed the merger agreement, and on the afternoon of July&#160;29, 2021, immediately following the close of trading, issued a joint press release announcing that they had entered into the merger agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recommendation of the Bioventus Board of Directors; Bioventus&#8217; Reasons for the Merger </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At a special meeting held on July&#160;28, 2021, the Bioventus board unanimously: (i)&#160;determined that the terms of the merger agreement, the mergers and the other transactions contemplated by the merger agreement, are fair to and in the best interests of Bioventus and its stockholders; (ii)&#160;approved and declared advisable the merger agreement and the transactions contemplated thereby, including the mergers and the share issuance, each on the terms and subject to the conditions set forth in the merger agreement; and (iii)&#160;recommended that Bioventus stockholders approve the Bioventus share issuance proposal. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ACCORDINGLY, THE BIOVENTUS BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT BIOVENTUS STOCKHOLDERS VOTE &#8220;FOR&#8221; THE BIOVENTUS SHARE ISSUANCE PROPOSAL AND &#8220;FOR&#8221; THE BIOVENTUS ADJOURNMENT PROPOSAL. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described under &#8220;&#8212;Background of the Merger,&#8221; in evaluating the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, the Bioventus board held a number of meetings and consulted with Bioventus senior management and its outside legal and financial advisors. In reaching its decision to approve the merger agreement and to recommend that Bioventus stockholders vote to approve the Bioventus share issuance proposal, the Bioventus board considered a number of factors, including, but not limited to the following (which are not necessarily presented in order of their relative importance to the Bioventus board): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benefits of the Acquisition.</div></div> The Bioventus board believe that the acquisition of Misonix enhances Bioventus&#8217; leadership position in the medical device industry. Combining Bioventus&#8217; and Misonix&#8217;s complementary technologies and markets is expected, taking into account publicly available information about other industry participants and management&#8217;s best view as to industry-related information that is not publicly available, to create an industry leading portfolio of clinically proven and cost-effective medical devices. In this regard, the Bioventus board noted: </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; and Misonix&#8217;s complementary focus on innovative medical device technologies, and that the combined company will be able to offer a broad range of safe, effective and clinically proven medical devices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">155 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the combined company will have greater research and development resources, engineering expertise and technology, which will allow Bioventus to better serve customers and accelerate innovation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the combined company&#8217;s complementary product offerings and engineering and technical strengths will be aligned with important growth trends, such as cost effective and hardware agnostic products used in spinal surgeries and the movement of a patient from the hospital to the ASC to the physician office for the treatment of wounds; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the cultures of Bioventus and Misonix are strongly aligned, including shared values and commitment to innovation, execution and results orientation, and that this culture, along with Bioventus&#8217; commitment to excellence, will accelerate high performance growth; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the expectation that the combined company will have increased financial strength and flexibility, with an estimated $400&#160;million in combined revenue in the twelve month period prior to signing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the merger would immediately diversify Bioventus&#8217; revenue streams and be accretive to Bioventus&#8217; revenue growth rate, without taking into account expected synergies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the expectation that the merger will create synergies of approximately $20&#160;million by the end of the 2<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">nd</div> full year subsequent to closing, driven primarily by lower operating expenses and cost of goods sold; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the expectation that the combined company will be well-capitalized with a stronger balance sheet. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exchange Ratio and Merger Consideration</div></div>. The Bioventus board considered the relative favorability of the exchange ratio relative to the exchange ratios historically implied by the relative trading prices of Bioventus and Misonix common stock over various periods and relative to the current assessment of the valuation of each company and of the synergies and other benefits of the merger, in addition to: </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that, the maximum cash amount payable by Bioventus will be an amount equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock shortly prior to the completion of the transaction, which as of September&#160;1, 2021, the latest practicable date before the filing of this merger, would be $183.0&#160;million; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that, upon completion of the merger, Bioventus stockholders and former Misonix stockholders will own approximately 75% and 25%, respectively, of the combined company (based on fully diluted shares outstanding of the combined company); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the oral opinion of Perella Weinberg, rendered to the Bioventus board on July&#160;28, 2021, subsequently confirmed in a written opinion dated July&#160;29, 2021, to the effect that, as of July&#160;29, 2021, and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken and other matters considered by Perella Weinberg in connection with the preparation of its opinion, the merger consideration to be paid by Bioventus pursuant to the merger agreement was fair, from a financial point of view, to Bioventus (which opinion is more fully described below under &#8220;&#8212;Opinion of Bioventus&#8217; Financial Advisor&#8212;Opinion of Perella Weinberg&#8221; and is attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex B</div> hereto); and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Factors Considered by the Bioventus Board of Directors</div></div>. In addition to considering the factors described above, the Bioventus board considered the following additional factors that weighed in favor of the mergers: </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">historical information concerning Bioventus&#8217; and Misonix&#8217;s respective businesses, financial condition, results of operations, earnings, trading prices, technology positions, managements, competitive positions and prospects on stand-alone and forecasted combined bases; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the current and prospective business environment in which Bioventus and Misonix operate, including international, national and local economic conditions and the competitive and regulatory environment, and the likely effect of these factors on Bioventus and the combined company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">156 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Terms of the Merger Agreement</div></div>. The Bioventus board considered that the terms of the merger agreement, taken as a whole, including the parties&#8217; representations, warranties and covenants, and the circumstances under which the merger agreement may be terminated, in its belief, are reasonable. The Bioventus board also reviewed and considered the conditions to the completion of the merger, and concluded that while the completion of the merger is subject to regulatory approval, such approval is likely to be satisfied on a timely basis. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board weighed these advantages and opportunities against a number of potentially negative factors in its deliberations concerning the merger agreement and the mergers, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that, because the exchange ratio under the merger agreement would not be adjusted for changes in the market price of Bioventus or Misonix common stock, the then-current trading price of the shares of Bioventus class A common stock to be issued to holders of shares of Misonix common stock upon the consummation of the merger could be significantly higher than the trading price prevailing at the time the merger agreement was entered into; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that the opinion of Perella Weinberg as to the fairness, from a financial point of view, of the merger consideration to be paid by Bioventus pursuant to the merger agreement, to Bioventus speaks only as of the date of such opinion and did not and will not take into account events occurring or information that has become available after such date, including any changes in the operations and prospects of Bioventus or Misonix, general economic, monetary, market and other conditions and other factors that may be beyond the control of Bioventus and Misonix and on which the fairness opinions were based, any of which may be material; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that Misonix&#8217;s financial performance may not meet Bioventus&#8217; expectations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that the merger may not be completed or may be delayed despite the parties&#8217; efforts, including the possibility that conditions to the parties&#8217; obligations to complete the merger may not be satisfied, and the potential resulting disruptions to Bioventus&#8217; and Misonix&#8217;s businesses; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential length of the regulatory approval process and the possibility that governmental authorities might seek to require certain actions of Bioventus or Misonix or impose certain terms, conditions or limitations on Bioventus&#8217; or Misonix&#8217;s businesses in connection with granting approval of the merger or might otherwise seek to prevent or delay the merger; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential challenges and difficulties in integrating the operations of Bioventus and Misonix and the risk that anticipated cost savings and operational efficiencies between the two companies, or other anticipated cost benefits of the merger, might not be realized or might take longer to realize than expected; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the difficulties and challenges inherent in completing the merger and integrating the businesses, operations and workforce of Misonix with those of Bioventus and the possibility of encountering difficulties in achieving expected revenue growth and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cost</div> synergies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possible diversion of management attention for an extended period of time during the pendency of the merger and, following closing, the integration of the two companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the substantial costs to be incurred in connection with the merger, including those incurred regardless of whether the merger is consummated; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that Bioventus would be required to pay to Misonix a termination fee of $ $20,661,000 in the event the merger agreement were to be terminated in certain circumstances if the Bioventus board changes its recommendation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">157 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that Misonix stockholders may not approve the adoption of the merger agreement at the Misonix special meeting; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of the Misonix board, subject to certain conditions, to change its recommendation supporting the merger in response to a superior proposal or an intervening event other than a superior proposal, if the Misonix board determines that failure to take such action would reasonably be expected to be inconsistent with the Misonix board&#8217;s fiduciary duties to its stockholders under applicable laws; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of the Misonix board, subject to certain conditions, to terminate the merger agreement in order to enter into a definitive agreement providing for a superior proposal; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks of the type and nature described under entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board considered all of these factors as a whole and, on balance, concluded that the potential benefits of the merger outweighed the risks and uncertainties of the merger. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the Bioventus board was aware of and considered that Bioventus directors and executive officers would have the right to continued service for, employment by and the right to continued indemnification by the combined company. See &#8220;Interests of Bioventus&#8217; Directors and Executive Officers in the Merger.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foregoing discussion of the information and factors that the Bioventus board considered is not intended to be exhaustive, but rather is meant to include the material factors that the Bioventus board considered. The Bioventus board collectively reached the conclusion to approve the merger agreement, the merger and the other transactions contemplated by the merger agreement in light of the various factors described above and other factors that the members of the Bioventus board believed were appropriate. In view of the complexity and wide variety of factors, both positive and negative, that the Bioventus board considered in connection with its evaluation of the merger, the Bioventus board did not find it practical, and did not attempt, to quantify, rank or otherwise assign relative or specific weights or values to any of the factors it considered in reaching its decision and did not undertake to make any specific determination as to whether any particular factor, or any aspect of any particular factor, was favorable or unfavorable to the ultimate determination of the Bioventus board. In considering the factors discussed above, individual directors may have given different weights to different factors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foregoing description of Bioventus&#8217; consideration of the factors supporting the merger is forward-looking in nature. This information should be read in light of the factors discussed under &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recommendation of the Misonix Board of Directors; Misonix&#8217;s Reasons for the Merger </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At a meeting held on July&#160;29, 2021, the Misonix board unanimously: (i)&#160;determined that the terms of the merger agreement and the transactions contemplated thereby are fair to, and in the best interests of, Misonix and its stockholders; (ii)&#160;declared advisable, approved and authorized in all respects the merger agreement, the performance by Misonix of its obligations thereunder and the consummation of the transactions contemplated thereby, on the terms and subject to the conditions set forth in the merger agreement; and (iii)&#160;recommended that Misonix stockholders adopt the merger agreement. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ACCORDINGLY, THE MISONIX BOARD UNANIMOUSLY RECOMMENDS THAT MISONIX STOCKHOLDERS VOTE &#8220;FOR&#8221; THE MISONIX MERGER PROPOSAL, &#8220;FOR&#8221; THE MISONIX COMPENSATION PROPOSAL AND &#8220;FOR&#8221; THE MISONIX ADJOURNMENT PROPOSAL. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described under &#8220;&#8212;Background of the Mergers,&#8221; in evaluating the merger agreement and the transactions contemplated thereby, including the mergers, the Misonix board met numerous times to consider a potential </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">transaction with Bioventus and consulted with Misonix&#8217;s senior management, its outside legal counsel and its financial advisor. In reaching its decision to approve the merger agreement and to recommend that Misonix stockholders vote to adopt the merger agreement, the Misonix board considered a number of factors, including, but not limited to the following (which are not necessarily presented in order of their relative importance to the Misonix board): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that the merger agreement provides for Misonix stockholders to receive, subject to the election described above and subject to proration, 1.6839 shares of Bioventus class A common stock or $28.00 in cash for each share of Misonix common stock held (the &#8220;merger consideration&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the merger consideration offers strong value for shares of Misonix common stock, based on a consideration of factors including: Misonix&#8217;s current and anticipated business and operations, historical results of operations, financial and market position, strategic business plans and prospects of Misonix on a standalone basis, value of Misonix as an independent entity based on the Misonix board and management&#8217;s experience and knowledge of the industry, opportunities and risks and uncertainties in executing Misonix&#8217;s strategic plans, and current and historical trading prices of Misonix common stock, including that the merger consideration, calculated as of July&#160;27, 2021 (the day prior to the Misonix board&#8217;s consideration of the transaction) and based on the volume weighted average price of Bioventus&#8217; class&#160;A common stock price for the seven-day period ending on July&#160;27, 2021 of $16.63, values Misonix at approximately $518 million in equity value, which is a level at which Misonix has never traded and may not be able to trade at in the near term, over an extended period of time, or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Misonix board&#8217;s belief that the increased merger consideration that Misonix was able to obtain as a result of negotiations with Bioventus was the highest price per share that Bioventus was willing to pay; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the premium of the merger consideration to the market trading price of Misonix common stock compared to comparable transactions, with the implied value of the merger consideration calculated as of July&#160;27, 2021 (the day prior to the Misonix board of director&#8217;s consideration of the transaction) and based on the volume weighted average price of Bioventus&#8217;s class A common stock price for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">seven-day</div> period ending on July&#160;27, 2021 of $16.63, representing premiums of approximately: </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20% over Misonix common stock&#8217;s closing price of $23.30 on the Nasdaq on July&#160;27, 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">23% over Misonix common stock&#8217;s volume weighted average price of $22.68 on the Nasdaq for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> period ended July&#160;27, 2021; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">29% over Misonix common stock&#8217;s volume weighted average price of $21.65 on the Nasdaq for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div> period ended July&#160;27, 2021; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">34% over Misonix common stock&#8217;s volume weighted average price of $20.92 on the Nasdaq for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day</div> period ended July&#160;27, 2021; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cash/stock election feature of the merger consideration, which offers Misonix stockholders the opportunity to participate post-closing in the potential growth and success of the combined company through the stock component of the merger consideration or to realize immediate and certain value for their investment through the cash component of the merger consideration, subject to a proration adjustment mechanism; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the strategic considerations of the mergers, including: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that Misonix&#8217;s stockholders would, to the extent they receive Bioventus class A common stock, benefit from being stockholders in a more risk-diversified business than Misonix currently maintains; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the opportunity to combine the complementary strengths of Misonix and Bioventus to broaden distribution access, expand complementary product and service offerings, increase the scale and breadth of each of Misonix&#8217;s and Bioventus&#8217;s distribution and sales capabilities as compared to remaining independent companies, and improve operating efficiency of the combined company&#8217;s </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">159 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">businesses, which are expected to position the combined company to be a strong player across a range of care settings and specialties, including pain treatments, restorative therapies, surgical solutions and sports medicine; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the strengths and increased size of the combined company would potentially cause Bioventus class A common stock to be afforded a higher valuation in the market that would benefit Misonix&#8217;s stockholders, to the extent they elect to receive Bioventus class A common stock as merger consideration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the combined company would have a greater market capitalization and increased trading liquidity as compared to Misonix&#8217;s historical market capitalization and trading liquidity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that Bioventus believes that the transaction will be accretive to its adjusted EBITDA in the first full year after completion of the mergers and accretive to its adjusted EBITDA margins by the second full year after completion of the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the assessment of the Misonix board and Misonix senior management of Bioventus&#8217;s business, prospects and strategic plan; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">positive guidance from Bioventus regarding its anticipated future operating performance, and analysis of potential cost synergies that could cause Bioventus class A common stock to appreciate after the transactions close, which increase in price would benefit Misonix stockholders who become Bioventus stockholders in the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the significant cash portion of the merger consideration would limit the impact of any decline in the trading price of Bioventus class A common stock on the aggregate value of the merger consideration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the Misonix board&#8217;s expectation that the transaction will result in Misonix stockholders being able to participate in approximately $20&#160;million of estimated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">run-rate</div> cost synergies expected within two years of the completion of the mergers resulting from, among other things reduction of duplicative corporate costs and including public company expenses and general support, systems and infrastructure costs, as well as significant revenue synergies across the combined business through enhanced scale and cross-selling opportunities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that two members of the Misonix board would be appointed to the Bioventus board and would be able to contribute to the future strategy and growth of the combined company&#8217;s business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to the extent that the above-described or other factors cause the price of Bioventus class A common stock to appreciate over the period until the transaction closes, the value of the merger consideration would increase fractionally in equal proportion to the benefit of all Misonix stockholders to the extent they receive Bioventus class A common stock; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the mixed stock and cash consideration would enable Misonix stockholders to have a significant ownership position in the combined company (expected to be approximately 25% of the combined company) and participate in the value and opportunities of the combined company after the mergers, including synergies and expected future growth; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the view of the Misonix board that the merger agreement was the product of arm&#8217;s length negotiations and contained customary terms and conditions for similar transactions, and its consideration of a number of other factors pertaining to the merger agreement, including: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the right of the Misonix board to terminate the merger agreement if the requisite stockholder vote for Misonix or Bioventus were not obtained, in each case after a vote on such approval was taken; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the limited scope of the closing conditions and the absence of a closing condition relating to Bioventus&#8217;s ability to finance its payment of the cash portion of the merger consideration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the end date under the merger agreement upon which either party, subject to specified exceptions, can terminate the merger agreement, should provide sufficient time to consummate the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">160 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s ability to specifically enforce Bioventus&#8217;s obligations under the merger agreement, including Bioventus&#8217;s obligation to consummate the mergers or to seek damages in the event of a willful and material breach of the merger agreement by Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the mergers are intended to qualify as a reorganization for U.S. federal income tax purposes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the merger agreement provides Misonix with sufficient operating flexibility between the signing of the merger agreement and the completion of the mergers to conduct its business in the ordinary course consistent with past practice; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the unanimous approval of the merger agreement by the Misonix board, which consists of a majority of independent directors who are not affiliated with Bioventus and are not employees of Misonix or any of its subsidiaries, and which retained and received advice from Misonix&#8217;s outside financial and legal advisors in evaluating, negotiating and recommending the terms of the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that based on a review of the terms of the merger agreement with Misonix&#8217;s outside legal advisors, and assuming the mergers are attractive to Misonix stockholders, there is a high likelihood of completing the mergers, particularly in light of the terms of the merger agreement and the conditions to completing the mergers (see the sections of this joint proxy statement/prospectus captioned &#8220;&#8212;Conditions to Completion of the Mergers&#8221; and &#8220;&#8212;Regulatory Approvals&#8221;). In making its determination, the Misonix board considered a number of factors, including: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is obliged to use reasonable best efforts to (1)&#160;complete the mergers and obtain the necessary approvals and clearances required to complete the mergers as promptly as reasonably practical, and (2)&#160;resolve impediments or objections, if any, asserted by any governmental authority with respect to the mergers under antitrust laws (including divestitures or behavioral remedies), except for such remedies that would reasonably be expected to have a material adverse effect on the results of operations of Misonix or a material adverse effect on the results of operations of Bioventus, where, for purposes of determining whether an effect is or would be materially adverse to the results of operations of Bioventus, Bioventus will be deemed to be the same size (in operations and from a financial point of view) as Misonix; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the voting and support agreement entered into in favor of Misonix by EW Healthcare Partners Acquisition Fund, L.P., White Pine Medical, LLC, Smith&#160;&amp; Nephew, Inc., Smith&#160;&amp; Nephew USD Ltd and AMP-CF Holdings, LLC as to approximately 67.4% of Bioventus shares; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may not terminate the merger agreement to take a superior proposal or in response to an intervening event; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">that the mergers are expected to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, as amended, and the rules and regulations promulgated thereunder, generally resulting in the mergers being <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> to Misonix stockholders to the extent they receive Bioventus class A common stock pursuant to the mergers and taxable to holders of Misonix stockholders to the extent they receive cash consideration; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the oral opinion that J.P. Morgan, Misonix&#8217;s financial advisor gave to the Misonix board on July&#160;28, 2021, subsequently confirmed in writing by delivery of J.P. Morgan&#8217;s written opinion addressed to the Misonix board dated July&#160;29, 2021, that, as of such date and based upon and subject to the assumptions made, procedures followed, matters considered, and qualifications and limitations undertaken by J.P. Morgan in preparing its opinion, the consideration to be paid to the Misonix stockholders pursuant to the merger agreement, was fair, from a financial point of view, to such holders, as more fully described in the section entitled &#8220;&#8212;Opinion of Misonix&#8217;s Financial Advisor, J.P. Morgan&#8221; of this joint proxy statement/prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the Misonix board determined that entering into the merger agreement with Bioventus presents the best opportunity to maximize value for the Misonix stockholders, based on consultation with senior </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">161 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">management and Misonix&#8217;s financial and legal advisors and an evaluation of alternative transactions (including maintaining the status quo). In making its determination, the Misonix board considered a number of factors, including: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Misonix board&#8217;s assessment of Misonix&#8217;s business and operations, historical results of operations, financial prospects and conditions, and the determination that continued operation of Misonix on a standalone basis was not likely to produce, on a risk-adjusted basis, more value for Misonix stockholders than the merger consideration offered by Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential to create meaningful business opportunities and favorable market valuation effects for Bioventus as a result of combining with Misonix, from which Misonix stockholders would have the opportunity to benefit (in proportion for all Misonix stockholders to the extent reflected in the price performance of Bioventus class A common stock prior to the closing, and thereafter fully reflected in the value of the merger consideration received in the form of Bioventus class A common stock that is retained by Misonix stockholders post-closing); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that the merger consideration proposed by Bioventus included a fixed-share component, the value of which would be subject to market fluctuations from the announcement of any transaction until the closing of such transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that a delay in executing a definitive merger agreement might lead to an increased risk of leaks and market rumors prior to execution, which might harm Misonix in the event that an agreement was not reached; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Misonix board&#8217;s assessment at the time of such determination of the relative certainty of being able to expeditiously execute a definitive merger agreement with Bioventus and the relative uncertainty of being able to execute a definitive merger agreement with Company C on a similar timeline or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk of delaying the execution of a definitive merger agreement, including that potential market volatility associated with COVID or otherwise, might have a negative effect on the value of Misonix common stock and the perceived value of its business in the marketplace, and might affect Company C&#8217;s willingness to pursue a transaction; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that Company C was no longer interested in pursuing an acquisition of Misonix, or that a transaction with Company C would be complicated, tax inefficient and may not be accomplished on favorable terms or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the determination of the Misonix board that negotiating a potential transaction with Bioventus was most likely to result in the best transaction reasonably available for Misonix stockholders based on: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s process of reviewing strategic alternatives, including discussions with other potential bidders as part of its market check and discussions of reasons not to pursue other bidders, was appropriate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">among the prospective bidders, Bioventus was best positioned to provide the highest value of consideration to Misonix stockholders in light of Bioventus&#8217;s strategic interest and priorities and the expected business opportunities and favorable market valuation effects for Bioventus arising from the mergers (benefitting all Misonix stockholders to the extent reflected in the price performance of Bioventus class A common stock prior to the closing of the merger and thereafter benefitting those Misonix stockholders who receive all or a portion of the merger consideration in Bioventus class A common stock that they continue to hold post-closing); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the merger agreement provides the Misonix board the right to terminate the merger agreement to accept a superior proposal if the Misonix board determines that failure to do so would reasonably be expected to be inconsistent with its fiduciary duties; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">162 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the course of discussions and negotiations between Misonix and Bioventus resulted in improvement in the value of the consideration to be received by Misonix stockholders and the terms of the merger agreement, as compared with the initial proposal made by Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that, while Misonix&#8217;s business continues to present opportunities for growth, it has also become subject to increasing competitive pressures, a changing competitive landscape, and continuing as a standalone company will subject Misonix&#8217;s stockholders to 100% of Misonix&#8217;s execution risk. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the course of its evaluation of the merger agreement and the mergers, the Misonix board also considered a variety of risks, uncertainties and other potentially negative factors, including the following (which are not necessarily presented in order of relative importance): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that Misonix is required to use its reasonable best efforts to call, hold and initially schedule a stockholder meeting within 45 days after the effectiveness of Bioventus&#8217;s registration statement in connection with the mergers (to the extent not a violation of law); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that Bioventus can terminate the merger agreement if the Misonix stockholder meeting is convened, a vote on the merger agreement is taken and the requisite approval of the Misonix stockholders is not obtained; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that Bioventus can terminate the merger agreement if the Misonix board changes its recommendation that stockholders approve the Misonix merger proposal, in which case Misonix will be obligated to pay the termination fee; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that a third party may be willing to enter into a strategic combination with Misonix on terms more favorable than the mergers and the potential that the no shop covenants and termination fees payable by Misonix under the merger agreement might deter alternative bidders that might have been willing to submit a superior proposal to Misonix, including the requirement that, if Misonix terminates the merger agreement under certain circumstances, Misonix may be required to pay Bioventus a termination fee of $20.7&#160;million, or approximately 4% of transaction value, although the Misonix board believes that the termination fee is reasonable in amount, is customary and consistent with fees and provisions in comparable transactions and would not be preclusive of other offers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that following receipt of the Misonix stockholder approval, the Misonix board would be unable to change its recommendation in response to a superior proposal or an intervening event or to terminate the merger agreement to accept a superior proposal; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that the merger consideration in part consists of a fixed exchange ratio of shares of Bioventus class A common stock per share of Misonix common stock, the merger agreement does not provide for either any adjustment of such exchange ratio if the trading price of Bioventus class A common stock decreases or a value-based termination right to Misonix, and the value of the stock portion of the merger consideration at the closing will not be known at the time Misonix stockholders vote on the Merger Proposal, meaning that Misonix stockholders could be adversely affected to an unpredictable extent and the implied value of the merger consideration could decline if there is a decrease in the trading price of Bioventus class A common stock prior to the closing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that the right of Misonix stockholders to elect to receive the cash portion of the merger consideration or the stock portion of the merger consideration is subject to proration such that the amount of cash to be received by Misonix stockholders in the mergers will, in the aggregate, be equal to $10.50 per share of Misonix common stock outstanding as of 5:00 p.m. New York City time on the election deadline, 2021, meaning that on an aggregate basis the merger consideration payable by Bioventus will be equal to $10.50 and 1.0524 shares of Bioventus class A common stock per share of Misonix common stock outstanding as of 5:00 p.m. New York City time on the election deadline, 2021 and Misonix stockholders will in the aggregate be fully exposed to fluctuations in price of Bioventus class A common stock prior to the completion of the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">163 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the portion of the merger consideration being paid in cash would prevent Misonix stockholders from realizing the benefit of any increase in the trading price of Bioventus class A common stock during the pendency of the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the significant costs involved in connection with entering into the merger agreement and the transactions contemplated thereby, and the substantial time and effort of management required to complete the transactions contemplated by the merger agreement, which may disrupt Misonix&#8217;s business operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that the consummation of the mergers requires receipt of regulatory approvals and the risk that, notwithstanding Bioventus&#8217;s obligations with respect to obtaining regulatory approvals as set forth in the merger agreement, governmental entities may delay or fail to grant the required regulatory approvals or impose unfavorable terms or conditions on such approvals or that remedies implemented by Bioventus or Misonix to obtain regulatory approvals may adversely affect the business and financial results of the combined company; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the restrictions in the merger agreement on the conduct of Misonix&#8217;s business during the period prior to consummation of the mergers, including that Misonix is required to conduct its business in the ordinary course, subject to specific limitations, which could delay or prevent Misonix from undertaking business opportunities or strategic transactions that may arise and that, absent the merger agreement, Misonix might have pursued; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that certain of Misonix&#8217;s directors and executive officers may have interests in the mergers that may be different from, or in addition to, those of Misonix&#8217;s stockholders generally; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that the mergers might not be consummated, which may cause Misonix to be required to pay its own expenses associated with the merger agreement and the transactions contemplated thereby; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that the mergers might not be consummated, and the possible adverse effect of termination of the merger agreement on Misonix&#8217;s business or the trading price of Misonix common stock </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risks that, even though the Misonix stockholder approval has been obtained, other conditions to the parties&#8217; obligations to complete the mergers may not be satisfied; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the effect of the public announcement of the merger agreement, including Misonix&#8217;s ability to attract and retain key personnel and to maintain client and distribution partner relations during the pendency of the transactions contemplated by the merger agreement, as well as the potential for litigation in connection with the mergers and the associated costs, burden and inconvenience involved in defending those proceedings; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that Bioventus may not be able to obtain sufficient financing to pay the cash portion of the merger consideration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that anticipated cost savings and operational efficiencies between the two companies, or other anticipated benefits of the mergers, including potential revenue synergies across the combined business, might not be realized or might take longer to realize than expected; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">challenges inherent in the combination of two businesses of the size, scope and complexity of Misonix and Bioventus, including the potential for unforeseen difficulties in integrating operations, systems and employees and the potential impact of such difficulties on employees and relationships with existing and prospective customers, distribution partners, suppliers and other third parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that Misonix may lose members of management and other key personnel following announcement of the transaction and may not be able to effectively replace such persons, which could adversely affect Misonix&#8217;s business during the period prior to consummation of the mergers or, if the mergers are not consummated, during the period prior to and after the termination of the merger agreement, as Misonix&#8217;s operations are largely dependent on the skill and experience of its management and key personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">164 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for the portion of the merger consideration paid in Bioventus class A common stock and retained by Misonix stockholders following the closing of the transaction, the risk that Bioventus fails to provide holders of Bioventus class A common stock with acceptable returns; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that execution of Misonix&#8217;s standalone business plan or other strategic alternatives available to Misonix may have provided greater value to Misonix stockholders than the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the uncertainty as to whether soliciting potential purchasers of Misonix other than Bioventus would yield greater value to Misonix and its stockholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that a combination with Company C or another party may have provided greater value to Misonix stockholders than the mergers; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks of the type and nature described under the sections entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix board believed that, overall, the potential benefits of the mergers to Misonix stockholders outweighed the risks and uncertainties of the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foregoing discussion of factors considered by the Misonix board in reaching its conclusions and recommendation includes the principal factors considered by the Misonix board, but is not intended to be exhaustive and may not include all of the factors considered by the Misonix board, but includes the material factors considered by the Misonix board. In light of the variety of factors considered in connection with its evaluation of the mergers, the Misonix board did not find it practicable to, and did not, quantify or otherwise assign relative or specific weights to the specific factors considered in reaching its determinations and recommendations. Rather, the Misonix board viewed its decisions as being based on the totality of the factors and information it considered. Moreover, each member of the Misonix board applied his or her own personal business judgment to the process and may have given different weight to different factors. The Misonix board based its recommendation on the totality of the information presented. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion of Bioventus&#8217; Financial Advisor </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion of Perella Weinberg </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus retained Perella Weinberg to act as its financial advisor in connection with the mergers. Bioventus selected Perella Weinberg based on its qualifications, expertise and reputation and its knowledge of the business and affairs of Bioventus, Misonix and the industries in which Bioventus and Misonix conduct their respective businesses. Perella Weinberg and its affiliates, as part of their investment banking business, are continually engaged in performing financial analyses with respect to businesses and their securities in connection with mergers and acquisitions, leveraged buyouts and other transactions as well as for corporate and other purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;28, 2021, Perella Weinberg rendered its oral opinion, subsequently confirmed in writing, to the Bioventus board that, as of such date and based upon and subject to the various assumptions made, procedures followed, matters considered and qualifications and limitations set forth therein, the per share merger consideration to be paid by Bioventus to the holders of shares of common stock of Misonix pursuant to the merger agreement was, as of the date of the opinion, fair, from a financial point of view, to Bioventus. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">The full text of Perella Weinberg&#8217;s written opinion, dated July&#160;29, 2021 which sets forth, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by Perella Weinberg, is attached hereto as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;B</div> and is incorporated by reference herein. Perella Weinberg&#8217;s opinion was not intended to be and does not constitute a recommendation to any holder of Bioventus common stock or any other person as to how such person should vote or otherwise act with respect to the mergers or any other matter. Perella Weinberg&#8217;s opinion </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">165 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">does not in any manner address the prices at which Misonix common stock or Bioventus common stock will trade at any time. In addition, Perella Weinberg expressed no opinion as to the fairness of the mergers to the holders of any class of securities, creditors or other constituents of Bioventus or Misonix or as to the underlying decision by any person to engage in the mergers or as to the relative merits of the mergers compared to alternative transactions or business strategies. Perella Weinberg provided its opinion for the information and assistance of the Bioventus board in connection with, and for the purposes of its evaluation of, the mergers. This summary is qualified in its entirety by reference to the full text of the opinion. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In arriving at its opinion, Perella Weinberg, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain publicly available financial statements and other publicly available business and financial information with respect to Misonix and Bioventus, including equity research analyst reports; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain publicly available financial forecasts relating to the business and financial prospects of Misonix, derived from a consensus of selected equity research analysts that were identified by Misonix&#8217;s management and discussed with Perella Weinberg by Misonix for use in Perella Weinberg&#8217;s analysis, as adjusted by Bioventus management, and which forecasts were extrapolated by the management of Bioventus for certain fiscal years (the &#8220;Adjusted and Extrapolated Misonix Street Forecasts&#8221;) and approved for Perella Weinberg&#8217;s use by Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain publicly available financial forecasts relating to the business and financial prospects of Bioventus, derived from a consensus of selected equity research analysts that were identified by Bioventus&#8217;s management, as adjusted by the management of Bioventus (the &#8220;Adjusted Bioventus Street Forecasts&#8221;), and approved for Perella Weinberg&#8217;s use by Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain internal financial statements, analyses and/or other financial and operating data relating to the business of Misonix and Bioventus, prepared by the management of Misonix and the management of Bioventus, respectively; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discussed the past and current business, operations, financial condition and prospects of Misonix with representatives of Misonix and Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discussed the past and current business, operations, financial condition and prospects of Bioventus with representatives of Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discussed with members of the senior managements of Misonix and Bioventus their assessment of the strategic rationale for, and the potential benefits of, the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain estimates as to the amount and timing of certain cost savings anticipated by the management of Bioventus to result from the consummation of the mergers (the &#8220;Cost Savings&#8221;), as prepared by the management of Bioventus and approved for Perella Weinberg&#8217;s use by Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compared the financial performance of Misonix and Bioventus with that of certain publicly-traded companies which Perella Weinberg believed to be generally relevant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compared the financial terms of the mergers with the publicly available financial terms of certain other transactions which Perella Weinberg believed to be generally relevant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed the historical trading prices for Misonix common stock and Bioventus common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">participated in discussions among representatives of Misonix and Bioventus and their respective advisors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed a draft of the merger agreement dated July&#160;28, 2021; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducted such other financial studies, analyses and investigations, and considered such other factors, as Perella Weinberg deemed appropriate. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">166 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of its opinion, Perella Weinberg assumed and relied upon, without independent verification, the accuracy and completeness of the financial and other information supplied or otherwise made available to it (including information that was available from generally recognized public sources) for purposes of its opinion and further relied upon the assurances of the management of Bioventus that such information did not contain any material omissions or misstatements of material fact. At Bioventus&#8217;s direction, Perella Weinberg relied on the Adjusted and Extrapolated Misonix Street Forecasts, the Cost Savings and the Adjusted Bioventus Street Forecasts. With respect to the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings, Perella Weinberg assumed, with Bioventus&#8217;s consent, that they had been reasonably prepared on bases reflecting the best then available estimates and good faith judgments of the management of Bioventus as to the matters covered thereby and Perella Weinberg expressed no view as to the assumptions on which they were based. In that regard, Perella Weinberg was advised by Bioventus, and assumed, with Bioventus&#8217;s consent, that the Adjusted and Extrapolated Misonix Street Forecasts and Cost Savings were a reasonable basis upon which to evaluate the future financial performance of Misonix and Perella Weinberg used the Adjusted and Extrapolated Misonix Street Forecasts and Cost Savings in its analysis. Perella Weinberg further assumed, with Bioventus&#8217;s consent, that the Adjusted Bioventus Street Forecasts represented the best then available estimates as to the matters covered thereby. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In arriving at its opinion, Perella Weinberg did not make and was not provided with any independent valuation or appraisal of the assets or liabilities (including any contingent, derivative or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance-sheet</div> assets and liabilities) of Misonix or Bioventus, nor any of their respective subsidiaries. Perella Weinberg did not assume any obligation to conduct, nor did it conduct, any physical inspection of the properties or facilities of Misonix or Bioventus. In addition, Perella Weinberg did not evaluate the solvency of any party to the merger agreement, or the impact of the mergers thereon, including under any applicable laws relating to bankruptcy, insolvency or similar matters. Perella Weinberg also assumed that the final executed merger agreement would not differ from the draft merger agreement reviewed by it in any respect material to its analysis, and that the mergers would be consummated in accordance with the terms set forth in the merger agreement, without modification, waiver or delay in any respect material to its analysis. In addition, Perella Weinberg assumed that in connection with the receipt of all the necessary approvals for the mergers, no delays, limitations, conditions or restrictions would be imposed that could have an adverse effect on Misonix, Bioventus or the contemplated benefits of the mergers, in each case, in any way material to its analysis. Perella Weinberg relied as to all legal matters relevant to rendering its opinion upon the advice of counsel. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg&#8217;s opinion addressed only the fairness from a financial point of view, as of the date thereof, of the Merger Consideration to be paid by Bioventus pursuant to the merger agreement. Perella Weinberg was not asked to, and it did not, offer any opinion as to any other term of the merger agreement or any other related document, the form, structure or financing of the mergers or the likely timeframe in which the mergers will be consummated. Perella Weinberg expressed no opinion with respect to the allocation of the cash election consideration and stock election consideration among the holders of Misonix common stock. In addition, Perella Weinberg expressed no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors or employees of any party to the mergers, or any class of such persons, relative to the merger consideration or otherwise. Perella Weinberg expressed no opinion as to the fairness of the mergers to the holders of any other class of securities, creditors or other constituencies of Bioventus or Misonix or as to the underlying decision by any person to engage in the mergers or as to the relative merits of the mergers compared to any alternative transactions or business strategies. Nor did Perella Weinberg express any opinion as to any tax or other consequences that may result from the transactions contemplated by the merger agreement or any related document, nor did its opinion address any legal, tax, regulatory or accounting matters, as to which it understood Bioventus had received such advice as it deemed necessary from qualified professionals. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg&#8217;s opinion was necessarily based on financial, economic, market and other conditions as in effect on, and the information made available to it as of, the date of its opinion. Subsequent developments may affect Perella Weinberg&#8217;s opinion and the assumptions used in preparing such opinion, and Perella Weinberg </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">167 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">does not have any obligation to update, revise, or reaffirm its opinion. The issuance of Perella Weinberg&#8217;s opinion was approved by a fairness opinion committee of Perella Weinberg. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Material Financial Analyses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following is a summary of the material financial analyses performed by Perella Weinberg and reviewed with the Bioventus board in connection with Perella Weinberg&#8217;s opinion and does not purport to be a complete description of the financial analyses performed by Perella Weinberg. The order of analyses described below does not represent the relative importance or weight given to those analyses by Perella Weinberg.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> Some of the</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> summaries of the financial analyses include information presented in tabular format. In order to</div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">fully</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> understand Perella Weinberg&#8217;s financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data below without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of Perella Weinberg&#8217;s financial analyses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus &#8211; Selected Publicly Traded Companies Analysis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg reviewed and compared certain financial information for Bioventus with corresponding financial information, ratios and public market multiples for the following publicly held companies in the medical technology and devices industry, or the Selected Bioventus Publicly Traded Companies. Although none of the following Selected Bioventus Publicly Traded Companies is identical to Bioventus, Perella Weinberg selected these companies because they had publicly traded equity securities and were deemed to be similar to Bioventus in one or more respects, including operating in the medical technology and devices industry. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected Bioventus Publicly Traded Companies</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alphatec Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anika Therapeutics, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Axogen, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONMED Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Globus Medical, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integra LifeSciences Holdings Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NuVasive, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organogenesis Holdings Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orthofix Medical Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SeaSpine Holdings Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surgalign Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vericel Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For each of the Selected Bioventus Publicly Traded Companies and Bioventus, Perella Weinberg calculated and compared financial information and various financial market multiples and ratios. For each of the Selected Bioventus Publicly Traded Companies, Perella Weinberg based its calculations on company filings for historical information and median consensus third-party research estimates. For Bioventus, Perella Weinberg based its calculations on Bioventus filings and on the Adjusted Bioventus Street Forecasts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">With respect to Bioventus and each of the Selected Bioventus Publicly Traded Companies for which relevant data was available, Perella Weinberg reviewed enterprise value, or EV (calculated as equity value including all outstanding restricted stock units and stock options (whether vested or unvested), and with respect to stock options, using the treasury stock method, plus debt and net <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> liabilities, less cash and cash equivalents), as of July&#160;27, 2021, the day before Perella Weinberg rendered its oral opinion to the Bioventus </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">168 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">board, as a multiple of 2021 and 2022 estimated revenue and as a multiple of 2021 and 2022 estimated adjusted EBITDA (calculated as earnings before interest, tax, depreciation and amortization). The results of these analyses are summarized in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 57%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EV/2021E and 2022E Revenue and EBITDA Multiples</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EV/2021E<br/>revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EV/2022E<br/>revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EV/2021E<br/>Adj.<br/>EBITDA</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EV/2022E<br/>Adj.<br/>EBITDA</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected Bioventus Publicly Traded Companies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alphatec Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anika Therapeutics, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Axogen, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONMED Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.2x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Globus Medical, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integra LifeSciences Holdings Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NuVasive, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.2x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organogenesis Holdings Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.2x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orthofix Medical Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.2x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SeaSpine Holdings Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Surgalign Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vericel Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Median</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.2x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multiple excluded from Perella Weinberg&#8217;s analysis because the relevant EBITDA value was negative and considered not meaningful, &#8220;NM&#8221;. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multiple excluded from Perella Weinberg&#8217;s analysis because the figure was greater than 50.0x and considered not meaningful, &#8220;NM&#8221;. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the multiples of enterprise value to estimated 2021 and 2022 revenue described above, Perella Weinberg&#8217;s analyses of the various Selected Bioventus Publicly Traded Companies and on professional judgments made by Perella Weinberg, Perella Weinberg applied ranges of multiples of 3.75x to 6.00x to Bioventus&#8217;s estimated 2021 revenue and a range of multiples of 3.25x to 5.25x to Bioventus&#8217;s estimated 2022 revenue to derive ranges of estimated implied values per share of Bioventus common stock of approximately $24.36 to $42.03 per share (the &#8220;Bioventus 2021 Revenue Implied Value Range&#8221;) and approximately $23.61 to $41.12 per share (the &#8220;Bioventus 2022 Revenue Implied Value Range&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the multiples of enterprise value to estimated 2021 and 2022 EBITDA described above, Perella Weinberg&#8217;s analyses of the various Selected Bioventus Publicly Traded Companies and on professional judgments made by Perella Weinberg, Perella Weinberg applied a range of multiples of 24.0x to 29.0x to Bioventus&#8217;s estimated 2021 EBITDA and a range of multiples of 21.0x to 24.0x to Bioventus&#8217;s estimated 2022 EBITDA to derive ranges of estimated implied values per share of Bioventus common stock of approximately $29.83 to $38.62 per share and approximately $30.66 to $37.48 per share, respectively. Perella Weinberg compared these ranges to the closing per share price of Bioventus common stock of $16.81 on July&#160;27, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg calculated an implied offer value per share of Misonix common stock by (i)&#160;multiplying each of the Bioventus 2021 Revenue Implied Value Range and the Bioventus 2022 Revenue Implied Value Range by 1.0524 and (ii)&#160;adding $10.50, representing the aggregate consideration to be paid for each share of Misonix common stock, to derive ranges of estimated implied offer values per share of Misonix common stock of approximately $36.14 to $54.74 per share (the &#8220;Bioventus 2021 Revenue Implied Offer Value Range&#8221;) and approximately $35.35 and $53.78 per share (the &#8220;Bioventus 2022 Revenue Implied Offer Value Range&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Selected Bioventus Publicly Traded Companies were used for comparison purposes, no business of any Selected Bioventus Publicly Traded Company was either identical or directly comparable to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">169 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217;s business. Accordingly, Perella Weinberg&#8217;s comparison of the Selected Bioventus Publicly Traded Companies to Bioventus and analysis of the results of such comparisons was not purely mathematical, but instead necessarily involved complex considerations and judgments concerning differences in financial and operating characteristics and other factors that could affect the relative values of the Selected Bioventus Publicly Traded Companies and Bioventus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus &#8211; Discounted Cash Flow Analysis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg conducted a discounted cash flow analysis for Bioventus based on company filings and the Adjusted Bioventus Street Forecasts to derive a range of implied enterprise values for Bioventus by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">calculating the present value as of July&#160;27, 2021 of the estimated standalone unlevered free cash flows (calculated as adjusted operating income after taxes, plus depreciation, minus capital expenditures, and adjusting for changes in net working capital) that Bioventus could generate for the second half of calendar year 2021 and the complete calendar years 2022 through 2025 using discount rates ranging from 7.75% to 8.75% based on estimates of the weighted average cost of capital of Bioventus derived using the CAPM, and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adding the present value as of July&#160;27, 2021 of the terminal value of Bioventus at the end of calendar year 2025 using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 7.75% to 8.75%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg estimated the range of perpetuity growth rates utilizing its professional judgment and experience, taking into account market expectations regarding long-term real growth of gross domestic product and inflation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg used discount rates ranging from of 7.75% to 8.75% derived by the application of the CAPM, which takes into account certain company-specific metrics, including Bioventus&#8217;s target capital structure, the cost of long-term debt and forecasted tax rate, and Bioventus&#8217;s unlevered beta as estimated with reference to the Bioventus Selected Publicly Traded Companies&#8217; predicted betas, as well as certain financial metrics for the United States financial markets generally. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">From the range of implied enterprise values, Perella Weinberg derived a range of implied equity values for Bioventus. To calculate the implied equity value from the implied enterprise value, Perella Weinberg added cash and cash equivalents and subtracted debt and net <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> liabilities. Perella Weinberg calculated implied equity value per share by dividing the implied equity value by fully diluted shares (derived by using the treasury stock method based on values implied using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 7.75% to 8.75%). This analysis resulted in a range of implied values per share of Bioventus common stock of approximately $22.52 to $33.99 per share (the &#8220;Bioventus DCF Implied Value Range&#8221;). Perella Weinberg compared this range to the closing price per share of Bioventus common stock of $16.81 on July&#160;27, 2021. Perella Weinberg calculated an implied offer value per share of Misonix common stock by (i)&#160;multiplying the Bioventus DCF Implied Value Range by 1.0524 and (ii)&#160;adding $10.50, representing the consideration to be paid for each share of Misonix common stock, in the aggregate, to derive a range of estimated implied offer values per share of approximately $34.20 to $46.27 per share (the &#8220;Bioventus DCF Implied Offer Value Range&#8221;). </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix &#8211; Selected Publicly Traded Companies Analysis </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg reviewed and compared certain financial information for Misonix with corresponding financial information, ratios and public market multiples for the following publicly traded companies in the medical technology and devices industry, or the Selected Misonix Publicly Traded Companies, and Bioventus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">170 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although none of the Selected Misonix Publicly Traded Companies is identical to Misonix, Perella Weinberg selected these companies because they had publicly traded equity securities and were deemed to be similar to Misonix in one or more respects, including operating in the medical technology and devices industry. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected Misonix Publicly Traded Companies</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alphatec Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anika Therapeutics, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Apyx Medical Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Axogen, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONMED Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Globus Medical, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integra LifeSciences Holdings Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MiMedx Group, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NuVasive, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organogenesis Holdings Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PolarityTE, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vericel Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For each of the Selected Misonix Publicly Traded Companies and Bioventus, Perella Weinberg calculated and compared financial information and various financial market multiples and ratios based on company filings and median consensus third-party research estimates. For Misonix, Perella Weinberg based its calculations on company filings and the Adjusted and Extrapolated Misonix Street Forecasts. For Bioventus, Perella Weinberg based its calculations on company filings and the Adjusted Bioventus Street Forecasts. Perella Weinberg calculated the Misonix implied equity value as $518&#160;million based on Bioventus&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">seven-day</div> VWAP of $16.6284 as of July&#160;27, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to each of the Selected Misonix Publicly Traded Companies and Bioventus, Perella Weinberg calculated the multiple of enterprise value, or EV, as of July&#160;27, 2021, to estimated 2021 and 2022 revenue. Perella Weinberg calculated the same multiples for Misonix based upon Misonix&#8217;s closing price of $23.20 as of July&#160;27, 2021. The results of these analyses are summarized in the following tables: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EV/2021E and 2022E Revenue Multiples</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected Misonix Publicly Traded Companies</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alphatec Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anika Therapeutics, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Apyx Medical Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Axogen, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONMED Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Globus Medical, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integra LifeSciences Holdings Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MiMedx Group, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NuVasive, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organogenesis Holdings Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PolarityTE, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vericel Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Median</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the multiples of enterprise value to estimated 2021 revenue and estimated 2022 revenue described above, Perella Weinberg&#8217;s analyses of the Selected Misonix Publicly Traded Companies and on professional judgments made by Perella Weinberg, Perella Weinberg applied ranges of multiples of 4.50x to 9.00x to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">171 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s estimated 2021 revenue and a range of 4.50x to 7.50x to Misonix&#8217;s estimated 2022 revenue to derive ranges of implied per share equity values for Misonix of approximately $19.14 to $40.45 per share and approximately $22.31 to $39.50 per share, respectively. Perella Weinberg compared these ranges to the closing per share price of Misonix common stock of $23.30 on July&#160;27, 2021, the Merger Consideration of $28.00 per share of Misonix common stock and the Bioventus 2021 Revenue Implied Offer Value Range and the Bioventus 2022 Revenue Implied Offer Value Range of approximately $36.14 to $54.74 per share and approximately $35.35 to $53.78 per share, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Selected Misonix Publicly Traded Companies were used for comparison purposes, no business of any Selected Misonix Publicly Traded Company was either identical or directly comparable to Misonix&#8217;s business. Accordingly, Perella Weinberg&#8217;s comparison of the Selected Misonix Publicly Traded Companies to Misonix and analysis of the results of such comparisons was not purely mathematical, but instead necessarily involved complex considerations and judgments concerning differences in financial and operating characteristics and other factors that could affect the relative values of the Selected Misonix Publicly Traded Companies and Misonix. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix &#8211;Discounted Cash Flow Analysis (Standalone) </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg conducted a discounted cash flow analysis for Misonix based on the Adjusted and Extrapolated Misonix Street Forecasts to derive a range of implied enterprise values for Misonix by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">calculating the present value as of July&#160;27, 2021 of the estimated standalone unlevered free cash flows (calculated as adjusted operating income after taxes, plus depreciation, minus capital expenditures, and adjusting for changes in net working capital) that Misonix could generate for the second half of calendar year 2021 and the complete calendar years 2022 through 2031, as included in the Adjusted and Extrapolated Misonix Street Forecasts, using discount rates ranging from 8.5% to 9.5% based on estimates of the weighted average cost of capital of Misonix derived using the capital asset pricing model, or CAPM, and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adding the present value as of July&#160;27, 2021 of the terminal value of Misonix at the end of calendar year 2031 using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 8.5% to 9.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg estimated the range of perpetuity growth rates utilizing its professional judgment and experience, taking into account market expectations regarding long-term real growth of gross domestic product and inflation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg used discount rates ranging from 8.5% to 9.5% derived by the application of the CAPM, which takes into account certain company-specific metrics, including Misonix&#8217;s target capital structure, the cost of long-term debt and forecasted tax rate, and Misonix&#8217;s unlevered beta as estimated with reference to the Misonix Selected Publicly Traded Companies&#8217; predicted betas and on professional judgments made by Perella Weinberg, as well as certain financial metrics for the United States financial markets generally. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From the range of implied enterprise value, Perella Weinberg derived a range of implied equity values for Misonix. To calculate the implied equity value from the implied enterprise value, Perella Weinberg added cash and cash equivalents and subtracted debt. Perella Weinberg calculated implied equity value per share by dividing the implied equity value by fully diluted shares (derived by using the treasury stock method based on values implied by using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 8.5% to 9.5%). This analysis resulted in a range of implied value per share of Misonix common stock of approximately $26.55 to $38.54 per share. Perella Weinberg compared this range to the closing per share price of Misonix common stock of $23.30 on July&#160;27, 2021, the Merger Consideration of $28.00 per share, and the Bioventus DCF Implied Offer Value Range of approximately $34.20 to $46.27 per share. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">172 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix&#8212;Discounted Cash Flow Analysis (Including Cost Savings) </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg conducted a discounted cash flow analysis for Misonix based on the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings to derive a range of implied enterprise values for Misonix by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">calculating the present value as of July&#160;27, 2021 of the estimated unlevered free cash flows (calculated as adjusted operating income after taxes, plus depreciation, minus capital expenditures, and adjusting for changes in net working capital) that Misonix could generate for the second half of the calendar year 2021 and the complete calendar years 2022 through 2031, as included in the Adjusted and Extrapolated Misonix Street Forecasts, using discount rates ranging from 8.5% to 9.5% based on estimates of the weighted average cost of capital of Misonix derived using the capital asset pricing model, or CAPM, and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adding the present value as of July&#160;27, 2021 of the terminal value of Misonix at the end of calendar year 2031 using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 8.5% to 9.5%, and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adding the present value as of July&#160;27, 2021 of the cost savings and related cash flows. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg estimated the range of perpetuity growth rates utilizing its professional judgment and experience, taking into account market expectations regarding long-term real growth of gross domestic product and inflation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg used discount rates ranging from 8.5% to 9.5% derived by the application of the CAPM, which takes into account certain company-specific metrics, including Misonix&#8217;s target capital structure, the cost of long-term debt and forecasted tax rate, and Misonix&#8217;s unlevered beta as estimated with reference to the Misonix Selected Publicly Traded Companies&#8217; predicted Barra betas and on professional judgments made by Perella Weinberg, as well as certain financial metrics for the United States financial markets generally. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From the range of implied enterprise values, Perella Weinberg derived a range of implied equity values for Misonix. To calculate the implied equity value from the implied enterprise value, Perella Weinberg added cash and cash equivalents and subtracted debt. Perella Weinberg calculated implied equity value per share by dividing the implied equity value by fully diluted shares (derived by using the treasury stock method based on values implied by using perpetuity growth rates ranging from 3.0% to 4.0% and using discount rates ranging from 8.5% to 9.5%). This analysis resulted in a range of implied value per share of Misonix common stock of approximately $42.28 to $60.62 per share. Perella Weinberg compared these range to the closing per share price of Misonix common stock of $23.30 on July&#160;27, 2021 and the Merger Consideration of $28.00 per share, and the Bioventus DCF Implied Offer Value Range of approximately $34.20 to $46.27 per share. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected Transactions Analysis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using publicly available information, Perella Weinberg reviewed the financial terms of nineteen selected precedent transactions, or the Selected Transactions, involving companies that operated in, or were exposed to, the medical technology and devices industry. Perella Weinberg selected these transactions in the exercise of its professional judgment and experience because Perella Weinberg deemed them to be most similar in size, scope and impact on the industry to Misonix or otherwise relevant to the mergers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For each of the Selected Transactions, Perella Weinberg calculated and compared the resulting enterprise value in the transaction as (i)&#160;a multiple of revenue over the last twelve months, referred to as LTM Revenue, publicly reported prior to or at the announcement of the transaction, referred to as EV/LTM Revenue and (ii)&#160;a multiple of revenue over the next twelve months, referred to as NTM Revenue, publicly reported prior to or at the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">173 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">announcement of the transaction, referred to as EV/NTM Revenue. The following table lists the Selected Transactions and summarizes the observed EV/LTM Revenue and EV/NTM Revenue multiples: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 27%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 30%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Announcement Date</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Target</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Acquiror</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EV/LTM<br/>Revenue<br/>Multiple</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">EV/NTM<br/>Revenue<br/>Multiple</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">March 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Lumenis&#160;Ltd.&#160;(Surgical&#160;Business)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Boston&#160;Scientific&#160;Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">N/A</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">5.4x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">January 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Preventice Solutions, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Boston Scientific Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7.8x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">N/A</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">January 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Cantel Medical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Steris plc</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">4.3x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">3.9x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">December 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">BioTelemetry, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Koninklijke Philips N.V.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">6.2x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">5.3x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">December 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">ACell, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Integra&#160;LifeSciences&#160;Holdings<br/>Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">4.0x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">N/A</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">October 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Key Surgical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Steris plc</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">N/A</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">5.0x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">July 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Medicrea International</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Medtronic plc</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7.6x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7.3x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">January 2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Arthrosurface, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Anika Therapeutics, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">3.4x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">N/A</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">November 2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Wright Medical Group N.V.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Stryker Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">5.8x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">5.5x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">July 2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Hu-Friedy</div> Manufacturing Co., LLC</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cantel Medical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">3.6x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">N/A</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">May 2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Vertiflex, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Boston Scientific Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">18.0x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">9.4x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">March 2019</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">MyoScience, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Pacira Pharmaceuticals Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">40.3x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">N/A</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">December 2018</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Buffalo Filter LLC</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">CONMED Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">8.3x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7.6x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">August 2018</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Cartiva, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Wright Medical Group N.V.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">18.0x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">12.4x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">December 2017</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Entellus Medical, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Stryker Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">8.2x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">6.3x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">October 2017</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Jotec GmbH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">CryoLife, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">4.4x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">3.8x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">June 2017</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Novadaq Technologies Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Stryker Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">7.8x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">6.0x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">February 2017</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">ZELTIQ Aesthetics, Inc.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Allergan plc</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">6.8x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">5.9x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">February 2016</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Sage Products LLC</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Stryker Corporation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">6.5x</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(9)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">N/A</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Mean</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">9.5x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">6.4x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Median</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">6.8x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">5.9x</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NTM calculated using expected 2021 revenues. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction value includes the approximately 22% of Preventice Solutions already owned by Boston Scientific Corporation; LTM calculated using 2020 revenues. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction value includes $300&#160;million upfront and a $100&#160;million earnout; LTM revenue calculated as of March&#160;31, 2020, the latest date for which filings were available. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction value includes approximately $40&#160;million of tax benefit; NTM calculated using expected 2020 revenues. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction value includes $60&#160;million upfront and a $40&#160;million earnout; LTM calculated using expected 2019 revenues. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction value includes $50&#160;million of milestone payments and $100&#160;million of tax benefits. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction value includes $465&#160;million upfront and a $100&#160;million earnout; LTM revenue uses 2018 revenues; NTM Revenue calculated using expected 2019 revenues. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction value includes $120&#160;million upfront and a $100&#160;million earnout. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(9)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction value includes $500&#160;million of tax asset. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the multiples of enterprise value to LTM Revenue described above, Perella Weinberg&#8217;s analyses of the various Selected Transactions and on professional judgments made by Perella Weinberg, Perella Weinberg applied a range of multiples of 4.50x to 8.50x to Misonix&#8217;s revenue for the last twelve months as of June&#160;30, 2021 to derive a range of implied equity values per share of Misonix of approximately $17.75 to $35.20. Perella Weinberg compared these ranges to the closing per share price of Misonix common stock of $23.30 on July&#160;27, 2021 and the Merger Consideration of $28.00 per share. Based on the multiples of enterprise value to NTM Revenue described above, Perella Weinberg&#8217;s analyses of the various Selected Transactions and on professional judgments made by Perella Weinberg, Perella Weinberg applied a range of multiples of 4.00x to 6.50x to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">174 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s NTM Revenue as of June&#160;30, 2021 in the Adjusted and Extrapolated Misonix Street Forecasts to derive a range of implied equity values per share of Misonix of approximately $18.51 to $31.53. Perella Weinberg compared these ranges to the closing per share price of Misonix common stock of $23.30 on July&#160;27, 2021 and the Merger Consideration of $28.00 per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Selected Transactions were used for comparison purposes, none of the Selected Transactions nor the companies involved in them was either identical or directly comparable to the transaction, Misonix or Bioventus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Additional Information </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg observed additional information that was not considered part of Perella Weinberg&#8217;s financial analysis with respect to its opinion, but which was noted as reference data for the Bioventus board, including the following: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Historical Stock Trading.</div></div> Perella Weinberg reviewed the closing prices of Bioventus and Misonix common stock on the&#160;Nasdaq for the 52 weeks ended on July&#160;27, 2021. Perella Weinberg observed that during such period, the closing&#160;trading price per share of Bioventus common stock ranged from $10.74 to $19.94 per share, as compared to the&#160;closing per share price of Bioventus common stock of $16.81 on July&#160;27, 2021, and the closing trading price per share of Misonix common stock ranged from $11.04 to $24.42 per share, as compared to the closing per share price of Misonix common stock of $23.30 on July&#160;27, 2021 and the cash election consideration of $28.00 per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Research Analyst Price Targets</div></div>. Perella Weinberg reviewed and analyzed recent publicly available&#160;third-party&#160;research analyst price targets for the Bioventus and Misonix common stock.&#160;Based on this review,&#160;Perella Weinberg&#160;noted that the range of recent equity analyst price targets for the shares of Bioventus common stock ranged from a low of $19.00 to a high of $23.00 per share, as compared to the closing per share price of&#160;Bioventus common stock of $16.81 on July&#160;27, 2021, and the recent equity analyst price targets for the shares of Misonix common stock, $23.00 per share, as compared to the closing price per share of&#160;Misonix common stock of $23.30 on July&#160;27, 2021 and the cash election consideration of $28.00 per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The public market trading price targets published by equity research analysts do not necessarily reflect current market trading prices for Bioventus common stock or Misonix common stock. Further, these estimates are subject to uncertainties, including the future financial performance of Bioventus and Misonix and future financial market conditions. However, these estimates provided general reference points which enabled Perella Weinberg to compare such estimates with the closing price per share on July&#160;27, 2021 of Bioventus common stock and Misonix common stock of $16.81 and $23.30, respectively, and the cash election consideration of $28.00 per share. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Miscellaneous </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of a fairness opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. Selecting portions of the analyses or of the summary set forth herein, without considering the analyses or the summary as a whole could create an incomplete view of the processes underlying Perella Weinberg&#8217;s opinion. In arriving at its fairness determination, Perella Weinberg considered the results of all of its analyses and did not attribute any particular weight to any factor or analysis considered. Rather, Perella Weinberg made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of its analyses. No company or transaction used in the analyses described herein as a comparison is directly comparable to Misonix, Bioventus or the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg prepared the analyses described herein for purposes of providing its opinion to the Bioventus board as to the fairness, from a financial point of view, as of the date of such opinion, of the Merger Consideration </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">175 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to Bioventus. These analyses do not purport to be appraisals or necessarily reflect the prices at which businesses or securities actually may be sold. Perella Weinberg&#8217;s analyses were based in part upon the Adjusted and Extrapolated Misonix Street Forecasts, the Cost Savings and the Adjusted Bioventus Street Forecasts, which are not necessarily indicative of actual future results, and which may be significantly more or less favorable than suggested by Perella Weinberg&#8217;s analyses. Because these analyses are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties to the merger agreement or their respective advisors, none of Bioventus, Perella Weinberg or any other person assumes responsibility if future results are materially different from those forecasted by Bioventus management or third parties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described above, the opinion of Perella Weinberg to the Bioventus board was one of many factors taken into consideration by the Bioventus board in making its determination to approve the merger. Also, as discussed above, Perella Weinberg&#8217;s opinion was not intended to be and does not constitute a recommendation to any holder of Bioventus common stock or any other person as to how such person should vote or otherwise act with respect to the merger or any other matter and does not in any manner address the prices at which Misonix common stock or Bioventus common stock will trade at any time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Perella Weinberg has acted as financial advisor to Bioventus in connection with the mergers and pursuant to the terms of the engagement letter between Perella Weinberg and Bioventus, dated July&#160;21, 2021, Bioventus agreed to pay Perella Weinberg $1.5&#160;million upon the delivery of Perella Weinberg&#8217;s opinion (which amount would have become payable if Perella Weinberg had determined that it was not able to deliver its opinion), and has agreed to pay Perella Weinberg an additional fee of $3.5&#160;million upon the closing of the mergers.&#160;In addition, Bioventus agreed to reimburse Perella Weinberg for certain reasonable expenses, including attorneys&#8217; fees and disbursements, and to indemnify Perella Weinberg and related persons for certain liabilities that may arise out of its engagement by Bioventus and the rendering of its opinion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except in connection with Perella Weinberg&#8217;s engagement as financial advisor to Bioventus in connection with the mergers, during the two year period prior to the date hereof, no material relationship existed between Perella Weinberg and its affiliates, on the one hand, and Bioventus, Misonix or any of their respective affiliates, on the other hand, pursuant to which Perella Weinberg or its affiliates have received or anticipate receiving compensation. However, Perella Weinberg and its affiliates in the future may provide investment banking and other financial services to Bioventus and/or Misonix and their respective affiliates and in the future may receive compensation for the rendering of these services. In the ordinary course of its business activities, Perella Weinberg or its affiliates may at any time hold long or short positions, and may trade or otherwise effect transactions, for its account or the accounts of clients, in debt, equity or other securities (or related derivative securities) or financial instruments (including bank loans or other obligations) of Bioventus, Misonix or their respective affiliates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion of Misonix&#8217;s Financial Advisor </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion of JP Morgan Securities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to an engagement letter, Misonix retained J.P. Morgan as its financial advisor in connection with a potential transaction involving a change of control of Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the meeting of the Misonix board on July&#160;28, 2021, J.P. Morgan rendered its oral opinion to the Misonix board that, as of such date and based upon and subject to the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P.&#160;Morgan in preparing its opinion, the merger consideration to be paid to the holders of Misonix common stock in the first merger was fair, from a financial point of view, to such holders. J.P. Morgan confirmed its July&#160;28, 2021 oral opinion by delivering its written opinion to the Misonix board, dated July&#160;29, 2021, that, as of such date, the merger consideration to be paid to the holders of Misonix common stock in the first merger was fair, from a financial point of view, to such holders. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">176 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The full text of the written opinion of J.P. Morgan dated July&#160;29, 2021, which sets forth, among other things, the assumptions made, procedures followed, matters considered and limitations on the review undertaken by J.P. Morgan, is attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex C</div> to this joint proxy statement/prospectus and is incorporated herein by reference. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The summary of the opinion of J.P. Morgan set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of such opinion. </div></div>Misonix stockholders are urged to read the opinion in its entirety. J.P. Morgan&#8217;s written opinion was addressed to the Misonix board (in its capacity as such) in connection with and for the purposes of its evaluation of the proposed first merger, was directed only to the merger consideration to be paid to the holders of Misonix common stock in the proposed first merger and did not address any other aspect of the proposed first merger. J.P. Morgan expressed no opinion as to the fairness of the merger consideration to the holders of any other class of securities, creditors or other constituencies of Misonix or as to the underlying decision by Misonix to engage in the proposed transactions. The issuance of J.P. Morgan&#8217;s opinion was approved by a fairness committee of J.P. Morgan. The summary of the opinion of J.P. Morgan set forth in this joint proxy statement/prospectus is qualified in its entirety by reference to the full text of such opinion. The opinion does not constitute a recommendation to any stockholder of Misonix as to how such stockholder should vote with respect to the Misonix merger proposal or any other matter. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In arriving at its opinion, J.P. Morgan, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain publicly available business and financial information concerning Misonix and Bioventus and the industries in which they operate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compared the proposed financial terms of the merger with the publicly available financial terms of certain transactions involving companies J.P. Morgan deemed relevant and the consideration paid for such companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compared the financial and operating performance of Misonix and Bioventus with publicly available information concerning certain other companies J.P. Morgan deemed relevant and reviewed the current and historical market prices of Misonix common stock and Bioventus class A common stock and certain publicly traded securities of such other companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain internal financial analyses and forecasts prepared by or at the direction of the management of Misonix relating to Misonix&#8217;s and Bioventus&#8217; respective businesses, as well as the estimated amount and timing of the cost synergies expected by the management of Misonix to result from the proposed first merger; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performed such other financial studies and analyses and considered such other information as J.P. Morgan deemed appropriate for the purposes of its opinion. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, J.P. Morgan held discussions with certain members of the management of Misonix and Bioventus with respect to certain aspects of the proposed first merger, and the past and current business operations of Misonix and Bioventus, the financial condition and future prospects and operations of Misonix and Bioventus, the effects of the first merger on the financial condition and future prospects of Misonix and Bioventus, and certain other matters J.P. Morgan believed necessary or appropriate to its inquiry. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In giving its opinion, J.P. Morgan relied upon and assumed the accuracy and completeness of all information that was publicly available or was furnished to or discussed with J.P. Morgan by Misonix and Bioventus or otherwise reviewed by or for J.P. Morgan. J.P. Morgan did not independently verify any such information or its accuracy or completeness and, pursuant to its engagement letter with Misonix, J.P. Morgan did not assume any obligation to undertake any such independent verification. J.P. Morgan did not conduct and was not provided with any valuation or appraisal of any assets or liabilities, nor did J.P. Morgan evaluate the solvency of Misonix or Bioventus under any state or federal laws relating to bankruptcy, insolvency or similar matters. In relying on financial analyses and forecasts provided to J.P. Morgan or derived therefrom, including the Misonix projected cost synergies, J.P. Morgan assumed that they were reasonably prepared based on assumptions reflecting the best </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">177 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">currently available estimates and judgments by Misonix management as to the expected future results of operations and financial condition of Misonix and Bioventus to which such analyses or forecasts relate. J.P. Morgan expressed no view as to such analyses or forecasts (including the Misonix projected cost synergies) or the assumptions on which they were based and J.P. Morgan expressed no opinion with respect to any other financial projections relating to Misonix or Bioventus provided to J.P. Morgan by Misonix or Bioventus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan also assumed that the proposed first merger and the other transactions contemplated by the merger agreement will be consummated as described in the merger agreement and this joint proxy statement/prospectus. J.P. Morgan also assumed that the representations and warranties made by Misonix, Bioventus, Merger Sub&#160;I, and Merger Sub&#160;II in the merger agreement and the related agreements were and will be true and correct in all respects material to its analysis. J.P. Morgan is not a legal, regulatory or tax expert and J.P. Morgan relied on the assessments made by advisors to Misonix with respect to such issues. J.P. Morgan further assumed that all material governmental, regulatory or other consents and approvals necessary for the consummation of the first merger will be obtained without any adverse effect on Misonix or Bioventus or on the contemplated benefits of the proposed first merger. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The projections furnished to J.P. Morgan were prepared by Misonix&#8217;s management as discussed more fully under<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;&#8220;Misonix Management&#8217;s Unaudited Prospective Financial Information&#8221;</div></div>, of this joint proxy statement/prospectus.&#160;Misonix does not publicly disclose internal management projections of the type provided to J.P. Morgan in connection with J.P. Morgan&#8217;s analysis of the proposed first merger, and such projections were not prepared with a view toward public disclosure. These projections were based on numerous variables and assumptions that are inherently uncertain and may be beyond the control of the Misonix&#8217;s management, including, without limitation, factors related to general economic and competitive conditions and prevailing interest rates. Accordingly, actual results could vary significantly from those set forth in such projections. For more information regarding the use of projections and other forward-looking statements, please refer to the section entitled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Management&#8217;s Unaudited Prospective Financial Information</div></div>&#8221; of this joint proxy statement/prospectus. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan&#8217;s opinion was necessarily based on economic, market and other conditions as in effect on, and the information made available to J.P. Morgan as of, the date of such opinion. J.P. Morgan&#8217;s opinion noted that subsequent developments may affect J.P. Morgan&#8217;s opinion, and that J.P. Morgan does not have any obligation to update, revise, or reaffirm such opinion. J.P. Morgan&#8217;s opinion is limited to the fairness, from a financial point of view, of the merger consideration to be paid to the holders of Misonix common stock in the proposed first merger, and J.P. Morgan has expressed no opinion as to the fairness of any consideration to be paid in connection with the proposed first merger to the holders of any other class of securities, creditors or other constituencies of Misonix or as to the underlying decision by Misonix to engage in the proposed first merger. Furthermore, J.P. Morgan expressed no opinion with respect to the amount or nature of any compensation to any officers, directors, or employees of any party to the proposed first merger, or any class of such persons relative to the merger consideration to be paid to the holders of Misonix common stock in the proposed first merger or with respect to the fairness of any such compensation. J.P. Morgan expressed no opinion as to the price at which the Misonix common stock or the Bioventus class A common stock will trade at any future time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The terms of the merger agreement, including the merger consideration, were determined through arm&#8217;s length negotiations between Misonix and Bioventus, and the decision to enter into the merger agreement was solely that of the Misonix board and the Bioventus board. J.P. Morgan&#8217;s opinion and financial analyses were only one of the many factors considered by the Misonix board in its evaluation of the proposed first merger and should not be viewed as determinative of the views of the Misonix board or management with respect to the proposed first merger or the merger consideration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with customary investment banking practice, J.P. Morgan employed generally accepted valuation methodology in rendering its oral opinion to the Misonix board on July&#160;28, 2021 (subsequently confirmed in writing on July&#160;29, 2021) and in the financial analysis presented to the Misonix board on July&#160;28, 2021 in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">connection with the rendering of such opinion. The following is a summary of the material financial analyses utilized by J.P. Morgan in connection with rendering its opinion to the Misonix board and does not purport to be a complete description of the analyses or data presented by J.P. Morgan. Some of the summaries of the financial analyses include information presented in tabular format. The tables are not intended to stand alone, and in order to more fully understand the financial analyses used by J.P. Morgan, the tables must be read together with the full text of each summary. Considering the data set forth below without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of J.P. Morgan&#8217;s analyses. In conducting its analyses, at the direction of Misonix&#8217;s management, J.P. Morgan used data included in, or calculated using, the Misonix Projections which are included in<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>the section entitled<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;&#8220;Misonix Management&#8217;s Unaudited Prospective Financial Information</div></div>&#8221;. At the direction of Misonix&#8217;s management and in accordance with the instructions of Misonix&#8217;s management, J.P. Morgan used the Misonix Projections as the underlying data for certain of J.P. Morgan&#8217;s analyses as discussed in this summary of J.P. Morgan&#8217;s opinion. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Misonix Financial Analyses </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Selected Public Trading Multiples Analysis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using publicly available information, J.P. Morgan compared selected financial data of Misonix with similar data for selected publicly traded companies engaged in businesses that J.P. Morgan judged to be sufficiently analogous to Misonix (or aspects thereof) based on J.P. Morgan&#8217;s experience and its familiarity with the industries in which Misonix operates. The companies selected by J.P. Morgan were: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ConvaTec Group plc; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integra LifeSciences Holdings Corporation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ConMed Corporation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NuVasive, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avanos Medical, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AxoGen, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orthofix Medical Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SurModics, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vapotherm, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anika Therapeutics, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intersect ENT, Inc.; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sientra, Inc. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These companies were selected, among other reasons, because they are publicly traded companies with operations and businesses that, for the purposes of J.P.&#160;Morgan&#8217;s analysis, may be considered similar to those of Misonix. However, certain of these companies may have characteristics that are materially different from those of Misonix. The analyses necessarily involve complex considerations and judgments concerning differences in financial and operational characteristics of the companies involved and other factors that could affect the selected companies differently than they would affect Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using publicly available information, J.P. Morgan calculated the firm value, which we refer to as the &#8220;FV,&#8221; for each of the selected companies (calculated as equity value, plus or minus, as applicable, net debt or net cash) as of July&#160;27, 2021, as a multiple of the analyst consensus estimates of calendar year 2021 and 2022 revenues for </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">179 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the applicable company (which we refer to as the &#8220;FV/2021E Revenue Multiple&#8221; and &#8220;FV/2022E Revenue Multiple,&#8221; respectively). The results of this analysis are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($ in<br/>millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Firm<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($ in<br/>millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FV/<br/>2021E<br/>Revenue<br/>Multiple</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FV/<br/>2022E<br/>Revenue<br/>Multiple</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ConvaTec Group plc</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,305</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integra LifeSciences Holdings Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,452</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ConMed Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NuVasive, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avanos Medical, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AxoGen, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orthofix Medical Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">712</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SurModics, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">777</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">755</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vapotherm, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anika Therapeutics, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">609</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intersect ENT, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">701</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sientra, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">439</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Median</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the results of this analysis and J.P. Morgan&#8217;s experience and professional judgment, J.P. Morgan selected a multiple reference range of 2.6x to 7.1x for FV/2021E Revenue and a multiple reference range of 2.5x to 6.3x for FV/2022E Revenue. J.P. Morgan then applied such reference ranges to Misonix&#8217;s revenue forecasts for the fiscal years ended June&#160;30, 2021 and 2022 (as applicable) that were included in the Misonix Projections. The analysis indicated the following ranges of implied equity value per share for the Misonix common stock (rounded to the nearest $0.10): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Implied&#160;Equity&#160;Value<br/>Per Share of<br/>Misonix common<br/>stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Low</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">High</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FV/2021E Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FV/2022E Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">J.P. Morgan compared the foregoing ranges of implied equity value per share for the Misonix common stock to the implied per share equity value of the merger consideration of $28.00 per share of Misonix common stock, calculated as of July&#160;27, 2021. The implied per share equity value of the merger consideration of $28.00 as used throughout this summary of J.P. Morgan&#8217;s opinion was calculated based on the sum of (A)&#160;a cash portion of merger consideration equal to $10.50 per share, and (B)&#160;a stock portion of merger consideration equal to 1.0524 shares of Bioventus common stock, valued at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">seven-day</div> volume-weighted average price per share of Bioventus class A common stock of $16.63 on July&#160;27, 2021. J.P. Morgan used this calculation for the implied value of the merger consideration throughout the Misonix Financial Analysis because regardless of whether Misonix stockholders elect to receive the cash merger consideration of $28.00 per share or the stock merger consideration of 1.6839 shares of Bioventus class A common stock for each share of their Misonix common stock, the aggregate cash paid by Bioventus in the first merger will be fixed at an amount equal to $10.50 multiplied by the number of shares of Misonix common stock outstanding on the election deadline and the cash and stock elections of the Misonix stockholders will be prorated such that this amount of cash is payable by Bioventus in the first merger. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Selected Transaction Multiples Analysis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using publicly available information, J.P. Morgan reviewed selected transactions involving businesses which J.P. Morgan judged to be analogous to Misonix&#8217;s business (or aspects thereof) based on J.P. Morgan&#8217;s experience and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">180 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">familiarity with the industries in which Misonix operates. The following transactions were selected by J.P. Morgan as relevant to the evaluation of the proposed first merger: </div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Target</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquiror</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Announcement Date</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BioTelemetry, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royal Philips</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;18, 2020</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wright Medical Group N.V.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stryker Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">November 04, 2019</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buffalo Filter LLC</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conmed Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;13, 2018</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">K2M Group Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stryker Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">August&#160;30, 2018</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Spectranetics Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royal Philips</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;28, 2017</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vascular Solutions, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teleflex Incorporated</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December 02, 2016</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LDR Holding Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Zimmer Biomet Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 07, 2016</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AngioScore Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Spectranetics Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">May&#160;27, 2014</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given Imaging Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Covidien plc</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December 08, 2013</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conceptus, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bayer Healthcare LLC</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;29, 2013</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None of the selected transactions reviewed was identical to the proposed first merger. However, the selected transactions were chosen because certain aspects of the transactions, for purposes of J.P.&#160;Morgan&#8217;s analysis, may be considered similar to the proposed first merger. The analyses necessarily involve complex considerations and judgments concerning differences in financial and operational characteristics of the companies involved and other factors that could affect the transactions differently than they would affect the proposed first merger. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using publicly available information, J.P. Morgan calculated, for each selected transaction, the multiple of the target company&#8217;s FV implied in the relevant transaction to the target company&#8217;s revenue for the twelve-month period after the announcement, which we refer to as the &#8220;NTM,&#8221; of the applicable transaction, which we refer to as the &#8220;FV/NTM Revenue Multiple.&#8221; The results of this analysis are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Target</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquiror</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Target&#160;Company<br/>FV Implied in<br/>the Transaction</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FV/NTM<br/>Revenue<br/>Multiple<br/>of Target<br/>Company</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BioTelemetry, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royal Philips</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,706</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Wright Medical Group N.V.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stryker Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buffalo Filter LLC</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conmed Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">365</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">K2M Group Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stryker Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,311</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Spectranetics Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royal Philips</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vascular Solutions, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teleflex Incorporated</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LDR Holding Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Zimmer Biomet Holdings, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AngioScore Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Spectranetics Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given Imaging Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Covidien plc</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">860</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conceptus, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bayer Healthcare LLC</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mean</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Median</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the above analysis, J.P. Morgan selected a FV/NTM Revenue Multiple reference range for Misonix of 3.7x to 7.5x. J.P. Morgan then applied such reference range to Misonix projected revenue for the twelve-month period ending December&#160;31, 2021. The analysis indicated a range of implied equity values per share of Misonix common stock (rounded to the nearest $0.10), of $16.10 to $31.80, which J.P. Morgan compared to the implied per share equity value of the merger consideration of $28.00 per share of Misonix common stock, calculated as of July&#160;27, 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">181 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Discounted Cash Flow Analysis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Excluding synergies: </div></div>Using the Misonix Projections, J.P. Morgan conducted a discounted cash flow analysis for the purpose of determining the fully diluted equity value per share of Misonix common stock (excluding cost synergies). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A discounted cash flow analysis is a valuation methodology used to derive a valuation of a company by calculating the present value of the company&#8217;s estimated future cash flows. A company&#8217;s &#8220;estimated future cash flows&#8221; are its projected unlevered free cash flows, and &#8220;present value&#8221; refers to the value today or as of an assumed date of the future cash flows or amounts and is obtained by discounting the estimated future cash flows or amounts by a discount rate that takes into account macroeconomic assumptions and estimates of risk, the opportunity cost of capital, capital structure, income taxes, expected returns and other appropriate factors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan calculated the unlevered free cash flow that Misonix is expected to generate from July&#160;1, 2021 through June&#160;30, 2026 using the Misonix Projections. J.P. Morgan also calculated a range of terminal values for Misonix at the end of this period by applying perpetual growth rates ranging from 3.0% to 4.0%, based on guidance provided by Misonix&#8217;s management, to estimates of the unlevered free cash flow of Misonix (excluding cost synergies) during fiscal year ending June&#160;30, 2026, as provided in the Misonix Projections. J.P. Morgan then discounted the unlevered free cash flow estimates (excluding cost synergies) and the range of terminal values to present value as of June&#160;30, 2021 using discount rates ranging from 10.25% to 12.25%, which range was chosen by J.P. Morgan using its professional judgment and experience based upon its analysis of a weighted average cost of capital of Misonix ranging from 10.25% to 12.25%. The present value of the unlevered free cash flow estimates and the range of terminal values were then adjusted by subtracting Misonix&#8217;s net debt as of June&#160;30, 2021. This analysis indicated a range of implied equity values for Misonix (excluding cost synergies), which J.P.&#160;Morgan divided by the number of outstanding shares of Misonix common stock, calculated on a fully-diluted basis (determined using the treasury stock method), to derive a range of implied equity values per share of Misonix common stock (rounded to the nearest $0.10) of $18.50 to $28.60, which J.P. Morgan compared to the implied per share equity value of the merger consideration of $28.00 per share of Misonix common stock, calculated as of July&#160;27, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Including synergies: </div></div>J.P. Morgan also conducted a discounted cash flow analysis for the purpose of determining the fully diluted equity value per share of Misonix common stock including cost synergies using the Misonix Projections. J.P. Morgan calculated the unlevered free cash flow that the Misonix projected cost synergies were expected to generate from July&#160;1, 2021 through December&#160;31, 2025 as set forth in the Misonix Projections. J.P. Morgan calculated a range of terminal values for Misonix projected cost synergies at the end of this period by applying perpetual growth rates ranging from 0.0% to 1.0%, based on guidance provided by Misonix&#8217;s management, to estimates of the unlevered free cash flow of the Misonix projected cost synergies during the year ending December&#160;31, 2025, as provided in the Misonix Projections. J.P. Morgan then discounted the unlevered free cash flow estimates of the Misonix projected cost synergies and the range of terminal values to present value as of June&#160;30, 2021 using discount rates ranging from 10.1% to 12.1%, which range was chosen by J.P. Morgan using its professional judgment and experience based upon its analysis of a weighted average cost of capital of Misonix and Bioventus of 10.1% to 12.1%. This analysis indicated a range of implied equity values for Misonix projected cost synergies. J.P. Morgan then adjusted the range of implied equity values for Misonix excluding cost synergies, as calculated pursuant to J.P. Morgan&#8217;s discounted cash flow analysis described above, by adding 50% of the implied equity value of the Misonix projected cost synergies applying 0.0% perpetual growth rate and 11.1% discount rate. J.P. Morgan selected a 0.0% perpetual growth rate based on guidance provided by the Misonix&#8217;s management, and an 11.1% discount rate was selected by J.P. Morgan using its professional judgment and experience based upon its analysis of the weighted average cost of capital of Misonix and Bioventus of 10.1% to 12.1%. This analysis indicated the range of implied equity values for Misonix including cost synergies, which J.P.&#160;Morgan divided by the number of outstanding shares of Misonix common stock, calculated on a fully-diluted basis (determined using the treasury stock method), to derive a range of implied equity values per share of Misonix common stock (rounded to the nearest $0.10) of $23.50 to $33.60, which J.P. Morgan compared to </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">182 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the implied per share equity value of the merger consideration of $28.00 per share of Misonix common stock, calculated as of July&#160;27, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Financial Analyses </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Selected Public Trading Multiples Analysis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using publicly available information, J.P. Morgan compared selected financial data of Bioventus with similar data for selected publicly traded companies engaged in businesses that J.P. Morgan judged to be sufficiently analogous to Bioventus (or aspects thereof) based on J.P. Morgan&#8217;s experience and its familiarity with the industries in which Bioventus operates. The companies selected by J.P. Morgan were: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Globus Medical, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Hill-Rom</div> Holdings, Inc.; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integra LifeSciences Holdings Corporation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ICU Medical, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ConMed Corporation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merit Medical Systems, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NuVasive, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medacta Group SA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avanos Medical, Inc.; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orthofix Medical Inc.; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anika Therapeutics, Inc. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These companies were selected, among other reasons, because they are publicly traded companies with operations and businesses that, for the purposes of J.P.&#160;Morgan&#8217;s analysis, may be considered similar to those of Bioventus. However, certain of these companies may have characteristics that are materially different from those of Bioventus. The analyses necessarily involve complex considerations and judgments concerning differences in financial and operational characteristics of the companies involved and other factors that could affect the selected companies differently than they would affect Bioventus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">183 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Using publicly available information, J.P. Morgan calculated the FV for each of the selected companies as of July 27, 2021 as a multiple of the analyst consensus estimates of (i)&#160;calendar year 2021 revenues for the applicable company (which we refer to as the &#8220;FV/2021E Revenue<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>Multiple&#8221;), (ii) calendar year 2022 revenues for the applicable company (which we refer to as the &#8220;FV/2022E Revenue Multiple&#8221;), (iii) calendar year 2021 earnings before interest, taxes, depreciation and amortization but after taking into account stock-based compensation expense, which we refer to as &#8220;Adjusted EBITDA,&#8221; for the applicable company (which we refer to as the &#8220;FV/2021E EBITDA Multiple&#8221;), and (iv)&#160;calendar year 2022 Adjusted EBITDA, for the applicable company (which we refer to as the &#8220;FV/2022E EBITDA Multiple&#8221;). The results of this analysis are as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($ in<br/>millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Firm<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($ in<br/>millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FV/<br/>2021E<br/>Revenue<br/>Multiple</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FV/<br/>2022E<br/>Revenue<br/>Multiple</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FV/<br/>2021E<br/>EBITDA<br/>Multiple</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FV/<br/>2021E<br/>EBITDA<br/>Multiple</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Globus Medical, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,808</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.2x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Hill-Rom</div> Holdings, Inc.</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,785</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.2x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integra LifeSciences Holdings Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,452</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ICU Medical, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,317</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,929</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.2x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ConMed Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merit Medical Systems, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,077</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.7x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NuVasive, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medacta Group SA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,989</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.9x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.4x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Avanos Medical, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orthofix Medical Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">712</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.5x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anika Therapeutics, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">609</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.0x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Median</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.6x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.1x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the results of this analysis and J.P. Morgan&#8217;s experience and professional judgment, J.P. Morgan selected a multiple reference range of 1.5x to 4.9x for FV/2021E Revenue, a multiple reference range of 1.5x to 4.6x for FV/2022E Revenue, a multiple reference range of 12.5x to 35.0x for FV/2021E EBITDA, and a multiple reference range of 11.1x to 24.1x for FV/2022E EBITDA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">J.P. Morgan then applied such reference ranges to the revenue projections for the calendar years 2021 and 2022 (as applicable) included in Adjusted Bioventus Street Forecasts (based on the Bioventus financial projections). The analysis indicated the following ranges of implied equity value per share for the Bioventus common stock (rounded to the nearest $0.10), which J.P. Morgan compared to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">seven-day</div> volume-weighted average price per share of Bioventus common stock of $16.63 on July&#160;27, 2021. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Implied Equity<br/>Value<br/>Per Share of<br/>Bioventus<br/>common stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Low</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">High</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FV/ 2021E Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FV/2022E Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FV/2021E EBITDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FV/2022E EBITDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Discounted Cash Flow Analysis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using the Adjusted Bioventus Street Forecasts, J.P. Morgan conducted a discounted cash flow analysis for the purpose of determining the fully diluted equity value per share of Bioventus class A common stock (excluding cost synergies). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">184 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">J.P. Morgan calculated the unlevered free cash flow that Bioventus is expected to generate from July&#160;1, 2021 through December&#160;31, 2025 using the Adjusted Bioventus Street Forecasts (as set forth in the section entitled <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Bioventus Management&#8217;s Unaudited Prospective Financial Information</div></div>&#8221;, which were discussed with, and approved by Misonix&#8217;s management for use by J.P. Morgan in connection with its financial analyses). J.P.&#160;Morgan also calculated a range of terminal values for Bioventus at the end of this period by applying perpetual growth rates ranging from 2.5% to 3.5%, based on guidance provided by Misonix&#8217;s management, to estimates of the unlevered free cash flow of Bioventus (excluding cost synergies) during year ending December&#160;31, 2025, as provided in the Bioventus Projections. J.P. Morgan then discounted the unlevered free cash flow estimates (excluding cost synergies) and the range of terminal values to present value as of June&#160;30, 2021 using discount rates ranging from 10.0% to 12.0%, which range was chosen by J.P. Morgan using its professional judgment and experience based upon its analysis of a weighted average cost of capital of Bioventus ranging from 10.0% to 12.0%. The present value of the unlevered free cash flow estimates and the range of terminal values were then adjusted by subtracting Bioventus&#8217; net debt and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests (which deduction was based upon Bioventus&#8217; balance sheet filed May&#160;13, 2021) as of June&#160;30, 2021. This analysis indicated a range of implied equity values for Bioventus (excluding cost synergies), which J.P.&#160;Morgan divided by the number of outstanding shares of Bioventus common stock, calculated on a fully-diluted basis (determined using the treasury stock method), to derive a range of implied equity values per share of Bioventus class A common stock (rounded to the nearest $0.10) of $17.10 to $25.70, which J.P. Morgan compared to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">seven-day</div> volume-weighted average price per share of Bioventus class A common stock of $16.63 on July&#160;27, 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Other Analyses </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Relative Implied Exchange Ratio Analysis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan compared the results for Misonix to the results for Bioventus with respect to the analyses referenced in the table below, assuming that Bioventus would pay 100% stock consideration in the proposed first merger. For each comparison, J.P. Morgan compared the highest equity value per share of Misonix common stock to the lowest equity value per share of Bioventus class A common stock to derive the range of exchange ratios implied by each pair of estimates. J.P. Morgan also compared the lowest equity value per share of Misonix common stock to the highest equity value per share of Bioventus class A common stock to derive the range of exchange ratios implied by each pair of estimates. The analysis indicated the following ranges of implied exchange ratios, which J.P. Morgan compared to the exchange ratio of 1.6839 shares of Bioventus common stock for a share of Misonix common stock, based on merger consideration of $28.00 per share of Misonix common stock, calculated as of July&#160;27, 2021, assuming 100% stock consideration in the proposed first merger. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Implied Exchange<br/>Ratio</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Low</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">High</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading Multiples &#8211; Misonix FV/2021E Revenue / Bioventus FV/2021E EBITDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2611x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0828x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading Multiples &#8211; Misonix FV/2022E Revenue / Bioventus FV/2022E EBITDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4535x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.5298x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discounted Cash Flow<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.7198x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.6725x</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excluding cost synergies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intrinsic Value Creation Analysis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan conducted an illustrative implied intrinsic value creation analysis, based on the Misonix Projections and the Bioventus Projections that compared the implied equity value of Misonix common stock derived from a discounted cash flow valuation on a standalone basis to the implied equity value attributable to the existing holders of Misonix common stock in the pro forma combined company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">185 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan determined the implied total equity value attributable to the existing holders of Misonix common stock in the pro forma combined company, which is referred to in this section entitled &#8220;Intrinsic Value Creation Analysis&#8221; as the implied value to holders of Misonix common stock, by calculating the sum of (i) (A)&#160;(1) the sum of the implied equity values of the Misonix common stock and the Bioventus class A common stock using the midpoint values determined pursuant to J.P. Morgan&#8217;s discounted cash flow analyses (without cost synergies) for each company described above, plus (2)&#160;the estimated midpoint present value of the Misonix projected cost synergies pursuant to J.P. Morgan&#8217;s discounted cash flow analysis for the cost synergies described above, minus (3)&#160;the aggregate amount of cash consideration to be paid to holders of Misonix common stock based on $10.50 per share of cash consideration, multiplied by (B)&#160;the equity ownership percentage of the pro forma combined company attributable to the existing holders of Misonix common stock pursuant to the proposed first merger, and (ii)&#160;the aggregate amount of cash consideration to be paid to holders of Misonix common stock based on $10.50 per share of cash consideration. The analysis indicated that, on an illustrative basis, the merger created hypothetical incremental implied value of 47% to holders of Misonix common stock. </div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Miscellaneous </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foregoing summary of certain material financial analyses does not purport to be a complete description of the analyses or data presented by J.P. Morgan. The preparation of a fairness opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. J.P. Morgan believes that the foregoing summary and its analyses must be considered as a whole and that selecting portions of the foregoing summary and these analyses, without considering all of its analyses as a whole, could create an incomplete view of the processes underlying the analyses and its opinion. As a result, the ranges of valuations resulting from any particular analysis or combination of analyses described above were merely utilized to create points of reference for analytical purposes and should not be taken to be the view of J.P. Morgan with respect to the actual value of Misonix or Bioventus. The order of analyses described does not represent the relative importance or weight given to those analyses by J.P. Morgan. In arriving at its opinion, J.P. Morgan did not attribute any particular weight to any analyses or factors considered by it and did not form an opinion as to whether any individual analysis or factor (positive or negative), considered in isolation, supported or failed to support its opinion. Rather, J.P. Morgan considered the totality of the factors and analyses performed in determining its opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Analyses based upon forecasts of future results are inherently uncertain, as they are subject to numerous factors or events beyond the control of the parties and their advisors. Accordingly, forecasts and analyses used or made by J.P. Morgan are not necessarily indicative of actual future results, which may be significantly more or less favorable than suggested by those analyses. Moreover, J.P. Morgan&#8217;s analyses are not and do not purport to be appraisals or otherwise reflective of the prices at which businesses actually could be acquired or sold. None of the selected companies reviewed as described in the above summary is identical to Misonix or Bioventus, and none of the selected transactions reviewed was identical to the merger. However, the companies selected were chosen because they are publicly traded companies with operations and businesses that, for purposes of J.P. Morgan&#8217;s analysis and based on its experience and professional judgment, may be considered similar to those of Misonix and Bioventus. The transactions selected were similarly chosen because their participants, size and other factors, for purposes of J.P. Morgan&#8217;s analysis and based on its experience and professional judgment, may be considered similar to the merger. The analyses necessarily involve complex considerations and judgments concerning differences in financial and operational characteristics of the companies involved and other factors that could affect the companies compared to Misonix and Bioventus and the transactions compared to the proposed first merger. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a part of its investment banking business, J.P. Morgan and its affiliates are continually engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, investments for passive and control purposes, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements, and valuations for corporate and other purposes. J.P. Morgan was selected to advise Misonix with respect to the merger on the basis of, among other things, such experience and its qualifications and reputation in connection with such matters and its familiarity with Misonix, Bioventus and the industries in which they operate. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">186 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Pursuant to the terms of J.P. Morgan&#8217;s engagement letter with Misonix, for services rendered in connection with the merger, Misonix has agreed to pay J.P. Morgan a transaction fee of approximately $8&#160;million, of which $1&#160;million was payable by Misonix to J.P. Morgan in connection with J.P. Morgan&#8217;s delivery of its opinion, and the balance of which becomes payable upon the closing of the merger. In addition, Misonix has agreed to reimburse J.P. Morgan for its expenses incurred in connection with its services, including the fees and disbursements of counsel, and will indemnify J.P. Morgan against certain liabilities arising out of J.P. Morgan&#8217;s engagement. During the two years preceding the date of J.P. Morgan&#8217;s opinion, J.P. Morgan and its affiliates have had commercial or investment banking relationships with Misonix, Bioventus and Bioventus LLC, an affiliate of Bioventus, for which J.P. Morgan and such affiliates have received customary compensation. Such services during such period have included acting as financial advisor to Misonix in connection with its acquisition of Solsys Medical in September 2019, joint lead arranger and joint bookrunner on Bioventus LLC&#8217;s term loan and revolving line of credit in December 2019 and active bookrunner and stabilization agent on Bioventus&#8217;s IPO in February 2021. In addition, J.P. Morgan and its affiliates hold, on a proprietary basis, less than 1% of the outstanding common stock of each of Misonix and Bioventus. During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> period preceding delivery of its written opinion ended on July&#160;29, 2021, the aggregate fees recognized by J.P. Morgan from Misonix were approximately $2&#160;million and from Bioventus and its affiliate, Bioventus LLC, were approximately $3.25&#160;million. In the ordinary course of their businesses, J.P. Morgan and its affiliates may actively trade the debt and equity securities or financial instruments (including derivatives, bank loans or other obligations) of Misonix or Bioventus for their own accounts or for the accounts of customers and, accordingly, they may at any time hold long or short positions in such securities or other financial instruments. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Unaudited Financial Projections </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Except for the annual guidance for fiscal year 2021, Bioventus does not normally publicly disclose long-term projections as to future revenues, earnings or other results due to, among other reasons, the uncertainty, unpredictability and subjectivity of the underlying assumptions and estimates. In connection with the merger, Bioventus management used certain publicly available financial forecasts relating to the business and financial prospects of Bioventus, derived from a consensus of selected equity research analysts concerning Bioventus for its 2021 through 2025 fiscal years, which Bioventus management adjusted for Bioventus&#8217; revised guidance for the 2021 fiscal year and the assumed growth rate for the 2023 through 2025 fiscal years, as well as assumed rates of depreciation, stock-based compensation, tax, capital expenditures and change in net working capital. These projections are referred to as the &#8220;Adjusted Bioventus Street Forecasts.&#8221; Also in connection with the merger, Bioventus used certain publicly available financial forecasts relating to the business and financial prospects of Misonix, derived from a consensus of selected equity research analysts concerning Misonix for fiscal years 2021 and 2022, which Bioventus management extrapolated for fiscal years 2023 through 2031 and adjusted for several different factors including assumed rates of depreciation and stock-based compensation and to calendarize to a December <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end.</div> These adjusted projections for the years ending December 2021 through December 2031 are referred to as the &#8220;Adjusted and Extrapolated Misonix Street Forecasts.&#8221; The Adjusted Bioventus Street Forecasts and the Adjusted and Extrapolated Misonix Street Forecasts were prepared for internal use only and were provided to the Bioventus board for the purposes of considering, analyzing and evaluating the merger. The Adjusted Bioventus Street Forecasts and Adjusted and Extrapolated Misonix Street Forecasts were also provided to Bioventus&#8217; financial advisor, Perella Weinberg, in connection with rendering its fairness opinion to the Bioventus board and in performing the related analyses. The Adjusted Bioventus Street Forecasts were also provided to Misonix&#8217;s financial advisor, JP Morgan Securities. The Adjusted Bioventus Street Forecasts and the Adjusted and Extrapolated Misonix Street Forecasts, were prepared treating each of Bioventus and Misonix on a stand-alone basis, without giving effect to the transaction, including the impact of negotiating or executing the merger agreement, the expenses that may be incurred in connection with consummating the mergers, the potential synergies that may be achieved by the combined company as a result of the transaction, the effect of any business or strategic decision or action that has been or will be taken as a result of the merger agreement having been executed, or the effect of any business or strategic decisions or actions which would likely have been taken if the merger agreement had not been executed but which were instead altered, accelerated, postponed or not taken in anticipation of the mergers. In connection with the transaction, Bioventus management also </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">187 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">independently prepared certain estimates as to the amount and timing of certain cost savings anticipated by the management of Bioventus to result following the closing, which are referred to as the &#8220;Cost Savings&#8221; and are summarized under &#8220;&#8212;Certain Cost Savings.&#8221; These Cost Savings are not reflected in the financial projections prepared by Bioventus or by Misonix. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of the Adjusted Bioventus Street Forecasts </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents certain publicly available financial forecasts relating to the business and financial prospects of Bioventus, derived from a consensus of selected equity research analysts concerning Bioventus for its 2021 through 2025 fiscal years, which Bioventus management adjusted for Bioventus&#8217; revised guidance for the 2021 fiscal year and the assumed growth rate for the 2023 through 2025 fiscal years, as well as assumed rates of depreciation, stock-based compensation, tax, capital expenditures and change in networking capital. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FY21E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FY22E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FY23E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FY24E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">FY25E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">525</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unlevered free cash flow<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Adjusted EBITDA, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, refers to earnings before interest, tax, depreciation and amortization, excluding the impact of stock-based compensation expense and other cash and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items that Bioventus does not consider in its evaluation of ongoing operating performance. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Unlevered free cash flow, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, refers to Adjusted EBITDA less stock-based compensation, which is treated as a cash expense, less taxes, change in net working capital and capital expenditures. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of the Adjusted and Extrapolated Misonix Street Forecasts </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition, as described under &#8220;&#8212;Misonix Unaudited Financial Projections,&#8221; Bioventus management identified certain publicly available financial forecasts relating to the business and financial prospects of Misonix, derived from a consensus of selected equity research analysts concerning Misonix for fiscal years 2021 and 2022, which Bioventus management extrapolated for fiscal years 2023 through 2031 and adjusted for several different factors including assumed rates of depreciation and stock-based compensation and to calendarize to a December <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end.</div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unlevered free cash flow<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2027E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2028E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2029E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2030E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2031E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">232</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unlevered free cash flow<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Adjusted EBITDA, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, refers to earnings before interest, tax, depreciation and amortization, excluding the impact of stock-based compensation expense and other cash and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items that Bioventus does not consider in its evaluation of ongoing operating performance. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Unlevered free cash flow, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, refers to Adjusted EBITDA less stock-based compensation, which is treated as a cash expense, less taxes, change in net working capital and capital expenditures. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">188 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Important Information about the Adjusted Bioventus Street Forecasts and the Adjusted and Extrapolated Misonix Street Forecasts </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Long-term forecasts or projections as to future performance, revenues, earnings or other results are subject to risks, due to, among other reasons, the inherent difficulty of accurately predicting financial performance for future periods and the uncertainty of the underlying assumptions and estimates. However, the Adjusted Bioventus Street Forecasts and Adjusted and Extrapolated Misonix Street Forecasts<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div>are being included in this joint proxy statement/prospectus to give stockholders access to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information provided to the Bioventus board and Bioventus&#8217; financial advisor and to Misonix&#8217;s financial advisor<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>for purposes of considering and evaluating the transaction. The inclusion of the Adjusted Bioventus Street Forecasts or the Adjusted and Extrapolated Misonix Street Forecasts should not be regarded as an indication that the Bioventus board, Bioventus, the Misonix board, Misonix, Perella Weinberg, J.P. Morgan Securities or any other recipient of this information considered, or now considers, it to be an assurance of the achievement of future results or an accurate prediction of future results, and they should not be relied on as such. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying Adjusted Bioventus Street Forecasts, Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings were not prepared with a view toward public disclosure or with a view toward compliance with the published guidelines established by the SEC or the American Institute of Certified Public Accountants for preparation or presentation of prospective financial information, or GAAP, but, in the view of Bioventus management, were reasonably prepared on bases reflecting the best available estimates and good faith judgments at the time of preparation, and presented as of the time of preparation, to the best of management&#8217;s knowledge and belief, the expected course of action and the expected future financial performance of Bioventus or Misonix, as applicable. However, this information is not fact and should not be relied upon as being necessarily indicative of future results, and readers of this joint proxy statement/prospectus are cautioned not to place undue reliance on the Adjusted Bioventus Street Forecasts, Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings. Although Bioventus management believes there is a reasonable basis for such projections and the Cost Savings, Bioventus cautions stockholders that future results could be materially different from the Adjusted Bioventus Street Forecasts and the Cost Savings. This summary of the Adjusted Bioventus Street Forecasts and the Cost Savings is not being included in this joint proxy statement/prospectus to influence any decision on whether to vote for the Bioventus share issuance proposal or the Misonix merger proposal, but rather because the Adjusted Bioventus Street Forecasts and the Cost Savings were shared between Bioventus and Misonix and provided to Bioventus&#8217; and Misonix&#8217;s respective boards of directors and financial advisors for purposes of considering and evaluating the merger and the merger agreement. Bioventus&#8217; independent registered public accounting firm, Grant Thornton LLP nor any other independent accountant, has not audited, reviewed, examined, compiled or applied agreed-upon procedures with respect to the Adjusted Bioventus Street Forecasts and, accordingly, does not express an opinion or any other form of assurance with respect thereto. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings are subject to estimates and assumptions in many respects and, as a result, subject to interpretation. While presented with numerical specificity, the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings are based upon a variety of estimates and assumptions that are inherently uncertain, though considered reasonable by Bioventus management as of the date of their preparation. These estimates and assumptions may prove to be inaccurate for any number of reasons, including general economic conditions, industry capital spending and unit production trends, competition and the risks discussed under &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221; See also &#8220;Where You Can Find More Information.&#8221; The Adjusted Bioventus Street Forecasts, Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings also reflect assumptions as to certain business decisions that are subject to change. Because the Adjusted Bioventus Street Forecasts and Adjusted and Extrapolated Misonix Street Forecasts were developed for Bioventus on a stand-alone basis without giving effect to the merger, they do not reflect any divestitures or other restrictions that may be imposed in connection with the receipt of any necessary governmental or regulatory approvals, any synergies that may be realized as a result of the merger or any changes to Bioventus&#8217; operations or strategy that may be implemented after completion of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">189 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">merger. There can be no assurance that the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings will be realized, and actual results may differ materially from those shown. Generally, the further out the period to which Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts and the Cost Savings relate, the less predictable and more unreliable the information becomes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Adjusted Bioventus Street Forecasts and the Adjusted and Extrapolated Misonix Street Forecasts<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div>contain certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures that Bioventus believes are helpful in understanding its past financial performance and future results. Bioventus management regularly uses a variety of financial measures that are not in accordance with GAAP for forecasting, budgeting and measuring financial performance. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures. While Bioventus believes these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures provide meaningful information to help investors understand the operating results and to analyze Bioventus&#8217; financial and business trends on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-to-period</div></div> basis, there are limitations associated with the use of these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures are not prepared in accordance with GAAP, are not reported by all of Bioventus&#8217; competitors and may not be directly comparable to similarly titled measures of Bioventus&#8217; competitors due to potential differences in the exact method of calculation. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Neither Bioventus nor Misonix has provided reconciliations of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures included in these projections to the comparable GAAP measure due to no reasonably accessible or reliable comparable GAAP measures for these measures and the inherent difficulty in forecasting and quantifying the measures that are necessary for such reconciliation. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">None of Bioventus, Misonix, the combined company or their respective affiliates, advisors, officers, directors or other representatives can provide any assurance that actual results will not differ from the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div>or the Cost Savings, and none of them undertakes any obligation to update, or otherwise revise or reconcile, the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings to reflect circumstances existing after the date the Adjusted Bioventus Street Forecasts or the Cost Savings were generated or to reflect the occurrence of future events even in the event that any or all of the assumptions underlying Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings, as applicable, are shown to be in error. Except as required by applicable laws, Bioventus does not intend to make publicly available any update or other revision to the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings, even in the event that any or all of the assumptions are shown to be in error. None of Bioventus or its affiliates, advisors, officers, directors or other representatives has made or makes any representation to any Bioventus stockholder or other person regarding Bioventus&#8217; ultimate performance compared to the information contained in the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings or that forecasted results will be achieved. Bioventus has made no representation to Misonix, in the merger agreement or otherwise, concerning the Adjusted Bioventus Street Forecasts, the Adjusted and Extrapolated Misonix Street Forecasts or the Cost Savings. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has not obtained, and does not intend to obtain, updated, revised or reaffirmed opinions from Perella Weinberg, and Bioventus has not updated, revised or reaffirmed, and does not intend to update, revise or reaffirm, any of the projections or assumptions that it provided to Perella Weinberg and upon which Perella Weinberg based its opinion. The opinion of Perella Weinberg does not speak as to the time when the merger will be completed or to any other date other than the date of each opinion. See &#8220;&#8212;Opinion of Bioventus&#8217; Financial Advisor.&#8221; Further, the projections that Bioventus provided to Perella Weinberg were not necessarily indicative of the results that Bioventus will achieve for any period ending after the date of the opinion. However, as of the date of this joint proxy statement/prospectus and except as otherwise publicly disclosed, Bioventus is not aware of, and does not anticipate to occur before the Bioventus special meeting, any material change or anticipated material change in its operations or performance, or to the projections or assumptions upon which Perella Weinberg based its opinion, since the date of such opinion. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">190 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix Unaudited Financial Projections </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than its quarterly financial guidance and business outlook, which may be updated from time to time, Misonix does not as a matter of course make other public projections as to future revenues, earnings or other results available. In particular, Misonix does not as a matter of course make public long-term projections or forecasts as to its future revenues, earnings or other results due to the uncertainty of the underlying assumptions and estimates. However, in connection with its evaluation of the potential strategic transactions, including the merger, Misonix management compiled certain unaudited prospective forecasted financial information, which is referred to as the &#8220;Misonix unaudited projections,&#8221; and provided the projections to the Misonix board of directors in connection with their consideration of the transactions contemplated by the merger agreement, and J.P. Morgan in connection with their preparation of financial analysis and fairness opinion. The Misonix unaudited projections were not provided to Bioventus in connection with its evaluation of a potential transaction. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying prospective financial information was not prepared with a view toward public disclosure or with a view toward complying with the guidelines established by the American Institute of Certified Public Accountants with respect to prospective financial information, but, in the view of the Company&#8217;s management, was prepared on a reasonable basis, reflects the best currently available estimates and judgments, and presents, to the best of management&#8217;s knowledge and belief, the expected course of action and the expected future financial performance of the Company. However, this information is not fact and should not be relied upon as being necessarily indicative of future results, and readers of this joint proxy statement/prospectus are cautioned not to place undue reliance on the prospective financial information. A summary of this information is presented below. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix unaudited projections were prepared treating Misonix on a standalone basis, without giving effect to the merger, including any impact of the negotiation or execution of the merger, the expenses that may be incurred in connection with the merger or the consummation thereof, the potential synergies that may be achieved by the combined company as a result of the merger, the effect of any business or strategic decision or action that has been or will be taken as a result of the merger agreement having been executed or in anticipation of the merger, or the effect of any business or strategic decisions or actions which would likely have been taken if the merger agreement had not been executed but which were instead altered, accelerated, postponed or not taken in anticipation of the merger. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although Misonix management believes there is a reasonable basis for the Misonix unaudited projections, Misonix cautions stockholders that future results could be materially different from the unaudited projections. This summary of the material portions of the Misonix unaudited projections is not being included in this joint proxy statement/prospectus to influence any decision whether to vote for the Misonix merger proposal, but because the Misonix unaudited projections were provided to Misonix&#8217;s financial advisor and the Misonix board of directors for purposes of considering and evaluating the merger. The prospective financial information of Misonix included in this joint proxy statement/prospectus has been prepared by, and is the responsibility of, Misonix management. Neither Misonix&#8217;s independent auditors, nor any other independent accountants, have compiled, examined, or performed any procedures with respect to the prospective financial information contained herein, nor have they expressed any opinion or any other form of assurance on such information or its achievability, and assume no responsibility for, and disclaim any association with, the prospective financial information. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Misonix unaudited projections are subject to estimates and assumptions in many respects and, as a result, subject to interpretation. While presented with numerical specificity, the Misonix unaudited projections are based upon a variety of estimates and assumptions that are inherently uncertain, though considered reasonable by Misonix&#8217;s management as of the date of their preparation. These estimates and assumptions may prove to be inaccurate for any number of reasons, including, among others, Misonix&#8217;s future results, general economic conditions, including the effects of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, and the risks discussed under &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221; Also see &#8220;Where You Can Find More Information.&#8221; Since the unaudited projections cover multiple years, such information by its nature becomes </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">191 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significantly less certain with each successive year. The Misonix unaudited projections also reflect assumptions as to certain business decisions that are subject to change. Because the Misonix unaudited projections were developed for Misonix on a standalone basis without giving effect to the merger, they do not reflect any restrictions that may be imposed in connection with the receipt of any necessary governmental or regulatory approvals, any synergies that may be realized as a result of the merger or any changes to Misonix&#8217;s operations or strategy that may be implemented after completion of the merger. There can be no assurance that the Misonix projections will be realized, and actual results may differ materially from those shown. Generally, the further out the period to which the Misonix projections relate, the less predictable and more unreliable the information becomes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None of Misonix, Bioventus, the combined company or their respective affiliates, advisors, officers, directors or other representatives can provide any assurance that actual results will not differ from the Misonix unaudited projections, and none of them undertakes any obligation to update, or otherwise revise or reconcile, the Misonix unaudited projections to reflect circumstances existing after the date the Misonix unaudited projections were generated or to reflect the occurrence of future events, even in the event that any or all of the assumptions underlying the Misonix unaudited projections are shown to be in error. Except as required by applicable securities laws, Misonix does not intend to make publicly available any update or other revision to the Misonix unaudited projections, even in the event that any or all assumptions are shown to be in error. None of Misonix or its affiliates, advisors, officers, directors or other representatives has made or makes any representation to any Misonix stockholder or other person regarding Misonix&#8217;s ultimate performance compared to the information contained in the Misonix unaudited projections or that forecasted results will be achieved. Misonix has not provided the Misonix unaudited projections to Bioventus or made any representation to Bioventus, in the merger agreement or otherwise, concerning the Misonix unaudited projections. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix has not obtained, and does not intend to obtain, updated, revised or reaffirmed opinions from J.P. Morgan, and Misonix has not updated, revised or reaffirmed, and does not intend to update, revise or reaffirm, any of the projections or assumptions that it provided to J.P. Morgan and upon which J.P. Morgan based their opinion. The opinion of J.P. Morgan does not speak as to the time when the merger will be completed or to any other date other than the date of the opinion. See &#8220;&#8212;Opinion of Misonix&#8217;s Financial Advisor.&#8221; Further, the projections that Misonix provided to J.P. Morgan were not necessarily indicative of the results that Misonix will achieve for any period ending after the date of the opinion. However, as of the date of this joint proxy statement/prospectus and except as otherwise publicly disclosed, Misonix is not aware of, and does not anticipate to occur before the Misonix special meeting, any material change or anticipated material change in its operations or performance, or to the projections or assumptions upon which J.P. Morgan based their opinion, since the date of such opinion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary of the Misonix Financial Projections </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Preliminary Unaudited Projections </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents certain unaudited prospective financial information of Misonix prepared by Misonix management for Misonix&#8217;s fiscal years ending 2022 through 2026, which we refer to as the Misonix preliminary unaudited projections, and which information was provided to the Misonix board of directors and J.P. Morgan as preliminary estimates that were subject to further refinement. The Misonix preliminary unaudited projections were not provided to Bioventus in connection with its evaluation of a potential transaction. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended, June&#160;30</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">156.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">194.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA (1)(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBIT (2)(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Operating Profit after Tax (3)(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unlevered Free Cash Flow (4)(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">192 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Adjusted EBITDA is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure which is calculated as earnings before interest expense, taxes, depreciation&#160;&amp; amortization and further adjusted to exclude <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items and certain other adjustments like stock based compensation expense. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Adjusted EBIT is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure which is calculated as Adjusted EBITDA further adjusted to exclude stock based compensation expense and depreciation&#160;&amp; amortization. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Net Operating Profit after Tax (&#8220;NOPAT&#8221;) is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, which is calculated as Adjusted EBIT less estimated tax expense, which assumes a marginal tax rate of 23% and accounts for Misonix&#8217;s net operating loss balance. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Unlevered Free Cash Flow is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, which is calculated as a NOPAT plus depreciation&#160;&amp; amortization, less capital expenditures and change in net working capital. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">See below under the heading <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-GAAP</div> Financial Measures&#8221; for a reconciliation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure to its related GAAP financial measure </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Revised Unaudited Projections </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following table presents certain unaudited prospective financial information of Misonix prepared by Misonix management for Misonix&#8217;s fiscal years ending 2022 through 2026, which we refer to as the Misonix revised unaudited projections, and, together with the Misonix preliminary unaudited projections, the Misonix unaudited projections, and which information was provided to the Misonix board of directors and J.P. Morgan. The Misonix revised unaudited projections were updated based on a number of developments, including, among other things, management&#8217;s general course of review, continuing developments in Misonix&#8217;s business and recent developments on the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. Misonix management instructed J.P. Morgan to use and rely upon the prospective information as a basis for its analysis in rendering its opinion described in the section of this proxy statement/prospectus entitled &#8220;The Merger&#8212;Opinion of Misonix&#8217;s Financial Advisor,&#8221; with such adjustments as are discussed in such section. The Misonix revised unaudited projections were not provided to Bioventus in connection with its evaluation of a potential transaction. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended, June&#160;30</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">130.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA (1)(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBIT (2)(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Operating Profit after Tax (3)(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unlevered Free Cash Flow (4)(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Adjusted EBITDA is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure which is calculated as earnings before interest expense, taxes, depreciation&#160;&amp; amortization and further adjusted to exclude <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items and certain other adjustments like stock based compensation expense. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Adjusted EBIT is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure which is calculated as Adjusted EBITDA further adjusted to exclude stock based compensation expense and depreciation&#160;&amp; amortization. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Net Operating Profit after Tax (&#8220;NOPAT&#8221;) is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, which is calculated as Adjusted EBIT less estimated tax expense, which assumes a marginal tax rate of 23% and accounts for Misonix&#8217;s net operating loss balance. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Unlevered Free Cash Flow is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, which is calculated as a NOPAT plus depreciation&#160;&amp; amortization, less capital expenditures and change in net working capital. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">See below under the heading <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-GAAP</div> Financial Measures&#8221; for a reconciliation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure to its related GAAP financial measure </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Financial Measures </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Misonix unaudited projections contain certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures that Misonix believes are helpful in understanding its past financial performance and future results. Misonix management regularly uses a </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">193 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">variety of financial measures that are not in accordance with GAAP for forecasting, budgeting and measuring financial performance. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures. While Misonix believes that these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures provide meaningful information to help investors understand the operating results and to analyze Misonix&#8217;s financial and business trends on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-to-period</div></div> basis, there are limitations associated with the use of these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures are not prepared in accordance with GAAP, are not reported by all of Misonix&#8217;s competitors and may not be directly comparable to similarly titled measures of Misonix&#8217;s competitors due to potential differences in the exact method of calculation. A reconciliation of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures to its respective comparable GAAP measure is provided below. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Preliminary Unaudited Projections </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended, June&#160;30</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">156.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">194.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(27.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(64.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(73.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(85.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(99.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(114.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(132.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income / (Loss) from Operations (GAAP)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2.6</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37.4</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bad Debt Expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjusted EBIT <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-GAAP)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2.1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.0</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">27.2</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38.2</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income / (Loss) from Operations (GAAP)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bad Debt Expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Adjusted EBIT <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-GAAP)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation&#160;&amp; Amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Based Compensation Expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjusted EBITDA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-GAAP)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.1</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.6</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33.7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">44.6</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Revised Unaudited Projections </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended, June&#160;30</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">130.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(46.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(70.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(75.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(100.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(116.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income / (Loss) from Operations (GAAP)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5.5</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.4</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.4</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24.4</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38.5</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Royalty Income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjusted EBIT <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-GAAP)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5.2</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">24.7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">38.8</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income / (Loss) from Operations (GAAP)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Royalty Income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Adjusted EBIT <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-GAAP)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation&#160;&amp; Amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Based Compensation Expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjusted EBITDA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-GAAP)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.2</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21.3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">31.5</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">45.7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain Cost Savings </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From April through June 2021, Bioventus and Misonix management independently prepared certain estimates as to the amount and timing of certain cost savings anticipated by the management of Bioventus to result in connection with the proposed transaction. Bioventus and Misonix management agreed that the Cost Savings </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">194 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">include approximately $20&#160;million of cost synergies estimated to be potentially realizable by the second full year subsequent to closing, which are referred to as the &#8220;Cost Savings.&#8221; The Cost Savings were provided to the Bioventus and Misonix boards of directors and to their respective financial advisors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Cost Savings assumed that the expected benefits of the merger would be realized, including that no restrictions, terms or other conditions would be imposed in connection with the receipt of any necessary governmental, regulatory or other approvals or consents in connection with the consummation of the mergers. See &#8220;&#8212;Bioventus Unaudited Financial Projections&#8221; and &#8220;&#8212;Misonix Unaudited Financial Projections&#8221; for further information regarding the uncertainties underlying the Cost Savings, as well as under &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; for further information regarding the uncertainties and factors associated with realizing the synergies in connection with the merger. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Closing and Effective Time of the Merger </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The closing of the merger will take place on a date to be designated jointly by Bioventus and Misonix, which date will be no later than the second business day after the satisfaction or waiver (to the extent permitted) of the last of the conditions to closing (described under &#8220;The Merger Agreement&#8212;Conditions to the Completion of the Merger&#8221;) to be satisfied or waived (other than such conditions that by their nature are to be satisfied at the closing, but subject to the satisfaction or waiver of each of such conditions at the closing), unless another date is agreed to in writing by Bioventus and Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the closing, the parties to the merger agreement will cause a certificate of merger relating to the first merger, and then a certificate of merger relating to the second merger, to be executed and filed with the Secretary of State of the State of Delaware and make all other filings or recordings required by the DGCL and the DLLCA in connection with effecting the merger. The first merger and second merger will become effective at the time when the respective certificate of merger is filed with the Secretary of State of the State of Delaware or at such later time as may be agreed to in writing by Bioventus and Misonix and specified in the applicable certificate of merger. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix currently expect the transaction to close by the end of the 2021 calendar year and are working to complete the transaction on this timeline and prior to the end date of January&#160;31, 2022 (which is subject to extension in certain circumstances related to the receipt of required regulatory approvals and the absence of restraints under certain competition laws to March&#160;31, 2022 pursuant to the terms of the merger agreement). However, it is possible that factors outside the control of the parties to the merger agreement could result in the merger being completed at a different time, or not at all. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Approvals </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the merger agreement, Bioventus, Merger Sub I, Merger Sub II and Misonix have each agreed to cooperate with each other and to use (and to cause their respective subsidiaries to use) reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary to cause the conditions to the closing to be satisfied as promptly as reasonably practicable (and in any event no later than the end date) and to consummate the transactions, including preparing and filing promptly and fully all documentation to effect all necessary filings to consummate the transaction including under the HSR Act. Bioventus and Misonix have agreed to use their respective reasonable best efforts to respond as promptly as reasonably practicable to any inquiries or requests for additional information or documentary material received from and Bioventus has agreed to use its reasonable best efforts to remove each and every impediment under antitrust laws to enable the consummation of the transactions, subject to the below limitations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any administrative or judicial action or proceeding including any proceeding by a private party, is instituted (or threatened to be instituted) challenging the transactions contemplated by the merger agreement as violative of any antitrust law, each of Bioventus and Misonix will use reasonable best efforts to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment, injunction or other order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation of the transactions contemplated by this Agreement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">195 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">However, Bioventus will not be required to do any of the following in order to obtain antitrust approval or otherwise to consummate the merger: (a)&#160;sell, divest, exclusively license, hold separate, or otherwise dispose of, or (b)&#160;grant any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license, accept any operational restrictions or take or commit to any actions which restrictions or actions would limit Bioventus&#8217; or any of its affiliates&#8217; freedom of action, in each case with respect to assets, licenses, product lines, operations or businesses of Bioventus, Misonix or either&#8217;s respective subsidiaries that, individually or in the aggregate, would reasonably be expected to have a materially adverse effect on (A)&#160;the results of operation of Misonix and its subsidiaries (taken as a whole) or (B)&#160;results of operations of Bioventus and its subsidiaries (taken as a whole), <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided that, </div></div>in each case, Bioventus and its subsidiaries, taken as a whole, shall be deemed to be the same size (in operations and from a financial point of view) as Misonix and its subsidiaries, taken as a whole. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding anything to the contrary, without the prior written consent of Bioventus, neither Misonix nor any of its subsidiaries will grant or offer to grant any accommodation or concession (financial or otherwise) to any third party in connection with seeking or obtaining its consent to the transactions contemplated by the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Risk Factors&#8212;Risks Relating to the Mergers.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ownership of the Combined Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the number of shares of Bioventus and Misonix common stock outstanding on September&#160;1, 2021, the latest practicable date prior to the date of this joint proxy statement/prospectus, upon completion of the mergers, former Misonix stockholders are expected to own approximately 25% of the outstanding shares of Bioventus common stock and Bioventus stockholders immediately prior to the mergers are expected to own approximately 75% of the outstanding shares of Bioventus common stock. The relative ownership interests of Bioventus stockholders and former Misonix stockholders in the combined company immediately following the mergers will depend on the number of shares of Bioventus and Misonix common stock issued and outstanding immediately prior to the merger. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors of the Combined Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has agreed to offer to at least two members of the Misonix board appointment to the Bioventus board as of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Federal Securities Law Consequences </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Assuming the effectiveness of the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> of which this joint proxy statement/prospectus forms a part, the shares of Bioventus class A common stock issued in the mergers will not be subject to any restrictions on transfer arising under the Securities Act or the Exchange Act, except for shares of Bioventus class A common stock issued to any Misonix stockholder who may be deemed an &#8220;affiliate&#8221; of Bioventus after the completion of the mergers. This joint proxy statement/prospectus does not cover resales of shares of Bioventus class A common stock received by any person upon the completion of the mergers, and no person is authorized to make any use of this joint proxy statement/prospectus, or the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> of which this joint proxy statement/prospectus forms a part, in connection with any resale of shares of Bioventus common stock. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting Treatment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus prepares its financial statements in accordance with GAAP. The mergers will be accounted for using the acquisition method of accounting under the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 805, Business Combinations, with Bioventus representing the accounting acquirer under this guidance. Bioventus will </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">196 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">record assets acquired, including identifiable intangible assets, and liabilities assumed from Misonix at their respective fair values at the date of completion of the mergers. Any excess of the purchase price over the net fair value of such assets and liabilities will be recorded as goodwill. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial condition and results of operations of Bioventus after completion of the mergers will reflect Misonix after completion of the mergers, but will not be restated retroactively to reflect the historical financial condition or results of operations of Misonix. The earnings of Bioventus following completion of the mergers will reflect acquisition accounting adjustments, including the effect of changes in the carrying value for assets and liabilities on depreciation expense and amortization expense. Indefinite-lived intangible assets, including goodwill, will not be amortized but will be tested for impairment at least annually, and all tangible and intangible assets including goodwill will be tested for impairment when certain indicators are present. If, in the future, Bioventus determines that tangible or intangible assets (including goodwill) are impaired, Bioventus would record an impairment charge at that time. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange of Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the closing date, Bioventus will select its transfer agent or, after consultation with Misonix, another reputable bank or trust company reasonably satisfactory to both parties to act as exchange agent with respect to the mergers. At or prior to the effective time, Bioventus will deposit with the exchange agent (a)&#160;certificates or evidence of book-entry shares representing the shares of Bioventus class A common stock issuable pursuant to the merger agreement and (b)&#160;cash sufficient to make payments (i)&#160;in lieu of fractional shares in accordance with the merger agreement with respect to the stock election consideration and (ii)&#160;in respect of the cash election consideration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">More information can be found under &#8220;The Merger Agreement&#8212;Exchange of Shares.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Listing of Bioventus Common Stock; Delisting and Deregistration of Misonix Common Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is a condition of the mergers that the shares of Bioventus class A common stock to be issued to Misonix stockholders in the merger be approved for listing on Nasdaq, subject to official notice of issuance. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the mergers are completed, Misonix common stock will be delisted from Nasdaq and deregistered under the Exchange Act, and Misonix will no longer be required to file periodic reports with the SEC with respect to Misonix common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix has agreed to cooperate with Bioventus and use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable laws and Nasdaq rules and policies to enable the delisting by the combined company of the shares of Misonix common stock from Nasdaq and the deregistration of the shares of Misonix common stock under the Exchange Act as promptly as practicable after the effective time. </div></div> <div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Litigation Relating to the Merger </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">O</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">n September 16, 2021, a purported stockholder of Misonix filed an action in the United States District Court for the Southern District of New York, captioned Ciccotelli v. Misonix, Inc. et al., Case No. 1:21-cv-07773 (S.D.N.Y.). The complaint asserts claims under Section 14(a) and Section 20(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, challenging the adequacy of disclosures in the proxy statement/prospectus filed with the SEC on September 8, 2021, regarding Misonix and Bioventus&#8217;s projections and J.P. Morgan&#8217;s financial analysis. The complaint purports to seek, among other relief, (i) injunctive relief preventing the parties from proceeding with the merger, (ii) rescission in the event that the merger is consummated, and (iii) an award of costs, including attorneys&#8217; and experts&#8217; fees.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and/or Misonix stockholders may file additional lawsuits challenging the merger, which may name Bioventus, Misonix, members of the Bioventus or Misonix boards of directors and/or others as defendants. No assurance can be made as to the outcome of such lawsuits or the complaint, including the amount of costs associated with defending, or any other liabilities that may be incurred in connection with the litigation of, such claims. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">197 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE MERGER AGREEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following description sets forth the principal terms of the merger agreement, which is attached as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A</div> hereto and incorporated by reference in this joint proxy statement/prospectus. The rights and obligations of the parties are governed by the express terms and conditions of the merger agreement and not by this description, which is summary by nature. This description does not purport to be complete and is qualified in its entirety by reference to the complete text of the merger agreement. You are encouraged to read the merger agreement carefully and in its entirety, as well as this joint proxy statement/prospectus and the documents incorporated by reference herein, before making any decisions regarding any of the proposals described in this joint proxy statement/prospectus. This section is intended to provide you with information regarding the terms of the merger agreement. Accordingly, the representations, warranties, covenants and other agreements in the merger agreement should not be read alone, and you should read the information provided elsewhere in this joint proxy statement/prospectus and in the public filings Bioventus and Misonix make with the SEC. See &#8220;Where You Can Find More Information.&#8221; </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Explanatory Note Regarding the Merger Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement and this summary of its terms have been included to provide you with information regarding the terms of the merger agreement. Bioventus and Misonix are responsible for considering whether additional disclosure of material information is required to make the statements in this joint proxy statement/prospectus not misleading. Factual disclosures about Bioventus and Misonix contained in this joint proxy statement/prospectus and in the public filings Bioventus and Misonix make with the SEC may supplement, update or modify the factual disclosures about Bioventus and Misonix contained in the merger agreement and described in this summary. The representations, warranties and covenants made in the merger agreement by Bioventus, Merger Sub I, Merger Sub II and Misonix are qualified and subject to important limitations agreed to by the parties to the merger agreement in connection with negotiating the terms of the merger agreement. In particular, in your review of the representations and warranties contained in the merger agreement and described in this summary, it is important to bear in mind that the representations and warranties were made solely for the benefit of the parties to the merger agreement, and were negotiated with the principal purpose of allocating risk between the parties to the merger agreement, rather than establishing matters as facts. The representations and warranties may also be subject to a contractual standard of materiality that may be different from that generally relevant to stockholders or applicable to reports and documents filed with the SEC, and in some cases are qualified by confidential disclosures that were made by each party to the other, which disclosures are not reflected in the merger agreement or otherwise publicly disclosed. The representations and warranties in the merger agreement will not survive the completion of the mergers. Moreover, information concerning the subject matter of the representations and warranties, which do not purport to be accurate as of the date of this joint proxy statement/prospectus, may have changed since the date of the merger agreement. If specific material facts exist that contradict the representations, warranties and covenants contained in the merger agreement, Bioventus and Misonix have disclosed those material facts in this joint proxy statement/prospectus. If subsequent information concerning the subject matter of the representations, warranties and covenants contained in the merger agreement has not been reflected in this joint proxy statement/prospectus, each of Bioventus and Misonix will make publicly available any material information necessary to provide stockholders a materially complete understanding of the provisions of the merger agreement. For the foregoing reasons, the representations, warranties and covenants or any descriptions of those provisions should not be read alone, but instead should be read together with the information provided elsewhere in this joint proxy statement/prospectus and in the public filings Bioventus and Misonix make with the SEC. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional information about Bioventus and Misonix can be found elsewhere in this joint proxy statement/prospectus and in the public filings Bioventus and Misonix make with the SEC. See &#8220;Where You Can Find More Information.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">198 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Structure of the Merger </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">First</div>, on the closing date, at the effective time, Merger Sub I will be merged with and into Misonix in accordance with the DGCL and on the terms and subject to the conditions set forth in the merger agreement, whereupon the separate existence of Merger Sub I will cease and Misonix will be the surviving corporation of the first merger and a wholly owned subsidiary of Bioventus. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Second</div>, on the closing date following the first merger, at the effective time of the second merger (the &#8220;Second Effective Time&#8221;), Misonix will be merged with and into Merger Sub II in accordance with the DGCL and the DLLCA, whereupon the separate existence of Misonix will cease and Merger Sub II will be the surviving limited liability company (the &#8220;Surviving Company&#8221;).</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Second Effective Time, all of the property, rights, powers, privileges and franchises of Misonix, Merger Sub I and Merger Sub II will vest in the Surviving Company as the surviving limited liability company, and all of the debts, obligations, liabilities, restrictions and duties of Misonix, Merger Sub I and Merger Sub II will become debts, obligations, liabilities, restrictions and duties of the Surviving Company as the surviving limited liability company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Completion and Effectiveness of the Mergers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The closing of the mergers will take place on a date to be designated jointly by Bioventus and Misonix, which date will be no later than the second business day after the satisfaction or waiver (to the extent permitted) of the last of the conditions to closing (described under &#8220;&#8212;Conditions to the Completion of the Mergers&#8221;) to be satisfied or waived (other than such conditions that by their nature are to be satisfied at the closing, but subject to the satisfaction or waiver of each of such conditions at the closing), unless another date is agreed to in writing by Bioventus and Misonix. The date on which the closing occurs is referred to as the &#8220;closing date.&#8221; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the closing, the parties to the merger agreement will cause separate certificates of merger relating to each merger to be executed and filed with the Secretary of State of the State of Delaware and make all other filings or recordings required by the DGCL in connection with each merger (and, in connection with the second merger, required by the DLLCA). Each merger will become effective at the time when the respective certificate of merger is filed with the Secretary of State of the State of Delaware or at such later time as may be agreed to in writing by Bioventus and Misonix and specified in the applicable certificate of merger. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger Consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the effective time, automatically, by virtue of the first merger and without any further action on the part of Misonix, Misonix stockholders, Bioventus or Merger Sub I: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all shares of Misonix common stock that are held in treasury by Misonix or are held directly by any direct or indirect subsidiary of Misonix, Bioventus or Merger Sub I immediately prior to the effective time will be cancelled and will cease to exist and no consideration will be paid or payable in respect thereof; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">except as described in the preceding bullet, each share of Misonix common stock that is issued and outstanding immediately prior to the effective time will be converted into the right to receive, at the election of the holder of such share, either (a)&#160;an amount of cash equal to $28, without interest (the &#8220;Cash Election Consideration&#8221;), or (b) 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Bioventus class A common stock (the &#8220;Stock Election Consideration&#8221;), based on the election of the holder thereof and subject to automatic proration and adjustment in accordance with the terms of the merger agreement as described below under &#8220;The Merger Agreement&#8212;The Mergers; Merger Consideration&#8212;Proration and Reallocation&#8221;; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each share of common stock, par value $0.0001 per share, of Merger Sub I that is issued and outstanding immediately prior to the effective time will be converted into one validly issued, fully paid </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">199 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> share of common stock, par value $0.0001 per share, of Misonix as the surviving corporation. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Second Effective Time, automatically, by virtue of the second merger and without any further action on the part of Misonix, Misonix stockholders, Bioventus, Merger Sub II or Merger Sub I: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each share of common stock, par value $0.0001 per share, of Misonix that is issued and outstanding immediately prior to the Second Effective Time will be cancelled and will cease to exist. Each limited liability company interest of Merger Sub II issued and outstanding immediately prior to the Second Effective Time will remain outstanding as a limited liability interest of the surviving limited liability company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treatment of Fractional Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">No fractional shares of Bioventus class A common stock will be issued in connection with the mergers. Each Misonix stockholder who would otherwise have been entitled to receive in the mergers a fractional share of Bioventus class A common stock pursuant to the merger agreement will, in lieu of such fractional share and upon surrender of such holder&#8217;s certificates representing shares of Misonix common stock or book-entry positions representing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> shares of Misonix common stock, in each case outstanding as of immediately prior to the effective time, be paid in cash the dollar amount (rounded to the nearest whole cent), without interest and subject to any required tax withholding, determined by multiplying such fraction by the average of the volume-weighted average trading price per share of Bioventus class A common stock on Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time (the &#8220;Average Company Stock Price&#8221;). No such holder will be entitled to dividends, voting rights or any other rights in respect of any fractional share of Bioventus class A common stock that would otherwise have been issuable as part of the merger consideration. The payment of cash in lieu of fractional share interests merely represents a mechanical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rounding-off</div> of the fractions in the exchange. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate amount of cash payable by Bioventus in the mergers will be equal to $10.50 multiplied by the number of outstanding shares of Misonix common stock at 5:00 p.m., New York City time, on the election deadline. In order to deliver this aggregate cash amount, the merger agreement provides for pro rata adjustments to, and reallocation of, the cash and stock elections made by Misonix stockholders, as well as the allocation of consideration to be paid with respect to shares of Misonix common stock as to which no election regarding the form of merger consideration to be paid to them, is received prior to the election deadline. Such no election shares will be exchanged for the cash consideration, the stock consideration or a combination of both. Additionally, depending on the elections made by other Misonix stockholders, each Misonix stockholder who elects to receive Bioventus class A common stock for their shares in the mergers, referred to as &#8220;stock election shares&#8221; may receive a portion of their consideration in cash, and each Misonix stockholder who elects to receive cash for their shares in the mergers, referred to as &#8220;cash election shares&#8221; may receive a portion of their consideration in Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration, which is the amount equal to the aggregate number of cash election shares multiplied by $28.00, exceeds the available cash amount, then: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all stock election shares and all no election shares will be exchanged for 1.6839 shares of Bioventus class A common stock; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a portion of the cash election shares of each Misonix stockholder will be exchanged for $28.00 in cash as follows: cash election shares exchanged for $28.00 in cash = </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of such stockholder&#8217;s cash election shares) * (maximum cash amount) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">elected cash consideration </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">200 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration is less than the available cash amount, which difference we refer to as the shortfall amount, then: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all cash election shares will be exchanged for the cash consideration; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all stock election shares and no election shares will be treated in the following manner: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the shortfall amount is less than or equal to the product of the aggregate number of no election shares and $28.00, which we refer to as the no election value, then (1)&#160;all stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock, and (2)&#160;a portion of the no election shares of each Misonix stockholder, calculated as follows, will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#8217;s no election shares, if any, will be exchanged for 1.6839 shares of Bioventus class A common stock): </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">no election shares exchanged for cash consideration = </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of no election shares of such stockholder) * (shortfall amount) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(no election value) </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the shortfall amount is more than the no election value, then (1)&#160;all no election shares will be exchanged for $28.00 in cash and (2)&#160;a portion of the stock election shares of each stockholder will be exchanged for $28.00 in cash as follows (and the remaining portion of such stockholder&#8217;s stock election shares will be exchanged for 1.6839 shares of Bioventus class A common stock): </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock election shares exchanged for cash consideration = </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(number of stock election shares of such stockholder) * (shortfall amount &#8211; no election value) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(aggregate number of stock election shares) * $28.00 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the elected cash consideration equals the available cash amount, then: (1)&#160;all cash election shares will be converted into the right to receive $28.00 in cash and (2)&#160;all stock election shares and all no election shares will be converted into the right to receive 1.6839 shares of Bioventus class A common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Election Procedures </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exchange agent will mail to Misonix stockholders of record not less than 30 days prior to the anticipated closing date of the first merger a letter of election and transmittal. The letter of election and transmittal enables Misonix stockholders to choose to make a cash election, a stock election or no election with respect to each share of Misonix common stock eligible to receive the merger consideration. Misonix intends to issue a press release at least five business days prior to the expiration of the election period informing Misonix stockholders of the expiration of the election period, which expiration we refer to as the &#8220;election deadline&#8221;. Misonix stockholders have until 5:00 p.m., New York City time, on the election deadline, to make their election and return their completed letter of election and transmittal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any election will have been properly made only if the exchange agent has actually received a properly completed letter of election and transmittal by the election deadline. Any election form may be revoked or changed by written notice received by the exchange agent prior to the election deadline. If an election form is revoked, the shares of Misonix common stock as to which such election previously applied will be no election shares unless an election is subsequently submitted by the Misonix stockholder prior to the election deadline. </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange of Shares </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exchange Agent </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the closing date, Bioventus must select its transfer agent or, after consultation with Misonix, another reputable bank or trust company reasonably satisfactory to both parties to act as exchange agent with respect to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">201 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the mergers. At or prior to the effective time, Bioventus must deposit with the exchange agent (a)&#160;certificates or evidence of book-entry shares representing the shares of Bioventus class A common stock issuable pursuant to the merger agreement and (b)&#160;cash sufficient to make payments (i)&#160;in lieu of fractional shares in accordance with the merger agreement with respect to the stock election consideration and (ii)&#160;in respect of the cash election consideration. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exchange of Misonix Stock Certificates and Misonix Book-Entry Shares </div></div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not less than 30 days prior to the anticipated closing date of the first merger, the exchange agent will mail to each holder of record of Misonix common stock a letter of election and transmittal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to certificates representing shares of Misonix common stock, which are referred to collectively as &#8220;Misonix stock certificates&#8221;, as promptly as reasonably practicable after the effective time, and in any event within three business days, the exchange agent must mail to each holder of record of each such Misonix stock certificate (a)&#160;a notice advising such holder of the effectiveness of the mergers, and (b)&#160;a letter of transmittal and (c)&#160;instructions for surrendering Misonix stock certificates to the exchange agent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon surrender of a Misonix stock certificate and a duly executed letter of election and transmittal (or letter of transmittal, if an election is not submitted) to the exchange agent in compliance with the instructions for surrender, the exchange agent must mail to each holder of record, as promptly as reasonably practicable following the effectiveness of the mergers: </div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a statement reflecting the number of whole shares of Bioventus class A common stock, if any, that such holder is entitled to receive pursuant to the merger agreement in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> book-entry form in the name of such record holder; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&#160;any applicable Cash Election Consideration, (b)&#160;any cash in lieu of fractional shares of Bioventus class A common stock plus (c)&#160;any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to the merger agreement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">With respect to book-entry positions representing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> shares of Misonix common stock, which are referred to as &#8220;Misonix book-entry shares&#8221;, that are not held through DTC, upon the later of the consummation of the mergers and the holder&#8217;s delivery to the exchange agent of a duly executed letter of election and transmittal (or letter of transmittal, if an election is not submitted), the exchange agent will pay and deliver to each such holder of record of any such Misonix book-entry shares: </div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the applicable Stock Election Consideration; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&#160;any applicable Cash Election Consideration, (b)&#160;any cash in lieu of fractional shares of Bioventus class A common stock plus (c)&#160;any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly cancel each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-DTC</div> book-entry share. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Misonix share certificates and Misonix book-entry shares not held through DTC, Misonix stockholders should complete and return the letter of election and transmittal to the exchange agent even if the stockholder is making no election because the exchange agent will require your transmittal information requested in the letter. Stockholders who do not return a letter of election and transmittal to the exchange agent prior to the election deadline will be mailed a letter of transmittal from the exchange agent following the consummation of the merger. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">202 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to Misonix book-entry shares that are held through DTC, Bioventus and Misonix must cooperate to establish procedures with the exchange agent and DTC to ensure that the exchange agent will transmit to DTC or its nominees as soon as practicable after the effective time, but in any event within three business days thereafter, upon surrender of shares held of record by DTC or its nominees in accordance with DTC&#8217;s customary surrender procedures: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the applicable Stock Election Consideration; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a check, or wire transfer of immediately available funds (provided that such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required tax withholdings as provided in the merger agreement) of (a)&#160;any applicable Cash Election Consideration, (b)&#160;any cash in lieu of fractional shares of Bioventus Class&#160;A Common Stock plus (c)&#160;any unpaid cash dividends and any other dividends or distributions that such holder has the right to receive pursuant to the merger agreement. The exchange agent will promptly cancel each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-DTC</div> book-entry share. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of a transfer of ownership of shares of Misonix common stock that is not registered in Misonix&#8217;s transfer records, the exchange agent may deliver the merger consideration, any cash in lieu of fractional shares of Bioventus common stock, and any unpaid cash dividends and any other dividends or other distributions, to such transferee if: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the case of Misonix book-entry shares, written instructions authorizing the transfer of the Misonix book-entry shares are presented to the exchange agent; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the case of Misonix stock certificates, the Misonix stock certificates formerly representing such shares of Misonix common stock are surrendered to the exchange agent; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">such Misonix stock certificates or Misonix book-entry shares are presented to the exchange agent accompanied by all documents required to evidence and effect such transfer and to evidence that any applicable transfer taxes have been paid or are not applicable, in each case, in form and substance reasonably satisfactory to Bioventus and the exchange agent. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lost, Stolen or Destroyed Certificates </div></div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event that any Misonix stock certificate has been lost, stolen or destroyed and has not been replaced by Misonix or its transfer agent prior to the election deadline, then, upon the making of an affidavit of that fact by the person claiming such Misonix stock certificate to be lost, stolen or destroyed and the posting by such person of a bond in a reasonable and customary amount and upon such terms as may reasonably be required as indemnity against any claim that may be made against it with respect to such Misonix stock certificate, the exchange agent will issue in exchange for such lost, stolen or destroyed Misonix stock certificate, the merger consideration, any cash in lieu of fractional shares of Bioventus class A common stock, and any unpaid cash dividends and any other dividends or other distributions, in each case, payable or issuable pursuant to the merger agreement, as if such lost, stolen or destroyed Misonix stock certificate had been surrendered. </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends and Distributions with Respect to Unexchanged Shares of Misonix Common Stock </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No dividends or other distributions declared or made with respect to shares of Bioventus class A common stock with a record date after the effective time will be paid or otherwise delivered to the holder of any unsurrendered Misonix stock certificate or Misonix book-entry shares with respect to the shares of Bioventus class A common stock that such holder has the right to receive pursuant to the mergers until the later to occur of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the date on which the holder surrenders such Misonix stock certificate or Misonix book-entry shares in accordance with the merger agreement; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the payment date for such dividend or distribution with respect to shares of Bioventus class A common stock (at which time such holder will be entitled, subject to the effect of applicable abandoned property, escheat or similar laws, to receive all such dividends and distributions, without interest). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">203 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rights of Misonix Stockholders Following the Effective Time and Transfers Following the Effective Time </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the effective time, all shares of Misonix common stock outstanding immediately prior to the effective time will automatically be cancelled and retired and will cease to exist, and all holders of Misonix stock certificates and of Misonix book-entry shares will cease to have any rights as Misonix stockholders, except the right to receive the merger consideration, any cash in lieu of fractional shares of Bioventus class A common stock, and any dividends or other distributions that such holder has the right to receive pursuant to the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None of Bioventus, Misonix, Merger Sub I, Merger Sub II nor the Surviving Company as the surviving limited liability company will be liable to any holder or former holder of shares of Misonix common stock or to any other person with respect to any portion of the merger consideration delivered to any public official pursuant to any applicable abandoned property law, escheat law or other similar law. If any Misonix stock certificate or Misonix book-entry share has not been surrendered prior to the date on which any portion of the merger consideration and any dividends or distributions, in each case, that a holder of such Misonix stock certificate or Misonix book-entry share has the right to receive pursuant to the merger agreement in respect of such Misonix stock certificate or Misonix book-entry share would otherwise escheat to or become property of any governmental entity, any such shares, cash, dividends or distributions in respect of such Misonix stock certificate or Misonix book-entry share will, to the extent permitted by applicable law, become the property of Bioventus, free and clear of all claims or interests of any person previously entitled thereto. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Withholding Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus, the exchange agent, Merger Sub I, Merger Sub II and Misonix, Misonix as the surviving corporation of the first merger and Surviving Company as the surviving entity of the second merger will each be entitled to deduct and withhold any amounts required to be deducted or withheld pursuant to applicable tax laws from the amounts that would otherwise be payable under the terms of the merger agreement. Any such amounts that are deducted or withheld and, if required, paid over to the appropriate governmental authorities will be treated as having been paid to the person in respect of which such deduction or withholding was made. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treatment of Misonix Equity Awards </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Restricted Stock </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the effective time, each outstanding award of Misonix restricted stock that is held by a Misonix employee immediately prior to the effective time, will accelerate in full (to the extent not otherwise previously vested in accordance with their terms) as of immediately prior to the effective time. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Options </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the effective time, any outstanding Misonix Option held by an &#8220;employee&#8221; of Bioventus (within the meaning of Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8)</div> (the &#8220;Assumed Misonix Options&#8221;) will be automatically converted into an option to acquire a number of shares of Bioventus class A common stock determined based on the option exchange ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aside from the foregoing adjustments, Assumed Misonix Options, if any, will generally remain subject to the same vesting and other terms and conditions that applied to such awards immediately prior to the effective time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Misonix Option that is not an Assumed Misonix Option and that is outstanding and unexercised will be accelerated in full (to the extent not otherwise previously vested in accordance with their terms) and be settled in cash immediately prior to the effective time in an amount equal to the product of (x)&#160;the number of shares of Misonix common stock subject to such Misonix Option, and (y)&#160;the excess, if any, of (i)&#160;the average of the volume-weighted average trading price per share of Bioventus class A common stock on Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii)&#160;the per share exercise price of such Misonix Option. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">204 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Employee Stock Purchase Plan </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Misonix&#8217;s Employee Stock Purchase Plan, which is referred to as the &#8220;ESPP&#8221;, Misonix is subject to the following requirements under the merger agreement: (a)&#160;no new offering periods under the ESPP may commence during the period from the date of the merger agreement through the closing date, (b)&#160;there may be no increase in the amount of payroll deductions permitted to be made by the participants in accordance with payroll deduction elections that are in effect as of the date of the merger agreement and (c)&#160;no individuals may commence participation in the ESPP during the period from the date of the merger agreement through the closing date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Governance of the Combined Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has agreed to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board to the Bioventus board as of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No other governance changes are planned in connection with the mergers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organizational Documents and Directors and Officers of the Surviving Corporation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the requirements described under &#8220;&#8212;Indemnification; Directors&#8217; and Officers&#8217; Insurance,&#8221;: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at the effective time, the certificate of incorporation of Misonix, as in effect immediately prior to the effective time, will continue to be the certificate of incorporation of the surviving corporation of the first merger until, subject to the terms of the merger agreement, thereafter changed or amended as provided therein or by applicable laws; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at the Second Effective Time, the certificate of formation of Merger Sub II, as in effect immediately prior to the Second Effective Time, will continue to be the certificate of formation of the Surviving Company as the surviving limited liability company of the second merger until, subject to the terms of the merger agreement, thereafter changed or amended as provided therein or by applicable laws; and </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the parties will take all requisite actions so that the limited liability company agreement of Merger Sub II will continue to be the limited liability company agreement of the Surviving Company until, subject to the terms of the merger agreement, thereafter changed or amended as provided therein or by applicable laws. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the effective time, the directors and officers of Merger Sub I immediately prior to the effective time will become the initial directors and officers of Misonix as the surviving corporation of the first merger. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Second Effective Time, the officers of Merger Sub II immediately prior to the Second Effective Time will become the initial officers of the Surviving Company as the surviving limited liability company of the second merger. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Representations and Warranties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement contains customary and, in certain cases, reciprocal, representations and warranties by Bioventus, Merger Sub I, Merger Sub II and Misonix that are subject, in some cases, to specified exceptions and qualifications contained in confidential disclosure letters and qualified by certain information filed by the parties with the SEC, excluding, in each case, any disclosures set forth in any risk factor section or &#8220;forward-looking statements&#8221; sections. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reciprocal representations and warranties relate to, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">organization, good standing and qualification to do business and subsidiaries&#8217; organization, good standing and qualification to do business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">205 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">capitalization; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">corporate authority and approval relating to the execution, delivery and performance of the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the absence of any violation of organizational documents, any conflict with or violation of applicable laws, any violation of or default under contracts, or any lien on the properties, rights or assets of a party or its subsidiaries as a result of the execution and delivery of the merger agreement and completion of the mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the proper filing of reports, schedules, forms, documents and financial statements required by the SEC and compliance with certain provisions of the Sarbanes-Oxley Act; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the maintenance of internal controls and procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the absence of undisclosed liabilities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the absence of certain material changes or events in the respective businesses of each of Bioventus and Misonix; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compliance with applicable laws and the holding of necessary permits; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">investigations, litigations and proceedings; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compliance with anti-corruption laws and regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tax matters; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product defects and warranties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compliance with healthcare laws and regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the absence of any need for action by governmental authorities in order to complete the mergers, except as may be required by the Securities Act, the Exchange Act, the DGCL, the HSR Act or other applicable competition laws, applicable state securities takeover and &#8220;blue sky&#8221; laws or Nasdaq rules and regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inapplicability of state anti-takeover statutes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">opinions of financial advisors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">broker&#8217;s and finder&#8217;s fees; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">information provided by a party for inclusion in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (including the joint proxy statement/prospectus). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement also contains additional representations and warranties by Misonix relating to, among other things, the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s required stockholder approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">intellectual property and information technology, including with respect to the enforceability of intellectual property, third-party intellectual property infringement claims, licensing arrangements, the protection of trade secrets, security breaches and compliance with privacy and security laws and regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">personal property owned and leased and real property leased by Misonix; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s significant contracts and agreements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">employee benefit plans and employment and labor practices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compliance with environmental laws and regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">206 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">insurance policies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the absence of ownership (as defined in Section&#160;203(c) of the DGCL) of shares of Bioventus common stock by Misonix and its subsidiaries. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement also contains additional representations and warranties by Bioventus relating to, among other things, the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of Bioventus&#8217;s, merger sub I&#8217;s and merger sub II&#8217;s required stockholder approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">intellectual property and information technology, including with respect to the enforceability of intellectual property and third-party intellectual property infringement claims; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">employee benefit plans and employment and labor practices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the absence of beneficial ownership of shares of Misonix common stock by Bioventus and its subsidiaries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">debt financing related to merger sub I and merger sub II; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">data privacy and security; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">top customers, suppliers and distributors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ownership or membership (as the case may be) and operation of merger sub I and merger sub II. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The representations and warranties will not survive the mergers. Many of the representations and warranties contained in the merger agreement are qualified by a &#8220;materiality&#8221; standard or by a &#8220;material adverse effect&#8221; standard. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Material Adverse Effect </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A material adverse effect, with respect to Bioventus or Misonix, as applicable, means any fact, circumstance, condition, event, change, development, occurrence, result, effect, action or omission that, individually or in the aggregate, (i)&#160;prevents, materially impairs, materially impedes or materially delays the consummation of the mergers and the other transactions contemplated by the merger agreement on a timely basis and in any event on or before the end date or (ii)&#160;results in a material adverse effect on the business, condition (financial or otherwise) or results of operations of the party and its subsidiaries, taken as a whole, excluding with respect to clause (ii)&#160;any fact, circumstance, condition, event, change, development, occurrence, result, effect, action or omission that results from or arises out of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">general economic, political, business, financial or market conditions affecting the industry in which the party and its subsidiaries operate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a pandemic (including the continuation or worsening of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic), epidemic, plague, or other outbreak of illness or public health event, hurricane, flood, tornado, earthquake or other natural disaster or act of God or changes resulting from weather conditions; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">changes in applicable laws or the interpretation thereof (including any measures related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic); </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in GAAP or any other applicable accounting standards or the interpretation thereof; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">geopolitical conditions, including trade and national security policies and export controls and executive orders relating thereto, any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a failure by the party or any of its subsidiaries to meet any internal or external projections or forecasts or any decline in stock price (excluding, in each case, the underlying causes of such failure or decline, as applicable, which may themselves constitute or be taken into account in determining whether there has been or would be a material adverse effect); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">207 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the public announcement or pendency of the mergers and the other transactions contemplated by the merger agreement, including, in any such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, business partners or employees&#160;(with certain limitations); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any action expressly required to be taken by the party pursuant to the terms of the merger agreement or at the express written direction or consent of the other party; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any claims, suits, actions or proceedings arising from allegations of breach of fiduciary duty or violation of applicable law or otherwise relating to the merger agreement or the transactions contemplated thereby; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">any breach, violation or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-performance</div> of any provision of the merger agreement by the party or any of its affiliates; provided, further, that any effect relating to or arising out of or resulting from any change or event referred to in the first five bullets above may constitute, and be taken into account in determining the occurrence of, a material adverse event if and only to the extent that such change or event has a disproportionate impact on the party and its subsidiaries as compared to other participants that operate in the industry in which the party and its subsidiaries operate. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conduct of Business Prior to the Completion of the Mergers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix have agreed that, except as may be required by applicable laws, as expressly required by the merger agreement, as set forth in their respective disclosure schedules, or unless the other party approves in writing (such approval not to be unreasonably withheld, conditioned or delayed), Bioventus and Misonix, as applicable, must, and must cause each of its subsidiaries to, use commercially reasonable efforts to conduct its business in the ordinary course of business. Misonix has also agreed that, except as may be required by applicable laws, as expressly permitted or required by the merger agreement, as set forth in Misonix&#8217;s disclosure schedule, or unless Bioventus approves in writing (in the case of the fourth through twelfth bullets, and in the thirteenth bullet, below, such approval not to be unreasonably withheld, conditioned or delayed), Misonix must not, and must not permit its subsidiaries to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amend its or its subsidiaries&#8217; organizational documents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">split, combine, subdivide, change, exchange, amend the terms of or reclassify any shares of Misonix&#8217;s capital stock or other equity interests of Misonix or any of its subsidiaries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">declare, set aside, make or pay any dividend or other distribution (whether payable in cash, stock or property) on any shares of its capital stock or the capital stock or equity interest of any subsidiary of Misonix, other than dividends or distributions only to the extent paid by any wholly owned subsidiary of Misonix to Misonix or another wholly owned subsidiary of Misonix. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">acquire (by merger, consolidation, operation of law, acquisition of stock, other equity interests or assets, formation of a joint venture or otherwise)&#160;(a) any other entity, (b)&#160;any equity interest in any other entity (other than investments in equity securities that constitute short term investments that are accounted for as cash equivalents), (c)&#160;any business or division or another entity, or (d)&#160;any material assets, except (i)&#160;acquisitions by Misonix from any of its wholly owned subsidiaries or among any of its wholly owned subsidiaries; (ii)&#160;the purchase of equipment, supplies and inventory in the ordinary course of business; and (iii)&#160;inbound licenses of intellectual property in the ordinary course of business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">except in connection with any transaction between Misonix and any of its subsidiaries or among any of its subsidiaries, sell, assign, transfer, lease or license to any third party, or incur any lien on any of its material tangible property or tangible assets (except for certain permitted encumbrances), or otherwise dispose of (by merger, consolidation, operation of law, division or otherwise), any of Misonix&#8217;s intellectual property or material tangible assets, other than (a)&#160;sales of inventory, goods or services in the ordinary course of business in a manner consistent with past practice or of obsolete equipment or assets in the ordinary course of business consistent with past practice, (b)&#160;pursuant to written contracts </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">208 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or commitments existing as of the date of the merger agreement, (c)&#160;as security for any borrowings permitted by the merger agreement, or (d)&#160;licenses granted to customers or other third parties in the ordinary course of business consistent with past practice; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">incur (other than draws on existing revolving loans), redeem, repurchase, prepay (other than prepayments of revolving loans), defease or cancel or guarantee any indebtedness for borrowed money, issue or sell any debt securities or rights to acquire any debt securities (directly, contingently or otherwise) or make any loans or capital contributions, except for indebtedness among Misonix and its wholly owned subsidiaries (and guarantees by Misonix or its subsidiaries in respect thereof); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a)&#160;adopt, terminate or amend any Misonix employee benefit plan (except to the extent permitted in this paragraph below), (b)&#160;increase, or accelerate the vesting or payment of, the compensation or benefits of any member of the board of directors of Misonix, (c)&#160;grant any rights to severance, retention, change in control or termination pay to any member of the Misonix board, any current or former employee of Misonix or its subsidiaries, (d)&#160;hire or promote any employee at or to the level of Vice President or above, or (e)&#160;terminate the employment of any employee of Misonix or its subsidiaries whose annual base salary exceeds $100,000 (other than for cause), except, in each case, for (i)&#160;amendments to Misonix employee benefit plans determined by it in good faith to be required to comply with applicable laws, (ii)&#160;hiring any person for employment (including by means of internal promotion) to fill any currently existing Vice President or higher position that becomes vacant after the date of the merger agreement, and, notwithstanding anything to the contrary in the merger agreement, provide such person with compensation and benefits for such position consistent with past practice, (iii)&#160;hiring any person for employment in accordance with Misonix&#8217;s present hiring plan made available to Bioventus or otherwise hiring an individual below the level of Vice President in the ordinary course of business in a manner consistent with past practice, (iv)&#160;increases in compensation or benefits required pursuant to any Misonix employee benfit plan in effect on the date of the merger agreement, (v)&#160;increases to total target cash opportunities (i.e.,&#160;annual base salary or wage rates and target annual cash bonus opportunities) in amounts that are in the ordinary course of business in a manner consistent with past practice,&#160;and (vi)&#160;any other actions set forth in Misonix&#8217;s disclosure schedule; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">except in the ordinary course of business, amend or terminate (except for terminations pursuant to the expiration of the existing term of any material contract or lease) certain material contracts or material property leases or waive, release or assign any materials rights under any material contracts or material property leases; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">make (except for elections made in the ordinary course of business), change or revoke any tax election, change any tax accounting period or method of tax accounting, amend any material tax return if such amendment would reasonably be expected to result in a material tax liability, settle or compromise any material liability for taxes or any tax audit, claim, or other proceeding relating to a material amount of taxes, enter into any agreement with a governmental entity relating to taxes if such agreement would reasonably be expected to result in a material tax liability, request any tax ruling from any governmental entity, surrender any right to claim a material refund of taxes, or, other than in the ordinary course of business, agree to an extension or waiver of the statute of limitations with respect to a material amount of taxes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other than consignment of Misonix products in the ordinary course of business, make any capital expenditure that is not contemplated by the capital expenditure budget set forth in Misonix&#8217;s disclosure schedule, unless such expenditures by Misonix and its subsidiaries do not, in the aggregate, exceed such budget by more than $200,000; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">settle or compromise any litigation, claim, suit, action or proceeding, except for (a)&#160;the payment, discharge or satisfaction, in the ordinary course of business in a manner consistent with past practice, of liabilities reflected or reserved against in the most recent balance sheet of Misonix, or (b)&#160;those that do not (i)&#160;impose any injunctive relief on Misonix or any of its subsidiaries, (ii)&#160;involve the payment of money greater than $250,000 in excess of existing insurance coverage, and (c)&#160;do not include an admission of liability or fault on the part of Misonix or any of its subsidiaries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">209 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">materially reduce insurance coverage or fail to renew material existing insurance policies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) amend any permits in a manner that adversely impacts Misonix&#8217;s ability to conduct its business in any material respect or terminate or allow to lapse any material permits; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">except in connection with any transaction between Misonix and any of its wholly owned subsidiaries or among any of its wholly owned subsidiaries, issue, sell, grant or otherwise permit to become outstanding any additional shares of its capital stock or other equity interests, any securities convertible into or exchangeable for any such shares, or any options, warrants or rights to acquire any such shares, other than (a)&#160;shares of Misonix common stock issuable upon exercise of Misonix outstanding stock options or the vesting of Misonix RSUs, or (b)&#160;pursuant to the ESPP and (to the extent not already covered), Misonix&#8217;s equity incentive plans, in the ordinary course of business consistent with past practice and in accordance with the merger agreement&#8217;s terms; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">directly or indirectly repurchase, redeem or otherwise acquire any shares of Misonix&#8217;s or any of its subsidiaries&#8217; capital stock or equity interests, or any other securities or obligations convertible (currently or after the passage of time or the occurrence of certain events) into or exchangeable for any shares of Misonix&#8217;s or any of its subsidiaries&#8217; capital stock or equity interests, except (a)&#160;shares of Misonix common stock repurchased from employees or consultants or former employees or consultants pursuant to the exercise of repurchase rights existing prior to the date of the merger agreement, or (b)&#160;shares of Misonix common stock accepted as payment for the exercise price of options to purchase Misonix common stock pursuant to Misonix&#8217;s stock incentive plan or for withholding taxes incurred in connection with the exercise, vesting or settlement of Misonix stock options or Misonix RSUs, as applicable, in accordance with the terms of the applicable award; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">change any methods of financial accounting or accounting practices in any material respect other than as required by changes in GAAP; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">enter into any contract or agreement that would constitute a material contract or material property lease; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">except as expressly required by applicable law or Misonix&#8217;s organizational documents, convene (a)&#160;any special meeting of Misonix stockholders, other than the Misonix special meeting to be held in connection with the transactions contemplated by the merger agreement, or (b)&#160;any other meeting of Misonix stockholders to consider a proposal that would reasonably be expected to impair, prevent or delay the transactions contemplated by the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">enter into any agreement, understanding or arrangement with respect to the voting of any of Misonix&#8217;s capital stock or other equity interests (including any voting trust), other than with respect to awards under Misonix&#8217;s equity plans otherwise permitted under the merger agreement or in connection with the granting of revocable proxies in connection with any meeting of Misonix stockholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adopt a plan of (a)&#160;complete or partial liquidation of Misonix or any of its subsidiaries or (b)&#160;dissolution, merger, consolidation, division, restructuring, recapitalization or other reorganization, other than, in the case of clause (b), transactions between Misonix&#8217;s wholly owned subsidiaries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fail to make any issuance, renewal, maintenance and other payments that become due with respect to any of Misonix&#8217;s material registered intellectual property or otherwise abandon, cancel or permit to lapse any material Misonix&#8217;s material registered intellectual property, other than in its reasonable business judgment or in the ordinary course of business consistent with past practice, or authorize the disclosure to any third party of any material trade secret in a way that results in loss of trade secret protection, other than in the ordinary course of business consistent with past practice; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">authorize, approve, enter or commit to do any of the foregoing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">210 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Bioventus has also agreed that, except as may be required by applicable laws, as expressly permitted or required by the merger agreement, as set forth in Bioventus&#8217;s disclosure schedule, or unless Misonix approves in writing (such approval not to be unreasonably withheld, conditioned or delayed), Bioventus will not, and will not permit its subsidiaries to:</div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amend its, merger sub I&#8217;s or merger sub II&#8217;s organizational documents in a manner that would be adverse in any material respect to the holders of Misonix common stock (after giving effect to the mergers); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">split, combine, subdivide, change, exchange, amend the terms of or reclassify any shares of Bioventus&#8217;s capital stock or other equity interests, except for any such transaction involving only wholly owned subsidiaries of Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">declare, set aside, make or pay any dividend or other distribution (whether payable in cash, stock or property) on any shares of its capital stock, except dividends or distributions may be paid by any wholly owned subsidiary of Bioventus to Bioventus or to another wholly owned subsidiary of Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">acquire (by merger, consolidation, operation of law, acquisition of stock, other equity interests or assets, formation of a joint venture or otherwise)&#160;(a) any other entity, (b)&#160;any equity interest in any other entity (other than investments in equity securities that constitute short term investments that are accounted for as cash equivalents), (c)&#160;any business or division or another entity; (d)&#160;any assets material to Misonix and subsidiaries of Misonix, taken as a whole, except in each case, (i)&#160;acquisitions by Bioventus from any of its wholly owned subsidiaries or among any of its wholly owned subsidiaries, (ii)&#160;the purchase of equipment, supplies and inventory in the ordinary course of business, (iii)&#160;inbound licenses of intellectual property in the ordinary course of business, or (iv)&#160;acquisitions that in each case would not reasonably be expected to (1)&#160;result in the holders of Misonix common stock having different rights and privileges than holders of Bioventus class A common stock following the consummation of the mergers, (2)&#160;materially delay, materially imped or prevent the consummation of the transactions contemplated by the merger agreement or (3)&#160;result in the failure of any of the conditions to closing set forth in the merger agreement to be satisfied prior to the end date; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">liquidate (completely or partially), dissolve or adopt a plan or resolution providing for any of the foregoing, in each case, with respect to Bioventus, merger sub I or merger sub II; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">authorize, approve, enter or commit to do any of the foregoing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Solicitation of Acquisition Proposals </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as expressly permitted by the merger agreement and described under &#8220;&#8212;No Change of Recommendation&#8212;Permitted Change of Recommendation&#8212;Superior Proposal&#8221; and &#8220;&#8212;No Change of Recommendation&#8212;Permitted Change of Recommendation&#8212;Intervening Event,&#8221; Bioventus and Misonix have agreed that neither Bioventus nor Misonix, nor any of their respective subsidiaries, will, and that they must cause their and their respective subsidiaries&#8217; representatives not, directly or indirectly: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries regarding, or the submission or announcement by any person (other than, in the case of Misonix, Bioventus or in the case of Bioventus, Misonix, or its respective affiliates and representatives) of, any proposal or offer that constitutes, or would reasonably be expected to lead to, an acquisition proposal (as defined below) (provided, however, that Bioventus or Misonix, as applicable, receiving such acquisition proposal, and its representatives, may refer the person making such proposal or offer to the provisions of the merger agreement and make inquiries of a person making an acquisition proposal involving such party (and its representatives) to solely clarify the terms of such acquisition proposal for the purpose of the Bioventus board or the Misonix board, as applicable, informing itself about such acquisition proposal); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">211 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">furnish any information regarding Bioventus or Misonix, as applicable, receiving such acquisition proposal, or of its subsidiaries (other than to the other party and its subsidiaries), or afford access to such party&#8217;s or its subsidiaries&#8217; representatives, books, records or property, in each case, in connection with or for the purpose of soliciting, initiating, encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to an acquisition proposal; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">engage in, enter into, continue or otherwise participate in any discussions or negotiations with any person (other than, in the case of Bioventus, Misonix, or in the case of Misonix, Bioventus, or its respective representatives) with respect to any acquisition proposal or any inquiry, proposal or offer that would reasonably be expected to lead to an acquisition proposal (provided, however, that each party and its representatives may refer the person making such proposal or offer to the provisions of the merger agreement and make inquiries of a person making such acquisition proposal to solely clarify the terms of such acquisition proposal for the purpose of the Bioventus board or the Misonix board, as applicable, informing itself about such acquisition proposal); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approve, adopt, recommend, agree to or enter into, or publicly propose to approve, adopt, recommend, agree to or enter into, any letter of intent, memorandum of understanding or similar document, agreement, commitment, or agreement in principle with respect to any acquisition proposal; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">resolve or agree to do any of the foregoing; provided, however, that, notwithstanding anything to the contrary contained in the merger agreement, prior to obtaining the applicable required stockholder approval, Bioventus and Misonix, as applicable, and its respective representatives may engage or otherwise participate in discussions or negotiations with, and provide information to, any person (including its representatives and financing sources and their representatives) that has made a bona fide written acquisition proposal after the date of the merger agreement that did not result from any breach of the foregoing restrictions by Bioventus or Misonix, their subsidiaries, or any of their representatives, if: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) prior to taking any such action, the Bioventus board or the Misonix board, as applicable, receiving such acquisition proposal determines in good faith, after consultation with its outside legal counsel and financial advisor, that such acquisition proposal either constitutes a superior proposal (as defined below) or would reasonably be expected to lead to a superior proposal; and </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">(ii) prior to providing any information regarding Bioventus or Misonix or any of their respective subsidiaries, as applicable, to such third party in response to such acquisition proposal, Bioventus or Misonix, as applicable, receives from such third party (or there is then in effect with such third party) an executed confidentiality agreement with nondisclosure provisions at least as restrictive of such third party as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> agreement with Bioventus or Misonix, as applicable, and that does not prohibit compliance of Bioventus or Misonix, as applicable, with the merger agreement&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> provisions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prior to or substantially concurrently with providing any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information to such third party, Bioventus or Misonix, as applicable, must make such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information available to the other party (to the extent such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information has not been previously made available by such party to the other party). Bioventus or Misonix, as applicable, must promptly (and in any event within 48 hours) inform the other party if such party furnishes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information and/or enters into discussions or negotiations as provided for in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> provisions of the merger agreement and must keep the other party reasonably informed, on a current basis (and, in any event, within 48 hours), of the status and material terms of any acquisition proposal (including any material changes to the material terms thereof) and the status of any material discussions and negotiations with respect thereto. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Bioventus or Misonix, as applicable, receives an acquisition proposal (or notice from any person that it intends to make an acquisition proposal) or any inquiry or request for information with respect to an acquisition proposal </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">212 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or that is reasonably likely to lead to an acquisition proposal, then Bioventus or Misonix, as applicable, must promptly (and in no event later than 48 hours after its receipt of such acquisition proposal or request) notify the other party in writing of such acquisition proposal or request (which notification must include the identity of the person making or submitting such request or acquisition proposal and an unredacted copy of any such written request or proposal (or, if not in writing, the material terms and conditions thereof)), together with copies of any proposed agreements relevant to such transaction, and Bioventus or Misonix, as applicable, must thereafter keep the other party reasonably informed, on a current basis (and, in any event, within 48 hours), of the status of such acquisition proposal, including informing such other party of any material change to the terms of such acquisition proposal, and the status of any negotiations, including any change in its intentions as previously notified. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Promptly following the execution and delivery of the merger agreement (and in any event within 24 hours after the execution and delivery of the merger agreement), Bioventus or Misonix, as applicable, must, and must cause each of its subsidiaries and must instruct their respective representatives to, promptly cease and cause to be terminated any existing solicitation of, or discussions or negotiations with, any person (other than the other party and its representatives) relating to any acquisition proposal made prior to the date of the merger agreement and any access any such persons may have to any physical or electronic data room relating to any potential acquisition proposal. Bioventus or Misonix, as applicable, must not, and must cause its affiliates not to, release any third party from, or waive, amend or modify any provision of, or grant permission under, or fail to enforce, any standstill provision in any agreement to which Bioventus or Misonix, or any of their respective affiliates, as applicable, is a party, unless the failure to take such action would reasonably be expected to be inconsistent with the Bioventus or Misonix board&#8217;s (as applicable) fiduciary duties to Bioventus or Misonix (as applicable) and its stockholders under applicable laws. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any violation of the restrictions contained in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitatoin</div> provisions of the merger agreement by any of the subsidiaries or any representatives of Bioventus or Misonix, as applicable, or any of its respective subsidiaries will be deemed to be a breach of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> provisions in the merger agreement by such party. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An &#8220;acquisition proposal&#8221; means any offer, indication of interest or proposal (other than an offer or proposal made or submitted by or on behalf of, in the case of Bioventus, Misonix or any of its affiliates, or in the case of Misonix, Bioventus or any of its affiliates) contemplating or otherwise relating to an acquisition transaction (as defined below). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An &#8220;acquisition transaction&#8221; means any transaction or series of related transactions (other than the mergers) involving: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any merger, consolidation, amalgamation, business combination, joint venture, reorganization or other similar transaction involving Bioventus or Misonix, as applicable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any transaction (i)&#160;in which any person or &#8220;group&#8221; (as defined in the Exchange Act) of persons acquires beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of Bioventus or Misonix, as applicable; or (ii)&#160;in which Bioventus or Misonix, as applicable, or any of its subsidiaries issues securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of Bioventus or Misonix, as applicable (after giving effect to such transaction);; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any sale, exchange, transfer, acquisition or disposition of 20% or more of the consolidated assets (including equity securities of respective subsidiaries) Bioventus and its subsidiaries, or of Misonix and its subsidiaries, as applicable, taken as a whole, or of any business or businesses (or the assets of any business or businesses, including equity securities of any subsidiary of Bioventus or Misonix, as applicable) that constitute or account for 20% or more of the consolidated net revenues or net income of Bioventus and its subsidiaries, or of Misonix and its subsidiaries, as applicable, taken as a whole; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">213 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any tender offer or exchange offer that if consummated would result in any person or &#8220;group&#8221; (as defined in the Exchange Act) of persons acquiring beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for such securities) representing 20% or more of the voting power of Bioventus or Misonix, as applicable; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any combination of the foregoing types of transactions if the sum of the percentage of the voting power of Bioventus or Misonix, as applicable, or of the consolidated net revenues, net income or assets of Bioventus and its subsidiaries or of Misonix and its subsidiaries, as applicable, taken as a whole, involved is 20% or more. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A &#8220;superior proposal&#8221; means any bona fide, unsolicited written acquisition proposal made to Bioventus or Misonix, as applicable, after the date of the merger agreement that: (a)&#160;if consummated, would result in any person or &#8220;group&#8221; (as defined in the Exchange Act) of persons (other than the other party) directly or indirectly becoming the beneficial owner of (i)&#160;any business or businesses that constitute or account for 50% or more of the net revenues, net income or assets of the other party, or (ii) 50% or more of the outstanding total voting power of the equity securities of the other party; and (b)&#160;the other party&#8217;s board of directors determines in good faith, after consultation with its outside legal counsel and financial advisor, is reasonably capable of being consummated on the terms proposed and which, taking into account such factors as the Bioventus board or the Misonix board, as applicable, reasonably considers in good faith to be appropriate and relevant, including the financial, legal, timing, likelihood of consummation, confidentiality, regulatory, financing and other aspects of such acquisition proposal would be more favorable to the holders of shares of common stock of Bioventus or Misonix, as applicable, from a financial point of view than the transactions contemplated by the merger agreement (after giving effect to any revisions to the terms of the merger agreement that is accepted by the other party would be legal binding on Bioventus or Misonix, as applicable, in response to such acquisition proposal pursuant to the merger agreement). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Change of Recommendation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix have agreed that, except as otherwise set forth in the merger agreement, neither the Bioventus board nor the Misonix board, nor any respective committee thereof, will: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withhold, withdraw, modify, amend or qualify (or publicly propose to do so), in a manner adverse to Bioventus, Merger Sub I and Merger Sub II, on the one hand, or to Misonix, on the other hand, the Misonix board&#8217;s required recommendation to Misonix stockholders to adopt the merger agreement, which is referred to as the &#8220;Misonix recommendation&#8221;, or the Bioventus board&#8217;s required recommendation to Bioventus stockholders to approve the share issuance, which is referred to as the &#8220;Bioventus recommendation&#8221;, as applicable or fail to include the Misonix recommendation or Bioventus recommendation, as applicable, in the joint proxy statement/prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approve, recommend or declare advisable (or publicly propose to do so) any acquisition proposal; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fail to publicly announce, within ten business days after a tender offer or exchange offer relating to the equity securities of Bioventus or Misonix, as applicable, have been commenced by any third party (and in no event later than one business day prior to the date of the Misonix special meeting or the Bioventus special meeting, as applicable, as either may be postponed or adjourned pursuant to this merger agreement), a statement disclosing that the Misonix board or the Bioventus board, as applicable, recommends rejection of such tender or exchange offer (for the avoidance of doubt, the taking of no position or a neutral position in respect of the acceptance of any such tender offer or exchange offer as of the end of such period will constitute a failure to publicly announce that such board of directors recommends rejection of such tender or exchange offer); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if requested by the other party, fail to issue, within ten business days after an acquisition proposal is publicly announced (and in no event later than one business day prior to the date of the Misonix special meeting or the Bioventus special meeting, as applicable, as it may be postponed or adjourned pursuant </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">214 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to the merger agreement), a press release reaffirming the Misonix recommendation or the Bioventus recommendation, as applicable, provided, further, that in no event will Misonix or Bioventus, as applicable, or its board of directors, be obligated to publicly reaffirm the Misonix recommendation or the Bioventus recommendation, as applicable, on more than one occasion with respect to each such publicly announced acquisition proposal or on more than one occasion with respect to each publicly announced material modification thereof (any action described in the foregoing being referred to as a &#8220;change in recommendation&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cause or permit Bioventus or Misonix, as the case may be, to enter into any contract, letter of intent, memorandum of understanding, agreement in principle or other arrangement or understanding (other than a confidentiality agreement entered into in compliance with the merger agreement) contemplating or relating to an acquisition transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">take any action to make the provisions of any anti-takeover or similar statute or regulation inapplicable to any acquisition proposal or counterparty thereto; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">publicly propose to do any of the foregoing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Permitted Change of Recommendation&#8212;Superior Proposal </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">However, Misonix, at any time prior to its stockholders voting on the Misonix merger proposal, and Bioventus, at any time prior to its stockholders voting on the Bioventus share issuance proposal, may make a change of recommendation related to an acquisition proposal and authorize termination of the merger agreement if and only if Bioventus or Misonix, as applicable, receives from a third party a bona fide written acquisition proposal that has not been withdrawn and that did not result from a breach of the merger agreement&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> provisions, if, prior to making such change of recommendation and/or authorizing termination of the merger agreement to concurrently enter into a definitive agreement with respect to such acquisition proposal: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the recipient&#8217;s board of directors determines in good faith, after consultation with its outside legal counsel and financial advisor, that such acquisition proposal constitutes a superior proposal and that failure to take such action would reasonably be expected to be inconsistent with the recipient&#8217;s board of directors&#8217; fiduciary duties to its stockholders under applicable laws; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the recipient delivers to the other party a written notice at least four business days in advance stating that the recipient&#8217;s board of directors intends to make a change of recommendation, which notice must include the identity of the person making such acquisition proposal and a copy of such proposal and a draft of the definitive agreement to be entered into in connection therewith (or, if not in writing, the material terms and conditions thereof); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">during such four business day period, if requested by the other party, the recipient engages in good faith negotiations with the other party regarding a possible amendment of the merger agreement so that the acquisition proposal that is the subject of the notice regarding a superior proposal ceases to be a superior proposal; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">after the expiration of the negotiation period described above and in a manner that would be binding upon Misonix, on the one hand, and Bioventus, Merger Sub I and Merger Sub II on the other, as applicable, if accepted by the other party, the Misonix board or the Bioventus board, as applicable, determines in good faith, after consultation with its outside legal counsel and financial advisor, after taking into account any amendments to the merger agreement that the other party has committed in writing to make as a result of the negotiations contemplated above, that such acquisition proposal continues to constitute a superior proposal, provided, that if there is any change to any of the financial terms or any other material terms of such acquisition proposal, the acquisition proposal&#8217;s recipient will, in each case, be required to deliver to the other party an additional notice consistent with that described above and a new negotiation period consistent with that described above will commence (except that the original four business day notice period referred to above must instead be equal to the longer of (i) </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">215 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11:59 p.m. New York City time on the second business day immediately following the receiving party&#8217;s receipt of such notice, and (ii)&#160;the period remaining under the original four business day notice period above), during which time Misonix or Bioventus, as applicable, will be required to comply with the requirements of the merger agreement anew with respect to such additional notice (but substituting the time periods therein with the foregoing two business day period). The actions of the applicable board of directors making a determination that an acquisition proposal constitutes a superior proposal and its authorizing and providing the notices to the other party required by the merger agreement will not in and of itself, constitute a change in recommendation or a violation of the merger agreement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Permitted Change of Recommendation&#8212;Intervening Event </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, Misonix, at any time prior to its stockholders voting on the Misonix merger proposal, and Bioventus, at any time prior to its stockholders voting on the Bioventus share issuance proposal, may make a change of recommendation if an intervening event (as defined below) arises and prior to making such change of recommendation: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Misonix board or the Bioventus board, as applicable, determines in good faith, after consultation with its outside legal counsel and financial advisor, that, in light of such intervening event, a failure to effect a change of recommendation would reasonably be expected to be inconsistent with such board of directors&#8217; fiduciary duties to Misonix or Bioventus, as applicable, and its stockholders under applicable laws; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">less than four business days prior to the making of such change in recommendation, Misonix or Bioventus, as applicable, receives a written notice from the other party confirming that the applicable board of directors intends to effect such change in recommendation, specifying the reasons therefor in reasonable detail; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">during such four business day period, if requested by the other party, the party experiencing the intervening event engages in good faith negotiations with the other party to amend the merger agreement in such a way that obviates the need for the applicable board of directors to effect a change of recommendation; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">after the expiration of such four business day period, the board of directors of the party experiencing the intervening event determines in good faith, after consultation with its outside legal counsel and financial advisor and after taking into account any amendments to the merger agreement that the other party has committed in writing to make a result of such negotiations contemplated by the clause above and in a manner that would be binding on such other party if accepted by the party experiencing the intervening event, that in light of such intervening event, a failure to effect a change of recommendation would reasonably be expected to be inconsistent with such board of directors&#8217; fiduciary duties to its stockholders under applicable laws, even if such changes committed to in writing were to be given effect. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The actions of the applicable board of directors making a determination that an intervening event has occurred and the applicable party&#8217;s authorizing and providing the notices to the other party required by the merger agreement will not in and of itself constitute a change in recommendation or a violation of the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An &#8220;intervening event&#8221; means any state of fact, event, change, effect, circumstance, occurrence or development, or combination thereof, that arises following the date of the merger agreement that (a)&#160;was neither known to nor reasonably foreseeable by the Misonix board or the Bioventus board, as applicable, as of the date of the merger agreement (or, if known to or reasonably foreseeable by such board of directors, the consequences of which were neither known to nor reasonably foreseeable by such board of directors as of the date of the merger agreement) and (b)&#160;is material to Bioventus and any of its subsidiaries or Misonix and any of its subsidiaries, as applicable, taken as a whole, and (c)&#160;is not related to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an acquisition proposal or a superior proposal or any inquiry or communications relating thereto, any matter relating thereto or consequences thereof; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">216 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in each case in and of itself, any changes in the market price or trading volume of the Bioventus class A common stock or Misonix common stock, as applicable, or the fact that Bioventus or Misonix, as applicable, meets, fails to meet or exceeds any internal or published projections, forecasts or estimates of its revenue, earnings or other financial performance or results of operations for any period (except that any underlying cause of any of the foregoing may be taken into account unless excluded pursuant the other bullet points); or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any event, condition or circumstance related to Bioventus and any of its subsidiaries or Misonix and any of its subsidiaries, as applicable. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Special Meetings </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus and Misonix must take all actions necessary under applicable laws and each party&#8217;s organizational documents to, in consultation with the other party as promptly as reasonably practicable after the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> of which this joint proxy statement/prospectus forms a part is declared effective by the SEC (and in any event within 45 days thereafter to the extent legally permitted), to, in the case of Bioventus, convene the Bioventus special meeting to vote on the Bioventus share issuance proposal, in the case of Misonix, convene the Misonix special meeting to vote on (a)&#160;a proposal to adopt the merger agreement, (b)&#160;a proposal for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding,</div> advisory vote of Misonix stockholders to approve certain compensation that may become payable to Misonix&#8217;s named executive officers in connection with the completion of the mergers, and (c)&#160;an adjournment proposal. Except as described above with respect to a change in recommendation, Bioventus and Misonix must use reasonable best efforts to solicit proxies in favor of their respective proposals and will not submit any other proposal to its stockholders in connection with the applicable special meeting without the prior written consent of the other party. Each of Misonix and Bioventus, in consultation with the other party, must set a record date for determining the persons entitled to notice of, and to vote at, the applicable special meeting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix may not postpone or adjourn the Bioventus special meeting and the Misonix special meeting, as applicable, unless the other party provides its prior written consent, other than: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to the extent reasonably necessary to ensure that any supplement or amendment to this joint proxy statement/prospectus which the Bioventus board or the Misonix board, as applicable, has determined in good faith, after consultation with the other party and its outside counsel, is required by applicable law is disclosed to Bioventus or Misonix stockholders, as applicable, and promptly disseminated to such stockholders within a reasonable amount of time (as determined by such board of directors in good faith after consultation with its outside counsel) prior to the applicable special meeting; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if required by applicable law or a request from the SEC or its staff; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, as of the time for which the Bioventus special meeting or the Misonix special meeting, as applicable, is scheduled, there are insufficient shares of Bioventus class A common stock or Misonix common stock, as applicable, represented (either in person or by proxy) to constitute a quorum necessary to conduct the business to be conducted at such special meeting. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, Bioventus or Misonix may, and if the other party so requests at any time, must, postpone or adjourn the Bioventus special meeting or the Misonix special meeting, as applicable, in order to solicit additional proxies in favor of the Bioventus share issuance proposal or Misonix merger proposal, as applicable, if on the date for which such special meeting is scheduled, there would be insufficient votes to obtain approval of such proposal, whether or not a quorum is present. In such case, except where the Bioventus board or the Misonix board, as applicable, has made a change in recommendation, Bioventus or Misonix, as applicable, must use reasonable best efforts during any such postponement or adjournment to solicit and obtain such proxies in favor of such proposal as soon as reasonably practicable. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, without Bioventus&#8217; or Misonix&#8217;s consent, as applicable, or except as may be required by applicable laws or a request from the SEC or its staff, no single adjournment or postponement may be for more than ten </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">217 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business days, and, subject to certain exceptions, all such adjournments and postponements together may not postpone the Bioventus or Misonix special meeting, as applicable, for more than twenty business days. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix must also use reasonable best efforts to initially hold their respective special meetings on the same date or, if notwithstanding such efforts, the other party&#8217;s special meeting is held on a date prior, as promptly as reasonably practicable following the date of the other party&#8217;s special meeting. Upon request of Bioventus or Misonix (which may not exceed one request per day), the other party must, during the ten business days prior to the date of such other party&#8217;s special meeting, advise the requesting party as to the aggregate number of shares of such other party&#8217;s common stock entitled to vote at such other party&#8217;s special meeting for which proxies have been received by such other party with respect to the required stockholder approval of such other party and the number of such proxies authorizing the holder thereof to vote in favor of the required stockholder approval of such other party.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory Approvals </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the merger agreement, Bioventus, Merger Sub I, Merger Sub II and Misonix have each agreed to cooperate with each other and use (and cause any of their respective subsidiaries to use) reasonable best efforts to take, or cause to be taken, all actions, and do, or cause to be done, all things, necessary to cause the conditions to the closing to be satisfied as promptly as reasonably practicable (and in any event no later than the end date) and to consummate the mergers, including to obtain (and to cooperate with each other in obtaining) the regulatory approvals described above as promptly as reasonably practicable (and in any event no later than the end date), subject to the limitations described below. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">However, Bioventus will not be required to do any of the following in order to obtain any regulatory approval or otherwise to consummate the mergers: (a)&#160;sell, divest, exclusively license, hold separate, or otherwise dispose of, or (b)&#160;grant any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license, accept any operational restrictions or take or commit to any actions which restrictions or actions would limit Bioventus&#8217; or any of its affiliates&#8217; freedom of action, in each case with respect to assets, licenses, product lines, operations or businesses of Bioventus, Misonix or either&#8217;s respective subsidiaries that, individually or in the aggregate, would reasonably be expected to have (i)&#160;an effect that results in a material adverse effect on the results of operations of Misonix and its subsidiaries, taken as a whole, or (ii)&#160;an effect that results in a material adverse effect on the results of operations of Bioventus and its subsidiaries (taken as a whole), but for purposes of determining whether an effect is or would be materially adverse to the results of operations of Bioventus and its subsidiaries, taken as a whole, Bioventus and its subsidiaries, taken as a whole, will be deemed to be the same size (in operations and from a financial point of view) as Misonix and its subsidiaries, taken as a whole. Notwithstanding anything to the contrary contained in the merger agreement, without the prior written consent of Bioventus, neither Misonix nor any of its subsidiaries or affiliates may grant or offer to grant any accommodation or concession (financial or otherwise) to any third party in connection with seeking or obtaining its consent to the transactions contemplated by the merger agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In furtherance and not in limitation of the covenants of the parties contained in the provisions regarding regulatory approvals in the merger agreement, if any administrative or judicial action or proceeding, including any proceeding by a private party, is instituted (or threatened to be instituted) challenging any transaction contemplated by the merger agreement as violative of any antitrust law, each of Bioventus and Misonix must use reasonable best efforts to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment, injunction or other order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation of the transactions contemplated by the merger agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Access to Information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to certain limitations, prior to the effective time, each of Bioventus and Misonix must afford the other party and its representatives reasonable access, during normal business hours upon prior notice, to Bioventus&#8217; or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">218 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s, as applicable, and its subsidiaries&#8217; personnel, properties, contracts, filings with governmental entities, books and records and, during such period, must furnish promptly to the other party all available information concerning Bioventus&#8217; or Misonix&#8217;s, as applicable, business as the other party may reasonably request. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consents of Merger Sub I and Merger Sub II; Vote of Bioventus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the period from the date of the merger agreement through the earlier of the effective time or the date of termination of the merger agreement, Merger Sub I and Merger Sub II must not engage in any activities of any nature except as provided in or contemplated by the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus must ensure that each of Merger Sub I and Merger Sub II duly performs, satisfies and discharges on a timely basis each of the covenants, obligations and liabilities of such entity under the merger agreement, and Bioventus will be jointly and severally liable with each of Merger Sub I and Merger Sub II for the due and timely performance and satisfaction of each such covenant, obligation and liability. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately following the execution of the merger agreement, Bioventus must execute and deliver, in accordance with the DGCL and DLLCA, as applicable, and in its capacity as the sole stockholder of Merger Sub I and sole member of Merger Sub II, a written consent adopting the merger agreement on behalf of Merger Sub I and Merger Sub II respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Publicity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix must consult with one another prior to issuing, and provide each other with the opportunity to review and comment upon, any public announcement, statement or other disclosure with respect to the merger agreement or the mergers and may not issue any such public announcement or statement prior to such consultation, except as may be required by applicable law or by Nasdaq rules and regulations (in which event Bioventus or Misonix, as applicable, must endeavor, on a basis reasonable under the circumstances, to provide a meaningful opportunity to the other party to review and comment upon such public announcement in advance, and must give due consideration to all reasonable additions, deletions or changes suggested thereto). Notwithstanding the foregoing: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of Bioventus and Misonix may make public announcements concerning the merger agreement or the merger that consist solely of information previously disclosed in previous public announcements, statements or other disclosures made by Bioventus and/or Misonix in compliance with the publicity provisions of the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of Bioventus and Misonix may make any public statements in response to questions by the press, analysts, investors or those participating in investor calls or industry conferences, so long as such public statements consist solely of information previously disclosed in previous press releases, public disclosures or public statements made by Bioventus and/or Misonix in compliance with the publicity provisions of the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix need not consult with Bioventus in connection with any public announcement or statement to be made with respect to any acquisition proposal; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix need not consult with the other party in connection with any public announcement or, statement to be made with respect to any change of recommendation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Benefits Matters </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For twelve months following the effective time, Bioventus will provide, or will cause to be provided, to (i)&#160;each employee of Misonix and its subsidiaries who continues employment with Bioventus or its subsidiaries with (a)&#160;an annual base salary or base wage rate that is, and (b)&#160;a target annual cash opportunity that, taken together with the annual base salary or base wage rate provided to such employee is, in each case, no less favorable than </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">219 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provided to each such employee immediately prior to the effective time and (ii)&#160;each such employee with employee welfare and retirement benefits (excluding any benefits under any defined benefit pension plan or post-retirement medical plan) that are substantially comparable or more favorable in the aggregate to those provided to such continuing employee by Misonix and its subsidiaries immediately prior to the effective time to at least&#160;those provided to similarly situated employees of Bioventus, except to the extent such recognition would result in the duplication of benefits. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus will provide service credit to continuing Misonix employees for purposes of determining eligibility to participate, vesting and accrual and level of benefits with respect to Bioventus benefit plans. For its welfare benefit plans, Bioventus will use commercially reasonable efforts to (a)&#160;waive limitations on preexisting conditions, exclusions and waiting periods for continuing Misonix employees, other than as are already in effect and have not been satisfied or waived prior to the effective time, and (b)&#160;credit annual deductibles, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> maximums paid under Misonix benefit plans during the applicable plan year, except to the extent such recognition would result in the duplication of benefits. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If requested by Bioventus not less than ten business days before the closing date, the Misonix board (or the appropriate committee thereof) must adopt resolutions and take such corporate action as is reasonably necessary to terminate Misonix&#8217;s 401(k) plan, effective as of the day prior to the closing date. In the event that Bioventus requests that Misonix&#8217;s 401(k) plan be terminated, (i)&#160;Misonix must provide Bioventus with evidence that such plan has been terminated (the form and substance of which will be subject to reasonable prior review and comment by Bioventus) not later than the day preceding the closing date and (ii)&#160;following the Second Effective Time and as soon as reasonably practicable following receipt of a favorable determination letter from the IRS on the termination of Misonix&#8217;s 401(k) plan, to the extent that Bioventus requests that Misonix seek such determination letter, the assets thereof will be distributed to the participants, and Bioventus must permit such continuing employees who are then actively employed to make rollover contributions of &#8220;eligible rollover distributions&#8221; (within the meaning of Section&#160;401(a)(31) of the Code, inclusive of loans) to Bioventus&#8217; 401(k) plan, in the form of cash, in an amount equal to the full account balance (including any promissory notes) distributed to such Misonix continuing employees from Misonix&#8217;s 401(k) plan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain Tax Matters </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus, Merger Sub I, Merger Sub II and Misonix intend to report and, except to the extent otherwise required pursuant to a &#8220;determination&#8221; within the meaning of Section&#160;1313(a) of the Code, will report, for U.S., state and other relevant tax purposes, the mergers as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, which is referred to as the &#8220;intended tax treatment.&#8221; Each of Bioventus, Merger Sub I, Merger Sub II and Misonix will use reasonable best efforts to cause the merger to qualify, and will not take any action or cause any action to be taken which action would reasonably be expected to prevent the mergers from qualifying, for the intended tax treatment. The merger agreement is intended to constitute a &#8220;plan of reorganization&#8221; for purposes of Treasury Regulations Sections <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.368-2(g)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.368-3(a),</div> to which each of Bioventus and Misonix are parties under Section&#160;368(b) of the Code. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each of Bioventus, Merger Sub I, Merger Sub II and Misonix will use commercially reasonable efforts to obtain from Jones Day or other nationally recognized tax counsel reasonably acceptable to Misonix any opinions and disclosures required to be filed with the SEC in connection with the registration of the applicable Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4,</div> including the appropriate officers of Bioventus, Merger Sub I, Merger Sub II and Misonix executing and delivering to the tax opinion counsel certificates setting forth certain representations and assumptions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix must use commercially reasonable efforts to cooperate with Bioventus and its affiliates to cause any subsidiary of Misonix that is treated as a corporation for U.S. federal income tax purposes to merge into Misonix LLC (as the surviving limited liability company of the second merger), which merger will be effective after the Second Effective Time and occur, at Bioventus&#8217; sole discretion, on the closing date after the closing or after the closing date. However, no officer or employee of Misonix or its subsidiaries will be obligated to execute </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">220 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">documents prior to the closing for purposes of effecting any such merger, and Misonix and its subsidiaries may not be obligated to make or have be effective any tax elections or tax filings in connection therewith prior to the closing. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification; Directors&#8217; and Officers&#8217; Insurance </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For at least six years following the Second Effective Time: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix as the surviving limited liability company must indemnify and hold harmless, and provide advancement of expenses to, all current or former directors and officers of Misonix or any of its subsidiaries, any person who becomes a director or officer of Misonix or any of its subsidiaries prior to the effective time and any current or former director of officer of Misonix or any of its subsidiaries who is, was or at any time prior to the effective time does serve as a director, officer, member, trustee or fiduciary of another corporation, partnership joint venture, trust, pension plan or employee benefit plan at the request of or for the benefit of Misonix or any of its subsidiaries (which individuals are referred to as the &#8220;indemnified parties&#8221;) to the fullest extent permitted by applicable laws; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix as the surviving limited liability company must maintain in effect the provisions in the organizational documents of Misonix and each of its subsidiaries and other agreements of Misonix or any of its subsidiaries with any indemnified party, in each case, regarding exculpation, elimination or limitation of liability, indemnification of officers, and directors or other fiduciaries and advancement of expenses that are in existence on the date of the merger agreement (including acts or omissions in connection with the approval of the merger agreement and the consummation of the mergers and the related transactions) and set forth in Misonix&#8217;s disclosure schedule, and no such provision may be amended, modified or repealed in any manner that would adversely affect the rights or protections thereunder of any such indemnified party in respect of acts or omissions occurring or alleged to have occurred at or prior to the effective time without the consent of such indemnified party. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, for at least six years following the Second Effective Time, Bioventus and Misonix as the surviving limited liability company must maintain in effect Misonix&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy (or a comparable replacement policy), which is referred to as the &#8220;D&amp;O Policy&#8221;, for claims arising from facts or events that occurred at or prior to the effective time (including with respect to the approval of the merger agreement and the consummation of the mergers) and covering each of Misonix&#8217;s current directors and officers on terms with respect to coverage and amounts that are no less favorable than those terms in effect on the date of the merger agreement. However, in no event will Bioventus or Misonix as the surviving limited liability company be required to expend in any one year an amount in excess of 300% of the current annual premium paid by Misonix for such insurance, and if the premium for such insurance exceeds such 300% allowance, then Bioventus and Misonix must purchase a policy with the greatest comparable coverage available not exceeding such allowance. However, in lieu of the foregoing obligation, Misonix may, or if Misonix is unable to, Bioventus may on its behalf, purchase, prior to the effective time, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-</div> year &#8220;tail&#8221; prepaid policy on the D&amp;O Policy with an annual cost not exceeding such 300% of the current annual premium paid by Misonix for such insurance. Each of the indemnified parties or other persons who are beneficiaries under the D&amp;O Policy or such &#8220;tail&#8221; policy (and, after the death of any of the foregoing persons, such person&#8217;s heirs and representatives) are intended to be third party beneficiaries of the merger agreement&#8217;s indemnification provisions, with full rights of enforcement as if a party thereto. Notwithstanding anything in the merger agreement to the contrary, if any indemnified party notifies Bioventus on or prior to the sixth anniversary of the effective time of a matter in respect of which such person may seek indemnification pursuant to the provisions regarding the D&amp;O Policy in the merger agreement, the provisions of the merger agreement that require Bioventus and Misonix (as the surviving limited liability company) to indemnify and advance expenses must continue in effect with respect to such matter until the final disposition of all claims, actions, investigations, suits and proceedings relating thereto. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing of the Mergers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From the date of the merger agreement, Misonix must, and must cause its subsidiaries and their respective representatives to, provide such cooperation as is reasonably requested by Bioventus, is reasonably and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">221 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">customarily necessary in connection with the contemplated debt financing in connection with the mergers (for which Bioventus has, prior to the date of the merger agreement, provided to Misonix an accurate and complete copy of the relevant executed debt commitment letter) and is customarily provided for issuers in financings of the type contemplated by such debt commitment letter, pursuant to which, upon the terms and subject only to the conditions therein, the debt financing sources party thereto have agreed to lend the amounts set forth therein. Subject to customary limitations and exceptions, such cooperation includes using commercially reasonable efforts to, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">furnish to Bioventus certain customary financial information with respect to the Misonix and its subsidiaries as is necessary for Bioventus to prepare the customary bank information memoranda, lender presentations, rating agency presentations and other similar customary documents, and to assist Bioventus in the preparation thereof; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provide Bioventus with requested information that is required in connection with the financing by U.S. regulatory authorities under applicable &#8220;know-your-customer&#8221; and anti-money laundering rules and regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">deliver, or cause the applicable Company Subsidiary to deliver, necessary prepayment and/or termination notices in accordance with the terms of each of existing credit facilities of Misonix and its subsidiaries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">execute and deliver credit agreements and to reasonably facilitate the pledging of collateral and the provision of guarantees in respect of the financing; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cause members of the senior management of Misonix and its representatives and advisors to participate in meetings, conference calls, roadshows and presentations with prospective lenders and investors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From the date of the merger agreement, Bioventus shall use its reasonable best efforts to, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintain the effect of the debt commitment letter; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">negotiate definitive financing agreements on the terms set forth in the debt commitment letter; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">satisfy the conditions in the debt commitment letter on a timely basis and consummate the financing contemplated thereby. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the financing contemplated by the debt commitment letter becomes unavailable, Bioventus shall as promptly as practicable following the occurrence thereof use its reasonable best efforts to obtain substitute financing. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain Additional Covenants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement also contains additional covenants, including, among others, covenants relating to coordination with respect to litigation relating to the mergers, the listing of Bioventus class A common stock and the delisting of shares of Misonix common stock from Nasdaq and the deregistration of Misonix under the Exchange Act (which are described under &#8220;The Merger&#8212;Listing of Bioventus Common Stock; Delisting and Deregistration of Misonix Common Stock&#8221;), reporting requirements under Section&#160;16 of the Exchange Act, resignations of Misonix directors, termination of Misonix&#8217;s credit facilities and handling of any applicable antitakeover or similar statutes. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conditions to the Completion of the Mergers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The obligations of each of Bioventus and Misonix to complete the mergers are subject to the satisfaction or waiver, as of the closing, of each of the following conditions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> of which this joint proxy statement/prospectus forms a part must have become effective in accordance with the provisions of the Securities Act, no stop order may have been issued by the SEC and remain in effect with respect to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> and no proceedings for that purpose may have been commenced or threatened in writing by the SEC and not withdrawn; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">222 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval by Misonix stockholders of the Misonix merger proposal must have been obtained; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval by Bioventus stockholders of the Bioventus share issuance proposal must have been obtained; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any waiting period (or any agreed upon extension of any waiting period or commitment not to consummate the mergers for any period of time) applicable to the consummation of the mergers under the HSR Act must have expired or been terminated by the relevant governmental entity, and there must be no pending agreement between Bioventus and any governmental entity not to close; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the shares of Bioventus class A common stock to be issued pursuant to the first merger, including the shares of Bioventus class A common stock to be issued upon the exercise of converted Misonix stock options and upon vesting of converted Misonix RSUs, must have been approved for listing (subject to notice of issuance) on Nasdaq; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">no law or order preventing, enjoining or making illegal the consummation of the mergers may have been entered, issued or adopted by any court of competent jurisdiction or other governmental entity of competent jurisdiction and remain in effect (any such law or order is referred to as a &#8220;relevant legal restraint&#8221;). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The obligation of Bioventus to complete the mergers is subject to the satisfaction or waiver, by Bioventus as of the closing, of each of the following conditions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s representations and warranties regarding the numbers of its issued, reserved for issuance and/or outstanding capital stock or other equity interests must have been true and accurate, other than de minimis inaccuracies, at and as of the date of the merger agreement, and must be true and accurate, other than de minimis inaccuracies, at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be true and accurate, other than de minimis inaccuracies, as of such particular date or period of time); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Misonix&#8217;s representations and warranties regarding (a)&#160;Misonix&#8217;s organization and good standing, (b)&#160;capitalization (other than regarding its capital stock as described in the preceding bullet), (c) corporate authority and approval, (d)&#160;Misonix&#8217;s required stockholder approval, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(e)&#160;non-violation</div> of Misonix&#8217;s or its subsidiaries&#8217; organizational documents, (f)&#160;takeover statutes and (g)&#160;any broker, finder or investment banker fees must have been true and accurate in all material respects at and as of the date of the merger agreement and must be true and accurate in all material respects at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be so true and accurate in all material respects as of such particular date or period of time), without giving effect to any materiality or material adverse effect qualifications contained therein; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s remaining representations and warranties must have been true and accurate in all respects at and as of the date of the merger agreement and must be true and accurate in all respects at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be so true and accurate as of such particular date or period of time), except as, individually or in the aggregate has not constituted or resulted in or would not reasonably be expected to constitute or result in, a material adverse effect, without giving effect to any materiality or material adverse effect qualifications contained therein (provided, that if there has been, from the date of the most recent company balance sheet provided by Misonix to Bioventus pursuant to the merger agreement through the date of the merger agreement, any fact, event, change, effect, circumstance, occurrence or development that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect to Misonix, such fact, event, change, effect circumstance, occurrence or development will be given effect); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">223 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s covenants required to be complied with or performed at or prior to the closing must have been complied with and performed in all material respects; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">since the date of the merger agreement, there must not have occurred any effects that, individually or in the aggregate, have constituted or resulted in, or would reasonably be expected to constitute or result in, a material adverse effect for Misonix; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus must have received a certificate, dated as of the closing date and executed by the Chief Executive Officer or Chief Financial Officer of Misonix, confirming that the conditions described in the preceding five bullets have been satisfied. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The obligation of Misonix to complete the mergers are subject to the satisfaction or waiver, by Misonix as of the closing, of each of the following conditions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; representations and warranties regarding the numbers of its issued, reserved for issuance and/or outstanding capital stock or other equity interests must have been true and accurate, other than de minimis inaccuracies, at and as of the date of the merger agreement and must be true and accurate, other than de minimis inaccuracies, at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be true and accurate, other than de minimis inaccuracies, as of such particular date or period of time); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bioventus&#8217; representations and warranties regarding (a)&#160;Bioventus&#8217;, Merger Sub I&#8217;s and Merger Sub II&#8217;s organization and good standing, (b)&#160;capitalization (other than regarding its capital stock as described in the preceding bullet), (c) corporate authority and approval, (d)&#160;Bioventus&#8217; required stockholder approval, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(e)&#160;non-violation</div> of Bioventus&#8217; or its subsidiaries&#8217; organizational documents and (e)&#160;any broker, finder or investment banker fees must have been true and accurate in all material respects at and as of the date of the merger agreement and will only be required to be true and accurate in all material respects at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty will only be required to be so true and accurate in all material respects as of such particular date or period of time), without giving effect to any materiality or material adverse effect qualifications contained therein; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; remaining representations and warranties must have been true and accurate in all respects at and as of the date of the merger agreement and will only be required to be true and accurate in all respects at and as of the closing date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty must be so true and accurate in all respects as of such particular date or period of time), except as, individually or in the aggregate, has not constituted or resulted in or would not reasonably be expected to constitute or result in, a material adverse effect, without giving effect to any materiality or material adverse effect qualifications contained therein (provided, that if there has been, from the date of the most recent company balance sheet provided by Bioventus to Misonix pursuant to the merger agreement through the date of the merger agreement, any fact, event, change, effect, circumstance, occurrence or development that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect to Misonix, such fact, event, change, effect circumstance, occurrence or development will be given effect); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; covenants required to be complied with or performed at or prior to the effective time must have been complied with and performed in all material respects; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">since the date of the merger agreement, there must not have occurred any effects that, individually or in the aggregate, have constituted or resulted in, or would reasonably be expected to constitute or result in, a material adverse effect for Bioventus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix must have received a certificate, dated as of the closing date and executed by the Chief Executive Officer or Chief Financial Officer of Bioventus, confirming that the conditions described in the preceding five bullets have been satisfied; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">224 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Misonix must have received an opinion from Jones Day or other nationally recognized tax counsel reasonably acceptable to Misonix, dated as of the closing date, to the effect that the mergers qualify for a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code at a level of comfort at least equivalent to the corresponding tax opinion provided by such tax opinion counsel in the registration statement contained in Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination of the Merger Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement may be terminated: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by mutual written consent of Bioventus and Misonix at any time prior to the effective time; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either Bioventus or Misonix, if the merger has not been consummated at or prior to 11:59 p.m. New York City time on January&#160;31, 2022, which is referred to as the &#8220;end date&#8221; (however, if all of the conditions to closing have been satisfied or waived or are capable of being satisfied at the relevant time other than any conditions to closing that cannot be satisfied or waived due to a relevant legal restraint involving antitrust laws, the end date will be automatically extended to 11:59 p.m. on March&#160;31, 2022), provided, that a party will not be permitted to terminate the merger agreement pursuant to this provision if the material breach by such party (or any affiliate of such party) of any of such party&#8217;s obligation under the merger agreement will have materially contributed to the failure of the closing to have occurred on or before the end date; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">by either Bioventus or Misonix at any time prior to the effective time if a relevant legal restraint permanently preventing, enjoining or making illegal the consummation of the mergers will have become final and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable;</div> provided, that the party seeking to terminate the merger agreement will have used reasonable best efforts to prevent the entry of and to remove such relevant legal restraint in accordance with the merger agreement; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">by Bioventus at any time prior to Misonix obtaining its required stockholder approval, if the Misonix board has made a change in recommendation or Misonix has willfully breached in any material respect the covenants applicable to it regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation,</div> special meetings and changes in recommendation; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">by Misonix at any time prior to Bioventus obtaining its required stockholder approval, if (a)&#160;the Bioventus board has made a change in recommendation, (b)&#160;Bioventus has willfully breached in any material respect the covenants applicable to it regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation,</div> special meetings and changes in recommendation or (c)&#160;if Bioventus has materially breached its representations and warranties regarding financing and solvency under the merger agreement or its covenants regarding financing and financing cooperation under the merger agreement (collectively referred to as the &#8220;financing requirements&#8221;) and (i)&#160;any such breach of the financing requirements is not cured by the earlier of the end date or prior to the twentieth business day after Misonix gives written notice of such breach to Bioventus, (ii)&#160;all of the conditions, the satisfaction or waiver of which would be necessary to trigger the obligation of Bioventus to consummate the mergers (not including the condition related to the certificate to be provided by Misonix), have been satisfied and continue to be satisfied (other than those conditions that by their nature cannot be satisfied other than at the closing), (iii) Misonix has irrevocably committed in a written notice delivered to Bioventus following the expiration of the cure period specified above that Misonix is ready, willing and able to consummate the transactions contemplated by the merger agreement; provided, however, that, with respect to such conditions and Misonix&#8217;s readiness, willingness and ability to consummate the transactions contemplated by the merger agreement, any such condition will be deemed satisfied if the failure of such condition resulted primarily from (1)&#160;any action or inaction by Bioventus, Merger Sub I or Merger Sub II, or (2)&#160;Bioventus&#8217; breach of the financing requirements, and (iv)&#160;Bioventus, Merger Sub I or Merger Sub II fails to consummate the transactions contemplated by the merger agreement by the earlier of the end date or within two business days following the written notice delivered by Misonix to Bioventus following the expiration of the cure period specified above; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">225 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Misonix, if prior to obtaining its required stockholder approval, (a)&#160;the Misonix board will have authorized Misonix to enter into a definitive agreement relating to a superior proposal in material compliance with the merger agreement and (b)&#160;substantially concurrently with the termination of the merger agreement, Misonix enters into the definitive agreement relating to a superior proposal and pays Bioventus the applicable termination fee pursuant to the merger agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either Bioventus or Misonix, if the approval by Misonix stockholders of the Misonix merger proposal has not been obtained after a vote on approval of such proposal has been taken at the Misonix special meeting (including any postponement or adjournment thereof); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either Bioventus or Misonix, if the approval by Bioventus stockholders of the Bioventus share issuance proposal has not been obtained after a vote on approval of such proposal has been taken at the Bioventus special meeting (including any postponement or adjournment thereof); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Bioventus (i)&#160;if any of Misonix&#8217;s representations and warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied or (ii)&#160;if Misonix has breached any covenant in the merger agreement and such breach (a)&#160;would result in the failure of a condition to closing, provided, that if an inaccuracy in any of Misonix&#8217;s representations and warranties or a breach of a covenant of Misonix is curable by Misonix by the end date and Misonix is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Bioventus may not terminate the merger agreement under this paragraph on account of such inaccuracy or breach unless such inaccuracy or breach remains uncured for a period of thirty business days commencing on the date that Misonix receives written notice of such inaccuracy or breach from Bioventus; provided, further, that Bioventus will not have the right to terminate the merger agreement pursuant to this paragraph if Bioventus is then in breach of any of its representations, warranties or agreements contained in the merger agreement, which breach would give rise to the failure of a condition to closing; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Misonix if: (i)&#160;any of Bioventus&#8217;, Merger Sub I&#8217;s or Merger Sub II&#8217;s representations and warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied; or (ii)&#160;any of Bioventus&#8217; covenants contained in the merger agreement will have been breached such that the conditions to closing would not be satisfied; provided, however, that for purposes of clauses (i)&#160;and (ii) above, if an inaccuracy in any of Bioventus&#8217;, Merger Sub I&#8217;s or Merger Sub II&#8217;s representations and warranties or a breach of a covenant of Bioventus is curable by Bioventus by the end date and Bioventus is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Misonix may not terminate the merger agreement under this paragraph on account of such inaccuracy or breach unless such inaccuracy or breach remains uncured for a period of thirty business days commencing on the date that Bioventus receives written notice of such inaccuracy or breach from Misonix; provided, further, that Misonix will not have the right to terminate the merger agreement pursuant to this paragraph if Misonix is then in breach of any of its representations, warranties or agreements contained in the merger agreement, which breach would give rise to the failure of a condition to closing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination Fees </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Termination Fee </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix will be obligated to pay to Bioventus a termination fee of $20,661,000 in cash if the merger agreement is terminated: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) by Misonix if prior to obtaining its required stockholder approval, (i)&#160;the Misonix board has authorized Misonix to enter into a definitive agreement relating to a superior proposal and (ii)&#160;substantially concurrently with the termination of the merger agreement, Misonix enters into the definitive agreement relating to a superior proposal, (b)&#160;by Bioventus at any time prior to Misonix obtaining its required stockholder approval, if the Misonix board has made a change in recommendation or Misonix has willfully breached in any material respect any covenant applicable to </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">226 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">it regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation,</div> special meetings and changes in recommendation, or (c)&#160;by either Bioventus or Misonix (x)&#160;if the merger has not been consummated on or prior 11:59 p.m. New York City time on the end date and at the end date all of the conditions to Misonix&#8217;s obligations to consummate the transactions other than receipt of its required stockholder approval have been satisfied, or are capable of satisfaction had the closing occurred on the end date, or (y)&#160;due to the failure of Misonix to obtain approval by Misonix stockholders of the Misonix merger proposal, in each of the previous cases under (c)&#160;above, at a time when Bioventus would have been entitled to terminate the merger agreement pursuant to (b)&#160;above; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) by either Bioventus or Misonix, if the approval by Misonix stockholders of the Misonix merger proposal has not been obtained after a vote on approval of such proposal has been taken at the Misonix special meeting, (b)&#160;by Bioventus (i)&#160;if any of Misonix&#8217;s representations and warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied or (ii)&#160;if Misonix has breached any covenant in the merger agreement and such breach would result in the failure of a condition to closing, or (c)&#160;by either Bioventus or Misonix, if the merger has not been consummated on or prior 11:59 p.m. New York City time on the end date and at the end date all of the conditions to Misonix&#8217;s obligations to consummate the transactions other than receipt of its required stockholder approval have been satisfied, or are capable of satisfaction had the closing occurred on the end date, at a time when the merger agreement could have been terminated pursuant to (a)&#160;or (b) above, and: (x)&#160;at or prior to the Misonix special meeting (in the case of a termination pursuant to (a)&#160;above), or at or prior to the time of the applicable breach by Misonix (in the case of a termination pursuant to (b)&#160;above), any person must have publicly announced an intention to make an acquisition proposal involving Misonix, or such an acquisition proposal must have been publicly disclosed, publicly announced, commenced, submitted or made and must not have been publicly withdrawn without qualification at least five business days prior to the date of the Misonix special meeting, in the case of a termination pursuant to (a)&#160;above, or the time of such breach, in the case of a termination pursuant to (b)&#160;above; and (ii)&#160;on or prior to the date that is twelve months following the termination of the merger agreement, either (A)&#160;an acquisition transaction involving Misonix is consummated or (B)&#160;a definitive agreement relating to such an acquisition transaction is entered into by Misonix and the transaction contemplated thereby is subsequently consummated (it being understood that, for purposes of this clause (B), each reference to 20% in the definition of &#8220;acquisition transaction&#8221; above will be deemed to be a reference to 50%). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The termination fee will be payable by Misonix only once and not in duplication even if the termination fee may be payable by Misonix pursuant to more than one of the circumstances described above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus Termination Fee </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus will be obligated to pay to Misonix a termination fee of $20,661,000 in cash if the merger agreement is terminated: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">(a) by Misonix at any time prior to Bioventus obtaining its required stockholder approval, if (i)&#160;the Bioventus board has made a change in recommendation, (ii)&#160;Bioventus has willfully breached in any material respect the covenants applicable to it regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation,</div> special meetings and changes in recommendation or (iii)&#160;if Bioventus has materially breached the financing requirements, (b)&#160;by either Bioventus or Misonix (x)&#160;if the merger has not been consummated on or prior to close of business on the end date or (y)&#160;if the approval by Bioventus stockholders of the Bioventus share issuance proposal has not been obtained after a vote on approval of such proposal has been taken at the Bioventus special meeting, in each of the previous cases under (b)&#160;above, at a time when Misonix would have been entitled to terminate the merger agreement pursuant to (a)&#160;above; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) by either Bioventus or Misonix, if the approval by Bioventus stockholders of the Bioventus share issuance proposal has not been obtained after a vote on approval of such proposal has been taken at the </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">227 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus special meeting, (b)&#160;by Misonix if: (i)&#160;any of Bioventus&#8217;, Merger Sub I&#8217;s or Merger Sub II&#8217;s representations and warranties contained in the merger agreement are inaccurate such that the conditions to closing would not be satisfied; or (ii)&#160;any of Bioventus&#8217; covenants contained in the merger agreement will have been breached such that the conditions to closing would not be satisfied or (c)&#160;by either Bioventus or Misonix, if the merger has not been consummated on or prior 11:59 p.m. New York City time on the end date, at a time when the merger agreement could have been terminated pursuant to (a)&#160;or (b) above, and: (x)&#160;at or prior to the Bioventus special meeting (in the case of a termination pursuant to (a)&#160;above), or at or prior to the time of the applicable breach by Bioventus (in the case of a termination pursuant to (b)&#160;above), any person must have publicly announced an intention to make an acquisition proposal involving Bioventus, or such an acquisition proposal must have been publicly disclosed, publicly announced, commenced, submitted or made and may not have been publicly withdrawn without qualification at least five business days prior to date of the Bioventus special meeting, in the case of a termination pursuant to (a)&#160;above, or the time of such breach, in the case of a termination pursuant to (b)&#160;above, and (y)&#160;on or prior to the date that is twelve months following the termination of the merger agreement, either (A)&#160;an acquisition transaction involving Bioventus is consummated or (B)&#160;a definitive agreement relating to such an acquisition transaction is entered into by Bioventus and the transaction contemplated thereby is subsequently consummated (it being understood that, for purposes of this clause (B), each reference to 20% in the definition of &#8220;acquisition transaction&#8221; above will be deemed to be a reference to 50%). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A termination fee will be payable by Bioventus only once and not in duplication even if the termination fee may be payable by Bioventus pursuant to more than one of the circumstances described above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Post-Termination Liability </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except in the case of fraud or in the case of intentional and material breach of the merger agreement, if a party receives a termination fee, then the receipt of the termination fee will be the receiving party&#8217;s sole and exclusive remedy against the paying party, its affiliates and its and their respective representatives in connection with the merger agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amendment and Waiver </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement may be amended at any time prior to the effective time by an instrument in writing signed on behalf of each of the parties to the merger agreement, except that: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Bioventus share issuance proposal is approved, no amendment may be made which by applicable law or Nasdaq regulation requires further approval of Bioventus stockholders without the further approval of such Bioventus stockholders; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Misonix merger proposal is approved, no amendment may be made which by applicable law or Nasdaq regulation requires further approval of Misonix stockholders without the further approval of such Misonix stockholders. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as otherwise provided in the merger agreement, any failure of any of the parties to comply with any obligation, covenant, agreement or condition therein may be waived by the party or parties entitled to the benefits thereof only by a written instrument signed by the party granting such waiver. Any such waiver will not be applicable or have any effect except in the specific instance in which it is given. No failure on the part of any party to exercise any power, right, privilege or remedy under the merger agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under the merger agreement, will operate as a waiver of such power, right, privilege or remedy. No single or partial exercise of any such power, right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assignment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger agreement is not assignable by any party to the merger agreement, in whole or in part, by operation of law or otherwise, without the express prior written consent of the other parties thereto. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">228 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-Party Beneficiaries </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus, Merger Sub I, Merger Sub II and Misonix have agreed that their respective representations and warranties set forth in the merger agreement are solely for the benefit of the other parties thereto, in accordance with and subject to the merger agreement&#8217;s terms. The merger agreement is not intended to, and does not, confer upon any person other than Bioventus, Merger Sub I, Merger Sub II and Misonix and their respective successors, legal representatives and permitted assigns any rights or remedies, express or implied, thereunder, including the right to rely upon the representations and warranties set forth in the merger agreement, except with respect to certain provisions (i)&#160;after the Second Effective Time, relating to payment of the merger consideration, any cash in lieu of fractional shares of Bioventus class A common stock, and any dividends or other distributions, which provisions inure to the benefit of, and are enforceable by, holders of Misonix common stock and Misonix equity awards as of immediately prior to the effective time to the extent necessary to receive the consideration and amount due to such persons thereunder, (ii)&#160;regarding indemnification of directors and officers of Misonix and (iii)&#160;intended for the benefit of certain entities that are debt financing sources in connection with the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The representations and warranties in the merger agreement are the product of negotiations among the parties. Any inaccuracies in such representations and warranties are subject to waiver by the parties in accordance with the merger agreement without notice or liability to any other person. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction; Specific Performance </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of Bioventus, Merger Sub I, Merger Sub II and Misonix has consented to the exclusive personal jurisdiction of the Delaware Court of Chancery (or if the Delaware Court of Chancery does not have jurisdiction, any federal court within the State of Delaware) in any legal actions or proceedings relating to the merger agreement or any of the transactions contemplated thereby. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of Bioventus, Merger Sub I, Merger Sub II and Misonix has also agreed that irreparable damage would occur in the event that any of the provisions of the merger agreement were not performed or were threatened to be not performed, or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. Accordingly, and in addition to any other remedy that each may be entitled to, Bioventus, Merger Sub I, Merger Sub II and Misonix have agreed that each will be entitled to an injunction or injunctions to prevent breaches of the merger agreement and to enforce specifically the terms and provisions of the merger agreement (except that Misonix, its subsidiaries and respective representatives will not be able to seek specific performance in relation to the proposed debt financing in connection with the mergers). Each of Bioventus, Merger Sub I, Merger Sub II and Misonix has also irrevocably waived any requirement for the securing or posting of any bond in connection with such injunctions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">229 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </div></div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 29, 2021, Bioventus, Misonix, Merger Sub I and Merger Sub II, entered into a merger agreement. The mergers contemplated by the merger agreement will be implemented through the merger of Merger Sub I with and into Misonix, with Misonix becoming a wholly owned subsidiary of Bioventus, the first merger. Misonix will then merge with and into Merger Sub II with Merger Sub II as the surviving limited liability company and will be Bioventus&#8217; wholly owned subsidiary, the second merger. </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On February&#160;16, 2021, Bioventus closed an Initial Public Offering (IPO) and the net proceeds were used to purchase membership interests from BV LLC. Bioventus is the sole managing member and owns 72.2% of BV LLC. Bioventus has a majority economic interest, the sole voting interest in, and controls the management of BV LLC. As a result, Bioventus consolidates the financial results of BV LLC and reports a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest representing the 27.8% interest not held by Bioventus. Bioventus&#8217; amended and restated certificate of incorporation and the Bioventus LLC agreement requires that Bioventus and BV LLC at all times maintain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> ratio between the number of shares of Class&#160;A common stock issued by Bioventus and the number LLC interests owned by Bioventus. As a result, after the second merger Bioventus will contribute the Merger Sub II assets to BV LLC resulting in Bioventus owning 79.0% of BV LLC and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest of 21.0%. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following unaudited pro forma condensed combined financial statements have been prepared to illustrate the estimated effects of the Bioventus IPO, the mergers and the financing required to complete the mergers (together, the Pro Forma Transactions). The unaudited pro forma condensed combined statements of operations for the fiscal year ended December&#160;31, 2020 and for six months ended July&#160;3, 2021 combines the historical consolidated statements of operations of Bioventus and Misonix, giving effect to the Pro Forma Transactions assuming they took place on January&#160;1, 2020. The unaudited pro forma condensed combined balance sheet combines the historical consolidated balance sheets of Bioventus and Misonix as of July&#160;3, 2021 and June&#160;30, 2021, respectively, giving effect to the Pro Forma Transactions assuming they took place on July&#160;3, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The pro forma balance sheet data and pro forma statement of operation data have been prepared utilizing period ends that differ by more than 93 days, as permitted by Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Because Bioventus&#8217; fiscal year end is December&#160;31 and Misonix&#8217;s fiscal year end is June&#160;30, the pro forma balance sheet data utilizes Misonix&#8217;s audited consolidated balance sheet as of June&#160;30, 2021. The pro forma statement of operations data for the fiscal year ended December&#160;31, 2020 were determined by adding Misonix&#8217;s audited consolidated statement of operations for the fiscal year ended June&#160;30, 2020, subtracting Misonix&#8217;s unaudited condensed consolidated statement of operations for the six months ended December&#160;31, 2019 and adding Misonix&#8217;s unaudited condensed consolidated statement of operations for the six months ended June&#160;30, 2021. The consolidated statement of operations of Misonix for the six months ended July&#160;3, 2021 were determined by adding Misonix&#8217;s audited consolidated statement of operations for the fiscal year ended June&#160;30, 2021 and subtracting Misonix&#8217;s unaudited condensed consolidated statement of operations for the six months ended December&#160;31, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial statements are based on, and should be read in conjunction with the historical audited consolidated financial statements of each of Bioventus and Misonix as of and for the year ended December&#160;31, 2020 and June&#160;30, 2021, respectively, as well as the Bioventus unaudited consolidated condensed financial statements for the three and six months ended July&#160;3, 2021 and June&#160;27, 2020 which are included in this joint proxy statement/prospectus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the consolidated financial position or results of operations that would have been realized had the mergers occurred as of the dates indicated, nor is it meant to be indicative of any future consolidated financial position or future results of operations that Bioventus will experience. The unaudited pro forma condensed combined financial statements combine the historical consolidated statements of Bioventus and Misonix for the period on a pro forma basis along with the Pro Forma Transactions, summarized below. The pro forma adjustments included in the accompanying unaudited pro forma condensed combined financial statements are based on currently available data and assumptions that management of Bioventus believes are reasonable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">230 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited pro forma condensed combined balance sheet </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of July&#160;3, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Dollar amounts in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 46%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical<br/>Bioventus</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical<br/>Misonix</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Merger<br/>Adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financing<br/>Adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/>Interest<br/>Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro Forma</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 3)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 6)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 7)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 8)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,065</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,046</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(244,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,248</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,155</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,003</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,003</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,029</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,350</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113,379</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,020</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,752</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,434</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid and other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,943</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,119</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,087</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">290,060</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,267</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(238,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,273</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">290,058</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,960</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,253</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,213</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,135</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,235</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47,041</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(c</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">257,848</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,530</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">424,470</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">702,848</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,669</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,289</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,958</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">481</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">481</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments and other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,483</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">286</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(129</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">327</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(c</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,967</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">646,636</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198,860</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">232,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,257,936</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and Stockholders&#8217; Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,881</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,368</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105,246</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,185</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,097</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117,528</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued equity-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of long-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,338</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,338</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,220</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,220</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,964</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,770</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,535</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">158,186</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,692</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,338</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,864</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, less current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166,084</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,346</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,346</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,569</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">334,653</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,410</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,388</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(n</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">156,871</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration, less current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,421</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,421</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,171</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,549</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,720</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">427,272</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,660</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,690</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180,907</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">735,529</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 3pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(i</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">146,199</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188,983</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123,056</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(i</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(106,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351,454</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53,785</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,078</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(j</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,307</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity attributable to Bioventus</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141,557</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,200</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">169,150</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,307</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(106,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">337,816</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77,807</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106,784</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184,591</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">219,364</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,200</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">169,150</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,307</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">522,407</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">646,636</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198,860</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">232,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,257,936</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See Notes to the Unaudited Pro Forma Condensed Combined Financial Information. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">231 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited pro forma condensed combined statement of operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended December&#160;31, 2020 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Dollar amounts in thousands, except unit/share and per unit/share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 42%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical<br/>BV LLC</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical<br/>Misonix</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Offering<br/>adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Merger<br/>adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financing<br/>Adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/>Interest<br/>Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro Forma</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 3)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 6)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 7)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 8)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321,161</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,608</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388,769</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales (including depreciation and amortization)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,642</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,967</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,939</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b<br/> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(d</div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(k</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;<br/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,548</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">233,519</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47,641</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(27,939</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">253,221</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,078</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,395</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,044</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,512</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k<br/> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(m</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;<br/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,307</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">282,336</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,202</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,276</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">781</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">337</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,596</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">563</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">563</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,439</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,198</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,779</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,858</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,237</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,825</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51,009</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,307</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57,132</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense (income)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,751</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,563</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(644</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(l</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,418</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,525</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,437</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense (income)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,323</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,554</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(644</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,418</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,088</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,914</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,782</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47,446</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,725</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(63,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,192</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(414</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(c</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,677</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(n</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(683</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,837</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,722</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,368</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47,383</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,087</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,776</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to equity holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,368</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,087</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income attributable to equity holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated unpaid preferred distribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income allocated to participating shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income attributable to Bioventus common unit holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,383</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per unit/share&#8212;basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.89</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(Note&#160;9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average units/shares used to compute net income (loss) per unit/share</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,900,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,044,744</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(Note&#160;9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,125,824</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See Notes to the Unaudited Pro Forma Condensed Combined Financial Information. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">232 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited pro forma condensed combined statement of operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the six months ended July&#160;3, 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Dollar amounts in thousands, except share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 42%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical<br/>Bioventus</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical<br/>Misonix</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Offering<br/>adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Merger<br/>adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financing<br/>Adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/>Interest<br/>Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro Forma</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 3)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 6)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note&#160;7)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Note 8)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,594</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,032</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">229,626</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales (including depreciation and amortization)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,725</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d<br/> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(k</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;<br/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77,857</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,869</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,019</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,769</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,642</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,544</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154,288</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,810</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,865</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(68</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,390</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">641</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,777</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,236</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(831</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,182</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of variable interest entity assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,674</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,319</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,731</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,731</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(l</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,818</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense (income)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(302</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,762</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">869</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,429</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,731</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,580</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,389</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,945</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,986</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,823</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(c</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,900</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(n</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(310</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,045</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(929</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,726</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,871</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to stock holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,045</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(929</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,855</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share&#8212;basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(Note&#160;9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares used to compute net loss per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,802,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,226,190</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(Note 9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,125,824</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bioventus per share information for the six months ended July&#160;3, 2021 represents loss per share of Class&#160;A common stock and weighted-average shares of Class&#160;A common stock outstanding from February&#160;16, 2021 through July&#160;3, 2021, the period following Bioventus Inc.&#8217;s IPO and related transactions described in the Bioventus 2020 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See Notes to the Unaudited Pro Forma Condensed Combined Financial Information.</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">233 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the unaudited pro forma condensed combined consolidated financial statements </div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except unit, share, per unit and per share data) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Description of the mergers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The merger agreement includes two mergers. After the first merger, each share of Misonix common stock issued and outstanding (Misonix Shares) immediately prior to the second merger will be converted into the right to receive $28.00 per share (Cash Election Shares) or 1.6839 shares of fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> Bioventus Class&#160;A common stock. If the settlement of the Cash Election Shares exceeds the maximum amount of cash consideration per share of $10.50 or $182.8&#160;million, then a portion of the Cash Election Shares will be settled in Bioventus Class&#160;A common stock (Bioventus Shares). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the mergers, Bioventus will assume each outstanding and unexercised option held by a Misonix employee to purchase shares of Misonix common stock (Assumed Options), which will be converted into and exchangeable for options to Bioventus Shares according to the option exchange ratio as defined in the merger agreement (Exchange Ratio). In the mergers, each outstanding option to purchase Misonix Shares will be cancelled and terminated without any payment. No fractional shares will be issued in connection with the mergers and Bioventus will pay cash in lieu of any such fractional shares. For option holders which are not a Misonix employee, Bioventus will settle each outstanding and unexercised option to purchase Misonix Shares in cash. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Basis of presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11, as amended by SEC Final Rule Release <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;33-10786,</div> Amendments to Financial Disclosures About Acquired and Disposed Businesses. In accordance with Release <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;33-10786,</div> the unaudited condensed combined pro forma balance sheet and statements of operations reflect transaction accounting adjustments irrespective of whether or not such adjustments is deemed to be recurring. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting in accordance with Accounting Standards Codification (ASC) 805, Business Combinations, with Bioventus as the accounting acquirer. Under the acquisition method of accounting, the Misonix identifiable assets acquired, and liabilities assumed are recognized and measured as of the acquisition date at fair value, defined in ASC 820, Fair Value Measurement, and added to those of Bioventus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial statements of Bioventus issued after the completion of the mergers may be different than the estimated values included in this unaudited pro forma condensed combined financial information. The financial statements of Bioventus issued after the completion of the mergers will not be retroactively restated to reflect the historical financial position or results of operations of Misonix. In addition, ASC 805 establishes that the consideration transferred be measured at the closing date of the mergers at the then-current share prices, which will likely result in a purchase price that is different from the amount assumed in these unaudited pro forma condensed combined financial statements (see Note 4 Estimated preliminary merger consideration and preliminary purchase price allocation). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under ASC 805, acquisition-related transaction costs (such as advisory, legal, valuation, other professional fees) are included in the unaudited pro forma condensed combined statement of operations. Such costs will be expensed in the historical consolidated statement of operations in the period incurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 820 defines the term &#8220;fair value&#8221; and sets forth the valuation requirements for any asset or liability measured at fair value, expands related disclosure requirements and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; This is an exit price concept for the valuation of the asset or liability. In </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">234 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">addition, market participants are assumed to be buyers and sellers unrelated to the company in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for an asset assume the highest and best use by these market participants. As a result of these standards, Bioventus may be required to record assets which are not intended to be used or sold and/or to value assets at fair value measures that do not reflect the intended use of those assets. Many of these fair value measurements can be highly subjective and it is also possible that others, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the merger consideration for the mergers depends upon certain estimates and assumptions, all of which are preliminary. The allocation of the merger consideration has been made for the purpose of developing the unaudited pro forma condensed combined financial information. The final determination of fair values of assets acquired and liabilities assumed relating to the mergers could differ materially from the preliminary allocation of purchase consideration. The final valuation will be based on the actual net tangible and intangible assets of Misonix existing immediately after the mergers. The final valuation may materially change the allocation of the merger consideration, which could materially affect the fair values assigned to the assets and liabilities and could result in a material change to the unaudited pro forma condensed combined financial information. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pro forma adjustments represent Bioventus management&#8217;s best estimates and are based upon currently-available information and certain assumptions that Bioventus management believes are reasonable under the circumstances. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma information is not necessarily indicative of what the combined company&#8217;s financial position or results of operations would have been had the mergers been completed on the dates indicated. In addition, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the combined company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no material transactions between Bioventus and Misonix during the periods presented in the unaudited pro forma condensed combined financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Accounting policies and reclassification adjustments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting policies used in the preparation of this unaudited pro forma condensed combined financial information are those set out in Bioventus&#8217; consolidated financial statements as of and for the year ended December&#160;31, 2020. Based on Bioventus management&#8217;s assessment to date, the accounting policies of Misonix are similar in all material respects to Bioventus&#8217; accounting policies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon consummation of the mergers, Bioventus management will perform a comprehensive review of Misonix&#8217;s accounting policies. The combined company may, as a result, identify additional differences between the accounting policies of the two companies which, when conformed, could have a material impact on the combined consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the acquisition method of accounting, the identifiable assets acquired, and liabilities assumed of Misonix are recognized and measured as of the acquisition date at fair value and added to those of Bioventus. The determination of fair value used in the transaction accounting adjustments presented herein. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">235 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s fiscal year end is June&#160;30 while Bioventus&#8217; is December 31. Bioventus management utilized Misonix financials as filed with the SEC to prepare financial information for the six months ended July&#160;3, 2021 and the twelve months ended December&#160;31, 2020. In addition, certain reclassifications have been made to amounts in the historical consolidated financial information of Misonix to conform to the Bioventus&#8217; financial statement presentation, including reclassifying the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical&#160;as&#160;of<br/>June&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/>June&#160;30,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">59,267</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">59,267</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,253</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,253</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">790</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(790</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,235</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,235</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,740</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">790</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,530</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,289</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,289</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">286</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">286</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">198,860</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">198,860</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and shareholders&#8217; equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,185</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,185</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,185</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">571</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(571</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of notes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,449</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,770</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,770</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,692</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,692</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> liabilities:</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,346</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,346</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">763</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(763</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">786</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">763</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,549</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,660</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,660</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shareholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,200</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,200</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and shareholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">198,860</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">198,860</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">236 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Twelve months ended December&#160;31, 2020 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 41%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>year&#160;ended<br/>June&#160;30,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the six<br/>months ended<br/>December&#160;31,<br/>2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the six<br/>months ended<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>twelve moths<br/>ended<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,484</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,868</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,992</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,608</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,774</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,182</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,375</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,967</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,710</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,686</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,617</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47,641</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,395</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,395</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,233</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,001</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,393</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(42,625</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,954</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,357</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,371</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,916</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,859</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,219</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,276</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,198</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,198</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,366</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,620</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">869</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,883</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,563</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,523</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">846</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,877</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,554</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,916</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,377</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,782</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,499</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,085</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(414</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,417</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,368</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six months ended July&#160;3, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 47%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; padding-bottom: 1pt; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/><br/><br/></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>year&#160;ended<br/>June&#160;30,<br/>2021</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/><br/>&#160;<br/>&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/><br/><br/></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the six<br/>months ended<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/><br/>&#160;<br/>&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/><br/><br/><br/></div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>six&#160;months<br/>ended<br/>July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<br/>&#160;<br/><br/>&#160;<br/>&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,024</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,992</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,032</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,388</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,375</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,636</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,617</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,019</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,642</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,642</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,087</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,393</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,555</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,371</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,029</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,219</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,810</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,236</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,236</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,035</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,366</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,620</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,883</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,731</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(304</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(302</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,306</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,877</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,429</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,341</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">237 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Estimated preliminary merger consideration and preliminary purchase price allocation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of the merger consideration expected to be transferred on the closing date is calculated as follows based on the Misonix Shares and Bioventus closing stock price on August&#160;26, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 53%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash election consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,410,045</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.50</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,805</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock election consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,322,984</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.39</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,991</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">464,796</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated cash to settle Misonix debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,994</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assumed Options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,306</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less cash acquired</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,587</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total estimated preliminary merger consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">517,509</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger consideration of $464.8&#160;million will be subject to change based on the Misonix Shares at the first merger, the cash versus stock election by holders of the Misonix Shares as well as changes in the Bioventus closing stock price. Assuming the Misonix Shares remain at 17,410,045 and the cash cap of $10.50 per Misonix Shares is met the cash election consideration would remain unchanged. The value of the stock election consideration will change based on fluctuations in the market price of Bioventus common shares since the right to receive 1.6839 shares of Bioventus Shares for each Misonix Share is fixed. A 10% fluctuation in market price of Bioventus Shares would have the following potential effect on stock election consideration: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;election<br/>consideration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As presented</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">15.39</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">281,991</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10% increase</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16.93</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">310,190</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10% decrease</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13.85</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">253,792</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total estimated preliminary merger consideration includes the value of the Assumed Options. The actual value of which will be subject to change based on the final Exchange Ratio which is dependent upon the underlying market price of both the Bioventus and Misonix Shares. The options were valued at $8.51 per option using a Black-Scholes valuation model with the assumptions shown in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term of stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.86</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price of stock options granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.39</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected term of the options is estimated using the remaining time until expiration and estimated timing of exercise. Expected volatility is based on the historical volatility of Bioventus&#8217; peers common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assuming the option Exchange Ratio remains unchanged, a 10% fluctuation in market price of Bioventus Shares would have the following potential effect on the value of the Assumed Options: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price&#160;per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumed&#160;Options<br/>value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As presented</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">15.39</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32,306</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10% increase</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16.93</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">37,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10% decrease</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13.85</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">27,079</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">238 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following sets forth a preliminary allocation of the total estimated preliminary merger consideration to the identifiable tangible and intangible Misonix assets acquired and liabilities assumed based on Misonix&#8217;s consolidated balance sheet as of June&#160;30, 2021, with the excess recorded to goodwill: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,350</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,414</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid and other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,119</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,253</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">155,276</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">445,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,446</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets acquired</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">644,858</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,768</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">571</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,461</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,549</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities assumed</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127,349</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net assets acquired</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">517,509</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill represents the excess of merger consideration over the fair value of the underlying net assets acquired. In accordance with ASC 350, Goodwill and Other Intangible Assets, goodwill will not be amortized but rather subject to annual impairment test, absent any indicators of impairment. Goodwill is attributable to planned growth in new markets and synergies expected to be achieved from the combined operations of Bioventus and Misonix. Goodwill recorded in the mergers is not expected to be deductible for tax purposes. Bioventus management is still in the process of valuing any identifiable intangible assets, to which the valuation may impact the final goodwill amount. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Offering adjustments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, Bioventus closed an IPO. The unaudited pro forma condensed combined financial statements reflect the following adjustments related to the IPO: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the IPO Bioventus granted new equity-based compensation awards to certain employees and directors and launched its employee stock purchase plan. Accordingly this results in additional estimated equity compensation expense. In addition, during the six months ended July&#160;3, 2021, in advance of the IPO, Bioventus recognized a change in fair value of accrued equity-based compensation resulting in a recovery of equity compensation expense. Adjustments to the statement of operations represents the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;Months<br/>Ended<br/>July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional equity compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,044</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of equity awards granted prior to IPO</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,654</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,044</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,454</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional equity compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">781</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of equity awards granted prior to IPO</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,741</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">781</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,865</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">239 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO an original LLC owner owned an Equity Participation Right Unit (EPR Unit). The EPR Unit was redeemed in connection with the IPO, at which time the EPR ceased to exist and all entitlements ended. Accordingly interest expense related to the EPR unit of $0.6&#160;million was removed for the year ended December&#160;31, 2020. During the six months ended July&#160;3, 2021, in advance of the IPO, Bioventus recognized a change in fair value of the EPR resulting in interest income totaling $2.8&#160;million which was also removed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax expense was adjusted to record the income tax impacts of the offering adjustments using an estimated statutory tax rate of 25.1%. This rate does not reflect the combined company&#8217;s effective tax rate, which includes other items and may be significantly different than the rates assumed for purposes of preparing these statements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Merger adjustments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial statements reflect the following adjustments related to the mergers: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to cash represents the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash election consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(182,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated cash to settle Misonix debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,994</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for transaction costs expected to be incurred through the consummation of the transactions<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(244,204</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fees directly related to this filing totaling $2.2&#160;million are estimated to be incurred by Bioventus and are recorded against APIC. $9.5&#160;million in transaction costs are estimated to be incurred by Misonix and $7.7&#160;million incurred by Bioventus which are included in the pro forma condensed combined statement of operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to acquired inventory, which consists primarily of raw materials and finished goods, at its preliminary fair value. The preliminary fair value considers replacement cost for raw materials and for finished goods, the estimated selling price adjusted for costs of the selling effort and a reasonable profit allowance for the selling effort. Bioventus will recognize the increased value of inventory in cost of goods sold as the inventory is sold, which for purposes of these unaudited pro forma condensed combined financial statements is assumed to occur within the first year after the mergers. The cost of goods sold associated with the increased inventory value totaling $5.7&#160;million is included in the unaudited pro forma condensed combined statements of operations for the twelve months ended December&#160;31, 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to eliminate Misonix&#8217;s historical goodwill of $108.2&#160;million and to recognize goodwill related to the proposed Combination of $155.3&#160;million. Goodwill is calculated as the difference between the estimated purchase price and the fair value of identifiable tangible and intangible assets acquired net of liabilities assumed. The adjustment is preliminary and subject to change based upon final determination of the fair value of assets acquired and liabilities assumed and finalization of the purchase price. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to acquired intangible assets, consisting of intellectual property at its preliminary fair value, and the required increase to historical Misonix amortization expense to the balances below. The estimated fair value was determined using an income approach, a valuation technique that estimates the fair value of an asset based on market participant expectations of the cash flows that an asset would generate over its remaining useful life. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 28%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 9%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 24%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization Expense</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended<br/>December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months&#160;ended<br/>July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangible assets<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">387,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Cost of sales</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,250</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,125</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">240 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The adjustment to amortization expense was determined using the straight line method over the estimated useful life of 20 years. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These preliminary estimates of fair value and estimated useful lives will likely differ from final amounts Bioventus will calculate after completing a detailed valuation analysis, and the difference could have a material effect on the accompanying unaudited pro forma condensed combined financial statements. With other assumptions held constant, a 10% change to the fair value of acquired finite lived intangible assets would result in an increase or decrease to amortization expense of $1.9&#160;million annually and $1.0&#160;million for a six month period. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(e)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Adjustment to eliminate $0.1&#160;million of historical deferred financing fee assets associated with Misonix&#8217;s historical revolving credit facility. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> of the deferred financing fee is recorded against accumulated deficit solely for the purposes of this presentation. As there is no continuing impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> on the combined company&#8217;s results, the debt deferred financing fee is not included in the unaudited pro forma condensed combined statements of operations. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(f)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to accrue for severance and change of control payments totaling $1.7&#160;million for the certain Misonix employees partially offset by $0.4&#160;million of accrued interest and $0.2&#160;million of accrued exit fees associated with Misonix&#8217;s historical debt obligations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(g)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to extinguish Misonix&#8217;s outstanding debt obligations of $40.6&#160;million. The cash to be paid for the extinguishment of Misonix&#8217;s outstanding debt obligations totaled $42.0&#160;million as described in Note 4. The difference between the cash to be paid and the carrying amount represents the loss on debt extinguishment from the prepayment penalties of $0.8&#160;million, $0.4&#160;million in accrued interest and $0.2&#160;million of accrued exit fees. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(h)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to remove Misonix&#8217;s outstanding loan under the Paycheck Protection Program of $5.2&#160;million as it is expected to be forgiven. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to remove Misonix historical common stock and APIC, issuance of stock election consideration, as well as Assumed Options: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">APIC</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Elimination of historical balance<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(188,983</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of stock election consideration<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281,972</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assumed Options<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,306</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123,056</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the elimination of Misonix&#8217;s APIC balance at June&#160;30, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the additional APIC value of the shares issued in connection with the mergers. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the fair value of the Assumed Options. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(j)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to eliminate Misonix&#8217;s historical accumulated deficit balance and Bioventus transaction fees totaling $7.7&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(k)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to share-based compensation expense for the acceleration of Misonix&#8217;s unvested stock compensation awards and awards granted to the two additional board members. These increases were partially offset by the removal of historical Misonix share-based compensation expense for each of the unaudited pro forma condensed combined statements of operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(l)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to eliminate the historical interest expense associated with Misonix&#8217;s historical debt obligations for each of the unaudited pro forma condensed combined statements of operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(m)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to add Misonix and Bioventus transaction costs totaling $17.2&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">241 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(n)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The mergers will qualify as a reorganization within the meaning of Section&#160;368(a) of the Code. Deferred tax liability was adjusted to reflect the estimated deferred tax impacts related to acquisition accounting adjustments primarily as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in fair value of intangible assets and inventory. The incremental deferred tax impacts were calculated based on the tax effect of the estimated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in book basis of the net assets of Misonix using an estimated statutory tax rate of 25.1%. Tax expense was adjusted to record the income tax impacts of the merger adjustments using the same rate. This rate does not reflect the combined company&#8217;s effective tax rate, which includes other items and may be significantly different than the rates assumed for purposes of preparing these statements. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Financing adjustments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance the mergers, Bioventus intends to consummate the following transactions: (i)&#160;borrowing of $262.0&#160;million in incremental term loans as allowed in the existing Bioventus credit agreement and (ii)&#160;pay $80.0&#160;million on the outstanding historical term loans under the existing Bioventus credit agreement (Debt Transactions). The unaudited pro forma condensed combined financial statements reflect the following adjustments related to the financing, the proceeds of which were used in part to fund the mergers: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to cash represents the following as of July&#160;3, 2021: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts borrowed under the Term Loan Facility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment on Bioventus outstanding historical term loan</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(80,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for fees related to the Term Loan Facility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,752</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179,248</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to debt represents the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of long-term debt:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Record current portion of the Term Loan Facility<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,338</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, less current portion:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Record noncurrent portion of the Term Loan Facility<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">249,663</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment on Bioventus outstanding historical term loan</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(80,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing fees related to the Term Loan Facility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,094</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total adjustment to long-term debt, less current portion</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,569</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Term Loan Facility, Bioventus is required to repay the amounts borrowed under the Term Loan Facility and the existing debt after the $80.0&#160;million payment in quarterly installments of 1.875% of the total principal amount through December&#160;31, 2022 and quarterly installments of 2.5% of the total principal amount through the maturity date, at which time the remaining principal balance will be due. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to record the new deferred financing fee asset of $0.3&#160;million associated with the Term Loan Facility and allocated to the revolver. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to record the financing fees not eligible for deferral totaling $1.3&#160;million associated with the Term Loan Facility. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">242 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(e)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to interest expense consists of the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months<br/>ended<br/>July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliminate historical Bioventus interest expense on long-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,998</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense on long-term debt subsequent to the Debt Transactions<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,010</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,368</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase in amortization of the original issue discount and certain deferred financing fees<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">406</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,418</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,239</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprised of interest expense related to on long-term debt subsequent to the Debt Transactions. The weighted average cash interest rate, calculated including the effects of quarterly principal payment, is approximately 1.83%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the original issue discount (OID) as well as certain fees paid to third parties for their services in arranging and structuring the financing. The OID and deferred financing fees are amortized using the straight line method which approximates the effective interest method </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A 0.125% change in the estimated interest rates on the variable rate indebtedness of $364.5&#160;million at the closing of the Debt Transactions, would result in an increase or decrease in the pro forma interest expense of approximately $0.5&#160;million for a twelve month period and $0.2&#160;million for a six month period. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(f)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax expense was adjusted to record the income tax impacts of the offering adjustments using an estimated statutory tax rate of 25.1%. This rate does not reflect the combined company&#8217;s effective tax rate, which includes other items and may be significantly different than the rates assumed for purposes of preparing these statements. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Noncontrolling interest adjustments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As described in the Bioventus 2020 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> following the completion of the IPO and and other transactions on February&#160;16, 2021, Bioventus owned 72.2% of BV LLC with a noncontrolling interest of 27.8%. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Bioventus LLC Agreement requires that Bioventus, at all times, maintain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> ratio between the number of shares of Bioventus Class&#160;A common stock issued and LLC interests owned by Bioventus. As a result, the issuance of Bioventus Class&#160;A common stock in connection with the mergers will decrease the noncontrolling interest. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The computation of the noncontrolling interest before and after the mergers are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Before</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">After</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BV LLC interest held by Bioventus Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,062,652</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59,385,636</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BV LLC noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,786,737</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,786,737</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,849,389</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,172,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">243 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pro forma noncontrolling interest as of July&#160;3, 2021 is computed as follows by adjustment: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BV&#160;LLC&#160;noncontrolling<br/>interest after mergers</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro forma<br/>noncontrolling<br/>interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historical Bioventus</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77,807</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Misonix</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">517,509</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus transaction costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing fees expensed</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,307</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">508,495</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21.0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106,784</div></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184,591</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pro forma net loss (income) attributable to noncontrolling interest for the twelve months ended December&#160;31, 2020 is computed as follows by adjustment: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BV LLC<br/>noncontrolling<br/>interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro&#160;forma&#160;loss&#160;(income)<br/>attributable to<br/>noncontrolling interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historical BV LLC loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historical BV LLC net income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,562</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,481</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historical Misonix net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,368</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,277</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,461</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">429</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,086</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,775</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pro forma net loss (income) attributable to noncontrolling interest for the six months ended July&#160;3, 2021 is computed as follows by adjustment: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 53%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BV LLC<br/>noncontrolling<br/>interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro&#160;forma&#160;loss&#160;(income)<br/>attributable to<br/>noncontrolling interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historical Bioventus loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historical BV LLC net income prior to IPO</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,977</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(23,270</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historical Misonix net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,728</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,045</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">639</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(929</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,809</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,871</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">244 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Combined company earnings per share information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted pro forma loss per share of the combined company&#8217;s Class&#160;A common stock: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;months<br/>ended<br/>July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator for basic and diluted earnings per share calculation:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47,383</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,726</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,776</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,871</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma net loss attributable to the combined company</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,855</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for basic and diluted earnings per share calculation:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average Bioventus&#8217; outstanding common stock<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,802,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,802,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued in connection with the mergers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,322,984</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,322,984</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma weighted average shares (basic and diluted)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,125,824</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,125,824</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma net loss per share&#8212;basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares of Bioventus Class&#160;A common stock outstanding, basic and diluted as of July&#160;3, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Shares of Bioventus Class&#160;B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class&#160;B common stock under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method has not been presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The potential shares of Bioventus common stock that were excluded from the computation of diluted net loss per share attributable to combined company common stockholders for the periods presented, because including them would have been anti-dilutive, are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 80%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BV LLC noncontrolling interest <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,786,737</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,398,979</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">951,911</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of Class&#160;A common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,698</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,172,325</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Shares reserved for future issuance upon redemption or exchange of LLC interests not held by Bioventus. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">245 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DESCRIPTION OF BIOVENTUS&#8217; BUSINESS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial public offering and organizational transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, Bioventus closed an initial public offering (IPO) of 9,200,000 shares of its Class&#160;A common stock at a public offering price of $13.00 per share, which included 1,200,000 shares issued pursuant to the underwriters&#8217; over-allotment option. Bioventus received $111.2&#160;million in proceeds, net of underwriting discounts and commissions, which Bioventus used to purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of its Class&#160;A common stock of $13.00. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is a holding company with no direct operations and its principal asset is the equity interest in BV LLC. In connection with the IPO, Bioventus completed a series of organizational transactions including, without limitation, the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the limited liability company agreement of BV LLC was amended and restated (Bioventus LLC agreement) to, among other things, (i)&#160;provide for a new single class of common membership interests in BV LLC (LLC interests), (ii) exchange all of the then existing membership interests of the holders of BV LLC membership interests (original LLC owners) for LLC interests and (iii)&#160;appoint Bioventus Inc. as the sole managing member of BV LLC; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the acquisition, by merger, of certain members of BV LLC (former LLC owners), for which Bioventus issued 31,838,589 shares of Class&#160;A common stock as merger consideration (Merger). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 4 Subsequent events</div></div> in the &#8220;Notes to the Audited Consolidated Financial Statements&#8221; included in this joint proxy statement/prospectus for more information about the above-mentioned transactions as well as the other transactions completed in connection with the IPO (Transactions). Following the completion of the Transactions, Bioventus owned 72.2% of BV LLC. Smith&#160;&amp; Nephew, Inc. (continuing LLC owner) owned the remaining 27.8% of BV LLC. Bioventus has a majority economic interest, the sole voting interest in, and control the management of, BV LLC. As a result, Bioventus will consolidate the financial results of BV LLC and will report a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest representing the LLC interests held by the continuing LLC owners. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company overview </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing process. Bioventus&#8217; devices are most often used to delay or replace the need for an elective surgical procedure and are focused on reaching patients early on in their treatment paradigm. The Company is headquartered in Durham, North Carolina. Bioventus has administrative facilities in the United States (U.S.), Canada, and the Netherlands, and a manufacturing facility in the U.S. Bioventus directly distributes products in the U.S., Canada, United Kingdom (U.K.), Germany and the Netherlands. In several of these and other markets, Bioventus also distributes its products through independent distributors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus believes its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> medical device and biologic products play a critical role in supporting the body&#8217;s own healing mechanisms to heal or eliminate the pain caused by orthopedic conditions and problems, which Bioventus defines as its active healing products. These products address an estimated $6.0&#160;billion market opportunity across pain treatment and joint preservation, spinal fusion surgery and bone fractures, each of which is experiencing growth through multiple industry tailwinds, including an aging population, increased participation in sports and active lifestyles and a rise in obesity rates. Bioventus&#8217; devices are most often used to delay or replace the need for an elective surgical procedure and are focused on reaching patients early on in their treatment paradigm. Bioventus&#8217; products are widely reimbursed by both public and private health insurers and are sold in the physician&#8217;s office or clinic, in ambulatory surgical centers (ASCs), and in the hospital setting in the U.S. and across 37 countries. Bioventus manages its business by its two reporting segments, U.S. and International which accounted for 91% and 9%, respectively, of its total net sales during the fiscal year ended </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">246 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">December&#160;31, 2020. Financial information regarding its reportable business segments and certain geographic information is included in &#8220;Bioventus&#8217;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>Management&#8217;s Discussion and Analysis&#8221;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>of this joint proxy statement/prospectus. See also <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 15. Segments</div></div> in the &#8220;Notes to the Audited Consolidated Financial Statements&#8221; included in this joint proxy statement/prospectus for further information regarding its business segments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; existing portfolio of products is grouped into three verticals based on its targeted customer focus. These verticals were updated and renamed after completing the acquisition of Bioness as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pain Treatments and Joint Preservation</div></div>. Bioventus is the largest pure play orthopedics-focused company in the pain treatment and joint preservation market. Bioventus has been the fastest growing hyaluronic acid (HA) participant over the last three years, driving its share to number two by revenue in the U.S. market. Bioventus offers the only complete portfolio of HA viscosupplementation therapies, including single, three and five injection regimens, for patients experiencing pain related to OA in the knee. Bioventus&#8217; HA products are all approved by the U.S. Food and Drug Administration (FDA) through premarket approvals (PMAs), and include: </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durolane, a single injection therapy, was launched in the United States in 2018 and is also marketed outside the United States in more than 30 countries including Europe through a CE mark, which is an abbreviation for Conformit&#233; Europ&#233;enne or European Conformity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3,</div> a three injection therapy, was launched in the United States in 2016; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SUPARTZ FX, a five injection therapy, was launched in the United States in 2001; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STIMROUTER, a peripheral nerve stimulation product offered through Bioness. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bone Graft Substitutes.</div></div> Bioventus is the fastest growing participant in the bone graft substitutes (BGSs) market and offer a broad portfolio of products including human tissue allografts and synthetics. Bioventus&#8217; BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient&#8217;s own bone, which is associated with additional cost and morbidity. Bioventus&#8217; products include an allograft-derived bone graft with growth factors (OsteoAMP), a demineralized bone matrix (DBM) (Exponent), a cancellous bone in different preparations (PureBone), bioactive synthetics (Signafuse and Interface), a collagen ceramic matrix (OsteoMatrix) and two bone marrow isolation systems (CellXtract and Extractor). Bioventus&#8217; products have received either 510(k) clearance from the FDA or are marketed pursuant to Section&#160;361 of the Public Health Service Act (PHSA) as Section&#160;361 HCT/Ps. HCT/Ps regulated solely under Section&#160;361 are human cells, tissues and cellular and tissue-based products that do not require marketing authorization to be marketed in the United States. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restorative Therapies.</div></div> This vertical consists of products from Bioventus&#8217; previous &#8220;minimally invasive fracture treatments&#8221; vertical and Bioness&#8217; advanced rehabilitation products. Bioventus&#8217; Exogen system was the number one prescribed device in the bone growth stimulatory market in 2018 (the latest period for which data is available). It has had marketing authorization via a PMA through the FDA for over 25 years. Bioventus is the only company to utilize advanced, pulsed ultrasound technology for bone growth in delayed and nonunion fractures in all fracture locations except spine, as well as in fresh fractures of the tibia and radius. Bioventus&#8217; Exogen system offers significant advantages over electrical based long bone stimulation systems, including a documented mechanism of action, shorter treatment times and superior nonunion heal rates. The system is also sold internationally under a CE mark for nonunions and fresh fractures and is the market-leading bone healing treatment in the delayed union and nonunion market in Japan. Bioness&#8217; advanced rehabilitation products include the L300 GO, which is a device that applies electrical stimulation to a patient&#8217;s leg to restore a patient&#8217;s normal walking gait and the Bioness Integrated Therapy System for Balance or &#8220;BITS&#8221;, which uses proprietary hardware and software programs to track movements, allowing clinicians to assess and tract patient balance throughout the restorative treatment continuum. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">247 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the measures imposed to contain the spread of the virus disrupted its business beginning in early March 2020 as healthcare systems across the U.S. were forced to limit patient visits and elective surgical procedures. The effects of the pandemic began to decrease in late April 2020 and Bioventus saw a very strong recovery for its products at the end of the second quarter as restrictions on orthopedic procedures were lifted across the United States and patients also returned to orthopedic offices. Refer to the information under<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>&#8220;Risk Factors&#8221; and &#8220;Bioventus&#8217;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>Management&#8217;s Discussion and Analysis&#8221;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>for more information regarding the impact and related risks of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; growth strategy </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus intends to pursue the following strategies to build a market-leading and customer-focused company centered on the pain treatment and joint preservation, BGSs and restorative therapies, and to continue to grow its net sales and Adjusted EBITDA: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Continue to expand market share in HA viscosupplementation</div></div>. Bioventus intends to increase sales of its HA viscosupplementation therapies and extend its market leadership in this category by building on its unique positioning as the only company to offer a one, three and five injection treatment regimen and by expanding payer coverage, which Bioventus has done successfully, increasing the number of lives under contract from 6&#160;million to 48&#160;million between 2017 and 2020. This increase in lives, along with its differentiated portfolio and dedicated direct sales team, has allowed Bioventus to achieve significant market share gains over the last several years and positioned Bioventus as the largest pure play orthopedic-focused company in the U.S. HA viscosupplementation market with a market share of approximately 17% as of September&#160;26, 2020. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Introduce new pain treatment and joint preservation products.</div></div> To expand its offering beyond HA viscosupplementation therapies and build a comprehensive portfolio for the pain treatment and joint preservation, Bioventus is planning to commercially launch a range of new therapies over the next several years, including: </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C.</div></div></div> An <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-the-shelf</div></div> aragonite implant designed for implantation into osteochondral defects in the knee. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant received breakthrough device designation by the FDA in the fourth quarter of 2020. Bioventus has an option to acquire 100% of CartiHeal&#8217;s shares pursuant to the terms and subject to the conditions set forth in the Option and Equity Purchase Agreement and as described above. See &#8220;Description of Bioventus&#8217; Business&#8212;Development and Clinical Pipeline&#8212;Treatment of Cartilage for Osteochondral defects&#8212;CartiHeal (developer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C)</div> investment and option and equity purchase agreement.&#8221; CartiHeal submitted the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> module of the PMA in January 2021 and expects to submit the final, clinical module of a Modular PMA in the fourth quarter of 2021 seeking FDA approval. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MOTYS.</div></div> A placental tissue injectable biologic for knee OA, for which on October&#160;29, 2020, Bioventus received FDA confirmation indicating its authorization of its investigational new drug application (IND), and a clinical trial for MOTYS has commenced in the first quarter of 2021. In parallel, Bioventus plans to pursue a required BLA premarket approval for this product, which Bioventus expects would expand insurance payment alternatives over time. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PROcuff.</div></div> A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bio-inductive</div> collagen implant for regeneration of tendon tissue in the rotator cuff. Bioventus expects to file a request for 510(k) clearance in either the second or third quarter of 2022. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Further develop and commercialize its BGS portfolio.</div></div> Bioventus intends to grow its presence in the BGS market and expand its reach into the operating room in both ASCs and hospitals. In the near-term, Bioventus plans to maintain and selectively expand its profitable product lines by adding to its U.S. distributor base in an effort to reach significantly underpenetrated markets. Over time, Bioventus intends to launch product line enhancements and invest in the development of next-generation BGS therapies to continue to grow its market share. Consistent with this strategy, Bioventus recently launched the Signafuse Bioactive Strip and OsteoAmp Flowable products. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">248 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expand indications for use for its Exogen system</div></div>. Bioventus is focused on generating incremental clinical data and peer-reviewed publications to expand its indications and continue to grow its market leading share. Bioventus is currently underway with the B.O.N.E.S. clinical studies, which are aimed at generating data to support label expansion in additional bone types and expanded reimbursement for the treatment of fresh fractures in patients at risk of nonunion due to certain comorbidities, such as diabetes or obesity. Bioventus commenced patient enrollment to study three specific bones in 2017 and began a rolling release of data in late 2020. Depending on the results from its studies, Bioventus plans to submit a total of three PMA supplements to the FDA, the first of which was submitted in December 2020 seeking approval for the adjunctive treatment of acute and delayed metatarsal fractures to reduce the risk of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-union.</div> Bioventus plans to submit the second PMA supplement in the second quarter of 2022 and the third PMA supplement in the second half of 2023. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Invest in research and development.</div></div> Bioventus is focused on internal research and development to broaden its portfolio of therapies for pain treatment and joint preservation, expand its Exogen system product label and undertake clinical research to support commercialization of its next-generation of BGS products. Bioventus sees significant opportunity to develop innovative and clinically differentiated products internally with its qualified research and development team. Bioventus relies on a team of 40 highly trained individuals to develop new products, conduct clinical investigations and help educate health care providers using its products. Bioventus&#8217; research and development team is comprised of 13 members holding PhDs and 18 members with more than 20 years of experience in the medical device industry. Bioventus collaborates with academic centers of excellence, leading contract research organizations and other industrial groups to complement and expedite execution of its research and development programs and minimize fixed costs. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pursue business development opportunities.</div></div> Consistent with its track record of pursuing investments. partnerships and acquisitions including those with respect to MOTYS, PROcuff and CartiHeal, Bioventus intends to continue to pursue business development opportunities that leverage its significant customer presence across orthopedics, broaden its portfolio and increase its global footprint. Bioventus will continue to search for clinically differentiated and cost-effective products and technologies that also balance its portfolio in terms of risk and time to market. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunistically grow its international markets.</div></div> Bioventus intends to focus its international business on markets where its existing portfolio can maintain profitable growth over time, either through direct or distributor based channels. For example, Bioventus launched OsteoAMP in Canada in 2020, where Durolane and Exogen had a market leading presence in 2016. Bioventus plans to selectively expand to new markets with Durolane, Exogen and its BGSs and intend to pursue further opportunities in the Asia Pacific markets. In particular, China represents an attractive and exciting market given its large and aging population as well as its rising middle class. Bioventus has added management in China and will be creating a legal entity as Bioventus seeks approval from the China Food and Drug Administration for Durolane, which Bioventus believes will be facilitated by the successful completion of its Chinese randomized controlled trial (RCT). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Developments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cartiheal </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;27, 2021, the Bioventus board, after its review of the statistical report for CartiHeal&#8217;s pivotal clinical trial and determination that the results of the statistical report indicated a Pivotal Clinical Trial Success (as contemplated by the Option and Equity Purchase Agreement), approved BV LLC and its affiliates&#8217; continued pursuit of a potential acquisition of CartiHeal. The report was delivered in connection with the Option and Equity Purchase Agreement entered into on July&#160;15, 2020, by and among BV LLC and CartiHeal (2009)&#160;Ltd., a privately-held company headquartered in Israel and the developer of the proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> implant for the treatment of joint surface lesions in traumatic and osteoarthritic joint, and its shareholders. The agreement provides BV LLC with an exclusive option to acquire 100% of CartiHeal&#8217;s shares under certain conditions, or the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">249 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Call Option, and provides CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal&#8217;s shares under certain conditions, or the Put Option. The Put Option is only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> device with a label consistent in all respects with pivotal clinical trial success. BV LLC and its affiliates thereafter deposited $50.0&#160;million in escrow in accordance with the terms of the Option and Equity Purchase Agreement. The closing of the transaction is subject to, among other things (including customary closing conditions), the valid exercise of the Call Option or the Put Option, the latter of which cannot be exercised unless and until premarket approval (PMA) by the Food and Drug Administration (FDA) is received with respect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant, which was granted Breakthrough Device Designation by the FDA last year. CartiHeal plans to submit the clinical module of their PMA later this year, and the decision from the FDA is expected in the second half of 2022. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioness </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;30, 2021, Bioventus completed the acquisition of Bioness, a global leader in neuromodulation and rehabilitation medical devices through its innovative peripheral nerve stimulation (&#8220;PNS&#8221;) therapy and premium rehabilitation solutions, for $45&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> consideration, with up to $65&#160;million of contingent consideration related to the achievement of certain key milestones. The acquisition includes the entire portfolio of Bioness products as well as its research and development pipeline. Under the merger agreement, Bioness has become a wholly-owned indirect subsidiary of Bioventus, and all Bioness employees have become employees of Bioventus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> consideration was funded exclusively through the use of cash on hand. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; products </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus offers a diverse portfolio of active healing products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery, in the physician&#8217;s office or clinic, ASCs or in the hospital setting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; portfolio of products is grouped into three verticals based on clinical use: (i)&#160;pain treatment and joint preservation, (ii)&#160;BGSs and (iii)&#160;restorative therapies (formerly, minimally invasive fracture treatments). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pain treatments and joint preservation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Knee OA is a degenerative condition that is chronic in nature and is characterized by gradual breakdown and destruction of the cartilage in the knee. This condition develops over years and is often found in patients who exhibit joint malalignment, have had a joint injury, or are overweight. The disease can involve joint inflammation and results in symptoms that include redness, warmth, swelling, stiffness, tenderness, limited range of motion and pain. As the condition advances, the knee joint gradually loses cartilage tissue and the cartilage layer attached to the bone deteriorates to the point where eventually the bone becomes exposed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus has the only complete one, three and five injection portfolio in the HA viscosupplementation market in the United States with Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> and SUPARTZ FX. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 29%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory&#160;pathway</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Region&#160;where&#160;marketed<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g09d44.jpg" style="width: 136px; height: 29px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Single injection HA</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">viscosupplementation therapy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;PMA</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Device&#160;approval by Health Canada</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;CE mark and other&#160;registrations<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;United&#160;States</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Canada</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Europe</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">250 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 29%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory&#160;pathway</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Region&#160;where&#160;marketed<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g09f66.jpg" style="width: 100px; height: 28px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three injection HA</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">viscosupplementation therapy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;PMA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;United&#160;States</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g09f66.jpg"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Five injection HA</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">viscosupplementation therapy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;PMA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;United&#160;States</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bioventus maintains exclusive distribution agreements with respect to Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> and SUPARTZ FX in the United States. Bioventus maintains exclusive distribution agreements and own certain assets with respect to Durolane outside the United States. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durolane is also approved for marketing in Argentina, Australia, Brazil, Columbia, India, Indonesia, Jordan, Malaysia, Mexico, New Zealand, Russia, Switzerland, Taiwan, Turkey and the United Arab Emirates (UAE). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Single Injection Therapy </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durolane is a sterile, transparent and viscoelastic gel that is a single injection therapy that is indicated for the symptomatic treatment of OA in the knee in the United States. Durolane is also indicated for the hip, ankle and shoulder, as well as for treatment of other small orthopedic joints outside the United States. Durolane contains high levels of HA and is injected directly into the joints affected by OA to relieve pain and restore lubrication and cushioning. This may improve joint function and help to potentially avoid or delay knee replacement surgery. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Physicians administer Durolane to the affected knee joint in a single injection and it has been observed to provide a benefit for pain reduction in patients with OA in the knee for up to 26 weeks. Durolane&#8217;s injection schedule results in economic advantages and greater patient convenience and compliance compared to other HA viscosupplementation therapies which require weekly injections over a period of three to five weeks. For example, Bioventus believes that changes in physician visiting patterns, as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, have led to increased preference for single injection therapies. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Durolane is highly purified and based upon a natural and patented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-animal</div> stabilized HA (NASHA), expanding use to patients who are allergic to animal derived solutions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comparison of major <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> single injection HA viscosupplementation therapies </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturer or</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">distributor</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Source and process</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Active ingredient /</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">treatment dosage</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Duration</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1em; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g09d44.jpg" style="width: 136px; height: 29px;"/></div></div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA&#160;of&#160;the&#160;knee</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-animalstabilized</div> HA</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">NASHA / (60 mg)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six months</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Synvisc-One</div></div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanofi S.A.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA of the knee</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Animal sourced Hylan A and Hylan B polymers</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Hylan <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">G-F</div> 20 / (48&#160;mg)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six months</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Monovisc</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">DePuy Orthopaedics, Inc.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA of the knee</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-animal</div> cross-linked sourced HA</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">2.2% sodium hyaluronate / (88 mg)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six months</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gel-One</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zimmer Biomet Holdings, Inc.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA of the knee</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Animal sourced HA</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">1.0% sodium hyaluronate /(30 mg)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Three months</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">251 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Durolane clinical data </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durolane&#8217;s proprietary stabilizing technology substantially extends the amount of time it remains in the joint. Multiple studies have been conducted to determine Durolane&#8217;s half-life, which is the amount of time needed for 50% of the injected material to be broken down and excreted from the body. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In one study, Durolane&#8217;s half-life in the joint was studied in a rabbit model. Results showed the Durolane remained in the joint with an observable half-life of 32 days, substantially longer than the half-lives of Synvisc and unmodified HA, as determined in comparable studies, which were 1.5 days and less than 1 day, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The long half-life of Durolane was also observed in the 2002 Lindqvist et al. human study where six healthy volunteers were given a single injection of Durolane that contained a radioactive isotope that could be traced, allowing scientists to measure Durolane&#8217;s elimination from the body over time. The results showed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> half-life, indicative of the expected long residence time in the joint due to Durolane&#8217;s proprietary stabilizing technology and preclinical studies. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In terms of efficacy, Durolane has been directly compared against the main intra-articular therapeutic options available for managing osteoarthritic pain: SUPARTZ FX, a five injection product, Synvisc One, a single injection product and methylprednisolone acetate, an intra-articular corticosteroid. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In a multi-center randomized, blinded, controlled trial of 349 patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mild-to-moderate</div></div> knee OA, Durolane was compared with SUPARTZ FX. This 2015 Zhang et al. study concluded that one injection of Durolane was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-inferior</div> to five weekly injections of SUPARTZ FX in terms of pain, stiffness, physical function and global self-assessment. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In an independent, investigator-initiated randomized, controlled study involving 213 patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mild-to-moderate</div></div> knee OA, Durolane was further compared to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Synvisc-One.</div> After following up with the patients over a span of 12 months following the treatment, the results from this 2013 McGrath et al. study showed that Durolane produced significantly more durable pain relief effects than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Synvisc-One,</div> while also providing longer-lasting improvements in range of motion and a reduction in the use of pain medication for study participants. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">252 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Greater Reduction in Knee Pain versus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Synvisc-One</div> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">&#160;
<img alt="" src="g180330g11g62.jpg" style="width: 588px; height: 402px;"/></div></div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 39%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">p</div></div>&lt;0.000 compared to Synvisc</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;#<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">p</div></div>&lt;0.000&#160;compared&#160;to DUROLANE&#160;baseline</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">p</div></div>=0.008&#160;compared&#160;to&#160;Synvisc&#160;baseline</div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(n=168) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mean values +/- standard deviation </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In a separate prospective, multi-center, randomized, active-controlled, double-blind, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-inferiority</div> clinical trial with 442 enrolled patients with knee OA, it was observed that single injection Durolane was well tolerated and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-inferior</div> compared to the corticosteroid methylprednisolone acetate at twelve weeks. Methylprednisolone acetate is a steroid injectable formulation used to treat pain and swelling that occurs with OA and other joint disorders. The effect size for pain, physical function and stiffness scores favored Durolane over methylprednisolone acetate from twelve to 26 weeks. The benefit of Durolane was maintained through 26 weeks, while that of methylprednisolone acetate declined during the same period. An additional injection of Durolane at 26 weeks conferred improvements through 52 weeks without increased sensitivity or risk of complications compared to the initial injection. One subset of 31 patients treated with Durolane remained pain free after six months from the first injection and did not elect to receive a second injection. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, over 2&#160;million injections of the Durolane formulation have been safely administered globally since its international launch in 2006. Bioventus launched Durolane in the United States in March 2018 and have owned certain Durolane assets outside of the United States relating to trademark, product registrations and clinical data since November 2015. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">253 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Injection Therapy </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> is an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> sterile, buffered solution of highly purified sodium hyaluronate that is administered as a three injection HA viscosupplementation therapy. It is indicated for the treatment of pain due to knee OA in patients who have failed to respond adequately to conservative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-pharmacologic</div> therapy and simple analgesics. The solution treats knee OA by providing temporary replacement for the diseased synovial fluid and restoring lubricity of bearing joint surfaces. Physicians administer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> to the affected knee joint once a week for three consecutive weeks. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> provides relief of knee pain and may help delay the need for total knee replacement surgery. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> is derived from bacterial fermentation, is highly purified and does not involve the use of animal products, thereby reducing the potential risk of an immune response following injection. Bioventus currently markets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> in the United States. As of December&#160;31, 2020, approximately 900,000 injections of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> HA formulation have been safely administered in the United&#160;States since its launch in 2016. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> clinical data </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The safety and efficacy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> was assessed in a prospective, multicenter, randomized, controlled, double-blind, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-inferiority</div> pivotal study that enrolled 381 adult patients with knee OA. Patients were randomized to receive three weekly injections of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> or three weekly injections of Synvisc 3, a three injection regimen commercialized in the United States by Sanofi S.A., with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> visits scheduled up to 26&#160;weeks. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3</div> was observed to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-inferior</div> to Synvisc 3 at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">26-week</div> time point. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Five Injection Therapy </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">SUPARTZ FX is an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> sterile and viscoelastic solution of HA that is administered as a five injection HA viscosupplementation therapy. It is indicated for the treatment of pain in patients with knee OA who failed to adequately respond to conservative nonpharmacological therapy and simple analgesics. The solution treats knee OA by providing temporary replacement for the diseased synovial fluid and restoring the lubricity of the bearing joint surfaces. Physicians administer SUPARTZ FX to the affected knee joint once a week for five consecutive weeks. SUPARTZ FX may also delay the need for total knee replacement. SUPARTZ FX is derived from HA extracted from certified and veterinary inspected chicken combs. Risks can include general knee pain, warmth and redness or pain at the injection site. Bioventus currently markets SUPARTZ FX in the United States. As of December&#160;31, 2020, over 410&#160;million injections of the SUPARTZ FX HA formulation have been safely administered globally since its launch in 1987. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SUPARTZ FX clinical data </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In a double blind, randomized, multi center, parallel group study conducted by Day et al. in 2004 of the effectiveness and tolerance of intra-articular SUPARTZ FX compared to control (saline) treatment for knee OA, it was observed that SUPARTZ FX reduced knee pain in patients during the post-injection period by about 50% from the baseline. Of 240 patients randomized for inclusion in the study, 223 patients were evaluable for the modified intention to treat analysis and the statistically significant difference from the control was apparent after the series of injections was complete. Intra-articular SUPARTZ FX therapy was shown to be more effective than saline in mild to moderate knee OA for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-week</div> post injection period of the study. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The safety and efficacy of SUPARTZ FX was observed by Strand et al. in an integrated analysis. This integrated analysis included five separate double-blind, randomized, saline-controlled trials, and included a total of 1,155 patients comparing five weekly injections of SUPARTZ FX versus a saline placebo. The pooled results from this study showed that SUPARTZ FX produced statistically significantly greater reduction from baseline in total Lequesne scores, a measure of overall function including pain. The incidence of adverse events were observed to be minimal and similar in both treatment arms. Furthermore, none of the reported adverse events were observed to be deemed treatment-related suggesting that SUPARTZ FX was safe and well-tolerated. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">254 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comparison of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> multi-injection HA viscosupplementation therapies </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 25%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 17%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturer&#160;or&#160;distributor</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Source and</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">process</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Active ingredient /</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">total treatment</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">dosage</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">injections</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">per course</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Duration</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g13h77.jpg" style="width: 150px; height: 48px;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA&#160;of&#160;the&#160;knee</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Fermented, bacterial derived HA</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.84% sodium hyaluronate</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(50.4 mg)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Three</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six&#160;months</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g13i88.jpg" style="width: 149px; height: 42px;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA of the knee</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Naturally derived, purified HA</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.0% sodium hyaluronate</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(75/125 mg)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Three&#160;to&#160;Five</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six months</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Synvisc</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanofi S.A.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA of the knee</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Hylan polymers, purified HA</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">0.8% Hylan <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">G-F</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 (48 mg)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Three</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six months</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Euflexx</div></div>a</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ferring</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmaceuticals Inc.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA of the knee</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Fermented, bacterial derived HA</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.0% sodium hyaluronate</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(60 mg)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Three</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six months</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hyalgan</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fidia Farmaceutici</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S.p.A.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA of the knee</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Naturally derived, purified HA</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.0% sodium hyaluronate</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(60 mg/100 mg)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Three to Five</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six months</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Genvisc-850</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">OrthogenRx, Inc.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">OA of the knee</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Fermented, bacterial derived HA</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.0% sodium hyaluronate</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(75/125 mg)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Three to Five</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Six months</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development and Clinical Pipeline </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amniotic tissue products for the treatment of OA </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaboration and development agreement for MOTYS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;29, 2019, Bioventus entered into a Development Agreement with Musculoskeletal Transplant Foundation, Inc. (MTF) to develop an injectable placental tissue product, MOTYS, for use in the pain treatment and joint preservation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The development and commercialization of the product is subject to the FDA&#8217;s BLA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> approval process. Once approved as a biologic, MOTYS will be eligible for health insurance reimbursement and hence gain access a broader patient population. Bioventus is planning to conduct randomized clinical trials to ultimately support the submission to the FDA of a BLA for the use of MOTYS in the pain treatment and joint preservation vertical. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on its preclinical evidence, Bioventus believes the MOTYS formulation holds potential for mitigating pain while protecting damaged cartilage and promoting anti-catabolic and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-anabolic</div> events that could ultimately result in delayed disease progression in OA. Bioventus has completed extensive in vitro and in vivo studies comparing the effect of MOTYS to the clinical standard of care (steroid injections). MOTYS provided <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-inferior</div> pain relief effects to a steroid, but was superior in its effect on cartilage protection and in promotion of new tissue formation. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2020, Bioventus received FDA confirmation indicating its authorization of its IND and plan to initiate clinical studies by year end. Amniotic products have been extensively and safely used in clinical practice, and FDA has granted Regenerative Medicine Advanced Therapy (RMAT), designation to other amniotic tissue products being investigated for use in OA, which enables an expedited development pathway as well as eligibility for increased and earlier interactions with FDA. Bioventus intends to submit a request for RMAT designation for MOTYS in 2022. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">255 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Implantable for the treatment of rotator cuff injuries </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development collaboration agreement for PROcuff </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;23, 2019, Bioventus entered into an exclusive Collaboration Agreement with Harbor Medtech Inc. (Harbor) to develop and license the rights to commercialize a woven-suture-collagen composite implant product, PROcuff, for the regeneration of tendon tissue. Concurrently with the execution of the agreement, Bioventus purchased $1.0&#160;million of shares of Harbor. As a result of Harbor&#8217;s achievement of certain milestones, on October&#160;5, 2020, Bioventus purchased $1.0&#160;million of additional shares of Harbor. The sole use of proceeds from these investments is for the development of the woven-suture-collagen composite implant product and Bioventus has the right to purchase the product from Harbor once it is cleared for marketing by the FDA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus terminated the collaboration agreement with Harbor on June 8, 2021 and determined that the termination was a triggering event requiring an impairment assessment of Harbor&#8217;s long lived assets. The assessment resulted in an impairment of $5,674, representing Harbor&#8217;s long-lived asset balance, which was recorded within impairment of variable entity assets in the consolidated condensed statements of operations and comprehensive (loss) income, of which $5,176 is attributable to the non-controlling interest. Bioventus stopped consolidating Harbor upon the termination of the collaboration agreement, as Bioventus ceased being the primary beneficiary because it no longer had the power to direct Harbor&#8217;s significant activities. Bioventus also assessed its Harbor investment post deconsolidation, which resulted in a $1,369 impairment, representing the remaining investment balance in Harbor and was recorded within other expense in the consolidated condensed statements of operations and comprehensive (loss) income. Bioventus continues to have license rights to certain technology obtained from Harbor and is continuing product development initiated under the Collaboration Agreement. See Note 3. Business combinations and investments within the Notes to the Unaudited Condensed Consolidated Financial Statements included in this joint proxy statement/prospectus for further details concerning the impairment and deconsolidation of Harbor. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treatment of Cartilage for Osteochondral defects </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">CartiHeal (developer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C)</div> investment and option and equity purchase agreement </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;15, 2020, BV LLC made a $15.0&#160;million equity investment in CartiHeal (2009)&#160;Ltd. (CartiHeal), a privately-held company headquartered in Israel and developer of the proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus believes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> is the only product in clinical development in the United States as an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-the-shelf</div></div> scaffold implant that is designed to regenerate hyaline cartilage and subchondral bone simultaneously. The associated surgical procedure is similar to osteochondral allograft implantation, but is a single-step process and is easier, faster and more cost-effective. Bioventus believes this is the first cartilage repair technology to be tested in trials designed for regulatory approval in the United States in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-OA</div> and OA patients, potentially unlocking applications for millions of patients with knee OA and cartilage defects. Bioventus also believes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> will enable the treatment of cartilage lesions in a significant population of OA patients, including those younger, active patients for whom available treatment options are limited. The FDA&#8217;s grant of breakthrough device designation in the fourth quarter of 2020 for the treatment of an International Cartilage Repair Society (ICRS) grade III or above knee-joint surface lesions(s), with a total treatable area of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-7cm2,</div> without severe osteoarthritis (Kellgren-Lawrence grade <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0-3)</div> is a promising development, as such designation may help patients receive more timely access to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> by expediting its development, assessment and review by the FDA. On January&#160;12, 2021, the Centers for Medicare and Medicaid Services (CMS) issued a final rule under which a breakthrough device designation by the FDA also provides a streamlined pathway to national Medicare coverage for a period of four years, beginning as early as the FDA approval for the product. On March&#160;12, 2021, CMS delayed by 60 days the effective date of the final rule on Medicare coverage for innovative technology, which was previously slated to become effective March&#160;15, 2021. The agency also provided a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> public comment period, which ends April&#160;16, 2021. Bioventus believes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> also has the potential for broader indications for use in other joints, providing entrance into the global market for cartilage repair products designed to delay or eliminate the need for knee replacements. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">256 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In preclinical studies <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> was associated with osteochondral regeneration, good lateral integration and hyaline cartilage formation in critical size defects at 20 months when implanted in a goat, with the implant being fully resorbed between six to 20 months. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant has been implanted in more than 190 patients outside the United States with follow up of more than four years and is CE marked. The implant is currently being evaluated in a pivotal study pursuant to an IDE filed with the FDA. The trial&#8217;s objective is to demonstrate the superiority of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant over the surgical standard of care (microfracture and debridement) for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes. The study&#8217;s protocol design, which is based on feedback from multiple <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-IDE</div> interactions with the FDA, involves broad inclusionary criteria, such as defect size, age, and etiology, multiple controls, including microfracture and debridement, and multiple <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-planned</div> secondary endpoints. The study has an adaptive design, which allows for a maximum of 500 planned patients, includes multiple interim analyses to estimate sample size needs and includes European Union (EU), Israeli and U.S. sites. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">BV LLC&#8217;s CartiHeal investment follows the recently completed enrollment and reporting of interim results in CartiHeal&#8217;s IDE multinational pivotal study for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C.</div> This investment is expected to enable CartiHeal to complete the study, including all patient <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up,</div> and submit a PMA to the FDA. Under the equity purchase agreement, CartiHeal can secure an additional $5.0&#160;million from us, if needed, for IDE study completion. BV LLC previously made an initial $2.5&#160;million investment in CartiHeal in January 2018 and a subsequent investment of $0.2&#160;million in January 2020 as part of prior CartiHeal financing rounds. Any additional investment Bioventus makes will be subject to customary closing conditions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Concurrent with the July&#160;15, 2020 investment, BV LLC entered into an Option and Equity Purchase Agreement with CartiHeal and its shareholders, which provides BV LLC with an exclusive option to acquire 100% of CartiHeal&#8217;s shares, or the Call Option, and provides CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal&#8217;s shares under certain conditions, or the Put Option. The Call Option is exercisable by BV LLC at any time after the closing of the investment. The Put Option is only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> device with a label consistent in all respects with pivotal clinical trial success. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If not previously exercised, the Call Option and the Put Option terminate 45 days following the FDA approval of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> (subject to final review by BV LLC of updated disclosures by CartiHeal). Should the Put Option or Call Option be exercised and the acquisition of CartiHeal consummated, consideration for the acquisition of all of the shares of CartiHeal pursuant to the Option and Equity Purchase Agreement would be $350.0&#160;million in cash, subject to customary adjustments, all of which would be payable at closing, with an additional $150.0&#160;million payable upon achievement of certain sales milestones related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Recent Developments&#8212;CartiHeal.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bone Graft Substitutes </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BGSs in spinal fusion and other procedures </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bone grafting is a surgical procedure used to fuse spinal vertebrae, replace missing bones, fix bones that are damaged from trauma or problem joints, or to facilitate growing bones around an implanted device, such as a total knee replacement. The bones used in a bone graft can come from a particular patient&#8217;s own body, referred to as an autograft, or from a donor, referred to as an allograft, or can be entirely <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">man-made,</div> referred to as a synthetic. Most bone grafts are expected to be reabsorbed and replaced as the natural bone heals over a few months. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; BGS product portfolio is comprised of clinically efficacious and cost effective bone graft solutions to meet a broad range of patient needs and procedures. Bioventus&#8217; products are designed to improve bone fusion rates following spinal and other orthopedic surgeries, including trauma and reconstructive foot and ankle procedures. These products include an allograft-derived bone graft with growth factors (OsteoAMP), a DBM </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">257 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exponent), cancellous bone in different preparations (PureBone), bioactive synthetics (Signafuse and Interface), a collagen ceramic matrix (OsteoMatrix) and two bone marrow isolation systems (CellXtract and Extractor). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As Bioventus builds the body of clinical evidence supporting its products, Bioventus continues to look for and execute on opportunities to innovate in its BGS portfolio. To meet growing market demand and evolving surgical techniques, Bioventus continues to develop product extensions and adjust formulations. For example, Bioventus launched OsteoAMP Select in 2019 and OsteoAMP Flowable in 2021. Bioventus designed OsteoAMP Flowable to be moldable and easy to use, with a convenient, ready to use syringe. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 30%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 27%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 27%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indications</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">pathway / year</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">launched</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="7" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allograft</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g16j01.jpg" style="width: 149px; height: 31px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Orthopedic, neurosurgical and reconstructive bone grafting procedures</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">An allogeneic bone graft that is available in multiple formats (fibers, putty, sponge and granules) that is processed with bone marrow cells to maintain the wide array of growth factors present in native bone</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;Section&#160;361 HCT/P /</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2009</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g16k02.jpg" style="width: 149px; height: 33px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Posterolateral spine procedures</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Derived from human allograft bone tissue and is combined with a migration-resistant resorbable carrier and formulated into a putty</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;510(k) / 2012</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g16l03.jpg" style="width: 149px; height: 33px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Orthopedic, neurosurgical and reconstructive bone grafting procedures</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">100% cancellous bone with compressible, elastic and sponge-like attributes, offered in filler, block and strip options, as well as mineralized chips</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;Section&#160;361</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HCT/P /</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2012</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synthetic</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g16m04.jpg" style="width: 149px; height: 34px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Standalone posterolateral spine, extremities and pelvis, as well as a bone graft extender in the posterolateral spine</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioactive synthetic bone graft substitute comprised of a mixture of calcium phosphate granules and bioglass granules</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspended in a resorbable polymer carrier that facilitates handling and delivery of the granule components to fill spaces of missing bone</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;510(k)&#160;/&#160;2014</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g17n05.jpg" style="width: 149px; height: 37px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Posterolateral spine when mixed with autograft, extremities and pelvis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Bioactive synthetic bone graft in the form of irregular granules of bioglass to repair bone defects</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;510(k) / 2011</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g17o06.jpg" style="width: 149px; height: 28px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Posterolateral spine, extremities and pelvis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Next-generation mineralized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-phase</div> calcium phosphate bone void filler comprised of a collagen scaffold designed for optimized intra-operative handling and biologic responsiveness at the defect site</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;510(k) / 2010</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">258 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 29%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 29%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 7%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;;text-align:center;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g16m04.jpg" style="width: 149px; height: 34px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Posterolateral spine, extremities and pelvis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Next-generation mineralized bone void filler comprised of bioglass and biphasic mineral granules embedded in a collagen scaffold designed for optimized intra-operative handling and biologic responsiveness at the defect site.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">&#8226;510(k)&#160;/&#160;2020</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restorative Therapies </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bone fractures </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Fractures, also known as broken bones, occur when there is a high force or impact put on a bone, most commonly from trauma resulting from sports injuries, car accidents, falls or from osteoporosis, which is bone weakening due to aging. Immediately following a fracture, patients are treated to realign the fractured bone ends. If possible or required, the affected limb is immobilized using plaster or a splint. In some cases, fractures require surgical fixation with devices such as screws, plates, rods and frames. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">X-rays,</div> CT and MRI imaging are utilized to verify alignment of the bone and to assess progress towards healing. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A fracture is considered a fresh fracture during the first 14 days after the fracture occurs. After a fracture is treated, new bone tissue begins to form and bridge the gap. With modern treatment methods, most fractures heal spontaneously over the course of several months following injury. However, some fractures fail to heal even when they receive the best surgical or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-surgical</div> treatments. This condition may be diagnosed as a nonunion fracture. Nonunions may occur due to mechanical instability of the fracture site, due to inadequate immobilization, poor blood supply, gaps in bone to bone contact, or a number of comorbidities experienced by the patient. In clinical literature, it is estimated that five to ten percent of all fractures fail to heal, often in high impact fractures or in patients that have compromised health from old age, obesity, cardiovascular disorders, arthritis, diabetes or smoking. A nonunion is considered to be established when the fracture site shows no visibly progressive signs of healing. Nonunions have a negative impact on quality of life with symptoms, such as reduced mobility, swelling, pain, tenderness, deformity and difficulty bearing weight. Patients with nonunions may undergo surgery when certain conditions occur, such as an unstable or misaligned fracture, or a larger inter-fragment gap. Some nonunions can be treated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-surgically</div> using bone stimulation devices. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long bone stimulation systems </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus offers its Exogen ultrasound bone healing system for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> treatment of established nonunion fractures and certain fresh fractures. Bioventus&#8217; Exogen system was the number one prescribed device in the long bone growth stimulatory market in 2018. It has been sold commercially for over 25 years and is the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> device on the market for the accelerated healing of fresh, closed posteriorly displaced distal fractures of the radius and fresh, closed or grade I open long bone fractures. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 24%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 24%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory pathway</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Region where</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">marketed<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;;text-align:center;"> <div style="text-align: center; text-indent: -1em; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">&#160;
<img alt="" src="g180330g18p07.jpg"/></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Ultrasound bone healing system for nonunion fractures and fresh fractures to the tibia and radius(2)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;PMA</div></div> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;Device approval by Health Canada</div></div> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;CE mark and other registrations<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;United States</div></div> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;Canada</div></div> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;Europe</div></div> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;Japan</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bioventus&#8217; Exogen system is indicated in the United States for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> treatment of established nonunions, excluding skull and vertebra, and for accelerating the time to a healed fracture for fresh, closed, </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">259 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">posteriorly displaced distal radius fractures and fresh, closed or Grade I open long bone fractures in skeletally mature individuals when these fractures are orthopedically managed by closed reduction and cast immobilization. Bioventus own its Exogen system and market it both in and outside the United States. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exogen is also approved for marketing in Australia, Japan, New Zealand, Saudi Arabia, Turkey and the UAE. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; Exogen system is used to administer treatment in a location of convenience, including at home or work, once daily, for 20 minutes, or as prescribed by the patient&#8217;s physician, for accelerating bone healing. This therapy provides a cost-effective treatment alternative to surgical intervention for nonunions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus&#8217; Exogen system consists of the portable device, a charger, a gel bottle and strap. The device features a transducer at the end of a coiled cord, a color screen, a power button and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mini-USB</div> charging port to allow for recharging the battery. The transducer sends specifically-programmed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-intensity</div> pulsed ultrasound to the fracture site through the skin and soft tissue, with little or no sensation felt by the patient during the treatment. The gel facilitates ultrasound signal transmission through the patient&#8217;s skin. Bioventus&#8217; Exogen system provides an easy to use interface that tracks treatment use and promotes compliance. In a clinical study of its Exogen system, Bioventus observed a 91% patient compliance with the treatment regimen, based on median total time of device usage. An additional support tool for the patient is Exogen Connects, a free smartphone app that provides daily automated treatment reminders and helpful healing information. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus&#8217; Exogen system utilizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-intensity</div> pulsed ultrasound technology to stimulate the body&#8217;s natural bone healing process. The ultrasound output intensity of the device is comparable to diagnostic ultrasound intensity levels used in obstetrical sonogram procedures for fetal monitoring and is typically only one to five percent of the output intensity of conventional therapeutic ultrasound devices used for physical therapy. Some patients report experiencing a tingling sensation at the treatment site. The depth and breadth of the Exogen ultrasound signal enables it to treat superficial and deep indicated fractures. Exogen ultrasound is osteoinductive, which means it stimulates cells to differentiate into osteoblasts, or cells that make new bone. The growth of this new bone helps bridge the gap at the fracture site. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of U.S. long bone stimulation devices </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 20%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturer</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Daily&#160;treatment</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">times</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Technology</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indications</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g18p07.jpg" style="width: 147px; height: 46px;"/></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">20 minutes</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-intensity</div> pulsed ultrasound</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Nonunions and select fresh fractures<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CMF OL1000</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">DJO Global, Inc.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">30 minutes</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Combined magnetic field</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Nonunions</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physio-Stim</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Orthofix International B.V.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">3 hours</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Pulsed electromagnetic field</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Nonunions</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EBI Bone Healing System</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zimmer Biomet Holdings, Inc.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">10 hours</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Pulsed electromagnetic field</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Nonunions</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OsteoGen</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zimmer Biomet Holdings, Inc.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">24 hours</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Direct electrical current (implanted)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Nonunions</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orthopak 2 Bone Growth Stimulator</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Zimmer Biomet Holdings, Inc.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">24 hours</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Capacitive coupling</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">Nonunions</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Heal rates for fresh fracture as compared to placebo. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">260 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Bioventus&#8217; Exogen system is indicated in the United States for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> treatment of established nonunions excluding skull and vertebra and for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open long bone fractures in skeletally mature individuals when these fractures are orthopedically managed by closed reduction and cast immobilization. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exogen clinical data </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In a meta-analysis published by Leighton et al. in 2017 studied heal rates of many different fracture nonunions treated with its Exogen system. A total of 13 eligible studies were identified which reported success of treatment with its Exogen system in 1,441 nonunions. Overall, that analysis estimated that 82% of nonunions of at least three months in age treated with its Exogen system successfully healed. Because healing of established nonunion is not expected without treatment, these findings are compelling. Bioventus&#8217; Exogen system may be most useful in patients for whom surgery is high risk. With an observed overall average nonunion heal rate of at least 80% after treatment with its Exogen system, the study authors concluded that treatment with its Exogen system was comparable to surgical treatment for nonunion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional published evidence supports the efficacy of its Exogen system in treating fracture nonunions. Established fracture nonunions rarely heal without corrective surgery, though nonunion revision surgery is expensive, invasive and the expected heal rate averages approximately 86%. In a study that looked at patient data collected over a four-year period, Zura et al. found that was that the Exogen system enhanced the heal rate among chronic nonunions and even healed fractures that had been nonunion for more than 10 years, without further surgical intervention. Heal rate was 86.2% among patients with fractures that had not healed for at least one year, 82.7% among 98 patients with chronic nonunion of greater than five years duration, and furthermore 12 patients healed after chronic nonunion of greater than 10 years. Therefore, its Exogen system offers a heal rate comparable to surgery, with fewer associated risks and morbidities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Developmental and clinical pipeline </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ongoing Bioventus-sponsored clinical studies (B.O.N.E.S.) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">While currently indicated for the treatment of both established nonunions, excluding skull and vertebrae, and certain types of conservatively managed acute fractures of the tibia and radius, its Exogen system&#8217;s use in fracture care management has grown over its 20 year clinical history in both the United States and internationally. The use of its Exogen system for the management of fresh fractures has been the subject of numerous published peer reviewed research articles. The current prescription data indicate that the product&#8217;s use in routine practice of fresh fracture management is based on clinician&#8217;s determination of medical necessity, in an effort to mitigate risk of progression to fracture nonunion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-risk</div> patients. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In order to quantify the effectiveness of its Exogen system in mitigating the risk of progression to fracture nonunion, and in an effort to obtain regulatory approval for expanded indications, Bioventus is seeking to supplement the body of clinical knowledge in an innovative population-based clinical development program, B.O.N.E.S., which stands for Bioventus Observational <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-interventional</div> Exogen Studies. With enrollment started in late 2017, the B.O.N.E.S. clinical study design includes the parallel conduct of three independent study protocols which, taken together, are designed to prospectively include more than 3,000 Exogen-treated patients presenting with certain risk factors to be observed over the course of 9 to 12 months. Bioventus&#8217; Exogen system treated patients will be propensity matched to one or more untreated controls extracted from a real-world health claims database provided by Truven Healthcare Analytics, generating a total sample size of at least 6,000 patients. The program involves the concurrent execution of three studies on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> anatomical locations, such as the tibia, scaphoid and fifth metatarsal, with the objective of determining if the use of its Exogen system mitigates risk of fracture nonunion in predisposed patients. Depending on the results from its studies, Bioventus plans to submit a total of three PMA supplements to the FDA, the first of which was submitted in December 2020 seeking approval for the adjunctive </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">261 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">treatment of acute and delayed metatarsal fractures to reduce the risk of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-union.</div> Bioventus plans to submit the second PMA supplement in the second quarter of 2022 and the third PMA supplement in either the third or fourth quarter of 2023. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2021, Bioventus received a letter from the FDA identifying certain deficiencies in the PMA supplement that must be addressed before the FDA can complete its review of the PMA supplement. The deficiencies include concerns about the data and endpoints from the B.O.N.E.S. study, and requests for re-analyses of certain data and provision of other information to support the findings. Bioventus continues to evaluate the FDA&#8217;s comments and is initiating discussions with them to address their concerns. Bioventus can give no assurance that it will be able to resolve the deficiencies identified by the FDA in a timely manner, or at all. Consequently, the FDA&#8217;s decision on the PMA supplement may be delayed beyond the time originally anticipated by Bioventus. Moreover, if Bioventus&#8217; responses do not satisfy the FDA&#8217;s concerns, the FDA may not approve Bioventus&#8217; PMA supplement seeking to expand the indications for use of EXOGEN as proposed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales and marketing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; expansive direct sales and distribution channel across its product portfolio provides Bioventus with broad and differentiated customer reach, and allows Bioventus to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Bioventus&#8217; products are widely reimbursed by both public and private health insurers and are sold in the physician&#8217;s office or clinic, ASCs, and in the hospital setting in the United States and across 37 countries. Bioventus&#8217; sales team and distributors work directly with its physician customers on a frequent basis, providing Bioventus with a significant opportunity to introduce new products and upsell from its current portfolio. Bioventus believes its sales organization will provide Bioventus with an opportunity to efficiently roll out its deep pipeline and participate in business development opportunities going forward. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; pain treatment and joint preservation products and its restorative therapies products are sold by a direct sales team of approximately 240 in the United States and approximately 45 internationally as of December&#160;31, 2020. This direct team is complimented by approximately 20 account representatives who work with its sales team to provide account access through IDNs, GPOs and payer contracting. Bioventus&#8217; direct sales organization, totaling approximately 305 globally, is supplemented by approximately 35 sales managers. Bioventus&#8217; sales leaders have considerable experience, with an average of five years of experience. Bioventus&#8217; BGS products are sold by approximately 170 independent distributors in the United States, each with their own independent sales force, supported by its 15 member regionalized sales support team as of December&#160;31, 2020. Bioventus markets its BGSs primarily to orthopedic spine surgeons and neurosurgeons for use in the operating room in both the hospital and ASC setting. Bioventus believes that its broad customer reach has and will continue to enable strong and durable growth in each of its verticals and provides a significant foundation for future product launches. Bioventus supports its sales organization with extensive training to help them excel, and Bioventus has a performance culture built on serving its core orthopedic patient customers and delivering its products to a variety of physicians and care settings. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and clinical operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus sees significant opportunity to develop innovative and clinically differentiated products internally with its experienced research and development team. Bioventus is focused on internal research and development to broaden its portfolio of therapies to manage pain and joint preservation, expand its Exogen system product label and undertake clinical research to support commercialization of its next-generation of BGS products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result, Bioventus expects its research and development expense to increase to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits as a percentage of net sales as Bioventus introduces new products, extend existing product lines and expand indications. Bioventus&#8217; research and development activities are focused on product development in BGSs, treatments for OA and soft tissue surgery. Bioventus&#8217; clinical research is focused on running the B.O.N.E.S. and MOTYS clinical programs, as well as continuing to build its body of clinical evidence to demonstrate the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">262 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">efficacy and value of its products through collaborations with prominent academic investigators. Bioventus collaborates with academic centers of excellence, leading contract research organizations and other industrial groups to complement and expedite execution of its research and development programs and minimize fixed costs. Research and development expense, including spending on its clinical evidence development efforts, totaled $11.2&#160;million, $11.1&#160;million and $8.1&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The medical device industry is highly competitive, subject to change and significantly affected by activities of industry participants. The multi-injection HA viscosupplementation therapies that Bioventus owns or distributes compete against Ferring Pharmaceutical Inc.&#8217;s Euflexxa, Fidia Farmaceutici S.p.A.&#8217;s Hyalgan, DePuy Orthopaedics, Inc. (Johnson&#160;&amp; Johnson&#8217;s) Orthovisc, Sanofi S.A.&#8217;s Synvisc and OrthogenRx Inc.&#8217;s GenVisc 850. These products have faced significant competition from single injection therapies, such as Sanofi S.A.&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Synvisc-One,</div> Zimmer Biomet Holdings, Inc.&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gel-One</div> and DePuy Orthopaedics, Inc. (Johnson&#160;&amp; Johnson&#8217;s) Monovisc. Bioventus&#8217; BGS product portfolio competes with products from Medtronic, DePuy Orthopaedics, Inc. (Johnson&#160;&amp; Johnson), Stryker Corporation, NuVasive, Inc., SeaSpine, Inc., Orthofix Medical Inc., Zimmer Biomet Holdings, Inc. and Globus Medical Inc. Bioventus&#8217; Exogen system competes with products marketed by Orthofix Medical Inc., Zimmer Biomet Holdings, Inc. and DJO Global Inc. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At any time, these or other market participants may develop alternative treatments, products or procedures that compete directly or indirectly with its products. They may also develop and patent processes or products earlier than Bioventus can or obtain regulatory clearance or approvals for competing products more rapidly than Bioventus can. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus strives to protect and enhance the proprietary technologies, inventions and improvements that Bioventus believes are important to its business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Bioventus&#8217; policy is to seek to protect its proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to its proprietary technology, inventions and improvements that are important to the development and implementation of its business. Bioventus also relies on trademarks, trade secrets and careful monitoring of and contractual obligations with respect to its proprietary information to protect aspects of its business that are not amenable to, or that Bioventus does not consider appropriate for, patent protection. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus&#8217; success will depend on its ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> related to its business, defend and enforce its patents, maintain its licenses to use intellectual property owned by third parties and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. For important factors related to its proprietary technology, inventions and improvements, please see &#8220;Risk Factors&#8212;Risks Relating to Intellectual Property Matters.&#8221; </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus owns numerous patents and/or patent applications which relate to its material products, including patents and/or patent applications with respect to its Exogen system, OsteoAMP and MOTYS. Although in the aggregate its intellectual property is of material importance to its business, Bioventus does not believe that any single patent is of material importance to its product portfolio. As of November&#160;13, 2020, Bioventus owned four issued U.S. patents and two pending U.S. patent applications relating to its material products. Bioventus also owned nine issued foreign patents and 11 pending foreign patent applications directed to its material products. Bioventus&#8217; patents and patent applications as of November&#160;30, 2020 directed to its material products are summarized below. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">263 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus owned three issued U.S. patents and one issued foreign patent in Australia directed to its Exogen system. The U.S. patents are expected to expire between 2025 and 2029, and the foreign patent is expected to expire in 2025. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus owned one issued U.S. patent, one pending U.S. patent application, eight issued foreign patents, and ten pending foreign patent applications directed to its OsteoAMP product, including foreign patents and patent applications in Europe, Asia, Canada and Australia. The issued U.S. patent is expected to expire in 2029. The issued foreign patents are expected to expire in 2029. The pending patent applications, if issued, are expected to expire in 2029, without accounting for potential patent term extensions and adjustments. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus also owns one pending U.S. patent application and one pending Patent Cooperation Treaty application directed to MOTYS. Patents issuing from these applications, if any, are expected to expire in 2040, without accounting for potential patent term extensions and adjustments. Bioventus&#8217; patents and pending patent applications directed to its material products (excluding those patents associated with the Bioness products) are detailed in the below table. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 6%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 20%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patent&#160;Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Status</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expected</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">AU</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2009324417</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2009324417</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">AU</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2014259553</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">November&#160;14,<br/>2014</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2014259553</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 6%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 20%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patent&#160;Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Status</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expected</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">AU</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2016213839</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;11,<br/>2016</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2016213839</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">CA</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2746668</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2746668</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">CN</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">200980155596.X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">200980155596.X</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">CN</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">201410413348.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;20,<br/>2014</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">201410413348.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">264 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 6%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patent&#160;Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Status</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expected</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">EP</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">HK</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">15105678.1</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">June&#160;16, 2015</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">HK1205007</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">IN</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2567/KOLNP/<br/>2011</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;4,<br/>2016</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">KR</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-2011-7016270</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">July&#160;2, 2019</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-1713346</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">15/016072</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">10383974</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Issued</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">16/459778</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February&#160;4,<br/>2016</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">GB</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">FR</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">DE</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">IT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">265 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 6%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 20%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patent&#160;Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Status</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expected</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">CH</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">BE</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">ES</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">PT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9832666.3</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December&#160;13,<br/>2009</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to methods of making osteoinductive implants</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">OsteoAMP</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">09/925,193</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;9,<br/>2001</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">7429248</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Granted</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">July 2025</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to applying ultrasound to tissue using a modal converter having a plurality of angled sides.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Exogen</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">AU</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2006203281</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;1,<br/>2006</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2006203281</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Granted</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August<br/>2025</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to treating a neuropathy disease with ultrasound using a specific frequency and pulse rate for the signal</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Exogen</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">11/462271</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August&#160;3,<br/>2006</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">8048006</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Granted</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">February<br/>2029</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to treating a neuropathy disease with ultrasound using a specific frequency and pulse rate for the signal</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Exogen</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">266 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 6%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 24%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Country</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Patent&#160;Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Application</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Status</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expected</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">12/296,333</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April&#160;7, 2007</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">8226582</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Granted</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">June 2028</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to applying ultrasound to tissue using a modal converter having an oblique angle and speed of sound similar to human tissue</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Exogen</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">US</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">17/097,350</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">November&#160;13,<br/>2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">November<br/>2040</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to placental tissue particulates compositions, methods of treating musculoskeletal or orthopedic conditions, methods of treating pain associated with osteoarthritis, kits and methods of making the compositions</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">MOTYS</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">PCT</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">PCT/US20/60393</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">November&#160;13,<br/>2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Pending</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">November<br/>2010</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Directed to placental tissue particulates compositions, for use in treating musculoskeletal or orthopedic conditions, methods of treating pain associated with osteoarthritis, kits and methods of making the compositions</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">MOTYS</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trademarks </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus owns registered trademarks for Bioventus, Cellxtract, Durolane, Exogen, Exponent, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gelsyn-3,</div> OsteoAMP, Osteofuse, Prohesion, PureBone, SAFHS, and Signafuse in the United States. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">267 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade secrets </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may rely on trade secret law to protect some of its technology, including the processing of tissue for OsteoAMP. Trade secrets, however, can be difficult to protect. Bioventus seeks to protect its proprietary technology and manufacturing process, in part, by confidentiality and invention assignment agreements with employees, under which they are bound to assign to Bioventus inventions that are made during the term of their employment and relate to its business, unless there is an exception. These agreements further prohibit its employees from using, disclosing, or bringing onto the premises any proprietary information belonging to any third-party. In addition, its consultants, scientific advisors and contractors are required to sign agreements under which they must assign to Bioventus any inventions that relate to its business. These agreements also prohibit these third-parties from incorporating into any inventions the proprietary rights of third-parties without informing Bioventus. It is its policy to require all employees to document potential inventions and other intellectual property in laboratory notebooks and to disclose inventions to patent counsel. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus also seeks to preserve the integrity and confidentiality of its data and trade secrets by taking commercially reasonable efforts to maintain the physical security of its premises and physical and electronic security of its information technology systems. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">While Bioventus has confidence in these individuals, organizations and systems, its security measures may be breached, or may otherwise prove inadequate to protect the integrity and confidentiality of its data and trade secrets. Further, its agreements may be breached (or not obtained in the first place) and Bioventus may not have adequate remedies for any breach. In addition, its trade secrets may otherwise become known or be independently discovered by competitors. To the extent that its consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and inventions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to patents, trademarks, and trade secrets, Bioventus also relies on assignment and license agreements, pursuant to which Bioventus may license rights under patents held by third parties, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> agreements, to protect its proprietary intellectual property. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus obtains assignments or licenses of varying durations for certain of its products from third parties. Bioventus typically acquires rights under such assignments or licenses in exchange for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> payments or arrangements under which Bioventus pays a percentage of sales to the licensor. However, while assignments or licenses to Bioventus generally are irrevocable, no assurance can be given that these arrangements will continue to be made available to Bioventus on terms that are acceptable to us, or at all. The terms of its license and assignment agreements vary in length from a specified number of years to the life of product patents or the economic life of the product. These agreements generally provide for royalty payments and termination rights in the event of a material breach. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing and supply </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; HA viscosupplementation therapies and certain of its surgical products are manufactured exclusively by single-source third-party manufacturers, pursuant to multi-year supply agreements. Bioventus works closely with each of its manufacturing partners and provide them with a forecast, which enables them to better capacity plan and sequence their production efficiently. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For Durolane, Bioventus is subject to minimum order volumes for each order and purchase amounts are also based in part on forecasts. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3,</div> Bioventus will be subject to certain annual minimum purchase requirements and purchase amounts based on rolling forecasts. For SUPARTZ FX, Bioventus is subject to certain annual minimum purchase requirements based on a percentage of its SUPARTZ FX annual forecast. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For Durolane, in December 2016, Bioventus entered into an amended and restated supply agreement, or the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med</div> Supply Agreement, with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med</div> AB, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med.</div> Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med</div> Supply Agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med</div> supplies Durolane products exclusively to Bioventus for sale in the United States for use in the in the prevention or </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">268 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">treatment of pain due to OA on a purchase order basis, based on the amounts of Durolane Bioventus requires as set forth in rolling forecasts and Bioventus is subject to certain semi-annual minimum purchase requirements based on a percentage of its Durolane forecast. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus assembles, inspects, tests and packages its Exogen system at its facility in Cordova, Tennessee with components supplied by third-party suppliers. Bioventus&#8217; Exogen system includes a transducer which is a key component that is supplied by a single-source supplier. Bioventus performs inspections of these components before use in its manufacturing operations. Bioventus believes its manufacturing operations are in compliance with regulations mandated by the FDA. Bioventus is an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-registered</div> medical device manufacturer. Bioventus&#8217; manufacturing facilities and processes are subject to periodic inspections and audits by various federal, state and foreign regulatory agencies. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MTF will exclusively manufacture and supply MOTYS under current Good Tissue Practices (cGTPs) to Bioventus to allow for its limited commercialization that began in the fourth quarter of 2020 under the tissue regulations while Bioventus pursues a BLA for the product. MTF is responsible for obtaining and storing all materials, including all tissue materials, required for the manufacture, testing, handling, packaging, labeling, release and delivery of the product to Bioventus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus intends to maintain sufficient supplies of the products and components from these single-source suppliers in the event that one or more of these suppliers were to encounter certain interruptions in supply. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government regulation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government regulation of medical devices </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies. The FDA and other U.S. and foreign governmental agencies regulate, among other things, with respect to medical devices: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">design, development and manufacturing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">testing, labeling, content and language of instructions for use and storage; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product safety; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketing, sales and distribution; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">premarket clearance and approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">record keeping procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advertising and promotion; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recalls and field safety corrective actions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">postmarket surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">postmarket approval studies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product import and export. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The regulations to which Bioventus is subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on its ability to carry on or expand its operations, higher than anticipated costs or lower than anticipated sales. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">269 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FDA premarket clearance and approval requirements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Each medical device Bioventus seeks to commercially distribute in the United States must first receive 510(k) clearance or approval of a PMA application from the FDA, unless specifically exempt. The FDA classifies all medical devices into one of three classes. Devices deemed to pose lower risk are categorized as either Class&#160;I or Class&#160;II. Class&#160;II devices require the manufacturer to submit to the FDA a 510(k) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> notification requesting clearance of the device for commercial distribution in the United States. Class&#160;I devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as life sustaining, life-supporting, selected implantable devices, or devices deemed not substantially equivalent to a previously 510(k) cleared device, are categorized as Class&#160;III, generally requiring submission and approval of a PMA. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">510(k) clearance process </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To obtain 510(k) clearance, Bioventus must submit a premarket notification to the FDA demonstrating the proposed device to be substantially equivalent to a predicate device. A predicate is a previously cleared 510(k) device, a device that was in commercial distribution before May&#160;28, 1976 for which the FDA has not yet called for the submission of PMA applications, or is a device that has been reclassified from Class&#160;III to either Class&#160;II or I. The standard review process for 510(k)s is between 30 days to 3 months, dependent upon the type of 510(k) filing submitted. Although many 510(k) premarket notifications are cleared without clinical data, in some cases, the FDA may require clinical data to support substantial equivalence. In reviewing a premarket notification, the FDA may request additional information, including clinical data, which may significantly prolong the review process and clearance is never assured. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">After a device receives 510(k) clearance, any subsequent modification of the device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require submission and approval of a PMA application in cases where new indications are sought for which there is no predicate. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-significant</div> changes are handled via internal documentation by the Company. Each manufacturer must judge the significance of modifications based on algorithms within FDA 510(k) guidance documents. FDA may review any such decision and may disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA may require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or PMA approval is obtained. Bioventus has modified aspects of some of its devices since receiving initial regulatory clearance. Bioventus concluded that some of those modifications did not significantly affect the safety or efficacy of the device and therefore, that new 510(k) clearances were not required. Bioventus has also obtained new 510(k) clearances from the FDA for other modifications to its devices. In the future, Bioventus may make additional modifications to its products after they have received FDA clearance or approval and in appropriate circumstances, determine that new clearance or approval is unnecessary. However, the FDA may disagree with its determination and if the FDA requires Bioventus to seek 510(k) clearance or submit new PMA applications for any modifications to a previously cleared product, Bioventus may be required to cease marketing or recall the modified device until Bioventus obtains the required clearance or approval. Under these circumstances, Bioventus may also be subject to significant regulatory fines or other penalties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has obtained 510(k) premarket clearance from the FDA for Signafuse Bioactive Bone Graft Putty, Interface Bioactive Bone Graft, Osteomatrix +, and Signafuse Mineralized Collagen Scaffold. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Premarket approval process </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A PMA application must be submitted if the medical device is in Class&#160;III (although the FDA has the discretion to continue to allow certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-amendment</div> Class&#160;III devices to use the 510(k) process) or cannot be cleared through the 510(k) process. A PMA application must be supported by, among other things, extensive technical, preclinical, clinical trials, manufacturing and labeling data to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">270 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">After a PMA application is submitted and filed, the FDA begins an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-depth</div> review of the submitted information. The standard review of such application is six months. During this review period, the FDA may request additional information or clarification of information already provided. This can extend the overall review process and typically PMAs take between one to three years in total for approval. Also during the review period, an advisory panel of experts from outside the FDA will usually be convened for a new type of device to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will conduct a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facility to ensure compliance with Quality System Regulation (QSR), which impose elaborate design development, testing, control, documentation and other quality assurance procedures in the design and manufacturing process. The FDA may approve a PMA application with post-approval conditions intended to ensure the safety and effectiveness of the device including, among other things, restrictions on labeling, promotion, sale and distribution and collection of long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> data from patients in the clinical study that supported approval. Failure to comply with the conditions of approval can result in materially adverse enforcement action, including the loss or withdrawal of the approval. PMA supplements are required for significant modifications to the manufacturing process, labeling of the product and design of a device that is approved through the PMA process. PMA supplements requires submission of information needed to support any changes from the device covered by the original PMA and typically do not require clinical data or the convening of an advisory panel. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-significant</div> changes must be reported to the FDA through an annual report filing with the FDA. In review of this joint proxy statement/prospectus, FDA may disagree with a manufacturer&#8217;s determination of the level of significance of the change. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA may require the manufacturer to cease marketing and/or recall the modified device until PMA supplement approval is obtained. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Durolane, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GELSYN-3,</div> SUPARTZ FX and its Exogen bone healing system have each been approved through the PMA process. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical trials </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A clinical trial is typically required to support a PMA and is sometimes required for a 510(k) premarket notification. In the United States, authorization to conduct a clinical trial generally requires submission of an application for an IDE to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the investigational protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number of patients, unless the product is deemed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-significant</div> risk device and eligible for abbreviated IDE requirements. Clinical trials for a significant risk device may begin once the IDE application is approved by the FDA as well as the appropriate institutional review boards (IRBs), at the clinical trial sites and the informed consent of the patients participating in the clinical trial is obtained. After a trial begins, the FDA may place it on hold or terminate it if, among other reasons, it concludes that the clinical subjects are exposed to an unacceptable health risk. Any trials Bioventus conducts must be conducted in accordance with FDA regulations as well as other federal regulations and state laws concerning human subject protection and privacy. Moreover, the results of a clinical trial may not be sufficient to obtain clearance or approval of the product. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pervasive and continuing FDA regulation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After a medical device is placed on the market, numerous FDA regulatory requirements apply, including, but not limited to the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QSRs, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures during the manufacturing process; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establishment Registration, which requires establishments involved in the production and distribution of medical devices, intended for commercial distribution in the United States, to register with the FDA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medical Device Listing, which requires manufacturers to list the devices they have in commercial distribution with the FDA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">271 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Labeling regulations, which prohibit &#8220;misbranded&#8221; devices from entering the market, as well as prohibit the promotion of products for unapproved or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses and impose other restrictions on labeling; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Postmarket surveillance, including Medical Device Reporting (MDR) requirements which requires manufacturers to report to the FDA if their device may have caused or contributed to a death or serious injury, or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corrections and Removal Reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the United States Federal Food, Drug, and Cosmetic Act (FDCA) that may present a risk to health. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA enforces these requirements by inspection and market surveillance. Failure to comply with applicable regulatory requirements may result in enforcement action by the FDA, which may include one or more of the following sanctions: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">untitled letters or warning letters; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, injunctions and civil penalties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">mandatory recall or seizure of its products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrative detention or banning of its products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operating restrictions, partial suspension or total shutdown of production; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusing its request for 510(k) clearances or PMA approvals for new product versions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">revocation of 510(k) clearances or PMA approvals previously granted; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">criminal prosecution and penalties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. regulation of HCT/Ps </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; products, including OsteoAMP and PureBone, are regulated as human cells, tissues and cellular and tissue-based products, or HCT/Ps. Section&#160;361 of the PHSA authorizes the FDA to issue regulations to prevent the introduction, transmission or spread of communicable disease. HCT/Ps regulated as &#8220;Section&#160;361&#8221; HCT/Ps are subject to requirements relating to registering facilities and listing products with the FDA, screening and testing for tissue donor eligibility, cGTP, when processing, storing, labeling and distributing HCT/Ps, including required labeling information, stringent record keeping and adverse event reporting, among other applicable requirements and laws. Specifically, cGTPs are requirements that govern the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps in a way that prevents the introduction, transmission, or spread of communicable diseases. Section&#160;361 HCT/Ps do not require 510(k) clearance, PMA approval, BLAs, or other premarket authorization from the FDA before marketing. However, to be regulated as a Section&#160;361 HCT/P, the product must, among other things, be &#8220;minimally manipulated,&#8221; which for structural tissue products means that the manufacturing processes do not alter the original relevant characteristics of the tissue relating to the tissue&#8217;s utility for reconstruction, repair, or replacement and for cells or nonstructural tissue products, means that the manufacturing processes do not alter the relevant biological characteristics of cells or tissues. A Section&#160;361 HCT/P must also be intended for &#8220;homologous use,&#8221; which refers to use in the repair, reconstruction, replacement, or supplementation of a recipient&#8217;s cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus believes its OsteoAMP product is properly regulated as a Section&#160;361 HCT/P and therefore have not sought or obtained 510(k) clearance, PMA approval, or licensure through a BLA. However, the FDA&#8217;s Center for Devices and Radiological Health (CDRH) issued Bioventus a letter in March 2016 in which it asserted that </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">272 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">OsteoAMP meets the definition of a medical device and requested that Bioventus provides CDRH with information in support of its position that OsteoAMP does not require 510(k) clearance or PMA approval. Bioventus provided CDRH with the requested information in support of this position in May 2016 and Bioventus has received no further inquiries to date. Bioventus believes that CDRH&#8217;s assertion is unfounded and inconsistent with a 2011 letter from the FDA concluding that OsteoAMP meets the criteria for regulation solely as a Section&#160;361 HCT/P. However, if the FDA were to disagree and if Bioventus is otherwise unsuccessful in asserting its position, the FDA may then require that Bioventus obtains 510(k) clearance or PMA approval and that Bioventus ceases marketing OsteoAMP and/or recall OsteoAMP unless and until Bioventus receives clearance or approval. Bioventus estimates that if Bioventus were to cease marketing OsteoAmp and/or recall OsteoAmp that its net sales would decrease, which would adversely affect its results of operations. See <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;</div></div>Risk Factors&#8212;Risks relating to government regulation&#8212;&#8221; Bioventus&#8217; HCT/P products are subject to extensive government regulation and its failure to comply with these requirements could cause its business to suffer. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HCT/Ps that do not meet the criteria of Section&#160;361 are regulated under Section&#160;351 of the PHSA. Unlike 361 HCT/Ps, HCT/Ps regulated as &#8220;351&#8221; HCT/Ps are subject to premarket review and/or approval by the FDA, as required. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2017, the FDA released a guidance document entitled &#8220;Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue&#8212;Based Products: Minimal Manipulation and Homologous Use&#8212;Guidance for Industry and Food and Drug Administration Staff.&#8221; The guidance outlined the FDA&#8217;s position that all lyophilized amniotic products are more than minimally manipulated and would therefore require a BLA to be lawfully marketed in the United States. The guidance also indicated that the FDA would exercise enforcement discretion, using a risk-based approach, with respect to the IND application and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-market</div> approval requirements for certain HCT/Ps for a period of 36 months from the issuance date of the guidance to allow manufacturers to pursue its IND application. Under this approach, FDA indicated that high-risk products and uses could be subject to immediate enforcement action. In July 2020, the FDA extended its period of enforcement discretion to May&#160;31, 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. regulation of drugs and biologics </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus expects that MOTYS will be regulated by the FDA as a biological product, or biologic. Bioventus planned to market MOTYS while it pursued a BLA for the product, but withdrew those plans and discontinued its limited marketing of MOTYS upon the expiration of the FDA&#8217;s enforcement discretion period for certain HCT/Ps. Biologics are regulated under both the FDCA and the PHSA and other federal, state, local and foreign statutes and regulations. Bioventus, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which Bioventus wishes to conduct studies or seek approval or licensure of its product candidates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The process required by the FDA before product candidates may be marketed in the United States generally involves the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice (GLP), regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an IND which must become effective before clinical trials may begin; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before the trial is commenced; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">273 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance of adequate and well-controlled human clinical trials to establish the safety and effectiveness of the proposed drug candidate and the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">preparation of and submission to the FDA of an New Drug Application (NDA) or BLA after completion of all pivotal clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">satisfactory completion of an FDA Advisory Committee review, if applicable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a determination by the FDA within 60 days of its receipt of a NDA or BLA to file the application for review; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">satisfactory completion of an FDA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP requirements, and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s safety and effectiveness, and of selected clinical investigation sites to assess compliance with GCPs; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review and approval of a NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical and Clinical Development </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to beginning the first clinical trial with a product candidate, Bioventus must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols clinical trials. The IND also includes results of animal and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls (CMC), information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with good clinical practices (GCPs), which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">274 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of regulatory approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1</div></div>. The investigational product is initially introduced into patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 2</div></div>. The investigational product is administered to a limited patient population to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 3</div></div>. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> Phase 4 studies may be made a condition to approval of the NDA or BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. The FDA or the sponsor or its data safety monitoring board may suspend a clinical study at any time on various grounds, including a finding that the research participant or participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-regulated</div> products may be required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">NDA or BLA Submission and Review </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a NDA or BLA requesting approval to market the product for one or more indications. The NDA or BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s CMCs and proposed labeling, among other things. The submission of a NDA or BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. The FDA has 60 days from the applicant&#8217;s submission of a NDA or BLA to either issue a refusal to file letter or accept the NDA or BLA for filing, indicating that it is sufficiently complete to permit substantive review. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once a NDA or BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">275 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significantly extended by FDA requests for additional information or clarification. The FDA reviews a NDA or BLA to determine, among other things, whether a product is safe and effective, or safe, pure, and potent, for its intended use, and whether the facility in which it is manufactured, processed, packed or held meets standards designed to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After the FDA evaluates a NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be manufactured, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the NDA or BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the NDA or BLA in condition for approval, including requests for additional information or clarification, including the potential requirement for additional clinical studies. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA or BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Post-Approval Requirements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any products manufactured or distributed by Bioventus pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">276 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon Bioventus and its third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Bioventus and any third-party manufacturers that Bioventus may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a Risk Evaluation and Mitigation Strategy (REMS) program. Other potential consequences include, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, warning or untitled letters or holds on post-approval clinical studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product seizure or detention, or refusal of the FDA to permit the import or export of products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">mandated modification of promotional materials and labeling and the issuance of corrective information; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injunctions or the imposition of civil or criminal penalties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of drugs and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Bioventus and approved by the FDA, but physicians may not submit claims for reimbursement that are false or fraudulent. Such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses are common across medical specialties. Physicians may believe that such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use of their products. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International regulation of medical devices </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of medical devices outside the United States are subject to foreign government regulations, which vary substantially from country to country. In order to market its products in other countries, Bioventus must obtain </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">277 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory approvals and comply with extensive safety and quality regulations in other countries. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA approval and the requirements may differ significantly. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EU regulation of medical devices </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The EU has adopted legislation, in the form of directives to be implemented in each Member State, concerning the regulation of medical devices within the EU. The directives include, among others, the Medical Device Directive (Council Directive 93/42/EEC) that establishes certain requirements, such as the essential requirements, with which medical devices must comply before they can be commercialized in the European Economic Area (EEA) (which is comprised of the Member States of the EU plus Norway, Liechtenstein and Iceland). Under the EU Medical Device Directive, medical devices are classified into four Classes, I, IIa, IIb and III, with Class&#160;I being the lowest risk and Class&#160;III being the highest risk. Under the Medical Device Directive, a competent authority is nominated by the government of each Member State to monitor and ensure compliance with the Directive. To demonstrate compliance of their medical devices with the essential requirements, manufacturers must undergo a conformity assessment evaluation, which varies according to the type of medical device and its classification. Except for certain types of low risk medical devices (Class I <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-sterile,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-measuring</div> devices), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the Medical Devices Directive, a conformity assessment evaluation requires the intervention of an organization accredited by a Member State of the EEA to conduct conformity assessments, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> Notified Body. The Notified Body would typically audit and examine the quality system for the manufacture, design and final inspection of the medical devices, along with conducting a technical review of data supporting the device&#8217;s safety and efficacy, before issuing a certification demonstrating compliance with the essential requirements. Both the quality system and the product are reviewed and certified. The Company is subject to annual surveillance audits by the Notified Body and must undergo <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-certification</div> every 5 years. During these audits, (minor or major) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-conformities</div> to the essential requirement may be issued to the Company. The Company could potentially lose marketing authorization if these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-conformities</div> are not remediated with the Notified Body. Significant modifications to the quality system or product changes for Class&#160;III devices must be submitted to the Notified Body for review prior to implementation. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-significant</div> changes are subject to review during the annual surveillance audits. Medical devices that comply with the essential requirements are entitled to bear the CE mark. Medical devices properly bearing the CE mark may be commercially distributed throughout the EEA. Bioventus has received CE certification from the British Standards Institute, a United Kingdom Notified Body, for conformity with the EU Medical Device Directive allowing Bioventus to place the CE mark on Durolane (Class III) and its Exogen bone healing system (Class IIa). Additional PMAs in individual EEA countries are sometimes required prior to marketing of a product. Failure to maintain the CE mark would preclude Bioventus from selling its products in the EEA, as could failure to comply with the specific requirements of the Member States. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;5, 2017, the European Parliament passed the Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA Member States, the regulations would be directly applicable without the need for adoption of EEA Member State laws implementing them in all EEA Member States and are intended to eliminate current differences in the regulation of medical devices among EEA Member States. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> diagnostic devices and ensure a high level of safety and health while supporting innovation. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">278 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Medical Devices Regulation was meant to become applicable three years after publication (in May 2020). However, on April&#160;23, 2020, to take the pressure off EEA national authorities, notified bodies, manufacturers and other actors so they can focus fully on urgent priorities related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the Medical Devices Regulation by one year (to May 2021). Once applicable, the new regulations will among other things: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">strengthen the rules on placing devices on the market and reinforce surveillance once they are available; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">establish explicit provisions on manufacturers&#8217; responsibilities for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> on the quality, performance and safety of devices placed on the market; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">improve the traceability of medical devices throughout the supply chain to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-user</div> or patient through a unique identification number; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These new rules and procedures may result in increased regulatory oversight of its devices and this may, in turn, increase the costs, time and requirements that Bioventus needs to meet in order to maintain or place such devices on the EEA market. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, the advertising and promotion of its products in the EEA is subject to the laws of individual EEA Member States implementing the EU Medical Devices Directive, Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, as well as other EEA Member State laws governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of its products to the general public and may impose limitations on its promotional activities with healthcare professionals. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other countries&#8217; regulation of medical devices </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many other countries have specific requirements for classification, registration and post marketing surveillance that are independent of the countries already listed. Bioventus obtains what Bioventus believes are the appropriate clearances for Durolane and its Exogen bone healing system and conduct its business in accordance with the applicable laws of each country. This landscape is constantly changing and Bioventus could be found in violation if Bioventus interprets the laws incorrectly or fail to keep pace with changes. In the event of either of these occurrences, Bioventus could be instructed to recall products, cease distribution and/or be subject to civil or criminal penalties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-kickback, false claims and other healthcare laws </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to FDA restrictions on the marketing of pharmaceutical, biological and medical device products, Bioventus is also subject to healthcare regulation and enforcement by the federal government and the states and foreign governments and authorities in the locations in which Bioventus conducts its business. These other agencies include, without limitation, CMS, other divisions of the U.S. Department of Health and Human Services (HHS), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, as well as state and local governments. Such agencies enforce a variety of laws which include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security and physician payment transparency laws and regulations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">279 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, by Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including cash, improper discounts and free or reduced price items and services. Among other things, the Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical, biotechnology and medical device manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil monetary penalties up to $100,000 for each violation, plus up to three times the remuneration involved, and may result in criminal fines of up to $100,000 and imprisonment of up to ten years, or exclusion from Medicare, Medicaid or other governmental programs. Further, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute also constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Federal law also includes a provision commonly known as the &#8220;Stark Law,&#8221; which prohibits a physician from referring Medicare or Medicaid patients to an entity providing &#8220;designated health services,&#8221; which includes durable medical equipment, if the physician or immediate family member of the physician, has an ownership or investment interest or compensation arrangement with such entity that does not comply with the requirements of a Stark exception. Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliant</div> arrangement, civil penalties, and exclusion from Medicare, Medicaid or other governmental programs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The federal false claims and civil monetary penalties laws, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the U.S. government. Violations of the False Claims Act can result in very significant monetary penalties and treble damages. The federal government is using the False Claims Act and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical, biotechnology and medical device companies throughout the country. Manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by for example, in connection with the promotion of products for unapproved or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties ranging from $11,181 to $22,363 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. In addition, companies found liable under the False Claims Act have been forced to implement extensive corrective action plans, and have often become subject to consent decrees or corporate integrity agreements, severely restricting the manner in which they conduct their business and imposing ongoing reporting and disclosure obligations. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">280 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Given the significant size of actual and potential settlements, it is expected that governmental authorities will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws. For drugs that are covered under Medicare Part B, the manufacturer must report average sales price (ASP), to CMS on a quarterly basis. Failure to report this information in a timely and accurate manner can lead to substantial civil and criminal penalties and to liability under the False Claims Act. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July of 2018 Bioventus became aware of allegations that certain of its sales personnel may have been completing Section B of the Certificate for Medical Necessity form (CMN) required in connection with Medicare claims for the Exogen system, which, under federal law, must be completed by the physician and/or physician staff. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Together with its outside counsel, Bioventus initiated an investigation into these allegations, and Bioventus determined that the CMN forms for a portion of Medicare claims for the Exogen system were in fact improperly completed by its sales representatives, some of which also failed to meet CMS coverage requirements. As a result of its findings Bioventus made a self-disclosure on November&#160;30, 2018 to the Office of Inspector General of the HHS (OIG), under the Provider Self-Disclosure Protocol. Bioventus&#8217; self-disclosure disclosed the extent of its findings relative to the inappropriate completion of CMN forms by its sales personnel and offered to make repayment for such claims which failed to meet CMS coverage requirements and which Bioventus submitted to the Medicare program between October&#160;1, 2012 and September&#160;30, 2018, the statutory period applicable to such conduct. The total value of impacted claims was $30.1&#160;million in the aggregate. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, its outside counsel received a letter from the Office of the United States Attorney in the Middle District of North Carolina (USAO) stating that the USAO would be working with the OIG to resolve its self-disclosure. After settlement discussions with the USAO and OIG, on January&#160;25, 2021 Bioventus reached an agreement in principle with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which its sales representatives completed Section B of the CMN forms. On February&#160;22, 2021, Bioventus finalized all terms related to the settlement and entered into a formal settlement agreement with the USAO and OIG consistent with its previous agreement in principle and which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type. Under the agreement, Bioventus resolved the potential liability related to its self-disclosure for $3.6&#160;million, of which $2.4&#160;million had already been paid through its 2019 return of overpayments described previously, leaving a net payment to be made of $1.2&#160;million. Bioventus made payment of the $1.2&#160;million net settlement amount due under the agreement on February&#160;23, 2021. The settlement amount noted above was recorded in the consolidated financial statements for the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2019, separate from the self-disclosure described above, as a result of its internal auditing of Exogen Medicare claims, Bioventus made repayments to its Medicare Administrative Contractors (MACs) for overpayments identified during such auditing totaling $7.5&#160;million for the period October&#160;1, 2012 through December&#160;31, 2018. This amount reflected certain Medicare claims for Exogen for which Bioventus lacked adequate documentation of medical necessity consistent with Medicare coverage requirements. Similarly, in July of 2020, Bioventus made repayments to the MACs of $1.5&#160;million after completing its internal auditing of Exogen Medicare claims for the period beginning January&#160;1, 2019 through December&#160;31, 2019. Bioventus maintains a reserve for reimbursement claims related to its Exogen system that may have been processed for payment without adequate medical records support. Bioventus&#8217; reserve is estimated using an extrapolation of an error rate from a statistical sample, which represents its best estimate as of the date of the financial statements, but because of the uncertainty inherent in such estimates, the ultimate repayment amounts may be materially different. </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Risk Factors&#8212;Risks Relating to Government Regulation.&#8221; Bioventus may be subject to enforcement action if Bioventus engages in improper claims submission practices and resulting audits or denials of its claims by government agencies could reduce its net sales or profits. </div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">281 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal Health Insurance Portability and Accountability Act of 1996, as amended by Health Information Technology for Economic and Clinical Health Act (HITECH), and the regulations that implement both laws, collectively known as HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $20,866 for each wrongful act. Moreover, in certain cases, providers who routinely waive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil False Claims Act, which can impose additional penalties associated with the wrongful act. One of the statutory exceptions to the prohibition is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-routine,</div> unadvertised waivers of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent its patient assistance programs are found to be inconsistent with applicable laws, Bioventus may be required to restructure or discontinue such programs, or be subject to other significant penalties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act, or collectively, the Affordable Care Act, imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and &#8220;transfers of value&#8221; provided to physicians and teaching hospitals, and, beginning in 2022, physician assistants, nurse practitioners and other practitioners, as well as ownership and investment interests held by such providers and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $176,495 per year and up to an aggregate of $1.177&#160;million per year for &#8220;knowing failures.&#8221; Covered manufacturers must submit reports by the 90th day of each calendar year. In addition, certain states require implementation of compliance programs and compliance with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities and/or require tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These laws impact the kinds of financial arrangements Bioventus may have with hospitals, physicians or other potential purchasers of its products. They particularly impact how Bioventus structures its sales offerings, including discount practices, customer support, education and training programs, physician consulting, research grants and other arrangements. If its operations are found to be in violation of any of the health regulatory laws </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">282 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">described above or any other laws or regulations that apply to us, Bioventus may be subject to penalties, including, without limitation, potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, imprisonment, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of its operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of its sale or distribution of products in a foreign country, Bioventus may be subject to similar foreign laws and regulations, which may include, for instance, applicable post marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus participates in state government-managed Medicaid programs as well as certain other qualifying federal and state government programs where discounts and mandatory rebates are provided to participating state and local government entities. In connection with several of these government programs, Bioventus is required to report prices to various government agencies. Pricing calculations vary among programs. The calculations are complex and are often subject to interpretation by the reporting entities, government agencies and the courts. Bioventus&#8217; methodologies for calculating these prices could be challenged under false claims laws or other laws. Bioventus could make a mistake in calculating reported prices and required discounts, which could result in retroactive liability to government agencies. Government agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. If Bioventus makes these mistakes or if governmental agencies make these changes, Bioventus could face, in addition to prosecution under federal and state false claims laws, substantial liability and civil monetary penalties, exclusion of its products from reimbursement under government programs, criminal fines or imprisonment, or prosecutors may impose a Corporate Integrity Agreement, Deferred Prosecution Agreement, or similar arrangement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA), requires that manufacturers report data to CMS on pricing of covered drugs reimbursed under Medicare Part B. These are generally drugs and biologicals, such as injectable products, that are administered &#8220;incident to&#8221; a physician service and in general are not self-administered. Effective January&#160;1, 2005, ASP became the basis for reimbursement to physicians and suppliers for drugs and biologicals covered under Medicare Part B, replacing the average wholesale price (AWP), provided and published by pricing services. In general, Bioventus must comply with all reporting requirements for any drug that is separately reimbursable under Medicare. The SUPARTZ FX product is reimbursed under Medicare Part B and, as a result, Bioventus provides ASP data on this product to CMS on a quarterly basis. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Privacy and data protection laws in the United States </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA and its implementing regulations, contain substantial restrictions and requirements with respect to the use and disclosure of certain protected health information (PHI). These restrictions and requirements are set forth in the HIPAA Privacy, Security and Breach Notification Rules. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some of its operations, such those involving the acceptance of payments, Bioventus is a &#8220;covered entity&#8221; under HIPAA and therefore required to comply with the Privacy, Security and Breach Notification Rules and is subject to significant civil and criminal penalties for failure to do so. Bioventus also provides services to customers that are covered entities themselves and Bioventus is required to provide satisfactory written assurances to these customers through written &#8220;business associate&#8221; agreements that Bioventus will provide its services in accordance with HIPAA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Final Rule published by HHS Office for Civil Rights (OCR) in January 2013 and effective March&#160;23, 2013, modified the HIPAA Privacy, Security, Breach Notification and Enforcement Rules, including revisions/additions made by the HITECH Act. The rule expanded the privacy and security requirements for business </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">283 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">associates that create, receive, maintain or transmit PHI for or on behalf of covered entities, increased penalties for noncompliance and strengthened requirements for reporting of breaches of unsecured PHI, among other changes. The rule also made business associates and their subcontractors directly liable for civil monetary penalties for impermissible uses and disclosures of PHI. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If Bioventus was to be found to have breached its obligations under HIPAA, Bioventus could be subject to enforcement actions by the OCR and state health regulators and lawsuits, including class action law suits, by private plaintiffs. In addition, OCR performs compliance audits in order to proactively enforce the HIPAA privacy and security standards. OCR has become an increasingly active regulator and has signaled its intention to continue this trend. OCR has the discretion to impose penalties without being required to attempt to resolve violations through informal means; further OCR may require companies to enter into resolution agreements and corrective action plans which impose ongoing compliance requirements. OCR enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition to enforcement by OCR, state attorneys general are authorized to bring civil actions under either HIPAA or relevant state laws seeking either injunctions or damages in response to violations that threaten the privacy of state residents. Although Bioventus has implemented and maintained policies, processes and a compliance program infrastructure to assist Bioventus in complying with these laws and regulations and its contractual obligations, Bioventus cannot provide assurance regarding how these laws and regulations will be interpreted, enforced or applied to its operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to HIPAA, Bioventus must adhere to state patient confidentiality laws that are not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-empted</div> by HIPAA, including those that are more stringent than HIPAA requirements. Numerous other state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or medical information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, all states have passed laws regulating the actions that a business must take if it experiences a data breach, such as prompt disclosure to affected customers. Generally, these laws are limited to electronic data and make some exemptions for smaller breaches. Congress has also been considering similar federal legislation relating to data breaches. The Federal Trade Commission (FTC) and states&#8217; Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. For example, the California Consumer Privacy Act (CCPA) took effect on January&#160;1, 2020. The CCPA establishes a new privacy framework for covered businesses and provides new and enhanced data privacy rights to California residents, such as affording consumers the right to access and delete their information and to opt out of certain sharing and sales of personal information. The CCPA imposes severe statutory damages as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action is expected to increase the likelihood of, and risks associated with, data breach litigation. It remains unclear how various provisions of the CCPA will be interpreted and enforced. The CCPA contains an exemption for medical information governed by the California Confidentiality of Medical Information Act (CMIA) and for PHI collected by a covered entity or business associate governed by the privacy, security and breach notification rules established pursuant to HIPAA and HITECH, but the precise application and scope of this exemption is not yet clear, and the law may still apply to certain aspects of its business. Additionally, a new privacy law, the California Privacy Rights Act (CPRA), was approved by California voters in the November&#160;3, 2020 election. The CPRA generally takes effect on January&#160;1, 2023 and significantly modifies the CCPA, including by expanding consumers&#8217; rights with respect to certain personal information, restricting use of sensitive personal information, which includes health information, and creating a new state agency to oversee implementation and enforcement efforts, potentially resulting in further uncertainty and requiring Bioventus to incur additional costs and expenses in an effort to comply. The CCPA and CPRA may lead other states to pass comparable legislation, with potentially greater penalties, and more rigorous compliance requirements relevant to its business, and that may not include </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">284 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exemptions for businesses subject to HIPAA. The effects of the CCPA, and other similar state or federal laws, are potentially significant and may require Bioventus to modify its data processing practices and policies and to incur substantial costs and potential liability in an effort to comply with such legislation. As with HIPAA, any laws regulating the collection, dissemination, use, access to, confidentiality and security of personal information may apply directly to its business or indirectly by contract when Bioventus provides services to other companies. Bioventus intends to continue to comprehensively protect all consumer data and to comply with all applicable laws regarding the protection of this data. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Privacy and data protection laws in Europe </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus is subject to European laws relating to its and its suppliers&#8217;, partners&#8217; and subcontractors&#8217; collection, control, processing and other use of personal data, such as data relating to an identifiable living individual, whether that individual can be identified directly or indirectly. Bioventus and its suppliers, partners and subcontractors process personal data including in relation to its employees, employees of customers, trial patients, health care professions and employees of suppliers including health and medical information. The data privacy regime in the EU includes the General Data Protection Regulation (GDPR), the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-Privacy</div> Directive (2002/58/EC) and national laws implementing or supplementing each of them. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The GDPR requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws and the data may then only be processed in a manner consistent with those purposes. The personal data collected and processed must be adequate, relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred outside of the EEA unless certain steps are taken to ensure an adequate level of protection and must not be retained for longer than necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain organizational steps to ensure that they have adequate records, policies, security, training and governance frameworks in place to ensure the protection of data subject rights, including as required to respond to complaints and requests from data subjects. In addition, to the extent a company processes, controls or otherwise uses &#8216;special category&#8217; personal data (including patients&#8217; health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances and the manner in which a company is legally permitted to process that data. Finally, GDPR provides a broad right for EU Member States to create supplemental national laws. Such laws and they are increasingly adopting different approaches to the role of the parties in clinical trials. Such laws, for example may relate to the processing of health, genetic and biometric data, which could further limit its ability to use and share such data or could cause its costs to increase and harm its business and financial condition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">From January&#160;1, 2021, Bioventus is also subject to the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20&#160;million (&#163;17.9 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> grace period agreed in the EU and UK Trade and Cooperation Agreement, ending 30&#160;June 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes will lead to additional costs and increase its overall risk exposure. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the United Kingdom&#8217;s withdrawal from the European Union means that the United Kingdom will become a &#8220;third country&#8221; for the purposes of data transfers from the European Union to the United Kingdom following the expiration of the four to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> personal data transfer grace period (from January&#160;1, 2021) set out in the EU and UK Trade and Cooperation Agreement, unless a relevant adequacy decision is adopted in favor </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">285 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the United Kingdom (which would allow data transfers without additional measures). These changes may require Bioventus to find alternative solutions for the compliant transfer of personal data into the United Kingdom. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus is also subject to evolving European laws on data export and electronic marketing. The rules on data export will apply when Bioventus transfers personal data to group companies or third parties outside of the EEA. For example, in 2015, the Court of Justice of the European Union (CJEU) ruled that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">U.S.-EU</div> Safe Harbor framework, one compliance method by which companies could transfer personal data regarding citizens of the EU to the United States, was invalid and could no longer be relied upon. European and U.S. negotiators agreed in February 2016 to a new framework, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-US</div> Privacy Shield framework, which replaced the Safe Harbor framework, however, on July&#160;16, 2020 the CJEU also invalidated the Privacy Shield framework as a method to transfer personal data from the EEA to US. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances; this has created uncertainty. These changes will require Bioventus to review and amend the legal mechanisms by which Bioventus makes and/ or receive personal data transfers to/ in the U.S. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, Bioventus could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if Bioventus is otherwise unable to transfer personal data between and among countries and regions in which Bioventus operates, it could affect the manner in which Bioventus provides its services, the geographical location or segregation of its relevant systems and operations, and could adversely affect its financial results. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus is also subject to evolving EU and UK privacy laws on cookies and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">e-marketing.</div> In the European Union and the United Kingdom, regulators are increasingly focusing on compliance with requirements in the online behavioral advertising ecosystem, and current national laws that implement the ePrivacy Directive are highly likely to be replaced by an EU regulation known as the ePrivacy Regulation which will significantly increase fines for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance.</div> In the European Union and the United Kingdom, informed consent is required for the placement of a cookie or similar technologies on a user&#8217;s device and for direct electronic marketing. The GDPR also imposes conditions on obtaining valid consent, such as a prohibition on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-checked</div> consents and a requirement to ensure separate consents are sought for each type of cookie or similar technology. While the text of the ePrivacy Regulation is still under development, a recent European court decision and regulators&#8217; recent guidance are driving increased attention to cookies and tracking technologies. If regulators start to enforce the strict approach in recent guidance, this could lead to substantial costs, require significant systems changes, limit the effectiveness of its marketing activities, divert the attention of its technology personnel, adversely affect its margins, increase costs and subject Bioventus to additional liabilities. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is subject to the supervision of local data protection authorities in those jurisdictions where Bioventus is established or collecting data from EU residents. Bioventus depends on a number of third parties in relation to its provision of its services, a number of which process personal data on its behalf. With each such provider Bioventus enters into contractual arrangements to ensure that they only process personal data according to its instructions, and that they have sufficient technical and organizational security measures in place. Where Bioventus transfers personal data outside the EEA, Bioventus does so in compliance with the relevant data export requirements. As previously described, following the CJEU&#8217;s decision to invalidate Privacy Shield, Bioventus is now required to review and amend the legal mechanisms by which Bioventus makes and/or receive personal data transfers to/in the U.S. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, Bioventus could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if Bioventus is otherwise unable to transfer personal data between and among countries and regions in which Bioventus operates, it could affect the manner in which Bioventus provides its services, the geographical location or segregation of its relevant systems and operations, and could adversely affect its financial results. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">286 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus takes its data protection obligations seriously, as any improper, unlawful or accidental disclosure, loss, alteration or access to, personal data, particularly sensitive personal data, such as special category, could adversely affect its business and/or its reputation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus may find it necessary or desirable to join self-regulatory bodies or other privacy-related organizations, particularly relating to biopharmacy and/or scientific research that require compliance with certain rules pertaining to privacy and data security. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There are costs and administrative burdens associated with compliance with GDPR and the resultant changes in the EU and EEA Member States&#8217; national laws and the introduction of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">e-Privacy</div> Regulation once it takes effect. Any failure or perceived failure to comply with global privacy laws carries with it the risk of significant penalties and sanctions. These laws or new interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose additional operational requirements on its business, and could affect the manner in which Bioventus uses and transmits patient information and could increase its cost of doing business. Claims of violations of privacy rights or contractual breaches, even if Bioventus is not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm its business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coverage and reimbursement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical, biological or medical device product. In the United States and markets in other countries, patients who are prescribed treatments or undergo procedures for their conditions and the providers performing the services generally rely on third-party payers to reimburse all or part of the associated healthcare costs. Patients are unlikely to use its products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of its products or related procedures. Sales of any products will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payers. Third-party payers include government authorities, managed care organizations, private health insurers and other organizations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The process for determining whether a third-party payer will provide coverage for a product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> products for a particular indication, or place products at certain formulary levels that result in lower reimbursement levels and higher cost-sharing obligation imposed on patients. A decision by a third-party payer not to cover any of its products or product candidates could reduce physician utilization of such products and adversely affect its business, results of operations and financial condition. Moreover, a third-party payer&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable Bioventus to maintain price levels sufficient to realize an appropriate return on its investment in product development. Additionally, coverage and reimbursement for products can differ significantly from payer to payer. One third-party payer&#8217;s decision to cover a particular medical product or service does not ensure that other payers will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will often require Bioventus to provide scientific and clinical support for the use of its products to each payer separately and can be a time-consuming process. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Third-party payers may not consider its products to be medically necessary or cost-effective for certain indications or for all uses, and as a result, may not provide coverage for its products. In order to obtain and maintain coverage and reimbursement for its products and product candidates, Bioventus may need to conduct expensive clinical trials in order to demonstrate the medical necessity and cost-effectiveness of such products, in addition to the costs required to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">287 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain regulatory approvals. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Any changes in coverage and reimbursement that further restrict coverage of its products or lower reimbursement for procedures using its devices could materially affect its business. See the information under &#8220;Risk Factors&#8212;Risks Relating to Bioventus&#8217; Business.&#8221; If Bioventus is unable to achieve and maintain adequate levels of coverage and/or reimbursement for its products, the procedures using its products, or any future products Bioventus may seek to commercialize, the commercial success of these products may be severely hindered. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outside of the United States, the pricing of medical devices and prescription pharmaceuticals is subject to governmental control in many countries. For example, in the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular therapy to currently available therapies or so called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of medical devices and pharmaceutical products could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. There can be no assurance that any country that has price controls or reimbursement limitations for medical devices or pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of its products, if approved in those countries. See the information under &#8220;Risk Factors&#8212;Risks Relating to Bioventus&#8217; Business.&#8221; Governments outside the United States may not provide coverage or reimbursement of its products, which may adversely affect its business, results of operations and financial condition. </div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exogen reimbursement and order fulfillment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus&#8217; Exogen system is classified as durable medical equipment, meaning the product is used by the patient in the home and that the patient and/or insurance company, rather than the physician, is billed for the product. Bioventus bills third-party payers, such as private insurance or Medicare, on behalf of its patients and bill the patient for their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> obligations and deductibles. An internal team and external consultants assist with billing and processing orders for its Exogen system and has been trained in verifying <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> benefits, obtaining prior authorization and billing and collecting payments from payers. Bioventus also has a separate dedicated team of employees that provides customer support services for its Exogen system. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has strong and established payer relationships, including the largest private payers in the United States. Based on its estimates, Bioventus is contracted as a provider with payers covering over 200&#160;million lives. These contracts allow patients to access its Exogen system at a competitive rate and copay comparable to other suppliers and easing its administrative burden in processing at both authorization and when billing. Bioventus&#8217; Exogen system is reimbursed under Healthcare Common Procedure Coding System (HCPCS) code E0760. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare reform </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage for the procedures associated with the use of its products, or result in lower reimbursement for those procedures. The cost containment measures that payers and providers are instituting and the effect of any healthcare reform initiative implemented in the future could significantly reduce its revenues from the sale of its products. By way of example, the Affordable Care Act substantially changed healthcare financing and delivery by both governmental and private insurers and significantly impacted the pharmaceutical and medical device industries. The Affordable Care Act imposed, among other things, a new federal excise tax on the sale of certain medical devices, provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research and implemented payment system reforms including a national pilot program on payment </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">288 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, including the permanent repeal of the federal excise tax on the sale of certain medical devices effective January&#160;1, 2020. Bioventus expects there will be additional challenges and amendments to the Affordable Care Act in the future. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013. Subsequent legislative amendments related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic suspended this Medicare sequestration payment reduction from May&#160;1, 2020 through March&#160;31, 2021, but extended sequestration through 2030. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012, was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, payment methodologies may be subject to changes due to healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare and review the relationship between pricing and manufacturer patient programs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EU, similar political, economic and regulatory developments have occurred or are being contemplated. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or Member State level may result in significant additional requirements or obstacles that may increase operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU Member States have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus expects that additional foreign, state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for its products or additional pricing pressure. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee and Human Capital Resources </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, Bioventus had approximately 700 employees, none of whom were covered by collective bargaining agreements. Most of these employees are located in the United States with approximately 90 located outside the United States. Bioventus believes that its relations with its employees are generally good. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus values its employees and regularly benchmark total rewards Bioventus provides, such as short and long term compensation, 401(k) contributions, health, welfare and quality of life benefits, paid time off and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">289 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">personal leave, against its industry peers to ensure Bioventus remains competitive and attractive to potential new hires. Bioventus seeks to create a workplace environment that fosters personal and business successes by offering training and development programs, which further assist its current employees in meeting and exceeding its established standards of performance. Additionally, through its Diversity, Equity and Inclusion Counsel, its employees work directly with its executive management team to address any internal concerns and continuously improve the ways in which Bioventus serves its employees and customers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Receivable Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus expects to obtain an increase in its share of the tax basis of the assets of BV LLC when the continuing LLC owner receives shares of Bioventus class A common stock or, if Bioventus and the continuing LLC owner agree, cash in connection with an exercise of the continuing LLC owner&#8217;s right to have its LLC interests redeemed by BV LLC or, at Bioventus&#8217; election, directly exchanged (such basis increases, together with the basis increases resulting from certain distributions (or deemed distributions) from BV LLC, the &#8220;basis adjustments&#8221;). Bioventus intends to treat such redemptions or exchanges of LLC interests as the direct purchase of LLC interests by Bioventus from the continuing LLC owner for U.S. federal income and other applicable tax purposes, regardless of whether such LLC interests are surrendered by the continuing LLC owner to BV LLC for redemption or sold to Bioventus upon the exercise of our election to acquire such LLC interests directly. A basis adjustment may have the effect of reducing the amounts that Bioventus would otherwise pay in the future to various tax authorities. The basis adjustments may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus entered into the TRA with the continuing LLC owner. The TRA provides for Bioventus&#8217; payment to the continuing LLC owner of 85% of the amount of tax benefits, if any, that Bioventus actually realizes, or in some circumstances are deemed to realize, as a result of any basis adjustments and certain other tax benefits arising from payments under the TRA. BV LLC has in effect an election under Section&#160;754 of the Code effective for each taxable year in which a redemption or exchange (including deemed exchange) of LLC interests for shares of our Class&#160;A common stock or cash occurs. These TRA payments are not conditioned upon any continued ownership interest in either BV LLC or Bioventus by the continuing LLC owner. The rights of the continuing LLC owner under the TRA are assignable to transferees of its LLC interests (other than Bioventus as transferee pursuant to subsequent redemptions or exchanges of the transferred LLC interests). Bioventus expects to benefit from the remaining 15% of tax benefits, if any, that it may actually realize. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The actual basis adjustments, as well as any amounts paid to the continuing LLC owner under the TRA, will vary depending on a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">the timing of any subsequent redemptions or exchanges&#8212;</div></div>for instance, the increase in any tax deductions will vary depending on the fair value, which may fluctuate over time, of the depreciable or amortizable assets of BV LLC at the time of each redemption or exchange; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">the price of shares of our Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A common stock at the time of redemptions or exchanges</div></div>&#8212;the basis adjustments, as well as any related increase in any tax deductions, is directly related to the price of shares of our Class&#160;A common stock at the time of each redemption or exchange; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">the extent to which such redemptions or exchanges are taxable&#8212;</div></div>if a redemption or exchange is not taxable for any reason, increased tax deductions will not be available; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">the amount and timing of our income&#8212;</div></div>the TRA generally requires Bioventus to pay 85% of the tax benefits as and when those benefits are treated as realized under the terms of the TRA. Except as discussed below in cases of (i)&#160;a material breach of a material obligation under the TRA, (ii)&#160;a change of control or (iii)&#160;an early termination of the TRA, if Bioventus does not have taxable income, it will generally not be required to make payments under the TRA for that taxable year because no tax benefits will have been realized. However, any tax benefits that do not result in realized tax benefits in a given taxable year may generate tax attributes that may be utilized to generate tax benefits in future taxable years. The utilization of any such tax attributes will result in payments under the TRA. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">290 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of the TRA, cash savings in income tax will be computed by comparing Bioventus&#8217; actual income tax liability to the amount of such taxes that it would have been required to pay had there been no basis adjustments and had the TRA not been entered into. The TRA generally applies to each of Bioventus&#8217; taxable years, beginning with the first taxable year ending after the consummation of the offering. There is no maximum term for the TRA; however, the TRA may be terminated by Bioventus pursuant to an early termination procedure that requires Bioventus to pay the continuing LLC owner an agreed upon amount equal to the estimated present value of the remaining payments to be made under the agreement (calculated based on certain assumptions, including regarding tax rates and utilization of the basis adjustments). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The payment obligations under the TRA are Bioventus&#8217; obligation and not BV LLC&#8217;s. Although the actual timing and amount of any payments that may be made under the TRA will vary, Bioventus expects that the payments that we may be required to make to the continuing LLC owner could be significant. Any payments made by Bioventus to the continuing LLC owner under the TRA generally reduces the amount of overall cash flow that might have otherwise been available to Bioventus or to BV LLC and, to the extent that Bioventus is unable to make payments under the TRA for any reason, the unpaid amounts generally are deferred and accrue interest until paid by Bioventus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decisions made by Bioventus in the course of running Bioventus&#8217; business, such as with respect to mergers, asset sales, other forms of business combinations or other changes in control, may influence the timing and amount of payments that are received by the continuing LLC owner under the TRA. For example, the earlier disposition of assets following a transaction that results in a basis adjustment generally accelerate payments under the TRA and increase the present value of such payments. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The TRA provides that if (i)&#160;Bioventus materially breaches any of its material obligations under the TRA, (ii)&#160;certain mergers, asset sales, other forms of business combination, or other changes of control were to occur, on or before December&#160;31, 2021 or (iii)&#160;Bioventus elects an early termination of the TRA, then its obligations, or its successor&#8217;s obligations, under the TRA would be based on certain assumptions, including an assumption that it would have sufficient taxable income to fully utilize all potential future tax benefits that are subject to the TRA. The TRA also provides that in the case of certain mergers, asset sales, other forms of business combination or other changes of control occurring on or after December&#160;31, 2021, payments under the TRA would be based on certain assumptions, including an assumption that in each taxable year ending on or after the change of control, Bioventus would have taxable income equal to the greater of (A)&#160;actual taxable income for such taxable year and (B)&#160;the product of (x)&#160;four and (y)&#160;the highest taxable income in any of the four fiscal quarters ended prior to the change in control (increased by 10% for each taxable year beginning with the second taxable year following the change in control), in each case, as adjusted to take into account our actual percentage ownership in BV LLC for the taxable year for which the tax benefit payment is being determined. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the foregoing, (i)&#160;we could be required to make cash payments to the continuing LLC owner that are greater than the specified percentage of the actual benefits Bioventus ultimately realizes in respect of the tax benefits that are subject to the TRA, and (ii)&#160;if Bioventus materially breach any of its material obligations under the TRA or if it elected to terminate the TRA early, it would be required to make an immediate cash payment equal to the present value of the anticipated future tax benefits that are the subject of the TRA, which payment may be made significantly in advance of the actual realization, if any, of such future tax benefits. In these situations, Bioventus&#8217; obligations under the TRA could have a material adverse effect on our liquidity and could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combination, or other changes of control. There can be no assurance that Bioventus will be able to finance its obligations under the TRA. Bioventus anticipates funding ordinary course payments under the TRA from distributions from BV LLC out of distributable cash, to the extent permitted by its agreements governing its indebtedness. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments under the TRA are based on the tax reporting positions that Bioventus determines. Pursuant to the TRA, the continuing LLC owner is required to reimburse Bioventus for cash payments previously made to it pursuant to the TRA if any tax benefits actually realized by Bioventus are subsequently challenged by a taxing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">291 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">authority and ultimately disallowed. In addition, but without duplication of any amounts previously reimbursed by the continuing LLC owner, any excess cash payments made by us to the continuing LLC owner will be netted against any future cash payments that we might otherwise be required to make under the terms of the TRA. However, a challenge to any tax benefits actually realized by Bioventus may not arise for a number of years following the initial time of such payment and Bioventus might not determine that it has effectively made an excess cash payment to the continuing LLC owner for a number of years following the initial time of such payment. Moreover, there can be no assurance that any excess cash payments for which the continuing LLC owner has a reimbursement obligation under the TRA will be repaid to Bioventus. As a result, it is possible that Bioventus could make cash payments under the TRA that are substantially greater than its actual cash tax savings. The applicable U.S. federal income tax rules are complex and factual in nature, and Bioventus cannot assure you that the IRS or a court will not disagree with its tax reporting positions. Bioventus has full responsibility for, and sole discretion over, all of its and BV LLC&#8217;s tax matters, including the filing and amendment of all tax returns and claims for refund and defense of all tax contests, subject to certain participation and approval rights held by the continuing LLC owner. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments are generally due under the TRA within a specified period of time following the filing of Bioventus&#8217; tax return for the taxable year with respect to which the payment obligation arises, although interest on such payments begin to accrue at a rate of LIBOR plus 100 basis points from the due date, without extensions, of such tax return and ending on the date that such payments are required to be made under the terms of the TRA. Any late payments that may be made under the TRA continue to accrue interest at LIBOR plus 500 basis points from the due date of such payments under the TRA until such payments are made, including any late payments that Bioventus may subsequently make because Bioventus did not have enough available cash to satisfy its payment obligations at the time at which they originally arose, including as a result of restrictions on payments to its equity owners in the agreements governing our indebtedness. To date, there have been no payments to the continuing LLC owner made by Bioventus pursuant to this agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus LLC Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus operates its business through BV LLC and its subsidiaries. Bioventus and the continuing LLC owner entered into the Bioventus LLC agreement, which sets forth terms for the operations of BV LLC, and the rights and obligations of the holders of LLC interests. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Appointment as Manager </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the Bioventus LLC agreement, Bioventus is a member and the sole manager of BV LLC. As the sole manager, Bioventus is able to control all of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> business affairs and decision-making of BV LLC. As such, Bioventus, through our officers and directors, are responsible for all operational and administrative decisions of BV LLC and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> management of BV LLC&#8217;s business. Pursuant to the terms of the Bioventus LLC agreement, Bioventus cannot, under any circumstances, be removed as the sole manager of BV LLC except by Bioventus&#8217; election. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is not entitled to compensation for its services as manager. Bioventus is entitled to reimbursement or capital contribution credit by BV LLC for fees and expenses incurred on behalf of BV LLC, including all expenses associated with Bioventus&#8217; IPO and maintaining its corporate existence. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recapitalization. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus LLC agreement recapitalizes the units that were held prior to the IPO in BV LLC into a new single class of common membership units, which Bioventus refers to as the &#8220;LLC interests.&#8221; Each LLC interest entitles the holder to a pro rata share of the net profits and net losses and distributions of BV LLC. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">292 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus LLC agreement requires &#8220;tax distributions&#8221; to be made by BV LLC to its members, as that term is defined in the agreement. Tax distributions will be made to members on a pro rata basis, including Bioventus, in an amount sufficient to allow the members, including Bioventus, to pay taxes owed in respect of income allocated by BV LLC and to allow Bioventus to meet its obligations under the TRA (as described above under the heading &#8220;Tax Receivable Agreement&#8221; above). For tax distributions made in the fiscal year ending December&#160;31, 2021 (the 2021 fiscal year), the tax rate that Bioventus expect to use for purposes of determining tax distributions from BV LLC to its members will equal the combined federal, state, and local statutory tax rate applicable to it for the 2021 fiscal year, taking into account the deductibility of state and local taxes for federal purposes. For each subsequent fiscal year, the tax rate applicable to Bioventus for the 2021 fiscal year will apply with respect to tax distributions made during such fiscal year unless the Bioventus board determines otherwise. The tax rate used to determine tax distributions will apply regardless of the actual final tax liability of any such member. Tax distributions will also be made only to the extent all distributions from BV LLC for the relevant period were otherwise insufficient to enable each member to cover its tax liabilities as calculated in the manner described above. The Bioventus LLC agreement allows for distributions to be made by BV LLC to its members on a pro rata basis out of &#8220;distributable cash,&#8221; as that term is defined in the agreement. We expect BV LLC may make distributions out of distributable cash periodically to the extent permitted by our agreements governing Bioventus&#8217; indebtedness and necessary to enable us to cover our operating expenses and other obligations, including Bioventus&#8217; tax liability and obligations under the TRA, as well as to make dividend payments, if any, to the holders of Bioventus class A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">LLC Interest Redemption Right </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Bioventus LLC agreement provides a redemption right to the continuing LLC owner which entitles it to have its LLC interests redeemed, at its election, for newly-issued shares of Bioventus class A common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis or a cash payment equal to a volume weighted average market price of one share of Bioventus class A common stock for each LLC interest redeemed (subject to customary adjustments, including for stock splits, stock dividends and reclassifications). If the continuing LLC owner elects to receive a cash payment, Bioventus may elect to settle such redemption with Bioventus class A common stock in lieu of a cash payment, provided that if it elects to do so, the continuing LLC owner has the option to rescind its redemption request within a specified time period. Upon the exercise of the redemption right, the redeeming member will surrender its LLC interests to BV LLC for cancellation. The Bioventus LLC agreement requires that Bioventus contribute cash or shares of Bioventus class A common stock to BV LLC in exchange for an amount of newly-issued LLC interests in BV LLC that will be issued to us equal to the number of LLC interests redeemed from the continuing LLC owner. BV LLC will then distribute the cash or shares of Bioventus class A common stock to the continuing LLC owner to complete the redemption. In the event of such a redemption election by the continuing LLC owner, Bioventus may effect a direct exchange of cash or Bioventus class A common stock for such LLC interests in lieu of such a redemption. Whether by redemption or exchange, we are obligated to ensure that at all times the number of LLC interests that Bioventus owns equals the number of shares of Bioventus class A common stock issued by Bioventus (subject to certain exceptions for treasury shares and shares underlying certain convertible or exchangeable securities). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus LLC agreement provides for indemnification of the manager, members and officers of BV LLC and their respective subsidiaries or affiliates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Available Information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; website is located at www.bioventus.com. Information on its website or connected to its website is not incorporated by references into this joint proxy statement/prospectus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">293 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_23" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS&#8217; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion and analysis of Bioventus&#8217; financial condition and results of operations should be read in conjunction with the disclosure under &#8220;Risk Factors&#8221; and Bioventus&#8217; consolidated financial statements and the related notes to those statements included elsewhere in this joint proxy statement/prospectus. In addition to historical consolidated financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Bioventus&#8217; actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in this joint proxy statement/prospectus. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive summary </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing process. Bioventus operates its business through two reportable segments, U.S. and International, and Bioventus&#8217; portfolio of products is grouped into three verticals: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pain Treatments and Joint Preservation includes the legacy osteoarthritis (OA) joint pain treatment and joint preservation products, plus the Peripheral Nerve Stimulation (PNS) products sold previously by Bioness. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bone Graft Substitutes (BGS) is comprised of human tissue allograft and synthetic products used primarily in spine surgery; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restorative Therapies includes the legacy minimally invasive fracture treatments, plus the rehabilitation products sold previously by Bioness. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus&#8217; U.S. segment offers its full existing portfolio of products. This includes its pain treatment and joint preservation products, which address the entire market for HA viscosupplementation with offerings for single, three and five injection therapies: (i)&#160;Durolane, a single injection therapy, which Bioventus launched in the United States in the first half of 2018 and also market outside the United States in more than 30 countries; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(ii)&#160;GELSYN-3,</div> a three injection therapy, which Bioventus has marketed in the United States since the second half of 2016; and (iii)&#160;SUPARTZ FX, a five injection therapy, which Bioventus has marketed in the United States since May 2012. Bioventus&#8217; U.S. segment also offers its BGS products, which are targeted at improving bone fusion rates following spinal fusion and other orthopedic surgeries. These products include allograft-derived bone graft with growth factors (OsteoAMP), a DBM (Exponent), cancellous bone in different preparations (PureBone), bioactive synthetics (Signafuse and Interface), a collagen ceramic matrix (OsteoMatrix) and two bone marrow isolation systems (CellXtract and Extractor). Further, its U.S. segment offers its Exogen system, which Bioventus believes offers significant advantages over electrical based long bone stimulation systems, including documented mechanism of action, shorter treatment times and superior nonunion heal rates. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; International segment offers Durolane, or single injection therapy, OsteoAMP, its allograft-derived bone graft with growth factors, and its Exogen system. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">294 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth total net sales, net income from continuing operations, Adjusted EBITDA and pro forma net income (loss) per unit attributable to common unit holders - basic and diluted: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321,161</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">340,141</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,594</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,506</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA(1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,957</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,188</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per unit attributable to common unit holders - basic and diluted(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.89</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">See below under<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Components of Bioventus&#8217; results of operations-Adjusted EBITDA</div></div> for a definition of Adjusted EBITDA and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Results from continuing operations</div></div> for a reconciliation of net income from continuing operations to Adjusted EBITDA. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See below for a computation of pro forma net income per unit attributable to common unit holders - basic and diluted after the recapitalization described below which was in conjunction with Bioventus&#8217; IPO. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, Bioventus&#8217; limited liability company agreement was amended and restated to, among other things, (i)&#160;provide for a new single class of common membership interests in the Company (LLC Interests) and (ii)&#160;exchange all of the existing membership interests for LLC Interests. For purposes of calculating pro forma earnings per unit, Bioventus has adjusted the number of outstanding membership units retroactively to give effect to the amendment and resulting recapitalization. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma basic net income per unit is computed by dividing net income by the pro forma weighted-average number of units outstanding during the period. Pro forma diluted net income per unit is computed by dividing net income by the pro forma weighted-average number of units outstanding adjusted to give effect to potentially dilutive securities. As a result of the recapitalization and the New LLC Owner assuming the obligations of the Company&#8217;s Phantom Plan awards there are no dilutive securities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a reconciliation of the numerators and denominators used to compute pro forma basic and diluted net income per unit for the years ended December&#160;31 as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations attributable to common unit holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,666</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income attributable to common unit holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,851</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma net income per unit attributable to common unit holders&#8212;basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma net income from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.15</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma net income attributable to common unit holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.29</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma weighted average units used in computing basic and diluted net income per common unit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,825,325</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,825,325</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">295 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strategic transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has pursued and continue to pursue business development opportunities that leverage its significant customer presence across orthopedics, broaden its portfolio and increase its global footprint. Below is a summary of some of Bioventus&#8217; recent transactions: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration and development agreement for MOTYS </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;29, 2019, Bioventus entered into a collaboration and development agreement (Development Agreement), with Musculoskeletal Transplant Foundation, Inc., or MTF, to develop an injectable placental tissue product, MOTYS, for use in the pain treatment and joint preservation. The development and commercialization of the product is anticipated to take place in two stages. In consideration for achieving its development milestones, Bioventus paid MTF $1.5&#160;million and are obligated to pay additional payments totaling $0.8&#160;million if certain further milestones are achieved. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development collaboration agreement for PROcuff </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;23, 2019, Bioventus entered into an exclusive Collaboration Agreement with Harbor, to develop and license the rights to commercialize a woven-suture-collagen composite implant product. Concurrently with the execution of the agreement, Bioventus purchased $1.0&#160;million of shares of Harbor. As a result of Harbor&#8217;s achievement of certain milestones, on October&#160;5, 2020, Bioventus purchased $1.0&#160;million of additional shares of Harbor. Furthermore, Bioventus is obligated to make two additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payments totaling $6.0&#160;million in aggregate upon Harbor&#8217;s achievement of (i)&#160;receiving regulatory approval and (ii)&#160;achieving a certain net sales target. The sole use of proceeds from these investments is for the development of the implant product that is the subject of its agreement. Bioventus intends to negotiate and enter into a definitive supply agreement with Harbor if and when the product is cleared for marketing by the FDA at a price per unit not to exceed an agreed upon maximum. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of the foregoing transactions have had a significant impact on Bioventus&#8217; financial results of operations for the periods in which they occurred, and they have affected the comparability of these statements for the corresponding comparative periods. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outlook </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus plans to continue to expand its business and to increase its net sales and profitability by executing on the following strategies: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continue to expand market share in HA viscosupplementation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">introduce new pain treatment and joint preservation products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">further develop and commercialize Bioventus&#8217; BGS portfolio; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expand indications for use for Bioventus&#8217; Exogen system; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">invest in research and development; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pursue business development opportunities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">opportunistically grow Bioventus&#8217; international markets. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus expects to face challenges as Bioventus executes on its business strategy. Bioventus&#8217; industry is highly competitive, subject to rapid change and significantly affected by market activities of industry participants, new product introductions and other technological advancements. Bioventus believes its experienced management team positions Bioventus for success in facing these and other challenges. However, there are several factors </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">296 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">affecting Bioventus&#8217; business that are beyond its control, such as its ability to successfully introduce new products and line extensions, expand labels, continue to obtain reimbursement for its products at acceptable rates and receive necessary governmental approvals. In addition, Bioventus expects that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among its customers, which may exert further downward pressure on the prices of its products. For information about additional factors that may affect its outlook, see<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>&#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; sections of this joint proxy statement/prospectus. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Developments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Misonix Acquisition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;29, 2021, Bioventus entered into the Misonix Merger Agreement to acquire Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-and-stock</div></div> transaction. The Transaction is expected to close in the fourth quarter of 2021 and is subject to regulatory approvals, the approval of Bioventus&#8217; stockholders, Misonix stockholder approval and customary closing conditions. Misonix is a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Misonix stockholders will receive aggregate consideration that values Misonix at approximately $518.0&#160;million on a fully diluted basis, based on the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7-day</div> weighted average stock price of $16.6284 per share as of July&#160;27, 2021. The Transaction involves both cash and stock consideration based on the election of the Misonix stockholder. Each share of Misonix Common Stock issued and outstanding immediately prior to the Transaction, will be converted into the right to receive either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Class&#160;A common stock of the Company, $0.001 par value per share, based on the election of the holder. The maximum cash amount payable by the Company will be an amount equal to $10.50 multiplied by the number of outstanding shares of Misonix Common Stock shortly prior to the completion of the Transaction. The Company expects to fund the cash portion of the acquisition with cash on hand and through committed financing provided by Wells Fargo Bank, National Association (Wells Fargo Bank). The number of shares held by Misonix stockholders electing to receive cash will be reduced on a pro rata basis if the cash elected to be received exceeds the maximum cash amount payable and will be paid with stock consideration of 1.6839 of shares of the Company&#8217;s Class&#160;A common stock. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioness Acquisition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2021, Bioventus completed the acquisition of Bioness, a global leader in neuromodulation and advanced rehabilitation medical devices through its innovative PNS therapy and premium advanced rehabilitation solutions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioness acquisition gives Bioventus access into two large and growing markets: PNS and the advanced rehabilitation market, and Bioventus estimates their medical devices address total global market opportunities approaching $8&#160;billion per year. Bioventus believes both of these markets offer attractive growth opportunities driven by demographic trends and the need for safe, effective, treatment options for the many patients suffering from post-surgical pain, stroke, multiple sclerosis, traumatic brain injury, spinal cord injury and cerebral palsy. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioness advanced rehabilitation solutions have a broad portfolio of offerings, including proprietary electrical stimulation exoskeletal devices for both the upper and lower extremities, robotic gait and fall safety systems, and high-tech, interactive software learning and recovery assessment platforms. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These products play an essential role in helping patients regain mobility due to stroke, traumatic brain injury, multiple sclerosis and osteoarthritis, and are used by physical or occupational therapists in a clinical setting or by the patient at home, with the guidance of a clinician through telemedicine. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">297 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioness PNS Systems help patients suffering from pain after surgery on an extremity, which affects over 16&#160;million patients each year globally, and addresses the growing need to reduce opioid usage. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Merger Agreement pursuant to which Bioventus acquired Bioness (the Bioness Merger Agreement), Bioventus paid $48.9&#160;million at the closing of the transaction and agreed to pay up to an additional $43.0&#160;million of discounted contingent consideration related to the achievement of certain key milestones. The acquisition includes the entire portfolio of Bioness products as well as its research and development pipeline. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> consideration was funded exclusively through the use of cash on hand. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CartiHeal </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;15, 2020, BV LLC entered into an Option and Equity Purchase Agreement with CartiHeal (2009)&#160;Ltd., a privately-held company headquartered in Israel and the developer of the proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div> implant for the treatment of joint surface lesions in traumatic and osteoarthritic joint, and its shareholders. The agreement provides BV LLC with an exclusive option to acquire 100% of CartiHeal&#8217;s shares under certain conditions, or the Call Option, and provides CartiHeal with a put option that would require BV LLC to purchase 100% of CartiHeal&#8217;s shares under certain conditions, or the Put Option. The Put Option is only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> device with a label consistent in all respects with pivotal clinical trial success. The pivotal clinical trial&#8217;s objective is to demonstrate the superiority of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant over the surgical standard of care, including microfracture and debridement, for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes. The investment follows the recently completed enrollment and outcome of interim analysis in CartiHeal&#8217;s IDE multinational pivotal study for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C.</div> This new round of funding is expected to enable CartiHeal to complete all patient <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> study and submit an application for PMA to the FDA. Under the terms of BV LLC&#8217;s investment in CartiHeal, CartiHeal can secure an additional $5.0&#160;million equity investment from BV LLC, if needed, for IDE study completion. BV LLC previously made an initial $2.5&#160;million investment in CartiHeal in January 2018 and a subsequent investment of $0.2&#160;million in January 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August&#160;2, 2021, pursuant to the Option and Equity Purchase Agreement, CartiHeal provided BV LLC with a statistical report containing the results of the pivotal clinical trial. On August&#160;27, 2021, the Bioventus board, after its review of the statistical report for CartiHeal&#8217;s pivotal clinical trial and determination that the results of the statistical report indicated a Pivotal Clinical Trial Success (as contemplated by the Option and Equity Purchase Agreement), approved BV LLC&#8217;s continued pursuit of a potential acquisition of CartiHeal. BV LLC thereafter deposited $50.0&#160;million in escrow in accordance with the terms of the Option and Equity Purchase Agreement. The closing of the transaction is subject to, among other things (including customary closing conditions), the valid exercise of the Call Option or the Put Option, the latter of which cannot be exercised unless and until premarket approval (PMA) by the Food and Drug Administration (FDA) is received with respect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant, which was granted Breakthrough Device Designation by the FDA last year. CartiHeal plans to submit the clinical module of their PMA later this year, and the decision from the FDA is expected in the second half of 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Should the Put Option or Call Option be exercised and the acquisition of CartiHeal consummated, the consideration for the acquisition of all of the shares of CartiHeal, excluding those Bioventus owns, would be $350&#160;million payable in cash, subject to customary adjustments, all of which would be payable at closing, with an additional $150.0&#160;million payable upon achievement of certain sales milestones related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C.</div> Should the closing occur, the $50&#160;million escrowed by BV LLC will be applied towards the consideration payable by BV LLC pursuant to the Option and Equity Purchase Agreement. CartiHeal has announced that it expects to submit its PMA application to the FDA later this year. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BONES Trial </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus submitted a supplemental PMA to the FDA in December 2020 seeking approval of an expanded indication for EXOGEN, specifically, for the adjunctive treatment of acute and delayed metatarsal fractures to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">298 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">reduce the risk of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-union.</div> This PMA supplement was based on and supported by clinical data in metatarsal fractures from the ongoing B.O.N.E.S. study. In April 2021, Bioventus received a letter from the FDA identifying certain deficiencies in the PMA supplement that must be addressed before the FDA can complete its review of the PMA supplement. The deficiencies include concerns about the data and endpoints from the B.O.N.E.S. study, and requests for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-analyses</div> of certain data and provision of other information to support the findings. Bioventus continues to evaluate the FDA&#8217;s comments and are initiating discussions with them to address their concerns. Bioventus can give no assurance that Bioventus will be able to resolve the deficiencies identified by the FDA in a timely manner, or at all. Consequently, the FDA&#8217;s decision on the PMA supplement may be delayed beyond the time originally anticipated. Moreover, if Bioventus&#8217; responses do not satisfy the FDA&#8217;s concerns, the FDA may not approve Bioventus&#8217; PMA supplement seeking to expand the indications for Bioventus of EXOGEN as proposed. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impact </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2020, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic spread around the world and in the United States. New variants of the virus have emerged, some of which have shown to be more contagious. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments have implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of businesses, work from home, supply chain logistical changes and other measures, which caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Bioventus&#8217; business, results of operations and financial condition have been and may continue to be, materially impacted by fluctuations in patient visits and elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments from customers, supply chain interruptions, extended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;shelter-in-place&#8221;</div></div> orders or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on Bioventus&#8217; business will depend on many factors, including, but not limited to, the duration and severity of the pandemic, the spread of new variants of the virus, new and ongoing measures taken in response to the pandemic, the availability, adoption and effectiveness of vaccines, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on Bioventus&#8217; partners, patients and communities in which Bioventus operates, all of which continue to be uncertain. As of the date of this joint proxy statement/prospectus, the extent to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could materially impact the Company&#8217;s financial conditions, liquidity or results of operations is uncertain. </div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To the extent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> disruptions continue to adversely impact Bioventus&#8217; business, results of operations and financial condition, it may also have the effect of heightening risks relating to Bioventus&#8217; ability to successfully commercialize newly developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of Bioventus&#8217; numerous contractual relationships. For additional information on the risks Bioventus may face as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> refer to &#8220;Risk Factors&#8212;Risks Relating to Bioventus&#8217; Business&#8212;Bioventus&#8217; business may continue to experience adverse impacts as a result of the COVID-19 pandemic.&#8221; </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Components of its results of operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net sales </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus generates net sales from a portfolio of active healing products that serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Bioventus reports sales net of contractual allowances, rebates and returns. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus sells its pain treatment and joint preservation products and restorative therapies through its direct sales team, who manage and maintain the sales relationship with healthcare providers, distribution centers or specialty </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">299 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">pharmacies. In certain international markets, Bioventus also sells to independent distributors on prearranged business terms, who manage or maintain the sales relationship with their physician customers. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;2. Summary of significant accounting policies</div></div> in the &#8220;Notes to the Audited Consolidated Financial Statements&#8221;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>included in this joint proxy statement/prospectus for further information. Bioventus recognizes revenue at the point in time when control is transferred to the customer, typically, in the case of its pain treatment and joint preservation products, when these products are shipped to the customer and, in the case of its Exogen system, when the patient has accepted the product. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; BGSs are primarily sold in the U.S. market through independent distributors. Bioventus generally consigns its BGS products to hospitals so its neurosurgeon and orthopedic spine surgeon customers can use them in procedures. Bioventus recognizes revenue based upon consumption in a surgical procedure. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of sales </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus&#8217; cost of sales primarily consist of costs of products purchased from its third-party suppliers, direct labor and allocated overhead associated with the assembly of its Exogen system, excess and obsolete inventory charges, shipping, inspection and related costs incurred in making its products available for sale or use. In addition, cost of sales includes depreciation related to production as well as amortization of product-related intellectual property and distribution rights associated with commercialized products. Bioventus&#8217; pain treatment and joint preservation products and BGS products are manufactured by or obtained from third-party suppliers primarily located in Japan, Switzerland, Sweden and the United States. Bioventus receives the components for its Exogen system from suppliers and assemble each system <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> at its Cordova, Tennessee facility. In the future, Bioventus expects its cost of sales to increase due to increased sales volume. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gross profit and gross margin </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit consists of net sales less cost of sales. Bioventus calculates gross margin as gross profit divided by net sales. Bioventus&#8217; gross margin has been and will continue to be affected by a variety of factors, including costs of products purchased from its third-party suppliers, manufacturing costs, product mix and implementation over time of cost-reduction strategies. Bioventus expects net sales and product mix to vary quarter by quarter and therefore its gross profit will likely fluctuate from quarter to quarter. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Selling, general and administrative expense </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense primarily consists of salaries, benefits and other related costs, including equity-based compensation, for personnel employed in sales, marketing, finance, legal, compliance, administrative, information technology, medical education and training, quality and human resource departments. Selling, general and administrative expense also includes third-party marketing, supply chain and distribution, product recall costs, information technology, legal, human resources, insurance and facilities expenses, selling, general and administrative expenses also include commissions, generally based on a percentage of sales, to its direct sales team and independent distributors. Bioventus expects its selling, general and administrative expenses will increase with the continued expansion of its sales organization and commercialization of its current and pipeline products. Bioventus plans to hire more personnel to support the growth of its business. In addition, as a public company, Bioventus will be implementing additional procedures and processes to address the standards and requirements applicable to public companies. Bioventus expects to incur additional annual selling, general and administrative expenses related to these additional procedures and processes including, among other things, equity-based compensation, increased liability insurance for its directors and officers, director fees, reporting requirements of the SEC, transfer agent fees, hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar expenses. Bioventus also expects a change in the timing over which compensation expense is recognized as a result of the termination of the Phantom Plan and the receipt by participants of shares of Class&#160;A common stock upon settlement of their awards, which settlement is expected to take place twelve months after the date of such termination. However, over time, as Bioventus grows its net sales, Bioventus expects selling, general and administrative expenses to decline as a percentage of net sales. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">300 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expense </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expense primarily consists of employee compensation, equity compensation and related expenses, as well as contract research organization service expenses related to clinical trials. Bioventus expenses internal research and development costs as incurred and research and development costs incurred by third parties as they perform contracted work. Bioventus&#8217; research and development expenses may vary substantially from period to period based on the timing of research and development activities. Bioventus is focused on internal research and development to broaden its product portfolio across all verticals, expand its Exogen system product label and undertake clinical research to support commercialization of all of its products. As a result, Bioventus expects its research and development expenses to increase to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits as a percentage of net sales as it introduces new products, extends existing product lines and expands indications. Bioventus sees significant opportunity to develop innovative and clinically differentiated products <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> with its experienced research and development team. Bioventus is currently funding its B.O.N.E.S. clinical study, which began enrollment in 2018 and is aimed at broadening the label of its Exogen system to include a broader range of bones that may be treated as fresh fractures in predisposed patients at risk of nonunion. In addition, Bioventus is planning preclinical and animal model studies for MOTYS and PROcuff. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restructuring costs </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs primarily consist of employee severance, legal, consulting and temporary labor expenses. During the periods presented, restructuring costs were associated with headcount reductions in its international business to improve operating efficiency. Key assumptions in determining the restructuring costs include headcount reductions, as well as terms and negotiated payments to terminate certain contractual obligations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Depreciation and amortization </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense primarily consists of depreciation of computer equipment and software as well as leasehold improvements, furniture, fixtures, machinery and equipment. Amortization expense primarily consists of amortization expense related to customer relationships and other intangible assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest expense </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense primarily consists of interest on its indebtedness, which currently consists of its term loan and revolving credit facility, which was incurred pursuant to the 2019 Credit Agreement. Bioventus has entered into interest rate swaps to limit its exposure to changes in the variable interest rate on its term loan. Interest expense includes any fair value gain or losses on these swaps. Interest expense also includes the revaluation for the liability related to its Equity Participation Right, or EPR, Unit. The EPR Unit&#8217;s entitlement is 0.55% of available distributions arising from a distribution event as defined in the Bioventus LLC Agreement and was settled in cash as part of its IPO. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other (income) expense </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense primarily consists of foreign currency transaction and remeasurement gains and losses on transactions denominated in currencies other than its functional currency. Bioventus&#8217; foreign currency transaction and remeasurement gains and losses are primarily related to foreign currency denominated cash, liabilities and intercompany receivables and payables. Other (income) expense may also include certain nonrecurring items. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income tax expense </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BV LLC is a partnership for U.S. federal tax purposes. Accordingly, the members include the profits and losses of BV LLC in their income tax returns. Certain wholly-owned subsidiaries of BV LLC are taxable entities for </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">301 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. or foreign tax purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal and state and international income taxes, including certain taxes applicable to BV LLC and U.S. federal income taxes for one of its subsidiaries that is treated as a corporation for U.S. federal tax purposes. Certain income and expense items in income tax returns are not reported in the same year as financial statements. Bioventus reports the income tax effects of these differences as deferred income taxes. Valuation allowances recognized reduce the related deferred tax assets to an amount which will, more likely than not, be realized. Bioventus recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is subject to U.S. federal, state and local income taxes at the prevailing corporate tax rates with respect to its taxable income. In addition to tax expenses, Bioventus is obligated to make payments under the TRA, which could be significant. The TRA, obligates Bioventus to pay to the Continuing LLC Owner 85% of the amount of any realized tax benefits, (or in some circumstances are deemed to realize) resulting from (i)&#160;increases in the tax basis of assets of BV LLC as a result of (a)&#160;any future redemptions or exchanges of LLC Interests described under &#8220;Description of Bioventus&#8217; Business&#8212;Bioventus LLC agreement&#8212;LLC Interest Redemption Right&#8221;, and (b)&#160;certain distributions (or deemed distributions) by BV LLC and (ii)&#160;certain other tax benefits arising from its making payments under the TRA. For more information, see &#8220;Description of Bioventus&#8217; Business&#8212;Tax Receivable Agreement.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Financial Measures - Adjusted EBITDA </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus presents Adjusted EBITDA, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure because Bioventus believes it is a useful indicator of its operating performance. Bioventus&#8217; management uses Adjusted EBITDA principally as a measure of its operating performance and believes that Adjusted EBITDA is useful to its investors because it is frequently used by securities analysts, investors and other interested parties frequently use it in their evaluation of the operating performance of companies in industries similar to Bioventus&#8217;. Bioventus&#8217; management also uses Adjusted EBITDA for planning purposes, including the preparation of its annual operating budget and financial projections. Bioventus defines Adjusted EBITDA as net income (loss) from continuing operations before depreciation and amortization, provision of income taxes and interest expense, adjusted for the impact of certain cash, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> and other items that Bioventus does not consider in its evaluation of ongoing operating performance. These items include equity compensation, change in fair value of contingent consideration, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> benefits, succession and transition charges, loss on impairment of intangible assets, losses associated with debt refinancing, restructuring costs, foreign currency impact and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs. The allocation of corporate overhead costs is determined based on various methods but is primarily based on a ratio of net sales by segment to total consolidated net sales. See table within Results from continuing operations for a reconciliation of net income from continuing operations to Adjusted EBITDA. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim Periods </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company reports quarterly interim periods on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-week</div> basis within a standard calendar year. Each annual reporting period begins on January&#160;1 and ends on December 31. Each quarter ends on the Saturday closest to calendar <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">quarter-end,</div> with the exception of the fourth quarter, which ends on December 31. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-week</div> quarterly periods ended on March&#160;28, June&#160;27 and September&#160;26 for the year ended December&#160;31, 2020. As a result, the fourth and first quarters may vary in length depending on the calendar year. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">302 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth components of Bioventus&#8217; condensed consolidated statements of operations as a percentage of net sales for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales (including depreciation and amortization)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of variable interest entity assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a reconciliation of net (loss) income to Adjusted EBITDA for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,748</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,506</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense (income)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(b)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,559</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,771</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> benefits, net<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(c)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Succession and transition charges<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(d)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">344</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(e)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(64</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition and integration costs<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(f)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Inventory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> costs<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(g)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity loss in unconsolidated investments<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(h)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(i)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments related to variable interest entity<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(j)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(k)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">30,957</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">21,188</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes for the six months ended July&#160;3, 2021 and June&#160;27, 2020, respectively, depreciation and amortization of $10,854 and $10,599 in cost of sales, and $3,777 and $3,638 presented in the consolidated statements of operations and comprehensive (loss) income with the balance in research and development. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(b)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The six months ended July&#160;3, 2021 primarily includes equity-based compensation expense (income) resulting from awards granted under the Company&#8217;s current equity based compensation plan (2021 Plan) and compensation costs. The six months ended July&#160;3, 2021 also includes the change in fair market value of accrued equity-based compensation related to the BV LLC Phantom Profits Interest Plan (Phantom Plan) due to expected pricing with Bioventus&#8217; IPO. Equity compensation expenses for the six months ended June&#160;27, 2020 represents compensation from the Company&#8217;s management incentive plan and Phantom Plan as well as the change in fair market value of accrued equity-based compensation related to the plans due to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on Bioventus&#8217; business. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(c)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents income resulting from the CARES Act offset by additional cleaning and disinfecting expenses and contract termination fees for canceled events. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(d)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily represents costs related to the CEO transition. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(e)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact represents realized and unrealized gains and losses from fluctuations in foreign currency and is included within other expense (income) in the consolidated statements of operations and comprehensive (loss) income. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">303 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(f)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents costs incurred to acquire and integrate Bioness. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(g)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amortization of the inventory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> associated with the Bioness acquisition. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(h)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents CartiHeal equity investment losses. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(i)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents change in fair value of contingent consideration resulting from the Bioness Acquisition. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(j)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents loss on impairment of Harbor&#8217;s long-lived assets and the Company&#8217;s investment in Harbor. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(k)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs primarily includes charges associated with strategic transactions, such as potential acquisitions and public company preparation costs, primarily accounting and legal fees. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus presents Adjusted EBITDA, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measure, because Bioventus believes it is a useful indicator of Bioventus&#8217; operating performance. Bioventus&#8217; management uses Adjusted EBITDA principally as a measure of Bioventus&#8217; operating performance and believes that Adjusted EBITDA is useful to Bioventus&#8217; investors because it is frequently used by securities analysts, investors and other interested parties frequently use it in their evaluation of the operating performance of companies in industries similar to Bioventus&#8217;. Bioventus&#8217; management also uses Adjusted EBITDA for planning purposes, including the preparation of Bioventus&#8217; annual operating budget and financial projections. Bioventus defines Adjusted EBITDA as net (loss) income before depreciation and amortization, provision of income taxes and interest expense, adjusted for the impact of certain cash, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> and other items that Bioventus does not consider in Bioventus&#8217; evaluation of ongoing operating performance. These items include equity compensation, change in fair value of contingent consideration, Bioness acquisition costs, succession and transition charges, loss on impairment of intangible assets, losses associated with debt refinancing, foreign currency impact and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs. The allocation of corporate overhead costs is determined based on various methods but is primarily based on a ratio of net sales by segment to total consolidated net sales. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net sales </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for percentage)</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,526</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,594</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six months ended July&#160;3, 2021 compared to June&#160;27, 2020 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S.</div></div> </div> <div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales increased $48.1&#160;million, or 38.4%. The changes in net sales by vertical are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 78%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; &#160;&#160;&#160;&#160;Pain Treatments and Joint Preservation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.3&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; &#160;&#160;&#160;&#160;Bone Graft Substitutes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.7 million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; &#160;&#160;&#160;&#160;Restorative Therapies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.1 million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Revenue increased primarily due to volume growth as revenue in 2020 was negatively affected by the economic impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The Bioness acquisition contributed $9.4&#160;million in additional sales primarily within the Pain Treatments and Joint Preservation vertical. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net sales increased $6.8&#160;million, or 59.4%, primarily due to sales volume growth as revenue in 2020 was negatively affected by the economic impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The Bioness acquisition contributed $2.5&#160;million in additional sales, a majority of which was reported within Bioventus&#8217; Pain Treatments and Joint Preservation vertical. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">304 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gross profit and gross margin </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for percentage)</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90,014</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,571</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,869</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">135,869</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross margin</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six months ended July&#160;3, 2021 compared to June&#160;27, 2020 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit increased $33.4&#160;million, or 37.1%, primarily due to the increase in net sales. Gross margin remained consistent with the prior year comparable period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit increased $4.9&#160;million, or 64.3%, primarily due to the increase in net sales. Gross margin increased slightly due to product mix. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Selling, general and administrative expense </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for percentage)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,736</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,809</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,927</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six months ended July&#160;3, 2021 compared to June&#160;27, 2020 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Selling, general and administrative expenses increased $22.9&#160;million, or 28.4%, primarily due to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on Bioventus&#8217; business in 2020 as well as the Bioness Acquisition. The increases were primarily in the following areas: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; &#160;&#160;Compensation related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.0&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1.3em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; &#160;&#160;Equity compensation excluding change in the fair value discussed further below</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.6&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; &#160;&#160;Consulting expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.4&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; &#160;&#160;Corporate and employee health insurance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.7&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226; &#160;&#160;Legal and accounting expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These increases were partially offset by a higher change in fair value of Bioventus&#8217; accrued equity-based compensation resulting in an increased net recovery of expense compared to the prior year of $15.6&#160;million. The change in fair value for 2021 was due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering price. The change in fair value for 2020 was due to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on Bioventus&#8217; business. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">305 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for percentage)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,041</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six months ended July&#160;3, 2021 compared to June&#160;27, 2020 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expense increased by $1.0&#160;million, or 22.0%, partially due to Bioventus&#8217; cost reduction efforts implemented during 2020 as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic as well as the Bioness acquisition. In addition, compensation related expenses increased $1.0&#160;million and equity compensation, excluding the change in fair value discussed below, increased $0.9&#160;million. These increases were partially offset by a higher change in fair value of Bioventus&#8217; accrued equity-based compensation resulting in an increased net recovery of expense totaling $1.8&#160;million. The change in fair value during 2021 was due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering price. The change in fair value during 2020 was due to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on Bioventus&#8217; business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of contingent consideration </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The $0.6&#160;million change in fair value of Bioness Acquisition contingent consideration during the six months ended July&#160;3, 2021 resulted from the change in present value of discounted cash flows due to the passage of time. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Depreciation and amortization </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for percentage)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,777</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization remained consistent with the six months ended June&#160;27, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of variable interest entity assets </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company terminated the Harbor Collaboration Agreement on June&#160;8, 2021 which resulted in a $5.7&#160;million impairment on Harbor&#8217;s long-lived asset balances, of which $5.2&#160;million was recorded in loss attributable to noncontrolling interest. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 3. Business combinations and investments</div></div> within the &#8220;Notes to the Unaudited Condensed Consolidated Financial Statements&#8221; of the Bioventus financial statements included in this joint proxy statement/prospectus for further details concerning the impairment and deconsolidation of Harbor. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other (income) expense </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense (income)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,410</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense (income)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NM = Not meaningful </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six months ended July&#160;3, 2021 compared to June&#160;27, 2020 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest (income) expense changed $6.4&#160;million. In conjunction with Bioventus&#8217; IPO, Bioventus settled Bioventus&#8217; equity participation right (EPR) liability resulting in interest income of $2.8&#160;million. In addition, the change in the fair value of Bioventus&#8217; interest rate swap resulted in interest income of $1.3&#160;million during 2021 compared to interest expense of $2.0&#160;million in 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">306 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense increased $3.3&#160;million primarily due to the impairment of Bioventus&#8217; Harbor investment of $1.4&#160;million and $0.9&#160;million in net losses related to Bioventus&#8217; equity investment in CartiHeal. In addition, Bioventus had other income in 2020 resulting from a $1.2&#160;million Provider Relief Fund payment under the CARES Act. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income tax expense </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,712</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Income tax expense increased for the six months ended July&#160;3, 2021 and June&#160;27, 2020 primarily due to the increase in Bioventus&#8217; effective tax rate related to the change in structure resulting from Bioventus&#8217; IPO and associated Up C partnership structure as well as the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deductible</div> stock option expense during 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Noncontrolling interest </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Continuing LLC Owner</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harbor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,665</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">672</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">672</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subsequent to the IPO and Transactions, Bioventus is the sole managing member of BV LLC in which Bioventus owns 72.2%. Bioventus has a majority economic interest, the sole voting interest in, and control the management of BV LLC. As a result, Bioventus consolidates the financial results of BV LLC and report a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest representing the 27.8% which is owned by the Continuing LLC Owner. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus stopped consolidating Harbor upon the termination of the Collaboration Agreement, as Bioventus ceased being the primary beneficiary because Bioventus no longer had the power to direct Harbor&#8217;s significant activities. Prior to the deconsolidation, Bioventus&#8217; partial ownership and exclusive Collaboration Agreement with Harbor resulted in loss attributable to noncontrolling interest through June&#160;8, 2021. The $5.0&#160;million increase for the six months ended July&#160;3, 2021 and June&#160;27, 2020 is primarily due to the $5.7&#160;million impairment on Harbor&#8217;s long-lived asset balances. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Adjusted EBITDA </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA for each of Bioventus&#8217; reportable segments is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for percentage)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,996</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,773</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six months ended July&#160;3, 2021 compared to June&#160;27, 2020 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA increased $6.0&#160;million or 28.3% primarily due a $33.4&#160;million increase in gross profit resulting from the increase in sales. This increase was partially offset by the increase in compensation related charges of $21.3&#160;million previously discussed as well as higher public company costs. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">307 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA increased $3.8&#160;million primarily due to a $4.9&#160;million increase in gross profit resulting from the increase in sales. This increase was partially offset by the increase in compensation related charges of $1.1&#160;million previously discussed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2020 compared to the Year ended December&#160;31, 2019 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth components of our condensed consolidated statements of operations from continuing operations as a percentage of net sales for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales (including depreciation and amortization)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a reconciliation of net income from continuing operations to Adjusted EBITDA for the periods presented: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,722</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,113</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization(a)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,643</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,316</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,192</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,576</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,751</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,579</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation(b)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,103</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,844</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> benefits, net(c)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Succession and transition charges(d)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,609</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs(e)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">563</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">575</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact(f)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(117</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity loss in unconsolidated investments(g)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">467</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs(h)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,633</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,177</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes for the years ended December&#160;31, 2020 and 2019 depreciation and amortization of $21.2&#160;million and $22.4&#160;million in cost of sales and also includes $7.4&#160;million and $7.9&#160;million, respectively, presented in the consolidated statements of operations and comprehensive income (loss), with the balance in research and development. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents compensation as well as the change in fair market value resulting from two equity-based compensation plans, the MIP and the Phantom Plan. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents income resulting from the CARES Act offset by additional cleaning and disinfecting expenses and contract termination fees for canceled events. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily represents costs related to the CEO transition. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">308 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(e)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents costs related to a shift from direct to an indirect distribution model in our International business to improve performance. Various international subsidiaries were dissolved and or merged into other BV LLC entities. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(f)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact represents realized and unrealized gains and losses from fluctuations in foreign currency and is included within other (income) loss in the consolidated statements of operations and comprehensive income (loss). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(g)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents our share in the losses of CartiHeal for the year ended December&#160;31, 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(h)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> items in 2020 includes settlement and legal costs of $1.9&#160;million with the OIG. The remaining activities in 2020 and the balance in 2019 are primarily comprised of charges associated with potential strategic transactions, such as potential acquisitions and preparing to become a public company, primarily accounting and legal fees. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net sales </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293,697</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305,072</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,464</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,069</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,605</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321,161</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">340,141</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,980</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales decreased $11.4&#160;million, or 3.7%, for year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019. The changes in net sales by vertical (as named during the 2020 fiscal year) are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 75%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#160;&#160;&#160;&#160;Minimally invasive fracture treatment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">($</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.5)&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#160;&#160;&#160;&#160;OA joint pain treatment and joint restoration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">($</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.3) million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#160;&#160;&#160;&#160;Bone graft substitutes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.4&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Minimally invasive fracture treatment decreased primarily due to sales volume declines resulting from the disruption caused by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. OA joint pain and joint preservation decreased primarily due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic as well as more treatments being sold under contracts with major insurers at lower prices, partially offset by sales volume growth. These decreases were also offset by sales volume growth within our BGS vertical. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net sales decreased $7.6&#160;million, or 21.7%, for the year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019, primarily due to a decline in order volumes due to the disruption caused by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gross profit and gross margin </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214,572</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">224,957</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,947</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,249</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,302</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">233,519</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">249,206</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,687</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">309 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross margin</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Gross profit decreased $10.4&#160;million, or 4.6%, for the year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019, primarily due to the decline in net sales above described. Manufacturing variances created by maintaining consistent production levels in a period of low demand coupled with idle time attributed to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic caused a slight decrease of 0.6% in gross margin during 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Gross profit decreased $5.3&#160;million, or 21.9%, for the year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019, primarily due to the decrease in sales from the disruption caused by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Selling, general and administrative expense </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,078</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">198,475</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense declined $5.4&#160;million, or 2.7%, for the year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019, primarily due to: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 88%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;COVID-19</div> related decreases, including declines in travel and meetings from doing business virtually, lower compensation related expenses as well as various cost-reduction initiatives</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.3&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; line-height: normal;">&#8226;&#8195;&#8202;Lower legal and accounting expenses, which were higher in 2019 due to the OIG matter discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 12. Commitment and contingencies</div></div> within the &#8220;Notes to the Audited Consolidated Financial Statements&#8221; included in this joint proxy statement/prospectus</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.8&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These items were partially offset by the following increases: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Succession and transition charges associated with the transition to our new Chief Executive Officer</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.6&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5em; line-height: normal;">&#8226;&#8195;&#8202;Costs and services related to strategic transactions, product recall expenses and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> charges</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.1&#160;million</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expense </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,202</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,055</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development expense increased $0.1&#160;million, or 1.3%, for the year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019, primarily due to costs relating to the development agreement for MOTYS being almost entirely offset by cost reduction initiatives undertaken as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">310 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Depreciation and amortization </div></div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,439</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,908</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(469</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization during the year ended December&#160;31, 2020 remained consistent with the year ended December&#160;31, 2019, as it slightly decreased $0.5&#160;million, or 5.9%. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other expense (income) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,751</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,579</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,828</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(54.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(75</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,353</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense decreased $11.8&#160;million, or 54.8%, for the year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019, primarily due to decreased debt interest resulting from refinancing our debt in December 2019 as well as the decline in interest rates. This decrease was partially offset with an increase of $1.6&#160;million primarily resulting from the decline in value of our interest rate swap. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income during year ended December&#160;31, 2020 was primarily the result of receiving Provider Relief Fund payments of approximately $4.1&#160;million in the aggregate pursuant to the CARES Act. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income tax expense </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,192</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,576</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(384</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(24.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense decreased $0.4&#160;million, or 24.4%, for the year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019, primarily due to the change in income from continuing operations before income taxes. Our change in effective tax rate is the result of BV LLC&#8217;s pass-through structure for U.S. income tax purposes, while being treated as taxable in certain states and various foreign jurisdictions as well as for certain subsidiaries. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Adjusted EBITDA </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA for each of our reportable segments is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,252</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,673</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,191</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,515</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Adjusted EBITDA decreased $2.4&#160;million, or 3.4%, during the comparable time periods. The decline was the result of decreased gross profit, excluding depreciation and amortization in cost of sales, due to the decrease in sales primarily resulting from the economic impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which also led to lower expenses resulting from doing business virtually, lower compensation related expenses, as well as various other cost-reduction initiatives. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">311 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Adjusted EBITDA decreased $4.3&#160;million, or 57.5%, during the comparable time periods. The decline was the result of decreased gross profit, excluding depreciation and amortization in cost of sales, resulting from the decrease in sales primarily due to the economic impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which was partially offset by lower expenses resulting from doing business virtually, reduced compensation related expenses and various other cost-reduction initiatives. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Overview </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; principal liquidity needs have historically been for acquisitions, working capital, research and development, clinical trials, and capital expenditures. Bioventus expects these needs to continue as Bioventus develops and commercializes new products and further its expansion into international markets. Bioventus believes that its existing cash and cash equivalents, borrowing capacity under its revolving credit facility, cash flow from operations, and net proceeds from its IPO will be enough to meet its anticipated cash requirements for at least the next twelve months. Bioventus may require additional liquidity as Bioventus continues to execute its business strategy. Negative impacts to its liquidity would include a decline in sales of its products, including declines due to changes in its customers&#8217; ability to obtain third-party coverage and reimbursement for procedures that utilize its products, increased pricing pressures resulting from intensifying competition and cost increases, as well as general economic and industry factors. Bioventus anticipates that to the extent that Bioventus requires additional liquidity, Bioventus will obtain funding through the incurrence of other indebtedness, additional equity financings or a combination of these potential sources of liquidity. In addition, Bioventus may raise additional funds to finance future cash needs through receivables or royalty financings or corporate collaboration and licensing arrangements. If Bioventus raises additional funds by issuing equity securities or convertible debt, its stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, or making capital expenditures. If Bioventus raises additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to its products, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to us. The covenants under its credit agreement limit its ability to obtain additional debt financing. Bioventus cannot be certain that additional funding will be available on acceptable terms, or at all. Any failure to raise capital in the future could have a negative impact on its financial condition and its ability to pursue its business strategies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial public offering </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, in connection with its IPO, Bioventus issued and sold 9,200,000 shares of its Class&#160;A common stock at a price to the public of $13.00 per share, resulting in gross proceeds to Bioventus of approximately $119.6&#160;million, before deducting the underwriting discount, commissions and estimated offering expenses payable by us. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is a holding company and have no material assets other than its ownership of LLC Interests and no independent means of generating revenue. The limited liability company agreement of BV LLC provides for the payment of certain distributions to the Continuing LLC Owner and Bioventus in amounts sufficient to cover the income taxes imposed on such members with respect to the allocation of taxable income from BV LLC as well as to cover its obligations under the Tax Receivable Agreement (TRA). Additionally, in the event Bioventus declares any cash dividend, Bioventus intends to cause BV LLC to make distributions to us, in an amount sufficient to cover such cash dividends declared by us. Deterioration in the financial condition, earnings, or cash flow of BV LLC and its subsidiaries for any reason could limit or impair their ability to pay such distributions. In addition, the terms of its financing arrangements, including the 2019 Credit Agreement, contain covenants that may restrict BV LLC and its subsidiaries from paying such distributions, subject to certain exceptions. Further, BV LLC is generally prohibited under Delaware law from making a distribution to a member to the extent that, at </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">312 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the time of the distribution, after giving effect to the distribution, liabilities of BV LLC (with certain exceptions), as applicable, exceed the fair value of its assets. Subsidiaries of BV LLC are generally subject to similar legal limitations on their ability to make distributions to BV LLC. If Bioventus does not have sufficient funds to pay taxes or other liabilities or to fund its operations, Bioventus may have to borrow funds, which could materially adversely affect its liquidity and financial condition and subject Bioventus to various restrictions imposed by any such lenders. To the extent that Bioventus is unable to make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, under the TRA, Bioventus is required to make cash payments to the Continuing LLC Owner equal to 85% of the tax benefits, if any, that Bioventus actually realizes (or in certain circumstances are deemed to realize), as a result of (1)&#160;increases in the tax basis of assets of BV LLC resulting from (a)&#160;any future redemptions or exchanges of LLC Interests described under<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>&#8220;Description of Bioventus&#8217; Business&#8212;Bioventus LLC agreement&#8212;LLC Interest Redemption Right,&#8221; and (b)&#160;certain distributions (or deemed distributions) by BV LLC and (2)&#160;certain other tax benefits arising from payments under the TRA. Bioventus expects the amount of the cash payments required to be made under the TRA will be significant. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including the timing of redemptions or exchanges by the Continuing LLC Owner, the amount of gain recognized by the Continuing LLC Owner, the amount and timing of the taxable income Bioventus generates in the future, and the federal tax rates then applicable. Any payments made by Bioventus to the Continuing LLC Owner under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to Bioventus. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash as of July&#160;3, 2021 totaled $138.1&#160;million compared to $86.8&#160;million as of December&#160;31, 2020. The increase in cash was primarily due to the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(713</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,511</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,224</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(102.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from investing activities - continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,202</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48,094</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">171.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from discontinued operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(172</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate changes on cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(186</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,229</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NM = Not Meaningful </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from operating activities decreased $26.2&#160;million, primarily due to the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and annual incentive plan payments increased $14.9&#160;million during 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Completed and potential acquisition expenses increased in 2021 as well as other nonrecurring costs of $8.3&#160;million; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Larger net settlements in 2021 with the sole MIP awardee of $4.3&#160;million; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax payments increased $5.9&#160;million during 2021; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Larger directors and officers annual insurance premiums in 2021 for $4.6&#160;million; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement of Bioventus&#8217; EPR liability for $3.3&#160;million occurred in 2021 and; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Higher inventory purchases during 2021 of $2.9&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">313 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The above uses of cash were partially offset by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">An increase of $21.4&#160;million in net collections during 2021, primarily due to the economic impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> during 2020. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows used in investing activities increased $48.1&#160;million, primarily due to the $45.8&#160;million acquisition of Bioness as well as $1.6&#160;million in capital expenditures. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows provided by financing activities increased $64.0&#160;million, primarily due to the $107.8&#160;million in net proceeds from the issuance of Class&#160;A common stock sold during Bioventus&#8217; IPO and a $9.9&#160;million decrease in net partner distributions. These increases were partially offset with no draws on Bioventus&#8217; revolving credit facility compared to prior year draw of $49.0&#160;million and a $5.0&#160;million increase in debt payments due to the timing of Bioventus&#8217; quarter ends and the scheduled escalation in quarterly principal payments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit Facilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There have been no material changes to Bioventus&#8217; outstanding indebtedness or the terms of and available borrowing capacity under its credit facilities as disclosed in its 2020 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Bioventus was in compliance with all required financial covenants as of July&#160;3, 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Misonix Transaction, the Company entered into a debt commitment letter with Wells Fargo Bank, effective July&#160;29, 2021. Wells Fargo Bank has committed to provide a senior secured term loan facility (Term Loan Facility) in the aggregate principal amount of up to $262.0&#160;million plus, at the Company&#8217;s election, an amount sufficient to fund any original issue discount or upfront fees, subject to customary closing conditions. The Term Loan Facility stipulates a prepayment of $80.0&#160;million on the existing Term Loan under the 2019 Credit Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proceeds of the Term Loan Facility would be available through a single draw on the closing date of the Transaction and shall be used (i)&#160;to finance the Transaction; (ii)&#160;pay related fees, premiums and expenses and (iii)&#160;for working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions. The Term Loan Facility would have a three year term that would bear interest at either the base rate as prescribed in the Term Loan under the 2019 Credit Agreement or the Eurodollar rate, and, in each case, plus an applicable margin. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For information regarding Commitments and Contingencies, refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 9. Commitments and contingencies</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 3. Business combinations and</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">investments </div></div>to the<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> &#8220;</div></div>Notes to the Unaudited Condensed Consolidated Financial statements&#8221;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>of the Bioventus financial statements included in this joint proxy statement/prospectus. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">314 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents, as of December&#160;31, 2020, totaled $86.8&#160;million compared to $64.5&#160;million at December&#160;31, 2019. Changes in cash are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">(in thousands, except for percentage)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statement of cash flow data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in):</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,199</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,545</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,654</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities from continuing operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,672</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,760</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,951</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discontinued operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,604</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(87.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate changes on cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(104</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">693</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">NM</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,319</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,746</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">573</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Cash flows from operating activities from continuing operations increased $29.7&#160;million during the year ended December&#160;31, 2020 compared to year ended December&#160;31, 2019 due to collections on accounts receivables staying strong while selling, general and administrative expenses declined, partially offset by the timing of rebate payments. We experienced lower travel expense payments resulting from the near halting of all travel due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, a reduction in compensation related expenses due to the decline in sales and increased cash savings from cost cutting measures. We also received stimulus payments from government entities while we purchased less inventory due to the decline in sales. In addition, our interest expense was significantly lower during the year ended December&#160;31, 2020 due to the December 2019 refinancing. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows used in investing activities increased $12.8&#160;million during the year ended December&#160;31, 2020 compared to year ended December&#160;31, 2019 primarily due to $16.6&#160;million in payments for the 2020 CartiHeal investments and an increase of $1.8&#160;million in capital expenditures due to software and technology upgrades. These investing cash outflows were partially offset by the absence of payments for distribution rights in 2020 compared to $6.0&#160;million for the purchases of distribution rights during 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows used in financing activities increased $18.6&#160;million during the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 primarily due to a $10.7&#160;million increase in distribution to members as well as the $6.1&#160;million increase in debt payments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indebtedness </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;6, 2019, Bioventus entered into the 2019 Credit Agreement. The 2019 Credit Agreement is comprised of its $200.0&#160;million term loan and its $50.0&#160;million revolving credit facility. All obligations under the 2019 Credit Agreement are guaranteed by certain of its wholly owned domestic subsidiaries and secured by substantially all its and the guarantors&#8217; assets. The term loan and revolving credit facility mature on December&#160;6, 2024. The 2019 Credit Agreement contains various restrictive covenants, including a quarterly covenant not to exceed a consolidated leverage ratio of 3.50 to 1.00 and an interest coverage ratio of 3.00:1.00 for the prior four consecutive quarters. The leverage and interest coverage ratios are based on Consolidated EBITDA as defined in the 2019 Credit Agreement, which includes several differences from Adjusted EBITDA as calculated in this joint proxy statement/prospectus. Consolidated EBITDA as defined in the 2019 Credit Agreement permits, among other things, the exclusion of (1)&#160;certain extraordinary, unusual and/or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> expenses, some of which </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">315 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">are subject to an aggregate cap, including but not limited to severance, acquisitions, dispositions, debt refinancing/amendment and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IPO-related,</div> (2)&#160;foreign currency gains/losses recognized in the statement of operations and (3)&#160;franchise, excise and property taxes recognized in the statement of operations. The restrictive covenants include limitations on (1)&#160;the declaration or payment of certain distributions on or in respect of its equity interests, (2)&#160;restrictions on acquisitions, investments and certain other payments, (3)&#160;limitations on the incurrence of new indebtedness, (4)&#160;limitations on transfers, sales and other dispositions and (5)&#160;limitations on making changes to its business and organizational documents. As of December&#160;31, 2020, Bioventus complied with all covenants under the 2019 Credit Agreement and there was $190.0&#160;million of outstanding borrowings under the term loan. Bioventus has one nominal outstanding letter of credit. In March 2020, as a precautionary measure and in order to increase its cash position and preserve financial flexibility in view of the uncertainty resulting from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, Bioventus drew down $49.0&#160;million on its revolving credit facility. On September&#160;24, 2020, Bioventus repaid all borrowings outstanding under its revolving credit facility. Bioventus&#8217; revolving credit facility had $50.0&#160;million in borrowing capacity as of December&#160;31, 2020. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-balance</div> sheet arrangements </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus does not have any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual Obligations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus acquired leases as part of the Bioness Acquisition, which resulted in increases to contractual lease commitments previously disclosed in Bioventus&#8217; 2020 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> of $489, $808, $775, $776 and $638 for the years ended December&#160;31, 2021, 2022, 2023, 2024 and 2025, respectively. In addition, see above under &#8220;Recent Developments &#8212;Misonix Acquisition&#8221; for a description of contractual obligations under the Merger Agreement that are subject to regulatory approvals, stockholder approvals and other customary closing conditions. Other than the foregoing, there have been no material changes to Bioventus&#8217; contractual obligations s disclosed in Bioventus&#8217; 2020 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; contractual obligations as of December&#160;31, 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments Due by Period</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual Obligations (in</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">thousands)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">than 1</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">than</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5 years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">190,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest on long-term debt obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,606</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,073</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,139</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,818</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,960</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,955</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,232</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,921</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,068</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,655</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,920</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,920</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,495</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,221</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,948</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173,291</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,921</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293,381</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table above does not include certain obligations as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commitments under its multi-year exclusive supply agreements for its OA products except for those amounts that are contractually committed as of December&#160;31, 2020. Bioventus&#8217; purchase obligations under these supply agreements are generally based upon its forecasted requirements, subject in some cases to a contractual minimum per annum; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commitments under the Development Agreement with MTF, the Option and Equity Purchase Agreement with CartiHeal and its shareholders and the Collaboration Agreement with Harbor, for which the relevant contingent events requiring a payment under the respective agreements have not yet occurred; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">future milestone payments pursuant to the Development Agreement with MTF, the Option and Equity Purchase Agreement with CartiHeal and its shareholders, the Collaboration Agreement with Harbor and the amended and restated license agreement, or the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med</div> License Agreement, with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med</div> and NSH, as the </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">316 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payment obligations under these agreements are contingent upon future events and Bioventus is unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent accounting pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 2. Summary of significant accounting policies </div></div>in the &#8220;Notes to the Audited Consolidated Financial Statements&#8221; and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 1. Organization</div></div> in the &#8220;Notes to the Unaudited Condensed Consolidated Financial Statements&#8221;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>included in this joint proxy statement/prospectus for further information regarding recently adopted and proposed accounting pronouncements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal control over financial reporting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Presently, as a newly public company, its management is not required to perform an annual assessment of the effectiveness of its internal control over financial reporting. This requirement will first apply to its second Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Bioventus&#8217; independent public registered accounting firm will first be required to attest to the effectiveness of its internal control over financial reporting for its Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the first year Bioventus is no longer either an &#8220;emerging growth company&#8221; or a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-accelerated</div> filer,&#8221; as such terms are defined by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical accounting policies and estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The preparation of the consolidated financial statements requires Bioventus to make assumptions, estimates and judgments that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of sales and expenses during the reporting periods. Certain of its more critical accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. On an ongoing basis, Bioventus evaluates its judgments, including those related to inventories, recoverability of long-lived assets and the fair value of its common stock. Bioventus uses historical experience and other assumptions as the basis for its judgments in making these estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in its consolidated financial statements as they occur. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 1. Organization and basis of presentation of financial information</div></div> in the &#8220;Notes to the Audited Consolidated Financial Statements&#8221; included in this joint proxy statement/prospectus<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>for a further description of its significant accounting policies, however, Bioventus believes that the following accounting policies and estimates that are considered critical to its business in order to obtain a full understanding and to evaluate its reported financial results. The critical accounting policies addressed below reflect its most significant judgments and estimates used in the preparation of its consolidated financial statements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue recognition </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of products </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus derives revenue primarily from the sale of its pain treatment and joint preservation products, BGSs and restorative therapies. Bioventus sells these products directly to healthcare institutions, patients, distributors and dealers. Bioventus also enters into arrangements with pharmacy and health benefit managers that provide for privately negotiated rebates, chargebacks and discounts with respect to the purchase of its products. Bioventus recognizes revenue at a point in time upon transfer of control of the promised product to customers in an amount that reflects the consideration it expects to receive in exchange for those products. Bioventus excludes from revenues taxes collected from customers and remitted to governmental authorities. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">317 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are recorded at the transaction price, which is determined as the contracted price net of estimates of variable consideration resulting from discounts, rebates, returns, chargebacks, contractual allowances, estimated third-party payer settlements and certain distribution and administration fees offered in its customer contracts and other indirect customer contracts relating to the sale of its products. Bioventus establishes reserves for the estimated variable consideration based on the amounts earned or eligible for claim on the related sales. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted for relevant factors such as its historical experience, current contractual requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.&#160;The amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Bioventus regularly reviews all reserves and update them at the end of each reporting period as needed. There were no adjustments arising from the change in estimates of variable consideration for the years ended December&#160;31, 2020 and 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pain treatment and joint preservation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from customers such as healthcare providers, distribution centers or specialty pharmacies is recognized at the point in time when control is transferred to the customer, typically upon shipment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distributor chargebacks </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has preexisting contracts with established rates with many of the distributors&#8217; customers that require the distributors to sell its product at their established rate. Bioventus offers chargebacks to distributors who supply these customers with its products. Bioventus reduces revenue at the time of sale for the estimated future chargebacks. Bioventus records chargeback reserves as a reduction of accounts receivable and bases the reserves on the expected value by using probability-weighted estimates of volume of purchases, inventory holdings and historical chargebacks requested for each distributor. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discounts and rebates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus offers retrospective discounts and rebates linked to the volume of purchases which may increase at negotiated thresholds within a contract-buying period. Bioventus reduces revenue and records the reserve as a reduction to accounts receivable for the estimated discount and rebate at the most likely amount the customer will earn, based on historical buying trends and forecasted purchases. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bone graft substitutes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The majority of its BGS product sales are through consignment inventory with hospitals, where ownership remains with Bioventus until the hospital performs a surgery and consumes the consigned inventory. Bioventus recognizes the revenue when the surgery has been performed. The customer does not have control of the product until the customer consumes it, as Bioventus is able to require the return or transfer of the product to a third-party. An unconditional obligation to pay for the product does not exist until the customer consumes it. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restorative Therapies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus recognizes revenue from third-party payers, such as governmental agencies, insurance companies or managed care providers, when Bioventus transfers control of the Exogen system to the patient, typically when the patient has accepted the product or upon delivery. Bioventus records this revenue at the contracted rate, net of contractual allowances at the time of sale, or an estimated price based on historical data and other available information for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-contracted</div> payers. Bioventus records contractual allowances based on probability weighting historical data and collections. Bioventus recognizes revenue from patients <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(self-pay</div> and insured patients with coinsurance and deductible responsibilities) based on billed amounts giving effect to any discounts and implicit price concessions. Implicit price concessions represent differences between amounts billed and the amounts Bioventus expects to collect from patients, which considers historical collection experience and current market conditions. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">318 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price using the most likely outcome method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. Bioventus is not aware of any claims, disputes or unsettled matters with any payer that would materially affect revenues for which Bioventus has not been adequately provided. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product returns </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus estimates the amount of returns and reduce revenue in the period the related product revenue is recognized. Bioventus records a liability for expected returns based on probability weighted historical data. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts receivable, net </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net are amounts billed and currently due from customers. Bioventus records the amounts due net of allowance for doubtful accounts. Bioventus maintains allowances for credit losses to provide for receivables Bioventus does not expect to collect. Bioventus bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable. Collection of the consideration that Bioventus expects to receive typically occurs within 30 to 90 days of billing. Bioventus applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, Bioventus enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract assets </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets consist of unbilled amounts resulting from estimated future royalties from an international distributor that exceeds the amount billed. Contract assets are included in prepaid and other current assets on the consolidated balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract liabilities </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities consist of customer advance payments or deposits and deferred revenue. Occasionally for certain international customers, Bioventus requires payments in advance of shipping product and recognizing revenue resulting in contract liabilities. Contract liabilities are included in accrued liabilities on the consolidated balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shipping and handling </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other distribution costs are included in cost of sales. Bioventus has elected to recognize shipping and handling activities that occur after control of the related product transfers to the customer as fulfillment costs and are included in cost of sales. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract costs </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus applies the practical expedient of recognizing the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that Bioventus otherwise would have recognized is one year or less. These incremental costs include its sales incentive programs for the internal sales force and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">319 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">third-party sales agents as the compensation is commensurate with annual sales activities. These costs are included in selling, general and administrative expense on the consolidated statements of operations and comprehensive income (loss). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowances for doubtful accounts, inventory reserves, goodwill and intangible assets impairment, useful lives of long lived assets, noncontrolling interest, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair value </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus records certain assets and liabilities at fair value. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities are categorized based on the lowest level that is significant to the valuation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The three levels of inputs used to measure fair value are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2&#8212;Observable inputs other than quoted prices included within Level&#160;1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3&#8212;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business combinations </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus records identifiable assets acquired, liabilities assumed and any noncontrolling interest in an acquiree resulting from a business combination at their estimated fair values on the date of the acquisition. Bioventus generally has third-party valuations completed for intangible assets in a business combination using a discounted cash flow analysis, incorporating various assumptions. Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired, including the amount assigned to identifiable intangible assets. The most significant estimates and assumptions inherent in a discounted cash flow analysis include the amount and timing of projected future cash flows, discount rate used to measure the risks inherent in the future cash flows, assessment of the asset&#8217;s life cycle, and competitive and other trends impacting the asset, including consideration of technical, legal, regulatory, economic and other factors. Each of these factors and assumptions can significantly affect the value of the intangible asset. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">320 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, or IPR&amp;D, is the fair value of projects for which the related products have not received regulatory approval and have no alternative future use and is capitalized as an indefinite-lived intangible asset. Due to inherent uncertainty related to research and development, actual results could differ materially from the assumptions used in the discounted cash flow model. Additionally, there are risks including, but not limited to, delay or failure to receive regulatory requirements to conduct clinical trials, required market clearances, or patent issuance, and that the research and development project does not result in a successful commercial product. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval of the related technology or product, the indefinite-lived intangible asset is accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the research and development project is abandoned, the indefinite-lived asset is charged to expense. </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus recognizes contingent consideration liabilities resulting from business combinations at estimated fair value on the acquisition date. Contingent consideration liabilities are revalued subsequent to the acquisition date with changes in fair value recognized in earnings. Contingent payments related to acquisitions consist of development, regulatory and commercial milestone payments, and are valued using discounted cash flow techniques. Significant estimates and assumptions required for these valuations include the probability of achieving regulatory approval under specified time frames, product sales projections under various scenarios and discount rates used to calculate the present value of the estimated payments. Changes in the fair value of contingent consideration liabilities result from changes in these estimates and assumptions. Significant judgment is employed in determining the appropriateness of the estimates and assumptions as of the acquisition date and in post-acquisition periods. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Consideration </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue and the probability of achieving the specific targets. After the initial valuation, the Company will use its best estimate to measure contingent consideration at each subsequent reporting period. Gains and losses are recorded with selling, general and administrative expenses within the consolidated statements of operations and comprehensive (loss) income. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus evaluates goodwill and other indefinite-lived intangible assets for impairment annually during the fourth quarter, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Bioventus&#8217; reporting units are U.S. and International and Bioventus analyzes each reporting unit separately in its goodwill impairment evaluation. Bioventus used independent third-party valuation specialists in 2020 and 2019 using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> October data in each year to assist management in performing the annual review of goodwill for impairment. Bioventus also utilized valuation specialists in April 2020 as Bioventus believed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> represented a triggering event that might indicate impairment. The specialists assist management in the determination of fair value of reporting units based upon inputs and assumptions provided by management, which management uses for its impairment assessment. Bioventus analyzes all other indefinite-lived intangible assets qualitatively to determine if it is more likely than not for an impairment to exist. If Bioventus meets the criteria, Bioventus performs a quantitative analysis to determine if an impairment exists. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; goodwill impairment process includes applying a quantitative impairment analysis where the fair value of the reporting unit and compare it to its carrying value (including goodwill). Bioventus determines the fair value of U.S. and International reporting units based primarily on an income approach, which incorporates the use of a discounted free cash flow analysis. The discounted free cash flow analyses is based on significant judgments, including the current operating budgets, estimated long-term growth projections and future forecasts </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">321 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for each reporting unit. Bioventus discounts future cash flows based on a market comparable weighted average cost of capital rate for each reporting unit. The discount rates used in the discounted free cash flow analyses reflect the risks inherent in the expected future cash flows generated by the respective intangible assets. Market risk, industry risk and a small company premium has an impact on the discount rate. The value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price Bioventus estimates it would receive in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. Significant judgments inherent in this analysis include estimating the amount and timing of future cash flows and the selection of appropriate discount rates, royalty rate and long-term growth rate assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value for each reporting unit and for some of the reporting units and could result in an impairment charge, which could be material to its financial position and results of operations. There has been no impairment of its goodwill related to its U.S. and International reporting units since its formation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity compensation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO, the Company operated two equity-based compensation plans, the MIP and the Phantom Plans, which allows its employees to share its future profit without granting any additional voting rights. Awards granted under the MIP and certain Phantom Plan awards granted in 2015 and thereafter, or the 2015 Phantom Plan Units, are liability-classified. Those Phantom Plan awards granted from inception in 2012 and until the grant of the 2015 Phantom Plan Units, or the 2012 Phantom Plan Units, are equity-classified, as they do not contain a put option or other features requiring them to be liability-classified. Equity compensation includes compensation expense for all equity awards made to employees that are part of continuing operations and are based on estimated fair values as of the grant date for the 2012 Phantom Plan Units and period end fair value for the MIP units and 2015 Phantom Plan Units. Bioventus recognizes expense for performance-based awards when it expects them to be earned. Bioventus recognizes timed-based awards over the requisite service period, which is generally the vesting period of the award. Bioventus recognizes forfeitures as they occur. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus used independent third-party valuation specialists in 2020 and 2019 using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> October data in each year to assist management in performing the annual valuation of MIP and 2015 Phantom Plan Units. Bioventus also utilized valuation specialists in April 2020 as it believed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> represented a triggering event that might indicate impairment. The specialists assist management in the determination of fair value of awards granted using the Monte Carlo option pricing model. The subjective assumptions and the application of judgment in determining the fair value of the awards represent management&#8217;s best estimates. If factors change and different assumptions are used, its equity compensation expense could be materially different in the future. The most significant assumptions and judgments are as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility&#8212;Bioventus determines the expected price volatility based on the historical volatilities of its peer group, as Bioventus does not have a sufficient trading history for its units. Industry peers consist of several public companies in the medical device industry similar to Bioventus in size, stage of life cycle and financial leverage. Bioventus intends to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to liquidity event&#8212;The amount of time that the awards are expected to be outstanding. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate&#8212;Bioventus based the risk-free rate on U.S. Government Constant Maturity Treasury rates for a term corresponding to the Time to Liquidity Event. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield&#8212;Bioventus used a dividend rate of zero as it has not previously issued dividends and do not anticipate paying dividends in the foreseeable future. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">322 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assumptions utilized to determine the fair value of the awards are indicated in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to exit event (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of the fair value of awards also requires an estimate of its equity value, based on inputs from management and reporting unit valuation reports prepared by the specialists during the annual goodwill impairment process. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus determined the value of its equity utilizing methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Practice Aid, &#8220;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&#8221;. In the absence of a public trading market, its Board of Managers determines a reasonable estimate of the grant date fair value of its equity awards based on input from management and the annual valuation reports prepared by the specialists. In addition, Bioventus exercised judgment in evaluating and assessing the foregoing based on several factors including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the nature and history of its business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217; historical operating and financial results; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the market value of companies that are engaged in a similar business to Bioventus&#8217;; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the lack of marketability of its common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the overall inherent risks associated with its business at the time awards were approved; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the overall equity market conditions and general economic trends. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, there was approximately $9.7&#160;million of unrecognized compensation expense to be recognized over a weighted-average period of 1.3 years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income taxes </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">BV LLC is currently a partnership for U.S. federal income tax purposes. As a partnership, taxable income or loss is generally included in the income tax returns of its members. Bioventus also has a subsidiary that operates as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-corporation</div> that is subject to income tax requirements and international operations that are subject to foreign income tax requirements. Additionally, BV LLC is liable for various other state and local taxes. As a corporation, Bioventus will be subject to U.S. federal, state and local income taxes. Bioventus recognizes the effect of income tax positions only if these positions are more likely than not to be sustained. Bioventus reflects changes in recognition or measurement in the period in which the change in judgment occurs. Upon the redemption or exchange of BV LLC Units for shares of Class&#160;A common stock or cash, Bioventus will determine if it is likely to realize the resulting tax benefits. If it is, Bioventus will record (i)&#160;a deferred tax asset based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in basis resulting from the exchange and the then effective income tax rate, (ii)&#160;a payable to related party in respect of the corresponding 85% payment under the TRA and (iii)&#160;a tax benefit based on the net difference between (i)&#160;and (ii). As Bioventus realizes cash tax savings, it will reduce the deferred tax asset and the payments made under the TRA will reduce the payable to related party. Further, Bioventus will evaluate the likelihood that it will realize the benefit represented by the deferred tax asset and, to the extent that Bioventus estimates it is more likely than not that it will not realize the benefit, Bioventus will reduce the carrying amount of the deferred tax asset with a valuation allowance. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">323 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Long-lived assets </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost and are depreciated using the straight-line method over the shorter of the asset&#8217;s estimated useful life, or the lease term if related to leased property, as follows in years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer software and hardware</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus amortizes finite-lived identifiable intangible assets using the straight-line method over their estimated remaining weighted average useful lives as follows in years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus capitalizes costs incurred from third-party vendors for software design, configuration, coding and testing and amortizes these costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. Bioventus does not capitalize costs that are precluded from capitalization in authoritative guidance, such as preliminary project phase costs, planning, oversight, process <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-engineering</div> costs, training costs or data conversion costs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying values of property, equipment and finite lived intangible assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable, Bioventus will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. There were no events, facts or circumstances for the years ended December&#160;31, 2020 and 2019 that resulted in any impairment charges to its property, equipment or finite lived intangible assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">JOBS Act </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bioventus qualifies as an &#8220;emerging growth company&#8221; pursuant to the provisions of the JOBS Act. For as long as Bioventus is an &#8220;emerging growth company,&#8221; Bioventus may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, reduced disclosure obligations relating to the presentation of financial statements in the &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; section and exemptions from the requirements of holding advisory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;say-on-pay&#8221;</div></div> votes on executive compensation and shareholder advisory votes on golden parachute compensation. Bioventus has availed itself of the reduced reporting obligations and executive compensation disclosure in this joint proxy statement/prospectus and expects to continue to avail itself of the reduced reporting obligations available to emerging growth companies in future filings. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, an emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. However, Bioventus is choosing to &#8220;opt out&#8221; of such extended transition period, and as a result, Bioventus plans to comply with any new or revised accounting standards on the relevant dates on which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div> emerging growth companies must adopt such standards. Section&#160;107 of the JOBS Act provides that its decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">324 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus will continue to qualify as an emerging growth company until the earliest of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The last day of its fiscal year following the fifth anniversary of the date of its IPO; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The last day of its fiscal year in which have annual gross revenues of $1.07&#160;billion or more; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The date on which Bioventus has, during the previous three-year period, issued more than $1.0&#160;billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The date on which Bioventus is deemed to be a &#8220;large accelerated filer&#8221;, which will occur at such time as Bioventus (1)&#160;has an aggregate worldwide market value of common equity securities held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> of $700&#160;million or more as of the last business day of its most recently completed second quarter, (2)&#160;have been required to file annual and quarterly reports under the Exchange Act for a period of at least 12 months and (3)&#160;have filed at least one annual report pursuant to the Exchange Act. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">325 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_24" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS DIRECTOR AND OFFICER COMPENSATION </div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This section discusses the material components of the executive compensation program for our executive officers who are named in the &#8220;2020 Summary compensation table&#8221; below. In 2020, our &#8220;named executive officers&#8221; and their positions were as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kenneth M. Reali, Chief Executive Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gregory O. Anglum, Senior Vice President&#160;&amp; Chief Financial Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John E. Nosenzo, Senior Vice President&#160;&amp; Chief Commercial Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anthony D&#8217;Adamio, Senior Vice President&#160;&amp; General Counsel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alessandra Pavesio, Senior Vice President&#160;&amp; Chief Science Officer; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anthony P. Bihl III, former Chief Executive Officer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Reali became Chief Executive Officer and a member of the BV LLC board of managers, effective as of April&#160;13, 2020, in connection with Mr.&#160;Bihl&#8217;s retirement on April&#160;19, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 Summary Compensation Table </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information concerning the compensation of our named executive officers for the year ended December&#160;31, 2019 and 2020. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Principal Position</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bonus<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock<br/>Awards<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(7)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Awards<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(8)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Equity</div><br/>Incentive Plan<br/>Compensation<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(5)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">All Other<br/>Compensation<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(6)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Kenneth M. Reali</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428,135</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,282</td>
<td style="vertical-align: bottom; white-space: nowrap;">(2)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,111,191</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,631</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">426,634</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">277,719</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,291,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chief Executive Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Gregory O. Anglum</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">381,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,793</td>
<td style="vertical-align: bottom; white-space: nowrap;">(2)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">178,471</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">584,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Senior Vice President&#160;&amp; Chief Financial Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,019</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">143,479</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,386</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">539,884</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">John E. Nosenzo</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">504,893</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">(3)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">357,646</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,959</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">907,277</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Senior Vice President&#160;&amp; Chief Commercial Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">490,219</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295,322</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,584</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">808,125</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Anthony D&#8217;Adamio</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">396,597</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">(2)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195,674</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,959</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">618,292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Senior Vice President&#160;&amp; General Counsel</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">391,106</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,016</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,584</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">563,706</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Alessandra Pavesio</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">408,657</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,267</td>
<td style="vertical-align: bottom; white-space: nowrap;">(4)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,652</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,375</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">634,951</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Senior Vice President&#160;&amp; Chief Science Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">398,165</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">160,693</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">579,858</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Anthony P Bihl III</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">236,750</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214,111</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,639,984</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,090,845</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former Chief Executive Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">684,979</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">552,910</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,561</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,261,450</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reflect annual base salary earned with respect to 2019 and 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amounts reflect discretionary &#8220;make whole&#8221; bonuses paid to all employees who earned performance-based cash incentives under the 2020 Annual Incentive Plan in amounts equal to the additional cash incentives that would have otherwise been paid under such plan had salaries not been reduced in connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, as described below under &#8220;&#8212;2020 Salaries&#8221;. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">326 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amount reflects a discretionary &#8220;make whole&#8221; bonus paid to Mr.&#160;Nosenzo in respect of his performance-based cash incentive under the 2020 Executive Annual Incentive Plan &#8211; Chief Commercial Officer in an amount equal to (i)&#160;the additional cash incentive that he would have otherwise been paid under such plan had his salary not been reduced in connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, as described below under &#8220;&#8212;2020 Salaries&#8221; and (ii)&#160;in recognition of his sales efforts during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the additional cash incentive that he would have been paid had he been a participant in the 2020 Executive Annual Incentive Plan &#8211; Non Commercial. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amount reflects (i)&#160;a $3,167 discretionary &#8220;make whole&#8221; bonus paid to Ms.&#160;Pavesio in respect of her performance-based cash incentive under the 2020 Executive Annual Incentive Plan &#8211; Non Commercial in an amount equal to the additional cash incentive that she would have otherwise been paid under such plan had her salary not been reduced in connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, as described below under &#8220;&#8212;2020 Salaries&#8221;, and (ii) $100 bonus paid to Ms.&#160;Pavesio in connection with a CEO determination to pay $100 discretionary bonuses to all employees with five through nine years of service. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reflect the annual performance-based cash incentives earned by our named executive officers in 2019 and 2020 based on achievement of corporate and personal performance objectives as set forth in the 2019 and 2020 Executive Annual Incentive Plan &#8211; Non Commercial or the 2019 and 2020 Executive Annual Incentive Plan &#8211; Chief Commercial Officer, as applicable. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">2020 amounts reflect (i) $8,550, $8,550, $8,550, $8,550, $8,550, and $8,550 in matching 401(k) contributions made by us to the 401(k) accounts of Messrs. Reali, Anglum, Nosenzo, D&#8217;Adamio, Ms.&#160;Pavesio and Mr.&#160;Bihl, respectively, (ii)&#160;additional fixed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> contributions of $1,064, $12,402, $12,825, $12,825, $12,825, and $12,825 made by us to the 401(k) accounts of Messrs. Reali, Anglum, Nosenzo, D&#8217;Adamio, Ms.&#160;Pavesio and Mr.&#160;Bihl, respectively, (iii)&#160;reimbursement of cellular telephone expenses to Messrs. Reali, Anglum, Nosenzo, and D&#8217;Adamio equal to $1,056, $1440, $1,584 and $1,584, respectively, (iv)&#160;relocation allowance of $250,000 and tax gross up of $17,048 to Mr.&#160;Reali, (v)&#160;payments to Mr.&#160;Bihl of a $4,966 benefit stipend and $63,700 tax stipend in connection with his status as a partner and associated receipt of a guaranteed payment instead of a salary, and (vi)&#160;payments made to Mr.&#160;Bihl in connection with his retirement in an aggregate amount of $3,549,943 to reflect the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19-related</div></div> decrease in the repurchase value of his equity interests. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">2019 amounts reflect (i) $2,561 benefit stipend to Mr.&#160;Bihl (ii) $8,400, $8,400, $8,400, $8,400 and $8,400 in matching 401(k) contributions made by us to the 401(k) accounts of Messrs. Anglum, Nosenzo, D&#8217;Adamio, Ms.&#160;Pavesio and Mr.&#160;Bihl, respectively, (iii)&#160;additional fixed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> contributions of $12,600, $12,600, $12,600, $12,600 and $12,600 made by us to the 401(k) accounts of Messrs. Anglum, Nosenzo, D&#8217;Adamio, Ms.&#160;Pavesio and Mr.&#160;Bihl, respectively, and (iv)&#160;reimbursement of cellular telephone expenses to Messrs. Anglum, Nosenzo, and D&#8217;Adamio equal to $1,386, $1,584 and $1,584, respectively. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amount reflects the aggregate grant date fair value of phantom profits interests granted to Mr.&#160;Reali during the year ended December&#160;31, 2020 computed in accordance with FASB ASC Topic 718, Compensation&#8212;Stock Compensation. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 9. Equity-based compensation</div></div> within <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Part II, Item 8. Financial Statements and Supplementary Data</div></div> for a discussion of the relevant assumptions used in calculating this amount. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amount reflects the aggregate grant date fair value of options granted to Mr.&#160;Reali during the year ended December&#160;31, 2020 computed using a Black-Scholes calculation in accordance with FASB ASC Topic 718, Compensation&#8212;Stock Compensation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Narrative to Summary Compensation Table </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employment Letters </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The terms of employment for Messrs. Reali, Anglum, Nosenzo, D&#8217;Adamio and Ms.&#160;Pavesio in effect as of December&#160;31, 2020 are documented in their employment letters dated March&#160;12, 2020, August&#160;2, 2017, November&#160;18, 2016, July&#160;11, 2017 and June&#160;13, 2013, respectively, with Mr.&#160;Reali&#8217;s employment letter subsequently amended as of April&#160;24, 2020. The terms of Mr.&#160;Bihl&#8217;s prior employment are documented in his offer letter dated November&#160;4, 2013 as amended on October&#160;17, 2019 to reflect his status as a partner. Pursuant to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">327 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">their respective employment letters, Mr.&#160;Bihl was hired to serve as the Chief Executive Officer, Mr.&#160;Reali was hired to serve as the Chief Executive Officer following Mr.&#160;Bihl&#8217;s retirement, Mr.&#160;Anglum was promoted on August&#160;7, 2017 to serve as the Chief Financial Officer (after serving as the interim Chief Financial Officer effective May&#160;1, 2017), Mr.&#160;Nosenzo was hired to serve as Chief Commercial Officer, Mr.&#160;D&#8217;Adamio was hired to serve as Senior Vice President and General Counsel and Ms.&#160;Pavesio was hired to serve as Chief Science Officer. Mr.&#160;Bihl also served as a member of the BV LLC board of managers until his retirement on April&#160;19, 2020 and Mr.&#160;Reali now serves as a member of the BV LLC board of managers. In connection with our IPO, we entered into new employment agreements with Messrs. Reali, Anglum, Nosenzo, D&#8217;Adamio, and Ms.&#160;Pavesio (as further described below under &#8220;&#8212;Severance&#8221;). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Salaries </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The named executive officers were entitled to receive a base salary in 2020 to compensate them for services rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the named executive officer&#8217;s skill set, experience, role and responsibilities. The annual base salaries payable to Messrs. Reali, Anglum, Nosenzo, D&#8217;Adamio and Ms.&#160;Pavesio as of December&#160;31, 2020, were $615,000, $389,881, $518,451, $405,794 and $419,630 respectively, all of which reflect merit increases which were effective March&#160;29, 2020 for the named executive officers other than Mr.&#160;Reali. In connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, we implemented a 20% reduction in base salary for each of our employees with a base salary of $100,000 or greater, including each of our named executive officers, effective May&#160;31, 2020 and ending June&#160;27, 2020, which reductions are reflected in the actual salary paid in the summary compensation table. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective as of the consummation of our IPO, we increased the salaries of Messrs. Reali, Anglum, D&#8217;Adamio and Ms.&#160;Pavesio to $700,000, $430,000, $420,000 and $430,000, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Incentive Bonuses </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">With respect to their services in 2020, Messrs. Reali, Anglum, D&#8217;Adamio, Ms.&#160;Pavesio and Mr.&#160;Bihl were eligible to earn an annual performance-based cash bonus pursuant to the 2020 Executive Annual Incentive Plan &#8211; Non Commercial, or the Non Commercial AIP (with Mr.&#160;Bihl&#8217;s bonus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> for the portion of the year for which he provided service prior to his retirement date), and Mr.&#160;Nosenzo was eligible to earn an annual performance-based cash bonus pursuant to the 2020 Executive Annual Incentive Plan &#8211; Chief Commercial Officer, or the Commercial AIP. Bonuses earned by our named executive officers under both the Non Commercial AIP and Commercial AIP were based upon weighted minimum, target and maximum achievement of both business and personal performance measures. The Non Commercial AIP and the Commercial AIP objective business measures in 2020 were (1)&#160;Global Revenue, (2)&#160;Adjusted Global EBITDA and (3)&#160;multiple osteoarthritis treatment achievements, including submission of an IND application to FDA for &#8220;Biologic&#8221; placental tissue product in the third quarter of 2020, the launch of a GTP placental tissue product in the fourth quarter of 2020 and the achievement of $100,000 in 2020 revenue with respect to such placental tissue product. The personal performance standards were based on the named executive officers&#8217; performance ratings. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Reali&#8217;s and Mr.&#160;Bihl&#8217;s target incentive for 2020 was 100% of their respective eligible earnings (as defined under the applicable AIP); Mr.&#160;Nosenzo&#8217;s was 75% of his eligible earnings; and Messrs. Anglum, D&#8217;Adamio and Ms.&#160;Pavesio&#8217;s was 50% of their respective eligible earnings. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Objective business measures and personal performance were weighted as 80% and 20%, respectively, of the annual bonuses under the Non Commercial AIP and the Commercial AIP. Possible payouts for the objective business measures under the Non Commercial AIP and the Commercial AIP ranged from 50% for minimum achievement, 100% for target achievement, to 200% for maximum achievement, which amounts shall correspond to 95%, 100%, and 105% achievement of the applicable objective business measure target, respectively. The personal performance component of the award amount ranged from a 50% for minimum achievement, 100% for target achievement, to 200% for maximum achievement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">328 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">For 2020, the achievement percentage for the objective business measures for each of our NEOs was determined to be 93.6% (with Mr.&#160;Bihl&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> award calculated at actual achievement for the objective business measures). The achievement percentage for the personal performance component was determined to be 125% for each of Messrs. Reali, D&#8217;Adamio, Nosenzo, and Ms.&#160;Pavesio and 100% for Mr.&#160;Anglum (with Mr.&#160;Bihl&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> award calculated at target achievement (100%) for the personal performance component). In addition to the awards calculated under the applicable AIP for each of our NEOs, each of our employees who participated in an AIP, including our NEOs, received a discretionary &#8220;make whole&#8221; bonus with respect to each employee&#8217;s performance-based cash incentive under the applicable AIP in an amount equal to the additional cash incentive each employee would have otherwise received had salaries not been reduced in connection with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. In recognition of his sales efforts during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, Mr.&#160;Nosenzo also received an additional discretionary &#8220;make whole&#8221; bonus with respect to his performance-based cash incentive under the Commercial AIP in an amount equal to the additional cash incentive he would have received had he been a participant in the Non Commercial AIP. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-Based Compensation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to our IPO, we maintained the BV LLC profits interest plan, which we called the Management Incentive Plan (MIP), pursuant to which we granted 333,330 profits interest units of BV LLC (Profits Interest Units), to Mr.&#160;Bihl on December&#160;2, 2013. In connection with Mr.&#160;Bihl&#8217;s retirement, we redeemed all of his Profits Interest Units as described below under &#8220;&#8212;Severance.&#8221; In connection with our IPO the MIP was terminated and no further awards will be made under the MIP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to our IPO, we also maintained the Bioventus Phantom Profits Interest Plan, which was renamed the Bioventus Stock Plan on June&#160;1, 2020, and which we called the Phantom Plan, pursuant to which we granted time-vesting phantom plan units (Time Phantom Units) and performance-vesting phantom plan units (Performance Phantom Units). The Time Phantom Units generally vested ratably over five years (20% on the first anniversary of the date of grant and 5% quarterly thereafter) and entitled the holder to a cash payment, in an amount determined by reference to the value of our Profits Interest Units, with respect to any vested Time Phantom Units upon the earlier of a termination from service or certain distribution events with respect to the Company&#8217;s profits interest units. In the event of a qualifying distribution event prior to a termination, all Time Phantom Units fully vest. Generally, Performance Phantom Units were scheduled to vest on June&#160;1, 2021, subject to the achievement of 2020 corporate revenue goals, but could also become vested in whole or in part in the board of managers&#8217; discretion in the event such revenue goals were not satisfied. In connection with our IPO, on February&#160;11, 2021, we terminated the Phantom Plan and there will be no further awards made under the Phantom Plan. We will settle all awards thereunder 12 months following the termination. In connection with the Phantom Plan termination, Bioventus Inc. assumed the obligations of BV LLC and Phantom Plan awards will be paid in the form of shares of Class&#160;A common stock (or, in the case of former employees whose employment terminated prior to the offering and who hold vested Phantom Plan awards as of 12 months following the termination of the Phantom Plan, in the form of cash). The number of shares of Class&#160;A common stock received by each participant, including our named executive officers, were determined by dividing (A)&#160;the value of the participant&#8217;s vested Phantom Units (after giving effect to any accelerations in vesting in connection with our IPO, as described below) as of February&#160;11, 2021 by (B)&#160;the $13.00 IPO price of our Class&#160;A common stock (with any terminated employees holding vested Phantom Plan awards receiving the cash value of such shares determined as of the date of the IPO). It is anticipated that, to the extent that a Time Phantom Unit is not otherwise vested as of the date the Phantom Plan is terminated, settlement with respect to such Time Phantom Unit will be subject to the holder&#8217;s continued employment with us through the applicable vesting date or the twelve month anniversary of plan termination, if earlier. As a result of the $13.00 IPO price of our Class&#160;A common stock, the Performance Phantom Units had no value as the IPO date. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of our named executive officers holds Phantom Plan awards in BV LLC as set forth below in &#8220;&#8212;Outstanding Equity Awards at Fiscal-Year End.&#8221; On June&#160;25, 2020, in connection with the commencement of his employment with us, Mr.&#160;Reali was granted 417,804 Phantom Units. In addition, on July&#160;30, 2020, Mr.&#160;Reali </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">329 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">was granted an option to purchase up to 5,935 equity interests of BV LLC at a per unit price of $42.12 at any time prior to July&#160;30, 2021 (or the termination of his service, if earlier), but Mr.&#160;Reali forfeited this option prior to our IPO. No other named executive officers received a grant of equity or phantom equity awards in 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New Equity-Based Compensation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with our IPO, our Board adopted the 2021 Incentive Award Plan (2021 Incentive Plan), in order to facilitate the grant of cash and equity incentives to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, employees (including our named executive officers) and consultants and employees and consultants of our subsidiaries and to enable our Company and our subsidiaries to obtain and retain the services of these individuals, which is essential to our long-term success. In connection with our IPO, we granted the following under the 2021 Incentive Plan to certain of our employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, including the named executive officers: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">options to purchase 4,561,500 shares of Class&#160;A common stock that vest between two and four years from February&#160;11, 2021 and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">restricted stock unit (RSU) awards for 293,170 and 67,500 to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, respectively, of shares of Class&#160;A common stock released between one and four years from February&#160;11, 2021 </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with our IPO, our Board also adopted the 2021 Employee Stock Purchase Plan (ESPP). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Severance </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The employment letters in effect as of December&#160;31, 2020 for each of our named executive officers provide for severance payments upon termination of employment by us at any time without cause (other than as a result of death or disability) or a termination by the named executive officer for good reason (as defined below)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>during the two year period following the date of a change in control (as defined in the respective employment letter)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> In the event of a termination by us without cause, each of our named executive officers would be entitled to receive (1)&#160;twelve months&#8217; base salary, payable in a lump sum within 60 days following termination of employment, (2) 100% of their respective target annual cash incentive, payable in a lump sum within 60 days following termination of employment, and (3)&#160;payment of COBRA premiums for the first twelve months of coverage following termination of employment. In the event of a termination by Messrs. Anglum, Nosenzo, D&#8217;Adamio and Ms.&#160;Pavesio for good reason during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> period following a change in control, Messrs. Anglum, Nosenzo, D&#8217;Adamio and Ms.&#160;Pavesio would be entitled to receive the same severance payments and benefits as in the case of termination by us without cause. In the event of a termination by Mr.&#160;Reali for good reason during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> period following a change in control, under his employment letter Mr.&#160;Reali is entitled to receive enhanced severance equal to 18 months of each of his base salary and his target annual cash incentive, each payable in a lump sum on or about 60 days following termination of employment, as well as payment of COBRA premiums for the first 18 months of coverage following termination of employment. The severance payments are conditioned upon execution and delivery of a release and compliance with confidentiality and restrictive covenant obligations as set forth in a separate proprietary information agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with his retirement on April&#160;19, 2020, Mr.&#160;Bihl was not entitled to receive any severance or other benefits under his employment letter. Subsequent to his retirement, we entered into an agreement with Mr.&#160;Bihl on June&#160;12, 2020, pursuant to which he received (i)&#160;a payment on June&#160;16, 2020 of $9.25&#160;million, which represented a $918,953 payment in full for amounts due to Mr.&#160;Bihl under the Phantom Plan, a $6,328,629 payment for the redemption of 150,252 of his Profits Interest Units under the MIP, and an additional cash payment of $2,006,796 to reflect the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19-related</div></div> decrease in value of his Phantom Plan award and the redeemed portion of his MIP award and (ii)&#160;a payment on February&#160;8, 2021 of $12.3&#160;million, which represented a $10,802,387 payment for the redemption of the remaining 183,078 of his Profits Interest Units under the MIP, and an additional cash payment of $1,543,147 to reflect the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19-related</div></div> decrease in value. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">330 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with our IPO, we entered into new employment agreements with each of Messrs. Reali, Anglum, Nosenzo, D&#8217;Adamio, and Ms.&#160;Pavesio that became effective February&#160;11, 2021 and superseded their previous severance arrangements. Under these new employment agreements, it is anticipated that, upon a termination without cause or resignation by the named executive officer with good reason, each of our named executive officers are entitled to (i)&#160;twelve months&#8217; base salary (eighteen months in the case of Mr.&#160;Reali), payable in equal installments over the twelve month period (eighteen month period in the case of Mr.&#160;Reali) following such termination, (ii) 100% of target annual cash incentive (150% in the case of Mr.&#160;Reali), payable in equal installments over the twelve month period (eighteen month period in the case of Mr.&#160;Reali) following such termination, and (iii)&#160;payment of COBRA premiums for the first twelve months of coverage following termination of employment (eighteen months in the case of Mr.&#160;Reali). Additionally, upon a termination without cause or resignation by the named executive officer with good reason within the 24 month period following a change in control, each of our named executive officers are entitled to (i)&#160;eighteen months&#8217; base salary (twenty-four months in the case of Mr.&#160;Reali), payable in a lump sum within 60 days following such termination, (ii) 150% of target annual cash incentive (200% in the case of Mr.&#160;Reali), payable in a lump sum within 60 days following such termination, (iii)&#160;a lump sum payment equal to eighteen months (twenty-four months in the case of Mr.&#160;Reali) of COBRA premiums within 60 days following such termination, and (iv)&#160;full vesting acceleration of all equity awards. These severance payments will be conditioned upon execution and delivery of a release and compliance with the restrictive covenants described below in &#8220;&#8212;Restrictive Covenants.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restrictive Covenants </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of December&#160;31, 2020 our named executive officers were subject to certain post-employment restrictive covenants, including twelve-month <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> obligations, as set forth in proprietary information agreements entered into with each named executive officer. Further, the employment letters for each of our named executive officers provide for mutual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disparagement</div> obligations. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with our IPO, we entered into new post-employment restrictive covenants with our named executive officers, effective as of the date of tour IPO, including twelve-month (and eighteen months in the case of Mr.&#160;Reali) noncompetition and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> obligations (increased to eighteen-months (and twenty-four months in the case of Mr.&#160;Reali) in the event a named executive officer receives change in control severance, as described above) and perpetual confidentiality and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disparagement</div> obligations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Retirement Plans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">BV LLC currently maintains a 401(k) retirement savings plan, or the 401(k) plan, in which all BV LLC employees, including our named executive officers, who satisfy certain eligibility requirements may participate. The Internal Revenue Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> basis through contributions to the 401(k) plan. Under the terms of the 401(k) plan, we currently make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(a)&#160;non-discretionary</div> matching contributions equal to 50% of the employee&#8217;s contributions, up to a maximum of 6% of the employee&#8217;s eligible compensation and (b)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> contribution equal to 4.5% of the employee&#8217;s compensation for the plan year. Due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> crisis, we suspended the 4.5% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> contribution effective May&#160;3, 2020, but have reinstated such benefit effective December&#160;26, 2020. Further, our board of managers has discretion under the 401(k) plan to provide for (i)&#160;annual discretionary matching contributions based on eligible compensation contributed by each employee and (ii)&#160;discretionary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> contributions in an amount determined by the board at year end, subject to continued employment through year end. We believe that providing a vehicle for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-deferred</div> retirement savings though the 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. We anticipate that our employees will continue to be eligible to participate in a 401(k) plan maintained by us. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">331 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefits </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of our full-time employees and working partners, including our named executive officers, are eligible to participate in health and welfare plans maintained by BV LLC, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">medical, dental and vision benefits; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">medical flexible spending accounts and health savings account; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">short-term and long-term disability insurance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">basic life and accidental death&#160;&amp; dismemberment insurance; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">group accident, critical illness and hospital indemnity plans. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our named executive officers participate in these plans on the same basis as other eligible employees. We do not maintain any supplemental health and welfare plans for our named executive officers. We reimburse our named executive officers for the full cost of their personal cellular phones. We believe the benefits described above are necessary and appropriate to provide a competitive compensation package to our named executive officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Section&#160;280G </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The employment letters for Messrs. Reali, Anglum and D&#8217;Adamio in effect as of December&#160;31, 2020 and the new employment agreements we entered into with our named executive officers in connection with our IPO provide that, in the case of their receipt of any payments in connection with a change in control (as defined in the employment letter or agreement), or that would otherwise be considered an &#8220;excess parachute payment&#8221; within the meaning of Section&#160;280G of the Code, such payments will be reduced to the maximum amount that does not trigger the excise tax imposed by Section&#160;4999 of the Code if the named executive officer would be better off on a net <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> basis with such reduction. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Retention Plan </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;13, 2020, we initiated a retention plan with Mr.&#160;Nosenzo for an aggregate amount of $520,000 less applicable taxes. Payments of $260,000 will be paid on each of May&#160;4, 2021 and May&#160;4, 2022, subject to Mr.&#160;Nosenzo&#8217;s continued service through each such date; provided that if Mr.&#160;Nosenzo&#8217;s employment is terminated for a reason that would qualify Mr.&#160;Nosenzo for severance benefits under his offer letter (x)&#160;before the May&#160;4, 2021 payment date he will receive $260,000 in a single lump sum within 60 days following termination of employment and (y)&#160;after the May&#160;4, 2021 payment date but before the May&#160;4, 2022 payment date he will receive $260,000 in a lump sum within 60 days following the termination date. Any such payments are in addition to any severance benefits under Mr.&#160;Nosenzo&#8217;s offer letter. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">332 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Outstanding Equity Awards at Fiscal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-End</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the number of option awards and profits interest units (including the number of profits interest units underlying Phantom Units) for our named executive officers as of December&#160;31, 2020. For additional information about the outstanding equity awards granted to our named executive officers, please see the section titled &#8220;&#8212;Equity-based compensation&#8221; above. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 32%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="12" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option Awards<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(5)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>securities<br/>underlying<br/>unexercised<br/>options (#)<br/>exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>securities<br/>underlying<br/>unexercised<br/>options (#)<br/>unexercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Exercise<br/>Price ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Expiration<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;profits<br/>interest units<br/>(including profits<br/>interest units<br/>underlying&#160;phantom<br/>units<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div> that have not<br/>vested<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div> (#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market&#160;Value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(3)</div>&#160;of<br/>profits interest&#160;units<br/>(including profits<br/>interest units<br/>underlying&#160;phantom<br/>units) that have not<br/>vested ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kenneth Reali</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4/13/2020</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">417,804</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(4)</div>&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,716,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7/30/2020</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,935</div></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">42.12</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7/30/2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gregory O. Anglum</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">04/04/2016</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">94,300</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">05/01/2017</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,500</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,257,420</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9/17/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">580,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John E. Nosenzo</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">02/06/2017</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,250</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(7)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,378,750</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9/17/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(7)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">725,750</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anthony D&#8217;Adamio</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">8/14/2017</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(8)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">617,680</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9/17/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(8)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">435,450</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alessandra Pavesio</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9/17/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#160;(9)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">580,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Phantom Units do not have an expiration date; provided that any Phantom Units granted on September&#160;17, 2018 that do not vest as a result of achieving 2020 revenue targets on June&#160;1, 2021 will expire. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This column shows the number of profits interest units held by Mr.&#160;Bihl and the number of Phantom Units held by our other named executive officers that have not vested. Phantom Units generally represent the right to receive cash amounts from us based on the distributions that would be made to an equivalent number of profits interests with an equivalent benchmark amount. The benchmark amounts represent the cumulative distributions that must be made by us pursuant to the Bioventus LLC Agreement before a grantee is entitled to receive any distributions or payments in respect of such grantee&#8217;s units. The benchmark amount for Mr.&#160;Anglum&#8217;s 2016 grant of Phantom Units is $472,003,000, for Messrs. Nosenzo, Anglum, and D&#8217;Adamio&#8217;s 2017 grant is $510,000,000, for Messrs. Anglum, Nosenzo and D&#8217;Adamio&#8217;s and Ms.&#160;Pavesio&#8217;s 2018 grant of Phantom Units is $703,691,178, and for Mr.&#160;Reali&#8217;s 2020 grant of Phantom Units on June&#160;25, 2020 is $840,849,878. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market value is determined based on an independent valuation report on the fair market value of the Company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Reali was granted 417,804 Phantom Units on June&#160;25, 2020; 20% of such grant will vest on April&#160;13, 2021 and 5% will vest each quarter thereafter. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Reali was granted 5,935 options to purchase equity interests of BV LLC on July&#160;30, 2020, all of which were fully vested and exercisable at the time of grant. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Anglum was granted 20,000 Phantom Units on April&#160;4, 2016 and 95,000 Phantom Units on May&#160;1, 2017; 20% of each grant vested on the first anniversary of the grant date and 5% vests each quarter thereafter. Mr.&#160;Anglum was also granted 20,000 Phantom Units on September&#160;17, 2018; these units will vest on June&#160;1, 2021 at 100% if 2020 revenue is greater than or equal to $391.8&#160;million and at 75% if 2020 revenue is greater than or equal to $336.0&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Nosenzo was granted 125,000 Phantom Units on February&#160;6, 2017; 20% of these Phantom Units vested on February&#160;6, 2018 and 5% vests each quarter thereafter. Mr.&#160;Nosenzo was also granted 25,000 Phantom Units on September&#160;17, 2018; these units will vest on June&#160;1, 2021 at 100% if 2020 revenue is greater than or equal to $391.8&#160;million and at 75% if 2020 revenue is greater than or equal to $336.0&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">333 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;D&#8217;Adamio was granted 40,000 Phantom Units on August&#160;14, 2017; 20% of such grant vested on the first anniversary of the grant date and 5% vests each quarter thereafter. Mr.&#160;D&#8217;Adamio was also granted 15,000 Phantom Units on September&#160;17, 2018; these units will vest on June&#160;1, 2021 at 100% if 2020 revenue is greater than or equal to $391.8&#160;million and at 75% if 2020 revenue is greater than or equal to $336.0&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ms.&#160;Pavesio was granted 20,000 Phantom Units on September&#160;17, 2018; these units will vest on June&#160;1, 2021 at 100% if 2020 revenue is greater than or equal to $391.8&#160;million and at 75% if 2020 revenue is greater than or equal to $336.0&#160;million. Ms.&#160;Pavesio was also granted 83,333 Phantom Units on July&#160;22, 2013, 15,000 Phantom Units on June&#160;1, 2015, and 11,392 Phantom Units on April&#160;21, 2016, all of which were fully vested as of December&#160;31, 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information concerning the compensation of the current members of the BV LLC board of managers for the year ended December&#160;31, 2020. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fees&#160;Earned<br/>or Paid in<br/>Cash ($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">William A. Hawkins<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">90,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">90,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Susan M. Stalnecker<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guy P. Nohra</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Martin P. Sutter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bradley J. Cannon</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David J. Parker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Philip G. Cowdy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guido J. Neels</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2020</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Hawkins received an annual retainer of $40,000 for his service as a member of the board and an additional annual retainer fee of $50,000 for his service as chairman of the board. Ms.&#160;Stalnecker received an annual retainer fee of $50,000 for her service as a member of the board and an additional annual retainer fee of $10,000 for her service on the Audit and Risk Committee of the board. No other members of our board received any cash compensation in 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No members of our board received equity compensation awards in 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, Mr.&#160;Hawkins held 50,000 Phantom Units, 95% of which were vested and 5% of which were unvested, and Ms.&#160;Stalnecker held 50,000 Phantom Units, 40% of which were vested and 60% of which were unvested, respectively. The benchmark amount for Mr.&#160;Hawkins&#8217;s grant of Phantom Units is $472,003,000 and the benchmark amount for Ms.&#160;Stalnecker&#8217;s grant of Phantom Units is $703,691,178. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with our December&#160;11, 2015 offer to Mr.&#160;Hawkins to join the BV LLC board of managers as its chairman, we agreed, pursuant to an offer letter, effective January&#160;1, 2016, to (1)&#160;pay Mr.&#160;Hawkins an annual retainer fee of $40,000 for his service as a member of the board and $50,000 for his service as chairman of the board, each payable in quarterly installments in arrears and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> for any partial period of service and (2)&#160;award Mr.&#160;Hawkins a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> grant of 50,000 Phantom Units under the Phantom Plan. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Effective November&#160;28, 2018, pursuant to an offer letter with Ms.&#160;Stalnecker providing for her appointment as a member of our board and chair of the Audit and Risk Committee, we agreed to (1)&#160;pay Ms.&#160;Stalnecker an annual retainer fee of $50,000 for her service as a member of the board and $10,000 for her participation in the Audit and Risk Committee, each payable in quarterly installments in arrears and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rated</div> for any partial period of service and (2)&#160;award Ms.&#160;Stalnecker 50,000 Phantom Units under the Phantom Plan. Ms.&#160;Stalnecker received a prorated payment of $9,167 for her time on the board and one of the Audit and Risk Committee in 2018. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director compensation policy, which became effective February&#160;11, 2021, provides that each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director receives an annual cash retainer of $55,000. In addition, (i)&#160;the Chairperson of the Board </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">334 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">shall receive an additional annual retainer of $50,000, (ii) the Lead Director of the Board shall receive an additional annual retainer of $30,000, (iii) the Chairpersons of the Audit and Risk Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Compliance, Ethics and Culture Committee shall receive additional annual retainers of $20,000, $15,000, $10,000 and $10,000, respectively, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-Chairperson</div> members of the Audit and Risk Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Compliance, Ethics and Culture Committee shall receive additional annual retainers of $10,000, $7,500, $5,000 and $5,000, respectively. In addition, each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director receives an annual RSU award with a grant date value of $152,000, with all such annual RSU awards (other than those received in respect of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s initial year of service, as described below) vesting on the first anniversary of the grant date of the award (or immediately prior to the date of the annual shareholder meeting immediately following the date of grant, if sooner), subject to such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director continuing in service through such date. RSU awards for each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s initial year of service shall vest in three equal installments, with the first installment vesting on the first anniversary of the grant date of such initial award (or immediately prior to the date of the annual shareholder meeting immediately following the date of grant, if sooner) and the second and third installments vesting on the first and second anniversaries of such first vesting date, subject to such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director continuing in service through each such date (and any such nonemployee director who commences service on a date other than the date of the annual shareholder meeting receives a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> restricted stock unit award for such initial year of service). In addition, on February&#160;11, 2021, in connection with our IPO, each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director received a RSU award with a grant date value of $152,000 that vests on the first anniversary of the grant date of the award. Each RSU award awarded under the policy accelerates and vests in full upon a change in control (as defined in the 2021 Incentive Plan). In addition, each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director is reimbursed for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses in connection with his or her services. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">335 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_25" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AUTHORIZED FOR ISSUANCE UNDER BIOVENTUS&#8217; EQUITY COMPENSATION PLANS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, there was no public market for Bioventus&#8217; common stock and there were no equity compensation plans approved by security holders under which Bioventus&#8217; equity securities were authorized for issuance. The following table provides, as of March&#160;22, 2021, equity compensation plan information for all plans under which equity securities are authorized for issuance. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 37%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>securities&#160;to&#160;be<br/>issued upon<br/>exercise of<br/>outstanding<br/>options&#160;and&#160;rights<br/>(a)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>average&#160;exercise<br/>price of<br/>outstanding<br/>options and<br/>rights<br/>(b)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;securities<br/>remaining&#160;available&#160;for<br/>future issuance under<br/>equity&#160;compensation&#160;plans<br/>(excluding securities<br/>reflected under column<br/>(a))<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(4)</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(c)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation plans approved by security holders<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,922,170&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.00&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,212,626</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation plans not approved by security holders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of the Bioventus Inc. 2021 Incentive Award Plan (2021 Plan) and the Bioventus Inc. 2021 Employee Stock Purchase Plan (2021 ESPP). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes 4,561,500 outstanding options to purchase shares of Bioventus class A common stock and 360,670 outstanding restricted stock units under the 2021 Plan. There were no agreements outstanding to purchase shares of Bioventus class A common stock under the 2021 ESPP. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average exercise price in column (b)&#160;does not take into account outstanding restricted stock units, which do not have an exercise price. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes 2,670,306 shares of Bioventus class A common stock available for future issuance under the 2021 Plan and 542,320 shares of Bioventus class A common stock available for future issuance under the 2021 ESPP. The number of shares of Bioventus class A common stock reserved for issuance under the 2021 Plan will automatically increase on January&#160;1 of each calendar year from January&#160;1, 2022 through January&#160;1, 2031, by that number of shares of Bioventus class A common stock equal to the lesser of (i) 4.5% of the shares of all of the classes of Bioventus class A common stock outstanding on the last day of the immediately preceding fiscal year and (ii)&#160;such smaller number of shares of Bioventus class A common stock as determined by the board of directors. The number of shares of Bioventus class A common stock reserved for issuance under the 2021 ESPP will automatically increase on January&#160;1 of each calendar year from January&#160;1, 2022 through January&#160;1, 2031, by that number of shares of Bioventus class A common stock equal to the lesser of (A) 1% of the shares of all of Bioventus class A common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of Bioventus class A common stock as determined by the board of directors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to Bioventus&#8217; IPO, BV LLC maintained the Phantom Plan, pursuant to which Bioventus granted units in order to foster and promote its long-term success by helping attract and maintain a superior management team and to motivate superior performance by employees selected to participate in the Phantom Plan. As of December&#160;31, 2020, there were 1,651,709 units outstanding. In connection with its IPO, Bioventus terminated the Phantom Plan and Bioventus Inc. assumed the obligations of BV LLC. Vested Phantom Plan awards granted to employees that were active employees on February&#160;11, 2021 will be paid in the form of shares of Bioventus class A common stock after the one year anniversary. The number of shares of Bioventus class A common stock were determined by dividing (i)&#160;the value of the participant&#8217;s vested Phantom Units (after giving effect to any accelerations in vesting in connection with Bioventus&#8217; IPO) as of February&#160;11, 2021 by (ii)&#160;the $13.00 IPO price of Bioventus class A common stock. Upon the one year anniversary of Bioventus&#8217; IPO 798,422 shares of Bioventus class A common stock will be issued in settlement of the outstanding units. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">336 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_26" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INTERESTS OF BIOVENTUS DIRECTORS AND EXECUTIVE OFFICERS IN THE MERGER </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than with respect to continued service for, employment by and the right to continued indemnification by the combined company, as of the date of this joint proxy statement/prospectus, Bioventus directors and executive officers do not have interests in the merger that are different from, or in addition to, the interests of other Bioventus stockholders generally. The Bioventus board was aware of and considered these factors, among other matters, in reaching its determination that the terms of the merger agreement and the merger are fair to and in the best interests of Bioventus and its stockholders, approving and declaring advisable the merger agreement and the transactions contemplated thereby, including the merger and the share issuance, and recommending that Bioventus stockholders approve the Bioventus share proposal issuance. See &#8220;The Mergers&#8212;Background of the Merger&#8221; and &#8220;The Mergers&#8212;Recommendation of the Bioventus Board of Directors; Bioventus&#8217;s Reasons for the Merger.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217;s &#8220;executive officers&#8221; since the beginning of Bioventus&#8217;s last fiscal year are: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kenneth M. Reali, Chief Executive Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gregory O. Anglum, Senior Vice President&#160;&amp; Chief Financial Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John E. Nosenzo, Senior Vice President&#160;&amp; Chief Commercial Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anthony D&#8217;Adamio, Senior Vice President&#160;&amp; General Counsel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alessandra Pavesio, Senior Vice President&#160;&amp; Chief Science Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anthony P. Bihl III, former Chief Executive Officer; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Katrina Church, Senior Vice President and Chief Compliance Officer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus&#8217;s directors since the beginning of Bioventus&#8217;s last fiscal year are: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">William A Hawkins III; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Philip G. Cowdy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guido J. Neels; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guy P. Nohra; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David J. Parker; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Susan M. Stalnecker; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Martin P. Sutter; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mary Kay Ladone; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kenneth Reali. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Governance of the Combined Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has agreed to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board to the Bioventus board as of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No other governance changes are planned in connection with the mergers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;The Mergers Agreement&#8212;Governance of the Combined Company.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">337 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_27" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INTERESTS OF MISONIX DIRECTORS AND EXECUTIVE OFFICERS IN THE MERGERS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In considering the recommendations of the Misonix board, Misonix stockholders should be aware that Misonix directors and executive officers may have interests in the mergers, including financial interests, which may be different from, or in addition to, the interests of Misonix stockholders generally. These interests are described in more detail below and, with respect to Misonix&#8217;s named executive officers, are quantified under &#8220;Quantification of Payments and Benefits to Misonix Named Executive Officers.&#8221; The Misonix board was aware of and considered these interests, among other matters, in reaching its determination that the mergers are fair to and in the best interests of Misonix and its stockholders, approving and declaring advisable the Agreement and Plan of Merger and the transactions contemplated thereby, and recommending that Misonix stockholders approve the Misonix mergers. See &#8220;The Mergers&#8212;Background of the Mergers&#8221; and &#8220;The Mergers&#8212;Recommendation of the Misonix Board of Directors; Misonix&#8217;s Reasons for the Mergers.&#8221; The closing of the mergers are expected to constitute a &#8220;change of control&#8221; (or similar phrase) for purposes of each of the compensation plans and agreements, if applicable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s &#8220;named executive officers&#8221; are: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stavros G. Vizirgianakis, Chief Executive Officer and director; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joseph P. Dwyer, Chief Financial Officer, Treasurer and Secretary; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Robert S. Ludecker, Senior Vice President of Global Sales and Marketing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s &#8220;executive officers&#8221; are: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">its named executive officers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sharon W. Klugewicz, Chief Operating Officer; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jay Waggoner, Senior Vice President of Sales - Wound. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Ownership </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix&#8217;s directors and executive officers will receive the same merger consideration as other Misonix stockholders for each share of Misonix common stock that they own at the effective time. For information regarding beneficial ownership of Misonix common stock by each of Misonix current directors, named executive officers and all directors and executive officers as a group, see the section entitled &#8220;Certain Beneficial Owners of Misonix Common Stock.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treatment of Misonix Equity Awards </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the effective time, each outstanding Misonix stock option held by individuals who meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> definition of &#8220;employees&#8221; of Misonix, including executive officers and directors of Misonix, shall (i)&#160;become fully vested immediately upon the effective time and (ii)&#160;be assumed by Bioventus and converted automatically into an option to purchase Bioventus class A common stock based on the option exchange ratio (with the exercise price with respect to such option being adjusted based on the option exchange ratio). Aside from the foregoing adjustments, the assumed options will generally remain subject to the same vesting and other terms and conditions that applied to such awards immediately prior to the effective time. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For executive officers and directors who do not meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> definition of &#8220;employee&#8221; as of the effective time, each of their outstanding Misonix stock options will become fully vested and be settled in cash immediately prior to the effective time in an amount equal to the product of (x)&#160;the number of shares of Misonix common stock subject to the applicable option and (y)&#160;the excess, if any, of (i)&#160;the average of the volume-weighted average </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">338 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">trading price per share of Bioventus Class&#160;A Common Stock on Nasdaq (as reported by Bloomberg L.P.) on each of the five consecutive trading days ending on (and including) the trading day that is three trading days prior to the date of the effective time over (ii)&#160;the per share exercise price of such option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number and value of outstanding Misonix stock options and held by each named executive officer, other executive officer, and director of Misonix based on holdings as of August&#160;27, 2021 is set forth below. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 41%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Shares<br/>Underlying&#160;Unexercised<br/>Options<br/>(#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/>Exercise Price of<br/>Options</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value&#160;of&#160;Unexercised<br/>Options<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div><br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Named Executive Officers</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stavros G. Vizirgianakis</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">450,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,006,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joseph P. Dwyer</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">271,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,325,655</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Robert S. Ludecker</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">307,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,437,751</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Executive Officers</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sharon W. Klugewicz</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">576,124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jay Waggoner</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">528,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Directors</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul LaViolette</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">381,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael Koby</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">381,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thomas M. Patton</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,174,050</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patrick Beyer</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-the-money</div></div> value of the Misonix stock options based on the closing price per share of Misonix common stock of $26.02 on August&#160;27, 2021, as reported by Nasdaq. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective as of immediately prior to the effective time, all Misonix restricted stock shall accelerate in full and become fully vested (and, once vested, will be treated in the same manner as other shares of Misonix common stock in the mergers). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Vizirgianakis holds 159,800 shares of restricted stock with an aggregate value of $4,157,996 as of August&#160;27, 2021. None of the other named executive officers, executive officers or directors of Misonix held restricted stock as of such date. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treatment of Misonix&#8217;s ESPP </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix adopted an ESPP in 2021; however, no offering periods under the Misonix ESPP had commenced prior to the execution of the merger agreement. Therefore, no offering periods under the Misonix ESPP are currently active and none will be commenced prior to the closing date. The Misonix ESPP shall terminate immediately prior to the effective time, contingent upon the occurrence of the closing. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Governance of the Combined Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has agreed to appoint Stavros Vizirgianakis and Patrick Beyer, each a member of the Misonix board to the Bioventus board as of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;The Mergers&#8212;Board of Directors of the Combined Company.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">339 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification; Directors&#8217; and Officers&#8217; Insurance </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the merger agreement, certain directors and officers of Misonix and its subsidiaries will be entitled to certain ongoing indemnification and coverage under directors&#8217; and officers&#8217; liability and fiduciary liability insurance policies following the mergers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Compensation Arrangements with Bioventus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any Misonix executive officers and directors who become officers, directors or employees or who otherwise are retained to provide services to Bioventus or the surviving corporation may enter into new individualized compensation arrangements and may participate in cash or equity incentive or other benefit plans maintained by Bioventus. As of the date of this proxy statement/prospectus, no compensation arrangements between such persons and Bioventus and/or its affiliates have been established. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix Compensation Arrangements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vizirgianakis Employment Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;15, 2016, Misonix entered into an Employment Agreement (the &#8220;Vizirgianakis Agreement&#8221;) with Stavros G. Vizirgianakis pursuant to which Mr.&#160;Vizirgianakis serves as Misonix&#8217;s full time Chief Executive Officer. Mr.&#160;Vizirgianakis also serves as a member of the board of directors of Misonix. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Vizirgianakis Agreement, Mr.&#160;Vizirgianakis&#8217; employment is automatically renewed and extended for consecutive one year renewal terms on each September&#160;13, unless either party sends to the other party a notice of nonrenewal at least 90 days prior to the expiration of any then-current renewal term. Mr.&#160;Vizirgianakis receives an annual base salary of not less $360,000 per annum, subject to review by the board of directors of Misonix at least annually for increase but not for decrease. Mr.&#160;Vizirgianakis is also eligible to receive annual bonuses in the discretion of Misonix&#8217;s board of directors. If Misonix terminates Mr.&#160;Vizirgianakis&#8217; employment without cause (as defined in the Vizirgianakis Agreement), Misonix provides a notice of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-renewal,</div> or Mr.&#160;Vizirgianakis terminates his employment for good reason (as defined in the Vizirgianakis Agreement), Mr.&#160;Vizirgianakis will be entitled to receive (i)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> cash payment in an amount equal to 1.5 times the annual base salary as is in effect immediately prior to the date of such termination, and (ii)&#160;continuation of all employee benefits and fringe benefits to which he was entitled under the Vizirgianakis Agreement immediately prior to such termination of employment for a period of 18 months following the termination of employment. The Vizirgianakis Agreement also contains <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> covenants from Mr.&#160;Vizirgianakis during the term of employment and for a period of 18 months thereafter. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the execution of the Vizirgianakis Agreement in 2016, Mr.&#160;Vizirgianakis received grants of an aggregate of 400,000 shares of restricted stock pursuant to Misonix&#8217;s 2014 Employee Equity Incentive as follows: (i)&#160;a grant of 134,000 shares vesting in five equal installments on September&#160;1, 2017, 2018, 2019, 2020 and 2021; (ii) a performance grant of 133,000 shares, the performance targets for which have already been satisfied; and (iii)&#160;a performance grant of 133,000 shares which vests if both of the following conditions are satisfied simultaneously: (A)&#160;at any time prior to the fifth anniversary of the grant date, the most recent publicly reported trailing four fiscal quarter revenue of Misonix (exclusive of the impact of any acquisitions after the grant date) is at least $48,000,000 and (B)&#160;the closing price of Misonix common stock is at least $13.00 per share (subject to adjustment for stock splits, stock dividends and the like) for 10 consecutive trading days. Any unvested performance grants will vest on a change of control if the applicable share price threshold is met in such transaction (which share price threshold is expected to be met upon the closing). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dwyer Employment Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;21, 2017, Misonix entered into an Employment Agreement (the &#8220;Dwyer Agreement&#8221;) with Joseph P. Dwyer pursuant to which Mr.&#160;Dwyer serves as Misonix&#8217;s full time Chief Financial Officer. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">340 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Pursuant to the Dwyer Agreement, Mr.&#160;Dwyer&#8217;s employment is automatically renewed and extended for consecutive one year renewal terms on each August&#160;21, unless either party sends to the other party a notice of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-renewal</div> at least 90 days prior to the expiration of the then-current renewal term. Mr.&#160;Dwyer receives an annual base salary of not less than $275,000 per annum, subject to review by the Misonix board at least annually for increase but not for decrease. Mr.&#160;Dwyer is also eligible to receive annual bonuses in the discretion of the Misonix board. If Misonix terminates Mr.&#160;Dwyer&#8217;s employment without cause (as defined in the Dwyer Agreement), Misonix provides a notice of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-renewal,</div> or Mr.&#160;Dwyer terminates his employment for good reason (as defined in the Dwyer Agreement), Mr.&#160;Dwyer will be entitled to receive (i)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> cash payment in an amount equal to 100% of his annual base salary and (ii)&#160;continuation of all employee benefits and fringe benefits to which he was entitled under the Dwyer Agreement immediately prior to such termination of employment for a period of 12 months following the termination of employment. The Dwyer Agreement also contains <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> covenants from Mr.&#160;Dwyer during the term of employment and for a period of 12 months thereafter. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In conjunction with the execution of the Dwyer Agreement in 2017, Mr.&#160;Dwyer received a grant of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> stock option to purchase 100,000 shares (the &#8220;Dwyer Stock Option Award&#8221;) of Misonix common stock, under the Misonix, Inc. 2017 Equity Incentive Plan. The Dwyer Stock Option Award has an exercise price of $10.20 per share, which equals the fair market value on the date of grant as defined in the plan and vests and becomes exercisable in four equal annual installments from the date of grant. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ludecker Letter Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;15, 2016, Misonix entered into a letter agreement (the &#8220;Ludecker Agreement&#8221;) with Robert S. Ludecker, pursuant to which Mr.&#160;Ludecker serves as Misonix&#8217;s Senior Vice President of Global Sales and Marketing. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Ludecker Agreement, if Mr.&#160;Ludecker&#8217;s employment is terminated involuntarily or Mr.&#160;Ludecker terminates his employment for good reason (as described in the Ludecker Agreement) following a change in control of Misonix, then he will be entitled to receive a lump sum cash payment equal to 12 months of annual base salary within 60 days after the change in control takes place and his employment terminates. The Ludecker Agreement also contains <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disparagement</div> covenants from Mr.&#160;Ludecker following his termination of employment. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in Control Severance Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Effective as of July&#160;28, 2021, Misonix adopted a Change in Control Severance Plan, which provides for severance benefits for certain eligible employees in the event of a termination of employment with Misonix either (x)&#160;by Misonix or its successor other than for cause, death or disability or (y)&#160;by the participant for good reason, in each case that occurs within one year following a change in control (as defined therein). Subject to satisfaction of the requirements of the Change in Control Severance Plan (including the participant&#8217;s timely execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a general release of claims), the participant shall be entitled to receive a severance amount, which will be paid in cash within 60 days following such qualifying termination and shall equal (i) 3 months or 6 months (depending on the participant&#8217;s employee designation) of the participant&#8217;s monthly salary and (ii) 3 months or 6 months (depending on the participant&#8217;s employee designation) of the COBRA premium for health, dental and vision benefits in effect for the participant (and his or her spouse and dependents) immediately prior to such qualifying termination. Any amounts payable under the Change in Control Severance Plan shall be reduced by the amount of severance of termination payments (if any) payable by Misonix to the participant under any employment contract or other arrangement related to his or her employment with Misonix. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">341 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quantification of Payments and Benefits to Misonix Named Executive Officers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following information, table and the related footnotes present information about the compensation payable to Misonix named executive officers in connection with the mergers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Golden Parachute Compensation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The narrative and tables that follow are estimates based on multiple assumptions that may or may not actually occur. They describe potential payments and benefits to the named executive officers under their existing agreements, including payments and benefits that would be due to them in connection with the occurrence of a change of control, assuming the closing date occurred on August&#160;27, 2021 and that each named executive officer experienced a qualifying termination of employment on such closing date. The equity award values are calculated based on the average closing market price of Misonix common stock over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">five-day</div> period ending on August&#160;27, 2021, or $26.22. The actual amounts, if any, to be received by a named executive officer may differ from the amounts set forth below. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity<br/></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Perquisites/<br/>benefits<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(3)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>($)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stavros G. Vizirgianakis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,145,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,543,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,823</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,722,792</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joseph P. Dwyer</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">556,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,089,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,668,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Robert S. Ludecker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">404,430</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">527,657</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reflect the base salary severance payment due to such named executive officer upon a qualifying termination of employment pursuant to his existing employment arrangement (as described above under &#8220;Misonix Compensation Arrangements&#8221;) and the target bonus amount payable under Misonix&#8217;s fiscal year 2022 short-term incentive plan upon a change in control of Misonix. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reflect the potential value of full acceleration of: (a)&#160;for Mr.&#160;Vizirgianakis, all unvested options and restricted stock (which assumes that any stock price conditions and revenue targets, where applicable, have been met); and (b)&#160;for Mr.&#160;Dwyer and Mr.&#160;Ludecker, all unvested options, in each case upon a change in control of the Misonix (as defined in the applicable award agreements and equity plans) regardless of whether the executive&#8217;s employment is terminated. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts include benefits continuation payments upon a qualifying termination of employment pursuant to his existing employment arrangement (as described above under &#8220;Misonix Compensation Arrangements&#8221;). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">342 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_28" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE FIRST MERGER AND THE SECOND MERGER </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This section is a general discussion of certain material U.S. federal income tax consequences that may be relevant to U.S. holders and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders (each as defined below) of shares of Misonix common stock of (i)&#160;exchanging their Misonix common stock for Bioventus class A common stock in the mergers and (ii)&#160;holding and disposing of Bioventus class A common stock received by U.S. holders and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders in the mergers. The following discussion is based on the Code, applicable Treasury Regulations thereunder, administrative interpretations and published rulings of the IRS and court decisions, each as in effect as of the date of this proxy statement/prospectus, and all of which are subject to change and differing interpretations, possibly with retroactive effect. Any such change or differing interpretation could affect the accuracy of the statements set forth in this discussion. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This discussion is for general information purposes only and it is not a complete description of all tax considerations that may be relevant to holders of Misonix common stock and it is not a substitute for tax advice. This discussion addresses only holders of (i)&#160;Misonix common stock as of immediately before the first merger, and (ii)&#160;Bioventus class A common stock received in the first merger, in each case, who hold their shares of each as a capital asset within the meaning of Section&#160;1221 of the Code (generally, property held for investment), and does not address all aspects of U.S. federal income taxation that may be relevant to particular holders in light of their individual circumstances or to holders that are subject to special rules under the U.S. federal income tax laws, such as: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">banks or other financial institutions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pass-through entities or investors in pass-through entities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">real estate investment trusts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">insurance companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> organizations; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">brokers or dealers in securities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">traders in securities that elect to use a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> method of accounting; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulated investment companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">pension funds, individual retirement and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-deferred</div> accounts; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons that hold Misonix common stock or Bioventus class A common stock, as applicable, as part of a straddle, hedge, short sale, constructive sale or conversion transaction or other integrated or risk reduction transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons who purchased or sell their shares of Misonix common stock or Bioventus class A common stock, as applicable, as part of a wash sale; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons that own (directly, indirectly, or by attribution), or at any time during the five year period ending on the closing date owned, 5% or more (by vote or value) of Misonix common stock or Bioventus class A common stock, as applicable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain U.S. expatriates or U.S. holders that have a functional currency other than the U.S. dollar; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons required to accelerate the recognition of any item of gross income as a result of such income being recognized on an &#8220;applicable financial statement;&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons who exercise dissenters&#8217; rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies&#8221; and &#8220;personal holding companies&#8221;; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">343 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">holders who acquired their shares of Misonix common stock or Bioventus class A common stock, as applicable, through the exercise of an employee stock option or otherwise as compensation or through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-qualified</div> retirement plan. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the discussion does not address any tax consequences arising under the unearned income Medicare contribution tax, any alternative minimum tax or any state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> tax consequences of the mergers. This discussion also does not address any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-income</div> tax consequences of the mergers or (except as expressly discussed below) any reporting requirements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of this discussion, a U.S. holder is a beneficial owner of (i)&#160;Misonix common stock at the time of the first merger and (ii)&#160;Bioventus class A common stock received in the first merger, in each case, that is: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an individual who is a citizen or resident of the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a corporation, or any other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States or any state thereof or the District of Columbia; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a trust (1)&#160;that is subject to the primary supervision of a court within the United States and all the substantial decisions of which are controlled by one or more United States persons or (2)&#160;that has a valid election in effect under applicable Treasury Regulations to be treated as a United States person; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an estate that is subject to U.S. federal income tax on its income regardless of its source. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For purposes of this discussion, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder is a beneficial owner of (i)&#160;Misonix common stock at the time of the first merger and (ii)&#160;Bioventus class A common stock received in the first merger, in each case, that is neither a U.S. holder nor a partnership (or any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a partnership (including for this purpose any entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds shares of Misonix common stock or Bioventus class A common stock, as may be applicable, the tax treatment of a partner generally will depend on the status of the partner and the activities of the partnership. If you are a partner of a partnership holding shares of Misonix common stock or Bioventus class A common stock, you should consult your tax advisor regarding the tax consequences of the mergers and of the ownership and disposition of Bioventus class A common stock received in the mergers. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">THE FOLLOWING DISCUSSION DOES NOT PURPORT TO BE A COMPLETE ANALYSIS OR DISCUSSION OF ALL OF THE POTENTIAL TAX CONSEQUENCES OF THE MERGERS. ALL STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS AS TO THE SPECIFIC TAX CONSEQUENCES TO THEM OF THE MERGERS, INCLUDING TAX RETURN REPORTING REQUIREMENTS AND THE APPLICABILITY AND EFFECT OF THE ALTERNATIVE MINIMUM TAX AND ANY STATE, LOCAL, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</div> AND OTHER TAX LAWS IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. HOLDERS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Federal Income Tax Consequences of the First Merger and the Second Merger to U.S. Holders of Shares of Misonix Common Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treatment of the first merger and the second merger, taken together, as a Reorganization </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is intended that, for U.S. federal income tax purposes, the first merger and the second merger, taken together, qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code. It is a condition to Misonix&#8217;s obligation to complete the mergers that Misonix receive a tax opinion from Jones Day, dated as of the Closing Date, to the effect that, on the basis of facts, representations and assumptions set forth or referred to in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">344 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">such opinion, the first merger and the second merger, taken together, qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code. If Jones Day is unwilling or unable to provide such tax opinion, another nationally recognized tax counsel reasonably acceptable to Misonix, may deliver the tax opinion. Such tax opinion will be based on certain assumptions, representations and warranties and covenants, including those contained in the merger agreement and in tax representation letters provided by Misonix and Bioventus (on behalf of itself, Merger Sub I and Merger Sub II). If any of these assumptions, representations and warranties or covenants underlying the tax opinion described above is or becomes incorrect, incomplete, inaccurate or is violated, the validity of, and the conclusions reached in, such tax opinion may be affected or jeopardized, and the U.S. federal income tax consequences of the first merger and the second merger could differ materially from those discussed below. In addition, the opinion will be subject to certain qualifications and limitations as set forth therein. Moreover, an opinion of counsel is not binding on the IRS or any court. Neither Bioventus nor Misonix intends to request a ruling from the IRS regarding the U.S. federal income tax consequences of the first merger and the second merger. Accordingly, even if Misonix receives a tax opinion that concludes that the first merger and the second merger, taken together, qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, no assurance can be given that the IRS will not challenge the conclusions reflected in the opinion or that a court would not sustain such a challenge. If the first merger and the second merger, taken together, do not qualify as a reorganization for U.S. federal income tax purposes, the surrender of Misonix common stock by U.S. holders in exchange for the merger consideration pursuant to the first merger will be treated as a fully taxable exchange with respect to both Bioventus class A common stock and the cash portion of the merger consideration. U.S. holders are urged to consult their tax advisors regarding the U.S. federal income tax consequences of the mergers to them, including in the event that the first merger and the second merger, taken together, do not qualify as a reorganization. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exchange of Shares of Misonix Common Stock for the Merger Consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the discussion below relating to the receipt of cash in lieu of fractional shares, provided that the first merger and the second merger, taken together, qualify as a reorganization, a U.S. holder who surrenders shares of Misonix common stock in exchange for the merger consideration pursuant to the first merger will recognize gain (but not loss) equal to the lesser of: (i)&#160;the cash consideration (excluding cash received in lieu of fractional Misonix common stock, if any) received by such U.S. holder, and (ii)&#160;the excess, if any, of (a)&#160;the sum of the cash consideration (excluding cash received in lieu of fractional Misonix common stock, if any) plus the fair market value of the Bioventus class A common stock (including any fractional Bioventus class A common stock deemed received) received by such U.S. holder in the first merger, over (b)&#160;such U.S. holder&#8217;s tax basis in its shares of Misonix common stock surrendered. Any recognized gain generally will be long-term capital gain if the U.S. holder&#8217;s holding period with respect to the shares of Misonix common stock surrendered is more than one year. Long-term capital gain of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. holders currently is eligible for preferential U.S. federal income tax rates. In the event a holder elects, and receives, solely cash pursuant to the first merger, such holder can recognize loss realized in the mergers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A U.S. holder of shares of Misonix common stock generally will have an aggregate adjusted tax basis in the Bioventus class A common stock received in the first merger, including any fractional Bioventus class A common stock for which cash is received, equal to such holder&#8217;s aggregate adjusted tax basis in its shares of Misonix common stock surrendered in the first merger, increased by the amount of gain, if any, recognized (not including any gain recognized with respect to any cash received in lieu of fractional Bioventus class A common stock) in the first merger, and reduced by the amount of cash received (excluding any cash received in lieu of fractional Bioventus class A common stock). The holding period for Bioventus class A common stock received in the first merger, including any fractional Bioventus class A common stock for which cash is received, will include the holding period for the shares of Misonix common stock surrendered in exchange for such Bioventus class A common stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the case of a U.S. holder who holds shares of Misonix common stock with differing tax bases and/or holding periods, which generally occurs when blocks of shares are purchased at different times or for different </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">345 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prices, the preceding rules must be applied separately to each identifiable block of shares of Misonix common stock, and such U.S. holder may not offset a loss realized on one block of the shares against gain recognized on another block of the shares. There are complex rules that may apply if a holder elects to receive cash election consideration for some of its shares of Misonix common stock and stock election consideration for other of its shares of Misonix stock. Holders are urged to consult with their own tax advisor about the applicability of the tax basis rules to them and the tax implications of differing elections. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Received in Lieu of Fractional Shares of Bioventus Class&#160;A Common Stock </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A U.S. holder who receives cash in lieu of a fraction of a share of Bioventus class A common stock as part of the consideration in the first merger generally will be treated as having received the fractional share pursuant to the first merger and then as having sold to Bioventus that fraction of a share of Bioventus class A common stock for cash in a redemption transaction. As a result, a U.S. holder of shares of Misonix common stock generally will recognize gain or loss measured by the difference between the amount of cash received in lieu of a fractional share of Bioventus class A common stock in the first merger and the portion of the U.S. holder&#8217;s tax basis in the shares of Misonix common stock allocated to the fractional share of Bioventus class A common stock. Gain or loss recognized with respect to cash received in lieu of any fractional share of Bioventus class A common stock generally will be capital gain or loss, and generally will be long-term capital gain or loss if, as of the effective time of the first merger, the holding period for the shares of Misonix common stock surrendered in exchange for the fractional share of Bioventus class A common stock is greater than one year. Long-term capital gain of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. holders currently is eligible for preferential U.S. federal income tax rates. The deductibility of capital losses is subject to limitations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, cash received in lieu of fractional shares of Bioventus class A common stock could be treated as having the effect of a distribution of a dividend under the tests set forth in Section&#160;302 of the Code, in which case such U.S. holder could have dividend income up to the amount of the cash consideration received. Because the possibility of dividend treatment depends primarily upon the particular circumstances of a U.S. holder, including the application of certain constructive ownership rules, U.S. holders should consult their tax advisors regarding the potential tax consequences of the receipt of cash in lieu of fractional shares of Bioventus class A common stock to them. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reporting Requirements in Connection with the First Merger and the Second Merger </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A U.S. holder of Misonix common stock who receives Bioventus class A common stock in the first merger will be required to retain records pertaining to the mergers. Each U.S. holder of Misonix common stock who is required to file a U.S. federal income tax return and who is a &#8220;significant holder&#8221; that receives Bioventus class A common stock in the first merger will be required to file a statement with such U.S. federal income tax return in accordance with Treasury Regulations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.368-3</div> setting forth information regarding the parties to the mergers, the date of the mergers and such U.S. holder&#8217;s adjusted tax basis and fair market value of the Misonix common stock surrendered. A &#8220;significant holder&#8221; is a holder of Misonix common stock (i)&#160;who, immediately before the first merger, owned at least 5% of the outstanding stock of Misonix, or (ii)&#160;whose tax basis in the Misonix common stock for U.S. federal income tax purposes was at least $1&#160;million immediately before the first merger. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Federal Income Tax Consequences to U.S. Holders of Holding and Disposing of Bioventus class A common stock Received in the first merger </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributions on Bioventus Class&#160;A common stock </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The gross amount of any distribution on Bioventus class A common stock made from Bioventus&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes) generally will be taxable to a U.S. holder as dividend income on the date such distribution is actually or constructively received. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-corporate</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">346 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. holders may be eligible for a reduced rate of taxation on dividends provided that certain holding period requirements and other conditions are satisfied. For corporate U.S. holders, dividends (a)&#160;may be eligible for a dividends received deduction and (b)&#160;may be subject to the &#8220;extraordinary dividend&#8221; provisions of the Code, subject in each case to certain requirements and limitations. To the extent that the amount of a distribution exceeds Bioventus&#8217;s current and accumulated earnings and profits (as determined under U.S. federal income tax principles), such excess amount will be treated first as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-taxable&#160;return</div> of capital to the extent of the U.S. holder&#8217;s tax basis in its Bioventus class A common stock, and thereafter as capital gain recognized on a sale or exchange, which gain would be taxable as described below in the section titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Holders</div></div> &#8212; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale, Exchange, Redemption or Other Taxable Disposition of Bioventus class A common stock</div></div>.&#8221; </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale, Exchange, Redemption or Other Taxable Disposition of Bioventus Class&#160;A Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A U.S. holder generally will recognize gain or loss on any sale, exchange, redemption or other taxable disposition of Bioventus class A common stock in an amount equal to the difference between (i)&#160;the amount realized on the disposition and (ii)&#160;such U.S. holder&#8217;s adjusted tax basis in such shares. Any gain or loss recognized by a U.S. holder on a taxable disposition of Bioventus class A common stock generally will be capital gain or loss and will be long-term&#160;capital gain or loss if such U.S. holder&#8217;s holding period in such shares exceeds one year at the time of the disposition. Preferential tax rates may apply to long-term&#160;capital gains of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate&#160;U.S.</div> holders. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S. holder on the sale or exchange of Bioventus class A common stock generally will be treated as U.S. source gain or loss. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</div> HOLDERS </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">U.S. Federal Income Tax Consequences of the First Merger and the Second Merger to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holders of Shares of Misonix common stock </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treatment of the First Merger and the Second Merger, taken together, as a Reorganization </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">It is intended that, for U.S. federal income tax purposes, the first merger and the second merger, taken together, qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, subject to the limitations and assumptions described above in the section titled &#8220;U.S. HOLDERS &#8212; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treatment of the First Merger and the Second Merger, taken together, as a Reorganization</div></div>.&#8221; Accordingly, the U.S. federal income tax consequences described in the section titled &#8220;U.S. HOLDERS &#8212; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treatment of the First Merger and the Second Merger, taken together, as a Reorganization</div></div>&#8221; generally will be applicable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subject to the discussion on backup withholding and FATCA below, any gain recognized by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders pursuant to the first merger will not be subject to U.S. federal income tax, unless: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the gain is effectively connected with the conduct of a trade or business by such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder within the United States (or, under certain income tax treaties, is attributable to a U.S. permanent establishment or fixed base maintained by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder), in which case the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder will generally be subject to U.S. federal income tax on that gain on a net income basis in the same manner as if the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder were a U.S. person as defined under the Code, and a corporate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder may be subject to the branch profits tax at a 30% rate (or lower rate as may be specified by an applicable income tax treaty); or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder is an individual who is present in the United States for 183 days or more in the taxable year in which the first merger occurs and certain other conditions are met, in which case the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder will be subject to a 30% tax on the amount by which its capital gains allocable to U.S. sources, including gain from the taxable sale or exchange of Misonix common stock pursuant to the first merger, exceeds any capital losses allocable to U.S. sources, except as otherwise required by an applicable income tax treaty. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">347 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> holders should consult their tax advisors regarding the U.S. federal income tax consequences of the mergers to them, including in the event that the first merger and the second merger, taken together, do not qualify as a reorganization. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Received in Lieu of a Fractional Shares of Bioventus Class&#160;A Common Stock </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the discussion on backup withholding and FATCA below, the U.S. federal income tax consequences to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders on the receipt of cash in lieu of fractional shares of Bioventus class A common stock pursuant to the first merger will be the same as described above in the section titled &#8220;U.S. HOLDERS &#8212; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Received In Lieu of a Fractional Shares of Bioventus Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock</div></div>.&#8221; However, any gain or loss recognized by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders on their receipt of cash in lieu of fractional shares of Bioventus class A common stock in the first merger will be subject to U.S. federal income tax only if: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">such gain is effectively connected with the conduct of a trade or business by such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder within the United States (or, under certain income tax treaties, is attributable to a U.S. permanent establishment or fixed base maintained by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder), in which case the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder will generally be subject to U.S. federal income tax on that gain on a net income basis in the same manner as if the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder were a U.S. person as defined under the Code, and a corporate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder may be subject to the branch profits tax at a 30% rate (or lower rate as may be specified by an applicable income tax treaty), or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder is an individual who is present in the United States for 183 days or more in the taxable year in which the first merger occurs and certain other conditions are met, in which case the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder will be subject to a 30% tax on the amount by which its capital gains allocable to U.S. sources, including gain from the taxable sale or exchange of a fractional share of Bioventus class A common stock pursuant to the first merger, exceed any capital losses allocable to U.S. sources, except as otherwise required by an applicable income tax treaty. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, if any gain from the deemed sale of a fractional share of Bioventus class A common stock in exchange for cash is recharacterized as a dividend as described in the section titled &#8220;U.S. HOLDERS &#8212; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Received In Lieu of a Fractional Share of Bioventus Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock</div></div>,&#8221; such dividend generally will be subject to U.S. withholding tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty), unless such dividend is effectively connected with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder&#8217;s conduct of a trade or business within the United States. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">U.S. Federal Income Tax Consequences to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holders of Holding and Disposing of Bioventus class A common stock Received in the First Merger </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributions on Bioventus Class&#160;A Common Stock </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As described above in the section titled &#8220;U.S. HOLDERS&#8212;U.S. Federal Income Tax Consequences to U.S. Holders of Holding and Disposing of Bioventus class A common stock received in the first merger&#8212;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributions on Bioventus Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock</div></div>,&#8221; the gross amount of any distribution on Bioventus class A common stock made from Bioventus Inc.&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes) generally will be treated as dividend income on the date such distribution is actually or constructively received. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first be applied against and reduce, but not below zero, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder&#8217;s adjusted tax basis in the Bioventus class A common stock. Any excess will be treated as gain realized on the sale or other disposition of Bioventus class A common stock and will be treated as described under the section titled <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;NON-U.S.</div> HOLDERS &#8212; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale, Exchange, Redemption or Other Taxable Disposition of Bioventus Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock</div></div>&#8221; below. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Dividends on Bioventus class A common stock paid to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders generally will be subject to United&#160;States withholding tax at a gross rate of 30%, subject to any exemption or lower rate specified by an </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">348 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">applicable income tax treaty, except to the extent that the dividends are &#8220;effectively connected dividends,&#8221; as described below. Bioventus may withhold up to 30% of the gross amount of the entire distribution even if greater than the amount constituting a dividend, as described above, to the extent provided for in applicable Treasury regulations. If tax is withheld on the amount of a distribution in excess of the amount constituting a dividend, then a refund of any such excess amounts may be obtained if a claim for refund is timely filed with the IRS. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder holds Bioventus class A common stock in connection with the conduct of a trade or business in the United States, and dividends paid on Bioventus class A common stock are effectively connected with such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder&#8217;s U.S. trade or business (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base maintained by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder in the United States), the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder will be exempt from the aforementioned U.S. federal withholding tax. To claim the exemption, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder must furnish to us or the applicable withholding agent a properly executed IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8ECI</div> (or applicable successor form). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder that claims a reduction or exemption from withholding because of an applicable income tax treaty generally will be required to satisfy applicable certification (generally, IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN-E,</div></div> as applicable) and other requirements prior to the distribution date. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> holders that do not timely provide Bioventus or the applicable paying agent with the required certification may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> holders that hold Bioventus class A common stock through a financial institution or other agent acting on their behalf will be required to provide appropriate documentation to such agent, who then will be required to provide certification to Bioventus or the applicable paying agent. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> holders should consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty or applicability of other exemptions from withholding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale, Exchange, Redemption or Other Taxable Disposition of Bioventus Class&#160;A Common Stock </div></div></div> <div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the discussion on backup withholding and FATCA below, any gain or loss realized by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder on the taxable disposition of its Bioventus class A common stock will be treated in the same manner as any gain required to be recognized by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders pursuant to the mergers as discussed above in the section titled &#8220;U.S. Federal Income Tax Consequences of the First Merger and the Second Merger to Non-U.S. Holders of Shares of Misonix common stock&#8212;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treatment of the First Merger and the Second Merger, taken together, as a Reorganization.</div></div>&#8221; </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BACKUP WITHHOLDING </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Payments of cash and/or shares received by a U.S. holder or a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder in the mergers or as a result of distributions paid by or the disposition of Bioventus class A common stock may be subject to information reporting and backup withholding at the applicable rate (currently 24%). To avoid backup withholding, a U.S. Holder that does not otherwise establish an exemption should timely provide an IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-9,</div> certifying under penalties of perjury that such U.S. holder is a &#8220;United States person&#8221; (within the meaning of the Code), that the taxpayer identification number provided is correct and that such U.S. holder is not subject to backup withholding. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder generally may establish an exemption from backup withholding by certifying its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> person status under penalties of perjury on a properly completed applicable IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Backup withholding does not constitute an additional tax, and any amounts withheld from payments to a holder under the backup withholding rules will be allowed as a refund or credit against the holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FATCA </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sections&#160;1471 through 1474 of the Code and the Treasury regulations and administrative guidance promulgated thereunder (commonly referred to as FATCA) generally impose withholding at a rate of 30% in certain circumstances on certain &#8220;withholdable payments&#8221; in respect of securities which are held by or through </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">349 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">certain foreign financial institutions (including investment funds), unless any such institution (i)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (ii)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. For this purpose, withholdable payments generally include U.S.-source payments otherwise subject to nonresident withholding tax (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, a U.S. source dividend) and also include the entire gross proceeds from the sale or other disposition of stock of U.S. corporations, even if the payment would otherwise not be subject to U.S. nonresident withholding tax (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, because it is capital gain). The IRS issued proposed Treasury Regulations that would eliminate the application of this regime with respect to payments of gross proceeds from dispositions of stock (but not dividends). Pursuant to these proposed Treasury Regulations, Bioventus and any other withholding agent may (but are not required to) rely on this proposed change to FATCA withholding until final regulations are issued or until such proposed regulations are rescinded. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Accordingly, the entity through which shares of the Misonix common stock or Bioventus class A common stock are held will affect the determination of whether such FATCA withholding is required. Similarly, if the applicable withholding agent does not rely on the proposed Treasury Regulations, &#8220;withholdable payments&#8221; in respect of Misonix common stock or Bioventus class A common stock held by a stockholder that is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&#160;certifies to the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners&#8221;, which will in turn be provided to the U.S. Department of Treasury. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> holders should consult their tax advisors regarding the possible implications of FATCA on the mergers and their holding of Misonix common stock or Bioventus class A common stock. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus will not pay any additional amounts to any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holders or U.S. holders in respect of any amounts withheld, including pursuant to FATCA. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">THE PRECEDING DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. EACH STOCKHOLDER SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND LOCAL AND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</div> TAX CONSEQUENCES OF THE MERGERS AND OF HOLDING AND DISPOSING OF PARENT CLASS A COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">350 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_29" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMPARISON OF STOCKHOLDERS&#8217; RIGHTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix are Delaware corporations and the rights of Bioventus and Misonix stockholders are governed by the DGCL.&#160;Misonix stockholders&#8217; rights are also governed by the Misonix charter and bylaws.&#160;If the transaction is completed, the rights of Misonix stockholders who become Bioventus stockholders will be governed by the Bioventus charter and bylaws. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As Bioventus and Misonix are both Delaware corporations, the rights of Bioventus and Misonix stockholders are not materially different. However, there are certain differences in the rights of Bioventus stockholders under the Bioventus charter and bylaws and of Misonix stockholders under the Misonix charter and bylaws, as summarized in the table below. This summary does not purport to be a complete statement of all the differences, or a complete description of the specific provisions referred to.&#160;Further, the identification of specific differences is not intended to indicate that other equally or more significant differences do not exist.&#160;Bioventus and Misonix stockholders should carefully read the relevant provisions of the Bioventus charter, the Bioventus bylaws, the Misonix charter, the Misonix bylaws and the DGCL.&#160;Copies of the documents referred to in this summary may be obtained as described under &#8220;Where You Can Find More Information.&#8221; </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Authorized and Outstanding Capital Stock</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is authorized to issue 310,000,000 shares of stock, consisting of 250,000,000 shares of Bioventus class A common stock, par value $0.001 per share, 50,000,000 shares of Bioventus class B common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the close of business on the Bioventus record date, there were [&#9679;] shares of Bioventus common stock and no shares of serial preferred stock issued and outstanding.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix is authorized to issue is 47,000,000 shares, consisting of 45,000,000 shares of common stock, par value of $0.0001 per share, and 2,000,000 shares of preferred stock, par value of $0.0001 per share.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the close of business on the Misonix record date, there were [&#9679;] shares of Misonix common stock and no shares of preferred stock issued and outstanding.</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rights of Preferred Stock</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus is authorized to issue preferred stock in one or more series, each of such series to have such terms as stated or expressed in the Bioventus charter and in the resolution or resolutions providing for the creation and issuance of such series adopted by the Bioventus board.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to certain limitations, the Bioventus board may issue the preferred stock in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designation relating thereto in accordance with the DGCL to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights,</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The Misonix board is authorized, subject to limitations prescribed by law and the provisions of the Misonix charter, to provide for the creation and issuance from time to time in one or more series of any number of shares of preferred stock and, by filing a certificate pursuant to the DGCL, to establish the number of shares to be included in each such series, and to fix the designation, relative rights, preferences, qualifications and limitations of the shares of each such series.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">351 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rights of Preferred Stock</div></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">conversion rights, redemption privileges and liquidation preferences, and to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series as shall be stated and expressed in such resolutions, all to the fullest extent now or hereafter permitted by the DGCL.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as may be otherwise provided in the Bioventus charter, and subject to the rights, powers and preferences of the holders any series of preferred stock, each stockholder of Bioventus common stock shall be entitled to one (1)&#160;vote for each share of common stock held of record by such stockholder as of the record date for determining stockholders entitled to vote on such matter.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">Except as otherwise provided by the Bioventus charter, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. Except as otherwise provided by the Bioventus charter, the Bioventus bylaws, the rules or regulations of any stock exchange applicable to Bioventus, or applicable law or pursuant to any regulation applicable to Bioventus or its securities, each other matter presented to the stockholders at a duly called or convened meeting at which a quorum is present shall be decided by the affirmative vote of the holders of a majority in voting power of the votes cast (excluding abstentions and broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes)</div> on such matter.</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the rights of the holders of any series of preferred stock, each stockholder of Misonix common stock is entitled to one (1)&#160;vote on each matter submitted to a vote at a meeting of stockholders for each share of common stock held of record by such holder as of the record date for the meeting.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">Except as otherwise provided by the Misonix charter, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. Except where a larger vote is required by the Misonix bylaws, the Misonix charter, a certificate of designation relating to Misonix preferred stock, or by law each other matter at any meeting of stockholders in which a quorum is present shall be decided by the affirmative vote of a majority of the votes properly cast on the matter (excluding abstentions and broker <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-votes).</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributions and Dividends</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board, subject to any restrictions under applicable law (including the DGCL) and the Bioventuscharter, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property or in shares of Bioventus capital stock.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board may set apart out of any of the funds of Bioventus available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of Bioventus, and meeting contingencies.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The DGCL provides that, the directors of a corporation may, subject to any restrictions contained in its certificate of incorporation, declare and pay dividends upon the shares of its capital stock either (i)&#160;out of surplus or (ii)&#160;in the case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Subject to the rights of any other class or series of stock, the holders of shares of Misonix common stock shall be entitled to receive, if and when declared by the Misonix board, out of the assets of the Misonix legally available therefor such dividends as may be declared from time to time by the Misonix board.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">352 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Quorum</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">The Bioventus bylaws provide that, unless otherwise provided by law, or the Bioventus charter or bylaws, the holders of a majority in voting power of the stock issued and outstanding and entitled to vote at the meeting, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The Misonix bylaws provide that, unless otherwise provided by law or in a certificate of designation relating to Misonix preferred stock, the holders of a majority in voting power of the shares of stock issued and outstanding and entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum at a meeting of stockholders for the transaction of business thereat.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Record Date</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus board may fix a record date for purposes of, among other things, determining the rights of stockholders to notice of or to vote at any stockholder meeting and determining the identity of stockholders entitled to receive payment of any dividend or other distribution.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the case of determining stockholders entitled to vote at a stockholder meeting, the record date cannot be more than 60 nor less than ten days before the date of the meeting. In order that Bioventus may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment or any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of capital stock, for the purposes of any other lawful action (other than stockholder action by written consent), the record date cannot be more than 60 days before such action.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The record date for determining stockholders entitled to express written consent to corporate action without a meeting may also be fixed by the Bioventus board, which record date shall not precede, or be more than ten days after, the resolution adopted by the Bioventus board fixing the record date.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Misonix board may fix a record date for purposes of determining the rights of stockholders to notice of or to vote at any stockholder meeting and determining the identity of stockholders entitled to receive payment of any dividend or other distribution.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the case of determining stockholders entitled to vote at a stockholder meeting, the record date will not precede the date upon which the Board resolution fixing the same is adopted and will not be more than 60 nor less than 10 calendar days before the date of such meeting. In the case of any other lawful action, the record date cannot be more than 60 days before such action.</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Number of Directors</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">The Bioventus bylaws and Bioventus Charter provide that the total authorized number of directors shall be determined from time to time by resolution of the majority of the Bioventus board. No decrease in the number of directors shall shorten the term of any incumbent director. There are currently nine Bioventus directors.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The Misonix charter provides that the total authorized number of directors will be fixed exclusively by resolution of a majority of the entire Misonix board. There are currently five Misonix directors.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">353 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Election of Directors</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the certain rights of the holders of preferred stock (if issued) to elect directors, the directors of Bioventus shall be divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III. The directors in these three classes serve for rotational terms.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Bioventus bylaws, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bioventus charter expressly provides that the election of directors need not be by written ballot unless the Bioventus bylaws so provide.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus has agreed to offer at least two members of the Misonix board to the Bioventus board as of the effective time, with such directors to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal. See &#8220;Summary&#8212;Governance of the Combined Company.&#8221;</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The directors of Misonix are not divided into classes.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Misonix bylaws, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director.</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cumulative Voting</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Bioventus stockholders do not have cumulative voting rights.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Misonix stockholders do not have cumulative voting rights.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Removal of Directors</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Subject to the special rights of the holders of one or more outstanding series of preferred stock (if issued) to elect directors and subject to the Bioventus stockholders agreement, the Bioventus board or any individual director may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the voting power of all of the then outstanding shares of voting stock of Bioventus entitled to vote at an election of directors.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Under the DGCL, directors may be removed, with cause, by the holders of a majority of the shares of capital stock of Misonix entitled to vote generally in the election of directors, voting together as a single class.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director Nominations by Stockholders</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">The Bioventus bylaws provide that stockholders seeking to nominate persons for election to the Bioventus board must (i)&#160;be present at the annual or special meeting, (ii)&#160;be the record owner of shares of Bioventus both at the time of giving the required notice and at the time of the meeting (iii)&#160;be entitled to vote at the meeting and (iv)&#160;comply with the notice provisions set forth in the</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The Misonix bylaws provide that, subject to the rights, if any, of any series of preferred stock of Misonix to nominate or elect directors under circumstances specified in a certificate of designation, director nominations may only be made at an annual meeting of stockholders and only (i)&#160;by or at the direction of the Misonix board or (ii)&#160;by a</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">354 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director Nominations by Stockholders</div></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus bylaws. These notice requirements generally require that, among other things, the stockholder deliver a notice of any such nomination for election of a director at the annual meeting, to the offices of Bioventus not less than 90 days nor more than 120 days prior to the anniversary of the date of the preceding year&#8217;s annual meeting (which date of the preceding year&#8217;s annual meeting, for the first annual meeting, shall be deemed to be May&#160;14, 2021). For the notice to be timely for the nomination of a director at a special meeting, the stockholder must deliver notice to the Bioventus offices no earlier than 120 days nor any later than 90 days prior to such special meeting.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Separately, a stockholder (or a group of up to 20 stockholders) who complies with or meets, as applicable, the procedural, informational and stockholder eligibility requirements set forth in the proxy access provision of the Bioventus bylaws may also nominate a candidate to the Bioventus board at a meeting of stockholders pursuant to such provisions, in which case any such nominees nominated pursuant to such provisions shall be included by Bioventus in its proxy statement or form of proxy and ballot.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To nominate a candidate pursuant to such proxy access bylaw, the stockholder must meet certain requirements and, among other things, submit certain information to Bioventus&#8217; Secretary, as prescribed by the Bioventus bylaws, no less than 120 days prior to the first anniversary of the date of Bioventus&#8217; proxy materials released to stockholders in connection with the preceding year&#8217;s annual meeting.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stockholder who (A)&#160;has properly complied with the provisions of the Misonix bylaws, (B)&#160;was a stockholder of record at the time of giving the required notice of such nomination and is a stockholder of record at the time of the annual meeting, (C)&#160;is entitled to vote at the annual meeting and (D)&#160;has nominated a number of nomineeds that does not exceed the number of directors that will be elected at the annual meeting. A stockholder&#8217;s notice of a director nomination must contain the following information: (i)&#160;all of the information regarding the nominating person that is required by Section&#160;10 of the Misonix bylaws for proposing persons; and (ii)&#160;the following information regarding the nominee: (A)&#160;all of the information regarding the nominee that is required by Section&#160;10 of the Misonix bylaws for proposing persons; (B)&#160;all information that would be required to be disclosed in a proxy statement or other filing pursuant to Section&#160;14(a) of the Exchange Act to be made in connection with a general solicitation of proxies for an election of directors; (C)&#160;a description of all compensation and other material monetary agreements during the past three years, or any material relationships, between the nominating person and his or her affiliates and associates, on the one hand, and the proposed nominee and his or her affiliates or associates, on the other hand; (D)&#160;a completed questionnaire with respect to the identity, background and qualifications of the proposed nominee; and (E)&#160;a representation that the nominee (1)&#160;is qualified and intends to serve the entire term if elected; (2)&#160;is not and will not become party to any arrangement that has not been disclosed to the Misonix as to how the nominee will vote or act on any issues or questions or any such arrangement that could limit the nominee&#8217;s ability to comply with the nominee&#8217;s fiduciary duties; (3)&#160;is not and will not become a party to any agreement that has not been disclosed with any person other than the Misonix with respect to any form of compensation in connection with service as a director; and (4)&#160;if elected, will be in compliance and will comply with all policies of Misonix.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A stockholder is not entitled to have its nominees included in Misonix&#8217;s proxy statement solely as a result of such stockholder&#8217;s compliance with the foregoing provisions. If the nominating stockholder does not appear at the annual meeting to present its nominee in person, the nomination will be disregarded.</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">355 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap; width: 51%;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); width: 47%;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stockholder Proposals</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Business may be properly brought before an annual meeting by any stockholder present in person who (A)(1) is a stockholder of record both at the time of giving notice and at the time of the meeting, (2)&#160;is entitled to vote at the meeting, and (3)&#160;complies with the notice requirements set forth in the Bioventus bylaws; or (B)&#160;properly made such proposal in accordance with rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14a-8</div> under the Exchange Act, as amended, and the rules and regulations thereunder.</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To be timely, a stockholder&#8217;s notice must generally be delivered to Bioventus&#8217; Secretary no less than 90 days and no more than 120 days prior to the anniversary of the date of immediately precedent annual meeting of stockholders.</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: top; width: 47%;">Business may be properly brought before an annual meeting by any Misonix stockholder so long as the individual or entity is a Misonix stockholder of record both at the time the written notice provided for in the Misonix bylaws is delivered and at the time of the meeting, provided such stockholder has also complied with all applicable requirements of Sections 10 and 12 of the Misonix bylaws. The Misonix stockholder must also be entitled to vote at the meeting and comply with the notice requirements set forth in the Misonix bylaws.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stockholder Action by Written Consent</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;">Any action required or permitted to be taken by the Bioventus stockholders at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of stock of Bioventus entitled to vote thereon were present and voted and delivered to Bioventus in accordance with the DGCL; provided, however, that no action by stockholders may be taken by written consent in lieu of a meeting of stockholders unless such written consent and the taking of the action specified therein have been previously approved by the affirmative vote of the majority of the Bioventus board.</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: top; width: 47%;">The Misonix charter provides that any action required or permitted to be taken by the Misonix stockholders may be taken either at a duly called annual or special meeting of stockholders or without a meeting by written consent.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Special Stockholder Meetings</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 51%;">Subject to the special rights of the holders of one or more series of preferred stock (if issued), special meetings of the stockholders may be called only by the chairperson of the Bioventus board, the Chief Executive Officer, the President, the Secretary or a majority of the total number of authorized directors. The only matters to be brought before a special meeting are those specified in the meeting notice. Stockholders are not permitted to propose business (other than the election of directors) to be brought before a special meeting of stockholders.</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: top; width: 47%;">Special meetings of Misonix stockholders may be called only by (i)&#160;a majority of the total number of directors that Misonix would have if there were no vacancies on the Misonix board or (ii)&#160;stockholders holding 50% of the voting power of the shares of Misonix stock generally entitled to vote generally in the election of directors.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">356 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Notice of Stockholder Meetings</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Unless otherwise provided, the notice of any meeting of stockholders shall be sent or otherwise given in accordance with the notice provisions of Bioventus&#8217;s bylaws not less than ten nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting), and, in the case of a special meeting, the purpose or purposes for which the meeting is called.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Unless otherwise provided, the notice of any meeting of stockholders shall be sent or otherwise given in accordance with the notice provisions of Misonix&#8217;s bylaws not less than ten nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjournment of Stockholder Meetings</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No notice need be given of any adjourned meeting if the place, date and time of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting, are announced at the meeting at which the adjournment is taken; provided that notice must be given to any stockholder entitled to vote at the adjourned meeting if the adjournment is longer than 30 days or if a new record date is fixed for the adjourned meeting.</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At any adjourned meeting, Bioventus may transact any business which might have been transacted at the original meeting.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">No notice need be given of any adjourned meeting if the place, date and time of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting, are announced at the meeting at which the adjournment is taken; provided that notice must be given to any stockholder entitled to vote at the adjourned meeting if the adjournment is longer than 30 days or if a new record date is fixed for the adjourned meeting.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Limitation of Personal Liability of Directors</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">The Bioventus charter provides that no Bioventus director will be personally liable to Bioventus or its stockholders for monetary damages for breach of his or her fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL as the same exists or hereafter may be amended.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The Misonix charter provides that, to the full extent permitted by the DGCL and other applicable law, no Misonix director shall be personally liable to Misonix or any of its stockholders for or with respect to any breach of a fiduciary duty or other act or omission as a director of Misonix.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification of Directors and Officers</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Bioventus shall indemnify and hold harmless, to the fullest extent permitted by the DGCL, any current or former director or officer who was or is made or is threatened to be made a party or is otherwise involved in</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Misonix shall indemnify and hold harmless, to the fullest extent permitted by the DGCL, any current or former director or officer who was or is made or is threatened to be made a party to or is otherwise</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">357 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification of Directors and Officers</div></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">any action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that the person was a director or officer of Bioventus or, while serving as a director or officer of Bioventus, is or was serving at the request of Bioventus as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> entity, against all liability and loss suffered and expenses (including attorneys&#8217; fees, judgments, fines ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred by such person in connection with any such proceeding.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">subject to or involved in any claim, demand, action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director or an officer of Misonix or is or was serving at the request of Misonix as a director or officer, of another company or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan, whether the basis of such proceeding is alleged action in an official capacity as a director or officer or in any other capacity while serving as a director, officer, employee or agent, against all expense, liability and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rights Upon Liquidation</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Pursuant to the Bioventus charter, after payment of the debts and other liabilities of Bioventus, and the distribution of all preferential amounts to be distributed to stockholders in the event of liquidation of Bioventus, holders of outstanding Bioventus class A common stock are entitled to receive all of Bioventus&#8217; remaining assets available for distribution ratably in proportion to the number of shares held by each stockholder.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Pursuant to the Misonix charter, the rights of any series of preferred stock of Misonix upon the voluntary or involuntary dissolution of, or upon any distribution of the assets of, Misonix, shall be determined by the Misonix board upon authorizing such shares.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stockholder Rights Plan</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">The DGCL does not include a statutory provision expressly validating stockholder rights plans. However, such plans have generally been upheld by the decisions of courts applying Delaware law. Bioventus currently has a stockholder rights plan in place.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The DGCL does not include a statutory provision expressly validating stockholder rights plans. However, such plans have generally been upheld by the decisions of courts applying Delaware law. Misonix does not currently has a stockholder rights plan in place.</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain Business Combinations</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Section&#160;203 of the DGCL generally prohibits a Delaware corporation from engaging in a business combination with an &#8220;interested stockholder&#8221; that acquires more than 15% but less than 85% of the corporation&#8217;s outstanding voting stock for three years following the time that person becomes an &#8220;interested stockholder&#8221; (generally defined as a holder who (i)&#160;together with its affiliates and associates, owns or (ii)&#160;is an affiliate or associate of the corporation and,</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Section&#160;203 of the DGCL generally prohibits a Delaware corporation from engaging in a business combination with an &#8220;interested stockholder&#8221; that acquires more than 15% but less than 85% of the corporation&#8217;s outstanding voting stock for three years following the time that person becomes an &#8220;interested stockholder&#8221; (generally defined as a holder who (i)&#160;together with its affiliates and associates, owns or (ii)&#160;is an affiliate or associate of</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">358 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain Business Combinations</div></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">together with that person&#8217;s affiliates and associates, has owned at any time within the previous three years, at least 15% of the corporation&#8217;s outstanding shares), unless prior to the date the person becomes an interested stockholder, the corporation&#8217;s board of directors approves either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder or the business combination is approved by the corporation&#8217;s board of directors and by the affirmative vote of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the corporation&#8217;s outstanding voting stock that is not owned by the interested stockholder at a meeting of stockholders (and not by written consent) or other specified exceptions are met. The DGCL allows a corporation&#8217;s certificate of incorporation to contain a provision expressly electing not to be governed by Section&#160;203, but the Bioventus charter has not opted out of Section&#160;203.</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the DGCL permits a Delaware corporation&#8217;s certificate of incorporation to provide for a greater vote for a merger, consolidation or sale of substantially all the assets of a corporation than the vote described above, the Bioventus charter does not require a greater vote.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the corporation and, together with that person&#8217;s affiliates and associates, has owned at any time within the previous three years, at least 15% of the corporation&#8217;s outstanding shares), unless prior to the date the person becomes an interested stockholder, the corporation&#8217;s board of directors approves either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder or the business combination is approved by the corporation&#8217;s board of directors and by the affirmative vote of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of the corporation&#8217;s outstanding voting stock that is not owned by the interested stockholder at a meeting of stockholders (and not by written consent) or other specified exceptions are met. The DGCL allows a corporation&#8217;s certificate of incorporation to contain a provision expressly electing not to be governed by Section&#160;203, but the Misonix charter has not opted out of Section&#160;203.</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the DGCL permits a Delaware corporation&#8217;s certificate of incorporation to provide for a greater vote for a merger, consolidation or sale of substantially all the assets of a corporation than the vote described above, the Misonix charter does not require a greater vote.</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Forum</div></div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">The Bioventus charter provides that, unless Bioventus consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is, to the fullest extent permitted by law, the sole and exclusive forum for the following types of actions or proceedings: (i)&#160;any derivative action, suit, or proceeding brought on behalf of Bioventus; (ii)&#160;any action, suit, or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former Bioventus director, officer, other employee or stockholder to Bioventus or its stockholders; (iii)&#160;any action, suit, or proceeding asserting a claim arising pursuant to any provision of the DGCL, the Bioventus charter or the Bioventus bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine. The Bioventus bylaws also provide that, unless Bioventus consents in writing to the selection of an alternate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">The Misonix charter provide that, unless Misonix consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (a)&#160;any derivative action or proceeding brought on behalf of Misonix; (b)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee of Misonix to Misonix or the Misonix&#8217;s stockholders; (c)&#160;any action or proceeding asserting a claim against Misonix or any current or former director or officer or other employee of Misonix arising out of or pursuant to any provision of the DGCL, the Misonix charter or Misonix bylaws (including any right, obligation, or remedy thereunder); (d) any action or proceeding to interpret, apply, enforce or determine the validity of the Misonix charter or Misonix bylaws (including any right, obligation, or remedy thereunder); (e) any</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">359 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Forum</div></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">forum, the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Nothing in the Bioventus charter or the Bioventus bylaws would preclude stockholders that assert claims under the Exchange Act from bringing such claims in federal court to the extent the Exchange Act confers exclusive federal jurisdiction over such claims, subject to applicable law.</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (f)&#160;any action asserting a claim against Misonix or any director or officer or other employee of Misonix governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. Nothing in the Misonix charter would preclude stockholders that assert claims under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">360 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_30" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">APPRAISAL RIGHTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If the mergers are completed and you are the holder of one or more shares of Misonix common stock, you do not vote in favor of the Misonix merger proposal, you properly demand appraisal of your shares of Misonix common stock, you do not withdraw such demand or waive or lose your right to appraisal and otherwise comply with the requirements for perfecting and preserving your appraisal rights under Section&#160;262 of the DGCL, you will be entitled to appraisal rights under Delaware law and to have your shares appraised by the Delaware Court of Chancery and receive the &#8220;fair value&#8221; in cash of such shares (exclusive of any element of value arising from the accomplishment or expectation of the mergers) as of completion of the mergers in place of the merger consideration, as determined by the Delaware Court of Chancery. Any such Misonix stockholder awarded &#8220;fair value&#8221; for their shares by the court would receive payment of that fair value in cash, together with interest, if any, in lieu of the right to receive the merger consideration. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Failure to strictly comply with the procedures specified in Section</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;262 of the DGCL in a timely and proper manner will result in the loss of your appraisal rights under the DGCL.</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only a holder of record of Misonix common stock issued and outstanding at the time a demand for appraisal is made may assert appraisal rights for the shares of stock registered in that holder&#8217;s name. A person having a beneficial interest in shares of Misonix common stock held of record in the name of another person, such as your bank, broker or other nominee, must act promptly to cause the record holder to follow the steps summarized in this joint proxy statement/prospectus in a timely manner to perfect appraisal rights. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following discussion is not intended to be a full summary of the law pertaining to appraisal rights under the DGCL and is qualified in its entirety by the full text of Section&#160;262 of the DGCL that is attached to this joint proxy statement/prospectus as Annex D. All references in Section&#160;262 of the DGCL to a &#8220;stockholder&#8221; are to the record holder of the shares of Misonix common stock. The following discussion does not constitute any legal or other advice, nor does it constitute a recommendation that you exercise your rights to seek appraisal under Section&#160;262 of the DGCL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under Section&#160;262 of the DGCL, when a merger is submitted for approval at a meeting of stockholders as in the case of the Misonix merger proposal, the constituent corporation, in this case Misonix, not less than 20 days prior to the meeting, must notify each of its stockholders who was a stockholder on the record date for notice of such meeting and who is entitled to exercise appraisal rights, that appraisal rights are available and include in the notice a copy of Section&#160;262 of the DGCL. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THIS PROXY STATEMENT/PROSPECTUS CONSTITUTES THE NOTICE TO THE MISONIX STOCKHOLDERS OF THE AVAILABILITY OF APPRAISAL RIGHTS IN CONNECTION WITH THE MERGERS, AND THE COPY OF THE FULL TEXT OF SECTION 262 OF THE DGCL IS ATTACHED TO THIS PROXY STATEMENT/PROSPECTUS AS </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ANNEX D</div></div></div>. A holder of Misonix common stock who wishes to exercise appraisal rights or who wishes to preserve the right to do so should review the following discussion and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annex D</div> carefully and should consult with their legal advisor. Failure to strictly comply with the procedures of Section&#160;262 of the DGCL in a timely and proper manner will result in the loss of appraisal rights. A stockholder who loses their appraisal rights will be entitled to receive the Misonix merger consideration. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">How to Exercise and Perfect Your Appraisal Rights. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix stockholders wishing to exercise the rights to seek an appraisal of their shares must do ALL of the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">you must not vote in favor of the Misonix merger proposal. Because a proxy that is signed and submitted but does not otherwise contain voting instructions will, unless revoked, be voted in favor of Misonix merger proposal, if you vote by proxy and wish to exercise your appraisal rights, you must provide instructions in any such proxy to vote against the Misonix merger proposal or abstain from voting your shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">361 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">you must deliver to Misonix a written demand for appraisal of your shares before the vote on the Misonix merger proposal at the Misonix special meeting. This written demand for appraisal must be in addition to any proxy or vote abstaining from or voting against the Misonix merger agreement proposal. All demands for appraisal must be made by, or on behalf of, the record holder of shares, fully and correctly, as the record holder&#8217;s name appears, with respect to shares evidenced by certificates, on your stock certificate, or, with respect to shares held in &#8220;street name&#8221; through a bank, brokerage firm or other nominee, on the stock ledger. Your written demand must reasonably inform Misonix of your identity and your intention to demand appraisal of your shares of common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">you must hold the shares on the date of making the demand and must continuously hold such shares from the date of making the demand through the effective time. You will lose your appraisal rights if you transfer the shares for which you are seeking appraisal before the effective time; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">you or the Surviving Company must file a petition in the Delaware Court of Chancery requesting a determination of the fair value of the shares of Misonix common stock within 120 days after the effective time. The Surviving Company is under no obligation to file any such petition in the Delaware Court of Chancery and has no intention of doing so. Accordingly, it is the obligation of the Misonix stockholders to initiate all necessary action to perfect their appraisal rights in respect of shares of Misonix common stock within the time prescribed in Section&#160;262 of the DGCL. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you fail to comply with any of these conditions and the mergers are completed, you will be entitled to receive the merger consideration for your shares of Misonix common stock as provided for in the merger agreement, but you will have no appraisal rights with respect to your shares of Misonix common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Voting, in person or by proxy, against, abstaining from voting on or failing to vote on the Misonix merger proposal will not constitute a written demand for appraisal as required by Section&#160;262 of the DGCL. The written demand for appraisal must be in addition to and separate from any proxy or vote. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A demand for appraisal must be executed by or on behalf of the stockholder of record, fully and correctly, as the stockholder&#8217;s name appears on the stock certificates (or in the stock ledger). The demand for appraisal must reasonably inform Misonix of the identity of the stockholder and that the stockholder intends to demand appraisal of their Misonix common stock. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial owners who do not also hold their shares of Misonix common stock of record may not directly make appraisal demands to Misonix. The beneficial holder must, in such cases, have the owner of record, such as a bank, brokerage firm or other nominee, submit the required demand in respect of those shares of common stock. </div></div>A record owner, such as a bank, brokerage firm or other nominee, who holds shares of Misonix common stock as a nominee for others, may exercise his, her or its right of appraisal with respect to the shares of Misonix common stock held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares of Misonix common stock as to which appraisal is sought. Where no number of shares of Misonix common stock is expressly mentioned, the demand will be presumed to cover all shares of Misonix common stock held in the name of the record owner. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IF YOU HOLD YOUR SHARES IN BANK OR BROKERAGE ACCOUNTS OR OTHER NOMINEE FORMS, AND YOU WISH TO EXERCISE APPRAISAL RIGHTS, YOU SHOULD CONSULT WITH YOUR BANK, BROKERAGE FIRM OR OTHER NOMINEE, AS APPLICABLE, TO DETERMINE THE APPROPRIATE PROCEDURES FOR THE BANK, BROKERAGE FIRM OR OTHER NOMINEE TO MAKE A DEMAND FOR APPRAISAL OF THOSE SHARES. IF YOU HAVE A BENEFICIAL INTEREST IN SHARES HELD OF RECORD IN THE NAME OF ANOTHER PERSON, SUCH AS A BANK, BROKERAGE FIRM OR OTHER NOMINEE, YOU MUST ACT PROMPTLY TO CAUSE THE RECORD HOLDER TO FOLLOW PROPERLY AND IN A TIMELY MANNER THE STEPS NECESSARY TO PERFECT YOUR APPRAISAL RIGHTS. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">362 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you own shares of Misonix common stock jointly with one or more other persons, as in a joint tenancy or tenancy in common, demand for appraisal must be executed by or on behalf of you and all other joint owners. An authorized agent, including an agent for two or more joint owners, may execute the demand for appraisal on behalf of a stockholder of record; however, the agent must identify the record owner and expressly disclose the fact that, in exercising the demand, such person is acting as agent for the record owner. If you hold shares of Misonix common stock through a broker who in turn holds the shares through a central securities depository nominee such as Cede&#160;&amp; Co., a demand for appraisal of such shares must be made by or on behalf of the depository nominee and must identify the depository nominee as record holder. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you elect to exercise appraisal rights under Section&#160;262 of the DGCL, you must mail or deliver a written demand to: </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1938 New Highway, Farmingdale, </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, New York 11735 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Secretary </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bioventus&#8217; Actions after Completion of the Mergers. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Misonix merger is completed, the Surviving Company will give written notice that the mergers have become effective within 10 days after the effective time to you if you did not vote in favor of the Misonix merger proposal and you made a written demand for appraisal of any of your shares in accordance with Section&#160;262 of the DGCL. At any time within 60 days after the effective time, if you have demanded an appraisal but have not commenced an appraisal proceeding or joined such a proceeding as a named party, you have the right to withdraw the demand and to accept the merger consideration that was payable in respect of shares for which no election to receive cash or stock was made pursuant to the terms of the merger agreement for your shares of Misonix common stock for which you have made a written demand for appraisal. Any attempt to withdraw a demand made more than 60 days after the effective time will require the written approval of the Surviving Company. Within 120 days after the effective time, but not later, either you, provided you have complied with the requirements of Section&#160;262 of the DGCL, or the Surviving Company may commence an appraisal proceeding by filing a petition in the Delaware Court of Chancery, with a copy served on the Surviving Company in the case of a petition filed by you, demanding a determination of the fair value of the shares of Misonix common stock held by all stockholders entitled to appraisal. The Surviving Company is under no obligation to file an appraisal petition and has no intention of doing so in the event there are stockholders entitled to appraisal. Accordingly, if you desire to have any of your shares appraised, it is your obligation to initiate any petitions necessary for the perfection of their appraisal rights within the time period and in the manner prescribed in Section&#160;262 of the DGCL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you have not commenced an appraisal proceeding or joined such a proceeding as a named party you may withdraw a demand for appraisal and accept the merger consideration by delivering a written withdrawal of the demand for appraisal to the Surviving Company, except that any attempt to withdraw made more than 60 days after the effective time will require written approval of the Surviving Company, and no appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the Delaware Court of Chancery. Such approval may be conditioned on the terms the Delaware Court of Chancery deems just, provided, however, that this provision will not affect the right of any stockholder who has not commenced an appraisal proceeding or joined such proceeding as a named party to withdraw such stockholder&#8217;s demand for appraisal and to accept the terms offered in the mergers within 60 days after the effective time. If the Surviving Company does not approve your request to withdraw a demand for appraisal when the approval is required or, except if you withdraw your right to appraisal in accordance with the proviso in the immediately preceding sentence, if the Delaware Court of Chancery does not approve the dismissal of an appraisal proceeding, you would be entitled to receive only the appraised value determined in any such appraisal proceeding. This value </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">363 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">could be greater than, less than or the same as the value of the merger consideration. If you fail to perfect, successfully withdraw or otherwise waive or lose your right to appraisal, your shares will be converted into the right to receive the merger consideration, without interest thereon, less any withholding taxes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Within 120 days after the effective time, provided you have complied with the provisions of Section&#160;262 of the DGCL, you will be entitled to receive from the Surviving Company, upon written request, a statement setting forth the aggregate number of shares not voted in favor of the Misonix merger proposal and with respect to which Misonix has received demands for appraisal, and the aggregate number of holders of those shares. The Surviving Company must mail this statement to you within the later of 10 days of receipt of the request or 10 days after expiration of the period for delivery of demands for appraisal. If you are the beneficial owner of shares of stock held in a voting trust or by a nominee on your behalf you may, in your own name, file an appraisal petition or request from the Surviving Company the statement described in this paragraph. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a petition for appraisal is duly filed by you or another holder of Misonix common stock who has properly exercised his or her appraisal rights in accordance with the provisions of Section&#160;262 of the DGCL, you or such other holder (as applicable) must deliver a copy of the petition to the Surviving Company and the Surviving Company will then be obligated, within 20 days after receiving service of a copy of the petition, to provide the Register in Chancery with a duly verified list containing the names and addresses of all holders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the Surviving Company. Upon the filing of any such petition, the Delaware Court of Chancery may order the Register in Chancery to give notice of the time and place fixed for the hearing on the petition by registered or certified mail to the Surviving Company and to the stockholders shown on such duly verified list at the addresses therein stated. Such notice will also be published at least one week before the day of the hearing in a newspaper of general circulation published in the City of Wilmington, Delaware, or in another publication determined by the Delaware Court of Chancery. The costs of these notices are borne by the Surviving Company. The Delaware Court of Chancery is empowered to conduct a hearing upon the petition to determine which stockholders are entitled to appraisal rights and may require the stockholders demanding appraisal who hold certificated shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings and the Delaware Court of Chancery may dismiss any stockholder who fails to comply with this direction from the proceedings. If immediately before a transaction such as the mergers the shares of the class or series of stock of the constituent corporation as to which appraisal rights are available were listed on a national securities exchange, the Delaware Court of Chancery shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger for such total number of shares exceeds $1&#160;million or (3)&#160;the merger was approved pursuant to Section&#160;253 or 267 of the DGCL. Misonix common stock is listed on the Nasdaq Global Select Market and therefore this provision will be applicable in respect thereof. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Where proceedings are not dismissed or the demand for appraisal is not successfully withdrawn, the appraisal proceeding will be conducted as to the shares of Misonix common stock owned by such stockholders, in accordance with the rules of the Delaware Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding, the Delaware Court of Chancery will determine the fair value of the shares of Misonix common stock at the effective time held by dissenting stockholders, exclusive of any element of value arising from the accomplishment or expectation of the Misonix merger, together with interest, if any, to be paid upon the amount determined to be the fair value. Unless the Delaware Court of Chancery in its discretion determines otherwise for good cause shown, and except as otherwise provided in Section&#160;262 of the DGCL, interest from the effective time through the date of payment of the judgment will be compounded quarterly and will accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective time and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the Surviving Company may pay to each Misonix stockholder entitled to appraisal an amount in cash, in which case interest shall accrue after such payment only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Delaware Court of Chancery, and (2)&#160;interest </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">364 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">theretofore accrued, unless paid at that time. Upon application by the Surviving Company or by any holder of Misonix common stock entitled to participate in the appraisal proceeding, the Delaware Court of Chancery may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an appraisal. Any Misonix stockholder whose name appears on the verified list and who has submitted such stockholder&#8217;s stock certificates, if any, to the Register in Chancery, if such is required, may participate fully in all proceedings until it is finally determined that such stockholder is not entitled to appraisal rights under Section&#160;262 of the DGCL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In determining the fair value, the Delaware Court of Chancery is required to take into account all relevant factors. In <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Weinberger v. UOP, Inc.</div></div>, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered and that &#8220;[f]air price obviously requires consideration of all relevant factors involving the value of a company.&#8221; The Delaware Supreme Court has stated that, in making this determination of fair value, the court must consider market value, asset value, dividends, earnings prospects, the nature of the enterprise and any other factors which could be ascertained as of the date of the merger which throw any light on future prospects of the merged corporation. Section&#160;262 of the DGCL provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cede</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;&amp; Co. v. Technicolor, Inc.</div></div>, the Delaware Supreme Court stated that such exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Weinberger</div></div>, the Delaware Supreme Court construed Section&#160;262 of the DGCL to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221; In addition, Delaware courts have decided that the statutory appraisal remedy, depending on factual circumstances, may or may not be a dissenter&#8217;s exclusive remedy. An opinion of an investment banking firm as to the fairness from a financial point of view of the consideration payable in a merger is not an opinion as to, and does not in any manner address, fair value under Section&#160;262 of the DGCL. You should be aware that the fair value of their shares as determined under Section&#160;262 of the DGCL could be greater than, the same as, or less than the value of the merger consideration. We do not anticipate offering more than the merger consideration to any stockholder exercising appraisal rights and reserve the right to assert, in any appraisal proceeding, that, for purposes of Section&#160;262 of the DGCL, the &#8220;fair value&#8221; of a share of Misonix common stock is less than the merger consideration. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a petition for appraisal is not timely filed, then you will lose the right to an appraisal, and will instead receive the merger consideration that was payable in respect of shares for which no election to receive cash or stock was made pursuant to the terms of described in the merger agreement, without interest thereon, less any withholding taxes, upon following the applicable exchange procedures described in the merger agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Delaware Court of Chancery may determine the costs of the appraisal proceeding and may allocate those costs to the parties as the Delaware Court of Chancery determines to be equitable under the circumstances. However, costs do not include attorneys and expert witness fees. Each dissenting stockholder is responsible for its own attorneys and expert witnesses expenses, although, upon application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including reasonable attorneys&#8217; fees and the fees and expenses of experts utilized in the appraisal proceeding, to be charged pro rata against the value of all shares entitled to appraisal. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you have duly demanded an appraisal in compliance with Section&#160;262 of the DGCL you may not, after the effective time, vote the shares of Misonix common stock for any purpose or receive any dividends or other distributions on those shares, except dividends or other distributions payable to holders of record of Misonix shares as of a record date which is prior to the effective time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to follow the steps required by Section&#160;262 of the DGCL for perfecting appraisal rights will result in the loss of appraisal rights. In that event, you will be entitled to receive the merger consideration for your shares in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">365 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accordance with the merger agreement. In view of the complexity of the provisions of Section&#160;262 of the DGCL, if you are a Misonix stockholder and are considering exercising your appraisal rights under the DGCL, you should consult your own legal advisor. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE PROCESS OF DEMANDING AND EXERCISING APPRAISAL RIGHTS REQUIRES STRICT COMPLIANCE WITH TECHNICAL PREREQUISITES. IF YOU WISH TO EXERCISE YOUR APPRAISAL RIGHTS, YOU SHOULD CONSULT WITH YOUR OWN LEGAL COUNSEL IN CONNECTION WITH COMPLIANCE UNDER SECTION 262 OF THE DGCL. TO THE EXTENT THERE ARE ANY INCONSISTENCIES BETWEEN THE FOREGOING SUMMARY AND SECTION 262 OF THE DGCL, THE DGCL WILL GOVERN. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">366 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_31" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LEGAL MATTERS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The legality of the shares of Bioventus class A common stock offered hereby will be passed upon for Bioventus by Latham&#160;&amp; Watkins LLP. Certain U.S. federal income tax consequences relating to the first merger and second merger will be passed upon for Misonix by Jones Day. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">367 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_32" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXPERTS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statement of Bioventus Inc. as of December&#160;31, 2019 and December&#160;31, 2020 and the consolidated financial statements of Bioventus LLC as of and for the years ended December&#160;31, 2019 and December&#160;31, 2020 included in this joint proxy statement/prospectus and elsewhere in the registration statement have been so included in reliance upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of such firm as experts in accounting and auditing. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements of Bioventus LLC for the year end December&#160;31, 2018 included in this joint proxy statement/prospectus have been so included in reliance on the report (which contains an emphasis of matter paragraph relating to Bioventus LLC&#8217;s identification of noncompliance with certain U.S. Federal statutes and regulations to which Bioventus LLC is subject and the Bioventus LLC&#8217;s voluntary self-disclosure to the U.S. Department of Health and Human Services Office of Inspector General. As a result of the noncompliance, Bioventus LLC may be subject to civil monetary penalties, as well as repayment obligations related to previously reimbursed claims and fines as described in Notes 2 and 12 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements of Misonix, Inc., and the related financial statement schedules, incorporated in this joint proxy statement/prospectus by reference from Misonix, Inc.&#8217;s Annual Report on Form 10-K have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such financial statements and financial statement schedules have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">368 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div> <div id="toc180330_33" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CERTAIN BENEFICIAL OWNERS OF BIOVENTUS COMMON STOCK</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information as to the beneficial ownership of Bioventus class A common stock and Bioventus class B common stock, and of September&#160;1, 2021 (except as noted in the footnotes below), the latest practicable date prior to the date of this joint proxy statement/prospectus, for: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each person, or group of affiliated persons, known by Bioventus to beneficially own more than 5% of Bioventus class A common stock or Bioventus class B common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each named executive officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of Bioventus&#8217; directors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all executive officers and directors as a group. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As described in &#8220;Description of Bioventus&#8217; Business&#8212;Bioventus LLC Agreement,&#8221; the continuing LLC owner is entitled to have its LLC interests (as defined below) redeemed for Bioventus class A common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, or, if Bioventus and the continuing LLC owner agree, a cash payment equal to the market value of the applicable number of shares of Bioventus class A common stock. In addition, at Bioventus&#8217; election, Bioventus may effect a direct exchange of such Bioventus class A common stock or such cash (if mutually agreed) for such LLC interests in lieu of such a redemption. In connection with its IPO, Bioventus issued to the continuing LLC owner one share of Bioventus class B common stock for each LLC interest it owns. As a result, the number of shares of Bioventus class B common stock listed in the table below correlates to the number of LLC interests the continuing LLC owner owns. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC and includes voting or investment power with respect to securities. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options, or other rights, including the redemption right described above, held by such person that are currently exercisable or will become exercisable within 60 days of March&#160;22, 2021, are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each of the individuals and entities named below is c/o Bioventus Inc., 4721 Emperor Boulevard, Suite 100, Durham, NC 27703. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares of Class&#160;A<br/>Common Stock<br/>Beneficially Owned</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares of Class&#160;B<br/>Common Stock<br/>Beneficially Owned</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Combined<br/>Voting&#160;Power<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of Beneficial Owner</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5% Stockholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EW Healthcare Partners <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,021,324</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Smith&#160;&amp; Nephew <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,229,991</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,786,737</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Spindletop Healthcare Capital L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,906,395</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ampersand Capital<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,255,332</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Pantheon Global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Opportunities Fund L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,821,283</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alta Partners VIII, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,604,264</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Integrated Core Strategies (US) LLC<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,432,581</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">369 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares of Class&#160;A<br/>Common Stock<br/>Beneficially Owned</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares of Class&#160;B<br/>Common Stock<br/>Beneficially Owned</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Combined<br/>Voting&#160;Power<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of Beneficial Owner</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Name Executive Officers and Directors</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kenneth M. Reali</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gregory O. Anglum</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John E. Nosenzo</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anthony D&#8217;Adamio</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alessandra Pavesio</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">William A. Hawkins</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Philip G. Cowdy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guido J. Neels</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guy P. Nohra</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David J. Parker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Martin P. Sutter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Susan M. Stalnecker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mary Kay Ladone</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All directors and executive officers as a group (13&#160;persons)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents beneficial ownership of less than 1%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the voting power of each owner based on the voting power held through both the owner&#8217;s Bioventus class A common stock and Bioventus class B common stock. Represents percentage of voting power of the Bioventus class A common stock and Bioventus class B common stock voting together as a single class. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 12,096,702 shares held by EW Healthcare Partners Acquisition Fund, L.P., which Bioventus refers to as the &#8220;Essex Stockholder,&#8221; and 924,622 shares held by White Pine Medical, LLC, a subsidiary of the Essex Stockholder, which Bioventus refers to as &#8220;White Pine.&#8221; EW Healthcare Partners Acquisition Fund GP, L.P., a Delaware limited partnership, is the general partner of the Essex Stockholder and is referred to as the &#8220;Partnership,&#8221; and EW Healthcare Partners Acquisition Fund UGP, LLC, a Delaware limited liability company, is the general partner of the Partnership and is referred to as the &#8220;General Partner.&#8221; Martin P. Sutter, Petri Vainio, Ronald W. Eastman, and Scott Barry are the managers of the General Partner, and each is referred to as a &#8220;Manager&#8221; and collectively as the &#8220;Managers.&#8221; The Partnership is deemed to have sole voting and dispositive power with respect to the shares held by the Essex Stockholder and White Pine. The Managers are deemed to have shared voting and dispositive power with respect to the shares held by the Essex Stockholder and White Pine by unanimous consent and through the Partnership. Each Manager disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The address of the Essex Stockholder and White Pine is 21 Waterway Avenue, Suite 225, The Woodlands, Texas 77380. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the shares of Bioventus class A common stock held by Smith &amp; Nephew USD Limited, and the shares of Bioventus class B common stock held by Smith&#160;&amp; Nephew, Inc., a wholly owned indirect U.S. subsidiary of Smith&#160;&amp; Nephew plc. The address of Smith&#160;&amp; Nephew (Europe) B.V. is Bloemlaan 2, 2132 NP Hoofddorp, Netherlands. The address of Smith&#160;&amp; Nephew, Inc. is 7135 Goodlett Farms, Cordova, Tennessee 38106. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents shares held by Spindletop Healthcare Capital L.P. Evan Melrose, MD is the Manager of the General Partner of the General Partner of Spindletop Healthcare Capital L.P. and may be deemed to have shared voting and dispositive power with respect to the shares held by Spindletop Healthcare Capital L.P. The address of Spindletop Healthcare Capital L.P. is 3571 Far West Blvd., PMB #108, Austin, Texas 78731. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents shares held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AMP-CF</div> Holdings, LLC, which Bioventus refers to as the &#8220;Ampersand Capital Stockholder.&#8221; Herbert H. Hooper, the Managing Member of the General Partner of the General Partner of each of the members and managers of the Ampersand Capital Stockholder, may be deemed to have voting and dispositive power with respect to shares held by the Ampersand Capital Stockholder. The address of the Ampersand Capital Stockholder is in care of Ampersand Capital Partners, 55 William Street, Suite 240, Wellesley, Massachusetts 02481. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">370 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents shares held by Pantheon Global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Opportunities Fund L.P. David Braman, Susan Long McAndrews and Lily Wong are directors of Pantheon Global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Opportunities GP Limited, the general partner of Pantheon Global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Opportunities Fund, L.P. and make the investment and voting decisions with respect to shares held by of Pantheon Global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Opportunities Fund, L.P. The address of Pantheon Global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Opportunities Fund L.P. is 600&#160;Montgomery Street, 23rd Floor, San Francisco, CA 94111. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents shares held by Alta Partners VIII, L.P. Alta Partners Management VIII, LLC is the general partner of Alta Partners VIII, L.P. Guy Nohra, Daniel Janney and Farah Champsi are managing directors of Alta Partners Management VIII, LLC and exercise shared voting and investment powers with respect to the shares owned by Alta Partners VIII, L.P. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of their proportionate pecuniary interest therein, if any. The principal business address of Alta Partners VIII, L.P. is One Embarcadero Center, 37th Floor San Francisco, CA&#160;94111. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Schedule 13G filed with the SEC by Integrated Core Strategies (US), LLC (Integrated Core Strategies) et al, reporting ownership of these shares of Bioventus class A common stock as of March&#160;16, 2021. As reported in said Schedule 13G, Integrated Core Strategies reports shared voting and dispositive power with respect to 2,033,399 shares of Bioventus class A common stock, ICS Opportunities II LLC (ICS Opportunities II) reports shared voting and dispositive power with respect to 75,287 shares of Bioventus class A common stock, ICS Opportunities, Ltd. (ICS Opportunities) reports shared voting and dispositive power with respect to 310,116 shares of Bioventus class A common stock, Integrated Assets, Ltd. (Integrated Assets) reports shared voting and dispositive power with respect to 13,779 shares of Bioventus class A common stock, Millennium International Management LP (Millennium International Management) reports shared voting and dispositive power with respect to 399,182 shares of Bioventus class A common stock, Millennium Management LLC (Millennium Management) reports shared voting and dispositive power with respect to 2,432,581 shares of Bioventus class A common stock, Millennium Group Management LLC (Millennium Group Management) reports shared voting and dispositive power with respect to 2,432,581 shares of Bioventus class A common stock, and Israel A. Englander reports shared voting and dispositive power with respect to 2,432,581 shares of Bioventus class A common stock. Millennium International Management is the investment manager to ICS Opportunities II, ICS Opportunities and Integrated Assets (collective, the ICS Entities) and is deemed to have beneficial ownership of their respective securities. Millennium Management is the general partner of the managing member of Integrated Core Strategies and the general partner of the 100% owner of the ICS Funds is deemed to have beneficial ownership of the securities owned by each of Integrated Core Strategies and the ICS Entities (collectively, the Integrated Entities). Millennium Group Management is the managing member of Millennium Management and general partner of Millennium International Management and is deemed to have beneficial ownership of the securities owned by the Integrated Entities. The managing member of Millennium Group Management is a trust of which Mr.&#160;Englander, a United States citizen, currently serves as the sole voting trustee, and therefor Mr.&#160;Englander is deemed to have beneficial ownership of securities owned by the Integrated Entities. The address of Mr.&#160;Englander and each of the foregoing entities is 399 Park Avenue, New York, New York 10022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">371 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_34" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN BENEFICIAL OWNERS OF MISONIX COMMON STOCK </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To Misonix&#8217;s knowledge, the following table sets forth certain information regarding the beneficial ownership of Misonix common stock as of September&#160;1, 2021 (except as noted in the footnotes below), the latest practicable date prior to the date of this joint proxy statement/prospectus, by: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each named executive officer of Misonix; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each member of the Misonix board; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the members of the Misonix board and Misonix current executive officers as a group; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each person known by Misonix to beneficially own more than 5% of the outstanding shares of Misonix common stock. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix has determined beneficial ownership in accordance with the rules of the SEC. Except as noted in the footnotes below, Misonix believes, based on the information furnished to Misonix, that the persons and entities named in the tables below have sole voting and investment power with respect to all shares of Misonix common stock that they beneficially own. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 73%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Address <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficially</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Owned</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percent</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Of&#160;Class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stavros G. Vizirgianakis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,783,641</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1315 Capital</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,714,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SV Health Investors</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,714,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Robert S. Ludecker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">263,828</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joseph P. Dwyer</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159,531</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thomas M. Patton</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70,750</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michael Koby</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul LaViolette</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patrick J. Beyer</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All executive officers and Directors as a group (Eight&#160;people)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,705,784</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less than 1% </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as otherwise noted, the business address of each of the named individuals in this table is c/o Misonix, Inc., 1938 New Highway, Farmingdale, NY 11735. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes 124,563 shares which Mr.&#160;Vizirgianakis has the right to acquire upon exercise of stock options which are exercisable within 60 days. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes 252,328 shares which Mr.&#160;Ludecker has the right to acquire upon exercise of stock options which are exercisable within 60 days. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes 154,831 shares which Mr.&#160;Dwyer has the right to acquire upon exercise of stock options which are exercisable within 60 days. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes 63,750 shares which Mr.&#160;Patton has the right to acquire upon exercise of stock options which are exercisable within 60 days. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Does not reflect any securities owned by 1315 Capital. Mr.&#160;Koby is a member of 1315 Capital Management, LLC. Under the Amended and Restated Limited Liability Company Agreement of 1315 Capital Management, LLC, Mr.&#160;Koby is deemed to hold securities for the benefit of 1315 Capital who is deemed to have voting and dispositive power with respect the securities. Mr.&#160;Koby disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Does not reflect any securities owned by SV Health Investors. Mr.&#160;LaViolette is a member of SV Health Investors. Under the Limited Liability Company Agreement of SV Health Investors, Mr.&#160;LaViolette is </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">372 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">deemed to hold securities for the benefit of 1315 Capital who is deemed to have voting and dispositive power with respect the securities. Mr.&#160;LaViolette disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes 395,936 shares which such persons have the right to acquire upon exercise of stock options which are exercisable within 60 days. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">373 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_35" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STOCKHOLDER PROPOSALS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus will hold an annual meeting of stockholders in 2022, which is referred to as the &#8220;Bioventus 2022 annual meeting,&#8221; regardless of whether the merger has been completed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any stockholder proposals intended to be presented at the Bioventus 2022 annual meeting and considered for inclusion in Bioventus&#8217; proxy materials must have been received by Bioventus on or before January&#160;14, 2022. Such proposals must have been submitted in writing to: Bioventus Inc., Attn: Corporate Secretary, 4721 Emperor Boulevard, Suite 400, Durham, North Carolina 27703. Such proposals must also meet the other requirements and procedures prescribed by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14a-8</div> under the Exchange Act relating to stockholder proposals. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Bioventus bylaws, nominees for director submitted by stockholders must be received by Bioventus between January&#160;14, 2022 and February&#160;13, 2022. Such proposals must also meet the requirements set forth in the Bioventus bylaws. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix will hold an annual meeting of stockholders in 2021, which is referred to as the &#8220;Misonix 2021 annual meeting,&#8221; only if the mergers have not already been completed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any stockholder proposals intended to be presented at the Misonix 2021 annual meeting and considered for inclusion in Misonix&#8217;s proxy materials must have been received by Misonix no later than the close of business on January&#160;14, 2022. Such proposals must have been submitted in writing to: Misonix, Inc., Attn: Secretary, 1938 New Highway, Farmingdale, New York 11735. Such proposals must also meet the other requirements and procedures prescribed by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14a-8</div> under the Exchange Act relating to stockholder proposals. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our bylaws require that a proposal to be submitted by a stockholder for a vote of the Company&#8217;s stockholders at our annual meeting of stockholders, whether or not also submitted for inclusion in the Company&#8217;s proxy materials, must be preceded by adequate notice to the Secretary of the Company. To be adequate, the notice must set forth certain information specified in our bylaws about the stockholder and the proposal. Our bylaws are available in our SEC filings which can be accessed on our website at www.misonix.com under the &#8220;Investors Relations&#8221; tab and will be provided to any stockholder upon written request to Misonix, Inc., 1938 New Highway, Farmingdale, New York 11735, Attn: Secretary. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">374 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_36" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HOUSEHOLDING OF PROXY MATERIALS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC rules permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy statements and notices with respect to two or more stockholders sharing the same address by delivering a single proxy statement or a single notice addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; provides cost savings for companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus and Misonix have each previously adopted householding for stockholders of record. As a result, stockholders with the same address and last name may receive only one copy of this joint proxy statement/prospectus from Bioventus or Misonix, as applicable. Registered Bioventus or Misonix stockholders (those who hold shares directly in their name with Bioventus&#8217;s or Misonix&#8217;s transfer agent) may opt out of householding and receive a separate joint proxy statement/prospectus or other proxy materials by sending a written request to Bioventus or Misonix, as applicable, at the address below. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some brokers also household proxy materials, delivering a single proxy statement or notice to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement or notice, or if your household is receiving multiple copies of these documents and you wish to request that future deliveries be limited to a single copy, please notify your broker. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Requests for additional copies of this joint proxy statement/prospectus should be directed to, as applicable: Bioventus Inc., Attn: Corporate Secretary, tony.dadamio@bioventus.com, (919) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">474-6700;</div> or Misonix, Inc., Attn: Secretary, misonixproxy@misonix.com, (631) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">694-9555.</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">375 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_37" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WHERE YOU CAN FIND MORE INFORMATION </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus and Misonix file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including both Bioventus and Misonix, which you can access at www.sec.gov. In addition, you may obtain free copies of the documents Bioventus and Misonix file with the SEC, including the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> of which this joint proxy statement/prospectus forms a part, by going to Bioventus&#8217; and Misonix&#8217;s websites at www.bioventus.com and www.misonix.com, respectively. The websites of Bioventus and Misonix are provided as inactive textual references only. The information contained on or accessible through the websites of Bioventus and Misonix (other than the documents listed below that are incorporated by reference herein) does not constitute a part of this joint proxy statement/prospectus, and is not incorporated by reference herein. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Statements contained or incorporated by reference in this joint proxy statement/prospectus regarding the contents of any contract or other document are not necessarily complete, and each such statement is qualified in its entirety by reference to the full text of that contract or other document filed as an exhibit with the SEC. The SEC allows Misonix to &#8220;incorporate by reference&#8221; in this joint proxy statement/prospectus documents that Misonix files with the SEC, including certain information required to be included in the registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-4</div> of which this joint proxy statement/prospectus forms a part. This means that Misonix can disclose important information to you by referring you to those documents. The information incorporated by reference herein is considered to be a part of this joint proxy statement/prospectus, and later information Misonix file with the SEC will update and supersede that information. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Misonix incorporates by reference into this joint proxy statement/prospectus the information or documents listed below that Misonix has filed with the SEC (Commission File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;001-10986):</div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Misonix&#8217;s annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended June&#160;30, 2021, filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/880432/000149315221021878/form10-k.htm">September&#160;2, 2021</a>; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Misonix&#8217;s current reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</div> filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/880432/000119312521229212/d158299d8k.htm">July&#160;29, 2021</a> and <a href="http://www.sec.gov/Archives/edgar/data/880432/000149315221019555/form8-k.htm">August&#160;12, 2021</a>; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the description of Misonix common stock set forth in Misonix&#8217;s registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-A</div> (Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;1-10986)</div> filed with the SEC on January&#160;22, 1992 under Section&#160;12 of the Exchange Act and all amendments or reports filed by Misonix for the purpose of updating that description. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Misonix also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> and exhibits filed on such form that are related to such items unless such Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the date of the Misonix special meeting. Misonix will not, however, incorporate by reference in this joint proxy statement/prospectus any documents or portions thereof that are not deemed &#8220;filed&#8221; with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of Misonix&#8217;s current reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> unless, and except to the extent, specified in such current reports. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix hereby undertakes to provide without charge to each Misonix stockholder as of the record date, upon written or oral request of any such person, a copy of any and all of the information that has been or may be incorporated by reference in this joint proxy statement/prospectus. Requests for such copies should be directed to our secretary, at the following address or by calling the following telephone number: </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc. </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Secretary </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1938 New Highway </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, NY 11735 </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Telephone: (631) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">694-9555</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">376 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_38" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO BIOVENTUS INC. FINANCIAL STATEMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Explanatory Note: With respect to the following financial statements and notes to the financial statements, mentions of &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer to Bioventus Inc. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Page</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Financial Statements:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_1">Bioventus Inc.</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_2">Report of Independent Registered Public Accounting Firm</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_3">Balance Sheets as of December&#160;31, 2020 and 2019</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_4">Notes to Balance Sheets as of December&#160;31, 2020 and 2019</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_5">Bioventus LLC</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_6">Reports of Independent Registered Public Accounting Firms</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_7">Consolidated Statements of Operations and Comprehensive Income (Loss) for the Years Ended December&#160;31, 2020, 2019 and 2018</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_8">Consolidated Balance Sheets as of December&#160;31, 2020 and 2019</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_9">Consolidated Statements of Changes in Members&#8217; Equity for the Years Ended December&#160;31, 2020, 2019 and 2018</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_10">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2020, 2019 and 2018</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_11">Notes to the Audited Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_12">Unaudited Financial Statements:</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_13">Bioventus Inc.</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_14">Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income for the three and six months ended July&#160;3, 2021 and June&#160;27, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_15">Consolidated Condensed Balance Sheets as of July&#160;3, 2021 and December&#160;31, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_16">Consolidated Condensed Statements of Changes in Stockholders&#8217; and Members&#8217; Equity for the three and six months ended July&#160;3, 2021 and June&#160;27, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_17">Consolidated Condensed Statements of Cash Flows for the six months ended July&#160;3, 2021 and June&#160;27, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#findex180330_18">Notes to the Unaudited Condensed Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g33q08.jpg" style="width: 165px; height: 33px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 25%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 74%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GRANT THORNTON LLP</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td id="findex180330_2" style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">4140 ParkLake Ave., Suite 130</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Raleigh, NC 27612-3723</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">D +1 919 881 2700</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">F +1 919 881 2795</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors and Shareholders </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the financial statements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying balance sheets of Bioventus Inc. (a Delaware corporation) (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2019 and the related notes (collectively referred to as the &#8220;financial statement&#8221;). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, in conformity with accounting principles generally accepted in the United States of America. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for opinion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This financial statement is the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statement based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ GRANT THORNTON LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raleigh, North Carolina </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 25%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;26, 2021 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;;font-weight: bold;;font-size: .83em;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS INC. </div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="findex180330_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheets </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2020 and 2019 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 90%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:TotalAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:TotalAssets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:TotalLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:TotalLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:TotalStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:TotalStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></ix:nonFraction> par value - <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:TotalLiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:TotalLiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS INC. </div></div></div><div id="findex180330_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to balance sheets </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except share and per share amounts) </div></div></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. (the Company, we, us or our) was formed as a Delaware corporation on December&#160;22, 2015 for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (BV LLC). The notes to these financial statements should be read in conjunction with notes to BV LLC&#8217;s financial statements. As of December&#160;31, 2020, the Company had not engaged in any business activities except in connection with its formation. On February&#160;16, 2021, the Company closed an IPO of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,200,000</ix:nonFraction> shares of Class&#160;A common stock at a public offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.00</ix:nonFraction> per share, which includes <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction> shares issued pursuant to the underwriters&#8217; over-allotment option. The Company received $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">111,228</ix:nonFraction> in proceeds, net of underwriting discounts and commissions of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">8,372</ix:nonFraction>, which was used to purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.00</ix:nonFraction>. In addition to the underwriting discounts and commission the Company incurred offering expenses totaling $<ix:nonFraction name="bvs:SaleOfStockOfferingCosts" contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">4,310</ix:nonFraction>. Subsequent to the IPO and related transactions that occurred in connection with the IPO (the Transactions) as described in Note 4, the Company is the sole managing member of BV LLC and owns <ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" contextRef="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">72.2</ix:nonFraction>% of BV LLC. The Company has a majority economic interest, the sole voting interest in, and controls the management of BV LLC. As a result, subsequent to the IPO, the Company will consolidate the financial results of BV LLC and will report a non-controlling interest representing the <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn07_03_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">27.8</ix:nonFraction>% interest not held by the Company. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of significant accounting policies </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of accounting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The balance sheets have been prepared in accordance with accounting principles generally accepted in the United States of America. Separate statements of income, comprehensive income, changes in stockholder&#8217;s equity, and cash flows have not been presented in the financial statements as there has been no activity. </div></div></ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Stockholder&#8217;s equity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Corporation had <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction> outstanding shares at a nominal value as of December&#160;31, 2020. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_26389341"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Subsequent event </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and BV LLC completed the following Transactions regarding the IPO. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BV LLC amended and restated the Bioventus LLC Agreement, to, among other things, (i)&#160;provide for a new single class of common membership interests in BV LLC (LLC Interests), (ii)&#160;exchange all of the existing membership interests in BV LLC for new LLC Interests and (iii)&#160;appoint Bioventus Inc. as the sole managing member of BV LLC. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company amended and restated its certificate of incorporation to, among other things, provide for the (i)&#160;authorization of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000,000</ix:nonFraction> shares of Class&#160;A common stock with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction> per share; (ii)&#160;authorization of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction> shares of Class B common stock with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction> per share; (iii)&#160;authorization of <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn02_16_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> shares of undesignated preferred stock that may be issued from time to time by the Company&#8217;s Board of Directors (BOD) in one or more series; and (iv)&#160;establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389341" continuedAt="TextSelectionAppend_26389341_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;A and Class B common stock are entitled to <ix:nonFraction name="bvs:CommonStockNumberOfVotes" contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_Vote" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="bvs:CommonStockNumberOfVotes" contextRef="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_Vote" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction></ix:nonFraction>vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the <ix:nonFraction name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-to-one ratio between the number of LLC Interests held by the only member of BV LLC that remained a member (Continuing LLC Owner) and the number of shares of Class B common stock held by the Continuing LLC Owner. Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a <ix:nonFraction name="bvs:CancellationRatioRequiredStockToLLCInterestRatio" contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-for-one basis if the Company, at the election of a Continuing LLC Owner, redeem or exchange LLC Interests. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s amended and restated certificate of incorporation and the Bioventus LLC Agreement requires that the Company and BV LLC at all times maintain a <ix:nonFraction name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-to-one ratio between the number of shares of Class&#160;A common stock issued by the Company and the number of LLC Interests owned by the Company, as well as a <ix:nonFraction name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company acquired, by merger, <ix:nonFraction name="us-gaap:NumberOfBusinessesAcquired" contextRef="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_Entities" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten </ix:nonFraction>entities that were members of BV LLC (Former LLC Owners), for which the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> shares of Class&#160;A common stock as merger consideration (Merger). The only assets held by the Former LLC Owners were <ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" contextRef="PAsOn02_16_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> LLC Interests and a corresponding number of shares of Class B common stock. Upon consummation of the Merger, the Company canceled the <ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="P02_16_2021To02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> shares of Class B common stock and recognized the <span style="-sec-ix-hidden:hidden26390235">31,838.58</span>9 of LLC Interests at carrying value, as the Merger is considered to be a transaction between entities under common control. Following the Merger and IPO, the Company now holds <ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" contextRef="PAsOn08_10_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,038,589</ix:nonFraction> LLC Interests, representing a <ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" contextRef="P08_10_2021To08_10_2021_BioventusIncMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">72.2</ix:nonFraction>% ownership interest in BV LLC. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Receivable Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, the Company entered into a tax receivable agreement (TRA) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that Bioventus actually realizes as a result of (i)&#160;increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC and (ii)&#160;certain other tax benefits related to our making payments under the TRA. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, in connection with the IPO, the BV LLC Phantom Profits Interest Plan (Phantom Plan) terminated and the Company assumed the obligations of settling the vested awards. The awards will be settled <ix:nonNumeric name="bvs:ShareBasedPaymentAwardSettlementPeriod" contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durmonth">12</ix:nonNumeric> months following the Phantom Plan termination. Vested awardees whose BV LLC employment terminated prior to the IPO will have their awards settled in cash totaling $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,875</ix:nonFraction>. Vested awardees that were active BV LLC employees at the IPO will receive <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">798,422</ix:nonFraction> shares of Class&#160;A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, in connection with the IPO, the Company began operating <ix:nonFraction name="bvs:NumberOfEquityBasedCompensationPlans" contextRef="PAsOn02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_Plan" decimals="INF" scale="0" format="ixt-sec:numwordsen">two </ix:nonFraction>equity-based compensation plans. These are the Bioventus Inc. 2021 Incentive Award Plan (2021 Plan) and the Bioventus Inc. 2021 Employee Stock Purchase Plan (ESPP). </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389341_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2021 Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2021 Plan is designed to grant incentive awards to eligible employees and other service providers in order to attract, motivate and retain the talent for which the Company competes. The 2021 Plan provides for the grant of stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units (RSUs), other stock-based awards, and cash awards. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the IPO, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,592,476</ix:nonFraction> shares of Class&#160;A common stock were authorized for issuance. The number of shares available for issuance will be increased by an annual increase on January&#160;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (i)&#160;<ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" contextRef="PAsOn02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the IPO, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,561,500</ix:nonFraction> stock options were granted to certain employees with an exercise price of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.00</ix:nonFraction> per share and vest equally over <span style="-sec-ix-hidden:hidden26390211">two</span> or <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P02_01_2021To02_28_2021_MaximumMembersrtRangeAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> as indicated in each option agreement. Additionally, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">360,670</ix:nonFraction> RSUs to the directors and certain employees which vest equally over <span style="-sec-ix-hidden:hidden26390212">one</span> or <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P02_01_2021To02_28_2021_MaximumMembersrtRangeAxis_RestrictedStockUnitsAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> as indicated in each RSU agreement and entitles the recipient to the same number of shares of Class&#160;A common stock. <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P02_01_2021To02_28_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,670,306</ix:nonFraction> shares of Class&#160;A common stock remain available for issuance under the 2021 Plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ESPP </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ESPP allows for the Company to grant options to employees to purchase shares of the Company&#8217;s Class&#160;A common stock through payroll deductions of up to <ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" contextRef="PAsOn02_28_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>% of their eligible compensation as defined in the ESPP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the IPO, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn02_28_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">542,320</ix:nonFraction> shares of Class&#160;A common stock were authorized for issuance. The number of shares available for issuance will be increased by an annual increase on January&#160;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (i)&#160;<ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" contextRef="PAsOn02_28_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. There have been <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P03_22_2021To03_22_2021_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction>grants under the ESPP as of March&#160;22, 2021. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g33q08.jpg"/></div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 25%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 74%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 8pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">GRANT THORNTON LLP</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td id="findex180330_6" style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 8pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">4140 ParkLake Ave., Suite 130</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 8pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Raleigh, NC 27612-3723</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 8pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">D +1 919 881 2700</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 8pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">F +1 919 881 2795</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"></td></tr></table><div style="clear: both; max-height: 0pt; text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors and Shareholders </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the financial statements </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Bioventus LLC (a Delaware limited liability company) and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2019, the related consolidated statements of operations and comprehensive income (loss), changes in members&#8217; equity, and cash flows for the years then ended and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for opinion </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ GRANT THORNTON LLP </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2019. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raleigh, North Carolina </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 25%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;26, 2021 </div></div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Managers and Members of Bioventus LLC </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion on the Financial Statements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the consolidated statements of operations and comprehensive income (loss), of changes in members&#8217; equity and of cash flows of Bioventus LLC and its subsidiaries (the &#8220;Company&#8221;) for the year ended December&#160;31, 2018, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the results of operations and cash flows of the Company for the year ended December&#160;31, 2018 in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit of these consolidated financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emphasis of Matter </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Notes 2 and 12 to the consolidated financial statements, the Company has identified noncompliance with certain U.S. Federal statutes and regulations to which the Company is subject and made a voluntary self-disclosure to the U.S. Department of Health and Human Services Office of Inspector General. As a result of the noncompliance, the Company may be subject to civil monetary penalties, as well as repayment obligations related to previously reimbursed claims and fines. Management&#8217;s evaluation of the impact of these material contingencies is also discussed in Note 12. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ PricewaterhouseCoopers LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raleigh, North Carolina </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">August&#160;16, 2019, except for the effects of disclosing net loss per unit information discussed in Note 13 and the effects of discontinued operations discussed in Note 16 to the consolidated financial statements, as to which the date is October&#160;6, 2020 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We served as the Company&#8217;s auditor from 2012 to 2019. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;;font-weight: bold;;font-size: .83em;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS LLC </div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="findex180330_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statements of operations and comprehensive income (loss) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended December&#160;31, 2020, 2019 and 2018 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except unit and per unit data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">321,161</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">340,141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">319,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales (including depreciation and amortization of $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,169</ix:nonFraction>, $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,399</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,614</ix:nonFraction>, respectively)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">87,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90,935</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84,168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">233,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">249,206</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">235,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">193,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">198,475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,672</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,055</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on impairment of intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,751</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">226</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss attributable to noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss), net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in prior service cost and unrecognized (loss) gain for defined benefit plan adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in foreign currency translation adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">203</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations attributable to unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated and unpaid preferred distributions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,955</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income allocated to participating shareholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) from continuing operations attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,383</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,383</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17,988</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per unit attributable to common unit holders - basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average units used in computing basic and diluted net income (loss) per common unit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,900,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,900,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,900,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-8 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;;font-weight: bold;;font-size: .83em;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS LLC </div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="findex180330_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated balance sheets </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2020 and 2019 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,552</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,059</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">211,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">183,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,879</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">216,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,267</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments and other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,382</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">494,466</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">472,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and Members&#8217; Equity</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">52,827</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued equity-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">122,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173,378</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">187,965</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued equity-based compensation, less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,874</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,728</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">350,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">326,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (Note 12)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members&#8217; equity (preferred unit liquidation preference of $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">210,576</ix:nonFraction> and $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">204,443</ix:nonFraction> at December&#160;31, 2020 and 2019, respectively)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">144,539</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity attributable to unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">142,241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">142,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,919</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total members&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and members&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">494,466</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">472,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;;font-weight: bold;;font-size: .83em;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS LLC </div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="findex180330_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statements of changes in members&#8217; equity </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended December&#160;31, 2020, 2019 and 2018 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 43%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Members&#8217;<br/>Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Income&#160;(Loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/>Interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Members&#8217;<br/>Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2017</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">119,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">165,457</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MembersEquityDecreaseFromProfitInterestForfeiture" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MembersEquityDecreaseFromProfitInterestForfeiture" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to members</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromDistributionToMembers" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromDistributionToMembers" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined benefit plan adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">139,821</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,267</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromProfitInterestForfeiture" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromProfitInterestForfeiture" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to members</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromDistributionToMembers" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromDistributionToMembers" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined benefit plan adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2019To12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">465</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromProfitInterestForfeiture" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromProfitInterestForfeiture" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to members</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromDistributionToMembers" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromDistributionToMembers" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other equity compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MembersEquityDecreaseFromEquityForfeitures" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MembersEquityDecreaseFromEquityForfeitures" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt conversion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined benefit plan adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">144,539</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,919</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS LLC </div></div></div><div id="findex180330_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated statements of cash flows </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Years ended December&#160;31, 2020, 2019 and 2018 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss from discontinued operations</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on impairment of intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of contingent consideration in excess of amount established in purchase accounting</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,558</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for expected credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest plan, liability-classified and other equity awards compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of Equity Participation Rights unit</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ChangeInFairValueOfEquityParticipationRightsUnit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ChangeInFairValueOfEquityParticipationRightsUnit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">565</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ChangeInFairValueOfEquityParticipationRightsUnit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of interest rate swap</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt discount and capitalized loan fees, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,583</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on debt retirement and modification</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetRetirementObligationAccretionExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,941</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,427</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,256</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,646</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets and liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,882</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,545</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">52,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities of discontinued operations</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,713</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and acquisition of distribution rights</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:InvestmentAndAcquisitionOfDistributionRights" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:InvestmentAndAcquisitionOfDistributionRights" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:InvestmentAndAcquisitionOfDistributionRights" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of VIE</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AcquisitionOfVariableInterestEntity" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,093</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,342</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,672</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,912</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities from discontinued operations</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,912</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowing on revolver</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLongTermLinesOfCredit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment on revolver</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermLinesOfCredit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from the issuance of long-term debt, net of issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">198,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">199,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">317</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to members</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ProceedsFromMembers" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,886</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ProceedsFromMembers" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,137</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ProceedsFromMembers" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">29,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,951</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,256</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate changes on cash</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at the beginning of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at the end of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,944</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for interest</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,450</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of noncash investing and financing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities for distribution rights</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt conversion</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable for purchase of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">184</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued member distribution</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MemberDistributionsIncurredButNotYetPaid" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MemberDistributionsIncurredButNotYetPaid" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MemberDistributionsIncurredButNotYetPaid" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 9pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-11 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS LLC </div></div></div><div id="findex180330_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to consolidated financial statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except unit, share, per unit and per share data) </div></div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26388600"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization and basis of presentation of financial information&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus LLC and its subsidiaries (the Company, we, us or our), is a limited liability company formed under the laws of the state of Delaware on November&#160;23, 2011 and operates as a partnership. The Company commenced operations in May 2012 in Durham, North Carolina, USA, which is its headquarters. Bioventus is a global medical device company, conducting business in various countries, primarily in North America and Europe, with approximately <ix:nonFraction name="dei:EntityNumberOfEmployees" contextRef="PAsOn12_31_2020_BVLLCMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_employee" decimals="INF" scale="0" format="ixt:numdotdecimal">700</ix:nonFraction>&#160;employees. The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing processes. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus Inc. was formed as a Delaware corporation for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of the Company. Bioventus Inc. acquired, by merger, <ix:nonFraction name="us-gaap:NumberOfBusinessesAcquired" contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_BVLLCMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_Business" decimals="0" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> entities that were members of the Company (Former LLC Owners) and upon consummation of the merger, owned <ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> Common LLC Interests (as defined below). On February&#160;16, 2021, Bioventus Inc. (New LLC Owner) closed an IPO of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,200,000</ix:nonFraction> shares of Class&#160;A common stock at a public offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.00</ix:nonFraction> per share, which includes <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction> shares issued pursuant to the underwriters&#8217; over-allotment option. The New LLC Owner received $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">111,228</ix:nonFraction> in proceeds, net of underwriting discounts and commissions which was used to make a capital contribution to the Company in exchange for <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,200,000</ix:nonFraction> newly-issued membership interests (Common LLC Interests) from the Company at a price per interest equal to the IPO price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.00</ix:nonFraction>. Subsequent to the IPO and related transactions that occurred in connection with the IPO (Transactions), the New LLC Owner is the sole managing member of the Company. Following the completion of the IPO and Transactions, the New LLC Owner owns <ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" contextRef="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">72.2</ix:nonFraction>% of the Company. The New LLC Owner has a majority economic interest, the sole voting interest in, and controls the management of the Company. As a result, subsequent to the IPO, the New LLC Owner will consolidate the financial results of the Company and will report a non-controlling interest representing the interests owned by the only member of BV LLC that remained a member (Continuing LLC Owner). Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 17. Subsequent Events</div></div> for further details regarding the IPO and related transactions. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim periods </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January&#160;1 and ends on December&#160;31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December&#160;31. The 13-week quarterly periods ended on March&#160;28,&#160;June&#160;27 and September&#160;26 for the year ended December&#160;31, 2020. As a result, the fourth and first quarters may vary in length depending on the calendar year. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). The consolidated financial statements include the Company, its subsidiaries and investments in which the Company has control. Amounts pertaining to the non-controlling ownership interests held by third parties in the operating results and financial position of the Company&#8217;s controlled subsidiaries are reported as non-controlling interests. All intercompany balances and transactions have been eliminated in consolidation. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-12 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388600" continuedAt="TextSelectionAppend_26388600_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain prior period amounts have been reclassified to conform to the current period presentation. These changes had no effect on previously reported total revenues, net income (loss), other comprehensive income (loss), members&#8217; equity or cash flows. Unless otherwise noted, all financial information in the consolidated financial statement footnotes reflect the Company&#8217;s results from continuing operations. Discontinued operations are discussed further in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 16. Discontinued operations</div></div>. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment reporting </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identifies a business as an operating segment if: (i)&#160;it engages in business activities from which it may earn revenues and incur expenses; (ii)&#160;its operating results are regularly reviewed by the Chief Operating Decision Maker (CODM), to make decisions about resources to be allocated to the segment and assess its performance; and (iii)&#160;it has available discrete financial information. The Company&#8217;s CODM is its Chief Executive Officer. The CODM reviews financial information at the operating segment level to allocate resources and to assess the operating results and financial performance for each operating segment. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s two reportable segments are U.S. and International. U.S. and International products are primarily sold to physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery, as well as directly to their patients. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 14. Net sales</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 15. Segments</div></div> for further information regarding our business segments. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in accordance with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowances for doubtful accounts, inventory reserves, goodwill and intangible assets impairment, useful lives of long lived assets, noncontrolling interest, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19 pandemic impact </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, the COVID-19 pandemic spread around the world and in the U.S. and, more recently, new variants of the virus have emerged, some of which have shown to be more contagious. The COVID-19 pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments have implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of business, work from home, supply chain logistical changes and other measures, which have caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted due to the decrease in patient visits and elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments from customers, supply chain interruptions, extended &#8220;shelter-in-place&#8221; orders or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of COVID-19 on our business will depend on many factors, including, but not limited to, the duration and </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-13 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388600_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability and effectiveness of vaccines to combat COVID-19, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on our partners, patients and communities in which we operate, all of which continue to be uncertain. For example, there has been a decrease in patient visits to hospitals due to risk and fear of exposure to COVID-19, as well as decreases in, or temporary moratoriums on, elective procedures, which may be re-imposed in the future. In addition to lower sales, we have experienced decreased costs as a result of the pandemic including declines in travel and lower compensation related expenses. We have also implemented other various cost reduction initiatives and measures to safeguard liquidity. As of the date of issuance of these consolidated financial statements, the extent to which COVID-19 could materially impact the Company&#8217;s financial conditions, liquidity or results of operations is uncertain. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent COVID-19 disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully commercialize new developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual relationships. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law, which was aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. The CARES Act allowed the Company to defer $<ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,889</ix:nonFraction> in employer social security payroll tax payments from May 2020 through December&#160;31, 2020. A total of <ix:nonFraction name="bvs:PercentageOfDeferredPayrollTax" contextRef="PAsOn12_31_2021_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% is deferred until December&#160;31, 2021 and has been recorded in accrued liabilities, with the remaining balance deferred until December&#160;31, 2022 which has been recorded in other long-term liabilities both on the consolidated balance sheet. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 10. Income Taxes</div></div> for further information. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the CARES Act and at the direction of the U.S. Department of Health and Human Services (HHS), the Company received a $<ix:nonFraction name="bvs:ProceedsFromGovernmentalAssistance" contextRef="P04_01_2020To04_30_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,247</ix:nonFraction> Provider Relief Fund Payment in April 2020. The Company determined it complied with the conditions to be able to keep and use the funds to reimburse for health care related expenses and lost revenue attributable to the public health emergency resulting from COVID-19. A second Provider Relief Fund Payment totaling $<ix:nonFraction name="bvs:ProceedsFromGovernmentalAssistance" contextRef="P07_01_2020To07_31_2021_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,854</ix:nonFraction> was received in July 2020. The payments were recorded as other income on the consolidated statement of operations and comprehensive income (loss) for the year ended December&#160;31, 2020. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389512"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of significant accounting policies </div></div></div><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389664"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent accounting pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected to comply with non-accelerated public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are specific to non-accelerated public company filers, which are generally earlier than when emerging growth companies are required to adopt. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Pronouncements Recently Adopted </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FASB issued Accounting Standards Update 2016-13, Financial Instruments-Credit Losses (ASU 2016-13), in June 2016 that significantly changes accounting for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment methodology in prior GAAP with a methodology that considers a broad range of information for the estimation of credit losses. The Company adopted ASU 2016-13 on January&#160;1, 2020 prospectively and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-14 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389512" continuedAt="TextSelectionAppend_26389512_1"><ix:continuation id="TextSelection_26389664" continuedAt="TextSelectionAppend_26389664_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the FASB issued Accounting <div style="letter-spacing: 0px; top: 0px;;display:inline;">Standards</div> Update 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (ASU 2018-15), addressing a customer&#8217;s accounting for implementation costs incurred in a cloud-computing arrangement (CCA) that is considered a service contract. Under ASU 2018-15, implementation costs for a CCA should be evaluated for capitalization using the same approach as implementation costs associated with internal-use software. The capitalized implementation costs should be expensed over the term of the hosting arrangement, which includes any reasonably certain renewal periods. Capitalized implementation costs should be assessed for impairment like long-lived assets. The Company adopted ASU 2018-15 on January&#160;1, 2020 prospectively and it had no material impact on the Company&#8217;s consolidated financial statements. </div></div> </ix:continuation></ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_1" continuedAt="TextSelectionAppend_26389512_2"><ix:continuation id="TextSelectionAppend_26389664_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (ASU 2018-13), modifying the disclosure requirements on fair value measurements and eliminates the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements. ASU 2018-13 modifies certain disclosures related to investments measured at net asset value and clarifies that companies are to disclose uncertainties in measurements as of the reporting date. ASU 2018-13 requires additional disclosure related to changes in unrealized gains and losses included in other comprehensive income (loss) for recurring Level 3 fair value measurements as well as the range and weighted average, or other quantitative information that would be a more reasonable and rational method, of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted ASU 2018-13 on January&#160;1, 2020 and it did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New Accounting Pronouncements Not Yet Adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (ASU 2019-12), which amended the accounting for income taxes. ASU 2019-12 eliminates certain exceptions to the guidance for income taxes related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU 2019-12 is effective for annual and interim periods beginning after December&#160;15, 2020. Early adoption is permitted in interim or annual periods for which financial statements have not been made available for issuance. Entities that elect to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Certain amendments are to be applied prospectively while others are retrospective. The Company adopted ASU 2019-12 on January&#160;1, 2021 and the Company has assessed it will not have a material impact on its consolidated financial statements. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:ConsolidationVariableInterestEntityPolicy" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389665"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable Interest Entity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews each investment and collaboration agreement to determine if it has a variable interest in the entity. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgments regarding the purpose and design of entity, the value of the licensed assets to the entity, the value of the entity&#8217;s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that variable interest entity (VIE), based on a number of factors, including: (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii)&#160;the parties&#8217; contractual rights and responsibilities pursuant to the collaboration agreement, and (iii)&#160;which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statement of the VIE into the Company&#8217;s consolidated financial statements. On a quarterly basis, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">evaluates </div>whether </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-15 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_2" continuedAt="TextSelectionAppend_26389512_3"><ix:continuation id="TextSelection_26389665" continuedAt="TextSelectionAppend_26389665_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period the determination is <div style="letter-spacing: 0px; top: 0px;;display:inline;">made.</div> </div></div> </ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_26389512_3" continuedAt="TextSelectionAppend_26389512_4"><ix:continuation id="TextSelectionAppend_26389665_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities recorded as a result of consolidating financial results of the VIE into the Company&#8217;s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company&#8217;s general assets or liabilities for which creditors have recourse to the Company&#8217;s general assets. </div></div> </ix:continuation> <ix:nonNumeric name="bvs:NonControllingInterestPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling Interest </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records noncontrolling interest related to the consolidated VIEs on its consolidated balance sheet. The Company records loss attributable to noncontrolling interest on its consolidated statements of operations, which reflects the VIE&#8217;s net loss for the reporting period, adjusted for changes in the noncontrolling interest holders claim to net assets, including contingent milestone and royalty payments, which are evaluated each reporting period. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DiscontinuedOperationsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deconsolidation and discontinued operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i)&#160;the aggregate of (a)&#160;the fair value of any consideration received, (b)&#160;the fair value of any retained noncontrolling investment in the former subsidiary and (c)&#160;the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii)&#160;the carrying amount of the former subsidiary&#8217;s assets and liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on if the deconsolidation represents a strategic shift that has or will have a major effect on the Company&#8217;s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one-year period following such date, it will present the former subsidiary as a discontinued operation for all periods presented. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of foreign currency </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars at rates of exchange in effect at the close of their month end. Equity accounts are translated at their historical rates. Revenues and expenses are translated at the exchange rate on the transaction date. Translation gains and losses are accumulated within accumulated other comprehensive income (loss) as a separate component of members&#8217; equity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency transaction gains and losses are included in other expense on the consolidated statements of operations and comprehensive income (loss). There were gains of $<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117</ix:nonFraction></ix:nonFraction> for the year ended December&#160;31, 2020, nominal losses for the year ended December&#160;31, 2019, and losses of $<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction> for the year ended December&#160;31, 2018. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) consists of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S.&#160;GAAP are recorded as an element of members&#8217; equity and are excluded from net income (loss). The Company&#8217;s other comprehensive income (loss) consists of a defined benefit plan adjustment and foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-16 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_4" continuedAt="TextSelectionAppend_26389512_5"> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389669"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div></ix:nonNumeric> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_5" continuedAt="TextSelectionAppend_26389512_6"><ix:continuation id="TextSelection_26389669"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents consist of highly liquid investments with an original maturity of<div style="letter-spacing: 0px; top: 0px;;display:inline;"> three</div> months or less at date of purchase. The Company&#8217;s cash is primarily held in financial institutions in the United States and the Netherlands. The Company maintains cash balances in the United States in excess of the federally insured limits. The Company did not have restricted cash as of December&#160;31, 2020 and 2019. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company uses derivative instruments to manage exposures to interest rates. Derivatives are recorded on the balance sheet at fair value at each balance sheet date and the Company does not designate whether the derivative instrument is an effective hedge. Changes in the fair values of derivative instruments are recognized in the consolidated statements of operations and comprehensive income (loss). The Company has entered, and may in the future enter, into derivative contracts related to its debt. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 5. Financial instruments</div></div> for further details regarding the Company&#8217;s derivatives. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records certain assets and liabilities at fair value. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 7. Fair value measurements</div></div> for details regarding assets and liabilities measured at fair value. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities are categorized based on the lowest level that is significant to the valuation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The three levels of inputs used to measure fair value are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#8212;Observable inputs other than quoted prices included within Level&#160;1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </div></div></td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389673"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Products </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derives revenue primarily from the sale of its (i)&#160;osteoarthritic, or OA, joint pain treatment and joint preservation products, which are hyaluronic acid, or HA, viscosupplementation therapies, (ii)&#160;Bone Graft Substitutes (BGS) products and (iii)&#160;a Minimally Invasive Fracture Treatment product. The Company sells product directly to healthcare institutions, patients, distributors and dealers. The Company also enters arrangements with pharmacy and health benefit managers that provide for negotiated rebates, chargebacks and discounts with respect to the purchase of the Company&#8217;s products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue at a point in time upon transfer of control of the promised product to customers in an amount that reflects the consideration it expects to receive in exchange for those products. The Company excludes taxes collected from customers and remitted to governmental authorities from revenues. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-17 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_6" continuedAt="TextSelectionAppend_26389512_7"><ix:continuation id="TextSelection_26389673" continuedAt="TextSelectionAppend_26389673_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are recorded at the transaction price, which is determined as the contracted price net of estimates of variable consideration resulting from discounts, rebates, returns, chargebacks, contractual allowances, estimated third-party payer settlements, and certain distribution and administration fees offered in our customer contracts and other indirect customer contracts relating to the sale of our products. The Company establishes reserves for the estimated variable consideration based on the amounts earned or eligible to be claimed on the related sales. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted for relevant factors such as the Company&#8217;s historical experience, current contractual requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company regularly reviews all reserves and updates them at the end of each reporting period as needed. There were <ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction></ix:nonFraction>adjustments arising from the change in estimates of variable consideration that were significant for the years ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">OA Joint Pain Treatment and Joint Preservation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from customers, such as healthcare providers, distribution centers or specialty pharmacies is recognized at the point in time when control is transferred to the customer, typically upon shipment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributor chargebacks </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has preexisting contracts with established rates with many of the distributors&#8217; customers who require the distributors to sell our product at their established rate. The Company offers chargebacks to distributors who supply these customers with our products. The Company reduces revenue at the time of sale for the estimated future chargebacks. The Company records chargeback reserves as a reduction of accounts receivable and base the reserves on the expected value by using probability-weighted estimates of volume of purchases, inventory holdings and historical chargebacks requested for each distributor. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Discounts and gross-to-net deductions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company offers retrospective discounts and gross-to-net deductions linked to the volume of purchases which may increase at negotiated thresholds within a contract-buying period. The Company reduces revenue and records the reserve as a reduction to accounts receivable for the estimated discount and rebate at the expected amount the customer will earn, based on historical buying trends and forecasted purchases. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bone Graft Substitute </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the Company&#8217;s BGS product sales are through consignment inventory with hospitals, where ownership remains with the Company until the hospital or ambulatory surgical center (ASC) performs a surgery and consumes the consigned inventory. The Company recognizes revenue when the surgery has been performed. Control of the product is not transferred until the customer consumes it, as the Company is able to require the return or transfer of the product to a third-party. An unconditional obligation to pay for the product does not exist until the customer consumes it. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Minimally Invasive Fracture Treatment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue from third-party payers, such as governmental agencies, insurance companies or managed care providers, when the Company transfers control to the patient, typically when the patient has accepted the product or upon delivery. The Company records this revenue at the contracted rate, net of contractual allowances and estimated third-party payer settlements at the time of sale, or an estimated price based on historical data and other available information for non-contracted payers. The Company estimates the contractual allowances using the portfolio approach and based on probability weighting historical data and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-18 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_7" continuedAt="TextSelectionAppend_26389512_8"><ix:continuation id="TextSelectionAppend_26389673_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collections history within those portfolios. The portfolios determined using the portfolio approach consist of the following customer groups: government payers, commercial payers, and patients. The Company recognizes revenue from patients (self-pay and insured patients with coinsurance and deductible responsibilities) based on billed amounts giving effect to any discounts and implicit price concessions. Implicit price concessions represent differences between amounts billed and the amounts the Company expects to collect from patients, which considers historical collection experience and current market conditions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price using the expected amount method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. The Company is not aware of any claims, disputes or unsettled matters with any payer that would materially affect revenues for which the Company has not adequately provided for or disclosed in the accompanying consolidated financial statements. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 12. Commitments and contingencies</div></div> for further information. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product returns </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimates the amount of returns and reduces revenue in the period the related product revenue is recognized. The Company records a liability for expected returns based on probability-weighted historical data. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts receivable, net </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for doubtful accounts. The Company maintains an estimated allowance for doubtful accounts to provide for receivables the Company does not expect to collect. The Company bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. </div></div></ix:nonNumeric> <ix:nonNumeric name="bvs:ContractAssetsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract assets </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets consist of unbilled amounts resulting from estimated future royalties from an international distributor that exceeds the amount billed. Contract assets totaling $<ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">81</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">261</ix:nonFraction> as of December&#160;31, 2020 and 2019, are included in prepaid and other current assets on the consolidated balance sheets, respectively. </div></div></ix:nonNumeric> <ix:nonNumeric name="bvs:ContractLiabilitiesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract liabilities </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities consist of customer advance payments and deferred revenue. Occasionally for certain international customers, the Company requires payments in advance of shipping product and recognizing revenue resulting in contract liabilities. Contract liabilities were nominal as of December&#160;31, 2020 and 2019 and are included in accrued liabilities on the consolidated balance sheets. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShippingAndHandlingCostPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389677"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shipping and handling </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other distribution costs are included in cost of sales. The </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-19 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_8" continuedAt="TextSelectionAppend_26389512_9"><ix:continuation id="TextSelection_26389677"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company has elected to recognize shipping and handling activities that occur after control of the related product transfers to the customer as fulfillment costs and these are included in<div style="display:inline;"> cost</div> of sales.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></ix:continuation><ix:nonNumeric name="bvs:ContractCostsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the practical expedient of recognizing the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less. These incremental costs include the Company&#8217;s sales incentive programs for the internal sales force and third-party sales agents as the compensation is commensurate with annual sales activities. These costs are included in selling, general and administrative expense on the consolidated statements of operations and comprehensive income (loss). </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company values its inventory at the lower of cost or net realizable value and adjusts for the value of inventory that is estimated to be excess, obsolete or otherwise unmarketable. Cost is determined using the first-in, first-out (FIFO) method. Elements of cost in inventory include raw materials, direct labor, manufacturing overhead and inbound freight. The Company records allowances for excess and obsolete inventory based on historical and estimated future demand and market conditions. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business combinations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting for acquisitions requires the Company to recognize separately from goodwill assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While best estimates and assumptions are used to accurately value assets acquired and liabilities assumed at the acquisition date, as well as contingent consideration where applicable, estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations and comprehensive income (loss). Subsequent changes in the estimated fair value of contingent<div style="display:inline;"> considerat</div>ion are recognized in earnings in the period of change. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense are recognized using the straight-line method over the estimated useful life of each asset, or the shorter of the lease term or useful life if related to leasehold improvements. <ix:nonNumeric name="bvs:PropertyPlantAndEquipmentUsefulLivesTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389490">The useful lives in years are as follows:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26389490">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer software and hardware</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">7</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">7</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">7</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:continuation></ix:nonNumeric></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-20 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_9" continuedAt="TextSelectionAppend_26389512_10"><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389682"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and intangible assets&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div></div></ix:nonNumeric> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_10" continuedAt="TextSelectionAppend_26389512_11"><ix:continuation id="TextSelection_26389682"><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Fini</div>te-lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight-line method over their estimated useful lives in years are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis" format="ixt-sec:duryear">17.3</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis" format="ixt-sec:duryear">12.7</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis" format="ixt-sec:duryear">10.0</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis" format="ixt-sec:duryear">8.3</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is not amortized but is evaluated for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. The Company reviews goodwill for impairment by applying a quantitative impairment analysis where the fair value of the reporting unit is compared with the carrying value, including goodwill. The Company determines the fair value of each reporting unit based on an income approach. The value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company performs its annual goodwill impairment test on October&#160;31st. If the fair value of the reporting unit is less than its carrying value, the Company will recognize the difference as an impairment loss, which is limited to the amount of goodwill allocated to the reporting units. There were no goodwill impairment charges for the years ended December&#160;31, 2020, 2019 and 2018. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Software development costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company capitalizes internal and external costs incurred to develop internal-use software during the application development stage for software design, configuration, coding and testing upon placing the asset in service and then amortizes these costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. The Company does not capitalize costs that are precluded from capitalization in authoritative guidance, such as preliminary project phase costs, training costs or data conversion costs. Capitalized software costs totaled $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,653</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,119</ix:nonFraction> as of December&#160;31, 2020 and 2019 and the related accumulated amortization totaled $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,264</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,184</ix:nonFraction>, respectively. Amortization expense was $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,184</ix:nonFraction>, $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,138</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,204</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying values of property, equipment, intangible assets as well as other long-lived and indefinite lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable the Company will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. If quoted market prices are not available, the Company estimates fair value using an undiscounted value of estimated future cash flows. During 2018, the Company determined that it would no longer sell a specific BGS product and as a result, an intangible asset related to this product was fully written off and the Company recognized impairment charges of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">489</ix:nonFraction> for the year ended December&#160;31, 2018, which is included in the consolidated statements of operations and comprehensive income (loss). Upon retirement or sale of property and equipment, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is included in income from operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#8217;s property, equipment, intangible or other long-lived assets. </div></div></ix:nonNumeric> </ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-21 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_11" continuedAt="TextSelectionAppend_26389512_12"><ix:nonNumeric name="us-gaap:InProcessResearchAndDevelopmentPolicy" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired in-process research and development </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of in-process research and development (IPR&amp;D) assets acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets and are not amortized until development is completed and the product is available for sale. Once the product is available for sale, the asset is transferred to developed technology and amortized over its estimated useful life. Impairment tests for IPR&amp;D assets occur at least annually in December, or more frequently if events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than the carrying amount, an impairment loss is recognized for the difference. There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#8217;s IPR&amp;D. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Offering Costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs, consisting of legal, accounting, filing and other fees related to the initial public offering, are capitalized. The deferred offering costs will be offset against proceeds from the initial public offering upon the effectiveness of the initial public offering. In the event the initial public offering is terminated, all capitalized deferred offering costs would be expensed. Deferred offering costs capitalized totaled $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,187</ix:nonFraction> as of December&#160;31, 2020 and there were there were <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no </ix:nonFraction>deferred offering costs capitalized as of December&#160;31, 2019. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company provides credit, in the normal course of business, to its customers. The Company does not require collateral or other securities to support customer receivables. Credit losses are provided for through allowances and have historically been materially within management&#8217;s estimates. </div></div><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable to these significant suppliers at December&#160;31 were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2020_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,983</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2019_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2020_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2019_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2020_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2019_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain products provide the Company with a significant percentage of total sales for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-22 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_12" continuedAt="TextSelectionAppend_26389512_13"><ix:nonNumeric name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has restructured portions of its operations and future restructuring activities are possible. Identifying and calculating the cost to exit these operations requires certain assumptions to be made, the most significant of which are anticipated future liabilities. Although estimates have been reasonably accurate in the past, significant judgment is required, and these estimates and assumptions may change as additional information becomes available and facts or circumstances change. Restructuring costs are recorded at estimated fair value. Key assumptions in determining the restructuring costs include negotiated terms and payments to terminate contractual obligations. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures profits interest compensation cost at the grant date based on the fair value of the award and recognizes this cost as compensation expense over the required or estimated service period for awards expected to vest. Certain awards are liability-classified, which require they be remeasured at each reporting date. Compensation expense is included in Selling, general and administrative expense and Research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employees who were granted the awards. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:AdvertisingCostsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs include costs incurred to promote the Company&#8217;s business and are expensed as incurred. Advertising costs were $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,769</ix:nonFraction>, $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,351</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,916</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense consist primarily of employee compensation and related expenses as well as contract research organization services. Internal research and development costs are expensed as incurred. Research and development costs incurred by third parties are expensed as the contracted work is performed. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CollaborativeArrangementAccountingPolicy" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative agreements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and we account for these alliances as a collaborative arrangement by reporting costs incurred from transactions within research and development expense in our consolidated statements of operations. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. Legal fees expected to be incurred in connection with a loss contingency are not included in the estimated loss contingency. The Company accrues for any legal costs as they are incurred. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389695"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is treated as a partnership for U.S. tax purposes. Accordingly, the profits and losses are passed through to the members and included in their income tax returns. The Company has been required to make tax </div></div></ix:nonNumeric> </ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-23 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389512_13"><ix:continuation id="TextSelection_26389695"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distributions to its members in an amount equal to <ix:nonFraction name="bvs:PercentageOfMembersTaxDistributionToTaxableIncome" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>% of the members&#8217; taxable income attributable to their ownership. The tax rate applied for purposes of this distribution may be changed only by approval of the Company&#8217;s Board of Managers. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain wholly owned subsidiaries of the Company are taxable entities for U.S. or foreign tax purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred tax assets to an amount which will, more likely than not, be realized. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a tax benefit from any uncertain tax positions only if they are more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. Components of the reserve, if relevant, are classified as a current or noncurrent liability in the consolidated balance sheet based on when the Company expects each of the items to be settled. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per common unit </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic income (loss) per common unit is determined by dividing the net income (loss) allocable to common unit holders by the weighted average number of common units outstanding during the periods presented. Diluted loss per common unit is computed by dividing the net income (loss) allocable to common unit holders on an &#8220;if converted&#8221; basis by the weighted average number of actual common units outstanding and, when dilutive, the unit equivalents that would arise from the assumed conversion of convertible instruments, if any. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has considered the effects of subsequent events through March&#160;26, 2021, the date the Company&#8217;s consolidated financial statements were issued. </div></div></ix:nonNumeric> </ix:continuation><ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26388651"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Balance sheet information&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:nonNumeric name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net of allowances, consisted of the following as of December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">92,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Allowance for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to make required payments. The allowance for credit losses is calculated by region and by customer type, where appropriate considering several factors including age of accounts, collection history, historical account write-offs, current economic conditions, and supportable forecasted economic expectations. Due to the short-term nature of its receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. An increase in the provision for credit losses may be required when the financial condition of the Company&#8217;s customers or its collection experience deteriorates. The Company </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-24 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388651" continuedAt="TextSelectionAppend_26388651_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">has a diverse customer base with no single customer representing ten percent of sales or accounts receivable. Historically, the Company&#8217;s reserves have been adequate to cover credit losses. The Company&#8217;s exposure to credit losses may increase if its customers are adversely affected by changes in health care laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic, or other customer-specific factors. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Estimates are used to determine the allowance, which are based on an assessment of anticipated payment and all other historical, current and future information that is reasonably available.</div></div> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388651_1" continuedAt="TextSelectionAppend_26388651_2"> <ix:nonNumeric name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in credit losses were as follows for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2018_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,787</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,949</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">416</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consisted of the following as of December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and supplies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,665</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,988</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,858</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess and obsolete reserves</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">868</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="bvs:ScheduleOfInventoryValuationReservesTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in excess and obsolete reserves for inventory were as follows for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2018_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:InventoryValuationReservesProvisionForLosses" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:InventoryValuationReservesProvisionForLosses" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:InventoryValuationReservesWriteOffs" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:InventoryValuationReservesWriteOffs" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">868</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-25 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; text-indent: 0px;"><ix:continuation id="TextSelectionAppend_26388651_2" continuedAt="TextSelectionAppend_26388651_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,918</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets not yet placed in service</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_AssetUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_AssetUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,731</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,879</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,106</ix:nonFraction>, $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,579</ix:nonFraction> and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,439</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and intangible assets, net </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfGoodwillTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were <ix:nonFraction name="us-gaap:GoodwillPeriodIncreaseDecrease" contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillPeriodIncreaseDecrease" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> changes to goodwill during the years ended December&#160;31, 2020 and 2019. Following is a summary of goodwill by reportable segment: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 685.438px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 368.188px;"></td>
<td style="vertical-align: bottom; width: 43.4062px;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 43.4062px;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 43.4375px;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S.</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020 and 2019</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41,040</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,760</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,800</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="bvs:ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets consisted of the following as of December&#160;31:</div></div></div> <div style="color: rgb(0, 0, 0); font-family: Century; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Century; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 433.797px;"></td>
<td style="vertical-align: bottom; width: 37.1719px;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 37.1875px;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">263,422</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">263,422</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60,700</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,700</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,700</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,700</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="PAsOn12_31_2020_AcquiredInProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,445</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="PAsOn12_31_2019_AcquiredInProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,095</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology and other</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,999</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,649</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total carrying amount</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">397,266</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">396,566</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated amortization:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117,281</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,982</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,461</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,716</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51,247</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,407</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology and other</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,786</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,404</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accumulated amortization</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">206,775</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">179,509</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net before currency translation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="bvs:IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">190,491</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="bvs:IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">217,057</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="bvs:FiniteLivedIntangibleAssetsCurrencyTranslation" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,159</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="bvs:FiniteLivedIntangibleAssetsCurrencyTranslation" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">547</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,650</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">216,510</ix:nonFraction></div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> </ix:nonNumeric> <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company filed a 510(k) in 2019 and began commercializing a next-generation surgical product in the third quarter of 2020. As a result, $<ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ReclassificationOfIprdMemberBVSEventAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,650</ix:nonFraction> of IPR&amp;D was reclassified to developed technology and will be amortized over <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ReclassificationOfIprdMemberBVSEventAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years. On December&#160;22, 2020, the Company entered into an amended and restated distribution agreement with the sole supplier of the Company&#8217;s five injection OA product.&#160;This agreement provided non-exclusive U.S. market</div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-26 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388651_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distribution rights until December&#160;31, 2028. The amended and restated distribution agreement created a $<ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="P01_01_2020To12_31_2020_AccountsPayableMemberusgaapBalanceSheetLocationAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction> distribution right that will be amortized over <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P01_01_2020To12_31_2020_AccountsPayableMemberusgaapBalanceSheetLocationAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">8</ix:nonNumeric> years, which was capitalized as an intangible asset and included in <div style="display:inline;">accrued</div> liabilities on the consolidated balance sheets as of December&#160;31, 2020.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense related to intangible assets was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,565</ix:nonFraction>, $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,252</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,622</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018 of which $<ix:nonFraction name="bvs:AmortizationExpenseIncludedInInventory" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,455</ix:nonFraction>, $<ix:nonFraction name="bvs:AmortizationExpenseIncludedInInventory" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,416</ix:nonFraction> and $<ix:nonFraction name="bvs:AmortizationExpenseIncludedInInventory" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,766</ix:nonFraction> are included in ending inventory at December&#160;31, 2020, 2019 and 2018, respectively. Estimated amortization expense for the years ended December&#160;31, 2021 through 2025 is expected to be $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,262</ix:nonFraction>, $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,910</ix:nonFraction>, $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,297</ix:nonFraction>, $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,297</ix:nonFraction> and $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,259</ix:nonFraction>, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consisted of the following at December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net deductions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:GrossToNetDeductionsCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:GrossToNetDeductionsCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,622</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus and commission</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserve for estimated overpayments from third-party payers</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AccruedSalariesAndEmployeeBenefitsCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AccruedSalariesAndEmployeeBenefitsCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,231</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income and other taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,244</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,418</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">52,827</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="bvs:BusinessCombinationsAndInvestmentsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26388760"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Business combinations and investments&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VIE </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;23, 2019, the Company purchased <ix:nonFraction name="bvs:VariableInterestEntitySharesIssuedDuringPeriod" contextRef="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">285,714</ix:nonFraction> shares of Harbor&#8217;s Series C Preferred Stock or <ix:nonFraction name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">3.1</ix:nonFraction>% of fully diluted shares for $<ix:nonFraction name="bvs:VariableInterestEntityIssuedCost" contextRef="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction>. The Company and Harbor entered into an exclusive collaboration agreement for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. As a result of these transactions, the Company determined that it had a variable interest in Harbor. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounted for the Harbor investment as a business combination using the acquisition method of accounting whereby the total purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The results of Harbor operations have been included in the accompanying consolidated financial statements subsequent to acquisition date. The Company did not disclose post-acquisition or pro forma losses attributable to Harbor as they did not have a material effect on the Company&#8217;s consolidated statements of operations and comprehensive income (loss). </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-27 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388760" continuedAt="TextSelectionAppend_26388760_1"><ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property (10-year useful life)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value of net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus purchase price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P01_01_2020To12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Harbor&#8217;s noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020 two convertible promissory notes to Harbor shareholders totaling $<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500</ix:nonFraction> were converted into <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">142,858</ix:nonFraction> of Harbor Series C Preferred Stock and warrants for <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborCommonStockMemberusgaapStatementEquityComponentsAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">428,572</ix:nonFraction> shares of the Harbor common stock exercisable at a price of $<ix:nonFraction name="bvs:DebtInstrumentConvertibleConversionExercisablePrice" contextRef="PAsOn03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">1.167</ix:nonFraction> per share with a 5-year exercise period expiring <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" format="ixt:datemonthdayyearen">March 27, 2025</ix:nonNumeric>. Promissory notes of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">320</ix:nonFraction> owed to a certain Harbor shareholder were converted into <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P11_30_2020To11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">92,500</ix:nonFraction> of Harbor Series C Preferred Stock at $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.50</ix:nonFraction> per share in November 2020. On October&#160;5, 2020, the Company purchased an additional <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P10_05_2020To10_05_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">285,714</ix:nonFraction> shares of Harbor&#8217;s Series C Preferred Stock for $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P10_05_2020To10_05_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction>. The Company continues to conclude that it is the primary beneficiary since it controls the significant activities of Harbor through the collaboration agreement. The noncontrolling interest related to Harbor was <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">91.2</ix:nonFraction>% as of December&#160;31, 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Harbor intellectual property and IPR&amp;D was determined using the income approach through an excess earnings analysis, with projected earnings discounted at a rate of <ix:nonFraction name="bvs:FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">16.5</ix:nonFraction>%. The $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,445</ix:nonFraction> of IPR&amp;D consists of research and development progress toward developing a product for orthopedic uses. The fair value of the noncontrolling interest was calculated as estimated fair value of net assets acquired less the Company&#8217;s purchase price. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harbor assets that can only be used to settle Harbor obligations and Harbor liabilities for which creditors do not have recourse to the general credit of the Company are as follows for the years ended December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">231</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">366</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">458</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nearly all the liabilities assumed are payable to Harbor shareholders. As of December&#160;31, 2019, other current liabilities primarily consisted of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,845</ix:nonFraction> in promissory notes to various Harbor shareholders and were scheduled </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-28 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388760_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" format="ixt:datemonthdayyearen">August 31, 2020</ix:nonNumeric>. These promissory notes were refinanced with additional borrowings in August 2020 and total $<ix:nonFraction name="bvs:DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,811</ix:nonFraction> as of December&#160;31, 2020. The Harbor promissory notes carry an <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>% interest rate and are due on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" format="ixt:datemonthdayyearen">August 31, 2021</ix:nonNumeric> with payments due <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">monthly</ix:nonNumeric>. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Method </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in which the Company can exercise significance influence, but do not control, are recorded under the equity method of accounting and are included in investments and other assets on the consolidated balance sheets. The Company&#8217;s share of net earnings or losses is included in other (income) loss within the consolidated statements of operations and comprehensive income (loss) on a quarter lag. The Company evaluates investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired. Impairment losses are recorded within earnings within the current period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;30, 2018, the Company purchased <ix:nonFraction name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" contextRef="P01_30_2018To01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">337,397</ix:nonFraction> shares of CartiHeal, a privately held entity, Series F Convertible Preferred Stock or <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction>% of fully diluted shares for $<ix:nonFraction name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="PAsOn01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction> in cash. The investment does not have a readily determinable fair value. On January&#160;22, 2020, the Company made an additional investment in CartiHeal, through a Simple Agreement for Future Equity (SAFE) by paying cash of $<ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="P01_22_2020To01_22_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SimpleAgreementForFutureEquityMemberBVSAgreementForFutureEquityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">152</ix:nonFraction>. On July&#160;15, 2020, CartiHeal completed an equity financing that the Company participated in and as a result, the Company received <ix:nonFraction name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" contextRef="P07_15_2020To07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesG1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">12,825</ix:nonFraction> in Series G-1 Preferred Shares and the SAFE terminated. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, on July&#160;15, 2020, the Company entered into an Option and Equity Purchase Agreement with CartiHeal. Under the terms of the agreement, the Company purchased <ix:nonFraction name="bvs:EquityMethodInvestmentAdditionalInvestmentPurchasedShares" contextRef="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,014,267</ix:nonFraction> shares of CartiHeal Series G Preferred Shares for $<ix:nonFraction name="bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" contextRef="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction>. As a result, the Company&#8217;s equity ownership in CartiHeal increased to <ix:nonFraction name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" contextRef="P07_15_2020To07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">10.03</ix:nonFraction>% of its fully diluted shares. The CartiHeal investment, included capitalized transaction costs of $<ix:nonFraction name="bvs:EquityMethodInvestmentCapitalizedTransactionCosts" contextRef="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,427</ix:nonFraction> and the $<ix:nonFraction name="bvs:EquityMethodInvestmentCapitalizedTransactionCosts" contextRef="PAsOn01_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">152</ix:nonFraction> investment in January 2020, totaling $<ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,579</ix:nonFraction> was recorded as an equity method investment beginning in July 2020, as the Company can exercise significant influence over CartiHeal but does not have control. It is included within investments and other assets on the consolidated balance sheet. The CartiHeal investment carrying value is $<ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,689</ix:nonFraction> as of December&#160;31, 2020, after recording net losses of $<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">467</ix:nonFraction> incurred during 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will, if needed, purchase an additional <ix:nonFraction name="bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">338,089</ix:nonFraction> of CartiHeal Series G Preferred Shares for $<ix:nonFraction name="bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction>, for the completion of a certain study. The Company has an exclusive option to acquire the remaining equity in CartiHeal, which may be exercised at any time up to and within <ix:nonNumeric name="bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:durday">45</ix:nonNumeric> days following notice of the U.S. Food and Drug Administration (FDA) approval for a CartiHeal product currently in development. In addition, upon the same FDA approval, CartiHeal may exercise an option within <ix:nonNumeric name="bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:durday">45</ix:nonNumeric> days that requires the Company to complete the acquisition of the remaining equity in CartiHeal. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26388892"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Financial instruments&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 Credit Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;6, 2019, the Company entered into a $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">250,000</ix:nonFraction> credit and guaranty agreement (2019 Credit Agreement) with Wells Fargo Bank National Association (Wells), as well as a syndicate of other banks, or Lenders. The 2019 Credit Agreement is comprised of a $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">200,000</ix:nonFraction> term loan (Term Loan), with an original issue discount (OID) of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">666</ix:nonFraction>, and a $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction> revolving facility (Revolver). All obligations under the 2019 Credit Agreement are guaranteed by the Company and certain of the Company&#8217;s wholly owned subsidiaries. Substantially all the assets of the Company collateralize the obligations under the 2019 Credit Agreement. The Term Loan and Revolver mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" format="ixt:datemonthdayyearen">December 6, 2024</ix:nonNumeric> (Maturity). </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-29 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388892" continuedAt="TextSelectionAppend_26388892_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Term Loan </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, $<ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">188,378</ix:nonFraction> was outstanding on the Term Loan, net of original issue discount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction> and deferred financing costs of $<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,098</ix:nonFraction>. As of December&#160;31, 2020, the Term Loan interest rate including a margin of <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.25</ix:nonFraction>% was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.40</ix:nonFraction>%. <ix:nonNumeric name="bvs:ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26390133">Scheduled quarterly principal payments are as follows with the final payment of $<ix:nonFraction name="bvs:DebtInstrumentFinalPrincipalPaymentAtMaturity" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">125,000</ix:nonFraction> at Maturity:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26390133">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarterly<br/>payment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 and 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodOneMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 and 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr></table></ix:continuation><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may voluntarily prepay the Term Loan without premium or penalty upon prior notice. The Company may be required to make additional principal payments on the Term Loan dependent upon the generation of certain cash flow events as defined in the 2019 Credit Agreement. These additional prepayments will be applied to the scheduled installments of principal in direct order of maturity of the Base Rate (BR) portions of the Term Loan first and then the Eurodollar portions of the Term Loan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of the Term Loan as of December&#160;31, 2020 was $<ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">189,534</ix:nonFraction>. The fair value of these obligations was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar obligations and are classified as Level 2 instruments within the fair value hierarchy. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revolver </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Revolver is a <ix:nonNumeric name="us-gaap:LineOfCreditFacilityExpirationPeriod" contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> revolving credit facility of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction> which includes revolving and swingline loans as well as letters of credit (LOC) and, inclusive of all, cannot exceed $50,000 at any one time. LOCs are available in an amount not to exceed $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_LetterOfCreditMemberBVSRevolvingCreditFacilitySubAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,500</ix:nonFraction>. Revolving loans are due at the earlier of termination or Maturity. Swingline loans are available as BR interest rate option loans only and must be <ix:nonNumeric name="us-gaap:LineOfCreditFacilityDescription" contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">outstanding for at least <ix:nonNumeric name="us-gaap:LineOfCreditFacilityExpirationPeriod" contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" format="ixt-sec:durwordsen">five days</ix:nonNumeric>. Swingline loans are due the <span style="-sec-ix-hidden:hidden26390228">fifteenth</span> or last day of a calendar month or Maturity whichever is earlier</ix:nonNumeric>. The Company had increased its cash position by borrowing $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,000</ix:nonFraction> on its Revolver as a precautionary measure to preserve financial flexibility in view of the current uncertainty resulting from the COVID-19 pandemic during the first quarter of 2020. The $<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P07_01_2020To09_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,000</ix:nonFraction> was repaid during the third quarter of 2020. As of December&#160;31, 2020, there was one nominal LOC outstanding leaving approximately $<ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,912</ix:nonFraction> available. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Term Loan and Revolver permits the Company to elect either Eurodollar or BR interest rate options for the entire amount or certain portions of the loans and have interest rates equal to a formula driven base interest rate plus a margin, tied to a leverage ratio. The leverage ratio is the ratio of debt to consolidated EBITDA as defined in the 2019 Credit Agreement, or Bank EBITDA, for four consecutive quarters at the end of each period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BR portions of the Term Loan have interest due the last day of each calendar quarter-end. Eurodollar portions of the Term Loan have one, two, three or six-month interest reset periods and interest is due on the last day of each three-month period or the last day of the loan term if less than three months. In advance of the last day of the current Eurodollar Loan, the Company may select a new loan type so long as it does not extend beyond Maturity. The outstanding Term Loan has been a Eurodollar Loan since inception and is an auto-renewing one-month loan for setting an interest rate. In addition, the Term Loan has an interest due date concurrent with any scheduled principal repayment or prepayment. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest is calculated based on a 360-day year except for BR loans where the base interest is the Wells Prime Rate, in which case it is calculated based on a calendar-day year. The base interest rate for all BR loans is equal to the highest of (a)&#160;the Wells Prime Rate, (b)&#160;the greater of the Federal Funds Effective Rate or Overnight Bank </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-30 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_26388892_1" continuedAt="TextSelectionAppend_26388892_2">Funding Rate plus <span style="-sec-ix-hidden:hidden26390186">1/2</span>% and (c)&#160;the Eurodollar Rate for a USD deposit with a maturity of one month plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_BrInterestRateBasisMemberBVSInterestRateBasisAxis_EurodollarMemberusgaapVariableRateAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>%. The base interest rate for all Eurodollar Loans is equal to the rate determined for such day in accordance with the following formula with the Term Loan having a floor of <ix:nonFraction name="bvs:DebtInstrumentFloorRatePercentage" contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_BrInterestRateBasisMemberBVSInterestRateBasisAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%:</ix:continuation> </div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388892_2" continuedAt="TextSelectionAppend_26388892_3"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">LIBOR </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#8212;Eurocurrency Reserve Requirements </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pricing grids are used to determine the loan margins based on the type of loan and the leverage ratio. The initial Eurodollar and BR loans had a margin of <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.25</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P12_06_2019To12_06_2019_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.25</ix:nonFraction>%, respectively. <ix:nonNumeric name="bvs:ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26390137">Loan margin is adjusted after the quarterly financial statements are delivered to the lenders in accordance with the pricing grid below:</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_26390137"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Leverage ratio</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eurodollar</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BR</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt;1.50 to 1.00 and &lt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 1.25 to 1.00 and &lt;1.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 0.75 to 1.00 and &lt;1.25 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&lt; 0.75 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Revolver includes a commitment fee at <ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>% of the average daily amount of the available revolving commitment, assuming any swingline loans outstanding are $<ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">0</ix:nonFraction>. There were <ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> swingline loans outstanding as of December&#160;31, 2020. The fee is payable quarterly in arrears on the last day of the calendar quarters and at Maturity. <ix:nonNumeric name="bvs:ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26390136">The commitment fee rate is adjusted after the quarterly financial statements are delivered to lenders based on the pricing grid below:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26390136">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 81%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 15%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Leverage ratio</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitment<br/>fee&#160;rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt;1.50 to 1.00 and &lt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 1.25 to 1.00 and &lt;1.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 0.75 to 1.00 and &lt;1.25 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&lt; 0.75 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fees are charged on all outstanding LOCs at an annual rate equal to the margin in effect on Eurodollar revolving loans. A fronting fee of <ix:nonFraction name="bvs:FrontingFeePercentageOnUndrawnAmount" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%&#160;per year on the undrawn and unexpired amount of each LOC is payable as well. The fees are payable quarterly in arrears on the last day of the calendar quarters. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company&#8217;s effective weighted average interest rate on all outstanding debt, including the commitment fee and interest rate swap, was <ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.72</ix:nonFraction>%. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of the Company&#8217;s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of Company assets, as well as limitations on making changes to the Company&#8217;s business and organizational documents. Financial covenant requirements include a maximum debt leverage ratio as well as an interest coverage ratio not less than <ix:nonFraction name="bvs:InterestCoverageRatio" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:numdotdecimal">3.00</ix:nonFraction> to 1.00 as defined in the 2019 Credit Agreement. As of December&#160;31, 2020, the Company complied with the financial covenants in the 2019 Credit Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Lender may provide an additional Term or Revolving Loan by executing and delivering notice specifying the terms, if doing so would not cause certain undesired events to occur as defined in the 2019 Credit Agreement </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-31 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388892_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or extend repayment beyond Maturity. The aggregate amount of all additional borrowings may not exceed the greater of $<ix:nonFraction name="bvs:ThresholdMaximumAggregateAdditionalBorrowings" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction> and the trailing four quarters Bank EBITDA without the consent of the Lenders holding more than <ix:nonFraction name="bvs:PercentageOfTotalOutstandingDebtLoanedByLenders" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of the total outstanding debt under the 2019 Credit Agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During December 2019, the Company paid financing costs totaling $<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,117</ix:nonFraction> in order to refinance our prior term loan facility, that was repaid in full (Prior Credit Agreement). The Company recorded $<ix:nonFraction name="bvs:DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">269</ix:nonFraction> directly to selling, general and administrative expense and the remaining $<ix:nonFraction name="us-gaap:InterestCostsCapitalized" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,848</ix:nonFraction> was capitalized to the consolidated balance sheet. One lender participating in the Prior Credit Agreement became a lender in the 2019 Credit Agreement and, as a result, $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,985</ix:nonFraction> related to the Prior Credit Agreement was written off and recorded as interest expense. The $269 recorded in selling, general and administrative expense and the $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,985</ix:nonFraction> recorded in interest expense total the $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,252</ix:nonFraction> of loss on debt retirement and modification. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total capitalized deferred fees for the Term Loan of $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,398</ix:nonFraction> and Revolver of $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">653</ix:nonFraction> are being amortized to interest expense on a straight-line basis over each of the respective lives, which approximates the effective interest method. The Company recorded $<ix:nonFraction name="bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">543</ix:nonFraction>, $<ix:nonFraction name="bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">711</ix:nonFraction> and $<ix:nonFraction name="bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">745</ix:nonFraction> in interest expense associated with these deferred costs for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual maturities of long-term debt as of December&#160;31, 2020, were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">140,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025 and thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturingInYearsFourAndFive" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,098</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Original issue discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">188,378</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173,378</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company enters into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. On March&#160;26, 2020, the Company entered an interest rate swap agreement with one of its Lenders, which expires in December 2024. The interest rate swap was not designated as a hedge. The Company has no other active derivatives and the swap is carried at fair value on the balance sheet. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note&#160;7. Fair value measurements</div></div> for further details regarding the Company&#8217;s interest rate swap. There were <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> outstanding derivatives as of December&#160;31, 2019. Interest expense of $<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,599</ix:nonFraction> was recorded within the consolidated statements of operations and comprehensive income (loss) related to the change in fair value of the swap for the year ended December&#160;31, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The notional value of the swap totaled $<ix:nonFraction name="us-gaap:DerivativeNotionalAmount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction> or <ix:nonFraction name="us-gaap:PercentageOfDebtHedgedByInterestRateDerivatives" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">52.6</ix:nonFraction>%, of the Term Loan outstanding principal at December&#160;31, 2020. The swap locked in the variable portion of the interest rate on the $<ix:nonFraction name="us-gaap:DerivativeNotionalAmount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction> notional at <ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.64</ix:nonFraction>%, with a stated fixed rate of <ix:nonFraction name="bvs:DerivativeStatedFixedInterestRate" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.25</ix:nonFraction>%. The effective interest rate of the swap was <ix:nonFraction name="bvs:DerivativeEffectiveInterestRate" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.89</ix:nonFraction>% as of December&#160;31, 2020. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-32 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><br/></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:MembersEquityNotesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6. Members&#8217; equity </div> <ix:nonNumeric name="bvs:ScheduleOfMembersEquityTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members&#8217; equity consisted of the following at December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">168,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">168,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitIssuanceValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">113,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitIssuanceValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">113,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Profits interest and other equity awards (Refer to<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Note 9. Equity-based compensation</div></div>)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersCapital" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersCapital" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The authorized number of common and preferred units were unlimited. On May&#160;4, 2012, <ix:nonFraction name="bvs:ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" contextRef="P05_01_2012To05_31_2012_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,900,000</ix:nonFraction> common units and <ix:nonFraction name="bvs:ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" contextRef="P05_01_2012To05_31_2012_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelvePreferredUnitsMemberusgaapPreferredUnitsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,100,000</ix:nonFraction> preferred units (2012 Preferred Units) were issued. During November 2015, the Company obtained a $<ix:nonFraction name="bvs:PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" contextRef="P11_01_2015To11_30_2015_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction> capital contribution from its existing members and <ix:nonFraction name="bvs:ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" contextRef="P11_01_2015To11_30_2015_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,490,000</ix:nonFraction> in preferred units were issued (2015 Preferred Units). The common and preferred members have stated rights and privileges, which include, but are not limited to: (1)&#160;voting and Company governance, (2)&#160;the transfer of membership interests and (3)&#160;dissolution and liquidation of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each preferred unit carried a priority payout (Liquidation Preference), as defined in the Company&#8217;s limited liability company agreement in effect at December&#160;31, 2020. The initial Liquidation Preference for the 2012 and 2015 Preferred Units were $<ix:nonFraction name="bvs:PreferredUnitsLiquidationPreferencePerUnit" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelvePreferredUnitsMemberusgaapPreferredUnitsByNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">23.14</ix:nonFraction> and $<ix:nonFraction name="bvs:PreferredUnitsLiquidationPreferencePerUnit" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">33.57</ix:nonFraction>, respectively. The preferred units accrued a distribution right at a rate of <ix:nonFraction name="bvs:PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%&#160;per annum and was added annually to the Liquidation Preference. On February&#160;11, 2021, the common and preferred units, including the preferred distribution rights, were converted into Common LLC Interests as discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 1. Organization and basis of presentation of financial information</div></div> and no further distribution rights accrued. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Continuing LLC Owner owned the only Equity Participation Right Unit (EPR Unit). The EPR Unit was junior to the common units and its only entitlement was <ix:nonFraction name="bvs:EquityParticipationRightEntitledPercentageOfDistributions" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.55</ix:nonFraction>% of available distributions arising from the closing of a sale of units representing a percentage interest of more than <ix:nonFraction name="bvs:DistributionEventTriggerPercentageOfSaleOfAssets" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">66.66</ix:nonFraction>%, or the sale of all or substantially all of the assets of the Company, provided such event constitutes a change of control (Distribution Event) as described in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 7. Fair value measurements.</div></div> In February 2021, the EPR Unit was redeemed in exchange for $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P02_01_2021To02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,327</ix:nonFraction> in connection with the IPO at which time the EPR ceased to exist and all entitlements ended. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 17. Subsequent events</div></div> for further details regarding the impact of the IPO on members&#8217; equity. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26388921"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Fair value measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, there were no assets measured at fair value and there were no liabilities measured at fair value using Level&#160;1 inputs. <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26388922">The following table provides information for liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs.</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26388922">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swap</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,602</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,602</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management incentive plan and liability-classified awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Participation Rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,457</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,602</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-33 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388921" continuedAt="TextSelectionAppend_26388921_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate swap </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company values interest rate swaps using discounted cash flows. Forward curves and volatility levels are used to estimate future cash flows that are not certain. These are determined using observable market inputs when available and based on estimates when not available. The fair value of the swap was recorded in the Company&#8217;s consolidated balance sheets within accrued liabilities. Changes in fair value are recognized as interest expense within the consolidated statements of operations and comprehensive income (loss). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management incentive plan and liability-classified awards </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO, the Company had operated <ix:nonFraction name="bvs:NumberOfEquityBasedCompensationPlans" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_Plan" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction>-equity-based compensation plans, the Management Incentive Plan (MIP) and the Phantom Profits Interest Plan (Phantom Plan). The estimated fair value reflects assumptions made by management as of December&#160;31, 2020, including the impact of COVID-19 on significant unobservable assumptions, such as the expected timing and volume of elective procedures and the impact of these procedures on future revenues which impact the equity value. However, the actual amount ultimately paid could be higher or lower than the fair value. The Company has classified $<ix:nonFraction name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,054</ix:nonFraction> as accrued equity-based compensation and $<ix:nonFraction name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,249</ix:nonFraction> as accrued equity-based compensation, less current portion as of December&#160;31, 2020. Any changes in fair value are recorded as an operating expense and included within selling, general administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. </div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26388926"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,002</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2020, the sole MIP awardee exercised the right to force a cash settlement for <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">150,252</ix:nonFraction> of the <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">333,330</ix:nonFraction> vested units resulting in a payment of $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P06_01_2020To06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,329</ix:nonFraction>. The remaining <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">183,078</ix:nonFraction> units were settled for $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P02_01_2021To02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,802</ix:nonFraction> in February 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EPR Unit </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO, after which the EPR ceased to exist and all entitlements ended, the Continuing LLC owners owned the only EPR Unit and its only entitlement was <ix:nonFraction name="bvs:EquityParticipationRightEntitledPercentageOfDistributions" contextRef="PAsOn02_15_2021_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.55</ix:nonFraction>% of available distributions arising from a Distribution Event. The estimated fair value reflects assumptions made by management as of December&#160;31, 2020, including potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. The fair value of the EPR Unit was recorded in the Company&#8217;s consolidated balance sheets as other long-term liabilities. The revaluation for the EPR liability is recognized in interest expense on the consolidated statements of operations and comprehensive income (loss). </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-34 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388921_1"><ix:continuation id="TextSelection_26388926"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">565</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,457</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of the Plans and EPR Unit using a Monte Carlo simulation. This fair value measurement is based on significant inputs that are unobservable in the market, and thus represents a Level 3 measurement. The key assumptions used in applying the valuation model include the Company&#8217;s equity value, the expected timing until a liquidity event, applicable discount rates applied, and equity volatility. In addition, for the EPR Unit, the estimated accrued preferred distribution at the liquidity event date totaling $<ix:nonFraction name="us-gaap:CashAvailableForDistributions" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,854</ix:nonFraction> as of December&#160;31, 2020 as it is senior in order of payment. Significant changes in these assumptions could result in a significantly higher or lower fair value. </div></div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a range of key assumptions used within the valuation of the awards as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation technique</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted Average</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Option pricing approach</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Time to liquidity event</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_Business" decimals="1" scale="0" format="ixt:numdotdecimal">0.4</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" unitRef="Unit_Business" decimals="1" scale="0" format="ixt:numdotdecimal">0.4</ix:nonFraction></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Risk free rate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_Business" decimals="2" scale="0" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" unitRef="Unit_Business" decimals="2" scale="0" format="ixt:numdotdecimal">0.10</ix:nonFraction>%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Equality volatility</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_Business" decimals="2" scale="0" format="ixt:numdotdecimal">35.13</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MaximumMembersrtRangeAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_Business" decimals="2" scale="0" format="ixt:numdotdecimal">101.25</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" unitRef="Unit_Business" decimals="1" scale="0" format="ixt:numdotdecimal">50.0</ix:nonFraction>%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Equity value</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">$<ix:nonFraction name="bvs:EquityParticipationRightsUnitEquityValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,065,000</ix:nonFraction>&#160;-&#160;$<ix:nonFraction name="bvs:EquityParticipationRightsUnitEquityValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MaximumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,240,000</ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">$<ix:nonFraction name="bvs:EquityParticipationRightsUnitEquityValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,145,000</ix:nonFraction></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Lack of marketability discount</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputDiscountForLackOfMarketabilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_Business" decimals="1" scale="0" format="ixt:numdotdecimal">7.0</ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><ix:nonFraction name="bvs:EquityParticipationRightsUnitMeasurableInput" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputDiscountForLackOfMarketabilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis" unitRef="Unit_Business" decimals="1" scale="0" format="ixt:numdotdecimal">7.0</ix:nonFraction>%</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26390023"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Restructuring costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs are not allocated to the Company&#8217;s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring expenses in the consolidated statement of operations and comprehensive income (loss). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fourth quarter of 2020 and 2018, the Company adopted restructuring plans to improve the performance of International operations, principally through headcount reduction and closing offices in certain countries as the Company shifts to an indirect distribution model in these countries. The plans were completed in 2020 and 2019, respectively, and the Company recorded total pre-tax charges of $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">563</ix:nonFraction>, $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">575</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,373</ix:nonFraction> primarily related to severance for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company&#8217;s costs totaled $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwentyPlanMemberusgaapRestructuringPlanAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">563</ix:nonFraction> for the 2020 plan and $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndEighteenPlanMemberusgaapRestructuringPlanAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,948</ix:nonFraction> for the 2018 plan. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-35 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26390023"><ix:nonNumeric name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s restructuring charges and payments for all plans are comprised of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee<br/>severance&#160;and<br/>temporary<br/>labor&#160;costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>charges</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">206</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,203</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses incurred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments made</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">290</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,778</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses incurred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments made</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389368"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Equity-based compensation&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-based compensation plans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operated <ix:nonFraction name="bvs:NumberOfEquityBasedCompensationPlans" contextRef="PAsOn02_10_2021_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_Plan" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> equity-based compensation plans, the MIP and the Phantom Plan (the Plans) prior to the IPO. The awards granted under both plans represented a non-managing, non-voting interest in the Company designed for grantees to share in the future appreciation of the value of the Company. Awards granted under the MIP Plan and the 2015 Phantom Units are liability-classified and the 2012 Phantom Units are equity-classified. On February&#160;11, 2021, in conjunction with the IPO, the Plans were terminated and there were no further awards, under the Plans. As a result, the New LLC Owner assumed the obligations of the Company&#8217;s Phantom Plan awards on February&#160;10, 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The awards granted under the MIP fully vested at December&#160;2, 2017. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction></ix:nonFraction>MIP awards granted for the years ended December&#160;31, 2020, 2019 and 2018. In June 2020, the sole MIP awardee exercised the right to force a cash settlement for <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">150,252</ix:nonFraction> of the <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">333,330</ix:nonFraction> vested units resulting in a payment of $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P06_01_2020To06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,329</ix:nonFraction>. As of December&#160;31, 2020 and 2019, respectively, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">183,078</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">333,330</ix:nonFraction> vested awards outstanding both with a grant date fair value of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">4.89</ix:nonFraction>. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest compensation of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,103</ix:nonFraction>, $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,844</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,325</ix:nonFraction> for all plans, was recognized for the years ended December&#160;31, 2020, 2019 and 2018 respectively. The expense is included in selling, general and administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. As of December&#160;31, 2020, there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,741</ix:nonFraction> of unrecognized compensation expense to be recognized over a weighted-average period of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="1" scale="0" format="ixt:numdotdecimal">1.3</ix:nonFraction> years. </div></div><ix:nonNumeric name="bvs:ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the award activity of the Phantom Plan for the year ended December&#160;31, 2020 is as follows (number of awards in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 43%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2012 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2015 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(awards in thousands)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted to cash</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">12.98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards vested at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">8.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-36 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389368"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction>2012 Phantom Unit awards granted in 2019. The weighted average grant date fair value per Other Phantom Unit awards granted in the year ended December&#160;31, 2019 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">15.31</ix:nonFraction>. </div></div><ix:nonNumeric name="bvs:ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 36%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2012 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2015 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(awards in thousands)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nonvested at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.01</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">12.71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested during 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.01</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nonvested at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">11.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total fair value of 2012 Phantom Unit awards vested in the year ended December&#160;31, 2020 was nominal. The total fair value of Other Phantom Unit awards vested in the year ended December&#160;31, 2020 was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,703</ix:nonFraction>. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Defined contribution plans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has various defined contribution plans or plans that share profit which are offered in Canada, Germany, the Netherlands and the United Kingdom. These plans are required by local laws or regulations in some cases. Contributions are primarily discretionary, except in some countries where contributions are contractually required. These plans cover substantially all eligible employees in the countries where the plans are offered either voluntarily or statutorily. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the U.S., the Company provides a 401(k) defined contribution plan (U.S. Plan) that covers substantially all U.S. employees that meet minimum age requirements. The Company matches <ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of the employees&#8217; contribution up to <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>% of the employees&#8217; wages. The Company also contributes <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>% of the employees&#8217; wages to the U.S. Plan. The 4.5% Company contribution was suspended in May 2020 due to the COVID-19 crisis and reinstated in late December 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2020, 2019 and 2018, Company contributions totaled $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,379</ix:nonFraction>, $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,401</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,462</ix:nonFraction> respectively, for all global plans. The expense is included in cost of sales, selling, general and administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389126"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Income taxes&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of net income from continuing operations before taxes for the years ended December&#160;31 are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxable subsidiaries:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Domestic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,679</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,967</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">693</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,646</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other domestic subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,221</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,043</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-37 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389126" continuedAt="TextSelectionAppend_26389126_1"><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">891</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">294</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">380</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax rates - deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The differences between the effective income tax rate and the federal statutory income tax rates for the years ended December&#160;31 by taxable and other subsidiaries are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. statutory federal corporate income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC flow-through structure</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">20.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">8.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">15.7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State and local income taxes, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">7.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">11.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">3.9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">3.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">16.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">27.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rate differs from statutory rates primarily due to Bioventus LLC&#8217;s pass-through structure for U.S. income tax purposes while being treated as taxable in certain states and various foreign jurisdictions as well as for certain subsidiaries. In addition, certain states assess income taxes on pass-through structures. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389861"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></ix:nonNumeric> <ix:continuation id="TextSelection_26389861"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,874</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,920</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liability:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangible</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:DeferredTaxLiabilitiesAcquiredIntangibles" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,939</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:DeferredTaxLiabilitiesAcquiredIntangibles" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,874</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the need for a valuation allowance against our deferred tax assets. A valuation allowance of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,822</ix:nonFraction>, has been applied to all of Harbor&#8217;s deferred tax assets. The Company also has a valuation allowance of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NonUsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">171</ix:nonFraction> representing the entire balance of deferred tax assets relating to our international operations. These valuation allowances were recorded as the Company believes it is more-likely-than-not that it will receive future benefit. At December&#160;31, 2020, the Company had federal and state net operating loss carryforwards related to Harbor of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FederalAndStateMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,537</ix:nonFraction> expiring at various dates from 2021 through 2037 and approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FederalAndStateMemberusgaapIncomeTaxAuthorityAxis_IndefinitelyMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,141</ix:nonFraction> with no expiration date. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-38 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389126_1" continuedAt="TextSelectionAppend_26389126_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company<div style="display:inline;">&#160;</div>evaluates its tax positions in accordance with the recognition and measurement provisions of ASC&#160;740-10 (&#8220;FIN 48&#8221;) and in accordance with that guidance, has determined that a reserve for any significant uncertain tax positions is not needed as of December&#160;31, 2020 and <div style="letter-spacing: 0px; top: 0px;;display:inline;">2019</div>. </div></div> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389126_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under current tax law, the utilization of tax attributes will be restricted if an ownership change, as defined, were to occur. Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, provides, in general, that if an &#8220;ownership change&#8221; occurs with respect to a corporation with net operating and other loss carryforwards, such carryforwards will be available to offset taxable income in each taxable year after the ownership change only up to the &#8220;Section&#160;382 Limitation&#8221; for each year. The Company&#8217;s ability to use its loss carryforwards will be limited in the event of an ownership change. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2018, Dutch income taxes were imposed on a negotiated percentage of sales. The Company has an agreement with the Dutch taxing authorities where the Company&#8217;s Netherlands subsidiary will incur but not have to pay income taxes in years when the subsidiary is operating at a loss. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Minimal tax related interest and penalties were incurred for the years ended December&#160;31, 2020 and 2019. The Company is subject to audit by various taxing jurisdictions for the years <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2020MemberusgaapTaxPeriodAxis"><ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2015MemberusgaapTaxPeriodAxis">2015</ix:nonNumeric></ix:nonNumeric> through 2020. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Related-party transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made cash tax distributions of $<ix:nonFraction name="bvs:CashDistributionMadeToMembersTowardsTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,886</ix:nonFraction>, $<ix:nonFraction name="bvs:CashDistributionMadeToMembersTowardsTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,137</ix:nonFraction> and $<ix:nonFraction name="bvs:CashDistributionMadeToMembersTowardsTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,846</ix:nonFraction> to its members in an amount equal to approximately <ix:nonFraction name="bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the members&#8217; estimated taxable income for the years ended December&#160;31, 2020, 2019 and 2018, respectively. At December&#160;31, 2020 and December&#160;31, 2019, there were tax distributions payable to tax authorities on the members&#8217; behalf totaling $<ix:nonFraction name="bvs:RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">541</ix:nonFraction> and $<ix:nonFraction name="bvs:RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">473</ix:nonFraction>, respectively, and nominal tax distributions payable to the members. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_26389133"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Commitments and contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under finance leases. The remaining lease terms range from 3 months to 8 years. </div></div> <ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease cost were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,529</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">358</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,887</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*Includes</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">variable lease cost and sublease income, which are immaterial. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information and non-cash activity related to leases were as follow: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of operating lease liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,567</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use assets obtained in exchange for operating lease obligations:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,016</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-39 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389133" continuedAt="TextSelectionAppend_26389133_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current and noncurrent operating and finance lease liabilities are included in other current liabilities and other long-term liabilities, respectively, on the consolidated balance sheet. <ix:nonNumeric name="bvs:AssetsAndLiabilitiesLesseeTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389137">Other balance sheet information related to leases are as follows:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26389137">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,267</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities&#8212;current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,814</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities&#8212;noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,068</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining operating lease term in years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" format="ixt-sec:duryear">7.2</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" format="ixt-sec:duryear">8.0</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate for operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> </ix:continuation> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities as of December&#160;31, 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,460</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,476</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total future lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,077</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of future lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,068</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">OIG&#8217;s Provider Self-Disclosure </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company identified non-compliance with certain U.S. federal statutes and requirements governing the Medicare program in 2018 related to improper completion of Certificate for Medical Necessity (CMN) forms and in November 2018 made a voluntary self-disclosure to the Office of Inspector General of the U.S. Department of Health and Human Services (OIG) pursuant to the OIG&#8217;s Provider Self-Disclosure Protocol related to this matter. After settlement discussions with the Office of the United States Attorney in the Middle District of North Carolina (USAO) and OIG, on January&#160;15, 2021, the Company reached a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which the Company&#8217;s sales representatives completed Section B of the CMN form. On February&#160;22, 2021, the Company finalized all terms related to the settlement and entered into a formal settlement agreement with the USAO and OIG consistent with the previous agreement in principle and which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type and resolved the potential liability related to the Company&#8217;s self-disclosure for $<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,600</ix:nonFraction>, of which $<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,400</ix:nonFraction> had previously been paid. The remaining $<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P02_23_2021To02_23_2021_BioVentusLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsaoAndOigMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,200</ix:nonFraction></ix:nonFraction> net settlement amount due under the agreement was recorded in accrued liabilities within the consolidated balance sheets as of December&#160;31, 2020 and paid on February&#160;23, 2021. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 17. Subsequent events</div></div> for further details regarding the resolution. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserve for estimated overpayments from all third-party payers </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a reserve for reimbursement claims related to its Minimally Invasive Fracture Treatment product that may have been processed for payment by the Company without adequate medical records support. The Company held a reserve of $<ix:nonFraction name="us-gaap:LossContingencyAccrualProductLiabilityNet" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,790</ix:nonFraction> and $<ix:nonFraction name="us-gaap:LossContingencyAccrualProductLiabilityNet" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,801</ix:nonFraction> at December&#160;31, 2020 and 2019, respectively for these </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-40 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389133_1" continuedAt="TextSelectionAppend_26389133_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amounts. The Company refunded Medicare $<ix:nonFraction name="bvs:RefundOfExcessPaymentsToThirdPartyCustomers" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,519</ix:nonFraction> and $<ix:nonFraction name="bvs:RefundOfExcessPaymentsToThirdPartyCustomers" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,458</ix:nonFraction> during the years ended December&#160;31, 2020 and 2019, respectively, related to known and estimated overpayments for medical necessity included in this reserve for periods through December&#160;31, 2019. Certain of these overpayments were identified as potential overpayments in the Company&#8217;s OIG self-disclosure in November 2018. The Company&#8217;s reserve was estimated using extrapolation of an error rate from a statistical sample, which represents the Company&#8217;s best estimate as of the date of the financial statements, but because of the uncertainty inherent in such estimates, the ultimate resolution may be materially different. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product recall </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, we voluntarily recalled our ultrasound gel, an accessory to the Minimally Invasive Fracture Treatment product. We have incurred, and expect to incur in the future, costs associated with this recall. Based on the information that has been received, we have estimated the probable loss related to this recall globally to be approximately $<ix:nonFraction name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,684</ix:nonFraction>. We have recorded reserves representing the probable loss within accrued liabilities on the consolidated balance sheet. The final outcome of this recall is dependent on many factors that are difficult to predict. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other matters </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;23, 2019, the Company and Harbor entered into an exclusive collaboration agreement for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. As part of the agreement a third-party license was assigned to us and the Company is subject to a <ix:nonFraction name="bvs:CollaborativeArrangementRoyaltyPercentage" contextRef="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>% royalty on certain commercial sales, or a nominal minimum amount per quarter, beginning in 2023. The Company is obligated to pay up to $<ix:nonFraction name="bvs:MilestonePaymentPayable" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,000</ix:nonFraction> upon achieving certain milestones. Unless earlier terminated, the agreement will remain in effect until the earlier of 8 years or until the payment of certain milestones are met. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;29, 2019, the Company and Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF. The first phase has been completed. Additional fees for the subsequent phases will be determined as the development work progresses. The Development Agreement continues until the date when the parties execute a supply agreement for the commercial products. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection OA product with the supplier of the Company&#8217;s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement totaled $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,021</ix:nonFraction>, $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,622</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,082</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018 respectively, and are included in cost of sales on the consolidated statement of operations and comprehensive income (loss). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of a supply agreement entered on February&#160;9, 2016 for the Company&#8217;s three injection OA product, the Company is subject to annual minimum purchase requirements for <ix:nonNumeric name="bvs:SupplyCommitmentTerm" contextRef="P02_09_2016To02_09_2016_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. After the initial <ix:nonNumeric name="bvs:SupplyCommitmentTerm" contextRef="P02_09_2016To02_09_2016_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>, the agreement will automatically renew for an additional <ix:nonNumeric name="bvs:SupplyCommitmentRenewalTerm" contextRef="P02_09_2016To02_09_2016_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric> unless terminated by the Company or the seller in accordance with the agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of a supply agreement for the Company&#8217;s five injection OA product, that was amended and restated on December&#160;22, 2020, the Company is subject to annual minimum purchase requirements for <ix:nonNumeric name="bvs:CollaborativeArrangementTerm" contextRef="P12_22_2020To12_22_2020_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" format="ixt-sec:durwordsen">eight years</ix:nonNumeric>. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the license products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive income (loss). </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-41 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389133_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company causes LOCs to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of December&#160;31, 2020 and 2019, the Company had one LOC outstanding for a nominal amount. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#8220;claims made&#8221; basis for expenses in excess of $<ix:nonFraction name="bvs:StopLossInsuranceThresholdPerMemberPerYear" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150</ix:nonFraction> per member per year. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to the business. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#8217;s complete control and may not be known for extended periods of time. Other than the matters discussed above, management of the Company, after consultation with legal counsel, does not believe there are any unrecorded matters that will have a material adverse effect upon the Company&#8217;s financial statements. </div></div></ix:continuation><ix:nonNumeric name="bvs:NetIncomeLossPerUnitTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. Net income (loss) per unit </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the computation of basic and diluted net income (loss) per unit for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss attributable to noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations attributable to unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated and unpaid preferred distributions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,955</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income allocated to participating shareholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) from continuing operations attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:NetIncomeLossFromContinuingOperations" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,383</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:NetIncomeLossFromContinuingOperations" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:NetIncomeLossFromContinuingOperations" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,383</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17,988</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per unit attributable to common unit holders - basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,900,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,900,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,900,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The computation of diluted earnings per unit for the years ended December&#160;31, 2020, 2019 and 2018 excludes the effect of the <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,590</ix:nonFraction></ix:nonFraction></ix:nonFraction> potential common units that would be issued upon the conversion of preferred units. The effect of these units would be antidilutive due to the impact of the accumulated and unpaid preferred distributions as well as the Company being in a net loss position for the years ended December&#160;31, 2019 and 2018. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-42 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="bvs:NetSalesTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26390214"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14. Net Sales</div></div></div></ix:nonNumeric> <div style="margin-top: 1em; margin-bottom: 1em"></div> </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26390214" continuedAt="TextSelectionAppend_26390214_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the location from which the sale originated. <ix:nonNumeric name="bvs:DisaggregationOfRevenueBasedOnGeographyTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389475">The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) for the years ended December&#160;31 as follows:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;</div></div> </ix:continuation> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_26390214_1"> <ix:continuation id="TextSelection_26389475">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary geographic markets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">293,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">305,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">282,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,069</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">321,161</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">340,141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">319,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vertical:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OA joint pain treatment and joint preservation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">171,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">182,082</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">155,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Minimally invasive fracture treatment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">103,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">121,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bone graft substitutes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">321,161</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">340,141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">319,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation> </ix:continuation><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. Segments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment information by asset is not disclosed as it is not reviewed by the CODM or used to allocate resources or to assess the operating results and financial performance. We believe EBITDA, adjusted for additional non-operational factors disclosed in the table below, or Adjusted EBITDA, is a key measure for internal reporting. Adjusted EBITDA should not be considered in isolation or as a substitute for consolidated net income (loss) attributable to the Company, the most closely analogous U.S. GAAP measure. Adjusted EBITDA is not defined in the same manner by all companies and may not be comparable to other similarly titled measures of other companies unless the definition is the same. <ix:nonNumeric name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389245">The following table presents segment adjusted EBITDA reconciled to income from continuing operations before income taxes for the years ended December&#160;31 as follows:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26389245">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment adjusted EBITDA from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,691</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,751</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19 benefits, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnusualOrInfrequentItemNetGainLoss" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Succession and transition charges</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:SuccessionAndTransitionCharges" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity loss in unconsolidated investments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other non-recurring costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,723</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389492"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16. Discontinued operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, the Company, under the direction and authority of the Company&#8217;s Board of Managers, committed to shut down the bone morphogenetic protein (BMP) research and development program, which had been reported as its own segment in previous years. Substantially all operations, including project close </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-43 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389492"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">documentation, contract termination, vacating the facility and ultimately the termination of the employees, ceased by March 2019 and as a result the BMP research and development program met the criteria for discontinued operations. The Company sold the remaining $<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">172</ix:nonFraction> held for sale asset and paid the remaining $<ix:nonFraction name="bvs:DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">400</ix:nonFraction> accrued liability from the BMP research and development program during the year ended December&#160;31, 2020. </div></div> <ix:nonNumeric name="bvs:DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the statement of operations and comprehensive income (loss) from discontinued operations for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,773</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on disposal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_26389342"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17. Subsequent events </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;4, 2021, the Company made a convertible debt investment of $<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherInvestments" contextRef="P01_04_2021To01_04_2021_BioVentusLlcMemberdeiLegalEntityAxis_ConvertibleDebtInstrumentsMemberusgaapInvestmentTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">1,500</ix:nonFraction> in a medical device company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recapitalization </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, the following Transactions occurred. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Company amended and restated its limited liability company agreement (New LLC Agreement) to, among other things, (i)&#160;provide for the new single class of common membership interests in the Company as discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 1. Organization and basis of presentation for financial information</div></div>; (ii)&#160;exchange all of the then existing membership interests of the common and preferred unit holders (Original LLC Owners) for Common LLC Interests and (ii)&#160;appoint the New LLC Owner as the sole managing member of the Company. The amendment resulted in the Company&#8217;s common and preferred units, including the preferred distribution rights, being converted into <ix:nonFraction name="bvs:CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" contextRef="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_RestatedLimitedLiabilityCompanyAgreementMemberBVSEventAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">47,625,326</ix:nonFraction> Common LLC Interests. </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The New LLC Owner amended and restated its certificate of incorporation to, among other things, (i)&#160;provide for Class&#160;A common stock and Class B common stock, each share of which entitles its holders to one vote per share on all matters presented to the New LLC Owner&#8217;s stockholders and (ii)&#160;issue <ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction> shares of Class B common stock to the Continuing LLC Owner, on a one-to-one basis with the number of LLC Interests it owns. While the Class B common stock holds voting rights it holds no economic interest in the New LLC Owner. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The New LLC Owner acquired, by merger, the Former LLC Owners and upon consummation of the merger, owned <ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" contextRef="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> Common LLC Interests. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The New LLC Owner closed an IPO of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,200,000</ix:nonFraction> shares of Class&#160;A common stock at a public offering price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:numdotdecimal">13.00</ix:nonFraction> per share. The New LLC Owner received $<ix:nonFraction name="bvs:ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" contextRef="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">111,228</ix:nonFraction> in proceeds, net of underwriting discounts and commissions, which was used to make a capital contribution to the Company in exchange for <ix:nonFraction name="bvs:CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" contextRef="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,200,000</ix:nonFraction> Common LLC Interests of the Company at a price per interest equal to the IPO price of $13.00. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to the Transactions, the New LLC Owner owns <ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" contextRef="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">41,038,589</ix:nonFraction> Common LLC Interests or <ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" contextRef="P02_17_2021To02_17_2021_BioventusIncMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">72.2</ix:nonFraction>% of the Company and the Continuing LLC Owner owns <ix:nonFraction name="bvs:LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" contextRef="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction> or <ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" contextRef="P02_17_2021To02_17_2021_BioventusIncMembersrtOwnershipAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">27.8</ix:nonFraction>%. The New LLC Owner has a majority economic interest, the sole voting interest in, and controls the management of the Company. As a result, the New LLC Owner will consolidate the financial results of the Company and will report a non-controlling interest representing the interests owned by the Continuing LLC Owner. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-44 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389342"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The New LLC Agreement requires that the Company, at all times, maintain (i)&#160;a one-to-one ratio between the number of shares of Class&#160;A common stock issued by the New LLC Owner and the number of Common LLC Interests owned by the New LLC Owner and (ii)&#160;a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2021, the Company finalized all terms related to a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which our sales representatives completed Section B of the CMN forms. The Company entered into a formal settlement agreement with the USAO and OIG which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type and resolved the potential liability related to the Company&#8217;s self-disclosure in this matter for $<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,600</ix:nonFraction>, of which $<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,400</ix:nonFraction> has already been paid through the Company&#8217;s 2019 return of overpayments described previously. The remaining $<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P02_23_2021To02_23_2021_BioVentusLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsaoAndOigMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,200</ix:nonFraction></ix:nonFraction> net settlement amount due under the agreement was recorded in accrued liabilities within the consolidated balance sheets as of December&#160;31, 2020 and was paid on February&#160;23, 2021. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-45 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div></div><div id="findex180330_14" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated condensed statements of operations and comprehensive (loss) income </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three and six months ended July&#160;3, 2021 and June&#160;27, 2020 </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except share and per share data) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">109,816</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales (including depreciation and amortization of $<div style="display:inline;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,618</ix:nonFraction>, $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,292</ix:nonFraction></div>, $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,854</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,599</ix:nonFraction> respectively)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,668</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,725</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,077</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">135,869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">97,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">103,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,836</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,742</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,813</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of variable interest entity assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating (loss) income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,593</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense (income)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense (income)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,337</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,389</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,748</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,506</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss attributable to noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income attributable to Bioventus Inc.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,748</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,506</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss), net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in foreign currency translation adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">859</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">256</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive (loss) income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,767</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,889</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss attributable to noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,882</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive (loss) income attributable to Bioventus Inc.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P03_28_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,922</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss per share of Class&#160;A common stock, basic and diluted<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal" id="Fact_26388121">0.10</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal" id="Fact_26388122">0.12</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares of Class&#160;A common stock outstanding, basic and diluted<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal" id="Fact_26388127"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,805,347</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal" id="Fact_26388128"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,802,840</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Per share information for the six months ended July&#160;3, 2021 represents loss per share of Class&#160;A common stock and weighted-average shares of Class&#160;A common stock outstanding from February&#160;16, 2021 through July&#160;3, 2021, the period following Bioventus Inc.&#8217;s initial public offering and related transactions described in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 1. Organization</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 7. Earnings per share </div></div>within the<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Notes to the Unaudited Condensed Consolidated Financial Statements.</div></div> </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-46 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div></div><div id="findex180330_15" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated condensed balance sheets as of July&#160;3, 2021 (Unaudited) and December&#160;31, 2020 </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136,065</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,552</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">290,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">211,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,879</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">52,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">257,848</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,382</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">646,636</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">494,466</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and Stockholders&#8217; and Members&#8217; Equity</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">105,246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued equity-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,964</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">122,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173,378</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued equity-based compensation, less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration, less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,728</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">427,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">350,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (Note 8)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; and Members&#8217; Equity:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn07_03_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn07_03_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn07_03_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">0 </ix:nonFraction></ix:nonFraction>shares issued</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction> par value <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">41,062,652</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">146,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity attributable to Bioventus Inc. and members&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">141,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; and members&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">219,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and stockholders&#8217; and members&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">646,636</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">494,466</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-47 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div></div><div id="findex180330_16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated condensed statements of changes in stockholders&#8217; and members&#8217; equity </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three and six months ended July&#160;3, 2021 and June&#160;27, 2020 </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except share data) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended July&#160;3, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 32%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A Common<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B Common<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div> -<br/>Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">comprehensive</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">income</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">controlling</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">and</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">members&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at Balance at April&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn04_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,038,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn04_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn04_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn04_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn04_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">142,923</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn04_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn04_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,041</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn04_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn04_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">220,282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_04_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">24,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_04_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution of Continuing LLC Owner</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_04_2021To07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deconsolidation of variable interest entity</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P04_04_2021To07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,062,652</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">146,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">219,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended June&#160;27, 2020 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Members&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at Balance at March&#160;28, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn03_28_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">155,590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to members</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromDistributionToMembers" contextRef="P03_29_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P03_29_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P03_29_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;27, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">141,791</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-48 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Six Months Ended July&#160;3, 2021 </div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 29%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A&#160;Common<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B&#160;Common<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Members&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div> -<br/>Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">comprehensive</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">income</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">controlling</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Stockholders&#8217;<br/>and</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">members&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Refund from members</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MembersEquityIncreaseFromRefundsFromMembers" contextRef="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MembersEquityIncreaseFromRefundsFromMembers" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other equity forfeiture</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromEquityForfeitures" contextRef="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromEquityForfeitures" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income prior to&#160;Organizational Transactions</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment prior to Organizational Transactions</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,507</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,507</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Organizational Transactions</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityChangeInReportingEntity" contextRef="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">168,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:StockholdersEquitySharesChangeInReportingEntity" contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityChangeInReportingEntity" contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:StockholdersEquitySharesChangeInReportingEntity" contextRef="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityChangeInReportingEntity" contextRef="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityChangeInReportingEntity" contextRef="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityChangeInReportingEntity" contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">79,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityChangeInReportingEntity" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">55,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial public offering, net of offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">106,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To07_03_2021_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">106,450</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">24,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to Continuing LLC Owner</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net&#160;loss subsequent to&#160;Organizational Transactions</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:NetLossSubsequentToOrganizationalTransactions" contextRef="P01_01_2021To07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:NetLossSubsequentToOrganizationalTransactions" contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:NetLossSubsequentToOrganizationalTransactions" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,229</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Deconsolidation of variable interest entity</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity based compensation subsequent to Organizational Transactions</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,821</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,015</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,836</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment subsequent to Organizational Transactions</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2021To07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,062,652</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">146,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">219,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six Months Ended June&#160;27, 2020 </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Members&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2018_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">145,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest forfeiture</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromProfitInterestForfeiture" contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to members</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:MembersEquityDecreaseFromDistributionToMembers" contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,713</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt conversion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,506</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">256</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;27, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">141,791</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-49 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div></div><div id="findex180330_17" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated condensed statements of cash flows </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Six months ended July&#160;3, 2021 and June&#160;27, 2020 </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,748</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,506</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income to net cash provided by (used in) operating activities from continuing operations:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Recovery) provision for expected credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based compensation from 2021 Stock Incentive Plan</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,797</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest plan, liability-classified and other equity awards compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of interest rate swap</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,001</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of Equity Participation Rights unit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ChangeInFairValueOfEquityParticipationRightsUnit" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ChangeInFairValueOfEquityParticipationRightsUnit" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments related to variable interest entity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ImpairmentOfVariableInterestEntityAndRelatedAssets" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,043</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ImpairmentOfVariableInterestEntityAndRelatedAssets" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets and liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,011</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">713</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of Bioness, Inc, net of cash acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">49,296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from investing activities - discontinued operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">49,296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of Class&#160;A common stock sold in initial public offering, net of underwriting discounts and offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of Class&#160;A and B common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowing on revolver</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLongTermLinesOfCredit" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLongTermLinesOfCredit" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refunds (distributions) - members</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ProceedsFromMembers" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">813</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:ProceedsFromMembers" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash from financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">101,409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">37,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of exchange rate changes on cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51,229</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at the beginning of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at the end of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">138,068</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">126,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of noncash investing and financing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued member distributions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MemberDistributionsIncurredButNotYetPaid" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">305</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:MemberDistributionsIncurredButNotYetPaid" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">787</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable for purchase of property, plant and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-50 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div></div><div id="findex180330_18" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the Unaudited Condensed Consolidated Financial Statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Amounts in thousands, except unit, share, per unit and per share data) </div></div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388598"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. (the Company, we, us or our) was formed as a Delaware corporation for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (BV LLC). The Company is headquartered in Durham, North Carolina. BV LLC, is a limited liability company formed under the laws of the state of Delaware on November&#160;23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. BV LLC is a global medical device company, conducting business in various countries, primarily in North America and Europe, with approximately <ix:nonFraction name="dei:EntityNumberOfEmployees" contextRef="PAsOn07_03_2021_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_EMPLOYEE" decimals="0" scale="0" format="ixt:numdotdecimal">900</ix:nonFraction> employees. The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing processes. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial Public Offering </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;16, 2021, the Company closed an IPO of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,200,000</ix:nonFraction> shares of Class&#160;A common stock at a public offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.00</ix:nonFraction> per share, which includes <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction> shares issued pursuant to the underwriters&#8217; over-allotment option. The Company received $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">111,228</ix:nonFraction> in proceeds, net of underwriting discounts and commissions of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,372</ix:nonFraction>, which was used to purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.00</ix:nonFraction>. The Company also incurred offering expenses totaling $<ix:nonFraction name="bvs:SaleOfStockOfferingCosts" contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,778</ix:nonFraction> in addition to the underwriting discounts and commissions. Offering expenses of $<ix:nonFraction name="bvs:PaymentsOfStockIssuanceCostsAdditionalCosts" contextRef="P01_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,327</ix:nonFraction> were paid in 2020 and $<ix:nonFraction name="bvs:PaymentsOfStockIssuanceCostsAdditionalCosts" contextRef="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,451</ix:nonFraction> were paid in 2021. Subsequent to the IPO and related transactions that occurred in connection with the IPO (the Transactions), the Company is the sole managing member of BV LLC and owns <ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" contextRef="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">72.2</ix:nonFraction>% of BV LLC. The Company has a majority economic interest, the sole voting interest in, and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest representing the <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn07_03_2021_BVLLCMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">27.8</ix:nonFraction>% interest not held by the Company. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPO Transactions </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company and BV LLC completed the following Transactions in connection with the IPO. BV LLC amended and restated the Bioventus LLC Agreement, to, among other things, (i)&#160;provide for a new single class of common membership interests in BV LLC (LLC Interests), (ii) exchange all of the existing membership interests in BV LLC for new LLC Interests and (iii)&#160;appoint Bioventus Inc. as the sole managing member of BV LLC. The Company amended and restated its certificate of incorporation to, among other things, provide for the (i)&#160;authorization of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">250,000,000</ix:nonFraction> shares of Class&#160;A common stock with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction> per share; (ii)&#160;authorization of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction> shares of Class&#160;B common stock with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction> per share; (iii)&#160;authorization of <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn02_16_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> shares of undesignated preferred stock that may be issued from time to time by the Company&#8217;s Board of Directors (BOD) in one or more series; and (iv)&#160;establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms. Holders of Class&#160;A / Class&#160;B common stock are entitled to <ix:nonFraction name="bvs:CommonStockNumberOfVotes" contextRef="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Vote" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class&#160;B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class&#160;B common stock may only be issued to the extent necessary to maintain the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-to-one</div></div> ratio between the number of LLC Interests held by the only member of BV LLC that remained a member following the Transactions (Continuing LLC Owner) and the number of shares of Class&#160;B common stock held by the Continuing LLC Owner. Shares of Class&#160;B common stock are transferable only together with an equal number of LLC Interests. Shares of Class&#160;B common stock will be canceled on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="bvs:CancellationRatioRequiredStockToLLCInterestRatio" contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-for-one</div></div> basis if the Company, at the election of a Continuing LLC Owner, redeem or exchange LLC Interests. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-51 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388598" continuedAt="TextSelectionAppend_26388598_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company&#8217;s amended and restated certificate of incorporation and the Bioventus LLC Agreement requires that the Company and BV LLC at all times maintain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-to-one</div></div> ratio between the number of shares of Class&#160;A common stock issued by the Company and the number of LLC Interests owned by the Company, as well as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-to-one</div></div> ratio between the number of shares of Class&#160;B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. The Company acquired, by merger, <ix:nonFraction name="us-gaap:NumberOfBusinessesAcquired" contextRef="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_Business" decimals="0" scale="0" format="ixt-sec:numwordsen">ten </ix:nonFraction>entities that were members of BV LLC (Former LLC Owners), for which the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> shares of Class&#160;A common stock as merger consideration (Merger). The only assets held by the Former LLC Owners were <ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> LLC Interests and a corresponding number of shares of Class&#160;B common stock. Upon consummation of the Merger, the Company canceled the <ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="P02_16_2021To02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> shares of Class&#160;B common stock and recognized the <ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">31,838,589</ix:nonFraction> LLC Interests at carrying value, as the Merger is considered to be a recapitalization transaction. Following the Merger and IPO, as of August&#160;10, 2021, the Company holds <ix:nonFraction name="bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" contextRef="PAsOn08_10_2021_BioventusIncMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,062,652</ix:nonFraction> LLC Interests, representing a <ix:nonFraction name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" contextRef="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">72.2</ix:nonFraction>% ownership interest in BV LLC. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements for periods prior to the IPO and Transactions have been adjusted to combine the previously separate entities for presentation purposes. Prior to the Transactions, Bioventus Inc. had no operations. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim periods </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company reports quarterly interim periods on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-week</div> basis within a standard calendar year. Each annual reporting period begins on January&#160;1 and ends on December 31. Each quarter ends on the Saturday closest to calendar <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">quarter-end,</div> with the exception of the fourth quarter, which ends on December 31. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-week</div> quarterly periods for fiscal year 2021 end on April&#160;3, July&#160;3 and October 2. Comparable periods for 2020 ended on March&#160;28, June&#160;27 and September 26. The fourth and first quarters may vary in length depending on the calendar year. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited interim financial information </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-01</div> of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Pursuant to these rules and regulations they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company&#8217;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company&#8217;s 2020 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> The balance sheet at December&#160;31, 2020 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impact </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2020, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic spread around the world and in the United States. New variants of the virus have emerged, some of which have shown to be more contagious. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of businesses, work from home, supply chain logistical changes and other measures, which caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted by fluctuations in patient visits and elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments </div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-52 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388598_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">from customers, supply chain interruptions, extended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;shelter-in-place&#8221;</div></div> orders or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on our business will depend on many factors, including, but not limited to, the duration and severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability, adoption and effectiveness of vaccines, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on our partners, patients and communities in which we operate, all of which continue to be uncertain. As of the date of issuance of these consolidated financial statements, the extent to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could materially impact the Company&#8217;s financial conditions, liquidity or results of operations is uncertain. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To the extent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully commercialize newly developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual relationships. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law, which was aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the CARES Act and at the direction of the U.S. Department of Health and Human Services (HHS), the Company received a $<ix:nonFraction name="bvs:ProceedsFromGovernmentalAssistance" contextRef="P04_01_2020To04_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,247</ix:nonFraction> Provider Relief Fund Payment in April 2020. The Company determined it complied with the conditions to be able to keep and use the funds to reimburse for health care related expenses and lost revenue attributable to the public health emergency resulting from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The payment was recorded as other income on the consolidated statement of operations and comprehensive (loss) income for the three and six months ended June&#160;27, 2020. </div><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_04_2021To07_03_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent accounting pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has elected to comply with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are generally earlier than when emerging growth companies are required to adopt. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Pronouncements Recently Adopted </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div>(ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12),</div> which amended the accounting for income taxes. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> eliminates certain exceptions to the guidance for income taxes related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in the tax basis of goodwill. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> on January&#160;1, 2021 and it did not have a material impact on its consolidated financial statements. </div></ix:nonNumeric> </ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-53 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388650"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Balance sheet information </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of cash and cash equivalents and restricted cash is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136,065</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">138,068</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted cash consists of deposits into escrow with a financial institution for the purpose of paying specific indebtedness of a company acquired as part of a business combination (refer to<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Note 3. Business combinations and investments</div></div>). </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net of allowances, consisted of the following as of: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">105,048</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">92,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Allowance for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,019</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to make required payments. The allowance for credit losses is calculated by region and by customer type, where appropriate considering several factors including age of accounts, collection history, historical account write-offs, current economic conditions, and supportable forecasted economic expectations. Due to the short-term nature of its receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. An increase in the provision for credit losses may be required when the financial condition of the Company&#8217;s customers or its collection experience deteriorates. The Company has a diverse customer base with no single customer representing ten percent of sales or accounts receivable. Historically, the Company&#8217;s reserves have been adequate to cover credit losses. The Company&#8217;s exposure to credit losses may increase if its customers are adversely affected by changes in health care laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, or other customer-specific factors. The Company considered the current and expected future economic and market conditions surrounding the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and determined that the estimate of credit losses was not significantly impacted. Estimates are used to determine the allowance, which are based on an assessment of anticipated payment and all other historical, current and future information that is reasonably available. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-54 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388650" continuedAt="TextSelectionAppend_26388650_1"> <ix:nonNumeric name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388657"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in credit losses were as <div style="letter-spacing: 0px; top: 0px;;display:inline;">follows</div>: </div></div></ix:nonNumeric> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388650_1"><ix:continuation id="TextSelection_26388657">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn04_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,811</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn03_28_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,684</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recovery (provision)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">684</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,019</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,019</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consisted of the following as of: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and supplies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,665</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,988</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess and obsolete reserves</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">868</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consisted of the following as of: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> deductions</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="bvs:GrossToNetDeductionsCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="bvs:GrossToNetDeductionsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus and commission</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,493</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AccruedSalariesAndEmployeeBenefitsCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AccruedSalariesAndEmployeeBenefitsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income and other taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,034</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">105,246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">88,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company completed a restructuring plan during the fourth quarter of 2020 and the remaining $<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:RestructuringReserveCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">247</ix:nonFraction></ix:nonFraction> accrued liabilities were paid during the six months ended July&#160;3, 2021. </div></div> </ix:continuation> <ix:nonNumeric name="bvs:BusinessCombinationsAndInvestmentsDisclosureTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388759"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Business combinations and investments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2021, in order to broaden its portfolio and increase its global footprint, the Company acquired <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% of the capital stock of Bioness, Inc. (Bioness). Bioness is a global leader in neuromodulation and advanced rehabilitation medical devices through its innovative peripheral nerve stimulation therapy and premium advanced rehabilitation solutions. The Company had previously made a $<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,500</ix:nonFraction> convertible debt investment in Bioness on </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-55 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388759" continuedAt="TextSelectionAppend_26388759_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;4, 2021 as part of an exclusive negotiation to purchase Bioness, which was subsequently repaid in conjunction with the acquisition. <ix:nonNumeric name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388761">The consideration paid for Bioness is comprised of the following:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26388761">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consideration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash consideration at closing</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Bioness consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">91,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Contingent consideration is comprised of future <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> payments contingent upon the achievement of certain research and development projects as well as sales milestones related to Bioness products. Contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> payments could total up to $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,000</ix:nonFraction> for the achievement of the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ObtainingFDAApprovalOfCertainProductsMemberusgaapContingentConsiderationByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction> for obtaining FDA approval for U.S. commercial distribution of a certain product for certain indications on or before June&#160;30, 2022; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMemberusgaapContingentConsiderationByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction> for meeting net sales targets for certain implantable products over a three year period ending on June&#160;30, 2025 at the latest; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMemberusgaapContingentConsiderationByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction> for meeting net sales milestones for certain implantable products over a three year period ending on June&#160;30, 2025 at the latest; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ForObtainingCMSCoverageAndReimbursementForCertainProductsMemberusgaapContingentConsiderationByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction> for maintaining Centers for Medicare&#160;&amp; Medicaid Services coverage and reimbursement for certain products at specified levels as of December&#160;31, 2024. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the purchase price is preliminary and subject to change. The primary areas of the purchase price that are not yet finalized are related to contingent consideration, working capital, intangible assets and the residual goodwill. Accordingly, adjustments may be made to the values of assets and liabilities assumed as additional information is obtained about the facts and circumstances that existed at the acquisition date. <ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388762">The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date and the resulting goodwill, which is expected to be deductible for tax purposes:</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_26388762" continuedAt="TextSelectionAppend_26388762_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">91,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets acquired and liabilities assumed:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,947</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">87,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,616</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,930</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,598</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Resulting goodwill<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(b)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,335</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of cash and cash equivalents of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,143</ix:nonFraction> and restricted cash deposited by the former majority owner of Bioness of $<ix:nonFraction name="bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction>, into escrow with financial institutions for the purpose of paying specific Bioness indebtedness. The Company previously deposited $<ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,207</ix:nonFraction> into escrow for the same purpose. Prior to the acquisition, Bioness had entered into <ix:nonFraction name="bvs:DebtInstrumentNumberOfLoans" contextRef="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis" unitRef="Unit_Loans" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> loans in connection with the Paycheck Protection Program (the PPP) under the Coronavirus Aid, Relief and Economic Security Act (CARES Act) administered by the U.S. </div></div></td></tr></table> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-56 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388759_1" continuedAt="TextSelectionAppend_26388759_2"><ix:continuation id="TextSelectionAppend_26388762_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Small business Administration. Bioness received proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingApril102022MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,204</ix:nonFraction> from an unsecured PPP loan that was scheduled to mature on April&#160;10, 2022. Bioness applied and was granted forgiveness of this loan during 2021. Bioness received proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingFebruary52026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,003</ix:nonFraction> from a second unsecured PPP loan bearing an interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn03_29_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% scheduled to mature on February&#160;5, 2026. Bioness applied for forgiveness of this loan during 2021. As part of the Bioness acquisition, the balance of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingFebruary52026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,003</ix:nonFraction> was placed in restricted cash to cover the repayment of the outstanding unsecured PPP loan in the event it is not forgiven. The $<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn07_03_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction> outstanding unsecured PPP loan balance covered by the former majority owner is included in other current liabilities within the condensed consolidated balance sheets. </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(b)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The U.S. segment was allocated the resulting goodwill from the Bioness acquisition. </div></div> </td> </tr> </table> </ix:continuation> <ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the preliminary fair values of identifiable intangible assets and their useful lives: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful&#160;Life</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:durwordsen">10 years</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; text-align: center;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; text-align: center;"><ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:durwordsen">2 years</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 72%;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">87,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate amortization expense related to acquired intangible assets for the following five periods is as follows: $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="PAsOn03_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,238</ix:nonFraction>&#8212;remainder of 2021, $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn03_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,475</ix:nonFraction>&#8212;2022, $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn03_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,381</ix:nonFraction>&#8212;2023, $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn03_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction>&#8212;2024 and $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn03_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,350</ix:nonFraction>&#8212;2025. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company incurred $<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,833</ix:nonFraction> and $<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,029</ix:nonFraction> in acquisition and integration costs during the three and six months ended July&#160;3, 2021, respectively, which are included in selling general and administrative expense within the consolidated condensed statement of operations and other comprehensive (loss) income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioness&#8217; advanced rehabilitation revenue is comprised of Exoskeletal Systems, Vector Units and Bioness Integrated Therapy Systems (BITS), which is included within the Company&#8217;s Restorative Therapies vertical. The Company&#8217;s Pain Treatment and Joint Preservation vertical will encompass Bioness&#8217; peripheral nerve stimulation therapy products, which includes the StimRouter, an implantable neuromodulation device used to treat chronic peripheral nerve pain. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from Bioness&#8217; products is primarily recognized at a point in time upon transfer of control of its products to customers such as medical facilities and individual patients. Revenue is recognized net of discounts, which can be offered through a variety of factors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consolidated Pro Forma Results </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s consolidated condensed statements of operations reflect net sales and net loss attributable to Bioness of $<ix:nonFraction name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,870</ix:nonFraction> and $<ix:nonFraction name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,529</ix:nonFraction>, respectively, for the three and six months ended July&#160;3, 2021. <ix:nonNumeric name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388765">Consolidated unaudited pro forma results of operations for the Company are presented below assuming the 2021 Bioness Acquisition had occurred January&#160;1, 2020. Pro forma operating results for the three and six months ended June&#160;27, 2020 include operating expenses of $<ix:nonFraction name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,939</ix:nonFraction> and $<ix:nonFraction name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,135</ix:nonFraction>, respectively, for acquisition integration costs and inventory related adjustments.</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_26388765"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">109,816</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="P03_28_2020To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,955</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">200,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaRevenue" contextRef="P12_28_2019To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">157,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="P03_28_2020To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" contextRef="P12_28_2019To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,376</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share of Class&#160;A common stock(1):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.03</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" contextRef="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" contextRef="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.08</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388759_2" continuedAt="TextSelectionAppend_26388759_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VIE </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has a fully diluted <ix:nonFraction name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">8.8</ix:nonFraction>% ownership of Harbor Medtech Inc.&#8217;s (Harbor) Series C Preferred Stock. The Company and Harbor entered into an exclusive Collaboration Agreement in 2019 for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. The Company&#8217;s partial ownership and exclusive Collaboration Agreement created a variable interest in Harbor. As a result, Harbor had been consolidated in the Company&#8217;s consolidated financial statements since the third quarter of 2019. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harbor assets that could only be used to settle Harbor obligations and Harbor liabilities for which creditors did not have recourse to the general credit of the Company were as follows at December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">366</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company terminated the Collaboration Agreement on June&#160;8, 2021 and determined that the termination was a triggering event requiring an impairment assessment of Harbor&#8217;s long lived assets. The assessment resulted in an impairment of $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,674</ix:nonFraction>, representing Harbor&#8217;s long-lived asset balance, which was recorded within impairment of variable entity assets in the consolidated condensed statements of operations and comprehensive (loss) income, of which $<ix:nonFraction name="bvs:AssetImpairmentChargesAttributableToNoncontrollingInterest" contextRef="P06_08_2021To06_08_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,176</ix:nonFraction> is attributable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. The Company stopped consolidating Harbor upon the termination of the Collaboration Agreement, as the Company ceased being the primary beneficiary because it no longer had the power to direct Harbor&#8217;s significant activities. The Company also assessed its Harbor investment post deconsolidation, which resulted in a $<ix:nonFraction name="bvs:VariableInterestEntityImpairment" contextRef="P06_08_2021To06_08_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,369</ix:nonFraction> impairment, representing the remaining investment balance in Harbor and was recorded within other expense in the consolidated condensed statements of operations and comprehensive (loss) income. The Company continues to have license rights to certain technology obtained from Harbor and is continuing product development initiated under the Collaboration Agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Method </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an equity investment in CartiHeal Ltd. (CartiHeal), a privately held entity that does not have a readily determinable fair value, which the Company began recording as an equity investment during the third quarter of 2020. The CartiHeal investment carrying value totaled $<ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,737</ix:nonFraction> as of July&#160;3, 2021, yielding a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn07_03_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">10.03</ix:nonFraction>% fully diluted equity ownership. Net losses from CartiHeal for the three and six months ended July&#160;3, 2021 totaled $<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">432</ix:nonFraction> and $<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">901</ix:nonFraction>, respectively, which are included in other expense within the consolidated condensed statement of operations and other comprehensive (loss) income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will, if needed to support the completion of a certain study, purchase an additional <ix:nonFraction name="bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" contextRef="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">338,089</ix:nonFraction> of CartiHeal Series G Preferred Shares for $<ix:nonFraction name="bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" contextRef="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction>. The Company has an exclusive option to acquire the remaining equity in CartiHeal, which may be exercised at any time up to and within <ix:nonNumeric name="bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" contextRef="P01_01_2021To07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis" format="ixt-sec:durday">45</ix:nonNumeric> days following notice of the U.S. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388759_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Food and Drug Administration (FDA) approval for a CartiHeal product currently in development. In addition, upon the same FDA approval, CartiHeal may exercise an option within <ix:nonNumeric name="bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" contextRef="P01_01_2021To07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis" format="ixt-sec:durday">45</ix:nonNumeric> days that requires the Company to complete the acquisition of the remaining equity in CartiHeal. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;15, 2020, the Company entered into an Option and Equity Purchase Agreement with CartiHeal. The agreement provides the Company with an exclusive option to acquire <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% of CartiHeal&#8217;s shares under certain conditions, or the Call Option, and provides CartiHeal with a put option that would require us to purchase <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% of CartiHeal&#8217;s shares under certain conditions, or the Put Option. The Put Option is only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> device with a label consistent in all respects with pivotal clinical trial success. The pivotal clinical trial&#8217;s objective is to demonstrate the superiority of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant over the surgical standard of care, including microfracture and debridement, for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August&#160;2, 2021, CartiHeal provided a statistical report containing the results of the pivotal clinical trial. The Company is currently reviewing the report to assess if it is consistent with the terms of the agreement and assessing the findings to determine if all required endpoint have been achieved. CartiHeal continues to work toward submitting the final, clinical module of a Modular PMA in the fourth quarter of 2021 seeking FDA approval. The Company has the right to terminate the Call Option and Put Option at any time ending <ix:nonNumeric name="bvs:BusinessAcquisitionPeriodOfNoticeForTermination" contextRef="P08_02_2021To08_02_2021" format="ixt-sec:durday">30</ix:nonNumeric> days after receipt of the statistical report from CartiHeal upon payment of a break fee of $<ix:nonFraction name="bvs:BusinessAcquisitionPaymentDueUponTerminationOfAgreement" contextRef="P08_02_2021To08_02_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,000</ix:nonFraction>. If the Company determines that the results satisfy the requirements of the contract, and elect not to exercise its right to terminate the Call Option and Put Option, the Company will be required to put $<ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="PAsOn08_02_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction> into escrow as a deposit towards the purchase price. Consideration for the acquisition of all of the shares of CartiHeal, excluding those the Company owns, pursuant to the Call Option or Put Option would be $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P08_02_2021To08_02_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">314,895</ix:nonFraction>, inclusive of the deposit, all of which would be payable at closing, with an additional $<ix:nonFraction name="bvs:BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" contextRef="P08_02_2021To08_02_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,000</ix:nonFraction> payable upon achievement of certain sales milestones related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C.</div> Such closing would be subject to customary closing conditions. CartiHeal has announced that it expects to submit its PMA application to the FDA later this year. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;24, 2021, the Company purchased <ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="PAsOn06_24_2021_VaporoxMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">406,504</ix:nonFraction> shares of Vaporox, Inc&#8217;s (Vaporox) Series A Preferred Stock or <ix:nonFraction name="bvs:InvestmentOwnedOwnershipPercentage" contextRef="PAsOn06_24_2021_VaporoxMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">6.0</ix:nonFraction>% of fully diluted shares for $<ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="PAsOn06_24_2021_VaporoxMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction>. Vaporox, a privately held entity, is a medical device company dedicated to healing diabetic foot ulcers and does not have a readily determinable fair value. Under the measurement alternative, the investment is recorded at cost, less any impairment, plus or minus any changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388891"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Financial instruments </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt consists of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term loan due December 2024 (<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn07_03_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.60</ix:nonFraction>% at July&#160;3, 2021)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">182,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,098</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">457</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">166,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173,378</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-59 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26388891"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2019 Credit Agreement requires the Company to comply with financial and other covenants. The Company complied with all covenants as of July&#160;3, 2021. The 2019 Credit Agreement contains a $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction> revolving credit facility, from which there were <ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction>outstanding borrowings as of July&#160;3, 2021 and December&#160;31, 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of the Term Loan as of July&#160;3, 2021 was $<ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">184,505</ix:nonFraction>. The fair value of these obligations was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar obligations and are classified as Level&#160;2 instruments within the fair value hierarchy. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company enters into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. The Company has <ix:nonFraction name="us-gaap:DerivativeNumberOfInstrumentsHeld" contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_Segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-designated</div> interest rate swap agreement and has no other active derivatives. The swap is carried at fair value on the balance sheet (Refer to<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Note 5. Fair value measurements</div></div>) with changes in fair value recorded as interest income or expense within the consolidated statements of operations and comprehensive (loss) income. Net interest expense of $<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P04_04_2021To07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">255</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P03_29_2020To06_27_2020_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">933</ix:nonFraction> was recorded related to the change in fair value of the interest rate swap for the three months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. Net interest income of $<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2021To07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,310</ix:nonFraction> and expense of $<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2020To06_27_2020_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,001</ix:nonFraction> was recorded related to the change in fair value of the interest rate swap for the six months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The notional amount of the swap totaled $<ix:nonFraction name="us-gaap:DerivativeNotionalAmount" contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction>, or <ix:nonFraction name="us-gaap:PercentageOfDebtHedgedByInterestRateDerivatives" contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">54.8</ix:nonFraction>% of the Term Loan outstanding principal at July&#160;3, 2021. The swap locked in the variable portion of the interest rate on the $<ix:nonFraction name="us-gaap:DerivativeNotionalAmount" contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction> notional at <ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.64</ix:nonFraction>%. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388920"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Fair value measurements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our process for determining fair value has not changed from that described in the Company&#8217;s 2020 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level&#160;1 inputs. <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388923">The following table provides information for liabilities measured at fair value on a recurring basis using Level&#160;2 and Level&#160;3 inputs:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26388923">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swap</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,602</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,602</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term contingent consideration, less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management incentive plan and liability-classified awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Participation Right</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:EquityParticipationRightFairValueDisclsoure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,602</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate swap </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company values interest rate swaps using discounted cash flows. Forward curves and volatility levels are used to estimate future cash flows that are not certain. These are determined using observable market inputs when available and based on estimates when not available. The fair value of the swap was recorded in the Company&#8217;s consolidated balance sheets within accrued liabilities. Changes in fair value are recognized as interest expense (income) within the consolidated statements of operations and comprehensive (loss) income. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-60 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><ix:continuation id="TextSelection_26388920" continuedAt="TextSelectionAppend_26388920_1">Contingent consideration</ix:continuation> </div></div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388920_1" continuedAt="TextSelectionAppend_26388920_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue and the probability of achieving the specific targets as discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 3. Business combinations and investments</div></div>. <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388924">After the initial valuation, the Company will use its best estimate to measure contingent consideration related to the Bioness Acquisition at each subsequent reporting period using the following unobservable Level&#160;3 inputs:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><ix:continuation id="TextSelection_26388924"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation Technique</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioness contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Discounted cash flow</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">Payment discount rate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:numdotdecimal">5.0</ix:nonFraction>% - <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:numdotdecimal">6.8</ix:nonFraction>%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">Payment period</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2021 - 2025</td></tr></table></ix:continuation><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The contingent consideration reported in the above table resulted from the March&#160;30, 2021 Bioness acquisition, which is adjusted on a monthly basis based upon the passage of time or success or failure of achieving certain milestones. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 3. Business combinations and investments</div></div> for further details. Changes in contingent consideration related to the Bioness acquisition totaled $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">641</ix:nonFraction> for the three and six months ended July&#160;3, 2021, which were recorded as the change in fair value of contingent consideration within the consolidated statements of operations and comprehensive (loss) income. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management incentive plan (MIP) and liability-classified awards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">BV LLC had operated <ix:nonFraction name="bvs:NumberOfEquityBasedCompensationPlans" contextRef="PAsOn07_03_2021" unitRef="Unit_Business" decimals="0" scale="0" format="ixt-sec:numwordsen">two </ix:nonFraction>equity-based compensation plans, the management incentive plan (MIP) and the BV LLC Phantom Profits Interest Plan (Phantom Plan and, together with the MIP, the Plans), which were terminated on February&#160;11, 2021 in connection with the Company&#8217;s IPO. Awards granted under the MIP Plan and the 2015 Phantom Units were liability-classified and the 2012 Phantom Units were equity-classified. Prior to the IPO and during the six months ended July&#160;3, 2021, the Company settled the remaining <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">183,078</ix:nonFraction> units with the sole MIP awardee for $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,802</ix:nonFraction>. No awards under the Plans were granted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-IPO</div> and the Phantom Plan awards will be settled <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" format="ixt-sec:durmonth">12</ix:nonNumeric> months following the termination. Vested awardees whose BV LLC employment terminated prior to the IPO will have their awards settled for $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P01_01_2021To07_03_2021_BVLLCEmployeesTerminatedPriorToIPOMembersrtTitleOfIndividualAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,875</ix:nonFraction>, which is included in accrued equity-based compensation on the consolidated condensed balance sheets. Awardees that were active BV LLC employees at the IPO will receive an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2021To07_03_2021_BVLLCEmployeesActiveAtIPOMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">798,422</ix:nonFraction> shares of Class&#160;A common stock. </div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26388927"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level&#160;3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">829</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phantom plan conversion to Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Participation Right (EPR) Unit </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO, the Continuing LLC owner owned the only EPR Unit and its only entitlement was <ix:nonFraction name="bvs:EquityParticipationRightEntitledPercentageOfDistributions" contextRef="PAsOn02_15_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.55</ix:nonFraction>% of available distributions arising from a distribution event such as the IPO. The EPR Unit was redeemed in exchange for $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P02_16_2021To02_16_2021_EquityParticipationRightUnitMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,327</ix:nonFraction> in connection with the IPO in February 2021, at which time the EPR ceased to exist and all entitlements ended. The revaluation for the EPR liability is recognized in interest (income) expense on the consolidated statements of operations and comprehensive (loss) income. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-61 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26388920_2"><ix:continuation id="TextSelection_26388927"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level&#160;3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2021To07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2021To07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389021"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Equity-based compensation </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Terminated plans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to the IPO, BV LLC operated <ix:nonFraction name="bvs:NumberOfEquityBasedCompensationPlans" contextRef="PAsOn02_10_2021" unitRef="Unit_Plan" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> equity-based compensation plans, the MIP and the Phantom Plan, which were terminated on February&#160;11, 2021 in conjunction with the IPO. Prior to the Plans termination, during the six months ended July&#160;3, 2021, (i) the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_12_2021To02_10_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">90,000</ix:nonFraction> Phantom Plan units; (ii)&#160;there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_12_2021To02_10_2021_ManagementIncentivePlanAwardMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> MIP awards granted; (iii) <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_12_2021To02_10_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">900</ix:nonFraction> Phantom Plan units were forfeited and (iv)&#160;other Phantom Units were redeemed for $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" contextRef="P01_12_2021To02_10_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">479</ix:nonFraction>. Compensation expense related to the Phantom Plan of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_12_2021To02_10_2021_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">829</ix:nonFraction> for the six months ended July&#160;3, 2021. This amount excludes the $<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,185</ix:nonFraction> decrease in fair market value of accrued equity-based compensation due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering price, of which $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To07_03_2021_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,777</ix:nonFraction> was recorded in research and development expense within the consolidated statement of operations and comprehensive (loss) income for the six months ended July&#160;3, 2021. Compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P03_28_2020To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">663</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P12_28_2019To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,078</ix:nonFraction> was recorded for the three and six months ended June&#160;27, 2020, excluding $<ix:nonFraction name="bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" contextRef="P03_28_2020To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">408</ix:nonFraction> and $<ix:nonFraction name="bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" contextRef="P12_28_2019To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,849</ix:nonFraction> in fair market value decreases, respectively, within accrued equity-based compensation due to the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the market and economy. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2021 Plan </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company operates an equity-based compensation plan (2021 Plan). The 2021 Plan is designed to grant incentive awards to eligible employees and other service providers in order to attract, motivate and retain the talent for which the Company competes. The 2021 Plan allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (RSUs), other stock-based awards, and cash awards. (collectively, Awards). Generally, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> Awards granted under the 2021 Plan are equity-classified. As of July&#160;3, 2021, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn07_03_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,592,476</ix:nonFraction> shares of Class&#160;A common stock were authorized to be awarded and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn07_03_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,024,123</ix:nonFraction> shares were available for award. The number of shares available for issuance will be increased annually on January&#160;1 of each calendar year beginning in 2022 through 2031, equal to the lesser of (i) <ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" contextRef="PAsOn07_03_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,778</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P12_28_2019To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,722</ix:nonFraction> was recognized for the three and six months ended July&#160;3, 2021, respectively, for Awards granted under the 2021 Plan. The expense is primarily included in selling, general and administrative expense with a nominal amount in research and development expense on the consolidated statement of operations and comprehensive (loss) income based upon the classification of the employee. There was <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_04_2021To07_03_2021_A2021PlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_04_2021To07_03_2021_A2021PlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> income tax benefit related to this expense for the three and six months ended July&#160;3, 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the three and six months ended July&#160;3, 2021, the Company granted employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors time-based RSUs which vest at various dates through May&#160;10, 2025. The compensation expense, which represents the fair value of the stock measured at the market price on the date of grant, is recognized over the vesting period, which is typically between <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P12_28_2019To06_27_2020_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1</ix:nonNumeric> and <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P12_28_2019To06_27_2020_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">4</ix:nonNumeric> years. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-62 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389021" continuedAt="TextSelectionAppend_26389021_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> RSUs were vested or settled during the three and six months ended July&#160;3, 2021. Unamortized compensation expense related to the RSUs amounted to $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,976</ix:nonFraction> at July&#160;3, 2021, and is expected to be recognized over a weighted average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To07_03_2021" format="ixt-sec:duryear">0.69</ix:nonNumeric> years. A <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389022">summary of the RSU award activity for the six months ended July&#160;3, 2021 is as follows (number of units in thousands):</ix:nonNumeric> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26389022">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> average&#160;grant-<br/> date fair value<br/> per unit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2021To04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/canceled</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three and six months ended July&#160;3, 2021, the Company granted employees time-based stock options which vest over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">2</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">4</ix:nonNumeric> years following the date of grant and expire within <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">2</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">4</ix:nonNumeric> years, net of actual forfeitures. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389023">A summary of the Company&#8217;s assumptions used in determining the fair value of the stock options granted during the six months ended July&#160;3, 2021 is shown in the following table.</ix:nonNumeric> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26389023">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.59</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.19</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">33.1</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">33.5</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5.75</ix:nonNumeric><div style="display:inline;">&#160;-&#160;</div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">6.25</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of stock options granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">4.21</ix:nonFraction>&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Company&#8217;s peers common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> options vested, expired, forfeited or were exercisable during the six months ended July&#160;3, 2021. Unamortized compensation expense related to the options amounted to $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,797</ix:nonFraction> at July&#160;3, 2021, and is expected to be recognized over a weighted average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_04_2021To07_03_2021" format="ixt-sec:duryear">1.19</ix:nonNumeric> years. <ix:nonNumeric name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389024">A summary of stock option activity is as follows for the six months ended July&#160;3, 2021 (number of options in thousands):</ix:nonNumeric> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_26389024">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> average&#160;exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual&#160;term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To04_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To04_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn04_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn04_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P04_04_2021To07_03_2021" format="ixt-sec:duryear">3.3</ix:nonNumeric> years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-63 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389021_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value of options outstanding as of July&#160;3, 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,095</ix:nonFraction> and is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#8217;s common stock for options that had exercise prices lower than $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.51</ix:nonFraction>, the closing price of the Company&#8217;s stock on July&#160;2,&#160;2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, in connection with the IPO, the Company began operating the 2021 Employee Stock Purchase Plan (ESPP). The ESPP provides for the issuance of shares of the Company&#8217;s common stock to eligible employees of the Company and its subsidiaries that elect to participate in the plan and purchase shares of common stock through payroll deductions (including executive officers). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During each enrollment period, eligible employees may designate between <ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" contextRef="PAsOn07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% and <ix:nonFraction name="bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" contextRef="PAsOn07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>% of their compensation to be deducted for the purchase of common stock under the plan (or such other percentage in order to comply with regulations applicable to employees domiciled in or resident of a member state of the European Union). The purchase price of the shares under the ESPP is equal to <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% of the fair market value on the first day of the offering period or, if lower, on the last day of the offering period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of July&#160;3, 2021, the aggregate number of shares reserved for issuance under the ESPP was <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">518,257</ix:nonFraction>. During the three and six months ended July&#160;3, 2021, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_04_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">24,063</ix:nonFraction> shares were issued and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75</ix:nonFraction> of expense was recognized. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389096"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Earnings per share </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted loss per share of Class&#160;A common stock for the period following the Transactions (amounts in thousands, except share and per share data): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;16,<br/> 2021 through<br/> July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P02_16_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,229</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P02_16_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Bioventus Inc. Class&#160;A common stockholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_16_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares of Class&#160;A common stock outstanding - basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">41,805,347</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_16_2021To07_03_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_16_2021To07_03_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">41,802,840</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share of Class&#160;A common stock, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.10</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_16_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_16_2021To07_03_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.12</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Shares of Class&#160;B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class&#160;B common stock under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method has not been presented. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-64 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;">&#160;</div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389096"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following number of weighted-average potentially dilutive shares as of July&#160;3, 2021 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion: </div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three<br/> Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC Interests held by Continuing LLC&#160;Owner<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_04_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,786,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_04_2021To07_03_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,622,287</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,602,747</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,221,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">941,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_04_2021To07_03_2021_UnvestedClassACommonSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">32,458</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To07_03_2021_UnvestedClassACommonSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,698</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">21,663,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">21,365,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Shares reserved for future issuance upon redemption or exchange of LLC Interests by Continuing LLC Owner. </div></div></td></tr></table></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389125"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Income taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As a result of the Transactions, Bioventus Inc. became the sole managing member of BV LLC, which is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, BV LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by BV LLC is passed through to and included in the taxable income or loss of its members, including the Company following the Transactions, on a pro rata basis. Bioventus Inc. is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to its allocable share of any taxable income of BV LLC<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>following the Transactions. The Company is also subject to taxes in foreign jurisdictions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The tax provision for interim periods is determined using an estimate of the Company&#8217;s annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Company&#8217;s annual effective tax rate, are subject to variation due to several factors, including variability in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For the three months ended July&#160;3, 2021 and June&#160;27, 2020 the Company&#8217;s estimated effective tax rate was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">18.9</ix:nonFraction>% and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.8</ix:nonFraction>%, respectively. For the six months ended July&#160;3, 2021 and June&#160;27, 2020 the Company&#8217;s estimated effective tax rate was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">10.7</ix:nonFraction>% and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.6</ix:nonFraction>%, respectively. The increase was primarily driven by the change in structure resulting from the IPO and associated Up C structure as well as the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deductible</div> stock option expense during 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recorded deferred taxes with the offset to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital in connection with the Transaction. The deferred tax asset of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">481</ix:nonFraction> was due to tax credits and the deferred tax liability of $<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesInvestments" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,410</ix:nonFraction> was for the difference between the book value and the tax basis of the Company&#8217;s investment in BV LLC. The Company maintains a valuation allowance on certain deferred tax assets that has determined are not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be realizable. The Company assesses the need for an adjustment to this valuation allowance on a quarterly basis. The assessment is based on estimates of future sources of taxable income for the jurisdictions in which the Company operates and the periods over which deferred tax assets will be realizable. In the event the Company determines that it will be able to realize all or part of its net deferred tax assets in the future, all or part of the valuation allowance will be reversed in the period in which the Company makes such determination. The release of all or part of the valuation allowance against deferred tax assets may cause greater volatility in the effective tax rate in the periods in which it is reversed. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-65 </div></div> </div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389125"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax Receivable Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, the Company entered into a tax receivable agreement (TRA) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i)&#160;increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC and (ii)&#160;certain other tax benefits related to our making payments under the TRA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will maintain a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be realized. As of July&#160;3, 2021, Continuing LLC Owner had not exchanged LLC Interests for shares of Class&#160;A common stock and therefore the Company had not recorded any liabilities under the TRA. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389134"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Commitments and contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn07_03_2021_MinimumMembersrtRangeAxis" format="ixt-sec:durmonth">1</ix:nonNumeric> month to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn07_03_2021_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">7.25</ix:nonNumeric> years. </div></div> <ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease cost were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">912</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">646</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,614</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes variable lease cost and sublease income, which are immaterial. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Supplemental cash flow information and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> activity related to operating leases were as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,269</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-66 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389134" continuedAt="TextSelectionAppend_26389134_1"><ix:nonNumeric name="bvs:AssetsAndLiabilitiesLesseeTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389138"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental balance sheet and other information related to operating leases <div style="display:inline;">were </div>as fo<div style="display:inline;">llow</div>s:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></ix:nonNumeric> </ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26389138"><ix:continuation id="TextSelectionAppend_26389134_1" continuedAt="TextSelectionAppend_26389134_2">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities- current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,918</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities- noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,068</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn07_03_2021" format="ixt-sec:duryear">6.2</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020" format="ixt-sec:duryear">7.2</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn07_03_2021" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">4.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_26389134_2" continuedAt="TextSelectionAppend_26389134_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Recall </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, the Company voluntarily recalled our ultrasound gel, an accessory to one of the Restorative Therapies product. The Company has incurred, and expects to incur in the future, costs associated with this recall. Based on the information that has been received, the estimated probable loss related to this recall globally was approximately $<ix:nonFraction name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="PAsOn07_03_2021_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,055</ix:nonFraction> as of July&#160;3, 2021. Reserves of $<ix:nonFraction name="us-gaap:LossContingencyAccrualCarryingValueCurrent" contextRef="PAsOn07_03_2021_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">434</ix:nonFraction> and $<ix:nonFraction name="us-gaap:LossContingencyAccrualCarryingValueCurrent" contextRef="PAsOn12_31_2020_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,684</ix:nonFraction> were recorded within accrued liabilities on the consolidated balance sheets at July&#160;3, 2021 and December&#160;31, 2020, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal Contingencies </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to the business. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company operates. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#8217;s complete control and may not be known for extended periods of time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the closing of our acquisition of Bioness, Bioness had been named as a defendant in a lawsuit, for which we are indemnified for under the indemnification provisions contained in the Merger Agreement pursuant to which we acquired Bioness (the Bioness Merger Agreement). The case relates to an action brought in February 2021 in the Delaware State Court of Chancery by a former minority shareholder and director of Bioness, seeking a temporary restraining order contesting our acquisition of Bioness. While the complaint to block the Bioness acquisition was dismissed by the court, a separate action was brought against the Company under the indemnification provisions of the Bioness Certificate of Incorporation to recover $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2021To07_03_2021_BionessIncMemberusgaapLitigationStatusAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,200</ix:nonFraction> in attorney fees and other expenses incurred by the director and shareholder in connection with the dismissed case and filed a motion on May&#160;21, 2021 for summary judgment of their claims. The Company is vigorously defending the matter. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other matters </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a <ix:nonFraction name="bvs:CollaborativeArrangementRoyaltyPercentage" contextRef="P08_23_2019To08_23_2019_HarborMembersrtCounterpartyNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>% royalty on certain commercial sales, or a nominal minimum amount per quarter, beginning in 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;29, 2019, the Company and the Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF (the Development Agreement). The first phase has been completed. Additional fees for the subsequent phases will be determined as the development work progresses. The Development Agreement continues until the date when the parties execute a supply agreement for the commercial products. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-67 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_26389134_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (OA) product with the supplier of the Company&#8217;s single injection OA product for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement totaled $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P04_04_2021To07_03_2021_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,548</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P03_29_2020To06_27_2020_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,767</ix:nonFraction> during the three months ended July&#160;3, 2021 and June&#160;27, 2020, respectively, and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2021To07_03_2021_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,925</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2020To06_27_2020_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,969</ix:nonFraction> during the six months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive (loss) income. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of a supply agreement entered on February&#160;9, 2016 for the Company&#8217;s three injection OA product, the Company is subject to annual minimum purchase requirements for <ix:nonNumeric name="bvs:SupplyCommitmentTerm" contextRef="P02_09_2016To02_09_2016_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. After the initial <ix:nonNumeric name="bvs:SupplyCommitmentTerm" contextRef="P02_09_2016To02_09_2016_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years, the agreement will automatically renew for an additional <ix:nonNumeric name="bvs:SupplyCommitmentRenewalTerm" contextRef="P02_09_2016To02_09_2016_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis" format="ixt-sec:duryear">5</ix:nonNumeric> years unless terminated by the Company or the seller in accordance with the agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of a supply agreement for the Company&#8217;s five injection OA product, that was amended and restated on December&#160;22, 2020, the Company is subject to annual minimum purchase requirements for <ix:nonNumeric name="bvs:CollaborativeArrangementTerm" contextRef="P12_22_2020To12_22_2020_HarborMembersrtCounterpartyNameAxis" format="ixt-sec:duryear">8</ix:nonNumeric> years. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the licensed products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive (loss) income. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company causes letters of credit (LOCs) to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of July&#160;3, 2021 and December&#160;31, 2020, the Company had one LOC outstanding for a nominal amount. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#8220;claims made&#8221; basis for expenses in excess of $<ix:nonFraction name="bvs:StopLossInsuranceThresholdPerMemberPerYear" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">200</ix:nonFraction> per member per year. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Revenue recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our policies for recognizing sales have not changed from those described in the Company&#8217;s 2020 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389214">The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) as follows:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_26389214">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary geographic markets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_04_2021To07_03_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">98,682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P03_29_2020To06_27_2020_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">53,166</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To07_03_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To06_27_2020_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">125,136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_04_2021To07_03_2021_NonUsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P03_29_2020To06_27_2020_NonUsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To07_03_2021_NonUsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,374</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To06_27_2020_NonUsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,526</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">109,816</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vertical:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pain Treatments and Joint Preservation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_04_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P03_29_2020To06_27_2020_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,868</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">98,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To06_27_2020_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">70,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restorative Therapies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_04_2021To07_03_2021_RestorativeTherapiesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P03_29_2020To06_27_2020_RestorativeTherapiesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To07_03_2021_RestorativeTherapiesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To06_27_2020_RestorativeTherapiesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41,433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bone Graft Substitutes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_04_2021To07_03_2021_BoneGraftSubstitutesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,601</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P03_29_2020To06_27_2020_BoneGraftSubstitutesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To07_03_2021_BoneGraftSubstitutesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,028</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To06_27_2020_BoneGraftSubstitutesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">109,816</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-68 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389364"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">11. Segments</div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> reportable segments are U.S. and International. The Company&#8217;s products are primarily sold to <div style="letter-spacing: 0px; top: 0px;;display:inline;">orthopedists,</div> musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company&#8217;s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true"><ix:continuation id="TextSelection_26389364"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents segment adjusted EBITDA reconciled to income before income taxes: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment adjusted EBITDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P04_04_2021To07_03_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P03_29_2020To06_27_2020_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2021To07_03_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2020To06_27_2020_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P04_04_2021To07_03_2021_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P03_29_2020To06_27_2020_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2021To07_03_2021_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" contextRef="P01_01_2020To06_27_2020_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest (expense) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> benefits, net</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnusualOrInfrequentItemNetGainLoss" contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnusualOrInfrequentItemNetGainLoss" contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Succession and transition charges</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:SuccessionAndTransitionCharges" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:SuccessionAndTransitionCharges" contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:SuccessionAndTransitionCharges" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:SuccessionAndTransitionCharges" contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition and integration costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Inventory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> costs</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:InventoryStepUpCost" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="bvs:InventoryStepUpCost" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity loss in unconsolidated investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments related to variable interest entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,043</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,043</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_04_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P03_29_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To07_03_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,389</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To06_27_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2021To07_03_2021" escape="true" continuedAt="TextSelection_26389340"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Subsequent events </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of Misonix, Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;29, 2021, the Company entered into an Agreement and Plan of Merger (the Misonix Merger Agreement) to acquire Misonix, Inc. (Misonix), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-and-stock</div></div> transaction (the Transaction). The closing of the Transaction is subject to regulatory approvals, the Company&#8217;s stockholders&#8217; approval, Misonix stockholder approval and customary closing conditions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Misonix stockholders will receive aggregate consideration that values Misonix at approximately $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">518,000</ix:nonFraction> on a fully diluted basis, based on the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7-day</div> weighted average stock price of $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:numdotdecimal">16.6284</ix:nonFraction> per share as of July&#160;27, 2021. The Transaction involves both cash and stock consideration based on the election of the Misonix stockholder. Each share of Misonix Common Stock issued and outstanding immediately prior to the Transaction, will be converted into the right to receive, either an amount in cash equal to $<ix:nonFraction name="bvs:BusinessAcquisitionConsiderationTransferredPerShareCash" contextRef="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">28.00</ix:nonFraction> or <ix:nonFraction name="bvs:BusinessAcquisitionConsiderationTransferredPerShareShares" contextRef="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_shares" decimals="4" scale="0" format="ixt:numdotdecimal">1.6839</ix:nonFraction> validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Class&#160;A common stock of the Company, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction> par value per share, based on the election of the holder. The maximum cash amount payable by the Company will be an amount equal to $<ix:nonFraction name="bvs:BusinessAcquisitionConsiderationTransferredPerShareMaximum" contextRef="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.50</ix:nonFraction> multiplied by the number of outstanding shares of Misonix Common Stock shortly prior to the completion of the Transaction. The Company expects to fund the cash portion of the acquisition with cash on </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_26389340"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hand and through committed financing provided by Wells Fargo Bank, National Association (Wells Fargo Bank). The number of shares held by Misonix stockholders electing to receive cash will be reduced on a pro rata basis if the cash elected to be received exceeds the maximum cash amount payable and will be paid with stock consideration of 1.6839 of shares of the Company&#8217;s Class&#160;A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt Commitment Letter </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the transaction, the Company entered into a debt commitment letter with Wells Fargo Bank, effective July&#160;29, 2021. Wells Fargo Bank has committed to provide a senior secured term loan facility (Term Loan Facility) in the aggregate principal amount of up to $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_29_2021_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanFacilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">262,000</ix:nonFraction> plus, at the Company&#8217;s election, an amount sufficient to fund any original issue discount or upfront fees, subject to customary closing conditions. The Term Loan Facility stipulates a prepayment of $<ix:nonFraction name="bvs:DebtInstrumentCovenantRequiredPrepayment" contextRef="PAsOn07_29_2021_A2019CreditAgreementMemberusgaapDebtInstrumentAxis_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,000</ix:nonFraction> on the existing Term Loan under the 2019 Credit Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proceeds of the Term Loan Facility would be available through a single draw on the closing date of the Transaction and shall be used (i)&#160;to finance the Transaction; (ii)&#160;pay related fees, premiums and expenses and (iii)&#160;for working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions. The Term Loan Facility would have a <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P07_29_2021To07_29_2021_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanFacilityMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen">three year</ix:nonNumeric> term that would bear interest at either the base rate as prescribed in the Term Loan under the 2019 Credit Agreement or the Eurodollar rate, and, in each case, plus an applicable margin. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting and Support Agreements </div></div></div> <div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;">On July&#160;29, 2021, following the execution of the Misonix Merger Agreement, Misonix entered into Voting and Support Agreements with each EW Healthcare Partners Acquisition Fund, L.P. White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.), Smith&#160;&amp; Nephew, Inc., Smith&#160;&amp; Nephew USD Ltd. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AMP-CF</div> Holdings, LLC (together, the &#8220;Bioventus supporting stockholders&#8221;). The Bioventus Supporting Stockholders have agreed to vote their shares in (i)&#160;favor of the issuance of shares of the Company&#8217;s common stock in connection with the Transaction and against approval of any proposal made in opposition to, in competition with or inconsistent with the Misonix Merger Agreement. As of the record date for the Bioventus special meeting, the Bioventus supporting stockholders are the beneficial owners of approximately </div>[&#9679;]% <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the currently outstanding Class&#160;A and Class&#160;B common stock of the Company. </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Other Matters </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The unsecured PPP loan of $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P07_01_2021To07_31_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_PaycheckProtectionProgramLoanMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,003</ix:nonFraction> associated with Bioness was forgiven in July 2021. The loan amount was recorded in other current liabilities and restricted cash within the consolidated condensed balance sheet at July&#160;3, 2021. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 3. Business combinations and investments</div></div> for further details. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_40" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annex A </div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AGREEMENT AND PLAN OF MERGER </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by and among: </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BIOVENTUS INC., </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Delaware corporation; </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OYSTER MERGER SUB I, INC., </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Delaware corporation; </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OYSTER MERGER SUB II, LLC, </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Delaware limited liability company; </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MISONIX, INC. </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Delaware corporation </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dated as of July&#160;29, 2021 </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 75%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Page</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE I. THE MERGERS</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">The Mergers; Effect of Mergers</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Closing; Effective Time</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Certificate of Incorporation and Bylaws</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.4</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Directors and Officers</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.5</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Treatment of Capital Stock in the Mergers</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.6</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Dissenting Shares</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.7</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Proration</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.8</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Certain Adjustments</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.9</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Treatment of Equity Awards</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.10</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">No Fractional Shares</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.11</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Closing of Transfer Books</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.12</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Exchange of Certificates and Cancellation of Book-Entry Positions</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.13</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Further Action</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.14</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Tax Withholding</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.15</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Election Procedures</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE II. REPRESENTATIONS AND WARRANTIES OF THE COMPANY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Due Organization and Good Standing; Subsidiaries</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Organizational Documents</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Capitalization</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.4</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Authority; Binding Nature of Agreement</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.5</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Vote Required</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.6</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Contravention;</div> Consents</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.7</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Reports; Financial Statements; Internal Controls</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.8</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Absence of Certain Changes</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.9</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Intellectual Property and Related Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.10</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Title to Assets; Real Property</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.11</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Contracts</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.12</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Compliance with Legal Requirements</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.13</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Legal Proceedings; Investigations; Orders</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.14</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Certain Business Practices</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.15</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Tax Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.16</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Employee Benefit Plans</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.17</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Labor Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.18</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Environmental Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.19</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Insurance</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.20</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Product Defects and Warranties</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.21</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Regulatory Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.22</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Takeover Statutes</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.23</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Ownership of Parent Class&#160;A Common Stock</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.24</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Opinion of Financial Advisor</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.25</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Brokers</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.26</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Related Party Transactions</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;2.27</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Information Supplied</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 75%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE III. REPRESENTATIONS AND WARRANTIES OF PARENT AND ACQUISITION SUBS</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Due Organization and Good Standing; Subsidiaries</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Organizational Documents</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Capitalization</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-34</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.4</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Authority; Binding Nature of Agreement</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.5</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Vote Required</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.6</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Contravention;</div> Consents</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.7</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Reports; Financial Statements; Internal Controls</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.8</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Absence of Certain Changes</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.9</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Compliance with Legal Requirements</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.10</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Legal Proceedings; Investigations; Orders</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.11</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Certain Business Practices</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.12</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Regulatory Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.13</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Employee Benefit Plans</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.14</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Labor Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.15</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Financing; Solvency</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.16</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Takeover Statutes</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.17</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Ownership of Company Common Stock</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.18</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Intellectual Property</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.19</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Tax Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.20</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Opinion of Financial Advisor</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.21</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Brokers</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.22</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Information Supplied</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.23</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Data Privacy and Security</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.24</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Parent Top Customers, Distributors and Suppliers</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.25</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Product Defects and Warranties</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;3.26</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Acquisition Subs</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE IV. COVENANTS</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Interim Operations</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Company No Solicitation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Parent No Solicitation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.4</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Registration Statement; Joint Proxy Statement/Prospectus</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.5</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Meeting of the Company&#8217;s Stockholders; Company Change in Recommendation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.6</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Meeting of Parent&#8217;s Stockholders; Parent Change in Recommendation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.7</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Filings; Other Action</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.8</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Access</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.9</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Acquisition Sub Consents; Parent Vote</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.10</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Publicity</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.11</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Employee Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.12</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Certain Tax Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.13</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Indemnification; Directors&#8217; and Officers&#8217; Insurance</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.14</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Financing and Financing Cooperation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.15</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Stockholder Litigation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.16</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Stock Exchange Listing and Delisting</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.17</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Section&#160;16 Matters</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.18</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director Resignations</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.19</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Payoff Documentation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;4.20</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Takeover Statutes</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 75%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE V. CONDITIONS TO EACH PARTY&#8217;S OBLIGATION TO EFFECT THE MERGERS</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;5.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Conditions Precedent to Each Party&#8217;s Obligations</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;5.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Additional Conditions Precedent to Parent&#8217;s Obligations</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;5.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Additional Conditions Precedent to the Company&#8217;s Obligations</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE VI. TERMINATION</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;6.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Termination</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;6.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Effect of Termination</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;6.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Termination Fees</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE VII. MISCELLANEOUS PROVISIONS</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Amendment</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Waiver</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">No Survival of Representations and Warranties</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.4</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Entire Agreement; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Reliance;</div> Third-Party Beneficiaries</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.5</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Applicable Law; Jurisdiction</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.6</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Payment of Expenses</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.7</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Assignability; Parties in Interest</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.8</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Notices</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.9</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Severability</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.10</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Counterparts</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.11</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Specific Performance</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.12</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Disclosure Schedules</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.13</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Recourse</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;7.14</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Construction</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">A-86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 10%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 88%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;A</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Certain Definitions</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;B-1</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Company Support Agreement</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Parent Support Agreement</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit C</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Form of First Certificate of Merger</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit D</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Form of Second Certificate of Merger</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AGREEMENT AND PLAN OF MERGER </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">THIS AGREEMENT AND PLAN OF MERGER</div></div> (this &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Agreement</div>&#8221;) is made and entered into as of July&#160;29, 2021, by and among: Bioventus Inc., a Delaware corporation (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent</div>&#8221;); Oyster Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition Sub I</div>&#8221;), Oyster Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition Sub II</div>,&#8221; and together with Acquisition Sub I, the &#8220;Acquisition Subs&#8221;); and Misonix, Inc., a Delaware corporation (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company</div>&#8221;). Certain capitalized terms used in this Agreement are defined in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit A</div>. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RECITALS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">A. </div></div>The parties to this Agreement desire to, on the terms and subject to the conditions set forth herein, enter into an integrated transaction pursuant to which, first, Acquisition Sub I, in accordance with the General Corporation Law of the State of Delaware (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">DGCL</div>&#8221;) will merge with and into the Company, with the Company as the surviving corporation (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">First Merger</div>&#8221;), and, second, the Company, as the surviving corporation in the First Merger, and in accordance with the DGCL and the Delaware Limited Liability Company Act (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">DLLCA</div>&#8221;), will merge with and into Acquisition Sub II, with Acquisition Sub II as the surviving limited liability company (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Second Merger,</div>&#8221; and together with the First Merger, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Mergers</div>&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B. </div></div>The Company Board has unanimously: (i)&#160;determined that the Mergers are fair to, and in the best interests of, the Company and its stockholders; (ii)&#160;approved and declared advisable this Agreement and the consummation of the transactions contemplated by this Agreement, including the Mergers, upon the terms and subject to the conditions contained in this Agreement; and (iii)&#160;resolved, subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>, to recommend that the Company&#8217;s stockholders adopt this Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">C. </div></div>The Parent Board has unanimously: (i)&#160;determined that the terms of this Agreement and the Mergers are fair to, and in the best interests of, Parent and its stockholders; (ii)&#160;approved and declared advisable this Agreement and the consummation of the transactions contemplated by this Agreement, including the Mergers and the issuance of shares of Parent Class&#160;A Common Stock in connection therewith, each upon the terms and subject to the conditions contained in this Agreement; and (iii)&#160;resolved, subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div>, to recommend that Parent&#8217;s stockholders approve the issuance of shares of Parent Class&#160;A Common Stock in connection with the First Merger on the terms and subject to the conditions set forth in this Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">D. </div></div>The board of directors of Acquisition Sub I has: (i)&#160;determined that it is advisable and in the best interests of Acquisition Sub I and its sole stockholder for Acquisition Sub I to enter into this Agreement; (ii)&#160;approved and declared advisable this Agreement and the consummation of the transactions contemplated hereby, including the Mergers, upon the terms and subject to the conditions contained in this Agreement; and (iii)&#160;recommended that its sole stockholder adopt this Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">E. </div></div>Parent, as the sole member of Acquisition Sub II, has (i)&#160;determined that it is advisable and in the best interests of Acquisition Sub II and its sole member to enter into this Agreement and (ii)&#160;approved and declared advisable this Agreement and the consummation of the transactions contemplated hereby, including the Mergers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">F.</div></div> It is intended that, for U.S. federal income Tax purposes, (a)&#160;the First Merger will be treated as part of a binding plan that includes the Second Merger, (b)&#160;the First Merger will be integrated with the Second Merger and treated as a single transaction, (c)&#160;the Mergers, taken together, will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and (d)&#160;this Agreement will be a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.368-2(g)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.368-3(a).</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">G. </div></div>Concurrently with the execution and delivery of this Agreement, (i)&#160;certain stockholders of the Company are entering into Company Support Agreements with Parent substantially in the form attached hereto as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div>&#160;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div></div> (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Support Agreements</div>&#8221;) and (ii)&#160;certain stockholders of Parent are entering into Parent </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Support Agreements with the Company substantially in the form attached hereto as <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div></div> (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Support Agreements</div>&#8221;). </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AGREEMENT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The parties to this Agreement, in consideration of the representations, warranties, covenants and agreements set forth herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, agree as follows: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE I. THE MERGERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Section&#160;1.1 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Mergers; Effect of Mergers.</div></div> At the First Effective Time, Acquisition Sub I shall be merged with and into the Company in accordance with the DGCL and upon the terms and subject to the conditions set forth in this Agreement, whereupon the separate existence of Acquisition Sub I shall cease, and the Company shall be the surviving corporation (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Initial Surviving Corporation</div>&#8221;) in the First Merger. At the Second Effective Time, the Company shall be merged with and into Acquisition Sub II in accordance with the DGCL and the DLLCA, whereupon the separate existence of the Company shall cease, with Acquisition Sub II continuing its existence as the surviving limited liability company (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Surviving Company</div>&#8221;). From and after the Second Effective Time, all the property, rights, powers, privileges and franchises of the Company and the Acquisition Subs shall be vested in the Surviving Company and all of the debts, obligations, liabilities, restrictions and duties of the Company and Acquisition Subs shall become the debts, obligations, liabilities and duties of the Surviving Company, all as provided under the DGCL and DLLCA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.2 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Closing; Effective Time.</div></div> The consummation of the Mergers (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Closing</div>&#8221;) shall be held remotely by exchange of documents and signatures (or their electronic counterparts) unless a place for the Closing to be held in person is agreed to in writing by the parties to this Agreement, on a date to be designated jointly by Parent and the Company, which shall be no later than the second Business Day after the satisfaction or, to the extent permitted hereunder and by applicable Legal Requirements, waiver of the last to be satisfied or waived of all conditions to the parties&#8217; respective obligations to effect the Mergers set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Sections</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.1</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">5.2</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">5.3</div>, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions at the Closing, unless another time or date is agreed to in writing by Parent and the Company. The date on which the Closing actually takes place is referred to as the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Closing Date</div>.&#8221; Subject to the provisions of this Agreement, at the Closing, the parties shall cause a certificate of merger with respect to the First Merger in the form set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit C</div> hereto (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">First Certificate of Merger</div>&#8221;) and immediately thereafter a certificate of merger with respect to the Second Merger in the form set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit D</div> hereto (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Second Certificate of Merger</div>,&#8221; together with the First Certificate of Merger, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Merger</div>&#8221;) to be duly executed and filed with the Secretary of State of the State of Delaware (the&#160;&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Delaware Secretary of State</div>&#8221;) and make all other filings or recordings required by the Company, the Acquisition Subs or Parent under the DGCL and DLLCA in connection with effecting the Mergers. The Mergers shall become effective on the date and at such time as the Certificates of Merger are filed with the Delaware Secretary of State or at such later time as may be mutually agreed to in writing by Parent and the Company and specified in the Certificates of Merger (the time at which the First Merger becomes effective being referred to in this Agreement as the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">First Effective Time</div>&#8221; and the time at which the Second Merger becomes effective being referred to in this Agreement as the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Second Effective Time</div>&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.3 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Certificate of Incorporation and Bylaws</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) At the First Effective Time, the certificate of incorporation of the Company, as in effect immediately prior to the First Effective Time, shall continue to be the certificate of incorporation of the Initial Surviving Corporation until, subject to the requirements of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div>, thereafter changed or amended as provided therein or by applicable Legal Requirements. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(b) At the First Effective Time, the bylaws of the Company in effect immediately prior to the First Effective Time shall continue to be the bylaws of the Initial Surviving Corporation until, subject to the requirements of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div>, thereafter changed or amended as provided therein or by applicable Legal Requirements. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) At the Second Effective Time, the certificate of formation of Acquisition Sub II in effect immediately prior to the Second Effective Time shall continue to be the certificate of formation of the Surviving Company until, subject to the requirements of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div>, thereafter amended as provided therein or by applicable Legal Requirements. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) The limited liability company agreement of Acquisition Sub II in effect immediately prior to the Second Effective Time will continue to be the limited liability company agreement of the Surviving Company until, subject to the requirements of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div>, thereafter changed or amended as provided therein or by applicable Legal Requirements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.4 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Directors and Officers</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) From and after the First Effective Time, the directors and officers of the Acquisition Sub I immediately prior to the First Effective Time shall be the directors and officers of the Initial Surviving Corporation until their successor has been duly elected, designated or qualified, or until their earlier death, resignation or removal in accordance with the certificate of incorporation and bylaws of the Initial Surviving Corporation. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) From and after the Second Effective Time, the officers of Acquisition Sub II immediately prior to the Second Effective Time shall be the officers of the Surviving Company, each to hold office in accordance with the limited liability company agreement of the Surviving Company until their respective successors have been duly elected, designated or qualified, or until their earlier death, resignation or removal in accordance with the limited liability company agreement of the Surviving Company. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Prior to the First Effective Time, Parent shall offer at least two members of the Company Board mutually agreed by Parent and the Company the opportunity to join the Parent Board effective as of the First Effective Time, and shall take all necessary action so that upon the First Effective Time, such offered members of the Company Board shall become members of the Parent Board, each to hold office until the earliest to occur of the appointment or election and qualification of his or her respective successor or his or her death, resignation, disqualification or proper removal as a member of the Parent Board. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.5 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treatment of Capital Stock in the Mergers</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treatment of Capital Stock in the First Merger. </div></div>Subject to the terms and conditions of this Agreement, at the First Effective Time, automatically, by virtue of the First Merger and without any further action on the part of Parent, Acquisition Sub I, the Company or any stockholder of the Company: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(i) all shares of Company Common Stock that are held in the Company&#8217;s treasury or are held directly by a Company Subsidiary, Parent or Acquisition Sub I immediately prior to the First Effective Time (collectively, with the Dissenting Shares, &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Excluded Shares</div>&#8221;) shall be cancelled and shall cease to exist, and no consideration shall be paid or payable in respect thereof; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(ii) except as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(i)</div> and Section<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.6</div> with respect to Excluded Shares, each share of Company Common Stock that is issued and outstanding immediately prior to the First Effective Time shall be converted into the right to receive, without interest, at the election of the holder thereof in accordance with the procedures set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.15</div> (such consideration, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Merger Consideration</div>&#8221;): </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">(A) for each share of Company Common Stock with respect to which an election to receive cash has been made and not revoked or lost pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.15</div> (such share of Company Common Stock, together with any share of Company Common Stock for which an election to receive cash is </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;">deemed to have been made under clause (C)&#160;below, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cash Election Shares</div>&#8221;) an amount of cash equal to $28.00, without interest (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cash Election Consideration</div>&#8221;), as the same may be adjusted pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.7(a)(ii)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.7(b)(ii)</div>; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">(B) for each share of Company Common Stock with respect to which an election to receive stock has been made and not revoked or lost pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.15</div> (such share of Company Common Stock, together with any share of Company Common Stock for which an election to receive stock is deemed to have been made under clause (C)&#160;below, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Stock Election Shares</div>&#8221;), 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Parent Class&#160;A Common Stock (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Stock Election Consideration</div>&#8221;), as the same may be adjusted pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.7(a)(ii)</div>; and </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">(C) for each share of Company Common Stock with respect to which no election to receive cash or stock has been made, the Cash Election Consideration or the Stock Election Consideration, as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.7</div> (such share of Company Common Stock described in this clause (C), the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Election Shares</div>&#8221;). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(iii) each share of common stock, par value $0.0001 per share, of Acquisition Sub I that is issued and outstanding immediately prior to the First Effective Time shall be converted into one validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> share of common stock, par value $0.0001 per share, of the Initial Surviving Corporation. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treatment of Capital Stock in Second Merger</div></div>. Subject to the terms and conditions of this Agreement, at the Second Effective Time, automatically, by virtue of the Second Merger and without any action on the part of Parent, the Initial Surviving Corporation or Acquisition Sub II, each share of common stock, par value $0.0001 per share, of the Initial Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be cancelled and shall cease to exist. Each limited liability company interest of Acquisition Sub II issued and outstanding immediately prior to the Second Effective Time shall remain outstanding as a limited liability company interest of the Surviving Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.6 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dissenting Shares</div></div>. Notwithstanding <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)</div>, shares of Company Common Stock issued and outstanding immediately prior to the First Effective Time and held by a holder who is entitled to, and has properly exercised and perfected his, her or its demand for, appraisal rights under Section&#160;262 of the DGCL (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Dissenting Shares</div>&#8221;) shall not be converted into the right to receive the Merger Consideration, but each holder of such Dissenting Shares shall be entitled to receive such consideration as shall be determined pursuant to Section&#160;262 of the DGCL (it being understood and acknowledged that at the First Effective Time, such Dissenting Shares shall no longer be outstanding, shall automatically be cancelled and shall cease to exist and such holder shall cease to have any rights with respect thereto other than the right to receive the fair market value of such Dissenting shares to the extent afforded by Section&#160;262 of the DGCL); <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that if any such holder shall have failed to perfect or shall have effectively withdrawn or lost his or her right to appraisal and payment under Section&#160;262 of the DGCL (whether occurring before, at or after the First Effective Time), such holder&#8217;s shares of Company Common Stock shall thereupon be deemed to have been converted as of the First Effective Time solely into the right to receive the Merger Consideration as if such shares were No Election Shares, without any interest thereon, and such shares shall not be deemed to be Dissenting Shares. The Company shall give Parent prompt written notice of any demands for appraisal of Company Common Stock received by the Company, written withdrawals or attempted withdrawals of such demands and any other instruments, notices or demands served on the Company pursuant to Section&#160;262 of the DGCL. The Company shall not, without the prior written consent of Parent, voluntarily make any payment with respect to, or settle or offer to settle, any such demands, waive any failure to timely deliver a written demand for appraisal under the DGCL, or approve any withdrawal of any such demands or agree to do or commit to do any of the foregoing. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;1.7 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proration</div></div>. Notwithstanding any provision of this Agreement to the contrary: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) If the product of the aggregate number of Cash Election Shares <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">multiplied by</div></div> the Cash Election Consideration (such product being the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Elected Cash Consideration</div>&#8221;) exceeds the Maximum Cash Amount, then: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) all Stock Election Shares and all No Election Shares will be exchanged for the Stock Election Consideration; and </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) a portion of the Cash Election Shares of each holder of shares of Company Common Stock will be exchanged for the Cash Election Consideration, with such portion being equal to the product obtained by multiplying (A)&#160;the number of such holder&#8217;s Cash Election Shares by (B)&#160;a fraction, the numerator of which will be the Maximum Cash Amount and the denominator of which will be the Elected Cash Consideration, with the remaining portion of such holder&#8217;s Cash Election Shares being deemed to be Stock Election Shares and exchanged for the Stock Election Consideration. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) If the Elected Cash Consideration is less than the Maximum Cash Amount (such difference being the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Shortfall Amount</div>&#8221;), then: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) all Cash Election Shares will be exchanged for the Cash Election Consideration; and </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(ii) all Stock Election Shares and No Election Shares will be treated in the following manner: (A)&#160;if the Shortfall Amount is less than or equal to the product of the aggregate number of No Election Shares <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">multiplied by</div></div> $28.00 (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Election Value</div>&#8221;), then (1)&#160;all Stock Election Shares will be exchanged for the Stock Election Consideration and (2)&#160;the No Election Shares of each holder of shares of Common Stock will be exchanged for the Cash Election Consideration in respect of that number of No Election Shares equal to the product obtained by multiplying (x)&#160;the number of No Election Shares of such holder by (y)&#160;a fraction, the numerator of which is the Shortfall Amount and the denominator of which is the No Election Value, with the remaining portion of such holder&#8217;s No Election Shares (if any) being deemed to be Stock Election Shares and exchanged for the Stock Election Consideration or (B)&#160;if the Shortfall Amount exceeds the No Election Value, then (1)&#160;all No Election Shares will be exchanged for the Cash Election Consideration and (2)&#160;a portion of the Stock Election Shares of each holder of shares of Company Common Stock will be exchanged for the Cash Election Consideration, with such portion being equal to the product obtained by multiplying (x)&#160;the number of Stock Election Shares of such holder by (y)&#160;a fraction, the numerator of which is the amount by which the Shortfall Amount exceeds the No Election Value, and the denominator of which is the product obtained by multiplying the aggregate number of Stock Election Shares by $28.00, with the remaining portion of such holder&#8217;s Stock Election Shares being deemed to be Stock Election Shares and exchanged for the Stock Election Consideration. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) If the Elected Cash Consideration equals the Maximum Cash Amount, then: </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) all Cash Election Shares will be converted into the right to receive the Cash Election Consideration; and </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) all Stock Election Shares and all No Election Shares will be converted into the right to receive the Stock Election Consideration. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.8 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Certain Adjustments</div></div>. Notwithstanding anything in this Agreement to the contrary, if, during the period from the date of this Agreement through the First Effective Time, the outstanding shares of Parent Class&#160;A Common Stock or Company Common Stock are changed or converted into a different number or class or series of shares of capital stock by reason of any stock split, division, combination, change, exchange or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reorganization, reclassification, recapitalization or other similar transaction, or a record date with respect to any such event shall occur during such period, then the Merger Consideration shall be adjusted to the extent appropriate to proportionately reflect such change and to otherwise provide the same economic effect to the Company&#8217;s stockholders as contemplated by this Agreement prior to such action. Nothing in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.8</div> shall be construed to permit the parties to take any action except to the extent consistent with, or not otherwise prohibited by, the terms of this Agreement. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;1.9 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treatment of Equity Awards</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Effective as of the First Effective Time, each Company Option held by an individual who, as of immediately after the First Effective Time, constitutes an &#8220;employee&#8221; of Parent within the meaning of Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8,</div> that is outstanding and unexercised, whether vested or unvested, immediately prior to the First Effective Time (each, an &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Assumed Company Option</div>&#8221;) shall cease to represent a right to acquire shares of Company Common Stock and shall be assumed by Parent and converted automatically into a Parent Option on the same terms and conditions (including applicable vesting, exercise and expiration provisions) as applied to such Assumed Company Option immediately prior to the First Effective Time, except that: (i)&#160;the number of shares of Parent Class&#160;A Common Stock subject to each Assumed Company Option shall be determined by multiplying: (A)&#160;the number of shares of Company Common Stock subject to such Assumed Company Option immediately prior to the First Effective Time; by (B)&#160;the Option Exchange Ratio, and rounding such product down to the nearest whole share; (ii)&#160;the per share exercise price of each Assumed Company Option shall be determined by dividing: (A)&#160;the per share exercise price of the Assumed Company Option immediately prior to the First Effective Time; by (B)&#160;the Option Exchange Ratio, and rounding such quotient up to the nearest whole cent, and (iii)&#160;the Assumed Company Option shall become fully vested immediately upon the First Effective Time. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Prior to the First Effective Time, the Company shall take all corporate action necessary to provide that each Company Option and all Company Restricted Stock shall accelerate in full (to the extent not otherwise previously vested in accordance with their terms) as of immediately prior to the First Effective Time. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Effective as of the First Effective Time, each Company Option that is not an Assumed Company Option and that is outstanding and unexercised shall be settled in cash immediately prior to the First Effective Time in an amount equal to the product of (x)&#160;the number of shares of Company Common Stock subject to the Company Option, and (y)&#160;the excess, if any, of (i)&#160;the Average Company Stock Price, over (ii)&#160;the per share exercise price of such Company Option. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) The Company shall ensure that (a)&#160;no new offering periods under the Company ESPP will commence during the period from the date of this Agreement through the Closing Date, (b)&#160;there will be no increase in the amount of payroll deductions permitted to be made by the participants under the Company ESPP during the current offering periods, except those made in accordance with payroll deduction elections that are in effect as of the date of this Agreement and (c)&#160;no individuals shall commence participation in the Company ESPP during the period from the date of this Agreement through the Closing Date. To the extent applicable, no later than five days prior to the Closing Date, in the case of any outstanding purchase rights under the Company ESPP, any then-current offering period under the Company ESPP shall end and each participant&#8217;s accumulated payroll deductions shall be used to purchase shares of Company Common Stock in accordance with the terms of the Company ESPP. Shares of Company Common Stock held in participants&#8217; Company ESPP account balances immediately prior to the Closing Date shall be treated the same as all other shares of Company Common Stock in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)</div>. The Company shall ensure that the Company ESPP shall terminate immediately prior to the First Effective Time contingent upon the occurrence of the Closing. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) Parent shall take all corporate action necessary to reserve for issuance a sufficient number of shares of Parent Class&#160;A Common Stock for delivery with respect to all Assumed Company Options. Parent shall file and cause to be effective as of no later than the First Effective Time, a registration statement under the Securities Act on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> or other appropriate form under the Securities Act, relating to shares of Parent Class&#160;A Common Stock issuable with respect to all Assumed Company Options, and Parent shall use its best efforts to cause such registration statement to remain in effect for so long as such Assumed Company Options remain outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.10 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">No Fractional Shares</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) No fractional shares of Parent Class&#160;A Common Stock shall be issued in connection with the First Merger, and no certificates or scrip for any such fractional shares shall be issued. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(b) Any holder of Company Common Stock who would otherwise be entitled to receive a fraction of a share of Parent Class&#160;A Common Stock pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)</div> (after aggregating all fractional shares of Parent Class&#160;A Common Stock otherwise issuable to such holder pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)</div>) shall, in lieu of such fraction of a share and upon surrender of such holder&#8217;s certificates representing shares of Company Common Stock outstanding as of immediately prior to the First Effective Time (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Stock Certificates</div>&#8221;) or book-entry positions representing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> shares of Company Common Stock outstanding as of immediately prior to the First Effective Time (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Book-Entry Shares</div>&#8221;) in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12</div>, be paid in cash the dollar amount (rounded to the nearest whole cent), without interest and subject to any required Tax withholding, determined by multiplying such fraction by the Average Parent Stock Price. No such holder shall be entitled to dividends, voting rights or any other rights in respect of any fractional share of Parent Class&#160;A Common Stock that would otherwise have been issuable as part of the Merger Consideration. The payment of cash in lieu of fractional share interests pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10(b)</div> is not a separately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bargained-for</div> consideration but merely represents a mechanical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">rounding-off</div> of the fractions in the exchange. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.11 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Closing of Transfer Books</div></div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the First Effective Time: </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) all shares of Company Common Stock outstanding immediately prior to the First Effective Time shall automatically be cancelled and shall cease to exist, and all holders of Company Stock Certificates and of Company Book-Entry Shares shall cease to have any rights as stockholders of the Company, except (unless such holder holds Excluded Shares, which are subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(i)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.6</div>) the right to receive the Merger Consideration pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)</div>, cash in lieu of any fractional share of Parent Class&#160;A Common Stock pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10(b)</div> and any dividends or other distributions pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(f)</div>; and </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) the stock transfer books of the Company shall be closed with respect to all shares of Company Common Stock outstanding immediately prior to the First Effective Time and no further transfer of any such shares of Company Common Stock shall be made on such stock transfer books after the First Effective Time. If, after the First Effective Time, a valid Company Stock Certificate or a Company Book-Entry Share is presented to the Exchange Agent or to the Initial Surviving Corporation, the Surviving Company or Parent, such Company Stock Certificate or Company Book-Entry Share shall be cancelled and shall be exchanged as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.12 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exchange of Certificates and Cancellation of Book-Entry Positions</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Prior to the Mailing Date, Parent shall select Parent&#8217;s transfer agent or another reputable bank or trust company, in either case, reasonably satisfactory to both Parent and the Company, to act as exchange agent with respect to the Mergers (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Agent</div>&#8221;). Promptly following the First Effective Time, (but in any event within one Business Day following the Closing Date), Parent shall cause to be deposited with the Exchange Agent: (i)&#160;certificates or evidence of book-entry shares representing the shares of Parent Class&#160;A Common Stock issuable pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)</div>; and (ii)&#160;cash sufficient to pay the Cash Election Consideration pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)</div> and to make payments in lieu of fractional shares in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10(b)</div>. The shares of Parent Class&#160;A Common Stock and cash amounts so deposited with the Exchange Agent pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(a)</div>, together with any dividends or distributions received by the Exchange Agent with respect to such shares of Parent Class&#160;A Common Stock, and any interest or other income with respect to such cash amount, are referred to collectively as the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Fund</div>.&#8221; The Exchange Agent shall invest the cash available in the Exchange Fund as reasonably directed by Parent; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that any investment of such cash shall in all events be limited to (w)&#160;direct obligations of, or guaranteed by, the U.S. government, (x)&#160;in commercial paper rated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">P-1</div> or better by Moody&#8217;s Investors Service, Inc. or Standard&#160;&amp; Poor&#8217;s Corporation, respectively, (y)&#160;in certificates of deposit, bank repurchase agreements or banker&#8217;s acceptances of commercial banks with capital exceeding $1&#160;billion (based on the most recent financial statements of such bank that are then publicly available) or (z)&#160;a money </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">market fund having assets of at least $1&#160;billion; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">further</div></div>, that no losses on such investments shall affect the cash payable to former holders of shares of Company Common Stock pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;I</div> (and Parent shall promptly deliver to the Exchange Agent cash in an amount sufficient to replenish any deficiency in the Exchange Fund). The Payment Fund shall not be used for any purpose that is not expressly provided for in this Agreement. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) With respect to Company Stock Certificates, as promptly as reasonably practicable, after the First Effective Time, and in any event within three Business Days, Parent shall cause the Exchange Agent to mail to each holder of record of each such Company Stock Certificate (i)&#160;a notice advising such holder of the effectiveness of the Mergers, (ii)&#160;a letter of transmittal in customary form and reasonably acceptable to each of Parent and the Company specifying that delivery shall be effected, and risk of loss and title to a Company Stock Certificate shall pass, only upon delivery of the Company Stock Certificate (or affidavit of loss in lieu of a Company Certificate as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(e)</div>) to the Exchange Agent (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Letter of Transmittal</div>&#8221;) and (iii)&#160;instructions for surrendering a Company Stock Certificate (or affidavit of loss in lieu of a Company Stock Certificate as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(e)</div>) to the Exchange Agent. Upon surrender to the Exchange Agent of a Company Stock Certificate (or affidavit of loss in lieu of a Company Stock Certificate as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(e)</div>) together with a duly executed and completed Letter of Transmittal and such other documents as may reasonably be required pursuant to such instructions, Parent shall cause the Exchange Agent to mail to each holder of record of any such Company Stock Certificate in exchange therefor, as promptly as reasonably practicable thereafter, (i)&#160;a statement reflecting the number of whole shares of Parent Class&#160;A Common Stock, if any, that such holder is entitled to receive pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)</div> in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> book-entry form in the name of such record holder (subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(i)</div>) and (ii)&#160;a check, or wire transfer of immediate funds (provided such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000), in the amount (after giving effect to any required Tax withholdings as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.14</div>) of (A)&#160;the applicable Cash Election Consideration such holder is entitled to receive pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)</div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">plus</div></div> (B)&#160;any cash in lieu of fractional shares of Parent Class&#160;A Common Stock pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">plus</div></div> (C)&#160;any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(f)</div>. Any Company Stock Certificate that has been so surrendered shall be cancelled by the Exchange Agent. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) With respect to Company Book-Entry Shares not held through DTC (each, a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-DTC</div> Book-Entry Share</div>&#8221;), Parent shall cause the Exchange Agent to pay and deliver to each holder of record of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-DTC</div> Book-Entry Share, as promptly as reasonably practicable after the First Effective Time, but in any event within two Business Days thereafter, (i)&#160;a statement reflecting the number of whole shares of Parent Class&#160;A Common Stock, if any, that such holder is entitled to receive pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)</div> in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-certificated</div> book-entry form in the name of such record holder (subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(i)</div>) and (ii)&#160;a check or wire transfer of immediately available funds (provided such holder has provided wire transfer instructions and is entitled to cash in excess of $250,000) in the amount (after giving effect to any required Tax withholdings as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.14</div>) of (A)&#160;the applicable Cash Election Consideration such holder is entitled to receive pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)</div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">plus</div></div> (B)&#160;any cash in lieu of fractional shares of Parent Class&#160;A Common Stock pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">plus</div></div> (C)&#160;any unpaid cash dividends and any other dividends or other distributions that such holder has the right to receive pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(f)</div>, and each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-DTC</div> Book-Entry Share shall be promptly cancelled by the Exchange Agent. Subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(i)</div>, payment of the Merger Consideration with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-DTC</div> Book-Entry Shares shall only be made to the Person in whose name such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-DTC</div> Book-Entry Shares are registered. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) With respect to Company Book-Entry Shares held through DTC, prior to the First Effective Time, Parent and the Company shall cooperate to establish procedures with the Exchange Agent and DTC to provide that the Exchange Agent will transmit to DTC or its nominees as promptly as reasonably practicable after the First Effective Time, but in any event within three Business Days thereafter, upon surrender of shares held of record by DTC or its nominees in accordance with DTC&#8217;s customary surrender procedures, the Merger Consideration, cash in lieu of fractional shares of Parent Common Stock pursuant to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10</div>, if any, and any unpaid cash dividends and any other dividends or other distributions, in each case, that such holder has the right to receive pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(f)</div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) In the event that any Company Stock Certificate shall have been lost, stolen or destroyed, then, upon the making of an affidavit of that fact (in form reasonably acceptable to Parent and the Exchange Agent) by the Person claiming such Company Stock Certificate to be lost, stolen or destroyed and the posting by such Person of a bond in a reasonable and customary amount and upon such terms as may reasonably be required as indemnity against any claim that may be made against it with respect to such Company Stock Certificate, the Exchange Agent will issue in exchange for such lost, stolen or destroyed Company Stock Certificate, the Merger Consideration, cash in lieu of fractional shares of Parent Class&#160;A Common Stock pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10</div>, if any, and any unpaid cash dividends and any other dividends or other distributions, in each case, payable or issuable pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(f)</div>, as if such lost, stolen or destroyed Company Stock Certificate had been surrendered. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) No dividends or other distributions declared or made with respect to Parent Class&#160;A Common Stock with a record date after the First Effective Time shall be paid or otherwise delivered to the holder of any unsurrendered Company Stock Certificate or Company Book-Entry Shares, as applicable, with respect to the shares of Parent Class&#160;A Common Stock that such holder has the right to receive in the Mergers until the later to occur of: (A)&#160;the date on which the holder surrenders such Company Stock Certificate or Company Book-Entry Shares in accordance with this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12</div>; and (B)&#160;the payment date for such dividend or distribution with respect to Parent Class&#160;A Common Stock (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar laws, to receive all such dividends and distributions, without interest). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(g) Any portion of the Exchange Fund that remains undistributed to holders of Company Stock Certificates or Company Book-Entry Shares as of the date that is one year after the Closing Date shall be delivered to Parent upon demand. Any holders of Company Stock Certificates or Company Book-Entry Shares who have not theretofore surrendered their Company Stock Certificates or Company Book-Entry Shares in accordance with this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12</div> shall thereafter be entitled to look to Parent for, and be entitled to receive from Parent, the Merger Consideration pursuant to the provisions of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)</div>, cash in lieu of any fractional shares of Parent Class&#160;A Common Stock in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10(b)</div> and any dividends or distributions with respect to shares of Parent Class&#160;A Common Stock pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(f)</div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(h) None of Parent, the Initial Surviving Corporation, nor the Surviving Company shall be liable to any holder or former holder of shares of Company Common Stock or to any other Person with respect to any portion of the Merger Consideration delivered to any public official pursuant to any applicable abandoned property law, escheat law or other similar Legal Requirement. If any Company Stock Certificate or Company Book-Entry Share has not been surrendered prior to the date on which any portion of the Merger Consideration and any dividends or distributions, in each case, that a holder of such Company Stock Certificates or Company Book-Entry Share has the right to receive pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;I</div> in respect of such Company Stock Certificate or Company Book-Entry Share would otherwise escheat to or become property of any Governmental Entity, any such shares, cash, dividends or distributions in respect of such Company Stock Certificate or Company Book-Entry Share shall, to the extent permitted by applicable Legal Requirement, become the property of Parent, free and clear of all claims or interests of any Person previously entitled thereto. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(i) In the event of a transfer of ownership of any shares of Company Common Stock that is not registered in the transfer records of the Company, the Exchange Agent may deliver the Merger Consideration (and, to the extent applicable, cash in lieu of fractional shares pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10(b)</div> or any dividends or distributions pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(f)</div>) to such transferee if (A)&#160;in the case of Company Book-Entry Shares, written instructions authorizing the transfer of the Company Book-Entry Shares are presented to the Exchange Agent, (B)&#160;in the case of Company Stock Certificates, the Company Stock Certificates formerly representing such shares of Company Common Stock are surrendered to the Exchange </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agent, and (C)&#160;the written instructions, in the case of clause (A), and Company Stock Certificates, in the case of clause (B), are accompanied by all documents required to evidence and effect such transfer and to evidence that any applicable stock transfer Taxes have been paid or are not applicable, in each case, in form and substance, reasonably satisfactory to Parent and the Exchange Agent. If any Merger Consideration is to be delivered to a Person other than the holder in whose name any shares of Company Common Stock are registered, it shall be a condition of such exchange that the Person requesting such delivery shall pay any transfer or other similar Taxes required by reason of the transfer of shares of Parent Class&#160;A Common Stock to a Person other than the registered holder of any shares of Company Common Stock, or shall establish to the satisfaction of Parent and the Exchange Agent that such Tax has been paid or is not applicable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.13 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Further Action</div></div>. If, at any time after the First Effective Time, any further action is determined by Parent, the Initial Surviving Corporation or the Surviving Company to be necessary to carry out the purposes of this Agreement, the officers and directors of Parent shall (in the name of Acquisition Subs, in the name of the Company or otherwise) be fully authorized to take such action. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.14 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax Withholding</div></div>. Each of Parent, the Exchange Agent, Acquisition Sub I, Acquisition Sub II, the Company and the Initial Surviving Corporation and the Surviving Company, as applicable, shall be entitled to deduct and withhold from any amounts otherwise payable pursuant to this Agreement any amounts as are required to be deducted and withheld with respect to the making of such payment pursuant to the Code or any other applicable Legal Requirement relating to Taxes. To the extent that amounts are so deducted or withheld and, if required, paid over to the appropriate Governmental Entity, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding were made. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;1.15 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Election Procedures</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Not less than 30 days prior to the anticipated First Effective Time (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Mailing Date</div>&#8221;), Parent will cause to be mailed to each record holder of shares of Company Common Stock (other than Excluded Shares) as of five business days prior to the Mailing Date (or another date selected by Parent which is reasonably acceptable to the Company) an election form in a form mutually satisfactory to Parent and the Company (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Election Form</div>&#8221;). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Each Election Form will permit the holder (or the beneficial owner through customary documentation and instructions) of shares of Company Common Stock to specify (i)&#160;the number of shares of Company Common Stock with respect to which such holder elects to receive the Stock Election Consideration, (ii)&#160;the number of Shares with respect to which such holder elects to receive the Cash Election Consideration or (iii)&#160;that such holder makes no election with respect to such holder&#8217;s shares of Company Common Stock. Any shares of Company Common Stock with respect to which the Exchange Agent does not receive a properly completed Election Form during the period (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Election Period</div>&#8221;) from the Mailing Date to 5:00 p.m., New York Time, on the Business Day that is three Trading Days prior to the Closing Date or such other date as Parent and the Company will, prior to the Closing, mutually agree (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Election Deadline</div>&#8221;) will be deemed to be No Election Shares. Parent and the Company will publicly announce the anticipated Election Deadline at least five Business Days prior to the anticipated Closing Date. If the Closing Date is delayed to a subsequent date, the Election Deadline shall be similarly delayed to a subsequent date, and Parent and the Company shall promptly announce any such delay and, when determined, the rescheduled Election Deadline. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) Any election made pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.15</div> will have been properly made only if the Exchange Agent has actually received a properly completed Election Form during the Election Period. Any Election Form may be revoked or changed by the Person submitting it, by written notice received by the Exchange Agent during the Election Period. In the event an Election Form is revoked during the Election Period, the Shares represented by such Election Form will be deemed to be No Election Shares, except to the extent a subsequent election is properly made during the Election Period. Subject to the terms of this </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agreement and of the Election Form, the Exchange Agent will have reasonable discretion to determine whether any election, revocation or change has been properly or timely made and to disregard immaterial defects in the Election Forms, and any good faith decisions of the Exchange Agent regarding such matters will be binding and conclusive. None of Parent, the Company or the Exchange Agent will be under any obligation to notify any Person of any defect in an Election Form. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE II.REPRESENTATIONS AND WARRANTIES OF THE COMPANY </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company hereby represents and warrants to Parent and Acquisition Sub that, except as set forth or incorporated by reference in the Company SEC Documents filed and publicly available prior to the date of this Agreement (excluding any disclosures contained in such documents under the heading &#8220;Risk Factors&#8221; or in any other section&#160;to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature) or, subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.12</div>, in the disclosure schedule delivered to Parent concurrent with the execution of this Agreement (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Disclosure Schedule</div>&#8221;): </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.1 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Due Organization and Good Standing; Subsidiaries</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware. The Company has the requisite corporate power and authority to own, lease and operate its assets and to carry on its business as it is being conducted as of the date of this Agreement, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. The Company is duly qualified and has all necessary Governmental Authorizations to do business, and (where such concept is recognized under the Laws of the applicable jurisdictions) is in good standing, in each other jurisdiction where the nature of its business makes such qualification necessary, except where the failure to be so qualified or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Exhibit 21.1 of the Most Recent Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> is a correct and complete list of each Entity that is a Company Subsidiary as of the date of this Agreement. Neither the Company nor any Company Subsidiary owns any equity interest or joint venture, partnership or similar interest in any other Entity, other than the Entities identified in Exhibit 21.1 of the Most Recent Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Each Company Subsidiary is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has the requisite corporate or other organizational power and authority and Governmental Authorizations to own, lease and operate its assets and to carry on its business as it is being conducted as of the date of this Agreement, except where the failure to be so organized, existing and in good standing or to have such power and authority, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. Each Company Subsidiary is duly qualified and has all necessary Governmental Authorizations to do business, and (where such concept is recognized under the laws of the applicable jurisdictions) is in good standing, in each other jurisdiction where the nature of its business makes such qualification necessary, except where the failure to be so qualified or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. All of the outstanding shares of capital stock of each Company Subsidiary are duly authorized, validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> and are owned directly or indirectly by the Company free and clear of all Liens, except for restrictions on transfer under applicable securities laws. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.2 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Organizational Documents</div></div>. Prior to the date of this Agreement, the Company has made available to Parent copies of the Organizational Documents of the Company and each Company Subsidiary, including all amendments thereto in effect prior to the date of this Agreement. The Organizational Documents of the Company and each Company Subsidiary are in full force and effect and neither (a)&#160;the Company nor (b)&#160;except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, any Company Subsidiary is in violation of any of the provisions of such Organizational Documents. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;2.3 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capitalization</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) The authorized capital stock of the Company consists of: (i) 45,000,000 shares of Company Common Stock and (ii) 2,000,000 shares of preferred stock, par value $0.0001 per share (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Preferred Stock</div>&#8221;). All of the outstanding shares of Company Common Stock have been, and all shares of Company Common Stock reserved for issuance pursuant to the Company Equity Agreements will be when issued, duly authorized and validly issued, and are, or will be when issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable.</div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Except as set forth in the Company&#8217;s Organizational Documents or the Company Equity Agreements: (i)&#160;none of the outstanding shares of Company Common Stock is entitled or subject to any preemptive right, right of repurchase, right of participation or any similar right granted by the Company or a Company Subsidiary; (ii)&#160;none of the outstanding shares of Company Common Stock is subject to any right of first refusal in favor of the Company or any Company Subsidiary; (iii)&#160;there are no bonds, debentures, notes or other indebtedness issued by the Company or any Company Subsidiary and outstanding having the right to vote (or convertible or exercisable or exchangeable for securities having the right to vote) on any matters on which stockholders of the Company may vote; and (iv)&#160;there is no Contract to which the Company or any Company Subsidiary is a party relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from granting any option or similar right with respect to), any shares of Company Common Stock. Except as set forth in the Company Equity Agreements, neither the Company nor any Company Subsidiary is under any obligation, nor is it bound by any Contract pursuant to which it will become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Company Common Stock, capital or other equity interests of any Company Subsidiary or any other securities of any other Entity. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) As of July&#160;27,&#160;2021 (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Capitalization Date</div>&#8221;): (i) 17,410,045 shares of Company Common Stock were issued and outstanding, which total includes 159,800 shares of Company Restricted Stock; (ii)&#160;no shares of Company Preferred Stock were issued and outstanding, (iii) 2,202,301 shares of Company Common Stock were subject to issuance pursuant to outstanding Company Options, (iv) 400,000 shares of Company Common Stock were reserved for issuance pursuant to the Company ESPP; (v) 524,736 shares of Company Common Stock were reserved for issuance pursuant to the Company Equity Incentive Plans (excluding securities reflected in clauses (iii)&#160;and (iv)); and (vi)&#160;no other shares of capital stock or other voting securities of the Company were issued, reserved for issuance or outstanding. From the Company Capitalization Date through the date of this Agreement, neither the Company nor any of the Company Subsidiaries has issued any shares of Company Common Stock or other equity interests of the Company or any Company Subsidiary, other than pursuant to Company Options, in each case, that were outstanding as of the Company Capitalization Date. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Except as set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.3(c)</div>, there is no: (i)&#160;subscription, option, call, warrant or other right (whether or not currently exercisable) to acquire any shares of the capital stock or other equity interests, or any restricted stock unit, stock-based performance unit, shares of phantom stock, stock appreciation right, profit participation right or any other right that is linked to, or the value of which is based on or derived from, the value of any shares of capital stock or other equity interest of the Company or any Company Subsidiary, in each case, to which the Company or any Company Subsidiary is a party; (ii)&#160;outstanding security, instrument, bond, debenture or note that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company or any Company Subsidiary; or (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which the Company or any Company Subsidiary is or may become obligated to sell or otherwise issue any shares of its capital stock or other equity interest or any other securities. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) Prior to the date of this Agreement, the Company has made available to Parent accurate and complete copies of: (A)&#160;the Company Equity Plans; and (B)&#160;the forms of all stock option agreements evidencing Company Options outstanding as of the date of this Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.4 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Authority; Binding Nature of Agreement</div></div>. The Company has the requisite corporate power and authority to enter into and to perform its obligations under this Agreement and, subject to receipt of the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Required Company Stockholder Vote, to consummate the First Merger. Assuming the accuracy of Parent&#8217;s and Acquisition Subs&#8217; representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.17</div> hereof, on or prior to the date hereof, the Company Board has unanimously: (a)&#160;duly and validly authorized and approved the execution, the delivery and, subject to the receipt of the Required Company Stockholder Vote, the performance of this Agreement and the consummation of the First Merger by the Company; (b)&#160;determined that the First Merger is fair to and in the best interests of the Company and its stockholders; (c)&#160;approved and declared advisable this Agreement and the consummation of the transactions contemplated by this Agreement, including the First Merger; and (d)&#160;resolved that (i)&#160;this Agreement be submitted to a vote of the Company&#8217;s stockholders and, (ii)&#160;subject to the terms and conditions contained in this Agreement, including <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>, to recommend that the Company&#8217;s stockholders adopt this Agreement (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Board Recommendation</div>&#8221;), and to include the Company Board Recommendation in the Joint Proxy Statement/Prospectus. Assuming the accuracy of Parent&#8217;s and Acquisition Subs&#8217; representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.17</div> hereof, the execution and delivery of this Agreement by the Company and the consummation by the Company of the First Merger and other transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of the Company, and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement, in each case other than, with respect to the consummation of the Mergers, the receipt of the Required Company Stockholder Vote and the filing of the Certificates of Merger as required by the DGCL. This Agreement has been duly executed and delivered on behalf of the Company and, assuming the due authorization, execution and delivery of this Agreement on behalf of Parent and the Acquisition Subs and the accuracy of Parent&#8217;s and Acquisition Subs&#8217; representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.17</div> hereof, constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to: (i)&#160;laws of general application relating to bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, affecting creditors&#8217; rights generally; and (ii)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Enforceability Exception</div>&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.5 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vote Required</div></div>. Assuming the accuracy of Parent&#8217;s and Acquisition Subs&#8217; representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.17</div> hereof, the adoption of this Agreement by the affirmative vote of the holders of at least a majority of the shares of Company Common Stock issued and outstanding on the record date for the Company Stockholder Meeting and entitled to vote on the proposal to adopt this Agreement (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Required Company Stockholder Vote</div>&#8221;) is the only vote of the holders of any class or series of the Company&#8217;s capital stock necessary under applicable Legal Requirements and the Company Organizational Documents to adopt this Agreement or for the Company to consummate the transactions contemplated hereby, including the Mergers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.6 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Contravention;</div> Consents</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) The execution and delivery of this Agreement by the Company and, assuming receipt of the Required Company Stockholder Vote and the accuracy of Parent&#8217;s and Acquisition Subs&#8217; representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.17</div> hereof, the consummation by the Company of the Mergers will not: (i)&#160;cause a violation of any of the provisions of the Organizational Documents of the Company or any Company Subsidiary; (ii)&#160;assuming the consents and filings referred to in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.6(b)</div> are made and obtained, conflict with or violate any applicable Legal Requirements; or (iii)&#160;subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7</div>, result in any loss, limitation or impairment of any right of the Company or any Company Subsidiary to own or use any assets, result in any violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation, first offer, first refusal, modification or acceleration of any obligation or to the loss of a benefit under any Material Contract, or result in the creation of any Liens of any kind (other than Company Permitted Encumbrances) upon any of the properties, rights or assets of the Company or any Company Subsidiary, except, in the cases of clauses &#8220;(ii)&#8221; and &#8220;(iii),&#8221; as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Except as (i)&#160;may be required by the applicable requirements of the Securities Act, the Exchange Act, the DGCL, the DLLCA, the HSR Act or other applicable Antitrust Laws, applicable state securities takeover and &#8220;blue sky&#8221; laws, the rules and regulations of Nasdaq, (ii)&#160;in connection with the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">filing of the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> with the SEC or (iii)&#160;the filing of all material applications and notices, consents, approvals, clearances, authorizations, registrations, and exemptions, as required by the FDA and any other federal, state, local or foreign Governmental Entity that is concerned with or regulates the development, marketing, labeling, sale, use, handling and control, safety, efficacy, reliability or manufacturing of, or payment for biological products, human cells, tissues, and cellular or tissue-based products (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">HCT/Ps</div>&#8221;), medical devices or durable medical equipment or is concerned with or regulates public health care programs (each, a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare Regulatory Authority</div>&#8221;), the Company and the Company Subsidiaries are not required to make any filing, registration, or declaration with, give any notice to, or obtain any consent, Order, license, permit, clearance, waiver or approval from, any Governmental Entity for the execution and delivery of this Agreement by the Company, the performance by the Company of its covenants and obligations hereunder or the consummation by the Company of the Mergers, in each case, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.7 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reports; Financial Statements; Internal Controls</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) All reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated by reference therein) required to be filed or furnished by the Company with the SEC under the Exchange Act or Securities Act since January&#160;1, 2019 (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company SEC Documents</div>&#8221;) have been filed or furnished by or on behalf of the Company with the SEC on a timely basis. As of the time it was filed with the SEC (or if amended or superseded, then on the date of such amended or superseding filing): (i) each of the Company SEC Documents complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act (as the case may be) and the applicable regulations promulgated thereunder and the listing requirements and corporate governance rules and regulations of Nasdaq, each as in effect on the date such Company SEC Document was filed; and (ii)&#160;none of the Company SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. No Company Subsidiary has been required to file any forms, reports or other documents with the SEC at any time since January&#160;1, 2019. Since January&#160;1, 2019 no executive officer of the Company has failed in any respect to make the certifications required of him or her under Section&#160;302 or 906 of the Sarbanes-Oxley Act. Neither the Company nor any of its executive officers has received notice from any Governmental Entity challenging or questioning the accuracy, completeness, form or manner of filing of such certifications. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) The financial statements (including any related notes) contained or incorporated by reference in the Company SEC Documents: (i)&#160;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)&#160;were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited statements, as permitted by the rules and regulations of the SEC applicable thereto, and except that unaudited financial statements may not contain footnotes and are subject to normal and recurring <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> adjustments); (iii) fairly present, in all material respects, the financial position of the Company and the Company&#8217;s consolidated Subsidiaries as of the respective dates thereof and the results of operations and consolidated cash flows of the Company and the Company&#8217;s consolidated Subsidiaries for the periods covered thereby subject, with respect to unaudited interim statements, to normal and recurring <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> adjustments; and (iv)&#160;have been prepared from, and are in accordance with, the books and records of the Company and the Company&#8217;s consolidated Subsidiaries in all material respects. No financial statements of any Person other than the Company and the Company&#8217;s consolidated Subsidiaries are required by GAAP to be included in the consolidated financial statements of the Company. The books and records of the Company and the Company Subsidiaries have been, and are being, maintained in all material respects in accordance with GAAP and any other applicable legal and accounting requirements. As of the date of this Agreement, Deloitte&#160;&amp; Touche LLP has not resigned (or informed the Company that it intends to resign) or been dismissed as independent public accountants of the Company. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) The Company maintains, and at all times since January&#160;1, 2019 has maintained, a system of internal control over financial reporting (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)</div> under the Exchange </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Act) which is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures that: (i)&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company and the Company Subsidiaries; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations of management and directors of the Company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of the Company and the Company Subsidiaries that could have a material effect on the financial statements. The Company&#8217;s management has completed an assessment of the effectiveness of the Company&#8217;s system of internal control over financial reporting in compliance with the requirements of Section&#160;404 of the Sarbanes-Oxley Act for the most recent fiscal quarter ended March&#160;31, 2021 and such assessment concluded that such controls were effective. Management of the Company has disclosed to the Company&#8217;s auditors and the audit committee of the Company Board (x)&#160;any significant deficiencies or material weaknesses in the design and operation of internal controls over financial reporting since January&#160;1, 2019 and (y)&#160;any fraud, whether or not material, that involves management or any other employees who have a significant role in the Company&#8217;s internal control over financial reporting, and each such deficiency, weakness and fraud so disclosed to auditors, if any, has been made available to Parent prior to the date hereof. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Since January&#160;1, 2019, (i) none of the Company or any Company Subsidiary nor, to the knowledge of the Company, any director or officer of the Company or any Company Subsidiary has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding accounting, internal accounting controls or auditing practices, procedures, methodologies or methods of the Company or any Company Subsidiary or any material complaint, allegation, assertion or claim from employees of the Company or any Company Subsidiary regarding questionable accounting or auditing matters with respect to the Company or any Company Subsidiary, and (ii)&#160;to the knowledge of the Company, no attorney representing the Company or any Company Subsidiary, whether or not employed by the Company or any Company Subsidiary, has reported evidence of a violation of securities laws, breach of fiduciary duty or similar violation by the Company, any Company Subsidiary or any of their respective officers, directors, employees or agents to the Company Board or any committee thereof, or to the Chief Financial Officer or Chief Executive Officer of the Company. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) The Company maintains disclosure controls as required by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;13a-15</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15</div> under the Exchange Act. As of the date of this Agreement, the Company is in compliance in all material respects with all current listing requirements of the Nasdaq Global Select Market (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Nasdaq</div>&#8221;). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) Neither the Company nor any Company Subsidiary is a party to, or has a commitment to effect, enter into or create, any joint venture, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-balance</div> sheet arrangement&#8221; (as defined in Item 303(a) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> under the Exchange Act). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the Company SEC Documents, and none of the Company SEC Documents is, to the knowledge of the Company, the subject of ongoing SEC review or investigation. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) Neither the Company nor any Company Subsidiary has any liabilities of any nature or type (whether accrued, absolute, determined, contingent or otherwise and whether due or to become due), that would be required by GAAP to be reflected on a condensed consolidated balance sheet of the Company and its consolidated Company Subsidiaries, except for: (i)&#160;liabilities disclosed in the financial statements (including any related notes) contained in the Most Recent Company Balance Sheet; (ii)&#160;liabilities incurred in the ordinary course of business in a manner consistent with past practice since the date of the Most Recent Company Balance Sheet; (iii)&#160;liabilities that, individually or in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse Effect; and (iv)&#160;liabilities and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obligations incurred in connection with this Agreement, the preparation and negotiation of this Agreement or the transactions contemplated by this Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.8 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Absence of Certain Changes</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Since the date of the Most Recent Company Balance Sheet, there has not been any fact, event, change, effect, circumstance, occurrence or development that, individually or in the aggregate, has had or would reasonably be expected to have a Company Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) From the date of the Most Recent Company Balance Sheet to the date of this Agreement, the businesses of the Company and the Company Subsidiaries have been conducted in all material respects in the ordinary course of business (other than in connection with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures) in a manner consistent with past practice, and neither the Company nor any Company Subsidiary has undertaken any action that if proposed to be taken after the date of this Agreement would require Parent&#8217;s consent pursuant to subsections (ii), (iii), (iv), (vi), (vii), (xi), (xii), (xvi), (xvii), (xix) and (xx)&#160;of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.9 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intellectual Property and Related Matters</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.9(a)</div> of the Company Disclosure Schedule&#160;sets forth an accurate and complete list as of the date of this Agreement, of all material Company IP that is Registered IP (excluding domain name registrations) (collectively, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Registered IP</div>&#8221;), including for each item: (i)&#160;the jurisdiction of application or registration; and (ii)&#160;the application or registration number. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) To the knowledge of the Company, all Company Registered IP is currently in compliance with all formal legal requirements (including, as applicable, payment of filing, examination and maintenance fees, inventor declarations, proofs of working or use, timely post-registration filing of affidavits of use and incontestability, and renewal applications) to maintain such Registered Company Intellectual Property in full force and effect, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. To the knowledge of the Company, all material Company Registered IP is valid, subsisting and enforceable (or solely in the case of applications, applied for and pending), since January&#160;1, 2019, none of the material Company Registered IP has ever been found invalid, unpatentable or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding, except for claims rejected or refused in connection with the prosecution of any Registered Company Intellectual Property. Since January&#160;1, 2019, neither the Company nor any Company Subsidiary has received any written notice or claim challenging the validity or enforceability of any Company Registered IP or indicating an intention on the part of any Person to bring a claim that any of the Company Registered IP is invalid or unenforceable, and there is currently no Legal Proceeding pending or threatened in writing, in which the validity, enforceability or ownership of any Company Registered IP is being contested or challenged. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) To the knowledge of the Company, the Company or a Company Subsidiary, as applicable, solely owns or has a valid and enforceable exclusive license (as applicable) to all Company IP, free and clear of all Liens other than Company Permitted Encumbrances. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Neither the Company nor any Company Subsidiary is subject to any outstanding or potential Order that restricts in any material manner the use, transfer or licensing of any material Company IP. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) To the knowledge of the Company, the operations of the businesses of the Company and the Company Subsidiaries as currently conducted, including the Company&#8217;s and the Company Subsidiaries&#8217; design, manufacture, provision, use and sale of any Company Products, do not infringe, misappropriate or otherwise violate, and, to the knowledge of the Company, since January&#160;1, 2019 have not infringed, misappropriated or otherwise violated, any Intellectual Property owned by any other Person except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. No Legal Proceeding is pending or, to the Company&#8217;s Knowledge, threatened in writing against the Company or any Company Subsidiary alleging that the operation of the business of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company or any Company Subsidiary, the Company Products, Company Intellectual Property or Company Technology (or the exploitation of any of the foregoing) infringes, misappropriates, or violates (or in the past infringed, misappropriated or violated) any Intellectual Property of any Person, or that any of the Company Intellectual Property or Company Technology is invalid or unenforceable. Neither the Company nor any Company Subsidiary has received any written complaints, claims or notices since January&#160;1, 2019 alleging any infringement, misappropriation or violation of any Intellectual Property of any other Person by the Company or any Company Subsidiary. To the knowledge of the Company, there is no unauthorized use, unauthorized disclosure, infringement, misappropriation or other violation of any material Company IP by any third Person. Since January&#160;1, 2019, neither Company nor any Company Subsidiary has brought any Legal Proceeding against any other Person, or provided any other Person with written notice or other assertion, alleging any Person is infringing, misappropriating or otherwise violating any material Company IP. </div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) To the knowledge of the Company, no material Company IP was developed using any material support, funding, resources or assistance from any government entities, or from any university, college, other academic institutions, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> research centers (other than in connection with customer agreements in the ordinary course of business in a manner consistent with past practice). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) As of the date of this Agreement, (i)&#160;neither the Company nor any Company Subsidiary is obligated to grant licenses to any material Company IP to any industry standards organization, body, working group, patent pool, trade association, or similar organization and (ii)&#160;neither the Company nor any Company Subsidiary, nor any material Company IP is subject to any licensing, assignment, contribution, disclosure, or other requirements or restrictions of any industry standards organization, body, working group, patent pool, trade association, or similar organization. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) The Company and each Company Subsidiary have taken commercially reasonable steps to protect all Trade Secrets owned, used or held for use by the Company or a Company Subsidiaries and that are material to the Company or the Company Subsidiaries taken as a whole.&#160;&#160;&#160;&#160;Each Person who is or was involved in the creation or development of any Company Product has entered into a valid and enforceable agreement with the Company or a Company Subsidiary, containing an assignment to the Company or the Company Subsidiaries, as applicable, of Intellectual Property in such Person&#8217;s contribution to the Company IP except to the extent not legally assignable and except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. To the knowledge of the Company, no Person has materially violated such agreement or otherwise misappropriated any Trade Secret that constitutes material Company IP. Since January&#160;1, 2019, no Person has notified the Company or any Company Subsidiary in writing that it is claiming any ownership of or right to use any material Company IP (other than the right to use Company IP expressly granted to such Person under a Contract with the Company or a Company Subsidiary). </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(i) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.9(i)</div> of the Company Disclosure Schedule sets forth an accurate and complete list as of the date of this Agreement of, (i)&#160;all Contracts pursuant to which a third Person has licensed (including covenants not to sue) to the Company or a Company Subsidiary any material Intellectual Property and which Contract is material to the Company and the Company Subsidiaries, taken as a whole (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Bound</div> Licenses</div>&#8221;); and (ii)&#160;each Contract pursuant to which the Company has granted to any third Person any right or license (including covenants not to sue) to any material Company IP and which Contract is material to the Company and the Company Subsidiaries, taken as a whole (other than, in all cases, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> licenses granted in the ordinary course of business in a manner consistent with past practice) (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Out-Bound</div> Licenses</div>&#8221; and, together with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Bound</div> Licenses, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company IP Licenses</div>&#8221;). Neither the Company nor any Company Subsidiary is bound by, and no Company IP is subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of the Company or a Company Subsidiary to use, exploit, assert, or enforce any of its Intellectual Property in any material respect anywhere in the world. Without limiting the foregoing, neither the Company nor any Company Subsidiary has granted any exclusive licenses to any material Company IP. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(j) Except as, individually or in the aggregate, has not been and would not reasonably be expected to be material to the Company and the Company Subsidiaries, taken as a whole, the Company and each Company Subsidiary is in compliance, and has since January&#160;1, 2019 complied, with all applicable Data Protection Laws. To the knowledge of the Company, since January&#160;1, 2019, there have not been any material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-permitted</div> disclosures, material security incidents or material breaches involving the Company, the Company Subsidiaries, or any of its agents, employees or contractors relating to any Personal Data in its possession or control except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) To the knowledge of the Company, since January&#160;1, 2019, there has been no material failure or any material unauthorized intrusions or material breaches of security with respect to the information technology systems owned or controlled by the Company or any Company Subsidiary that has resulted in a material disruption or material interruption in the operation of the business of the Company or any Company Subsidiary, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.10 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Title to Assets; Real Property</div></div>. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, (a)&#160;the Company or a Company Subsidiary owns, and has good and marketable title to, or in the case of assets purported to be leased by the Company or a Company Subsidiary, leases and has valid leasehold interest in, each of the material tangible assets owned or leased by the Company or a Company Subsidiary, free and clear of all Liens (other than Company Permitted Encumbrances), (b) either the Company or a Company Subsidiary has a good and valid binding leasehold interest in each material property under which the Company or any Company Subsidiary uses or occupies or has the right to use or occupy any real property (such real property, collectively, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Leased Real Property</div>&#8221;), in each case pursuant to a written lease, sublease, license, or other use or occupancy agreement, in each case that is a valid and binding obligation of the Company or a Company Subsidiary and, to the knowledge of the Company, each other party thereto, (c)&#160;(i) none of the Company or any Company Subsidiary is in default of any provision of any such lease and (ii)&#160;the Company has made available to Parent a true and correct copy of each such material lease in effect as of the date of this Agreement, and (d)&#160;all buildings, structures, improvements, fixtures, building systems and improvements situated on the Company Leased Real Property comprise all of the material real property used or intended to be used in the conduct of the business of the Company or the Company Subsidiaries. Neither the Company nor the Company Subsidiaries owns any real property. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.11 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contracts</div></div>. <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.11</div> of the Company Disclosure Schedule&#160;contains a list as of the date of this Agreement of each of the following Contracts to which the Company or a Company Subsidiary is a party, other than Company Plans (each such Contract (x)&#160;required to be listed in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.11</div> of the Company Disclosure Schedule, (y)&#160;that is a Company IP License or (z)&#160;that is required to be filed as a &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> under the Exchange Act) as an exhibit to the Most Recent Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> under the Exchange Act prior to the date of this Agreement (other than any Company Plan), being referred to as a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Material Contract</div>&#8221;): </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) each Contract that restricts in any material respect the ability of the Company, any Company Subsidiary or any Affiliate of any of them to (i)&#160;engage or compete in any geographic area or line of business, market or field, or to develop, sell, supply, manufacture, market, distribute, or support any material product or service, or (ii)&#160;transact with any Person (or that would so restrict Parent, any Parent Subsidiary or any Affiliate of any of them following the Closing); </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) each joint venture agreement, partnership agreement or similar agreement with a third party; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) each material acquisition or divestiture Contract that contains any material indemnification obligations of the Company or a Company Subsidiary or any &#8220;earnout&#8221; or other material contingent payment obligations that are outstanding obligations of the Company or any Company Subsidiary as of the date of this Agreement; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) each Contract evidencing indebtedness for money borrowed by the Company or any Company Subsidiary from a third party lender, and each Contract pursuant to which any such indebtedness for borrowed money is guaranteed by the Company or any Company Subsidiary, in each case in excess of $250,000; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) each Contract expressly limiting or restricting the ability of the Company or any Company Subsidiary (i)&#160;to make distributions or declare or pay dividends in respect of their capital stock, membership interests or other equity interests, as the case may be, (ii)&#160;to pledge their capital stock or other equity interests, (iii)&#160;to issue any guaranty, or (iv)&#160;to make loans to the Company or any Company Subsidiary; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) each Contract that obligates the Company or any Company Subsidiary to make any loans, or capital contributions to, or investments in, any Person in excess of $250,000 individually; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) each Contract that grants a third party any material right of first refusal, first notice, first negotiation or right of first offer or similar right with respect to any material assets, rights or properties of the Company or any Company Subsidiary; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) each Contract or series of related Contracts (excluding (i)&#160;purchase orders given or received in the ordinary course of business in a manner consistent with past practice and (ii)&#160;Contracts between the Company and any wholly owned Company Subsidiary or among any wholly owned Company Subsidiaries) under which the Company or any Company Subsidiary (A)&#160;paid in excess of $750,000 in fiscal year 2020, or is expected to pay in excess of $750,000 in fiscal year 2021 or (B)&#160;received in excess of $750,000 in fiscal year 2020, or is expected to receive in excess of $750,000 in fiscal year 2021; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) each &#8220;single source&#8221; supply Contract pursuant to which goods or materials are supplied to the Company or a Company Subsidiary from a sole source which is expected to involve payments by the Company and Company Subsidiaries in excess of $250,000 in fiscal year 2021; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(j) each Contract containing any &#8220;take or pay&#8221;, minimum commitments or similar provisions which, in each case, is expected to involve payments (including penalty or deficiency payments) by the Company and Company Subsidiaries in excess of $250,000 in fiscal year 2021; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) each lease involving real property pursuant to which the Company or any Company Subsidiary is required to pay a monthly base rental in excess of $50,000; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(l) each lease or rental Contract involving personal property (and not relating primarily to real property) pursuant to which the Company or any Company Subsidiary is required to make rental payments in excess of $25,000 per month (excluding leases or rental Contracts for office equipment entered into in the ordinary course of business in a manner consistent with past practice); </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(m) each Contract relating to the acquisition, sale or disposition of any business unit or product line of the Company or any Company Subsidiary and with any outstanding obligations that are material to the Company and the Company Subsidiaries, taken as a whole, as of the date of this Agreement; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(n) any Government Contract with any outstanding obligations under which the Company or the Company Subsidiaries received in excess of $750,000 in fiscal year 2020, or is expected to receive in excess of $750,000 in fiscal year 2021; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(o) each Contract with any material &#8220;most favored nation&#8221; provision or that otherwise requires the Company or any Company Subsidiary (or, following the Closing, would require Parent or any Parent Subsidiary) to conduct business with any Person on a preferential or exclusive basis, or that includes a price protection provision in favor of the counterparty to such Contract; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(p) each settlement agreement entered into since January&#160;1, 2019 (i) with a Governmental Entity that imposes material ongoing obligations or restrictions on the Company or any Company Subsidiary; (ii)&#160;that requires the Company or any Company Subsidiary to pay more than $250,000 in excess of insurance coverage after the date of this Agreement; or (iii)&#160;that imposes any material restrictions on the business of the Company or any Company Subsidiary after the date of this Agreement; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(q) each Contract (excluding purchase orders given or received in the ordinary course of business in a manner consistent with past practice) with any Top Customer, Top Distributor or Top Supplier of the Company and the Company Subsidiaries; and </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(r) each Contract relating to the creation of a Lien (other than Company Permitted Encumbrances) with respect to any material asset of the Company or any Company Subsidiary. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, there are no existing breaches or defaults on the part of the Company or any Company Subsidiary under any Material Contract, and, to the knowledge of the Company, there are no existing breaches or defaults on the part of any other Person under any Material Contract. Each Material Contract is valid, has not been terminated prior to the date of this Agreement, is enforceable against the Company or the applicable Company Subsidiary that is a party to such Material Contract, and, to the knowledge of the Company, is enforceable against the other parties thereto, in each case subject to the General Enforceability Exception, and, in each case, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. Prior to the date of this Agreement, the Company has made available to Parent accurate and complete copies of each Material Contract in effect as of the date of this Agreement, together with all amendments and supplements thereto in effect as of the date of this Agreement (excluding purchase orders given or received in the ordinary course of business in a manner consistent with past practice). As of the date of this Agreement, no Top Customer, no Top Distributor and no Top Supplier has canceled, terminated or substantially curtailed its relationship with the Company or any Company Subsidiary, given written notice to the Company or any Company Subsidiary of any intention to cancel, terminate or substantially curtail its relationship with the Company or any Company Subsidiary, or, to the knowledge of the Company, threatened in writing to do any of the foregoing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.12 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compliance with Legal Requirements</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) The Company and the Company Subsidiaries are, and since January&#160;1, 2019 have been, in compliance with all Legal Requirements applicable to them and their businesses, except where the failure to comply with such Legal Requirements, individually or in the aggregate, has not been or would not reasonably be expected to be material to the Company and the Company Subsidiaries, taken as a whole. Neither the Company nor any Company Subsidiary has, since January&#160;1, 2019: (i) to the knowledge of the Company, received any written notice from any Governmental Entity regarding any potential or actual material violation by the Company or any Company Subsidiaries of any Legal Requirement; or (ii)&#160;provided any notice to any Governmental Entity regarding any potential or actual material violation by the Company or any Company Subsidiary of any Legal Requirement. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) The Company and the Company Subsidiaries hold, and have at all times since January&#160;1, 2019 held, all Governmental Authorizations necessary for the lawful operation of the businesses of the Company and the Company Subsidiaries as they are now being conducted (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Permits</div>&#8221;) and have paid all fees and assessments due and payable in connection therewith, except where the failure to have, file or pay, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, (i)&#160;all Company Permits are valid and in full force and effect, are not subject to any administrative or judicial proceeding that could result in any modification, termination or revocation thereof and, to the knowledge of the Company, no suspension or cancellation of any such Company Permit is threatened; (ii)&#160;the Company and each Company Subsidiary is in compliance with the terms and requirements of all Company Permits; and (iii)&#160;no consent from or notice to any Government Entity is required in order for each Company Permit to continue in full force and effect upon consummation of the Mergers and the other transactions contemplated by this Agreement. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Except where the failure to comply with such Legal Requirements, individually or in the aggregate, has not been or would not reasonably be expected to be material to the Company and the Company Subsidiaries, taken as a whole, the Company and each Company Subsidiary have at all times </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">since January&#160;1, 2019 complied with applicable Sanctions Laws and Export Control Laws. Neither the Company or any Company Subsidiary has been the subject of or otherwise involved in investigations or enforcement actions by any Governmental Entity or other Legal Proceedings with respect to any actual or alleged violations of Export Control Laws or Sanctions Laws, and neither the Company or any Company Subsidiary has been notified of any such pending or threatened actions. Neither the Company, any Company Subsidiary, nor any director or officer of the Company or any Company Subsidiary, or, to the knowledge of the Company, any other employee, independent contractor, consultant, agent, or other person acting on behalf of the Company or any Company Subsidiary, is a Prohibited Person or is subject to debarment or any list-based designations under the Export Control Laws. Since January&#160;1, 2019, the Company and the Company Subsidiaries have secured and maintained all necessary permits, registrations, agreements or other authorizations, including amendments thereof pursuant to the Export Control Laws or Sanctions Laws, including for (i)&#160;the export, import and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-export</div> of its products, services, Software and technologies, and (ii)&#160;releases of technologies and Software to foreign nationals located in the United States and abroad (the&#160;&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Export Approvals</div>&#8221;), and each of the Company and the Company Subsidiaries is and, since January&#160;1, 2019, has been in compliance in all material respects with the terms of all Export Approvals. None of the officers, directors, or employees of the Company or any of the Company Subsidiaries is a foreign or domestic Government Official. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.13 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal Proceedings; Investigations; Orders</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) There is no Legal Proceeding pending or, to the knowledge of the Company, threatened in writing against the Company or any Company Subsidiary or affecting any of their respective properties or assets that: (i)&#160;would adversely affect the Company&#8217;s ability to perform any of its obligations under, or consummate any of the transactions contemplated by, this Agreement; or (ii)&#160;individually or in the aggregate, had or would reasonably be expected to have a Company Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) There is no Order under which the Company or any Company Subsidiary is subject to ongoing obligations that, individually or in the aggregate, has had or would reasonably be expected to have a Company Material Adverse Effect. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.14 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Certain Business Practices</div></div>. Except as, individually or in the aggregate, has not been or would not reasonably be expected to be material to the Company and the Company Subsidiaries, taken as a whole, since January&#160;1,&#160;2019, neither the Company nor any Company Subsidiary nor, any director, officer, employee, or, to the Company&#8217;s knowledge, other agent or Person acting on behalf of the Company or any Company Subsidiary has, directly or indirectly (a)&#160;violated or taken any action that could potentially result in a violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act of 2010 or its predecessor laws, or any other Legal Requirements concerning corrupt payments (collectively, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Anti-Corruption Laws</div>&#8221;) applicable to the Company or any Company Subsidiary or (b)&#160;(i) used, offered to use or authorized the use of any funds of the Company or a Company Subsidiary for unlawful contributions, unlawful gifts or unlawful entertainment, or for other unlawful payments, related to political activity or otherwise; (ii)&#160;made, offered to make or authorized any unlawful payment from funds of the Company or any Company Subsidiary to foreign or domestic Government Officials or to foreign or domestic political parties or campaigns; (iii)&#160;established or maintained any unlawful fund of monies or other unlawful pool of assets of the Company or any Company Subsidiary; (iv)&#160;made any fraudulent entry on the books or records of the Company or any Company Subsidiary; (v)&#160;made, offered to make or authorized any bribe, unlawful rebate, unlawful payoff, unlawful influence payment, unlawful kickback or other unlawful payment to any Person, private or public, in any form; or (vi)&#160;engaged in or facilitated any transaction or dealing in property or interests in property of a Prohibited Person, received funds, goods or services from or made any contribution of funds, goods or services to or for the benefit of a Prohibited Person, or otherwise engaged in or facilitated any transactions with, any Prohibited Person. Neither the Company nor any Company Subsidiary is or within the past five years has (i)&#160;been to the knowledge of the Company, under investigation by any Governmental Entity for any potential or actual violation of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-Corruption</div> Laws or (ii)&#160;received any written notice from any Governmental Entity regarding any potential or actual violation of, or potential or actual failure to comply with, any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-Corruption</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laws. Since January&#160;1, 2019, neither the Company nor any Company Subsidiary has made any disclosure (voluntary or otherwise) to any Governmental Entity with respect to any potential violation or liability arising under or relating to any Anti-Corruption Laws. </div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.15 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax Matters</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect: </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) The Company and the Company Subsidiaries have timely filed (taking into account any extension of time within which to file) all Tax Returns that are required to be filed by or with respect to any of them and all such Tax Returns are accurate and complete; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) The Company and the Company Subsidiaries have timely paid in full to the appropriate Governmental Entity all Taxes required to be paid by any of them or, in respect of any Taxes accrued but not yet payable by the Company or any Company Subsidiary, adequate reserves have been recorded in the financial statements of the Company and the Company Subsidiaries in accordance with GAAP; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii) Each of the Company and the Company Subsidiaries has (i)&#160;timely paid, deducted, withheld and collected all amounts required to be paid, deducted, withheld or collected by any of them with respect to any payment made or owing to, or received from, their employees, creditors, independent contractors, shareholders, customers and other third parties (and have timely paid over any amounts so withheld, deducted or collected to the appropriate Governmental Entity) and (ii)&#160;otherwise complied with all applicable Legal Requirements relating to such withholding, collection and remittance of Taxes (including information reporting requirements); </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) Within the last three years, no claim has been made in writing by any Tax authority in a jurisdiction where the Company or any Company Subsidiary has not filed Tax Returns of a particular type that the Company or any Company Subsidiary is or may be subject to such type of Tax by, or required to file Tax Returns with respect to Taxes in, such jurisdiction; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) Neither the Company nor any Company Subsidiary will be required to include an item of income (or exclude an item of deduction) in any taxable period (or portion thereof) beginning after the Closing Date as a result of (i)&#160;a change in or incorrect method of accounting occurring prior to the Closing Date, (ii)&#160;a prepaid amount received (or deferred revenue recognized) or paid, prior to the Closing Date, (iii)&#160;any agreement entered into on or prior to the Closing Date with a Governmental Entity relating to Taxes, or (iv)&#160;any open transaction or installment sale entered into on or prior to the Closing Date; and </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(vi) There are no: (i)&#160;examinations, investigations, audits, or other proceedings pending or, to the knowledge of the Company, threatened in writing with respect to any Taxes of the Company or any Company Subsidiary or any Tax Returns; (ii)&#160;extensions or waivers of the limitation period applicable to any Tax Return or the period for the assessment of any Taxes of the Company or the Company Subsidiaries which period has not yet expired; (iii)&#160;deficiencies for Taxes that have been claimed, proposed or assessed by any Governmental Entity in writing against the Company or any Company Subsidiary that have not been fully satisfied by payment; or (iv)&#160;Liens in respect of or on account of material Taxes (other than Company Permitted Encumbrances) upon any of the property or assets of the Company or any Company Subsidiary. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Neither the Company nor any of the Company Subsidiaries (i)&#160;is or has been, within the last six years, a member of any affiliated, combined, consolidated, unitary or similar group for purposes of filing Tax Returns or paying Taxes, except for any such group of which the Company is the common parent or (ii)&#160;has any liability for Taxes of any Person (other than the Company or any Company Subsidiary) under Treasury Regulations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.1502-6</div> (or any similar state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> Legal Requirement) or as transferee or successor. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Neither the Company nor any Company Subsidiary is a party to or bound by, or has any obligation under, any Tax indemnity, sharing, allocation, or reimbursement agreement or arrangement, other </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">than: (i)&#160;customary tax provisions in ordinary course commercial agreements, the principal purpose of which is not related to Taxes; and (ii)&#160;any agreement or arrangement solely between or among the Company and/or the Company Subsidiaries. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Neither the Company nor any Company Subsidiary is bound with respect to the current or any future taxable period by any closing agreement (within the meaning of Section&#160;7121(a) of the Code or any similar or analogous state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> Legal Requirement) or other ruling or written agreement with a Tax authority, in each case, with respect to Taxes. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) Within the last two years, neither the Company nor any Company Subsidiary has distributed stock of another Person or has had its stock distributed by another Person in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355(a) of the Code. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) Neither the Company nor any Company Subsidiary has participated in any &#8220;listed transaction&#8221; within the meaning of Treasury Regulations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.6011-4(b)(2)</div> (or any similar state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> Legal Requirement). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) Neither the Company nor any Company Subsidiary has taken or agreed to take any action or has knowledge of any facts that would prevent the Mergers from qualifying for the Intended Tax Treatment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.16 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Benefit Plans</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.16(a)</div> of the Company Disclosure Schedule&#160;sets forth a list of all material Company Plans as of the date of this Agreement. There are no Company Plans that are governed by the laws of any jurisdiction other than the United States or provide compensation or benefits to any employee or former employee of the Company or any Company Subsidiary (or any dependent thereof) who resides outside of the United States. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) The Company has made available to Parent copies of, to the extent applicable: (i)&#160;the plan document for each material Company Plan; (ii)&#160;the most recent annual report (Form Series 5500 and all schedules and financial statements attached thereto) with respect to each material Company Plan; (iii)&#160;the most recent summary plan description with respect to each material Company Plan; (iv)&#160;the most recent IRS determination or opinion letter issued with respect to each Company Plan intended to be qualified under Section&#160;401(a) of the Code; and (v)&#160;all material correspondence from any Governmental Entity regarding any active or, to the Company&#8217;s knowledge, threatened Legal Proceeding regarding any Company Plan. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) No Company Plan is, and neither the Company nor any Company Subsidiary nor any Company Commonly Controlled Entity contributes to, has at any time in the previous six years contributed to or has or had any liability or obligation, whether fixed or contingent, with respect to (i)&#160;a multiemployer plan, as defined in Section&#160;3(37) of ERISA, (ii)&#160;a single employer plan or other pension plan that is subject to Title IV of ERISA or Section&#160;302 of ERISA or Section&#160;412 of the Code, (iii)&#160;a multiple employer plan (within the meaning of Section&#160;413(c) of the Code), (iv) a multiple employer welfare arrangement (within the meaning of Section&#160;3(40) of ERISA), (v) a voluntary employee benefit association under Section&#160;501(a)(9) of the Code, or (vi)&#160;a plan providing for post-employment or post-retirement health, medical, or life insurance benefits for current, former or retired employees of Company or any of the Company Subsidiaries, except as required under Section&#160;4980B of the Code or otherwise except as may be required pursuant to any other applicable Legal Requirements. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Each Company Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination letter (or opinion letter, if applicable) from the IRS stating that such Company Plan is so qualified and, to the knowledge of the Company, nothing has occurred since the date of such letter that would reasonably be expected to adversely affect the qualified status of such Company Plan. Each Company Plan has been operated in compliance in all material respects with its terms and with all applicable Legal Requirements. Without limiting the foregoing, no liability under Title IV of ERISA has been incurred by the Company or any Company Commonly Controlled Entity that has not been satisfied in full and, to the knowledge of the Company, no condition exists that presents a risk to the Company or any Company Commonly Controlled Entity of incurring a liability under such Title. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(e) Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby could (either alone or together with any other event): (i) entitle any current or former employee, officer, director or independent contractor of the Company or any Company Subsidiary to any payment or benefit under any Company Plan or otherwise; (ii)&#160;increase the amount of any compensation or other benefits otherwise payable by the Company or any Company Subsidiary under any Company Plan or otherwise; or (iii)&#160;result in the acceleration of the time of payment, funding or vesting of any compensation or other benefits under any Company Plan. No Company Plan provides for, and no current or former employee, officer, director or independent contractor of the Company or any Company Subsidiary is entitled to, any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">gross-up,</div> make-whole or other similar payment or benefit in respect of any Taxes under Section&#160;4999 of the Code or Section&#160;409A of the Code. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) Each Company Plan has been maintained and operated in documentary and operational compliance in all material respects with Section&#160;409A of the Code or an available exemption therefrom. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) The per share exercise price of each Company Option was at least equal to the fair market value of one share of Company Common Stock on the date of grant of such Company Option. Prior to the date of this Agreement, the Company has made available to Parent a list of all Company Options outstanding as of the date of this Agreement, including the holder of such Company Option, the number of shares of Company Common Stock subject to such Company Option, the grant date of such Company Option, the per share exercise price of such Company Option, the vesting schedule for such Company Option, and the date on which such Company Option expires. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.17 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Labor Matters</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Neither the Company nor any Company Subsidiary is a party to, nor does the Company or any Company Subsidiary have a duty to bargain for, any collective bargaining agreement with a labor organization or works council representing any of its employees and, as of the date of this Agreement, there are no labor organizations or works councils representing, purporting to represent or, to the knowledge of the Company, seeking to represent any employees of the Company or any Company Subsidiary. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) As of the date of this Agreement (i)&#160;and since January&#160;1, 2019, there has not been any strike, slowdown, work stoppage, lockout, job action, picketing, labor dispute, union organizing activity, or any similar activity or dispute, affecting the Company, any Company Subsidiary or any of their employees and (ii)&#160;to the knowledge of the Company, no Person is currently threatening in writing to commence, any such strike, slowdown, work stoppage, lockout, job action, picketing, labor dispute or union organizing activity or any similar activity or dispute. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) As of the date of this Agreement there is no material claim or grievance pending or, to the knowledge of the Company, threatened by or on behalf of any employees of the Company or Company Subsidiary relating to any employment Contract, wages and hours, mass layoffs or reductions in force, plant closing notification, employment statute or regulation, labor dispute, workers&#8217; compensation policy or long-term disability policy, safety, retaliation, privacy right, immigration or discrimination matters involving any employee of the Company or any Company Subsidiary, including material charges of unfair labor practices or material harassment complaints, material claims or material judicial or administrative proceedings, in each case, which are pending. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, (i)&#160;the Company and the Company Subsidiaries are in compliance in all material respects with all applicable Legal Requirements respecting employment and employment practices, terms and conditions of employment of employees, former employees and prospective employees, wages and hours, pay equity, discrimination in employment, wrongful discharge, collective bargaining, mass layoffs or reductions in force, plant closing notification, fair labor standards, occupational health and safety, personal rights or any other labor and employment-related matters, and (ii)&#160;the Company and the Company Subsidiaries have properly classified all of their service providers as either employees or independent contractors and as exempt or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exempt</div> for all purposes. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(e) Within the last two years, no employee of the Company or any Company Subsidiary has transferred into employment with the Company or any Company Subsidiary by means of a relevant transfer pursuant to the Acquired Rights Directive pursuant to EC Directive no. 2001/23 dated March&#160;12, 2001, as amended from time to time, or domestic legislation implementing such directive into the national applicable law of any country in the EEA, as amended from time to time, or any legislation that has substantially the same effect in any country outside the EEA. For purposes of this Section, &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">EEA</div>&#8221; means European Economic Area, as constituted from time to time, and shall be deemed to include Switzerland. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.18 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Environmental Matters</div></div>. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, the Company and the Company Subsidiaries are, and since January&#160;1, 2019 have been, in compliance with all applicable Environmental Laws (which compliance includes the possession, and the compliance with the terms and conditions, by the Company and each Company Subsidiary of all Company Permits required under applicable Environmental Laws to conduct their respective business and operations), and there are no investigations, actions, suits or proceedings pursuant to any Environmental Laws pending or, to the knowledge of the Company, threatened against the Company or any Company Subsidiary. During the three-year period prior to the date of this Agreement, neither the Company nor any Company Subsidiary has received any written notice from a Governmental Entity that alleges that the Company or any Company Subsidiary is violating, or has or may have, violated any Environmental Law, or may have any liability or obligation arising under, retained or assumed by Contract or by operation of law, except for such violations, liabilities and obligations that, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. Since January&#160;1, 2019, there has been no release of any hazardous materials by the Company or any Company Subsidiary at or from any facilities owned or leased by the Company or any Company Subsidiary or at any other locations where any hazardous materials were generated, manufactured, refined, transferred, stored, produced, imported, used, processed or disposed of by the Company or any Company Subsidiary and, in each case, for which the Company or any Company Subsidiary would reasonably be expected to be subject to any liability, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.19 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Insurance</div></div>. Since January&#160;1, 2019, neither the Company nor any Company Subsidiary has received any written communication notifying the Company or any Company Subsidiary of any: (a)&#160;premature cancellation or invalidation of any material insurance policy held by the Company or any Company Subsidiary; or (b)&#160;refusal of any coverage or rejection of any material claim under any insurance policy held by the Company or any Company Subsidiary. As of the date of this Agreement, there is no pending material claim by the Company or any Company Subsidiary against any insurance carrier under any insurance policy held by the Company or any Company Subsidiary. The Company and the Company Subsidiaries maintain insurance with reputable insurers in such amounts and against such risks as the management of the Company has in good faith determined to be prudent and appropriate in all material respects. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, all insurance policies maintained by or on behalf of the Company or any of the Company Subsidiaries are in full force and effect, all premiums and other payments due on such policies have been paid by the Company or a Company Subsidiary and all claims thereunder have been filed in due and timely fashion, and neither the Company nor any of Company Subsidiary is in breach or default under, has received any written notice of, or has taken any action that would reasonably be likely to permit cancellation, termination or modification of, any such insurance policies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.20 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Defects and Warranties.</div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Since January&#160;1, 2019, all Company Products sold or supported by the Company or any of the Company Subsidiaries have been provided in conformity with the Company&#8217;s and the Company Subsidiaries&#8217; applicable contractual commitments, warranties and specifications, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) The Company&#8217;s warranty reserve reflected on the Most Recent Company Balance Sheet was calculated utilizing historical warranty experience rates consistent with past practice and, to the knowledge </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Company, was sufficient as of the date of the Most Recent Company Balance Sheet to cover the unexpired warranty liabilities of the Company and the Company Subsidiaries for any products (including Company Products) sold by the Company or the Company Subsidiaries to their respective customers prior to the date of the Most Recent Company Balance Sheet. Since the date of the Most Recent Company Balance Sheet, the Company has not materially modified its practices in calculating warranty reserves. To the knowledge of the Company, the Company&#8217;s current warranty reserve is sufficient as of the date of this Agreement to cover the unexpired warranty liabilities of the Company and the Company Subsidiaries for any products (including Company Products) sold by the Company or the Company Subsidiaries to their respective customers prior to the date of this Agreement, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.21 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Regulatory Matters.</div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, the Company and each of the Company Subsidiaries is, and has since January&#160;1, 2019 been, in compliance with (i)&#160;all applicable Healthcare Laws and (ii)&#160;all Healthcare Regulatory Authorizations. &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare Laws</div>&#8221; means: (i)&#160;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167; 201 et seq.) and the Medical Devices Regulation and the Medical Devices Directive; (ii)&#160;all applicable federal, state, local and foreign health care related fraud and abuse, false claims, anti-kickback, self-referral and transparency Legal Requirements, including the Anti-Kickback Statute (42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7b(b)),</div> the Civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), the Exclusion Laws (42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7),</div> the Civil Monetary Penalties Law (42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7a),</div> the criminal False Claims Law (42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7b(a)),</div> the Physician Payments Sunshine Act (42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7h),</div> the federal Stark Law (42 U.S.C. &#167; 1395nn), and all criminal Legal Requirements relating to health care fraud and abuse, including 18 U.S.C. &#167;&#167; 286 and 287, and the health care fraud criminal provisions under HIPAA; (iii)&#160;Legal Requirements relating to price reporting requirements and the requirements relating to the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1396r-8),</div> any state supplemental rebate program, and Medicare average sales price reporting (42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1395w-3a);</div> (iv) the Medicare statute (Title XVIII of the Social Security Act), the Medicaid statute (Title XIX of the Social Security), the federal TRICARE statute (10 U.S.C. &#167; 1071 et seq.), and other Legal Requirements relating to Government Programs; (v)&#160;any other applicable Legal Requirements relating to the research, development, design, testing, manufacturing, labeling, marketing, promotion, sale and distribution of biological products, HCT/Ps, or medical devices, or durable medical equipment; (vi)&#160;Legal Requirements relating to consulting agreements, royalty agreements, and other arrangements with healthcare professionals, physician ownership/investment interests, and continuing education and trade shows for healthcare professionals; and (vii)&#160;in each case, as amended and the regulations promulgated thereunder. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Since January&#160;1, 2019, neither the Company nor any of the Company Subsidiaries has received written notice of any pending or threatened claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other action by any Healthcare Regulatory Authority alleging that any Company Product, operation, or activity of the Company or any Company Subsidiary is in material violation of any applicable Healthcare Laws, or otherwise (i)&#160;proposing to modify, suspend, revoke or withdraw a material Healthcare Regulatory Authorization or (ii)&#160;contesting the clearance, approval or marketing of any Company Product. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) The Company and each of the Company Subsidiaries, as applicable, possess all Healthcare Regulatory Authorizations required for the conduct of its respective business, including all Healthcare Regulatory Authorizations required for any Company Product, and all such Healthcare Regulatory Authorizations are in full force and effect, except where the failure to possess such Healthcare Regulatory Authorizations or for such Healthcare Regulatory Authorizations to be in full force and effect would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. Since January&#160;1, 2019, neither the Company nor any of the Company Subsidiaries has received written notice of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any termination, revocation, withdrawal, suspension, rejection or denial of, any Healthcare Regulatory Authorization, and to the Company&#8217;s knowledge, no event has occurred which allows, or after notice or lapse of time would allow, or would reasonably be expect to lead to, the revocation, withdrawal, termination, suspension, rejection or denial of any Healthcare Regulatory Authorization (or any filing or application therefor) or result in any other impairment of the rights of the holder of any Healthcare Regulatory Authorization (or any filing or application therefor), except for such terminations, revocations, withdrawals, suspensions, rejections, denials or impairments as, individually or in the aggregate, have not had or would not reasonably be expected to have a Company Material Adverse Effect.&#160;&#160;&#160;&#160; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect: all reports, documents, registrations, authorizations, claims and notices required to be filed, maintained, or furnished to any Healthcare Regulatory Authority pursuant to any applicable Health Care Laws by the Company or any of the Company Subsidiaries have been so filed, maintained or furnished and were complete and correct on the date filed (or were corrected in or supplemented by a subsequent filing). </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) Since January&#160;1, 2019, neither the Company nor any of the Company Subsidiaries has voluntarily or involuntarily initiated, conducted or issued, or caused to be initiated, conducted or issued (or received any written notices from any Healthcare Regulatory Authority issuing, requiring or causing the Company or any of the Company Subsidiaries to issue) any recalls, seizures, detentions, field notifications, field corrections, market withdrawals or replacements, warnings, &#8220;dear doctor&#8221; letters, investigator notices, safety alerts or other written notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of, or enjoining manufacture or distribution of, any Company Product, except in each case as are immaterial in nature or amount, and to the knowledge of the Company, none of any Healthcare Regulatory Authority or the Company or any Company Subsidiary is considering such action. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) All preclinical studies, tests and clinical trials conducted by or on behalf of the Company or any of the Company Subsidiaries, or in which the Company or any of the Company Subsidiaries has participated with respect to its products or product candidates (collectively, &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Studies</div>&#8221;) were and, if still pending, have been and are being conducted in compliance with all applicable Healthcare Laws, except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. Neither the Company nor any of the Company Subsidiaries has received any written notice from any Healthcare Regulatory Authority requiring or threatening, the termination or suspension of any ongoing or planned Studies, and to the knowledge of the Company, there are no reasonable grounds for the same, except for such terminations or suspensions as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) Since January&#160;1, 2019, neither the Company nor any of the Company Subsidiaries has received, (i)&#160;from FDA, any FDA Form 483, warning letter or untitled letter or (ii)&#160;from any other Healthcare Regulatory Authority, any similar written notice alleging or asserting material noncompliance with any Healthcare Laws or Healthcare Regulatory Authorizations held by Company or any of the Company Subsidiaries. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) Neither the Company nor any of the Company Subsidiaries is a party to, has any ongoing obligations pursuant to, or is bound by, any order, individual integrity agreement, corporate integrity agreement, deferred prosecution agreement, settlement agreement, consent agreement, consent decree or other similar form agreement with any Governmental Entity resulting from a failure, or alleged failure, to comply with any applicable Healthcare Laws of the FDA, Centers for Medicare and Medicaid Services and other Healthcare Regulatory Authorities. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) Since January&#160;1, 2019, neither the Company, any of the Company Subsidiaries nor any Company Products are the subject of any pending or, to the Company&#8217;s knowledge, threatened investigation by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto. Neither the Company nor any of the Company Subsidiaries, nor any of their respective officers, directors, employees, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">nor to the knowledge of the Company, any of their respective contractors, suppliers, agents, or any other company or individual performing research or product-related work on behalf of the Company or any of the Company Subsidiaries, nor any other Person described in 42 C.F.R. &#167; 1001.1001(a)(1)(ii), (i) has committed any act, made any untrue statement of material fact or failed to make any statement that, at the time such act, statement or disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy; (ii)&#160;has been charged with any conduct for which debarment is mandated by 21 U.S.C. &#167; 335a or any criminal offense relating to the delivery of an item or service under any federal health care program; (iii)&#160;has been charged with or been convicted of any crime for which exclusion is mandated or permitted from the federal health care programs under Section&#160;1128 of the Social Security Act of 1935, or any similar Law; (iv)&#160;is or has been debarred, excluded suspended or is otherwise ineligible from participation in any federal health care program, as such term is defined in 42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7b(f),</div> or any other government program; (v)&#160;has had a civil monetary penalty assessed against it under Section&#160;1128A of the Social Security Act; (vi)&#160;is or has been listed on the General Services Administration published list of parties excluded from federal procurement programs and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-procurement</div> programs; or (vii)&#160;has been debarred by any federal or international agency. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.22 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Takeover Statutes</div></div>. Assuming the accuracy of Parent&#8217;s and Acquisition Subs&#8217; representation in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.17</div>, the Company Board has taken all action necessary to render Section&#160;203 of the DGCL, all other potentially applicable state anti-takeover statutes and any similar provisions of the Company Organizational Documents inapplicable to the Mergers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.23 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ownership of Parent Class</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;A Common Stock</div></div>. During the three years prior to the date of this Agreement, none of the Company, any Company Subsidiary or any &#8220;affiliate&#8221; or &#8220;associate&#8221; (as such terms are defined in Section&#160;203(c) of the DGCL) of any of the foregoing &#8220;owns&#8221; or &#8220;owned&#8221; (as such terms are defined in Section&#160;203(c) of the DGCL), directly or indirectly, any shares of Parent Class&#160;A Common Stock or other securities convertible into, exchangeable into or exercisable for shares of Parent Class&#160;A Common Stock. There are no voting trusts or other agreements or understandings to which the Company or any Company Subsidiary is a party with respect to the disposition or voting of the capital stock or other equity interest of Parent or any Parent Subsidiary. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.24 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opinion of Financial Advisor</div></div>. The Company Board has received the opinion of J.P. Morgan Securities LLC (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Financial Advisor</div>&#8221;), financial advisor to the Company, dated as of the date of this Agreement, to the effect that, as of such date and subject to the assumptions, qualifications and limitations set forth in such opinion, the Merger Consideration pursuant to this Agreement is fair, from a financial point of view, to the holders of shares of Company Common Stock (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Fairness Opinion</div>&#8221;). The Company will make available to Parent a copy of such opinion as soon as practicable following the execution of this Agreement for information purposes only. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.25 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Brokers</div></div>. No broker, finder or investment banker (other than the Company Financial Advisor) is entitled to any brokerage, finder&#8217;s or other similar fee or commission in connection with the Mergers based upon arrangements made by or on behalf of the Company. The Company has made available to Parent accurate and complete copies of all engagement, fee and similar Contracts between the Company (or any Subsidiary of the Company) and the Company Financial Advisor. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.26 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Related Party Transactions</div></div>. Except as disclosed in the Company SEC Documents, neither the Company nor any Company Subsidiary is party to any transaction or arrangement under which any (a)&#160;present or former executive officer or director of the Company or any Company Subsidiary, (b)&#160;beneficial owner (within the meaning of Section&#160;13(d) of the Exchange Act) of 5% or more of any class of equity of the Company or (c)&#160;Affiliate, &#8220;associate&#8221; or member of the &#8220;immediate family&#8221; (as such terms are respectively defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16a-1</div> of the Exchange Act) of any of the foregoing is a party to any actual or proposed loan, lease or other Contract with or binding upon the Company or any Company Subsidiary or owns or </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">has any interest in any of their respective properties or assets, in each case as would be required to be disclosed by the Company pursuant to Item 404 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> promulgated under the Exchange Act. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;2.27 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Information Supplied</div></div>. The information supplied or to be supplied by the Company for inclusion in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (including the Joint Proxy Statement/Prospectus) will not, at the time the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (and any amendment or supplement thereto) is declared effective, on the date that the Joint Proxy Statement/Prospectus is first mailed to the stockholders of the Company and the stockholders of Parent, or on the date of the Company Stockholder Meeting or the Parent Stockholder Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading, except that, no representation or warranty is made by the Company with respect to statements made therein based on information supplied by Parent for inclusion therein. Notwithstanding the foregoing, the Company makes no representation or warranty with respect to any information supplied by Parent, the Acquisition Subs or any of their Representatives for inclusion in the Joint Proxy Statement/Prospectus. For purposes of the Joint Proxy Statement/Prospectus, any information concerning or related to the Company, its Affiliates, or the Company Stockholder Meeting will be deemed to have been provided by the Company, and any information concerning or related to Parent, its Affiliates, or the Parent Stockholder Meeting will be deemed to have been provided by Parent. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE III. REPRESENTATIONS AND WARRANTIES OF PARENT AND ACQUISITION SUBS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Parent and each Acquisition Sub hereby jointly and severally represent and warrant to the Company that, except as set forth or incorporated by reference in the Parent SEC Documents filed and publicly available prior to the date of this Agreement (excluding any disclosures contained in such documents under the heading &#8220;Risk Factors&#8221; or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature) or, subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.12</div>, in the disclosure schedule delivered to the Company concurrent with the execution of this Agreement (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Disclosure Schedule</div>&#8221;): </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.1 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Due Organization and Good Standing; Subsidiaries.</div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Parent and each Acquisition Sub are corporations duly organized, validly existing and in good standing under the laws of their respective states of incorporation. Parent and each Acquisition Sub have the requisite corporate power and authority to own, lease and operate their respective assets and to carry on their respective businesses as it is being conducted as of the date of this Agreement, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Parent and each Acquisition Sub are duly qualified and have all necessary Governmental Authorizations to do business, and (where such concept is recognized under the Laws of the applicable jurisdictions) are in good standing, in each other jurisdiction where the nature of their business makes such qualification necessary, except where the failure to be so qualified or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Neither Parent nor either Acquisition Sub nor any Parent Subsidiary owns any equity interest or joint venture, partnership or similar interest in any other Entity, other than the Entities identified in Exhibit 21.1 of Parent&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2021 (filed with the SEC on March&#160;26, 2021) and any other wholly owned Parent Subsidiary. Each Parent Subsidiary is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has the requisite corporate or other organizational power and authority and Governmental Authorizations to own, lease and operate its assets and to carry on its business as it is being conducted as of the date of this Agreement, except where the failure to be so organized, existing and in good standing or to have such power and authority, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Each Parent Subsidiary is duly qualified and has all necessary Governmental Authorizations to do business, and (where such concept is recognized under the laws of the applicable jurisdictions) is in good standing, in each other jurisdiction where the nature of its business makes such qualification necessary, except where the failure to be so qualified or in good standing, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. All of the outstanding shares of capital stock of each Parent Subsidiary are duly authorized, validly issued, fully paid and nonassessable and are owned directly or indirectly by Parent free and clear of all Liens, except for restrictions on transfer under applicable securities laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.2 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Organizational Documents</div></div>. Prior to the date of this Agreement, Parent has made available to the Company copies of the Organizational Documents of Parent and each Acquisition Sub, including all amendments thereto in effect prior to the date of this Agreement. The Organizational Documents of Parent, each Acquisition Sub and each Parent Subsidiary are in full force and effect and neither (a)&#160;Parent, either Acquisition Sub nor (b)&#160;except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, any Parent Subsidiary, is in violation of any of the provisions of such Organizational Documents. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.3 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capitalization</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) The authorized capital stock of Parent consists of: (i) 250,000,000 shares of Parent Class&#160;A Common Stock, (ii) 50,000,000 shares of Class&#160;B common stock, par value $0.001 per share (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Class</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;B Common Stock</div>&#8221; and together with the Parent Class&#160;A Common Stock, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Common Stock</div>&#8221;) and (iii) 10,000,000 shares of preferred stock, par value $0.001 per share. All of the outstanding shares of Parent Common Stock have been, and all shares of Parent Common Stock reserved for issuance pursuant to the Parent Equity Plan will be when issued, duly authorized and validly issued, and are, or will be when issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable.</div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Except as set forth in Parent&#8217;s restated articles of organization (as amended), Parent&#8217;s bylaws or the Parent Equity Agreements: (i)&#160;none of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of repurchase, right of participation or any similar right granted by Parent or a Parent Subsidiary; (ii)&#160;none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent; (iii)&#160;there are no bonds, debentures, notes or other indebtedness issued by Parent or any Parent Subsidiary and outstanding having the right to vote (or convertible or exercisable or exchangeable for securities having the right to vote) on any matters on which stockholders of Parent may vote; and (iv)&#160;there is no Contract to which Parent is a party relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from granting any option or similar right with respect to), any shares of Parent Common Stock. Except as set forth in the Parent Equity Agreements, Parent is not under any obligation, nor is it bound by any Contract pursuant to which it will become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities of any other Entity. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) As of June&#160;25, 2021 (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Capitalization Date</div>&#8221;): (i) 41,062,601 shares of Parent Class&#160;A Common Stock were issued and outstanding; (ii) 15,786,737 shares of Parent Class&#160;B Common Stock were issued and outstanding; (iii)&#160;zero shares of preferred stock, par value $0.001 per share, were issued and outstanding; (iv) 4,627,100 shares of Parent Class&#160;A Common Stock were subject to issuance pursuant to outstanding Parent Options; (v) 936,203 shares of Parent Class&#160;A Common Stock were subject to issuance pursuant to outstanding Parent RSUs; (vi) 542,320 shares of Parent Class&#160;A Common Stock were reserved for issuance pursuant to the Parent ESPP; (vii) 7,592,476 shares of Parent Class&#160;A Common Stock were reserved for issuance pursuant to the Parent Equity Plan and (viii)&#160;no other shares of capital stock or other voting securities of Parent were issued, reserved for issuance or outstanding. From the Parent Capitalization Date through the date of this Agreement, neither Parent nor any of the Parent Subsidiaries has issued any shares of Parent Common Stock or other equity interests of Parent or any Parent Subsidiary, other than pursuant to Parent Options, Parent RSUs or the Parent ESPP, in each case, that were outstanding as of the Parent Capitalization Date. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Except as set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.3(c)</div>, there is no: (i)&#160;outstanding subscription, option, call, warrant or other right (whether or not currently exercisable) to acquire any shares of the capital stock or other equity interests, or any restricted stock unit, stock-based performance unit, shares of phantom stock, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock appreciation right, profit participation right or any other right that is linked to, or the value of which is based on or derived from, the value of any shares of capital stock or other equity interest of Parent; (ii)&#160;outstanding security, instrument, bond, debenture or note that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent; or (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Parent is or may become obligated to sell or otherwise issue any shares of its capital stock or other equity interest or any other securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.4 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Authority; Binding Nature of Agreement</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Parent has the requisite corporate power and authority to enter into and to perform its obligations under this Agreement and, subject to receipt of the Required Parent Stockholder Vote, to consummate the Mergers. Assuming the accuracy of the Company&#8217;s representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.23</div>, on or prior to the date hereof, the Parent Board has unanimously: (i)&#160;duly and validly authorized and approved the execution, the delivery and, subject to the receipt of the Required Parent Stockholder Vote, the performance of this Agreement and the consummation of the Mergers, by Parent; (ii)&#160;determined that the Mergers are fair to and in the best interests of Parent and its stockholders; (iii)&#160;approved and declared advisable this Agreement and the transactions contemplated by this Agreement, including the Mergers; (iv)&#160;subject to the terms and conditions hereof, approved the issuance of shares of Parent Class&#160;A Common Stock in the First Merger as contemplated by this Agreement (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Share Issuance</div>&#8221;); and (v)&#160;directed that the Parent Share Issuance be submitted to a vote of Parent&#8217;s stockholders, recommended the approval of the Parent Share Issuance for purposes of the rules and regulations of Nasdaq by the holders of shares of Parent Common Stock (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Board Recommendation</div>&#8221;), and resolved to include the Parent Board Recommendation in the Joint Proxy Statement/Prospectus, subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div>. Assuming the accuracy of the Company&#8217;s representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.23</div>, the execution and delivery of this Agreement by Parent and the consummation by Parent of the Mergers and other transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of Parent, and no other corporate proceedings on the part of Parent are necessary to authorize this Agreement, in each case other than the adoption of this Agreement by Parent as the sole stockholder of Acquisition Sub I and the sole member of Acquisition Sub II (which shall occur immediately following the execution of this Agreement) and, with respect to the Parent Share Issuance, the receipt of the Required Parent Stockholder Vote. This Agreement has been duly executed and delivered on behalf of Parent and, assuming the due authorization, execution and delivery of this Agreement on behalf of the Company, constitutes the valid and binding obligation of Parent, enforceable against Parent in accordance with its terms, subject to the General Enforceability Exception. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Each Acquisition Sub is a newly formed, wholly owned Subsidiary of Parent and has the requisite corporate power and authority to enter into and to perform its obligations under this Agreement. The board of directors of Acquisition Sub I has: (i)&#160;determined that the transactions contemplated by this Agreement are fair to, and in the best interests of, Acquisition Sub and its stockholder; (ii)&#160;declared that this Agreement is advisable and recommended that its sole stockholder adopt this Agreement; and (iii)&#160;authorized and approved the execution, delivery and performance of this Agreement by Acquisition Sub. The sole member of Acquisition Sub II has (i)&#160;determined that the transactions contemplated by this Agreement are fair to, and in the best interests of, Acquisition Sub; (ii)&#160;declared that this Agreement is advisable; and (iii)&#160;authorized and approved the execution, delivery and performance of this Agreement by Acquisition Sub II. The execution and delivery of this Agreement by each Acquisition Sub and the consummation by each Acquisition Sub of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of each Acquisition Sub, and no other corporate proceedings on the part of either Acquisition Sub are necessary to authorize this Agreement other than, with respect to the Mergers: (A)&#160;the adoption of this Agreement by Parent as the sole stockholder of Acquisition Sub I and the sole member of Acquisition Sub II (which, in each case, shall occur immediately following the execution of this Agreement); and (B)&#160;the filing of the Certificates of Merger as required by the DGCL and DLLCA. Parent, as the sole stockholder of Acquisition Sub I and sole member of Acquisition Sub II, will </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vote to adopt this Agreement immediately after the execution and delivery of this Agreement. This Agreement has been duly executed and delivered by each Acquisition Sub and, assuming the due authorization, execution and delivery of this Agreement on behalf of the Company, constitutes the valid and binding obligation of each Acquisition Sub, enforceable against each Acquisition Sub in accordance with its terms, subject to the General Enforceability Exception. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;">Section&#160;3.5 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vote Required</div></div>. Assuming the accuracy of the Company&#8217;s representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.23</div>, the approval of the Parent Share Issuance by a majority of the outstanding shares of Parent Common Stock present in person or by proxy at the Parent Stockholder Meeting and entitled to vote on the proposal to approve the Parent Share Issuance (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Required Parent Stockholder Vote</div>&#8221;) is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary under applicable Legal Requirements and Parent&#8217;s Organizational Documents for Parent to consummate the transactions contemplated hereby, including the Mergers. The approval of the adoption of this Agreement by Parent as the sole stockholder of Acquisition Sub I and sole member of Acquisition Sub II, which consent will be delivered immediately following the execution hereof in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.9(c)</div>, is the only vote of the holders of any class or series of Acquisition Sub I&#8217;s capital stock and Acquisition Sub II&#8217;s membership interests necessary under applicable Legal Requirements and each Acquisition Sub&#8217;s Organizational Documents for each Acquisition Sub to consummate the transactions contemplated hereby, including the Mergers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.6 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Contravention;</div> Consents</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) The execution and delivery of this Agreement by Parent and, assuming receipt of the Required Parent Stockholder Vote and the accuracy of the Company&#8217;s representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.23</div>, the consummation by Parent of the Mergers will not: (i)&#160;cause a violation of any of the provisions of the Organizational Documents of Parent or any Parent Subsidiary; (ii)&#160;assuming the consents and filings referred to in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.6(b)</div> are made and obtained, conflict with or violate any applicable Legal Requirements; or (iii)&#160;subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7</div>, result in any loss, limitation or impairment of any right of Parent or any Parent Subsidiary to own or use any assets, result in any violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation, first offer, first refusal, modification or acceleration of any obligation or to the loss of a benefit under any Parent Material Contract, or result in the creation of any Liens of any kind (other than Parent Permitted Encumbrances) upon any of the properties, rights or assets of Parent or any Parent Subsidiary, except, in the cases of clauses &#8220;(ii)&#8221; and &#8220;(iii),&#8221; as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Except as (i)&#160;may be required by the applicable requirements of the Securities Act, the Exchange Act, the DGCL, the DLLCA, the HSR Act or other applicable Antitrust Laws, applicable state securities takeover and &#8220;blue sky&#8221; laws or the rules and regulations of Nasdaq, (ii)&#160;in connection with the filing of the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> with the SEC or (iii)&#160;the filing of all material applications and notices, consents, approvals, clearances, authorizations, registrations, and exemptions, as required by the FDA and any Healthcare Regulatory Authority, neither Parent nor either Acquisition Sub, nor any Parent Subsidiary, is required to make any filing, registration, or declaration with, give any notice to, or obtain any consent, Order, license, permit, clearance, waiver or approval from, any Governmental Entity for the execution and delivery of this Agreement by Parent or the consummation by Parent of the Mergers, the performance by Parent of its covenants and obligations hereunder or the consummation by Parent of the Mergers, in each case, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.7 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reports; Financial Statements; Internal Controls</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) All reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated by reference therein) required to be filed or furnished by Parent with the SEC </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">under the Exchange Act or Securities Act since February&#160;11, 2021 (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent SEC Documents</div>&#8221;) have been filed or furnished by or on behalf of Parent with the SEC on a timely basis. As of the time it was filed with the SEC (or, if amended or superseded, then on the date of such amended or superseding filing): (i) each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act (as the case may be) and the applicable regulations promulgated thereunder and the listing requirements and corporate governance rules and regulations of Nasdaq, each as in effect on the date such Parent SEC Document was filed; and (ii)&#160;none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Since February&#160;11, 2021, no executive officer of Parent has failed in any respect to make the certifications required of him or her under Section&#160;302 or 906 of the Sarbanes-Oxley Act. Neither the Parent nor any of its executive officers has received notice from any Governmental Entity challenging or questioning the accuracy, completeness, form or manner of filing of such certifications. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i)&#160;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)&#160;were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited statements, as permitted by the rules and regulations of the SEC applicable thereto, and except that unaudited financial statements may not contain footnotes and are subject to normal and recurring <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> adjustments); (iii) fairly present, in all material respects, the financial position of Parent and Parent&#8217;s consolidated Subsidiaries as of the respective dates thereof and the results of operations and consolidated cash flows of Parent and Parent&#8217;s consolidated Subsidiaries for the periods covered thereby subject, with respect to unaudited interim statements, to normal and recurring <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> adjustments; and (iv)&#160;have been prepared from, and are in accordance with, the books and records of Parent and Parent&#8217;s consolidated Subsidiaries in all material respects. No financial statements of any Person other than Parent and Parent&#8217;s consolidated Subsidiaries are required by GAAP to be included in the consolidated financial statements of Parent. The books and records of Parent and the Parent Subsidiaries have been, and are being, maintained in all material respects in accordance with GAAP and any other applicable legal and accounting requirements. As of the date of this Agreement, Grant Thornton LLP has not resigned (or informed Parent that it intends to resign) or been dismissed as independent public accountants of Parent. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) Parent maintains, and at all times since February&#160;11, 2021 has maintained, a system of internal control over financial reporting (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)</div> under the Exchange Act) which is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures that: (i)&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of Parent and the Parent Subsidiaries; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations of management and directors of Parent; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of Parent and the Parent Subsidiaries that could have a material effect on the financial statements. Parent&#8217;s management has completed an assessment of the effectiveness of Parent&#8217;s system of internal control over financial reporting in compliance with the requirements of Section&#160;404 of the Sarbanes-Oxley Act for its most recent fiscal year, and such assessment concluded that such controls were effective and Parent&#8217;s independent registered accountant has issued an attestation report concluding that Parent maintained effective internal control over financial reporting. Management of Parent has disclosed to Parent&#8217;s auditors and the audit committee of the Parent Board (x)&#160;any significant deficiencies or material weaknesses in the design and operation of internal controls over financial reporting since January&#160;1, 2019 and (y)&#160;any fraud, whether or not material, that involves management or any other employees who have a </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significant role in Parent&#8217;s internal control over financial reporting, and each such deficiency, weakness and fraud so disclosed to auditors, if any, has been made available to the Company prior to the date hereof. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Since January&#160;1, 2019, (i) none of Parent or any Parent Subsidiary nor, to the knowledge of Parent, any director or officer of Parent or any Parent Subsidiary has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding accounting, internal accounting controls or auditing practices, procedures, methodologies or methods of Parent or any Parent Subsidiary or any material complaint, allegation, assertion or claim from employees of Parent or any Parent Subsidiary regarding questionable accounting or auditing matters with respect to Parent or any Parent Subsidiary, and (ii)&#160;to the knowledge of Parent, no attorney representing Parent or any Parent Subsidiary, whether or not employed by Parent or any Parent Subsidiary, has reported evidence of a violation of securities laws, breach of fiduciary duty or similar violation by Parent, any Parent Subsidiary or any of their respective officers, directors, employees or agents to the Parent Board or any committee thereof, or to the General Counsel or Chief Executive Officer of Parent. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) Parent maintains disclosure controls as required by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15</div> under the Exchange Act. As of the date of this Agreement, Parent is in compliance in all material respects with all current listing requirements of Nasdaq. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) Neither Parent nor any Parent Subsidiary is a party to, or has a commitment to effect, enter into or create, any joint venture, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-balance</div> sheet arrangement&#8221; (as defined in Item 303(a) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> under the Exchange Act). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the Parent SEC Documents, and none of the Parent SEC Documents is, to the knowledge of Parent, the subject of ongoing SEC review or investigation. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) Neither Parent nor any Parent Subsidiary has any liabilities of any nature or type (whether accrued, absolute, determined, contingent or otherwise and whether due or to become due), that would be required by GAAP to be reflected on a condensed consolidated balance sheet of Parent and its consolidated Parent Subsidiaries, except for: (i)&#160;liabilities disclosed in the financial statements (including any related notes) contained in the Most Recent Parent Balance Sheet; (ii)&#160;liabilities incurred in the ordinary course of business in a manner consistent with past practice since the date of the Most Recent Parent Balance Sheet; (iii)&#160;liabilities that, individually or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect; and (iv)&#160;liabilities and obligations incurred in connection with this Agreement, the preparation and negotiation of this Agreement or the transactions contemplated by this Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.8 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Absence of Certain Changes</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Since the date of the Most Recent Parent Balance Sheet, there has not been any fact, event, change, effect, circumstance, occurrence, or development that, individually or in the aggregate, has had or would reasonably be expected to have a Parent Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) From the date of the Most Recent Parent Balance Sheet to the date of this Agreement, the businesses of Parent and the Parent Subsidiaries have been conducted in all material respects in the ordinary course of business (other than in connection with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures) in a manner consistent with past practice, and neither Parent nor any Parent Subsidiary has undertaken any action that if proposed to be taken after the date of this Agreement would require the Company&#8217;s consent pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.9 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compliance with Legal Requirements</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Parent is, and since January&#160;1, 2019 has been, in compliance with all Legal Requirements applicable to it and its businesses, except where the failure to comply with such Legal Requirements would not, individually or in the aggregate, has not been or would not reasonably be expected to be material to Parent and the Parent Subsidiaries, taken as a whole. Neither Parent nor any Parent Subsidiary has, since </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1, 2019: (i) to the knowledge of Parent, received any written notice from any Governmental Entity regarding any material violation by Parent of any Legal Requirement; or (ii)&#160;provided any notice to any Governmental Entity regarding any material violation by Parent or any Parent Subsidiary of any Legal Requirement. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Parent and the Parent Subsidiaries hold, and have at all times since January&#160;1, 2019 held, all Governmental Authorizations necessary for the lawful operation of the businesses of Parent and the Parent Subsidiaries as they are now being conducted (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Permits</div>&#8221;) and have paid all fees and assessments due and payable in connection therewith, except where the failure to have, file or pay, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;all Parent Permits are valid and in full force and effect, are not subject to any administrative or judicial proceeding that could result in any modification, termination or revocation thereof and, to the knowledge of Parent, no suspension or cancellation of any such Parent Permit is threatened, (ii)&#160;Parent and each Parent Subsidiary is in compliance with the terms and requirements of all Parent Permits and (iii)&#160;no consent from or notice to any Government Entity is required in order for each Parent Permit to continue in full force and effect upon consummation of the Mergers and the other transactions contemplated by this Agreement. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Except where the failure to comply with such Legal Requirements, individually or in the aggregate, has not been or would not reasonably be expected to be material to Parent and the Parent Subsidiaries, taken as a whole, Parent and each Parent Subsidiary have at all times since January&#160;1, 2019 complied with applicable Sanctions Laws and Export Control Laws. Neither Parent nor any Parent Subsidiary has been the subject of or otherwise involved in investigations or enforcement actions by any Governmental Entity or other Legal Proceedings with respect to any actual or alleged violations of Export Control Laws or Sanctions Laws, and neither Parent nor any Parent Subsidiary has been notified of any such pending or threatened actions. Neither Parent, any Parent Subsidiary, nor any director or officer of Parent or any Parent Subsidiary, or, to the knowledge of Parent, any other employee, independent contractor, consultant, agent, or other Person acting on behalf of Parent or any Parent Subsidiary, is a Prohibited Person or is subject to debarment or any list-based designations under the Export Control Laws. Since January&#160;1, 2019, Parent and the Parent Subsidiaries have secured and maintained all necessary Export Approvals, and each of Parent and the Parent Subsidiaries is and, since January&#160;1, 2019, has been in compliance in all material respects with the terms of all Export Approvals. None of the officers, directors, or employees of Parent or any of the Parent Subsidiaries is a foreign or domestic Government Official. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.10 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal Proceedings; Investigations; Orders</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) There is no Legal Proceeding pending or, to the knowledge of Parent, threatened against Parent, the Acquisition Subs or any Parent Subsidiary or affecting any of their respective properties or assets that: (i)&#160;would adversely affect Parent&#8217;s or each Acquisition Sub&#8217;s ability to perform any of its obligations under, or consummate any of the transactions contemplated by, this Agreement; or (ii)&#160;individually or in the aggregate, has had or would reasonably be expected to have a Parent Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) There is no Order under which Parent, each Acquisition Sub or any Parent Subsidiary is subject to ongoing obligations that, individually or in the aggregate, has had or would reasonably be expected to have a Parent Material Adverse Effect. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.11 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Certain Business Practices</div></div>. Except as, individually or in the aggregate, has not been or would not reasonably be expected to be material to Parent or any Parent Subsidiary, taken as a whole, since January&#160;1, 2019, neither Parent nor any of the Parent Subsidiaries, nor, any director, officer, employee, or, to the knowledge of Parent, other agent or Person acting on behalf of Parent or any of the Parent Subsidiaries has, directly or indirectly, (a)&#160;violated or taken any action that could potentially result in a violation of any provision of Anti-Corruption Laws applicable to Parent or any Parent Subsidiary or (b): (i) used, offered to use or authorized the use of any funds of Parent or the Parent Subsidiaries for unlawful contributions, unlawful gifts or unlawful </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entertainment, or for other unlawful payments, related to political activity or otherwise; (ii)&#160;made, offered to make or authorized any unlawful payment from funds of Parent or any Parent Subsidiaries to foreign or domestic Government Officials or employees or to foreign or domestic political parties or campaigns; (iii)&#160;established or maintained any unlawful fund of monies or other unlawful pool of assets of Parent or any Parent Subsidiaries; (iv)&#160;made any fraudulent entry on the books or records of Parent or any of the Parent Subsidiaries; (v)&#160;made, offered to make or authorized any bribe, unlawful rebate, unlawful payoff, unlawful influence payment, unlawful kickback or other unlawful payment to any Person, private or public, in any form; or (vi)&#160;engaged in or facilitated any transaction or dealing in property or interests in property of a Prohibited Person, received funds, goods or services from or made any contribution of funds, goods or services to or for the benefit of a Prohibited Person or otherwise engaged in or facilitated any transactions with, any Prohibited Person. Neither Parent nor any Parent Subsidiary is or within the past five years has (i)&#160;been to the knowledge of Parent, under investigation by any Governmental Entity for any potential or actual violation of any Anti-Corruption Laws or (ii)&#160;received any written notice from any Governmental Entity regarding any potential or actual violation of, or potential or actual failure to comply with, any Anti-Corruption Laws. Since January&#160;1, 2019 neither Parent nor any of Parent Subsidiaries have made any disclosure (voluntary or otherwise) to any Governmental Entity with respect to any potential violation or liability arising under or relating to any Anti-Corruption Laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.12 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Regulatory Matters.</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Except as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect, Parent and each of the Parent Subsidiaries is and has been since January&#160;1, 2019, in compliance in all material respects with (i)&#160;all applicable Healthcare Laws and (ii)&#160;all Healthcare Regulatory Authorizations. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Since January&#160;1, 2019, neither Parent nor any of the Parent Subsidiaries has received written notice of any pending or threatened claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other action by any Healthcare Regulatory Authority alleging that any Parent Product, operation or activity of Parent or the Parent Subsidiaries is in material violation of any applicable Healthcare Laws or otherwise (i)&#160;proposing to modify, suspend, revoke or withdraw a material Healthcare Regulatory Authorization or (ii)&#160;contesting the clearance, approval or marketing of any Parent Product. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Parent and each of the Parent Subsidiaries, as applicable, possess all Healthcare Regulatory Authorizations required for the conduct of its respective business, including without limitation, all Healthcare Regulatory Authorizations required for any Parent Product, and all such Healthcare Regulatory Authorizations are in full force and effect, except where the failure to possess such Healthcare Regulatory Authorizations or for such Healthcare Regulatory Authorizations to be in full force, would not, whether individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. Since January&#160;1, 2019, neither Parent nor any of the Parent Subsidiaries has received written notice of any termination, revocation, withdrawal, suspension, rejection or denial of, any Healthcare Regulatory Authorization, and to Parent&#8217;s knowledge, no event has occurred which allows, or after notice or lapse of time would allow, or would reasonably be expect to lead to, the revocation, withdrawal, termination, suspension, rejection or denial of any Healthcare Regulatory Authorization (or any filing or application therefor) or result in any other impairment of the rights of the holder of any material Healthcare Regulatory Authorization (or any filing or application therefor) except for such terminations, revocations, withdrawals, suspensions, rejections, denials or impairments, that would not, whether individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Except as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect: all reports, documents, registrations, authorizations, claims and notices required to be filed, maintained, or furnished to any Healthcare Regulatory Authority pursuant to any applicable Healthcare Laws by Parent or any of the Parent Subsidiaries have been so filed, maintained or furnished and were complete and correct on the date filed (or were corrected in or supplemented by a subsequent filing). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) Since January&#160;1, 2019, neither Parent nor any of the Parent Subsidiaries has voluntarily or involuntarily initiated, conducted or issued, or caused to be initiated, conducted or issued (or received any written notices from any Healthcare Regulatory Authority issuing, requiring or causing Parent or a Parent Subsidiary to issue) any recalls, seizures, detentions, field notifications, field corrections, market withdrawals or replacements, warnings, &#8220;dear doctor&#8221; letters, investigator notices, safety alerts or other written notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of, or enjoining manufacture or distribution of, any Parent Product, except in each case as are immaterial in nature or amount, and to Parent&#8217;s knowledge none of any Healthcare Regulatory Authority, or Parent or any of the Parent Subsidiaries is considering such action. </div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) All preclinical studies, tests and clinical trials conducted by or on behalf of Parent or any of the Parent Subsidiaries, or in which Parent or any of the Parent Subsidiaries has participated in with respect to Parent Products (collectively, &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Studies</div>&#8221;) were and, if still pending, have been and are being conducted in compliance with all applicable Healthcare Laws, except as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. Neither Parent nor any of the Parent Subsidiaries has received any written notice from any Healthcare Regulatory Authority requiring or threatening, in writing, the termination or suspension of any ongoing or planned Parent Studies, and to the knowledge of Parent, there are no reasonable grounds for the same, except for such terminations or suspensions as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) Since January&#160;1, 2019, neither Parent nor any Parent Subsidiary has received, (i)&#160;from FDA, any FDA Form 483, warning letter or untitled letter or (ii)&#160;from any other Healthcare Regulatory Authority, any similar written notice alleging or asserting material noncompliance with any Healthcare Laws or Healthcare Regulatory Authorizations held by Parent or any Parent Subsidiaries. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) Neither Parent nor any Parent Subsidiary is a party to, has any ongoing obligations pursuant to, or is bound by, any order, individual integrity agreement, corporate integrity agreement, deferred prosecution agreement, settlement agreement, consent agreement, consent decree or other similar form agreement with any Governmental Entity resulting from a failure, or alleged failure, to comply with any applicable Healthcare Laws of the FDA, Centers for Medicare and Medicaid Services and other Healthcare Regulatory Authorities. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(i) Since January&#160;1, 2019, neither Parent nor any Parent Subsidiary or their Parent Products are the subject of any pending or, to Parent&#8217;s knowledge, threatened investigation by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto, or otherwise. Neither Parent nor any of the Parent Subsidiaries, any of their respective officers, directors, employees, nor, to Parent&#8217;s knowledge, any of their respective contractors, suppliers, agents, or other company or individual performing research or Parent Product-related work on behalf of Parent or any of the Parent Subsidiaries, nor any other Person described in 42 C.F.R. &#167; 1001.1001(a)(1)(ii), (i) has committed any act, made any untrue statement of material fact or failed to make any statement that, at the time such act, statement or disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy; (ii)&#160;has been charged with any conduct for which debarment is mandated by 21 U.S.C. &#167; 335a or any criminal offense relating to the delivery of an item or service under any federal health care program; (iii)&#160;has been charged with or been convicted of any crime for which exclusion is mandated or permitted from the federal health care programs under Section&#160;1128 of the Social Security Act of 1935, or any similar Law; (iv)&#160;is or has been debarred, excluded, suspended or is otherwise ineligible from participation in any federal health care program, as such term is defined in 42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7b(f),</div> or any other government program; (v)&#160;has had a civil monetary penalty assessed against it under Section&#160;1128A of the Social Security Act; (vi)&#160;is or has been listed on the General Services Administration published list of parties excluded from federal procurement programs and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-procurement</div> programs; or (vii)&#160;has been debarred by any federal or international agency. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;3.13 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Benefit Plans</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) No Parent Plan is, and neither Parent nor any Parent Subsidiary nor any Parent Commonly Controlled Entity contributes to, has at any time in the previous six years contributed to or has or had any liability or obligation, whether fixed or contingent, with respect to (i)&#160;a multiemployer plan, as defined in Section&#160;3(37) of ERISA, (ii)&#160;a single employer plan or other pension plan that is subject to Title IV of ERISA or Section&#160;302 of ERISA or Section&#160;412 of the Code, (iii)&#160;a multiple employer plan (within the meaning of Section&#160;413(c) of the Code), (iv) a multiple employer welfare arrangement (within the meaning of Section&#160;3(40) of ERISA), (v) a voluntary employee benefit association under Section&#160;501(a)(9) of the Code, or (vi)&#160;a plan providing for postemployment or post-retirement health, medical, or life insurance benefits for former or retired employees of Parent or any of the Parent Subsidiaries, except as required under Section&#160;4980B of the Code or otherwise except as may be required pursuant to any other applicable Legal Requirements. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Each Parent Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination letter (or opinion letter, if applicable) from the IRS stating that such Parent Plan is so qualified and, to the knowledge of Parent, nothing has occurred since the date of such letter that would reasonably be expected to adversely affect the qualified status of such Parent Plan. Each Parent Plan has been operated in compliance in all material respects with its terms and with all applicable Legal Requirements. Without limiting the foregoing, no liability under Title IV of ERISA has been incurred by Parent or any Parent Commonly Controlled Entity that has not been satisfied in full and, to the knowledge of Parent, no condition exists that presents a risk to Parent or any Parent Commonly Controlled Entity of incurring a liability under such Title. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Each Parent Plan has been maintained and operated in documentary and operational compliance in all material respects with Section&#160;409A of the Code or an available exemption therefrom. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.14 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Labor Matters</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Neither Parent nor any Parent Subsidiary is a party to, nor does Parent or any Parent Subsidiary have a duty to bargain for, any collective bargaining agreement with a labor organization or works council representing any of its employees and, as of the date of this Agreement, there are no labor organizations or works councils representing, purporting to represent or, to the knowledge of Parent, seeking to represent any employees of Parent or any Parent Subsidiary. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) As of the date of this Agreement (i)&#160;and since January&#160;1, 2019, there has not been any strike, slowdown, work stoppage, lockout, job action, picketing, labor dispute, union organizing activity, or any similar activity or dispute, affecting Parent, any Parent Subsidiary or any of their employees and, (ii)&#160;to the knowledge of Parent, no Person is currently threatening in writing to commence, any such strike, slowdown, work stoppage, lockout, job action, picketing, labor dispute or union organizing activity or any similar activity or dispute. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) As of the date of this Agreement there is no material claim or grievance pending or, to the knowledge of Parent, threatened by or on behalf of any employees of Parent or any Parent Subsidiary relating to any employment Contract, wages and hours, mass layoffs or reductions in force, plant closing notification, employment statute or regulation, labor dispute, workers&#8217; compensation policy or long-term disability policy, safety, retaliation, immigration or discrimination matters involving any employee of Parent or any Parent Subsidiary, including material charges of unfair labor practices or material harassment complaints, claims or judicial or administrative proceedings, in each case, which are pending. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.15 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financing; Solvency</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Parent has delivered to the Company an accurate and complete copy of the fully executed debt commitment letter, together with any related fee letters (in the case of the fee letters, redacted in a customary manner for confidential provisions related to fees, flex terms related to fees and pricing and other </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">economic terms, none of which adversely affect the conditionality, enforceability, availability, termination or aggregate principal amount of the Debt Financing contemplated thereby in any respect), dated as of the date hereof, by and among the Debt Financing Sources, the Acquisition Subs and other parties thereto, providing for debt financing as described therein (together, including all exhibits, schedules and annexes and the fee letters associated therewith, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Debt Commitment Letter</div>&#8221;), pursuant to which, upon the terms and subject only to the conditions set forth therein, the Debt Financing Sources party thereto have agreed to lend the amounts set forth therein (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Debt Financing</div>&#8221;). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) The Debt Commitment Letter is in full force and effect and constitutes the valid, binding and enforceable obligation of the Acquisition Subs and, to the knowledge of Parent, the other parties thereto, enforceable in accordance with its terms (subject to the applicable bankruptcy, reorganization, fraudulent conveyance, insolvency, moratorium or other similar Laws affecting creditor&#8217;s rights generally and the availability of equitable relief and any implied covenant of good faith and fair dealing). As of the date hereof, there are no conditions precedent or subsequent related to the funding of the Debt Financing contemplated by the Debt Commitment Letter, other than the conditions precedent set forth in the Debt Commitment Letter (such conditions precedent, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financing Conditions</div>&#8221;). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) As of the date hereof, the Debt Commitment Letter has not been amended, waived, supplemented or modified in any manner, and the respective commitments contained therein have not been terminated, reduced, withdrawn or rescinded in any respect by the Acquisition Subs or, to the knowledge of Parent, any other party thereto, and no such termination, reduction, withdrawal or rescission is contemplated by the Acquisition Subs or, to the knowledge of Parent, any other party thereto. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) As of the date hereof, Parent has no reason to believe that (i)&#160;any of the Financing Conditions will not be satisfied on or prior to the Closing Date or (ii)&#160;the Financing contemplated by the Debt Commitment Letter will not be available to the Acquisition Subs on the Closing Date. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) As of the date hereof, the Acquisition Subs are not in default or breach under the terms and conditions of the Debt Commitment Letter or any related fee letters and, to the knowledge of Parent, no event has occurred that, with or without notice, lapse of time or both, would or would reasonably be expected to constitute a default or breach or a failure to satisfy a condition under the terms and conditions of the Debt Commitment Letter. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) No Debt Financing Source has notified Parent or the Acquisition Subs of its intention to terminate its commitment under the Debt Commitment Letter or to not provide the Debt Financing. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) The Acquisition Subs have paid in full all commitment or other fees required by the Debt Commitment Letter or any related fee letter that are due as of the date hereof. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.16 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Takeover Statutes</div></div>. Assuming the accuracy of the Company&#8217;s representation in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.23</div>, the Parent Board has taken all action necessary to render Section&#160;203 of the DGCL, all other potentially applicable state anti-takeover statutes and any similar provisions of the Parent&#8217;s Organizational Documents inapplicable to the Mergers and the Parent Share Issuance. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.17 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ownership of Company Common Stock</div></div>. During the three years prior to the date of this Agreement, neither Parent nor any Parent Subsidiary beneficially owns or owned, directly or indirectly, any shares of Company Common Stock or other securities convertible into, exchangeable into or exercisable for shares of Company Common Stock (other than pursuant to any Parent Plan). There are no voting trusts or other agreements or understandings to which Parent or any Parent Subsidiary is a party with respect to the voting of the capital stock or other equity interest of the Company or any Company Subsidiary. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.18 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intellectual Property.</div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) To the knowledge of Parent, all material Intellectual Property owned or purported to be owned by Parent or any Parent Subsidiary (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent IP</div>&#8221;) that is Registered IP (collectively, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Registered</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">IP</div>&#8221;) is valid, subsisting and enforceable (or solely in the case of applications, applied for and pending). Since January&#160;1, 2019 , neither Parent nor any Parent Subsidiary has received any written notice or claim challenging the validity or enforceability of any Parent Registered IP or indicating an intention on the part of any Person to bring a claim that any of the Parent Registered IP is invalid or unenforceable, and there is currently no Legal Proceeding pending or threatened in writing, in which the validity, enforceability or ownership of any Parent Registered IP is being contested or challenged. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) To the knowledge of Parent, neither Parent nor any Parent Subsidiary is subject to any outstanding or potential Order that restricts in any material manner the use, transfer or licensing of any material Parent IP. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) To the knowledge of Parent, the operations of the businesses of Parent and the Parent Subsidiaries as currently conducted do not infringe, misappropriate or otherwise violate and since January&#160;1, 2019 have not, to the knowledge of Parent, infringed, misappropriated or otherwise violated, any Intellectual Property owned by any other Person in a manner that would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. Neither Parent nor any Parent Subsidiary has received any written complaints, claims or notices since January&#160;1, 2019 alleging any infringement, misappropriation or violation of any Intellectual Property of any other Person by Parent or any Parent Subsidiary. To the knowledge of Parent, there is no unauthorized use, unauthorized disclosure, infringement, misappropriation or other violation of any Parent IP by any third Person that would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Parent and each Parent Subsidiary have taken commercially reasonable steps to protect all Trade Secrets owned by Parent or a Parent Subsidiaries and that are material to Parent or the Parent Subsidiaries, taken as a whole. Parent and each Parent Subsidiary has, and uses commercially reasonable measures to enforce, a policy requiring all employees and consultants of Parent or any Parent Subsidiary, in each case, who have been engaged in the development of any Parent Product, to enter into proprietary information and intellectual property assignment agreements with Parent or a Parent Subsidiary, for the benefit of Parent or a Parent Subsidiary, as applicable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.19 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Tax Matters</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Except as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect: </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) Parent and the Parent Subsidiaries have timely filed (taking into account any extension of time within which to file) all Tax Returns that are required to be filed by or with respect to any of them and all such Tax Returns are accurate and complete. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) Parent and the Parent Subsidiaries have timely paid in full to the appropriate Governmental Entity all Taxes required to be paid by any of them or, in respect of any Taxes accrued but not yet payable by Parent or any Parent Subsidiary, adequate reserves have been recorded in the financial statements of Parent and the Parent Subsidiaries in accordance with GAAP. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii) Each of Parent and the Parent Subsidiaries has (i)&#160;timely paid, deducted, withheld and collected all amounts required to be paid, deducted, withheld or collected by any of them with respect to any payment made or owing to, or received from, their employees, creditors, independent contractors, shareholders, customers and other third parties (and have timely paid over any amounts so withheld, deducted or collected to the appropriate Governmental Entity) and (ii)&#160;otherwise complied with all applicable Legal Requirements relating to such withholding, collection and remittance of Taxes (including information reporting requirements). </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) Within the last three years, no claim has been made in writing by any Tax authority in a jurisdiction where Parent or any Parent Subsidiary has not filed Tax Returns of a particular type that Parent or any Parent Subsidiary is or may be subject to such type of Tax by, or required to file Tax Returns with respect to Taxes in, such jurisdiction. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) Neither Parent nor any Parent Subsidiary will be required to include an item of income (or exclude an item of deduction) in any taxable period (or portion thereof) beginning after the Closing Date as a result of (i)&#160;a change in or incorrect method of accounting occurring prior to the Closing Date, (ii)&#160;a prepaid amount received (or deferred revenue recognized) or paid, prior to the Closing Date, (iii)&#160;any agreement entered into on or prior to the Closing Date with a Governmental Entity relating to Taxes, or (iv)&#160;any open transaction or installment sale entered into on or prior to the Closing Date. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(vi) There are no: (i)&#160;examinations, investigations, audits, or other proceedings pending or, to the knowledge of Parent, threatened in writing with respect to any Taxes of Parent or any Parent Subsidiary or any Tax Returns; (ii)&#160;extensions or waivers of the limitation period applicable to any Tax Return or the period for the assessment of any Taxes of Parent or the Parent Subsidiaries which period has not yet expired; (iii)&#160;deficiencies for Taxes that have been claimed, proposed or assessed by any Governmental Entity in writing against Parent or any Parent Subsidiary that have not been fully satisfied by payment; or (iv)&#160;Liens in respect of or on account of material Taxes (other than Parent Permitted Encumbrances) upon any of the property or assets of Parent or any Parent Subsidiary. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Neither Parent nor any of the Parent Subsidiaries (i)&#160;is or has been, within the last six years, a member of any affiliated, combined, consolidated, unitary or similar group for purposes of filing Tax Returns or paying Taxes, except for any such group of which Parent is the common parent or (ii)&#160;has any liability for Taxes of any Person (other than Parent or any Parent Subsidiary) under Treasury Regulations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.1502-6</div> (or any similar state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> Legal Requirement) or as transferee or successor. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Neither Parent nor any Parent Subsidiary is a party to or bound by, or has any obligation under, any Tax indemnity, sharing, allocation, or reimbursement agreement or arrangement, other than: (i)&#160;customary tax provisions in ordinary course commercial agreements, the principal purpose of which is not related to Taxes; and (ii)&#160;any agreement or arrangement between or among Parent and any Parent Subsidiary. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Neither Parent nor any Parent Subsidiary is bound with respect to the current or any future taxable period by any closing agreement (within the meaning of Section&#160;7121(a) of the Code or any similar or analogous state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> Legal Requirement) or other ruling or written agreement with a Tax authority, in each case, with respect to Taxes. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) Within the last two years, neither Parent nor any Parent Subsidiary has distributed stock of another Person or has had its stock distributed by another Person in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355(a) of the Code. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) Neither Parent nor any Parent Subsidiary has participated in any &#8220;listed transaction&#8221; within the meaning of Treasury Regulations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.6011-4(b)(2)</div> (or any similar state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> Legal Requirement). </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) Neither Parent nor any Parent Subsidiary has taken or agreed to take any action or has knowledge of any facts that would prevent the Mergers from qualifying for the Intended Tax Treatment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.20 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opinion of Financial Advisor</div></div>. The Parent Board has received the opinion of Perella Weinberg Partners LP (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Financial Advisor</div>&#8221;), financial advisor to Parent, dated as of the date of this Agreement, to the effect that, on such date and subject to the various assumptions and limitations set forth in such opinion, the aggregate Merger Consideration to be paid by Parent pursuant to this Agreement is fair, from a financial point of view, to Parent (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Fairness Opinion</div>&#8221;). Parent will make available to the Company a copy of such opinion as soon as practicable following the execution of this Agreement for information purposes only. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.21 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Brokers</div></div>. No broker, finder or investment banker (other than the Parent Financial Advisor) is entitled to any brokerage, finder&#8217;s or other similar fee or commission in connection with the Mergers based upon arrangements made by or on behalf of Parent. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;3.22 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Information Supplied</div></div>. The information supplied or to be supplied by Parent for inclusion in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (including the Joint Proxy Statement/Prospectus) will not, at the time the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (and any amendment or supplement thereto) is declared effective, on the date that the Joint Proxy Statement/Prospectus is first mailed to the stockholders of the Company and the stockholders of Parent, or on the date of the Company Stockholder Meeting or the Parent Stockholder Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading, except that, no representation or warranty is made by Parent with respect to statements made therein based on information supplied by the Company for inclusion therein. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.23 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Data Privacy and Security</div></div>. Except as, individually or in the aggregate, has not been and would not reasonably be expected to be material to Parent and the Parent Subsidiaries, taken as a whole, Parent and each Parent Subsidiary is in compliance, and has since January&#160;1, 2019 complied, with all applicable Data Protection Laws. To the knowledge of Parent, since January&#160;1, 2019, there have not been any material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-permitted</div> disclosures, material security incidents or material breaches involving Parent, Parent Subsidiaries, or any of its agents, employees or contractors relating to any Personal Data in its possession or control that would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the knowledge of Parent, since January&#160;1, 2019, there has been no material failure or any material unauthorized intrusions or material breaches of security with respect to the information technology systems owned or controlled by Parent and each of the Parent Subsidiaries that has resulted in a material disruption or material interruption in the operation of the business of Parent and each of the Parent Subsidiaries that would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.24 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent Top Customers, Distributors and Suppliers</div></div>. As of the date of this Agreement, no Parent Top Customer, no Parent Top Distributor and no Parent Top Supplier has canceled, terminated or substantially curtailed its relationship with Parent or any Parent Subsidiary, given written notice to Parent or any Parent Subsidiary of any intention to cancel, terminate or substantially curtail its relationship with Parent or any Parent Subsidiary, or, to the knowledge of Parent, threatened in writing to do any of the foregoing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.25 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Defects and Warranties</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Since January&#160;1, 2019, all Parent Products sold or supported by Parent or any of the Parent Subsidiaries have been provided in conformity with Parent&#8217;s and the Parent Subsidiaries&#8217; applicable contractual commitments, warranties and specifications, except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) To the knowledge of Parent, Parent&#8217;s warranty reserve reflected on the Most Recent Parent Balance Sheet was sufficient as of the date of the Most Recent Parent Balance Sheet to cover the unexpired warranty liabilities of Parent and the Parent Subsidiaries for any products (including Parent Products) sold by Parent or the Parent Subsidiaries to their respective customers prior to the date of the Most Recent Parent Balance Sheet. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;3.26 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Acquisition Subs</div></div>. Parent is the sole stockholder of Acquisition Sub I and the sole member of Acquisition Sub II. Since their respective dates of incorporation, Acquisition Sub I and Acquisition Sub II have not carried on any business or conducted any operation other than the execution of this Agreement, the performance of its obligations hereunder and matters ancillary thereto. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE IV.COVENANTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Section&#160;4.1 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interim Operations.</div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) The Company agrees that, during the period from the date of this Agreement through the earlier of the Closing or the termination of this Agreement, except (1)&#160;to the extent Parent shall otherwise </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">give its prior consent in writing (such consent not to be unreasonably withheld, conditioned or delayed), (2) as set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)</div> of the Company Disclosure Schedule, (3)&#160;as may be required by applicable Legal Requirements (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures) or (4)&#160;as expressly required by this Agreement, the Company shall, and shall cause the Company Subsidiaries to, use commercially reasonable efforts to conduct its business in the ordinary course of business; provided that any action expressly permitted by the remaining provisions of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)</div> (including <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)</div> of the Company Disclosure Schedule will not constitute a violation of the foregoing. During the period from the date of this Agreement through the earlier of the Closing or the termination of this Agreement, except (1)&#160;to the extent Parent shall otherwise give its prior consent in writing (in the case of subsections (iv), (vi), (viii), (ix), (x), (xii), (xiii), (xvii), (xxviii), and (xxix)(B) of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.01(a)</div>, such consent not to be unreasonably withheld, conditioned or delayed), (2) as set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)</div> of the Company Disclosure Schedule, (3)&#160;as may be required by applicable Legal Requirements (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures) or (4)&#160;as expressly or required by this Agreement, the Company shall not (and shall not permit any Company Subsidiary to), in each case by merger, consolidation, division, operation of law, or otherwise: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) amend the Company&#8217;s Organizational Documents or the Organizational Documents of any Company Subsidiary; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) split, combine, subdivide, change, exchange, amend the terms of or reclassify any shares of the Company&#8217;s capital stock or other equity interests of the Company or any Company Subsidiary; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii) declare, set aside, make or pay any dividend or other distribution (whether payable in cash, stock or property) with respect to any shares of the Company&#8217;s capital stock or the capital stock or other equity interest of any Company Subsidiary, other than dividends or distributions only to the extent paid by any wholly owned Company Subsidiary to the Company or another wholly owned Company Subsidiary; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) acquire (by merger, consolidation, operation of law, acquisition of stock, other equity interests or assets, formation of a joint venture or otherwise)&#160;(A) any other Person, (B)&#160;any equity interest in any other Person (other than investments in equity securities that constitute short term investments that are accounted for as cash equivalents), (C) any business or division of another Person, or (D)&#160;any material assets except, (1)&#160;acquisitions by the Company from any wholly owned Company Subsidiary or among any wholly owned Company Subsidiaries; (2)&#160;the purchase of equipment, supplies and inventory in the ordinary course of business or (3)&#160;inbound licenses or other grants or assignments of Intellectual Property in the ordinary course of business; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) except in connection with any transaction between the Company and any wholly owned Company Subsidiary of or among any wholly owned Company Subsidiaries, issue, sell, grant or otherwise permit to become outstanding any additional shares of, or securities convertible or exchangeable for, or options, warrants or rights to acquire, any shares of its capital stock or other equity interests, other than shares of Company Common Stock issuable upon exercise of outstanding Company Options; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(vi) except in connection with any transaction between the Company and any wholly owned Company Subsidiary or among any wholly owned Company Subsidiaries of the Company, sell, assign, transfer, lease or license to any third party, or incur any Lien on any of its material tangible property or tangible assets, except for Company Permitted Encumbrances, or otherwise dispose of (by merger, consolidation, operation of law, division or otherwise), any material Company IP or material tangible assets of the Company, other than: (A)&#160;sales of inventory, goods or services in the ordinary course of business in a manner consistent with past practice or of obsolete equipment or assets in the ordinary course of business consistent with past practice; (B)&#160;pursuant to written Contracts or commitments existing as of the date of this Agreement; or (C)&#160;as security for any borrowings permitted by <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)(viii)</div>; or (D)&#160;licenses granted to customers or other third parties in the ordinary course of business in a manner consistent with past practice; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(vii) directly or indirectly repurchase, redeem or otherwise acquire any shares of the Company&#8217;s or any Company Subsidiary&#8217;s capital stock or equity interests, or any other securities or obligations </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">convertible (currently or after the passage of time or the occurrence of certain events) into or exchangeable for any shares of the Company&#8217;s or any Company Subsidiary&#8217;s capital stock or equity interests, except: (A)&#160;shares of Company Common Stock repurchased from employees or consultants or former employees or consultants of the Company pursuant to the exercise of repurchase rights existing prior to the date of this Agreement; or (B)&#160;shares of Company Common Stock accepted as payment for the exercise price of Company Options or for withholding Taxes incurred in connection with the exercise, vesting or settlement of Company Options, as applicable, in accordance with the terms of the applicable award; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(viii) incur (other than draws on existing revolving loans), redeem, repurchase, prepay (other than prepayments of revolving loans), defease, or cancel any indebtedness for borrowed money, guarantee any such indebtedness, issue or sell any debt securities or rights to acquire any debt securities (directly, contingently or otherwise) or make any loans or capital contributions to any other Person, except for any indebtedness among the Company and its wholly owned Company Subsidiaries or among any wholly owned Company Subsidiaries (and guarantees by the Company or the Company Subsidiaries in respect thereof); </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(ix)&#160;(A) adopt, terminate or amend any Company Plan except to the extent permitted by clauses (B), (C), (D) or (E)&#160;of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)(ix)</div>, (B) increase, or accelerate the vesting or payment of, the compensation or benefits of any member of the Company Board, current employee, or former employee of the Company or any Company Subsidiary, (C)&#160;grant any rights to severance, retention, change in control or termination pay to any member of the Company Board, current employee or former employee of the Company or any Company Subsidiary, (D)&#160;hire or promote any employee at or to the level of Vice President or above, or (E)&#160;terminate the employment of any employee of the Company or any Company Subsidiary whose annual base salary exceeds $100,000 (other than for cause); except, in each case, for: (1)&#160;amendments to Company Plans determined by the Company in good faith to be required to comply with applicable Legal Requirements; (2)&#160;hiring any Person for employment (including by means of internal promotion) to fill any currently existing Vice President or higher position that becomes vacant after the date of this Agreement, and, notwithstanding anything to the contrary in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)(ix)</div>, provide such Person with compensation and benefits for such position consistent with past practice; (3)&#160;hiring any Person for employment in accordance with the Company&#8217;s present hiring plan made available to Parent or otherwise hiring an individual below the level of Vice President in the ordinary course of business in a manner consistent with past practice; (4)&#160;increases in compensation or benefits required pursuant to any Company Plan in effect on the date hereof; (5)&#160;increases to total target cash opportunities (i.e.,&#160;annual base salary or wage rates and target annual cash bonus opportunities) in amounts that are in the ordinary course of business in a manner consistent with past practice;&#160;and (6)&#160;any other actions set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)(ix)</div> of the Company Disclosure Schedule; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(x) except in the ordinary course of business, (i)(A)&#160;amend or terminate (except for terminations pursuant to the expiration of the existing term of any Material Contract) any Material Contract or (B)&#160;waive, release or assign any material rights under any Material Contracts, or (ii)&#160;enter into any Contract or agreement that, if in effect on the date of this Agreement, would constitute a Material Contract; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xi) change any of its methods of financial accounting or accounting practices in any material respect other than as required by changes in GAAP; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xii) make (except for elections made in the ordinary course of business), change or revoke any material Tax election, change any Tax accounting period or material method of Tax accounting, amend any material Tax Return if such amendment would reasonably be expected to result in a material Tax liability, settle or compromise any material liability for Taxes or any Tax audit, claim, or other proceeding relating to a material amount of Taxes, enter into any agreement with a Governmental Entity relating to Taxes if such agreement would reasonably be expected to result in a material Tax liability, request any Tax ruling from any Governmental Entity, surrender any right to claim a material refund of Taxes, or, other than in the ordinary course of business, agree to an extension or waiver of the statute of limitations with respect to a material amount of Taxes; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(xiii) other than consignment of Company Products in the ordinary course of business, make any capital expenditure that is not contemplated by the capital expenditure budget (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">CapEx Budget</div>&#8221;) set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)(xiii)</div> of the Company Disclosure Schedule&#160;(a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Budgeted</div> Capital Expenditure</div>&#8221;), except that the Company or any Company Subsidiary may make any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Budgeted</div> Capital Expenditure that, when added to all other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Budgeted</div> Capital Expenditures made by the Company and the Company Subsidiaries since the date of this Agreement would not, in the aggregate, exceed the aggregate CapEx Budget by more than $200,000; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xiv) except as expressly required by applicable Legal Requirements or the Company&#8217;s Organizational Documents, convene (A)&#160;any special meeting of the Company&#8217;s stockholders other than the Company Stockholder Meeting or (B)&#160;any other meeting of the Company&#8217;s stockholders to consider a proposal that would reasonably be expected to impair, prevent or delay the consummation of the transactions contemplated hereby; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xv) enter into any agreement, understanding or arrangement with respect to the voting of any capital stock or other equity interests of the Company (including any voting trust), other than with respect to awards under the Company Equity Plans otherwise permitted under this Agreement or in connection with the granting of revocable proxies in connection with any meeting of the Company&#8217;s stockholders; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xvi) adopt a plan of (A)&#160;complete or partial liquidation of the Company or any Company Subsidiary or (B)&#160;dissolution, merger, consolidation, division, restructuring, recapitalization or other reorganization, other than, in the case of clause (B), transactions between or among direct or indirect wholly owned Company Subsidiaries; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xvii) settle or compromise any litigation, claim, suit, action or proceeding, except for settlements or compromises other than (A)&#160;the payment, discharge or satisfaction, in the ordinary course of business in a manner consistent with past practice, of liabilities reflected or reserved against in the Most Recent Company Balance Sheet, or (B)&#160;those that do not (x)&#160;impose any injunctive relief on the Company or any Company Subsidiary (other than confidentiality obligations), (y) involve the payment of money greater than $250,000 in excess of existing insurance coverage, and (z)&#160;do not include an admission of liability or fault on the part of the Company or any Company Subsidiary; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xviii) materially reduce the amount of insurance coverage or fail to renew or maintain any material existing insurance policies; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xix)&#160;(A) amend any Company Permits in a manner that adversely impacts the Company&#8217;s ability to conduct its business in any material respect or (B)&#160;terminate or allow to lapse any material Company Permits; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xx)&#160;(A) fail to pay any issuance, renewal, maintenance and other payments that become due with respect to any material Company Registered IP or otherwise abandon, cancel, or permit to lapse any material Company Registered IP, other than in its reasonable business judgment or in the ordinary course of business in a manner consistent with past practice, or (B)&#160;authorize the disclosure to any third party of any material Trade Secret included in the Company IP in a way that results in loss of trade secret protection, other than in the ordinary course of business in a manner consistent with past practice; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(xxi) take or cause to be taken any action, or knowingly fail to take or cause to be taken any action, which action or failure to act would reasonably be expected to prevent the Merger from qualifying as a reorganization within the meaning of Section&#160;368(a) of the Code; or </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(xxii) authorize, approve or enter into any agreement or make any commitment to take any of the actions described in clauses &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(i)</div>&#8221; through &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(xxi)</div>&#8221; of this sentence. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Parent agrees that, during the period from the date of this Agreement through the earlier of the Closing or the termination of this Agreement, except (i)&#160;to the extent the Company shall otherwise give its prior consent in writing (such consent not to be withheld, conditioned or delayed), (ii) as set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(b)</div> of the Parent Disclosure Schedule, (iii)&#160;as may be required by applicable Legal Requirements </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures) or (iv)&#160;as expressly required by this Agreement, Parent shall, and shall cause the Parent Subsidiaries to, use commercially reasonable efforts to conduct its business in the ordinary course of business. Parent agrees that, during the period from the date of this Agreement through the earlier of the Closing or the termination of this Agreement, except (1)&#160;to the extent the Company shall otherwise give its prior consent in writing, (2)&#160;as set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(b)</div> of the Parent Disclosure Schedule, (3)&#160;as may be required by applicable Legal Requirements (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures) or (4)&#160;as expressly permitted or required by this Agreement, Parent shall not (and shall not permit any Parent Subsidiary to), in each case by merger, consolidation, division, operation of law, or otherwise: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) amend Parent&#8217;s or either of the Acquisition Subs&#8217; Organizational Documents or amend the Organizational Documents of any Parent Subsidiary in any manner that would be adverse in any material respect to the holders of Company Common Stock (after giving effect to the Mergers); </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) split, combine, subdivide, change, exchange, amend the terms of or reclassify any shares of Parent&#8217;s capital stock or other equity interests of the Company, except for any such transaction involving only wholly owned Parent Subsidiaries; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii) declare, set aside, make or pay any dividend or other distribution (whether payable in cash, stock or property) with respect to any shares of Parent&#8217;s capital stock or the capital stock of any Parent Subsidiary, except for dividends or distributions only to the extent paid by any wholly owned Parent Subsidiary to Parent or another wholly owned Parent Subsidiary; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(iv) acquire (by merger, consolidation, operation of law, acquisition of stock, other equity interests or assets, formation of a joint venture or otherwise)&#160;(A) any other Person, (B)&#160;any equity interest in any other Person (other than investments in equity securities that constitute short term investments that are accounted for as cash equivalents), (C) any business or division of another Person, or (D)&#160;any assets material to the Company and the Company Subsidiaries, taken as a whole, except in each case, (1)&#160;acquisitions by Parent from any wholly owned Parent Subsidiary or among any wholly owned Parent Subsidiaries; (2)&#160;the purchase of equipment, supplies and inventory in the ordinary course of business; (3)&#160;inbound licenses or other grants or assignments of Intellectual Property in the ordinary course of business or (4)&#160;acquisitions that in each case would not reasonably be expected to (x)&#160;result in the holders of Company Common Stock having different rights and privileges than holders of Parent Class&#160;A Common Stock following the consummation of the Mergers, (y)&#160;materially delay, materially impede or prevent the consummation of the transactions contemplated by this Agreement or (z)&#160;result in the failure of any of the conditions set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE V</div> to be satisfied prior to the End Date; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) liquidate (completely or partially), dissolve or adopt any plan or resolution providing for any of the foregoing, in each case, with respect to Parent, Acquisition Sub I or Acquisition Sub II; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(vi) take or cause to be taken any action, or knowingly fail to take or cause to be taken any action, which action or failure to act would reasonably be expected to prevent the Merger from qualifying as a reorganization within the meaning of Section&#160;368(a) of the Code; or </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(vii) authorize, approve or enter into any agreement or make any commitment to take any of the actions described in clauses &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(i)</div>&#8221; through &#8220;(vi)&#8221; of this sentence. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.2 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Company No Solicitation</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) The Company will not, and the Company will cause each of the Company Subsidiaries not to, and will instruct its and their respective Representatives not to, except as expressly permitted by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>, directly or indirectly: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(i) solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries regarding, or the submission or announcement by any Person (other than Parent or its Affiliates or their respective Representatives) of, any proposal or offer that constitutes, or would reasonably be expected to lead to, any Company Acquisition Proposal (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided, however</div></div>, that the Company and its </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;">Representatives may refer the Person making such proposal or offer to the provisions of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2</div> and make inquiries of a Person making a Company Acquisition Proposal (and its Representatives) to solely clarify the terms of such Company Acquisition Proposal for the purpose of the Company Board informing itself about such Company Acquisition Proposal); </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) furnish any information regarding the Company or any Company Subsidiary (other than to Parent and the Parent Subsidiaries), or afford access to the Company&#8217;s or the Company Subsidiaries&#8217; Representatives, books, records or property, in each case, in connection with, or for the purpose of soliciting, initiating, encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to a Company Acquisition Proposal; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(iii) engage in, enter into, continue or otherwise participate in any discussions or negotiations with any Person (other than Parent or its Representatives) with respect to any Company Acquisition Proposal or any inquiry, proposal or offer that would reasonably be expected to lead to any Company Acquisition Proposal (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that the Company and its Representatives may refer the Person making any such inquiry, proposal or offer to the provisions of this Section&#160;4.2 and make inquiries of a Person making a Company Acquisition Proposal (and its Representatives) to solely clarify the terms of, such Company Acquisition Proposal for the purpose of the Company Board informing itself about such Company Acquisition Proposal); </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) approve, adopt, recommend, agree to or enter into, or publicly propose to approve, adopt, recommend, agree to or enter into, any letter of intent, memorandum of understanding or similar document, agreement, commitment, or agreement in principle with respect to any Company Acquisition Proposal; or </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) resolve or agree to do any of the foregoing; </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that, notwithstanding anything to the contrary contained in this Agreement, prior to obtaining the Required Company Stockholder Vote, the Company and its Representatives may engage or otherwise participate in discussions or negotiations with, and provide information to, any Person (or its Representatives and financing sources and their Representatives) that has made a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">bona fide</div></div> written Company Acquisition Proposal after the date hereof that did not result from any breach of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2(a)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2(c)</div> by the Company, any of the Company Subsidiaries or any of its or their respective Representatives if: (A)&#160;prior to taking any such action, the Company Board determines in good faith, after consultation with the Company&#8217;s outside legal counsel and its financial advisor, that such Company Acquisition Proposal either constitutes a Company Superior Proposal or would reasonably be expected to lead to a Company Superior Proposal; and (B)&#160;prior to providing any information regarding the Company or any Subsidiary of the Company to such third party in response to such Company Acquisition Proposal, the Company receives from such third party (or there is then in effect with such party) an executed confidentiality agreement that contains nondisclosure provisions that are at least as restrictive of such third party as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement and that does not prohibit compliance by the Company with this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2</div>. Prior to or substantially concurrently with providing any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information to such third party, the Company shall make such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information available to Parent (to the extent such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information has not been previously made available by the Company to Parent). The Company shall promptly (and in any event within 48 hours) inform Parent if the Company furnishes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information and/or enters into discussions or negotiations as provided for in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2(a)</div> and will keep Parent reasonably informed, on a current basis (and, in any event, within 48 hours), of the status and material terms of any Company Acquisition Proposal (including any material changes to the material terms thereof) and the status of any material discussions and negotiations with respect thereto. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) If the Company receives a Company Acquisition Proposal (or notice from any Person that it intends to make a Company Acquisition Proposal) or any inquiry or request for information with respect to a Company Acquisition Proposal or that is reasonably likely to lead to a Company Acquisition Proposal, then the Company shall promptly (and in no event later than 48 hours after its receipt of such Company Acquisition Proposal or request) notify Parent in writing of such Company Acquisition Proposal or request (which notification shall include the identity of the Person making or submitting such request or Company </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition Proposal and an unredacted copy of any such written request or proposal (or, if not in writing, the material terms and conditions thereof)), together with copies of any proposed transaction agreements, and the Company shall thereafter keep Parent reasonably informed, on a current basis (and, in any event, within 48 hours), of the status of such Company Acquisition Proposal, including informing Parent of any material change to the terms of such Company Acquisition Proposal, and the status of any negotiations, including any change in its intentions as previously notified. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Promptly following the execution and delivery of this Agreement (and in any event within 24 hours after the execution and delivery of this Agreement), the Company shall, and shall cause each of the Company Subsidiaries and shall instruct their respective Representatives to, promptly cease and cause to be terminated any existing solicitation of, or discussions or negotiations with, any Person (other than Parent and its Representatives) relating to any Company Acquisition Proposal made prior to the date hereof and any access any such Persons may have to any physical or electronic data room relating to any potential Company Acquisition Proposal. The Company shall not, and shall cause its Affiliates not to, release any third party from, or waive, amend or modify any provision of, or grant permission under, or fail to enforce, any standstill provision in any agreement to which the Company or any of its Affiliates is a party, unless the failure to take such action would reasonably be expected to be inconsistent with the Company&#8217;s Board&#8217;s fiduciary duties to the Company and its stockholders under applicable Legal Requirements. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Any violation of the restrictions contained in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2</div> by any of the Company Subsidiaries or any Representatives of the Company or any of the Company Subsidiaries shall be deemed to be a breach of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2</div> by the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.3 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Parent No Solicitation</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Parent will not, and Parent will cause each of the Parent Subsidiaries not to and instruct their respective Representatives not to, except as expressly permitted by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div>, directly or indirectly: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) solicit, initiate, knowingly encourage, knowingly induce, knowingly assist or knowingly facilitate any inquiries regarding, or the submission or announcement by any Person of, any proposal or offer that constitutes, or would reasonably be expected to lead to, any Parent Acquisition Proposal (provided, however, that Parent and its Representatives may refer the Person making such proposal or offer to the provisions of this Section&#160;4.3 and make inquiries of a Person making a Parent Acquisition Proposal (and its Representatives) to solely clarify the terms of, such Parent Acquisition Proposal for the purpose of the Parent Board informing itself about such Parent Acquisition Proposal); </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) furnish any information regarding Parent or any Parent Subsidiary (other than to the Company and the Company Subsidiaries (and their Representatives)), or afford access to Parent&#8217;s or the Parent Subsidiary&#8217;s Representatives, books, records or property, in each case, in connection with, for the purpose of soliciting, initiating, encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes or would reasonably be expected to lead to a Parent Acquisition Proposal; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(iii) engage in, enter into, continue or otherwise participate in any discussions or negotiations with any Person with respect to any Parent Acquisition Proposal or any inquiry, proposal or offer that would reasonably be expected to lead to any Parent Acquisition Proposal (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that Parent and its Representatives may refer the Person making any such inquiry, proposal or offer to the provisions of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div> and make inquiries of a Person making a Parent Acquisition Proposal (and its Representatives) solely to clarify the terms of, such Parent Acquisition Proposal for the purpose of the Parent Board informing itself about such Parent Acquisition Proposal); or </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) approve, adopt, recommend, agree to or enter into, or publicly propose to approve, adopt, recommend, agree to or enter into, any letter of intent, memorandum of understanding or similar document, agreement, commitment, or agreement in principle with respect to any Parent Acquisition Proposal; or </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) resolve or agree to do any of the foregoing; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that, notwithstanding anything to the contrary contained in this Agreement, prior to obtaining the Required Parent Stockholder Vote, Parent and its Representatives may engage or otherwise participate in discussions or negotiations with, and provide information to, any Person (or its Representatives or its financing sources or their Representatives) that has made a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">bona fide</div></div> written Parent Acquisition Proposal after the date hereof that did not result from any breach of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3(a)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3(c)</div> by Parent, any of the Parent Subsidiaries or any of its or their respective Representatives if: (A)&#160;prior to taking any such action, the Parent Board determines in good faith, after consultation with Parent&#8217;s outside legal counsel and its financial advisor, that such Parent Acquisition Proposal either constitutes a Parent Superior Proposal or would reasonably be expected to lead to a Parent Superior Proposal; and (B)&#160;prior to providing any information regarding Parent or any Parent Subsidiary to such third party in response to such Parent Acquisition Proposal, Parent receives from such third party (or there is then in effect with such party) an executed confidentiality agreement that contains nondisclosure provisions that are at least as restrictive of such third party as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement and that does not prohibit compliance by Parent with this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div>. Prior to or substantially concurrently with providing any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information to such third party, Parent shall make such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information available to the Company (to the extent such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information has not been previously made available by Parent to the Company). Parent shall promptly (and in any event within 48 hours) inform the Company if Parent furnishes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information and/or enters into discussions or negotiations as provided for in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3(a)</div> and will keep the Company reasonably informed, on a current basis (and, in any event, within 48 hours), of the status and material terms of any Parent Acquisition Proposal (including any material changes to the material terms thereof) and the status of any material discussions and negotiations with respect thereto. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) If Parent receives a Parent Acquisition Proposal or any inquiry or request for information with respect to a Parent Acquisition Proposal or that is reasonably likely to lead to a Parent Acquisition Proposal, then Parent shall promptly (and in no event later than 48 hours after its receipt of such Parent Acquisition Proposal) notify the Company in writing of such Parent Acquisition Proposal or request (which notification shall include the identity of the Person making or submitting such request or Parent Acquisition Proposal and an unredacted copy of any such written request or proposal (or, if not in writing, the material terms and conditions thereof)), together with copies of any proposed transaction agreements, and Parent shall thereafter keep the Company reasonably informed, on a current basis (and, in any event, within 48 hours), of the status of such Parent Acquisition Proposal or request, including informing the Company of any material change to the terms of such Parent Acquisition Proposal, and the status of any negotiations, including any change in its intentions as previously notified. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Promptly following the execution and delivery of this Agreement (and in any event within 24 hours after the execution and delivery of this Agreement), Parent shall, and shall cause each of the Parent Subsidiaries and shall instruct its and their respective Representatives to, promptly cease and cause to be terminated any existing solicitation of, or discussions or negotiations with, any Person (other than the Company and its Representatives) relating to any Parent Acquisition Proposal made prior to the date hereof and any access any such Persons may have to any physical or electronic data room relating to any potential Parent Acquisition Proposal. Parent shall not, and shall cause its Affiliates not to, release any third party from, or waive, amend or modify any provision of, or grant permission under, or fail to enforce, any standstill provision in any agreement to which Parent or any of its Affiliates is a party unless the failure to take such action would reasonably be expected to be inconsistent with the Parent Board&#8217;s fiduciary duties to Parent and its stockholders under applicable Legal Requirements. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Any violation of the restrictions contained in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div> by any of the Parent Subsidiaries or any Representatives of Parent or any of the Parent Subsidiaries shall be deemed to be a breach of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div> by Parent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.4 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Registration Statement; Joint Proxy Statement/Prospectus</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) As promptly as reasonably practicable after the date of this Agreement, Parent and the Company shall jointly prepare and cause to be filed with the SEC the Joint Proxy Statement/Prospectus, in preliminary form, and Parent shall prepare and cause to be filed with the SEC the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">Statement, in which the Joint Proxy Statement/Prospectus, in preliminary form, will be included as a prospectus. Each of the parties shall: (i)&#160;use reasonable best efforts to cause the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement and the Joint Proxy Statement/ Prospectus to comply in all material respects with all applicable rules, regulations and requirements of the Exchange Act or Securities Act; (ii)&#160;promptly notify the other upon receipt of, and cooperate with each other and use reasonable best efforts to respond to, any comments or requests of the SEC or its staff, including for any amendment or supplement to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement of Joint Proxy Statement/Prospectus; (iii)&#160;promptly provide the other party with copies of all written correspondence and a summary of all oral communications between it or its Representatives, on the one hand, and the SEC or its staff, on the other hand, relating to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement or the Joint Proxy Statement/Prospectus; (iv)&#160;use reasonable best efforts to have the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC; (v)&#160;use reasonable best efforts to keep the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement effective through the Closing in order to permit the consummation of the Mergers; and (vi)&#160;cooperate with, and provide the other party with a reasonable opportunity to review and comment in advance on the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement and the Joint Proxy Statement/Prospectus (including any amendments or supplements to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-4</div> Registration Statement or the Joint Proxy Statement/Prospectus) and any substantive correspondence (including all responses to SEC comments), prior to filing with the SEC or mailing, and shall provide to the other a copy of all such filings or communications made with the SEC, except to the extent such disclosure or communication relates to a Company Acquisition Proposal or Parent Acquisition Proposal. The Company will, prior to filing the preliminary Joint Proxy Statement/Prospectus, obtain all necessary consents of the Company Financial Advisor to permit the Company to include in the Joint Proxy Statement/Prospectus the Company Fairness Opinion. Parent will, prior to filing the preliminary Joint Proxy Statement/Prospectus, obtain all necessary consents of the Parent Financial Advisor to permit Parent to include in the Joint Proxy Statement/Prospectus the Parent Fairness Opinion. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Parent shall advise the Company, promptly after receipt of notice thereof, of the time when the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement becomes effective or any supplement or amendment has been filed, the issuance of any stop order relating thereto, or the suspension of the shares of Parent Class&#160;A Common Stock for offering or sale in any jurisdiction, or any request by the SEC or its staff for any amendment of or supplement to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement or the Joint Proxy Statement/Prospectus or comments thereon and responses thereto or requests by the SEC for additional information, and Parent shall use its reasonable best efforts to as promptly as practicable have any stop order relating to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement or any such suspension of the shares of Parent Class&#160;A Common Stock lifted, reversed or otherwise terminated. Parent shall cause the Joint Proxy Statement/Prospectus to be mailed to Parent&#8217;s stockholders, and the Company shall cause the Joint Proxy Statement/Prospectus to be mailed to the Company&#8217;s stockholders, in each case as promptly as practicable after the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement is declared effective under the Securities Act. Each of the parties shall promptly furnish the other parties all information concerning such party, its Subsidiaries, directors, officers and (to the extent reasonably available to such party) stockholders that may be required by applicable Legal Requirements or reasonably requested by the other party or its Representatives in connection with any action contemplated by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.4</div>. If, at any time prior to obtaining the Required Company Stockholder Vote or Required Parent Stockholder Vote, any party becomes aware of any information that should be disclosed in an amendment or supplement to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement or the Joint Proxy Statement/Prospectus in order to make any statement therein, in the light of the circumstances under which it is made, not false or misleading with respect to a material fact, or in order to avoid the omission of a material fact necessary to make the statements in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement or the Joint Proxy Statement/Prospectus not misleading, then such party: (A)&#160;shall promptly inform the other party thereof; (B)&#160;shall provide the other party (and its counsel) with a reasonable opportunity to review and comment on any amendment or supplement to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement or the Joint Proxy Statement/Prospectus prior to it being filed with the SEC, other than such disclosures that relate to a Company Acquisition Proposal or a Parent Acquisition Proposal; (C)&#160;shall provide the other party with a copy of such amendment or supplement promptly after it is filed with the SEC; and (D)&#160;if mailing is required by law or otherwise appropriate, shall </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cooperate in mailing such amendment or supplement to the stockholders of Parent or the stockholders of the Company. For purposes of the Joint Proxy Statement/Prospectus, any information concerning or related to the Company, its Affiliates, or the Company Stockholder Meeting will be deemed to have been provided by the Company, and any information concerning or related to Parent, its Affiliates, or the Parent Stockholder Meeting will be deemed to have been provided by Parent. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) Prior to the First Effective Time, Parent shall use its reasonable best efforts to take all other actions required to be taken under the Securities Act and the rules and regulations of the SEC promulgated thereunder, the Exchange Act and the rules and regulations of the SEC promulgated thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws and the rules and regulations thereunder, in connection with the issuance of Parent Class&#160;A Common Stock to be issued in the First Merger, including the Parent Class&#160;A Common Stock to be issued upon the exercise of converted Company Options; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that Parent shall not be required to qualify to do business in any jurisdiction in which it is not now so qualified or file a general consent to service of process in any jurisdiction. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.5 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Meeting of the Company</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8217;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">s Stockholders; Company Change in Recommendation</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) The Company: (i)&#160;shall take all action necessary under all applicable Legal Requirements and the Company&#8217;s Organizational Documents to, in consultation with Parent and as promptly as reasonably practicable after the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement is declared effective, duly call, give notice of and initially schedule a meeting of the holders of shares of Company Common Stock (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Stockholder Meeting</div>&#8221;), which to the extent permitted by applicable Legal Requirements, shall be within 45 days thereafter, which meeting will be held to vote on (A)&#160;a proposal to adopt this Agreement; (B)&#160;a proposal for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding,</div> advisory vote of the Company&#8217;s stockholders to approve certain compensation that may become payable to the Company&#8217;s named executive officers in connection with the completion of the Mergers and (C)&#160;an adjournment proposal; and (ii)&#160;shall submit such proposals to, and, except in the case where the Company Board has made a Company Change in Recommendation, use its reasonable best efforts to solicit proxies in favor of the proposal to adopt this Agreement from, such holders at the Company Stockholder Meeting, and the Company shall not submit any other proposals to its stockholders in connection with the Company Stockholder Meeting without the prior written consent of Parent. The Company, in consultation with Parent, shall set a record date for determining the Persons entitled to notice of, and to vote at, the Company Stockholder Meeting. The Company shall ensure that all proxies solicited in connection with the Company Stockholder Meeting are solicited in compliance with all applicable Legal Requirements. Notwithstanding anything to the contrary contained in this Agreement, (A)&#160;the Company shall not postpone or adjourn the Company Stockholder Meeting without the prior written consent of Parent, other than: (1)&#160;to the extent reasonably necessary to ensure that any supplement or amendment to the Joint Proxy Statement/Prospectus that the Company Board has determined in good faith after consultation with outside counsel is required by applicable Legal Requirements is disclosed to the Company&#8217;s stockholders and for such supplement or amendment to be promptly disseminated to the Company&#8217;s stockholders within a reasonable amount of time (as determined by the Company Board in good faith after consultation with outside counsel) prior to the Company Stockholder Meeting; (2)&#160;if required by applicable Legal Requirement or a request from the SEC or its staff; or (3)&#160;if as of the time for which the Company Stockholder Meeting is scheduled there are insufficient shares of Company Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct the business to be conducted at the Company Stockholder Meeting; and (B)&#160;the Company may, and if Parent so requests at any time shall, postpone or adjourn the Company Stockholder Meeting in order to solicit additional proxies in favor of the adoption of this Agreement if, on the date for which the Company Stockholder Meeting is scheduled, there would be insufficient votes to obtain the Required Company Stockholder Vote, whether or not a quorum is present, in which case, except in the case where the Company Board has made a Company Change in Recommendation, the Company shall use its reasonable best efforts during any such postponement or adjournment to solicit and obtain such proxies in favor of the adoption of this Agreement as soon as reasonably practicable; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that (x)&#160;without the prior written consent of Parent (not to be unreasonably withheld, conditioned, or delayed in the cases of clauses (A)(1) and (A)(2)), no single such adjournment or </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">postponement pursuant to clauses (A)&#160;or (B) shall be for more than ten Business Days, except as may be required by applicable Legal Requirements or a request from the SEC or its staff, (y)&#160;the Company shall not be required to effect, and Parent shall not be required to consent to, any such adjournments or postponements that together cause the date of the Company Stockholder Meeting to be more than 20 Business Days after the date for which the Company Stockholder Meeting was originally scheduled or, in the case of the foregoing clauses (A)(3) and (B), less than five Business Days prior to the End Date and (z)&#160;except as required by Legal Requirements in connection with adjournments or postponements of the Company Stockholder Meeting effected in accordance with the foregoing, in no event shall the Company change the record date for determining the stockholders entitled to notice of and to vote at the Company Stockholder Meeting without Parent&#8217;s consent. Subject to the foregoing and applicable Legal Requirements, (I)&#160;the Company shall cooperate with Parent and use its reasonable best efforts to cause the Company Stockholder Meeting to initially be called for the same date as the Parent Stockholder Meeting; and (II)&#160;if, notwithstanding such efforts, the Parent Stockholder Meeting is initially called for a date prior to the Company Stockholder Meeting, the Company shall use its reasonable best efforts to call its meeting on a date that is as promptly as reasonably practicable following the date of the Parent Stockholder Meeting. Upon written request by Parent (which shall not exceed one request per day), the Company shall, during the ten Business Days prior to the date of the Company Stockholder Meeting, advise Parent as to the aggregate number of shares of Company Common Stock entitled to vote at the Company Stockholder Meeting for which proxies have been received by the Company with respect to the Required Company Stockholder Vote and the number of such proxies authorizing the holder thereof to vote in favor of the Required Company Stockholder Vote. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(c)</div>, the Joint Proxy Statement/Prospectus shall include the Company Board Recommendation. Neither the Company Board nor any committee thereof shall, except as otherwise expressly permitted by this Agreement: (i)&#160;withhold, withdraw, modify, amend or qualify (or publicly propose to withdraw, modify, amend or qualify), in a manner adverse to Parent or Acquisition Subs, the Company Board Recommendation, or fail to include the Company Board Recommendation in the Joint Proxy Statement/Prospectus; (ii)&#160;approve, recommend or declare advisable (or publicly propose to do so) any Company Acquisition Proposal; (iii)&#160;fail to publicly announce, within ten Business Days after a tender offer or exchange offer relating to the equity securities of the Company shall have been commenced by any third party other than Parent and its Affiliates (and in no event later than one Business Day prior to the date of the Company Stockholder Meeting, as it may be postponed or adjourned pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(a)</div>), a statement disclosing that the Company Board recommends rejection of such tender or exchange offer (for the avoidance of doubt, the taking of no position or a neutral position by the Company Board in respect of the acceptance of any such tender offer or exchange offer as of the end of such period shall constitute a failure to publicly announce that the Company Board recommends rejection of such tender or exchange offer); or (iv)&#160;if requested by Parent, fail to issue, within ten Business Days after a Company Acquisition Proposal is publicly announced (and in no event later than one Business Day prior to the date of the Company Stockholder Meeting, as it may be postponed or adjourned pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(a)</div>), a press release reaffirming the Company Board Recommendation, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that the Company must receive the request from Parent at least 48 hours prior to such reaffirmation being required; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">further</div></div>, that in no event shall the Company or the Company Board be obligated to publicly reaffirm the Company Board Recommendation on more than one occasion with respect to each such publicly announced Company Acquisition Proposal or on more than one occasion with respect to each publicly announced material modification thereof (any action described in clauses (i)&#160;through (iv) being referred to as a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Change in Recommendation</div>&#8221;); (v) cause or permit the Company to enter into any Contract, letter of intent, memorandum of understanding, agreement in principle or other arrangement or understanding (other than a confidentiality agreement entered into in compliance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2(a)</div>) contemplating or relating to a Company Acquisition Transaction; (vi)&#160;take any action to make the provisions of any anti-takeover or similar statute or regulation inapplicable to any Company Acquisition Proposal or counterparty thereto; or (vii)&#160;publicly propose to do any of the foregoing. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(c) Notwithstanding anything to the contrary contained in this Agreement, at any time prior to obtaining the Required Company Stockholder Vote, the Company Board may make a Company Change in Recommendation related to a Company Acquisition Proposal and/or terminate this Agreement in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(f)</div> if (x)&#160;the Company receives from a third party a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">bona fide</div></div> written Company Acquisition Proposal after the date of this Agreement that did not result from a breach of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2</div>, and has not been withdrawn, and (z)&#160;prior to making such Company Change in Recommendation or terminating this Agreement in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(f)</div>: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) the Company Board determines in good faith, after consultation with the Company&#8217;s outside legal counsel and its financial advisor, that such Company Acquisition Proposal constitutes a Company Superior Proposal and that failure to take such action would reasonably be expected to be inconsistent with the Company Board&#8217;s fiduciary duties to its stockholders under applicable Legal Requirements; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(ii) the Company delivers to Parent a written notice (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Superior Proposal Notice</div>&#8221;) no less than four Business Days in advance stating that the Company Board intends to make a Company Change in Recommendation or terminate this Agreement, which such Company Superior Proposal Notice shall include the identity of the Person making such Company Acquisition Proposal and a copy of such proposal and a draft of the definitive agreement to be entered into in connection therewith (or, if not in writing, the material terms and conditions thereof); and </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(iii)&#160;(A) during the four Business Day period commencing on the date of Parent&#8217;s receipt of such Company Superior Proposal Notice, if requested by Parent, the Company engages in good faith negotiations with Parent regarding a possible amendment of this Agreement so that the Company Acquisition Proposal that is the subject of the Company Superior Proposal Notice ceases to be a Company Superior Proposal; and (B)&#160;after the expiration of the negotiation period described in clause (A)&#160;above, the Company Board determines in good faith, after consultation with its outside legal counsel and its financial advisor, and after taking into account any amendments to this Agreement that Parent and each Acquisition Sub have committed in writing to make as a result of the negotiations contemplated by clause (A)&#160;above and in a manner that would be binding upon Parent and each Acquisition Sub if accepted by the Company, that such Company Acquisition Proposal continues to constitute a Company Superior Proposal; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that if there is any change to any of the financial terms or any other material terms of such Company Acquisition Proposal, the Company shall, in each case, be required to deliver to Parent an additional notice consistent with that described in clause (ii)&#160;above and a new negotiation period under clause &#8220;(A)&#8221; above shall commence (except that the original four Business Day notice period referred to in clause (A)&#160;above shall instead be equal to the longer of (1) 11:59 p.m. New York Time on the second Business Day immediately following Parent&#8217;s receipt of such notice, and (2)&#160;the period remaining under the original four Business Day notice period of clause (A)&#160;above), during which time the Company shall be required to comply with the requirements of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(c)(iii)</div> anew with respect to such additional notice (but substituting the time periods therein with the foregoing two Business Day period). The actions of the Company Board making a determination that a Company Acquisition Proposal constitutes a Company Superior Proposal and the Company&#8217;s authorizing and providing the notices to Parent required by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(c) </div>shall not in and of itself, constitute a Company Change in Recommendation, a violation of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>, or a termination of this Agreement. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Notwithstanding anything to the contrary contained in this Agreement, at any time prior to obtaining the Required Company Stockholder Vote, the Company Board may make a Company Change in Recommendation that is not related to a Company Acquisition Proposal if any state of fact, event, change, effect, circumstance, occurrence or development, or combination thereof, arises following the date of this Agreement (I)&#160;that (x) was neither known to nor reasonably foreseeable by the Company Board as of the date of this Agreement (or, if known to or reasonably foreseeable by the Company Board, the consequences of which were neither known to nor reasonably foreseeable by the Company Board as of the date of this Agreement) and (y)&#160;is material to the Company and the Company Subsidiaries, taken as a whole, and (II)&#160;that is not related to (A)&#160;a Company Acquisition Proposal or a Company Superior Proposal or any inquiry or communications relating thereto, any matter relating thereto or consequences thereof, (B)&#160;in each </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">case in and of itself, any changes in the market price or trading volume of Company Common Stock or the fact that the Company meets, fails to meet or exceeds any internal or published projections, forecasts or estimates of its revenue, earnings or other financial performance or results of operations for any period (it&#160;being understood, however, that any underlying cause of any of the foregoing may be taken into account unless excluded pursuant to clause (A)&#160;or (C)), or (C)&#160;any event, condition or circumstance related to Parent or any of the Parent Subsidiaries (any such state of fact, event, change, effect, circumstance, occurrence, development, condition, circumstance, or combination thereof, being referred to as a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Intervening Event</div>&#8221;); and, prior to making such Company Change in Recommendation, (1)&#160;the Company Board determines in good faith, after consultation with its outside legal counsel and its financial advisor, that, in light of such Company Intervening Event, a failure to effect a Company Change in Recommendation would reasonably be expected to be inconsistent with the Company Board&#8217;s fiduciary duties to its stockholders under applicable Legal Requirements; (2)&#160;less than four Business Days prior to the making of such Company Change in Recommendation, Parent receives a written notice from the Company confirming that the Company Board intends to effect such Company Change in Recommendation, specifying the reasons therefor in reasonable detail; (3)&#160;during such four Business Day period, if requested by Parent, the Company engages in good faith negotiations with Parent to amend this Agreement in such a manner that obviates the need for the Company Board to effect a Company Change in Recommendation; and (4)&#160;following the end of such four Business Day period, the Company Board determines in good faith, after consultation with its outside legal counsel and financial advisor and after taking into account any amendments to this Agreement that Parent and each Acquisition Sub have committed in writing to make as a result of the negotiations contemplated by clause (3)&#160;above and in a manner that would be binding upon Parent and each Acquisition Sub if accepted by the Company, that, in light of such Company Intervening Event, a failure to effect a Company Change in Recommendation would reasonably be expected to be inconsistent with the Company Board&#8217;s fiduciary duties to its stockholders under applicable Legal Requirements, even if such changes committed to in writing were to be given effect. The actions of the Company Board making a determination that a Company Intervening Event has occurred and the Company&#8217;s authorizing and providing the notices to Parent required by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(d)</div> shall not in and of itself, constitute a Company Change in Recommendation or a violation of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) Notwithstanding any Company Change in Recommendation, unless this Agreement has been earlier terminated in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1</div>, this Agreement shall be submitted to the holders of shares of Company Common Stock at the Company Stockholder Meeting for the purpose of voting on the adoption of this Agreement and nothing contained in this Agreement shall be deemed to relieve the Company of such obligation. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) Nothing contained in this Agreement shall prohibit the Company, the Company Board or their Representatives from (i)&#160;taking and disclosing to the stockholders of the Company a position contemplated by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14e-2,</div> Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14d-9</div> or Item 1012 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-A</div> promulgated under the Exchange Act or issuing a &#8220;stop, look and listen&#8221; statement to the stockholders of the Company pursuant to Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14d-9(f)</div> promulgated under the Exchange Act pending disclosure of its position thereunder or (ii)&#160;directing any Person (or the Representative of that Person) who makes a Company Acquisition Proposal to the provisions of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that in the case of either clause (i)&#160;or clause (ii), no such communication or statement that would constitute a Company Change in Recommendation shall be permitted, made or taken except in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(c)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(d)</div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(g) Any violation of the restrictions contained in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div> by any of the Company&#8217;s Subsidiaries, or any Representatives of the Company or any of the Company Subsidiaries, shall be deemed to be a breach of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div> by the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.6 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Meeting of Parent</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8217;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">s Stockholders; Parent Change in Recommendation</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Parent: (i)&#160;shall take all action necessary under all applicable Legal Requirements and Parent&#8217;s Organizational Documents to, in consultation with the Company as promptly as reasonably practicable after the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-4</div> Registration Statement is declared effective, duly call, give notice of and initially schedule a </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">meeting of the holders of shares of Parent Common Stock (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Stockholder Meeting</div>&#8221;), which to the extent permitted by applicable Legal Requirements, shall be within 45 days thereafter, which meeting will be held to vote on a proposal to approve the Parent Share Issuance; and (ii)&#160;shall submit such proposal to, and, except in the case where the Parent Board has made a Parent Change in Recommendation, use its reasonable best efforts to solicit proxies in favor of such proposal from, such holders at the Parent Stockholder Meeting, and Parent shall not submit any other proposal to its stockholders in connection with the Parent Stockholder Meeting without the prior written consent of the Company. Parent, in consultation with the Company, shall set a record date for determining the Persons entitled to notice of, and to vote at, the Parent Stockholder Meeting. Parent shall ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Legal Requirements. Notwithstanding anything to the contrary contained in this Agreement, (A)&#160;Parent shall not postpone or adjourn the Parent Stockholder Meeting without the prior written consent of the Company, other than: (1)&#160;to the extent reasonably necessary to ensure that any supplement or amendment to the Joint Proxy Statement/Prospectus that the Parent Board has determined in good faith after consultation with outside counsel is required by applicable Legal Requirements is disclosed to Parent&#8217;s stockholders and for such supplement or amendment to be promptly disseminated to Parent&#8217;s stockholders within a reasonable amount of time (as determined by the Parent Board in good faith after consultation with outside counsel) prior to the Parent Stockholder Meeting; (2)&#160;if required by applicable Legal Requirement or a request from the SEC or its staff; or (3)&#160;if as of the time for which the Parent Stockholder Meeting is scheduled there are insufficient shares of Parent Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct the business to be conducted at the Parent Stockholder Meeting; and (B)&#160;Parent may, and if the Company so requests at any time shall, postpone or adjourn the Parent Stockholder Meeting in order to solicit additional proxies in favor of the approval of the Parent Share Issuance, if, on the date for which the Parent Stockholder Meeting is scheduled, there would be insufficient votes to obtain the Required Parent Stockholder Vote, whether or not a quorum is present, in which case, except in the case where the Parent Board has made a Parent Change in Recommendation, Parent shall use its reasonable best efforts during any such postponement or adjournment to solicit and obtain such proxies in favor of the approval of the Parent Share Issuance as soon as reasonably practicable; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that (x)&#160;without the prior written consent of the Company (not to be unreasonably withheld, conditioned, or delayed in the cases of clauses (A)(1) and (A)(2)), no single such adjournment or postponement pursuant to clauses (A)&#160;or (B) shall be for more than ten Business Days, except as may be required by applicable Legal Requirements or a request from the SEC or its staff, (y)&#160;Parent shall not be required to effect, and the Company shall not be required to consent to, any such adjournments or postponements that together cause the date of the Parent Stockholder Meeting to be more than twenty Business Days after the date for which the Parent Stockholder Meeting was originally scheduled or, in the case of the foregoing clauses (A)(3) and (B), less than four Business Days prior to the End Date and (z)&#160;except as required by Legal Requirements in connection with adjournments or postponements of the Parent Stockholder Meeting effected in accordance with the foregoing, in no event shall Parent change the record date for determining the stockholders entitled to notice of and to vote at the Parent Stockholder Meeting without the Company&#8217;s consent. Subject to the foregoing and applicable Legal Requirements, (I)&#160;Parent shall cooperate with the Company and use its reasonable best efforts to cause the Parent Stockholder Meeting to initially be called for the same date as the Company Stockholder Meeting; and (II)&#160;if, notwithstanding such efforts, the Company Stockholder Meeting is initially called for a date prior to the Parent Stockholder Meeting, Parent shall use its reasonable best efforts to call its meeting on a date that is as promptly as reasonably practicable following the date of the Company Stockholder Meeting. Upon request of the Company (which shall not exceed one request per day), Parent shall, during the ten Business Days prior to the date of the Company Stockholder Meeting, advise the Company as to the aggregate number of shares of Parent Common Stock entitled to vote at the Parent Stockholder Meeting for which proxies have been received by Parent with respect to the Required Parent Stockholder Vote and the number of such proxies authorizing the holder thereof to vote in favor of the Required Parent Stockholder Vote. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(c)</div>, the Joint Proxy Statement/Prospectus shall include the Parent Board Recommendation. Neither the Parent Board nor any committee thereof shall, except as otherwise expressly </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">permitted by this Agreement: (i)&#160;withhold, withdraw, modify, amend or qualify (or publicly propose to withdraw, modify, amend or qualify), in a manner adverse to the Company, the Parent Board Recommendation, or fail to include the Parent Board Recommendation in the Joint Proxy Statement/Prospectus; (ii)&#160;approve, recommend or declare advisable (or publicly propose to do so) any Parent Acquisition Proposal; (iii)&#160;fail to publicly announce, within ten Business Days after a tender offer or exchange offer relating to the equity securities of Parent shall have been commenced by any third party (and in no event later than one Business Day prior to the date of the Parent Stockholder Meeting, as it may be postponed or adjourned pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(a)</div>), a statement disclosing that the Parent Board recommends rejection of such tender or exchange offer (for the avoidance of doubt, the taking of no position or a neutral position by the Parent Board in respect of the acceptance of any such tender offer or exchange offer as of the end of such period shall constitute a failure to publicly announce that the Parent Board recommends rejection of such tender or exchange offer); or (iv)&#160;if requested by the Company, fail to issue, within ten Business Days after a Parent Acquisition Proposal is publicly announced (and in no event later than one Business Day prior to the date of the Parent Stockholder Meeting, as it may be postponed or adjourned pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(a)</div>), a press release reaffirming the Parent Board Recommendation <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that Parent must receive the request from the Company at least 48 hours prior to such reaffirmation being required; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">further</div></div>, that in no event shall Parent or the Parent Board be obligated to publicly reaffirm the Parent Board Recommendation on more than one occasion with respect to each such publicly announced Company Acquisition Proposal or on more than one occasion with respect to each publicly announced material modification thereof (any action described in clauses (i)&#160;through (iv) being referred to as a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Change in Recommendation</div>&#8221;); (v) cause or permit Parent to enter into any Contract, letter of intent, memorandum of understanding, agreement in principle or other arrangement or understanding (other than a confidentiality agreement entered into in compliance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3(a)</div>) contemplating or relating to a Parent Acquisition Transaction; (vi)&#160;take any action to make the provisions of any anti-takeover or similar statute or regulation inapplicable to any Parent Acquisition Proposal or counterparty thereto; or (vii)&#160;publicly propose to do any of the foregoing. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) Notwithstanding anything to the contrary contained in this Agreement, at any time prior to obtaining the Required Parent Stockholder Vote, the Parent Board may make a Parent Change in Recommendation related to a Parent Acquisition Proposal if and only if (x)&#160;Parent receives from a third party a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">bona fide</div></div> written Parent Acquisition Proposal after the date of this Agreement that did not result from a breach of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div>, and has not been withdrawn, and (z)&#160;prior to making such Parent Change in Recommendation: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) the Parent Board determines in good faith, after consultation with Parent&#8217;s outside legal counsel and its financial advisor, that such Parent Acquisition Proposal constitutes a Parent Superior Proposal and that failure to take such action would reasonably be expected to be inconsistent with the Parent Board&#8217;s fiduciary duties to Parent and its stockholders under applicable Legal Requirements; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(ii) Parent delivers to the Company a written notice (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Superior Proposal Notice</div>&#8221;) no less than four Business Days in advance stating that the Parent Board intends to make a Parent Change in Recommendation, which Parent Superior Proposal Notice shall include the identity of the Person making such Parent Acquisition Proposal and a copy of such proposal and a draft of the definitive agreement to be entered into in connection therewith (or, if not in writing, the material terms and conditions thereof); and </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii)&#160;(A) during the four Business Day period commencing on the date of the Company&#8217;s receipt of such Parent Superior Proposal Notice, if requested by the Company, Parent engages in good faith negotiations with the Company regarding a possible amendment of this Agreement so that the Parent Acquisition Proposal that is the subject of the Parent Superior Proposal Notice ceases to be a Parent Superior Proposal; and (B)&#160;after the expiration of the negotiation period described in clause (A)&#160;above and in a manner that would be binding upon Parent and each Acquisition Sub if accepted by the Company, the Parent Board determines in good faith, after consultation with its outside legal counsel and its financial advisor, and after taking into account any amendments to this Agreement that the Company has committed in writing to make as a result of the negotiations contemplated by clause (A)&#160;above, that such Parent </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;">Acquisition Proposal continues to constitute a Parent Superior Proposal <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that if there is any change to any of the financial terms or any other material terms of such Parent Acquisition Proposal, Parent shall, in each case, be required to deliver to the Company an additional notice consistent with that described in clause (ii)&#160;above and a new negotiation period under clause &#8220;(A)&#8221; above shall commence (except that the original four Business Day notice period referred to in clause &#8220;(A)&#8221; above shall instead be equal to the longer of (1) 11:59 p.m. New York Time on the second Business Day immediately following the Company&#8217;s receipt of such notice, and (2)&#160;the period remaining under the original four Business Day notice period of clause &#8220;(A)&#8221; above), during which time Parent shall be required to comply with the requirements of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(c)(iii)</div> anew with respect to such additional notice (but substituting the time periods therein with the foregoing two Business Day period). The actions of the Parent Board making a determination that a Parent Acquisition Proposal constitutes a Parent Superior Proposal and Parent&#8217;s authorizing and providing the notices to the Company required by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(c)</div> shall not in and of itself, constitute a Parent Change in Recommendation or a violation of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div>. </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Notwithstanding anything to the contrary contained in this Agreement, at any time prior to obtaining the Required Parent Stockholder Vote, the Parent Board may make a Parent Change in Recommendation that is not related to a Parent Acquisition Proposal if any state of fact, event, change, effect, circumstance, occurrence or development, or combination thereof, arises following the date of this Agreement (I)&#160;that (x) was neither known to nor reasonably foreseeable by the Parent Board as of the date of this Agreement (or, if known to or reasonably foreseeable by the Parent Board, the consequences of which were neither known to nor reasonably foreseeable by the Parent Board as of the date of this Agreement) and (y)&#160;is material to Parent and the Parent Subsidiaries, taken as a whole, and (II)&#160;that is not related to (A)&#160;a Parent Acquisition Proposal or a Parent Superior Proposal or any inquiry or communications relating thereto, any matter relating thereto or consequences thereof, (B)&#160;in each case in and of itself, any changes in the market price or trading volume of Parent Class&#160;A Common Stock or the fact that Parent meets, fails to meet or exceeds any internal or published projections, forecasts or estimates of its revenue, earnings or other financial performance or results of operations for any period (it being understood, however, that any underlying cause of any of the foregoing may be taken into account unless excluded pursuant to clauses (A)&#160;or (C)), or (C)&#160;any event, condition or circumstance related to the Company or any of the Company Subsidiaries (any such state of fact, event, change, effect, circumstance, occurrence, development, condition, circumstance, or combination thereof, being referred to as a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Intervening Event</div>&#8221;); and, prior to making such Parent Change in Recommendation, (1)&#160;the Parent Board determines in good faith, after consultation with its outside legal counsel and its financial advisor, that, in light of such Parent Intervening Event, a failure to effect a Parent Change in Recommendation would reasonably be expected to be inconsistent with the Parent Board&#8217;s fiduciary duties to Parent and its stockholders under applicable Legal Requirements; (2)&#160;less than four Business Days prior to the making of such Parent Change in Recommendation, the Company receives a written notice from Parent confirming that the Parent Board intends to effect such Parent Change in Recommendation, specifying the reasons therefor in reasonable detail; (3)&#160;during such four Business Day period, if requested by the Company, Parent engages in good faith negotiations with the Company to amend this Agreement in such a manner that obviates the need for the Parent Board to effect a Parent Change in Recommendation; and (4)&#160;following the end of such four Business Day period, the Parent Board determines in good faith, after consultation with its outside legal counsel and financial advisor and after taking into account any amendments to this Agreement that the Company has committed in writing to make as a result of the negotiations contemplated by clause (3)&#160;above and in a manner that would be binding upon the Company if accepted by Parent, that, in light of such Parent Intervening Event, a failure to effect a Parent Change in Recommendation would reasonably be expected to be inconsistent with the Parent Board&#8217;s fiduciary duties to its stockholders under applicable Legal Requirements, even if such changes committed to in writing were to be given effect. The actions of the Parent Board making a determination that a Parent Intervening Event has occurred and Parent&#8217;s authorizing and providing the notices to the Company required by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(d)</div> shall not in and of itself constitute a Parent Change in Recommendation or a violation of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div>. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(e) Notwithstanding any Parent Change in Recommendation, unless this Agreement has been earlier terminated in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1</div>, the Parent Share Issuance shall be submitted to the holders of shares of Parent Common Stock at the Parent Stockholder Meeting for the purpose of the approval of the Parent Share Issuance and nothing contained in this Agreement shall be deemed to relieve the Parent of such obligation. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) Nothing contained in this Agreement shall prohibit Parent, the Parent Board or their Representatives from (i)&#160;taking and disclosing to the stockholders of Parent a position contemplated by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14e-2,</div> Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14d-9</div> or Item 1012 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">M-A</div> promulgated under the Exchange Act or issuing a &#8220;stop, look and listen&#8221; statement to the stockholders of Parent pursuant to Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14d-9(f)</div> promulgated under the Exchange Act pending disclosure of its position thereunder or (ii)&#160;directing any Person (or the Representative of that Person) who makes a Parent Acquisition Proposal to the provisions of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div>; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that in the case of either clause (i)&#160;or clause (ii), no such communication or statement that would constitute a Parent Change in Recommendation shall be permitted, made or taken except in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(c)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(d)</div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(g) Any violation of the restrictions contained in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div> by any of Parents&#8217; Subsidiaries, or any Representatives of Parent or the Parent Subsidiaries shall be deemed to be a breach of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div> by Parent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.7 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filings; Other Action</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Subject to the terms and conditions of this Agreement, each of the parties hereto shall cooperate with the other and use (and shall cause their respective Subsidiaries to use) their respective reasonable best efforts to: (i)&#160;take, or cause to be taken, all actions, and do, or cause to be done, all things, necessary to cause the conditions to Closing to be satisfied as promptly as reasonably practicable (and in any event no later than the End Date) and to consummate and make effective, as promptly as practicable, the transactions contemplated by this Agreement, including preparing and filing promptly and fully all documentation to effect all necessary filings, notifications, notices, petitions, statements, registrations, submissions of information, applications and other documents (including any required or recommended filings under applicable Antitrust Laws) that are or may become necessary in connection with the consummation of the transactions contemplated by this Agreement; (ii)&#160;obtain as promptly as reasonably practicable (and in any event no later than the End Date) all approvals, consents, clearances, expirations or terminations of waiting periods, registrations, permits, authorizations and other confirmations from any Governmental Entity or third party that are or may become necessary to consummate the transactions contemplated by this Agreement; (iii)&#160;obtain all necessary consents, approvals or waivers from third parties. For purposes of this Agreement, &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Antitrust Laws</div>&#8221; shall mean the Sherman Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade Commission Act, as amended, and all other applicable Legal Requirements issued by a Governmental Entity that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening of competition through merger or acquisition. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Each party shall use their respective reasonable best efforts to file, as soon as practicable and advisable after the date of this Agreement, all notices, reports and other documents required to be filed by such party with any Governmental Entity with respect to the Mergers and the other transactions contemplated by this Agreement, and to submit as promptly as reasonably practicable any additional information requested by any such Governmental Entity. Without limiting the generality of the foregoing, each of Parent and the Company shall, in consultation and cooperation with the other, within 10 Business Days after the date of this Agreement (or such other date as may be mutually agreed to by Parent and the Company), prepare and file the notifications required under the HSR Act. Parent and the Company shall use their respective reasonable best efforts to respond as promptly as reasonably practicable to any inquiries or requests for additional information or documentary material received from any state attorney general, antitrust authority or other Governmental Entity in connection with antitrust or related matters. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(c) Subject to the provisions of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement, Parent and the Company each shall promptly supply the other with any information that may be required in order to effectuate any filings (including applications) pursuant to (and to otherwise comply with its obligations set forth in) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7(a)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7(b)</div>. Each of Parent and the Company, as it deems advisable and necessary, may reasonably designate competitively sensitive material provided to the other as &#8220;outside counsel only&#8221; or with similar restrictions. Each of Parent and the Company may also reasonably redact material as necessary to (i)&#160;comply with other contractual arrangements or applicable Legal Requirements or (ii)&#160;prevent the loss of protection under the attorney-client privilege or the attorney work product doctrine but shall use commercially reasonable efforts to allow for such disclosure (or as much of it as possible) in a manner that does not result in a violation of contractual arrangements, or Legal Requirements, or a loss of attorney-client privilege. Such materials and the information contained therein shall be given only to the outside legal counsel of the recipient, or otherwise as the restriction indicates, and be subject to any additional confidentiality or joint defense agreement between the parties. Except where prohibited by applicable Legal Requirements or any Governmental Entity, and subject to the provisions of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement, each of Parent and the Company shall: (i)&#160;consult with the other in good faith prior to taking a position with respect to any filing required or advisable pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7(a)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7(b)</div>; (ii) permit the other to review and discuss in advance, and consider in good faith the views of the other in connection with, any analyses, appearances, presentations, memoranda, letters, responses to requests, briefs, white papers, arguments, opinions and proposals before making or submitting any of the foregoing to any Governmental Entity by or on behalf of any party in connection with any such filing or any Legal Proceeding in connection with this Agreement or the transactions contemplated hereby; (iii)&#160;coordinate with the other in preparing and exchanging such information; (iv)&#160;promptly provide the other party&#8217;s counsel with copies of all filings, notices, analyses, presentations, memoranda, letters, responses to requests, briefs, white papers, opinions, proposals and other submissions (and a summary of any oral presentations) made or submitted by such party with or to any Governmental Entity in connection with any filing required by <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7(a)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7(b)</div> in connection with this Agreement or the transactions contemplated hereby; and (v)&#160;consult with the other party in advance of any meeting, video conference or teleconference with any Governmental Entity or, in connection with any proceeding by a private party, with any other Person, and, to the extent not prohibited by the Governmental Entity or other Person, give the other party the opportunity to attend and participate in such meetings, video conferences and teleconferences. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Without limiting the generality of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7(a)</div>, Parent shall use reasonable best efforts to take, or cause to be taken, all actions necessary to avoid or eliminate each and every impediment under any Antitrust Laws to enable the parties to close the transactions contemplated by this Agreement as promptly as practicable, and in any event prior to the End Date, including proposing, negotiating, committing to and effecting, whether by consent decree, hold separate orders, or otherwise, to sell, divest, hold separate, lease, license, transfer, dispose of, commit to behavioral or conduct remedies, or otherwise encumber, limit or impair or take any other action with respect to Parent&#8217;s or any of its Subsidiaries&#8217; ability to own or operate any assets, properties, businesses or product lines of Parent or any of its Subsidiaries or any assets, properties, businesses or product lines of the Company or any of its Subsidiaries; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that, notwithstanding anything to the contrary set forth in this Agreement, (I)&#160;the Company and the Company Subsidiaries shall not enter into or make any consents, offers, agreements or commitments with respect to the actions contemplated by clauses (i)&#160;and (ii) except as and to the extent requested in writing by Parent as to actions that are conditioned upon the consummation of the Mergers, (II)&#160;no party shall be required pursuant to the foregoing to commit to or effect any action that is not conditioned upon the consummation of the Mergers, and (III)&#160;Parent shall not be required to (x)&#160;sell, divest, exclusively license, hold separate, or otherwise dispose of, or (y)&#160;grant any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license, accept any operational restrictions or take or commit to any actions which restrictions or actions would limit Parent&#8217;s or any of its Affiliates&#8217; freedom of action with respect to assets, licenses, product lines, operations or businesses of Parent, the Company or any of their respective Subsidiaries that, individually or in the aggregate, would reasonably be expected to have an (A)&#160;Effect that results in a material adverse effect on the results of operations of the Company and the Company Subsidiaries, taken as a whole, or (B)&#160;Effect that results in a material adverse effect on the results </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">of operations of the Parent and the Parent Subsidiaries, taken as a whole; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that for purposes of determining whether an Effect is or would be materially adverse to the results of operations of Parent and the Parent Subsidiaries, taken as a whole, Parent and the Parent Subsidiaries, taken as a whole, shall be deemed to be the same size (in operations and from a financial point of view) as the Company and the Company Subsidiaries, taken as a whole. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) Notwithstanding anything to the contrary contained in this Agreement, without the prior written consent of Parent, neither the Company nor any of the Company Subsidiaries will grant or offer to grant any accommodation or concession (financial or otherwise) to any third party in connection with seeking or obtaining its consent to the transactions contemplated by this Agreement. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) In furtherance and not in limitation of the covenants of the parties contained in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7</div>, if any administrative or judicial action or proceeding, including any proceeding by a private party, is instituted (or threatened to be instituted) challenging any transaction contemplated by this Agreement as violative of any Antitrust Law, each of Parent and the Company shall use reasonable best efforts to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment, injunction or other order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation of the transactions contemplated by this Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.8 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Access</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) Upon reasonable prior notice, the Company shall afford Parent and its Representatives reasonable access, during normal business hours throughout the period prior to the First Effective Time, to the Company&#8217;s and the Company Subsidiaries&#8217; personnel, properties, Contracts, filings with Governmental Entities and books and records and, during such period, the Company shall furnish promptly to Parent all available information concerning its business as Parent may reasonably request; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that the Company shall not be required to permit any inspection or provide other access, or to disclose any information, that in the reasonable judgment of the Company would: (i)&#160;violate any obligation of the Company with respect to confidentiality or privacy; (ii)&#160;jeopardize protections afforded the Company under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-client</div> privilege, the attorney work product doctrine or similar legal privilege or protection; (iii)&#160;violate any Legal Requirement; or (iv)&#160;result in the disclosure of any trade secrets of any third parties, competitively sensitive information, information concerning the valuation of the Company or any of the Company Subsidiaries or personal information that would expose the Company to the risk of liability; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that in each case the Company shall inform Parent of the nature of the information being withheld, and shall use its commercially reasonable best efforts to make alternative arrangements that would allow Parent (or its applicable Representative) access to such information. All information obtained by or provided to Parent and its Representatives pursuant to this Agreement shall be treated as &#8220;Confidential Information&#8221; of the Company for purposes of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Upon reasonable prior notice, Parent shall afford the Company and its Representatives reasonable access, during normal business hours throughout the period prior to the First Effective Time, to Parent&#8217;s and the Parent Subsidiaries&#8217; personnel, properties, Contracts, filings with Governmental Entities and books and records and, during such period, Parent shall furnish promptly to the Company all available information concerning its business as the Company may reasonably request; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that Parent shall not be required to permit any inspection or provide other access, or to disclose any information, that in the reasonable judgment of Parent would: (i)&#160;violate any obligation of Parent with respect to confidentiality or privacy; (ii)&#160;jeopardize protections afforded Parent under the attorney-client privilege, the attorney work product doctrine or similar legal privilege or protection; (iii)&#160;violate any Legal Requirement; or (iv)&#160;result in the disclosure of any trade secrets of any third parties, competitively sensitive information, information concerning the valuation of Parent or any of the Parent Subsidiaries or personal information that would expose Parent to the risk of liability; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that in each case Parent shall inform the Company of the nature of the information being withheld, and shall use its commercially reasonable best efforts to make alternative arrangements that would allow the Company (or its Representatives) access to such information. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">All information obtained by or provided to the Company and its Representatives pursuant to this Agreement shall be treated as &#8220;Confidential Information&#8221; of Parent for purposes of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) To the extent that any of the information or material furnished pursuant to this Agreement may include material subject to the attorney-client privilege, work product doctrine or any other applicable privilege, the parties understand and agree that they have a commonality of interest with respect to such matters and it is their desire, intention and mutual understanding that the sharing of such material is not intended to, and shall not, waive or diminish in any way the confidentiality of such material or its continued protection under the attorney-client privilege, work product doctrine or any other applicable privilege. All such information that is entitled to protection under the attorney-client privilege, work product doctrine or any other applicable privilege shall remain entitled to such protection under these privileges, this Agreement, and under the joint defense doctrine. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) No exchange of information or investigation by Parent or its Representatives shall affect or be deemed to affect, modify or waive the representations and warranties of the Company set forth in this Agreement. No exchange of information or investigation by the Company or its Representatives shall affect or be deemed to affect, modify or waive the representations and warranties of Parent set forth in this Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.9 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Acquisition Sub Consents; Parent Vote</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) During the period from the date of this Agreement through the earlier of the First Effective Time or the date of termination of this Agreement, the Acquisition Subs shall not engage in any activities of any nature except as provided in or contemplated by this Agreement. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) Parent shall ensure that each Acquisition Sub duly performs, satisfies and discharges on a timely basis each of the covenants, obligations and liabilities of such Acquisition Sub under this Agreement, and Parent shall be jointly and severally liable with each Acquisition Sub for the due and timely performance and satisfaction of each such covenant, obligation and liability. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Immediately following the execution of this Agreement, Parent shall execute and deliver, in accordance with the DGCL and DLLCA, as applicable, and in its capacity as the sole stockholder of Acquisition Sub I and sole member of Acquisitions Sub II, a written consent adopting this Agreement on behalf of Acquisition Sub I and Acquisition Sub II respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.10 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Publicity</div></div>. Parent and the Company shall consult with one another prior to issuing, and shall provide each other with the opportunity to review and comment upon, any public announcement, statement or other disclosure with respect to this Agreement or the Mergers and shall not issue any such public announcement or statement prior to such consultation, except as may be required by applicable Legal Requirement or by the rules and regulations of Nasdaq (in which event Parent or the Company, as applicable, shall endeavor, on a basis reasonable under the circumstances, to provide a meaningful opportunity to the other party to review and comment upon such public announcement or statement in advance, and shall give due consideration to all reasonable additions, deletions or changes suggested thereto by Parent or the Company, as applicable); <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that (i)&#160;each of the Company and Parent may make public announcements, statements or other disclosures concerning this Agreement or the Mergers that consist solely of information previously disclosed in previous public announcements, statements or other disclosures made by the Company and/or Parent in compliance with this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.10</div>, (ii) each of the Company and Parent may make any public statements in response to questions by the press, analysts, investors or those participating in investor calls or industry conferences, so long as such statements consist solely of information previously disclosed in previous press releases, public disclosures or public statements made by the Company and/or Parent in compliance with this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.10</div>, (iii) the Company need not consult with Parent in connection with any public announcement, statement or other disclosure to be issued or made with respect to any Company Acquisition Proposal or Company Change in Recommendation, in each case, in compliance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>; and (iv)&#160;Parent need not consult with the Company in connection with any public announcement, statement or other disclosure to be issued or made with respect to any </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;">Parent Change in Recommendation, in each case, in compliance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div>. The Company and Parent agree to issue the previously agreed upon form of joint press release announcing the execution and delivery of this Agreement promptly following the execution of this Agreement. </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.11 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Matters</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) During the period commencing on the Closing Date and ending on the first anniversary of the Closing Date, Parent shall, or shall cause one of the Parent Subsidiaries (including the Surviving Company and its Subsidiaries) to provide: (i)&#160;each employee of the Company or any Subsidiary of the Company who continues employment with Parent or any of the Parent Subsidiaries (including the Surviving Company or any of its Subsidiaries) after the Second Effective Time (a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Continuing Employee</div>&#8221;) with (A)&#160;an annual base salary or base wage rate that is, and (B)&#160;a target annual cash bonus opportunity that, taken together with the annual base salary or base wage rate provided to such Continuing Employee after the First Effective Time is, in each case, no less favorable than provided to such Continuing Employee by the Company immediately prior to the First Effective Time; and (ii)&#160;each Continuing Employee with employee welfare and retirement benefits (excluding any benefits provided under any defined benefit pension plan or post-retirement medical plan) that are substantially comparable or more favorable in the aggregate to those provided to such Continuing Employee by the Company and the Company Subsidiaries immediately prior to the First Effective Time. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) All service of the Continuing Employees to the Company and the Company Subsidiaries and their respective predecessors shall be recognized for purposes of determining eligibility to participate, vesting and accrual and level of benefits with respect to each Parent Plan in which any Continuing Employee will participate after the Second Effective Time (excluding any defined benefit pension or post-retirement medical plan) to at least the same extent as such similarly situated Parent Employees are entitled to credit for service under such Parent Plans, except to the extent such recognition would result in the duplication of benefits. In addition, Parent or the Subsidiaries of Parent (including the Surviving Company and its Subsidiaries), as applicable, shall use commercially reasonable efforts to cause each Parent Plan that is a welfare benefit plan, within the meaning of Section&#160;3(1) of ERISA to: (i)&#160;waive all limitations as to preexisting conditions, exclusions and waiting periods with respect to participation and coverage requirements other than preexisting condition limitations, exclusions or waiting periods that are already in effect with respect to such Continuing Employees and that have not been satisfied or waived as of the First Effective Time under the analogous welfare benefit plan maintained for the Continuing Employees immediately prior to the First Effective Time; and (ii)&#160;recognize for each Continuing Employee and his or her spouse, domestic partner and dependents for purposes of applying annual deductible, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> maximums under such Parent Plan any deductible, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses paid by the Continuing Employee and his or her spouse, domestic partner and dependents under an analogous Company Plan during the plan year of such plan in which occurs the date on which the Continuing Employee begins participation in such Parent Plan, except to the extent such recognition would result in the duplication of benefits. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) If requested by Parent not less than ten Business Days before the Closing Date, the Company Board (or the appropriate committee thereof) shall adopt resolutions and take such corporate action as is reasonably necessary to terminate the Company&#8217;s 401(k) plan (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company 401(k) Plan</div>&#8221;), effective as of the day prior to the Closing Date. In the event that Parent requests that the Company 401(k) Plan be terminated, (i)&#160;the Company shall provide Parent with evidence that such plan has been terminated (the form and substance of which shall be subject to reasonable prior review and comment by Parent) not later than the day preceding the Closing Date and (ii)&#160;following the Second Effective Time and as soon as reasonably practicable following receipt of a favorable determination letter from the IRS on the termination of the Company 401(k) Plan, to the extent that Parent requests that the Company seek such determination letter, the assets thereof shall be distributed to the participants, and Parent shall permit the Continuing Employees who are then actively employed to make rollover contributions of &#8220;eligible rollover distributions&#8221; (within the meaning of Section&#160;401(a)(31) of the Code, inclusive of loans) to Parent&#8217;s 401(k) Plan, in the form of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cash, in an amount equal to the full account balance (including any promissory notes) distributed to such Continuing Employees from the Company 401(k) Plan. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Nothing in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.11</div> or elsewhere in this Agreement, expressed or implied, shall be construed to create a right in any employee of the Company or any of the Company Subsidiaries to employment with Parent, the Surviving Company or any of their Subsidiaries or shall interfere with or restrict in any way the rights of Parent or any of its Affiliates, which rights are hereby expressly reserved, to discharge or terminate the services of any Continuing Employee at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between Parent, the Company or any of their respective Affiliates and the Continuing Employee. Nothing in this Agreement shall be deemed to amend or modify any compensation or benefit arrangement of Parent, the Company, or their respective Affiliates. Nothing herein shall be construed to limit the right of Parent, the Surviving Company or any of their Subsidiaries to amend or terminate any Parent Plan, any Company Plan, or any other employee benefit plan. Notwithstanding any provision in this Agreement to the contrary, nothing in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.11</div> shall create any third party rights, benefits or remedies of any nature whatsoever in any employee of the Company or any of the Company Subsidiaries (or any beneficiaries or dependents thereof) or any other Person that is not a party to this Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.12 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Certain Tax Matters</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) For U.S. federal income Tax purposes, (i)&#160;the parties hereto intend that the Mergers will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Intended Tax Treatment</div>&#8221;) and (ii)&#160;this Agreement is intended to be, and is hereby adopted as, a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;1.368-2(g)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.368-3(a),</div> to which the Parent, each Acquisition Sub and the Company are parties under Section&#160;368(b) of the Code. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) The parties hereto (i)&#160;shall use their respective reasonable best efforts to cause the Mergers to qualify, and will not take any action or cause any action to be taken which action would reasonably be expected to prevent the Mergers from qualifying, for the Intended Tax Treatment and (ii)&#160;shall not take any Tax reporting position inconsistent with the treatment of the Mergers as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code for U.S. federal, state and other relevant Tax purposes, unless otherwise required pursuant to a &#8220;determination&#8221; within the meaning of Section&#160;1313(a) of the Code. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) Each of the parties shall use its commercially reasonable efforts in order for any Tax opinions and disclosures required to be filed with the SEC in connection with the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement to be obtained from Tax Opinion Counsel, including the appropriate officers of Parent, the Acquisition Subs and Company executing and delivering to Tax Opinion Counsel certificates substantially in the forms set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.12</div> of the Parent Disclosure Letter (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Representation Letter</div>&#8221;) and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.12</div> of the Company Disclosure Letter (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Representation Letter</div>&#8221; and collectively with the Parent Representation Letter, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Representation Letters</div>&#8221;), respectively. Each Representation Letter shall be dated on or before the date of such Tax opinion and shall not have been withdrawn or modified in any material respect except as otherwise agreed to in writing by the parties. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) The Company shall use commercially reasonable efforts to cooperate with Parent and its Affiliates to cause any Company Subsidiary that is treated as a corporation for U.S. federal income tax purposes to merge into the Surviving Company, which merger shall be effective after the Second Effective Time and occur, at Parent&#8217;s sole discretion, on the Closing Date after the Closing or after the Closing Date, provided that no officer or employee of the Company or Company Subsidiaries shall be obligated to execute documents prior to the Closing for purposes of effecting any such merger and the Company and Company Subsidiaries shall not be obligated to make or have be effective any Tax elections or Tax filings in connection therewith prior to the Closing. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;4.13 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Indemnification; Directors</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8217;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> and Officers</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8217;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> Insurance</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) For a period of no less than six years after the First Effective Time, the Surviving Company shall (and Parent shall cause the Surviving Company to) indemnify and hold harmless, and provide advancement of expenses to, all current or former directors and officers of the Company or any of the Company Subsidiaries, any Person who becomes a director or officer of the Company or any of the Company Subsidiaries prior to the First Effective Time and any current or former director of officer of the Company or any of the Company Subsidiaries who is, was or at any time prior to the First Effective Time serves or served as a director, officer, member, trustee or fiduciary of another corporation, partnership joint venture, trust, pension plan or employee benefit plan at the request of or for the benefit of the Company or any of the Company Subsidiaries (together with their respective heirs and representatives, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Indemnified Parties</div>&#8221;) to the fullest extent permitted by applicable Legal Requirements in respect of acts or omissions occurring or alleged to have occurred at or prior to the First Effective Time, whether asserted or claimed prior to, at or after the First Effective Time, by reason of the fact of such Persons serving as an officer or director of the Company or any of the Company Subsidiaries or, while a director or officer of the Company or any of the Company Subsidiaries, was serving at the request of the Company or any of the Company Subsidiaries as a director, officer, member, trustee or fiduciary of another corporation, partnership joint venture, trust, pension plan or employee benefit plan, and the Surviving Company shall (and Parent shall cause the Surviving Company to) also advance expenses to the Indemnified Parties as incurred to the fullest extent permitted by applicable Legal Requirements; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that the Indemnified Party to whom expenses are advanced provides an undertaking to repay such advances if it is ultimately determined by a final and nonappealable judicial determination that such Indemnified Party is not entitled to indemnification under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(a)</div> or otherwise. The parties hereto agree that for six years after the First Effective Time all rights to elimination or limitation of liability, indemnification, exculpation or advancement of expenses for acts or omissions occurring or alleged to have occurred at or prior to the First Effective Time, whether asserted or claimed prior to, at or after the First Effective Time, now existing in favor of the Indemnified Parties as provided in the Organizational Documents of the Company or any of the Company Subsidiaries or in any written agreement between the Company or any of the Company Subsidiaries and such Person shall survive the Mergers and shall continue in full force and effect. For six years after the First Effective Time, the Surviving Company shall cause to be maintained in effect the provisions in: (i)&#160;the Organizational Documents of the Company and each of the Company Subsidiaries; and (ii)&#160;any other agreements of the Company or any of the Company Subsidiaries with any Indemnified Party, in each case, regarding exculpation, elimination or limitation of liability, indemnification of officers and directors or other fiduciaries and advancement of expenses that are in existence on the date of this Agreement, and no such provision shall be amended, modified or repealed in any manner that would materially and adversely affect the rights or protections thereunder of any such Indemnified Party in respect of acts or omissions occurring or alleged to have occurred at or prior to the First Effective Time without the consent of such Indemnified Party. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) For a period of no less than six years following the First Effective Time, Parent and the Surviving Company shall cause to be maintained in effect the existing policy of the Company&#8217;s directors&#8217; and officers&#8217; liability insurance (or a comparable replacement policy) (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">D&amp;O Policy</div>&#8221;) covering claims arising from facts or events that occurred at or prior to the First Effective Time (including for acts or omissions occurring in connection with this Agreement and the consummation of the transactions contemplated by this Agreement) and covering each of the Company&#8217;s current directors and officers, in any case on terms with respect to coverage and amounts that are no less favorable than those terms in effect on the date of this Agreement; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that in no event shall Parent or the Surviving Company be required to expend in any one year an amount in excess of 300% of the current annual premium paid by the Company (which annual premium is set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div> of the Company Disclosure Schedule) for such insurance (such 300% amount, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Maximum Annual Premium</div>&#8221;); and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided further</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that if the annual premium of such insurance coverage exceeds the Maximum Annual Premium, Parent and the Surviving Company shall be obligated to obtain a policy with the greatest comparable coverage available for a cost not exceeding the Maximum Annual Premium. Notwithstanding anything to the contrary in this </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">Agreement, in lieu of Parent&#8217;s obligations under the first sentence of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div>, the Company may, or if the Company is unable to, Parent may on its behalf, prior to the First Effective Time, purchase a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-year</div> &#8220;tail&#8221; prepaid policy on the D&amp;O Policy with an annual cost not in excess of the Maximum Annual Premium, and in the event that Parent or the Company shall purchase such a &#8220;tail&#8221; policy, Parent and the Surviving Company shall maintain such &#8220;tail&#8221; policy in full force and effect and continue to honor their respective obligations thereunder, in lieu of all other applicable obligations of Parent and the Surviving Company under the first sentence of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div> for so long as such &#8220;tail&#8221; policy shall be maintained in full force and effect. Notwithstanding anything in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div> to the contrary, if any Indemnified Party notifies Parent on or prior to the sixth anniversary of the First Effective Time of a matter in respect of which such Person may seek indemnification pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div>, the provisions of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div> that require Parent and the Surviving Company to indemnify and advance expenses shall continue in effect with respect to such matter until the final disposition of all claims, actions, investigations, suits and proceedings relating thereto. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) The obligations under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div> shall not be terminated, amended or otherwise modified in such a manner as to adversely affect any Indemnified Party (or any other Person who is a beneficiary under the D&amp;O Policy or the &#8220;tail&#8221; policy referred to in Section&#160;4.13(b) and any of such Person&#8217;s heirs, executors, beneficiaries or representatives) without the prior written consent of such affected Indemnified Party or other Person who is a beneficiary under the D&amp;O Policy or the &#8220;tail&#8221; policy referred to in Section&#160;4.13(b) (and, after the death of any of the foregoing Persons, such Person&#8217;s heirs, executors, beneficiaries or representatives). Each of the Indemnified Parties or other Persons who are beneficiaries under the D&amp;O Policy or the &#8220;tail&#8221; policy referred to in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div> (and, after the death of any of the foregoing Persons, such Person&#8217;s heirs and representatives) are intended to be third party beneficiaries of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div>, with full rights of enforcement as if a party thereto. The rights of the Indemnified Parties (and other Persons who are beneficiaries under the D&amp;O Policy or the &#8220;tail&#8221; policy referred to in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div> (and their heirs and representatives)) under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div> shall be in addition to, and not in substitution for, any other rights that such Persons may have under the Organizational Documents of the Company or any of the Company Subsidiaries, any and all indemnification agreements of or entered into by the Company or any of the Company Subsidiaries, or applicable Legal Requirements (whether at law or in equity). In the event of any breach by the Surviving Company or Parent of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div>, Parent or the Surviving Company shall pay all reasonable expenses, including attorneys&#8217; fees, that may be incurred by the Indemnified Parties in enforcing the indemnity and other obligations provided in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div> as such fees are incurred upon the written request of such Indemnified Party. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) In the event that Parent, the Surviving Company or any of their respective Subsidiaries (or any of their respective successors or assigns) shall (i)&#160;consolidate or merge with any other Person and shall not be the continuing or surviving corporation or entity in such consolidation or merger, or (ii)&#160;sell or transfer a substantial portion of their respective assets to any other Person, then in each case, to the extent necessary to protect the rights of the Indemnified Parties and other Persons who are beneficiaries under the D&amp;O Policy or the &#8220;tail&#8221; policy referred to in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div> (and their respective heirs and representatives), proper provision shall be made so that the continuing or surviving corporation or entity or the purchaser or transferee entity, as applicable (or its successors or assigns, if applicable) shall assume the obligations set forth in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.14 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financing and Financing Cooperation</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) From the date of this Agreement, the Company shall, and shall cause the Company Subsidiaries and their respective Representatives to, provide such cooperation as is reasonably requested by Parent, is reasonably and customarily necessary in connection with the Debt Financing and is customarily provided for issuers in financings of the type contemplated by the Debt Commitment Letter, but limited to, using commercially reasonable efforts to (i)&#160;furnish to Parent (x)&#160;the Required Information and (y)&#160;such other customary financial information with respect to the Company and the Company Subsidiaries as may be reasonably requested by the Parent as is necessary for Parent to prepare the materials referred to in clause </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">(vii)&#160;below (including the pro forma financial information and pro forma financial statements contemplated by Paragraph 5 of Exhibit C of the Debt Commitment Letter (provided that, for the avoidance of doubt, the Company and the Company Subsidiaries shall not be required to provide, and Parent shall be solely responsible for, the preparation of pro forma financial statements)), (ii)&#160;provide Parent all documentation and other information with respect to the Company and the Company Subsidiaries within three Business Days prior to the Closing Date as shall have been reasonably requested in writing (including by email) by Parent at least ten Business Days prior to the Closing Date that is required in connection with the Debt Financing by U.S. regulatory authorities under applicable &#8220;know-your-customer&#8221; and anti-money laundering rules and regulations, including the Patriot Act and 31 C.F.R. &#167; 1010.230, and that are required by Paragraph 7 of Exhibit C of the Debt Commitment Letter as in effect on the date hereof, (iii)&#160;deliver, or cause the applicable Company Subsidiary to deliver, necessary prepayment and/or termination notices in accordance with the terms of each of the Company Credit Facilities (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that such prepayment and termination notices may be conditioned on the occurrence of the Closing), (iv) reasonably facilitate the pledging of collateral and the provision of guarantees, in each case, only to the extent such pledge or guaranty is a condition in the Debt Commitment Letter to the funding of the Debt Financing on the Closing Date, (v) executing and delivering or helping to procure credit agreements, hedging arrangements, notes, mortgages, pledge and security documents, landlord waivers, estoppels, consents, and approvals and other definitive financing documents or other requested certificates or documents, in each case, only to the extent that delivery of such documents is a condition in the Debt Commitment Letter to the funding of the Debt Financing on the Closing Date (in each case, subject to and only effective upon the occurrence of the Closing), (vi) cause members of its senior management, representatives and advisors to participate in a reasonable number of meetings, conference calls, presentations and roadshows with prospective lenders and investors, due diligence sessions (including accounting due diligence sessions), drafting sessions and sessions with the ratings agencies, in all such cases upon reasonable advanced notice and at reasonable times and locations mutually agreed upon, and (vii)&#160;assist Parent, each Acquisition Sub and the Debt Financing Sources with the preparation of customary bank information memoranda, lender presentations, investor presentations, offering documents, rating agency presentations and similar customary documents required in connection with the Debt Financing, in each case, to the extent such materials relate to information concerning the Company and the Company Subsidiaries and (viii)&#160;to the extent required by the Debt Financing Sources, executing and delivering customary authorization letters to the Debt Financing Sources authorizing the distribution of information to prospective lenders, subject to customary confidentiality restrictions and customary exculpatory provisions; provided that such cooperation shall not be required to the extent it would: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) require the Company, a Company Subsidiary, or any of their Affiliates or any of its or their Representatives to execute, deliver or enter into, or perform any document (including any agreement, instrument, guaranty, warranty, indemnity or certificate) with respect to the Debt Financing that is not contingent upon the Closing or that would be effective prior to Closing (other than the authorization and representation letters referred to above), </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) cause any director or officer to incur any personal liability (including that no member of the Company Board, or the board of directors of any Company Subsidiary or any of its or their Affiliates shall be required to enter into any resolutions or take any similar action approving the Financing until the Closing has occurred), </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii) require the delivery of any financial statements in a form or subject to a standard different than those provided to Parent on or prior to the date hereof, </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iv) prior to the Closing, (x)&#160;pay any commitment or other fee for which the Company, any Company Subsidiary, or any of their Affiliates has not received prior reimbursement or (y)&#160;provide any indemnity or security or incur any liability or obligation in connection with the Debt Financing or any other financing, </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(v) take or permit the taking of any action that would reasonably be expected to conflict with, result in any violation or breach of, or default (with or without lapse of time, or both) under, any </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organizational Documents of the Company, any Company Subsidiary, or any of their Affiliates, or any applicable Legal Requirements or Contracts of the Company, any Company Subsidiary, or any of their Affiliates, </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(vi) require any cooperation to the extent that it would materially or unreasonably interfere with the business or operations of the Company, any Company Subsidiary, or any of their Affiliates, or </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(vii) require the Company, any Company Subsidiary, or any of their Affiliates to make any representation, warranty or certification that, in the good faith determination of the Company, any Company Subsidiary, or any of their Affiliates, is not true. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Parent agrees that in no event shall Company, any Company Subsidiary, or any of their Affiliates be required to execute or deliver any documents in connection with the Debt Financing which is not conditioned upon, and shall become effective from and after, the Closing. Parent shall indemnify and hold harmless the Company, each Company Subsidiary, and each of their Affiliates and its and their respective Representatives from and against any and all liabilities, losses, damages, claims and reasonable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs and expenses (including reasonable attorney&#8217;s fees) interest, awards, judgments, losses and penalties suffered or incurred in connection with any and all of the matters contemplated by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.14</div> (other than the use of any information provided by the Company, any Company Subsidiary, or any of their Affiliates or any of its or their Representatives, in each case, in writing for use in connection with the Debt Financing) or in connection with the arrangement of the Debt Financing or any information utilized in connection therewith, except to the extent arising from fraud, gross negligence or willful misconduct by any of Company, any Company Subsidiary, or any of their Affiliates or any of its or their Representatives, whether or not the transactions are consummated or this Agreement is terminated. As a condition to the Company and the Company Subsidiaries obligations pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.14</div>, Parent shall promptly, upon request by the Company or a Company Subsidiary, reimburse the Company, the Company Subsidiaries and their Affiliates for all reasonable and documented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs and expenses (including reasonable and documented attorney&#8217;s fees and expenses and disbursements) incurred by the Company, any Company Subsidiary, or any of their Affiliates or its and their Representatives in connection with the cooperation contemplated by this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.14</div>. All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information regarding Company and its Affiliates provided to Parent, its Affiliates or its Representatives pursuant to this Section&#160;4.14 shall be kept confidential by them, except for disclosure to potential lenders, investors, rating agencies or their respective Representatives in connection with the Debt Financing subject to customary confidentiality provisions including exercising commercially reasonable best efforts to make Company an express third-party beneficiary to the confidentiality agreement. The obligations in this clause (b)&#160;shall survive the termination of this Agreement. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Parent shall use its reasonable best efforts to (i)&#160;maintain in effect the Debt Commitment Letter in accordance with its terms, (ii)&#160;negotiate definitive financing agreements with respect to the Debt Financing on the terms and conditions set forth in the Debt Commitment Letter (taking into account any &#8220;market flex&#8221; provisions), so that such agreements are in effect as promptly as practicable but in any event no later than the Closing Date, (iii)&#160;satisfy on a timely basis all Financing Conditions on the Closing Date applicable to Parent or the Parent Subsidiaries and under the control of Parent or the Parent Subsidiaries and (iv)&#160;consummate on the Closing Date the Debt Financing required to consummate the transactions contemplated hereby in accordance with the terms of the Debt Commitment Letter (which, for the avoidance of doubt, shall include agreeing to consummate the Debt Financing even if any flex rights are exercised to their maximum extent). Prior to the Closing, Parent shall not permit the Acquisition Subs (without the prior written consent of the Company) to agree to, or permit, any amendment or modification of, or waiver under, the Debt Commitment Letter that (i)&#160;reduces the aggregate amount of the Debt Financing to an amount such that the Closing could not be consummated, (ii)&#160;imposes any additional (or adversely modifies any existing) condition precedent to the availability of the Debt Financing that could reasonably be expected to adversely affect (including with respect to timing) the ability or likelihood of Parent or the Company to timely consummate the transactions contemplated by this Agreement, (iii)&#160;would otherwise reasonably be expected to prevent, impede or delay the funding on the Closing Date of the Debt Financing required to consummate </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">the transactions contemplated by this Agreement, or (iv)&#160;would adversely impact the ability of the Acquisition Subs or their respective Affiliates to enforce their rights against the other parties to the Debt Commitment Letter or the definitive agreements with respect thereto and shall, in each case, be deemed to be material for purposes of this Agreement; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that the Acquisition Subs may, without the Company&#8217;s prior written consent, amend, replace, supplement or otherwise modify the Debt Commitment Letter solely to add lenders, lead arrangers, bookrunners, syndication agents or similar entities that had not executed the Debt Commitment Letter as of the date hereof. Upon any such amendment, replacement, supplement or modification, the term &#8220;Debt Commitment Letter&#8221; shall refer to the Debt Commitment Letter as so amended, replaced, supplemented or otherwise modified. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) Parent shall keep Company informed on a reasonably current basis and in reasonable detail of the status of Parent&#8217;s efforts to arrange the Debt Financing and promptly provide to Company copies of all definitive documents related to the Debt Financing contemplated by the Debt Commitment Letters. In the event that, in the reasonable opinion of Parent, all conditions applicable to each of the Debt Commitment Letters have been satisfied, Parent shall use commercially reasonable efforts to cause the lenders and the other Persons providing such Debt Financing contemplated by the Debt Commitment Letters to fund the Debt Financing contemplated by the Debt Commitment Letters required to consummate the transactions contemplated by this Agreement on or prior to the Closing Date. The Parent shall promptly notify the Company (A)&#160;of any breach (or threatened breach) or default by any party to the Debt Commitment Letter or definitive agreements related to the Debt Financing of which Parent or any of its Affiliates becomes aware, (B)&#160;of the receipt by Parent, any of the Parent Subsidiaries (including the Acquisition Subs) of any written notice or communication from any Debt Financing Source with respect to any breach (or threatened breach) or default, or any termination or repudiation, in each case by any party to the Debt Commitment Letter or any definitive document related to the Debt Financing and (C)&#160;if for any reason Parent at any time believes it will not be able to obtain all or any portion of the Debt Financing necessary to consummate the transactions contemplated by this Agreement and pay all related fees and expenses payable by Parent hereunder on the terms, in the manner or from the sources contemplated by the Debt Commitment Letters. Parent shall promptly, but in any event within three days of the date of a written request from the Company, provide any information reasonably requested by Company relating to any circumstance referred to in clause (A), (B) or (C)&#160;of the immediately preceding sentence. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) If the Debt Financing required to consummate the transactions contemplated by this Agreement becomes unavailable under the Debt Commitment Letter or any definitive agreements with respect thereto, as applicable, Parent shall, and shall cause the Parent Subsidiaries to, as promptly as practicable following the occurrence of such event, use its or their reasonable best efforts to obtain substitute financing sufficient, together with other financial resources available to Parent, to consummate the Merger (any such financing, a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Substitute Financing</div>&#8221;). In the event any Substitute Financing is obtained, references in this Agreement to the Debt Financing shall also be deemed to refer to such Substitute Financing, and references in this Agreement to the Debt Commitment Letter and the definitive financing agreements with respect thereto shall also be deemed to refer to the Substitute Financing and the definitive financing agreements with respect thereto, and all obligations of Parent pursuant to this Section<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.14</div> shall be applicable thereto as to the same extent as Parent&#8217;s obligations with respect to the Debt Financing. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) Parent and each Acquisition Sub expressly acknowledges and agrees that, notwithstanding anything in this Agreement to the contrary, their obligations hereunder, including their obligation to consummate the Closing, are not subject to, or conditioned on, receipt of the Debt Financing or any Substitute Financing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.15 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholder Litigation</div></div>. The Company shall provide Parent with prompt written notice of, and copies of all pleadings and material correspondence relating to, any Legal Proceeding against the Company or any of its directors or officers by any holder of shares of Company Common Stock arising out of or relating to this Agreement or the transactions contemplated by this Agreement. The Company shall give Parent the opportunity to participate, at Parent&#8217;s sole cost and expense, in the defense, settlement, or compromise of any </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">such Legal Proceeding (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that the Company shall, subject to the Company&#8217;s consultation with Parent and good faith consideration of its views, control the defense, strategy and settlement thereof), and no such settlement or compromise shall be agreed to without the prior written consent of Parent (not to be unreasonably withheld, conditioned or delayed). Parent shall provide the Company with prompt written notice of, and copies of all pleadings and material correspondence relating to, any Legal Proceeding against Parent or any of its directors or officers by any holder of shares of Parent Class&#160;A Common Stock arising out of or relating to this Agreement or the transactions contemplated by this Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.16 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Exchange Listing and Delisting</div></div>. Parent shall use its reasonable best efforts to cause the shares of Parent Class&#160;A Common Stock to be issued in the First Merger, including the shares of Parent Class&#160;A Common Stock to be issued upon the exercise of converted Company Options, to be approved for listing (subject to notice of issuance) on Nasdaq at or prior to the First Effective Time. Prior to the Closing, the Company and Parent shall cooperate to cause the shares of Company Common Stock to be delisted from Nasdaq and deregistered under the Exchange Act as soon as practicable following the First Effective Time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.17 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Section</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;16 Matters</div></div>. Prior to the First Effective Time, the Parent Board and the Company Board, respectively, shall take all actions that may be required or appropriate to cause any dispositions of shares of Company Common Stock (including derivative securities with respect to shares of Company Common Stock) or acquisitions of Parent Class&#160;A Common Stock (including derivative securities with respect to Parent Class&#160;A Common Stock) in connection with the transactions contemplated by <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;I</div> by each individual who is, or as a result of the transactions contemplated by this Agreement will be, subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to the Company or is, or will as a result of the transactions contemplated by this Agreement become, subject to such reporting requirements with respect to Parent, to be exempt under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16b-3</div> promulgated under the Exchange Act. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.18 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Director Resignations</div></div>. Prior to the Closing, the Company shall use commercially reasonable efforts to deliver to Parent resignations, in form and substance reasonably satisfactory to Parent, executed by each director of the Company in office as of immediately prior to the First Effective Time, in each case, conditioned and effective upon the First Effective Time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.19 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payoff Documentation</div></div>. Prior to the Closing, the Company shall use commercially reasonable efforts to deliver to Parent a payoff letter in form and substance reasonably acceptable to Parent and the Debt Financing Sources with respect to each of the Company Credit Facilities (such payoff letters, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Payoff Letters</div>&#8221;) duly executed by the applicable agent(s) to each of the Company Credit Facilities pursuant to which such agent(s) shall agree that upon payment of the payoff amount specified in such Payoff Letter: (i)&#160;all obligations of the Company and the Company Subsidiaries arising under or related to the applicable Company Credit Facility shall be paid in full; (ii)&#160;all Liens in connection therewith shall be released; and (iii)&#160;all pledged collateral securing the outstanding obligations under the applicable Company Credit Facility shall be returned in accordance with the terms of the Payoff Letter. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;4.20 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Takeover Statutes</div></div>. If any antitakeover or similar statute or regulation is or may become applicable to the transactions contemplated by this Agreement, each of the parties hereto and its respective Board of Directors shall (a)&#160;grant any approvals and take all any actions necessary so that the transactions contemplated by this Agreement may be consummated as promptly as practicable on the terms contemplated hereby and (b)&#160;otherwise act to eliminate or minimize the effects of any such statute or regulation on the transactions contemplated by this Agreement. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE V. CONDITIONS TO EACH PARTY&#8217;S OBLIGATION TO EFFECT THE MERGERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Section&#160;5.1 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conditions Precedent to Each Party</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8217;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">s Obligations</div></div>. The obligations of each party to effect the Mergers and otherwise cause the transactions contemplated by this Agreement to be consummated are subject to the satisfaction or waiver, as of the Closing, of each of the following conditions: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Effectiveness of Registration Statement</div>. The Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement shall have become effective in accordance with the provisions of the Securities Act, no stop order shall have been issued by the SEC and shall remain in effect with respect to the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement, and no proceedings for that purpose shall have been commenced or be threatened in writing by the SEC that has not been withdrawn. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Stockholder Approvals</div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) The Required Company Stockholder Vote shall have been obtained. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) The Required Parent Stockholder Vote shall have been obtained. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Governmental Approvals</div>. Any waiting period (or any agreed upon extension of any waiting period or commitment not to consummate the Mergers for any period of time) applicable to the consummation of the Mergers under the HSR Act shall have expired or been terminated by the relevant Governmental Entity, and there shall be no pending agreement between Parent and any such Governmental Entity not to close. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Listing</div>. The shares of Parent Class&#160;A Common Stock to be issued pursuant to the First Merger, including the shares of Parent Class&#160;A Common Stock to be issued upon the exercise of converted Company Options, shall have been approved for listing (subject to notice of issuance) on Nasdaq. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Restraints</div>. No Legal Requirement or Order preventing, enjoining or making illegal the consummation of the Mergers shall have been entered, issued or adopted by any court of competent jurisdiction or other Governmental Entity of competent jurisdiction and remain in effect (any such Legal Requirement or Order issued by a court of competent jurisdiction or other Governmental Entity of competent jurisdiction, a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Relevant Legal Restraint</div>&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;5.2 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional Conditions Precedent to Parent</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8217;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">s Obligations</div></div>. The obligation of Parent to cause the Mergers to be effected and otherwise cause the transactions contemplated by this Agreement to be consummated are subject to the satisfaction or waiver by Parent, as of the Closing, of each of the following conditions: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Accuracy of Representations</div>. (i)&#160;The representations and warranties of the Company contained in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.3(c)</div> shall have been true and accurate, other than <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de minimis</div></div> inaccuracies, at and as of the date of this Agreement and shall be true and accurate, other than <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de minimis</div></div> inaccuracies, at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty shall only be required to be true and accurate, other than <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;minimis</div></div> inaccuracies, as of such particular date or period of time); (ii) the representations and warranties of the Company contained in the first sentence of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.1(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.3</div> (other than <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.3(c)</div>), <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.4</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.5</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.6(a)(i)</div>, and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.25</div> shall have been true and accurate in all material respects at and as of the date of this Agreement and shall be true and accurate in all material respects at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty shall only be required to be true and accurate in all material respects as of such particular date or period of time); <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that, in the case of this clause (ii), for purposes of determining the accuracy of such representations and warranties, all materiality, &#8220;Company Material Adverse Effect&#8221; and similar qualifications set forth in such representations and warranties shall be disregarded; and (iii)&#160;the representations and warranties of the Company set forth in this Agreement (other than those representations </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">and warranties referred to in the foregoing clauses (i)&#160;and (ii)) shall have been true and accurate in all respects at and as of the date of this Agreement and shall be true and accurate in all respects at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty shall only be required to be so true and accurate as of such particular date or period of time), except as, individually or in the aggregate has not constituted or resulted in or would not reasonably be expected to constitute or result in, a Company Material Adverse Effect; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that, in the case of this clause (iii), for purposes of determining the accuracy of such representations and warranties, all materiality, &#8220;Company Material Adverse Effect&#8221; and similar qualifications set forth in such representations and warranties shall be disregarded; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that the reference to Company Material Adverse Effect in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.8(a)</div> shall be given effect. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Performance of Covenants</div>. The covenants in this Agreement that the Company is required to comply with or to perform at or prior to the Closing shall have been complied with and performed in all material respects. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Company Material Adverse Effect</div>. Since the date of this Agreement, there shall not have occurred any Effects that, individually or in the aggregate, have constituted or resulted in, or would reasonably be expected to constitute or result in, a Company Material Adverse Effect. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Certificate</div>. Parent shall have received a certificate, dated as of the Closing Date and executed by the Chief Executive Officer or Chief Financial Officer of the Company, confirming that the conditions set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(b)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(c)</div> have been duly satisfied. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;5.3 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional Conditions Precedent to the Company</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8217;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">s Obligations</div></div>. The obligation of the Company to effect the Mergers and otherwise consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver by the Company, as of the Closing, of each of the following conditions: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Accuracy of Representations</div>. (i)&#160;The representations and warranties of Parent contained in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.3(c)</div> shall have been true and accurate, other than <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de minimis</div></div> inaccuracies, at and as of the date of this Agreement and shall be true and accurate, other than <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de minimis</div></div> inaccuracies, at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty shall only be required to be true and accurate, other than <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">de minimis</div></div> inaccuracies, as of such particular date or period of time); (ii) the representations and warranties of Parent and each Acquisition Sub contained in the first sentence of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.1(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.3</div> (other than <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.3(c)</div>), <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.4</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.5</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.6(a)(i</div>), and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.21</div> shall have been true and accurate in all material respects at and as of the date of this Agreement and shall only be required to be true and accurate in all material respects at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty shall only be required to be true and accurate in all material respects as of such particular date or period of time); <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that, in the case of this clause (ii), for purposes of determining the accuracy of such representations and warranties, all materiality, &#8220;Parent Material Adverse Effect&#8221; and similar qualifications set forth in such representations and warranties shall be disregarded; and (iii)&#160;the representations and warranties of Parent and each Acquisition Sub set forth in this Agreement (other than those representations and warranties referred to in the foregoing clauses (i)&#160;and (ii)) shall have been true and accurate in all respects at and as of the date of this Agreement and shall only be required to be true and accurate in all respects at and as of the Closing Date as if made at and as of such time (except to the extent that any such representation and warranty expressly speaks as of a particular date or period of time, in which case such representation and warranty shall be so true and accurate as of such particular date or period of time), except as, individually or in the aggregate, has not constituted or resulted in or would not reasonably be expected to constitute or result in, a Parent Material Adverse Effect; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that, in the case of this clause (iii), for purposes of determining the accuracy of such representations and warranties, all materiality, &#8220;Parent Material Adverse Effect&#8221; and similar qualifications set forth in such representations and </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;">warranties shall be disregarded, provided that the reference to Parent Material Adverse Effect in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.8(a)</div> shall be given effect. </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Performance of Covenants</div>. The covenants in this Agreement that Parent is required to comply with or to perform at or prior to the Closing shall have been complied with and performed in all material respects. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Parent Material Adverse Effect</div>. Since the date of this Agreement, there shall not have occurred any Effects that, individually or in the aggregate, have constituted or resulted in, or would reasonably be expected to constitute or result in, a Parent Material Adverse Effect. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Tax Opinion</div>. Company shall have received an opinion from Tax Opinion Counsel, dated as of the Closing Date, to the effect that the Mergers qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code at a level of comfort at least equivalent to the corresponding Tax opinion provided by Tax Opinion Counsel in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement. In rendering such opinion, Tax Opinion Counsel shall be entitled to rely upon the Representation Letters. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Certificate</div>. The Company shall have received a certificate, dated as of the Closing Date and executed by the Chief Executive Officer or Chief Financial Officer of Parent, confirming that the conditions set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.3(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.3(b)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.3(c)</div> have been duly satisfied. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE VI. TERMINATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Section&#160;6.1 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Termination</div></div>. This Agreement may be terminated and the Mergers may be abandoned: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) by mutual written consent of Parent and the Company at any time prior to the First Effective Time; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) by Parent or the Company if the Mergers shall not have been consummated by 11:59 p.m. New York Time on January&#160;31, 2022 (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">End Date</div>&#8221;); <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that if any of the conditions to the Closing set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.1(c)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.1(e)</div> (solely if the applicable Relevant Legal Restraint relates to any Antitrust Law) has not been satisfied or waived on or prior to 11:59 p.m. New York Time on the End Date but all other conditions to Closing set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Sections</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.1</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">5.2</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">5.3</div> have been satisfied (other than those conditions that by their nature are to be satisfied at the Closing, so long as such conditions are reasonably capable of being satisfied if the Closing were to occur on the End Date) or waived, the End Date will be automatically extended, without any action on the part of any party hereto, to 11:59 p.m. New York Time on March&#160;31, 2022 and, if so extended, such date shall be the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">End Date</div>&#8221;; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">further</div></div>, that a party shall not be permitted to terminate this Agreement pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(b)</div> if the material breach by such party (or any Affiliate of such party) of any of such party&#8217;s obligation under this Agreement shall have materially contributed to the failure of the First Effective Time to have occurred on or before the End Date; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) by Parent or the Company at any time prior to the First Effective Time if a Relevant Legal Restraint permanently preventing, enjoining or making illegal the consummation of the Mergers shall have become final and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable;</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that the party seeking to terminate the Agreement shall have used reasonable best efforts to prevent the entry of and to remove such Relevant Legal Restraint in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7</div>; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) by Parent at any time prior to obtaining the Required Company Stockholder Vote if (i)&#160;the Company Board shall have made a Company Change in Recommendation or (ii)&#160;the Company shall have Willfully Breached in any material respect <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.2</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) by the Company (i)&#160;at any time prior to obtaining the Required Parent Stockholder Vote if the Parent Board shall have made a Parent Change in Recommendation, (ii)&#160;if Parent has Willfully Breached in any material respect <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.3</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div> or (iii)&#160;if Parent has materially breached its representations and warranties set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.15</div> (Financing; Solvency) or its covenants set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.14</div> (Financing and Financing Cooperation) (any failure to satisfy any condition set forth in the Debt </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">Commitment Letter with respect to Bioventus, LLC, a Delaware limited liability company (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">BV Opco</div>&#8221;), or its Subsidiaries, including those any condition related to the solvency of BV Opco or any of its Subsidiaries shall be deemed a material breach for purposes of this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(e)(iii)</div>), to the extent not waived by the Debt Financing Sources (collectively, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financing Requirements</div>&#8221;) and (1)&#160;any such breach of the Financing Requirements is not cured by the earlier of the End Date or prior to the 20<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">th</div> Business Day after the Company gives written notice of such breach to Parent; (2)&#160;all of the conditions set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.1</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(b)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(c)</div> have been satisfied and continue to be satisfied (other than those conditions that by their nature cannot be satisfied other than at the Closing) and the Company has irrevocably committed in a written notice delivered to Parent following the expiration of the cure period specified in clause (1)&#160;above that the Company is ready, willing and able to consummate the transactions contemplated by this Agreement; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided, however</div></div>, that, with respect to the conditions set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.1</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(b)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(c)</div> and the Company&#8217;s readiness, willingness and ability to consummate the transactions contemplated by this Agreement, any condition forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.1</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(b)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(c)</div> shall be deemed satisfied if the failure of such condition resulted primarily from (A)&#160;any action or inaction by Parent or an Acquisition Sub, or (B)&#160;Parent&#8217;s breach of the Financing Requirements, and (3)&#160;Parent or an Acquisition Sub fails to consummate the transactions contemplated by this Agreement by the earlier of the End Date or within two Business Days following the written notice delivered by the Company to Parent following the expiration of the cure period specified in clause (1)&#160;above; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) by the Company, at any time prior to obtaining the Required Company Stockholder Vote, in the event that (i)&#160;the Company Board has authorized the Company to enter into a definitive agreement relating to a Company Superior Proposal in material compliance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(c)</div>; and (ii)&#160;substantially concurrently with the termination of this Agreement, the Company enters into the definitive agreement relating to a Company Superior Proposal and pays Parent the Termination Fee payable to Parent pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3(a)</div>; </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) by either Parent or the Company if: (i)&#160;the Company Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed; and (ii)&#160;the Required Company Stockholder Vote shall not have been obtained, in each case after a vote on such approval was taken; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(h) by either Parent or the Company if: (i)&#160;the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed; and (ii)&#160;the Required Parent Stockholder Vote shall not have been obtained, in each case after a vote on such approval was taken; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(i) by Parent if: (i)&#160;any of the Company&#8217;s representations and warranties contained in this Agreement shall be inaccurate such that the condition set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(a)</div> would not be satisfied; or (ii)&#160;any of the Company&#8217;s covenants contained in this Agreement shall have been breached such that the condition set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(b)</div> would not be satisfied; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that for purposes of clauses (i)&#160;and (ii) above, if an inaccuracy in any of the Company&#8217;s representations and warranties or a breach of a covenant of the Company is curable by the Company by the End Date and the Company is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then Parent may not terminate this Agreement under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(i)</div> on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of 30 Business Days commencing on the date that the Company receives written notice of such inaccuracy or breach from Parent; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">further</div></div>, that Parent shall not have the right to terminate this Agreement pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(i)</div> if Parent is then in breach of any of its representations, warranties or agreements contained in this Agreement, which breach would give rise to the failure of a condition set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.3(a)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.3(b)</div>; or </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(j) by the Company if: (i)&#160;any of Parent&#8217;s or Acquisition Subs&#8217; representations and warranties contained in this Agreement shall be inaccurate such that the condition set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.3(a)</div> would not be satisfied; or (ii)&#160;any of Parent&#8217;s covenants contained in this Agreement shall have been breached such that the condition set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.3(b)</div> would not be satisfied; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that for purposes of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">clauses (i)&#160;and (ii) above, if an inaccuracy in any of Parent&#8217;s or Acquisition Subs&#8217; representations and warranties or a breach of a covenant of Parent is curable by Parent by the End Date and Parent is continuing to exercise its reasonable best efforts to cure such inaccuracy or breach, then the Company may not terminate this Agreement under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(j)</div> on account of such inaccuracy or breach unless such inaccuracy or breach shall remain uncured for a period of 30 Business Days commencing on the date that Parent receives written notice of such inaccuracy or breach from the Company; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided, further</div></div>, that the Company shall not have the right to terminate this Agreement pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(j)</div> if the Company is then in breach of any of its representations, warranties or agreements contained in this Agreement, which breach would give rise to the failure of a condition set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(a)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.2(b)</div>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Except for a termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(a)</div>, the party seeking to terminate this Agreement pursuant to this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1</div> shall give written notice of such termination to the other parties in accordance with <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.8</div>, specifying the provision of this Agreement pursuant to which such termination is effected. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;6.2 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Effect of Termination</div></div>. In the event of the termination of this Agreement as provided in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1</div>, this Agreement shall be of no further force or effect with no liability to any Person on the part of any party to this Agreement (or any of its Representatives or Affiliates); <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that: (a)&#160;the last sentence of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.8(a)</div>, the last sentence of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.8(b)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.10</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.14(b)</div>, this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.2</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;VII</div> shall survive the termination of this Agreement and shall remain in full force and effect; and (b)&#160;subject to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3(e)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3(f)</div>, the termination of this Agreement shall not relieve any party from any liability for any fraud or any Willful Breach of this Agreement that is material. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement shall not be affected by a termination of this Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;6.3 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Termination Fees</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) If this Agreement is terminated by the Company pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(f)</div>, by Parent pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(d)</div>, or by either Parent or the Company pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(b)</div> (and at the End Date all of the conditions to the Company&#8217;s obligations to close other than receipt of the Required Company Stockholder Vote have been satisfied, or are capable of satisfaction had the Closing occurred on the End Date) or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(g)</div>, in each case, at a time when Parent would have been entitled to terminate this Agreement pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(d)</div>, then, within two Business Days after (or in the case of termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(f)</div>, substantially current with) the termination of this Agreement, the Company shall cause to be paid to Parent the Termination Fee. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) If this Agreement is terminated by the Company pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(e)</div>, or by either Parent or the Company pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(b)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(h)</div> at a time when the Company would have been entitled to terminate this Agreement pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(e)</div>, then, within two Business Days after the termination of this Agreement, Parent shall cause to be paid to the Company the Termination Fee. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) If this Agreement is terminated by Parent or the Company pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(g)</div> or by Parent pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(i)</div> (or by the Company or Parent pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(b)</div> (and at the End Date all of the conditions to the Company&#8217;s obligations to close other than receipt of the Required Company Stockholder Vote have been satisfied, or are capable of satisfaction had the Closing occurred on the End Date) at a time when this Agreement could have been terminated pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(g)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(i)</div>) and: (i)&#160;at or prior to the Company Stockholder Meeting (in the case of a termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(g)</div>), or at or prior to the time of the applicable breach by the Company (in the case of a termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(i)</div>), any Person shall have publicly announced an intention to make a Company Acquisition Proposal, or a Company Acquisition Proposal shall have been publicly disclosed, publicly announced, commenced, submitted or made and shall not have been publicly withdrawn without qualification at least five Business Days prior to the date of the Company Stockholder Meeting, in the case of a termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(g)</div>, or the time of such breach, in the case of a termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(i)</div>; and (ii)&#160;on or prior to the date that is 12 months following the termination of this Agreement, either (A)&#160;a Company Acquisition Transaction is consummated or (B)&#160;a definitive agreement </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">relating to a Company Acquisition Transaction is entered into by the Company and the transaction contemplated thereby is subsequently consummated (it being understood that, for purposes of this clause&#160;&#8220;(B),&#8221; each reference to 20% in the definition of &#8220;Company Acquisition Transaction&#8221; in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit A</div> shall be deemed to be a reference to 50%, then, within two Business Days after the consummation of such Company Acquisition Transaction, the Company shall cause to be paid to Parent the Termination Fee. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) If this Agreement is terminated by Parent or the Company pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(h)</div> or by the Company pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(j)</div> (or by the Company or Parent pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(b)</div> at a time when this Agreement could have been terminated pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(h)</div> or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(j)</div>) and: (i)&#160;at or prior to the Parent Stockholder Meeting (in the case of a termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(h)</div>), or at or prior to the time of the applicable breach by Parent (in the case of a termination pursuant to or <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(j)</div>), any Person shall have publicly announced an intention to make a Parent Acquisition Proposal, or a Parent Acquisition Proposal shall have been publicly disclosed, publicly announced, commenced, submitted or made and shall not have been publicly withdrawn without qualification at least five Business Days prior to date of the Parent Stockholder Meeting, in the case of a termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(h)</div>, or the time of such breach, in the case of a termination pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(j)</div>; and (ii)&#160;on or prior to the date that is 12 months following the termination of this Agreement, either (A)&#160;a Parent Acquisition Transaction is consummated or (B)&#160;a definitive agreement relating to a Parent Acquisition Transaction is entered into by Parent and the transaction contemplated thereby is subsequently consummated (it being understood that, for purposes of this clause &#8220;(B),&#8221; each reference to 20% in the definition of &#8220;Parent Acquisition Transaction&#8221; in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit A</div> shall be deemed to be a reference to 50%), then, within two Business Days after the consummation of such Parent Acquisition Transaction, Parent shall cause to be paid to the Company the Termination Fee. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) Any Termination Fee due and payable by the Company under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3</div> shall be paid by wire transfer of immediately available funds to an account designated in writing by Parent. For the avoidance of doubt, the Termination Fee shall be payable by the Company only once and not in duplication even though the Termination Fee may be payable by the Company under one or more provisions hereof. If the Company fails to pay the Termination Fee when due and payable by the Company, then the Company shall pay to Parent interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to Parent) at a rate per annum equal to the &#8220;prime rate&#8221; (as published in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Wall Street Journal</div></div>) in effect on the date such amount was originally required to be paid, and the Company shall pay the costs and expenses (including reasonable and documented legal fees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses) in connection with any action, including the filing of any lawsuit or other legal action, taken by Parent to collect payment. In any circumstance where performance by the Company of its obligations under this Agreement would relieve the Company of its obligation to pay to Parent the Termination Fee, Parent and Acquisition Subs may, in their sole discretion (i)&#160;seek specific performance pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.11</div>, (ii) withdraw any claim for specific performance and require the Company to pay the Termination Fee if Parent is entitled to payment of the Termination Fee under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3</div> or (iii)&#160;if Parent and Acquisition Subs are unable for any reason to obtain specific performance, require the Company to pay the Termination Fee if Parent is entitled to payment of the Termination Fee under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3</div>.&#160;&#160;&#160;&#160;The parties agree that if the Termination Fee becomes payable by, and is paid by, the Company, then such Termination Fee shall be Parent&#8217;s sole and exclusive remedy for damages against the Company and its Affiliates and its and their Representatives in connection with this Agreement, and in no event will Parent or any other Person seek to recover any other money damages or seek any other remedy based on a claim in law or equity for any reason in connection with this Agreement; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that nothing contained herein shall relieve any party from satisfying any claim in law or equity or from any liability, in each case arising from fraud or any Willful Breach of this Agreement that is material. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(f) Any Termination Fee due and payable by Parent under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3</div> shall be paid by wire transfer of immediately available funds to an account designated in writing by the Company. For the avoidance of doubt, the Termination Fee shall be payable by Parent only once and not in duplication even </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">though a termination fee may be payable by Parent under one or more provisions hereof. If Parent fails to pay the Termination Fee when due and payable by Parent, then Parent shall pay to the Company interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the Company) at a rate per annum equal to the &#8220;prime rate&#8221; (as published in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Wall Street Journal</div></div>) in effect on the date such amount was originally required to be paid, and Parent shall pay the costs and expenses (including reasonable and documented legal fees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses) in connection with any action, including the filing of any lawsuit or other legal action, taken by the Company to collect payment. In any circumstance where performance by Parent and Acquisition Subs of their respective obligations under this Agreement would relieve Parent of its obligation to pay to the Company the Termination Fee, the Company may, in its sole discretion (i)&#160;seek specific performance pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.11</div>, (ii) withdraw any claim for specific performance and require Parent to pay the Company the Termination Fee if the Company is entitled to payment of the Termination Fee under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3</div> or (iii)&#160;if the Company is unable for any reason to obtain specific performance, require Parent to pay the Termination Fee to the Company if the Company is entitled to payment of the Termination Fee under this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3</div>; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that, in the event the Company terminates this Agreement pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(e)(iii)</div> and the Company requires Parent to pay the Termination Fee, receipt of the Termination Fee shall be the Company&#8217;s sole and exclusive remedy for damages against Parent, each Acquisition Sub and their respective Affiliates and its and their Representatives for the matters set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(e)(iii)</div>. The parties agree that if the Termination Fee becomes payable by, and is paid by, Parent, then such Termination Fee shall be the Company&#8217;s sole and exclusive remedy for damages against Parent, each Acquisition Sub and their respective Affiliates and its and their Representatives in connection with this Agreement, and in no event will the Company or any other Person seek to recover any other money damages or seek any other remedy based on a claim in law or equity for any reason in connection with this Agreement; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, that nothing contained herein (other than as provided herein with respect to the matters set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(e)(iii))</div> shall relieve any party from satisfying any claim in law or equity or from any liability, in each case arising from fraud or any Willful Breach of this Agreement that is material. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(g) Each of the parties hereto acknowledges that the Termination Fee is not intended to be a penalty, but rather is liquidated damages in a reasonable amount that will compensate the recipient in the circumstances in which the Termination Fee is due and payable and which do not involve fraud or Willful Breach of this Agreement by the other party, for the efforts and resources expended and opportunities foregone while negotiating this Agreement and in reliance on this Agreement and on the expectation of the consummation of the Mergers, which amount would otherwise be impossible to calculate with precision.&#160;Each of the parties acknowledges that the agreements contained in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3</div> are an integral part of the transactions contemplated by this Agreement, and that without these agreements the parties would not enter into this Agreement. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE VII. MISCELLANEOUS PROVISIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Section&#160;7.1 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amendment</div></div>. This Agreement may be amended at any time prior to the First Effective Time (whether before or after receipt of the Required Company Stockholder Vote or the Required Parent Stockholder Vote) by an instrument in writing signed on behalf of each of the parties hereto; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that: (a)&#160;after the Required Parent Stockholder Vote has been received, no amendment shall be made which by applicable Legal Requirement or rule or regulation of Nasdaq requires further approval of the stockholders of Parent without the further approval of such stockholders; and (b)&#160;after the Required Company Stockholder Vote has been received, no amendment shall be made which by applicable Legal Requirement or regulation of Nasdaq requires further approval of the stockholders of the Company without the further approval of such stockholders, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">further</div></div>, that any amendment, modification, waiver, supplement or change of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.14(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3(e)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3(f)</div>, this proviso of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.1</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.4(d)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.5(b)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.5(c)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.13</div> (in each case, solely to the extent that such provision relates to the Debt Financing Sources Related Parties), and including, in each case, the definitions of defined terms used therein, that is, in each case, adverse to </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the interests of the Debt Financing Sources Related Parties, will not be effective against the Debt Financing Sources Related Parties without the prior written consent of the Debt Financing Sources (which consent shall not be unreasonably withheld, conditioned or delayed). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.2 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Waiver</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) Except as otherwise provided in this Agreement, any failure of any of the parties to comply with any obligation, covenant, agreement or condition herein may be waived by the party or parties entitled to the benefits thereof only by a written instrument signed by the party granting such waiver. Any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy. No single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.3 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">No Survival of Representations and Warranties</div></div>. None of the representations, warranties, covenants and agreements contained in this Agreement, or contained in any certificate, schedule or document delivered pursuant to this Agreement or in connection with any of the transactions contemplated by this Agreement, shall survive the First Effective Time, except that this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.3</div> shall not limit any covenant or agreement contained in this Agreement that by its terms is to be performed in whole or in part after the First Effective Time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.4 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Entire Agreement; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Reliance;</div> Third-Party Beneficiaries</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) This Agreement, the Company Disclosure Schedule, the Parent Disclosure Schedule, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement, constitute the entire agreement and supersede all prior and contemporaneous agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) Without limiting the generality of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.4(a)</div>, except for the representations and warranties expressly contained in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;II</div>: (i)&#160;Parent and each Acquisition Sub acknowledge and agree that the Company has not made and is not making any representations or warranties, express or implied, whatsoever regarding the subject matter of this Agreement, that none of Parent, either Acquisition Sub or any Parent Subsidiary or any of their respective Representatives is relying on, and none of the foregoing has relied on, in connection with each of Parent and each Acquisition Sub&#8217;s entry into this Agreement and agreement to consummate the transactions contemplated hereby or otherwise, any representations or warranties, express or implied, whatsoever regarding the Company, any of its Affiliates, any of their respective Representatives, any other subject matter of this Agreement or any other matter, express or implied, except for the representations and warranties expressly set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE II</div>, and that no Representative of the Company or any other Person has made or is making any representations or warranties, express or implied, whatsoever regarding the Company, any of its Affiliates, any of their respective Representatives, any other subject matter of this Agreement or any other matter; and (ii)&#160;without limiting the foregoing, Parent and each Acquisition Sub acknowledge and agree that (x)&#160;the Company has not made and is not making any representations or warranties whatsoever regarding, (y)&#160;neither the Company nor any other Person will have or be subject to any liability or other obligation to Parent, Acquisition Subs or their respective Representatives or Affiliates or any other Person resulting from Parent&#8217;s, each Acquisition Sub&#8217;s or their Representatives&#8217; or Affiliates&#8217; use of, and (z)&#160;none of Parent, the Parent Subsidiaries or any of their respective Representatives has relied on, (A)&#160;any forecasts, projections, estimates or budgets discussed with, delivered to or made available to Parent or either Acquisition Sub or to any of their Representatives, or otherwise (including in certain &#8220;data rooms,&#8221; &#8220;virtual rooms,&#8221; management presentations or in any form in expectation of, or in connection with, the transactions contemplated hereby) regarding the future revenues, future results of operations (or any component thereof), future cash flows or future financial condition (or </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any component thereof) of the Company or any Subsidiary of the Company or the future business and operations of the Company or any Subsidiary of the Company or (B)&#160;oral or written information made available to Parent or Parent&#8217;s Affiliates or Representatives in the course of their due diligence investigation of the Company, the negotiation of this Agreement or in the course of the transactions contemplated hereby. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) Without limiting the generality of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.4(a),</div> except for the representations and warranties expressly contained in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE III</div>: (i)&#160;the Company acknowledges and agrees that Parent has not made and is not making any representations or warranties, express or implied, whatsoever regarding the subject matter of this Agreement, that none of the Company, the Company Subsidiaries or any of their respective Representatives is relying on, and none of the foregoing has relied on, in connection with the Company&#8217;s entry into this Agreement and agreement to consummate the transactions contemplated hereby or otherwise, any representations or warranties, express or implied, whatsoever regarding Parent, any of its Affiliates, any of their respective Representatives, any other subject matter of this Agreement or any other matter, express or implied, except for the representations and warranties expressly set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE III</div>, and that no Representative of Parent or any other Person has made or is making any representations or warranties, express or implied, whatsoever regarding Parent, any of its Affiliates, any of their respective Representatives, any other subject matter of this Agreement or any other matter; and (ii)&#160;without limiting the foregoing, the Company acknowledges and agrees that (x)&#160;Parent has not made and is not making any representations or warranties whatsoever regarding, (y)&#160;none of Parent, either Acquisition Sub nor any other Person will have or be subject to any liability or other obligation to the Company or their Representatives or Affiliates or any other Person resulting from the Company&#8217;s or their Representatives&#8217; or Affiliates&#8217; use of and (z)&#160;none of the Company, the Company Subsidiaries or any of their respective Representatives has relied on, (A)&#160;any forecasts, projections, estimates or budgets discussed with, delivered to or made available to the Company or to any of its Representatives, or otherwise (including in certain &#8220;data rooms,&#8221; &#8220;virtual rooms,&#8221; management presentations or in any form in expectation of, or in connection with, the transactions contemplated hereby) regarding the future revenues, future results of operations (or any component thereof), future cash flows or future financial condition (or any component thereof) of Parent or any Subsidiary of Parent or the future business and operations of Parent or any Subsidiary of Parent or (B)&#160;any oral or written information made available to the Company or the Company&#8217;s Affiliates or Representatives in the course of their due diligence investigation of Parent, the negotiation of this Agreement or in the course of the transactions contemplated hereby. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(d) Parent, the Company and each Acquisition Sub agree that their respective representations and warranties set forth in this Agreement are solely for the benefit of the other parties hereto, in accordance with and subject to the terms of this Agreement, and this Agreement is not intended to, and does not, confer upon any Person other than Parent, the Company, and each Acquisition Sub and their respective successors, legal representatives and permitted assigns any rights or remedies, express or implied, hereunder, including the right to rely upon the representations and warranties set forth in this Agreement, except as set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.7</div>; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.14(a)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3(e)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.3(f)</div>, the second proviso to the first sentence of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.1</div>, this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.4(d)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.5(b)</div>, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.5(c)</div> and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.13</div> shall (solely to the extent that any such provision relates to the Debt Financing Sources Related Parties) be for the benefit of, and enforceable by, the Debt Financing Sources Related Parties. The representations and warranties in this Agreement are the product of negotiations among the parties. Any inaccuracies in such representations and warranties are subject to waiver by the parties in accordance with this Agreement without notice or liability to any other Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties of risks associated with particular matters regardless of the knowledge of any of the parties. Consequently, Persons other than the parties may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date of this Agreement or as of any other date. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) Notwithstanding the foregoing, nothing in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.4</div> shall restrain, limit, restrict or prohibit any claim based on fraud. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;7.5 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Applicable Law; Jurisdiction</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) This Agreement is made under, and shall be construed and enforced in accordance with, the laws of the State of Delaware applicable to agreements made and to be performed solely therein, without giving effect to principles of conflicts of law. Each of the parties hereto: (i)&#160;consents to and submits to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware or, if that court does not have jurisdiction, a federal court sitting in Delaware in any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement; (ii)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined in any such court; (iii)&#160;shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court; and (iv)&#160;shall not bring any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court. Each of the parties hereto waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other Person with respect thereto. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LEGAL REQUIREMENTS ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT (INCLUDING ANY DISPUTE ARISING OUT OF OR RELATING TO THE DEBT FINANCING OR THE DEBT COMMITMENT LETTER OR THE PERFORMANCE OF SERVICES THEREUNDER OR RELATED THERETO). Each of the parties hereto acknowledges that it and the other parties have been induced to enter into this Agreement and the transactions contemplated by this Agreement, as applicable, by, among other things, the mutual waivers and certifications in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.5</div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(c) Notwithstanding anything to the contrary contained in this Agreement, the Company acknowledges and irrevocably agrees, all disputes against the Debt Financing Sources Related Party in any way relating to this Agreement or any of the transactions contemplated hereby, including but not limited to any dispute arising out of or relating in any way to the Debt Financing or the performance thereof or the Transactions, whether in contract, tort or otherwise, will be governed by, and construed in accordance with, the Laws of the State of New York applicable to contracts executed in and to be performed entirely within the State, without regard to conflict of law principles that would result in the application of any Law other than the Law of the State of New York. Each of the parties agrees that it will not bring or support any suit, action or Legal Proceeding of any kind or description, whether in law or in equity, whether in contract or in tort or otherwise, against the Debt Financing Sources Related Parties in any way relating to this Agreement or any of the transactions contemplated by this Agreement, including but not limited to any dispute arising out of or relating in any way to the Debt Commitment Letter or the performance thereof, in any forum other than the Supreme Court of the State of New York, County of New York, or, if under applicable law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the Southern District of New York (and appellate courts thereof), and makes the agreements, waivers and consents set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.5(a)</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">mutatis mutandis</div></div> but with respect to the courts specified in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.5(c)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.6 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payment of Expenses</div></div>. Whether or not the Mergers are consummated, each party hereto shall pay its own expenses incident to preparing for, entering into and carrying out this Agreement and the transactions contemplated hereby <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided, however</div></div>, that Parent shall pay all filing fees and printing and mailing costs for the Joint Proxy Statement/Prospectus. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.7 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assignability; Parties in Interest</div></div>. This Agreement shall be binding upon, and shall be enforceable by and inure to the benefit of, the parties hereto and their respective successors and permitted assigns. This Agreement shall not be assignable by any party, in whole or in part, by operation of law or otherwise, without the express prior written consent of the other parties hereto. Except for the provisions of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;I</div> (which, from and after the First Effective Time, shall be for the benefit of Persons who are holders of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">shares of Company Common Stock immediately prior to the First Effective Time and holders of Company Options) and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13</div> (which, from and after the First Effective Time shall be for the benefit of the Indemnified Parties and the other Persons identified therein), nothing in this Agreement (including <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.11</div>), express or implied, is intended to or shall confer upon any Person, other than the parties hereto, any right, benefit or remedy of any nature. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.8 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notices</div></div>. All notices and other communications hereunder shall be in writing in one of the following formats and shall be deemed given (a)&#160;upon actual delivery if personally delivered to the party to be notified if received prior to 6:00 p.m. in the place of receipt on a Business Day, otherwise such notice or communication shall be deemed not to have been received until the next succeeding Business Day; (b)&#160;when sent if sent by email to the party to be notified if received prior to 6:00 p.m. in the place of receipt on a Business Day, otherwise such notice or communication shall be deemed not to have been received until the next succeeding Business Day; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that notice given by email shall not be effective unless (i)&#160;such notice specifically states that it is being delivered pursuant to this Section&#160;7.8 and (ii)&#160;either (A) a duplicate copy of such email notice is promptly given by one of the other methods described in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.8</div> or (B)&#160;the receiving party delivers a written confirmation of receipt for such notice either by email (excluding &#8220;out of office&#8221; or similar automated replies) or any other method described in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.8</div>; or (c)&#160;when delivered if sent by a courier (with confirmation of delivery) if received prior to 5 p.m. in the place of receipt on a Business Day, otherwise such notice or communication shall be deemed not to have been received until the next succeeding Business Day; in each case to the Party to be notified at the following address: </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if to Parent or Acquisition Subs: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 100 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attn: Kenneth Reali, Chief Executive Officer </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;">E-mail: <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">kenneth.reali@bioventusglobal.com</div> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with a copy (which shall not constitute notice) to: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 100 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Anthony D&#8217;Adamio </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;">Email:&#160;&#160;&#160;&#160;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">tony.dadamio@bioventus.com</div> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with a copy (which shall not constitute notice) to: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Latham&#160;&amp; Watkins LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1271 Avenue of the Americas </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, NY 10020 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Charles Ruck; Mark Bekheit </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;">Email: &#160;&#160;&#160;&#160;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">charles.ruck@lw.com;</div> </div> <div style="text-indent: 13%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;mark.bekheit@lw.com</div> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if to the Company: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1938 New Highway </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, New York </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Chief Financial Officer </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;">Email: &#160;&#160;&#160;&#160;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">jdwyer@misonix.com</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with a copy (which shall not constitute notice) to: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jones Day </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">250 Vesey Street </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, NY 10281-1047 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attention: Jonn R. Beeson; Randi Lesnick </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;">Email: &#160;&#160;&#160;&#160;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">jbeeson@jonesday.com; rclesnick@jonesday.com</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.9 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severability</div></div>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.10 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Counterparts</div></div>. This Agreement may be executed and delivered (including by facsimile or other form of electronic transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. The exchange of a fully executed Agreement (in counterparts or otherwise) by facsimile or other electronic delivery shall be sufficient to bind the parties to the terms and conditions of this Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.11 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Specific Performance</div></div>. Each of the parties hereto agrees that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. It is accordingly agreed that, in addition to any other remedy that a party hereto may have under law or in equity, in the event of any breach or threatened breach by Parent, either Acquisition Sub or the Company of any covenant or obligation of such party contained in this Agreement, the other parties shall be entitled to obtain: (i)&#160;an Order of specific performance to enforce the observance and performance of such covenant; and (ii)&#160;an injunction restraining such breach or threatened breach. In the event that any action is brought in equity to enforce the provisions of this Agreement, no party hereto shall allege, and each party hereto hereby waives the defense or counterclaim, that there is an adequate remedy at law. Each party hereto further agrees that no other party hereto or any other Person shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.11</div>, and each party hereto irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument. In no event will the Company, any of the Company&#8217;s Subsidiaries or any of their respective Representatives be entitled to specific performance or any other enforcement of Parent&#8217;s or any Acquisition Sub&#8217;s obligations under this Agreement to cause the Debt Financing to be funded (or to themselves directly cause the Debt Financing to be funded under the Debt Commitment Letter or otherwise). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.12 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Disclosure Schedules</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(a) The Company Disclosure Schedule&#160;has been arranged, for purposes of convenience only, in separate sections&#160;and subsections&#160;corresponding to the Sections&#160;and subsections&#160;of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE II</div> and, as applicable, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE </div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">IV</div>. Any information set forth in any subsection&#160;of the Company Disclosure Schedule&#160;shall be deemed to be disclosed and incorporated by reference in each of the other subsections&#160;of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company Disclosure Schedule&#160;as though fully set forth in such other subsections&#160;(whether or not specific cross-references are made) to the extent it is reasonably apparent on its face that such disclosure also qualifies or applies to such other subsections. No reference to or disclosure of any item or other matter in the Company Disclosure Schedule&#160;shall be construed, in and of itself, as an admission or indication that such item or other matter is material or that such item or other matter is required to be referred to or disclosed in the Company Disclosure Schedule. The information set forth in the Company Disclosure Schedule&#160;is disclosed solely for purposes of this Agreement, and no information set forth therein shall be deemed, in and of itself, to be an admission by any party hereto to any third party of any matter whatsoever, including any violation of Legal Requirement or breach of any Contract. </div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(b) The Parent Disclosure Schedule&#160;has been arranged, for purposes of convenience only, in separate sections&#160;and subsections&#160;corresponding to the Sections&#160;and subsections&#160;of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;III</div> and, as applicable, <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ARTICLE</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;IV</div>. Any information set forth in any subsection&#160;of the Parent Disclosure Schedule&#160;shall be deemed to be disclosed and incorporated by reference in each of the other subsections&#160;of the Parent Disclosure Schedule&#160;as though fully set forth in such other subsections&#160;(whether or not specific cross-references are made) to the extent it is reasonably apparent on its face that such disclosure also qualifies or applies to such other subsections. No reference to or disclosure of any item or other matter in the Parent Disclosure Schedule&#160;shall be construed, in and of itself, as an admission or indication that such item or other matter is material or that such item or other matter is required to be referred to or disclosed in the Parent Disclosure Schedule. The information set forth in the Parent Disclosure Schedule&#160;is disclosed solely for purposes of this Agreement, and no information set forth therein shall be deemed, in and of itself, to be an admission by any party hereto to any third party of any matter whatsoever, including any violation of Legal Requirement or breach of any Contract. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.13 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Recourse</div></div></div>. In no event will the Company, any of the Company&#8217;s Subsidiaries or any of their respective Representatives (i)&#160;seek to enforce this Agreement against, make any claims for breach of this Agreement against, or seek to recover monetary damages from, any of the Debt Financing Sources Related Parties or (ii)&#160;seek to enforce the commitments contained in the Debt Commitment Letter against, make any claims for breach of the commitments contained in the Debt Commitment Letter against, or seek to recover monetary damages from, or otherwise sue, the Debt Financing Sources Related Parties for any reason, including in connection with the Debt Financing or the obligations of the Debt Financing Sources Related Parties thereunder. The Company, on behalf of itself and the Company Subsidiaries and its and their respective Representatives, hereby waives any and all claims and causes of action (whether in contract or in tort, in law or in equity) against the Debt Financing Sources Related Parties that may be based upon, arise out of or relate to this Agreement, the Debt Commitment Letter or the Debt Financing. Nothing in this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;7.13</div> will in any way limit or qualify the obligations and liabilities of the parties hereto to each other or in connection with, or otherwise restrict the Parent or any of its Affiliates from enforcing its rights under, the Debt Commitment Letter. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Section&#160;7.14 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Construction</div></div>. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. If a term is defined as one part of speech, it shall have a corresponding meaning when used as another part of speech. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation,&#8221; and the words &#8220;hereof,&#8221; &#8220;hereby,&#8221; &#8220;herein,&#8221; &#8220;hereunder&#8221; and similar terms in this Agreement shall refer to this Agreement as a whole and not any particular section&#160;or article in which such words appear. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) For purposes of this Agreement, any reference to a Legal Requirement shall include any rules and regulations promulgated thereunder, and any reference to a Legal Requirement in this Agreement shall only be a reference to such Legal Requirement as of the date of this Agreement. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">(e) Except as otherwise indicated, all references in this Agreement to &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Sections</div>,&#8221; &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits</div>,&#8221; &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Annexes</div>&#8221; and &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Schedules</div>&#8221; are intended to refer to Sections&#160;of this Agreement and Exhibits, Annexes and Schedules to this Agreement. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) All references in this Agreement to &#8220;$&#8221; are intended to refer to United States dollars. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) The table of contents and headings to this Agreement are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or otherwise affect any of the provisions of this Agreement. The Exhibits, Schedules and Annexes attached to this Agreement constitute a part of this Agreement and are incorporated herein for all purposes. </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">[<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Remainder of page intentionally left blank</div></div>] </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent, Acquisition Sub I and Acquisition Sub II have caused this Agreement to be executed as of the date first written above. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;;width:40%;">
<tr style="font-size: 0px;">
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 87%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BIOVENTUS INC.</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;">a Delaware corporation</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.75pt;">By:</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">/s/ Ken Reali</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Ken Reali</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Chief Executive Officer</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OYSTER MERGER SUB, INC.</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;">a Delaware corporation</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.75pt;">By:</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">/s/ Anthony D&#8217;Adamio</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Anthony D&#8217;Adamio</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">President and Secretary</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OYSTER MERGER SUB LLC</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;">a Delaware limited liability company</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.75pt;">By:</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">/s/ Anthony D&#8217;Adamio</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Anthony D&#8217;Adamio</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Authorized Person</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURE PAGE TO AGREEMENT AND PLAN OF MERGER </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has caused this Agreement to be executed as of the date first written above. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;;width:40%;">
<tr style="font-size: 0px;">
<td style="width: 12%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 87%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MISONIX, INC.</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;">a Delaware corporation</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.75pt;">By:</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">/s/ Joseph P. Dwyer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Joseph P. Dwyer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Chief Financial Officer</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURE PAGE TO AGREEMENT AND PLAN OF MERGER </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXHIBIT A </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN DEFINITIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For purposes of the Agreement (including this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit A</div>): </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition Subs</div>&#8221; shall have the meaning set forth in the Preamble. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A Person shall be deemed to be an &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Affiliate</div>&#8221; of another Person if such Person directly or indirectly controls, is directly or indirectly controlled by or is directly or indirectly under common control with such other Person. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Agreement</div>&#8221; shall mean the Agreement and Plan of Merger to which this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit A</div> is attached, together with this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit A</div> and each of the other Schedules and Exhibits&#160;hereto, as such Agreement and Plan of Merger (including this <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit A</div> and the other Schedules and Exhibits&#160;hereto) may be amended from time to time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Anti-Corruption Laws</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.14(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Antitrust Laws</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.7(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Assumed Company Option</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.9(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Average Company Stock Price</div>&#8221; shall mean the average of the daily volume weighted average trading prices per share of Company Common Stock on Nasdaq (as reported by Bloomberg L.P. or, if not reported therein, in another authoritative source mutually selected by the parties) on each of the five consecutive Company Trading Days ending on (and including) the Company Trading Day that is three Company Trading Days prior to the date of the First Effective Time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Average Parent Stock Price</div>&#8221; shall mean the average of the daily volume weighted average trading prices per share of Parent Class&#160;A Common Stock on Nasdaq (as reported by Bloomberg L.P. or, if not reported therein, in another authoritative source mutually selected by the parties) on each of the five consecutive Trading Days ending on (and including) the Trading Day that is three Trading Days prior to the date of the First Effective Time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Business Day</div>&#8221; shall mean any day other than a Saturday, a Sunday or other day on which the SEC or banking institutions in the City of New York are authorized or required by Legal Requirements to be closed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">BV Opco</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(e)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">CapEx Budget</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)(xiii)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cash Election Consideration</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)(A)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cash Election Shares</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)(A)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Closing</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.2</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Closing Date</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.2</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Code</div>&#8221; shall mean the United States Internal Revenue Code of 1986, as amended. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company</div>&#8221; shall have the meaning set forth in the Preamble. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company 401(k) Plan</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.11(c)</div>. </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Acquisition Proposal</div>&#8221; shall mean any offer, indication of interest or proposal (other than an offer or proposal made or submitted by or on behalf of Parent or any of its Affiliates) contemplating or otherwise relating to any Company Acquisition Transaction. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Acquisition Transaction</div>&#8221; shall mean any transaction or series of related transactions (other than the Mergers) involving: </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) any merger, consolidation, amalgamation, business combination, joint venture, reorganization or other similar transaction involving the Company; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) any transaction (i)&#160;in which any Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules thereunder) of Persons acquires beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of the Company; or (ii)&#160;in which the Company or any of the Company Subsidiaries issues securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of the Company (after giving effect to such transaction); </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) any sale, exchange, transfer, acquisition or disposition of 20% or more of the consolidated assets (including equity securities of the Company Subsidiaries) of the Company and the Company Subsidiaries, taken as a whole, or of any business or businesses (or the assets of any business or businesses, including equity securities of any Company Subsidiary) that constitute or account for 20% or more of the consolidated net revenues or net income of the Company and the Company Subsidiaries, taken as a whole; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) any tender offer or exchange offer that if consummated would result in any Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules thereunder) of Persons acquiring beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for such securities) representing 20% or more of the outstanding voting power of the Company; or </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) any combination of the foregoing types of transaction if the sum of the percentage of the voting power of the Company or of the consolidated net revenues, net income or assets of the Company and the Company Subsidiaries, taken as a whole, involved is 20% or more. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Board</div>&#8221; shall mean the board of directors of the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Board Recommendation</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.4</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Book-Entry Shares</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Capitalization Date</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.3(c)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Change in Recommendation</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Common Stock</div>&#8221; shall mean the common stock, par value $0.01 per share, of the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Commonly Controlled Entity</div>&#8221; shall mean any entity, trade or business that is a member of a group described in Section&#160;414(b), (c), (m) or (o)&#160;of the Code or Section&#160;4001(b)(1) of ERISA that includes the entity, trade or business that is a member of the same &#8220;controlled group&#8221; as the Company, pursuant to Section&#160;4001(a)(14). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Credit Facilities</div>&#8221; means, collectively, (x)&#160;that certain Loan and Security Agreement, dated as of December&#160;26, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time), by and among Silicon Valley Bank, the Company and certain of affiliates of the Company and (y)&#160;that </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain Amended and Restated Credit Agreement, dated as of September&#160;27, 2019 (as amended, restated, supplemented or otherwise modified from time to time), by and among SWK Holdings Corporation, the Company and certain affiliates of the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Disclosure Schedule</div>&#8221; shall have the meaning set forth in the introductory paragraph of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;II</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Equity Agreements</div>&#8221; shall mean the Company Equity Plans (together with all grant agreements evidencing the Company Options). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Equity Plans</div>&#8221; shall mean the Company&#8217;s 2005 Employee Equity Incentive Plan, 2009 Employee Equity Incentive Plan, 2009 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Director Stock Option Plan, 2012 Employee Equity Incentive Plan, 2012 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Director Stock Option Plan, 2014 Employee Equity Incentive Plan, and 2017 Equity Incentive Plan, each as amended. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company ESPP</div>&#8221; shall mean the Company&#8217;s Employee Stock Purchase Plan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Fairness Opinion</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.24</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Financial Advisor</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.24</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Intervening Event</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(d)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company IP</div>&#8221; shall mean all Intellectual Property owned by the Company or any Company Subsidiary. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company IP Licenses</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.9(h)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Material Adverse Effect</div>&#8221; shall mean any state of facts, circumstance, condition, event, change, development, occurrence, result, effect, action or omission (each, an &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Effect</div>&#8221;) that, individually or in the aggregate with any one or more other Effects, (i)&#160;results in a material adverse effect on the business, condition (financial or otherwise) or results of operations of the Company and the Company Subsidiaries, taken as a whole or (ii)&#160;prevents, materially impairs, materially impedes or materially delays the consummation of the Mergers and the other transactions contemplated hereby on a timely basis and in any event on or before the End Date; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that with respect to clause (i)&#160;only, no Effect to the extent resulting or arising from any of the following, shall, to such extent, be deemed to constitute, or be taken into account in determining the occurrence of, a Company Material Adverse Effect: (A)&#160;general economic, political, business, financial or market conditions affecting the industry in which the Company and the Company Subsidiaries operate; (B)&#160;geopolitical conditions, including trade and national security policies and export controls and executive orders relating thereto, any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); (C) any pandemic (including the continuation or worsening of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic), epidemic, plague, or other outbreak of illness or public health event, hurricane, flood, tornado, earthquake or other natural disaster or act of God or changes resulting from weather conditions; (D)&#160;any failure by the Company or any of the Company Subsidiaries to meet any internal or external projections or forecasts or any decline in the price of Company Common Stock (but excluding, in each case, the underlying causes of such failure or decline, as applicable, which may themselves constitute or be taken into account in determining whether there has been, or would be, a Company Material Adverse Effect); (E) the public announcement or pendency of the Mergers and the other transactions contemplated hereby, including, in any such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, business partners or employees<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>(<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that this clause (E)&#160;shall not apply to (x)&#160;any representation or warranty in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.6</div> to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Mergers or (y)&#160;any action or omission by the Company, any Company Subsidiary or their respective Representatives in order to </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">comply with the Company&#8217;s obligations under <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)</div>); (F) changes in applicable Legal Requirements (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures) or the interpretation thereof; (G)&#160;changes in GAAP or any other applicable accounting standards or the interpretation thereof; (H)&#160;any action expressly required to be taken by the Company pursuant to the terms of this Agreement or at the express written direction or consent of Parent or the Acquisition Subs; (I)&#160;any claims, suits, actions or Legal Proceedings arising from allegations of breach of fiduciary duty or violation of Law or otherwise relating to this Agreement or the transactions contemplated by this Agreement; or (J)&#160;any breach, violation or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-performance</div> of any provision of this Agreement by Parent or any of its Affiliates; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">further</div></div>, that any Effect relating to or arising out of or resulting from any change or event referred to in clause (A), (B), (C), (F) or (G)&#160;above may constitute, and be taken into account in determining the occurrence of, a Company Material Adverse Effect if and only to the extent that such change or event has a disproportionate impact on the Company and the Company Subsidiaries as compared to other participants that operate in the industry in which the Company and the Company Subsidiaries operate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Options</div>&#8221; shall mean options to purchase shares of Company Common Stock from the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Permits</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.12(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Permitted Encumbrances</div>&#8221; shall mean: (a)&#160;Liens for Taxes or governmental assessments, charges or claims of payment not yet due and payable or which are being contested in good faith by appropriate proceedings; (b)&#160;vendors&#8217;, mechanics&#8217;, materialmen&#8217;s, carriers&#8217;, workers&#8217;, construction and other similar Liens arising or incurred in the ordinary course of business or with respect to liabilities that are not yet due and payable or, if due, are not delinquent or are being contested in good faith by appropriate proceedings; (c)&#160;encumbrances or imperfections of title relating to liabilities for which appropriate reserves have been established and are reflected in the Most Recent Company Balance Sheet or imposed or promulgated by applicable Legal Requirements, including zoning, entitlement, building codes, or other Legal Requirements with respect to land use; (d)&#160;Liens, pledges or encumbrances arising from or otherwise relating to transfer restrictions under the securities laws of any jurisdiction; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(e)&#160;non-exclusive</div> licenses of Intellectual Property granted in the ordinary course of business; (f)&#160;Liens, encumbrances or imperfections of title which do not and would not reasonably be expected to, individually or in the aggregate, materially impair the use of the subject property as used by the Company and the Company Subsidiaries and (g)&#160;Liens arising under any Company indentures or the Company&#8217;s existing credit facility (or any replacement or refinancing thereof in accordance with this Agreement). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Plan</div>&#8221; shall mean each &#8220;employee benefit plan&#8221; (within the meaning of Section&#160;3(3) of ERISA, whether or not subject to ERISA) and each other employment, bonus, deferred compensation, equity-based, pension, severance, change in control, employee loan, fringe benefit, or other employee benefit plan, policy, agreement, program or arrangement, which the Company or any Company Subsidiary maintains for the benefit of its current or former employees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Preferred Stock</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.3(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Products</div>&#8221; shall mean any and all products and services that are or have been since January&#160;1, 2019 marketed, offered, sold, licensed, provided, manufactured, packaged, distributed or supported by the Company or any Company Subsidiary. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Registered IP</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.9(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Representation Letter</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.12(c)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Restricted Stock</div>&#8221; shall mean shares of Company Common Stock subject to vesting conditions based on continuing service, based on performance, or based on both continuing service and performance. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company SEC Documents</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.7(a)</div>. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Stock Certificates</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.10(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Stockholder Meeting</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Subsidiary</div>&#8221; shall mean any direct or indirect <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-Subsidiary</div> of the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Superior Proposal</div>&#8221; shall mean any <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">bona fide</div></div>, unsolicited written Company Acquisition Proposal made after the date of this Agreement that: (a)&#160;if consummated, would result in any Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules thereunder) of Persons (other than Parent) directly or indirectly becoming the beneficial owner of (i)&#160;any business or businesses that constitute or account for 50% or more of the net revenues, net income or assets of the Company, or (ii) 50% or more of the outstanding total voting power of the equity securities of the Company; and (b)&#160;the Company Board determines in good faith, after consultation with the Company&#8217;s outside legal counsel and its financial advisor, is reasonably capable of being consummated on the terms proposed and which, taking into account such factors as the Company Board reasonably considers in good faith to be appropriate and relevant, including the financial, legal, timing, likelihood of consummation, confidentiality, regulatory, financing and other aspects of such Company Acquisition Proposal, would be more favorable to the holders of shares of Company Common Stock from a financial point of view than the transactions contemplated by this Agreement (after giving effect to any revisions to the terms of the Agreement that if accepted by the Company would be legally binding on Parent in response to such Company Acquisition Proposal pursuant to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5</div>). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Superior Proposal Notice</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.5(c)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Trading Day</div>&#8221; shall mean a day on which shares of Company Common Stock are traded on Nasdaq. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Continuing Employee</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.11(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Contract</div>&#8221; shall mean any contract, subcontract, note, bond, mortgage, indenture, lease, license, sublicense, guaranty, security agreement, franchise or other legally binding instrument, commitment or obligation, whether oral or in writing, excluding any permits, in each case, that is legally binding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div>&#8221; means <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> any evolutions or mutations of the virus and illness, and any related or associated epidemics, pandemics or disease outbreaks. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures</div>&#8221; means any quarantine, isolation, &#8220;shelter in place,&#8221; &#8220;stay at home,&#8221; workforce reduction, social distancing, shut down, closure, sequester or any other Legal Requirement, decree, judgment, injunction or other order, directive, guidelines or recommendations by any Governmental Entity or industry group in connection with or in response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> including, the&#160;Coronavirus Aid,&#160;Relief, and&#160;Economic Security (CARES) Act. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">D&amp;O Policy</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Data Protection Laws</div>&#8221; means all Legal Requirements (including any applicable Legal Requirements of jurisdictions where personal information is collected) governing the privacy or security of personal information, including, to the extent applicable: <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA</div>, the Federal Trade Commission Act, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAN-SPAM</div> Act, the Telephone Consumer Protection Act, the Telemarketing and Consumer Fraud and Abuse Prevention Act, the Computer Fraud and Abuse Act, state social security number protection applicable laws, state data security laws, state data breach notification applicable laws, state consumer protection laws, any applicable Legal Requirements concerning requirements for website and internet-connected device privacy policies and practices, data or web scraping, call or electronic monitoring or recording of any outbound communications, the Data Protection Act 2018, the Data Protection Act 1998 and all other applicable national Laws and secondary legislation </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">implementing European Directive 95/46/EC, the General Data Protection Regulation (EU) 2016/679 (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">GDPR</div>&#8221;) and all applicable national Legal Requirements implementing or supplementing the GDPR and all related national Laws and secondary legislation, the Privacy and Electronic Communications (EC Directive) Regulations 2003 (SI 2003/2426), all other applicable Laws and secondary legislation implementing European Directive 2002/58/EC, and any other laws applicable to the collection, storage or processing of personal information. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Debt Commitment Letter</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.15(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Debt Financing</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.15(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">D&amp;O Policy</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Debt Financing Sources</div>&#8221; means the agents, arrangers, lenders and other entities that have committed to provide or arrange or otherwise have entered into agreements pursuant to the Debt Commitment Letter or in connection with all or any part of the Debt Financing described therein, or replacement debt financings, in connection with the transactions contemplated hereby, including the parties to any commitment letters, joinder agreements, indentures or credit agreements entered pursuant thereto or relating thereto, and their respective successors and assigns. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Debt Financing Sources Related Party</div>&#8221; means the Debt Financing Sources together with their respective Affiliates, and the respective directors, officers, employees, agents, advisors, other Representatives and successors of each of the foregoing and their respective Affiliates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Delaware Secretary of State</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.2</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">DGCL</div>&#8221; shall have the meaning set forth in the Recitals. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">DTC</div>&#8221; shall mean The Depository Trust Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Elected Cash Consideration</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.7(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Election Deadline</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.15(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Election Form</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.15(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Election Period</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.15(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">End Date</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;6.1(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Entity</div>&#8221; shall mean any corporation (including any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity (including any Governmental Entity). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Environmental Law</div>&#8221; shall mean any Legal Requirement relating to pollution or protection, preservation or restoration of the environment (including air, surface water, groundwater, drinking water supply, surface land, subsurface land, plant and animal life or any other natural resource), including any such Legal Requirement regulating emissions, discharges or releases of pollutants, contaminants, wastes, toxic substances, exposure to or release of, or the management of any hazardous materials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">ERISA</div>&#8221; shall mean the Employee Retirement Income Security Act of 1974, as amended. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Act</div>&#8221; shall mean the Securities Exchange Act of 1934, as amended. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Agent</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Fund</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Excluded Shares</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(i)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Export Approvals</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.12(c)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Export Control Laws</div>&#8221; shall mean (a)&#160;all applicable trade, export control, import, and antiboycott laws and regulations imposed, administered, or enforced by the U.S. government, including the Arms Export Control Act (22 U.S.C. &#167; 2778), the International Emergency Economic Powers Act (50 U.S.C. &#167;&#167; 1701&#8211;1706), Section&#160;999 of the Internal Revenue Code, Title 19 of the U.S. Code, the International Traffic in Arms Regulations (22 C.F.R. Parts <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">120-130),</div> the Export Administration Regulations (15 C.F.R. Parts <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">730-774),</div> the Export Control Reform Act of 2018 (50 U.S.C. &#167;&#167; 4801-4852), the U.S. customs regulations at 19 C.F.R. Chapter 1, and the Foreign Trade Regulations (15 C.F.R. Part 30); and (b)&#160;all applicable trade, export control, import, and antiboycott laws and regulations imposed, administered or enforced by any other country, except to the extent inconsistent with U.S. law. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">FDA</div>&#8221; means the United States Food and Drug Administration, or any successor thereto. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Financing Conditions</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.13(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">First Certificate of Merger</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.2</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">First Effective Time</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.2</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> Registration Statement</div>&#8221; shall mean the registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> to be filed with the SEC by Parent in connection with the Parent Share Issuance, as such registration statement may be amended prior to the time it is declared effective by the SEC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">GAAP</div>&#8221; shall mean United States generally accepted accounting principles. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">General Enforceability Exception</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.4</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Generally Available Software</div>&#8221; means generally, commercially available <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-the-shelf</div></div> software and (i)&#160;is used in the general operation of the business but is not material to the Company or any of the Company Subsidiaries, and (ii)&#160;has not been modified or customized for the Company or any of the Company Subsidiaries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Government Contract</div>&#8221; means any prime contract, subcontract, basic ordering agreement, letter contract, purchase order, delivery order, change order, arrangement or other commitment of any kind between the Company or any Company Subsidiary, on the one hand, and any Governmental Entity or prime contractor or subcontractor to a Governmental Entity, on the other hand. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Government Official</div>&#8221; means (a)&#160;any elected or appointed government official, officer, employee or Person acting in an official or public capacity on behalf of a Governmental Entity, (b)&#160;any official or employee of a quasi-public or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> international organization, (c)&#160;any employee or other Person acting for or on behalf of any entity that is wholly or partially government owned or controlled by a Governmental Entity, (d)&#160;any Person exercising legislative, administrative, judicial, executive, or regulatory functions for or pertaining to a Governmental Entity (including any independent regulator), (e) any political party official, officer, employee, or other Person acting for or on behalf of a political party and (f)&#160;any candidate for public office. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Government Programs</div>&#8221; means any foreign, federal, or state healthcare program, including the U.S. federal health program as defined in 42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7b(f),</div> including Title XVIII (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Medicare</div>&#8221;) and Title XIX </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid</div>&#8221;) of the Social Security Act, CHAMPUS, TRICARE and any other federal health care program, as defined in 42 U.S.C. &#167; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1320a-7b(f),</div> any health insurance program for the benefit of federal employees, including those under chapter 89 of title 5 or State health care program, as defined in 42 U.S.C. &#167; 1320a-7(h), or successor programs to any of the above. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Governmental Authorization</div>&#8221; shall mean any franchise, grants, easement, variance, exception, consent, certificate, approval, clearance, permission, permit, license, registration, qualification or authorization granted by any Governmental Entity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Governmental Entity</div>&#8221; shall mean any federal, state, local or foreign governmental authority, any transnational governmental organization or any court of competent jurisdiction, arbitral, administrative agency or commission or other governmental authority or instrumentality, domestic or foreign, or Notified Body. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Harmful Code</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.9(h)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">HCT/Ps</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.6(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare Regulatory Authority</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.6(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare Regulatory Authorizations</div>&#8221; means any Governmental Authorizations required by the Company or any of the Company Subsidiaries to conduct its respective business under applicable Healthcare Laws, including without limitation, any such Governmental Authorizations required for the testing, manufacturing, marketing, promotion, sale, distribution, packaging, storage, export or import, of any Company Product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA</div>&#8221; means the Health Insurance Portability and Accountability Act of 1996 and all regulations promulgated thereunder, including the Privacy Standards (45 C.F.R. Parts 160 and 164), the Electronic Transactions Standards (45 C.F.R. Parts 160 and 162), and the Security Standards (45 C.F.R. Parts 160, 162 and 164), as amended by the HITECH Act, the final HIPAA/HITECH Omnibus Rules published by the U.S. Department of Health and Human Services on January&#160;25, 2013, and as otherwise may be amended from time to time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">HITECH Act</div>&#8221; means the Health Information Technology for Economic and Clinical Health Act provisions of the American Recovery and Reinvestment Act of 2009, Pub. Law <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;111-5</div> and its implementing regulations, including 42 C.F.R. &#167;&#167; 412, 413, 422 and 495, as amended by the HIPAA Omnibus Rule, issued on January&#160;25, 2013, effective as of March&#160;26, 2013. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">HSR Act</div>&#8221; shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Bound</div> Licenses</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.9(h)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Indemnified Parties</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Initial Surviving Corporation</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.1</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property</div>&#8221; shall mean any and all past, present and future common law or statutory rights anywhere in the world arising under or associated with: (i)&#160;patents, patent applications, statutory invention registrations, registered designs, industrial designs and design patents, and similar or equivalent rights in inventions and designs, and all intellectual property rights therein provided by international treaties and conventions, including all divisions, continuations, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">continuations-in-part,</div></div> reissues, renewals, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-examinations,</div> provisionals and extensions thereof (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Patents</div>&#8221;); (ii) trademarks, service marks, trade dress, trade names, company names, logos and other designations of origin, together with any registrations, applications for registration, renewals, and extensions thereof, and the goodwill associated with any of the foregoing (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Marks</div>&#8221;); </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(iii) URL and domain name registrations, uniform resource locators, and Internet Protocol addresses, social media handles and other names, identifiers and locators associated with Internet addresses, sites and services; (iv)&#160;copyrights and any other equivalent rights in works of authorship (including intellectual property rights in Software as a work of authorship), whether registered or unregistered, moral rights, and any other rights of authors, and any registrations and applications for registration thereof (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Copyrights</div>&#8221;); (v) mask work rights (as defined in the Semiconductor Chip Protection Act, 17 U.S.C. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#167;&#160;&#167;&#160;901-914)</div> and any other intellectual property right in semiconductor topology or mask works, and any registration therefore (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Mask Work Rights</div>&#8221;) (vi) trade secrets and industrial secret rights, proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and confidential and proprietary data and business or technical information, including any ideas, formulas, compositions, inventions (whether patentable or not and however documented), processes, techniques, specifications, business plans, proposals, designs, technical data, invention disclosures, customer data, financial information, pricing and cost information, bills of material or other similar information, in each case, excluding any of the foregoing that comprise or are protected by issued Patents or published Patent applications (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Trade Secrets</div>&#8221;); (vii) all claims and causes of actions arising out of or related to any past, current or future infringement or misappropriation of any of the foregoing; and (viii)&#160;other similar or equivalent intellectual property rights anywhere in the world. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Intended Tax Treatment</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.12(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">IRS</div>&#8221; shall mean the United States Internal Revenue Service. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Joint Proxy Statement/Prospectus</div>&#8221; shall mean the joint proxy statement/prospectus to be sent to the Company&#8217;s stockholders in connection with the Company Stockholder Meeting and to Parent&#8217;s stockholders in connection with the Parent Stockholder Meeting. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">knowledge of the Company</div>&#8221; or &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">the Company&#8217;s knowledge</div>&#8221; shall mean the current actual knowledge, after inquiry of direct reports reasonably likely to have knowledge of the applicable subject matter, of the individuals listed in Part &#8220;Definitions&#8221; of the Company Disclosure Schedule. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">knowledge of Parent</div>&#8221; shall mean the current actual knowledge, after inquiry of director reports reasonably likely to have knowledge of the applicable subject matter, of the individuals listed in Part &#8220;Definitions&#8221; of the Parent Disclosure Schedule. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Legal Proceeding</div>&#8221; shall mean any legal or administrative proceeding (including before the United States Patent and Trademark Office or the Patent Trial and Appeal Board), lawsuit, arbitration, mediation, court action, or other proceeding before any court or public or private body or tribunal or other Governmental Entity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Legal Requirement</div>&#8221; shall mean any law (including common law), statute, ordinance, rule regulation, judgment, order, injunction, decision, decree, guidance, ruling, administrative or judicial doctrine, or requirement of any Governmental Entity, including but not limited to the Anti-Corruption Laws as defined herein. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Letter of Transmittal</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lien</div>&#8221; shall mean, with respect to any property or asset, any mortgage, lien, pledge, charge, security interest, encumbrance or limitation on transfer in respect of such property or asset, but excluding, with respect to Intellectual Property, licenses. A Person shall be deemed to own subject to a Lien any property or asset that it has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such property or asset. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any statement in the Agreement to the effect that any information, document or other material has been &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">made available</div>&#8221; by the Company shall mean that such information, document or material was: (a)&#160;uploaded to the virtual data room maintained by the Company in connection with the transactions contemplated by the Agreement, (b)&#160;publicly filed with the SEC or (c)&#160;otherwise delivered to Parent or its Representatives (with </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">receipt thereof confirmed by Parent or its Representatives). Any statement in the Agreement to the effect that any information, document or other material has been &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">made available</div>&#8221; by Parent shall mean that such information, document or material was: (i)&#160;uploaded to the virtual data room maintained by Parent in connection with the transactions contemplated by the Agreement (ii)&#160;publicly filed with the SEC or (iii)&#160;otherwise delivered to the Company or its Representatives (with receipt thereof confirmed by the Company or its Representatives). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Mailing Date</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.15(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Material Contract</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.11</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Maximum Annual Premium</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.13(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Maximum Cash Amount</div>&#8221; shall mean an amount equal to the product of $10.50 multiplied by the aggregate number of shares of Company Common Stock issued and outstanding as of 5:00 p.m., New York Time on the Election Deadline. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Medical Devices Directive</div>&#8221; shall mean Directive 93/42/EEC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Medical Devices Regulation</div>&#8221; shall mean Regulation (EU) 2017/45. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Mergers</div>&#8221; shall have the meaning set forth in the Recitals. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Merger Consideration</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Most Recent Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div></div>&#8221; shall mean the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June&#160;30, 2020 (filed with the SEC on September&#160;3, 2020). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Most Recent Company Balance Sheet</div>&#8221; shall mean the balance sheet of the Company as of March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Most Recent Parent Balance Sheet</div>&#8221; shall mean the balance sheet of Parent as of April&#160;3, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Nasdaq</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.7(e)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Election Shares</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)(C)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">No Election Value</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.7(b)(ii)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Budgeted</div> Capital Expenditure</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(a)(xiii)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Disclosure</div> Agreement</div>&#8221; shall mean that certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> agreement, dated as of June&#160;2, 2021, by and between the Company and Parent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-DTC</div> Book-Entry Share</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.12(c)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Notified Body</div>&#8221; means an independent conformity assessment body designated in accordance with the Medical Devices Regulation or the Medical Devices Directive. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">OFAC</div>&#8221; shall mean the U.S. Department of Treasury, Office of Foreign Assets Control. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Option Exchange Ratio</div>&#8221; means the quotient (rounded to the 4th decimal place) obtained by dividing (i)&#160;the Average Company Stock Price by (ii)&#160;the Average Parent Stock Price (as adjusted as appropriate to reflect any stock splits, stock dividends, combinations, reorganizations, reclassifications or similar events). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Order</div>&#8221; shall mean any order, decision, judgment, writ, injunction, stipulation, award, or decree, issued by any Governmental Entity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Organizational Documents</div>&#8221; shall mean, with respect to any Entity: (a)&#160;if such Entity is a corporation, such Entity&#8217;s certificate or articles of incorporation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">by-laws</div> and similar organizational documents, as amended; (b)&#160;if such Entity is a limited liability company, such Entity&#8217;s certificate or articles of formation and operating agreement, as amended; and (c)&#160;if such Entity is a limited partnership, such Entity&#8217;s certificate or articles of formation and limited partnership agreement, as amended. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Out-Bound</div> Licenses</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.9(h)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent</div>&#8221; shall have the meaning set forth in the Preamble. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Acquisition Proposal</div>&#8221; shall mean any offer, indication of interest or proposal (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates) contemplating or otherwise relating to any Parent Acquisition Transaction. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Acquisition Transaction</div>&#8221; shall mean any transaction or series of related transactions (other than the Mergers) involving: </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) any merger, consolidation, amalgamation, business combination, joint venture, reorganization or other similar transaction involving Parent; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(b) any transaction (i)&#160;in which any Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules thereunder) of Persons acquires beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of Parent; or (ii)&#160;in which Parent or any Parent Subsidiaries issues securities (or instruments convertible into or exercisable or exchangeable for, such securities) representing 20% or more of the outstanding voting power of Parent (after giving effect to such transaction); </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) any sale, exchange, transfer, acquisition or disposition of 20% or more of the consolidated assets (including equity securities of the Parent Subsidiaries) of Parent and the Parent Subsidiaries, taken as a whole, or of any business or businesses (or the assets of any business or businesses, including equity securities of any Subsidiaries of Parent) that constitute or account for 20% or more of the consolidated net revenues or net income of Parent and the Parent Subsidiaries, taken as a whole; </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) any tender offer or exchange offer that if consummated would result in any Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules thereunder) of Persons acquiring beneficial or record ownership of securities (or instruments convertible into or exercisable or exchangeable for such securities) representing 20% or more of the outstanding voting power of Parent; or </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) any combination of the foregoing types of transaction if the sum of the percentage of the voting power of Parent or of the consolidated net revenues, net income or assets of Parent and the Parent Subsidiaries, taken as a whole, involved is 20% or more. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Board</div>&#8221; shall mean the board of directors of Parent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Board Recommendation</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.4(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Capitalization Date</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.3(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Change in Recommendation</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Class</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A Common Stock</div>&#8221; shall mean the Class&#160;A common stock, par value $0.01 per share, of Parent. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Class</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;B Common Stock</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.3(a)</div>. </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Common Stock</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.3(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Commonly Controlled Entity</div>&#8221; shall mean any entity, trade or business that is a member of a group described in Section&#160;414(b), (c), (m) or (o)&#160;of the Code or Section&#160;4001(b)(1) of ERISA that includes the entity, trade or business that is a member of the same &#8220;controlled group&#8221; as Parent, pursuant to Section&#160;4001(a)(14). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Disclosure Schedule</div>&#8221; shall have the meaning set forth in the introductory paragraph of <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;III</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Equity Agreements</div>&#8221; shall mean the agreements pursuant to which outstanding awards are granted under the Parent Equity Plan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Equity Plan</div>&#8221; shall mean the 2004 Equity Incentive Plan of Parent, as amended and restated from time to time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent ESPP</div>&#8221; shall mean Parent&#8217;s 2021 Employee Stock Purchase Plan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Fairness Opinion</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.17</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Financial Advisor</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.20</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Intervening Event</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(d)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent IP</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.18(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Material Adverse Effect</div>&#8221; shall mean any Effect that, individually or in the aggregate with any one or more other Effects, (i)&#160;results in a material adverse effect on the business, condition (financial or otherwise) or results of operations of Parent and the Parent Subsidiaries, taken as a whole or (ii)&#160;prevents, materially impairs, materially impedes or materially delays the consummation of the Mergers and the other transactions contemplated hereby on a timely basis and in any event on or before the End Date; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that with respect to clause (i)&#160;only, no Effect to the extent resulting or arising from any of the following, shall, to such extent, be deemed to constitute, or be taken into account in determining the occurrence of, a Parent Material Adverse Effect: (A)&#160;general economic, political, business, financial or market conditions affecting the industry in which Parent and the Parent Subsidiaries operate; (B)&#160;geopolitical conditions, including trade and national security policies and export controls and executive orders relating thereto, any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); (C) any pandemic (including the continuation or worsening of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic), epidemic, plague, or other outbreak of illness or public health event, hurricane, flood, tornado, earthquake or other natural disaster or act of God or changes resulting from weather conditions; (D)&#160;any failure by Parent or any of the Parent Subsidiaries to meet any internal or external projections or forecasts or any decline in the price of Parent Class&#160;A Common Stock (but excluding, in each case, the underlying causes of such failure or decline, as applicable, which may themselves constitute or be taken into account in determining whether there has been, or would be, a Parent Material Adverse Effect); (E) the public announcement or pendency of the Mergers and the other transactions contemplated hereby, including, in any such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, business partners or employees, (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that this clause (E)&#160;shall not apply to (x)&#160;any representation or warranty in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.6</div> to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Mergers or (y)&#160;any action or omission by Parent, any Parent Subsidiary or their respective Representatives in order to comply with Parent&#8217;s obligations under <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.1(b)</div>); (F) changes in applicable Legal Requirements (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Measures) or the interpretation thereof; (G)&#160;changes in GAAP or any other applicable accounting standards or the interpretation </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-101 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">thereof; or (H)&#160;any action expressly required to be taken by Parent pursuant to the terms of this Agreement or at the express written direction or consent of the Company; (I)&#160;any claims, suits, actions or Legal Proceedings arising from allegations of breach of fiduciary duty or violation of Law or otherwise relating to this Agreement or the transactions contemplated by this Agreement; or (J)&#160;any breach, violation or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-performance</div> of any provision of this Agreement the Company or any of its Affiliates; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">further</div></div>, that any Effect relating to or arising out of or resulting from any change or event referred to in clause (A), (B), (C), (F) or (G)&#160;above may constitute, and be taken into account in determining the occurrence of, a Parent Material Adverse Effect if and only to the extent that such change or event has a disproportionate impact on Parent and the Parent Subsidiaries as compared to other participants that operate in the industry in which Parent and the Parent Subsidiaries operate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Options</div>&#8221; shall mean options to purchase shares of Parent Class&#160;A Common Stock from Parent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Permits</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.9(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Permitted Encumbrances</div>&#8221; shall mean: (a)&#160;Liens for Taxes or governmental assessments, charges or claims of payment not yet due and payable or which are being contested in good faith by appropriate proceedings; (b)&#160;vendors&#8217;, mechanics&#8217;, materialmen&#8217;s, carriers&#8217;, workers&#8217;, construction and other similar Liens arising or incurred in the ordinary course of business or with respect to liabilities that are not yet due and payable or, if due, are not delinquent or are being contested in good faith by appropriate proceedings; (c)&#160;Liens, encumbrances or imperfections of title relating to liabilities for which appropriate reserves have been established and are reflected in the Most Recent Parent Balance Sheet or imposed or promulgated by applicable Legal Requirements, including zoning, entitlement, building codes, or other Legal Requirements with respect to land use; (d)&#160;Liens, pledges or encumbrances arising from or otherwise relating to transfer restrictions under the securities laws of any jurisdiction; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(e)&#160;non-exclusive</div> licenses of Intellectual Property granted in the ordinary course of business; (f)&#160;Liens, encumbrances or imperfections of title which do not and would not reasonably be expected to, individually or in the aggregate, materially impair the use of the subject property as used by Parent and the Parent Subsidiaries; and (g)&#160;Liens arising under any Parent indentures or existing credit facility of Parent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Plan</div>&#8221; shall mean each &#8220;employee benefit plan&#8221; (within the meaning of Section&#160;3(3) of ERISA) and each other employment, bonus, deferred compensation, equity-based, pension, severance, change in control, employee loan, fringe benefit, or other employee benefit plan, policy, agreement, program or arrangement, which Parent or any Parent Subsidiary maintains for the benefit of its employees or former employees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Products</div>&#8221; shall mean any and all products and services that are or have been since January&#160;1, 2019 tested, marketed, offered, sold, licensed, provided, manufactured, packaged, distributed or supported by the Parent or any Parent Subsidiary, including any and all products and services currently under development by the Parent or any Parent Subsidiary. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Registered IP</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.18(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Representation Letter</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.12(c)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent RSUs</div>&#8221; shall mean restricted stock units representing the right to vest in and be issued shares of Parent Class&#160;A Common Stock by Parent that are subject to vesting restrictions based on continuing service or based on performance. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent SEC Documents</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.7(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Share Issuance</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.4(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Stockholder Meeting</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(a)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Subsidiary</div>&#8221; shall mean any direct or indirect Subsidiary of Parent. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-102 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Superior Proposal</div>&#8221; shall mean any <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">bona fide</div></div>, unsolicited written Parent Acquisition Proposal made after the date of this Agreement that: (a)&#160;if consummated, would result in any Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules thereunder) of Persons (other than the Company) directly or indirectly becoming the beneficial owner of (i)&#160;any business or businesses that constitute or account for 50% or more of the net revenues, net income or assets of Parent, or (ii) 50% or more of the outstanding total voting power of the equity securities of the Parent; and (b)&#160;the Parent Board determines in good faith, after consultation with Parent&#8217;s outside legal counsel and its financial advisor, is reasonably capable of being consummated on the terms proposed and which, taking into account such factors as the Parent Board reasonably considers in good faith to be appropriate and relevant, including the financial, legal, timing, likelihood of consummation, confidentiality, regulatory, financing and other aspects of such Parent Acquisition Proposal would be more favorable to the holders of shares of Parent Common Stock from a financial point of view than the transactions contemplated by this Agreement (after giving effect to any revisions to the terms of the Agreement that if accepted by the Company would be legally binding on the Company in response to such Parent Acquisition Proposal pursuant <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6</div>). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Superior Proposal Notice</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.6(c)(ii)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Top Customer</div>&#8221; shall mean a top ten customer of the Parent and the Parent Subsidiaries, taken as a whole, based on revenues during the 12 months ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Top Distributor</div>&#8221; shall mean a top five distributor of the Parent and the Parent Subsidiaries, taken as a whole, based on revenues during the 12 months ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Top Supplier</div>&#8221; shall mean a top five supplier of inventory or manufacturing services to the Parent and the Parent Subsidiaries, taken as a whole, based on expenditures during the 12 months ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Payoff Letters</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.19</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Person</div>&#8221; shall mean any individual or Entity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Personal Data</div>&#8221; means any information that relates to, identifies, could reasonably be used to identify, or is otherwise identifiable with an individual, including any information relating to an identified or identifiable natural Person (an identifiable natural Person is one who can be identified directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person, and any information that is defined as &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;individually identifiable health information,&#8221; &#8220;Protected Health Information&#8221; or &#8220;personal information&#8221; under any applicable Data Protection Laws. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Prohibited Person</div>&#8221; shall mean any Person that is the target of Sanctions Laws, including (a)&#160;a Person that has been determined by a competent authority to be the subject of a prohibition on such conduct of any law, regulation, rule or executive order administered by OFAC; (b)&#160;the government, including any political subdivision, agency or instrumentality thereof, of any country against which the United States maintains comprehensive economic sanctions or embargoes (currently Iran, Syria, Cuba, North Korea, and the Crimea region of Ukraine); (c) any Person that acts on behalf of or is owned or controlled by a government of a country against which the United States maintains comprehensive economic sanctions or embargoes; (d)&#160;any Person organized or resident in a country or territory subject to comprehensive sanctions; (e)&#160;any Person that has been identified on the OFAC Specially Designated Nationals and Blocked Persons List (Appendix A to 31 C.F.R. Ch. V), as amended from time to time, or 50% or more of which is owned, directly or indirectly, by any such Person or Persons, or, where relevant under applicable Sanctions Laws, controlled by any such Person or Persons or acting for or on behalf of such Person or Persons; or (f)&#160;any Person that has been designated on any similar list or Order published by a Governmental Entity in the United States. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-103 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Protected Health Information</div>&#8221; means individually identifiable health information transmitted or maintained by a covered entity or its business associates in any form or medium as defined at 45 C.F.R. &#167; 160.103. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Registered IP</div>&#8221; shall mean all U.S., international or foreign (a)&#160;issued Patents and Patent applications, (b)&#160;registered Marks and applications to register Marks, (c)&#160;registered Copyrights and applications for Copyright registration, (d)&#160;registered Mask Work Rights and applications to register Mask Work Rights, (e)&#160;domain name registrations and (f)&#160;all other Intellectual Property, in each case of (a)&#160;through (f) that are registered with, issued by or applied for by or with any Governmental Entity (or, in the case of domain name registrations, other public or quasi-public legal authorities such as domain name registrars). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Relevant Legal Restraint</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;5.1(e)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Representation Letters</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;4.12(c)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Representatives</div>&#8221; shall mean, with respect to a Person, all of the officers, directors, employees, consultants, legal representatives, agents, advisors, auditors, investment bankers, Affiliates and other representatives of such Person. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Required Company Stockholder Vote</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2.5</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Required Information</div>&#8221; means the financial statements regarding the Company and the Company Subsidiaries that are necessary to satisfy the condition set forth in Paragraph 5 of Exhibit C (Conditions Annex) to the Debt Commitment Letter as in effect on the date hereof. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Required Parent Stockholder Vote</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;3.5</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Sanctions Laws</div>&#8221; shall mean applicable economic or financial sanctions or trade embargoes imposed, administered, or enforced by relevant Governmental Entities, including those administered by OFAC or the U.S. Department of State, the European Union or its Member States, or Her Majesty&#8217;s Treasury of the United Kingdom. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">SEC</div>&#8221; shall mean the United States Securities and Exchange Commission. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Securities Act</div>&#8221; shall mean the Securities Act of 1933, as amended. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Shortfall Amount</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.7(b)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Software</div>&#8221; shall mean any computer software, programs and databases in any applicable form, including object code, source code, firmware and embedded versions thereof tools, assemblers, applets, compilers, application programming interfaces, developers kits, utilities, graphical user interfaces, menus, images, icons, and forms, and all versions, updates, corrections, enhancements and modifications thereof, and all related documentation, developer notes, comments and annotations related thereto. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Stock Election Consideration</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)(B)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Stock Election Shares</div>&#8221; shall have the meaning set forth in <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Section</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;1.5(a)(ii)(B)</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An Entity shall be deemed to be a &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Subsidiary</div>&#8221; of another Person if such Person directly or indirectly owns, beneficially or of record: (a)&#160;an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity&#8217;s board of directors or comparable governing body; or (b)&#160;at least 50% of the outstanding voting equity interests issued by such Entity. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-104 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Tax Opinion Counsel</div>&#8221;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>means Jones Day (or other nationally recognized tax counsel reasonably acceptable to the Company). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Tax Returns</div>&#8221; shall mean any and all returns, reports, elections, claims for refund, estimated Tax filings, declarations, certificates or other documents filed or required to be filed with any Governmental Entity with respect to Taxes, including any schedules or attachments thereto, and any amendments thereof. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Taxes</div>&#8221; shall mean any and all U.S. federal, state, local and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> taxes, assessments, levies, duties, tariffs, imposts and other similar charges and fees imposed by any Governmental Entity, including, without limitation, any income, franchise, windfall or other profits, gross receipts, premiums, property, sales, use, net worth, capital stock, payroll, employment, social security, workers&#8217; compensation, unemployment compensation, excise, withholding, ad valorem, stamp, transfer, value-added, and license, registration and documentation fees, severance, occupation, environmental, disability, real property, personal property, registration, alternative or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">add-on</div> minimum, or estimated tax, and including any interest, penalty, additions to tax and any additional amounts imposed with respect thereto, whether disputed or not. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Termination Fee</div>&#8221; shall mean an amount in cash equal to $20,661,000. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Top Customer</div>&#8221; shall mean a top ten customer of the Company and the Company Subsidiaries, taken as a whole, based on revenues during the 12 months ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Top Distributor</div>&#8221; shall mean a top five distributor of the Company and the Company Subsidiaries, taken as a whole, based on revenues during the 12 months ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Top Supplier</div>&#8221; shall mean a top five supplier of inventory or manufacturing services to the Company and the Company Subsidiaries, taken as a whole, based on expenditures during the 12 months ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Trading Day</div>&#8221; shall mean a day on which shares of Parent Class&#160;A Common Stock are traded on Nasdaq. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Treasury Regulations</div>&#8221; shall mean the regulations prescribed under the Code (including any temporary regulations, amended or successor provisions with respect to such regulations). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Willful Breach</div>&#8221; means a breach that is the result of a willful or intentional act or failure to act where the breaching party knows, or would reasonably be expected to have known, that such act or failure to act is, or would reasonably be expected to result in, a breach. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A-105 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_41" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Annex B</div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g20u43.jpg" style="width: 161px; height: 56px;"/></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">767 Fifth Avenue</div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, NY 10153</div></div> <div style="text-align: left; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&#160;&#160;&#160;&#160;212.287.3200</div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F&#160;&#160;&#160;&#160;212.287.3201</div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pwpartners.com</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">July&#160;29, 2021 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board of Directors of Bioventus Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4721 Emperor Boulevard, Suite 100 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Durham, North Carolina 27703 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members of the Board: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We understand that Bioventus Inc. (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent</div>&#8221;), Oyster Merger Sub I, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition Sub I</div>&#8221;), Oyster Merger Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Parent (&#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition Sub II</div>&#8221;), and Misonix, Inc. (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company</div>&#8221;), a Delaware corporation, propose to enter into an Agreement and Plan of Merger (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Merger Agreement</div>&#8221;) pursuant to which, among other things, Acquisition Sub I will merge with and into the Company, with the Company as the surviving corporation (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">First Merger</div>&#8221;), and the Company, as the surviving corporation in the First Merger, will merge with and into Acquisition Sub II, with Acquisition Sub II as the surviving limited liability company (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Second Merger</div>,&#8221; and together with the First Merger, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Mergers</div>&#8221;), and each share of common stock, par value $0.01 per share (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Company Common Stock</div>&#8221;), of the Company issued and outstanding immediately prior to the effective time of the First Merger, other than Excluded Shares (as defined in the Merger Agreement), will be converted into the right to receive, at the option of the holder thereof and subject to certain limitations and proration procedures set forth in the Merger Agreement (as to which we express no opinion), (i) $28.00 in cash (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cash Election Consideration</div>,&#8221;) or (ii) 1.6839 shares of Class&#160;A Common Stock of Parent (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Parent Class</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;A Common Stock</div>&#8221;) (such number of shares, the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Stock Election Consideration</div>,&#8221; and the aggregate consideration described in clauses (i)&#160;and (ii), the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Merger Consideration</div>&#8221;). The terms and conditions of the Mergers are more fully set forth in the Merger Agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You have requested our opinion as to the fairness, from a financial point of view, to Parent of the Merger Consideration to be paid by Parent pursuant to the Merger Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of the opinion set forth herein, we have, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain publicly available financial statements and other publicly available business and financial information with respect to the Company and Parent, including equity research analyst reports; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">reviewed certain publicly available financial forecasts relating to the business and financial prospects of the Company, derived from a consensus of selected equity research analysts that were identified by the Company&#8217;s management and discussed with us by the Company for use in our analysis, as adjusted by Parent management, and which forecasts were extrapolated by the management of Parent for certain fiscal years (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted and Extrapolated Company Street Forecasts</div>&#8221;) and approved for our use by Parent; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">3.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">reviewed certain publicly available financial forecasts relating to the business and financial prospects of Parent, derived from a consensus of selected equity research analysts that were identified by Parent&#8217;s management, as adjusted by the management of Parent (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted Parent Street Forecasts</div>&#8221;), and approved for our use by Parent; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">4.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed certain internal financial statements, analyses and/or other financial and operating data relating to the business of the Company and Parent, prepared by the management of the Company and the management of Parent, respectively; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">5.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discussed the past and current business, operations, financial condition and prospects of the Company with representatives of the Company and Parent; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">6.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discussed the past and current business, operations, financial condition and prospects of Parent with representatives of Parent; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">7.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discussed with members of the senior managements of the Company and Parent their assessment of the strategic rationale for, and the potential benefits of, the Mergers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">8.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">reviewed certain estimates as to the amount and timing of certain cost savings anticipated by the management of Parent to result from the consummation of the Mergers (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cost Savings</div>&#8221;), as prepared by the management of Parent and approved for our use by Parent; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">9.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compared the financial performance of the Company and Parent with that of certain publicly-traded companies which we believe to be generally relevant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">10.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compared the financial terms of the Mergers with the publicly available financial terms of certain other transactions which we believe to be generally relevant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">11.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewed the historical trading prices for the Company Common Stock and the Parent Class&#160;A Common Stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">12.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">participated in discussions among representatives of the Company and Parent and their respective advisors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">13.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">reviewed a draft of the Merger Agreement dated July&#160;28, 2021 (the &#8220;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Draft Merger Agreement</div>&#8221;); and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">14.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducted such other financial studies, analyses and investigations, and considered such other factors, as we have deemed appropriate. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For purposes of our opinion, we have assumed and relied upon, without independent verification, the accuracy and completeness of the financial and other information supplied or otherwise made available to us (including information that is available from generally recognized public sources) for purposes of this opinion and have further relied upon the assurances of the management of Parent that such information does not contain any material omissions or misstatements of material fact. At your direction, we have relied on the Adjusted and Extrapolated Company Street Forecasts, the Cost Savings and the Adjusted Parent Street Forecasts. With respect to the Adjusted and Extrapolated Company Street Forecasts and the Cost Savings, we have assumed, with your consent, that they have been reasonably prepared on bases reflecting the best currently available estimates and good faith judgments of the management of Parent as to the matters covered thereby and we express no view as to the assumptions on which they are based. In that regard, we have been advised by you, and have assumed, with your consent, that the Adjusted and Extrapolated Company Street Forecasts and Cost Savings are a reasonable basis upon which to evaluate the future financial performance of the Company and we have used the Adjusted and Extrapolated Company Street Forecasts and Cost Savings in our analysis. We have further assumed, with your consent, that the Adjusted Parent Street Forecasts represent the best currently available estimates as to the matters covered thereby. In arriving at our opinion, we have not made or been provided with any independent valuation or appraisal of the assets or liabilities (including any contingent, derivative or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance-sheet</div> assets and liabilities) of the Company or Parent, nor any of their respective subsidiaries. We have not assumed any obligation to conduct, nor have we conducted, any physical inspection of the properties or facilities of the Company or Parent. In addition, we have not evaluated the solvency of any party to the Merger Agreement, or the impact of the Mergers thereon, including under any applicable laws relating to bankruptcy, insolvency or similar matters. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have assumed that the final executed Merger Agreement will not differ from the Draft Merger Agreement reviewed by us in any respect material to our analysis, and that the Mergers will be consummated in accordance with the terms set forth in the Merger Agreement, without modification, waiver or delay in any respect material </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to our analysis. In addition, we have assumed that in connection with the receipt of all the necessary approvals for the Mergers, no delays, limitations, conditions or restrictions will be imposed that could have an adverse effect on the Company, Parent or the contemplated benefits of the Mergers, in each case, in any way material to our analysis. We have relied as to all legal matters relevant to rendering our opinion upon the advice of counsel. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This opinion addresses only the fairness from a financial point of view, as of the date hereof, of the Merger Consideration to be paid by Parent pursuant to the Merger Agreement. We have not been asked to, nor do we, offer any opinion as to any other term of the Merger Agreement or any other related document, the form, structure or financing of the Mergers or the likely timeframe in which the Mergers will be consummated. Nor do we express any opinion with respect to the allocation of the Cash Election Consideration and Stock Election Consideration among the holders of Company Common Stock. In addition, we express no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors or employees of any party to the Mergers, or any class of such persons, relative to the Merger Consideration or otherwise. We express no opinion as to the fairness of the Mergers to the holders of any other class of securities, creditors or other constituencies of Parent or the Company or as to the underlying decision by any person to engage in the Mergers or as to the relative merits of the Mergers compared to any alternative transactions or business strategies. Nor do we express any opinion as to any tax or other consequences that may result from the transactions contemplated by the Merger Agreement or any related document, nor does our opinion address any legal, tax, regulatory or accounting matters, as to which we understand Parent has received such advice as it deems necessary from qualified professionals. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have acted as financial advisor to Parent with respect to the Mergers and will receive a fee for our services, a portion of which is payable upon the rendering of this opinion (or would have become payable if we had determined that we were not able to render this opinion) and a significant portion of which is contingent upon the consummation of the Mergers.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>In addition, Parent has agreed to reimburse us for certain expenses and indemnify us for certain liabilities that may arise out of our engagement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except in connection with our engagement as financial advisory to Parent in connection with the Mergers, during the two year period prior to the date hereof, no material relationship existed between Perella Weinberg Partners LP and its affiliates, on the one hand, and Parent, the Company or any of their respective affiliates, on the other hand, pursuant to which we or our affiliates have received or anticipate receiving compensation. However, Perella Weinberg Partners LP and its affiliates in the future may provide investment banking and other financial services to Parent and/or the Company and their respective affiliates and in the future may receive compensation for the rendering of these services. In the ordinary course of our business activities, Perella Weinberg Partners LP or its affiliates may at any time hold long or short positions, and may trade or otherwise effect transactions, for our own account or the accounts of clients, in debt, equity or other securities (or related derivative securities) or financial instruments (including bank loans or other obligations) of Parent, the Company or their respective affiliates. The issuance of this opinion was approved by a fairness opinion committee of Perella Weinberg Partners LP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This opinion is for the information and assistance of the Board of Directors of Parent in connection with, and for the purposes of its evaluation of, the Mergers. This opinion is not intended to be and does not constitute a recommendation to any holder of Parent Class&#160;A Common Stock or any other person as to how such person should vote or otherwise act with respect to the proposed Mergers or any other matter. We express no opinion as to what the value of the Parent Class&#160;A Common Stock actually will be when issued or the prices at which the Company Common Stock or Parent Class&#160;A Common Stock will trade at any time. Our opinion is necessarily based on financial, economic, market and other conditions as in effect on, and the information made available to us as of, the date hereof. Subsequent developments may affect this opinion and the assumptions used in preparing it, and we do not have any obligation to update, revise, or reaffirm this opinion. </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein, we are of the opinion that, on the date hereof, the Merger Consideration to be paid by Parent pursuant to the Merger Agreement is fair, from a financial point of view, to Parent. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;;width:40%;">
<tr style="font-size: 0px;">
<td style="width: 100%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Very truly yours,</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 24pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">/s/ PERELLA WEINBERG PARTNERS LP</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_42" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annex C </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g180330g11i11.jpg" style="width: 128px; height: 28px;"/></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">July&#160;29, 2021 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board of Directors </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Misonix, Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1938 New Highway </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Farmingdale, NY 11735 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members of the Board of Directors: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You have requested our opinion as to the fairness, from a financial point of view, to the holders of common stock, par value $0.01 per share (the &#8220;Company Common Stock&#8221;), of Misonix, Inc. (the &#8220;Company&#8221;) of the consideration to be paid to such holders in the proposed merger (the &#8220;Transaction&#8221;) of the Company with a wholly-owned subsidiary of Bioventus Inc. (the &#8220;Acquiror&#8221;). Pursuant to the Agreement and Plan of Merger, dated as of July&#160;29, 2021 (the &#8220;Agreement&#8221;), among the Company, the Acquiror and the Acquiror&#8217;s subsidiaries, Acquisition Sub I (as defined in the Agreement) and Acquisition Sub II (as defined in the Agreement), the Company will become a wholly-owned subsidiary of the Acquiror, and each outstanding share of Company Common Stock (other than shares of Company Common Stock held in treasury or held directly by any Company subsidiary, the Acquiror or Acquisition Sub I, and the Dissenting Shares (as defined in the Agreement)) will be converted into the right to receive, at the election of the holder of such shares of Company Common Stock, consideration per share equal to (i) $28.00 in cash (the &#8220;Cash Consideration&#8221;) or (ii) 1.6839 shares of the Acquiror&#8217;s Class&#160;A common stock, par value $0.01 per share (the &#8220;Acquiror Common Stock&#8221;), per share Company Common Stock (the &#8220;Stock Consideration&#8221;, and, together with the Cash Consideration, the &#8220;Consideration&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with preparing our opinion, we have (i)&#160;reviewed the Agreement; (iii)&#160;reviewed certain publicly available business and financial information concerning the Company and the Acquiror and the industries in which they operate; (iv)&#160;compared the proposed financial terms of the Transaction with the publicly available financial terms of certain transactions involving companies we deemed relevant and the consideration paid for such companies; (v)&#160;compared the financial and operating performance of the Company and the Acquiror with publicly available information concerning certain other companies we deemed relevant and reviewed the current and historical market prices of the Company Common Stock and the Acquiror Common Stock and certain publicly traded securities of such other companies; (vi)&#160;reviewed certain internal financial analyses and forecasts prepared by or at the direction of the managements of the Company and the Acquiror relating to their respective businesses, as well as the estimated amount and timing of the cost savings and related expenses and synergies expected to result from the Transaction (the &#8220;Synergies&#8221;); and (vii)&#160;performed such other financial studies and analyses and considered such other information as we deemed appropriate for the purposes of this opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we have held discussions with certain members of the management of the Company and the Acquiror with respect to certain aspects of the Transaction, and the past and current business operations of the Company and the Acquiror, the financial condition and future prospects and operations of the Company and the Acquiror, the effects of the Transaction on the financial condition and future prospects of the Company and the Acquiror, and certain other matters we believed necessary or appropriate to our inquiry. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In giving our opinion, we have relied upon and assumed the accuracy and completeness of all information that was publicly available or was furnished to or discussed with us by the Company and the Acquiror or otherwise reviewed by or for us. We have not independently verified any such information or its accuracy or completeness and, pursuant to our engagement letter with the Company, we did not assume any obligation to undertake any such independent verification. We have not conducted or been provided with any valuation or appraisal of any assets or liabilities, nor have we evaluated the solvency of the Company or the Acquiror under any state or </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">federal laws relating to bankruptcy, insolvency or similar matters. In relying on financial analyses and forecasts provided to us or derived therefrom, including the Synergies, we have assumed that they have been reasonably prepared based on assumptions reflecting the best currently available estimates and judgments by management as to the expected future results of operations and financial condition of the Company and the Acquiror to which such analyses or forecasts relate. We express no view as to such analyses or forecasts (including the Synergies) or the assumptions on which they were based. We have also assumed that the Transaction and the other transactions contemplated by the Agreement will be consummated as described in the Agreement. We have also assumed that the representations and warranties made by the Company, the Acquiror and the Acquisition Subs (as defined in the Agreement) in the Agreement and the related agreements are and will be true and correct in all respects material to our analysis. We are not legal, regulatory or tax experts and have relied on the assessments made by advisors to the Company with respect to such issues. We have further assumed that all material governmental, regulatory or other consents and approvals necessary for the consummation of the Transaction will be obtained without any adverse effect on the Company or the Acquiror or on the contemplated benefits of the Transaction. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our opinion is necessarily based on economic, market and other conditions as in effect on, and the information made available to us as of, the date hereof. It should be understood that subsequent developments may affect this opinion and that we do not have any obligation to update, revise, or reaffirm this opinion. Our opinion is limited to the fairness, from a financial point of view, of the Consideration to be paid to the holders of the Company Common Stock in the proposed Transaction and we express no opinion as to the fairness of any consideration paid in connection with the Transaction to the holders of any other class of securities, creditors or other constituencies of the Company or as to the underlying decision by the Company to engage in the Transaction. Furthermore, we express no opinion with respect to the amount or nature of any compensation to any officers, directors, or employees of any party to the Transaction, or any class of such persons relative to the Consideration to be paid to the holders of the Company Common Stock in the Transaction or with respect to the fairness of any such compensation<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">. </div></div>We are expressing no opinion herein as to the price at which the Company Common Stock or the Acquiror Common Stock will trade at any future time. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have acted as financial advisor to the Company with respect to the proposed Transaction and will receive a fee from the Company for our services, a substantial portion of which will become payable only if the proposed Transaction is consummated. In addition, the Company has agreed to indemnify us for certain liabilities arising out of our engagement. During the two years preceding the date of this letter, we and our affiliates have had commercial or investment banking relationships with the Company, the Acquiror and Bioventus LLC, an affiliate of the Acquiror, for which we and such affiliates have received customary compensation. Such services during such period have included acting as financial advisor to the Company in connection with its acquisition of Solsys Medical in September 2019, joint lead arranger and joint bookrunner on Bioventus LLC&#8217;s term loan and revolving line of credit in December 2019 and active bookrunner and stabilization agent on the Acquiror&#8217;s IPO in February 2021<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>In addition, we and our affiliates hold, on a proprietary basis, less than 1% of the outstanding common stock of each of the Company and the Acquiror. In the ordinary course of our businesses, we and our affiliates may actively trade the debt and equity securities or financial instruments (including derivatives, bank loans or other obligations) of the Company or the Acquiror for our own account or for the accounts of customers and, accordingly, we may at any time hold long or short positions in such securities or other financial instruments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the basis of and subject to the foregoing, it is our opinion as of the date hereof that the Consideration to be paid to the holders of the Company Common Stock in the proposed Transaction is fair, from a financial point of view, to such holders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuance of this opinion has been approved by a fairness opinion committee of J.P. Morgan Securities LLC. This letter is provided to the Board of Directors of the Company (in its capacity as such) in connection with and for the purposes of its evaluation of the Transaction. This opinion does not constitute a recommendation to any shareholder of the Company as to how such shareholder should vote with respect to the Transaction or any other </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">C-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">matter. This opinion may not be disclosed, referred to, or communicated (in whole or in part) to any third party for any purpose whatsoever except with our prior written approval. This opinion may be reproduced in full in any proxy or information statement mailed to shareholders of the Company but may not otherwise be disclosed publicly in any manner without our prior written approval. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Very truly yours, </div></div> <div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ J.P. MORGAN SECURITIES LLC </div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">J.P. Morgan Securities LLC </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">C-3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="margin-top: 1em; margin-bottom: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_43" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annex D </div></div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SECTION 262 OF THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#167; 262 Appraisal rights </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger or consolidation, who has otherwise complied with subsection (d)&#160;of this section and who has neither voted in favor of the merger or consolidation nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; and the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Appraisal rights shall be available for the shares of any class or series of stock of a constituent corporation in a merger or consolidation to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263 or &#167; 264 of this title: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders to act upon the agreement of merger or consolidation (or, in the case of a merger pursuant to &#167; 251(h), as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f) of this title. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent corporation if the holders thereof are required by the terms of an agreement of merger or consolidation pursuant to &#167;&#167; 251, 252, 254, 255, 256, 257, 258, 263 and 264 of this title to accept for such stock anything except: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 22%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares of stock of the corporation surviving or resulting from such merger or consolidation, or depository receipts in respect thereof; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 22%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger or consolidation will be either listed on a national securities exchange or held of record by more than 2,000 holders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 22%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">c.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 22%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">d.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">3.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">D-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">4.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">[Repealed.] </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation or the sale of all or substantially all of the assets of the corporation. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d),(e) and (g)&#160;of this section, shall apply as nearly as is practicable. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Appraisal rights shall be perfected as follows: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a proposed merger or consolidation for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations, and shall include in such notice a copy of this section and, if one of the constituent corporations is a nonstock corporation, a copy of &#167; 114 of this title. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger or consolidation, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger or consolidation shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger or consolidation, the surviving or resulting corporation shall notify each stockholder of each constituent corporation who has complied with this subsection and has not voted in favor of or consented to the merger or consolidation of the date that the merger or consolidation has become effective; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the merger or consolidation was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253 or &#167; 267 of this title, then either a constituent corporation before the effective date of the merger or consolidation or the surviving or resulting corporation within 10 days thereafter shall notify each of the holders of any class or series of stock of such constituent corporation who are entitled to appraisal rights of the approval of the merger or consolidation and that appraisal rights are available for any or all shares of such class or series of stock of such constituent corporation, and shall include in such notice a copy of this section and, if one of the constituent corporations is a nonstock corporation, a copy of &#167; 114 of this title. Such notice may, and, if given on or after the effective date of the merger or consolidation, shall, also notify such stockholders of the effective date of the merger or consolidation. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, within the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days after the date of giving such notice, demand in writing from the surviving or resulting corporation the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger or consolidation, either (i)&#160;each such constituent corporation shall send a second notice before the effective date of the merger or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">D-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 18%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">consolidation notifying each of the holders of any class or series of stock of such constituent corporation that are entitled to appraisal rights of the effective date of the merger or consolidation or (ii)&#160;the surviving or resulting corporation shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger or consolidation, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">e)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Within 120 days after the effective date of the merger or consolidation, the surviving or resulting corporation or any stockholder who has complied with subsections (a)&#160;and (d)&#160;of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger or consolidation, any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such stockholder&#8217;s demand for appraisal and to accept the terms offered upon the merger or consolidation. Within 120 days after the effective date of the merger or consolidation, any stockholder who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the corporation surviving the merger or resulting from the consolidation a statement setting forth the aggregate number of shares not voted in favor of the merger or consolidation (or, in the case of a merger approved pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of holders of such shares. Such statement shall be given to the stockholder within 10 days after such stockholder&#8217;s request for such a statement is received by the surviving or resulting corporation or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section hereof, whichever is later. Notwithstanding subsection (a)&#160;of this section, a person who is the beneficial owner of shares of such stock held either in a voting trust or by a nominee on behalf of such person may, in such person&#8217;s own name, file a petition or request from the corporation the statement described in this subsection. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">f)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the filing of any such petition by a stockholder, service of a copy thereof shall be made upon the surviving or resulting corporation, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all stockholders who have demanded payment for their shares and with whom agreements as to the value of their shares have not been reached by the surviving or resulting corporation. If the petition shall be filed by the surviving or resulting corporation, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving or resulting corporation and to the stockholders shown on the list at the addresses therein stated. Such </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">D-3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">notice shall also be given by one or more publications at least one week before the day of the hearing, in a newspaper of general circulation published in the City of Wilmington, Delaware or such publication as the Court deems advisable. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving or resulting corporation. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">g)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the hearing on such petition, the Court shall determine the stockholders who have complied with this section and who have become entitled to appraisal rights. The Court may require the stockholders who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with such direction, the Court may dismiss the proceedings as to such stockholder. If immediately before the merger or consolidation the shares of the class or series of stock of the constituent corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger or consolidation for such total number of shares exceeds $1&#160;million or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">h)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After the Court determines the stockholders entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger or consolidation, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving or resulting corporation or by any stockholder entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an appraisal. Any stockholder whose name appears on the list filed by the surviving or resulting corporation pursuant to subsection (f)&#160;of this section and who has submitted such stockholder&#8217;s certificates of stock to the Register in Chancery, if such is required, may participate fully in all proceedings until it is finally determined that such stockholder is not entitled to appraisal rights under this section. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving or resulting corporation to the stockholders entitled thereto. Payment shall be so made to each such stockholder, in the case of holders of uncertificated stock forthwith, and the case of holders of shares represented by certificates upon the surrender to the corporation of the certificates representing such stock. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving or resulting corporation be a corporation of this State or of any state. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">j)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a stockholder, the Court may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">D-4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">k)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From and after the effective date of the merger or consolidation, no stockholder who has demanded appraisal rights as provided in subsection (d)&#160;of this section shall be entitled to vote such stock for any purpose or to receive payment of dividends or other distributions on the stock (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger or consolidation); provided, however, that if no petition for an appraisal shall be filed within the time provided in subsection (e)&#160;of this section, or if such stockholder shall deliver to the surviving or resulting corporation a written withdrawal of such stockholder&#8217;s demand for an appraisal and an acceptance of the merger or consolidation, either within 60 days after the effective date of the merger or consolidation as provided in subsection (e)&#160;of this section or thereafter with the written approval of the corporation, then the right of such stockholder to an appraisal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be dismissed as to any stockholder without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just; provided, however that this provision shall not affect the right of any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such stockholder&#8217;s demand for appraisal and to accept the terms offered upon the merger or consolidation within 60 days after the effective date of the merger or consolidation, as set forth in subsection (e)&#160;of this section. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">l)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of the surviving or resulting corporation to which the shares of such objecting stockholders would have been converted had they assented to the merger or consolidation shall have the status of authorized and unissued shares of the surviving or resulting corporation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">D-5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc180330_39" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II: INFORMATION NOT REQUIRED IN PROSPECTUS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;20. Indemnification of Directors and Officers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;145 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) authorizes a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director or officer of the corporation (or is or was serving at the request of the corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise) against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the case of an action or suit brought by or in the right of a corporation, the corporation may indemnify any person who was or is a party or is threatened to be made a party to any such threatened, pending or completed action by reason of the fact that the person is or was a director or officer, of the corporation (or is or was serving at the request of the corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise) only against expenses (including attorneys&#8217; fees) actually and reasonably incurred by him in connection with the defense or settlement of such action if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification may be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent the appropriate court finds that, in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as the court shall deem proper. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In accordance with DGCL, Article IX of Bioventus&#8217; Amended and Restated Bylaws (the &#8220;Bioventus bylaws&#8221;) provides that Bioventus will indemnify and hold harmless, to the fullest extent permitted by the DGCL, any current or former director or officer of Bioventus who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of Bioventus or, while serving as a director or officer of Bioventus, is or was serving at the request of Bioventus as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&#8217; fees, judgments, fines ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred by such person in connection with any such proceeding. Notwithstanding the preceding sentence, subject to the Bioventus bylaws, Bioventus will be required to indemnify a person in connection with a proceeding initiated by such person only if the proceeding was authorized in the specific case by the Bioventus board. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Article IX further provides that Bioventus&#8217; will have the power to indemnify and hold harmless, to the fullest extent permitted by applicable law, any current or former employee or agent of Bioventus who was or is made or is threatened to be made a party or is otherwise involved in any proceeding by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was an employee or agent of Bioventus or is or was serving at the request of Bioventus as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such proceeding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of Bioventus, or is or was serving at the request of Bioventus as a director, officer, employee or agent of another corporation, partnership, joint venture, trust enterprise or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> entity against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not Bioventus would have the power to indemnify him or her against such liability under the provisions of the DGCL. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;21. Exhibits and Financial Statement Schedules </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;&#160;2.1&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="#toc180330_40">Agreement and Plan of Merger, dated July&#160;29, 2021, among Bioventus Inc., Oyster Merger Sub I, Inc., Oyster Merger Sub II, LLC and Misonix, Inc. (included as Annex&#160;A to the joint proxy statement/prospectus, which forms a part of this registration statement).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;&#160;3.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521045802/d134776dex31.htm">Amended and Restated Certificate of Incorporation of Bioventus Inc. (incorporated by reference to Exhibit 3.1 to Bioventus&#8217; Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on February&#160;17, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;&#160;3.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521045802/d134776dex32.htm">Amended and Restated Bylaws of Bioventus Inc. (incorporated by reference to Exhibit 3.2 to Bioventus&#8217; Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on February&#160;17, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;&#160;4.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex41.htm">Specimen Stock Certificate evidencing the shares of Class&#160;A common stock (incorporated by reference to Exhibit 4.1 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;&#160;4.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000162828021005771/exhibit42.htm">Description of Securities (incorporated by reference to Exhibit 4.2 to Bioventus&#8217; Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</span> filed with the SEC on March&#160;26, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;&#160;5.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="d180330dex51.htm">Opinion of Latham&#160;&amp; Watkins LLP. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;&#160;8.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="d180330dex81.htm">Opinion of Jones Day LLP regarding certain tax matters. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521045802/d134776dex102.htm">Tax Receivable Agreement, dated as of February&#160;16, 2021, by and among Bioventus Inc., Bioventus LLC and its Members (incorporated by reference to Exhibit 10.2 to Bioventus&#8217; Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on February&#160;17, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521045802/d134776dex103.htm">Registration Rights Agreement, dated February&#160;16, 2021, by and among Bioventus Inc. and the Original LLC (incorporated by reference to Exhibit 10.3 to Bioventus&#8217; Current Report on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;8-K,</span> filed with the SEC on February&#160;17, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521045802/d134776dex101.htm">Second Amended and Restated Limited Liability Company Agreement of Bioventus LLC dated as of February&#160;16, 2021 (incorporated by reference to Exhibit 10.1 to Bioventus&#8217; Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on February&#160;17, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521045802/d134776dex104.htm">Stockholders Agreement, dated February&#160;16, 2021, by and among Bioventus Inc., Bioventus LLC and the Principal Stockholders (incorporated by reference to Exhibit 10.4 to Bioventus&#8217; Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on February&#160;17, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.5&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex105.htm">Amended and Restated License Agreement, dated as of December&#160;9, 2016, by and between Bioventus LLC, <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med</span> AB and Nestl&#233; Skin Health S.A. (incorporated by reference to Exhibit 10.5 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.6&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex106.htm">Amended and Restated Supply Agreement, dated as of December&#160;9, 2016, by and between Bioventus LLC and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Q-Med</span> AB (incorporated by reference to Exhibit 10.6 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.7&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex107.htm">Exclusive License, Supply and Distribution Agreement, dated as of February&#160;9, 2016, by and between IBSA Institut Biochimique SA (Switzerland) and Bioventus LLC (incorporated by reference to Exhibit 10.7 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.7(a)&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex107a.htm">Amendment No.&#160;1 to Exclusive License, Supply and Distribution Agreement, dated as of December&#160;31, 2018, by and between IBSA Institut Biochimique SA (Switzerland) and Bioventus LLC (incorporated by reference to Exhibit 10.7(a) to Bioventus&#8217; Registration Statement on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.7(b)&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521028021/d58473dex107b.htm">Amendment No.&#160;2 to Exclusive License, Supply and Distribution Agreement, dated as of December&#160;31, 2018, by and between IBSA Institut Biochimique SA (Switzerland) and Bioventus LLC (incorporated by reference to Exhibit 10.7(b) to Bioventus&#8217; Registration Statement on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1/A,</span> filed with the SEC on February&#160;4, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.8&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex109.htm">Amended and Restated Exclusive Distribution Agreement No.&#160;2 by and between Seikagaku Corporation and Bioventus LLC, effective December&#160;22, 2020 (incorporated by reference to Exhibit 10.9 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.9</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1010.htm">Option and Equity Purchase Agreement, dated as of July&#160;15, 2020, among Bioventus LLC, CartiHeal (2009)&#160;Ltd., the Securityholders set forth on Schedule 1.01(a) thereto, each of the Securityholders from time to time party thereto and Elron Electronic Industries Ltd., in its capacity as the Securityholder Representative (incorporated by reference to Exhibit 10.10 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1011.htm">Credit and Guaranty Agreement, dated as of December&#160;6, 2019, among Bioventus LLC, Wells Fargo Bank, N.A., as administrative agent, and the lenders thereto (incorporated by reference to Exhibit 10.11 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.11#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521028021/d58473dex1012.htm">Bioventus LLC Management Incentive Plan dated as of May&#160;4, 2012 (incorporated by reference to Exhibit 10.12 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;4, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.12#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1013.htm">Bioventus LLC Phantom Profits Interest Plan, as amended and restated (incorporated by reference to Exhibit 10.13 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.13#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1014.htm">Management Incentive Plan Award Agreement, dated as of December&#160;2, 2013, by and between Bioventus LLC and Anthony P. Bihl III (incorporated by reference to Exhibit 10.14 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.14#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1015.htm">Phantom Profits Interest Plan Award Agreement, dated as of April&#160;21, 2016, by and between Bioventus LLC and Anthony P. Bihl III (incorporated by reference to Exhibit 10.15 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.15#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1016.htm">Phantom Profits Interest Plan Award Agreement, dated as of September&#160;17, 2018, by and between Bioventus LLC and Anthony P. Bihl III (incorporated by reference to Exhibit 10.16 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.16#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1017.htm">Phantom Profits Interests Plan Award Agreement, dated as of January&#160;1, 2016, by and between Bioventus LLC and William A. Hawkins (incorporated by reference to Exhibit 10.17 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">10.17#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1018.htm">Phantom Profits Interests Plan Award Agreement, dated as of October&#160;9, 2018, by and between Bioventus LLC and Susan M. Stalnecker (incorporated by reference to Exhibit 10.18 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.18#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1019.htm">Phantom Profits Interests Plan Award Agreement, dated as of June&#160;25, 2020, by and between Bioventus LLC and Kenneth M. Reali (incorporated by reference to Exhibit 10.19 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.19#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1020.htm">Phantom Profits Interests Plan Award Agreement, dated as of April&#160;4, 2016, by and between Bioventus LLC and Gregory O. Anglum (incorporated by reference to Exhibit 10.20 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.20#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1021.htm">Phantom Profits Interests Plan Award Agreement, dated as of May&#160;1, 2017, by and between Bioventus LLC and Gregory O. Anglum (incorporated by reference to Exhibit 10.21 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.21#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1022.htm">Phantom Profits Interests Plan Award Agreement, dated as of October&#160;27, 2017, by and between Bioventus LLC and Gregory O. Anglum (incorporated by reference to Exhibit 10.22 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.22#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1023.htm">Phantom Profits Interests Plan Award Agreement, dated as of February&#160;6, 2017, by and between Bioventus LLC and John E. Nosenzo (incorporated by reference to Exhibit 10.23 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.23#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1024.htm">Phantom Profits Interests Plan Award Agreement, dated as of September&#160;17, 2018, by and between Bioventus LLC and John E. Nosenzo (incorporated by reference to Exhibit 10.24 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.24#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1025.htm">Phantom Profits Interests Plan Award Agreement, dated as of July&#160;22, 2013, by and between Bioventus LLC and Alessandra Pavesio (incorporated by reference to Exhibit 10.25 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.25#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1026.htm">Phantom Profits Interests Plan Award Agreement, dated as of June&#160;1, 2015, by and between Bioventus LLC and Alessandra Pavesio (incorporated by reference to Exhibit 10.26 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.26#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1027.htm">Phantom Profits Interests Plan Award Agreement, dated as of April&#160;21, 2016, by and between Bioventus LLC and Alessandra Pavesio (incorporated by reference to Exhibit 10.27 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.27#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1028.htm">Phantom Profits Interests Plan Award Agreement, dated as of September&#160;17, 2018, by and between Bioventus LLC and Alessandra Pavesio (incorporated by reference to Exhibit 10.28 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.28#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1029.htm">Phantom Profits Interests Plan Award Agreement, dated as of October&#160;27, 2017, by and between Bioventus LLC and Anthony D&#8217;Adamio (incorporated by reference to Exhibit 10.29 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.29#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1030.htm">Phantom Profits Interests Plan Award Agreement, dated as of September&#160;17, 2018, by and between Bioventus LLC and Anthony D&#8217;Adamio (incorporated by reference to Exhibit 10.30 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.30#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1033.htm">Director Offer Letter, dated as of December&#160;11, 2015, by and between Bioventus LLC and William&#160;A. Hawkins (incorporated by reference to Exhibit 10.33 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.31#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1035.htm">Retention Letter, dated as of April&#160;13, 2020, by and between Bioventus LLC and John E. Nosenzo (incorporated by reference to Exhibit 10.35 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.32#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1038.htm">Director Offer Letter, dated as of October&#160;3, 2018, by and between Bioventus LLC and Susan&#160;M.&#160;Stalnecker (incorporated by reference to Exhibit 10.38 to Bioventus&#8217; Registration Statement on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.33#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1041.htm">Payout Agreement Letter, dated as of June&#160;12, 2020, by and between Bioventus LLC and Anthony&#160;P.&#160;Bihl, III (incorporated by reference to Exhibit 10.41 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.34#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1042.htm">Phantom Profits Interest Plan Award Agreement, dated as of June&#160;25, 2020, by and between Bioventus LLC and Kenneth M. Reali (incorporated by reference to Exhibit 10.42 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.35</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521011667/d58473dex1043.htm">Option Letter, dated as of July&#160;30, 2020, by and between Bioventus LLC and Kenneth M. Reali (incorporated by reference to Exhibit 10.43 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</span> filed with the SEC on January&#160;20, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.36#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521028021/d58473dex1044.htm">Bioventus Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.44 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;4, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.37#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1045.htm">Bioventus Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.45 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.38#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1047.htm">Form of Notice of Stock Option Grant and Stock Option Agreement (incorporated by reference to Exhibit 10.47 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.39#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1048.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.48 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.40</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1050.htm">Assignment and Assumption Agreement, dated as of February&#160;9, 2021, by and between Bioventus Inc. and Bioventus LLC (incorporated by reference to Exhibit 10.50 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.41#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1051.htm">Bioventus Inc. <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</span> Director Compensation Policy (incorporated by reference to Exhibit&#160;10.51 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.42#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1052.htm">Employment Agreement, dated as of February&#160;9, 2021, by and among Bioventus Inc., Bioventus LLC and Kenneth Reali (incorporated by reference to Exhibit 10.52 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.43#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1053.htm">Employment Agreement, dated as of February&#160;9, 2021, by and among Bioventus Inc., Bioventus LLC and Gregory O. Anglum (incorporated by reference to Exhibit 10.53 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.44#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1054.htm">Employment Agreement, dated as of February&#160;9, 2021, by and among Bioventus Inc., Bioventus LLC and John E. Nosenzo (incorporated by reference to Exhibit 10.54 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.45#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1055.htm">Employment Agreement, dated as of February&#160;9, 2021, by and among Bioventus Inc., Bioventus LLC and Anthony D&#8217;Adamio (incorporated by reference to Exhibit 10.55 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.46#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1056.htm">Employment Agreement, dated as of February&#160;9, 2021, by and among Bioventus Inc., Bioventus LLC and Alessandra Pavesio (incorporated by reference to Exhibit 10.56 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.47#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521035490/d58473dex1057.htm">Option Forfeiture Letter, dated as of February&#160;3, 2021, by and between Bioventus LLC and Kenneth Reali (incorporated by reference to Exhibit 10.57 to Bioventus&#8217; Registration Statement on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1/A,</span> filed with the SEC on February&#160;10, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.48#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521028021/d58473dex1046.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.46 to Bioventus&#8217; Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A,</span> filed with the SEC on February&#160;4, 2021). </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.49</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000162828021005771/exhibit1049.htm">Settlement Agreement, dated as of February&#160;22, 2021, by and between the United States of America, acting through the United States Attorney&#8217;s Office for the Middle District of North Carolina and on behalf of the Office of Inspector General of the Department of Health and Human Services, and Bioventus LLC, through their authorized representatives (incorporated by reference to Exhibit 10.49 to Bioventus&#8217; Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</span> filed with the SEC on March&#160;26, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.50</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521100715/d167123dex101.htm">Agreement and Plan of Merger, dated as of March&#160;30, 2021, by and among Bioventus LLC, Bioness Inc., Perseus Intermediate, Inc., Perseus Merger Sub, Inc., Alfred E. Mann Living Trust and Mann Group, LLC. (incorporated by reference to Exhibit 10.1 to Bioventus&#8217; Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on March&#160;31, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">21.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000162828021005771/exhibit211.htm">List of Subsidiaries of Bioventus Inc. (incorporated by reference to Exhibit 21.1 Bioventus&#8217; Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</span> filed with the SEC on March&#160;26, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d180330dex231.htm">Consent of Grant Thornton LLP, independent registered public accounting firm of Bioventus Inc. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d180330dex232.htm">Consent of Grant Thornton LLP, independent registered public accounting firm of Bioventus LLC. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d180330dex233.htm">Consent of PricewaterhouseCoopers LLP, former independent registered public accounting firm of Bioventus Inc. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d180330dex234.htm">Consent of Deloitte&#160;&amp; Touche LLP, independent registered public accounting firm of Misonix, Inc. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.5</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d180330dex51.htm">Consent of Latham&#160;&amp; Watkins LLP (included in Exhibit&#160;5.1). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.6</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d180330dex81.htm">Consent of Jones Day LLP (included in Exhibit 8.1). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">24.1*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/0001665988/000119312521267967/d180330ds4.htm#ii180330_sig">Power of Attorney. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">99.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d180330dex991.htm">Consent of Perella Weinberg Partners LLC. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">99.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d180330dex992.htm">Consent of J.P. Morgan Securities LLC. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">99.3*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521267967/d180330dex993.htm">Consent of Stavros Vizirgianakis, to be named as director. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">99.4*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521267967/d180330dex994.htm">Consent of Patrick Beyer, to be named as director. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">99.5*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521267967/d180330dex995.htm">Form of Proxy Card for Special Meeting of Bioventus Inc. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">99.6*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521267967/d180330dex996.htm">Form of Proxy Card for Special Meeting of Misonix, Inc. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">99.7</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521229264/d155859dex991.htm">Form of Misonix Support Agreement, dated as of July 29, 2021, by and between Bioventus Inc. and the Misonix Supporting Stockholders (incorporated by reference to Exhibit&#160;99.1 to Bioventus, Current Report on Form&#160;8-K filed with the SEC on July&#160;29, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">99.8</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1665988/000119312521229264/d155859dex992.htm">Form of Bioventus Support Agreement, dated as of July&#160;29, 2021, by and between Misonix, Inc. and the Bioventus Supporting Stockholders (incorporated by reference to Exhibit&#160;99.2 to Bioventus, Current Report on Form&#160;8-K filed with the SEC on July&#160;29, 2021). </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Previously filed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">#</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicates management contract or compensatory plan. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8224;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Schedules have been omitted pursuant to Item 601(a)(5) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> The undersigned registrant hereby undertakes to provide a copy of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;22. Undertakings </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i)&#160;to include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;); (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the U.S. Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and (iii)&#160;to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes that, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(e)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant undertakes that in a primary offering of securities of the registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i)&#160;any preliminary prospectus or prospectus of the registrant relating to the offering required to be filed pursuant to Rule 424; (ii) any free writing prospectus relating to the offering prepared by or on behalf of the registrant or used or referred to by the registrant; (iii)&#160;the portion of any other free writing prospectus relating to the offering containing material information about the registrant or its securities provided by or on behalf of the registrant; and (iv)&#160;any other communication that is an offer in the offering made by the registrant to the purchaser. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(f)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(g)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(h)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant undertakes that every prospectus: (i)&#160;that is filed pursuant to the paragraph immediately preceding; or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the undersigned registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(j)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item 4, 10(b), 11 or 13 of this Form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(k)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;">S<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">IGNATURES</div></div> </div> <div style="text-indent: 0px;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina on September 22, 2021. </div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;;width:40%;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 92%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bioventus Inc.</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Kenneth M. Reali</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Name: Kenneth M. Reali</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Title: &#160;&#160;Chief Executive Officer and Director</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 29%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 50%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 19%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Signature</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Title</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Kenneth M. Reali</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Chief Executive Officer and Director</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">Kenneth M. Reali</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">(Principal Executive Officer)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Gregory O. Anglum</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Senior Vice President and Chief Financial Officer</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">Gregory O. Anglum</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">(Principal Financial Officer and Principal Accounting Officer)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: top;;text-align:center;">Chairman</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">William A. Hawkins III</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Philip G. Cowdy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guido J. Neels</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Guy P. Nohra</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David J. Parker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Susan M. Stalnecker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Martin P. Sutter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">September 22, 2021</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;">Mary Kay Ladone</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:40%;">
<tr style="font-size: 0px;">
<td style="width: 10%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*By:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Kenneth M. Reali</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Kenneth M. Reali</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Attorney-in-fact</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-9 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d180330dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">650 Town Center Drive, 20th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Costa Mesa, California 92626-1925</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tel: +1.714.540.1235 Fax: +1.714.755.8290</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">www.lw.com</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g180330g0920114743216.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Moscow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Century City</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orange&nbsp;County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">September&nbsp;22, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">D&uuml;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shanghai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bioventus Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4721 Emperor Boulevard, Suite 400</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Washington,&nbsp;D.C.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Durham, North Carolina 27703</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Milan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4;</FONT> Shares of common stock, par value
$0.001 per share, of Bioventus Inc. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Bioventus Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the proposed
issuance of up to 18,322,984 shares of Class&nbsp;A Common Stock, par value $0.001 per share, of the Company (the &#147;<B><I>Shares</I></B>&#148;), pursuant to the Agreement and Plan of Merger, dated as of July&nbsp;29, 2021 (the &#147;<B><I>Merger
Agreement</I></B>&#148;), by and among the Company, Oyster Merger Sub I, Inc., Oyster Merger Sub II, LLC and Misonix, Inc. (&#147;<B><I>Misonix</I></B>&#148;). The Shares are included in a registration statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), filed with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on September&nbsp;8, 2021 (the
&#147;<B><I>Registration Statement</I></B>&#148;). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as
to any matter pertaining to the contents of the Registration Statement or related Prospectus, other than as expressly stated herein with respect to the issue of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter.
With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to General Corporation Law of
the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), and we express no opinion with respect to any other laws. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>September&nbsp;22, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g180330g0921001458208.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as
of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the applicable Misonix stockholders, and have been issued by the Company against payment
therefor (not less than par value) in the circumstances contemplated by the Registration Statement and the Merger Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the
Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering the foregoing opinion, we have assumed that (i)&nbsp;prior to the delivery of any Shares, the Registration Statement will have
been declared effective under the Act and that the registration will apply to all of the Shares and will not have been modified or rescinded and that there will not have occurred any change in law affecting the validity of the issuance of such
Shares, and (ii)&nbsp;the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under the heading &#147;Legal Matters.&#148; We further
consent to the incorporation by reference of this letter and consent into any registration statement or post-effective amendment to the Registration Statement filed pursuant to Rule 462(b) with respect to the Shares. In giving such consent, we do
not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>/s/ Latham&nbsp;&amp; Watkins LLP </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>d180330dex81.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g180330g0922110749216.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 LOUISIANA AVENUE, N.W&#149; WASHINGTON, DC 20001.2113 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TELEPHONE: +1.202.879.3939 &#149; JONESDAY.COM </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Misonix Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1938 New Highway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Farmingdale, New York 11735 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel
to Misonix Inc. (&#147;Misonix&#148;), a Delaware corporation, in connection with the proposed Mergers to be undertaken by Misonix, Bioventus Inc. (&#147;Parent&#148;), a Delaware corporation, Oyster Merger Sub I, Inc., a Delaware corporation and
wholly owned subsidiary of Parent, and Oyster Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent, pursuant to the Agreement and Plan of Merger dated as of July&nbsp;29, 2021 (the &#147;Merger
Agreement&#148;), and the preparation and filing with the Securities and Exchange Commission of the registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> filed September&nbsp;22, 2021, related to the Mergers (the
&#147;Registration Statement&#148;). This opinion letter is being delivered in connection with, and appears as an exhibit to, the Registration Statement. Any capitalized terms used but not defined herein have the meaning given to such terms in the
Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In providing our opinion, we have examined and relied on the Merger Agreement, the Registration Statement, the
statements and representations made by Parent and Misonix in their respective officer&#146;s certificates dated as of the date hereof and delivered to us for purposes of this opinion (the &#147;Officer&#146;s Certificates&#148;), and such other
documents as we have deemed necessary or appropriate for purposes of this opinion. In addition, we have assumed that (i)&nbsp;the Mergers and related transactions will be consummated in accordance with the provisions of the Merger Agreement and as
described in the Registration Statement (and no transaction or condition described therein will be waived by any party), (ii) the statements concerning the Mergers and related transactions and the parties thereto set forth in the Merger Agreement
and in the Registration Statement are true, complete and correct and will remain true, complete and correct at all times up to and including, and thereafter where relevant, the effective time of each transaction contemplated by the Merger Agreement,
(iii)&nbsp;the statements and representations made in the Officer&#146;s Certificates are true, complete and correct and will remain true, complete and correct at all times up to and including, and thereafter where relevant, the effective time of
each transaction contemplated by the Merger Agreement, (iv)&nbsp;any such statement or representation set forth in the Merger Agreement, the Registration Statement or the Officer&#146;s Certificates that is qualified by belief, knowledge, intention,
materiality or any comparable or similar qualification, is and will be true, complete and correct as if made without such qualification, (v)&nbsp;all documents submitted to us as originals are authentic, all documents submitted to us as copies
conform to the originals, all relevant documents have been or will be duly executed in the form presented to us and all natural persons who have executed such documents are of legal capacity, (vi)&nbsp;the parties to the Merger Agreement and their
respective subsidiaries will treat the transactions for U.S. federal income tax purposes in a manner consistent with this opinion, (vii)&nbsp;such parties have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMSTERDAM &#149; ATLANTA &#149; BEIJING
&#149; BOSTON &#149; BRISBANE &#149; BRUSSELS &#149; CHICAGO &#149; CLEVELAND &#149; COLUMBUS &#149; DALLAS &#149; DETROIT DUBAI &#149; DSSELDORF &#149; FRANKFURT &#149; HONG&nbsp;KONG &#149; HOUSTON &#149; IRVINE &#149; LONDON &#149;
LOS&nbsp;ANGELES &#149; MADRID &#149; MELBOURNE MEXICO&nbsp;CITY &#149; MIAMI &#149; MILAN &#149; MINNEAPOLIS &#149; MUNICH &#149; NEW&nbsp;YORK &#149; PARIS &#149; PERTH &#149; PITTSBURGH &#149; SAN&nbsp;DIEGO &#149; SAN&nbsp;FRANCISCO
S&#195;O&nbsp;PAULO &#149; SAUDI&nbsp;ARABIA &#149; SHANGHAI &#149; SILICON&nbsp;VALLEY &#149; SINGAPORE &#149; SYDNEY &#149; TAIPEI &#149; TOKYO &#149; WASHINGTON </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g180330g91k37.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complied with and will continue to comply with the obligations, covenants and agreements contained in the Merger Agreement, (viii)&nbsp;all applicable reporting requirements have been or will be
satisfied and (ix)&nbsp;there will be no change in applicable U.S. federal income tax law from the date hereof through the effective time of each transaction contemplated by the Merger Agreement. If any of the above described assumptions is untrue
for any reason or if the transaction is consummated in a manner that is different from the manner described in the Merger Agreement, the Registration Statement, or the Officer&#146;s Certificates, this opinion may be adversely affected. We have not
undertaken any independent investigation of any factual matter set forth in any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing
and our consideration of such other matters of fact and law as we have considered necessary or appropriate, we hereby confirm that, subject to the assumptions, exceptions, limitations and qualifications set forth herein and in the Registration
Statement, the discussion set forth in the Registration Statement under the caption &#147;MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE FIRST MERGER AND THE SECOND MERGER&#151;U.S. HOLDERS&#151; U.S. Federal Income Tax Consequences of the
First Merger and the Second Merger to U.S. Holders of Shares of Misonix Common Stock&#148; insofar as such discussion contains statements of U.S. federal income tax law, constitutes our opinion as to the material U.S. federal income tax consequences
of the Mergers to U.S. holders (as defined in the Registration Statement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion on any issue relating to the tax
consequences of any transactions contemplated by the Merger Agreement or the Registration Statement other than the opinion set forth above. Our opinion set forth above is based on the Code, Treasury Regulations promulgated thereunder, published
pronouncements of the Internal Revenue Service and judicial precedents, all as of the date hereof. The foregoing authorities may be repealed, revoked or modified, and any such change may have retroactive effect. Any change in applicable laws or
facts and circumstances surrounding the Mergers, or any inaccuracy in the statements, facts, assumptions and representations on which we have relied may affect the validity of the opinion set forth herein. We assume no responsibility to inform
Misonix of any such change or inaccuracy that may occur or come to our attention. In addition, our opinion is being delivered prior to the consummation of the Mergers and therefore is prospective and dependent on future events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you solely in connection with the Registration Statement and this opinion is not to be relied upon for any other
purpose. We hereby consent to the filing of this opinion as an exhibit to the Registration Statement, and to the references therein to us. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is
required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and regulations thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Jones Day</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d180330dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have issued our report dated March&nbsp;26, 2021, with respect to the financial statement of Bioventus Inc. contained in the Registration Statement and
Joint Proxy Statement/Prospectus. We consent to the use of the aforementioned report in this Registration Statement and Joint Proxy Statement/Prospectus, and to the use of our name as it appears under the caption &#147;Experts.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ GRANT THORNTON LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raleigh, North Carolina </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>d180330dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have issued our report dated March&nbsp;26, 2021, with respect to the consolidated financial statements of Bioventus LLC contained in the Registration
Statement and Joint Proxy Statement/Prospectus. We consent to the use of the aforementioned report in this Registration Statement and Joint Proxy Statement/Prospectus, and to the use of our name as it appears under the caption &#147;Experts.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ GRANT THORNTON LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raleigh, North Carolina </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>6
<FILENAME>d180330dex233.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> of Bioventus Inc. of our report dated
August&nbsp;16, 2019, except for the effects of disclosing net loss per unit information discussed in Note 13 and the effects of discontinued operations discussed in Note 16 to the consolidated financial statements, as to which the date is
October&nbsp;6, 2020, relating to the financial statements of Bioventus LLC, which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raleigh, North Carolina </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>7
<FILENAME>d180330dex234.htm
<DESCRIPTION>EX-23.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Registration Statement on Form&nbsp;S-4&nbsp;of our report dated September&nbsp;2, 2021, relating to the
financial statements of Misonix, Inc, appearing in the Annual Report on Form&nbsp;10-K of Misonix, Inc. for the year ended June&nbsp;30, 2021. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jericho,
New York </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>8
<FILENAME>d180330dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Perella Weinberg&nbsp;Partners LP </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in Amendment No. 1 to the&nbsp;Registration Statement&nbsp;of Bioventus Inc. on&nbsp;Form <FONT
STYLE="white-space:nowrap">S-4&nbsp;and</FONT> in the Joint&nbsp;Proxy Statement/Prospectus of Bioventus Inc. and Misonix, Inc., which is part of the&nbsp;Registration Statement, filed on September&nbsp;8, 2021 (the &#147;Registration
Statement&#148;), of our opinion dated July&nbsp;29, 2021 appearing as Annex B to such&nbsp;Joint Proxy Statement/Prospectus, and to the description of such opinion and to the references to our name contained therein under the heading
&#147;Summary&#151;Opinion of Bioventus&#146;s Financial Advisor&#148;, &#147;Risk Factors&#151;Risks Related to the Mergers&#148;, &#147;The Merger&#151;Background of the Merger&#148;, &#147;The Merger&#151;<B> </B>Recommendation of the Bioventus
Board of Directors; Bioventus&#146;s Reasons for the Merger&#148;, &#147;The Merger&#151;Opinion of Bioventus&#146;s Financial Advisor&#148;&nbsp;and&nbsp;&#147;The Merger&#151;Certain Unaudited Prospective Financial Information&#148;.&nbsp;In
giving the foregoing consent, we do not admit that we come within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or the rules and regulations
promulgated thereunder, nor do we admit that we are experts with respect to any part of such Registration Statement within the meaning of the term &#147;experts&#148; as used in the Securities Act or the rules and regulations promulgated thereunder.
Additionally, such consent does not cover any future amendments to the Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">By: <U>/s/ Perella
Weinberg Partners LP&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>9
<FILENAME>d180330dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to (i)&nbsp;the inclusion of our opinion letter dated July&nbsp;29, 2021 to the Board of Directors of Misonix, Inc. (the
&#147;Company&#148;) included in Annex C to the Joint Proxy Statement/Prospectus relating to the proposed merger of the Company and Bioventus Inc., and (ii)&nbsp;the references to such opinion in such Joint Proxy Statement/Prospectus. In giving such
consent, we do not admit that we come within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder, nor do
we hereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term &#147;experts&#148; as used in the Securities Act of 1933, as amended, or the rules and regulations of the Securities and
Exchange Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/<SMALL>S</SMALL>/ J.P. MORGAN SECURITIES LLC</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;22, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>bvs-20210703.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-September-2021 [01:59:44] {PM}-->
<schema targetNamespace="http://bio.com/20210703" elementFormDefault="qualified" xmlns:bvs="http://bio.com/20210703" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://bio.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome" id="ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome">
<link:definition>1002 - Statement - Consolidated condensed statements of operations and comprehensive (loss) income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical" id="ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical">
<link:definition>1003 - Statement - Consolidated condensed statements of operations and comprehensive (loss) income (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/ConsolidatedCondensedBalanceSheets" id="ConsolidatedCondensedBalanceSheets">
<link:definition>1004 - Statement - Consolidated condensed balance sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" id="ConsolidatedCondensedBalanceSheetsParenthetical">
<link:definition>1005 - Statement - Consolidated condensed balance sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity" id="ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity">
<link:definition>1006 - Statement - Consolidated condensed statements of changes in stockholders' and members' equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows" id="ConsolidatedCondensedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated condensed statements of cash flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/Organization" id="Organization">
<link:definition>1008 - Disclosure - Organization</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformation" id="BalanceSheetInformation">
<link:definition>1010 - Disclosure - Balance sheet information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BusinessCombinationsAndInvestments" id="BusinessCombinationsAndInvestments">
<link:definition>1011 - Disclosure - Business combinations and investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FinancialInstruments" id="FinancialInstruments">
<link:definition>1012 - Disclosure - Financial instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1013 - Disclosure - Fair value measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EquityBasedCompensation" id="EquityBasedCompensation">
<link:definition>1014 - Disclosure - Equity-based compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EarningsPerShare" id="EarningsPerShare">
<link:definition>1015 - Disclosure - Earnings per share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1016 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1017 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/NetIncomeLossPerUnit" id="NetIncomeLossPerUnit">
<link:definition>1018 - Disclosure - Net income (loss) per unit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RestructuringCosts" id="RestructuringCosts">
<link:definition>1019 - Disclosure - Restructuring costs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/MembersEquity" id="MembersEquity">
<link:definition>1020 - Disclosure - Members' equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1021 - Disclosure - Related-party transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/NetSales" id="NetSales">
<link:definition>1022 - Disclosure - Net Sales</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
<link:definition>1023 - Disclosure - Discontinued Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/StockholderSEquity" id="StockholderSEquity">
<link:definition>1024 - Disclosure - Stockholder's Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RevenueRecognition" id="RevenueRecognition">
<link:definition>1025 - Disclosure - Revenue recognition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/Segments" id="Segments">
<link:definition>1026 - Disclosure - Segments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1027 - Disclosure - Subsequent events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/OrganizationPolicies" id="OrganizationPolicies">
<link:definition>1028 - Disclosure - Organization (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1029 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1030 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RestructuringCostsTables" id="RestructuringCostsTables">
<link:definition>1031 - Disclosure - Restructuring costs (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/MembersEquityTables" id="MembersEquityTables">
<link:definition>1032 - Disclosure - Members' equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/NetSalesTables" id="NetSalesTables">
<link:definition>1033 - Disclosure - Net sales (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/DiscontinuedOperationsTables" id="DiscontinuedOperationsTables">
<link:definition>1034 - Disclosure - Discontinued Operations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SegmentsTables" id="SegmentsTables">
<link:definition>1035 - Disclosure - Segments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RevenueRecognitionTables" id="RevenueRecognitionTables">
<link:definition>1036 - Disclosure - Revenue recognition (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/NetIncomeLossPerUnitTables" id="NetIncomeLossPerUnitTables">
<link:definition>1037 - Disclosure - Net income (loss) per unit (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1038 - Disclosure - Commitments and contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationTables" id="BalanceSheetInformationTables">
<link:definition>1039 - Disclosure - Balance sheet information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsTables" id="BusinessCombinationsAndInvestmentsTables">
<link:definition>1040 - Disclosure - Business combinations and investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FinancialInstrumentsTables" id="FinancialInstrumentsTables">
<link:definition>1041 - Disclosure - Financial instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1042 - Disclosure - Fair value measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EquityBasedCompensationTables" id="EquityBasedCompensationTables">
<link:definition>1043 - Disclosure - Equity-based compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
<link:definition>1044 - Disclosure - Earnings per share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1045 - Disclosure - Income taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/OrganizationDetails" id="OrganizationDetails">
<link:definition>1046 - Disclosure - Organization (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" id="BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails">
<link:definition>1047 - Disclosure - Balance sheet information - Cash, cash equivalents and restricted cash (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails" id="BalanceSheetInformationComponentsOfAccountsReceivableDetails">
<link:definition>1048 - Disclosure - Balance sheet information - Components of accounts receivable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails" id="BalanceSheetInformationAllowanceForCreditLossDetails">
<link:definition>1049 - Disclosure - Balance sheet information - Allowance for credit loss (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationInventoryDetails" id="BalanceSheetInformationInventoryDetails">
<link:definition>1050 - Disclosure - Balance sheet information - Inventory (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails" id="BalanceSheetInformationAccruedLiabilitiesDetails">
<link:definition>1051 - Disclosure - Balance sheet information - Accrued liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationNarrativeDetails" id="BalanceSheetInformationNarrativeDetails">
<link:definition>1052 - Disclosure - Balance sheet information - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails" id="BalanceSheetInformationScheduleOfInventoryValuationReservesDetails">
<link:definition>1053 - Disclosure - Balance sheet information - Schedule Of Inventory Valuation Reserves (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails" id="BalanceSheetInformationPropertyPlantAndEquipmentDetails">
<link:definition>1054 - Disclosure - Balance sheet information - Property, Plant and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails" id="BalanceSheetInformationScheduleOfGoodwillDetails">
<link:definition>1055 - Disclosure - Balance sheet information - Schedule of Goodwill (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails" id="BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails">
<link:definition>1056 - Disclosure - Balance sheet information - Schedule Of Intangible Assets Net Excluding Goodwill  (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails" id="BusinessCombinationsAndInvestmentsNarrativeDetails">
<link:definition>1057 - Disclosure - Business combinations and investments - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails" id="BusinessCombinationsAndInvestmentsConsiderationTransferredDetails">
<link:definition>1058 - Disclosure - Business combinations and investments - Consideration transferred (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" id="BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
<link:definition>1059 - Disclosure - Business combinations and investments - Fair value of assets acquired and liabilities assumed (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails" id="BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails">
<link:definition>1060 - Disclosure - Business combinations and investments - Components of intangible assets acquired (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails" id="BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails">
<link:definition>1061 - Disclosure - Business combinations and investments - Variable interest entity's assets and liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails" id="BusinessCombinationsAndInvestmentsProFormaResultsDetails">
<link:definition>1062 - Disclosure - Business combinations and investments - Pro forma results (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails" id="FinancialInstrumentsScheduleOfLongTermDebtDetails">
<link:definition>1063 - Disclosure - Financial instruments - Schedule Of Long-Term Debt (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FinancialInstrumentsNarrativeDetails" id="FinancialInstrumentsNarrativeDetails">
<link:definition>1064 - Disclosure - Financial instruments - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails" id="FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails">
<link:definition>1065 - Disclosure - Fair value measurements - Liabilities measured at fair value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails" id="FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails">
<link:definition>1066 - Disclosure - Fair value measurements - Acquisition unobservable level 3 inputs (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails" id="FairValueMeasurementsAdditionalInformationDetails">
<link:definition>1067 - Disclosure - Fair value measurements - Additional information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails" id="FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails">
<link:definition>1068 - Disclosure - Fair value measurements - MIP and liability-classified awards (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails" id="FairValueMeasurementsEquityParticipationRightUnitDetails">
<link:definition>1069 - Disclosure - Fair value measurements - Equity participation right unit (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail" id="FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail">
<link:definition>1070 - Disclosure - Fair value measurements - Summary of range of key assumptions used within the valuation of the awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EquityBasedCompensationNarrativeDetails" id="EquityBasedCompensationNarrativeDetails">
<link:definition>1071 - Disclosure - Equity-based compensation - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails" id="EquityBasedCompensationRestrictedStockUnitActivityDetails">
<link:definition>1072 - Disclosure - Equity-based compensation - Restricted stock unit activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails" id="EquityBasedCompensationFairValueAssumptionsDetails">
<link:definition>1073 - Disclosure - Equity-based compensation - Fair value assumptions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EquityBasedCompensationOptionActivityDetails" id="EquityBasedCompensationOptionActivityDetails">
<link:definition>1074 - Disclosure - Equity-based compensation - Option activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails" id="EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails">
<link:definition>1075 - Disclosure - Earnings per share - Computation of Basic and Diluted Earnings Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
<link:definition>1076 - Disclosure - Earnings per share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails" id="IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails">
<link:definition>1077 - Disclosure - Income taxes - Summary of Net Income From Continuing Operations Before Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails" id="IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails">
<link:definition>1078 - Disclosure - Income taxes - Summary Of Components Of Income Tax Expense Benefit (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails">
<link:definition>1079 - Disclosure - Income taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition>1080 - Disclosure - Income taxes - Summary of Deferred Tax Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>1081 - Disclosure - Income taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RelatedPartyTransactionsNarrativeDetail" id="RelatedPartyTransactionsNarrativeDetail">
<link:definition>1082 - Disclosure - Related-party transactions - Narrative (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails" id="CommitmentsAndContingenciesLeaseCostDetails">
<link:definition>1083 - Disclosure - Commitments and contingencies - Lease Cost (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails" id="CommitmentsAndContingenciesSupplementalCashFlowInformationDetails">
<link:definition>1084 - Disclosure - Commitments and contingencies - Supplemental Cash Flow Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails" id="CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails">
<link:definition>1085 - Disclosure - Commitments and contingencies - Supplemental Balance Sheet Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails" id="CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails">
<link:definition>1086 - Disclosure - Commitments and contingencies - Summary of Lessee Liability Maturity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails" id="CommitmentsAndContingenciesNarrativeDetails">
<link:definition>1087 - Disclosure - Commitments and contingencies - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail" id="NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail">
<link:definition>1088 - Disclosure - Net income (loss) per unit - Summary of Earnings Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails" id="NetIncomeLossPerUnitNarrativeDetails">
<link:definition>1089 - Disclosure - Net income (loss) per unit - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RevenueRecognitionDetails" id="RevenueRecognitionDetails">
<link:definition>1090 - Disclosure - Revenue recognition (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SegmentsDetails" id="SegmentsDetails">
<link:definition>1091 - Disclosure - Segments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>1092 - Disclosure - Subsequent events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/StockholderSEquityAdditionalInformationDetail" id="StockholderSEquityAdditionalInformationDetail">
<link:definition>1093 - Disclosure - Stockholder's Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails" id="DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails">
<link:definition>1094 - Disclosure - Discontinued Operations - Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails" id="DiscontinuedOperationsAdditionalInformationDetails">
<link:definition>1095 - Disclosure - Discontinued Operations - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/NetSalesDetails" id="NetSalesDetails">
<link:definition>1096 - Disclosure - Net Sales (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail" id="SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail">
<link:definition>1097 - Disclosure - Summary of Significant Accounting Policies - Summary of useful lives in assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail" id="SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail">
<link:definition>1098 - Disclosure - Summary of Significant Accounting Policies - Summary of Finite-lived intangible assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail" id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail">
<link:definition>1099 - Disclosure - Summary of Significant Accounting Policies - Summary of significant percentage of total sales (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail" id="SummaryOfSignificantAccountingPoliciesNarrativeDetail">
<link:definition>1100 - Disclosure - Summary of Significant Accounting Policies - Narrative (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails" id="MembersEquitySummaryOfMembersEquityDetails">
<link:definition>1101 - Disclosure - Members' equity - Summary of Members Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/MembersEquityNarrativeDetails" id="MembersEquityNarrativeDetails">
<link:definition>1102 - Disclosure - Members' equity - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails" id="RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails">
<link:definition>1103 - Disclosure - Restructuring costs - Summary of restructuring charges and payments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/RestructuringCostsAdditionalInformationDetails" id="RestructuringCostsAdditionalInformationDetails">
<link:definition>1104 - Disclosure - Restructuring costs - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail" id="EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail">
<link:definition>1105 - Disclosure - Equity-based compensation - Summary of Phantom Plan Award activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail" id="FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail">
<link:definition>1106 - Disclosure - Financial instruments - Summary of Debt Instruments Periodic Payments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail" id="FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail">
<link:definition>1107 - Disclosure - Financial instruments - Schedule of Loan margin Adjusted on  Pricing Grid  (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail" id="FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail">
<link:definition>1108 - Disclosure - Financial instruments - Schedule of Commitment Fee  Adjusted Based on Pricing Grid (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail" id="FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail">
<link:definition>1109 - Disclosure - Financial instruments - Summary of Contractual maturities of long-term debt (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1" id="ConsolidatedCondensedStatementsOfCashFlowsAlternate1">
<link:definition>1110 - Statement - Consolidated condensed statements of cash flows Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="bvs-20210703_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bvs-20210703_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bvs-20210703_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bvs-20210703_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
<element name="BioVentusLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BioVentusLlcMember" substitutionGroup="xbrli:item" />
<element name="TotalAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_TotalAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TotalStockholdersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_TotalStockholdersEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TotalLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_TotalLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TotalLiabilitiesAndStockholdersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_TotalLiabilitiesAndStockholdersEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PublicOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PublicOfferingMember" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" substitutionGroup="xbrli:item" />
<element name="MembersEquityDecreaseFromEquityForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_MembersEquityDecreaseFromEquityForfeitures" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MembersEquityDecreaseFromProfitInterestForfeiture" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_MembersEquityDecreaseFromProfitInterestForfeiture" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MembersEquityIncreaseFromRefundsFromMembers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_MembersEquityIncreaseFromRefundsFromMembers" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MembersEquityDecreaseFromDistributionToMembers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_MembersEquityDecreaseFromDistributionToMembers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockholdersEquitySharesChangeInReportingEntity" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_StockholdersEquitySharesChangeInReportingEntity" substitutionGroup="xbrli:item" />
<element name="NetLossSubsequentToOrganizationalTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_NetLossSubsequentToOrganizationalTransactions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInFairValueOfEquityParticipationRightsUnit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ChangeInFairValueOfEquityParticipationRightsUnit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ImpairmentOfVariableInterestEntityAndRelatedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InvestmentAndAcquisitionOfDistributionRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_InvestmentAndAcquisitionOfDistributionRights" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AcquisitionOfVariableInterestEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_AcquisitionOfVariableInterestEntity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromMembers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ProceedsFromMembers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MemberDistributionsIncurredButNotYetPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_MemberDistributionsIncurredButNotYetPaid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SupplementalDisclosureOfCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SupplementalDisclosureOfCashFlowInformationAbstract" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationsAndInvestmentsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="NetIncomeLossPerUnitTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_NetIncomeLossPerUnitTextBlock" substitutionGroup="xbrli:item" />
<element name="MemberEquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_MemberEquityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="MemberEquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_MemberEquityLineItems" substitutionGroup="xbrli:item" />
<element name="NetSalesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_NetSalesTextBlock" substitutionGroup="xbrli:item" />
<element name="NonControllingInterestPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_NonControllingInterestPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ContractAssetsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ContractAssetsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ContractLiabilitiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ContractLiabilitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ContractCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ContractCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="BioventusIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BioventusIncMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfMembersEquityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ScheduleOfMembersEquityTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisaggregationOfRevenueBasedOnGeographyTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AssetsAndLiabilitiesLesseeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_AssetsAndLiabilitiesLesseeTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfInventoryValuationReservesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ScheduleOfInventoryValuationReservesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" substitutionGroup="xbrli:item" />
<element name="EquityParticipationRightUnitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_EquityParticipationRightUnitMember" substitutionGroup="xbrli:item" />
<element name="OtherPhantomUnitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_OtherPhantomUnitMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="BVLLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BVLLCMember" substitutionGroup="xbrli:item" />
<element name="SaleOfStockOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_SaleOfStockOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CancellationRatioRequiredStockToLLCInterestRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_CancellationRatioRequiredStockToLLCInterestRatio" substitutionGroup="xbrli:item" />
<element name="PaymentsOfStockIssuanceCostsAdditionalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromGovernmentalAssistance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ProceedsFromGovernmentalAssistance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommonStockNumberOfVotes" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_CommonStockNumberOfVotes" substitutionGroup="xbrli:item" />
<element name="SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" substitutionGroup="xbrli:item" />
<element name="PercentageOfDeferredPayrollTax" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_PercentageOfDeferredPayrollTax" substitutionGroup="xbrli:item" />
<element name="LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" substitutionGroup="xbrli:item" />
<element name="GrossToNetDeductionsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_GrossToNetDeductionsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedSalariesAndEmployeeBenefitsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_AccruedSalariesAndEmployeeBenefitsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmortizationExpenseIncludedInInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_AmortizationExpenseIncludedInInventory" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_EventDomain" substitutionGroup="xbrli:item" />
<element name="ReclassificationOfIprdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ReclassificationOfIprdMember" substitutionGroup="xbrli:item" />
<element name="InventoryValuationReservesProvisionForLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_InventoryValuationReservesProvisionForLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InventoryValuationReservesWriteOffs" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_InventoryValuationReservesWriteOffs" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ComputerEquipmentAndSoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ComputerEquipmentAndSoftwareMember" substitutionGroup="xbrli:item" />
<element name="InternationalSegmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_InternationalSegmentMember" substitutionGroup="xbrli:item" />
<element name="USSegmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_USSegmentMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" substitutionGroup="xbrli:item" />
<element name="FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" substitutionGroup="xbrli:item" />
<element name="IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FiniteLivedIntangibleAssetsCurrencyTranslation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AcquiredInProcessResearchAndDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_AcquiredInProcessResearchAndDevelopmentMember" substitutionGroup="xbrli:item" />
<element name="BionessIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BionessIncMember" substitutionGroup="xbrli:item" />
<element name="CartiHealMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_CartiHealMember" substitutionGroup="xbrli:item" />
<element name="VaporoxMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_VaporoxMember" substitutionGroup="xbrli:item" />
<element name="CartiHealLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_CartiHealLtdMember" substitutionGroup="xbrli:item" />
<element name="ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" substitutionGroup="xbrli:item" />
<element name="ObtainingFDAApprovalOfCertainProductsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ObtainingFDAApprovalOfCertainProductsMember" substitutionGroup="xbrli:item" />
<element name="MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" substitutionGroup="xbrli:item" />
<element name="MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" substitutionGroup="xbrli:item" />
<element name="AssetImpairmentChargesAttributableToNoncontrollingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="VariableInterestEntityImpairment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_VariableInterestEntityImpairment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" substitutionGroup="xbrli:item" />
<element name="EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" substitutionGroup="xbrli:item" />
<element name="BusinessAcquisitionPeriodOfNoticeForTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_BusinessAcquisitionPeriodOfNoticeForTermination" substitutionGroup="xbrli:item" />
<element name="BusinessAcquisitionPaymentDueUponTerminationOfAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" substitutionGroup="xbrli:item" />
<element name="EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InvestmentOwnedOwnershipPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_InvestmentOwnedOwnershipPercentage" substitutionGroup="xbrli:item" />
<element name="VariableInterestEntitySharesIssuedDuringPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_VariableInterestEntitySharesIssuedDuringPeriod" substitutionGroup="xbrli:item" />
<element name="VariableInterestEntityIssuedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_VariableInterestEntityIssuedCost" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EquityMethodInvestmentAdditionalInvestmentPurchasedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentConvertibleConversionExercisablePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_DebtInstrumentConvertibleConversionExercisablePrice" substitutionGroup="xbrli:item" />
<element name="FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" substitutionGroup="xbrli:item" />
<element name="EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EquityMethodInvestmentCapitalizedTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityMethodInvestmentCapitalizedTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="HarborMedtechIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_HarborMedtechIncMember" substitutionGroup="xbrli:item" />
<element name="HarborSeriesCPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_HarborSeriesCPreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesG1PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SeriesG1PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesFConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SeriesFConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="PromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="HarborCommonStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_HarborCommonStockMember" substitutionGroup="xbrli:item" />
<element name="AgreementForFutureEquityAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_AgreementForFutureEquityAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementForFutureEquityDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_AgreementForFutureEquityDomain" substitutionGroup="xbrli:item" />
<element name="SimpleAgreementForFutureEquityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SimpleAgreementForFutureEquityMember" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="OptionAndEquityPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_OptionAndEquityPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="PaycheckProtectionProgramCARESActMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PaycheckProtectionProgramCARESActMember" substitutionGroup="xbrli:item" />
<element name="PaycheckProtectionProgramCARESActMaturingApril102022Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" substitutionGroup="xbrli:item" />
<element name="PaycheckProtectionProgramCARESActMaturingFebruary52026Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtInstrumentNumberOfLoans" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_DebtInstrumentNumberOfLoans" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TermLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TermLoanMember" substitutionGroup="xbrli:item" />
<element name="CreditAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_CreditAgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CreditAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_CreditAgreementDomain" substitutionGroup="xbrli:item" />
<element name="TwoThousandNineteenCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TwoThousandNineteenCreditAgreementMember" substitutionGroup="xbrli:item" />
<element name="PriorCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PriorCreditAgreementMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentFinalPrincipalPaymentAtMaturity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfTotalOutstandingDebtLoanedByLenders" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" substitutionGroup="xbrli:item" />
<element name="AdditionalMarginPercentageToReferenceRates" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_AdditionalMarginPercentageToReferenceRates" substitutionGroup="xbrli:item" />
<element name="ThresholdMaximumAggregateAdditionalBorrowings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_ThresholdMaximumAggregateAdditionalBorrowings" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmortizationOfDebtInstrumentCapitalizedDeferredFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DerivativeStatedFixedInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_DerivativeStatedFixedInterestRate" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentFloorRatePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_DebtInstrumentFloorRatePercentage" substitutionGroup="xbrli:item" />
<element name="InterestCoverageRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_InterestCoverageRatio" substitutionGroup="xbrli:item" />
<element name="DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DerivativeEffectiveInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_DerivativeEffectiveInterestRate" substitutionGroup="xbrli:item" />
<element name="FrontingFeePercentageOnUndrawnAmount" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_FrontingFeePercentageOnUndrawnAmount" substitutionGroup="xbrli:item" />
<element name="InterestRateBasisAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_InterestRateBasisAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InterestRateBasisDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_InterestRateBasisDomain" substitutionGroup="xbrli:item" />
<element name="BrInterestRateBasisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BrInterestRateBasisMember" substitutionGroup="xbrli:item" />
<element name="RevolvingCreditFacilitySubAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_RevolvingCreditFacilitySubAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RevolvingCreditFacilitySubDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_RevolvingCreditFacilitySubDomain" substitutionGroup="xbrli:item" />
<element name="SwingLineCreditFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SwingLineCreditFacilityMember" substitutionGroup="xbrli:item" />
<element name="ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EquityParticipationRightFairValueDisclsoure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityParticipationRightFairValueDisclsoure" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BVLLCEmployeesTerminatedPriorToIPOMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BVLLCEmployeesTerminatedPriorToIPOMember" substitutionGroup="xbrli:item" />
<element name="BVLLCEmployeesActiveAtIPOMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BVLLCEmployeesActiveAtIPOMember" substitutionGroup="xbrli:item" />
<element name="ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" substitutionGroup="xbrli:item" />
<element name="NumberOfEquityBasedCompensationPlans" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_NumberOfEquityBasedCompensationPlans" substitutionGroup="xbrli:item" />
<element name="EquityParticipationRightEntitledPercentageOfDistributions" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityParticipationRightEntitledPercentageOfDistributions" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EquityParticipationRightsUnitMeasurableInput" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityParticipationRightsUnitMeasurableInput" substitutionGroup="xbrli:item" />
<element name="EquityParticipationRightsUnitEquityValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_EquityParticipationRightsUnitEquityValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MeasurementInputEquityVolatilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_MeasurementInputEquityVolatilityMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" substitutionGroup="xbrli:item" />
<element name="ManagementIncentivePlanAwardMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ManagementIncentivePlanAwardMember" substitutionGroup="xbrli:item" />
<element name="A2021PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_A2021PlanMember" substitutionGroup="xbrli:item" />
<element name="LimitedLiabilityCompanyInterestsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_LimitedLiabilityCompanyInterestsMember" substitutionGroup="xbrli:item" />
<element name="UnvestedClassACommonSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_UnvestedClassACommonSharesMember" substitutionGroup="xbrli:item" />
<element name="IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TaxableSubsidiariesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TaxableSubsidiariesAbstract" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" substitutionGroup="xbrli:item" />
<element name="DeferredTaxLiabilitiesAcquiredIntangibles" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_DeferredTaxLiabilitiesAcquiredIntangibles" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FederalAndStateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_FederalAndStateMember" substitutionGroup="xbrli:item" />
<element name="HarborMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_HarborMember" substitutionGroup="xbrli:item" />
<element name="IndefinitelyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_IndefinitelyMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" substitutionGroup="xbrli:item" />
<element name="CashDistributionMadeToMembersTowardsTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_CashDistributionMadeToMembersTowardsTax" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SupplierOfSingleInjectionOAProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SupplierOfSingleInjectionOAProductMember" substitutionGroup="xbrli:item" />
<element name="ThreeInjectionOAProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ThreeInjectionOAProductMember" substitutionGroup="xbrli:item" />
<element name="SupplyCommitmentRenewalTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_SupplyCommitmentRenewalTerm" substitutionGroup="xbrli:item" />
<element name="CollaborativeArrangementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_CollaborativeArrangementTerm" substitutionGroup="xbrli:item" />
<element name="CollaborativeArrangementRoyaltyPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_CollaborativeArrangementRoyaltyPercentage" substitutionGroup="xbrli:item" />
<element name="RefundOfExcessPaymentsToThirdPartyCustomers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_RefundOfExcessPaymentsToThirdPartyCustomers" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_MilestonePaymentPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SupplyCommitmentTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_SupplyCommitmentTerm" substitutionGroup="xbrli:item" />
<element name="StopLossInsuranceThresholdPerMemberPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_StopLossInsuranceThresholdPerMemberPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UsaoAndOigMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_UsaoAndOigMember" substitutionGroup="xbrli:item" />
<element name="NetIncomeLossFromContinuingOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_NetIncomeLossFromContinuingOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PreferredUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PreferredUnitsMember" substitutionGroup="xbrli:item" />
<element name="PainTreatmentsAndJointPreservationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PainTreatmentsAndJointPreservationMember" substitutionGroup="xbrli:item" />
<element name="RestorativeTherapiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_RestorativeTherapiesMember" substitutionGroup="xbrli:item" />
<element name="BoneGraftSubstitutesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BoneGraftSubstitutesMember" substitutionGroup="xbrli:item" />
<element name="SuccessionAndTransitionCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_SuccessionAndTransitionCharges" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InventoryStepUpCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_InventoryStepUpCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaycheckProtectionProgramLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_PaycheckProtectionProgramLoanMember" substitutionGroup="xbrli:item" />
<element name="TermLoanFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TermLoanFacilityMember" substitutionGroup="xbrli:item" />
<element name="A2019CreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_A2019CreditAgreementMember" substitutionGroup="xbrli:item" />
<element name="MisonixIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_MisonixIncMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentCovenantRequiredPrepayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_DebtInstrumentCovenantRequiredPrepayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessAcquisitionConsiderationTransferredPerShareCash" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" substitutionGroup="xbrli:item" />
<element name="BusinessAcquisitionConsiderationTransferredPerShareShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" substitutionGroup="xbrli:item" />
<element name="BusinessAcquisitionConsiderationTransferredPerShareMaximum" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" substitutionGroup="xbrli:item" />
<element name="ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" substitutionGroup="xbrli:item" />
<element name="CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" substitutionGroup="xbrli:item" />
<element name="ShareBasedPaymentAwardSettlementPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ShareBasedPaymentAwardSettlementPeriod" substitutionGroup="xbrli:item" />
<element name="InvestorAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_InvestorAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InvestorDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_InvestorDomain" substitutionGroup="xbrli:item" />
<element name="ContinuingLlcOwnerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ContinuingLlcOwnerMember" substitutionGroup="xbrli:item" />
<element name="NewLlcOwnerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_NewLlcOwnerMember" substitutionGroup="xbrli:item" />
<element name="ConvertibleDebtInstrumentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ConvertibleDebtInstrumentsMember" substitutionGroup="xbrli:item" />
<element name="RestatedLimitedLiabilityCompanyAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_RestatedLimitedLiabilityCompanyAgreementMember" substitutionGroup="xbrli:item" />
<element name="RestrictedStockUnitsAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_RestrictedStockUnitsAgreementMember" substitutionGroup="xbrli:item" />
<element name="DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BmpResearchAndDevelopmentProgrammeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_BmpResearchAndDevelopmentProgrammeMember" substitutionGroup="xbrli:item" />
<element name="DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OAJointPainTreatmentAndJointPreservationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_OAJointPainTreatmentAndJointPreservationMember" substitutionGroup="xbrli:item" />
<element name="MinimallyInvasiveFractureTreatmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_MinimallyInvasiveFractureTreatmentMember" substitutionGroup="xbrli:item" />
<element name="ConcentrationRiskBySupplierNameAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ConcentrationRiskBySupplierNameAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ConcentrationRiskBySupplierNameDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ConcentrationRiskBySupplierNameDomain" substitutionGroup="xbrli:item" />
<element name="ProductDMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ProductDMember" substitutionGroup="xbrli:item" />
<element name="SupplierCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SupplierCMember" substitutionGroup="xbrli:item" />
<element name="ProductAMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ProductAMember" substitutionGroup="xbrli:item" />
<element name="ProductBMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ProductBMember" substitutionGroup="xbrli:item" />
<element name="ProductCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_ProductCMember" substitutionGroup="xbrli:item" />
<element name="SupplierAMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SupplierAMember" substitutionGroup="xbrli:item" />
<element name="SupplierBMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_SupplierBMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfMembersTaxDistributionToTaxableIncome" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_PercentageOfMembersTaxDistributionToTaxableIncome" substitutionGroup="xbrli:item" />
<element name="ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="PreferredUnitsLiquidationPreferencePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_PreferredUnitsLiquidationPreferencePerUnit" substitutionGroup="xbrli:item" />
<element name="PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" substitutionGroup="xbrli:item" />
<element name="DistributionEventTriggerPercentageOfSaleOfAssets" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_DistributionEventTriggerPercentageOfSaleOfAssets" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwelvePreferredUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TwoThousandAndTwelvePreferredUnitsMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndFifteenPreferredUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TwoThousandAndFifteenPreferredUnitsMember" substitutionGroup="xbrli:item" />
<element name="EmployeeSeveranceAndTemporaryLaborCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_EmployeeSeveranceAndTemporaryLaborCostsMember" substitutionGroup="xbrli:item" />
<element name="OtherChargesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_OtherChargesMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEighteenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TwoThousandAndEighteenPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TwoThousandAndTwentyPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TwoThousandAndTwelveMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_TwoThousandAndFifteenMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentSchedulePeriodicPaymentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_DebtInstrumentSchedulePeriodicPaymentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DebtInstrumentSchedulePeriodicPaymentDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_DebtInstrumentSchedulePeriodicPaymentDomain" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" substitutionGroup="xbrli:item" />
<element name="LeverageRatioRangeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_LeverageRatioRangeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="LeverageRatioRangeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_LeverageRatioRangeDomain" substitutionGroup="xbrli:item" />
<element name="LeverageRatioRangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_LeverageRatioRangeTwoMember" substitutionGroup="xbrli:item" />
<element name="LeverageRatioRangeThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_LeverageRatioRangeThreeMember" substitutionGroup="xbrli:item" />
<element name="LeverageRatioRangeFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_LeverageRatioRangeFourMember" substitutionGroup="xbrli:item" />
<element name="LeverageRatioRangeFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_LeverageRatioRangeFiveMember" substitutionGroup="xbrli:item" />
<element name="LeverageRatioRangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bvs_LeverageRatioRangeOneMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>bvs-20210703_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-September-2021 [01:59:44] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedBalanceSheets" roleURI="http://bio.com/role/ConsolidatedCondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfCashFlows" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationComponentsOfAccountsReceivableDetails" roleURI="http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationInventoryDetails" roleURI="http://bio.com/role/BalanceSheetInformationInventoryDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationAccruedLiabilitiesDetails" roleURI="http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationPropertyPlantAndEquipmentDetails" roleURI="http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails" roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails" roleURI="http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesLeaseCostDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SegmentsDetails" roleURI="http://bio.com/role/SegmentsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails" roleURI="http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquitySummaryOfMembersEquityDetails" roleURI="http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail" roleURI="http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfCashFlowsAlternate1" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_MembersEquity" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermDebtNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" use="optional" order="21" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_LongTermInvestments" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="33" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestmentAndAcquisitionOfDistributionRights" xlink:label="loc_BVS_InvestmentAndAcquisitionOfDistributionRights" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_BVS_InvestmentAndAcquisitionOfDistributionRights" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AcquisitionOfVariableInterestEntity" xlink:label="loc_BVS_AcquisitionOfVariableInterestEntity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_BVS_AcquisitionOfVariableInterestEntity" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromMembers" xlink:label="loc_BVS_ProceedsFromMembers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_BVS_ProceedsFromMembers" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xlink:label="loc_BVS_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BVS_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="25" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ChangeInFairValueOfEquityParticipationRightsUnit" xlink:label="loc_BVS_ChangeInFairValueOfEquityParticipationRightsUnit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BVS_ChangeInFairValueOfEquityParticipationRightsUnit" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" xlink:label="loc_BVS_ImpairmentOfVariableInterestEntityAndRelatedAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BVS_ImpairmentOfVariableInterestEntityAndRelatedAssets" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="30" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="33" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="37" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="38" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="39" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" use="optional" order="41" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xlink:label="loc_BVS_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_BVS_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" use="optional" order="43" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" use="optional" order="44" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="45" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" use="optional" order="46" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" use="optional" order="47" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" use="optional" order="48" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="49" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AssetRetirementObligationAccretionExpense" use="optional" order="51" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" use="optional" order="52" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationInventoryDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross" xlink:to="loc_us-gaap_InventoryFinishedGoods" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryValuationReserves" use="optional" order="4" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_GrossToNetDeductionsCurrent" xlink:label="loc_BVS_GrossToNetDeductionsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_BVS_GrossToNetDeductionsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedBonusesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" xlink:label="loc_BVS_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_BVS_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="loc_BVS_AccruedSalariesAndEmployeeBenefitsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_BVS_AccruedSalariesAndEmployeeBenefitsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_TaxesPayableCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_DepreciationAndAmortization" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_AssetImpairmentCharges" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" use="optional" order="24" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" use="optional" order="26" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" use="optional" order="30" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="31" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:label="loc_us-gaap_LongTermDebtMaturingInYearsFourAndFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebtMaturingInYearsFourAndFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_DeferredFinanceCostsNet" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebt" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_BVS_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_BVS_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" xlink:label="loc_BVS_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_BVS_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" use="optional" order="3" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/SegmentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:label="loc_BVS_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_BVS_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_DepreciationAndAmortization" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemNetGainLoss" xlink:label="loc_us-gaap_UnusualOrInfrequentItemNetGainLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_UnusualOrInfrequentItemNetGainLoss" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SuccessionAndTransitionCharges" xlink:label="loc_BVS_SuccessionAndTransitionCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_BVS_SuccessionAndTransitionCharges" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryStepUpCost" xlink:label="loc_BVS_InventoryStepUpCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_BVS_InventoryStepUpCost" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_AssetImpairmentCharges" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OtherNonrecurringExpense" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="14" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" xlink:label="loc_BVS_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BVS_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" xlink:label="loc_BVS_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BVS_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="4" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" xlink:label="loc_BVS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_BVS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="loc_BVS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_BVS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:label="loc_BVS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_BVS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" use="optional" order="14" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" xlink:label="loc_BVS_FiniteLivedIntangibleAssetsCurrencyTranslation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="loc_BVS_FiniteLivedIntangibleAssetsCurrencyTranslation" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" xlink:label="loc_BVS_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="loc_BVS_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital" xlink:label="loc_us-gaap_MembersCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MembersCapital" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MembersCapital" xlink:to="loc_us-gaap_CommonUnitIssuanceValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" xlink:label="loc_BVS_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MembersCapital" xlink:to="loc_BVS_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="loc_us-gaap_DerivativeLiabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" xlink:label="loc_BVS_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="loc_BVS_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightFairValueDisclsoure" xlink:label="loc_BVS_EquityParticipationRightFairValueDisclsoure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="loc_BVS_EquityParticipationRightFairValueDisclsoure" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_ShortTermLeaseCost" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>bvs-20210703_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-September-2021 [01:59:44] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CoverPage" roleURI="http://bio.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedBalanceSheets" roleURI="http://bio.com/role/ConsolidatedCondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedBalanceSheetsParenthetical" roleURI="http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfCashFlows" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#Organization" roleURI="http://bio.com/role/Organization" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformation" roleURI="http://bio.com/role/BalanceSheetInformation" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestments" roleURI="http://bio.com/role/BusinessCombinationsAndInvestments" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstruments" roleURI="http://bio.com/role/FinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurements" roleURI="http://bio.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensation" roleURI="http://bio.com/role/EquityBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxes" roleURI="http://bio.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetIncomeLossPerUnit" roleURI="http://bio.com/role/NetIncomeLossPerUnit" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RestructuringCosts" roleURI="http://bio.com/role/RestructuringCosts" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquity" roleURI="http://bio.com/role/MembersEquity" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RelatedPartyTransactions" roleURI="http://bio.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetSales" roleURI="http://bio.com/role/NetSales" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperations" roleURI="http://bio.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#Segments" roleURI="http://bio.com/role/Segments" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SubsequentEvents" roleURI="http://bio.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RestructuringCostsTables" roleURI="http://bio.com/role/RestructuringCostsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquityTables" roleURI="http://bio.com/role/MembersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetSalesTables" roleURI="http://bio.com/role/NetSalesTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperationsTables" roleURI="http://bio.com/role/DiscontinuedOperationsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SegmentsTables" roleURI="http://bio.com/role/SegmentsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetIncomeLossPerUnitTables" roleURI="http://bio.com/role/NetIncomeLossPerUnitTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesTables" roleURI="http://bio.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationTables" roleURI="http://bio.com/role/BalanceSheetInformationTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsTables" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsTables" roleURI="http://bio.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsTables" roleURI="http://bio.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationTables" roleURI="http://bio.com/role/EquityBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesTables" roleURI="http://bio.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#OrganizationDetails" roleURI="http://bio.com/role/OrganizationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationComponentsOfAccountsReceivableDetails" roleURI="http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationAllowanceForCreditLossDetails" roleURI="http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationInventoryDetails" roleURI="http://bio.com/role/BalanceSheetInformationInventoryDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationAccruedLiabilitiesDetails" roleURI="http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationNarrativeDetails" roleURI="http://bio.com/role/BalanceSheetInformationNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationScheduleOfInventoryValuationReservesDetails" roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationPropertyPlantAndEquipmentDetails" roleURI="http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationScheduleOfGoodwillDetails" roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails" roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsNarrativeDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsConsiderationTransferredDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsProFormaResultsDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsNarrativeDetails" roleURI="http://bio.com/role/FinancialInstrumentsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails" roleURI="http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails" roleURI="http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails" roleURI="http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsEquityParticipationRightUnitDetails" roleURI="http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail" roleURI="http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationNarrativeDetails" roleURI="http://bio.com/role/EquityBasedCompensationNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationFairValueAssumptionsDetails" roleURI="http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesDetails" roleURI="http://bio.com/role/IncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RelatedPartyTransactionsNarrativeDetail" roleURI="http://bio.com/role/RelatedPartyTransactionsNarrativeDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesLeaseCostDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesSupplementalCashFlowInformationDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesNarrativeDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail" roleURI="http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetIncomeLossPerUnitNarrativeDetails" roleURI="http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RevenueRecognitionDetails" roleURI="http://bio.com/role/RevenueRecognitionDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SegmentsDetails" roleURI="http://bio.com/role/SegmentsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SubsequentEventsDetails" roleURI="http://bio.com/role/SubsequentEventsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails" roleURI="http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperationsAdditionalInformationDetails" roleURI="http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetSalesDetails" roleURI="http://bio.com/role/NetSalesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetail" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquitySummaryOfMembersEquityDetails" roleURI="http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquityNarrativeDetails" roleURI="http://bio.com/role/MembersEquityNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails" roleURI="http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RestructuringCostsAdditionalInformationDetails" roleURI="http://bio.com/role/RestructuringCostsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail" roleURI="http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail" roleURI="http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail" roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail" roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail" roleURI="http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#OrganizationPolicies" roleURI="http://bio.com/role/OrganizationPolicies" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsScheduleOfLongTermDebtDetails" roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationOptionActivityDetails" roleURI="http://bio.com/role/EquityBasedCompensationOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails" roleURI="http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EarningsPerShare" roleURI="http://bio.com/role/EarningsPerShare" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EarningsPerShareTables" roleURI="http://bio.com/role/EarningsPerShareTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingencies" roleURI="http://bio.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RevenueRecognition" roleURI="http://bio.com/role/RevenueRecognition" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RevenueRecognitionTables" roleURI="http://bio.com/role/RevenueRecognitionTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#StockholderSEquity" roleURI="http://bio.com/role/StockholderSEquity" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#StockholderSEquityAdditionalInformationDetail" roleURI="http://bio.com/role/StockholderSEquityAdditionalInformationDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentType_9" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityRegistrantName_14" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentInformationTable_3" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_5" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_5_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityFilerCategory_29" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntitySmallBusiness_30" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityEmergingGrowthCompany_31" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1105695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AmendmentDescription_1105695" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityExTransitionPeriod_32" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AmendmentFlag_35" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCentralIndexKey_36" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105613" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_48" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_57" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ProfitLoss_58" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_59" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLoss_60" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_45" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_61" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_GrossProfit_46" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_AssetImpairmentCharges_51" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OperatingIncomeLoss_52" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_53" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_55" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_47" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_54" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1101466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1101466" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1101458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1101458" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_63" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_64" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_EarningsPerShareAbstract_42" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42" xlink:to="loc_us-gaap_EarningsPerShareBasic_65" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42" xlink:to="loc_us-gaap_EarningsPerShareDiluted_66" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_62" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_DepreciationAndAmortization_50" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_1106276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_1106276" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_1106280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_1106280" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1101461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1101461" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1101462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1101462" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_StatementTable_1105610" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105610" xlink:to="loc_dei_LegalEntityAxis_1105618" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105618" xlink:to="loc_dei_EntityDomain_1105620" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105620_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105618" xlink:to="loc_dei_EntityDomain_1105620_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105620" xlink:to="loc_bvs_BioVentusLlcMember_1105621" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1101456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_RestructuringCharges_1101456" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1101468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1101468" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1106248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1106248" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1101467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1101467" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1101471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1101471" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_1101474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_1101474" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1101475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1101475" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1101473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1101473" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1101464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1101464" use="optional" order="48" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105645" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105645" xlink:to="loc_us-gaap_StatementTable_1105642" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105642" xlink:to="loc_dei_LegalEntityAxis_1105646" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105646" xlink:to="loc_dei_EntityDomain_1105647" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105647_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105646" xlink:to="loc_dei_EntityDomain_1105647_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105647" xlink:to="loc_bvs_BioVentusLlcMember_1105648" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105645" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_71" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_StatementTable_74" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_74" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_76" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_76_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_76_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76" xlink:to="loc_us-gaap_CommonClassAMember_83" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_84" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76" xlink:to="loc_us-gaap_CommonClassBMember_84" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_74" xlink:to="loc_dei_LegalEntityAxis_1105638" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105638" xlink:to="loc_dei_EntityDomain_1105640" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105640_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105638" xlink:to="loc_dei_EntityDomain_1105640_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105640" xlink:to="loc_bvs_BioVentusLlcMember_1105680" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_AssetsAbstract_78" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_91" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_91" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_Goodwill_92" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_94" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_94" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_AssetsCurrentAbstract_79" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_88" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_InventoryNet_88" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_89" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_AssetsCurrent_90" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_86" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_RestrictedCashCurrent_86" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_87" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_87" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_85" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_95" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_95" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_LongTermInvestments_96" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_Assets_97" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalAssets" xlink:label="loc_bvs_TotalAssets_1106484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_bvs_TotalAssets_1106484" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_81" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_AccountsPayableCurrent_98" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_99" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_100" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_LongTermDebtCurrent_101" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_103" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_LiabilitiesCurrent_104" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_102" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_105" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_109" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_Liabilities_110" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_MembersEquity_112" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_115" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_116" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_CommonStockValue_113" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_AdditionalPaidInCapital_114" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_120" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalStockholdersEquity" xlink:label="loc_bvs_TotalStockholdersEquity_1106487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_bvs_TotalStockholdersEquity_1106487" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_MinorityInterest_118" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_StockholdersEquity_117" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_122" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_107" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_108" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalLiabilities" xlink:label="loc_bvs_TotalLiabilities_1106485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_bvs_TotalLiabilities_1106485" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalLiabilitiesAndStockholdersEquity" xlink:label="loc_bvs_TotalLiabilitiesAndStockholdersEquity_1106486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_bvs_TotalLiabilitiesAndStockholdersEquity_1106486" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_106" use="optional" order="54" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_128" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_136" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_131" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_132" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_StatementTable_125" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementClassOfStockAxis_126" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_126" xlink:to="loc_us-gaap_ClassOfStockDomain_127" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_127_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_126" xlink:to="loc_us-gaap_ClassOfStockDomain_127_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_127" xlink:to="loc_us-gaap_CommonClassAMember_129" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_127" xlink:to="loc_us-gaap_CommonClassBMember_130" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_dei_LegalEntityAxis_1105652" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105652" xlink:to="loc_dei_EntityDomain_1105653" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105653_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105652" xlink:to="loc_dei_EntityDomain_1105653_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105653" xlink:to="loc_bvs_BioVentusLlcMember_1105654" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PreferredStockSharesIssued_133" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_134" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_CommonStockSharesIssued_137" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_1101488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_1101488" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_135" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_147" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_147" xlink:to="loc_us-gaap_StatementTable_140" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_143" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144" xlink:to="loc_us-gaap_IPOMember_155" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PublicOfferingMember" xlink:label="loc_bvs_PublicOfferingMember_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144" xlink:to="loc_bvs_PublicOfferingMember_156" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_141" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_141" xlink:to="loc_us-gaap_EquityComponentDomain_142" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_142_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_141" xlink:to="loc_us-gaap_EquityComponentDomain_142_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_152" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_RetainedEarningsMember_153" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_NoncontrollingInterestMember_154" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_MemberUnitsMember_149" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_CommonStockMember_150" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_151" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_StatementClassOfStockAxis_145" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_145" xlink:to="loc_us-gaap_ClassOfStockDomain_146" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_146_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_145" xlink:to="loc_us-gaap_ClassOfStockDomain_146_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_146" xlink:to="loc_us-gaap_CommonClassBMember_158" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_146" xlink:to="loc_us-gaap_CommonClassAMember_157" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_dei_LegalEntityAxis_1105685" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105685" xlink:to="loc_dei_EntityDomain_1105686" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105686_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105685" xlink:to="loc_dei_EntityDomain_1105686_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105686" xlink:to="loc_bvs_BioVentusLlcMember_1105687" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:label="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_147" xlink:to="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromEquityForfeitures" xlink:label="loc_bvs_MembersEquityDecreaseFromEquityForfeitures_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_MembersEquityDecreaseFromEquityForfeitures_164" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromProfitInterestForfeiture" xlink:label="loc_bvs_MembersEquityDecreaseFromProfitInterestForfeiture_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_MembersEquityDecreaseFromProfitInterestForfeiture_165" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_MembersEquity_161" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityIncreaseFromRefundsFromMembers" xlink:label="loc_bvs_MembersEquityIncreaseFromRefundsFromMembers_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_MembersEquityIncreaseFromRefundsFromMembers_163" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_167" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromDistributionToMembers" xlink:label="loc_bvs_MembersEquityDecreaseFromDistributionToMembers_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_MembersEquityDecreaseFromDistributionToMembers_166" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_SharesOutstanding_159" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_160" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_162" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_ProfitLoss_168" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" xlink:label="loc_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity_169" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_170" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_171" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_172" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityChangeInReportingEntity" xlink:label="loc_us-gaap_StockholdersEquityChangeInReportingEntity_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockholdersEquityChangeInReportingEntity_173" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_StockholdersEquitySharesChangeInReportingEntity" xlink:label="loc_bvs_StockholdersEquitySharesChangeInReportingEntity_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_StockholdersEquitySharesChangeInReportingEntity_174" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetLossSubsequentToOrganizationalTransactions" xlink:label="loc_bvs_NetLossSubsequentToOrganizationalTransactions_1106473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_NetLossSubsequentToOrganizationalTransactions_1106473" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_1101592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_1101592" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_176" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105659" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_ProfitLoss_188" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_189" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_190" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_ShareBasedCompensation_191" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xlink:label="loc_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation_192" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_193" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_194" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ChangeInFairValueOfEquityParticipationRightsUnit" xlink:label="loc_bvs_ChangeInFairValueOfEquityParticipationRightsUnit_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_bvs_ChangeInFairValueOfEquityParticipationRightsUnit_195" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" xlink:label="loc_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets_196" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_197" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_198" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_199" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_200" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_201" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1101520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1101520" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1101519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1101519" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1101506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1101506" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense_1101516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_AssetRetirementObligationAccretionExpense_1101516" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1101508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1101508" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1101512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1101512" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1101514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1101514" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_202" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1101503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1101503" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1101497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1101497" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_204" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_203" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_205" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_206" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_207" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_208" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestmentAndAcquisitionOfDistributionRights" xlink:label="loc_bvs_InvestmentAndAcquisitionOfDistributionRights_1101521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_bvs_InvestmentAndAcquisitionOfDistributionRights_1101521" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AcquisitionOfVariableInterestEntity" xlink:label="loc_bvs_AcquisitionOfVariableInterestEntity_1101522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_bvs_AcquisitionOfVariableInterestEntity_1101522" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_209" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_210" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_211" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_212" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromMembers" xlink:label="loc_bvs_ProceedsFromMembers_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_bvs_ProceedsFromMembers_213" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_215" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_1101523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_1101523" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1101524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1101524" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_217" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_218" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberDistributionsIncurredButNotYetPaid" xlink:label="loc_bvs_MemberDistributionsIncurredButNotYetPaid_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" xlink:to="loc_bvs_MemberDistributionsIncurredButNotYetPaid_220" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_221" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_1101533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" xlink:to="loc_us-gaap_LiabilitiesAssumed1_1101533" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_1101534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" xlink:to="loc_us-gaap_StockIssued1_1101534" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_216" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:label="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract_1101530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract_1101530" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_1101531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract_1101530" xlink:to="loc_us-gaap_IncomeTaxesPaid_1101531" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1101532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract_1101530" xlink:to="loc_us-gaap_InterestPaidNet_1101532" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_StatementTable_1105656" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105656" xlink:to="loc_dei_LegalEntityAxis_1105661" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105661" xlink:to="loc_dei_EntityDomain_1105662" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105662_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105661" xlink:to="loc_dei_EntityDomain_1105662_default" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105662" xlink:to="loc_bvs_BioVentusLlcMember_1105664" use="optional" order="62" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/Organization">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103904" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103904" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_224" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1103901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103904" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1103901" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103901" xlink:to="loc_dei_LegalEntityAxis_1103902" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103902" xlink:to="loc_dei_EntityDomain_1103903" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103903_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103902" xlink:to="loc_dei_EntityDomain_1103903_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103903" xlink:to="loc_bvs_BioVentusLlcMember_1103906" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103915" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1101680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103915" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1101680" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1103911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103915" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1103911" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103911" xlink:to="loc_dei_LegalEntityAxis_1103912" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103912" xlink:to="loc_dei_EntityDomain_1103913" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103913_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103912" xlink:to="loc_dei_EntityDomain_1103913_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103913" xlink:to="loc_bvs_BioVentusLlcMember_1103914" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105704" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105704" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_274" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105704" xlink:to="loc_us-gaap_StatementTable_1105701" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105701" xlink:to="loc_dei_LegalEntityAxis_1105705" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105705" xlink:to="loc_dei_EntityDomain_1105706" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105706_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105705" xlink:to="loc_dei_EntityDomain_1105706_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105706" xlink:to="loc_bvs_BioVentusLlcMember_1105707" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1102785" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" xlink:label="loc_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102785" xlink:to="loc_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock_322" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1102785" xlink:to="loc_us-gaap_StatementTable_1102782" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102782" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102783" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102783" xlink:to="loc_us-gaap_ClassOfStockDomain_1102784" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102784_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102783" xlink:to="loc_us-gaap_ClassOfStockDomain_1102784_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102782" xlink:to="loc_dei_LegalEntityAxis_1102786" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102786" xlink:to="loc_dei_EntityDomain_1102787" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102787_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102786" xlink:to="loc_dei_EntityDomain_1102787_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102787" xlink:to="loc_bvs_BioVentusLlcMember_1102788" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstruments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_1103274" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1103273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_1103274" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1103273" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1103273" xlink:to="loc_dei_LegalEntityAxis_1103275" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103275" xlink:to="loc_dei_EntityDomain_1103276" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103276_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103275" xlink:to="loc_dei_EntityDomain_1103276_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103276" xlink:to="loc_bvs_BioVentusLlcMember_1103277" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_1103274" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_498" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102938" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102938" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_530" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102938" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102937" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102937" xlink:to="loc_dei_LegalEntityAxis_1102939" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102939" xlink:to="loc_dei_EntityDomain_1102940" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102940_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102939" xlink:to="loc_dei_EntityDomain_1102940_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102940" xlink:to="loc_bvs_BioVentusLlcMember_1102941" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103148" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103148" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_624" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1103145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1103148" xlink:to="loc_us-gaap_StatementTable_1103145" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103145" xlink:to="loc_dei_LegalEntityAxis_1103151" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103151" xlink:to="loc_dei_EntityDomain_1103152" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103152_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103151" xlink:to="loc_dei_EntityDomain_1103152_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103152" xlink:to="loc_bvs_BioVentusLlcMember_1103154" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103145" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103146" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103146" xlink:to="loc_us-gaap_ClassOfStockDomain_1103147" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103146" xlink:to="loc_us-gaap_ClassOfStockDomain_1103147_default" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105434" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105434" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_756" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105434" xlink:to="loc_us-gaap_StatementTable_1105431" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105431" xlink:to="loc_dei_LegalEntityAxis_1105435" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105435" xlink:to="loc_dei_EntityDomain_1105436" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105435" xlink:to="loc_dei_EntityDomain_1105436_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105436" xlink:to="loc_bvs_BioVentusLlcMember_1105437" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/NetIncomeLossPerUnit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1102314" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102314" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102311" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102311" xlink:to="loc_dei_LegalEntityAxis_1102315" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102315" xlink:to="loc_dei_EntityDomain_1102316" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102316_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102315" xlink:to="loc_dei_EntityDomain_1102316_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102316" xlink:to="loc_bvs_BioVentusLlcMember_1102317" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetIncomeLossPerUnitTextBlock" xlink:label="loc_bvs_NetIncomeLossPerUnitTextBlock_1105124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102314" xlink:to="loc_bvs_NetIncomeLossPerUnitTextBlock_1105124" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/RestructuringCosts">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1103069" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103069" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103068" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103068" xlink:to="loc_dei_LegalEntityAxis_1103073" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103073" xlink:to="loc_dei_EntityDomain_1103075" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103075_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103073" xlink:to="loc_dei_EntityDomain_1103075_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103075" xlink:to="loc_bvs_BioVentusLlcMember_1103076" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1103070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103069" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1103070" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquity">
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems_1103040" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:label="loc_us-gaap_MembersEquityNotesDisclosureTextBlock_1103044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103040" xlink:to="loc_us-gaap_MembersEquityNotesDisclosureTextBlock_1103044" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable_1103037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bvs_MemberEquityLineItems_1103040" xlink:to="loc_bvs_MemberEquityTable_1103037" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_MemberEquityTable_1103037" xlink:to="loc_dei_LegalEntityAxis_1103041" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103041" xlink:to="loc_dei_EntityDomain_1103042" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103042_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103041" xlink:to="loc_dei_EntityDomain_1103042_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103042" xlink:to="loc_bvs_BioVentusLlcMember_1103043" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1102984" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1102979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102984" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1102979" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1102984" xlink:to="loc_us-gaap_StatementTable_1102981" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102981" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102982" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102982" xlink:to="loc_us-gaap_ClassOfStockDomain_1102983" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102983_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102982" xlink:to="loc_us-gaap_ClassOfStockDomain_1102983_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102981" xlink:to="loc_dei_LegalEntityAxis_1102985" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102985" xlink:to="loc_dei_EntityDomain_1102986" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102986_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102985" xlink:to="loc_dei_EntityDomain_1102986_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102986" xlink:to="loc_bvs_BioVentusLlcMember_1102989" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/NetSales">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1102359" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1102358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102359" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1102358" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102358" xlink:to="loc_dei_LegalEntityAxis_1102360" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102360" xlink:to="loc_dei_EntityDomain_1102361" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102361_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102360" xlink:to="loc_dei_EntityDomain_1102361_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102361" xlink:to="loc_bvs_BioVentusLlcMember_1102362" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetSalesTextBlock" xlink:label="loc_bvs_NetSalesTextBlock_1105019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102359" xlink:to="loc_bvs_NetSalesTextBlock_1105019" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102246" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102246" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102245" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102245" xlink:to="loc_dei_LegalEntityAxis_1102247" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102247" xlink:to="loc_dei_EntityDomain_1102248" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102248_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102247" xlink:to="loc_dei_EntityDomain_1102248_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102248" xlink:to="loc_bvs_BioVentusLlcMember_1102249" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1102198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102246" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1102198" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/Segments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105024" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105024" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_841" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105024" xlink:to="loc_us-gaap_StatementTable_1105021" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105021" xlink:to="loc_dei_LegalEntityAxis_1105022" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105022" xlink:to="loc_dei_EntityDomain_1105023" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105023_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105022" xlink:to="loc_dei_EntityDomain_1105023_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105023" xlink:to="loc_bvs_BioVentusLlcMember_1105025" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103920" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1103917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103920" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1103917" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103917" xlink:to="loc_dei_LegalEntityAxis_1103918" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103918" xlink:to="loc_dei_EntityDomain_1103919" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103919_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103918" xlink:to="loc_dei_EntityDomain_1103919_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103919" xlink:to="loc_bvs_BioVentusLlcMember_1103921" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103920" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_874" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1101687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1101687" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1102391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1102391" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_1102392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_1102392" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NonControllingInterestPolicyTextBlock" xlink:label="loc_bvs_NonControllingInterestPolicyTextBlock_1102393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_bvs_NonControllingInterestPolicyTextBlock_1102393" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1102395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1102395" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1102396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1102396" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1102397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1102397" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_1102399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_1102399" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractAssetsPolicyTextBlock" xlink:label="loc_bvs_ContractAssetsPolicyTextBlock_1102404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_bvs_ContractAssetsPolicyTextBlock_1102404" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractLiabilitiesPolicyTextBlock" xlink:label="loc_bvs_ContractLiabilitiesPolicyTextBlock_1102406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_bvs_ContractLiabilitiesPolicyTextBlock_1102406" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1102408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1102408" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractCostsPolicyTextBlock" xlink:label="loc_bvs_ContractCostsPolicyTextBlock_1102409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_bvs_ContractCostsPolicyTextBlock_1102409" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1102410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_1102410" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1102394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1102394" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1102400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1102400" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1102401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1102401" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1102402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1102402" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1102424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1102424" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1102428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1102428" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_1102416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_1102416" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1102418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1102418" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_1102419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_1102419" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1102411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1102411" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1102415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1102415" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1102425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1102425" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1102426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1102426" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1102429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1102429" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1102430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1102430" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1102420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1102420" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_1102421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_1102421" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_1102422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_1102422" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1102412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1102412" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1102431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1102431" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_StatementTable_1105691" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105691" xlink:to="loc_dei_LegalEntityAxis_1105696" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105696" xlink:to="loc_dei_EntityDomain_1105697" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105697_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105696" xlink:to="loc_dei_EntityDomain_1105697_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105697" xlink:to="loc_bvs_BioVentusLlcMember_1105698" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105935" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1102481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105935" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1102481" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_1102480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105935" xlink:to="loc_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_1102480" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1102482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105935" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1102482" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105935" xlink:to="loc_us-gaap_StatementTable_1105934" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105934" xlink:to="loc_dei_LegalEntityAxis_1105936" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105936" xlink:to="loc_dei_EntityDomain_1105937" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105937_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105936" xlink:to="loc_dei_EntityDomain_1105937_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105937" xlink:to="loc_bvs_BioventusIncMember_1105938" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/RestructuringCostsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1103084" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103084" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103083" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103083" xlink:to="loc_dei_LegalEntityAxis_1103086" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103086" xlink:to="loc_dei_EntityDomain_1103087" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103087_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103086" xlink:to="loc_dei_EntityDomain_1103087_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103087" xlink:to="loc_bvs_BioVentusLlcMember_1103089" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1103085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103084" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1103085" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquityTables">
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems_1103053" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable_1103050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bvs_MemberEquityLineItems_1103053" xlink:to="loc_bvs_MemberEquityTable_1103050" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_MemberEquityTable_1103050" xlink:to="loc_dei_LegalEntityAxis_1103054" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103054" xlink:to="loc_dei_EntityDomain_1103055" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103055_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103054" xlink:to="loc_dei_EntityDomain_1103055_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103055" xlink:to="loc_bvs_BioVentusLlcMember_1103056" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfMembersEquityTableTextBlock" xlink:label="loc_bvs_ScheduleOfMembersEquityTableTextBlock_1103057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103053" xlink:to="loc_bvs_ScheduleOfMembersEquityTableTextBlock_1103057" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/NetSalesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1102369" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1102365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102369" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1102365" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102365" xlink:to="loc_dei_LegalEntityAxis_1102366" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102366" xlink:to="loc_dei_EntityDomain_1102367" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102367_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102366" xlink:to="loc_dei_EntityDomain_1102367_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102367" xlink:to="loc_bvs_BioVentusLlcMember_1102368" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" xlink:label="loc_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock_1102370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102369" xlink:to="loc_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock_1102370" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102215" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock_1102202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102215" xlink:to="loc_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock_1102202" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102215" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102210" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102210" xlink:to="loc_dei_LegalEntityAxis_1102211" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102211" xlink:to="loc_dei_EntityDomain_1102212" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102212_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102211" xlink:to="loc_dei_EntityDomain_1102212_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102212" xlink:to="loc_bvs_BioVentusLlcMember_1102214" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SegmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105030" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105030" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_844" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105030" xlink:to="loc_us-gaap_StatementTable_1105027" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105027" xlink:to="loc_dei_LegalEntityAxis_1105028" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105028" xlink:to="loc_dei_EntityDomain_1105029" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105028" xlink:to="loc_dei_EntityDomain_1105029_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105029" xlink:to="loc_bvs_BioVentusLlcMember_1105031" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/NetIncomeLossPerUnitTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1102324" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1102300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102324" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1102300" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102324" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102320" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102320" xlink:to="loc_dei_LegalEntityAxis_1102321" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102321" xlink:to="loc_dei_EntityDomain_1102322" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102322_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102321" xlink:to="loc_dei_EntityDomain_1102322_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102322" xlink:to="loc_bvs_BioVentusLlcMember_1102323" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1102427" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1102427" xlink:to="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_768" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1102407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1102427" xlink:to="loc_us-gaap_LossContingenciesTable_1102407" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1102407" xlink:to="loc_dei_LegalEntityAxis_1102413" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102413" xlink:to="loc_dei_EntityDomain_1102414" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102413" xlink:to="loc_dei_EntityDomain_1102414_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102414" xlink:to="loc_bvs_BioVentusLlcMember_1102417" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1102427" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_767" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1102398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1102427" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1102398" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105943" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_277" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_278" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_279" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_280" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_281" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_282" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfInventoryValuationReservesTableTextBlock" xlink:label="loc_bvs_ScheduleOfInventoryValuationReservesTableTextBlock_1101940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_bvs_ScheduleOfInventoryValuationReservesTableTextBlock_1101940" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1101941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1101941" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1101944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1101944" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock_1101961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock_1101961" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_StatementTable_1105939" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105939" xlink:to="loc_dei_LegalEntityAxis_1105940" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105940" xlink:to="loc_dei_EntityDomain_1105941" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105941_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105940" xlink:to="loc_dei_EntityDomain_1105941_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105941" xlink:to="loc_bvs_BioventusIncMember_1105942" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1102794" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_325" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_326" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_327" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_328" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_329" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_StatementTable_1102791" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102791" xlink:to="loc_dei_LegalEntityAxis_1102796" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102796" xlink:to="loc_dei_EntityDomain_1102797" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102797_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102796" xlink:to="loc_dei_EntityDomain_1102797_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102797" xlink:to="loc_bvs_BioVentusLlcMember_1102798" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102791" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102792" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102792" xlink:to="loc_us-gaap_ClassOfStockDomain_1102793" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102793_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102792" xlink:to="loc_us-gaap_ClassOfStockDomain_1102793_default" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1103288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_us-gaap_StatementTable_1103288" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103288" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103289" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103289" xlink:to="loc_us-gaap_ClassOfStockDomain_1103290" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103290_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103289" xlink:to="loc_us-gaap_ClassOfStockDomain_1103290_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103288" xlink:to="loc_dei_LegalEntityAxis_1103292" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103292" xlink:to="loc_dei_EntityDomain_1103293" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103293_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103292" xlink:to="loc_dei_EntityDomain_1103293_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103293" xlink:to="loc_bvs_BioVentusLlcMember_1103294" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_501" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" xlink:label="loc_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock_1103295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock_1103295" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" xlink:label="loc_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock_1103311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock_1103311" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" xlink:label="loc_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock_1103320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock_1103320" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1103321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1103321" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_533" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_534" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_535" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1102930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1102930" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1102931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1102930" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1102931" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1102931_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1102930" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1102931_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_1102932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1102931" xlink:to="loc_bvs_EquityParticipationRightUnitMember_1102932" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" xlink:to="loc_dei_LegalEntityAxis_1102933" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102933" xlink:to="loc_dei_EntityDomain_1102934" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102934_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102933" xlink:to="loc_dei_EntityDomain_1102934_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102934" xlink:to="loc_bvs_BioVentusLlcMember_1102935" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103162" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" xlink:label="loc_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock_1103172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock_1103172" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1103159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_us-gaap_StatementTable_1103159" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1106240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103159" xlink:to="loc_us-gaap_AwardTypeAxis_1106240" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1106240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106241" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106241_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1106240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106241_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherPhantomUnitMember" xlink:label="loc_bvs_OtherPhantomUnitMember_1106242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106241" xlink:to="loc_bvs_OtherPhantomUnitMember_1106242" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103159" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103160" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103160" xlink:to="loc_us-gaap_ClassOfStockDomain_1103161" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103161_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103160" xlink:to="loc_us-gaap_ClassOfStockDomain_1103161_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103159" xlink:to="loc_dei_LegalEntityAxis_1103166" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103166" xlink:to="loc_dei_EntityDomain_1103167" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103167_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103166" xlink:to="loc_dei_EntityDomain_1103167_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103167" xlink:to="loc_bvs_BioVentusLlcMember_1103168" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_628" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_627" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_629" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeTaxDisclosureLineItems" xlink:label="loc_bvs_IncomeTaxDisclosureLineItems_1105728" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1102603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1102603" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1102604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1102604" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1102625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1102625" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1102692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1102692" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeTaxDisclosureTable" xlink:label="loc_bvs_IncomeTaxDisclosureTable_1105726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_bvs_IncomeTaxDisclosureTable_1105726" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_IncomeTaxDisclosureTable_1105726" xlink:to="loc_dei_LegalEntityAxis_1105731" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105731" xlink:to="loc_dei_EntityDomain_1105733" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105733_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105731" xlink:to="loc_dei_EntityDomain_1105733_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105733" xlink:to="loc_bvs_BioVentusLlcMember_1105736" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/OrganizationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_243" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_254" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_262" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_230" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_dei_LegalEntityAxis_235" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_235" xlink:to="loc_dei_EntityDomain_236" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_236_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_235" xlink:to="loc_dei_EntityDomain_236_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_236" xlink:to="loc_bvs_BioventusIncMember_247" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_srt_OwnershipAxis_233" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_233" xlink:to="loc_srt_OwnershipDomain_234" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_234_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_233" xlink:to="loc_srt_OwnershipDomain_234_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCMember" xlink:label="loc_bvs_BVLLCMember_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_234" xlink:to="loc_bvs_BVLLCMember_246" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCMember" xlink:label="loc_bvs_BVLLCMember_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_240" xlink:to="loc_bvs_BVLLCMember_250" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_StatementClassOfStockAxis_231" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_231" xlink:to="loc_us-gaap_ClassOfStockDomain_232" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_231" xlink:to="loc_us-gaap_ClassOfStockDomain_232_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_232" xlink:to="loc_us-gaap_CommonClassAMember_244" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_232" xlink:to="loc_us-gaap_CommonClassBMember_245" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_237" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_237" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_237" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238" xlink:to="loc_us-gaap_IPOMember_248" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238" xlink:to="loc_us-gaap_OverAllotmentOptionMember_249" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_239" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_239" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_240" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_240_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_239" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_240_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1101655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1101655" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1101656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1101655" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1101656" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1101656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1101655" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1101656_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1101657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1101656" xlink:to="loc_us-gaap_SubsequentEventMember_1101657" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_255" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_256" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SaleOfStockOfferingCosts" xlink:label="loc_bvs_SaleOfStockOfferingCosts_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_SaleOfStockOfferingCosts_257" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_260" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_261" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityNumberOfEmployees" xlink:label="loc_dei_EntityNumberOfEmployees_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_dei_EntityNumberOfEmployees_252" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_266" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_267" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_268" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_253" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" xlink:label="loc_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts_258" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_270" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromGovernmentalAssistance" xlink:label="loc_bvs_ProceedsFromGovernmentalAssistance_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_ProceedsFromGovernmentalAssistance_271" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest_259" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_263" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonStockNumberOfVotes" xlink:label="loc_bvs_CommonStockNumberOfVotes_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_CommonStockNumberOfVotes_264" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_265" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_1101581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_1101581" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfDeferredPayrollTax" xlink:label="loc_bvs_PercentageOfDeferredPayrollTax_1101582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_PercentageOfDeferredPayrollTax_1101582" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:label="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld_1104997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld_1104997" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105959" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105959" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_285" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105959" xlink:to="loc_us-gaap_RestrictedCashCurrent_286" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105959" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_287" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105959" xlink:to="loc_us-gaap_StatementTable_1105956" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105956" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105957" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105957" xlink:to="loc_us-gaap_ClassOfStockDomain_1105958" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105957" xlink:to="loc_us-gaap_ClassOfStockDomain_1105958_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105956" xlink:to="loc_dei_LegalEntityAxis_1105963" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105963" xlink:to="loc_dei_EntityDomain_1105964" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105964_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105963" xlink:to="loc_dei_EntityDomain_1105964_default" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105970" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105970" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_290" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105970" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_291" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105970" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_292" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105970" xlink:to="loc_us-gaap_StatementTable_1105967" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105967" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105968" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105968" xlink:to="loc_us-gaap_ClassOfStockDomain_1105969" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105969_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105968" xlink:to="loc_us-gaap_ClassOfStockDomain_1105969_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105967" xlink:to="loc_dei_LegalEntityAxis_1105971" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105971" xlink:to="loc_dei_EntityDomain_1105972" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105972_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105971" xlink:to="loc_dei_EntityDomain_1105972_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105972" xlink:to="loc_bvs_BioventusIncMember_1105973" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105984" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105984" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_296" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_297" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_298" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_299" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105984" xlink:to="loc_us-gaap_StatementTable_1105981" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105981" xlink:to="loc_dei_LegalEntityAxis_1105985" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105985" xlink:to="loc_dei_EntityDomain_1105986" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105986_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105985" xlink:to="loc_dei_EntityDomain_1105986_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105986" xlink:to="loc_bvs_BioventusIncMember_1105987" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105981" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105982" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105982" xlink:to="loc_us-gaap_ClassOfStockDomain_1105983" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105983_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105982" xlink:to="loc_us-gaap_ClassOfStockDomain_1105983_default" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationInventoryDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105992" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_303" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryFinishedGoods_304" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryGross_305" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryValuationReserves_306" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryNet_307" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_StatementTable_1105989" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105989" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105990" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105990" xlink:to="loc_us-gaap_ClassOfStockDomain_1105991" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105991_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105990" xlink:to="loc_us-gaap_ClassOfStockDomain_1105991_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105989" xlink:to="loc_dei_LegalEntityAxis_1105993" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105993" xlink:to="loc_dei_EntityDomain_1105994" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105993" xlink:to="loc_dei_EntityDomain_1105994_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105994" xlink:to="loc_bvs_BioventusIncMember_1105995" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105907" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_GrossToNetDeductionsCurrent" xlink:label="loc_bvs_GrossToNetDeductionsCurrent_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_bvs_GrossToNetDeductionsCurrent_310" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_AccruedBonusesCurrent_311" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_312" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_TaxesPayableCurrent_313" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_314" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_315" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" xlink:label="loc_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent_1102423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent_1102423" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_StatementTable_1105904" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105904" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105905" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105905" xlink:to="loc_us-gaap_ClassOfStockDomain_1105906" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105906_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105905" xlink:to="loc_us-gaap_ClassOfStockDomain_1105906_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105904" xlink:to="loc_dei_LegalEntityAxis_1105908" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105908" xlink:to="loc_dei_EntityDomain_1105909" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105908" xlink:to="loc_dei_EntityDomain_1105909_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105909" xlink:to="loc_bvs_BioVentusLlcMember_1105910" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1102449" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_RestructuringReserveCurrent_318" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_PaymentsForRestructuring_319" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1102442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_Depreciation_1102442" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_1102443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_1102443" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_StatementTable_1102446" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102447" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102447" xlink:to="loc_us-gaap_ClassOfStockDomain_1102448" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102447" xlink:to="loc_us-gaap_ClassOfStockDomain_1102448_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventAxis" xlink:label="loc_bvs_EventAxis_1102450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_bvs_EventAxis_1102450" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventDomain" xlink:label="loc_bvs_EventDomain_1102451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_EventAxis_1102450" xlink:to="loc_bvs_EventDomain_1102451" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventDomain" xlink:label="loc_bvs_EventDomain_1102451_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_EventAxis_1102450" xlink:to="loc_bvs_EventDomain_1102451_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ReclassificationOfIprdMember" xlink:label="loc_bvs_ReclassificationOfIprdMember_1102473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_EventDomain_1102451" xlink:to="loc_bvs_ReclassificationOfIprdMember_1102473" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102474" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102474" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102474" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1102476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1102476" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_1102487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475" xlink:to="loc_us-gaap_DistributionRightsMember_1102487" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1102488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1102488" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102488" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102489" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102489_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102488" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102489_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember_1102490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1102489" xlink:to="loc_us-gaap_AccountsPayableMember_1102490" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_dei_LegalEntityAxis_1105795" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105795" xlink:to="loc_dei_EntityDomain_1105796" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105796_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105795" xlink:to="loc_dei_EntityDomain_1105796_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105796" xlink:to="loc_bvs_BioventusIncMember_1105798" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1102477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1102477" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1102479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1102479" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1102494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1102494" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AmortizationExpenseIncludedInInventory" xlink:label="loc_bvs_AmortizationExpenseIncludedInInventory_1102495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_bvs_AmortizationExpenseIncludedInInventory_1102495" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1102497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1102497" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1102498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1102498" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1102499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1102499" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1102500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1102500" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1102501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1102501" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1106003" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryValuationReservesProvisionForLosses" xlink:label="loc_bvs_InventoryValuationReservesProvisionForLosses_1102208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1106003" xlink:to="loc_bvs_InventoryValuationReservesProvisionForLosses_1102208" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryValuationReservesWriteOffs" xlink:label="loc_bvs_InventoryValuationReservesWriteOffs_1102209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1106003" xlink:to="loc_bvs_InventoryValuationReservesWriteOffs_1102209" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_1102207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1106003" xlink:to="loc_us-gaap_InventoryValuationReserves_1102207" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1106000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1106003" xlink:to="loc_us-gaap_StatementTable_1106000" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1106004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1106000" xlink:to="loc_dei_LegalEntityAxis_1106004" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1106004" xlink:to="loc_dei_EntityDomain_1106005" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106005_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1106004" xlink:to="loc_dei_EntityDomain_1106005_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1106006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1106005" xlink:to="loc_bvs_BioventusIncMember_1106006" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1106001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1106000" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1106001" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1106002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1106001" xlink:to="loc_us-gaap_ClassOfStockDomain_1106002" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1106002_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1106001" xlink:to="loc_us-gaap_ClassOfStockDomain_1106002_default" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1102242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1102242" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1102243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1102243" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1102244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1102244" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1106007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" xlink:to="loc_dei_LegalEntityAxis_1106007" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1106007" xlink:to="loc_dei_EntityDomain_1106008" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106008_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1106007" xlink:to="loc_dei_EntityDomain_1106008_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1106010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1106008" xlink:to="loc_bvs_BioventusIncMember_1106010" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102234" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102234" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102234" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ComputerEquipmentAndSoftwareMember" xlink:label="loc_bvs_ComputerEquipmentAndSoftwareMember_1102236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_bvs_ComputerEquipmentAndSoftwareMember_1102236" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1102237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1102237" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1102238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1102238" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1102239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_1102239" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="loc_us-gaap_AssetUnderConstructionMember_1102240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_us-gaap_AssetUnderConstructionMember_1102240" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_1102280" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1102286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1102280" xlink:to="loc_us-gaap_Goodwill_1102286" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1102274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_1102280" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1102274" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1102275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1102274" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1102275" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1102276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1102275" xlink:to="loc_us-gaap_SegmentDomain_1102276" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1102276_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1102275" xlink:to="loc_us-gaap_SegmentDomain_1102276_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InternationalSegmentMember" xlink:label="loc_bvs_InternationalSegmentMember_1102278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1102276" xlink:to="loc_bvs_InternationalSegmentMember_1102278" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_USSegmentMember" xlink:label="loc_bvs_USSegmentMember_1102277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1102276" xlink:to="loc_bvs_USSegmentMember_1102277" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_1102282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1102274" xlink:to="loc_srt_ConsolidationItemsAxis_1102282" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_1102283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1102282" xlink:to="loc_srt_ConsolidationItemsDomain_1102283" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_1102283_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1102282" xlink:to="loc_srt_ConsolidationItemsDomain_1102283_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_1102284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1102283" xlink:to="loc_us-gaap_OperatingSegmentsMember_1102284" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1106011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1102274" xlink:to="loc_dei_LegalEntityAxis_1106011" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1106011" xlink:to="loc_dei_EntityDomain_1106012" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106012_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1106011" xlink:to="loc_dei_EntityDomain_1106012_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1106013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1106012" xlink:to="loc_bvs_BioventusIncMember_1106013" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails">
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102302" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102302" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102302" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_1102304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" xlink:to="loc_us-gaap_IntellectualPropertyMember_1102304" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1102354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1102354" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_1102305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" xlink:to="loc_us-gaap_DistributionRightsMember_1102305" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1102306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1102306" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1106015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" xlink:to="loc_dei_LegalEntityAxis_1106015" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1106015" xlink:to="loc_dei_EntityDomain_1106016" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106016_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1106015" xlink:to="loc_dei_EntityDomain_1106016_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1106017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1106016" xlink:to="loc_bvs_BioventusIncMember_1106017" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1102308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1102308" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1102309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1102308" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1102309" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1102309_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1102308" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1102309_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AcquiredInProcessResearchAndDevelopmentMember" xlink:label="loc_bvs_AcquiredInProcessResearchAndDevelopmentMember_1102310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1102309" xlink:to="loc_bvs_AcquiredInProcessResearchAndDevelopmentMember_1102310" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" xlink:label="loc_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation_1102349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" xlink:to="loc_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation_1102349" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1102352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1102352" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1102345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1102345" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation_1106215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation_1106215" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1102336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1102336" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1102332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1102332" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1102333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1102333" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_353" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_335" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_335" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_336" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_336_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_335" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_336_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_337" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_337" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_338" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_338_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_337" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_338_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_333" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_333" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_333" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334" xlink:to="loc_bvs_BionessIncMember_354" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CartiHealMember" xlink:label="loc_bvs_CartiHealMember_355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334" xlink:to="loc_bvs_CartiHealMember_355" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_341" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_341" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_342" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_341" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_342_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VaporoxMember" xlink:label="loc_bvs_VaporoxMember_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_342" xlink:to="loc_bvs_VaporoxMember_363" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CartiHealLtdMember" xlink:label="loc_bvs_CartiHealLtdMember_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_342" xlink:to="loc_bvs_CartiHealLtdMember_364" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_srt_ConsolidatedEntitiesAxis_345" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_345" xlink:to="loc_srt_ConsolidatedEntitiesDomain_346" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_346_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_345" xlink:to="loc_srt_ConsolidatedEntitiesDomain_346_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_346" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_366" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_339" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_339" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_340" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_340_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_339" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_340_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" xlink:label="loc_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_340" xlink:to="loc_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember_362" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ObtainingFDAApprovalOfCertainProductsMember" xlink:label="loc_bvs_ObtainingFDAApprovalOfCertainProductsMember_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_340" xlink:to="loc_bvs_ObtainingFDAApprovalOfCertainProductsMember_359" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" xlink:label="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_340" xlink:to="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember_360" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" xlink:label="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_340" xlink:to="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember_361" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_343" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_343" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_344" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_344_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_343" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_344_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_344" xlink:to="loc_us-gaap_ConvertibleDebtMember_365" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_srt_OwnershipAxis_347" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_347" xlink:to="loc_srt_OwnershipDomain_348" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_348_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_347" xlink:to="loc_srt_OwnershipDomain_348_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMedtechIncMember" xlink:label="loc_bvs_HarborMedtechIncMember_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_348" xlink:to="loc_bvs_HarborMedtechIncMember_367" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_StatementClassOfStockAxis_349" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_349" xlink:to="loc_us-gaap_ClassOfStockDomain_350" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_350_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_349" xlink:to="loc_us-gaap_ClassOfStockDomain_350_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_368" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_369" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborSeriesCPreferredStockMember" xlink:label="loc_bvs_HarborSeriesCPreferredStockMember_1102842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_bvs_HarborSeriesCPreferredStockMember_1102842" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SeriesG1PreferredStockMember" xlink:label="loc_bvs_SeriesG1PreferredStockMember_1102860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_bvs_SeriesG1PreferredStockMember_1102860" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SeriesFConvertiblePreferredStockMember" xlink:label="loc_bvs_SeriesFConvertiblePreferredStockMember_1102856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_bvs_SeriesFConvertiblePreferredStockMember_1102856" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_srt_RangeAxis_351" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_351" xlink:to="loc_srt_RangeMember_352" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_352_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_351" xlink:to="loc_srt_RangeMember_352_default" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_352" xlink:to="loc_srt_MaximumMember_370" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1102839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_DebtInstrumentAxis_1102839" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1102840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1102839" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1102840" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1102840_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1102839" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1102840_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PromissoryNoteMember" xlink:label="loc_bvs_PromissoryNoteMember_1102841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1102840" xlink:to="loc_bvs_PromissoryNoteMember_1102841" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1102843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1102843" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1102844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1102843" xlink:to="loc_us-gaap_EquityComponentDomain_1102844" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1102844_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1102843" xlink:to="loc_us-gaap_EquityComponentDomain_1102844_default" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborCommonStockMember" xlink:label="loc_bvs_HarborCommonStockMember_1102845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1102844" xlink:to="loc_bvs_HarborCommonStockMember_1102845" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102850" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102850" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102851" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102851_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102850" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102851_default" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1102852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102851" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1102852" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_dei_LegalEntityAxis_1102834" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102834" xlink:to="loc_dei_EntityDomain_1102836" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102836_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102834" xlink:to="loc_dei_EntityDomain_1102836_default" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102836" xlink:to="loc_bvs_BioVentusLlcMember_1102837" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementForFutureEquityAxis" xlink:label="loc_bvs_AgreementForFutureEquityAxis_1102857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_bvs_AgreementForFutureEquityAxis_1102857" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementForFutureEquityDomain" xlink:label="loc_bvs_AgreementForFutureEquityDomain_1102858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_AgreementForFutureEquityAxis_1102857" xlink:to="loc_bvs_AgreementForFutureEquityDomain_1102858" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementForFutureEquityDomain" xlink:label="loc_bvs_AgreementForFutureEquityDomain_1102858_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_AgreementForFutureEquityAxis_1102857" xlink:to="loc_bvs_AgreementForFutureEquityDomain_1102858_default" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SimpleAgreementForFutureEquityMember" xlink:label="loc_bvs_SimpleAgreementForFutureEquityMember_1102859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_AgreementForFutureEquityDomain_1102858" xlink:to="loc_bvs_SimpleAgreementForFutureEquityMember_1102859" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementAxis" xlink:label="loc_bvs_AgreementAxis_1102861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_bvs_AgreementAxis_1102861" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementDomain" xlink:label="loc_bvs_AgreementDomain_1102863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_AgreementAxis_1102861" xlink:to="loc_bvs_AgreementDomain_1102863" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementDomain" xlink:label="loc_bvs_AgreementDomain_1102863_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_AgreementAxis_1102861" xlink:to="loc_bvs_AgreementDomain_1102863_default" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OptionAndEquityPurchaseAgreementMember" xlink:label="loc_bvs_OptionAndEquityPurchaseAgreementMember_1102864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_AgreementDomain_1102863" xlink:to="loc_bvs_OptionAndEquityPurchaseAgreementMember_1102864" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1102853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1102853" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102853" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102854" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102854_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102853" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102854_default" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1102855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1102854" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1102855" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_371" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1102881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1102881" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_373" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_375" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_376" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_377" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_378" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_379" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_384" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_AssetImpairmentCharges_385" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" xlink:label="loc_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest_386" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntityImpairment" xlink:label="loc_bvs_VariableInterestEntityImpairment_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_VariableInterestEntityImpairment_387" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EquityMethodInvestments_388" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_380" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_381" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_383" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xlink:label="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment_393" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xlink:label="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased_394" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionPeriodOfNoticeForTermination" xlink:label="loc_bvs_BusinessAcquisitionPeriodOfNoticeForTermination_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_BusinessAcquisitionPeriodOfNoticeForTermination_395" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" xlink:label="loc_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement_396" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EscrowDeposit_397" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_389" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_390" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares_391" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount_392" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones_398" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_399" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestmentOwnedOwnershipPercentage" xlink:label="loc_bvs_InvestmentOwnedOwnershipPercentage_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_InvestmentOwnedOwnershipPercentage_401" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_402" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_400" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntitySharesIssuedDuringPeriod" xlink:label="loc_bvs_VariableInterestEntitySharesIssuedDuringPeriod_1102870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_VariableInterestEntitySharesIssuedDuringPeriod_1102870" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntityIssuedCost" xlink:label="loc_bvs_VariableInterestEntityIssuedCost_1102872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_VariableInterestEntityIssuedCost_1102872" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1102873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1102873" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_1102887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_1102887" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" xlink:label="loc_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount_1102888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount_1102888" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1102889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1102889" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1102890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1102890" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions_1102891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions_1102891" use="optional" order="115" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_1102894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_1102894" use="optional" order="116" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1102896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1102896" use="optional" order="117" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares_1102901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares_1102901" use="optional" order="118" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1102874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1102874" use="optional" order="119" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_1102877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_1102877" use="optional" order="120" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentConvertibleConversionExercisablePrice" xlink:label="loc_bvs_DebtInstrumentConvertibleConversionExercisablePrice_1102879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_DebtInstrumentConvertibleConversionExercisablePrice_1102879" use="optional" order="121" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1102880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1102880" use="optional" order="122" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1102882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1102882" use="optional" order="123" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1102883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1102883" use="optional" order="124" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1102884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1102884" use="optional" order="125" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1102885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1102885" use="optional" order="126" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" xlink:label="loc_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage_1102886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage_1102886" use="optional" order="127" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue_1102907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue_1102907" use="optional" order="128" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_1102908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_1102908" use="optional" order="129" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentCapitalizedTransactionCosts" xlink:label="loc_bvs_EquityMethodInvestmentCapitalizedTransactionCosts_1102909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentCapitalizedTransactionCosts_1102909" use="optional" order="130" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_408" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_408" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_410" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_408" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_411" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_408" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_412" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_408" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_405" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_405" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_406" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_406" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_407" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_407_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_406" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_407_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_407" xlink:to="loc_bvs_BionessIncMember_409" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_423" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" xlink:to="loc_us-gaap_DebtInstrumentAxis_420" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_420" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_421" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_421_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_420" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_421_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMember" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMember_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_421" xlink:to="loc_bvs_PaycheckProtectionProgramCARESActMember_422" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_PaycheckProtectionProgramCARESActMember_422" xlink:to="loc_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member_427" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_PaycheckProtectionProgramCARESActMember_422" xlink:to="loc_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member_428" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_416" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_416" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_416" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417" xlink:to="loc_bvs_BionessIncMember_425" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_419" xlink:to="loc_bvs_BionessIncMember_426" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMedtechIncMember" xlink:label="loc_bvs_HarborMedtechIncMember_1102823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417" xlink:to="loc_bvs_HarborMedtechIncMember_1102823" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" xlink:to="loc_dei_LegalEntityAxis_418" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_418" xlink:to="loc_dei_EntityDomain_419" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_419_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_418" xlink:to="loc_dei_EntityDomain_419_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_429" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash_430" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_431" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_432" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_433" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1102808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1102808" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_1102820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_1102820" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_434" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_443" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_Goodwill_442" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_441" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1102815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1102815" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_435" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_440" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_439" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities_438" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_437" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_436" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentNumberOfLoans" xlink:label="loc_bvs_DebtInstrumentNumberOfLoans_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_bvs_DebtInstrumentNumberOfLoans_446" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_447" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_448" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_LongTermDebtCurrent_449" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_444" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_EscrowDeposit_445" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_457" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_457" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_453" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_453" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_454" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_454_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_453" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_454_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_454" xlink:to="loc_bvs_BionessIncMember_458" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_455" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" xlink:to="loc_us-gaap_IntellectualPropertyMember_459" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_460" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" xlink:to="loc_us-gaap_CustomerRelationshipsMember_461" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_457" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_462" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_457" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_463" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_471" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_476" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_477" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_478" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_475" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_481" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_482" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_480" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_Assets_479" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_474" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" xlink:to="loc_dei_LegalEntityAxis_1102827" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102827" xlink:to="loc_dei_EntityDomain_1102828" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102828_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102827" xlink:to="loc_dei_EntityDomain_1102828_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102828" xlink:to="loc_bvs_BioVentusLlcMember_1102829" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" xlink:to="loc_srt_OwnershipAxis_469" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_469" xlink:to="loc_srt_OwnershipDomain_470" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_470_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_469" xlink:to="loc_srt_OwnershipDomain_470_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMedtechIncMember" xlink:label="loc_bvs_HarborMedtechIncMember_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_470" xlink:to="loc_bvs_HarborMedtechIncMember_473" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" xlink:to="loc_srt_ConsolidatedEntitiesAxis_467" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_467" xlink:to="loc_srt_ConsolidatedEntitiesDomain_468" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_468_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_467" xlink:to="loc_srt_ConsolidatedEntitiesDomain_468_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_468" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_472" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1102826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1102826" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_Liabilities_483" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_489" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_489" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_492" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_489" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_493" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_489" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_490" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_490" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_494" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_490" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_495" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_489" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_487" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_487" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_487" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" xlink:to="loc_bvs_BionessIncMember_491" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_517" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentTable_512" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_513" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_513" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_514" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_514_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_513" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_514_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_514" xlink:to="loc_us-gaap_InterestRateSwapMember_518" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1103385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1103385" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1103386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1103385" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1103386" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1103386_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1103385" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1103386_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TermLoanMember" xlink:label="loc_bvs_TermLoanMember_1103387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1103386" xlink:to="loc_bvs_TermLoanMember_1103387" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CreditAgreementAxis" xlink:label="loc_bvs_CreditAgreementAxis_1103388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_bvs_CreditAgreementAxis_1103388" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CreditAgreementDomain" xlink:label="loc_bvs_CreditAgreementDomain_1103389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_CreditAgreementAxis_1103388" xlink:to="loc_bvs_CreditAgreementDomain_1103389" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CreditAgreementDomain" xlink:label="loc_bvs_CreditAgreementDomain_1103389_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_CreditAgreementAxis_1103388" xlink:to="loc_bvs_CreditAgreementDomain_1103389_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandNineteenCreditAgreementMember" xlink:label="loc_bvs_TwoThousandNineteenCreditAgreementMember_1103390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_CreditAgreementDomain_1103389" xlink:to="loc_bvs_TwoThousandNineteenCreditAgreementMember_1103390" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PriorCreditAgreementMember" xlink:label="loc_bvs_PriorCreditAgreementMember_1103719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_CreditAgreementDomain_1103389" xlink:to="loc_bvs_PriorCreditAgreementMember_1103719" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_515" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_515" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_516" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_516_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_515" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_516_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_516" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_519" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_dei_LegalEntityAxis_1103377" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103377" xlink:to="loc_dei_EntityDomain_1103378" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103378_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103377" xlink:to="loc_dei_EntityDomain_1103378_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103378" xlink:to="loc_bvs_BioVentusLlcMember_1103379" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestRateBasisAxis" xlink:label="loc_bvs_InterestRateBasisAxis_1103570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_bvs_InterestRateBasisAxis_1103570" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestRateBasisDomain" xlink:label="loc_bvs_InterestRateBasisDomain_1103572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_InterestRateBasisAxis_1103570" xlink:to="loc_bvs_InterestRateBasisDomain_1103572" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestRateBasisDomain" xlink:label="loc_bvs_InterestRateBasisDomain_1103572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_InterestRateBasisAxis_1103570" xlink:to="loc_bvs_InterestRateBasisDomain_1103572_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BrInterestRateBasisMember" xlink:label="loc_bvs_BrInterestRateBasisMember_1103574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_InterestRateBasisDomain_1103572" xlink:to="loc_bvs_BrInterestRateBasisMember_1103574" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1103395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_CreditFacilityAxis_1103395" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1103396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1103395" xlink:to="loc_us-gaap_CreditFacilityDomain_1103396" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1103396_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1103395" xlink:to="loc_us-gaap_CreditFacilityDomain_1103396_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1103397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1103396" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1103397" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_1103593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_VariableRateAxis_1103593" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_1103593" xlink:to="loc_us-gaap_VariableRateDomain_1103594" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_1103593" xlink:to="loc_us-gaap_VariableRateDomain_1103594_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_1103595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1103594" xlink:to="loc_us-gaap_EurodollarMember_1103595" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_1103853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1103594" xlink:to="loc_us-gaap_BaseRateMember_1103853" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RevolvingCreditFacilitySubAxis" xlink:label="loc_bvs_RevolvingCreditFacilitySubAxis_1103550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_bvs_RevolvingCreditFacilitySubAxis_1103550" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RevolvingCreditFacilitySubDomain" xlink:label="loc_bvs_RevolvingCreditFacilitySubDomain_1103551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_RevolvingCreditFacilitySubAxis_1103550" xlink:to="loc_bvs_RevolvingCreditFacilitySubDomain_1103551" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RevolvingCreditFacilitySubDomain" xlink:label="loc_bvs_RevolvingCreditFacilitySubDomain_1103551_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_RevolvingCreditFacilitySubAxis_1103550" xlink:to="loc_bvs_RevolvingCreditFacilitySubDomain_1103551_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_1103554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_RevolvingCreditFacilitySubDomain_1103551" xlink:to="loc_us-gaap_LetterOfCreditMember_1103554" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SwingLineCreditFacilityMember" xlink:label="loc_bvs_SwingLineCreditFacilityMember_1103564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_RevolvingCreditFacilitySubDomain_1103551" xlink:to="loc_bvs_SwingLineCreditFacilityMember_1103564" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1103643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_srt_RangeAxis_1103643" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1103644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1103643" xlink:to="loc_srt_RangeMember_1103644" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1103644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1103643" xlink:to="loc_srt_RangeMember_1103644_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1103645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1103644" xlink:to="loc_srt_MinimumMember_1103645" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DerivativeNotionalAmount_525" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_527" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1103393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1103393" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LongTermDebtFairValue_522" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_523" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives" xlink:label="loc_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives_526" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1103466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LongTermDebt_1103466" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1103510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1103510" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1103512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1103512" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1103514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1103514" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" xlink:label="loc_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity_1103516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity_1103516" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_524" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCredit_521" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1103391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1103391" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1103392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1103392" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1103531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1103531" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_1103535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_1103535" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1103394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1103394" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_1103524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_1103524" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" xlink:label="loc_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders_1103674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders_1103674" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_1103681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_1103681" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_1103545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_1103545" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_1103720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_InterestCostsCapitalized_1103720" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_1103722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_1103722" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_1103725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_InterestExpenseDebt_1103725" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AdditionalMarginPercentageToReferenceRates" xlink:label="loc_bvs_AdditionalMarginPercentageToReferenceRates_1103557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_AdditionalMarginPercentageToReferenceRates_1103557" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ThresholdMaximumAggregateAdditionalBorrowings" xlink:label="loc_bvs_ThresholdMaximumAggregateAdditionalBorrowings_1103668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_ThresholdMaximumAggregateAdditionalBorrowings_1103668" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_1103891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DerivativeLiabilities_1103891" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" xlink:label="loc_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees_1103751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees_1103751" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DerivativeStatedFixedInterestRate" xlink:label="loc_bvs_DerivativeStatedFixedInterestRate_1103763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DerivativeStatedFixedInterestRate_1103763" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentFloorRatePercentage" xlink:label="loc_bvs_DebtInstrumentFloorRatePercentage_1103619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DebtInstrumentFloorRatePercentage_1103619" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_1103637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_1103637" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestCoverageRatio" xlink:label="loc_bvs_InterestCoverageRatio_1103642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_InterestCoverageRatio_1103642" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" xlink:label="loc_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing_1103712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing_1103712" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1103858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1103858" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1103726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1103726" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1103736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1103736" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DerivativeEffectiveInterestRate" xlink:label="loc_bvs_DerivativeEffectiveInterestRate_1103772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DerivativeEffectiveInterestRate_1103772" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1103825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1103825" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FrontingFeePercentageOnUndrawnAmount" xlink:label="loc_bvs_FrontingFeePercentageOnUndrawnAmount_1103916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_FrontingFeePercentageOnUndrawnAmount_1103916" use="optional" order="84" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_539" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_539" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_540" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_540_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_539" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_540_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_540" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_544" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_541" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_541" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_541" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_545" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_546" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" xlink:to="loc_dei_LegalEntityAxis_1102962" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102962" xlink:to="loc_dei_EntityDomain_1102963" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102963_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102962" xlink:to="loc_dei_EntityDomain_1102963_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102963" xlink:to="loc_bvs_BioVentusLlcMember_1102964" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_DerivativeLiabilities_547" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_548" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_549" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure_550" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_552" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightFairValueDisclsoure" xlink:label="loc_bvs_EquityParticipationRightFairValueDisclsoure_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_bvs_EquityParticipationRightFairValueDisclsoure_551" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_564" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_570" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_us-gaap_ValuationTechniqueAxis_560" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_560" xlink:to="loc_us-gaap_ValuationTechniqueDomain_561" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_561_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_560" xlink:to="loc_us-gaap_ValuationTechniqueDomain_561_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_561" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_568" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_562" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_562" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_563" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_563_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_562" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_563_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_563" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_569" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_srt_RangeAxis_558" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_558" xlink:to="loc_srt_RangeMember_559" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_559_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_558" xlink:to="loc_srt_RangeMember_559_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_559" xlink:to="loc_srt_MaximumMember_567" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_559" xlink:to="loc_srt_MinimumMember_566" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_556" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_556" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_557" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_557_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_556" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_557_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_557" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_565" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_589" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NumberOfEquityBasedCompensationPlans" xlink:label="loc_bvs_NumberOfEquityBasedCompensationPlans_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_bvs_NumberOfEquityBasedCompensationPlans_590" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_591" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_srt_TitleOfIndividualAxis_574" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_574" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_574" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCEmployeesTerminatedPriorToIPOMember" xlink:label="loc_bvs_BVLLCEmployeesTerminatedPriorToIPOMember_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575" xlink:to="loc_bvs_BVLLCEmployeesTerminatedPriorToIPOMember_583" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCEmployeesActiveAtIPOMember" xlink:label="loc_bvs_BVLLCEmployeesActiveAtIPOMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575" xlink:to="loc_bvs_BVLLCEmployeesActiveAtIPOMember_584" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_AwardTypeAxis_576" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_576" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_576" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577" xlink:to="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_585" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577" xlink:to="loc_bvs_EquityParticipationRightUnitMember_586" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_1103244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103240" xlink:to="loc_bvs_EquityParticipationRightUnitMember_1103244" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_580" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_580" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_581" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_581_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_580" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_581_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_581" xlink:to="loc_bvs_BionessIncMember_588" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_StatementClassOfStockAxis_578" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_578" xlink:to="loc_us-gaap_ClassOfStockDomain_579" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_579_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_578" xlink:to="loc_us-gaap_ClassOfStockDomain_579_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_579" xlink:to="loc_us-gaap_CommonClassAMember_587" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1103239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1103239" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1103239" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103240" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103240_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1103239" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103240_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1103267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1103267" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1103268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103267" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1103268" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1103268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103267" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1103268_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1103269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1103268" xlink:to="loc_us-gaap_SubsequentEventMember_1103269" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_dei_LegalEntityAxis_1103251" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103251" xlink:to="loc_dei_EntityDomain_1103253" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103253_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103251" xlink:to="loc_dei_EntityDomain_1103253_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103253" xlink:to="loc_bvs_BioVentusLlcMember_1103255" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_592" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_593" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_594" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1103266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1103266" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightEntitledPercentageOfDistributions" xlink:label="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions_595" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_1103223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_1103223" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaap_CashAvailableForDistributions_1103237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_CashAvailableForDistributions_1103237" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_1105172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_1105172" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_601" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_601" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_599" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_599" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_600" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_600_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_599" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_600_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_600" xlink:to="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_603" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" xlink:to="loc_dei_LegalEntityAxis_1102957" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102957" xlink:to="loc_dei_EntityDomain_1102958" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102957" xlink:to="loc_dei_EntityDomain_1102958_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102958" xlink:to="loc_bvs_BioVentusLlcMember_1102959" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_601" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_605" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_606" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_607" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity_608" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_604" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures_1102955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures_1102955" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_615" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_615" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_613" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_613" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_614" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_614_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_613" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_614_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_614" xlink:to="loc_bvs_EquityParticipationRightUnitMember_617" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" xlink:to="loc_dei_LegalEntityAxis_1102965" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102965" xlink:to="loc_dei_EntityDomain_1102966" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102965" xlink:to="loc_dei_EntityDomain_1102966_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102966" xlink:to="loc_bvs_BioVentusLlcMember_1102967" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_615" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_618" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_619" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_620" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102993" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102993" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1103008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_srt_RangeAxis_1103008" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1103009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1103008" xlink:to="loc_srt_RangeMember_1103009" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1103009_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1103008" xlink:to="loc_srt_RangeMember_1103009_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1103011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1103009" xlink:to="loc_srt_MinimumMember_1103011" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1103010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1103009" xlink:to="loc_srt_MaximumMember_1103010" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_1103012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1103009" xlink:to="loc_srt_WeightedAverageMember_1103012" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1103013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1103013" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1103014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1103013" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1103014" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1103014_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1103013" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1103014_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1103015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1103014" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1103015" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1103016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1103014" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1103016" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeasurementInputEquityVolatilityMember" xlink:label="loc_bvs_MeasurementInputEquityVolatilityMember_1103017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1103014" xlink:to="loc_bvs_MeasurementInputEquityVolatilityMember_1103017" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_1103019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1103014" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_1103019" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1103023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1103023" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1103023" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103024" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103024_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1103023" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103024_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_1103027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103024" xlink:to="loc_bvs_EquityParticipationRightUnitMember_1103027" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1103028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1103028" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1103029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1103028" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1103029" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1103029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1103028" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1103029_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1103030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1103029" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1103030" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_dei_LegalEntityAxis_1103031" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103031" xlink:to="loc_dei_EntityDomain_1103032" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103032_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103031" xlink:to="loc_dei_EntityDomain_1103032_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103032" xlink:to="loc_bvs_BioVentusLlcMember_1103033" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightsUnitMeasurableInput" xlink:label="loc_bvs_EquityParticipationRightsUnitMeasurableInput_1103003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102993" xlink:to="loc_bvs_EquityParticipationRightsUnitMeasurableInput_1103003" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightsUnitEquityValue" xlink:label="loc_bvs_EquityParticipationRightsUnitEquityValue_1103007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102993" xlink:to="loc_bvs_EquityParticipationRightsUnitEquityValue_1103007" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NumberOfEquityBasedCompensationPlans" xlink:label="loc_bvs_NumberOfEquityBasedCompensationPlans_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_bvs_NumberOfEquityBasedCompensationPlans_654" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_655" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy_661" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_656" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_658" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_659" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_srt_RangeAxis_639" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_639" xlink:to="loc_srt_RangeMember_640" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_640_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_639" xlink:to="loc_srt_RangeMember_640_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_640" xlink:to="loc_srt_MinimumMember_651" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_640" xlink:to="loc_srt_MaximumMember_652" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_641" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_641" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_642" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_642_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_641" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_642_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_642" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_653" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_AwardTypeAxis_637" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_637" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_637" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_us-gaap_EmployeeStockMember_650" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAwardMember" xlink:label="loc_bvs_ManagementIncentivePlanAwardMember_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_bvs_ManagementIncentivePlanAwardMember_646" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_647" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_648" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_1103245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_1103245" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherPhantomUnitMember" xlink:label="loc_bvs_OtherPhantomUnitMember_1103246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_bvs_OtherPhantomUnitMember_1103246" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_StatementClassOfStockAxis_633" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_633" xlink:to="loc_us-gaap_ClassOfStockDomain_634" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_634_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_633" xlink:to="loc_us-gaap_ClassOfStockDomain_634_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_634" xlink:to="loc_us-gaap_CommonClassAMember_644" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_PlanNameAxis_635" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_635" xlink:to="loc_us-gaap_PlanNameDomain_636" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_636_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_635" xlink:to="loc_us-gaap_PlanNameDomain_636_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_A2021PlanMember" xlink:label="loc_bvs_A2021PlanMember_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_636" xlink:to="loc_bvs_A2021PlanMember_645" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_dei_LegalEntityAxis_1103241" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103241" xlink:to="loc_dei_EntityDomain_1103242" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103241" xlink:to="loc_dei_EntityDomain_1103242_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103242" xlink:to="loc_bvs_BioVentusLlcMember_1103243" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_660" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_677" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_678" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_672" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_673" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_665" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_666" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_662" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_663" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_667" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_668" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_669" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease_664" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee_676" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_SharePrice_675" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103248" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_674" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1103249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1103249" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1103250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1103250" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1103261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1103261" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1103262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1103262" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_1103263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_1103263" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1103264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_1103264" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103254" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1103259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1103259" use="optional" order="62" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_684" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_684" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_681" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_681" xlink:to="loc_us-gaap_AwardTypeAxis_682" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_687" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_684" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_689" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_688" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_690" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_684" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_693" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_694" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_692" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_707" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" xlink:to="loc_srt_RangeAxis_699" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_699" xlink:to="loc_srt_RangeMember_700" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_700_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_699" xlink:to="loc_srt_RangeMember_700_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_700" xlink:to="loc_srt_MinimumMember_704" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_700" xlink:to="loc_srt_MaximumMember_705" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" xlink:to="loc_us-gaap_AwardTypeAxis_701" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_701" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_702" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_702_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_701" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_702_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_702" xlink:to="loc_us-gaap_EmployeeStockOptionMember_706" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_711" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_708" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_709" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_710" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_712" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_713" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_748" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_748" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_745" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_745" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_746" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_746" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_746" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyInterestsMember" xlink:label="loc_bvs_LimitedLiabilityCompanyInterestsMember_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" xlink:to="loc_bvs_LimitedLiabilityCompanyInterestsMember_749" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" xlink:to="loc_us-gaap_EmployeeStockOptionMember_750" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_751" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_UnvestedClassACommonSharesMember" xlink:label="loc_bvs_UnvestedClassACommonSharesMember_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" xlink:to="loc_bvs_UnvestedClassACommonSharesMember_752" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_748" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_753" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105743" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1102915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1102915" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_us-gaap_StatementTable_1105740" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105740" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105741" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105741" xlink:to="loc_us-gaap_ClassOfStockDomain_1105742" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105742_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105741" xlink:to="loc_us-gaap_ClassOfStockDomain_1105742_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105740" xlink:to="loc_dei_LegalEntityAxis_1105744" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105744" xlink:to="loc_dei_EntityDomain_1105745" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105745_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105744" xlink:to="loc_dei_EntityDomain_1105745_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105745" xlink:to="loc_bvs_BioVentusLlcMember_1105768" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" xlink:label="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign_1102618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign_1102618" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" xlink:label="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries_1102619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries_1102619" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TaxableSubsidiariesAbstract" xlink:label="loc_bvs_TaxableSubsidiariesAbstract_1102615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_bvs_TaxableSubsidiariesAbstract_1102615" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1102617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_TaxableSubsidiariesAbstract_1102615" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1102617" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1102616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_TaxableSubsidiariesAbstract_1102615" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1102616" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105750" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102655" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1102658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102655" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1102658" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1102661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102655" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1102661" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_1102675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_1102675" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1102676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1102676" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_StatementTable_1105747" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105747" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105748" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105748" xlink:to="loc_us-gaap_ClassOfStockDomain_1105749" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105749_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105748" xlink:to="loc_us-gaap_ClassOfStockDomain_1105749_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105747" xlink:to="loc_dei_LegalEntityAxis_1105751" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105751" xlink:to="loc_dei_EntityDomain_1105752" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105752_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105751" xlink:to="loc_dei_EntityDomain_1105752_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105752" xlink:to="loc_bvs_BioVentusLlcMember_1105770" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102645" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1102649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102645" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1102649" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1102650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102645" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1102650" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102664" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1102666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102664" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1102666" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1102671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102664" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1102671" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105757" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1102755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1102755" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" xlink:label="loc_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage_1102758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage_1102758" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1102759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1102759" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" xlink:label="loc_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage_1102762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage_1102762" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1102768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1102768" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1102773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1102773" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_StatementTable_1105754" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105754" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105755" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105755" xlink:to="loc_us-gaap_ClassOfStockDomain_1105756" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105756_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105755" xlink:to="loc_us-gaap_ClassOfStockDomain_1105756_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105754" xlink:to="loc_dei_LegalEntityAxis_1105759" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105759" xlink:to="loc_dei_EntityDomain_1105760" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105760_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105759" xlink:to="loc_dei_EntityDomain_1105760_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105760" xlink:to="loc_bvs_BioVentusLlcMember_1105771" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105765" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105765" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1102699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1102699" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1102700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1102700" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1102697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1102697" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1102701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1102701" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1102698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1102698" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1102702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105765" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1102702" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DeferredTaxLiabilitiesAcquiredIntangibles" xlink:label="loc_bvs_DeferredTaxLiabilitiesAcquiredIntangibles_1102705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1102702" xlink:to="loc_bvs_DeferredTaxLiabilitiesAcquiredIntangibles_1102705" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1102707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105765" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1102707" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105765" xlink:to="loc_us-gaap_StatementTable_1105762" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105762" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105763" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105763" xlink:to="loc_us-gaap_ClassOfStockDomain_1105764" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105764_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105763" xlink:to="loc_us-gaap_ClassOfStockDomain_1105764_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105762" xlink:to="loc_dei_LegalEntityAxis_1105766" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105766" xlink:to="loc_dei_EntityDomain_1105767" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105766" xlink:to="loc_dei_EntityDomain_1105767_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105767" xlink:to="loc_bvs_BioVentusLlcMember_1105776" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_1102804" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable" xlink:label="loc_us-gaap_ValuationAllowanceTable_1102803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_ValuationAllowanceTable_1102803" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1102818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1102818" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1102819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1102818" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1102819" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1102819_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1102818" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1102819_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FederalAndStateMember" xlink:label="loc_bvs_FederalAndStateMember_1102821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1102819" xlink:to="loc_bvs_FederalAndStateMember_1102821" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_dei_LegalEntityAxis_1102809" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102809" xlink:to="loc_dei_EntityDomain_1102810" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102810_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102809" xlink:to="loc_dei_EntityDomain_1102810_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102810" xlink:to="loc_bvs_BioVentusLlcMember_1102822" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1102814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_srt_StatementGeographicalAxis_1102814" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1102816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1102814" xlink:to="loc_srt_SegmentGeographicalDomain_1102816" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1102816_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1102814" xlink:to="loc_srt_SegmentGeographicalDomain_1102816_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_1102817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1102816" xlink:to="loc_us-gaap_NonUsMember_1102817" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1102811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_srt_CounterpartyNameAxis_1102811" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1102812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1102811" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1102812" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1102812_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1102811" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1102812_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMember" xlink:label="loc_bvs_HarborMember_1102862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1102812" xlink:to="loc_bvs_HarborMember_1102862" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1102830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_us-gaap_TaxPeriodAxis_1102830" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1102831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1102830" xlink:to="loc_us-gaap_TaxPeriodDomain_1102831" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1102831_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1102830" xlink:to="loc_us-gaap_TaxPeriodDomain_1102831_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IndefinitelyMember" xlink:label="loc_bvs_IndefinitelyMember_1102833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1102831" xlink:to="loc_bvs_IndefinitelyMember_1102833" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2015Member" xlink:label="loc_us-gaap_TaxYear2015Member_1102835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1102831" xlink:to="loc_us-gaap_TaxYear2015Member_1102835" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2020Member" xlink:label="loc_us-gaap_TaxYear2020Member_1102838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1102831" xlink:to="loc_us-gaap_TaxYear2020Member_1102838" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" xlink:label="loc_bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember_1102832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1102831" xlink:to="loc_bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember_1102832" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1102805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1102805" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1102806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1102806" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_1102807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_OpenTaxYear_1102807" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1105401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1105401" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_1105404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_1105404" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1105398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1105398" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/RelatedPartyTransactionsNarrativeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103002" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CashDistributionMadeToMembersTowardsTax" xlink:label="loc_bvs_CashDistributionMadeToMembersTowardsTax_1103018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103002" xlink:to="loc_bvs_CashDistributionMadeToMembersTowardsTax_1103018" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1103002" xlink:to="loc_us-gaap_StatementTable_1102999" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102999" xlink:to="loc_dei_LegalEntityAxis_1103004" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103004" xlink:to="loc_dei_EntityDomain_1103005" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103005_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103004" xlink:to="loc_dei_EntityDomain_1103005_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103005" xlink:to="loc_bvs_BioVentusLlcMember_1103006" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1102999" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103000" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103000" xlink:to="loc_us-gaap_ClassOfStockDomain_1103001" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103001_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103000" xlink:to="loc_us-gaap_ClassOfStockDomain_1103001_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" xlink:label="loc_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome_1103021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103002" xlink:to="loc_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome_1103021" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" xlink:label="loc_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers_1103025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103002" xlink:to="loc_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers_1103025" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105475" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105475" xlink:to="loc_us-gaap_OperatingLeaseCost_771" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105475" xlink:to="loc_us-gaap_ShortTermLeaseCost_772" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105475" xlink:to="loc_us-gaap_LeaseCost_773" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105475" xlink:to="loc_us-gaap_StatementTable_1105472" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105472" xlink:to="loc_dei_LegalEntityAxis_1105478" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105478" xlink:to="loc_dei_EntityDomain_1105479" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105479_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105478" xlink:to="loc_dei_EntityDomain_1105479_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105479" xlink:to="loc_bvs_BioVentusLlcMember_1105485" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105500" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105500" xlink:to="loc_us-gaap_OperatingLeasePayments_776" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1102444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105500" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1102444" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105500" xlink:to="loc_us-gaap_StatementTable_1105497" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105497" xlink:to="loc_dei_LegalEntityAxis_1105504" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105504" xlink:to="loc_dei_EntityDomain_1105506" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105506_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105504" xlink:to="loc_dei_EntityDomain_1105506_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105506" xlink:to="loc_bvs_BioVentusLlcMember_1105509" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105517" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_781" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_784" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_StatementTable_1105514" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105514" xlink:to="loc_dei_LegalEntityAxis_1105518" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105518" xlink:to="loc_dei_EntityDomain_1105519" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105519_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105518" xlink:to="loc_dei_EntityDomain_1105519_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105519" xlink:to="loc_bvs_BioVentusLlcMember_1105520" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_779" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_780" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseLiability_782" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_783" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105539" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1102433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1102433" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1102434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1102434" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1102435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1102435" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1102436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1102436" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1102439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1102439" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1102437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1102437" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1102438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1102438" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1102440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1102440" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1102441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_OperatingLeaseLiability_1102441" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_StatementTable_1105536" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105536" xlink:to="loc_dei_LegalEntityAxis_1105541" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105541" xlink:to="loc_dei_EntityDomain_1105542" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105542_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105541" xlink:to="loc_dei_EntityDomain_1105542_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105542" xlink:to="loc_bvs_BioVentusLlcMember_1105544" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_800" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingenciesTable_787" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_srt_CounterpartyNameAxis_788" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_788" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_788" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMember" xlink:label="loc_bvs_HarborMember_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789" xlink:to="loc_bvs_HarborMember_801" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierOfSingleInjectionOAProductMember" xlink:label="loc_bvs_SupplierOfSingleInjectionOAProductMember_802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789" xlink:to="loc_bvs_SupplierOfSingleInjectionOAProductMember_802" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_792" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_792" xlink:to="loc_us-gaap_LossContingencyNatureDomain_793" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_793_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_792" xlink:to="loc_us-gaap_LossContingencyNatureDomain_793_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_793" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_804" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_srt_ProductOrServiceAxis_790" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_790" xlink:to="loc_srt_ProductsAndServicesDomain_791" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_791_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_790" xlink:to="loc_srt_ProductsAndServicesDomain_791_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_SupplyCommitmentAxis_794" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_794" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_795" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_795_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_794" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_795_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ThreeInjectionOAProductMember" xlink:label="loc_bvs_ThreeInjectionOAProductMember_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_795" xlink:to="loc_bvs_ThreeInjectionOAProductMember_805" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_srt_RangeAxis_796" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_796" xlink:to="loc_srt_RangeMember_797" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_797_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_796" xlink:to="loc_srt_RangeMember_797_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_797" xlink:to="loc_srt_MaximumMember_807" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_797" xlink:to="loc_srt_MinimumMember_806" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_LitigationStatusAxis_798" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_798" xlink:to="loc_us-gaap_LitigationStatusDomain_799" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_798" xlink:to="loc_us-gaap_LitigationStatusDomain_799_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_799" xlink:to="loc_bvs_BionessIncMember_808" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1102463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1102463" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102463" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102464" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102464_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102463" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102464_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1102465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1102464" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1102465" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_dei_LegalEntityAxis_1102469" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102469" xlink:to="loc_dei_EntityDomain_1102470" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102470_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102469" xlink:to="loc_dei_EntityDomain_1102470_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102470" xlink:to="loc_bvs_BioVentusLlcMember_1102471" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_1102457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_srt_MajorCustomersAxis_1102457" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1102458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1102457" xlink:to="loc_srt_NameOfMajorCustomerDomain_1102458" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1102458_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1102457" xlink:to="loc_srt_NameOfMajorCustomerDomain_1102458_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_UsaoAndOigMember" xlink:label="loc_bvs_UsaoAndOigMember_1102459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1102458" xlink:to="loc_bvs_UsaoAndOigMember_1102459" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1102460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1102460" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1102461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1102460" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1102461" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1102461_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1102460" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1102461_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1102462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1102461" xlink:to="loc_us-gaap_SubsequentEventMember_1102462" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplyCommitmentRenewalTerm" xlink:label="loc_bvs_SupplyCommitmentRenewalTerm_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_SupplyCommitmentRenewalTerm_816" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CollaborativeArrangementTerm" xlink:label="loc_bvs_CollaborativeArrangementTerm_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_CollaborativeArrangementTerm_817" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_809" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_810" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_811" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_812" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CollaborativeArrangementRoyaltyPercentage" xlink:label="loc_bvs_CollaborativeArrangementRoyaltyPercentage_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_CollaborativeArrangementRoyaltyPercentage_813" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1102452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1102452" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_1102453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_1102453" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_RoyaltyExpense_814" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RefundOfExcessPaymentsToThirdPartyCustomers" xlink:label="loc_bvs_RefundOfExcessPaymentsToThirdPartyCustomers_1102455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_RefundOfExcessPaymentsToThirdPartyCustomers_1102455" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MilestonePaymentPayable" xlink:label="loc_bvs_MilestonePaymentPayable_1102456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_MilestonePaymentPayable_1102456" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplyCommitmentTerm" xlink:label="loc_bvs_SupplyCommitmentTerm_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_SupplyCommitmentTerm_815" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityNet_1102454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyAccrualProductLiabilityNet_1102454" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:label="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear_1105169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear_1105169" use="optional" order="57" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1102342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1102342" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102328" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102328" xlink:to="loc_dei_LegalEntityAxis_1102329" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102329" xlink:to="loc_dei_EntityDomain_1102330" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102329" xlink:to="loc_dei_EntityDomain_1102330_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102330" xlink:to="loc_bvs_BioVentusLlcMember_1102334" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1102337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1102337" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1102339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1102339" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1102340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1102340" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetIncomeLossFromContinuingOperations" xlink:label="loc_bvs_NetIncomeLossFromContinuingOperations_1102350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_bvs_NetIncomeLossFromContinuingOperations_1102350" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1102343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1102343" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1102346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1102346" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1102347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1102347" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_1102373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_1102373" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1102374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1102374" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1102371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1102371" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1102375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1102375" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1102389" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1102389" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" xlink:to="loc_dei_LegalEntityAxis_1102383" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102383" xlink:to="loc_dei_EntityDomain_1102384" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102383" xlink:to="loc_dei_EntityDomain_1102384_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102384" xlink:to="loc_bvs_BioVentusLlcMember_1102385" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1102386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1102386" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1102387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1102386" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1102387" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1102387_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1102386" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1102387_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsMember" xlink:label="loc_bvs_PreferredUnitsMember_1102388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1102387" xlink:to="loc_bvs_PreferredUnitsMember_1102388" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1102390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1102389" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1102390" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/RevenueRecognitionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_832" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_832" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_838" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_832" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_827" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_827" xlink:to="loc_srt_ProductOrServiceAxis_830" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_830" xlink:to="loc_srt_ProductsAndServicesDomain_831" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_831_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_830" xlink:to="loc_srt_ProductsAndServicesDomain_831_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PainTreatmentsAndJointPreservationMember" xlink:label="loc_bvs_PainTreatmentsAndJointPreservationMember_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_831" xlink:to="loc_bvs_PainTreatmentsAndJointPreservationMember_835" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestorativeTherapiesMember" xlink:label="loc_bvs_RestorativeTherapiesMember_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_831" xlink:to="loc_bvs_RestorativeTherapiesMember_836" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BoneGraftSubstitutesMember" xlink:label="loc_bvs_BoneGraftSubstitutesMember_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_831" xlink:to="loc_bvs_BoneGraftSubstitutesMember_837" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_827" xlink:to="loc_srt_StatementGeographicalAxis_828" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_828" xlink:to="loc_srt_SegmentGeographicalDomain_829" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_829_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_828" xlink:to="loc_srt_SegmentGeographicalDomain_829_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_829" xlink:to="loc_us-gaap_NonUsMember_834" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_829" xlink:to="loc_country_US_833" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SegmentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_852" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_NumberOfReportableSegments_857" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_861" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemNetGainLoss" xlink:label="loc_us-gaap_UnusualOrInfrequentItemNetGainLoss_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_UnusualOrInfrequentItemNetGainLoss_862" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SuccessionAndTransitionCharges" xlink:label="loc_bvs_SuccessionAndTransitionCharges_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_bvs_SuccessionAndTransitionCharges_863" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_865" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryStepUpCost" xlink:label="loc_bvs_InventoryStepUpCost_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_bvs_InventoryStepUpCost_866" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_867" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_868" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_OtherNonrecurringExpense_870" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_871" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1102192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_RestructuringCharges_1102192" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" xlink:to="loc_srt_ConsolidationItemsAxis_850" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_850" xlink:to="loc_srt_ConsolidationItemsDomain_851" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_851_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_850" xlink:to="loc_srt_ConsolidationItemsDomain_851_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_851" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_856" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_851" xlink:to="loc_us-gaap_OperatingSegmentsMember_855" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" xlink:to="loc_dei_LegalEntityAxis_1102193" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102193" xlink:to="loc_dei_EntityDomain_1102194" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102194_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102193" xlink:to="loc_dei_EntityDomain_1102194_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102194" xlink:to="loc_bvs_BioVentusLlcMember_1102195" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_848" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_848" xlink:to="loc_us-gaap_SegmentDomain_849" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_849_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_848" xlink:to="loc_us-gaap_SegmentDomain_849_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_USSegmentMember" xlink:label="loc_bvs_USSegmentMember_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_849" xlink:to="loc_bvs_USSegmentMember_853" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InternationalSegmentMember" xlink:label="loc_bvs_InternationalSegmentMember_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_849" xlink:to="loc_bvs_InternationalSegmentMember_854" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_864" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:label="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_858" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_AssetImpairmentCharges_869" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_DepreciationAndAmortization_859" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_860" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_892" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_SubsequentEventTable_877" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_878" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_878" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_879" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_879_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_878" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_879_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_879" xlink:to="loc_us-gaap_SubsequentEventMember_893" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_dei_LegalEntityAxis_888" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_888" xlink:to="loc_dei_EntityDomain_889" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_889_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_888" xlink:to="loc_dei_EntityDomain_889_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_889" xlink:to="loc_bvs_BioVentusLlcMember_1102057" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_DebtInstrumentAxis_880" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_880" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_881" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_881_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_880" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_881_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramLoanMember" xlink:label="loc_bvs_PaycheckProtectionProgramLoanMember_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_881" xlink:to="loc_bvs_PaycheckProtectionProgramLoanMember_894" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TermLoanFacilityMember" xlink:label="loc_bvs_TermLoanFacilityMember_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_881" xlink:to="loc_bvs_TermLoanFacilityMember_895" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_A2019CreditAgreementMember" xlink:label="loc_bvs_A2019CreditAgreementMember_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_881" xlink:to="loc_bvs_A2019CreditAgreementMember_896" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_886" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_886" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_886" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MisonixIncMember" xlink:label="loc_bvs_MisonixIncMember_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" xlink:to="loc_bvs_MisonixIncMember_899" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" xlink:to="loc_bvs_BionessIncMember_900" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCMember" xlink:label="loc_bvs_BVLLCMember_1105689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" xlink:to="loc_bvs_BVLLCMember_1105689" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_srt_OwnershipAxis_890" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_890" xlink:to="loc_srt_OwnershipDomain_891" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_891_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_890" xlink:to="loc_srt_OwnershipDomain_891_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_891" xlink:to="loc_bvs_BioventusIncMember_902" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_882" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_882" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_883" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_883_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_882" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_883_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_883" xlink:to="loc_us-gaap_SecuredDebtMember_897" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_srt_StatementScenarioAxis_884" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_884" xlink:to="loc_srt_ScenarioUnspecifiedDomain_885" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_885_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_884" xlink:to="loc_srt_ScenarioUnspecifiedDomain_885_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_885" xlink:to="loc_srt_ScenarioForecastMember_898" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestorAxis" xlink:label="loc_bvs_InvestorAxis_1102066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_bvs_InvestorAxis_1102066" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestorDomain" xlink:label="loc_bvs_InvestorDomain_1102067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_InvestorAxis_1102066" xlink:to="loc_bvs_InvestorDomain_1102067" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestorDomain" xlink:label="loc_bvs_InvestorDomain_1102067_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_InvestorAxis_1102066" xlink:to="loc_bvs_InvestorDomain_1102067_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContinuingLlcOwnerMember" xlink:label="loc_bvs_ContinuingLlcOwnerMember_1102068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_InvestorDomain_1102067" xlink:to="loc_bvs_ContinuingLlcOwnerMember_1102068" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NewLlcOwnerMember" xlink:label="loc_bvs_NewLlcOwnerMember_1102070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_InvestorDomain_1102067" xlink:to="loc_bvs_NewLlcOwnerMember_1102070" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102072" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102072" xlink:to="loc_us-gaap_ClassOfStockDomain_1102073" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102073_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102072" xlink:to="loc_us-gaap_ClassOfStockDomain_1102073_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1102074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1102073" xlink:to="loc_us-gaap_CommonClassAMember_1102074" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1102491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1102073" xlink:to="loc_us-gaap_CommonClassBMember_1102491" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_1102147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_srt_MajorCustomersAxis_1102147" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1102148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1102147" xlink:to="loc_srt_NameOfMajorCustomerDomain_1102148" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1102148_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1102147" xlink:to="loc_srt_NameOfMajorCustomerDomain_1102148_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_UsaoAndOigMember" xlink:label="loc_bvs_UsaoAndOigMember_1102150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1102148" xlink:to="loc_bvs_UsaoAndOigMember_1102150" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1102548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_PlanNameAxis_1102548" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1102549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1102548" xlink:to="loc_us-gaap_PlanNameDomain_1102549" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1102549_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1102548" xlink:to="loc_us-gaap_PlanNameDomain_1102549_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_A2021PlanMember" xlink:label="loc_bvs_A2021PlanMember_1102576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1102549" xlink:to="loc_bvs_A2021PlanMember_1102576" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1102054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_InvestmentTypeAxis_1102054" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1102055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1102054" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1102055" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1102055_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1102054" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1102055_default" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConvertibleDebtInstrumentsMember" xlink:label="loc_bvs_ConvertibleDebtInstrumentsMember_1102056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1102055" xlink:to="loc_bvs_ConvertibleDebtInstrumentsMember_1102056" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventAxis" xlink:label="loc_bvs_EventAxis_1102060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_bvs_EventAxis_1102060" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventDomain" xlink:label="loc_bvs_EventDomain_1102061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_EventAxis_1102060" xlink:to="loc_bvs_EventDomain_1102061" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventDomain" xlink:label="loc_bvs_EventDomain_1102061_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_EventAxis_1102060" xlink:to="loc_bvs_EventDomain_1102061_default" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestatedLimitedLiabilityCompanyAgreementMember" xlink:label="loc_bvs_RestatedLimitedLiabilityCompanyAgreementMember_1102062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_EventDomain_1102061" xlink:to="loc_bvs_RestatedLimitedLiabilityCompanyAgreementMember_1102062" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1102551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_AwardTypeAxis_1102551" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1102552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1102551" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1102552" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1102552_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1102551" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1102552_default" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1102566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1102552" xlink:to="loc_us-gaap_EmployeeStockMember_1102566" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1102562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_srt_RangeAxis_1102562" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1102562" xlink:to="loc_srt_RangeMember_1102563" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102563_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1102562" xlink:to="loc_srt_RangeMember_1102563_default" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1102564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1102563" xlink:to="loc_srt_MaximumMember_1102564" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1102565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1102563" xlink:to="loc_srt_MinimumMember_1102565" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementAxis" xlink:label="loc_bvs_AgreementAxis_1105004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_bvs_AgreementAxis_1105004" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementDomain" xlink:label="loc_bvs_AgreementDomain_1105005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_AgreementAxis_1105004" xlink:to="loc_bvs_AgreementDomain_1105005" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementDomain" xlink:label="loc_bvs_AgreementDomain_1105005_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_AgreementAxis_1105004" xlink:to="loc_bvs_AgreementDomain_1105005_default" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestrictedStockUnitsAgreementMember" xlink:label="loc_bvs_RestrictedStockUnitsAgreementMember_1105007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_AgreementDomain_1105005" xlink:to="loc_bvs_RestrictedStockUnitsAgreementMember_1105007" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OptionAndEquityPurchaseAgreementMember" xlink:label="loc_bvs_OptionAndEquityPurchaseAgreementMember_1105006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_AgreementDomain_1105005" xlink:to="loc_bvs_OptionAndEquityPurchaseAgreementMember_1105006" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentCovenantRequiredPrepayment" xlink:label="loc_bvs_DebtInstrumentCovenantRequiredPrepayment_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_DebtInstrumentCovenantRequiredPrepayment_910" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_909" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_903" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_904" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash_905" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares_906" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum_908" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_DebtInstrumentTerm_911" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_1102063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_1102063" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1102140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1102140" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_1102141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_1102141" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1102071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1102071" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1102075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1102075" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xlink:label="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany_1102078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany_1102078" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xlink:label="loc_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod_1102081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod_1102081" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" xlink:label="loc_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers_1102088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers_1102088" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_1102099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_1102099" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1102515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1102515" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1102519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1102519" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest_1102521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest_1102521" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_913" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_1102051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_1102051" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" xlink:label="loc_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany_1102059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany_1102059" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1102486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1102486" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NumberOfEquityBasedCompensationPlans" xlink:label="loc_bvs_NumberOfEquityBasedCompensationPlans_1102574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_NumberOfEquityBasedCompensationPlans_1102574" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1102575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1102575" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1102492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1102492" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1102493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1102493" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonStockNumberOfVotes" xlink:label="loc_bvs_CommonStockNumberOfVotes_1102502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_CommonStockNumberOfVotes_1102502" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_1102503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_1102503" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_1102504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_1102504" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_1102509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_1102509" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1102571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1102571" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1102573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1102573" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedPaymentAwardSettlementPeriod" xlink:label="loc_bvs_ShareBasedPaymentAwardSettlementPeriod_1102569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_ShareBasedPaymentAwardSettlementPeriod_1102569" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease_1102577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease_1102577" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:label="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld_1104996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld_1104996" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee_1102587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee_1102587" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1102583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1102583" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1102580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1102580" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1102579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1102579" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1102578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1102578" use="optional" order="115" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1102279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1102279" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" xlink:to="loc_dei_LegalEntityAxis_1102253" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102253" xlink:to="loc_dei_EntityDomain_1102255" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102255_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102253" xlink:to="loc_dei_EntityDomain_1102255_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102255" xlink:to="loc_bvs_BioVentusLlcMember_1102256" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102257" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102257" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102258" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102258_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102257" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102258_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BmpResearchAndDevelopmentProgrammeMember" xlink:label="loc_bvs_BmpResearchAndDevelopmentProgrammeMember_1102262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102258" xlink:to="loc_bvs_BmpResearchAndDevelopmentProgrammeMember_1102262" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense_1102269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense_1102269" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit_1102281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit_1102281" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1102285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1102285" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102291" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" xlink:to="loc_dei_LegalEntityAxis_1102293" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102293" xlink:to="loc_dei_EntityDomain_1102294" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102294_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102293" xlink:to="loc_dei_EntityDomain_1102294_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102294" xlink:to="loc_bvs_BioVentusLlcMember_1102296" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102312" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102312" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102313" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102313_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102312" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102313_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BmpResearchAndDevelopmentProgrammeMember" xlink:label="loc_bvs_BmpResearchAndDevelopmentProgrammeMember_1102318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102313" xlink:to="loc_bvs_BmpResearchAndDevelopmentProgrammeMember_1102318" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1102325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102291" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1102325" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities_1102338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102291" xlink:to="loc_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities_1102338" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/NetSalesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1102380" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1102379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102380" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1102379" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102379" xlink:to="loc_dei_LegalEntityAxis_1102483" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1102483" xlink:to="loc_dei_EntityDomain_1102484" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1102483" xlink:to="loc_dei_EntityDomain_1102484_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1102484" xlink:to="loc_bvs_BioVentusLlcMember_1102485" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1102507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102379" xlink:to="loc_srt_StatementGeographicalAxis_1102507" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1102508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1102507" xlink:to="loc_srt_SegmentGeographicalDomain_1102508" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1102508_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1102507" xlink:to="loc_srt_SegmentGeographicalDomain_1102508_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_USSegmentMember" xlink:label="loc_bvs_USSegmentMember_1102512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1102508" xlink:to="loc_bvs_USSegmentMember_1102512" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InternationalSegmentMember" xlink:label="loc_bvs_InternationalSegmentMember_1102514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1102508" xlink:to="loc_bvs_InternationalSegmentMember_1102514" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1102516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102379" xlink:to="loc_srt_ProductOrServiceAxis_1102516" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1102518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1102516" xlink:to="loc_srt_ProductsAndServicesDomain_1102518" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1102518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1102516" xlink:to="loc_srt_ProductsAndServicesDomain_1102518_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OAJointPainTreatmentAndJointPreservationMember" xlink:label="loc_bvs_OAJointPainTreatmentAndJointPreservationMember_1102520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1102518" xlink:to="loc_bvs_OAJointPainTreatmentAndJointPreservationMember_1102520" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MinimallyInvasiveFractureTreatmentMember" xlink:label="loc_bvs_MinimallyInvasiveFractureTreatmentMember_1102522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1102518" xlink:to="loc_bvs_MinimallyInvasiveFractureTreatmentMember_1102522" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BoneGraftSubstitutesMember" xlink:label="loc_bvs_BoneGraftSubstitutesMember_1102525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1102518" xlink:to="loc_bvs_BoneGraftSubstitutesMember_1102525" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1102506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102380" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1102506" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102669" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102669" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102656" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102656" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102656" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1102659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" xlink:to="loc_us-gaap_ComputerEquipmentMember_1102659" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1102662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1102662" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1102663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_1102663" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1102665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1102665" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1102651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" xlink:to="loc_srt_RangeAxis_1102651" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1102651" xlink:to="loc_srt_RangeMember_1102652" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102652_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1102651" xlink:to="loc_srt_RangeMember_1102652_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1102653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1102652" xlink:to="loc_srt_MinimumMember_1102653" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1102654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1102652" xlink:to="loc_srt_MaximumMember_1102654" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" xlink:to="loc_dei_LegalEntityAxis_1105805" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105805" xlink:to="loc_dei_EntityDomain_1105806" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105805" xlink:to="loc_dei_EntityDomain_1105806_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105806" xlink:to="loc_bvs_BioventusIncMember_1105807" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1102674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102669" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1102674" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1102690" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1102690" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" xlink:to="loc_dei_LegalEntityAxis_1105818" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105818" xlink:to="loc_dei_EntityDomain_1105819" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105819_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105818" xlink:to="loc_dei_EntityDomain_1105819_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105819" xlink:to="loc_bvs_BioventusIncMember_1105821" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1102681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" xlink:to="loc_srt_RangeAxis_1102681" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1102681" xlink:to="loc_srt_RangeMember_1102682" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102682_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1102681" xlink:to="loc_srt_RangeMember_1102682_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_1102683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1102682" xlink:to="loc_srt_WeightedAverageMember_1102683" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102684" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102684" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102684" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_1102686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" xlink:to="loc_us-gaap_IntellectualPropertyMember_1102686" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_1102687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" xlink:to="loc_us-gaap_DistributionRightsMember_1102687" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1102688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1102688" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1102689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1102689" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1102691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1102690" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1102691" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1102728" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1102704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1102728" xlink:to="loc_us-gaap_ConcentrationRiskTable_1102704" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1102724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1102724" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1102725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1102724" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1102725" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1102725_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1102724" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1102725_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_1102726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1102725" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_1102726" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_1102727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1102725" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_1102727" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConcentrationRiskBySupplierNameAxis" xlink:label="loc_bvs_ConcentrationRiskBySupplierNameAxis_1102706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_bvs_ConcentrationRiskBySupplierNameAxis_1102706" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConcentrationRiskBySupplierNameDomain" xlink:label="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameAxis_1102706" xlink:to="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConcentrationRiskBySupplierNameDomain" xlink:label="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameAxis_1102706" xlink:to="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductDMember" xlink:label="loc_bvs_ProductDMember_1102722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_ProductDMember_1102722" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierCMember" xlink:label="loc_bvs_SupplierCMember_1102716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_SupplierCMember_1102716" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductAMember" xlink:label="loc_bvs_ProductAMember_1102717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_ProductAMember_1102717" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductBMember" xlink:label="loc_bvs_ProductBMember_1102718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_ProductBMember_1102718" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductCMember" xlink:label="loc_bvs_ProductCMember_1102719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_ProductCMember_1102719" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierAMember" xlink:label="loc_bvs_SupplierAMember_1102709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_SupplierAMember_1102709" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierBMember" xlink:label="loc_bvs_SupplierBMember_1102710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_SupplierBMember_1102710" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1105712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1105712" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1105713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1105712" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1105713" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1105713_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1105712" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1105713_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1105714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1105713" xlink:to="loc_us-gaap_SalesRevenueNetMember_1105714" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_dei_LegalEntityAxis_1105825" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105825" xlink:to="loc_dei_EntityDomain_1105826" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105826_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105825" xlink:to="loc_dei_EntityDomain_1105826_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105826" xlink:to="loc_bvs_BioventusIncMember_1105827" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1102730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1102728" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1102730" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1102731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1102728" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1102731" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105930" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1102743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1102743" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_1102744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_1102744" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1102745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1102745" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_1102747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_1102747" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_1102750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_1102750" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_1102752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_1102752" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1102753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1102753" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_1102754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_DeferredOfferingCosts_1102754" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_StatementTable_1105927" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105927" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105928" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105928" xlink:to="loc_us-gaap_ClassOfStockDomain_1105929" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105929_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105928" xlink:to="loc_us-gaap_ClassOfStockDomain_1105929_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1105927" xlink:to="loc_dei_LegalEntityAxis_1105931" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1105931" xlink:to="loc_dei_EntityDomain_1105932" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105932_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1105931" xlink:to="loc_dei_EntityDomain_1105932_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1105932" xlink:to="loc_bvs_BioventusIncMember_1105933" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_1102756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_AdvertisingExpense_1102756" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfMembersTaxDistributionToTaxableIncome" xlink:label="loc_bvs_PercentageOfMembersTaxDistributionToTaxableIncome_1105892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_bvs_PercentageOfMembersTaxDistributionToTaxableIncome_1105892" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails">
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems_1103065" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue_1103078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_us-gaap_CommonUnitIssuanceValue_1103078" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" xlink:label="loc_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue_1103079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue_1103079" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue_1103077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue_1103077" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital" xlink:label="loc_us-gaap_MembersCapital_1103080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_us-gaap_MembersCapital_1103080" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable_1103064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_bvs_MemberEquityTable_1103064" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_MemberEquityTable_1103064" xlink:to="loc_dei_LegalEntityAxis_1103071" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103071" xlink:to="loc_dei_EntityDomain_1103072" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103072_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103071" xlink:to="loc_dei_EntityDomain_1103072_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103072" xlink:to="loc_bvs_BioVentusLlcMember_1103074" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquityNarrativeDetails">
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems_1103105" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable_1103090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_MemberEquityTable_1103090" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_dei_LegalEntityAxis_1103091" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103091" xlink:to="loc_dei_EntityDomain_1103092" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103092_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103091" xlink:to="loc_dei_EntityDomain_1103092_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103092" xlink:to="loc_bvs_BioVentusLlcMember_1103093" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1103099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1103099" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1103100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103099" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1103100" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1103100_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103099" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1103100_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1103101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1103100" xlink:to="loc_us-gaap_SubsequentEventMember_1103101" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsByNameAxis" xlink:label="loc_us-gaap_PreferredUnitsByNameAxis_1103094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_us-gaap_PreferredUnitsByNameAxis_1103094" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsClassDomain" xlink:label="loc_us-gaap_PreferredUnitsClassDomain_1103095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PreferredUnitsByNameAxis_1103094" xlink:to="loc_us-gaap_PreferredUnitsClassDomain_1103095" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsClassDomain" xlink:label="loc_us-gaap_PreferredUnitsClassDomain_1103095_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PreferredUnitsByNameAxis_1103094" xlink:to="loc_us-gaap_PreferredUnitsClassDomain_1103095_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwelvePreferredUnitsMember" xlink:label="loc_bvs_TwoThousandAndTwelvePreferredUnitsMember_1103096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsClassDomain_1103095" xlink:to="loc_bvs_TwoThousandAndTwelvePreferredUnitsMember_1103096" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndFifteenPreferredUnitsMember" xlink:label="loc_bvs_TwoThousandAndFifteenPreferredUnitsMember_1103098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsClassDomain_1103095" xlink:to="loc_bvs_TwoThousandAndFifteenPreferredUnitsMember_1103098" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1103102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_us-gaap_AwardTypeAxis_1103102" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1103103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1103102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1103103" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1103103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1103102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1103103_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_1103104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1103103" xlink:to="loc_bvs_EquityParticipationRightUnitMember_1103104" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xlink:label="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany_1103106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany_1103106" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" xlink:label="loc_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany_1103107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany_1103107" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xlink:label="loc_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod_1103108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod_1103108" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsLiquidationPreferencePerUnit" xlink:label="loc_bvs_PreferredUnitsLiquidationPreferencePerUnit_1103109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_PreferredUnitsLiquidationPreferencePerUnit_1103109" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" xlink:label="loc_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum_1103111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum_1103111" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightEntitledPercentageOfDistributions" xlink:label="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions_1103114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions_1103114" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DistributionEventTriggerPercentageOfSaleOfAssets" xlink:label="loc_bvs_DistributionEventTriggerPercentageOfSaleOfAssets_1103118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_DistributionEventTriggerPercentageOfSaleOfAssets_1103118" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1103120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1103120" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1103117" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="loc_us-gaap_RestructuringCostsAbstract_1103119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103117" xlink:to="loc_us-gaap_RestructuringCostsAbstract_1103119" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1103121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostsAbstract_1103119" xlink:to="loc_us-gaap_RestructuringReserve_1103121" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1103122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostsAbstract_1103119" xlink:to="loc_us-gaap_RestructuringCharges_1103122" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_1103123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostsAbstract_1103119" xlink:to="loc_us-gaap_PaymentsForRestructuring_1103123" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103117" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1103127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1103127" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1103128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1103127" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1103128" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1103128_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1103127" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1103128_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EmployeeSeveranceAndTemporaryLaborCostsMember" xlink:label="loc_bvs_EmployeeSeveranceAndTemporaryLaborCostsMember_1103129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1103128" xlink:to="loc_bvs_EmployeeSeveranceAndTemporaryLaborCostsMember_1103129" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherChargesMember" xlink:label="loc_bvs_OtherChargesMember_1103130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1103128" xlink:to="loc_bvs_OtherChargesMember_1103130" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" xlink:to="loc_dei_LegalEntityAxis_1103134" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103134" xlink:to="loc_dei_EntityDomain_1103135" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103135_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103134" xlink:to="loc_dei_EntityDomain_1103135_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103135" xlink:to="loc_bvs_BioVentusLlcMember_1103136" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/RestructuringCostsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1103153" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103153" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_1103163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" xlink:to="loc_us-gaap_RestructuringPlanAxis_1103163" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_1103164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_1103163" xlink:to="loc_us-gaap_RestructuringPlanDomain_1103164" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_1103164_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_1103163" xlink:to="loc_us-gaap_RestructuringPlanDomain_1103164_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndEighteenPlanMember" xlink:label="loc_bvs_TwoThousandAndEighteenPlanMember_1103170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_1103164" xlink:to="loc_bvs_TwoThousandAndEighteenPlanMember_1103170" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwentyPlanMember" xlink:label="loc_bvs_TwoThousandAndTwentyPlanMember_1103171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_1103164" xlink:to="loc_bvs_TwoThousandAndTwentyPlanMember_1103171" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" xlink:to="loc_dei_LegalEntityAxis_1103173" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103173" xlink:to="loc_dei_EntityDomain_1103174" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103173" xlink:to="loc_dei_EntityDomain_1103174_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103174" xlink:to="loc_bvs_BioVentusLlcMember_1103175" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1103156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103153" xlink:to="loc_us-gaap_RestructuringCharges_1103156" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" xlink:to="loc_dei_LegalEntityAxis_1103186" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103186" xlink:to="loc_dei_EntityDomain_1103187" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103187_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103186" xlink:to="loc_dei_EntityDomain_1103187_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103187" xlink:to="loc_bvs_BioVentusLlcMember_1103188" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1103189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" xlink:to="loc_us-gaap_PlanNameAxis_1103189" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1103190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1103189" xlink:to="loc_us-gaap_PlanNameDomain_1103190" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1103190_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1103189" xlink:to="loc_us-gaap_PlanNameDomain_1103190_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwelveMember" xlink:label="loc_bvs_TwoThousandAndTwelveMember_1103191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103190" xlink:to="loc_bvs_TwoThousandAndTwelveMember_1103191" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndFifteenMember" xlink:label="loc_bvs_TwoThousandAndFifteenMember_1103192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1103190" xlink:to="loc_bvs_TwoThousandAndFifteenMember_1103192" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1106227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" xlink:to="loc_us-gaap_AwardTypeAxis_1106227" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1106227" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106228" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106228_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1106227" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106228_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherPhantomUnitMember" xlink:label="loc_bvs_OtherPhantomUnitMember_1106234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106228" xlink:to="loc_bvs_OtherPhantomUnitMember_1106234" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue_1103224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue_1103224" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1103225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1103225" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103221" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103194" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1103195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1103195" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod_1103204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod_1103204" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1103215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1103215" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1103236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1103236" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1103222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1103222" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1103220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1103220" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1103235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1103235" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1103238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1103238" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1103309" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1103310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103309" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1103310" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1103298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103309" xlink:to="loc_us-gaap_DebtInstrumentTable_1103298" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentAxis" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis_1103302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103298" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis_1103302" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentDomain" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis_1103302" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentDomain" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis_1103302" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember_1103304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember_1103304" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember_1103305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember_1103305" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103298" xlink:to="loc_dei_LegalEntityAxis_1103299" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103299" xlink:to="loc_dei_EntityDomain_1103300" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103300_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103299" xlink:to="loc_dei_EntityDomain_1103300_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103300" xlink:to="loc_bvs_BioVentusLlcMember_1103301" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1103306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103298" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1103306" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1103307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1103306" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1103307" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1103307_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1103306" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1103307_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TermLoanMember" xlink:label="loc_bvs_TermLoanMember_1103308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1103307" xlink:to="loc_bvs_TermLoanMember_1103308" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1103341" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1103325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103341" xlink:to="loc_us-gaap_DebtInstrumentTable_1103325" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_1103337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103325" xlink:to="loc_us-gaap_VariableRateAxis_1103337" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_1103337" xlink:to="loc_us-gaap_VariableRateDomain_1103338" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103338_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_1103337" xlink:to="loc_us-gaap_VariableRateDomain_1103338_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_1103339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1103338" xlink:to="loc_us-gaap_EurodollarMember_1103339" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_1103340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1103338" xlink:to="loc_us-gaap_BaseRateMember_1103340" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103325" xlink:to="loc_dei_LegalEntityAxis_1103327" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103327" xlink:to="loc_dei_EntityDomain_1103328" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103327" xlink:to="loc_dei_EntityDomain_1103328_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103328" xlink:to="loc_bvs_BioVentusLlcMember_1103329" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeAxis" xlink:label="loc_bvs_LeverageRatioRangeAxis_1103330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103325" xlink:to="loc_bvs_LeverageRatioRangeAxis_1103330" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeDomain" xlink:label="loc_bvs_LeverageRatioRangeDomain_1103331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_LeverageRatioRangeAxis_1103330" xlink:to="loc_bvs_LeverageRatioRangeDomain_1103331" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeDomain" xlink:label="loc_bvs_LeverageRatioRangeDomain_1103331_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_LeverageRatioRangeAxis_1103330" xlink:to="loc_bvs_LeverageRatioRangeDomain_1103331_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeTwoMember" xlink:label="loc_bvs_LeverageRatioRangeTwoMember_1103333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeTwoMember_1103333" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeThreeMember" xlink:label="loc_bvs_LeverageRatioRangeThreeMember_1103334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeThreeMember_1103334" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFourMember" xlink:label="loc_bvs_LeverageRatioRangeFourMember_1103335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeFourMember_1103335" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFiveMember" xlink:label="loc_bvs_LeverageRatioRangeFiveMember_1103336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeFiveMember_1103336" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeOneMember" xlink:label="loc_bvs_LeverageRatioRangeOneMember_1103332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeOneMember_1103332" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1103342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103341" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1103342" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1103353" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1103316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103353" xlink:to="loc_us-gaap_DebtInstrumentTable_1103316" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103316" xlink:to="loc_dei_LegalEntityAxis_1103317" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103317" xlink:to="loc_dei_EntityDomain_1103318" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103318_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103317" xlink:to="loc_dei_EntityDomain_1103318_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103318" xlink:to="loc_bvs_BioVentusLlcMember_1103319" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1103343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103316" xlink:to="loc_us-gaap_CreditFacilityAxis_1103343" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1103344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1103343" xlink:to="loc_us-gaap_CreditFacilityDomain_1103344" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1103344_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1103343" xlink:to="loc_us-gaap_CreditFacilityDomain_1103344_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1103345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1103344" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1103345" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeAxis" xlink:label="loc_bvs_LeverageRatioRangeAxis_1103346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1103316" xlink:to="loc_bvs_LeverageRatioRangeAxis_1103346" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeDomain" xlink:label="loc_bvs_LeverageRatioRangeDomain_1103347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bvs_LeverageRatioRangeAxis_1103346" xlink:to="loc_bvs_LeverageRatioRangeDomain_1103347" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeDomain" xlink:label="loc_bvs_LeverageRatioRangeDomain_1103347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bvs_LeverageRatioRangeAxis_1103346" xlink:to="loc_bvs_LeverageRatioRangeDomain_1103347_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeTwoMember" xlink:label="loc_bvs_LeverageRatioRangeTwoMember_1103349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeTwoMember_1103349" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeThreeMember" xlink:label="loc_bvs_LeverageRatioRangeThreeMember_1103350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeThreeMember_1103350" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFourMember" xlink:label="loc_bvs_LeverageRatioRangeFourMember_1103351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeFourMember_1103351" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFiveMember" xlink:label="loc_bvs_LeverageRatioRangeFiveMember_1103352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeFiveMember_1103352" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeOneMember" xlink:label="loc_bvs_LeverageRatioRangeOneMember_1103348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeOneMember_1103348" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1103354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103353" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1103354" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103361" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1103365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1103365" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1103358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_StatementTable_1103358" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103358" xlink:to="loc_dei_LegalEntityAxis_1103362" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1103362" xlink:to="loc_dei_EntityDomain_1103363" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103363_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1103362" xlink:to="loc_dei_EntityDomain_1103363_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1103363" xlink:to="loc_bvs_BioVentusLlcMember_1103364" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1103358" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103359" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103359" xlink:to="loc_us-gaap_ClassOfStockDomain_1103360" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103360_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103359" xlink:to="loc_us-gaap_ClassOfStockDomain_1103360_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1103366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1103366" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1103367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1103367" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1103368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1103368" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:label="loc_us-gaap_LongTermDebtMaturingInYearsFourAndFive_1103369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturingInYearsFourAndFive_1103369" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1103370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1103370" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1103371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1103371" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1103372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebt_1103372" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_1103373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtCurrent_1103373" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1103374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1103374" use="optional" order="18" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>bvs-20210703_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-September-2021 [01:59:44] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BioVentusLlcMember" xml:lang="en-US">Bio Ventus LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BioVentusLlcMember" xml:lang="en-US">Bio Ventus LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BioVentusLlcMember" xlink:to="lab_bvs_BioVentusLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BioVentusLlcMember" xml:lang="en-US">Bio Ventus LLC</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Net sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">(Loss) income before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income from continuing operations before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income from continuing operations before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net (loss) income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Loss attributable to noncontrolling interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net loss attributable to noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income attributable to Bioventus Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of Goods and Services Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of sales (including depreciation and amortization of $5,618, $5,292, $10,854 and $10,599 respectively)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Change in foreign currency translation adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Impairment of variable interest entity assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Impairments related to variable interest entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest expense (income)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest (expense) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Other expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other expense (income)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Net income from continuing operations attributable to unit holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Net (loss) income attributable to Bioventus Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Loss on impairment of intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Loss on impairment of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Net income (loss) from continuing operations attributable to common unit holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive (loss) income attributable to Bioventus Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share of Class A common stock, basic (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share of Class A common stock, diluted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Weighted Average Number Of Shares Outstanding [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average shares of Class A common stock outstanding - basic (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average units used in computing basic and diluted net income (loss) per common unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average shares of Class A common stock outstanding - diluted (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Change in fair value of contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Change in fair value of contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xml:lang="en-US">Net income (loss) from continuing operations attributable to common unit holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xml:lang="en-US">Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net income from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net income from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net income from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Net loss from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Expenses incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xml:lang="en-US">Net income allocated to participating shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US">Accumulated and unpaid preferred distributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net income (loss) attributable to common unit holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net income (loss) attributable to common unit holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic and Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net income (loss) attributable to common unit holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net income (loss) attributable to common unit holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Net income (loss) from continuing operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Net income (loss) from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xml:lang="en-US">Change in prior service cost and unrecognized (loss) gain for defined benefit plan adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xml:lang="en-US">Cost, Depreciation and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Investment and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalAssets" xlink:label="loc_bvs_TotalAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TotalAssets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_TotalAssets" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TotalAssets" xlink:to="lab_bvs_TotalAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TotalAssets" xml:lang="en-US">Total assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' and Members' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xml:lang="en-US">Accrued equity-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current portion of long-term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current portion of long-term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xml:lang="en-US">Current portion of contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term debt, less current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders' and Members' Equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MembersEquity" xml:lang="en-US">Members' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MembersEquity" xml:lang="en-US">Members' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_MembersEquity" xml:lang="en-US">Members' equity, beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_MembersEquity" xml:lang="en-US">Members' equity, ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersEquity" xlink:to="lab_us-gaap_MembersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total stockholders' and members' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalStockholdersEquity" xlink:label="loc_bvs_TotalStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TotalStockholdersEquity" xml:lang="en-US">Total Stockholders Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_TotalStockholdersEquity" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TotalStockholdersEquity" xlink:to="lab_bvs_TotalStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TotalStockholdersEquity" xml:lang="en-US">Total Stockholders' Equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity attributable to Bioventus Inc. and members' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' and members' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Contingent consideration, less current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Long-term contingent consideration, less current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalLiabilities" xlink:label="loc_bvs_TotalLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TotalLiabilities" xml:lang="en-US">Total Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_TotalLiabilities" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TotalLiabilities" xlink:to="lab_bvs_TotalLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TotalLiabilities" xml:lang="en-US">Total liabilities.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalLiabilitiesAndStockholdersEquity" xlink:label="loc_bvs_TotalLiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TotalLiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities And Stockholders Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_TotalLiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TotalLiabilitiesAndStockholdersEquity" xlink:to="lab_bvs_TotalLiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TotalLiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xml:lang="en-US">Accrued equity-based compensation, less current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, Shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PublicOfferingMember" xlink:label="loc_bvs_PublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PublicOfferingMember" xml:lang="en-US">Public Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PublicOfferingMember" xml:lang="en-US">Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PublicOfferingMember" xlink:to="lab_bvs_PublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PublicOfferingMember" xml:lang="en-US">Public Offering</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xml:lang="en-US">Accumulated other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Non- controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MemberUnitsMember" xml:lang="en-US">Member Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MemberUnitsMember" xml:lang="en-US">Members' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MemberUnitsMember" xlink:to="lab_us-gaap_MemberUnitsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In -Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:label="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xml:lang="en-US">Increase (Decrease) In Stockholders' Equity And Members' Equity [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:to="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xml:lang="en-US">Increase (Decrease) In Stockholders' Equity And Members' Equity</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromEquityForfeitures" xlink:label="loc_bvs_MembersEquityDecreaseFromEquityForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MembersEquityDecreaseFromEquityForfeitures" xml:lang="en-US">Members' Equity, Decrease From Equity Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_MembersEquityDecreaseFromEquityForfeitures" xml:lang="en-US">Other equity forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MembersEquityDecreaseFromEquityForfeitures" xlink:to="lab_bvs_MembersEquityDecreaseFromEquityForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MembersEquityDecreaseFromEquityForfeitures" xml:lang="en-US">Members' Equity, Decrease From Equity Forfeitures</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromProfitInterestForfeiture" xlink:label="loc_bvs_MembersEquityDecreaseFromProfitInterestForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MembersEquityDecreaseFromProfitInterestForfeiture" xml:lang="en-US">Members' Equity, Decrease From Profit Interest Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_MembersEquityDecreaseFromProfitInterestForfeiture" xml:lang="en-US">Profits interest forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MembersEquityDecreaseFromProfitInterestForfeiture" xlink:to="lab_bvs_MembersEquityDecreaseFromProfitInterestForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MembersEquityDecreaseFromProfitInterestForfeiture" xml:lang="en-US">Members' Equity, Decrease From Profit Interest Forfeiture</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityIncreaseFromRefundsFromMembers" xlink:label="loc_bvs_MembersEquityIncreaseFromRefundsFromMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MembersEquityIncreaseFromRefundsFromMembers" xml:lang="en-US">Members' Equity, Increase From Refunds From Members'</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_MembersEquityIncreaseFromRefundsFromMembers" xml:lang="en-US">Refund from members</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MembersEquityIncreaseFromRefundsFromMembers" xlink:to="lab_bvs_MembersEquityIncreaseFromRefundsFromMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MembersEquityIncreaseFromRefundsFromMembers" xml:lang="en-US">Members' Equity, Increase From Refunds From Members'</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US">Debt conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromDistributionToMembers" xlink:label="loc_bvs_MembersEquityDecreaseFromDistributionToMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MembersEquityDecreaseFromDistributionToMembers" xml:lang="en-US">Members' Equity, Decrease From Distribution To Members</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_MembersEquityDecreaseFromDistributionToMembers" xml:lang="en-US">Distribution to members</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MembersEquityDecreaseFromDistributionToMembers" xlink:to="lab_bvs_MembersEquityDecreaseFromDistributionToMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MembersEquityDecreaseFromDistributionToMembers" xml:lang="en-US">Members' Equity, Decrease From Distribution To Members</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ending balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xml:lang="en-US">Distribution of Continuing LLC Owner</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" xlink:label="loc_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" xml:lang="en-US">Noncontrolling Interest, Increase From Deconsolidation Of Variable Interest Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" xml:lang="en-US">Deconsolidation of variable interest entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" xlink:to="lab_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" xml:lang="en-US">Noncontrolling Interest, Increase From Deconsolidation Of Variable Interest Entity</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Equity based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Defined benefit plan adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Cumulative Foreign Currency Transaction And Translation Adjustment, Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Cumulative Foreign Currency Transaction And Translation Adjustment, Net Of Tax</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityChangeInReportingEntity" xlink:label="loc_us-gaap_StockholdersEquityChangeInReportingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityChangeInReportingEntity" xml:lang="en-US">Stockholders' Equity, Change in Reporting Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityChangeInReportingEntity" xml:lang="en-US">Effect of Organizational Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityChangeInReportingEntity" xlink:to="lab_us-gaap_StockholdersEquityChangeInReportingEntity" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_StockholdersEquitySharesChangeInReportingEntity" xlink:label="loc_bvs_StockholdersEquitySharesChangeInReportingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_StockholdersEquitySharesChangeInReportingEntity" xml:lang="en-US">Stockholders' Equity, Shares, Change In Reporting Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_StockholdersEquitySharesChangeInReportingEntity" xml:lang="en-US">Effect of Organizational Transactions (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_StockholdersEquitySharesChangeInReportingEntity" xlink:to="lab_bvs_StockholdersEquitySharesChangeInReportingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_StockholdersEquitySharesChangeInReportingEntity" xml:lang="en-US">Stockholders' Equity, Shares, Change In Reporting Entity</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetLossSubsequentToOrganizationalTransactions" xlink:label="loc_bvs_NetLossSubsequentToOrganizationalTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_NetLossSubsequentToOrganizationalTransactions" xml:lang="en-US">Net Loss Subsequent To Organizational Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_NetLossSubsequentToOrganizationalTransactions" xml:lang="en-US">Net loss subsequent to Organizational Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NetLossSubsequentToOrganizationalTransactions" xlink:to="lab_bvs_NetLossSubsequentToOrganizationalTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_NetLossSubsequentToOrganizationalTransactions" xml:lang="en-US">Net loss subsequent to Organizational Transactions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xml:lang="en-US">Acquisition of noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Initial public offering, net of offering costs (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during period shares new issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock shares issued during the period shares new issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Initial public offering, net of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued during period value new issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities from continuing operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">(Recovery) provision for expected credit losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for expected credit losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Recovery (provision)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Equity-based compensation from 2021 Stock Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xlink:label="loc_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xml:lang="en-US">Profits Interest Plan, Liability Classified And Other Equity Awards Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xml:lang="en-US">Profits interest plan, liability-classified and other equity awards compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xlink:to="lab_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xml:lang="en-US">Profits Interest Plan, Liability Classified And Other Equity Awards Compensation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Change in fair value of interest rate swap</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ChangeInFairValueOfEquityParticipationRightsUnit" xlink:label="loc_bvs_ChangeInFairValueOfEquityParticipationRightsUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ChangeInFairValueOfEquityParticipationRightsUnit" xml:lang="en-US">Change In Fair Value Of Equity Participation Rights Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_ChangeInFairValueOfEquityParticipationRightsUnit" xml:lang="en-US">Change in fair value of Equity Participation Rights unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ChangeInFairValueOfEquityParticipationRightsUnit" xlink:to="lab_bvs_ChangeInFairValueOfEquityParticipationRightsUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ChangeInFairValueOfEquityParticipationRightsUnit" xml:lang="en-US">Change In Fair Value Of Equity Participation Rights Unit</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" xlink:label="loc_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" xml:lang="en-US">Impairment Of Variable Interest Entity And Related Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" xml:lang="en-US">Impairments related to variable interest entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" xlink:to="lab_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" xml:lang="en-US">Impairment Of Variable Interest Entity And Related Assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xml:lang="en-US">Increase (Decrease) in Other Current Assets and Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xml:lang="en-US">Other current assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash used in operating activities of discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by operating activities from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetRetirementObligationAccretionExpense" xml:lang="en-US">Asset Retirement Obligation, Accretion Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetRetirementObligationAccretionExpense" xml:lang="en-US">Loss on debt retirement and modification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationAccretionExpense" xlink:to="lab_us-gaap_AssetRetirementObligationAccretionExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xml:lang="en-US">Payment of contingent consideration in excess of amount established in purchase accounting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of debt discount and capitalized loan fees, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Purchase of Bioness, Inc, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash from investing activities - discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestmentAndAcquisitionOfDistributionRights" xlink:label="loc_bvs_InvestmentAndAcquisitionOfDistributionRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InvestmentAndAcquisitionOfDistributionRights" xml:lang="en-US">Investment And Acquisition Of Distribution Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_InvestmentAndAcquisitionOfDistributionRights" xml:lang="en-US">Investment and acquisition of distribution rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InvestmentAndAcquisitionOfDistributionRights" xlink:to="lab_bvs_InvestmentAndAcquisitionOfDistributionRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InvestmentAndAcquisitionOfDistributionRights" xml:lang="en-US">Investment and acquisition of distribution rights.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AcquisitionOfVariableInterestEntity" xlink:label="loc_bvs_AcquisitionOfVariableInterestEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AcquisitionOfVariableInterestEntity" xml:lang="en-US">Acquisition of Variable Interest Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_AcquisitionOfVariableInterestEntity" xml:lang="en-US">Acquisition of VIE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AcquisitionOfVariableInterestEntity" xlink:to="lab_bvs_AcquisitionOfVariableInterestEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AcquisitionOfVariableInterestEntity" xml:lang="en-US">Acquisition of variable interest entity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US">Other, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from issuance of Class A common stock sold in initial public offering, net of underwriting discounts and offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of Class A and B common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xml:lang="en-US">Proceeds from Long-term Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xml:lang="en-US">Borrowing on revolver</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayments of Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Payments on long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromMembers" xlink:label="loc_bvs_ProceedsFromMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProceedsFromMembers" xml:lang="en-US">Proceeds From Members</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ProceedsFromMembers" xml:lang="en-US">Refunds (distributions) - members</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProceedsFromMembers" xlink:to="lab_bvs_ProceedsFromMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProceedsFromMembers" xml:lang="en-US">Proceeds From Members</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xml:lang="en-US">Repayments of Long-term Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xml:lang="en-US">Payment on revolver</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US">Proceeds from the issuance of long-term debt, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberDistributionsIncurredButNotYetPaid" xlink:label="loc_bvs_MemberDistributionsIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MemberDistributionsIncurredButNotYetPaid" xml:lang="en-US">Member Distributions Incurred But Not Yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_MemberDistributionsIncurredButNotYetPaid" xml:lang="en-US">Accrued member distributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MemberDistributionsIncurredButNotYetPaid" xlink:to="lab_bvs_MemberDistributionsIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MemberDistributionsIncurredButNotYetPaid" xml:lang="en-US">Member Distributions Incurred But Not Yet Paid</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Accounts payable for purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Accrued liabilities for distribution rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Debt conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of exchange rate changes on cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:label="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SupplementalDisclosureOfCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SupplementalDisclosureOfCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="lab_bvs_SupplementalDisclosureOfCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xml:lang="en-US">Schedule of Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xml:lang="en-US">Schedule of Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Balance sheet information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" xlink:label="loc_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" xml:lang="en-US">Business Combinations And Investments Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" xml:lang="en-US">Business combinations and investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" xlink:to="lab_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" xml:lang="en-US">Business combinations and investments disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair value measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Equity-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetIncomeLossPerUnitTextBlock" xlink:label="loc_bvs_NetIncomeLossPerUnitTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_NetIncomeLossPerUnitTextBlock" xml:lang="en-US">Net Income Loss Per Unit [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_NetIncomeLossPerUnitTextBlock" xml:lang="en-US">Net income (loss) per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NetIncomeLossPerUnitTextBlock" xlink:to="lab_bvs_NetIncomeLossPerUnitTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_NetIncomeLossPerUnitTextBlock" xml:lang="en-US">Net income (loss) per unit [Text Block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">Restructuring and Related Activities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MembersEquityAbstract" xml:lang="en-US">Members' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersEquityAbstract" xlink:to="lab_us-gaap_MembersEquityAbstract" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MemberEquityTable" xml:lang="en-US">Member Equity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MemberEquityTable" xlink:to="lab_bvs_MemberEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MemberEquityTable" xml:lang="en-US">Member equity.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MemberEquityLineItems" xml:lang="en-US">Member Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MemberEquityLineItems" xlink:to="lab_bvs_MemberEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MemberEquityLineItems" xml:lang="en-US">Member equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:label="loc_us-gaap_MembersEquityNotesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MembersEquityNotesDisclosureTextBlock" xml:lang="en-US">Members' Equity Notes Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MembersEquityNotesDisclosureTextBlock" xml:lang="en-US">Members' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:to="lab_us-gaap_MembersEquityNotesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related-party transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetSalesTextBlock" xlink:label="loc_bvs_NetSalesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_NetSalesTextBlock" xml:lang="en-US">Net Sales [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_NetSalesTextBlock" xml:lang="en-US">Net Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NetSalesTextBlock" xlink:to="lab_bvs_NetSalesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_NetSalesTextBlock" xml:lang="en-US">Net sales [Text Block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Variable Interest Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NonControllingInterestPolicyTextBlock" xlink:label="loc_bvs_NonControllingInterestPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_NonControllingInterestPolicyTextBlock" xml:lang="en-US">Non Controlling Interest [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_NonControllingInterestPolicyTextBlock" xml:lang="en-US">Noncontrolling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NonControllingInterestPolicyTextBlock" xlink:to="lab_bvs_NonControllingInterestPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_NonControllingInterestPolicyTextBlock" xml:lang="en-US">Non controlling interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Effect of foreign currency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractAssetsPolicyTextBlock" xlink:label="loc_bvs_ContractAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ContractAssetsPolicyTextBlock" xml:lang="en-US">Contract Assets [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ContractAssetsPolicyTextBlock" xml:lang="en-US">Contract assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ContractAssetsPolicyTextBlock" xlink:to="lab_bvs_ContractAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ContractAssetsPolicyTextBlock" xml:lang="en-US">Contract assets.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractLiabilitiesPolicyTextBlock" xlink:label="loc_bvs_ContractLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ContractLiabilitiesPolicyTextBlock" xml:lang="en-US">Contract Liabilities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ContractLiabilitiesPolicyTextBlock" xml:lang="en-US">Contract liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ContractLiabilitiesPolicyTextBlock" xlink:to="lab_bvs_ContractLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ContractLiabilitiesPolicyTextBlock" xml:lang="en-US">Contract liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xml:lang="en-US">Shipping and handling</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractCostsPolicyTextBlock" xlink:label="loc_bvs_ContractCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ContractCostsPolicyTextBlock" xml:lang="en-US">Contract Costs [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ContractCostsPolicyTextBlock" xml:lang="en-US">Contract costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ContractCostsPolicyTextBlock" xlink:to="lab_bvs_ContractCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ContractCostsPolicyTextBlock" xml:lang="en-US">Contract costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xml:lang="en-US">Deconsolidation and discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xml:lang="en-US">Software development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">Acquired in-process research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xml:lang="en-US">Deferred Policy Acquisition Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xml:lang="en-US">Deferred Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="lab_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business combinations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xml:lang="en-US">Collaborative agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net income (loss) per common unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xml:lang="en-US">Restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Profits interest compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Summary of Finite-lived intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Property Plant And Equipment Useful Lives [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Summary of useful lives in assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="lab_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Property plant and equipment useful lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Summary of significant percentage of total sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BioventusIncMember" xml:lang="en-US">Bioventus, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BioventusIncMember" xml:lang="en-US">Bio Ventus LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BioventusIncMember" xlink:to="lab_bvs_BioventusIncMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Summary of restructuring charges and payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfMembersEquityTableTextBlock" xlink:label="loc_bvs_ScheduleOfMembersEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ScheduleOfMembersEquityTableTextBlock" xml:lang="en-US">Schedule Of Members Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ScheduleOfMembersEquityTableTextBlock" xml:lang="en-US">Summary of Members Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ScheduleOfMembersEquityTableTextBlock" xlink:to="lab_bvs_ScheduleOfMembersEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ScheduleOfMembersEquityTableTextBlock" xml:lang="en-US">Schedule of members equity.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" xlink:label="loc_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" xml:lang="en-US">Disaggregation Of Revenue Based On Geography [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" xml:lang="en-US">Disaggregated By Geographic Markets And Major Products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" xlink:to="lab_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" xml:lang="en-US">Disaggregation Of Revenue Based On Geography.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" xml:lang="en-US">Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" xml:lang="en-US">Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" xlink:to="lab_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" xml:lang="en-US">Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US">Schedule Of Reconciliation Of Operating Profit (Loss) From Segments To Consolidated</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xml:lang="en-US">Schedule of Assets and Liabilities, Lessee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xml:lang="en-US">Assets And Liabilities, Lessee</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Schedule of Lease, Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of lessee liability maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xml:lang="en-US">Schedule of Restrictions on Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xml:lang="en-US">Summary of Accounts Receivable, Allowance for Credit Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfInventoryValuationReservesTableTextBlock" xlink:label="loc_bvs_ScheduleOfInventoryValuationReservesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ScheduleOfInventoryValuationReservesTableTextBlock" xml:lang="en-US">Schedule Of Inventory Valuation Reserves [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ScheduleOfInventoryValuationReservesTableTextBlock" xml:lang="en-US">Schedule Of Inventory Valuation Reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ScheduleOfInventoryValuationReservesTableTextBlock" xlink:to="lab_bvs_ScheduleOfInventoryValuationReservesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ScheduleOfInventoryValuationReservesTableTextBlock" xml:lang="en-US">Schedule of inventory valuation reserves.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xml:lang="en-US">Schedule of Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" xml:lang="en-US">Schedule Of Intangible Assets Net Excluding Goodwill [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" xml:lang="en-US">Schedule Of Intangible Assets Net Excluding Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" xlink:to="lab_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" xml:lang="en-US">Schedule of intangible assets net excluding goodwil.l</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xml:lang="en-US">Business Acquisition, Pro Forma Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xml:lang="en-US">Schedule of Variable Interest Entities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Schedule of Long-term Debt Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" xlink:label="loc_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" xml:lang="en-US">Schedule of Debt Instruments Periodic Payments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" xml:lang="en-US">Summary of Debt Instruments Periodic Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" xlink:to="lab_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" xml:lang="en-US">Schedule of debt instruments periodic payments.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" xlink:label="loc_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" xml:lang="en-US">Schedule of Commitment Fee Adjusted Based on Pricing Grid [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" xml:lang="en-US">Schedule of Commitment Fee Adjusted Based on Pricing Grid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" xlink:to="lab_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" xml:lang="en-US">Schedule of commitment fee adjusted based on pricing grid.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" xlink:label="loc_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" xml:lang="en-US">Schedule of Loan margin Adjusted on Pricing Grid [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" xml:lang="en-US">Schedule of Loan margin Adusted on Pricing Grid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" xlink:to="lab_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" xml:lang="en-US">Schedule of loan margin adjusted on pricing grid.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Summary of Contractual maturities of long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of Liabilities Measured At Fair Value on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of range of key assumptions used within the valuation of the awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityParticipationRightUnitMember" xml:lang="en-US">Equity Participation Right Unit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EquityParticipationRightUnitMember" xml:lang="en-US">Equity Participation Right Unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityParticipationRightUnitMember" xlink:to="lab_bvs_EquityParticipationRightUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityParticipationRightUnitMember" xml:lang="en-US">Equity Participation Right Unit</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherPhantomUnitMember" xlink:label="loc_bvs_OtherPhantomUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_OtherPhantomUnitMember" xml:lang="en-US">Other Phantom Unit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_OtherPhantomUnitMember" xlink:to="lab_bvs_OtherPhantomUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_OtherPhantomUnitMember" xml:lang="en-US">Other phantom unit.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" xlink:label="loc_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" xml:lang="en-US">Share Based Compensation Phantom Plan Shares Award Unvested Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" xml:lang="en-US">Summary of Phantom Plan Award activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" xml:lang="en-US">Share based compensation phantom plan shares award unvested activity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Stock Options Roll Forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeTaxDisclosureTable" xlink:label="loc_bvs_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_IncomeTaxDisclosureTable" xlink:to="lab_bvs_IncomeTaxDisclosureTable" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeTaxDisclosureLineItems" xlink:label="loc_bvs_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems" xlink:to="lab_bvs_IncomeTaxDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Summary of net income from continuing operations before taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Summary Of Components Of Income Tax Expense Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Summary of Effective Income Tax Rate Reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary of Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCMember" xlink:label="loc_bvs_BVLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BVLLCMember" xml:lang="en-US">BV LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BVLLCMember" xml:lang="en-US">BV LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BVLLCMember" xlink:to="lab_bvs_BVLLCMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Price per share in public offering (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Proceeds from public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of underwriting discounts and commissions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SaleOfStockOfferingCosts" xlink:label="loc_bvs_SaleOfStockOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SaleOfStockOfferingCosts" xml:lang="en-US">Sale Of Stock, Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SaleOfStockOfferingCosts" xml:lang="en-US">Sale of stock, offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SaleOfStockOfferingCosts" xlink:to="lab_bvs_SaleOfStockOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SaleOfStockOfferingCosts" xml:lang="en-US">Sale Of Stock, Offering Costs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling interest, ownership percentage by noncontrolling owners</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityNumberOfEmployees" xlink:label="loc_dei_EntityNumberOfEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityNumberOfEmployees" xml:lang="en-US">Entity Number of Employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityNumberOfEmployees" xml:lang="en-US">Number of employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xml:lang="en-US">Cancellation Ratio, Required Stock To LLC Interest Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xml:lang="en-US">Cancellation ratio, required stock to LLC interest ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:to="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CancellationRatioRequiredStockToLLCInterestRatio" xml:lang="en-US">Cancellation ratio, required stock to LLC interest ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xml:lang="en-US">Number of Businesses Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xml:lang="en-US">Number of entities acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Number of shares issued in acquisition (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Number of shares issued in public offering (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" xlink:label="loc_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" xml:lang="en-US">Payments Of Stock Issuance Costs, Additional Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" xml:lang="en-US">Payment of offering expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" xlink:to="lab_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" xml:lang="en-US">Payments Of Stock Issuance Costs, Additional Costs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xml:lang="en-US">Number of shares cancelled (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromGovernmentalAssistance" xlink:label="loc_bvs_ProceedsFromGovernmentalAssistance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProceedsFromGovernmentalAssistance" xml:lang="en-US">Proceeds From Governmental Assistance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ProceedsFromGovernmentalAssistance" xml:lang="en-US">Cash received from provident relief fund</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProceedsFromGovernmentalAssistance" xlink:to="lab_bvs_ProceedsFromGovernmentalAssistance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProceedsFromGovernmentalAssistance" xml:lang="en-US">Proceeds from governmental assistance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" xml:lang="en-US">Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" xml:lang="en-US">Managing member, ownership interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonStockNumberOfVotes" xlink:label="loc_bvs_CommonStockNumberOfVotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CommonStockNumberOfVotes" xml:lang="en-US">Common Stock, Number Of Votes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_CommonStockNumberOfVotes" xml:lang="en-US">Number of votes per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CommonStockNumberOfVotes" xlink:to="lab_bvs_CommonStockNumberOfVotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CommonStockNumberOfVotes" xml:lang="en-US">Common stock, number of votes.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xml:lang="en-US">Shares Issued Or Issuable, Required Stock To LLC Interest Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xml:lang="en-US">Shares issued or issuable, required stock to LLC interest ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:to="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xml:lang="en-US">Shares issued or issuable, required stock to LLC interest ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xml:lang="en-US">Accrued Payroll Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xml:lang="en-US">Employer social security payroll tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfDeferredPayrollTax" xlink:label="loc_bvs_PercentageOfDeferredPayrollTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PercentageOfDeferredPayrollTax" xml:lang="en-US">Percentage Of Deferred Payroll Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_PercentageOfDeferredPayrollTax" xml:lang="en-US">Percentage of deferred payroll tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PercentageOfDeferredPayrollTax" xlink:to="lab_bvs_PercentageOfDeferredPayrollTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PercentageOfDeferredPayrollTax" xml:lang="en-US">Percentage of deferred payroll tax.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:label="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xml:lang="en-US">Limited Liability Company LLC Or Limited Partnership LP Managing Member Or General Partner Number Of Interests Held</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xml:lang="en-US">Number of LLC interest held (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:to="lab_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xml:lang="en-US">Limited liability company LLC or limited partnership LP managing member or general partner number of interests held.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Less: Allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xml:lang="en-US">Write-offs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xml:lang="en-US">Recoveries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies" xml:lang="en-US">Raw materials and supplies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSupplies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryGross" xml:lang="en-US">Inventory, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryGross" xml:lang="en-US">Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryValuationReserves" xml:lang="en-US">Inventory Valuation Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_InventoryValuationReserves" xml:lang="en-US">Excess and obsolete reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_InventoryValuationReserves" xml:lang="en-US">Balance, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_InventoryValuationReserves" xml:lang="en-US">Balance, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_GrossToNetDeductionsCurrent" xlink:label="loc_bvs_GrossToNetDeductionsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_GrossToNetDeductionsCurrent" xml:lang="en-US">Gross-To-Net Deductions, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_GrossToNetDeductionsCurrent" xml:lang="en-US">Gross-to-net deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_GrossToNetDeductionsCurrent" xlink:to="lab_bvs_GrossToNetDeductionsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_GrossToNetDeductionsCurrent" xml:lang="en-US">Gross-To-Net Deductions, Current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Accrued Bonuses, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Bonus and commission</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xml:lang="en-US">Accrued Salaries And Employee Benefits, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xml:lang="en-US">Compensation and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:to="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xml:lang="en-US">Accrued Salaries And Employee Benefits, Current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Taxes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Income and other taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" xlink:label="loc_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" xml:lang="en-US">Reserve For Estimated Overpayments From Third Party Payers Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" xml:lang="en-US">Reserve for estimated overpayments from third-party payers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" xlink:to="lab_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" xml:lang="en-US">Reserve for estimated overpayments from third party payers current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xml:lang="en-US">Restructuring Reserve, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xml:lang="en-US">Restructuring reserve, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments for Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments for restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments made</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xml:lang="en-US">Goodwill, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xml:lang="en-US">Goodwill, Increase (Decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite-lived Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite lived intangible assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired finite lived intangible assets, Weighted average useful life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Useful Life (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AmortizationExpenseIncludedInInventory" xlink:label="loc_bvs_AmortizationExpenseIncludedInInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AmortizationExpenseIncludedInInventory" xml:lang="en-US">Amortization Expense Included In Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_AmortizationExpenseIncludedInInventory" xml:lang="en-US">Amortization expense included in inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AmortizationExpenseIncludedInInventory" xlink:to="lab_bvs_AmortizationExpenseIncludedInInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AmortizationExpenseIncludedInInventory" xml:lang="en-US">Amortization expense included in inventory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Expected future amortization, year one</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Expected future amortization, year two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Expected future amortization, year three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Expected future amortization, year four</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Expected future amortization, year five</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventAxis" xlink:label="loc_bvs_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EventAxis" xlink:to="lab_bvs_EventAxis" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventDomain" xlink:label="loc_bvs_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EventDomain" xlink:to="lab_bvs_EventDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ReclassificationOfIprdMember" xlink:label="loc_bvs_ReclassificationOfIprdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ReclassificationOfIprdMember" xml:lang="en-US">Reclassification Of IPRD [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ReclassificationOfIprdMember" xml:lang="en-US">Reclassification Of IPRD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ReclassificationOfIprdMember" xlink:to="lab_bvs_ReclassificationOfIprdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ReclassificationOfIprdMember" xml:lang="en-US">Reclassification of IPR&amp;D [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xml:lang="en-US">Developed Technology Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xml:lang="en-US">Developed Technology Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DistributionRightsMember" xml:lang="en-US">Distribution Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DistributionRightsMember" xml:lang="en-US">Distribution rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember" xlink:to="lab_us-gaap_DistributionRightsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableMember" xml:lang="en-US">Accounts Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableMember" xml:lang="en-US">Accounts Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryAdjustmentsAbstract" xlink:label="loc_us-gaap_InventoryAdjustmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryAdjustmentsAbstract" xml:lang="en-US">Inventory Adjustments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryAdjustmentsAbstract" xlink:to="lab_us-gaap_InventoryAdjustmentsAbstract" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryValuationReservesProvisionForLosses" xlink:label="loc_bvs_InventoryValuationReservesProvisionForLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InventoryValuationReservesProvisionForLosses" xml:lang="en-US">Inventory Valuation Reserves Provision For Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_InventoryValuationReservesProvisionForLosses" xml:lang="en-US">Provision for losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InventoryValuationReservesProvisionForLosses" xlink:to="lab_bvs_InventoryValuationReservesProvisionForLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InventoryValuationReservesProvisionForLosses" xml:lang="en-US">Inventory valuation reserves provision for losses.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryValuationReservesWriteOffs" xlink:label="loc_bvs_InventoryValuationReservesWriteOffs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InventoryValuationReservesWriteOffs" xml:lang="en-US">Inventory Valuation Reserves Write Offs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_InventoryValuationReservesWriteOffs" xml:lang="en-US">Write-offs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InventoryValuationReservesWriteOffs" xlink:to="lab_bvs_InventoryValuationReservesWriteOffs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InventoryValuationReservesWriteOffs" xml:lang="en-US">Inventory valuation reserves write offs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ComputerEquipmentAndSoftwareMember" xlink:label="loc_bvs_ComputerEquipmentAndSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ComputerEquipmentAndSoftwareMember" xml:lang="en-US">Computer Equipment And Software [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ComputerEquipmentAndSoftwareMember" xml:lang="en-US">Computer equipment and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ComputerEquipmentAndSoftwareMember" xlink:to="lab_bvs_ComputerEquipmentAndSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ComputerEquipmentAndSoftwareMember" xml:lang="en-US">Computer equipment and software [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="loc_us-gaap_AssetUnderConstructionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xml:lang="en-US">Asset under Construction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xml:lang="en-US">Assets not yet placed in service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetUnderConstructionMember" xlink:to="lab_us-gaap_AssetUnderConstructionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xml:lang="en-US">Schedule of Goodwill [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InternationalSegmentMember" xlink:label="loc_bvs_InternationalSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InternationalSegmentMember" xml:lang="en-US">International Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_InternationalSegmentMember" xml:lang="en-US">International Segment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_InternationalSegmentMember" xml:lang="en-US">International</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InternationalSegmentMember" xlink:to="lab_bvs_InternationalSegmentMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_USSegmentMember" xlink:label="loc_bvs_USSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_USSegmentMember" xml:lang="en-US">U.S. Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_USSegmentMember" xml:lang="en-US">U.S</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_USSegmentMember" xlink:to="lab_bvs_USSegmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillLineItems" xml:lang="en-US">Goodwill [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsAxis" xml:lang="en-US">Consolidation Items [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidationItemsAxis" xml:lang="en-US">Consolidation Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsDomain" xml:lang="en-US">Consolidation Items [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidationItemsDomain" xml:lang="en-US">Consolidation Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingSegmentsMember" xml:lang="en-US">Operating Segments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingSegmentsMember" xml:lang="en-US">Operating Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" xml:lang="en-US">Schedule Of Intangible Assets Net Excluding Goodwill [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" xlink:to="lab_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual property</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember" xlink:to="lab_us-gaap_IntellectualPropertyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Technology-Based Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Developed technology and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xml:lang="en-US">Customer Relationships [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xml:lang="en-US">Customer relationships</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" xml:lang="en-US">Schedule Of Intangible Assets Net Excluding Goodwill [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" xlink:to="lab_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" xml:lang="en-US">Less accumulated amortization:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" xlink:to="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" xlink:label="loc_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" xml:lang="en-US">Intangible Assets Net Excluding Goodwill Before Currency Translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" xml:lang="en-US">IntangibleAssets, net before currency translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" xlink:to="lab_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" xml:lang="en-US">Intangible assets net excluding goodwill before currency translation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" xml:lang="en-US">Finite Lived Intangible Assets, Currency Translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" xml:lang="en-US">Currency translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" xlink:to="lab_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" xml:lang="en-US">Finite Lived Intangible Assets, Currency Translation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Total carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AcquiredInProcessResearchAndDevelopmentMember" xlink:label="loc_bvs_AcquiredInProcessResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AcquiredInProcessResearchAndDevelopmentMember" xml:lang="en-US">Acquired In Process Research And Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_AcquiredInProcessResearchAndDevelopmentMember" xml:lang="en-US">IPR&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AcquiredInProcessResearchAndDevelopmentMember" xlink:to="lab_bvs_AcquiredInProcessResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AcquiredInProcessResearchAndDevelopmentMember" xml:lang="en-US">AcquiredIn process research and development [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BionessIncMember" xml:lang="en-US">Bioness, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BionessIncMember" xml:lang="en-US">Bioness, Inc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BionessIncMember" xlink:to="lab_bvs_BionessIncMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CartiHealMember" xlink:label="loc_bvs_CartiHealMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CartiHealMember" xml:lang="en-US">Carti Heal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_CartiHealMember" xml:lang="en-US">CartiHeal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CartiHealMember" xlink:to="lab_bvs_CartiHealMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VaporoxMember" xlink:label="loc_bvs_VaporoxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_VaporoxMember" xml:lang="en-US">Vaporox [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_VaporoxMember" xml:lang="en-US">Vaporox</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_VaporoxMember" xlink:to="lab_bvs_VaporoxMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CartiHealLtdMember" xlink:label="loc_bvs_CartiHealLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CartiHealLtdMember" xml:lang="en-US">Carti Heal Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_CartiHealLtdMember" xml:lang="en-US">CartiHeal Ltd</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CartiHealLtdMember" xlink:to="lab_bvs_CartiHealLtdMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xml:lang="en-US">Contingent Consideration by Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xml:lang="en-US">Contingent Consideration by Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" xlink:label="loc_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" xml:lang="en-US">For Obtaining CMS Coverage And Reimbursement For Certain Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" xml:lang="en-US">For Obtaining CMS Coverage And Reimbursement For Certain Products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" xlink:to="lab_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ObtainingFDAApprovalOfCertainProductsMember" xlink:label="loc_bvs_ObtainingFDAApprovalOfCertainProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ObtainingFDAApprovalOfCertainProductsMember" xml:lang="en-US">Obtaining FDA Approval Of Certain Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ObtainingFDAApprovalOfCertainProductsMember" xml:lang="en-US">Obtaining FDA Approval Of Certain Products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ObtainingFDAApprovalOfCertainProductsMember" xlink:to="lab_bvs_ObtainingFDAApprovalOfCertainProductsMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" xlink:label="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" xml:lang="en-US">Meeting Net Sales Targets Over A Three-Year Period, Payment One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" xml:lang="en-US">Meeting Net Sales Targets Over A Three-Year Period, Payment One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" xlink:to="lab_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" xlink:label="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" xml:lang="en-US">Meeting Net Sales Targets Over A Three-Year Period, Payment Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" xml:lang="en-US">Meeting Net Sales Targets Over A Three-Year Period, Payment Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" xlink:to="lab_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Percentage of business acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Contingent consideration at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US">Expected future amortization, remainder of fiscal year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xml:lang="en-US">Variable interest entity, ownership percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xml:lang="en-US">Variable interest entity, ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" xlink:label="loc_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" xml:lang="en-US">Asset Impairment Charges, Attributable To Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" xml:lang="en-US">Impairment of variable interest entity assets, attributable to noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" xlink:to="lab_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" xml:lang="en-US">Asset impairment charges, attributable to noncontrolling interest.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntityImpairment" xlink:label="loc_bvs_VariableInterestEntityImpairment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_VariableInterestEntityImpairment" xml:lang="en-US">Variable Interest Entity, Impairment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_VariableInterestEntityImpairment" xml:lang="en-US">Impairment of variable interest entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_VariableInterestEntityImpairment" xlink:to="lab_bvs_VariableInterestEntityImpairment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_VariableInterestEntityImpairment" xml:lang="en-US">Variable interest entity, impairment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity method investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity method investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US">Business Combination, Acquisition Related Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US">Acquisition costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US">Acquisition and integration costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xml:lang="en-US">Revenue of acquiree since acquisition date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xml:lang="en-US">Business Combination, Integration Related Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xml:lang="en-US">Acquisition integration costs and inventory related adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xlink:label="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xml:lang="en-US">Equity Method Investment, Period After FDA Approval For Investor To Purchase Remaining Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xml:lang="en-US">Period after FDA approval for which company may exercise option to purchase remaining equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xml:lang="en-US">Period after FDA approval for which company may exercise option to purchase remaining equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xlink:to="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xml:lang="en-US">Equity method investment, period after FDA approval for investor to purchase remaining investment.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xlink:label="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xml:lang="en-US">Equity Method Investment, Period After FDA Approval For Investee To Exercise Option For Remaining Equity To Be Purchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xml:lang="en-US">Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xml:lang="en-US">Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xlink:to="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xml:lang="en-US">Equity method investment, period after FDA approval for investee to exercise option for remaining equity to be purchased.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionPeriodOfNoticeForTermination" xlink:label="loc_bvs_BusinessAcquisitionPeriodOfNoticeForTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessAcquisitionPeriodOfNoticeForTermination" xml:lang="en-US">Business Acquisition, Period Of Notice For Termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessAcquisitionPeriodOfNoticeForTermination" xml:lang="en-US">Period after receipt of statistical report for which the company may terminate agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessAcquisitionPeriodOfNoticeForTermination" xlink:to="lab_bvs_BusinessAcquisitionPeriodOfNoticeForTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessAcquisitionPeriodOfNoticeForTermination" xml:lang="en-US">Business acquisition, period of notice for termination.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" xlink:label="loc_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" xml:lang="en-US">Business Acquisition, Payment Due Upon Termination Of Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" xml:lang="en-US">Payment due upon termination of agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" xlink:to="lab_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" xml:lang="en-US">Business acquisition, payment due upon termination of agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EscrowDeposit" xml:lang="en-US">Escrow Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EscrowDeposit" xml:lang="en-US">Escrow deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method investment, ownership percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method investment ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (loss) from equity method investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Net losses from equity method investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Equity loss in unconsolidated investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xml:lang="en-US">Equity Method Investment, Additional Investment To Be Purchased Upon Completion Of Study, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xml:lang="en-US">Additional shares to be purchased upon completion of study (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xml:lang="en-US">Additional shares to be purchased upon completion of study (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xlink:to="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xml:lang="en-US">Equity method investment, additional investment to be purchased upon completion of study, shares.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xml:lang="en-US">Equity Method Investment, Additional Investment To Be Purchased Upon Completion Of Study, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xml:lang="en-US">Additional investment to be purchased upon completion of study</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xml:lang="en-US">Additional investment to be purchased upon completion of study</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xlink:to="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xml:lang="en-US">Equity method investment, additional investment to be purchased upon completion of study, amount.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" xml:lang="en-US">Business Combination, Consideration Transferred Upon Achievement Of Certain Sales Milestones</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" xml:lang="en-US">Consideration transferred upon achievement of certain sales milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" xlink:to="lab_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" xml:lang="en-US">Business combination, consideration transferred upon achievement of certain sales milestones.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Consideration payable upon closing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Fair value of consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestmentOwnedOwnershipPercentage" xlink:label="loc_bvs_InvestmentOwnedOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InvestmentOwnedOwnershipPercentage" xml:lang="en-US">Investment Owned, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_InvestmentOwnedOwnershipPercentage" xml:lang="en-US">Investment owned, ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InvestmentOwnedOwnershipPercentage" xlink:to="lab_bvs_InvestmentOwnedOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InvestmentOwnedOwnershipPercentage" xml:lang="en-US">Investment owned, ownership percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xml:lang="en-US">Investment Owned, at Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xml:lang="en-US">Investment owned, cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xml:lang="en-US">Investment Owned, Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xml:lang="en-US">Investment owned, balance, shares (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntitySharesIssuedDuringPeriod" xlink:label="loc_bvs_VariableInterestEntitySharesIssuedDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_VariableInterestEntitySharesIssuedDuringPeriod" xml:lang="en-US">Variable Interest Entity Shares Issued During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_VariableInterestEntitySharesIssuedDuringPeriod" xml:lang="en-US">Variable interest entity shares purchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_VariableInterestEntitySharesIssuedDuringPeriod" xlink:to="lab_bvs_VariableInterestEntitySharesIssuedDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_VariableInterestEntitySharesIssuedDuringPeriod" xml:lang="en-US">Variable interest entity shares issued during period.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntityIssuedCost" xlink:label="loc_bvs_VariableInterestEntityIssuedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_VariableInterestEntityIssuedCost" xml:lang="en-US">Variable Interest Entity Issued Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_VariableInterestEntityIssuedCost" xml:lang="en-US">Variable interest entity cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_VariableInterestEntityIssuedCost" xlink:to="lab_bvs_VariableInterestEntityIssuedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_VariableInterestEntityIssuedCost" xml:lang="en-US">Variable interest entity issued cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt conversion converted instrument amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xml:lang="en-US">Intangible assets fair value disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" xlink:label="loc_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" xml:lang="en-US">Debt Instrument Refinanced With Additional Borrowings Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" xml:lang="en-US">Refinanced with additional borrowings amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" xlink:to="lab_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" xml:lang="en-US">Debt instrument refinanced with additional borrowings amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt instrument interest rate percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Debt instrument frequency of periodic payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" xml:lang="en-US">Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" xml:lang="en-US">Number of shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xml:lang="en-US">Equity Method Investment, Aggregate Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xml:lang="en-US">Equity method investment aggregate cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US">Payments to Acquire Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US">Additional investment,cash paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" xml:lang="en-US">Equity Method Investment Additional Investment Purchased Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" xml:lang="en-US">Additional shares purchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" xlink:to="lab_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" xml:lang="en-US">Equity method investment additional investment purchased shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt conversion converted instrument shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Debt conversion converted instrument warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentConvertibleConversionExercisablePrice" xlink:label="loc_bvs_DebtInstrumentConvertibleConversionExercisablePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentConvertibleConversionExercisablePrice" xml:lang="en-US">Debt Instrument Convertible Conversion Exercisable Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_DebtInstrumentConvertibleConversionExercisablePrice" xml:lang="en-US">Debt instrument convertible conversion exercisable price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentConvertibleConversionExercisablePrice" xlink:to="lab_bvs_DebtInstrumentConvertibleConversionExercisablePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentConvertibleConversionExercisablePrice" xml:lang="en-US">Debt instrument convertible conversion exercisable price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument, face amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt instrument convertible conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Percentage of noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" xlink:label="loc_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" xml:lang="en-US">Fair Value Of Intangible Assets Used To Determined Using The Income Approach Through Excess Earnings Analysis With Projected Earnings Discounted Rate,Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" xml:lang="en-US">Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" xlink:to="lab_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" xml:lang="en-US">Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate,percentage.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" xml:lang="en-US">Equity Method Investment Additional Investment To Be Purchased Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" xml:lang="en-US">Additional shares purchased Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" xlink:to="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" xml:lang="en-US">Equity method investment additional investment to be purchased value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xml:lang="en-US">Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xml:lang="en-US">Increase in equity ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentCapitalizedTransactionCosts" xlink:label="loc_bvs_EquityMethodInvestmentCapitalizedTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityMethodInvestmentCapitalizedTransactionCosts" xml:lang="en-US">Equity Method Investment Capitalized Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_EquityMethodInvestmentCapitalizedTransactionCosts" xml:lang="en-US">Equity method investment capitalized transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityMethodInvestmentCapitalizedTransactionCosts" xlink:to="lab_bvs_EquityMethodInvestmentCapitalizedTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityMethodInvestmentCapitalizedTransactionCosts" xml:lang="en-US">Equity method investment capitalized transaction costs.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMedtechIncMember" xlink:label="loc_bvs_HarborMedtechIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_HarborMedtechIncMember" xml:lang="en-US">Harbor Medtech Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_HarborMedtechIncMember" xml:lang="en-US">Harbor Medtech Inc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_HarborMedtechIncMember" xlink:to="lab_bvs_HarborMedtechIncMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaap_SeriesGPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xml:lang="en-US">Series G Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xml:lang="en-US">Series G Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesGPreferredStockMember" xlink:to="lab_us-gaap_SeriesGPreferredStockMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborSeriesCPreferredStockMember" xlink:label="loc_bvs_HarborSeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_HarborSeriesCPreferredStockMember" xml:lang="en-US">Harbor Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_HarborSeriesCPreferredStockMember" xml:lang="en-US">Harbor Series C Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_HarborSeriesCPreferredStockMember" xlink:to="lab_bvs_HarborSeriesCPreferredStockMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SeriesG1PreferredStockMember" xlink:label="loc_bvs_SeriesG1PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SeriesG1PreferredStockMember" xml:lang="en-US">Series G1 Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SeriesG1PreferredStockMember" xml:lang="en-US">Series G1 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SeriesG1PreferredStockMember" xlink:to="lab_bvs_SeriesG1PreferredStockMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SeriesFConvertiblePreferredStockMember" xlink:label="loc_bvs_SeriesFConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SeriesFConvertiblePreferredStockMember" xml:lang="en-US">Series F Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SeriesFConvertiblePreferredStockMember" xml:lang="en-US">Series F Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SeriesFConvertiblePreferredStockMember" xlink:to="lab_bvs_SeriesFConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PromissoryNoteMember" xlink:label="loc_bvs_PromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PromissoryNoteMember" xml:lang="en-US">Promissory Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PromissoryNoteMember" xml:lang="en-US">Promissory Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PromissoryNoteMember" xlink:to="lab_bvs_PromissoryNoteMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborCommonStockMember" xlink:label="loc_bvs_HarborCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_HarborCommonStockMember" xml:lang="en-US">Harbor Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_HarborCommonStockMember" xml:lang="en-US">Harbor Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_HarborCommonStockMember" xlink:to="lab_bvs_HarborCommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">IPR&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementForFutureEquityAxis" xlink:label="loc_bvs_AgreementForFutureEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AgreementForFutureEquityAxis" xml:lang="en-US">Agreement For Future Equity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AgreementForFutureEquityAxis" xlink:to="lab_bvs_AgreementForFutureEquityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AgreementForFutureEquityAxis" xml:lang="en-US">Agreement for future equity.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementForFutureEquityDomain" xlink:label="loc_bvs_AgreementForFutureEquityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AgreementForFutureEquityDomain" xml:lang="en-US">Agreement For Future Equity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AgreementForFutureEquityDomain" xlink:to="lab_bvs_AgreementForFutureEquityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AgreementForFutureEquityDomain" xml:lang="en-US">Agreement for future equity.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SimpleAgreementForFutureEquityMember" xlink:label="loc_bvs_SimpleAgreementForFutureEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SimpleAgreementForFutureEquityMember" xml:lang="en-US">Simple Agreement For Future Equity [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SimpleAgreementForFutureEquityMember" xml:lang="en-US">Simple Agreement For Future Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SimpleAgreementForFutureEquityMember" xlink:to="lab_bvs_SimpleAgreementForFutureEquityMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementAxis" xlink:label="loc_bvs_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AgreementAxis" xlink:to="lab_bvs_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementDomain" xlink:label="loc_bvs_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AgreementDomain" xlink:to="lab_bvs_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AgreementDomain" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OptionAndEquityPurchaseAgreementMember" xlink:label="loc_bvs_OptionAndEquityPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_OptionAndEquityPurchaseAgreementMember" xml:lang="en-US">Option And Equity Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_OptionAndEquityPurchaseAgreementMember" xml:lang="en-US">Option and Equity Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_OptionAndEquityPurchaseAgreementMember" xlink:to="lab_bvs_OptionAndEquityPurchaseAgreementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other Current Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Cash consideration at closing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMember" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMember" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMember" xml:lang="en-US">Paycheck Protection Program, CARES Act</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PaycheckProtectionProgramCARESActMember" xlink:to="lab_bvs_PaycheckProtectionProgramCARESActMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMember" xml:lang="en-US">Paycheck Protection Program, CARES Act</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" xml:lang="en-US">Paycheck Protection Program, CARES Act, Maturing April 10, 2022 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" xml:lang="en-US">Paycheck Protection Program, CARES Act, Maturing April 10, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" xlink:to="lab_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" xml:lang="en-US">Paycheck Protection Program, CARES Act, Maturing April 10, 2022</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" xml:lang="en-US">Paycheck Protection Program, CARES Act, Maturing February 5, 2026 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" xml:lang="en-US">Paycheck Protection Program, CARES Act, Maturing February 5, 2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" xlink:to="lab_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" xml:lang="en-US">Paycheck Protection Program, CARES Act, Maturing February 5, 2026</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xml:lang="en-US">Assets acquired and liabilities assumed:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Cash, Cash Equivalents And Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" xml:lang="en-US">Cash. cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" xlink:to="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Cash, Cash Equivalents And Restricted Cash</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xml:lang="en-US">IPR&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xml:lang="en-US">Fair value of Harbor's noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Net assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xml:lang="en-US">Deferred income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:to="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Liabilities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xml:lang="en-US">Operating lease assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentNumberOfLoans" xlink:label="loc_bvs_DebtInstrumentNumberOfLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentNumberOfLoans" xml:lang="en-US">Debt Instrument, Number Of Loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_DebtInstrumentNumberOfLoans" xml:lang="en-US">Number of loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentNumberOfLoans" xlink:to="lab_bvs_DebtInstrumentNumberOfLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentNumberOfLoans" xml:lang="en-US">Debt Instrument, Number Of Loans</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Paycheck Protection Program, CARES Act</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xml:lang="en-US">Restricted cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xml:lang="en-US">Variable Interest Entity [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xml:lang="en-US">Variable Interest Entity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xml:lang="en-US">Net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xml:lang="en-US">Net (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xml:lang="en-US">Business Acquisition, Pro Forma Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xml:lang="en-US">Earnings per share of Class A common stock(1):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xml:lang="en-US">Basic (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xml:lang="en-US">Diluted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Unamortized discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Original issue discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Original issue discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Term loan due December 2024 (2.60% at July 3, 2021)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Unamortized debt issuance cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">deferred financing costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestRateSwapMember" xml:lang="en-US">Interest Rate Swap [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestRateSwapMember" xml:lang="en-US">Interest Rate Swap</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TermLoanMember" xlink:label="loc_bvs_TermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TermLoanMember" xml:lang="en-US">Term Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TermLoanMember" xlink:to="lab_bvs_TermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TermLoanMember" xml:lang="en-US">Term loan.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CreditAgreementAxis" xlink:label="loc_bvs_CreditAgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CreditAgreementAxis" xml:lang="en-US">Credit Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CreditAgreementAxis" xlink:to="lab_bvs_CreditAgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CreditAgreementAxis" xml:lang="en-US">Credit agreement.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CreditAgreementDomain" xlink:label="loc_bvs_CreditAgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CreditAgreementDomain" xml:lang="en-US">Credit Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CreditAgreementDomain" xlink:to="lab_bvs_CreditAgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CreditAgreementDomain" xml:lang="en-US">Credit agreement.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandNineteenCreditAgreementMember" xlink:label="loc_bvs_TwoThousandNineteenCreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TwoThousandNineteenCreditAgreementMember" xml:lang="en-US">Two Thousand Nineteen Credit Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TwoThousandNineteenCreditAgreementMember" xlink:to="lab_bvs_TwoThousandNineteenCreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TwoThousandNineteenCreditAgreementMember" xml:lang="en-US">Two thousand nineteen credit agreement.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PriorCreditAgreementMember" xlink:label="loc_bvs_PriorCreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PriorCreditAgreementMember" xml:lang="en-US">Prior Credit Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PriorCreditAgreementMember" xlink:to="lab_bvs_PriorCreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PriorCreditAgreementMember" xml:lang="en-US">Prior credit agreement [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xml:lang="en-US">Derivative, Notional Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xml:lang="en-US">Derivative, notional amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xml:lang="en-US">Derivative, locked in interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of credit facility maximum borrowing capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Long-term Debt, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Long-term debt, fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xml:lang="en-US">Derivative, Number of Instruments Held</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xml:lang="en-US">Number of interest rate swap agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives" xlink:label="loc_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives" xml:lang="en-US">Percentage of Debt Hedged by Interest Rate Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives" xml:lang="en-US">Percentage of debt hedged by derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives" xlink:to="lab_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">custom sec</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Total long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt instrument, lending margin, interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" xlink:label="loc_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" xml:lang="en-US">Debt Instrument Final Principal Payment At Maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" xml:lang="en-US">Debt Instrument Final Principal Payment At Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" xlink:to="lab_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" xml:lang="en-US">Debt instrument final principal payment at maturity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest (income) expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Outstanding borrowings on line of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xml:lang="en-US">Line of Credit Facility, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xml:lang="en-US">Line of Credit Facility, Expiration Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" xlink:label="loc_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" xml:lang="en-US">Percentage Of Total Outstanding Debt Loaned By Lenders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" xml:lang="en-US">Percentage of total outstanding Debt loaned by lenders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" xlink:to="lab_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" xml:lang="en-US">Percentage of total outstanding debt loaned by lenders.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityDescription" xml:lang="en-US">Line of Credit Facility, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityDescription" xml:lang="en-US">Line of Credit Facility, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityDescription" xlink:to="lab_us-gaap_LineOfCreditFacilityDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestCostsCapitalized" xml:lang="en-US">Interest Costs Capitalized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestCostsCapitalized" xml:lang="en-US">Interest Costs Capitalized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xml:lang="en-US">Extinguishment of Debt, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xml:lang="en-US">Extinguishment of Debt, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xml:lang="en-US">Unsecured PPP loan forgiven</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AdditionalMarginPercentageToReferenceRates" xlink:label="loc_bvs_AdditionalMarginPercentageToReferenceRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AdditionalMarginPercentageToReferenceRates" xml:lang="en-US">Additional Margin Percentage To Reference Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_AdditionalMarginPercentageToReferenceRates" xml:lang="en-US">Additional margin percentage to reference Rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AdditionalMarginPercentageToReferenceRates" xlink:to="lab_bvs_AdditionalMarginPercentageToReferenceRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AdditionalMarginPercentageToReferenceRates" xml:lang="en-US">Additional margin percentage to reference rates.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ThresholdMaximumAggregateAdditionalBorrowings" xlink:label="loc_bvs_ThresholdMaximumAggregateAdditionalBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ThresholdMaximumAggregateAdditionalBorrowings" xml:lang="en-US">Threshold Maximum Aggregate Additional Borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ThresholdMaximumAggregateAdditionalBorrowings" xml:lang="en-US">Threshold maximum aggregate additional borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ThresholdMaximumAggregateAdditionalBorrowings" xlink:to="lab_bvs_ThresholdMaximumAggregateAdditionalBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ThresholdMaximumAggregateAdditionalBorrowings" xml:lang="en-US">Threshold maximum aggregate additional borrowings.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Interest rate swap</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" xlink:label="loc_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" xml:lang="en-US">Amortization Of Debt Instrument Capitalized Deferred Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" xml:lang="en-US">Amortization of debt Instrument capitalized deferred fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" xlink:to="lab_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" xml:lang="en-US">Amortization of debt Instrument capitalized deferred fees.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DerivativeStatedFixedInterestRate" xlink:label="loc_bvs_DerivativeStatedFixedInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DerivativeStatedFixedInterestRate" xml:lang="en-US">Derivative Stated Fixed Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DerivativeStatedFixedInterestRate" xlink:to="lab_bvs_DerivativeStatedFixedInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DerivativeStatedFixedInterestRate" xml:lang="en-US">Derivative stated fixed nterest rate.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentFloorRatePercentage" xlink:label="loc_bvs_DebtInstrumentFloorRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentFloorRatePercentage" xml:lang="en-US">Debt Instrument Floor Rate Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_DebtInstrumentFloorRatePercentage" xml:lang="en-US">Debt instrument floor rate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentFloorRatePercentage" xlink:to="lab_bvs_DebtInstrumentFloorRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentFloorRatePercentage" xml:lang="en-US">Debt instrument floor rate percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xml:lang="en-US">Debt, Weighted Average Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xml:lang="en-US">Debt, Weighted Average Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestCoverageRatio" xlink:label="loc_bvs_InterestCoverageRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InterestCoverageRatio" xml:lang="en-US">Interest Coverage Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_InterestCoverageRatio" xml:lang="en-US">Interest coverage ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InterestCoverageRatio" xlink:to="lab_bvs_InterestCoverageRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InterestCoverageRatio" xml:lang="en-US">Interest coverage ratio.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" xlink:label="loc_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" xml:lang="en-US">Debt Financing Costs Charged To Selling General Adminstrative Expense On Refinancing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" xml:lang="en-US">Debt financing costs charged to selling general adminstrative expense on refinancing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" xlink:to="lab_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" xml:lang="en-US">Debt financing costs charged to selling general adminstrative expense on refinancing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xml:lang="en-US">commitment fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument, Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument capitalized deferred fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DerivativeEffectiveInterestRate" xlink:label="loc_bvs_DerivativeEffectiveInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DerivativeEffectiveInterestRate" xml:lang="en-US">Derivative Effective Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DerivativeEffectiveInterestRate" xlink:to="lab_bvs_DerivativeEffectiveInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DerivativeEffectiveInterestRate" xml:lang="en-US">Derivative effective interest rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FrontingFeePercentageOnUndrawnAmount" xlink:label="loc_bvs_FrontingFeePercentageOnUndrawnAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_FrontingFeePercentageOnUndrawnAmount" xml:lang="en-US">Fronting Fee Percentage On Undrawn Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_FrontingFeePercentageOnUndrawnAmount" xml:lang="en-US">Fronting fee percentage on undrawn amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FrontingFeePercentageOnUndrawnAmount" xlink:to="lab_bvs_FrontingFeePercentageOnUndrawnAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_FrontingFeePercentageOnUndrawnAmount" xml:lang="en-US">Fronting fee percentage on undrawn amount.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestRateBasisAxis" xlink:label="loc_bvs_InterestRateBasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InterestRateBasisAxis" xml:lang="en-US">Interest Rate Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InterestRateBasisAxis" xlink:to="lab_bvs_InterestRateBasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InterestRateBasisAxis" xml:lang="en-US">Interest rate basis [Axis].</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestRateBasisDomain" xlink:label="loc_bvs_InterestRateBasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InterestRateBasisDomain" xml:lang="en-US">Interest Rate Basis [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InterestRateBasisDomain" xlink:to="lab_bvs_InterestRateBasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InterestRateBasisDomain" xml:lang="en-US">Interest rate basis.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BrInterestRateBasisMember" xlink:label="loc_bvs_BrInterestRateBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BrInterestRateBasisMember" xml:lang="en-US">BR Interest Rate Basis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BrInterestRateBasisMember" xlink:to="lab_bvs_BrInterestRateBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BrInterestRateBasisMember" xml:lang="en-US">BR interest rate basis [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EurodollarMember" xml:lang="en-US">Eurodollar [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BaseRateMember" xml:lang="en-US">Base Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RevolvingCreditFacilitySubAxis" xlink:label="loc_bvs_RevolvingCreditFacilitySubAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_RevolvingCreditFacilitySubAxis" xml:lang="en-US">Revolving Credit Facility Sub [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RevolvingCreditFacilitySubAxis" xlink:to="lab_bvs_RevolvingCreditFacilitySubAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_RevolvingCreditFacilitySubAxis" xml:lang="en-US">Revolving credit facility sub [Axis].</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RevolvingCreditFacilitySubDomain" xlink:label="loc_bvs_RevolvingCreditFacilitySubDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_RevolvingCreditFacilitySubDomain" xml:lang="en-US">Revolving Credit Facility Sub [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RevolvingCreditFacilitySubDomain" xlink:to="lab_bvs_RevolvingCreditFacilitySubDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_RevolvingCreditFacilitySubDomain" xml:lang="en-US">Revolving credit facility sub</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SwingLineCreditFacilityMember" xlink:label="loc_bvs_SwingLineCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SwingLineCreditFacilityMember" xml:lang="en-US">Swing Line Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SwingLineCreditFacilityMember" xlink:to="lab_bvs_SwingLineCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SwingLineCreditFacilityMember" xml:lang="en-US">Swing line credit facility [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" xml:lang="en-US">Management Incentive Plan And Liability-Classified Awards, Fair Value Disclsoure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" xml:lang="en-US">Management incentive plan and liability-classified awardsManagement incentive plan and liability-classified awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" xlink:to="lab_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" xml:lang="en-US">Management Incentive Plan And Liability-Classified Awards, Fair Value Disclsoure</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightFairValueDisclsoure" xlink:label="loc_bvs_EquityParticipationRightFairValueDisclsoure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityParticipationRightFairValueDisclsoure" xml:lang="en-US">Equity Participation Right, Fair Value Disclsoure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EquityParticipationRightFairValueDisclsoure" xml:lang="en-US">Equity Participation Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityParticipationRightFairValueDisclsoure" xlink:to="lab_bvs_EquityParticipationRightFairValueDisclsoure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityParticipationRightFairValueDisclsoure" xml:lang="en-US">Equity Participation Right, Fair Value Disclsoure</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Approach and Technique [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Approach and Technique [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Approach and Technique [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Approach and Technique [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xml:lang="en-US">Payment discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCEmployeesTerminatedPriorToIPOMember" xlink:label="loc_bvs_BVLLCEmployeesTerminatedPriorToIPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BVLLCEmployeesTerminatedPriorToIPOMember" xml:lang="en-US">BV LLC Employees Terminated Prior To IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BVLLCEmployeesTerminatedPriorToIPOMember" xml:lang="en-US">BV LLC Employees Terminated Prior To IPO</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BVLLCEmployeesTerminatedPriorToIPOMember" xlink:to="lab_bvs_BVLLCEmployeesTerminatedPriorToIPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BVLLCEmployeesTerminatedPriorToIPOMember" xml:lang="en-US">BV LLC Employees Terminated Prior To IPO</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCEmployeesActiveAtIPOMember" xlink:label="loc_bvs_BVLLCEmployeesActiveAtIPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BVLLCEmployeesActiveAtIPOMember" xml:lang="en-US">BV LLC Employees Active At IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BVLLCEmployeesActiveAtIPOMember" xml:lang="en-US">BV LLC Employees Active At IPO</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BVLLCEmployeesActiveAtIPOMember" xlink:to="lab_bvs_BVLLCEmployeesActiveAtIPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BVLLCEmployeesActiveAtIPOMember" xml:lang="en-US">BV LLC Employees Active At IPO</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xml:lang="en-US">Management Incentive Plan And Liability-Classified Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xml:lang="en-US">Management Incentive Plan And Liability-Classified Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xlink:to="lab_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xml:lang="en-US">Management Incentive Plan And Liability-Classified Awards</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NumberOfEquityBasedCompensationPlans" xlink:label="loc_bvs_NumberOfEquityBasedCompensationPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_NumberOfEquityBasedCompensationPlans" xml:lang="en-US">Number Of Equity-Based Compensation Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_NumberOfEquityBasedCompensationPlans" xml:lang="en-US">Number of equity-based compensation plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NumberOfEquityBasedCompensationPlans" xlink:to="lab_bvs_NumberOfEquityBasedCompensationPlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_NumberOfEquityBasedCompensationPlans" xml:lang="en-US">Number Of Equity-Based Compensation Plans</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of awards outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Ending Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xml:lang="en-US">Cash paid to settle award</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Number of shares issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Number of equity instruments other than options outstanding, including both vested and non-vested instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Number of equity instruments other than options outstanding, including both vested and non-vested instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightEntitledPercentageOfDistributions" xlink:label="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityParticipationRightEntitledPercentageOfDistributions" xml:lang="en-US">Equity Participation Right, Entitled Percentage Of Distributions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EquityParticipationRightEntitledPercentageOfDistributions" xml:lang="en-US">EPR unit, entitled percentage of distributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions" xlink:to="lab_bvs_EquityParticipationRightEntitledPercentageOfDistributions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityParticipationRightEntitledPercentageOfDistributions" xml:lang="en-US">Equity Participation Right, Entitled Percentage Of Distributions</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaap_CashAvailableForDistributions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAvailableForDistributions" xml:lang="en-US">Cash Available for Distributions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAvailableForDistributions" xml:lang="en-US">Equity participation right estimated accrued preferred distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAvailableForDistributions" xlink:to="lab_us-gaap_CashAvailableForDistributions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xml:lang="en-US">Other Deferred Compensation Arrangements, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xml:lang="en-US">Accrued equity-based compensation, less current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Initial estimate (vesting)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Conversion To Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" xml:lang="en-US">Phantom plan conversion to Class A common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" xlink:to="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Conversion To Equity</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" xml:lang="en-US">Forfeitures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" xlink:to="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Forfeitures.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightsUnitMeasurableInput" xlink:label="loc_bvs_EquityParticipationRightsUnitMeasurableInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityParticipationRightsUnitMeasurableInput" xml:lang="en-US">Equity Participation Rights Unit Measurable Input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityParticipationRightsUnitMeasurableInput" xlink:to="lab_bvs_EquityParticipationRightsUnitMeasurableInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityParticipationRightsUnitMeasurableInput" xml:lang="en-US">Equity Participation Rights Unit Measurable Input.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightsUnitEquityValue" xlink:label="loc_bvs_EquityParticipationRightsUnitEquityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EquityParticipationRightsUnitEquityValue" xml:lang="en-US">Equity Participation Rights Unit Equity Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EquityParticipationRightsUnitEquityValue" xlink:to="lab_bvs_EquityParticipationRightsUnitEquityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EquityParticipationRightsUnitEquityValue" xml:lang="en-US">Equity Participation Rights Unit Equity Value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeasurementInputEquityVolatilityMember" xlink:label="loc_bvs_MeasurementInputEquityVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MeasurementInputEquityVolatilityMember" xml:lang="en-US">Measurement Input Equity Volatility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MeasurementInputEquityVolatilityMember" xlink:to="lab_bvs_MeasurementInputEquityVolatilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xml:lang="en-US">Measurement Input, Discount for Lack of Marketability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of awards granted (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Compensation expense net yet amortized, period for recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Granted (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number&#160;of&#160;awards, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, COVID-19 Impact On Economy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" xml:lang="en-US">Decrease in fair value due to the impact of COVID-19 on the market and economy</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" xlink:to="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, COVID-19 Impact On Economy</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of awards forfeited (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited/canceled (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of awards, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Equity compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Equity compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Equity compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Purchase price of common stock, percentage of fair market value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Compensation expense net yet amortized, period for recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of Equity instruments other than options granted during period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Number of shares authorized to be awarded (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Number of shares available to be awarded (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Unamortized compensation expense, RSUs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Unamortized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unamortized compensation expense, options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Number of options vested (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Number&#160;of&#160;awards, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized, Annual Percentage Increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xml:lang="en-US">Annual percentage increase in number of shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xlink:to="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized, Annual Percentage Increase</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Compensation Deducted During Offering Period, Percentage Per Employee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xml:lang="en-US">Percentage of employee compensation deducted to purchase common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xlink:to="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Compensation Deducted During Offering Period, Percentage Per Employee</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Common stock closing price, (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Options outstanding, aggregate intrinsic value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Defined contribution plan maximum annual contributions per employee percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xml:lang="en-US">Defined contribution plan employer matching contribution, percent of match</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xml:lang="en-US">Defined contribution plan employers matching contribution annual vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted&#160;average grant-date&#160;fair&#160;value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Ending balance (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Beginning balance (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Granted (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">Employee Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">Employee Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAwardMember" xlink:label="loc_bvs_ManagementIncentivePlanAwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ManagementIncentivePlanAwardMember" xml:lang="en-US">Management Incentive Plan Award [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ManagementIncentivePlanAwardMember" xml:lang="en-US">Management Incentive Plan Award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ManagementIncentivePlanAwardMember" xlink:to="lab_bvs_ManagementIncentivePlanAwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ManagementIncentivePlanAwardMember" xml:lang="en-US">Management Incentive Plan Award</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PhantomShareUnitsPSUsMember" xml:lang="en-US">Phantom Share Units (PSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PhantomShareUnitsPSUsMember" xml:lang="en-US">Phantom Share Units (PSUs)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PhantomShareUnitsPSUsMember" xlink:to="lab_us-gaap_PhantomShareUnitsPSUsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_A2021PlanMember" xlink:label="loc_bvs_A2021PlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_A2021PlanMember" xml:lang="en-US">2021 Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_A2021PlanMember" xml:lang="en-US">2021 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_A2021PlanMember" xlink:to="lab_bvs_A2021PlanMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Cancelled (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Expected stock price volatility, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk-free interest rate, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Expected stock price volatility, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average fair value of stock options granted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Ending balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding, weighted average remaining contractual term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Ending balance (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Beginning balance (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyInterestsMember" xlink:label="loc_bvs_LimitedLiabilityCompanyInterestsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LimitedLiabilityCompanyInterestsMember" xml:lang="en-US">Limited Liability Company Interests [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_LimitedLiabilityCompanyInterestsMember" xml:lang="en-US">LLC Interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LimitedLiabilityCompanyInterestsMember" xlink:to="lab_bvs_LimitedLiabilityCompanyInterestsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LimitedLiabilityCompanyInterestsMember" xml:lang="en-US">Limited Liability Company Interests</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_UnvestedClassACommonSharesMember" xlink:label="loc_bvs_UnvestedClassACommonSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_UnvestedClassACommonSharesMember" xml:lang="en-US">Unvested Class A Common Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_UnvestedClassACommonSharesMember" xml:lang="en-US">Unvested shares of Class A common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_UnvestedClassACommonSharesMember" xlink:to="lab_bvs_UnvestedClassACommonSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_UnvestedClassACommonSharesMember" xml:lang="en-US">Unvested Class A Common Shares</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" xlink:label="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" xml:lang="en-US">Income From Continuing Operations Before Income Taxes Domestic And Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" xlink:to="lab_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" xml:lang="en-US">Income from continuing operations before income taxes domestic and foreign.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" xlink:label="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" xml:lang="en-US">Income From Continuing Operations Before Income Taxes Domestic And Foreign Other Domestic Subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" xml:lang="en-US">Other domestic subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" xlink:to="lab_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" xml:lang="en-US">Income From Continuing Operations Before Income Taxes Domestic And Foreign Other Domestic Subsidiaries.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TaxableSubsidiariesAbstract" xlink:label="loc_bvs_TaxableSubsidiariesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TaxableSubsidiariesAbstract" xml:lang="en-US">Taxable Subsidiaries [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_TaxableSubsidiariesAbstract" xml:lang="en-US">Taxable subsidiaries:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TaxableSubsidiariesAbstract" xlink:to="lab_bvs_TaxableSubsidiariesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TaxableSubsidiariesAbstract" xml:lang="en-US">Taxable subsidiaries [Abstract].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Foreign income taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xml:lang="en-US">Change in tax rates - deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Federal income taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">State income taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">U.S. statutory federal corporate income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" xlink:label="loc_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" xml:lang="en-US">Effective Income Tax Reconciliation LLC Flow Through Structure Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" xml:lang="en-US">LLC flow-through structure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" xlink:to="lab_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" xml:lang="en-US">Effective income tax reconciliation llc flow through structure percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State and local income taxes, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" xlink:label="loc_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" xml:lang="en-US">Effective Income Tax Reconciliation Provision To Return Adjustment Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" xml:lang="en-US">Provision to return adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" xlink:to="lab_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" xml:lang="en-US">Effective income tax reconciliation provision to return adjustment percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective income tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Gross deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance on deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credit carryforwards and other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred tax assets, tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liability:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DeferredTaxLiabilitiesAcquiredIntangibles" xlink:label="loc_bvs_DeferredTaxLiabilitiesAcquiredIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DeferredTaxLiabilitiesAcquiredIntangibles" xml:lang="en-US">Deferred Tax Liabilities Acquired Intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_bvs_DeferredTaxLiabilitiesAcquiredIntangibles" xml:lang="en-US">Acquired intangible</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DeferredTaxLiabilitiesAcquiredIntangibles" xlink:to="lab_bvs_DeferredTaxLiabilitiesAcquiredIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DeferredTaxLiabilitiesAcquiredIntangibles" xml:lang="en-US">Deferred tax liabilities acquired intangibles.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable" xlink:label="loc_us-gaap_ValuationAllowanceTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceTable" xml:lang="en-US">Valuation Allowance [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xml:lang="en-US">Valuation Allowance [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating losses carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open Tax Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open tax year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xml:lang="en-US">Deferred Tax Liabilities, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xml:lang="en-US">Deferred tax liabilities, difference between the book value and tax basis of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FederalAndStateMember" xlink:label="loc_bvs_FederalAndStateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_FederalAndStateMember" xml:lang="en-US">Federal And State [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_FederalAndStateMember" xlink:to="lab_bvs_FederalAndStateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonUsMember" xml:lang="en-US">Non-US [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonUsMember" xml:lang="en-US">International</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMember" xlink:label="loc_bvs_HarborMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_HarborMember" xml:lang="en-US">Harbor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_HarborMember" xml:lang="en-US">Harbor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_HarborMember" xlink:to="lab_bvs_HarborMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_HarborMember" xml:lang="en-US">Harbor</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IndefinitelyMember" xlink:label="loc_bvs_IndefinitelyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_IndefinitelyMember" xml:lang="en-US">Indefinitely [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_IndefinitelyMember" xlink:to="lab_bvs_IndefinitelyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2015Member" xlink:label="loc_us-gaap_TaxYear2015Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxYear2015Member" xml:lang="en-US">Tax Year 2015 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2015Member" xlink:to="lab_us-gaap_TaxYear2015Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2020Member" xlink:label="loc_us-gaap_TaxYear2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxYear2020Member" xml:lang="en-US">Tax Year 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2020Member" xlink:to="lab_us-gaap_TaxYear2020Member" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" xlink:label="loc_bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" xml:lang="en-US">Year Two Thousand Twenty One To Year Two Thousand And Thirty Seven [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" xlink:to="lab_bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CashDistributionMadeToMembersTowardsTax" xlink:label="loc_bvs_CashDistributionMadeToMembersTowardsTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CashDistributionMadeToMembersTowardsTax" xml:lang="en-US">Cash Distribution Made To Members Towards Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_CashDistributionMadeToMembersTowardsTax" xml:lang="en-US">Cash distributions made to members towards tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CashDistributionMadeToMembersTowardsTax" xlink:to="lab_bvs_CashDistributionMadeToMembersTowardsTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CashDistributionMadeToMembersTowardsTax" xml:lang="en-US">Cash distribution made to members towards tax.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" xlink:label="loc_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" xml:lang="en-US">Cash Distributions As A Percentage Of Members Total Taxable Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" xml:lang="en-US">Cash distributions as a percentage of members total taxable income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" xlink:to="lab_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" xml:lang="en-US">cash distributions as a percentage of members total taxable income.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" xlink:label="loc_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" xml:lang="en-US">Related Party Transaction Tax Distributions Payable To Tax Authorities On Behalf Members</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" xml:lang="en-US">Related party transaction tax distributions payable to tax authorities on behalf members</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" xlink:to="lab_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" xml:lang="en-US">Related party transaction tax distributions payable to tax authorities on behalf members.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash flows from operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities- noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate for operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities- current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total future lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierOfSingleInjectionOAProductMember" xlink:label="loc_bvs_SupplierOfSingleInjectionOAProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SupplierOfSingleInjectionOAProductMember" xml:lang="en-US">Supplier Of Single Injection OA Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SupplierOfSingleInjectionOAProductMember" xml:lang="en-US">Supplier of Single Injection OA Product</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplierOfSingleInjectionOAProductMember" xlink:to="lab_bvs_SupplierOfSingleInjectionOAProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SupplierOfSingleInjectionOAProductMember" xml:lang="en-US">Supplier Of Single Injection OA Product</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xml:lang="en-US">Damages from Product Defects [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xml:lang="en-US">Damages from Product Defects</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xml:lang="en-US">Supply Commitment [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xml:lang="en-US">Supply Commitment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xml:lang="en-US">Supply Commitment Arrangement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xml:lang="en-US">Supply Commitment Arrangement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ThreeInjectionOAProductMember" xlink:label="loc_bvs_ThreeInjectionOAProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ThreeInjectionOAProductMember" xml:lang="en-US">Three Injection OA Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ThreeInjectionOAProductMember" xml:lang="en-US">Three Injection OA Product</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ThreeInjectionOAProductMember" xlink:to="lab_bvs_ThreeInjectionOAProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ThreeInjectionOAProductMember" xml:lang="en-US">Three Injection OA Product</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationStatusAxis" xml:lang="en-US">Litigation Status [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationStatusAxis" xml:lang="en-US">Litigation Status [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationStatusDomain" xml:lang="en-US">Litigation Status [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationStatusDomain" xml:lang="en-US">Litigation Status [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplyCommitmentRenewalTerm" xlink:label="loc_bvs_SupplyCommitmentRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SupplyCommitmentRenewalTerm" xml:lang="en-US">Supply Commitment, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SupplyCommitmentRenewalTerm" xml:lang="en-US">Supply commitment, renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplyCommitmentRenewalTerm" xlink:to="lab_bvs_SupplyCommitmentRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SupplyCommitmentRenewalTerm" xml:lang="en-US">Supply Commitment, Renewal Term</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CollaborativeArrangementTerm" xlink:label="loc_bvs_CollaborativeArrangementTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CollaborativeArrangementTerm" xml:lang="en-US">Collaborative Arrangement, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_CollaborativeArrangementTerm" xml:lang="en-US">Collaborative agreement, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementTerm" xlink:to="lab_bvs_CollaborativeArrangementTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CollaborativeArrangementTerm" xml:lang="en-US">Collaborative Arrangement, Term</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, operating lease, remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xml:lang="en-US">Estimated probable loss related to product recall</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xml:lang="en-US">Loss Contingency, Accrual, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xml:lang="en-US">Recorded reserves for product recall</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CollaborativeArrangementRoyaltyPercentage" xlink:label="loc_bvs_CollaborativeArrangementRoyaltyPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CollaborativeArrangementRoyaltyPercentage" xml:lang="en-US">Collaborative Arrangement, Royalty Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_CollaborativeArrangementRoyaltyPercentage" xml:lang="en-US">Collaborative agreement, royalty percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CollaborativeArrangementRoyaltyPercentage" xlink:to="lab_bvs_CollaborativeArrangementRoyaltyPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CollaborativeArrangementRoyaltyPercentage" xml:lang="en-US">Collaborative Arrangement, Royalty Percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss Contingency Accrual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss contingency accrual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xml:lang="en-US">Loss Contingency Accrual, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xml:lang="en-US">Loss contingency accruals payments made during the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RefundOfExcessPaymentsToThirdPartyCustomers" xlink:label="loc_bvs_RefundOfExcessPaymentsToThirdPartyCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_RefundOfExcessPaymentsToThirdPartyCustomers" xml:lang="en-US">Refund Of Excess Payments To Third Party Customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_RefundOfExcessPaymentsToThirdPartyCustomers" xml:lang="en-US">Refund of excess payments to third party customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RefundOfExcessPaymentsToThirdPartyCustomers" xlink:to="lab_bvs_RefundOfExcessPaymentsToThirdPartyCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_RefundOfExcessPaymentsToThirdPartyCustomers" xml:lang="en-US">Refund of excess payments to third party customers.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MilestonePaymentPayable" xlink:label="loc_bvs_MilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MilestonePaymentPayable" xml:lang="en-US">Milestone Payment Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_MilestonePaymentPayable" xml:lang="en-US">Milestone payment payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MilestonePaymentPayable" xlink:to="lab_bvs_MilestonePaymentPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MilestonePaymentPayable" xml:lang="en-US">Milestone payment payable.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplyCommitmentTerm" xlink:label="loc_bvs_SupplyCommitmentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SupplyCommitmentTerm" xml:lang="en-US">Supply Commitment, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_SupplyCommitmentTerm" xml:lang="en-US">Supply commitment, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplyCommitmentTerm" xlink:to="lab_bvs_SupplyCommitmentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SupplyCommitmentTerm" xml:lang="en-US">Supply Commitment, Term</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualProductLiabilityNet" xml:lang="en-US">Loss Contingency Accrual, Product Liability, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualProductLiabilityNet" xml:lang="en-US">Loss contingency accrual product liability net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:to="lab_us-gaap_LossContingencyAccrualProductLiabilityNet" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:label="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear" xml:lang="en-US">Stop Loss Insurance Threshold Per Member Per Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear" xml:lang="en-US">Stop loss insurance, threshold per member per year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:to="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_StopLossInsuranceThresholdPerMemberPerYear" xml:lang="en-US">Stop Loss Insurance, Threshold Per Member Per Year</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_UsaoAndOigMember" xlink:label="loc_bvs_UsaoAndOigMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_UsaoAndOigMember" xml:lang="en-US">USAO And OIG [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_UsaoAndOigMember" xml:lang="en-US">USAO And OIG</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_UsaoAndOigMember" xlink:to="lab_bvs_UsaoAndOigMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_UsaoAndOigMember" xml:lang="en-US">USAO And OIG</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetIncomeLossFromContinuingOperations" xlink:label="loc_bvs_NetIncomeLossFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_NetIncomeLossFromContinuingOperations" xml:lang="en-US">Net Income Loss From Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_NetIncomeLossFromContinuingOperations" xml:lang="en-US">Net income (loss) from continuing operations attributable to common unit holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NetIncomeLossFromContinuingOperations" xlink:to="lab_bvs_NetIncomeLossFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_NetIncomeLossFromContinuingOperations" xml:lang="en-US">Net income loss from continuing operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net income (loss) per unit attributable to common unit holders - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common units outstanding, basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsMember" xlink:label="loc_bvs_PreferredUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PreferredUnitsMember" xml:lang="en-US">Preferred Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PreferredUnitsMember" xml:lang="en-US">Preferred Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PreferredUnitsMember" xlink:to="lab_bvs_PreferredUnitsMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PainTreatmentsAndJointPreservationMember" xlink:label="loc_bvs_PainTreatmentsAndJointPreservationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PainTreatmentsAndJointPreservationMember" xml:lang="en-US">Pain Treatments And Joint Preservation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PainTreatmentsAndJointPreservationMember" xml:lang="en-US">Pain Treatments and Joint Preservation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PainTreatmentsAndJointPreservationMember" xlink:to="lab_bvs_PainTreatmentsAndJointPreservationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PainTreatmentsAndJointPreservationMember" xml:lang="en-US">Pain Treatments And Joint Preservation</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestorativeTherapiesMember" xlink:label="loc_bvs_RestorativeTherapiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_RestorativeTherapiesMember" xml:lang="en-US">Restorative Therapies [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_RestorativeTherapiesMember" xml:lang="en-US">Restorative Therapies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RestorativeTherapiesMember" xlink:to="lab_bvs_RestorativeTherapiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_RestorativeTherapiesMember" xml:lang="en-US">Restorative Therapies</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BoneGraftSubstitutesMember" xlink:label="loc_bvs_BoneGraftSubstitutesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BoneGraftSubstitutesMember" xml:lang="en-US">Bone Graft Substitutes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BoneGraftSubstitutesMember" xml:lang="en-US">Bone Graft Substitutes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_BoneGraftSubstitutesMember" xml:lang="en-US">Bone graft substitutes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BoneGraftSubstitutesMember" xlink:to="lab_bvs_BoneGraftSubstitutesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BoneGraftSubstitutesMember" xml:lang="en-US">Bone Graft Substitutes</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">U.S.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xml:lang="en-US">Segment Reconciling Items [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xml:lang="en-US">Segment Reconciling Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemNetGainLoss" xlink:label="loc_us-gaap_UnusualOrInfrequentItemNetGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnusualOrInfrequentItemNetGainLoss" xml:lang="en-US">Unusual or Infrequent Item, or Both, Net (Gain) Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnusualOrInfrequentItemNetGainLoss" xml:lang="en-US">COVID-19 benefits, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemNetGainLoss" xlink:to="lab_us-gaap_UnusualOrInfrequentItemNetGainLoss" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SuccessionAndTransitionCharges" xlink:label="loc_bvs_SuccessionAndTransitionCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SuccessionAndTransitionCharges" xml:lang="en-US">Succession And Transition Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_SuccessionAndTransitionCharges" xml:lang="en-US">Succession and transition charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SuccessionAndTransitionCharges" xlink:to="lab_bvs_SuccessionAndTransitionCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SuccessionAndTransitionCharges" xml:lang="en-US">Succession And Transition Charges</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryStepUpCost" xlink:label="loc_bvs_InventoryStepUpCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InventoryStepUpCost" xml:lang="en-US">Inventory Step-Up Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_bvs_InventoryStepUpCost" xml:lang="en-US">Inventory step-up costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InventoryStepUpCost" xlink:to="lab_bvs_InventoryStepUpCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InventoryStepUpCost" xml:lang="en-US">Inventory Step-Up Cost</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonrecurringExpense" xml:lang="en-US">Other Nonrecurring Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_OtherNonrecurringExpense" xml:lang="en-US">Other non-recurring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringExpense" xlink:to="lab_us-gaap_OtherNonrecurringExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign currency impact</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:label="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xml:lang="en-US">Segment adjusted EBITDA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:to="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xml:lang="en-US">Adjusted earnings before interest, taxes, depreciation, amortization and other non-operating items.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramLoanMember" xlink:label="loc_bvs_PaycheckProtectionProgramLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PaycheckProtectionProgramLoanMember" xml:lang="en-US">Paycheck Protection Program Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PaycheckProtectionProgramLoanMember" xml:lang="en-US">PPP Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PaycheckProtectionProgramLoanMember" xlink:to="lab_bvs_PaycheckProtectionProgramLoanMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TermLoanFacilityMember" xlink:label="loc_bvs_TermLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TermLoanFacilityMember" xml:lang="en-US">Term Loan Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_TermLoanFacilityMember" xml:lang="en-US">Term Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TermLoanFacilityMember" xlink:to="lab_bvs_TermLoanFacilityMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_A2019CreditAgreementMember" xlink:label="loc_bvs_A2019CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_A2019CreditAgreementMember" xml:lang="en-US">2019 Credit Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_A2019CreditAgreementMember" xml:lang="en-US">2019 Credit Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_A2019CreditAgreementMember" xlink:to="lab_bvs_A2019CreditAgreementMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MisonixIncMember" xlink:label="loc_bvs_MisonixIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MisonixIncMember" xml:lang="en-US">Misonix, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_MisonixIncMember" xml:lang="en-US">Misonix, Inc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MisonixIncMember" xlink:to="lab_bvs_MisonixIncMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredDebtMember" xml:lang="en-US">Secured Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecuredDebtMember" xml:lang="en-US">Secured Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentCovenantRequiredPrepayment" xlink:label="loc_bvs_DebtInstrumentCovenantRequiredPrepayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentCovenantRequiredPrepayment" xml:lang="en-US">Debt Instrument, Covenant, Required Prepayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_DebtInstrumentCovenantRequiredPrepayment" xml:lang="en-US">Debt instrument, required prepayment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentCovenantRequiredPrepayment" xlink:to="lab_bvs_DebtInstrumentCovenantRequiredPrepayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentCovenantRequiredPrepayment" xml:lang="en-US">Debt instrument, covenant, required prepayment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business acquisition, share price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" xml:lang="en-US">Business Acquisition, Consideration Transferred Per Share, Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" xml:lang="en-US">Business acquisition, consideration transferred per share, cash (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" xlink:to="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" xml:lang="en-US">Business acquisition, consideration transferred per share, cash.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" xml:lang="en-US">Business Acquisition, Consideration Transferred Per Share, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" xml:lang="en-US">Business acquisition, consideration transferred per share (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" xlink:to="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" xml:lang="en-US">Business acquisition, consideration transferred per share, shares</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" xml:lang="en-US">Business Acquisition, Consideration Transferred Per Share, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" xml:lang="en-US">Business acquisition, consideration transferred per share, maximum amount payable (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" xlink:to="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" xml:lang="en-US">Business acquisition, consideration transferred per share, maximum.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common stock shares subscribed but not issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_us-gaap_CommonStockSharesSubscribedButUnissued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xlink:label="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xml:lang="en-US">Proceeds From The Issuance Of Common Units Of Limited Liability Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xml:lang="en-US">Proceeds from the issuance of common units of limited liability company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xml:lang="en-US">Proceeds from the issuance of common units of limited liability company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xlink:to="lab_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xml:lang="en-US">Proceeds from the issuance of common units of limited liability company.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xlink:label="loc_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xml:lang="en-US">Common Units Of Limited Liability Company Issued During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xml:lang="en-US">Common units of limited liability company issued during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xlink:to="lab_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xml:lang="en-US">Common units of limited liability company issued during the period.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" xlink:label="loc_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" xml:lang="en-US">Limited Liability Company Number Of Interests Held By Persons Other Than Managing Members</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" xml:lang="en-US">Limited liability company number of interests held by persons other than managing member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" xlink:to="lab_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" xml:lang="en-US">Limited liability company number of interests held by persons other than managing member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xml:lang="en-US">Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xml:lang="en-US">Limited liability owenrship pinterest held by members</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xml:lang="en-US">Payments to Acquire Other Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xml:lang="en-US">Payment to acquire debt investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" xlink:label="loc_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" xml:lang="en-US">Common And Preferrred Units Converted Into Interests In Limited Liability Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" xml:lang="en-US">Common and preferred units converted into interests in limited liability company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" xlink:to="lab_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" xml:lang="en-US">Common and preferrred units converted into interests in limited liability company.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedPaymentAwardSettlementPeriod" xlink:label="loc_bvs_ShareBasedPaymentAwardSettlementPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ShareBasedPaymentAwardSettlementPeriod" xml:lang="en-US">Share Based Payment Award Settlement Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ShareBasedPaymentAwardSettlementPeriod" xml:lang="en-US">Share based payment award, Settlement period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ShareBasedPaymentAwardSettlementPeriod" xlink:to="lab_bvs_ShareBasedPaymentAwardSettlementPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ShareBasedPaymentAwardSettlementPeriod" xml:lang="en-US">Share based payment award settlement period.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestorAxis" xlink:label="loc_bvs_InvestorAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InvestorAxis" xml:lang="en-US">Investor [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InvestorAxis" xlink:to="lab_bvs_InvestorAxis" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestorDomain" xlink:label="loc_bvs_InvestorDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_InvestorDomain" xml:lang="en-US">Investor [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_InvestorDomain" xlink:to="lab_bvs_InvestorDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_InvestorDomain" xml:lang="en-US">Investor</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContinuingLlcOwnerMember" xlink:label="loc_bvs_ContinuingLlcOwnerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ContinuingLlcOwnerMember" xml:lang="en-US">Continuing LLC Owner [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ContinuingLlcOwnerMember" xml:lang="en-US">Continuing LLC Owner</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ContinuingLlcOwnerMember" xlink:to="lab_bvs_ContinuingLlcOwnerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ContinuingLlcOwnerMember" xml:lang="en-US">Continuing LLC Owner</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NewLlcOwnerMember" xlink:label="loc_bvs_NewLlcOwnerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_NewLlcOwnerMember" xml:lang="en-US">New LLC Owner [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_NewLlcOwnerMember" xml:lang="en-US">New LLC Owner</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_NewLlcOwnerMember" xlink:to="lab_bvs_NewLlcOwnerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_NewLlcOwnerMember" xml:lang="en-US">New LLC Owner</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConvertibleDebtInstrumentsMember" xlink:label="loc_bvs_ConvertibleDebtInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ConvertibleDebtInstrumentsMember" xml:lang="en-US">Convertible Debt Instruments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_ConvertibleDebtInstrumentsMember" xml:lang="en-US">Convertible Debt Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ConvertibleDebtInstrumentsMember" xlink:to="lab_bvs_ConvertibleDebtInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ConvertibleDebtInstrumentsMember" xml:lang="en-US">Convertible Debt Instruments</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestatedLimitedLiabilityCompanyAgreementMember" xlink:label="loc_bvs_RestatedLimitedLiabilityCompanyAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_RestatedLimitedLiabilityCompanyAgreementMember" xml:lang="en-US">Restated Limited Liability Company Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_RestatedLimitedLiabilityCompanyAgreementMember" xml:lang="en-US">Restated Limited Liability Company Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RestatedLimitedLiabilityCompanyAgreementMember" xlink:to="lab_bvs_RestatedLimitedLiabilityCompanyAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_RestatedLimitedLiabilityCompanyAgreementMember" xml:lang="en-US">Restated Limited Liability Company Agreement</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestrictedStockUnitsAgreementMember" xlink:label="loc_bvs_RestrictedStockUnitsAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_RestrictedStockUnitsAgreementMember" xml:lang="en-US">Restricted Stock Units Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_RestrictedStockUnitsAgreementMember" xml:lang="en-US">Restricted Stock Units Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_RestrictedStockUnitsAgreementMember" xlink:to="lab_bvs_RestrictedStockUnitsAgreementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xml:lang="en-US">Loss on disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">Disposal Group Discontinued Operation Research And Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" xlink:to="lab_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">Disposal group discontinued operation research and development expense.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" xml:lang="en-US">Disposal Group Discontinued Operation Income Tax Expense Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" xlink:to="lab_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" xml:lang="en-US">Disposal group discontinued operation income tax expense benefit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Group Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Group Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BmpResearchAndDevelopmentProgrammeMember" xlink:label="loc_bvs_BmpResearchAndDevelopmentProgrammeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_BmpResearchAndDevelopmentProgrammeMember" xml:lang="en-US">BMP Research And Development Programme [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_BmpResearchAndDevelopmentProgrammeMember" xml:lang="en-US">BMP Research And Development Programme</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_BmpResearchAndDevelopmentProgrammeMember" xlink:to="lab_bvs_BmpResearchAndDevelopmentProgrammeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xml:lang="en-US">Disposal group, including discontinued operation, consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" xml:lang="en-US">Disposal Group Discontinued Operations Payment Of Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" xml:lang="en-US">Disposal group discontinued operations payment of accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" xlink:to="lab_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" xml:lang="en-US">Disposal group discontinued operations payment of accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OAJointPainTreatmentAndJointPreservationMember" xlink:label="loc_bvs_OAJointPainTreatmentAndJointPreservationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_OAJointPainTreatmentAndJointPreservationMember" xml:lang="en-US">O A Joint Pain Treatment And Joint Preservation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_OAJointPainTreatmentAndJointPreservationMember" xml:lang="en-US">OA joint pain treatment and joint preservation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_OAJointPainTreatmentAndJointPreservationMember" xlink:to="lab_bvs_OAJointPainTreatmentAndJointPreservationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_OAJointPainTreatmentAndJointPreservationMember" xml:lang="en-US">O A Joint Pain Treatment And Joint Preservation.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MinimallyInvasiveFractureTreatmentMember" xlink:label="loc_bvs_MinimallyInvasiveFractureTreatmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_MinimallyInvasiveFractureTreatmentMember" xml:lang="en-US">Minimally Invasive Fracture Treatment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_MinimallyInvasiveFractureTreatmentMember" xml:lang="en-US">Minimally invasive fracture treatment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_MinimallyInvasiveFractureTreatmentMember" xlink:to="lab_bvs_MinimallyInvasiveFractureTreatmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_MinimallyInvasiveFractureTreatmentMember" xml:lang="en-US">Minimally Invasive Fracture Treatment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTable" xml:lang="en-US">Concentration Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xml:lang="en-US">Product Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConcentrationRiskBySupplierNameAxis" xlink:label="loc_bvs_ConcentrationRiskBySupplierNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ConcentrationRiskBySupplierNameAxis" xml:lang="en-US">Concentration Risk By Supplier Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameAxis" xlink:to="lab_bvs_ConcentrationRiskBySupplierNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ConcentrationRiskBySupplierNameAxis" xml:lang="en-US">Concentration risk by supplier name.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConcentrationRiskBySupplierNameDomain" xlink:label="loc_bvs_ConcentrationRiskBySupplierNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ConcentrationRiskBySupplierNameDomain" xml:lang="en-US">Concentration Risk By Supplier Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain" xlink:to="lab_bvs_ConcentrationRiskBySupplierNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ConcentrationRiskBySupplierNameDomain" xml:lang="en-US">Concentration risk by supplier name.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductDMember" xlink:label="loc_bvs_ProductDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProductDMember" xml:lang="en-US">Product D [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProductDMember" xlink:to="lab_bvs_ProductDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProductDMember" xml:lang="en-US">Product D.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierCMember" xlink:label="loc_bvs_SupplierCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SupplierCMember" xml:lang="en-US">Supplier C [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplierCMember" xlink:to="lab_bvs_SupplierCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SupplierCMember" xml:lang="en-US">Supplier C.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductAMember" xlink:label="loc_bvs_ProductAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProductAMember" xml:lang="en-US">Product A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProductAMember" xlink:to="lab_bvs_ProductAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProductAMember" xml:lang="en-US">Product A.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductBMember" xlink:label="loc_bvs_ProductBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProductBMember" xml:lang="en-US">Product B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProductBMember" xlink:to="lab_bvs_ProductBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProductBMember" xml:lang="en-US">Product B.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductCMember" xlink:label="loc_bvs_ProductCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProductCMember" xml:lang="en-US">Product C [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProductCMember" xlink:to="lab_bvs_ProductCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProductCMember" xml:lang="en-US">Product C.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierAMember" xlink:label="loc_bvs_SupplierAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SupplierAMember" xml:lang="en-US">Supplier A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplierAMember" xlink:to="lab_bvs_SupplierAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SupplierAMember" xml:lang="en-US">Supplier A.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierBMember" xlink:label="loc_bvs_SupplierBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_SupplierBMember" xml:lang="en-US">Supplier B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_SupplierBMember" xlink:to="lab_bvs_SupplierBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_SupplierBMember" xml:lang="en-US">Supplier B.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xml:lang="en-US">Concentration Risk [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue Benchmark [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xml:lang="en-US">Revenue, change in estimates of variable consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xml:lang="en-US">Contract assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xml:lang="en-US">Capitalized Computer Software, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xml:lang="en-US">Capitalized Computer Software, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xml:lang="en-US">Capitalized Computer Software, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xml:lang="en-US">Capitalized Computer Software, Accumulated Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xml:lang="en-US">Capitalized Computer Software, Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xml:lang="en-US">Amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfMembersTaxDistributionToTaxableIncome" xlink:label="loc_bvs_PercentageOfMembersTaxDistributionToTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PercentageOfMembersTaxDistributionToTaxableIncome" xml:lang="en-US">Percentage of Members Tax Distribution to Taxable Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_PercentageOfMembersTaxDistributionToTaxableIncome" xml:lang="en-US">Percentage of member's tax distribution to taxable income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PercentageOfMembersTaxDistributionToTaxableIncome" xlink:to="lab_bvs_PercentageOfMembersTaxDistributionToTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PercentageOfMembersTaxDistributionToTaxableIncome" xml:lang="en-US">Percentage of members tax distribution to taxable income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonUnitIssuanceValue" xml:lang="en-US">Common Unit, Issuance Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonUnitIssuanceValue" xml:lang="en-US">Common</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitIssuanceValue" xlink:to="lab_us-gaap_CommonUnitIssuanceValue" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" xlink:label="loc_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" xml:lang="en-US">Profit Interest and Other Equity Wards Units Issuance Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" xml:lang="en-US">Profits interest and other equity awards (Refer to&#160;Note 9. Equity-based compensation)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" xlink:to="lab_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" xml:lang="en-US">Profit interest and other equity wards units issuance value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" xml:lang="en-US">Limited Liability Company (LLC) Preferred Unit, Issuance Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" xml:lang="en-US">Preferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital" xlink:label="loc_us-gaap_MembersCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MembersCapital" xml:lang="en-US">Members' Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_MembersCapital" xml:lang="en-US">Members' Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersCapital" xlink:to="lab_us-gaap_MembersCapital" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" xlink:label="loc_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" xml:lang="en-US">Proceeds From The Issuance Of Preferred Units Of Limited Liability Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" xml:lang="en-US">Proceeds from the issuance of preferred units of limited liability company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" xlink:to="lab_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" xml:lang="en-US">Proceeds from the issuance of preferred units of limited liability company.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xlink:label="loc_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xml:lang="en-US">Preferred Units Of Limited Liability Company Issued During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xml:lang="en-US">Preferred units of limited liability company issued during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xlink:to="lab_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xml:lang="en-US">Preferred units of limited liability company issued during the period.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsLiquidationPreferencePerUnit" xlink:label="loc_bvs_PreferredUnitsLiquidationPreferencePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PreferredUnitsLiquidationPreferencePerUnit" xml:lang="en-US">Preferred Units Liquidation Preference Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_PreferredUnitsLiquidationPreferencePerUnit" xml:lang="en-US">Preferred units liquidation preference per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PreferredUnitsLiquidationPreferencePerUnit" xlink:to="lab_bvs_PreferredUnitsLiquidationPreferencePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PreferredUnitsLiquidationPreferencePerUnit" xml:lang="en-US">Preferred units liquidation preference per unit.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" xlink:label="loc_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" xml:lang="en-US">Preferred Units Percentage of Accrued Distribution Right Per Annum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" xml:lang="en-US">Preferred units percentage of accrued distribution right per annum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" xlink:to="lab_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" xml:lang="en-US">Preferred units percentage of accrued distribution right per annum.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DistributionEventTriggerPercentageOfSaleOfAssets" xlink:label="loc_bvs_DistributionEventTriggerPercentageOfSaleOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DistributionEventTriggerPercentageOfSaleOfAssets" xml:lang="en-US">Distribution Event Trigger Percentage of Sale of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_DistributionEventTriggerPercentageOfSaleOfAssets" xml:lang="en-US">Distribution Event Trigger Percentage of Sale of Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DistributionEventTriggerPercentageOfSaleOfAssets" xlink:to="lab_bvs_DistributionEventTriggerPercentageOfSaleOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DistributionEventTriggerPercentageOfSaleOfAssets" xml:lang="en-US">Distribution event trigger percentage of sale of assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsByNameAxis" xlink:label="loc_us-gaap_PreferredUnitsByNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredUnitsByNameAxis" xml:lang="en-US">Preferred Units by Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredUnitsByNameAxis" xlink:to="lab_us-gaap_PreferredUnitsByNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsClassDomain" xlink:label="loc_us-gaap_PreferredUnitsClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredUnitsClassDomain" xml:lang="en-US">Preferred Units, Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredUnitsClassDomain" xlink:to="lab_us-gaap_PreferredUnitsClassDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwelvePreferredUnitsMember" xlink:label="loc_bvs_TwoThousandAndTwelvePreferredUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TwoThousandAndTwelvePreferredUnitsMember" xml:lang="en-US">Two Thousand and Twelve Preferred Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TwoThousandAndTwelvePreferredUnitsMember" xlink:to="lab_bvs_TwoThousandAndTwelvePreferredUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TwoThousandAndTwelvePreferredUnitsMember" xml:lang="en-US">Two thousand and twelve preferred units.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndFifteenPreferredUnitsMember" xlink:label="loc_bvs_TwoThousandAndFifteenPreferredUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TwoThousandAndFifteenPreferredUnitsMember" xml:lang="en-US">Two Thousand and Fifteen Preferred Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TwoThousandAndFifteenPreferredUnitsMember" xlink:to="lab_bvs_TwoThousandAndFifteenPreferredUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TwoThousandAndFifteenPreferredUnitsMember" xml:lang="en-US">Two thousand and fifteen preferred units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="loc_us-gaap_RestructuringCostsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostsAbstract" xml:lang="en-US">Restructuring Costs [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAbstract" xlink:to="lab_us-gaap_RestructuringCostsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Restructuring Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EmployeeSeveranceAndTemporaryLaborCostsMember" xlink:label="loc_bvs_EmployeeSeveranceAndTemporaryLaborCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_EmployeeSeveranceAndTemporaryLaborCostsMember" xml:lang="en-US">Employee Severance and Temporary Labor Costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_EmployeeSeveranceAndTemporaryLaborCostsMember" xlink:to="lab_bvs_EmployeeSeveranceAndTemporaryLaborCostsMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherChargesMember" xlink:label="loc_bvs_OtherChargesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_OtherChargesMember" xml:lang="en-US">Other Charges [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_OtherChargesMember" xlink:to="lab_bvs_OtherChargesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanAxis" xml:lang="en-US">Restructuring Plan [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanDomain" xml:lang="en-US">Restructuring Plan [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndEighteenPlanMember" xlink:label="loc_bvs_TwoThousandAndEighteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TwoThousandAndEighteenPlanMember" xml:lang="en-US">Two Thousand and Eighteen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_TwoThousandAndEighteenPlanMember" xml:lang="en-US">2018 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TwoThousandAndEighteenPlanMember" xlink:to="lab_bvs_TwoThousandAndEighteenPlanMember" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwentyPlanMember" xlink:label="loc_bvs_TwoThousandAndTwentyPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TwoThousandAndTwentyPlanMember" xml:lang="en-US">Two Thousand and Twenty Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bvs_TwoThousandAndTwentyPlanMember" xml:lang="en-US">2020 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TwoThousandAndTwentyPlanMember" xlink:to="lab_bvs_TwoThousandAndTwentyPlanMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xml:lang="en-US">Share-based Payment Arrangement, Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwelveMember" xlink:label="loc_bvs_TwoThousandAndTwelveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TwoThousandAndTwelveMember" xml:lang="en-US">Two Thousand and Twelve [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TwoThousandAndTwelveMember" xlink:to="lab_bvs_TwoThousandAndTwelveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TwoThousandAndTwelveMember" xml:lang="en-US">Two thousand and twelve.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndFifteenMember" xlink:label="loc_bvs_TwoThousandAndFifteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_TwoThousandAndFifteenMember" xml:lang="en-US">Two Thousand and Fifteen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_TwoThousandAndFifteenMember" xlink:to="lab_bvs_TwoThousandAndFifteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_TwoThousandAndFifteenMember" xml:lang="en-US">Two thousand and fifteen.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Coverted In Cash Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value, Converted to cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" xlink:to="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options coverted in cash weighted average grant date fair value.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Converted In Cash Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" xml:lang="en-US">Number of awards, Converted to cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" xlink:to="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options converted in cash period.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Equity Instruments Other than Options Vested And Expected To Vest Outstanding Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Number of awards, Awards vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share based compensation arrangement by share based payment equity instruments other than options vested and expected to vest outstanding number.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average grant-date fair value, Awards vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding weighted average exercise price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xml:lang="en-US">Debt Instruments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentAxis" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentSchedulePeriodicPaymentAxis" xml:lang="en-US">Debt Instrument Schedule Periodic Payment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis" xlink:to="lab_bvs_DebtInstrumentSchedulePeriodicPaymentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentSchedulePeriodicPaymentAxis" xml:lang="en-US">Debt instrument schedule periodic payment.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentDomain" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentSchedulePeriodicPaymentDomain" xml:lang="en-US">Debt Instrument Schedule Periodic Payment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain" xlink:to="lab_bvs_DebtInstrumentSchedulePeriodicPaymentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentSchedulePeriodicPaymentDomain" xml:lang="en-US">Debt instrument schedule periodic payment.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" xml:lang="en-US">Debt Instrument Schedule Periodic Payment Period One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" xlink:to="lab_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" xml:lang="en-US">Debt instrument schedule periodic payment period one.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" xml:lang="en-US">Debt Instrument Schedule Periodic Payment Period Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" xlink:to="lab_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" xml:lang="en-US">Debt instrument schedule periodic payment period two.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeAxis" xlink:label="loc_bvs_LeverageRatioRangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LeverageRatioRangeAxis" xml:lang="en-US">Leverage Ratio Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LeverageRatioRangeAxis" xlink:to="lab_bvs_LeverageRatioRangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LeverageRatioRangeAxis" xml:lang="en-US">Leverage ratio range.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeDomain" xlink:label="loc_bvs_LeverageRatioRangeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LeverageRatioRangeDomain" xml:lang="en-US">Leverage Ratio Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LeverageRatioRangeDomain" xlink:to="lab_bvs_LeverageRatioRangeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LeverageRatioRangeDomain" xml:lang="en-US">Leverage ratio range.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeTwoMember" xlink:label="loc_bvs_LeverageRatioRangeTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LeverageRatioRangeTwoMember" xml:lang="en-US">Leverage Ratio Range Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LeverageRatioRangeTwoMember" xlink:to="lab_bvs_LeverageRatioRangeTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LeverageRatioRangeTwoMember" xml:lang="en-US">Leverage ratio range two.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeThreeMember" xlink:label="loc_bvs_LeverageRatioRangeThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LeverageRatioRangeThreeMember" xml:lang="en-US">Leverage Ratio Range Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LeverageRatioRangeThreeMember" xlink:to="lab_bvs_LeverageRatioRangeThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LeverageRatioRangeThreeMember" xml:lang="en-US">Leverage ratio range three.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFourMember" xlink:label="loc_bvs_LeverageRatioRangeFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LeverageRatioRangeFourMember" xml:lang="en-US">Leverage Ratio Range Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LeverageRatioRangeFourMember" xlink:to="lab_bvs_LeverageRatioRangeFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LeverageRatioRangeFourMember" xml:lang="en-US">Leverage ratio range four.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFiveMember" xlink:label="loc_bvs_LeverageRatioRangeFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LeverageRatioRangeFiveMember" xml:lang="en-US">Leverage Ratio Range Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LeverageRatioRangeFiveMember" xlink:to="lab_bvs_LeverageRatioRangeFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LeverageRatioRangeFiveMember" xml:lang="en-US">Leverage ratio range five.</label>
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeOneMember" xlink:label="loc_bvs_LeverageRatioRangeOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bvs_LeverageRatioRangeOneMember" xml:lang="en-US">Leverage Ratio Range One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bvs_LeverageRatioRangeOneMember" xlink:to="lab_bvs_LeverageRatioRangeOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bvs_LeverageRatioRangeOneMember" xml:lang="en-US">Leverage ratio range one.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:label="loc_us-gaap_LongTermDebtMaturingInYearsFourAndFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturingInYearsFourAndFive" xml:lang="en-US">Long-Term Debt, Maturity, Year Four and Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturingInYearsFourAndFive" xml:lang="en-US">2025 and thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:to="lab_us-gaap_LongTermDebtMaturingInYearsFourAndFive" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>bvs-20210703_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 22-September-2021 [01:59:44] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CoverPage" roleURI="http://bio.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedBalanceSheets" roleURI="http://bio.com/role/ConsolidatedCondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedBalanceSheetsParenthetical" roleURI="http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#ConsolidatedCondensedStatementsOfCashFlows" roleURI="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#Organization" roleURI="http://bio.com/role/Organization" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformation" roleURI="http://bio.com/role/BalanceSheetInformation" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestments" roleURI="http://bio.com/role/BusinessCombinationsAndInvestments" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstruments" roleURI="http://bio.com/role/FinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurements" roleURI="http://bio.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensation" roleURI="http://bio.com/role/EquityBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EarningsPerShare" roleURI="http://bio.com/role/EarningsPerShare" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxes" roleURI="http://bio.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingencies" roleURI="http://bio.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetIncomeLossPerUnit" roleURI="http://bio.com/role/NetIncomeLossPerUnit" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RestructuringCosts" roleURI="http://bio.com/role/RestructuringCosts" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquity" roleURI="http://bio.com/role/MembersEquity" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RelatedPartyTransactions" roleURI="http://bio.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetSales" roleURI="http://bio.com/role/NetSales" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperations" roleURI="http://bio.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#StockholderSEquity" roleURI="http://bio.com/role/StockholderSEquity" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RevenueRecognition" roleURI="http://bio.com/role/RevenueRecognition" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#Segments" roleURI="http://bio.com/role/Segments" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SubsequentEvents" roleURI="http://bio.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#OrganizationPolicies" roleURI="http://bio.com/role/OrganizationPolicies" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RestructuringCostsTables" roleURI="http://bio.com/role/RestructuringCostsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquityTables" roleURI="http://bio.com/role/MembersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetSalesTables" roleURI="http://bio.com/role/NetSalesTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperationsTables" roleURI="http://bio.com/role/DiscontinuedOperationsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SegmentsTables" roleURI="http://bio.com/role/SegmentsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RevenueRecognitionTables" roleURI="http://bio.com/role/RevenueRecognitionTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetIncomeLossPerUnitTables" roleURI="http://bio.com/role/NetIncomeLossPerUnitTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesTables" roleURI="http://bio.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationTables" roleURI="http://bio.com/role/BalanceSheetInformationTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsTables" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsTables" roleURI="http://bio.com/role/FinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsTables" roleURI="http://bio.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationTables" roleURI="http://bio.com/role/EquityBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EarningsPerShareTables" roleURI="http://bio.com/role/EarningsPerShareTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesTables" roleURI="http://bio.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#OrganizationDetails" roleURI="http://bio.com/role/OrganizationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationComponentsOfAccountsReceivableDetails" roleURI="http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationAllowanceForCreditLossDetails" roleURI="http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationInventoryDetails" roleURI="http://bio.com/role/BalanceSheetInformationInventoryDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationAccruedLiabilitiesDetails" roleURI="http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationNarrativeDetails" roleURI="http://bio.com/role/BalanceSheetInformationNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationScheduleOfInventoryValuationReservesDetails" roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationPropertyPlantAndEquipmentDetails" roleURI="http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationScheduleOfGoodwillDetails" roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails" roleURI="http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsNarrativeDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsConsiderationTransferredDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#BusinessCombinationsAndInvestmentsProFormaResultsDetails" roleURI="http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsScheduleOfLongTermDebtDetails" roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsNarrativeDetails" roleURI="http://bio.com/role/FinancialInstrumentsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails" roleURI="http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails" roleURI="http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails" roleURI="http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsEquityParticipationRightUnitDetails" roleURI="http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail" roleURI="http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationNarrativeDetails" roleURI="http://bio.com/role/EquityBasedCompensationNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationFairValueAssumptionsDetails" roleURI="http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationOptionActivityDetails" roleURI="http://bio.com/role/EquityBasedCompensationOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails" roleURI="http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#IncomeTaxesDetails" roleURI="http://bio.com/role/IncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RelatedPartyTransactionsNarrativeDetail" roleURI="http://bio.com/role/RelatedPartyTransactionsNarrativeDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesLeaseCostDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesSupplementalCashFlowInformationDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#CommitmentsAndContingenciesNarrativeDetails" roleURI="http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail" roleURI="http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetIncomeLossPerUnitNarrativeDetails" roleURI="http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RevenueRecognitionDetails" roleURI="http://bio.com/role/RevenueRecognitionDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SegmentsDetails" roleURI="http://bio.com/role/SegmentsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SubsequentEventsDetails" roleURI="http://bio.com/role/SubsequentEventsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#StockholderSEquityAdditionalInformationDetail" roleURI="http://bio.com/role/StockholderSEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails" roleURI="http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#DiscontinuedOperationsAdditionalInformationDetails" roleURI="http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#NetSalesDetails" roleURI="http://bio.com/role/NetSalesDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetail" roleURI="http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquitySummaryOfMembersEquityDetails" roleURI="http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#MembersEquityNarrativeDetails" roleURI="http://bio.com/role/MembersEquityNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails" roleURI="http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#RestructuringCostsAdditionalInformationDetails" roleURI="http://bio.com/role/RestructuringCostsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail" roleURI="http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail" roleURI="http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail" roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail" roleURI="http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail" />
<roleRef xlink:type="simple" xlink:href="bvs-20210703.xsd#FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail" roleURI="http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail" />
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_5" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_6" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentType_9" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityRegistrantName_14" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityFilerCategory_29" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntitySmallBusiness_30" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityEmergingGrowthCompany_31" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityExTransitionPeriod_32" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AmendmentFlag_35" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1105695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AmendmentDescription_1105695" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCentralIndexKey_36" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_41" xlink:to="loc_us-gaap_StatementTable_1105610" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105610" xlink:to="loc_dei_LegalEntityAxis_1105618" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105618" xlink:to="loc_dei_EntityDomain_1105620" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105620" xlink:to="loc_bvs_BioVentusLlcMember_1105621" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105610" xlink:to="loc_us-gaap_StatementLineItems_1105613" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_45" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_GrossProfit_46" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_47" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_48" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1101456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_RestructuringCharges_1101456" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_DepreciationAndAmortization_50" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1101458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1101458" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_AssetImpairmentCharges_51" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OperatingIncomeLoss_52" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_53" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_54" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_55" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1101460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1101460" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_56" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_57" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1101461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1101461" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1101462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1101462" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ProfitLoss_58" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_59" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLoss_60" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1101464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1101464" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_61" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1106248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1106248" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_62" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_63" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_64" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_EarningsPerShareAbstract_42" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42" xlink:to="loc_us-gaap_EarningsPerShareBasic_65" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42" xlink:to="loc_us-gaap_EarningsPerShareDiluted_66" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1101466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1101466" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1101467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1101467" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1101468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1101468" use="optional" order="42" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_1106276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_1106276" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_1106280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_1106280" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1101471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1101471" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105613" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1101473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1101473" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_1101474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_1101474" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1101475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1101475" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1101476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_1101472" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1101476" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_StatementTable_1105642" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105642" xlink:to="loc_dei_LegalEntityAxis_1105646" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105646" xlink:to="loc_dei_EntityDomain_1105647" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105647" xlink:to="loc_bvs_BioVentusLlcMember_1105648" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105642" xlink:to="loc_us-gaap_StatementLineItems_1105645" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105645" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_71" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_73" xlink:to="loc_us-gaap_StatementTable_74" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_74" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_76" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76" xlink:to="loc_us-gaap_CommonClassAMember_83" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76" xlink:to="loc_us-gaap_CommonClassBMember_84" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_74" xlink:to="loc_dei_LegalEntityAxis_1105638" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105638" xlink:to="loc_dei_EntityDomain_1105640" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105640" xlink:to="loc_bvs_BioVentusLlcMember_1105680" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_74" xlink:to="loc_us-gaap_StatementLineItems_77" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_AssetsAbstract_78" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_AssetsCurrentAbstract_79" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_85" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_RestrictedCashCurrent_86" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_87" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_87" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_InventoryNet_88" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_89" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79" xlink:to="loc_us-gaap_AssetsCurrent_90" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_91" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_Goodwill_92" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_94" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_95" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_LongTermInvestments_96" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_us-gaap_Assets_97" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalAssets" xlink:label="loc_bvs_TotalAssets_1106484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_78" xlink:to="loc_bvs_TotalAssets_1106484" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_81" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_AccountsPayableCurrent_98" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_99" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_100" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_LongTermDebtCurrent_101" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_102" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_103" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81" xlink:to="loc_us-gaap_LiabilitiesCurrent_104" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_105" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_106" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_107" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_108" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_109" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_Liabilities_110" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalLiabilities" xlink:label="loc_bvs_TotalLiabilities_1106485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_bvs_TotalLiabilities_1106485" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_MembersEquity_112" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_CommonStockValue_113" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_AdditionalPaidInCapital_114" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_115" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_116" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_StockholdersEquity_117" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalStockholdersEquity" xlink:label="loc_bvs_TotalStockholdersEquity_1106487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_bvs_TotalStockholdersEquity_1106487" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_MinorityInterest_118" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_82" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_120" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_122" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TotalLiabilitiesAndStockholdersEquity" xlink:label="loc_bvs_TotalLiabilitiesAndStockholdersEquity_1106486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_80" xlink:to="loc_bvs_TotalLiabilitiesAndStockholdersEquity_1106486" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_124" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_124" xlink:to="loc_us-gaap_StatementTable_125" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementClassOfStockAxis_126" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_126" xlink:to="loc_us-gaap_ClassOfStockDomain_127" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_127" xlink:to="loc_us-gaap_CommonClassAMember_129" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_127" xlink:to="loc_us-gaap_CommonClassBMember_130" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_dei_LegalEntityAxis_1105652" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105652" xlink:to="loc_dei_EntityDomain_1105653" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105653" xlink:to="loc_bvs_BioVentusLlcMember_1105654" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementLineItems_128" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_131" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_132" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_PreferredStockSharesIssued_133" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_134" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_135" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_136" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_CommonStockSharesIssued_137" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_1101488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_128" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_1101488" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_139" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_139" xlink:to="loc_us-gaap_StatementTable_140" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_dei_LegalEntityAxis_1105685" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105685" xlink:to="loc_dei_EntityDomain_1105686" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105686" xlink:to="loc_bvs_BioVentusLlcMember_1105687" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_141" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_141" xlink:to="loc_us-gaap_EquityComponentDomain_142" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_MemberUnitsMember_149" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_CommonStockMember_150" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_151" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_152" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_RetainedEarningsMember_153" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_142" xlink:to="loc_us-gaap_NoncontrollingInterestMember_154" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_143" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144" xlink:to="loc_us-gaap_IPOMember_155" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PublicOfferingMember" xlink:label="loc_bvs_PublicOfferingMember_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144" xlink:to="loc_bvs_PublicOfferingMember_156" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_StatementClassOfStockAxis_145" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_145" xlink:to="loc_us-gaap_ClassOfStockDomain_146" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_146" xlink:to="loc_us-gaap_CommonClassAMember_157" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_146" xlink:to="loc_us-gaap_CommonClassBMember_158" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_140" xlink:to="loc_us-gaap_StatementLineItems_147" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward" xlink:label="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_147" xlink:to="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_SharesOutstanding_159" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_160" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_MembersEquity_161" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_162" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityIncreaseFromRefundsFromMembers" xlink:label="loc_bvs_MembersEquityIncreaseFromRefundsFromMembers_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_MembersEquityIncreaseFromRefundsFromMembers_163" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromEquityForfeitures" xlink:label="loc_bvs_MembersEquityDecreaseFromEquityForfeitures_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_MembersEquityDecreaseFromEquityForfeitures_164" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromProfitInterestForfeiture" xlink:label="loc_bvs_MembersEquityDecreaseFromProfitInterestForfeiture_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_MembersEquityDecreaseFromProfitInterestForfeiture_165" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MembersEquityDecreaseFromDistributionToMembers" xlink:label="loc_bvs_MembersEquityDecreaseFromDistributionToMembers_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_MembersEquityDecreaseFromDistributionToMembers_166" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_167" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_1101592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_1101592" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_ProfitLoss_168" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetLossSubsequentToOrganizationalTransactions" xlink:label="loc_bvs_NetLossSubsequentToOrganizationalTransactions_1106473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_NetLossSubsequentToOrganizationalTransactions_1106473" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1101590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1101590" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity" xlink:label="loc_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity_169" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_170" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_171" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_172" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityChangeInReportingEntity" xlink:label="loc_us-gaap_StockholdersEquityChangeInReportingEntity_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockholdersEquityChangeInReportingEntity_173" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_StockholdersEquitySharesChangeInReportingEntity" xlink:label="loc_bvs_StockholdersEquitySharesChangeInReportingEntity_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_bvs_StockholdersEquitySharesChangeInReportingEntity_174" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_176" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_SharesOutstanding_177" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_178" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward_148" xlink:to="loc_us-gaap_MembersEquity_179" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_181" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_181" xlink:to="loc_us-gaap_StatementTable_1105656" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105656" xlink:to="loc_dei_LegalEntityAxis_1105661" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105661" xlink:to="loc_dei_EntityDomain_1105662" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105662" xlink:to="loc_bvs_BioVentusLlcMember_1105664" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105656" xlink:to="loc_us-gaap_StatementLineItems_1105659" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_ProfitLoss_188" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1101497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1101497" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1101503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1101503" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_189" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1101506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1101506" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_193" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1101508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1101508" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1101509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1101509" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_190" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_ShareBasedCompensation_191" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation" xlink:label="loc_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation_192" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_194" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1101512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1101512" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1101514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1101514" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:label="loc_us-gaap_AssetRetirementObligationAccretionExpense_1101516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_AssetRetirementObligationAccretionExpense_1101516" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ChangeInFairValueOfEquityParticipationRightsUnit" xlink:label="loc_bvs_ChangeInFairValueOfEquityParticipationRightsUnit_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_bvs_ChangeInFairValueOfEquityParticipationRightsUnit_195" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets" xlink:label="loc_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets_196" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_197" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_183" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_198" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_199" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_200" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_201" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1101519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1101519" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1101520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_184" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1101520" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_182" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_202" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestmentAndAcquisitionOfDistributionRights" xlink:label="loc_bvs_InvestmentAndAcquisitionOfDistributionRights_1101521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_bvs_InvestmentAndAcquisitionOfDistributionRights_1101521" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AcquisitionOfVariableInterestEntity" xlink:label="loc_bvs_AcquisitionOfVariableInterestEntity_1101522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_bvs_AcquisitionOfVariableInterestEntity_1101522" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_203" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_204" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_205" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_206" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_207" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_185" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_208" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_209" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_210" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_211" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_1101523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_1101523" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1101524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1101524" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_212" use="optional" order="49" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromMembers" xlink:label="loc_bvs_ProceedsFromMembers_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_bvs_ProceedsFromMembers_213" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_186" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_215" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_216" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_217" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_218" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_219" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:label="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract_1101530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract_1101530" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_1101531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract_1101530" xlink:to="loc_us-gaap_IncomeTaxesPaid_1101531" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1101532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_SupplementalDisclosureOfCashFlowInformationAbstract_1101530" xlink:to="loc_us-gaap_InterestPaidNet_1101532" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105659" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_1101533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" xlink:to="loc_us-gaap_LiabilitiesAssumed1_1101533" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_1101534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" xlink:to="loc_us-gaap_StockIssued1_1101534" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_221" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberDistributionsIncurredButNotYetPaid" xlink:label="loc_bvs_MemberDistributionsIncurredButNotYetPaid_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_187" xlink:to="loc_bvs_MemberDistributionsIncurredButNotYetPaid_220" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/Organization">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_223" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1103901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_223" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1103901" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103901" xlink:to="loc_dei_LegalEntityAxis_1103902" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103902" xlink:to="loc_dei_EntityDomain_1103903" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103903" xlink:to="loc_bvs_BioVentusLlcMember_1103906" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103901" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103904" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103904" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_224" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1101678" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1103911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1101678" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1103911" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103911" xlink:to="loc_dei_LegalEntityAxis_1103912" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103912" xlink:to="loc_dei_EntityDomain_1103913" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103913" xlink:to="loc_bvs_BioVentusLlcMember_1103914" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103911" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103915" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1101680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103915" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1101680" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_273" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_273" xlink:to="loc_us-gaap_StatementTable_1105701" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105701" xlink:to="loc_dei_LegalEntityAxis_1105705" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105705" xlink:to="loc_dei_EntityDomain_1105706" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105706" xlink:to="loc_bvs_BioVentusLlcMember_1105707" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105701" xlink:to="loc_us-gaap_StatementLineItems_1105704" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105704" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_274" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1102780" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1102780" xlink:to="loc_us-gaap_StatementTable_1102782" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102782" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102783" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102783" xlink:to="loc_us-gaap_ClassOfStockDomain_1102784" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102782" xlink:to="loc_dei_LegalEntityAxis_1102786" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102786" xlink:to="loc_dei_EntityDomain_1102787" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102787" xlink:to="loc_bvs_BioVentusLlcMember_1102788" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1102785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102782" xlink:to="loc_us-gaap_StatementLineItems_1102785" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock" xlink:label="loc_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102785" xlink:to="loc_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock_322" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstruments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_497" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1103273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_497" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1103273" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1103273" xlink:to="loc_dei_LegalEntityAxis_1103275" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103275" xlink:to="loc_dei_EntityDomain_1103276" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103276" xlink:to="loc_bvs_BioVentusLlcMember_1103277" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_1103274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1103273" xlink:to="loc_us-gaap_ShortTermDebtLineItems_1103274" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_1103274" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_498" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_529" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_529" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102937" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102937" xlink:to="loc_dei_LegalEntityAxis_1102939" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102939" xlink:to="loc_dei_EntityDomain_1102940" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102940" xlink:to="loc_bvs_BioVentusLlcMember_1102941" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102937" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102938" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102938" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_530" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_623" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1103145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_623" xlink:to="loc_us-gaap_StatementTable_1103145" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103145" xlink:to="loc_dei_LegalEntityAxis_1103151" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103151" xlink:to="loc_dei_EntityDomain_1103152" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103152" xlink:to="loc_bvs_BioVentusLlcMember_1103154" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103145" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103146" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103146" xlink:to="loc_us-gaap_ClassOfStockDomain_1103147" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103145" xlink:to="loc_us-gaap_StatementLineItems_1103148" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103148" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_624" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EarningsPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_726" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_726" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_727" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_755" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_755" xlink:to="loc_us-gaap_StatementTable_1105431" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105431" xlink:to="loc_dei_LegalEntityAxis_1105435" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105435" xlink:to="loc_dei_EntityDomain_1105436" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105436" xlink:to="loc_bvs_BioVentusLlcMember_1105437" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105431" xlink:to="loc_us-gaap_StatementLineItems_1105434" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105434" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_756" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_763" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_763" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/NetIncomeLossPerUnit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1102307" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1102307" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102311" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102311" xlink:to="loc_dei_LegalEntityAxis_1102315" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102315" xlink:to="loc_dei_EntityDomain_1102316" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102316" xlink:to="loc_bvs_BioVentusLlcMember_1102317" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1102314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102311" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1102314" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetIncomeLossPerUnitTextBlock" xlink:label="loc_bvs_NetIncomeLossPerUnitTextBlock_1105124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102314" xlink:to="loc_bvs_NetIncomeLossPerUnitTextBlock_1105124" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RestructuringCosts">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1103067" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1103067" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103068" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103068" xlink:to="loc_dei_LegalEntityAxis_1103073" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103073" xlink:to="loc_dei_EntityDomain_1103075" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103075" xlink:to="loc_bvs_BioVentusLlcMember_1103076" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1103069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103068" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1103069" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1103070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103069" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1103070" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1103035" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable_1103037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1103035" xlink:to="loc_bvs_MemberEquityTable_1103037" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103037" xlink:to="loc_dei_LegalEntityAxis_1103041" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103041" xlink:to="loc_dei_EntityDomain_1103042" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103042" xlink:to="loc_bvs_BioVentusLlcMember_1103043" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems_1103040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103037" xlink:to="loc_bvs_MemberEquityLineItems_1103040" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:label="loc_us-gaap_MembersEquityNotesDisclosureTextBlock_1103044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103040" xlink:to="loc_us-gaap_MembersEquityNotesDisclosureTextBlock_1103044" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1102978" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1102978" xlink:to="loc_us-gaap_StatementTable_1102981" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102981" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102982" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102982" xlink:to="loc_us-gaap_ClassOfStockDomain_1102983" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102981" xlink:to="loc_dei_LegalEntityAxis_1102985" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102985" xlink:to="loc_dei_EntityDomain_1102986" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102986" xlink:to="loc_bvs_BioVentusLlcMember_1102989" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1102984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102981" xlink:to="loc_us-gaap_StatementLineItems_1102984" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1102979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102984" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1102979" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/NetSales">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1102356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1102358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1102356" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1102358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102358" xlink:to="loc_dei_LegalEntityAxis_1102360" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102360" xlink:to="loc_dei_EntityDomain_1102361" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102361" xlink:to="loc_bvs_BioVentusLlcMember_1102362" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1102359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102358" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_1102359" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetSalesTextBlock" xlink:label="loc_bvs_NetSalesTextBlock_1105019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102359" xlink:to="loc_bvs_NetSalesTextBlock_1105019" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1102197" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1102197" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102245" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102245" xlink:to="loc_dei_LegalEntityAxis_1102247" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102247" xlink:to="loc_dei_EntityDomain_1102248" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102248" xlink:to="loc_bvs_BioVentusLlcMember_1102249" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102245" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1102198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102246" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1102198" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/StockholderSEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1101690" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1101691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1101690" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1101691" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RevenueRecognition">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_820" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_820" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_821" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/Segments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_840" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_840" xlink:to="loc_us-gaap_StatementTable_1105021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105021" xlink:to="loc_dei_LegalEntityAxis_1105022" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105022" xlink:to="loc_dei_EntityDomain_1105023" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105023" xlink:to="loc_bvs_BioVentusLlcMember_1105025" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105021" xlink:to="loc_us-gaap_StatementLineItems_1105024" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105024" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_873" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1103917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_873" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1103917" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103917" xlink:to="loc_dei_LegalEntityAxis_1103918" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103918" xlink:to="loc_dei_EntityDomain_1103919" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103919" xlink:to="loc_bvs_BioVentusLlcMember_1103921" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1103917" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103920" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_1103920" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_874" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/OrganizationPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_226" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_226" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_227" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1101685" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1101685" xlink:to="loc_us-gaap_StatementTable_1105691" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105691" xlink:to="loc_dei_LegalEntityAxis_1105696" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105696" xlink:to="loc_dei_EntityDomain_1105697" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105697" xlink:to="loc_bvs_BioVentusLlcMember_1105698" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105691" xlink:to="loc_us-gaap_StatementLineItems_1105694" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1101687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1101687" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1102391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1102391" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_1102392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_1102392" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NonControllingInterestPolicyTextBlock" xlink:label="loc_bvs_NonControllingInterestPolicyTextBlock_1102393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_bvs_NonControllingInterestPolicyTextBlock_1102393" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1102394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1102394" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1102395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1102395" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1102396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1102396" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1102397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1102397" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_1102399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_1102399" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1102400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1102400" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1102401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1102401" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1102402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1102402" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractAssetsPolicyTextBlock" xlink:label="loc_bvs_ContractAssetsPolicyTextBlock_1102404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_bvs_ContractAssetsPolicyTextBlock_1102404" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractLiabilitiesPolicyTextBlock" xlink:label="loc_bvs_ContractLiabilitiesPolicyTextBlock_1102406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_bvs_ContractLiabilitiesPolicyTextBlock_1102406" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1102408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1102408" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContractCostsPolicyTextBlock" xlink:label="loc_bvs_ContractCostsPolicyTextBlock_1102409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_bvs_ContractCostsPolicyTextBlock_1102409" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1102410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_1102410" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1102411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1102411" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1102412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1102412" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1102415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1102415" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_1102416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_1102416" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1102418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1102418" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_1102419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_1102419" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1102420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1102420" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_1102421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_1102421" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_1102422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_1102422" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1102424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1102424" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1102425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1102425" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1102426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1102426" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1102428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1102428" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1102429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1102429" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1102430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1102430" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1102431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105694" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1102431" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1102478" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1102478" xlink:to="loc_us-gaap_StatementTable_1105934" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105934" xlink:to="loc_dei_LegalEntityAxis_1105936" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105936" xlink:to="loc_dei_EntityDomain_1105937" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105937" xlink:to="loc_bvs_BioventusIncMember_1105938" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105934" xlink:to="loc_us-gaap_StatementLineItems_1105935" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_1102480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105935" xlink:to="loc_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_1102480" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1102481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105935" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1102481" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1102482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105935" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1102482" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RestructuringCostsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1103082" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1103082" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103083" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103083" xlink:to="loc_dei_LegalEntityAxis_1103086" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103086" xlink:to="loc_dei_EntityDomain_1103087" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103087" xlink:to="loc_bvs_BioVentusLlcMember_1103089" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1103084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103083" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1103084" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1103085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103084" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1103085" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1103048" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable_1103050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1103048" xlink:to="loc_bvs_MemberEquityTable_1103050" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103050" xlink:to="loc_dei_LegalEntityAxis_1103054" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103054" xlink:to="loc_dei_EntityDomain_1103055" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103055" xlink:to="loc_bvs_BioVentusLlcMember_1103056" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems_1103053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103050" xlink:to="loc_bvs_MemberEquityLineItems_1103053" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfMembersEquityTableTextBlock" xlink:label="loc_bvs_ScheduleOfMembersEquityTableTextBlock_1103057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103053" xlink:to="loc_bvs_ScheduleOfMembersEquityTableTextBlock_1103057" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/NetSalesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1102364" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1102365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1102364" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1102365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102365" xlink:to="loc_dei_LegalEntityAxis_1102366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102366" xlink:to="loc_dei_EntityDomain_1102367" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102367" xlink:to="loc_bvs_BioVentusLlcMember_1102368" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1102369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102365" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_1102369" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock" xlink:label="loc_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock_1102370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102369" xlink:to="loc_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock_1102370" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1102200" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1102200" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102210" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102210" xlink:to="loc_dei_LegalEntityAxis_1102211" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102211" xlink:to="loc_dei_EntityDomain_1102212" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102212" xlink:to="loc_bvs_BioVentusLlcMember_1102214" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102210" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102215" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock_1102202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102215" xlink:to="loc_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock_1102202" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SegmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_843" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_843" xlink:to="loc_us-gaap_StatementTable_1105027" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105027" xlink:to="loc_dei_LegalEntityAxis_1105028" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105028" xlink:to="loc_dei_EntityDomain_1105029" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105029" xlink:to="loc_bvs_BioVentusLlcMember_1105031" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105027" xlink:to="loc_us-gaap_StatementLineItems_1105030" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105030" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_844" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RevenueRecognitionTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_823" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_823" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_824" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/NetIncomeLossPerUnitTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1102299" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1102299" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102320" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102320" xlink:to="loc_dei_LegalEntityAxis_1102321" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102321" xlink:to="loc_dei_EntityDomain_1102322" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102322" xlink:to="loc_bvs_BioVentusLlcMember_1102323" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1102324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102320" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1102324" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1102300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102324" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1102300" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_766" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1102407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_766" xlink:to="loc_us-gaap_LossContingenciesTable_1102407" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1102407" xlink:to="loc_dei_LegalEntityAxis_1102413" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102413" xlink:to="loc_dei_EntityDomain_1102414" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102414" xlink:to="loc_bvs_BioVentusLlcMember_1102417" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1102427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1102407" xlink:to="loc_us-gaap_LossContingenciesLineItems_1102427" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1102427" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_767" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1102427" xlink:to="loc_bvs_AssetsAndLiabilitiesLesseeTableTextBlock_768" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1102398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1102427" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1102398" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_276" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_276" xlink:to="loc_us-gaap_StatementTable_1105939" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105939" xlink:to="loc_dei_LegalEntityAxis_1105940" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105940" xlink:to="loc_dei_EntityDomain_1105941" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105941" xlink:to="loc_bvs_BioventusIncMember_1105942" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105939" xlink:to="loc_us-gaap_StatementLineItems_1105943" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_277" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_278" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_279" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_280" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_281" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfInventoryValuationReservesTableTextBlock" xlink:label="loc_bvs_ScheduleOfInventoryValuationReservesTableTextBlock_1101940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_bvs_ScheduleOfInventoryValuationReservesTableTextBlock_1101940" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1101941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1101941" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1101944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1101944" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock_1101961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock_1101961" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105943" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_282" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1102789" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1102789" xlink:to="loc_us-gaap_StatementTable_1102791" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102791" xlink:to="loc_dei_LegalEntityAxis_1102796" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102796" xlink:to="loc_dei_EntityDomain_1102797" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102797" xlink:to="loc_bvs_BioVentusLlcMember_1102798" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102791" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102792" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102792" xlink:to="loc_us-gaap_ClassOfStockDomain_1102793" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1102794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102791" xlink:to="loc_us-gaap_StatementLineItems_1102794" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_325" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_326" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_327" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_328" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102794" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_329" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_500" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1103288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500" xlink:to="loc_us-gaap_StatementTable_1103288" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103288" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103289" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103289" xlink:to="loc_us-gaap_ClassOfStockDomain_1103290" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103288" xlink:to="loc_dei_LegalEntityAxis_1103292" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103292" xlink:to="loc_dei_EntityDomain_1103293" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103293" xlink:to="loc_bvs_BioVentusLlcMember_1103294" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103288" xlink:to="loc_us-gaap_StatementLineItems_1103291" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_501" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock" xlink:label="loc_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock_1103295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock_1103295" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock" xlink:label="loc_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock_1103320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock_1103320" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock" xlink:label="loc_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock_1103311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock_1103311" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1103321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103291" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1103321" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_532" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_532" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1102930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1102930" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1102931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1102930" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1102931" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_1102932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1102931" xlink:to="loc_bvs_EquityParticipationRightUnitMember_1102932" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" xlink:to="loc_dei_LegalEntityAxis_1102933" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102933" xlink:to="loc_dei_EntityDomain_1102934" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102934" xlink:to="loc_bvs_BioVentusLlcMember_1102935" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102928" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_533" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_534" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_535" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1102927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102929" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1102927" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1103157" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1103159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1103157" xlink:to="loc_us-gaap_StatementTable_1103159" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103159" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103160" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103160" xlink:to="loc_us-gaap_ClassOfStockDomain_1103161" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103159" xlink:to="loc_dei_LegalEntityAxis_1103166" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103166" xlink:to="loc_dei_EntityDomain_1103167" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103167" xlink:to="loc_bvs_BioVentusLlcMember_1103168" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1106240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103159" xlink:to="loc_us-gaap_AwardTypeAxis_1106240" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1106240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106241" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherPhantomUnitMember" xlink:label="loc_bvs_OtherPhantomUnitMember_1106242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106241" xlink:to="loc_bvs_OtherPhantomUnitMember_1106242" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103159" xlink:to="loc_us-gaap_StatementLineItems_1103162" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_627" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_628" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_629" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock" xlink:label="loc_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock_1103172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103162" xlink:to="loc_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock_1103172" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EarningsPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_729" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_729" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_730" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_729" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_731" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1102602" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeTaxDisclosureTable" xlink:label="loc_bvs_IncomeTaxDisclosureTable_1105726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1102602" xlink:to="loc_bvs_IncomeTaxDisclosureTable_1105726" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncomeTaxDisclosureTable_1105726" xlink:to="loc_dei_LegalEntityAxis_1105731" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105731" xlink:to="loc_dei_EntityDomain_1105733" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105733" xlink:to="loc_bvs_BioVentusLlcMember_1105736" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeTaxDisclosureLineItems" xlink:label="loc_bvs_IncomeTaxDisclosureLineItems_1105728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncomeTaxDisclosureTable_1105726" xlink:to="loc_bvs_IncomeTaxDisclosureLineItems_1105728" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1102603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1102603" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1102604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1102604" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1102625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1102625" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1102692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_IncomeTaxDisclosureLineItems_1105728" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1102692" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/OrganizationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_229" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_229" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_230" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_StatementClassOfStockAxis_231" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_231" xlink:to="loc_us-gaap_ClassOfStockDomain_232" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_232" xlink:to="loc_us-gaap_CommonClassAMember_244" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_232" xlink:to="loc_us-gaap_CommonClassBMember_245" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_srt_OwnershipAxis_233" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_233" xlink:to="loc_srt_OwnershipDomain_234" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCMember" xlink:label="loc_bvs_BVLLCMember_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_234" xlink:to="loc_bvs_BVLLCMember_246" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_dei_LegalEntityAxis_235" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_235" xlink:to="loc_dei_EntityDomain_236" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_236" xlink:to="loc_bvs_BioventusIncMember_247" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_237" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_237" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238" xlink:to="loc_us-gaap_IPOMember_248" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_238" xlink:to="loc_us-gaap_OverAllotmentOptionMember_249" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_239" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_239" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_240" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCMember" xlink:label="loc_bvs_BVLLCMember_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_240" xlink:to="loc_bvs_BVLLCMember_250" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1101655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1101655" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1101656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1101655" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1101656" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1101657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1101656" xlink:to="loc_us-gaap_SubsequentEventMember_1101657" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_230" xlink:to="loc_us-gaap_ClassOfStockLineItems_243" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityNumberOfEmployees" xlink:label="loc_dei_EntityNumberOfEmployees_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_dei_EntityNumberOfEmployees_252" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_253" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_254" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_255" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_256" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SaleOfStockOfferingCosts" xlink:label="loc_bvs_SaleOfStockOfferingCosts_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_SaleOfStockOfferingCosts_257" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaymentsOfStockIssuanceCostsAdditionalCosts" xlink:label="loc_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts_258" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest_259" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_260" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_261" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_262" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_263" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonStockNumberOfVotes" xlink:label="loc_bvs_CommonStockNumberOfVotes_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_CommonStockNumberOfVotes_264" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_265" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_266" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_267" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_268" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_270" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromGovernmentalAssistance" xlink:label="loc_bvs_ProceedsFromGovernmentalAssistance_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_ProceedsFromGovernmentalAssistance_271" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_1101581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_1101581" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfDeferredPayrollTax" xlink:label="loc_bvs_PercentageOfDeferredPayrollTax_1101582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_PercentageOfDeferredPayrollTax_1101582" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:label="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld_1104997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_243" xlink:to="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld_1104997" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_284" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_284" xlink:to="loc_us-gaap_StatementTable_1105956" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105956" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105957" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105957" xlink:to="loc_us-gaap_ClassOfStockDomain_1105958" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105956" xlink:to="loc_dei_LegalEntityAxis_1105963" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105963" xlink:to="loc_dei_EntityDomain_1105964" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105956" xlink:to="loc_us-gaap_StatementLineItems_1105959" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105959" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_285" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105959" xlink:to="loc_us-gaap_RestrictedCashCurrent_286" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105959" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_287" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_289" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_289" xlink:to="loc_us-gaap_StatementTable_1105967" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105967" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105968" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105968" xlink:to="loc_us-gaap_ClassOfStockDomain_1105969" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105967" xlink:to="loc_dei_LegalEntityAxis_1105971" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105971" xlink:to="loc_dei_EntityDomain_1105972" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105972" xlink:to="loc_bvs_BioventusIncMember_1105973" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105967" xlink:to="loc_us-gaap_StatementLineItems_1105970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105970" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_290" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105970" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_291" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105970" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_292" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_294" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_294" xlink:to="loc_us-gaap_StatementTable_1105981" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105981" xlink:to="loc_dei_LegalEntityAxis_1105985" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105985" xlink:to="loc_dei_EntityDomain_1105986" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105986" xlink:to="loc_bvs_BioventusIncMember_1105987" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105981" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105982" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105982" xlink:to="loc_us-gaap_ClassOfStockDomain_1105983" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105981" xlink:to="loc_us-gaap_StatementLineItems_1105984" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105984" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_296" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_297" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_298" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_299" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_300" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationInventoryDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_302" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_302" xlink:to="loc_us-gaap_StatementTable_1105989" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105989" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105990" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105990" xlink:to="loc_us-gaap_ClassOfStockDomain_1105991" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105989" xlink:to="loc_dei_LegalEntityAxis_1105993" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105993" xlink:to="loc_dei_EntityDomain_1105994" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105994" xlink:to="loc_bvs_BioventusIncMember_1105995" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105989" xlink:to="loc_us-gaap_StatementLineItems_1105992" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_303" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryFinishedGoods_304" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryGross_305" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryValuationReserves_306" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105992" xlink:to="loc_us-gaap_InventoryNet_307" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_309" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_309" xlink:to="loc_us-gaap_StatementTable_1105904" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105904" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105905" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105905" xlink:to="loc_us-gaap_ClassOfStockDomain_1105906" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105904" xlink:to="loc_dei_LegalEntityAxis_1105908" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105908" xlink:to="loc_dei_EntityDomain_1105909" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105909" xlink:to="loc_bvs_BioVentusLlcMember_1105910" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105904" xlink:to="loc_us-gaap_StatementLineItems_1105907" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_GrossToNetDeductionsCurrent" xlink:label="loc_bvs_GrossToNetDeductionsCurrent_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_bvs_GrossToNetDeductionsCurrent_310" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_AccruedBonusesCurrent_311" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent" xlink:label="loc_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent_1102423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent_1102423" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_bvs_AccruedSalariesAndEmployeeBenefitsCurrent_312" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_TaxesPayableCurrent_313" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_314" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105907" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_315" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_317" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_317" xlink:to="loc_us-gaap_StatementTable_1102446" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102447" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102447" xlink:to="loc_us-gaap_ClassOfStockDomain_1102448" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventAxis" xlink:label="loc_bvs_EventAxis_1102450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_bvs_EventAxis_1102450" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventDomain" xlink:label="loc_bvs_EventDomain_1102451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_EventAxis_1102450" xlink:to="loc_bvs_EventDomain_1102451" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ReclassificationOfIprdMember" xlink:label="loc_bvs_ReclassificationOfIprdMember_1102473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_EventDomain_1102451" xlink:to="loc_bvs_ReclassificationOfIprdMember_1102473" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102474" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102474" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1102476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1102476" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_1102487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102475" xlink:to="loc_us-gaap_DistributionRightsMember_1102487" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1102488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1102488" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102488" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102489" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember_1102490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1102489" xlink:to="loc_us-gaap_AccountsPayableMember_1102490" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_dei_LegalEntityAxis_1105795" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105795" xlink:to="loc_dei_EntityDomain_1105796" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105796" xlink:to="loc_bvs_BioventusIncMember_1105798" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1102449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102446" xlink:to="loc_us-gaap_StatementLineItems_1102449" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_RestructuringReserveCurrent_318" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_PaymentsForRestructuring_319" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1102442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_Depreciation_1102442" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_1102443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_1102443" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1102477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1102477" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1102479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1102479" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1102494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1102494" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AmortizationExpenseIncludedInInventory" xlink:label="loc_bvs_AmortizationExpenseIncludedInInventory_1102495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_bvs_AmortizationExpenseIncludedInInventory_1102495" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1102497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1102497" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1102498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1102498" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1102499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1102499" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1102500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1102500" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1102501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1102449" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1102501" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryAdjustmentsAbstract" xlink:label="loc_us-gaap_InventoryAdjustmentsAbstract_1102205" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1106000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryAdjustmentsAbstract_1102205" xlink:to="loc_us-gaap_StatementTable_1106000" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1106004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1106000" xlink:to="loc_dei_LegalEntityAxis_1106004" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1106004" xlink:to="loc_dei_EntityDomain_1106005" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1106006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1106005" xlink:to="loc_bvs_BioventusIncMember_1106006" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1106001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1106000" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1106001" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1106002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1106001" xlink:to="loc_us-gaap_ClassOfStockDomain_1106002" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1106003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1106000" xlink:to="loc_us-gaap_StatementLineItems_1106003" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_1102207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1106003" xlink:to="loc_us-gaap_InventoryValuationReserves_1102207" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryValuationReservesProvisionForLosses" xlink:label="loc_bvs_InventoryValuationReservesProvisionForLosses_1102208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1106003" xlink:to="loc_bvs_InventoryValuationReservesProvisionForLosses_1102208" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryValuationReservesWriteOffs" xlink:label="loc_bvs_InventoryValuationReservesWriteOffs_1102209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1106003" xlink:to="loc_bvs_InventoryValuationReservesWriteOffs_1102209" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_1102213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1106003" xlink:to="loc_us-gaap_InventoryValuationReserves_1102213" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1102224" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1102224" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102234" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102234" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ComputerEquipmentAndSoftwareMember" xlink:label="loc_bvs_ComputerEquipmentAndSoftwareMember_1102236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_bvs_ComputerEquipmentAndSoftwareMember_1102236" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1102237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1102237" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1102238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1102238" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1102239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_1102239" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="loc_us-gaap_AssetUnderConstructionMember_1102240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102235" xlink:to="loc_us-gaap_AssetUnderConstructionMember_1102240" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1106007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" xlink:to="loc_dei_LegalEntityAxis_1106007" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1106007" xlink:to="loc_dei_EntityDomain_1106008" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1106010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1106008" xlink:to="loc_bvs_BioventusIncMember_1106010" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102233" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1102242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1102242" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1102243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1102243" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1102244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102241" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1102244" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1102273" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1102274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1102273" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1102274" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1102275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1102274" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1102275" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1102276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1102275" xlink:to="loc_us-gaap_SegmentDomain_1102276" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_USSegmentMember" xlink:label="loc_bvs_USSegmentMember_1102277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1102276" xlink:to="loc_bvs_USSegmentMember_1102277" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InternationalSegmentMember" xlink:label="loc_bvs_InternationalSegmentMember_1102278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1102276" xlink:to="loc_bvs_InternationalSegmentMember_1102278" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_1102282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1102274" xlink:to="loc_srt_ConsolidationItemsAxis_1102282" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_1102283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1102282" xlink:to="loc_srt_ConsolidationItemsDomain_1102283" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_1102284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1102283" xlink:to="loc_us-gaap_OperatingSegmentsMember_1102284" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1106011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1102274" xlink:to="loc_dei_LegalEntityAxis_1106011" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1106011" xlink:to="loc_dei_EntityDomain_1106012" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1106013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1106012" xlink:to="loc_bvs_BioventusIncMember_1106013" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_1102280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1102274" xlink:to="loc_us-gaap_GoodwillLineItems_1102280" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1102286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1102280" xlink:to="loc_us-gaap_Goodwill_1102286" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1102292" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1102292" xlink:to="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102302" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102302" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_1102304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" xlink:to="loc_us-gaap_IntellectualPropertyMember_1102304" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_1102305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" xlink:to="loc_us-gaap_DistributionRightsMember_1102305" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1102306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1102306" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1102354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102303" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1102354" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1102308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1102308" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1102309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1102308" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1102309" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AcquiredInProcessResearchAndDevelopmentMember" xlink:label="loc_bvs_AcquiredInProcessResearchAndDevelopmentMember_1102310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1102309" xlink:to="loc_bvs_AcquiredInProcessResearchAndDevelopmentMember_1102310" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1106015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" xlink:to="loc_dei_LegalEntityAxis_1106015" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1106016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1106015" xlink:to="loc_dei_EntityDomain_1106016" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1106017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1106016" xlink:to="loc_bvs_BioventusIncMember_1106017" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems" xlink:label="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable_1102301" xlink:to="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1102332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1102332" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1102333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1102333" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1102336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1102336" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems_1102331" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1102345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1102345" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation" xlink:label="loc_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation_1102349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" xlink:to="loc_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation_1102349" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FiniteLivedIntangibleAssetsCurrencyTranslation" xlink:label="loc_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation_1106215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" xlink:to="loc_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation_1106215" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1102352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract_1102344" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1102352" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_331" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_331" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_dei_LegalEntityAxis_1102834" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102834" xlink:to="loc_dei_EntityDomain_1102836" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102836" xlink:to="loc_bvs_BioVentusLlcMember_1102837" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_333" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_333" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334" xlink:to="loc_bvs_BionessIncMember_354" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CartiHealMember" xlink:label="loc_bvs_CartiHealMember_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334" xlink:to="loc_bvs_CartiHealMember_355" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_335" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_335" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_336" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_337" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_337" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_338" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_339" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_339" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_340" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ObtainingFDAApprovalOfCertainProductsMember" xlink:label="loc_bvs_ObtainingFDAApprovalOfCertainProductsMember_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_340" xlink:to="loc_bvs_ObtainingFDAApprovalOfCertainProductsMember_359" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember" xlink:label="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_340" xlink:to="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember_360" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember" xlink:label="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_340" xlink:to="loc_bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember_361" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember" xlink:label="loc_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_340" xlink:to="loc_bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember_362" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_341" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_341" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_342" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VaporoxMember" xlink:label="loc_bvs_VaporoxMember_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_342" xlink:to="loc_bvs_VaporoxMember_363" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CartiHealLtdMember" xlink:label="loc_bvs_CartiHealLtdMember_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_342" xlink:to="loc_bvs_CartiHealLtdMember_364" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_343" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_343" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_344" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_344" xlink:to="loc_us-gaap_ConvertibleDebtMember_365" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_srt_ConsolidatedEntitiesAxis_345" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_345" xlink:to="loc_srt_ConsolidatedEntitiesDomain_346" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_346" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_366" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_srt_OwnershipAxis_347" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_347" xlink:to="loc_srt_OwnershipDomain_348" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMedtechIncMember" xlink:label="loc_bvs_HarborMedtechIncMember_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_348" xlink:to="loc_bvs_HarborMedtechIncMember_367" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_StatementClassOfStockAxis_349" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_349" xlink:to="loc_us-gaap_ClassOfStockDomain_350" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_368" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_369" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborSeriesCPreferredStockMember" xlink:label="loc_bvs_HarborSeriesCPreferredStockMember_1102842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_bvs_HarborSeriesCPreferredStockMember_1102842" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SeriesFConvertiblePreferredStockMember" xlink:label="loc_bvs_SeriesFConvertiblePreferredStockMember_1102856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_bvs_SeriesFConvertiblePreferredStockMember_1102856" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SeriesG1PreferredStockMember" xlink:label="loc_bvs_SeriesG1PreferredStockMember_1102860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_350" xlink:to="loc_bvs_SeriesG1PreferredStockMember_1102860" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_srt_RangeAxis_351" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_351" xlink:to="loc_srt_RangeMember_352" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_352" xlink:to="loc_srt_MaximumMember_370" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1102839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_DebtInstrumentAxis_1102839" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1102840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1102839" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1102840" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PromissoryNoteMember" xlink:label="loc_bvs_PromissoryNoteMember_1102841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1102840" xlink:to="loc_bvs_PromissoryNoteMember_1102841" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1102843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1102843" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1102844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1102843" xlink:to="loc_us-gaap_EquityComponentDomain_1102844" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborCommonStockMember" xlink:label="loc_bvs_HarborCommonStockMember_1102845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1102844" xlink:to="loc_bvs_HarborCommonStockMember_1102845" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102850" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102850" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102851" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1102852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102851" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1102852" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1102853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1102853" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102853" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102854" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1102855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1102854" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1102855" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementForFutureEquityAxis" xlink:label="loc_bvs_AgreementForFutureEquityAxis_1102857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_bvs_AgreementForFutureEquityAxis_1102857" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementForFutureEquityDomain" xlink:label="loc_bvs_AgreementForFutureEquityDomain_1102858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_AgreementForFutureEquityAxis_1102857" xlink:to="loc_bvs_AgreementForFutureEquityDomain_1102858" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SimpleAgreementForFutureEquityMember" xlink:label="loc_bvs_SimpleAgreementForFutureEquityMember_1102859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_AgreementForFutureEquityDomain_1102858" xlink:to="loc_bvs_SimpleAgreementForFutureEquityMember_1102859" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementAxis" xlink:label="loc_bvs_AgreementAxis_1102861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_bvs_AgreementAxis_1102861" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementDomain" xlink:label="loc_bvs_AgreementDomain_1102863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_AgreementAxis_1102861" xlink:to="loc_bvs_AgreementDomain_1102863" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OptionAndEquityPurchaseAgreementMember" xlink:label="loc_bvs_OptionAndEquityPurchaseAgreementMember_1102864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_AgreementDomain_1102863" xlink:to="loc_bvs_OptionAndEquityPurchaseAgreementMember_1102864" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_332" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_353" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_371" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_373" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_375" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_376" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_377" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_378" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_379" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_380" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_381" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_383" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_384" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_AssetImpairmentCharges_385" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest" xlink:label="loc_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest_386" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntityImpairment" xlink:label="loc_bvs_VariableInterestEntityImpairment_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_VariableInterestEntityImpairment_387" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EquityMethodInvestments_388" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_389" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_390" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares_391" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount_392" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xlink:label="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment_393" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xlink:label="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased_394" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionPeriodOfNoticeForTermination" xlink:label="loc_bvs_BusinessAcquisitionPeriodOfNoticeForTermination_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_BusinessAcquisitionPeriodOfNoticeForTermination_395" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement" xlink:label="loc_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement_396" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EscrowDeposit_397" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones" xlink:label="loc_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones_398" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_399" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_400" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestmentOwnedOwnershipPercentage" xlink:label="loc_bvs_InvestmentOwnedOwnershipPercentage_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_InvestmentOwnedOwnershipPercentage_401" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_402" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntitySharesIssuedDuringPeriod" xlink:label="loc_bvs_VariableInterestEntitySharesIssuedDuringPeriod_1102870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_VariableInterestEntitySharesIssuedDuringPeriod_1102870" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_1102871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_1102871" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_VariableInterestEntityIssuedCost" xlink:label="loc_bvs_VariableInterestEntityIssuedCost_1102872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_VariableInterestEntityIssuedCost_1102872" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1102873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_1102873" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1102874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1102874" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_1102877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_1102877" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentConvertibleConversionExercisablePrice" xlink:label="loc_bvs_DebtInstrumentConvertibleConversionExercisablePrice_1102879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_DebtInstrumentConvertibleConversionExercisablePrice_1102879" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1102880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1102880" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1102881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1102881" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1102882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1102882" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1102883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1102883" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1102884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1102884" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1102885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1102885" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage" xlink:label="loc_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage_1102886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage_1102886" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_1102887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_1102887" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount" xlink:label="loc_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount_1102888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount_1102888" use="optional" order="106" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1102889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1102889" use="optional" order="107" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1102890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1102890" use="optional" order="108" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions_1102891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions_1102891" use="optional" order="109" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1102892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1102892" use="optional" order="110" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_1102894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_1102894" use="optional" order="111" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1102896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1102896" use="optional" order="112" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares_1102901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares_1102901" use="optional" order="113" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue_1102907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue_1102907" use="optional" order="114" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_1102908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_1102908" use="optional" order="115" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentCapitalizedTransactionCosts" xlink:label="loc_bvs_EquityMethodInvestmentCapitalizedTransactionCosts_1102909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentCapitalizedTransactionCosts_1102909" use="optional" order="116" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_1102910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_EquityMethodInvestments_1102910" use="optional" order="117" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1102911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1102911" use="optional" order="118" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares_1102912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares_1102912" use="optional" order="119" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount" xlink:label="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount_1102913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount_1102913" use="optional" order="120" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment" xlink:label="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment_1102914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment_1102914" use="optional" order="121" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased" xlink:label="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased_1102916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_353" xlink:to="loc_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased_1102916" use="optional" order="122" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_404" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_404" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_405" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_405" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_406" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_406" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_407" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_407" xlink:to="loc_bvs_BionessIncMember_409" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_405" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_408" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_408" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_410" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_408" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_411" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_408" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_412" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_414" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_414" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_416" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_416" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417" xlink:to="loc_bvs_BionessIncMember_425" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMedtechIncMember" xlink:label="loc_bvs_HarborMedtechIncMember_1102823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_417" xlink:to="loc_bvs_HarborMedtechIncMember_1102823" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" xlink:to="loc_dei_LegalEntityAxis_418" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_418" xlink:to="loc_dei_EntityDomain_419" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_419" xlink:to="loc_bvs_BionessIncMember_426" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" xlink:to="loc_us-gaap_DebtInstrumentAxis_420" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_420" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_421" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMember" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMember_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_421" xlink:to="loc_bvs_PaycheckProtectionProgramCARESActMember_422" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_PaycheckProtectionProgramCARESActMember_422" xlink:to="loc_bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member_427" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member" xlink:label="loc_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_PaycheckProtectionProgramCARESActMember_422" xlink:to="loc_bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member_428" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_415" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_423" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_429" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash_430" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_431" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1102813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1102813" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_432" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_433" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_434" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_435" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_436" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_437" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities_438" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_439" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_440" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1102815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1102815" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1102808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1102808" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_441" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_Goodwill_442" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_1102820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_424" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_1102820" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_443" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_444" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_EscrowDeposit_445" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentNumberOfLoans" xlink:label="loc_bvs_DebtInstrumentNumberOfLoans_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_bvs_DebtInstrumentNumberOfLoans_446" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_447" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_448" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_423" xlink:to="loc_us-gaap_LongTermDebtCurrent_449" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_451" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_451" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_453" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_453" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_454" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_454" xlink:to="loc_bvs_BionessIncMember_458" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_455" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" xlink:to="loc_us-gaap_IntellectualPropertyMember_459" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_460" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_456" xlink:to="loc_us-gaap_CustomerRelationshipsMember_461" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_452" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_457" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_457" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_462" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_457" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_463" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_465" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_465" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" xlink:to="loc_srt_ConsolidatedEntitiesAxis_467" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_467" xlink:to="loc_srt_ConsolidatedEntitiesDomain_468" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_468" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_472" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" xlink:to="loc_srt_OwnershipAxis_469" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_469" xlink:to="loc_srt_OwnershipDomain_470" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMedtechIncMember" xlink:label="loc_bvs_HarborMedtechIncMember_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_470" xlink:to="loc_bvs_HarborMedtechIncMember_473" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" xlink:to="loc_dei_LegalEntityAxis_1102827" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102827" xlink:to="loc_dei_EntityDomain_1102828" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102828" xlink:to="loc_bvs_BioVentusLlcMember_1102829" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_466" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_471" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_474" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_475" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_476" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_477" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_478" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_Assets_479" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_480" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_481" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1102826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1102826" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_482" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_471" xlink:to="loc_us-gaap_Liabilities_483" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_485" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_485" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_487" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_487" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" xlink:to="loc_bvs_BionessIncMember_491" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_486" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_489" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_489" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_492" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_489" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_493" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_489" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_490" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_490" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_494" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_490" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_495" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_503" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_503" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_504" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_503" xlink:to="loc_us-gaap_LongTermDebtCurrent_505" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_503" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_506" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_503" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_507" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_503" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_508" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_503" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_509" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_511" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_511" xlink:to="loc_us-gaap_DebtInstrumentTable_512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_513" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_513" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_514" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_514" xlink:to="loc_us-gaap_InterestRateSwapMember_518" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_515" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_515" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_516" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_516" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_519" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_dei_LegalEntityAxis_1103377" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103377" xlink:to="loc_dei_EntityDomain_1103378" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103378" xlink:to="loc_bvs_BioVentusLlcMember_1103379" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1103385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1103385" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1103386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1103385" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1103386" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TermLoanMember" xlink:label="loc_bvs_TermLoanMember_1103387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1103386" xlink:to="loc_bvs_TermLoanMember_1103387" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CreditAgreementAxis" xlink:label="loc_bvs_CreditAgreementAxis_1103388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_bvs_CreditAgreementAxis_1103388" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CreditAgreementDomain" xlink:label="loc_bvs_CreditAgreementDomain_1103389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CreditAgreementAxis_1103388" xlink:to="loc_bvs_CreditAgreementDomain_1103389" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandNineteenCreditAgreementMember" xlink:label="loc_bvs_TwoThousandNineteenCreditAgreementMember_1103390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CreditAgreementDomain_1103389" xlink:to="loc_bvs_TwoThousandNineteenCreditAgreementMember_1103390" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PriorCreditAgreementMember" xlink:label="loc_bvs_PriorCreditAgreementMember_1103719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_CreditAgreementDomain_1103389" xlink:to="loc_bvs_PriorCreditAgreementMember_1103719" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1103395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_CreditFacilityAxis_1103395" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1103396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1103395" xlink:to="loc_us-gaap_CreditFacilityDomain_1103396" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1103397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1103396" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1103397" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RevolvingCreditFacilitySubAxis" xlink:label="loc_bvs_RevolvingCreditFacilitySubAxis_1103550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_bvs_RevolvingCreditFacilitySubAxis_1103550" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RevolvingCreditFacilitySubDomain" xlink:label="loc_bvs_RevolvingCreditFacilitySubDomain_1103551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_RevolvingCreditFacilitySubAxis_1103550" xlink:to="loc_bvs_RevolvingCreditFacilitySubDomain_1103551" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_1103554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_RevolvingCreditFacilitySubDomain_1103551" xlink:to="loc_us-gaap_LetterOfCreditMember_1103554" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SwingLineCreditFacilityMember" xlink:label="loc_bvs_SwingLineCreditFacilityMember_1103564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_RevolvingCreditFacilitySubDomain_1103551" xlink:to="loc_bvs_SwingLineCreditFacilityMember_1103564" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestRateBasisAxis" xlink:label="loc_bvs_InterestRateBasisAxis_1103570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_bvs_InterestRateBasisAxis_1103570" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestRateBasisDomain" xlink:label="loc_bvs_InterestRateBasisDomain_1103572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_InterestRateBasisAxis_1103570" xlink:to="loc_bvs_InterestRateBasisDomain_1103572" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BrInterestRateBasisMember" xlink:label="loc_bvs_BrInterestRateBasisMember_1103574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_InterestRateBasisDomain_1103572" xlink:to="loc_bvs_BrInterestRateBasisMember_1103574" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_1103593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_VariableRateAxis_1103593" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_1103593" xlink:to="loc_us-gaap_VariableRateDomain_1103594" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_1103595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1103594" xlink:to="loc_us-gaap_EurodollarMember_1103595" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_1103853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1103594" xlink:to="loc_us-gaap_BaseRateMember_1103853" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1103643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_srt_RangeAxis_1103643" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1103644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1103643" xlink:to="loc_srt_RangeMember_1103644" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1103645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1103644" xlink:to="loc_srt_MinimumMember_1103645" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_512" xlink:to="loc_us-gaap_DebtInstrumentLineItems_517" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCredit_521" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LongTermDebtFairValue_522" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_523" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_524" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DerivativeNotionalAmount_525" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives" xlink:label="loc_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives_526" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_527" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1103391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1103391" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1103392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1103392" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1103393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1103393" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1103394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1103394" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1103466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LongTermDebt_1103466" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1103510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1103510" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1103512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1103512" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1103514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1103514" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity" xlink:label="loc_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity_1103516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity_1103516" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_1103524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_1103524" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1103531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1103531" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_1103535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_1103535" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1103825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1103825" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_1103545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_1103545" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AdditionalMarginPercentageToReferenceRates" xlink:label="loc_bvs_AdditionalMarginPercentageToReferenceRates_1103557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_AdditionalMarginPercentageToReferenceRates_1103557" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentFloorRatePercentage" xlink:label="loc_bvs_DebtInstrumentFloorRatePercentage_1103619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DebtInstrumentFloorRatePercentage_1103619" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1103858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1103858" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_1103637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_1103637" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InterestCoverageRatio" xlink:label="loc_bvs_InterestCoverageRatio_1103642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_InterestCoverageRatio_1103642" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ThresholdMaximumAggregateAdditionalBorrowings" xlink:label="loc_bvs_ThresholdMaximumAggregateAdditionalBorrowings_1103668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_ThresholdMaximumAggregateAdditionalBorrowings_1103668" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfTotalOutstandingDebtLoanedByLenders" xlink:label="loc_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders_1103674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders_1103674" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_1103681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_1103681" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing" xlink:label="loc_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing_1103712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing_1103712" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_1103720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_InterestCostsCapitalized_1103720" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_1103722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_1103722" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_1103725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_InterestExpenseDebt_1103725" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1103726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1103726" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1103736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1103736" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees" xlink:label="loc_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees_1103751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees_1103751" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DerivativeStatedFixedInterestRate" xlink:label="loc_bvs_DerivativeStatedFixedInterestRate_1103763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DerivativeStatedFixedInterestRate_1103763" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DerivativeEffectiveInterestRate" xlink:label="loc_bvs_DerivativeEffectiveInterestRate_1103772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_DerivativeEffectiveInterestRate_1103772" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_1103891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_us-gaap_DerivativeLiabilities_1103891" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FrontingFeePercentageOnUndrawnAmount" xlink:label="loc_bvs_FrontingFeePercentageOnUndrawnAmount_1103916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_517" xlink:to="loc_bvs_FrontingFeePercentageOnUndrawnAmount_1103916" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_537" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_537" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_539" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_539" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_540" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_540" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_544" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_541" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_541" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_545" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_542" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_546" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" xlink:to="loc_dei_LegalEntityAxis_1102962" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102962" xlink:to="loc_dei_EntityDomain_1102963" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102963" xlink:to="loc_bvs_BioVentusLlcMember_1102964" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_538" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_DerivativeLiabilities_547" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_548" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_549" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure_550" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightFairValueDisclsoure" xlink:label="loc_bvs_EquityParticipationRightFairValueDisclsoure_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_bvs_EquityParticipationRightFairValueDisclsoure_551" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_543" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_552" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_554" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_554" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_556" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_556" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_557" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_557" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_565" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_srt_RangeAxis_558" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_558" xlink:to="loc_srt_RangeMember_559" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_559" xlink:to="loc_srt_MinimumMember_566" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_559" xlink:to="loc_srt_MaximumMember_567" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_us-gaap_ValuationTechniqueAxis_560" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_560" xlink:to="loc_us-gaap_ValuationTechniqueDomain_561" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_561" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_568" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_562" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_562" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_563" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_563" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_569" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_555" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_564" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_564" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_570" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_572" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_572" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_srt_TitleOfIndividualAxis_574" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_574" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCEmployeesTerminatedPriorToIPOMember" xlink:label="loc_bvs_BVLLCEmployeesTerminatedPriorToIPOMember_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575" xlink:to="loc_bvs_BVLLCEmployeesTerminatedPriorToIPOMember_583" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCEmployeesActiveAtIPOMember" xlink:label="loc_bvs_BVLLCEmployeesActiveAtIPOMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_575" xlink:to="loc_bvs_BVLLCEmployeesActiveAtIPOMember_584" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_AwardTypeAxis_576" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_576" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577" xlink:to="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_585" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_577" xlink:to="loc_bvs_EquityParticipationRightUnitMember_586" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_StatementClassOfStockAxis_578" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_578" xlink:to="loc_us-gaap_ClassOfStockDomain_579" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_579" xlink:to="loc_us-gaap_CommonClassAMember_587" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_580" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_580" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_581" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_581" xlink:to="loc_bvs_BionessIncMember_588" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1103239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1103239" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1103239" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103240" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_1103244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103240" xlink:to="loc_bvs_EquityParticipationRightUnitMember_1103244" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_dei_LegalEntityAxis_1103251" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103251" xlink:to="loc_dei_EntityDomain_1103253" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103253" xlink:to="loc_bvs_BioVentusLlcMember_1103255" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1103267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1103267" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1103268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103267" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1103268" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1103269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1103268" xlink:to="loc_us-gaap_SubsequentEventMember_1103269" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_573" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_589" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NumberOfEquityBasedCompensationPlans" xlink:label="loc_bvs_NumberOfEquityBasedCompensationPlans_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_bvs_NumberOfEquityBasedCompensationPlans_590" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_591" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_592" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_593" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_594" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightEntitledPercentageOfDistributions" xlink:label="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions_595" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_1103223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_1103223" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaap_CashAvailableForDistributions_1103237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_CashAvailableForDistributions_1103237" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1103266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1103266" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_1105172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_582" xlink:to="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_1105172" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_597" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_597" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_599" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_599" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_600" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_600" xlink:to="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_603" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" xlink:to="loc_dei_LegalEntityAxis_1102957" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102957" xlink:to="loc_dei_EntityDomain_1102958" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102958" xlink:to="loc_bvs_BioVentusLlcMember_1102959" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_598" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_601" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_601" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_604" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_605" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_606" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures_1102955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures_1102955" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_607" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity_608" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_609" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_611" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_611" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_613" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_613" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_614" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_614" xlink:to="loc_bvs_EquityParticipationRightUnitMember_617" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" xlink:to="loc_dei_LegalEntityAxis_1102965" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102965" xlink:to="loc_dei_EntityDomain_1102966" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102966" xlink:to="loc_bvs_BioVentusLlcMember_1102967" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_612" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_615" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_615" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_618" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_619" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_620" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_616" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_621" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1102987" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1102987" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1103008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_srt_RangeAxis_1103008" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1103009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1103008" xlink:to="loc_srt_RangeMember_1103009" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1103010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1103009" xlink:to="loc_srt_MaximumMember_1103010" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1103011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1103009" xlink:to="loc_srt_MinimumMember_1103011" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_1103012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1103009" xlink:to="loc_srt_WeightedAverageMember_1103012" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1103013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1103013" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1103014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1103013" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1103014" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1103015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1103014" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1103015" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1103016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1103014" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1103016" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MeasurementInputEquityVolatilityMember" xlink:label="loc_bvs_MeasurementInputEquityVolatilityMember_1103017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1103014" xlink:to="loc_bvs_MeasurementInputEquityVolatilityMember_1103017" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_1103019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1103014" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_1103019" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1103023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1103023" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1103023" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103024" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_1103027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1103024" xlink:to="loc_bvs_EquityParticipationRightUnitMember_1103027" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1103028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1103028" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1103029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1103028" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1103029" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1103030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1103029" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1103030" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_dei_LegalEntityAxis_1103031" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103031" xlink:to="loc_dei_EntityDomain_1103032" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103032" xlink:to="loc_bvs_BioVentusLlcMember_1103033" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1102990" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102993" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightsUnitMeasurableInput" xlink:label="loc_bvs_EquityParticipationRightsUnitMeasurableInput_1103003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102993" xlink:to="loc_bvs_EquityParticipationRightsUnitMeasurableInput_1103003" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightsUnitEquityValue" xlink:label="loc_bvs_EquityParticipationRightsUnitEquityValue_1103007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1102993" xlink:to="loc_bvs_EquityParticipationRightsUnitEquityValue_1103007" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_dei_LegalEntityAxis_1103241" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103241" xlink:to="loc_dei_EntityDomain_1103242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103242" xlink:to="loc_bvs_BioVentusLlcMember_1103243" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_StatementClassOfStockAxis_633" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_633" xlink:to="loc_us-gaap_ClassOfStockDomain_634" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_634" xlink:to="loc_us-gaap_CommonClassAMember_644" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_PlanNameAxis_635" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_635" xlink:to="loc_us-gaap_PlanNameDomain_636" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_A2021PlanMember" xlink:label="loc_bvs_A2021PlanMember_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_636" xlink:to="loc_bvs_A2021PlanMember_645" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_AwardTypeAxis_637" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_637" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAwardMember" xlink:label="loc_bvs_ManagementIncentivePlanAwardMember_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_bvs_ManagementIncentivePlanAwardMember_646" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_us-gaap_EmployeeStockMember_650" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember" xlink:label="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_1103245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember_1103245" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherPhantomUnitMember" xlink:label="loc_bvs_OtherPhantomUnitMember_1103246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638" xlink:to="loc_bvs_OtherPhantomUnitMember_1103246" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_srt_RangeAxis_639" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_639" xlink:to="loc_srt_RangeMember_640" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_640" xlink:to="loc_srt_MinimumMember_651" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_640" xlink:to="loc_srt_MaximumMember_652" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_641" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_641" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_642" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_642" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_653" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_632" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NumberOfEquityBasedCompensationPlans" xlink:label="loc_bvs_NumberOfEquityBasedCompensationPlans_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_bvs_NumberOfEquityBasedCompensationPlans_654" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_655" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_656" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_658" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_659" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_660" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy" xlink:label="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy_661" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_662" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_663" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease_664" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_665" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_666" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_667" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_668" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_669" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_672" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_673" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_674" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_SharePrice_675" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee_676" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_677" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_678" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1103247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1103247" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103248" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1103249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1103249" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1103250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1103250" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103254" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1103256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1103256" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1103257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1103257" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1103258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1103258" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1103259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1103259" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1103261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1103261" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1103262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1103262" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_1103263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_1103263" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1103264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_643" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_1103264" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_680" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_680" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_681" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_681" xlink:to="loc_us-gaap_AwardTypeAxis_682" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_683" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_687" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_684" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_684" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_688" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_689" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_690" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_691" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_684" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_692" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_693" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_694" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_695" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_697" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_697" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" xlink:to="loc_srt_RangeAxis_699" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_699" xlink:to="loc_srt_RangeMember_700" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_700" xlink:to="loc_srt_MinimumMember_704" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_700" xlink:to="loc_srt_MaximumMember_705" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" xlink:to="loc_us-gaap_AwardTypeAxis_701" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_701" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_702" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_702" xlink:to="loc_us-gaap_EmployeeStockOptionMember_706" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_707" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_708" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_709" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_710" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_711" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_712" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_703" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_713" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_715" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_715" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_716" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_716" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_718" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_716" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_719" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_716" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_720" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_715" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_717" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_721" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_722" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_723" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_715" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_724" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_733" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_733" xlink:to="loc_us-gaap_NetIncomeLossAbstract_734" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_734" xlink:to="loc_us-gaap_ProfitLoss_736" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_734" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_737" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_734" xlink:to="loc_us-gaap_NetIncomeLoss_738" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_733" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_735" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_735" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_739" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_735" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_740" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_733" xlink:to="loc_us-gaap_EarningsPerShareBasic_741" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_733" xlink:to="loc_us-gaap_EarningsPerShareDiluted_742" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_744" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_744" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_745" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_745" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_746" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_746" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyInterestsMember" xlink:label="loc_bvs_LimitedLiabilityCompanyInterestsMember_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" xlink:to="loc_bvs_LimitedLiabilityCompanyInterestsMember_749" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" xlink:to="loc_us-gaap_EmployeeStockOptionMember_750" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_751" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_UnvestedClassACommonSharesMember" xlink:label="loc_bvs_UnvestedClassACommonSharesMember_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_747" xlink:to="loc_bvs_UnvestedClassACommonSharesMember_752" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_745" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_748" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_748" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_753" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1102614" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1102614" xlink:to="loc_us-gaap_StatementTable_1105740" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105740" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105741" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105741" xlink:to="loc_us-gaap_ClassOfStockDomain_1105742" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105740" xlink:to="loc_dei_LegalEntityAxis_1105744" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105744" xlink:to="loc_dei_EntityDomain_1105745" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105745" xlink:to="loc_bvs_BioVentusLlcMember_1105768" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105740" xlink:to="loc_us-gaap_StatementLineItems_1105743" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TaxableSubsidiariesAbstract" xlink:label="loc_bvs_TaxableSubsidiariesAbstract_1102615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_bvs_TaxableSubsidiariesAbstract_1102615" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1102616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_TaxableSubsidiariesAbstract_1102615" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1102616" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1102617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_TaxableSubsidiariesAbstract_1102615" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1102617" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign" xlink:label="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign_1102618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign_1102618" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries" xlink:label="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries_1102619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries_1102619" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1102915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105743" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1102915" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1102642" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1102642" xlink:to="loc_us-gaap_StatementTable_1105747" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105747" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105748" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105748" xlink:to="loc_us-gaap_ClassOfStockDomain_1105749" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105747" xlink:to="loc_dei_LegalEntityAxis_1105751" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105751" xlink:to="loc_dei_EntityDomain_1105752" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105752" xlink:to="loc_bvs_BioVentusLlcMember_1105770" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105747" xlink:to="loc_us-gaap_StatementLineItems_1105750" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102645" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1102649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102645" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1102649" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1102650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102645" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1102650" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102655" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1102658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102655" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1102658" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1102661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102655" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1102661" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102664" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1102666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102664" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1102666" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1102671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1102664" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1102671" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_1102675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_1102675" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1102676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105750" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1102676" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1102746" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1102746" xlink:to="loc_us-gaap_StatementTable_1105754" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105754" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105755" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105755" xlink:to="loc_us-gaap_ClassOfStockDomain_1105756" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105754" xlink:to="loc_dei_LegalEntityAxis_1105759" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105759" xlink:to="loc_dei_EntityDomain_1105760" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105760" xlink:to="loc_bvs_BioVentusLlcMember_1105771" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105754" xlink:to="loc_us-gaap_StatementLineItems_1105757" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1102755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1102755" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage" xlink:label="loc_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage_1102758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage_1102758" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1102759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1102759" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1102773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1102773" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage" xlink:label="loc_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage_1102762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage_1102762" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1102768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105757" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1102768" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1102695" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1102695" xlink:to="loc_us-gaap_StatementTable_1105762" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105762" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105763" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105763" xlink:to="loc_us-gaap_ClassOfStockDomain_1105764" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105762" xlink:to="loc_dei_LegalEntityAxis_1105766" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105766" xlink:to="loc_dei_EntityDomain_1105767" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105767" xlink:to="loc_bvs_BioVentusLlcMember_1105776" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105762" xlink:to="loc_us-gaap_StatementLineItems_1105765" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105765" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1102697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1102697" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1102698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1102698" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1102699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1102699" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1102700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1102700" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1102701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1102696" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1102701" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1102702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105765" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1102702" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DeferredTaxLiabilitiesAcquiredIntangibles" xlink:label="loc_bvs_DeferredTaxLiabilitiesAcquiredIntangibles_1102705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_1102702" xlink:to="loc_bvs_DeferredTaxLiabilitiesAcquiredIntangibles_1102705" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1102707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105765" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1102707" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1102799" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceTable" xlink:label="loc_us-gaap_ValuationAllowanceTable_1102803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1102799" xlink:to="loc_us-gaap_ValuationAllowanceTable_1102803" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_dei_LegalEntityAxis_1102809" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102809" xlink:to="loc_dei_EntityDomain_1102810" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102810" xlink:to="loc_bvs_BioVentusLlcMember_1102822" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1102811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_srt_CounterpartyNameAxis_1102811" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1102812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1102811" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1102812" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMember" xlink:label="loc_bvs_HarborMember_1102862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1102812" xlink:to="loc_bvs_HarborMember_1102862" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1102814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_srt_StatementGeographicalAxis_1102814" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1102816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1102814" xlink:to="loc_srt_SegmentGeographicalDomain_1102816" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_1102817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1102816" xlink:to="loc_us-gaap_NonUsMember_1102817" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1102818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1102818" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1102819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1102818" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1102819" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_FederalAndStateMember" xlink:label="loc_bvs_FederalAndStateMember_1102821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1102819" xlink:to="loc_bvs_FederalAndStateMember_1102821" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1102830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_us-gaap_TaxPeriodAxis_1102830" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1102831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1102830" xlink:to="loc_us-gaap_TaxPeriodDomain_1102831" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember" xlink:label="loc_bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember_1102832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1102831" xlink:to="loc_bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember_1102832" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_IndefinitelyMember" xlink:label="loc_bvs_IndefinitelyMember_1102833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1102831" xlink:to="loc_bvs_IndefinitelyMember_1102833" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2015Member" xlink:label="loc_us-gaap_TaxYear2015Member_1102835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1102831" xlink:to="loc_us-gaap_TaxYear2015Member_1102835" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2020Member" xlink:label="loc_us-gaap_TaxYear2020Member_1102838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1102831" xlink:to="loc_us-gaap_TaxYear2020Member_1102838" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_1102804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_1102803" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_1102804" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1102805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1102805" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1102806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1102806" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_1102807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_OpenTaxYear_1102807" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1105398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1105398" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1105401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1105401" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_1105404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1102804" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_1105404" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RelatedPartyTransactionsNarrativeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1102997" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1102999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1102997" xlink:to="loc_us-gaap_StatementTable_1102999" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102999" xlink:to="loc_dei_LegalEntityAxis_1103004" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103004" xlink:to="loc_dei_EntityDomain_1103005" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103005" xlink:to="loc_bvs_BioVentusLlcMember_1103006" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102999" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103000" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103000" xlink:to="loc_us-gaap_ClassOfStockDomain_1103001" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1102999" xlink:to="loc_us-gaap_StatementLineItems_1103002" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CashDistributionMadeToMembersTowardsTax" xlink:label="loc_bvs_CashDistributionMadeToMembersTowardsTax_1103018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103002" xlink:to="loc_bvs_CashDistributionMadeToMembersTowardsTax_1103018" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome" xlink:label="loc_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome_1103021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103002" xlink:to="loc_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome_1103021" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers" xlink:label="loc_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers_1103025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103002" xlink:to="loc_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers_1103025" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_770" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_770" xlink:to="loc_us-gaap_StatementTable_1105472" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105472" xlink:to="loc_dei_LegalEntityAxis_1105478" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105478" xlink:to="loc_dei_EntityDomain_1105479" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105479" xlink:to="loc_bvs_BioVentusLlcMember_1105485" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105472" xlink:to="loc_us-gaap_StatementLineItems_1105475" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105475" xlink:to="loc_us-gaap_OperatingLeaseCost_771" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105475" xlink:to="loc_us-gaap_ShortTermLeaseCost_772" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105475" xlink:to="loc_us-gaap_LeaseCost_773" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_775" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_775" xlink:to="loc_us-gaap_StatementTable_1105497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105497" xlink:to="loc_dei_LegalEntityAxis_1105504" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105504" xlink:to="loc_dei_EntityDomain_1105506" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105506" xlink:to="loc_bvs_BioVentusLlcMember_1105509" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105497" xlink:to="loc_us-gaap_StatementLineItems_1105500" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105500" xlink:to="loc_us-gaap_OperatingLeasePayments_776" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1102444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105500" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1102444" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_778" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_778" xlink:to="loc_us-gaap_StatementTable_1105514" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105514" xlink:to="loc_dei_LegalEntityAxis_1105518" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105518" xlink:to="loc_dei_EntityDomain_1105519" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105519" xlink:to="loc_bvs_BioVentusLlcMember_1105520" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105514" xlink:to="loc_us-gaap_StatementLineItems_1105517" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_779" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_780" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_781" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseLiability_782" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_783" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105517" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_784" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1102432" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1102432" xlink:to="loc_us-gaap_StatementTable_1105536" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105536" xlink:to="loc_dei_LegalEntityAxis_1105541" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105541" xlink:to="loc_dei_EntityDomain_1105542" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1105544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105542" xlink:to="loc_bvs_BioVentusLlcMember_1105544" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105536" xlink:to="loc_us-gaap_StatementLineItems_1105539" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1102433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1102433" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1102434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1102434" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1102435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1102435" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1102436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1102436" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1102437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1102437" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1102438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1102438" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1102439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1102439" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1102440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1102440" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1102441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105539" xlink:to="loc_us-gaap_OperatingLeaseLiability_1102441" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_786" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_786" xlink:to="loc_us-gaap_LossContingenciesTable_787" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_srt_ProductOrServiceAxis_790" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_790" xlink:to="loc_srt_ProductsAndServicesDomain_791" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_792" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_792" xlink:to="loc_us-gaap_LossContingencyNatureDomain_793" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_793" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_804" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_srt_CounterpartyNameAxis_788" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_788" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_HarborMember" xlink:label="loc_bvs_HarborMember_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789" xlink:to="loc_bvs_HarborMember_801" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierOfSingleInjectionOAProductMember" xlink:label="loc_bvs_SupplierOfSingleInjectionOAProductMember_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_789" xlink:to="loc_bvs_SupplierOfSingleInjectionOAProductMember_802" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="loc_us-gaap_SupplyCommitmentAxis_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_SupplyCommitmentAxis_794" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_794" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_795" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ThreeInjectionOAProductMember" xlink:label="loc_bvs_ThreeInjectionOAProductMember_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_795" xlink:to="loc_bvs_ThreeInjectionOAProductMember_805" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_srt_RangeAxis_796" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_796" xlink:to="loc_srt_RangeMember_797" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_797" xlink:to="loc_srt_MinimumMember_806" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_797" xlink:to="loc_srt_MaximumMember_807" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_LitigationStatusAxis_798" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_798" xlink:to="loc_us-gaap_LitigationStatusDomain_799" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_799" xlink:to="loc_bvs_BionessIncMember_808" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_1102457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_srt_MajorCustomersAxis_1102457" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1102458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1102457" xlink:to="loc_srt_NameOfMajorCustomerDomain_1102458" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_UsaoAndOigMember" xlink:label="loc_bvs_UsaoAndOigMember_1102459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1102458" xlink:to="loc_bvs_UsaoAndOigMember_1102459" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1102460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1102460" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1102461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1102460" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1102461" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1102462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1102461" xlink:to="loc_us-gaap_SubsequentEventMember_1102462" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1102463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1102463" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1102464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1102463" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1102464" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1102465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1102464" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1102465" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_dei_LegalEntityAxis_1102469" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102469" xlink:to="loc_dei_EntityDomain_1102470" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102470" xlink:to="loc_bvs_BioVentusLlcMember_1102471" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_787" xlink:to="loc_us-gaap_LossContingenciesLineItems_800" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_809" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_810" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_811" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_812" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CollaborativeArrangementRoyaltyPercentage" xlink:label="loc_bvs_CollaborativeArrangementRoyaltyPercentage_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_CollaborativeArrangementRoyaltyPercentage_813" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_RoyaltyExpense_814" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplyCommitmentTerm" xlink:label="loc_bvs_SupplyCommitmentTerm_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_SupplyCommitmentTerm_815" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplyCommitmentRenewalTerm" xlink:label="loc_bvs_SupplyCommitmentRenewalTerm_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_SupplyCommitmentRenewalTerm_816" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CollaborativeArrangementTerm" xlink:label="loc_bvs_CollaborativeArrangementTerm_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_CollaborativeArrangementTerm_817" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1102452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1102452" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_1102453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_1102453" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualProductLiabilityNet" xlink:label="loc_us-gaap_LossContingencyAccrualProductLiabilityNet_1102454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_us-gaap_LossContingencyAccrualProductLiabilityNet_1102454" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RefundOfExcessPaymentsToThirdPartyCustomers" xlink:label="loc_bvs_RefundOfExcessPaymentsToThirdPartyCustomers_1102455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_RefundOfExcessPaymentsToThirdPartyCustomers_1102455" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MilestonePaymentPayable" xlink:label="loc_bvs_MilestonePaymentPayable_1102456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_MilestonePaymentPayable_1102456" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_StopLossInsuranceThresholdPerMemberPerYear" xlink:label="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear_1105169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_800" xlink:to="loc_bvs_StopLossInsuranceThresholdPerMemberPerYear_1105169" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1102327" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1102327" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102328" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102328" xlink:to="loc_dei_LegalEntityAxis_1102329" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102329" xlink:to="loc_dei_EntityDomain_1102330" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102330" xlink:to="loc_bvs_BioVentusLlcMember_1102334" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1102328" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1102337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1102337" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1102339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1102339" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1102340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1102340" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1102341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1102341" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1102342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1102342" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1102343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1102343" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NetIncomeLossFromContinuingOperations" xlink:label="loc_bvs_NetIncomeLossFromContinuingOperations_1102350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_bvs_NetIncomeLossFromContinuingOperations_1102350" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1102346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1102346" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1102347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1102347" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1102335" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1102371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1102371" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_1102373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_1102373" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1102374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1102374" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1102375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1102348" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1102375" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1102381" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1102381" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" xlink:to="loc_dei_LegalEntityAxis_1102383" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102383" xlink:to="loc_dei_EntityDomain_1102384" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102384" xlink:to="loc_bvs_BioVentusLlcMember_1102385" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1102386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1102386" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1102387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1102386" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1102387" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsMember" xlink:label="loc_bvs_PreferredUnitsMember_1102388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1102387" xlink:to="loc_bvs_PreferredUnitsMember_1102388" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1102389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1102382" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1102389" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1102390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1102389" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1102390" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RevenueRecognitionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_826" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_826" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_827" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_827" xlink:to="loc_srt_StatementGeographicalAxis_828" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_828" xlink:to="loc_srt_SegmentGeographicalDomain_829" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_829" xlink:to="loc_country_US_833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_829" xlink:to="loc_us-gaap_NonUsMember_834" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_827" xlink:to="loc_srt_ProductOrServiceAxis_830" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_830" xlink:to="loc_srt_ProductsAndServicesDomain_831" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PainTreatmentsAndJointPreservationMember" xlink:label="loc_bvs_PainTreatmentsAndJointPreservationMember_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_831" xlink:to="loc_bvs_PainTreatmentsAndJointPreservationMember_835" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestorativeTherapiesMember" xlink:label="loc_bvs_RestorativeTherapiesMember_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_831" xlink:to="loc_bvs_RestorativeTherapiesMember_836" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BoneGraftSubstitutesMember" xlink:label="loc_bvs_BoneGraftSubstitutesMember_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_831" xlink:to="loc_bvs_BoneGraftSubstitutesMember_837" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_827" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_832" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_832" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_838" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SegmentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_846" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_846" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_848" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_848" xlink:to="loc_us-gaap_SegmentDomain_849" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_USSegmentMember" xlink:label="loc_bvs_USSegmentMember_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_849" xlink:to="loc_bvs_USSegmentMember_853" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InternationalSegmentMember" xlink:label="loc_bvs_InternationalSegmentMember_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_849" xlink:to="loc_bvs_InternationalSegmentMember_854" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" xlink:to="loc_srt_ConsolidationItemsAxis_850" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_850" xlink:to="loc_srt_ConsolidationItemsDomain_851" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_851" xlink:to="loc_us-gaap_OperatingSegmentsMember_855" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_851" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_856" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" xlink:to="loc_dei_LegalEntityAxis_1102193" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102193" xlink:to="loc_dei_EntityDomain_1102194" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102194" xlink:to="loc_bvs_BioVentusLlcMember_1102195" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_847" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_852" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_NumberOfReportableSegments_857" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems" xlink:label="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems_858" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_DepreciationAndAmortization_859" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_860" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_861" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemNetGainLoss" xlink:label="loc_us-gaap_UnusualOrInfrequentItemNetGainLoss_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_UnusualOrInfrequentItemNetGainLoss_862" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SuccessionAndTransitionCharges" xlink:label="loc_bvs_SuccessionAndTransitionCharges_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_bvs_SuccessionAndTransitionCharges_863" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1102192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_RestructuringCharges_1102192" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_864" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_865" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InventoryStepUpCost" xlink:label="loc_bvs_InventoryStepUpCost_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_bvs_InventoryStepUpCost_866" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_867" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_868" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_AssetImpairmentCharges_869" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_OtherNonrecurringExpense_870" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_852" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_871" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_876" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_876" xlink:to="loc_us-gaap_SubsequentEventTable_877" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_878" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_878" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_879" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_879" xlink:to="loc_us-gaap_SubsequentEventMember_893" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_DebtInstrumentAxis_880" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_880" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_881" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PaycheckProtectionProgramLoanMember" xlink:label="loc_bvs_PaycheckProtectionProgramLoanMember_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_881" xlink:to="loc_bvs_PaycheckProtectionProgramLoanMember_894" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TermLoanFacilityMember" xlink:label="loc_bvs_TermLoanFacilityMember_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_881" xlink:to="loc_bvs_TermLoanFacilityMember_895" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_A2019CreditAgreementMember" xlink:label="loc_bvs_A2019CreditAgreementMember_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_881" xlink:to="loc_bvs_A2019CreditAgreementMember_896" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_882" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_882" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_883" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_883" xlink:to="loc_us-gaap_SecuredDebtMember_897" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_srt_StatementScenarioAxis_884" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_884" xlink:to="loc_srt_ScenarioUnspecifiedDomain_885" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_885" xlink:to="loc_srt_ScenarioForecastMember_898" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_886" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_886" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MisonixIncMember" xlink:label="loc_bvs_MisonixIncMember_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" xlink:to="loc_bvs_MisonixIncMember_899" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BionessIncMember" xlink:label="loc_bvs_BionessIncMember_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" xlink:to="loc_bvs_BionessIncMember_900" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BVLLCMember" xlink:label="loc_bvs_BVLLCMember_1105689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887" xlink:to="loc_bvs_BVLLCMember_1105689" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_dei_LegalEntityAxis_888" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_888" xlink:to="loc_dei_EntityDomain_889" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_889" xlink:to="loc_bvs_BioVentusLlcMember_1102057" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_srt_OwnershipAxis_890" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_890" xlink:to="loc_srt_OwnershipDomain_891" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_891" xlink:to="loc_bvs_BioventusIncMember_902" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1102054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_InvestmentTypeAxis_1102054" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1102055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1102054" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1102055" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConvertibleDebtInstrumentsMember" xlink:label="loc_bvs_ConvertibleDebtInstrumentsMember_1102056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1102055" xlink:to="loc_bvs_ConvertibleDebtInstrumentsMember_1102056" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventAxis" xlink:label="loc_bvs_EventAxis_1102060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_bvs_EventAxis_1102060" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EventDomain" xlink:label="loc_bvs_EventDomain_1102061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_EventAxis_1102060" xlink:to="loc_bvs_EventDomain_1102061" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestatedLimitedLiabilityCompanyAgreementMember" xlink:label="loc_bvs_RestatedLimitedLiabilityCompanyAgreementMember_1102062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_EventDomain_1102061" xlink:to="loc_bvs_RestatedLimitedLiabilityCompanyAgreementMember_1102062" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestorAxis" xlink:label="loc_bvs_InvestorAxis_1102066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_bvs_InvestorAxis_1102066" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InvestorDomain" xlink:label="loc_bvs_InvestorDomain_1102067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_InvestorAxis_1102066" xlink:to="loc_bvs_InvestorDomain_1102067" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ContinuingLlcOwnerMember" xlink:label="loc_bvs_ContinuingLlcOwnerMember_1102068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_InvestorDomain_1102067" xlink:to="loc_bvs_ContinuingLlcOwnerMember_1102068" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NewLlcOwnerMember" xlink:label="loc_bvs_NewLlcOwnerMember_1102070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_InvestorDomain_1102067" xlink:to="loc_bvs_NewLlcOwnerMember_1102070" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1102072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1102072" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1102073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1102072" xlink:to="loc_us-gaap_ClassOfStockDomain_1102073" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1102074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1102073" xlink:to="loc_us-gaap_CommonClassAMember_1102074" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1102491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1102073" xlink:to="loc_us-gaap_CommonClassBMember_1102491" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_1102147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_srt_MajorCustomersAxis_1102147" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1102148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1102147" xlink:to="loc_srt_NameOfMajorCustomerDomain_1102148" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_UsaoAndOigMember" xlink:label="loc_bvs_UsaoAndOigMember_1102150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1102148" xlink:to="loc_bvs_UsaoAndOigMember_1102150" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1102548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_PlanNameAxis_1102548" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1102549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1102548" xlink:to="loc_us-gaap_PlanNameDomain_1102549" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_A2021PlanMember" xlink:label="loc_bvs_A2021PlanMember_1102576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1102549" xlink:to="loc_bvs_A2021PlanMember_1102576" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1102551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_AwardTypeAxis_1102551" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1102552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1102551" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1102552" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1102566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1102552" xlink:to="loc_us-gaap_EmployeeStockMember_1102566" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1102562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_srt_RangeAxis_1102562" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1102562" xlink:to="loc_srt_RangeMember_1102563" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1102564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1102563" xlink:to="loc_srt_MaximumMember_1102564" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1102565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1102563" xlink:to="loc_srt_MinimumMember_1102565" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementAxis" xlink:label="loc_bvs_AgreementAxis_1105004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_bvs_AgreementAxis_1105004" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_AgreementDomain" xlink:label="loc_bvs_AgreementDomain_1105005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_AgreementAxis_1105004" xlink:to="loc_bvs_AgreementDomain_1105005" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OptionAndEquityPurchaseAgreementMember" xlink:label="loc_bvs_OptionAndEquityPurchaseAgreementMember_1105006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_AgreementDomain_1105005" xlink:to="loc_bvs_OptionAndEquityPurchaseAgreementMember_1105006" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_RestrictedStockUnitsAgreementMember" xlink:label="loc_bvs_RestrictedStockUnitsAgreementMember_1105007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_AgreementDomain_1105005" xlink:to="loc_bvs_RestrictedStockUnitsAgreementMember_1105007" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_877" xlink:to="loc_us-gaap_SubsequentEventLineItems_892" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_903" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_904" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareCash" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash_905" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareShares" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares_906" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum" xlink:label="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum_908" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_909" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentCovenantRequiredPrepayment" xlink:label="loc_bvs_DebtInstrumentCovenantRequiredPrepayment_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_DebtInstrumentCovenantRequiredPrepayment_910" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_DebtInstrumentTerm_911" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_913" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_1102051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_1102051" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany" xlink:label="loc_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany_1102059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany_1102059" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_1102063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_1102063" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1102071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1102071" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1102075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1102075" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xlink:label="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany_1102078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany_1102078" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xlink:label="loc_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod_1102081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod_1102081" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers" xlink:label="loc_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers_1102088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers_1102088" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_1102099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_1102099" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1102140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1102140" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_1102141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_1102141" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1102486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1102486" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1102492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1102492" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1102493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1102493" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CommonStockNumberOfVotes" xlink:label="loc_bvs_CommonStockNumberOfVotes_1102502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_CommonStockNumberOfVotes_1102502" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_1102503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio_1102503" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_CancellationRatioRequiredStockToLLCInterestRatio" xlink:label="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_1102504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_CancellationRatioRequiredStockToLLCInterestRatio_1102504" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_1102509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_1102509" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1102515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1102515" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1102519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1102519" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest_1102521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest_1102521" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedPaymentAwardSettlementPeriod" xlink:label="loc_bvs_ShareBasedPaymentAwardSettlementPeriod_1102569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_ShareBasedPaymentAwardSettlementPeriod_1102569" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1102571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1102571" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1102573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1102573" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_NumberOfEquityBasedCompensationPlans" xlink:label="loc_bvs_NumberOfEquityBasedCompensationPlans_1102574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_NumberOfEquityBasedCompensationPlans_1102574" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1102575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1102575" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease_1102577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease_1102577" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1102578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1102578" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1102579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1102579" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1102580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1102580" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1102583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1102583" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee_1102587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee_1102587" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld" xlink:label="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld_1104996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_892" xlink:to="loc_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld_1104996" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/StockholderSEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1101695" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1101696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1101695" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1101696" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1102250" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1102250" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" xlink:to="loc_dei_LegalEntityAxis_1102253" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102253" xlink:to="loc_dei_EntityDomain_1102255" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102255" xlink:to="loc_bvs_BioVentusLlcMember_1102256" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102257" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102257" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102258" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BmpResearchAndDevelopmentProgrammeMember" xlink:label="loc_bvs_BmpResearchAndDevelopmentProgrammeMember_1102262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102258" xlink:to="loc_bvs_BmpResearchAndDevelopmentProgrammeMember_1102262" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102252" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense_1102269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense_1102269" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1102279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_1102279" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit_1102281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit_1102281" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1102285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102264" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1102285" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1102288" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1102288" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" xlink:to="loc_dei_LegalEntityAxis_1102293" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102293" xlink:to="loc_dei_EntityDomain_1102294" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102294" xlink:to="loc_bvs_BioVentusLlcMember_1102296" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102312" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102312" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102313" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BmpResearchAndDevelopmentProgrammeMember" xlink:label="loc_bvs_BmpResearchAndDevelopmentProgrammeMember_1102318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102313" xlink:to="loc_bvs_BmpResearchAndDevelopmentProgrammeMember_1102318" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1102290" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102291" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1102325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102291" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_1102325" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities" xlink:label="loc_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities_1102338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1102291" xlink:to="loc_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities_1102338" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/NetSalesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1102378" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1102379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1102378" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1102379" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1102483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102379" xlink:to="loc_dei_LegalEntityAxis_1102483" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1102484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1102483" xlink:to="loc_dei_EntityDomain_1102484" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1102485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1102484" xlink:to="loc_bvs_BioVentusLlcMember_1102485" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1102507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102379" xlink:to="loc_srt_StatementGeographicalAxis_1102507" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1102508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1102507" xlink:to="loc_srt_SegmentGeographicalDomain_1102508" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_USSegmentMember" xlink:label="loc_bvs_USSegmentMember_1102512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1102508" xlink:to="loc_bvs_USSegmentMember_1102512" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_InternationalSegmentMember" xlink:label="loc_bvs_InternationalSegmentMember_1102514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1102508" xlink:to="loc_bvs_InternationalSegmentMember_1102514" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1102516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102379" xlink:to="loc_srt_ProductOrServiceAxis_1102516" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1102518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1102516" xlink:to="loc_srt_ProductsAndServicesDomain_1102518" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OAJointPainTreatmentAndJointPreservationMember" xlink:label="loc_bvs_OAJointPainTreatmentAndJointPreservationMember_1102520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1102518" xlink:to="loc_bvs_OAJointPainTreatmentAndJointPreservationMember_1102520" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MinimallyInvasiveFractureTreatmentMember" xlink:label="loc_bvs_MinimallyInvasiveFractureTreatmentMember_1102522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1102518" xlink:to="loc_bvs_MinimallyInvasiveFractureTreatmentMember_1102522" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BoneGraftSubstitutesMember" xlink:label="loc_bvs_BoneGraftSubstitutesMember_1102525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1102518" xlink:to="loc_bvs_BoneGraftSubstitutesMember_1102525" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1102380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1102379" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_1102380" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1102506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1102380" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1102506" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1102643" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1102643" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1102651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" xlink:to="loc_srt_RangeAxis_1102651" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1102651" xlink:to="loc_srt_RangeMember_1102652" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1102653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1102652" xlink:to="loc_srt_MinimumMember_1102653" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1102654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1102652" xlink:to="loc_srt_MaximumMember_1102654" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102656" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1102656" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1102659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" xlink:to="loc_us-gaap_ComputerEquipmentMember_1102659" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1102662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1102662" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1102663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_1102663" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1102665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1102657" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1102665" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" xlink:to="loc_dei_LegalEntityAxis_1105805" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105805" xlink:to="loc_dei_EntityDomain_1105806" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105806" xlink:to="loc_bvs_BioventusIncMember_1105807" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1102648" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102669" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1102674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1102669" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1102674" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1102678" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1102678" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1102681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" xlink:to="loc_srt_RangeAxis_1102681" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1102681" xlink:to="loc_srt_RangeMember_1102682" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_1102683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1102682" xlink:to="loc_srt_WeightedAverageMember_1102683" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102684" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1102684" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_1102686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" xlink:to="loc_us-gaap_IntellectualPropertyMember_1102686" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_1102687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" xlink:to="loc_us-gaap_DistributionRightsMember_1102687" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1102688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1102688" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1102689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1102685" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1102689" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" xlink:to="loc_dei_LegalEntityAxis_1105818" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105818" xlink:to="loc_dei_EntityDomain_1105819" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105819" xlink:to="loc_bvs_BioventusIncMember_1105821" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1102690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1102679" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1102690" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1102691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1102690" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1102691" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1102703" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1102704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1102703" xlink:to="loc_us-gaap_ConcentrationRiskTable_1102704" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConcentrationRiskBySupplierNameAxis" xlink:label="loc_bvs_ConcentrationRiskBySupplierNameAxis_1102706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_bvs_ConcentrationRiskBySupplierNameAxis_1102706" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ConcentrationRiskBySupplierNameDomain" xlink:label="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameAxis_1102706" xlink:to="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierAMember" xlink:label="loc_bvs_SupplierAMember_1102709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_SupplierAMember_1102709" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierBMember" xlink:label="loc_bvs_SupplierBMember_1102710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_SupplierBMember_1102710" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_SupplierCMember" xlink:label="loc_bvs_SupplierCMember_1102716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_SupplierCMember_1102716" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductAMember" xlink:label="loc_bvs_ProductAMember_1102717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_ProductAMember_1102717" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductBMember" xlink:label="loc_bvs_ProductBMember_1102718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_ProductBMember_1102718" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductCMember" xlink:label="loc_bvs_ProductCMember_1102719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_ProductCMember_1102719" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProductDMember" xlink:label="loc_bvs_ProductDMember_1102722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_ConcentrationRiskBySupplierNameDomain_1102708" xlink:to="loc_bvs_ProductDMember_1102722" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1102724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1102724" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1102725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1102724" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1102725" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_1102726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1102725" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_1102726" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_1102727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1102725" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_1102727" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1105712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1105712" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1105713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1105712" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1105713" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1105714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1105713" xlink:to="loc_us-gaap_SalesRevenueNetMember_1105714" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_dei_LegalEntityAxis_1105825" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105825" xlink:to="loc_dei_EntityDomain_1105826" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105826" xlink:to="loc_bvs_BioventusIncMember_1105827" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1102728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1102704" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_1102728" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1102731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1102728" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1102731" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1102730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1102728" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1102730" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1102742" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1105927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1102742" xlink:to="loc_us-gaap_StatementTable_1105927" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1105928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105927" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1105928" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1105929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1105928" xlink:to="loc_us-gaap_ClassOfStockDomain_1105929" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1105931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105927" xlink:to="loc_dei_LegalEntityAxis_1105931" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1105932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1105931" xlink:to="loc_dei_EntityDomain_1105932" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioventusIncMember" xlink:label="loc_bvs_BioventusIncMember_1105933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1105932" xlink:to="loc_bvs_BioventusIncMember_1105933" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1105930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1105927" xlink:to="loc_us-gaap_StatementLineItems_1105930" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1102743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1102743" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_1102744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_1102744" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1102745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_1102745" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_1102747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_1102747" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_1102750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_1102750" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_1102752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_1102752" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1102753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1102753" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_1102754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_DeferredOfferingCosts_1102754" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_1102756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_us-gaap_AdvertisingExpense_1102756" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PercentageOfMembersTaxDistributionToTaxableIncome" xlink:label="loc_bvs_PercentageOfMembersTaxDistributionToTaxableIncome_1105892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1105930" xlink:to="loc_bvs_PercentageOfMembersTaxDistributionToTaxableIncome_1105892" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1103063" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable_1103064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1103063" xlink:to="loc_bvs_MemberEquityTable_1103064" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103064" xlink:to="loc_dei_LegalEntityAxis_1103071" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103071" xlink:to="loc_dei_EntityDomain_1103072" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103072" xlink:to="loc_bvs_BioVentusLlcMember_1103074" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems_1103065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103064" xlink:to="loc_bvs_MemberEquityLineItems_1103065" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue_1103077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue_1103077" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue_1103078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_us-gaap_CommonUnitIssuanceValue_1103078" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue" xlink:label="loc_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue_1103079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue_1103079" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital" xlink:label="loc_us-gaap_MembersCapital_1103080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103065" xlink:to="loc_us-gaap_MembersCapital_1103080" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/MembersEquityNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1103088" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityTable" xlink:label="loc_bvs_MemberEquityTable_1103090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1103088" xlink:to="loc_bvs_MemberEquityTable_1103090" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_dei_LegalEntityAxis_1103091" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103091" xlink:to="loc_dei_EntityDomain_1103092" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103092" xlink:to="loc_bvs_BioVentusLlcMember_1103093" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsByNameAxis" xlink:label="loc_us-gaap_PreferredUnitsByNameAxis_1103094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_us-gaap_PreferredUnitsByNameAxis_1103094" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsClassDomain" xlink:label="loc_us-gaap_PreferredUnitsClassDomain_1103095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsByNameAxis_1103094" xlink:to="loc_us-gaap_PreferredUnitsClassDomain_1103095" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwelvePreferredUnitsMember" xlink:label="loc_bvs_TwoThousandAndTwelvePreferredUnitsMember_1103096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsClassDomain_1103095" xlink:to="loc_bvs_TwoThousandAndTwelvePreferredUnitsMember_1103096" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndFifteenPreferredUnitsMember" xlink:label="loc_bvs_TwoThousandAndFifteenPreferredUnitsMember_1103098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsClassDomain_1103095" xlink:to="loc_bvs_TwoThousandAndFifteenPreferredUnitsMember_1103098" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1103099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1103099" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1103100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1103099" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1103100" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1103101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1103100" xlink:to="loc_us-gaap_SubsequentEventMember_1103101" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1103102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_us-gaap_AwardTypeAxis_1103102" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1103103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1103102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1103103" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightUnitMember" xlink:label="loc_bvs_EquityParticipationRightUnitMember_1103104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1103103" xlink:to="loc_bvs_EquityParticipationRightUnitMember_1103104" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_MemberEquityLineItems" xlink:label="loc_bvs_MemberEquityLineItems_1103105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityTable_1103090" xlink:to="loc_bvs_MemberEquityLineItems_1103105" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany" xlink:label="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany_1103106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany_1103106" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany" xlink:label="loc_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany_1103107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany_1103107" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod" xlink:label="loc_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod_1103108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod_1103108" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsLiquidationPreferencePerUnit" xlink:label="loc_bvs_PreferredUnitsLiquidationPreferencePerUnit_1103109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_PreferredUnitsLiquidationPreferencePerUnit_1103109" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum" xlink:label="loc_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum_1103111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum_1103111" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EquityParticipationRightEntitledPercentageOfDistributions" xlink:label="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions_1103114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_EquityParticipationRightEntitledPercentageOfDistributions_1103114" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DistributionEventTriggerPercentageOfSaleOfAssets" xlink:label="loc_bvs_DistributionEventTriggerPercentageOfSaleOfAssets_1103118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_bvs_DistributionEventTriggerPercentageOfSaleOfAssets_1103118" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1103120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_MemberEquityLineItems_1103105" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1103120" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1103115" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1103115" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1103127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1103127" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1103128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1103127" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1103128" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_EmployeeSeveranceAndTemporaryLaborCostsMember" xlink:label="loc_bvs_EmployeeSeveranceAndTemporaryLaborCostsMember_1103129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1103128" xlink:to="loc_bvs_EmployeeSeveranceAndTemporaryLaborCostsMember_1103129" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherChargesMember" xlink:label="loc_bvs_OtherChargesMember_1103130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1103128" xlink:to="loc_bvs_OtherChargesMember_1103130" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" xlink:to="loc_dei_LegalEntityAxis_1103134" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103134" xlink:to="loc_dei_EntityDomain_1103135" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103135" xlink:to="loc_bvs_BioVentusLlcMember_1103136" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1103117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103116" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1103117" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostsAbstract" xlink:label="loc_us-gaap_RestructuringCostsAbstract_1103119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103117" xlink:to="loc_us-gaap_RestructuringCostsAbstract_1103119" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1103121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostsAbstract_1103119" xlink:to="loc_us-gaap_RestructuringReserve_1103121" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1103122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostsAbstract_1103119" xlink:to="loc_us-gaap_RestructuringCharges_1103122" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_1103123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostsAbstract_1103119" xlink:to="loc_us-gaap_PaymentsForRestructuring_1103123" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1103124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostsAbstract_1103119" xlink:to="loc_us-gaap_RestructuringReserve_1103124" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/RestructuringCostsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1103142" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1103142" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_1103163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" xlink:to="loc_us-gaap_RestructuringPlanAxis_1103163" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_1103164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_1103163" xlink:to="loc_us-gaap_RestructuringPlanDomain_1103164" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwentyPlanMember" xlink:label="loc_bvs_TwoThousandAndTwentyPlanMember_1103171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_1103164" xlink:to="loc_bvs_TwoThousandAndTwentyPlanMember_1103171" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndEighteenPlanMember" xlink:label="loc_bvs_TwoThousandAndEighteenPlanMember_1103170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_1103164" xlink:to="loc_bvs_TwoThousandAndEighteenPlanMember_1103170" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" xlink:to="loc_dei_LegalEntityAxis_1103173" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103173" xlink:to="loc_dei_EntityDomain_1103174" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103174" xlink:to="loc_bvs_BioVentusLlcMember_1103175" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1103153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1103150" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1103153" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1103156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1103153" xlink:to="loc_us-gaap_RestructuringCharges_1103156" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1103184" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1103184" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" xlink:to="loc_dei_LegalEntityAxis_1103186" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103186" xlink:to="loc_dei_EntityDomain_1103187" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103187" xlink:to="loc_bvs_BioVentusLlcMember_1103188" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1103189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" xlink:to="loc_us-gaap_PlanNameAxis_1103189" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1103190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1103189" xlink:to="loc_us-gaap_PlanNameDomain_1103190" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndTwelveMember" xlink:label="loc_bvs_TwoThousandAndTwelveMember_1103191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103190" xlink:to="loc_bvs_TwoThousandAndTwelveMember_1103191" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TwoThousandAndFifteenMember" xlink:label="loc_bvs_TwoThousandAndFifteenMember_1103192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1103190" xlink:to="loc_bvs_TwoThousandAndFifteenMember_1103192" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1106227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" xlink:to="loc_us-gaap_AwardTypeAxis_1106227" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1106227" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106228" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_OtherPhantomUnitMember" xlink:label="loc_bvs_OtherPhantomUnitMember_1106234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1106228" xlink:to="loc_bvs_OtherPhantomUnitMember_1106234" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1103185" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103194" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1103195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1103195" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod_1103204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod_1103204" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1103215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1103215" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1103236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1103236" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1103216" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1103220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_1103220" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103221" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1103222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1103222" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue_1103224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue_1103224" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1103225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1103225" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1103238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1103238" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1103226" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1103235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1103193" xlink:to="loc_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1103235" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_1103297" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1103298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_1103297" xlink:to="loc_us-gaap_DebtInstrumentTable_1103298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103298" xlink:to="loc_dei_LegalEntityAxis_1103299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103299" xlink:to="loc_dei_EntityDomain_1103300" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103300" xlink:to="loc_bvs_BioVentusLlcMember_1103301" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentAxis" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis_1103302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103298" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis_1103302" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentDomain" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentAxis_1103302" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember_1103304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember_1103304" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember" xlink:label="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember_1103305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_DebtInstrumentSchedulePeriodicPaymentDomain_1103303" xlink:to="loc_bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember_1103305" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1103306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103298" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1103306" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1103307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1103306" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1103307" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_TermLoanMember" xlink:label="loc_bvs_TermLoanMember_1103308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1103307" xlink:to="loc_bvs_TermLoanMember_1103308" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1103309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103298" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1103309" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1103310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103309" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1103310" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_1103324" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1103325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_1103324" xlink:to="loc_us-gaap_DebtInstrumentTable_1103325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103325" xlink:to="loc_dei_LegalEntityAxis_1103327" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103327" xlink:to="loc_dei_EntityDomain_1103328" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103328" xlink:to="loc_bvs_BioVentusLlcMember_1103329" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeAxis" xlink:label="loc_bvs_LeverageRatioRangeAxis_1103330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103325" xlink:to="loc_bvs_LeverageRatioRangeAxis_1103330" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeDomain" xlink:label="loc_bvs_LeverageRatioRangeDomain_1103331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeAxis_1103330" xlink:to="loc_bvs_LeverageRatioRangeDomain_1103331" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeOneMember" xlink:label="loc_bvs_LeverageRatioRangeOneMember_1103332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeOneMember_1103332" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeTwoMember" xlink:label="loc_bvs_LeverageRatioRangeTwoMember_1103333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeTwoMember_1103333" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeThreeMember" xlink:label="loc_bvs_LeverageRatioRangeThreeMember_1103334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeThreeMember_1103334" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFourMember" xlink:label="loc_bvs_LeverageRatioRangeFourMember_1103335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeFourMember_1103335" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFiveMember" xlink:label="loc_bvs_LeverageRatioRangeFiveMember_1103336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103331" xlink:to="loc_bvs_LeverageRatioRangeFiveMember_1103336" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_1103337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103325" xlink:to="loc_us-gaap_VariableRateAxis_1103337" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_1103337" xlink:to="loc_us-gaap_VariableRateDomain_1103338" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember" xlink:label="loc_us-gaap_EurodollarMember_1103339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1103338" xlink:to="loc_us-gaap_EurodollarMember_1103339" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_1103340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1103338" xlink:to="loc_us-gaap_BaseRateMember_1103340" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1103341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103325" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1103341" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1103342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103341" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1103342" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_1103315" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1103316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_1103315" xlink:to="loc_us-gaap_DebtInstrumentTable_1103316" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103316" xlink:to="loc_dei_LegalEntityAxis_1103317" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103317" xlink:to="loc_dei_EntityDomain_1103318" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103318" xlink:to="loc_bvs_BioVentusLlcMember_1103319" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1103343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103316" xlink:to="loc_us-gaap_CreditFacilityAxis_1103343" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1103344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1103343" xlink:to="loc_us-gaap_CreditFacilityDomain_1103344" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1103345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1103344" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1103345" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeAxis" xlink:label="loc_bvs_LeverageRatioRangeAxis_1103346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103316" xlink:to="loc_bvs_LeverageRatioRangeAxis_1103346" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeDomain" xlink:label="loc_bvs_LeverageRatioRangeDomain_1103347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeAxis_1103346" xlink:to="loc_bvs_LeverageRatioRangeDomain_1103347" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeOneMember" xlink:label="loc_bvs_LeverageRatioRangeOneMember_1103348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeOneMember_1103348" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeTwoMember" xlink:label="loc_bvs_LeverageRatioRangeTwoMember_1103349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeTwoMember_1103349" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeThreeMember" xlink:label="loc_bvs_LeverageRatioRangeThreeMember_1103350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeThreeMember_1103350" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFourMember" xlink:label="loc_bvs_LeverageRatioRangeFourMember_1103351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeFourMember_1103351" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_LeverageRatioRangeFiveMember" xlink:label="loc_bvs_LeverageRatioRangeFiveMember_1103352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bvs_LeverageRatioRangeDomain_1103347" xlink:to="loc_bvs_LeverageRatioRangeFiveMember_1103352" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1103353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1103316" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1103353" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1103354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1103353" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1103354" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_1103356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1103358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1103356" xlink:to="loc_us-gaap_StatementTable_1103358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1103362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103358" xlink:to="loc_dei_LegalEntityAxis_1103362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1103363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1103362" xlink:to="loc_dei_EntityDomain_1103363" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bvs-20210703.xsd#bvs_BioVentusLlcMember" xlink:label="loc_bvs_BioVentusLlcMember_1103364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1103363" xlink:to="loc_bvs_BioVentusLlcMember_1103364" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1103359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103358" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1103359" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1103360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1103359" xlink:to="loc_us-gaap_ClassOfStockDomain_1103360" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1103361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1103358" xlink:to="loc_us-gaap_StatementLineItems_1103361" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1103365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1103365" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1103366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1103366" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1103367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1103367" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1103368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1103368" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturingInYearsFourAndFive" xlink:label="loc_us-gaap_LongTermDebtMaturingInYearsFourAndFive_1103369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtMaturingInYearsFourAndFive_1103369" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1103370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1103370" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1103371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1103371" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1103372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebt_1103372" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_1103373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtCurrent_1103373" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1103374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1103361" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1103374" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g180330g03a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g03a11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1904&AO=&]S:&]P(#,N,  X0DE-! 0
M    %C2^5H0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'*_^^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              R@
M Y4          0                         !              .5
MR@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MR@    !29VAT;&]N9P   Y4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ,H     4F=H=&QO;F<
M  .5     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MSJX_NUL^G8[^36N3ZW];,/.LJQL/.&+B.(%V18RZO0_2=]"ISF-;^9O8Q_\
MA?T:J=&Z9=];>LYW5\][AB47OQZ6CD-8?9CUS/I,:S99>_\ PMMJET_I^'G=
M7S.G9C&TXU/KM996=KFFI^UI-CR]KOT.[=ZC5'DF 8Q)E'C- Q_[YMX\4(V9
M>J4!Q2'Z,;_J_I)^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&B0E)S(T-FB!A[3_Q  = 0$  @(# 0$             !08$!P$" P@)_\0
M3Q$  @$# P(#!0()" <$"P   0(#  01!1(A!C$305$'%")A<3*!%2,U-D)R
MD:'P4F)T=;&RL\$D,S=3<X2T"!9#T24T5(.4E:.UU.'Q_]H # ,!  (1 Q$
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M^ZAM&/NI6,=<^T='DZJD2-6=VM+,*B*69B4. J@$DGR !-=]>!;4G"@DF.,
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M9Z>K9CLXG+!N<A[B4A3.X[@;5C0X*1ALL=$7NHSWAVG$4(.5B0G'U<]W/IG
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M*J!CQCE@N?\ ]\]^:MHHM HVKZJ'HNMZ?6:%2Z_&^4!U2GA!M=KXJ-ZLK4U
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(*4=*4=*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g180330g03b22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g03b22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[11R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %%:^4@8X0DE-! 0      &$< 5H  QLE1QP"   "A< < E  "')R,CDS
M-S0Y' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@3WES=&5R("T@4RTT
M(%],5R Y+C S+C(Q7S$R-3<Q.#4Q-BXY7RYD #A"24T$)0      $,?L3Y^\
MG06E$,H[VX?F DLX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              "-   #@0         !
M      $              X$   "-                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     "=4    !    H
M !D   '@   NX   ";D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( !D H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R05
M4L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6W8\[%>(]!HC&!_Z#3VA=@3X]MC^Z1/^=.C]''UV?VDZ6_D]0WYM/'LMNO\
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M>8?L1\@\,:JT-(;&$) ]?G/RG3E^>>O31XTU4*S^OL9S[?9^F85C]_ZCS_\
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MTJSOVYS]N<_90<8^W/\ :\Q$W?MB>IB4X_\ <)^7XEZ=3^-A>W D "X;M
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MD*5_51_,.E6TW8"BQPQ6=Y*VF0I!2\JT;<DK:C!( 46ZO7REIY8 *DOL4A#
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M@&GNN^*.>('I#0I]?['NG04'B:DN3YM4GK>-T_J>1VG%)::9Z2;8MA4K@5J
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E:N5R#@(!MQA"W&Y>QRQ11!M@L<N]]'R.TTZ/MC'XL8QXTU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g180330g0920114743216.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g0920114743216.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 .L# 2(  A$! Q$!_\0
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M@9W9F^T2\L<G[U=V[K'&SL0%49)/85Y-\,/&7AW1?!4-GJ.JP6]P)I&,;YR
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M64*6)C X"9/W@!T/6NC6]NAXEH*FI)^\CAM'UV:S^$6HPO(YN[25[-23SDG
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H_ A_B_R/.?@A_P AC4?]S^M>X445.'_AHVSG_>Y?+\@HHHK<\H__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g180330g0921001458208.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g0921001458208.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  , *(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U;X;DM\/-
M&))),)Y/^\U<SX[O;F7Q(UY:387PU#%=/&&QYCNX++[_ +I2?QKGOASXGUE-
M:TG01>9TT%D$1B3IM9OO8SU]Z[/0_#.C:^-;OM5T^"[NI=2N$,LJ LJJ0JA3
MV  KF4N>"2/;J4OJN)G4J:IZZ>;^72Z+'Q$TW3=5\%WFK/$)9K>T:2UF#L-N
M[!R,'![=:J>*-(L="^%6I1Z;;F!)%BE<*[,2Q>,$\D^@J&!GN?@8ZRNS;;)X
M@>^U6*C] *V?'$8?X;WB'.#%#T_WTJG9IR\C*FY0E"E?13M]S1DZIK\NJ^(_
M#$+:+JNGA=0W;[R)45OW;\##'FD^)'VC5;NUT>RN/)EM;:75&(;!+(-L2_BQ
M/Y5N>*4#:UX7)S\NHY'_ '[>J%GH.EZ_XN\1W&K6,%X\,L,$0F0,(T$8.!GI
MDL2:&F[Q[_Y"ISA'EJVLHI^?VK=?4M:YKB7GPLO-8A./M.G$K@_=9UVX^H)Q
M7$3W%Y)X!_X0P2N=1BOY;-SGYC#$#-N^FW:*T?)6/X=:II2DBUM];-K&O=8_
MM"-M_4UM6^E6O_"X;^Y*DNVF*Y4GY=Q(0G'KM4"I=Y-&U-0HQDK?"VU\K6_,
MM6NMW2^!-#N+*-YKNZMX@%1 [<1[GP"1DX4\9JKXHU!;CPYH_B.)ABPU&*25
MDZ%-YBDQ['/?VJUX%L;:[^'VF6UU"EQ%&9 JRJ&QMD<#\<5?\4:;9_\ "$:Q
M:1V\<4!LY6V1*% (7(.![@?E5ZN%_(Y;PAB.2VTG]U['#P:[-I?C/5M?FD)L
M[^.\B@!/RYM0NTCZ[7K5NDFTCX4:;I2RE+W4DBM0S'D/,<R$GV!<_A6/KVD6
MTOPM\+1MO_U\)+!OF/FAM^3[[C75^(M/M-7\9:%IU_ D]DD%Q-Y#C*,P"J,C
MO@$XJ%?7^MSJJ.%XOLW_ .27M^!#X0MK;5/"M[X;U(?:4TZZ>T<%S^\C5MT;
M9!SC!7\JK_#SP_I=LVIW\-KMNH-2NK:.3S&.V,/@+@G'2K6B:;9Z'\1-1L=-
M@2VM+C3HIWAC&%#J[*"!VX-7?!"!++5P,\ZO='G_ 'ZN*U5^ASUIM1J<K=I6
M?W[G%Z"S:_K]SX:N9#%81:C=7TR,<&\Q,0L8_P!D$9;\/K78:P2/B-X74'"_
M9[S@=/NI7)WULEKX/U#68&:._P!-UR>>VF4\J6F"LI]5(/(KK-1_>^._"\S<
M-]FNC@=.52ICM;T-:VL^9;6FK>=M7\[HY/5+^ZT'XFZKX@5W;3[=[6VOXQR%
MBEC&'Q_LLH_.M?2H=0O_  1XG@TJ;;>RZC>K X?'.\]#VR. ?>M&STZVU#Q1
MXQM+I/,@N8[:.13W!B(KG_"5Q/HWPCU2ZLYF6XMWG>.1P&.X8Y.1@TEH]=M2
MI/FIKE7O+D7EM=7^=_D:O@NXT2SM-1@T_29M+U:"%6O+6YW;F(!VMDGY@23R
M/7Z5MW&OO'97DR>07ATU;N,==SD.2,9Y'R#WKF_AA/-X@MKSQ)J<IGU"?%J3
MM 18UY "@=R3G.:[E=-L5V[;*V&T$+B)> >N..^:TIW<58Y,7RPKR4]7IUO^
K?0YB37/%RR,(O#Z2Q@D)(3LWCL=I;*Y]#THKL:*KE?<Q]O'^1?C_ )G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g180330g0922110749216.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g0922110749216.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  / 'T# 2(  A$! Q$!_\0
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;VM2:<Z6%[:06\4OF)DNA.<@'/?\ 2N^H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g180330g09d44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g09d44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &-J^8V(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0']            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              EP
M L0          0                         !              +$
MEP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MEP    !29VAT;&]N9P   L0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   )<     4F=H=&QO;F<
M  +$     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M'--==FZG?0W&93:_T?3LL?;99ZS[/]++ZIN9?UMSK3^F:+["
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M @<    $!0,& 0('" D5 !(3%!$6%PJW(24Q.#EV>/_$ !T!  $% 0$! 0
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MKNI6>:*94:-!'*I0Q):=.W7EM::9$: ;IZDIW,J?5XVR<J.2<D\ Y*G -_\
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MT%__ $W/_M,]+_\ [>ZM_P!O.1?HW\3/]7TO_P!CJ?\ 46^I6M_Y];_DJ_\
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M!7+K?5N30=,Y5:Z/^3=F*G-I_-=?%)HH=_LB;=K7S[,S=V$T9:!%H0J'9EC
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F=T"E"X3!SMB9MR0KP,1Q9;8 .-S'Z])=MYSC'O\ 7/'V_;GK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g180330g09f66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g09f66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+2^8R0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'*_^^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              6
M 3@          0                         !              $X
M6                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M6     !29VAT;&]N9P   3@    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   %@     4F=H=&QO;F<
M  $X     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MO^,3KXRQT_J]3'8;_3L-S*T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      #_X4"!:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M
M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^
M"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#DM,3A4
M,#,Z-34Z,C0K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP
M.DUO9&EF>41A=&4^,C R,2TP.2TQ.%0P-#HQ-SHU,BLP-3HS,#PO>&UP.DUO
M9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#DM
M,3A4,#0Z,3<Z-3(K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E
M+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H
M;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H
M;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C4U-#1#,C0U,#DQ.$5#,3$Y04%!045%-S P-S0S.3=$/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.C4R-#1#,C0U,#DQ.$5#,3$Y04%!045%-S P-S0S.3=$/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/GAM<"YD:60Z-3(T-$,R-#4P.3$X14,Q,3E!04%!144W,# W-#,Y-T0\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O
M<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYC<F5A=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-3(T-$,R
M-#4P.3$X14,Q,3E!04%!144W,# W-#,Y-T0\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#DM,3A4,#,Z
M-34Z,C0K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N
M=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IP87)A;65T97)S/F9R;VT@:6UA9V4O<&YG('1O(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4S-#1#,C0U,#DQ.$5#,3$Y
M04%!045%-S P-S0S.3=$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3$X5# T.C$W.C0T*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-30T-$,R-#4P.3$X14,Q,3E!04%!144W,# W-#,Y-T0\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C$M,#DM,3A4,#0Z,3<Z-3(K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4U-#1#,C0U,#DQ.$5#,3$Y
M04%!045%-S P-S0S.3=$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3$X5# T.C$W.C4R*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C4T-#1#,C0U,#DQ.$5#,3$Y04%!045%-S P-S0S.3=$/"]S=%)E
M9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX
M;7 N9&ED.C4R-#1#,C0U,#DQ.$5#,3$Y04%!045%-S P-S0S.3=$/"]S=%)E
M9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/GAM<"YD:60Z-3(T-$,R-#4P.3$X14,Q,3E!04%!144W,# W-#,Y
M-T0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO
M<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < &0# 1$
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M&6, ?Z2DDES1C"Z[SSZ:;17<4%F[WAE*=;F\]C,300(&(V\LW!1\Z5=D%C\
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M=JXV"M0PT%F"ABTFD*(MJ*2.:26RR-)+-(\GD>0H.14 CD7=B^N82Q.D2)'
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M==<5W["CY7V2!ZV?GIZ\)\$9X1YL[SY*3]KL]FXCT==TRO\ '4UF0Q'O_/\
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+L_7==UGZ[KNO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g180330g10c33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g10c33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &02^9 0X0DE-! 0      &$< 5H  QLE1QP"   "A< < E  "')R,CDS
M-S0Y' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@3WES=&5R("T@4RTT
M(%],5R Y+C S+C(Q7S$R-3<Q.#4Q-BXY7RYD #A"24T$)0      $,?L3Y^\
MG06E$,H[VX?F DLX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5\            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _0      !( -0    $ +0    8       $X0DE- _<
M     !P  /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &               K    H          !
M  $              *     K                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<    K     %)G:'1L;VYG    H     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    *P    !29VAT;&]N9P   *     #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     #PX    !    H    "L
M  '@  !0H   #O( &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( "L H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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ML8Q,8P^T,\6TUOJQ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@ + "B 0$1 /_$ !T
M  (" @,!              D*!P@%!@,$"P+_Q  L$  !! ,  @(" @$%  ,
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M8;*NO9<84DM:6WW'5N8_H<O"W"'DRF- 0GCIA.>]O<TT3H3;I%XZ\WI:X?\
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L$_'WCU_R5[RZ4I0E*$)2A"<82E*<82E*<?UC"4XQC&,8Q_6,8QZQ^?7Y_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g180330g11g62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g11g62.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1JL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &I"^:  X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'*_^^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             $YP
M!RT          0                         !              <M   $
MYP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
MYP    !29VAT;&]N9P  !RT    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !.<     4F=H=&QO;F<
M  <M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5))4.J=;Z=TDTC-L-9R"
M17#2Z=NW=]$?RTE),TGU<..]^O\ VW<K:S^I96/3?AMM>&D7;B#/'IWM[*_R
MDI=)0NNKHJ?=82*ZP7/(!, :GVLW.3L>U[&O;.UP!$@@P?Y+O<DIDDA.R*F7
MUX[B?5M#G, :XB&QOEX&QOTOSG(J2E))*M;F%EYH919<YK6O<6;  '%[6_SM
ME7^B>DILI*C3?DU[YQLFW>\O&\T>T'_!LVW,_1L_-W*U1<R^BN]DAEK6O;.A
MAPW"4E)$',R/LV+;>&[S6TD-F)/AN]VU&5;J)QQA6_:7.93$/<P%S@">S6M>
M[_HI*1VLSK75N?CU34[>R,BQON@L]VW'&_VO^@]3IR<@Y7V>^IC"6>HUS'EX
MT.PAVZJGQ5D&1/BJI_Y5;_X7=_U;4E-M))))2DDDDE/_T/55%S&.(+FAQ'$B
M>X=_WU26=U;I>1U T&G/OP?1)+FTD 63'\[P_P#1Q^C]^S_2>HDI-F_SV'_Q
M_P#Z+N5M4.I4O??AEMUE0-T0S9$^G=[_ -)78KZ2G*ZUUGI^)5?B9%A;<^AS
MF@,<X0X/:WW,:YOTFHG3NM=.S?T.-8Y[ZJP]X+'-TT'Y[6KF_KD">J0!).,T
M >9==XJ7U0_IN1/_ ''X_M!)39=]>_JS9ET9#<E^QM=C3^AMF7FDL_P?\ARZ
M'I^?B]2PZLW$<7X]P)K<6EI(!+?H/#7M^BO$JOYMG]4+UKZD_P#B6Z?_ %'?
M]6]39<<8BQ>]:KI1 =Q5:_\ E*__ (FG_JLE6E5K_P"4K_\ B*?^JR5"M;2J
M]+_Y,Q/^(K_ZAJM*KTO_ ),Q/^(K_P"H:DIM+%ZYUOIM%.3A6V.;>U@EH8\C
MW0YOO:W:MI<%]:PX]8R@T22VL :#\UO[R2GL<#JV#U%UC<1Y>:8WRUS?I;MO
M\XUO[B<_\JM_\+N_ZMJPOJ5K9G'_ (K_ -'+>+'_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M             /_A0(%H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q
M,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \
M>&UP.D-R96%T941A=&4^,C R,2TP.2TQ.%0P,SHU-3HR-"LP-3HS,#PO>&UP
M.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 Y
M+3$X5# T.C$U.C,V*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C R,2TP.2TQ.%0P-#HQ-3HS-BLP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^
M"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @
M/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @
M(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,S(T1C9!.40P-S$X
M14,Q,3E!04%!144W,# W-#,Y-T0\+WAM<$U-.DEN<W1A;F-E240^"B @(" @
M(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,D8T1C9!.40P-S$X14,Q
M,3E!04%!144W,# W-#,Y-T0\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HR1C1&-D$Y1# W
M,3A%0S$Q.4%!04%%13<P,#<T,SDW1#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-R
M96%T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HR1C1&-D$Y1# W,3A%0S$Q.4%!04%%13<P
M,#<T,SDW1#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,2TP.2TQ.%0P,SHU-3HR-"LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!I
M;6%G92]P;F<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z,S T1C9!.40P-S$X14,Q,3E!04%!144W,# W-#,Y-T0\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#DM,3A4,#0Z,34Z,C4K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS,31&-D$Y
M1# W,3A%0S$Q.4%!04%%13<P,#<T,SDW1#PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP.2TQ.%0P-#HQ
M-3HS-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z,S(T1C9!.40P-S$X14,Q,3E!04%!144W,# W-#,Y-T0\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#DM,3A4,#0Z,34Z,S8K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-
M33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,S$T1C9!.40P-S$X
M14,Q,3E!04%!144W,# W-#,Y-T0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @
M(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,D8T1C9!.40P-S$X
M14,Q,3E!04%!144W,# W-#,Y-T0\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HR1C1&
M-D$Y1# W,3A%0S$Q.4%!04%%13<P,#<T,SDW1#PO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T
M(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_  !$( 9("3 ,!$0 "$0$#$0'_Q  ?  $  00# 0$!
M            " 8'"0H$!0L# @'_Q !@$   !@(!  (+"P8*!@4*!P   @,$
M!08!!P@)$1(3%"$V-SAV=[6V"A46&3%8=7B7M]474Y*TN-$8(B,U05&!EM?P
M)5978<'4,C-E<:$:)"92<Y&5F+/3*$)(5%64TO_$ !P! 0 " @,!
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M+QZ\<K&.LX=.G"JB[A=4YE%55#J',8QLYR'(> @\SXGSES!,B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M!$!$!$!$C[RT\E7DS]7W<WW<V00W(^!\I*\QXCSE4Z#\1>EO1-KGV/A@7D/
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MEA5OX?I#URR_Q?1/JDY1:5@(@(@(@(D%>7?COZ-[O?\ ZS[)_9_^"CE_W_\
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M)EE)8QW"3UE7;*JLX*N5NF5J9BBF=-557+HAD2I+0<]@!\3CR!DC;GTLX^8
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M(M*P$0$0$0$2"G+OQW]&]]<^R?L4<OQ!YKX^HR1R;P]8DZQ,B B B B B B
MB6AY!^(3=_HAV5[&30E>8\1YQ-+T9YKP$0$0$38RZ'3R?=D>F:2]AJ*,3\QX
M>LS*G(^/J$RW"DO 1 1*1H="J&L*C"4.@P3.LU"N-U6D)!,,KF9QS==TX>JI
M(9<K+KY*=VZ<+F[8L?/9JFZLXQU8PY1SE7!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$C[RT\E7DS]7W<WW<V00W(^!\I*\QXCSE4Z#\
M1>EO1-KGV/A@7D/ >4-S/B?.79$R("("("(")I%WWPZNOG=9?73T;$UY281
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M04Y=^._HW?KGV3]B?E^(/-?'U&2.3>'K$G6)D0$0$0$0$0$0$2T/(/Q";O\
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M":.7QSG27?.>EOLZT]_AZ/:__A#]&_\ [77_ .8UO_N9V_\ D?0?\$_^(_\
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M:?K(^1Z(^MUOY-+.L]/_ !M/]%_,3;)'E4Z[ 1 1 1 1,"O3/>$7'[Z%V/\
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M>WP'JQ'?^4@\Q?\ 8]QK_N_L_P#Q2':__EYT/_VOI/\ \72_^TG)_P @:?\
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MK=*1N1&89QI 2,@9 (.,\1V5LZ"TZ([==<2JLW\&#@9 ^+WS<7'D,ZO 1 1
M1 1+0\@_$)N_T0[*]C)H2O,>(\XFEZ,\UX"("(")L9=#IY/NR/3-)>PU%&)^
M8\/69E3D?'U"2XY\^0_R\^K;NC[OI\<GT#_/?1']I:+_ #%<V])^]:?ZZO\
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M B B B;&70Z>3[LCTS27L-11B?F/#UF94Y'Q]0DN.?/D/\O/JV[H^[Z?')]
M_P ]]$?VEHO\Q7-O2?O6G^NK_.)YKH^BIZ! 1 1 1-UOW.3Y$>ROK,W/[M=2
M#QS]8G\\Z7^S*O\ -:R=.Z;_ 'T_03/]T>_,^,S^CH4XB B B B B B B B
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MO9#;"S,-X:8FVCN3<21JN1QV;O*IHQ'&<IDDA=Q"DE<G:6&TD#."5!8 D8R
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M67UT]&Q->4F$0$0$3,[T-'C#W;YF57UY(?V_Y[W](H_(>/J,R)R/O_I[^$V
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MEHO\Q7-O2?O6G^NK_.)YKH^BIZ! 1 1 1-UOW.3Y$>ROK,W/[M=2#QS]8?\
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M* B B7)TUXX-4^DFC>U$6-?5_NFJ_J]W^&TQW?)6_5O^*D3U#Q\SSSN B B
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MZD'CGZP_YYTG]F5?YK63I_3?[Z?JT_*/?L]9S^CH4X> B B B B B B B B
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MCO'WB;$U!?=*IBFW1QC[$Q3=6K[MU]CG&>K_ -*V'R]6<CUO]7''1=)XX_\
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M D'ISHC!'\Y:+M_[Q7-O2?O6G^NK_.)YL ^C,'N,] R.\0&#W&1D=X^^!$F
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M)]L;V[_P'LG&ST9/1YYSG.>%W&W.<]_.<ZFJ'7G/]>?]&!L7N_$^V-[=_P"
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MNK.,X[V<9[V<!L7N_$^V-[=_X#V3C_%D]'G\RWC;]DM0_# V+W?B?;&]N_\
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MR;C/]D%-_"@W-_3?^^WMCK;/Z9^^/BP.CJ^9-QG^R"F_]W_\5_5W@W-_3?\
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MJ DD*NYGVJ.2KN9FP,#<S-S))NF$K 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MFY2GFK;0"6>.5LKAGE)0V%&"9BN((()!Y@@X(.>P@Y!!&>P\B)4%ZVKL1RC
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M=SN=V=VL=G<^E8[.[,SN68YP3@ #*F(F. B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M6-2G;K:UH]OE_(-X2NQCB7D#-6"9R*.GF6;90S5H4Q%'*F2)DSUGQD2!D@9
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M3T6QE6D=-L7$/--TGS-)\5I)0[XB+Z/DVB2V$Y".<HD=,'!%6[E--1(Y<5F
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MB6/=T[89>=I],J%UB9^6-N77J\@L:YZODK7%1UCTFBUK-*0G5BG;5NA78DJ
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M:JQTF4]@9D05ERN5Z=WI=Y[>!Y=W,@#EGAC)Y@:P9@*U%Q499Q@V 5.WH,2
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M1=:XZ12A7+G#=AQR<Y1<86L3]N,MK$GTAM9]MCDEB6)088Y&07):W()!%H[
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M22"1<GR5)%,J29<G.90^<$)@I<9.H8QSYQCK,<QC9Z\YSG*)] B B B B B
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MN+G9H\\7*I.H"K6J7ETEHB71,S[;%2!&US6X7?@8XY 92ZX(!+("709( 9E
M)(P3F;9T.I&G&IV(U>YU9$OT[ZFH5D!WU&C2UM7IZLD!;KZ*ZG8@([$@20(I
M-2 B6XK&W-=7.POJM6+*A+3L<>W)NV:+&513*:AW!>@7#"+YTP0CW>("Z-7E
M:?&:.EREE63UNEE3+)UE*Y1PN\J=H*KN[,LI=1]J@F;3:+5)IVU;4L-,MM%#
M7>B4%NIH;545G!)W64(]@&."J0V#PE4VJSP-)K%CN=ID4H>L5&!F+/8Y9=-=
M5&+@8"/<2LO(K)-4EW*J3*/:.'*B;=!9<Y$LE1244R4F:>_=YS64%F"C&6(
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M.6Z"('3?1))  Z2T1)/  #45Y)/8!-C2<-3IR> ZZO\ ,)YOWP.MW^JUC_\
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MG@HPVGTE]%\['XGT&;T6^*=B\)6 B B B B B B B B B B B B B B B B
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M@, HR_E"H-JE2AJJ]4Z.UNF>O3ZE6%;):H-52TKH[['>^S05U5U*RT5UVHE
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MNS*J;LVWQ^VZI?;E>=<2<GK'&L5=0L-DM-@JP]RDY*5NL^MIQWL6INZ!'V:
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M[GVN;?')G=2E^DJSB&IEAU]LK6^Y6]8C6>QG"F*Y,6"P5O8U-X_.J:[E<33
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M4WS?6*NLY&&O5H:61G?28/6W4D^D[+%5$M/0>9N#>Q*/%7$ E7&*L\,[6?\
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MS(*FS\=?ZIMHK!*XP.D;)/P6MKI#3D''2U@)36:41*NH T5VUEBUM:'8A*!
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MS<*LWB&5$C')A9J[07:N4NOLT'"*J"I2JIG+A$Y 1 1 1 1 1 1 1 1 1 1
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M3]N!GP$C<Q4(6)52S!<G:&8*&8#D"P1 Q R0J@YVC'=!(@(@(@(@(@(G15B
M@JM782N5B%B:Y7H6,9QT- P,<SB(:)CVR!$VS&,BX]%NQ8,VZ>,$0:M4$D$B
M8P5,A2XZ@))XDY/>9+,SL69BS,<EF)+$]Y)R2?G,[T)$!$!$!$!$!$!$!$!$
F!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g180330g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g11i11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %>2^5@0X0DE-! 0      #T< 5H  QLE1QP"   "-G@< E  "')R,3DU
M-C<V' (% !Q-:6-R;W-O9G0@5V]R9" M(%))1$52($0N9&]C #A"24T$)0
M    $.E2_H6AMCK]7EO<82Y9@^XX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              !8   !D          !
M                  $              9    !8
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   !8     %)G:'1L;VYG   !
MD     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    6     !29VAT;&]N9P   9     #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     "X@
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M?:UOT%Z(O/?K;_\ E)Z#_5H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 ! P0" P$     !0(#! 8' 0@) !$2"A,4%18A%R,Q(O_$ !H!  (# 0$
M               " P0% 0;_Q  U$0 #  (! P($! 4$ 04    ! @,$$1(
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M-'O2/QA ]O;L%_R;4+CAV<7(%8*#=;]FA:F6G2V:A$*34CZS9!W7UP?[J5_
M&V1)U(AS\5-H7,:Z^NQELV7V=<@/6-J8\:*TJUB9O;TP3I&'MR.@P;C]O(WU
M5PU3"[VV*4CD0GDVFZVC&ZTG'U"!NB-K84;*%.7[>-(;X-/46IWS.-N\@>E;
M%9K%Z4\;Z:=I=I,W0J1-V:RT\B:*)"&)I<SUTR4Y#+0C R/.*3)TF0(2%>;D
M_P 1V.RS6^'<RU)Y.#EL[96#5D9J,S.TRQ )9OJ.F# $D_25\Z( M?%&#"5L
M7N.$B)A]Q@E$6:A42BHO)0J_0NU*DJH Y<O&]DY-_4%>C-U$2LOSS!M8OV3
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M"(?$L+;D0G7(A5S]N+*@]GPX\]#G6)#J6NJ6VWQ(S)3M%)^+#/0(1KEH\25
M\;Y$ :V-[._V3X55:1[Y.I'HMVURX;\NQRTQ.B 5&R#HD>X'ZUWTS2JS??U%
M/C8-;1;!H1 \OV*RMBYGW<'R2U:;U,T#>(0^]['(,CC$.$4CQ9C;T=)"!"E_
MM_O165H7*FM?BG!6B\E&$SA3[$IZS L/9M.JD ^-@'6QT^#5X_!_<FFW%SGS
M3D/S!7^71M'W7DK,I(T=$C>B>FO\U_B3_(_#^UEO+.2 !M[L^KYYL.Y#*&%'
MB;)KH.EJE1IZRG(_(JK%,"MRHY]L2IQ3DYT=(>B1I1AYM$B;X@[?S[?=L.*K
M5[ROD"8 >RSV#L:^LKOD%^Y&P">J_P -]SX=SQESLAVDF/;'Q6JY9,=J:(X[
MWQ#:X['ML;.AX7GR0CQOR48AXGR+Q?62UXD-[WG&D%23M5M%>J^+9O3JD7BF
M6M!LYD4,8J!>#PP+&,57I%FX%)$5QH6-E(9=D,Q=U [KC]OAV]&<C(E9B4=4
MA%)L"*.P4(1R50N^3:/$$CJ;LY/9LKN>1W)UF#BW@HYHU,FU**1Z,U+%U/$D
MOQ]-=_41[=:9]9:Q@V=?(!Y:H>3>9VMZ^0->9V*!F7/\RFYIGF.8F7<)PSMG
MO1:,-L0B&+XU"L2AK :B6"QQXL:?&A+'I)P6"-S,MC2[EARAB?,]R])A+=#&
M4(-L,]&"LNM!]!).P .N.P#2P(9=NTYM;YIQ.T>NAM^&+5R<D<2LY*2K%ME.
M7*J(25+;T2,7X8J_(_4<ZIW2$TV+<)?C$?(-PZ(HPNN-IY H'(+4*6<XP2)K
M8A\BIF$)<&!Q^3WO68$1M+:.Y^/ZG_E537@*' ',2Y</RS( +:+>/<D#9^P&
MMZ65Z)^#H>AZIF.Y$*;<>?O;>PGTKLGP 6T/=O<=67-JR"L/ZE?>YYH;&(R:
MAX\"V.NKE)_<X+/=8RP"DG';5W\.3&@Y\O%8=4E2F$3G5M=0OJ5\>*(WQ7DE
M@"4PE=-C?%M17D/L"%9A^OG^G7,AW3X*PPI(%,]D?7\R<\E^)/Z%T0Z^^NK#
MYJ$#A/ZBCW1P;#:A)*^3:@<(IC\_;1,+2)N+L/$)"$]XER2XTGB%.JYU7V_+
M_?W7W[MB+Q^*>Y #0.'-CKV+'Y?9.O8^0//O[^Y/4>:Q;X.[7R.RN?15W[A1
M\UH#]M__ #_;K=0_XY2N8^E_0/ICS5Z*LF-V'U%_7R=BK)G/ZGIH%PX-6\Y'
MLM(49>$S*R9X[+(2%-DW;.&5((REN"'&>1&(NB.U&.7DY>)E-!LP@Y"-)*KR
M'\\^1'!M[/U<UV3X]NLH]Y6^%B86;AIDI@[&.ZVI!^)T.%>(8.F@!]/!M*H#
M#R3"H^*>A5/R%>_+F,;EL^0V;4="CZGI7HZOFVN;-?+NX<CFSA.Q&AG]"E40
MVIGL1P6+4+A18[CG&FUJDD.S5_@TTP:8<,C(@]JBULI6'KTIR!8L1Q&FU^4:
M _N=M_'K4[A+.R<7&R4A$PCANG^FE+CQ4(IY^5]^3<B?;V"ZG?9OQBU'W/F^
M<Y'L?H;>X] S?E9GP1-:?S1@C8+;6JZ_6V[K:;,;SLW9BQTE&F3YA!O^V8$N
M$9STQ Y+R&%,OG]H3N,I0R,K)].7 @)Z(9G1"GJ.[29F9@26&PNSX4=)VWO=
M.UVMD8V)B>K;FK,XL0DW</Z4T6R(J*0H'TEM#7+7CIZ[/Y9N&P>4[+YL?]-;
M)6K$=&C!L?>P"JU7=/A,B28^?'0\ND"*:*?:ELP/ZTO_ %\81+)P9,E#\SBW
MG'%6,C#I?"IB?-W1G  R%X+4 $'1]-44@ZTV@"5)!)]S5QLZ>-GSS1A8[JA+
M'%?F\6+*P)'J-1@03R798*0-#KQKODB=L/FZL>;2OH7:*\)%5VH@+1H8!^E3
M-+OZJ?T-)AE;#8K?4K2E@D0+!(Q8M,%Q(<R?(<?:DRG&'GFW"V";8J8C95U5
M41'HOIFM3/B0S.Z/HEE#$KH[^_1C]P&/FTS5Q,9V9Z.D7%1"0IR#*B3I/:A6
M*@,2 /( /GKVO0?C',/5V+T_%O11 ]IHVHW:D7]-HFLUP)9#%@I!E))EV>W7
M@(P!%C'QRIM:L,8,%&-S 9.>S&Y#E.MRFNY7;XYN.F/E%[!'2G,\%<LC;!/!
M54!AM6XJNU)T03OKF)W*^!DTR<-4@U)TEZ8YO-4HO$ZYNSDJVG0LS:8#W UT
MJ?>7QT4GY JW3Z-IVR[#0Z!2#X^W!:AEKF?A8G+:*A$!PVP/EC5&L%@_E0()
M.6Q"C1BL:!%_<ZZU%X__ -GU#W'M<^YK.=KWG*;BBSCZ2CFH(#%FFS; )UH@
M#[#J?M?>*]I>E88V/6U4:;4OZS'TV(+(%6J)HE022I8Z]]>.K9K'A>K;(+PL
MS<-.OSV[>;+%_E60>BX<"B#="$E>M+BR(9\2*J8^CV*M&("DC+%77*S"AEX2
M>J_.*06N?U[]N2ZX[/:OS.(_.&4!,54_<,JJLW1AI74H R_HWU=)C]TIC-E+
M.$1BYJ>GD89-3%E]P49J-5'4^4?F2I_4>.HB+X<<O^WY1Z$]3ZGW>KS@W2TG
M&*X,H@S-<OI!\QUCDB\*J+!BUE;#>668L9N 6.6J6*#NQVIP0",(MHEI4=N]
M7)CE9EOF:8W+Y=%F(QFS'_<*<J%Z>!IF?2D JH(WTQ[IZ.+D8>!#Y267Q^9<
MV:UZJN]2]0K-4EY.U5 S D.S D=*V[_%T*O/KRM^W)OJ_P!'B]QI8J56J;,$
M1,+CUNNT^4DZRY4VJZ[CC\(J+5$L96(_*.\*&9;3S:Y91YZ+%=9AIV=:9R=P
M.9E#)FO"948X14TPX</0TR_4V^6R=^2=#4TN^-+M[]L&#AMBT8/4,<HT>@X?
MB%_F=JVT4@)Q4$>% )!J/S 4]^_8UYWS8)ZD@><=9L_I[+HV-$++5R5IJ^N:
ML/8+*JF?W((&$E _],1-.PSJ7+,&E4UH^+#-$X2TNQ6NQ]]3U,?%BN8N+=\R
M/H,Z%TM8<N,Z*JL.))#?4OI\@H8>1U-\.T$LG,NV"<S'GA7.0$HLWQX,5#UF
MS,K<@NUTC"A4MQ/OU@Z\"/U'GG*E6;5B>Y>2-KJF95LS<K!3DU8 ,D%:Y5AL
M@L5C1&H.:YW(4_P;"?6W&AV84ZO\>M1Y/[O[:%YU%^*<2;6.1A72*L[SXJ.2
M("Q\"4O.AOZ77SX\]:DF^#LVL\<8N?C4NZS2O-V"O1N*DEKU&MD;)1OZ>^]]
MVOQ>#]MV3RO\B%$U#4O)_I:'D58<19:+%JI],RFVX*Z7G4FS5B["3H(K&AKL
M):/#?D,.L*9E=<F0YJVXJX^D^ O<6P^Z3M;"RQ!-4EP?Z'4L9LE%96 +$#8(
MU[@]9*=R?MB9_9ZPAGX1R* SJ:)JDW"BLWDRLI/!2='W T0-@QISX<<P*[Z-
M])PO2WJ<+JQ6F$:!LEKA7FO.'=NJAF8F28#V4F_5%=J< C$9@@DP<[C56"$K
MXH5 JL:OOCHDUH?L46R5RAEYBV,S*[BJ\LA&_,KDII PTNIA J@!.) (9/B.
MZ8IPSA8#02JVQD,G"XM$&D9%%/Q"K;<FQH7=F+E@Q'5XHOQ95*B>TB7NR'Z4
M]"$]E/QXP.S02/,?33+!18D(,)8S^6#@Y5$<BUUH-7@PQF2-FP[$QR T2:.)
M,]<(K>79DEGGN(R\ILA@%<'T/3:8"J)%1$:3BJ@$$-L!N7/ZNH:]]I7MJ]K;
M#Q!C(2\ROS'JI4EF]4.;D%^3LQ!4H=\2O'P)*G_&2 IGM:Q>[H'IKT-,U^XL
MM [<(G?\0]HM@H#+X=3><204;+(\B'6F8H 3$CS!I"'9V%PTDD'_ .W>E3WV
M3M"3[@_<AEY1R* )0'T/3>0X_A%/1\+I%&U(8$<@W+9ZY3O;T[:G:SA8@QI[
M:9'S'JI4\OQ@YN=OMV)!4H=ZX\= =._K7ZQ.CZ.CH^CHZ/HZ.CZ.CH^CHZ/H
MZ.CZ.CH^CHZ/HZ.L[>D_+&-^KZ@ J&P R<UNG6\-H-$LM:L!>HW6@WNO.+="
M6ZFVH#*AE0AL>IQ?&WV7E,O-K4S*COLJZWVIEX6/FHJ75CZ;BLW1VG25%_*\
MW4AE8?X_4'JYA9V3@4>F.RCU)M*J41:2K)_#3I-P593^A&Q[@@]40AX^'W 6
MY6-7W_T;L-$D<0T3SZZ6ZCA:O88'/RXZ&M:\PSC/+#;0$UI7\8L"LI\J)-Q.
MKBF8D]AY]MU#@AQPMDY61/V:5'DJ./\ J_HQDSJ?NKL0W\P/4H[B4;GCXF%C
M5&^-I3LU$)_FGZ][)-Q_*R(K*?*D'SUKR)$BP(L:#!CL0X4*.S$AQ(S2&(T6
M+&;2S'CQV6TI;988:0AIIIM*4-MI2A*>)YSGU=          T !X  '@ #V'
B6>2222222223LDGR22?))/DD^_7L?7>N='T='1]'1U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g180330g13h77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g13h77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &O:^:0(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'*_^^         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              E@
M =4          0                         !              '5
ME@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
ME@    !29VAT;&]N9P   =4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   )8     4F=H=&QO;F<
M  '5     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MOHY!X;#V.L_-?].IKV?14V0D&,0>&-"OK^DN/9Y[%^H Z7]8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( #  E@,!$0 "$0$#$0'_Q  =   " @,! 0$
M           ("0 '! 8*!0$#_\0 .A   00#  $#!  #! <)    ! (#!08!
M!P@) !(4$1,5%@H7(A@:E]89(2,F.55X)$115UB8MK?7_\0 ' $  @(# 0$
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MYYSP:_CF_P"']Q!_TE\\_P#U/4_0/F7_ &1:[_ROJ/\ E<O%2]_;EK_")O\
MS&X$/S@<X;6Z.XO0#J&(/M=@U9LVN[7E*+%M$%2EPK4-7[97Y<*(C1?H_+2L
M6BS-3K,6RKY9P4;(#QC1,NN/$?N\HWZU#5LVG$4=BO)669L!8I'>-T9F((16
MZ90MX!8%B$W$<0^.G+6K<R\D=/1X'N6=)U6KK$M"(.TMVK7KW*\T4,:$--+&
M+0L"%27E2&1(5:<Q(VC<\RWC9\M5(U*<7K&JU[:?/+\+.GZ<%0Q2;92L1 Z8
MY4&TY7TQAELT\J66"4%B->;CTF!0@\T+"R+AD*_MNIKW+4MI18D>M>#(+7>:
M*;>2P?+[A':V;@<C=AG*EEPW%+EVQ\-/B]2T>5],J0:MRV\%A]% 6E=T\P*(
M_3YK])[>C=8QN@C(A9XX%G2&020$VO(CQI =P\SV[4I. @;W&_[WZCLY6,H_
M7-APXQ&(O+Y"$J<;AI\9\NMSZ<(>PB,E'3V6%R,?'NLBM#U5](U"*T,M"WW5
MF,?[I Y&X8^;(0)$_OE )VD@N_Q&Y*K\]<KW-'?9'?C_ (9H]M_]ZZE K=$L
MV"1#.K/6L=F^YE9U4R)&5YP2>M^I_(KKK0/BJ>A+33]TBW60I_7E^F&59>=H
MNH) =MH^>;2M3[18. 52%[:D,BJG;U6Z_' %K1:'@<O0TS3M"GN\Q[XI:AB6
M72H5\=:TI.U,_(@XAQG9$[L0#&"/FMN<.;/B1IV@?"8P6Z.N)=EI<Y:C,O<Z
M?HTB@23;22'79U+XDV">_7KQ1NRW"G'0!VGJNE:/\6/1>H]<Q+<'2->\MW>L
M5V.1G"W&P8ZL%-Y),?\ :E1DG(/Y>D94]W&7Y"3*+.(4I\AQ64O2;$MOF*C9
MG;?-/J,4DC?5FD!P!\E'8*/"J !V''T+SMI5'0_A3S+H^FPB"CIW*>H5:T0[
MD1Q4Y%W.WEY9&S)+(?=)*SR,2S$\(7\8766W/'A6M# ='.$'\-];B24[K?8;
M>2S([2]_9L,I SH<@ZMK.8R,*-B5R5I@6\N#8CSQ;U!+R4Q<(TERYATVKKDE
MUJ&%UC3&"6*YVAK< 171E&?<RA@D;]CN!A<8,3<< ^%O-FL?#>MR_%S*QDY$
MYQ1[&F:D-[0Z'J1L20SQS.PQ#$YB,MN $J(W6_ 04NHS#?,U)UJ\VOBH"OV/
M,M):LW=7=PVV-JM)VKLX\2CN%01,>?D74&O]ANAO3;$:8] M3"8IJ9:86\ 0
M\SC*\!^4H)TCU5VC5$LU)*<3SV:=-&G]P*@W;-8/L) ?I[RA.& /';_BCRCJ
M/-_[BGTRSI<$6F\R5=4FFU"\E2*>",Q.L=-MLAM6)@IZ,<8P^,EU'EFM>\AW
M$%HA?S,-T_J)UW,H) 8JAUI&AME?L9[K8\=5OY3S*8_9W[7)$.M#QM7_ %+]
M@D2%I8"CGW<X1Z!2\MZ]"^R32KH&PR=982]7I*"S2^L3=5Z*@$O+UNFH!+,,
M'CL!KS#S&V,9W8RF",@EQE,$=P=V"._@\5C9:QR9XU ^G^U[\==W)/>-_C;5
MM?8,K#'[%N"%G9%A*CKVK"52M(E8K7\"M+0D'$DH?%B\.)>FIM8XHSPEJ*76
M.:&TK0ZZP;:%=XJ=9)%K0X7,DUF4S2['LR=VD<89\82/)(.Q#8MF&LI4B,$1
MIE8T&3EF8]E+'YNWN(P"< #@,/#198/?VW/(3VKJL2,HW/\ T?M^A"ZYU*Q+
MUIZR1,[KJJ&1EYV)>JG6)66$HMEV7)RS$ZY$'.L2T@E3TL^@V-?AIB2.<[12
M:=3Y<T.VSV-1TRE8-FX4E$3QV9E>"M7FE5&L1540Q[U!1>R#:P>-+6HJ84J5
M9/=-!$W4D&2")&WI&K'\:Q@GW+[=S,!G&39WD&X#EY^7>ZNY>434]X5,INUV
M2%KK^(I^VOQ>5%N6RMN,_;2)?1$H^\>/EQL6VBM.X<3F=4K$X)T36E11INHX
MDJR#I1O(-RQ*W;HR#R8#X4]S$V/"=TX)\0>0)II6YJY7WU=:JR"W:KUFZ36F
MB)<W:A7&R^A&Z5,A+BACCU)86;J\?7D @.JJH[4;RZ!7MXTV'2=90DIP%$6V
M#')#CE7."]V<,"?4TX :>ALN8S&R)K#@25QI@Z1ZFMZ*^G2]6$,].5]J'\31
M.06Z+_,C"L8W_252&]RDDW\/N?X>:JQHWRD&NTX.K910$ANUT>.(WH!X0B26
M)+,'B*61#'F.151.'+VXH'Q">47KGG#I8I&ON=^Q[NYNC1NWYO&!J7&%R<]8
M)*)#FYQ?VQ8R'89L\E1+++F8:8K]AJT.;*I"KLSB:9?=6I2<Y<JZ/J>ECU&I
M:+7%'4*2',[A(XU=HT[L[DQ+8B09,D<KK'NE3IGMEB-M2H5[$/OGJ(8;$0_$
M%'<2*OD@CR?RQW .'Q=K\C:1\@V@(O6^SM@VR UD-:83:@=SU3:ZS%/$J@8:
M?!$(_8YB$M,&[7'0+ :42ZT-C"\L#/(.:9;=2[S_ $+6+W+NHO9JUH9+1ADJ
M&"W#*X'4DC9ATDDBDZH:(* 3VR05)Q@15GDJ3B1(T=P&79*A93N&.Z]B3]/S
MQQRE\F\>\['^:/3.N^"]C;4W/I#F)+6U-[[=N%L@+96$VJK.2KP4349RJUFL
MPTK!O6%VGUA@I"#_ ,S+/V0R*()A(-9SG6]8UK4EY(NV>8*M.C?U4FII]."&
M2&7HR[ SS)-+,Z2",33$978@B5@))  P6;4GV5(]J""&6RPCKHD0239V+R$$
MD@=B/ /?QWR&C_Q"P43)3OC&CI\2./@3^RX,*;!F&!BH@V(*-IS$D)*BFH<#
M)C20G'V3F"T+%>%6ZV0A32EXRI_#EF5.:6C++(NARLC(2'5E$I4J5((8-@J1
MW! ((/%/1"0+Y7.?2G&/.<G&.&[_ -E_QU_^GCBS_"71O^7_ $G?:O,?_"6M
M_P!,O_YS@7U+G\99_P :7^O@2O.2#$1GB'ZAC:^'&Q\#'UO2@,(!##BB1 ,0
M)O74C$:'%"A(;"&C1@FV601Q&T"LBH:;'0EI*$X,<AL[<Y:2TC,TC2W6D9R2
M[.:%PLSELL6+$EB3DG)/?BWH^?M2KG.>H^<^<]-\YS\_KP2OCONU,#X%XG$+
MMU8%*&Y0Y\8)&(GXI@@=]K5-50ZR^RZ6EQIUM:5(<;<2E:%8RE6,9QG'H7S)
M#,>8=<(BD(.KZB00C$$>KE[@@8(XKWD?UEKVM_;$WZ)_C&_+C<.D>Y] \IV_
M1U0W#,S$)G?=C?K]6M3,.ZY181H9L7#TY;;@0Z+"1,.V7)0XCRF2CCAFI1F7
M+!'@!SY46I0TB[J,5R6JB/Z*,22QEP)FR3[8HAEV;"L>X"G:5#%RJE"YGYZT
M#E"[H=+7)IZS:]:>K6L]!O0US&$#S7;;E(8(E>6)&PSR+U!*\:P))*B1/-/K
M77G)FR.?N\N:YB/UMU%-;;# /K55=888VQ%NPDO)2=N/K@.<8D,NN# U*Y%L
ML_"MT?<V!IK),@MEXEMY4GGU.O>T:^AL:<E9F624$FJX=56-9&_#Y:6('O$8
MB4PN0.&?&W3--Y1U/EWG_EF>/3.:YM9CBDJ5" -:B>&5YK4E6/O*25CIW750
MEN*\J3%I3&6Z= 7GB0@R"!UB$$"CO/B.9PI8KSK2''1UJQC&%+86I3:LXQC&
M<ISGZ8]<_(P2 <@$@$>#@^?Y>/J)26521M)4$J?*DC)!_8>W"!^,!QT></R5
M+0PRA:-<U#*%(:;2I/RA=1/E92I*<93DE_&'B/IG&7GL8<=]R\>[TYZJ3^Y'
M0!DXZ\_S^C60/Y@2!]!XX^?N2E4?'7XH$*H(T[3<$  C?6T9WP<=M[ ,WZS#
M)R>_#(?)=_P_NP_^G[9/_P >+] M _UZTO\ PV#_ ,8XZ5\3?]KWG/\ YN:K
M_DDG B<$\[ZOZH\/.@])[>@TS50ME$LJ,NLY;:EZ_,#;&NKD/:*V>MIW,98(
M,O."0"TMN-KQ]X$]@R,,."))ZS>L:=S1=MU7V2Q3KY[JZF&,/&Z_I(X[,/V,
M"& (3^0>7-*YK^#?+VAZS7%BE<TV8$@A9J\R7[AAM5I #TK-=\/&X!&04</&
M[HR >AX?I[FO</(_ _0"OW"DZ;Z?H%[YYVVMM]&;1JV=LU=@1X(=QW#V'0H!
MT(=AN(**=DJ:4DRN-OG5ANK/,NE$Z??K:EK=+[J6UIT\%ZKV^[L*CN9"!C!D
M&3N VR@B3VR=0'YYYI3FOEG5.4/A[S$3>H:+S7I>H<M:T0ZBUI,MF"NM5,[A
MLK.1]TTAEI.7K;I*IJ..W4FF4\RQAW NJ5HJVQS"A8^TDP46_8P15I4A8P<V
MZ*J3%86E:TJ98*0VI*E8RG.%9QGDPFF6-H1-*(6.6B$CB-CV[L@.TGL.Y&>P
MX^\,G&,G'TR<?S?R#^;@1>4.X:/TO.[OUS,PS&H=X\_;4MFM=A:<LEJC).T,
M1\$^UF"V)$XP)#D2E&N<<\B0A)H>-^'_ $/,Y)=3A@@@QJ^@SZ7'0LI(;E'4
M:<-JO=BB982T@(DK.<N%G@<;70MN[@X'<#?-6>$1OG?'+&KI(H.TY.&7/R9&
M&U@>^<'&""02YX5K::\UG2$_RRN$>U6%R%7HCJ^1H61EZZD^GWMJ((I313\1
M]8,W9 >O&)I$V4(MUP?"9T224F>7+8RP:EZJ/D;3(]6#BVVLR/HZV,^I32A3
M(GVA_O%JM9,?34X!^[*@QB/%J7>-/A6<'>9W,&X'>(=@#]SWZ9D[*,8W!B/#
M<:)VMU7MKK3;1W#/*,5,X!S+'UW:%D6P7"OS;D,5D.R1YY3[22*YK6OO_P"R
MLDD4PP79C&TQ C),84,!9]&DZ;6TRJ-8U)T#;5DKH"'"!QF-E .)+$@&8U7(
MC4[R0P9HOFOG7FO5N;=6?D?E2*8Q]:6KJ<^UX&L- YCM1RNPW5M*K-[;4KJK
MVI%Z*J\+I'<:/QSQSKWD'7B:[7D-3MZG6A2=@[ (%0U)6.293E20@DY][D96
M(MQQY$-#(=4EO"W3C7"I,LLIU=U35)M3GWOE($)$$ .513^DWR:1NV]\?15
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MB0&E7ZG8]FV3$3:B[0)<C'6(DH4:AUAR':K641X%JE)20%5$QST<"0KU](E
M#2RB4:?+/(P*%%ECJQ;XEA,"Y=2UB4.906:%%5M[!FVHL+ Y8AA$SY\@L% "
M8VG!\MNS\@![CQG:_P!@=C3>8\;85$B:D@YYX<*2KU,Q/8+?<8@T&(GF)/9<
M$]3@H1\J?<"E' Y9J=;B?H W(J8AL7[S8KZ+'N:O8>;: Q22?IE0#(1L*U'$
MYD"QAD#1E"XW%,R>GC+ "=C%A@'W$(1^S&\,3VRH.1W[^<:E!V[N^%K%>AG*
M3"S%MS$N-R,G/0#$C&DDK#N>2K/*2H>TXI$>:).A4D=BA1H3C1\5/&$1DR..
MV<JE[GAY?DFE?U$B0[P55'*, &@Q$B&HY96C:<FPS JT8#1EBO7FV MG=M7/
MU[CZ#\/<8\L!Y[8[]KJFBNH,EZ^,AT03;L>_L>&O0SL ._#SX#>[-<5JDV)@
M#]S%+AI(O4:;I>V4LR<H.,3@J-+"2^Z&!F@@TK;95^H0PK/7/4(>-O0V9;$9
M;H%9%6YT:_=$+#:ZL0&;CR.CM?.<DH4[]P-DA<9P00&VKX!/8_4<4?,;1[8M
MVO5RU9U['0LK<J.DVK 0E=:->CC3\6B(D"R[78-A06((T-J-JMUJ&9"FF9/$
MN8\*?$O$P<Z7$WTJZ%#9"36'=(9]LS/*5#!>DZ@115I"ZL6EKS[9UVF R*X$
MD:OD)$&PS'VGOWP2?(&TJ?\ BMW&"/EG'&[YV'V,;F)?_EU"UZ-BJE BWMS-
M6Q/2Y%_:L%(C;R?1HQG98GY>GQT%,7"=JK#BG)2=77$MLN&/H%A['7%;1E+C
MU+REYG, $QC05S'.T"SNU0[)FD2&.4C"1B0D@ EX\;8<8R<LQP=P 53^ ,<'
M!^3>0OGC6R+KWHZ'&RKFLJ<Z0I4Z2FNA!MQA,>J(UA4I"$>E"/YN$ RSMDOT
M[<8YZKXDV(T%5:BXA=KPQA5YD=RP<O[G3U4P V#J,Q97WVIED"#T891%7C@8
M2["S=5I.CG^#KZVUQG#L>WGYDER,8*X&U0#D9_%^6.+2V#>.CXS6L)+:\JSE
MBMI$9?WEHDM=##R!\_&+5C6L-(TU_;<,FLPUL1AY4W92K8I^*P*#DZ"KCDT^
M-!5*T&F/9D2S+TH0U<#;9)58W'\)=9Q3?JO"<;(A#A\L%DDV!G\!8RS G &,
M$/D ?I$':-Q_5& #D]\#)U5^\=8*-&,72\BM#-S UH0+3&S1:PM^YU$-K%3#
M;VLV_ME E1_,R@<LJ/J[BFLOR @9,RHK6P^T0:0 5ZV<E&B)F*F7$,K8F;T9
M]'NEV(R@S>["EECQ9XR%B*@;L,2N/=^3 EB4PGNQGN>W<@  GRTG]LA0//QT
M+&Q4C.F:FGT;B@[A%PJ&!=BL104]#_-+B+OAN+*E96-<IB5Q!MHBH-F>-E'2
M)I(0[JMFW0C)J2R.RQK<C]%)"TA+5B[1OM#P NJ(PF]ZQ/(4"[8]Q''H] F3
MR!N&P@^%Q@@*1W(R3^+OC&>^>,:$V+VY(,Q+$UKJOP[I\[6 !C0*BN39,A)&
MVQL;>92?S([*KI5+=IU5?D)R!P[%2V;44-]@8-_[+#<O)*VA+O*69'VQRL0T
MQ3;(L+/ D6VK)UQ-*%CD]R=$')89.S#+""=K$C&?(# X[ ?B#9/8X)  SG)P
M/D78>^(:D@G/5W7UOLT=3P<XK4C74P1\_:1IV!K*V)>TC[.*BP,2$2=-7TXL
M*#0.QB);AAFD*>5DB/'R^\S*)+,,33'[U93(J0M')*-D1J!V*2*E<!GRV_J$
MX_#Z9:Q+ ,RC)PWD ;68>W;W]P">?GDXQQBOVGO&Q4>XN,UFFUF7Q4I,*K?!
MKCJYZ4GY2*VD.'-L.3EWCF(,BN2L5K@AB-EZ[EN3;ES%O?::+3F&ST=!CFA'
M5FE4S*9=TH$:1H]0E#TZ[&02H]D%TDRAC7&<'? M8.F78KO&[/R0=/(PH();
M+C(8XV^!XX8..EY##*"74/D):;2^\VUEAMYY*$X==;8RZ]EE#B\*6AK+SN6T
MYPC+KF4^_*\<9.!@9. 3D@?($X&<?7 S]!Q5X ;J+CU6QY'%^U8D*(NYA+3%
MDC'2<1L9/L&J^(5,X?0C*1)5AAY:Y7'T^W, H?5E"Y/&4R)6CJ/17I3Y:,#V
M,!EDP,A"/)7P%^:GM^'&U2USETVY/5T D=AV GB+;(Y0QVF4'&%D4',GRD0,
M0#( '(706@ZMHBJIBHI+<C9))MAVTVAUE*"Y8M"?K@<?Z^Y8D.&M3B8\!*\X
M3A2R2%/&/OO+J6[<EJ3<V5C4GIQY[*/J?JQ^9_D';@QI.E0:7!L3#SN 9Y\8
;:1A^BOS6)23L3/U9LL2>+Y]5."O$]3B<?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g180330g13i88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g13i88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &.B^8W8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RO_O@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  "$   !TP         !                          $
M =,   "$                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   "$     %)G:'1L;VYG   !TP    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    A     !29VAT
M;&]N9P   =,    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #KL    !    H    "T   '@  !48   #I\
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "T H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54EPGUDZO]8NI_
M6G_FOT/)& VJL/NO.CG$M;>[])M?9L96^IK*Z?TC[/4]2STE<^JV1]<L/J]O
M1NN5NS<5C/4KZD(VM_<;ZQ%7VCU/H[-GVJBSZ?ZO^D3SC(C=C;BX>O"FM'KT
MER'U<ZYU;,^N76NG960;</$W?9Z=C!LA[6?38QMKO;_I'HO^,?K/4^C="JRN
MF7G&O=DMK<\-8^6FN^S;MO9:SZ=;$O;/$(Z6:_%5:T]4DN$^M/6/K,WZR=-Z
M1T;.&*<[&:X![*RPV$W%SWO?1D6-]E7YB!U'._QD_5JIO4NHY.-U+"8X-NK8
MUH #CL;O<S&P[:][W;&6L]799_.5(C$2!K'U;#JKA?0DEB]1^LV+B?5C_G P
M2RVAEN-4[EUEP;]GI=M/^D>WU=OT/TBK_4;ZP/ZYT*M^0\69V*?0RSH-S@)K
MOVC_ $]1:_\ XWUOW$W@/"95H#2J+T22X_\ QA];ZOTFOIPZ7DG%?DW.K>=E
M;YT;LGUZ[MNUSOS%0S:_\:72L6SJ%O4,7,IQ@;+:6-826-]UAV_9,-SVM;]+
MT\AEO^B3AC) /$!>UJI[])<8WJ'UM^L_2L#J7U<RZ.G:6UY]-L._2M<UC0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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ME9U,RRJ\KII]BJ;;54L-/7!Z>2G!6.>!!ZD.#A@JL,G'JRI&?4""QUN3Q?\
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MI!N-;*O;A]&5C4XRVXG@DDD@>=JC/)U)%/\ '_+UILAEQL6B=;3%J/,9D"[
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<SG!^O///OI=Z3K&CT:-'HT:/1HT>C1H]&C7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g180330g16j01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g16j01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %VR^698X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              @@
M FP          0                         !              )L
M@@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M@@    !29VAT;&]N9P   FP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ((     4F=H=&QO;F<
M  )L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#K[,[J#.IY%E5AT>YOI.UK
MV5Z:L<?9[6[WV>Q5>J?7A[:O1Z;4U]\19D.)=4T_\!]!V1_6]E/_ !ZJ=0R\
MKK_5+<;&9^K!Q8VM@@VBL[?7R7_GU[OYIMGZ*O\ XQ:%?U- K#LAQ<>]51 /
M_;KP?^BQ12E*6D-OWEI).WVN=]3>J=3R/K#8W)OLR1D4.=;O,ANQS?3>Q@_1
MU,_2OKV5M9_.+K>K=:P.D5,LRW'?<[9136"^VQW[E53?<Y4.E##Z7FLP*L=E
M(S&.<UX!WE]1=N9<]Y<]_P"C]]?^C_2H>*RN[Z\9S\G6[&Q*1@APXK>7_:;:
M_P"5ZOZ+?_83L8(C1-FTQ%"B;3X_UMP'Y56+EX^5TVR\[:#F5>DU[O\ 1LL#
MK&;_ .NK/5>N8O3+*:'57965D;C5BXS/4L+6_P Y9MEC
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( !\ E0,!$0 "$0$#$0'_Q  >   !! (# 0
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M!YDG8 62=JQ"WUG\UG4WJ>2G^8*L+1\R"9&==9=C9;-2"<Z;QD2T"NMP81E
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M"XD*^-10-G8;]KKN>V"R!5['&7GROPCI/9Z!Z#NE&_,]=Y<&"!1K9_9+8O\
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JQ@=!,%*E#K*A  YCB:MF+$+)S44 ?* 69B0<2&_6=C-QGZ,&,_1@Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g180330g16k02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g16k02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %3Z^5#@X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              B@
M FT          0                         !              )M
MB@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MB@    !29VAT;&]N9P   FT    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   (H     4F=H=&QO;F<
M  )M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M##Z>GY[7O=[EHV=;8RH?H7#(/-1(AO\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%#I_.XG0.M8Y;3HL+CXXJL0NP\M-ET9RY8I'[,E-;,.K#-\LD>EG<G4SGFJ
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:?&&#XPP?&&#XPP?&&#XPP?&&#XPP?&&/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g180330g16l03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g16l03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %@2^5C8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              B
M FP          0                         !              )L
MB                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MB     !29VAT;&]N9P   FP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   (@     4F=H=&QO;F<
M  )L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M W>UJL9O6>G8&17CY=OI.LKLN#G [ RJ#:Y]GT&?3_.4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M! (# 0             $  4'" 8) 0(#"O_$ #,0  (" P ! P0 ! (+
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MAL%2W5O89IJBJ:*%-IZ)VDXL?6K3HK,OM%@0O"%RS$CB]D#F0!U/+&N.8/\
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M;RX%?.P4!&,YA2HY,SG22D8THJUU;BM*K,13% #^Y]Y3R8DOR_,/M]V?[?\
M:[TO=K]HKT-TWS=HM]NQU8E#F&CLC6'?9V::9EJ[?MWT=+5:.6::&#B?B>0S
M2,6^J.SNY=GMF[&;-<DL5*%1Z$)F<X#6+PCX;H"(#+8L^LI,KJB/)[.%7@4
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@>?\ ^/M#K;:W^Y^X?]17_P!MOU+_ -=9UJ6E]&C7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g180330g16m04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g16m04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<04&AO=&]S:&]P(#,N,  X0DE-! 0
M    %O2^6'8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              C@
M FP          0                         !              )L
MC@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MC@    !29VAT;&]N9P   FP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   (X     4F=H=&QO;F<
M  )L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MN53AY.%4W)MZ?D-R?LCSM%H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (" P$!               " 0,$!08'"/_$ #D1  ("  0$ P8$!00# 0
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MASR3*<-TS25>*,0_3,B5S?#&*(;2)S'.9%D$(C*D$Z" #OU&HCE8.VXY@X+
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M!ZX"010 'YXMZ^LK"X_-,^5[U[ZW]$^[/0/(;U8[N77^?=TO'*>9</KV[/\
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MVTF^NNV^<[8QGZ,&,FQYGS=NX:6%MS^D-+ [5Y1NGC&J(37#=+G2&+*=HS)
ME-/5YC''CRO+GE$SI!#IF']L6F-;ES.81%C2>98T;6B+*ZHC\]:J&"JU[Z@
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#,?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g180330g17n05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g17n05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %B"^5F0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              F@
M FT          0                         !              )M
MF@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MF@    !29VAT;&]N9P   FT    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   )H     4F=H=&QO;F<
M  )M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M'3<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MR)[!6>B.6)A[F,"LCW&\1ZS:4B@_L)"Y?6J(DEUP,H&GRH7XGE./B7I13(5
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MO4N8+?1JI%.K[\74Z!<="5%F'(C@@\2:2'6B5LZ@ 6?=T)'OZ$8.U=?CW^.
M<W=>O^35\<7VI2\>;83%?DZ[J?QV.SY5?3P%LPVN>EQW7ZE9#_UY=CH<7#$F
M<G1D8>8Q/B/_ )JM%?\ UY;K_P KK^1\<)^OWV^_UO$B%J\&>L^1?@6!XX^6
M'75MT[:%,+:*_P!.6*=I(*I:DT)$%8&9D9P!/=<"+#FE>L5C( 5LW2YR=/B+
M=L/$Y+E,3/%H=K;J#Z'L#Z[6"??W[KB/"D#^NKXWT@'QYI7-*1T2M5H#2L4/
MI$QE L)2- ''@53"C<N[O68]5JJ#72%5!T6HEE!!10 Y'P ,*-%$/Q*#0%!
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(?!@PO@P8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g180330g17o06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g17o06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[11@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %$2^48@X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              5P
M =$          0                         !              '1
M5P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M5P    !29VAT;&]N9P   =$    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   %<     4F=H=&QO;F<
M  '1     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ ' "5 P$1  (1 0,1 ?_$ !T
M  $%  ,!              @ ! 4&!P$#"0K_Q  N$  !!0$  0,$ @$"!P
M   $ 0(#!08'"  1% D2$Q46(1<*(R0E,C0Y>+;_Q  < 0 " @,! 0
M         P$"! 8'!0C_Q  ^$0 " 0(% 04%!08$!P     ! @,$$0 %$B$Q
M4083(D%A%#)QP? C0H&1H0<S4K'1X19R@O$D)31$8H.S_]H # ,!  (1 Q$
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M4]#Y!]1KK:WSWC?03X6SW--2TU@^N.T^ZU%?KC>;X_'0SJ$QVF-ULX4A-A
M)&6>/8C!-::P4:&,C D1BUQ:^Y-[ ;<X+>H^/UO^F''+/+)VGZ4!Q/LG'=[X
MY]=OJBROL7GMR?E-'F.B5=-'%/=LP/0<5<W.;O[NA$FC/O<U)(!?5]>YU@@,
MX4))$$I+J;0Z-&V]@;$,!S9AL;=+]>AQ&(3;>8UBO1M=RKQ\X%TCR7U7-RX*
M[IMKD+?%8KGN(NYAH3'Y$O?= O:2FM]P*&4&2?F*)MA/6,*;#9DAF0&"C0TQ
MU%8XVD*^\00%7TN=BWIB;>H'Q^K_ $>F)S$>9O/=GRSMN_FR^[Q^L\=*'17/
M8^+;.J"I>H9"6@RQNO@%DKG64U/8 ZBF!E+Q^DK[>?/7L#OOBL8GCFPBR)E*
M.UB#&"70[,+ FW0W'!X. "Y Z_[8\]S?KI<8ER=9NLOX[^16EQXQS >@Z2/.
MTX=!STLBSE"KJFPT,=H?GCM!9A?"MPJQUM7"RBVM<+^T2R4T,)'MBV!$;D?>
M.UE/2_!/'3G$Z3>UQ?X_7//Y>9Q8MM];G@>=*K+W*\?[OT#CCS:JIONU562;
M3XZJO;, :QES@#[R42.UT-3 0L=G5%'4LZD#$_K/V0:0&3R:Q 00CE3]\#:_
M)&_3SW&^W2YI/X]//ZY^C@M_)SZAO O&/E?.^FW1=QNI>QUP-KR/'8H: G1[
MBNL:\"R'MX(K&<*&MI(8+:I:8>6Y2(R+(0,0 XZ3XJ-DG2-5;WM>ZA>3Z_#?
MY8@ DVXZW\K=<"OG/K/<G*UG.N;[KQ^\A.8].Z%L\YDQ\AK<S6U:UPFMMPJ:
MBU3S+NQHBC*"<PM\<SH:F,YCA"/C!F1(V9RO:UNJF-U9B!8@#G8'>VU_HXMH
M/EO\.O3>WI]6N'Y7EU< _6?-*7 =W)SD=<WAR84:I+D>ZQ_8P8__ "FS/K9(
M#_CK\B+H_P"4?C_-^C5#OP>ZJWTGO?\ BB=+6MHMZ\:C_P"/G??;!I\/(YYY
M\N/G;IY7VP>W-_JBX7R'ZG+P?F/#.]6EH[::GG_0=>-7506=YE3UPEE"S;VF
MFJK"Y$ @M):N\9GAC9:L\@FFE;'_ ,;, (4]:D.VA4?E@Q%O" #XO,;^5[<?
M"]2+<^8N/K^O0X$/Z>_D%R?Q8\$^R=PP=!Y)]JYYG_(.Y$W,%U7843591L^4
MQQ,VE&H1]R?62YJ%+6HCTUU!<.M9[4PFY-I@*0,@H-<#K%"[@2,HD(8'3<;#
M>P-K;BYOSY6WQ)%R+[7 M;X;?T_M@]3_ *HG ++2^.^(Y-4;3M^U\D*L>YS.
M8Y[#GY#\?6S$2B33=#?<WU9!FY:PBOT'[L9'FSTHF7O;&R:.#"%.<XU*7C5
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M+$Q<KEK149#&U%L2_)FM((._I/\ N9IIY9))O^MRR.]W*BJGH;:A'K;_ .F
M>^?BWSQC'42"N%6_T??,KH&6N-9P#!^-O(\=K):VO2VARNFCS!Q8-P0-(J0Q
M67V:BLOZ!KWQ261V(E%%FC,A&^ZC73V64@E%10?0[GCK8@CR-L1R6 \S<>O.
MW3X?SXP[\\/-7QZ\MO)3P.#X0MAKXL%WC'3:#I!F5O,R-$_2;K!J%BP/Y'5U
M=L9*S]21;V*2BPA0.^%\"0V26P429I4EDAT7-G%V((Y9;#<>E\646)OM8<?K
M?\/G@Q8?_/05_P"M#?\ YD?T[_O?_7\L5^[_ *OEAC]%N&! O.\EL;$(E\BK
M@>69&I^22$=FCD@C<_V]U9%(42YC554:Z:14]E>OO%+Q/_G/SP-]W_*/KZZ^
MF!:^G'Y*\S\6_IA>2'0NE@5FF$LO(3<9+.<^LOP21=(TM_R?F8X>0E'GB(CD
MJC!FEDZ2>08F('."6A;ARGQQ"$+@D6.FD9K&\C +Y,2J[=;=?2_GB6!+ >=A
M?]><9-X$U^E^G!Y%<GWWE-R^EQ6$\O<#)5X[?$(:V3C1MM>Q&AT=W-9R.;FV
MFC-H5UH%E,19U-!:T5D5<Q?I=?6+6&]/(K2* )5L&W&BYX(MMY7'D+;\XEMQ
ML?=YWY'7FQ^N//ZW$5'(CFJCFN1%:Y%145%3W145/Z5%3^T5/Z5/7IX7CQ;Z
MOY-Y+FW4-A4<@HR5EI])>#$VMH4X2G!O5L9DT(]!6UBP&D5+;G]D2)*19A,:
M243&.)/4M!C9WS*?V:U':&BRG..T=:Z.^6TJQTU'O43TBIKHI*RHE#+'4"F:
M-)$CB8LBQEY5J!+J^?<W_:?3=GJ[-\F[.4*ND>9U;2559_T\%:7[NNBHJ:(H
MSTQJ8Y)(GEF55=I0D+4YBTMJ?5]C[TL5QM=#85F05S7NLBHF"PDP>SD5F6H8
MOBBER/1/Q.L_Q0@,^V523R3(FASWSF?LEV#1Z>C@@J,TTV6BA?O9E8@6:OJ6
M,CPH#XNZ9FE>X$<0C)D4R6+M=V]=:BKGGI\J+7:OF01P%=P5R^E18TG?[ID0
M+$N_>SLZB-O6?"28?*\VS;J,J"FQ=?5BQAEW)4(OXFSD?C?+9F$2,A4\NRFD
M4N9TGVD6$\CHU=^5GOQ"IJ*[.LPFJ71ZFMK)'D:."-F8Z5)T11(&81Q1)I10
M#HB07)"DX[C34]!DF70TR/'2T-'&D8DGE1%74X&N65RJ]Y-*^IV.G7+(; %@
M,-@^8\7K=1_/:_GG,:_:%F3HNS#R.6$U!)\CB(R/?0PU\=M,5(Z$IDRJ8Z61
M8IT>J_8_VP?9W#&T#:E76UHSJ52%.HV6X6SH;G;Q+_$+YO?16![V.Q<Q@ZU
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17HP87HP87HP87HP87HP8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g180330g18p07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g18p07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S84&AO=&]S:&]P(#,N,  X0DE-! 0
M    '+R^<U8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              P0
M F0          0                         !              )D
MP0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MP0    !29VAT;&]N9P   F0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ,$     4F=H=&QO;F<
M  )D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MQWMIJW-_XQ_^#J?^D7*_XJ+F5_MF]YAC*L9[CY#[4Y<MA=3P,SH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M2QP#CQ232[ZQZYVQ5T<<DTB0Q(\DLKK''&BEG>1V"HB* 2S,Q"JH!)) '?@
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M^K1B37IP%&R$&>-?@-(%*X[^$9F*_;"]NW9_'PF^.N5^8_"_#KI6JZIEZCZ
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MQ4T22-U.59'74PRL#X((/ 5= C4AEU.)64@@@*"".X((ER"#P!_P9],MG/\
MY7@HJ'RV\\DXEZ,BZS53>=-)7EB55&NX26#I%$3%69BA1:.IJBZK2U&JL1JP
M%G(M-80R?[VA^"3_ #[5AL\HDV+<%R]IAIS+901Q/-)OCJV'$2R2%!,DK2/$
MKLF]5/\ 8N'NLQI)IB;YXY[%8H>HK(&<?H<[0Q/N!#$ G+ ''VD/0//-*]3?
M4D7'BO1U^&]!L'=C[!;DV^=L#O4W/>*:]$FKYWV9UWRLL$U6@2--8]XY-US
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M(IQBX^-G_N./:7_W?V=_^G:?J[N9_P#1GH?^YT7_ (5N)5J/_0&G_P"U7_\
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MV=2Y]YIHPK!'J1GC10J>KAALNH'C\Z1#,V!V&^1P!V'@<"XM7U"% B66VCL
MX60@?8%U8X_Q_P#3@EO*GQS>,?%<I+'SMPVM4VSGA[ ,+TQ*<7"^EA2?^I 6
MEOM[%V[6KB]L:;F*DQ2U25O%#O.#OO#%MH+U;F76]< 74K\L\2G<M=0D-<,/
M#&&%8XW9?[7=6=<G##)X;V;MJV1ZB9Y #D+G" _<(N%S^^,\0SY/%?M'?RQ9
MK;X-Z VIW=N>'#W&.NJ*I2;>9TVH "F0V:EKEEUK%G@_R' L\=@KNBH:%FV9
M)=:Z/F:1U%KJORJVA_BT4/,%9)]/LJ8.H\T\"U9F*F*=W@FA/2R#'*7)1%DZ
MIP(SQW0-4646XF^!_8QW,IC)(VOE2"0#V8=_:20,@<9HN%?)[\:WK6C*JC\R
M'!$Q/HRD8FKS;T(/RUS"=>P%LDL 6+.3Q<-/T>KV-=IKA8RK@B<JJ9)%V:+\
M)=C)$B^T+_*O,^CV'FY*U!QID^)4TXVT*UV<9;I"\9*TL3?J25G$V"$;J;1(
MQ^;3=0JN9-*G8UI/<J)*/;GX 8E'7/A@2<8W>,\=3O/R,_#IY2Y!T2M_&'Y_
M263OW1Z;8:(BZU+SRZ+=>="6U28A:.H;CVF/;I<[ ,(W>=;7J^#$G;'ZC?W+
M&,8?<<CC3^6>=-7NUI>:M1DBTZK/'8DI^I@?U+0NLB)T*)]*%9EP\LC;T4MT
MU).1S#IVJVY4;49G2"-P[J\BDG;WPJ(2@!\%SV )(R<CAKWT\?BV_P#E3R#8
M[UUE ;4^@>D+:MO,=5:BR@O4'/$"?*RB#V &?&LZ]NTW86.R_P!?/K&2$J>J
MASX!6>APD$1^I&N5]6UJ.O3D6:MID+5S*C!HY+,C[[!C8=F1-L46X$AGC<J2
MNTD=KEQ+=L"(AHH$Z:L#[6;)+LOQC.%!'D*#XQPV;TIX^\T>P*L)3_2''JGU
M)2MWFE2DN("P+'7IB===29:W;D1:JU5[8K$<6#-4SD*,[$46AFD^D>FN(AI>
MM:IHLS3Z9=FJ.X D"%6BE S@2PR*\,NW)VET8KD[2,G@;!9GK/O@E>-ODJ>Q
M'V8>"/Y!X7;4_I^/BUJMB@L.>#O;+_%G_DC([9U7I+>NQR:[_?'K.LTLHF&4
M$>?VQ_$;3'BSZ8^PJ$C7.V-I)-]1>;)HS'^(1Q9&#)#4JI)]CAC$VTG[H%(_
MM(X?-K6I,I4V2 1C*I&K#^&500?C.<_X]^' U"G5+GU824JAUA!3*?6@(5=>
MJU64 (*\C6CXSB$%4G5CBKP!8_WVSK */%'C;;;;[?NVVSF&3336)9)[$LD\
MTK%Y)9G:221CY9W<EF)^Y)/ MF9V+,2S,269B223Y))[DG@8D_@;R,@]-&>Q
MU''%P?I0\ULQ+Z?K:+U*=,8\J\],:SYK\]HEJ&F2ZR3.KVTCK^D<6DF2(-(C
M-=2-2LG,.L2Z6NBO=9M+545:O1KA0(Y1,@Z@A$WME ?)DR3V.5[<.#<LFN*I
ME8UQC$6%VC#;Q\9_4<^?/!@_H+PVX#[G?@;R-RCT%</5'/N.+JYWV_&V]A;N
MAPV>]'&.3+ZRPWML\B1I:#JP+EPQQ@F30!(+&+M_Q@Z"Q?\ '^C-GF'6+FG0
M:39NM+IU80K#6,5=505UV0CJ)$LK;%./=(V?+9/?AS);LRPI7DE9H8]I2,A<
M+M!5<8&>P)'<_/!@_H-PVXICI'H#D_+J'8NAV"X)3DM;_P Q'G#0.$K1TT<<
M_A:SW2LHEV&<&6EHK&B)W_>HH9M3T^5#3#.(3"\O,+VMI]NU8BK1PN))3!@R
M(Z(J62@@ED;:=D4O4CV2$;7#KM+;ESVL;L<!3\')!P ?!)QV!^#\_'$&H_M'
MRQT$HQ<A[SR?1P+?.A<X@1L>BTD-VVLO+R"=+?&E59L$AK,,  ?#[!(T6V?\
M=)#<SQP!%12;.)]$U6N%:2A;*&O6LF1*T[1I%;"F$N_3"JS,W3P3_G0R DCC
MIH95 )C?!5&R%;&'&Y<G&.X.1QW%GK;RJZ3P6!/Z7X V0DO457'=+>Q<\.53
M66T3N1:U7XSQK%*+NZL)%=L$*-9K+DUM(B<:@0D96&_@3;1]61S&^EZBD@CD
MF*-2LJXBB"-+(5,8(CC$L9D?&U!(FXC>N=&*4'!CD!P3@HP.!C)QCP,C)\#(
MSYXE(G?>%'V2YTX'M')S+=SG(^O0:N+T2HSV&C;%G#*Q<6]-$WV8UO)#,P-;
M#AP.'F0\L8+7]R9XHMTFT^^L4$[4;:PV<^GE-:81SX4N>BY3;+A%9CL+>U2W
M@$\:Z;X!V/AOTG:<-VSV.,'MW[?'?CSWCT3Y_P"8SS"]([GQ[GY0[0A(0-=>
METRK$P.1%U6;EJ9H'CH&6)D(HO-*:E [Z:DC++?6&$T6@C]5,7NOINHV@#5H
M7;(*"0&"K/,#&6E0.#'&P*%X)T#>"\,J@EHW Q8Y'_2CM\^U6/8D@'L#\JP_
MD'['B/=$]4\"YC;:WSNR=0I>_2[79><UM+S%9;*N7T<G;J-Q24BL/<4J1T/8
M-JQAJ^#+8NH098!E$1A\6I.H^8]E*VDZA:ADLQ59O2Q1697M-%**P])#)/+'
MUPACZNR-@J%@2Y5203QM8I&!8*VU0Q+$';[021NQC.!XSYX^-]4<%3=D:\$M
M/2ZA2^GA?X9HHK5SM%:K)]V)O<!\Z0&A -7([2UG:; 9&/%6K]Y1S#%XNF)I
M3(L9Q=)U"2DNH0U9YZAZV^6"*658! 5#M89$*0J=V5+L 55CV"GC.C(4$@1F
M4@G*@D*%."6(&%[^,\263T)P2*PWJHR]NY'%:N7IY[#TJMR]'IT;[GJ$72&0
MMW=U.[G4^JJ1(R1I"F+V $0;0D;>>:/6>'.Z0T[4#'!,*-PPVG$=6459S'9D
M/81P/LVS.2" L99B0<#L>-=.0A2$<ASA#M.&/P%[=R?@#.>^/''&F]3>9!J%
MCJA'HGAD',<V*2H8Z+-UBAQ4;-KBTVDDK.+7N^U19?QQ:;S;I\'Y8:P:[3Y'
MQ#C._P"E/PG5#8](--OFUTNMZ;T=CU'1_P"UZ/3ZG3SVW[=N>V<\9TI-VWIO
MN(W;=K;L??&,X_?@'O;WF'XK;JPY[T'V#QWC7W=CMA%67]K)9#\Q@)9#\[N7
M21F=XZM5[11RR%1U=HK,-*R:N6V"VQB56)']C'66,]H6J\VP+9K:-=O?T4(E
M:@%:T0ALP52D%.6*<!UEG0R(B)M19'/Z2"[K6K\(9:TTRA!DQJ2P[L%[1D,,
M@D? QW/GCR\2\/\ P_\ F/HG-9.7<_\ ,R'J]_# M'&LV[HPG1;U:@R\?RE-
MGY1#TZYVQN=H1K%F94_I,6<RZ:2;!&;:_DSG+^O<Y:K6M"W9U22I79H;HAK-
M6KPL.SQ7/2P0HN,X>.<]C@,OCC<UW4;",)9IVC4E7 !5!XRKA H[=NS?_?!I
M6WUYYMJ,E[62=EYO8KAS:,G:X<WJ-[IS_I2>4+?&IP9=)%?:O!C0=/R3&C&#
M#2"P0$23XCQ#O^P2'1]3F%=_16HH;)'1M35YXZKAL[6$YCZ95L8!4G)P!G/#
M40RG!V,%(R&96"D8)_5C'<#M]^/94?5/ [8PJ%;VZGSZL]!O.Q6E:Y79NA<^
M'Z6SW%(/AQH%5%5K;EL=RH%Q# 757(?G<#[9=\12Z3PPZFTG485FE])9EK0
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M2C9U6VXF,<$2,9K&J%DVHJPK!&")&)<<F;VA%!"CIXRW?V-(^20 ,EI#C [
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$"/'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g180330g20u43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g20u43.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5'#:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C M8S P," W.2XR
M,3=B8V$V+" R,#(Q+S V+S$T+3$X.C(X.C$Q(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SII
M;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P
M<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C
M.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG.31D-#8\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@
M(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^
M1FEL92!.86UE.B @(" @(" @(" @(" @(&<V,6@R,"YA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!R<C(S-38T,B8C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,#(M36%R8V@M,C R," Q,3HP,SHT-R8C>$$[15-4(%1I;64Z
M(" @(" @(" @(" @(" P,BU-87)C:"TR,#(P(#$R.C S.C0W)B-X03M38W)I
M<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I
M;VXZ(" @(#(R+C N,28C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@
M0VAA<G0F(WA!.R8C>$$[XH"B(#0S(&)L86-K('1E>'0@8VAA<F%C=&5R<R!C
M:&%N9V5D('1O(&]V97)P<FEN="XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F
M;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @3F5W<T=O=&AI8T)4+5)O;6%N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @
M(" @("!";&%C:R8C>$$[(" @(" @(" @(%!!3E1/3D4@,S P-2!#)B-X03LF
M(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<V,6@R,"YA
M:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(S-38T,B8C>$$[3&]C
M86P@5&EM93H@(" @(" @(" @(" @,#(M36%R8V@M,C R," Q,3HP-#HS-B8C
M>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P,BU-87)C:"TR,#(P(#$R.C T
M.C,V)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S
M=')A=&]R(%9E<G-I;VXZ(" @(#(R+C N,28C>$$[1W)A<&AI8R!T>7!E.B @
M(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C
M:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS
M(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[(" @(" @(" @($YE=W-';W1H:6-"5"U2;VUA;B8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z
M)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!004Y43TY%(#,P
M,#4@0R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @
M("!3=&%M<%\V+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,CDV
M-#$Y)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q,2U$96,M,C R," Q
M,CHS-3HT,28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q,2U$96,M,C R
M," P,SHP-3HT,28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X
M03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@
M='EP93H@(" @(" @(" @0F%R($-H87)T)B-X03LF(WA!.RHJ*E1H92!P<F5F
M;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L
M(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X
M03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U
M;65N=#HF(WA!.R @(" @(" @("!.97=S1V]T:&EC0E0M4F]M86XF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @4$%.
M5$].12 S,# U($,F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @
M(" @(" @(" @9S,S83$Q+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @
M($1E;&PF(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(Q+4%U9RTR,#(Q
M(#$S.C,U.C4T)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(Q+4%U9RTR
M,#(Q(# T.C U.C4T)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F
M(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI
M8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R
M969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU
M86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[(" @(" @(" @($YE=W-';W1H:6-"5"U2;VUA;B8C>$$[
M(" @(" @(" @($UY<FEA9%!R;RU296=U;&%R)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!
M.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @(%!!3E1/3D4@,S P-2!#
M)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<Y
M-&0T-BYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!$96QL)B-X03M,
M;V-A;"!4:6UE.B @(" @(" @(" @(" R,2U!=6<M,C R,2 Q-#HP.3HQ,"8C
M>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R,2U!=6<M,C R,2 P-#HS.3HQ
M,"8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R
M871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @
M(" @(" @0F%R($-H87)T)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE
M8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A
M<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!
M.R @(" @(" @("!.97=S1V]T:&EC0E0M4F]M86XF(WA!.R @(" @(" @("!-
M>7)I8610<F\M4F5G=6QA<B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R
M<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @
M0FQA8VLF(WA!.R @(" @(" @("!004Y43TY%(#,P,#4@0R8C>$$[)B-X03LM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G.31D-#8N86DF(WA!
M.U5S97)N86UE.B @(" @(" @(" @(" @1&5L=&$F(WA!.TQO8V%L(%1I;64Z
M(" @(" @(" @(" @(# T+5-E<"TR,#(Q(# Q.C,Q.C0Q)B-X03M%4U0@5&EM
M93H@(" @(" @(" @(" @(# S+5-E<"TR,#(Q(#$V.C Q.C0Q)B-X03M38W)I
M<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I
M;VXZ(" @(#(S+C N,R8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@
M0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP
M;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T
M960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N
M=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @
M($YE=W-';W1H:6-"5"U2;VUA;B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O
M;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @0FQA8VLF(WA!.R @(" @(" @("!004Y43TY%(#,P,#4@0R8C>$$[)B-X
M03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!D<W Q-#$N86DF
M(WA!.U5S97)N86UE.B @(" @(" @(" @(" @4V%N:F]Y)B-X03M,;V-A;"!4
M:6UE.B @(" @(" @(" @(" P-BU397 M,C R,2 Q-SHT.3HT-R8C>$$[15-4
M(%1I;64Z(" @(" @(" @(" @(" P-BU397 M,C R,2 R,#HT.3HT-R8C>$$[
M4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!6
M97)S:6]N.B @(" R-2XT+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @
M07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O
M;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L
M971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($)L86-K)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B
M965N(&9L86=G960@9F]R($-3.B8C>$$[)B-X03M);FL@9&5N<VET>2!T;V\@
M:&EG:"!O;B!#35E+(&]B:F5C=',F(WA!.T5M8F5D9&5D(&EM86=E(&ES(&QO
M=R!R97,F(WA!.TEM86=E('-U<'!L:65D('=I=&@@:6YA9&5Q=6%T92!B;&5E
M9"8C>$$[1&]C=6UE;G0@8V]L;W)S(&%R92!I;F-O;G-I<W1E;G0@=VET:"!C
M;VQO<G,@;&ES=&5D(&]N(%=O<FL@3W)D97(F(WA!.T9O;G1S(&YO="!E;6)E
M9&1E9"!O<B!P<F]V:61E9"8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@
M(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q+3 Y+3 V5#$W.C4P.C$R
M+3 W.C P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF
M>41A=&4^,C R,2TP.2TP-E0Q-SHU,#HQ,BTP-SHP,#PO>&UP.DUO9&EF>41A
M=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 Y+3 V5#$W.C4P
M.C$R+3 W.C P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A
M=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B R-2XT("A7:6YD;W=S*3PO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=)
M;6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIH96EG:'0^.3(\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M
M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%1
M4VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311
M:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$
M:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W
M9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"
M451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O
M9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!6$%%04%W15(F(WA!
M.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'
M05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&
M0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A1
M5D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1
M>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q
M4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S
M8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L
M<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)
M1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!
M.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%
M9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K
M=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV
M9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!-%@K;#E7
M+S5B6B\K4G(O,7A:52LF(WA!.R]V2VQP85AN:W914F51>#-)3VTR=%)-;V-(
M;$%L9G1!.6-73'=V.$%0-WEF<2]K5#9R-7<X;&%N96%46E140T,O<V)E9599
M;S5856PF(WA!.TI%5&Q122]%<7DY06%5-C1P0V$O:THO>FM"<5!M6%4T+TLS
M;7!K9E9*5EDV9'%32TDO5TM+5V%+5E9O=E!I0U9:44%E;$LY5E-(=C(F(WA!
M.TM(67%K+VUM-6Q45&AA44@O4V(Y,71O=FLO,FHX=4])5DY,84),93-I9VHK
M>$5I;W1E=$9&3CA65DU69DHO.$%Z;%(U9C%(4G9/1G(F(WA!.W(Y;E!.1EDV
M,T935E5D;%9B;3-!5G1G841L1U50>G)I:TIN+T%--&UE97 O,'9Q;FQ7+W5(
M:T8T9W9B07E-5R]E>$1J36=R6#=38U<F(WA!.R]W0FEC5DPP4"]N2FIY>F0V
M<"M8:C9R679);#EO56=U=C-41E,Q=3E%;D)O4G-"4B]W1%DT;V9/2#5/9FU"
M9F57=GI$,&TK=DQU4CDF(WA!.U!M:RMQ6'EY3WI+26)J-$,U-4@Y:'%0.4=+
M4T@S2F57:T8U850R;'=V3T,T:F%+6E!&2%5Q=RLT-&]F1C)I+VPW-6IK+T]H
M9DEL>F0F(WA!.S-,43)T-%1D4T=2+VES62\S,W%D4B]E43!P-W1I;#EQ<7%Q
M;U9106]&04)S04)I:'9&5DLV=4DW83)L=4I44T]&4S=(,E56>%9+9DLF(WA!
M.U5%,S90:W9P-BMV<4UJ6$1$=U9J.$DK-V9%<6YE2W9(+W=$;DME965$.'-%
M:V=K84HO,&IB:FUJ1E11<$HS1TMH.#1F;$9Q97!39FTF(WA!.V8U66IK=35N
M4G129T1),&I%16-X,4)/2U,K,CEA.')E6'1B=%IB6%4W0TLT:FQ"1$U6-'E!
M;CEP6D8T=6IE-FM(1D0U33@W-C4K63,F(WA!.S52*V8W:E-D2SAW6&LR;6=*
M9%=%5C-),7A%.71+5%%02$IY4V]:5U%S;T).2S=9<&922#5.+VUT869M2#5E
M:W5M:5<Q,65X6EET4W0F(WA!.T9.5D)C17!);&0K16Y%,'(P24DY.%5-+WA6
M,DMU>%8R2W5X5C)+=7A6*V$R3$HK:"]K;B]!2E%Z45 X071N5VXO2FA-5TQ#
M+RMC;$<F(WA!.V=(-4]A,DI#3UIE>D5.9C4O<F-23E X05EC<U9$-5$O2UE8
M4B]--WER.5=R-FXV571#,4M6.4U43#9V6"]I=FQI>4PW.7A9=7A626\F(WA!
M.V8Y>5!M:5=B<F(V56YP4BM";FPK,E(X;#)W<6YU0EA9<3@K+U!F>5HO:78X
M=#E3=&]9*V5O5T$K=C)(:C9K04I:4C=V1U=5935X5C@F(WA!.UEE5&9-=#$U
M63@P-EAR.715>39F8TI-54@W8V1A4U(O2C!,2V9N:7EF;T=J85IR=6EH:'AU
M=$PQ4S)"2#AS<T9X2"MP:V)&:2]0-WHF(WA!.W(U6G502R]M>E9D06Y*3&%F
M8U!%:FYQ.&8R;VXO=T)N1U9B-F-75#=3+TI$>FXO:7HX=4Y,=G!:4%5V-U)F
M<4]O1V]*.6$S05AK,4\F(WA!.S=P>&8V8U=,230O2U=I>"MB6G9.87<P,65E
M>E-W95AT-DM31U0O9VEA06YW07A63V-69&EQ42MA;F4T5S P94EK4V%H2T))
M4C%%2V8F(WA!.T4U=VA5.&IJ4T].63!(1D5!5E9(64%507=+=7A6-#,O04TU
M5R]W1&MR52\W84YV+T%-46MX55!M=CAN=B]*<&56=CA!=&\R+R]%>&DF(WA!
M.WE,-S1X679L5"]N34%W9C1S,$5,5#9W3$)Z2C0X1$TS1#AE5TM1=2\U=RM&
M>"]I;EAY=&9Q-'-9>$HT8WI-3T9F96Y,1E,K<6-53W@F(WA!.U8R2W5X5C)+
M=7A6,DMV>E=X6E P13AT879P;6TK4U!,.&PO9%(R>71P='%51'-!>F-917)X
M6#=457%/9WA9=D5F>G<X=V5B=GI):W0F(WA!.W9,2&MZ4613=3E'='!V5W5T
M464R;&=H;FU!2V]&955);VI3<#-E;%0W0W5+47E(.&EF.$%N2"LU.&\S>2M:
M9DUR4G9R65)K<W)+36@F(WA!.S!T=5DT<S=31%IP0W!++T1S0EAC,3)62F4U
M66]1,G S>5=/;GHS8CE)54Q!94HV2U!P3S)+;U1Y,UEV86%62#8R.7IC13-&
M=U0Q3'DF(WA!.V)M=GE&0FEQ85EQ-T9867$K1&9Z;3AM9C12+TU45F1-:FHY
M3WAL9C8S<#1(,F9Q.7A6;%9F6D<U4B\W2$9K2#!B+WII,S5Z+T%%,34F(WA!
M.T)B4EHS-5AV;"M4,$%$,4YT3%8T5#E"-7 X;$=+0W=B+VY,;GE96611,'9Z
M9F)2+W4W<&9Q1V]-2R\S<4%V0W@O=T):3U,O-T59<44F(WA!.W$O-7A0.#4O
M;S-Z8F5E5V)I4VQT<E58<5=W2C)&,6)G=%%F-CA83"]!2459<5@Q;FEH,DMU
M>%9)3DHO,TEE64PW57IV1&$O-DAA;G0F(WA!.U9D-4=(,"]R=W%N*T)867$X
M8B\U>70O.&QA;B]!1S!B9B]I16U+:#@Q+VLY+W=#5%,X<F8Y=$<S+W=#2FI&
M:U@R,W(O04HR.'0V2$0F(WA!.TLY-V1'4U=+;TYR8DDY>$]72#=0<'A",D)0
M=E1&:2M84$YN:WHX,E!Z8C@X5#8Q1C5E=4Y-<TI!<T9M*V]G,C!C3G1(6&AY
M3&=->$HF(WA!.UES,T)7,TIP:6PY1F9L3BM6*VUF;#DU9$]N=U-F5V12=6U7
M6%4W,FY(,4I!2TMQ:G-I5E!%9DTY.%5-,GA6,DMU>%8R2W5X5C)+=7@F(WA!
M.U8K83),2BMH+VMN+T%*47I14#A!=&Y7;B]*:$U72V19<3=&6%EQ:U=V9C9D
M<59H;S0S4FTK=%A9+W=#2V\O<V<K>DYT:%908T-U>%8F(WA!.S)+=7A6-$PO
M04TU6BM3>F8K5V)(>E9B2E<T,&54,$QW9T=P=')G9TMX+S%*868X04)(1DE9
M,R]Z:"]O1C@R<&$W-6=,<VQG:U-70W F(WA!.RMX3$LW0U9J,#9X2W$O.$%"
M-'%8=68U<&54,3@S95$Y6#!-2T1C>E%M4WE*-UA-4#=Y3&9T>5IE2CEI8U50
M:B]!4$DO>35Q3W-F;7 F(WA!.V]D=&)M4S-A>'5"93-C:2]#,&-D<65B03$O
M;4E%9CA!<W-74F9D94Q&,DMP9G(K;T=W,&TT=48O=F500T5$<5I(*T9A9E-A
M-'%U,% F(WA!.U1X<"ML5SEQ9G1O=%I4-'4R-V9I8U92,DMU>%8T,R]Z;&(O
M-4LQ4"LR:F(O05!%2DU61#5R+THW+W=!;6PU5R\W84YV+W=!5$=,278F(WA!
M.W9J1FDW1EA9<3=&6%EQ-T9867$W1EA9<3=&6'AP+S!+>BMA+RLK8DPO<$I8
M*VU+8F984&QQ>'5.4#AU85996$E!=4Q3>G0T2F=P<4\F(WA!.V-54V\Q1#,S
M1TM%>7A6,DMU>%9+.4PP*S545711=C=S05-Z=4DW8T$Q<$%G*T@U8W4T>%9.
M359D:7)S5F1I<5@K661$<SEE,$LO,&$F(WA!.SE&8EA524I,95AX06M5:FM0
M9&5O>%9)9GEQ.&IJ>58U2# O46U:6'4T=S Q.4MN4C4U5'EE;G-U>6HR1TMS
M=7A69U!K8CAR3$AY=C4F(WA!.S,X,2M9-'5.3F-M53)583=E;$5W17,T.75C
M-4\S9V]X5FXR2W5X5DMT53 K-79D5# X36\K;U=Z1V589F-Y2U S67 W67%M
M=4MU>%8F(WA!.S)+=D\O=T$Y+TDK=F5C+TDV-E!O:7AV96DX:&Y);6-2<G=2
M6$(K23$O;4=+=D=F>3DO-7@P+TUN47901V@V>&9W,F=S<D,X:6YU0VPF(WA!
M.W='64EJ5DY&<'9I;3,Q5FEH,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7@F(WA!.U8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M;T<Q,5)B;E5R=7I333A,34E(;7)S6&,F(WA!.U8T9U4W67%I<FE:24QE5V1W
M4VM333=!9&%+2VUM2W!8+VE735%I-&MS3'E/,DMH>D]9,4MH4TLX:GAD:E0V
M35923C5R349S='-Y4E,F(WA!.S-8,7EV;TQ!1EES079/=GA-=C=/2W5T9%9K
M;FY7239F9%%"<2]V6E9124M#=35$<V9W>%92+WA#:E14>%$R3C-0.5AK84=2
M-#!1<GHF(WA!.UAR4W)J>'A615=M<C(Q,6)45$MK:V)7,5)00DEV1U)3;S55
M2S$W:G!V:7%%9SAY0S1H4V%(5&(R4TIX5DA#4C!)+S5'67%I,S%72TTF(WA!
M.U=F<7A3>'1E4#9A4G-&-4MX0E!X-S=D3S%C5E)U2W%&;F5X6&%Y=$='06AL
M949U5D(X56)C4U)1;F)&5F9&541B87I:6$]O,T9H1U<F(WA!.SEE,RLP4TM+
M,4MC=4IR=GA*04]+;S=&54Y&<45-;"].63!:6C155U$X9TM-<CDQ,S=(631Q
M=%168E(Y5&LP,5-F<DU566QC8E5O5# F(WA!.S8Y9'@Y*TMR:'%%2C%%,D-Q
M>&U7251/=T$T2W!B:4%45W14.'-6445(;5)B:4E3=V%D95-X16M,27%2,%!%
M;%14.34T:D955DIQ,%4F(WA!.U9V8E1445-X1S9M5T));D-H,5HR2V=S03%+
M8E8R3TMU=71:<W)854QE>&Y*4U<U0DU4;6Y#;TY/2DYE<#=B67%R,V0W1F$K
M:C9G62LF(WA!.W9+<TMC86)-.6%%,4DR,GA61%AM<W!B6&XQ3F)7-'5:=E1%
M>#E"55E"5UEQ2SAM6'5U2W)R2%=)8G4T93)-33%T8TEO9C!P,4-K;U0F(WA!
M.U1K=$-W27(W-'%O='(V*W901D99,U9X.5AC>%-34DEH6&M!1%%68TAO8U96
M5S%H23E/;78U-V%E0T]#=DM+4E9%:$%P=6]$154S.&,F(WA!.U91.'9M25%O
M6DHY3W99;U8S959O,$MQ4$4X6%DP2'EX5D=8=7%75FY::3AM9CEY,5!4-&EP
M8W1U;U5D>6-646-8;4)Z3$=S*VY89'8F(WA!.TA+=U9*6&IQ05<V8V=P2EA&
M53-X5C)+=7A6478W=4]Z<S5R<50W14M&>5!'9S)(,#E-5E%(;&DP:V<P<%IP
M=CDV8GAJ8WIN=GEK,T@F(WA!.R]#,'A61V%R+W=!8W4X+S1W4V8X44]+<%!"
M2C5G=4Y':'1O8DM'3EI916I7-&5B:T%P441L=T-E2&%U1E<W,GEU3%=447)/
M,&Q66F\F(WA!.U1):5-Y2U=8-%E$56Q14C%(=FEQ85=55W)P2U1E6$5-<UA'
M9U=/36]E5E)V57,S8D%Q4C).>')K36UR=EE7,%9X170W37I",EE/5T,F(WA!
M.W)52T%+2&%M1D-V;S9V4'!U;V%T3$UK:S$O2#AA4F=H62]347%%,S-Q2S<T
M<%=E6&].96)28E%W6%5#46U0-$5E1FU90W V:T]-54DF(WA!.WI7=W=U=$=$
M:T9V<E$U16)!;C R<F=3;D]+<%@U9CA!-W$Y+S5J<FXO:S1C5E)'<C9G3$14
M<')M;DHQ1DEK-CAP1S)19F5C5EEX2D\F(WA!.S%J6E=.>$A:6&$S5FEX:W5:
M<$EU2W5S=CDO5G$Y-C%&8TM'67A32DQ':W-:-5)U;UI'2%%G:6]/0DM4-C!6
M<W13<TY62D-X:&IA,U0F(WA!.V8X5GDW<5-F0EA'2W!B1VI1=S)N;4IW5F5A
M-6%3-'(R=#=I:V$Q.6Q526-+13 X=7(V-'4Y56)R9E1%>$@O:6U,-$DO,44T
M16]$>34F(WA!.T1R:F%00S%T9%%2=T9P94-017I-4#-R5G%1-#<K,D9#33$P
M5$,S,&]434AL1B]B8S)58U%4>3-)1E141DLS53E0='11,3%B5S17<5 F(WA!
M.UEY54DV<7=M4VI+9D59<6=:8C8U5U=X,')51%<K=#=Y0FML-U11,4E%9SDK
M>EEO4C$S2'%$*UIN1FQ.2$,T<V\K6FM1=4-05F9P4FPF(WA!.WA3<#(U=C=8
M>DI#3E)D2C5B>48T<E=32W%"1FHO94]'43$K,5%B,7A6,6A&<3<S5W!M>G5)
M66]V<FIG<DI'6%!,,# S<4=8=&EQ='(F(WA!.W%8:2M78C!88VE3>F-$5C0Q
M2TQ3;W!S4S)"54IQ=#DU:$-*85A55G1A=UAP341864QY2VY-53-',4,S8G1H
M47)8.71&6EAV;"M*>50F(WA!.V%7-65(;3-4,5!40WA%*SE185EP4D=V6"MR
M-F9B>EAK0S(W5W-+<5-S;E Q0U-13S%",WA63TU#=7A6,DMP1C5J4#%Y-7-D
M1UAP9%,F(WA!.V5R8S W47AF15%F.5DY34MP-S!W2W-M:5-A1C1:0E9*1DM/
M3VUZ0VAX5C!-4U%W<$1'2TI';U)",3)554=+;V4O=T),=&(W,'98-6<F(WA!
M.W=K=$<P8G-J06M53S9K2'!I<6YA-DIA5S V>GAV3UA3=$$X,&IR=4-.,5EK
M2')I<4IT8D\S=&I-659++U=*5VUL<5-A=7=!2C,K5TLF(WA!.W%55VPR8TPS
M5%))548T87IQ0V5*2D9#44]G2C<P>%9#4BM6.4UJ44I',7=I3'-Q<E!+05!K
M03).<6E,:E)B2S1T;TQE6#%#;'5E550F(WA!.V5O-&-':$9E9&589D97<E12
M8E,Q;D4P8GIS-C%!1'I33W4T<#EL:5)I<6LO;'I4;6QK:T14;UI885)W:S!I
M<GEC,5DP1$%D8U922#8F(WA!.TES>D9B4D](:U,Q:SE72&TW36592DE,16UR
M57)T6$955DQ':W-B>'E+1VIC1EA5.4-#2T59<7 R5FY$6C)S9'1!0TEO:%)!
M>$Q%0W0F(WA!.V5P>%8Q-UI7.3=A>5=T=W9/1U5!3W1A9$158FHS1TMT5%=.
M=$Y:3EI32E<S6E!42V8U3DM$1E8Y=D)&8G=2=U),>&EI54EI*T%554<F(WA!
M.TMP86YL:E1%6&I',#9*56M+<SAQ9U9.5%%"=DA',5)8-DMT1&)W44YZ9$QA
M5EIO:3=S>F,Q67-#5TIQ9'HS>%973G!!8G-89% S-G@F(WA!.VU)3E4P-$UW
M66EN>EA&5G0Q<#EP9%-W4WIX:'!,6B]5:&9O5EEF3'0W67%O6'5I,E8U8VDU
M;$UI>D)"2'EJ:V50-%%3=T(T:V0R>%8F(WA!.W5Y,%14<E-C,T5333%W4G@Y
M858S:UE,-$%U5%1&5DM8>3EP.&LX<S%::V5:=6-G:FUK449I2U9O<$$W67%Q
M3&]T:TQ/83!9>5-1,T<F(WA!.S!G:VMD>CE"66MJ1E569%=S1C%B>5<Y=V=K
M:&Q(1C%08UEQ<VPP*S!M<VA:>G V,79X0SA:0U=.0C!03')8,WA60DPU83 V
M<65S,#DF(WA!.WA(1V%P1%!-.&M9239F05148D95,7A6,DMU>%9)=$,O,#=6
M3E$Q8S=X;'9Q;&]F*TLT+W1%97I.=FA64&-#<58S4#A!5C=7869J>3DF(WA!
M.T9':S0Q<%AI0V%6>%9+4G)E<G)A0SAK,'-F5G5!;%EX>G$W:$-/5F5*5F$W
M9'$T5E1*=%)T0G S-E$U+S9.-F9R0G8X;6QF=G=+;S8F(WA!.TYQ;S%+,$UX
M:4U%>4U5;6=9,4MS3GAV4611465M2W%.>'$Y+RMK<')','-L=41!:4\W=$XV
M9C(V,#(T3C19<79S.5=U6F)M5WIU<E0F(WA!.S9T94Q(-G-59G%",&M7=%!H
M8T%D*W4R2V]78E<Y6FEU-V4Q9E,P.6$U1&U)0S5&4#-90F%P.5 S=W%Q-FQR
M;'AP=&A"8S-6;BLX;&TF(WA!.T54=U)Y8WEO25DX9V5)-6),,'=+:3=N5319
M.4IK,4M':SA3>$=6041134%+.6%';C-9<6]8*W-45SA&:SA.<THU8C%L4DEZ
M2G=!3$LF(WA!.U<K,7AB=SA-5E@R.3-R5'I)<S)N4GA212](24QG3U%02&IW
M1F-6541R1W!36'0Q8E=L9W-Y,G)H1VMA8U(Q3$M'-F-'.&9(1E9A>#$F(WA!
M.V-Z3F-1,V-"=$QM,4%E5TES2$)19VM/<D-L4G0T67%G;V1D,6UE15AL=G!2
M:W-M,VHO97%*5U0K64I4.$LT5E0Q1TQ)<D93<$E"2VTF(WA!.VQ26'-A649B
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W!:-6IV;G,Y2FUA
M3&4T;7!"8F=D5$I*.$EP.'5U2V]N4W(F(WA!.T9,1%1R93!8<$-G56MD,C9S
M9G!9;D955FEQ1C%8+VIL,VXO1T-4+VE">%9+8E<R.'<S5VMW5R]R5S!&=DQ!
M:2MQ:74P;U%O0G-#470F(WA!.V%95E5T6%(Q3FIO5FQ!,3%&07%46%516E9*
M:&E)0TMX67%V>$U..%9B9W5R>3(X=VEE-7,R<S=B56=S3&-N:F-'9$%E0G%H
M3DMR.$\F(WA!.TMT5%)A<DHU;79V,&902$%W:&@Y47ER>G%0:7!41E8O;#5:
M-3E3=6)J57!I*W$R=TU"9V]%4DEY95%:05!T0G9(1E56<5@O2U(V3B\F(WA!
M.W$S6"]!0D)C5F0U:2LQ<% O8E%H+W=#279I<58V-TA*;SEN97=O0V1,=FMF
M,'=0.3!4<U!S+S9J+V=C54EN5C!L:V<P2DEP1$1),# F(WA!.UE754%-5E!P
M2&5J5D=+53%T3$A5;W!W."MP4&-2:719;6EI54=O.%952$%Q4W=W-C(K<C9U
M9$YN:6E54W!Y5U9/5E<Y355O93)&0W8F(WA!.S5D-%-R95@Q.4U:3"MN;S-S
M8F=+26Q3=G="4BMZ,W(S>%-O*VM,2%1:3#-2=%9(,4].5$EL=$YX:VHX94%*
M;S9F3')I<DE,1S1A-7,F(WA!.V)E-%IE1%122DE5.$,V9S O2$%Q=FER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U915V\O;WHQ8E0V-U0Q4%=(
M,5-V3"LF(WA!.SDW57 O2$958FER<U95-VHP9G$X=G(P.4AG,W$Q-F-A9D98
M-DU69&(K:CE8:3E#;F\X1CE+;E1J5#1A9E)I<6Q".5$K=EA8;SAF<FPF(WA!
M.TDO<E90=%5P.$9F;WA6<E5F,&8V2R]8=4AP96]N1&XO04PX<CA.4&5U2W1X
M9E5F<C@O<#AF<G9"4%AP.7)J=G=R*T]+<D<O4FXV5E,F(WA!.W9(.4IE:V%5
M<GHY2W9E;F%V:FEQ*V8V:CED='97-"]7-E-F5F$O87!197!4-DM6>%8Q-SE2
M<F(O049V:E@Q;"MR8W8Y+U501VYV4W4F(WA!.TMR<B]!3W!F535F<G9$-G!X
M+V4K<#EM;G9I<40Q6#E!9E5O4#!J-F8Q4V\Y1&Y8:EAJ=%-N*U1I<4)S4#A&
M9EA)=G%8;V97=5@W;FHF(WA!.WDU8W9B0W%C5W8Q2#9X9&96*U!R.'@Y830Y
M95A(8FPO<V-#<DEV,%HK:S5V4S1F<$1G=C%J:EAL>#(T.'4S>7A62THO.$1F
M6"]W0C<F(WA!.SE6*W,X="\U3UAV5#10=G=Q>4U5;TMD3S)"6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6"\O6CPO>&UP1TEM9SII;6%G93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*
M(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#HW,F8T-&)E,2TY-S!D+6(T-&4M.#$T,RTS930V
M8C9D864Y8C@\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$
M;V-U;65N=$E$/GAM<"YD:60Z-S)F-#1B93$M.3<P9"UB-#1E+3@Q-#,M,V4T
M-F(V9&%E.6(X/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X
M-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I
M=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#YX;7 N:6ED.F$Y96,Y,S%A+39D.#8M-F0T,BTY8V8X+3 W,SEC.&8R
M83%F.3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O
M8W5M96YT240^>&UP+F1I9#IA.65C.3,Q82TV9#@V+39D-#(M.6-F."TP-S,Y
M8SAF,F$Q9CD\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T
M03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z
M<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^
M"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#ID.68X.3 Y-"TQ,&(S+6%E-&,M.3!F92UB,#,Y-F5F
M8S8V,CD\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C M,#,M,#)4,3 Z-3@Z-#4M,#4Z,# \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E($EL;'5S=')A=&]R($-#(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HW,F8T-&)E,2TY-S!D+6(T-&4M.#$T,RTS930V8C9D864Y8C@\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C$M,#DM,#94,3<Z-3 Z,3(M,#<Z,# \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL
M;'5S=')A=&]R(#(U+C0@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T
M;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A
M=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E
M871O<E-U8E1O;VP^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @
M(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP
M5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z
M3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X
M4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W1$:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \
M<W1$:6TZ:#XQ,# X+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y"
M;&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H
M1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO
M>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P
M5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^4$%.5$].12 S,# U($,\+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y34$]4/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1I
M;G0^,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/DQ!0CPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SI,/C0S+CDR,38P,#PO>&UP1SI,/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SI!/BTR,3PO>&UP1SI!
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SI"/BTU.#PO>&UP
M1SI"/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \
M+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'
M<F]U<',^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A
M<GD@,34N,# \+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #@ H0,!$0 "
M$0$#$0'_Q  ?   ! P0# 0              !08'" D*"P(#! '_Q  V$  !
M!0 ! P,# @0""P     $ 0(#!08'  @1"1(3"A05%B$7(C)R0K$8)4%2559A
ME)74UO_$ !@! 0$! 0$                ! @,$_\0 ,!$  0," P<$ 00#
M 0       0 1(3%! E&! Q)A<9&AL2+!T? R0G+A\2-28K+_V@ , P$  A$#
M$0 _ *2?I?\ 5ZBX]5C'A6VDO[0-W"O,TCA+&XL31G/91@JQZP$DRQ*]BJJM
M<K/+?*^%3SU& H -%Z=L ,(8 >H6X%9*'U'?"5IQAVHS=_O;;N-OV]=P_ N[
MP$>CWG#VMON/+#?X+=ZFNP<E-M(LL?5CZ@NJT^AS-A4V-W$>0+5Q7=&])JVV
MD@BJY[)CB&'$'!!@V-7!J*6S51/T_?J-<G^HIV8V^AYUF#M.:^$N09^+=GK0
M*\2JBW]8[/TVBRVT.K*Z$:LKKXT.S,I[X:L%%KR+"B?<"BA1VR "%-I@W,3"
MA#CW"OJ*J-17.5$:B*JJJHB(B)Y555?V1$3]U5?V1.BYJ)>)W2WP^EY'G<]R
M<@7;S*%KW.5L.'HV.IL@L+5_E;%<"0%:U/"N7Y--(Q7>&-:RF(RKSOTIIS61
M<YGL('SJNCN$X7S7<9P9RWP/L)21<YRWQ]J<%96 +G,L:=-'4%5XM]52LDB?
M!<9\V8:ZJ"&21O'L@!9V/:Z-%2+8+$'(@]%KZ_09[DN3^P+U<])V@]P.AMQ:
M[E;1ZOM5WE=>6YYE75<Q931F1\9W8/W\ON(=:ZZM+Q%&5$B0&5_(WW[4DB6"
M5D8"@ 7HVF$8L Q80S!XR-:9>Q54GU7/;INN&.XO@OO>XROM5G*+F&H'X^VY
MF?N;6N@I^8.+8(C<?>R2BDP1C66HP*#!5K8$5Z?PP.*<K))$5YA5@^;*;$@@
MX2 2)$6O/ ^>F2[PYK,CZS?I"54]M:PU=IW*<"&X_8V5:]\$N!YZROOI[6[%
M@$=&0*W)<NYJ'6T0SVQ.-IH*F98GB'L^2KD7P8_VF]Q_(2'Z%O8]N>QGL/RN
M1YC'L8.>>4-3H>4N6QK>QFMCJ,^RFCH\EDV&D33R,&H\3241)(#7,A$T=OHW
M,C1Y$LDA@*!DVF(8L1(HP AOLNKR/184+<?.?J]WR)R&][WU8QC.,\@GN=\#
MZS'E$NU%I"U%^)ZV6S*LZQ9T]ZR#9H)S7(QWA=& !J=:=O*R)).@Y"O=3._^
MAW]KO\EZRM+64_39ZS56WJ_\)@VFET%D%)D.>UD#L+FQ,%D6/B;8/C5XY),D
M+EC>UKF*YBJUR(YOA41>HPR"]6V & L )%EE$?4=<*6''7:#8=^O;OM=KV_=
MQ/;YM^/)+CD/AW67W'=SNL)O-C3\>$9[8ORA]5'IWUNDT^:MZ@V[8>37AB7%
M1$[\;=G0/JY;)CBW2'&(&#F []E*OT\WJ5<K>HEVG;-O/Q(MYS9V_P"UK<+I
MMP'7AU?\0<S?TB6^/U-Q7UT E8)J5<'?TMZVK"$ -2G N&P1%VA<,13:X!@Q
M,'8AYM)C3JK_ 'T7-'1$=$1T1'1%K,/I<'(SU7L@]R.5&<(<U.5&,?(]4;1
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M/90![Y1Z&J$K_N9//S&D0Q)]Y8DJJN5Q=B8Z<XMZN59"2)7JJJY>A+DG- &
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MKJ>5")1[#-X?21EZ'6YX4N![)H7Y2#+W^=&-AD8X"709EKG+-/ I%859P''
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MT4Q4BI@?> <I_558#25=;35@[!*VI #K*\6-/$8P( \8HD#$_P!R&"*.-O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g180330g33q08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g33q08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1,04&AO=&]S:&]P(#,N,  X0DE-! 0
M    $O2^2%(X0DE-! 0      &$< 5H  QLE1QP"   "_VD< E  "')R,CDS
M-S0Y' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@3WES=&5R("T@4RTT
M(%],5R Y+C S+C(Q7S$R-3<Q.#4Q-BXY7RYD #A"24T$)0      $'^'V2B@
MX\AO0B]@$2\VDB<X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5\            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &               A    HP         !
M      $              *,    A                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     "'0    !    H
M "    '@   \    "%@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( "$
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MVR+D5IL:*'*?]J+,]O[ %^.T.)UQ=(R##K\VGQ^AR(3W)ZN\NTD1SBD@@ G
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M,ZE<##NC2.QP@K35MQKN^>*L&P@X*=)PP:C')3B Y;"0( 5SU+;$5)B&^^<
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M;.:7<;JNM;4OI\.HO#Y=3TFXJ DZR"2=+3+F"203J,& .:O+HUG$,+=&P+)
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J !.B*OHB.B(Z(CHB.B(Z(CHB.B(Z(CHB.B(Z(CHB.B(Z(CHB.B(Z(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g180330g91k37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180330g91k37.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M=#;,HCV@@ ?/SP?TH LZ=X>U:+Q->:SJ>LI=B:V^SPVT=N8T@7=GCYCDGO0
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MO>>$-!@T9]0AN[: L4<0&-^3G!^8CJ30!U% !0 4 % !0 4 % !0 4 % !0
64 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>d180330ds4a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bvs="http://bio.com/20210703"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bvs-20210703.xsd" xlink:type="simple"/>
    <context id="P04_04_2021To07_03_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P03_28_2020To06_27_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2020-03-28</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_04_2021To07_03_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P12_28_2019To06_27_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2019-12-28</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="PAsOn07_03_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn02_10_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="P02_16_2021To07_03_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2021To04_03_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-03</endDate>
        </period>
    </context>
    <context id="P01_12_2021To02_10_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-01-12</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn02_15_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-02-15</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="P06_08_2021To06_08_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P08_02_2021To08_02_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2021-08-02</endDate>
        </period>
    </context>
    <context id="PAsOn08_02_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2021-04-03</instant>
        </period>
    </context>
    <context id="PAsOn03_28_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2020-03-28</instant>
        </period>
    </context>
    <context id="PAsOn06_27_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
        </entity>
        <period>
            <instant>2020-06-27</instant>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:LimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_UnvestedClassACommonSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:UnvestedClassACommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_NonUsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsAndJointPreservationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_RestorativeTherapiesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_BoneGraftSubstitutesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_A2021PlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P04_04_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P03_28_2020To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-28</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_28_2020To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-28</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BVLLCMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:HarborMedtechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:HarborMedtechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bvs:RevolvingCreditFacilitySubAxis">bvs:SwingLineCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:HarborMedtechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bvs:UsaoAndOigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AssetUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bvs:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:BmpResearchAndDevelopmentProgrammeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AcquiredInProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bvs:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NonUsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FederalAndStateMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bvs:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bvs:YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FederalAndStateMemberusgaapIncomeTaxAuthorityAxis_IndefinitelyMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bvs:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bvs:IndefinitelyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:HarborMedtechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bvs:MeasurementInputEquityVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MaximumMembersrtRangeAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bvs:MeasurementInputEquityVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bvs:MeasurementInputEquityVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputDiscountForLackOfMarketabilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputDiscountForLackOfMarketabilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MaximumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelvePreferredUnitsMemberusgaapPreferredUnitsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PreferredUnitsByNameAxis">bvs:TwoThousandAndTwelvePreferredUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PreferredUnitsByNameAxis">bvs:TwoThousandAndFifteenPreferredUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:HarborMedtechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bvs:UsaoAndOigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AssetUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bvs:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AcquiredInProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bvs:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_04_2021To07_03_2021_A2021PlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P12_28_2019To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-28</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P12_28_2019To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-28</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P12_28_2019To06_27_2020_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-28</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P12_28_2019To06_27_2020_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-28</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:HarborMedtechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:BmpResearchAndDevelopmentProgrammeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:PreferredUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ReclassificationOfIprdMemberBVSEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:EventAxis">bvs:ReclassificationOfIprdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountsPayableMemberusgaapBalanceSheetLocationAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bvs:USSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:OAJointPainTreatmentAndJointPreservationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:MinimallyInvasiveFractureTreatmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2015MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2020MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:OtherChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndEighteenPlanMemberusgaapRestructuringPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:OtherPhantomUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodOneMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:DebtInstrumentSchedulePeriodicPaymentAxis">bvs:DebtInstrumentSchedulePeriodicPaymentPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:DebtInstrumentSchedulePeriodicPaymentAxis">bvs:DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:LeverageRatioRangeAxis">bvs:LeverageRatioRangeFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bvs:UsaoAndOigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:BmpResearchAndDevelopmentProgrammeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:PreferredUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bvs:USSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:OAJointPainTreatmentAndJointPreservationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:MinimallyInvasiveFractureTreatmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:OtherChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:OtherPhantomUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:OtherPhantomUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:OtherPhantomUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:PriorCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bvs:BmpResearchAndDevelopmentProgrammeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:PreferredUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bvs:USSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:OAJointPainTreatmentAndJointPreservationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:MinimallyInvasiveFractureTreatmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:ProductDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:ConcentrationRiskBySupplierNameAxis">bvs:SupplierCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwentyPlanMemberusgaapRestructuringPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">bvs:TwoThousandAndTwentyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="PAsOn07_03_2021_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_BVLLCMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ObtainingFDAApprovalOfCertainProductsMemberusgaapContingentConsiderationByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:ObtainingFDAApprovalOfCertainProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMemberusgaapContingentConsiderationByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMemberusgaapContingentConsiderationByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ForObtainingCMSCoverageAndReimbursementForCertainProductsMemberusgaapContingentConsiderationByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bvs:ForObtainingCMSCoverageAndReimbursementForCertainProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_EquityParticipationRightUnitMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_BVLLCMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="P02_16_2021To02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_RestatedLimitedLiabilityCompanyAgreementMemberBVSEventAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:EventAxis">bvs:RestatedLimitedLiabilityCompanyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:InvestorAxis">bvs:ContinuingLlcOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:InvestorAxis">bvs:NewLlcOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:MisonixIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:MisonixIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2021-08-10</endDate>
        </period>
    </context>
    <context id="P08_10_2021To08_10_2021_BioventusIncMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2021-08-10</endDate>
        </period>
    </context>
    <context id="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingApril102022MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PaycheckProtectionProgramCARESActMaturingApril102022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingFebruary52026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PaycheckProtectionProgramCARESActMaturingFebruary52026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="P07_29_2021To07_29_2021_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanFacilityMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-29</startDate>
            <endDate>2021-07-29</endDate>
        </period>
    </context>
    <context id="PAsOn03_29_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="P07_01_2021To07_31_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_PaycheckProtectionProgramLoanMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BionessIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="PAsOn07_29_2021_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanFacilityMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-29</instant>
        </period>
    </context>
    <context id="PAsOn07_29_2021_A2019CreditAgreementMemberusgaapDebtInstrumentAxis_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:A2019CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-29</instant>
        </period>
    </context>
    <context id="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-23</startDate>
            <endDate>2019-08-23</endDate>
        </period>
    </context>
    <context id="P08_23_2019To08_23_2019_HarborMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-23</startDate>
            <endDate>2019-08-23</endDate>
        </period>
    </context>
    <context id="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:HarborMedtechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-23</startDate>
            <endDate>2019-08-23</endDate>
        </period>
    </context>
    <context id="P02_09_2016To02_09_2016_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">bvs:ThreeInjectionOAProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-09</startDate>
            <endDate>2016-02-09</endDate>
        </period>
    </context>
    <context id="P02_09_2016To02_09_2016_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">bvs:ThreeInjectionOAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-09</startDate>
            <endDate>2016-02-09</endDate>
        </period>
    </context>
    <context id="P12_22_2020To12_22_2020_HarborMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:HarborMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="P12_22_2020To12_22_2020_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">bvs:ThreeInjectionOAProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2020-12-22</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:LimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_UnvestedClassACommonSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bvs:UnvestedClassACommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_NonUsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsAndJointPreservationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_RestorativeTherapiesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_BoneGraftSubstitutesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_BVLLCEmployeesTerminatedPriorToIPOMembersrtTitleOfIndividualAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bvs:BVLLCEmployeesTerminatedPriorToIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_BionessIncMemberusgaapLitigationStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bvs:BionessIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_BVLLCEmployeesActiveAtIPOMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bvs:BVLLCEmployeesActiveAtIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bvs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bvs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bvs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:CartiHealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-07-03</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_NonUsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsAndJointPreservationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_RestorativeTherapiesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_BoneGraftSubstitutesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="PAsOn02_15_2021_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-15</instant>
        </period>
    </context>
    <context id="PAsOn08_10_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bvs:BVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="PAsOn08_10_2021_BioventusIncMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_NonUsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:PainTreatmentsAndJointPreservationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_RestorativeTherapiesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:RestorativeTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_BoneGraftSubstitutesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bvs:BoneGraftSubstitutesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:USSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bvs:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bvs:SupplierOfSingleInjectionOAProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="P03_29_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-06-27</endDate>
        </period>
    </context>
    <context id="PAsOn06_24_2021_VaporoxMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:VaporoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-24</instant>
        </period>
    </context>
    <context id="P01_01_2021To04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-04-03</endDate>
        </period>
    </context>
    <context id="P01_12_2021To02_10_2021_ManagementIncentivePlanAwardMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-12</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="P01_12_2021To02_10_2021_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-12</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_31_2021_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="P01_04_2021To01_04_2021_BioVentusLlcMemberdeiLegalEntityAxis_ConvertibleDebtInstrumentsMemberusgaapInvestmentTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bvs:ConvertibleDebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-04</endDate>
        </period>
    </context>
    <context id="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:InvestorAxis">bvs:NewLlcOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:InvestorAxis">bvs:NewLlcOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="P02_17_2021To02_17_2021_BioventusIncMembersrtOwnershipAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:InvestorAxis">bvs:ContinuingLlcOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="P02_17_2021To02_17_2021_BioventusIncMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:InvestorAxis">bvs:NewLlcOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:InvestorAxis">bvs:ContinuingLlcOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:InvestorAxis">bvs:NewLlcOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="P02_23_2021To02_23_2021_BioVentusLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsaoAndOigMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bvs:UsaoAndOigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-23</startDate>
            <endDate>2021-02-23</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_28_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:A2021PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_28_2021_MaximumMembersrtRangeAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:AgreementAxis">bvs:OptionAndEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_28_2021_MaximumMembersrtRangeAxis_RestrictedStockUnitsAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:AgreementAxis">bvs:RestrictedStockUnitsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_28_2021_MinimumMembersrtRangeAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:AgreementAxis">bvs:OptionAndEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_28_2021_MinimumMembersrtRangeAxis_RestrictedStockUnitsAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:AgreementAxis">bvs:RestrictedStockUnitsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="P03_22_2021To03_22_2021_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="PAsOn03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bvs:HarborSeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborCommonStockMemberusgaapStatementEquityComponentsAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bvs:HarborCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bvs:HarborSeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="P11_30_2020To11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bvs:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bvs:HarborSeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P10_05_2020To10_05_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bvs:HarborSeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-05</startDate>
            <endDate>2020-10-05</endDate>
        </period>
    </context>
    <context id="PAsOn01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-30</instant>
        </period>
    </context>
    <context id="P01_30_2018To01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bvs:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-30</startDate>
            <endDate>2018-01-30</endDate>
        </period>
    </context>
    <context id="P01_22_2020To01_22_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SimpleAgreementForFutureEquityMemberBVSAgreementForFutureEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:AgreementForFutureEquityAxis">bvs:SimpleAgreementForFutureEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-22</startDate>
            <endDate>2020-01-22</endDate>
        </period>
    </context>
    <context id="P07_15_2020To07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesG1PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bvs:SeriesG1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-15</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="P07_15_2020To07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:AgreementAxis">bvs:OptionAndEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-15</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:AgreementAxis">bvs:OptionAndEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bvs:CartiHealLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="P05_01_2012To05_31_2012_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-01</startDate>
            <endDate>2012-05-31</endDate>
        </period>
    </context>
    <context id="P05_01_2012To05_31_2012_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelvePreferredUnitsMemberusgaapPreferredUnitsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PreferredUnitsByNameAxis">bvs:TwoThousandAndTwelvePreferredUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-01</startDate>
            <endDate>2012-05-31</endDate>
        </period>
    </context>
    <context id="P11_01_2015To11_30_2015_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PreferredUnitsByNameAxis">bvs:TwoThousandAndFifteenPreferredUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="P06_01_2020To06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_LetterOfCreditMemberBVSRevolvingCreditFacilitySubAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bvs:RevolvingCreditFacilitySubAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_BrInterestRateBasisMemberBVSInterestRateBasisAxis_EurodollarMemberusgaapVariableRateAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bvs:InterestRateBasisAxis">bvs:BrInterestRateBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="P12_06_2019To12_06_2019_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bvs:RevolvingCreditFacilitySubAxis">bvs:SwingLineCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bvs:RevolvingCreditFacilitySubAxis">bvs:SwingLineCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_BrInterestRateBasisMemberBVSInterestRateBasisAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bvs:InterestRateBasisAxis">bvs:BrInterestRateBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bvs:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-06</startDate>
            <endDate>2019-12-06</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bvs:CreditAgreementAxis">bvs:TwoThousandNineteenCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn02_10_2021_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-03</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-03</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-03</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-03</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-03</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:OtherChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioventusIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioventusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:OtherChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:EmployeeSeveranceAndTemporaryLaborCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bvs:OtherChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:OtherPhantomUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:OtherPhantomUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:OtherPhantomUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bvs:OtherPhantomUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bvs:TwoThousandAndFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bvs:BioVentusLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:EquityParticipationRightUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-03</instant>
        </period>
    </context>
    <context id="PAsOn06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-27</instant>
        </period>
    </context>
    <context id="PAsOn03_28_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-28</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001665988</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-03</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_EMPLOYEE">
        <measure>bvs:EMPLOYEE</measure>
    </unit>
    <unit id="Unit_employee">
        <measure>bvs:employee</measure>
    </unit>
    <unit id="Unit_Plan">
        <measure>bvs:Plan</measure>
    </unit>
    <unit id="Unit_Segment">
        <measure>bvs:Segment</measure>
    </unit>
    <unit id="Unit_Business">
        <measure>bvs:Business</measure>
    </unit>
    <unit id="Unit_Loans">
        <measure>bvs:Loans</measure>
    </unit>
    <unit id="Unit_Vote">
        <measure>bvs:Vote</measure>
    </unit>
    <unit id="Unit_Entities">
        <measure>bvs:Entities</measure>
    </unit>
    <dei:DocumentType contextRef="P01_01_2021To07_03_2021" id="hidden26389481">S-4/A</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2021To07_03_2021">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2021To07_03_2021">0001665988</dei:EntityCentralIndexKey>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P02_01_2021To02_28_2021_MinimumMembersrtRangeAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="hidden26390211">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P02_01_2021To02_28_2021_MinimumMembersrtRangeAxis_RestrictedStockUnitsAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="hidden26390212">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      id="hidden26390228">P15D</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <bvs:AdditionalMarginPercentageToReferenceRates
      contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="4"
      id="hidden26390186"
      unitRef="Unit_pure">0.0050</bvs:AdditionalMarginPercentageToReferenceRates>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="hidden26390235"
      unitRef="Unit_shares">31838589</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <dei:AmendmentDescription contextRef="P01_01_2021To07_03_2021">Amendment No. 1</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="P01_01_2021To07_03_2021">BIOVENTUS INC.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory contextRef="P01_01_2021To07_03_2021">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2021To07_03_2021">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2021To07_03_2021">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2021To07_03_2021">true</dei:EntityExTransitionPeriod>
    <bvs:TotalAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:TotalAssets>
    <bvs:TotalAssets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:TotalAssets>
    <bvs:TotalLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:TotalLiabilities>
    <bvs:TotalLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:TotalLiabilities>
    <bvs:TotalStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:TotalStockholdersEquity>
    <bvs:TotalStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:TotalStockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">10</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">10</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">10</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">10</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">10</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">10</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <bvs:TotalLiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:TotalLiabilitiesAndStockholdersEquity>
    <bvs:TotalLiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:TotalLiabilitiesAndStockholdersEquity>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Organization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bioventus Inc. (the Company, we, us or our) was formed as a Delaware corporation on December&#160;22, 2015 for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (BV LLC). The notes to these financial statements should be read in conjunction with notes to BV LLC&#x2019;s financial statements. As of December&#160;31, 2020, the Company had not engaged in any business activities except in connection with its formation. On February&#160;16, 2021, the Company closed an IPO of 9,200,000 shares of Class&#160;A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#x2019; over-allotment option. The Company received $111,228 in proceeds, net of underwriting discounts and commissions of $8,372, which was used to purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of $13.00. In addition to the underwriting discounts and commission the Company incurred offering expenses totaling $4,310. Subsequent to the IPO and related transactions that occurred in connection with the IPO (the Transactions) as described in Note 4, the Company is the sole managing member of BV LLC and owns 72.2% of BV LLC. The Company has a majority economic interest, the sole voting interest in, and controls the management of BV LLC. As a result, subsequent to the IPO, the Company will consolidate the financial results of BV LLC and will report a non-controlling interest representing the 27.8% interest not held by the Company. &lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">9200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">111228</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">8372</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.00</us-gaap:SaleOfStockPricePerShare>
    <bvs:SaleOfStockOfferingCosts
      contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">4310</bvs:SaleOfStockOfferingCosts>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest
      contextRef="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.722</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn07_03_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.278</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Summary of significant accounting policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of accounting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The balance sheets have been prepared in accordance with accounting principles generally accepted in the United States of America. Separate statements of income, comprehensive income, changes in stockholder&#x2019;s equity, and cash flows have not been presented in the financial statements as there has been no activity. &lt;/div&gt;&lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of accounting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The balance sheets have been prepared in accordance with accounting principles generally accepted in the United States of America. Separate statements of income, comprehensive income, changes in stockholder&#x2019;s equity, and cash flows have not been presented in the financial statements as there has been no activity. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Stockholder&#x2019;s equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Corporation had 10 outstanding shares at a nominal value as of December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">10</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Subsequent event &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company and BV LLC completed the following Transactions regarding the IPO. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BV LLC amended and restated the Bioventus LLC Agreement, to, among other things, (i)&#160;provide for a new single class of common membership interests in BV LLC (LLC Interests), (ii)&#160;exchange all of the existing membership interests in BV LLC for new LLC Interests and (iii)&#160;appoint Bioventus Inc. as the sole managing member of BV LLC. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company amended and restated its certificate of incorporation to, among other things, provide for the (i)&#160;authorization of 250,000,000 shares of Class&#160;A common stock with a par value of $0.001 per share; (ii)&#160;authorization of 50,000,000 shares of Class B common stock with a par value of $0.001 per share; (iii)&#160;authorization of 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company&#x2019;s Board of Directors (BOD) in one or more series; and (iv)&#160;establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holders of Class&#160;A and Class B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests held by the only member of BV LLC that remained a member (Continuing LLC Owner) and the number of shares of Class B common stock held by the Continuing LLC Owner. Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a one-for-one basis if the Company, at the election of a Continuing LLC Owner, redeem or exchange LLC Interests. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s amended and restated certificate of incorporation and the Bioventus LLC Agreement requires that the Company and BV LLC at all times maintain a one-to-one ratio between the number of shares of Class&#160;A common stock issued by the Company and the number of LLC Interests owned by the Company, as well as a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company acquired, by merger, ten entities that were members of BV LLC (Former LLC Owners), for which the Company issued 31,838,589 shares of Class&#160;A common stock as merger consideration (Merger). The only assets held by the Former LLC Owners were 31,838,589 LLC Interests and a corresponding number of shares of Class B common stock. Upon consummation of the Merger, the Company canceled the 31,838,589 shares of Class B common stock and recognized the &lt;span style="-sec-ix-hidden:hidden26390235"&gt;31,838.58&lt;/span&gt;9 of LLC Interests at carrying value, as the Merger is considered to be a transaction between entities under common control. Following the Merger and IPO, the Company now holds 41,038,589 LLC Interests, representing a 72.2% ownership interest in BV LLC. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax Receivable Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;16, 2021, the Company entered into a tax receivable agreement (TRA) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that Bioventus actually realizes as a result of (i)&#160;increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC and (ii)&#160;certain other tax benefits related to our making payments under the TRA. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, in connection with the IPO, the BV LLC Phantom Profits Interest Plan (Phantom Plan) terminated and the Company assumed the obligations of settling the vested awards. The awards will be settled 12 months following the Phantom Plan termination. Vested awardees whose BV LLC employment terminated prior to the IPO will have their awards settled in cash totaling $10,875. Vested awardees that were active BV LLC employees at the IPO will receive 798,422 shares of Class&#160;A common stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, in connection with the IPO, the Company began operating two equity-based compensation plans. These are the Bioventus Inc. 2021 Incentive Award Plan (2021 Plan) and the Bioventus Inc. 2021 Employee Stock Purchase Plan (ESPP). &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2021 Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The 2021 Plan is designed to grant incentive awards to eligible employees and other service providers in order to attract, motivate and retain the talent for which the Company competes. The 2021 Plan provides for the grant of stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units (RSUs), other stock-based awards, and cash awards. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In conjunction with the IPO, 7,592,476 shares of Class&#160;A common stock were authorized for issuance. The number of shares available for issuance will be increased by an annual increase on January&#160;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (i)&#160;4.5% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In conjunction with the IPO, 4,561,500 stock options were granted to certain employees with an exercise price of $13.00 per share and vest equally over &lt;span style="-sec-ix-hidden:hidden26390211"&gt;two&lt;/span&gt; or four years as indicated in each option agreement. Additionally, the Company granted 360,670 RSUs to the directors and certain employees which vest equally over &lt;span style="-sec-ix-hidden:hidden26390212"&gt;one&lt;/span&gt; or four years as indicated in each RSU agreement and entitles the recipient to the same number of shares of Class&#160;A common stock. 2,670,306 shares of Class&#160;A common stock remain available for issuance under the 2021 Plan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ESPP &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The ESPP allows for the Company to grant options to employees to purchase shares of the Company&#x2019;s Class&#160;A common stock through payroll deductions of up to 15% of their eligible compensation as defined in the ESPP. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In conjunction with the IPO, 542,320 shares of Class&#160;A common stock were authorized for issuance. The number of shares available for issuance will be increased by an annual increase on January&#160;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (i)&#160;1% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. There have been no grants under the ESPP as of March&#160;22, 2021. &lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn02_16_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <bvs:CommonStockNumberOfVotes
      contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_Vote">1</bvs:CommonStockNumberOfVotes>
    <bvs:CommonStockNumberOfVotes
      contextRef="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_Vote">1</bvs:CommonStockNumberOfVotes>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_pure">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <bvs:CancellationRatioRequiredStockToLLCInterestRatio
      contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_pure">1</bvs:CancellationRatioRequiredStockToLLCInterestRatio>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_pure">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_pure">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_Entities">10</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">31838589</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn02_16_2021"
      decimals="0"
      unitRef="Unit_shares">31838589</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="P02_16_2021To02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">31838589</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn08_10_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">41038589</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest
      contextRef="P08_10_2021To08_10_2021_BioventusIncMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.722</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest>
    <bvs:ShareBasedPaymentAwardSettlementPeriod contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P12M</bvs:ShareBasedPaymentAwardSettlementPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10875000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">798422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <bvs:NumberOfEquityBasedCompensationPlans
      contextRef="PAsOn02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_Plan">2</bvs:NumberOfEquityBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">7592476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease
      contextRef="PAsOn02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.045</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">4561500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P02_01_2021To02_28_2021_MaximumMembersrtRangeAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P02_01_2021To02_28_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">360670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P02_01_2021To02_28_2021_MaximumMembersrtRangeAxis_RestrictedStockUnitsAgreementMemberBVSAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P02_01_2021To02_28_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2670306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee
      contextRef="PAsOn02_28_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn02_28_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">542320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease
      contextRef="PAsOn02_28_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P03_22_2021To03_22_2021_EmployeeStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">321161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">340141000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">319177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">21169000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">22399000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">20614000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">87642000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">90935000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">84168000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">233519000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">249206000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">235009000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">193078000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">198475000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">191672000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">11202000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">11055000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8095000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-739000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">563000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">575000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1373000</us-gaap:RestructuringCharges>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">7439000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">7908000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8615000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">489000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">21237000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">31193000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">25504000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-9751000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-21579000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-19171000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4428000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-226000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-5323000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-21504000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-19397000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15914000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">9689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6107000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1192000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1576000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1664000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14722000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8113000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4443000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1815000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16650000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14722000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6298000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-12207000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1689000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-553000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16411000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-12207000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-131000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2126000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-322000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-334000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2072000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-203000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">18483000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6451000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-12410000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16411000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8666000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4443000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6133000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5955000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5781000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5895000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1555000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4383000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1156000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1338000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1815000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-16650000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4383000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-659000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-17988000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.89</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.37</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.40</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">4900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">4900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">4900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">86839000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">64520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">88283000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">85128000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">29120000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">27326000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">7552000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6059000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">211794000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">183033000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6879000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4489000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">49800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">49800000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">191650000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">216510000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14961000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15267000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">19382000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3308000</us-gaap:LongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">494466000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">472407000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4422000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6440000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">88187000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">52827000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">11054000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15547000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">10000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3926000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4201000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">122589000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">89015000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">173378000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">187965000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">29249000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">25255000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3362000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3874000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">21728000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">20681000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">350306000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">326790000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">210576000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">204443000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">285173000</us-gaap:MembersEquity>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">285147000</us-gaap:MembersEquity>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1607000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-465000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-144539000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-141700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">142241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">142982000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1919000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2635000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">144160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">145617000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">494466000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">472407000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">285114000</us-gaap:MembersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-119795000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">165457000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <bvs:MembersEquityDecreaseFromProfitInterestForfeiture
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-39000</bvs:MembersEquityDecreaseFromProfitInterestForfeiture>
    <bvs:MembersEquityDecreaseFromProfitInterestForfeiture
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-39000</bvs:MembersEquityDecreaseFromProfitInterestForfeiture>
    <bvs:MembersEquityDecreaseFromDistributionToMembers
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7819000</bvs:MembersEquityDecreaseFromDistributionToMembers>
    <bvs:MembersEquityDecreaseFromDistributionToMembers
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">7819000</bvs:MembersEquityDecreaseFromDistributionToMembers>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-12207000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-12207000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">131000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">131000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-334000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-334000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">285153000</us-gaap:MembersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-65000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-139821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">145267000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <bvs:MembersEquityDecreaseFromProfitInterestForfeiture
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</bvs:MembersEquityDecreaseFromProfitInterestForfeiture>
    <bvs:MembersEquityDecreaseFromProfitInterestForfeiture
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</bvs:MembersEquityDecreaseFromProfitInterestForfeiture>
    <bvs:MembersEquityDecreaseFromDistributionToMembers
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8730000</bvs:MembersEquityDecreaseFromDistributionToMembers>
    <bvs:MembersEquityDecreaseFromDistributionToMembers
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8730000</bvs:MembersEquityDecreaseFromDistributionToMembers>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3188000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3188000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6851000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-553000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6298000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-78000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-78000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2019To12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-322000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-322000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">285147000</us-gaap:MembersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-465000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-141700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2635000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">145617000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <bvs:MembersEquityDecreaseFromProfitInterestForfeiture
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">12000</bvs:MembersEquityDecreaseFromProfitInterestForfeiture>
    <bvs:MembersEquityDecreaseFromProfitInterestForfeiture
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">12000</bvs:MembersEquityDecreaseFromProfitInterestForfeiture>
    <bvs:MembersEquityDecreaseFromDistributionToMembers
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">19250000</bvs:MembersEquityDecreaseFromDistributionToMembers>
    <bvs:MembersEquityDecreaseFromDistributionToMembers
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">19250000</bvs:MembersEquityDecreaseFromDistributionToMembers>
    <bvs:MembersEquityDecreaseFromEquityForfeitures
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-38000</bvs:MembersEquityDecreaseFromEquityForfeitures>
    <bvs:MembersEquityDecreaseFromEquityForfeitures
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-38000</bvs:MembersEquityDecreaseFromEquityForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">16411000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1689000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14722000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-54000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-54000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2126000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2126000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">285173000</us-gaap:MembersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-144539000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1919000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">144160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14722000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6298000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-12207000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1815000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16650000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14722000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8113000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4443000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">28643000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">30316000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">29238000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">489000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-739000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">945000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3558000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1215000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2242000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2538000</us-gaap:ProvisionForDoubtfulAccounts>
    <bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-10103000</bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation>
    <bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-10844000</bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation>
    <bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-14325000</bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation>
    <bvs:ChangeInFairValueOfEquityParticipationRightsUnit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-644000</bvs:ChangeInFairValueOfEquityParticipationRightsUnit>
    <bvs:ChangeInFairValueOfEquityParticipationRightsUnit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-565000</bvs:ChangeInFairValueOfEquityParticipationRightsUnit>
    <bvs:ChangeInFairValueOfEquityParticipationRightsUnit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1009000</bvs:ChangeInFairValueOfEquityParticipationRightsUnit>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1599000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-511000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-348000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-79000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">543000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1583000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetRetirementObligationAccretionExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3352000</us-gaap:AssetRetirementObligationAccretionExpense>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-67000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">395000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">106000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3941000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14909000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">12130000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">528000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1427000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-3256000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">20510000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6646000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">12148000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">733000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3882000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">422000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">72199000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">42545000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">52310000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-400000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1832000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-7123000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">71799000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">40713000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">45187000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <bvs:InvestmentAndAcquisitionOfDistributionRights
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-16579000</bvs:InvestmentAndAcquisitionOfDistributionRights>
    <bvs:InvestmentAndAcquisitionOfDistributionRights
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-6000000</bvs:InvestmentAndAcquisitionOfDistributionRights>
    <bvs:InvestmentAndAcquisitionOfDistributionRights
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-3500000</bvs:InvestmentAndAcquisitionOfDistributionRights>
    <bvs:AcquisitionOfVariableInterestEntity
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">430000</bvs:AcquisitionOfVariableInterestEntity>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4093000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2342000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2561000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-20672000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-7912000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-6061000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">172000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-40000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-20500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-7912000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-6101000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">49000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">49000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">198134000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">10000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">199500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5250000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">317000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-448000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-160000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <bvs:ProceedsFromMembers
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-19886000</bvs:ProceedsFromMembers>
    <bvs:ProceedsFromMembers
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-9137000</bvs:ProceedsFromMembers>
    <bvs:ProceedsFromMembers
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-7846000</bvs:ProceedsFromMembers>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-29569000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-10951000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-13256000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">589000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-104000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">-160000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">22319000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">21746000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">25670000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">64520000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">42774000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">17104000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">86839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">64520000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">42774000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1541000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1577000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1944000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">7486000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15450000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">17273000</us-gaap:InterestPaidNet>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">973000</us-gaap:StockIssued1>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">336000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">184000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <bvs:MemberDistributionsIncurredButNotYetPaid
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">31000</bvs:MemberDistributionsIncurredButNotYetPaid>
    <bvs:MemberDistributionsIncurredButNotYetPaid
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">499000</bvs:MemberDistributionsIncurredButNotYetPaid>
    <bvs:MemberDistributionsIncurredButNotYetPaid
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">906000</bvs:MemberDistributionsIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Organization and basis of presentation of financial information&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bioventus LLC and its subsidiaries (the Company, we, us or our), is a limited liability company formed under the laws of the state of Delaware on November&#160;23, 2011 and operates as a partnership. The Company commenced operations in May 2012 in Durham, North Carolina, USA, which is its headquarters. Bioventus is a global medical device company, conducting business in various countries, primarily in North America and Europe, with approximately 700&#160;employees. The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#x2019;s natural healing processes. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Bioventus Inc. was formed as a Delaware corporation for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of the Company. Bioventus Inc. acquired, by merger, ten entities that were members of the Company (Former LLC Owners) and upon consummation of the merger, owned 31,838,589 Common LLC Interests (as defined below). On February&#160;16, 2021, Bioventus Inc. (New LLC Owner) closed an IPO of 9,200,000 shares of Class&#160;A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#x2019; over-allotment option. The New LLC Owner received $111,228 in proceeds, net of underwriting discounts and commissions which was used to make a capital contribution to the Company in exchange for 9,200,000 newly-issued membership interests (Common LLC Interests) from the Company at a price per interest equal to the IPO price of $13.00. Subsequent to the IPO and related transactions that occurred in connection with the IPO (Transactions), the New LLC Owner is the sole managing member of the Company. Following the completion of the IPO and Transactions, the New LLC Owner owns 72.2% of the Company. The New LLC Owner has a majority economic interest, the sole voting interest in, and controls the management of the Company. As a result, subsequent to the IPO, the New LLC Owner will consolidate the financial results of the Company and will report a non-controlling interest representing the interests owned by the only member of BV LLC that remained a member (Continuing LLC Owner). Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 17. Subsequent Events&lt;/div&gt;&lt;/div&gt; for further details regarding the IPO and related transactions. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interim periods &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January&#160;1 and ends on December&#160;31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December&#160;31. The 13-week quarterly periods ended on March&#160;28,&#160;June&#160;27 and September&#160;26 for the year ended December&#160;31, 2020. As a result, the fourth and first quarters may vary in length depending on the calendar year. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). The consolidated financial statements include the Company, its subsidiaries and investments in which the Company has control. Amounts pertaining to the non-controlling ownership interests held by third parties in the operating results and financial position of the Company&#x2019;s controlled subsidiaries are reported as non-controlling interests. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassifications &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Certain prior period amounts have been reclassified to conform to the current period presentation. These changes had no effect on previously reported total revenues, net income (loss), other comprehensive income (loss), members&#x2019; equity or cash flows. Unless otherwise noted, all financial information in the consolidated financial statement footnotes reflect the Company&#x2019;s results from continuing operations. Discontinued operations are discussed further in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 16. Discontinued operations&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company identifies a business as an operating segment if: (i)&#160;it engages in business activities from which it may earn revenues and incur expenses; (ii)&#160;its operating results are regularly reviewed by the Chief Operating Decision Maker (CODM), to make decisions about resources to be allocated to the segment and assess its performance; and (iii)&#160;it has available discrete financial information. The Company&#x2019;s CODM is its Chief Executive Officer. The CODM reviews financial information at the operating segment level to allocate resources and to assess the operating results and financial performance for each operating segment. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s two reportable segments are U.S. and International. U.S. and International products are primarily sold to physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery, as well as directly to their patients. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 14. Net sales&lt;/div&gt;&lt;/div&gt; and &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 15. Segments&lt;/div&gt;&lt;/div&gt; for further information regarding our business segments. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in accordance with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowances for doubtful accounts, inventory reserves, goodwill and intangible assets impairment, useful lives of long lived assets, noncontrolling interest, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19 pandemic impact &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2020, the COVID-19 pandemic spread around the world and in the U.S. and, more recently, new variants of the virus have emerged, some of which have shown to be more contagious. The COVID-19 pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments have implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of business, work from home, supply chain logistical changes and other measures, which have caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted due to the decrease in patient visits and elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments from customers, supply chain interruptions, extended &#x201c;shelter-in-place&#x201d; orders or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of COVID-19 on our business will depend on many factors, including, but not limited to, the duration and &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability and effectiveness of vaccines to combat COVID-19, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on our partners, patients and communities in which we operate, all of which continue to be uncertain. For example, there has been a decrease in patient visits to hospitals due to risk and fear of exposure to COVID-19, as well as decreases in, or temporary moratoriums on, elective procedures, which may be re-imposed in the future. In addition to lower sales, we have experienced decreased costs as a result of the pandemic including declines in travel and lower compensation related expenses. We have also implemented other various cost reduction initiatives and measures to safeguard liquidity. As of the date of issuance of these consolidated financial statements, the extent to which COVID-19 could materially impact the Company&#x2019;s financial conditions, liquidity or results of operations is uncertain. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent COVID-19 disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully commercialize new developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual relationships. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On March&#160;27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law, which was aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. The CARES Act allowed the Company to defer $1,889 in employer social security payroll tax payments from May 2020 through December&#160;31, 2020. A total of 50% is deferred until December&#160;31, 2021 and has been recorded in accrued liabilities, with the remaining balance deferred until December&#160;31, 2022 which has been recorded in other long-term liabilities both on the consolidated balance sheet. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 10. Income Taxes&lt;/div&gt;&lt;/div&gt; for further information. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result of the CARES Act and at the direction of the U.S. Department of Health and Human Services (HHS), the Company received a $1,247 Provider Relief Fund Payment in April 2020. The Company determined it complied with the conditions to be able to keep and use the funds to reimburse for health care related expenses and lost revenue attributable to the public health emergency resulting from COVID-19. A second Provider Relief Fund Payment totaling $2,854 was received in July 2020. The payments were recorded as other income on the consolidated statement of operations and comprehensive income (loss) for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="PAsOn12_31_2020_BVLLCMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_employee">700</dei:EntityNumberOfEmployees>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_BVLLCMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_Business">10</us-gaap:NumberOfBusinessesAcquired>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">31838589</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">9200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">111228</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_16_2021To02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">9200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest
      contextRef="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.722</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1889</us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent>
    <bvs:PercentageOfDeferredPayrollTax
      contextRef="PAsOn12_31_2021_BioventusIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</bvs:PercentageOfDeferredPayrollTax>
    <bvs:ProceedsFromGovernmentalAssistance
      contextRef="P04_01_2020To04_30_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1247000</bvs:ProceedsFromGovernmentalAssistance>
    <bvs:ProceedsFromGovernmentalAssistance
      contextRef="P07_01_2020To07_31_2021_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2854000</bvs:ProceedsFromGovernmentalAssistance>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Summary of significant accounting policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recent accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has elected to comply with non-accelerated public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are specific to non-accelerated public company filers, which are generally earlier than when emerging growth companies are required to adopt. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Pronouncements Recently Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The FASB issued Accounting Standards Update 2016-13, Financial Instruments-Credit Losses (ASU 2016-13), in June 2016 that significantly changes accounting for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment methodology in prior GAAP with a methodology that considers a broad range of information for the estimation of credit losses. The Company adopted ASU 2016-13 on January&#160;1, 2020 prospectively and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the FASB issued Accounting &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Standards&lt;/div&gt; Update 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (ASU 2018-15), addressing a customer&#x2019;s accounting for implementation costs incurred in a cloud-computing arrangement (CCA) that is considered a service contract. Under ASU 2018-15, implementation costs for a CCA should be evaluated for capitalization using the same approach as implementation costs associated with internal-use software. The capitalized implementation costs should be expensed over the term of the hosting arrangement, which includes any reasonably certain renewal periods. Capitalized implementation costs should be assessed for impairment like long-lived assets. The Company adopted ASU 2018-15 on January&#160;1, 2020 prospectively and it had no material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (ASU 2018-13), modifying the disclosure requirements on fair value measurements and eliminates the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements. ASU 2018-13 modifies certain disclosures related to investments measured at net asset value and clarifies that companies are to disclose uncertainties in measurements as of the reporting date. ASU 2018-13 requires additional disclosure related to changes in unrealized gains and losses included in other comprehensive income (loss) for recurring Level 3 fair value measurements as well as the range and weighted average, or other quantitative information that would be a more reasonable and rational method, of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted ASU 2018-13 on January&#160;1, 2020 and it did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;New Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (ASU 2019-12), which amended the accounting for income taxes. ASU 2019-12 eliminates certain exceptions to the guidance for income taxes related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU 2019-12 is effective for annual and interim periods beginning after December&#160;15, 2020. Early adoption is permitted in interim or annual periods for which financial statements have not been made available for issuance. Entities that elect to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Certain amendments are to be applied prospectively while others are retrospective. The Company adopted ASU 2019-12 on January&#160;1, 2021 and the Company has assessed it will not have a material impact on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable Interest Entity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews each investment and collaboration agreement to determine if it has a variable interest in the entity. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgments regarding the purpose and design of entity, the value of the licensed assets to the entity, the value of the entity&#x2019;s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that variable interest entity (VIE), based on a number of factors, including: (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, (ii)&#160;the parties&#x2019; contractual rights and responsibilities pursuant to the collaboration agreement, and (iii)&#160;which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statement of the VIE into the Company&#x2019;s consolidated financial statements. On a quarterly basis, the Company &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;evaluates &lt;/div&gt;whether &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period the determination is &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;made.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities recorded as a result of consolidating financial results of the VIE into the Company&#x2019;s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company&#x2019;s general assets or liabilities for which creditors have recourse to the Company&#x2019;s general assets. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Noncontrolling Interest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records noncontrolling interest related to the consolidated VIEs on its consolidated balance sheet. The Company records loss attributable to noncontrolling interest on its consolidated statements of operations, which reflects the VIE&#x2019;s net loss for the reporting period, adjusted for changes in the noncontrolling interest holders claim to net assets, including contingent milestone and royalty payments, which are evaluated each reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deconsolidation and discontinued operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i)&#160;the aggregate of (a)&#160;the fair value of any consideration received, (b)&#160;the fair value of any retained noncontrolling investment in the former subsidiary and (c)&#160;the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii)&#160;the carrying amount of the former subsidiary&#x2019;s assets and liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on if the deconsolidation represents a strategic shift that has or will have a major effect on the Company&#x2019;s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one-year period following such date, it will present the former subsidiary as a discontinued operation for all periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of foreign currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars at rates of exchange in effect at the close of their month end. Equity accounts are translated at their historical rates. Revenues and expenses are translated at the exchange rate on the transaction date. Translation gains and losses are accumulated within accumulated other comprehensive income (loss) as a separate component of members&#x2019; equity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency transaction gains and losses are included in other expense on the consolidated statements of operations and comprehensive income (loss). There were gains of $117 for the year ended December&#160;31, 2020, nominal losses for the year ended December&#160;31, 2019, and losses of $234 for the year ended December&#160;31, 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income (loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive income (loss) consists of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S.&#160;GAAP are recorded as an element of members&#x2019; equity and are excluded from net income (loss). The Company&#x2019;s other comprehensive income (loss) consists of a defined benefit plan adjustment and foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents consist of highly liquid investments with an original maturity of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; three&lt;/div&gt; months or less at date of purchase. The Company&#x2019;s cash is primarily held in financial institutions in the United States and the Netherlands. The Company maintains cash balances in the United States in excess of the federally insured limits. The Company did not have restricted cash as of December&#160;31, 2020 and 2019. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company uses derivative instruments to manage exposures to interest rates. Derivatives are recorded on the balance sheet at fair value at each balance sheet date and the Company does not designate whether the derivative instrument is an effective hedge. Changes in the fair values of derivative instruments are recognized in the consolidated statements of operations and comprehensive income (loss). The Company has entered, and may in the future enter, into derivative contracts related to its debt. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 5. Financial instruments&lt;/div&gt;&lt;/div&gt; for further details regarding the Company&#x2019;s derivatives. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company records certain assets and liabilities at fair value. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 7. Fair value measurements&lt;/div&gt;&lt;/div&gt; for details regarding assets and liabilities measured at fair value. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities are categorized based on the lowest level that is significant to the valuation. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The three levels of inputs used to measure fair value are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#x2014;Observable inputs other than quoted prices included within Level&#160;1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#x2014;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sale of Products &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company derives revenue primarily from the sale of its (i)&#160;osteoarthritic, or OA, joint pain treatment and joint preservation products, which are hyaluronic acid, or HA, viscosupplementation therapies, (ii)&#160;Bone Graft Substitutes (BGS) products and (iii)&#160;a Minimally Invasive Fracture Treatment product. The Company sells product directly to healthcare institutions, patients, distributors and dealers. The Company also enters arrangements with pharmacy and health benefit managers that provide for negotiated rebates, chargebacks and discounts with respect to the purchase of the Company&#x2019;s products. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue at a point in time upon transfer of control of the promised product to customers in an amount that reflects the consideration it expects to receive in exchange for those products. The Company excludes taxes collected from customers and remitted to governmental authorities from revenues. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues are recorded at the transaction price, which is determined as the contracted price net of estimates of variable consideration resulting from discounts, rebates, returns, chargebacks, contractual allowances, estimated third-party payer settlements, and certain distribution and administration fees offered in our customer contracts and other indirect customer contracts relating to the sale of our products. The Company establishes reserves for the estimated variable consideration based on the amounts earned or eligible to be claimed on the related sales. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted for relevant factors such as the Company&#x2019;s historical experience, current contractual requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company regularly reviews all reserves and updates them at the end of each reporting period as needed. There were no adjustments arising from the change in estimates of variable consideration that were significant for the years ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;OA Joint Pain Treatment and Joint Preservation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from customers, such as healthcare providers, distribution centers or specialty pharmacies is recognized at the point in time when control is transferred to the customer, typically upon shipment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distributor chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has preexisting contracts with established rates with many of the distributors&#x2019; customers who require the distributors to sell our product at their established rate. The Company offers chargebacks to distributors who supply these customers with our products. The Company reduces revenue at the time of sale for the estimated future chargebacks. The Company records chargeback reserves as a reduction of accounts receivable and base the reserves on the expected value by using probability-weighted estimates of volume of purchases, inventory holdings and historical chargebacks requested for each distributor. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Discounts and gross-to-net deductions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company offers retrospective discounts and gross-to-net deductions linked to the volume of purchases which may increase at negotiated thresholds within a contract-buying period. The Company reduces revenue and records the reserve as a reduction to accounts receivable for the estimated discount and rebate at the expected amount the customer will earn, based on historical buying trends and forecasted purchases. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Bone Graft Substitute &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of the Company&#x2019;s BGS product sales are through consignment inventory with hospitals, where ownership remains with the Company until the hospital or ambulatory surgical center (ASC) performs a surgery and consumes the consigned inventory. The Company recognizes revenue when the surgery has been performed. Control of the product is not transferred until the customer consumes it, as the Company is able to require the return or transfer of the product to a third-party. An unconditional obligation to pay for the product does not exist until the customer consumes it. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Minimally Invasive Fracture Treatment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue from third-party payers, such as governmental agencies, insurance companies or managed care providers, when the Company transfers control to the patient, typically when the patient has accepted the product or upon delivery. The Company records this revenue at the contracted rate, net of contractual allowances and estimated third-party payer settlements at the time of sale, or an estimated price based on historical data and other available information for non-contracted payers. The Company estimates the contractual allowances using the portfolio approach and based on probability weighting historical data and &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;collections history within those portfolios. The portfolios determined using the portfolio approach consist of the following customer groups: government payers, commercial payers, and patients. The Company recognizes revenue from patients (self-pay and insured patients with coinsurance and deductible responsibilities) based on billed amounts giving effect to any discounts and implicit price concessions. Implicit price concessions represent differences between amounts billed and the amounts the Company expects to collect from patients, which considers historical collection experience and current market conditions. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price using the expected amount method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. The Company is not aware of any claims, disputes or unsettled matters with any payer that would materially affect revenues for which the Company has not adequately provided for or disclosed in the accompanying consolidated financial statements. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 12. Commitments and contingencies&lt;/div&gt;&lt;/div&gt; for further information. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimates the amount of returns and reduces revenue in the period the related product revenue is recognized. The Company records a liability for expected returns based on probability-weighted historical data. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts receivable, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for doubtful accounts. The Company maintains an estimated allowance for doubtful accounts to provide for receivables the Company does not expect to collect. The Company bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets consist of unbilled amounts resulting from estimated future royalties from an international distributor that exceeds the amount billed. Contract assets totaling $81 and $261 as of December&#160;31, 2020 and 2019, are included in prepaid and other current assets on the consolidated balance sheets, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities consist of customer advance payments and deferred revenue. Occasionally for certain international customers, the Company requires payments in advance of shipping product and recognizing revenue resulting in contract liabilities. Contract liabilities were nominal as of December&#160;31, 2020 and 2019 and are included in accrued liabilities on the consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Shipping and handling &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other distribution costs are included in cost of sales. The &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company has elected to recognize shipping and handling activities that occur after control of the related product transfers to the customer as fulfillment costs and these are included in&lt;div style="display:inline;"&gt; cost&lt;/div&gt; of sales.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies the practical expedient of recognizing the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less. These incremental costs include the Company&#x2019;s sales incentive programs for the internal sales force and third-party sales agents as the compensation is commensurate with annual sales activities. These costs are included in selling, general and administrative expense on the consolidated statements of operations and comprehensive income (loss). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company values its inventory at the lower of cost or net realizable value and adjusts for the value of inventory that is estimated to be excess, obsolete or otherwise unmarketable. Cost is determined using the first-in, first-out (FIFO) method. Elements of cost in inventory include raw materials, direct labor, manufacturing overhead and inbound freight. The Company records allowances for excess and obsolete inventory based on historical and estimated future demand and market conditions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Business combinations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting for acquisitions requires the Company to recognize separately from goodwill assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While best estimates and assumptions are used to accurately value assets acquired and liabilities assumed at the acquisition date, as well as contingent consideration where applicable, estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations and comprehensive income (loss). Subsequent changes in the estimated fair value of contingent&lt;div style="display:inline;"&gt; considerat&lt;/div&gt;ion are recognized in earnings in the period of change. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense are recognized using the straight-line method over the estimated useful life of each asset, or the shorter of the lease term or useful life if related to leasehold improvements. The useful lives in years are as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 91%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer software and hardware&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3-5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Machinery and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and intangible assets&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;Fini&lt;/div&gt;te-lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight-line method over their estimated useful lives in years are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Useful&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Developed technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is not amortized but is evaluated for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. The Company reviews goodwill for impairment by applying a quantitative impairment analysis where the fair value of the reporting unit is compared with the carrying value, including goodwill. The Company determines the fair value of each reporting unit based on an income approach. The value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company performs its annual goodwill impairment test on October&#160;31st. If the fair value of the reporting unit is less than its carrying value, the Company will recognize the difference as an impairment loss, which is limited to the amount of goodwill allocated to the reporting units. There were no goodwill impairment charges for the years ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Software development costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company capitalizes internal and external costs incurred to develop internal-use software during the application development stage for software design, configuration, coding and testing upon placing the asset in service and then amortizes these costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. The Company does not capitalize costs that are precluded from capitalization in authoritative guidance, such as preliminary project phase costs, training costs or data conversion costs. Capitalized software costs totaled $17,653 and $14,119 as of December&#160;31, 2020 and 2019 and the related accumulated amortization totaled $13,264 and $12,184, respectively. Amortization expense was $1,184, $1,138 and $1,204 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying values of property, equipment, intangible assets as well as other long-lived and indefinite lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable the Company will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. If quoted market prices are not available, the Company estimates fair value using an undiscounted value of estimated future cash flows. During 2018, the Company determined that it would no longer sell a specific BGS product and as a result, an intangible asset related to this product was fully written off and the Company recognized impairment charges of $489 for the year ended December&#160;31, 2018, which is included in the consolidated statements of operations and comprehensive income (loss). Upon retirement or sale of property and equipment, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is included in income from operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#x2019;s property, equipment, intangible or other long-lived assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired in-process research and development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of in-process research and development (IPR&amp;amp;D) assets acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets and are not amortized until development is completed and the product is available for sale. Once the product is available for sale, the asset is transferred to developed technology and amortized over its estimated useful life. Impairment tests for IPR&amp;amp;D assets occur at least annually in December, or more frequently if events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than the carrying amount, an impairment loss is recognized for the difference. There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#x2019;s IPR&amp;amp;D. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred offering costs, consisting of legal, accounting, filing and other fees related to the initial public offering, are capitalized. The deferred offering costs will be offset against proceeds from the initial public offering upon the effectiveness of the initial public offering. In the event the initial public offering is terminated, all capitalized deferred offering costs would be expensed. Deferred offering costs capitalized totaled $2,187 as of December&#160;31, 2020 and there were there were no deferred offering costs capitalized as of December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company provides credit, in the normal course of business, to its customers. The Company does not require collateral or other securities to support customer receivables. Credit losses are provided for through allowances and have historically been materially within management&#x2019;s estimates. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable to these significant suppliers at December&#160;31 were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,983&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,586&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain products provide the Company with a significant percentage of total sales for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has restructured portions of its operations and future restructuring activities are possible. Identifying and calculating the cost to exit these operations requires certain assumptions to be made, the most significant of which are anticipated future liabilities. Although estimates have been reasonably accurate in the past, significant judgment is required, and these estimates and assumptions may change as additional information becomes available and facts or circumstances change. Restructuring costs are recorded at estimated fair value. Key assumptions in determining the restructuring costs include negotiated terms and payments to terminate contractual obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profits interest compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures profits interest compensation cost at the grant date based on the fair value of the award and recognizes this cost as compensation expense over the required or estimated service period for awards expected to vest. Certain awards are liability-classified, which require they be remeasured at each reporting date. Compensation expense is included in Selling, general and administrative expense and Research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employees who were granted the awards. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advertising costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advertising costs include costs incurred to promote the Company&#x2019;s business and are expensed as incurred. Advertising costs were $2,769, $2,351 and $2,916 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expense consist primarily of employee compensation and related expenses as well as contract research organization services. Internal research and development costs are expensed as incurred. Research and development costs incurred by third parties are expensed as the contracted work is performed. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaborative agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and we account for these alliances as a collaborative arrangement by reporting costs incurred from transactions within research and development expense in our consolidated statements of operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. Legal fees expected to be incurred in connection with a loss contingency are not included in the estimated loss contingency. The Company accrues for any legal costs as they are incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is treated as a partnership for U.S. tax purposes. Accordingly, the profits and losses are passed through to the members and included in their income tax returns. The Company has been required to make tax &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;distributions to its members in an amount equal to 40% of the members&#x2019; taxable income attributable to their ownership. The tax rate applied for purposes of this distribution may be changed only by approval of the Company&#x2019;s Board of Managers. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain wholly owned subsidiaries of the Company are taxable entities for U.S. or foreign tax purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred tax assets to an amount which will, more likely than not, be realized. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes a tax benefit from any uncertain tax positions only if they are more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. Components of the reserve, if relevant, are classified as a current or noncurrent liability in the consolidated balance sheet based on when the Company expects each of the items to be settled. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per common unit &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic income (loss) per common unit is determined by dividing the net income (loss) allocable to common unit holders by the weighted average number of common units outstanding during the periods presented. Diluted loss per common unit is computed by dividing the net income (loss) allocable to common unit holders on an &#x201c;if converted&#x201d; basis by the weighted average number of actual common units outstanding and, when dilutive, the unit equivalents that would arise from the assumed conversion of convertible instruments, if any. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has considered the effects of subsequent events through March&#160;26, 2021, the date the Company&#x2019;s consolidated financial statements were issued. &lt;/div&gt;&lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recent accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has elected to comply with non-accelerated public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are specific to non-accelerated public company filers, which are generally earlier than when emerging growth companies are required to adopt. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Pronouncements Recently Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The FASB issued Accounting Standards Update 2016-13, Financial Instruments-Credit Losses (ASU 2016-13), in June 2016 that significantly changes accounting for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment methodology in prior GAAP with a methodology that considers a broad range of information for the estimation of credit losses. The Company adopted ASU 2016-13 on January&#160;1, 2020 prospectively and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the FASB issued Accounting &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Standards&lt;/div&gt; Update 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (ASU 2018-15), addressing a customer&#x2019;s accounting for implementation costs incurred in a cloud-computing arrangement (CCA) that is considered a service contract. Under ASU 2018-15, implementation costs for a CCA should be evaluated for capitalization using the same approach as implementation costs associated with internal-use software. The capitalized implementation costs should be expensed over the term of the hosting arrangement, which includes any reasonably certain renewal periods. Capitalized implementation costs should be assessed for impairment like long-lived assets. The Company adopted ASU 2018-15 on January&#160;1, 2020 prospectively and it had no material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (ASU 2018-13), modifying the disclosure requirements on fair value measurements and eliminates the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements. ASU 2018-13 modifies certain disclosures related to investments measured at net asset value and clarifies that companies are to disclose uncertainties in measurements as of the reporting date. ASU 2018-13 requires additional disclosure related to changes in unrealized gains and losses included in other comprehensive income (loss) for recurring Level 3 fair value measurements as well as the range and weighted average, or other quantitative information that would be a more reasonable and rational method, of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted ASU 2018-13 on January&#160;1, 2020 and it did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;New Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (ASU 2019-12), which amended the accounting for income taxes. ASU 2019-12 eliminates certain exceptions to the guidance for income taxes related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU 2019-12 is effective for annual and interim periods beginning after December&#160;15, 2020. Early adoption is permitted in interim or annual periods for which financial statements have not been made available for issuance. Entities that elect to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Certain amendments are to be applied prospectively while others are retrospective. The Company adopted ASU 2019-12 on January&#160;1, 2021 and the Company has assessed it will not have a material impact on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable Interest Entity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews each investment and collaboration agreement to determine if it has a variable interest in the entity. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgments regarding the purpose and design of entity, the value of the licensed assets to the entity, the value of the entity&#x2019;s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that variable interest entity (VIE), based on a number of factors, including: (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, (ii)&#160;the parties&#x2019; contractual rights and responsibilities pursuant to the collaboration agreement, and (iii)&#160;which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statement of the VIE into the Company&#x2019;s consolidated financial statements. On a quarterly basis, the Company &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;evaluates &lt;/div&gt;whether &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period the determination is &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;made.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities recorded as a result of consolidating financial results of the VIE into the Company&#x2019;s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company&#x2019;s general assets or liabilities for which creditors have recourse to the Company&#x2019;s general assets. &lt;/div&gt;&lt;/div&gt; </us-gaap:ConsolidationVariableInterestEntityPolicy>
    <bvs:NonControllingInterestPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Noncontrolling Interest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records noncontrolling interest related to the consolidated VIEs on its consolidated balance sheet. The Company records loss attributable to noncontrolling interest on its consolidated statements of operations, which reflects the VIE&#x2019;s net loss for the reporting period, adjusted for changes in the noncontrolling interest holders claim to net assets, including contingent milestone and royalty payments, which are evaluated each reporting period. &lt;/div&gt;&lt;/div&gt;</bvs:NonControllingInterestPolicyTextBlock>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deconsolidation and discontinued operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i)&#160;the aggregate of (a)&#160;the fair value of any consideration received, (b)&#160;the fair value of any retained noncontrolling investment in the former subsidiary and (c)&#160;the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii)&#160;the carrying amount of the former subsidiary&#x2019;s assets and liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on if the deconsolidation represents a strategic shift that has or will have a major effect on the Company&#x2019;s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one-year period following such date, it will present the former subsidiary as a discontinued operation for all periods presented. &lt;/div&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of foreign currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars at rates of exchange in effect at the close of their month end. Equity accounts are translated at their historical rates. Revenues and expenses are translated at the exchange rate on the transaction date. Translation gains and losses are accumulated within accumulated other comprehensive income (loss) as a separate component of members&#x2019; equity. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency transaction gains and losses are included in other expense on the consolidated statements of operations and comprehensive income (loss). There were gains of $117 for the year ended December&#160;31, 2020, nominal losses for the year ended December&#160;31, 2019, and losses of $234 for the year ended December&#160;31, 2018. &lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">117000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">117000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">234000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income (loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive income (loss) consists of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S.&#160;GAAP are recorded as an element of members&#x2019; equity and are excluded from net income (loss). The Company&#x2019;s other comprehensive income (loss) consists of a defined benefit plan adjustment and foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency. &lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents consist of highly liquid investments with an original maturity of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; three&lt;/div&gt; months or less at date of purchase. The Company&#x2019;s cash is primarily held in financial institutions in the United States and the Netherlands. The Company maintains cash balances in the United States in excess of the federally insured limits. The Company did not have restricted cash as of December&#160;31, 2020 and 2019. &lt;/div&gt;&lt;/div&gt; </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company uses derivative instruments to manage exposures to interest rates. Derivatives are recorded on the balance sheet at fair value at each balance sheet date and the Company does not designate whether the derivative instrument is an effective hedge. Changes in the fair values of derivative instruments are recognized in the consolidated statements of operations and comprehensive income (loss). The Company has entered, and may in the future enter, into derivative contracts related to its debt. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 5. Financial instruments&lt;/div&gt;&lt;/div&gt; for further details regarding the Company&#x2019;s derivatives. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company records certain assets and liabilities at fair value. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 7. Fair value measurements&lt;/div&gt;&lt;/div&gt; for details regarding assets and liabilities measured at fair value. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities are categorized based on the lowest level that is significant to the valuation. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The three levels of inputs used to measure fair value are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#x2014;Observable inputs other than quoted prices included within Level&#160;1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#x2014;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sale of Products &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company derives revenue primarily from the sale of its (i)&#160;osteoarthritic, or OA, joint pain treatment and joint preservation products, which are hyaluronic acid, or HA, viscosupplementation therapies, (ii)&#160;Bone Graft Substitutes (BGS) products and (iii)&#160;a Minimally Invasive Fracture Treatment product. The Company sells product directly to healthcare institutions, patients, distributors and dealers. The Company also enters arrangements with pharmacy and health benefit managers that provide for negotiated rebates, chargebacks and discounts with respect to the purchase of the Company&#x2019;s products. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue at a point in time upon transfer of control of the promised product to customers in an amount that reflects the consideration it expects to receive in exchange for those products. The Company excludes taxes collected from customers and remitted to governmental authorities from revenues. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues are recorded at the transaction price, which is determined as the contracted price net of estimates of variable consideration resulting from discounts, rebates, returns, chargebacks, contractual allowances, estimated third-party payer settlements, and certain distribution and administration fees offered in our customer contracts and other indirect customer contracts relating to the sale of our products. The Company establishes reserves for the estimated variable consideration based on the amounts earned or eligible to be claimed on the related sales. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted for relevant factors such as the Company&#x2019;s historical experience, current contractual requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company regularly reviews all reserves and updates them at the end of each reporting period as needed. There were no adjustments arising from the change in estimates of variable consideration that were significant for the years ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;OA Joint Pain Treatment and Joint Preservation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from customers, such as healthcare providers, distribution centers or specialty pharmacies is recognized at the point in time when control is transferred to the customer, typically upon shipment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distributor chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has preexisting contracts with established rates with many of the distributors&#x2019; customers who require the distributors to sell our product at their established rate. The Company offers chargebacks to distributors who supply these customers with our products. The Company reduces revenue at the time of sale for the estimated future chargebacks. The Company records chargeback reserves as a reduction of accounts receivable and base the reserves on the expected value by using probability-weighted estimates of volume of purchases, inventory holdings and historical chargebacks requested for each distributor. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Discounts and gross-to-net deductions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company offers retrospective discounts and gross-to-net deductions linked to the volume of purchases which may increase at negotiated thresholds within a contract-buying period. The Company reduces revenue and records the reserve as a reduction to accounts receivable for the estimated discount and rebate at the expected amount the customer will earn, based on historical buying trends and forecasted purchases. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Bone Graft Substitute &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of the Company&#x2019;s BGS product sales are through consignment inventory with hospitals, where ownership remains with the Company until the hospital or ambulatory surgical center (ASC) performs a surgery and consumes the consigned inventory. The Company recognizes revenue when the surgery has been performed. Control of the product is not transferred until the customer consumes it, as the Company is able to require the return or transfer of the product to a third-party. An unconditional obligation to pay for the product does not exist until the customer consumes it. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Minimally Invasive Fracture Treatment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue from third-party payers, such as governmental agencies, insurance companies or managed care providers, when the Company transfers control to the patient, typically when the patient has accepted the product or upon delivery. The Company records this revenue at the contracted rate, net of contractual allowances and estimated third-party payer settlements at the time of sale, or an estimated price based on historical data and other available information for non-contracted payers. The Company estimates the contractual allowances using the portfolio approach and based on probability weighting historical data and &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;collections history within those portfolios. The portfolios determined using the portfolio approach consist of the following customer groups: government payers, commercial payers, and patients. The Company recognizes revenue from patients (self-pay and insured patients with coinsurance and deductible responsibilities) based on billed amounts giving effect to any discounts and implicit price concessions. Implicit price concessions represent differences between amounts billed and the amounts the Company expects to collect from patients, which considers historical collection experience and current market conditions. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price using the expected amount method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. The Company is not aware of any claims, disputes or unsettled matters with any payer that would materially affect revenues for which the Company has not adequately provided for or disclosed in the accompanying consolidated financial statements. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 12. Commitments and contingencies&lt;/div&gt;&lt;/div&gt; for further information. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimates the amount of returns and reduces revenue in the period the related product revenue is recognized. The Company records a liability for expected returns based on probability-weighted historical data. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts receivable, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for doubtful accounts. The Company maintains an estimated allowance for doubtful accounts to provide for receivables the Company does not expect to collect. The Company bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. &lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <bvs:ContractAssetsPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets consist of unbilled amounts resulting from estimated future royalties from an international distributor that exceeds the amount billed. Contract assets totaling $81 and $261 as of December&#160;31, 2020 and 2019, are included in prepaid and other current assets on the consolidated balance sheets, respectively. &lt;/div&gt;&lt;/div&gt;</bvs:ContractAssetsPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">81000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">261000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <bvs:ContractLiabilitiesPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities consist of customer advance payments and deferred revenue. Occasionally for certain international customers, the Company requires payments in advance of shipping product and recognizing revenue resulting in contract liabilities. Contract liabilities were nominal as of December&#160;31, 2020 and 2019 and are included in accrued liabilities on the consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;</bvs:ContractLiabilitiesPolicyTextBlock>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Shipping and handling &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other distribution costs are included in cost of sales. The &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company has elected to recognize shipping and handling activities that occur after control of the related product transfers to the customer as fulfillment costs and these are included in&lt;div style="display:inline;"&gt; cost&lt;/div&gt; of sales.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <bvs:ContractCostsPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies the practical expedient of recognizing the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less. These incremental costs include the Company&#x2019;s sales incentive programs for the internal sales force and third-party sales agents as the compensation is commensurate with annual sales activities. These costs are included in selling, general and administrative expense on the consolidated statements of operations and comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;</bvs:ContractCostsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company values its inventory at the lower of cost or net realizable value and adjusts for the value of inventory that is estimated to be excess, obsolete or otherwise unmarketable. Cost is determined using the first-in, first-out (FIFO) method. Elements of cost in inventory include raw materials, direct labor, manufacturing overhead and inbound freight. The Company records allowances for excess and obsolete inventory based on historical and estimated future demand and market conditions. &lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Business combinations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting for acquisitions requires the Company to recognize separately from goodwill assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While best estimates and assumptions are used to accurately value assets acquired and liabilities assumed at the acquisition date, as well as contingent consideration where applicable, estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations and comprehensive income (loss). Subsequent changes in the estimated fair value of contingent&lt;div style="display:inline;"&gt; considerat&lt;/div&gt;ion are recognized in earnings in the period of change. &lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense are recognized using the straight-line method over the estimated useful life of each asset, or the shorter of the lease term or useful life if related to leasehold improvements. The useful lives in years are as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 91%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer software and hardware&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3-5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Machinery and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bvs:PropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">The useful lives in years are as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 91%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer software and hardware&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3-5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Machinery and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bvs:PropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">3</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">5</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">7</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">7</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">7</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and intangible assets&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;Fini&lt;/div&gt;te-lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight-line method over their estimated useful lives in years are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Useful&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Developed technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is not amortized but is evaluated for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. The Company reviews goodwill for impairment by applying a quantitative impairment analysis where the fair value of the reporting unit is compared with the carrying value, including goodwill. The Company determines the fair value of each reporting unit based on an income approach. The value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company performs its annual goodwill impairment test on October&#160;31st. If the fair value of the reporting unit is less than its carrying value, the Company will recognize the difference as an impairment loss, which is limited to the amount of goodwill allocated to the reporting units. There were no goodwill impairment charges for the years ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;Fini&lt;/div&gt;te-lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight-line method over their estimated useful lives in years are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Useful&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Developed technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis">P17Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis">P12Y8M12D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis">P8Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Software development costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company capitalizes internal and external costs incurred to develop internal-use software during the application development stage for software design, configuration, coding and testing upon placing the asset in service and then amortizes these costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. The Company does not capitalize costs that are precluded from capitalization in authoritative guidance, such as preliminary project phase costs, training costs or data conversion costs. Capitalized software costs totaled $17,653 and $14,119 as of December&#160;31, 2020 and 2019 and the related accumulated amortization totaled $13,264 and $12,184, respectively. Amortization expense was $1,184, $1,138 and $1,204 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying values of property, equipment, intangible assets as well as other long-lived and indefinite lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable the Company will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. If quoted market prices are not available, the Company estimates fair value using an undiscounted value of estimated future cash flows. During 2018, the Company determined that it would no longer sell a specific BGS product and as a result, an intangible asset related to this product was fully written off and the Company recognized impairment charges of $489 for the year ended December&#160;31, 2018, which is included in the consolidated statements of operations and comprehensive income (loss). Upon retirement or sale of property and equipment, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is included in income from operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#x2019;s property, equipment, intangible or other long-lived assets. &lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">17653000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14119000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">13264000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">12184000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1184000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1138000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1204000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">489000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired in-process research and development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of in-process research and development (IPR&amp;amp;D) assets acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets and are not amortized until development is completed and the product is available for sale. Once the product is available for sale, the asset is transferred to developed technology and amortized over its estimated useful life. Impairment tests for IPR&amp;amp;D assets occur at least annually in December, or more frequently if events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than the carrying amount, an impairment loss is recognized for the difference. There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#x2019;s IPR&amp;amp;D. &lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred offering costs, consisting of legal, accounting, filing and other fees related to the initial public offering, are capitalized. The deferred offering costs will be offset against proceeds from the initial public offering upon the effectiveness of the initial public offering. In the event the initial public offering is terminated, all capitalized deferred offering costs would be expensed. Deferred offering costs capitalized totaled $2,187 as of December&#160;31, 2020 and there were there were no deferred offering costs capitalized as of December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt;</us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2187000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company provides credit, in the normal course of business, to its customers. The Company does not require collateral or other securities to support customer receivables. Credit losses are provided for through allowances and have historically been materially within management&#x2019;s estimates. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable to these significant suppliers at December&#160;31 were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,983&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,586&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain products provide the Company with a significant percentage of total sales for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable to these significant suppliers at December&#160;31 were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,983&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,586&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplier C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain products provide the Company with a significant percentage of total sales for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product A&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2983000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2019_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3586000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">471000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2019_SupplierBMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">697000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2019_SupplierCMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">360000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductAMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductBMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductCMemberBVSConcentrationRiskBySupplierNameAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ProductDMemberBVSConcentrationRiskBySupplierNameAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has restructured portions of its operations and future restructuring activities are possible. Identifying and calculating the cost to exit these operations requires certain assumptions to be made, the most significant of which are anticipated future liabilities. Although estimates have been reasonably accurate in the past, significant judgment is required, and these estimates and assumptions may change as additional information becomes available and facts or circumstances change. Restructuring costs are recorded at estimated fair value. Key assumptions in determining the restructuring costs include negotiated terms and payments to terminate contractual obligations. &lt;/div&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profits interest compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures profits interest compensation cost at the grant date based on the fair value of the award and recognizes this cost as compensation expense over the required or estimated service period for awards expected to vest. Certain awards are liability-classified, which require they be remeasured at each reporting date. Compensation expense is included in Selling, general and administrative expense and Research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employees who were granted the awards. &lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advertising costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advertising costs include costs incurred to promote the Company&#x2019;s business and are expensed as incurred. Advertising costs were $2,769, $2,351 and $2,916 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2769000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2351000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2916000</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expense consist primarily of employee compensation and related expenses as well as contract research organization services. Internal research and development costs are expensed as incurred. Research and development costs incurred by third parties are expensed as the contracted work is performed. &lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaborative agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and we account for these alliances as a collaborative arrangement by reporting costs incurred from transactions within research and development expense in our consolidated statements of operations. &lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. Legal fees expected to be incurred in connection with a loss contingency are not included in the estimated loss contingency. The Company accrues for any legal costs as they are incurred. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is treated as a partnership for U.S. tax purposes. Accordingly, the profits and losses are passed through to the members and included in their income tax returns. The Company has been required to make tax &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;distributions to its members in an amount equal to 40% of the members&#x2019; taxable income attributable to their ownership. The tax rate applied for purposes of this distribution may be changed only by approval of the Company&#x2019;s Board of Managers. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain wholly owned subsidiaries of the Company are taxable entities for U.S. or foreign tax purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred tax assets to an amount which will, more likely than not, be realized. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes a tax benefit from any uncertain tax positions only if they are more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. Components of the reserve, if relevant, are classified as a current or noncurrent liability in the consolidated balance sheet based on when the Company expects each of the items to be settled. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <bvs:PercentageOfMembersTaxDistributionToTaxableIncome
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</bvs:PercentageOfMembersTaxDistributionToTaxableIncome>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per common unit &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic income (loss) per common unit is determined by dividing the net income (loss) allocable to common unit holders by the weighted average number of common units outstanding during the periods presented. Diluted loss per common unit is computed by dividing the net income (loss) allocable to common unit holders on an &#x201c;if converted&#x201d; basis by the weighted average number of actual common units outstanding and, when dilutive, the unit equivalents that would arise from the assumed conversion of convertible instruments, if any. &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has considered the effects of subsequent events through March&#160;26, 2021, the date the Company&#x2019;s consolidated financial statements were issued. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Balance sheet information&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net of allowances, consisted of the following as of December&#160;31: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85,128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to make required payments. The allowance for credit losses is calculated by region and by customer type, where appropriate considering several factors including age of accounts, collection history, historical account write-offs, current economic conditions, and supportable forecasted economic expectations. Due to the short-term nature of its receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. An increase in the provision for credit losses may be required when the financial condition of the Company&#x2019;s customers or its collection experience deteriorates. The Company &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;has a diverse customer base with no single customer representing ten percent of sales or accounts receivable. Historically, the Company&#x2019;s reserves have been adequate to cover credit losses. The Company&#x2019;s exposure to credit losses may increase if its customers are adversely affected by changes in health care laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic, or other customer-specific factors. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Estimates are used to determine the allowance, which are based on an assessment of anticipated payment and all other historical, current and future information that is reasonably available.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in credit losses were as follows for the years ended December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write-offs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,787&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recoveries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(416&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(356&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory consisted of the following as of December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished goods&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,509&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Excess and obsolete reserves&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in excess and obsolete reserves for inventory were as follows for the years ended December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision for losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write-offs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consisted of the following as of December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Machinery and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets not yet placed in service&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,731&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,879&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense was $2,106, $2,579 and $3,439 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and intangible assets, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no changes to goodwill during the years ended December&#160;31, 2020 and 2019. Following is a summary of goodwill by reportable segment: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; width: 685.438px; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 368.188px;"/&gt;
&lt;td style="vertical-align: bottom; width: 43.4062px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align: bottom; width: 43.4062px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align: bottom; width: 43.4375px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020 and 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;41,040&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;8,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;49,800&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets consisted of the following as of December&#160;31:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="color: rgb(0, 0, 0); font-family: Century; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Century; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 433.797px;"/&gt;
&lt;td style="vertical-align: bottom; width: 37.1719px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align: bottom; width: 37.1875px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;263,422&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;263,422&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution rights&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;60,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;59,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,445&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,095&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Developed technology and other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,999&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,649&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;397,266&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;396,566&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less accumulated amortization:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(117,281&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100,982&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution rights&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34,461&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28,716&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(51,247&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(46,407&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Developed technology and other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,786&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,404&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(206,775&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(179,509&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net before currency translation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;190,491&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;217,057&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,159&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(547&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;191,650&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;216,510&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company filed a 510(k) in 2019 and began commercializing a next-generation surgical product in the third quarter of 2020. As a result, $9,650 of IPR&amp;amp;D was reclassified to developed technology and will be amortized over 10 years. On December&#160;22, 2020, the Company entered into an amended and restated distribution agreement with the sole supplier of the Company&#x2019;s five injection OA product.&#160;This agreement provided non-exclusive U.S. market&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;distribution rights until December&#160;31, 2028. The amended and restated distribution agreement created a $1,000 distribution right that will be amortized over 8 years, which was capitalized as an intangible asset and included in &lt;div style="display:inline;"&gt;accrued&lt;/div&gt; liabilities on the consolidated balance sheets as of December&#160;31, 2020.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization expense related to intangible assets was $27,565, $26,252 and $26,622 for the years ended December&#160;31, 2020, 2019 and 2018 of which $7,455, $6,416 and $7,766 are included in ending inventory at December&#160;31, 2020, 2019 and 2018, respectively. Estimated amortization expense for the years ended December&#160;31, 2021 through 2025 is expected to be $28,262, $23,910, $22,297, $22,297 and $21,259, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consisted of the following at December&#160;31: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross-to-net deductions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,656&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,622&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonus and commission&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reserve for estimated overpayments from third-party payers&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,801&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income and other taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,434&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,244&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,418&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52,827&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net of allowances, consisted of the following as of December&#160;31: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85,128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net of allowances, consisted of the following as of December&#160;31: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85,128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">92273000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">89274000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3990000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4146000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">88283000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">85128000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in credit losses were as follows for the years ended December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write-offs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,787&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recoveries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(416&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(356&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4146000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2018_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4497000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1215000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2242000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1787000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2949000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">416000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">356000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3990000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4146000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory consisted of the following as of December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished goods&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,509&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,858&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Excess and obsolete reserves&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3665000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3349000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">26323000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">24509000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">29988000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">27858000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">868000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">532000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">29120000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">27326000</us-gaap:InventoryNet>
    <bvs:ScheduleOfInventoryValuationReservesTableTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in excess and obsolete reserves for inventory were as follows for the years ended December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance, beginning of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision for losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write-offs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;568&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </bvs:ScheduleOfInventoryValuationReservesTableTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">532000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2018_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">570000</us-gaap:InventoryValuationReserves>
    <bvs:InventoryValuationReservesProvisionForLosses
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-904000</bvs:InventoryValuationReservesProvisionForLosses>
    <bvs:InventoryValuationReservesProvisionForLosses
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-870000</bvs:InventoryValuationReservesProvisionForLosses>
    <bvs:InventoryValuationReservesWriteOffs
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">568000</bvs:InventoryValuationReservesWriteOffs>
    <bvs:InventoryValuationReservesWriteOffs
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">908000</bvs:InventoryValuationReservesWriteOffs>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">868000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">532000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consisted of the following as of December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Machinery and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets not yet placed in service&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,731&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,879&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">20547000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_ComputerEquipmentAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">16854000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3126000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2918000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1474000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1451000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1234000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1138000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_AssetUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">819000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_AssetUnderConstructionMemberusgaapPropertyPlantAndEquipmentByTypeAxis_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">370000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">27200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">22731000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">20321000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">18242000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6879000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4489000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2106000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2579000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2018To12_31_2018_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3439000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no changes to goodwill during the years ended December&#160;31, 2020 and 2019. Following is a summary of goodwill by reportable segment: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; width: 685.438px; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 368.188px;"/&gt;
&lt;td style="vertical-align: bottom; width: 43.4062px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align: bottom; width: 43.4062px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align: bottom; width: 43.4375px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consolidated&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020 and 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;41,040&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;8,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;49,800&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="P01_01_2019To12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">41040000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">41040000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">8760000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">8760000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">49800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">49800000</us-gaap:Goodwill>
    <bvs:ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets consisted of the following as of December&#160;31:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="color: rgb(0, 0, 0); font-family: Century; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Century; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 433.797px;"/&gt;
&lt;td style="vertical-align: bottom; width: 37.1719px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align: bottom; width: 37.1875px;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;263,422&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;263,422&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution rights&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;60,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;59,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;57,700&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,445&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,095&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Developed technology and other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,999&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,649&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;397,266&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;396,566&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less accumulated amortization:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(117,281&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(100,982&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution rights&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(34,461&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28,716&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(51,247&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(46,407&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Developed technology and other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,786&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,404&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(206,775&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(179,509&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net before currency translation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;190,491&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;217,057&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency translation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,159&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(547&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;191,650&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;216,510&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </bvs:ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">263422000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">263422000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">60700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">59700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">57700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">57700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="PAsOn12_31_2020_AcquiredInProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1445000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="PAsOn12_31_2019_AcquiredInProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">11095000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">13999000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4649000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">397266000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">396566000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">117281000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">100982000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">34461000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">28716000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">51247000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">46407000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3786000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3404000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">206775000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">179509000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <bvs:IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">190491000</bvs:IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation>
    <bvs:IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">217057000</bvs:IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation>
    <bvs:FiniteLivedIntangibleAssetsCurrencyTranslation
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1159000</bvs:FiniteLivedIntangibleAssetsCurrencyTranslation>
    <bvs:FiniteLivedIntangibleAssetsCurrencyTranslation
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">547000</bvs:FiniteLivedIntangibleAssetsCurrencyTranslation>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">191650000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2019_BioventusIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">216510000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ReclassificationOfIprdMemberBVSEventAxis"
      decimals="-3"
      unitRef="Unit_USD">9650000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ReclassificationOfIprdMemberBVSEventAxis">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="P01_01_2020To12_31_2020_AccountsPayableMemberusgaapBalanceSheetLocationAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P01_01_2020To12_31_2020_AccountsPayableMemberusgaapBalanceSheetLocationAxis_DistributionRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P8Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27565000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">26252000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">26622000</us-gaap:AmortizationOfIntangibleAssets>
    <bvs:AmortizationExpenseIncludedInInventory
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7455000</bvs:AmortizationExpenseIncludedInInventory>
    <bvs:AmortizationExpenseIncludedInInventory
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6416000</bvs:AmortizationExpenseIncludedInInventory>
    <bvs:AmortizationExpenseIncludedInInventory
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">7766000</bvs:AmortizationExpenseIncludedInInventory>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28262000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23910000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22297000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22297000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21259000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consisted of the following at December&#160;31: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross-to-net deductions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,656&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,622&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonus and commission&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reserve for estimated overpayments from third-party payers&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,801&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income and other taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,434&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,244&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,418&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52,827&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bvs:GrossToNetDeductionsCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">43656000</bvs:GrossToNetDeductionsCurrent>
    <bvs:GrossToNetDeductionsCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14622000</bvs:GrossToNetDeductionsCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15188000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14200000</us-gaap:AccruedBonusesCurrent>
    <bvs:ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2790000</bvs:ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent>
    <bvs:ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6801000</bvs:ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent>
    <bvs:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5875000</bvs:AccruedSalariesAndEmployeeBenefitsCurrent>
    <bvs:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3231000</bvs:AccruedSalariesAndEmployeeBenefitsCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2434000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2555000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">18244000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">11418000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">88187000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">52827000</us-gaap:AccruedLiabilitiesCurrent>
    <bvs:BusinessCombinationsAndInvestmentsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Business combinations and investments&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;VIE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;23, 2019, the Company purchased 285,714 shares of Harbor&#x2019;s Series C Preferred Stock or 3.1% of fully diluted shares for $1,000. The Company and Harbor entered into an exclusive collaboration agreement for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. As a result of these transactions, the Company determined that it had a variable interest in Harbor. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounted for the Harbor investment as a business combination using the acquisition method of accounting whereby the total purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The results of Harbor operations have been included in the accompanying consolidated financial statements subsequent to acquisition date. The Company did not disclose post-acquisition or pro forma losses attributable to Harbor as they did not have a material effect on the Company&#x2019;s consolidated statements of operations and comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,430&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property (10-year useful life)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,445&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value of net assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bioventus purchase price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Harbor&#x2019;s noncontrolling interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;27, 2020 two convertible promissory notes to Harbor shareholders totaling $500 were converted into 142,858 of Harbor Series C Preferred Stock and warrants for 428,572 shares of the Harbor common stock exercisable at a price of $1.167 per share with a 5-year exercise period expiring March 27, 2025. Promissory notes of $320 owed to a certain Harbor shareholder were converted into 92,500 of Harbor Series C Preferred Stock at $3.50 per share in November 2020. On October&#160;5, 2020, the Company purchased an additional 285,714 shares of Harbor&#x2019;s Series C Preferred Stock for $1,000. The Company continues to conclude that it is the primary beneficiary since it controls the significant activities of Harbor through the collaboration agreement. The noncontrolling interest related to Harbor was 91.2% as of December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Harbor intellectual property and IPR&amp;amp;D was determined using the income approach through an excess earnings analysis, with projected earnings discounted at a rate of 16.5%. The $1,445 of IPR&amp;amp;D consists of research and development progress toward developing a product for orthopedic uses. The fair value of the noncontrolling interest was calculated as estimated fair value of net assets acquired less the Company&#x2019;s purchase price. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harbor assets that can only be used to settle Harbor obligations and Harbor liabilities for which creditors do not have recourse to the general credit of the Company are as follows for the years ended December&#160;31: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,863&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;458&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nearly all the liabilities assumed are payable to Harbor shareholders. As of December&#160;31, 2019, other current liabilities primarily consisted of $1,845 in promissory notes to various Harbor shareholders and were scheduled &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;to mature on August 31, 2020. These promissory notes were refinanced with additional borrowings in August 2020 and total $1,811 as of December&#160;31, 2020. The Harbor promissory notes carry an 8% interest rate and are due on August 31, 2021 with payments due monthly. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity Method &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in which the Company can exercise significance influence, but do not control, are recorded under the equity method of accounting and are included in investments and other assets on the consolidated balance sheets. The Company&#x2019;s share of net earnings or losses is included in other (income) loss within the consolidated statements of operations and comprehensive income (loss) on a quarter lag. The Company evaluates investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired. Impairment losses are recorded within earnings within the current period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;30, 2018, the Company purchased 337,397 shares of CartiHeal, a privately held entity, Series F Convertible Preferred Stock or 2.8% of fully diluted shares for $2,500 in cash. The investment does not have a readily determinable fair value. On January&#160;22, 2020, the Company made an additional investment in CartiHeal, through a Simple Agreement for Future Equity (SAFE) by paying cash of $152. On July&#160;15, 2020, CartiHeal completed an equity financing that the Company participated in and as a result, the Company received 12,825 in Series G-1 Preferred Shares and the SAFE terminated. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, on July&#160;15, 2020, the Company entered into an Option and Equity Purchase Agreement with CartiHeal. Under the terms of the agreement, the Company purchased 1,014,267 shares of CartiHeal Series G Preferred Shares for $15,000. As a result, the Company&#x2019;s equity ownership in CartiHeal increased to 10.03% of its fully diluted shares. The CartiHeal investment, included capitalized transaction costs of $1,427 and the $152 investment in January 2020, totaling $16,579 was recorded as an equity method investment beginning in July 2020, as the Company can exercise significant influence over CartiHeal but does not have control. It is included within investments and other assets on the consolidated balance sheet. The CartiHeal investment carrying value is $18,689 as of December&#160;31, 2020, after recording net losses of $467 incurred during 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will, if needed, purchase an additional 338,089 of CartiHeal Series G Preferred Shares for $5,000, for the completion of a certain study. The Company has an exclusive option to acquire the remaining equity in CartiHeal, which may be exercised at any time up to and within 45 days following notice of the U.S. Food and Drug Administration (FDA) approval for a CartiHeal product currently in development. In addition, upon the same FDA approval, CartiHeal may exercise an option within 45 days that requires the Company to complete the acquisition of the remaining equity in CartiHeal. &lt;/div&gt;&lt;/div&gt;</bvs:BusinessCombinationsAndInvestmentsDisclosureTextBlock>
    <bvs:VariableInterestEntitySharesIssuedDuringPeriod
      contextRef="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="0"
      unitRef="Unit_shares">285714</bvs:VariableInterestEntitySharesIssuedDuringPeriod>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="3"
      unitRef="Unit_pure">0.031</us-gaap:VariableInterestEntityOwnershipPercentage>
    <bvs:VariableInterestEntityIssuedCost
      contextRef="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</bvs:VariableInterestEntityIssuedCost>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,430&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property (10-year useful life)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,445&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value of net assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bioventus purchase price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of Harbor&#x2019;s noncontrolling interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">1430000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">4834000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">1445000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">70000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">932000</bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">1696000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">697000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">266000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">4188000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P01_01_2020To12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">3188000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_HarborMedtechIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:Goodwill>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="0"
      unitRef="Unit_shares">142858</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborCommonStockMemberusgaapStatementEquityComponentsAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis"
      decimals="0"
      unitRef="Unit_shares">428572</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <bvs:DebtInstrumentConvertibleConversionExercisablePrice
      contextRef="PAsOn03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">1.167</bvs:DebtInstrumentConvertibleConversionExercisablePrice>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P03_27_2020To03_27_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">2025-03-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">320000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P11_30_2020To11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="0"
      unitRef="Unit_shares">92500</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn11_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P10_05_2020To10_05_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="0"
      unitRef="Unit_shares">285714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P10_05_2020To10_05_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.912</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <bvs:FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.165</bvs:FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1445000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harbor assets that can only be used to settle Harbor obligations and Harbor liabilities for which creditors do not have recourse to the general credit of the Company are as follows for the years ended December&#160;31: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,863&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,599&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;458&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">803000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">1127000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">173000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">60000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">5635000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">6122000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">231000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">59000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">6863000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">7599000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">366000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">458000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">2004000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">2395000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">215000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">659000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">872000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">3029000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">3940000</us-gaap:Liabilities>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">1845000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">2020-08-31</us-gaap:DebtInstrumentMaturityDate>
    <bvs:DebtInstrumentRefinancedWithAdditionalBorrowingsAmount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">1811000</bvs:DebtInstrumentRefinancedWithAdditionalBorrowingsAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">2021-08-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PromissoryNoteMemberusgaapDebtInstrumentAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions
      contextRef="P01_30_2018To01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">337397</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.028</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="PAsOn01_30_2018_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_USD">2500000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="P01_22_2020To01_22_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SimpleAgreementForFutureEquityMemberBVSAgreementForFutureEquityAxis"
      decimals="-3"
      unitRef="Unit_USD">152000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions
      contextRef="P07_15_2020To07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesG1PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">12825</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions>
    <bvs:EquityMethodInvestmentAdditionalInvestmentPurchasedShares
      contextRef="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1014267</bvs:EquityMethodInvestmentAdditionalInvestmentPurchasedShares>
    <bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue
      contextRef="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
      contextRef="P07_15_2020To07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_OptionAndEquityPurchaseAgreementMemberBVSAgreementAxis"
      decimals="4"
      unitRef="Unit_pure">0.1003</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
    <bvs:EquityMethodInvestmentCapitalizedTransactionCosts
      contextRef="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1427000</bvs:EquityMethodInvestmentCapitalizedTransactionCosts>
    <bvs:EquityMethodInvestmentCapitalizedTransactionCosts
      contextRef="PAsOn01_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_USD">152000</bvs:EquityMethodInvestmentCapitalizedTransactionCosts>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn07_15_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_USD">16579000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_USD">18689000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_USD">-467000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">338089</bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares>
    <bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">5000000</bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount>
    <bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">P45D</bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment>
    <bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_CartiHealLtdMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">P45D</bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Financial instruments&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 Credit Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;6, 2019, the Company entered into a $250,000 credit and guaranty agreement (2019 Credit Agreement) with Wells Fargo Bank National Association (Wells), as well as a syndicate of other banks, or Lenders. The 2019 Credit Agreement is comprised of a $200,000 term loan (Term Loan), with an original issue discount (OID) of $666, and a $50,000 revolving facility (Revolver). All obligations under the 2019 Credit Agreement are guaranteed by the Company and certain of the Company&#x2019;s wholly owned subsidiaries. Substantially all the assets of the Company collateralize the obligations under the 2019 Credit Agreement. The Term Loan and Revolver mature on December 6, 2024 (Maturity). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Term Loan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, $188,378 was outstanding on the Term Loan, net of original issue discount of $524 and deferred financing costs of $1,098. As of December&#160;31, 2020, the Term Loan interest rate including a margin of 2.25% was 2.40%. Scheduled quarterly principal payments are as follows with the final payment of $125,000 at Maturity:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quarterly&lt;br/&gt;payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 and 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 and 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may voluntarily prepay the Term Loan without premium or penalty upon prior notice. The Company may be required to make additional principal payments on the Term Loan dependent upon the generation of certain cash flow events as defined in the 2019 Credit Agreement. These additional prepayments will be applied to the scheduled installments of principal in direct order of maturity of the Base Rate (BR) portions of the Term Loan first and then the Eurodollar portions of the Term Loan. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The estimated fair value of the Term Loan as of December&#160;31, 2020 was $189,534. The fair value of these obligations was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar obligations and are classified as Level 2 instruments within the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revolver &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Revolver is a five-year revolving credit facility of $50,000 which includes revolving and swingline loans as well as letters of credit (LOC) and, inclusive of all, cannot exceed $50,000 at any one time. LOCs are available in an amount not to exceed $7,500. Revolving loans are due at the earlier of termination or Maturity. Swingline loans are available as BR interest rate option loans only and must be outstanding for at least five days. Swingline loans are due the &lt;span style="-sec-ix-hidden:hidden26390228"&gt;fifteenth&lt;/span&gt; or last day of a calendar month or Maturity whichever is earlier. The Company had increased its cash position by borrowing $49,000 on its Revolver as a precautionary measure to preserve financial flexibility in view of the current uncertainty resulting from the COVID-19 pandemic during the first quarter of 2020. The $49,000 was repaid during the third quarter of 2020. As of December&#160;31, 2020, there was one nominal LOC outstanding leaving approximately $49,912 available. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Term Loan and Revolver permits the Company to elect either Eurodollar or BR interest rate options for the entire amount or certain portions of the loans and have interest rates equal to a formula driven base interest rate plus a margin, tied to a leverage ratio. The leverage ratio is the ratio of debt to consolidated EBITDA as defined in the 2019 Credit Agreement, or Bank EBITDA, for four consecutive quarters at the end of each period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BR portions of the Term Loan have interest due the last day of each calendar quarter-end. Eurodollar portions of the Term Loan have one, two, three or six-month interest reset periods and interest is due on the last day of each three-month period or the last day of the loan term if less than three months. In advance of the last day of the current Eurodollar Loan, the Company may select a new loan type so long as it does not extend beyond Maturity. The outstanding Term Loan has been a Eurodollar Loan since inception and is an auto-renewing one-month loan for setting an interest rate. In addition, the Term Loan has an interest due date concurrent with any scheduled principal repayment or prepayment. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest is calculated based on a 360-day year except for BR loans where the base interest is the Wells Prime Rate, in which case it is calculated based on a calendar-day year. The base interest rate for all BR loans is equal to the highest of (a)&#160;the Wells Prime Rate, (b)&#160;the greater of the Federal Funds Effective Rate or Overnight Bank &lt;/div&gt;&lt;/div&gt;Funding Rate plus &lt;span style="-sec-ix-hidden:hidden26390186"&gt;1/2&lt;/span&gt;% and (c)&#160;the Eurodollar Rate for a USD deposit with a maturity of one month plus 1.0%. The base interest rate for all Eurodollar Loans is equal to the rate determined for such day in accordance with the following formula with the Term Loan having a floor of 0%: &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;LIBOR &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&#x2014;Eurocurrency Reserve Requirements &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pricing grids are used to determine the loan margins based on the type of loan and the leverage ratio. The initial Eurodollar and BR loans had a margin of 2.25% and 1.25%, respectively. Loan margin is adjusted after the quarterly financial statements are delivered to the lenders in accordance with the pricing grid below: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leverage ratio&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Eurodollar&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;BR&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 2.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt;1.50 to 1.00 and &amp;lt; 2.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 1.25 to 1.00 and &amp;lt;1.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 0.75 to 1.00 and &amp;lt;1.25 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;lt; 0.75 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Revolver includes a commitment fee at 0.25% of the average daily amount of the available revolving commitment, assuming any swingline loans outstanding are $0. There were no swingline loans outstanding as of December&#160;31, 2020. The fee is payable quarterly in arrears on the last day of the calendar quarters and at Maturity. The commitment fee rate is adjusted after the quarterly financial statements are delivered to lenders based on the pricing grid below: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leverage ratio&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commitment&lt;br/&gt;fee&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 2.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt;1.50 to 1.00 and &amp;lt; 2.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 1.25 to 1.00 and &amp;lt;1.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 0.75 to 1.00 and &amp;lt;1.25 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;lt; 0.75 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fees are charged on all outstanding LOCs at an annual rate equal to the margin in effect on Eurodollar revolving loans. A fronting fee of 0.125%&#160;per year on the undrawn and unexpired amount of each LOC is payable as well. The fees are payable quarterly in arrears on the last day of the calendar quarters. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the Company&#x2019;s effective weighted average interest rate on all outstanding debt, including the commitment fee and interest rate swap, was 2.72%. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of the Company&#x2019;s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of Company assets, as well as limitations on making changes to the Company&#x2019;s business and organizational documents. Financial covenant requirements include a maximum debt leverage ratio as well as an interest coverage ratio not less than 3.00 to 1.00 as defined in the 2019 Credit Agreement. As of December&#160;31, 2020, the Company complied with the financial covenants in the 2019 Credit Agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each Lender may provide an additional Term or Revolving Loan by executing and delivering notice specifying the terms, if doing so would not cause certain undesired events to occur as defined in the 2019 Credit Agreement &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;or extend repayment beyond Maturity. The aggregate amount of all additional borrowings may not exceed the greater of $100,000 and the trailing four quarters Bank EBITDA without the consent of the Lenders holding more than 50% of the total outstanding debt under the 2019 Credit Agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financing costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During December 2019, the Company paid financing costs totaling $2,117 in order to refinance our prior term loan facility, that was repaid in full (Prior Credit Agreement). The Company recorded $269 directly to selling, general and administrative expense and the remaining $1,848 was capitalized to the consolidated balance sheet. One lender participating in the Prior Credit Agreement became a lender in the 2019 Credit Agreement and, as a result, $2,985 related to the Prior Credit Agreement was written off and recorded as interest expense. The $269 recorded in selling, general and administrative expense and the $2,985 recorded in interest expense total the $3,252 of loss on debt retirement and modification. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total capitalized deferred fees for the Term Loan of $1,398 and Revolver of $653 are being amortized to interest expense on a straight-line basis over each of the respective lives, which approximates the effective interest method. The Company recorded $543, $711 and $745 in interest expense associated with these deferred costs for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual maturities of long-term debt as of December&#160;31, 2020, were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;140,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025 and thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred financing costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Original issue discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total long-term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;188,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company enters into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. On March&#160;26, 2020, the Company entered an interest rate swap agreement with one of its Lenders, which expires in December 2024. The interest rate swap was not designated as a hedge. The Company has no other active derivatives and the swap is carried at fair value on the balance sheet. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note&#160;7. Fair value measurements&lt;/div&gt;&lt;/div&gt; for further details regarding the Company&#x2019;s interest rate swap. There were no outstanding derivatives as of December&#160;31, 2019. Interest expense of $1,599 was recorded within the consolidated statements of operations and comprehensive income (loss) related to the change in fair value of the swap for the year ended December&#160;31, 2020. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The notional value of the swap totaled $100,000 or 52.6%, of the Term Loan outstanding principal at December&#160;31, 2020. The swap locked in the variable portion of the interest rate on the $100,000 notional at 0.64%, with a stated fixed rate of 2.25%. The effective interest rate of the swap was 2.89% as of December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">666000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">2024-12-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">188378000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">524000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">1098000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="4"
      unitRef="Unit_pure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="4"
      unitRef="Unit_pure">0.0240</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <bvs:ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">Scheduled quarterly principal payments are as follows with the final payment of $125,000 at Maturity:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quarterly&lt;br/&gt;payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 and 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 and 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;</bvs:ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock>
    <bvs:DebtInstrumentFinalPrincipalPaymentAtMaturity
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">125000000</bvs:DebtInstrumentFinalPrincipalPaymentAtMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodOneMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3750000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">189534000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_LetterOfCreditMemberBVSRevolvingCreditFacilitySubAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">7500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityDescription contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">outstanding for at least five days. Swingline loans are due the fifteenth or last day of a calendar month or Maturity whichever is earlier</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis">P5D</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">49000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P07_01_2020To09_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">49000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">49912000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_BrInterestRateBasisMemberBVSInterestRateBasisAxis_EurodollarMemberusgaapVariableRateAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="3"
      unitRef="Unit_pure">0.010</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <bvs:DebtInstrumentFloorRatePercentage
      contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_BrInterestRateBasisMemberBVSInterestRateBasisAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">0</bvs:DebtInstrumentFloorRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P12_06_2019To12_06_2019_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="4"
      unitRef="Unit_pure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P12_06_2019To12_06_2019_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="4"
      unitRef="Unit_pure">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bvs:ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">Loan margin is adjusted after the quarterly financial statements are delivered to the lenders in accordance with the pricing grid below: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leverage ratio&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Eurodollar&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;BR&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 2.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt;1.50 to 1.00 and &amp;lt; 2.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 1.25 to 1.00 and &amp;lt;1.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 0.75 to 1.00 and &amp;lt;1.25 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;lt; 0.75 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </bvs:ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P01_01_2020To12_31_2020_BaseRateMemberusgaapVariableRateAxis_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCredit
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SwingLineCreditFacilityMemberBVSRevolvingCreditFacilitySubAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LineOfCredit>
    <bvs:ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">The commitment fee rate is adjusted after the quarterly financial statements are delivered to lenders based on the pricing grid below:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leverage ratio&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commitment&lt;br/&gt;fee&#160;rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 2.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt;1.50 to 1.00 and &amp;lt; 2.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 1.25 to 1.00 and &amp;lt;1.50 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;gt; 0.75 to 1.00 and &amp;lt;1.25 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;lt; 0.75 to 1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </bvs:ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeTwoMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeThreeMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFourMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeFiveMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0010</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <bvs:FrontingFeePercentageOnUndrawnAmount
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="5"
      unitRef="Unit_pure">0.00125</bvs:FrontingFeePercentageOnUndrawnAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="4"
      unitRef="Unit_pure">0.0272</us-gaap:DebtWeightedAverageInterestRate>
    <bvs:InterestCoverageRatio
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">3.00</bvs:InterestCoverageRatio>
    <bvs:ThresholdMaximumAggregateAdditionalBorrowings
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">100000000</bvs:ThresholdMaximumAggregateAdditionalBorrowings>
    <bvs:PercentageOfTotalOutstandingDebtLoanedByLenders
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</bvs:PercentageOfTotalOutstandingDebtLoanedByLenders>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">2117000</us-gaap:PaymentsOfFinancingCosts>
    <bvs:DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">269000</bvs:DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing>
    <us-gaap:InterestCostsCapitalized
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">1848000</us-gaap:InterestCostsCapitalized>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">2985000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">2985000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PriorCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">3252000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TermLoanMemberusgaapLongtermDebtTypeAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">1398000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TwoThousandNineteenCreditAgreementMemberBVSCreditAgreementAxis"
      decimals="-3"
      unitRef="Unit_USD">653000</us-gaap:DebtInstrumentFeeAmount>
    <bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">543000</bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees>
    <bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">711000</bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees>
    <bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">745000</bvs:AmortizationOfDebtInstrumentCapitalizedDeferredFees>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual maturities of long-term debt as of December&#160;31, 2020, were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;140,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025 and thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred financing costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Original issue discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total long-term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;188,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">140000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturingInYearsFourAndFive
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturingInYearsFourAndFive>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1098000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">524000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">188378000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">173378000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">1599000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:PercentageOfDebtHedgedByInterestRateDerivatives
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="3"
      unitRef="Unit_pure">0.526</us-gaap:PercentageOfDebtHedgedByInterestRateDerivatives>
    <us-gaap:DerivativeNotionalAmount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0064</us-gaap:DerivativeFixedInterestRate>
    <bvs:DerivativeStatedFixedInterestRate
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0225</bvs:DerivativeStatedFixedInterestRate>
    <bvs:DerivativeEffectiveInterestRate
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0289</bvs:DerivativeEffectiveInterestRate>
    <us-gaap:MembersEquityNotesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;6. Members&#x2019; equity &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Members&#x2019; equity consisted of the following at December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Preferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;113,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;113,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Profits interest and other equity awards (Refer to&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Note 9. Equity-based compensation&lt;/div&gt;&lt;/div&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;285,173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;285,147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The authorized number of common and preferred units were unlimited. On May&#160;4, 2012, 4,900,000 common units and 5,100,000 preferred units (2012 Preferred Units) were issued. During November 2015, the Company obtained a $50,000 capital contribution from its existing members and 1,490,000 in preferred units were issued (2015 Preferred Units). The common and preferred members have stated rights and privileges, which include, but are not limited to: (1)&#160;voting and Company governance, (2)&#160;the transfer of membership interests and (3)&#160;dissolution and liquidation of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Each preferred unit carried a priority payout (Liquidation Preference), as defined in the Company&#x2019;s limited liability company agreement in effect at December&#160;31, 2020. The initial Liquidation Preference for the 2012 and 2015 Preferred Units were $23.14 and $33.57, respectively. The preferred units accrued a distribution right at a rate of 3%&#160;per annum and was added annually to the Liquidation Preference. On February&#160;11, 2021, the common and preferred units, including the preferred distribution rights, were converted into Common LLC Interests as discussed in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 1. Organization and basis of presentation of financial information&lt;/div&gt;&lt;/div&gt; and no further distribution rights accrued. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Continuing LLC Owner owned the only Equity Participation Right Unit (EPR Unit). The EPR Unit was junior to the common units and its only entitlement was 0.55% of available distributions arising from the closing of a sale of units representing a percentage interest of more than 66.66%, or the sale of all or substantially all of the assets of the Company, provided such event constitutes a change of control (Distribution Event) as described in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 7. Fair value measurements.&lt;/div&gt;&lt;/div&gt; In February 2021, the EPR Unit was redeemed in exchange for $3,327 in connection with the IPO at which time the EPR ceased to exist and all entitlements ended. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 17. Subsequent events&lt;/div&gt;&lt;/div&gt; for further details regarding the impact of the IPO on members&#x2019; equity. &lt;/div&gt;</us-gaap:MembersEquityNotesDisclosureTextBlock>
    <bvs:ScheduleOfMembersEquityTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Members&#x2019; equity consisted of the following at December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Preferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;168,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;113,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;113,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Profits interest and other equity awards (Refer to&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Note 9. Equity-based compensation&lt;/div&gt;&lt;/div&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;285,173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;285,147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bvs:ScheduleOfMembersEquityTableTextBlock>
    <us-gaap:LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">168000000</us-gaap:LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue>
    <us-gaap:LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">168000000</us-gaap:LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue>
    <us-gaap:CommonUnitIssuanceValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">113373000</us-gaap:CommonUnitIssuanceValue>
    <us-gaap:CommonUnitIssuanceValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">113373000</us-gaap:CommonUnitIssuanceValue>
    <bvs:ProfitInterestAndOtherEquityWardsUnitsIssuanceValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3800000</bvs:ProfitInterestAndOtherEquityWardsUnitsIssuanceValue>
    <bvs:ProfitInterestAndOtherEquityWardsUnitsIssuanceValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3774000</bvs:ProfitInterestAndOtherEquityWardsUnitsIssuanceValue>
    <us-gaap:MembersCapital
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">285173000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">285147000</us-gaap:MembersCapital>
    <bvs:ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany
      contextRef="P05_01_2012To05_31_2012_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4900000000</bvs:ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany>
    <bvs:ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany
      contextRef="P05_01_2012To05_31_2012_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelvePreferredUnitsMemberusgaapPreferredUnitsByNameAxis"
      decimals="-3"
      unitRef="Unit_USD">5100000000</bvs:ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany>
    <bvs:PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod
      contextRef="P11_01_2015To11_30_2015_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis"
      decimals="0"
      unitRef="Unit_shares">50000</bvs:PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod>
    <bvs:ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany
      contextRef="P11_01_2015To11_30_2015_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1490000000</bvs:ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany>
    <bvs:PreferredUnitsLiquidationPreferencePerUnit
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelvePreferredUnitsMemberusgaapPreferredUnitsByNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">23.14</bvs:PreferredUnitsLiquidationPreferencePerUnit>
    <bvs:PreferredUnitsLiquidationPreferencePerUnit
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenPreferredUnitsMemberusgaapPreferredUnitsByNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">33.57</bvs:PreferredUnitsLiquidationPreferencePerUnit>
    <bvs:PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</bvs:PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum>
    <bvs:EquityParticipationRightEntitledPercentageOfDistributions
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0055</bvs:EquityParticipationRightEntitledPercentageOfDistributions>
    <bvs:DistributionEventTriggerPercentageOfSaleOfAssets
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.6666</bvs:DistributionEventTriggerPercentageOfSaleOfAssets>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P02_01_2021To02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3327000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, there were no assets measured at fair value and there were no liabilities measured at fair value using Level&#160;1 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest rate swap&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management incentive plan and liability-classified awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity Participation Rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interest rate swap &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company values interest rate swaps using discounted cash flows. Forward curves and volatility levels are used to estimate future cash flows that are not certain. These are determined using observable market inputs when available and based on estimates when not available. The fair value of the swap was recorded in the Company&#x2019;s consolidated balance sheets within accrued liabilities. Changes in fair value are recognized as interest expense within the consolidated statements of operations and comprehensive income (loss). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Management incentive plan and liability-classified awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the IPO, the Company had operated two-equity-based compensation plans, the Management Incentive Plan (MIP) and the Phantom Profits Interest Plan (Phantom Plan). The estimated fair value reflects assumptions made by management as of December&#160;31, 2020, including the impact of COVID-19 on significant unobservable assumptions, such as the expected timing and volume of elective procedures and the impact of these procedures on future revenues which impact the equity value. However, the actual amount ultimately paid could be higher or lower than the fair value. The Company has classified $11,054 as accrued equity-based compensation and $29,249 as accrued equity-based compensation, less current portion as of December&#160;31, 2020. Any changes in fair value are recorded as an operating expense and included within selling, general administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial estimate (vesting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeitures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,002&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial estimate (vesting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,734&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeitures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2020, the sole MIP awardee exercised the right to force a cash settlement for 150,252 of the 333,330 vested units resulting in a payment of $6,329. The remaining 183,078 units were settled for $10,802 in February 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;EPR Unit &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the IPO, after which the EPR ceased to exist and all entitlements ended, the Continuing LLC owners owned the only EPR Unit and its only entitlement was 0.55% of available distributions arising from a Distribution Event. The estimated fair value reflects assumptions made by management as of December&#160;31, 2020, including potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. The fair value of the EPR Unit was recorded in the Company&#x2019;s consolidated balance sheets as other long-term liabilities. The revaluation for the EPR liability is recognized in interest expense on the consolidated statements of operations and comprehensive income (loss). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;565&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of the Plans and EPR Unit using a Monte Carlo simulation. This fair value measurement is based on significant inputs that are unobservable in the market, and thus represents a Level 3 measurement. The key assumptions used in applying the valuation model include the Company&#x2019;s equity value, the expected timing until a liquidity event, applicable discount rates applied, and equity volatility. In addition, for the EPR Unit, the estimated accrued preferred distribution at the liquidity event date totaling $43,854 as of December&#160;31, 2020 as it is senior in order of payment. Significant changes in these assumptions could result in a significantly higher or lower fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a range of key assumptions used within the valuation of the awards as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 26%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 22%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation technique&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Option pricing approach&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Time to liquidity event&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;0.4&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Risk free rate&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;0.10%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Equality volatility&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;35.13%&#160;-&#160;101.25%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;50.0%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Equity value&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;$1,065,000&#160;-&#160;$1,240,000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;$1,145,000&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Lack of marketability discount&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;7.0%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;7.0%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">The following table provides information for liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs.
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest rate swap&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management incentive plan and liability-classified awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity Participation Rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1602000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1602000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">40303000</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">40303000</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">40802000</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">6101000</bvs:EquityParticipationRightFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:EquityParticipationRightFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">6101000</bvs:EquityParticipationRightFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">5457000</bvs:EquityParticipationRightFairValueDisclsoure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">48006000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1602000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">46404000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">46259000</us-gaap:LiabilitiesFairValueDisclosure>
    <bvs:NumberOfEquityBasedCompensationPlans
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_Plan">2</bvs:NumberOfEquityBasedCompensationPlans>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">11054000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">29249000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial estimate (vesting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeitures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,002&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial estimate (vesting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,734&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeitures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,298&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;565&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">33063000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5464000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-1013000</bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">6290000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3002000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">40802000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4734000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-1298000</bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">6641000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">10576000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">40303000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">150252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">333330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P06_01_2020To06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6329000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">183078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P02_01_2021To02_28_2021_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10802000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <bvs:EquityParticipationRightEntitledPercentageOfDistributions
      contextRef="PAsOn02_15_2021_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0055</bvs:EquityParticipationRightEntitledPercentageOfDistributions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4892000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">565000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5457000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">644000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">6101000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CashAvailableForDistributions
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">43854000</us-gaap:CashAvailableForDistributions>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a range of key assumptions used within the valuation of the awards as of December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 26%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 22%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation technique&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Option pricing approach&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Time to liquidity event&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;0.4&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Risk free rate&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;0.10%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;0.10%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Equality volatility&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;35.13%&#160;-&#160;101.25%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;50.0%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Equity value&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;$1,065,000&#160;-&#160;$1,240,000&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;$1,145,000&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Lack of marketability discount&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;7.0%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:center;"&gt;7.0%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="1"
      unitRef="Unit_Business">0.4</bvs:EquityParticipationRightsUnitMeasurableInput>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_Business">0.4</bvs:EquityParticipationRightsUnitMeasurableInput>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      unitRef="Unit_Business">0.10</bvs:EquityParticipationRightsUnitMeasurableInput>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_Business">0.10</bvs:EquityParticipationRightsUnitMeasurableInput>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      unitRef="Unit_Business">35.13</bvs:EquityParticipationRightsUnitMeasurableInput>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MaximumMembersrtRangeAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      unitRef="Unit_Business">101.25</bvs:EquityParticipationRightsUnitMeasurableInput>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputEquityVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_Business">50.0</bvs:EquityParticipationRightsUnitMeasurableInput>
    <bvs:EquityParticipationRightsUnitEquityValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="0"
      unitRef="Unit_USD">1065000</bvs:EquityParticipationRightsUnitEquityValue>
    <bvs:EquityParticipationRightsUnitEquityValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MaximumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="0"
      unitRef="Unit_USD">1240000</bvs:EquityParticipationRightsUnitEquityValue>
    <bvs:EquityParticipationRightsUnitEquityValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_USD">1145000</bvs:EquityParticipationRightsUnitEquityValue>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputDiscountForLackOfMarketabilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="1"
      unitRef="Unit_Business">7.0</bvs:EquityParticipationRightsUnitMeasurableInput>
    <bvs:EquityParticipationRightsUnitMeasurableInput
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputDiscountForLackOfMarketabilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis_WeightedAverageMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_Business">7.0</bvs:EquityParticipationRightsUnitMeasurableInput>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Restructuring costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring costs are not allocated to the Company&#x2019;s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring expenses in the consolidated statement of operations and comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the fourth quarter of 2020 and 2018, the Company adopted restructuring plans to improve the performance of International operations, principally through headcount reduction and closing offices in certain countries as the Company shifts to an indirect distribution model in these countries. The plans were completed in 2020 and 2019, respectively, and the Company recorded total pre-tax charges of $563, $575 and $1,373 primarily related to severance for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company&#x2019;s costs totaled $563 for the 2020 plan and $1,948 for the 2018 plan. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s restructuring charges and payments for all plans are comprised of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&lt;br/&gt;severance&#160;and&lt;br/&gt;temporary&lt;br/&gt;labor&#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt;charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenses incurred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments made&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,778&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenses incurred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;563&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments made&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;247&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">563000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">575000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1373000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwentyPlanMemberusgaapRestructuringPlanAxis"
      decimals="-3"
      unitRef="Unit_USD">563000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndEighteenPlanMemberusgaapRestructuringPlanAxis"
      decimals="-3"
      unitRef="Unit_USD">1948000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s restructuring charges and payments for all plans are comprised of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&lt;br/&gt;severance&#160;and&lt;br/&gt;temporary&lt;br/&gt;labor&#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt;charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenses incurred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments made&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(290&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,778&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenses incurred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;563&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments made&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;247&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">997000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">206000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1203000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">491000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">84000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">575000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1488000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">290000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1778000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">408000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">155000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">563000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">242000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">316000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EmployeeSeveranceAndTemporaryLaborCostsMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">166000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherChargesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">81000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">247000</us-gaap:RestructuringReserve>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. Equity-based compensation&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity-based compensation plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company operated two equity-based compensation plans, the MIP and the Phantom Plan (the Plans) prior to the IPO. The awards granted under both plans represented a non-managing, non-voting interest in the Company designed for grantees to share in the future appreciation of the value of the Company. Awards granted under the MIP Plan and the 2015 Phantom Units are liability-classified and the 2012 Phantom Units are equity-classified. On February&#160;11, 2021, in conjunction with the IPO, the Plans were terminated and there were no further awards, under the Plans. As a result, the New LLC Owner assumed the obligations of the Company&#x2019;s Phantom Plan awards on February&#160;10, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The awards granted under the MIP fully vested at December&#160;2, 2017. There were no MIP awards granted for the years ended December&#160;31, 2020, 2019 and 2018. In June 2020, the sole MIP awardee exercised the right to force a cash settlement for 150,252 of the 333,330 vested units resulting in a payment of $6,329. As of December&#160;31, 2020 and 2019, respectively, there were 183,078 and 333,330 vested awards outstanding both with a grant date fair value of $4.89. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profits interest compensation of $10,103, $10,844 and $14,325 for all plans, was recognized for the years ended December&#160;31, 2020, 2019 and 2018 respectively. The expense is included in selling, general and administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. As of December&#160;31, 2020, there was approximately $9,741 of unrecognized compensation expense to be recognized over a weighted-average period of 1.3 years. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of the award activity of the Phantom Plan for the year ended December&#160;31, 2020 is as follows (number of awards in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 43%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2012 Phantom Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2015 Phantom Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(awards in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted to cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awards vested at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no 2012 Phantom Unit awards granted in 2019. The weighted average grant date fair value per Other Phantom Unit awards granted in the year ended December&#160;31, 2019 was $15.31. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 36%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2012 Phantom Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2015 Phantom Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(awards in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nonvested at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested during 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nonvested at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;927&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total fair value of 2012 Phantom Unit awards vested in the year ended December&#160;31, 2020 was nominal. The total fair value of Other Phantom Unit awards vested in the year ended December&#160;31, 2020 was $4,703. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined contribution plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has various defined contribution plans or plans that share profit which are offered in Canada, Germany, the Netherlands and the United Kingdom. These plans are required by local laws or regulations in some cases. Contributions are primarily discretionary, except in some countries where contributions are contractually required. These plans cover substantially all eligible employees in the countries where the plans are offered either voluntarily or statutorily. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the U.S., the Company provides a 401(k) defined contribution plan (U.S. Plan) that covers substantially all U.S. employees that meet minimum age requirements. The Company matches 50% of the employees&#x2019; contribution up to 6% of the employees&#x2019; wages. The Company also contributes 4.5% of the employees&#x2019; wages to the U.S. Plan. The 4.5% Company contribution was suspended in May 2020 due to the COVID-19 crisis and reinstated in late December 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, Company contributions totaled $3,379, $5,401 and $5,462 respectively, for all global plans. The expense is included in cost of sales, selling, general and administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. &lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <bvs:NumberOfEquityBasedCompensationPlans
      contextRef="PAsOn02_10_2021_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_Plan">2</bvs:NumberOfEquityBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">150252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">333330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P06_01_2020To06_30_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6329000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">183078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">333330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">10103000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">10844000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14325000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">9741000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_shares">1.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bvs:ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of the award activity of the Phantom Plan for the year ended December&#160;31, 2020 is as follows (number of awards in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 43%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2012 Phantom Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2015 Phantom Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(awards in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Converted to cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awards vested at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;</bvs:ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">0</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">-146</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.45</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">658</bvs:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.72</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">495</bvs:ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.15</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <bvs:ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 36%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2012 Phantom Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2015 Phantom Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(awards in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant-date&#160;fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nonvested at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;667&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested during 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nonvested at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;927&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;</bvs:ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">147</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.81</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis_TwoThousandAndFifteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherPhantomUnitMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4703000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.045</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3379000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5401000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5462000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Income taxes&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of net income from continuing operations before taxes for the years ended December&#160;31 are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Taxable subsidiaries:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Domestic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,679&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,967&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;693&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,646&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other domestic subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,221&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal income taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;782&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;891&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(294&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign income taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State income taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in tax rates - deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The differences between the effective income tax rate and the federal statutory income tax rates for the years ended December&#160;31 by taxable and other subsidiaries are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. statutory federal corporate income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;LLC flow-through structure&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State and local income taxes, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign rate differential&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision to return adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s effective tax rate differs from statutory rates primarily due to Bioventus LLC&#x2019;s pass-through structure for U.S. income tax purposes while being treated as taxable in certain states and various foreign jurisdictions as well as for certain subsidiaries. In addition, certain states assess income taxes on pass-through structures. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,874&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,920&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,423&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liability:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired intangible&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,874&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses the need for a valuation allowance against our deferred tax assets. A valuation allowance of $2,822, has been applied to all of Harbor&#x2019;s deferred tax assets. The Company also has a valuation allowance of $171 representing the entire balance of deferred tax assets relating to our international operations. These valuation allowances were recorded as the Company believes it is more-likely-than-not that it will receive future benefit. At December&#160;31, 2020, the Company had federal and state net operating loss carryforwards related to Harbor of $25,537 expiring at various dates from 2021 through 2037 and approximately $2,141 with no expiration date. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;evaluates its tax positions in accordance with the recognition and measurement provisions of ASC&#160;740-10 (&#x201c;FIN 48&#x201d;) and in accordance with that guidance, has determined that a reserve for any significant uncertain tax positions is not needed as of December&#160;31, 2020 and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under current tax law, the utilization of tax attributes will be restricted if an ownership change, as defined, were to occur. Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, provides, in general, that if an &#x201c;ownership change&#x201d; occurs with respect to a corporation with net operating and other loss carryforwards, such carryforwards will be available to offset taxable income in each taxable year after the ownership change only up to the &#x201c;Section&#160;382 Limitation&#x201d; for each year. The Company&#x2019;s ability to use its loss carryforwards will be limited in the event of an ownership change. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2018, Dutch income taxes were imposed on a negotiated percentage of sales. The Company has an agreement with the Dutch taxing authorities where the Company&#x2019;s Netherlands subsidiary will incur but not have to pay income taxes in years when the subsidiary is operating at a loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Minimal tax related interest and penalties were incurred for the years ended December&#160;31, 2020 and 2019. The Company is subject to audit by various taxing jurisdictions for the years 2015 through 2020. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of net income from continuing operations before taxes for the years ended December&#160;31 are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Taxable subsidiaries:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Domestic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,679&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,967&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;693&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,646&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other domestic subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,221&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">306000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2679000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2925000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-387000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-2967000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">693000</bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign>
    <bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5646000</bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign>
    <bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1532000</bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign>
    <bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15221000</bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries>
    <bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4043000</bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries>
    <bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4575000</bvs:IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15914000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">9689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6107000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal income taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;782&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;891&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(294&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign income taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State income taxes:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;380&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in tax rates - deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">782000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">932000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">891000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-508000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-345000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-294000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">707000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">815000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">472000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">180000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">214000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">177000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">380000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-3000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-3000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1192000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1576000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1664000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The differences between the effective income tax rate and the federal statutory income tax rates for the years ended December&#160;31 by taxable and other subsidiaries are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. statutory federal corporate income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;LLC flow-through structure&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State and local income taxes, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign rate differential&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision to return adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">-0.201</bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage>
    <bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">-0.088</bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage>
    <bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">-0.157</bvs:EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.073</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.115</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <bvs:EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.039</bvs:EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage>
    <bvs:EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.031</bvs:EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.075</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.163</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.272</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,874&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,920&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,423&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liability:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired intangible&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,874&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3874000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3530000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">696000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">390000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4570000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3920000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2993000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2423000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1577000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1497000</us-gaap:DeferredTaxAssetsNet>
    <bvs:DeferredTaxLiabilitiesAcquiredIntangibles
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-4939000</bvs:DeferredTaxLiabilitiesAcquiredIntangibles>
    <bvs:DeferredTaxLiabilitiesAcquiredIntangibles
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-5371000</bvs:DeferredTaxLiabilitiesAcquiredIntangibles>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3362000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3874000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">2822000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_NonUsMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">171000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FederalAndStateMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMemberusgaapTaxPeriodAxis"
      decimals="-3"
      unitRef="Unit_USD">25537000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_FederalAndStateMemberusgaapIncomeTaxAuthorityAxis_IndefinitelyMemberusgaapTaxPeriodAxis"
      decimals="-3"
      unitRef="Unit_USD">2141000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OpenTaxYear contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2020MemberusgaapTaxPeriodAxis">2015</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2015MemberusgaapTaxPeriodAxis">2015</us-gaap:OpenTaxYear>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11. Related-party transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company made cash tax distributions of $19,886, $9,137 and $7,846 to its members in an amount equal to approximately 40% of the members&#x2019; estimated taxable income for the years ended December&#160;31, 2020, 2019 and 2018, respectively. At December&#160;31, 2020 and December&#160;31, 2019, there were tax distributions payable to tax authorities on the members&#x2019; behalf totaling $541 and $473, respectively, and nominal tax distributions payable to the members. &lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <bvs:CashDistributionMadeToMembersTowardsTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">19886000</bvs:CashDistributionMadeToMembersTowardsTax>
    <bvs:CashDistributionMadeToMembersTowardsTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">9137000</bvs:CashDistributionMadeToMembersTowardsTax>
    <bvs:CashDistributionMadeToMembersTowardsTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">7846000</bvs:CashDistributionMadeToMembersTowardsTax>
    <bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome>
    <bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome>
    <bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</bvs:CashDistributionsAsAPercentageOfMembersTotalTaxableIncome>
    <bvs:RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">541000</bvs:RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers>
    <bvs:RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">473000</bvs:RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. Commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under finance leases. The remaining lease terms range from 3 months to 8 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of lease cost were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,529&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,887&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*Includes&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;variable lease cost and sublease income, which are immaterial. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental cash flow information and non-cash activity related to leases were as follow: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,567&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use assets obtained in exchange for operating lease obligations:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current and noncurrent operating and finance lease liabilities are included in other current liabilities and other long-term liabilities, respectively, on the consolidated balance sheet. Other balance sheet information related to leases are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,961&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,267&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&#x2014;current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,814&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&#x2014;noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining operating lease term in years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate for operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities as of December&#160;31, 2020 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,460&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,476&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total future lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,077&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of future lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;OIG&#x2019;s Provider Self-Disclosure &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company identified non-compliance with certain U.S. federal statutes and requirements governing the Medicare program in 2018 related to improper completion of Certificate for Medical Necessity (CMN) forms and in November 2018 made a voluntary self-disclosure to the Office of Inspector General of the U.S. Department of Health and Human Services (OIG) pursuant to the OIG&#x2019;s Provider Self-Disclosure Protocol related to this matter. After settlement discussions with the Office of the United States Attorney in the Middle District of North Carolina (USAO) and OIG, on January&#160;15, 2021, the Company reached a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which the Company&#x2019;s sales representatives completed Section B of the CMN form. On February&#160;22, 2021, the Company finalized all terms related to the settlement and entered into a formal settlement agreement with the USAO and OIG consistent with the previous agreement in principle and which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type and resolved the potential liability related to the Company&#x2019;s self-disclosure for $3,600, of which $2,400 had previously been paid. The remaining $1,200 net settlement amount due under the agreement was recorded in accrued liabilities within the consolidated balance sheets as of December&#160;31, 2020 and paid on February&#160;23, 2021. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 17. Subsequent events&lt;/div&gt;&lt;/div&gt; for further details regarding the resolution. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reserve for estimated overpayments from all third-party payers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains a reserve for reimbursement claims related to its Minimally Invasive Fracture Treatment product that may have been processed for payment by the Company without adequate medical records support. The Company held a reserve of $2,790 and $6,801 at December&#160;31, 2020 and 2019, respectively for these &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amounts. The Company refunded Medicare $1,519 and $7,458 during the years ended December&#160;31, 2020 and 2019, respectively, related to known and estimated overpayments for medical necessity included in this reserve for periods through December&#160;31, 2019. Certain of these overpayments were identified as potential overpayments in the Company&#x2019;s OIG self-disclosure in November 2018. The Company&#x2019;s reserve was estimated using extrapolation of an error rate from a statistical sample, which represents the Company&#x2019;s best estimate as of the date of the financial statements, but because of the uncertainty inherent in such estimates, the ultimate resolution may be materially different. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product recall &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2020, we voluntarily recalled our ultrasound gel, an accessory to the Minimally Invasive Fracture Treatment product. We have incurred, and expect to incur in the future, costs associated with this recall. Based on the information that has been received, we have estimated the probable loss related to this recall globally to be approximately $1,684. We have recorded reserves representing the probable loss within accrued liabilities on the consolidated balance sheet. The final outcome of this recall is dependent on many factors that are difficult to predict. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other matters &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;23, 2019, the Company and Harbor entered into an exclusive collaboration agreement for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. As part of the agreement a third-party license was assigned to us and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter, beginning in 2023. The Company is obligated to pay up to $6,000 upon achieving certain milestones. Unless earlier terminated, the agreement will remain in effect until the earlier of 8 years or until the payment of certain milestones are met. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;29, 2019, the Company and Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF. The first phase has been completed. Additional fees for the subsequent phases will be determined as the development work progresses. The Development Agreement continues until the date when the parties execute a supply agreement for the commercial products. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection OA product with the supplier of the Company&#x2019;s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement totaled $10,021, $7,622 and $3,082 for the years ended December&#160;31, 2020, 2019 and 2018 respectively, and are included in cost of sales on the consolidated statement of operations and comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of a supply agreement entered on February&#160;9, 2016 for the Company&#x2019;s three injection OA product, the Company is subject to annual minimum purchase requirements for ten years. After the initial ten years, the agreement will automatically renew for an additional five years unless terminated by the Company or the seller in accordance with the agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of a supply agreement for the Company&#x2019;s five injection OA product, that was amended and restated on December&#160;22, 2020, the Company is subject to annual minimum purchase requirements for eight years. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the license products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive income (loss). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, the Company causes LOCs to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of December&#160;31, 2020 and 2019, the Company had one LOC outstanding for a nominal amount. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#x201c;claims made&#x201d; basis for expenses in excess of $150 per member per year. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to the business. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#x2019;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#x2019;s complete control and may not be known for extended periods of time. Other than the matters discussed above, management of the Company, after consultation with legal counsel, does not believe there are any unrecorded matters that will have a material adverse effect upon the Company&#x2019;s financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of lease cost were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,529&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,887&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*Includes&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;variable lease cost and sublease income, which are immaterial. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental cash flow information and non-cash activity related to leases were as follow: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,567&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use assets obtained in exchange for operating lease obligations:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,016&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2610000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2529000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">388000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">358000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2998000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2887000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2567000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2343000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1497000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5016000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <bvs:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">Other balance sheet information related to leases are as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,961&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,267&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&#x2014;current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,814&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&#x2014;noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining operating lease term in years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate for operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </bvs:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14961000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15267000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1960000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1814000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14108000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14513000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16068000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16327000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_pure">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_pure">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities as of December&#160;31, 2020 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,460&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,476&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total future lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,077&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of future lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2714000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2645000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2460000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2476000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">2569000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6281000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">19145000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">3077000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16068000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis"
      decimals="-3"
      unitRef="Unit_USD">3600000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis"
      decimals="-3"
      unitRef="Unit_USD">2400000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P02_23_2021To02_23_2021_BioVentusLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsaoAndOigMembersrtMajorCustomersAxis"
      decimals="-3"
      unitRef="Unit_USD">1200000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis"
      decimals="-3"
      unitRef="Unit_USD">1200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualProductLiabilityNet
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2790000</us-gaap:LossContingencyAccrualProductLiabilityNet>
    <us-gaap:LossContingencyAccrualProductLiabilityNet
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">6801000</us-gaap:LossContingencyAccrualProductLiabilityNet>
    <bvs:RefundOfExcessPaymentsToThirdPartyCustomers
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1519000</bvs:RefundOfExcessPaymentsToThirdPartyCustomers>
    <bvs:RefundOfExcessPaymentsToThirdPartyCustomers
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">7458000</bvs:RefundOfExcessPaymentsToThirdPartyCustomers>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1684000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <bvs:CollaborativeArrangementRoyaltyPercentage
      contextRef="P08_23_2019To08_23_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</bvs:CollaborativeArrangementRoyaltyPercentage>
    <bvs:MilestonePaymentPayable
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_HarborMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">6000000</bvs:MilestonePaymentPayable>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">10021000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">7622000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">3082000</us-gaap:RoyaltyExpense>
    <bvs:SupplyCommitmentTerm contextRef="P02_09_2016To02_09_2016_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">P10Y</bvs:SupplyCommitmentTerm>
    <bvs:SupplyCommitmentTerm contextRef="P02_09_2016To02_09_2016_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">P10Y</bvs:SupplyCommitmentTerm>
    <bvs:SupplyCommitmentRenewalTerm contextRef="P02_09_2016To02_09_2016_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">P5Y</bvs:SupplyCommitmentRenewalTerm>
    <bvs:CollaborativeArrangementTerm contextRef="P12_22_2020To12_22_2020_BioVentusLlcMemberdeiLegalEntityAxis_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">P8Y</bvs:CollaborativeArrangementTerm>
    <bvs:StopLossInsuranceThresholdPerMemberPerYear
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</bvs:StopLossInsuranceThresholdPerMemberPerYear>
    <bvs:NetIncomeLossPerUnitTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13. Net income (loss) per unit &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the computation of basic and diluted net income (loss) per unit for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income from continuing operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss attributable to noncontrolling interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income from continuing operations attributable to unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated and unpaid preferred distributions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income allocated to participating shareholders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) from continuing operations attributable to common unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to common unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per unit attributable to common unit holders - basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) from continuing operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to common unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3.67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average common units outstanding, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,900,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,900,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,900,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The computation of diluted earnings per unit for the years ended December&#160;31, 2020, 2019 and 2018 excludes the effect of the 6,590 potential common units that would be issued upon the conversion of preferred units. The effect of these units would be antidilutive due to the impact of the accumulated and unpaid preferred distributions as well as the Company being in a net loss position for the years ended December&#160;31, 2019 and 2018. &lt;/div&gt;&lt;/div&gt;</bvs:NetIncomeLossPerUnitTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the computation of basic and diluted net income (loss) per unit for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income from continuing operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss attributable to noncontrolling interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income from continuing operations attributable to unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated and unpaid preferred distributions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income allocated to participating shareholders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) from continuing operations attributable to common unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to common unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per unit attributable to common unit holders - basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) from continuing operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to common unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3.67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average common units outstanding, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,900,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,900,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,900,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">14722000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8113000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4443000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1689000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-553000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16411000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8666000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4443000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16411000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">8666000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4443000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6133000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5955000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5781000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">5895000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1555000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <bvs:NetIncomeLossFromContinuingOperations
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4383000</bvs:NetIncomeLossFromContinuingOperations>
    <bvs:NetIncomeLossFromContinuingOperations
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1156000</bvs:NetIncomeLossFromContinuingOperations>
    <bvs:NetIncomeLossFromContinuingOperations
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-1338000</bvs:NetIncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">1815000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">16650000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">4383000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-659000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">-17988000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.89</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.37</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.40</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">4900000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">4900000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">4900000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">6590</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">6590</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">6590</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <bvs:NetSalesTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14. Net Sales&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the location from which the sale originated. The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) for the years ended December&#160;31 as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primary geographic markets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;293,697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;305,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;282,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,069&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36,282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;321,161&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;340,141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;319,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vertical:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OA joint pain treatment and joint preservation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;171,178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182,082&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;155,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Minimally invasive fracture treatment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;103,504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;121,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bone graft substitutes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61,359&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;321,161&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;340,141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;319,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </bvs:NetSalesTextBlock>
    <bvs:DisaggregationOfRevenueBasedOnGeographyTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) for the years ended December&#160;31 as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primary geographic markets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;293,697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;305,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;282,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,069&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36,282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;321,161&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;340,141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;319,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vertical:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;OA joint pain treatment and joint preservation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;171,178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182,082&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;155,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Minimally invasive fracture treatment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;103,504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;121,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bone graft substitutes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;61,359&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;321,161&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;340,141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;319,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bvs:DisaggregationOfRevenueBasedOnGeographyTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">293697000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">305072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_USSegmentMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">282895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">27464000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">35069000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">36282000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">321161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">340141000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">319177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">171178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">182082000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">155576000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">88624000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">103504000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MinimallyInvasiveFractureTreatmentMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">121032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">61359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">54555000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BoneGraftSubstitutesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">42569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">321161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">340141000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">319177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15. Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment information by asset is not disclosed as it is not reviewed by the CODM or used to allocate resources or to assess the operating results and financial performance. We believe EBITDA, adjusted for additional non-operational factors disclosed in the table below, or Adjusted EBITDA, is a key measure for internal reporting. Adjusted EBITDA should not be considered in isolation or as a substitute for consolidated net income (loss) attributable to the Company, the most closely analogous U.S. GAAP measure. Adjusted EBITDA is not defined in the same manner by all companies and may not be comparable to other similarly titled measures of other companies unless the definition is the same. The following table presents segment adjusted EBITDA reconciled to income from continuing operations before income taxes for the years ended December&#160;31 as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment adjusted EBITDA from continuing operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,252&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,673&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,691&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(28,643&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19 benefits, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Succession and transition charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,609&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(563&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency impact&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity loss in unconsolidated investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other non-recurring costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,723&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">The following table presents segment adjusted EBITDA reconciled to income from continuing operations before income taxes for the years ended December&#160;31 as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment adjusted EBITDA from continuing operations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,252&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,673&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,191&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,691&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(28,643&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19 benefits, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,123&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Succession and transition charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,609&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(563&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency impact&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity loss in unconsolidated investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(467&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other non-recurring costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,723&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from continuing operations before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">69252000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">71673000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">67480000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">3191000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">7515000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">4691000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">28643000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">30316000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">29238000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-9751000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-21579000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-19171000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">10103000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">10844000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">14325000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:UnusualOrInfrequentItemNetGainLoss
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4123000</us-gaap:UnusualOrInfrequentItemNetGainLoss>
    <bvs:SuccessionAndTransitionCharges
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">5609000</bvs:SuccessionAndTransitionCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">563000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">575000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">1373000</us-gaap:RestructuringCharges>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">117000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-8000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-234000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-467000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNonrecurringExpense
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">5633000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:OtherNonrecurringExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">6177000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:OtherNonrecurringExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">1723000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">15914000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">9689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">6107000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16. Discontinued operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2018, the Company, under the direction and authority of the Company&#x2019;s Board of Managers, committed to shut down the bone morphogenetic protein (BMP) research and development program, which had been reported as its own segment in previous years. Substantially all operations, including project close &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;documentation, contract termination, vacating the facility and ultimately the termination of the employees, ceased by March 2019 and as a result the BMP research and development program met the criteria for discontinued operations. The Company sold the remaining $172 held for sale asset and paid the remaining $400 accrued liability from the BMP research and development program during the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the statement of operations and comprehensive income (loss) from discontinued operations for the years ended December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,773&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on disposal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">172000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <bvs:DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">400000</bvs:DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities>
    <bvs:DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the statement of operations and comprehensive income (loss) from discontinued operations for the years ended December&#160;31: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,773&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on disposal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </bvs:DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock>
    <bvs:DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1773000</bvs:DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense>
    <bvs:DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">-7127000</bvs:DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">52000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">9638000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <bvs:DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</bvs:DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit>
    <bvs:DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">115000</bvs:DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">1815000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">16650000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17. Subsequent events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;4, 2021, the Company made a convertible debt investment of $1,500 in a medical device company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recapitalization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;16, 2021, the following Transactions occurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;The Company amended and restated its limited liability company agreement (New LLC Agreement) to, among other things, (i)&#160;provide for the new single class of common membership interests in the Company as discussed in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 1. Organization and basis of presentation for financial information&lt;/div&gt;&lt;/div&gt;; (ii)&#160;exchange all of the then existing membership interests of the common and preferred unit holders (Original LLC Owners) for Common LLC Interests and (ii)&#160;appoint the New LLC Owner as the sole managing member of the Company. The amendment resulted in the Company&#x2019;s common and preferred units, including the preferred distribution rights, being converted into 47,625,326 Common LLC Interests. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The New LLC Owner amended and restated its certificate of incorporation to, among other things, (i)&#160;provide for Class&#160;A common stock and Class B common stock, each share of which entitles its holders to one vote per share on all matters presented to the New LLC Owner&#x2019;s stockholders and (ii)&#160;issue 15,786,737 shares of Class B common stock to the Continuing LLC Owner, on a one-to-one basis with the number of LLC Interests it owns. While the Class B common stock holds voting rights it holds no economic interest in the New LLC Owner. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The New LLC Owner acquired, by merger, the Former LLC Owners and upon consummation of the merger, owned 31,838,589 Common LLC Interests. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The New LLC Owner closed an IPO of 9,200,000 shares of Class&#160;A common stock at a public offering price of $13.00 per share. The New LLC Owner received $111,228 in proceeds, net of underwriting discounts and commissions, which was used to make a capital contribution to the Company in exchange for 9,200,000 Common LLC Interests of the Company at a price per interest equal to the IPO price of $13.00. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent to the Transactions, the New LLC Owner owns 41,038,589 Common LLC Interests or 72.2% of the Company and the Continuing LLC Owner owns 15,786,737 or 27.8%. The New LLC Owner has a majority economic interest, the sole voting interest in, and controls the management of the Company. As a result, the New LLC Owner will consolidate the financial results of the Company and will report a non-controlling interest representing the interests owned by the Continuing LLC Owner. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The New LLC Agreement requires that the Company, at all times, maintain (i)&#160;a one-to-one ratio between the number of shares of Class&#160;A common stock issued by the New LLC Owner and the number of Common LLC Interests owned by the New LLC Owner and (ii)&#160;a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;22, 2021, the Company finalized all terms related to a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which our sales representatives completed Section B of the CMN forms. The Company entered into a formal settlement agreement with the USAO and OIG which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type and resolved the potential liability related to the Company&#x2019;s self-disclosure in this matter for $3,600, of which $2,400 has already been paid through the Company&#x2019;s 2019 return of overpayments described previously. The remaining $1,200 net settlement amount due under the agreement was recorded in accrued liabilities within the consolidated balance sheets as of December&#160;31, 2020 and was paid on February&#160;23, 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="P01_04_2021To01_04_2021_BioVentusLlcMemberdeiLegalEntityAxis_ConvertibleDebtInstrumentsMemberusgaapInvestmentTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">1500</us-gaap:PaymentsToAcquireOtherInvestments>
    <bvs:CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany
      contextRef="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_RestatedLimitedLiabilityCompanyAgreementMemberBVSEventAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">47625326</bvs:CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">15786737</us-gaap:CommonStockSharesSubscribedButUnissued>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn02_16_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">31838589</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">9200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">13.00</us-gaap:SharesIssuedPricePerShare>
    <bvs:ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany
      contextRef="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">111228</bvs:ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany>
    <bvs:CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod
      contextRef="P02_17_2021To02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">9200000</bvs:CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_NewLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">41038589</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest
      contextRef="P02_17_2021To02_17_2021_BioventusIncMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.722</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest>
    <bvs:LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers
      contextRef="PAsOn02_17_2021_BioVentusLlcMemberdeiLegalEntityAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">15786737</bvs:LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="P02_17_2021To02_17_2021_BioventusIncMembersrtOwnershipAxis_ContinuingLlcOwnerMemberBVSInvestorAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.278</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis"
      decimals="-3"
      unitRef="Unit_USD">3600000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis"
      decimals="-3"
      unitRef="Unit_USD">2400000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P02_23_2021To02_23_2021_BioVentusLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_UsaoAndOigMembersrtMajorCustomersAxis"
      decimals="-3"
      unitRef="Unit_USD">1200000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_UsaoAndOigMembersrtMajorCustomersAxis"
      decimals="-3"
      unitRef="Unit_USD">1200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">109816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">58017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">191594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">136662000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">5618000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">5292000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">10854000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">10599000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">33503000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">17668000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">55725000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">39077000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">76313000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">40349000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">135869000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">97585000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">69050000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">40533000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">103736000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">80809000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">4836000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">2596000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">5783000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">4742000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">641000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">641000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DepreciationAndAmortization
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1852000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1813000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3777000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">3638000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">5674000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">5674000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-5740000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-4593000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">16258000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">8396000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-1681000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-2834000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1195000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-5215000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-1645000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1337000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-2064000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1254000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-3326000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-1497000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-869000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-3961000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-9066000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-6090000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">15389000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">4435000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1714000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-110000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1641000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-71000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-10780000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-5980000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">13748000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">4506000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-6654000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-214000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-7062000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-672000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-4126000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-5766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">20810000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">5178000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-10780000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-5980000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">13748000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">4506000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">23000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-859000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-256000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-10757000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-5767000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">12889000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">4250000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-6648000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-214000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-6882000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-672000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-4109000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P03_28_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-5553000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">19771000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">4922000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_04_2021To07_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_04_2021To07_03_2021"
      decimals="2"
      id="Fact_26388121"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_04_2021To07_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_04_2021To07_03_2021"
      decimals="2"
      id="Fact_26388122"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_04_2021To07_03_2021"
      decimals="0"
      id="Fact_26388127"
      unitRef="Unit_shares">41805347</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_04_2021To07_03_2021"
      decimals="0"
      unitRef="Unit_shares">41805347</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_04_2021To07_03_2021"
      decimals="0"
      id="Fact_26388128"
      unitRef="Unit_shares">41802840</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_04_2021To07_03_2021"
      decimals="0"
      unitRef="Unit_shares">41802840</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">136065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">86839000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">2003000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">102029000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">88283000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">34020000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">29120000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">15943000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7552000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">290060000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">211794000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">8960000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6879000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">52135000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">49800000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">257848000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">191650000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">17669000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14961000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">481000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">19483000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19382000</us-gaap:LongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">646636000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">494466000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">9881000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4422000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">105246000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">88187000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">10875000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11054000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">13220000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3964000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3926000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">158186000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">122589000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">166084000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">173378000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">29249000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">48410000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3362000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">30421000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">24171000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21728000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">427272000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">350306000</us-gaap:Liabilities>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">144160000</us-gaap:MembersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn07_03_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn07_03_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn07_03_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">41062652</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">41062652</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">41062652</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">41062652</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">41000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15786737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15786737</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15786737</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15786737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">146199000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-5167000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">468000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">141557000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">144160000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">77807000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">219364000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">144160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">646636000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">494466000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn04_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">41038589</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn04_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn04_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">15786737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn04_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn04_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">142923000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn04_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">451000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn04_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1041000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn04_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">77892000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn04_03_2021"
      decimals="-3"
      unitRef="Unit_USD">220282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_04_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">24063</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">314000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_04_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">314000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1393000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1319000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="P04_04_2021To07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4126000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-6654000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-10780000</us-gaap:ProfitLoss>
    <bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity
      contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3746000</bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity>
    <bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3746000</bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_04_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4355000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1498000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">5853000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P04_04_2021To07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">17000</bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P04_04_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">23000</bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">41062652</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">15786737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">146199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">468000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5167000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">77807000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">219364000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MembersEquity
      contextRef="PAsOn03_28_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">155590000</us-gaap:MembersEquity>
    <bvs:MembersEquityDecreaseFromDistributionToMembers
      contextRef="P03_29_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8032000</bvs:MembersEquityDecreaseFromDistributionToMembers>
    <us-gaap:ProfitLoss
      contextRef="P03_29_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5980000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P03_29_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MembersEquity
      contextRef="PAsOn06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">141791000</us-gaap:MembersEquity>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">144160000</us-gaap:MembersEquity>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">144160000</us-gaap:MembersEquity>
    <bvs:MembersEquityIncreaseFromRefundsFromMembers
      contextRef="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">123000</bvs:MembersEquityIncreaseFromRefundsFromMembers>
    <bvs:MembersEquityIncreaseFromRefundsFromMembers
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">123000</bvs:MembersEquityIncreaseFromRefundsFromMembers>
    <bvs:MembersEquityDecreaseFromEquityForfeitures
      contextRef="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">39000</bvs:MembersEquityDecreaseFromEquityForfeitures>
    <bvs:MembersEquityDecreaseFromEquityForfeitures
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">39000</bvs:MembersEquityDecreaseFromEquityForfeitures>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">25977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">25977000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1507000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-1507000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquityChangeInReportingEntity
      contextRef="P01_01_2021To07_03_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-168714000</us-gaap:StockholdersEquityChangeInReportingEntity>
    <bvs:StockholdersEquitySharesChangeInReportingEntity
      contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">31838589</bvs:StockholdersEquitySharesChangeInReportingEntity>
    <us-gaap:StockholdersEquityChangeInReportingEntity
      contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:StockholdersEquityChangeInReportingEntity>
    <bvs:StockholdersEquitySharesChangeInReportingEntity
      contextRef="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">15786737</bvs:StockholdersEquitySharesChangeInReportingEntity>
    <us-gaap:StockholdersEquityChangeInReportingEntity
      contextRef="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:StockholdersEquityChangeInReportingEntity>
    <us-gaap:StockholdersEquityChangeInReportingEntity
      contextRef="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">33623000</us-gaap:StockholdersEquityChangeInReportingEntity>
    <us-gaap:StockholdersEquityChangeInReportingEntity
      contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">79119000</us-gaap:StockholdersEquityChangeInReportingEntity>
    <us-gaap:StockholdersEquityChangeInReportingEntity
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-55924000</us-gaap:StockholdersEquityChangeInReportingEntity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">9200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">106441000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To07_03_2021_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">106450000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">24063</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">314000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">314000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">191000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">191000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <bvs:NetLossSubsequentToOrganizationalTransactions
      contextRef="P01_01_2021To07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5167000</bvs:NetLossSubsequentToOrganizationalTransactions>
    <bvs:NetLossSubsequentToOrganizationalTransactions
      contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-7062000</bvs:NetLossSubsequentToOrganizationalTransactions>
    <bvs:NetLossSubsequentToOrganizationalTransactions
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-12229000</bvs:NetLossSubsequentToOrganizationalTransactions>
    <bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity
      contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3746000</bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity>
    <bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3746000</bvs:NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2015000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">7836000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2021To07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">468000</bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2021To07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">180000</bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">648000</bvs:OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">41062652</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">15786737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">146199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">468000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5167000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">77807000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">219364000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2018_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">145617000</us-gaap:MembersEquity>
    <bvs:MembersEquityDecreaseFromProfitInterestForfeiture
      contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">12000</bvs:MembersEquityDecreaseFromProfitInterestForfeiture>
    <bvs:MembersEquityDecreaseFromDistributionToMembers
      contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8713000</bvs:MembersEquityDecreaseFromDistributionToMembers>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4506000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-256000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MembersEquity
      contextRef="PAsOn06_27_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">141791000</us-gaap:MembersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">13748000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">4506000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">14663000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">14513000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-359000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1162000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">7797000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensation>
    <bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">24356000</bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation>
    <bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">6771000</bvs:ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">641000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1310000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-2001000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <bvs:ChangeInFairValueOfEquityParticipationRightsUnit
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">2774000</bvs:ChangeInFairValueOfEquityParticipationRightsUnit>
    <bvs:ChangeInFairValueOfEquityParticipationRightsUnit
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">788000</bvs:ChangeInFairValueOfEquityParticipationRightsUnit>
    <bvs:ImpairmentOfVariableInterestEntityAndRelatedAssets
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">7043000</bvs:ImpairmentOfVariableInterestEntityAndRelatedAssets>
    <bvs:ImpairmentOfVariableInterestEntityAndRelatedAssets
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:ImpairmentOfVariableInterestEntityAndRelatedAssets>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-255000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-134000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">9370000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-16631000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-3913000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">6329000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">2917000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1587000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">13011000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">867000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-713000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">25511000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">45790000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">2642000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1050000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">864000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">152000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-49296000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-1202000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">172000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-49296000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-1030000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">107777000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">330000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">49000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">7500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">2500000</us-gaap:RepaymentsOfLongTermDebt>
    <bvs:ProceedsFromMembers
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">813000</bvs:ProceedsFromMembers>
    <bvs:ProceedsFromMembers
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-9075000</bvs:ProceedsFromMembers>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-11000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">101409000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">37425000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-171000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-186000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">51229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">61720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">86839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">64520000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">138068000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">126240000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bvs:MemberDistributionsIncurredButNotYetPaid
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">305000</bvs:MemberDistributionsIncurredButNotYetPaid>
    <bvs:MemberDistributionsIncurredButNotYetPaid
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">787000</bvs:MemberDistributionsIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">695000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Organization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bioventus Inc. (the Company, we, us or our) was formed as a Delaware corporation for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (BV LLC). The Company is headquartered in Durham, North Carolina. BV LLC, is a limited liability company formed under the laws of the state of Delaware on November&#160;23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. BV LLC is a global medical device company, conducting business in various countries, primarily in North America and Europe, with approximately 900 employees. The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#x2019;s natural healing processes. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial Public Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On February&#160;16, 2021, the Company closed an IPO of 9,200,000 shares of Class&#160;A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#x2019; over-allotment option. The Company received $111,228 in proceeds, net of underwriting discounts and commissions of $8,372, which was used to purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of $13.00. The Company also incurred offering expenses totaling $4,778 in addition to the underwriting discounts and commissions. Offering expenses of $1,327 were paid in 2020 and $3,451 were paid in 2021. Subsequent to the IPO and related transactions that occurred in connection with the IPO (the Transactions), the Company is the sole managing member of BV LLC and owns 72.2% of BV LLC. The Company has a majority economic interest, the sole voting interest in, and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest representing the 27.8% interest not held by the Company. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPO Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company and BV LLC completed the following Transactions in connection with the IPO. BV LLC amended and restated the Bioventus LLC Agreement, to, among other things, (i)&#160;provide for a new single class of common membership interests in BV LLC (LLC Interests), (ii) exchange all of the existing membership interests in BV LLC for new LLC Interests and (iii)&#160;appoint Bioventus Inc. as the sole managing member of BV LLC. The Company amended and restated its certificate of incorporation to, among other things, provide for the (i)&#160;authorization of 250,000,000 shares of Class&#160;A common stock with a par value of $0.001 per share; (ii)&#160;authorization of 50,000,000 shares of Class&#160;B common stock with a par value of $0.001 per share; (iii)&#160;authorization of 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company&#x2019;s Board of Directors (BOD) in one or more series; and (iv)&#160;establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms. Holders of Class&#160;A / Class&#160;B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class&#160;B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class&#160;B common stock may only be issued to the extent necessary to maintain the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-to-one&lt;/div&gt;&lt;/div&gt; ratio between the number of LLC Interests held by the only member of BV LLC that remained a member following the Transactions (Continuing LLC Owner) and the number of shares of Class&#160;B common stock held by the Continuing LLC Owner. Shares of Class&#160;B common stock are transferable only together with an equal number of LLC Interests. Shares of Class&#160;B common stock will be canceled on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis if the Company, at the election of a Continuing LLC Owner, redeem or exchange LLC Interests. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s amended and restated certificate of incorporation and the Bioventus LLC Agreement requires that the Company and BV LLC at all times maintain a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-to-one&lt;/div&gt;&lt;/div&gt; ratio between the number of shares of Class&#160;A common stock issued by the Company and the number of LLC Interests owned by the Company, as well as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-to-one&lt;/div&gt;&lt;/div&gt; ratio between the number of shares of Class&#160;B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. The Company acquired, by merger, ten entities that were members of BV LLC (Former LLC Owners), for which the Company issued 31,838,589 shares of Class&#160;A common stock as merger consideration (Merger). The only assets held by the Former LLC Owners were 31,838,589 LLC Interests and a corresponding number of shares of Class&#160;B common stock. Upon consummation of the Merger, the Company canceled the 31,838,589 shares of Class&#160;B common stock and recognized the 31,838,589 LLC Interests at carrying value, as the Merger is considered to be a recapitalization transaction. Following the Merger and IPO, as of August&#160;10, 2021, the Company holds 41,062,652 LLC Interests, representing a 72.2% ownership interest in BV LLC. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements for periods prior to the IPO and Transactions have been adjusted to combine the previously separate entities for presentation purposes. Prior to the Transactions, Bioventus Inc. had no operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interim periods &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company reports quarterly interim periods on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13-week&lt;/div&gt; basis within a standard calendar year. Each annual reporting period begins on January&#160;1 and ends on December 31. Each quarter ends on the Saturday closest to calendar &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;quarter-end,&lt;/div&gt; with the exception of the fourth quarter, which ends on December 31. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13-week&lt;/div&gt; quarterly periods for fiscal year 2021 end on April&#160;3, July&#160;3 and October 2. Comparable periods for 2020 ended on March&#160;28, June&#160;27 and September 26. The fourth and first quarters may vary in length depending on the calendar year. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unaudited interim financial information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-01&lt;/div&gt; of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Pursuant to these rules and regulations they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company&#x2019;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company&#x2019;s 2020 Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K.&lt;/div&gt; The balance sheet at December&#160;31, 2020 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic impact &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In 2020, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic spread around the world and in the United States. New variants of the virus have emerged, some of which have shown to be more contagious. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of businesses, work from home, supply chain logistical changes and other measures, which caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted by fluctuations in patient visits and elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;from customers, supply chain interruptions, extended &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;shelter-in-place&#x201d;&lt;/div&gt;&lt;/div&gt; orders or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; on our business will depend on many factors, including, but not limited to, the duration and severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability, adoption and effectiveness of vaccines, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on our partners, patients and communities in which we operate, all of which continue to be uncertain. As of the date of issuance of these consolidated financial statements, the extent to which &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; could materially impact the Company&#x2019;s financial conditions, liquidity or results of operations is uncertain. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;To the extent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully commercialize newly developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual relationships. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On March&#160;27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law, which was aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As a result of the CARES Act and at the direction of the U.S. Department of Health and Human Services (HHS), the Company received a $1,247 Provider Relief Fund Payment in April 2020. The Company determined it complied with the conditions to be able to keep and use the funds to reimburse for health care related expenses and lost revenue attributable to the public health emergency resulting from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; The payment was recorded as other income on the consolidated statement of operations and comprehensive (loss) income for the three and six months ended June&#160;27, 2020. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recent accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has elected to comply with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-accelerated&lt;/div&gt; public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are generally earlier than when emerging growth companies are required to adopt. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Pronouncements Recently Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;(ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12),&lt;/div&gt; which amended the accounting for income taxes. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; eliminates certain exceptions to the guidance for income taxes related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in the tax basis of goodwill. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; on January&#160;1, 2021 and it did not have a material impact on its consolidated financial statements. &lt;/div&gt; </us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="PAsOn07_03_2021_BioventusIncMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_EMPLOYEE">900</dei:EntityNumberOfEmployees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">9200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_16_2021To02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">111228000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">8372000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.00</us-gaap:SaleOfStockPricePerShare>
    <bvs:SaleOfStockOfferingCosts
      contextRef="P02_16_2021To02_16_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">4778000</bvs:SaleOfStockOfferingCosts>
    <bvs:PaymentsOfStockIssuanceCostsAdditionalCosts
      contextRef="P01_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">1327000</bvs:PaymentsOfStockIssuanceCostsAdditionalCosts>
    <bvs:PaymentsOfStockIssuanceCostsAdditionalCosts
      contextRef="P01_01_2021To07_03_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">3451000</bvs:PaymentsOfStockIssuanceCostsAdditionalCosts>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest
      contextRef="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.722</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn07_03_2021_BVLLCMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.278</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn02_16_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn02_16_2021"
      decimals="0"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <bvs:CommonStockNumberOfVotes
      contextRef="P01_01_2021To07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_Vote">1</bvs:CommonStockNumberOfVotes>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_pure">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <bvs:CancellationRatioRequiredStockToLLCInterestRatio
      contextRef="PAsOn02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_pure">1</bvs:CancellationRatioRequiredStockToLLCInterestRatio>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_pure">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio
      contextRef="PAsOn07_03_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_pure">1</bvs:SharesIssuedOrIssuableRequiredStockToLLCInterestRatio>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_Business">10</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P02_16_2021To02_16_2021_BVLLCMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">31838589</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">31838589</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="P02_16_2021To02_16_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">31838589</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn02_16_2021_BioventusIncMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">31838589</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld
      contextRef="PAsOn08_10_2021_BioventusIncMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">41062652</bvs:LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest
      contextRef="P08_10_2021To08_10_2021_BVLLCMembersrtOwnershipAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.722</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest>
    <bvs:ProceedsFromGovernmentalAssistance
      contextRef="P04_01_2020To04_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1247000</bvs:ProceedsFromGovernmentalAssistance>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_04_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recent accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has elected to comply with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-accelerated&lt;/div&gt; public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are generally earlier than when emerging growth companies are required to adopt. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Pronouncements Recently Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;(ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12),&lt;/div&gt; which amended the accounting for income taxes. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; eliminates certain exceptions to the guidance for income taxes related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in the tax basis of goodwill. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; on January&#160;1, 2021 and it did not have a material impact on its consolidated financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Balance sheet information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of cash and cash equivalents and restricted cash is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,065&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Restricted cash consists of deposits into escrow with a financial institution for the purpose of paying specific indebtedness of a company acquired as part of a business combination (refer to&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Note 3. Business combinations and investments&lt;/div&gt;&lt;/div&gt;). &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net of allowances, consisted of the following as of: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105,048&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to make required payments. The allowance for credit losses is calculated by region and by customer type, where appropriate considering several factors including age of accounts, collection history, historical account write-offs, current economic conditions, and supportable forecasted economic expectations. Due to the short-term nature of its receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. An increase in the provision for credit losses may be required when the financial condition of the Company&#x2019;s customers or its collection experience deteriorates. The Company has a diverse customer base with no single customer representing ten percent of sales or accounts receivable. Historically, the Company&#x2019;s reserves have been adequate to cover credit losses. The Company&#x2019;s exposure to credit losses may increase if its customers are adversely affected by changes in health care laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic, or other customer-specific factors. The Company considered the current and expected future economic and market conditions surrounding the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and determined that the estimate of credit losses was not significantly impacted. Estimates are used to determine the allowance, which are based on an assessment of anticipated payment and all other historical, current and future information that is reasonably available. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in credit losses were as &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;follows&lt;/div&gt;: &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,811&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recovery (provision)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;359&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write-offs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;252&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recoveries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory consisted of the following as of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,202&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished goods&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,740&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Excess and obsolete reserves&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consisted of the following as of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross-to-net&lt;/div&gt;&lt;/div&gt; deductions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;63,980&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,656&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonus and commission&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,493&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income and other taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,434&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company completed a restructuring plan during the fourth quarter of 2020 and the remaining $247 accrued liabilities were paid during the six months ended July&#160;3, 2021. &lt;/div&gt;&lt;/div&gt; </us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of cash and cash equivalents and restricted cash is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,065&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of cash and cash equivalents and restricted cash is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,065&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,003&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">136065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">86839000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">2003000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">138068000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">86839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net of allowances, consisted of the following as of: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105,048&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Allowance for credit losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">105048000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">92273000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3019000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3990000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">102029000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">88283000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in credit losses were as &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;follows&lt;/div&gt;: &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,811&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recovery (provision)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;359&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write-offs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;252&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recoveries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(193&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn04_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3811000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn03_28_2020"
      decimals="-3"
      unitRef="Unit_USD">4684000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3990000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4146000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-550000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">619000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-359000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1162000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">278000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">167000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">684000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">252000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">113000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">72000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">193000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3019000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">5249000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3019000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">5249000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory consisted of the following as of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,202&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished goods&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,740&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Excess and obsolete reserves&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">4202000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3665000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">31538000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26323000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">35740000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">29988000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1720000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">868000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">34020000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">29120000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consisted of the following as of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross-to-net&lt;/div&gt;&lt;/div&gt; deductions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;63,980&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,656&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bonus and commission&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,493&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,188&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income and other taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,434&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;88,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bvs:GrossToNetDeductionsCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">63980000</bvs:GrossToNetDeductionsCurrent>
    <bvs:GrossToNetDeductionsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43656000</bvs:GrossToNetDeductionsCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">12493000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15188000</us-gaap:AccruedBonusesCurrent>
    <bvs:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">7932000</bvs:AccruedSalariesAndEmployeeBenefitsCurrent>
    <bvs:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5875000</bvs:AccruedSalariesAndEmployeeBenefitsCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">2385000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2434000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">18456000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21034000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">105246000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">88187000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">247000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">247000</us-gaap:RestructuringReserveCurrent>
    <bvs:BusinessCombinationsAndInvestmentsDisclosureTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Business combinations and investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;30, 2021, in order to broaden its portfolio and increase its global footprint, the Company acquired 100% of the capital stock of Bioness, Inc. (Bioness). Bioness is a global leader in neuromodulation and advanced rehabilitation medical devices through its innovative peripheral nerve stimulation therapy and premium advanced rehabilitation solutions. The Company had previously made a $1,500 convertible debt investment in Bioness on &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January&#160;4, 2021 as part of an exclusive negotiation to purchase Bioness, which was subsequently repaid in conjunction with the acquisition. The consideration paid for Bioness is comprised of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash consideration at closing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Bioness consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Contingent consideration is comprised of future &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;earn-out&lt;/div&gt; payments contingent upon the achievement of certain research and development projects as well as sales milestones related to Bioness products. Contingent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;earn-out&lt;/div&gt; payments could total up to $65,000 for the achievement of the following: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$15,000 for obtaining FDA approval for U.S. commercial distribution of a certain product for certain indications on or before June&#160;30, 2022; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$20,000 for meeting net sales targets for certain implantable products over a three year period ending on June&#160;30, 2025 at the latest; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Up to $10,000 for meeting net sales milestones for certain implantable products over a three year period ending on June&#160;30, 2025 at the latest; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$20,000 for maintaining Centers for Medicare&#160;&amp;amp; Medicaid Services coverage and reimbursement for certain products at specified levels as of December&#160;31, 2024. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The allocation of the purchase price is preliminary and subject to change. The primary areas of the purchase price that are not yet finalized are related to contingent consideration, working capital, intangible assets and the residual goodwill. Accordingly, adjustments may be made to the values of assets and liabilities assumed as additional information is obtained about the facts and circumstances that existed at the acquisition date. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date and the resulting goodwill, which is expected to be deductible for tax purposes: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;91,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired and liabilities assumed:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid and other current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,947&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;673&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,616&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,598&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Resulting goodwill&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(b)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,335&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consists of cash and cash equivalents of $2,143 and restricted cash deposited by the former majority owner of Bioness of $1,000, into escrow with financial institutions for the purpose of paying specific Bioness indebtedness. The Company previously deposited $4,207 into escrow for the same purpose. Prior to the acquisition, Bioness had entered into two loans in connection with the Paycheck Protection Program (the PPP) under the Coronavirus Aid, Relief and Economic Security Act (CARES Act) administered by the U.S. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;Small business Administration. Bioness received proceeds of $3,204 from an unsecured PPP loan that was scheduled to mature on April&#160;10, 2022. Bioness applied and was granted forgiveness of this loan during 2021. Bioness received proceeds of $2,003 from a second unsecured PPP loan bearing an interest rate of 1% scheduled to mature on February&#160;5, 2026. Bioness applied for forgiveness of this loan during 2021. As part of the Bioness acquisition, the balance of $2,003 was placed in restricted cash to cover the repayment of the outstanding unsecured PPP loan in the event it is not forgiven. The $1,000 outstanding unsecured PPP loan balance covered by the former majority owner is included in other current liabilities within the condensed consolidated balance sheets. &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(b)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The U.S. segment was allocated the resulting goodwill from the Bioness acquisition. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the preliminary fair values of identifiable intangible assets and their useful lives: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Useful&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: center;"&gt;N/A&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: center;"&gt;2 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate amortization expense related to acquired intangible assets for the following five periods is as follows: $2,238&#x2014;remainder of 2021, $4,475&#x2014;2022, $4,381&#x2014;2023, $4,350&#x2014;2024 and $4,350&#x2014;2025. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company incurred $1,833 and $5,029 in acquisition and integration costs during the three and six months ended July&#160;3, 2021, respectively, which are included in selling general and administrative expense within the consolidated condensed statement of operations and other comprehensive (loss) income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bioness&#x2019; advanced rehabilitation revenue is comprised of Exoskeletal Systems, Vector Units and Bioness Integrated Therapy Systems (BITS), which is included within the Company&#x2019;s Restorative Therapies vertical. The Company&#x2019;s Pain Treatment and Joint Preservation vertical will encompass Bioness&#x2019; peripheral nerve stimulation therapy products, which includes the StimRouter, an implantable neuromodulation device used to treat chronic peripheral nerve pain. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from Bioness&#x2019; products is primarily recognized at a point in time upon transfer of control of its products to customers such as medical facilities and individual patients. Revenue is recognized net of discounts, which can be offered through a variety of factors. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Consolidated Pro Forma Results &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s consolidated condensed statements of operations reflect net sales and net loss attributable to Bioness of $11,870 and $3,529, respectively, for the three and six months ended July&#160;3, 2021. Consolidated unaudited pro forma results of operations for the Company are presented below assuming the 2021 Bioness Acquisition had occurred January&#160;1, 2020. Pro forma operating results for the three and six months ended June&#160;27, 2020 include operating expenses of $3,939 and $7,135, respectively, for acquisition integration costs and inventory related adjustments. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net sales&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;109,816&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200,541&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;157,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net (loss) income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(6,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(11,376&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share of Class&#160;A common stock(1):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;VIE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has a fully diluted 8.8% ownership of Harbor Medtech Inc.&#x2019;s (Harbor) Series C Preferred Stock. The Company and Harbor entered into an exclusive Collaboration Agreement in 2019 for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. The Company&#x2019;s partial ownership and exclusive Collaboration Agreement created a variable interest in Harbor. As a result, Harbor had been consolidated in the Company&#x2019;s consolidated financial statements since the third quarter of 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harbor assets that could only be used to settle Harbor obligations and Harbor liabilities for which creditors did not have recourse to the general credit of the Company were as follows at December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,863&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company terminated the Collaboration Agreement on June&#160;8, 2021 and determined that the termination was a triggering event requiring an impairment assessment of Harbor&#x2019;s long lived assets. The assessment resulted in an impairment of $5,674, representing Harbor&#x2019;s long-lived asset balance, which was recorded within impairment of variable entity assets in the consolidated condensed statements of operations and comprehensive (loss) income, of which $5,176 is attributable to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest. The Company stopped consolidating Harbor upon the termination of the Collaboration Agreement, as the Company ceased being the primary beneficiary because it no longer had the power to direct Harbor&#x2019;s significant activities. The Company also assessed its Harbor investment post deconsolidation, which resulted in a $1,369 impairment, representing the remaining investment balance in Harbor and was recorded within other expense in the consolidated condensed statements of operations and comprehensive (loss) income. The Company continues to have license rights to certain technology obtained from Harbor and is continuing product development initiated under the Collaboration Agreement. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity Method &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has an equity investment in CartiHeal Ltd. (CartiHeal), a privately held entity that does not have a readily determinable fair value, which the Company began recording as an equity investment during the third quarter of 2020. The CartiHeal investment carrying value totaled $17,737 as of July&#160;3, 2021, yielding a 10.03% fully diluted equity ownership. Net losses from CartiHeal for the three and six months ended July&#160;3, 2021 totaled $432 and $901, respectively, which are included in other expense within the consolidated condensed statement of operations and other comprehensive (loss) income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will, if needed to support the completion of a certain study, purchase an additional 338,089 of CartiHeal Series G Preferred Shares for $5,000. The Company has an exclusive option to acquire the remaining equity in CartiHeal, which may be exercised at any time up to and within 45 days following notice of the U.S. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Food and Drug Administration (FDA) approval for a CartiHeal product currently in development. In addition, upon the same FDA approval, CartiHeal may exercise an option within 45 days that requires the Company to complete the acquisition of the remaining equity in CartiHeal. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On July&#160;15, 2020, the Company entered into an Option and Equity Purchase Agreement with CartiHeal. The agreement provides the Company with an exclusive option to acquire 100% of CartiHeal&#x2019;s shares under certain conditions, or the Call Option, and provides CartiHeal with a put option that would require us to purchase 100% of CartiHeal&#x2019;s shares under certain conditions, or the Put Option. The Put Option is only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Agili-C&lt;/div&gt; device with a label consistent in all respects with pivotal clinical trial success. The pivotal clinical trial&#x2019;s objective is to demonstrate the superiority of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Agili-C&lt;/div&gt; implant over the surgical standard of care, including microfracture and debridement, for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On August&#160;2, 2021, CartiHeal provided a statistical report containing the results of the pivotal clinical trial. The Company is currently reviewing the report to assess if it is consistent with the terms of the agreement and assessing the findings to determine if all required endpoint have been achieved. CartiHeal continues to work toward submitting the final, clinical module of a Modular PMA in the fourth quarter of 2021 seeking FDA approval. The Company has the right to terminate the Call Option and Put Option at any time ending 30 days after receipt of the statistical report from CartiHeal upon payment of a break fee of $30,000. If the Company determines that the results satisfy the requirements of the contract, and elect not to exercise its right to terminate the Call Option and Put Option, the Company will be required to put $50,000 into escrow as a deposit towards the purchase price. Consideration for the acquisition of all of the shares of CartiHeal, excluding those the Company owns, pursuant to the Call Option or Put Option would be $314,895, inclusive of the deposit, all of which would be payable at closing, with an additional $150,000 payable upon achievement of certain sales milestones related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Agili-C.&lt;/div&gt; Such closing would be subject to customary closing conditions. CartiHeal has announced that it expects to submit its PMA application to the FDA later this year. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;24, 2021, the Company purchased 406,504 shares of Vaporox, Inc&#x2019;s (Vaporox) Series A Preferred Stock or 6.0% of fully diluted shares for $1,000. Vaporox, a privately held entity, is a medical device company dedicated to healing diabetic foot ulcers and does not have a readily determinable fair value. Under the measurement alternative, the investment is recorded at cost, less any impairment, plus or minus any changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. &lt;/div&gt;&lt;/div&gt;</bvs:BusinessCombinationsAndInvestmentsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1500000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="P01_01_2021To07_03_2021">The consideration paid for Bioness is comprised of the following:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash consideration at closing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Bioness consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">48933000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">43000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">91933000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_USD">65000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ObtainingFDAApprovalOfCertainProductsMemberusgaapContingentConsiderationByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMemberusgaapContingentConsiderationByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMemberusgaapContingentConsiderationByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_ForObtainingCMSCoverageAndReimbursementForCertainProductsMemberusgaapContingentConsiderationByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2021To07_03_2021">The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date and the resulting goodwill, which is expected to be deductible for tax purposes: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;91,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired and liabilities assumed:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid and other current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,947&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;673&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,616&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,598&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Resulting goodwill&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(b)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,335&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consists of cash and cash equivalents of $2,143 and restricted cash deposited by the former majority owner of Bioness of $1,000, into escrow with financial institutions for the purpose of paying specific Bioness indebtedness. The Company previously deposited $4,207 into escrow for the same purpose. Prior to the acquisition, Bioness had entered into two loans in connection with the Paycheck Protection Program (the PPP) under the Coronavirus Aid, Relief and Economic Security Act (CARES Act) administered by the U.S. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;Small business Administration. Bioness received proceeds of $3,204 from an unsecured PPP loan that was scheduled to mature on April&#160;10, 2022. Bioness applied and was granted forgiveness of this loan during 2021. Bioness received proceeds of $2,003 from a second unsecured PPP loan bearing an interest rate of 1% scheduled to mature on February&#160;5, 2026. Bioness applied for forgiveness of this loan during 2021. As part of the Bioness acquisition, the balance of $2,003 was placed in restricted cash to cover the repayment of the outstanding unsecured PPP loan in the event it is not forgiven. The $1,000 outstanding unsecured PPP loan balance covered by the former majority owner is included in other current liabilities within the condensed consolidated balance sheets. &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(b)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The U.S. segment was allocated the resulting goodwill from the Bioness acquisition. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">91933000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">3143000</bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">4124000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">7318000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">1947000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">673000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">87000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">3616000</bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">132000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">11405000</bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">2020000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">4930000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">89598000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">2335000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">2143000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</bvs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:EscrowDeposit
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">4207000</us-gaap:EscrowDeposit>
    <bvs:DebtInstrumentNumberOfLoans
      contextRef="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis"
      decimals="0"
      unitRef="Unit_Loans">2</bvs:DebtInstrumentNumberOfLoans>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingApril102022MemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3204000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingFebruary52026MemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2003000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn03_29_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P12_30_2020To03_29_2021_BionessIncMemberdeiLegalEntityAxis_PaycheckProtectionProgramCARESActMaturingFebruary52026MemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2003000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn07_03_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the preliminary fair values of identifiable intangible assets and their useful lives: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Useful&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual property&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: center;"&gt;N/A&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; width: 72%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer relationships&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: center;"&gt;2 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 72%;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">43500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">43250000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_CustomerRelationshipsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">250000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">87000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="PAsOn03_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2238000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn03_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4475000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn03_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4381000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn03_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4350000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn03_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4350000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1833000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">5029000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">11870000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3529000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="P01_01_2021To07_03_2021">Consolidated unaudited pro forma results of operations for the Company are presented below assuming the 2021 Bioness Acquisition had occurred January&#160;1, 2020. Pro forma operating results for the three and six months ended June&#160;27, 2020 include operating expenses of $3,939 and $7,135, respectively, for acquisition integration costs and inventory related adjustments. &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net sales&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;109,816&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200,541&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;157,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net (loss) income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(6,841&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,333&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(11,376&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share of Class&#160;A common stock(1):&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">3939000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">7135000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">109816000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="P03_28_2020To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">65955000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">200541000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="P12_28_2019To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">157570000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">-6841000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="P03_28_2020To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">-12962000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">16333000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="P12_28_2019To06_27_2020_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">-11376000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="P01_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="P01_01_2021To07_03_2021"
      decimals="3"
      unitRef="Unit_pure">0.088</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Harbor assets that could only be used to settle Harbor obligations and Harbor liabilities for which creditors did not have recourse to the general credit of the Company were as follows at December&#160;31, 2020: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,863&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">803000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">173000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">5635000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">6863000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">366000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">2004000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">659000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">3029000</us-gaap:Liabilities>
    <us-gaap:AssetImpairmentCharges
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">5674000</us-gaap:AssetImpairmentCharges>
    <bvs:AssetImpairmentChargesAttributableToNoncontrollingInterest
      contextRef="P06_08_2021To06_08_2021"
      decimals="-3"
      unitRef="Unit_USD">5176000</bvs:AssetImpairmentChargesAttributableToNoncontrollingInterest>
    <bvs:VariableInterestEntityImpairment
      contextRef="P06_08_2021To06_08_2021"
      decimals="-3"
      unitRef="Unit_USD">1369000</bvs:VariableInterestEntityImpairment>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">17737000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_03_2021"
      decimals="4"
      unitRef="Unit_pure">0.1003</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">432000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">901000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares
      contextRef="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">338089</bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares>
    <bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount
      contextRef="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis_SeriesGPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">5000000</bvs:EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount>
    <bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment contextRef="P01_01_2021To07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis">P45D</bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment>
    <bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased contextRef="P01_01_2021To07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis">P45D</bvs:EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn07_03_2021_CartiHealMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <bvs:BusinessAcquisitionPeriodOfNoticeForTermination contextRef="P08_02_2021To08_02_2021">P30D</bvs:BusinessAcquisitionPeriodOfNoticeForTermination>
    <bvs:BusinessAcquisitionPaymentDueUponTerminationOfAgreement
      contextRef="P08_02_2021To08_02_2021"
      decimals="-3"
      unitRef="Unit_USD">30000000</bvs:BusinessAcquisitionPaymentDueUponTerminationOfAgreement>
    <us-gaap:EscrowDeposit
      contextRef="PAsOn08_02_2021"
      decimals="-3"
      unitRef="Unit_USD">50000000</us-gaap:EscrowDeposit>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P08_02_2021To08_02_2021"
      decimals="-3"
      unitRef="Unit_USD">314895000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <bvs:BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones
      contextRef="P08_02_2021To08_02_2021"
      decimals="-3"
      unitRef="Unit_USD">150000000</bvs:BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="PAsOn06_24_2021_VaporoxMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="0"
      unitRef="Unit_shares">406504</us-gaap:InvestmentOwnedBalanceShares>
    <bvs:InvestmentOwnedOwnershipPercentage
      contextRef="PAsOn06_24_2021_VaporoxMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.060</bvs:InvestmentOwnedOwnershipPercentage>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="PAsOn06_24_2021_VaporoxMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt consists of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term loan due December 2024 (2.60% at July&#160;3, 2021)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;190,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of long-term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;166,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The 2019 Credit Agreement requires the Company to comply with financial and other covenants. The Company complied with all covenants as of July&#160;3, 2021. The 2019 Credit Agreement contains a $50,000 revolving credit facility, from which there were no outstanding borrowings as of July&#160;3, 2021 and December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The estimated fair value of the Term Loan as of July&#160;3, 2021 was $184,505. The fair value of these obligations was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar obligations and are classified as Level&#160;2 instruments within the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company enters into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. The Company has one &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-designated&lt;/div&gt; interest rate swap agreement and has no other active derivatives. The swap is carried at fair value on the balance sheet (Refer to&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Note 5. Fair value measurements&lt;/div&gt;&lt;/div&gt;) with changes in fair value recorded as interest income or expense within the consolidated statements of operations and comprehensive (loss) income. Net interest expense of $255 and $933 was recorded related to the change in fair value of the interest rate swap for the three months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. Net interest income of $1,310 and expense of $2,001 was recorded related to the change in fair value of the interest rate swap for the six months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The notional amount of the swap totaled $100,000, or 54.8% of the Term Loan outstanding principal at July&#160;3, 2021. The swap locked in the variable portion of the interest rate on the $100,000 notional at 0.64%. &lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt consists of the following: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term loan due December 2024 (2.60% at July&#160;3, 2021)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;190,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of long-term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(457&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;166,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn07_03_2021"
      decimals="4"
      unitRef="Unit_pure">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">182500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">190000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">959000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1098000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">457000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">524000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">166084000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">173378000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LineOfCredit>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">184505000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="0"
      unitRef="Unit_Segment">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P04_04_2021To07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">255000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P03_29_2020To06_27_2020_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">933000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2021To07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">1310000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2020To06_27_2020_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">2001000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:PercentageOfDebtHedgedByInterestRateDerivatives
      contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="3"
      unitRef="Unit_pure">0.548</us-gaap:PercentageOfDebtHedgedByInterestRateDerivatives>
    <us-gaap:DerivativeNotionalAmount
      contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      unitRef="Unit_USD">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="PAsOn07_03_2021_InterestRateSwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0064</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Fair value measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Our process for determining fair value has not changed from that described in the Company&#x2019;s 2020 Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K.&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level&#160;1 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level&#160;2 and Level&#160;3 inputs:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest rate swap&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term contingent consideration, less current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management incentive plan and liability-classified awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity Participation Right&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interest rate swap &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company values interest rate swaps using discounted cash flows. Forward curves and volatility levels are used to estimate future cash flows that are not certain. These are determined using observable market inputs when available and based on estimates when not available. The fair value of the swap was recorded in the Company&#x2019;s consolidated balance sheets within accrued liabilities. Changes in fair value are recognized as interest expense (income) within the consolidated statements of operations and comprehensive (loss) income. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;Contingent consideration&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue and the probability of achieving the specific targets as discussed in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 3. Business combinations and investments&lt;/div&gt;&lt;/div&gt;. After the initial valuation, the Company will use its best estimate to measure contingent consideration related to the Bioness Acquisition at each subsequent reporting period using the following unobservable Level&#160;3 inputs:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 26%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 22%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation Technique&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bioness contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Discounted cash flow&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;Payment discount rate&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;5.0% - 6.8%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;Payment period&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2021 - 2025&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The contingent consideration reported in the above table resulted from the March&#160;30, 2021 Bioness acquisition, which is adjusted on a monthly basis based upon the passage of time or success or failure of achieving certain milestones. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 3. Business combinations and investments&lt;/div&gt;&lt;/div&gt; for further details. Changes in contingent consideration related to the Bioness acquisition totaled $641 for the three and six months ended July&#160;3, 2021, which were recorded as the change in fair value of contingent consideration within the consolidated statements of operations and comprehensive (loss) income. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Management incentive plan (MIP) and liability-classified awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;BV LLC had operated two equity-based compensation plans, the management incentive plan (MIP) and the BV LLC Phantom Profits Interest Plan (Phantom Plan and, together with the MIP, the Plans), which were terminated on February&#160;11, 2021 in connection with the Company&#x2019;s IPO. Awards granted under the MIP Plan and the 2015 Phantom Units were liability-classified and the 2012 Phantom Units were equity-classified. Prior to the IPO and during the six months ended July&#160;3, 2021, the Company settled the remaining 183,078 units with the sole MIP awardee for $10,802. No awards under the Plans were granted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;post-IPO&lt;/div&gt; and the Phantom Plan awards will be settled 12 months following the termination. Vested awardees whose BV LLC employment terminated prior to the IPO will have their awards settled for $10,875, which is included in accrued equity-based compensation on the consolidated condensed balance sheets. Awardees that were active BV LLC employees at the IPO will receive an aggregate of 798,422 shares of Class&#160;A common stock. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level&#160;3: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(25,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial estimate (vesting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;829&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Phantom plan conversion to Class&#160;A common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity Participation Right (EPR) Unit &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the IPO, the Continuing LLC owner owned the only EPR Unit and its only entitlement was 0.55% of available distributions arising from a distribution event such as the IPO. The EPR Unit was redeemed in exchange for $3,327 in connection with the IPO in February 2021, at which time the EPR ceased to exist and all entitlements ended. The revaluation for the EPR liability is recognized in interest (income) expense on the consolidated statements of operations and comprehensive (loss) income. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level&#160;3: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2021To07_03_2021">The following table provides information for liabilities measured at fair value on a recurring basis using Level&#160;2 and Level&#160;3 inputs:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest rate swap&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term contingent consideration, less current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management incentive plan and liability-classified awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity Participation Right&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46,404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">292000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">292000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1602000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1602000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">13220000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">13220000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">30421000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">30421000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">40303000</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">40303000</bvs:ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:EquityParticipationRightFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:EquityParticipationRightFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:EquityParticipationRightFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">6101000</bvs:EquityParticipationRightFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bvs:EquityParticipationRightFairValueDisclsoure>
    <bvs:EquityParticipationRightFairValueDisclsoure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">6101000</bvs:EquityParticipationRightFairValueDisclsoure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">43933000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn07_03_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">292000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">43641000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">48006000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1602000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">46404000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2021To07_03_2021">After the initial valuation, the Company will use its best estimate to measure contingent consideration related to the Bioness Acquisition at each subsequent reporting period using the following unobservable Level&#160;3 inputs:&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 26%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 22%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation Technique&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Range&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bioness contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;Discounted cash flow&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;Payment discount rate&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;5.0% - 6.8%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;Payment period&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;2021 - 2025&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis"
      decimals="1"
      unitRef="Unit_pure">5.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis"
      decimals="1"
      unitRef="Unit_pure">6.8</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">641000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bvs:NumberOfEquityBasedCompensationPlans
      contextRef="PAsOn07_03_2021"
      decimals="0"
      unitRef="Unit_Business">2</bvs:NumberOfEquityBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">183078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10802000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P01_01_2021To07_03_2021_BVLLCEmployeesTerminatedPriorToIPOMembersrtTitleOfIndividualAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10875000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2021To07_03_2021_BVLLCEmployeesActiveAtIPOMembersrtTitleOfIndividualAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">798422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level&#160;3: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;40,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(25,185&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial estimate (vesting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;829&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Phantom plan conversion to Class&#160;A common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level&#160;3: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,774&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">40303000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-25185000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">829000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11281000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity
      contextRef="P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4666000</bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <bvs:EquityParticipationRightEntitledPercentageOfDistributions
      contextRef="PAsOn02_15_2021"
      decimals="4"
      unitRef="Unit_pure">0.0055</bvs:EquityParticipationRightEntitledPercentageOfDistributions>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P02_16_2021To02_16_2021_EquityParticipationRightUnitMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3327000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">6101000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2021To07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-2774000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2021To07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3327000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Equity-based compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Terminated plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Prior to the IPO, BV LLC operated two equity-based compensation plans, the MIP and the Phantom Plan, which were terminated on February&#160;11, 2021 in conjunction with the IPO. Prior to the Plans termination, during the six months ended July&#160;3, 2021, (i) the Company granted 90,000 Phantom Plan units; (ii)&#160;there were no MIP awards granted; (iii) 900 Phantom Plan units were forfeited and (iv)&#160;other Phantom Units were redeemed for $479. Compensation expense related to the Phantom Plan of $829 for the six months ended July&#160;3, 2021. This amount excludes the $25,185 decrease in fair market value of accrued equity-based compensation due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering price, of which $1,777 was recorded in research and development expense within the consolidated statement of operations and comprehensive (loss) income for the six months ended July&#160;3, 2021. Compensation expense of $663 and $1,078 was recorded for the three and six months ended June&#160;27, 2020, excluding $408 and $7,849 in fair market value decreases, respectively, within accrued equity-based compensation due to the impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; on the market and economy. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2021 Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company operates an equity-based compensation plan (2021 Plan). The 2021 Plan is designed to grant incentive awards to eligible employees and other service providers in order to attract, motivate and retain the talent for which the Company competes. The 2021 Plan allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (RSUs), other stock-based awards, and cash awards. (collectively, Awards). Generally, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; Awards granted under the 2021 Plan are equity-classified. As of July&#160;3, 2021, 7,592,476 shares of Class&#160;A common stock were authorized to be awarded and 2,024,123 shares were available for award. The number of shares available for issuance will be increased annually on January&#160;1 of each calendar year beginning in 2022 through 2031, equal to the lesser of (i) 4.5% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-based compensation expense of $5,778 and $7,722 was recognized for the three and six months ended July&#160;3, 2021, respectively, for Awards granted under the 2021 Plan. The expense is primarily included in selling, general and administrative expense with a nominal amount in research and development expense on the consolidated statement of operations and comprehensive (loss) income based upon the classification of the employee. There was no income tax benefit related to this expense for the three and six months ended July&#160;3, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During the three and six months ended July&#160;3, 2021, the Company granted employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors time-based RSUs which vest at various dates through May&#160;10, 2025. The compensation expense, which represents the fair value of the stock measured at the market price on the date of grant, is recognized over the vesting period, which is typically between 1 and 4 years. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No RSUs were vested or settled during the three and six months ended July&#160;3, 2021. Unamortized compensation expense related to the RSUs amounted to $9,976 at July&#160;3, 2021, and is expected to be recognized over a weighted average period of approximately 0.69 years. A summary of the RSU award activity for the six months ended July&#160;3, 2021 is as follows (number of units in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; average&#160;grant-&lt;br/&gt; date fair value&lt;br/&gt; per unit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at April&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/canceled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three and six months ended July&#160;3, 2021, the Company granted employees time-based stock options which vest over 2 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 2 to 4 years, net of actual forfeitures. A summary of the Company&#x2019;s assumptions used in determining the fair value of the stock options granted during the six months ended July&#160;3, 2021 is shown in the following table. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.59%&#160;-&#160;1.19%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33.1%&#160;-&#160;33.5%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life of stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;5.75&lt;div style="display:inline;"&gt;&#160;-&#160;&lt;/div&gt;6.25&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average fair value of stock options granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$4.21&#160;-&#160;5.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Company&#x2019;s peers common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No options vested, expired, forfeited or were exercisable during the six months ended July&#160;3, 2021. Unamortized compensation expense related to the options amounted to $15,797 at July&#160;3, 2021, and is expected to be recognized over a weighted average period of approximately 1.19 years. A summary of stock option activity is as follows for the six months ended July&#160;3, 2021 (number of options in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 50%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; average&#160;exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&#160;term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at April&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.3 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value of options outstanding as of July&#160;3, 2021 was $16,095 and is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#x2019;s common stock for options that had exercise prices lower than $16.51, the closing price of the Company&#x2019;s stock on July&#160;2,&#160;2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, in connection with the IPO, the Company began operating the 2021 Employee Stock Purchase Plan (ESPP). The ESPP provides for the issuance of shares of the Company&#x2019;s common stock to eligible employees of the Company and its subsidiaries that elect to participate in the plan and purchase shares of common stock through payroll deductions (including executive officers). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During each enrollment period, eligible employees may designate between 1% and 15% of their compensation to be deducted for the purchase of common stock under the plan (or such other percentage in order to comply with regulations applicable to employees domiciled in or resident of a member state of the European Union). The purchase price of the shares under the ESPP is equal to 85% of the fair market value on the first day of the offering period or, if lower, on the last day of the offering period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of July&#160;3, 2021, the aggregate number of shares reserved for issuance under the ESPP was 518,257. During the three and six months ended July&#160;3, 2021, 24,063 shares were issued and $75 of expense was recognized. &lt;/div&gt;&lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <bvs:NumberOfEquityBasedCompensationPlans
      contextRef="PAsOn02_10_2021"
      decimals="0"
      unitRef="Unit_Plan">2</bvs:NumberOfEquityBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_12_2021To02_10_2021"
      decimals="0"
      unitRef="Unit_shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_12_2021To02_10_2021_ManagementIncentivePlanAwardMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_12_2021To02_10_2021"
      decimals="0"
      unitRef="Unit_shares">900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="P01_12_2021To02_10_2021"
      decimals="-3"
      unitRef="Unit_USD">479000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_12_2021To02_10_2021_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">829000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">25185000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To07_03_2021_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1777000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P03_28_2020To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P12_28_2019To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1078000</us-gaap:AllocatedShareBasedCompensationExpense>
    <bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy
      contextRef="P03_28_2020To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">408000</bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy>
    <bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy
      contextRef="P12_28_2019To06_27_2020_PhantomShareUnitsPSUsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">7849000</bvs:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn07_03_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">7592476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn07_03_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">2024123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease
      contextRef="PAsOn07_03_2021_A2021PlanMemberusgaapPlanNameAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      unitRef="Unit_pure">0.045</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">5778000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P12_28_2019To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">7722000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_04_2021To07_03_2021_A2021PlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_04_2021To07_03_2021_A2021PlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P12_28_2019To06_27_2020_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P12_28_2019To06_27_2020_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">9976000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To07_03_2021">P0Y8M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2021To07_03_2021">summary of the RSU award activity for the six months ended July&#160;3, 2021 is as follows (number of units in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; average&#160;grant-&lt;br/&gt; date fair value&lt;br/&gt; per unit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at April&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;945&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/canceled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2021To04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn04_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To07_03_2021">A summary of the Company&#x2019;s assumptions used in determining the fair value of the stock options granted during the six months ended July&#160;3, 2021 is shown in the following table.
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.59%&#160;-&#160;1.19%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33.1%&#160;-&#160;33.5%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life of stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;5.75&lt;div style="display:inline;"&gt;&#160;-&#160;&lt;/div&gt;6.25&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average fair value of stock options granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$4.21&#160;-&#160;5.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_04_2021To07_03_2021"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">15797000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_04_2021To07_03_2021">P1Y2M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="P01_01_2021To07_03_2021">A summary of stock option activity is as follows for the six months ended July&#160;3, 2021 (number of options in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 50%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; average&#160;exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&#160;term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at April&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.3 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To04_03_2021"
      decimals="0"
      unitRef="Unit_shares">4621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To04_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn04_03_2021"
      decimals="0"
      unitRef="Unit_shares">4621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn04_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P04_04_2021To07_03_2021"
      decimals="0"
      unitRef="Unit_shares">4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P04_04_2021To07_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn07_03_2021"
      decimals="0"
      unitRef="Unit_shares">4625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn07_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P04_04_2021To07_03_2021">P3Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">16095000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="PAsOn07_03_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.51</us-gaap:SharePrice>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee
      contextRef="PAsOn07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee>
    <bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee
      contextRef="PAsOn07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</bvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn07_03_2021"
      decimals="0"
      unitRef="Unit_shares">518257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_04_2021To07_03_2021"
      decimals="0"
      unitRef="Unit_shares">24063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_04_2021To07_03_2021_EmployeeStockMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Earnings per share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the computation of basic and diluted loss per share of Class&#160;A common stock for the period following the Transactions (amounts in thousands, except share and per share data): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;br/&gt; Ended July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;16,&lt;br/&gt; 2021 through&lt;br/&gt; July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,229&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss attributable to noncontrolling interests&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,654&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss attributable to Bioventus Inc. Class&#160;A common stockholders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average shares of Class&#160;A common stock outstanding - basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,805,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,802,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per share of Class&#160;A common stock, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Shares of Class&#160;B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class&#160;B common stock under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method has not been presented. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following number of weighted-average potentially dilutive shares as of July&#160;3, 2021 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&lt;br/&gt; Months&lt;br/&gt; Ended July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months&lt;br/&gt; Ended July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;LLC Interests held by Continuing LLC&#160;Owner&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,786,737&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,786,737&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,622,287&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,602,747&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,221,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;941,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested shares of Class&#160;A common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,458&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,698&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,663,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,365,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A Shares reserved for future issuance upon redemption or exchange of LLC Interests by Continuing LLC Owner. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the computation of basic and diluted loss per share of Class&#160;A common stock for the period following the Transactions (amounts in thousands, except share and per share data): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;br/&gt; Ended July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;16,&lt;br/&gt; 2021 through&lt;br/&gt; July&#160;3, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,780&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,229&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss attributable to noncontrolling interests&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,654&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss attributable to Bioventus Inc. Class&#160;A common stockholders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,167&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average shares of Class&#160;A common stock outstanding - basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,805,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,802,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per share of Class&#160;A common stock, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-10780000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P02_16_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-12229000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-6654000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P02_16_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-7062000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-4126000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_16_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-5167000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_04_2021To07_03_2021"
      decimals="0"
      unitRef="Unit_shares">41805347</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_04_2021To07_03_2021"
      decimals="INF"
      unitRef="Unit_shares">41805347</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_16_2021To07_03_2021"
      decimals="0"
      unitRef="Unit_shares">41802840</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_16_2021To07_03_2021"
      decimals="INF"
      unitRef="Unit_shares">41802840</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_04_2021To07_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_04_2021To07_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_16_2021To07_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_16_2021To07_03_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following number of weighted-average potentially dilutive shares as of July&#160;3, 2021 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&lt;br/&gt; Months&lt;br/&gt; Ended July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months&lt;br/&gt; Ended July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;LLC Interests held by Continuing LLC&#160;Owner&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,786,737&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,786,737&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,622,287&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,602,747&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,221,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;941,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested shares of Class&#160;A common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,458&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34,698&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,663,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,365,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A Shares reserved for future issuance upon redemption or exchange of LLC Interests by Continuing LLC Owner. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_04_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">15786737</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">15786737</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_04_2021To07_03_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">4622287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">4602747</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">1221555</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">941031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_04_2021To07_03_2021_UnvestedClassACommonSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">32458</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To07_03_2021_UnvestedClassACommonSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">34698</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_04_2021To07_03_2021"
      decimals="INF"
      unitRef="Unit_shares">21663037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To07_03_2021"
      decimals="INF"
      unitRef="Unit_shares">21365213</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As a result of the Transactions, Bioventus Inc. became the sole managing member of BV LLC, which is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, BV LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by BV LLC is passed through to and included in the taxable income or loss of its members, including the Company following the Transactions, on a pro rata basis. Bioventus Inc. is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to its allocable share of any taxable income of BV LLC&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;following the Transactions. The Company is also subject to taxes in foreign jurisdictions. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The tax provision for interim periods is determined using an estimate of the Company&#x2019;s annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Company&#x2019;s annual effective tax rate, are subject to variation due to several factors, including variability in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For the three months ended July&#160;3, 2021 and June&#160;27, 2020 the Company&#x2019;s estimated effective tax rate was 18.9% and 1.8%, respectively. For the six months ended July&#160;3, 2021 and June&#160;27, 2020 the Company&#x2019;s estimated effective tax rate was 10.7% and 1.6%, respectively. The increase was primarily driven by the change in structure resulting from the IPO and associated Up C structure as well as the impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-deductible&lt;/div&gt; stock option expense during 2021. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recorded deferred taxes with the offset to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital in connection with the Transaction. The deferred tax asset of $481 was due to tax credits and the deferred tax liability of $48,410 was for the difference between the book value and the tax basis of the Company&#x2019;s investment in BV LLC. The Company maintains a valuation allowance on certain deferred tax assets that has determined are not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be realizable. The Company assesses the need for an adjustment to this valuation allowance on a quarterly basis. The assessment is based on estimates of future sources of taxable income for the jurisdictions in which the Company operates and the periods over which deferred tax assets will be realizable. In the event the Company determines that it will be able to realize all or part of its net deferred tax assets in the future, all or part of the valuation allowance will be reversed in the period in which the Company makes such determination. The release of all or part of the valuation allowance against deferred tax assets may cause greater volatility in the effective tax rate in the periods in which it is reversed. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tax Receivable Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;16, 2021, the Company entered into a tax receivable agreement (TRA) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i)&#160;increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC and (ii)&#160;certain other tax benefits related to our making payments under the TRA. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will maintain a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be realized. As of July&#160;3, 2021, Continuing LLC Owner had not exchanged LLC Interests for shares of Class&#160;A common stock and therefore the Company had not recorded any liabilities under the TRA. &lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_04_2021To07_03_2021"
      decimals="INF"
      unitRef="Unit_pure">0.189</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P03_29_2020To06_27_2020"
      decimals="INF"
      unitRef="Unit_pure">0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To07_03_2021"
      decimals="INF"
      unitRef="Unit_pure">0.107</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To06_27_2020"
      decimals="INF"
      unitRef="Unit_pure">0.016</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">481000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">48410000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. Commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 7.25 years. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of lease cost were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;912&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;646&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,614&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;740&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Includes variable lease cost and sublease income, which are immaterial. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Supplemental cash flow information and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; activity related to operating leases were as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental balance sheet and other information related to operating leases &lt;div style="display:inline;"&gt;were &lt;/div&gt;as fo&lt;div style="display:inline;"&gt;llow&lt;/div&gt;s:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,961&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities- current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities- noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,989&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,907&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Recall &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2020, the Company voluntarily recalled our ultrasound gel, an accessory to one of the Restorative Therapies product. The Company has incurred, and expects to incur in the future, costs associated with this recall. Based on the information that has been received, the estimated probable loss related to this recall globally was approximately $2,055 as of July&#160;3, 2021. Reserves of $434 and $1,684 were recorded within accrued liabilities on the consolidated balance sheets at July&#160;3, 2021 and December&#160;31, 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legal Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to the business. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company operates. As a result, interaction with governmental agencies is ongoing. The Company&#x2019;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#x2019;s complete control and may not be known for extended periods of time. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to the closing of our acquisition of Bioness, Bioness had been named as a defendant in a lawsuit, for which we are indemnified for under the indemnification provisions contained in the Merger Agreement pursuant to which we acquired Bioness (the Bioness Merger Agreement). The case relates to an action brought in February 2021 in the Delaware State Court of Chancery by a former minority shareholder and director of Bioness, seeking a temporary restraining order contesting our acquisition of Bioness. While the complaint to block the Bioness acquisition was dismissed by the court, a separate action was brought against the Company under the indemnification provisions of the Bioness Certificate of Incorporation to recover $1,200 in attorney fees and other expenses incurred by the director and shareholder in connection with the dismissed case and filed a motion on May&#160;21, 2021 for summary judgment of their claims. The Company is vigorously defending the matter. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other matters &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter, beginning in 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;29, 2019, the Company and the Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF (the Development Agreement). The first phase has been completed. Additional fees for the subsequent phases will be determined as the development work progresses. The Development Agreement continues until the date when the parties execute a supply agreement for the commercial products. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;On December&#160;9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (OA) product with the supplier of the Company&#x2019;s single injection OA product for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-U.S.&lt;/div&gt; market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement totaled $3,548 and $1,767 during the three months ended July&#160;3, 2021 and June&#160;27, 2020, respectively, and $5,925 and $3,969 during the six months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive (loss) income. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of a supply agreement entered on February&#160;9, 2016 for the Company&#x2019;s three injection OA product, the Company is subject to annual minimum purchase requirements for ten years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of a supply agreement for the Company&#x2019;s five injection OA product, that was amended and restated on December&#160;22, 2020, the Company is subject to annual minimum purchase requirements for 8 years. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the licensed products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive (loss) income. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, the Company causes letters of credit (LOCs) to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of July&#160;3, 2021 and December&#160;31, 2020, the Company had one LOC outstanding for a nominal amount. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#x201c;claims made&#x201d; basis for expenses in excess of $200 per member per year. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn07_03_2021_MinimumMembersrtRangeAxis">P1M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn07_03_2021_MaximumMembersrtRangeAxis">P7Y3M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of lease cost were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;912&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;646&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,614&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;740&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Includes variable lease cost and sublease income, which are immaterial. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Supplemental cash flow information and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; activity related to operating leases were as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">912000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">646000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1614000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1292000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">212000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">94000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">329000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">204000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1124000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">740000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1943000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1496000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">1696000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">1269000</us-gaap:OperatingLeasePayments>
    <bvs:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental balance sheet and other information related to operating leases &lt;div style="display:inline;"&gt;were &lt;/div&gt;as fo&lt;div style="display:inline;"&gt;llow&lt;/div&gt;s:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,961&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities- current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities- noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,989&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,907&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,068&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bvs:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">17669000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14961000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">2918000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1960000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">15989000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14108000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">18907000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16068000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn07_03_2021">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn07_03_2021"
      decimals="INF"
      unitRef="Unit_pure">0.044</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_pure">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="PAsOn07_03_2021_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis"
      decimals="-3"
      unitRef="Unit_USD">2055000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="PAsOn07_03_2021_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis"
      decimals="-3"
      unitRef="Unit_USD">434000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="PAsOn12_31_2020_DamagesFromProductDefectsMemberusgaapLossContingenciesByNatureOfContingencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1684000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2021To07_03_2021_BionessIncMemberusgaapLitigationStatusAxis"
      decimals="-3"
      unitRef="Unit_USD">1200000</us-gaap:LossContingencyDamagesSoughtValue>
    <bvs:CollaborativeArrangementRoyaltyPercentage
      contextRef="P08_23_2019To08_23_2019_HarborMembersrtCounterpartyNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</bvs:CollaborativeArrangementRoyaltyPercentage>
    <us-gaap:RoyaltyExpense
      contextRef="P04_04_2021To07_03_2021_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">3548000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P03_29_2020To06_27_2020_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1767000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2021To07_03_2021_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">5925000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2020To06_27_2020_SupplierOfSingleInjectionOAProductMembersrtCounterpartyNameAxis"
      decimals="-3"
      unitRef="Unit_USD">3969000</us-gaap:RoyaltyExpense>
    <bvs:SupplyCommitmentTerm contextRef="P02_09_2016To02_09_2016_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">P10Y</bvs:SupplyCommitmentTerm>
    <bvs:SupplyCommitmentTerm contextRef="P02_09_2016To02_09_2016_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">P10Y</bvs:SupplyCommitmentTerm>
    <bvs:SupplyCommitmentRenewalTerm contextRef="P02_09_2016To02_09_2016_ThreeInjectionOAProductMemberusgaapSupplyCommitmentAxis">P5Y</bvs:SupplyCommitmentRenewalTerm>
    <bvs:CollaborativeArrangementTerm contextRef="P12_22_2020To12_22_2020_HarborMembersrtCounterpartyNameAxis">P8Y</bvs:CollaborativeArrangementTerm>
    <bvs:StopLossInsuranceThresholdPerMemberPerYear
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">200000</bvs:StopLossInsuranceThresholdPerMemberPerYear>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Revenue recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Our policies for recognizing sales have not changed from those described in the Company&#x2019;s 2020 Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K.&lt;/div&gt; The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primary geographic markets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;98,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,166&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;125,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,374&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;109,816&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vertical:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pain Treatments and Joint Preservation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56,704&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;98,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restorative Therapies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bone Graft Substitutes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,601&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;109,816&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2021To07_03_2021">The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) as follows:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primary geographic markets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;98,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,166&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;173,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;125,136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,374&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,526&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;109,816&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vertical:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pain Treatments and Joint Preservation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56,704&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,868&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;98,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restorative Therapies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,511&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,968&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bone Graft Substitutes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,601&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;109,816&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;58,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_04_2021To07_03_2021_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">98682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P03_29_2020To06_27_2020_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">53166000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To07_03_2021_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">173220000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To06_27_2020_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">125136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_04_2021To07_03_2021_NonUsMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">11134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P03_29_2020To06_27_2020_NonUsMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">4851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To07_03_2021_NonUsMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">18374000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To06_27_2020_NonUsMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">11526000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">109816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">58017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">191594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">136662000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_04_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">56704000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P03_29_2020To06_27_2020_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">28868000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">98234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To06_27_2020_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">70151000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_04_2021To07_03_2021_RestorativeTherapiesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">32511000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P03_29_2020To06_27_2020_RestorativeTherapiesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">17968000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To07_03_2021_RestorativeTherapiesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">54332000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To06_27_2020_RestorativeTherapiesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">41433000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_04_2021To07_03_2021_BoneGraftSubstitutesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">20601000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P03_29_2020To06_27_2020_BoneGraftSubstitutesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">11181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To07_03_2021_BoneGraftSubstitutesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">39028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To06_27_2020_BoneGraftSubstitutesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">25078000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">109816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">58017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">191594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">136662000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11. Segments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s two reportable segments are U.S. and International. The Company&#x2019;s products are primarily sold to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;orthopedists,&lt;/div&gt; musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company&#x2019;s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents segment adjusted EBITDA reconciled to income before income taxes: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment adjusted EBITDA&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,149&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest (expense) income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,853&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,771&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; benefits, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Succession and transition charges&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,801&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency impact&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition and integration costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Inventory &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity loss in unconsolidated investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments related to variable interest entity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Loss) income before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,389&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="P01_01_2021To07_03_2021"
      decimals="INF"
      unitRef="Unit_Segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="P01_01_2021To07_03_2021"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents segment adjusted EBITDA reconciled to income before income taxes: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;July&#160;3,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;27,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment adjusted EBITDA&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,149&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,439&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27,147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest (expense) income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,853&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,771&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; benefits, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Succession and transition charges&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,801&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency impact&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition and integration costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Inventory &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity loss in unconsolidated investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(901&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of contingent consideration&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(641&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments related to variable interest entity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,043&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Loss) income before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,389&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P04_04_2021To07_03_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">17149000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P03_29_2020To06_27_2020_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7439000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2021To07_03_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">27147000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2020To06_27_2020_OperatingSegmentsMembersrtConsolidationItemsAxis_USSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      unitRef="Unit_USD">21151000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P04_04_2021To07_03_2021_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">2738000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P03_29_2020To06_27_2020_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-497000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2021To07_03_2021_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">3810000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems
      contextRef="P01_01_2020To06_27_2020_InternationalSegmentMemberusgaapStatementBusinessSegmentsAxis_OperatingSegmentsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">37000</bvs:AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems>
    <us-gaap:DepreciationAndAmortization
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">7479000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">7248000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">14663000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">14513000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1681000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2834000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">1195000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5215000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">5853000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">255000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-16559000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-6771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:UnusualOrInfrequentItemNetGainLoss
      contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1101000</us-gaap:UnusualOrInfrequentItemNetGainLoss>
    <us-gaap:UnusualOrInfrequentItemNetGainLoss
      contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1101000</us-gaap:UnusualOrInfrequentItemNetGainLoss>
    <bvs:SuccessionAndTransitionCharges
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">187000</bvs:SuccessionAndTransitionCharges>
    <bvs:SuccessionAndTransitionCharges
      contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">3801000</bvs:SuccessionAndTransitionCharges>
    <bvs:SuccessionAndTransitionCharges
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">344000</bvs:SuccessionAndTransitionCharges>
    <bvs:SuccessionAndTransitionCharges
      contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">4574000</bvs:SuccessionAndTransitionCharges>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">12000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">46000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">64000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-40000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">1833000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">5029000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <bvs:InventoryStepUpCost
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">2106000</bvs:InventoryStepUpCost>
    <bvs:InventoryStepUpCost
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">2106000</bvs:InventoryStepUpCost>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-432000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">-901000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">641000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">641000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AssetImpairmentCharges
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">7043000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">7043000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNonrecurringExpense
      contextRef="P04_04_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">1710000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:OtherNonrecurringExpense
      contextRef="P03_29_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">41000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:OtherNonrecurringExpense
      contextRef="P01_01_2021To07_03_2021_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">2659000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:OtherNonrecurringExpense
      contextRef="P01_01_2020To06_27_2020_MaterialReconcilingItemsMembersrtConsolidationItemsAxis"
      decimals="-3"
      unitRef="Unit_USD">283000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_04_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">-9066000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P03_29_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">-6090000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To07_03_2021"
      decimals="-3"
      unitRef="Unit_USD">15389000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To06_27_2020"
      decimals="-3"
      unitRef="Unit_USD">4435000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2021To07_03_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. Subsequent events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition of Misonix, Inc. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;29, 2021, the Company entered into an Agreement and Plan of Merger (the Misonix Merger Agreement) to acquire Misonix, Inc. (Misonix), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, in a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-and-stock&lt;/div&gt;&lt;/div&gt; transaction (the Transaction). The closing of the Transaction is subject to regulatory approvals, the Company&#x2019;s stockholders&#x2019; approval, Misonix stockholder approval and customary closing conditions. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Misonix stockholders will receive aggregate consideration that values Misonix at approximately $518,000 on a fully diluted basis, based on the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7-day&lt;/div&gt; weighted average stock price of $16.6284 per share as of July&#160;27, 2021. The Transaction involves both cash and stock consideration based on the election of the Misonix stockholder. Each share of Misonix Common Stock issued and outstanding immediately prior to the Transaction, will be converted into the right to receive, either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-assessable&lt;/div&gt; shares of Class&#160;A common stock of the Company, $0.001 par value per share, based on the election of the holder. The maximum cash amount payable by the Company will be an amount equal to $10.50 multiplied by the number of outstanding shares of Misonix Common Stock shortly prior to the completion of the Transaction. The Company expects to fund the cash portion of the acquisition with cash on &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hand and through committed financing provided by Wells Fargo Bank, National Association (Wells Fargo Bank). The number of shares held by Misonix stockholders electing to receive cash will be reduced on a pro rata basis if the cash elected to be received exceeds the maximum cash amount payable and will be paid with stock consideration of 1.6839 of shares of the Company&#x2019;s Class&#160;A common stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt Commitment Letter &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the transaction, the Company entered into a debt commitment letter with Wells Fargo Bank, effective July&#160;29, 2021. Wells Fargo Bank has committed to provide a senior secured term loan facility (Term Loan Facility) in the aggregate principal amount of up to $262,000 plus, at the Company&#x2019;s election, an amount sufficient to fund any original issue discount or upfront fees, subject to customary closing conditions. The Term Loan Facility stipulates a prepayment of $80,000 on the existing Term Loan under the 2019 Credit Agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The proceeds of the Term Loan Facility would be available through a single draw on the closing date of the Transaction and shall be used (i)&#160;to finance the Transaction; (ii)&#160;pay related fees, premiums and expenses and (iii)&#160;for working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions. The Term Loan Facility would have a three year term that would bear interest at either the base rate as prescribed in the Term Loan under the 2019 Credit Agreement or the Eurodollar rate, and, in each case, plus an applicable margin. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Voting and Support Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="-sec-ix-redline: true;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;On July&#160;29, 2021, following the execution of the Misonix Merger Agreement, Misonix entered into Voting and Support Agreements with each EW Healthcare Partners Acquisition Fund, L.P. White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.), Smith&#160;&amp;amp; Nephew, Inc., Smith&#160;&amp;amp; Nephew USD Ltd. and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AMP-CF&lt;/div&gt; Holdings, LLC (together, the &#x201c;Bioventus supporting stockholders&#x201d;). The Bioventus Supporting Stockholders have agreed to vote their shares in (i)&#160;favor of the issuance of shares of the Company&#x2019;s common stock in connection with the Transaction and against approval of any proposal made in opposition to, in competition with or inconsistent with the Misonix Merger Agreement. As of the record date for the Bioventus special meeting, the Bioventus supporting stockholders are the beneficial owners of approximately &lt;/div&gt;[&#x25cf;]% &lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the currently outstanding Class&#160;A and Class&#160;B common stock of the Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Matters &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The unsecured PPP loan of $2,003 associated with Bioness was forgiven in July 2021. The loan amount was recorded in other current liabilities and restricted cash within the consolidated condensed balance sheet at July&#160;3, 2021. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 3. Business combinations and investments&lt;/div&gt;&lt;/div&gt; for further details. &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="-3"
      unitRef="Unit_USD">518000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">16.6284</us-gaap:BusinessAcquisitionSharePrice>
    <bvs:BusinessAcquisitionConsiderationTransferredPerShareCash
      contextRef="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">28.00</bvs:BusinessAcquisitionConsiderationTransferredPerShareCash>
    <bvs:BusinessAcquisitionConsiderationTransferredPerShareShares
      contextRef="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="4"
      unitRef="Unit_shares">1.6839</bvs:BusinessAcquisitionConsiderationTransferredPerShareShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <bvs:BusinessAcquisitionConsiderationTransferredPerShareMaximum
      contextRef="P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.50</bvs:BusinessAcquisitionConsiderationTransferredPerShareMaximum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_29_2021_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanFacilityMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">262000000</us-gaap:DebtInstrumentFaceAmount>
    <bvs:DebtInstrumentCovenantRequiredPrepayment
      contextRef="PAsOn07_29_2021_A2019CreditAgreementMemberusgaapDebtInstrumentAxis_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">80000000</bvs:DebtInstrumentCovenantRequiredPrepayment>
    <us-gaap:DebtInstrumentTerm contextRef="P07_29_2021To07_29_2021_SecuredDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TermLoanFacilityMemberusgaapDebtInstrumentAxis">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P07_01_2021To07_31_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_PaycheckProtectionProgramLoanMemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2003000</us-gaap:ExtinguishmentOfDebtAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_26388121"
          xlink:label="Fact_26388121"
          xlink:type="locator"/>
        <link:footnote id="FN_89660" xlink:label="FN_89660" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Per share information for the six months ended July 3, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through July 3, 2021, the period following Bioventus Inc.&#x2019;s initial public offering and related transactions described in Note 1. Organization and Note 7. Earnings per share within the Notes to the Unaudited Condensed Consolidated Financial Statements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_26388121"
          xlink:to="FN_89660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_26388122"
          xlink:label="Fact_26388122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_26388122"
          xlink:to="FN_89660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_26388127"
          xlink:label="Fact_26388127"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_26388127"
          xlink:to="FN_89660"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_26388128"
          xlink:label="Fact_26388128"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_26388128"
          xlink:to="FN_89660"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674802934248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOVENTUS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment No. 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001665988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674806362296">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated condensed statements of operations and comprehensive (loss) income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 109,816<span></span>
</td>
<td class="nump">$ 58,017<span></span>
</td>
<td class="nump">$ 191,594<span></span>
</td>
<td class="nump">$ 136,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including depreciation and amortization of $5,618, $5,292, $10,854 and $10,599 respectively)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,503<span></span>
</td>
<td class="nump">17,668<span></span>
</td>
<td class="nump">55,725<span></span>
</td>
<td class="nump">39,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,313<span></span>
</td>
<td class="nump">40,349<span></span>
</td>
<td class="nump">135,869<span></span>
</td>
<td class="nump">97,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,050<span></span>
</td>
<td class="nump">40,533<span></span>
</td>
<td class="nump">103,736<span></span>
</td>
<td class="nump">80,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,836<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">5,783<span></span>
</td>
<td class="nump">4,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">641<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">641<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">3,777<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of variable interest entity assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,674<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,740)<span></span>
</td>
<td class="num">(4,593)<span></span>
</td>
<td class="nump">16,258<span></span>
</td>
<td class="nump">8,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,681<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
<td class="num">(1,195)<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,645<span></span>
</td>
<td class="num">(1,337)<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
<td class="num">(1,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,326<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="nump">3,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,066)<span></span>
</td>
<td class="num">(6,090)<span></span>
</td>
<td class="nump">15,389<span></span>
</td>
<td class="nump">4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,066)<span></span>
</td>
<td class="num">(6,090)<span></span>
</td>
<td class="nump">15,389<span></span>
</td>
<td class="nump">4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,714<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,780)<span></span>
</td>
<td class="num">(5,980)<span></span>
</td>
<td class="nump">13,748<span></span>
</td>
<td class="nump">4,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,654<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">7,062<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Bioventus Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,126)<span></span>
</td>
<td class="num">(5,766)<span></span>
</td>
<td class="nump">20,810<span></span>
</td>
<td class="nump">5,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="num">(859)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,757)<span></span>
</td>
<td class="num">(5,767)<span></span>
</td>
<td class="nump">12,889<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations attributable to common unit holders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,648<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">6,882<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income attributable to Bioventus Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,109)<span></span>
</td>
<td class="num">$ (5,553)<span></span>
</td>
<td class="nump">$ 19,771<span></span>
</td>
<td class="nump">$ 4,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted Average Number Of Shares Outstanding [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,805,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,802,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">41,805,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,802,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract', window );"><strong>Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average units used in computing basic and diluted net income (loss) per common unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">41,805,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,802,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,161<span></span>
</td>
<td class="nump">$ 340,141<span></span>
</td>
<td class="nump">$ 319,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including depreciation and amortization of $5,618, $5,292, $10,854 and $10,599 respectively)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,642<span></span>
</td>
<td class="nump">90,935<span></span>
</td>
<td class="nump">84,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,519<span></span>
</td>
<td class="nump">249,206<span></span>
</td>
<td class="nump">235,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,078<span></span>
</td>
<td class="nump">198,475<span></span>
</td>
<td class="nump">191,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,202<span></span>
</td>
<td class="nump">11,055<span></span>
</td>
<td class="nump">8,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
<td class="nump">7,908<span></span>
</td>
<td class="nump">8,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Loss on impairment of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,237<span></span>
</td>
<td class="nump">31,193<span></span>
</td>
<td class="nump">25,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,751<span></span>
</td>
<td class="nump">21,579<span></span>
</td>
<td class="nump">19,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,428)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,323<span></span>
</td>
<td class="nump">21,504<span></span>
</td>
<td class="nump">19,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,914<span></span>
</td>
<td class="nump">9,689<span></span>
</td>
<td class="nump">6,107<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,914<span></span>
</td>
<td class="nump">9,689<span></span>
</td>
<td class="nump">6,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="nump">8,113<span></span>
</td>
<td class="nump">4,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">16,650<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
<td class="num">(12,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Bioventus Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,411<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
<td class="num">(12,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Change in prior service cost and unrecognized (loss) gain for defined benefit plan adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income attributable to Bioventus Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,483<span></span>
</td>
<td class="nump">$ 6,451<span></span>
</td>
<td class="num">$ (12,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted Average Number Of Shares Outstanding [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations attributable to unit holders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,411<span></span>
</td>
<td class="nump">$ 8,666<span></span>
</td>
<td class="nump">$ 4,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Accumulated and unpaid preferred distributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,133)<span></span>
</td>
<td class="num">(5,955)<span></span>
</td>
<td class="num">(5,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,895)<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net income (loss) from continuing operations attributable to common unit holders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic', window );">Loss from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">16,650<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common unit holders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,383<span></span>
</td>
<td class="num">$ (659)<span></span>
</td>
<td class="num">$ (17,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract', window );"><strong>Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net income (loss) from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare', window );">Loss from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="nump">3.40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net income (loss) attributable to common unit holders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average units used in computing basic and diluted net income (loss) per common unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Per share information for the six months ended July 3, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through July 3, 2021, the period following Bioventus Inc.&#8217;s initial public offering and related transactions described in Note 1. Organization and Note 7. Earnings per share within the Notes to the Unaudited Condensed Consolidated Financial Statements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805976968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated condensed statements of operations and comprehensive (loss) income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 5,618<span></span>
</td>
<td class="nump">$ 5,292<span></span>
</td>
<td class="nump">$ 10,854<span></span>
</td>
<td class="nump">$ 10,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,169<span></span>
</td>
<td class="nump">$ 22,399<span></span>
</td>
<td class="nump">$ 20,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674806708520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated condensed balance sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 136,065<span></span>
</td>
<td class="nump">$ 86,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">2,003<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">102,029<span></span>
</td>
<td class="nump">88,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">34,020<span></span>
</td>
<td class="nump">29,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">15,943<span></span>
</td>
<td class="nump">7,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">290,060<span></span>
</td>
<td class="nump">211,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,960<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">52,135<span></span>
</td>
<td class="nump">49,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">257,848<span></span>
</td>
<td class="nump">191,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">17,669<span></span>
</td>
<td class="nump">14,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investment and other assets</a></td>
<td class="nump">19,483<span></span>
</td>
<td class="nump">19,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">646,636<span></span>
</td>
<td class="nump">494,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_TotalAssets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,881<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">105,246<span></span>
</td>
<td class="nump">88,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued equity-based compensation</a></td>
<td class="nump">10,875<span></span>
</td>
<td class="nump">11,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">13,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,964<span></span>
</td>
<td class="nump">3,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">158,186<span></span>
</td>
<td class="nump">122,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">166,084<span></span>
</td>
<td class="nump">173,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Accrued equity-based compensation, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">48,410<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, less current portion</a></td>
<td class="nump">30,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">24,171<span></span>
</td>
<td class="nump">21,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">427,272<span></span>
</td>
<td class="nump">350,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_TotalLiabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' and Members' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">146,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(5,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity attributable to Bioventus Inc. and members' equity</a></td>
<td class="nump">141,557<span></span>
</td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_TotalStockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">77,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' and members' equity</a></td>
<td class="nump">219,364<span></span>
</td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' and members' equity</a></td>
<td class="nump">646,636<span></span>
</td>
<td class="nump">494,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_TotalLiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,839<span></span>
</td>
<td class="nump">64,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,283<span></span>
</td>
<td class="nump">85,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,120<span></span>
</td>
<td class="nump">27,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,552<span></span>
</td>
<td class="nump">6,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,794<span></span>
</td>
<td class="nump">183,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,800<span></span>
</td>
<td class="nump">49,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,650<span></span>
</td>
<td class="nump">216,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,961<span></span>
</td>
<td class="nump">15,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investment and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,382<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,466<span></span>
</td>
<td class="nump">472,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
<td class="nump">6,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,187<span></span>
</td>
<td class="nump">52,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,054<span></span>
</td>
<td class="nump">15,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">4,201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,589<span></span>
</td>
<td class="nump">89,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,378<span></span>
</td>
<td class="nump">187,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Accrued equity-based compensation, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,249<span></span>
</td>
<td class="nump">25,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
<td class="nump">3,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728<span></span>
</td>
<td class="nump">20,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,306<span></span>
</td>
<td class="nump">326,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' and Members' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,173<span></span>
</td>
<td class="nump">285,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,539)<span></span>
</td>
<td class="num">(141,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="num">(465)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity attributable to Bioventus Inc. and members' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,241<span></span>
</td>
<td class="nump">142,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,919<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' and members' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,160<span></span>
</td>
<td class="nump">145,617<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' and members' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494,466<span></span>
</td>
<td class="nump">$ 472,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' and Members' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' and Members' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_TotalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_TotalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_TotalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_TotalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_TotalLiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total liabilities and stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_TotalLiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_TotalStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Stockholders' Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_TotalStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70258-108054<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70434-108055<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70229-108054<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674801944440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated condensed balance sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary Equity, Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,576<span></span>
</td>
<td class="nump">$ 204,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">41,062,652<span></span>
</td>
<td class="nump">41,062,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">41,062,652<span></span>
</td>
<td class="nump">41,062,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,786,737<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,786,737<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674799854120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated condensed statements of changes in stockholders' and members' equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Members' equity</div></th>
<th class="th">
<div>Members' equity </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class A</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common Class B</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>IPO </div>
<div>Common Class A</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Public Offering </div>
<div>Common Class A</div>
</th>
<th class="th"><div>Additional Paid-In -Capital</div></th>
<th class="th">
<div>Additional Paid-In -Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-In -Capital </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Accumulated other comprehensive income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- controlling interest</div></th>
<th class="th"><div>Bio Ventus LLC [Member]</div></th>
<th class="th">
<div>Bio Ventus LLC [Member] </div>
<div>Members' equity</div>
</th>
<th class="th">
<div>Bio Ventus LLC [Member] </div>
<div>Accumulated other comprehensive income</div>
</th>
<th class="th">
<div>Bio Ventus LLC [Member] </div>
<div>Accumulated Deficit</div>
</th>
<th class="th">
<div>Bio Ventus LLC [Member] </div>
<div>Non- controlling interest</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="num">$ (119,795)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromProfitInterestForfeiture', window );">Profits interest forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromDistributionToMembers', window );">Distribution to members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Defined benefit plan adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(139,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, ending balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromProfitInterestForfeiture', window );">Profits interest forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromDistributionToMembers', window );">Distribution to members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,851<span></span>
</td>
<td class="num">(553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Defined benefit plan adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(465)<span></span>
</td>
<td class="num">(141,700)<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, ending balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,147<span></span>
</td>
<td class="nump">285,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromProfitInterestForfeiture', window );">Profits interest forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromDistributionToMembers', window );">Distribution to members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, ending balance at Jun. 27, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(465)<span></span>
</td>
<td class="num">(141,700)<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,147<span></span>
</td>
<td class="nump">285,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromEquityForfeitures', window );">Other equity forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromProfitInterestForfeiture', window );">Profits interest forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromDistributionToMembers', window );">Distribution to members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,411<span></span>
</td>
<td class="num">(1,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Defined benefit plan adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,607<span></span>
</td>
<td class="num">$ (144,539)<span></span>
</td>
<td class="nump">$ 1,919<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, ending balance at Dec. 31, 2020</a></td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,173<span></span>
</td>
<td class="nump">285,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, beginning balance at Mar. 28, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromDistributionToMembers', window );">Distribution to members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, ending balance at Jun. 27, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Members' equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,173<span></span>
</td>
<td class="nump">$ 285,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution of Continuing LLC Owner</a></td>
<td class="num">(191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityIncreaseFromRefundsFromMembers', window );">Refund from members</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MembersEquityDecreaseFromEquityForfeitures', window );">Other equity forfeiture</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">13,748<span></span>
</td>
<td class="nump">$ 25,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NetLossSubsequentToOrganizationalTransactions', window );">Net loss subsequent to Organizational Transactions</a></td>
<td class="num">(12,229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,167)<span></span>
</td>
<td class="num">(7,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Defined benefit plan adjustment</a></td>
<td class="nump">7,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity', window );">Deconsolidation of variable interest entity</a></td>
<td class="nump">3,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation</a></td>
<td class="nump">7,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="num">(1,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityChangeInReportingEntity', window );">Effect of Organizational Transactions</a></td>
<td class="num">(55,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (168,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_StockholdersEquitySharesChangeInReportingEntity', window );">Effect of Organizational Transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,063<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">$ 106,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="nump">$ 106,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jul. 03, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,062,652<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jul. 03, 2021</a></td>
<td class="nump">219,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="num">(5,167)<span></span>
</td>
<td class="nump">77,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Apr. 03, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,038,589<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Apr. 03, 2021</a></td>
<td class="nump">220,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="num">(1,041)<span></span>
</td>
<td class="nump">77,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution of Continuing LLC Owner</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(10,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,126)<span></span>
</td>
<td class="num">(6,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Defined benefit plan adjustment</a></td>
<td class="nump">5,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity', window );">Deconsolidation of variable interest entity</a></td>
<td class="nump">3,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity based compensation</a></td>
<td class="nump">5,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jul. 03, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,062,652<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jul. 03, 2021</a></td>
<td class="nump">$ 219,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="num">$ (5,167)<span></span>
</td>
<td class="nump">$ 77,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Stockholders' Equity And Members' Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MembersEquityDecreaseFromDistributionToMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members' Equity, Decrease From Distribution To Members</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MembersEquityDecreaseFromDistributionToMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MembersEquityDecreaseFromEquityForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members' Equity, Decrease From Equity Forfeitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MembersEquityDecreaseFromEquityForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MembersEquityDecreaseFromProfitInterestForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members' Equity, Decrease From Profit Interest Forfeiture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MembersEquityDecreaseFromProfitInterestForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MembersEquityIncreaseFromRefundsFromMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members' Equity, Increase From Refunds From Members'</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MembersEquityIncreaseFromRefundsFromMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NetLossSubsequentToOrganizationalTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss subsequent to Organizational Transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NetLossSubsequentToOrganizationalTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase From Deconsolidation Of Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Cumulative Foreign Currency Transaction And Translation Adjustment, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_StockholdersEquitySharesChangeInReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Shares, Change In Reporting Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_StockholdersEquitySharesChangeInReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70258-108054<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70434-108055<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70229-108054<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityChangeInReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impact on total stockholders' equity of cumulative effect of change in reporting entity. A change in reporting entity is considered as follows: (1) presenting consolidated statements in place of the financial statements of individual reporting entities; (2) changing the combination of subsidiaries that make up the group for which the consolidated financial statements are presented; and (3) changing the entities included in the combined financial statements. A business combination accounted for under the purchase method and the consolidation of a variable interest entity are not considered a change in reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22624-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityChangeInReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674802259672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated condensed statements of cash flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 13,748<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14,663<span></span>
</td>
<td class="nump">14,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for expected credit losses</a></td>
<td class="num">(359)<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">(Recovery) provision for expected credit losses</a></td>
<td class="num">(359)<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation from 2021 Stock Incentive Plan</a></td>
<td class="nump">7,797<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation', window );">Profits interest plan, liability-classified and other equity awards compensation</a></td>
<td class="num">(24,356)<span></span>
</td>
<td class="num">(6,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of interest rate swap</a></td>
<td class="num">(1,310)<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ChangeInFairValueOfEquityParticipationRightsUnit', window );">Change in fair value of Equity Participation Rights unit</a></td>
<td class="num">(2,774)<span></span>
</td>
<td class="num">(788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets', window );">Impairments related to variable interest entity</a></td>
<td class="nump">7,043<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="num">(255)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(9,370)<span></span>
</td>
<td class="nump">16,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">3,913<span></span>
</td>
<td class="num">(6,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,917<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet', window );">Other current assets and liabilities</a></td>
<td class="num">(13,011)<span></span>
</td>
<td class="num">(867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash from operating activities</a></td>
<td class="num">(713)<span></span>
</td>
<td class="nump">25,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchase of Bioness, Inc, net of cash acquired</a></td>
<td class="num">(45,790)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2,642)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(864)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash from investing activities</a></td>
<td class="num">(49,296)<span></span>
</td>
<td class="num">(1,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash from investing activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash from investing activities</a></td>
<td class="num">(49,296)<span></span>
</td>
<td class="num">(1,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of Class A common stock sold in initial public offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">107,777<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Class A and B common stock</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing on revolver</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromMembers', window );">Refunds (distributions) - members</a></td>
<td class="nump">813<span></span>
</td>
<td class="num">(9,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash from financing activities</a></td>
<td class="nump">101,409<span></span>
</td>
<td class="nump">37,425<span></span>
</td>
<td class="num">$ (29,569)<span></span>
</td>
<td class="num">$ (10,951)<span></span>
</td>
<td class="num">$ (13,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">51,229<span></span>
</td>
<td class="nump">61,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">86,839<span></span>
</td>
<td class="nump">64,520<span></span>
</td>
<td class="nump">64,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">138,068<span></span>
</td>
<td class="nump">126,240<span></span>
</td>
<td class="nump">86,839<span></span>
</td>
<td class="nump">64,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable for purchase of property and equipment</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberDistributionsIncurredButNotYetPaid', window );">Accrued member distributions</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
<td class="num">(12,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">16,650<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="nump">8,113<span></span>
</td>
<td class="nump">4,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities from continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,643<span></span>
</td>
<td class="nump">30,316<span></span>
</td>
<td class="nump">29,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Loss on impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment of contingent consideration in excess of amount established in purchase accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(945)<span></span>
</td>
<td class="num">(3,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for expected credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">2,242<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">(Recovery) provision for expected credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">2,242<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation', window );">Profits interest plan, liability-classified and other equity awards compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,103<span></span>
</td>
<td class="nump">10,844<span></span>
</td>
<td class="nump">14,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(511)<span></span>
</td>
<td class="num">(348)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and capitalized loan fees, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationAccretionExpense', window );">Loss on debt retirement and modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ChangeInFairValueOfEquityParticipationRightsUnit', window );">Change in fair value of Equity Participation Rights unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,941)<span></span>
</td>
<td class="num">(14,909)<span></span>
</td>
<td class="num">(12,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="num">(1,427)<span></span>
</td>
<td class="nump">3,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,510<span></span>
</td>
<td class="nump">6,646<span></span>
</td>
<td class="nump">12,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet', window );">Other current assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(733)<span></span>
</td>
<td class="num">(3,882)<span></span>
</td>
<td class="num">(422)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,199<span></span>
</td>
<td class="nump">42,545<span></span>
</td>
<td class="nump">52,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="num">(1,832)<span></span>
</td>
<td class="num">(7,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,799<span></span>
</td>
<td class="nump">40,713<span></span>
</td>
<td class="nump">45,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_InvestmentAndAcquisitionOfDistributionRights', window );">Investment and acquisition of distribution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,579)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AcquisitionOfVariableInterestEntity', window );">Acquisition of VIE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,093)<span></span>
</td>
<td class="num">(2,342)<span></span>
</td>
<td class="num">(2,561)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash from investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,672)<span></span>
</td>
<td class="num">(7,912)<span></span>
</td>
<td class="num">(6,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash from investing activities - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash from investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,500)<span></span>
</td>
<td class="num">(7,912)<span></span>
</td>
<td class="num">(6,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing on revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payment on revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from the issuance of long-term debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(199,500)<span></span>
</td>
<td class="num">(5,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromMembers', window );">Refunds (distributions) - members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,886)<span></span>
</td>
<td class="num">(9,137)<span></span>
</td>
<td class="num">(7,846)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="num">(448)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,319<span></span>
</td>
<td class="nump">21,746<span></span>
</td>
<td class="nump">25,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">$ 86,839<span></span>
</td>
<td class="nump">$ 64,520<span></span>
</td>
<td class="nump">64,520<span></span>
</td>
<td class="nump">42,774<span></span>
</td>
<td class="nump">17,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,839<span></span>
</td>
<td class="nump">64,520<span></span>
</td>
<td class="nump">42,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SupplementalDisclosureOfCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,486<span></span>
</td>
<td class="nump">15,450<span></span>
</td>
<td class="nump">17,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Accrued liabilities for distribution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable for purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberDistributionsIncurredButNotYetPaid', window );">Accrued member distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AcquisitionOfVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AcquisitionOfVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ChangeInFairValueOfEquityParticipationRightsUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Equity Participation Rights Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ChangeInFairValueOfEquityParticipationRightsUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Variable Interest Entity And Related Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InvestmentAndAcquisitionOfDistributionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment and acquisition of distribution rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InvestmentAndAcquisitionOfDistributionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MemberDistributionsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Member Distributions Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MemberDistributionsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ProceedsFromMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Members</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ProceedsFromMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits Interest Plan, Liability Classified And Other Equity Awards Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SupplementalDisclosureOfCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SupplementalDisclosureOfCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674733220968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. (the Company, we, us or our) was formed as a Delaware corporation for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (BV LLC). The Company is headquartered in Durham, North Carolina. BV LLC, is a limited liability company formed under the laws of the state of Delaware on November&#160;23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012. BV LLC is a global medical device company, conducting business in various countries, primarily in North America and Europe, with approximately 900 employees. The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing processes. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial Public Offering </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;16, 2021, the Company closed an IPO of 9,200,000 shares of Class&#160;A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#8217; over-allotment option. The Company received $111,228 in proceeds, net of underwriting discounts and commissions of $8,372, which was used to purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of $13.00. The Company also incurred offering expenses totaling $4,778 in addition to the underwriting discounts and commissions. Offering expenses of $1,327 were paid in 2020 and $3,451 were paid in 2021. Subsequent to the IPO and related transactions that occurred in connection with the IPO (the Transactions), the Company is the sole managing member of BV LLC and owns 72.2% of BV LLC. The Company has a majority economic interest, the sole voting interest in, and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest representing the 27.8% interest not held by the Company. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPO Transactions </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company and BV LLC completed the following Transactions in connection with the IPO. BV LLC amended and restated the Bioventus LLC Agreement, to, among other things, (i)&#160;provide for a new single class of common membership interests in BV LLC (LLC Interests), (ii) exchange all of the existing membership interests in BV LLC for new LLC Interests and (iii)&#160;appoint Bioventus Inc. as the sole managing member of BV LLC. The Company amended and restated its certificate of incorporation to, among other things, provide for the (i)&#160;authorization of 250,000,000 shares of Class&#160;A common stock with a par value of $0.001 per share; (ii)&#160;authorization of 50,000,000 shares of Class&#160;B common stock with a par value of $0.001 per share; (iii)&#160;authorization of 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company&#8217;s Board of Directors (BOD) in one or more series; and (iv)&#160;establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms. Holders of Class&#160;A / Class&#160;B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class&#160;B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class&#160;B common stock may only be issued to the extent necessary to maintain the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> ratio between the number of LLC Interests held by the only member of BV LLC that remained a member following the Transactions (Continuing LLC Owner) and the number of shares of Class&#160;B common stock held by the Continuing LLC Owner. Shares of Class&#160;B common stock are transferable only together with an equal number of LLC Interests. Shares of Class&#160;B common stock will be canceled on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis if the Company, at the election of a Continuing LLC Owner, redeem or exchange LLC Interests. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company&#8217;s amended and restated certificate of incorporation and the Bioventus LLC Agreement requires that the Company and BV LLC at all times maintain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> ratio between the number of shares of Class&#160;A common stock issued by the Company and the number of LLC Interests owned by the Company, as well as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> ratio between the number of shares of Class&#160;B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. The Company acquired, by merger, ten entities that were members of BV LLC (Former LLC Owners), for which the Company issued 31,838,589 shares of Class&#160;A common stock as merger consideration (Merger). The only assets held by the Former LLC Owners were 31,838,589 LLC Interests and a corresponding number of shares of Class&#160;B common stock. Upon consummation of the Merger, the Company canceled the 31,838,589 shares of Class&#160;B common stock and recognized the 31,838,589 LLC Interests at carrying value, as the Merger is considered to be a recapitalization transaction. Following the Merger and IPO, as of August&#160;10, 2021, the Company holds 41,062,652 LLC Interests, representing a 72.2% ownership interest in BV LLC. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements for periods prior to the IPO and Transactions have been adjusted to combine the previously separate entities for presentation purposes. Prior to the Transactions, Bioventus Inc. had no operations. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim periods </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company reports quarterly interim periods on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-week</div> basis within a standard calendar year. Each annual reporting period begins on January&#160;1 and ends on December 31. Each quarter ends on the Saturday closest to calendar <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">quarter-end,</div> with the exception of the fourth quarter, which ends on December 31. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13-week</div> quarterly periods for fiscal year 2021 end on April&#160;3, July&#160;3 and October 2. Comparable periods for 2020 ended on March&#160;28, June&#160;27 and September 26. The fourth and first quarters may vary in length depending on the calendar year. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited interim financial information </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-01</div> of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Pursuant to these rules and regulations they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company&#8217;s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company&#8217;s 2020 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> The balance sheet at December&#160;31, 2020 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impact </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2020, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic spread around the world and in the United States. New variants of the virus have emerged, some of which have shown to be more contagious. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of businesses, work from home, supply chain logistical changes and other measures, which caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted by fluctuations in patient visits and elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">from customers, supply chain interruptions, extended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;shelter-in-place&#8221;</div></div> orders or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on our business will depend on many factors, including, but not limited to, the duration and severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability, adoption and effectiveness of vaccines, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on our partners, patients and communities in which we operate, all of which continue to be uncertain. As of the date of issuance of these consolidated financial statements, the extent to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could materially impact the Company&#8217;s financial conditions, liquidity or results of operations is uncertain. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To the extent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully commercialize newly developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual relationships. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law, which was aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the CARES Act and at the direction of the U.S. Department of Health and Human Services (HHS), the Company received a $1,247 Provider Relief Fund Payment in April 2020. The Company determined it complied with the conditions to be able to keep and use the funds to reimburse for health care related expenses and lost revenue attributable to the public health emergency resulting from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The payment was recorded as other income on the consolidated statement of operations and comprehensive (loss) income for the three and six months ended June&#160;27, 2020. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent accounting pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has elected to comply with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are generally earlier than when emerging growth companies are required to adopt. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Pronouncements Recently Adopted </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div>(ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12),</div> which amended the accounting for income taxes. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> eliminates certain exceptions to the guidance for income taxes related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in the tax basis of goodwill. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> on January&#160;1, 2021 and it did not have a material impact on its consolidated financial statements. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus Inc. (the Company, we, us or our) was formed as a Delaware corporation on December&#160;22, 2015 for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (BV LLC). The notes to these financial statements should be read in conjunction with notes to BV LLC&#8217;s financial statements. As of December&#160;31, 2020, the Company had not engaged in any business activities except in connection with its formation. On February&#160;16, 2021, the Company closed an IPO of 9,200,000 shares of Class&#160;A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#8217; over-allotment option. The Company received $111,228 in proceeds, net of underwriting discounts and commissions of $8,372, which was used to purchase newly-issued membership interests from BV LLC at a price per interest equal to the IPO price of $13.00. In addition to the underwriting discounts and commission the Company incurred offering expenses totaling $4,310. Subsequent to the IPO and related transactions that occurred in connection with the IPO (the Transactions) as described in Note 4, the Company is the sole managing member of BV LLC and owns 72.2% of BV LLC. The Company has a majority economic interest, the sole voting interest in, and controls the management of BV LLC. As a result, subsequent to the IPO, the Company will consolidate the financial results of BV LLC and will report a non-controlling interest representing the 27.8% interest not held by the Company. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization and basis of presentation of financial information&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus LLC and its subsidiaries (the Company, we, us or our), is a limited liability company formed under the laws of the state of Delaware on November&#160;23, 2011 and operates as a partnership. The Company commenced operations in May 2012 in Durham, North Carolina, USA, which is its headquarters. Bioventus is a global medical device company, conducting business in various countries, primarily in North America and Europe, with approximately 700&#160;employees. The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body&#8217;s natural healing processes. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bioventus Inc. was formed as a Delaware corporation for the purpose of facilitating an initial public offering (IPO) and other related transactions in order to carry on the business of the Company. Bioventus Inc. acquired, by merger, ten entities that were members of the Company (Former LLC Owners) and upon consummation of the merger, owned 31,838,589 Common LLC Interests (as defined below). On February&#160;16, 2021, Bioventus Inc. (New LLC Owner) closed an IPO of 9,200,000 shares of Class&#160;A common stock at a public offering price of $13.00 per share, which includes 1,200,000 shares issued pursuant to the underwriters&#8217; over-allotment option. The New LLC Owner received $111,228 in proceeds, net of underwriting discounts and commissions which was used to make a capital contribution to the Company in exchange for 9,200,000 newly-issued membership interests (Common LLC Interests) from the Company at a price per interest equal to the IPO price of $13.00. Subsequent to the IPO and related transactions that occurred in connection with the IPO (Transactions), the New LLC Owner is the sole managing member of the Company. Following the completion of the IPO and Transactions, the New LLC Owner owns 72.2% of the Company. The New LLC Owner has a majority economic interest, the sole voting interest in, and controls the management of the Company. As a result, subsequent to the IPO, the New LLC Owner will consolidate the financial results of the Company and will report a non-controlling interest representing the interests owned by the only member of BV LLC that remained a member (Continuing LLC Owner). Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 17. Subsequent Events</div></div> for further details regarding the IPO and related transactions. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim periods </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January&#160;1 and ends on December&#160;31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December&#160;31. The 13-week quarterly periods ended on March&#160;28,&#160;June&#160;27 and September&#160;26 for the year ended December&#160;31, 2020. As a result, the fourth and first quarters may vary in length depending on the calendar year. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principles of consolidation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). The consolidated financial statements include the Company, its subsidiaries and investments in which the Company has control. Amounts pertaining to the non-controlling ownership interests held by third parties in the operating results and financial position of the Company&#8217;s controlled subsidiaries are reported as non-controlling interests. All intercompany balances and transactions have been eliminated in consolidation. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain prior period amounts have been reclassified to conform to the current period presentation. These changes had no effect on previously reported total revenues, net income (loss), other comprehensive income (loss), members&#8217; equity or cash flows. Unless otherwise noted, all financial information in the consolidated financial statement footnotes reflect the Company&#8217;s results from continuing operations. Discontinued operations are discussed further in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 16. Discontinued operations</div></div>. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment reporting </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identifies a business as an operating segment if: (i)&#160;it engages in business activities from which it may earn revenues and incur expenses; (ii)&#160;its operating results are regularly reviewed by the Chief Operating Decision Maker (CODM), to make decisions about resources to be allocated to the segment and assess its performance; and (iii)&#160;it has available discrete financial information. The Company&#8217;s CODM is its Chief Executive Officer. The CODM reviews financial information at the operating segment level to allocate resources and to assess the operating results and financial performance for each operating segment. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s two reportable segments are U.S. and International. U.S. and International products are primarily sold to physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery, as well as directly to their patients. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 14. Net sales</div></div> and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 15. Segments</div></div> for further information regarding our business segments. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in accordance with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowances for doubtful accounts, inventory reserves, goodwill and intangible assets impairment, useful lives of long lived assets, noncontrolling interest, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19 pandemic impact </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, the COVID-19 pandemic spread around the world and in the U.S. and, more recently, new variants of the virus have emerged, some of which have shown to be more contagious. The COVID-19 pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments have implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of business, work from home, supply chain logistical changes and other measures, which have caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted due to the decrease in patient visits and elective procedures and any future temporary cessations of elective procedures and could be further impacted by delays in payments from customers, supply chain interruptions, extended &#8220;shelter-in-place&#8221; orders or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of COVID-19 on our business will depend on many factors, including, but not limited to, the duration and </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability and effectiveness of vaccines to combat COVID-19, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on our partners, patients and communities in which we operate, all of which continue to be uncertain. For example, there has been a decrease in patient visits to hospitals due to risk and fear of exposure to COVID-19, as well as decreases in, or temporary moratoriums on, elective procedures, which may be re-imposed in the future. In addition to lower sales, we have experienced decreased costs as a result of the pandemic including declines in travel and lower compensation related expenses. We have also implemented other various cost reduction initiatives and measures to safeguard liquidity. As of the date of issuance of these consolidated financial statements, the extent to which COVID-19 could materially impact the Company&#8217;s financial conditions, liquidity or results of operations is uncertain. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent COVID-19 disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully commercialize new developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual relationships. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law, which was aimed at providing emergency assistance and health care for individuals, families, and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations. The CARES Act allowed the Company to defer $1,889 in employer social security payroll tax payments from May 2020 through December&#160;31, 2020. A total of 50% is deferred until December&#160;31, 2021 and has been recorded in accrued liabilities, with the remaining balance deferred until December&#160;31, 2022 which has been recorded in other long-term liabilities both on the consolidated balance sheet. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 10. Income Taxes</div></div> for further information. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the CARES Act and at the direction of the U.S. Department of Health and Human Services (HHS), the Company received a $1,247 Provider Relief Fund Payment in April 2020. The Company determined it complied with the conditions to be able to keep and use the funds to reimburse for health care related expenses and lost revenue attributable to the public health emergency resulting from COVID-19. A second Provider Relief Fund Payment totaling $2,854 was received in July 2020. The payments were recorded as other income on the consolidated statement of operations and comprehensive income (loss) for the year ended December&#160;31, 2020. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674922672824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of significant accounting policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of accounting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The balance sheets have been prepared in accordance with accounting principles generally accepted in the United States of America. Separate statements of income, comprehensive income, changes in stockholder&#8217;s equity, and cash flows have not been presented in the financial statements as there has been no activity. </div></div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of significant accounting policies </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent accounting pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected to comply with non-accelerated public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are specific to non-accelerated public company filers, which are generally earlier than when emerging growth companies are required to adopt. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Pronouncements Recently Adopted </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FASB issued Accounting Standards Update 2016-13, Financial Instruments-Credit Losses (ASU 2016-13), in June 2016 that significantly changes accounting for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment methodology in prior GAAP with a methodology that considers a broad range of information for the estimation of credit losses. The Company adopted ASU 2016-13 on January&#160;1, 2020 prospectively and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the FASB issued Accounting <div style="letter-spacing: 0px; top: 0px;;display:inline;">Standards</div> Update 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (ASU 2018-15), addressing a customer&#8217;s accounting for implementation costs incurred in a cloud-computing arrangement (CCA) that is considered a service contract. Under ASU 2018-15, implementation costs for a CCA should be evaluated for capitalization using the same approach as implementation costs associated with internal-use software. The capitalized implementation costs should be expensed over the term of the hosting arrangement, which includes any reasonably certain renewal periods. Capitalized implementation costs should be assessed for impairment like long-lived assets. The Company adopted ASU 2018-15 on January&#160;1, 2020 prospectively and it had no material impact on the Company&#8217;s consolidated financial statements. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (ASU 2018-13), modifying the disclosure requirements on fair value measurements and eliminates the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements. ASU 2018-13 modifies certain disclosures related to investments measured at net asset value and clarifies that companies are to disclose uncertainties in measurements as of the reporting date. ASU 2018-13 requires additional disclosure related to changes in unrealized gains and losses included in other comprehensive income (loss) for recurring Level 3 fair value measurements as well as the range and weighted average, or other quantitative information that would be a more reasonable and rational method, of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted ASU 2018-13 on January&#160;1, 2020 and it did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New Accounting Pronouncements Not Yet Adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (ASU 2019-12), which amended the accounting for income taxes. ASU 2019-12 eliminates certain exceptions to the guidance for income taxes related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU 2019-12 is effective for annual and interim periods beginning after December&#160;15, 2020. Early adoption is permitted in interim or annual periods for which financial statements have not been made available for issuance. Entities that elect to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Certain amendments are to be applied prospectively while others are retrospective. The Company adopted ASU 2019-12 on January&#160;1, 2021 and the Company has assessed it will not have a material impact on its consolidated financial statements. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable Interest Entity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews each investment and collaboration agreement to determine if it has a variable interest in the entity. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgments regarding the purpose and design of entity, the value of the licensed assets to the entity, the value of the entity&#8217;s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that variable interest entity (VIE), based on a number of factors, including: (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii)&#160;the parties&#8217; contractual rights and responsibilities pursuant to the collaboration agreement, and (iii)&#160;which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statement of the VIE into the Company&#8217;s consolidated financial statements. On a quarterly basis, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">evaluates </div>whether </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period the determination is <div style="letter-spacing: 0px; top: 0px;;display:inline;">made.</div> </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities recorded as a result of consolidating financial results of the VIE into the Company&#8217;s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company&#8217;s general assets or liabilities for which creditors have recourse to the Company&#8217;s general assets. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling Interest </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records noncontrolling interest related to the consolidated VIEs on its consolidated balance sheet. The Company records loss attributable to noncontrolling interest on its consolidated statements of operations, which reflects the VIE&#8217;s net loss for the reporting period, adjusted for changes in the noncontrolling interest holders claim to net assets, including contingent milestone and royalty payments, which are evaluated each reporting period. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deconsolidation and discontinued operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i)&#160;the aggregate of (a)&#160;the fair value of any consideration received, (b)&#160;the fair value of any retained noncontrolling investment in the former subsidiary and (c)&#160;the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii)&#160;the carrying amount of the former subsidiary&#8217;s assets and liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on if the deconsolidation represents a strategic shift that has or will have a major effect on the Company&#8217;s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one-year period following such date, it will present the former subsidiary as a discontinued operation for all periods presented. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of foreign currency </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars at rates of exchange in effect at the close of their month end. Equity accounts are translated at their historical rates. Revenues and expenses are translated at the exchange rate on the transaction date. Translation gains and losses are accumulated within accumulated other comprehensive income (loss) as a separate component of members&#8217; equity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency transaction gains and losses are included in other expense on the consolidated statements of operations and comprehensive income (loss). There were gains of $117 for the year ended December&#160;31, 2020, nominal losses for the year ended December&#160;31, 2019, and losses of $234 for the year ended December&#160;31, 2018. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) consists of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S.&#160;GAAP are recorded as an element of members&#8217; equity and are excluded from net income (loss). The Company&#8217;s other comprehensive income (loss) consists of a defined benefit plan adjustment and foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents consist of highly liquid investments with an original maturity of<div style="letter-spacing: 0px; top: 0px;;display:inline;"> three</div> months or less at date of purchase. The Company&#8217;s cash is primarily held in financial institutions in the United States and the Netherlands. The Company maintains cash balances in the United States in excess of the federally insured limits. The Company did not have restricted cash as of December&#160;31, 2020 and 2019. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company uses derivative instruments to manage exposures to interest rates. Derivatives are recorded on the balance sheet at fair value at each balance sheet date and the Company does not designate whether the derivative instrument is an effective hedge. Changes in the fair values of derivative instruments are recognized in the consolidated statements of operations and comprehensive income (loss). The Company has entered, and may in the future enter, into derivative contracts related to its debt. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 5. Financial instruments</div></div> for further details regarding the Company&#8217;s derivatives. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records certain assets and liabilities at fair value. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 7. Fair value measurements</div></div> for details regarding assets and liabilities measured at fair value. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities are categorized based on the lowest level that is significant to the valuation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The three levels of inputs used to measure fair value are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#8212;Observable inputs other than quoted prices included within Level&#160;1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </div></div></td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Products </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derives revenue primarily from the sale of its (i)&#160;osteoarthritic, or OA, joint pain treatment and joint preservation products, which are hyaluronic acid, or HA, viscosupplementation therapies, (ii)&#160;Bone Graft Substitutes (BGS) products and (iii)&#160;a Minimally Invasive Fracture Treatment product. The Company sells product directly to healthcare institutions, patients, distributors and dealers. The Company also enters arrangements with pharmacy and health benefit managers that provide for negotiated rebates, chargebacks and discounts with respect to the purchase of the Company&#8217;s products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue at a point in time upon transfer of control of the promised product to customers in an amount that reflects the consideration it expects to receive in exchange for those products. The Company excludes taxes collected from customers and remitted to governmental authorities from revenues. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are recorded at the transaction price, which is determined as the contracted price net of estimates of variable consideration resulting from discounts, rebates, returns, chargebacks, contractual allowances, estimated third-party payer settlements, and certain distribution and administration fees offered in our customer contracts and other indirect customer contracts relating to the sale of our products. The Company establishes reserves for the estimated variable consideration based on the amounts earned or eligible to be claimed on the related sales. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted for relevant factors such as the Company&#8217;s historical experience, current contractual requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company regularly reviews all reserves and updates them at the end of each reporting period as needed. There were no adjustments arising from the change in estimates of variable consideration that were significant for the years ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">OA Joint Pain Treatment and Joint Preservation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from customers, such as healthcare providers, distribution centers or specialty pharmacies is recognized at the point in time when control is transferred to the customer, typically upon shipment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributor chargebacks </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has preexisting contracts with established rates with many of the distributors&#8217; customers who require the distributors to sell our product at their established rate. The Company offers chargebacks to distributors who supply these customers with our products. The Company reduces revenue at the time of sale for the estimated future chargebacks. The Company records chargeback reserves as a reduction of accounts receivable and base the reserves on the expected value by using probability-weighted estimates of volume of purchases, inventory holdings and historical chargebacks requested for each distributor. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Discounts and gross-to-net deductions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company offers retrospective discounts and gross-to-net deductions linked to the volume of purchases which may increase at negotiated thresholds within a contract-buying period. The Company reduces revenue and records the reserve as a reduction to accounts receivable for the estimated discount and rebate at the expected amount the customer will earn, based on historical buying trends and forecasted purchases. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bone Graft Substitute </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the Company&#8217;s BGS product sales are through consignment inventory with hospitals, where ownership remains with the Company until the hospital or ambulatory surgical center (ASC) performs a surgery and consumes the consigned inventory. The Company recognizes revenue when the surgery has been performed. Control of the product is not transferred until the customer consumes it, as the Company is able to require the return or transfer of the product to a third-party. An unconditional obligation to pay for the product does not exist until the customer consumes it. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Minimally Invasive Fracture Treatment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue from third-party payers, such as governmental agencies, insurance companies or managed care providers, when the Company transfers control to the patient, typically when the patient has accepted the product or upon delivery. The Company records this revenue at the contracted rate, net of contractual allowances and estimated third-party payer settlements at the time of sale, or an estimated price based on historical data and other available information for non-contracted payers. The Company estimates the contractual allowances using the portfolio approach and based on probability weighting historical data and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collections history within those portfolios. The portfolios determined using the portfolio approach consist of the following customer groups: government payers, commercial payers, and patients. The Company recognizes revenue from patients (self-pay and insured patients with coinsurance and deductible responsibilities) based on billed amounts giving effect to any discounts and implicit price concessions. Implicit price concessions represent differences between amounts billed and the amounts the Company expects to collect from patients, which considers historical collection experience and current market conditions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price using the expected amount method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. The Company is not aware of any claims, disputes or unsettled matters with any payer that would materially affect revenues for which the Company has not adequately provided for or disclosed in the accompanying consolidated financial statements. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 12. Commitments and contingencies</div></div> for further information. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product returns </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimates the amount of returns and reduces revenue in the period the related product revenue is recognized. The Company records a liability for expected returns based on probability-weighted historical data. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts receivable, net </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for doubtful accounts. The Company maintains an estimated allowance for doubtful accounts to provide for receivables the Company does not expect to collect. The Company bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract assets </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets consist of unbilled amounts resulting from estimated future royalties from an international distributor that exceeds the amount billed. Contract assets totaling $81 and $261 as of December&#160;31, 2020 and 2019, are included in prepaid and other current assets on the consolidated balance sheets, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract liabilities </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities consist of customer advance payments and deferred revenue. Occasionally for certain international customers, the Company requires payments in advance of shipping product and recognizing revenue resulting in contract liabilities. Contract liabilities were nominal as of December&#160;31, 2020 and 2019 and are included in accrued liabilities on the consolidated balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shipping and handling </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other distribution costs are included in cost of sales. The </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company has elected to recognize shipping and handling activities that occur after control of the related product transfers to the customer as fulfillment costs and these are included in<div style="display:inline;"> cost</div> of sales.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the practical expedient of recognizing the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less. These incremental costs include the Company&#8217;s sales incentive programs for the internal sales force and third-party sales agents as the compensation is commensurate with annual sales activities. These costs are included in selling, general and administrative expense on the consolidated statements of operations and comprehensive income (loss). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company values its inventory at the lower of cost or net realizable value and adjusts for the value of inventory that is estimated to be excess, obsolete or otherwise unmarketable. Cost is determined using the first-in, first-out (FIFO) method. Elements of cost in inventory include raw materials, direct labor, manufacturing overhead and inbound freight. The Company records allowances for excess and obsolete inventory based on historical and estimated future demand and market conditions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business combinations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting for acquisitions requires the Company to recognize separately from goodwill assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While best estimates and assumptions are used to accurately value assets acquired and liabilities assumed at the acquisition date, as well as contingent consideration where applicable, estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations and comprehensive income (loss). Subsequent changes in the estimated fair value of contingent<div style="display:inline;"> considerat</div>ion are recognized in earnings in the period of change. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense are recognized using the straight-line method over the estimated useful life of each asset, or the shorter of the lease term or useful life if related to leasehold improvements. The useful lives in years are as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer software and hardware</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3-5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and intangible assets&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Fini</div>te-lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight-line method over their estimated useful lives in years are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is not amortized but is evaluated for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. The Company reviews goodwill for impairment by applying a quantitative impairment analysis where the fair value of the reporting unit is compared with the carrying value, including goodwill. The Company determines the fair value of each reporting unit based on an income approach. The value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company performs its annual goodwill impairment test on October&#160;31st. If the fair value of the reporting unit is less than its carrying value, the Company will recognize the difference as an impairment loss, which is limited to the amount of goodwill allocated to the reporting units. There were no goodwill impairment charges for the years ended December&#160;31, 2020, 2019 and 2018. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Software development costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company capitalizes internal and external costs incurred to develop internal-use software during the application development stage for software design, configuration, coding and testing upon placing the asset in service and then amortizes these costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. The Company does not capitalize costs that are precluded from capitalization in authoritative guidance, such as preliminary project phase costs, training costs or data conversion costs. Capitalized software costs totaled $17,653 and $14,119 as of December&#160;31, 2020 and 2019 and the related accumulated amortization totaled $13,264 and $12,184, respectively. Amortization expense was $1,184, $1,138 and $1,204 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying values of property, equipment, intangible assets as well as other long-lived and indefinite lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable the Company will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. If quoted market prices are not available, the Company estimates fair value using an undiscounted value of estimated future cash flows. During 2018, the Company determined that it would no longer sell a specific BGS product and as a result, an intangible asset related to this product was fully written off and the Company recognized impairment charges of $489 for the year ended December&#160;31, 2018, which is included in the consolidated statements of operations and comprehensive income (loss). Upon retirement or sale of property and equipment, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is included in income from operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#8217;s property, equipment, intangible or other long-lived assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired in-process research and development </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of in-process research and development (IPR&amp;D) assets acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets and are not amortized until development is completed and the product is available for sale. Once the product is available for sale, the asset is transferred to developed technology and amortized over its estimated useful life. Impairment tests for IPR&amp;D assets occur at least annually in December, or more frequently if events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than the carrying amount, an impairment loss is recognized for the difference. There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#8217;s IPR&amp;D. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Offering Costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs, consisting of legal, accounting, filing and other fees related to the initial public offering, are capitalized. The deferred offering costs will be offset against proceeds from the initial public offering upon the effectiveness of the initial public offering. In the event the initial public offering is terminated, all capitalized deferred offering costs would be expensed. Deferred offering costs capitalized totaled $2,187 as of December&#160;31, 2020 and there were there were no deferred offering costs capitalized as of December&#160;31, 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company provides credit, in the normal course of business, to its customers. The Company does not require collateral or other securities to support customer receivables. Credit losses are provided for through allowances and have historically been materially within management&#8217;s estimates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable to these significant suppliers at December&#160;31 were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,983</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,586</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">471</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">697</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain products provide the Company with a significant percentage of total sales for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has restructured portions of its operations and future restructuring activities are possible. Identifying and calculating the cost to exit these operations requires certain assumptions to be made, the most significant of which are anticipated future liabilities. Although estimates have been reasonably accurate in the past, significant judgment is required, and these estimates and assumptions may change as additional information becomes available and facts or circumstances change. Restructuring costs are recorded at estimated fair value. Key assumptions in determining the restructuring costs include negotiated terms and payments to terminate contractual obligations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures profits interest compensation cost at the grant date based on the fair value of the award and recognizes this cost as compensation expense over the required or estimated service period for awards expected to vest. Certain awards are liability-classified, which require they be remeasured at each reporting date. Compensation expense is included in Selling, general and administrative expense and Research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employees who were granted the awards. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs include costs incurred to promote the Company&#8217;s business and are expensed as incurred. Advertising costs were $2,769, $2,351 and $2,916 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense consist primarily of employee compensation and related expenses as well as contract research organization services. Internal research and development costs are expensed as incurred. Research and development costs incurred by third parties are expensed as the contracted work is performed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative agreements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and we account for these alliances as a collaborative arrangement by reporting costs incurred from transactions within research and development expense in our consolidated statements of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. Legal fees expected to be incurred in connection with a loss contingency are not included in the estimated loss contingency. The Company accrues for any legal costs as they are incurred. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is treated as a partnership for U.S. tax purposes. Accordingly, the profits and losses are passed through to the members and included in their income tax returns. The Company has been required to make tax </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distributions to its members in an amount equal to 40% of the members&#8217; taxable income attributable to their ownership. The tax rate applied for purposes of this distribution may be changed only by approval of the Company&#8217;s Board of Managers. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain wholly owned subsidiaries of the Company are taxable entities for U.S. or foreign tax purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred tax assets to an amount which will, more likely than not, be realized. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a tax benefit from any uncertain tax positions only if they are more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. Components of the reserve, if relevant, are classified as a current or noncurrent liability in the consolidated balance sheet based on when the Company expects each of the items to be settled. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per common unit </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic income (loss) per common unit is determined by dividing the net income (loss) allocable to common unit holders by the weighted average number of common units outstanding during the periods presented. Diluted loss per common unit is computed by dividing the net income (loss) allocable to common unit holders on an &#8220;if converted&#8221; basis by the weighted average number of actual common units outstanding and, when dilutive, the unit equivalents that would arise from the assumed conversion of convertible instruments, if any. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has considered the effects of subsequent events through March&#160;26, 2021, the date the Company&#8217;s consolidated financial statements were issued. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798110728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance sheet information</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Balance sheet information </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of cash and cash equivalents and restricted cash is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,065</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,839</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,003</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,068</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,839</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted cash consists of deposits into escrow with a financial institution for the purpose of paying specific indebtedness of a company acquired as part of a business combination (refer to<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Note 3. Business combinations and investments</div></div>). </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net of allowances, consisted of the following as of: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105,048</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,273</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Allowance for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,029</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to make required payments. The allowance for credit losses is calculated by region and by customer type, where appropriate considering several factors including age of accounts, collection history, historical account write-offs, current economic conditions, and supportable forecasted economic expectations. Due to the short-term nature of its receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. An increase in the provision for credit losses may be required when the financial condition of the Company&#8217;s customers or its collection experience deteriorates. The Company has a diverse customer base with no single customer representing ten percent of sales or accounts receivable. Historically, the Company&#8217;s reserves have been adequate to cover credit losses. The Company&#8217;s exposure to credit losses may increase if its customers are adversely affected by changes in health care laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, or other customer-specific factors. The Company considered the current and expected future economic and market conditions surrounding the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and determined that the estimate of credit losses was not significantly impacted. Estimates are used to determine the allowance, which are based on an assessment of anticipated payment and all other historical, current and future information that is reasonably available. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in credit losses were as <div style="letter-spacing: 0px; top: 0px;;display:inline;">follows</div>: </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,811</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,684</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recovery (provision)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">550</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(619</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">359</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,162</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">278</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">684</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">252</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(72</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(193</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consisted of the following as of: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and supplies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,202</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,665</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,538</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,323</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,740</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,988</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess and obsolete reserves</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(868</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,020</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,120</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consisted of the following as of: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> deductions</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">63,980</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">43,656</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus and commission</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,493</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,932</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income and other taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,385</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,434</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,456</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,034</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105,246</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,187</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company completed a restructuring plan during the fourth quarter of 2020 and the remaining $247 accrued liabilities were paid during the six months ended July&#160;3, 2021. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance sheet information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Balance sheet information&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net of allowances, consisted of the following as of December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,273</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,274</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Allowance for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,128</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains an allowance for credit losses for estimated losses resulting from the inability of its customers to make required payments. The allowance for credit losses is calculated by region and by customer type, where appropriate considering several factors including age of accounts, collection history, historical account write-offs, current economic conditions, and supportable forecasted economic expectations. Due to the short-term nature of its receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. An increase in the provision for credit losses may be required when the financial condition of the Company&#8217;s customers or its collection experience deteriorates. The Company </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">has a diverse customer base with no single customer representing ten percent of sales or accounts receivable. Historically, the Company&#8217;s reserves have been adequate to cover credit losses. The Company&#8217;s exposure to credit losses may increase if its customers are adversely affected by changes in health care laws, coverage and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic, or other customer-specific factors. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Estimates are used to determine the allowance, which are based on an assessment of anticipated payment and all other historical, current and future information that is reasonably available.</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in credit losses were as follows for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,497</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,215</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,787</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,949</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(416</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(356</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consisted of the following as of December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and supplies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,665</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,349</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,323</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,509</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,988</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,858</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess and obsolete reserves</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(868</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(532</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,120</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,326</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in excess and obsolete reserves for inventory were as follows for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(532</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(570</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(904</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(870</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">568</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">908</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(868</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(532</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,547</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,854</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,126</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,918</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,474</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,451</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,234</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,138</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets not yet placed in service</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">819</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">370</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,200</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,731</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,879</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,489</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense was $2,106, $2,579 and $3,439 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and intangible assets, net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no changes to goodwill during the years ended December&#160;31, 2020 and 2019. Following is a summary of goodwill by reportable segment: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 685.438px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 368.188px;"/>
<td style="vertical-align: bottom; width: 43.4062px;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 43.4062px;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 43.4375px;"/>
<td/>
<td/>
<td/></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S.</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020 and 2019</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;">41,040</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;">8,760</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;">49,800</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table>  <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets consisted of the following as of December&#160;31:</div></div></div> <div style="color: rgb(0, 0, 0); font-family: Century; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Century; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 433.797px;"/>
<td style="vertical-align: bottom; width: 37.1719px;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 37.1875px;"/>
<td/>
<td/>
<td/></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">263,422</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">263,422</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">60,700</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">59,700</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">57,700</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">57,700</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,445</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,095</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology and other</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,999</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,649</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total carrying amount</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">397,266</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">396,566</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated amortization:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(117,281</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(100,982</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(34,461</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28,716</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(51,247</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(46,407</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology and other</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,786</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,404</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accumulated amortization</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(206,775</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(179,509</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net before currency translation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">190,491</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">217,057</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,159</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(547</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">191,650</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">216,510</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table>  <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company filed a 510(k) in 2019 and began commercializing a next-generation surgical product in the third quarter of 2020. As a result, $9,650 of IPR&amp;D was reclassified to developed technology and will be amortized over 10 years. On December&#160;22, 2020, the Company entered into an amended and restated distribution agreement with the sole supplier of the Company&#8217;s five injection OA product.&#160;This agreement provided non-exclusive U.S. market</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distribution rights until December&#160;31, 2028. The amended and restated distribution agreement created a $1,000 distribution right that will be amortized over 8 years, which was capitalized as an intangible asset and included in <div style="display:inline;">accrued</div> liabilities on the consolidated balance sheets as of December&#160;31, 2020.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense related to intangible assets was $27,565, $26,252 and $26,622 for the years ended December&#160;31, 2020, 2019 and 2018 of which $7,455, $6,416 and $7,766 are included in ending inventory at December&#160;31, 2020, 2019 and 2018, respectively. Estimated amortization expense for the years ended December&#160;31, 2021 through 2025 is expected to be $28,262, $23,910, $22,297, $22,297 and $21,259, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consisted of the following at December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net deductions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,656</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,622</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus and commission</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,200</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserve for estimated overpayments from third-party payers</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,790</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,801</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,231</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income and other taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,434</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,555</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,244</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,418</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,187</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,827</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803289272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business combinations and investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock', window );">Business combinations and investments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Business combinations and investments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2021, in order to broaden its portfolio and increase its global footprint, the Company acquired 100% of the capital stock of Bioness, Inc. (Bioness). Bioness is a global leader in neuromodulation and advanced rehabilitation medical devices through its innovative peripheral nerve stimulation therapy and premium advanced rehabilitation solutions. The Company had previously made a $1,500 convertible debt investment in Bioness on </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;4, 2021 as part of an exclusive negotiation to purchase Bioness, which was subsequently repaid in conjunction with the acquisition. The consideration paid for Bioness is comprised of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consideration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash consideration at closing</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">48,933</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Bioness consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91,933</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Contingent consideration is comprised of future <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> payments contingent upon the achievement of certain research and development projects as well as sales milestones related to Bioness products. Contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">earn-out</div> payments could total up to $65,000 for the achievement of the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$15,000 for obtaining FDA approval for U.S. commercial distribution of a certain product for certain indications on or before June&#160;30, 2022; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$20,000 for meeting net sales targets for certain implantable products over a three year period ending on June&#160;30, 2025 at the latest; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to $10,000 for meeting net sales milestones for certain implantable products over a three year period ending on June&#160;30, 2025 at the latest; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$20,000 for maintaining Centers for Medicare&#160;&amp; Medicaid Services coverage and reimbursement for certain products at specified levels as of December&#160;31, 2024. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of the purchase price is preliminary and subject to change. The primary areas of the purchase price that are not yet finalized are related to contingent consideration, working capital, intangible assets and the residual goodwill. Accordingly, adjustments may be made to the values of assets and liabilities assumed as additional information is obtained about the facts and circumstances that existed at the acquisition date. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date and the resulting goodwill, which is expected to be deductible for tax purposes: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">91,933</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets acquired and liabilities assumed:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,143</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,318</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,947</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">673</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,616</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,020</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,598</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Resulting goodwill<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(b)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,335</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of cash and cash equivalents of $2,143 and restricted cash deposited by the former majority owner of Bioness of $1,000, into escrow with financial institutions for the purpose of paying specific Bioness indebtedness. The Company previously deposited $4,207 into escrow for the same purpose. Prior to the acquisition, Bioness had entered into two loans in connection with the Paycheck Protection Program (the PPP) under the Coronavirus Aid, Relief and Economic Security Act (CARES Act) administered by the U.S. </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Small business Administration. Bioness received proceeds of $3,204 from an unsecured PPP loan that was scheduled to mature on April&#160;10, 2022. Bioness applied and was granted forgiveness of this loan during 2021. Bioness received proceeds of $2,003 from a second unsecured PPP loan bearing an interest rate of 1% scheduled to mature on February&#160;5, 2026. Bioness applied for forgiveness of this loan during 2021. As part of the Bioness acquisition, the balance of $2,003 was placed in restricted cash to cover the repayment of the outstanding unsecured PPP loan in the event it is not forgiven. The $1,000 outstanding unsecured PPP loan balance covered by the former majority owner is included in other current liabilities within the condensed consolidated balance sheets. </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(b)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The U.S. segment was allocated the resulting goodwill from the Bioness acquisition. </div></div> </td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the preliminary fair values of identifiable intangible assets and their useful lives: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful&#160;Life</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">43,500</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; text-align: center;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; text-align: center;">2 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 72%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate amortization expense related to acquired intangible assets for the following five periods is as follows: $2,238&#8212;remainder of 2021, $4,475&#8212;2022, $4,381&#8212;2023, $4,350&#8212;2024 and $4,350&#8212;2025. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company incurred $1,833 and $5,029 in acquisition and integration costs during the three and six months ended July&#160;3, 2021, respectively, which are included in selling general and administrative expense within the consolidated condensed statement of operations and other comprehensive (loss) income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioness&#8217; advanced rehabilitation revenue is comprised of Exoskeletal Systems, Vector Units and Bioness Integrated Therapy Systems (BITS), which is included within the Company&#8217;s Restorative Therapies vertical. The Company&#8217;s Pain Treatment and Joint Preservation vertical will encompass Bioness&#8217; peripheral nerve stimulation therapy products, which includes the StimRouter, an implantable neuromodulation device used to treat chronic peripheral nerve pain. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from Bioness&#8217; products is primarily recognized at a point in time upon transfer of control of its products to customers such as medical facilities and individual patients. Revenue is recognized net of discounts, which can be offered through a variety of factors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consolidated Pro Forma Results </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s consolidated condensed statements of operations reflect net sales and net loss attributable to Bioness of $11,870 and $3,529, respectively, for the three and six months ended July&#160;3, 2021. Consolidated unaudited pro forma results of operations for the Company are presented below assuming the 2021 Bioness Acquisition had occurred January&#160;1, 2020. Pro forma operating results for the three and six months ended June&#160;27, 2020 include operating expenses of $3,939 and $7,135, respectively, for acquisition integration costs and inventory related adjustments. </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">109,816</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">65,955</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">200,541</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">157,570</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(6,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(12,962</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,333</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(11,376</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share of Class&#160;A common stock(1):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VIE </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has a fully diluted 8.8% ownership of Harbor Medtech Inc.&#8217;s (Harbor) Series C Preferred Stock. The Company and Harbor entered into an exclusive Collaboration Agreement in 2019 for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. The Company&#8217;s partial ownership and exclusive Collaboration Agreement created a variable interest in Harbor. As a result, Harbor had been consolidated in the Company&#8217;s consolidated financial statements since the third quarter of 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harbor assets that could only be used to settle Harbor obligations and Harbor liabilities for which creditors did not have recourse to the general credit of the Company were as follows at December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">803</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,635</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">178</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,863</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">366</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,004</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">659</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,029</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company terminated the Collaboration Agreement on June&#160;8, 2021 and determined that the termination was a triggering event requiring an impairment assessment of Harbor&#8217;s long lived assets. The assessment resulted in an impairment of $5,674, representing Harbor&#8217;s long-lived asset balance, which was recorded within impairment of variable entity assets in the consolidated condensed statements of operations and comprehensive (loss) income, of which $5,176 is attributable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest. The Company stopped consolidating Harbor upon the termination of the Collaboration Agreement, as the Company ceased being the primary beneficiary because it no longer had the power to direct Harbor&#8217;s significant activities. The Company also assessed its Harbor investment post deconsolidation, which resulted in a $1,369 impairment, representing the remaining investment balance in Harbor and was recorded within other expense in the consolidated condensed statements of operations and comprehensive (loss) income. The Company continues to have license rights to certain technology obtained from Harbor and is continuing product development initiated under the Collaboration Agreement. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Method </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an equity investment in CartiHeal Ltd. (CartiHeal), a privately held entity that does not have a readily determinable fair value, which the Company began recording as an equity investment during the third quarter of 2020. The CartiHeal investment carrying value totaled $17,737 as of July&#160;3, 2021, yielding a 10.03% fully diluted equity ownership. Net losses from CartiHeal for the three and six months ended July&#160;3, 2021 totaled $432 and $901, respectively, which are included in other expense within the consolidated condensed statement of operations and other comprehensive (loss) income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will, if needed to support the completion of a certain study, purchase an additional 338,089 of CartiHeal Series G Preferred Shares for $5,000. The Company has an exclusive option to acquire the remaining equity in CartiHeal, which may be exercised at any time up to and within 45 days following notice of the U.S. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Food and Drug Administration (FDA) approval for a CartiHeal product currently in development. In addition, upon the same FDA approval, CartiHeal may exercise an option within 45 days that requires the Company to complete the acquisition of the remaining equity in CartiHeal. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;15, 2020, the Company entered into an Option and Equity Purchase Agreement with CartiHeal. The agreement provides the Company with an exclusive option to acquire 100% of CartiHeal&#8217;s shares under certain conditions, or the Call Option, and provides CartiHeal with a put option that would require us to purchase 100% of CartiHeal&#8217;s shares under certain conditions, or the Put Option. The Put Option is only exercisable by CartiHeal upon pivotal clinical trial success, including achievement of certain secondary endpoints and FDA approval of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> device with a label consistent in all respects with pivotal clinical trial success. The pivotal clinical trial&#8217;s objective is to demonstrate the superiority of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C</div> implant over the surgical standard of care, including microfracture and debridement, for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August&#160;2, 2021, CartiHeal provided a statistical report containing the results of the pivotal clinical trial. The Company is currently reviewing the report to assess if it is consistent with the terms of the agreement and assessing the findings to determine if all required endpoint have been achieved. CartiHeal continues to work toward submitting the final, clinical module of a Modular PMA in the fourth quarter of 2021 seeking FDA approval. The Company has the right to terminate the Call Option and Put Option at any time ending 30 days after receipt of the statistical report from CartiHeal upon payment of a break fee of $30,000. If the Company determines that the results satisfy the requirements of the contract, and elect not to exercise its right to terminate the Call Option and Put Option, the Company will be required to put $50,000 into escrow as a deposit towards the purchase price. Consideration for the acquisition of all of the shares of CartiHeal, excluding those the Company owns, pursuant to the Call Option or Put Option would be $314,895, inclusive of the deposit, all of which would be payable at closing, with an additional $150,000 payable upon achievement of certain sales milestones related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Agili-C.</div> Such closing would be subject to customary closing conditions. CartiHeal has announced that it expects to submit its PMA application to the FDA later this year. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;24, 2021, the Company purchased 406,504 shares of Vaporox, Inc&#8217;s (Vaporox) Series A Preferred Stock or 6.0% of fully diluted shares for $1,000. Vaporox, a privately held entity, is a medical device company dedicated to healing diabetic foot ulcers and does not have a readily determinable fair value. Under the measurement alternative, the investment is recorded at cost, less any impairment, plus or minus any changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock', window );">Business combinations and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Business combinations and investments&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VIE </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;23, 2019, the Company purchased 285,714 shares of Harbor&#8217;s Series C Preferred Stock or 3.1% of fully diluted shares for $1,000. The Company and Harbor entered into an exclusive collaboration agreement for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. As a result of these transactions, the Company determined that it had a variable interest in Harbor. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounted for the Harbor investment as a business combination using the acquisition method of accounting whereby the total purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The results of Harbor operations have been included in the accompanying consolidated financial statements subsequent to acquisition date. The Company did not disclose post-acquisition or pro forma losses attributable to Harbor as they did not have a material effect on the Company&#8217;s consolidated statements of operations and comprehensive income (loss). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,430</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property (10-year useful life)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,834</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,445</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(932</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,696</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(697</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(266</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value of net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus purchase price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Harbor&#8217;s noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020 two convertible promissory notes to Harbor shareholders totaling $500 were converted into 142,858 of Harbor Series C Preferred Stock and warrants for 428,572 shares of the Harbor common stock exercisable at a price of $1.167 per share with a 5-year exercise period expiring March 27, 2025. Promissory notes of $320 owed to a certain Harbor shareholder were converted into 92,500 of Harbor Series C Preferred Stock at $3.50 per share in November 2020. On October&#160;5, 2020, the Company purchased an additional 285,714 shares of Harbor&#8217;s Series C Preferred Stock for $1,000. The Company continues to conclude that it is the primary beneficiary since it controls the significant activities of Harbor through the collaboration agreement. The noncontrolling interest related to Harbor was 91.2% as of December&#160;31, 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Harbor intellectual property and IPR&amp;D was determined using the income approach through an excess earnings analysis, with projected earnings discounted at a rate of 16.5%. The $1,445 of IPR&amp;D consists of research and development progress toward developing a product for orthopedic uses. The fair value of the noncontrolling interest was calculated as estimated fair value of net assets acquired less the Company&#8217;s purchase price. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harbor assets that can only be used to settle Harbor obligations and Harbor liabilities for which creditors do not have recourse to the general credit of the Company are as follows for the years ended December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">803</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,127</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,635</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,122</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">178</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">231</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,863</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,599</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">366</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">458</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,004</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,395</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">659</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,029</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,940</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nearly all the liabilities assumed are payable to Harbor shareholders. As of December&#160;31, 2019, other current liabilities primarily consisted of $1,845 in promissory notes to various Harbor shareholders and were scheduled </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to mature on August 31, 2020. These promissory notes were refinanced with additional borrowings in August 2020 and total $1,811 as of December&#160;31, 2020. The Harbor promissory notes carry an 8% interest rate and are due on August 31, 2021 with payments due monthly. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Method </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in which the Company can exercise significance influence, but do not control, are recorded under the equity method of accounting and are included in investments and other assets on the consolidated balance sheets. The Company&#8217;s share of net earnings or losses is included in other (income) loss within the consolidated statements of operations and comprehensive income (loss) on a quarter lag. The Company evaluates investments for impairment whenever events or changes in circumstances indicate that the carrying amounts of such investments may be impaired. Impairment losses are recorded within earnings within the current period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;30, 2018, the Company purchased 337,397 shares of CartiHeal, a privately held entity, Series F Convertible Preferred Stock or 2.8% of fully diluted shares for $2,500 in cash. The investment does not have a readily determinable fair value. On January&#160;22, 2020, the Company made an additional investment in CartiHeal, through a Simple Agreement for Future Equity (SAFE) by paying cash of $152. On July&#160;15, 2020, CartiHeal completed an equity financing that the Company participated in and as a result, the Company received 12,825 in Series G-1 Preferred Shares and the SAFE terminated. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, on July&#160;15, 2020, the Company entered into an Option and Equity Purchase Agreement with CartiHeal. Under the terms of the agreement, the Company purchased 1,014,267 shares of CartiHeal Series G Preferred Shares for $15,000. As a result, the Company&#8217;s equity ownership in CartiHeal increased to 10.03% of its fully diluted shares. The CartiHeal investment, included capitalized transaction costs of $1,427 and the $152 investment in January 2020, totaling $16,579 was recorded as an equity method investment beginning in July 2020, as the Company can exercise significant influence over CartiHeal but does not have control. It is included within investments and other assets on the consolidated balance sheet. The CartiHeal investment carrying value is $18,689 as of December&#160;31, 2020, after recording net losses of $467 incurred during 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will, if needed, purchase an additional 338,089 of CartiHeal Series G Preferred Shares for $5,000, for the completion of a certain study. The Company has an exclusive option to acquire the remaining equity in CartiHeal, which may be exercised at any time up to and within 45 days following notice of the U.S. Food and Drug Administration (FDA) approval for a CartiHeal product currently in development. In addition, upon the same FDA approval, CartiHeal may exercise an option within 45 days that requires the Company to complete the acquisition of the remaining equity in CartiHeal. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations and investments disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674733553848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financial instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Financial instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt consists of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term loan due December 2024 (2.60% at July&#160;3, 2021)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,500</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">190,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(959</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(457</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(524</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166,084</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173,378</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2019 Credit Agreement requires the Company to comply with financial and other covenants. The Company complied with all covenants as of July&#160;3, 2021. The 2019 Credit Agreement contains a $50,000 revolving credit facility, from which there were no outstanding borrowings as of July&#160;3, 2021 and December&#160;31, 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of the Term Loan as of July&#160;3, 2021 was $184,505. The fair value of these obligations was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar obligations and are classified as Level&#160;2 instruments within the fair value hierarchy. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company enters into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. The Company has one <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-designated</div> interest rate swap agreement and has no other active derivatives. The swap is carried at fair value on the balance sheet (Refer to<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Note 5. Fair value measurements</div></div>) with changes in fair value recorded as interest income or expense within the consolidated statements of operations and comprehensive (loss) income. Net interest expense of $255 and $933 was recorded related to the change in fair value of the interest rate swap for the three months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. Net interest income of $1,310 and expense of $2,001 was recorded related to the change in fair value of the interest rate swap for the six months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The notional amount of the swap totaled $100,000, or 54.8% of the Term Loan outstanding principal at July&#160;3, 2021. The swap locked in the variable portion of the interest rate on the $100,000 notional at 0.64%. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Financial instruments&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 Credit Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;6, 2019, the Company entered into a $250,000 credit and guaranty agreement (2019 Credit Agreement) with Wells Fargo Bank National Association (Wells), as well as a syndicate of other banks, or Lenders. The 2019 Credit Agreement is comprised of a $200,000 term loan (Term Loan), with an original issue discount (OID) of $666, and a $50,000 revolving facility (Revolver). All obligations under the 2019 Credit Agreement are guaranteed by the Company and certain of the Company&#8217;s wholly owned subsidiaries. Substantially all the assets of the Company collateralize the obligations under the 2019 Credit Agreement. The Term Loan and Revolver mature on December 6, 2024 (Maturity). </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Term Loan </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, $188,378 was outstanding on the Term Loan, net of original issue discount of $524 and deferred financing costs of $1,098. As of December&#160;31, 2020, the Term Loan interest rate including a margin of 2.25% was 2.40%. Scheduled quarterly principal payments are as follows with the final payment of $125,000 at Maturity:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarterly<br/>payment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 and 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 and 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may voluntarily prepay the Term Loan without premium or penalty upon prior notice. The Company may be required to make additional principal payments on the Term Loan dependent upon the generation of certain cash flow events as defined in the 2019 Credit Agreement. These additional prepayments will be applied to the scheduled installments of principal in direct order of maturity of the Base Rate (BR) portions of the Term Loan first and then the Eurodollar portions of the Term Loan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of the Term Loan as of December&#160;31, 2020 was $189,534. The fair value of these obligations was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar obligations and are classified as Level 2 instruments within the fair value hierarchy. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revolver </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Revolver is a five-year revolving credit facility of $50,000 which includes revolving and swingline loans as well as letters of credit (LOC) and, inclusive of all, cannot exceed $50,000 at any one time. LOCs are available in an amount not to exceed $7,500. Revolving loans are due at the earlier of termination or Maturity. Swingline loans are available as BR interest rate option loans only and must be outstanding for at least five days. Swingline loans are due the <span style="-sec-ix-hidden:hidden26390228">fifteenth</span> or last day of a calendar month or Maturity whichever is earlier. The Company had increased its cash position by borrowing $49,000 on its Revolver as a precautionary measure to preserve financial flexibility in view of the current uncertainty resulting from the COVID-19 pandemic during the first quarter of 2020. The $49,000 was repaid during the third quarter of 2020. As of December&#160;31, 2020, there was one nominal LOC outstanding leaving approximately $49,912 available. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Term Loan and Revolver permits the Company to elect either Eurodollar or BR interest rate options for the entire amount or certain portions of the loans and have interest rates equal to a formula driven base interest rate plus a margin, tied to a leverage ratio. The leverage ratio is the ratio of debt to consolidated EBITDA as defined in the 2019 Credit Agreement, or Bank EBITDA, for four consecutive quarters at the end of each period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BR portions of the Term Loan have interest due the last day of each calendar quarter-end. Eurodollar portions of the Term Loan have one, two, three or six-month interest reset periods and interest is due on the last day of each three-month period or the last day of the loan term if less than three months. In advance of the last day of the current Eurodollar Loan, the Company may select a new loan type so long as it does not extend beyond Maturity. The outstanding Term Loan has been a Eurodollar Loan since inception and is an auto-renewing one-month loan for setting an interest rate. In addition, the Term Loan has an interest due date concurrent with any scheduled principal repayment or prepayment. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest is calculated based on a 360-day year except for BR loans where the base interest is the Wells Prime Rate, in which case it is calculated based on a calendar-day year. The base interest rate for all BR loans is equal to the highest of (a)&#160;the Wells Prime Rate, (b)&#160;the greater of the Federal Funds Effective Rate or Overnight Bank </div></div>Funding Rate plus <span style="-sec-ix-hidden:hidden26390186">1/2</span>% and (c)&#160;the Eurodollar Rate for a USD deposit with a maturity of one month plus 1.0%. The base interest rate for all Eurodollar Loans is equal to the rate determined for such day in accordance with the following formula with the Term Loan having a floor of 0%: <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">LIBOR </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1&#8212;Eurocurrency Reserve Requirements </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pricing grids are used to determine the loan margins based on the type of loan and the leverage ratio. The initial Eurodollar and BR loans had a margin of 2.25% and 1.25%, respectively. Loan margin is adjusted after the quarterly financial statements are delivered to the lenders in accordance with the pricing grid below: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Leverage ratio</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eurodollar</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BR</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt;1.50 to 1.00 and &lt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 1.25 to 1.00 and &lt;1.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 0.75 to 1.00 and &lt;1.25 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&lt; 0.75 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Revolver includes a commitment fee at 0.25% of the average daily amount of the available revolving commitment, assuming any swingline loans outstanding are $0. There were no swingline loans outstanding as of December&#160;31, 2020. The fee is payable quarterly in arrears on the last day of the calendar quarters and at Maturity. The commitment fee rate is adjusted after the quarterly financial statements are delivered to lenders based on the pricing grid below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 81%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 15%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Leverage ratio</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitment<br/>fee&#160;rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt;1.50 to 1.00 and &lt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 1.25 to 1.00 and &lt;1.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 0.75 to 1.00 and &lt;1.25 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&lt; 0.75 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fees are charged on all outstanding LOCs at an annual rate equal to the margin in effect on Eurodollar revolving loans. A fronting fee of 0.125%&#160;per year on the undrawn and unexpired amount of each LOC is payable as well. The fees are payable quarterly in arrears on the last day of the calendar quarters. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company&#8217;s effective weighted average interest rate on all outstanding debt, including the commitment fee and interest rate swap, was 2.72%. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of the Company&#8217;s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of Company assets, as well as limitations on making changes to the Company&#8217;s business and organizational documents. Financial covenant requirements include a maximum debt leverage ratio as well as an interest coverage ratio not less than 3.00 to 1.00 as defined in the 2019 Credit Agreement. As of December&#160;31, 2020, the Company complied with the financial covenants in the 2019 Credit Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each Lender may provide an additional Term or Revolving Loan by executing and delivering notice specifying the terms, if doing so would not cause certain undesired events to occur as defined in the 2019 Credit Agreement </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or extend repayment beyond Maturity. The aggregate amount of all additional borrowings may not exceed the greater of $100,000 and the trailing four quarters Bank EBITDA without the consent of the Lenders holding more than 50% of the total outstanding debt under the 2019 Credit Agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing costs </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During December 2019, the Company paid financing costs totaling $2,117 in order to refinance our prior term loan facility, that was repaid in full (Prior Credit Agreement). The Company recorded $269 directly to selling, general and administrative expense and the remaining $1,848 was capitalized to the consolidated balance sheet. One lender participating in the Prior Credit Agreement became a lender in the 2019 Credit Agreement and, as a result, $2,985 related to the Prior Credit Agreement was written off and recorded as interest expense. The $269 recorded in selling, general and administrative expense and the $2,985 recorded in interest expense total the $3,252 of loss on debt retirement and modification. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total capitalized deferred fees for the Term Loan of $1,398 and Revolver of $653 are being amortized to interest expense on a straight-line basis over each of the respective lives, which approximates the effective interest method. The Company recorded $543, $711 and $745 in interest expense associated with these deferred costs for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual maturities of long-term debt as of December&#160;31, 2020, were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025 and thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Original issue discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(524</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188,378</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173,378</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company enters into interest rate swap agreements to limit its exposure to changes in the variable interest rate on its long-term debt. On March&#160;26, 2020, the Company entered an interest rate swap agreement with one of its Lenders, which expires in December 2024. The interest rate swap was not designated as a hedge. The Company has no other active derivatives and the swap is carried at fair value on the balance sheet. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note&#160;7. Fair value measurements</div></div> for further details regarding the Company&#8217;s interest rate swap. There were no outstanding derivatives as of December&#160;31, 2019. Interest expense of $1,599 was recorded within the consolidated statements of operations and comprehensive income (loss) related to the change in fair value of the swap for the year ended December&#160;31, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The notional value of the swap totaled $100,000 or 52.6%, of the Term Loan outstanding principal at December&#160;31, 2020. The swap locked in the variable portion of the interest rate on the $100,000 notional at 0.64%, with a stated fixed rate of 2.25%. The effective interest rate of the swap was 2.89% as of December&#160;31, 2020. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798408872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Fair value measurements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our process for determining fair value has not changed from that described in the Company&#8217;s 2020 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level&#160;1 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level&#160;2 and Level&#160;3 inputs:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swap</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,220</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,220</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term contingent consideration, less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,421</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,421</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management incentive plan and liability-classified awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Participation Right</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,933</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,641</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,006</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,404</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate swap </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company values interest rate swaps using discounted cash flows. Forward curves and volatility levels are used to estimate future cash flows that are not certain. These are determined using observable market inputs when available and based on estimates when not available. The fair value of the swap was recorded in the Company&#8217;s consolidated balance sheets within accrued liabilities. Changes in fair value are recognized as interest expense (income) within the consolidated statements of operations and comprehensive (loss) income. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>Contingent consideration<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue and the probability of achieving the specific targets as discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 3. Business combinations and investments</div></div>. After the initial valuation, the Company will use its best estimate to measure contingent consideration related to the Bioness Acquisition at each subsequent reporting period using the following unobservable Level&#160;3 inputs:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation Technique</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioness contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Discounted cash flow</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">Payment discount rate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">5.0% - 6.8%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">Payment period</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2021 - 2025</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The contingent consideration reported in the above table resulted from the March&#160;30, 2021 Bioness acquisition, which is adjusted on a monthly basis based upon the passage of time or success or failure of achieving certain milestones. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 3. Business combinations and investments</div></div> for further details. Changes in contingent consideration related to the Bioness acquisition totaled $641 for the three and six months ended July&#160;3, 2021, which were recorded as the change in fair value of contingent consideration within the consolidated statements of operations and comprehensive (loss) income. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management incentive plan (MIP) and liability-classified awards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">BV LLC had operated two equity-based compensation plans, the management incentive plan (MIP) and the BV LLC Phantom Profits Interest Plan (Phantom Plan and, together with the MIP, the Plans), which were terminated on February&#160;11, 2021 in connection with the Company&#8217;s IPO. Awards granted under the MIP Plan and the 2015 Phantom Units were liability-classified and the 2012 Phantom Units were equity-classified. Prior to the IPO and during the six months ended July&#160;3, 2021, the Company settled the remaining 183,078 units with the sole MIP awardee for $10,802. No awards under the Plans were granted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-IPO</div> and the Phantom Plan awards will be settled 12 months following the termination. Vested awardees whose BV LLC employment terminated prior to the IPO will have their awards settled for $10,875, which is included in accrued equity-based compensation on the consolidated condensed balance sheets. Awardees that were active BV LLC employees at the IPO will receive an aggregate of 798,422 shares of Class&#160;A common stock. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level&#160;3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">829</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,281</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phantom plan conversion to Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Participation Right (EPR) Unit </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO, the Continuing LLC owner owned the only EPR Unit and its only entitlement was 0.55% of available distributions arising from a distribution event such as the IPO. The EPR Unit was redeemed in exchange for $3,327 in connection with the IPO in February 2021, at which time the EPR ceased to exist and all entitlements ended. The revaluation for the EPR liability is recognized in interest (income) expense on the consolidated statements of operations and comprehensive (loss) income. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level&#160;3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Fair value measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, there were no assets measured at fair value and there were no liabilities measured at fair value using Level&#160;1 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swap</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management incentive plan and liability-classified awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,802</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Participation Rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,457</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,006</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,404</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,259</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest rate swap </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company values interest rate swaps using discounted cash flows. Forward curves and volatility levels are used to estimate future cash flows that are not certain. These are determined using observable market inputs when available and based on estimates when not available. The fair value of the swap was recorded in the Company&#8217;s consolidated balance sheets within accrued liabilities. Changes in fair value are recognized as interest expense within the consolidated statements of operations and comprehensive income (loss). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management incentive plan and liability-classified awards </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO, the Company had operated two-equity-based compensation plans, the Management Incentive Plan (MIP) and the Phantom Profits Interest Plan (Phantom Plan). The estimated fair value reflects assumptions made by management as of December&#160;31, 2020, including the impact of COVID-19 on significant unobservable assumptions, such as the expected timing and volume of elective procedures and the impact of these procedures on future revenues which impact the equity value. However, the actual amount ultimately paid could be higher or lower than the fair value. The Company has classified $11,054 as accrued equity-based compensation and $29,249 as accrued equity-based compensation, less current portion as of December&#160;31, 2020. Any changes in fair value are recorded as an operating expense and included within selling, general administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,063</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,464</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,290</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,002</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,802</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,734</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,641</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2020, the sole MIP awardee exercised the right to force a cash settlement for 150,252 of the 333,330 vested units resulting in a payment of $6,329. The remaining 183,078 units were settled for $10,802 in February 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EPR Unit </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the IPO, after which the EPR ceased to exist and all entitlements ended, the Continuing LLC owners owned the only EPR Unit and its only entitlement was 0.55% of available distributions arising from a Distribution Event. The estimated fair value reflects assumptions made by management as of December&#160;31, 2020, including potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. The fair value of the EPR Unit was recorded in the Company&#8217;s consolidated balance sheets as other long-term liabilities. The revaluation for the EPR liability is recognized in interest expense on the consolidated statements of operations and comprehensive income (loss). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,892</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">565</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,457</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">644</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of the Plans and EPR Unit using a Monte Carlo simulation. This fair value measurement is based on significant inputs that are unobservable in the market, and thus represents a Level 3 measurement. The key assumptions used in applying the valuation model include the Company&#8217;s equity value, the expected timing until a liquidity event, applicable discount rates applied, and equity volatility. In addition, for the EPR Unit, the estimated accrued preferred distribution at the liquidity event date totaling $43,854 as of December&#160;31, 2020 as it is senior in order of payment. Significant changes in these assumptions could result in a significantly higher or lower fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a range of key assumptions used within the valuation of the awards as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation technique</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted Average</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Option pricing approach</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Time to liquidity event</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.4</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Risk free rate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.10%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Equality volatility</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">35.13%&#160;-&#160;101.25%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">50.0%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Equity value</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">$1,065,000&#160;-&#160;$1,240,000</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">$1,145,000</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Lack of marketability discount</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">7.0%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">7.0%</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798098904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-based compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Equity-based compensation </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Terminated plans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Prior to the IPO, BV LLC operated two equity-based compensation plans, the MIP and the Phantom Plan, which were terminated on February&#160;11, 2021 in conjunction with the IPO. Prior to the Plans termination, during the six months ended July&#160;3, 2021, (i) the Company granted 90,000 Phantom Plan units; (ii)&#160;there were no MIP awards granted; (iii) 900 Phantom Plan units were forfeited and (iv)&#160;other Phantom Units were redeemed for $479. Compensation expense related to the Phantom Plan of $829 for the six months ended July&#160;3, 2021. This amount excludes the $25,185 decrease in fair market value of accrued equity-based compensation due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering price, of which $1,777 was recorded in research and development expense within the consolidated statement of operations and comprehensive (loss) income for the six months ended July&#160;3, 2021. Compensation expense of $663 and $1,078 was recorded for the three and six months ended June&#160;27, 2020, excluding $408 and $7,849 in fair market value decreases, respectively, within accrued equity-based compensation due to the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the market and economy. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2021 Plan </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company operates an equity-based compensation plan (2021 Plan). The 2021 Plan is designed to grant incentive awards to eligible employees and other service providers in order to attract, motivate and retain the talent for which the Company competes. The 2021 Plan allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (RSUs), other stock-based awards, and cash awards. (collectively, Awards). Generally, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> Awards granted under the 2021 Plan are equity-classified. As of July&#160;3, 2021, 7,592,476 shares of Class&#160;A common stock were authorized to be awarded and 2,024,123 shares were available for award. The number of shares available for issuance will be increased annually on January&#160;1 of each calendar year beginning in 2022 through 2031, equal to the lesser of (i) 4.5% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based compensation expense of $5,778 and $7,722 was recognized for the three and six months ended July&#160;3, 2021, respectively, for Awards granted under the 2021 Plan. The expense is primarily included in selling, general and administrative expense with a nominal amount in research and development expense on the consolidated statement of operations and comprehensive (loss) income based upon the classification of the employee. There was no income tax benefit related to this expense for the three and six months ended July&#160;3, 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the three and six months ended July&#160;3, 2021, the Company granted employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors time-based RSUs which vest at various dates through May&#160;10, 2025. The compensation expense, which represents the fair value of the stock measured at the market price on the date of grant, is recognized over the vesting period, which is typically between 1 and 4 years. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No RSUs were vested or settled during the three and six months ended July&#160;3, 2021. Unamortized compensation expense related to the RSUs amounted to $9,976 at July&#160;3, 2021, and is expected to be recognized over a weighted average period of approximately 0.69 years. A summary of the RSU award activity for the six months ended July&#160;3, 2021 is as follows (number of units in thousands): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> average&#160;grant-<br/> date fair value<br/> per unit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">945</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">945</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.90</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/canceled</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.53</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">943</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three and six months ended July&#160;3, 2021, the Company granted employees time-based stock options which vest over 2 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 2 to 4 years, net of actual forfeitures. A summary of the Company&#8217;s assumptions used in determining the fair value of the stock options granted during the six months ended July&#160;3, 2021 is shown in the following table. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.59%&#160;-&#160;1.19%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">33.1%&#160;-&#160;33.5%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">5.75<div style="display:inline;">&#160;-&#160;</div>6.25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of stock options granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$4.21&#160;-&#160;5.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Company&#8217;s peers common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No options vested, expired, forfeited or were exercisable during the six months ended July&#160;3, 2021. Unamortized compensation expense related to the options amounted to $15,797 at July&#160;3, 2021, and is expected to be recognized over a weighted average period of approximately 1.19 years. A summary of stock option activity is as follows for the six months ended July&#160;3, 2021 (number of options in thousands): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 50%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> average&#160;exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual&#160;term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,621</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,621</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.90</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,625</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value of options outstanding as of July&#160;3, 2021 was $16,095 and is calculated as the difference between the exercise price of the underlying options and the market price of the Company&#8217;s common stock for options that had exercise prices lower than $16.51, the closing price of the Company&#8217;s stock on July&#160;2,&#160;2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, in connection with the IPO, the Company began operating the 2021 Employee Stock Purchase Plan (ESPP). The ESPP provides for the issuance of shares of the Company&#8217;s common stock to eligible employees of the Company and its subsidiaries that elect to participate in the plan and purchase shares of common stock through payroll deductions (including executive officers). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During each enrollment period, eligible employees may designate between 1% and 15% of their compensation to be deducted for the purchase of common stock under the plan (or such other percentage in order to comply with regulations applicable to employees domiciled in or resident of a member state of the European Union). The purchase price of the shares under the ESPP is equal to 85% of the fair market value on the first day of the offering period or, if lower, on the last day of the offering period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of July&#160;3, 2021, the aggregate number of shares reserved for issuance under the ESPP was 518,257. During the three and six months ended July&#160;3, 2021, 24,063 shares were issued and $75 of expense was recognized. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Equity-based compensation&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-based compensation plans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operated two equity-based compensation plans, the MIP and the Phantom Plan (the Plans) prior to the IPO. The awards granted under both plans represented a non-managing, non-voting interest in the Company designed for grantees to share in the future appreciation of the value of the Company. Awards granted under the MIP Plan and the 2015 Phantom Units are liability-classified and the 2012 Phantom Units are equity-classified. On February&#160;11, 2021, in conjunction with the IPO, the Plans were terminated and there were no further awards, under the Plans. As a result, the New LLC Owner assumed the obligations of the Company&#8217;s Phantom Plan awards on February&#160;10, 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The awards granted under the MIP fully vested at December&#160;2, 2017. There were no MIP awards granted for the years ended December&#160;31, 2020, 2019 and 2018. In June 2020, the sole MIP awardee exercised the right to force a cash settlement for 150,252 of the 333,330 vested units resulting in a payment of $6,329. As of December&#160;31, 2020 and 2019, respectively, there were 183,078 and 333,330 vested awards outstanding both with a grant date fair value of $4.89. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest compensation of $10,103, $10,844 and $14,325 for all plans, was recognized for the years ended December&#160;31, 2020, 2019 and 2018 respectively. The expense is included in selling, general and administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. As of December&#160;31, 2020, there was approximately $9,741 of unrecognized compensation expense to be recognized over a weighted-average period of 1.3 years. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the award activity of the Phantom Plan for the year ended December&#160;31, 2020 is as follows (number of awards in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 43%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2012 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2015 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(awards in thousands)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.72</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,139</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.24</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">553</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.29</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted to cash</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.45</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(124</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.98</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.72</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,422</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.41</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards vested at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.72</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">495</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.15</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no 2012 Phantom Unit awards granted in 2019. The weighted average grant date fair value per Other Phantom Unit awards granted in the year ended December&#160;31, 2019 was $15.31. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 36%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2012 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2015 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(awards in thousands)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nonvested at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.01</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">667</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.71</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested during 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.01</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.81</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nonvested at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">927</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.62</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total fair value of 2012 Phantom Unit awards vested in the year ended December&#160;31, 2020 was nominal. The total fair value of Other Phantom Unit awards vested in the year ended December&#160;31, 2020 was $4,703. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Defined contribution plans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has various defined contribution plans or plans that share profit which are offered in Canada, Germany, the Netherlands and the United Kingdom. These plans are required by local laws or regulations in some cases. Contributions are primarily discretionary, except in some countries where contributions are contractually required. These plans cover substantially all eligible employees in the countries where the plans are offered either voluntarily or statutorily. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the U.S., the Company provides a 401(k) defined contribution plan (U.S. Plan) that covers substantially all U.S. employees that meet minimum age requirements. The Company matches 50% of the employees&#8217; contribution up to 6% of the employees&#8217; wages. The Company also contributes 4.5% of the employees&#8217; wages to the U.S. Plan. The 4.5% Company contribution was suspended in May 2020 due to the COVID-19 crisis and reinstated in late December 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended December&#160;31, 2020, 2019 and 2018, Company contributions totaled $3,379, $5,401 and $5,462 respectively, for all global plans. The expense is included in cost of sales, selling, general and administrative expense and research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employee. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674799448344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Earnings per share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted loss per share of Class&#160;A common stock for the period following the Transactions (amounts in thousands, except share and per share data): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;16,<br/> 2021 through<br/> July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,229</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,654</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Bioventus Inc. Class&#160;A common stockholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares of Class&#160;A common stock outstanding - basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,805,347</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,802,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share of Class&#160;A common stock, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Shares of Class&#160;B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class&#160;B common stock under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method has not been presented. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following number of weighted-average potentially dilutive shares as of July&#160;3, 2021 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion: </div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three<br/> Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC Interests held by Continuing LLC&#160;Owner<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,786,737</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,786,737</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,622,287</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,602,747</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,221,555</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">941,031</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,458</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,698</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,663,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,365,213</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Shares reserved for future issuance upon redemption or exchange of LLC Interests by Continuing LLC Owner. </div></div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803059752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Income taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As a result of the Transactions, Bioventus Inc. became the sole managing member of BV LLC, which is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, BV LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by BV LLC is passed through to and included in the taxable income or loss of its members, including the Company following the Transactions, on a pro rata basis. Bioventus Inc. is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to its allocable share of any taxable income of BV LLC<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>following the Transactions. The Company is also subject to taxes in foreign jurisdictions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The tax provision for interim periods is determined using an estimate of the Company&#8217;s annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Company&#8217;s annual effective tax rate, are subject to variation due to several factors, including variability in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For the three months ended July&#160;3, 2021 and June&#160;27, 2020 the Company&#8217;s estimated effective tax rate was 18.9% and 1.8%, respectively. For the six months ended July&#160;3, 2021 and June&#160;27, 2020 the Company&#8217;s estimated effective tax rate was 10.7% and 1.6%, respectively. The increase was primarily driven by the change in structure resulting from the IPO and associated Up C structure as well as the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deductible</div> stock option expense during 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recorded deferred taxes with the offset to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital in connection with the Transaction. The deferred tax asset of $481 was due to tax credits and the deferred tax liability of $48,410 was for the difference between the book value and the tax basis of the Company&#8217;s investment in BV LLC. The Company maintains a valuation allowance on certain deferred tax assets that has determined are not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be realizable. The Company assesses the need for an adjustment to this valuation allowance on a quarterly basis. The assessment is based on estimates of future sources of taxable income for the jurisdictions in which the Company operates and the periods over which deferred tax assets will be realizable. In the event the Company determines that it will be able to realize all or part of its net deferred tax assets in the future, all or part of the valuation allowance will be reversed in the period in which the Company makes such determination. The release of all or part of the valuation allowance against deferred tax assets may cause greater volatility in the effective tax rate in the periods in which it is reversed. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax Receivable Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, the Company entered into a tax receivable agreement (TRA) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i)&#160;increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC and (ii)&#160;certain other tax benefits related to our making payments under the TRA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will maintain a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be realized. As of July&#160;3, 2021, Continuing LLC Owner had not exchanged LLC Interests for shares of Class&#160;A common stock and therefore the Company had not recorded any liabilities under the TRA. </div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Income taxes&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of net income from continuing operations before taxes for the years ended December&#160;31 are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxable subsidiaries:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Domestic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">306</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,679</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,925</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">387</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,967</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">693</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,646</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,532</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other domestic subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,221</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,043</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,575</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,914</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,107</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">782</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">891</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(508</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(345</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(294</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">707</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">472</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">380</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax rates - deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,192</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,576</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,664</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The differences between the effective income tax rate and the federal statutory income tax rates for the years ended December&#160;31 by taxable and other subsidiaries are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. statutory federal corporate income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC flow-through structure</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State and local income taxes, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.3</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.5</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.9</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rate differs from statutory rates primarily due to Bioventus LLC&#8217;s pass-through structure for U.S. income tax purposes while being treated as taxable in certain states and various foreign jurisdictions as well as for certain subsidiaries. In addition, certain states assess income taxes on pass-through structures. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,874</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,530</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">696</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">390</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,570</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,920</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,423</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,577</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,497</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liability:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangible</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,939</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,371</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,362</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,874</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the need for a valuation allowance against our deferred tax assets. A valuation allowance of $2,822, has been applied to all of Harbor&#8217;s deferred tax assets. The Company also has a valuation allowance of $171 representing the entire balance of deferred tax assets relating to our international operations. These valuation allowances were recorded as the Company believes it is more-likely-than-not that it will receive future benefit. At December&#160;31, 2020, the Company had federal and state net operating loss carryforwards related to Harbor of $25,537 expiring at various dates from 2021 through 2037 and approximately $2,141 with no expiration date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company<div style="display:inline;">&#160;</div>evaluates its tax positions in accordance with the recognition and measurement provisions of ASC&#160;740-10 (&#8220;FIN 48&#8221;) and in accordance with that guidance, has determined that a reserve for any significant uncertain tax positions is not needed as of December&#160;31, 2020 and <div style="letter-spacing: 0px; top: 0px;;display:inline;">2019</div>. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under current tax law, the utilization of tax attributes will be restricted if an ownership change, as defined, were to occur. Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, provides, in general, that if an &#8220;ownership change&#8221; occurs with respect to a corporation with net operating and other loss carryforwards, such carryforwards will be available to offset taxable income in each taxable year after the ownership change only up to the &#8220;Section&#160;382 Limitation&#8221; for each year. The Company&#8217;s ability to use its loss carryforwards will be limited in the event of an ownership change. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2018, Dutch income taxes were imposed on a negotiated percentage of sales. The Company has an agreement with the Dutch taxing authorities where the Company&#8217;s Netherlands subsidiary will incur but not have to pay income taxes in years when the subsidiary is operating at a loss. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Minimal tax related interest and penalties were incurred for the years ended December&#160;31, 2020 and 2019. The Company is subject to audit by various taxing jurisdictions for the years 2015 through 2020. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803289768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Commitments and contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 7.25 years. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease cost were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">912</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">646</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,614</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">329</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">740</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,496</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes variable lease cost and sublease income, which are immaterial. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Supplemental cash flow information and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> activity related to operating leases were as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,269</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental balance sheet and other information related to operating leases <div style="display:inline;">were </div>as fo<div style="display:inline;">llow</div>s:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities- current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities- noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,989</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,907</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,068</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Recall </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, the Company voluntarily recalled our ultrasound gel, an accessory to one of the Restorative Therapies product. The Company has incurred, and expects to incur in the future, costs associated with this recall. Based on the information that has been received, the estimated probable loss related to this recall globally was approximately $2,055 as of July&#160;3, 2021. Reserves of $434 and $1,684 were recorded within accrued liabilities on the consolidated balance sheets at July&#160;3, 2021 and December&#160;31, 2020, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal Contingencies </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to the business. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company operates. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#8217;s complete control and may not be known for extended periods of time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the closing of our acquisition of Bioness, Bioness had been named as a defendant in a lawsuit, for which we are indemnified for under the indemnification provisions contained in the Merger Agreement pursuant to which we acquired Bioness (the Bioness Merger Agreement). The case relates to an action brought in February 2021 in the Delaware State Court of Chancery by a former minority shareholder and director of Bioness, seeking a temporary restraining order contesting our acquisition of Bioness. While the complaint to block the Bioness acquisition was dismissed by the court, a separate action was brought against the Company under the indemnification provisions of the Bioness Certificate of Incorporation to recover $1,200 in attorney fees and other expenses incurred by the director and shareholder in connection with the dismissed case and filed a motion on May&#160;21, 2021 for summary judgment of their claims. The Company is vigorously defending the matter. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other matters </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter, beginning in 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;29, 2019, the Company and the Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF (the Development Agreement). The first phase has been completed. Additional fees for the subsequent phases will be determined as the development work progresses. The Development Agreement continues until the date when the parties execute a supply agreement for the commercial products. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (OA) product with the supplier of the Company&#8217;s single injection OA product for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement totaled $3,548 and $1,767 during the three months ended July&#160;3, 2021 and June&#160;27, 2020, respectively, and $5,925 and $3,969 during the six months ended July&#160;3, 2021 and June&#160;27, 2020, respectively. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive (loss) income. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of a supply agreement entered on February&#160;9, 2016 for the Company&#8217;s three injection OA product, the Company is subject to annual minimum purchase requirements for ten years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of a supply agreement for the Company&#8217;s five injection OA product, that was amended and restated on December&#160;22, 2020, the Company is subject to annual minimum purchase requirements for 8 years. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the licensed products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive (loss) income. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company causes letters of credit (LOCs) to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of July&#160;3, 2021 and December&#160;31, 2020, the Company had one LOC outstanding for a nominal amount. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#8220;claims made&#8221; basis for expenses in excess of $200 per member per year. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Commitments and contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under finance leases. The remaining lease terms range from 3 months to 8 years. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease cost were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,610</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,529</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">358</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,998</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,887</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*Includes</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">variable lease cost and sublease income, which are immaterial. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information and non-cash activity related to leases were as follow: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of operating lease liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,567</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,343</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use assets obtained in exchange for operating lease obligations:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,497</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,016</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table>   <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current and noncurrent operating and finance lease liabilities are included in other current liabilities and other long-term liabilities, respectively, on the consolidated balance sheet. Other balance sheet information related to leases are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,267</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities&#8212;current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,814</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities&#8212;noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,068</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining operating lease term in years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate for operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities as of December&#160;31, 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,714</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,645</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,460</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,476</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,569</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,281</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total future lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,145</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,077</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of future lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,068</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">OIG&#8217;s Provider Self-Disclosure </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company identified non-compliance with certain U.S. federal statutes and requirements governing the Medicare program in 2018 related to improper completion of Certificate for Medical Necessity (CMN) forms and in November 2018 made a voluntary self-disclosure to the Office of Inspector General of the U.S. Department of Health and Human Services (OIG) pursuant to the OIG&#8217;s Provider Self-Disclosure Protocol related to this matter. After settlement discussions with the Office of the United States Attorney in the Middle District of North Carolina (USAO) and OIG, on January&#160;15, 2021, the Company reached a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which the Company&#8217;s sales representatives completed Section B of the CMN form. On February&#160;22, 2021, the Company finalized all terms related to the settlement and entered into a formal settlement agreement with the USAO and OIG consistent with the previous agreement in principle and which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type and resolved the potential liability related to the Company&#8217;s self-disclosure for $3,600, of which $2,400 had previously been paid. The remaining $1,200 net settlement amount due under the agreement was recorded in accrued liabilities within the consolidated balance sheets as of December&#160;31, 2020 and paid on February&#160;23, 2021. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 17. Subsequent events</div></div> for further details regarding the resolution. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserve for estimated overpayments from all third-party payers </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a reserve for reimbursement claims related to its Minimally Invasive Fracture Treatment product that may have been processed for payment by the Company without adequate medical records support. The Company held a reserve of $2,790 and $6,801 at December&#160;31, 2020 and 2019, respectively for these </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amounts. The Company refunded Medicare $1,519 and $7,458 during the years ended December&#160;31, 2020 and 2019, respectively, related to known and estimated overpayments for medical necessity included in this reserve for periods through December&#160;31, 2019. Certain of these overpayments were identified as potential overpayments in the Company&#8217;s OIG self-disclosure in November 2018. The Company&#8217;s reserve was estimated using extrapolation of an error rate from a statistical sample, which represents the Company&#8217;s best estimate as of the date of the financial statements, but because of the uncertainty inherent in such estimates, the ultimate resolution may be materially different. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product recall </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, we voluntarily recalled our ultrasound gel, an accessory to the Minimally Invasive Fracture Treatment product. We have incurred, and expect to incur in the future, costs associated with this recall. Based on the information that has been received, we have estimated the probable loss related to this recall globally to be approximately $1,684. We have recorded reserves representing the probable loss within accrued liabilities on the consolidated balance sheet. The final outcome of this recall is dependent on many factors that are difficult to predict. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other matters </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;23, 2019, the Company and Harbor entered into an exclusive collaboration agreement for purposes of developing a product for orthopedic uses to be commercialized by the Company and supplied by Harbor. As part of the agreement a third-party license was assigned to us and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter, beginning in 2023. The Company is obligated to pay up to $6,000 upon achieving certain milestones. Unless earlier terminated, the agreement will remain in effect until the earlier of 8 years or until the payment of certain milestones are met. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;29, 2019, the Company and Musculoskeletal Transplant Foundation, Inc. d/b/a MTF Biologics (MTF), entered into a collaboration and development agreement to develop one or more products for orthopedic application to be commercialized by the Company and supplied by MTF. The first phase has been completed. Additional fees for the subsequent phases will be determined as the development work progresses. The Development Agreement continues until the date when the parties execute a supply agreement for the commercial products. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection OA product with the supplier of the Company&#8217;s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement totaled $10,021, $7,622 and $3,082 for the years ended December&#160;31, 2020, 2019 and 2018 respectively, and are included in cost of sales on the consolidated statement of operations and comprehensive income (loss). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of a supply agreement entered on February&#160;9, 2016 for the Company&#8217;s three injection OA product, the Company is subject to annual minimum purchase requirements for ten years. After the initial ten years, the agreement will automatically renew for an additional five years unless terminated by the Company or the seller in accordance with the agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of a supply agreement for the Company&#8217;s five injection OA product, that was amended and restated on December&#160;22, 2020, the Company is subject to annual minimum purchase requirements for eight years. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has an exclusive license agreement for bioactive bone graft putty. The Company is required to pay a royalty on all commercial sales revenue from the license products with a minimum annual royalty payment through 2023, the date the agreement will expire, upon the expiration of the patent held by the licensor. These royalties are included in cost of sales on the consolidated statement of operations and comprehensive income (loss). </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company causes LOCs to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of December&#160;31, 2020 and 2019, the Company had one LOC outstanding for a nominal amount. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a &#8220;claims made&#8221; basis for expenses in excess of $150 per member per year. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to the business. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the U.S. and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company&#8217;s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company&#8217;s complete control and may not be known for extended periods of time. Other than the matters discussed above, management of the Company, after consultation with legal counsel, does not believe there are any unrecorded matters that will have a material adverse effect upon the Company&#8217;s financial statements. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798267384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per unit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NetIncomeLossPerUnitTextBlock', window );">Net income (loss) per unit</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. Net income (loss) per unit </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the computation of basic and diluted net income (loss) per unit for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,722</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,113</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss attributable to noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">553</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,666</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations attributable to unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,666</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated and unpaid preferred distributions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,955</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income allocated to participating shareholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) from continuing operations attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,383</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,156</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,650</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,383</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(659</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,988</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per unit attributable to common unit holders - basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.89</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.40</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.89</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.67</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,900,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,900,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,900,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The computation of diluted earnings per unit for the years ended December&#160;31, 2020, 2019 and 2018 excludes the effect of the 6,590 potential common units that would be issued upon the conversion of preferred units. The effect of these units would be antidilutive due to the impact of the accumulated and unpaid preferred distributions as well as the Company being in a net loss position for the years ended December&#160;31, 2019 and 2018. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NetIncomeLossPerUnitTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) per unit [Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NetIncomeLossPerUnitTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798176776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring costs</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Restructuring costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs are not allocated to the Company&#8217;s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring expenses in the consolidated statement of operations and comprehensive income (loss). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fourth quarter of 2020 and 2018, the Company adopted restructuring plans to improve the performance of International operations, principally through headcount reduction and closing offices in certain countries as the Company shifts to an indirect distribution model in these countries. The plans were completed in 2020 and 2019, respectively, and the Company recorded total pre-tax charges of $563, $575 and $1,373 primarily related to severance for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company&#8217;s costs totaled $563 for the 2020 plan and $1,948 for the 2018 plan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s restructuring charges and payments for all plans are comprised of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee<br/>severance&#160;and<br/>temporary<br/>labor&#160;costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>charges</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">997</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">206</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,203</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses incurred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">491</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">575</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments made</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,488</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(290</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses incurred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">408</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">155</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">563</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments made</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(74</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">247</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674846030984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityNotesDisclosureTextBlock', window );">Members' equity</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">6. Members&#8217; equity </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members&#8217; equity consisted of the following at December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Profits interest and other equity awards (Refer to<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Note 9. Equity-based compensation</div></div>)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,800</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,774</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,173</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,147</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The authorized number of common and preferred units were unlimited. On May&#160;4, 2012, 4,900,000 common units and 5,100,000 preferred units (2012 Preferred Units) were issued. During November 2015, the Company obtained a $50,000 capital contribution from its existing members and 1,490,000 in preferred units were issued (2015 Preferred Units). The common and preferred members have stated rights and privileges, which include, but are not limited to: (1)&#160;voting and Company governance, (2)&#160;the transfer of membership interests and (3)&#160;dissolution and liquidation of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each preferred unit carried a priority payout (Liquidation Preference), as defined in the Company&#8217;s limited liability company agreement in effect at December&#160;31, 2020. The initial Liquidation Preference for the 2012 and 2015 Preferred Units were $23.14 and $33.57, respectively. The preferred units accrued a distribution right at a rate of 3%&#160;per annum and was added annually to the Liquidation Preference. On February&#160;11, 2021, the common and preferred units, including the preferred distribution rights, were converted into Common LLC Interests as discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 1. Organization and basis of presentation of financial information</div></div> and no further distribution rights accrued. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Continuing LLC Owner owned the only Equity Participation Right Unit (EPR Unit). The EPR Unit was junior to the common units and its only entitlement was 0.55% of available distributions arising from the closing of a sale of units representing a percentage interest of more than 66.66%, or the sale of all or substantially all of the assets of the Company, provided such event constitutes a change of control (Distribution Event) as described in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 7. Fair value measurements.</div></div> In February 2021, the EPR Unit was redeemed in exchange for $3,327 in connection with the IPO at which time the EPR ceased to exist and all entitlements ended. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 17. Subsequent events</div></div> for further details regarding the impact of the IPO on members&#8217; equity. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MemberEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Member equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MemberEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquityNotesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the formation, structure, control and ownership of a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -URI http://asc.fasb.org/topic&amp;trid=2124037<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquityNotesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798405512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-party transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Related-party transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made cash tax distributions of $19,886, $9,137 and $7,846 to its members in an amount equal to approximately 40% of the members&#8217; estimated taxable income for the years ended December&#160;31, 2020, 2019 and 2018, respectively. At December&#160;31, 2020 and December&#160;31, 2019, there were tax distributions payable to tax authorities on the members&#8217; behalf totaling $541 and $473, respectively, and nominal tax distributions payable to the members. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803164200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Sales<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NetSalesTextBlock', window );">Net Sales</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14. Net Sales</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the location from which the sale originated. The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) for the years ended December&#160;31 as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary geographic markets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293,697</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305,072</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">282,895</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,464</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,069</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36,282</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321,161</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">340,141</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">319,177</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vertical:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OA joint pain treatment and joint preservation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">171,178</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,082</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">155,576</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Minimally invasive fracture treatment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,624</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,504</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121,032</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bone graft substitutes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,359</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,555</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,569</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321,161</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">340,141</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">319,177</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NetSalesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net sales [Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NetSalesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803138792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued operations</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16. Discontinued operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, the Company, under the direction and authority of the Company&#8217;s Board of Managers, committed to shut down the bone morphogenetic protein (BMP) research and development program, which had been reported as its own segment in previous years. Substantially all operations, including project close </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">documentation, contract termination, vacating the facility and ultimately the termination of the employees, ceased by March 2019 and as a result the BMP research and development program met the criteria for discontinued operations. The Company sold the remaining $172 held for sale asset and paid the remaining $400 accrued liability from the BMP research and development program during the year ended December&#160;31, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the statement of operations and comprehensive income (loss) from discontinued operations for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,773</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,127</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on disposal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,638</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,650</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803221016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Stockholder&#8217;s equity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Corporation had 10 outstanding shares at a nominal value as of December&#160;31, 2020. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674801947912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Revenue recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our policies for recognizing sales have not changed from those described in the Company&#8217;s 2020 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary geographic markets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,682</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,166</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173,220</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,136</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,134</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,851</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,374</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,526</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,816</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,017</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,594</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vertical:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pain Treatments and Joint Preservation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,704</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,868</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,234</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70,151</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restorative Therapies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,511</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,968</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,332</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,433</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bone Graft Substitutes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,601</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,181</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,028</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,078</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,816</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,017</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,594</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803318728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">11. Segments</div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s two reportable segments are U.S. and International. The Company&#8217;s products are primarily sold to <div style="letter-spacing: 0px; top: 0px;;display:inline;">orthopedists,</div> musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company&#8217;s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents segment adjusted EBITDA reconciled to income before income taxes: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment adjusted EBITDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,149</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,439</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,147</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,151</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,738</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(497</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,810</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest (expense) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,195</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,215</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(255</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,559</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,771</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> benefits, net</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Succession and transition charges</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(187</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,801</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(344</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition and integration costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Inventory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> costs</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity loss in unconsolidated investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(432</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments related to variable interest entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,710</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(283</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,389</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,435</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. Segments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment information by asset is not disclosed as it is not reviewed by the CODM or used to allocate resources or to assess the operating results and financial performance. We believe EBITDA, adjusted for additional non-operational factors disclosed in the table below, or Adjusted EBITDA, is a key measure for internal reporting. Adjusted EBITDA should not be considered in isolation or as a substitute for consolidated net income (loss) attributable to the Company, the most closely analogous U.S. GAAP measure. Adjusted EBITDA is not defined in the same manner by all companies and may not be comparable to other similarly titled measures of other companies unless the definition is the same. The following table presents segment adjusted EBITDA reconciled to income from continuing operations before income taxes for the years ended December&#160;31 as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment adjusted EBITDA from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,252</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,673</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,480</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,191</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,515</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,691</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,751</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,103</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19 benefits, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,123</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Succession and transition charges</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,609</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(563</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(575</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(234</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity loss in unconsolidated investments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(467</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other non-recurring costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,914</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,107</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674845915064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Subsequent events </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of Misonix, Inc. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;29, 2021, the Company entered into an Agreement and Plan of Merger (the Misonix Merger Agreement) to acquire Misonix, Inc. (Misonix), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-and-stock</div></div> transaction (the Transaction). The closing of the Transaction is subject to regulatory approvals, the Company&#8217;s stockholders&#8217; approval, Misonix stockholder approval and customary closing conditions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Misonix stockholders will receive aggregate consideration that values Misonix at approximately $518,000 on a fully diluted basis, based on the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7-day</div> weighted average stock price of $16.6284 per share as of July&#160;27, 2021. The Transaction involves both cash and stock consideration based on the election of the Misonix stockholder. Each share of Misonix Common Stock issued and outstanding immediately prior to the Transaction, will be converted into the right to receive, either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-assessable</div> shares of Class&#160;A common stock of the Company, $0.001 par value per share, based on the election of the holder. The maximum cash amount payable by the Company will be an amount equal to $10.50 multiplied by the number of outstanding shares of Misonix Common Stock shortly prior to the completion of the Transaction. The Company expects to fund the cash portion of the acquisition with cash on </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hand and through committed financing provided by Wells Fargo Bank, National Association (Wells Fargo Bank). The number of shares held by Misonix stockholders electing to receive cash will be reduced on a pro rata basis if the cash elected to be received exceeds the maximum cash amount payable and will be paid with stock consideration of 1.6839 of shares of the Company&#8217;s Class&#160;A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt Commitment Letter </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the transaction, the Company entered into a debt commitment letter with Wells Fargo Bank, effective July&#160;29, 2021. Wells Fargo Bank has committed to provide a senior secured term loan facility (Term Loan Facility) in the aggregate principal amount of up to $262,000 plus, at the Company&#8217;s election, an amount sufficient to fund any original issue discount or upfront fees, subject to customary closing conditions. The Term Loan Facility stipulates a prepayment of $80,000 on the existing Term Loan under the 2019 Credit Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proceeds of the Term Loan Facility would be available through a single draw on the closing date of the Transaction and shall be used (i)&#160;to finance the Transaction; (ii)&#160;pay related fees, premiums and expenses and (iii)&#160;for working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions. The Term Loan Facility would have a three year term that would bear interest at either the base rate as prescribed in the Term Loan under the 2019 Credit Agreement or the Eurodollar rate, and, in each case, plus an applicable margin. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting and Support Agreements </div></div></div> <div style="-sec-ix-redline: true;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;">On July&#160;29, 2021, following the execution of the Misonix Merger Agreement, Misonix entered into Voting and Support Agreements with each EW Healthcare Partners Acquisition Fund, L.P. White Pine Medical, LLC (a subsidiary of EW Partners Acquisition Fund, L.P.), Smith&#160;&amp; Nephew, Inc., Smith&#160;&amp; Nephew USD Ltd. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AMP-CF</div> Holdings, LLC (together, the &#8220;Bioventus supporting stockholders&#8221;). The Bioventus Supporting Stockholders have agreed to vote their shares in (i)&#160;favor of the issuance of shares of the Company&#8217;s common stock in connection with the Transaction and against approval of any proposal made in opposition to, in competition with or inconsistent with the Misonix Merger Agreement. As of the record date for the Bioventus special meeting, the Bioventus supporting stockholders are the beneficial owners of approximately </div>[&#9679;]% <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the currently outstanding Class&#160;A and Class&#160;B common stock of the Company. </div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Other Matters </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The unsecured PPP loan of $2,003 associated with Bioness was forgiven in July 2021. The loan amount was recorded in other current liabilities and restricted cash within the consolidated condensed balance sheet at July&#160;3, 2021. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 3. Business combinations and investments</div></div> for further details. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Subsequent event </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and BV LLC completed the following Transactions regarding the IPO. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BV LLC amended and restated the Bioventus LLC Agreement, to, among other things, (i)&#160;provide for a new single class of common membership interests in BV LLC (LLC Interests), (ii)&#160;exchange all of the existing membership interests in BV LLC for new LLC Interests and (iii)&#160;appoint Bioventus Inc. as the sole managing member of BV LLC. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company amended and restated its certificate of incorporation to, among other things, provide for the (i)&#160;authorization of 250,000,000 shares of Class&#160;A common stock with a par value of $0.001 per share; (ii)&#160;authorization of 50,000,000 shares of Class B common stock with a par value of $0.001 per share; (iii)&#160;authorization of 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company&#8217;s Board of Directors (BOD) in one or more series; and (iv)&#160;establishment of a classified BOD, divided into three classes, each of whose members will serve for staggered three-year terms. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;A and Class B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests held by the only member of BV LLC that remained a member (Continuing LLC Owner) and the number of shares of Class B common stock held by the Continuing LLC Owner. Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a one-for-one basis if the Company, at the election of a Continuing LLC Owner, redeem or exchange LLC Interests. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s amended and restated certificate of incorporation and the Bioventus LLC Agreement requires that the Company and BV LLC at all times maintain a one-to-one ratio between the number of shares of Class&#160;A common stock issued by the Company and the number of LLC Interests owned by the Company, as well as a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company acquired, by merger, ten entities that were members of BV LLC (Former LLC Owners), for which the Company issued 31,838,589 shares of Class&#160;A common stock as merger consideration (Merger). The only assets held by the Former LLC Owners were 31,838,589 LLC Interests and a corresponding number of shares of Class B common stock. Upon consummation of the Merger, the Company canceled the 31,838,589 shares of Class B common stock and recognized the <span style="-sec-ix-hidden:hidden26390235">31,838.58</span>9 of LLC Interests at carrying value, as the Merger is considered to be a transaction between entities under common control. Following the Merger and IPO, the Company now holds 41,038,589 LLC Interests, representing a 72.2% ownership interest in BV LLC. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Receivable Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, the Company entered into a tax receivable agreement (TRA) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that Bioventus actually realizes as a result of (i)&#160;increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC and (ii)&#160;certain other tax benefits related to our making payments under the TRA. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, in connection with the IPO, the BV LLC Phantom Profits Interest Plan (Phantom Plan) terminated and the Company assumed the obligations of settling the vested awards. The awards will be settled 12 months following the Phantom Plan termination. Vested awardees whose BV LLC employment terminated prior to the IPO will have their awards settled in cash totaling $10,875. Vested awardees that were active BV LLC employees at the IPO will receive 798,422 shares of Class&#160;A common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2021, in connection with the IPO, the Company began operating two equity-based compensation plans. These are the Bioventus Inc. 2021 Incentive Award Plan (2021 Plan) and the Bioventus Inc. 2021 Employee Stock Purchase Plan (ESPP). </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2021 Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2021 Plan is designed to grant incentive awards to eligible employees and other service providers in order to attract, motivate and retain the talent for which the Company competes. The 2021 Plan provides for the grant of stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units (RSUs), other stock-based awards, and cash awards. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the IPO, 7,592,476 shares of Class&#160;A common stock were authorized for issuance. The number of shares available for issuance will be increased by an annual increase on January&#160;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (i)&#160;4.5% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the IPO, 4,561,500 stock options were granted to certain employees with an exercise price of $13.00 per share and vest equally over <span style="-sec-ix-hidden:hidden26390211">two</span> or four years as indicated in each option agreement. Additionally, the Company granted 360,670 RSUs to the directors and certain employees which vest equally over <span style="-sec-ix-hidden:hidden26390212">one</span> or four years as indicated in each RSU agreement and entitles the recipient to the same number of shares of Class&#160;A common stock. 2,670,306 shares of Class&#160;A common stock remain available for issuance under the 2021 Plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ESPP </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ESPP allows for the Company to grant options to employees to purchase shares of the Company&#8217;s Class&#160;A common stock through payroll deductions of up to 15% of their eligible compensation as defined in the ESPP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the IPO, 542,320 shares of Class&#160;A common stock were authorized for issuance. The number of shares available for issuance will be increased by an annual increase on January&#160;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (i)&#160;1% of the shares of our Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (ii)&#160;a smaller number of shares as determined by our board of directors. There have been no grants under the ESPP as of March&#160;22, 2021. </div></div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17. Subsequent events </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;4, 2021, the Company made a convertible debt investment of $1,500 in a medical device company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recapitalization </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2021, the following Transactions occurred. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The Company amended and restated its limited liability company agreement (New LLC Agreement) to, among other things, (i)&#160;provide for the new single class of common membership interests in the Company as discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 1. Organization and basis of presentation for financial information</div></div>; (ii)&#160;exchange all of the then existing membership interests of the common and preferred unit holders (Original LLC Owners) for Common LLC Interests and (ii)&#160;appoint the New LLC Owner as the sole managing member of the Company. The amendment resulted in the Company&#8217;s common and preferred units, including the preferred distribution rights, being converted into 47,625,326 Common LLC Interests. </div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The New LLC Owner amended and restated its certificate of incorporation to, among other things, (i)&#160;provide for Class&#160;A common stock and Class B common stock, each share of which entitles its holders to one vote per share on all matters presented to the New LLC Owner&#8217;s stockholders and (ii)&#160;issue 15,786,737 shares of Class B common stock to the Continuing LLC Owner, on a one-to-one basis with the number of LLC Interests it owns. While the Class B common stock holds voting rights it holds no economic interest in the New LLC Owner. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The New LLC Owner acquired, by merger, the Former LLC Owners and upon consummation of the merger, owned 31,838,589 Common LLC Interests. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The New LLC Owner closed an IPO of 9,200,000 shares of Class&#160;A common stock at a public offering price of $13.00 per share. The New LLC Owner received $111,228 in proceeds, net of underwriting discounts and commissions, which was used to make a capital contribution to the Company in exchange for 9,200,000 Common LLC Interests of the Company at a price per interest equal to the IPO price of $13.00. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to the Transactions, the New LLC Owner owns 41,038,589 Common LLC Interests or 72.2% of the Company and the Continuing LLC Owner owns 15,786,737 or 27.8%. The New LLC Owner has a majority economic interest, the sole voting interest in, and controls the management of the Company. As a result, the New LLC Owner will consolidate the financial results of the Company and will report a non-controlling interest representing the interests owned by the Continuing LLC Owner. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The New LLC Agreement requires that the Company, at all times, maintain (i)&#160;a one-to-one ratio between the number of shares of Class&#160;A common stock issued by the New LLC Owner and the number of Common LLC Interests owned by the New LLC Owner and (ii)&#160;a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owner and the number of LLC Interests owned by the Continuing LLC Owner. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;22, 2021, the Company finalized all terms related to a settlement agreement with the USAO and the OIG with respect to the submission of Medicare claims that did not meet CMS coverage requirements and for which our sales representatives completed Section B of the CMN forms. The Company entered into a formal settlement agreement with the USAO and OIG which included releases from associated False Claims Act liability and further Civil Monetary Penalties that are customary in self-disclosures of this type and resolved the potential liability related to the Company&#8217;s self-disclosure in this matter for $3,600, of which $2,400 has already been paid through the Company&#8217;s 2019 return of overpayments described previously. The remaining $1,200 net settlement amount due under the agreement was recorded in accrued liabilities within the consolidated balance sheets as of December&#160;31, 2020 and was paid on February&#160;23, 2021. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798329768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent accounting pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has elected to comply with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are generally earlier than when emerging growth companies are required to adopt. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Pronouncements Recently Adopted </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div>(ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12),</div> which amended the accounting for income taxes. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> eliminates certain exceptions to the guidance for income taxes related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in the tax basis of goodwill. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> on January&#160;1, 2021 and it did not have a material impact on its consolidated financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804491672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of accounting </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The balance sheets have been prepared in accordance with accounting principles generally accepted in the United States of America. Separate statements of income, comprehensive income, changes in stockholder&#8217;s equity, and cash flows have not been presented in the financial statements as there has been no activity. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent accounting pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has elected to comply with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are generally earlier than when emerging growth companies are required to adopt. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Pronouncements Recently Adopted </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div>(ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12),</div> which amended the accounting for income taxes. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> eliminates certain exceptions to the guidance for income taxes related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in the tax basis of goodwill. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> on January&#160;1, 2021 and it did not have a material impact on its consolidated financial statements. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent accounting pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected to comply with non-accelerated public company filer effective dates of adoption. Therefore, the required effective dates for adopting new or revised accounting standards as described below are specific to non-accelerated public company filers, which are generally earlier than when emerging growth companies are required to adopt. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Pronouncements Recently Adopted </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FASB issued Accounting Standards Update 2016-13, Financial Instruments-Credit Losses (ASU 2016-13), in June 2016 that significantly changes accounting for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment methodology in prior GAAP with a methodology that considers a broad range of information for the estimation of credit losses. The Company adopted ASU 2016-13 on January&#160;1, 2020 prospectively and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the FASB issued Accounting <div style="letter-spacing: 0px; top: 0px;;display:inline;">Standards</div> Update 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (ASU 2018-15), addressing a customer&#8217;s accounting for implementation costs incurred in a cloud-computing arrangement (CCA) that is considered a service contract. Under ASU 2018-15, implementation costs for a CCA should be evaluated for capitalization using the same approach as implementation costs associated with internal-use software. The capitalized implementation costs should be expensed over the term of the hosting arrangement, which includes any reasonably certain renewal periods. Capitalized implementation costs should be assessed for impairment like long-lived assets. The Company adopted ASU 2018-15 on January&#160;1, 2020 prospectively and it had no material impact on the Company&#8217;s consolidated financial statements. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the FASB issued Accounting Standards Update 2018-13, Fair Value Measurement (ASU 2018-13), modifying the disclosure requirements on fair value measurements and eliminates the requirement to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels and the valuation processes for Level 3 fair value measurements. ASU 2018-13 modifies certain disclosures related to investments measured at net asset value and clarifies that companies are to disclose uncertainties in measurements as of the reporting date. ASU 2018-13 requires additional disclosure related to changes in unrealized gains and losses included in other comprehensive income (loss) for recurring Level 3 fair value measurements as well as the range and weighted average, or other quantitative information that would be a more reasonable and rational method, of significant unobservable inputs used to develop Level 3 fair value measurements. The Company adopted ASU 2018-13 on January&#160;1, 2020 and it did not have a material impact on the Company&#8217;s consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New Accounting Pronouncements Not Yet Adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (ASU 2019-12), which amended the accounting for income taxes. ASU 2019-12 eliminates certain exceptions to the guidance for income taxes related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences as well as simplifying aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU 2019-12 is effective for annual and interim periods beginning after December&#160;15, 2020. Early adoption is permitted in interim or annual periods for which financial statements have not been made available for issuance. Entities that elect to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Certain amendments are to be applied prospectively while others are retrospective. The Company adopted ASU 2019-12 on January&#160;1, 2021 and the Company has assessed it will not have a material impact on its consolidated financial statements. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable Interest Entity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews each investment and collaboration agreement to determine if it has a variable interest in the entity. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgments regarding the purpose and design of entity, the value of the licensed assets to the entity, the value of the entity&#8217;s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that variable interest entity (VIE), based on a number of factors, including: (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii)&#160;the parties&#8217; contractual rights and responsibilities pursuant to the collaboration agreement, and (iii)&#160;which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statement of the VIE into the Company&#8217;s consolidated financial statements. On a quarterly basis, the Company <div style="letter-spacing: 0px; top: 0px;;display:inline;">evaluates </div>whether </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period the determination is <div style="letter-spacing: 0px; top: 0px;;display:inline;">made.</div> </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities recorded as a result of consolidating financial results of the VIE into the Company&#8217;s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company&#8217;s general assets or liabilities for which creditors have recourse to the Company&#8217;s general assets. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NonControllingInterestPolicyTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling Interest </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records noncontrolling interest related to the consolidated VIEs on its consolidated balance sheet. The Company records loss attributable to noncontrolling interest on its consolidated statements of operations, which reflects the VIE&#8217;s net loss for the reporting period, adjusted for changes in the noncontrolling interest holders claim to net assets, including contingent milestone and royalty payments, which are evaluated each reporting period. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Deconsolidation and discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deconsolidation and discontinued operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i)&#160;the aggregate of (a)&#160;the fair value of any consideration received, (b)&#160;the fair value of any retained noncontrolling investment in the former subsidiary and (c)&#160;the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii)&#160;the carrying amount of the former subsidiary&#8217;s assets and liabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses whether a deconsolidation is required to be presented as discontinued operations in its consolidated financial statements on the deconsolidation date. This assessment is based on if the deconsolidation represents a strategic shift that has or will have a major effect on the Company&#8217;s operations or financial results. If the Company determines that a deconsolidation requires presentation as a discontinued operation on the deconsolidation date, or at any point during the one-year period following such date, it will present the former subsidiary as a discontinued operation for all periods presented. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Effect of foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of foreign currency </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars at rates of exchange in effect at the close of their month end. Equity accounts are translated at their historical rates. Revenues and expenses are translated at the exchange rate on the transaction date. Translation gains and losses are accumulated within accumulated other comprehensive income (loss) as a separate component of members&#8217; equity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency transaction gains and losses are included in other expense on the consolidated statements of operations and comprehensive income (loss). There were gains of $117 for the year ended December&#160;31, 2020, nominal losses for the year ended December&#160;31, 2019, and losses of $234 for the year ended December&#160;31, 2018. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss) </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) consists of two components: net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that under U.S.&#160;GAAP are recorded as an element of members&#8217; equity and are excluded from net income (loss). The Company&#8217;s other comprehensive income (loss) consists of a defined benefit plan adjustment and foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents consist of highly liquid investments with an original maturity of<div style="letter-spacing: 0px; top: 0px;;display:inline;"> three</div> months or less at date of purchase. The Company&#8217;s cash is primarily held in financial institutions in the United States and the Netherlands. The Company maintains cash balances in the United States in excess of the federally insured limits. The Company did not have restricted cash as of December&#160;31, 2020 and 2019. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company uses derivative instruments to manage exposures to interest rates. Derivatives are recorded on the balance sheet at fair value at each balance sheet date and the Company does not designate whether the derivative instrument is an effective hedge. Changes in the fair values of derivative instruments are recognized in the consolidated statements of operations and comprehensive income (loss). The Company has entered, and may in the future enter, into derivative contracts related to its debt. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 5. Financial instruments</div></div> for further details regarding the Company&#8217;s derivatives. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records certain assets and liabilities at fair value. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 7. Fair value measurements</div></div> for details regarding assets and liabilities measured at fair value. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities are categorized based on the lowest level that is significant to the valuation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The three levels of inputs used to measure fair value are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#8212;Observable inputs other than quoted prices included within Level&#160;1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Products </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company derives revenue primarily from the sale of its (i)&#160;osteoarthritic, or OA, joint pain treatment and joint preservation products, which are hyaluronic acid, or HA, viscosupplementation therapies, (ii)&#160;Bone Graft Substitutes (BGS) products and (iii)&#160;a Minimally Invasive Fracture Treatment product. The Company sells product directly to healthcare institutions, patients, distributors and dealers. The Company also enters arrangements with pharmacy and health benefit managers that provide for negotiated rebates, chargebacks and discounts with respect to the purchase of the Company&#8217;s products. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue at a point in time upon transfer of control of the promised product to customers in an amount that reflects the consideration it expects to receive in exchange for those products. The Company excludes taxes collected from customers and remitted to governmental authorities from revenues. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are recorded at the transaction price, which is determined as the contracted price net of estimates of variable consideration resulting from discounts, rebates, returns, chargebacks, contractual allowances, estimated third-party payer settlements, and certain distribution and administration fees offered in our customer contracts and other indirect customer contracts relating to the sale of our products. The Company establishes reserves for the estimated variable consideration based on the amounts earned or eligible to be claimed on the related sales. Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted for relevant factors such as the Company&#8217;s historical experience, current contractual requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company regularly reviews all reserves and updates them at the end of each reporting period as needed. There were no adjustments arising from the change in estimates of variable consideration that were significant for the years ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">OA Joint Pain Treatment and Joint Preservation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from customers, such as healthcare providers, distribution centers or specialty pharmacies is recognized at the point in time when control is transferred to the customer, typically upon shipment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributor chargebacks </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has preexisting contracts with established rates with many of the distributors&#8217; customers who require the distributors to sell our product at their established rate. The Company offers chargebacks to distributors who supply these customers with our products. The Company reduces revenue at the time of sale for the estimated future chargebacks. The Company records chargeback reserves as a reduction of accounts receivable and base the reserves on the expected value by using probability-weighted estimates of volume of purchases, inventory holdings and historical chargebacks requested for each distributor. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Discounts and gross-to-net deductions </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company offers retrospective discounts and gross-to-net deductions linked to the volume of purchases which may increase at negotiated thresholds within a contract-buying period. The Company reduces revenue and records the reserve as a reduction to accounts receivable for the estimated discount and rebate at the expected amount the customer will earn, based on historical buying trends and forecasted purchases. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bone Graft Substitute </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the Company&#8217;s BGS product sales are through consignment inventory with hospitals, where ownership remains with the Company until the hospital or ambulatory surgical center (ASC) performs a surgery and consumes the consigned inventory. The Company recognizes revenue when the surgery has been performed. Control of the product is not transferred until the customer consumes it, as the Company is able to require the return or transfer of the product to a third-party. An unconditional obligation to pay for the product does not exist until the customer consumes it. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Minimally Invasive Fracture Treatment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue from third-party payers, such as governmental agencies, insurance companies or managed care providers, when the Company transfers control to the patient, typically when the patient has accepted the product or upon delivery. The Company records this revenue at the contracted rate, net of contractual allowances and estimated third-party payer settlements at the time of sale, or an estimated price based on historical data and other available information for non-contracted payers. The Company estimates the contractual allowances using the portfolio approach and based on probability weighting historical data and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collections history within those portfolios. The portfolios determined using the portfolio approach consist of the following customer groups: government payers, commercial payers, and patients. The Company recognizes revenue from patients (self-pay and insured patients with coinsurance and deductible responsibilities) based on billed amounts giving effect to any discounts and implicit price concessions. Implicit price concessions represent differences between amounts billed and the amounts the Company expects to collect from patients, which considers historical collection experience and current market conditions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price using the expected amount method. These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. The Company is not aware of any claims, disputes or unsettled matters with any payer that would materially affect revenues for which the Company has not adequately provided for or disclosed in the accompanying consolidated financial statements. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 12. Commitments and contingencies</div></div> for further information. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product returns </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimates the amount of returns and reduces revenue in the period the related product revenue is recognized. The Company records a liability for expected returns based on probability-weighted historical data. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts receivable, net </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for doubtful accounts. The Company maintains an estimated allowance for doubtful accounts to provide for receivables the Company does not expect to collect. The Company bases the allowance on an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and other information as applicable. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ContractAssetsPolicyTextBlock', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract assets </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets consist of unbilled amounts resulting from estimated future royalties from an international distributor that exceeds the amount billed. Contract assets totaling $81 and $261 as of December&#160;31, 2020 and 2019, are included in prepaid and other current assets on the consolidated balance sheets, respectively. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ContractLiabilitiesPolicyTextBlock', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract liabilities </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities consist of customer advance payments and deferred revenue. Occasionally for certain international customers, the Company requires payments in advance of shipping product and recognizing revenue resulting in contract liabilities. Contract liabilities were nominal as of December&#160;31, 2020 and 2019 and are included in accrued liabilities on the consolidated balance sheets. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shipping and handling </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other distribution costs are included in cost of sales. The </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company has elected to recognize shipping and handling activities that occur after control of the related product transfers to the customer as fulfillment costs and these are included in<div style="display:inline;"> cost</div> of sales.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ContractCostsPolicyTextBlock', window );">Contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the practical expedient of recognizing the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less. These incremental costs include the Company&#8217;s sales incentive programs for the internal sales force and third-party sales agents as the compensation is commensurate with annual sales activities. These costs are included in selling, general and administrative expense on the consolidated statements of operations and comprehensive income (loss). </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company values its inventory at the lower of cost or net realizable value and adjusts for the value of inventory that is estimated to be excess, obsolete or otherwise unmarketable. Cost is determined using the first-in, first-out (FIFO) method. Elements of cost in inventory include raw materials, direct labor, manufacturing overhead and inbound freight. The Company records allowances for excess and obsolete inventory based on historical and estimated future demand and market conditions. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business combinations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting for acquisitions requires the Company to recognize separately from goodwill assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While best estimates and assumptions are used to accurately value assets acquired and liabilities assumed at the acquisition date, as well as contingent consideration where applicable, estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations and comprehensive income (loss). Subsequent changes in the estimated fair value of contingent<div style="display:inline;"> considerat</div>ion are recognized in earnings in the period of change. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and equipment </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense are recognized using the straight-line method over the estimated useful life of each asset, or the shorter of the lease term or useful life if related to leasehold improvements. The useful lives in years are as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer software and hardware</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3-5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and intangible assets&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Fini</div>te-lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight-line method over their estimated useful lives in years are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill is not amortized but is evaluated for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. The Company reviews goodwill for impairment by applying a quantitative impairment analysis where the fair value of the reporting unit is compared with the carrying value, including goodwill. The Company determines the fair value of each reporting unit based on an income approach. The value of each reporting unit is determined on a stand-alone basis from the perspective of a market participant and represents the price estimated to be received in a sale of the reporting unit in an orderly transaction between market participants at the measurement date. The Company performs its annual goodwill impairment test on October&#160;31st. If the fair value of the reporting unit is less than its carrying value, the Company will recognize the difference as an impairment loss, which is limited to the amount of goodwill allocated to the reporting units. There were no goodwill impairment charges for the years ended December&#160;31, 2020, 2019 and 2018. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Software development costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company capitalizes internal and external costs incurred to develop internal-use software during the application development stage for software design, configuration, coding and testing upon placing the asset in service and then amortizes these costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. The Company does not capitalize costs that are precluded from capitalization in authoritative guidance, such as preliminary project phase costs, training costs or data conversion costs. Capitalized software costs totaled $17,653 and $14,119 as of December&#160;31, 2020 and 2019 and the related accumulated amortization totaled $13,264 and $12,184, respectively. Amortization expense was $1,184, $1,138 and $1,204 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying values of property, equipment, intangible assets as well as other long-lived and indefinite lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable the Company will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. If quoted market prices are not available, the Company estimates fair value using an undiscounted value of estimated future cash flows. During 2018, the Company determined that it would no longer sell a specific BGS product and as a result, an intangible asset related to this product was fully written off and the Company recognized impairment charges of $489 for the year ended December&#160;31, 2018, which is included in the consolidated statements of operations and comprehensive income (loss). Upon retirement or sale of property and equipment, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is included in income from operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#8217;s property, equipment, intangible or other long-lived assets. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired in-process research and development </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of in-process research and development (IPR&amp;D) assets acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets and are not amortized until development is completed and the product is available for sale. Once the product is available for sale, the asset is transferred to developed technology and amortized over its estimated useful life. Impairment tests for IPR&amp;D assets occur at least annually in December, or more frequently if events or changes in circumstances indicate that the asset might be impaired. If the fair value of the intangible assets is less than the carrying amount, an impairment loss is recognized for the difference. There were no events, facts or circumstances for the years ended December&#160;31, 2020, 2019 and 2018 that resulted in any impairment charges to the Company&#8217;s IPR&amp;D. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy', window );">Deferred Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Offering Costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs, consisting of legal, accounting, filing and other fees related to the initial public offering, are capitalized. The deferred offering costs will be offset against proceeds from the initial public offering upon the effectiveness of the initial public offering. In the event the initial public offering is terminated, all capitalized deferred offering costs would be expensed. Deferred offering costs capitalized totaled $2,187 as of December&#160;31, 2020 and there were there were no deferred offering costs capitalized as of December&#160;31, 2019. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company provides credit, in the normal course of business, to its customers. The Company does not require collateral or other securities to support customer receivables. Credit losses are provided for through allowances and have historically been materially within management&#8217;s estimates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable to these significant suppliers at December&#160;31 were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,983</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,586</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">471</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">697</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain products provide the Company with a significant percentage of total sales for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has restructured portions of its operations and future restructuring activities are possible. Identifying and calculating the cost to exit these operations requires certain assumptions to be made, the most significant of which are anticipated future liabilities. Although estimates have been reasonably accurate in the past, significant judgment is required, and these estimates and assumptions may change as additional information becomes available and facts or circumstances change. Restructuring costs are recorded at estimated fair value. Key assumptions in determining the restructuring costs include negotiated terms and payments to terminate contractual obligations. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Profits interest compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profits interest compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures profits interest compensation cost at the grant date based on the fair value of the award and recognizes this cost as compensation expense over the required or estimated service period for awards expected to vest. Certain awards are liability-classified, which require they be remeasured at each reporting date. Compensation expense is included in Selling, general and administrative expense and Research and development expense on the consolidated statement of operations and comprehensive income (loss) based upon the classification of the employees who were granted the awards. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs include costs incurred to promote the Company&#8217;s business and are expensed as incurred. Advertising costs were $2,769, $2,351 and $2,916 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense consist primarily of employee compensation and related expenses as well as contract research organization services. Internal research and development costs are expensed as incurred. Research and development costs incurred by third parties are expensed as the contracted work is performed. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative agreements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company periodically enters into strategic alliance agreements with counterparties to produce products and/or provide services to customers. Alliances created by such agreements are not legal entities, have no employees, no assets and have no true operations. These arrangements create contractual rights and we account for these alliances as a collaborative arrangement by reporting costs incurred from transactions within research and development expense in our consolidated statements of operations. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. Legal fees expected to be incurred in connection with a loss contingency are not included in the estimated loss contingency. The Company accrues for any legal costs as they are incurred. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is treated as a partnership for U.S. tax purposes. Accordingly, the profits and losses are passed through to the members and included in their income tax returns. The Company has been required to make tax </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distributions to its members in an amount equal to 40% of the members&#8217; taxable income attributable to their ownership. The tax rate applied for purposes of this distribution may be changed only by approval of the Company&#8217;s Board of Managers. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain wholly owned subsidiaries of the Company are taxable entities for U.S. or foreign tax purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred tax assets to an amount which will, more likely than not, be realized. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes a tax benefit from any uncertain tax positions only if they are more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. Components of the reserve, if relevant, are classified as a current or noncurrent liability in the consolidated balance sheet based on when the Company expects each of the items to be settled. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net income (loss) per common unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per common unit </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic income (loss) per common unit is determined by dividing the net income (loss) allocable to common unit holders by the weighted average number of common units outstanding during the periods presented. Diluted loss per common unit is computed by dividing the net income (loss) allocable to common unit holders on an &#8220;if converted&#8221; basis by the weighted average number of actual common units outstanding and, when dilutive, the unit equivalents that would arise from the assumed conversion of convertible instruments, if any. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has considered the effects of subsequent events through March&#160;26, 2021, the date the Company&#8217;s consolidated financial statements were issued. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ContractAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ContractAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ContractCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ContractCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ContractLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ContractLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NonControllingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NonControllingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35755530&amp;loc=d3e11264-158415<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798908536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables) - Bio Ventus LLC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Summary of useful lives in assets</a></td>
<td class="text">The useful lives in years are as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer software and hardware</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3-5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Finite-lived intangible assets</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Fini</div>te-lived intangible assets were initially recorded at fair value upon acquisition and are amortized using the straight-line method over their estimated useful lives in years are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of significant percentage of total sales</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain suppliers provide the Company with product that results in a significant percentage of total sales for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable to these significant suppliers at December&#160;31 were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,983</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,586</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">471</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">697</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplier C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain products provide the Company with a significant percentage of total sales for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product A</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product B</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product C</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798176776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of restructuring charges and payments</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s restructuring charges and payments for all plans are comprised of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee<br/>severance&#160;and<br/>temporary<br/>labor&#160;costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/>charges</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">997</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">206</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,203</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses incurred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">491</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">575</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments made</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,488</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(290</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses incurred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">408</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">155</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">563</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments made</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(74</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">247</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798365400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfMembersEquityTableTextBlock', window );">Summary of Members Equity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members&#8217; equity consisted of the following at December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Profits interest and other equity awards (Refer to<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Note 9. Equity-based compensation</div></div>)</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,800</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,774</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,173</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">285,147</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MemberEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Member equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MemberEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ScheduleOfMembersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of members equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ScheduleOfMembersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674846153864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock', window );">Disaggregated By Geographic Markets And Major Products</a></td>
<td class="text">The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) for the years ended December&#160;31 as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary geographic markets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293,697</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305,072</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">282,895</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,464</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,069</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36,282</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321,161</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">340,141</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">319,177</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vertical:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OA joint pain treatment and joint preservation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">171,178</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,082</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">155,576</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Minimally invasive fracture treatment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,624</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,504</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121,032</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bone graft substitutes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,359</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,555</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,569</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321,161</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">340,141</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">319,177</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disaggregation Of Revenue Based On Geography.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798249320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock', window );">Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the statement of operations and comprehensive income (loss) from discontinued operations for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,773</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,127</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on disposal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,638</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,650</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798397608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule Of Reconciliation Of Operating Profit (Loss) From Segments To Consolidated</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents segment adjusted EBITDA reconciled to income before income taxes: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment adjusted EBITDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,149</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,439</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,147</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,151</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,738</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(497</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,810</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest (expense) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,195</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,215</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(255</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,559</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,771</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> benefits, net</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Succession and transition charges</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(187</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,801</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(344</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,574</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition and integration costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Inventory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> costs</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity loss in unconsolidated investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(432</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(901</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of contingent consideration</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments related to variable interest entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> costs</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,710</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(283</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,389</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,435</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule Of Reconciliation Of Operating Profit (Loss) From Segments To Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The following table presents segment adjusted EBITDA reconciled to income from continuing operations before income taxes for the years ended December&#160;31 as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment adjusted EBITDA from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,252</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,673</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,480</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,191</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,515</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,691</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,751</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,103</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19 benefits, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,123</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Succession and transition charges</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,609</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(563</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(575</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency impact</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(234</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity loss in unconsolidated investments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(467</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other non-recurring costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,914</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,107</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803213960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The following table presents our net sales by segment disaggregated by geographic markets and major products (Vertical) as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary geographic markets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,682</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,166</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173,220</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,136</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,134</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,851</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,374</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,526</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,816</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,017</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,594</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vertical:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pain Treatments and Joint Preservation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,704</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,868</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,234</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70,151</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restorative Therapies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,511</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,968</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,332</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,433</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bone Graft Substitutes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,601</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,181</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,028</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,078</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total net sales</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,816</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,017</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,594</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674733489704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per unit (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted loss per share of Class&#160;A common stock for the period following the Transactions (amounts in thousands, except share and per share data): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;16,<br/> 2021 through<br/> July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,229</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,654</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Bioventus Inc. Class&#160;A common stockholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares of Class&#160;A common stock outstanding - basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,805,347</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,802,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share of Class&#160;A common stock, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the computation of basic and diluted net income (loss) per unit for the years ended December&#160;31 as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,722</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,113</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss attributable to noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">553</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,666</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from continuing operations attributable to unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,666</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated and unpaid preferred distributions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,955</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income allocated to participating shareholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) from continuing operations attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,383</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,156</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,650</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,383</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(659</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,988</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per unit attributable to common unit holders - basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.89</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.40</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to common unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.89</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.67</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,900,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,900,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,900,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674730946600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease, Cost</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease cost were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">912</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">646</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,614</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">329</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">740</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,943</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,496</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes variable lease cost and sublease income, which are immaterial. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Supplemental cash flow information and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> activity related to operating leases were as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,269</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Assets and Liabilities, Lessee</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental balance sheet and other information related to operating leases <div style="display:inline;">were </div>as fo<div style="display:inline;">llow</div>s:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities- current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities- noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,989</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,907</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,068</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease cost were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,610</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,529</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">388</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">358</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,998</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,887</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*Includes</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">variable lease cost and sublease income, which are immaterial. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information and non-cash activity related to leases were as follow: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of operating lease liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,567</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,343</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use assets obtained in exchange for operating lease obligations:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,497</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,016</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Assets and Liabilities, Lessee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other balance sheet information related to leases are as follows:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,267</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities&#8212;current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,814</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities&#8212;noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,068</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining operating lease term in years</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate for operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of lessee liability maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities as of December&#160;31, 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,714</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,645</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,460</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,476</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,569</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,281</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total future lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,145</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,077</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of future lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,068</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674731383976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of cash and cash equivalents and restricted cash is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,065</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,839</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,003</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,068</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,839</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of cash and cash equivalents and restricted cash is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,065</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,839</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,003</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,068</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,839</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net of allowances, consisted of the following as of: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105,048</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,273</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Allowance for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,029</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net of allowances, consisted of the following as of December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,273</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,274</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Allowance for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,128</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Summary of Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in credit losses were as <div style="letter-spacing: 0px; top: 0px;;display:inline;">follows</div>: </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div>&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,811</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,684</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recovery (provision)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">550</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(619</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">359</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,162</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">278</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">167</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">684</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">252</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(72</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(193</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,019</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consisted of the following as of: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and supplies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,202</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,665</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,538</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,323</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,740</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,988</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess and obsolete reserves</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(868</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,020</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,120</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consisted of the following as of: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> deductions</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">63,980</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">43,656</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus and commission</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,493</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,932</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income and other taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,385</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,434</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,456</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,034</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105,246</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,187</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restrictions on Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net of allowances, consisted of the following as of December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,273</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,274</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Allowance for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,283</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,128</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Summary of Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in credit losses were as follows for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,497</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for credit losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,215</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,787</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,949</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recoveries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(416</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(356</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending balance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consisted of the following as of December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and supplies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,665</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,349</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,323</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,509</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,988</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,858</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess and obsolete reserves</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(868</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(532</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,120</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,326</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfInventoryValuationReservesTableTextBlock', window );">Schedule Of Inventory Valuation Reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in excess and obsolete reserves for inventory were as follows for the years ended December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(532</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(570</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(904</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(870</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Write-offs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">568</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">908</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(868</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(532</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,547</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,854</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,126</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,918</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,474</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,451</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,234</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,138</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets not yet placed in service</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">819</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">370</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,200</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,731</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,321</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,879</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,489</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no changes to goodwill during the years ended December&#160;31, 2020 and 2019. Following is a summary of goodwill by reportable segment: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 685.438px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 368.188px;"/>
<td style="vertical-align: bottom; width: 43.4062px;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 43.4062px;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 43.4375px;"/>
<td/>
<td/>
<td/></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S.</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consolidated</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020 and 2019</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;">41,040</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;">8,760</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;">49,800</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock', window );">Schedule Of Intangible Assets Net Excluding Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets consisted of the following as of December&#160;31:</div></div></div> <div style="color: rgb(0, 0, 0); font-family: Century; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: Century; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 620.156px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 433.797px;"/>
<td style="vertical-align: bottom; width: 37.1719px;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 37.1875px;"/>
<td/>
<td/>
<td/></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">263,422</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">263,422</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">60,700</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">59,700</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">57,700</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">57,700</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,445</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11,095</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology and other</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13,999</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,649</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total carrying amount</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">397,266</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">396,566</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated amortization:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(117,281</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(100,982</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution rights</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(34,461</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28,716</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(51,247</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(46,407</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology and other</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,786</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,404</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accumulated amortization</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(206,775</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(179,509</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net before currency translation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">190,491</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">217,057</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top; font-size: 10pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,159</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(547</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">191,650</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">216,510</div></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consisted of the following at December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net deductions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,656</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,622</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bonus and commission</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,200</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reserve for estimated overpayments from third-party payers</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,790</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,801</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation and benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,231</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income and other taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,434</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,555</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,244</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,418</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,187</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,827</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of intangible assets net excluding goodwil.l</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ScheduleOfInventoryValuationReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of inventory valuation reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ScheduleOfInventoryValuationReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674732131016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business combinations and investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text">The consideration paid for Bioness is comprised of the following:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Consideration</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash consideration at closing</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">48,933</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Bioness consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91,933</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date and the resulting goodwill, which is expected to be deductible for tax purposes: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">91,933</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets acquired and liabilities assumed:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,143</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,318</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,947</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">673</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,616</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,405</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,020</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,598</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Resulting goodwill<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(b)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,335</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of cash and cash equivalents of $2,143 and restricted cash deposited by the former majority owner of Bioness of $1,000, into escrow with financial institutions for the purpose of paying specific Bioness indebtedness. The Company previously deposited $4,207 into escrow for the same purpose. Prior to the acquisition, Bioness had entered into two loans in connection with the Paycheck Protection Program (the PPP) under the Coronavirus Aid, Relief and Economic Security Act (CARES Act) administered by the U.S. </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Small business Administration. Bioness received proceeds of $3,204 from an unsecured PPP loan that was scheduled to mature on April&#160;10, 2022. Bioness applied and was granted forgiveness of this loan during 2021. Bioness received proceeds of $2,003 from a second unsecured PPP loan bearing an interest rate of 1% scheduled to mature on February&#160;5, 2026. Bioness applied for forgiveness of this loan during 2021. As part of the Bioness acquisition, the balance of $2,003 was placed in restricted cash to cover the repayment of the outstanding unsecured PPP loan in the event it is not forgiven. The $1,000 outstanding unsecured PPP loan balance covered by the former majority owner is included in other current liabilities within the condensed consolidated balance sheets. </td> </tr> </table> <div style="clear: both; max-height: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(b)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The U.S. segment was allocated the resulting goodwill from the Bioness acquisition. </div></div> </td> </tr> </table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the preliminary fair values of identifiable intangible assets and their useful lives: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful&#160;Life</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">43,500</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; text-align: center;">N/A</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; text-align: center;">2 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 72%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 72%;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text">Consolidated unaudited pro forma results of operations for the Company are presented below assuming the 2021 Bioness Acquisition had occurred January&#160;1, 2020. Pro forma operating results for the three and six months ended June&#160;27, 2020 include operating expenses of $3,939 and $7,135, respectively, for acquisition integration costs and inventory related adjustments. <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;27,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">109,816</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">65,955</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">200,541</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">157,570</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(6,841</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(12,962</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,333</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(11,376</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share of Class&#160;A common stock(1):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr> </table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harbor assets that could only be used to settle Harbor obligations and Harbor liabilities for which creditors did not have recourse to the general credit of the Company were as follows at December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">803</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,635</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">178</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,863</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">366</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,004</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">659</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,029</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,430</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual property (10-year useful life)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,834</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,445</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(932</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,696</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(697</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(266</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value of net assets acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioventus purchase price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of Harbor&#8217;s noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,188</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Harbor assets that can only be used to settle Harbor obligations and Harbor liabilities for which creditors do not have recourse to the general credit of the Company are as follows for the years ended December&#160;31: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">803</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,127</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,635</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,122</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">178</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">231</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,863</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,599</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">366</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">458</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,004</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,395</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">659</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,029</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,940</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805968968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt consists of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term loan due December 2024 (2.60% at July&#160;3, 2021)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182,500</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">190,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(959</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(457</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(524</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166,084</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173,378</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock', window );">Summary of Debt Instruments Periodic Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Scheduled quarterly principal payments are as follows with the final payment of $125,000 at Maturity:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quarterly<br/>payment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 and 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 and 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock', window );">Schedule of Loan margin Adusted on Pricing Grid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Loan margin is adjusted after the quarterly financial statements are delivered to the lenders in accordance with the pricing grid below: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Leverage ratio</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eurodollar</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BR</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt;1.50 to 1.00 and &lt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 1.25 to 1.00 and &lt;1.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 0.75 to 1.00 and &lt;1.25 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&lt; 0.75 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock', window );">Schedule of Commitment Fee Adjusted Based on Pricing Grid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The commitment fee rate is adjusted after the quarterly financial statements are delivered to lenders based on the pricing grid below:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 81%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 15%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Leverage ratio</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitment<br/>fee&#160;rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt;1.50 to 1.00 and &lt; 2.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 1.25 to 1.00 and &lt;1.50 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&gt; 0.75 to 1.00 and &lt;1.25 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&lt; 0.75 to 1.00</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Summary of Contractual maturities of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual maturities of long-term debt as of December&#160;31, 2020, were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025 and thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred financing costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,098</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Original issue discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(524</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188,378</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173,378</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of commitment fee adjusted based on pricing grid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of debt instruments periodic payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of loan margin adjusted on pricing grid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805265656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Liabilities Measured At Fair Value on Recurring Basis</a></td>
<td class="text">The following table provides information for liabilities measured at fair value on a recurring basis using Level&#160;2 and Level&#160;3 inputs:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swap</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,220</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,220</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term contingent consideration, less current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,421</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,421</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management incentive plan and liability-classified awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Participation Right</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,933</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,641</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,006</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,404</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">After the initial valuation, the Company will use its best estimate to measure contingent consideration related to the Bioness Acquisition at each subsequent reporting period using the following unobservable Level&#160;3 inputs:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation Technique</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bioness contingent consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Discounted cash flow</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">Payment discount rate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">5.0% - 6.8%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">Payment period</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2021 - 2025</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level&#160;3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">829</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,281</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phantom plan conversion to Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level&#160;3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of range of key assumptions used within the valuation of the awards</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level&#160;3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">829</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,281</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phantom plan conversion to Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level&#160;3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,774</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Liabilities Measured At Fair Value on Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The following table provides information for liabilities measured at fair value on a recurring basis using Level 2 and Level 3 inputs.
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:92%;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest rate swap</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management incentive plan and liability-classified awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,802</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Participation Rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,457</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,006</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,404</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,259</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,063</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,464</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,290</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,002</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,802</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,734</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,641</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,892</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">565</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,457</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">644</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of range of key assumptions used within the valuation of the awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the MIP and liability-classified awards at fair value using significant unobservable inputs or Level 3: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,063</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,464</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,290</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,002</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,802</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial estimate (vesting)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,734</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,641</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of the beginning and ending balances for the EPR Unit at fair value using significant unobservable inputs Level 3: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,892</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">565</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,457</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">644</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember', window );">Equity Participation Right Unit [Member] | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a range of key assumptions used within the valuation of the awards as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation technique</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted Average</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Option pricing approach</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Time to liquidity event</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.4</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Risk free rate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.10%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Equality volatility</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">35.13%&#160;-&#160;101.25%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">50.0%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Equity value</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">$1,065,000&#160;-&#160;$1,240,000</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">$1,145,000</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Lack of marketability discount</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">7.0%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">7.0%</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of range of key assumptions used within the valuation of the awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a range of key assumptions used within the valuation of the awards as of December&#160;31, 2020: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 23%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation technique</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted Average</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Option pricing approach</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Time to liquidity event</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.4</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Risk free rate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.10%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">0.10%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Equality volatility</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">35.13%&#160;-&#160;101.25%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">50.0%</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Equity value</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">$1,065,000&#160;-&#160;$1,240,000</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">$1,145,000</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Lack of marketability discount</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">7.0%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">7.0%</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804326056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text">summary of the RSU award activity for the six months ended July&#160;3, 2021 is as follows (number of units in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> average&#160;grant-<br/> date fair value<br/> per unit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">945</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">945</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.90</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/canceled</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.53</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">943</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text">A summary of the Company&#8217;s assumptions used in determining the fair value of the stock options granted during the six months ended July&#160;3, 2021 is shown in the following table.
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.59%&#160;-&#160;1.19%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">33.1%&#160;-&#160;33.5%</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">5.75<div style="display:inline;">&#160;-&#160;</div>6.25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average fair value of stock options granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$4.21&#160;-&#160;5.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Roll Forward</a></td>
<td class="text">A summary of stock option activity is as follows for the six months ended July&#160;3, 2021 (number of options in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 50%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> average&#160;exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> remaining<br/> contractual&#160;term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,621</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,621</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.90</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,625</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock', window );">Summary of Phantom Plan Award activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the award activity of the Phantom Plan for the year ended December&#160;31, 2020 is as follows (number of awards in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 43%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2012 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2015 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(awards in thousands)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.72</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,139</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.24</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">553</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.29</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Converted to cash</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.45</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(124</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.98</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.72</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,422</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.41</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards vested at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.72</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">495</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.15</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Other Phantom Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock', window );">Summary of Phantom Plan Award activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 36%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2012 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2015 Phantom Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">(awards in thousands)</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">grant-date&#160;fair&#160;value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nonvested at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.01</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">667</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.71</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested during 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.01</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.81</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nonvested at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">927</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.62</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation phantom plan shares award unvested activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bvs_OtherPhantomUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bvs_OtherPhantomUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674800439080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted loss per share of Class&#160;A common stock for the period following the Transactions (amounts in thousands, except share and per share data): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;16,<br/> 2021 through<br/> July&#160;3, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,229</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,654</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Bioventus Inc. Class&#160;A common stockholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares of Class&#160;A common stock outstanding - basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,805,347</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,802,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share of Class&#160;A common stock, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following number of weighted-average potentially dilutive shares as of July&#160;3, 2021 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion: </div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three<br/> Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<br/> Ended July&#160;3,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC Interests held by Continuing LLC&#160;Owner<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,786,737</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,786,737</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,622,287</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,602,747</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,221,555</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">941,031</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of Class&#160;A common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,458</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,698</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,663,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,365,213</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Shares reserved for future issuance upon redemption or exchange of LLC Interests by Continuing LLC Owner. </div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798197016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables) - Bio Ventus LLC [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of net income from continuing operations before taxes</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of net income from continuing operations before taxes for the years ended December&#160;31 are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxable subsidiaries:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Domestic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">306</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,679</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,925</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">387</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,967</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">693</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,646</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,532</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other domestic subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,221</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,043</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,575</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,914</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,107</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary Of Components Of Income Tax Expense Benefit</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">782</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">891</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(508</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(345</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(294</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">707</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">472</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State income taxes:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">380</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax rates - deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,192</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,576</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,664</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The differences between the effective income tax rate and the federal statutory income tax rates for the years ended December&#160;31 by taxable and other subsidiaries are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:84%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. statutory federal corporate income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC flow-through structure</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State and local income taxes, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.5</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.4</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.3</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.5</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.9</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating losses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,874</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,530</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">696</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">390</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,570</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,920</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,423</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,577</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,497</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liability:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired intangible</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,939</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,371</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,362</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,874</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804896680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>USD ($) </div>
<div>Entities </div>
<div>Business </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>EMPLOYEE </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>employee </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromGovernmentalAssistance', window );">Cash received from provident relief fund | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld', window );">Number of LLC interest held (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember', window );">BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of entities acquired | Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember', window );">BV LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of entities acquired | Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld', window );">Number of LLC interest held (in shares)</a></td>
<td class="nump">41,038,589<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SaleOfStockOfferingCosts', window );">Sale of stock, offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,778,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts', window );">Payment of offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,451,000<span></span>
</td>
<td class="nump">$ 1,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SaleOfStockOfferingCosts', window );">Sale of stock, offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | EMPLOYEE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromGovernmentalAssistance', window );">Cash received from provident relief fund | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent', window );">Employer social security payroll tax | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PercentageOfDeferredPayrollTax', window );">Percentage of deferred payroll tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld', window );">Number of LLC interest held (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld', window );">Number of LLC interest held (in shares)</a></td>
<td class="nump">41,062,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC | BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of entities acquired | Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bvs_BVLLCMember', window );">BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest, ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bvs_BVLLCMember', window );">BV LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest', window );">Managing member, ownership interest</a></td>
<td class="nump">72.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest, ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CommonStockNumberOfVotes', window );">Number of votes per common share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of shares issued in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | BV LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of shares issued in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in public offering (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | IPO | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in public offering (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Over-Allotment Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Bio Ventus LLC | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in public offering (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Bio Ventus LLC | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CommonStockNumberOfVotes', window );">Number of votes per common share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio', window );">Shares issued or issuable, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CancellationRatioRequiredStockToLLCInterestRatio', window );">Cancellation ratio, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of shares cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CommonStockNumberOfVotes', window );">Number of votes per common share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio', window );">Shares issued or issuable, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CancellationRatioRequiredStockToLLCInterestRatio', window );">Cancellation ratio, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of shares cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CancellationRatioRequiredStockToLLCInterestRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation ratio, required stock to LLC interest ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CancellationRatioRequiredStockToLLCInterestRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CommonStockNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, number of votes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CommonStockNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Limited liability company LLC or limited partnership LP managing member or general partner number of interests held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PaymentsOfStockIssuanceCostsAdditionalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Stock Issuance Costs, Additional Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PaymentsOfStockIssuanceCostsAdditionalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PercentageOfDeferredPayrollTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of deferred payroll tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PercentageOfDeferredPayrollTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ProceedsFromGovernmentalAssistance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from governmental assistance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ProceedsFromGovernmentalAssistance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SaleOfStockOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SaleOfStockOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued or issuable, required stock to LLC interest ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bvs_BVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bvs_BVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803262520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 136,065<span></span>
</td>
<td class="nump">$ 86,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">2,003<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 138,068<span></span>
</td>
<td class="nump">$ 86,839<span></span>
</td>
<td class="nump">$ 126,240<span></span>
</td>
<td class="nump">$ 64,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674811455928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Components of accounts receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 105,048<span></span>
</td>
<td class="nump">$ 92,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: Allowance for credit losses</a></td>
<td class="num">(3,019)<span></span>
</td>
<td class="num">(3,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 102,029<span></span>
</td>
<td class="nump">88,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,273<span></span>
</td>
<td class="nump">$ 89,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: Allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,990)<span></span>
</td>
<td class="num">(4,146)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,283<span></span>
</td>
<td class="nump">$ 85,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674806132568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information - Allowance for credit loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="num">$ (3,811)<span></span>
</td>
<td class="num">$ (4,684)<span></span>
</td>
<td class="num">$ (3,990)<span></span>
</td>
<td class="num">$ (4,146)<span></span>
</td>
<td class="num">$ (4,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Recovery (provision)</a></td>
<td class="nump">550<span></span>
</td>
<td class="num">(619)<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="num">(1,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="num">$ (3,019)<span></span>
</td>
<td class="num">$ (5,249)<span></span>
</td>
<td class="num">(3,019)<span></span>
</td>
<td class="num">(5,249)<span></span>
</td>
<td class="num">(3,990)<span></span>
</td>
<td class="num">$ (4,146)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,990)<span></span>
</td>
<td class="num">$ (4,146)<span></span>
</td>
<td class="num">(4,146)<span></span>
</td>
<td class="num">(4,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Recovery (provision)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,215)<span></span>
</td>
<td class="num">(2,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">2,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,990)<span></span>
</td>
<td class="num">$ (4,146)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674732072072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials and supplies</a></td>
<td class="nump">$ 4,202<span></span>
</td>
<td class="nump">$ 3,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">31,538<span></span>
</td>
<td class="nump">26,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross</a></td>
<td class="nump">35,740<span></span>
</td>
<td class="nump">29,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Excess and obsolete reserves</a></td>
<td class="num">(1,720)<span></span>
</td>
<td class="num">(868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 34,020<span></span>
</td>
<td class="nump">29,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials and supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
<td class="nump">$ 3,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,323<span></span>
</td>
<td class="nump">24,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,988<span></span>
</td>
<td class="nump">27,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Excess and obsolete reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(868)<span></span>
</td>
<td class="num">(532)<span></span>
</td>
<td class="num">$ (570)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,120<span></span>
</td>
<td class="nump">$ 27,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674846007288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Accrued liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_GrossToNetDeductionsCurrent', window );">Gross-to-net deductions</a></td>
<td class="nump">$ 63,980<span></span>
</td>
<td class="nump">$ 43,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus and commission</a></td>
<td class="nump">12,493<span></span>
</td>
<td class="nump">15,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AccruedSalariesAndEmployeeBenefitsCurrent', window );">Compensation and benefits</a></td>
<td class="nump">7,932<span></span>
</td>
<td class="nump">5,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income and other taxes</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">18,456<span></span>
</td>
<td class="nump">21,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 105,246<span></span>
</td>
<td class="nump">88,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_GrossToNetDeductionsCurrent', window );">Gross-to-net deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,656<span></span>
</td>
<td class="nump">$ 14,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus and commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,188<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent', window );">Reserve for estimated overpayments from third-party payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">6,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AccruedSalariesAndEmployeeBenefitsCurrent', window );">Compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,875<span></span>
</td>
<td class="nump">3,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income and other taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,244<span></span>
</td>
<td class="nump">11,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,187<span></span>
</td>
<td class="nump">$ 52,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AccruedSalariesAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Salaries And Employee Benefits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AccruedSalariesAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_GrossToNetDeductionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross-To-Net Deductions, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_GrossToNetDeductionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reserve for estimated overpayments from third party payers current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805127208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Restructuring reserve, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,565<span></span>
</td>
<td class="nump">$ 26,252<span></span>
</td>
<td class="nump">$ 26,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AmortizationExpenseIncludedInInventory', window );">Amortization expense included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,455<span></span>
</td>
<td class="nump">6,416<span></span>
</td>
<td class="nump">7,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
<td class="nump">$ 3,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Goodwill, Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution rights | Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets, Weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EventAxis=bvs_ReclassificationOfIprdMember', window );">Reclassification Of IPRD | Developed Technology Rights | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets, Weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AmortizationExpenseIncludedInInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization expense included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AmortizationExpenseIncludedInInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EventAxis=bvs_ReclassificationOfIprdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EventAxis=bvs_ReclassificationOfIprdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798690744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet information - Schedule Of Inventory Valuation Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Balance, end of period</a></td>
<td class="num">$ (868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Balance, beginning of period</a></td>
<td class="num">(532)<span></span>
</td>
<td class="num">$ (570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_InventoryValuationReservesProvisionForLosses', window );">Provision for losses</a></td>
<td class="num">(904)<span></span>
</td>
<td class="num">(870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_InventoryValuationReservesWriteOffs', window );">Write-offs</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Balance, end of period</a></td>
<td class="num">$ (868)<span></span>
</td>
<td class="num">$ (532)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InventoryValuationReservesProvisionForLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory valuation reserves provision for losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InventoryValuationReservesProvisionForLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InventoryValuationReservesWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory valuation reserves write offs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InventoryValuationReservesWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804577224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 8,960<span></span>
</td>
<td class="nump">$ 6,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,200<span></span>
</td>
<td class="nump">$ 22,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,321)<span></span>
</td>
<td class="num">(18,242)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bvs_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,547<span></span>
</td>
<td class="nump">16,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Assets not yet placed in service | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bvs_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bvs_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804286088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 52,135<span></span>
</td>
<td class="nump">$ 49,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,800<span></span>
</td>
<td class="nump">$ 49,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember', window );">U.S. Segment [Member] | Operating Segments | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,040<span></span>
</td>
<td class="nump">41,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember', window );">International Segment | Operating Segments | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,760<span></span>
</td>
<td class="nump">$ 8,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674806389080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet information - Schedule Of Intangible Assets Net Excluding Goodwill  (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract', window );"><strong>Less accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 257,848<span></span>
</td>
<td class="nump">$ 191,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioventusIncMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems', window );"><strong>Schedule Of Intangible Assets Net Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,266<span></span>
</td>
<td class="nump">$ 396,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract', window );"><strong>Less accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206,775)<span></span>
</td>
<td class="num">(179,509)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation', window );">IntangibleAssets, net before currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,491<span></span>
</td>
<td class="nump">217,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation', window );">Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
<td class="num">(547)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,650<span></span>
</td>
<td class="nump">216,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bvs_AcquiredInProcessResearchAndDevelopmentMember', window );">IPR&amp;D | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems', window );"><strong>Schedule Of Intangible Assets Net Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">11,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual property | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems', window );"><strong>Schedule Of Intangible Assets Net Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,422<span></span>
</td>
<td class="nump">263,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract', window );"><strong>Less accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,281)<span></span>
</td>
<td class="num">(100,982)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution rights | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems', window );"><strong>Schedule Of Intangible Assets Net Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,700<span></span>
</td>
<td class="nump">59,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract', window );"><strong>Less accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,461)<span></span>
</td>
<td class="num">(28,716)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems', window );"><strong>Schedule Of Intangible Assets Net Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,700<span></span>
</td>
<td class="nump">57,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract', window );"><strong>Less accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,247)<span></span>
</td>
<td class="num">(46,407)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Developed technology and other | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems', window );"><strong>Schedule Of Intangible Assets Net Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,999<span></span>
</td>
<td class="nump">4,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract', window );"><strong>Less accumulated amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,786)<span></span>
</td>
<td class="num">$ (3,404)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Accumulated Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FiniteLivedIntangibleAssetsCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Currency Translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FiniteLivedIntangibleAssetsCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets net excluding goodwill before currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bvs_AcquiredInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bvs_AcquiredInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674719876376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business combinations and investments - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Mar. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 05, 2020</div></th>
<th class="th"><div>Jul. 15, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Jan. 22, 2020</div></th>
<th class="th"><div>Aug. 23, 2019</div></th>
<th class="th"><div>Jan. 30, 2018</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 24, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization, remainder of fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Acquisition integration costs and inventory related adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Variable interest entity, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of variable interest entity assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,674<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest', window );">Impairment of variable interest entity assets, attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_VariableInterestEntityImpairment', window );">Impairment of variable interest entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,737<span></span>
</td>
<td class="nump">$ 17,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.03%<span></span>
</td>
<td class="nump">10.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessAcquisitionPeriodOfNoticeForTermination', window );">Period after receipt of statistical report for which the company may terminate agreement</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement', window );">Payment due upon termination of agreement</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones', window );">Consideration transferred upon achievement of certain sales milestones</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration payable upon closing</a></td>
<td class="nump">$ 314,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Variable interest entity, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.03%<span></span>
</td>
<td class="nump">10.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,737<span></span>
</td>
<td class="nump">$ 17,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Net losses from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_VaporoxMember', window );">Vaporox</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned, balance, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_InvestmentOwnedOwnershipPercentage', window );">Investment owned, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment owned, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of business acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration payable upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc | Obtaining FDA Approval Of Certain Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc | Meeting Net Sales Targets Over A Three-Year Period, Payment One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc | Meeting Net Sales Targets Over A Three-Year Period, Payment Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc | For Obtaining CMS Coverage And Reimbursement For Certain Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealMember', window );">CartiHeal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of business acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment', window );">Period after FDA approval for which company may exercise option to purchase remaining equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased', window );">Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment', window );">Period after FDA approval for which company may exercise option to purchase remaining equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased', window );">Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealMember', window );">CartiHeal | Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares', window );">Additional shares to be purchased upon completion of study (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,089<span></span>
</td>
<td class="nump">338,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount', window );">Additional investment to be purchased upon completion of study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares', window );">Additional shares to be purchased upon completion of study (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,089<span></span>
</td>
<td class="nump">338,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount', window );">Additional investment to be purchased upon completion of study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage', window );">Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Intangible assets fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | Promissory Note | Harbor Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Debt conversion converted instrument warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | Harbor Medtech Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion converted instrument amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DebtInstrumentConvertibleConversionExercisablePrice', window );">Debt instrument convertible conversion exercisable price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">Aug. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount', window );">Refinanced with additional borrowings amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt instrument frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Promissory Note | Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Series C Preferred Stock | Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion converted instrument shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument convertible conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Medtech Inc | Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Variable interest entity, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_VariableInterestEntitySharesIssuedDuringPeriod', window );">Variable interest entity shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Variable interest entity, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_VariableInterestEntityIssuedCost', window );">Variable interest entity cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | CartiHeal Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment', window );">Period after FDA approval for which company may exercise option to purchase remaining equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased', window );">Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment aggregate cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentCapitalizedTransactionCosts', window );">Equity method investment capitalized transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Net losses from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment', window );">Period after FDA approval for which company may exercise option to purchase remaining equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased', window );">Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | CartiHeal Ltd | Option and Equity Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions', window );">Increase in equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | CartiHeal Ltd | Simple Agreement For Future Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Additional investment,cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | CartiHeal Ltd | Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares', window );">Additional shares to be purchased upon completion of study (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount', window );">Additional investment to be purchased upon completion of study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares', window );">Additional shares to be purchased upon completion of study (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount', window );">Additional investment to be purchased upon completion of study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | CartiHeal Ltd | Series G Preferred Stock | Option and Equity Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares', window );">Additional shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue', window );">Additional shares purchased Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | CartiHeal Ltd | Series F Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | CartiHeal Ltd | Series G1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset impairment charges, attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, payment due upon termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessAcquisitionPeriodOfNoticeForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, period of notice for termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessAcquisitionPeriodOfNoticeForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination, consideration transferred upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentConvertibleConversionExercisablePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible conversion exercisable price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentConvertibleConversionExercisablePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument refinanced with additional borrowings amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment additional investment purchased shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, additional investment to be purchased upon completion of study, amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, additional investment to be purchased upon completion of study, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment additional investment to be purchased value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityMethodInvestmentCapitalizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment capitalized transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityMethodInvestmentCapitalizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, period after FDA approval for investee to exercise option for remaining equity to be purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, period after FDA approval for investor to purchase remaining investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate,percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InvestmentOwnedOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment owned, ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InvestmentOwnedOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_VariableInterestEntityImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable interest entity, impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_VariableInterestEntityImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_VariableInterestEntityIssuedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable interest entity issued cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_VariableInterestEntityIssuedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_VariableInterestEntitySharesIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable interest entity shares issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_VariableInterestEntitySharesIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative number of shares issued or sold by the subsidiary or equity method investee on all stock transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_VaporoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_VaporoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_ObtainingFDAApprovalOfCertainProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_ObtainingFDAApprovalOfCertainProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_CartiHealMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_CartiHealMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bvs_HarborCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bvs_HarborCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bvs_HarborMedtechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bvs_HarborMedtechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bvs_HarborSeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bvs_HarborSeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_CartiHealLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_CartiHealLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AgreementAxis=bvs_OptionAndEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AgreementAxis=bvs_OptionAndEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AgreementForFutureEquityAxis=bvs_SimpleAgreementForFutureEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AgreementForFutureEquityAxis=bvs_SimpleAgreementForFutureEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bvs_SeriesFConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bvs_SeriesFConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bvs_SeriesG1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bvs_SeriesG1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803886696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business combinations and investments - Consideration transferred (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th"><div>Mar. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="nump">$ 314,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration at closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674801847448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business combinations and investments - Fair value of assets acquired and liabilities assumed (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2021 </div>
<div>USD ($) </div>
<div>Loans</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="nump">$ 314,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,800<span></span>
</td>
<td class="nump">$ 52,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BionessIncMember', window );">Bioness, Inc | Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DebtInstrumentNumberOfLoans', window );">Number of loans | Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BionessIncMember', window );">Bioness, Inc | Paycheck Protection Program, CARES Act, Maturing April 10, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BionessIncMember', window );">Bioness, Inc | Paycheck Protection Program, CARES Act, Maturing February 5, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash', window );">Cash. cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_HarborMedtechIncMember', window );">Harbor Medtech Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,696)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of Harbor's noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Cash, Cash Equivalents And Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentNumberOfLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Loans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentNumberOfLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_HarborMedtechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_HarborMedtechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674731338184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business combinations and investments - Components of intangible assets acquired (Details) - Bioness, Inc<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">$ 87,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">$ 43,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">$ 43,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805718824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business combinations and investments - Variable interest entity's assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 136,065<span></span>
</td>
<td class="nump">$ 86,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,960<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">257,848<span></span>
</td>
<td class="nump">191,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">17,669<span></span>
</td>
<td class="nump">14,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">646,636<span></span>
</td>
<td class="nump">494,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,964<span></span>
</td>
<td class="nump">3,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">48,410<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">24,171<span></span>
</td>
<td class="nump">21,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 427,272<span></span>
</td>
<td class="nump">350,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,839<span></span>
</td>
<td class="nump">$ 64,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,650<span></span>
</td>
<td class="nump">216,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,961<span></span>
</td>
<td class="nump">15,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,466<span></span>
</td>
<td class="nump">472,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">4,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
<td class="nump">3,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728<span></span>
</td>
<td class="nump">20,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,306<span></span>
</td>
<td class="nump">326,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary | Harbor Medtech Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary | Harbor Medtech Inc | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,635<span></span>
</td>
<td class="nump">6,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,863<span></span>
</td>
<td class="nump">7,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,029<span></span>
</td>
<td class="nump">$ 3,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bvs_HarborMedtechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bvs_HarborMedtechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674858314392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business combinations and investments - Pro forma results (Details) - Bioness, Inc - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net sales</a></td>
<td class="nump">$ 109,816<span></span>
</td>
<td class="nump">$ 65,955<span></span>
</td>
<td class="nump">$ 200,541<span></span>
</td>
<td class="nump">$ 157,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (6,841)<span></span>
</td>
<td class="num">$ (12,962)<span></span>
</td>
<td class="nump">$ 16,333<span></span>
</td>
<td class="num">$ (11,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Earnings per share of Class A common stock(1):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674733539352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Schedule Of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan due December 2024 (2.60% at July 3, 2021)</a></td>
<td class="nump">$ 182,500<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(959)<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">$ 166,084<span></span>
</td>
<td class="nump">$ 173,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674730645768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 06, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding borrowings on line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">custom sec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of Credit Facility, Expiration Period</a></td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AdditionalMarginPercentageToReferenceRates', window );">Additional margin percentage to reference Rates</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees', window );">Amortization of debt Instrument capitalized deferred fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 543<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FrontingFeePercentageOnUndrawnAmount', window );">Fronting fee percentage on undrawn amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Dec.  06,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, Weighted Average Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ThresholdMaximumAggregateAdditionalBorrowings', window );">Threshold maximum aggregate additional borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders', window );">Percentage of total outstanding Debt loaned by lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_InterestCoverageRatio', window );">Interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, lending margin, interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, lending margin, interest rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member] | BR Interest Rate Basis [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding borrowings on line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility maximum borrowing capacity</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of Credit Facility, Expiration Period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument capitalized deferred fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member] | Revolving Credit Facility [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility maximum borrowing capacity</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member] | Revolving Credit Facility [Member] | Swing Line Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding borrowings on line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of Credit Facility, Description</a></td>
<td class="text">outstanding for at least five days. Swingline loans are due the fifteenth or last day of a calendar month or Maturity whichever is earlier<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand Nineteen Credit Agreement [Member] | Revolving Credit Facility [Member] | Swing Line Credit Facility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of Credit Facility, Expiration Period</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Prior Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing', window );">Debt financing costs charged to selling general adminstrative expense on refinancing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest Costs Capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Term Loan [Member] | Two Thousand Nineteen Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="nump">$ 666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">custom sec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, lending margin, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity', window );">Debt Instrument Final Principal Payment At Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument capitalized deferred fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Term Loan [Member] | Two Thousand Nineteen Credit Agreement [Member] | BR Interest Rate Basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DebtInstrumentFloorRatePercentage', window );">Debt instrument floor rate percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of interest rate swap agreements | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 933<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
<td class="nump">$ 2,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives', window );">Percentage of debt hedged by derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, locked in interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives', window );">Percentage of debt hedged by derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, locked in interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DerivativeStatedFixedInterestRate', window );">Derivative Stated Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DerivativeEffectiveInterestRate', window );">Derivative Effective Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AdditionalMarginPercentageToReferenceRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional margin percentage to reference rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AdditionalMarginPercentageToReferenceRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of debt Instrument capitalized deferred fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt financing costs charged to selling general adminstrative expense on refinancing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument final principal payment at maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentFloorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument floor rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentFloorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DerivativeEffectiveInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative effective interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DerivativeEffectiveInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DerivativeStatedFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative stated fixed nterest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DerivativeStatedFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FrontingFeePercentageOnUndrawnAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fronting fee percentage on undrawn amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FrontingFeePercentageOnUndrawnAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest coverage ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PercentageOfTotalOutstandingDebtLoanedByLenders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of total outstanding debt loaned by lenders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PercentageOfTotalOutstandingDebtLoanedByLenders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ThresholdMaximumAggregateAdditionalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold maximum aggregate additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ThresholdMaximumAggregateAdditionalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of an entity's outstanding debt that is designated as a hedged item in cash flow, fair value, or net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CreditAgreementAxis=bvs_TwoThousandNineteenCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CreditAgreementAxis=bvs_TwoThousandNineteenCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InterestRateBasisAxis=bvs_BrInterestRateBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InterestRateBasisAxis=bvs_BrInterestRateBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_RevolvingCreditFacilitySubAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_RevolvingCreditFacilitySubAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_RevolvingCreditFacilitySubAxis=bvs_SwingLineCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_RevolvingCreditFacilitySubAxis=bvs_SwingLineCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CreditAgreementAxis=bvs_PriorCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CreditAgreementAxis=bvs_PriorCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805773016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Liabilities measured at fair value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">$ 13,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Long-term contingent consideration, less current portion</a></td>
<td class="nump">30,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">13,220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Long-term contingent consideration, less current portion</a></td>
<td class="nump">30,421<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure', window );">Management incentive plan and liability-classified awardsManagement incentive plan and liability-classified awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightFairValueDisclsoure', window );">Equity Participation Right</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">43,933<span></span>
</td>
<td class="nump">48,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure', window );">Management incentive plan and liability-classified awardsManagement incentive plan and liability-classified awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightFairValueDisclsoure', window );">Equity Participation Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Long-term contingent consideration, less current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure', window );">Management incentive plan and liability-classified awardsManagement incentive plan and liability-classified awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightFairValueDisclsoure', window );">Equity Participation Right</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2 | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure', window );">Management incentive plan and liability-classified awardsManagement incentive plan and liability-classified awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightFairValueDisclsoure', window );">Equity Participation Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">13,220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Long-term contingent consideration, less current portion</a></td>
<td class="nump">30,421<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure', window );">Management incentive plan and liability-classified awardsManagement incentive plan and liability-classified awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightFairValueDisclsoure', window );">Equity Participation Right</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 43,641<span></span>
</td>
<td class="nump">46,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3 | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure', window );">Management incentive plan and liability-classified awardsManagement incentive plan and liability-classified awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,303<span></span>
</td>
<td class="nump">40,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightFairValueDisclsoure', window );">Equity Participation Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
<td class="nump">5,457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,404<span></span>
</td>
<td class="nump">$ 46,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityParticipationRightFairValueDisclsoure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Participation Right, Fair Value Disclsoure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityParticipationRightFairValueDisclsoure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Management Incentive Plan And Liability-Classified Awards, Fair Value Disclsoure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803219080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Acquisition unobservable level 3 inputs (Details) - Fair Value, Inputs, Level 3 - Valuation Technique, Discounted Cash Flow - Measurement Input, Discount Rate<br></strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Payment discount rate</a></td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Payment discount rate</a></td>
<td class="nump">6.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674799275576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Additional information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2021 </div>
<div>USD ($) </div>
<div>Plan</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Business </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Business </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Business </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 15, 2021</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NumberOfEquityBasedCompensationPlans', window );">Number of equity-based compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightEntitledPercentageOfDistributions', window );">EPR unit, entitled percentage of distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,875<span></span>
</td>
<td class="nump">$ 10,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NumberOfEquityBasedCompensationPlans', window );">Number of equity-based compensation plans | Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NumberOfEquityBasedCompensationPlans', window );">Number of equity-based compensation plans | Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightEntitledPercentageOfDistributions', window );">EPR unit, entitled percentage of distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,054<span></span>
</td>
<td class="nump">$ 15,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember', window );">Equity Participation Right Unit [Member] | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAvailableForDistributions', window );">Equity participation right estimated accrued preferred distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember', window );">Management Incentive Plan And Liability-Classified Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember', window );">Management Incentive Plan And Liability-Classified Awards | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of equity instruments other than options outstanding, including both vested and non-vested instruments | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="nump">333,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Accrued equity-based compensation, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember', window );">Management Incentive Plan And Liability-Classified Awards | Bio Ventus LLC [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_EquityParticipationRightUnitMember', window );">Equity Participation Right Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="nump">$ 3,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_EquityParticipationRightUnitMember', window );">Equity Participation Right Unit [Member] | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightEntitledPercentageOfDistributions', window );">EPR unit, entitled percentage of distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_EquityParticipationRightUnitMember', window );">Equity Participation Right Unit [Member] | Bio Ventus LLC [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bvs_BVLLCEmployeesTerminatedPriorToIPOMember', window );">BV LLC Employees Terminated Prior To IPO | Management Incentive Plan And Liability-Classified Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bvs_BVLLCEmployeesActiveAtIPOMember', window );">BV LLC Employees Active At IPO | Management Incentive Plan And Liability-Classified Awards | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityParticipationRightEntitledPercentageOfDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Participation Right, Entitled Percentage Of Distributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityParticipationRightEntitledPercentageOfDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NumberOfEquityBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Equity-Based Compensation Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NumberOfEquityBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAvailableForDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAvailableForDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the liabilities, classified as other, for deferred compensation arrangements payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bvs_EquityParticipationRightUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bvs_EquityParticipationRightUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bvs_BVLLCEmployeesTerminatedPriorToIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bvs_BVLLCEmployeesTerminatedPriorToIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bvs_BVLLCEmployeesActiveAtIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bvs_BVLLCEmployeesActiveAtIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674806224936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - MIP and liability-classified awards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 25,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember', window );">Management Incentive Plan And Liability-Classified Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">40,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(25,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial estimate (vesting)</a></td>
<td class="nump">829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment</a></td>
<td class="num">(11,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity', window );">Phantom plan conversion to Class A common stock</a></td>
<td class="num">(4,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 40,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember', window );">Management Incentive Plan And Liability-Classified Awards | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 40,303<span></span>
</td>
<td class="nump">40,802<span></span>
</td>
<td class="nump">$ 33,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,641<span></span>
</td>
<td class="nump">6,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial estimate (vesting)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,734<span></span>
</td>
<td class="nump">5,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures', window );">Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,298)<span></span>
</td>
<td class="num">(1,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,576)<span></span>
</td>
<td class="num">(3,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,303<span></span>
</td>
<td class="nump">$ 40,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Conversion To Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Forfeitures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674731392296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Equity participation right unit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 25,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember', window );">Equity Participation Right Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">6,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(2,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment</a></td>
<td class="num">(3,327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 6,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember', window );">Equity Participation Right Unit | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 6,101<span></span>
</td>
<td class="nump">5,457<span></span>
</td>
<td class="nump">$ 4,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,101<span></span>
</td>
<td class="nump">$ 5,457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674851882776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Summary of range of key assumptions used within the valuation of the awards (Detail) - Equity Participation Right Unit [Member] - Valuation Technique, Option Pricing Model [Member] - Bio Ventus LLC [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Business</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Measurement Input, Discount for Lack of Marketability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitEquityValue', window );">Equity Participation Rights Unit Equity Value | $</a></td>
<td class="nump">$ 1,240,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input Equity Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">101.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitEquityValue', window );">Equity Participation Rights Unit Equity Value | $</a></td>
<td class="nump">$ 1,065,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input Equity Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">35.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitEquityValue', window );">Equity Participation Rights Unit Equity Value | $</a></td>
<td class="nump">$ 1,145,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member] | Measurement Input Equity Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightsUnitMeasurableInput', window );">Equity Participation Rights Unit Measurable Input</a></td>
<td class="nump">7.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityParticipationRightsUnitEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Participation Rights Unit Equity Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityParticipationRightsUnitEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityParticipationRightsUnitMeasurableInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Participation Rights Unit Measurable Input.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityParticipationRightsUnitMeasurableInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bvs_EquityParticipationRightUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bvs_MeasurementInputEquityVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bvs_MeasurementInputEquityVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674806915496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 10, 2021 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Business </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 03, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Business </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Business </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NumberOfEquityBasedCompensationPlans', window );">Number of equity-based compensation plans</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares) | shares</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of awards forfeited (in shares) | shares</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available to be awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,257<span></span>
</td>
<td class="nump">518,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unamortized compensation expense, RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,976<span></span>
</td>
<td class="nump">$ 9,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized compensation expense, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,797<span></span>
</td>
<td class="nump">$ 15,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of options vested (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense net yet amortized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,095<span></span>
</td>
<td class="nump">$ 16,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unamortized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,976<span></span>
</td>
<td class="nump">$ 9,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Compensation expense net yet amortized, period for recognition | shares</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAwardMember', window );">Management Incentive Plan Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Compensation expense net yet amortized, period for recognition | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Phantom Share Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="nump">$ 829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy', window );">Decrease in fair value due to the impact of COVID-19 on the market and economy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="nump">$ 829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Phantom Share Units (PSUs) | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of awards forfeited (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Equity instruments other than options granted during period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943<span></span>
</td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted&#160;average grant-date&#160;fair&#160;value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Compensation expense net yet amortized, period for recognition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.90<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee', window );">Percentage of employee compensation deducted to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee', window );">Percentage of employee compensation deducted to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember', window );">Management Incentive Plan And Liability-Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bvs_A2021PlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock closing price, (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.51<span></span>
</td>
<td class="nump">$ 16.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to be awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,592,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,592,476<span></span>
</td>
<td class="nump">7,592,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available to be awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,024,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,024,123<span></span>
</td>
<td class="nump">2,024,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease', window );">Annual percentage increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NumberOfEquityBasedCompensationPlans', window );">Number of equity-based compensation plans | Plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,103<span></span>
</td>
<td class="nump">$ 10,844<span></span>
</td>
<td class="nump">$ 14,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unamortized compensation expense, RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,103<span></span>
</td>
<td class="nump">$ 10,844<span></span>
</td>
<td class="nump">14,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unamortized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Compensation expense net yet amortized, period for recognition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan maximum annual contributions per employee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan employer matching contribution, percent of match</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Defined contribution plan employers matching contribution annual vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,379<span></span>
</td>
<td class="nump">$ 5,401<span></span>
</td>
<td class="nump">$ 5,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Management Incentive Plan And Liability-Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Equity instruments other than options granted during period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of equity instruments other than options outstanding, including both vested and non-vested instruments | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,078<span></span>
</td>
<td class="nump">333,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted&#160;average grant-date&#160;fair&#160;value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Other Phantom Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, COVID-19 Impact On Economy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NumberOfEquityBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Equity-Based Compensation Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NumberOfEquityBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Compensation Deducted During Offering Period, Percentage Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized, Annual Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bvs_A2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bvs_A2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bvs_OtherPhantomUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bvs_OtherPhantomUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674846130984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Restricted stock unit activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Apr. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled (in shares)</a></td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.90<span></span>
</td>
<td class="nump">14.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674800340520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Fair value assumptions (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 03, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.19%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">33.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">33.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of stock options</a></td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted (in dollars per share)</a></td>
<td class="nump">$ 4.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of stock options</a></td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted (in dollars per share)</a></td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674828102936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Apr. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,625<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 13.03<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">14.90<span></span>
</td>
<td class="nump">13.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 13.03<span></span>
</td>
<td class="nump">$ 13.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual term</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674802889304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="5">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th" colspan="2"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (10,780)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,980)<span></span>
</td>
<td class="num">$ (12,229)<span></span>
</td>
<td class="nump">$ 13,748<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 13,748<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="nump">6,654<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">214<span></span>
</td>
<td class="nump">7,062<span></span>
</td>
<td class="nump">7,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Bioventus Inc.</a></td>
<td class="num">$ (4,126)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,766)<span></span>
</td>
<td class="num">$ (5,167)<span></span>
</td>
<td class="nump">$ 20,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of Class A common stock outstanding - basic (in shares)</a></td>
<td class="nump">41,805,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,802,840<span></span>
</td>
<td class="nump">41,802,840<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of Class A common stock outstanding - diluted (in shares)</a></td>
<td class="nump">41,805,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,802,840<span></span>
</td>
<td class="nump">41,802,840<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of Class A common stock, basic (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of Class A common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Per share information for the six months ended July 3, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through July 3, 2021, the period following Bioventus Inc.&#8217;s initial public offering and related transactions described in Note 1. Organization and Note 7. Earnings per share within the Notes to the Unaudited Condensed Consolidated Financial Statements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798723912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">21,663,037<span></span>
</td>
<td class="nump">21,365,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_LimitedLiabilityCompanyInterestsMember', window );">LLC Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">15,786,737<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">4,622,287<span></span>
</td>
<td class="nump">4,602,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">1,221,555<span></span>
</td>
<td class="nump">941,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_UnvestedClassACommonSharesMember', window );">Unvested shares of Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">32,458<span></span>
</td>
<td class="nump">34,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_LimitedLiabilityCompanyInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_LimitedLiabilityCompanyInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_UnvestedClassACommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_UnvestedClassACommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674811248088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary of Net Income From Continuing Operations Before Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_TaxableSubsidiariesAbstract', window );"><strong>Taxable subsidiaries:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="num">$ (9,066)<span></span>
</td>
<td class="num">$ (6,090)<span></span>
</td>
<td class="num">$ (6,090)<span></span>
</td>
<td class="nump">$ 15,389<span></span>
</td>
<td class="nump">$ 15,389<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_TaxableSubsidiariesAbstract', window );"><strong>Taxable subsidiaries:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 2,679<span></span>
</td>
<td class="nump">$ 2,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
<td class="num">(1,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign', window );">Income From Continuing Operations Before Income Taxes Domestic And Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="nump">5,646<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries', window );">Other domestic subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,221<span></span>
</td>
<td class="nump">4,043<span></span>
</td>
<td class="nump">4,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,914<span></span>
</td>
<td class="nump">$ 9,689<span></span>
</td>
<td class="nump">$ 6,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income from continuing operations before income taxes domestic and foreign.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income From Continuing Operations Before Income Taxes Domestic And Foreign Other Domestic Subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_TaxableSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Taxable subsidiaries [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_TaxableSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804578520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary Of Components Of Income Tax Expense Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="num">$ (71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
<td class="nump">$ 891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(508)<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Foreign income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Change in tax rates - deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,192<span></span>
</td>
<td class="nump">$ 1,576<span></span>
</td>
<td class="nump">$ 1,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674731777128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">18.90%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory federal corporate income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage', window );">LLC flow-through structure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.10%)<span></span>
</td>
<td class="num">(8.80%)<span></span>
</td>
<td class="num">(15.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage', window );">Provision to return adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation llc flow through structure percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation provision to return adjustment percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804210408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards and other</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,874<span></span>
</td>
<td class="nump">$ 3,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,570<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,993)<span></span>
</td>
<td class="num">(2,423)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DeferredTaxLiabilitiesAcquiredIntangibles', window );">Acquired intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,939<span></span>
</td>
<td class="nump">5,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,362<span></span>
</td>
<td class="nump">$ 3,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DeferredTaxLiabilitiesAcquiredIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities acquired intangibles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DeferredTaxLiabilitiesAcquiredIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674845889496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">18.90%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Deferred tax assets, tax credits</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Deferred tax liabilities, difference between the book value and tax basis of investment</a></td>
<td class="nump">$ 48,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance on deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,993<span></span>
</td>
<td class="nump">$ 2,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Deferred tax assets, tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Tax Year 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Tax Year 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Federal And State [Member] | Year Two Thousand Twenty One To Year Two Thousand And Thirty Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Federal And State [Member] | Indefinitely [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance on deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Harbor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance on deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=bvs_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=bvs_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bvs_IndefinitelyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bvs_IndefinitelyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bvs_HarborMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bvs_HarborMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803075176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party transactions - Narrative (Detail) - Bio Ventus LLC [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CashDistributionMadeToMembersTowardsTax', window );">Cash distributions made to members towards tax</a></td>
<td class="nump">$ 19,886<span></span>
</td>
<td class="nump">$ 9,137<span></span>
</td>
<td class="nump">$ 7,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome', window );">Cash distributions as a percentage of members total taxable income</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers', window );">Related party transaction tax distributions payable to tax authorities on behalf members</a></td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CashDistributionMadeToMembersTowardsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash distribution made to members towards tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CashDistributionMadeToMembersTowardsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>cash distributions as a percentage of members total taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction tax distributions payable to tax authorities on behalf members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674731993528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 912<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,124<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
<td class="nump">$ 1,943<span></span>
</td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,610<span></span>
</td>
<td class="nump">$ 2,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,998<span></span>
</td>
<td class="nump">$ 2,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803178952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,696<span></span>
</td>
<td class="nump">$ 1,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,567<span></span>
</td>
<td class="nump">$ 2,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="nump">$ 5,016<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805386920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 17,669<span></span>
</td>
<td class="nump">$ 14,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities- current</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities- noncurrent</a></td>
<td class="nump">15,989<span></span>
</td>
<td class="nump">14,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 18,907<span></span>
</td>
<td class="nump">$ 16,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,961<span></span>
</td>
<td class="nump">$ 15,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities- current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities- noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,108<span></span>
</td>
<td class="nump">14,513<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,068<span></span>
</td>
<td class="nump">$ 16,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674845800920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies - Summary of Lessee Liability Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 18,907<span></span>
</td>
<td class="nump">$ 16,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,068<span></span>
</td>
<td class="nump">$ 16,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674719830344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2021</div></th>
<th class="th"><div>Dec. 22, 2020</div></th>
<th class="th"><div>Aug. 23, 2019</div></th>
<th class="th"><div>Feb. 09, 2016</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_StopLossInsuranceThresholdPerMemberPerYear', window );">Stop loss insurance, threshold per member per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_RefundOfExcessPaymentsToThirdPartyCustomers', window );">Refund of excess payments to third party customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,519<span></span>
</td>
<td class="nump">$ 7,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_StopLossInsuranceThresholdPerMemberPerYear', window );">Stop loss insurance, threshold per member per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProductLiabilityNet', window );">Loss contingency accrual product liability net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">6,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bvs_UsaoAndOigMember', window );">USAO And OIG [Member] | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss contingency accruals payments made during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bvs_UsaoAndOigMember', window );">USAO And OIG [Member] | Subsequent Event [Member] | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss contingency accruals payments made during the year</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=bvs_ThreeInjectionOAProductMember', window );">Three Injection OA Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SupplyCommitmentTerm', window );">Supply commitment, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SupplyCommitmentRenewalTerm', window );">Supply commitment, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=bvs_ThreeInjectionOAProductMember', window );">Three Injection OA Product | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SupplyCommitmentTerm', window );">Supply commitment, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SupplyCommitmentRenewalTerm', window );">Supply commitment, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CollaborativeArrangementTerm', window );">Collaborative agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_HarborMember', window );">Harbor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CollaborativeArrangementRoyaltyPercentage', window );">Collaborative agreement, royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CollaborativeArrangementTerm', window );">Collaborative agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_HarborMember', window );">Harbor | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CollaborativeArrangementRoyaltyPercentage', window );">Collaborative agreement, royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MilestonePaymentPayable', window );">Milestone payment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_SupplierOfSingleInjectionOAProductMember', window );">Supplier of Single Injection OA Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,548<span></span>
</td>
<td class="nump">$ 1,767<span></span>
</td>
<td class="nump">$ 5,925<span></span>
</td>
<td class="nump">$ 3,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bvs_SupplierOfSingleInjectionOAProductMember', window );">Supplier of Single Injection OA Product | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,021<span></span>
</td>
<td class="nump">$ 7,622<span></span>
</td>
<td class="nump">$ 3,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember', window );">Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimated probable loss related to product recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Recorded reserves for product recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember', window );">Damages from Product Defects | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimated probable loss related to product recall</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_RefundOfExcessPaymentsToThirdPartyCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refund of excess payments to third party customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_RefundOfExcessPaymentsToThirdPartyCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_StopLossInsuranceThresholdPerMemberPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stop Loss Insurance, Threshold Per Member Per Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_StopLossInsuranceThresholdPerMemberPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SupplyCommitmentRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SupplyCommitmentRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SupplyCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply Commitment, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SupplyCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProductLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of the estimated aggregate accrual for damages arising from third-party use of the entity's product(s) or process(es) as of the balance sheet date (if the accrual qualifies for discounting).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProductLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bvs_UsaoAndOigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bvs_UsaoAndOigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=bvs_ThreeInjectionOAProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=bvs_ThreeInjectionOAProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bvs_HarborMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bvs_HarborMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bvs_SupplierOfSingleInjectionOAProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bvs_SupplierOfSingleInjectionOAProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674846211864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per unit - Summary of Earnings Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest</a></td>
<td class="nump">$ 6,654<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 7,062<span></span>
</td>
<td class="nump">$ 7,062<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,722<span></span>
</td>
<td class="nump">$ 8,113<span></span>
</td>
<td class="nump">$ 4,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to Bioventus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,411<span></span>
</td>
<td class="nump">8,666<span></span>
</td>
<td class="nump">4,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations attributable to unit holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,411<span></span>
</td>
<td class="nump">8,666<span></span>
</td>
<td class="nump">4,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Accumulated and unpaid preferred distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,133)<span></span>
</td>
<td class="num">(5,955)<span></span>
</td>
<td class="num">(5,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,895)<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NetIncomeLossFromContinuingOperations', window );">Net income (loss) from continuing operations attributable to common unit holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">16,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common unit holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,383<span></span>
</td>
<td class="num">$ (659)<span></span>
</td>
<td class="num">$ (17,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per unit attributable to common unit holders - basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net income (loss) from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare', window );">Loss from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="nump">3.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net income (loss) attributable to common unit holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common units outstanding, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NetIncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income loss from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NetIncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674802938120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per unit - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">21,663,037<span></span>
</td>
<td class="nump">21,365,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,590<span></span>
</td>
<td class="nump">6,590<span></span>
</td>
<td class="nump">6,590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_PreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bvs_PreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805156104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">$ 109,816<span></span>
</td>
<td class="nump">$ 58,017<span></span>
</td>
<td class="nump">$ 58,017<span></span>
</td>
<td class="nump">$ 191,594<span></span>
</td>
<td class="nump">$ 191,594<span></span>
</td>
<td class="nump">$ 136,662<span></span>
</td>
<td class="nump">$ 136,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bvs_PainTreatmentsAndJointPreservationMember', window );">Pain Treatments and Joint Preservation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">56,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bvs_RestorativeTherapiesMember', window );">Restorative Therapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">32,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bvs_BoneGraftSubstitutesMember', window );">Bone Graft Substitutes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">20,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">98,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">$ 11,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_PainTreatmentsAndJointPreservationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_PainTreatmentsAndJointPreservationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_RestorativeTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_RestorativeTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_BoneGraftSubstitutesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_BoneGraftSubstitutesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674811257752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">$ (1,852)<span></span>
</td>
<td class="num">$ (1,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income</a></td>
<td class="num">(1,681)<span></span>
</td>
<td class="num">(2,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="num">(5,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition and integration costs</a></td>
<td class="num">(1,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss in unconsolidated investments</a></td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(641)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(641)<span></span>
</td>
<td class="num">(641)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairments related to variable interest entity</a></td>
<td class="num">(5,674)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="num">(9,066)<span></span>
</td>
<td class="num">$ (6,090)<span></span>
</td>
<td class="num">$ (6,090)<span></span>
</td>
<td class="nump">$ 15,389<span></span>
</td>
<td class="nump">15,389<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
<td class="nump">4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,439)<span></span>
</td>
<td class="num">$ (7,908)<span></span>
</td>
<td class="num">$ (8,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,751)<span></span>
</td>
<td class="num">(21,579)<span></span>
</td>
<td class="num">(19,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,103)<span></span>
</td>
<td class="num">(10,844)<span></span>
</td>
<td class="num">(14,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(563)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(1,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,914<span></span>
</td>
<td class="nump">9,689<span></span>
</td>
<td class="nump">6,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(7,479)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income</a></td>
<td class="num">(1,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="num">(5,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemNetGainLoss', window );">COVID-19 benefits, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SuccessionAndTransitionCharges', window );">Succession and transition charges</a></td>
<td class="num">(187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency impact</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition and integration costs</a></td>
<td class="num">(1,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_InventoryStepUpCost', window );">Inventory step-up costs</a></td>
<td class="num">(2,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss in unconsolidated investments</a></td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairments related to variable interest entity</a></td>
<td class="num">(7,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonrecurringExpense', window );">Other non-recurring costs</a></td>
<td class="num">(1,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,643)<span></span>
</td>
<td class="num">(30,316)<span></span>
</td>
<td class="num">(29,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,751)<span></span>
</td>
<td class="num">(21,579)<span></span>
</td>
<td class="num">(19,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,103)<span></span>
</td>
<td class="num">(10,844)<span></span>
</td>
<td class="num">(14,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemNetGainLoss', window );">COVID-19 benefits, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SuccessionAndTransitionCharges', window );">Succession and transition charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(563)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(1,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity loss in unconsolidated investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonrecurringExpense', window );">Other non-recurring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,633)<span></span>
</td>
<td class="num">(6,177)<span></span>
</td>
<td class="num">(1,723)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember', window );">U.S | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems', window );">Segment adjusted EBITDA</a></td>
<td class="nump">17,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember', window );">U.S | Operating Segments | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems', window );">Segment adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,252<span></span>
</td>
<td class="nump">71,673<span></span>
</td>
<td class="nump">67,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember', window );">International Segment | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems', window );">Segment adjusted EBITDA</a></td>
<td class="nump">$ 2,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember', window );">International Segment | Operating Segments | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems', window );">Segment adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,191<span></span>
</td>
<td class="nump">$ 7,515<span></span>
</td>
<td class="nump">$ 4,691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted earnings before interest, taxes, depreciation, amortization and other non-operating items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InventoryStepUpCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Step-Up Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InventoryStepUpCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SuccessionAndTransitionCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Succession And Transition Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SuccessionAndTransitionCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=114868883&amp;loc=SL114871943-224233<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemNetGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (gain) loss for an event or transaction that is unusual in nature or occurs infrequently, or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125520798&amp;loc=SL114871939-224231<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=114868883&amp;loc=SL114871943-224233<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemNetGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bvs_USSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bvs_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674720398056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 29, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>Business </div>
<div>Entities </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2021 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>Business </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 03, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>Vote </div>
<div>Business </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2021 </div>
<div>Business </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Share-based Payment Arrangement, Cash Used to Settle Award | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NumberOfEquityBasedCompensationPlans', window );">Number of equity-based compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.90<span></span>
</td>
<td class="nump">$ 13.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld', window );">Limited Liability Company LLC Or Limited Partnership LP Managing Member Or General Partner Number Of Interests Held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee', window );">Percentage of employee compensation deducted to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee', window );">Percentage of employee compensation deducted to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to be awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,592,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,592,476<span></span>
</td>
<td class="nump">7,592,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease', window );">Annual percentage increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CommonStockNumberOfVotes', window );">Number of votes per common share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio', window );">Shares issued or issuable, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CancellationRatioRequiredStockToLLCInterestRatio', window );">Cancellation ratio, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of shares cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany', window );">Proceeds from the issuance of common units of limited liability company | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NumberOfEquityBasedCompensationPlans', window );">Number of equity-based compensation plans | Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC | USAO And OIG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss contingency accruals payments made during the year | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember', window );">Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember', window );">BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of entities acquired | Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember', window );">BV LLC | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of shares issued in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Misonix, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 518,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.6284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash', window );">Business acquisition, consideration transferred per share, cash (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares', window );">Business acquisition, consideration transferred per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum', window );">Business acquisition, consideration transferred per share, maximum amount payable (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedPaymentAwardSettlementPeriod', window );">Share based payment award, Settlement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Share-based Payment Arrangement, Cash Used to Settle Award | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_NumberOfEquityBasedCompensationPlans', window );">Number of equity-based compensation plans | Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to be awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,592,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease', window );">Annual percentage increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,561,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum | Option and Equity Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum | Restricted Stock Units Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Minimum | Option and Equity Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Minimum | Restricted Stock Units Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee', window );">Percentage of employee compensation deducted to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CommonStockNumberOfVotes', window );">Number of votes per common share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Class A | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized to be awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease', window );">Annual percentage increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Class A | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,670,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CommonStockNumberOfVotes', window );">Number of votes per common share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio', window );">Shares issued or issuable, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CancellationRatioRequiredStockToLLCInterestRatio', window );">Cancellation ratio, required stock to LLC interest ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Number of shares cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest', window );">Managing member, ownership interest</a></td>
<td class="nump">72.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bio Ventus LLC | Continuing LLC Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Limited liability owenrship pinterest held by members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bio Ventus LLC | USAO And OIG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss contingency accruals payments made during the year | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bio Ventus LLC | Continuing LLC Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock shares subscribed but not issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers', window );">Limited liability company number of interests held by persons other than managing member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,786,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bio Ventus LLC | New LLC Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany', window );">Proceeds from the issuance of common units of limited liability company | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod', window );">Common units of limited liability company issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld', window );">Limited Liability Company LLC Or Limited Partnership LP Managing Member Or General Partner Number Of Interests Held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,038,589<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bio Ventus LLC | New LLC Owner | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock shares issued during the period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bio Ventus LLC | Restated Limited Liability Company Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany', window );">Common and preferred units converted into interests in limited liability company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,625,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bio Ventus LLC | Convertible Debt Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payment to acquire debt investments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | BV LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of entities acquired | Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld', window );">Limited Liability Company LLC Or Limited Partnership LP Managing Member Or General Partner Number Of Interests Held</a></td>
<td class="nump">41,038,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | BV LLC | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of shares issued in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,838,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | PPP Loan | Bioness, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Unsecured PPP loan forgiven | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,003,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2019 Credit Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DebtInstrumentCovenantRequiredPrepayment', window );">Debt instrument, required prepayment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessAcquisitionConsiderationTransferredPerShareCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, consideration transferred per share, cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessAcquisitionConsiderationTransferredPerShareCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, consideration transferred per share, maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_BusinessAcquisitionConsiderationTransferredPerShareShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, consideration transferred per share, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_BusinessAcquisitionConsiderationTransferredPerShareShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CancellationRatioRequiredStockToLLCInterestRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation ratio, required stock to LLC interest ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CancellationRatioRequiredStockToLLCInterestRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common and preferrred units converted into interests in limited liability company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CommonStockNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, number of votes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CommonStockNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common units of limited liability company issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentCovenantRequiredPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, covenant, required prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentCovenantRequiredPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Limited liability company LLC or limited partnership LP managing member or general partner number of interests held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Limited liability company number of interests held by persons other than managing member.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_NumberOfEquityBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Equity-Based Compensation Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_NumberOfEquityBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the issuance of common units of limited liability company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Compensation Deducted During Offering Period, Percentage Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized, Annual Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedPaymentAwardSettlementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based payment award settlement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedPaymentAwardSettlementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued or issuable, required stock to LLC interest ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bvs_A2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bvs_A2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bvs_UsaoAndOigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bvs_UsaoAndOigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_BVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bvs_MisonixIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bvs_MisonixIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AgreementAxis=bvs_OptionAndEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AgreementAxis=bvs_OptionAndEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_AgreementAxis=bvs_RestrictedStockUnitsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_AgreementAxis=bvs_RestrictedStockUnitsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InvestorAxis=bvs_ContinuingLlcOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InvestorAxis=bvs_ContinuingLlcOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_InvestorAxis=bvs_NewLlcOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_InvestorAxis=bvs_NewLlcOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EventAxis=bvs_RestatedLimitedLiabilityCompanyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EventAxis=bvs_RestatedLimitedLiabilityCompanyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bvs_ConvertibleDebtInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bvs_ConvertibleDebtInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bvs_A2019CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bvs_A2019CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798289480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholder's Equity - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, Shares outstanding</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798303032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss) (Details) - Bio Ventus LLC - BMP Research And Development Programme - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 1,773<span></span>
</td>
<td class="nump">$ 7,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on disposal</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">9,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">$ 1,815<span></span>
</td>
<td class="nump">$ 16,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group discontinued operation income tax expense benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group discontinued operation research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_BmpResearchAndDevelopmentProgrammeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_BmpResearchAndDevelopmentProgrammeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803508696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Details) - Bio Ventus LLC - BMP Research And Development Programme<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal group, including discontinued operation, consideration</a></td>
<td class="nump">$ 172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities', window );">Disposal group discontinued operations payment of accrued liabilities</a></td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group discontinued operations payment of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_BmpResearchAndDevelopmentProgrammeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bvs_BmpResearchAndDevelopmentProgrammeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804444536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Sales (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Jun. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">$ 109,816<span></span>
</td>
<td class="nump">$ 58,017<span></span>
</td>
<td class="nump">$ 58,017<span></span>
</td>
<td class="nump">$ 191,594<span></span>
</td>
<td class="nump">$ 191,594<span></span>
</td>
<td class="nump">$ 136,662<span></span>
</td>
<td class="nump">$ 136,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bvs_BoneGraftSubstitutesMember', window );">Bone graft substitutes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="nump">$ 20,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,161<span></span>
</td>
<td class="nump">$ 340,141<span></span>
</td>
<td class="nump">$ 319,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | OA joint pain treatment and joint preservation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,178<span></span>
</td>
<td class="nump">182,082<span></span>
</td>
<td class="nump">155,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Minimally invasive fracture treatment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,624<span></span>
</td>
<td class="nump">103,504<span></span>
</td>
<td class="nump">121,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Bone graft substitutes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,359<span></span>
</td>
<td class="nump">54,555<span></span>
</td>
<td class="nump">42,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,697<span></span>
</td>
<td class="nump">305,072<span></span>
</td>
<td class="nump">282,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,464<span></span>
</td>
<td class="nump">$ 35,069<span></span>
</td>
<td class="nump">$ 36,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_BoneGraftSubstitutesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_BoneGraftSubstitutesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_OAJointPainTreatmentAndJointPreservationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_OAJointPainTreatmentAndJointPreservationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bvs_MinimallyInvasiveFractureTreatmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bvs_MinimallyInvasiveFractureTreatmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bvs_USSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bvs_USSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bvs_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bvs_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674731970520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of useful lives in assets (Detail) - Bio Ventus LLC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674802070696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Finite-lived intangible assets (Detail) - Weighted Average [Member] - Bio Ventus LLC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">17 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803858680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of significant percentage of total sales (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierAMember', window );">Supplier A [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">$ 2,983<span></span>
</td>
<td class="nump">$ 3,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierAMember', window );">Supplier A [Member] | Supplier Concentration Risk [Member] | Revenue Benchmark [Member] | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierBMember', window );">Supplier B [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierBMember', window );">Supplier B [Member] | Supplier Concentration Risk [Member] | Revenue Benchmark [Member] | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierCMember', window );">Supplier C [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierCMember', window );">Supplier C [Member] | Supplier Concentration Risk [Member] | Revenue Benchmark [Member] | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductAMember', window );">Product A [Member] | Product Concentration Risk [Member] | Revenue Benchmark [Member] | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductBMember', window );">Product B [Member] | Product Concentration Risk [Member] | Revenue Benchmark [Member] | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductCMember', window );">Product C [Member] | Product Concentration Risk [Member] | Revenue Benchmark [Member] | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductDMember', window );">Product D [Member] | Product Concentration Risk [Member] | Revenue Benchmark [Member] | Bio Ventus LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ConcentrationRiskBySupplierNameAxis=bvs_SupplierCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ConcentrationRiskBySupplierNameAxis=bvs_ProductDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674846145656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Detail) - Bio Ventus LLC - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign Currency Transaction Gain (Loss)</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue, change in estimates of variable consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized Computer Software, Gross</a></td>
<td class="nump">17,653<span></span>
</td>
<td class="nump">14,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization', window );">Capitalized Computer Software, Accumulated Amortization</a></td>
<td class="nump">13,264<span></span>
</td>
<td class="nump">12,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Loss on impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 2,769<span></span>
</td>
<td class="nump">$ 2,351<span></span>
</td>
<td class="nump">$ 2,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PercentageOfMembersTaxDistributionToTaxableIncome', window );">Percentage of member's tax distribution to taxable income</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PercentageOfMembersTaxDistributionToTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of members tax distribution to taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PercentageOfMembersTaxDistributionToTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioventusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioventusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674733550616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Members' equity - Summary of Members Equity (Details) - Bio Ventus LLC [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue', window );">Preferred</a></td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssuanceValue', window );">Common</a></td>
<td class="nump">113,373<span></span>
</td>
<td class="nump">113,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue', window );">Profits interest and other equity awards (Refer to&#160;Note 9. Equity-based compensation)</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Members' Capital</a></td>
<td class="nump">$ 285,173<span></span>
</td>
<td class="nump">$ 285,147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MemberEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Member equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MemberEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit interest and other equity wards units issuance value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated value of common units of ownership issued by a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated value of preferred units of ownership issued by a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674805131448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>May 31, 2012</div></th>
<th class="th"><div>Feb. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightEntitledPercentageOfDistributions', window );">EPR unit, entitled percentage of distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bvs_EquityParticipationRightUnitMember', window );">Equity Participation Right Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="nump">$ 3,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany', window );">Proceeds from the issuance of common units of limited liability company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum', window );">Preferred units percentage of accrued distribution right per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightEntitledPercentageOfDistributions', window );">EPR unit, entitled percentage of distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Equity Participation Right Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_EquityParticipationRightEntitledPercentageOfDistributions', window );">EPR unit, entitled percentage of distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_DistributionEventTriggerPercentageOfSaleOfAssets', window );">Distribution Event Trigger Percentage of Sale of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.66%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Subsequent Event [Member] | Equity Participation Right Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash paid to settle award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand and Twelve Preferred Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany', window );">Proceeds from the issuance of preferred units of limited liability company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PreferredUnitsLiquidationPreferencePerUnit', window );">Preferred units liquidation preference per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand and Fifteen Preferred Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_MemberEquityLineItems', window );"><strong>Member Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany', window );">Proceeds from the issuance of preferred units of limited liability company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod', window );">Preferred units of limited liability company issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_PreferredUnitsLiquidationPreferencePerUnit', window );">Preferred units liquidation preference per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DistributionEventTriggerPercentageOfSaleOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Distribution event trigger percentage of sale of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DistributionEventTriggerPercentageOfSaleOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_EquityParticipationRightEntitledPercentageOfDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Participation Right, Entitled Percentage Of Distributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_EquityParticipationRightEntitledPercentageOfDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_MemberEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Member equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_MemberEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PreferredUnitsLiquidationPreferencePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred units liquidation preference per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PreferredUnitsLiquidationPreferencePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred units of limited liability company issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred units percentage of accrued distribution right per annum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the issuance of common units of limited liability company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the issuance of preferred units of limited liability company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bvs_EquityParticipationRightUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bvs_EquityParticipationRightUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsByNameAxis=bvs_TwoThousandAndTwelvePreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsByNameAxis=bvs_TwoThousandAndTwelvePreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsByNameAxis=bvs_TwoThousandAndFifteenPreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsByNameAxis=bvs_TwoThousandAndFifteenPreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804192472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs - Summary of restructuring charges and payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostsAbstract', window );"><strong>Restructuring Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments made</a></td>
<td class="num">$ (247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostsAbstract', window );"><strong>Restructuring Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">$ 1,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(1,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bvs_EmployeeSeveranceAndTemporaryLaborCostsMember', window );">Employee Severance and Temporary Labor Costs [Member] | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostsAbstract', window );"><strong>Restructuring Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(242)<span></span>
</td>
<td class="num">(1,488)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bvs_OtherChargesMember', window );">Other Charges [Member] | Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostsAbstract', window );"><strong>Restructuring Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bvs_EmployeeSeveranceAndTemporaryLaborCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bvs_EmployeeSeveranceAndTemporaryLaborCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bvs_OtherChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bvs_OtherChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674806092456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs - Additional Information (Details) - Bio Ventus LLC [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 1,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=bvs_TwoThousandAndTwentyPlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=bvs_TwoThousandAndEighteenPlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">$ 1,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=bvs_TwoThousandAndTwentyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=bvs_TwoThousandAndTwentyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=bvs_TwoThousandAndEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=bvs_TwoThousandAndEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674731615336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based compensation - Summary of Phantom Plan Award activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number&#160;of&#160;awards, Granted</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of awards, Forfeited</a></td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number&#160;of&#160;awards, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number&#160;of&#160;awards, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Other Phantom Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand and Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number&#160;of&#160;awards, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod', window );">Number of awards, Converted to cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of awards, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of awards, Awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Converted to cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.72<span></span>
</td>
<td class="nump">$ 5.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average grant-date fair value, Awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand and Twelve [Member] | Other Phantom Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number&#160;of&#160;awards, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand and Fifteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number&#160;of&#160;awards, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod', window );">Number of awards, Converted to cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of awards, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of awards, Awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Converted to cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.41<span></span>
</td>
<td class="nump">$ 10.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average grant-date fair value, Awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member] | Two Thousand and Fifteen [Member] | Other Phantom Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number&#160;of&#160;awards, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.62<span></span>
</td>
<td class="nump">$ 12.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options converted in cash period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options coverted in cash weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment equity instruments other than options vested and expected to vest outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bvs_OtherPhantomUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bvs_OtherPhantomUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bvs_TwoThousandAndTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bvs_TwoThousandAndTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bvs_TwoThousandAndFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bvs_TwoThousandAndFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674798367400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Summary of Debt Instruments Periodic Payments (Detail) - Bio Ventus LLC [Member] - Term Loan [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Debt Instrument Schedule Periodic Payment Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="nump">$ 3,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Debt Instrument Schedule Periodic Payment Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentSchedulePeriodicPaymentAxis=bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentSchedulePeriodicPaymentAxis=bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bvs_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_DebtInstrumentSchedulePeriodicPaymentAxis=bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_DebtInstrumentSchedulePeriodicPaymentAxis=bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674804616328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Schedule of Loan margin Adjusted on  Pricing Grid  (Detail) - Bio Ventus LLC [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range One [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range One [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Two [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Two [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Three [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Three [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Four [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Four [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Five [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Five [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674803635784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Schedule of Commitment Fee  Adjusted Based on Pricing Grid (Detail) - Bio Ventus LLC [Member] - Revolving Credit Facility [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Leverage Ratio Range Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Line of Credit Facility, Commitment Fee Percentage</a></td>
<td class="nump">0.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bvs_LeverageRatioRangeAxis=bvs_LeverageRatioRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140674922152184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Summary of Contractual maturities of long-term debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">$ (959)<span></span>
</td>
<td class="num">$ (1,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="nump">$ 166,084<span></span>
</td>
<td class="nump">173,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember', window );">Bio Ventus LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturingInYearsFourAndFive', window );">2025 and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,378<span></span>
</td>
<td class="nump">$ 187,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturingInYearsFourAndFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth and fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturingInYearsFourAndFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bvs_BioVentusLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bvs_BioVentusLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>147
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M8+<N+)$\YK">8J.G".KY03$6Y1S'Z"$K5;XH!L=8J*25-ZW.'RI99!_7.L%
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MGH&P0%,(,JKA3YKYP7O\63/?=AH$3"A[57MG5_N1TZCX-4]:R'(_(<=R[)J
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MOM1?U-,_9+\@ULZW4F73_1\]'6R%,5[M&ZVV_6"#8%M4A[_YM]X1)P,0]0S
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MTW9/[XQR:F]4IFZXI0Y2UX@GPK.G46S5( XB_;M2ZZ>B+$%BCYU+,HS(F&T
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M;<J+4W-Q(5F:GR.W3*I3:3Z,, HQUP#U?,>8?+[01]/JMXOE_U!+ P04
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M4YSYPH<P'7C'9'<,A^FS9)^\#WVL]#:ZJ#>3X]F0?4#;MAY!32CP'*1DOB8
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M=4P<D=J1#TF3SW&IT3E:UL,NE=7;J<MD07U2:=A.%8"A9$P1QT\DS4_/-#]
M2*#Y 1S.:,R5'7&1(KDOS>NV:A>G[TO4D0M-DXM.1!9*+7>5B'H8MOI&=IU?
MF0P$O3=IQEH'N8/-J8:N,=4,_:^6H6K09GO=U L-7ZE>B[??S;:MSM/O^]K:
MUOJ%Y5V;RNRP>N)A!*U-0T+"F=3_>-8&<!%+4\=:]&AB=L0>1H?+1U8!=0@9
MBE+?Q0%03 %'832==5UVO1YC:TGF>."N:^[@79"&F5,@7PAA19;%9#RH'QXA
MP^KKKO[<HJ9K;\YU"K)&2W4-T@B%$B.>!<)":1:/"NNXCZ:Y[Y-::6\>T OM
MQF-?7V_MIO:=WN_6:GVM>MB%0T[+@R@& )T7F>01B1WQT6_)FBC$:WY,"(!B
MAG3,1Y_"?"M@2P/%!:J-&6:97VT"<%0RXF6#Y0[&'WE)P84WW0S"X:S@GJ'F
M((X2'BDY4\>X-,VX,[U-+NQ>JKXLIFJ$K9<L=GFG7CK&F*#)@!00R^ 10ZA<
M^/8*43P/C 5-E3'?5!!*Q-S*,3H]@='WY1ICDY>3FYG8]*YJU /QF"I'7T\%
MSICE0O[FF)# UT*8T+%)3!5'\S2=GUZ=+#RJ1J17.;I6-W7;VMU^92_HJ*ON
MP/R!AMEI+G(:Z!;"!.,D\_WB&.SQ"9"+1U@Z'GFZ"92-*8XHSX"0@N:9"(Z/
M !P1A/GJ SC F#, EK*2BU(83L:#G[>;36//<'4,9L*KIANVO0U3VJZUUCD(
M;;6!CN^VCR5QX09+AQM!2<4<)&R>E2ZR,-H0A5_- T X4LMC+AYAZ7CD_:X$
M-!$Z>D3TH*1AJ$&S0-(0)&/%('9P1)J.1B[K#OVB#;@=T/??7Z%__F!%_E?J
M6;JX@:7/.9]\KNNHGQVG_NC);LF@ T5)B+^80I@@A;>"YP!*9\ DBUG>$3([
MG@*;$[$I?#D]UYTQ()'-,??E!@NRL2H(<_3(CM/C[HPZ?M@,/A7@[!%Z*B$L
MQWZH.P=0C+'(D3%SA,G2>?'_W<D\=T3'TT3WU+/YDH=<0G+A'\/, !C-*/;B
MNCDT6T%HY+B).V;BZ?SY>[-"M$;U_MAI=^2G [3:EMQM_1IJ8N%A-LSR2,V?
M.X+BSSN%?$)?P9P#9Y&2QD1SM,-/2H-3TABY=?RO!MNKI5U$<RW2O*ZIMAYN
MK?\ZMJTF+M;S0-L0!_+C@OG;$(2BG,?\PO$6/U)!?EZG0<G#'!D3?_.< 2A"
M_$+S'$+QJ,L?= >ET^UO[Z<H>9AN0UJ&*$A+ !77TE$X3U/X?Z%CH>1@KI\%
M6QP$RYF?;T(P1DFDO,)=(,"?UZET4E]#R0&>YT5L+W$TS],T7ZJ5ZGN[(4RL
M5WV)N!I0HN9^_6<&H:C?;#>'4#*FBB-U?N24]H (C5U-77!?0[:^M:@VM<Y\
MZM^UODU7Z0>AU! K>)4\3%5Y2)O@V:T?QD HD4=J/<+% B(="SR0IM6T5V/=
MV]S.ZKKNEGI1+6)K9B8 OJ>Q8RKA>%RD>?P/;( I14CLPE^M,P#$A<].  AG
M6<3CA(L11#I&2!9,2P&POY"^^"&(^LGK' #A6'.J<&&$2+?C_D&=*,)QN4AS
M^6F=**4 RMNT\!LR9Q ,L\(O\,Y!',&QPS7A^%ND^3O=LE(*H%[.2>YK 575
M&9&^$B$L7BP6!WV^:7)^;F-+*4*.)!GWN^QF $P(YN<4 $H_(!8)/80C7)$F
MW&<VP)0"*#A+ZN_\$(KFN1]603!&8ONLXVUQXGGT86KZQ(04U#VD9DEPX1<H
M 1@C/,@* !@GA\V8C[5W5"_25+_7?I>+PYJ;&.#D<DLI@.9DYI\6SB 4SFGP
MU &8Q"36Z^X87Z89_UG-4:4$^I6Q#!XJ &-9T$0UAV <QTJ4TH4.,EV<?FH3
ME70\+=,\/<V\#XULM]10[^/$@[(MZFU( AH1:BP67 96A&@_\QUI#L%H]-A9
M.E:7QVK2CY3[Y<,,BOYDF*ZS&"-*1_#R3VCW*B5 T"PK_/T6@A$:I+$@C(M(
MBY]T;"_3;/^L!J!20JW&F9!^-13"R0('R@$PD465<W& _-;FLB>U:9428'1?
MYSD .F<Q'SSX.="W=IR! @,LK0.:8/N'<-!S F "QWY>(!WKRSRY13ZUGTLZ
M1I5I1CVU_:>4(;,E>GMRQVSYD8:RAZ)F^O8YT'2<NK]CG_PI#5SF5/BPB>MQ
MM]&^76T/B?6DS7(@\RSRZ.\(<L=I>9K3GM0+5>80>64!*\U 7%$$"V$. 3F)
M'3OECK[R-'T]IVNJS('BL[:RWY0R@W %IGZR!<%DSB+95N[H,4_38[I<D(?$
M1?V?"LP T#D+ZFL0*MHQDSL*S$^@P#^F8Z;,H9HTQ7XP!<&P##)(",:%C&GL
M>#%/\^*?VEB3ARU@4&,- (,::W(@U0YA,P#&PA^5S0$8EH>M68\-ZM@Y/U(#
M_U/:=,H\Y%NHK0:  3:: [#'-GJL_,$/?M/LG>B^V;]-0:^LZ=4@0=GV\4T=
ML>?'>\/0IJJ7]FCI6)4_A\K90>D-1/EMUG,(5;"(%0L7*!3'.[T.%9H.3R!E
M"B#M90$I "BM,O>= H))(B,9?>'BCN)_VY)5N(BB.-J29>M^!]4Q:^(3\^,"
M*E('<0. $M'HK7!A0Y$.&TIS J*S$QTU#I%#PB)D]2+Z^!RG%R?6M+^YCZTL
M@ " !MX*@/S-&\#@/+;N'/L7:?9_8K-;N9OND+>HOY$ &.:7I>8 J A./RX.
M7G>S5OV-?3&1.3G6#V=Z0\G^ZO[E1^_M*W^\ZY?X]14&KI?X]7QZM9&;?GK3
MT@]5KSE_0(U:Z5MEKTR2WD\O+YJ^C-W&OFSGNAO';FT_WJIJJ7H#T']?==WX
M\,7<8/\*J7?_ 5!+ P04    " !71#93%G!>0&87   T30  &    'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;.U<:W,;QW+]*UN,G2*K0) $)9&R'E44)45R
M;$LQ)=]4I?)AN#L QEKLXNZ#$/WK<T[WS.PNN*18RO6-KW,_V *!G9GNGGZ<
M?@!/-V7UJ5Y:VR2?5WE1/]M9-LWZNX.#.EW:E:FGY=H6^&1>5BO3X,]J<5"O
M*VLR6;3*#V:'AX\.5L85.\^?RGOOJ^=/R[;)76'?5TG=KE:FNGYA\W+S;.=H
M)[SQLULL&[YQ\/SIVBSLA6T^KM]7^.L@[I*YE2UJ5Q9)9>?/=LZ.OCL_X?/R
MP"_.;NK>ZX2<7);E)_[Q-GNV<TB";&[3ACL8_'-ESVV><R.0\5>_YTX\D@O[
MK\/NKX5W\')I:GM>YG]Q6;-\MG.ZDV1V;MJ\^;G<O+&>GX?<+RWS6OZ?;/39
MXY.=)&WKIESYQ:!@Y0K]UWSV<N@M.#V\9<',+YC==\&Q7W LC"IEPM9+TYCG
M3ZMRDU1\&KOQA<A&5H,;5_ 6+YH*GSJL:YZ_JQ:F<+\9RO3I08,=^?Y!ZE>_
MT-6S6U8_2GXLBV99)Z^*S&8CZ\_O7G\TNV.# [ 2^9D%?E[,[MSQ^S:?)H?'
MDV1V.#L:(^CNY2]M.DV.CV3YX1WD'$?Q'LM^Q[?L=P&KR]K<)N4\>5M<V;J!
M!31U\E\_X,'D;6-7]7_?<<R#>,P#.>;!5][BW:N/IDE_@^3#TB;GY6IMBNOD
MA2NO0'%;@WR(9K?I/ILD&SM)\$E9)65;[24;4R?T*S9+\,HD+VUN-J:R25I6
MZ[+2S?% PDW6+=ZK13!SD[K<-?B\6"2F2%SA&F=R/'*9NQ1/S&W%CW;?OG^W
MAP>RI,0.%9Q(;AH<UE2FJ(VXA1J+04^&3YLR24U572<XE =>MC7XKFN>V''U
MPP_GLJ/#I=3M9>TR9RIGZV3WQ2_\<&\Z$(>KDR5\Y5];4S6VPMDX[F5;+<UJ
MDOQ45LTR.3=5"0&;::(;3+C&)+E;.=*:.W-)9J\A%-W22ZPMA&B<!:$)D7Q=
M0RHBHRA+</,3B%]=XNF9Z/G1D<ID;2%B4"ZR7X/ PE;UTJT#)3P1VI?:\&R0
MUX_FFMO,XH-"\2(O+W$)H,VE^#>S5RZU@>H)7A19F\J51<EBKRM(KX1<T[(M
M&@IRDJPKAP#A\FM^KD(Z6^%&4R-TOVHKD -E<OC K-=5^1G/-Q;//SX\3.QJ
MG9?7UM8W+F)>PC^2F8+$(1ZM57\R9;1*H4/N-[Z7XD+(!+;,'+4)=^^H.F2C
M;A([G[O4X4U9#2\+ G*A]\K4B#+0,&N\Y39+@P7% B%.GK;%TD"FJF)E=OVO
M_W(Z.SIY4B>%:=H*@H.^Y"0"C*40$AEYZQ7\O2KXNZ#@[XKDM;VLH%S7R=$C
M]6&3I&=RX*0DRS 2V +UXO$$\7IR"$'52ZB'*,YY;G 99R(&" <Q)/V4@&IS
MPZ)P-:FHUS='QU/L ;70?7 =2Y<N(8$T;S-L>[1]CJOK%I3 C.O60'(P-Q(J
M:KRIH.M5[4610%VK?0BT%!%"^:AYP^NL;&HAZ R$'.&HV2EU121F,ZA0 3@#
M*N/FI#USM2A9':\<)(E*DY_3R?')+'!!QR2J B)!<+I$W,>>F_QZW[.Q$H.B
MM>!@6G:-?>=5N0HFH>(3<5%(X:'$PA7D@7G>R99(AVR:O"XIT[:B[XC78#\#
ME$$SL$^CRO+-@\G)B0C!9)D3Q[DMX#ME,.V4*FXN-$V.9R?PVW D:^/$?3'2
MR?)OCB</'A[=^!#1X0*.$8S:[IK)*=>,NF QD3+U7&(7^(K"PS:Q\K"#1),/
MO:5[0VUWM3K!$@%T90JS(#]Z5>+%?XGNN]S@W)/9=/9M]\%0]$MQBROS:UG1
M^UK05*Y@"^$F)]U15Z4(-]ZQ*R9>OG!IP%ORI-!C5:&[$\]X"!8!1&X9+KA#
M7,C$0_.#.6)$01?E'Z^W.*HL0B8O-BG*8M\?+;I!R?6%-M0P+.W<_3JW<CL\
M#ZO+#==_V J7M]Q.C 8&3&;B=$B51"3=<AA%SQ:5%7F \1("@^M9^$#=+'$N
MS'C7[=&HKUQF!0<8&F&"X+& U%/Q6A""=UNC)@ER/56[_-_;\,$>-\?N]C.,
MNZ!KSO,00^UG5S>=YMRZ(RDB/8.-A6MLC;T1FTJLVX9$YCY*NN4&QB1*!)+:
MJG&(13[HPU/TD--M4NU+E)10RJ9MEE!T#^BPU>RA>._[1 H-Q$00B.9YJ\[L
M$+[LJ(L/3U3<-XZYXY077WG*V#%'8\?0,]9N48@TD=+"_]'_Z''BDU8 .I<V
MA"YQ[PU24G%J_/?RNF^S,9*_*$V5"0ASB%--61$=OGNY)U@3,!YR7Y5PFK4E
MX'GB5>8*VHBK1<"ME\%-&-5R7#'.QQ83>'#>';VD>%:8D#Y"X&0-8A=6;98$
MREY[(3BH-HZZTAO'$8N%0%%9O7]M(5$H[PHQX$V99US2N^F#\=L@LB0H:G*-
MDF0+;M!V=T&N)K0ONVZH\Z*#&P?"*H0&"":;*&FRK"D75I14O.[0P@LQ3D"\
M1F@K?) 60I:>XH4%>!4,MDT9MQ_A;(2?HFP&*SW&\"(O,K5MH9F/7MK1IVFO
M"+/ LI>MNLQV[3.*W('Q3)22%UG#!;2JH16V+3(Z@G8=W)#7*D33NPV#2EH6
M>5]3?="UGQOJ$9PU<"0Q(MYGH:;!?_( ;FV_*?=%)_$2ZB&O/XSH]*@+NM/]
M\,D[O'Y0 Q_^F_&81!@%>=/:ZHYVLTVY?_EA$">%2 7A5'QHIBMQB0!<9;6-
M2P8Q;FEPCY?6$DS]VM:-2A1"OV02+LEHA>P&:0ND7ENX) I E(&9H!P&QO"&
M2L*GKC"P]_VS^V=.MJ/$TF30LE[B-=48XU:1D2$>UNCO$TW)189/\T:2H^/]
MC;6?PF/[EC8:WOQ8F#:3I#.L[63I"BT AG3?I#ZQ$YV-"WNH)1N_B:%R]T0-
MB4&0BO^X>Y5)FB1NOV?=*?T)]3 5(.N3$AP#Z"+!F;M_+(2:BT;0$XX,^>/N
MQ^G%-/FWL[/W>W)-=S.JYNX1CBM@TVU K&7"HB#BROY_\'\(0A?[_SGERW^?
M)N?O?GG[<O_H,6Y,T+)'=N'=^$("BM;LX)LF2=VNU^ 1B,052EK5KKUZB"W3
M &F1L\,G]=+FO$%7[*]SDUIY^^C)R"D?!LX@OOV.>3Q2FV1V,NE3659E8:Y<
M!44\<]".GVWN[%PS[X"!+RRP.E'Q6=HDN^=G/[^ZX$NMZ#"DA@"5FTT_IS).
M:CV-AR"2;8!U7&^*JT6<@Z+PTGD8TV"(/J5GUJL2/XSL"=*8FY7+I5C 1T,]
M@;4,9#$I[SZ$YL!N#VA''0QTRR;>!V42LCUL$%VBQKRD;C8A*K]1TKCJ30L(
M!WE4+'8@S+]Y<[&5D\1,U3";FCTX@1,0_%4%T;X&$$G>FVO9'C=_!H7.Y4J&
M*#"S#--.A-LH6B<LB!K*"HN+^HEH "PA6.63M6NA%CFM8ON6T4R"EEM=(B-7
M$?=%'A*UF UR?<[B!UR?+8"_$(\EQH53M$@G]0*_47>W*GC>M^A\N)4I1)!*
M&:5OS5"R%EJ@_F([)9-Z?G3(-!?AGSD/?4,N-:T,MQHW?#_<4$_$NK.L%$\"
M(WV)][1 =GCT6*_O=?0(O:W@4(H,V"Y O-W79Q<O]D+4'7WPXYK.4#;>/YI-
MZ-QA[<D'\QDR]>_N3<(K>$J[W@<&\'^/%:3OK,VRB?-=O89#>+8C,0BP;^?O
M6[ M^_*<"6L/_T&KN(!Y4F3A3O4MT*)>EFV>T=S8%//Y\:_0MRY!CMOHYA%3
MC>TG)0&IWWH1AN;"9"MN9AZOLK"H01-O1VZEVZ5PQ$/PD<3=*3+2:#?]9S7Q
MSUA-?/N5%<%A7>U^%<CCH\._9^V//@C*D2(*Z=*?F$D^^%.5!.LQ:0XYE(2T
M![SO52V419HTC%0,(]EX0A,9OLM]9R?3TV^[S^F" $2SK4K(-+FC1_DP]B@?
MWMEEA+=.?HGN^HX-'\4-'_V>O=63>,S)_Z:W>G[GZOO%;P&]!G"9K Q23<;5
ML5R&SO#P^,G]_[D%(]P>.._ #7^$EF:?G2_U-6]OTDZ2CQ=G,3K5(H9>?Q?1
MNQ/5'Z4I>O(G;8IN ==_G&&"@:/<;@ZDH38*CRKI4P5O;XNNNB2BDYY;*/!N
ME51V69D "335=QL:@)(M94C&"<Y?]3/<< P"(/@!WCP]/IT\/'W,'8G@AOV-
M78FZ<TE#+SG4M7<;<MS.+'[RO1(A:N]/!R8'[/UM(>5-'+DRGRR[ V8-U<T5
M5OB"<R"_ V]=EXOZWXGYRQAT=TP%]GPGI%^Q_6I\^KO!Q9$V\?"&OH ,!U;Z
M.C9#M= BC=*>"8V5D<?.'&+,P1$W5>CWA9N#P^^+.8<$WA]Y;E?WOQ9^=IJI
MSLK#3FE_W #UHBN59== RF_^ >@T-VRY9^>.6(J:J^.6-.+H9*";KZXD;OT-
M2_"*WZBSTM"H?<4()IU;ODK8F)LFK]C3,T71FB P<7:R(_POE%;V_=X4ZGU]
M.-73>D4$OY,G+CY!Z5TPQF;&I_=UH\'+4S'H%$0+TYI"SP#FP'E-W#ZXW%$Z
M*+.M/@1D%62D1>XR%J=/)\GW;<'$0SB[8/5?@=^C&,VEA:D+;Y1-1D8L/*W<
M;NXJ\!O0F[32KBA&7 GX7^"IS"+1E4JUE];6_;SOF@\RBA",(939OMP1^;]K
M@4SO2:&/G'TKGMS, "0MZ*55+C1JAW6K.C@EW,Q*PQWNGFT],7)U.-L>H=P4
M-V)3EW<ZF W!ONO8]\ >2X,7TNL.W ']N;[^;K<[P^&<!Q@P*:5QFJ'BS-M<
M%^MX>:Y_ABP'B0#O4TEIQAN.EDF23B1H<.O428KE?AH@]4G+N4K.]S2]5S!>
MK-VNE>V-$4CE7#+#(&V)IG!R?GT_H105 5!6_%"'MJ25-@M-HM<)C7*1FE#H
M$WBPX[3NO0L7PW"L&)J2J>R2,_Y7=OL1#T@"\F*W&%$0;*:F7B9SQ&,(^6.1
M"ZJ.PP6LM<)3L6D\WM3S"O(EK8>7*!LMW%9VSJ;#J)X$[=)67A=8^GW;E\1U
M\LDPXZ0N$?.U-4'=G$Y)L),/0(]N7WEA%[Z%'@+"(*O+&#'GHJZ]BC#UKF<7
MM=_#S;^3"2 7$C*QH;%"LO#HL;3.QL #%O&>O0. ,L7JH)_ZH:L8,4@QI46;
MFTJ4Y\K93:]QMV1K[%U<!<?NI"[Y(Y O@_B[ES\2UGDHG/F/L>UEV5(R-;Q\
M:F,K#/@M-4TW&Q'8E]8?$TI-YG&>J KL-,SE* >*QJZ,RZ7?Q7NK;&/'E6PZ
M.D)!DD/10-E[]=FF+;^6PNE+ ./*+^2#*I#ZMM9TL^7F C\YDW@R&3CNB4+\
M3AG8O9>;[,0AT58GC+8/'6>WV91>045B_EF]=XE!/$H 52$\&42$\?>9-[%,
MHFN[2@@,6(OJR^O:@5[<?@T2BH 6624!L1DPLS>C=C7QT4S(5\ FQ1EH^\0[
MKE]E:J\BWHXM_PGNO\A\'LT4QWYN "W%,";B*U23BD\Y]EF7B!=(R%($#^;6
M")?P]^W* %RO66SDLX5MJS)^#NW:6#@M9M?2@LZOO:HZ.'8(0IM#6R#UP120
MO$EJP\BO;SV<!O=0)Q^UQ(%X),4@Q:N*,D;*A8.(?P. 1-C0#>[T$HI@A]U1
MWK#:U;J7N6E[7BZGBZ(^7''<#9KI=3 4"6.37YOS-3%J6UD/MJB%8L6W+?1-
M?5]!'.8G';\#\=]&W,#/Q?Y'UE9!W31\2C6$GK98E%+7(\Z?]&5E.;\8YGKK
MGLSZNMG(#%_,@4M%)/#&3 1HVYL.2^CU8RW]_I7PW3U L\W*]K*9MWF C'(2
M,YJRDMX\J\QX;U&6F61FZLF1D2P<3==+U\&^7:43NVUMN5_.XRB<G&.FN<XY
MR-,30J,Q9,3A#1=F.%?6\#;])?#6%EV%NW>_@TOU.*%A"UUU0['!/K^>)X43
MWHUWQ#]V<N?'ZGT[+<512U=##E*>Y:T"YD%NH+)MJ&=\*VU"Q.Y7_W"-JGE;
M*EX1=.7.7NF]:6.XAA^C*+L2=^JJM%WIP(NO%?029@VS"M)8/I1DD5<)*Z,T
M?VVSX$XEWFEF4E4RCR6RO<.@.D+9OV';FM[4K)E\$/DPSBN;/G),.273]E)Z
M!G\M H=:4-E7Y-X(%/QQ9J5J >V!Z8^/1,6G]*NEH*ULO<UORBK/O$9V SDR
M7"I#M)6?YYC(+#8KYZ8W9Z:#3(*$=1H%RVIJ3Y2Q?%8OD6'XVY)=J7MF06 ;
M0O(VI<0#1,,;P"VE>I)49NTRB-)>E?E5J*.W!3Y%A-$PJ&(0Q?.]@;I,G6U
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M32%7E)<<Y;05'\#G+.J'/WA _*&TY_\#4$L#!!0    ( %=$-E-EODI),2D
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M]3BH,+ ^DA9QE52$"UGU^'"@<'S8<BJ]I.X+VB<5LB$X*)QM/51LWXSGLC>
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MNP#Y(2M6NJ+<$+832/GDO>(Y@EU',G""C;OFR6C0S::MQ:S5IXU*#^!O\\]
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MC?71?'(DE4_".TMGHJ,8A3IPDZI[VDFW40+"6JEYQL?A(T55J]D'@W#RY"E
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MN9MIG'7V8:)Q39_HTQ0[VRY1I.+,?NC63+O$HS'?_.JQYJ]1Z ,&.(D"(W!
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MIY,@&L][A+C%=+)K5QR):[B=RMDA3_^"=F6"@>Q*9&;FJ^]*D9=)H2WF*N0
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M_HI^T64</=XL&@:SY:QK%CV8]CZ;+>=XY)TSEY;QU/E[%LVX!$<=!48P>PW
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M)7_WI2[W_"M;J[*NRQU_W/)/$=$#N$_E4_>%%FA_I^W-?P-02P,$%     @
M5T0V4X9K]99N$   &S$  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
MY5M9;QPW$G[7KR"T<B !X]&<.AS;@"7;6"_DV"L[R4.P#YQNS@S7?87LUGCR
MZ_>K(IO=/5?D; (LL"^:/LCJJF+55P>IYZO<?+%+I4KQ-4TR^^)X69;%L_-S
M&RU5*FT_+U2&-_/<I++$K5F<V\(H&?.D-#D?#087YZG4V?'+Y_SLHWGY/*_*
M1&?JHQ&V2E-IUC<JR5<OCH?']8-[O5B6].#\Y?-"+M0G5?Y8?#2X.P]48IVJ
MS.H\$T;-7QR_&CZ[O:3Q/. GK5:V=2U(DEF>?Z&;=_&+XP$QI!(5E41!XN=!
MW:HD(4)@XU=/\SA\DB:VKVOJ;UEVR#*35MWFR<\Z+I<OCJ^.1:SFLDK*^WSU
M=^7EF1*]*$\L_Q4K-W9T?2RBRI9YZB>#@U1G[E=^]7IH3;@:[)DP\A-&CYTP
M]A/&+*CCC,5Z+4OY\KG)5\+0:%"C"]8-SX8T.J-5_%0:O-685[Y\JS.915HF
M0F>V-!46J+3/STN0I@'GD2=SX\B,]I"Y$._SK%Q:\2:+5;QC_NWA^</1 0+G
MD"D(-JH%NQD=I/B/*NF+P;@G1H/1<!=#AZ>_5E%?C(<\?7" G7'0\YCIC??0
M^[3,3?FT5"85K]6L%+_<88!X5ZK4_NL ^4D@/V'RD_]V&0^2(<AX9@L9J1?'
MP 2KS(,Z?CGIBYWDQ5V>+9Q(,8D4Y?!MB^?Y7)1+)>9Y HS0V>+9$19C+; 6
MT*I*9\J09H\^T\PDEYF(*]6\@L(GXG34OQ@\$;(4]51:QC-Q(H97H]YT,*"K
MZT%O,!@<W2EKGQW=5L: *U% SX0/8"+I\G<ZG-)X<=9<'?V8R90F_*9B-TA;
M6T%4!6DLIEQ/KWE\;W!]M3E<VRBO\,73R?22!DW!]]D1^+JXZ VN)L3AY;@W
MOKPZ^@QMC ;#:W%K5*Q+\6IAE"(= @=_K30TS0J[S=-"9FM1YOAZ6D#NE2Z7
M8AZ4+[-8Y!AI\/Y!X2D 7'QNS>1I&LSQ1)DDS4 A>6':ZG1S=S.&Q2P1 S!-
MG$Q9S^#U(4\>L)XB<J/G,M*)+M<],3=Y*E9+'2U)$*/$BOYDN4#<L"78IEFS
MW!BVAUV\L&QM\V#'<QPJ6VH -L2:2VW$@TQ@+][(V(CNR(AVT%SAV<GP:@*#
MF3I26P0L+F:)7D@R&LLS8D4V \^(Q6PM*DN\R[#<>!I)BU6!;8LTCU7"800+
MDP&OG0TB'GY! -88C;7%*H-Y"/T@=2)GB:(%;JTW<P8^=%94M$Z&C ^J@KY8
M:#"1S\@7>:ZG'0/LX6&(QSH%5=.1@G3)9!)IK9Z304"N._4 9D<=%R8[T9ES
MUT8U2ZV,--%RW;4N1?)8$BOORB;L2A9"UL9C2< $?$$%N%%?B]Q6AL6.EC);
M**+!WWR01K-477)0)4WL^F^7ER4M=T8VECV-E=6+C'7U0X[I6.NWC3"IDO1U
MQQB1R'+2$KE3RO[K+8EE*/-2)J!S,ARPT?<$5#R=]*^>;!M<V[8+H^&B!1$M
M=_@8TT[RZ M(;XK> BQZOJ4)>EBST^*]%(/^Q>1)7QR('M,0/:8'H\>-SL5/
MT$\%([F[%;^\9R\\%)<N N6+OR+L70;REW]*V+L]2&9WV)ON"7O?_>UJ-!A_
M__B?/0C[(6OP[J+'@WJ=,,#NQ@8#QP$,CSP.>_0E)U]4T@#<UXWO(7+N^MJ9
MBP@_(UVV< ZSR,6-S+Z('Z2WIU?6YI"4+?&4AYWU"#16N*1?*>P:IAZQ4<Y]
M%)J!A&47N5-(VXP]%%&TY?!D-(/EG"7R5EV&3. TN!<^[X(8/,/HA28F*3BK
M5N#]\.[U&9$ZN4#(=:BW(UK584J<WO,S9<[ZXA7$:D-F1?RS^G=S3W#JM:T<
M)K>7BCX=*4,1L_9C_XIL8'CY/12Y1#H$)%]17+'5S.I8 P(4=/8)=P"2$H:&
M$12UB0"@6S7)5!/ADP1K8&2")(3??(,4;GE:(1-LUSI!8"D)I/--LZ1L[#V]
M@PJAN&;V*V9N*V;W*.1>4=[#T;2-DA[- HF>R!3C[[X5IK6EM(H816VF#/F#
MSX<H#\E]NGG""5I_/TM=Y.YB+) [J6(7Y1%=%VX-1_W1] E+,.I/!L#93RB@
MXXJ"PZ^P Q# 6C6P7\BUBS!D*)CDDE\78%UX9?G\,,?SR&6A@/):O\^^&5R.
M_EDS<Q32*%R,D'V.>Y?3 3T=UT\I)W7?;(?25*X%; #ZACVR4 IL;JB,Y,!2
MTLM45RGY?('$,H%;5076%9K (PI/D>IOD9^I.M.-*0M(Y1<H*89M.O#9H<9-
M4\'R%X0QT!U_CUXN5 9'J(-G[7]-=H9\QR>^L!W.YWSLW>\<=H,O%1A::?@E
MY)"%R[!]#F>#55"(@.]Z]N<MH?#5&*)'6'9#_HF7J5_PVKUOD$**>[+&TYO[
MLSHGL-M)QUP;Z[ ?SYTT;RJ3QP0+9O^\;T^DMYRHSJ:O>]/QY ]ET__GJ71
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M\$># PO0W$VE"O-9YT15J)W-Y5P@YY<T .]G"JF\N:$%V@^#7_T'4$L#!!0
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M]%7(#="'+?R41'6B<MK-K9LK6WI$6\E[.\L@5AV4D8*)TR#ZP<J.?-H)JB8
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M#HCJGB3=AY&M?P:LI,%'A1=K?,6!<@JXOY980?V'.V#_+IS_"U!+ P04
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M!?A]:XRKO] !S7]IO/HW4$L#!!0    ( %=$-E-P$+@+'10   -&   9
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;.U<;7/;1I+^KE\QI?->R5LPQ3=1
M9&*[2I;/&Z<BVQ4EFP]7]V$(#,F) 0R# 23S?OT]W3UXHRA9\>[>7O;\100!
MS$Q/OS[=/=3S6U=\]!MC2O4I2W/_XGA3EMMO3D]]O#&9]@.W-3F>K%R1Z1)?
MB_6IWQ9&)SPH2T_'P^'L--,V/W[YG.]]*%X^=U69VMQ\*)2OLDP7NU<F=;<O
MCD?']8T?[7I3THW3E\^W>FVN3?GS]D.!;Z?-+(G-3.ZMRU5A5B^.+T;?7$[I
M?7[AK];<^LZUHITLG?M(7]XF+XZ'1)!)35S2#!H?-^;2I"E-!#)^"W,>-TO2
MP.YU/?L;WCOVLM3>7+KT%YN4FQ?'\V.5F)6NTO)'=_N="?LYH_EBEWK^JV[E
MW;/QL8HK7[HL# 8%F<WE4W\*?.@,F _O&3 . \:/'3 ) R:\4:&,M_5:E_KE
M\\+=JH+>QFQTP;SAT=B-S4F*UV6!IQ;CRI>7+LML";&47ND\4;'+2YNO31Y;
MXY^?EEB"7CR-PW2O9+KQ/=/-U!4FV'CU'WEBD@/C+Q\>/QH_,,$I]M9L<%QO
M\-7XP1F_K]*!&DXB-1Z.1X<(>GCX:Q,/U&3$PX</D#-I^#WA^2:/Y/=EE]_J
MM?5QZGQ5&/6?%TM?%M#R_WI@U6FSZI17G?Z]I/S@=.19OO%;'9L7QW =WA0W
MYOCE8J >7$;]8&!N7OVT,?3B5N<[E<HMB_?=:F5CHU8ZMJDMZ7WMU2W,FSY=
MN3&%VA9P7D6YB]2-V=@X-;**^:VR6UI45="90M%+FM8-TP]Z2^K4NWK=&+/!
MT=5K[T^4.QB<3M4*?W,\[TY7&'*1S2*J-$7F5:&Q6[4J7*9&*B-%5J53YX/Q
MF=H9782Q,4AQ.7/)K<+XV/D2VX7@L=V52^%=_3='/VT*8WH6H:[MI]Z-(RCX
M3D&_OZ]RH\;G=-&_<?2^SQ!9ZXE:P-B>J-ETAK^C:#::\N=X,3ZZWKBB?$9;
MZHXXT4_5&&,64S49+V 0TZ.?7 G^]&8=1:,QS70^'?*WQ73"G]/%[.C?_VT^
M'L^^56_S.*T2".!&%U8O4].=@D3JJZ7<L3F892)U"WEOE 9[+*(-*+,:9GU=
M;;>I(8F!BEC[C5J!;Q@DT8W#!&;+7?Z,GAY]EG<=5C73>9'GOE8)TQ;"O/%L
MT2=FJ5-6&8G$1(2H<)>TPJ3824(:<F=RU@12@H9$."*3+3$%G-$=B6KO3<DD
MG4<ST(*+:;28C>Z\F(+=P;Z>(;P4!6G[$S6.%J.YB&LV?'@0F%F/&YU%B_F"
MEAH-YT$7W/UC:?YYM!B>T\4L&L[F1[]PE 4/] V&K0^;E3IAVWFJ9H,QV=+=
M40G<IJM $98V:CJ8JC^IL\$0?S\4+JGB4OUH8@U7\C9O^4@./5)EQS7<N!23
M0"7!\8('8 U7%0J0H- >*R1J;=((\@3\B(WWKMBQ^* ]L&2:ZT>#D$T<N#%D
MZX7>TLZW0D;?$VU@Z5:8F43BR3YM@6X\3<D/\)<G754E0D+$]D%^T;O8LNK<
M6O(P&^L#O0/U"EP#T3*NJVWE1I>\Y-(8TKW8@,1$& ":;<83@M"E&*3SOJNA
MG474.L5+*9ATB^GT%F,^\7#<>3*.AF=G[+)7C2.BR#L@SE"@X"=/II,I[_@)
M;&@^%77'[*Y(PJXLL[BH\+6K0F%C""S>I39AZGJV!H+*WL*\3-=X@N 1MXC9
M8$*Z&R VK:&\_6#\5M;*B85P+U $SV)>5A[QT/N^\D#OK4MLS(Q9&G);)%[H
M%-A,@B1?YRH$G53;3")7JF]]A> GTE\[J',>' B8&AN3@!IY%3.1E-8L3"_2
M9'<(6A,9PE(R#7D#]0MI1]@G/?T="T3@^D<3G%;,6[2\'[8'FR= IL6NSP$H
M"/SVKV$Q\ZDDK']#<EU7J2CA<J=ROM*P(E^2M3(?'-C6)T_74@@F\//@>A#H
M#%3]6A76@^'"$-R6&-&E2)P1A>P+;))8 4N.\"[<BI8T@BWHGI5)W=8.'.K9
M+06QT?FWGNC/$UV0T=!DT$#+IAN[L*Y,'K;OBGT^TQV;LX!<3H(0NP<(*6P-
M,Y!WB28Q4" =U6'#)/S<E;6QE <()+FEIF1S*0ND%K1^IG<\;FG4Q]S=Y@ ;
MA0B+3$^TF)>#2S #.%"+YT&U")L2G7A*:J!CT.HM\Q&W7N&3S2)<P-LDXFUR
MG9&W)AD@P\)*&KZ:++RV@(BI$ '>FJ#8B<ERN[(820\%DHE7"T]B42IH\HWU
MS!3:*.*'&!R]>V6*-89=K(&C&-EM8<45+8\MM>O11N"%&\I/:&S]97^.IP'%
M47P2#\EBUWF0C5H6KD* (AK>F&51(3L65Q2(>HU!M[3':[: 2_"R) 9>;LB/
MX668B:9-9U@6$-05MMS!O6'(QJ7$!A)D HIC*%&/]=Z8CR0AC<@)D%G0TE P
MA"^)JN1@"V83*2'=N%>.\!\;BTA0!L0*MR5L6\)</ZHNA[H34$Q /,ZLIT"$
MG<AX;!%>#O1M-9M&;7X4D *[]!HK  !V+?A14@^AMZ;F$JA>WF-W#;#IBBW'
M9(H>CN,,[)UBSW@X9#TLP<?<[-3*A)Q"7 S%XYP3E!"FZ_TTO&>PVA$,)@-S
M<]-Q+O)^S1#6&AJULH0N-+($X7NNKF"9XU&(6J3RH;("3Y>L67EEH[8(,:0/
M)^!\;NS:@9D>$4CLC)T*WD%TALL;J/>\+?GFU?M<751K>'(UYF Y6O0=.H=W
M[^TZ9TKA9XKD&>0'94SA[G(*AV3$ =W4>!*K@PV)061UDD[1?N^/%%I-_J0*
MM],I)L:$=58&I8,! .FDRFLD>Y$BAC=9&?[:K,J4SACZP7.IWV!JV%D$K[.V
M.2L\Y@$_)P/:+#-X<6BG-8%7E8\K.+F/!GX3:_R$A,Y#\S'_&X)_K$,1J=1
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M[ ;ZOI)TH-W".NC[ZL7_4$L#!!0    ( %=$-E,OH[=8400  .,)   9
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;(U636_;.!"]YU<,O,&B!;RV),NQ
MG#H&ZC2+#9!@@[3;/11[H*6Q190259*RXW^_,Y2L*D%B]")^SILW;\@1%WMM
MOML<T<%3H4I[-<B=JR['8YOF6 @[TA66M++1IA".AF8[MI5!D7FC0HVC(+@8
M%T*6@^7"SSV8Y4+73LD2'PS8NBB$.:Q0Z?W5(!P<)Q[E-G<\,5XN*K'%S^C^
MJ1X,C<8=2B8++*W4)1C<7 T^AI>K*>_W&[Y*W-M>'SB2M=;?>7";70T")H0*
M4\<(@IH=7J-2#$0T?K28@\XE&_;[1_0_?>P4RUI8O-;J7YFY_&J0#"##C:B5
M>]3[O["-QQ-,M;+^"_MF;QP/(*VMTT5K3 P*63:M>&IUZ!DDP1L&46L0>=Z-
M(\_RDW!BN3!Z#X9W$QIW?*C>FLC)DI/RV1E:E63GEH]HG:E35QM9;B'5UMG%
MV!$P+X_3%F35@$1O@(01W.O2Y19NR@RSYP!C8M31BHZT5M%)Q$^8CF 2#B$*
MHN $WJ0+<^+QXC?P5E+#5RQ=;>'N[AJ^W6.Q1O/?">2X0XX]\N27!+PF 4&4
M&= TFAW"MSO:#[<."WO*V[3S-CT9QR^FZS1(,H)7<%Z=$P:AU!224CH5#C-P
M&ER.%&A1B?+P^V])%,X^6+J?E39.K!6"Q2W=6C:VO/70@53".- ;;]]N@@J-
MKRQEBE"@L+5!!MO62AAUH-Z.[B&Y71_HU)=4)MAJ!%]RTA?27)@M-BQEF:J:
M#A]UR*H?"3Y1!;.TC5;8=:I+JY7,?#C64>.9$#$J=49PL; ^ARG%:##G"K3S
M#G2!\$YI:]^/X+8!V^C:N!Q^U!0;&@;A$^O-HR!,AGVQ0&2Z8J?/^55*D$/2
M59([39[8I*\+@=Z6A%YZ;D+U> ZA(HQ45I2@ QD:76]SR*DZI[JFH QF=5O^
M."#BSA[U9B/31I 4*6O<\G8C\9BUCK/-Y<9Y>J(D@TP:JJ>028I KFL/7>@,
M5:LN9^4(Y=/4AK='@UY0A:Y)4E^G^9 UJ="7:'48^OD^"W*J3>:/GR,!*"U_
M./'4'0!2Z'QZ,1G2=S;UQN?A<#*;L#KTKY'^)*GC^;6X(_U869+8NSF@,!:0
MBQ=0Z?'%H2L_0\^PE](^U2;&E[>AN3R>*R$RM<Z5#YLU.=*<QTEO,4S\XNNP
MS\]-=_H)IQ*'YLXQ$IV%5G71BFZD)1[MU=MHNLQ[0K@\NZ%\Z ,B_$T+!KXP
MX;.54%X<X5YJ0>3.83Z?T3<*+N@;#J-@<G;S\X*EM:$C!_$\A"0&2L;9PY%9
M(3*Z/>$P3A)X#^^B><!-.)S-:'S*Z1R\ -&'E^UKCH,$PND42/&7GJ,X8H>S
MF+^3\.*D4\H117?!,28AAQO/7JO>X]Z/MT#*!C\O;',#FG]P-]N]8#XV/^Z?
MVYOGSSTE4U+*%&[(-!C-J(:;YDG1#)RN_&]\K1T]"GR7[SD:WD#K&ZW=<< .
MNG?=\G]02P,$%     @ 5T0V4TWK]%B)!0  80P  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C N>&ULC5?;;MLX$'W/5PR\Z=8!M+8E^9)DDP#-I=@"21ND
MEWTH]H&6:(M;BE1)RJ[[]3M#THJ3)L&^6!3%F3ESY@Q)GZRU^68KSAW\J*6R
MI[W*N>9X.+1%Q6MF![KA"K\LM*F9PU>S'-K&<%9ZHUH.L]%H.JR94+VS$S]W
M:\Y.=.ND4/S6@&WKFIG-.9=Z?=I+>]N).[&L'$T,STX:MN0?N?O<W!I\&W9>
M2E%S98568/CBM/<F/3Z?T'J_X(O@:[LS!LIDKO4W>GE7GO9&!(A+7CCRP/"Q
MXA=<2G*$,+Y'G[TN)!GNCK?>W_K<,9<YL_Q"R[]%Z:K3WF$/2KY@K71W>OT7
MC_EX@(66UO_".JS-9CTH6NMT'8T102U4>+(?D8<=@\/1,P99-,@\[A#(H[QD
MCIV=&+T&0ZO1&PU\JMX:P0E%1?GH#'X5:.?.;G@]Y\:^!OZ]%6YS,G3HE#X-
MB^C@/#C(GG&09G"CE:LL7*F2EP\=#!%-!RG;0CK/7O1XR8L!Y&D"V2@;O> O
M[U+,O;_Q,_[.A88O7+G6PO7U!7P-*?_S@N=QYWGL/><OD@=7GCKX>HV?X9WC
MM7W)^:1S/GD1]O^HS,L.I@.(/G[_[3!+9W]&3\_,%AH[S3I>@EZ JS@LM,26
M%6H)S $6)22;I\=[5!BL3GJT=XL]Q(U!HWU(IX?):#2Z'^U=Z+K&SDO3/,EG
M^?:)1GHAG 6A'#?<.F *@V)(L\7"ULR4%OIWY!V<AO?:<3@:1*K_H#XL$7&-
M>Y-EOKWSY!!CY\EL-M[;A^QPDJ08,H[&L[U/F!%K7:6-^(FVJO798*I% $D8
MFBZ;5A' -<+#H12U0%X&\$'!#=O F*299@D.CD8CGW-T$LS(%0:-GQX[[9,M
MW!/WF68/0BQA;4N!+EM#O+_7JT ZFDP27Q2DM&%J WKN<,=%<P;[DXB!-<(Q
M285T1LQ;3\O"Z!HH+/^!Q26G=:B^1YDFXZ-@+-33V0=$'O3D%] #(%:?)' ;
MI6(K#M8QTI6A'=+&A6(E)%]RF\"Z$D6%  K9ECP!! X,(ROM(#*/"CB&?GH
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M:F'"A3:\.-WX2^1<.[R2^F&%_P&XH07X?:$1>GRA -V_BK/_ %!+ P04
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MBZ\TW:G0WD&63*=C>D^3+)^>W)-YH#*1?9.:Y/ A.1]?G'1-+XA7N@<&5RK
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M\GGTK6T^IY:U,KBVX-JZEO9IA9KV"S$6SXX;M:LX.))\WL@=WB)_:];66\G
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M*_\2H0T!?G]+_JA[(R08WK;\-U!+ P04    " !71#93@-\**4X#  #?!@
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MH]G0%PBU"Z#]@U+VO' %+M^TU=]02P,$%     @ 5T0V4QC,3J6>!@  !!
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M9'XS,,AT[O[*>\^'SH:KTT<V3/R&R8]NF/H-4R;48<9DO9&5?/VR-!M1TFI
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M8'/ZH"",$O9 !^4^1O+Q!!-ZGEO)#_?9)]0?4.,6:NJ@,IQ=B:K%0G$4[GN
MT<Y2J(_M: R.\JJ"(ZW*M4%:H>*:$,%QF4@-_,)"QCK5U8,X_$K//M"S=_[9
M$9D9T=%:2E%J:&$!_?)" 3OK@LYZ-KF8L$$4:0WEA\$,L3DD%A&Y*0_"UHN%
MCC5Q G 6-=O @S"E7FK29&UMK6!<-G8GECAQ42*6B84B7V#K^>^ 2IM=*$>>
M!)]A+.DJY)2P3[5.Y7>IA*QU4:>@SK+:*N@9BP6D/;LZ#49.U*A[;=D"6BC
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M #VYJ7H[0U7GF)[['(YQIJ5S-;B:+!;9.0+)O':^LBY\EIIJ$)Y(E_%C#9R
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M[ &IRPE<H!]DUHU2PLAE84<N+#:RU6I5Y%M12JLD7=FJ7JDZ#5@3\Y@ P0<
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ME'_!;O/ &"\Q6K"?N@XT)QD&7X3&R8G4VU2D4WAY>7(+(>90.FY(&1./57(
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M/HC<$ZO:U_@07D^G0 3%?AVWZ8BZHA$Q;XF0O'#NC8MS?.K5.9#_D00H4@=
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M*%1V<#..4#I@!E\%\L((A7N*<X]O6K4#>XKS N++FTE"[^1R.!F= KV Z_&
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M??\\Z]K&'_>N^5Y1,6LJF< 5A2;'8_H\3-?0.L/I)C21I7;4DL*RHG\ &N]
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MU5[GVX61&W<CGDM#]VM'KND/")7=0-^74II^80UL_ZDF?P%02P,$%     @
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M&Z6TW:CN)M%]&+ETA_&9-'2T=\V2+E^H[ #Z/Y?2K#_L!)OKW,4_4$L#!!0
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M4=L[Y%QHO)':;LYHQJ29@.\70NC-@W'0_0TQ_0=02P,$%     @ 5T0V4[A
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MX_WHXC#4RXR7L:UU,)/-+%['L?6-RNNV;E]EFX+)"^M5+2SN+NEK0=72V1@
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M:[H=;O!'"J01P/65$'HW,1O4OV:S?P%02P,$%     @ 5T0V4\RJ,/<6!P
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M;M\>./;3XEOOO(G.[;#F"4IFFEXP<#Q]/8O!,G"#IQ#8@V*JF6B"[0EFV3#
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MD>D$'>P?->P?_4A=P=_P%8G(]UCRFJH+FW/#_ZCJNG'_3VS??@VW<KWBA^W
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MOT:\7G%VG3\$:?174'O>NPM:!%',WI\L"BZ[*K$(A9SS1HXID?.Q?#A&V/B
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MVH%H#M#-0/%=?:1<<Z4/J/7E5G]T@# &>G[#N7H=F%-J]QFS_!]02P,$%
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M=O9:NPSDLFS"%2EW7-79-$^;1O^Z;&\/GM_2R[NJ76_#5+\>X*?_DN>*I+#
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M%5>Z%=MAH2]+$"9 ?\\Y5_N)2=!<OY,_4$L#!!0    ( %=$-E/!#Z>2P0,
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MU;RHS^"ZH_C*GDHSKO099YM+_=T"PA3H\3GG:MTQ!YW[$AK^ U!+ P04
M" !71#93GKK'+MP$  !.%@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6S%F-MNXS80AE^%,!9% JPCD=3!2AT#B=W=IDC;(-G=7A2]H"W:%I8BO205
M)T4?OI2L2+)UB!W$R(VMP\SPY\SH$\7A6LCO:DFI!H\QX^JBM]1Z=6Y9:K:D
M,5%G8D6YN3,7,B;:G,J%I5:2DC!SBIF%;-NS8A+QWFB87;N5HZ%(-(LXO95
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ML5)H])[&]"$*(_9S9XNHE.+ YX]W$^!SE/,'O/;1;0:R8-0@VP-^]PEL[ZV
MST'15X/B^A,D\8)"T+4^>I6.6J91*$/)C_50@8B2!]CM*V;@,.FK8?*2Y$7*
M'H7TU 1\U,I7=8+_^N$'TS =Z0;0G'!8K9^%ZQYD95NW&_6@JMSR.8;[ZD/'
MNN\>2$C[%]"IWST%6&;? A)*3=00?PM[,V;/2*95P$-X1 Q "MU505&?5C>^
MK X%][S/\3FP^VI@W^%IW8VF:U^3LPLX*P3J0+KC0);,H''XPN![6>9'HA#5
M]X<R337]0\B0S^8O*ETYMP3:VY/O"MSL"A+":@AMBC1ED[^ WJ(YK)WUYZMM
MA3G3!./=K02<.@)US+S9'KP-NH45V.\+) -.+8'V/F4WY]1A3YV,.MX@&15P
MJ@G&2T8%G"P"-="6^M:A))H";T#H4VVE)DD1T^?J[V7/I#\$DC)"B#1QSRNW
M@*-UH$9KA6+5$42C5Q>]^]^5!1R^ ^W]]*@K9Z.(+1!*",>[PP:SK89A/^\<
MLS5?*=%W?#EM1FF]/#*=]7S-1UD[S XZ/27.V!!*_0PU?@\,]/J"N].F?T\,
M'P[Z2A -4U!LY!-!]\C&T^J;(!DVA$H\8[P3 S:$@CE##>P[%S-\THU@'6!U
MB:8A5-,9ZL-$G[;-#EEE1.6*2LK.%<B+#:$FSE"3PO<PHWH$O1F%&C5#S12]
M9NQY<_RIZ7 8.6!#J#DS-J0'?G5UD4^5\Q4JP(P1P5RLWM:4;V]2[7F&)377
MV'6\M:N%&VD[W^V[6L"MZFPU9.]<ROE9-X*IJ\\6"[1U%=J[E5;>8$G)],]V
M7_8 BV73FKKIO_D2_4:GC_XJ&8LUU9JBZG_8/?J-3M\ALQ<H9\L*[@VVB'H
M_181:&C+VFQ$'A]3^L@R$ST0_[GINO7ZJS?_A\6*:$U)=*]2(5E&.9E'?[)+
M,5:(2D+E-XJ<-2.MA:]KE61?L*0^&CL]J7PL%DAKRI(W*(X[:_K2P[LL/Z6
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MU@TS+(F5W(&RT<1F!\X;AZ9JN+"G^&@4[7+"F639:%K1&C)9K[A@UEL-3.3
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M1*#:KME.C-RXQK.2AMJ8&Y;THT%E VB_D-*\36POZW]=R2]02P,$%     @
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MD_;C:Z.TL[9I!#>/OVL_KP>O!S-E)1^)[)]TIA;'G4$'S/@MJS)U+>[?\69
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M\_)#E4^Y7$5:K[!ZI+Z5=MQHVIR&R!-EBT48YN)/1?D 7#)5R;28@].E3#,
M5QT'"D7$(A/V7SS\EH8PC$,]N(3S60ENI<A_JLB:W+CPPR@BGO18^,$P_9Z:
MGG,^E97>4 %:)R@.-4V6D^C%.8DL)U$8;L^5H,;,9H+TYA2W)PAM=)!A8FXF
M*#1>BSV$7ZPG119QB#QC5SIJM&T&;PB'V!<]"S]$7[R2+.I0&'4C5BX.0:+_
M J[MZ='76S]CTRS$,DV4=L'<;PU![,!7=^:^"%C8H7!;=YHDHC)N2)YP[=,T
M:^L 1HV63>L$(@]>D*4?VM$,FF"8 /P8E58?W"X0^2-@$8?"B+O0V_!""?G0
M:G/HV.QC.&BWB2W!<+0#*GS)TE6]";70ZV_2=#ZKC7^;*XW*K29X2/H>5RS?
M\$Z^Z>9//=2^F PLS1N)5@>@XT#<]X0?6X#A,,!T'\J*>:KK+C1VY)@>]+T]
M'M[8&X=[O(_+&CIZH<HX*X,>8'?ZQ3#V.& YB,,<_%@G/V"6N$G'GJ8+6^SA
M<,^WGO1+]L#JR.O<LR21%=_B7ZM';A/8A9!$GOTQMGC$83Q^W)H'N[QP:=@U
M;W@\3E@<XC .5T[L,N["L$N&V&?<TA"':?B!JQ]?_+6:=SDX&-*A#TH6A#@,
MPL";DQ%V.8BP[YT(L1PD80X^BO_$!:"?_\0"D(0!>+V]]@9#3UP$^K>:Q#*0
MA!FX\^70B+A[7((B#_R)Y1\)\^\=DU,AP26?Z69V43?YGR^YV1"&VCRR\=HO
MO)-]2C-)+,Y(&&>/:R8GQ"58((F67R1^Z5Z26$Z1,*<>,W$FQ.65GC>^ 5M<
MD3"N]EFY)\2%%1E@3^-(+*M(F%4[ULT):>G;/ .FEE8T3*LG+)L3ZL*K._2M
MY-3"BX;A]9A%<T)=>G5A//0T,=3BBX;QM<^B.:%N"]>-AQZ"44LP&B;8F-]R
M::9;6B0BYT"Q;ZW6W?:MBV+?R"W?:+A]N[BZ_I7ER]_'K39;>C="/&LFW?B^
ML>.%W5Y=PH2ZE"-PX&D2J*4<#7=IP<\K;E/FFW,6=#0,NFVVK]:KWTI0")WN
M0DF19:9[3YN7V:U>N?3#_D!8^M'GV[I.:,NG"9? O8VOS.97!Y=,SM.BU'N3
M6RT6'?:UO%Q]R%^=*+&L/SQ/A5(BKP\7G.FUSSR@[]\*H;Z?F&_9ZY]3G/P/
M4$L#!!0    ( %=$-E/3H'9*Q@(  .((   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;+56;4_;,!#^*U8T32 Q$J<M+:RM1%M-J\2D"L;V8=H'-[DT
M%DX<;*>%?[^S$](R:(J$^)+X[7GNN3OG+L.-5'<Z!3#D(1.Y'GFI,<6%[^LH
MA8SI4UE CCN)5!DS.%4K7Q<*6.Q F?##(#CS,\9S;SQT:PLU'LK2")[#0A%=
M9AE3CQ,0<C/RJ/>T<,U7J;$+_GA8L!7<@+DM%@IG?L,2\PQRS65.%"0C[Y)>
M3&C7 MR)7QPV>F=,K"M+*>_L9!Z/O, J @&1L10,7VN8@A"6"77<UZ1>8],"
M=\=/[-^<\^C,DFF82O&;QR8=>0./Q)"P4IAKN?D.M4,]RQ=)H=V3;.JS@4>B
M4AN9U6!4D/&\>K.'.A [@)#N 80U('2Z*T-.Y8P9-AXJN2'*GD8V.W"N.C2*
MX[G-RHU1N,L19\:34N.*UB22V9+GS(9*$Y;'A.=KT 838#3Y0J8R*V3N)C+!
M/</R%5\*($QKP$46W9=<04R.9F 8%_H801,D0^X3,L\C\@E1Y&<J2XWL>N@;
M5&\U^%&M=%(I#?<H_<'4*>D$)R0,0GI[,R-'GXZ?L_CH>Q. L E Z&@[AP)P
M:3W0W-V5/U>X1N8&,OVWQ4:GL=%Q-KI[;,S_#]=KWE<4/4=AOZ7U>- /@F#H
MKU^QW&TL=P]9Q@N/7T#)!"D4?LS*/+9XU&MX>Q\6M;/&QEFK]EL-22G(%4^
M'.'=>02F]/%KH6OGH4$%;9'4;R3UWY_(_HM$=CN]?8D<-)8'[987UY]95GR=
MM7AQWG"=?UCR:+ M+,'[8U5S/ ]6V-L3++I3U6BK\:FKG*"P<8BJIJ6\:+L!
M=%LOZ,<5#+JM&+2]9+S]\A\@"@]>?KHM)O1@-7E#2KLO4OHRH?Y.Q[+='XO[
MBF/C$9 @*CCM(UQ5#;6:&%FX)K:4!A/KABG^A("R!W _D=(\36Q?;'YKQO\
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M:#=W+%FS6@:(\YNJXD\[\K-G_UU\^3]02P,$%     @ 5T0V4T6MA&0X P
MBPD  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULI59M;]HP$/XK5M0/
M(+7DC02* *F\3.NT3JA=MP_3/KB)(58=F]H.=/]^9R?-*$W3;OL"MG///?=<
M+G<>[X6\5QDA&CWFC*N)DVF]';FN2C*28]436\+AR5K('&O8RHVKMI+@U()R
MY@:>%[LYIMR9CNW92D['HM",<K*22!5YCN6O&6%B/W%\Y^G@FFXR;0[<Z7B+
M-^2&Z-OM2L+.K;VD-"=<4<&1).N)<^&/ED-C;PV^4;)7!VMDE-P)<6\VE^G$
M\4Q A)%$&P\8_G9D3A@SCB",A\JG4U,:X.'ZR?L'JQVTW&%%YH)]IZG.)L[0
M02E9XX+I:['_2"H]D?&7"*;L+]I7MIZ#DD)ID5=@B""GO/S'CU4>#@#@IQD0
M5(#@&-!_!1!6@/"]#/T*T'\O0U0!K'2WU&X3M\ :3\=2[)$TUN#-+&SV+1KR
M1;FIDQLMX2D%G)[."@4G2J%$Y'>48_/V%,(\193OB-)0$EJA,[22 MFJA.)0
M\!(4ZBR(QI2I+CR= 0J<G*)+GL#V]F:!.B===()<I#(,"/"&;CG58')BUE\S
M42A@46-7@PH3BYM4$<_*B(-7(@[1E> Z4VC)4Y(VX!?M^+@%[T+VZA0&3RF<
M!:T./Q6LA[SP% 5>X#?$,W\+SGLH&%BXUR3G_]B7_\S^+!EA74^A]1>^54\7
MR4-!%;7=X,=G.$.7FN3J9PM'O^;H6X[^*QQ?H'TJS$AC\930R$)-D]Q-?>]\
MZ,=C=W?X3EZ:Q=%Y%#VW6KRT@OX;]?WG9LL&SF@0#;S:[)G,J)89O2FSPX2"
M+XQR^#Q)D]SH!?59/#P.<-Y@Y0?G<7 D]Z69'X=A>*2VR9D?#N)FM7&M-FXM
MG"66G/*-0ELBRZ:!Q!K-&3:U9+I3#H4$[3"Y[_C=44L5#6K"06MZ9UC1!'6@
M&:6",2P/F+M-F2Z]#0YE>SWO*#F+9JMA<VZ&=:C#UE 7E!6:I'\1[/!=P39;
M'0?K'DR7G,B-'>MF8!1<EXVA/JUO#A=V8!Z=S_S1W&\X7\!-H[P8_'%?7E.N
ML-Q0F$>,K('*ZPV@ZF0Y^LN-%EL[V^Z$ADEIEQG<EH@T!O!\+81^VAB"^OXU
M_0U02P,$%     @ 5T0V4R TYIGM @  Z0<  !D   !X;"]W;W)K<VAE971S
M+W-H965T-C,N>&ULC95A;]HP$(;_RBGJI%9J24A(@ J06E"U3IU6E7;[,.V#
M20Z(ZMC,=DJ[7[^S22,H@>U+8B?WOG[N<K$':ZF>]1+1P&O!A1YZ2V-6E[ZO
MTR463+?D"@6]F4M5,$-3M?#U2B'+G*C@?A@$B5^P7'BC@7MVKT8#61J>"[Q7
MH,NB8.KM&KE<#[VV]_[@(5\LC7W@CP8KML IFJ?5O:*97[MD>8%"YU* POG0
MNVI?CGLVW@5\SW&MM\9@,YE)^6PGM]G0"RP0<DR-=6!T>\$Q<FZ-".-WY>G5
M2UKA]OC=_<;E3KG,F,:QY#_RS"R'7L^##.>LY.9!KC]CE4]L_5+)M;O"NHH-
M/$A+;611B8F@R,7FSEZK.FP)VIT#@K 2A/\KB"I!Y!+=D+FT)LRPT4#)-2@;
M36YVX&KCU)1-+NQ7G!I%;W/2F=%-+IA(<\8A%]JHDCZ0T7 !4VJ7K.0(W^9P
M)\7BXA%5 1.<&3B=H&$YUV<4]C2=P.G)&9R0'!Z7LM1,9'K@&T*S"_AIA7&]
MP0@/8'PI>0N"Z!S"(&PWR,?'Y1-,6Q"UG3S8E?M4D+HJ85V5T/E%!_THSTFN
M4RYUJ1!^7LVH.-1ROXZ81[5YY,P[!\Q=);ED K(2J:0I%C-4%KT#IV$K"3X!
M,T 5>8.J(&=-!=TL$KM%[+_Z,FKWPCB@]%^V"]<0U@^"K;"='#IU#IVC.8Q+
MI:A38"65^QOEG#*B+C$VMXRJUT2\L4RV4"[:<;!'_,^P'>*X)HZ/$C\)5EC8
M/Y@Y0,BU+JGU$5*I&W'C?8Y^W/\ VQ#4#OJ]9M:D9DW^GY6Z4):BD3#97[P3
M=S\0-@3%8:<9L%L#=H\"WNU\ZW/@J#7M5CL]T03<W6_&) EZG0_(#6'=*.H>
MJ&JOANX=A;X51(S:@&(&884J)5HZJ9I CSNYG[1I)_"W-F)["'YE:D'[*M5G
M3D9!JTLYJ<W!LID8N7)[\TP:VNG=<$EG,2H;0._G4IKWB=WNZ]-]]!=02P,$
M%     @ 5T0V4PZ =_;D"@  ]3T  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C0N>&ULS5M9;^,X$GZ>_15$, MT QE;%W4,D@")D[332/<&24_/PV ?&)NV
MA99$+T7G&.R/WZ*LB+(ED7(2-S8/B1VSBE6JJJ\.TD>/C/_(%Y0*])0F67Y\
ML!!B^?MPF$\6-"7Y@"UI!I_,&$^)@+=\/LR7G))I090F0\>R_&%*XNS@Y*CX
MWPT_.6(KD<09O>$H7Z4IX<]G-&&/QP?VP<L_;N/Y0LA_#$^.EF1.[ZCX8WG#
MX=VPXC*-4YKE,<L0I[/C@U/[]\\1E@3%BN\Q?<QKKY%4Y9ZQ'_+-U?3XP)(2
MT81.A&1!X,\#'=$DD9Q CO^43 ^J/25A_?4+]\M">5#FGN1TQ)(_XZE8'!^$
M!VA*9V25B%OV.*:E0H6 $Y;DQ6_T6*ZU#M!DE0N6EL0@01IGZ[_DJ7P0?0B<
MDL#9(G#"#@*W)'"W">P. J\D\/H2X)( ]Q7)+PG\OCL$)4'0ER L"<*^!%%)
M$/4EL*T7RUF%!ZU-7OC+.1'DY(BS1\3E>N G7Q1.5]"#F\29C(\[P>'3&.C$
MR66<D6P2DP3%62[X"EQ?Y.@W])5P3J3KH@_G5) XR3^B7V$-^K9@JYQDT_QH
M*&!_R64X*?<Z6^_E=.QU3B<#9/F'R+'LZ(^[<_3AUX\M7$9Z+I]7"7!Q)1?'
M+KG<T;D4O(79N9[9'5T.D&L5S*QND2Y,(F4#Y 0F+I?OJ=BG=Q%IW,-BKFWB
M<M6;B\[NG_MS"5NY#,'WJP!PJ@!P"K9N)]M[@:XJWT=_7<,"="5HFO];P]ZM
MV+L%>Z^#_;]6(A<0+G$V1_>, S6\RA%D!KD2L1F:<#J-VRP\6G/&!6>9YQY.
MK*/A0]VAC"O&NA4;"GF50IY>(1[/ 3, +_)\1=$TSB=LU>JAHS4CO[:WAX,M
M#7JL&3?78,=KUP)76F"M%M<;#Q_-R"1.8O$LH35.5ZDR%9J0)7PHGML4Q$W!
M+/C94M&T:D,!OU+ URH )0#E(#R:K0%<2LIRT8;*([\A0(2C+2%[K!DWU]A6
M%+;K$51Z!%H]SF*&OD/<K7)T?3U"?WVAZ3WENL@+*\[A/@([JMA'[Q0'XZB_
M_]J6RMN6=O]U=8!R.FF%=:MIJS!T@PYKV;5RP7XOOQN7K/HYC*T VW9ZQ>YH
M';N79>P>HHNG92R+%@#7&\IC-FTM4?3,;8RFY#G7.(BMH-_68__I%.0#:<!)
MH/< ;T%+RB?@B]!X(,%D>T$YS284W1)!VPLJ_0[6 %O_U,FJ4-W6P_IIRKB(
M_UX_/7BXTZWH 1B,!4GBO\'TR@=HJ]3C<J]ZUL&>NXDF5RV+ MO>7/2Y;9&'
M.SQ(@;^M1_]+SC(A71<4J-L$5%]E4TX>H6]+NZ+9P-L:V [6VD1!O*W'^ YL
M1/]%WQY958BCKT F*,U> N)TSBE=0YX936T%U':P#SRU%5[;H5;=8@/5A<BD
M3+OM<%9RJ[N&HTFLM@)V6X_L7XA8<5D,3"$J6W?6TQ>%JG_XCU]^@:K9TY6H
M"NP=/=C+1W.(_BR:?8B[TP?*I;]>90( )!<%?K3YJH&M,P@<G:LZ*BTX^K3P
M;0%R+%@RK2HH,@<WG(-<B"@85!5PJ[1VPZ*VU6U1IU;BZT']IA;B,T!> #+$
M:H5YX7D)(QD\V_MGE-!L2GF[B/J-L#6PM(#LJ.3AZ*']W8(?*+[$66&3'GC@
MJ(SA>/O  T>AM*-'TLJ[)ZST]R*YMYJE66.['4ZCT-?Y2>@+%!<KSJ8L20CO
M90.%R<Y>,-E1F.SLA,F'16S(D%D7-(?P66DDW@&6A@V<@3Y;.@JV'3WLOJ>]
MSDB^+LKZF,M5,.Y:>YDU*!AV]3#\=G,9-K -YG(5)KMZJ'Q7<]UNID)IOSA_
M?0"ZM>F.NQ>+*I1U]77YU@:'FXI"SS.;T>*( :DDUVI7_3:V(6^Y"K5=/6J_
MIUUOZ0-+'J3_;O5ZO8RHD-[U]V)$!=.N?LCQAB'@N&3=8X+G*E1W]:#[+M.O
M,[=9@&OJ;U<!N:L'\K?U]P;F&#U3LEW;;0Y"%9Q[^O+YAK,)I=,<S3A+D10[
M5W*WV=)K3F6\J/.)>0KV/3TJW](E>5Z?W,#^9D'.O6:EK1-$@;KWRM',+95G
MM=*CSBK?&G7[UKC<9U/ R'8Z!%1X[>FKZ@E+TUBLVTO:VC(9&%B&!.C5YN@[
M(?MN$Q:O.1?Q<4?)ZRGL]OZ?L!L675,!V:SF,3UPW5.X[NT%USV%ZYX>U]\'
M1[TFP@>X,Q85R'MZD/_IQKPK-"V>R2O2M:?R@Q?MPZQ8X3K6X_I;TC5N0GR'
M);&"=ZR']TY4/:?YA,=+F1';',O MCX!F3&.B(!V@4!E.9/EI)R"#]8V+;26
MXY$<$0Z?K"@2"PK+9M)QQ (!<2()@4;*2<#=9>,!Q7;*RL^KH=KC(IXL*#3T
M""IT2,5)3+G.:BKWX)_74+R7O^\V>\$JC>&]M!U8)2>L3TYOJ\$,S(U'++AV
MC/O:C'4#PO%7C<2Q2C!X+PD&JP2#]0GFIE;6758';J.. [>KDEL=?!S;#CKP
M1V42W&,(M'7>AR8+PN=0H0B&<IHD\H,YS2@G"2+3M)A!K.\/T:<ES?+B<(73
MBDNK^&%3?#_JD%ZE"ZRO^*N&N7ALLNI\*;-:96@>UMJAUW%FZ:N4XNM3RL63
M/&]:Q?FB<!0PYWJD?]IUO''E-Q.)$X4=1U^^RB6^'O2KIW%1FD7*T;I_\_!6
ML[]":5^/TI^@#4 ?KEF>?Y0>T?Y<6N5QFB->!W<T!+Y"4O_58W;*H:F#K+>?
M@S=?8;&_ET&[KT#4-UR&8=G\-R'5G19..2,Q1P\D6;4V2'YSUFZ'$78[;C3X
MM1LM^H'[CN=_);>-\S_-:9&O0-<W3&MZW^PX\YNEN^_[V]=FFJC<>?_#5Z#L
MZT%9?__#;T*I[OZ'K]#4UZ/I+O<_2E:;YWF=%X84E@;FP] W#;G'A@U,9Q*!
M0MN@QSS^[=/;L6$;9^!II[>!@N= #\_;6'-9! +44F#JI7RU+DC0J:@J^E9Y
MF^,;NSB<[["]@NM #]=O&IJ4O#>"PNWT1X7/@;Z<W6\*,1]OZ RO<D" ]Y%D
M H7NP8[HGC"HSV6$UF[@M&&L@:_IQ#VHW434X_ZE3'O?9=J3<;J$[O@074.G
MFB!'QU\A=K"7"XF!PN; ,#C?)8^/@A9T#CULX<WT=6E>MWD]4^%XJ(?939^^
M>R1+W:U/A;FAO8_''"J,#/48^74EPT[6JAN)!N6@ 2(O 9S+"4'G[?U1V"QG
MM^Z^76J7;,JN\#/4XV?US#\ HK.4?GQISPX1 %&KH,T;Y [>\I&+ED61ZV[K
MTUQDN_;6;>E/;?M95I?B"J1#T[2=QP]%0PJ:LO(Z4F=Q.0J;\_6MJTBE3L9U
MF_(J/ [U-?GFE:7B-N:"3N?K"TK32IE6V?6<L3<(MQ&S5&9WPDWM5#((3<E
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ME,7)#\L*GUK0/@#OUTK9_<:/?_=XYV]02P,$%     @ 5T0V4RF<ZIB,!P
M72P  !D   !X;"]W;W)K<VAE971S+W-H965T-C<N>&ULS5IK3^.X&OXK5K4K
MS4A 8SOI905(4.#066#07-@/J_/!;5QJ;2X=VX$=Z?SX\SH)==HF;F"*U/G
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MV'\BS8&<P%0PY3YAW]@&'J25TJ)HP$9!07G]C7\V@3@"&)YN0-@ PN> X1E
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M$1?&!D',D_R7/16)J!B0XQH#4AB0#'<>*$-YSC0;#:58(VE'&V_V(IMJ9FW
M\<2R<J>EN<N-G1Y=,"[1BD4IH!B82B68E&N%_D)W.4](3)%DR0SLQ0*>$5.&
MP:5-J4*I@M  UG.>(#V'S!'+LFT&VPZV9C)4Z.,Y:,:C3\;ME\>4ZV=TPZ3F
M 5_FH[.' =TG7*/OUQ!/0/YGACZ4WKY",$_X8PI'Z-\L-+J1QCJ9H6L10E0U
M&G.!'LP44H6NKL[*.T-/FVS9.7M!D9EQGAE2DYES"-J(XB-$?.+?WYVCCQ\^
MC5-E1BGUVIMG<EXFGI2))YG[3HW[:Y=M=)DL4WV$OCPMS;-J,OH59%R#_%4L
M6L:B62S:1++-ILG?J5)@^&5)B*XXF_"(:PX*%7!"9-F ()729M>.^D<DLNP8
M,\45^GYE J!+#;%J@M<IX74:4U'_2*C\F<C!L4D$>:HVD9F'P'X6PVK1:N2W
M.T-OM0%8MP36W96C6ZX6Z$*"1:)!@M+HEFG8AJU>&;5WB&SU2WC]/\]6'F+P
MBBR\F:Q!B6NP*UGG7 4B-6WS]D)7+%A86;IF<F'4*,OE\S:\'9< C@^1-^P[
MJ??_/'-%C%Z%NOYFXG#E'82;J6-//$ZWDCSL]!63@Z3#B3*FOT=',2"; _J!
M/FRD(X_1K="!2<<WGQI2G"CC9E7^F12#X$V)E1!%9.!O6U#8Z2_N'B2'3JIQ
M[QU*JO=&#;&/VZ1;0Z%3:MPLU=<\V;JNG,SBP4%RXF08'[]#71V_K2N_UZVM
M*^)4F#2K\,^D[*^NB!-<@@^10U)9'#>OCO=25T6,:EW1;AO3&@:=<)-FX?Z6
M;?5,:DY7(,W6=2MNG.Z2SD%RXT29-*^*]U)?18Q7]84[#?7E))DT2W(M.YL*
M[1<V7<3)+^D?))-.RDGSDGD_53;88>=%G(J39A7?D<;?V)=1)]W4/T1"J=-U
MVKR0W@NA18RM-F?4*3IM5O2=^/RU]Q^MG(<<Y($(=2\!^@Y'(D6,ZE:M6R.O
MU*D_;5;_'>MR/UMPZM2?'N3A"74O!?H.QR=%C*9-N%<Y$[;GZR;G,YXH%,'4
MV/CMOJ%9YD?6>4.+979,/!%:BSB[G ,+0=H!YOY4"/W2L"?/Y1\'H_\!4$L#
M!!0    ( %=$-E-C<>F PPP  .=.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<Q+GAM;,U<ZV_;.!+_5XC<WJ$%DEC46[TT0&*G<=QT&S37[H?%?5!LQA8J
M2UX]\CCL'W^D'J8>Y(A.&L %=F/+P]$,9SB_&7*DD\<X^9FN",G0TSJ,TH\'
MJRS;?!B-TOF*K/WT.-Z0B/YR'R=K/Z-?D^4HW23$7Q2#UN%(US1[M/:#Z.#T
MI+AVDYR>Q'D6!A&Y25":K]=^\GQ.POCQXP$^J"]\"Y:KC%T8G9YL_"6Y)=GW
MS4U"OXVV7!;!FD1I$$<H(?<?#\[PAVNLV6Q$0?(C((]IXS-BNMS%\4_VY6KQ
M\4!C(I&0S#/&PZ=_'LB8A"%C107YJ^)ZL+TI&]C\7'/_5&A/M;GS4S*.PS^"
M1;;Z>. >H 6Y]_,P^Q8_3DFED<7XS>,P+?Z/'BM:[0#-\S2+U]5@*L$ZB,J_
M_E,U$XT!!I8,T*L!>F> [D@&&-4 HS/ M"0#S&J V15)IH-5#;"Z(LETL*L!
MMJI(3C7 41W@5@-<59&\:H#7O8-L -9JRVG=>9)9 F^-W;6VU'BX-C<N[#TJ
M':OPRHF?^:<G2?R($D9/^;$/A6L7XZDS!A%;AK=90G\-Z+CL].*O/,B>CY@C
M+] \7M/EG?K%^CA"O_M)XK-%@MY-2.8'8?H>_89&*%WY"4E1$*'O49"EA_0B
M_?R?59RG?K1(3T89%8RQ'\TK(<Y+(72)$!A]B:-LE:*+:$$6@O$3>+PQ-/X2
M'F\/C9\-R*\##$;4(ENSZ+59SG60XR=R=XRP=HAT3<??;R?HW6_O;T(_*J=>
M(.$8YC?+HV-DE/RTBI^4UV2(5WB,-*,EVWF>4JHTY>XAY7X!<S_;))R[ KM/
M"HKK3DMQD8.\J<K3-^5^]4MF8 9SF9 Y=2#<XL(<4D&^S\J<L5=Q5N!ZK<[5
M!1R^M3J-;= T"N:&A/DM8U3%S'$S9I[1@!DM"4U3,G3WC)IT-_YS<?GLT4\6
MZ,]KRA)=962=_A<0R-P*9!8"F1*!?L_7=R1!\3TBTGB^8>%#%)M+UG;!FF5M
M#Z?ZR>BA&0\&*2X'*:8014MG:ZNSI:BSSZ8T14LZ]QG5^AT%H]+4[]'?2.I
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MJAM^(DR ?K[@7*TG9H/F+\3X+U!+ P04    " !71#93H+0#3]\#   M#P
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M 298E34&WU/^QQF6B,3BD[+TXWD&/G[X!#X 0L'W'3L(1",Q-*42K:<VU[G
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M##9WDX7;S57I+5<S$6L2PA1#P ]03$%M;A\W#2,7Z5W62!HCH_1Q#ASU+!F
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MVA19-\Q-WT1I#<S^7 B]FM@#VDX\_@=02P,$%     @ 5T0V4]_'R>X] P
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MX-4$KTT(]A#\FN"_-T)0$X+W1@AK0M@F1'L(44V(WALAK@FQ/JRJNOIH9E#
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MB@M-+B_IJ*!W3%)5W7SJB9&EJZX+::A6NV%&_1J5-:#]I93F96(/:/\!3/X
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M.F@-&:F9NN7;;] E%!F^E#/97-&VB_4<E-92\:(#:P<%+=L[>>X*L0/ X0&
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M[')!R8QRU0!^GS,F-S?JQ8/B/:&C_P%02P,$%     @ 5T0V4P7?W9-%!0
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MZ<%WE: A:U,BP\1PNIEB1+:G=OT.<1DRL+GL&(0$4R3'["37L0W# (9JMV%
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M?SK';$4^Y;?(5V7]+WABM,X!6&S+*E^SP42"=9HU_T^^,TT( Y!J &(#T/X
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MQAC,*603:[A,OJ?K[5H3B4#N2J$_2JP#N;N!>G_SE>B-ZID8=)K+=#<S,/#
M,R8G0B<,]QE0[S1FN%B0528/=>B%6\UV '")E]M%U;B-S;98/!*,I!0[KRE=
M@WY>Z$\<YU_2Z/^% ^<O&-A5&G=@4._!^@:89B8#Y!X)QJ,8(.+PC_3P;S9
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MMC<"KWN(F8;]G%_[;!)R_ _U^/^6SR93PURF9XR0HWJH1W6[^XIIV"\Q\OP
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MN* $Y/?W>5ZUW] _J[#[BS8?_@]02P,$%     @ 5T0V4\[.2XX' @  ? 0
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M:W-H965T<R]S:&5E=#DT+GAM;(U646_;. S^*X2QAPYHZ]AI[&Y( C3)[JY
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MS&EJH[(&]#Z3TKQL[ 7=_X#Y_U!+ P04    " !71#93!*0>Y*@"  #F!0
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M"E#?%XS)W4OJH+R,'?\+4$L#!!0    ( %=$-E.[\&/P\0(  $<+   9
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M!\VDNL8/YM5KZ);(A'(%#&/CZEWT3>N4U0.CFFB1VTM]([0Y4W:8FD<9RM+
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M2PVT:\&2LXB06( U9RF06P*H$#G.(B,T$4M3]4QI,1)ZG-"42B5'"<4KFNB
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MT!><[PF5@^HNW!!ZU%4C6_ ?^'5!0]3%A-Y'TK!KLM!^NZ@;&V<I=WN%M52
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M>28%H.I.2STQ<E5U-V;2&)E7PZ7-#U6YP+Z?2VF>)J6#IM\U_@E02P,$%
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M1AS!'( '#$F2YCVX]SZ*U^^I>/.?OM%O4$L#!!0    ( %=$-E.7BKL<P
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M+[+&?--I.I-MVMW,M$TF[O2V(X,<:PK"*X'[\>M7X+J58GAG;TZY2HP)?GQ
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M/E"30&WY0.941@>(U&$-T-J4:P-X;0JV <0V)=L 9INB;0"U3=DV@-NF<!M
M;E.Z#6"W*=X&T-NKWAZ@MU>]/4!OW[UL _3VJK<'Z.U5;P_0VZO>'J"W5[T]
M0&^O>GN WE[U]@"]O>KM 7H'U3L ] ZJ=P#H'53O - [=!]+ 'H'U3L ] ZJ
M=P#H'53O - [J-X!H'=0O0- [Z!Z!X#>4?6. +VCZAT!>D?5.P+TCJIW!.@=
MNX_= +VCZAT!>D?5.P+TCJIW!.@=5>\(T#NJWA&@=U*]$T#OI'HG@-Y)]4X
MO9/JG0!Z)]4[ ?1.W<]*@-Y)]4X O9/JG0!Z)]4[ ?1.JG<"Z)U5[PS0.ZO>
M&:!W5KTS0.^L>F> WEGUS@"]L^J= 7KG;K,)0.^L>F> WEGUS@"]L^J= 7H7
MU;L ]"ZJ=P'H753O M"[J-X%H'=1O0M [Z)Z%X#>1?4N +U+MUD0H'=1O0M
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M<' N>&UL4$L! A0#%     @ 5T0V4WE"T +O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 5T0V4YE<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !71#93ORU.5M8"  #Q"   &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 5T0V4WFG6?+U
M#0  X$8  !@              ("!&@L  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( %=$-E-\E/OR\P(  $P)   8              "
M@449  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !71#93
M?J!B1]\)  !Z-0  &               @(%N'   >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ 5T0V4T-'',O) P  QQ   !@
M     ("!@R8  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M %=$-E.!*A1^NPL  $%'   8              " @8(J  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " !71#93(87+]AP.  !.2@  &
M            @(%S-@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ 5T0V4Q9P7D!F%P  -$T  !@              ("!Q40  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %=$-E-EODI),2D  '*(
M   8              " @6%<  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " !71#93)&FE>C,.  #0*@  &0              @('(A0
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %=$-E-M0K-.
MWQ@  +--   9              " @3*4  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ 5T0V4X9K]99N$   &S$  !D
M ("!2*T  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !7
M1#93V/>Y%K ,   D+   &0              @('MO0  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %=$-E/2"_D+\@X  -8O   9
M          " @=3*  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#
M%     @ 5T0V4W-CG"U[!   (PH  !D              ("!_=D  'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !71#93])NF:(@,  "Q
M(0  &0              @(&OW@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;%!+ 0(4 Q0    ( %=$-E-P$+@+'10   -&   9              " @6[K
M  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 5T0V4UT)
M<?=K!   8PL  !D              ("!PO\  'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6Q02P$"% ,4    " !71#93+Z.W6%$$  #C"0  &0
M    @(%D! $ >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M %=$-E--Z_18B04  &$,   9              " @>P( 0!X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ 5T0V4U9DC#_4 @  3@8  !D
M             ("!K X! 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " !71#93S""*Y9,#  "9!P  &0              @(&W$0$ >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %=$-E._7^&E(00
M $@)   9              " @8$5 0!X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ 5T0V4^CG?EY  @  YP0  !D              ("!
MV1D! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !71#93
M@-\**4X#  #?!@  &0              @(%0' $ >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( %=$-E,8S$ZEG@8   00   9
M      " @=4? 0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ 5T0V4S.S$R#8$@  ;3D  !D              ("!JB8! 'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !71#93TL6#4(8"  "F!0
M&0              @(&Y.0$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( %=$-E/EXS+H%"T  '*B   9              " @78\ 0!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 5T0V4P>-3$G0
M P  5 D  !D              ("!P6D! 'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " !71#93)RR4$-<"  !A!@  &0
M@('(;0$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %=$
M-E.K5F2ODP(  )L%   9              " @=9P 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ 5T0V4^[/A]=, P  \08  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( %=$-E,"JAM.C 4  )(0   9
M  " @7^( 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M5T0V4[A 7839"   2QT  !D              ("!0HX! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " !71#93T0?=O>0)   "'   &0
M            @(%2EP$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( %=$-E,L!I:]V@0  *8-   9              " @6VA 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 5T0V4\RJ,/<6!P
MIB(  !D              ("!?J8! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " !71#93.WB3)28%   3$   &0              @('+
MK0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %=$-E.8
M]"@_300  ,\)   9              " @2BS 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ 5T0V4\VKY9][!0  H@T  !D
M     ("!K+<! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %=$-E/)!6?(*@,  !8+   9              "
M@:W0 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 5T0V
M4W9XX2^M P  T@P  !D              ("!#M0! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " !71#939MS+#(L$   B$0  &0
M        @('RUP$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( %=$-E-C(.LMM0(  (H'   9              " @;3< 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 5T0V4\$/IY+! P  Q@\
M !D              ("!H-\! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " !71#93A:23@KD"   5"0  &0              @(&8XP$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( %=$-E.>NL<N
MW 0  $X6   9              " @8CF 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ 5T0V4S=QW!X0$   XF(  !D
M ("!F^L! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !7
M1#93J$,DNX("  #&!@  &0              @('B^P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %=$-E-VM0(QVP8  %HA   9
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M970V,RYX;6Q02P$"% ,4    " !71#93#H!W]N0*  #U/0  &0
M    @(&H%0( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M %=$-E,)L(OFD04  $4A   9              " @<,@ @!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ 5T0V4]-9$VI7 @  R 4  !D
M             ("!BR8" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " !71#93*9SJF(P'  !=+   &0              @($9*0( >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( %=$-E/]K!OX1P0
M *\/   9              " @=PP @!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ 5T0V4Z97"GV- P  :0P  !D              ("!
M6C4" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !71#93
M5$VY,6@$  !$&   &0              @($>.0( >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( %=$-E-C<>F PPP  .=.   9
M      " @;T] @!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ 5T0V4Z.SH!G  P  T@T  !D              ("!MTH" 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " !71#93+-D9,DL#  "P"P
M&0              @(&N3@( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( %=$-E-W($!600,  $T*   9              " @3!2 @!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ 5T0V4V"V*QPA
M!0  >!,  !D              ("!J%4" 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    " !71#93.M#7P"$#  !.#   &0
M@($ 6P( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( %=$
M-E.@M -/WP,  "T/   9              " @5A> @!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ 5T0V4XF.?J74 P  &0\  !D
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M=#@R+GAM;%!+ 0(4 Q0    ( %=$-E/?Q\GN/0,  'T+   9
M  " @>IU @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @
M5T0V4Y# J6GL @  #0@  !D              ("!7GD" 'AL+W=O<FMS:&5E
M=',O<VAE970X-"YX;6Q02P$"% ,4    " !71#93]CC5=),#  "L#0  &0
M            @(&!? ( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4
M Q0    ( %=$-E,\";&D^P(  %D)   9              " @4N  @!X;"]W
M;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ 5T0V4X=>0\?'!@
M,R0  !D              ("!?8," 'AL+W=O<FMS:&5E=',O<VAE970X-RYX
M;6Q02P$"% ,4    " !71#93!=_=DT4%  !H%@  &0              @(%[
MB@( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( %=$-E-.
M-4%XZ (  $D)   9              " @?>/ @!X;"]W;W)K<VAE971S+W-H
M965T.#DN>&UL4$L! A0#%     @ 5T0V4P">4Q?W P  SQ   !D
M     ("!%I," 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %=$-E,$I![DJ (  .8%   9              "
M@;6U @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%     @ 5T0V
M4T/H>0"B!   F!4  !D              ("!E+@" 'AL+W=O<FMS:&5E=',O
M<VAE970Y-BYX;6Q02P$"% ,4    " !71#93N_!C\/$"  !'"P  &0
M        @(%MO0( >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0
M   ( %=$-E-\'$IP\P(  /()   9              " @97  @!X;"]W;W)K
M<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ 5T0V4ZG)FG5"!   "1@
M !D              ("!O\," 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q0
M2P$"% ,4    " !71#93M/#$'^ #  #L"P  &@              @($XR (
M>&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " !71#93=F1)
M^9X"  "K!@  &@              @(%0S ( >&PO=V]R:W-H965T<R]S:&5E
M=#$P,2YX;6Q02P$"% ,4    " !71#93?C_Q=<($  "6%0  &@
M    @($FSP( >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4
M" !71#93?\7N6AL$   4$0  &@              @($@U ( >&PO=V]R:W-H
M965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " !71#93T5>YJJX"  !)"
M&@              @(%SV ( >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q0
M2P$"% ,4    " !71#935>>$.E0&  !2)0  &@              @(%9VP(
M>&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4    " !71#93:/!$
MVG\"  ##!@  &@              @('EX0( >&PO=V]R:W-H965T<R]S:&5E
M=#$P-BYX;6Q02P$"% ,4    " !71#93]8"SA90#  #[$@  &@
M    @(&<Y ( >&PO=V]R:W-H965T<R]S:&5E=#$P-RYX;6Q02P$"% ,4
M" !71#93:X?!$/<"   G"P  &@              @(%HZ ( >&PO=V]R:W-H
M965T<R]S:&5E=#$P."YX;6Q02P$"% ,4    " !71#93"Z*IB5P#  #G"P
M&@              @(&7ZP( >&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6Q0
M2P$"% ,4    " !71#93D?KA S8#  #V$P  #0              @ $K[P(
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %=$-E.7BKL<P    !,"   +
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4!08     =0!U #0@  "F  ,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>565</ContextCount>
  <ElementCount>696</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>161</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated condensed statements of operations and comprehensive (loss) income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome</Role>
      <ShortName>Consolidated condensed statements of operations and comprehensive (loss) income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated condensed statements of operations and comprehensive (loss) income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical</Role>
      <ShortName>Consolidated condensed statements of operations and comprehensive (loss) income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated condensed balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/ConsolidatedCondensedBalanceSheets</Role>
      <ShortName>Consolidated condensed balance sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated condensed balance sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated condensed balance sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated condensed statements of changes in stockholders' and members' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity</Role>
      <ShortName>Consolidated condensed statements of changes in stockholders' and members' equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated condensed statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows</Role>
      <ShortName>Consolidated condensed statements of cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Balance sheet information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformation</Role>
      <ShortName>Balance sheet information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Business combinations and investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BusinessCombinationsAndInvestments</Role>
      <ShortName>Business combinations and investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FinancialInstruments</Role>
      <ShortName>Financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Equity-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Net income (loss) per unit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/NetIncomeLossPerUnit</Role>
      <ShortName>Net income (loss) per unit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Restructuring costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RestructuringCosts</Role>
      <ShortName>Restructuring costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Members' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/MembersEquity</Role>
      <ShortName>Members' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Related-party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Net Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/NetSales</Role>
      <ShortName>Net Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/StockholderSEquity</Role>
      <ShortName>Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Organization (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/OrganizationPolicies</Role>
      <ShortName>Organization (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://bio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://bio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Restructuring costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RestructuringCostsTables</Role>
      <ShortName>Restructuring costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/RestructuringCosts</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Members' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/MembersEquityTables</Role>
      <ShortName>Members' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/MembersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Net sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/NetSalesTables</Role>
      <ShortName>Net sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/DiscontinuedOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/Segments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Revenue recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/RevenueRecognition</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Net income (loss) per unit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/NetIncomeLossPerUnitTables</Role>
      <ShortName>Net income (loss) per unit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/NetIncomeLossPerUnit</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Balance sheet information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationTables</Role>
      <ShortName>Balance sheet information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/BalanceSheetInformation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Business combinations and investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BusinessCombinationsAndInvestmentsTables</Role>
      <ShortName>Business combinations and investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/BusinessCombinationsAndInvestments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/FinancialInstruments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/FairValueMeasurements</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Equity-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/EquityBasedCompensation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/EarningsPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bio.com/role/IncomeTaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bio.com/role/OrganizationPolicies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Balance sheet information - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Balance sheet information - Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Balance sheet information - Components of accounts receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails</Role>
      <ShortName>Balance sheet information - Components of accounts receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Balance sheet information - Allowance for credit loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails</Role>
      <ShortName>Balance sheet information - Allowance for credit loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Balance sheet information - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationInventoryDetails</Role>
      <ShortName>Balance sheet information - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Balance sheet information - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails</Role>
      <ShortName>Balance sheet information - Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Balance sheet information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationNarrativeDetails</Role>
      <ShortName>Balance sheet information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Balance sheet information - Schedule Of Inventory Valuation Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails</Role>
      <ShortName>Balance sheet information - Schedule Of Inventory Valuation Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Balance sheet information - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Balance sheet information - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Balance sheet information - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails</Role>
      <ShortName>Balance sheet information - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Balance sheet information - Schedule Of Intangible Assets Net Excluding Goodwill  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails</Role>
      <ShortName>Balance sheet information - Schedule Of Intangible Assets Net Excluding Goodwill  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Business combinations and investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails</Role>
      <ShortName>Business combinations and investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Business combinations and investments - Consideration transferred (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails</Role>
      <ShortName>Business combinations and investments - Consideration transferred (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Business combinations and investments - Fair value of assets acquired and liabilities assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Business combinations and investments - Fair value of assets acquired and liabilities assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Business combinations and investments - Components of intangible assets acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Business combinations and investments - Components of intangible assets acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Business combinations and investments - Variable interest entity's assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails</Role>
      <ShortName>Business combinations and investments - Variable interest entity's assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Business combinations and investments - Pro forma results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails</Role>
      <ShortName>Business combinations and investments - Pro forma results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Financial instruments - Schedule Of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails</Role>
      <ShortName>Financial instruments - Schedule Of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Financial instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Fair value measurements - Liabilities measured at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair value measurements - Liabilities measured at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Fair value measurements - Acquisition unobservable level 3 inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails</Role>
      <ShortName>Fair value measurements - Acquisition unobservable level 3 inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Fair value measurements - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair value measurements - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Fair value measurements - MIP and liability-classified awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails</Role>
      <ShortName>Fair value measurements - MIP and liability-classified awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Fair value measurements - Equity participation right unit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails</Role>
      <ShortName>Fair value measurements - Equity participation right unit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Fair value measurements - Summary of range of key assumptions used within the valuation of the awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail</Role>
      <ShortName>Fair value measurements - Summary of range of key assumptions used within the valuation of the awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Equity-based compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EquityBasedCompensationNarrativeDetails</Role>
      <ShortName>Equity-based compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Equity-based compensation - Restricted stock unit activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Equity-based compensation - Restricted stock unit activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Equity-based compensation - Fair value assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails</Role>
      <ShortName>Equity-based compensation - Fair value assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Equity-based compensation - Option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EquityBasedCompensationOptionActivityDetails</Role>
      <ShortName>Equity-based compensation - Option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Earnings per share - Computation of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings per share - Computation of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Earnings per share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Earnings per share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Income taxes - Summary of Net Income From Continuing Operations Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails</Role>
      <ShortName>Income taxes - Summary of Net Income From Continuing Operations Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Income taxes - Summary Of Components Of Income Tax Expense Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income taxes - Summary Of Components Of Income Tax Expense Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Income taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Income taxes - Summary of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income taxes - Summary of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bio.com/role/IncomeTaxesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Related-party transactions - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RelatedPartyTransactionsNarrativeDetail</Role>
      <ShortName>Related-party transactions - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Commitments and contingencies - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails</Role>
      <ShortName>Commitments and contingencies - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Commitments and contingencies - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Commitments and contingencies - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Commitments and contingencies - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Commitments and contingencies - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Commitments and contingencies - Summary of Lessee Liability Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails</Role>
      <ShortName>Commitments and contingencies - Summary of Lessee Liability Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Commitments and contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Net income (loss) per unit - Summary of Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail</Role>
      <ShortName>Net income (loss) per unit - Summary of Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bio.com/role/NetIncomeLossPerUnitTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Net income (loss) per unit - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails</Role>
      <ShortName>Net income (loss) per unit - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bio.com/role/NetIncomeLossPerUnitTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Revenue recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RevenueRecognitionDetails</Role>
      <ShortName>Revenue recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bio.com/role/RevenueRecognitionTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SegmentsDetails</Role>
      <ShortName>Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bio.com/role/SegmentsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bio.com/role/SubsequentEvents</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Stockholder's Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/StockholderSEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholder's Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Discontinued Operations - Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails</Role>
      <ShortName>Discontinued Operations - Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Net Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/NetSalesDetails</Role>
      <ShortName>Net Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bio.com/role/NetSales</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Summary of Significant Accounting Policies - Summary of useful lives in assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of useful lives in assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Summary of Significant Accounting Policies - Summary of Finite-lived intangible assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Finite-lived intangible assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Summary of Significant Accounting Policies - Summary of significant percentage of total sales (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of significant percentage of total sales (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Summary of Significant Accounting Policies - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>1101 - Disclosure - Members' equity - Summary of Members Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails</Role>
      <ShortName>Members' equity - Summary of Members Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>1102 - Disclosure - Members' equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/MembersEquityNarrativeDetails</Role>
      <ShortName>Members' equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>1103 - Disclosure - Restructuring costs - Summary of restructuring charges and payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails</Role>
      <ShortName>Restructuring costs - Summary of restructuring charges and payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>1104 - Disclosure - Restructuring costs - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/RestructuringCostsAdditionalInformationDetails</Role>
      <ShortName>Restructuring costs - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>1105 - Disclosure - Equity-based compensation - Summary of Phantom Plan Award activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail</Role>
      <ShortName>Equity-based compensation - Summary of Phantom Plan Award activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>1106 - Disclosure - Financial instruments - Summary of Debt Instruments Periodic Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail</Role>
      <ShortName>Financial instruments - Summary of Debt Instruments Periodic Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>1107 - Disclosure - Financial instruments - Schedule of Loan margin Adjusted on  Pricing Grid  (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail</Role>
      <ShortName>Financial instruments - Schedule of Loan margin Adjusted on  Pricing Grid  (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>1108 - Disclosure - Financial instruments - Schedule of Commitment Fee  Adjusted Based on Pricing Grid (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail</Role>
      <ShortName>Financial instruments - Schedule of Commitment Fee  Adjusted Based on Pricing Grid (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="d180330ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>1109 - Disclosure - Financial instruments - Summary of Contractual maturities of long-term debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail</Role>
      <ShortName>Financial instruments - Summary of Contractual maturities of long-term debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-4/A" original="d180330ds4a.htm">d180330ds4a.htm</File>
    <File>bvs-20210703.xsd</File>
    <File>bvs-20210703_cal.xml</File>
    <File>bvs-20210703_def.xml</File>
    <File>bvs-20210703_lab.xml</File>
    <File>bvs-20210703_pre.xml</File>
    <File>d180330dex231.htm</File>
    <File>d180330dex232.htm</File>
    <File>d180330dex233.htm</File>
    <File>d180330dex234.htm</File>
    <File>d180330dex51.htm</File>
    <File>d180330dex81.htm</File>
    <File>d180330dex991.htm</File>
    <File>d180330dex992.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g180330g03a11.jpg</File>
    <File>g180330g03b22.jpg</File>
    <File>g180330g09d44.jpg</File>
    <File>g180330g09f66.jpg</File>
    <File>g180330g10c33.jpg</File>
    <File>g180330g11g62.jpg</File>
    <File>g180330g11i11.jpg</File>
    <File>g180330g13h77.jpg</File>
    <File>g180330g13i88.jpg</File>
    <File>g180330g16j01.jpg</File>
    <File>g180330g16k02.jpg</File>
    <File>g180330g16l03.jpg</File>
    <File>g180330g16m04.jpg</File>
    <File>g180330g17n05.jpg</File>
    <File>g180330g17o06.jpg</File>
    <File>g180330g18p07.jpg</File>
    <File>g180330g20u43.jpg</File>
    <File>g180330g33q08.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>153
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d180330ds4a.htm": {
   "axisCustom": 10,
   "axisStandard": 48,
   "contextCount": 565,
   "dts": {
    "calculationLink": {
     "local": [
      "bvs-20210703_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bvs-20210703_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d180330ds4a.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bvs-20210703_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bvs-20210703_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bvs-20210703.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 993,
   "entityCount": 1,
   "hidden": {
    "http://bio.com/20210703": 2,
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 8
   },
   "keyCustom": 140,
   "keyStandard": 556,
   "memberCustom": 88,
   "memberStandard": 62,
   "nsprefix": "bvs",
   "nsuri": "http://bio.com/20210703",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://bio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Balance sheet information",
     "role": "http://bio.com/role/BalanceSheetInformation",
     "shortName": "Balance sheet information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
       "div",
       "div",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1100 - Disclosure - Summary of Significant Accounting Policies - Narrative (Detail)",
     "role": "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
       "div",
       "div",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bvs:ScheduleOfMembersEquityTableTextBlock",
       "us-gaap:MembersEquityNotesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1101 - Disclosure - Members' equity - Summary of Members Equity (Details)",
     "role": "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails",
     "shortName": "Members' equity - Summary of Members Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bvs:ScheduleOfMembersEquityTableTextBlock",
       "us-gaap:MembersEquityNotesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn02_15_2021",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "bvs:EquityParticipationRightEntitledPercentageOfDistributions",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1102 - Disclosure - Members' equity - Narrative (Details)",
     "role": "http://bio.com/role/MembersEquityNarrativeDetails",
     "shortName": "Members' equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:MembersEquityNotesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "2",
      "lang": null,
      "name": "bvs:PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1103 - Disclosure - Restructuring costs - Summary of restructuring charges and payments (Details)",
     "role": "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails",
     "shortName": "Restructuring costs - Summary of restructuring charges and payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1104 - Disclosure - Restructuring costs - Additional Information (Details)",
     "role": "http://bio.com/role/RestructuringCostsAdditionalInformationDetails",
     "shortName": "Restructuring costs - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2018To12_31_2018_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwentyPlanMemberusgaapRestructuringPlanAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_12_2021To02_10_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1105 - Disclosure - Equity-based compensation - Summary of Phantom Plan Award activity (Detail)",
     "role": "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
     "shortName": "Equity-based compensation - Summary of Phantom Plan Award activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bvs:ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TwoThousandAndTwelveMemberusgaapPlanNameAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodOneMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1106 - Disclosure - Financial instruments - Summary of Debt Instruments Periodic Payments (Detail)",
     "role": "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail",
     "shortName": "Financial instruments - Summary of Debt Instruments Periodic Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_DebtInstrumentSchedulePeriodicPaymentPeriodOneMemberBVSDebtInstrumentSchedulePeriodicPaymentAxis_TermLoanMemberusgaapLongtermDebtTypeAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1107 - Disclosure - Financial instruments - Schedule of Loan margin Adjusted on  Pricing Grid  (Detail)",
     "role": "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail",
     "shortName": "Financial instruments - Schedule of Loan margin Adjusted on  Pricing Grid  (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EurodollarMemberusgaapVariableRateAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1108 - Disclosure - Financial instruments - Schedule of Commitment Fee  Adjusted Based on Pricing Grid (Detail)",
     "role": "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
     "shortName": "Financial instruments - Schedule of Commitment Fee  Adjusted Based on Pricing Grid (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_LeverageRatioRangeOneMemberBVSLeverageRatioRangeAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1109 - Disclosure - Financial instruments - Summary of Contractual maturities of long-term debt (Detail)",
     "role": "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail",
     "shortName": "Financial instruments - Summary of Contractual maturities of long-term debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:BusinessCombinationsAndInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Business combinations and investments",
     "role": "http://bio.com/role/BusinessCombinationsAndInvestments",
     "shortName": "Business combinations and investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:BusinessCombinationsAndInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Financial instruments",
     "role": "http://bio.com/role/FinancialInstruments",
     "shortName": "Financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Fair value measurements",
     "role": "http://bio.com/role/FairValueMeasurements",
     "shortName": "Fair value measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Equity-based compensation",
     "role": "http://bio.com/role/EquityBasedCompensation",
     "shortName": "Equity-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Earnings per share",
     "role": "http://bio.com/role/EarningsPerShare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Income taxes",
     "role": "http://bio.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Commitments and contingencies",
     "role": "http://bio.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:NetIncomeLossPerUnitTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Net income (loss) per unit",
     "role": "http://bio.com/role/NetIncomeLossPerUnit",
     "shortName": "Net income (loss) per unit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:NetIncomeLossPerUnitTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Restructuring costs",
     "role": "http://bio.com/role/RestructuringCosts",
     "shortName": "Restructuring costs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated condensed statements of operations and comprehensive (loss) income",
     "role": "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
     "shortName": "Consolidated condensed statements of operations and comprehensive (loss) income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MembersEquityNotesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Members' equity",
     "role": "http://bio.com/role/MembersEquity",
     "shortName": "Members' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MembersEquityNotesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Related-party transactions",
     "role": "http://bio.com/role/RelatedPartyTransactions",
     "shortName": "Related-party transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:NetSalesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Net Sales",
     "role": "http://bio.com/role/NetSales",
     "shortName": "Net Sales",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:NetSalesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Discontinued Operations",
     "role": "http://bio.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Stockholder's Equity",
     "role": "http://bio.com/role/StockholderSEquity",
     "shortName": "Stockholder's Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Revenue recognition",
     "role": "http://bio.com/role/RevenueRecognition",
     "shortName": "Revenue recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Segments",
     "role": "http://bio.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Subsequent events",
     "role": "http://bio.com/role/SubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_04_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Organization (Policies)",
     "role": "http://bio.com/role/OrganizationPolicies",
     "shortName": "Organization (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated condensed statements of operations and comprehensive (loss) income (Parenthetical)",
     "role": "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical",
     "shortName": "Consolidated condensed statements of operations and comprehensive (loss) income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Restructuring costs (Tables)",
     "role": "http://bio.com/role/RestructuringCostsTables",
     "shortName": "Restructuring costs (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MembersEquityNotesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:ScheduleOfMembersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Members' equity (Tables)",
     "role": "http://bio.com/role/MembersEquityTables",
     "shortName": "Members' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MembersEquityNotesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:ScheduleOfMembersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:DisaggregationOfRevenueBasedOnGeographyTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Net sales (Tables)",
     "role": "http://bio.com/role/NetSalesTables",
     "shortName": "Net sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:DisaggregationOfRevenueBasedOnGeographyTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://bio.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bvs:DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Segments (Tables)",
     "role": "http://bio.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Revenue recognition (Tables)",
     "role": "http://bio.com/role/RevenueRecognitionTables",
     "shortName": "Revenue recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Net income (loss) per unit (Tables)",
     "role": "http://bio.com/role/NetIncomeLossPerUnitTables",
     "shortName": "Net income (loss) per unit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "bvs:NetIncomeLossPerUnitTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Commitments and contingencies (Tables)",
     "role": "http://bio.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Balance sheet information (Tables)",
     "role": "http://bio.com/role/BalanceSheetInformationTables",
     "shortName": "Balance sheet information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated condensed balance sheets",
     "role": "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
     "shortName": "Consolidated condensed balance sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Business combinations and investments (Tables)",
     "role": "http://bio.com/role/BusinessCombinationsAndInvestmentsTables",
     "shortName": "Business combinations and investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Financial instruments (Tables)",
     "role": "http://bio.com/role/FinancialInstrumentsTables",
     "shortName": "Financial instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Fair value measurements (Tables)",
     "role": "http://bio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair value measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Equity-based compensation (Tables)",
     "role": "http://bio.com/role/EquityBasedCompensationTables",
     "shortName": "Equity-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Earnings per share (Tables)",
     "role": "http://bio.com/role/EarningsPerShareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Income taxes (Tables)",
     "role": "http://bio.com/role/IncomeTaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "us-gaap:CommonStockSharesOutstanding",
       "us-gaap:CommonStockSharesAuthorized",
       "us-gaap:CommonStockSharesIssued",
       "us-gaap:CommonStockSharesOutstanding",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Organization (Details)",
     "role": "http://bio.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_01_2020To04_30_2020",
      "decimals": "-3",
      "lang": null,
      "name": "bvs:ProceedsFromGovernmentalAssistance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Balance sheet information - Cash, cash equivalents and restricted cash (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Balance sheet information - Cash, cash equivalents and restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Balance sheet information - Components of accounts receivable (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
     "shortName": "Balance sheet information - Components of accounts receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn04_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Balance sheet information - Allowance for credit loss (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
     "shortName": "Balance sheet information - Allowance for credit loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn04_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated condensed balance sheets (Parenthetical)",
     "role": "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
     "shortName": "Consolidated condensed balance sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Balance sheet information - Inventory (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationInventoryDetails",
     "shortName": "Balance sheet information - Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bvs:GrossToNetDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Balance sheet information - Accrued liabilities (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
     "shortName": "Balance sheet information - Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bvs:GrossToNetDeductionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PaymentsForRestructuring",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Balance sheet information - Narrative (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
     "shortName": "Balance sheet information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PaymentsForRestructuring",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Balance sheet information - Schedule Of Inventory Valuation Reserves (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails",
     "shortName": "Balance sheet information - Schedule Of Inventory Valuation Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bvs:ScheduleOfInventoryValuationReservesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "bvs:InventoryValuationReservesProvisionForLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Balance sheet information - Property, Plant and Equipment (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
     "shortName": "Balance sheet information - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Balance sheet information - Schedule of Goodwill (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
     "shortName": "Balance sheet information - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:Goodwill",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis_OperatingSegmentsMembersrtConsolidationItemsAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Balance sheet information - Schedule Of Intangible Assets Net Excluding Goodwill  (Details)",
     "role": "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
     "shortName": "Balance sheet information - Schedule Of Intangible Assets Net Excluding Goodwill  (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "bvs:ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioventusIncMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn03_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Business combinations and investments - Narrative (Details)",
     "role": "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
     "shortName": "Business combinations and investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn03_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P08_02_2021To08_02_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Business combinations and investments - Consideration transferred (Details)",
     "role": "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails",
     "shortName": "Business combinations and investments - Consideration transferred (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P08_02_2021To08_02_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Business combinations and investments - Fair value of assets acquired and liabilities assumed (Details)",
     "role": "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "Business combinations and investments - Fair value of assets acquired and liabilities assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn03_29_2021_PaycheckProtectionProgramCARESActMemberusgaapDebtInstrumentAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated condensed statements of changes in stockholders' and members' equity",
     "role": "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
     "shortName": "Consolidated condensed statements of changes in stockholders' and members' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2017_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Business combinations and investments - Components of intangible assets acquired (Details)",
     "role": "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
     "shortName": "Business combinations and investments - Components of intangible assets acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P03_30_2021To03_30_2021_BionessIncMemberusgaapBusinessAcquisitionAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Business combinations and investments - Variable interest entity's assets and liabilities (Details)",
     "role": "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
     "shortName": "Business combinations and investments - Variable interest entity's assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_HarborMedtechIncMembersrtOwnershipAxis_VariableInterestEntityPrimaryBeneficiaryMembersrtConsolidatedEntitiesAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Business combinations and investments - Pro forma results (Details)",
     "role": "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails",
     "shortName": "Business combinations and investments - Pro forma results (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021_BionessIncMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Financial instruments - Schedule Of Long-Term Debt (Details)",
     "role": "http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails",
     "shortName": "Financial instruments - Schedule Of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LineOfCredit",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Financial instruments - Narrative (Details)",
     "role": "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Fair value measurements - Liabilities measured at fair value (Details)",
     "role": "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "Fair value measurements - Liabilities measured at fair value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Fair value measurements - Acquisition unobservable level 3 inputs (Details)",
     "role": "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
     "shortName": "Fair value measurements - Acquisition unobservable level 3 inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueDiscountedCashFlowMemberusgaapValuationTechniqueAxis",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Fair value measurements - Additional information (Details)",
     "role": "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair value measurements - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAvailableForDistributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Fair value measurements - MIP and liability-classified awards (Details)",
     "role": "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails",
     "shortName": "Fair value measurements - MIP and liability-classified awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021_ManagementIncentivePlanAndLiabilityClassifiedAwardsMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Fair value measurements - Equity participation right unit (Details)",
     "role": "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
     "shortName": "Fair value measurements - Equity participation right unit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated condensed statements of cash flows",
     "role": "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
     "shortName": "Consolidated condensed statements of cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "bvs:EquityParticipationRightsUnitMeasurableInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Business",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Fair value measurements - Summary of range of key assumptions used within the valuation of the awards (Detail)",
     "role": "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
     "shortName": "Fair value measurements - Summary of range of key assumptions used within the valuation of the awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_EquityParticipationRightUnitMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "bvs:EquityParticipationRightsUnitMeasurableInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Business",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn02_10_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bvs:NumberOfEquityBasedCompensationPlans",
      "reportCount": 1,
      "unitRef": "Unit_Plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Equity-based compensation - Narrative (Details)",
     "role": "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
     "shortName": "Equity-based compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_12_2021To02_10_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Equity-based compensation - Restricted stock unit activity (Details)",
     "role": "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Equity-based compensation - Restricted stock unit activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Equity-based compensation - Fair value assumptions (Details)",
     "role": "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
     "shortName": "Equity-based compensation - Fair value assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn04_03_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Equity-based compensation - Option activity (Details)",
     "role": "http://bio.com/role/EquityBasedCompensationOptionActivityDetails",
     "shortName": "Equity-based compensation - Option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Earnings per share - Computation of Basic and Diluted Earnings Per Share (Details)",
     "role": "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails",
     "shortName": "Earnings per share - Computation of Basic and Diluted Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P02_16_2021To07_03_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Earnings per share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)",
     "role": "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Earnings per share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021_LimitedLiabilityCompanyInterestsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Income taxes - Summary of Net Income From Continuing Operations Before Taxes (Details)",
     "role": "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
     "shortName": "Income taxes - Summary of Net Income From Continuing Operations Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Income taxes - Summary Of Components Of Income Tax Expense Benefit (Details)",
     "role": "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails",
     "shortName": "Income taxes - Summary Of Components Of Income Tax Expense Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Income taxes - Summary of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income taxes - Summary of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Organization",
     "role": "http://bio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwards",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Income taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Income taxes (Details)",
     "role": "http://bio.com/role/IncomeTaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OpenTaxYear",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_TaxYear2015MemberusgaapTaxPeriodAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bvs:CashDistributionMadeToMembersTowardsTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure - Related-party transactions - Narrative (Detail)",
     "role": "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail",
     "shortName": "Related-party transactions - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bvs:CashDistributionMadeToMembersTowardsTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure - Commitments and contingencies - Lease Cost (Details)",
     "role": "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails",
     "shortName": "Commitments and contingencies - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1084 - Disclosure - Commitments and contingencies - Supplemental Cash Flow Information (Details)",
     "role": "http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails",
     "shortName": "Commitments and contingencies - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1085 - Disclosure - Commitments and contingencies - Supplemental Balance Sheet Information (Details)",
     "role": "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails",
     "shortName": "Commitments and contingencies - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1086 - Disclosure - Commitments and contingencies - Summary of Lessee Liability Maturity (Details)",
     "role": "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails",
     "shortName": "Commitments and contingencies - Summary of Lessee Liability Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bvs:StopLossInsuranceThresholdPerMemberPerYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1087 - Disclosure - Commitments and contingencies - Narrative (Details)",
     "role": "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bvs:StopLossInsuranceThresholdPerMemberPerYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1088 - Disclosure - Net income (loss) per unit - Summary of Earnings Per Share (Detail)",
     "role": "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail",
     "shortName": "Net income (loss) per unit - Summary of Earnings Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "bvs:NetIncomeLossPerUnitTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "bvs:NetIncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1089 - Disclosure - Net income (loss) per unit - Narrative (Details)",
     "role": "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails",
     "shortName": "Net income (loss) per unit - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "div",
       "div",
       "bvs:NetIncomeLossPerUnitTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_PreferredUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://bio.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1090 - Disclosure - Revenue recognition (Details)",
     "role": "http://bio.com/role/RevenueRecognitionDetails",
     "shortName": "Revenue recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021_PainTreatmentsAndJointPreservationMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1091 - Disclosure - Segments (Details)",
     "role": "http://bio.com/role/SegmentsDetails",
     "shortName": "Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2021To07_03_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P08_02_2021To08_02_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1092 - Disclosure - Subsequent events (Details)",
     "role": "http://bio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P10_01_2021To12_31_2021_MisonixIncMemberusgaapBusinessAcquisitionAxis_ScenarioForecastMembersrtStatementScenarioAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1093 - Disclosure - Stockholder's Equity - Additional Information (Detail)",
     "role": "http://bio.com/role/StockholderSEquityAdditionalInformationDetail",
     "shortName": "Stockholder's Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bvs:DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bvs:DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1094 - Disclosure - Discontinued Operations - Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss) (Details)",
     "role": "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails",
     "shortName": "Discontinued Operations - Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bvs:DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2019To12_31_2019_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bvs:DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1095 - Disclosure - Discontinued Operations - Additional Information (Details)",
     "role": "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
     "shortName": "Discontinued Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_BmpResearchAndDevelopmentProgrammeMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P04_04_2021To07_03_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1096 - Disclosure - Net Sales (Details)",
     "role": "http://bio.com/role/NetSalesDetails",
     "shortName": "Net Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioVentusLlcMemberdeiLegalEntityAxis_OAJointPainTreatmentAndJointPreservationMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1097 - Disclosure - Summary of Significant Accounting Policies - Summary of useful lives in assets (Detail)",
     "role": "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of useful lives in assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1098 - Disclosure - Summary of Significant Accounting Policies - Summary of Finite-lived intangible assets (Detail)",
     "role": "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Finite-lived intangible assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "P01_01_2020To12_31_2020_BioventusIncMemberdeiLegalEntityAxis_IntellectualPropertyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_WeightedAverageMembersrtRangeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1099 - Disclosure - Summary of Significant Accounting Policies - Summary of significant percentage of total sales (Detail)",
     "role": "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of significant percentage of total sales (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d180330ds4a.htm",
      "contextRef": "PAsOn12_31_2020_SupplierAMemberBVSConcentrationRiskBySupplierNameAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 161,
   "tag": {
    "bvs_A2019CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2019 Credit Agreement [Member]",
        "terseLabel": "2019 Credit Agreement"
       }
      }
     },
     "localname": "A2019CreditAgreementMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_A2021PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Plan [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "localname": "A2021PlanMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_AccruedSalariesAndEmployeeBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Salaries And Employee Benefits, Current",
        "label": "Accrued Salaries And Employee Benefits, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "AccruedSalariesAndEmployeeBenefitsCurrent",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AcquiredInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AcquiredIn process research and development [Member].",
        "label": "Acquired In Process Research And Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_AcquisitionOfVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of variable interest entity.",
        "label": "Acquisition of Variable Interest Entity",
        "verboseLabel": "Acquisition of VIE"
       }
      }
     },
     "localname": "AcquisitionOfVariableInterestEntity",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AdditionalMarginPercentageToReferenceRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional margin percentage to reference rates.",
        "label": "Additional Margin Percentage To Reference Rates",
        "terseLabel": "Additional margin percentage to reference Rates"
       }
      }
     },
     "localname": "AdditionalMarginPercentageToReferenceRates",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted earnings before interest, taxes, depreciation, amortization and other non-operating items.",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items",
        "terseLabel": "Segment adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAmortizationAndOtherNonOperatingItems",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_AgreementForFutureEquityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for future equity.",
        "label": "Agreement For Future Equity [Axis]"
       }
      }
     },
     "localname": "AgreementForFutureEquityAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_AgreementForFutureEquityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for future equity.",
        "label": "Agreement For Future Equity [Domain]"
       }
      }
     },
     "localname": "AgreementForFutureEquityDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_AmortizationExpenseIncludedInInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization expense included in inventory.",
        "label": "Amortization Expense Included In Inventory",
        "terseLabel": "Amortization expense included in inventory"
       }
      }
     },
     "localname": "AmortizationExpenseIncludedInInventory",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AmortizationOfDebtInstrumentCapitalizedDeferredFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of debt Instrument capitalized deferred fees.",
        "label": "Amortization Of Debt Instrument Capitalized Deferred Fees",
        "terseLabel": "Amortization of debt Instrument capitalized deferred fees"
       }
      }
     },
     "localname": "AmortizationOfDebtInstrumentCapitalizedDeferredFees",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset impairment charges, attributable to noncontrolling interest.",
        "label": "Asset Impairment Charges, Attributable To Noncontrolling Interest",
        "terseLabel": "Impairment of variable interest entity assets, attributable to noncontrolling interest"
       }
      }
     },
     "localname": "AssetImpairmentChargesAttributableToNoncontrollingInterest",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities, Lessee"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_BVLLCEmployeesActiveAtIPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BV LLC Employees Active At IPO",
        "label": "BV LLC Employees Active At IPO [Member]",
        "terseLabel": "BV LLC Employees Active At IPO"
       }
      }
     },
     "localname": "BVLLCEmployeesActiveAtIPOMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BVLLCEmployeesTerminatedPriorToIPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BV LLC Employees Terminated Prior To IPO",
        "label": "BV LLC Employees Terminated Prior To IPO [Member]",
        "terseLabel": "BV LLC Employees Terminated Prior To IPO"
       }
      }
     },
     "localname": "BVLLCEmployeesTerminatedPriorToIPOMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BVLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BV LLC [Member]",
        "terseLabel": "BV LLC"
       }
      }
     },
     "localname": "BVLLCMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BioVentusLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio Ventus LLC",
        "label": "Bio Ventus LLC [Member]",
        "terseLabel": "Bio Ventus LLC"
       }
      }
     },
     "localname": "BioVentusLlcMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformation",
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestments",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails",
      "http://bio.com/role/CommitmentsAndContingenciesTables",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical",
      "http://bio.com/role/DiscontinuedOperations",
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails",
      "http://bio.com/role/DiscontinuedOperationsTables",
      "http://bio.com/role/EquityBasedCompensation",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FairValueMeasurements",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FairValueMeasurementsTables",
      "http://bio.com/role/FinancialInstruments",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail",
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail",
      "http://bio.com/role/FinancialInstrumentsTables",
      "http://bio.com/role/IncomeTaxes",
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
      "http://bio.com/role/IncomeTaxesTables",
      "http://bio.com/role/MembersEquity",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails",
      "http://bio.com/role/MembersEquityTables",
      "http://bio.com/role/NetIncomeLossPerUnit",
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail",
      "http://bio.com/role/NetIncomeLossPerUnitTables",
      "http://bio.com/role/NetSales",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/NetSalesTables",
      "http://bio.com/role/Organization",
      "http://bio.com/role/RelatedPartyTransactions",
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail",
      "http://bio.com/role/RestructuringCosts",
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails",
      "http://bio.com/role/RestructuringCostsTables",
      "http://bio.com/role/Segments",
      "http://bio.com/role/SegmentsDetails",
      "http://bio.com/role/SegmentsTables",
      "http://bio.com/role/SubsequentEvents",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPolicies",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BionessIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bioness, Inc [Member]",
        "terseLabel": "Bioness, Inc"
       }
      }
     },
     "localname": "BionessIncMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BioventusIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bioventus, Inc [Member]",
        "terseLabel": "Bio Ventus LLC"
       }
      }
     },
     "localname": "BioventusIncMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails",
      "http://bio.com/role/BalanceSheetInformationTables",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BmpResearchAndDevelopmentProgrammeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BMP Research And Development Programme [Member]",
        "terseLabel": "BMP Research And Development Programme"
       }
      }
     },
     "localname": "BmpResearchAndDevelopmentProgrammeMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BoneGraftSubstitutesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bone Graft Substitutes",
        "label": "Bone Graft Substitutes [Member]",
        "terseLabel": "Bone Graft Substitutes",
        "verboseLabel": "Bone graft substitutes"
       }
      }
     },
     "localname": "BoneGraftSubstitutesMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BrInterestRateBasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BR interest rate basis [Member].",
        "label": "BR Interest Rate Basis [Member]"
       }
      }
     },
     "localname": "BrInterestRateBasisMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_BusinessAcquisitionConsiderationTransferredPerShareCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, consideration transferred per share, cash.",
        "label": "Business Acquisition, Consideration Transferred Per Share, Cash",
        "terseLabel": "Business acquisition, consideration transferred per share, cash (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionConsiderationTransferredPerShareCash",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bvs_BusinessAcquisitionConsiderationTransferredPerShareMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, consideration transferred per share, maximum.",
        "label": "Business Acquisition, Consideration Transferred Per Share, Maximum",
        "terseLabel": "Business acquisition, consideration transferred per share, maximum amount payable (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionConsiderationTransferredPerShareMaximum",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bvs_BusinessAcquisitionConsiderationTransferredPerShareShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, consideration transferred per share, shares",
        "label": "Business Acquisition, Consideration Transferred Per Share, Shares",
        "terseLabel": "Business acquisition, consideration transferred per share (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionConsiderationTransferredPerShareShares",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, payment due upon termination of agreement.",
        "label": "Business Acquisition, Payment Due Upon Termination Of Agreement",
        "terseLabel": "Payment due upon termination of agreement"
       }
      }
     },
     "localname": "BusinessAcquisitionPaymentDueUponTerminationOfAgreement",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessAcquisitionPeriodOfNoticeForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, period of notice for termination.",
        "label": "Business Acquisition, Period Of Notice For Termination",
        "terseLabel": "Period after receipt of statistical report for which the company may terminate agreement"
       }
      }
     },
     "localname": "BusinessAcquisitionPeriodOfNoticeForTermination",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, consideration transferred upon achievement of certain sales milestones.",
        "label": "Business Combination, Consideration Transferred Upon Achievement Of Certain Sales Milestones",
        "terseLabel": "Consideration transferred upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Cash, Cash Equivalents And Restricted Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Cash, Cash Equivalents And Restricted Cash",
        "terseLabel": "Cash. cash equivalents and restricted cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsCashCashEquivalentsAndRestrictedCash",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Liabilities",
        "negatedTerseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-Of-Use Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Restricted Cash",
        "terseLabel": "Restricted cash acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_BusinessCombinationsAndInvestmentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combinations and investments disclosure.",
        "label": "Business Combinations And Investments Disclosure [Text Block]",
        "terseLabel": "Business combinations and investments"
       }
      }
     },
     "localname": "BusinessCombinationsAndInvestmentsDisclosureTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_CancellationRatioRequiredStockToLLCInterestRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation ratio, required stock to LLC interest ratio.",
        "label": "Cancellation Ratio, Required Stock To LLC Interest Ratio",
        "terseLabel": "Cancellation ratio, required stock to LLC interest ratio"
       }
      }
     },
     "localname": "CancellationRatioRequiredStockToLLCInterestRatio",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bvs_CartiHealLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carti Heal Ltd [Member]",
        "terseLabel": "CartiHeal Ltd"
       }
      }
     },
     "localname": "CartiHealLtdMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_CartiHealMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carti Heal [Member]",
        "terseLabel": "CartiHeal"
       }
      }
     },
     "localname": "CartiHealMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_CashDistributionMadeToMembersTowardsTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash distribution made to members towards tax.",
        "label": "Cash Distribution Made To Members Towards Tax",
        "verboseLabel": "Cash distributions made to members towards tax"
       }
      }
     },
     "localname": "CashDistributionMadeToMembersTowardsTax",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_CashDistributionsAsAPercentageOfMembersTotalTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "cash distributions as a percentage of members total taxable income.",
        "label": "Cash Distributions As A Percentage Of Members Total Taxable Income",
        "verboseLabel": "Cash distributions as a percentage of members total taxable income"
       }
      }
     },
     "localname": "CashDistributionsAsAPercentageOfMembersTotalTaxableIncome",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_ChangeInFairValueOfEquityParticipationRightsUnit": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Fair Value Of Equity Participation Rights Unit",
        "label": "Change In Fair Value Of Equity Participation Rights Unit",
        "negatedTerseLabel": "Change in fair value of Equity Participation Rights unit"
       }
      }
     },
     "localname": "ChangeInFairValueOfEquityParticipationRightsUnit",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_CollaborativeArrangementRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalty Percentage",
        "label": "Collaborative Arrangement, Royalty Percentage",
        "terseLabel": "Collaborative agreement, royalty percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyPercentage",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Collaborative agreement, term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common and preferrred units converted into interests in limited liability company.",
        "label": "Common And Preferrred Units Converted Into Interests In Limited Liability Company",
        "terseLabel": "Common and preferred units converted into interests in limited liability company"
       }
      }
     },
     "localname": "CommonAndPreferrredUnitsConvertedIntoInterestsInLimitedLiabilityCompany",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_CommonStockNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, number of votes.",
        "label": "Common Stock, Number Of Votes",
        "terseLabel": "Number of votes per common share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotes",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bvs_CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common units of limited liability company issued during the period.",
        "label": "Common Units Of Limited Liability Company Issued During The Period",
        "terseLabel": "Common units of limited liability company issued during the period"
       }
      }
     },
     "localname": "CommonUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software [Member].",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ConcentrationRiskBySupplierNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk by supplier name.",
        "label": "Concentration Risk By Supplier Name [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskBySupplierNameAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_ConcentrationRiskBySupplierNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk by supplier name.",
        "label": "Concentration Risk By Supplier Name [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBySupplierNameDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ContinuingLlcOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing LLC Owner",
        "label": "Continuing LLC Owner [Member]",
        "terseLabel": "Continuing LLC Owner"
       }
      }
     },
     "localname": "ContinuingLlcOwnerMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ContractAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract assets.",
        "label": "Contract Assets [Policy Text Block]",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractAssetsPolicyTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ContractCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract costs.",
        "label": "Contract Costs [Policy Text Block]",
        "terseLabel": "Contract costs"
       }
      }
     },
     "localname": "ContractCostsPolicyTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ContractLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liabilities.",
        "label": "Contract Liabilities [Policy Text Block]",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractLiabilitiesPolicyTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ConvertibleDebtInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt Instruments",
        "label": "Convertible Debt Instruments [Member]",
        "terseLabel": "Convertible Debt Instruments"
       }
      }
     },
     "localname": "ConvertibleDebtInstrumentsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_CreditAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit agreement.",
        "label": "Credit Agreement [Axis]"
       }
      }
     },
     "localname": "CreditAgreementAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_CreditAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit agreement.",
        "label": "Credit Agreement [Domain]"
       }
      }
     },
     "localname": "CreditAgreementDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt financing costs charged to selling general adminstrative expense on refinancing.",
        "label": "Debt Financing Costs Charged To Selling General Adminstrative Expense On Refinancing",
        "terseLabel": "Debt financing costs charged to selling general adminstrative expense on refinancing"
       }
      }
     },
     "localname": "DebtFinancingCostsChargedToSellingGeneralAdminstrativeExpenseOnRefinancing",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DebtInstrumentConvertibleConversionExercisablePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument convertible conversion exercisable price.",
        "label": "Debt Instrument Convertible Conversion Exercisable Price",
        "verboseLabel": "Debt instrument convertible conversion exercisable price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionExercisablePrice",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bvs_DebtInstrumentCovenantRequiredPrepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, covenant, required prepayment.",
        "label": "Debt Instrument, Covenant, Required Prepayment",
        "terseLabel": "Debt instrument, required prepayment"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRequiredPrepayment",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DebtInstrumentFinalPrincipalPaymentAtMaturity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument final principal payment at maturity.",
        "label": "Debt Instrument Final Principal Payment At Maturity",
        "terseLabel": "Debt Instrument Final Principal Payment At Maturity"
       }
      }
     },
     "localname": "DebtInstrumentFinalPrincipalPaymentAtMaturity",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DebtInstrumentFloorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument floor rate percentage.",
        "label": "Debt Instrument Floor Rate Percentage",
        "terseLabel": "Debt instrument floor rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentFloorRatePercentage",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_DebtInstrumentNumberOfLoans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Loans",
        "label": "Debt Instrument, Number Of Loans",
        "terseLabel": "Number of loans"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfLoans",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument refinanced with additional borrowings amount.",
        "label": "Debt Instrument Refinanced With Additional Borrowings Amount",
        "verboseLabel": "Refinanced with additional borrowings amount"
       }
      }
     },
     "localname": "DebtInstrumentRefinancedWithAdditionalBorrowingsAmount",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DebtInstrumentSchedulePeriodicPaymentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument schedule periodic payment.",
        "label": "Debt Instrument Schedule Periodic Payment [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentSchedulePeriodicPaymentAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_DebtInstrumentSchedulePeriodicPaymentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument schedule periodic payment.",
        "label": "Debt Instrument Schedule Periodic Payment [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentSchedulePeriodicPaymentDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DebtInstrumentSchedulePeriodicPaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument schedule periodic payment period one.",
        "label": "Debt Instrument Schedule Periodic Payment Period One [Member]"
       }
      }
     },
     "localname": "DebtInstrumentSchedulePeriodicPaymentPeriodOneMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument schedule periodic payment period two.",
        "label": "Debt Instrument Schedule Periodic Payment Period Two [Member]"
       }
      }
     },
     "localname": "DebtInstrumentSchedulePeriodicPaymentPeriodTwoMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_DeferredTaxLiabilitiesAcquiredIntangibles": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities acquired intangibles.",
        "label": "Deferred Tax Liabilities Acquired Intangibles",
        "negatedLabel": "Acquired intangible"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAcquiredIntangibles",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DerivativeEffectiveInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative effective interest rate.",
        "label": "Derivative Effective Interest Rate"
       }
      }
     },
     "localname": "DerivativeEffectiveInterestRate",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_DerivativeStatedFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative stated fixed nterest rate.",
        "label": "Derivative Stated Fixed Interest Rate"
       }
      }
     },
     "localname": "DerivativeStatedFixedInterestRate",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_DisaggregationOfRevenueBasedOnGeographyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disaggregation Of Revenue Based On Geography.",
        "label": "Disaggregation Of Revenue Based On Geography [Table Text Block]",
        "terseLabel": "Disaggregated By Geographic Markets And Major Products"
       }
      }
     },
     "localname": "DisaggregationOfRevenueBasedOnGeographyTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/NetSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group discontinued operation income tax expense benefit.",
        "label": "Disposal Group Discontinued Operation Income Tax Expense Benefit",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "DisposalGroupDiscontinuedOperationIncomeTaxExpenseBenefit",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group discontinued operation research and development expense.",
        "label": "Disposal Group Discontinued Operation Research And Development Expense",
        "negatedLabel": "Research and development expense"
       }
      }
     },
     "localname": "DisposalGroupDiscontinuedOperationResearchAndDevelopmentExpense",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group discontinued operations payment of accrued liabilities.",
        "label": "Disposal Group Discontinued Operations Payment Of Accrued Liabilities",
        "terseLabel": "Disposal group discontinued operations payment of accrued liabilities"
       }
      }
     },
     "localname": "DisposalGroupDiscontinuedOperationsPaymentOfAccruedLiabilities",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income",
        "label": "Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income [Table Text Block]",
        "terseLabel": "Summary Of Disposal Group Discontinued Operations Statement Of Operations And Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "DisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_DistributionEventTriggerPercentageOfSaleOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution event trigger percentage of sale of assets.",
        "label": "Distribution Event Trigger Percentage of Sale of Assets",
        "verboseLabel": "Distribution Event Trigger Percentage of Sale of Assets"
       }
      }
     },
     "localname": "DistributionEventTriggerPercentageOfSaleOfAssets",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax reconciliation llc flow through structure percentage.",
        "label": "Effective Income Tax Reconciliation LLC Flow Through Structure Percentage",
        "terseLabel": "LLC flow-through structure"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationLlcFlowThroughStructurePercentage",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax reconciliation provision to return adjustment percentage.",
        "label": "Effective Income Tax Reconciliation Provision To Return Adjustment Percentage",
        "terseLabel": "Provision to return adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationProvisionToReturnAdjustmentPercentage",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_EmployeeSeveranceAndTemporaryLaborCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance and Temporary Labor Costs [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceAndTemporaryLaborCostsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment additional investment purchased shares.",
        "label": "Equity Method Investment Additional Investment Purchased Shares",
        "verboseLabel": "Additional shares purchased"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalInvestmentPurchasedShares",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, additional investment to be purchased upon completion of study, amount.",
        "label": "Equity Method Investment, Additional Investment To Be Purchased Upon Completion Of Study, Amount",
        "terseLabel": "Additional investment to be purchased upon completion of study",
        "verboseLabel": "Additional investment to be purchased upon completion of study"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, additional investment to be purchased upon completion of study, shares.",
        "label": "Equity Method Investment, Additional Investment To Be Purchased Upon Completion Of Study, Shares",
        "terseLabel": "Additional shares to be purchased upon completion of study (in shares)",
        "verboseLabel": "Additional shares to be purchased upon completion of study (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment additional investment to be purchased value.",
        "label": "Equity Method Investment Additional Investment To Be Purchased Value",
        "verboseLabel": "Additional shares purchased Value"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_EquityMethodInvestmentCapitalizedTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment capitalized transaction costs.",
        "label": "Equity Method Investment Capitalized Transaction Costs",
        "verboseLabel": "Equity method investment capitalized transaction costs"
       }
      }
     },
     "localname": "EquityMethodInvestmentCapitalizedTransactionCosts",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, period after FDA approval for investee to exercise option for remaining equity to be purchased.",
        "label": "Equity Method Investment, Period After FDA Approval For Investee To Exercise Option For Remaining Equity To Be Purchased",
        "terseLabel": "Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity",
        "verboseLabel": "Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, period after FDA approval for investor to purchase remaining investment.",
        "label": "Equity Method Investment, Period After FDA Approval For Investor To Purchase Remaining Investment",
        "terseLabel": "Period after FDA approval for which company may exercise option to purchase remaining equity",
        "verboseLabel": "Period after FDA approval for which company may exercise option to purchase remaining equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_EquityParticipationRightEntitledPercentageOfDistributions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Participation Right, Entitled Percentage Of Distributions",
        "label": "Equity Participation Right, Entitled Percentage Of Distributions",
        "terseLabel": "EPR unit, entitled percentage of distributions"
       }
      }
     },
     "localname": "EquityParticipationRightEntitledPercentageOfDistributions",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_EquityParticipationRightFairValueDisclsoure": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Participation Right, Fair Value Disclsoure",
        "label": "Equity Participation Right, Fair Value Disclsoure",
        "terseLabel": "Equity Participation Right"
       }
      }
     },
     "localname": "EquityParticipationRightFairValueDisclsoure",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_EquityParticipationRightUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Participation Right Unit",
        "label": "Equity Participation Right Unit [Member]",
        "terseLabel": "Equity Participation Right Unit"
       }
      }
     },
     "localname": "EquityParticipationRightUnitMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FairValueMeasurementsTables",
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_EquityParticipationRightsUnitEquityValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Participation Rights Unit Equity Value.",
        "label": "Equity Participation Rights Unit Equity Value"
       }
      }
     },
     "localname": "EquityParticipationRightsUnitEquityValue",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_EquityParticipationRightsUnitMeasurableInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Participation Rights Unit Measurable Input.",
        "label": "Equity Participation Rights Unit Measurable Input"
       }
      }
     },
     "localname": "EquityParticipationRightsUnitMeasurableInput",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "bvs_EventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Axis]"
       }
      }
     },
     "localname": "EventAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_EventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Domain]"
       }
      }
     },
     "localname": "EventDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Conversion To Equity",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Conversion To Equity",
        "negatedTerseLabel": "Phantom plan conversion to Class A common stock"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionToEquity",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Forfeitures.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Forfeitures",
        "terseLabel": "Forfeitures"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForfeitures",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, COVID-19 Impact On Economy",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, COVID-19 Impact On Economy",
        "terseLabel": "Decrease in fair value due to the impact of COVID-19 on the market and economy"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsCOVID19ImpactOnEconomy",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate,percentage.",
        "label": "Fair Value Of Intangible Assets Used To Determined Using The Income Approach Through Excess Earnings Analysis With Projected Earnings Discounted Rate,Percentage",
        "verboseLabel": "Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate, percentage"
       }
      }
     },
     "localname": "FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_FederalAndStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal And State [Member]"
       }
      }
     },
     "localname": "FederalAndStateMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets Accumulated Amortization",
        "label": "Finite Lived Intangible Assets Accumulated Amortization [Abstract]",
        "terseLabel": "Less accumulated amortization:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationAbstract",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_FiniteLivedIntangibleAssetsCurrencyTranslation": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets, Currency Translation.",
        "label": "Finite Lived Intangible Assets, Currency Translation",
        "negatedLabel": "Currency translation"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsCurrencyTranslation",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "For Obtaining CMS Coverage And Reimbursement For Certain Products [Member]",
        "terseLabel": "For Obtaining CMS Coverage And Reimbursement For Certain Products"
       }
      }
     },
     "localname": "ForObtainingCMSCoverageAndReimbursementForCertainProductsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_FrontingFeePercentageOnUndrawnAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fronting fee percentage on undrawn amount.",
        "label": "Fronting Fee Percentage On Undrawn Amount",
        "terseLabel": "Fronting fee percentage on undrawn amount"
       }
      }
     },
     "localname": "FrontingFeePercentageOnUndrawnAmount",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_GrossToNetDeductionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross-To-Net Deductions, Current",
        "label": "Gross-To-Net Deductions, Current",
        "terseLabel": "Gross-to-net deductions"
       }
      }
     },
     "localname": "GrossToNetDeductionsCurrent",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_HarborCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Harbor Common Stock [Member]",
        "terseLabel": "Harbor Common Stock"
       }
      }
     },
     "localname": "HarborCommonStockMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_HarborMedtechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Harbor Medtech Inc [Member]",
        "terseLabel": "Harbor Medtech Inc"
       }
      }
     },
     "localname": "HarborMedtechIncMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_HarborMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harbor",
        "label": "Harbor [Member]",
        "terseLabel": "Harbor"
       }
      }
     },
     "localname": "HarborMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_HarborSeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Harbor Series C Preferred Stock [Member]",
        "terseLabel": "Harbor Series C Preferred Stock"
       }
      }
     },
     "localname": "HarborSeriesCPreferredStockMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ImpairmentOfVariableInterestEntityAndRelatedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Variable Interest Entity And Related Assets",
        "label": "Impairment Of Variable Interest Entity And Related Assets",
        "terseLabel": "Impairments related to variable interest entity"
       }
      }
     },
     "localname": "ImpairmentOfVariableInterestEntityAndRelatedAssets",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income from continuing operations before income taxes domestic and foreign.",
        "label": "Income From Continuing Operations Before Income Taxes Domestic And Foreign"
       }
      }
     },
     "localname": "IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeign",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income From Continuing Operations Before Income Taxes Domestic And Foreign Other Domestic Subsidiaries.",
        "label": "Income From Continuing Operations Before Income Taxes Domestic And Foreign Other Domestic Subsidiaries",
        "terseLabel": "Other domestic subsidiaries"
       }
      }
     },
     "localname": "IncomeFromContinuingOperationsBeforeIncomeTaxesDomesticAndForeignOtherDomesticSubsidiaries",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Stockholders' Equity And Members' Equity",
        "label": "Increase (Decrease) In Stockholders' Equity And Members' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityAndMembersEquityRollForward",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_IndefinitelyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinitely [Member]"
       }
      }
     },
     "localname": "IndefinitelyMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets net excluding goodwill before currency translation.",
        "label": "Intangible Assets Net Excluding Goodwill Before Currency Translation",
        "positiveLabel": "IntangibleAssets, net before currency translation"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillBeforeCurrencyTranslation",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_InterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest coverage ratio.",
        "label": "Interest Coverage Ratio",
        "terseLabel": "Interest coverage ratio"
       }
      }
     },
     "localname": "InterestCoverageRatio",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bvs_InterestRateBasisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate basis [Axis].",
        "label": "Interest Rate Basis [Axis]"
       }
      }
     },
     "localname": "InterestRateBasisAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_InterestRateBasisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate basis.",
        "label": "Interest Rate Basis [Domain]"
       }
      }
     },
     "localname": "InterestRateBasisDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_InternationalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "International Segment [Member]",
        "terseLabel": "International Segment",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "InternationalSegmentMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_InventoryStepUpCost": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Step-Up Cost",
        "label": "Inventory Step-Up Cost",
        "negatedTerseLabel": "Inventory step-up costs"
       }
      }
     },
     "localname": "InventoryStepUpCost",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_InventoryValuationReservesProvisionForLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory valuation reserves provision for losses.",
        "label": "Inventory Valuation Reserves Provision For Losses",
        "terseLabel": "Provision for losses"
       }
      }
     },
     "localname": "InventoryValuationReservesProvisionForLosses",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_InventoryValuationReservesWriteOffs": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory valuation reserves write offs.",
        "label": "Inventory Valuation Reserves Write Offs",
        "terseLabel": "Write-offs"
       }
      }
     },
     "localname": "InventoryValuationReservesWriteOffs",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_InvestmentAndAcquisitionOfDistributionRights": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment and acquisition of distribution rights.",
        "label": "Investment And Acquisition Of Distribution Rights",
        "verboseLabel": "Investment and acquisition of distribution rights"
       }
      }
     },
     "localname": "InvestmentAndAcquisitionOfDistributionRights",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_InvestmentOwnedOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment owned, ownership percentage.",
        "label": "Investment Owned, Ownership Percentage",
        "terseLabel": "Investment owned, ownership percentage"
       }
      }
     },
     "localname": "InvestmentOwnedOwnershipPercentage",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_InvestorAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Axis]"
       }
      }
     },
     "localname": "InvestorAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_InvestorDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investor",
        "label": "Investor [Domain]"
       }
      }
     },
     "localname": "InvestorDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LeverageRatioRangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio range.",
        "label": "Leverage Ratio Range [Axis]"
       }
      }
     },
     "localname": "LeverageRatioRangeAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_LeverageRatioRangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio range.",
        "label": "Leverage Ratio Range [Domain]"
       }
      }
     },
     "localname": "LeverageRatioRangeDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LeverageRatioRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio range five.",
        "label": "Leverage Ratio Range Five [Member]"
       }
      }
     },
     "localname": "LeverageRatioRangeFiveMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LeverageRatioRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio range four.",
        "label": "Leverage Ratio Range Four [Member]"
       }
      }
     },
     "localname": "LeverageRatioRangeFourMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LeverageRatioRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio range one.",
        "label": "Leverage Ratio Range One [Member]"
       }
      }
     },
     "localname": "LeverageRatioRangeOneMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LeverageRatioRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio range three.",
        "label": "Leverage Ratio Range Three [Member]"
       }
      }
     },
     "localname": "LeverageRatioRangeThreeMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LeverageRatioRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio range two.",
        "label": "Leverage Ratio Range Two [Member]"
       }
      }
     },
     "localname": "LeverageRatioRangeTwoMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LimitedLiabilityCompanyInterestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited Liability Company Interests",
        "label": "Limited Liability Company Interests [Member]",
        "terseLabel": "LLC Interests"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyInterestsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited liability company LLC or limited partnership LP managing member or general partner number of interests held.",
        "label": "Limited Liability Company LLC Or Limited Partnership LP Managing Member Or General Partner Number Of Interests Held",
        "terseLabel": "Number of LLC interest held (in shares)"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerNumberOfInterestsHeld",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited liability company number of interests held by persons other than managing member.",
        "label": "Limited Liability Company Number Of Interests Held By Persons Other Than Managing Members",
        "terseLabel": "Limited liability company number of interests held by persons other than managing member"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyNumberOfInterestsHeldByPersonsOtherThanManagingMembers",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Incentive Plan And Liability-Classified Awards, Fair Value Disclsoure",
        "label": "Management Incentive Plan And Liability-Classified Awards, Fair Value Disclsoure",
        "terseLabel": "Management incentive plan and liability-classified awardsManagement incentive plan and liability-classified awards"
       }
      }
     },
     "localname": "ManagementIncentivePlanAndLiabilityClassifiedAwardsFairValueDisclsoure",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ManagementIncentivePlanAndLiabilityClassifiedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Incentive Plan And Liability-Classified Awards",
        "label": "Management Incentive Plan And Liability-Classified Awards [Member]",
        "terseLabel": "Management Incentive Plan And Liability-Classified Awards"
       }
      }
     },
     "localname": "ManagementIncentivePlanAndLiabilityClassifiedAwardsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ManagementIncentivePlanAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Incentive Plan Award",
        "label": "Management Incentive Plan Award [Member]",
        "terseLabel": "Management Incentive Plan Award"
       }
      }
     },
     "localname": "ManagementIncentivePlanAwardMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_MeasurementInputEquityVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Equity Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputEquityVolatilityMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Meeting Net Sales Targets Over A Three-Year Period, Payment One [Member]",
        "terseLabel": "Meeting Net Sales Targets Over A Three-Year Period, Payment One"
       }
      }
     },
     "localname": "MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Meeting Net Sales Targets Over A Three-Year Period, Payment Two [Member]",
        "terseLabel": "Meeting Net Sales Targets Over A Three-Year Period, Payment Two"
       }
      }
     },
     "localname": "MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_MemberDistributionsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Distributions Incurred But Not Yet Paid",
        "label": "Member Distributions Incurred But Not Yet Paid",
        "terseLabel": "Accrued member distributions"
       }
      }
     },
     "localname": "MemberDistributionsIncurredButNotYetPaid",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_MemberEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member equity.",
        "label": "Member Equity [Line Items]"
       }
      }
     },
     "localname": "MemberEquityLineItems",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquity",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails",
      "http://bio.com/role/MembersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_MemberEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member equity.",
        "label": "Member Equity [Table]"
       }
      }
     },
     "localname": "MemberEquityTable",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquity",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails",
      "http://bio.com/role/MembersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_MembersEquityDecreaseFromDistributionToMembers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Members' Equity, Decrease From Distribution To Members",
        "label": "Members' Equity, Decrease From Distribution To Members",
        "negatedTerseLabel": "Distribution to members"
       }
      }
     },
     "localname": "MembersEquityDecreaseFromDistributionToMembers",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_MembersEquityDecreaseFromEquityForfeitures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Members' Equity, Decrease From Equity Forfeitures",
        "label": "Members' Equity, Decrease From Equity Forfeitures",
        "negatedTerseLabel": "Other equity forfeiture"
       }
      }
     },
     "localname": "MembersEquityDecreaseFromEquityForfeitures",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_MembersEquityDecreaseFromProfitInterestForfeiture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Members' Equity, Decrease From Profit Interest Forfeiture",
        "label": "Members' Equity, Decrease From Profit Interest Forfeiture",
        "negatedTerseLabel": "Profits interest forfeiture"
       }
      }
     },
     "localname": "MembersEquityDecreaseFromProfitInterestForfeiture",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_MembersEquityIncreaseFromRefundsFromMembers": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Members' Equity, Increase From Refunds From Members'",
        "label": "Members' Equity, Increase From Refunds From Members'",
        "terseLabel": "Refund from members"
       }
      }
     },
     "localname": "MembersEquityIncreaseFromRefundsFromMembers",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_MilestonePaymentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment payable.",
        "label": "Milestone Payment Payable",
        "terseLabel": "Milestone payment payable"
       }
      }
     },
     "localname": "MilestonePaymentPayable",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_MinimallyInvasiveFractureTreatmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimally Invasive Fracture Treatment.",
        "label": "Minimally Invasive Fracture Treatment [Member]",
        "terseLabel": "Minimally invasive fracture treatment"
       }
      }
     },
     "localname": "MinimallyInvasiveFractureTreatmentMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/NetSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_MisonixIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Misonix, Inc [Member]",
        "terseLabel": "Misonix, Inc"
       }
      }
     },
     "localname": "MisonixIncMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_NetIncomeLossFromContinuingOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income loss from continuing operations.",
        "label": "Net Income Loss From Continuing Operations",
        "verboseLabel": "Net income (loss) from continuing operations attributable to common unit holders"
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperations",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_NetIncomeLossPerUnitTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income (loss) per unit [Text Block].",
        "label": "Net Income Loss Per Unit [Text Block]",
        "terseLabel": "Net income (loss) per unit"
       }
      }
     },
     "localname": "NetIncomeLossPerUnitTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/NetIncomeLossPerUnit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_NetLossSubsequentToOrganizationalTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss subsequent to Organizational Transactions.",
        "label": "Net Loss Subsequent To Organizational Transactions",
        "terseLabel": "Net loss subsequent to Organizational Transactions"
       }
      }
     },
     "localname": "NetLossSubsequentToOrganizationalTransactions",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_NetSalesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales [Text Block].",
        "label": "Net Sales [Text Block]",
        "terseLabel": "Net Sales"
       }
      }
     },
     "localname": "NetSalesTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/NetSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_NewLlcOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New LLC Owner",
        "label": "New LLC Owner [Member]",
        "terseLabel": "New LLC Owner"
       }
      }
     },
     "localname": "NewLlcOwnerMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_NonControllingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non controlling interest.",
        "label": "Non Controlling Interest [Policy Text Block]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NonControllingInterestPolicyTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase From Deconsolidation Of Variable Interest Entity",
        "label": "Noncontrolling Interest, Increase From Deconsolidation Of Variable Interest Entity",
        "terseLabel": "Deconsolidation of variable interest entity"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromDeconsolidationOfVariableInterestEntity",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_NumberOfEquityBasedCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Equity-Based Compensation Plans",
        "label": "Number Of Equity-Based Compensation Plans",
        "terseLabel": "Number of equity-based compensation plans"
       }
      }
     },
     "localname": "NumberOfEquityBasedCompensationPlans",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bvs_OAJointPainTreatmentAndJointPreservationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "O A Joint Pain Treatment And Joint Preservation.",
        "label": "O A Joint Pain Treatment And Joint Preservation [Member]",
        "terseLabel": "OA joint pain treatment and joint preservation"
       }
      }
     },
     "localname": "OAJointPainTreatmentAndJointPreservationMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/NetSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ObtainingFDAApprovalOfCertainProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obtaining FDA Approval Of Certain Products [Member]",
        "terseLabel": "Obtaining FDA Approval Of Certain Products"
       }
      }
     },
     "localname": "ObtainingFDAApprovalOfCertainProductsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_OptionAndEquityPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option And Equity Purchase Agreement [Member]",
        "terseLabel": "Option and Equity Purchase Agreement"
       }
      }
     },
     "localname": "OptionAndEquityPurchaseAgreementMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_OtherChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Charges [Member]"
       }
      }
     },
     "localname": "OtherChargesMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Cumulative Foreign Currency Transaction And Translation Adjustment, Net Of Tax",
        "label": "Other Comprehensive Income (Loss), Cumulative Foreign Currency Transaction And Translation Adjustment, Net Of Tax",
        "terseLabel": "Translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCumulativeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_OtherPhantomUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other phantom unit.",
        "label": "Other Phantom Unit [Member]"
       }
      }
     },
     "localname": "OtherPhantomUnitMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PainTreatmentsAndJointPreservationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pain Treatments And Joint Preservation",
        "label": "Pain Treatments And Joint Preservation [Member]",
        "terseLabel": "Pain Treatments and Joint Preservation"
       }
      }
     },
     "localname": "PainTreatmentsAndJointPreservationMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PaycheckProtectionProgramCARESActMaturingApril102022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act, Maturing April 10, 2022",
        "label": "Paycheck Protection Program, CARES Act, Maturing April 10, 2022 [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act, Maturing April 10, 2022"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMaturingApril102022Member",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PaycheckProtectionProgramCARESActMaturingFebruary52026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act, Maturing February 5, 2026",
        "label": "Paycheck Protection Program, CARES Act, Maturing February 5, 2026 [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act, Maturing February 5, 2026"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMaturingFebruary52026Member",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program Loan [Member]",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PaymentsOfStockIssuanceCostsAdditionalCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Stock Issuance Costs, Additional Costs",
        "label": "Payments Of Stock Issuance Costs, Additional Costs",
        "terseLabel": "Payment of offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCostsAdditionalCosts",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_PercentageOfDeferredPayrollTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of deferred payroll tax.",
        "label": "Percentage Of Deferred Payroll Tax",
        "verboseLabel": "Percentage of deferred payroll tax"
       }
      }
     },
     "localname": "PercentageOfDeferredPayrollTax",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_PercentageOfMembersTaxDistributionToTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of members tax distribution to taxable income.",
        "label": "Percentage of Members Tax Distribution to Taxable Income",
        "terseLabel": "Percentage of member's tax distribution to taxable income"
       }
      }
     },
     "localname": "PercentageOfMembersTaxDistributionToTaxableIncome",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_PercentageOfTotalOutstandingDebtLoanedByLenders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total outstanding debt loaned by lenders.",
        "label": "Percentage Of Total Outstanding Debt Loaned By Lenders",
        "terseLabel": "Percentage of total outstanding Debt loaned by lenders"
       }
      }
     },
     "localname": "PercentageOfTotalOutstandingDebtLoanedByLenders",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_PreferredUnitsLiquidationPreferencePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred units liquidation preference per unit.",
        "label": "Preferred Units Liquidation Preference Per Unit",
        "verboseLabel": "Preferred units liquidation preference per unit"
       }
      }
     },
     "localname": "PreferredUnitsLiquidationPreferencePerUnit",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bvs_PreferredUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Units [Member]",
        "terseLabel": "Preferred Units"
       }
      }
     },
     "localname": "PreferredUnitsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred units of limited liability company issued during the period.",
        "label": "Preferred Units Of Limited Liability Company Issued During The Period",
        "verboseLabel": "Preferred units of limited liability company issued during the period"
       }
      }
     },
     "localname": "PreferredUnitsOfLimitedLiabilityCompanyIssuedDuringThePeriod",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred units percentage of accrued distribution right per annum.",
        "label": "Preferred Units Percentage of Accrued Distribution Right Per Annum",
        "verboseLabel": "Preferred units percentage of accrued distribution right per annum"
       }
      }
     },
     "localname": "PreferredUnitsPercentageOfAccruedDistributionRightPerAnnum",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_PriorCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior credit agreement [Member].",
        "label": "Prior Credit Agreement [Member]"
       }
      }
     },
     "localname": "PriorCreditAgreementMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ProceedsFromGovernmentalAssistance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from governmental assistance.",
        "label": "Proceeds From Governmental Assistance",
        "terseLabel": "Cash received from provident relief fund"
       }
      }
     },
     "localname": "ProceedsFromGovernmentalAssistance",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ProceedsFromMembers": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Members",
        "label": "Proceeds From Members",
        "terseLabel": "Refunds (distributions) - members"
       }
      }
     },
     "localname": "ProceedsFromMembers",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from the issuance of common units of limited liability company.",
        "label": "Proceeds From The Issuance Of Common Units Of Limited Liability Company",
        "terseLabel": "Proceeds from the issuance of common units of limited liability company",
        "verboseLabel": "Proceeds from the issuance of common units of limited liability company"
       }
      }
     },
     "localname": "ProceedsFromTheIssuanceOfCommonUnitsOfLimitedLiabilityCompany",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from the issuance of preferred units of limited liability company.",
        "label": "Proceeds From The Issuance Of Preferred Units Of Limited Liability Company",
        "verboseLabel": "Proceeds from the issuance of preferred units of limited liability company"
       }
      }
     },
     "localname": "ProceedsFromTheIssuanceOfPreferredUnitsOfLimitedLiabilityCompany",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ProductAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product A.",
        "label": "Product A [Member]"
       }
      }
     },
     "localname": "ProductAMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ProductBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product B.",
        "label": "Product B [Member]"
       }
      }
     },
     "localname": "ProductBMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ProductCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product C.",
        "label": "Product C [Member]"
       }
      }
     },
     "localname": "ProductCMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ProductDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product D.",
        "label": "Product D [Member]"
       }
      }
     },
     "localname": "ProductDMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ProfitInterestAndOtherEquityWardsUnitsIssuanceValue": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_MembersCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit interest and other equity wards units issuance value.",
        "label": "Profit Interest and Other Equity Wards Units Issuance Value",
        "verboseLabel": "Profits interest and other equity awards (Refer to\u00a0Note 9. Equity-based compensation)"
       }
      }
     },
     "localname": "ProfitInterestAndOtherEquityWardsUnitsIssuanceValue",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 43.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profits Interest Plan, Liability Classified And Other Equity Awards Compensation",
        "label": "Profits Interest Plan, Liability Classified And Other Equity Awards Compensation",
        "negatedTerseLabel": "Profits interest plan, liability-classified and other equity awards compensation"
       }
      }
     },
     "localname": "ProfitsInterestPlanLiabilityClassifiedAndOtherEquityAwardsCompensation",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_PromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "terseLabel": "Promissory Note"
       }
      }
     },
     "localname": "PromissoryNoteMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment useful lives.",
        "label": "Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Summary of useful lives in assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ReclassificationOfIprdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of IPR&amp;D [Member].",
        "label": "Reclassification Of IPRD [Member]",
        "terseLabel": "Reclassification Of IPRD"
       }
      }
     },
     "localname": "ReclassificationOfIprdMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_RefundOfExcessPaymentsToThirdPartyCustomers": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refund of excess payments to third party customers.",
        "label": "Refund Of Excess Payments To Third Party Customers",
        "terseLabel": "Refund of excess payments to third party customers"
       }
      }
     },
     "localname": "RefundOfExcessPaymentsToThirdPartyCustomers",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction tax distributions payable to tax authorities on behalf members.",
        "label": "Related Party Transaction Tax Distributions Payable To Tax Authorities On Behalf Members",
        "verboseLabel": "Related party transaction tax distributions payable to tax authorities on behalf members"
       }
      }
     },
     "localname": "RelatedPartyTransactionTaxDistributionsPayableToTaxAuthoritiesOnBehalfMembers",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for estimated overpayments from third party payers current.",
        "label": "Reserve For Estimated Overpayments From Third Party Payers Current",
        "terseLabel": "Reserve for estimated overpayments from third-party payers"
       }
      }
     },
     "localname": "ReserveForEstimatedOverpaymentsFromThirdPartyPayersCurrent",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_RestatedLimitedLiabilityCompanyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restated Limited Liability Company Agreement",
        "label": "Restated Limited Liability Company Agreement [Member]",
        "terseLabel": "Restated Limited Liability Company Agreement"
       }
      }
     },
     "localname": "RestatedLimitedLiabilityCompanyAgreementMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_RestorativeTherapiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restorative Therapies",
        "label": "Restorative Therapies [Member]",
        "terseLabel": "Restorative Therapies"
       }
      }
     },
     "localname": "RestorativeTherapiesMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_RestrictedStockUnitsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Agreement [Member]",
        "terseLabel": "Restricted Stock Units Agreement"
       }
      }
     },
     "localname": "RestrictedStockUnitsAgreementMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_RevolvingCreditFacilitySubAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving credit facility sub [Axis].",
        "label": "Revolving Credit Facility Sub [Axis]"
       }
      }
     },
     "localname": "RevolvingCreditFacilitySubAxis",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_RevolvingCreditFacilitySubDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving credit facility sub",
        "label": "Revolving Credit Facility Sub [Domain]"
       }
      }
     },
     "localname": "RevolvingCreditFacilitySubDomain",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SaleOfStockOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Offering Costs",
        "label": "Sale Of Stock, Offering Costs",
        "terseLabel": "Sale of stock, offering costs"
       }
      }
     },
     "localname": "SaleOfStockOfferingCosts",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of commitment fee adjusted based on pricing grid.",
        "label": "Schedule of Commitment Fee Adjusted Based on Pricing Grid [Table Text Block]",
        "verboseLabel": "Schedule of Commitment Fee Adjusted Based on Pricing Grid"
       }
      }
     },
     "localname": "ScheduleOfCommitmentFeeAdjustedBasedOnPricingGridTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of debt instruments periodic payments.",
        "label": "Schedule of Debt Instruments Periodic Payments [Table Text Block]",
        "verboseLabel": "Summary of Debt Instruments Periodic Payments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsPeriodicPaymentsTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Net Excluding Goodwill [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsNetExcludingGoodwillLineItems",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Net Excluding Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsNetExcludingGoodwillTable",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of intangible assets net excluding goodwil.l",
        "label": "Schedule Of Intangible Assets Net Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Schedule Of Intangible Assets Net Excluding Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsNetExcludingGoodwillTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ScheduleOfInventoryValuationReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of inventory valuation reserves.",
        "label": "Schedule Of Inventory Valuation Reserves [Table Text Block]",
        "verboseLabel": "Schedule Of Inventory Valuation Reserves"
       }
      }
     },
     "localname": "ScheduleOfInventoryValuationReservesTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of loan margin adjusted on pricing grid.",
        "label": "Schedule of Loan margin Adjusted on Pricing Grid [Table Text Block]",
        "verboseLabel": "Schedule of Loan margin Adusted on Pricing Grid"
       }
      }
     },
     "localname": "ScheduleOfLoanMarginAdjustedOnPricingGridTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ScheduleOfMembersEquityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of members equity.",
        "label": "Schedule Of Members Equity [Table Text Block]",
        "verboseLabel": "Summary of Members Equity"
       }
      }
     },
     "localname": "ScheduleOfMembersEquityTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_SeriesFConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Convertible Preferred Stock [Member]",
        "terseLabel": "Series F Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesFConvertiblePreferredStockMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SeriesG1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G1 Preferred Stock [Member]",
        "terseLabel": "Series G1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesG1PreferredStockMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Compensation Deducted During Offering Period, Percentage Per Employee",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Compensation Deducted During Offering Period, Percentage Per Employee",
        "terseLabel": "Percentage of employee compensation deducted to purchase common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationDeductedDuringOfferingPeriodPercentagePerEmployee",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options converted in cash period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Converted In Cash Period",
        "verboseLabel": "Number of awards, Converted to cash"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedInCashPeriod",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options coverted in cash weighted average grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Coverted In Cash Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant-date fair value, Converted to cash"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCovertedInCashWeightedAverageGrantDateFairValue",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "verboseLabel": "Weighted average grant-date fair value, Awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "bvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized, Annual Percentage Increase",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized, Annual Percentage Increase",
        "terseLabel": "Annual percentage increase in number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bvs_ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment equity instruments other than options vested and expected to vest outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Equity Instruments Other than Options Vested And Expected To Vest Outstanding Number",
        "verboseLabel": "Number of awards, Awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation phantom plan shares award unvested activity.",
        "label": "Share Based Compensation Phantom Plan Shares Award Unvested Activity [Table Text Block]",
        "verboseLabel": "Summary of Phantom Plan Award activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bvs_ShareBasedPaymentAwardSettlementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment award settlement period.",
        "label": "Share Based Payment Award Settlement Period",
        "terseLabel": "Share based payment award, Settlement period"
       }
      }
     },
     "localname": "ShareBasedPaymentAwardSettlementPeriod",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_SharesIssuedOrIssuableRequiredStockToLLCInterestRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued or issuable, required stock to LLC interest ratio.",
        "label": "Shares Issued Or Issuable, Required Stock To LLC Interest Ratio",
        "terseLabel": "Shares issued or issuable, required stock to LLC interest ratio"
       }
      }
     },
     "localname": "SharesIssuedOrIssuableRequiredStockToLLCInterestRatio",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bvs_SimpleAgreementForFutureEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Simple Agreement For Future Equity [Member]",
        "terseLabel": "Simple Agreement For Future Equity"
       }
      }
     },
     "localname": "SimpleAgreementForFutureEquityMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_StockholdersEquitySharesChangeInReportingEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity, Shares, Change In Reporting Entity",
        "label": "Stockholders' Equity, Shares, Change In Reporting Entity",
        "terseLabel": "Effect of Organizational Transactions (in shares)"
       }
      }
     },
     "localname": "StockholdersEquitySharesChangeInReportingEntity",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_StopLossInsuranceThresholdPerMemberPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stop Loss Insurance, Threshold Per Member Per Year",
        "label": "Stop Loss Insurance Threshold Per Member Per Year",
        "terseLabel": "Stop loss insurance, threshold per member per year"
       }
      }
     },
     "localname": "StopLossInsuranceThresholdPerMemberPerYear",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_SuccessionAndTransitionCharges": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Succession And Transition Charges",
        "label": "Succession And Transition Charges",
        "negatedTerseLabel": "Succession and transition charges"
       }
      }
     },
     "localname": "SuccessionAndTransitionCharges",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_SupplementalDisclosureOfCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalDisclosureOfCashFlowInformationAbstract",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_SupplierAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier A.",
        "label": "Supplier A [Member]"
       }
      }
     },
     "localname": "SupplierAMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SupplierBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier B.",
        "label": "Supplier B [Member]"
       }
      }
     },
     "localname": "SupplierBMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SupplierCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier C.",
        "label": "Supplier C [Member]"
       }
      }
     },
     "localname": "SupplierCMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SupplierOfSingleInjectionOAProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Of Single Injection OA Product",
        "label": "Supplier Of Single Injection OA Product [Member]",
        "terseLabel": "Supplier of Single Injection OA Product"
       }
      }
     },
     "localname": "SupplierOfSingleInjectionOAProductMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_SupplyCommitmentRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Renewal Term",
        "label": "Supply Commitment, Renewal Term",
        "terseLabel": "Supply commitment, renewal term"
       }
      }
     },
     "localname": "SupplyCommitmentRenewalTerm",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_SupplyCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Commitment, Term",
        "label": "Supply Commitment, Term",
        "terseLabel": "Supply commitment, term"
       }
      }
     },
     "localname": "SupplyCommitmentTerm",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bvs_SwingLineCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing line credit facility [Member].",
        "label": "Swing Line Credit Facility [Member]"
       }
      }
     },
     "localname": "SwingLineCreditFacilityMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TaxableSubsidiariesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxable subsidiaries [Abstract].",
        "label": "Taxable Subsidiaries [Abstract]",
        "terseLabel": "Taxable subsidiaries:"
       }
      }
     },
     "localname": "TaxableSubsidiariesAbstract",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bvs_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ThreeInjectionOAProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Injection OA Product",
        "label": "Three Injection OA Product [Member]",
        "terseLabel": "Three Injection OA Product"
       }
      }
     },
     "localname": "ThreeInjectionOAProductMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_ThresholdMaximumAggregateAdditionalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold maximum aggregate additional borrowings.",
        "label": "Threshold Maximum Aggregate Additional Borrowings",
        "terseLabel": "Threshold maximum aggregate additional borrowings"
       }
      }
     },
     "localname": "ThresholdMaximumAggregateAdditionalBorrowings",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_TotalAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total assets.",
        "label": "Total Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "TotalAssets",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_TotalLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total liabilities.",
        "label": "Total Liabilities",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "TotalLiabilities",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_TotalLiabilitiesAndStockholdersEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total liabilities and stockholders' equity.",
        "label": "Total Liabilities And Stockholders Equity",
        "terseLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "TotalLiabilitiesAndStockholdersEquity",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_TotalStockholdersEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Stockholders' Equity.",
        "label": "Total Stockholders Equity",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "TotalStockholdersEquity",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_TwoThousandAndEighteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand and Eighteen Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandAndEighteenPlanMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TwoThousandAndFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fifteen.",
        "label": "Two Thousand and Fifteen [Member]"
       }
      }
     },
     "localname": "TwoThousandAndFifteenMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TwoThousandAndFifteenPreferredUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fifteen preferred units.",
        "label": "Two Thousand and Fifteen Preferred Units [Member]"
       }
      }
     },
     "localname": "TwoThousandAndFifteenPreferredUnitsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TwoThousandAndTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twelve.",
        "label": "Two Thousand and Twelve [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwelveMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TwoThousandAndTwelvePreferredUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twelve preferred units.",
        "label": "Two Thousand and Twelve Preferred Units [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwelvePreferredUnitsMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TwoThousandAndTwentyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand and Twenty Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyPlanMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_TwoThousandNineteenCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen credit agreement.",
        "label": "Two Thousand Nineteen Credit Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenCreditAgreementMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_USSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Segment [Member]",
        "terseLabel": "U.S"
       }
      }
     },
     "localname": "USSegmentMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_UnvestedClassACommonSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Class A Common Shares",
        "label": "Unvested Class A Common Shares [Member]",
        "terseLabel": "Unvested shares of Class A common stock"
       }
      }
     },
     "localname": "UnvestedClassACommonSharesMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_UsaoAndOigMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "USAO And OIG",
        "label": "USAO And OIG [Member]",
        "terseLabel": "USAO And OIG"
       }
      }
     },
     "localname": "UsaoAndOigMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_VaporoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vaporox [Member]",
        "terseLabel": "Vaporox"
       }
      }
     },
     "localname": "VaporoxMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bvs_VariableInterestEntityImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable interest entity, impairment.",
        "label": "Variable Interest Entity, Impairment",
        "terseLabel": "Impairment of variable interest entity"
       }
      }
     },
     "localname": "VariableInterestEntityImpairment",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_VariableInterestEntityIssuedCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable interest entity issued cost.",
        "label": "Variable Interest Entity Issued Cost",
        "verboseLabel": "Variable interest entity cost"
       }
      }
     },
     "localname": "VariableInterestEntityIssuedCost",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bvs_VariableInterestEntitySharesIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable interest entity shares issued during period.",
        "label": "Variable Interest Entity Shares Issued During Period",
        "verboseLabel": "Variable interest entity shares purchased"
       }
      }
     },
     "localname": "VariableInterestEntitySharesIssuedDuringPeriod",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bvs_YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand Twenty One To Year Two Thousand And Thirty Seven [Member]"
       }
      }
     },
     "localname": "YearTwoThousandTwentyOneToYearTwoThousandAndThirtySevenMember",
     "nsuri": "http://bio.com/20210703",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformation",
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails",
      "http://bio.com/role/BalanceSheetInformationTables",
      "http://bio.com/role/BusinessCombinationsAndInvestments",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails",
      "http://bio.com/role/CommitmentsAndContingenciesTables",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical",
      "http://bio.com/role/DiscontinuedOperations",
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails",
      "http://bio.com/role/DiscontinuedOperationsTables",
      "http://bio.com/role/EquityBasedCompensation",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FairValueMeasurements",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FairValueMeasurementsTables",
      "http://bio.com/role/FinancialInstruments",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail",
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail",
      "http://bio.com/role/FinancialInstrumentsTables",
      "http://bio.com/role/IncomeTaxes",
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
      "http://bio.com/role/IncomeTaxesTables",
      "http://bio.com/role/MembersEquity",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails",
      "http://bio.com/role/MembersEquityTables",
      "http://bio.com/role/NetIncomeLossPerUnit",
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail",
      "http://bio.com/role/NetIncomeLossPerUnitTables",
      "http://bio.com/role/NetSales",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/NetSalesTables",
      "http://bio.com/role/Organization",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/RelatedPartyTransactions",
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail",
      "http://bio.com/role/RestructuringCosts",
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails",
      "http://bio.com/role/RestructuringCostsTables",
      "http://bio.com/role/Segments",
      "http://bio.com/role/SegmentsDetails",
      "http://bio.com/role/SegmentsTables",
      "http://bio.com/role/SubsequentEvents",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPolicies",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformation",
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails",
      "http://bio.com/role/BalanceSheetInformationTables",
      "http://bio.com/role/BusinessCombinationsAndInvestments",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails",
      "http://bio.com/role/CommitmentsAndContingenciesTables",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical",
      "http://bio.com/role/DiscontinuedOperations",
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails",
      "http://bio.com/role/DiscontinuedOperationsTables",
      "http://bio.com/role/EquityBasedCompensation",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FairValueMeasurements",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FairValueMeasurementsTables",
      "http://bio.com/role/FinancialInstruments",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail",
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail",
      "http://bio.com/role/FinancialInstrumentsTables",
      "http://bio.com/role/IncomeTaxes",
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
      "http://bio.com/role/IncomeTaxesTables",
      "http://bio.com/role/MembersEquity",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails",
      "http://bio.com/role/MembersEquityTables",
      "http://bio.com/role/NetIncomeLossPerUnit",
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail",
      "http://bio.com/role/NetIncomeLossPerUnitTables",
      "http://bio.com/role/NetSales",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/NetSalesTables",
      "http://bio.com/role/Organization",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/RelatedPartyTransactions",
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail",
      "http://bio.com/role/RestructuringCosts",
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails",
      "http://bio.com/role/RestructuringCostsTables",
      "http://bio.com/role/Segments",
      "http://bio.com/role/SegmentsDetails",
      "http://bio.com/role/SegmentsTables",
      "http://bio.com/role/SubsequentEvents",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPolicies",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r171",
      "r366",
      "r371",
      "r379",
      "r605",
      "r606",
      "r614",
      "r615",
      "r704",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r171",
      "r366",
      "r371",
      "r379",
      "r605",
      "r606",
      "r614",
      "r615",
      "r704",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r171",
      "r231",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r255",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r376",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r171",
      "r231",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r255",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r376",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r89",
      "r91",
      "r168",
      "r169",
      "r387",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r261",
      "r467",
      "r472",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r386",
      "r429",
      "r491",
      "r494",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r773",
      "r777",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r386",
      "r429",
      "r491",
      "r494",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r773",
      "r777",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r261",
      "r467",
      "r472",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r257",
      "r467",
      "r470",
      "r724",
      "r772",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r257",
      "r467",
      "r470",
      "r724",
      "r772",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r386",
      "r429",
      "r480",
      "r491",
      "r494",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r773",
      "r777",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r386",
      "r429",
      "r480",
      "r491",
      "r494",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r773",
      "r777",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r90",
      "r91",
      "r168",
      "r169",
      "r387",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r181",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r181",
      "r187",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r258",
      "r259",
      "r467",
      "r471",
      "r775",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r467",
      "r471",
      "r775",
      "r805",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r181",
      "r187",
      "r348",
      "r492",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r263",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r715",
      "r717",
      "r720",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r65",
      "r707"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r737",
      "r761"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Summary of Accounts Receivable, Allowance for Credit Loss"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r26",
      "r45",
      "r264",
      "r265"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r70"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Bonus and commission"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent": {
     "auth_ref": [
      "r737",
      "r761"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.",
        "label": "Accrued Payroll Taxes",
        "verboseLabel": "Employer social security payroll tax"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r62",
      "r316"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r96",
      "r97",
      "r98",
      "r756",
      "r782",
      "r783"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Useful Life (in years)",
        "verboseLabel": "Acquired finite lived intangible assets, Weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r46",
      "r526",
      "r707"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r523",
      "r524",
      "r525",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In -Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Debt conversion"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r495",
      "r497",
      "r529",
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity based compensation",
        "verboseLabel": "Defined benefit plan adjustment"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities from continuing operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "verboseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r497",
      "r519",
      "r528"
     ],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Equity compensation",
        "terseLabel": "Equity compensation",
        "verboseLabel": "Equity compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r270",
      "r278",
      "r279",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r52",
      "r270",
      "r278"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedTerseLabel": "Less: Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "negatedTerseLabel": "Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r146",
      "r406",
      "r418",
      "r419",
      "r682"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "verboseLabel": "Amortization of debt discount and capitalized loan fees, net"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r146",
      "r295",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)",
        "verboseLabel": "Antidilutive securities excluded from the computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r95",
      "r98",
      "r106",
      "r107",
      "r108",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r146",
      "r313"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 15.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://bio.com/role/SegmentsDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Impairments related to variable interest entity",
        "terseLabel": "Impairment of variable interest entity assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetRetirementObligationAccretionExpense": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 51.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.",
        "label": "Asset Retirement Obligation, Accretion Expense",
        "verboseLabel": "Loss on debt retirement and modification"
       }
      }
     },
     "localname": "AssetRetirementObligationAccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Asset under Construction [Member]",
        "terseLabel": "Assets not yet placed in service"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r163",
      "r239",
      "r246",
      "r253",
      "r276",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r379",
      "r380",
      "r605",
      "r614",
      "r665",
      "r705",
      "r707",
      "r730",
      "r752"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r86",
      "r163",
      "r276",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r379",
      "r380",
      "r605",
      "r614",
      "r665",
      "r705",
      "r707"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r498",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r634",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Accounting, Policy"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r490",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r490",
      "r493",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails",
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of business acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information [Abstract]",
        "terseLabel": "Earnings per share of Class A common stock(1):"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r577",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r577",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "verboseLabel": "Fair value of Harbor's noncontrolling interest"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "negatedTerseLabel": "Acquisition and integration costs",
        "verboseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r590",
      "r591",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Fair value of consideration",
        "verboseLabel": "Consideration payable upon closing"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r145",
      "r597"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 44.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 13.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://bio.com/role/SegmentsDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Change in fair value of contingent consideration",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r589",
      "r592",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Contingent consideration at fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r589",
      "r593"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Payment discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r589",
      "r593"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, less current portion",
        "verboseLabel": "Long-term contingent consideration, less current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Acquisition integration costs and inventory related adjustments"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue of acquiree since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred income tax"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "verboseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r581",
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r581",
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r581",
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Assets acquired and liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r581",
      "r582"
     ],
     "calculation": {
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r151",
      "r152",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accounts payable for purchase of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.",
        "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": {
     "auth_ref": [
      "r825"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.",
        "label": "Capitalized Computer Software, Accumulated Amortization",
        "verboseLabel": "Capitalized Computer Software, Accumulated Amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r824",
      "r826"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r825"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "verboseLabel": "Capitalized Computer Software, Gross"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r58",
      "r148"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAvailableForDistributions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement.",
        "label": "Cash Available for Distributions",
        "terseLabel": "Equity participation right estimated accrued preferred distribution"
       }
      }
     },
     "localname": "CashAvailableForDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r141",
      "r148",
      "r154"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "totalLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r141",
      "r670"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r16",
      "r141"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash from investing activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r16",
      "r141"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 52.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "verboseLabel": "Net cash used in operating activities of discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r160",
      "r163",
      "r192",
      "r193",
      "r194",
      "r198",
      "r202",
      "r212",
      "r214",
      "r216",
      "r276",
      "r366",
      "r371",
      "r372",
      "r373",
      "r379",
      "r380",
      "r427",
      "r428",
      "r432",
      "r436",
      "r665",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestments",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/CoverPage",
      "http://bio.com/role/EquityBasedCompensation",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail",
      "http://bio.com/role/FinancialInstrumentsTables",
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/RelatedPartyTransactions",
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r360",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r363",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r173",
      "r174",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r44",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Common stock, Shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/StockholderSEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Common stock shares subscribed but not issued"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r44",
      "r707"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonUnitIssuanceValue": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_MembersCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).",
        "label": "Common Unit, Issuance Value",
        "verboseLabel": "Common"
       }
      }
     },
     "localname": "CommonUnitIssuanceValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Profits interest compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liability:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r101",
      "r103",
      "r104",
      "r114",
      "r743",
      "r767"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income attributable to Bioventus Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r101",
      "r103",
      "r113",
      "r603",
      "r604",
      "r626",
      "r742",
      "r766"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Net income (loss) from continuing operations attributable to common unit holders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r101",
      "r103",
      "r112",
      "r602",
      "r626",
      "r741",
      "r765"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r222",
      "r223",
      "r261",
      "r662",
      "r663",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r261",
      "r662",
      "r663",
      "r784",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r261",
      "r662",
      "r663",
      "r784",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r218",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r222",
      "r223",
      "r261",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r219",
      "r222",
      "r223",
      "r224",
      "r662",
      "r664",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r222",
      "r223",
      "r261",
      "r662",
      "r663",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r613",
      "r617",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r455",
      "r456",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "verboseLabel": "Revenue, change in estimates of variable consideration"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r381",
      "r383",
      "r384",
      "r386",
      "r396",
      "r397",
      "r398",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r120",
      "r724"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 10.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including depreciation and amortization of $5,618, $5,292, $10,854 and $10,599 respectively)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "auth_ref": [
      "r334",
      "r335",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r554",
      "r562"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r554"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r554",
      "r562"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r151",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Debt conversion converted instrument amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r151",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Debt conversion converted instrument shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "auth_ref": [
      "r151",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "verboseLabel": "Debt conversion converted instrument warrants issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r400",
      "r407",
      "r408",
      "r410",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r162",
      "r171",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r416",
      "r417",
      "r418",
      "r419",
      "r683",
      "r731",
      "r732",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, lending margin, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r40",
      "r411",
      "r732",
      "r751"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Term loan due December 2024 (2.60% at July 3, 2021)"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r385",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Debt instrument convertible conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r383",
      "r416",
      "r417",
      "r681",
      "r683",
      "r684"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount",
        "verboseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Debt Instrument capitalized deferred fees"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r75",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "verboseLabel": "Debt instrument frequency of periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r72",
      "r414",
      "r681",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r72",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate percentage",
        "verboseLabel": "Debt instrument interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r73",
      "r386",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r75",
      "r162",
      "r171",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r416",
      "r417",
      "r418",
      "r419",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r75",
      "r162",
      "r171",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r416",
      "r417",
      "r418",
      "r419",
      "r444",
      "r447",
      "r448",
      "r449",
      "r680",
      "r681",
      "r683",
      "r684",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail",
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r396",
      "r680",
      "r684"
     ],
     "calculation": {
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Original issue discount",
        "negatedTerseLabel": "Unamortized discount",
        "verboseLabel": "Original issue discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Debt, Weighted Average Interest Rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Accrued equity-based compensation"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Accrued equity-based compensation, less current portion"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r555",
      "r562"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r64",
      "r396",
      "r682"
     ],
     "calculation": {
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Deferred financing costs",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "terseLabel": "deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r555",
      "r562"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r538",
      "r539"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 33.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r146",
      "r164",
      "r555",
      "r562",
      "r563",
      "r564"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 49.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r538",
      "r539"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes",
        "verboseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r85",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "verboseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r555",
      "r562"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r552",
      "r553"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r551",
      "r552",
      "r553"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Deferred tax assets, tax credits",
        "verboseLabel": "Tax credit carryforwards and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "verboseLabel": "Valuation allowance on deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "terseLabel": "Deferred tax liabilities, difference between the book value and tax basis of investment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "verboseLabel": "Defined Contribution Plan, Cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "verboseLabel": "Defined contribution plan employer matching contribution, percent of match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage",
        "verboseLabel": "Defined contribution plan employers matching contribution annual vesting percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "verboseLabel": "Defined contribution plan maximum annual contributions per employee percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r146",
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r146",
      "r314"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 14.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://bio.com/role/SegmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedTerseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r146",
      "r234"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 42.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Derivative, locked in interest rate"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 45.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedTerseLabel": "Change in fair value of interest rate swap"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r91",
      "r635",
      "r637",
      "r639",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r87",
      "r88",
      "r91",
      "r661"
     ],
     "calculation": {
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of interest rate swap agreements"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r628",
      "r630",
      "r632",
      "r633",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/NetSales",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/NetSalesTables",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/NetSales",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/NetSalesTables",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r3",
      "r5",
      "r7",
      "r18"
     ],
     "calculation": {
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Loss on disposal"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 26.0,
       "parentTag": "us-gaap_EarningsPerShareBasicAndDiluted",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation, when the per share amount is the same.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic and Diluted Share",
        "terseLabel": "Loss from discontinued operations, net of tax",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "terseLabel": "Deconsolidation and discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Disposal group, including discontinued operation, consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r23",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r490",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "terseLabel": "Distribution rights"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r115",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r192",
      "r198",
      "r201",
      "r202",
      "r207",
      "r208",
      "r647",
      "r648",
      "r744",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net loss per share of Class A common stock, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net income (loss) attributable to common unit holders",
        "totalLabel": "Net income (loss) attributable to common unit holders"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income (loss) per unit attributable to common unit holders - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted Average Number Of Shares Outstanding [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/NetIncomeLossPerUnit",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail",
      "http://bio.com/role/NetIncomeLossPerUnitTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r115",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r192",
      "r198",
      "r201",
      "r202",
      "r207",
      "r208",
      "r647",
      "r648",
      "r744",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net loss per share of Class A common stock, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net income (loss) per common unit"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r670"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r166",
      "r541",
      "r566"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory federal corporate income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r541",
      "r566"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r541",
      "r566"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Share-based Payment Arrangement, Cash Used to Settle Award",
        "terseLabel": "Cash paid to settle award",
        "verboseLabel": "Share-based Payment Arrangement, Cash Used to Settle Award"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense net yet amortized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized compensation expense, RSUs",
        "verboseLabel": "Unamortized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized compensation expense, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r106",
      "r107",
      "r108",
      "r173",
      "r174",
      "r175",
      "r177",
      "r184",
      "r186",
      "r211",
      "r277",
      "r443",
      "r450",
      "r523",
      "r524",
      "r525",
      "r558",
      "r559",
      "r646",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r778",
      "r779",
      "r780",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "verboseLabel": "Equity method investment aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage",
        "verboseLabel": "Equity method investment ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r59",
      "r240",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investments",
        "verboseLabel": "Equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r736",
      "r808"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Unsecured PPP loan forgiven",
        "verboseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurements",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r649",
      "r650",
      "r651",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurements",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r398",
      "r416",
      "r417",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r650",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r649",
      "r650",
      "r653",
      "r654",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r398",
      "r416",
      "r417",
      "r481",
      "r482",
      "r487",
      "r488",
      "r650",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r398",
      "r416",
      "r417",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r650",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Liabilities Measured At Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail",
      "http://bio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r655",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r655",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation",
        "verboseLabel": "Summary of range of key assumptions used within the valuation of the awards"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r656"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r657"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Initial estimate (vesting)"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsEquityParticipationRightUnitDetails",
      "http://bio.com/role/FairValueMeasurementsMipAndLiabilityClassifiedAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r398",
      "r416",
      "r417",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Federal income taxes:"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected future amortization, year one"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization, remainder of fiscal year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Expected future amortization, year five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Expected future amortization, year four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Expected future amortization, year three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Expected future amortization, year two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r296",
      "r300",
      "r304",
      "r308",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets, Fair Value Disclosure",
        "verboseLabel": "Intangible assets fair value disclosure"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r304",
      "r726"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r296",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r669"
     ],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency impact",
        "verboseLabel": "Foreign Currency Transaction Gain (Loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SegmentsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Effect of foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Foreign income taxes:"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r146",
      "r420",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r290",
      "r291",
      "r707",
      "r729"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r292",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Goodwill, Increase (Decrease)"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r118",
      "r163",
      "r239",
      "r245",
      "r249",
      "r252",
      "r255",
      "r276",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r379",
      "r380",
      "r665"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r146",
      "r309"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 46.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 17.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Loss on impairment of intangible assets",
        "verboseLabel": "Loss on impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D",
        "verboseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r63",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r119",
      "r147",
      "r178",
      "r179",
      "r180",
      "r181",
      "r195",
      "r202",
      "r601"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Net income from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Net income from continuing operations",
        "verboseLabel": "Net income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r165",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r109",
      "r239",
      "r245",
      "r249",
      "r252",
      "r255",
      "r727",
      "r739",
      "r746",
      "r769"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://bio.com/role/SegmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income from continuing operations before income taxes",
        "totalLabel": "(Loss) income before income taxes",
        "verboseLabel": "Income from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r165",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "negatedLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r163",
      "r176",
      "r239",
      "r245",
      "r249",
      "r252",
      "r255",
      "r276",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r379",
      "r380",
      "r602",
      "r648",
      "r665"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 31.0,
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net (loss) income attributable to Bioventus Inc.",
        "verboseLabel": "Net income from continuing operations attributable to unit holders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 25.0,
       "parentTag": "us-gaap_EarningsPerShareBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share",
        "terseLabel": "Net income (loss) from continuing operations",
        "verboseLabel": "Net income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r18",
      "r21",
      "r569",
      "r763"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 37.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Net loss from discontinued operations",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations, net of tax",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r15",
      "r18",
      "r602"
     ],
     "calculation": {
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r110",
      "r146",
      "r236",
      "r274",
      "r738",
      "r762"
     ],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Net losses from equity method investment",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Income (loss) from equity method investments",
        "verboseLabel": "Equity loss in unconsolidated investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r490",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperations",
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails",
      "http://bio.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r17",
      "r19",
      "r20",
      "r21",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/DiscontinuedOperations",
      "http://bio.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://bio.com/role/DiscontinuedOperationsSummaryOfDisposalGroupDiscontinuedOperationsStatementOfOperationsAndComprehensiveIncomeLossDetails",
      "http://bio.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r318",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r542",
      "r544",
      "r550",
      "r560",
      "r567",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r167",
      "r185",
      "r186",
      "r237",
      "r540",
      "r561",
      "r568",
      "r770"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 21.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability",
        "terseLabel": "Change in tax rates - deferred"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r536",
      "r537",
      "r544",
      "r545",
      "r549",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r143",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "verboseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 38.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 39.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 41.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Assets and Liabilities, Net",
        "negatedTerseLabel": "Other current assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r299",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Total carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r294",
      "r302"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest Costs Capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r124",
      "r404",
      "r415",
      "r418",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest Expense Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r745"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest (income) expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 19.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://bio.com/role/SegmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "negatedLabel": "Interest expense (income)",
        "terseLabel": "Interest (expense) income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r137",
      "r142",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryAdjustmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Adjustments [Abstract]"
       }
      }
     },
     "localname": "InventoryAdjustmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r25",
      "r83",
      "r707"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r84",
      "r156",
      "r210",
      "r285",
      "r286",
      "r288",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r83",
      "r287"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationInventoryDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedPeriodEndLabel": "Balance, end of period",
        "negatedPeriodStartLabel": "Balance, beginning of period",
        "negatedTerseLabel": "Excess and obsolete reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r785"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment Owned, at Cost",
        "terseLabel": "Investment owned, cost"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r786",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned, balance, shares (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r789",
      "r790",
      "r791",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r789",
      "r790",
      "r791",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r695",
      "r697"
     ],
     "calculation": {
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of lessee liability maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lessee, operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r69",
      "r163",
      "r247",
      "r276",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r379",
      "r380",
      "r606",
      "r614",
      "r615",
      "r665",
      "r705",
      "r706"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r51",
      "r163",
      "r276",
      "r665",
      "r707",
      "r735",
      "r759"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' and members' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' and Members' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r151",
      "r152",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Accrued liabilities for distribution rights"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r71",
      "r163",
      "r276",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r379",
      "r380",
      "r606",
      "r614",
      "r615",
      "r665",
      "r705",
      "r706",
      "r707"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest",
        "terseLabel": "Managing member, ownership interest"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).",
        "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest",
        "terseLabel": "Limited liability owenrship pinterest held by members"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_MembersCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated value of preferred units of ownership issued by a limited liability company (LLC).",
        "label": "Limited Liability Company (LLC) Preferred Unit, Issuance Value",
        "verboseLabel": "Preferred"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r40",
      "r732",
      "r751"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Outstanding borrowings on line of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "commitment fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityDescription": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.",
        "label": "Line of Credit Facility, Description",
        "terseLabel": "Line of Credit Facility, Description"
       }
      }
     },
     "localname": "LineOfCreditFacilityDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Line of Credit Facility, Expiration Period"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Line of credit facility maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r40",
      "r397",
      "r412",
      "r416",
      "r417",
      "r732",
      "r753"
     ],
     "calculation": {
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "custom sec",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less current portion",
        "negatedTerseLabel": "Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturingInYearsFourAndFive": {
     "auth_ref": [
      "r364",
      "r402"
     ],
     "calculation": {
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth and fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four and Five",
        "verboseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturingInYearsFourAndFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r171",
      "r364",
      "r402"
     ],
     "calculation": {
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r171",
      "r364",
      "r402"
     ],
     "calculation": {
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r171",
      "r364",
      "r402"
     ],
     "calculation": {
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r171",
      "r364",
      "r402"
     ],
     "calculation": {
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, less current portion",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLongTermDebtDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investment and other assets"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r75",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfDebtInstrumentsPeriodicPaymentsDetail",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r354",
      "r357",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r354",
      "r357",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.",
        "label": "Loss Contingency, Accrual, Current",
        "terseLabel": "Recorded reserves for product recall"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss contingency accruals payments made during the year"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualProductLiabilityNet": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of the estimated aggregate accrual for damages arising from third-party use of the entity's product(s) or process(es) as of the balance sheet date (if the accrual qualifies for discounting).",
        "label": "Loss Contingency Accrual, Product Liability, Net",
        "terseLabel": "Loss contingency accrual product liability net"
       }
      }
     },
     "localname": "LossContingencyAccrualProductLiabilityNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r347",
      "r350",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss Contingency, Damages Sought, Value"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r351",
      "r356",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimated probable loss related to product recall"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r354",
      "r357",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.",
        "label": "Measurement Input, Discount for Lack of Marketability [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MemberUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest in limited liability company (LLC).",
        "label": "Member Units [Member]",
        "terseLabel": "Members' equity"
       }
      }
     },
     "localname": "MemberUnitsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MembersCapital": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Members' Capital",
        "totalLabel": "Members' Capital"
       }
      }
     },
     "localname": "MembersCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/MembersEquitySummaryOfMembersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MembersEquity": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r216",
      "r450"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.",
        "label": "Members' Equity",
        "periodEndLabel": "Members' equity, ending balance",
        "periodStartLabel": "Members' equity, beginning balance",
        "terseLabel": "Members' equity"
       }
      }
     },
     "localname": "MembersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MembersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Members' Equity [Abstract]"
       }
      }
     },
     "localname": "MembersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MembersEquityNotesDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the formation, structure, control and ownership of a limited liability company (LLC).",
        "label": "Members' Equity Notes Disclosure [Text Block]",
        "verboseLabel": "Members' equity"
       }
      }
     },
     "localname": "MembersEquityNotesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/MembersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r80",
      "r163",
      "r276",
      "r366",
      "r371",
      "r372",
      "r373",
      "r379",
      "r380",
      "r665",
      "r734",
      "r758"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distribution of Continuing LLC Owner"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "verboseLabel": "Percentage of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r141",
      "r144",
      "r147"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r141",
      "r144",
      "r147"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r99",
      "r102",
      "r108",
      "r111",
      "r147",
      "r163",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r185",
      "r186",
      "r195",
      "r239",
      "r245",
      "r249",
      "r252",
      "r255",
      "r276",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r379",
      "r380",
      "r648",
      "r665",
      "r740",
      "r764"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net (loss) income attributable to Bioventus Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r99",
      "r102",
      "r108",
      "r185",
      "r186",
      "r608",
      "r625"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Loss attributable to noncontrolling interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r189",
      "r190",
      "r197",
      "r202",
      "r239",
      "r245",
      "r249",
      "r252",
      "r255"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income (loss) attributable to common unit holders",
        "verboseLabel": "Net income (loss) attributable to common unit holders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [
      "r190",
      "r202"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 28.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
        "totalLabel": "Net income (loss) from continuing operations attributable to common unit holders"
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 27.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.",
        "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic",
        "negatedLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationPolicies",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r451",
      "r583",
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "verboseLabel": "Acquisition of noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r450",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 18.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of entities acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r239",
      "r245",
      "r249",
      "r252",
      "r255"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating (loss) income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r689",
      "r697"
     ],
     "calculation": {
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities- current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities- noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r687",
      "r691"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r694",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r693",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r423",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r172",
      "r188",
      "r225",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r70"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 23.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in foreign currency translation adjustments",
        "verboseLabel": "Translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r100",
      "r103",
      "r602",
      "r603",
      "r611"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 22.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 24.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Change in prior service cost and unrecognized (loss) gain for defined benefit plan adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r478",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable within one year or the operating cycle, if longer.",
        "label": "Other Deferred Compensation Arrangements, Liability, Current",
        "terseLabel": "Accrued equity-based compensation, less current portion"
       }
      }
     },
     "localname": "OtherDeferredCompensationArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r70",
      "r707"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 20.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other expense (income)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonrecurringExpense": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense that is infrequent in occurrence or unusual in nature.",
        "label": "Other Nonrecurring Expense",
        "negatedTerseLabel": "Other non-recurring costs"
       }
      }
     },
     "localname": "OtherNonrecurringExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "verboseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 47.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "negatedLabel": "Payment of contingent consideration in excess of amount established in purchase accounting"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r128",
      "r131"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r139",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments made",
        "terseLabel": "Payments for restructuring"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Payments of Financing Costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payment of underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r129",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Cash consideration at closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Purchase of Bioness, Inc, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "verboseLabel": "Additional investment,cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "terseLabel": "Payment to acquire debt investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PercentageOfDebtHedgedByInterestRateDerivatives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of an entity's outstanding debt that is designated as a hedged item in cash flow, fair value, or net investment hedge.",
        "label": "Percentage of Debt Hedged by Interest Rate Derivatives",
        "terseLabel": "Percentage of debt hedged by derivative"
       }
      }
     },
     "localname": "PercentageOfDebtHedgedByInterestRateDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PhantomShareUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded as phantom share or unit.",
        "label": "Phantom Share Units (PSUs) [Member]",
        "terseLabel": "Phantom Share Units (PSUs)"
       }
      }
     },
     "localname": "PhantomShareUnitsPSUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r498",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r190",
      "r203"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 29.0,
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedLabel": "Accumulated and unpaid preferred distributions"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r43",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r43",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredUnitsByNameAxis": {
     "auth_ref": [
      "r452",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of preferred units or special units.",
        "label": "Preferred Units by Name [Axis]"
       }
      }
     },
     "localname": "PreferredUnitsByNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredUnitsClassDomain": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type or class of preferred units or special units.",
        "label": "Preferred Units, Class [Domain]"
       }
      }
     },
     "localname": "PreferredUnitsClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/MembersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r27",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of Class A common stock sold in initial public offering, net of underwriting discounts and offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Class A and B common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from the issuance of long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r133",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from Lines of Credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowing on revolver"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r134",
      "r136"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r21",
      "r99",
      "r102",
      "r108",
      "r140",
      "r163",
      "r176",
      "r185",
      "r186",
      "r239",
      "r245",
      "r249",
      "r252",
      "r255",
      "r276",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373",
      "r375",
      "r377",
      "r379",
      "r380",
      "r602",
      "r607",
      "r609",
      "r625",
      "r626",
      "r648",
      "r665",
      "r746"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 36.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r62",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r61",
      "r315"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r36",
      "r37",
      "r317",
      "r707",
      "r747",
      "r760"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r317",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r36",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r36",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r116",
      "r280"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlowsAlternate1": {
       "order": 48.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedLabel": "Recovery (provision)",
        "terseLabel": "(Recovery) provision for expected credit losses",
        "verboseLabel": "Provision for expected credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r245",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule Of Reconciliation Of Operating Profit (Loss) From Segments To Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related-party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "terseLabel": "Repayments of convertible debt"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r135",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of Lines of Credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "negatedLabel": "Payment on revolver"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r534",
      "r723",
      "r825"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r310",
      "r311",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Software development costs"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r24",
      "r35",
      "r154"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r326",
      "r328",
      "r331",
      "r341",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RestructuringCosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r146",
      "r325",
      "r335",
      "r338"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 16.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://bio.com/role/SegmentsDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Expenses incurred",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Restructuring costs",
        "terseLabel": "Restructuring costs",
        "verboseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RestructuringCosts",
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails",
      "http://bio.com/role/RestructuringCostsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs [Abstract]"
       }
      }
     },
     "localname": "RestructuringCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r328",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveCurrent": {
     "auth_ref": [
      "r39",
      "r328",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Restructuring reserve, current"
       }
      }
     },
     "localname": "RestructuringReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r47",
      "r450",
      "r526",
      "r707",
      "r757",
      "r781",
      "r783"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r173",
      "r174",
      "r175",
      "r177",
      "r184",
      "r186",
      "r277",
      "r523",
      "r524",
      "r525",
      "r558",
      "r559",
      "r646",
      "r778",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r230",
      "r231",
      "r244",
      "r250",
      "r251",
      "r257",
      "r258",
      "r261",
      "r466",
      "r467",
      "r724"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 9.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total net sales",
        "verboseLabel": "Net sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetSalesDetails",
      "http://bio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r469",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfCommitmentFeeAdjustedBasedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r692",
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from public offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share in public offering (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r222",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://bio.com/role/NetIncomeLossPerUnitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsComponentsOfIntangibleAssetsAcquiredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsConsiderationTransferredDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsProFormaResultsDetails",
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary Of Components Of Income Tax Expense Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r75",
      "r171",
      "r416",
      "r418",
      "r444",
      "r447",
      "r448",
      "r449",
      "r680",
      "r681",
      "r684",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareTables",
      "http://bio.com/role/NetIncomeLossPerUnitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r192",
      "r193",
      "r198",
      "r202",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/NetIncomeLossPerUnit",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail",
      "http://bio.com/role/NetIncomeLossPerUnitTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r296",
      "r303",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFiniteLivedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r296",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of net income from continuing operations before taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r33",
      "r53",
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/Organization",
      "http://bio.com/role/SubsequentEvents",
      "http://bio.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/Organization",
      "http://bio.com/role/SubsequentEvents",
      "http://bio.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "verboseLabel": "Summary of Contractual maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r62",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationPropertyPlantAndEquipmentDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfUsefulLivesInAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r35",
      "r154",
      "r728",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RestructuringCosts",
      "http://bio.com/role/RestructuringCostsAdditionalInformationDetails",
      "http://bio.com/role/RestructuringCostsSummaryOfRestructuringChargesAndPaymentsDetails",
      "http://bio.com/role/RestructuringCostsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r332",
      "r333",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of restructuring charges and payments"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/RestructuringCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r239",
      "r242",
      "r248",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r498",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstruments"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r77",
      "r160",
      "r212",
      "r214",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r436",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r605",
      "r606",
      "r614",
      "r615",
      "r616",
      "r618",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r616",
      "r618",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r219",
      "r222",
      "r223",
      "r224",
      "r662",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of significant percentage of total sales"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r226",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r330",
      "r340",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r239",
      "r243",
      "r249",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series G preferred stock or outstanding series G preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G Preferred Stock"
       }
      }
     },
     "localname": "SeriesGPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation from 2021 Stock Incentive Plan"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited/canceled (in shares)",
        "negatedTerseLabel": "Number of awards, Forfeited",
        "terseLabel": "Number of awards forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled (in dollars per share)",
        "verboseLabel": "Weighted average grant-date fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Number\u00a0of\u00a0awards, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "presentationGuidance": "Compensation expense net yet amortized, period for recognition",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Weighted average grant-date fair value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "verboseLabel": "Weighted\u00a0average grant-date\u00a0fair\u00a0value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)",
        "verboseLabel": "Number of Equity instruments other than options granted during period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r504",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments",
        "verboseLabel": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized to be awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available to be awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationOptionActivityDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r505",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r496",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationRestrictedStockUnitActivityDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationOptionActivityDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock closing price, (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r516",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of options vested (in shares)",
        "verboseLabel": "Number\u00a0of\u00a0awards, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant-date fair value, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationSummaryOfPhantomPlanAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and handling"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstruments"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r690",
      "r697"
     ],
     "calculation": {
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r155",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State income taxes:"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r8",
      "r226",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r292",
      "r319",
      "r330",
      "r340",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfGoodwillDetails",
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r160",
      "r163",
      "r192",
      "r193",
      "r194",
      "r198",
      "r202",
      "r212",
      "r214",
      "r216",
      "r276",
      "r366",
      "r371",
      "r372",
      "r373",
      "r379",
      "r380",
      "r427",
      "r428",
      "r432",
      "r436",
      "r443",
      "r665",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestments",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/CoverPage",
      "http://bio.com/role/EquityBasedCompensation",
      "http://bio.com/role/EquityBasedCompensationNarrativeDetails",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail",
      "http://bio.com/role/FinancialInstrumentsTables",
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/RelatedPartyTransactions",
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail",
      "http://bio.com/role/SubsequentEventsDetails",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r78",
      "r106",
      "r107",
      "r108",
      "r173",
      "r174",
      "r175",
      "r177",
      "r184",
      "r186",
      "r211",
      "r277",
      "r443",
      "r450",
      "r523",
      "r524",
      "r525",
      "r558",
      "r559",
      "r646",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r778",
      "r779",
      "r780",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformation",
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails",
      "http://bio.com/role/BalanceSheetInformationTables",
      "http://bio.com/role/BusinessCombinationsAndInvestments",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables",
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical",
      "http://bio.com/role/EquityBasedCompensation",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail",
      "http://bio.com/role/FinancialInstrumentsTables",
      "http://bio.com/role/IncomeTaxes",
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
      "http://bio.com/role/RelatedPartyTransactions",
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail",
      "http://bio.com/role/Segments",
      "http://bio.com/role/SegmentsTables",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r211",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformation",
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails",
      "http://bio.com/role/BalanceSheetInformationAllowanceForCreditLossDetails",
      "http://bio.com/role/BalanceSheetInformationCashCashEquivalentsAndRestrictedCashDetails",
      "http://bio.com/role/BalanceSheetInformationComponentsOfAccountsReceivableDetails",
      "http://bio.com/role/BalanceSheetInformationInventoryDetails",
      "http://bio.com/role/BalanceSheetInformationNarrativeDetails",
      "http://bio.com/role/BalanceSheetInformationScheduleOfInventoryValuationReservesDetails",
      "http://bio.com/role/BalanceSheetInformationTables",
      "http://bio.com/role/BusinessCombinationsAndInvestments",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsTables",
      "http://bio.com/role/CommitmentsAndContingenciesLeaseCostDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSummaryOfLesseeLiabilityMaturityDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalBalanceSheetInformationDetails",
      "http://bio.com/role/CommitmentsAndContingenciesSupplementalCashFlowInformationDetails",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncomeParenthetical",
      "http://bio.com/role/EquityBasedCompensation",
      "http://bio.com/role/EquityBasedCompensationTables",
      "http://bio.com/role/FinancialInstrumentsSummaryOfContractualMaturitiesOfLongTermDebtDetail",
      "http://bio.com/role/FinancialInstrumentsTables",
      "http://bio.com/role/IncomeTaxes",
      "http://bio.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://bio.com/role/IncomeTaxesSummaryOfNetIncomeFromContinuingOperationsBeforeTaxesDetails",
      "http://bio.com/role/RelatedPartyTransactions",
      "http://bio.com/role/RelatedPartyTransactionsNarrativeDetail",
      "http://bio.com/role/Segments",
      "http://bio.com/role/SegmentsTables",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetail",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r151",
      "r152",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "verboseLabel": "Debt conversion"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r43",
      "r44",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Number of shares issued in acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r43",
      "r44",
      "r443",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Stock issued during period shares new issues",
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Initial public offering, net of offering costs (in shares)",
        "verboseLabel": "Stock shares issued during the period shares new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r43",
      "r44",
      "r443",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Initial public offering, net of offering costs",
        "verboseLabel": "Stock issued during period value new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r43",
      "r44",
      "r443",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Number of shares cancelled (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r44",
      "r49",
      "r50",
      "r163",
      "r272",
      "r276",
      "r665",
      "r707"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity attributable to Bioventus Inc. and members' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityChangeInReportingEntity": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact on total stockholders' equity of cumulative effect of change in reporting entity. A change in reporting entity is considered as follows: (1) presenting consolidated statements in place of the financial statements of individual reporting entities; (2) changing the combination of subsidiaries that make up the group for which the consolidated financial statements are presented; and (3) changing the entities included in the combined financial statements. A business combination accounted for under the purchase method and the consolidation of a variable interest entity are not considered a change in reporting entity.",
        "label": "Stockholders' Equity, Change in Reporting Entity",
        "terseLabel": "Effect of Organizational Transactions"
       }
      }
     },
     "localname": "StockholdersEquityChangeInReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r107",
      "r163",
      "r173",
      "r174",
      "r175",
      "r177",
      "r184",
      "r276",
      "r277",
      "r450",
      "r523",
      "r524",
      "r525",
      "r558",
      "r559",
      "r599",
      "r600",
      "r624",
      "r646",
      "r665",
      "r671",
      "r672",
      "r676",
      "r779",
      "r780",
      "r830"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' and members' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets",
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' and Members' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r450",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity Note Disclosure"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/StockholderSEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r677",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r677",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r677",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r677",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://bio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://bio.com/role/MembersEquityNarrativeDetails",
      "http://bio.com/role/OrganizationDetails",
      "http://bio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r708",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative number of shares issued or sold by the subsidiary or equity method investee on all stock transactions.",
        "label": "Subsidiary or Equity Method Investee, Cumulative Number of Shares Issued for All Transactions",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.",
        "label": "Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions",
        "verboseLabel": "Increase in equity ownership percentage"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfChangesInStockholdersAndMembersEquity",
      "http://bio.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance sheet information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantPercentageOfTotalSalesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r41",
      "r733",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement [Domain]"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r41",
      "r733",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment [Axis]"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2015Member": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2015.",
        "label": "Tax Year 2015 [Member]"
       }
      }
     },
     "localname": "TaxYear2015Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2020Member": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2020.",
        "label": "Tax Year 2020 [Member]"
       }
      }
     },
     "localname": "TaxYear2020Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income and other taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BalanceSheetInformationScheduleOfIntangibleAssetsNetExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "verboseLabel": "Temporary Equity, Liquidation Preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r196",
      "r199",
      "r200"
     ],
     "calculation": {
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 30.0,
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedLabel": "Net income allocated to participating shareholders"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemNetGainLoss": {
     "auth_ref": [
      "r126",
      "r127",
      "r235",
      "r569"
     ],
     "calculation": {
      "http://bio.com/role/SegmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (gain) loss for an event or transaction that is unusual in nature or occurs infrequently, or both.",
        "label": "Unusual or Infrequent Item, or Both, Net (Gain) Loss",
        "negatedLabel": "COVID-19 benefits, net"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemNetGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Valuation Technique, Discounted Cash Flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsAcquisitionUnobservableLevel3InputsDetails",
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique, Option Pricing Model [Member]"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FairValueMeasurementsSummaryOfRangeOfKeyAssumptionsUsedWithinTheValuationOfTheAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Variable interest entity, ownership percentage",
        "verboseLabel": "Variable interest entity, ownership percentage"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r605",
      "r606",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/BusinessCombinationsAndInvestmentsNarrativeDetails",
      "http://bio.com/role/BusinessCombinationsAndInvestmentsVariableInterestEntitysAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/FinancialInstrumentsNarrativeDetails",
      "http://bio.com/role/FinancialInstrumentsScheduleOfLoanMarginAdjustedOnPricingGridDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r191",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "presentationGuidance": "Weighted average units used in computing basic and diluted net income (loss) per common unit",
        "terseLabel": "Diluted weighted average common shares outstanding (in shares)",
        "verboseLabel": "Weighted-average shares of Class A common stock outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common units outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/NetIncomeLossPerUnitSummaryOfEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r189",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average common shares outstanding (in shares)",
        "verboseLabel": "Weighted-average shares of Class A common stock outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/ConsolidatedCondensedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bio.com/role/EarningsPerShareComputationOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=125520798&loc=SL114871939-224231"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22624-107794"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70258-108054"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "272",
   "URI": "http://asc.fasb.org/topic&trid=2124037"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e14981-108350"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r827": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r828": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r829": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>154
<FILENAME>0001193125-21-278969-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-278969-xbrl.zip
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M5DP,3?S,@/S.XF"X-I #.C"QO,2^!H'[2CVOV\+<;*5@6\60T6H9PFD_Z__
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MQ>5QAS 7AG4Y[HZ/ABDH/5>EI+V)H@2A;D2#,L?F3OCLY)KU:_!"F"\NPN!
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M*M_78+8,DLCVW7N8YC$A_D;?YN94:U1TC'$T8/L:6!/POI>0UR"2/ #@8X!
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MB5XL21^T_Y^/MR63SRABN-+O3WKJXZ1_1L]!0*&=+B!,XC9<;#6P Q*K<KH
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M.U@C=B-7)X/0!8,WSWK8S=;%;>2@74;B<C->OKI5NHWCE#KBWH:$9!!,TN<
M>0]$ )BP(O=;T&W#Q>5-,D(XC@ZZG+H9@,]C@"4F+Q*>&,*\57</X=WBT,V
M_2KAQ7WI'36*$.HQ]*79S33J[A&L @[=C+Y_A*O\4%O/1"QU\!-5&3F(8L;4
M0?H]'/NJ.I0G/!0<\[@E1RI\(3]NQMU72:V8@Y@)R&P?;-S22 %NS:^;X?:\
M24)W'=2H.W*0-3A4A^O;L91S-V::2Z).Y9$CJ\.BF_'U MY+/\PN5@MN(P>K
MA9&XW(SQOX0K#+WB5:E5 !F2H7^VI%G%_X=]+W6YU*GNXIP@&1=-!TT=)MU,
M$,#8IF\#DSW(990^)[,T*"(;Y3.]I-K(\90SIQ_</R2.F^1WU?0P$@1%%4:.
MG8BMG@/@12?7&4KBXM*->D=P,O$448]9*MZS5X#]6(%9?CCLI?&1XMNG"-1A
M]%:VWOI)1ZJYGB[85N0V)(M-2I\_4^4I.97,"8-1,%(E'%Q.;F81N"3;XQ=
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M;'</%:6C1 3JXT!P]+L-EC.\VS .H/OJVO/C^2-UYS"$,VDZ V7-/418R;,
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M%4B$06H:9D'80??[K-C#2M))FVV?K)?Y"P92VDI_!RUM+3HGS<X[&Y$3#%<
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MOP,^L'B27E?-#X;O:_EZP+7J7TD%:<4,19OC?;P6N/:1;)K[8QFRT"A"HE2
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MO@'RNUZA$:V[R8$!I#K\OI:!:XZ%4QY58M2#"S;G#"_' ==NX%HN_'EYSCT
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M1M42?1R7]UE1W,(:6?(W6S749B.S@O(N7C"X. FQ840E,[FRYA)W.!>.-IF
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MPK.TG^:S6:*^INN&#HX/2"L(J?@L7_EFB,(QER_IO07N%J]L]'N6C8Q$MC$
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M/G4L]-(-8F1E4%@?>M,L+^._%MZN+2PJV2L'UAIH@#G^2ND:8D+DUSZH8IV
MSS]F<+ S."J2^8@OLV6)6.1<-!M<HP@PH5\FF2:X$.E0F!L4VX0$U5?VHWS^
MSI(W]B5+R]>&'EN#B6M>=?+T;8\9B<NF,&#80?H/%N7/WS-GRZ*>K^9,QY)5
M6D)%%@%%+DL#)/!^E5[6<,::.QU3R5J#199"8.$\");;;*ZR>#:;L.+-Z4&
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M>7J=36=9RFL0F_I59.-JI!\LU,L0,B)<BCR'+4*U.Z'T^1H9=>27(??EHM,
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M@]KG&_)6VVRI??B":)+72T=BAWJ8Y\/7J%CM8.I25$:#:S0D):>5"W=7#K:
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M3FI_;R.<-0#A^$?J8F';9??+ZRC/WT'!U=70-!H/H$F#H5M(S0)?. Z354"
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M/C<5Y0A?:>O_MTG-.#TA#7O=FP-%@1Z1*849Y6I>\%(IQ74V?8G3*J/A6CB
M>2Y#!CL(T!8)=ZU \7X-G&#*P*#FDP)_2"/X]K8ZVK+H_V_O6Y<:U[5UWV4]
MP%H--+=3M4]5H*$W^]"$ KIG[5^4293$<R8VRQ>Z64]_)%N!)-;0Q=;PD)G]
M9\X&)'M\WY!U&3<!0XC" M,""N=L@C&*WI_+62+-CPAY(.VR!(RE[A'DWZ(D
MFK.ZN*J()!$%59=1LD'&Z_DRRO-X%K/IZ&>43=\/2:) VC)/.4W <N_GX8]8
M%XZ&,DY\4P4,%IH8\S>FML5-<_6PL>O(<9)&3?8V==C0 *B[>^+]Q;]+/NQN
MHZR(1?%>\8([D5ED/P$X/.$1[2;;0%3:B@\@OF(]'_8:O#>:<.GSZM'?D_0I
M9]F+L+'4!J_:^$45P;=>83=$O+8(R--U>SPDJ9C58J^PH:-*"W[W:[M/?SP\
M)EV-S3KSM@E30P\GXNU^LF#3<LG&,P4I^=GKQD^FD$O71_'9"<<%HXVL;*O[
M=N@\QD-2!,2)^;L:SP]LLDCB?Y?0);_Z#IQ7G._=R2/04H/*T:##&4[D6U-*
MHZ,<ZL*A(6VMK$,A=)S;:FD33#BA:Y[U1.UPP%&8R0=!8595R"L+OK/I>90O
M+I?I3Z.#V_XAG 92LZG^>[)6J19=."%GNUNW!_Y&P_('=>'0 G")^UP ]4C#
M"2!3R6F<7.%.'!Z5U]R.>7MM;0(*)] +05^A+(?^%6=:$BF"O'8E7L_V(K7;
MN!2:.W/8I X?TY=DIT8(E_<PKS<]YEFQH4/^TZ[^^*\>[Z)D#BUQ6W_G*P/.
M1J3W]4P!RWO\5@LE@%_*3@LN,=+G8%R/%,P!U&Z*ZCUL"YE<ZL6C#<M^H[4Z
ML"VKTVKYWFK#9T&2J"'E4&WRK) 5+V[+CF'.D9'AS39<:I*0:5N&F[(&%$75
M6S+:(8Z.R$Z++K@#"GDBRC["JAWO/>E,J,N@<'O$/L*3AJYWZMT&X0 P;EI"
M23OKF+%T-*2TLT.PQ)<1HR&BJ-^HD[=;$:Z269JM*GLT>:4H?6Q0%0RT&2-3
M$<W_G":BH%ID&Y^"\;K'0Y(B?/;A%Z,L$WO-2OGG"_'/*UG3;#PS16SL:<CL
M20+.;QA1S=['C'HRZ956#[$WRDC'FU*0.I[5\7F<&S;E>$0=Y_INS&640-=I
MV'1]/#P-(X(9>4RX\1%.J,S](LI80]2-\7KV^MY$WNA8Q6#7(-]+-^;C8L&R
M!SZXQQ6N_"9-7EA>L&E-BRX"JR\9./EA!-KV-$'U3&PX$40>B;:NV.CI58^'
MQSBN6KO"C3V-3!S6/(8M]F4)?8@+8:NZ2J;Q2SPM(\@4![;ER'$RB-N5+?"K
MSX:A54,!6GA5.SW^$1>+.[:L(.6+^/DA->3AMW@*!XYT++=RHVF48:$Y&VAH
M455AZY3:GM:'<DV&L^[YG6<_KJ_/+U;/R_25L?R!92MQ2.,;G2Q.LX?TZG:L
M+]A@V9TO<R1WS[7^J)H'%S>H'J*N+/0UJFY8&!5N:FKTXB*3%-A TPZ ,)Q(
MJNH 81%TNM6.8P_ =]C'+D8#'R^,RK]9((>.CN^XDJFP>-Q$*W,D),;K.*?4
M#DF%CEL>U%OCQXL*^[N.*>K-63"#R^CZ=+)G^BK1H=TLM'X>7V1)':!X$T1S
MO]&1)+12:U %@>]<&UJMFSMRR4DK<O:I7ELV?(0(]JY'<?73?B#5[KMO(L]>
MM[^X]UI]'&0C&]&5HH B%!6A>H;3 ]"##]T 4K;[/$=HB0@H*%$EI_AGQLQ;
M.6-?CI8ZS5NK!WO5*6 %%&&(KL10-M=8VO0;+@A5I!5B\+V;J1[M5C,N'6F2
MMN7'H#"/*8'XJ SFZ]Q;1$6UB:O6\/'LOD@G?QF6-[ /7PH"2&'K<X$S4&$H
M$]:GHC<%-$Z'S<8<#U52G"77:@5!2 #-4)B>/&@FE)7)HXI,B]$^14 :/P"O
MTJ02>&0,66\VYK,_:0%OZ&, ] +(#^B#-)1J]S!JGS/6[%<?0H.Z4[2'E<R2
M$D#YI)<38MDR^@FL,]E10LE:TXT*PY#")PD8EJ0)K1]Y6(:RX1C&^#3N92AL
M7O<E!R2N.2TN7OA_+((B@!XU2J0B \&NET8R %536,84LIH]U% ?B1#)'F-_
M&C3Q;ZVV75B XBAR95$4%\K<C:5!XVQ+8F?;EMIX>%2VEPA)\Q@M/B KO>TB
M O)S@KR-\6 ?Z4Z$X%8[+0& R@*[E)'+&MBEC#5[3:+5D@,L!W8IHY"5>F'Q
M0+=I[3@@OY212TD2[ 4/4*77"Y0<X)7"@+0.6[_G$V,\8>HXIW4]Y8O9C$T*
M\=-WWN(AO6=%L61UA)EF'??VCL?#TS"N5NHI"=,S<<"PHS 0M4Y\KO[S@^6B
M(L,MR^)TJJNKX?,UG$.2-*+!Y::#W 'CC\3PTQ9<]=O\*L]+-KU*:G@8 U#U
M'L[B1PF<Q!V!,'G $"0Q2+5%=Y/*(@_-(A!ED1=1,N5*P*OIX?!Z>;(EC=P>
MS*!MQ2LPGKL'J4%QRM7V=\DEYV=T+ELT9^/9EYB+&C^55=:D8VBX\7G\NPVC
MLET/]8DZD@0,!@I3WQ<V8UFV_0V\#_O-O F'>\';/[3^8/;_5OLW'VP!I5=(
M8O?XP6;T$L5+P<EEFIDF':M^TCM*&I#4][BP) 10/45P8%7;2C6<6\XCK9XG
MF#G<._Y;V1\Z$@4,H36%O99J_18_Z_(C?Q=M;3^ CCY13 J#KB!WBA,YT'\%
MN4KWZ)%%&ZQYK"!'.FJ]!NL>GG[(0-U3T(]N04<X%5P_=C#DT:>PXW.KP8 ^
M0^G(^9!55\,<B=3>]V$,29.#OWL%B7#*PAQ]^BA&']T4TS0E=F3,=ZU6Q$"T
M_5.D>XV"V_UH"?!=B14E0HJ+2A4SK26OR;-:<M_W3Z.13+T0>F#;M$IY*<30
M)0J-"TD2A0P/S^8RH),\G(JD'B?/\V@Y*>L"KG?I<GF99F)MZV=?JGXW7U _
MGM&X'[N/CM" :K&J#,ZBDG #7;X-;YN+MWW95Z[5Z[0JF+(LIR*"Y2+*$M[,
MRD"$+0-G_Z/XXW7#RS"V^V$YH-JPGI%7L5D]CN?Z?9S5CQ*+1#YV-QG%NWR=
M>IS60=25![&_P;KQ4L[O1PE.(!^Q#5K1"N%Z%OQ<W.65B0/70UJ'B 'G%/3W
M<MY(:]"1#,<>F?51TI=X(LT!R-6S$.90[?LXJQ\E8KZ_Z=."41^5B?N8.3E+
M,Q87_$%07#+>"Z6AY>]W6.J+5D/MY%[#RW1EO7_'EG6P,Y%4.Q]R;-G1'HZU
MD2"V;*]QVQ8N:[]CRQ3!"D=[. YT6N]JK>\6L645';]CRWJ*;=A#VKU[BBVK
M!@-9(,\>G,_Z>R3Z)YO:I3Z,(8D?6X9Y.]'1WD>QMNHFC>9QS9::086%'>$<
MO8/;N&@)&$A8&%:-@/9A84>-PP<L^4#"PHZ.J-<P#VP/("P,J0QPJ["PH\:M
MHR;)?X>%]60YW?LHL0A]FVQTA'Z L+# /&A[']WCNP=>S(S(Z,<-[0H]?'&/
MM'3T(,=S2Y9_AX7AQ2_M(V7=_OU&<8-60UA8KW[E^W*UBK+7\>Q.U%L9S_X?
M>QWE>;FJI,M%H5>!/$X>%DSTK7".9_RGS;(F=)YG+BLK\HVD0_4XX0UNTB3;
MT8^#R]G'>^H3T"FI[;P##FM'<]=W2)YPYA\[+[-?=1MF&7]\A>5?SK-B8X3R
MGW9')__58S7M (;7K;]7A<,^(46'MC.Y>E3<U@@!<*,YA>T5!5JK=EI(H:DN
MLP4(!%C>%1G-Y8G',[79M0OA7AUZ'8C_QBE;E2LM]5MM:@![.)?4&/;)X.!M
M4@[([-O3YDAV],M,]F8;*3C)H<2%;+7,OIUD;F3_P82KE4U'+RR+#).+LJT$
M0I)E[$"^07;?3K3VV_&- UAUCK2X%A+J(N&%%$*'M2VRI\*#XPY1T\9H([B3
MA$@=M&;6@+WF=H&%XQU$TAWU7@U?B:8='8FS;%?LBU_/;,(7BP>6P=L0^\X2
M.VDRCLWG9:=3';Z '$N[8M_%^5^7&6-72<$REA=W40'O=MP?(CD@]:K[T[$-
M3A\.%G7]OMT!5\4'_DB%G5[8S/7%^JPZ2Q2D\9;NVFJ#ST>:.=(7^27.)VF9
M%)=I=AU-_AK/OD797ZR0GA'G;]/F<9(74B>LOZ_4#7&(Z=U>DX4JI$C7K(1Y
MVK'DPT?"='A1=0$F:M2,4Y_ +$>%84CADV1(H?X]+#TS'LKA<ACCTWA0=3(.
M]IY,5*/XX E%;U-)<Y_L0A&@8 J;X%L<S0.;+)+XWZ7)]JON(+']'1SBMD0
M2J8P'C9%-2X24!>)C\J9;DN^K<IV00%A#10V0@2EA;(@XVC/M(#N4U@%FT+7
MU][>9GR92.;?TBE;&BT/]@^IN3@@#9<U?V6V^C6C!#3=/@X),4>72XP3GA'6
M^JA%#^BKO740)7F4RXH47M V0[=FKTFT6G* Y?:6-S26J5<D#W0;EYWN=0([
MYNAR*4FN!8('://XI),<X-7);N-T'L[K0YN8"]_.AXXG8]4C9+A0&%<T84:5
MMR<&4#6>Z:,21_JT@(Q3E^X221AF$%(5*TD!U+LV&V E&]6R5#?!;][K?!-E
M623N"J.J6?E^03UPW?39ZWN3V^A5_*I*=;JV2!?J_O#'H\_=JX/?E&*TCF>
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MDV>%K'BY=TA5&XX.@R@: #'<E#6@DH+U!O.^X <(L:Y<BU<)^O3!HII>G(8
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M#AM6JLUF''$ %\CWLC@U80,Y&Q15?ZS-N8V]%M6=\C"M>OHW!0<40&*3::^
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M+8VW?Z9\3<F+=,4RR-2E;EAC.,0QY2(Z@G1( &UX\&Q;:4.$P8]G6P)JPWO
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M@@<42:*OL[B6?%V*WEFCZXX2ZX"^3U=<@ XI3"5R^KCX]<R27/<5;C?DDTQ
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MW^JY+*KOKNEEOK:( /+UBEJ!)R1%/M[<[!W!V$>6^'B19 PGYD@;=N)?YZ8
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M^9";(\--N_T((*G'<4<-:2&CHATH<$QS/+4'877I:\LG2G*0+&'6]P;W/1+
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M?)+<@(-6GGLMGGZ^V&DE$0R79A /6GWM]1OU4\9.*ZE_D@KT7GENX G(XZD
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MHBJQ[, YL$O1( JH5)DG+5'[$A'5A5A!##-ZX13)_8$POVDA$%R$U<:??GI
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MHYT>\]KDUG8I_AD3VJ5,Y-N8I6H$OEW**/82+FI@5JF:/+.9I);<MW<7C>1
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MT$@/E98?D\)*VPZIA^0*I?*J&EURXZW54+-A+1SMK9JMU:"#XSTU C.+?N^
M,#?%XUY#B\][R@-._O?> 57:B9:])M%JR0G*H+=DF7KQ]D"W,9C0RPW7G=+L
M]PY(0L3@ =J<QG62&W( ^O-HC*;3N);B*IFEV:I>HCZZ^^*0PDY'9/)!NE#/
MD\GGL!$;VPEH$(6)/'T (I388.Q1MJ_9.,(QXN)NO0[![!T#TD#=)D)0HTD
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M1U'3GGUVAX:?0>UWUK<#0OJ 0 :N&;&4CT<S.LV_:DH;RCL"P0\#3MP#IY"
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M+;CNW='E2Y1FW/F]9@<1;/_=1#I/W;BL]@6H5.2+1F4ZB;FA.%[W!;HYY=]
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M,G6"4:CI""FA<3CA74X2M$QG?2?00*]IZ!CT #[DJST.OH]>Z5FP_?7*N /
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M2F8$)GTEN:G/RQZ93QO_!<Y9L;H<FA9JQ&^JX=?KA84&,M*=A08OH/L'I[T
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M_-31=X-O(OY1](Y^]KL=ZK^,FD^C]MM(^#@+#!4^C_KO[Q#A@/H3A ?_#C?
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M*.5[IW]'M &H-[V83:_IUE6S+F515TVYSZ"'IAP[3JZ+XPGG%5.9RY(=$K!
MV*O7ODT3:\N8[CG/$YIW[W-TQ).^\#:?\QD\L<UXF8 ,ZMZ&(Z_7T(D-M4(*
MK]A0)68[J7?U,R[OGZ.\+HZ3CJFNL2=G5,OK&&2L(6I:FGU.7]Z:>9Q%#\W#
M(-MX98Z#?6H&^TR:KA1JK%27AB.J!:Q!Q73CY_P%TPC#R[A.7VPJWJ[] 5\!
MR6N.B71S0/LV3PA$\ITBT0\@_@7$[7C[#=1^)( XP.W'J;]A&8P,'Y*H(0,6
MP;RZV@R"FL/4&:LXY^UUAS^\B$7=:>WBB2*DXKK#;M>(I6QTIT4,?#BTVOMX
MJ(G,=_SJL(N'N.RO$V<$2Z_S(9!0ZI7&R'3OS3YQP<'4?(0;EQUBWT'-AW9"
MO(_PK6!"!M[2H(41O[VF NJCN]?4/A [];EH;&=?<)9Q3_W4RMH'7(DNB!6:
M-P(F_>DHHIYDHSF,J%<7S]&\ (Y&&'9C@4+HS<0";8#Q7@0#]J7(LH]%R<Y-
M9K@G=I1@_ ]+*8UKI;@@(DH%-60"5.YM!0Y#?YV@:UC877 +4S<RK],DS<[$
M>. '>D?/[NUY10&<?"1#1#=G9[Z1N]M_B,H\S0\T!0AS6MS4>+V/P=2A7&^L
MC*4<A<^@_CNH_1"BP$7"IVBG]F,T8PYWO0.T'+ #&(9E65OA#'4S5]:VV0?'
M-WE<'/%C].U]6L5902."&#0UQ\#ZYIX.=0W\CF''FR+2%O6-&\T#N]J8&F_Q
M_'!JL-><]-LTQS<U/JH",::[P$V^R+<E &@7Q/J$A )I B:0((T^4.UXRM@5
MWA<E[IDD_ZGJ-+[,$^)4X?20SRHI/XLR4*7Y>:-@+L_.P/O$B*(>RCO4$F:/
M&!O2 3H4JPU*?X-$BU^E?"28GT4TK4[S,WW01"M=1GS'T@Q9'7T+Q:]8I"6F
MDO<+5 3$7%"GILAI]$;+/>'XPS=Z T3DR/$^G9--9@95$#,Q1_J)Q'8-/<%@
MT-6NH8G>-52_"] \K#(8C6FX&XS%G7(L&IIA&(39>J W!K.5 ,00?-CO,3T4
M[>W6EZC&H^>![I9@#ED04S!+?I,MZ B*V*<T0WTBO?98]%Z"[5"$80KF:X+>
M%LQ7 Z"L_7M<EK28V#=5]HD9=L"1(E!^?S>IS9G).2T&]:9 U+BJ77B*OW@$
MQ.3DDP,0AKK/PKJI7L ,H,-=.%[Q-X.Z$T:K7G 7B2/NI^_0GKK'I^I#1Y#;
MP=6E +P%5.%IXL9/!:;Y"E&5M: ,Y%]C12"_^O/=UYS,TW-ZTCQT4[3Q '(5
M9U*X>OMWD/=M:W#H YS:.6ZAJ)U@7\#3OD!3MO(-/NW[)V%R09Y[K<6E=Q"J
MWU89)GOV5=+5+[>WU\9W4(,6GBZ*AEQ)M11_0>3/@"_K;=B#NII23*AX$Z68
M38_N)%NZFX7<=&,YT=ZC"ZGC>#SIW,/J?"[3):4?KW$#QGTZBD:DC%U$(TQ\
M[I:BSDVEI01P&^YAVBIIN_C<)^GYEK87D;"UV+$R%KB/BP+:(-FSS_D]$7[9
M\R24YNAT?LK2F,A$=N+T)O(=^5U29%E45GW#[T W31.PDG9,$YB"T8CK(J_2
MI+GE_8)C3&M\W^6/9917]%68_)9-/00V=&!TQTK""84:T$ M$9K\4R #KF:S
M)+TOBQCCI.)W_R.U"T2_[$%J4#I[A'K4Q+:@8,/C356=(S(ZUT55FSPP<S>/
M>C;!OP2VMJ)GY]FT/1#K J-"\X2@,IQS JBO-,R4+%%)6L7%.6_.R%EEM*J"
M?MAG ["QTMB@:WY.A5XC[QHKHT.[N;FO? =Z?I6+QEVW:+3-(: ]AW."YXIS
MWGE=L8IS;VD$)I R2 K@ R963_PW@(O']>A3FA?$G+VVA>B[@RWBK<94] .^
M>OU,YH[6I"+N..&7-S$L5@MH>ES)ED@^GMEA,]22)'/<'6KV5.E-T*@#;P:S
M&&XX#FDW#D4W#J?!..3##H5R''PNGXOU8;RV+E8&9V-0X?C[0_'R0X)3;@?(
M#TS]F>*3?_SY0UX3CCZ?Z?'CW?[#\905KQBK5-K8VH.RFKF5$G2REH@W93%,
M;6._JN7&=<\NUK'K0P,L@-%BVP(5L]W%:^IY9AG?M-'__8+_>D[+YAWX8W%[
M>]VJ$ONSQHUT)^/)O9PAGW16+)! K-$.M52:7=9CP>YF6DJ\E7^/=&UA2RYL
MV0K+W%=4<V';U8:W@G)BY^)7=&Y!P6OC] +.*U3&JM;279VK-,=5A:O+F'-K
M\(1-G3RZND;>]<M1WQRU[6%<U)G\8[I$T9C-2,.]3\=R&C]CSW$:/#YO$-J#
M(9R\/]-=*W%?TR)I\M=1OJJ4O1LSW1[8T_!Y<^ @F;2C[XXTB='BO1'OOFN2
M5NZ02 +HQF"!A+TV-8D$4RXL+;'>]V2W=;P![!6=*TJEZP-7B,)<XK6F@?/%
M^;UQO\.S( -SA6<CW\0-7@_<)GOL30?<D*[PYDAJT$G5+7H(>CD#NH:;/6O<
MSMZ%FFY$+I.$V8 H,]UC.%'PM/=TDTI[EW>GOLLC2UU' ^H*9!4)J69U&H3Y
MVT^P2Y$92!2WDE PM-E%0L+1M^O\!9_($#[3!*B7>?(%U]2/EUV,*>_9FHQO
M!]I>/K4/+?1GM^D-!;53#>A&SY=36K5C?@)"A QEE9X!5*4#[8C2^:MT$\I$
M$WW]5+S@,F<F)[NLJK2JZ?#J%F>+CK[69!L9M#%<M!<2NZ&^'\#J.T>6ZZAZ
M1F4;8<>#TLKB)4WH2ESB+,5[M#_G((<W;B ;K+M^$6:UW"Y"&IN8@XBTJ.L'
M=29[FQ[3&B=])<WB>(KRU]O;Z[NR^1LMUM=<N-[>?XKRZ$",$']X<5?^A,F?
MHJQIT]W,MD?7AL5X\R][7+^W'T6Y#C6C*A:7Y=]$[\A7OT-%B=HFPI?)'^^_
MVZ'V\XA_GS9N.&@;BV$7+1<P+H/_H>U&Y\A(B)$7J68H?+H8GC1V[)5X4M?Y
ME][%\5CD@[.-7XI:N1TP-_=UB:WG5UK>6=/1J1S9LK'V #?2]ISW#OL+;<%>
MH<1<FDKURL;;#?,$6 8WR3Z08G5C[(R8)C0U'\["BG7>FH/#NY*=&SQE>%ZD
MR4Q:/JNWS9!466RJ.T2_*U%+*M30DY4%;X[8B;.1=H*''(:R".%2]350>%L7
M6H.?;:B-T&4<EV=66HF&D#[2E*W7Y[*D99;RA :7\G\8-C36%'S6#;>62JKX
MRWNBIBMZ5"6Q7<S_1%'(Y6(T494EJHHX)?N;BJ>X?T6G1JXZ^@9:A-P-=E)Y
M<C?,S3\F["*M^TQ?_4=U1X03G7P=#T[Q+AW8]/'U=T)"-T$3((JC+A&#N'Y)
M*P8P\.W1-#@+] <EJW/ ]>=B':]<MTO/8N4N_63>I;?;C';)K_X59ZI836]?
M]F0Q_(RB_9$>]9+NU =ZM_?2:=Z==)HGG!ET3"#*A?\]!<S0]N<0 X?SF;2&
MOCGTK+6B47UK*FMCF6%5-^M4-Q94E^R!LJ;!::BZQ^%1,VUY:%2W:2D<WJ2=
MZE+<0NV3[HBK<IEE14UG@A>MTR9=L^CC<2]DXES*I$?:7G2-FQ*$0'G:5N,?
M<I\S"9OQSF82,QXQWSX?$**7-0E4)WMXQ+N>:RG/7]-2#+0'R;.Z*>L^X3Z!
MF#'8)^ "#'7^9 9K4[<Z] 6&_U@2&S3MVI=;&"CW*X! T*JB1)R-TBCAYC-0
M]?Q4X;^>R9+UX87\SR/YX,1*H>WA,_Q4R[5<Z*!MB5A31-L&8&\GQET*L30/
M.BQ@)NVLH0\L:+1F2 .; *S/Y/A;0"<4:S.Y#].TAP.-=O\B 09VZS67[8"0
M;=YM&9'A]Q:6I0/DN2;IK?%/95&U=UKFRU=C1[]WKF89%%>M/ =BWV/7U@ZE
M6^"O[$4.^2>Z+G&2UNB6D-NAAB",1LP7LNQZ -^[6@!-<=UJ@3*?^M+"XV-1
MOB_.3_7^G,E,6JB/&QV?VN0HH95R^=2J/W Y<WR(:IP\6BG70IEOR:[HCR,A
M8RYD5E1 +S$70592Q#EX#4XOOQ191N;F:U2:,N#,H!6<?@XE7::CZ%=*C=8;
MI^2 /,+@Q Y/A17HGJ?&"F@'I\J+]3= I5T,V:T6T>8%;!V5]3IZJCHYQ8<T
MS^G=[%.4K?L65"7,ASS93!1"VR!'>(9CF;4(UD3\J4QK?+??FTZ#G2D%9S1$
M*9?ZXHQ6L=^'O,2;Y&5_NR "O &'6T+G/.V3H!F<&M+BXR_$YAHSA;B3"DX1
M!W(NU<2&V.L;V!8;Y>[_&+Y&RD"=Z3Y+*/6HDS<Y/4\NRM<OT==/9*;+-,IH
M:?"'\^F4F75PNJM'G;.08XRUK@M1G^@KZGJQY#QMOQUB)X@P*]P,H:@DQX$D
M5=,84J%L4396(%N(02C,QS1/JV><_%04B96:C#I *,>89X-*M$T1:QN&&DRQ
MW_%\H V" +P2)5J8*R$" 6XVVS:@;AI"@+GET0#BC4!;U%%F#5H=FTK>0# Z
MF&PM-@<S#8')7Z+LW!0ZK'#Y8N>;*#I!8%7%NQ:WJ&N-VN:@?KV3%!^^Q32>
MD7H>Q5-%/E5C5&XLA<-YHY,L5_Q$CE[VMX>-Q9XF22%? S]NG"<)IO.BDP'$
M^FC56FN)M#H]^UDFLVV/Q6=<O\?)F>57-L2T3/;P] S2S+5RO;EX+"Y(>]1W
M (I3F<M_75SDA/^DZP#U)M ",N);/E]XL7F#MQUN_.<#N2KR<X7M M!4[?WG
M^I XUF7V:!K"!Y)9<<T:C*H$!Y"X0XT/39H.-3AFKRH-U0>R]M+3O<L\:6O(
M7>$<[]-Z8HUQZ.]IQ7&12 ?KMC,BO;OJA:CM#[@<+1&./F/&><6==JH$3TT7
MJ.7)&7OB8@4#/)NE"PB 'M<UEB/H/GJUBPM5MO:XIJFY'8\\:X6:9L#KF1W'
M-SE9Q3#?Q=;/N*098&"/T VX&*]F!E#X3$1 QZW1N3;=0VKCJ4UU])F28$H&
MZ5T_ TMK:80NP*B?*4C6-P5-3F %)2E#@16.9GMWS>'#QZ+\4-4IO7-+:$Z$
M4U.SA::@?WQ.2Y;.Y)5H(YDFL[NWA* G_V^1S/)=/R-&(V911PZ)]'CM!T:1
MI4IZ19PFG(^XR0#0: [<#4 A#@ K25!3BA<G-@ G1A/*JUR.>='-# 3P-GXG
MW+PC<=Y1DR\2*KD0X;PNSW'-ZMPT8DPOZ,9>'E=S,_>*6>I;MQ<QP,OX$@G*
M5H)8+8'/!=T"1^/5W )$'A6AK<Q&#,* ,8,6Z+MX5 $#W]KB<]1,#1K#8'\N
MZ^4VK ]O[;9@_A@EH(\!IC ^UM I@'M4S_?X5.(X5:[H@H3#9A[5<,3?& +B
MGV&4;0&#/B&JFN<Q+%63[!&*-)3K:YIE_%[_)H]+'%7X/>;_-8!SJJ-'N$[*
M(-T9-AUV355+U/9![]I>4C)7/\!>((J%##ZQ;P>LL3;8H<JC?M"0QQIGM#+B
M#=F#Y8?T*<.7587KJLD6EOQHT!*[[AYUQ5(>5>AJC2]8/]1W1+QGFQ'.<T+H
M561"7*:TERGB,D4:F7PJD0OZQJKD CVO@1'\VYR]6Q5[?\+IX9EXK9<ON(P.
M^.<*[\_9;;HWOI)>1-9KF,4B^>5;PZ8FCEE#=Z@EBAJJB)-%E"Y<799MQF)O
MU&QA+*)F+,Y\++(MQL(RC&75D1#FEB6H?\51"5O9>@VUE\-BENN\3\MW+,HZ
M_1OS]%E.^ &G)MLVT=&G]9J20=))H0.-[)4L$Y"^+9(#?Z/1-+"I$*S )&F,
M%9+F1Y0)Y#_P,2(N?'9.J&)V\=&:^T7;SKYBR6QE,2*EZ8G:KN0'U'4&B"%;
M1:@&_F1E;80B*TRJ$\I;1)D3]@;A9/Z!9Q5+MOU<0=W3&19LA=2?\;?Z\2O.
M7O"G(J^?32OE4L+>-^(+QD"S1;]5;@!VS!+%S/\7J._0OQ'/$-WE0&[OZH/0
M2;D_U^>2>/P#8:D;C I96/];^J785V_VEP(_6!- 4?KX557_>2&]8!6^EWA%
M/2<$WX*>ZV6W4.]:EC%<]1[A>IE6CT =MC*3[YN.\V93#%NA&ZG75&E*\LTH
MM49^&[56R1FX8HL87T&U18 'K=P?"=Y6U6U.,&C5;F1>4;,IQ;>BV!KI+?1Z
MKY R;+46T;U<JT5HAZW4I.VZ2LT(AJW47.8UE9KT>3-*K9;>1JD54@:NU *Z
M5U!J =JS#]-9)1U-];?1WST=B8L<2:C@99; *KDI1TP\Y96&:]G$:*NL22U\
M3HZV@EHS/8 5TS0C)TV1>S4TS?.W.(NJ*MVG<7O;=2H3;8FSZ2[>GK 9^58D
MI!TT1W=[='/_Y3U0P;,5)8![0S8-G.$K,4^HL7L'MFSL"S;V_RDZGOYK#Z$
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M@-!8!2SPX_/XE^X3?\X37%X7.:^(1WS Z9AL8S>?Q[1F_J6C5[8M/M/V2.P
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M4)M"W82+^S[=;,^OK!65=?JO.,K,9;3&K7S5S)*XD\)X: M$FT#6PK)CD[8
M*W&EGN=!/2OU)&^<T:C?)7 +^@G7SP79^;_@JJ8;?/FW&-.S0$/JKF4D/65&
M6BBW?);<=MPUY\1 .<!@Y/*55VD-M(JYE]: ZL8*JF/!F'ALJI,G)9OD?1IN
M8!G(MN/=E[+8(4=4!SO8S'9V?HE.15E\,[HZHS:>')TQ9^.Y;?X.Z.-8<@CE
MWRBG5O1NE/.ZW&V^K1,[SUEHZ-MY%GDT^,^D60@^]"2W+;/@KK0T]TIO6IIX
M;RE"<?(AK],ZQ79Y;L?-O:<(E?C59]K$"6K;!I#M=E7&_:<(5>-$G2)4#1(
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M6IJD)L$;H88H.=$<44-UJ=-'&-LT3_16R(0(>:9""J!DEV(A&AT'3$\9']^
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MR_7]]<,ZUD=7UM2^[@582R.Q!$:)SJ2HHETA1DT,!#+"FELTL+L&;@!L73\
M0)_-"LGG4,UH^*PJ1_J\/N;)_J<?20<_C_0%Z@Z#<0\:F8>-55U8)GU&K%/T
MTX\K1/L-VI7X4T.X;L<$?S=/Y 7[TS@GF,&?WY%]Q$_Y*<K?_I5T\6_3N#)I
MEZ$Y,[G<HX>R[A;]*QO,?UN"0_.DBN"=FL84!KFUN>U@4L<&  */NQGU O$R
M.SPE*5/8/8ZSYY1F.+O9$B4FNR1J$GA7R\KM.MT*>S'D;T3?V\^X7#\591[%
MNEHNLWW1X][)?%KKXJK^$A(^M4+GCR'Q:W4=A_I[;)]<W,.L/KE"Y*/HC_JS
M0%N:_I18J242U;(7U!+Q3OX7Y);/S(;8W2F:V0H'AV=3\E5M&O.6=*^/_H\>
ML;Q&>[I+1HCN,>$[H;GYZ=\4\1TP3YX"1&C->_)\]9$()R#_)E_G_Q\)#+*3
MTS.+[._^ ]70AH3^^@<44UUA05=4U_E95[%$5[Y"6FB-]6+B]^,[;()J:/4O
MRH<L-,IOC0OI!1-Y":7NW-//YQ<:_VOT"01G@8GEKPP<U+N.64VF@DQF=;/W
MLB(P&>V<RP.3Q2[4#]+4\BEA],V3XQ.^MU!/)VK,DVMK/KE\1Z;3GE+,I?JK
MGG'-Z:!ZEK50C]1RM'<Y/D;)]OK;$:<%)NW9/3K^-XA03<_/0CV:B\:!@KF*
M*U2QQ0CYY5#>8OF.<<P@U-JA6LF85N)*?Y%4.TOUI\ZNP5M :.,7%NJ/;](M
MWB5I4N+;Y)7^LUT,UUO<:.!BH;[7K%UO,6;-R ?&2;^P.M25:%AU!Y$2!,">
MYPU5K8P9UF$R"0I6,W:SNR5_>WR)TI]^_+&JU/B9C%R6EF04"3?/1 1,#P^:
MJN%N;G'LMV"=WVA-V;DXX3.TZ#G]$"K)EQ#Y5%U\=87:7T/UYU:(E4P'J67M
M4W7MPO \(=@_%RAM:R6I>@K,ITUC<A:>:QI[6VA =Y=G1YR7;W<$.&7U7),E
MA_(4RFF^O] @3J=13^%;S0+YB3*Q:AX7 V9A@U)QW9;I *MTL-3XS6B^<T9N
M1MM=J$^DI]J5.-6YMZ_=1<F'%^H%I3KTM5](;RW4+J_Z^O*=GI5&&]&[-YK>
MB\-3V^:LVWM*PURHB_N,/=YG7ZP3XUKR=W]]>B>5E='>IY.2:XQ>S8_:%];?
MBS\2#&GF^^@+]SA758&[Q^B;\$=/3DCU\87Z):4N/;FJ^ON(,*!+Q#-<J;]P
MI:;X.2KQUJ<'L]9MHX0DC;,#1F7T[;TX-;VMSNGG](:Z4-=W/M+P=T J?'&A
M3JZM-4^>[:/\T/,=+!_UZA3.=]_7+1&)[<U[F-DSO(4Z+7KLT<M0QRZR^%HX
M:AA8J$O3ZM37,K/A0?S[BE^@FRN >_3^>-I%T_SNH/!Z^KTX/[,-S[IF-1KP
M0EUC/W.G3[^H_/I"G:):FYZO%[]C=VBOXTWKQO [](D&X_5P27B,-_258$+\
M0_6$\"YZ8WVD6_*;_(1%8HGK"X6QY:::<!^#:1WFVLEA-B]-*QX9><6ECSU"
MK4\-=H0:K1TKK=%9*JJT!NQ]@U%:RS&'PM7RTU"\?_^RT/4%BPK.JZ?V5?R9
M5Q>*;R]T;:'2I*>5!0^FA1V7]3MYGVBK5ZZ ][6CK+7..9</6M,,8O&P.;*:
M$^GS+8X*?)\\OY2;W9="_3C0-P,+7 P8=>II4F[X0(P1Q#CYL-E]^%+,]B;0
M:S8Y9T6?-;)G&H%S<S!V/%=$[M&(?4?>"S7FP9/+%7XJ;]*BS)F6/Y]HING-
M[C:+4M5LH*7PY+[U7/?O 3V5Z-Q\A3@!VNP0(_'O%=WXK]C-=F@O8]>7_[*
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M3Q/T<((UAJ2(:28/O+V,BI>/^^RK,4ARZ0368-2RJ8'74*_0F1[1#FAYG:_
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MU5!9\,!7*2VMBL6"65K] E95O_YVQ#'?S#\X5U67$0-659?*8E&!O*9CM8M
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M7+J;8750?Y9=2&37C_B7$?OTJJ[?!+@4\*7,1A/'6A-B?K!5IX@9VU.K-LK
M$U+/;[#2N&Y6:_7H[ZX/QWWVAO$#SE\)5W)W_)DFY*)%+)D8Q6-61GOQ[Y=9
M47[.RO_$K!3!<TJ/0WE@2B+5^_-1Z$\:'^B;$8]^T;N.G</3YN.U:Z1?([_E
M1]SG#ZZJW1%VQBU\%,9%@NMUVHL!/KTFC-EW/2F,S2\AFB0!<)*SQG:;S]-\
M8PFQHD0S<VP<-U^!WP^>24N"B$>IB(N(XE2&,EG0IK*2=W'(]1MSK* G7%T6
MWL7Q5D^O<&=;O]75Y^$=&8RJ*P7,>1L1_(:O40GG4YH*-HD F^P,FXSWUUP
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MZ(FE,Z0&'*5O=8;L0IGLQ878@S$XR=+%3T6(&DI4D389Z@N@U"_CQ+J]/ L
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M[=6#I(T^$'P=X 'LRG 8"%9#HHM@-1X\(M@&N#!XU8WZK-BT24BK8XXO^<-
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M19Z\JP!M3I!SFKF.]+6 N4XN,<',OR[![KK@'#77"<@,T [7.S+X$QICI[\
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M<-5PK$:"(C>P!]!.R:XWZ)I0T8*O"1*>($Q/[>*H4 <%NL:>P=OC57;22AL
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M*R'%SRR6\ZJ+1DIZT6DK2(GE4GK+<S\-YEOI[P,"O%56_/F _\R OQ6!GS7
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M$6N-:!^HZ83%U-4?A'X %POC15VCOS&!CE32LI&4GO57?Q"Z@7)%P] JNAY
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MC<-<L1KQD';+>&+\@QOE10K(KI),^8F(!K1;@LDQ;_6T?F(1/U]!V<D_7M(
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M8X;'=+R4,6J3K5HPQ+P]](JWZ[BNDUD0QA*F[CX\/*'AIA9_Q"P5@Q#S\HB
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MNNM7UYMS/R,0^R,>(N;&/NNF)YMX\U.>UD#S98D<6/I@\F>0ACP:LWBXJ@N
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M^778BRQC>7;+SVT6A>_2_M^:,]2'!;'W=]_29$R<7G2V$%Q]K?2'*1""AVB
MLFG-^I2G594,6618P9=6U->S14/NP^ UC,+\XT BE'M:P?#@G/C W;= [Y6P
MO>@$\AA\<!K<)JD*M8 E,E]&FWGK#8?8!;)OX;5$LM;=23:+EA!ZS-[##$
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M:'S8BU/2$B%ZTJM(_]NSLI7!^4 <R[5[%\L4N;462)1;% *:FRJ9K1H$DLF
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MQ0?Q0^OHG+I,FT6&(.>T!@&0+C2FGVG4ZK3.V.@OT^3]]S$+*YF 'TI1*(4
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M]H4%/$^:4\GT;-">HZ3=\2?J]")S/<(<("(<?M7DV+UZK2\4RK$UK;QS31D
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M:O=3;8.RJS+H>_V4EW7B;\,XS!D'O),*J)27%K/5Y'33[A,(C16H?2BHMB!
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MA+;W'@CMHXG^S*9E[2LBH[Q^_1.;)RDO/J%A?6-#AF?'1P1G9YNJ'Y\.J1M
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M4G,%T9F:P^V[Q0\HJ>M:-6>.7LSW".^4U >G .!S+-Q;$EPCW'LDZ57DI5,
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M?/6YKOD;S.30TKN #4YF]NE)HE4BT ;-+;L=US;^QS2YY5>/UF\@:8B:X4Q
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MP HXV\9/M /RQ_$EMA80(!AQ;F)#'K<1F JT78]B7;XA#]*<KA)>\AYF $<
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M$XY=\BGB@X RCB2+F'Z7*DP(M_VZ@K8ITPM-_"G(V7/.7;VUPAY,9::4_B1
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MF^]S%F=,7OX,&P)4(2\.8,QK.1B$Q7X5CET3YZ1"HE&B4CP$J.)4JISIYRP
M@U0%:%_9=9\L7E5O&DPXA?[.QE,VOOQ8#Q^LR"#3I0UG AHZ4//04" :843D
MQ-?B/[?A=][?<@58:S?8&06T<<K&,MP0$#P(KWTK_[-.F-M@Q PK$Z^&U/F(
M_AEC:D (JXU=6L0=7+NM;UI1RS_3S0 9(@?&7C-B.5CW/BSSI(+OW$]XF:1I
MPC.IKH(Y_"7_T/3"J*:I:>B?F=<,)"(HQGXXIS:,+T%>I#QW7:4(8(-J^OAG
M_^E 0EAN[,"CWAO6'%F:GKN2!L>?_5/QQ2 01OKFK[-5K[Z,H1\XE6"J^<TJ
M\"!\]LLSMTF8,OGO&98?C ?Q>C[$@?9^C4]14\YW!4\'("(:OGGTL&+>-Y,)
M&W'+MF7)<\$\-0U]/^*U42)E(O?D&!1F0V^9L[#]18]I&(_".?P0?)2%&98Z
M#)(A;31'30U_SO\6"!%^^^7@$]DT-]_G85KR#,0\3&3Q/)WA%<4\#/68@4/$
MP2\?X&.:C!@;9[= /PX_T\C 0,=4M#GRSPNH@0CAME_5OY_8O-K> * NM]$Q
M-6W\"_=I($*X[5<I<-%V]L1X<G083]LZ^_")JEQJ#\/ 36$BPN)7O7 1^&N6
MC=*P!&8H'6LCJX^**EO6LC@(<2'\WU/ZGM .N!B/PVH]7X)T&L8K\^4E>>)K
M8O'_W]ZW=36N*]W^E^\'[-W<X>6,$6CHS3DT80#=:WQ/#),HB?=*;+8O=+-_
M_9%L)7%BE2ZV[)),OZS5@&5KSEF6I:I2:5(L?*$-Q_HWX/NR_0GR-H4'R-R3
M;U!GN;>,XX1U6KJTUVI7)HMC%W!OMZR3H0*T],O_)QJ@KN+5*LP*_$3/Q6-P
M%[Y+RJD*H(V'<B5&P$;\<P3^1<+Y(B/3T3M)*$+MG!YIR_)=.O)GV#?&!9SJ
M@>G>6W?T*BX[_LCX!L9XX;5\$Y _?GP-)(!./;GEQ/5BZ=_21;R<\FR!T7R>
M% ?<;N<=F_4$- ,SND?)QJD_(W,+A(#>/?G=Q%5D*_FBSW$6+,=YEF9!-*4]
M9Z2PRN L?_2.G5.:0(H;WJ5D!*M@24/-&V,$5/?+__:P\3OQDVBC>1&;ECE;
M@28E,^<>^EJ5@ "I>W*^@0NMW>Y>+>C"D4R?XR>RI*WGWTA$/T[+T705,CZ*
MY&&^660<T27ENK%D16;G ;QRLU^?^"[@ V;DEUMN._=AG 1O(1TR67ZJ9,2
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MW8 RYGI8OY7QF;  ;(KS*U6U7/ ]![\YM$L2D5DHVQ(.M*"<8$=N.K4,*6S
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MXHC+K/#PR\&)<ME9NY;3@)R!HZFD!@I;I=#1Q3S\HB_F^EI. _*2LZF8=12
MF-ZX@NHSPSN-W7V25GQ.Z9<SUP@7D#3@C?.HGWSZ<^R422TMQ69@A!$P!V,_
M$_(^FT:[^11[U\Z_(._Q;&$#.M  Z?TJVD6!1OP#)U=Z?17'CYSRVD[:.A9
M2[^.@T0HP'9RA+W3LH4E-($*&(I?ISKVNAGWY!A[.Y7-N8 *)V ??A[;N+M3
MY#9Z)V4)2TW+$+?E7#FW1&AB$RJ$@#6XO7WBD2S99IT'EM3TG 11&DR*0?">
M6GS ALMR4T7O>RJ@?FELK% U+22_V!2;Z!-5BW*-M,?(05U]7L6O$H1IZ/LH
MCKY@CW\0\[LZ2;L_W.T3%!^2^T)*>%T;<<>'M'V"(G*H[EO);SUZ(^N[6]LG
MFG^?;-6?I:P@YT/HC7T&8-S:6&$LL87ZLY0'%TY<E\LDUE<&Z$_-1LJ#*T4N
MS-Y6 0JL71;"[^)5D"Z^AG2:'+[FK$??@REYCLN/1_H<%VX%NL($/I::K4OL
MV"F^,DWJWU)C:)8V632-P&BIFX[2T?;@C_%L R<+EA0,L^S2":FIM_;]2IJP
M\TG;64 #L):V:%BU"6"Q7%8BV()]"#X8HN>XDGX;DG0<79)%L%R#!^S$ZC,X
MG:[4[-6RG8X(Z+"<8I>NO*MXM0I+I^0HFI:1C3F))A3J'0E2<A6G&5:)%$G?
MC(JF&-WGY>SLBU].OI/C,^0)6 ."=;U]);BA>_LH2E=F8'O,:WG[RNX/U]M'
M\2&YT:6$J[U]9<>'Y.T[.3Y'=+R*^=7U]I5]'XJWK[G'@++FRHQ1.MKIH/#<
ML;?-8EM/]K2R^=87TV^YD^O&4ANQFA *2YX\U+2,)[I,R9Y)LM*1LWXQ)<(5
M5YZVG! *2ZX\5#EU5*S"=N74/FWQ]CIOZQB4/L\PE:Q]GO*WMV5!2+!D'BMV
MROUM-(N35?'0S[:L]NVHTV/LHV4:$*R_K(:/C1G0LOK$O22:DGF]9?7)L)-H
M*#[$S V0<(UE]0F<MN'ILOH$JVPOS*_VLOH$+M7[J9;5)^ZES8A&.QT4@UI6
M/P0?JIQX<8,7M"--=33265[O(AG"$OLQG"^R\>Q'2HKM'N-7.HF/V.$8U[\G
MBX#.SV[B9)>#]1: #UGZ>?.[%ODNQ\>N3'2T#<4*Y*Y6^0ZL&"^#)=MT\K0@
M)/O$J\9SSU:-)]AU:AL0K+UJ/(%+U@YIU>A,.MP>\YJK1CCE;1BK1JQ"E5+"
M=5:-<#5*7U>-AXB'B(CYU5\U'H+KC,^U:L0JVVPVVNF@&-2J<6]^K+UXW&M'
MO_#(6T!EBNFL(86 AK"4!%8W5WG":-46?+_AR]FY*WZ@AHJ+$0TAH@O@O(^C
M25/5MVTI36YF8Y@+OP_*5F380>W-%:>4N)FF8:YS"<727@S4XZ5W ?Y%V$>+
M3$?O]+=S\DC8)'7]1Y:M<J MN_I6E$0W,S^T[4$7HZU-%@Z- WO0F8N&'1G%
MZDSQ'4U-+45P*\JBHW[BAI8"8K1UNH<[GN'5*D@^QK,[0B?!VP'T>Y#EQ>D+
MG\HM7/C_-\77O7$-'R%'\QJ2K.\>/@*#?$-R#Q^[,LO>8U[3/7P,%Z%S3:1&
M[N%CQ--T0<)UW,/'X%385_<P5E0:YE??/0R'ES^7>_C(%?>A=+330>&Y>[B<
M^0$+Z76BS=><W-,)Y_,OLGPGW^D7?B'3O.DM^=S T57G$5C[I3W>(?B==5G@
M!P-9L!]^)TZCHTO0]F93@SD$E[41>/IDV:+(^%Z<2E>VBW9C,;M A^#J-H%_
M$^>R@P5,;\6)=#1OUH[%[.*TY3WWQF#"=UMC#+L5)]*5)(AN#&8'YR"\Z+KP
M1S/:38MFLW,_SJDKZ8+6;0< VYESW44#LF SG#E7%M+6S62+S]99VZBA7"GL
M']&4QYS(]/KWA%XZ6K&?FIH)=#^^Q\'13)Z&-J,&V_H0\(O2@"(R9U7^W(CQ
MMLGU*)EQ)>*@;09*.+8."7<E0+MW]LEGB<2>G9]BC-#LS+UJSU316'$#VGN_
M2CR<@WYO&4!+$5F;L[4TR2IJTY_VE::_>GE(XFD^R<;)$TG>PPD!XK30I2]G
M%\A?3YDHNS+*,5B*UF()R$R;8TK!6*[T>DH#TA=0+@PH(@3!4G@7=^&T;]67
M'_<L"XF,9]M?0TD5YC>AQ"%GN^J_QDW168HS.V06'*_RL!!)*TH-<H#15$8=
M8Q! M!27QCT0,E@%<Y+>4 [Y$,@.0:0#(9@WHMGR!?VL>*5^8MFU<#D83M;Z
MLE\5:_CDC171OP]6LJF9Z%(Z=B+[3,VF9C &!R.\6@(^DK<\F2SHVGPT3TAY
M+-(>2.E43;L]I0G)[RD7KBZR(234.*TP7>]?0?(:)])$O>HE= 1"G%0;LKTK
MEQ@*:B!4J$A1SR4DR7CV1 <:=@C-OTEQVLAXQ+\)4K5TFU/X2%-D*TJ:P1Q$
M]+* _+'U_JB.2Q1<3N<>3DV,=-9%,(Y!A!1K\)*$%;)B_U1.@Y5M*4_8:5"@
M>IIJBR%9BQG:&[>+E"S#P5K:A@Y=KHDG%J,^.FO@:AVT0YL%,PHD:Y?-WRDY
MR!EE9@N6O8YW%FSK12#PM=N[@F)%"N<(* <TJ?844 75\:.ERO<P"E?Y2JK+
MSC5TF$!Z?83$U[41]!90QWW?S/?@MUJ=ZC44+_9[HU"GWEM '<]2Z\,LG!=<
MLP2+/%7%3 274\J\\:2I<0"J>I;\O@=/'0,1-J",("<,PCKIZ5K% 2B+Z9RY
MI'TA:7H;*?>V[EQ&QQ_L-T["<WW^+NX_D%* ZD71_+K].TZN\C2+5_31DKE[
M_<(R^>P$.>7';"(O0P%HV'.I!3/YF#=P/-M!)8TS@-=S&I!>194T=2$U@ !Z
M=E^503@\_DB#>!1-Q^%<.CSN7\;A(,9\-)BNCY(P#$"5[DLR6'-*OJ;D/SDE
M[?J=[:*G#U1ZFX4M2DI.O<FITX8#*.Q/F8<Z0.6<$VS#:<%..%=IIBWU/BI
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MD@?+JR!)/NBO?@;+G*A/,]*_"64.V2]IQ2R4" ';\*S*Z"YHOAWN*<[GBZR
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MU>A^)\EKC&>P#^O./F7QY.^OX7LX)=&4'?I3;&@<3?^=IYDJ.JQ_$TX?<L)
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MB#V=ZTR@2K*I8DX+M* ,8F=N&DYKI4!:[]MT55SV3[HX4TYRE6TI3\CS(ZF
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MTP?P"X:ZI;QM;/H0R0D*LZP?FSZ$3\CL*5^@^T6V3G1:IWDY'F$?'M>++T:
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M7>,T__[O->4D(1<'TI=2UQ0@E+9V-Z--!UA<F%=<OR?JNE#"ZSD=KLWU0=&
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M_^+]%C?/7]&'@<7/#>KUZA7JGG!=NLIT]8XWFJZO]=EC3L[Z'_ #4$L#!!0
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MB3A"MN@DB&O(-+A@U1<F@7,"RL;6 H$BADE)>R3L73HA\H':RB0L;J<J5A]
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M7[0&M#\@-Y6+Y2RBAQB48KWTY!-9H %-,1@S5)6[0-R@!GUB[,%52+EK>YP
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MAOIP3ZBKJIL6&!?O!G01?NNU2OPM,F/<*D3*P&LR06(+2C&635MNB\P9E!/
M![A;#(Z3T:]EC,-P W<,R9M _A0L&(]6<:<,?H)WS;P05G,O]"!2*&R?K+^W
M94.J2=/9=NOG%6M<X\;US,G N-%M"\.SC;%GZ&'/M#Y:XZ',CW'LN)XS+KY.
M++=GC,UR/'5=TW;UN#^R^L;0*8:V>6<"^4$QX=C3F]ZT6#\P;-LH1Z8W<2R/
M#*8]PRHF\8"!,[G6$]<38_SI>CKQ],3(&0^E[C[!KW)V6N7<FMQ9)=^V,QX4
MW^HUVW$E 6,\-&VS8.C&&$RL@OD;T^XYTPE0N3%_M?J.W-*WO/MBA67<6.4
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M^OAF?$M, E,?B#'>LV\4?B*&UP9HB-^^7,-$&>#._IT:*4S</TPA!H"Y?23
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MFX 38*SHU#Z;W!$'[)+[E_#K\MM@"TTC2#B?32")P%41^$39Z,:*9S/?6.;
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MD66*L[CH0A*4 N,_W;_T'$LM?S[8K%&')RS)&5>><V>-X]S<\/TR<^Z"C,B
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M3M_?EIAQ!T-%Q<M?!^4R*"5SG>MOT"8;;FL]RXM)^^H)6=N6=BE[E7(G%@_
MMG=UJ@2@!&!. +8C5[ZNYL\^%,59VAW85AP*(+8[N8!88]@4X!KM[+8.<Q80
M$6V+NL-W>88^/[U93T/+M8FI@8GQ]$:-U]"GS.L518W)^"]GDU*KDZ"B;/:@
M$21Y*;""QFD\0MMM#Z&'80 56&!+(/1*?P%5;#89HC-(4 >,'F*L3DZ,'A88
MU\/MLJ/%@ON*+,-42H#6LZ92$>;846'A!4=>K3ST\DK\2?SE=98>Y2U6ET#K
MZCD_G6< *JC?TX57\#O=I+AXG<.ZI3O3SLW$]TW')=]GII(D81;,I.L:XZQ.
M=]%./"K,,;(PM"@;W5CQBSQN+'/@P/<8OAV4H)$8+"L&<ROG-+[ZHXC!H,9X
M?Z2OEO&JFP-!Y"NB\@4H"O_X+Q+\]0#_-%<CIS(S45%C:;BA#BB$^Q<Q[0##
M&>3HN7TI0YO"5ODE2]1GGX64"!72D%919TN)Y/>,^7DMC[ A.2.V;@="-/4+
M?^+2999F&09A47'ULV2P;=V%-3G7:!7 !'&J+IVI$/#E) LZ4BI7E,I2HK^&
MK G9\F1)CTI=#/H"#D 2()MY ))HN]HAW0J E.MR0];ETAP3EDU*B,U9/Q/^
M3=7M.60D3C\I(364$.G?7$!DM@[CK3J'I RM($.S[IU<1KIZ;_#$#< L[:GY
M[E8IG#43SER.4YZP.0LX*PQ@G3=Y2LVSO.8II:Q*AF[<'),+AEPP2K5@2!VP
M@@Y8_)"NR4%9!08KE5^K-.V0KA2RW#J.Q(N?+A8O+MTK95D/I8LRR*O.'\5^
M6FBN3^>YW<I_Y7HI85R.8W%QTVB[N"L46@?/>.W.<I=%+W/U3BF9NZ[[D1=_
M<0;)XB_?3"D0@-K!;FM_S5 [DU#+ [4S";7EH-;58#T' A#C@>C:M7E.QKI#
MC)J!: XO9Q*AHGRU5/W:5 U7 ZOQP6*\<I/C,+WO.GCP_63=629VP"S#@";^
M]JAAC%^)2M5$QB-U"%CSVB5A)DS);A;'TV=?34Y*"1Y_J8M\'D?DTP8%I#I>
M23M>4^.Q]SW*UO)GRV>EL8=B.&.2Z^7;\9KX)O>'<G^X>:C)_:'<'ZX3:G)_
MN-W]X=KX*O>'%=\?K@L9<G^XZ?WANC@I)7B;^\-"N=KN!&6:UZZYJWL(61;U
M/G>@)3DM;6$P2$&UG!,HS1D$(I>:_$N-1%4^5,EE;]EE3R)L(\5.KXC.?A##
MI6>3>/O2PV_>R-=4I53B,F?M@]'8L":4]N@K902HCV7D*:@(1MCDAO0M=F[9
M\2+EP"-K1 .U<F.IA%M!947BALOPSB8/OG8AFM<8>_?.D++S(6$#*@%6),"F
M"5M!%"U13BBX B.*)EQ)2GV/PH;ADZ!'UBTBZ\:-2"LH#6Z\>RDD<%8 3HR&
M%41.;EN>_S!U>4O]MXA3$Y?V=Z86.D$LO?)YP()=*9_H3-8DIK1&,3]9*VOD
MEEUNV:N)2^\J7;S!4=7'W/9_U =#!_5R<P XGPH2:3.0)FV8]3M8UL>_O(5-
MI:9HB*98VV8ZWYI42HR4A#5K5 (RKD/&=91=@>0NUB7C.FH7U[%U5,FXCIK'
M=6P=8=))))U$)33(95Q'7D[G!GQEXCJV[J"4<1TUB.O8OO-*:K#&:K!M6W52
M@]5!@VW;!N.3?1C".ZU1TN4>JW(A8]B*#D7*%\.6^WW)FB0!E*>X6\4%><UP
MEJ%U&PNMDX!>>)67^EGJYY*;&VN&L]3/4C^7$M!3H3I-.;*9FKCTAV=BZ5A&
M0<@HB*)0>KP^E,HHB,9&06P;53(*HNY1$%M&6"D1(EDCC>B:&=%KP]*)-**E
M$5UZMV[.<PII1-?1B-XVJN0Z6I]U=%U8ZK1D//"&XX%7Q<(ZBV#)],M5TR_+
MS%VY(%2P1%VDU+F4SJU+YQH+V<MUN&+K<.%8.'KN'$M-O4%-W3K:[1P7QS\0
MY!/)OTWR;W^W<U(8_R*6DKR>L$H6TH&\5G)#UTJN<AVH"^/D3,,!/W_O742(
M/Z+$=AG]3;>M@T[[^ O\ZO?B_Q1TB_VD]VD/":-V2K?>S/G/2_0[AG:9O>*/
M2_3Y!R4LI4_785_PIR5ZO 5R#S.ZY+\MT><%F63T"+\LT1_P]1E@\MQ#5D1Z
MUO17D)G@3WSHSAU11AR++0V2Z1[PVPMJ6B/=3.TY-T[BG7Q.3&(N&2YO'V[N
M_[B\3*$MW^%X/R]!8.JEPV7T[/^\1,]H;F?TBC\MT6-/:**,3KU?E^CWS+5U
MD]IIBH#[;;V?E^CYQB)F5K?\MR7Z_&$Y6=S"GY;HD7NJ]51%R-'E_3RG9_W]
M"Z,&WU[;0WVLO#!K]$A?[%\_7!'5>>X<[9^<M#OM#XIC>5_?/9^<'AVU/GS.
M^W!GE8>/5WGX)/WAS_QIVW*92FWQYY 2#9;/7SZ#=/_V"_RCV,[$ &O@!53J
MKJW_%_VBM/?W.B?C]Z_*B+"!;NXZUOB+TAH[P1=]RW&L$33<.SJFHZ]?^;-O
M%+T67Y2^96A?/_SV"U&&C+[\^N%OL*A_^.T)SUT5ZT4YQU44#.U?/A-O%$IT
M&+C"[A)#'YA?%-P84P9]Q5J\Z9HS_**<[!WJYE<EVMZ@+^$8F1@-<1TK^ X;
M>%]YG<Y]N<+G]D)&NC'YHOSC+]=ROCZ!;6,K=_1->;1&Q!1?>BT%!4\BQ,JD
M'O^.OU(WT<#";]Z1<I$1&=2!4>S:8Z+JYD"T4+P>W[]^U71[;) )V"X&Z(#$
MLU&N<*;,;[W4/!<=8]=67G2#:LJ;[@P59TB5[WN]/:5'59=Q25:(J2F7[^J0
MF .JX)V\NHVFI +_Z]&Q(RS,3F='02M.\; \]6\F:SDTZLW91SK0P:KF>B,N
M/4/=H?RM,!G3>F-DO#@'[ZR]?_RM?=3ZNK\/.];#T_W3CD_R%"Y,,R-"S_V\
M]$RA0*2'16<@AI^)%FRU._046CLWR_L6 ^7J?;>K6H;% &V#_L?6CH+_^Y1L
MXNFR-HXV_@L?R!?%M@Q=6Q$YB\PU%SLZE9UK80J^?9 D5"<+%'$L'<R"LNAU
M%<TP_;*I47]=U[HP>]PI=)A^\?>[ZZ?+"Z7WU'VZ["VNV&O)TB7XU[L\__YX
M_70--.S>72B7_WG^>_?NVZ5R?G][>]WK7=_?I2KJM5"UM8*"7Z_Q(H:V*&O^
M3< .-P>.9>XH%WOG>V"#'!Z<+D'/A%DK*,))P2U4@3Y/:7;:_Q$W=7V>Q)!X
MM)I>GGIXS7HYI-+V);K:9OB22@:V@Z9E<K>2KBHF0:<PQH=U1]34T%EQ06V5
MZ6,T(C\HGOOS$?=T#ZWV<XN?+;2?K/#,%VQ[_U$%;$2ES;><X3O2[,/-JO1R
M6NM; @ HF6Q^-'"E+<9XNKI_O%UURY7+6/H%'C;]E^S:5-W5WW>'N@88_B+^
M@]ZATX,3D,O>[B^?L?EO!S,V:DWB=4FLXI2=^^6WZ][38_<)K31N"-]>WCUM
M6G%NSFKSC S38B-B%,%3WI_N !G4M W&Q>6C)&8QQ'SZ_5*);C7.GY3[*Z5]
MNK^_-(6+-XH/JVH4%X[#3B>O*MZX_2*&5I@!*W(;?!^HZ6#AF)P&[-GU_0_0
MM]][RO7=^5X.^W7+!PC5</E_O'PG*NP)@ ]X!A1R1B&VTAM3E<<Y*KJI7#NV
M@M4IH?M/I=A45UY_1,5L96?[4G*:,L[__M]^X9F80'/#&!,-$S5__=#ZP/_V
M.N9_3S'RW3O2$U05WZ@N8\ [SI=5!,[C%/1CD+$-W_J?@I]B<_XJN-QNM?X#
M@8=S8BDT$[M)_K.6.,3</\ G?_GL:(G?7RF&@Q/#AZ9@3GI;OZ].1E\^%@'M
M*W8+_[*T>?K$3I!YFL!C,J"[?4;)3]AKV[H&WY-7BPO"[/D#NKY^C<AJ(.Z;
MVZ1?4(.\$0R.BBJE_)SSI6#N$R68Z_[)0;L)\SP]V&V=GK1.CE)FVVBP?^0!
MTKA68T5IAN7'T0OX:7N@V':@1LPH\#98%3&^'I@.,YHHP%-3(TP#GFHNQMP2
MHU3V;+O:=/83=D3)=>7<TJ@"&X<^6+*I#E8I/57@ZL?KQY[BW<K I+@41]AK
M+ZG $Y<[:R];3,1:#/_BGB%.<]6@A'%9&2*%W@-B>(<XF^320:4WZ0?'G38B
MG3*+*6>6:]!76"QVE)ZK@REPT&I)[\=RA+UPV9",=@#BS!DJYX3!WM\D2N?X
MN)7F*:T833^>MD\_%1]C>'!\L'MTW&JEG%=M,V!8A@IO=/'M:AJCMKVCZ'XY
M+^7_Z&-N6^WP,.$G:M#QT#)]4VM'"0I_*5W8>WE-8T['?_SMI-,^_FHK8!B;
MF'-O*)?O5'4Q"UNY?X$EB=IISL><XIG"IP8Y)8MU:&[@6&1* &L:)+24 /Z+
MFB:%1>MV#^0'J+WAHU.I'&?M-X<Z?9G27$RRJ#PL.M.M5XHUU7!5VI.<*0]G
MEMGL2&958P,E^11K7<AVC._RA'TV8V<F*;^MC1*&5NPH2VR7](SM4G> 4=PO
MH!U[E+V"82%W1')'5&Y)VVSTX[DUQEQEQ_J2*1@%1>.LG<R%QO;4*<)GFO*K
MQ_P<MM82IW-P4NHXG6W;!///R>IH%OR;V@:=*+];Q@@+I)334&XF:VX)^ZF<
MT9\P<4=RIDR<N2$.[#;%PO8/,H+-TK^)\Q/TH')S\R!95296M0]:2D\%.B@7
M3'^EDCEE8LXM-0U+>0 ]MZ.< \%A+VGJ1#D]:'4.2\BIG.$T:XZ[/#ILK>$P
M?;]SLGMPY+ML5HQ&*VX_6^=XMCI*]#\MTU0>]\!LH3;6O[BT_]HKH20WFT/0
M+2]F*ME2'K;LMX_:RJVN#JD!@B.,%?^LZ6266I;,VD)@*GN%#W&;I7/4[I20
M2^6P64X/UA$ >'BXOWM\B/7P9]HLRX8&ISI5Y7%&>8XSEI*:X[W#,AQ>K%?@
MNN,QL][U$69H:5Z:EFJ-1M14^9T6^#>T&%LV!<N:B+J[6&?5#DNL BKQF[';
M-W3U2XP771MP JL4L:$7HJ)!CGY\\@)3@H=T6V'1ZJ*V?Y6& K]H5#4(@]?2
MEQ>J8EC27G;H;I4YO,K8%UZ0IKC7IWA@*]A D=S !\X96*]&"C# :V$!%YA(
MK%?!=D>.0,N@[BZV%DP$@!!E"&C#IP!+8V).^($Q-(/>H&?\TM )0$P\_XV:
ME!%#N38!":[H^-N.,@:=:U,%+!WUI_<.P[#>L-N^]>Z5C?7_/3T^./@Z+X!
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MT5[G. ^SGZ++S,*SGW+1I_B&@][G,"\,%,[TW3;% DA77)S8P2J5ZD04IR,
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MV'W3?((:LRK0M?E]?.ISFAZYDT_M1,J+,!Z\H>&5M;/ZKC[5^6Z/QY/7,VW
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MD&@6:NXTV>^WCUX?'F/M7Q@,)\0!1-#R!CDZ)JAL!PV'!ZDG EZ"6"] $9)
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MX5D5^AEQ#YHKOGV^@V@PY<G#>3SP1"J5^X6#S!0%@+DN8;+36JUC/DUR+0;
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M/R>G3IZR<%(O$^I$] M*=36%BEO3A8TB 46^8*NB996OY!Z_J>\G@7. +^
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M8NC#Q:5.9JZ63+%&7>J\ZU[!5_J+,AI"VWM'\L._!ITGQ/@OLEN=?J[A5;6
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M%8[T9CYKM?C#?8!-E#HTIRQ\YUY8-[N/;DA\,'L5//Y!5;)Q.J:>D0ZT_GE
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M,,B!F258'J:[D!GJ/'5LU2#Y\)T^*_+7)W?2-U;J><UQ@%)G,5N/K 9--3O
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M1V@P2C_X(T\I]%C7;;PBW<2R/FK1.*XJS#&RP0_,KRP^8"=$;"#S^V)M_J7
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M&J!$D0JPB8?F^7(!I "K^T%Z;.)'Z2C,,G](@+0-GO-$A#PWK5X#S*Y_$R,
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MI>=9DHF>&J8E"7/\0; !M^R />IB6S'L\4SB?WT?M1AR4D/G"8\V=@#&%A(
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MOK][Y@#L-]BGN-4(TE=A@Y'!1AR1@>[]/Y^<_'84.7S6VB&K\7R+8]C6EO'
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M5N?:U)4G!9;2W]>N>&;F!E&*6;J&<?77ZZQQ#3;8NR;P?&5;H3H(,FUAM+Z
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M(D!%_';2)V,F9;$CBQU9[,B#MB-'S@&C4E 7'(0S0#^"I"TV8+$!BPUXT#:
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M:AO8':_8= P1$,><GFU*K0 D7LNU\OX<O'=2"-?^Y:0"/NX\CTO@H][;7_\
M)L\CWQ9'1.>3+"F6AQ:L$_6<9+Y3J%O2KPT$'?:T\BJT25^LI3R9#^*VWK5Y
M(0E0*;RF]PC=;'X9C+K9JI(L>L'X39OF&#,=5L-X$=S!/+0 E>X"*BE+Q!DT
MQ0@'^>\1S$0H11+$!6?&RS%A6,"A=)> *!O<)^>V>H'S&];6Q6)00G:(7_-"
M2Y[6[*#@9 %B59[%,RV3 I%4T)MQ:9#30PL17013A*48_.CL$Y-ML)_0YOD1
M K=^3N>)ATXFRTH@YY=5,#IE,)'L6\2KIQ@M&&YA57X'P*H!KZ:)*ADRJX!@
M;V[\ZM)>V[#:#H!]1>U@MB!B5A7W"E9=CF9;6;(R=2V< Q3=N<*:^2-=($A5
MZ6K_#W&C7;VC8W7%!'V,%9+V954A\3#LQ$'F[@/FGF Y6-ZQY!KS$PLI,5>[
M!T!H<$IZ$.XA?PD6FCPFG"MK]$!H5TV2[8X1<RN$%5PZDYC#+F;$'J>(RD;]
M-H:637[%L#PIN/EKTP@JES*--+L&C,'U(X-%4)6\+T/?Q93[XHQ=N;\U3.")
MD2? V"%;7KP1I+O'^%%F5TI\G-N*"==CQ[ 3M5__YTW9;H8#C._&:0?,?=;C
MS"(4*-K)-ZQT3OH=NIC&2(R@,%: J:0_YP@_)U=Z$$:AZ75C,R^#PO17#-F7
MR^+A"[?-&6+/W H9#A5FU!I:)LE>W>:TJ8O,:#7(/:B\)3[O!_)B$KQH8(E:
M7(7[N@K/W*;*6R6]L)%D<W-HAEJ<L<@:E-PT%9$M2.00%\/.KE/S='T[P4=X
MH@9;0U9/6,%H))M62>./>5E((B9D.C3C8DXR#_75ZN]*2Z<M;)85:1%7849E
M2_'U[CD_F8<V1%,?\=[X^J>U[(QOE/&G:;N.#_H1)@Q@G\55->9FU'/Z\*_W
MP/1IPJNI7V3^.GD)3@3@FF3?S++/%' ]R#=%[*9-ZNLF;PM9Q1SX<!!;=A07
MF6MC0;K]3=Y,Y)7/VN\(;QJ-ODQ&R?KO\UOP?$C)/4LR.=JI1*N97X[^/V:(
M75O(II1%M7_( &K6N5J@L$OZ?TG_O_?T_]G][@DF7=T,N[T<(HI=&1EP,72Q
M[XU$NR=$\K4 =6TU+/#G#R?MH:=:Y35_;F4#]$),<K0+-&:Q/8OM>1"VAUP*
M#1X#+3*\"5=KVEX]"W,?.?I]*44D9<.,E1)3%F/)IZN  2@T6^:#[<=>EOHG
M(Z\LY>O3=CZN4WH?#%2@)=*5N!-B<_A$W/?>M)J3RKO%7BWV:K%7#\1>74P;
M%:XKV[3@ACK' 2DRS3B-:FH!^+#8B,5&+#;BP=@(3;C$69:[DBL^^SF;3"J[
MN/:45"TEV?_,5?DMLC/T?\9/9M0K#*>27X#6)<K( H?2HAP2TNU:2UWPQP\:
M?_SY@C]>\,>_M0/SZXL'YOS)]B[Y<C^L<^@N)-^6KE.)'ISVLR/Z;>6?69"=
MJ)0L3W%JVSCX3NK>EP\X1B<L4L4?Y\Y=7-V':6*T+!O+YBB(;LX#3M DYTKZ
M@+JFSO"9RG*G&#[V;YE9$[YOQ-,AH%J/W5G _/>?V!=Q[-'M.04*: ]'&&;G
M%:Q;-ZM$6,T08)7;F: =%[+30$A_V@M;L=7]%Y#-?4$V<\2!XRA1V#;I_[CH
M;ORB)M/ZQG5IG_[PW]\]>_3X:YT\>J("]+'O$Y*#46J&GD^J-__"S58.$WOQ
M3%]+"@<8Z[\W+>V<O[B\ZO>K']I=7I?_4AII0[KD?J 0>G^?M_33)Y\]^2QC
M.$]WI$<'<JUM.J&IVU7-VIE\(Q197.$_1P<4\Q6=KE9_3N3>-[[M*M;9DHN3
M)7[;:T%V^[BU0Y_\@+?SU*BNOBG;IA8A!)") ^9%H2378RIY\#!B?>>JK8Q4
MP.$R%;OI_O@+!\I9)2-?8_0J;36+OXG1NHEX-=^!G?^9T:0]4PLWT0)Z5YMT
MTAPT9UOV9 YIO%(X%H0K2N@K I[)6HUH#>P%Z627#VU,2KV7>SBHOG7:S^6!
MVKZ5ZT[6:[<J!@,=BH </YVVCVR3=9--</])(U77,-X 7HAV[.P&.KLP@E,^
M=[J0X-5H_@M3:MLEFV_H]TT;(JU]<[OZYU!N7BHK/D]XWMM(R $2K<8@]27"
MQ=9P!D\)L-B#NUK]Y"IW PBZ<1RR^" ]';=3C%Y?:YI*U^S7?]1<$[;/30-J
MYGNUJ''"$K W=,WY+C492)6.8D"'PGX5&Q*,$'V->[2  B[/M&*@C\CX77_I
M#)K;R&AQF\ +DY:!$UOZ3_U M/FM)^\6H3![0WUR5A$[H6YL^\0/Z>:TQA11
M7%>J*=JV^5#H>6V0&?_UAK>N=N$>&O3<JGU*>A/[2&1P//GYR,9V57.+=BSL
M W1,Z<S0]FOE7^_0\GU[XTQ(XHT;.QJ3](0>6ST^.#@JN:C)&?,*1\K6J>*:
MI_$)*W&BVRQ/DQS5.,42(_6N3'X,$C43,%[FDBK*)F_:U,%:>(RO;Z()D"TS
M]^Q\"B)B=KT%J]IL:%_<O?R6  "2IIB.LHV8K<\;YQY\EJRH6Z!1"LNJ*H6T
MW_[$U>KZ_)^E+2A>-KNF*7!P2Y-54'>Y3^?NZZA5?82H_I\#:#ST\VXV2*JH
MTM'0>7AW:..BW]"YQ<>I?AM?DA*AD%S[=AWZRO6+IZL_?/9EMOJ3F:RG0;:2
M.\8I; FXJ-:IL$JXL;\%/T-+=[%[D5^(,Q=-1S&ON@*T-DU;6)^9_K2(5Q92
M!3VY\YPTG5F#7+PLQ5*Q7P6%% P,#(U7L;96S+CEGS8,>9?5(+"M7I61V-B=
MY]G&9D-S7Q=\*4.ZLK\C\A!B!/OH'O@V0V7M54>/;3,K P(#W/E-Q8UH<RI!
MOJ/OG)^.(VJC;30ZU'&7HMT@8BR8C+!O$?%-@_"1\HH[S[N]<_TB4/2+]O5W
MO]# VDKIQ5W="K+(K#^MY(J\113UZT%*-ASB O[HKU[/W&SF7G?<BL&9%@"J
MG!AKO[=>=PE-.)DYPE(I.K-8?7>+58^2H^A> \-*/_QX9UTX:ZL4HU/';T-[
MN 4I2:_W+Q%,?1?^CC'0?IEDVTP'4J'M22)B-4BK[#^&8A>ZX(*84R;*P10Z
MYRV"032^J\)2Q&DQ8ND(UF6.A*-JZMTC_"*XE\W05TWS4B(-J=MYA/W9//Q4
M)UB"QE&:10YZ'@)O5;D]R1</H\Y-;O!.7);[+G[?7J3T$%[1_C5%CW^YT['@
M5SXD*_KE%PM^Y;>'7UFDB^\G78Q#"?D0 (IWH"^ K]?H:5I5PLW&N<(CCH9>
M\U=<_<27GC9#R^;UZ1[^6NM3=^QUX1\>+?@)>,K5-$M7O4=Q^!_+Y;SN)9O@
M?PQMV162?I.;;EW!@F=2N]WTS!31>U:O9_9Q?'=?*Y3R+?^B._NPGUJ:BSSQ
MBDZE&R:#&PX=WR2BH<-16O&3' ><I&O7WZ+*F+(RC#&6=LQHA#+/WG&OKG36
MCV@:I9NBP[\T[;SAP,_JG\S[]'.)3FDV(;=%,N -DNQ.JMJ.(I7FY#Y:!IGI
M7E'=3?$CD;&MX+-$WT-*5/&MMVUI:H.<JG65AE@,;J*UXR6H9,X>^*[J]CF<
MK/M:F+46#QN-*4:[T3];)&)U.FH>6L4*:;-B<0OCV,8YN'O='U>?E)^*7R.A
M05O>*$./#@A^E?YHM6[1FLJ.W]K1>VP3]I5OZ)+Q-2]<".YG*YF,U:;*RP-3
MW+0L(\D9]&T)0DI0X!0#;,%M:' W2C56[B+?-A9<LPWL]V_F-R^^']F352Q^
M:?L_I82GM_G%KV,X@./0=D,N=49<Q&>$;(4\^_/3OX[E<767C3]>GVA%",RF
M2^N6N CVW!8&*U[6YJ+??S>QW-<GY<TO?7$IZ\AL<012\_:N0%1#H0A-4;.A
M3513./5?#1,KV=:=6AE=VI,1D B3PE^IJ"6GA)!;\&/)$W51/NY;$PJ\IDW,
MR:LU6%8]<9G^ "0_:@G$ .AFM9+Q^$HV\M'>U)^G<X&L572?A. J$CNE=_Q8
MM.9>R%$@:^W)$[\JI5R'G!V/+Q0E'9\JMOF3@84-M!'G>F1BB5E*EIR,T44]
M =7U9L/$53OD<0! T]]S !\O@VYZ;'")"BM<R,G"W(ZI1V8/3G[7OUV]N#IS
M\$B:9\8'XS<FIZFI;GCOP2HBG0JX1;HG<\V)J%B\F:6P)=)1N5K]A4SMC=H>
MY'JZ%,FAAD>I:W1[R'YT$$9&OI(SL/J@X;0/E@]EU!:G7#TGR*A[\.XG_3AV
MR,_,SW5V,(4'3!1K\]@2SJDPL['SEAJ5\K&[;.JBVQ+0P2 <^D;<:'&3O#,=
M)YK0'TY+";U1O'Q@YN&T@"8),"3O;<4;T:<S"WEN_N6%D6(VG7PC(<L-A88@
M/$I\ J'$!31Y[]BC-=E3&3E=V>D)?VZ!KO(=F#C/X'LL)+K?4,E<D2D9G*<D
MS#WXX9(%X;*&DG(*)]W%K*W4,O#&-^6N(6^OXT0IGZ;X&8^:5:%UPZ?L=A<7
M*ZQB*4O6:/>V0RO><Y3'C0BK01+,]29 3. 7&SFAFCXE%\#"Q'#(X,06NO.L
M6'<1^UY8.9:CUS<65U2-'T\"HL\S]^:!B<D-.L=@JPKIU?9POW3PC+7[3:)V
MWXW-_(FA/3]=DKGW)=C7">5_^8B^1EC_(2?.)L/HRQ6O@=N9XG0^"G TV6$!
M&K]3H*DAFLF4*V[HED'2RO?BCP]N0CLT+-> O#1\X9K>&<C0O X)C9NR'?3X
M=5P9IY]US<$%(\=_Z_;-+3O'9#3YJDS&NH/=$\_XG0T ,&?['.<&>=T\&-F*
M;E 6%?A2O0-=T#FN6%H!003HE>+'< (YH "UT@<')A2X8OI[ORD\9<W5ZODD
M/ GX1QW/$G@(_)O.@8/+.VX.5 ;6+9T[?"R3NT.^WK_&B/(P-8PRT)X#K[P]
MQN.&JM\$NLG$Q)!+B!&?F;:LD>O3=*+V,6I".@YKLABK78Y#4-B2!:$+ 5_]
ME4! !?JVR3&QXC4$:F,HC4A<OF] =)C .JMF!_[?#;P"Y;D/D H;L"Q>A1S]
M%#:!?EH"?%3AJY'K$0%PZ9:V-2R+80A;SVXLS,@Z^5?38R:\VFS14V+,&6US
M?GSTZF2J-9%:U[7+?%$VQO<KFE4*V:%2?:2[(6B&.Z-K5+R<&R?)G,(:4>-N
MTY[<3W+_,7_T!C;5V[,_W5C?DKET,3-E08?QJ9.'49IIGN?-0/[W@>L!R63S
M@-LL99)Y 6+GC=N--WY!Q>AT%$'@=W0.T-\W3G$WR9G#>ZH[B[Y<2M[OL>3]
MY5+ROESR3E:"M+/+8/ZVBN%O:ITB*U^0@6U:\0RDW=^??5%4+S1UG2*/O&Y/
M\%&?B_V$WY2-4$8!N_ZV':BF/G^:C=N'N&OLE_0.R?&+A$O4\1+<%#B@L3_C
MO:(^?RG)0T!-46H<#Z(J"<3X>C[UV"&BL\N4 V[RS4;P<,R*O\[[MS>PUJ]H
MN"P!4$W:X$+KJ/=A13Q">PHGKVX- >)A<$%%KE[V[/W.S22 <#6?NNH;V!%^
M. RUI+ \&V14)1-A%:0U:/ZCM$;LF<3L\,]1/'^5P[&UA#*>B)N0\TLN"EUI
MWW3,5^M[=-"PHTGYG$G(*<84OY+^^-9G+>K]L>?&&+&X3O"4:,_"Y2T!DT#)
M;,97&M%WO_$';]TC;;G2)T^0H8G>!@:N:FZ1?<LK/%E*;A]B^,*_<^$S<I,@
M/FJLM>@";;?2!%9;6,&8;+XG<EVN%L?2&T-508Q]:7X66@=-$B&)+;7&1=82
MX]A"N\+H_;B:K5IMWG T]*I;MQM !!]UX-&Q)B5A]=XF&^9[K_;F<W//RHZ\
MU\[,V#5%!J>N[ Q@S44I]80+1_NA\FP-'X85?Y?]MI/ZZ=M^\3C&B^W3I&OF
M385L&<PM]^5@I7IY 3EQ< GQXQRKV1PBHGYU"J0;T6LPTH;1I8ADYNJY'*ZV
MMJ)6,OY=>RG5&16 NH$EVP ZX8HA!5YX"^03<-86T$FD5RU$W4WZ1&"ZL*\Z
M+<<C>>+& D=F9/;<>[_)A:R(8KOVE"5SD?9K2A_O -=A:!7X/3VKTON78CF:
M6EC-$2C6'87O_*0E=Y]RGQL.AI&5LK2!/H0VE3"PQ=&,04 "$^4/'@F]^0Y<
M*IA[NGJ@0103%%@Y9#[H???E\1[[[$/,U+^GQ'+4^"[^)2-]X"V8#QE$2&QA
MO,^L[HQGQ6>=RWO?@O"/!F5Y[M9H;W*K+<F:3IO,OOS\]]GJRR]^SS_[XNO?
MSZZXONEYB4DYT/!?)W**P+N-),DSMW$8)(GA/W^<:>;YR6>/O^9+TW_\(8OZ
MM*I3?-Y*$5 A"NP9^,8J_]P< 22&55Y$R+@OJ13K@T=EN2T'.IR9"J;*O7(;
M+NI!!JQM;AF6 >]S=PK[$F--C[2E9:6_C".3X>@;%.0YX<8<C#&\-T$M74.)
M#MEDT-5@*1&(IT"/Q<IPT6=#VU1Y3:_SQ@^X/W_[UQ?_\U^//C=_E)[DQ=]^
MO/[IY_^S>OZ_N;:=4):2/==TL]A,X9-SDO:W!;)Z\OCQE]GJN5NW ]Q76B9?
M\6_"%SY[,EDI*DYYSR'1HVXRHG^YAK-/CALNP]^7K>&/&/*W6^'!$U&Y+%X^
M6J]>AVXD?JY?NQW!EI!02LO@J?RPRLCB*$@YY[.D$_UUD[VFY.9=$]-T6TZ.
M7U"2#,D2-1MB#7R/961CU-_)S-?Q,7#J%MGJR)@.3KQ8;>I%>,MQ3V'->1]I
M _5D&LS]BPYT#OCZTLN QO8*%3F3?6"CY3;[ND')9R-]9]AU2BSW<WQHX/J(
M=]M>4;;GLU8&;K+C0"@D((_('$WQ5)NLKJL9+YLJY.J7 -B16A==F8'1]U\?
MSV3E<9),%I^5(>/E%]VLLT[C&BC C%LG'\$%'P[AE["(-/T ZQRF\6K><Y<@
M+/1MKFFFR6#YEPQ1(E.&E+'*)A.?622!\Z3PKQ-C=\*^D>-B8QW=,)S1:/N!
M7(415[W:9C+JD^0CIP\!8)OD'T?;?1% 6UA,%Q;3]\YB2ON87"(D8(1T0NGA
MO(J]\CJXHI.LB4\HP-$7_AJ+S2UWO<AY+-9AL0X/PCJH)V&@FQG7;.J%2UO<
MU,T2U#0\I0H8G;H&2&&Q%(NE6"S%0[ 4$A<,9;>_4#/08GHC75#"L211:-,N
M?L-B#19K\#"L <\Y'?A;Z^?UR7^4[RK , 9)25#PT9^$*%^1T65;/&)F*->E
MI86:Z3.1&)^_2%5N&*Q@5B:ZT&):%M.RF)8'85H*=Z!@@FN/&?*@VKFH]'>
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M<!SWIP[TQ'6*][Z"</NH(6_4%9)'?<)SS#3R &R2NZ4Q9(FJEJCJO4=53,E
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M+QO^H6QXI9R5,D1/2]E)0[?VDDN96HI9$(OD)@.T?VZ;JFRZ\S_C8*N;IOF
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M8$D?3$&GY$EH)8RMWMF1=W9JO292P_Z#U$;X1G@6#M3@)K]A"Y%4'6?8HA%
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MH^T]5_-]</=QJUK329M-S"P1 ?"O5M?G+IE%QCF*9Z3#0#DG<>6AYC>FV\3
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M)6MZH U9VK3$AKEHNAF273[<=\RA74?T?%(,0Z&V"L5OKN6_6?77UUL*LZM
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M[L2',<^/VO194C@)PZWYG>\GDTAOUNZT<YO1SC.%"UTPWH.UY0]?IB&#R6F
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M(V[G\"M,47&S2PQE;?"7YGW.C,);E,>%*VRD[H+J.<.U8FJ<3EF@AC5M/T$
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M+J9B,16+J7@0IL(2--I98O3)(F$ 89\V: J>E.QO5M@.!39F9QH$XTX^"/V
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M[B)YANCA;7M:;YH^)!U3H-DY22M].H<L*XLE 0?H()R3H1G?CR):Y%0DSW;
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MO,U7[7S5?O"K=H#_26KS9[*H%4$/]V_'*K.>HW7SP9\/_CTZ^"D"%6,YKTL
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M1#<M)D3"SI;)NNF7!W(1R 1:\8"$7@\LN.Z!J^.J$I?U&(7BW3%Q\P:\CU!
M8@CP:GOE6>(2$(6&^Z!D%1#ACR-S, Q@N@E;7-XL[.1*'LZ&N#((=<%SIP>
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MSE]Q1D%>!G?),)L.&I?U1DG<;U9P^6H;@B51-7?" N<X,U:*^X[;?B=MHF)
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M@7 D0U$%WR%SAL$&;AHN7=-*S5@#ZL(%'$0HN70WA3S1%!8[#P5Y^#WNY6$
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M+'2G\S;<)P@<G1T/*%/K,>9;7,E-'K @>;/M>-KIO%P\I]<G+12G4D]"BR4
MR%.9HVQZ"&?S$:-4A*Y*J"9V1>$GJ%]Y*,P]&=,93UPUBL41KY$=DV95SWND
M 7>I5.'PVJB(8$ 6EY"I"$UWP>ES7,-R=*[8&9 :E$R'-[UD,8[N4[! 4QHF
M!]MA-$PRW$&+1W;:0"K[#CHLYISNF9PNO-V21."MZS:UA^D;%V;'DJUI5:GL
M=!05-Y:3C+-QR";AK0'>06V9,1L(?Y^ HA?F=#F"SX5CN40Y&OQ!RS3PVY<
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M**\DD,(*[7SPNCD[1?,7YO GA(CYT35J&B"4=6=.[@$J,QFVA3%&;&.D*=_
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M)Y1&$;XHOFZAP93H1!0WAW"-%3 NUBX;WWEF;]UL"S[/] [\F?4*G:[F4/@
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M>5#Z6OZ8+[?_MO^4]" GO-RUO:(5K18D(@5S!T:[M-_CXX](3V8/'CP0\&_
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MZ^H*=[W@OWST\(O/L[]\^1E_E3N2/Z8)G?KNY<,OOA"%2NM1<;^6_0SG4U=
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MT;DG0\""<]$IBN EB3U*UHI0_ 6=<1? 4$L;<#52[A"@?A:6[B)3SBRZX*1
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M22=41$D7<S.]Z9@GP+]S3"W#H]+I8=G'%BX;7656!]?D;NVV?63KX*17J6)
MF,I6@,L*XY(C6?@*.$ J(JRFLB+\51=EL)"#8[VWWUPH1A4E@A"!2B%**_:1
M&%O::U#YG93+MB<3 Z=X?P[@'U/3.U& 4(#MR1W+PUI-!5(QT9L"^:H-/L"
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M)\N!(,)> HYHS]1%?Z-V;26^<"OY+$>"T-2\T&XK<]8U&"GDZE;QH7#=87J
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M:K:FIB2=$P80.0[TN,2_AH.B4W#/E@US=BNJ\.9CCE3?<#LQJ';?/,8WX?"
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MVO?C7.V[1]6^FR=C^<J2$Z&AC2*F*V.!T#JJ]$.8&XN2G6@E">"*Q]N%@_2
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M;QY*(O-T; MIEJ!>"2R4*RIE*WHO8A'C3TNVT5=> E0497\?:L-D?MRT4TS
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M\QEVU3/LU*ZNQU MQQY/E59*<9L2N0/,D/ BTVZEDM'/=@5>(K];?JD/-FA
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M5R?]2VZ]G#LL9S3!C";XXF@";:I\VJ4VP( ,T6F 1.(:7.?"$<SN^ZY,88-
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MB_S"^E%B7*S%NC0$'OKG8#KRD+Q7==Y<)DW0_F7:(,OTKAD\7RO>H3>K\YI
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M/%'#(SJ[7D17.IBLT<"P%KCVJN$=_1I#2&>QZD<VR%JE$6''(XL8?8T!H]7
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M"N!&7F;)3'UP5O-.O_^KM2[ES/^AE^"P7R*OUS1:*%<3EOGGGRW?DWS:[S@
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MDK=<9PCZ.+8N\)+3NX"V8E,>2>0,TU:?S'&]->LG-@ B$TN;!VZ?)K1^U/5
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M>P.1?_OKW@>A43;3Y>@'!T*(;N#J(L,K")O=\C(DV)3OVM%$C"-N/$-Q.#/
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MS686*/,H+99)62*+*@ZZ_W-!G*)::&L^G 73BRPKJ%1Y&7U&%+FC($+X1>U
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M12]^*"XL !@/?CLXJ1,Q24]WF><0S[-EEMVRJD\+NM2D?,R+[&=KDJS:TPV
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ME/C:@S7/S=]KQ'5$Q^V3)XMDVWN$F-5E&BM^$\&!< ;,5IN29A%1U[P#%OB
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MESLH^F'"ZH38/!#VDL5?5@NL2J$A\5191:$\2:$IN0+N8%6/I#H\WW;X&31
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M7.5W6I\ 6@>RE5-(1NHUL-C#(7B[G=G=)3AY+/98[+'X[O(SN1O;<!:+;(W
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M?EY[XK=[Z$YW[<R=(1FJ##X&,Y&U.Q2^LGLMNZ[_)H_R= XB'4?Y)'W*=^B
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M7JIYJ;8G4DU:*RT1(,-!0K)<D7.5K8 !W&NGY0'N5A3=8S+2JK;H]Z@"#)
M,/P_BJ / U)#H!N:3!DJW\ID#P+.E>;V;[[D>;]+G@]]R?/JDF=?V+Q[0O/5
M2J'9+]VZN^:QR"*K@Z?5W[//FNKF67-+/IUK+3D/,WA_SGU4G!9Z5@K(/$IS
M37^(.C;(%A!?\$T^5\\KT#YLYS7H#?Q"_>VRW";&;3C3579,3:U2G,( +'"
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MASM;@CU;H#U;*P)J[4C?Z>B$8TG',  K\+0ZMI=6<A"[$-D+>R)Q;]^\OUH
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M*N'DB-N%ISE@#$B^(!XUS,WR:AD?5LI?2_H71["V39(<A$,2S] OV@3-&O6
M]G7S^J)8H(&H6>@ <7'4%;*_YHTHP-N7S7Z[&A -+?[5TBL.57D3]I':S18?
MJ7/1O.BL/M+6-!E0W*8>B5;D,<-U%9H72+\_L?[Z.VB9U,'WAIAIYGVF>_@*
M.Q9HRA2T7$$XFIC)W8\+_!?^ 7H(@ [TG@&\&!02G>@I26<:)*,WR.;E)29J
M"[[< J-"QENHX,QUK*')ZQF^E2"5>VSP5\M"!3]EF4#$CR_2JKX\B-3T5^^.
MT"E=D_Y]#X0(T^<UXB,0!=B4H/4H/#=Q])'T(V'P3);PM*-774KCD0=:XCV\
MQ1?+%784<0 H,<'BMKZ!&6P+ W7G])MTR@4=$CO*])MZHYBTN@B0*$W!# KQ
M1V.$OPJU5;Z%4:H.=9-JFO<^Y E:0PUI,8LT(W,;V 2@3YH/_I1*80ZZ7I+Y
M 9A,:(R5]+H\R^'GA6X)R$"Z:E06L2;SP;^7GI0G RQCO1>LJU_B.W%;M<5Y
M$M\&J*I,1 0(&1I:Z3P.T/'*FJN(D'^.ECDPG$M2$BLLQ=*D$Z^DK$J2J6=@
M]0J99BJ4-D4$V5#J>' KPD7CN93H#-.'Q#G<# :Z_4B@B]_9H\30$H&>$(5<
M8.3Y01(!2U+&H0?Z@4\$%(I[)$;D5X2K0;K$P=(<(#S/ NE8007&,D*!0:7Y
M;(9-CSA&,\<7-Z6GAR@P3MC-(WU 18 F41^I%5+@(,!_@(2!M0&Q-XB>X[PP
ME17G,A<Q5_#Q:'?3&#,BXCP<>3C:,\/?(^NC(\._4#=2[Y;GAZ5R0(HD7. K
M:LUP"<*F]S$"3IL$M_AKT*#0]M9P'L$[DEG LT0K8D6&W<]:1YJ'&<''#T/R
MMF9&' LO9A2,Z&;\+$L",.WQ0 N^#,SU2CPF4E*IX L<_X3038I[*M[9]'[W
M670L;8SB7?ARZP0(5%BX0"-V+0]\NG_>+>:8)32A@O9;&4_S_#'VN2]?Y>KC
M-[W?)+.'<^%E&TD"Y'>4CFX-KB)2R#C$*&%X)F'3-5Y#R><;ABR0Z#4C5_':
M'L-CUXN6$(-YBL37>E"C(J,<OWB1+.CQH@W?E-)]2SXGB66DEDA,:RB[P5!0
M4#_ I<F\D>$/?(9J[N!OT@>T%TQ^6>GI=_'70PUXM:]Z+OZZ.OY:J<T@-%UD
M=H>("OS*B"9])3.GX(YL#A(_3$@T#[B1@!^D.$P)>&65J<@Z"=F%OG+A#S"1
MFY44U+<$F),!VG,>CGD$H;D J"QP^11P9=ECM9P;0V&[@2_E)P4?\GG\U) Q
M>XK?QVGF??%OJ=9963YZL8+;+S_-AT3KK*Q] F8'0Q_-*5(/Z+3*]I1Z UM9
MO(2" N H=EKP(Y3QLQC-O@0N-T4=[3:6\GX*.F&:3R:"]E>1Y;,$MJ;W VP9
MM YIT18J6H*YBB@$Z8V5YC>8@P.!HI#!3N".<E LT')AA8UNEWI*@$P4BUA9
MCX"F21QJA16UOB(ZSJJ)YT\ JJ1EL<H2)(8MZOFC6[B[Q(C&ZONH4 -);P1M
MB\*MH->EI ."BBU26A3%Z" (T0L2C$O70;! 6SP)"#%'P9AL^XQE.6CS*:73
MT=W+#AD:-8 V@547IPB2D3KNRPW"I\O);WCO2INJ"!K6:5@8"937/RO,!, D
M_YM ^XC<*J:*!)=3M0ZPC)G_3:EUMJV %@AF?]P* SN;WDV8QJ2NP?F&>9JN
MD<BG#JBBI0%*LQ'[3@=L9HQB4412LR CPPB]N/$,D&A4[ @."S8AG&M5X*@2
MZ_'Q:7RG V/X:3HET_(VSHBQT!-WF+H(\%R*RAHT:KT!: 2M(>L8:*U$R,RC
M"+\:C1+D6542H=HE5>M&O O LD*OH\ E\!T9H.N+I:DE@IGZ)$LY1FZ$VIEM
M>J:<QTL"=(ND,T\['*6)R.9OGJ0Y2!^=B@($HBT5$4T4D^-] S9G=P(H<#FI
M-!J9C'I$4MAP7[95 ,-PU*(<&+&K9EFD>:_;S:4:-"GW1R($49$L5J8A**(\
MDS)[%N=PCCNBAZD/1#] XJ.:4I*R005WFOHCS314!"HHLB*4-2[W8YJ.YRSL
MZ;96GQ-DNY&!,1;$]%YW:P^OW,7RCI2]S[_^6"Q6#6HP?F<#N'.QO!%*BV(5
M '[F ]72^=!?$J6V1QX80@QV[R*5T,9M*_=/2LM35K)T*\>H'(D9*#J5Q\>
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MPE"7;WYN*M"!^*<HXI(*4"'U?6"0Z-O%GYD1,<Z;)Q'C#:<JH\MP(,D=O)1
MUDTF%221&=J]N@;V9M@9(7UE4IE7PS)2L-"/,6.E%,NR5T2-6L6FR&\PXA#T
MR/3]X3\-1R&)*/2QS3E8CJ'8!@>G0:NC)"',P1:@ +'GP SITF)A, -2E:'V
M2,IVBG138)N=/*#'X\%D=AF?#CW %-\K!>H:IN_"=@RQ"V;N!SJ3C=TKM?EP
M6BL)DC13:Z+%A[&^A^-\\!("I'Q+T[H=V!HL.Y/7LWR7]HT-%LJR5,>] X8%
MQ+3R3BN,[VN%*977?<C <Y'/0PTHM:\N7>3359XNH>-7,NC0APN;5&*LS+=0
M$3/88CW#8JLYE=G,V;2!?CP4CV249%.,X#5V+)'DKAN4G)9E_G#*SMBE&QV)
MH6R>_C>9L86D\WC- !2J>^^]Q!OBP_#F/XES8O'J EX* $3U[2W\FVRO7&?)
M82X9-W$ODE\&BR*/M6GM>[OCBKX:Z6\2,VHPHDBO"Z(USPN_^2L'HA@''"IF
MMV 6@ :[L$ZL<W=,+#63<6RQH\0<R3<E_C!TF"<3Y5/U1]9A2F^W= !MTY5I
M J6DC*,46?>VMG8F%Q[Z>#\9Y1#BQL\K%>]HI#TG9J83[0RKHG7>I<PMQ%^,
M+,G=H$UQ"AI5;(2+4IQH0^I"Y=OM=$(982JB4C['K5;MWU:^Q/U< C>*-=27
M4[ELQ_KR"4O'*C8T#'U^NO"W-#"I<Q2H@+G\G8P  BX&=ED&.OOT?HP<3V D
M02HU0O5;^!6;;4LP-'U,E.H!I('6'B?*5Z&BA8(<$J5PMY&0B[>&^%I>@U]P
M%$3]U=C98\*Q!N&;EU4*N)J_,J.N54%6M81$,;XYKA(O1UTK2UU.RO"M2$_6
M5ITE;I<E_XH:7V-;E\^V#RXW9!^\]!9XO>_>K1A-)W_47;]/'C*PSN6*M=HU
M:SUC0)[KAK>$Z5;)>#G)Z]UV.]XY.G=T[NA\QW2N<C.6*\B-0"N:'T:DL6@L
M BH7+!"AO#>#Q<M)&T$TRM,LX2X[TA4 GX."-$=]7#C6XEB+8RTGP5K,KFJF
M+:_XAY66J,(**JFH@@U5/*F8EFD>&U'(HJ.7Y9E$)882U,2M+]MFRT1WPRM
M'H\QU9<"B](K.?[D^)/C3Z?'G\P&9R.IC,A>+V9+BFKEAKA6!<>JT9 4UU*N
MPW69E-W&2_;TH(SDHBV8;(11-/>J=-':VV<GY\WR3Y9T0DJ"&YGI:=HC9Y_%
ML4G')AV;/ DVN60A8B540G4-I::0,@-XK'OYZKK] >6VRE9?''LRXE1FW5W!
ML#@9/)I4-<:W^)>J5S!25(N*5<J,N0,")-_^M.@#-%+5(Z3^!3,C06N(I:3I
M(@*5%%F<'F DZ]&JMTLQ0ZQ!5)6&-?&K=_1"QQT==W3<\02XH]0/42DJU""C
MK"++1X'DBQ:3-')5C =-A=&O5 @IE O:G9KQ794)4%,'M0TN<TH!2UUC9X)]
M*L*1JAKFEN.HZRM1.!.S@<P9J)<,%;:"$3M62W'J0_I [H;R5<QQ$@SAD30#
MM(]6FBZRXU7E'AHEBT=WS3-[ZZF ?6H:1 ^ORC4Q^AA6[D<</>[%]6\RC1,S
MLFZ3S$"$@<"T!]73@;40@X)DV^H@^BL/DL5+24L'9)]P;+XN,(_*5V"FBG/_
MA9$J9<H3?[B0?(R;FJDL&^RA5=EQO,(\CF4:<0YF,;6WA.N@IOJJ1I]HQ;K1
M10U567596F-EM1/9I)7=8K%5F8N$1:%S096AL$=,SQXO.%,$N;-YHJ*^BZ$@
M!P]H("Q5"99J6675-9U-M_RJVA+#G+-'=*46=_60Z8OF!O7V>?/4MR2N.2S2
M73YD!J+JGG573)EHQE,V])%UYQB5'T6CSPCP1C5O@X8IX&NL)"U>B5LRI#A9
M(1HN2CE2Q572Z622CL\M#L9B1(TZ0_\NM>P"K&I+\GDV7& Q7;$T:&F@T6-G
M.LD7J)80GJ34*RP_?-ATD>" MYAGP>/1>!*BA42@LE_N:ZJ.!6O\R9:#;5$T
M2H4WBK38/EIP>QQ=K;TPS"C59-E,C)6=>]3+!V#@N!3[ TZQOW(I]B[%_E#0
M4:J/EE@VFCD#2RS&T1G"UU!TB^16[2<IM62"BS341SN'H-  :Q5F76=/@L[L
MO%IP:RZ07I$:3&G_O-45RYP]CH^?Z^)N@QW'5E:#T>D,3_5@ZG+9.BA21XWZ
M*MZ.9/Y+3C);FM;),>,RGS*4Z-A58$L AVF\)(57I*\7'2&LL#.6N0K0 WW3
M55CNCD:=D 8<:\;\:MGSIVBQ)1._EQ[D%Z^17FT30?790)_ _O%19M#DG9\D
M/K5I]]3<R>6&M W5R_1+/I#-:=@86_KXXP,G$;JI@?Y&]@6DS4@P94DNI)F1
MH-.86E2%H:*0M&@=(O5LU7#8AH)L+.T#FDS\$-ND3W!$?<P&(0[RI0;"V1*-
M2C-(&JZH\J:I/9M3M;8S";!,Q*RAPR6(TK[&W$7?OB \GS[6! "?1/C*Y7T7
ME0>T(S+3*-$?VSL6)J_R$FF4,SSO=DFG!'H\D.7AJOLUJ?LCV$C1\P*6J&0W
ML;;R;7( TV@</.#=V#GO^<H[T<S4,D3->R*\-(,9Y7B$+0\+ Y::/V+YPH+-
MFCWW3&#:),]Q,=SCD]Z[/LZ_(Q^D(%[<9\E7,*A2-*PPIK#18FU+GY=]C]?A
M5?:8$5W H7T%",D06S;JF),!:?/J)%YEB[FH%7D5]515A3-%;_D'/7'<E<_8
M!B$*6],2662_!-(_LO@.*[[DR ]YMAP'+GREQC=+*VE[3W?JQ''"J*2EA5=&
MZAW,.^Q.H+K]I^YB,Q K6GO68[5AX19-\8OZRH;NY:B8.H!>3=<0\)9X!@=6
M[B*1!1GW U+#.F33=H$J*+FE\+;1CDVXR\S-<$@]@"8TU8+;L"KMDOOLWU+_
M?JOQJM'PTRI2*E]:$WO!,J6:;A[@M7ZB5<&<VPZ9-V1T48H3O-@W81Q3?R6-
MZB OYR'8\8)KFI2BG$H4Q**G#">,2(K<_S2+#3 $DQ-(YK ^/SCYPJB'*O7,
M[L.:^A4%-51V3X%Z)@U11K66ST6LP,1J4EL*4Z_$(:F)1*/HT;94;K=J^\9
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MZ_+08H;_3A&'Y_D  !8N@)/Z04AH%$1CO!0$D1WU2\1M(.X0(Q4TLP*:B''
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MNCJNY@*[JW/@@_@KF!8SD26+O93/NAMZX(9^CQ=^Z'V>@M$Y3]WE'-;E_"B
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MNND?8&5+R8O_4F3M)D<YC_P.>PVM\82[F!T7!6WSB:JQ-)W&5>MR;_-ZUL3
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MPQPN E;WTBE:KO 3M;-A/(-WPR7&PV_>&>G^V-.7F^Y&@&,BS;S7K6:[==[
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M(CZ._TAS;($P@IVI\R[MCYZ8X5WPO V ?3S Z2'PX&"A+TH!<<5)S97@R8+
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M,&=; 5)HFB3'0TXS(.%M<9ZEF<]$0@I<NI;]#Q_ZK ^^4?H@7#H<Z4PIC8@
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MG%:Q CK=YN71:!7.Z7%X/=M.W!-RV6BWG<Y2!YVKQD6OXZ!3 YV+YK43//7
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M[$T$\ -8!)Z*9T;J09LS#^!I,'LG4^]',12S@4CXVRY_W?/RQW!+2E))X1/
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MS"I=MQS'I$TE9$KKS6&2J&FPQ#0 '@)200L@0_KA0B7Q9\'4!HM<"9%C"4!
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MI'4JZR@,TDQB:1[)?Q3;;:"LN26U/_2'Y&Z1#-TP0<9D7* H8QM(X;O:F6T
MWOD&7T(=%[6"PC59I?Q+-Y",T7+0,QXWT*L%U\@ORZ;RJ#@AK<1F\#K_@JLC
M85]P # "\DP7JY9OA18"^SU35T-]D!!Y ^ QH)[2K^2V&Q7$"0H).K7DI;.D
M)E'$?$2XX.DA!T\O7?#4]=!;0L?/)5<\VIVU:A"+"1(YC'\EEH%\,Q7)+2GS
MH'1HV[K,B@H>V-!\<HI.J$DBF(EB>PM+B)FJ@3<6;!-A9[A["A2!$'O=9QH'
M (5DQL,OF$F];EO?$,>&%W"S#=TVK10BJMIW901)A"#!V$MJN4@4VU2-G_1V
M0$N-\?;4%LB^)8TIC"E.)W4OI>"@'V8T"M@W40VN1 2S 5REL$Z ]Z&4U"@E
MMDW9EI5W@C]4E]>0$S-U^U4AI3_P%7H-2W#T"\<YK!SR:>\ OB@EQ S,T-+]
M3< >!Z5-^9%!Y@Q \+!!#3HG'3O/'L:\IO<C-YTC;+V+Y?S/.9C<0N]WA'*[
M9JE*%U:%CC3U02^9^F14P4V0THSP7%:[V-L&0G@:S-.54K3XUZ^_OD>8%2^T
M^F4P*2WWX"#W(XKQ\C[Q])1V-00)'9,IB]HSW+J,67W!IS1MRKY]M)3L2TC+
MZ#FILN>:;S5*9&^'J<37H)&A\^&QOL1ANDB]3V(DXUS>%S'/J$N@UVFUKQO>
MGQ3A#05 VT_(*YRP24.?#^+X6Y+#:TACLF"H;Q7YEA?&$D9@>H.M@B= \4=X
M"E@?9/ANU:"07BU55 [3%:\A.&>$H?^5Z743O/&*OFZI]_'SOW#=#V*0Y AX
M[I)E$>U#J ;BB".'9.. AI7A0C)N2/X;\MJTOU.LP6R\5N[>1;'V>IO:()^-
M=R4#>GR#]"B%ID2M@C;+O!(5>I"TVK,KJ.N:W7?L6G5HL0/ Q))@X7@2D3^_
MY%"CV(%6P=%94!(6'5LD()#H&9M@K8MJE.FW:EU037K6TH0*&?OQ@9:(,HE3
M\U6",5586 ]B"CH2&%V5TX?YG6J#*(/ZAGF&'FQ-PLB"DYR9]UG!XBEGDSR-
ME#X:?2-**KQV7CP [85YW'E=L$(E2V!+HCO8_)#R*G@#,HVB^&PL&94T11KT
ME7:@DE%!1\W(O9^!LD-$ OM".8'Q>70SLE\?K9\@8F9F'UQZ*:J._W ;NZ?G
M<ZT9JGZXB']?X]GUE1:=?8MNOF:N\#[2M'^ZQY!M@5-11 UT53_<,2%\BH*&
MVM(R[RB.I"-FG.L.9*2=J)@+%*)#$K'L#4D4<_(XAYVT YX*6H%>X"7H:3,0
M3H4E1I0O9EOUV,B2/"'<.%6J0QD@?1[-448-6>QD"RGL*681W!KA(R/>2DVK
MYH4#P&@$]G&UUET Q&BA3!$*I:%IL/BW?A"2HEI04A'B8.4'!0H;$(J9,4<U
MYZ63!R0MZ3FE='%T:X+2DM//M%-%<C4,</H):C_D(;4=G38?0K9I=>RF_MP&
M7NC0224@= ]:JYN?ZN2*CGV$E(5S>'9ZHXE\R@2@>\(GBC;/YD/=5=OTL3DN
MZ-6H[\ME$M7$>8117X"O#%NB!O"&W=.F]@?(YM\W=,=?L@: JO-$*O6RCQO<
M.;;4O8L3TFKES\DGG0J;$H@ BI1+F2DI$RS7Z'W>5#F6-]B([P$#L5AF5_BI
MM?>-8:<2F"7N))$4MX*E\"MQ4MR#O)_'W,>N:AT3B[J\J(7'V#(V@0=42"#3
M_OM"$UB)85(MKD8RQG7JEB[0,XO1%D2-0M_>N+:))W\#+VM*T<.(JL]L8JPB
M-@96J55Y=6]_"<7U4!T/_Y-Y0>K":S'_ZYI3 A0+>?RK6#WEA"F) M2^&J,]
M&"2+HY"%C/R=;,XNZ:38TB#VDU%Y2(LT_G5:48/1_K^$1"B)I#M=91T;\:UU
M3_W4$U-S3_,X2PQ\R:9M>)\Q/2CTO?^(((++GS2JN!*[M%12QE+F60WD2(V/
M5(*'@@CQ)5&D!ZP/F^I#EGO_5YSQGY^59?%%J\F/NY*G(6*CA(D99=P#')2E
M:MM<VKC0M6%OC.*P(JEMPIE)0D8<XW( L>S$"F; 6,C#I.)* 1L3XA[ 44)5
M]JW)T0F4VRQ=:!3KE/'<5>XTI U,*BBM*S6_>8P.9KR=(JO<7!D @TF%NN7Z
M<OYUD4NG]$+KZ+1GA@QECBT*P8>B %.3Q208 G\?!BGY:1)/.E=I'^A>' A!
MGY-;3Z>Z5;RY##)T)E$\$A=@Z IT<"2/WE9:["M5<T(HSAP&W] $)J\5O88W
M%]1N2"7L&3N"=ZN$$T)0- _)!15BDW\V2D'(XY[@'\#ULGD<<=X)KB7?B)*/
MTPS,M%9YV[5ZN'59U3HH4K@+I1UB*.W*A=)<*.U0T!'C+6C0<>ZC%K+*3#)F
ML.C":ED\0Q(]F,F(DWJ :YV(@:<%:RM$D<&B+-%-42B2"D6C<2.HI6R;U0KU
M>WSY%WZYKL-#0R91.7KD["47B'J&5)[.N_=R_^82IK8-&J_YE4Y?E-F(1?:+
M911J"T(#%L!0'!I$01% 7#<5Z1 ]B[MM /&E*"S)UE0_EUV-+Z(41U,2,529
MXY\Z)]W+=M(M^>C<](%#:R&UYOB!UK&/'W!+NWD,5LOU=O^E]ES_7Y0F/]F^
MY8/LP;Y---L=N,^P')ES+-+S+<#9C158_O6'_^VT?W*3(([LRCKNRH[MRKKN
MRH[MRB[<E1W;E?6V=V6N]_PI])Z7<RL.HR?\ZRVT.[]H=X^]%?Q6P'+9<6!9
M!DNOTW-@J0!+WX&E BR7%Q?',L[%"<M-M"A0 1DYT*DFY<3-:'F(<*ZNCYV=
M; TTUT<OE[<WN:;E8%,+F\Z5@TT=;"XV"QMG^9Z",/]W%&*]"&5]"%$TQ]Z"
M5.^\#*G>:SL65 >:HW="; \T3G#5JLF;-2]/"33]S5H0FQMPID(#[>]*\FZM
M6H;.<D3A,>&(^Y7AB.?%'MQ4Q*6$J@LW%7%;4Q%+KI:&YV^^O#:*HS<_W]Q\
MEMA<I G/A)_FB6AP'C]E_NLF"%S!PH6F(LUD5NM2%;$_PW[V_Y69K^*^NDZO
MMM985N,9K1E)/\5_;@4,N+H$ ZPXD[5Z%4TE5$4L-13'SEM6*\TXXI;]LN\J
MMO7GHE!,4"XZDFR Y3K6LT_6TSEEUE-G&.Z=!Y5X(O?-JD^WU\/#,CF,API;
MZ3B2O:C66_X]]GE9V26#4_0K<O<W2M6NHNC1%47K]P[87X&1U2K.ZE%?5>>F
M#O! ;Z:&*GVKK)WA=O3CP/53<?U4:ONIN'*BPU& UBLGNKQ<74Y4-:?^"24N
M;NF36/I02TAVEOGZ8E-?7:723L'M*I5VC^*H"!YP0KZ[K-)E'7*-DKNLTF6Y
MZJ2CNS)7G71T5[;%ZB1W9=NYLDM74.;2ZEYT05F_M;>DG(.$Q_7^DI0.$A[M
M]OX0Y)#!TCGZFH^M@.7XDV:W I:KHTG9=UJ#JZP[G+S8L^<GFI_O31QO#2K[
MJQL[7)BTCU[P; \T1Z^J;(^2'&CJ0-,]&I7%N4-<E>'1DMG9\SG0"6HX9\_W
MPIP@5%S59:T7TT&FUB/C0%.G_&W6L_G]9FL%7-;NH6;M7O5<UNZ)+7VH.8^[
MR@%P0P!<:NU.P.U2:_>2YW+E4I..[<KZ[LJ.[<JNW94=V95U6^[*CNW*ME@F
MXH(4IQ"D./F<S4[KZ)UZ6P%+]^@;ZFX%++VC]XYO!2S]HP^G; ,LW98; O"2
MA*5+5=P0X5Q<'CL[V1IH>@XTM3-7CEXV;PTT;JI&?9'29I-=G=E["I+<Y>9M
MW$1P<JO63#AZXVE[BJ"K1*A5!(^^EG1[H-FL(KBY9#0W <"UX783 -P$ #<!
MP$T .%G6XR8 [(,'O< ) $8NY[.2^OL;RNFOPU>9VN$]T@_TQ#/MQD'2[O>]
MDL?"^C]C5];(!?3TE,\A9I;3BX4HL+CPSE^DQOU/D[(>C<S24S3:Q2T;"G&[
MUVUXZC_G[UZ]K2\,Z38[?7S:VFKS\JIBM_+C=V9ZC4?Y-;!1WYL"1?[]U?\
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M%TK;($11DS#K1%Z!FQ^](?8'0!^*$;I;61I+F"HQL.;5-VAC"89*PD6CB.D
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M\T'$:7HW=NW@,@R*VA>XCOCN);&9-7BYIA]J*88XH!XJJ@.,XH#&>M4!A1*
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M=O_50RO;X^R-$%NKX>'_SLL_4?$Y@T;E-U(O2>,0 &0.(]:!KTWUQGE8F?S
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M/]=+) *K.MCEOU A:=^0-T[<06N5:X_:'\",^.=,3-,^2^VEX.$A&4:5I">
MV78C]EB>!U$.FE(T.DU^6(FVN20)PN@]\5K/T,N63KW"HF/FB"00'*JL,57E
MP>4&G'__74Q5>:2I*D4.]ZRS\Y?/7KQX]O\]?_:'@S?MS7?G?"2FX&]_>YO\
M_/;7O[[]-7G]UU_?OOWY[2^_W:(;]SKNH[LM6O\M8+)@@N,-9RQK9M2RO5X
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MM-H_[ @\114GJCA1Q;F[ )PGP7>U.(^T+/'DQY-_&PZ7:&4<M95Q>_;%7 6
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MXXDR=P2.&WN Y@O?T=5'YZ>D96WMLN9V67'3XV5XJNA24#Q*E?%Y-R-+.'9
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MJL6Z6I9%)GV ZB;\[2!<F$Z-#MBS5'W927XD.EJ1KA$NQH@D7%\6V,&F\LG
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MBM&FH# D8&SAU& TIX6%3_D^2Y2>@!0M23/!*=2R:2;8YI #="D3;,*AHF\
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ML@L;,6R%_F5*%H&!VZ42>^)F'?BD]+%*6U#7TF7)2C!3&NKF$OZM+A3L>NM
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MN64LV5^1$2B2<.^V+GNNRIGI:9%+!PL,W+4 J%G7-U0!U&@!9]&T'3HWVM?
M??BU60:F[WI64L-[F%$:ZI2#[!<+R3O:+$4$C @8$? ($-#DY]O::TJT$F+1
M2E^I$NNR4?FK*$J)B4>UZ4[JM9V3?+6\UV.U;UK=]((6%YCHQ!'8F9X\7OK"
M J9 A9.65MMES4VD]7[V;8<$&DQ(*!:\=HE:O_?YA:>%?F';'90F?;>J&WBG
M'(=W]>GCIDTCDBS =22UU%FCA8_DBKP(JA.2$E)Z83P.,/M7PW-WAH7F6M0A
M^SHJP"-%<1'%11071R N+#:EZ!MNB)B9?12VBPS"5&Y1'[$#BTLO:AC_[GHT
MQQ+E>RE1/G\62Y1WER@'6P$;9U0=K^;AQ<O[E@X^N[<=,+OU;[_V^_Y+O6?7
M_%$=ZV2T-<>OV9&,KS"GL6QK]L;FI&K:Y%>%ZO8V8*P?!14Y+=*%'YW#ESA%
MW,]FZ. '5-5V9KL)GF!LX7BR)3\LSD@_QC:7Z  ^81Y ^@:4:ZSYX(!C7WFQ
M/,HHU65.[APNS^'94PB/ZD+<>ETA<3Y11*$E9?XR)LS(@]35/QP(J/>YSZ/R
M'97OJ'S?OO)-I=0%)E<($ )6)._\N@7_\W=[DS3&I=B<J  ()S79LQFF$E0T
MR0]SR?\G7,%Q45!S-&G+(+_EN;:Q?U=$J(A0QX%0\"=1.=?K!7R K'8+C&GE
MVA!;I[86RY!5!Q4OI/)E)7+Q+[>#*JVQ9G=PS;-'H&=KD?WR;^:!HY!_A0K=
M?+FW-XT(6Q&V(FP=!6SEB#D-$3.@T4IX10$Q[O'''54)Q[C;">,,#&,;HB8G
M5RMMPF**R12HR5/JT,D$EDZ3NAI@VXC!P6*6N2UI=_X=K6F]406;U=4<<FT#
MW$J&3<(HK,2/=,CO(^Y%W(NX=Q2X9Z@ 3JCCXV1*$D*637DJU57*_ '2 !$^
M$[B:R17EQDH:E3 L6K<CJ>3W&JY*"%*X1ZCK0\VOF,C#;/:]Z8@1).8/;F>,
M5?\70>-.T//@,FOZRL\]8@*R@;W"J'95-QVWH_)_:QOS25$FUNS3DW)?/QSW
M4I7$0>#U<<6IV9@YH3EG>W$&F3_I5ZZ#*F7]T@IZ07[7112=B$,-U7(J=R#"
MJ !4$;!K*U3"9J6N4:E[L\1T[Z2$[5)RTX1(CHN92!Y,Q3]R*\-<-NSC;7OT
M&$L?17P/55>[WIX[6PIX+3B+:E%CDY2RR'35:MO==)QO<LC U.#U<FKAN%&!
MM\+B5$$W[WP%R,FYC.5ZR1SB7UDI,EOR8KG4U*U7.!UPI38-;+!27_"^KORQ
MW)LE8RMY'8ZZK)$GC[*ZN9EJVZ_70:LV\=W  C^7>7N$H.3W3A/ODV*]89>X
M*7"9&_?:M2[T(EY,KAVF-A&V+/U@M/71<\5.6;=$&.7'$";OPXY_)E<O=!Z2
M9:!>B(0943>*NE'4C8Y"-S+9WDA)),G@S$DDZ>#E]I0:+[3400#%7I!+3OT0
M)-];FDU3NR^7+1YDQ@P;B ]S*"U@AZ[_D<L_9MM%#(H8="P8]/"S[;[\39R_
M/!PT) &(\G_&J4?W\XY^J9,/Q%S?647VM6<AOY<Z\#9X&?N6\WH)0]\>OH)W
MLR9O)V@%7%[/G":/-DNNVZPI%K;<DX#HV2L*^3Q_!6O]1EJH+I-?L>( 0TBT
M[G+%>WN7/1=^Z*F?:F-?$-WI_!7-XM;N^@X/+PAR5 7>HD!/S6V=1883,+8>
MF'?:SZQ**EV0G\!=7CE2AI3^<%!0-$:%0!*\T/#&S"/.0:)QX>IMLN[;#O2/
MGIHOX:_YZQWC&#[$1N-KQMZE>$G+"4[3_)0_)+N/0%0MHFH158O;C]2SS$*[
M P05=:C\6)'/!PZLKM#E15W,W(<%]ET(/L$P?4L>&/?9$NY?HBPT3=K0P\R]
MXBY4P_WLA/P3@,2V0$.LJ>J^RE@42#@+(+K%V-J.HE8+?4%(:W"19SWY#>>X
MHLL"FUHN8>HP<\;@ ::=PD#,GFZI7=!IC7ZWH=N8W8/[.%] V\+_IM0,SM,8
M[/ G(#]SO2S0:[K097UUFIRP):GS-%G55_H2'?9T\^#I[3,.^$:Q"1\G8G%>
MZ\1-4]O6=/#X*84;&[TT?+S\:M;JHQUO8EW8.T:3;ID2=9I0ENY*$5>W82A*
M$-YF;J5<_@9/A$KC3F:>Y!2G!=L?S7D,^V*F29"$,KLXEK9VTS?4AE">QBW^
MHH8];O:W$>+TX03Y*P9$<,XP1UW"PR[JOIN_^1VFR<7BF?LIGCF/Q3.QOU_4
M#Z-^^ #TPV7?5$6[$B7.Q>ZM&G>#*@?I"^/:%S]R+YJ$81Y ^3[5?_V4"^B7
M,-^<B.=;BO(YK<#/E9\C]Q]I/HNZ_MC2L]0-)V(YCH#0;3]!*"6T\P.U0=1O
M\?R3!D[_-IJW<'I9;=KHS45%&BNH4EIT1Z-C;],#%--KZ*5SRE8,<4:,CQA_
M%!BOJPMLJ5)4)JJ /(.4 09XTX=)61SVS(H-6O:29X65E7W;FEX7E;ZH"<CP
M;TNF=X -/V>>[[/TIXSXD;$WQ48S:=R)ZW0?FGXA?,Z;\"1&0M$V=*L^ !-\
MWCB.5G449U&<17%V?]%R$R*G3!S6URD"ES+*)=(,S!-UJ,KW"T"/TKAUF67K
M^B.AZ. )F[Q2S%Q=ZW7= +#V:_QT1-G;%K NJK$%N:G/;,#Q?<M([H"Z0/@J
M*I#%Y339VK3:'A.#(M1%J#L.J*/<0DD[-( TDP7T*IE1.#%;H$/X\!L,=ROI
MJB"ITEW#"? 5]E7D%GG3/"PV';I>X*4F=]SC>K%<+AZ7MN562:<3($;ZG=.,
MYS1^4I+%LMEEP.PS7E+)H:>U"UQ@!NZ-9>/HT*=T=AQ%>GJA^ESW32:?FLR*
M870*C8$54>?DV)IG 78&C #_1EJ:3L_8%:Y5YJ[.C3QZ7IAR!,J7M]4=""R@
M* ^W$+,1%]E$88CO^N/G"=-,QODH ]]:L1PFA-QFFMK-Y%6%@8#O_W1_.'!2
MG'J%""9(NC7V#I=P?;8Q=8#S-LDU6GA8%(.'ZJ*N<ZR[H.-#&]*T)74.43PD
MV*L;=W2I+ZCG5%^!L>8?%=S0.5BLM;&.YV<@&5&^EU-AR1"G=^V*IE_'&3H>
MD5/%[C*?;V+?8?V4VP$NS_QZ;ON)8SJ3-C;8(<:W[E/2AB[J77[_:T00M-2@
MC>YVPCNY 8C&,B=-A+7",T/;;?@++"K$EJY9CZ\8=@U":X49_5@+Z("2?EQA
ML9"E#_.<*+ CL1=:Q^T5!1TOM75T^%-4-+$P^K@J.DW'7*,R<=6HS?4//TSN
M*S<[V8*#!SAHB6T68%YS[AX^Z:I8%!@[6,-U2OHK'S3:_D;TM[(2K9>$*VOA
MWM?95!3]"T[H^?-9@^:]5818%F)'9BZ"@[WFFELS47)P7F]E6=B\E:</M9C1
M3CWP1%*:*'D*:8"[G;:Z5& RHSXY$1(\L?VNB8SZ'J:'>AL>H 7V4\!BQZ+N
M,?N9=3D[]\76SU0:/\GIV35>!>RB]0;W%&<\L6^>RRQQE\$'7[\$U;]OJ",Z
MSG6T<,72GX_$?O4MG=3Y=UOE?S9NE9:;'NW2TK&?N)@VY$,6V^3NT66W2QU?
MT4>M-Z-%][0.7@4TT7 9C.<A6:@6I!J^UC1XK^GHQ:9F#H WQH9R]>+&!S\;
M^QBT='+=0*5;L&%L"T<DN5LO3XTU8VX^)*7W7R)>.@X460<6CMC5=PC7]Z2X
MOSM0F%KM9S:<A*>B1J)]9\:)8<J%Z!T[(_/6Z_(P'0H91, ,_RH2*_#Q<B=U
M['6<GMTAJ?XQV_!^L@V?QVS#QY=M>!P4T^/M6$MTO6A]L5@6'S&>O#^JGK+I
M]P4Z4U6+RH1L$Y)T9J2KN#+8NP=XO.EV![0=<)X2-DLH/%"X',GT@4,APUB1
MK7A >!:ZCIZ%93=WBV%;MK-NX#!XSR8)EJI9IXX9';%_TJT(RP-+@837N<K8
M9-[8OC,TA'%+>D/YX@E]?*03NV=.I[0)O)-/SB'*!38KJR^86XW$#MS?Y";8
M8@R8EM6Z\"65^E(Q9\>0ZY&MW<,W"DV#W_^=*W&[=D::>&YGF_1 E_O3&ZIB
MK- 9?6Y_<D8ZH]OY*IP_%>H\S_>0EDD<"G4*NS6)>"/K?%BF?*PJWWL#.2&[
M#KNBQ/Q!ZAQ0]YKMK$DQ:^,]_SH J^L/?7H-\S]UI@W7BYJXP2B)UUY75-S1
M<.QA'$9,,+YB\3G3JN6N8U*82C0\[',F7B!:B$]%RY 65F*G0IJX-] SE:8V
MFW \BM@ WBC3C7S6Q"(/0$ :M#-.P[B[-4G,%FQYGASEHNI@N>=FM6TQB$IY
M"<AHU<#+R_ >*FEJ, R&D]S4';L])Z=['?^#[6;@[0=<)Z^>CCLGI(3,2CJT
M^2Y2-%VX:$X5EY8:&,E-ZMPP 5M[V[Q8ZNW+=>5<14CY%2GG37-7.XW(F&E^
MQ13GA'U2EMY8<I0"GB<6M-,+L,-3[IYWG):&,0GQL4G?"9^ABH,WV@_;[(U,
M+!!AAYW7PE"/Y^"G (]UP)X$TSO%Z&*?$=%GWC,/7CT]S/"'-@??:X\LE?N#
M+A]WCO*OL35U49<!O5@0R!Q%M6_7<U07U_ <20&LT0>&#'O5=H2:A[KGW08>
MQ-&#FU!C$MAB.<['[#<U"!#?@Z=MCITM<*@>O_OH=64X*J; VW!*K+6J6GG;
M2T1&9&'([(&PM)FAPNX$(/5$7C+;3"C'G"'!?!Z8:%'!%EFI<DGPO#?#>[ /
M?>P\)/5[]N>G'FN@F#PN!224@8'@\^G@QZ'BIZ*C3N\K;VW&6\M?.-P6VF2.
MTV(C=OB4CD/]RO0 <27<D1\D9AC&#,-[SS DK\$T);2"B5VHM?SE=0'&IA_R
M:<#NG ZZU#L*?9, /=V,XP!])I9O1,2)B',TB!-H88ZX6RQRST]36VJXBZ;N
M-T8M\34WT2'?2K^AY'76(8>/]: (^7T+*EX%/Z&<0W*W8Y4WD94W[:K8D'O4
M,<2?D':*KBSV-0,VTKOFEA]2%_))-UG1<O2HL1V/Z.\E.L3)5'&#GCIC#F'O
M^;,_L>NCL>XAS)<T6=J7-5VUJ:^XUN0@E"2Z\M&"?H;!&%B)1=OVNGWTRS/;
MI6X8/#A]%>5-E#=1WAR-O&E5&;2DH[-.KI*@RPD%$3:U:WHR@4%.2<:@!'?L
M\-*JQKU&R$2>]+Z=#HIAAKAK&%/\)B#C:X:IVJ-F(#S(L"N)^;> .17Q\-/L
MO-@/ DX^*T<PICM2S2+SZ9#!A./4U'2%DI+VO8A*8Y4+W*;7$OVA>'F]'N0S
MW]HR1]:V8\^C>A'SJ!Y?'E74::).<Z0Z#2;[ZL9%;HQVXY/8%$O7?0FDI(DU
MF^Y)MV%HHV)PUY;V]2W)SS6NHU48$30BZ)$@J!?)&-?"=]L-&S1!7+,PB1IK
M+_,6=1AU\2788DR0G79-&E@UC6>N[;9O;L:*Y' -BH'6!]2[;#[SZ*/N1L2.
M:LS'X7;+!H&)9)(K@Q)\%S4$I6S,I'2-BX$/YY'X =0 XU(.%(KTEC6*'5F:
MIS-M1T#W@/-ADFY]1035#QS<M4&=]XCL\49\,U8H#CNH@X=(C;]^:D3?V=W5
MV#%\""R4^SOE@QG<AAD,;$?=P;<V6U 8(Y:RLG73W@7K0U@)DJF-,2(7&A_6
M5U_KRLMF=P4!,"Z%.5+#C$%:HWE?I!HN%3^/E.A_)DN&FV5-FD,S6!63/H=<
M-YNFX-X8N2U3\%UG)&O,8J2\4C#_8DU5$U0/4ZQPX-H[<!1Q'S 9X+PN^E)A
MI]S4(Z#!&_-+5N1[W,/-R.<8)D\[< D:4>,77WLM95TS^Z"5[*%RCHL7O8VP
MH0P"^/EE 8!KC_KU&\3.!7<XB=(D%@XK(N;)<S"7-\/^5NZ>?I:X73'>Y8M"
MV-X.K$XZE#T#V3+;7HI<)M/Y#\U9>]*MV^;Z=3VE;FV'M1ZSS<-AP[J,RKU]
MDU/;LFP*8*MIA#5MS+SX"+,A=EJ;PC!N81:S!:/5'*WF>[>:4<5#78!K&O-&
M7:52NN/5\ORSAP5:,F73%.MJC@32IUPD"8]<H5X.ZB#H%Z'UDB8_,\A\H!;(
M!%K>!^]2HQ#6%6@H5'?)15>NB,<W&_B*$0I9]=?R%C:AA' #AN4OJ%I0*^AI
M..3,&])NE[IIN+A"]$^QB\RPS:B%)!A*MGW: $L/F:_[R6C&S'C+3@S4Y"BW
M!WF?#IJQ&WAFSF&^C5>AY1<O3S\W7CTW_I3ZA"-Q^BD\TB<J^^IH[?\,?Y,\
MZ=N8QA-%3Q0]1R%Z+%>W10;*U]'8A$"S.X%S_'9*G1V\V1$I(E)$I#@"I# J
MAT4!TW+6,G&@!]UZ?G.U-60*:E]0W2\LG/6^'N3_(;.;V ,9S3+V,@T+YG?1
MUJ#:ZS_%/.N U5]!*T*?VUIK4S09:IB#"\9!@];0\"(OP4(G@)W=ID9?/IKR
M^>]UW^ ?H=,*5,H)$@KE-+9$Z$W9,\IMRD,M?489GN)18^& &N3OTI_-DK7*
MRQV]UA/3FH;@PK"@YG6_Z-AB$,=RC00WB4L0Q1U3Z;YKR(\IGXIG#[V/LOSL
M1C3#6HJ'/7M-6?\DR;JEY84HZISKMKT A?(Y!D8;/W'4RA-._L]:L]A0)PK,
M*#"/0V 62\/I-1GJ2)T1CW5 ^Z7H7/?N=HQ,^0.4<$5WJ'2+*=_'G?+]=4SY
MCBG?CTU(?[]32$]+T]N(&C\.V3<754?[!%.(6\MEAO20RZ*QN47S7NQ0XNSQ
M9+NN3<N^0:$KC5!\D4C:OD>HXX5(QFF$F($SUO)3E&<U2-\+)<1B5A:;![O)
MIT(N4LPDL6*\SC+53E%*$]$4FS9CY6".*_6:PT^,;)DR*7QEV)(DYHQ*R=80
MM.6ZS9IBX=+57(XHIR@-PB7*!$L</^9DL"1:4$\0G*,%=912A,DP,?* Z9+=
MO O0LIVQA9$R>:5I+\JTNC5VX\NZ]'I]1M.YSJ&6A$<U#0(270$?AEU* SZX
M'>V2:+*$A134]1L'S38$FN!J.XRA+2)D1,B(D$>!D!UW)+%:E6E2THV:UM-%
M@#Q?X4\ 1LGY; C$B)V<$_(E[YE=[E[2R2YRYKJA='28N71DXCXTL;0O0DV$
MFF.!FIGLCZFFR7=9O?80\^_IW_:-77NE9\8K.MA\V41G!%*.T?TPEXY/R8W/
M7WTP]7'OIQI,W6VR_M],+VVGQG<<IH<;N(#$B!U=BK4D!=6X540U#MMN^.Z<
MSQC;"VX$&9W>7=#:X)Y@B0WB#ET\EL=WOLT7-2OHNU7=P#+:Y@Q>^>RHDJ98
M<B5255+SP<_H!*N"?(B#VV3;[MJV2Z/)6*Z\/JA3_;$'Y.</J+LI=MCQ.K!+
MLQ_RG<V^5>FU:-X:F5P'O#<8/FACZMNH7+Y9<"^$L VMYWB;K6CZ82J $O6C
MJ!]%_>B.3#%JD)$5F\*'L_NI_MW3\WU?LW>+Y+?28>6019*O)ENK'-8Q)3JY
M(K)&9#T^9#6-V&S->=!CS&JOTM07, S#S%AEVS>#M"HLE,LO2:5'_U>0)7L0
MD(\Z \_JBZ8*3&9US;Z3\T!.EH-M*<GAWO [4,V7-F-V4L-DJ!X'(*I*<E;)
MFT?H_>7M*",J1U2.J'P4J)SWC06G$;I*0CVAQ>XDV!#<=74!NVM( #/N>#\$
M_@:TXH9;J&)Z:4LTAU0ZS7'9&7N\K1WDS_L[BM:TD?O=*S\0+/?O/-:DJ?]F
M:QALQA<PAU#$Q(B)$1./ !/]YL&;H@F<@1Z(F7(CEP.G%D@?8)H3&_H&0A_+
MB&2XD/H-C# B8[!D#0/7]VZRAX#+84P'L-S%U33!^G!H/=D=N$#D54Q0EU$8
MVX@&:T9,LU4-Y0RZO@V73NZWH;<V 'I4Q/$]?O$#SBUZZX=X:^ 6/8N1H#AM
M)$[\O%?#5$RJ-]%NN>;B71BWLZLG_%W2LD8J$@.]?G>W\SDYZK%K&$F/R;=$
M.$%1 4S>HEQ:2[^!T46V]"8-/;3=V+B J8DH'CN;,!@Q<<:PO/!JZD >-((4
M"7)Y:7(BO$YNNS0%@!3,:JP4R3SE9D&"*XUL.WUK12=>(^>+>?RRKBXLU6*L
MD3GR&IEO8HW,[AJ98"N 9(1=P*L9JV<>H+X;JV>N<_S/SW_XYOMD<[8^H\'_
MIVX^)F_0/4@)#**RM1K]:Z& *4 HY<B06FYA%F597YFR&H[^$\]MP$Y+GV\Z
M*]=91+$6Z5K>B4^2I=9:%17IH11VN9;((S%W"OH?^P[8*4H/=5 9CFFK[BL)
ME"F]]:-+]!WK=G-VOT+Y/QU:'VD5)XN^(U9O4KO,>G(J"3V5>#>+RDW"XSN_
MJJ<<(Z=GR6^D*W5^'WLOA#7A;A9OL++:LRFNH>R6SX_T40=P+Y$!/V,UTCPL
MK\2DQ]V^BCG^6'IGXC!6S+@ -]3E,@UUV;FR'J:#N"SJ<F=J14PY>Y I9^]0
MJL)IQIWTEHKN[B_E[)[ _)TS58X_VXT2TR@P9MXZEUKZ]/0+#7+I-%%-@:Y1
M1IMKY%Y%SMK'I?I%5^=1ZJ@/V??'A-LP>HEK977;$2RE(<&3D-OO@+?/RGF:
M(8C:E>)TD#9L.\[$7*@(NQ%VGP;LEFA'4CGQ1$93P..TMN1ZOCHULJ_2P\#&
M5@^,4JPHO7]H%E*ELR'U, 'VG=:METPE.+QGVD0YM=PZ!X=J;:;1DIH7.:#&
MU*<.@#X"803""(1' 80WF'[$D(5Z7%-H[O-$29DC*_9SLY,PP$?4VM/%7)6X
M'I,KM66XK!>7Z,5M)7X,<[=4JCM!]! E-J8<11R,.'@T.#B7<K0'&/$'$P!B
M\L\/1<1;-^8Y7^.><GF\1!X.CLUF\HAHR4IB++I.-E<MZ._/;"+OZM WXFCN
M'JOOXS"71DI/@2OEF0G^^^0R!O-*KS0_)DSRHL ?\O/&-KN' \U-QRO'8(('
MLLY(UN92@QC<(XQ<WT/(\E8CEL>Z;UY7AKEQ],;'_9FI=P&NV)*HV@2I>*53
M.;3P=]%D_;KMN,&6;!GJ X"M:RYU66^X6Q@1$[ENY)WI?<A[D -089[$WJ[-
MKFGS%=(@2-^&CU5]1>Q+%5$H68S$1(!6:SXBV\]/F'5="W9.T!1HV>GLG,T,
M.+-R@%L=+:<JX_8;G*M!.'K-AYYKD'#8,YV&79:QZ87-2*T'+=HEIW6J4[O?
MIGWFL@.ZM=-4,C<59KDP!!\Q,ADMHF@1W;]%-),+16)YG (EV>Y%A5K!5D3&
MNJ^$O+CU2#69UBZEZP&%NJ!U$7_)O_>@4V3.W7F>8\;V_61L?QLSMF-7@R@"
MHPA\ "+0+ZN:2+QUE6"M;3ROFH\:>_X6;$9UC2);^K(N^[55SIVZG96J;9/7
M)"O1A84.&U_/]C^?:J= 6=(J$YOJ( ([["W4<M<DYMR OZ6#FM9Y*U(<UJEB
MJ4Z$E>U*DVM &K#A[P%,85TZNI<&<WY-D18Q"!HT.;$;$XA?-%1;1_3M?).@
M0BSQ#8O)R5Y"&J*&KT1M6(IB(:GO09T8?DYNK9+BU\)SOIPDTS1=D]@:";R?
M?47I # R,HGX_0&MRV/1ER6^5^SHW)Y&1MZ(\A'ECP7E$2V,A\Q0[9#]X;G'
M?/[16W26//7RB[MYX1^DR][/W&6OG2BFN/TRBG 7V9H$+%UF-OJRM'&"2H,)
MW&)\9S*(0R-P*Z' M5\W%ZHJ_J6D$"NO83M+?"\5<JI!5'%4'X[)</5Z@R2K
MJO6=DQML B)S<+%3D+5%VTGTU#70A3]^@D-^\Z2T'[[Z6MZ7=:U20]_?44[C
MU#]MW33^#']3E5I/6@6R:]%C8E&_=&K/Q3>.U%[B9_[P]HWM FF1PC29_/H;
MSA@D[X0L@_1>_D31.PK-EEOIO ( <IJ:U>],LQ6_*3-!$/Q3#ZM)!ITCX2Z7
M=:>O478RN*/5#OW[S?6I].YFW?;*8_<!52JO-]VDXSEU3F?O)Z35W0Y)L42$
M4]D8$@#?RA,LW4/ZP5%\A V&OE"Y:3HEO6-TU7K1-M8@X7.,H6U-.P<9SYZZ
M2JUQ'WW264_[J%XNP1B@U$R?#LZ>-ZJ\U.,05SOPDQ-7 S7YI#-EEO(L><L:
M,94&#2D6PM+,^6!;FNS H[[5?@[H K1]/"=UPZD"P@I-QZU@4V@)>E0CCU,T
M9@JX&F;:?!L;(@29B)V)'%^&O[E&H>R9E?1@<;B#\9JZYQW*Z;TF_9:\C([;
MRD,_6%EAVO8%N7=4#X'0E)>PU1WE062@HG*<9DE!-H[HFJ@9\Q6V";$8EJQM
M2'IPO>3M8(ZBDM[?\\]\-N4T.ZJ0Z,R6Y7)IVQ[7ZXZ[!U1-K'P&!D>6M-B-
M0Z$IW#$M[=O)S98FKI]5C'9%(S :@?=N!(9JFZ?H.MV;FN&U/3?V9%G5]@ '
MMF>=(TJDT0[10XW..DI=,,Z](,UAA$ KY?&@YX?F#HY9H/(@GU R"5-4C/TL
MG]#L(+6Y:+.R;H=VL6?[^G)[LO3.VA<P5JLIO8F'HWR'0.R+TJU\942MR86'
MTAOKM$_"!=F1-A$FGQ^29BG+<AK6!\T+X%@E$Z5#E Y'(1VD_F4&",F6E?H8
M5\>'C@-I> W0OUS&H$%$A(@(QX,(?C8IZ1YHT4_I<T,S<Z#9[;,R0<UJLY7.
M^Y+I2#%UE'Q\H*N@:XEH0,GMUP:NQ"^++3=Z@]FG%2IC)Y*H6E2FHP*,LMBR
M7GLZHE.%)6[Z=:@X8V"ES]C_8@MIN)! OD*GE10KSS@R8G7!-5F2)A7RM=H*
MY\7(X84\[B+&6I_]B'U8Z6=X5*Z[U7%GY>Q$-UY%CTENQL&XW_L=//^(]6E$
MUBQ.=>NFXT,]M34G#Z>M30I.*'KM:,O7"W(OL[L9YS;H.()-3C2]%+@U.K+L
MB2K0G42'\BQY)_5.S/@K21%7=/\OLB;7*M]5E#&]J<8Y)OO<QE)VS#8T/KQL
M+6M*>YYN?S-@ @ZOGUFST8X8M&^!%U37U7STZJG4C]A.H<85;E^DJ2)S[]/&
M,JR_<IQYI&W401)KYA7D]D -.87MGH!LN$"[WML F(3D[P^Y(1[-=<WN&#BQ
MNCK(DQKS>N\GK_>[F-?[^/)Z;P@-']QV#/A^2!U*;5\:U%8E!,P8Q_F.F(\A
MU+86F81VT<,FE/ 7++U'<:A0+OL^TCUJT0#HKF" ;4A9]%2$V(X@M2I!>]T3
MJ::N;92/@2[E<7!Z\"):RQ&MUJ:ZSG9N0S&*N6&YI4^1&Z5#M=I*TPGE<:5+
M[#^-U;TX/'F6TP/3;N8K+@^X^5GRCPVUU6:97$]WOTY.6/<U>YESA*E+BODE
M6(2X!4]'CRU&@VAZ9"6#B-[!M&6>8%C'/_<(*>=V:,D\HND4AID;U\UXZ"\N
ML+L4#%[UZP7W?G#V\NS= K/9C\A+_/W@>7HVA-%75PH3C+#OMQ""N5"%OX+#
M_ WSH*1F>:&1L3$Q#.]0+;=[>E]W#IIOPV4RI!1<V0<>&EW7GL?981#U=-,2
M?]47?:DZS%5Z+>MX/ZF)]_3\_[!$^.,<LIE.3.F@#9,O%>B,458DC2,L]UQ9
M(*E1]"UO4?PE2@]*]>-" E=%,) 2?IIO1T+G=)?4P71.KJ&G8=GK164(J9_E
MR5Z9O!Y=F@/<\I48_KR "T/7&E_*M>:V46@M1"IU*PE\"Q1C7=$N"_2T'21@
MQFF/8)]A&G0CF@@&S"O.9SHUV4D40UUC,4B8R\9]6F4R8L.?V-_,O1;T"-&U
M\,-3DV)J3HFRIV34G>CFGR]0$/&;LE@7G12IN/L3*_>=JV/6N'="W*;6#;M!
MA3VKK [A^]Z,BZK:3BVW+>6Y*GB/3K_R'URN:*NQ256.Q)==RG4V+?P!KP-T
M7%VA!XL4LE:#I(!ATO 6B!1URSEP\(7-)[UHE' 7W4HBJ9VGO$8[5R85XF4T
MA4JP+  175,8:I>&T[BE#KK@_$ND69(+6"$8_L9^2SY$VF*3CAJOG$ MET5)
M-'>6#@CAKEY3)53&7KN@DFV4%MJV5!(F#]A2^S-RU^-JP)]>.5;MB+ &\8:
M 94C!EY[E!GT%(9I6-\B[TDS9\K10&]+]Y(F$=:?%"Y35GB8*%''U)4)B92P
M7H#N")M4FRM%TY^N01ND@(Z+.,84%[A/B]N<4&@*C<I/3H93 @###BQ+JNAK
M\#S1,'X*JO$[N^D6],*M0]O,%5%59FNUTL^:YM3*7?\7II]-CMJ"(=&R=AO"
M*;R+RI\8<:2A&U+YY8B4K 5SOBPT-E9HK_G2SY)?!F8AG%(2V58< [PW*+;Q
M'\JD;$UK/ =E+'N'S[#)F#E7(4H,:Y,<:I!QQU!*VOV298 #5RR3!%/(L3+!
M!%#_P+].W/+YD'UJT X>O\D-'=LX:[O5^J/$B:R8I^F:9Y2%@U6K6H.-4XQQ
M<ZQ0Q^L*>0?V6-_@@E.H"[>H<&TYQ<1(^0QWB?(Z.>$+*70[WH>4N]P*7X?I
MR#RI<LUNW(+K;U6.J,+%0)<D!W\']8\Y"3.SDV P="B0,>\41"KWM=]0/ &/
MP"5Y2#BIOFBIP2.%G'/D:X+)@'B X^&QZ)GO3S&<59:ZNC"C>_OIH.V$IUR8
MR"YMA;%"GT"#OJ=27:6BM0X1[SJ%%#23EJ-< *A%:Y),J5'H>,V,RDW2[U)E
M^ 0HQ9?T7RS!;C U$P\79GCT3:6Y$#'7&3Q8BF_D_V?OS9_;-K*%T7\%Y3OY
MBJIJ*R2X*DZFRK&3&<^7V*G8<^][/[T"B::(& 0X6"3K_O6OS^ENH &"$L5-
M6$[55$8FP4;WZ;.OM^K2@K_2('M%J,*/+L:+E%0 ((7 O4 ]X(!D@2,;O4!Q
MDQ,871,1.W0K1/0^.)@%N_+F7H+J!:K;L:KZ1@THSM5( W,/)GQR,^QL)+=8
MJ.2+#P&6WR.\.^1G^+SMZ#=L.59T2N;U@#(38@\J=X"BW9U9UEEF#3*3V&0(
M#EY-YC.5.4ZYRU3H ]#'<X/=F#R9'8!3!LWD:\-(H'!H7>-/]F!&X5 *A]8%
M'4MI'[M')!E&A.8S,B,PX')H^H:C8LF4J;/ 3C/"T(!@&FK\MZ"*8/!4<#:,
MJN#C\S#\&BO%!VHD8QF3-:<3Z);;R&.%ZBN4RU7NY:L:;@Z^U3O'\Q&1/$/8
MH0&#?6GVR8+9 D?&D)WMXC\PI@P_A0I+D5;R% J^DP:?]+48/GTI7DTG_QOK
MOU4E=RZ#.Z2]O,_CJ:HE4I9/]433W2A,;V5N,G<BW^-9**^HX^A<P6PUH^GT
MCL79$U<F:18#R#CZ0SO=0;&_0PZ@;2KQ'BBPRY/+5#&M*_W3)S4!FNX!R-$?
MP6O6)FHM]8EK<5/9F@*[8; L/B09,=3VK<1Q>2P3%  WP//J",,T>T'!N\"L
M<"[DJN%C\SUG+KB_OF&9)@%,_\$8>[V-384Z^\R]A\64OE2D8S!NT1$)K_ +
M@:,GCZV'P+BI])NHDYGMR/ =" YM>"_EZC+I5IW8/'#AO ]=P<$/.R>EJP88
MCS&-,@+C+R3L7>Y[&- "3K$ C0"O)2M???^/=[_A@^]_^^W=VVJ%)9">1 ?.
MHA)"P"<<0J6FD;-0A2_XT)KK?(D"^C!C=IMV4V+[$WWR+=8K8##G*\=?[H&;
M>:3$WQN)NJLU_ &]"?%V.Z0!/.)Z4 7,DDX@2\L)=#L5/;\ZCE.9.Y7->N!F
MP#TO$-]LPBA) T\.WHHX1$7P5[(>($%'A&R"B2TB%^+/($P%F4KJ-MH_:8^B
M*A<',565VK1-.*: D,?5F6AP#F[4#VSO 'Z=[R$#@&+@>:$W>TXJNZI\^NC$
MKO,?*TI]KJT6=)&CX(-8DXSNRJ2"_2LFN)")D&/%I,25HM;P#^4RT^Q-%Z,#
M2-^E@V,@Q!4O4[]\B65C9?>][H8J,&3W3HZ,P N!C<,P&!2G.+C&57$V# +Y
M?L'#I:IYP,G%9=<C!(MNHQJGM[=RREPB&X%?;4?5$K.M)[5/H7)8*H=]\7+8
M)]SBSH,<!5;!4&+3&_.T%)#VC9J/A7J:+V/<AGL'PDM>F,:RJ8AJ4.+EGU=N
MPQ!8<97$4J5Q@OD7SOB]D2RMFL8)(Z"@JVXR)<6(KNY0BJEG"+%$8HE=8HF&
M_FPP("R\C3=@7H(6)6L;@&_H.881!@J=P/$?X@33:R&Y$F=/ H^$=$E,\EAX
M&SE8!<QA]8RPB05AR4P[5ZAO,B%IR7'X%S#"T/)#2"^("VJ@L;UC^2_L'EHJ
M"\40TPWE"TQFJQO/%UY+')@X,'%@XL#/"VO*R=_@-"BX1W(F4I&8N,.K4?0I
MR#PS9$I;*=48W=B>GD53PXG#$(=I#8>IUNVJ^4W9^?8LKL/V9SN[)D_3;(E+
M8,0O0OL,'SBW?N8!7T( ZG><<-BI'(5?P0:YY_Z=0%.QUJH\';B<5%F*]2I7
M-A;1X =F-:1."$"G=U;R@\86U[!_HEX'RC4PD\ +A%VE?J9&5A<4 ]V<IO!;
M>"2?@@!QWR"%+$VHK!(27N5$XS_O(=<ADG5QF!>M6OKG Q$2"+ G>HV%$Z^*
M/GNLCY*%)EECB;S?_3YOSA(H=.PC@Y(7%^O"L/T.=C3'0F\YWP#J("F/M*Z)
M>_;@AO)(*8^T+NAH\IH\6R9G.$:RR"-)]I)'>@767EQ()OMD_^+^$MK^R3AL
MXD5239IK =R3@_UT[4_VN9JEA/4P2]DN7'YEP=P7M-I\)]#=QUX;2\,Q%E Q
M*+Z_4MW@(UG:FD!5$"8F@2/*D5Q4]^_)^6JYQ%5" KUV97ZM!!5L/SOR_.%Q
M ;<OI$%EA"%%3IQ(8%?LP1.8XT1B(6'*IIAWI[=1KO_5HQD+K?3Q#*")W@;2
M%-:UO*@9*SBX*4;"=;J0OJ*+9U%5*R)6S*,[&,*RB 14$UVJI2Y%7T0.E<=J
M;+E@&)[,$<.H?>:C%>+W3C6PP7EQBT4$PAVSRO@=]TVX;.G]1KM'C<("-07\
M?E4JC*:1PM=;BA=H66@R1 N)PT;DWJA3R[2?>P<PR6R$(+V__)LG3Y)WI,C*
M_G5JH/BM[-:#2:P2:(]!U9R9@LD30/&^V*#[4*HVPW(XV?E J$UYTPO0)AWL
MM?-HA4]!0U,WKC0M01*I>%2 0VSGY#T'%N'KC8-Z:*QG5X&OZ-2O.?F"89J\
M#I>O-^'B*T\*!"OL1F^=KF.!YIZK^&W6@M3$1+-+E)%P@_SW09BA9^0M+<[-
M7.KR YG)E!,[$(<:7:0Z9Q;;<DG=K]!!QD4.M=5#5I7><ED8+.@*9)EL>)%P
MKIM(7:G".!P2)VXG]-,\1QC;9"A)%T&%*:2 2J>(('.OT+VET/A&)Z9G6\K:
M38SZ@][7*T0?9M!WWJ];G++(!,QC8G-=Q+([F3A?F*R<-4C&SQ]Y,S8AT%L4
MYFIFJQ8R]K2(,3DQ*#?P(<2P\"TR"@=K0HM>9&OYRE9/)42M9>JJ5$)P9)A*
M0],)U$8#&X.Q2SA4Y(&9*',E<:;8&T="45Q)EI9E@K&DQA4] )\YB ;KE^QN
MOFC%[\F&O88O 9NG;; 3@F,H5UK>2IJ79)-727SX\[-NKE$J;7@4C8J<9Q^D
MP.X&\NZJ=J3FMV'OE:S;6M;* BKGO7FJ^IMD-?N@*F"R2C%%7J(2SIC<J31*
MMX<CZ3J0M1>@'ZKO\3T8D8X OG=R'([<A(Z7HM=9:.2HP_C&D]EVX4E\:O#&
MZJEY/3+*BCF)L,AGZ?&46 $@=JYZP\&5)LUWH<M5,X!8%=O[H1 15Y55KH4K
M4N]"4A _ V^*3" /])@@<4URI" ^EV+S+3D#?.[X2#2]K38$:R_&^9$!-/"^
M*M\,0COOJ%\!=42\1U"+LKR?K U35=I?G&\OZDT]H F=!RX'5W)<<.O)LL9*
M92;O=Y6E'^>#Z&%VIZ*^ B_1M+8'J0V&@Z&@M2*=(;^16Y-]9O]]_?E:!1MD
MMW54NB%5XPXW(JY FS:LF)P=YUL4K,P8/?R,/0XGL^TMH@Q#/6#)(]7%3!5S
MJ/=)*,,W8GL)] '!.C#]XE_*F3C[WU]F%CW6MB-KP*=3%"%AQ_&]I9JTD+5B
M2W3"3][-(V\UJ#XSV@.JHZLOGNJ!I9IJ%"X%>8_:"V;]Z]*G'1"SOE0E8&(_
M#_U\:=B'N@'I*0&%L^KFRP;Q%SA%*GCJGT;:O$*$^/06S^!:X-5KNW=[=4Z[
M2KX%2$R/'A:P4G4 CZ:"@4C6#7FDC;1%$_,"35S0=#D%Z>SA45 -!Q%=_Q4*
M0\1Z[SSD6;B!:K&'OT=K[W\5ZJJ9?"99R.Y\I>G,JEF?%V1FAYEL9O9'A,$"
M'G3ZS<(L,*9@Q\3APKQS=4.&_7JVH><:PXRFFB4;+)LZ?=CEJ>H]Y8Q2U7A&
M)S. O0)G=@?03,5;@JD-A1SB4*KWL8"5[K-B]C[1%R$TX'0MNZRWWR;?:@>U
M!W&4NJ-N]\<S>KEEXDA61BF7\(,9$=4MFI#KRUZP3F9ZPWUJ-<!:<JCD\0'+
M8.:Y*?O16 #L <F04]EOO[W#$9Q8:)E&=]X=X  Z"+E1'2M]XWD7TEA:@U+P
M7&F1K^20-HD,.WZ9J#*HW69DN%BDT$F]HGTF%G<"^4=<UG\I:[!HO&;OT!]C
MT[SRA])?D+5?#4)->-@$LR(>71U2EB=4Q<0J?J*J82GX6M=HE]![*/CZ>/"U
M@ J>T&V"1$*3PK(71%0W7*0R@;[2YUG6SA6C-<=S25;,BFIK5>!1E^>6N=E:
M]4)6@P],9@[M&(5D$1:FV3KY6]8VJ*AZH:,,Y6#56<B7\G3;4)>O ZFF"7B^
ML=[KB=A:/,*]?E+:H_[L _060?]8Q[+8='3<B@7&0R2JG,I6J8%043)E9U-V
M=DVSLY]AGJ"5YBF.*1L/X9R"E1.M?56 EW?14&T1UJHW-_CF FDJR>D=BE)
MOD&( L,FBO=*D\4PV0US84<3;]5Y0\[CA<C.'+*]H1U%MJSJYRW-D7W6?#(K
M"_/+=QX#N[\_ZWVP;TA#O7=D4_)\YNRC6W%#]#!$,J:;'YCIUS/5O(=9V*"9
MH^ZQ]-QTH:UAW1C%,'P9>N$" =&5MY'=IBS$GXBK==A69EB>D66D,\ YDGPF
M%8(ERERO^LG](*0&<.4C$F3FRV.^<"7@N:N]BLH->V4&OM"'+0,/,FZ85$[N
MI'HEDH@D$5LC$0^5@6O'PT$!1J9=:5J "NR9T1](F,LLSU))AHZ(;/&[/.:8
MQ9_V%(AY"569!3Z4ZQSRT0;\VR+U-[H/E&QJKT-SQ3D*&618OGZ>5:9EMQKB
ME<GU+(2AA8\^XTYE02<3X_A13\@N3.4Q)I+O:O!I9BXL5 \3R%W0UU,5OS#G
M]54NJF<'5O7F-]MR27$GVW*:/?NO5+?&1 4"Q#[*J1!&4S ]2EU",0BS0842
MRW1[+F>-L4@AY$/7TZF=$=]PQ^?90"]!-H%N%R-#IVID#82(<A1&KU"LYBHD
MV@6!7@89BU.-27$G6XBE^S3@P)YE!=S1#1UI][$0N[?&P"+Y);C@Y8SK1S0>
M<QJ,,?^E>E>7K/0[64#F5SG,!/+D99CZ,-.[/#_HA!ROC+A9EK-;Y4()2RZ4
M_#U>YDS9P%C[!\RA=,QZ 8'+OJ.8@WSF:J\\B/?_QUEOWGRR_L#?*+5/0G/A
M.]X:=$=/^OP@TKK4^*JF<2"M/ ,I#8Y3U<[O%,SE2F4DJNACUN"U/*=>V22[
M#"J9+[F=-X\+0ZD<LF3,$3-8\(YR.%DC(1?,L6,/%FT$BL3OQ.HR80/#/Y73
M=Y^!M*4I?RA/,EX(G2"!@HQ,.#7=.D;A.A0J8];-5X%2I;QO(K[VTK7,X#;*
M3@"G%/=1V*RZKBYU?QK\V?9C:H:P:BV#;W: JN42F)KX2(/+31HM5E#@Z&CB
MR639+<8SL0EF1DCY_69]X/,QQEEG^>S]Q0OR/9[F<Q)5OT&CXV\^\$[()2Q6
M]7(]Q8-<#I6$4.AT"WD-LC.M[ G+LC,],7G$.7TF@>"LKQ6#1_10;$3P/5^G
M[HB+Q*M7T%987F0T6O/*REA#W>V[".>3H-EUELXE\YBVK-U<YY+.D3SO55K>
M6@O+FVF63J-?604-Q; QBR^/!KL"\U9:4]C"&+4-EHTQB&5F%'(N&"ZK6X@6
MYL)<*2TPS[O"H7;Y.+7B:7:PG.P]99TU5]WEJ#F9#:NU(:&00C^G13;\"H9Z
MZ::ALC'G(]/N=HP&RV(UH9R"EXT*VU:K8+ --B(WV&*P)8X$^B+>!9"<$BO'
M3H6<PO3P-2:.EA0V*5.->T'ZQ+SM+8 9N9@EVR<W)RJP:>><M-(BN_OVX\1(
M9.T[..,S,B[0!U3T:"I+)#=!="=A+(\W)%Q9>,K(H 2K$"F>+_'>0\,/1[9Z
M6J*C^Q,U$):/.Y;MR'2_>" /3&:1'E7%.&)I52C82KRCX-[.B)4<QB@3:[%6
M1YEH78K:[3,-@Q6T"J.1L4R>JO1*).4YX.5!7B#HLXI16821C1S=+F6J+LUB
MI:>VO:^4 50?7!,Z 64 4?N%NJ#C0G PL6#D%2HE=[C^"I-T7#Y/]"1DJ<!5
M_40[_'J@E4O5*5=(A 53,F >9\!FCX'<,PS9VVFDBT^PER?'BM)-IMQEM2@J
M0U+M7A:=HLHDX29=!QXX!W*P9&^%(^ ,@0B-^.SLF2*6/&Q*0)H_Z&*^JM>Q
M@H:(T&&RE;ZN-(QU?>9?TE^03RW+R^2EEN,%3-D5A6N)0V$I0I36U,.E*Q$!
MB[#TN?*J:'=&[GQ5:U];Y@1,!9R'0AD_NNBQ2,G++1=3G$G/#UA1L:SS?RJ+
MF<%^0#%)9!$_@)K29"@H2$'!%P\*ZEF*A3XBNF(CYP_YI'>SUW.5X_?1#%&I
M".?B"1AQ_EI9Q[9Q=/>![.US)_A:>/&:K\-(O,%AR/)PQHU16L*@^QEZ)6YY
ML'BPMNM.)"=2[6V,-V4Q2VD6H),=FUT7&L8J)R<X&O.\U'!)W:.)+1);; 5;
MW-&9([?;36ZDBZJR&,P.%3I7YH0VB456:G(4=!@0]LDJC#RC$-3(QE+>Z*]!
M>/_Z02B"KR7'XI'V3<O\O,1[+?0L+M0Y!Y? -AE58ZJ(4Q&G(D[5"DZ5#<O,
M^@F4ZI#?J2#QY[P@5*@UV<]R90PUF@<=G(?)&F;?&HC*@/VY8R:GM''UH%1,
M:M)MX&07M:4X3SX,]C$MD9@3,2=B3JU@3A53?34_,#(\'=TD)XM\*&8AFV=#
M*T#NWJK(%N)D@J7I.H4HSQ$4W]^FPBH+$L[C4KBWH(%1:COQ&>(SK>$S4O&1
M93^9$S_F 00DQ'L$DNA<Z[+B48[CJJ0(\504EWKT C]9<PY*3<R,H6ERHAJS
MHM!QXU5XK],83)^3*EH.L_BQ=%NI-AYZ?%LC<W?K'>K/#?AXY:B>1/+>=[7T
MHF %L7EB\[5D\UE>?I[GES7UK8S+DBE)M$^TWPK:#_AMF&!W.QS8X:$6E7O4
MS8)!,^NB4'WV&*,@>Y"8!3&+EC +.??CH9Q?]2@+ +[A8,T M-=U8B]6:6BJ
M/HV78GB%]##, )@WL_CRY294/ )0->I\QU7I=B=ID-5V;9MZ3HP=W#<)I%+'
M.Z8(8-VZK'J4$Q=D*_ZGS43=MA9'+LB&R-E1J!/9OEW=W[J2-AW?>@>W!_,-
MNE2P4-ERV_%C.61*0$@PH1Q$"PTBEC?_+;@KT"^EP9@7SV ;62A2JD[;@K"<
M+,0I_,;(^I49J;Z*Z!6:62]\)XZMMTBD8H$X"1=?,\\\^/RSWPBJC(K1O\)O
ML"KYHQ.[SG^,WY>;+.N?Y@5\OWQ30V_?BM.HCCF00N;R>!%Y<ZYG#ZD<BB]9
M90R6Q]EO?JLZU3NYL\^PLS?6^^P8L+'W.S=E_DKWW6&JPS[F8L@$$:FF5G3[
M'DRT.6L>"E:(A2374[;R]V45S^RI:2;;05@Y+"MP?75V[$*?1XTAF03ZT..$
MCS!/E8/A (+7[3V=K<,LSLCKEL3T3F:T&X7N'2S1 OK+RZ@+*0/5!8[(O50I
M0*'S2%08:H0>?U3[\OD*./$-.I=F,0'5*I29KY4%NUHAR-5%<OJ2+4>V7&[+
M)>69!_E4>O&/LXT[4-B=%6PG*V&9R09]0KW_]I!OXWL=8$MQHB34W&#\3E9W
MJN[#V,T^KQ'?D<ZT79LM!'6JTC-1)D.#(K%Q"Y$:*\?5"W@@:XLR&P9&2,C\
MRW6QITQ5^ORYP:AZ*YE%UK(WH9/H/M"EP\B)< O9:"E98:.-0":YWD=RC&?I
MH-#] <[F1LY]H%WPY_2G40'LRQ3 VE0 V[P"6%(32$UHH<LW:SAF-!!"QP(T
M;3:R@K+>#]+K D.3PEC\S-01A-23WCWN4@29. 1QB-9Q""-64,$C"I$$:,05
M0VW_@A.W(&Y!W*(CW")X /]AHIKX>:$<=X]N<MEO _M[8!M]77M0\1NHRLK#
MES@'-BS'E+.!K6I]_=,E1J.O3+=\WC-D9T?F/#+RS\]_8E D9U;\VP8+5,-H
M:Y"\LN&S!BNWX/D/8->"W7&(!JB!MA@BE6O.L4TJ-!LMI."(SY-[OM7+$XY6
ML6H&%#\$<B4&2@R4&&@+&"@&9+*0[Q,!8]GA5/E-R]TVEUX$3;G5&+KBV-O#
MWI"U9N+?H'-1S&5E60#7S-VB_6B%F[QO"/X0.U?J:K3R;_[\_.^8E?5#J7JJ
MSE,ZEMPSHE>RNA8G&RA=\PJ<ZC(<3LF)Q!B),;:&,4)G>><>.U5'JG41,"X,
M2_, (EN>'!FQ=KYB0SZ8'.'X3RI^Q; -.I%A3H9B>:!;NH*5J4E/,,LK3*-$
M,K'UAN,TJ+_2R(M=+PN@RQJH*J5M]\\J0UV];(Q&X>C; PT<G:>3*:+R\(+)
M)Q&4?^B\&DJU/#3GHB@L=Z57>/&^V14%=PJE6I!D(LG44,E4SAHTBZ.U!GSO
M1-!? ?(@BJWO@S2KOH;,:2EV,'<19C7F35?1D:H:S(1IDDT06#@;#P2,4KJU
M\(&429R; ^(L3N*R:IU$J9K@HIK'LJQRUPDL5S T(4_7'B3_RR<6<GZFG$"3
MLZO'RXBS'N$PA^%$;]0CN/'-<LS"VH%1HN:#*#/EP!W9DU5S8S6_4<ZKT<*U
M>&'F?3V [T=\%_OBT8T@=,VJ'57BGD)VIP1"5/) X4 4F7P#(]2>?A4.M<$>
MMZ7)-$= +X?&D_N](B\2B2022:<520?+AIYS)0%27L$<%XD_OPU# )64!\SJ
MS=4/E630C_8,?I&_!F1.480(EI'7 .1=6Q=R*-$<YN F5^(UBZML$##/VC"J
M\2@J9"B><G><(F-O1B#1^-W)4_EZ7&TD"(/7=UXH.SKF29+;4-YJL*:GTNV:
MURE.NU0OR4H =-X_@J5WJ[[&X6-1^!7,@*4G1R9&JI^)C 0XP5<8@,GYTX(;
M<S&%X("X2.1)FP]2(^/G">O'9?4S7M)-^1R'SP+:<\0RRR99WLI)17J:;*B&
M=LK5T;T0Y2]3HSOUT_])Q2-Z,E.LZZ1T#:9WD813$OLD]KLA]FMCB8)#4=;0
M/:IW["MDSBE;2*3L(5*>*3D4)!PL?14XZ;DISAM!=4.VO+V]!6U0_'XEUH:D
M G"6R])L-20Z3GW9NQO=ES@7&IXS&D_.Y2B\12(WGZ^0+V#!@!9GEWBZC(RS
M>GJ6#5/=QY<J+P/.#IC/9#WM%D+#=$[0@8,DGQ[K^.B3B5><)_F0'"./MC <
MHAR=K1A:&(7I[6HOKPJV^A1_802$6;+HE66P7'B1T$G!)(#YL$:=OH"=*W[C
MAYML3N+3B,$0.BO'S:]_]]7+R3H[;R@?7*0&Y#QRCKV/@40D]B%0A^O0R06=
M&51&\S)E-$,JHZ$R&E*\2?&NH>)MMA,I*'48-(:AS5C%*E4V*+H5GPA]I#RM
M62N^)?6\N BVS<U6V>5S(.<^,1MB-JU@-H(ER)Y;3]@)1LHYV&O(/Y06+=/*
MI:H</\,.N../F(=L'P/A^;8AAL 5@Z6<3N)DQ,E:P\ER]TBNX8";Q8/,%P<'
M:DI_CF ^+M;;['(*XO!=-=M8U>2\6WE\:?V"GT+/DD]+L90,M<FO?LVF<V9?
M+7/W!$PJ\*#.YU;ZBDI-,1^)D2[A;3)0&AM:FTP$%&H;Y6 >DX-YP@97AJ^.
M$C!)C) 8:;H8T2D:E(&Y3^"-$C I 9-$$HFD5HNDPV5#EH%97H*I!K0P&];Z
MD/E\L?NJ\<6'AJ=L5D"N7CF;6QL\(&E3)F;RNB=F/DLR4;(F)6N2BD J JD(
M3;-:ZY.M>9# Z:*<T=;U8S+E4%'RC.Q-1NF;ITK?+!3Y:_\PI6^V-7V3]!S2
M<TC/N:2><Z+DN'P:!>H,E"-'3(>8#C&=[N;(98R6^!CQ,>)CK>!CV=R-NN3'
M94SFG!ERETWSI0*^ERG@&U$!'Q7PD9PE.5O1,*M2X 56N/$"<,&CF_=?82!V
M\]YYR)/N A7@%SJU^%EX&XA-"97:@:'9:1!SW]2ZG06XU_6 B,RQ^9@@947G
M0R[W=/:Q]&$_R*$4>5->,_U M>)%QX22C&ON!*HU>F&R]7 RZSE7>B/O0A4Q
M$1=T)XXBFPF+-R7PJ1!_ F+@4+ES?)Y[JA=A!/Z-4"8K B@T$$VGMXR]&%]J
M>*D=[IA@FOOHO3/.,KTN2X@S)LQW=_+VE^(L]'S0MO4VBW)T;.+V5I0'FH5#
M!#0; $,5 "2^27R_N)D\AT!\(F0O#E=.T/\?Q#AC>UF:IY15_,A< HP=/!)7
M(%\:,0EB$FUA$MQ#,R'G"'EI.5/I)%KHZWP:%4W4H^>V0I&#P0_C&VMSO;[&
M+?^_8?35>@>9+LA9A"[U+R=(G>A!:?0#9ME]VV8JR6A[E =L0=D-7+ KL#JT
MQ=!;A?<<*Q?%5B&"J2V4W.FF)L*!JE_A5\N*'^5@DXA#(KGV,<PY_"I_5EDV
MV401>9X\(UT.0ZEZ,UI%"R>0X*M\O9NBT>58NP:60-9UZ&,R$62])1'8@[YS
M'S/)I!5HLNP1\$_ @)<%&G^8,>9*F!H7)&[C=R=:K(IW<<6L4F*13!132<3J
M%!O0^1(5H<D4P.IDH&*VD+AC7!_G'6HDTW$<8$L"#[0))M^;C4Q<+CW?4P&L
M_/LK/36Q\&E>;I#7R^93#;?VB&=#'-%[\?$^D\B;I_J84/?J>'X:\;(UK).%
MLF"9+*V5KK?"%9$$)0E*$O2T$O1Q4;:O;HMB9#<'!H[G!&)QP1A.-6TKYSIS
MO@C7,*40ZG$PW'-JSQ&4#3F;#7=\($5%H&56CX$I9+HQYU\59WN"O>>'2&-N
M!/+A4."#6X)/#B6B IOBATGT(#DW,M>(K\75Z0SCG5(0W)2"6C%9%7.9JK9$
M!2'$78F[GI"[&CZ#*EZJ&:V<8*^K,I\HD%2JG_[M/'0B%\T,60JA\J>!Y"%V
ML19T[3JZ98G^$3P.[&>9@KHFE4>5T6@DVNN,1L6.=;IE<2*VEQA%I6=AOG$H
M7N?)J@FF:!?V!3M<<P[21/IDY,GC[:,37R.^1GSMA'SM40W1T"6?R=>R6GE@
M./DR>[,XHP8^_W7'>!VP^=Y"0<$SW=82@)F1GD,B><9 J:7,YD)_BKC)T!>+
M+QX>\Q"H<GHS7;]ZL?Q?BS 45L.3OH<>\!1IB&"D?I<#+%]8H2#6[.M9MK)V
MWS-J]U&75AX5W;:K<@GPNV&Q7!KE"7%"@/B>S'(KN)C*A0?)/5A"7*CB\S06
M&!#'XCEPUH@;R@@,JIGB+!J1#RHWMVB2G*  +SM*E6N//=+*#)Z6_D296CSG
M5L 78F..L#A@UY%W>ZLNX]&)MMK+6;#9>@"IXOSX;%M@N3B&M\A(251%'163
M$:Y8I7,2J2,$(S/5/\Z_-'MA)*LP+GH]P9*3M^AA$DB*KLT*!Z3AODQ,?]85
MPM^[*BA:GL#*NW"!R2) J=+]!_RG?+$N]^$>)!QRF.8]XV09Z\:+"E8QH)\N
M^T1F(>$P![L0SZ1W@VYBQWU@R! UW6GN5KHW83H&L401647)UQMY20K1MZW'
MW"C.7,PRX1TMSHS#AA)]#<@;$35CZHSC(EEDNT4:D3OVL KT!)MF>2EPCHW:
M&^S",ZYQ\4KW-IR9I5]F.?J"U(5$%8)9)AGU!@9_R>D.NCSAWZ:M4&P,@VJ[
MV0\&<_][]J[V*OOP+:9XWEUYD2=>C0>OHO%G@WT/9JD3F^[# H,LD\-.$MHU
M0N4(:KJ$'4%IQ"^31CRF-.+'TX@+J !=C8)$0I,2C,D([IP1_'+)!V:B0690
M/,O2+IC913]B'I-0C=T@\=D0HTBTT(T4@NXN%^J%AW&@7+"C)J\"((Y0CU"2
M@ND3;L+8P4S@S.:6U=6/QR2DJJ+->FC*EH!1JN/,BE;]AWR%9#L#=5OKTV?"
M \7R1%CG><B9L"X<5!/##H)Z3L-Y8.QIR?F3C4 HVDTLFUAV6UCV/OEBFCV;
M=HO!OK,ZDJRR17*,C <5$LVD. "S!;U)CG47)IA%EKTER_DQ?R_[@#E?>>;7
MR'92]$$*VS%SY(!%*Y9(-F&0.?P<]Z\PC0+57TB88^&2>O$02R.6UEF6EC]8
MQ=2,;U>03YHURC\S>S/>2PR.&!PQ.&)PFL'EK"&+#7I9NO1VK.+1\&FAOK7:
MR 6F%V0=/V4=;44W#",]/N_!64Z.ST. WK(0B<I"OC+I7@9D=^\) KQ&G#%S
M&^C&0ZJA4#DDXACQD'R_6]GQ",U\SL6#CL@_'[Q8))W'/9S\:,:@)R\&AB/3
M*W,-6X<A=-S!+.WR8AU'5*8__\:CA1=SY6/9F:Z)$02$G'$ZR&K'+6($-C#P
M"ZI!X1J?2!?5@7"H W B\;FS6:',6T"1=9*)O*IWBA_[$#_9_8#L&AR+!V4P
M6U:>&[UD5QYDMQ8C,3+O ,-+89"WR2K$'%7=_<X@=N5N,&9F-*+*46>91B!O
M%0[E0,QJ+-!YA14GP$H.JK+(H%M(G_!B>7$"30U<DPA;D4+!RABJ7[@'.]!E
M/>H]DMX@%4 <*N85)175)(>C#$@G(9V$=))VZ"299%K^4,Q8JAACLF.\3#FD
M7T,5YDU1A]EQ/B.A[.F]F?4B/,CUH&,VN2/9!26GD"G"8N1HWRY\)X4_C0MS
M\7@RIX ]I@B=^5(?59P*DL]0G8R\S KEJ?BK\ZE/F1NTE<I3#L7#U:=LUO4N
MY4F#\%RJDZ%'-TQQNN1H7>H4!+#_%49A/:<MT.%@>T:+H.=!#?_.](1G@V/'
M>CC);;&[I6<)BA5 ;'F'I0(;FV>9R3*)=N,\%+/_G*U0O. "?[/[;#(9L'Z_
M#YQEX<2K4AN'G.<!-Z.^360:D6E4'],(NAL6S*-#$Z.\G8E1X#X]5TJ4-@AJ
MG.)D5%:UIZRUX 4O5GI1T^AV9WM/*-N;FD8W37NY>51[J58SSF%!/5,I:$+5
M+"N4S3[1%Z?W+0^O[M/J30HI*1Z?[/.VY5%SDM)GNSJVE:.F>8GFDR5;A0GA
M"^YMDMPY\XC4KJJ_9!4]X0KEIC!#T&P!9K;^,@\JK^1!@5IU>BNY;PPU3"H;
MQZ91XN!.LX .6N]X81KC',]8^1$S1%$>7.SUAA=X7PSM2@=4#B6H^$W\9S=_
MRW0O5866C[6@B%X7&#^9K6TV6UN7';[+6*1$*C,L\>S\J?TUE+V;T))F<IAF
M4A+XE;>^*,G^W&M<E.TZJPZN=YX%A05\?\@5S8JYI8]49LA#P-QQQ";3653Y
M9GSEE03/]HOD]6=L2#M)\HZSF5J\_YOGI3=CBK5@8^*Y?&++)A5HLH )*T$0
MIL%"SF[QT!I5M+$6W @^=!8"%V)),D:EH6[]FY&%.!42XJZ?E*:_9CL0K!N0
M G!H>U=,AW+ASSB=JP8?V-72E912G Q97!N<>F[DW ?9]//"!/-\*(L:=V;&
MD L798ZHW,F9#\0.!)V)#08_>\ZB%8ILSF1-;F2>2::+QM QQX=&PT((K,I]
M'/;RB"J6V7N;96(4T,!@/-O(H_(9<M8IUOE9K_.T3[4*[0KOBZ6?%D4;=*TQ
MFFP%;IDO%GML8 &"^($'.0KS6/!%Z2XVM]OS$M6:&TT8P3-#5S5G*2>L8"1?
M9JW $9FE<AR67 Y>%[NS^]_I2]<GEW!7'9=VG%)W()>M:4I=5F2K'J?XHG'_
MNZM+1N.?Y]@<V'7S;'Y9;=<::SAOG(=R^G,8P !:@#4@F6S09+DI,GG\/?2=
MU<I$>5TUQ:9B69/DU[*1-TS="O+VWUZT2-<0YEAP<\0C(D;YOIN4.7'9'(!<
M]^M\%D I$WQ''D#&4BD+@-PIY$XYDSNE%(X_=9-0,TA_6)/03./L=I=0SW1O
M/-TG]+%^<J;#YURA$^4+D5-FM!E4]DN8,8/FER'O&8Z8/QJ.R!+D3A2,<"@8
M0=*3I"<%(^K+4"E]J]WI6U-*WZ+TK:8)SH:F;[VX0^?1Z#*5Q-:F)+96 >I:
MQ&@?;2]UX2BMF891USBMT8?^Q2*UJI[X7(%:,TC[N-E?FS"MFA;P4.LH;;GN
M_()QVN)@>(K44J1V'_WF[3YQ6D-VGC92FR],L=K+Q&K_"./DM1FF_<W38VPZ
M%ZS]Y=N";Y*R/%I&3NK*J3B%SS--0I5*EH>>[Q0D.)=83N7-VFAL17Y5/Q%L
M>Y$G&%91D:;/[%$4/,6AZ7'H2PKEWQ:^T "@\P3P3*&$W$*+$#TI^"'[*<.P
M5S:B70H1_$@*$R_202>Y6&Z2W,G CI = 5^HN44[FN@WF4POQ(XA-)9EZ_Z/
MG(?6(9+\4F4>*;GA &RXN_<\\/F#- #B)$IEMD2 [6L YV/O-I!VW9RO''\)
MQ%8(< F: .-ZQUP$!H0%O ,4(LJ[:)8#C")'K?34>?O&>KQ8!7+ _ Y"R5=,
M1H-6N.K@]&"Z,7SG'A2#CT[L.O^![(K4=]2\/<Q"B'5KJT*D:$=L2EOOF,]0
M\3,T :M_:T:[*>9-G(LX5QLXUZZBN4OSJ\K"OKVX5=4OR1GS;(/44?5F]] L
M,)LXO+/7("C#9MV>C,J4M%B<<:9:]^ 36>T;R^(UK#@NVRC_ W\A3DQ#?,,Q
MS=E,56G9@DM0O:V0T+4"]W7 EV!*)G)"A70B :9FW20-)5UIYH7%;S'6!6H[
M8)F<$GUMO=43<]78Z*R!Y+P0>P@C-4E./"XM!*V\*XBJZ:H+W 6J"F H(#EY
MZ$J&SHW!M?4QS,$<9+O3()<[-?N+RH$=]]#H$J/2T'I>&.L^O\5-*8-\]V!Q
MIGQL,$S6>=C]3LC-D^_,QX0<\U:$HYQ\S@$7'6,NM\QZ>6IYA!7L1H(?$4.P
MB0PR:OO[+2;WLXDX#$*14)75F.()S8FRE3,4BS)2P ?VV#*Y)IYP3<1 FDBC
M77=(>#),["!$M"^[P 1V> *!KX22*,3?\#2#GTIB4Q$1);0S"< *LI=_ \^;
MCN1I_@F!&QYD+D.%\YK[ TTDX5,83JED+YE*-J-4LN:EDETP*ZHA0N++RHO<
MUW\@&_P9];Z%YT3>,[LJ-UQF&/DC9D97\5\?"D-^I(8*DL+-LIYVAUPJLL!B
MCBW_D]6C66 0%Q*Z]U*E9RC-_%&Q@5(+^M-';CXA6;82F?^%-4C5TBZ+14'\
M2EB!CPE2#*VY:#%(I=<-.7X#MDFP%#])-V%@IOT8_3@.@'9E3$MHHPLA6<-(
M+"1T0ZRR*D:Y<+XR1.,P74=*_QAWA:PBSK1) 3Z626J0]3!?6DZ<$C!%W1O
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MD_&P-@X!BE76P-9XSY=<&!:NY06+<,VMQ/G6XCCE:,9& RHH/ QXT\NSCG8
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M2PS>]X_-MFFMZ3MEHXY,@3@][$9L<$-5#:0$U%-<=Q6S>@,VG3:C')UR3&L
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MP_)/2@1_;"K*T]DE@)^/N $*W'J/G*Y<"P$=QWO2**1XRTO&6\84;WD\WE)
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ME+2A P7Z8,)NCJYJ(H%>+X%.9OL%RT5C[D2+%<I]E]]Q/]RL!7@Z(O1'[&9
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M3J( !;LNDJN6&G+-",+3DLAI6)>4"!W3\&&$XA!$>D:]'0C]74]J]XL/'P:
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M-["[O4V;5!E/[K%Y.$]EG:8]S(EEA)GV,'5,&_N2Q=C[.,UQ>4$K)ZM]AA4
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MM\\BN)OX*!+Q*]%="-]X0PNJ>AF09# KO7(QG4;PQY+8_1BZ#<Q<QG<G$=
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M#66"Y$ P@P.6S OS+C@$7@!7=0F#Q-*?#+-8<2G>\'2 BWG3OT6&1IY+4<#
MC/$*JV<)QJFGQ>)T/$N XJ#W\R.#"E0B)5C5XOY8 EX78#^I6;%\CJR#6+^\
MOL(K,$4J0N5- S9+$8P 9 .;V(7@YLTDGFWW+0I@Q7YERY31S0=H")P:XLF
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M]T0.;+Y@J/VL#"\>+[M;575'-[U5+*GFQ\'[ZFS1KXOU6O>$% 0,U>J_QGG
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MAD8U@4/;N>F;EX?DZXQB,+X4'R8EN$/U7@PC4Q\TY0J;:!VMLV>PHQW\(,&
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MP"ZB?M]5E?>+E7\2$@V^5!$!([)!LU(J\Y?D@'/@=>:-;1BY,U0R36#R:N\
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MB#IU_<D"(L( 4N-R&P@M V3>S?'$P=.] 3+O8LB\%BLXK&-I)1W ] :U]?.
MD=TSK-D+H6:O"&GV_J,R;@.Z[39B46PW=* GS2,@3=,Z[<&=N%J G_,'G]^0
ML<(H4$MB]!WBU'QM2>*L&G>NB6M_YQTD;C7 A=O5 >+/$N!%93IZ6PU@$@JT
MLG6 8@G'. @(EB%T'^-$;6!-[29'B@I%#]L_3 Q)Z R:5UY'Y\[@(,)>R&9X
MO2##"/ -_=,V$^ (,8J+%U;]K\*7[(\>/]Z/4>P^D*RB<SL2E!A/$0.($L&(
MPN^?'_P=;P@?!?BWFDB/PUPO #RUI'U9L!Q)Y^:2CW:KGC60&"(!=Y-?S20%
M?E<TV[QWSCRP:DH!_9FX=Y1-';Y_Y.04Y%<Q%S$%MX2,%\8'O$0'+=-U,L87
M6084 Q(6?98''8*$/EN42X8)--4:"UH0SR159D]VD__(&$XH((>50F*R..B_
M\\ :@9-:Y'R^]_<DG;5Q%_O).!+H-\8Q(\MM45;POAB$T6W<I3QQEG81I3SX
M8;@W1C[<.O#A#8F)HX#%%L2# 8X:0-\4GLT*'N(,2(&3?C Y-F) 2;#TIGC8
M35Y'/-XC/BIB7CTDGM,G954IAJ7R(%B!$?<\<U6T5L;BB[@41Z:P###E#!T/
MI.J/4^!*95@KT*U?6"#04IX__;MBZ0GK,:/E97D"E+PZ@ E"N\!DE\?B% "D
MKFRJG35I<6"&9259-__=D*&DLG8FR&IX(!A36#A <2E%3;$ \IZL.UKN$G;-
M9%&5I-XB"N(+#9WWKJFESU^D)/8-_3G,_0- +7F=^#N)S+T$Z[4C3_Y94_$@
MKEZ8T-W$1TCX&YX_W27A*6OS(H0/8\\Z(-?<*LLJR 38:EC$B"3Q[C/WN!?/
M.T_L?CL8<LZ2N))O8; V_AI@/;+QI>,0Y)/XJ_</PF-U,2*/+GV\(Q7CBU7L
MN8]Z3D0);6G5]A5*;8H@9FJADP&,:&IM.<E8J4#.RK;2>L<9SJGY:D#6P0Q\
M!4C <@7)KF!UWB)<9:0CZ:KOL J_GZ[?8"'>RBQF,2\AV[U10;>2V"D1 FV!
MC<*:>_#K[H?=/W9?[Q[O/OPJR+>K-KK_8Y$AK",Q&A+F$42A^M4MGY<!\+]C
MR(H1L3*A?Z90@.N5F,N *291R4C+D;.83IHZ]BL5@;$[6[5'F'B434&'#1IT
M J-/GL\?LR!9#,3#0C01'G0@XBKLTH)<:HP;I^?PAV\&'U(%U_2E_;DB"./U
MO>K?D35:"EW7'2:+U;$28HNN&?^% A=8W,W25&43NR@KPS,@3S,2BW"N+7T"
M>00I0D*Y44115Q"CJ-HK@1J$1G8;'I3K2K"JNI2DU]80!2LL$MBC&\N.OXFL
M"P]V*_3,Z(RY1TX-D6R9%1XW?"GQ@J0P\ .R>CV2,0NPI12Y>4EB?8Z%0MSC
M'H9A-@HP7&[:2GC"E0>%TGH'[W>]TJH7MXB"2X86!SOQR?]H4KB!:V=UB@U8
MJ/_7:WHJ%5W<Z6MI.5).;V]).>;37)FYU&>LP_17L#F9D'07Q^T\+$>,I4P\
M8HTYX;64;$+GPCP.,I<EA#N,)[1E9'O,C2XC*XI2!$>R*E<*G[DC3!="&D&W
M)0K;32OP,M<!JY)  \HW%AV6]V&LHHF-_BOGI#\XO!@,Q317'M(].Q85H0ZD
M*2HRG06JMDXKC88RP#"B$>+ZA0_KPEI/#;!J%9'?6$6/AAMJ<@AA''B1LO#=
MD8\@SV J;\/]1+NZ1&66$(Q>EYY .M%*82>.V*66EVBFKRJ!F:YR7=\;6=&'
MH[V]/?W4'1<=\&8FQ!2H0IPAAJSJ#697(+[!M:6WD%?><JOYNR8H*V'Q] +7
MD/DJL8A+_?R-99QEI,;&+!%7BEQ,/L]D(9\((]QY!DWA;B9BUA4(9;X C5S
M?LLE6;=T0;YS5E:Y^%3XK#S-EI;E,/C6 7-SV.ESU<!'D1'*K+R.$(PAR4MG
MB!;MHL>IAHMLNEPA3$02I14^>,J$#H+JLTAX!GHFIZ_,3Y4=$"E0+6&^&%+
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M/C'^%E'R1QRK ?AP #[LV]$!U^7V XH-B'$#\.$=I>\ ?/@3R:D!^'  /AR
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M'1T>WD 9X*K*<GG2LU%RL+?W;/N)PX.#IT^>;W\(^\U5 !8&%8#;KWF\N@K
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MX%3-%[-<U:&=;Y(#97/&L02TE'=Z#!GHBQN+$5&HC)$;H!M>Z253X$7)1#"
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MP1E<H  KC<)H:K=V5MDMQMK0.VG1KF'DG$3R[M7K2-**J8;?71;&:J5MI)[
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M'S]??:H3"9N),A8%?E*I:/Q1&!<4$0[*L3U/'5/!1G'(8MRPM> GZ:G"EF@
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M4*C,K+'<CJSX,6B$#X,18L#G#JZVU!\5@A[&R2F \0P3S0?Q,(B'>R0>3LN
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MG>;UU&-FQ3Q@2!:J8@#J%WBMSP9IFR^JJM \M.:$+_,X-;01&!N!L1$8/X#
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MBEJG)KA:H>ZJ9;-B!8@?01H"?\5P#%.QAU<F[GRK]TIWH/K-U"50I4%]AF*
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M3:*7L-$M>FL+Y-1F2I<7!1["501=PYVP\1 !K+:T'5#GPJ$S@Y[H]0^B'#W
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MP@G3@*K,E+M5WNH6(\JAX8DD")AL( OAOMWD/_3'07$_A\R<!,R7)(1]O(Q
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M.O[+IQVX'&3O0;+UXL7AMC]N'NMC(ZTBO='W)M!P2 R0[0\.T#(3R!HLC^<
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MH*3$M1X0P*PVU\)":BF6H^:!;"BJ+.M/=*2H$,OB!1E&(7LJT]G\YXWV6$$
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M.3A);P.23SG%3B4'VI75X/!&G;11M4$,$ +F1M2''5ZD6OSWM^$H]^D*J0B
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MTEQ-O^72/-_RE8K3V+)9.]$K:U*10Z[FT]@N)< 6*CXXZR*) PZ7^6YX?L.
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M./-C=5\7Q0KCP49\P$$!MFJ&D'+N6N6>C#K)ZAA&CZ =#]P7W[.%L5'BO(A
M_(A\BCY.:$5Z>BQJ;D #R[5E8X4K0X2A1Q 0]9.9YO.Z0G@O_^3ECE3DV/)*
M'-%FO#<9P+N:<CEX_,LF _A]9@!_W#R@B$Z3UF%;%3PG)[.Q$,NTCO6$<5JA
M)'K:@,F)63BQQ66L6O?/;%$(>&)E=-!E'ON;4!-G3C+.BF4@TB@:Z1E5$^O
MC!\RK5.!^2A7$_?OM89U;"%SF6+@MB'?E%CO8R6QY"]U ^!DA,FU7*-LHBXH
MRH(=;ACQJ,9</3&I-9+&<'/D;',.CK'/-2?J$&8V'7&A=I/3/)<,3XCC\V1*
MQ?X;2H8\-U2$!_A5F[PQ"3NO%C6-]*N^0&O\3WIQ^@#B<39ED4M0WNOJF%ZK
M[<>A&$MTG09/0U"D/T'ADII]V%F'/E%^QF,E3ZVQ)),TSQOR*=WA4JM<?T6*
M>2(ZFC,Y_FE"8<$-%=PR7%!Y<D.>W_W(++^*BS][!8QJ!PLA4AR:5CL, 65F
M]8\CVWVH:X@ILN=/%%UT&N>TS#YH/2P^Y<QHZD<R$E^?7.0T/Y=DX#I-DJN_
M*EP6O$/PHSM4Q'D1,&=JNS(#8&]?<&P=D1B<T27D9_QR=A2XBV N7?.F@]?8
MRFA?[9QK<,7D"=ME-RV4D5"$L;<=AS9GY%&S?.;/]<PW(^(;KK"[ACP>W^'>
MH+ZI2U+;2A/U8FBYQQ, 62=+(\IH-WD5IR*8<AAR.^H\."L^B&*@>"&FLHT"
M$MQBPMGDA?9?U)T3[;S+NNSFN?97)]"F!VN2AZU!+;R3(YOV=K?ICKFA@-(2
M\PO\+N_%PD8/0K3W34"%T\5*=0RN0(]W#"T=.;!NDQSP5]RV( &9)KG 9E"W
MXSY!6JUPQ@7=8&9%JW#C:7Y&/6D+R@R'?E6H'XH/6SA>R)53:H5C!55MVN-)
MZ&P5CA/]X@*=K@K$E0/=7B_D25.=A3K__L310J^9-PGPT(X!^0EV</QTEC^R
M\RS0>U:/QC]A<_AHM0?1&]'SM13N;UX4MA&0.\[NK76O!_,\^%")M-.AN]4H
M[:A#M$FDKTND'W^HS_.^O.2" -I4LZZ<N6W^C1/K@^TJHV:8,QA=J9<O4T@3
M1W7'AU$/,VDUJ=0BTBE#N0Y7H !$)?0B\M@4_/."^^X:D@B]0!%_E8HA,?=3
M"L->*$DK[E#QGM++S@IHM5X&S!:VT!7MB*MD._AQ*C.\W#V-FS81/#+JWFT
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M T]LDY*]2Q+WX/'C34KV^TS)_HC)V#-G<)82\\LKXJ1!"+=N%V0UD3@,<><
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M$61$L;HM*C2K]U@+([-%Z(:&R6;:B0P 1X;(&L9.R1FBB6@ZAJIA AF0=4$
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M=,A"?K=S;@AU_5=Y]TH79!AEC\S"&VQ^]C(5[ (2,LL8E[(_/J\ON9QL_=E
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MC=M9%<J*]<BDO1+33-5)S#-/Y;S+C)NI]9NMNDE=-E(HR5V+SJED4GCZI7D
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M,E514X.Y:.A3):+8]:-N#@7R]?D$+*SPTB2<A8YCN88Y"?M/8DUA4=-+315
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MBD256V<$O0$<C_BFN2.9IXIBO;SH%Z%&!/ZD.A^_]RC1.V+T?%W'J@LHQ'7
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MF. BB!1_$XI1^JCJA<AW\ 9+J]BU[-I.[;7=XK7]E"N*)<5!EK,OZ>Z^_VB
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MU,HKB&Y ;Z%>7F?7;6<=YZ--.<=I:RM';.*<HF;R,<4.Q5OWM49Q]"81J'?
MXXI7L+DS;Z^C=>B.!M;4V0@_P.U=[)_]KF,I)UY-WQ3 DQ-9YK-KZ2U=M'J9
MUL%[1(94I?R^&;;2+BI8+OKN^6DDZ^]D]R[=WK@Y;I@35W0: YUR*NL\&E6G
M,3MV*NO<)7C0\2/:- B_IM?MK@+8/%JW5"@ YS5X,JAFFB(3-3V,Z&#YXX/7
M8<V75Y56]3S]?><Z:Z,TU _4;!2&ULA0=PC*X@C$8W%6H%@<Q*Z@A">$1+B_
M/RGB5+WL]SI]_C8L)M2/O>SW.^?ECX.('()%&U0:+I2Q$^@9OKRH?HG&NNA<
MECYUG43(I?"QK5!XYQ805PZ!G0BG%,R0*?Q#L0Q\M0&>A6-C$GDBY@*(]T;H
M\OXS#(N\=IW;()W3>!,O]"(?_XYOKNU7TG%J.-QF_,PRB\<SBXEE%EO*5\I1
MZ<SZ"L>3SBU0'?Y+%VSN1==T'V9>D."ROHG4N?'"3. -R4)"P"68C/0V=@1%
M&]],/"FFY7'A[9%T:<S?/WSB1$OX^1.,#SOD?((_VYMUT)OEVYNU[9NEQ$SU
MH@#=7[W[_/Z+\\Y'*3F3<*4F=PZ2)]X5+W20M"/\ @F?0 ;1#*4@?* *+[50
MB]+$@T%@@HL@XILV$TH%\%&4A7 107C!;.SU.NCUFMKKM97K]2D)8([P(KA6
MA@B3\-]$A*0(IC'?L?<?C63^'9#_&B-RO+$9.MZ2%;J.;!3N6IEPGH:\^X0U
M[8<N!MUQ]81+_ZQQHE"@H;H.L2A%4R8"V"GR@O#6NY/&^<^3"D,@KN+HJS+
M*1OI)KWAP'7T?UZ_??'#>E?&H-,?X[=+4^V,+FIFJSY^:V+?.01^!Q/UG'DB
M9O]X\;<T]E_\UU=BUF <7<&S>''^_H/W2%JI,"&UWG%G& "EK+(D-<>$9\,8
MO:4 #WWTPHJ0IX@0847(]FV?BN#P'#D/9BEK:M,@$:A=P<?HUE"_3K'5<3#)
M2-M:Q%,1HGT49XE#\!BLAH$2-\E ;Q.2P+N#Q3*);PBL>X:K!\VLX_P)<BS.
M4$TTOR:S"=!- '\3:(LE E\HX_ &)HA*'VAV"Y%<DQ,$1HXIS>NG/YW??KMR
M8$T@[(35]0Y[46?VHNZRRL'4_.  0W@#7XTLRG^]]@+E^4,?'UI$>*%G(99H
M*;<@.C6J+\ O!%([*J?D&<3+39?LC.VYUWDV]=9<D/:^'O2^7MO[NFW!BN)0
MSKU$Z'NBKB$JGQYL[#_AHI8"%??&*>S]..C]F+?M?NPQ-QZ&79"PH'A;'@&3
M,'1(HH*%E+A&MQ]IHQALZU4B846(ZN.'7SL.=IE)Q )D'#D),4!&>E_^'NU?
M-P):%.;#"[G,/2@DD0+TU<,[%=B!XX&RB8% )?V<98RF8H"::0KB3%P'/KM5
M\+4Q.O5EAF$R:3SI^?_. O:[L.P#OK#TJ#0:5-:)(-'G.<ML$L)H. TOHOB>
MGIGG^W$6I=H%RMN#GLV.LTL'SN:$V!L_WC%R+U#]JF< ?\YI^,FTN6:\((7K
MZ->#H'/TMHR6O\:[U)(TC$8W%KKL/[>QT/#R_L9"=;(@SS\R<W@>\7,KAA[8
M=DB/'L:V0VI>.R1[J#LXU"O*A6AD\YA=,HM28RG7$=]]L4S)=%N*!(\!7OL8
M^V!#LCOACD6VQ]2QG=@.>TRU\\0>K*\YP#&^;.X9-NST#GQ0KQHIDRTD15/<
MTO_J?.FTMUZS?SEP1Y<G 6VSB^T;=(=N]^(DFL7L8OO.>CUWL#&,X0:0;,V%
M/#D;=#:'JGOU>D_RR$J:;?7'T9D\S1 YNVOM<N&>C_;?9:%-6S@ T3.RN-L;
M,=D+=]2UXJ=N9_J]O<F?$X>9: J@T(DL\VA )IJR82>R3$L7EBZV2A=/D)X[
MD6=-&=6Z0=M@G&)*UQ=,Z6J&8;H39UZ_Y_9&)]&R=2?;=]YU>^=V^Y[M"QV[
ME^.N-49KMF;8V;2;N+5%CPOP[536>3161V-V[%36:2G#4H:U2'=HD?Y]VW4_
M3\- >4JMC\J7VE/U#F:\U!3N;&OAHZ:!OQ352E/A)X+@YU[V>A6021>Q$P:=
MBU<NI2\_6'7J<F5:4D */?"5WB67YC%J'E7C1?G,)G=Y28ESYDDG\A8PS)0;
MAN+@5+@W"R0^@"]Z3=5Z'H)YA6%\*W]T[C]+6WZUT_*KT?BYY5<7PU>;,DXU
MTN7ZNJ0-7W!4W[;^R#;X([&?7']4ZB=G_O?W( I@?N$==BGT"#-CAF"'&3#%
M%$Z.VA8VPY5YM@MO$HBOX>N2_-JJ>\>FDAWU[?CXSODK#J(43@'KL_1]H&IY
M_D,B9!HS_DR+;\FH,WCM'-G]L#*F*;?HIS@2SG7BS5*"74N#-$O;'!\;52RB
M'=R80]OD_;76SJ,4"L. +-!(IIE "Y#MN)LXS!8"GT,:DW7HSD"&2;8D?$#?
MRW L,/[P#UM'G+GZ^.>'G]_H<D-@.7#Y%X'?<<KRH9 *!-"4W#!4]#UKW>=L
M3=#Y16R>!EC- G=6QB&BNX%IEF->2T:G67A_@2D/_!5.,9&.ESI@*L-CL"!?
M2!?>D2 B#2RL -HNG2/PX=MT3G:[%/F.*.1%ZEIQ[Q=SA+@L<7[Z]4MNG14X
M-6WW-95!+P_A=*KU_EQT1JO.'TR)5=Z?1^&./<,#Y*[>)4\S"\()10>#HB%I
MWK8&, T+B_00L?^:(/3C,HEG >O:U_0!+\Q")37%5V>ADO8VM(5*V@KTPLFB
MZEBHI!8>JH5*LE!)%BK)GIB%2K)020<^PX:=GH5*LO&29\5+GN85V4]TQ?2&
MU'D]=A\Z:4@ZXO&5&1S3&NW.-6M4FXR\MW2T(Q1J@\8E ;0<_Z]W[@XM@-VS
MMZ]_[EX.+7SBLVM>N^Y@; &8ZK;F?&\UK];(.B9Y=$HH@5@2?WX2W'5W0(OG
M;O_<H@1N!C_@#KJ;JDCM%%+]7F=3VK+(#$<%AW4BRSR:ZONF;-B)+-/2A:4+
MB\E@W: -BNWMQ^S\&J=-,3=WXL@;#-QA[R3LI)ULW_FEV^]NZK ZV>T[ZPW=
MT7ASO/4VFIBCSL!:F/M0I1J#;W4JZSP:6Z(Q.W8JZ[2482G#VID[M#/_OBV<
M :,L9*-*S/&6"C%7C%BU7RI;V'FB3?W,->W')!UT+RN@=N5_UEQXLJVKZQ"+
MD@-A(F9Q@@Z$\-:[D\;YSW.54:=L=[NOWCJ: PQPRD8 O#<<N([^S^NW+WY8
M7\T[Z/3'^.W25#NCBYK9JH_?FJF]#N7VPD0]9YZ(V3]>_"V-?3#;J2HWGCE7
M\"QB(OS]!^^1M%+AF6J]X\XP $HQGT>713['A&?#1;TEGP9]I#3KUM0*C\^?
M6RL\.K^_5KC7W5W9[3U(@ T9>A-WH*WH/>(:DV94]";Q[6-K?9Y3/O2$X5MZ
MS/?7^&YU^T^=E9PLC36[H->>U=Y*>6WBZZE6%_*2;'7A00,9AY[',8UJ]\RF
MA:QGRLVK1FA.==S.(M 7@\ZF30U?_->K]D7F85^VT"&^??MRUK656Y97GGCE
MUNBRLWDKTQ8R!]@7*TSJF>86]F5?3-.RPRVPPZLX(M>3EXIIR[GA1=^J2FM4
MR"TD=[9O7W:F0FXM[Z5M?0@.UO.RA EO]I_LUO6?/.^,]M^!@/H+%#T(BJ:4
MWB2^P3])/PDF8MIQ?O>B;$9-4;#OQ@V,XD4^/(BK2KDGP<(+HA3^CP_X( $"
MB6DIN '3S*?^!:&X$2&UO_00^3:(IYB_$L:W\*8%HN;[<;8,831JX1%,0Y@D
M'(;CI2E,(TN+Q>ZM!8EJN> Y,L2[DY\C3ARN\BM<3 GK7S7NQ#.RO3X.?]F&
MG<'J7</:]H-=-B8?H!2^:?<W![(]/IK3X^.+  J*KEWG6D0B 3I'CN5-%\#Q
M9(H-]8!CBN]+$<'QVHX?6\SB&S\_B>_Y#3]&/=OPXTE#VX8?-CWP^-,#[:':
MAA^VX<>QDUVS\P/MB=F&'[;AA\W*M0T_;$9#4T&!GN#L:$:$;Q?@+;W+@=N]
M&&\\MY9MRM@]O]@<V;M5FX) LI<6Y:<62'8; ?(&!CS[:SC[,;!L'?2C $E-
M,+)_@';H/SK647[ <G=".WB>JWP\OM]5WC^\9[@ABF5GN'_5DM_YL'*YE?#B
M__[;N-\?@:0>]RZ'^ ^PA[>5F&,B0DH9T+%0Z3I!Y(<97A_-F"A) )C6C6 V
MMA BA3^K<.DTQD<GF<0GI7,3)&GFA>&=B[D$(B%N!&R.XM'YZQ3KDXXGG5NX
MH/@OYC'$F80OR/0-L"^5IP <,PV(8<HVJK67E9CX5I6'1N=F-NW^U5Z7WXB&
M0W&M1;CO V-"\L]IV,6#\.= QXEPYC H? $N# I6,]O@XX=?83)X@S&[P,\D
M9A7 <P<.I/\1IP*D<,>YBA>+(%U@EA!G_] J1>0'^N*IZX?Y0.12%PYM6?<M
MCB'U.M\![\ K;N:=.K\$D0<CP29^2>$#?(ND+_?>*G[#FP$C2^<OX"B4JO3]
M#A:B'O\!?I=+X:=9*]G L#/>-1NP.GH5:WDN,/D'Z$ORY06M&40-R"XGGLVD
M2#'I!TEZ!CI;?(MW'FB5Q:15D(]90=ZP[/9A57K#%QS5MZTIL%-38(\,L58#
M^I+Y/BCVJ(JC7@!V !P19T;.84&DP\L89'NJ<X6191J/@5X09XD3P72OYH&8
M.>^_"S\C#\C'V2SP1=)>I_6P,[+:?2.N5+TQ#*:F)+*6(KD),(=>6ZA M>2H
M$]>!S]3LD3TJ79U$#X_"CH2&+0OC@"(%"O[63?DHCL D1J$+CZN+HJY?&Z_-
M>:=W=-JPS<G^#.JTEX EC!=ABN4E\9+L29N(W9I$[ ?05(>[2VD^SJ&WE./=
MU-Q*F[-K$['MH=I$;)N(?01D9Q.QC^_$;"*V3<0^N3.TZ=C-=97;=.P'_1SM
M=6?W>BXH$3;;N+(GW:'-P"[OR?GF:<8'VY"=95_WMHW"U?2\C@<=PCJ=8NJ\
M[%9<_I3Z##NV?V@8GX)"% ?"E(\<+*:8OG>="$I*HJG]_O'K_WQQ)@(?]L(%
M?!O>F 8P@)E'@J,ZM5F-#HALH 'OFX@P#=*#IV06I@AJM$]TI?6H,[;YWN%T
MC4&O:YOOW=]\KU91Y1A& ]OR[2!^N%:/KMF1HPHH_BR6B<#,$IU\XBUB$);_
MX0_61Q/77I%#GK,-:38TI#FT(4T;TK31+QO2M(=J0YHVI'E49&=#FL=W8C:D
M:4.:%EO*!C-M,+,)P<Q[?2SMC61>N.>#R^.-4>UF2RZ[%EZKC)=T/MJ<2-J(
M(S7L;+XO%D=J4_:L^YL\*CCJ) *;PHBIV0\FK]=\1*#4DTZ0JM8K&"T51NQV
MN!J[!1)YU7F@2M[63NG'/U+=H(Z+GP61'R_$:ULQ=?3AA>$#>%S'&0.PX85&
MF+K6$VW#"R=QJ#:\8,,+-KQ@3\R&%VQXP887&G3?;'C!AA?NHR9J1BOD"=1&
M7;H7P]Z&XVX(&WB\F]?ON<.+35W*)[M[9[V>.^YO'KMI9:3BO+/YQM2%*G8B
MF:S,V8+,85]Z[D,/8RG;*W;.SMWS0U[])F_-%AHCM7)?SMW!</-2U!9*BS]^
MW^K<;$S[43:!&4KN]2I ^!Q+!B&^_T+@8EI3,4F=0$^;ZW,Q\$X-4!(QX^X&
M\ $"':N'\_?0\&:C$RXGIM8J^%PQKI<*V7&^8@\$_6[G%KZP@DM/87LORNNG
ML<3Q9:^"-6PLJ#+CR@1NO#"C(7#VI=DX\M9;/C:(?^QDR6H#:PTZL^+AK HZ
MGWRC<6>+\NT$OA+<X#B?DO@&U+S$^2Q"A,#^)8NF<*QWU @#'_66V.\"ADFQ
M;/QE%0#740TWO.OK1%SCR2RS1&9>E&H"OWKW^?T7YYV?VIR+Q^9<?."C3KWO
M%J&V-?D6#R'4CHXR*:+Y0S<UA&I#\S;?XAD!G9,]3IMI83,M;*:%C?D>;8Y%
MP\[*9E<<\^G9[ J;7='@2->J!Z.]@:Z>V[O<%'IVMQD"#=VVX<7(;MN38V2#
M\;F-D-7L2_^\L_G&V'R*8Y(R[V<SX5._3A0T&!=JAI39&9%?=#9/''C5OKO?
M&VT;P'I'^[(3<75,HS:?EL[&.TK+L]D6#T<Y2Z7[YZOI%BCC]Y]N@=_SR?O,
M61$T;<I7\&$/@BBC!(NE2 C[0#J,7ZT?A/5A\L3'+#$&$2N2RPED)4C_TY_.
M;[]=84/@WL5;S+60\DTZ!_/U>@ZGE61^FL%;<"_^U?G2,5Z'(?AE+(5TD3Q#
MH2#@4]A:;"",B1[>=PK(PDQ\(&P/_I4I)GD0DL,-K#[.) X-]!@Y?V5)(*<!
M=QDV\T7PW?GWLPGH-P%\%5=K(_V/B_1_$=<$U_]N^E<F\7#>__3AZ\_OGA#N
M?QXW&#6-&50W $E+>/Y<9_\D8ADGG$4@><\DWA@BPC",;^6/#]"<38MH:%I$
MU\)0/&EH"T-ATR)..BW"'JI-CK#)$8T@NV8G1]@3.[84B4:>F$V4L(D2-E'"
M)DKLQ.^!KKMF!*UV$:P>7;K]8;-S(QJ\>Q<]=W2Q:6#K9'?OK.^>]S?%/6EG
MJL3 9DJ<F)BARN:(XE->V%YY,W![EQ;JZ+GBQAWV-DTO.=G-0^B*ODW,JP4Z
MVDK64@,S*IX0@]YO5)GR 0X1/*Y&<8U\CGY=/L> TCF,9A&<KD%1T13FA&[<
M()X2]D2!#''K55,EBO> U2H1]R">!2DYA,,,[6AXXKYV%9@'$4L:2GHA)DX8
MJ1\YX@5F.>!?[\>O$'X<Q8O =P)8BD]CEOHXUW'-I]+#U<<_/_S\IG>IHC1X
M9_RYXX4RAJ$HUR6,;XNV#;(ZSVF,/TXR"</!=MT$29HAC(>KOH?' %_DS4E$
M2'DC>C#73 '1N2(Q853@)KY)Q#3SU;8&*6[Y39$2LBXP/WZLIK4V+C_>4EC^
M@;;<S@87YPEKVH]:..CU*FD3:SN4ES@?ZK?5=8A%28GG)"A0XL-;[TX:S'>>
M6PC:@]?MOGKK:$UY@%,VG$Z]X<!U]']>OWWQP_K<CD&G/\9OEZ;:&5W4S%9]
M_-9TX#GDP8.)>LX\$;-_O/A;&OLO_NLK<2.XQ5?P+.:=_/T'[Y&TLK<6[CLG
MQ_W*KY*UTC1!=MX9U.! @8[34$E6#[&T5J(9@N]PDJP66VIR]VRI1B*)&DS=
M(]=*N8_/EV=-3F[<CU3Y+?AW%DR#](YV],I;XCUW/@L99XD/;WS*A7[^+CXA
MQ;')&:(?P4ZZ"6#E)Y<2^E,0WX <S:1*@48F%?G!$F@IS"DL$F(JG;EW(YQY
M(-,X09,2>,9$B(@203P?'I4!Y2Z[SFV<?$,FX3-1$G<$>Q&5YPC1]&Y$&"\Q
MN]1UD$/C8$Z: !M"K1>>4-]CG@$3R!)D!?E,Z7,_):8.[)4G!]Q4Y8D+U)B+
MA]7KF/$ :UJ(!/AZ"%LFX:NWR/N1\_#?9UG",' IO<6+)',D&#THB4LXPF\B
M+<UJ@MANP+1@6EZJ1H#-XHV0<[4R^$' 7MV 0  MQ\6@:A+?JMV",X/=SJ*I
MFD(B;N*0$.1 E,!&.#-X(H1G7!YI!JR:N7*1&,];& $KAY7YM#?T!([WX=-'
MYQ8$*LS5$1'EN,/*%D+P?#W8/SQZY-<T?H)3300G M,YIT!@'D@^E%P1Z%9.
M"C8*D,4"]GY>VHZ%=Z>_[V"856U<052E4])G1P<IO@L_PV1]>&LN:&2*"?S7
M=QVX!-<D'I3$I*_@H\70MW$63C%7'Z0YO-U$.V1)#$(6OZ'/WE7/LN2G9Z66
MT5Q.(*DH ;[B@\82 PWE]\6;T(G@H_&$DO33>9!,WZ!DO8-U 6<!?9T.)1'!
M8I(EDC:4$ZCPB*9(WTPU61H@9:Y.3JDK<#D):!*4$RGI:Q7IC%0*1#N[(Z)!
M09P&N0Y#.HL>K&QA7HL(YAD6V@@^'T136&URAV0'E[YTO 6MJ*EK=>8[=9:D
MCXJG%2'(6DIPC0>).M4^SN BL*+'Y1@X/,R>4K!]1JQ4F(V(N2FF2":N^09\
M*9Q!CL\I48GT<%LF =]D'(2YR#+&>0-C<+0 A3_E4^PX'Z)\9+=*Y5X@2S2.
M$R>JY#<+^("J2.A.*7:EUL08D:C TN22^,X+5Z;LQ\DRIO(52A.?Q$FAEX(X
MPP.';?*2!"F5+BO,=V9N/\Y0KDX1E+T Z B_K?9*PLU+X"&A7AR1 Q'U:]QC
MEP@3+H#_;0YB'&X!'Q@RY"2@4YD&88;OZ#@_(Q!JOA#XZLSQ;KP@Q,6ZZHHJ
ME3R(#!J?!=]%CHX)M #&FRKYP?7BA@<1LD6$PTR$8D[,<]6%QTL'KR66L CH
M<N#>"J!EK*^!7XG;%1<W];X)1X)0"69(^KYBI#)#D245T=$>%SO(^P'C+CQ3
MV%6$UJ..01/#8T]7]VT%-L,*/%YFD ZX-Q/DRT"^TDMH::!_!Q$*YSD!O9*I
M1+9OSC8+/J/(%*2.0#$JL99I082@GH%%PM*F>.EIZ3#"=8(HI#Q/)!I@?R)9
MJ /!"45QBI.:>3>Q,M1B)U,66G%0A<Q3DBX_6S[#ZHDI%E$YCX+<3%8%DU:3
MT&54-+G*,> F:]F8TRFNQ_,QWY6GCDNCE>/WP[#CO(N0.P+-)[0P9@6:%!1J
MJ[[]1/&D1'EP1B49AN_!%:KYPW?AZDT+SEU9/:&_ULO'(R\,VU>@-B!6O\R
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M61].$TF"C37TQ(2"'*'Y&M%+7_K.WFVNDDY6FDK97-9.\&E^J*1$YBNYSY:
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MNL&2<&QH \]'!3)@T=;I9>^\<UG&BU.-7!$"XVT5Z7L'LMJR",LB+(O8"XN
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M.;NT=S;ET2<IO 97F[J)GBM&??JXU;TMDUJ2AS94VQYX@LB+Y=T-ELHD61+
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MM,0,X1@S\T C48*O!WM*M0=J,TCJ:.(3 DC"1PUKYC-2V+.DD$<QM6B%?8N
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MGHA?PA;&.-:=I80"A;[ EO-F@6L$B1-YZ'9PI7>BN-3*F'C@J4&$P]MA)[Y
M!PIN&Q5Q D*V )L(Q3A(!!KUCOD; 4"\0"EQYX4Y80]"2[_(E1EI?"I,20&M
MB:X0!7.$/XX30A6P$5 Z&0H5=>8.0:3Y)J:0K/#@:/A"H:X'@\0 :QIL;^2K
M.#E>-"@)^!:\.+Q\>!]J6,6X>Q.\,D) Y]-2L8 ;7!-03N'O,6$NQAZ\KL'!
MQ%?!$AJV"MI03-+<%R@92""0N@?D/0Y2V :@,N>U ,WD(1TO#WV@I EZ#0QL
M @5GDL2S^F:NHX7#;#^51JOY/6L5I$],$.?8VF,X/L1.&$ +#CZWG(-R9%1,
M=P(^WR2@R9SUV@8EW#!:U[7V'^W=>+19?4@^@0FI4LK&!W,)&.%<P9'4Z]4^
M(]>9QO= $(G),49@/L%G4L 065-V*ME-#XI@,Z,-7>RH%&OV+)7^49X&I XC
M&T]\QM-X1&P=CP,T0(YC '_D:W,MUKR,%M'"Q%2;B2K1_'A )GB^#P^CDP-.
M&]\K>I,2!?3=)LE0/6J>*K2I:0!KD>QQ*GU/B^Z_([O.!4DAN!&";\.PQ7VY
M3YX6&%\\CA#JO-*#@,'36 $%?P+&$-R17L>H ;H8;#0P1"XIE8H,Y\A5LD1X
ME*K&.K1D\2!WDCNF60528(2_?DEU1@;E<=R1[@AF7T#JA-Y(BE%0*<+UE?B@
M:HXS=G!,A1=FTS%RPR "MI'E4J6?PZJLA<$YLR08Y? F?JL/OP'.9[['"U/@
M?>@R(,\!:(5)@AH$\R364*8>8.!X04OP:X&S16#59E*9321K5GXT%!T .3B^
M@,U&XC;. H_S?$?(W5Q44Y);@7TYY,[ 7F"UG5XI\^"4X"TRCR78)4#,@T@B
M_E_C\E!8 %L.6-,&SBHX&IC!"5/48*1E0DZ2B62U\2Q UJMB=K"#<0YW-6,
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MJX';O]J767\B,'3;@^-N^F%52@NE@X=2!Q3OP:75&JTC?*\@''2&;M=V\S@
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ML@#,C3Y615;@,K1:O"8$F#,683CW?!\6^MN+]@OZMUR8_BU?R7NC%SCC/$G
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M[C'AW7AY%E><P_31"RMU'R-U>Z<I=97031WO47)72]V/28N9GQP>A!)**8Z
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MYS:)T]3)YWQ)EV[[8EAR <EMGZF%05G$@Z>EAZBZ"A8 D^7"O1H,0+.-Q"0
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M:TNP["P+PFJ@$.^QD-^=*Z7(F!YI1K8HON>WIH]Y:\OY4 ]68M[1AYO/H(,
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MO&TF'N-1"8'1!9@GU23L,O%0Q+7-Z3WP.V#K0#P@<@'$88Z^[=)2RZ#G-BD
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M\95,*F<(3KT@$X?RD&GIMNKW-X9665Z&]?WZ^LXM)_J%"P<7QLX?'B8$+!P
M3,)MZ+CSW!EF4DB_^"1(4IJ% %\GJ4R.P"^HM K^SH56N'6P!J2G']9$)!>4
M-?E*ICJHC"7X+0AZGZM)/9:WLH&(6Q;1AL4Q6F#R RR)YY5"NRCI LQI)G"W
MID%XD3Y^ X@H/H5K QS"@$,6GJ9B)'5R4:G8("#N6"2(HZC6Z))]!^,665U[
MD2H)J D+HZJ@B942\Z-]W$F7F8>P#8/) A&B_K(B3%G:+B<,-1QTDBL\:*D$
M4'2O+L4J=M*FXRDHPS+O#'_<1$#P9YJ3/:JUJ[*/4=;-J2YL*LIS&P/5NV#
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M#:2JY2S2M<O)<  8GI!FF=L:V<*8JP.W19TQGEV$^7.Y9X[.XKM'U@'2E2?
M8CZ5!!-E!)7[U:CAV=00!NM:@('<HL"6M(AM-?JP:+O=AOVA[EG,O0(T1@7A
M1E$W-6<9\+.E*7N8A:?JQ%7.X851QEWYL%O*8*MNM6%4EYJ,J?+:Z&5$3UBD
M\5KQ9R[B1H:P=$V#J98&CC%\5%FJP5;E?,QF@!8E@PU=B&CRGV+=9]]ELB&G
MZW#7DRJH5%DE59Y,Y2A&U?Y(0YZ[0 $"P0UMT%F/DR 7*O.2!ND]O"M,(%U^
MA.YCCK#&WBN#6GAZV36IUJ;40<TT*#K'J F 2V]G*7:85_:0#FK3Z?:93M>U
MZ70VG6Z+Z71KS._;OK*( P'/WT=^"7M/7*?Y6II6P]Y=$ *P1<K(SDJ#:N5H
M+349%\O^&@=;FY."RBLL>9[D0$A3KRO3TA]RQZRT2UO.+ZA&%!W,2B7%U 23
M4MD-9"L/]](S?5;[1US0]*C'0"ID3U5I7\I6%^7. 7+X%1=,F.X89?B1?V<]
M>5?R\?V8P.,E]A =X$UR=("YU*''"XRUN8=6H].^U_V)Y-0RIWZWP:G/-U7^
MV9:7V.'2A[V[DUF:HPIUC%Q'%)%:NW:\:\EF'4G5A?XSSQX3BSKN98!O *>(
M_O:BTWWQT)J2L_ _SPT]M.TZ^+]7U4>4$FMP+/F-]/%@YP"_%,G3VJ')V#=V
M :U6RU@!8%5LF0'57Q8 K2SWNOC19:L___[B[V?]5TU.I8-'B,%SQ0<>#"/1
M85=WMG^VUVA=-&]\<Z-J;1=&&2]H XP5%<12M\;:_3EJ8VL'X!_GCOZAHSX6
M0S^!$M[D='YR-G&B-/TK3:)]YV5BQUQ8L\]G*TX_*;OXKZ/DY[^#T9ACYHE(
MZ9^%32S_"79G@N$XG_ZMAD">_=<K^K?\%DG\.*2GO?)-KUQ__P27;HF5=5\"
M_'MY+?2/FP1#86<O7QT'V=F++%WD/.!6I/3/)Q!ZIW.+C5KQ07!7!E<\D8V=
MV>5,%UQV.]-'AJOZ@2<+[BP79D^U_ Z?VKY!W)%<A4/@U"HHBC-Z)3;4!<&P
M_7=VU3M1SEAJ. J>]M%+OHF,(?,OG%BR [SH26Q0Y$586 WH\)<[(:]72XE@
MI])W$_=#I[/2_^",O/$WS#Z/?!,5NVU,W^CA@*!^_]6Z7HJFG'XU\>.<0NV[
M3NHO!9GIC0>5YO_?(HI$-N6DUQ_T'3R>B3W(&#8^U\7/G=[/&.Y\+/+_ $=>
M^[H: V GL.JAP.Q0]G%,JUJ8/07,MLS=RHD&/\)U*1%JZTRW<^D.VQ>/UC>:
MC*8M;VV+JM]5ZP)5/[Z#LXN2 KA[:?/B[R\WN_%+][(S<(<7[0TOZ/&DM4.E
M<=V@U8&P@]WK/Y<_]]I/I/\\#][6=Z]Z_:UPMD-!PA_S56WA?BGA3W84.!:N
M>=%M=;HG<O'/@V 5!^P<HCKR5'A_3%KUH9#',9WNB96PMO7<'8SG[M=$W,;)
MPOG<DJ7J^_7>M2]^AO]UVYV!I<WGP,\.91_'M*J%V=.HMYLP-*6+=K$(>%=*
MX^9NIT'%[73HX+RZ<'L;P_.@M)U3<#FU^S^W.RBT+RT3.ZSK.NU]'-.J%F9'
M)+2';M]*[>W!L^-V^Y?N1?>D!/=6W12'0C^-XOWJY\XE2O>AY7:'=5NGO8]C
M6M7"[(BD>]O:Y-N$9W_8=@?/TBBWP84'@@O_C*>1\[[ER.9S>PXM=']N#ZR7
MX@#Y^FGOXYA6M3 ['CVFAV;U >LQET>FQW3<WN70O=P8I >ER5@OA>5V)RDA
M#F4?Q[2JA=GQ2/=N_["]%,<FW2\!H"<FVZV78CM>BNLHF\;1HC*?9[_.BN'/
MG0OKJSA [G[:^SBF52W,CD>;Z5P<MC8S/#)M9M"Y= ?#D])FK*?"\KJ3E ^'
MLH]C6M7"[(AD^X%[*HY-ME_T^NZ%]5183T6#IP+'5GJ1GWC.C7<GTGU[*:PF
M<Z"<_;3W<4RK6I@=CR9SZ)FA5T>FR>PW,Q3^Q.;]99UB' HO^0N\;OIZYGU7
M@ET.\:N/ U0=BCL_532!M2;)=.N-C1_3%?G[RJ[(+S9J@5SN'/-#,P8/?:+@
MVMJH!/C%,O(T,)NFP,K>X0\B]9(?+QU)RR-F=ZWB'I1"BR-22U-)'3_&!M3<
MB=J+'*&G"#3./\?9U^7?J[&B\(,O8IX9DTL[ESBYM#/D7\KW8)-KG'.*\]#3
M/*0A\=YX&H@[;*N-G>_@BSL1Y3@B/KD5.!H^<OZ91T(N*B>'T_!OVFQMNN@6
M6)(ES?5)LVM)<TND&:1XQ?DL<M)I?%\=6+QDW/!4A+XS6A2#Y]\$TY#F&9=_
M7J9:]2N<! R$(%8,)2XUJG>X27VKR@1$)!(O#!= O'/8'. _O9X4$YPXG(BQ
MP%7'7CIUO%F<1_"K20(+Y*G#TX-QQ##\!."2)<$HY_% ]/+[.,?="KA#7^!J
MR*?^DP=W7H@O6@ZB%-A$-JT\/A+1> K8\$WNH^4@4ZQ^FE9.,LYG>>@19!IV
M.,O33&\0P J'FN=)FN/T,=@O+O FB(&M9?#-;[^]=:YO$R%FO!T<"@_\D!FI
M<  +X',>MFQ #CEO^<UQXLR]!2Z")T9^.A=C8JAI/IZJ]62.1<KHTGQ8!R=3
M:P3BME3Z=]@;BA>KHQ'L]>7%)?9<Z:$F[_)"(DV35!>AN++/E4M(6<[Y,%]R
M*5^":_8[9!G4UU1+R;57+8E??4SEF:3WQGS?<-6A+N% @ZN.V[D<\KY+$**N
M^\9:(+26K%627=T^C_*F-PPOVN[PXLH=7@ZM -NK .M9 ;85 <9S6YP['-F"
M*.X+^/D,OO,+#@^L&!W,<T%>9GJ6E4W@MG&2*2$P\8($#URL!Y2%7[R-9W/@
MA)9B]DHQ%Y9BMD,Q)8'BW'N%.25[\J\C3E[#GS^5Q3Z;1V1KX8CK>1*$TGSJ
M2?L)95K_)^,Y 5:8\Y_<2^ $2&J .1/XJZ6TO5):WU+:KBF-.L0[:AXI:-R@
MN8^G(+#(:,@6AC4!-/;F7Z2_$R&&"UZSUV9"!$T1J D>NI\&0$SW\"MGDJ-5
M)$=[(=$98TX=CVV+# Z-/Z,=68+;*\$-+,%ME^#88BM1'(=]ZJ+-D%,7+MN=
M2#%7_>;'/WH+PR<(IIB2@R3*6 Y*PE-J99"@]S&*P*!.4B]9*+62'T:'IQ*,
M=T3P2X5BT_&\,(T?/.,2'^EK7!U8#OMT2M*[[OL$MH%TX023LL,T0! +C_<*
MFC:8K,#"O!"9VLO>5:<UY'7@_L. E'$?U[KL/W:IWJ#5+BUEF=9>F=:E95K;
M95K*O61RK4YW"1_Z18P28!&2&0TJS(CINORC@BLU_7;X6!YD[K;,A);LV#*A
M'PA-FYD%ZZ+W\MR$S:>/U#9H$J_,&"N3[\,)A3]XIJ>ASEZO5[WATG^,79GG
MH*S"ZCGP,X,CLQ,>.')X[RU2X_ZG284M$V]W%,/JX9:-%(-.'^QK]<>KUR]^
M7HI"G5ZK.\1?E[;:&EPV[%9^S&DJ<G2R0[.38:.>,TW$Y&\O_BN+QR_^_I5$
M)K"=M_ L1@;^^K.W)JY41($\[[#5#P!3ZH)![C'AW7AY%E>R.>FC%U:0/T:0
M#ZT@WZX@+\>&RAZV959(?INKV=^=BXHT-UQL.S<M&O9>DNX=*]VMB?%4G.G*
M<J;M<*9*1'HMQ\BI4G0C,$H\;MAS4>UKB((HYVNW2\ @E:L9>A58P&-TB$['
M[5UU5WJANOR#P<..7?(-OQ-CXY9Z#/GV4Y@EFU-/9[B^NB]54-) 'Y[8_#1T
M]2Y(Q#@#C,,(L8A2CBJ;D'\(=H^SC@:'9AUA7L\$1$=\CXF4+-=23)\$RR:;
M.D$T0<Y'4!G'T5@D$3V'J4TFQ*36(L6;,R.$3M7',OHQBKW$Q\_@ "!S$GH)
M/;  W'4PN.^O20U+K*/NQA8V+[&'-&W>)&L);!8=D-XPO*BK#<;2^.0296%P
M^5-S3<D*94(7-Q@_V_(23[OT)B6;PZV,I9((6/@&:C3P6)1_''O_Y,U$F:NN
M76O2O'6FN$?7;/UXE4>M1*14Y?'@(.W=@O=_@'\^"7@!8G"$Z&\ONB^>*:A_
M$2)EN+SWDDCX?QTE/_\=Q-B-%_@@+NF?;S%=^>SEJRU6F%VV^EAA1A4M5>5D
M2[=MD69G2/,USCQI'.P&+;J[1HN-N@YT["#I@_$D_!NM:&_F7+><?WCWW^ J
MME\'2[G1=1/JT66M6VE^L$S1_R'HH2WR6.KZT=.\^/O+S>IZK[91)[W;TO'G
M A/;M.7@&>.7//4BYV/+^0*R.A+C;R(Y<<[(S&SW)+N53HJGR,N.&# [9&A6
M'WQ*MO=KOG!NL.IRFGC/ARDM:0FSE66:J)1B\MW7>]VLA975Q8Z$*7WT &X1
M\J4O.?[2,J9C)38+JX-@3%:G>DKV]2;Q_% LG'^VG+=>%,61Y5_'2I,65@?!
MORQGVE*^DW<7^,B7;K!+AM6KCI;6+*P.@B]9O>HIN=?-- B#N?,KJ%7QO;^P
MW.M8*=+"ZB"XE^5+V_*A!WZ,6M4G(<+4LJ5C)34+J\>RI6V4HMCF[;9VT#9O
M?X*J9IGOIWH#8V,Q+#W&4KM$9!X\3>V07\H29RS.P>;2J4CN@K'@]NM<V:,*
M>[BBAVK[8"G 9BP&\L+:JA-!W05>]I>N/)YZ 8 I*JULE/H523DKM]_T(OAX
MBT?H-*\LZ[FO<UB 5OL]2+]A5=DLR#(A*L?Z%,OVV4:A%/;4YLT8!UQPZ^M2
MK540[:I T'(GV[_^J;D3D,)J(I#M%$LDX-W#(ZFEA(.@!-L(>SN4<+VB&MQU
M:E*<9C'T&TK_7>>J_U.E[-SH)%K[+H_X6[?<^]Z0N"M>==%>\:I![<OB77+N
M )!XN%AGO( \MFZ?O]YH 3W1HGGQ^EG76=_H\O^45?J/JS0OU4*;2/_B[Q^H
MECM"Z ,OI5D7R'?+F->170]PH@=V9HCK& B?_1D'T>H2;U"Y$&Y*OW,!#QP/
MQU@ #IC#+DCUPS<QV;B.@'\1?CC_]**BV9WNK0"_ 1.!/YQ[B_KV5JB'/Z+A
M/E9Y=;E7#VR-! G 2;;M";$W< H8%^HA'!Y(#"_AX1,ET[@I5_>Q?&6>Q.>)
M!T0G$0P/@)KE').L #ISD00Q79H^$FP#%!P&)\G:!NAN?Z,Q,&-L:BSWJ2FP
MB?, )_&Y Y+^_";T=+N?)Z"B]QH_/\5W!N%TA]QF925Z,]4U\5H>G(5-%I2)
MX<WG0&49C7VI8&BA+N&5$1HJ'%QFB1@$6">AAOULV<BJVD^$A.-@KDV;U7L_
M*9)J@/:C4'VU<8R81'M4XW[HSJ[<SN!20Y];B$>5.P(Z? B+6/7N#)^0WCX#
MKF_](J,X.A>S>1@OA&([OFH)4[(XYG$8C!>NU&5&8NP!Y H156[(VI'=DUPU
M!D_.>R+L?=(S2'0PA2$Y%$K^GCYU0&HY'PH'B.N<!1)9:7X*<A9 ZK1H]?*&
MT,4V/'W,F9ZJX>F%;7AZ? U/M\1!EZ-C.L5V9,5@N%7>SD*\(R<(7A')_R8\
MW]$=LTI\X+%K]XJUY>(&BTD?UF%*[;J,SS_%LR""3T%]PI^]C9,Y"4'G5]#1
MDLB+QL)\G)\!WAG@-Z[S/@/VSCK#VSS,\L1XNGK&I0>D[;_LRA.^Y/YRKM9\
M#"VH; 6[N]%5SH([R<E14!A@ENA>Z=5US#!74'UYZ?;IO_T"XOTZP"L2CZ0S
M=6K=MXC^_<L?[.*4@RC-;K!ZKAD@5I?/Q \!G&CSU352YXQC#=1<,9O&J2BT
MQ/( R!W8="M.KETM 6BYJ#53%[A"9W;1D@#=:9P$(QP&)\+X_M7_S]Z;.+>-
M7'NC_PIJ;O*55 4KVBS;\?UN%2W3MA)94D1Y)GFO7MT"R::(&1!@L$AF_OIW
MEMZPD91,4A+=5<E8)(%&H_OTV<_OD'L)2>T! +KR&U[1'5CR<#(1PQ!^ KMA
M"IIZJKIMEB[G=00*3,48A A%:P0]V[[? L^S!J"G^PAUF26@3J>[/FQ._W=<
M9WC4YHEL "(CC N:?*R-DGR<)L6M)'J<^IY--F@D;%QC7404DB,08"E9BV#(
M2KA0VP*4A\)0B/7C(TF(%DG-ZDEI23LU,P'[.I0?PW18-H);7G-H;E-O'(I,
MOR%?IN[%.3QKTC5,FY9KAP.Y,_X*AE6CFO'NQPF:=K!& Y'9\=M KKC-+)?>
M1L/%U^9MD.79R+#S-!R@99^!,OL' ?E*BL0S6R+4RO'9K<B\6B\18[J&S5[B
MLZM+_^D,6?1K/$@ZLN'-V.F/%!E[7A=?USR6_@M3,7X9]@YXP6 @(H&Z#^LS
M_%A82$3]]8HI$=D *.M6R.7-TR0"HD4Y-Z*6I](#1MC+9S&:'*CXH+^GNG6;
MWX,04T?"2;](L2TKDMK*'[]ZGW*1OTI&KZ9P3D1>LHK%=]1F1=9$Z.C?+WLU
MLW9/E_-U/*6OX[7S=<SW=32F;3-B[W/U@H1#>&8R.'B[?W2T_[^'KW]9FIQ7
MGR/P0H#,>]W3;]=G-V?=GM?Y=O/E\OKL_^E^]#Y=7GMGO=ZWSL5IU_MV\;%[
M[7TXN_RU>W'SK2<U;:_[CV]G-__R3B^_7G4O>IV;L\L+[^J\<]%;(PSZ'#?_
MLTR^H$8KU&8@QD:O?9#VJL\XBL$/87('U%BH[ 32+T&6L'HFM74< /\#(S2E
M-,%T,*HZQ8@!6KLS5-.+%*]C55/%@3@"47ND'%/>A!H]/0W.U3A)86%88(<9
M1B0'@C,NJL#O*EKAR\X$7X-T,)91S4.E%[9-OH053P$QT'GXK>R)U^<9S)NF
M@WU_D;#O1PM@WP^.U@?:?G#X_,?^D:*N=2+"/[A0Q"%!/Q (OY!Y$004;KB@
MC+4F_&]?T,_(!M'.!,.1/LLFX$+=#L9-EH-X@7GR9^Y&+I,,XB'_04I71A?L
M!!7XR><$'.X(I8333#^*X2O:N #>'DX\+Y0B _IEFI+[:BY!H I"GVU2Z#M2
M>"&DP#R#5R89\;^&<_#&BDD08FL>>?;O@C!"-80_@DI%5XT*"J\I[8KU,N8L
MI)7QU;9F)W/#4(MCJA'?!U%!Z6FU&8PB04Y)UO9@]8M)K+C..C#OCYLP[_%Y
MF]N9G<'Z#M&S1ZW ;7*EX0OHJ?LH4V\-P---C4,V4)V^Z;+G8_\=F*H';_97
M--$U[(3JU?'8RO,??J<'0.@OO>X'1WO[SWC-CYYZS==&\$?^X<&A?W)XLDT0
MX$[TK%7TQ$D^7_QLMXQX3C B;I7<*FT&9F5+'.;/R#WN$%%>:*7U:0([0QE!
M,H==!=,PY6:OFGS3H:0?3,'Q=N@GRL;127A--W=5UEF/(H!713H8!YFP!^GV
MKJYV'7*!P_#8@O,$A!\56.5V[+\^.<#<>\_R1'O*"YUC[%R>!,JAI -HSL\@
M"K+,Z]2CYT<G^_[)F_*@C5F0=JVD/JH4Z[:B[U3\RBFR]H"/FEWE<7BHW9EV
M:"1;<*8Q/^1>QJ \&7[R= "2HTZ4.8EN?F^G+VN,AHE@^S(/_L +L/1],"#$
MC<6G5Y77#A,:8AQP+5GYJ>Y\/>GY.G;G:[4R\Q!%FW^T?_( F:C">Y0LU1C5
M*XM !OXY/O2/#O?7]!@6?<@U8I7BL/R3X"J1WE62OQI?Y#Z,(DJ4PD0SH#A"
M?A@ J6=4PU&&BL$G4YH\7"CB89!R.<0H328-H#*'A[JJI/XCY@+V9UQ-\(@7
MY HE61D4B2SC^W?"7>]XCQ&9J*!'CX?)<_)+&G"IIY24+BXD@,NPI$'7.)3+
ME<1 ,-1(F U4L0@A582J^I^*23(X*1',^!$O3J4-<# F5-U *ZB@)N!F55J0
MK9=RD#:WC7(ZN]Y!.]T\G%!&(9;5+J24\GH0K7S8-*F\0,BMIVJ8H H2:^G"
M5,8E0;LP=83*J(<UD)DRB%$E]9@+IBCC(^0Z)])3\,I1DN6"Z6,*9R;)!:&
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MZ:ELP 6KL^=]FTJ^W[3HI0&LB7EOWKWUCT':+;\+DD)D)BL5\.9Y)!0>%<W
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MI/HAQ:>&*6M)6E_L,Y*+]>+F9>BRO/SJOLQ<4G!30P&*1TJ?AG=A1JQW[G3
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M([.:J I%+E BCP<)0YW#B*4AR*JSHO^[G)H6D+@M*E^.A2+W I>KRXF3F6R
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M=3Q\TVB(O625O1Q@Q7(PT&UE]*O81:VTG=@N2F]<8X7KAIC6D^$WE%8 29>
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M>C4LY0"ML^&3)@%5^TZ1N)II\X"9M<&ZPTL:(:GAI9=(320#A%A_0$F*$HN
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M)2NNF9-I8 71/SB$5,QC"V(6B.-40(SSBNZ.,_*)LMDRJQ 'NY*X=LG%,A"
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MX)UDYVK4A6(DTV#54@QUGR&/HXPS7NRS6'S8+ P0PV^V;XQ]C];W7 LLWN*
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MO(:/V\4'GU@W0-T;KN/IZ:DTXBRC!"Q>H1TA1>* LW%'] ,L4PJ/T.K2+DF
M$6B]1UNP8RO#M,EOBWPJ)&;Y9T0AC86KCE+<:8*[S3=Y5WMEU^.5/=)>V=WP
MRAYKK^Q,=/_6_MYIH5?V\N:KT;Y S^P__V5<-^Y;=Y>+^F>WW,Y!L<0GQX]Q
MZ'Q(IH3E8@B<#V/'6?2L;UL^_HGB@.CX\[U?J#*@L@9B)QB\&'WF@(H-8CFE
M;*(ZP*4]Y7LF&B@7S,'$</?PR4/-8H1.L91V@O%(T@]1$M- 7E%0VXW?39:#
M ;K[@\.R;S5(%Q*?":U K,!E8CA$[5]])6@4%.U'73D(%*N.CYIW7K+FG1#*
M0R\*&*ZAVG)"_.*7416Q'DD10/#$ ']WVVWM+FY$!&F/D?5$E=&@!#[: $,'
M=4!OC%JE"E("6@HU@">#WNCY8/TV,,$/+C5R0C/]$"':!/+@#AP+;@3KL %*
M+])6Y,:WYX)9Z(V%K@E7_V\/*"*+6Y_@=T)@.-+ !SU-<?+ZB1*%77'&8\?N
MH2 I@<;V8 <AV;=YSZ=W?\#1$U-E>'H-C\YS+QQZ"4C1MGU^#CIKUDNM+A[_
M*?0M-QB@0OL SQX2! #D!NJ\F.VBPAUA):$#I,3&%CF39X($7LO-T*R5C@Y#
MYO*U\]3/.<!H2F]"S V8XSWM"R5U/+ALR8O)$(LO;-+&FI-))M;6"(C('CL%
M?-AR8YA'+L6)>G <GV=%!:$?]7C21XX7AFB$+FTP !1A_0S;;;NP@1<OXM^-
MOR9V1M]^(0N-3L[M8ECN);9U4FB;X!N<B;XG]FVFGZ,OXQEL-V)PIM!V:!-H
MS>&KR39,>CP J))G@&/!5OCJZ+<"6):,RP%A)QI;(2" 24^BV\ES'RB'+1CB
MEH",X%SV&&D)R'B"Y)Z\B*X390T^GT."A==HXH_V@&\LP0WR3.(J!!]YS<#H
M**N:S&HX8=_K18G QLW++<<TBI ?1&$$()+HQ9 &#4>D3J-@E,B&C-0TX$U6
M("#ZHM[CNQ/M'3\%E\+2\V(Y*3C,P_*#(=U0EPEV3,?.\*F%8G*AY[Z4^E8?
M#NS][Z[\'GH 3./@K')VN'P/W=')T<?CD[(T@5,,M\!7*1P3!)C_K7@I8(_'
MM<H*]GA\=O3QK%ZOEXJ-4^U(6+LCH:X="=,="2E4D+TER]2!=TM<#"?:Q3"3
M$'Y\:]VUC'^UOQO-QHUQ<7GSQ;ANPU\N;R[:=]>-^\OVS0K=#%.D7K[U-; !
M\;CGWS3^C$ E83[:7QB'XQGE(/1!4H6@->7:\US#5QWJL<'5:371E*8?8$\@
M3>'_:*=)3S>I$:AYT=\S[^%>",5//^N]/',)-1L[""+R4I":@B=D6$;FPXE[
MEN.\I+9H\K %?1'3B8U<0$DO &I#Z+_GSGOIJP]8K_3@/8+JIX9R\%FRJ[H4
M=!CX+*-K*9K6E-LIVBQ/>$!;TL] "",*%P"7Y8OBSL<CJ2@,!$3F-(]A.WCU
MJ/2::  ^>"+H-Y%4I0 @-E<%QL0 3RE'7%M.ATQ,Z5L"W=1YX6@8+P)[SX<W
MJOQQO,3"4+9%*Q CQ> 8*>/,10<6^@GXNBH2"FP641U?X(F-[#T<^E[TP*]R
M]E8./)%X)X+4":HXZ#WH<X-7Q 9]W$1/JI0418MW:O *E4-80515HJ$2VF&$
ML2:ZD+E57I-3)5]FUAO?,7#;27B#<@'^E"W*9GLS$3?A*I0J(.0S0@SM.V[Z
M]L+$UR'O29J/ALL0 \!V=E[B= T.1W)ZD6<UH5S8$G!A)PY(VO N^#O8%^%+
M^@0B+#J(P'I%].27*!AJP9Z0GQ!B6UBN,;2[=EC KH%->D]!C(WP,N'D5$":
MVH_T=\X-V 2A:=<JRPL*>5Y> %?XG66^"7^80V\ZBUPZ=T2>R^V I?!)X8<>
M,<O-  DE$%6VH6_0'J'<M!!Y%*APGT=\1>2ZP3_$'N\8_I-,;!9E<U]XG*7#
MX?XJ5L(S<=1W%XH^[J>)QGW$//QN$&%A$NL+/4)9Y!TYC]RN K(@RVD(Y/-<
M?IBY!\^?RO83#WH@*#L%KX.F-P*)2/D8%_8JTGMN/%%P62Y7/E;*9Z?'A[_/
M9:,?O]E&/UZ2C:Y++J>5 "]>ETEBX'C*6I6"M=Y>B+R159U9158D67%;9W5Z
M>J7\\1\"PV45]@#D!;SYA5F^P?,S_QZYC .]5C9%!FL.'T%)*1T9PS <__[I
MDV+S?&KXO2&HR,$GU@=-Z1.P9^O3Z6GYJ%;]5 :^<'16J]1!,X#53T]./R%S
M@\W]*@W#$>AM;!Q24PZ^C2K?!3H_/B<.I)45@FHNI+G0?G*AC&MG=7SH].,_
M3,F'ELU9*L!9JO5JI5H]@W\^]2OUT^K96?]4\):_1X[(WJZ>)7R%-,=EL+,*
M1B2(G9U*;M:('J) C+RII'@9O53S,\W/-#];"C\CAQB5+XRYH31(3&/*T>*)
M!>D2L"P3?&_?Z>G'AB"/@SOUU:LSRZ11-I4#IPI=L)2X<G96%1GG'4;)')*E
M2;=UJH #>9L%EKF%71ZYJ>KYL63A[U3*;Z0Z.H[ 7.9E-V33<P\;6+7*O996
MRC17Y@N@A)PB/QFY#47JA"P+4'V]6=$\B'S7#H8 1'XEEX"F1K54KB*4Z9>3
M4KF"8%R9!!< ))<E=QK*>T7"0?\EBL'$%4TE/=PO1)_"+D9QLA#]9=5;9<]8
MW82)A''ZI7"7REPES'CK9QQ,@))!A'XT>%9@?F!4:@?6H8G_Z>%_CA#LE?I!
M_S"/&#!V97N^?!FYJL1C<78?EILD93:E^ -R;[E>B-E)3PRXLUF,0W,[61'9
M$A<2YN0"4M&YJ'&5=!E+7[5HQ25<O73'TJ];Y)'%-Z@^JP1?57 68^TZ5=.X
M,LVAK#".X)/MO\QTC1!A<&:;NU^D%CL; 6T %XD9A=8O3EF"R@A),(,4*,)_
MH! %Q3AR,EMI;M) ..@QA9>(Q4Q7)&$ PR=O"4\[$T$7I2D57%J<IXL?26$D
MEDXYQ!'1X^85F&INO8AXP1MC1)C2JV24<?S@<=[<%#&J]@J2A"J1R3KP,.9"
M-"5'1F%EF8$A:QE_2IX)F</&0\Q3=B/TH/Q>G$6WY-RCC<5-GK'V;G#8N!RL
M!A(-XKJ2KK>_T,@6+>XO)')'Q&T ..XE"_M]U9FC.G%T8Y&S=G*L$T=WHP+U
M5*>'SN[U</.E]4_COFV<7[;_:-W<?^\8ES?-$B:*-FZ:EXTKHW/?N&]=PT>K
M+$==1(>CGV/GV\(G+E@/.T#;O;RQJO"[:X4>Z"XW7@@O_I&M%$WIP0/;M5RR
MJ"<+31.S/^\ITQAQ=8DL$6'S*HTEXA).\=$3R_X%]/CX3_A*\><H[L40U^ZD
MBT#FNMCMGQK.-\F]^IR5;+J?7UF;)^;G.MO/ZK^1,%G$&2^FSZ>^-N-G[NZ<
MW-\\%$^:R-Q1BX+-&N*.$Y$U#A>)*,RSS.1B<'MP7^Y?/U0_S%I87"__]:,B
ML<NF@?\[S#XB+TA!&_&)8'*!YP!\U#!(+$=O 9I+.O3;[Y=C_JLOF(>&)G4'
M697RD=2K5<=V4HH%O7'.SNB;*-@;49\*'R]B29,D)?^>Q^_G1J5B4IF!@G.?
M/I>9;?BJFGIVB7H2@V> 4'P6)D5%+5M"S2DQ?#0Q:6+: &):*WE4L9:=)Y(.
M@#SZ;,P(:FJ+D=NH"W:6T>CU/&Q; !;3A>V/LG3T'A24Y]%[A3:9MXRJL)'O
M KV>'RM+W9RFD:VDD1J($,NQ,)[7&3*&S@&R][^PGI)Y7*M0NEZ9S/AJN7*V
M%P12U02B">0($\:$JTQ32@&EU-Z%4L3MDJ<@_2Z)0]R7]TJM,?:L''U8TKJ:
MY/? "*NK1MC555/;8-H&VRA:6BMU'$L;+%C8" OV0G0>:R534\G)A[\U/9>B
M*Y1GJ33L *IICQFOA>"16XR_^FS(X'8>&;K]L-OEP947!(=Q^<"_F.4'1HOJ
M6/,55).T4ZFFGNX%K9UJ6M.T=IJA-6W4%5#+F:8632UG4R53DTI[:,+7-=%+
MW*6L]6=DAR]:'DWWP)<UB6D2JY2GTY@5#(T+:C>FJ6DJ->F EJ:FGY6*XK!'
M8I&91RD2RTM#V@\B>9^@EG;5[PVU;Y&KOE+%2<[6]%1$[;W7WGM-7J\BKYK.
M1]34M-'4M%[Z.,H8>O +0"U8S.$O//W"[R]-PG"([?.I[Z_];(S@!,,@[F,I
M.[W5>-,U>BSI;ED]X3;C7NB_1SK>IBGQ9Z5>2(FYX8!\$LIWO>P'&9UH,M)D
M5#F>4Z I<8*.,M(P-=)D:OQ B[<YZ5*'N#5=_JQD\TD*Z7(RMJ#I:QI]U77$
M3M/7S\II)L:0.!432M/Q!B*8503E_O+:'K>Z=]*V]$[*N9?Y.KN\I?^.O!C6
M7YQ5 (+;HP= B/"O'SX8@=_[ZX<'SBX>:K4_RZ>E?X\?/F1QX[B.J\;(@=@!
M**#;WRRE_<WI6KK?5)?4_2;SM9.C9-FU:PW+[.^W+-J='2SY>M>XN3?NO[7O
M;N[;-\;5U>TDH2TN@M5O8,.W3 7ZZT3>^P'EKG7;OKLWVA<&MEZ[;<$_ *2[
MUM?+SGWKKO7%N/U^?G79-!K-9OO[S?WES5?CXO+N>A)F.X641Y6CLG%K^;^N
MK%_,:#RRDFET(IS)6ZF5EX$IL[ZQ@S"]LQQ$1-.X:1K5D^-*]6/MI%K3P'P5
M,+\8_ZMBG%7.C-/3"D"SK)'R=7"\2,/QK/[><'RU*5-D$"_6Z/)X+L-<Z#3K
ML<'//<OO4TT&M8CW?!X4[0PMGPD_<G&SYC> 9CZ?Q7I!4]PVLQ@*K_?B5$[?
M I)-3&1ICVV7!B2YA6U05]AE=@N([P<SAM8C,Z1["Z%D]7J\ RP6ZG9%N#3@
MX=+4O'9"R@/+^,(<ZPEGJ,A)$@#R0^, UQ(M845+6=$7]G"^(BSZ@4_(X -U
M>$O; [3PY&1[,=V9SY6P^ CA>'S+Q&7+]Y=@ZS2%PN/X819AAX%S= A+!I;M
M.R\X^84&;(QP<+--LSFH,6^076+L!;:<S:4TU9WOY/2:GD?3.S!*1L-GK*1Z
M>NS;\)8Q3@I_8"[S84<O^#F.$XT'?W]W[;C8@%[:&,&6>Y;F(Z]@Q%9@\Q"*
MP)C]YAHTESV/7.Q $&PPQOGH7=M!]$V30#SJ"'8$BB)^KV2T(S_[+9N\[V*4
M%9!&#'K!S+/+Y>VG:P5\3!<2._&XH&0 ST-F91ECWI9 (:R![8_$8#QJ7!!/
M?1(=#"05*YT,VJ &!HBQ!E=D#E)T!VQ0L*/;9J-]GC! '-1#L\+^C.QDB+RM
M]$]XRNG[+=^/7*B'8X.(-\>[_%[JE(P!ZR-'P D[D0\\"#  V',0<U-K/(:C
MD"?/CY"%X =PYLBQXF[@-.@J^3X^$<_Y4L:JRR7I;//RE25U:M\@<OA!<]7Z
M$<TW2C"MZ)8 /=T^H$H,:0&^^R$.!$P^%;C!)S<],0,;PQ/(Q\P7$^>$X*:A
M2MW0@A>"U15X+MVN%0213Z^VNCB5ZFG(Q)R]?%F'-(U9&+"K6+SA3<L'S'B%
M?L2'6_D^C:B"K\$V\  *A@8T44W%;U0T3 SYP6'@6' BYCX !Z /Q9EP"IDX
M$VR# Q&VXL)6:'2=YQB@??C*_OD$,AHEUPC ].3=()5;>&(3E"9@!:^B.5X$
M<J1E?.6\KS.Z %(\8LY$1\&T^'RX+-]B@P'77ER:<97/&Q<Y-:$8_(CJ"0)5
M<$Q7C!\4K]]?\FRK%(ES^UA,0ER9\GJL'_D\V@M$@\ C*68'OX)":I WET-)
M,PC%5(DXNP.D=2X(^YSI(TK13DI&AP:_)0_'IV'/ $@7EC(1R2PCQ&EQ7=19
M3(/A9#ID L#B+<(3SC=&*, X:P>(]1PO$&L6G8H+:0%(.>-3O/_1<B(YPY05
M:*H1BF*>X?7@V@,000!$V*@](@65YE%V7Q2MP$1E^8GA;-4@^PHD!]3#A7YN
MJ:IV[MZ!1W>98[-'P4\5!B&G]UDJ\^PF&E]B)^PO#7T*/AF3\96]!8<TFP/F
M/R)6![E,G/ +)R+:2']HV.TO B71 9I'W;1 J &=[JMG[]KR>T.17W<LTN[F
M20C00]K6,D'P8_9V=*)1)M$H-\>0IU',FX(T%PGGH%K.[CXKYRV=UMAH:QQ-
MZ;%H.0D,LW*V5I&R%4^[R[06GYO^W^!+7&!2VT9>:-I_OO"%KCI#=TO ."M4
MH.'Z.K@>-(0=2':?%P4 430:^1CX8$B.4FZMBM_Z5F@=SH#W9F8P;EP"XQ+F
M]TU/8,Q+-#PKQXF&N>F-,],7Z5LS?US^LI1/\;JTE%GC .=*7I\YT>[-JTRL
MM:FS -\O?9$7'F5R$?5U;>YU8>_4E5S7&\A_1E::T;5ZOQY\D(-]]2:JY2/0
M,FJG\$^]?CB+2TRFKNEJJXD9D4' T/I[!7X4TMRKTJ__ZVT+Y%5"_<5^_MWU
MW O?ZI$OVK5&L&KW,?C]W@LMAQ_] X5SX,MW:#??-H*V6ZG^K%5^(IO[8$2N
MS3_!$/+/[YTO'XP^Z]EP9\%?/WQ$<PLV"*O"3Q@ZL,*_?K"?P]__PWRO;P5#
MA-%IM5(%\*0WLU38+;C*SE]<Y6S[+JZ E\JF?A.JXQ(:&[T/VJ19VUP\4PA3
M>J@&>GW?BR@U(B6+9[/1MYLG>W9(C1$:(XHQ8G7:GM;CWJS'7=D6Y>C9;!.4
MN66L\@K%0 '"]JMUFR?)M_&RMT05?.5E:P-\ZQDWI>Z&O.P%O?J(R?!%YO;>
MFY6OCM]LY](:CNMD0)JUO)FUY+7]8]3C;W]51!4FO-^AUA3UG6N%42N,^5R]
MMG%<'15&P/$ D=HT_BL?]Z/@XX-EC7_G#Q,!W%I^VZ<*N/X?EA.Q6^93/?^B
MM/!SS/R?XIL)55S>7,1D44Z3A1N-^EXH'BTBUN5L.)=AOW7#Y5*Y,D')$W_
M,B<#"R*8\=&8^XRTK: =A;+>::'#4?9/L.)KX%N\#(*(]3=U=XTH''H^$-6T
M'4YB\SON<+XK7NL69U[Q6G<WUQ4O%PEQ5.0LLE_&'W@6']:FR".:ADV701X!
M+T&=O=/;<]"!9(%6VO6%[[7&OO=Y 7!TGE^WPT'@S3BCQ@>-#SHG8 O]O^3\
M@BW%<5)>ZK_)7N'W3R94PL@-MZ_=PWN52?J&R]=:YSYJG1N2EK<7A]08H3%B
MAN8I.SE/-G+&@P_Q8'$K9U%_^8I*Y"5U?LDKIN5U8@)P;YKCH*QG@V2S>WDM
M(C.-9'GS5EY/3.W-'K!)H>S7%@Y90%WTDI%*><UZ9W5$V,1.*?O5**6:=T,3
M<%A2EY2W-TG9F&%,Z^OK,2]J[FV/A/EZLDRT1SG2[5%FPS:>LM?5?5+6T\]#
M-(+,:^DA4PMN(NH<GHF:M/T'R[7_0ZT7DUF(\ LURVX/;I76C.=18&.[TR\L
MZ/GV&/\$-G#21?D6OHPYR/=PL><.6,898[A<^5GF7I![3_6(P'+6&!'"C]C2
M8+Y+]%4I&>H]+=2V_/50*VIAOB5 4_L8OW^?]TV9-G*@M+3$QL*F 9_P?JB'
MQI-%S5%'O/EE_@@([$6;[MM4K6+?IDH]KV?R ';IV"%O\4HF@AW2( 7>>=T;
M#( 'P4<'E[=MWC_=HQ:[<CA$Z%MNP%U:Q/W(HD3)TK-\_T4V7^X*1I0>9'%U
MU:05L1ML$'4#NV];/OJP#\[_P \/>6]K5QD)&Q1,$PF Z3I][.4.BFM?S''X
M=^1RER#U (^7X8M/:V ?4%/KPH$19JHI_-"B$1EQ5VWJ</V2'!F!\\A]\T(>
M\-VY3-D<@H#[#ZG?;=LU+EC7CRQ?S(BNB&Z5Z5=C^V#*(#'@=G"_TP/N'<MA
M[0&Y0$&VP+'@%R4MZ-*]3RXS*PFJ/RO'R/TK]U[R\T\>PF\Z5A T^*3Y*,!7
MQ=-XZ2/QSL:S'?R$C:8>E-?^HFR.'L1/V)\1K-%"=,E^2?GH_F7,\"NS\X+*
M<V8%G9G5<MDLER>3@V0>#QH3>#1^.PT 5I*Q:5AA,N4@)J QB'*BN!GIG H<
M;O$K4U(BM^4B"A,TJ_-F:=5*>7<1:U/8^=ON#65G[& +Z #G5S0<QZ.RL#:I
M9IM/%Y69="%RVD# !!$V&A<#-*C?_Y-OATI $GN)@S4A0&!X8\[Z5"W !_9K
M8Z?G^6D&56(;)W'@8W?B^^W%;_1]R>-5EU&!ZZB>3EX%B!?J5L_0!'$9.?KB
M"T!6A(WGDS;TO7BP2# '>[JU7DA""A @Q: !V?2"B78M6PO94[-V4IV JV0R
MJ(-14WT<GQ'YO:$%2HG+GIR7CP+[1[338&B/^4 )%J!T][V14#V$@""!@#Q,
M/H0Q>E!#!,V@2-="8]E"@V:08=,S@F*6/4VCCLPD(&I$V4_D.WL>,S<@#1-]
M\_"7@CO#R+0"KK988*<HZ,BLY616XR@-^585R_DDI!Q[@H^,Z E0YZC-<@4R
MFA0>']"LNSZY/;K\J^CR,H[2^K.8FQ5X#N,#,/#:./62I?)';*)X3^XLK>+*
M'N$$*IEO\")> BNT??'9K>6'+N<,5[?7XH7\5MK^5SY23CS3?A(/7@KFD$6-
MTY^5LD2-^.>?YW_ ^_B*@1_&BRP)&X#=I4@Q27_X6)V*#R?5TB1#_2V!<5KL
M#\FV'5G_]GR<2,;@X-X(=&G))\WDUAX]HMF8@]JN&9?8^Y[#[S>9;:*^L1'0
MZ)$@<F#!( \QT\CR9#N.&BK+##WA*P49O*$O\:E!\#8X_4>Q,R>U;7B"N^WD
MH)7IJ'9MNP0:B1OQ/0/?1\<LG/;\Y<9SE7?Q1_+DP<G/<FVCD:=Z4IK4<GY+
M@(?&]Y"A]?^B7E@V9)!RJLYPLG:263G;X"TM&ORX)8Z_*@J&$>R?9A:J<XK4
MD48"^@L[S(5?/'./+_S?C;O++??A\HF=<(O*S>V1+Q>E6":D1@.+NHRA4<;&
MEE!DL@,*ES=EMH,O0?&D>$=IP!YHLLQ$?1;V,015%0SCY*\T8Y(<N$KN<.PB
MY;G#0K):P= 8.-Z3.!IR7WD\E&#)'G,=M7QFD\](R-/W7$^Z2&>R[,5X^$2J
M)ZJ 7^*A:QM'^MO.QFN ?(7(LV]<H*D$9#!"L+9R\;G=23E./:4L-2Y@Y7KL
MR,8IF;P6?MIL[3<I86F]\FUZEVBZ%;%^ \Z/2W68PTW)G]7CVNE9[:BBJ3H'
MF8]25CO#F]#A[+FX@.K)V#ONQVUF5!B$-8R*!RS%^.CJ 5BEWA/RE128TL-2
MP01_Y\F-Z].;A<M@A%/(^\(C1FH3AU<Z:-YX\)F8U1IZ)N82X11E,64:WA>8
MQH%]R#FQ'+.*L7\+_=0X%_,!Q_&@<Q<YMXA=YGJM09436SO ?Z3#(3C$-\A7
M,#FC'$?#BFFP[-D.PL2=5K@L;@LWE5J=S@_KRQ=8X[$'7S8RJ1+6/.Z[?<&@
M%-GEH1&F&/2P= !MZY!)HR!14XI02<4@A'>,6K*913P&>)G]/MX4IUA%D'3^
MIB+5.@5)7Y] P$U"I=W0[ C0ZYHJK1G(R^G<E-.Z*4D-^*SPJ37@Z_DVX.L"
MZ&J<;Q2FOAMXWPM37XFJMSX;, R2O0);UXM[E;EP#P.TZ!<F03:6AQ4X2%'"
MD?6"V7\B D_!]A D+45S\+_IV$#LG#CW0-\D\]7VP1KT?$P^;'\YI%1&EV'B
MY<CS:>*XS8+/0C%YE(I/@+5I=C"4L26+:U4@8F$3L(YI@#)@]\DG1G$ET-OX
M(PS3PZW>$+_U-,1D3*$H\9 133@GB0NO>'A@/NF!\.V/+PQH#32#T4155M:V
MWO "K3T;95W+&V6M2[0VM40+B$EXC#@+QCJC J_1%-=28SP&33Q^]&?EP](L
MD(U#\6_<U3ZAV2++S-4=,&\=0]ZAPY.IBM-E%)5!)FS^@=G<18Y S(E(PMKK
MT&QQ>_-X83\&K(<B\<GS^P%SIW6S6!H0WDUI>C404/+.[JGXB!D]2D65VX\K
MKM EC3;LDQU@1<"?$4AW^)1$*WTM]!X8&;F4:I+VB+CDQX#-A83.KLC[4YOJ
MJ)&Y#!;C\B4C2PQYN,^+!I)OBFQ7H3*X_2#)(.%!MMRGT=X'6@Q]NQMQ)UHT
M%LEJC@T'Y\5AJ(@$@>=$7)_T85GNUH_&TF,3ITUTIJO\J&EYKJ.J6R)E!G 0
M]2 7=A8$&,V'OX\LT'PL$1&<DA"GY%^W?<HJ!8%P)VZ.D/+>N[IJ2A?1'9YJ
M>C;+.C ^F^.R",9/X#?P^8](">2> 6B'3Q@N13BZD?1QI=UF:A8,7=%$+AOI
MRC[#6T'_D'S@H,E%&&($/D:Y/[S<)_V^&>9@.@UG<LF9R(5T02F H.%SE0"/
M$5,K-S==D2A; (:9+R&2 NSM8?P=R0E)?IKXH><<GE*._[X"+]=KOBX7+^$+
MA)A=2O:P4^S#Q @A,0.A G&S* \93$#$/F,C9$>Q"SESDWOGNXTMTUP?[E3_
MK:36@EB!E(,BK3;,#]-@?!>H(Z23QLQ[&G5HUOTZUCV/(UC(U[3S(H<MI\6
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MKQ+U2]W'U.JIKW>-FWOC_EO[[N:^?6-<7=T6\H6)ZRR^^3=L/TV@\2LQC7*
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MHH<N8@=6V"/;I7<+'IMTD!,=S%W:M=\7R4ABE]]+G9(Q8-A%&^<Q]B+>O-
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M.T7WF^=7.#*/JLM.G4D72.P"BU_%I:\S7VK9B3&[=^.KN/ -$.?5ZMI[Q.F
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MJN'SYQ>FKK9Q:<=FU)>U88U-3S0U@TIM6*/A!,,)IJ[V!)U.4U>[H?4K\>+
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MV^!=EL"!2Y+;:#KR0SI*M^J(W>HG[":.\4A2U)Z?SD\AQUFY&R^YY+/OC/P
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M1F<UZ&1%SRMG 'G?I+C'/O;]NUF"FQPBW5D0S21 "S% C&+3_Q,_<V%O<7^
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M/(F^&[(LCM3?@9>?&"APK CSX=DIK(^?#A^,'" $TJYI68F+<V">U$J<H#@
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M#U]A?)(]+UZ86^E5EJN?Z%Q\V$Q172':2*>[(K?N0>CG'$Q0$!LLIW_T?(?
MEEE:8D]B5'H544XR%JJ>4=H*I8 P:44!*#Y9"E[DS,Q%FWZ<(7/H.">,9+P
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M=O.7XJW)@FR:-17X?XB"6KTU::6=@SNVA9U#I5R$O+$?J\:JB"16?+*Q$=&
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MODL]FRCKW<0]J&<7'T5*(A4@+CE0FH#'XM;P&>&%5<*.<3(0E+./H- 2 KJ
M_R2QI\<EJA8@YT4A4GYG5;G#%#0(ZO8?8*3^R=N:,IY=7P2>(OV#\^-*WZP
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MREO6Z,@X&G6L8.\SG[C+2Y 4OG49&@6Q&PB7#T6TL@+LW%*(&9A&8=%DL M
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MPUFV(T412HI\6JB(T'.?7D:NF)/!.JAVB1<Z8%\AX=,)?TH@2 AB+:_=D8C
MY0J0XO!;<58T(VZA0"0_<^7($F_ZH:.!33VZL1?K]RR4$>'3%5:<+&QQ'F+&
M 4*4RTZ4LZFSD4Z#1SNO$L/<P"R%F/-7X'V48)'IT\<$;(J81Y1BL3K!1+RX
MWF6K6A=EQX/'S(O(4AKF%+F^FH0A'7'%,!JZLL_'JV$$/4RI(B:)@D>,%'Q0
M%"_OA1K7B%"!>ID-3R5H7#AB!,7%2YA>"P@2] .>"I8V_UJ2V^%ON#&?B"P[
M=9W12U"E&.]NE;/<X/7_+<05]Z]*+,]EIL[S1?$K0A_.$_7#BK%I- F7<J8S
MZJ5 )RB4KS"EPBF%[BC]$PUK!^D&YP@=+8<+4UGSK<W(U<4:>E_T%A[L!%P,
M%PI/CR<U$"X(Y#".:E%G#V.[=/7"++RJ\5H-PTGJ]C 6-9WZLE:#1\#XK$YT
MAY>"E6F,HX3SJ>=T1,N6+$&MBKBT(-12]+1S@2FIPK,7Q53)XKQV64DZ4S05
MW]1+'I8-><Q!K"C5*%68?(,J+S[/>Y:<^(KVCX5Q[DO;4+_'("IN0H^F!MR(
M+,]7E>3A/:D&1Z^&LWJSF'+CD:]E8=)3/;I+"4$VQ*+)+VQP4'W>0G'3LJ!C
M?B.\1L075=R-P^Q%V2@=9X'*A2Z#)R[$#M?<@_(06F=AOL2BNZ+E)60;H7!"
MBF\Q<A(IUM2#H[!D8Y)M*-,9(.C\] G\U@D.E@1;19,NTA#6*\[IW@^BP#\%
MNR D*U9_<;UM(#?.T*2;H6.'7T*EK7PH69N]6#6YQ&.3+7AY&)J,6)4-[W?P
M6]<=$(]SLNJ1.^ M2YVA^#9,HARB22NKZSV*9-,0\6(ED22(<A<PDTH#CB1J
M-C?)U';)-7%/A4PXY690T%F-RYW"K>;GUIWK.@EEJX)Y:?PQK[2C3H0%#T6]
MG_#EN:. +%!ZYQ&;1S1KF;\W.-LRUN'RDAD*4G"[C\Q!.;W.E]"^#+LI*M#_
M)*F>,\YI])BHZF2.4&B07.O70')')%I0VQ1/>?U:*"\+2R&O4M_70D%=',V=
M(&_=!8%,(-T\X(&&G%;128<7X>M903<)'2=R[]I[I1%N(#QZS8RYJOI_.FU?
M6,H'SZ6E<W:3W(4U#?(;=A='RJ%BV>L:#SR'L7=9M<A-Q@S8"U&T6<P(=%>;
M$B9BD1*4L (-O0#J3K$.6<P6K!U:M4Z.?\YQQ8PP;Y PU_'>6BO1=2)H8EV9
MQ81$[:I0L,07$25-PM4O6FO<7A0-N$7AKO56I 7W0TYKET_!2D[Q9*Q&F/BS
MF:A^YF7EHEX38PO<Z)9A7:E\_%#98?H:-9VAKYR:DN2 TXWD3F4 'YR9.&.E
MX=1KI<U+QGY^$Y2Y";U_PANA\KN-DK1!"%I71ABM@I"2G$VI$K&#K9-&NC/J
M!J"FP:-"][D8TB <T$IZ49EV8;XX!BY$9_MWO=F]\G(" >#Q<ARBZ: \"+@<
M(/NAV.C%OU,Z^:XHH=6>>=10-!7!TW95$EUO= C;64AT C@TPVVJA:ZWP:%9
MI>^._%@4ACX)W"X>A.1)GF72F>?Z?0DQRO/LSCB5X"EY]7PYE907X)8:8&E8
M1!:,03-,.>Q'(E$\J-JA))]U@BW._L.+15Y4B7!L@.CTWV[^G^?DGG0O$<TV
MXQ\VP"13#@+GJ3;;8NL2 Y0JSKVPE&8 N1QQAZK#Q$SR:(2^8+$A64Q.AWN%
MB6BU@6LS<BL=%>V+4_]/@?3)$\Y"4,B 7SDW0@;;DX]WI+H1,;\RGX27+&0J
M9('4XIL+ 5+9%\5[H> ;B"G_2,7]#[$SS=&;A.,;B&_"QZX<%)C7GXF.J@?N
M6<N"]RG21&$$4>DCE2+B&$%>(1-FZL:Y=)4+J;90Q7 JVX*'X0#0!32L1Z9V
MH\IG??Z\P.=[MY]DJY:1B_7+1;49K1:)8O2F3^)!$D0((1P/)A!8$VKS02\4
M[/X 9!@:S&+4%9T[+.G+A85*?N;WE./%M-I/@G'CTWQMG"$1P4*8&D5!4B\+
M><&M3"TG:0G9+R\7'?MQ@GT MO@IRE+K]<=/'^_>J,K1#T%^XFE-%-"3;RC%
M8^P\J?H\*O$C?+S &46QC;U6V9@:W/"Y6-@]88XG:@A'X-\C]"MQ_9(*H;SE
MAQ<(T2QCBNU+ N1O5-695&R"$DDHCTUI&VA@Z>H"Y:T$UCLD+[P@K&(D:G@3
M4SET\ ,KMP'UDMJ'%M7XB4(ABFUA>:_[G\Q/.'?GL?9"HV/!BV-@G/"264K1
M/D211T72<E:.2W?(VPH*\Q,3; KV<N 7[>%\6+(VP?C<^B6_MS+MRA?X^L#.
M1)2ZRY'FI5H9K=T:90U]610Q5=Z[-$Y9,RTW627"9OH@V$<X%3(OIB31@M^8
MY1T!<O:A@\XO)ZY0!Q6/6T[0A178>KA2U?NF);H\271/475DZV]+AB)^@4K%
M5-D['Q.2UX+'- Z5@TR]Y^(<7T@?'\IM=%O#[1@A/CE>K:QNU2*PN!*=(_%B
MK@,*]>\B#+ IT;BYK'4ID!(:CW&"*J&*<^X[MWZ=Y38O:+5$J\9:7""JW#&E
MBBJ[-7)V*K]F<1R>?$M!+VQ?L'C9/BEDFRKA\UX"JXC$IV'[(GFS>%?F^K?\
MB6YQ]KBF1O/)G:+]F+/=NCB+Y$DN?JD8;F%2.<*?$$!1L=(8GT.O\Q+]?!\C
M)=+Y?>"$Z4WH?8"-F>53LXV#4<NXI"A\. MHC/+R^JK=DVT+K=UDMTRR-#=T
M)3^WSD=;0@9J=$IY 3*/Z/'J5%3#U!2&8$W82HG=7:HO3XL[@:Y;]6<5,BG)
ML=S-PN *<L\9OJCPK'+;)!>I8"!@/73@CYD"1:;C0)U;=*<)#@E3<"\!X6&A
M_J%F*NUR?ZP"Z: :Z'N(D86MIC$\670O+8U(+Q62O](S/N.L'\H ;2\N-R@H
MVZZ^X.*ZP_USM?Y'KJ_R/C=MK'196;PPR+\DY]8K'Y:MD[C\%CO(XFZ8M2(J
M;CN&D2^(7D:DYAHTF/%RN#"74;LS!SVH&H]XW2W/8U_UMJ_^L73.XD7%G$6^
M]R^\__%<3$,!%[=@<X6S=)*FA3"5B!80>F=:6KS7N;"M7G\(_PP&;\H[7#WU
M<B%?+8$QSBB?OR-;8^G<RD(VFY[8J$F6Z(UEJ'.2:)Q2/R_/[,8>_E*T+M;-
M#17<+^74IN-&Y:$!'REE].9D6SW%SC9#2U?=11]F2J4&;U^M;A5<JB!5A[>F
M*7>G&W^7NZ&>Q[^9)?A62U_JW?S[?,;H!H0^EDWY94F<?D5_BM3N/_IEW7AV
MHB1P?BPCP:!,@ATRY_YDH9%R+W= *RUD(]T.>[35+GS2-F'+X_WJ'U='>8B-
M07,HJ%MPJ^&GN!0G,&?]L&==;8/^S):<=7.*7UZ?G<6A3XE\PD#W?^#/1F$?
M^!"K78!G?A1[T+PS#/]@5*NJ)'?AR:MZ'AK9I=&JGHQ>Q_1DM!3<]7J;=HUN
M9XW E$4G(),^A:D3TI34PZ)MK&^<'/;VDBQ>JO(K&.>H\J!Y)1&5%LIM%2GE
ME[9SK"HXJ% L&XOHIARP;F>K$];=HB.*&'EE#[,[85X6L+OQ1Q\,"H9VRL+!
M/%#"\63SXRLK<Y#NG%W!H.*5& LGB/?(XP9Q&$Y]LKA6#D23#?32+MDG+[+F
MF^?&^="X<G9\57KWR+*S)N&*LJ[_TZHT:K>[/(^J7[;JQQ>X\L.7>/+23Q%;
MFQMUQ%S;NHJK[K)P+]@RV*3POU_U7JV[K]A3_JL>?.S8%O[O3?DK<F<T7A%_
M$0J?BA +;FRELGNQ/;#2&OE?@1%:$ FC^&\'?(4;(#FP3HUOP/U^SAV?_?'S
M$K;K^=?$Q8\^H@;F%B,82FPLG(G 35L#:LO-4!E(&^]POOOO.NUES$R/HZVP
MBM_-_^7\.XIO$3.%[B7%GI ]%6GNA1'Q7A:C-?7J']VK\X4J !-1;\?Y?Z]#
MW- A:6TX_<"G7Z?\5R)\+6>_=WZ<V31C(1RJ%% BKU!I.;823?R9$1*'$1*2
M^%]UVM<B)SKGG:.4$T8"O-Q&8(\L //4LU+F3D(0M@_&13B0D2!)_UU1OCY;
M8;A_-Z&0M->?LYOH_(IQ<36=+96]DL.S5+0<+$." <'P.N^]Q9%STYGCQ[S#
MC<" </)#;,%%..=#S1[SQQ8"XZ8T;DMKYG7]V,VF.++"I0\\V*E4#%53W?Y3
MY!!LX.8/6QSAPZ>!J>^7WFO$X:-HEI9C_2=SD)LYS%#A[9U@GOB)Z% G7))"
M;S%'A<-QDG@C1!L7F$@S)]:GL;E.'-.SZ$I]K%S>Y*V_OH)$22H>2LUWI:<J
M;!%"K*>.:3G:DM]YY=5%$!:\BT430^!X8&<\W-Q/M.EY<!8%_#BUD4N0$@2-
M\EU_YH02 ED,@90073@0L P8(V:$<(!B HU:1E=:&T5T@WEATJ <*[GX&FIP
MM-XECQWH16K#@E"<<-P< 5^E&$=CAQ2!%."!=VX::=C+27IN?1IOS!W4X0G,
M'-+CRIRAHPS0\W/D"QK J,9I"H@R[?6P0UZB&^!S_*DOZ%R<GY4C9@1!Y#K:
M=XHORR&[@.\%_G0E3>#<Q@\LQPKBJ2\68NZM&J3:SA&JX8?AB\9B?07^<F)W
M(C00OM%-Z,DVC&^B+<BTS]=? "'W @2-VBJ#80C'?T84^Y,TG<#DH^+O'^(7
M!?;'P0?AI H*JN^?93A 5=$W!S\1B"H<PT0C.\CV!S['*K^*X:@@G)@:COV'
MC,-QX*^>!$Q%X4>2 5/HL"!7/05M.([A%S_Z"D:0S_DE,R$1L*<"<9&K%SVW
MSA7,^K9SKD8(?-4F0P3'L-( %OA3S(3T*:E2->-)D5J\"!^^A--,0<9R)$(^
MA4Q^452.A)C/GD2Q-! >,M]S:,@6'T"*@U\92MO0B6F.)V'2S":.7+*-ZDHB
M3";<WL&)@$AMG JK@+O/K5OUDEZ^.>)U<7P,6S]9);]#60[^$H.&:,[HF.Z5
M?3GH/V]\S/,7>>#9,=T+N]N]?N;X&(7N) $3=&"( M##RYGC)K_UC7;G!K%+
MW^Y=7NR:7;9?]J$9J&=WAXO++@\!NJF"_7@"+GL!:;1;=G=9T[8CPBRARWX7
MW+W.%WQH3K"[_>'.^7^3-0^U-0\/O.9>I^+,/]O;6#D[ZU3#-]\7(A"D?&0A
MA9UW&MH5E94+ T<"#1&+JID]Q-X#7],JP&1QS"$,PXBP$'JR&- 3$Y5]Z3*[
M<AYX(>Z39 \/Z&]S*\V:1=@<@#/.-><38?@(0YM ^RD(1(XXS7;&)ZOHD;#V
MRE3 &Z!MR ,1_.T"MNB$BPA!:4 KV>(B;(++*;KCW#/F<Z8%PA[A%.+ ZH47
M04.V K^.UH-LP!04+(51.'4I%/?H^ $'32Q,(54 BGKU:\*->3B;.%T>XP%P
MWSPR5,:A=9UD8HVQ>%5A*O(SE%:%JCP!"IP*</,P(DY!> YB'PO/'0XCM=[]
M\JTP*XL&Y/#A6+88N5C@01TOBC977OS$YRP$L$M@G0.#('JB,IITL%X)X+<8
MN("%KY&>G]1%=^-RZ)I'M8GOFR<\+X85AJ<N.E=(3MQF%4K2D=IW"+U.L)8Q
M2WT1F4.'5 0 9Y6 :;9X.I]F).0,BKN(HI_CE?;R2B U(:VFT:/T CD(*!__
M;//O$R_)$6X/"$**D)FPEC*-Q#KI/CE!VJ-MM)@AC_#;0LQCH+\@Y9^MR+FP
MX=LAHL>P/17G6X0VRQ,2UBD_B5M>T';$<.L0/DV?9K/[-+NF3_.49V=UNUOU
MBJUK__H4WL<1PGG+5,--Z&G9AB.$S]_B3#81C_=&PE7#Z\_XUJ :H+T1XU_S
M2'>[D@K%[.,F]'G]Z?[K?SG3V=OW;Q;@P"DA.ZJ854"VDJL%JLDX<J4_09C^
MB>86+NW9D\UWQ9("' T0%-Y2I-1QG$8.>"]] /BC\H%X3L/!X2)WF")=^SU;
MSV D!8#^/-%2*"G2+4<)XX]YW,J<!;AOQ>PQ-W@4T=7,;SYS+B4T7*UH K9
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MBQTF:(&H'0CO&"GL>/,E9.S1@RL<!7,\;IYUN;>,&XZ=D 8%,^>:[HB>F3>
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M^4'01P02-AR!Q*\@A1/<EQA;7]WCI5#N)K[ORHG$'Q.6"'?@5%@!EG(2FEP
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MQ8Q!% 3,&TR-,+ \[FK?]QA,_6)+_^F%YZ",OK$P!V3TD7;^6F[\8[+OU?&
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M[_TGUWE.P8G+/Z<Q:I$17T<.\/$ V,()_0"$LY^ F@<,1&# "?P<V>49S*$
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MG(010./=Q^_OC0E>,6 ^A?PX(</0"7BH"HG%:CY'@6^C7QO,_]X9%8$Q'H*
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MQH"=PK=#V#3R-2:^K#\&5R!NK;04<CCP43D0-@WN'U=,6&+\[YB%=ONRV!#
MI (@?&S44NW>)& #*Z((3( @5!:69Z,&A@_0-6,JN1"A ESVRWD2IALH[1<'
MC&[IZBL',?)D8"B<2B1$DBFP4\(QO/OK]M-%X]( IK#9&$2*A,X1*388;%%=
M'V#@I(_3$H[X'@>.[H8+.:*7<$3]4@"3GS-'"#2RB>78Z7T QSFP\_NP-",2
M^(82A$$V>?Z8\J7 VLLD#(-6$:8G@C;\HL 1J/$-K+P8SV%%.^^<#O]EHP#'
M+S:M=.1CQ<B'RA0]R\C'G*+!"5KS80Y6A%+4#.90Z7<J0 XVPQPKGL= 1<#_
MB# DW3_LTB-O%F:CZ]+>@>D09.%,#)*!O'()7HA.1^1:AAV &>51$'-F#A/P
M7>/L;)!=\H;! E+!*JUG9I -*W1/]F]H\1!2"OT"4[/94RB@55+XAY\_WCXB
M%,YJ=R%4)T]%]^)[ L5IZ$<!C<H&$28I*XG,8R_+HVIY9H%[?U9]@X"GYE_9
M9)E#F<9ITY8(%ENWDJH7\%MMI<L=\0;0<L XKSZUV6#,H(#UKPMA*R?<!C:4
M:NHD>#?^R.&J$6+A_&A4.9SXOB$/3/I1=2Y$N;\S!%)R@@#RY+1H "XQFUX(
MDU-];6889<&E2"!*>K+M1Z8&%Z?=,CS86/'RZ809W(=?4+5SL#(3>%%0Q,BG
M3VSJPS^)^X\G*VT9I,G+X7&&'<!FY@(4%KW6!BP!X7<(O RS6B]@_NQ5U"4I
MTM'\Z#8!>$P$O;*R8 ;.:G:G>>8+N&%XP/%8*GI)1(5IZFXRN8N,;S3I!C?^
M[4S.Z6V*U^&\#1"2G,!AY:V29;2Z]0OD08P;4\QO(GK3P D7XOZ5S$K<E:P8
MEU)8H)9@JTAQGVLF??L&]/R"=RL)$$] ,&6!NJ"0B.LFLW)2^@:G,0(K!I^&
MH_3.>B],X^+IO7M*?0SRWY(F-OYZPVPL]#=N(@^$15R<(BZJ80IWH(<\M)>$
MKM"]Z(^G4+U5UX7JI]&+?G^5YD8!/0[$P,N+4_)%^6M4\#?AB$3"#/@>F^<K
M!C,;_>Z;WQM_;\HPYENR"=X-4E(V941\CZ6Y ?XU)CEA_%&J\$R6$ 8QI/%%
MD]EUA>%:D?"/0?H=5"T:AQ9RG] W$AJD@QCITM(]5"2NW+JP42LL2%RBG6>,
MQ;R6IJ=3"3!D%F)/5S0 \!)R@&#I9",G97\QS*KR*N./,@Z!2*49NKX?S*_V
M+:@-Q"\@^>?RQS8W)NOS245J5U=N.E_ )[_E;:&5=&^%8%#R\G$-8=IZLU0U
MEI5.OX['L7*DC^9K8]\"HLYO N2*'EQ;;WVY_7CWO6#WUR/0D5N?#<(D:WY
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M<5DS;G.UDDL+5-57;KV!/U:H(OE[GVV@_O=-X/S%4>>R %5$@+K(BDZ4+5+
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MY>[50\7^BKH,M]CW@)_$];9Q;V%@PIF(9=.Q(65BO/M\_YU^DL:+^I5X\U_
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M3F*#-45V/V$I-<< VI&8>@#ZN^(J]<SD4LNLEUX>O)+M<_:U:=7 &SF'->H
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M&78UFJ&^JS[UNVJ-9E@E-,-Y'BTJL@,4Q(#Q<< [:9T%6G79HE/2*Y22O@E
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MT'Q2:3[YH62D%)'B&SP(2=WNC9,.G:RW6UG[W>$_C6' &%T&Z*-3\M%!\MX
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MI"D^5GME UPI51>0JA)-\;$R&,FH]EH*57FF^$!1VZ4')DI3?!V&=@&&&DZ
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M,/"E1Y?R RX^!?FCX!E,G$.3QV1]/-A&SA"&;Q0EW@+9]U8].%XY]V'.@4M
M@;"C::X],0%?:J_IU8!D(!G84[B0) :"<RVQP_!T1%EKBJ1\!2,3C$#>2")T
M;##/#JAAIF_@[-(LSB(F$S;3[4:JRX2W0\!".(!'>EI(3,;.OR+=%V UO>EK
M;-Z',I)NS9)^Z,Y>*6#0VV MHS\CO_XG/\(1\0O;S?+=35PN/#&UOV-B^/9&
MYZ+UYALK1TJGO1=_[6;"=RY1=^A4?G UV^.^!>^CZ>FPRP#_7KY)35X[*[6/
M1X?OXYUUZTO:]:K:(B%OWC.//_$3W,GP&.2E  >BZ;^D1EIH  =US6,'%(&/
M<G :V65;/(@8OWL-7_J8^/Q7&.G!"?W\#P[#*[ 5+]?6]^0+@K$R&FT6P%0N
MM]@<FMB>NMBQHF8YE_%XNMQRS^_9>NIRA\JHM\E:/&P14"_X I@+ ?Y;X/4?
MH?\)$ LX:[[SPXGC3;S)70P/;V<QF7S->N"6!?=X%]?BN'-HB]L"5YE_(U\!
M5WF!;N4'K[*75==OWPL_1]Z"<&^$)@C "9_M!&/=9CX< S-3:QPA8;"Y0K/?
M?(+]M>/"DGTCTVX;,Z<*('+N =DXL, (B@Q^YFE)V%IA^[FU54[I7+-@_<A>
M1-X[5.(66 ="D9*?.SZ%!R=QO07/O[4_L$>%\B1.R&@_ZQ9LS^E0%"D*/BI[
MP\WR:&FA51AE;&=AVJ'YN%W^5L*6<7FXWO=OJS$!,&UA^NA/P&Z7O&_Z([5U
MH..I]L2Q_2S5;E?:$UGV1*=%$NQAHJ$G&72427$Z'8\P+XXC(_L]CL<[FCY;
MQC-1U>J;'_]"6:O/;1>WC3#&+$X#D[4@G9DZG+8P2M15==6BE_O# :TN*:A@
MA3S1N:E;8:-?P+/FDGD@ W8OD8CK8<-GQ)"%SXWNP,)GKP_$^[32U# N7< W
MXL$)7KIYQ&7><A:FTB4+H-#<0YTXXJ!AW;^R2_\QJ;AV/+^@[K[UCOA,M[CE
M'-.!N!NM;?<X@H5K-DLPL%=VFQWM[#;;OTRWV1R&/2-C4':;K6[[4MEMME+L
MDMUF9<+P-EFZ38-,ABJ:F"J\"JF.@*MX]Q\=9:"6W@)$RH(0UT,=I=\IO=J1
MK&DFL&:_GSNN_Q[M^H1J_[\"Z/9R*C(S<CP -016\-W1J.PM+<5!'!W?[9<N
M#K($A)AEFYJPQFH4@!"#5DU8H_0\U J?\OXQS?8Z"(Q%L=M@Z?!#BD"Y/H;1
M2+:)$0YQ"%*-J1&+K 8&%818C5CDUB)DJ6@+'7"-RU8^QY6]Q/,+JP?LC,\8
M' KQMH9G#$J*SA H%H/5\E@+QCC4W1Q>[/8R B00V2</>99__^;W_WMCZU9@
M4&__;M@RPK9Z #S!_]*V@E"6 695,JE+!#JQDE>X^?$5'M&N(,#0YT1CV;\8
M\PY?L]:#=B^Q3>L26G8?+)<62WH&2XSEDLTLYQG(RT%A5/T#T-][]BXBP"?,
M=4]4%0M#$-.!:#(.3<:AR3@T&=@DX] DNV0<FO0&[Y<ES.<$-IAA#6.6X8OY
MO@Q5Q^5RDG7(G-EZAD3<[,*D7K'-'@7Q):8#E^ZT5Y;@)*)ON3\HW;$HY4$@
M1W.WMYG"*8:C60:SB7 \?,=IO'=F[['$6ECCVYEBTAL_'.A+6.D-3X_U8\&9
M J%YO>]&'@N,>+>S/SW*BL7?AG2[L3^%5/OLN&E5$;7%>17O[%"5WEB>'544
MFA(/F+[25C>KRY1QP*S<D!OE!#9>R'9Y"5.;?%]IZ;H5)Q^OEY=+G"1;+K::
M4YU\5PUR04L=KZID'%IZO-O]H>97#UDX&;\."R&'/O^H+G*ZI&^JF$#2XN;W
M, F#G1<[B$9)?3)1&MA^#',45N^OUVX)2P !DY@CB]T\1/U?O#FE?BN[%@&6
MO.'M<2:VD>CT]P6[)M&""A,<4*9E^.;W6T:-U*)2US";%RY:.O$_XSBIU@7,
MX?L5R"6O:]AU37_G=<WP,M<U WE=(_W_-;NND8R2%S72$W=2P0#NC&NB6RWM
M_5CSEXA3*%+M*>/!9JW(@M,V\\GSK!"7"_9PJ7VED_N=VB&Z6P;BEQV1W(A%
M7ES?U(-,C5AD,8A28L7<L6+"Q\<*>7>N0L^+A(_QY5GHA!4(/P)\S+OJ5%/A
MXQ%<+AH_*B.U5P)\E*9_G=3YZM9( (U>3F&A+1O^6TP9@31[3U';>>?XEZ;:
MJ\?NHE5\3^FK>8=92A=!!2KG-&&-HCL(Q*!2$]8HW0,5P9.\ M2.)!X!0*0H
M!J- J'&@M >U08T5X&_1,'&@=#OR)DG>'M1TD:(#14'(U(A%2@=EK0#EO]D\
MJ %TAT/V,=GE;AUELIAST^:-[03 F1?V7F4WZ4MCD8AZ$TZ\[Q'MV)M8*EW-
M X0FD,=[C^J_&H&+/'CS^[#560]BKRBFK#HO#P:<6WDY:K4OR$MIU%=)!\,G
M=*SF04 \,_.S&Z!^#[(%U_;LQY!NWX%L86?[_)T ZSWK;[Y]/K1K?;^5?U3
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M;0>) Q/.;9WMFHW@1CP'^4$<FA\LA 3/WA;Y'K^^;E0F50&H'[KWQC'$,9_
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MIP$+\:X*2<W"2#1^)/#S.THW]P*7 <DE:$R,6PA=VIKI\N(O<9P6FP)(E<7
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M^,(KO.41"GC)(!^ISF2$[X.NJA \KO"G.F:@ &6*T!=LQ0,KP*_3V8SJ/)8
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M@2/Z+4QU%BBI)FO@%*N!N\)IX*;U:9T^>;]&OK)/FFL#D;P/S'W"&NY0SW]
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M8GF97!G<\-EQ829V6/)1?R7F K[:7)=M2(_KD!S,W.4?C%RV/-\GW_:\9>L
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M] <D=JEN4<UEGI Y:L676 'R9&!Y_LOSO]GG?XE%'-9.A6W@0T?BSH"\/BL
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MWU'4;J.B9(5C:OY*MC=61NW23U,)E2NOBV]L7[,?32R+P'T9S4;)*W)P^Q=
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M!XTRJJK9,4522%)(4NA$E?\OS0KHD1K_7+?7R;K\5)S8564G!;D%)84DA2I
MH<+4> .UL PQJ[8]_]'TN.L)-T98.=.T RPI^^7+-;E]MM=22>JB%*3:E!22
M%)(4*IM">ZXMUSL;?Z0Z')8>_>PZBZ3N]K9=&_POOW<HQ@[-+?Q"Z8[S]A.6
M=WTI-Y>DD*@4$DG[%'DC?E@015=M5/Q]$\ZXW.(F\C:]T^>3O $7U6+^_]E[
MU^:VD61M\/M&['] >*;?L"-@-2_B1?;L1-"2W:UY;4LKJ?O=\\D! D41TR#
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M$6?M"ISJLM+@%Z1M(<I4YES?,*6ADT*EIT \-HL9!8?^B@[]4U!K_VAT#B\
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MY4#QY5COM)8_)2EPXT8\)0S/0AP8(WX(M 3(2 "52D^!>*SZQ[]K=NK-(Y4
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M)TXF/,'[#>B ;W^IY?CA=[>4R$VG6W2ROFYR<F*R_'8T!L[E"=LA\PA2)@Y
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MX&9T+EU'6"</XO=WFV_/#HR[W85J'0&=YNL8T>89BY8>U+\&#W=*3CSR6 ;
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MX*T0Y;-[W/U1K\D]3O_^\>E/>)]H61C&Z2 D:J=4_HP!@5E>4+YZFHQ9'B>
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MJ8,0[YGO;M[1K;7/\"9]%( _&#&\-?THU-6+(#BJE;[G1D-INUM<S8)Z@4G
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M1JU^Q1EIVNA-F?UCRAT<%>GME][CIW>R!"OWP3_&% PH_/S@3-_7&V9.B/0
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MK(OND*,5HD\3Y5\E.SSM.G?F"20!%#TG"BT3CK9J$:";'[I1#HS"AWGQ?V2
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M"OWW02(0_ QYSRO"Y#2Q9,ROG@W+'KKLA='-)TS)!CZQ7)^ZCF$2 UU+._"
M%XSIF7$8_)O9,)B%.52>A_\;@9R*#* BBV(4@?!KS\),N3A(]0W\#B';H@M#
M(<\>5YYX.!W4@,D8Y[7B=ORP/LR/;]9/=Y2,^*-1&#]8\.(BU4:[E>O=T&U(
M#EMD+T*,Y5<>[74MIH4W'NT#(4A7Z,*"KI)G;BS6C>F(RXG6+TM" .*99L[]
M!1K3JCU%M[HX4K?1:"\>*N\JA-OEZVK>!2]>=#G-;YO+MNHK9<-76VK=]6.>
MV?SEIM<;@\1_L;R[P357*?=" :@#+9C<ITGA:4!+Q%T@9VW M U+S)N^^N/B
M\8* '%EHNYCGY49QZ/8I!XNNVU-]*=0;_4I^!MXG<#?/?\3G0X,GDAC_2GR6
MR0YL?#3F+)L90T;A-]L#-4<FW!!9]F?*G?P:4PMG+9RU<-;">=:D9 S?]9W%
MCVBN/P$U61S=P3;WGH8A8_\#0N6>A6[@B,N[.Y\=1%8W:HME]8@OPO!9++R.
MF*\C*WA'6)+#A8OT.XP 5@H".\:U&A-8+*7E!@Y6>N"0L%]S<KF%-SIH^Z([
M$\5:2FLIK:7TD4OI/X[!_=]45C^]!H>QJS>2U4J$:#_B&H-76F1KD:U%]E&+
M[&H+ZR]!F 8^KK\]7J/D I;M^<X#<T?])(PHC J/52$2LM2ZALG)6,@U9=%R
M0?V-RMQ"(6S_ES4:?Q2?N8[QR$)>_&:+A9/4#=6E9Z1]*N%!5D=CF-; Q=)L
MO&*(>*="8Z[1%0KWRXL]B/)3 BZP/"_@X2<9P4\K0,8A[!A>1XU#YKDC.#0A
M+T",DC[>[J"%!$\"/_)"0WA^1(]@:>J"T>(A;"@\ -(B!H4-FP[#>K &ASY5
MKH24:ZC,_9AIO ;A7\A\HI83:V9CF 65Z5E1A'[>%$4!?IA8GO$<!,ZKZWD7
M1L^V0;/ [[V):5C.OQ-9KCVR)D:?\;I(>#_^G#+T:"G*N"H^ 'R<C'#N\"=H
M4)P?O,SU^=$2MWD\=(A/]8.$FQX#RQ:CV6YH)Z,HQDK.B).'_>0=.H69HE32
M& Y09^URF@=F!\\^TO86$USH"/5H';)\%Z2/@J;4XXO9O:/J&I4V#<Y]T^ZC
MW!:!"0 +P90CSCP*XTU3)E/>DILB*YP7[DX^(54N23RR0B6;R*HGV#WV$\2/
MX,D^DRW.<+)T"V;]1!8?!Q&+5I7^K%U7TUB[D*W=R"]DJUY5D:X3PCJARU]V
MS%Y9W7EUM_&/Y\>ZTN44DN2_I%*=\DH.E6Y8;IV+3B+4280GGP=^#FNL# RP
M5BLK4*76\PP^[#6EO0R)4XU!==W'T==]8,FQ:=A8>,S@T(!)1D$1'J7#?";R
M@?'[16!$K47A\IEW?9S^Z.KB<OSSS3_?6N_FD=_.HAAR >+C?.0&7><U8C<"
M59,_B5N*__]YNI\4;I:[B=]5L*2R:=8OJVIEGJ-VKYZLPA!N@M(I9#8#UH:S
M<7:28XEO68ST>$AI.XO#4 4A<6G6&U7M4*3-GN,1)8BK[,=!.-$"I  !DE*S
M@A*C8S;K)]P#7LN"G67!O8 TG'8*%M=,XJ)1BXBB;0Q!\<\_Q\R/,!>&-S^D
M[RHH0NKF56XG@1,1(=KHV)N@"<9 -IY,@]$6*IK6XJ4 \2))>X^YPO#$9TG=
M"HJ3=D>'.;286.:;S*2U:0E1B(\BJ5I%$Z/;J3">G+8QCD=XW(TIN<1_QJ8E
MT=E*D*(O6%*R?D6J/N"[[P9_1*RR/DO3;-</WIQ6FQE5EA04ZCA3^5"&A4$$
M_1[XMAKJJ*!HJ#<;IRL8M*&Q[\O8L36A!']JA3;?2_.$1<O;O29WJ%\(VM]S
MTL.OYGND5U'PU,W+6JM@V?/FG^]T=N9QB(R[S.7*6<N($J]8E"^(X!44! VS
MUB@ZV+$O.: -C+U*"RTE"I824P?E" 3%I7G5/(B@T&5%NJQ(EQ7ILB*^B=]9
M/ LZ<,+*:(^ZB%7Q?KY[9;:NJIHRJ!635DQ'HY@TWD)5--C#'-1-">5\_0.4
M\Y6+X/";(%8%M53#;#:+CJ5J)74J38_.8I%+.CMIW-8*P685@-MZN3XF:ZEU
MZAJN=6?  41 BF("\R/8 4)#G,4?@"\WQW7=_N8$7B^2QL4$*JGP\^KC\Y :
M8/1Q !. ?_8GHCM7.&((X?KO('3CB1&\^O!/(+)LP+:8WD7?9E<>AZ">FXE+
M:*,!XEV&P:OQZL9#@C#UJ?,/2+#8C1/>S$<V21/PD$C:L35!TUL VMHIU=%%
MZ0,E\!\<2Q4H/+;\"2)@OKA!$GD393-7G(C/-+<;_G@%"7MI-FKS9509NDK:
M1; P2< +XSYT\?-@%LW33 DYM!#Z'>004(G&6\S+-T#Q6]BO,,'RD.\)+O]N
M\#6P_-E#7V\(>M4(@ZUQE4\[A[E?V;/E?893$$\(]/G>FMA#9O]U'P8Q1^^$
MOYY#:W3=>_C\V+-CE>K9">417$QN2O):2O%:AN+O(V8CU5]!%T?,?_//^#68
M)[B'PP&9<+4^GQYG:"2OG+HQG;LA)F^\I0?N[]_!_$#7T_/701CXUHL+BS%Z
MKF,:#\QSV8#$TF=X03 "?G]D8(&@W(&E&V^)"/CG.\-R1JZ/J+?A5%916ZU5
M8,YSG3O7Z>4I#(&=3;IN02;=(JO )E:>L0LV YW>8$U[ GQ\WVK/X.*J6[S
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M6EO<Y;6@.IQ%[5I%-IFQ80!HRS7MQ[3\\K[5F6V@FOF?!:AG9);/+H2-,LY
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M: 3"WX"ATY%-95!4*U*GH*X2&JH4-<+84_!9O.N.W@-?I?J$#YFQ):J@6"C
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MP[^MT+C_UI,7J8,@ <Z9N96I@_1A?^&(JK29CY40[="?H+P#F=XSJ]*(,HH
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MCI%M<JJ_%0L0X8AXR[R,T:]4$\V?96$<GA77*><P7MN[^>+^9(ZZHL-PVMH
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MS(6NMNN:&14;7\HH C7>[17>:2&XMA#,M5:8MN+7;GP@@WL>5/H]PEMF9!7
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MG H=>NH*_"5 O](X=($!MH]R]^AJ#-R_T]"CCE&OMS7F[ ?FE%%TZLK]^XF
MY1&>;>.H?I0W!NKCT%G73FO\S/I>V'-XB?U7!5GD?C@T"P*L2BQ28X3&"(T1
M&B,T1FB,T!BA,6)C1Z/PQX1)?2*#2Q:7#DUI<6WF3# )J49G :C6;>8^=S=]
MCN&W]D'D@O'L '# 6J5+.$N#._%W$11?/GE.0JZ].N!V='0[Y.S<&XU-=\(>
MT3,@F#T'%<&P6-X#@Z<M+X2?^\PRQ9 -'.])U-A7S\?<<BQ:_@C/8P&P1\\!
M[,,$=)C1(W?@JL]A%'@R\!@,;H]P\$$8A'!].A@+AF9 ][I>P"P@8=-V:PQF
M*3A=[G,LGPYS[ZLY>3W!_4?$?83K3X[UR-";PIZ&W&7FHVD[]"/.JF?B!#PW
MGH"Z"]\5WTEO8P/3]B5 L.M<,%3H\60*YG,+&4(?7D0_*/!1WL')F:!Z[A@[
M82*<>J9CNA8\/>0<)V4'0WC,M"P_Y/WDD7F-G0]-]X'@GWP[+AK?^.#"+O>9
MF=@?_CSF+L#EO>U:WHA_B$;'2:4F(0+XA[Q"N!AOK H;RJV"1\<^!S (+.'V
MWO&$^,#DB#6VE 0DWG5F<7P1'\TBS^D(F^".TM=T%8ZX;UOS,1M*$&"E!.[/
M^'36(^,UEK@;,OYZV*ZOQ+M2;!P#2697@=<2L3(]/O!\C)5QGLR)(/<6#3F,
M'6I/=C\8XKSK[\Y8) !;.-]$Q8'&<<M@T9\/9P>_+,*%1JO6[.##J8G6VB<9
M<U67SY)RAI&@@6F:;.BC$_,?@6<=9(;NU,G]=T_< <@"JW\BB?SZBZD6R5[
MH/1N*SAT:L<VH$_R=@S;B2?ORVF:8>#-Q/70I8UAT$J:308\]DJ _SJC[#"[
M_Z^#>UC4'7<X.9Q_--NM3N>T63]0+3> [7:#F9NZ8V"D_?C6'XV#3]-:L+-]
M1F?UJ\5DMX $=X=)+T)G?N%K0*FY!%<WI14EU1/;!4%I.DZLJ"SJH0+RTB&Y
M!ZI&3Y7Y13$7U?F-U!F3C7VO%U4JE7A.JHUCA8X9=9P=>\@6X,7 %B=4\%3
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M"9$WJ#C3VW@SK$3\,(4O[R9/:/:M$4[< K"3P\W>=S\9<SF [=JC<"3O%7Y
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M?#7!Z$.*X&6PI*DDX%?>\T/35PRBT5 B5/)T5QYX3L>=C6N\O+FN,=E%B#T
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MGAC45JV4D@T$6D-4+RE"Y*X0X4A>VTGIE-;!IRZ;*9ZBY!]EY9V<82V4>$Y
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MO$B,S["R5ZU=/+NK@/VVU77[7VPGQ!XX;ZYAO!A0>V[HHZ8F*RH3=R9M4/"
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M;>H"!^,DRO(XN,BQ!F8D-] ^01<4R#>O1RH/J BQN:98=NSOSE3 E%2('=_
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M8;O]4 3^) T!D+4B[/VE7@:<B[L"-0J?/X2.E.>]"?!#_&2"0B("H&\)!P_
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MQ]!DMBOW!)&C-X&A! ]H0'QZ:/,!NQYS3 -Q']@7V%:!-WXW?W)_.JC/'VW
M9L]G(8QL!S@;TP&F;P:@BG/AA;X%M\+O^ -Y-&E\+QX9;@H=5:EE8+NF"[!Q
M&/Q,DW,M'A,W,_M_A2+@?7;Q^?+^2Y?9<JQH/;#9 QL0QG;L8 ( #U!822SB
M?06F.0QY8:$P"38._3' 3:!>TU<_PWQ[7AA$:\4'X-?I@@//H!7))>/ B17!
MK0;CIC7,P/':C.*9MA*6B^);#I1KP?)I0M>#>%4W!)EOGA#H=8X(_=X#+8V.
M_V&S^F^2UN3R3MHWS.XOEMJ;8L.-9A'Y\, #G'C"+9<;.\9R <B\Q (T]M6V
M222U7<L;<29-A>A;8#YS\9$MEV5JXLTWFXQRB+?;C R-8H*!!;QJ;/;Q6(.$
M 7Y7 ]/WE%E +U#ZJ#3RY14K]'V 'QE";XJR4)X#&,@QQP(N1Y_BGU*+3BMV
M;-&9A-3;6<K;H53P=N===+R0^7L3C+W%CI'I8ZM\UD-//Y,/)F/#5F$WG1<R
M^=@J;BVFD'YJV!+=)=Q$;Q]F?C! 9T!@]U\'[8.7!E;X+K\FXZ*F+K3T+9&#
M(D%'ZA=ZTT<93Y8Z%HVMT[>H6^L88LB'?<[9=[AO*-@%&"[].8==8?9/[USR
M[CO[>3?[5G7>T*PJAOTG="82+BWCUY[_RR>&"NV>\8<*[Y[+)5R:)]/MJ^OM
MVY?MT\2WS[NW6^)[BXS>4#K \J7(?(#Y<QG=(B"ITF7[/=+.C)719K%JL[E
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M4SDVFHV-X]#N5%"M7&Y N;SX.\0Z.8#2B,_:Z?BQJ^H6]>^&IL\_FX+WSQ/
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M,A9ETEA&)^MB:H@+FE]KATS!L*>0FN516V//7F!/(?71]L;5D&ICSPOQ'1M
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M08G[TP*[0G.CUW(C36^%I+=FWO1V+M.R(UK#(AFX=$UHFM!*16BMW D-[Q[
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MRSV8)7)0?@X%S% (H$,L8F.5U%>IJ:W*U)9[! LF%I?9':GCPZI,7KD'L%R
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M,M^?O*Y7,NHGPK\MJ3M$6[4AJ]OGUW?3NN/IW,W0PE!J\GTWEW+'DK?UP=T
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MH;363A!FW)4:WIZ14RVU/'RT951\M T\S5-V<^GP#5Z#:)(;_/+1N=-2URK
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M6,UZ"<9%R5@:F,:E6R+DV>14?$1H15-!SX/IZFYKO-4[(3;S%5FW-]\':B$
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M=L;CF&=YCI;!T3RN;6^G%78K0R4&8K?,"GAZ1NQ5@B2V!)DT5%,4A(4K<!>
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M\.K2.AHNMZ-%3@93YWL5U5H,1[7Z)248NR-2,^6C>_OYC2'POF_7^\Y-M]_
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M-%T_??@ *P3O>/'T>?3RV7?W\0X^I.\+]'?1\OB0QT7MXM:<XRA=ZCD-R Q
MM7LKZU5S++?.E;.W<K:'0NFJ-.0"\76 5S)E)2 :F"L^S&[;R>PGK7X;.2.F
M$G0LR#JFT3O#=(%"%! T0KNQ.G%4@4ZZH;U,KKOS/0D.,,S2 KMB'_=>'%B_
MO7+DDT%_X!&@$I^>/(,;1W&)CCWGN"=8D+.HLC4;$*7\[X+X7@5.:\6,+:,C
M1;/#WS%4+?!%RIL;&Y;H(%T#P8HRRL? F>[*<:226]GK@'_2%AGWY5E\>3('
MD4PPTH&E\G2NY5,;* 'Q!CG0, D_ CDYTD7&DBENU+HJEV 3^?Z2^"6NY2%V
MMV Z8-6_4' ^4L^0@S"&9@/SZ#3(4IH(553QA=9HY'_?7ZIIR[3%:>^<XMM:
M\^YM[%E^K(SI15@*+_2_)99@&J=+Y,9ID%%)-1W9H*Y?!#,L@][09(D:OAY&
MW$>_&MUQGGC?:_ V0%T>.3X#_6%!NCD7S+ARMN&BB46W+C/B+0:+VQ0&$^^R
MV.=LU6^Y)?[J&0N>BN+3//=-=F[=YJ\>YNZG"EK8^MXGE?Y0D270>'>;?HVQ
MWQ/5P+O0,I.4[;2!ZEAI9)L%NAJAAJPU+2^;S0YP;,.>PJ<8,&0';ONA].Q>
M$=8]/=DE5=BYXI->SWZ4&JG?#%K&+)&?X/A&4#*EH5AE"K1+KD3&HIDX@2T:
MZ3!V^7VFJ"YY;2Z70[)W+Y.]WQV2O8?:VIX\?E2J/6,R.#;,_Y8-VWZ8EFRI
M>)1..+.!,1WMR>P<+(65AIGY+EHX71M,CB108%?+A[8\3_2.4Z.'E]AC\[>>
MG9R]%,%"7XM"V63O][%,^KE[=?]88C4O*OZVB(ML19TM?K"0(TX\.MG&3A*2
M. :ON >&+2'C=QA"WJZ6YSO&T_13A.<R]?RM !VAD+48&3/5;+Z@=9(KKRV0
MRN%C-73#WB_A?<LXDT9$IOO%G#'K X$0^B(R+#H)$7CG0L-2NH3$N*KM3^/D
M2A(S6TR2$(VQ(!RQ@C,%"RXV&3;?*+2XN.XLQ89+9( PJ3*_TB5Q2,.\<<U3
MI1U17AW*.OEK86FRW.00R8=U[NH0W884>S,Y=*<\=7AFC^" /S]Y8:(I9""!
MPY<6CGR.+VU2(B/*PY5SLH+YJ,-V(#:6?5$L1XG0!_23_W,]=?]#-24?JO+K
M#9?;X>3^#O^F_%E;'^Z3N[E//-4N6DHT>U\'=_+606W5S6T'-#1E3SA*/%VG
M.<Q-7<",D/[;$@CKV2AW.@L5AIHZ2HL%U"0)')\(^5E35#3UR,\9!^ R<IMQ
M!327#94Y4?)P3^C0#2"]G)5K;+L[UNS6DFGX=!Y>U[:EV2*?.Q^_^?;G-[^@
M2]G9E-K9$Q8D<]MI;3I*17H9Y\O Y8ETTLXY3EH+@I,<]&3I]%[3H7CK*@#S
MP4%QW%)QH( V6=.BW$C 6;!G2N'BT*UTSUQ:$"B>VRU>8/]D[[H+=59%(XNL
M!=?:=/(.6IITD19I%>=:\<'Q=@<J,H^++U6[;A8<4T;CI\#_AEDYX*QHML+5
M S%L5T[LU^MX7934!](VZS6U!B#43(&,A6Y(8J&<&20Z'/&5<>8W"I/1B51M
MSD<1^TQ>4#$71<*)US5;N&8RSN"/MF"*#)ADEBX=Y4JQ5EIB)"A/4"YW81S\
M+!OP3O<8]$US(UFQGH&P1^4WNZ0!)XVL.ML/VAWLFKNR:\@^#I.>R)T&QS2K
M\)*]2CV/QD&V&;K3&(3H#XZ-RK<VXA%#6!$U)H1NG)SW90?^Z=[=OZ:I*6=U
M.RSP< LMLEF7B&Q$^^.AG(*-%DB'P#;C>X/R6T-KCU!W[,5#:+JTZB?=S&GP
M\TW6(NN5__7Z-EA;P.0FAE"Z0\O+[$3>,_K1L&%;E[FGNDZ[6'M[I""_VZ&"
MO', ^V]E\83SHDA4 +.2*#]&<>M^Y>/^Y!^U-N0;O#3'R+ZUVW"XB;[A)IK@
M(<MQ9_1L43:.:<M-*^*)-9;-%B6LXXAWC6&Z!LE"3@MM)+N2M0=/>!S[",K.
M]N&-I6<-7^5SCDV2![2$6T60W;"4O#^,AAB]<7J D$?%7??\Y*4&->'HM[EA
M?,E+Y)S(P8EJ3-U(!I(')E@J7:S=HHUI@!5F)L$OT"'!I2<VDN[+O<-#D*EE
MC!\?Z>[A_V(C-6'1+M'-6W/'R8;;$E0S4-67Q[Q"].\++ICAEC*Q,W1*-,2*
M?0-7+<_E7UR*4H)_6$5^70KZG(GEML I+^"'IJ/%L@//G]D4$*XL?4':C#0.
MGM_4<RLJ2.LA9''H5&-;*.<EQ*^@__B2H7_JP#H-0MHT;']7@(*95SC1&M9G
M+64C5C]AB_8,JV/$^\7),6G,=*@9%\)[[4 9TR9H8+%O67$Q/R4>6/OG[#@R
M'SPXW=G^&!A[43IG+CM#@^]''QU]6KFVNXC/)XO*.U_T>N7I7S"$*?_URR]O
MSOD___'I(W[#1GF<5YVCPU6U<$9_H9"/UP:6>S29]V)/0^K0Y@C='$&8]9<;
M%3L.')'[1U$>_"H(6YN+=02S^2VND_@_;LH, >]E4;A]:BQ^YH"BV4L4S<L#
MBN: HMFL>OU<##7$N'/']].3YZ8!BJ@.9)KN-LAR$T.833,4\$X@O99D&1I(
M=61\@4B0(G&.?T2>)C($(C^30Q:9+<P4]C'P:E=:$1)(.OWT]GRF)/.LG9<I
M]OC*(U; 8$Z6"Z[\PW,!NQ[JAFF X<1O5B&R0*T^T;Z2Q$C2JS0OUYRO@^WZ
M0K$W>$D\3[DL%.PT>&E;DW50)+G#5=]4)0XK7J:(5T^QUV[,F84\TR@X8:N+
M%OOM<4\2*4_5%J081IJ#I5I>9#@M6%5DR8.UN6Q7" @'.Q(O$ HMR@KBWUK,
M2A"M/WZ@]0ORX]G1/4?^_O'F\]\_U-W$/Z8<%M1"X K%A6SNMJ)3KQ_A9J\U
M@K9A>Y@%'4G)\P9SJ!79E1=5O,*2L7AQ&5E8_+U-E%Y.[_[( \.FB0:9VUV!
M4*X\6*2EO>+=AK;(>4=BS\?2/SP1>S ()XJ-51"Q.\*58>3#2/T(NZP<3>4C
M&\U^K\B'@24%2Q]).\F6=XXO5NM@A(DL<CG>4E^"#PJ=,HV!WC)2U4>!]2,E
M5%H KRYBC4&X,&0,N;#C(R.9'G?I5K+L">O6'D5_7^XP^OLQ79<5QDE^ B^Z
MH*:9!@0$?WV/9D"A+FV9[W7L%KEI*IY/9)C[X3^7W$+%:7]@4[>V'<.130JD
M3'Y;&[(:)9B@\R+@J:%>$_C5-"N.NTVSN<T$7I]M563U99^=PK,:+!6HZUWA
M[WT/;%9G^-;_@;L.?'=IQ1;-GIZ>O=HI0LWKJ=%)0%E 47@14',.(5=\4PJ[
MZDI'';AZ,P*G&=@FMD!&5H18>WIXO\6:KVS)S(7*S+)&!9!(4T$#7M*:&&GL
MW?L^B@C?%5)GGTK_>._:\7J,4!&04"M[-I^ D6H[UF_TO\W]]RFNYG&1UD]^
M_YJG-_31D52F$"Z*W?]CFW9PWVL=96S2V.92EV;5OOXJ%P[@JIOFL_@N1E;0
M-;/1%Z>5C&N'3-+=$]J0T +;/>]B/%R&FZ&M40PL?M:"FFM3JRLXUF>V"\U)
M$E>+T.7P1/<[G<-/7TI4-U 9I4F<TK\3;CA/M@AEO*VRDA_1O9F[(=M%5L$D
M,-V-5E^G O'&=H GIIS9*JMS[C.#/9Y" 5X#,7,'CZO*UA%K45&P-HAC-:AW
MW.*&?D6'<EA%G<P^#:LO;!K,!@[VI4$K/^TQ">&8E]Q>7 PO!]YG5G-AL'<D
M<&9^\+#+;"78(EE![S)^=OH4/WUU^ITY?[UC-<[P+J94;R),&& Z2(H=220W
M0U;? KNFIH5RY?P''!,<:1?!$IF20Z:>ICHR=H<*7D#K?S(7M;<Z>W6KSSDC
MNS3&B7,NG N;]YUS_,0*=>P<Z_*VG:'<Q*#J[YBP":;%^[@J)T^*+KE!Q6>.
MB]6^#1/JNHE!.LIK.'I4U!# [/U\?OZ!G\$HT%B)"\GXQYMR)MP7F'@1ZS\K
M$[;Q\:%'MJF6!(;1&E_$36KJ,YAO2SMV!_<$^T,Y60.<85O$L$E<_J_?HPC$
MVB0UQ ZZQ2)I:(,[EF+LP;XN.$"<&S$?L'C 3I8-STLYLYT488'F7BXC0JZ$
M;C'$G82-;L /? )&AN9 DS_:NJ'1'@L=&A7+Y,0=5RO .2AZD>".=>+(H!6
MA79]9(OM*1&GF26TZ[[C;#9"WH6J+-%P#N;?S4,YX47?Y]8%)I[E/7Z!/>67
M>7D=K/39;G3J#W>%NI%F<[*G?0"XE1:J.\I6GI#N@0ATJ=W<KLJB#C14D"@7
M=D<YL%#,R_*+'B[\^ Y6?4@*R;X(JP?.<VH72)OH_$;AK/PT%FE#-KRD&L;H
M,.\A0V-TWLZEW=LN7I<9R&<_K5)NS8&!S\PIP K?)H/:W@O6.JHQ)Q0$?0R_
M:XN>?>XZ34-<!V_3O$3ES%+W?^(52/7G$O1^.OOEEP\F#@.CS"YP^.1=D7^<
M^BO! 6&NZRN2FJNO\$?$G\$5#5D-QFG-MRL:&>N4+ V-1,HTXM#N[)&MLO!;
MH^G>:O/6AO:WH=>/^.Q,+*%B@:'6^@:N\149DAJ-D1CXC+*@5HK9-L?M1D\O
M29<J61_I9KW[7CW/XB=G+XZ6!KYS'WRX9R\2[R6!P,@A-;N7J=GO#ZG90VIV
M;U$QX+D?6XZO1"\RY%Y!E&?B=0='9&;%(2S359MM72?CN RJ8C4-V%XSX*^@
M[;$DPBQ1\NL67-8Z';0 (JF=%T+.YA*^#!8_W)B9N#-469E0(V*\AAU_%E%B
MZ/X(JHTNG+100@ U<OCN+KPVZ2G\+C<,1T)K(/Z)4$?V0?B4G6)"7\^I"R/3
MQHPIURL>W2<N[/8&46DM"%L:7C$I.Z.3-HE10FCJX*[[!AF]59#?M?BF:,UD
M1%EM33]&N5)%1F!W_6P^#@0$']2?82[@'DYECQ':1#\G+9$599BV8/6=EO7(
MXF!ZXJ&C9"DK+ 2=,O24([7;>_O=Y?5;4%)/TG;&(/;CP:&=\6B8C-O@+!W:
M5AH;0^-YQCS[&N>EC"J7$UY1[&R0=N$6%AE)#0:1[#:S O%#_%[T\?GI\^&P
MHW%Z5V7-,H>HAJS&=/]_P*[$.DE.7?P:5XM+B6>2F?GTC':!\QMV"1 4P,X2
M;8/VJ:.\'T>3S>J<P$/-L@9"LM)"F_5I: G)[2XKISP8_T \?.AV]&+VS&!P
M]-60T"()_D5!84L8 MJZH/8*4GT4ZQ2IN09[ ;>2U2@C3_"'G )<.Y#?[E;6
MPWLY8K[3^;MQ1KFL8&;(H>P1;^KX(M6Q5U@>ZPFK1]B'%4SE30K?N+XT&6UW
M 6# W6"F6>O)0BK1-,S!<*]Z7=6;R"PDZWN<%';Z\_99]S2B/!O"#$Q&89 J
M;XA?9_\8P!\*O)L<C^1((LH_AI)<PSC^ H.TLN)?P"M#^OWNSQEZHM<,)7O"
M^9?AUWCI#8_)$L$;!BP#'WJ#8-=93B]I3+1-(G2>4R7+1YU5Z6VU@"^L[ &[
MKE!_T"<EH=?L+6?#(9$]$TZ,Q![\BF69KT:T'PAD9\TIQ%S!;9@0?$PT#OUA
M.LI>/]E^KIPDLAIA\AOM2FCJB T"NP+NQ+4318@S8T(-@9^&W2AN!:@/.'Y5
MD=[82C:ULB>\KJ-?976F-P")1%Y1$\+/A$>3)=*O:.ETM8QFZ)-R_G^9)>V"
MECII&8*H/ ;V"5TDUKAT\#)EE1MUUP1B9,W R!4'^.6%%M'VKU!YL+UH&T-X
M9O3PFTOD-["(H-_U[%?RT3N3S?P]J!;V3WLCR6LP.J=7&/)[&@70P<?>>4P+
MXW&BQRF$)NL$ZWM/X;/AV!DEL#?'@UU!RNJ.-3N>"<6/A&@\#!>15S,&9/9S
M7LX1A9:2*_DK08/O'5C+[]Z6,&.'XKL\WK:/O-/ 1]"IU,%:3CZ9F,@\*S0J
M#@,MWC-8I9:R<NKTG+\/&97-!<7V!+8>14I6OKY,8?.IB)FM8BWOZ<2WWZ,[
M]NST&:( 09H^FO3Q?8#\_SEZF/9*;![*9KTXGJ92;'LOC[<#H3B&+I$YZS3N
M0O\M W+LRZ5V_T"8P)C%X@$\E))L$T0LJR<8S(3:$NP IKZ+BQ(G@T^JP)Q(
MKQF(<H66%QMW^W=+/I2\7&ZMW4B78:6SA%^=1E+:VAZ>=;-.;<\+L',K;O$X
M!]%J4;]9HE*JL<&K*76Z9G"K+(29RR.0-(W-).'LAS\<:TL5BEK-!S/1MJ^.
MXG,2+ CHH")$_XGF"X3.&)?O_"(41W,;MKO,7<YB6<\]&XZH3<98R3-^Q5#4
M1PY%&;-39O0)9^2&;]W1P&O:JK(/*M%/88+!MF(<T;RM,V[M5U!8D,!L#LJ)
M3OT:^8/499,XC:^#I@XR-$K<YVE5"E?I/94I=/$@[O H_7JH5=W?A.BK0T+T
MD!#=VUO8K>]R]7&_)+[O&KIY,[*ITHNRR1Q*RBZ+5R]%.,Y)NW<-2;[?94.2
M>:VQJ#>2MWU#_L;>5F,]E!T9:ZQ\ZSM?W1$%ME'6@O(WQ.-"Z=%HQFY>9+QF
MMP(#7.,%ASF8T\:I<-["<*@U.LXFPUU5->Z/:""DW_1JW&J+IK1G4B.Q'Q:?
MAM DL[S5[I>#@,Q-)JK+X1/0H'<>E'CS^_^^?POVA6SSKR UF*8XGFXKBRN\
MO1-&41!D9.'C(C3@G-5<"E^F*8.2[Q&'[_!6&MGG%H0=#CPIK/9:7F(KQ%0N
M$G0PI$TL-V^-J$<I_7_ZGZ_R__E_KO1_Y*]?N2+NZ*NFFF%XCX(J[ RTX]2;
M8F?7Z*L=7J-8RYRC"PX*&/L=( :*]<)'<6M_Y937OMZJ>+T] E&$73>BV-72
M;VTRYI,4< MQ7\KP.,PG% ,-]C"YL+&U7=2C7=%WO_\P4_:2C\0 024D\%>G
M3W)28N)H5L2KU.=8.9X=@1^5<XHNEW#@CDJOO=%VJ3%L (? A3%UCD]7/[@=
M:-+9'VV5U4EFX%XNISN3@YBI=BML&UL['/KZK&A7<^Q*M3_GZ %IV#YOA%WD
M5B!]*436%M.N-X FPU\NN5J)*T"\')L-Y%'MG2T7B0PCCBD,Q>AAK*R*M-LN
M/G29ID35@1:QSXW"$(ER22?PNJR^:#"?&M8RJ!"L@>:))Q\.&=)RF27Q5<8I
MP59BKUB["2\'(YMQMI'4X13I=8<SZ9AK?CFQRP@F9PG-,0]> U@*V/(*+OB]
M)C.V+_PDDV2GI]5Z0D3M(ZBU0RW)6"8\MWTBJ#MNF:<L9XU3R^FN=F3J3;FK
M+[9QIOP-*)UA@%SDI5LVC!97,T6L&G-'E"V)@TR@+=8Q&K,<,<*4D3L'[33,
MRZZUX7$"8BVB=X4V;S7/#-'/'W \*/YM2MMM9QHWH,XH'$P^_2'Q_(J)18?"
M)<2?5"M3CV0IIDKF6(7\>+/Z39@L8M<0M)2E8F6(D5MJCL^F-1=:K=1O-R'S
M">\@'1(J(V9!XS(P7@>_U8]3%XB^ M59QC(:NI8M'&98MD4X>N(0J?O';=2M
M'BU*(0W^8+9:Q9BC5)0(EPP'+I: QYQ.S[HT46]A*N3+A2E=9NOQ5<(>XZDB
MT$#3L4SI'J3)_GGQ#W6%+B9<H5V\5QB>YM^!HNY@OVJ+E+"-=ES-0L9@C=@G
MH?0B,()]&-U"[C7^_D,T6X+UR<8JLGZI"2KDOS96,,[W>Q #!Q.[/1K&*>PG
MT? 1!^N2%!.BW9B,A2LYX*[(M K716M*3 7?SN8-QK*7C)%CN5"CQOV5%8G#
M7CK=UR<=:8=+0#Z^9; O=B\ $^_K-@7I%2R,/%);,'!I0>003Z:1[1D0&9,6
MJ2V[-\('0T"9E&0P9L42+T%XPBJKB1=P#3+4I#XZ09CPZ8*; %(9+3R6I+6^
M..F^.0F^.F&86-BLQ@N0VP::4@:YY/?&K/XM8 )DM6,%F&7MBL0_=9FCL*$0
M;+@VK*((]<WB)SU)O?H45^+UWX=L__YF^Y^>'K+]X]G^X(6'RSD=![!IZ>!O
M#R8"V\C^SL$+VTW]5D"&66!?'V@K)I1_N#K:WL7C02.LAY O?$X7EP66 ]U0
M^(1*2;^ND4,EU$<(SR_!0X_-;5MW;]LZ<CK=U$*P(BYSO>F6UKOY>.QN=IUN
M+O\8\+.WF?V(%SY.E+=-N,+42A$-.D5CN/"'^*_'RC/UCJ4Z!EE"(2%W5U$"
MV;T^4*,KZ=DW4PN/)L3U3-RB*/TZ;/(\O+_88I9HPO1XP+U)AC(C8L(UEUF5
MR!2G1:8F;O.<R.E8^GKFF-I1W45F0G<N<4_Z6T#AMWZ$2PB3M*XN\H5"?DMB
M3.O'1$W>ZK''V+6$]0D3O+U!4^"!KH8'K&K9*/U%&13(:ZH (8@-G83>ZM?M
M&HOYHMFR+1+A=:_+MA*&?-C_C($[EG3SPI!N<@/03)2P^4);(,%Z3=$^2O>A
M[2_RM(B3=)4ML-4Q=6OF&/E]E,L49?$$9'&9-2)!6"V)-?XB,AOQ)XNVAFW!
M06M6=!*J93*8Y% #,[4&QB1AMPSDPU,$KLG.[@6V>=2 9*TAKF"*NY2[+P$A
M@"=1#"PF2CNO*_>\3+"L5K)X%Z">UY@JI!U?E]A_HZFHJ+^NRT5F>R5HQ:O[
MM$[&>+NY1N:ST'3Z<3T3?:/::=",O-)4VYG-6QZH>T^:*\$O2JQ,]$]C3CM?
MMT.0T"D0^MR)[Q&4(6A-7"G0C,K%*LSIY3<SAP(']-:Z%J8GY+BA8/QGVI9/
MZ:(BTIIK*@JBI![10^><Y\007L"T&X@T*B,0][44Z>W7T ^&*@4OA\F(Z\L2
M+&BA8^S]_W>X&&KV7):D'RJZ(X5:Q!)@F@:$/D0U'([D%&S!F2JJ#AU*B\06
MO:=9SXU)&*D?DM2@/:U;+%$ODP/S&,SP$R2 5\F%$QJ]T'TOZ!>E%B[%I:-S
MC(%'PECD-S)J7@)+1?SP8<TI=I4(#%-.\G/R&^,["C^0B]JW)F_7YR0OT#E!
M,V%R$F,HK<-F\:@'X0T0[?=EUB$7';D@;136,)#6["NJI>@E9U'=$[<^D@)+
M>]/0?7/4(:WU?N3)#7)8U+"<=#5+JP K?]HV=*:]0B<?F^/]NQ60@^:1 !.S
MZ<#$V9UA$F=(OV%,0<X=LU34'LR900>QYX73X1##+W'K-6WS)E0H)'V<FYX@
M8[[X#P-G>4!&A+-Z\)8;2Y]%O7ONWOD>[MPG>U\\^1'Q22(]OX@E[J,QN]!)
M,6%D]?H[[2X8;K.C2KK!& 8[<7>0RB(3)HC#D*:[W_VU:M2PV5.;X>A^W&4#
MVI#],9Z2+NF=NK]_/O']O6TVRZ_FF"^$:<OTQ]W18=HIJ!I.0/@0;QW%1G07
M01?G-THX,>C!*A^4'#C/0+XQ9]A#*#*X8*9<K10FCV^X^;OGQG+O)P>V-^4B
M8,LFTF2&\I%%#A!0,P;XND'3V],RRLT!?[SFV#:?/O":\^1D]F_I#T]34#R&
M29G<"O2HQQP_Z@&XQN(EP4C6(;O^\-GULT-V_<]=2W^7OLH6Q?5'?QPC7]/V
M3KI4!$_STN?#\9[M+*5^;]NAN%>7E8WO&AS]2#Z4OXZ1+E-#XG02>1LW,6IQ
MY8'^);ZN)T06QM#_C519"];,E%F;U;J?;(GB:47\;?@7T^XF8\3,CGA?+9#^
ML?&IA)GG,=606@<H&(ULJB5SI*:B%\P]Y5$V+N3*+XG52K*)<BVQA0\CH/V
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M]\+H]XF5]MD.\R6]"_;U[+UW>[^>_4XIR4/:))0VP:Y@Z"/V#!7G\K]UCF\
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MFOBFK4V22#[U"IAZ?!A>.3?@RF5;Q[EU9$#"X@O)+OPA%/?= 7!6QF(EOVU
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M)D].)"?:,2W!D,S#UDB!94M9.6(*@ 1DF8!2.6DEB86V.E(VQ9X39@!M[[C
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M3WG]%>&%9:5+M!XI2\VI5RFW?-NP:T%GD1D2,X#IDU59?L4>9(5AQ$9XQ#1
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MW;B>'27ITWV/AIO%PS!&8R[FQ0BF#1QAB-4X\&XTOC2$MN,(3F>JJR_S=+O
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M MAD"":3#;^*B@@)@)RLF/>'XUOV9D1ST_M@&4H%*F0!KO,X.B^Q<QME0:_
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M1A_^92\./_7O_?2T^\/G)Z?BJ;PM(5Y1KC*_Y;KU<$>JK_(R2PK&Y3<N_ S
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M=+9FQCR4E_F"-GYLF^KX$ UEAFUR,EEA8,+T8.R4Q)*/XG\U>F-L'PG8DP)
M4RMN^!/[]@XLICVT?!$0=#GG-X*QXES9+(X(8M:([4G1,":@3 JWX=QPXQ:?
MC>N'O9:;D B+LW<"'++X5[^ZA:9^::^*)XG -?$GYJF/Q.YK]PGR?]DWI'$%
M4.KB(@,*85;P-';\6^9T /7I(&4ZN3X1CF[N7XX4Q^^M.]1^Q=_[+6JQ5_/"
MY123W*%T3-%+69PU)*SYP+4KK%:891["N&<&)4-%\\/))XA74F(&XC&D]1:X
M]EZT7/U']P=M2LX8B[I$X<EF1KVPJB4Y1T6]R3<$5+A@!52S%_,B%2_"&@XP
MPQ9O(%LXM!&' LBL:Z?J6^7HQI55ZAJ-7-WI2,$&<*VXTM,\*;X"?^T"(RV=
M$HPU[S? 8[,;HN?+BYI=;A-9PN(IJWQ[V6XI(4I-F[Q9&+<NYQ9Q!+8S#=0Y
M81U7-]8<:%L+0P%UL0T^K7'A\FQIX?LY:SLN2O,X"5E;(*\&6#<ZH/A?EE_;
MK,2SL#'ULJ-JHT+O;Y9RQ*@(9I0K2>XQ)P.&C3TW3(37GXBD;"Z2HFDSW*-X
M'0_=%X-9A_ Q<(F]V%,W &_M(TS7,$PG)Z769-?,^AG;2\0*0-J'.B8]:B1(
M3:!8,H=3A811L=UN7B.)W(J@550$E(,$CQY[7_&!,J0&3;<+? 8FCF AYGJ1
M(X[!=VUD$P2DX<8J<7IG(N/2RE97<.PR79K9S3Y;+7C^T!:]JZ<[Y%\5-5O'
M6E>)"ML(3N 78]^O,D(*J+*&34R$C(R9:9 8Q76JH KDJAL'O:QL#H23G>]8
MUD&5"+QKC[?@WKU=#9OOUUY21>LY#LM%\03UF,:V)\5*\X!2R)8)\%!"<T^%
M250G=^N<='4RZH.[/:><+0[ELL;@7@)DH=19)@U(0H9++>5Q@RD47J*$&(@0
M3^6PV)_S4J%*W1H+Y!-2#+:T18!"SR%TOF>\#BM85O 20=3!L$[.<#J9?:[O
MMIF@HC_" @D)4[KC%S]2R5@W==W+V?P>MHJT(+:=UL,<*E:++Z$Y06=H#4WH
M%@.W6NEYL/$0)ILM:+;_^.@T-70$@HU+MUDX)S2]BM#+/5:$OB1?,^CQP\98
M"-#]>M!976\O!49)!8^%]2*X%N(B4P&JV.;'^PJ2>,3:\BAW>1.:C]/CTV=T
MGU@CQM^42462&ZR-N5H)ZYI3:4?P3AM[?/KTF3T*_O[V5Z)P9Q=8B6FJ= .V
M39LEOLF?;&3"N*)<V[!>$@BJKN.AW.T\_:'2%<:M?R>4NV;&? 5.^.UO677.
M1[:'F+^ 3?6AAJS>(AL.2?>W>W[:X^[YX]J$A/5%OJ;2 94&"7)K-E2Y^.KO
MIG?;2O82 !Q$6LMSKKN0:*/[AZ@G8D%KJ+PFC)KY7X@SNT1?<?G C-9=+Z+R
M5-29"RDU3&]5FYPR:9A;^[:X@(:41/Z$K('?LFH!2(45=88/W.E(97.:O1(*
M>#L[9IUISC]=E83PJ+:U)D>T^$$69P5-^TV"B:?:9J,' 20*\]AL<L*$9KE1
MB:Q%LLXW2'OG#1SFXVZL/%W#BLJ]Y9]M%-\4-M?/>]Q<'\Q (2(4R#8^LH[?
M<;"2^?!^%N &OO1E.32N._AFM$<QV";,J&UDH0\&^:MNHJ/]T!!^^-A@()0&
MG$_(V(YPB0\?FQ2)>\B=\O.YQ^A>)@=8PL/#$IX=8 D'6,)N(>Q=6HN6&3,6
MC"N34+/*ZTVH. E]?W6YRI ?VP-D*1&5.J9_6;&E5/"'LUZMSUO2/8:H30'M
MA?A;XY 9,UR<B^>)K\A89Q^NT= *\ZTY>XR+A$=%I55*48RM+$4:@\'A_.+V
M,GH8J^?F]]_ZM\)R,CXFN6QJ^&WYA=#&#FEN'$!J!_QHP: =&G>:L-5R!>N!
M::)8Q'^VCG[G& &;868SWS47DF0"@&%M.@[+ W9B]/E)H]>_W]6/2VJ[$<^>
MVLE%J/:/*I5,$#C>5;X@;6A/.(E1DO!@6T .H\;RDG)+9EL#JX!3T[._LA[1
M(?.G2K-]$XS #&E_M!D*$;OSX/S-E(-F=D[TYG=LUFG)Q8PEF!TSC9<F[@1=
M1!-C<[7*M>B3\B.A5;K[?6S]MK]B(;=,F_=,@S=-*>CNBP28T\DC_4-HKUVJ
M(_JYX>''$#G?FGU[AY,I#.P7]8>>&;!LP8A>X8&FM(@WUHPK;"EZ=HSRLCV^
MPT'6\=#JMGTPVT(DJX""H,:.+O47QWX8CW@G>LK6FUG[(ZME<Y%75E)^SROD
M8 %MP5Y9L$PUC#>[82EWC+UP%6?L%)V[<2#6-7->;A!+MUI%7RI@ZOP,?,20
MT@JD!L+VLDA=+<0>7QYK0(>IC27##2FPZXL2^ #&O![S'FWKK.Y\PTOSGZ"Z
M @_"3A<L-&YU<J3[B(K5?8E8K-VNS'&_&=, UFX+*I4T@O'-DG/R##$#FUUE
MJW(MY*<A)1-\7$0^%C0]9JL2]6$.;W%)>Q2>,]>F9RVF)ZEK$WOY_-/<Y=\W
MD>8]A.Y4Z'G\=P_]PI.LG5ZQZ]5>BUW?#@0 NRC=[^'8^-OAV. IR&=C'%\Z
M-\PSK&Y$[-'89VJPAD!HL< &"NS@_+9QTB,DGTL,81SSDNSDC(X5LS4^99MM
M5=3NG CI:7(_;K,*XF+ZR\C3D=871L:R4-?<P7>PBV#W5>"A*1Q4W<8\(2T"
MGO*V9BI>3"(/GL\2.U3L;/.92#\WTUF!N-N<@%C13;8QU[@AD/R@,VW,0VKN
M#T\)R('JRM-%K2#/E[J#F?MIL+*F6;Q'C%< Y__WL[-#U*[67<[<1N,&%((\
MBRQ5"Q&T-R@6)Z >2J_05D<W*"/3(&TW@=47O +VKLH%&LLS9(K,$D3O"FGM
M,7]'W?\L<<?!*9 B8<RF:2]BVW*!W>1IALS?U,RAY *@ADT:W/ +;+85F(34
MKR$2D^Z3(^05:.Y:!'*0H@*W(97VG=TX^&\_;H>36(-#YKH$!/%-96,IU3SN
M!+3H^(#FS3&#*C4^=G?-CTRLSY*!;"*.7'>;]HY)\IG4$]SM^M2'_VI;\FJ&
M='9L_59)O=&P$2*'PZRZHB!+,TVTPCL%SN#$J6="#NG/;977:4XS=XU9BV'^
M)FJ?(#= G^MP(C#S_1802)N;-8//1^ JD 4"W4N5SZ66!+@,+2/4!\*MZ^P%
M/(?W&$U#0,L/V@3Q<OJ5#QK7DZX,/S]4AG_LRO!?3)OY:@?Z/&QUF?O!%9V0
M66056Y":TW@46&YF<0K]:2H-6C,I9&V2;[@DUB;(+DEL&<]7(8 LES-S5S->
MQ*JWW'"QRVOFP1P?Z93!711_-\'ZX&88Y;/Z<729F5.%Q%\H\,0BV4)813O;
MAGQ&[[7Q!< =XN9_ZY\=82<]2[E5T!"RS3 J."\@A3[#,A^ZC/TWTAU0CD\0
M=P-&%P!3'&AS8O+!L*Z;<Y#PR"'Z:ZLO@[[J&EK_H*3((&$<11/&K%9$#Y4
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M&^&PA,\_B(6 DP*6--(N3 Y%=OITGTW?K/IEQO<7BT@X2XV[6%8^K.Q+B"_
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M:P4CQ=WS"<8U'\T.)A#;M6Q!E29K[,X9;4]O1W:ZA"4W"VOM)]OZVT'C/3P
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M+ZLQ7;"5N)N&?TM)@'J"? 6/E0B^L0!O!\!HL69@D*=9.:F0AD<B\'Q[)>>
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M+/(%7#*)JM($ <UG6Y<;RDSV/F4H5V&;?O2\-SH*I"E')*$Q Z*2E!"74)L
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M*+/O-C=D_ZYR<UB3';V4SH,DO4*D">^B29Y>ZO!JE%^M#:Y](VSKL'?^*C!
M-#EWM?UG-J5J\2]76=.VZO=>K2QN"]\33*(<9C.%UH4LH?F^%XI!.C/!O^M\
MJ5U3I5I6B:N8F:]@#I&NB&/=,.F8,]9WLO03 1"*0F\UKT2FF]YKF**U-T&L
M&:+ !VR/#+72.7]QV,$D #0.2)%!_INQT[5V?^2FOUCLX1EA#QN&0%%P2T4T
M+\9M ^\V25X5D/K]8YT79@B.'61LCR_-]^Q[9X?QN<WKR@U:;SNAU,]\YN=(
M$'.:Z=E2)2,Z!%5]GKF1N8!LR[ ;\[@F"LH>U$#/H6/.C)H[\=@+5HXO_,7Z
MQ #]0M@7GN]4.,_K>DN'#5?AS1/Q$>D\-L*U*((-LPB*6IV59F@K+Z_\=I74
M-=GD,QCG2WSR<O$5775LG!4L0;*R/=I_&E^E3G/&)?/;"!2 69>:SF;(]U].
MR_T?=^:(W:6C$A=<P>&</5AH(KSH2 T+CD1*H(=DI1$S@5RA5.-Z7+D>;Q&=
MWL[U\M##;0N@W[525[FQ!ABY7!D_,$O]AAA71V[4/5W:8=B&8G86#G\JK#1@
M]+I,UT4U^QUW4Q?KN*4FP!B.'1YPSDW,LD,8U)-=<J\H+"B^3X\ A96WMQ 4
MG56%8^$A(#)L+EU)$^*H$D;66$!SKE24KVF @E5IPL,1:XR^5\%%=!O4^.>9
MY'Z02ZRWIDM&Q-Z)[8F0D/EQ3$>/5IL1A5$(,BQF=M:KY-$QFSV7"M<'R(%M
M"+4 'L%M-05A@(<[]Q#L@/,A)W]R#=4>/KD]9#SVTUP@K@!*M^3<9PSVF6J:
M;.0YJ6-X4J0@$,=&&E/,(0DT,>S)KB"=+IM]D5>+[25$=-!+2 :"LMF4^8"8
M"5LTHV6RJG%B+O,:$*(V;/-PIS9/NS2K7GA\[-,E5V5.1KNTC&3+YJ^4 R\O
M) @ZWJGY@[J98Z<%!LV-%>-EG<U2'6D-2ZO: K3189_[M>N^:@3&C>];<A'N
M-YO=*OU2%E-.)(^<"FN'<H@2,$'>RNC%D<*K-5( ?*10W#\N[!_@E#IZ.VH.
M><8DR4$@J8ZI: 1MW9E+/&+?\?WSI21;" _N3LM5<NU[>,A08H8220SIN0]%
M[$D6L9\?BMB'(O9DD=JN8I 7UOCTFC8^93PGW\/LA3Y5X=PQ'%!"A64_',XJ
M-MU(%=F4'-^W0L>X@7^U6:*0L_M;EFW(D6IB"C&AP#V)W%[7UO9-QS^A]-9W
M/%S R=[UV7R$X(0RGM@8H)#BO^15O8G>V[ 8[ASOG Q"U#)6CZD2P1!;>X(R
MNMY\J^BI/W(. X$+G-QRV 55Z(?#?;LZI]D$1Y QW"THPW=?4;*'+E9&SSNJ
MW9.;KT""Y/3IZ_EJ:S[YBOF2TY/7X#/4 X^@[Q4(F)LYV,&L%./!S4\$UBPS
M3 5+#8M0*WWD!1'B0;F(K%KD1*1GGODJJS8J@/UCC2_W^J$Y5GXL[I]6?X27
ML#'S\.^MN>(20Y/4S,JVSK&L$LB..Q06^;UP,1-V1+5<)*=\)?C#QJ$^SXJ,
M0!]8(<)L4E9=Y;3FS"@N.NXS(0#TBST"H.4L\(]5/:/[>Q;.S3[,S6M]1)K]
M+@;@K>W:^R2\C9/7?U#%9P4BY$9..=TX>>ER,MP>XP/O NG41GK>9M3_J,Z3
M(O]/PD69=TQ#2;UJ=" $R73(W=D1M#ZE]'L<I5OHPL,FP'-P/+B8R@UK1(X-
MK"+UXB(SWP5#=>EO/.7>NL*-78/Z%#N"K_,I?5_YWQZ/EL:'W8)9+ A9+Z_O
MZ7ST+J;8==U()_"+*#41*'D3.-]RC\N&VWJ1K? LN<*\<N&R;HGKI(:,#K"N
M-IH;5*I-?1FKBO=#RC'/D0(O%LX)@B?<\+,O@_O)KWQ8'ED3K58(B0 <;5;4
M*@].E1'(F)O0_B; RF*O723@\7.G*W(3<96FPW%#S&X6 (U1SDER7I!Q3_\L
MMU4AB2O-+97[EHAZZWT]AYH!LJE%\+#CAX6Y:R1VTB$7T7@I*KPALQV/B0"X
M0Q:>ZEM.Y9]E<H7E?$:P]"\O[N;$-Y,)3'S836!G=14^P>/AL<(.-LHBJ@%K
M=SIVS&)_H+JY (YH>C\(JAS0EEPIZ[-[Z*9>TR[;N\XVF)X&Z0'J-X*])NQK
MUH'G)MX,.!FX=&LM*8\.;W>@EQQXHY!*G]DNV)J*5%V4G<4)Y@FG.&/7D8/*
M5.,"ED(KA&4/=9W^?B=4F=8"AA>163";-8":$3V!V_0NEX7.LQNWXT2>I:OD
MZU6#O)GI0?;PU4: MAH;SED*2_J7^J1_G9Q_0O(G]'Z-='J_MP0>@RU*CL B
MX#)?8I8,81V=PS#/G,=D[E!GTNP_YB9\V'HEH^32O!_5#Z'$>^0/E9^CLCSS
MMQB_F=_>W[/ZS#%]ZJH98\><BC2640=H D-P*B0O/WKFKI_8+ J^/\Q!6P,S
MM$?,%(MCQQD7M FY&0<X5G..A/N<NDH !^8*1\S^"/U$+-]4P3N#L;J940>-
M\$*:%_WWMJRVE_YN D885FMSP36M&?X(.I$&3Z0&)Z3^MG$UR"([7K.Z=%@M
MC15@=HS;6!]=8I9#6>&^NLYG/).MK^*=S+GKV;#GT.ZS'/,T7PONP)MK.*%J
M!XX8AXP +Y?X>H!_H]RXF<V1'J;V6])(J>>^?*3V^3'D-:7;RJ-<E=FV&U*Y
MA7HR@>2"1DG\P%UG-('C&XK975'C)'-W=$ =?>.MM<,Q&QVQ+N,\0X(I^\IP
M#8B)8D<(A41,X&B9YW%)5%@G:(I,(+N%_S1^@SFN:;.;_SP%^JC"3)(9C)40
M>*CY*X,:(8?R\,.7AU\<RL/]Y>%@<@Z&\U X?LC"L7=:K+<55(G0QBD+1;L;
M?+8W,Y<U6B)%$D4.QKH9@_E&_)UW9J5J'=K;X$9'^)$F[+KI#;L:I0]*&P9P
MZH'ONBI&K-C,G2DF&3\U>!+X"/>? TT[EH]^-X>QTW9(3Y_Z(]HD#AGO0%V#
M@VT6O0E3="X4JC>QY\(TM7*\<^K93)S2.&+.J03Z/*ZRQG-Z0<9[\Y-W)*EJ
M?OL?GB^W-O2B" 5Q ?QO[RR,&&A:!XQ474!FQ&4,O->//<)-2\=H+RX4AE"8
M'<BP>#%@,,W2R+*,S@\T /V\<(\!%_XG8TC].<6D?W]J^.A#Y[YJ].*K0L*(
M])[;% ,;P27N(7 R_\%4R#B4)ABG@4Z\%K'N,.K#!QMKMK51<&?S,\8#UX.(
MP#V:>JZ$'FAL>'T;/Q^'#]H"S'_;$D8A=Q;VV7'5')_+41NH[G<_COX)A?LF
M>ZHC\6;B5V=289.#D2DR^VVS=*#(, L,0"R1#.8!FL=)@)AP>*?'THDGJ]3V
M!R?GYR"B8*Y2;"_G)/8VD"C0FW;L'G4F6L(KA_-AQN)6?J<) !\5P]H$MGH=
M'=49O^;"G #_D?'EGVY$]X5?J1G\#=YW@M"D^4R;OD?1#/+"2KK$XW*P;;YE
M/R7A9QV.S3SDG$!N?K-@[!*I&&XRVZ<JF]:=Y [5G'V#M E0ZGKU2#]]H.KC
M&#^7$#_#?Z55<ATS^Z:BXQ3@RE$9%GL<_NF,*)#-HC$.!21&L.?.(?G@JQI:
M#IU5\>#H>:2?8X=\; NT)LVQ:I96QI(R#%@4)TN'QKUK@%)(_LPB-FR=2'N/
M)D;>RUY/I.XM?W3;4I.;FL G:28*ML "*Y@Z^DNSE1-,S>;&P\0M \>D,Z T
M" N.)QJLKJKQH$%,JFA4^SC5X=32[W7; Z@&]!0'0.*IIBHO9_ZAPZY'8J]$
MX\%LN43U37$]ADZA8)G(KFWP7?YDM]_J]_"*:JVE(_$-L1M*<(YIN9USM9)U
MJ;#;'J:!ECPZ;D6VW0!NS?ZUJ]XB9[(D1A=@^+R^=OV,':O>E3IP_\HQ#8I0
MEL58UQ@4IV]K#][I&)("L6,DXK*/[=>42J.U= #F'&$%>IMZ(,'>?*OTL"WW
MLRWQC+:TV #Y6>9MVO[PD3?!O/Z#/U0W)M<KWVUKJU;"F0.5YI*S2H3,K+*'
M7>8LAD&31;X$M=])(F6219<'GYSEM@*/(# Y_2F>,N04&YM1&JMU+D5_:\-D
M7H;]/] ZL9D^K,TN%DD=$IY!=@0Z)=JF<JAE<L?;!.Y@^XC1JQ:Z)@D"CE0S
M?IK5BRJ?,Q)'$H>YS2014QI*O,N*-><.YUN1G'-/V,I^8+$ +)&.CC-6X%$'
M"9PR*QW/?C6 A2#'O).&?-RE"B^]HE%25?#,4@3T%>BU*D32(Z>(#XO3@Y%*
M"RWU* ZY4W?(*7H(W;S%,4?8-?GB9'E>*T:^C7  \%K77?1*B9(=0>!R>P(_
M,>$:NEIU?IF;*(TD:XB+P?7OF*E0Z5B[DOHW-B!ZS/BH-G:H98$'=^4X/L-!
MH"+CMTGA(([^4%=^^+KRRT-=^<=N.[[+-.@.Y63HT+P;:.M=D,^$LF@0?!&U
MRB L2C?=#D24++5IF;-:*+1VR>\1''LOCT^.EB*K:2)WBV[2P^[K-R=>NFSB
M2O;]4SZ@IQ%UJ]HKA9E'L J,\R.1#610/!5>R8XS39\MQ-L=S<J+&&@,[D>U
MP\@&_,7VV-\FU';X4-J ^2Q@U"ULO?81ZG$G1#T$F!?8^@JA"0+^EP3^TG+-
M<C,7!_+>T@U:"I=9K=4Y\GF+Z=?*%Q'%2]Z+HIHW8KV2:K?147L]O8ILWE@J
M+.SHJ<994\]XF+WV6K86P._X$'X^ +)$"O94;JM&QENQJD.<UU/DP)1 6MLH
M<H0'U./32)>FM_Z[WFEG*=[A747Z#QZ?UMK_S!P\2ULW2;,E0FB W%4K'\+V
M:24H+/(+0US<0M\OT4NHH$EM$ G9C\YF&@;36F52*>+:)V. M._3@(,U=:"'
MU@<.;;#PHY=Q5IPGYTT;'U MM^+<YV;98P@"Q98ZIZ8GQ:7<\"#JLKUU@FM/
M8$^("V/41[/^T[434+M5FG-ZCH-&+XZ6JUWGE:?GH$9 9BJ0%57]TG,LZ-_%
M.0IGQ<[G)FY/>A_:[93)7&!VJ:FT@%%CV[%6Y77TI1L("BK8"WPDU<+BUOS5
MB/9%O[P]D'6+Y34XBI'H# N\ Q_.M@EQ&SB1SPP],K2D874WP! UWM4P[[C-
MZE;76,\ZFV3AAK;8DJPG0@P5\M7/)MH%QFK>E6J;;ICFICT*2WT'0(*:+SIN
MHK;9L]".1:';UMBY:'ME$""&-JH#W]@U!HB!Z]!.)^>,?\FN"ZY1XG&B*TB)
MGZ KT9&H98BU$YAVP/3SP_/==/&DR[(HC>LLP6V0 11*\C^KTLPAUBB@!^GD
MY&\O7D7KX\MC/./^_[+ZBD>>'#!U!D>I_TBY>8T4L#2>/OC $53P08-6]50E
M*NR;77)NR7%\C1X6VUO5&(J9A9<R9![>K(TN:G4!H&":==V;JF>/(*PE="&Z
M($*1 >N[61[D_H?F3CJ:;S>D7P/FS:)W,5>($\)>5UX$X/71YKH,>3<S(A 0
M^K?&>2[9PZ_D3\A)J<@X!E*$NT6![>A48VF=,I.\.PV,CFUTA\/C(2B'5<,^
MM$-\YZ0F08+EV6H9AX^^[O;7I*FV_6B&2X[3DJ"1;LFVO-\I<5H]5'(I?4S5
M"PE2*/T\MI*1BU@.!W;$_HXXE9C]K]BVM&G.^1A 'EOC&R T$1#"5]FJ7--X
MD #,W-E+%AU*JAR"H:[&$,_M5]U!U$F-#68%8\B_%N5U09U-GOH#F/TZRZBQ
M)02Q=-#(KOMRY&_OL-L-8EDV-82W2,YO[D'NP#7XMO?^!MQ )TV+J 4@7K'?
M,]3D(_)%/H@!%<.F:[-.Q9?ZX,U+>\$IFJXA>$'?N<AN?5[ MKD)B,*U19V(
MMV*S"2@^T>_5G-@E:2-N<?D[$YL'H,+# Q5^.@ 5?FR@PGYP"=AFW'8374[!
M2I&8WW[-@ DNIV/,'/;H!UR5J^UEUMFFQX!-5#UI@V^S#)H\H:Q#V7?S;X;"
M9UE:LUTS(UZ0G4,$57V1H9//2'KXO5F0YD6H_3@S_NTEMI/0^Z"65P'8^"Q!
MUO#:P?A<AL085608YS.:LE]X"6JO14,JLG,<VQ[E&[(S!)]D$&!9FI.-L<><
MK8'?D,]Z@TW<A&%<!I%? H*G,\7+_VT+K'>8P2$!]38]@,\.\!;82^@_A)3P
MQCHLDH9'>Z^\E3:ANLT;^1VIZ@0DV"G1='V7>Q3[SI%]R-8O.KRFA\6Q?H"5
M:EX8GN$]O'@3P(ILCK>J\,>*1>ZADM.PE#'?9]65O$=OO7WLM\O0W(_QSR=;
MR;79L=ZZH]<!<VD;G4;.LTU2,#BH58FU]!N6]0  QM(H,E3?Y%D8^3"0;LJ7
M-Q)_T)2P2PC&$+NP;'N\68=FNE\[*CG.\)%F<4?I[%X*7+#QL2&SC82AQ)E7
ME"CG5]1_2)4.16W@#^,NBYB+5,^E;].+XW2K6?>XW/]&;VWR'[P ]>RA"E!_
M9;-(ASP,$;ZW>(UN@JD@(G.,D3T]+1"$%SP =Y9B;HTWXN[8Q4@/2>2!)'(J
M58<[2R)3^N)QIY&GE"(^RH*YVA&G/<<7#9MN%<1-^+3*,X5["A(V/8)I?7E\
MXHKM/@Y&BI+$0JXXAL>K%HRDJ<$"+*EYP:6N2B$8PE[W'A+0 G'5F)GOR<2[
M5W&:5R;RR[,KOPPKQQGW5^9CY&'VN-:7N-9'OJRQZ1?YW&\:#+E9-/IYU1(_
M1M?[2/6@R6FA>13".FY>,MEQ&S0]F4\@B7'GN@LGS[,GIZ*X<%^W2)^\XCN8
M\?M@WLI,[<DIO/LGUUIWY_?][<D9WU6+?3F@@B<<!A%+76_)B^"D (C9Q]&J
M++_B3*[0>1*,B%(8'IY6G8ZYQT%VC24CWGB=T0'@=%XE*V:7X,:*E1'AA"QO
M4BZ7TX-!J$=LF?R=02,!KC]^:P95$/3DZZ&B&@^KW[+YZ-R#B2+))LO/T*#
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M!.T34IF,'FB_.LL.<J AI^$!U4 '56S>^$9$ZX!ZC:RW$P/M&]9;:H&B:P%
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ML$0O>303<#!U-')1\;5"$YV6 M0$@\\[3/K&^J)!]ZI^$N5?/>>)L]OTJ,(
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MIY')=APOM+6$)QX"XY5K+P.,1!SB(>X^QVH@[POVF_%YKJ!X7_M"%9&.&2-
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MU@I0[H[H[-8(H/ECJ+P@/VUDB<S8Z'9,ZS;9M;[W%^R+DZB)/E\NH=](U=<
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MXSLWC'$*3(,<LE1--"'2BA<ZSU*5E%'"1#ON!>/?I:4^<L=2-XNS8K)B[?9
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M80MTJ4Y5+;Y5@MT"'%L\3 MF#UNZ-G*DB%#10T7%W/)V6B3I9&Z8,MD!]LI
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M)IG<J&MWN-%6!_B(&9[ *GA]24)'KO*S>XN.&PZ*N]6C;LCF;6<4@-1IT53
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M+V'+U-PN;_%> ]^19ANPV&5->*YQ%J=395M;#OEVRR39R("->(6!=MJ$2.C
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MY"VSBPVC?A6GG1LEF!,]V@[<&M(D@A'T\4O&U$<@VI!+38K2L+PX;"LMA-K
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MX3YXNO_L^5-A*^ *'?/:WGEZ=9/S%/<5\5!C#-R8LC.92WAH.<GQY-EY"A%
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MN^/J3(8,3G"#%S.(^1%%46Z+=H ;G<@9$T66GS$+R1.C"JS/IN>>%S[N-C0
M]>]0(!C>A4I<''YOL!PN]9M4#DH6E04<')@?@[^%T"GU7G%-UK;?7=[40 M-
M\05H!2'X!4MG!OY,@X78/JW5,#)-'HP A5 K]>UUW!#C7&B]0W]7>F]E-A,
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M0E? 23R-@<O$O9 X=(&.9B_8IP7C6,8":?5,=X[-W"G&KF8J_EKQ V(N[&P
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M5B7RK'/,]ZC04Q [F)!S1'/PAR$&US816]KN/S&=,0-91,7;,WIBB)U(U&H
M#SS+H( 7;X.,^703+BH-N<P;M8#W""_\N/3,RE*>I3FUS^JQBH8>Y [T*:X
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M@6M?-@1B-HQZ&PL)^M=.&_P7@+HP-4J0BWIN:K*@0;;2M^,"2)1%9O^ST)>
M<?!M3M(=9NKO^F\\VTVU0;O]U4,&WA'IR=GUUZZ!<L(\U L;A)D WR@E%P9R
MSZT(M(]X(*\D!SRXSW^+"(F0D[T8T!I&KO8,5,AO^:5E0'-I"1F@# 0_VH+5
MQ49NV_^6,%N@L0N)LT/PXWWA-98=:U HU9: VDZD P1R!P\E^IHL864<VJT4
M0',+,$*O&XI?IU/5+AN]D=GHY[ML](^=C;Z7_:C/>$FY/XEE@:,)10W0/BY*
MIU![H-5V-E^A]20(%4<0R!T_H>]?#;8%W/C"Z:IS,YFZ4*3"GR=Z;-.<_!LQ
M"OS(M@A>-%GI0L[R#KI8*:N(G0*][5@!!FH/PE4Q:>4UWBZ$AC]<]C/LP_=)
MA9(IR!G:!3,\Z!SNRF.HMML@>_;G!R4J!\QHRV,[)-,O'?,FEN3I=-KD)N%A
MZI?LV7"ZQ^I_>G0&659<LW>F7;W*MW@3V.L)M46PC5%IK0E)R36P<XAA2?XZ
MF_NEL;+^<P[OPAM0O&%B&H-:6?C3KT^?1K/]Z;Y$M_2\4 [7M-N%+NYOI ;S
M;3P?.G6SF "W@%MO;CHOAFYOX>2TS' :+0JRB*H=O]5DIE,LUGWP:]L6]?I2
M_QQ-8_U6^%]M;BMPX;9]"C;$]_9=[C4/JC\,P.M"1\IL$<^KLSV/FAR1U@86
MY*ZL-#/!\U91F%?2#2FTW8656M >H"/;?-H%9BO8.]1&1I0TE"6!H-!L;J R
M-'8>#[7+G,YJ/1SS=HZH88X'I3W,I.(4QFC;@HX_LZYR:[P)P Z'"E:$I "O
M2^6TQ@%%FDK=MW/4)Y@LLNO."V.VSAYF"?!<,@> I$ F>G<HH0" NZ1:/<8E
MFL(8U@-<?89U'CX/!Z[1EB\1SLC>V)7>]K X(CS&,'D*1P%CZ.UE$@4X"(OR
MES^.''=;08K.^AS264S?;6V'.$G 7OSUYI;:S7ST%:VVFQE::XH? -C2Y:AK
M\^#^Z@47^B) =VSQ^B[S+VL$![])H9=*W53:@1LOP,K=.S'C.B?AQ:MG!]'Q
M5-O5>H.\*9I,7<6E]L7.FE2KXH.G[6:@CV5>WC;E93P=1A\QFWP4EX7^(HZ>
MO7KUM!V3>RQ3<EC76CW^WRK/M?*.3I4V2X?1T66J(/D'&!LP)S^A15"N>XJ.
MGX#A\NN]F1-?:1;V2YB%_QZ))+G(BE&<[6LUVA^IW6FK\)02A0Q9_]P5U;HL
M3@,>LE8&$10S[/373G_M]-=.?ZVJOR#Z#I+_,-?N)W0A8T*SPT2/H%CWO!RC
MSB)OL?N_]Z7*:CT1^TF,,V UV4Z'[738 TS8^[C68HJW>3R=O8[^%==?T[R*
MWK__O.[SN*8Y.7CVZB Z1 )+"6P>3E69CN/JD<Z(A3)__ MT^K/'JM4=%79T
M&9=0=G#:C+^^CC[$Y=?HC?IZJ=)ZW7-#:BQZ:#TVI@G9+_6$_'=V#0KL]8H:
M[.#Y?=$$]$W"0TR(^PP]N*_[(]H?/#D[[7Z[>*I30O;(E?>'M"KR]-OP,?N?
M![\\_QEO^[O>KU#^\SBGX5T,/ 4720S%M*:ZYW'.A:>D(3KZSM"%;TIT=#T:
M^DMR/5?E?T]);"S603OP\?K!QR]VX.,M A_?WFY;3;*$>9XVT8[;16EN.&'_
M+'*%"(YU*ZXUO?^SET^C/U6EH!JN5&KM'O9FA&&>_7SPY.#IBU>/=#8<,T^?
MCSPZW8_>**5-F]?1*11(1^]5E:?CM5O!ZS+V1C@9__T%9$<2SS$>$Y7CC&;%
M^_RVH8C[ N'_\H @_#, \7)-:0N)G\^Q?PJSB3'+=I<QF!"Y4#MQI4T&9.]H
M<K>05+CCM%8C8!]_X#$^.!1RS#-XJ2*\(?< ,W=,I>$FH4Z!!0TY.;#52VR:
M#IA" <L8L_QVA7XV$PIWWMQC<[,O8_M+T3?N6^U')UR$D!+I77(A]>HQ\PHB
M@>)TII#:W)L1?1 RK+,RA.?=,?'[+9C]<)VNU\N'1\)-X1"2*<Q_+A 3<9=X
ML^):(?(3>4JH>KT]LB$Q .J]:V'<T751)EAR,[LLXXIZ-V&O&0*-QDAEWK.)
MNN_.9E3W"]F0=*<VD;OI3JBG70]AG!45$ T"Q1?5! F=--8"N5R3JX\MV%\H
M6&0-;7&*:%HDB#M%>G2L3+["7QBF0TM5J;ZI<@S06;L2%T 23G4HJ6'](7BN
MM-I8M OL N#S;KX"X7GN61>D"8K'EZE^Q6&+V7]6Z-DW>Q8ZB!33=#QL-2.C
M>NRFG!45%2$N'_8&%5@=/'U X8YL/*J$=6^569UWV?1A9PI7%;%_"E;<J0,<
MS8%9'F'VRC)&8F<]O1+ZO(_KLM *EO@LIFD%*S\P)5FEWNK(NV''16>%&P_H
M8S!1B!=N[57H:@ L&\S2X_Q:,345.5*(<C>OT4:0$\H[!J&=7J!(!N(8N,;<
MH(Z_*J".NB#B$%,!*$X9O(845U;QU"$%HIX/ZMOX,LZY54 T::!TQ8S'*ZWT
MWL-C*1CT3+,SO:8HS;QBU4!P+V5.$N!X\,Z\UQ"-28NH=6"@/]HFG9>#AS2&
M1%-]MOQ8_KE9Q##I\J&5R F# BB)I['>#T3-5D"C#I'1).6->I?;>EP2[7X;
M^EFH!RR!7+!)!W!P&+W+7?!*^K6MOH!HV/@22E^-4ISJ_5T#C2&-&LX7U#FE
M$]NB<<BO(@0=^O&)^G<#)Y.+6[&V6(].JS-4Q#0\O5Y";$@/(\:QA!M8>MU"
MS(U@:GQ2'A!5:(I0 6B7$,Z;7*ZSI3<E.U#_4VL;X&*C#_596]*_UF]"*?<<
M U0IIM(&IS6M*"0:]%(V2)]>Q+$1M+S)N!!Y!+=PJ+/UE'\J$^HV;!;9HW0K
M1!73,T:5*J_P&V9@,5?*:.5EVJV)8[![OS0YF:32<\+8B0OFM67+F%T>&X8W
M(24V:]<>]Z*3 '7K(;8F_?_J0CE-%[UKF$N)*9!1XPC3<BGR&'FSA\8Z+K'N
M+[#+]=>6[=Q[RD1;;+"JKD30H[5+;:X,=20V>\ 0+IL] &UARSRM<,:U_5,;
M%F>W^"U%(DMAH&ZW;*<&+['3.M;<7CBS^07U&58E/W^KZN,.3,.V\"YQB5@=
MMFQJCIG65@2A[8R+Q.>,9]&L$S-APE(Y))=T='I7#4^.WB]T<-!@=L2/VZ6\
MTQ?WM@VD6Q(G*%2\O<K'5+Q9$J!NQVRXM"5'[==&6E8LQ=LAA2(:QPT[.2V>
M3K+A)@W2-.P9<I%II3)XDT0OQA@*=%>[@3Q^$6&FM<LVR2YZ]H!VT=NT C\9
MB,#.P&!HLC9MP[)Y>4"R9NRY8;5U8.PTA] T'<M(L<O6!9A!4(CL>I:&>1^V
M?YZ1<6'\D(I[J8NFQ!X6_H=:;,&I*SBF1#;XV?+?W2.)V.'I^<G1^^/H1"B^
M8N@!T.(CO^^'WZ^</_G3C6&ZS<8]@E82Q3+S9N+K539/V+-,Z')VH*%S@]Y+
MI1#_HC[EWN/&;;4V8' 3[) )FXA,>+E#)BQ&)@1U $SG#K/04EA18(K6M+%7
M$GPQ^#/@MW%LRY.H:-CV2+.]:Y^+U]B8X[*HJB=&.!(S+S2I&K3"P\3ZHL\)
M4#!ADX39C,D%<F3HG<1CSFI0$L.^0YQ51:2]MPS"[&2?SI 7!*W=X*CWHX^%
M([+)67-NR;9\6JNIC=!1#U$)0:RN14SS@:&T"8"L3JUMV@GI9G _.9I*X8Y$
M6#+L^X:' @V_@) XSLA-7W:UZW6B$VJ=0#L!EIA]P3M20+17_:XT0VGE/)(;
ME+6MM$YOE1R"4ST/9MZ[=F@X-.\F6FRGWJ6@%6^1 U=Z%&7"W_#>X$F]UG->
M%9!G=<G^X8*KM,A,U(A:(IS2]$M3 0FPT U!9$*#@S;:>7'^>LT]$!^VO=,Y
M4;K ].TL_Z#Q_1 QEI-U>A</\H+?[6(LVZ0/Y&&L,I2=SE]=YZ^\K#^NRN]_
MQ14T_K+YV2G\10I_$P*/SQ\P\.A9*I=Z_^*#D.3RNHQGM\"0%OF34P68FLK+
M[(HT?_#(NR6^5.JKGP#S^X10YZHAP+0(*L7]72?>ING[%6*!Z &E@F1?V4GU
M(A^U]XXK=L@"EL&T_S44TOI15+UJ)T1[X^XKO^]WWG[UB7$S 5J>,DIIQ3F:
M\)8@3>:*A4"*+G!?3D&[F9.;+5)M.)/WW?#X$/3H2&G9.+&2T !<Q#WS-C<:
M'K6A&%^XO8>MC"LF@('QW/8GI@8Y#8MVS@[O+>[J-@RU@AO<IKL;@1X(_32*
M0>=P5Y025KG5:4T99ME6$G]QLS5_*&!C^(3KVY%3%79[E)I./SH"B>JI(%-L
MWMG'L &RE("XJ3+[NH6N 9$2&YNM* /GIG5$$:R0,I+8LE"R?(,=?#B!YD1(
M*XQ<_"2S<&GTM^CR5M*HO7^9-TDWOWA0<"$:L.X>V[ADX)HBJ9"#?+?$: 6D
M(IB(K,)RF"&QQ*M?"5^H']8 -B!OIB,#1B35P0B9K"GCC"S@*R#1!<;E^#5^
M-XVK<0,#BBZ4PY7O_GRBIH!7(%A0KAH06G1Q]=J_H/<6]BFA>X@B\3YOW<6_
M0^N)%4+H&>4-OH&:H';7#A(@,4%(, I*04N-M';!Z@!R<:,P4Q4CQ@5!HDU%
MMXESB\NQM]J\WN7KVLH<4^NO($"SIJ&<SMB1"<:3EWH.N'8Z2B\:DO,QM15#
MAU,[>L#C["KPI(PGM:43]YN"H2-O;#SOJ:@: %:KQVE<K3"\=;>XXT%T6-%1
MZ,$G4LT&TZ[SD17"=3BOWC< ?7*_O-)F%&OY6KK,>@OIQ;88ICHADR&FWK\
MT-9FBL5BMW]%'-W*0,B] 4NW-^>.[O@ZU_,@Y1KGT]$\]&F:ASY%D\%]CF"\
MZ V[C7;HS3#NTC4Q":Y'O>XHTE&;F$0Z1OW@QQ>UC0/?4.45UQ=#^(?>%+K=
MQN4ROI0=P&"M (.?=@"#'YOZX"[UR/?P'SR0'DF6V[L4_7!"ZW$@ .I;AF)9
MD(]8*C"&29M &Y8FNT!7WD8VR Y>Z4%],AAR?6AA^+= ^=F]2VR\U80[H6^Z
MH;&G!M*[% 9OG&7.+F MB*@BRLQT9TK/!RN[>XY<,,:TK6+OZZG'WR[345H_
M\%,/\UQ]$SAMP+*ZMSGV@;SFR:7RNN 9H^2LFSGL-+*6&1Q&_%;XJ7E2U[;9
MQ0K^L3<98-.[%8_<_[%TH?[(4Q"+9]0O*]'F<5Q6FR>)UC7=%^3/UF(_C-E^
MH$:D*@8G)K!3<;XG6"7D($,FCIH@F$A2M&E\)+ 0."\]OI )F5KYS*0(*Y8)
M4HC?GD9[ N&IYFS6-9;_!5[6&7Z\Z 5H$SH@!$ZV8KH#FL"S0;!L^]V=-;\@
M6/K_=BU4^/>#=<P[1:X*KML#F]Q2#&"'.S@<T2B+\Z_N9/U_.Q#X9OIH;>*A
MG8_V(_MHWYFCV;@-*B7-[5KF$U(![4]/*&*.B=@.<PD%VBPYA._U3+!GM?1X
MC$?%E5HMNN2)ZMN)+KK%'<FN?T3_^__V?Y%=,%99-H/2]/SB?_WMZ=_P;[X]
M_LTC&150AHV/B<9-"3..Y^\N**N=?1O1<YZ,P9:;5?I*^9?YRGOWUW1<7CP%
M.PM?J@S,'=4:X-=)6ZX\0POM[W72\[T^+%<*@HQQ)@>1UFOASWY^96^K_[<,
MC6WUX^=(S#2OT@0DYE61)O:E]"SI><G_U]^>FQ5KCUKODM;NNM^DZ9N33W\>
M?SS_XRPZ^7BT[R.0-FY:XNBMRN+K&!E;R,3#7.^B@?)0\-#ZFT#4%)Y9?YN8
M$3W[V\*K'V)V%LQ(Q"+!RJ;]5R]Q>&_FOP:V?<\1D3-+?SYQ-/;3803_-VA?
MPN>'']?ZDHW8JLCP-42X+1T-OM&]#N7OU=^A7Q_UZMN(%?S;/S[&4W6#M;KA
M?/[M'YOVON=0U'^?+]S3@?'&4B(@E=8F S90<7SZZ^S\^#3Z<'SZF_[/V1]O
MACL-LM,@CT&#A)OE;<1RWK\ZV>B7OW?=\KE4,"H.-IZI<8G [)UNN6?=$KU_
M?_3C:!8,ERL+(IXCHVZ<WWR?[/3,3L]LIJC=Z9E[??M&OWVI!YPP"9_[XOI_
M(2;HAS''F8I++4[KR]?3^-L3E@$<J[Q).?X]Y;K6%'4^._GMX^'Y'Z?'T>?#
MWXZC\T_1X6^GQ\<?CC^>1X<?WT:?WQ]^C#Z]$U6SPR!N:OK@\,G//^_R6[O\
MUL9N4)?B#_@\=IFK7>9JE[FZ1R?QP\G9IX\G_[,+.^[<P4?A#OZSJ-3L,OJ\
M'[V%MJ$;L8[W[P=NYEL_4!*KTRAWYP;NW,#'[@;^LG,#M\ -7+1'[Y[E]@=I
MQ'O\/[^?O#G1(FE9>]U[G,*;".]-G,.CX]/SPY./T=OC=R<?3\Y//GT\6VDV
M[Y\;I5N0J/P&7,+ =*\D/%R$$1W21 Q^[34([G]&[KN2S0<5MPK+6DTDA8NC
M2Q"HE<-TE*EUTNH<=GKQM!O(W?=4"C.1/X?("N@U"TJY?Q/_:;J?,&&D]$+1
M\U!J5W6(%"H+K\F(2:$H%UQ*35. =JW(Y7?$7.;0:M*(UKF*][U&(DM"^QRV
M=TOB (3A<Q8C'\D'55Y0M1YW'7Q $83MK+CT"S@ON=,A,\\]X#A,\R6/I-:O
M59,:-B9N1O(9I$?%G;9P<M<DX0VQR*JO,Q#^.>W:8S$G<I'5^A1@89[^[S8?
MHKQ.GQP59=G,4&^\CZ]OH3>V@$'OV?[!B[UXL"J%V@^]X'795/7C7>H7^Z\>
MQ4I750,VDV3I/LWL!#^R%3_8_^51K/B5*J&LV=#&UL7XJS;HT[%::"/%_#N3
MF]5O'5T5F=X^$?F\D+OEB^H22_2AP3EP)<R(&*SD  P]^(A,4WJ^_L?'N$KB
M?T=[,7"=S_3&(B/W35840*QX$;W?_[ROC=PAV--0CF^N8O9P9@LGE1X36H@H
M;J,*F66C:5,W,9'C0Y=FRT?&Q'D#&(=K[4S@QU!G+X43,OAS?L&W\;R*%#$7
M B4N$_Z323/P^'F=GQ#/7@J$:\#0%[PI]89G>C[+7*.B=Y@0/T:N 1C2^98;
M'[REF!SVP;<K/_<HBRNV" ]_S*U[@RW;OU5W6S2P1=\TE?Y'5<&L]&Y*..!)
M+*U9]:SJCZ*SN&Y*_>D0_JU'$,]MZP?\(S>^IXK.CH^P^4"<?R5F:F+_0'81
M:=644I\#F+._BO(K<G_$%CB))-G<1T+OGPY95L7!$VKML,U+]J<V=<;%HS1T
M?MH_V%/;;^@<Q;/C;]&;)KE0P>C/UJ_S"[W.\6#O6YJFCV&UJ\OH.&.F>: ]
M3_6]XD?LS;R$Q==+OW?XV%;_#&RWQQFV>&3+KLT4?>$C7>EGCV5]M5W=3K+M
M%GE[%KE(%KOR/E?F"2 [<G1;KE3>0/0D0<?SX)>??Z*F?)2BV>HIX]+9.\_=
M[\!\:P?S_?)T!^;;UL;U#U/M]3#2)WKQ]&#OZP S^H]2.6O_^F!OW+&R;X(H
M_]'VW-I5GD>*^;DL9D459PMCKL5D0BU>36=>:"P'LZ\JY&^>\5VB/3<TF],/
MO0N@]S'VHFQ&4RA'%!"6UYUQ21.[ 7%93V?0)8%Z1KK=\/A3[EX;>NGS,LXK
MZL"X_19.WYLO7/':7D>=0TON6%AR7TGG@LI;=9!6!$S2ZY3F5T5VA:.]YVG^
M 0C9XP'U3L;)&6)>"<JPN/]3/(VSBWAJND%Q.F1<3$=ISI]^*?2ABZ!G;U.J
MH5Z+HKS0>N$_L:P3-_J6+DS.(IJ5</.IKU<DR]_^M1D-.MO>-"PVS:7@"L:?
MZKGFTWM1%LU,3A%D+Z5S'[L*Q]_&^EA<*'T,:P.9HV8OMJ'+ *4>WEK[7F/J
MC:@%8J[O->;VYM"UMTRBXCK7UUVF,^SAI\9-25WF]A"Z"NWA3(-@+ $;87LL
MZG"NOJERG%9DW\&?-#3\>P*I500;VIL.(,E*;6YAYSQ[^E_PLVE1FBQET=15
M'5,B]*J@-G;%-3&_>QO-ZYV<NBDY$5->+^EP1]ZTJAK]GQ_EK?5VF& WR!0/
MGO0'Y"X[SEX;[ ZB',0Q'41M*F@!)TLUI,E"(R1VM)E>%KA#(7].0HMEY2P2
M(V@+NG(AL]13V=U3"W;@H/WEH@;2>M3Q5^!;,&WMJ'$O=;PW$A[2T?QOWM"(
MO:"!+KS8[:X=? W7_C$CFP\(C^"TOH"C-QX738[.Q=))S!6@+S!RA"."O_]_
M]MZ\MVTLVQ?]_P'W.Q"%/@\V0+LLVYDZ[US Y3A5[I-4 CO5?0\N'BXH<DMB
M0I$J#G;4G_ZN:4\<)#NQDY0DH#LE2QSVN/8:?NNWL#C&7'W=\.QV@=X%B1Q'
M2JIHB!:M]X-\P[ 2+D;:S.<T-[=%DV$)L:K):EV=^IN=6;@0O_6A];AGUFY!
M\H)4O" =;=1@I&!DIP4IELN%2$]7[^2K8'V:>CXPG3!J#K!LU1%:E&M%4.@)
MH-(1G5\CJ5EAQCU1N8OHKO6E_O)6XR]%5"8K8PICO *'F?.EBK(]YEM@6],H
M!5<*<\1 6&\O5N+X\'0+HFQZTHM/!Q=Y72ZW&R8Q.@*[>6MF_3Q:4,$S\;9L
M;3S]^/"DQV._N=/.FG":[Z0\AFN>;-66=W(45JI"DB)>X84AIA,$-U'6J.!O
M1X='(YL+$6Z?@L1#F"TIF"QI]Q>8&KD:Y:_H$O+[<+S(>$!T+D4$%V-B"/DY
M K)HP8RMXC(=LR$KVT(6[N@4%FX8@.2"?^;[Y(\L]IT:OQH$4[9N/#H:P9U[
M(S)W+ZXNK\^D"5R[FRSB>S:7#*((C!69 X>1P+/,H\I=+"&2?%1-Q&R?W49&
MT,C3_6U84J5*TCIX#;=E9/+[*PG74!42_R:GSF"UVKW/,M?L^E)E'<$2>5/0
M<J.*"^@^6+IUW+7#$&?LE8II]N0$?!J"23AZ0:X304IA-*:JI;"XY+=S,7?]
M;=4L%AD]FY-(;,AR7B3I).U+B(?%.F;3-8)=- VNH<>P6H)_PF91H(A&.8B;
MMI6K>X<;P\1,^\SAO:4[*#LDTP^)9!KMD$Q_;5JR35J/6K2<.1+N2B2<ELL#
M(O1:+6I7ACY;+4,?1%K^Z[^"WV#)I%CH_-SRXPZ+S$%YN35NOU=IA8F+3:D,
MH\N70613U&F2!OV"2]2(HVD9+2BS=@/LH,O+K;&!+CBP:'9UK[/+&$*MNQ#7
M6 5[/O<2W@"+ <F,S$,#=8/UK^(60$6X-*IM4&O=(;O+&$L!&XQ.'#T)+N:+
MK%@JI1]SF>,1AXGC^$"4M4<O[G:1=R#.TEI15V#0\N(6MO#]._A[D1_H-\LL
MOI*(@:3_\RR;1HR.[]!2N.@':.GIVI;B\0(7/AOZG?@&MBGC(KBX?O_^7@O<
M#+$05S1E/(LJ'L M&*_745J2+^'=(LVWU?-X?'B\/0$FR\]^EMRD55'NIGS3
MIYQ2\FX43>3%S0#9YL9/.<87DNV)+UP.GX/X =<$.3$;D 28J %6ZI*P5(:Y
MJ 6>[8+]MF(4@S<I*%75E@;BCP]?[,VV9].\C> V.1M5"6H@<V2M#">15PE]
M#Y,HKC$XD)9Q,T<48*PH$R-)V3&$D+(:OA'8<0)_9\6"O5E%S 7$8DJ]0(!E
M*)AN1"6;%(QY6E64/X":??@-.+1[^L\07\[8 L.:6<\(:\G@XBD8WE,<$C;(
M48#DRN(DR5;GQ\)@F40([C01947!7$]#)-,@\/9"P&$2 '-&-]B;&+W&]>CM
M,U"4GPUSA'(NXL2BK\+P^3D'"X(+8G]TRV%(4GA.6G:^4PD#FYUO$Y4A79L&
M(A+<UD%!2L93BQ/92Y*R.6L@OA%%.R9NLHA<E_"&<52E_ "![5)[ UY5[*QG
M<"Y<@>"3ESUN=OR,YF\YC[+[+Z2!YQ'J)>Y>OB@+=-HDKF<T_-Z-FA6W,&ZE
MWR:*;]%2AV6VD"2,.,-*BG9U8Y0ZA&;*PM><?+!1<1IX?4JV(2PXXM0@#[23
MM#(ILJRXA5]"%D"A2?;@IX0^P[Y%X(<\Q[*$"?FL ?FP&!(%(S9/<^T<LX((
M7HRT=VM$X]^#O3/IY%3EL+FR "1/#I(J#H-%@4'4.,I"9\]Z&Q6$_2=5VWU<
MH9L<CS=I#@B9ID(P7&]:SZH]*UL=EO+>+Z:!A6F1\THWU8&#[/A<1B+#A96.
MW^*]<2HDY.HS,D2:H@#RG>9RI+IHE9,O:DC7<4*;FJ)D)+[@Y\:DV*D*6F;V
M/B7T81@:5"V\= *OQ\"'@M55<N0");O\=1MA DN)TS\K8.HY?!UR_@4+/]SF
MZ9136PHXF&$@ IC4LH E-W?S5N+E&+:1^6D?QO"<0=HPS(F"N?6)X56G)[<%
M+!%:5+)\']R?=O[NGY>O#D8O1"?1#=N'<W.1TD=8?UDT;20SAH2F'GK*^\TR
MG?:R:,8PMB XHPSVL9S3,]@'L%)RN'^2%071_)=YE!3H5P,-[\\&-I1]=(Y4
MD;!<H*%157-.181GUB3XM:#)XH._<K8[[?%;%=$#[(*$X7XE2Q;'?!*E&<9,
M^M7R53EML-7G2M5T7:IY62C/03Z#F/VHY R![W&!Q-#Z2C\<5Q<,MS[;B7]U
MD"-X;]S4F$+!RX(H4\D!"4]4'!9C161)2PP%)*U*DF&ZC[@T^9U,%;-8P,1@
M##:4[3\GRE,UKU1VHZI6HM&=I-SM3$E&,>Q)*GL[5BH/>=5B@LM8W4'NX9ZX
M8#9663U1GL/K8BZE@(L*?:YYO/RZ8]P13J$^O&G$[*BBHH%G"MZ *DXN<@>>
M.$L7K"7!:]C4<Y6CD,^M&"0LB -452@RFM)'6,=UF<*4%OB7P1PAG2WFV] R
M$M]I]9W/92]^NO<#:BZL)% !#:T97,@&9V,".8=QK2]QRQH\$<ZU23BRHC4J
M,<"UW!@+\ZD>)$\IDB%3NOR4$16K1H1$7I0D)</CA&#YSP;UF8[@Y9?1D5TP
M5 L4<3B]2]FR7A%L29U<I9^C2;!TIJ[';O-%>#C@5Y&7I:56*5&EN'*ZC9(/
M05BH96"/=_"J'P_.<G;PXG@'K]K!JSKK,8;]#H)>2D5U(Y(%:!-3\5%PD; -
MD/+,=<QO0M7I];Y1AU&I,6I>'^6Y8VH\MA7Q5D4(3ZKVM;PGK1D$KQPVHF-!
M!WX50>_TXM>SL_=&*R?ESNF7**/D(\8$X:A,JK4O^:U[FH#=B8=;MK1$\4P)
MSXIORT9P4=WX/6K!5?_I)J>M/#^X+9%!21?#DW.,3M.\]FF4\*YVU4)H^Z73
M=E!ZTCFIERDZR2)K<?!TOR^+6"G&TOG^CRQ34^NO0^G'%10F:=+$=%8F34T'
MYDU:6-/Y370[S-S4?[(/*^(TINXMS#CR#Z>#W+#0;43Y\(LU+_*#A2HGJ,CF
MNKZ&]A20WED9M<3K(O1@#>W5SN'7UZA)4^(*ZG'X$=:$?7GNTG+\=T5#^\2X
MGSV?GJ9:*,41"T>B*F4O@R311L(9)I3\@O^<XS^O.;5$BYYH7(!>B :QZ^Q#
M/?;1O'V8<H\OH*R;'GV=+=-6YV;D-L?!1:*VDMQJM3%;"Q_<M]*E%Q%GU2*2
MD6(A2P56XA2NKB4E1CQ_%BWZM3[$+8A\"1AR,-)5\.\X[ N-D:*\LVK0'V2,
MK.W)2'N/NZL?QKH%H>+1\38E</)<UY1S&#?S<8EG\N &^GL ^B\/U)M4P49"
M>ID/T6<.!DY!DI<YGM48]$3^I6K. 478:>64+V(M"K?;(EK2N8YNHR4LHZ3A
MF 5\KZELA%4.W<:*_*VHT50UIR].BR)!ERNL/4QJ6*!@+E$/0"U":V*@PXVE
MQ2#&DZ*LQ$0)H4,HX]/8^4;."VB6-F2@[5%9HC/17'5;E)_<O^G<*IO8.&!\
MCD$>*'.@8HB9CBO#)524T%*.CC0ENXA<-JMV5 Y4G;'$1>04A^$9'D.J!I9@
M_$!?A_ZA'+U)K$A]W>#&,KC*63W4R3GJ>,8K#\I<6F>^!NMV9&(GVWD5NHI*
M=!.1V$$'=X#I+V!:5C/)K<'F@]XAU<ID1-\658W)Z%1235-21!DV+KB>82R!
M6XCEIX1[==YD4ZTGKS3DW#C;OXN</-J4W)I)2L^X23../Q6)A*YX0?08A9VY
MQ2Z!T@0#F[C[#(- *I$=Y VU9V@,&PM"#D?I0V4:NW8YY=I:PJDLNC7,:!_A
MRRKARU\^O"6PIZ2/:!)0R*5*;[1!D E@"=O2#_.B#(D[;2,8SHD_G'=<KKPD
MDX)=V[DF#^/B>E$%*N XHX+-8'#R"L3PZ#I,20_ @@-+E2%\JIHQAK2(%9@Z
M"TIC4W51;:L53<Q@G7KR6B\7GGK7<<LG6E,J8]"W73KJ<UK1@HHYC6W"Z<5+
MXB@3+W\6V=!1J21(KD/'1(E,BGR9T%ZTA<:-E;<->2Q#7.:DHI)O0!JB0U-"
M&5=C*#@WK'0X>K*TM#9&681.VOO)WHG-R@]-T! 9"8O:+#(0$'3!OE.'G:[C
M]XM8*_(& VK:QD,3!E:4I LRN>+!&!3J),2@845?5X@T$0B980D1M$%H(F]!
M5F">QP39\4Q?'<'9.PR,RX@Q_&#3*6&[@%28\[E6X@OY^T$NU9ZPQ3P">Q/^
MSX<2(;7DM>)O8&.SEE#SW&E@M0V+UUCY@Z0?6V DG&Q#$6<[Y92F.FQ6ZY,(
MOUC(Q?0%JF]4[-8HJK!IK#('1Q&< O^(\@8VGG!F2=(S0ZI0F!"3)R4\%QG\
M*WI!$@;:V8;':=X@;K6AZZ![GZ(I?C+1?U;S$!=@RN;NL.'<V2LU31'I Z/2
M#[;?@MV\%279[81[R(,W])BMG/A3]/5L$5';E1A_J\YNDN=K7**.WGBCQ"2P
MT%?2 =$A+FA*7CET#H3V1R<"Q-!>_0.,S*SG5O9JV)NV8+JP$O>K(FX&.04V
M?H,>'SY;+9EW^*#OCP\ZV>&#_MKXH(TJ%\<GU#E2Y$^P%->69CQN&_4P3?L,
M=I\J@[=*H4ZRE?-^2I6YMV?:C:6^TC?!\"]VQ<OG!P]F'+3;LGU,MM<-*.@I
MC/*=2B9^9U34N,@C!. I'Q?54 F-F&I!:_3@JJJ07*Z1JUCA;">21MW"KJ'_
MRPF>^R5IPN]5D\:M2LC0NGW9*SIP9?X:([6W!ERY%6RP;@T^TV2)KBC=M*:J
MTI-N)9I[5S$)=4YSW]/<NC9U@2B%OL(JZ^I=O>3 VMA0PUI'(A>[T/@T!M3:
M2'HHZX2F/A/_RS""&AH+RS/(*&R,HU2IC+.?H=<V_S1B IP0\T:<H&0<+;3:
M:<+[I@:2P-482,N51R6>3I$2RA3'>SSDG:2X<1T3GWE9.NZ^'MZ64OJH#R9@
MF*\;Y&<.X$S=1'GM);%BNK#N9<C#$&(J.(7<L_23RM(9/KB8> DM!,C C9W7
M<".13I=JVF01\BR:Q%UX@85J1!2 MWE\JS9\:/+K>&E-HAN0H3C2@B1D+80?
M=@=H6>1,Y8*J5\+E-RD(?5,L]!Z@WL&">AR?96QMU0.D5BUA11C).$9*THZ[
MW P S0D*AY3W5*'%"$XZPAH0:6TRO%>*41?CO1EZF*0);..Y'_P.8C7>SN(?
MJ(%OD4_Y0QG1UG\5K5#!02LB)@\.PZ^1BA@E) (#.J9^CZHD^G.C!]*XNGUB
MS:W;-Z/1=IBNG,:^TC;2N>Z8;#2V?^0%@L? <L&8-\S]-)I2';Y$U[O.%.73
M2XR<[C:?ITU$^<6AY0)QD#,3A.G,$#=H8#?MT]V6H0RIG$M::Z273?9S,4:<
MIX_I"JA&$TY2TRIPK@_#S+L4"UP/I/7Z#5X2CYP/Z*\T*O[Q\.Z/!W_@]=G5
M]<%Y\<^#XW PNO*@@R6O$6*I(FM,>M^\J7VVK9NT;(2(BNE7.&&)=6S6S-D^
M+>*4_M)D+@CD%8J72FHSXXXUC"Z;#"#[5EFO?<L=9^9/EG]$R@(&<R;R2GI=
MS52&AA/((@*QAOH!^O<:5!@03+-B;G_#3  X@V,$6R>< ( P);+E$'O$AB92
M735UD!2W:)MRZ0 4PG\VRE#LF&3;#DB<J)) 3(?!QR:9\C=I_K')+2^#R-L$
MBW]+INL-"?R4H/Z,Z"V]VFP5UX%8!K^Z.1M<=DH\/YQMQF6C&+692PXMN2Q8
MM+M&WJ/O3(=#!KK,:L-Y419YQ!OR+$U"_O8*^JTFM"OYBPMA\[)UC/;.SZXN
MKO?16;;!F^[5_QO-%R_?!>\)*[NMBN7)-H3"7D5UA!9X+;OT373;+PMATE?S
M$Q"<<R69 9R#;FY(A5I?286K*V*;2W/"Z5 [D"Z(*XVI9%]RQ+1_;U&F-U%,
M$L<HI9@9UO,<CT+*3]JU;?W[HRW8WR[?GYW9Y&D5O%8)\01^(*X]M&"%'><,
M-?7'(8L[^_W@^OW96UG"YD4?5*86,^0G/2<_J"K==>!=QK!:[?TTE[\NHX;]
MOV=CS$)YSU2@WNUHK#=US\5T!?/'RMEGYC)OJ*+?PK;&65>8::1O3'#QFMLZ
MOPAE M@_'-5?\:18]\EY*?^^?EG#O;&LSM+]GK+3U+A*Q5W-+'2J/I!#4:'/
MGU!J>D%[+(L+M-X0!AUR;_AI017#*J#E'..>Q,PNW"5PGL$Y-8=_ZZ*4E$$\
MO,M$,CPT^V+1Y)2&,6]R&9.*9ZHM"3 >='PT>C[\Z^C%B^<&P=UA_3 DDBA2
M!->-@#_,EL@0/BQL$3N U@\)T#K= ;3^V@"M1UF/Z5RJQY'GL<$\PRB78C[(
MU/;BR<^G3W^^.&>A\:NPXK:%QQ5'UO#CWL4?^RAFGO[\]-F+8.^1M9U?7[V_
M:A%Z:_G5*[FZPMX; ,D.L5]0I^$=YJG:L+^C,.1A>R_' 5YV887[N2>T8>3.
M[<#O.V-*E:M.@KWK2_KP\_'I\=/]L%](KY'-ZZ8;GG_\\Y/G-.':ER%N0'JP
M?9'H7KIZ+)F\<%)%3)9"V>%5)4=5GR*WR2JX&M>L"K)K=(MS*TX.1UN!1*,I
M?ZTQ!;NIWN2IWOE2ML:7XNWJX+IHR@XK#GM3F-B!B4$DY1R9IC.DS1::;$EB
M1]^JX6RAE<)!-&:-T-FL3NJZ3^=!=Y#.28@_A/38VJ!MAL3^@TA\MFU/KAB?
M3(Q?UCK(T1J#1(&]FHY5PF#"E+G&7<J'!&\P\"J.Z[7?M1K.U"$+9R<14J,Q
M#SS'1DVW>%KA31^+E DMS) X85&F'6+."K>>JHRE'3LN;\#=ZI8\2+ILQE43
MH[)3R$1'H/=,\TV.X?3O"]!8>?[>PTPMAW;)P+U^Y=O.$%MR1S,'[L^)%!^M
M*$\\C6DU&#J&T&Y-!DGB9?2R-@\U*<YV-F$+:(Y.@B&"F3LMM-=L11LW>NK!
M$$!LSC6&HZB:![*-H,]M*X_"T>'QYA^#OYZ_N?_DX@]7*D;@_49OB _G@QB>
M#R3O%D654G'W#V53U5N0"'(A-&SG436CX (BP".[([=.1*Q)7]Z@64<-[Y6*
M$OQN2R<;K. M,(W,;+\NROGVSO0V[>OWB.Y/MG>NMV%72\G,K9SDIX>C[9AC
M1/>MP9V7"WE5&Q#TX&@6J@-1%I-4H/#NR_?#0-?AU*7:9ND"@>USRLSM_5+S
M"2_]GS]24MV-AL@K@HF$08TZ><A,_-"]5F_UU_K9XZ6DK?2]+K8T<ORRBA)9
MY.M]S#DLYPP,50RO-"Y!K)A"->PT6)CB:44YA9WV[T@C/!7C,EMM[(%N;G*V
MV45^DY:%[N^;Z';E2NX$?#T^Y$61,;Y;0I:UCF0NF'+:C#SR)>L-H=.#;3N\
M&4E+S+<H)Q$2VR*_;TC@V3R1/Y(RS2FIEO[F<//2WH+4SY2PX7^!5*>U1&33
M.70I2R?*APSKFIW05O*I[;L.5%-IL6] .,Z,>:("7N.*B0Y;.R;F1L+"S(,6
M,:$[K!%8/SG_=8NU0A%\5'Q.8^H#U0U'5]SG!>&= ^-79;S[)-0LP[#DHJEP
M!C.V:1;].RJ3HJD,3?(FNQ&(>7=P*5->OZ:_O5*UGKM+SH(W:.8SKM$Z>O'L
ME$N.(M);)9L\;@[;P<KAN[9Y_!Y# @W7R?KAVD'8OC^$[<D.PK8:PM:[MW$X
M?WAPVT:PCUG!@O&FK32B1DBFN@U>$3W5K^$ANYG>[)D&)1K)<LGRV]*Y1E?G
M7KH-LXW<\,$9,A/=@,FQE=-]O"6,V#+9YUR)I"=5SK$A#&E;"UM.'"5LX9:U
M+6J"9:7*6H.HZW1<+&/HFL"HB>O*PKNE!A7B4[">)?/PA^SRH<1BP[WTQ^'U
MH5-@K8V1.D,BIU:OT,C9.SZF6\\/ ^S$LY?!\;-GS_<9G7Y):4P:SWXQQPKP
M>;P,3++L>Z1%J_A!3X[\!\GC1L^.1D19-GH)'Q&=[A6@>?'BA?:;R-O0!T%\
M;M!.'+\/5&AI9"ZCCO)/W39^*"-$^>!NHQZ[4'GLZOGAZ\.K0\(A/0+'P>CX
MZ&!T<K2O\Y&9=(_%ALR?N(J\=HV>/'*[GIT<'3Q[=MK7+KT6KM#.F6N[%Y/!
M!F?T]/G1Z.#T^9-C624T(7%3P>ZLO,4;8=Z8[MKY+%J@6VMD85JOP;("ZT R
M)%<,20!CVB+5^U9[K;W5K%>-..^0,$Y]1A:T5LHILA#F%3X$_B#D&@T3O'B#
MI>;K5RU'E07W_9&G7%8 47 P\P4GB+XJFVEK;X3:>6G@=AIDN<DC9V"/YZ90
MPE8J&"=; B!_G9:(^+(TY"AVW^(!NYWI0-N EN0YYQ+C" O&=N\F>U,G&]6I
MAR>].CB5$>.R7*).TK$Z'_ LFD!'Z=Y2Z5L"@6H]9F.9U'>29DB:K=,\L'P-
M:%26$+8O%T1^)0]+<%EA(D9,T7 .6@YT:1Y1T56)VB#I FH1PFD+"RA(B4$.
MICJ+4,E39D^*-05MV^"U^>O966\E-UHIOJ8F*(ML:<E^A>X9!1,,+&@MBVRC
M$QMT:OL%FP$:U'%!:O^V0I>/#T\W7H3_:M;^V4V49F1H7A>3&K-<^NP<LU>8
M_E*5,5=PCLS=#RYB'_R!Q61R .OV .GN)EY,M9*>LQVNR?Q3*3LM:1T:E(5%
MJ3U0C"'\'S<D>K&\L$9O:,G<JK;ID^I[E:M#:81NQ2SB)U+1T'F1@$[-ICN[
M)6!E)8$NUGOWMVSRTC:.PJ"?;];2(H*,GZLAPMEQ5*4Q4PL2F,CRQ7*+G/L6
M31G/"-LC1(0J@P,7L\3X;XF:R5].=6:+AW-)91D*] EF F:]OL6)OU/%UE#7
M-D ZK!E!J#2=Q0#5H3\ 1<E<(&/G"TP\[;O;OHN:CV_;CC7U;L+5/_K6E'67
M(X^J) 051%6"V$CXPWJQ.6>3RCM(]J93%!SYY+D$"N8*$_\P3*.YA::.Z(VI
MU$5,LYG#8H$#>D+KIW_*K(N1I(-]F'TQWOMG TO_0%X OSX*_'7J-%#63>KY
MNUT@*#0]=H?6&2=>?_YH37@E^T."]_'"URS+M[,BXV(OE&9-!YH[0;>Y2%KV
MN6;B)AT8V\1IH#1'?<:#D@AA#!\-LI-&CE?PAME-92G '7'#7Q)D4-?N""9"
M>EKISL$IA)7:!=39VZ@V:!:WX4+17K2/WH>FJWT6AP5H?VDLP./EJA4:WFOH
M.T^F(V[B#%B,E6FH?M#$KFU^ZW:(E?=E,2VC^2"#[X0#"F$P8>Y%F@!F_9NI
M**MG,>HO"WY*.T)&_GFY42[7EP9^+:73=LCLX0-))\='T<&S,4Q_A]M6 F+_
MZY^7EY>/SJ+U5L&F:ZN[S*0ES;C\7SM,Y(^)B7RZPT3N:/TZZ_';2(PT:4D,
M,;.NF?_5A:6'P?EO9V_?_W$=!A^N+I%TN\4OUY+)O@S_ 20SI21PV]*\:K!.
MAFF@L3JY(A[9+;H_#@N)>Q(58"+1^*-%1"'SYXQ]('G[!(^T:^=(N]]X2//W
M9OM\-IH0JSS D.C(?$5C.'VW0KF "3EK8/1+T:97)@^98BB8PL,I+IBVPI;O
M352F[*56VD5(^3 5%T:Q(;^0R]S=H*(29RHJ^2XJ>T+9-O*Y=@JVN [O$(V0
MS!(>HQ'E=H';9G$+/=KOMDSM'5(;C<XH^7]9$;/=)UIEX!IC>J#1J,&;B;+*
M6&7>E>U</<X>;)A'"U, %6%$7+IT='^,TYI:XYM!Q%?$?.BQ910W9D9_$YG6
M2]?FD9*'20'36+/M:O1F^/P[46C#HOFE2#9Y>?P6E?-)DQ&2;$L]^"_@&-AX
M)_YOYQ]^?K^=6)KCPZ?; *7YS9KV5]87=*:EWV[JMW3J^<@==!8-JWZ5+N[0
M*6R[/F:$^C/2:S=Q3668'19 $P)C[=Y!KSK=>$.5**P]@$"(HJF95$"T/I.R
M?:<N: NDQN,>BTG A#98I;DIY4^I^(')[<6\X'=44:8HU[LNTW$CN>]1_"F:
MTI5"Z&T0MZAA"-96W,AZ<-Z7!0[&)B]"6_FEBWOEJ0TNC6'X'@9)0PBH1 JC
M*?17)O'XQ5.'6=Z"E'&*FFQ*;)JU*=K>]F5J6OEK+&8>E4D5[)VV0.8@)>@%
MHZ>G@N-V^.<_N RL=WH(@L$UKMM8]ZOO#/$VIPTVS5ION]\N/UR<_V8KS"!W
M;!;0>/\LO[V;Y[ ^J^"*RMB33[R:M;(B7BETJ.NPH<P(OO>W!M85-+?$TBP5
M^N/_ 7LC*I<B1)^$B(0_D0AAY9#MM@!&5*B;@$48RH;_;O1RUY.R=LW;&D\?
M5#S+BZR8DI/>)I!0D2%X,(4]Y#[< D1VS*7(=?7QN2KA*DR=B N*&^.]5RK-
M;T"PT>2:Y(6C%V'POAD?HC1]>!?0[\6AP!A'HX,GQ@F4D+SWRB@X&]?=H:<F
M#\7/JQ@=A_ /++?38]X7IR^>]&\+V #>RL>"A57#!9$'EK"%N$4TIF^C,I[)
M14_YHDU>M-=7:WD@P"*L#ZXQ/^3@JH")*H(S]!H0->?E'%>D$$-;+HVG6\*E
M\>![Z#(_^*4P^='!&W9O;:N9MA6&^"7<"B*+?$OOF;%]*Z>;2B1L07;\99[6
M%.MI0+VZX=0FP]^VE3,_.AQMP:S7BNH^-3#U[[&*5(?QO^5WUU;.(D*Z/6'=
MIV\G#3+RD:.;:S1J.$=#9CX%4\F6Y^*B D&]+<H,GE@RI(AM;;_8-MK4?[<0
MUD54<PT _J -<U';[/M0T^22EVX0IM(Q&<H63115> AU?60J],S?49?X<V!>
M264%P+3/(FHDVNPW8'DC]HA[!YTR[W4?H2N*9QDAPLR0+V3(]?U2BT-7#R$=
MTH>0U:6*:EV)$O1R_3*/)"[#>M6BD3.Y6PI:IESWXZ.:O0;#)CM @] O&P^C
MA"HT36>N;J/L,3I6J@/UF6CQ>.CDW<;:@;?2-% 2,9L_-(&@;3YVW/Y]) @(
M-VS_DC#6G%V-?B+<#VPM!_(G_10D)=6XYS]RT(<K2YPI?X+M5[CE;G@9BU<#
M^E? @L6:,7ZY#WQ :[>YVY.,23\D:F>O?R"MFV):%,EMBGGDOFAP77RVL,>C
MXR9P/-NCOT-6_9#(JF<[9-4.6=5%5J4H*_^X>L/'-#P+SEV4?FT)UH 5A F7
MFH^5H 9<HPCOO)3BT51&M8!9#:*$!"R*42F@/5=)&E%"0:9<J2K"-D4M$DTM
M*3RE7] 1=>9=[BO26A<\$L\H'@,WHBW%Q6)I-"\7IM6KNX R]HG$.X,1D'#9
M!5RO5%W@]FN3<P1OHX?YS]H/L; \O=Y1PN!,:'+[=QC,"Z*_I<>VJY?*R^QC
M[07>M/&WJ\Z>;W94GYLIZ)S6-_NP-JM//%32M3T?$\8>^GDJ42KHQ#G.2KL@
M_.B9AHX]N!9DO9Y'+]W/+XY&!R]&I_N.2]7.TXJE@KVJO![!R]G9#)_-> S,
M+$\;RMUO<,9#4_Z%4W/5,WTP>UK7PAJ]I9(MYI@2_+59R3@,9<JUMAY\EC[!
MC0>SXC9TI@-&>,*R!?%%5+G>MH!*U^.7)M"),X&.?_+N.Q5^V_S3\,@(NH._
M-UDDNB/61M)VB#& ]O1V9PN*3YF2<O_PS=!<=8/*91$3UDDE^Z&N.$S\T]2:
M/TG-Q[BLP<[!WZ;5R*@M@UM4I$D:D\OV!COKM(Q8L3-BLL;F4]8AMH.NDI*'
M[3& @8M3*1D7%U7M_SH&S93$DLF2-"@O;3"V1I0KTL51Q<A#9WP[RBPE]^ @
M([<\5Y14FN9<;$2.)XA58'*I*+;VOFLG/_K688XH+BW7(_;PY$4C-<ZB="ZF
M;-0(+[D.9&J? ,;3R>(P-;L%],HNB+@I2TD[% \$##3&RDTVXCRM"+D)PV>2
M7/O&63BK;E*3J.I/H&_QKSP,>[T<&^Y'HIC7A^AS\ %=%$/T%AOO-CS=$CK5
MRZOKE?$YGYBBPQ8H8?P-'J!_4.T04-0^+RWCR\_P-T&,FF&&2AP]+CRRH)L-
M4<K/"W.S<+20\]7/QR?VQF<OJX"JELS WD.S8H"OQ6"B[+7!6T7X(G:\%$+I
M<J^G:A:8[D,W>+I1 <M4,E4MO)D_S7"&/'([^I:":=O*-:=/THC/-',3*.*3
MFG1ZQ*C1N<EU>K%<=%$2;"ZJBAS4.ZRP\TG!?V#AD*3OC(J#HZN:\4=\"NA$
M5%%%KH"5D-ZD28/>U0R-0K*#B%A2ANX5FD>L;IIQ]3%^KXQ^%US'H 0UV29+
M&F^0>?,][$1S9? ?:ZI%R&S73'/5G_=H(BFT%U:&ZC*Z&,T%/REE86YWG3OL
MS.PYNK7]@$G$.K+ E!%*%_V12SZ4VM \6RP4?/REB$JTZ9# M<'$*$F481N(
MO&(ZWPHS;"))IS&FD]-2:9Z3CF-SZHGTXP:3[,9%0EX$@L'FKA6V7=E4G>I0
MJQ=*=.NN!!O!W=<!52)'2,@PQJPVV&0.6H[('J:<32=\,&G^4<@=T!R/TTI_
M*I%G8=JDB7D2 91;*Q0KKPE_!#H'8#9SS1YAZUV)%=?+7.$L:[ >T=^@R[R)
MLH18L8/SHBP;RO@C(+>;C<EQV(U>(43X X-(Z&$8G+I- +,E!AO5O]B"[(LW
MJ1I,DPU9>9?T!^-@T5X-!F2HFI,9YC#Y4THGR."16-..E0>N,X<Q9P&4$W)!
MH9-&Y7$S'S.D'AYFTR.(<@D7X(3T#M,"6)>4,]'3!-S1QF'6;7@OI,6DY%:'
MP9FF=^'N@Q65( L6B8;B-C>Z"E'0X*#UCX50[M0!LIE%L:1OP*]H\53N4UC3
MX:%@[A@P@1,FE<DXGUMR3.AP$T)I]!]'F7))NN)HD:*4DZ)[^FCC5/.2$E-Q
M2,T=7HW$_N'\GNO]+'=L6^TI.S.-UPSMA(3FT6;&'\>-JCW'=C",_Q6GA0CF
M'GE;S='3:3@#_0W6RD?RU'#H#DW)8'],3VZCZN^6AZM99$64V)/L)BUIJ9,_
MORR*>8"13.11ZB9$#=CKM9L_@N ;Y#J(:GO_F5V#AF^+E2_0_WMX8J'UAMS*
M9F$(A9QRW J4B51CX0=!DM'YCX$#?-P.3_%#XBF>[_ 4.SQ%9SV6*E8I%M:0
ML#H%'\LY"Y&5NWT?SN1M. ID$+[J%$B_\!183=M]]P/ 87%==P"TPFC=(Z"5
MJCM\#JQ<6NN?LLE5M-_"8D,%[Q7,UK9:;T^V(=SV5LN!?@+@+9GMX\/1YB=E
MO(T^I_-F#H=BSC:LFJ?-?"OG^W1+Z@OI*3^/JEEP-D>*@14>VR"B*Q"-8NG8
M%\S<@%KGWT9'AT^.@GF3U>DB2^TY&4WA'$<V@B!OYF-V_U54#96553Y%S]G_
M2^%;C2PBS&I35T@10,%ANN/)WX^.@L7A_#"D,?YOQ,KAD&LB;>(H0$WCE8H2
M[.HF3R$Q*6;05:8G>$61,] _!B?27!&\./GY]/CGBXVN8M(>'UM <'" ["7!
MWL4?^\'QT>C9SZ=/-GJ0L*38%V3:X@]7*D;WX"870N#Q01VH2A.UU<FI7,AY
M"RHYOT6P+:QM1=4O^(AZ>*+8HX/_<KU: \B)-K!&5+0KQ;1*CU6:R[;.\$,M
M582E3M$%\(\F5U*.\0BI08Z/@KT^FQRY<Q9@VL/!+Y?SU1MM'_<LGE^BC )1
MUS.E5@-EQG)EA5>V,48=8I:3$8WG:$N&4UQ*7S&:\@0>R+-%F6;NNMSD<?P]
MJI+HSZT\N8X/G^VIS3^U?B^L]4/E$+>3/L7J*7OGVS7I_XRR9EM=LL_VQMNA
MFSX"6UU^\$N33%6M--O6N: ^+CYCH:,44YRV<EF='HY0E'Q.=POK"Q>6Q4K+
MN)FPW@J]#5,/N2[7XQ1-2]J-<@!/"<4@63^T5LXQJX<A%TKH+RB(W[-ZN5LD
M]UPD'\YEP'XIBD\'%WE=+EF#V4JI0^C0>/,%CE=(PI]I3<+M%=O#&'R!U4Z6
M!"2L*D('$/Y><P5Q-@?6GRX)[FW=$<.^8)U1,.A-W^ I>/?Z['QU2F67'AES
M;4%V+D.3D3%!'Q150#E#@&?% >,BV^2!8PS_Q6<I2GN%C^Q;PSB("(1+"<E2
M(J6IA:*<PN+$7(4YYG-G($?W@V)L$30)9BIQSHS 6@@8<Z.06=U/I$1"[YB*
MTUNTC'NQFQ\IUR+K1Y1\;"HY\&S".I%4EVJ"=@5SR=-M, 1I381W^!<U#G8F
MDS&,#6,9W.@6M*$OX@PVK*52()8^R7#'W-QZ "^S0UY^?^3EBQWR\J^-O'Q(
M>3N\0!];W&*.U\J$,E,S7&=^V02QVQ+S -W\L*I.%R:3++J-RH12O72RF  0
MMK(HVCM'=J,R)+C00>J _C0>'B8GA2"5Y!K^ <M&1[")#=MOZ/YJ0EU.)3RF
MH*G3.&/@2)I[=S^X63)>'F &J<-L9"E9O '2P-G*)7I_:7,6^CJN$P.S5!?U
M$"K,>P^#K9] :)D%Q:<1*V,-6K=51#83WZ%EJ._EBAC4OK)-/4_L;]T&[ZD'
M7YWOFGK'CK]E[/C#) OK83KO0>.:CS>:ID ,G#/,BF1>.,K$1'ZVU7K#9,+9
MXXDIDCIQ4B=+P_(6[$GJXXP!D72C=P'E8E#-W#'F-K,&@:DA>3!6\-9).YQO
MBX5A"L$96-,96E_5OI,0071DI5-8R$VPI/)9W8X[Q9FV:\:=CJ^<="?YA"9,
M46$VF =#]^9FI[@3SXXB0LSM([E?D=U08]>-\HNO&^6G X/LJ_\PE=_-5 1-
MCS.U:7"XG'&1I8E6LN=1-HT,=:%F4G0\!Z$04*$_H"E5VX_0)3=T)]',A&R'
ME\%JFWU[IF6\WUGQQIN$]+NS-&8^<\E0MVQ1T[)H%GH#]5#$&M_765P;RO22
MJJS9NG-4UYT?;5+6*ZEU'@MG98GR(,%$>-$/$2+."?VX+?>\XL055R  ?1.M
M;E@P!9$D?E8E&'Z:[5-)T^AO. E%A[4/W4=R(4[8PD5S?/0?E/B&="\BHUWD
M^4U!5RV*6\:OZS7&*6?MP;2)AXYX]BI <AV!OT(?8=Z)GFG*]5ET-J2D]CN+
M:G^WX_2.BWG'<7U,/4NAH9P(>1O(B85>!WA"H?^<],V3E:7DJ247NT.>@P0U
M8, YR\GGJW+7WKX+@I,]VW,9-#?ZA#04Q*H]*S+FPA'^&Y>^5W^614PI']S"
ME1>[?#F][>^4337MWM?DM+!?4B0*HJW&13()J[IN!)'-O&1.2&H5_HW^A+GZ
MTL'9+7Z]^!,Y;A17U=$ZLMX&\@WSF%!6;=7,Y\PV7S19@GZD)J.DX6]Z)C'=
MU[<]E![M3-JM15Z+:E_H;8R.V<-SO5R(O'2U2;X*EJ:^80$SB0Y@RS0X<%ZR
MD%PI<D)/X)2.N/PRN<RZ+^Z!RETTAW=<!W]U^X\(_U:#P/$*EUG2&>S-MX]I
M?*@F[AP=K=N;OW1R>+H-6?LR[0+AU-;SUI(UG!Q^PUJ:]S@4O]$J8&THS7<"
M -&\3[<AL5]//6)NOL6PGGG9^ZMS&;%-^B[A?"4T$9;6+(,;S%\(_G9T>#1"
MC8MY L(UA_4.)/3=04*CHZ,=2F@U2JA7Q.!X[O!#FR@3?UDK$S?^M.U7O 8%
MPP:L[N]_Y._6W#=4]G^0Z<Z6&FZ/] L,TUH9_%9"6,]U!!VOO+AET;4T5YJK
M*0K(YXH9%G&9CMG5*E,J:O7H%-3J$(%E\,]\G\)BA>9AU(@'?I5_X]'1"+,V
M1^20O;BZO#Z3)E!H@'VV]VPN^>VPHJI,06R'QO,=1Y7HE*!Y-F751$SYV6U?
M!.T[W62ZBN&B)E^&-4IQP+G*)M;+*Z-I&2UF.#<;(& N+R^W1;I<<%3.Y&NN
M+AYF()V5MY\X(NZQN"':NJ)RDK PL "G,-$['F]Y]?LLV@+\DM/9E2-\?'1T
MJB^^S%%%0AHWO,T:R"Z>EL(("&*C ,2D+.9!C3QYF'H$_]V"@;U^_WYP1%LE
MYC"Y-[B8+[)BJ93.DFK*>(95#[9C';Z.TI*.U7>+--]6%^')X>C9M@CXUZ;H
M\%ERDU9%;W[-%LSX\=&VS#A51+U1-(\7-U^$)M^ &<<P0+(U1N)E[QFX\9,,
M@OSY%KD"#%4[B')5@LYR04C-E7Z "UO:(G3*8F9<TT"K]9J]F;+\*%LA5Q:7
M1(!L?E 56F QH[BH6&]DRTE$TC9!D0IALS;G0UN'"KDD]=GDYC[L,S"+GXWU
MV1?"Q_K%Z!D?PKLH.1L]-&V&P4CG"]",.M^IA,&#SK>)@JFI#/B'@&T.Z$C2
M!DP#):M@L X&XM4P@03'$#5V>,,XJE)^@ #DJ+T!0^2<:IH7< 5&_%_V!#GP
M,V:>E?,H^[I4-N=Y!#6(NY<OR@)9 A(W.A1^[T;-BEL8M])O$SF3VJFL<18U
ML&#-ND9O6PC--'M'BL1\IEJDO#(E80<67(4?R?"2+!^&GF59<9MB&3G:CZ%!
M4_-30K\ZG$6YACS'LH0)8ZA!K[ 8$@4CA@4M$=.&BROFBKM$SP%F8;!:4/P]
MV#N3/DY5#KLJ"T ^Y<4\C<-@462P+>,H"YW-ZNU0D'R?5&TW,*Q1>JQN#4B7
MID)2GS9(?L5FE=T-:WCO%].TPK3%>9F+)68O(3XVUQFZIC8@WAOCD_%G]9GX
M<\4_J+^#2Z4:*!4;M[E6N!GK@HL1%DU-P4F26/!S8Q)45 4M,YN>TF$POS<J
MJ<C>!%Y?4XIZ%DGA/I3\\M=MA-!P*C$S*V#.,P*%A@QNKG5F+;&L(&B\@/,)
M!B* Z2P+6&MSKYSJ<@S[Q_RT#V-XSF#(!?13P:RZ5XO \GIR6\#BH-4DZ_;!
M<UC/W_WS\M7!Z(4<S;IA^V&@%BE]Q#*/T;113G5>/?24,Y=E&E<N57EG*LI@
M Y-0#(,9; !8*5C&=9(518([K<RC!&911:#I_-G 3K*/AO72X+J'AD95S;#E
MB(L;_%K09#%\MW+V.6WN6Q71 ^R"A.%^)4L6QWP2I1GZ5;VB5(Y(Z%O\L+OG
M2%G+-:>@.5)9&(4$?0;)^E'%ADX%ET8,[:[TLW%=P4#K@WQ1"E./&PGMPV\$
M>ZUBE_  %<&.A:=C%@,\B]65)2TTE(^5*9VI>\I<"OC^4)AEI"IW*-M_'E%U
MB'FE,JRYY&/Y[R3D;F=*LO)@9YIR6R&O7422C]5ZL8<;XV*?!XB74)3G\+98
MZ5I8S#T5+[_N$'<D5*B/;AHP.ZBH9L2VWE21B_"!)\[2!6M'5(2G:2E%0L 0
M@X %F8"*2M7@>-/'! L<IS"C!?YE(B<Z&9]6E'B]4'_[ ;4%/ICK&>@]^C2^
MD+W%^BQ66L8%1E7A]SX[^ZYT:G*)5(M*]#DO-\;(>:H'R5-$9,AP49>+HE)F
M?ZX:$9(Y49*4'%IC'5;]V: .T9%Y_#(Z+87G0<JLR4:!I]GZ;9(6M$HG1C5\
MZ4R=S<T%%:1"0A<K/</>O+JEO"8MM0*'YWB[N%N:\]'.JM4<5PWMGI8[N !9
M,!7+@J,3&[!:D,Q4PQ]1\+W>-R<:BB0CHX-.)7<OV^RQ%8&WQ"Y'F6JE#BBJ
M$J91%JU(2.C K[)@G%[\>G;VWIRN))J=?LE)0NX.#$=1(*K_)3N<X8^),QSM
M<(9_;3:R1UF01B3@,?);]Q@!6P]/M0Q5 BF:#O+?J)E6+W=#UR@54-VL^D\T
M.6'ET<0Q!L,M*49R=M$)FK>K>(#DNG3:"%I-.B>MC<@5(ZO3LQQ^7Q:Q4BAZ
MJY93(<O4U+J_<!W'A+.8I$D3TY&8-%QW_28MK%GZ)KH=9A3I/[K7%&MU;^%)
M^(?306Y8Z#:B?/A3!'F=%ZHD\BG06&3%BQ5.BF5E] ZOBW<A9-GYT?H:-6E*
M7$,]?C3'O>PN+L<M!H8\>7#+MF9)6T)RA84=%*E(52F[%LL)BQUPAGBS7_"?
M<_SG-2//M%80C0M0 -'0='UH3-[].$XTS!LE&K:<C9&V1LX67ZMO,W)&X]@B
MC5!)/JO:F(-%?A=/650Q@9P,$2L^"^)D2V%=UP*5$X>:!6I]N5-N\R,J3/ [
M#'HJ^'<<[X4&BMBZEFN]++36MR4%]3WNJGX V18$(E]L41R29[HF('+<S,<E
MGL6#F\CA!WV3*MA,R(KP(?K,D;6IR[MJ"=_1%0;[;,H7L?:$6VX1+>D\1W_0
M$A91TG < +[7# Q"=H2N6$7>2]1D*B&-GQ9%@@Y,6'E(_.J082^L!N80>X+T
M3HJR$I]!"!U"T9[&SC=R3$"SM&<!VAZ5)?KFS%6W1?G)_9M.J[*)+:NGQWK%
M V6.48S4TB%E*#"*$EK*$8>F9-^/2\'2#G%I#E)R.M/9#<,S/(8A'G()^N3U
M=>CXR=%-Q&KQUPUN["Z',%#.(J*^SE'%,VYOT.72.O,56+<_$SOGSAO1(52B
M,XAD#WJ- T1)CK.TF@EL$GLA_.=V8-<5HI,&%A6'=N"%\R:;:BUYI7_%C6#]
MN\C)34RX]TQH4L=-FG%DIT@D*,3+HL=7TYEA[!$H3#"\B3^\BTPELH^\D?;,
MC&%300B-"&1:IK'K+B,8OF5+02I=K8M_A"^KA"]_^?!VP)Z2/J)!0&&,RA1$
MAL7!/*G8%@1#93C#7/ <%1LPEC0F>?UF@N&<?-%JY169%.RYSC7S#?Z%E15
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M._'[I>+W9"=^OUS\:H7I<20O/[U'Z';DYJ#L^Z8BSO"EKQ)HX3>7:+LTH;\
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M]US]1&RK_AX'P'V3%&0@S ]3D:.+FH$8B#K&:VH>?7)ZXTM>&@B']\Y$$>X
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M-7?KMN5#(ZKC':+Z >UGJ[(B=9!@I +-5(>C2C6 Z*A+<_=Z+A7PR' +;(5
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MS^%'\C)TSS7W>=%0M@@>OV4EL=^4PR1CE2N,IZ#I?IM[^\*#7#%GEZPB*LD
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M=M']773_KZ;/O7B(X+[(;<F@1\"DL4;'2T:"2J'+13/.D F G$H1IM1%:/'
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MYC7-MZI+\ZTE-*]B]>M3=\M0=^6INU,ACMZ$OUZ<V=W+SD4;B+NC&'H?PZ)
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M-&,UZXTF^?SPTL'0 P RO)]IE#O$""\+I2LBL82:KHJ4+<7EPW*9C@_CWSJ
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MZI;JCC^KXJK]VUWJ.@D@"Z>_<Z]]6;9_)]<RL_TA5X>9W3?X)<8Q@T'M]:Q
MEY-[.5]@B.7/C&%?*30O8Y*$.CE![6RA$,O?3#!_:JY"^(,<ZZ=<$VQI]4<%
MQD_%96R_Q%>5@[#U(P:$IN^\ '@ W,_[=54Q7NNP?Q^!N,]O*PSKFKU:DI37
M/,F?>82#:Q[MIQW<M173C]6*_G/Z?Z @'%VWY0$<%A:7&MO+*_)O1C\D&<^3
M?TFXKZ\/+J\_);S75[;?)=<^3Z[;EROIXF\)X?.5^M^ON\X%ZH^,7L<%@+__
MX_.;CO)7GG[PI%<M!-Y?T?^@KDM9PJ_4_97^(+ONU_5/.ORBWS<& ,39]JK
MX*]@3:'.$'/'?UB79DY</\.\*N8_%!+@'RH.(/E[95Z'H?FK\*Y#0W:T!9N!
M''5ME:^6#MR?<)"N=9<-O,L/RC6C(/T'WRB6,*BS_9]$R% 8V!+\:U>4T;HR
M4KN67?)80&<GJ!P( H(!G4#FU]&[V__<U-%_=+Z27&D4["RI_R^,'\$99ONG
MKX;KY/]9HN)H^>>O#V2@K9,VT/)/,FPST*4=R,U)P5%>6T7YYP:%^E/\I\YH
M5E"8AX0MV/)GIF[]&+S\3_%5=LU!%D#GZQT*S04$<_J;[KH_Q7_NCF%J*06U
MA<+^D%S<'P:2<K\45V&H0B%7=S0GJ/WEUY CZ(^)0[>]3.1?I)BFUUO=7^08
ML*L-[1_$UROHS@^[RP^\^"[@=SGN=1/NQ\Z#2'#-74TH\C6/>6TD^%O"7EY^
MZ"Z;<P" Q&4;DP) #("[&+_8 F!*F$--08^D5 #P%]L [&L.8.YS97<Q!7@*
MP$1%145#Q41#P\3%0,? );R%B7F+D!@?GQ ?GQ@7\YI^N_T]P6%A8&!A8^%@
M8^,08&-C$UQ=L E^F.#^5QQ<O /@HEX&_Q(!CA8 CPN'@ MW,7,Y4/2+5CCQ
MRRB1X*[IMS0B .#@$9&045#1T#'@_E$)!X!'^*G$ < APB' (\(CH2"C(B%@
M\EPJ<1$0:?"XD"0T@/BT#K[<R 0Q&:62=/2$FLVF//=@?@-2* RQ6KOS>V:.
MO$2OROP9I>.TS67>9SKQW1[460#MES]M&7)>/)!EBL\*J$AH'5XZS*[\,+)\
MI&OA$IB84]4VNG+,+Z=GZ1J4E%O=/K;Z!1< #W\9+>)U3"C(2+S7(=!PX2%>
M1N! BX_$[1M#<!5!L^; +@^]Z3S,+U9*B]#,\=X> _)5 "B,O.\'+X/(O&TN
MH\/G!%KX%<)_' '3[R%<3 (P$:XQ<0'B@,.W&2-"WLJY8_T=%J+F+4I])>+U
MAF*ID=]5;.(VO TY#XH*R6X)F"X(^+K(A-<UWAIT_9C?9V;X]<5X^P4@X)PT
M?Z .],G0H\]5K]\SD.%V$V5BI)3^DV='/:?*-GP&GA> ]U/626IK)^XSCWAR
M+;@J%K4V*A-U76IS<K? ?"*-)>?86[.9VNZ,<.$*\6Z]"%1G*[,BZA'//;+A
M/M"<<C6M?X_U MS0#=W0#=W0#=W0#=W0#=W0)5W,W_>U<G*R%^+@@#BR Z]^
MQ+&;0>TXW(#V'%SLG!P $7$W>Z"9#<B)VA1D"8:(TN[4-]%2@\U%:?5X53A5
M[*5 5F!Y#QA(RT-5V\S#QDS0G%9<#%W$3<C-SMX.Y 2D=K.SA3@*N8G27CL7
MNFQ?B3EHJ:^[.-F(TE[_=*365U&GEH+"0-2\[#QL9IQ<7-1\?.Q<]WCY^+A8
MJ;DYN;@Y."__\;%QW1/BY1/BYJ?^C6C%T"^O(C!S"R%-:=G?X"XY4=K?QN7J
MZLKNRL,.A5ER< D*"EZYX>9FN^S!YN@.<0*ZL4$<Z7XX^>E'&N1H!@-?/Q>F
MON*!IE!G)U%:6G3J/]!OX[*S_P7TMPG\Y?G*^65O(2D8".@$A6E#H;9B/T;^
M^Q-]*2T^ZCMZ8(@YU-7QK@C'/W;_.T\@Z<N/&#<G-Q<;IR ;EX V)X\0+Z\0
M-S<+)Z\0#^<?G/SH^0\^5*#F8 OWO_BX)W1IS2OX1Q]_Z/F//B[GTQSH!/PO
M>?ECWY\YY_B'I/]/)\/<[-=<V#O#;*^GW-R, V0+L@-!G!POYX/KS_-A;B9D
M 879 9W$P'9 2Q 'R-[10H3C=^F_.T#[GS/]]S7S2_W7ROFE$KI^C'0Y&2"Q
M>R(<?R?^=P=].6TJ*O^\R.WL./[.TM%)QL7IGULZ7CT0X] $.4*=868@&9?+
M>:+[>U>:((O_CJO+[G3_N/945(04((Y.0,C5TU2Q2P$[&&PNQ"UQ3Y9/0E":
MDY]+0$:*BTM0XI)D9/@Y.?GO\0CR2U\7[I]-_^)6&FKF?%5CO[DUOW0K(WE/
MEI>?3U):FHO_G[G]@^E?W/YX? NT_1?<_XV+O\#(@QTOMQAWL3_E_;I,M$ .
M?Y;^5-B"K\O&'@ASO'YN+$K[,_&T?S&XLKDN!2&@V74AFEUO1^8B''^2_L=F
MX+].VG\^_+^8_L?^7:U D'^VA?ZAUW_LQ!%JX>0*A($D+"^S_)_M[']G\I<\
M<_Q(]/_&!$ A5\^U_QM3<(D#O/S>!L$<Q2Q@4#OJ'_NE/<22V@E*#;2WMP6;
M :]<<+A S'];F[_VII\@?_#Q?W&LCD"7?ZW4N 7^L_WA7RFU']^1_X]+[7?7
M9E9 B"7(7(SCI^%/P?]7,R;XOS]C@C<S]N_<3_Z3+>1JE_GC$>W_Y89B#H*!
M_SL%^H<H?^6)^O^W0?_K:_(_/67=K,D_2_]\]OIYGOOK6>WG$?1'6<I>%=9_
M;9Y%K@_5_],-]!],_\ZS^?_DV/H7T[_S#/U7#L;_H8N_9OL/2?WGOZM^2#6E
M9<70+VU_/OSXNQ+Y]],-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-
MR W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(
M#<@-R W(#<@-R W(#<@-R+\9!/WWUPF (.:BM*ZTXF(74P I -R_2%=._E4?
M<#_>&"<!QX  A_OSC7&M "H  !X>X8^O@P.@HZ(A(:,@(F# P5]VD+UZ)1S\
MU3OAX%!04#$N]4CP"(C(<"BH #1</'QT D(:+J+;M'2"$AI"0 >WF,IJ8A)&
M/=>,TG)2>@8F[GM\5KY!%9=^*"X!KI%^?ST#$C(B"AP\ BK:I5KM,B8X! 1X
M!"1X-%04Q$N<2PT $1<)CP:9"U]" X6 %NC [4M(Q\LG"8O)V-4T=7(N+2MO
MIN?AUW)\6H%*)#7 <$_;/SXALW)X?N_/[W#SCHS/S&86ALG%.$.$!I8-E)<>
MO^JK6$$(IU<8H-/>QEM]I>&'*_><@=Q#=S(N^%VSOJTY=] N.1QR!KX7,E%V
MP1HI17Q=6FV>7"YXUWXP@<=(C1$#PY-%AU:I, D00TJHH_[0@$XM-*>"/7VD
M+O:[J+!\>>+V@B0W#B FGYJ$,:'K Z9-3)V",0[>;88)PCQF[*4E)OOB%+V'
M@\$[W2^#W;47]M?/XG-Q#[<X6;;OYL"D=3/)/4VZ(5(A6C@&-5M;H29=4U[J
MIY]/]I9;_.\/B%:M"QV_F826?_<;6O'[A.50>'1O83F6-0'?Z'5]OYVM.74P
ML#*\9PD/UT]>S]GZ8><A>^B Z4A=?X%91<V+N]!<L)"U-;\>CV\<1>&L&H1Q
M/.O>(&]E<8.<E7NSVS<5I<04[FW<J3/CV.5<7'?GVA7,ERN"=KFO.#RM>YL*
M- JMM=CB*_R^+>HAMK*2FX5*J@1SZ<68$-S"L^4LP>CA?_7A5"W[:(H]:_<P
M[<W:.?KHL;??[!>9/=I(!9=8.LLO-H+S+G;O.0->P7!)N$](4W,^;F\WCA*D
MZ=-/4]?65OB]7S9,+:U[,#,K.T%,\S0TN_,11CD9[Y;4#'OM-'L@I!&"+OQH
M7\Z@.8@..-#^]O2]/KS8AKW^^#WO%,-R,5_ZT '$=^[<C"J%!''H]/GEM 3X
M8K;BNDY%J<(BL!8ZH[4D99G*%@ %.5;;[).7',&W62,!!NI<Z-D4NF2:0VGO
M)0+WJ./.C5(CY9R 2^\<VQ%=F)"+IPH"9/4H9PTO "I[!<';O;/5N\FC@9T:
M[V;*J;Y^RGU9:ML0\\9Q'Y>QXTMV?M";L4!8%-OJ<-9YP\HX^$M=ZKO*-]6Q
MZW.9\K11D*V0B-X]0F*C\(/5AS%2K-MT :0*J/2TX:4 \SGW.7BU#OQ'*C1O
M*RX ]%8:?($1;P,F"-!:%=!"K. .TE4?1[ON$:=(/S[4AXF.0U>QZI?#F4;2
M!S1+OVR$;8E]4:[AJS[>L;,O*#&-@\R5<!?O)A(#.U9JDTE,O+&M)OD!>$6<
M]T5#J(0V&H%C"11WC?2BC8*'C Q&VJO93QHBQD[WZVK"5>])/!]Z%"?B/QXI
M<-]^P;2/VZD3I2&'.@.'4<6A:DFA^VX8D=+F*GC2;KO8E2(Q'<'(J#LV+UL;
M22/1U94YYE54Q797)K4E/<(&)MZT?*EDH *9@,9G9 6Q^W"=C)64K(XH4>2#
M8V4NKN15Y,);)@ZN/F1J0V&^P@_YNMD4.H9&IA!Q P-%#O62$]!6YTU)B M;
M??=!]Q**Q2:K(O*MDFC'-*MLW T08U([Z6%M"F29B7SF)J@T/G8=;B!-&=?:
MRK1!-72W+C%NG@Y0)UE\)&K'!:"?D%$HK,A#2/-J&[BSIOCWC;Q/JBM4A%5$
M ZE9>=-/AUUFWG(&A"M@6</OHJ;VX0KYY= .(<NCEI-3#Q><MO<I6.BVW<;@
M>M1R(E?U&L_Q<UUEY:M/1N"QZ(FZU@UG>CQ6S#@[SC?1/MGFF/78]E.!PF/U
M#Z;I)2T#94+>2 ?(2]5OSAVO9 5I),S+*6H,QCME4]S]K6%]>\M7?B1^ [EY
M_/BE=JB,MF< J^Z+NW?>2P;[3<9&>1A-J/(-<F_T\5+RW.U*3V);H94!KW%4
M#'X%Q/EPJT47%;*P-,JN8[!@@$NVMXWDD!IP*V*[5E.8[S#Y8' )Z*CWM#+'
MWH:Z?Y-8(.?G:VPMICT_,0<5![JXC#Q3?(,9%OP@YH#ZLQ2Q2JQ5>^EGF$AF
M+G.6XZG58S(QO.Q#5_D35C2*XVA9L;=-]:N&+?+'3'<"F-;MC&VS;(F&#I<C
M%ZR:]Y./9;\X15.B2V'U//9C%%EX79WD@*T+P]-"=,FI'[2D;0G/^XC4@E;1
M\H'R_4A";; ;116I(I6CX!';EP?>'&QWM/*<[RBYY=N<<[QTYALJG)I6-9,B
M!W&PT^C'+S(*+$;+H@FP?B N17"Y#U\5I'*X$C:8D3G 2Z$YWC&_'"L[F.NN
MC\D1/+AF^T$6>T37N)9&GCZ.3D!BUE5S=[]NI73BF]$;/19D5AXU_6.7BHIJ
M>V'6\,V,1$H.S7))%)H!W[ER\L?2MZJZ8D@Q']=\[&PU5_:RL%0X+(D8G/1<
MJ^/NB.EV8!@N,Q;J=! I,^$(X:9%QI7%NY-D&B#3V5U>WWRT6EX,+=E)TJU:
M%[8)JV$SK:@<XK![T#4I8-:-B]6*-\W<+1*^WV5>K;XO@*P=8B8_OA+7E<;J
MR!]YQCZ06Q4A9:D!VB@T5WI94^9 ?OX83#K!F!M9JXW!C]=L^&3</3:<T]Y(
M6M&.Q85Y2:[+6*=JQB)P>]Q'5R>-*.IH5(99 J739XGJ[5O8:)W-HS7/P_+1
MPZE4L<562@S%6K\G)6+"-GG=AM/4 MU2+ $B?*,=:-E3'V-FQ;XP+>+NWNH(
M'&DQDQ@>M7)(,73H'CL.U5/SPB4:2F&4UI>1#Q'K5O6(]@/*=;]_,EY<2-;]
M<"+O<#2?P(??WW8LA@C!"39I:M*]DAUC'OZ%@2((,-?U*."%6HULYWB@-E.-
M5;"IK$AP5QI7YY;:UU'_ AWUJ-:0,UY,KPO V=8(U4&?=\O>^@5@<^P@C>.S
M7OJ,XK./WG>;3\N]_8Z.3ER[PE$F%XJ,!N[ (T9."@=JP <PRE$*8>H6R6N5
M6:@D+G*]>C,KMBUREF='?):OWVYT)B<75Y E/Y(Z.=C#3)MHP8 -GX<8^]@'
M<>R)&]%PRAWZ9XL @ (3B@\*8[$/%4?-<PN1&=WJ+FP1?=8=\>"B,<GM5(CZ
MXGY942;N<T+DKF^K61Y[\:#$<:UGCSXO"^A-%80G\[TFL#!P*E84\.F,52*+
MOR^J5"%Q_VLLD@R99P )IS)*?LB[1?].(U?J)T>TWE0M>9-[!</;E<T?'W]=
MR$J5U[*('):QKBXX[LXS5LO&'J$U>'I+V,#<N3A!V:<2F9-]6AM&%7&7>X[@
M,1B9+N:K3EBJY1J;^ZFG[NTPZ[$0WH;$<@DJ?.+4S/@&)IO'5KN9.+*C]]<5
MEX16UZHCS)S*47M>%M)1G\FHT><W-Q/WY_ D+QJ_$(9A;1WE\YF#R2)?UW&0
M60SB.1>-H'TH"4?FO>\T_FZC>?0P=ZDO[=-89PRSKCD0VB$!MSO(E2/'SPR!
M/CAB<29<SB?2,I"P) A#-PHWDK< <2O.83*G8Q'B*OGH1.X;8FP5/GKQ=> ;
M8P"=2M[KXP[ZV/;NN'?MQ!3K2T+9PSKV-NUW3SX410@^F" /'Q#ZWCHX./2.
MO1[FJ\O7'7KP-'M>CA7'LC)EE:1]@UCM4S[JO53==2ZVJA?>#KA+"DBIK:4I
M'D*R79Z1;8VZ:-,0>9!#^+*9"_%BBH^L(.'PNIZB\S=Z&S:\"8.Z,4:0?K!7
MEIMQ-'U1+G%7*7$>6,ND*7Y>H>O-T/I>@)G@-X=1^H]J=C2A"R0F"5[#CK)[
M\DW:]D7"E MUW&44)47APH%(\F?!R(TYFSJG/;JK!MB!KYN=#S]8 \NBGWZ
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M3\4OQVFJ[2NL[\=W$UJO*>;:LB K9FRT/1 W#%_C M-W<E+GB!KXVDD-O!3
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MYS"XYO-VVNQ<]:,(I?/IJ"K=+MZ.!Q< >P@)7(F!J[H;!E;](5O(R2( !I]
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M6^'F15B]]XI]T0*ZJ4,%D\2).E5HUS&F&(<@J)@%&A("GT@$C6O;6X,0$%(
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MLR@T>MO)YKK4-^[XPB'F%GXP/U/[+YWIMQFX!+_BJ!2,5;5][G0 7^H>;<K
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M/8+2*M/\8E&W)?H=52&J%A&U@)M53S99A$F/LON<$GBVHKMY+_IT4L0CJ89
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MN&K^+G&!*_S>@"-^;]RT='#]U="R0;C]:BC!'!1_-<[R^+MK>2M[F]\2\2-
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M@]A_V)U]4&4^ W[G$U^<HOQ8>=#)+EKG XIQT<:[R-+(;PE+/_N<K6 H'P
MWK,/=@. $H!R.GZZ"<"3LW:TA%@H: )03S\!""Y: .L'YW:G4X#' #PL+"QL
M+#QL;#QB7!Q<8G)"/#Q"<DI24G)24DIBO OZ[>N?"04?%Q>? )^(@("(C("
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ME2>&_]\Z_>_/R?_MA>]R3OZ9^]<-VK^Z?/[<%?PH2^7SPOK/C;/DQ3[GO[N
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M\- N7AI&#) !^)YH^JCYZ(O?:N1Q!7<(RW#=E2?BT4.S&@.HV7'MDJ0S:T1
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M*]+.[;.3C;VR[L]:T408TG,"T=6$E9Y;/1_C\D_N%\0+1V$E0"_0P+\2*EO
MM21^L)5Q#>K.LZ8?IUQ;:("%BZ\!X6:,PR%9X7[)$4M6[N_/J*YNJJL*TA=Z
M*-<N4NZ3Q&U_WWD_M;<:GM_[+GWXEI%O!GX!8:M^M1Z[ 3!)8(1)*$05FL>B
M".&CH(6-B+0_%G]8RICOPWJD;;]["N#OFA&C&1\U0;K:WH:*EPM=HR92K+Y#
MA+S=WQE!0*-C16*/4R%-88I%3(W053(IX4YN/A[M:2P=YL5!71J>T1B,3_T&
M^@RK??9406!6#42E3MR*NR2AKM<:G1W1UIJ5X-8\>:P"W3<6N=+]<)/WF5X-
M!W).T[3!U3B 5_'HA=37!=7DW<"[-Q[&3\T1=GIH-NX4R ^.\51S?"^0SCLF
ME;5XLR+M:B>5$K:'T/=O_V"J\Y74?K$OAT_.8".<M5*5KR^1-%.-3/^IRTT&
M#M7MAQAOL)P_?[RZ=RP8(D"FSJ1C$SOIHA@C2J_'^JFX QR#P:A=@D% SL&+
MGF.++:?+*C@&H>L>75Z8ZOMT=YE7O42_.X'JF9*=270[)VQ(#9YE6*B?8 (R
MSNT(C\NL'KZU(%Z7V84\Q )79ZSNT7M[KI.\=:S '9R ++*.CAR9S4WMRV_[
M7Y?A,>[B5&ET#?[&*>\:[)/0+G,UWJ+RN#2=O+,T7);A&)O^U1XM'ET:(UVF
M2"7NU*=7)1R:A;[CSJ+JY"'=J<T%J]X52+*B_'7YI]?SUTJW!CK&;+Y&Y;R,
M>B>VW-=1.56Q8MGD<_=I^WWWC9U-S/+K';4=^VKYWFL#1^)''WT'$65;KN]X
MA8X/VZOV^[8.OIJX27Z\]727BIF2_@A?*L,-_>#K^/<UTN^(U1,:'[?[4*#)
MH92"+TS2BZ?Q%'"U]#NZU0[M']76/NU^G)@M$@T-# U:6__:V1YOYN(S)3#%
M9]2J2QG*@[+"CWXKC*+*1/@P+M>)W5$EQP8__J'U,V]K<?[6JK@)O7U4)0C/
MK?AD#N^ Z"\KK^SH>< 2-N'5_"VQ\\ESZA$QH;K&02[ARB_=HFN\6$!N<VM)
M!KJU)TUL!5I*O%)EB)[ZJZS^S1AJY.*?1NR"E1]/T[GV=(&8G[\W"7H++^ %
M3BY5%37&F7[AS8Z9G"+>3P''&3\KO25K(IY8=QL7N@+P"U!8?W-?JI7@\&[L
M_E=)[SNY-/L=3TC>5O+XOK@RG7=#-SGK563L! 3=U5JZZ;/@. M>.%D.^R&[
MO'[6W*.\*<V:6]+;YOS%Q^#:P9U\T\88=54+YRQ0@HEME&YB[NO;\F0;#N7=
MF(+Z>?&A[[&=2D2B8O;D]@37-H*33#<Q;^#377':06R*%8Z/L[0^J"E#NW$G
M*;;$F(7B.+#CU5K"319GWKKD,!JQ;[?"%>+V]BPB5\J+@4.J+/MV$"DABD$"
M=_V=TLJC8>?@8M9L$N_8H=+LMH\Y$XYV^>5C#3%4WH<NDH^,7Y2N\.3>[527
M\R#K1G"6L(E#<215K826A"=0NK3I><SC5A<VJH[5!L=/ 4/#8L<BN=XGQS_'
M^LYW(^#GK_[CI O'5L?9^M*(U=XO>Q,G66L0KU/ W#+IQY/W=<96WV:E8F?"
M#@L_[QUC=5C<6B-L.$10$-Z1"=M\>GB/*?W^OMJ8W(V=,44*4^YXK1@-M"P^
M8+%KLM!L3]U1C@T/LQ&/?;M F'<>UJV)K:TPQRL5S[$Q((V?L6E4@IZ^IJ3U
M1L=+,Z(#GM35O?!+,[ZMN%F^X/28A?9M\JQZ(TH[//MQU#*KVNN=%:KWWO<V
MS"H9RYR/WE;) >(%%X?0M=X18!2^B$QBKR2YWN%6^J0SPKH5ZSO%\+/MB@@2
M9ZPWV=+<N42Y)DTF-W)$2(FU&ZGE8'"7FXN"E)Y""=@G%-WN.KDM8<T<M5/.
M&3$<! !GVBUM<)&=V4NFC0EL$EV1IZF=8G92NB*>,#M*VR8IOT+IA<&IQ!UK
M3BZ7G+?/1)3P:W?-&>:+:?N/J51,=G+7)_=$  XOJ'4LMI!MI,'7*&_&N.5P
M2)!4DMPH>"TGKA/,,5SYQ>GX&DAGW5>2CY3VKGVX[0CPL2_&<Y(47A,:<ST[
M$X%I9*7SYW!U.7$IE;129&])?6WFC$F8U:2([PX=^6L/D]J3FR);@I//0,6M
M?L*BAI'&X4]2G1@*T&L_8*AU,ANXK]";PD/'HNXKOI=M_W3DT3XWA&,)I$AR
M>P)I.[X1;_DARZ^LBZ!%/\\D.#80-G_UL6#"!^-C/=0!,?,ZXEZJ%NK"=N,O
M.8SXRK&=NNO4>JH*O.B/P@.HT3\0N  V1LRZ/UZMC2.C<YOIB@&/QEOYYYI%
M 1ODDJNST>]]+23)UI^OKR2)>1O 7SO.95PP>+4%/^0PJ;&AK)@YWK#HY:,D
ME0%!_=@7E1Q/<1=!)NV"W\W]6/PY5<'?6<!KJIA+\R0Y.?3:!R<#@:7^R/Y/
M+&A:B?XRP:6DXW>MW*])WF1?@J*UM3\+0=*9:S7D-=X@;)A28(4V\8P-:"P_
MR9JN[@7Z-_"H]W&+Z<&JG_8VHO"TYM?@V$5&EFZ^]K^*]BY,YVL8%53[DUD-
M;, T[;GH"^*Y*W7#G.YLS;=;:FT_=':IM[=4,:3/M@1PC']38Q\8YZCS1SRA
MDKLI+9@"<3\9 46HUA764/HSW31J<RB SJM3U!&-WY;KO(5)3Z3>%$.$VI2\
M;CR>! RKIVZPG+R*:N'RS+B8HO!FAX?N3 05MX3>&*5T,+#;.CXC@ :JZH$O
M7B-8#22JSFT.DS)H\(RZZ>#!,V9I.6.9;3'A'U8QS\E)N<!D_<$ORO8VRIV6
MT&#G5VI=1M:Y<I 5(Q_\B#C#7EIS@=HZ?*T/.5IF!HM=$02.K(1?IF#V4(>,
M5S%/PB>QY>O+TQ]'1J)6^144U=X=N'U#TWO*V<'8M=K3S'/:])"L33-)X@E;
M6[[JT[HL*9T(3A Q8_J "5=X->OH:&T+FC^CX2=M';JH0>E,SWTMG1+G@<9J
M*R115 UF4?EU(:C=&IO@RBUF7@=GTHSF\FQ^(OO 2 R4164U#0T/[:4IC!$/
MP[5;Q9RF*OU!GIHB?.W<E:6?6<4CMTT*'1H?M32CNXR&)V,0:;ER.\C8:%:\
MO"%F6E?S6CV&;0N9U#6)A)!S!B-U1Q2"5O/8N"F_).5UPO@Z^#I)+3OUEI:J
M#6/[W^.]=HL%DIL6-<FH)TZHR,\'N=0$)=\T3GLW;T&LQ,8C!-47M8DC#!0>
MDZ[M&*E/?0?7^DI-L-)54$I@*?&H<Y[&JF!MI1>X,!3BZM<KC?'96YKTS=S"
MUR.;@33I@HW>V:87&^UU62)\,%V'&Y[2=&IX1NFU^ER)[SWUDSPLJ*+)JL+G
M*@3%NHV#R31,&>%=S-RB^*G"&(S0AE)J/D N&8GJMG;TQ-H'S]V]A5)OE5!8
M5^R&BO]P#,I"1$L9:>ICY!Z)<YAV:(E)!UWNM,^T\WQ=KJ@3L_DH4W?$\"WO
M0(-)8G<(I5-Q;KU:69TTP]-N_9LUJL?H-RB-20XW;\0()[D6 [N^# V)XV!R
MR##2=SPJ_/H>]OY!Z<O^U*#CQ/M-VV.E4:F56Z&&\XGKN?M?1Q^6J(=3!3_,
M4 $&]H38*I/5#NQA"$K -9J%RD0SFNM%TKD6B#^G'SIMISWK4YYP'GK,DNR>
MQG^H'3"YO6??TV'B +%#&UF181C1\GSYR;_Q30YWSSJ<-J/7CCWP4+CMUJ(5
M8\(X]=?UA74]A0!R*DK!SR-QH>W.R4ICS!^%/C9.ZM,6B.N%>#C#<8C$4W4,
MKVB;,DH1!JYJ)PT48K+QV/A'!!^XDZ>%NQ/.[ZSW-,?8;8I\837S^1!(]JF.
MV^VJU8YEJR5\8FS+&K.(\D4-2?33MA2^TMLUY>MZ[,- Q@'QQYJY2N(9X;=Y
MBR)" 8"U9&>/[=3Z$7N:7J/E;](-GWLE9^F_KZM\^SQ66^3[WAIV6QM4DM+F
M10D,G5GQB:LGR'BI/$'>N8&UMQK%3'V#NQ6H@*,FZ\-8AE30%N*C>LQCA!&_
M+WU5#[^U:4.@[) ,HS&!;$U$\(VJL[@;/2D8K#NK@G,@_T0#'D?\4%Y>4*M1
MP/3C1IV(;U<USV0(CB;53K;1QY&EMWF27C$>H\N%$IK&:-]&<7-J=A-P&[JX
MU,F.%M$_TWC5^"ZOR,&"-4P/Z7I2?9J:XH*4KM@(&O)(\9J[Y$G+G@)(GTRN
M3K"VK<S[<FR@L\,8\=#T::4W6I??K1 _^+!,N-J($48OX[>]<]ATM#Q4'MY<
MDGJ[USDX>P_SC02]_2<[XG31OJ*T3*EL]9%2T6[I=,5:HRMU+G=>A/6Z?2O#
M-3<NN/W&A]YS\(KP9/!1(RH\QUJ+/VYYSG"6K&6]V_+=-;66S]X C4<=!;1R
M'7HKF!U2(IH) IYT!7TEJA+,??/)!YZ5SBF^M%XC[\>NC(1%]SPMD0@,<$IF
MK$*&\0\:OATW#E^C5*/W!55P&CM_KB\Z^8@03YZC5^EKE/;U#YP+E=P3Q['(
M>O,*+4Q=V^_SV/L!02W@8^3W'+JRV[N$8J%Y0T'2*]IQU2HC5WFCPV_==/ K
ME[!_&$%^8'8#RY,_P->H1E^Z@/H)IM>"#8NIEAN=4C)XS Y%(IE1V%'+N??I
M?O6!-?+V[I*YP^'G*X5)3R;Y;VT%T:4&[NYJ6XAOLZ3X[M4YPY^E%1J81&7$
MF(P9HQDYO'A>\BI=-_W-4P(W(7,#OODWQ.):U"8'L,Q,#&%W6^\VN:!:Y7:K
M]^Z(R'IED:7;^7!J!"MPBJPS:EU7_PT[#>BQT9 $7-7#6XM]6]3?I=_$@4@P
MAMV9+LSP.7"S)V>"!+Z:R=)=LV5>_3%Q!VD<[4^17U@VRC/2%:#ZB#Z&/'>P
M-2^+4S];/7&>8@MW4W0-PN=8K++AL25Y"IA$!IP"8@JDK8^C]J@-OC=B?GYL
M)G<2_-(4XG\2M'8*8+%O[)=^^'+OQO-30#1^QV%(B60E#'/XW<LJP?N><L//
M=N7N&W;3GR0/R 1\2E'1+BPMG&KJF_Y,6X!B<?0]1<!V=-]6H@K@J]Q ZI[N
MATV;Z)-R<^D:*4G(2'L4BIV[ 17CDA"5,OXSQIOSU(]0<^0;QQOCK=*(NXBL
M:^?#<RJGZVVAM!-?L#B6KY!4T^0%<NG(S4.-QV>[KL)2&F]@ZHT7IBB,3RYR
MFO4I)&$GX'<4:*:;@CA)_.&1-.C2EKR%BVJJV C^CVYQ'!5T)G(]G1TSN-VB
M;U6]HE^9%, HD;!/UR=A&BW.VP6U.\73W<0Q7DM8H+'DZ^+MAL4+[T46/,E#
M:S_W N>SG=/J<-./;8Q<F@-HS%F=/BW,2:K/X53JZ)-&O6E5&@Q7I9Q_=4V"
M@1!EXD1G.&P_W_^;Z\O#\IVMYRJ;]X^7ON>4I6F$BNU.>Q^UA?L=PDOH1_!5
M3P&>3RTZ;IP"D@CI-NEK3@%;<4>Q:1J19VKWCP,=5PS#UI]DW[>)5FB7L1&?
M[EN1?E^UN54LU>15=<2S=:8;\2U .Z>#NN=YV$K/]WGJPY$"];GWH!2I*9SH
M4H6VKHV9#$SZ0"@GQH,/BV36ZF;6+JP;I):US*X5<Y&J;U("K!98'CD],=R]
M/Y!B&[/R-6=;H_'A!(1 (5\XU"H\#62H/\YPU0@IR;@\J!]>G%&3QQ#M%%YB
M!__F!GGAQMV:WQ=#LE##2>*5?",T^>W (R$<B@6GPG(ZO:*\;I_<9#<9WIN=
M91DUC]67,V!L5,VKJ&O"YEN#QGN0AJ"/;!7 >7$C5W&PGJB]8C$'1'Q6Z'-!
M^^M"]"$N<\'<_C5*9>> N.!VDS:.D>$U_J"GX'Q>->P^^8U!&MO\%4I)XD$2
M[6R_!UIU5JMN.A]JK-[7<1JK%?0V9NG2W']\E?A*C,HSJ=CP3&QLTZ F_P)F
M%#L%#\S'=JW3%7W5O':#"!A8,1@=G)G!W)D<1QL[",E]IZ-0"N_AEG?>CO7.
MN$]=;SP2VT:(VO'D"0H1>#(Q7]@= =17]Q;MCQ;NEBAE(9 @C'ZX\8D/4 +G
M8R$=X)B3E]>)SG9U1-[#^3!]O/[2S50PS>.P:K$.E?G9;<L(=>@^*6H,?@Q[
MKJ2[@U,M*(UCI:'20B^2#ME686XN0FN[G5O?RU]L<ZVC62C,84&F*OA@R*!P
M;ZM?6-P==GN W_E!J]D*3ZA]DNN#ZO[U:M1Z;(EZ"0F**76GF]%L#.]"CSRC
M(LVOR,IA(=NM7L/B9>ZM;E-;IAE#L>Q,(A4Y<%3G5M*K%TIX[N!QP%RB0X5B
MR#C8K_MC=6A)!]3.C2WIPWNJ4W@.HRF%G1&Z23YVSL*!6/FM?CK/R-6OQU!E
M?'Q$<M,Z?)!%Q>-K_U4F^60XXD7WW;W5$*O$5-8A%L7%E$VC(X5>CH[DL)S6
MCU2/16F,=V(*8 JO'W1'-Q5HZ'F JI)7)'I5;D9_?%'L/!8(&G(T8-XFT=(E
M)UD0&=X3AV43-(<H[)>0X+^<*DW3SA-^8OF\R>2^ ;YH>#23DIM9@TE22T0_
MJYX="07@XK^8L!-]<>TP30VQA)M?2)WK3^@21K9I7O]([<WKWK&G+":#=+PO
M9>@^5!'S-7Q)>+N&UQ[/AU<]41S9[6L1+SK6OV8P+K(ZH@I3=[B!7IL#(13,
M#)0MB L';:A+";U*)_=KQ:(<[7&;FC[>LB^ES2\>'R.;),MCF@F,?<M*J+?.
M4[O9E"T"RNW4*,]CE.Q @WPU7)!L*_"OKB'?&%U[J<CSHBC,Z\X7I6[Y(W2-
M4X QBDYT^-V&:K 9V$(DCZN6:(<65_)@HN,=M$W"*%H9-,4DP (JSSF^Y9:;
MA=*F69M3"C)A;55&@@,WB=0P K&6JM=4VU$6^=(!XJ6-&9.S,[4^([04RU_Z
MLW18-!T;54OD@Y8,AU(#9.7;0/%G*TF:)FPZFAM])).=G&>IS98HF3KMY ZP
M++Y88N2%AE[*A( .A@@]+VOG]76OV,HA6WE!?U75)RTVT5,68_U2V?3%V>31
M7A,J8'>+:(1/=[TM(0ZRC7BMIU(!SB:/9Q<%H"$QK&:1\5OR^J(^O;WR 'E_
M6KK=1*T1,><&H[7#*./,'%Q2] PZ1B8Q%==8+PED-=7HD>2$&L>IW'^NW/(T
MN[Y<A_O6NY.NGADPY=!1YG>T6,7 R,6]O4 '.0O&P?>O [YH>L<-K[TAR".*
M8[TS&_OD(.8QDY+&OA9;(?F(8KT./M#*SBL@T&F6,2'$TSU>MSM2$C?D*E6?
M;%4I[-.3-CB\O]OD7D@#:R'T7@S%0AY&7]W=&-)7UPJJ)W7>E(*5B#GQ6Y+E
MU8-UDMDW7NHG+TCB#II/[)\"7 3H^SC'HL7VAWWN'1O0-QMU+(QJ3FCLM<#"
M)A+27L7<_,ZC\G+ZZ!30'WI\"NAAYUM^V@R>NO%MK>@DPO&;[&C[";%%4<F+
M4T ADGXNK_J)9X9OXY+V-_O>4\"&4RIX?VO]&?71D=B2H]X^1#>T<R_,U*=3
MYI"D8]ON/>6Q<]A,QY'W!( ?L(MG'W)TN]$DM*&HC#/-4PJWH/ 8[PJU,S'(
M)O2C3V;C0AJ=RPE\BN@SA>I5P9HE.)OH33?L7OY'E*QE@3F>M1LA=&S#(._O
M3CX2=)AYFKX4DS24QG+TP=X!K7;YM!'[$EYB^EH^)Y_;)S7G+(&*BQ2%S\>M
M"HZ],1=H7JOU$"PR9=YQ6%)9TA2?[(/'.V%KR& /^C?X%[YHC.)D+*#!!GT!
M=&O3$V#O5[KV$QD\D.T4IQ51+]3/$?Z8W].\Z+Z$[3-<6SG%B2B*IO'@6,K0
M(LL7I>'@)<O'^[#&[SBB/:IM\":F;4?(A#6D7.W#JS>6$X5!L6LZ1B9\>,/X
MOK('=<LVS?7RX0=1*RWCQ;TYL8%^E>4MD3E>^[:%;V:U,4&EY!YT,K9ARBB]
MJJO(FQ:1?F\9_-/P\KHW/J!\[BCV?'7]9@>'3]^*[NY)%;5V0VUP;,[==\O<
M0N4D4=!F!*PD+UG>Q70R)R@\I,"Z?>>SI7P+\J'#U:17-L/CQCZ)VVY>/*EZ
MC#@Z:@PT+.C?:!YG^Y,=5@V5I0'W%;$)Q&9I-?PBFRV$_)4D9^D$)YQ" 2O8
M\Q^Z;F'CM!-J6'YQ1'$)('O%=%UVW1VX^*:%0:UH-Y4</%XK:87]MC"^OMO[
MT)1 (?#-1D"PBVCSFXGNAT_)I;O:7G0D(Y;L6#P"/JIT2@H45@L_:2<*E_)U
M_9(BX>NQ,:02(J)3_+VYW77SJV^"O]7^]ZR^4T#9?9%7]$OE$6DX'ZXO?CKQ
M'3.U,0MG/GQP"OC<1/\<A'E"55>61%\JMO&ZRL!>3)4#V-;R AM:TH-3?I>!
M6_=.CWSWXV7GF$#FJTRO&:D$3RJVRS4(JLL<O-7Z:B6/L#$9PE7\,-%]*LH>
MH\VC''IN;/@_#BA50L&P" I]Y!]$_(!IG@F5"B@H3ASQI ./" T6H4C^9/NQ
MH/BFZ)!M.\EC5O%VR<.%A;)TE'X\0MFQO 5-?8V44X %Z.UWD)38*6!@4WOW
M.]_['=/\EX73:54B?=ND?0O;Q\8?S1<)E]%STNB7;&K2@K+LD-\\CHV3M(V\
M[[]8::HXEE$;I3P%+'EJ1Z8NGBB/O%#&/H[!RC/F&W^[UVYD,5Z:]D7Y>0G*
M*D>:[V];TV^[,)NTKX?6DX0%"??O6G_?]2N@7GWXO03!O#:5R#=?SQOQ/:TN
M3R;O>5VHQW<O8%8ZKQRG)9RX@ /'$UIU[XEOMA2\5C!/,?A)3"AMU9<W$W<X
M,.X$)"AC'<D,3$/&! OWIF"Z9E^E*SAHQA)Q3?6NK<E65_GU:L#$QW%?,^*N
MR^+,S7&PX4_V/)SU:??;K'-D=]SG]-YK"S']"D^3-\I742=;S7O)B5#3,'5:
M1XMD)C"QM^!+>J?>'ZTM]7:UY.Q2F6[7=':]=$T;+-Z:2CYIZ)N0:Y>>/@78
MOU.<.;;TC(]>. 4XI<7-FZ=H+X"]G%@ O-35  #:#(P.+?TL >;@H<4Q^KRH
M@5O'#T;N=]W>6B4,@TV!M]7O?2 ]C&T^?N0V=S3W_#ZRVGM^X,A#BOQ^/?ZM
M;S&IWQ\<?)VII2?+\T6128!^PI\*V'BR>3(ZL//,3'N?/K/V]CWLL<8*C[?V
M[42IMY$U?#,2)^JF/=CBR@8'Y<4%XEJNYT]@O:5J-_TZ!3@Z,M8^8F\,O=F-
M2WMCH5<^4Z\>*54Q4_ E(.93;6J*"HC4*5)VFP%5^P'F&]T;:ZO3R/T1Y1>V
M_>0)QKUEEL?5F]N?W_,8M9GHDQ/>)6-8&AQ:%*5,@!LST48DL\<JAP,EV3I9
M6ZLW(I;BB86<IB*4P.T<+6;*ZK>9'ZOD%>3U1]>3&$9??T\EK]>:'E."A:,+
MV( _5[EFN&4=N)O24=A:.%,Z]=6?XF9_^4M(V16;0?/P79'Z*:[P+P8$#BMT
M>-4+ UEO?6#",3RH&E)(#^,AW_P!3_4H*NNWB>V"\A45LMC^1*KZ6>I'@X)O
MG^@&UY<SL)I&V8$U6>W)U'(7S=4!8>)/A$K&ZQ8U0T@:B'. A:YP 1'V+F-+
M[CB2[P"6#/_M .V/.EO76H@J11Z5BVZ">!J7O!SL!Q,?/JN]:5=2PZ80" TH
M>B?(V)5=8,^(J@EBLN+%TE7U.. ,>EA 8E6[S-5*5Y/8\K+(GFJHP*3JS22'
M,^.MU^-.X6433#"B 05!,K!>1@=/5S^W*GEN?#C"?0*0G0P&W681ZS)2S:VY
MIYXZ(BU)[2=(&4&>S9]04FUAIZ#YX,GPNNY6OC<#8$[#7L.?]5UVT:-;9KL?
MQ=QZGMN-*0\5QDB'F"4Q9>_52+LB&JH#JVB=#V\.+:IA^_'&FH/BR'G5GC%Q
MTMS4>;M93<]G,9>\^_U;X6V99_B/3NAW./>UJSJ^W=F:=25<M-)1^4+J]O1H
M,/<^TO#]X5N5/ZEN?TJS.04,$IPL"9T"LK07V3:)]W)N?E\O>;D3VVPE97N
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M5VX#O[X\V<0>H1S"R(-&Q+4!R2'A1D>HMG'4?M'0AM1^26Y^9*M3TI+'42'
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MS]YWJS;*)G92[;'D=@YA5SX%RD9^R2DU%R($@VY7G_H#$4XRS'#82TUF-/\
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M!R '( <@!R '( <@!R '( <@!R '( <@_V80\K]>)P"!.RAR>7$I*^V. &H
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M>],<N\"Y#Y^^5B_OOOI_4$L#!!0   @( %=$-E/42LP=2R,  )EQ   1
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M6N9M$X9_QL'60X"!'!/\#2("?H"0@8"(@6!K!--1RJTF E5,E"0$./J61B*
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MJM#E J]*3&JB8IE4BNB@(9VI@4EKUN6<SB91,6.ZJ_<O;\AD3@0I5\86@9E
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MP7QW(]1AF-V<OVI"488@3ZBYEK7Y#[#]!-RXD"YF4 S6R\C9'8PS4P., 2@
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M=OOZT=TK(ID?2/LBA'O=_4'X=_G9=O=[_#\&',A?VQ& P,)WIY5P%]89B45
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M]80CT J^REQ[Q15PU[MF,2[@7@C&0YEK[VL2H+6!,5 #B8("942E1,#B$A)
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MT/7> E,82D2 69H_1X"/%:U_7M\9_']02P,$%   " @ 5T0V4R<1(X,,]
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M,$<'L"/$^DL3G*\E)RS\ ,?]"M>TM;;YL0#[:P&"MV_@$\M!6?[, TKM,1\
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M_!2KQCD[D*FJ&H>E!O:2V\,$_7B#I6)>BI"IQQ3*T^60K/((T+R?=TN3B[Q
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M1KZV5%)1Y/W5U[[MH[$7'"?VI0>NUM9OJF?_$OZ\A ,6Q9N/4H^QA/S&X8"
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M773@-%+ZJZ-PY5#O/?SUC861*O'5K$;F=Q*=/@1'F6EP ->-D6[?K:S]!3A
M,,4^?>[9')'_WG [$>V[$!\F2^KGW"JJ5#I$'!:6;F\//AS=,6 VX33)Z!5.
MC@@Z5&LLXG+=NA3$NU!@$J:5Q_A)2VE8UI64^:8WCTZ&Z@NNN6IQA4VN2"[#
MI8=8?:#,"H<"*[W;']VK<-R<&&9G)H6%J\*ZS/KY-J\&>XX(B*M,MQ2R\@L=
MN+GX1ZVPR$.X72ZHM9*)0)E[I3^TF(W=5F^ T=ME=W>E]VZZ%2OT]H[D5V[B
M2POH*\@(.[BE+=>;"ME=\+EX[O8P.5I$'D:,>,KP]K/6PAQ;FD\ MN A&CA
M!@^=P:E=4ZBVO':\.+4B,=6Z=K)UM+W_J$,]@JIEOVWT>-F59JVSGWJC(^J
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MLV[Z6T>7O3)[?L&#E3J$Q['?JF2[.0G"\Z*+OSPE!,6NDZ49J[VG=QOH8,1
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M4IV4BY3L(;L!A()2;JIFUOQHM;NMSV=\@&N:T^2]-+8I5=KK)Z;DG-HUW&G
M.FB$E#MDO?O=8L^WH\4.,X_X/NA8?-%D;FDF^5,YDI-DJ\IAWH+/K(* E[JN
MKC)NY,W?N1.;(#D"KVR;:MMEF4?4CLVUG=+@"4J5#BOJ!'M:](T:+E^#7FL6
MI.,N/4F.R4VJ^8)A'J[6MYBFI#"IZ&?&'$SE)[*&SDNU7N8?*4*Z(Q@<>V_;
M<D?B2>L'9H\%G&R27>M/<]J%):N(\59UB@^,0IW,;P4R+>%+0C1OWK#VJB[V
MA_L>81JIG%^[U@_TZKC= CHQ? 2:P_.43V.N?98YZ+1*M4]G'B$4/N(O<VL$
M?Q"QBDC+\S^#SO2P!K:U=I$'*[7;\])0M63[1TA"47H=.&GFU4;B=A3\BY''
M\HOEFD"OV%:\I3$'7:P[2PHU:I$;>-3?; D!9YJN<#@9G9?3>A,21Z=1LH\U
M/_=JAAC$Q1:*,4.J2C]?CHS8K>KP*E3@Q0M@5,-=K>KVUO +>;@)WTP5L)K$
MT_I)H*1AH=.-O0+-A$O;SW4' =\BH;"&Y9E-CE-15<(:DF;!6VH%N^4E/+SF
M=4SDW9H!C\_H+$N(%[=*PIM2<RSMR[B$!'HO!W#6-A1@V4>*-44U@IU[CG$8
MT\[UDR(5W!TUM042-KP%1Z<]>6_ @L'AXFF(EX7$25@J-$3&(7QFNU0P5XH1
M-V2IWB$*T33OBF30C//9VXSNXAUN5@3Y2/D4L[JY_8Y&L3]A4\2F%J>&Z?&G
M?GT;5LUV;D+=[)SL[TD'VJ],&*3\*[CC2Z>+5= <>H3?MTR?#)3T3&]::F/'
M+B<J2V[G,1=N?56"]C,@CW +&]);M!EUT\+DI!@2:6%2#"%W;X)F JP5X^Q6
MU>'2Q*X"J5-S12ZNPK'AB)V!/<UP>SD "I,1/>___MCT_^DKY$+Q)>VK@OR>
M)(O(OB<9@6WHB1C0A'6^P13"+$9(-$D7XJF.,1\" D5]_4C=.K1Y:>)9<:&$
M[G&#67MQI_:6W8IQ:D=]=#&B6NXEOO;\V6;&(=SBS5BR%$?[>YBJN%QRD4GO
MC  0O8T&'H2,?M6-LL0K9<HTD(N:3Q5KZMS#RVO"4B20**7$ZR=:BBQ:B^-2
MS9HS&3QBF]KWJ<P\S_&*GC2T&H[WF';+V6)ZUZ%C-;9JV*V@#A886Z,6'?GN
MM<%H6/*@1+.:8-$L?;,Y&NDB-&K G KET!$.=%]&74&)-+VLV>JLE\T>=-NV
MVN:YAR65ZZM#@ 6H^EB<S%2BJ8'YZM% ,0IU<92YFGOHJBU<!:X':YG9'.\K
MJ:L:Y:H(H?.I'&%7MM_9CIOT*%$7<T5\2J_?FQQ33@E@R<(HIV>QLI=D]B-A
M)$4-M'W=BJ]:@<XT2>6'CHK'7;2Q:RJCU.<R63,F%GL22\[8\$W6:4&KWH.U
MQ]1C3VL>CK=51A>\(8S-EYB-BVV5D"S<FID44XWD24C?-<Z3ZFMNJCDU<?^K
MI?=Y=;\UK4QE*#D<&4'>I_G0.M-RRB@'8DRK=&A'GJN;^VO*C@H8NQ==N#0]
M)@/88J&?$(/9>T5/:S(P+<8H6M$=HZI'"^T^0 RJXJU#F%%EGO[3J4/_'URL
MXA<O-1%ALX,?T2NB2[C$.U\2<7>J('!9BE\:\BY1J8 #H.5II/A9*HX!#E[Q
M&.MH6Z1,3UB+)L$:Y9A0@A@L'BP<AN$AI.X&V^]6%@193KBENM.$XYO:6G#-
M6@OB2T2V2V[.5!;O=',4XE$X/8]EBO%$<M\F>SD+V<I$F-999G(H%PAX>)':
MG%>;+) F*B,EJ42>L3-<= H$$C;7JW&N$XKNJN: L7QP!R5@JO,Z/),!-9/M
M=.^8UL,A<#KYAY.D@LE !%WSH]*1IGZYFDM_[7P),ALK&X>U<G?ZY.!R-@RU
M;8>QK7M6067J&Q/8;A$UW)WJ&GJVKAKG E7AG[[VS"ZSRE^HC7=,KX)*"XN*
M]:YKQW7JQU3VO2(,7HI)I+9+0B&Q4"_)8NHKS!:(DR4 N:_83.=0>EM,4(HB
M9'0JS4O*!6T-2(](N@DJ:)C0_KC)*EX09V SXM0<))MK4U.9,ZW_\62U/.61
MC6R_&2?<BND#+4M,OV:]Y\?=G4^ZC45C=8.]6C&=T."&#F9,+MA59_Q)7GS)
MA.;V>Z <.$]3CT/*%6>.:9I8[%510S!PO6U_?W^- <]/Q)8$%<M68<J@P]"!
MY%W5JM^N<A7'O1B@,V14=X9K=B^\$J%83V=6J<3EL\? Z)P]HZ.]XC2').VD
M6:)\(LS\2O(E5QZB5]KV2<.JLE;[5J\G%#S(LU_HB;F&HRW^I*1_'_%JW*.K
M*%#['8NJ),Z%O0K,54 K3[67QH"%0:B8[./JJ/HGWZ"M9VSQFY<:0G%-7/P3
M>6.87%Q-Q )U+:J^4IM5XV/Y=)MD6DF70_T6_9HNYB3UM0TNQ:],OKCFS [S
MCCD]L*E4G[,\&9303$KVUA^Y[,+QZ=:%FI9QZ]3T-Y97[& $?ZZGN=*)?C!F
M\4A5*P8K)H9)B%MIK2^>F)DU^$2_K)!QOE=;P-#MJ9J^-"I 3K28WT9>=/N2
M7>ER+VST_<2P-_\N6V$FO_&WG,*\,LO2X8W=L?FQT6I;7;:2=^.[%9^D7*KI
M':2@WP+:*L>M">NX?4MYN_B/K^O)COW2/_Y/Z/0+'X60$;5"U2T;'^)<)?_0
M8M7M*.BBU<D&/7;&HN'CY4@:C?.ZO'&+C.'WGL2].7.9W/FT<PT84;3*U":,
MD#M+]O.*ADDM_;1KQYRG&J?P*:NF.(V!4TWC1ZXN=(ESDW%F9K25'#__+W$N
M..8GZ1IX;0:W>C,<D(3#U-KY_BMV5#1?'':65G69:@ZIAI6R)-4NE])K)60?
M;GY+TD/I(+R*(LV>9XH,LE$J$;XM*9$#N4RO4SA7\''&E8HX!4BEU("A,%QD
M<[?_)#?S?WXYJ7V@Y>*N-JJ=3",6;E'UBZ^0:^&3<R@/](^ ,- ?=,C?5UBU
M[BW8)LEB#+<FX&7CM%Y&?M&+$D003HO4W9@"$'9X :KHR9Y3(+HWI?+(J5C$
M","RUQ=<+QP-9WK2:P8@>*)-?/CU1-=*=Q;LZB;>,#*]K%U3K/-@F;E],+_6
MFJNAIOZ9PP:13+WX*(]-*5>X)N<JF%B*X0$I]ZJBDFA10Z(B9TH(Z4M#L:?&
M]&ER.L!5!G5S& '?3IB?B\9.)=3\WG:WOKH>,L.J!#I=6J<J3&:N:.N4Z<E+
M\VJZL1FB+8[RM/%T/0'P+6"804^ 9;D4"6]F>.<@W5:ZQJ2+GF#W_<Z1P\,"
M8 *#OFDT$9APC5U=4](HF;?-$;I*<!8=C?;9G</>D;"+D=/:Q8R14P<XR:ZO
M]UHG)8$;$IZQLMKE"$T&O4GW9WLG/95H$BHW->T)?B+SJ-8%,38-9TDNK'%9
M6+G":>ZO\24HK-A'E?9)&\UCKJ:P^"P(2:XDP[+MU6W6)L>;+.J;6BW ^LH2
M83HM]V,TLG0F-9QC1O(EGLPM8-P@ ]+.!SP,YSM<A;HX#@VRESD;#6["5OD;
M:S4 "C,],[6&B"^OB&=SF>YCU'DG\@^%#S19+),*"[ X1Y/>C2\=Y&W:!8&N
MDPZI@:'FO!>HK^6[[208B;Q8XA2%,6"L,QC380%@OUQ8_L0D.5KO!S]S4@1V
MM/&];80]GK =!3C<;.^ER*@9%@FW[O+ZT".I0F[KZ2SGV0:75<<HXMWDC#L5
MN@T,H8["R0ABQ$Q9'(J)53-35649>%F01Y<8TJJ*0@N3!"#!W#"DM;GO"<>6
M%B7+M?&W%3_(EX]O'M14U.6!Y*E\>IRB04L_[##;1[L914W.=$*GG?J25^(>
M)[TPCLZ:2[G-)[F=W1E_N ND%GB<1M+E^%E'V:)*@:ELWIHP]"5'U;2V09[:
M_6-#WQ=4NIU-0//W^U2F(V4B+X>H$.)"I'4)FTX:TE5@##-&*;#8D@WM9$(W
MF.]^AS9ZTQOCE,'9*!498Y-$A,$!0^TZ,)O$QDRAS0_&P^92@\/#]H)7L.L%
M[QK2(B.HM,J27U]S!U3MYK)8_5SC:ZYM377FS.H/?[?7.\8A[BA<!HD]F;F)
M9E.ON-XHXTDPF81$"YEWB;Z#W7_1VR7_^#C%9'D'5E@?*\UTWR [^;$Z+?;
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MB6BNF2&8L,*.R[4:)5=6EE,G[>K-6EKIJV15J.R2REM%G1UC=Q)@;2@Y66;
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M\E=(:40#J=-#;9M3[7[Z\?/=R&2Z8**Q4&:$^+5OJO;F#J[8N6M(E&@*\Z;
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MMQG9<Y!/W?SV65;FI5DEZ4C) .GQG!;C1>1S Q 0J)QF@"VZ+O!N_U@@:C!
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M[V1+R6?N/A@#?F_C#&4TO+32OHNK=8E;%>S4.K;6F9I%Q1O-?I:XR5GL$[B
M-EQGZ\9._?GC<T</8DYP_Z+TR_!'JY^]V90##MD>Z^V8+Q%UOAU  !07S1YF
M&-G53>-*(>\NFI+K?3HQ=2G">Y(]N5M(Q_#LG38;Z\*E6!(93T!S>6ML;>/L
M'M&:OX[ ]3=2-;V;LY\,K3Y[6/T-$F:F%[W0M?H%<:-?H$O4TIQ?(].LA)O:
M9+1=VG&BRB8A8-9]LXEN3M(]MONEA/CIJJM84>7U>2;@X,"EY^*MC@T^:R98
M^S07<0^%KIO=9D?\\NLLHK0(16M.B]K;Y7[9T>1/9P<_$SQ")156-]7K;[SE
M4UI)J/5UZ,;"&0[@/ O/SXX!-A/DH];5$E/;O;!4CP]>Y%+S!2PU<6DON%*H
M!6/PO+0(JS9@)//2Z0QY\D5T6< KDZ%'#7^9K;DCE,UL0Q?3E INR#C,GC6>
MP,\M,L5LA\!RYG?TQA4"?G.UJTA1&%P)AZ/#$R%]5+'[;=?K(@]JZS-TTA=S
ME17"ZM#V8.=[+D&.%IJS?R[+8& C/=VW4G$_\ZHE"<)QZ"!Y,M3'$'67F'-K
M8JZS(V3>Z<+C.6)ECJX2"?Y*E[6)&<;Z<DKP5$)4DP'_:[0P?YQ(+<O?B@E?
M4D3P.51O8TDW'2[G&J&F%9XZDC5^LN*@I=1BP\76LQT[Q1=2!!&]761Q\\*%
M-/UT)2<)":SH\!::R[X+XMUZU4J].23]OM->0THL.>0/H))=_4O=317KO07V
M3OD:)Y4A=]6[+*4>!:US0:;93/:7Z,Y@8S5V>Q=LR5BU;8*&*?IY+1%+&H$Z
M[""3*1.FG?ON) >_N78S/\7J*GXX1&"DLMP15M<_4!JPQE(+?G_G&%?JF->:
MDTVG.Z]H7)FP%S$8Z@O8V=<+,=0L+7;L03TBV'B11W&[&AL.\?9BWY6=S531
MBO'12G;*2KLZS*C4CV8KU:A['R)],V[YWC+F7._A#SUE]TQV7*+.>"*I0/(+
M('/7&3QYP=T%R+WF\K C=2YY\O^-DIU_(<];]<?$*,^E.MW)NF-=<_MU:=4T
M= E1Q;Y :"JLY'-WJJ?P5-B[U_^-H_AO,,5<];OMB_^8/+[_8]JY^8_IA_ G
M]NR_2<?I,YN^/JV^;#G??$-&?+#RTJZONIXR1KQ"U\6C&&^!>J??Y__;]FNB
M7OWC#J^/7;)WX?=6>&RM_@3%N!_G[PM>VO6NLN_N:-= ?*KY!?Z2KEYOU,;3
M;M/AP/95-'Y_*JEW#"A(]/!(GA YP@.*5?3MS3'N^1AZ4#R']6XSD_Q7>T*F
MA7;5^%C:.!/2P[R9B;D^ CM#+-W3>XZ8>IF[/>]L-?^>4D_>>3:W6M]KJ@ U
MXB> QY%*\)F&Z-DV<F(BJ4>&'I&>MQ%KPVZX*P(0";JEN[;N.YNT]I\6=/E+
M9B9PKR)BZFJ$OMJM&P<!&AJ-7A$ZI1GK2H\1U3EROLZ\%KPECUSVPIZ_SJYX
M'M^?ZIW\M+(@Q-[&ZSVBF-*:K$>K!ST$GG&=T-@ZZFPT/U\JT--"FZL-5Z*$
M8,@XH9*$XAB'Y.,+?\<W+B1_"^$#[]'374*>4?,;!A=ET,1_3--=)M%N&"VJ
MPJ[E4EB]X9,[N!H180_I6:!F-FFVP0?AHFU=^7(X]MH%GOI;$4RBDI>"7[M_
M;'V;'[G6:+L%\U$(K24O^C<MGSW"@5>4HI=Q7!%5R8M2?0>-7[4#X9+U%U$/
M"+!:!9+<98C\>A/RHF+-SWN7';IJ;>PCX*'\M$QH@EI!0#A.IF'80;Y-;$>>
MJ\BS;8#CN*=!Q'F'MT.]/TEX5!+QVO6O\)H*DYBQC9_,CW3+?"0\#T?"F%OY
MFTFEO<3E[SA2H0]#W+7$6)H,*M*;G[]J0!*Q&WG,'^^N%*P"$[>?B)K0T1_U
M1GKU$L\&V2TYD>GT!-?]DXX2Q_#PR2Z/N20NWE=>\FH'"@J:8/RK)//QE+%=
MC?$AT6D6V_.2B]']>*V*"ZGJ\?8OL./Y Z<Q(0.9E#VII5D')-A(T.D8-K;0
M4VP?EZ8&,IYM9PP7V 2BA[?VVZU/]FB7,1K(QVD'I>N24TNS]I1//D/ZPZ=#
MWQT"$"%^TWI>RV@(8%"JI6C5\_W8KV^_K$:@ LW\W21=,[<X8/2K,[N7?TAH
ME)%OQ=?L:<L"H<D;ZP+:3N+!K"P7@D#I0J)YZ?H=9QJ0>L@ZQFUV:\(N/S+Z
MCQEM 3^78-Y'1#=L7WTF,H\#OK SKDQ[9 )$U:(^,<KE41GBNV+0@FF,XS'7
M9Q<S_Y3T/:E&5XNOWZYP]#'7:DVV8%7OL*>1?$$GS]:W*41R*<VVT+YO):^8
M*RV> T[G5Q9$/%L()1LB?-Q!YWB$]5IJOK,D?<Z3>);,O$TK#86'3V#J#HZV
MN02AT=U2 =@%B[;ZZMU*/(?P53M/_HN]UCOQT5<&!A3"8H-F+UX%--S%/'E7
M#'(%:QPEK:1J]WYK6NZZ_[6GVB0SJTGY\59\+*AW)^51Z@V; A@^O,C&W><!
M?X%"WO;J=D39.]:""#6FS3*AL4_GFWR828+\PKY"6F<<VBL&G[X2S[N4X^0.
M<I>1!_A)Z3SLY"4[R:L)+1T[*5Q5I+W_M*AX?#L)OW-XXPJBYCC5^QE#'N:?
M]C=QJL*P;NK%F<M7C@X?-"LTI?$N(J,]CSY^4$9E"JFP<M2JW ^V%& !/30T
MYG;251J"I)3BHA,)2$V8X1)UKBY6!G@$8X?*@+P9A],:0;4WP;AB92OO-/_W
M1AVMCG.\!2SJHAEL>]8M]B#LHPG\IV%*W9AHN](OXZ!5 ^OQSU/!AINTR24^
M/YJ1[6)_2U!A11DW!2,=S031&6&RX3E_=RVDS%=8YU/(@$P\%9O?L7BI0I/J
MO1C!!H6)EEP/.!_\K$3ZGK>QX\JF';[6-PG(^%13/S@R"P^ALV>8QK9FSWVS
M@O9E&X&A!?G:=/B$6FN\ UF_(',:Z C?]VS:^%;T#-6ML?513>X*T";J YM8
MU-F2C+,Y6=_+?KJVO)%]]\,1-A\8(*_KL?4J4D(P=%Q%J(N'>[WP.\LPY.]L
M0VAVK_/^!7X;*[.W7\->8)3D480+)EI+&$3L> NQEBU%H]6AR8C6L<U7Z=(Y
M@!(+#<MU>0CG/5Y7PIL=)M)BR;I221ZV#].-[X6"5^+N":2_EI&9U5X*:W2#
MV&&H:;?;0=XTJ.>[XVUY&$DK15Y+@7&R.JN_ U<@1=]332 PTXISTF+Z'>X%
M[NO>_TI):ZM'G?].0O@A5G4CZHWZ)C1:]H90X0;$-[2'+KL"74_<[LK3GD&]
M9N7VG V!\$3OT*<X6=AO.?- "'=?&A8V5&*^T!XUPJG.!.$6#1.[;B>=$AZW
MK%G;EH>$&I>>WEH@2@_C3*CD9G0S%=U(KFUU: =!=S#SV@[5"#TO5]-]Z<4J
M)*(['BF-?^NY1#&N[#1D0"G3F-'>>K5/FW"/F[XA.BX?W9Y<&#']?!"9H9YJ
M=D73:/N'C6XT3C/DT=('5NY(\8[-]P-=!AWK.JTY"5K,V'B,@<^T^5%B$\>&
MZI.['U&B!DKT._XW [\NT$5N1OCW6#(8LS$B#BYVY)[R5[#?4T8+T@%Z[X.L
M81/P7_P<P%@?Y*OW\D""+F#?251R*)!CQ+FXM6IM1/SF5683'IT#I38>G9*\
MJ9#\86LFF9><,4QKWEB.S]@82CS*QHHV7*/B7KG/S]JDA.Q.HU "6W\(M+[*
M"I)W##0-6!T+[K[5]B50D\&J]]>5^4:I.WF;7O8Z;TG]Q+SDD_(T=7YQ'P%_
M@)V5IYJ!TQX;'":D@Z>A!;Y1<NPN8!PH^TE6$7_NN;K712P%Q N!D<Q+L!7/
MPF6%GWV;NJ(D$9C2+(WBFK2P4+USEFZZ'8W=%O^;3&Y80CT':B'>N_7-/8A5
M=!)-YG[<L^81\%."=$R;?#/Y!_!!0U0\J@DO<-Z.YI]DA1I^AS^,_WV^"V&!
MJ?OXJ@;O!E>&*4J\NU0GSQGZ#-C7_\G.HX( ?!/7#>Z9-E;)\.AJZ'LM_ZO#
MJ^2I-WP;LM4(!>83SI?;S)X?:K<Z$+^-GX$HR%HIXVI@-'CXN, P>!?G?/#4
M5G^)IH02J2[@"!6)OEU+T!@2>'=<CD(=B<^T;.43@L[&8.U$;[AN8^&HDPF"
M"9=RP5RY2GTWWT[V,Z8HW4+C+THCSUVE20T^Z][(]7.B_$MFXH7F>V^GA(.C
MK@@7AO-1$1^6&J>W].H@ I.Q(MU&RN,1++ V"G?FCJ#\6:EY=(D6C;/V:0KP
MSQDR9$?9/N2]R]:+8+U_3(7\'-302OG2<M?6N'7\@\:K#6*!%!!*G8]HSY-]
MOAIP]#T&:6 5,'X\/,NPDQ\H4"GM;UO^B0]QQQN\?,]ZOM<$SQ6M27OGHG]]
M0("46\S/)LI-TV\>W]$,W\%-*[>[U<]SQV/?93"7;W(<B=^L[:VEV-0I4>VP
M\WY$0/>7;26K@&6&1FK2 8@1A)KG^!(D+D]4$F4M.I$MD#(F>6R&SI 6D@AY
MO'G*C>L98H=I&!K_=7UP<M-_DNZF&S);:)6PJY#K. 8T,Q2$YA+54_.XTJ<O
M7BXO2=4.8M8/965!7C1Q%*O;\2?^25Z"S:Z0#*>8%+HAR@"67F^$5^9FEN\!
M?N#_FBC]\K??E;S?%WG_,3GV5F>L7+[3(1?ROB\D]1^3JVKJ.9NM!^=LT+)5
MJ[<DX\RN984^RI-TD#<KD-'-O1ULZ%X[;%V9&O99:$?UC:=OH^Y4:-+A_RJ5
MRS7MS$(_I$BB!_N3%.+D#1M<Y.-JG/E5'-9U^E_BB_A-?XQXH6MNQ/^7"SM;
M^=VD[V9\MC+P>Y(S-JUVUGTW^-500[EJV/)F:17728 UTE$;Y(7D]BS656TM
MJ7Z_OWG[V?^R!]Y(EFV7=KC'EV4C W#)XALM4JMBB'OGCIG%%<@X>Y8";*A+
MLI5389^EM<)R8_ZLU,__WY/)2OI\2B..&*W)R"CG_BR@TJ$.]_<LN *C50/:
MLQ)+7M2^Z4W-\>A1+:G:2QF\'+KJXJE[ Y.[.!(9"N4"1!SV&CN$*N5!&F=!
MW@%JC9!WR8R!-K7LBV]\8M5P##EC)APX^?6W:TWG8JO\W+Z6'<8]VFN_<U)I
M\W?TY.9?D:V+?ZG5_YCZ_S$YK_QCR@F_>@S[Q_3W_6D=])17%S.^=S0I8:<M
M?;K8)5*>9A2#'D+-:$5\+3L=Z<'7#?UC"MM46Z> L^:RJ^K=G(-;"O\Q?>>N
M/_6=7A6LW KL-:F<V][_ 66G.19#/)6*"W0W@M4_ZA +9K8;YA3FS('#5/N)
MD@^).FLVX?31J%L[#@+TXMIB$[_NN:XC\1&K;\GV%]*(FLLQ]"@[DKX"N9"*
M)WMK\9R<T0TJ>$;6ZQA^K=$XF1>%L9SE,[\UT_*B3Q"VF YXT$&_4%.<L;S[
MJCWX:\+^@/A [$V<]M1@ 7:8MGF#D&O5QZKOT:! *%."^9A]'C<&K2KNMG0\
MS1@6:U&78\4H(GE,981_)GJW=H5WAJR[!26)B_LLN,3=(T3;I!^T0Z?ZG[$J
MU)(.V^4\JB7;YO2'\A+&HK9X%A=R)57?R0&=4Z)04S,#">@ZDV2).U^61EJ'
MPXX+S!^W5JX>3_IDC!"!H5>J1\;J 3UW][FX\)5*E E'I[5JNH4S+J/&FXA<
MHJ<EY@GL=?UZ9=S=N+P*F &QFW[(X(5BS=0,=XB(K4G2*XR(.F1L?$522YN_
MZ#M'\>,7"+$>2O%\J/;BG\@1KDT;^9(E1:*T))UR@H$Q$,4C>8]WL@R->$<>
M\E;9E+^*=BC9"8_A 0;I?^5R@M94E0Z))P>Y>R7)H:6E_IR<+.B?(['8]Z!Y
M+T&'#C3^GGI %/AVQT].3O:^YCR+"U5C$PU>NO994@S1_X'YPOG#Q&GC-3+6
MIC8HY;)I6#,_M0OCLW6D6+RZ:FPMWP,)WWRL6B1V98%0>-//J#;[5>O4*M=J
MJ,T'04_%;%D+4KJQM?A@,D@B8_+M%(KGC^1A>*< /4UC2O];<0!DMF$;MUHW
MB=_2V%[6ZL%\X>FTK]:,R(MI]O"^X=QZ+[XX:0C2?UO!R_.J=Z)7:I8Y2OU'
MF23W?8/>IY]LS@P[,5N?U^4=RC/F$[CE]-3Z3']JJYA\W)N*C7#)_S-MQ1SV
M,00'9PQ29_<,A$%8D!!&2O^.VE;J^HW%&H_<?6BG@XZ\U^[4@XEOA0RQI,PZ
MW7&7T7,E%Y^XB]=GYC_P=6]0&S&H8&*2*DJZ)H^->_/&\#^'89S)?G7@?Y*K
M;;N\RZXW&N?ID5O"]UN]YMW0A$GCPK*K*BK?$KTEMUC<K*M>XJLS==O%Z]ZY
M,*&-R)/+F8]G!A_-"CM;"_'K.,2QZ;@+F[Y5&;\OM^$8I\:F7JZIS05)RBIO
MMAB^>^^!AO/OMOFYXZP0U51(@4SPL;'1MP9UKQEF3QGG@;QLHQOKTKH3J<@D
MIFRF<]EWF3BS;9B8Q,QD,K-?'NLM@%N[6JINR/E&>/ # /<4WYAR5/"8,7$6
M!3"*O]BO?E$766L,,K9?98L1@;<,/OBEL\3OW\J%6W!4$#!CJ\LKSDFV2EAW
MNH"+SAU<IK(/S;UHD1&^$:#%8Q>7>,W]]X>L,HG0YYVA.L0/VMP*6<.^K6:Q
MC@L-X7: !,,LA"4#:K% FR4NV"O==<T)!2K?=:UBL(OSO9 -ES3*ISL6+5U6
M:7%$"41=4/]9IQY\9&PVZW&IG-(*C\Y.@9L5H>L-=20)+;WL[EFE!!6)%PYV
M;^QA6Z-O@3\<VDX?L(AIB[_FU[^M)72YN9GT8T^&54!/W,F\9/H?4WNX.4[4
MNG(2 YD=L&2?1X(32+>Y0AH #5+Y+YJS^K]Y=LK4;F!Y(FJ(%]0;[RVOR1YS
M3E(# 4OCJ]C(@Q\)2:V.]3LSY/'E[+1=%37+DBE#%:\U'A^U*&W=A.C5TVRJ
M'GFV4\J"&4_$XTI:] 1 9^',CID<3;<<G\5$:T.L^E_4*\_3,01L2_%VKXV)
MBW*754/5A,8I&HNX7=4>:T"6IQM1>6E4#Z7O0I]2_^=Z6O.5I,A&+K%'28W3
M])1R.@7W+0'<P#>%%=4%%H5)EXVL'6W-C-0<1Y%<<9_/74\K\93-3:9K);^3
M?JY#2FB^@4I-Y;-BWX?TC*-T1175)SAY?8847+"+LRHS7ZY*1FSX%;&E.SAM
M*WO-WEHO5[ZJ\UO_[U1L]A";CPO1 16K(8\J$<>+PC__0 FL3H9*H6X P92_
MNS0MPK,[N K%S4P*+3L;:*_3S#NY_K906]42;U6Y2UR;QBV^I[ZWOJ]*-E[P
M\9:4;ZP54FO62@W?YK/Q2.6[PU6S?CTW,_*[K85R<$@'YX>L+"U1JU#_'>IE
MY[IA60ZH!:5)F7G5W&G!U@T7YN8&C855:T+F>94K\ LE$8%97M2)!6%=2%M@
M:^T;M(*.;4.[Y3@N=SH0312\S7;?JZ$B.T4VL$JR:,JC0+9$B'V4?HM/*5L8
ML/"RR<C$:DAY.^5'NX*)>9O1=RD7XW&RM\R5EK0"4T9+EL_,=X>-4?V N.V&
M+-<_?^U-Y<U+O'BXV1YFAO3EYCU<<<PTN61:VF2:==H[CKC@WV8R[QZT=?N)
MYATY!^*;3\RTV1<!I/[-K][8^4GT,3NYHW.I^JV@?$X#!PGK"I6JDII1OTWG
MOV:\H-D!_2&TGBEL060[U\(,/6]ZINBN9"IO$3E<+ZM>I/0E=1_I97'X!=,
MO!LQ[S=+HVXSQLX$]B0S4-<DFJ^9,<MI7KL!21Y>60#I7V"0/,;CVW9#]L:Z
M?%*$'1WD&B)8M@0Y;_R<.R>QNL:\1=WT_XK6<ZG-\SJB.#LHEGHKY 9WC9=6
M8/=W)^205V%Q/G-^)+-Z!,1^P)(\<Q^ZE2O \$, ^$MX(IP-#9YZQF&XGO<#
MM'"WN*2;/3N7O>Q?X!W=?12/=;WGH(X>']PE5LPG1O$YC@6A6,OJ99W0*L2T
M<UB68AY?KH.4M/^7U<^:N0+NU<(>3"O_A3A2>V/8\,7G^MTU4S'?X-5^Y>**
M[<Z#*FX[LWX.S_/#?$8>_ _>IHJR:*F$"M4-<Z6*BL<Z#ZN_8^?=O2Q!G<N+
MYG5S"@#@H"><Y?8' Q\/4SB&QOL<:3T_6Q#2(Z+&WZ'$\=FCI(*DZ'$X2Z_-
M@F6)*,T!]E&G'O%.(=-Q]\S9,HZX<>%O0ZS FL366998II5[XB]$2>$H(B.!
M--_EI&"?@>1WPW*%^??-^!.:-46^T*OGC=-QXQ0G0EQ&2M:CI4.HOZNW?^=;
M'C5N:VLU$:4YTY_.U%HIGZX[T85#(Z#"\3$SG4>.\W;,:CZ]7EG<Q+#X9,^U
MRR+#RQ6!?;><'9DJLLT\F%Z?*\F2JYF!(1?2M(KXB0J>6=YMVS/VN7!%N/*\
M,T 3>Z-9>H+/BT78X\RVXJ]>\)P_B;Z:"+,JX>_^SD8I-J9>*"%0)I4D9W93
MG"*Y8B^[/8DM*#HAJME#W]SGF/UF^7"MUON]9I"HT,^Y2+:AY%0O,=Y.5(:I
MLL5G=^@@UQ#YJUCD2Q%]NIU/H9+/>+DW\6;U!^H5DM][GU;"CQL.-,JU><VU
MN*G"5LZ:V=0HP,A/7?0C,9_1M.R(&%]PE&O$54&/F#,9B4%E1G/5NP+Y30R:
M_QQYR>]DFIJ\V>_*\?BQ?_7+R,*%4#-QHB(LI$LAK09S[NF2F!.+3,@RF])3
MP^<YSY17Q?&$(+B<9JEF!H"Z> 2*;&D2F49'('MFS/-BEK&K_L8@4I80+PH#
M@O4,X8==_+.WIH"?5+YW2&89T5UD:V).[.RY:'Y_ND!ORDS&FJ.N_,FA$59;
MHJD#(%G)%I/K?O=86>EO,U3[87J: 8"GY]P/KC\[=]Y>V P(M.=HR6:[%G<O
MSS3)Z7]?V^;YN9L\%6DTD;@W T NK.=OF/%=MF3@6["VON8/9DT+5>=M/TUQ
M&%[J5/W/"RLT%3:O&QAW+?S]@^R[9VO:'N2\9M+DW\A9/+<X&SR_/?9!C_&/
M2:4LZ/U9PGL&*>,?T[.Q?TSC&9441N_:PI^CXZE?-- _ILMW7O4L%?>&_7(K
M3_W<MS)V;V*$_/OEKM>ORD,X[25J8-2QQ1Y%G;:Z_691KL7^&)H?W4I-/?(*
M[YV;4 B,ZZ>H_@@LCVO)^8K8955/W!XQGI4%VD=O?A"Z^C%P73OZRDV]DH63
MF) OY9,G7\PMKV2NHWJZX,1,]'!Y)5 []B2*"D-V^PI?&![]HQ36Y(3L,BWF
M_S;Y<J0E)[W0N-FOSP0[V*ZJ\K&Z_^K-QX\;CY,\.UEF%B:ZPR>RT5<S*,0[
M,?!W#X-3DE;,$>W>* 0X/C^OZ>M:ER:QCM!UI?.V]RXO=1O[:J2_X;O=='GN
MR1@&QS 15) ^X?Y[^U'D-[';[W2$6-.#.1,XKRKB$D;/J2I;L,AW.3Z]Z_&W
MR&CY/_VL+&$Q4#EY\DAB]JSJFP9$E-MRL-Y;V('PWDW71>5,RP\1 B0:.-'3
M)?"G%%QM+K6BZIB;V)I=T*P91J]SJFI+>VST"C9E<7V9%O/KUW'DO;-,&[S9
M6J?.3(CK&5PU8ID='J\Q*WS\2M)R&H^?!#\JR9Q>%DPFW;:T;3^_2Z>7WP_,
M.S%0=QN>?A?D7Z"%8PG+TH2K(?:R&VP):FHIJJ65V5/[Z\Z#CB9A?=UF]UMB
MNRL\TV,B3X)'_,6&]8,!0F/N!M>T/N1?;Q?P_L"7\/J<.D:J@"EM"%%^5>?.
M^/[YT#LO<\ #=B:AOBX[^QF+4]?W1(NA! MJ,I!(=K6XV?E%4"?YJ)7;>Y>_
M0X#1>9+.7FP\];XY>+*\1^D=R9EWBO4QZY6!\L+USU__,4&PE=ZK?@#%U]FI
M4,.G@")'Q,#&4_Y%#'#TK#]<K-R8U30.)=FY$IMC!LHM_!05%=[(?\&A1KIR
M/4TS[0&Q[J;\;1%O0U#KT*M/-]]=C)H$#O:Z1%G[_G'H]$Q7NQ6Y/G'KUBU)
M/CN?/D1 [8N]N^TXX;-*B7A( BM7\K=@%,[+MWJS\7Z]9+N43,U97T9B5KBU
MU>Y?^WU,-V )C!L=_N(J';CJC)&+@-K%1I?$-0=O J/Q?]>MS>>R%<#M5#H%
M\;+*:1YM**VFQG;E[]\_LZ?T2.'.K[-717L18OJQO<CETX(7&I35=V<+S+=J
MD?R]MCQ&^IO9K@40\J#^\LS,SNVT\ 04,N4'AN\A5"/#;#S,>LY)]R3X5N>W
MS0]15VYU<5+$\=:?7'!$AS(.E>58J4,W_:M)A\+= C_J/0[R_L^[O[E[+;5.
M/<!/<B<Z0ET&KJ_??/UNZV Y\T3TQLQ]OI]F$][C'J*2CDG$N,(^0.!'R9)V
M.\U9*\/NOW]#[ZN58.2#C>]=^_@,*"R>6H,1>REYY;QG>20\43GJ3#TIP2T]
M94]<&ZOSO<FUBZ8I&H[J:1R>?-\8;GJJ7\"_741)XU@2&^(*"U&O"POC]JIX
M/ZK6?+_/;-0;A% '#C(;Q;4.<$=/OGLJ ^,[QQS)>2#Q=.7EVS+0?00)Y#W1
MV'C?4X4?YK+3P\.=G>]=;WD*VP-/8H^FR0]=6V"UQ#F__7E2Z6X0%UGZ>OC0
MK,=W_L E=$M5B3VX.*BG&?'W#@F5>]@=)W3 [?UGI]TD !;^J%B$3_H?T^/A
MT/'C;J9QH$_6]6L40O+.>1<6^:OG<J\[75(Q.=/NR>,TSTPT?/I:=N*G8<5R
MK;D(]L@ZG;9=UGV[U@DX!GL.L##?^M+\[I<&/Q5J/F&$7$ZZJ_2Z H[8-@>!
M%\(:KH[SIH:)/>L87)ZGV!4UOTMO+.>JWN+'%C^WN:EY[E.H\M>BU;CC/ZPN
M:8U@.,%I" ?W^?B*X9"[;'PP/$0P4'VHR;+L_$WPA_DY:-=;H!-B2NK$_WS9
MVU-O$)U8?Z]F&-L-69KIKZZ/.5+<L7XMA]"9W38NV;GZ\_9.YFS^+C-MOTPS
M:#7'5CKW^0*G:#4Q2GSTL8UA )T_GW @\9"\^%U_>=V,^M5*>+S[E:'-V-A^
MKMQ)P3''<[WY!UR!@??B2[YZKU6_E=T!]_(]IE0Z<^+?FEV$"+HD0%\##?G#
M$@+$Q)X5F.'G_/SGR7O*'8?UQ@LSQPN8.6@#]1 BW7@_AM&V-E1MM7###]PM
M.H?SH,0,H9"6+I)/BVB_/.' *$%X! $*3RIM.+&\/^^'<AX/2['[>/2HYE$\
M 4V_[M"TR%#TDEPULU9+3O?T*81\V ODFFM7JI'B8A?67,QK$@8R=]]53G[=
M"K$ XO(YAASW^N2[+.ZH#GZ:V6F+O?H8W>HM$E]M,I?BTVI5WWF%3K&IUA0Q
MEU6*=HAMF_YCH>!L95@_#S/$50@L178:W>T(X/C;$W3&%?@'T+B;"!2OQ8I"
M5"TB6K?9 8BLM)T]'\$(89X?!PMF>FDSX.YT&#<)AG "7_&Q35L8,"G$(@A?
MXWB8(&PR.,3X_50%E6MG$^]UA^6-"=UR,V:<+SN^L3E+]U"*C@V3:'^M+#@'
M8\Q3K9:3ETF$>6CM?6S]$\A=^"4)HZA]@^52"6NP0YJZP*3K<'74"\+7G^W7
M:1-[#F$EG7KY25UZ!45M#Q9X!]/\45\;\HN]FKMG3-('@35!VJ(&LMM$._?#
M9G?@%'@R-9JZ?,82,3:VXJ1SX?'NRCV[,O-NV-E(<0FH7C5LZ8EIJ2:^6\IP
M>[9^5H06=WQ!<<=UG@:"&B@C! ZK =X6E*RX#W6#C_IV]^=SBU\%LD(:4V%3
MN\ 8M8F+!\7V]FV!SQ:Z)KNDF[\W>Z<_7>15@2#U =Y.QS<#MWO-#JL%66_=
M2/.9*/!6<+C$S.O1DM;M-^]ZE&EP+<0!>&;C@MXWWU6]_;SZAJUE/36Z+$%C
M =I8MUR "<S$U9VZ@:J\< A2CIL)I +;<L:\;!5Z/;_X2'J<&W+/N5+[C_P+
MK^FY7^T0ZE&O_ 9,9%\=[L,MTLX"W[#D2\0%IX@JE7&7RWU1TK)[\^"^?]0W
M)TV\0[96[:!L'(=6QC!^,P69P,YZ<_MC824GH8T'W-<)"5X>2O_&EX_F<VN
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MR(.5+H$.)=V HU*X^WYL3:!^\4N?,^\E6)')>/5643NSCZ?F[\A'/@O_F.3
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M?]BDE3LU/<LQC3I^[;>"=-/O;+?7WIB2?US!6AZ$S/-?5G<Y+=*X%BD$6ZD
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M[)ZN*^)#C"K/%/<7UYM-RM*UOPAR+VS@?FCG0'PD@^@B8YX- KX/51*JL\8
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M!\76!NU/UC! $\DVWWVB\)9P;Y2MD8/M!MB:@14>AW.S01%]??:Y>B)(;%;
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MT'\8LO^V\[^9_KW_HQXH[*\S/>F<K+(^T_^@]?=.R-/-43@>I>].RK'.VA7
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M$2 " #2T((#VA^\B;J)G8&0"T3'3D,0[."G?0@- M'0T:SKT-+1T#)M C$P
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M:Y)<DOP\/QERM( 8(B(B:F)R:+7GOP!02P,$%   " @ 5T0V4X'6PPB'.
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MD-5%]!Y./Q9U[.^=SR7G&D5'&[K_"^-'<8$Y_.&CX2+Y?Y2HPFW^^/&!;NZ
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MHUSR\WO7N8PRBIG&P/"X#)Y]$9]0A@? "47Z$1O-K]%F*<>>FW)K-=C.[S'
M*W6ZX9N6?9[A=YMK,!1&7M6X%>I91B:QMS:&%9)\4.0^!=AI6R4].O"4T]YW
MCI\'=K)]),EI=S90[G=0AC[-'4NN>2>101(E.)1PRPFC0]XLXVTNP)7*&Z=G
M7(?ZRJPZSZ=#!P9L$;<;*Z3V,J*15-KSQCT?3 PH>93I]Q5OBH4H<XO1^Y(9
M@VK$W'4KN:BI9C&^3!L]9A(MVJ/T8&M?Y_2U;KJ!(D+UJ,!>."2$932VP]#,
MJ.N1A=@F5$.Y0^4NHR)LD5J@N)9I.,U_F*\5RZ)VG&(2B;0OQF:RDPP('=U
MOT;&+4B%,@L5L*?%6X5]N]O9JB:S1.)%89TI6"E"D^F@B+O9O<:-JV;!,W&?
M*%W0Z N!Y@HOWC8_L^&K\:^YV,?A//V&%6YZ;GC5 @6*XR^%-EDV2%%5/ ZN
M:=@?!WR"JI916+YG5[E^(R_NJ=$;@FVASB^T,<^3&8>,,[25^8$YQ+W6R7S@
MXS>Y@@[#5THC:'->I0F97:%N^!C.LB(V?13LS=,3CVH(Y=$9NIZH\2J6(06S
M6ZULP+&<4O<ZMB=W*]?7#A<:@R*O=C<"0WI?7KR!P\<C<!8@.FN@H5S F&E9
MRJIEFTY#S/:-\+'IJ@Z"5>G6H5. YO%#&?^L^QFI;D+RSS6W/KS&68M6JD-O
M8C8PY]3+?%ZAO$KL8A)\7[EK>#D7M0*71A2IA&N;TI)\*B0;LYVI50O5#<,5
M\_/,IOZ8/=6S.0V)U'6OS1$WX'[HB<!0U1YN(??1U1G_Y$AS5I&]0B;-RL?Z
M1;[(E95 *D66>_JOA.*SLX>%,L28<K.&A=,JB_#K&JO]W8*3K2+MI?V[HPUB
MWG&T53"[1K:2;_J% Q^5X3VQINC4#FHDS-;E(Q>VMAQ3IDVL>1&"[ 28X?K2
M!WHT/0%O5[=;*6-DF3P%]!WY^''4#A8J#Z>4R_2LYJ=%QB<_]LP;9@+YI8^Y
MWDVJ("Z6H5HEZL?2ZN]]/CHRFPT,@U=J@@</X-+5O99W!F[H"T!(8F0VQYZ9
M8 \MQMXIE-4A:'M]6W;MD3U&*+L=J[E2K-6^*JKJ8(350Z#C,D79-WLRYLGZ
MJ>XW-N0";A$0E/C4>*^"6@^9P7U_E>QU5P7#U:_!/N/?3+2-XCHG0HXK'WL3
MLARUA<=37AV_J3;;O.BBU#R33&RH?2=[12BJ\%$69;L@F])4'<^5ZRBSZG!B
MR[=N:EB;&!'7$W07B_6F]0P+Z&KL7ELO\V<'Q0O:D;9V?9);UJ+G8+$,U]0W
MJ'OE[0&XOY*?4479]5RO)E2 FME 2LF)1+8:%R8=IM.#,Y7$Q3PX<)_"DY+#
MDKO\>NF,XEWPHTS/A _!AXC7^M+BPJ9VM,U]PFAUG-N,V*V"QTR:E).9T;Y7
M:D]H[ IMIV^@OU3#+XK1(**LZIL+^G#?70H8!ZS ",J*Q/4(D]56HWK]XOD]
M*0_9U12G98O(DMKILHT-2"AES>+F@SQG_XY>?6"Z=&*2Z<15'NH ARUM9;;:
MI^#@XX B?(=\J>+NC^#X*<.8I(7..HF<K/ [>;95+=12450]LXRAQAEJ:QLJ
MRA9 <A[YFX5>66K/UN,8'97\O0B.EG(#* FO-).X$;$>T(4S;[4YX=->L]\2
MB-S">\ZP6]\S*M".9\6?36R' 1\2J.O6:LY'I[A'B'D<9D$T@+[N_)X-/4:Y
M""^$DPUW"Q\<-Z7\ZA0@-<P)VTC?LQL.4)8C9R5C;[KY8#!*P+Q?D2$ZGX+N
M.?$$D)29C%#7@U4->/8=%MTX*@TD&B!:8J$^L-U&E;4%I=DN.['=Z7DY\SJT
M2E B8A%85258/_7"B(X]UF\\OT?I%8FJ'*S H+!)J?&UN6NJOEDFW=EG<Y>D
M%0_+0W.Z87@R5'^XBFG^2;7'PR(1P5U-._#.3( "Z%-7*6]WM#)OYD-NOF:0
M*]UC?2P@@,N@BGE,4SR7+L"(C;'X,8&B@"LG/6H4AH48RG3;O8#P;U*-,AUJ
M7UO#4HF$OA(?<>#>*+4F(\M]9($MD-0<$96>$(ARG2\BR3OZ*3L.Z:SNJA6]
MZ@WWSM2F.) :V+:+[4E:9WN[@@N(*)95^R&9 ';D) $FW::Z#!!G 9ZJY!PN
MW-$J!#D%C/FVF9ZD"%5\8^IK6#@%*$[;;=-^8RHZ!:@TG, ?>"NGMAJ< BA,
M5V>4MJ-P96R"?-)"2P(I:5%HC?KOOT7"%4J702&XOCL8(A=(PJ+@0)\AAU5M
M@.I,>:LP.""1&@O,HH8+HQ2%QT7U\_*%L@]')D6M+?J_[5XH;WE"I!\=!5/W
M8?]T<*19#$_)6)* #]Q;DI0L02T).ZKBDD#[Z(Q3HXO& M%8:L4B>_PU&Y-Z
MKTI5![_\B",NGL*E*DO!N88H-DV_4R?$AKPM[5X';MM3E[<,$8\*5H $(;=I
MBDUF'CP4*O&@'3;<J]EKGD[W#8%VA39E>J7>VDIND-<6Q.UNONXV%7IX;#C8
M+5I\QYR"O,QI9Z%Z1CK]K4Q3]=T8H? ;46%"UEGD\6R$,Q@2VH8Q?$_J0O28
M\H-.@KF!9?'(UAT2H^GDK@XW:69NC&MSP_(U:E-3*O$U7J;UCUQ/J; ?3BFR
M%T??X>\V1WGG.A$3@!F[\)@2=XM30VFS$ N8&RDVL&KLT9'(F/JR*V&1<;?F
MCJICZ1N)*AV7 +()0LA;Y0[%B?!BE"0+:8X77/PW(QTJOA3U[0N@)W3PX( ^
M&GEH>NR*[%?:?W( =Q@\LXHALGOAHA-J!6U:R JBV21[K,)Q:S:5$O%.,,9%
MPGCIQ"!%G#=A<=@R6"D6$\7P\6SL8A63_E&GHO[RE(M&W,=7>=Q@%5 = FWI
M,28/)K4%P:V,5U_#;+#U2T3ZJ1 N!62M)-57LP0*Y\A:84E+R^%WOX40(;6C
MWI=_]&CIP/WPL2)(4ZY?FRBG,XKG]G%@#29M" 8UC=.W6'9<'O^,NX,\_O39
M_9G?TER(%T"L2LXQ\_&;@4&'-N0>:^9MWEUM+P=2\M4WY&^1"ZWV;A_R1T@^
M)<)X[SZWM*&D0TOMPT*0CSE0.4D 8/1V))_&H*XIQ9TN;&)F;L -['#[)OGR
MRDEJM?HI@(;S/3O*L6?_*:#)[!30*K1L2NP[OI]T"EA<+#A19$9F1MVN+UD)
MOR)R17']$]\[;?8895:>56''/,]O;R8H5N;%TZL]Q]VXXS!YMA_>8F=_,;ZY
M_T#\$2.N$(/BJF A>++/=4IOC$VK)&5EQ3Q$#-*0&2;*=1R":8:I/D]SM[^V
M9&::T];SG;-%[#L!,P5ZZQ(>TQ?F58:WKBB]<VMJG2&,N-/4NA%RWY.&-J>V
MQ&E+$F4'N<$I<[D^];G)P9)C44U?HEQ1<H6>F?Q#ZC:G/6ILI/>!YB\>!KLJ
M)6BJ% L<# 6L]/(LRRSOK]H93G'6Q0TGBUW+WSMZB1VV*(7.944N>G^"A4'=
M(?F6C\=BS&*]P9"P].QG;F+/@"?O/$W2N@S[\-.'H]F?WBS2[IDMKXC<5Z6/
MBXXOJE/*S@B;4LP^^UH5Z,219\@Z0?76/[PR&NWJ<0BA;BR])8; I_QH4O\L
M>Z5G9ID"F7GZG7!_&_+YM^ X 3]5%O\P0WK&H-&]C7;\?B_\>9O2N<^X29;,
MM"I)OH);5Q9G9!?P9S-V7FU\'N'EZK:CGNN=T!PK<KV:5&Z8 5S'E6^4&#:K
M!JIQ 86)8NR3X.T1?@DT@K.G .GN^7BM $RZUI+GO5EM4IT*D#N#X":[UZ/I
M(+_*^X]O"G?YIV!0&N- -O QG 3?&<P2UKNUL=DM,SRJG)^-E[PN1ZE/<]#8
MB@DD6O*W!Y?P)]-+=MWT\]+Q;]?Y%%82F68%6LV32/6RHPO6DI4DW'TD:(51
M0I8@,R;%/H+QUD8F2M,FGCVDU,XD7T)N@''HT1/'PO9#D='>/%46+0;OM)--
MNZIH6E4UI*/RYZV,+7ENH1*D2=2+;EP0#/= LRN3^\O/1%E:!=$9FYS376MT
MUHLK)^2=>EE:5&:HNFB-QZ_*EMZ]N0V1)HU8BUR*.5)DJ"VR_WP**"]7)&E"
M&PMQY$;F43&71K+IRURNJNS,T!],1G$TN/F<_BT&>6@,RF,V!71+G?90M2UI
M=-MZ^R43^Z':&ET?^06%;.[=K(*\WJH9>SR4I^OR-TNGC)0*/TQHUA6,1WJR
MEN!DNE%(4FWVO)ZG=D]8]\!3^Y!C2)+\J!23%$]1?_Z9FG;$0S7O#3E=ADGG
M>6EI^B&F5^P#H4YY/%TWAJ:TM!.U4KT6Z*1D"%!B924SIZ]'OH3>\R:]I8%!
MK1Q=*ZJ^@">9!C"B\/>7&W1!OP6L8'@HX_PHFE1!T1P5D 3*C'C5LS$1KP93
M%W,5:.BI^/0.A%&VBAM5B^E/&\V84\!38"Z]:%)@'03$.ER+>J9KX/TUCS#*
M]A1P!TC)QO]"9#/+GB+NB<T0."ZS@)O2%#(<IMWCJDP<$*;3ZT2M-K"A6?2H
MJ?+J]2*Z*"P*05I^\:!#KB_R\_)8WKVS\;-)3U=1'#]48"<=^+*/LQS1/'[*
M?W,Z4*)WTDM/Q'"\U=EOMBW9_;,U=]*S>.=];]'P8,.3]ZKBU-DHU'#=-JV]
MO>IKDA%(OJ^IB(]@2U&Q3RPWGUYS]37:"SGI/D!UG>W8:J#>3KUFOV!O AON
MXR-#[K"3<A^>XM#M=8@%)7$]MC=.-]B^GJ/BV.")=MN:A64XR<DVX@VA*2V6
M2'55GGV<MVX.>$T!27_P?J24WWPF-QT61?3D.N73^W?+R&<<G_ :1G2)A3)^
M)1>/\29QOW. ?S-L>O-SK\EM>S[#>"ENA ^C<4^G?L&+;(,R R8>7L)U.?+H
ME.Y[@9V6#.4A B-E#9:I.D>QNX>>56EPFJRN\M%$-2Z,"HH69A..W-&0NXZ4
M\1C,M0>;Y5EC>;R5HKP,:XZK+TA[G$/"3P&B3B\:7FK-29\8G>VK6AQ\XXYY
M3@XF^PYW)--. 9D?/T^X^<2> E;D=[\,[U^A75Z?Z\S<;%DHX-GITU[WE7/)
M?=PM?[9S0"L"YF]5Q62[S3:LLS-I6TAXT%Z19']%%$)?TK A%2MNMXYWU]Z)
MS+]//!'PRBM]Q=! T_3EI*B%S;B@EQJ^FA MZ3/S4K:T.ZPOA=KW-AS'UB,G
M)KUL_.539_,VTY*6A$,_&/3XCB0MV>6LGBWT<ZG[T 'HY^1WM"72A[2':IC4
ML.4>69AZE#EJU+WHZ5HQ?N^:EF]'KPY67G>_E$MYJ5:9J[?*Q<\4!2\TM,<?
MF!DOT2ODTKVMV1&YQY5!J?&9JM-)[ EJ NI3.=D4LRLY(T.?=1HXLDQ,DI_-
MQRFZYBXK#L.!07U) 2%E[5I3"F@*9I@*BV'Z?<)M*HF*(\M,G5$=PRK$)$,.
M>(UL@\^XOJB3N6*W.[7WD@1OBF:@WEV8Q0DY&+%M=*Q.&:>$=*D#+<_:74#<
M*=?T>UZC/@PJ9';'FN7-?B&\#7KI.GRU9%^WO@P&.7<K!M-GQ#:\&R\Z_*Q]
MZ-G7B?ET*+1O09<,9.,!I-=W=4Q4QBW@UKR]=+?J"V^4A[U.22'S>-WK?)5P
M6?XG.FMZ.4 50W*+AZ]%@K>DU,Q7GVDRX[#9EN>W4PEF^8@R(P^_FEL7+_14
M=MHU-B_@<:W>"@KU>_7BWE)7<2%+]G.#:YM<TW@E;>)^>HP^<ZGLIP ?IQ/O
M%T<-_7+>:D/!I(AE7)^$1-ZWI%PSM;")5(G9> <KU_6=63VU^75*Y45'^T36
MHLB"U2^-Z,_[U>MKP^KTPNAQ13$4_(MH%"Q?;#"WM]2^J%+5\EAY_2 'JAAI
M+ K2L;XQK-U,_G595EH-<T;>#*5\X!1 4%C^L;[K% ":KFY(?QU\Z"VN4V"M
MY$I?A?^AD(BM;(,RWI,JI%A.[E[(%U.#?CO[.MV,#%,B"L-DQ65#@@8U+30_
M[G;&:+RRO;(F1R'QS;;PYP@7RD1^-$;Y56UE0?F1&4I*4YFU\(6L*.ZM+5[H
MS-B54L$.^))B; SGFN"Z/7O-3F_%5*J;XSN?P>$U1UZUQDR6EWKT.G+7F*EC
M[GW;S(G?8:6JRKCSOK*1*RU'YOTP<<?P4\8N8-N]1#V/Z9MFZQAD&$"KU2FT
M;@IH#L,R]TM(Q8';[NNMVG*6BOM1N1-H%@.&T42*@7-,%%*3"D1/\0BWRZ#T
M,TQ(FC[;6'P*<U+[RAI5.95%AJH/W4VP(D([@+ ;FN3J#L6*<F2L]ZB(\" 6
M"\;$">895\OTBA$3NU6LQ!EDA3HUNMJQAC>TKV)QJLB+V=Q@\Y';#1V@S4D7
MQ*VN8!:Q,/_4\74@(#:22!3'NI'W*CI,*F,F3.DDY-I#C0Y.M( O\R^Z:ZD"
MO\0GH4N3&-;UB$L]+,3.<R#1921W\M%?N^+/[$S]B#T9)BZG)+\V1LXD;P#4
MWZI0IG ;PPG')4-GX0)I: A@*5Z[GW#33RR<BO"U?6\EI<!Q;C.#V!'*O#Z8
M>-A6"%'K%WDPCEBP,%&PK2SZ%F_\E&_8G&?V2EOIH%?8C#69B[=O?&2TXJ##
M;24]]CYDX8S0:?)FK<S<K%*,.Z3*9NC ^VK"7L\6*\@+!Q+V&35['N%0-<I1
M:.NVXV<<WY%WV>A:[^'Z.&]/LDPQS?9U8V1HZLZMAZ77;9ML"=_)8EDEXO6=
MN#R$F0H!:T6^YE')+=@4 A52K14^^JUFRUN(\>[VLB<Z7L\J'HM;" PWV\5[
MU4;K79;NJNT0I<.(S0@L1>HB(-89J<(S^8;8R<MR-4#ACVC[K&(%>D(@I1U>
MYA!:OD=I8*#3@WED.]B31)0R'!W84F.E18<Y^C*]'G-35M^*/D/]J^2>6+!V
M4BSL)GT<Q3P0M#6H6<X'SK*0=7G.AFQ 82R9Z]B@]*J8+G?-V!*_*PI?JJ :
M7J7%_O7^Q*#MFKP8XB!^(/L)9DWN8/%X6 6J/?&8NT5\)ADJF"F (Y'.@ZG9
MDO!EX<-"5Q53:2''&>\/*V-/F?66##Y.;QN.5C'8$*-/$L>FK[(9K8Q6MTS>
MC:!_=BM0(FR]@C!*JMQ!@X/+K@-O0BE/HE_$-ZNE0:=OW%Z%\8,546$VN2<G
MYIVRX-Z^#WX%U7H862-S5EY.1]4GQ"%+=*EHOEQ.SO,G[]Z\/T+?'79AONK@
MJ%OM?6_JR#2K29;R,5*6:=[HGF,TH4#Z.O+=$)>@*'^*0'T8=?[P'1JT?$W-
M6SHR;>)46-B[.X]OX;&EW\GI$@O!)C&P++CZ-8X8>6&PZK'TL]O6_J1&7NB.
MN:6EPA9D,KVI=*4:R);@QJV)BBV 5SCY^"G S)7O@V7KJ+9"0A2^Q^S;J!(M
M;O&'T\Y!?&2/%X%[=XD'9])H6;W?9%'A&^0-?_2Y+\B035_FLVU1_X1FL<1\
M<1R%),KGF0:NG\/-.\V+M\H";O7%< B2=*>D\+S!&FT)0-HG\//IAN*J.^0*
M4Q\=M&9A0#:^&K9XDG>JL+74<',(,C*+ YI#P,!"T12EBDZEP,J/D32VT6F:
M\A;^%,2AM*1BYH31C&%CG5D;[AX^BEF^=QBD7Y%JPT( MMQ$]+D+L1G@CM)N
M[$HS/E#P[N(HCHWK4._(B\,K39.674A+U:)[==G!*[CQ)2&!,L20MH:RV1)I
M48#HE^T9P9?\+7;1%F?[TA8."H77<HE9ZS$5S"Q"S3.Y_6^5-P+0;>GZJ\?T
M5@C>5HR(2]$([ B RL@A#PQ((0C[?1DV@;HRI,1PQHRJ[:0H?]%]%"O_5J?;
M2-4E]]4M=ZGN;%/*5[./[\*&DKVH<6[",C+'2PEBAT,]A08V;8,BV%X:/S*_
M;8'Y?CPT?\J./"+[671S;3CV/>7FQIYX8F_63QIC6/R!B #O"MY.;2Z3Z%Q"
M64.IE9:L$HFQ$?#]]F+4R()YX.W2;N^<AGM$]QY4YIT"@J=:,0]LJ" 'H]XA
M$ O3$V.ID0R+? V&#Y/OC(C[YTW'2S49H<Q]&>1C%CXFJ=1HW$[)^:4?DV*2
MC9W9RV?#G^M[43L;R6G.#;[*6H0#B,G>ZW'WO&?;&,+O2) )$%9X*P<$WL=R
MWZRFLF1F:\-P0M(^ ;1A8,Q_D#J8,V)8_1 62,FZ6)XC(A4KHF2?ACYISKT2
M-$QZ U,^"_,$0H!;4:V\L]XJO%(/' U%T\E]X3_^I974(W*R%':RI*[#A6*V
MPGM5;]H.%$&W8QXC:R)$IEQ:X6*H%N;[J*2HJM5IS<OC(.INB%DQ^A!@WF;3
M1_]C_ZA@6'C(<&G4^%;A0O"X#.AX(5W9&%?LP?;F$UW^0KY0_N,:W(1N_C(R
M#RU7S:)@GYO(CZ*?%X2I2O"1*KT'AUO+5' J$0R]F;"*U9_TQ7))TO(I>.M<
M3H]/RW9540#=%\F2[4T24@C! < G$L-VTE?;#"5Z&H59QV=S&)O/\IIR>Q'N
MY)MA/QP5ASY[')^E.WB%VDU0>X&3L5NQM-V=&&RYAR^#[3G;,<EY66\:7:F\
MG0G0*TJ*L7W\-"^>H'/TV6OR':^LT9#G[S;>QNEOVH3X!^52EC87BT]'(^O'
MO/4J2UFJ@0$ J>S,>^T:8M\0; [:(<L)"=Z4P?BSU[ #T$8+9='$KVPK![V<
M?5&>!;*\F\WDC#[.\'PL1>!.__4H@HT"ZRG,CCRVL"Z*R? ^11P%95V.OOKW
M7Y!7@MY"/9NW2'"JQ9N=/^U@1;=3!KR]XM^*B2T/XU'_^#G$IMZ]U6_T=2U=
MMS*QX4H#_O)VU7UT/NS@^3$>(KD)2DJ/F-3NL,[B6&779!T?*1@&?HNR]:#&
MM)G9]!&;(">P*(UC*\[*NZRSF:]%H+VTXDVD8P'S7546_?E]9AFJ.')1KBY,
M9GLB[E0Z+J$UC(]XT:,S$8 >F).$[*C71XHHK%X]E]WZ=]3J&$)%"B-:J/>.
M,\&C%)VC\97A%<%/4(@(F55-U=A8^/!;&8P"R#-O+%@%;6X==7<"*W!5N8^&
M8MKS<.2!&59RSUUO,&0YD6]-'/K-?3D$%2H#NC.8\>:1JIYZN>[O U)\/(3:
MR$K&O5I;Y%^\>&>=:!#?HJ3"6M-8+%*[K'B@4)0I!'<0%G8+L\ -GB_4?4$?
M-.:Y810-N=OR>B^!73B@5_YVF*V\+EB[.]NX_P&%7+A&C+C(FA51QAA:OTI:
MJ',2]1=VL^5XBY>M:]\B$%M<SQ\:<?"0S4$?S 7@BYA(XSZ/USC  E?6;SN"
M CYXL*A1NU3SK(Z!\#FQ#2FZ>A8JES"[BD$2WTJHK&;,K&:(HS#:B1\D>3OQ
M[E#IS*"O<(CKMD6V'.D"69[4^E6V1''W.U.22S3F?_57F=UAO$&D$T!CN."\
M<P0'I.V"<*);M1ATPS+Z3&(.;-_L<9%;O6F7$HO]<FTQIV:V=8@='J]:*VX,
MB!QU179_XA"FT0:.H3*WTH S=\K@WN(!4/F_-\0O2F?-"PY6A@DH7A]U';!U
MB7E>:_$^M1B#=G5#/V*V2.VZ&&J)D!I)N8)6J\115QYD,BYS<DQ_,"7)8RUC
MQ:?0Q^8  X(+%M&FN$M)?$7TODTJ&9C,)_C;,!-P3>78H+PYA3-51^AF\ZY0
MDN_IV/\!4$L#!!0   @( %=$-E.2U06@)S,  'R!   1    9S$X,#,S,&<Q
M,VDX."YJ<&?M? 58E-W6]M#=(:5T=PI#=W>#H,/,D ,#PPRE""*A2 ZE2$BG
M(*V@(M(A#5(J2$@K(J@@\@\8K[[O>\[YON^<[_^O_[I8\,1>=:^]]MI[-L]P
M/8<3A[, 2CTM72T %A8V5B!6( !PN,&(:^(*1\)]7>'>;)(B8@!9-5U#7%P
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MR33H%7A8D1X<73AMJ4^FZ!T4R-]B\^8*00DY.8/ O>[.,@&M8)6P3OND]D,
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MKH_ZWM./!8U9+6Z:C/.M#LR)J":1K^O!S <OI@\NT-ZCZ(Z5D6&J=+N%CDS
ME] XJR=FTNUM*;KP))E'CU&0WF:;*J$;BYRU%FVJQF5%"(;UVC.EB)0#A+
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M#]E=L=4]7"EX^V/$,XYGM6TI4%GWZY+A&CPI-()R[,,46=,= ;.S89SIJQN
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MYU?L$'6A2G:I[,VGG4)4 7ZA=L_#UT]FJK6A?2!4UI;BY1R6#O*Q*_%(37L
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M-,Q06!P$17BOJ(,7R/KXP#2,%%44E=3D5>350&I&AB"0@9&QHI$*2$E)P<
MI*JJ0"S<7TU_<[L/#0TDU-AWMS""6_E_SNU/IK^YW7R1"?'[-]S_P<5O,*8^
M6/P2$ZKS2]Z)96(+#_A5NJ7P\R&6C3\$@R6^0=46WDJ\\&\&!!MB*6A H,1"
MA!*7(YB6W"_2OVWF\X=!^X?=_\WT;_L/]H:C_MX2^E.KO^T$B_;"!4,P<'T$
M/LO_:&7_D\EO>9;;3/1_QP"@480WO/_"$.!Q(/C[-AR#U?'"H)&"F^NE/PHA
MB$,+0OS]_7R@$((+N2 4[/O<W%Z;MD!^\O$_V%<L).C?+#70?V>I$>^1\JK_
MNZ7VPS74&X)"P&$Z<EN&6X+_4R.F\-\^8C]V-:01^T^L)_]@"2&L,C]OT?XW
M%Q08'./SKQ3H3U%NYTGP_UJG__TY^0]W6:0Y^:OTU[W7UG[N][W:UA9TLRR-
M"87USXVS%G%3_5]=0/]B^B?/L/_*MO4WTS]Y1O\[&^._Z>+W;/^4U+__7+4I
M!>\SUJ''VVZ]_/A3B?SGB01" B&!D$!(("00$@@)A 1" B&!D$!(("00$@@)
MA 1" B&!D$!(("00$@@)A 1" B&!D$!(("00$@@)A 1" B&!D$!(("00$@@)
MA 1" B&!D$!(("20_S (_8_/"<!1,&WA8&%=G8T1P! @^S>)X.3?]4&V^>TT
M(> L!1G;UK?3FH'= $!.3DY!]M,W%&FH:2FHR"CIR.GQ>D56@* &R"@HR*AH
M"=\N)7RAC(R<AA9@Y^"D8^/B%A(6$0WDV:&BJJ:/NW6\YCW>B _OC@+XQ2D9
MX6MK>,]XK1;A6V< %1D5%345.0W9II(-H&07 NE3<=A  JB%CS>\YU0P.'VE
M@@;\[-6B(H9+Q=;S1.7-JE^_4K:N]60%<<\Q@NM9#/TC<:EV5S'?:Q_?VGWQ
MDG!Z/$(91[$G(N?*UT)7>W(+A==6ARN<O)/N4/>S/KQZH>7TS3I)2:&@TX.2
MDLF#-_DCR1])1*JJL1ET-MZ8M3^&NL?OOWYW%?W^)=>A++L!WR/T4(68='^,
M\C3UYY; YW0W!6J#*EE#6X)Z7PUQ@I98(LSG=:8#/XQYWX\;"L\)S9C=TZ.;
MZ6:.39O9J=8V_-I><CF7:;4A+_:D8Q8RX$&.!GL_5_^QG/>I>JKHIZ&70+V+
M]P].?QEIU4NNLS)URO#BMP"R?'F]KVNV:^W8 !I3W0)B3)<FN+%B:\J-0HB0
M%\DW<H*]:/>SO)\:9AZ:.]0[%W+D@*(*4D!F-]+M =ODI)G#[GDN([MX<3/E
M8._B&C(/Z0KU":\,,S%VD+]QB2:5"@ PQ9SHCJU[N!"[ 5S6=F^N?RHY'19X
M>LZO1IS^JN1QV^.9MS_M.@%TUNJ4<TG.I)I=]$?X'?;A/IGOE%R=,#_/*P^X
MNZ39I9S@0'ZQ(W=:(5M:;$6XN[M7"SUW?![.4>N6V/YJ[+;U2D$<NS,*/C"=
ML1^*S8CGCA:">>1=?R1=/VT@7^Y%QOXN5;JR-> L9>:'UC:STR.FMU ),W8Y
M%E,<[NZNX?ZCEX./^G27N5ED.7BY/-P DBWSF(Y=ZVAZK-=A=$RZ;,K <D]5
M9?$& #IXX<!:A_9)"82P.TM/K4LGK=R-=N&;"B<6A IH/+766C-'/C76?AQ_
MU\ZF%W8SOE9._[8 [*BY5'NQ)6BH$/HN?>[!0':9GCJ\W,"X@UYWS] L*YNI
M8M5S&;_NU.::HKPQ^@7Y6@9R.XTVT;@%&^#I%1A%[_&V'38C74FBTN[73+(\
MAXQXKZT$NYW61MWW.V>8C$DL,U36X7[&6?5<]HMBL_%1JB"SN/XJ2*8$7_,L
MHJ=V8MQ68J0GC*_#,-FJ7,(@HV11BV(R1N  F&8A4:)QG:%-6\SJ6]VXHU+I
M4[V0"H6\9\&Y;][=M'AWHZ/1V;?[G8@RA20C\L8RV(SK@[^?2N_0F0YNNES3
M- 9#:-$,RW&^$W&-B(K5GJX+7E^/VKVK24GNA?9R)HWIC-LQR.VO[,_K )VQ
M&J)PM9QNA$7),Q4?N+=7MQ425)G"Y4$MMCODZ5N-K%C)8J?40R<^-@\,#.@R
M*M2OSQR2>-L6?TW'##EL/U.2EW3;[DWN52F>,%@6!FE\]E*A5K$BVVV5=TIB
M%]8P+1KV?.QRBG>29J1,)$V93\ PM$*Q19HO]?E>.7JMZ]>WNGCVL%R]U(6X
M8Q\649<J<!Y<I++J;IQYUX8[$=5_-2R/@SUTKY-WX!O6H42';/J*M'.+)G)U
MQTQ5KET">0Z6>]ZQ-_-TS.;76QSOHM?=!SG[0-NQ=5TLT=QUQ?BHQM ^'[L%
MK?EEQ^S<3Y+'W7LPK6FH$@][Q^@+D55C<%'.M2JZ>]'NTC.#EF3#ZF"+;JMK
M!6!:R PS)=OBUV^#L9^[ OP/[0QTS[32QMQ=,C1Y*XN"MGE7ZYP/3(H5ST:I
MJ]<^[O:+8L),6W,%6*B=+Y5]L,O><._]L6:MMEBSWB>=9\#-+!RNV!B.)<./
M:N?\69P662Q\(;99SH>>%%R E.&F^@?ILMT-BLZ,1 AUS)FW9+-'V8T<'68V
MT[_-<_OC6?\ODTF7^5HES<+,*AZ?,F0Y_C:NK*QLA&'UV/WP)U:G:QPOW!H4
MGU]BCI%HM^H\C/-%YEQQDBVOB+.T:+4K/LTF;>;$FI2<;A8[NS=U)5#K@L5-
M2?$D(*,@I$$PO0CD)F3F:2((2#\=_?H<'=\=5+KPX=/- ?9.J5D=J1<-1PY=
M?G%G]XN.]&_&JQT+=HG\JH6.K,+-2,<#%N?V@<N*WQM=V!,2(6IL3$OY91 E
M3_5HKX).<9W;D*E0[(.OGQY$Z=P+N3SJ^#E"LF]>SJ,YJ[-_EF5_U7*!1'J3
MY8?YV_E(NW>8G-=^(1<2TF[,W-\+=CF&=!\JD5SJ0S2D3AF8< [(0G<4.&3;
M+*R^D;]\;3@C>0/8<_=+2=UB\VD]_EIMD_BU93[/!OV0NBM&9ET:LH7Y/G!+
MA=NB-+-EJI[>:(M="MWTK=GYWM4I=8FGS^[.OL.:)G8*!GZY\^@SE)#'@7K5
MCSI'YER7,\9N"*^5]6\ YB)L(P$C"Q<=<)RUE/W)O;<3M:)=] X9M.4[E_/#
M9\'9TPI<[*R0(7DE)#?OZ^3>%;;R6,BRQ.&@')\C[L/@SRC#^@T@ID%$V)"#
M]?;Q79%8Y\)RS6I_7C&,2/*1F\901&EP>-,9V_F]@GO6[-M5#=2NM/(,,-+)
M2?"JB%K-%!6>'W"=#6G[O %P>+R[D>.@F,86?G8]J&OABJ,MW*EU[IMK\X@?
MLC#XS+?=L#;;G(OGHYY.MIP*4>I1$TT<C$DZ-KP>4#PQL)AC?9FE_S[Z>!/V
M> V9TYBYO%1 X"/U/3V6'G$W;$#"3JTC24@?\5U2+-5/ ZE=W;TRQ0V$:ZNS
MW^8.3]PW&?+_C/#\''TQ/NUQ4P8'/%V3HX4NPTTL+TVK^;J+&<R UVEHL!<U
M ] A*Z4#;B=S[A&4+^V* 4U<C.?I03-\/!I]KDA&H$BW=H'OCFIGY3GS7?5U
MV?A%NB:>.6'GS#&YH)SK:ZQ%^@5&.IPE ZK!&%3(0\&VV3;L#5#28?3MYT6G
MND"'%L!O;<KL8X1;LJ?#<O@P+.3U"XT;@-L&4-VXJ/ZIE??S@KOMV;O/IL(E
M.J9N3[GECX06FB96?Z;U=36Z[>PQ*_F<,N;DK<H;KZ?+XYF7$.CZO0M#KK-Y
MC,(%C57Q4C[2$/#UJRZ#NV@B#Z3&NNHI+[,MO>T4/E9L$:3A:#Y1<V!OC8_[
M<W#OC5BJN/T1G/G/DU.[Z :\\I&88-.>4YX/#F,O.YADJ[0-(D?BVOGIH\\D
MO.K7N'V>,9G_RT.G([?@>X9T8N=SWGSDBG?[K!4>^M:^]]O JY-KTB9,\>LB
M=\I6Z]O8?2^:ATK4=FP UFTPYYN#2#!?9]_=QX<6R]N0M^JR6TM>5DH:<CBU
M#@SOM7S'%V78/6XR=%#_UOR%,3#NHN-4\+$>MJ\Q7Q,%1CZ7G92N.5ZT-A,[
MWJ5M\I$+:N2>-7FF[N 'T#CSU7(7Z5O3;P_NFZV(22V-C_5*&4UYE5RMH$Y]
MVJE74$^*QI0\+J^GP3K";%?Z5,BNF^&C4K TWZ>Z]N(FC\ 'S?9?&V^7::]V
M@ 84B8A.S3CJ&7VTJ)HFNVA4FJ(WJ>QHDISL).TU.?)YQ,L2,Q'QO*N6JLKH
M0LBIB&Z35(N)Q!'F2WI/WX\N?!8P87?O1K%7Y/!UKVC ..\;O>NI26SUKJFY
M<7YH]N+>Q%OQ9A><LT9<U9<#!*"FDVG0Z3Y_GPQC_N#P-]J5#X+U;WM)=P95
M#B>/Y9P>I^B*C2T\\&ZJ4_GBJ*3LN96S7]/Z]-Q"5J=<B[\\=H=3.F3'5=]S
MLRTP=I+".-PE6_6])Y51(7-=*3W[Y3RG1U+O%*7Y.SD6B\SHLE&/5Y$SEYU$
M62@:=*5I:!Z7#*PFWM=/9GG;T#7S\MT&4-1EVVQPT$TLHF%0?1E1PQP=;G]X
M_GV_LJ>#SLI$0I&/[\'2.X+(@M0=M'[]#)E+"IR ;X<R>O3T4<.PM4[JSY^&
MZQ^M!VA72>]P[T.D/S*.-E<.6BRT.%EY1L/C2/M>Y[>WG-7<G[3<KRZ4#AV6
M+>'+'&PB4W7?]5)W?V;&B-+9K[D>X=.#]1H"-A\?JJ_KLG].2F:YOK3?76#B
MD92 ]4*$\[="U?ZK&H-WBN99N6_36O;Y#98TW.+GYW'38\@N=7>[VY>4<*[)
MP,W6K%(W2W_TK->A^:$1FXBPZ[N9D'K^6N^UM2+7RY;J'IZ4V+$$&ZM8&Q_1
MB#G1JJ2I;2_5%^2BFN6\XO*"INRC.NVI=YI.P^)#[LP9^=<PC*U#T%L-58R4
M)S2JH"<<3);&]IUT>I%D;I2*NU6YQ!E:,O+@U1&VI:.Z&6/C.\-9NDIX5Q*7
M!&:./!3U3=?)"(NBRSUAH).,TN!6:0SIS1IS/6T$F[C:V''J>'5VO6GMW:P&
MA:C[*(C-Z)M=-\IK)AU7+D50B[Z0BQ'H?+)6H?6V789AY?+RX<-*Y [[Y][,
MKX(K:V5 5R8%?3FX&)2$F=)=H= 8NI.#R B&B[?8&*IQ+8HY8S0CREP8FX:/
M%/XL5YIQ.GF?U:;:QY:65RYM *5?-P#\_E9E YC: ,:&-H!C&:GK?JW7W==:
M:&(^+5\(T_T8;KP';D.W 6@^L<QWXV0*3_]P,,W<UG_OKKV'U-*40YHS=%[S
MILC=2$M<OYBZ&K/./^!1+LXS.,8Q.V\A,UO/7\I\U$FA^/9'4>='+SS-/B@8
M%^X%ZYQRVXDPB6-OWW.8RFUG[=/B!Y4T0GI'&%N.@[6';QY$T0Z.I:KE.*T'
M&QBYIMP1L3*#A:X\NM]?;]ZR?C/IW4FZR]E'*,8$:KY* 50#J\;].I!A@6;F
MMFB-H*/ULU$/SED8G:,Y8?0@PZ PMZ6X:?Y17/AS*$PH-7[HV+6O]!^;T5',
M/=UW&%Z@$(;4;%PYQJ T%B'._/3L;T(TNW7GWU6R)<"/7QCV/?W-F9P_>&_+
MV/#+U3VWOPW/A49<?D+M6A70SLG<9/Y$\3B;D^.W)#9?!TA-B+V^E[-D5@2F
MS4L71TY63+EH6$H6/*7G'S Z/VHTEO<IY.A"FT9?8>>+%6$:+O$[3&!>[AXZ
M;-%,UV14S;-I%48?A@!S[:19[Y/,CP^T\@B/.%@5V]P1F^[B+F!.@OI+60,G
M=S,60MUT'V++7NO4KI2Q^K(6YR3(*JXKY/1I.T^/R!6(J9\IG]5J/+=.YS+I
M6ISGS7S>^^K=;&V?1V[2_6UE91$O"[PFGE29T8,I=RW$?';)97=V<6:,";;)
MESPQGN]VNN=H<..:ROJWN\ (LZSRFY!1>&^=1,#-@P)OW= 5%M'(@V)Y9)P:
MQS3CGVKTJR,UI&5UU(J;99O:K<X98R833&8?6?DUE3".29]^B\ $*EXZ'&G3
M>!P!>7>/Y\'[Y=>506,*+>^/<JTD')SF'GCZYD5ZU_J]-QO CE&9\/Z9".FU
MQA9-KI8<B;SL;#%?[]BT+L< OGU?3O4Y@.'*Z?0"BB%1HK/Y;T.>3T_O,JO4
MDFLLWW5Z1OMH[('%.)KS:S%#4GP421;+J0,JW]B<[V%V!Z KL.<%5*X%S83#
M*Y]8Q)PK?_+4Q#](P2$]OZ.NS++-H$Q$A-PY.-O/IB0I6U8M18+VI+HYM9&8
M>4FD^9#P3+Q6Y.'9UV;/!^]VG3O$/"9X3-J-1649?&NJR76NFWO5T6U.6[_J
MT@Q_[C?[1)\JY Z!"BZFW6F&?(&>5VCEGEO?RBS%W-%?U9>28=H7Z.CTFFU(
MM*YF-&CB*XN@%DTK5V/0P]>:?0<NNRY\L_CT)*?C#NYV02D_2P['I;ZP,9G,
M&MU/7N8C5-95-3L3(J(0$4I:(_X?!+SV-3$KE .Z%;<LI7=4@7<L[8)W\YMI
MZXG::'NO+:J.WY\^>LS^I.ZEM:1"H3KG.EW3M_UC>BO,X\STO:W.=5=Y6.(.
MI\U].WIF_MB!Z![6,RX5^:#\]&<!=14WTW@A417)H,C7CUB-93O<VG*?&,1&
M':],G):7:&,YD),B<?38QXEC%.BZZIBL=O$CYR[+1<S-\:50'I7J&K6-M%YZ
MJ,)@.;DDLDA5\.J4"C?H0^?*?/FW4<7Z_#"&\W=1[@DE;Z>.:X72+Z\M7L(>
MOZ+Z-DP@/[A2K?XL3X9K:(CD'9/HN+82]/FX;*7;L ^=A6[1P?'/ DIR8W96
MJ8S,0J8L?<M;&!/%YHO;#ZGVKY7?C?NT+K?RBBMP,>:>8M'SL"\9ZVS0CU:I
MA>KY-78E;XU*EW3<@RL8W1&J3$7]#J];W6OKM7SBLZ;-C.+ERHT=!MJI0N:?
MY7H\?'VJY6 0KZ&4 *\$]! 7XE*MNX'<)]V<I?N2S8FQ(9_.,&>.'9G3CAIZ
MR_S5R5CR_4")JY(,N,[PNIKKV6E40)?O&(;]:KSEU'3F*0[9-AVM3)?R\M$S
MSY9-JZIKL")]U(+ Y0]<QHTK+P]$7GEU;^=SW:YG:_O[QDKIG%USY$+?=?/[
M?!I.(1>YH2K$Q,52)1G#88D4+/^4\'2E%LDM/K(+J< (M43>2M-F$G%[AW2U
M1]I/Q2Q.?@O(&'GPM#I,ZE089[\)QZD)W.CI _LKU=YGJ5_!N0GAX&]@U0C#
M M-Z0Y]3@'F. R;BWBNJSXM+C!YM:8>F=]AC2[K:&8;K%SYL !("? .10IV:
MA?EU4?TF8KL_02]<?,2[/!Y5>2O\0[&L]TRR1,LS"XGX2,0RM8K&8[C!!G!N
M-TOAUQPQ6XNV+Q%O+I8D2Q6>'UVG%FEJ7TG_^#!Z.1ST:L!'P.9^\.I=6'R7
MLU=/E47K X,]XBY]O-,CG4_K]A2 /K.EBNJT:2!4'I ?N'ONO&H_F ?=H=.=
M\F(.[7O$5M3SR136!G&3=5)AL:0V45Q40N9%ZQ?/N,D.#'ZJ5>=)1V=XZ6JJ
M9UOV7K.<Y8\J>'/N_8 1+^Z\(+F9:)3_!G!]>?>X<_2A+G0*4YJ%9<3ZM0I9
M>#(TL,<56?#!F1N4U0351.PR,0)5C@O>6LT_9_<06&<8*GO5D%CW9-50^/'K
MK",JU+5G/E ?#A2I%[SX.C)NELG6/+I%D_'>O@2?Y*_&S$WKS?SK/+XS 5"M
M*?B%S H7D:"&6"J.'>4=&4V#4BV/CSHDYA=QK>!XG1LMZK7[61_>R'/2@(7T
M:D#=G5/47B<+Q[.KC5N?;N6-WF?$69QP6;(X$@  Z@?0RLM4]%Q/_6F:)FNF
M;H:A\RY1NWB(]ZO8>"\SG>K0.DJO/CVY2)E4D/ZAI1V9:,IWIS].;?39-7I=
M8P>H!!891!8FW>6GXPC*! M=4H.#^.KUSRG3,UZW72^3?S&1H'!Q(FJOJ'QS
M>:R)G!#5?AG9M!!!WFZ=]U\,#XM_F\L6CW%2"6D5G*&&R$T\=-99;.Q;>(QP
MMJ_I5.01R"]9S=?F&4'P#.O.LRO5P9'/==J!5X94'M?.U?"_6C68R&S,/;38
M F&*N,26F=E<'/WX)*L+MQAC$M3$-% ]@;(Y\5GU!A"'R;,IK2UM4#X2<-=C
MK/BLJ?>RB6#U*H;AA)1R7;9HP:PW;;>.XU+;Z"B_-+NIAX4FKVFKK]O9,9MQ
M^)!788V+5I5S/"9:NBU;5($V3ZY 1,J2]LQD;I_"=8<>Q?NU>E7!ESY%TKG%
M<:)JAF=M>CH;!].KE55V9_%+.*8S7C7B$2[(X],K5_$:S^P/TK :D#(VBB./
MB2DX^ZCQ3;7:W9U[3M!;\W@JQU;6WCP_S*0>E DG/PSV3 AO]E6Z4AA>/!U-
M+@YZG#24.7[FB_6.YYI5V=R,(^R<3-?)FVPJ[5BI6^+$(I$QV, DB\"0QZ]Y
MFPK=DNA9-1.8E(2R'(34^D[QW2AN/BDA-,@6"I;DMVG9>^5]HHLF_^<O*>XR
M*2JE<[Q-I>ZR:3NN@D I\)2LHT];5)*;=DRPZ25%WC8[,IU2=*9-:.?,0S?>
M<M_E9)N[TTS73W@,CM8\P;4$'9K @5,%/O6%&=CQ\K^L&DT6$Q(1B'PBEK?G
M'=>]H-07R6F0!N37B=W-$9AOINDO5I&/@Q*-. UGG=5OTO+:A6JV7<UFS<IL
M:A84;71M^7#MJ5V6S:WK&/C0-$N@!=."OVG!ZY3G[.H3:*>\E7NSI3P%[_.T
MSC?')P\9P3D;[I\]_1@Z],)A=Y=OJ85A34RLE_-;SI3/M?;\.:Z/396=CH3?
M>5":P:15*$>7+)&D>DP5QWAW.$MO]GVW]\[>#.]+UB)Q'4GI:A8>1RZG&YQ@
MJ?<M^)3[SEI:-E*\03-.-JVJ+_+]KH?\[$4EE'XMW@<G+$7OQ 8'G)AC"1*F
MJ0NQ9L\;F5&\LL<T804&EY"0&MF;]>2>]>2H>(JJ@J)&6AFO<;>/.57ER_M!
M69'(JPX.\52@LV<4?;J-6V:3XX UQV/U&A^HF]^"9V8O!(R=<V_V<4[AYA>]
M'KL8\.SCH+!FU7DP8TDU&4\NNTVJF,37-VMK'<:B\DQ/.ED7/>>F EA"T^<9
M&G,=+J%>[\"&Y<IQIMWAEP^VU9>VG4:MSLGOXS1WX\[U]'U10C[[E-&T3C-9
MZ;$^3UCDY:!6LIF4BX:F7K2")G80KVBWL=ZZURJ'-,B>2;9^(:].F4CKH$VF
MR\TMZF_XN.P^J)!> P_)1E<6&SV?O"GY1![Z_(W08_.*>X^C#G9HW"RILBGF
MUI[T081[IP&<I4]F&ZQP8]C[Y'<N* G"/UV,,W;UY=?>S?VP$0EU<[55DQT?
M<GQX QN3SSUB>5)?>JYZNNY*SUC$%^H11/WC-]2^<MP>(BUBX!?/SUOLGM@Q
MZ=Z@P.K@_4A\+T6+F:19WT'PR5RY*Q/H7IR.R)617<<N)!VD:=FA(]^P>)(E
M2?Y\T0;0R5RW 20:;0#/$%.=GX/7&N985H](;0!M 0G'2G6_Z:[OY\O12=SE
MR>*R <0O;  S3S> %4H=^>;Q<4:!'1Y?FW[R%PXY\2=AZL;0_P-02P,$%
M" @ 5T0V4[3-\>]?*0  0'8  !$   !G,3@P,S,P9S$V;# S+FIP9^U]=UA3
MW;+WAM![;]*+*#TT(?0.*DJ7HD@(20#32$)5P$Z1)@(B"JB (D7I"*BH@%1%
MI0JBTI6B(E($@2\$L;QZSKGWON?>^]SGRV#V7C.S9GZS9F:O[.P_MFN]:V\
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M%#%6V1F,*^*P@(("R_,>85W>]0KR#H_VOX.T3-W6OC_%DL=Z,S33*'/O;!)
M(0I1B$(4HA"%*$0A"OU_16N#AL>\B40<1%D90U""KO\H4X)AT<I!4)PR6$E%
M&= U",)!88?@1'%/.-('HR?YH:964MS'2T]RGX:UBC7.!.[M8QF"A]N'['&
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M.U-S?2:2[>;#CS^UR+^?*" 4$ H(!80"0@&A@%! *" 4$ H(!80"0@&A@%!
M*" 4$ H(!80"0@&A@%! *" 4$ H(!80"0@&A@%! *" 4$ H(!80"0@&A@%!
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MTW<V"K66-!EFSTYM/*MY**+QNNK*::O )9C*Y]0W&0+:FKID@J9'"F?XG_@
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M?M2C;I=6,_9>KZ(G(8I"4GJ0A(QS8 <I.]<1W.WBMD737*;3C8=+<3 %N8"
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MVG7R[_H [7T=CA^X@ ^BV?\Z7 ?  0 @ GS03Q^)) &(2<D("(GP\3!J:6H
M#V_W2W%$>" \PMT/Y1(0XA.!\(A)2&D!&CIZ!D9N7CX><R9F%BE9:0U(< W&
MAOW;U^1^^A #" ^?B)B D 2C5=C]EAM 0(!/1(B/1_Q-20,0T'(3TDEI$/&8
M\T).1!:NT$NG5;<1#S_57&7@ \L@4:=__01;S<9B/U6W^7NV@HY+SIG#J9.&
M93H&7GS!Q$'>?(97NW@E3Q^>PNN,?)#K2YH<K#>8GD2JP4+M^KHXTB;V.EW]
M#G#DBL^'VX),V_(;ZQ^7UKJB>H<<AAA"S(I<O/7EE/30@L?>'4C9Z(G,[F*?
M2:%_EN=W,QR98((>T&?UZPU0K8_Q?IF4;8]2#QWQ1JT,103M /'K0Q>C5G(/
MY\O3#(B(BH)*63P^I,NTQWTXWB'Y<(V[$Y$4=.7,BJ9+OQOCL<<^YZ.C[M]"
MNW&]C@Y]YY_J0Q,C<KWS3LB7F7>JE\-D.+S<RO/;1?/.50QD^K$*/T8Y\M2-
MY,9J<Z=/$':+79KWTBJJAI/UB$4D/ ^ZS'Y5\S)^$F.H4OP.8')8GGQE@I[D
MIDD'3T]?MBFWDF4\,JWV*0VA#H&TAU1#:>B!EX$P"V&[@\SNX"]'!:?3D.>,
M4W-K-4>+NW5+O29XKW)GK)?!2LQ(.^N^3+YXA+A2O9ILVCPM'A*#5M4<E5V(
M&GW47VD:]=#^I:?(^L,3S,2A<N[;?$F6MT:<>RP9E]#,#>'< I.?QG4LBRP9
MUBAEO'I>*8:><C5K8W-?ONV2CG8?\E7AN6YSJV2A(X"8[*VHOSGK#2COT'A\
M8[5'6-4A4AF),".^\QDT?:?!*6\^N+/-SX_2D@/JHP@O#HF1LK88D8M;\9M'
MIRJ+4)RHN3<(\;>D]PTM&5N&'8976RT]:HD:IA]$"SNP=!B4;L6Q"HB2@J?J
MM1/@WKE/*V3@Z%B"+7.FE2J)^=/;V_GA+_'"R^<NG.=T,BI98\@[9ZCF&'M]
M]52.X9;>@7.VJ/Y6#_#1:X9BIE7>TJ0Q!'>8":MSGEQUGC/0ONB4T9@<"!!2
MFI29^,K-M5X9(N([E1M,V=$TI^PYWKAL5#$9?%F:C>S-<EFSR(VR"]15K"_=
MC#FTF[B<;5DD:2':"U+.L>%EMR<G'->N];ZY6^6LWJP"%+J]:Z)<<8;2C2F-
MK,^X"?E]DM<?[C+^?+!9S/\VV8U#'Q>OM,K75+@.;QQX62_7QSY9U4KS<A&:
M7Y*X'(-ZUC2N6K<U%NKG/%B'5C012)@KG7I;/O: AGOVP<.IVD]BA\>6B$=O
M-XRFRHJ\4Y]T7.<1ZA@/=8L-Y8N=NS']4IH1\#KD++Z5L#%#1'S[T\PST\>D
M$L)L]393<_ECMYJ 2$%&O68=AX1*V7$;*A8!?>3)=ZM63\ZU"3(2D;/HUK#2
M-9Q\+7K\ \JUJBDZS5^OY/AGG_K/XQ0V=(GV@I=LMC+63[4ZO\_H,;10<X7V
M12J3E.ITH\]QWFT\(O[2HS9]!Z!SA%D],G_"IJ\Y>,^;Z1&"_F9:UN'SL><S
M4E-DRQ[-99K-U(%NE1[X^/GK":_C'^>[D[8EU>N/+XY76.&Q=]>^L;Q0(6]C
MP^,I\.!=D+5][T<;"\9NU1P-D</GW[;P2*WS';)#)8$?/>0)<\/['/B5,)<9
MKK=Q< 5=;LN!)\$7O .\Z;>?Y^,WXHV<HIC N^\;*7>#NE1$6$B?EB6.;LV0
MZ17<[TA5CLDZ_X=#BL)W7)(?[P!>U6O,D@X7_<HKRQ$GW5V,2[/('$6AT\>D
M&#2Y'MP7B/5Z] %>3*_.](9S*XU;UXC K#,?W>R9Z/[B,T. \(W!]CL((M#0
M5OE6Z';?UI4O_5;A0N=:AM[M ,0GOWJ_^?SUT@[P6,WZJQ)>R Z0W]HW5_TA
MW/U1J-I&B-Y0PJ+M5\JP.J=C3%^;#K;F&W/T7!,4]9B86ERF5[E>CR=0_I9T
MBF" EQ^J$_\$BF]6FHL/9%,\\TCD#"8^)_K,A&\P?Z@CXK0HM9X#L=?&;69B
M>,O56;S1ZY8CQX)%3!X_Z'BA\$*__+E'98=N\X+*^O2<[?7#5S^[I+,\])1<
MD]*J;W9Q7!]L#BD":U,R,8TX'QG%DW0>OWJLW!&OOO2Y3@UWP^@<913ME(B8
M1D!:0>.<QYJDZ(2I.O1U<74/1;ZA8PW]< ]%YD/;CR-V( (\$JYUWE(*:XG1
MFH&JI1;]XPU'8L_N /CNZJ/EK2Y+=_NR$C-6Z*?([I[-(:QO3DS*EN9)TXGY
M6"H](?%$:2/3BOF6@U%H35L88<^]M+[-LQT>-:+WP2Q4+%P?=&EE=;(&DQHO
MFQ]AM/\4<K-2[H[;X5<AWATLN5UNO@SMQSI[!41G_?4G^@]>8J^N*2A\WR/F
M?<!%A=^_JEISW?B=B@J5K_C(LL/QF="L/(]FR+5$9L. &7JC UV)(B(B+'V#
M[],S=/#QGKFGLPC5JCF 7<;RMZ^LW&#N$OS:&$=@W&)"<SH:9(UOKT5;XOGP
MH,5U"UK!3Y*;8FLB91-')#,\W5!7,QY5<[HCX3E*M*;/B9>CMS.W63?MIC\=
M=5Q4JT;//+K8:=W+,#YPU7\[?.BD)61!.''T))>E]#G7^[*GK)_8Y4_EDCL%
M<P3?[<E(4QTP&]Z<2VE83I16UHM]P9T2.P_IDW,)J84.Y0Q"4Z/[*]SBU,LC
MT^8DZ/6A<;TQ1ZWG>]ZNM)+ZW0!E1RF(J+H%\]%T\W[BZNMO?RX"\#'R2<?G
M)6>0:9X=/7?JC>L.D+.^N .\O=BU ^P ;"E=\O*VX1\JE\\.LE MWO,,71X_
MDGGT).U7SE$O5>JH8?LQBNU1FRF1QUVS>%8?G,'YEY\R!^AYPA\*RAM<S&Z_
MW6P9R^4C'QL@'=L?$0@"\587/?B,22YOJ+5"G6G;DSG[P"8_O&JD#JE$R/C=
MVQX:)_3#[:I*,UU%#B6Q0P5GS?P,>V3)@]"3%@$3\S>&[_%9F!(+U7^IU6N8
M?!U%J79U=?68\N'5]V_[@0"4Q]M9$3GERIJ#B^[N\"@7L\GTJ2Q).3?Q8Z$'
MPERZ&@=5&KN_3DDUI#5G:(4[S1$IA%MU#>6L'Z#\ JE<JSBD\?*.RU+8*Q7P
M^;5[Z>,<_@S*/CX^*U;7;26=+_C2I3>#<VP+SK\Z-,UOE$@< B9@?W/D4Y%Z
M\6DC!GI9S]G64]L;NNS/FQF&\_!]K<*+YTP/9<_[TKO$"RF3;^AG/),H*JCB
M'>^)('XHN)I25+6B)\JV>*UJN;AIL87)_+I:K&Q#I5C8C//=?)NRCU3>KVO>
M$/8W!8+OH,01MN8/IC978@N;C+>[TB].,V6$R,3;E?HM@(E*+ZENJ1O0+8K.
M9<Y-O8_2+V")D+XG7.4,*&I1ZQ.@JU^%SQ#Q76P+(QY\I<IXXJ1SW86LA,_=
MBS;'SQR9><W&9G*V>)00AI"MT5=-IRT]M.8F1!]/WL,M<$;VWA'F9_=NI&LG
M\)IK^==O\,=\_JK*3*PQ\_AU'.-ZYVISO*.*SI?2\JE7$#F-=I^CS0<..8K(
M/] S/:&Y#(A=S65OEV5/_VA(_:"-PO>0*XBU.RDQ+F^M_C-*,^%A T_[%$=
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MB<19P0*0#D8N#NM@JP8V."S6VQY)" ZT]O*#D\2L@ V  ["D/V\  M@#2(
M! .!%!/FP/76:V[TT03,MXA8O8)1: (*0W%)XIDHK0TL72U6>[R=W)Y&]J<>
M<_[08^M  @J+P9.DFRG]"B1@UCI!ZJ07;IVQ\\%;?M?@, ;?&0SA.[/+"XU?
M9ZQ\""'KC%$ VG"=(>7QNVM]N+_/MT2L!@C8F>@;D$Y@RC4" D%@@[UV8I^N
M#Z8)#O.+3!_]:SM]',+!$4,P%K9#$WXL!GTT O([N1T>3:#(;<+0.W'7U\3,
M(4@X 8LSA!%@ZU5AXV.#7ZL*\O6WLP$E"4AOPN_<.Y#*]G=R>SAZ56Z#@^]T
M71>SPW'80&=?)&EP2>.%POBL98R-K+ CQ:2/)1"P 6@LQN>;">N:AAS"#_(-
M:W([E(_OCPJ6-04IMG4QN7+ LZLQ@*]]505H -#:F5)58A0=V_<>Z![Z-L,V
M4%CRE!2D\'P_\^ %"L^T9@>B6(FOSE;FM>%?10$O4JY- 7EO;Y(&33K2?S-:
ME9S-REZ7*%&.;J3CFD25<I3]+J'X_$"Y)LVDE=\2>(JL_OMUE%PPKF:4$A=
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M2"5J\Y@RI&QL!7]^ZX63R!>4.!,E\2R*]R&70FM[!Y>M\0 BR$B HS1)8V@
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M!#@J !X'#@$'[GSZ8J#HY\UP8A=9(L%=T6]E1 #@X!&1D%%0T= QX/Y1"0?
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MPQT1"0$9#O[RG:6XMP </'R"VU34A()FE P<;M67X2YL$1'^^#ID) 1$9!0
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M, =TDT0Y:C2&S4NSDGJ'8BFRYKA#.:? M>B"1 R&AD)^&K@I4<^W($+.AY@
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M>VA#6-B#H^ZW19,/F-27&L1'!6 R@W>(N4Q4Y5\/A=)X>6W@C-G [[]Z><:
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M0/$R3)AWM^O+M^F^6=J.#]4</;/Z4"*;1[0HC9Y:3&A;&["XER7)9>I&O.2
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MYD2T(!=:"UZYW"F%-!(J;3:E#$A*$Q?002'H,W,Z5RAO#)IRAF)P2(D4A,C
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M#!P+V\/)*! K...Q:%3EI'G'LF>C8)C-^R WJ$+\O%OJKGR:FBIHO':++NJ
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MOG^^T&:ZX)=O+(] ,Y7-!QQZ]N%9AY*9!RM3(PK+<85NPK%9\_H.6OZ0N,[
MUO4//?E3]PN/_H)^@44;G0_W&7EZZ-</S8)MR_8]R;[J.;S<]JYV$:99..SP
MRGUWGXFV.0P_&9@Q:P;7=^7;7^4'3_Q^WA#'.[^<6U;?O+8[>&+5F#/&@Z/F
M*7Z< C^7 =NJU^;;CG[P8%Q-E4BG3DG@!P@F,V]5]TS87=G[4^3-F66E+;=]
ML_Z$ !VR>>1#_4M?7;#\H9^7/Q=Y[2??3^_=]]F!)9___ DR:_;>'X$'C_7>
MT';-[.G#EBV&]JQW5O3L]DBGI7<U\O8-/M2WQQ')W%?*=NSMO6OOK@T-7$,:
M6#R.\'-/WOVIE3UP]NEWUJL'_>IX\QQ'9YS8O:R]]+1ZP]%S]SY][KEZ4X8.
M.3<0YKKW%>XZ5+V_ZR;KI+)%O?M^5E*O<9<3J49/?=AI\?(6"R6;AK_$IUMD
M=:MGCMW[%;[NO1&;1P^;,;"!0/V1[%YJI IKVQ]MZ7E*-\0U0Z2N'G3?7M,K
M7W9TK2YO,JW'6OD0]2DIO&%+PYUMOE\V*OZB\/"85\_V;-G[BW,-V_Y+]\.E
M+OVJWQH];*[H>'RG<^5/YS.I;*O@F_YW#O4 2U.6IL,[?]SMTWFJ T^-[OE\
MB[N@T>.B/=<9YYKKMQKKV2JR]IC//MZYNO?._7O7-7OIN8Z-7G/N/OK4KLY[
M1YUY8/?\A+WI[6VF3FO5^SUTR@/^X<&'XZ^_V&\#;9\TZ_7;&TX[>-XPKOTA
MUH9AH[_P6[7W-?&M73EL_\=3Y\Q%=C1Z=>: !85-9]?LS;N7UENS$$,&[/KQ
M^<SZ?NV^3YYR]67'=^E]]X"!ETN:OHQ5'_AT];D6LR?O)O[UPXR5;S:F6_;\
MMA6S!]DRZ=BE>8M<1Y9WGG)2N*3MFQ/G/>^]N^?ZTZD3(Z?IJ%#PV'>?K9%-
M;-FES[;5Z)O'.VYUOW!W.\&@KE/JMMTQT]5^Z?IGX_6G?;O8L:'J]2E;T9[J
MU]9>+OGL^Q/]3O4=MN3M2Y4#EIUMNG[:W!ZB.5^>?$1$+OK ?^[CCN)W[@!V
M?Y/:;\BV.*YN(DPDJE?/>UK99$J'P?Z9"S^T=&56/S?V1.2%V3'D@_JM[^D0
M&W?DW>HCP_[-K^%=MK?$METN:32\9%RCMHW&;R@L;S!%UV>).''QB<3KV75G
MX(XK/G^Q]'))\U<GN?)1A(JL[;@E-+WRMN4_UUNQ<5S#-PS9DRO;+E6]>DCY
M\]X!WS[TZ/#;JA=+I2T(JGYBQAQ?O=N.O7K\SL%KG^LT1C>FO6CFL]^/\I]9
M;E.L:',*7NWMVB#2;M:FKF\/Q1NF7#\,^7)[X(XOF-.)R.L_!A][L5S7?4Q$
ML+2BD6&%8_[18T"ORD75NIBXWOCZ/_3Y5UN$F%SWH^JDX=XR]>V+]>TZSUSX
M6*3UYJW#9C]UBGC;+QF2'?5]TY9OC#EJ HAUC_6 \U5GE0.\C?L,GESR:75\
MU,X)/[<^H5@HG44TBZ-G=<J[/IM<WV:Z?6@U&$S/B;1Q-QWYX&W0^6D7/X^@
M+U8?@Q<5&M*G6NPT=_OLPW35\<=,OTR-CS_ZT-O3/SW\S7C'/.FL>6W>ZO+L
M8P\<[.#>^7C\=LUD'7?\R:T[EB]X[ N@SN&AS[_LD-=KUI@]77CQH>K3Z[\X
M*-G>Q;;R%7FLV=&Z[D=/O3[476_$1=7X1;;HB.U[>W58N/$^7=N#S5NO.[-\
MC*7-AF^6W]&I]?VOK1S3O?F'!?V _7V%3Q[M_M,9:;V30Y[>5V_DD&WM!6\M
M'+*I/##RYSD=-YJ-08VO_2!P:?-GNS>./2L*J":T?\Z2M:TTQ;_Y;O;YOA?F
M[]2=R?3Z'-_1>^?X5NDEO5Z@'NOST?X.BH:-&W=^ECC[0UM0W>FY?DV_GMMO
M]YRMH8GCWOQQ5'8].J=5]U,_?7314']O@P%/#'E&;Y42BKJ;/ <$^G?FU.^R
MY>?M]<J;.KI^J@^.V]JW^T?SQGZ\I<[T5\L[!?M<'#FQ#@# SS1ZN&FVD?O.
M,?/ZC94]]-;#FYC%V$35EN.OYH6+EE:.ZF%KVH_157__M&*V>+^5'RKMJ:&]
MHZD?-FTX_-*X]]NM/29^6_M%@QGN4=7I5=;*":7;CIQQ]&=DTFW/'%W>\G*)
M:-X;$VY[OO_M^^[7MRZT2^3L7_5_</ YG?#LN2VCAFCDC;G6$Y=_)#[9I<5@
M]_O)]\>6K$&8U'S)"V))IS8;&FQ\9KS(L=>^3%#1\,MQUA4K+VU(7QPHL0YU
MLDM'0 Y;O_.REKXU0X:LZF>Y=P%KZ;8Z>&>?P\U_[!2I<I=Z=M_>J>XZ&9*7
M??O41E"WK\/9R4,?^-&8&/=^@IP[[XN]6UZXEU^9/#'NB_*7NYX[.>_AGWNN
M1?K"=^0VU#^X>^>8=.]) W?\HEDG*A\[=,*I7EONGSE^_2GG/MWI$GG5]YN(
M>;OWNK]]^N,^*PP#U(W:L:HILWIMZ#!AT#3)_+9:9/:;OGW#L9Z3/O3\JU>L
M^E1T;\^U74]I_0WFF.YJ-59[.]>MJG!PX MW-A@Q2KMONGBAYM'/)ZPY$VRP
MHKH>>MN$L])==V@7[]IVQ+)D0RLL=/_ Q9_M73'+=\(W>I]@X* 67[V6FMTX
MJEH\=LUG]1>WG!@(B"HJ/N:L=Q_-WMF"Z:/JO=N5_.&KEE)J/4V:WNOR)!&[
M]W3]/;-?&=!\;;]Y*UL] M^_[?[ *\AMG];=M/95VQ.==XUNX?WQH'M6NT&)
M$4\]<:3=$??F[^^[.[''T7C;"YWN.W/ZZU,3GIAW>.+2M\Y=6C+ZVYD'TI2L
M4VC5UL763Y;)@<4C1+A:[DQYM0-&[N^\-3[:.7R3F G<]7E'Z<='](N7?^@:
M?Y>E7>OE71HR#VW?=:K=X+=V?R1:M&O9C\]/[A/8L:?WT<B!F:\M;+/WASM?
MW[3=/3ETH?6\MO&C@?5GA'=Z[OKRKD,JXZMV_[+^DU[=M3UM?.>9!L^T4:[L
ME?]AK>.Y\_V9LQ=E4QXY<>J12S*"^:;[Q:[?C_R!6W-R7I=M]_(9^*X?B!?/
MI?>\ /SXX#<GM)_T?/*#P9ODPV.K/URUHGK;P2?H1^M>>.$C\9'AVP0#WC2"
M'VV<OV"+'WK<_7/IWI?/V]5?/,_4'QQZ<&[[=X6KH<9+)Y%K6FT9/CQRJB4[
M;8-WVMVMFZXKK&P[?N:3;2Y<6MGKS+=O1M\*O#L3F;3;8>AZN638Y]87NMXQ
M=N3ST<JCATN6-6NW[^=^7;L]K]2VG31AWMG5*DBW-;IC*UJVI_W@LI&KM8T$
MZ[=.>&!<,SP7$=[_:(*LN$#-&;OS0/-MB]9Y[^\X1/5F9<MI\,,_A3[_</RK
MNXYLV9":7.@W0]KVF9:'FB^?\V[_URYN/(*;?[B_E[KBW)C)>']"]L@G4(LS
MGZ\5CS*\=G:"8$;%AN[-[=.^C*"5RSO,>E#0MZW]]@^&]%@VL\G#']\WFM5^
MTKU9AX;XE%(?OA,;W^FT<,TWJQL/'?8F]O6<V[$'VGXR:J$$.S92?20[[_Q*
MYWU+]VX95RT?+9_;D%XPX^-F[NES/%V>D-YY1GI:=OMH\1SZA67LVH7/[?<S
MVN_#77&IN "7JEX<WWI\ [QEW8G+NG1[^+NV;TQ<-V'>FGKPD4V[#9/G1"9#
MG7=.[E@';+V)6+7YA+?Z,_6A[TYNAS:\U^*8Z('Y5<Y8MT]_"IV<>@9?EIKS
MU*PE2S:7)MT1:,+I=6Z\<O-]DPZ,@X+WZ!^Z4'VGSC!1/E&^6S2]7+>E)3QU
M^P/3>G=_>/^@H9L>?D<<]#WD8\^O69Q(/"UI7]GT@,!S?-)+Y;+]0]XZ:CN\
MA(J42^6496SUL&D'S2,C=48<'%RM>['2-6[6HBC4[;7Y=Z!,/>F[ MES=X^^
MZ[[6RJD_-'K L^A#>#Q1KT,I=&1CWTYW%!Y>]V5IOU6%![?L20Y:M$"XX]NY
MD!07+1C_KS&:F=^4MCIYV\8-_;'9XKFMR*_T]Q_Z\IY2[>%=ZV80\+19H+1=
M\Q^KN[0_,.W\*VTO=(_LWMVH\Q;!J.5O4'W2F4'SW][\!K%HW/2G[[I<(NRU
MZ].QHU7M'XEA69.-@$^\-649')O<!U-:<EODZ[:^"'YX;Y]!LY_HM[ALX-HI
MMI672^X^]#3<XKUO9ORD>6'EW9F71R^8_&.#!:]OM&Z?6I\>5J_1W':-Z\(=
M; <?$\&CQSRXH?O4'L-$,\Z^/[OIQ76S]LV>^@DF4[YSYZK(L@_6RVVQWC&I
M9VK_ECNJ=KZV6N";T/6UBO6Z2/\6;0;I?/O0@V?./?X]-_K4X8??_#@X"]P0
M>&'F*S,G-8X<FE77</2YB=MZ314;NL\YO'3 3TOO;_/VKB$KCGZW5/'B_L".
M^?N@$R^5'FU!3_O^4*=]C_VPR_[IA3U[L<G#18KGQZE]KW5M6:5OW;?_BR<N
M#N[?:2+Q5KWWOI*^%YXZIORC\A5/JQLWN:LQV^A+P:J?<-DO]LV72[Z*K#I=
M"6\^W7E-AT\?DMFPUNS6P8-:M^[\Y@,3FS7\YL.VDB[@&Y-[O:PXVF'Q<N_/
MSNCBG4?F<<VPZ-B/9^LNS2-F5+28TKCR\2U&Y_!)]^<:=;F$N9H]\&A<\MBW
MS9?.+#DN6#NJAP8LN[/5C%X?7BYA6Y6/EEXNV?+F%QAXSG/W&Q]O%;Y5VM5D
M>J_9R:%DUT_K"-?/?;/_F)WKFZQS->37,B91G8<.1+&/FL\ A@NFG\R'%@_K
MKCP_=&6N\W?G7W2_=)\="V&OQO)XX?;7J/928FT_G427=>PY-G/9@N:+6@,'
MIC_XL<8SN7??KH.W^JOW[9PV]E^2^BVS,5%EP_!3X[><Z_QA=]'^@8T:31G!
M-)^"']CUZ0]/5B9WGQIT.+IJZ/D3+>N^-NC.\-T/QSMO;O_=&/?Q?CT2XQ:;
MCSXWDL(_:M4FLN6Q4=^V_AAU#'IG0\,E2P+:06.@NFT:UYN]8?@Y2R&R\NYS
M?=\X_4IK3W#[H>]>?NG%#G:VP>SA&_<WZX_1##>'$VAVU.TY>6<OW#U@Q_:Z
M]\N^_E;5LJ7WDT[=W\)>G'JI<_VA9(.!TPNK.I^_=^G$U^OL_ZZY[GCYTWK)
MQ%#3'7=W[/_5DW<E+QJ>AA<N^?C9#SN4SE+,6F\>+SH[MOU+P%#+I18NZ8.M
MA]U_JH/F@\\?/;CH8O>7[VE:[]2]E56=E\QW[9^23Q*E+?#T5GBNDUL0[$I\
M%WOSFPE5;:+UJ\:>ZE4*G_QJ@7XSW7B9M^&,<]LEDV-P\SO+XYM\,Q[=N'N4
M^XWMS_KF'5@Q[."A=FT_F?'>1\W-KTP/OC78IEKQZ.#'2[ML/C5A9O<>3M_L
M26=5+.0YTZ%NXY^>O6=;ST_O:IRY.$HYY;!_U^?8\=?K3=JQZ_&W)EWHVVM1
MW3-[-G47S*7:50QYLD>[B=->GSNN8<7SG*F_97!YQ6TMGIE WMYH<U/!B(5'
M9R\(E[!/O+H(.MTKV$W7;>T;8V9Y#I8OWBE865']AO7(=UV/=![W>+?C90,V
M=E_[QMS4PP-7'RT?_<@RX9;1NMM:12X]!O;9V$'XU*/0@_JNS1LH>SQCV-@N
M4"YT?K!YXNW(Q 7B:1H,UQRNDO;<S"52;0YK3D=6R.#J6>L%V+\(";%KUG9X
M5O5[+1RK3P]>\LF,CK_[ B[O_/\ 4$L#!!0   @( %=$-E/'.5^MJ1X  !MI
M   1    9S$X,#,S,&<S,W$P."YJ<&?M7 DXE.W7?\:2-6MV:8SQ*K(,1HR=
M0;+OE#!F!I,Q,V;&WB*5%A%)R5JT*)4D6Z2%LO629$V)45H422DEW\R(*/VW
M]_W^U_==UQP]RSGW.>=W[G.?^W[NYW%EIGOF*2"TP=+:$@"!V$!1H"@ F'DC
M*N081*02*4%$$EA+30/0-;.VX^  Z"0R4;/>^0<+H&1!&P%V&44K638 8)O!
MR;(Y MQDLJ:>UCIM/5DV3L#$#H<F$RG$ "K8@TC&@%7!CF3B%BR:"G:(HE"Q
M9+K 154;[&OK =93T]!2TX3YPC3AZV"Z<)B.FIZO&F867)&))K1C;\_J$[0&
MHIFZG["ZSF$E9AN"V?:,T4X_0$R.CT3&$:@.8512&)7.<C)DCA2JBS^1B&=J
M6!.H6"PA+&3NGG$UQY,9O"#3U@47R= PPU$9-C]\8LGVJ!"LJX6GZSS8K &]
M7\0 %RPUC.3@OP5-%_,#C@ 9(-)_ @ PX )@ 2H0!I"8)KRD>>TY-V9X*N%[
M1/S^83@\%4=@NJ3S/$QM<SLOF]ELZ#/TV507]5AD08\=2%0<D4"A2R68_2)1
M"7.=H'?2GSS/. =2['ZTD GF/Q@"]0=CZX^GS#/V@=3P><8B!(^<9^AY_.':
M#!T<^#T1LP$"SE9FYO0+._,> P9CB&'^)L2GP!Q9D0F_R,SPO^J9D3&N;@2J
MI8(SG@HL(#,\!KR4W)F"IS+ECI%X$X^;<V+><'H5$LE(%!4U7Q6.@8Z4N:I@
MW'^_FC.3@ V@+N7>E3Y)EI*[H/&S<D<RVL1K7BQ$GPXDCR L?7#IXX4C!,YE
M3(#1X$R/R8Q(I1)#\$1"X'<3_KD61@@+Y,OGY,ZXP*"%#7QS#?38YL6,RF%_
M,QL#^XUO<( -8)N[,JOJ#V:;P(\>&,?.6G$L9[*,&1_)Y*7F>3FFU_=,GF?.
M#L2T4A*:3?/<\,^BL']@WJ\'U ,"Z"UX^GG9=Z-9R<GC&?,23>9Y(_T\)X$S
MSZH_)$R?GYCW])DTLR2QOV T__UMS%QPSV:4&1? 9C)[?&^3F\_3+"_-N&.'
MST<_2_+T(W\^=;_20EG^=_W?*LS1CX4!((3A&07&QH#U)X81,)2?YB6:"IL+
MDU',"PH)^*GB +,?E<D,P_E'X3%"6T;!X]!8BCO>EC%U0(MP.)EM]!L1^L'%
M9*R1"WQS!9*)8:1%HF5$,BX0-[\J6K@PC!R8,CJ_'!5&)5IA"5@RBHK%,*./
M(LTMZKRSR@P)H\4Z)!#\7^@_>Q@9O^C1P$S^8HD=)7#QXV,9"D]U104ND@F@
ML70[;"35FK+>U<YV;H'BGA,O4N8)(I*C3?&XP+E,"<YV?OV<F)%=##8 %<9<
MH7C"L63J$NKN<^+%ZGS^@>9$/)&\(+G"LP9F5O,-C##LB03&E8=*)-$?0Q3L
MPL3QXNF)_$7*[\]<ZGZ1\Y$9"]I/8N8,6CUK1S_8C,> 'W)AYBUH=N7A6,'D
M& /*R>09^@ W]7O"3M />C& G@*  4/N"4@"H)GNF3< ORF&Z(_U-;>C;V7>
M @),#L#$,NQF'@&[ 7YN;FX>;GX>'GYA/EX^83%!?GY!,4E143%144EA?B9]
MORQ-H.5\?,L%E@L)" BM$! 06,$X":R8-1'^IPX %K&(12QB$8M8Q"(6_9=H
M9L!D51"52D*HJQ,H:BC&ME -30Q1CT21U&%J&NJ @7$D"84.QE+!_ECZRXDA
M9+3J!@2,PQA"/.!V&G8D<VP0;GTT&>L2;>^*C@Y&ZV$@QD:\!I&(R!!2"):*
M D>&X D41*0AA.D<0;]GB-4A8*8*-=@0PMR,@CWM','F1#(6#%?34D5KP&!@
M'1TUF#9<1P>V%JRI =-4UZ#_TU&%:2/@.@C-=>#O!#'BI9\-R)@ A#/2\CL<
MG3.$?.]71$2$6H26&I$<J [3T]-CN-'45*5KJ%*B"%14I"J!HC#K9,X/$DM!
MDW',+TU@!H^BOUM1#2$07O "F@4B+0!:E$!Z SV!6NKSGAG.Z4*$(YF("4-C
MR4:F:#+1'T4%(W$4*@Z/QY+!, TUF!I,![S: T? $",H:PS4%UG,Q:C^4Y#_
M:?#T_"\=_-SH+PJ>KHTP)V-15/I[$?VES<C1A8D#5\/@\6#Z&Q:%@0A7TU33
M-%#_6?<G-W9$#"X@"DE_N372U-"$J6KHJ6IHN\*T$)JZ"+B&B@8<H:4QZV2!
MYE*A8'_Q 4-HT@M$;Z&/!9H_QT&O1 R*BOJ7(EFH^W>/! 8]/Q D^HLVLU@Q
M:'4L'AN")5 I],& +1X,#!I!Q5'Q"WLT!VN*IRZ6SC7@<0PT!!Y%"#2$1*I^
M?P^&&/W5[]A$]&P>\+B?HE'_-1P#]24B9_0&/5LM2_3'!1OZN_X8S7V/_T<!
M++9G!O K&".$ "(Y!$4UPH6@ K'J6!(E@*G[7?J_,/?L[/[Q[ L)45_*DD*U
M"*?^8TL*X\.%NC.60@PCH[$6X?0:4EC:E3/V-^O7TJ[HZ@H_+PIV=@AK H6*
M(C"^>AG1!6HX' :A;:$'UX#!U\'A&D@+<QA,UQ2NJP?3,]4VTX*;FUHBF9-J
ML>DO;I%$=!BC_K^[Q3#<FO]K;A>8_N)V]C,;"O\7W"_AXA>8]?1UG4B.^O<J
MFEDV)!29POR^9PB92SSD%P.&#;,4$"@TLQ IJ' LQD!]D>SW1K@EANR?=OX7
MT]_[CPC"$GY=4K7A<TOJ JW?.V$L2A$H,M8TD)YCH]E]PH_?WYF[+'I4+F7R
M>]?H(/HRB,48J<\9S@E^&9@EEY;_(R.&_%\?L1\/0=:($8S01 +C$_._,6IT
M'!1]PTO?'AD%D(DA8!2)A,>A40PK]7 "YON*2YI/$94(7O@ ^L7)?[&S&"P9
M]^\4Z((HY_,$_O_6Z;\^)__I@X\U)Q=+?]Z@_>[Q.;<KF"U+2T9A_6OC;,#<
MY_RG"^A/IDMYQOPG.XE?3)?R3/PK>Y7?NO@UVPN2^K=O=>?G^6_>E.>:?WWE
MG&]",'\=1W\9Q!II&Z@O)?Z'0<]*G9&61KST#L]]FEBJKO]^8H&P0%@@+! 6
M" N$!<("88&P0%@@+! 6" N$!<("88&P0%@@+! 6" N$!<("88&P0%@@+! 6
M" N$!<("88&P0%@@+! 6" N$!<("88&P0%@@+! 6" OD;P;A_?&?_;$$C"$D
M F)L-/,(, = ?Y$83OZJ#]#,34"8&Y '3K.#A $V81"[,&BF#I # ! [)VCA
M'XKCXN9E8^?@7 ;BH;?K"@$@#C80.P<(Q,'%_#M^'" V=LYE7-P C["(Z IY
M&$1,W-2)5U'+;&=*L82DICG*/_3D+;JE+-TI:+%G$-,O-Q>]%2Y,QV5GXV#G
MY.*<50'1@V+GD!>!<2XS=8*@QD1WIMQJXUJAH!EZLE@<ZCSPSFRF%^!G9ZH)
M \9 QE[E2NOX=SNXPRTB.Q\]$W<Z<L]*Y. 1V<RX$V.-/!"BH*FR^=;+)_?$
M:#5-.@!CR"LW.O_L!SV5, @?<SYCAUBKNDYB&=49E0Z@-SWFV)G<IJ8KU5!>
MOBTB/I;Z"M3"/G[HW,OV<ST6#D<,6SX3,[M7(@)JT=K\V2U<DG<+G;-,!C]4
M-O*%W#KBG;Z'NEUJJ K7_^$MO$9X4U=_!9?\^(?3.E=['YYS6;]L<+ P6.*F
M',RN-QV^:L6R=06C*^$"4AB(>18IC/_301[V$^$TLL)74HGNKL=6P69>\+#C
MURMZ+"1.9699J<,J0S;?5U&&W^GHZ=/(E#*=%$L1!O;L\N<X9-FLDD]U"0M.
M_RRX-U=L ^AC:Y#VI8OIJM,)60)''X9H=%[_,_%@H]2]/837\9K<(3JEF5?C
MXZOL_0X#T)6MU_-0ULW[99MJ]2Q,UM-.:>M-0X417V0^"QS62W]FB6C)?HOV
M74U(;<:N?#6().<9/D!^VI\Z4%W?[.$M4.C]QFVD,/=F11#$?C#;4<&\5V!<
M>N2#T%4)G4/EX+KBGN!#>&3KCLV*KV &\(*:'3R?O\X YV> (N^GW5MWKFIQ
MAY2N+:Z?A!Y,+#@WX*N4/_H9HG?/H7Z<7#1=^##OY)4R!X'$%\_/?[:"-0VY
M?N,]<,F]ZG:DVY8\9:7^:=<$Q1N[I\9N;-]AG&N\(U=E\O/7"8M1I!72O?K3
M>**OD9O'I_-YA6E;(<IY50^'(KK.27>>'9#.Q;C*HR._Y!@;U]>FUG]+<_F:
MYO)9><(B1"G)PKW,7?W8>?C&B?>O7#T@"FY/3I,AG]V_G2)#]!]T%O6(;V+$
MOV.5T8[ZUGZDSP22^N/'0DCM;=\%@;WA(U('K<DJO#)QI6\Y]YFON^MA?;">
M>QU95%]ZV-19\<N%-WR*&_<T6%29B1V&7W98=7)[:V74!UULP1G#W*O!Q$O*
M Q>VZ9\I'L%I<0XDL7D+R&0E=U'[E#M:T!%K"SHK;B4.)=L#[!_48OU6)FQZ
MDWMS6W]?W+<O 6^J;R:BZP]N>*QL9[LQ[LS:73K7/_HA\$3QHT\5:,MJKFIR
MAG5:8%?&E3]+$O-3/+[F3COQ<W^FKI5"^^G:3V'YNGME*O+DZMTJ+[T2U\X<
M$'OK=4$G_XEI\&H-#9'E5LG:5Y_W^VC%L]LG['J5M2Q7B!!3Y9A(L]G4Y8^Z
M7A3ZI%W<6^C>6([U"]M="DT3Q[WXJ5*G0Z:6$6QV"N/U^/?4KW1?22KK+LV(
MSCMP>\-]Q4L(22O#/[:>E/11@FX[,0-X/.HC&:E;/MDKNB+;>=>+=7;7:5*#
M$<6X5;M\4F)-P5T$4ZBNSN.](@;(&.FI35ZQQY/9>[262X'9@ <:('9]@75Q
M7P^7W-;S.'<!QYOM2=B@"*\6LN\WU3[:KEG=W>@^E?6N^P%$]9[;QWYP<=26
MRHONS][[@LY&W8S,5 : <K&"BECN(IMWTAQ7DX?ANV7OK;QK>CW*RNVT=;!U
M$$FRFP>L@XS?-P,TLD^(V/9?4K]YLOXB>9/4YI5NJFLFZVWOYE6F==RR\;/]
M<\MY/9^V@9B4W/67'/@&$./W<_($G7I"D:8*94:\AE_1][VLPL?>&WF1^PEO
M3:AA3R*.HF6WTNS/]APW.GU[]5B?>V]TROC7EGJNXH(&RMI4L!--UXRG,E[(
M"YK_%4N,_Z!L*\3!'S8Z_OEST8FM,0-CWD(UW9_+])L21]-"KQAH- <&;:NB
M3E]5XPEV/J0[DB#<JN98_2FZK,L<RK-/QPQR&.LLATI543 3A>W<>=^J_EJ;
MWS2M@J<8=J]+]V[XX_;2)Z!X4/J0OD"S-U[9%K89O66Y1GK:RHMW=46OA,19
M9*>S">Y&U_;ZI)LZW5S=;M^(0B'-G,/.DFO41KZB(WT30HLU] EZ@YR!7P[Y
MO$ETN@QO::DEG7S=4$*P4>-*==JY+<33A+;ALHVU<*N7..@9AGR4'Y,"]<R-
M-@(][R$4W0W2"<#!?9Y>JP_UEL'DGBU+T\F_\J?F3K^<(FX%S";_6!H$RY^5
MKGS1PF4SIV+SP<+*C.K>*LG"AE0[K<?EXKTK&\IO\#D45/$)UP[>+K;S(N@<
M?P09<L^47DW._9AW[^.WFQ*TJ[K9H=2#NP1NZ.2N.MFP>U*IL+K*6KAE#3B6
MYR8I9:+_[.:O22\3)PV?JIU\X-YG>Z,K1N+(U3*9&2 [.M5UQ+UH3837R6-[
M\)#1LTTJRG%*&D>BO: 9H'3YM%>W38(Q&)%(!^=K!]%%QZ;=+I?)\MN*\(B.
MU9L+OT^K>6[)=[8*-?JM]Z/N\Z['Z6<R;_1_*5=\9!'X:!<IY)C7;?&"^N U
MKYS+6OHA%15Q,=:F<842RZJ[CE$I*X17E$"IIY=+[]K-YI=RV?CRRQG %KMM
M.RTBM&8M.:D+0XM^K]X8VE?DY):8'-B=TWOS_7+KE/N#=Y?K^6,IG<,=U,.-
MA^QU2^QI^5;KH<LG!6+=&V7Z7*$'SE83.2]IOC*(-I@T++I+SBJN4%M3.:K]
MY,')^\?M4?+&O-+*AE6!"7S[Q$V7?5[A_+#374JS%*QI:2U2G?JZJVJP:KKD
ML>C>*2+E1M)G>^*17D)9RCXK.5!\\,%1S5*H0<](B.'](?1#JXYF"SZYGC>J
M&[?Z=YG57/%=E;M!6%$O-_H2.RH ^S0U=\1FL+33+BQAY,S E U^Z/[KPZ'C
M>;RWV^&((N$_RE?EAXI&LC701%0LS6Q+VU*Y2YJE1-8UYKR7;K<=W[L?42*2
M?*_<B7"-;VVS_I_*\#^ZFR\JWKWX;GA544!G/"U.IV9HUX64MF>FID[)W>C;
MY5/WMD1,G4*Y2MN.[C0V'<U2<JGX<BYTE4V@A/1@)RTP\'B\DK7O8?S&;,,S
MX82.[>?S2P1DA-?J>'G&ZP>(RT_[:@GF7*N+[^6'G!K:N8*X)T#93>I0N!'7
M0&GTI:>/N\O]B ;+:*B7';4:%V8 ;17,PW:?A(1<IP.=_I\>IYV.1XF]$SP?
M#AFPJ%G1AI?$D@K=8^K6O/\4/0,X4GK"J[>]M:CSL6K#?/SDWC+]I/@VF:PQ
MTL[?2XU U!K>(0OOD>T0&!:Y!YR[&B?"J;P&B5BMR+]?TG,_0L:'%'<K)V44
M-KZ&8X1G<G7-I$M;^  E@M",6:.R><M6+PL0!_*#N%\)Q_0+3938BPM;0\J*
M5_,\,'Y0TF7;M;V@0_2A[*X[0<9'(TG!NTMS(RJ"H!:; A("M)-N[+%+BU7@
M'*C]PV-S+<&X&.VU=]WM];&C N/(D'U<H:F*X887JT[2O/_HELH5KY0L2YL*
M!%=PK;Y9XABK^6<W9VEI2 S>O/1\43RZN:[(5X8/EY9\),2PU]-&0XD]T.!A
M1=9DPS'91\'!]9^$L3YK+!]/$$?.NP;;O5$67!O\HK+>3O\ YYFC>X\>F/CJ
M[-TO)FNS-[-3^N'!SE,F#W36_L%?=^OA2I%-T)0RL_V/AZ_=W'JD-ON.CQSM
M<T!H@G=/?,"=7F=:^-6'Y<4=]KN[:)[WUM5ZB,)='#!6/4^\]F]L/,#A^5K8
M(MY\K49-2TUK(4DEY9YLPROQ+E?/T4K2QZZS;A];**B.M\TV.PM,(7ND+:G'
MI/-L-JJ.M<B]]I#)/&%^M79C%_Q2D%*@:9SU+2"9RPO\Q[%'Z .5-F4YR]7,
MM<.EGEBEWJ^B+>N2%-"R!-WOR=%/W&^D7<8A(+\*FO[X73X%):<G.^2AOZVE
M^I9M]^/IOO:0;%ZX_95;MMX>!;76>0+>TJ/-5T5>L,EC0OGN9JBW#4@GU7W;
M/&@K&Z*T;1#DLJ.I.&5\JPJD-C"[=G_*X,=/=:E%IUL.R&PYO"57$Q)E=4UW
MGX>"X88#%\='UWSH.GJ&D@+-&DWM] #;'HXY[C3R9KHY&W[+<-OQ\+'A,[;J
MLI2+Z-3AN($H\?J<9LDN_6 73.?=%*MMNT?<D^"BPP<N5PSJ[2<)MZ6I'+VV
M[HM@S 9P]MF^#!_Y ^\.#V=6^C@\JGZS)R>TEG^0"$'W5SX+H%S[*) C@>X?
MZ#(?/''GV,C7H\.R)5>.ES0UF-UIUC7MAU*^.*F(>#ZYCIGZ="Y=R*3>F6.R
MR1G9[Y6[,D9V#.CC\-9:<:Y[7:2[8"Y!MMS;?>1@H-E@5\]=9)E^4!^BSDQ9
MT"@GO&YG:PC';1/J_58#[(;.._(\J6MJ:,?#=#8WR+T*3Y\!E-^K81YR]J+5
M"@2CGG6WR"0=BIP:*>LU5R:9AWW3VS]P/%QB@VF)F8Z7HU1R8[+H-L<OFKG.
MG\#0Z/Y/X_:%J6)AMSYR/DW@*N(F^M\H3\NRE?4\@=$)CW(OT>R\+9FW'WN0
MAKE\!=S8G3/Q%IJ7X.LE:FC^^FN!?:[;F^G 0OV!]PDB/7K?5'<.Z:=N&!L_
MZ^*,C6!W%+L2HA*DZ9APZ7:>D:E72L\^MSBNL==RIBG->CRR+B?JUW*DECOX
M5'U[?7E4<\@R_&E,BD1;WXW$PLE7KA8?AG*<FO8_AX\_CU&>+-U7Y)IV;TN^
MV^NNKE?GA05&#PVK\%6>.)G=*O!GGK3NL* ZN/Q"BV2#)U+SGMRE4U#<9M'N
MYU_BCC1P[W^R-\:EGJ^WX$5&HD)XQ,O7K;KC;S,"28]#<M\8D=ZSLSUD$YI.
M.?:Q18[7<TL:UY5RZ,KX^ P.M96%L+U2ECSP?+[I8E\(6)XRW6_C<WW#*>0N
MJ90'UE.G7B=7-PZZOWNC8%I[76N'6S(Y6/O6A\Z,6Y$=UC:83%_NW@\Z1P;3
MOV1I;'FI!I,OOF)6#/UZ<-^)BR)24(B,V/X R@;;7>5>27N;88?B(@QO% ?+
MNE26*\%&+DE"[X7Z2+S3DJJ!O>0_??J.!1+<9W([O6CKG^8GTJZL;\R6;99N
M^GA]\ZL7^</I'[Y,I.X3DA"^>6UJ=%+M[=&-L1*-EX>,U\AK'^-B:\"SM2NP
M'SQG6&Z0;C%Y9KWA:&B*#DY&L/U)]HKTNO"61\/EK6OR7CT^MALWY?MB&G^]
M,,/Y]?48I]BW3859K]5+XA/$SR%H<B5L!3;!M,W+_9QES9,C):,<RY#!TSYH
M3,&#BR>R0[]IR0S521D.97]I(O?Q/)N4JO!*ICS:/$[;,AA]*.!9WXD>_?>R
M#5KGO/GU\]>/D.*N=I1+O_T\>$&&6W?- ]*M@GI%W=AGEY/!G)2'976NZ?%?
MAH'U6=3^%H<1YTTW-V0\^)SR*/KUI'BST++ZI.MUX48WZL?QT5NC:3)U.L9K
M2BYDLF=(D^_&1X?G7KIR8OW%#Y;G+52O?.'.2TZ*Z2K:W&$/;!D=V"<3\?+;
M#2_;8UFT6HD(HX'SJ]OJ4MW?B4=-QY?I5.]]8?+ &HK?$:S5VVFMT/_LK56I
M0:%38<>U;,,90%%[:FAY>:[1S7,;WF^*K^A?4WS+817-=:3/&W+GKGK ELOH
MG5N3%(/45HE"CYH\B+ QC!*(/7(1VFZ87BWGL=EC[7O5[9R;'^:TN]]^-M1U
MJK[QU)AVV76-Y_$']IS@33DL+5/PDJ/_:E58Y=IW,9KF!R6!+!&MZKOZZX33
MQ-YN#F]]%"\A%1C\]:S<G\66%7[$_'I\"&S35)>URF,OPP[2G:[DRXW0DEB2
MA1B_B -4L;R'4F/\)"HF6S=,I(NO22(\[(.$HV#>HPRXLJ#H>1?ULTZGJMZS
MR0P>$['=2Q7W-LO<S%8X<9BFF'K6,5M-*?3X0VB+Z7'YM?>SX,^P'04KX%,J
MJ&/:N^\:MR2LNKQ1LJ/FB/7^Z\F1A:8R'<^1T/%E>RXXV.1T;4\JV[HIO6*Y
MM%MPCB(*^9*2N*ZO_4MM\TXE"T'"I.%=O])X:ZW3&&^?WF<M%:=HW5^<1^JV
ML%%;C]YL#5-YRSUV5&Y=FYI'UM=-JF?)?%:*R]P/RZEQ--3;;)1??^"4A'Y&
M:PY2,/+UFRN2[I9W2ZR'G^"?'PN]=JFT5/UL;4&UT68'ZXH"'D0#-%M5\SD/
M5+3@5JQ>87.^5YU&N>7-*R:4""X_RG&!U+=[)O84=,$E:MW$C(\=\7V/]!WX
MZG))5PJ8 2#&^!U\[$3%YF>1:L+9NYOZ: )W*,HOAB;1["KUYS7!^<?J#X7%
M/8K'+$^M[[I8G%^]+>J5:Z.,B.%KK$L2;4+,\7Z;4_N#MD/2MPWA=GYN'8YF
MYUYZGKPDP&U^ $Y\Z=G#M_'<Q#E:7N*D6Z.%-=SEQ>FSYX\F.0V);,2IU&US
MC=N09&VYC7+2\8E!P3 T^9I8XHMAA8R"PJ$##9]:=&672]IN3W;*]&QR3S)T
M%#+I#>IP2U,](/](VAWFYA:KL%W%S:/.^EDTI/%P1HX?ZD+&^;*-;<GAAWS!
MD&KA7IF\R,3=5LC\NK@:21^$E8PSEX5HWL0%O"NDTPL5&?;G8TN[T/TT]QY%
M-L.K>IQI8EY=U,24IL\B>=TGL4:ET)BLR1,8LR1*6LOX^<(V\:%K8VN-C%LY
MM+;+"Z>K-TN+;(>%1GT\L.H)>OHPY(/^HQQCVPOC-<>4TE[L@URKKJR#7C9?
MG0S=>B+9Y+Z#KG-#*\&:XZ@[PO14C+%Y/U_ZL-9$I9O1-6C.B^ELW_?B]4_W
M?C'U,STRFL!USRGEVZ# Z6C##SOESD_L]WV33W]C/MO:C]P8.M9G8O. O!-F
MB_=.[UP;@#%OZZB-]B:\>W4P,_).R.X17YYGAY,_%NT>S[5N$Q]$O/J4 /X4
M*Z#5E*1[0 ?FA\+<$>QS$K+Q3+63M9F4@<9DM+[-HUH0>#-.HJ"AA2KUL8W8
M] HP=]!)9=R-LO3T_/T7<KQV/&]4\?YL7$-/P-%1CMN:&U,*- W6B=W(XPU:
M+W!T5*Z@])Q(:$>3 <T]2W;@EC;O\%I-"[Y5(I5-]>N:)ER4]/1NM="*?1X]
M[;8WF:I4OSRR\>T&8X<1+]5WKS*5VJ>$$P-'RJ6A+443.KJ]_?LN3SD=1(XE
M$N/V7-\6MG7/'118OOJ3?'*D7>1EW0J_S/HJ#F1E@C:I><"PH7L"_57I7.$
M II]EBOTB8XGF?90](AI>UO[O5"<R I,Z<[U3FO8Q76%XE:QGSDNG^B6 CT4
M47;'O>1!_Z5]Y2N%G6> 3QY?C3L0D'>Y>V: UAE -$]Y"H+XIS\S/?\#4$L!
M A0 %   " @ 5T0V4_BB^SD>)P  Q;P! !                       &)V
M<RTR,#(Q,#<P,RYX<V102P$"%  4   (" !71#930=K1ZS,<  !6SP$ %
M              !,)P  8G9S+3(P,C$P-S S7V-A;"YX;6Q02P$"%  4   (
M" !71#93,U=--5/;  " 6PX %                 "Q0P  8G9S+3(P,C$P
M-S S7V1E9BYX;6Q02P$"%  4   (" !71#93GA$EP#?J  #E_PT %
M           V'P$ 8G9S+3(P,C$P-S S7VQA8BYX;6Q02P$"%  4   (" !7
M1#93RI&P*##A  "!HP\ %                 "?"0( 8G9S+3(P,C$P-S S
M7W!R92YX;6Q02P$"%  4   (" !71#93&%[/LR("   /!0  $0
M       !ZP( 9#$X,#,S,&1E>#(S,2YH=&U02P$"%  4   (" !71#93!R"/
M)"H"   <!0  $0                !2[0( 9#$X,#,S,&1E>#(S,BYH=&U0
M2P$"%  4   (" !71#93*I6+"Y0"   *!@  $0                "K[P(
M9#$X,#,S,&1E>#(S,RYH=&U02P$"%  4   (" !71#93LJT [S("   R!0
M$0                !N\@( 9#$X,#,S,&1E>#(S-"YH=&U02P$"%  4   (
M" !71#93/@0SH!L+   2,   $                 #/] ( 9#$X,#,S,&1E
M>#4Q+FAT;5!+ 0(4 !0   @( %=$-E-ITP$4G0T  '<H   0
M     !@  P!D,3@P,S,P9&5X.#$N:'1M4$L! A0 %   " @ 5T0V4W"$0ILT
M!   !PL  !$                 XPT# &0Q.# S,S!D97@Y.3$N:'1M4$L!
M A0 %   " @ 5T0V4[SV&SZE P  NP@  !$                 1A(# &0Q
M.# S,S!D97@Y.3(N:'1M4$L! A0 %  (" @ ;40V4[RJT9L=BPP A+B.  \
M                &A8# &0Q.# S,S!D<S1A+FAT;5!+ 0(4 !0   @( %=$
M-E.7$-S^KUP  -:I   1                 '2A#P!G,3@P,S,P9S S83$Q
M+FIP9U!+ 0(4 !0   @( %=$-E,@<$.XAD@  *"3   1
M %+^#P!G,3@P,S,P9S S8C(R+FIP9U!+ 0(4 !0   @( %=$-E-[U5%19"P
M *MZ   1                  ='$ !G,3@P,S,P9S Y9#0T+FIP9U!+ 0(4
M !0   @( %=$-E/42LP=2R,  )EQ   1                 )IS$ !G,3@P
M,S,P9S Y9C8V+FIP9U!+ 0(4 !0   @( %=$-E/*W7^Z?"@  ,MO   1
M             !27$ !G,3@P,S,P9S$P8S,S+FIP9U!+ 0(4 !0   @( %=$
M-E,G$2.##/0  #U@ 0 1                 +^_$ !G,3@P,S,P9S$Q9S8R
M+FIP9U!+ 0(4 !0   @( %=$-E-YN,Q?FR,  )1O   1
M /JS$0!G,3@P,S,P9S$Q:3$Q+FIP9U!+ 0(4 !0   @( %=$-E.!UL,(AS@
M ,^'   1                 ,37$0!G,3@P,S,P9S$S:#<W+FIP9U!+ 0(4
M !0   @( %=$-E.2U06@)S,  'R!   1                 'H0$@!G,3@P
M,S,P9S$S:3@X+FIP9U!+ 0(4 !0   @( %=$-E.LR)A$528   %T   1
M             -!#$@!G,3@P,S,P9S$V:C Q+FIP9U!+ 0(4 !0   @( %=$
M-E-V-AC4;",  !-P   1                 %1J$@!G,3@P,S,P9S$V:S R
M+FIP9U!+ 0(4 !0   @( %=$-E.TS?'O7RD  $!V   1
M .^-$@!G,3@P,S,P9S$V;# S+FIP9U!+ 0(4 !0   @( %=$-E,=/=S+^R<
M &]U   1                 'VW$@!G,3@P,S,P9S$V;3 T+FIP9U!+ 0(4
M !0   @( %=$-E.+I;C#*2@  !IU   1                 *??$@!G,3@P
M,S,P9S$W;C U+FIP9U!+ 0(4 !0   @( %=$-E.PX>%\SR(  ,]N   1
M             /\'$P!G,3@P,S,P9S$W;S V+FIP9U!+ 0(4 !0   @( %=$
M-E-@G\]XLD$  +V1   1                 /TJ$P!G,3@P,S,P9S$X<# W
M+FIP9U!+ 0(4 !0   @( %=$-E,OPA\VF#H  $QI   1
M -YL$P!G,3@P,S,P9S(P=30S+FIP9U!+ 0(4 !0   @( %=$-E/'.5^MJ1X
M !MI   1                 *6G$P!G,3@P,S,P9S,S<3 X+FIP9U!+!08
1    (  @ .<'  !]QA,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
